6	NEURACEQ.xml:S1:4:1	6	CD	O	O
ADVERSE	NEURACEQ.xml:S1:6:7	advers	JJ	O	O
REACTIONS	NEURACEQ.xml:S1:14:9	reaction	NN	O	O

EXCERPT	NEURACEQ.xml:S1:34:7	excerpt	NN	O	O

:	NEURACEQ.xml:S1:41:1	:	:	O	O
The	NEURACEQ.xml:S1:45:3	the	DT	O	O
most	NEURACEQ.xml:S1:49:4	most	RBS	O	O
commonly	NEURACEQ.xml:S1:54:8	commonli	RB	O	O
reported	NEURACEQ.xml:S1:63:8	report	VBD	O	O
adverse	NEURACEQ.xml:S1:72:7	advers	JJ	O	O
reactions	NEURACEQ.xml:S1:80:9	reaction	NNS	O	O
were	NEURACEQ.xml:S1:90:4	were	VBD	O	O
:	NEURACEQ.xml:S1:94:1	:	:	O	O
injection	NEURACEQ.xml:S1:96:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	NEURACEQ.xml:S1:106:4	site	NN	I-AdverseReaction	I-AdverseReaction
reaction	NEURACEQ.xml:S1:111:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
consisting	NEURACEQ.xml:S1:120:10	consist	VBG	O	O
of	NEURACEQ.xml:S1:131:2	of	IN	O	O
erythema	NEURACEQ.xml:S1:134:8	erythema	NN	I-AdverseReaction	B-AdverseReaction
(	NEURACEQ.xml:S1:143:1	(	(	O	O
1.7	NEURACEQ.xml:S1:144:3	1.7	CD	O	O
)	NEURACEQ.xml:S1:149:1	)	)	O	O
,	NEURACEQ.xml:S1:150:1	,	,	O	O
irritation	NEURACEQ.xml:S1:152:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
(	NEURACEQ.xml:S1:163:1	(	(	O	O
1.2	NEURACEQ.xml:S1:164:3	1.2	CD	O	O
)	NEURACEQ.xml:S1:169:1	)	)	O	O
,	NEURACEQ.xml:S1:170:1	,	,	O	O
and	NEURACEQ.xml:S1:172:3	and	CC	O	O
pain	NEURACEQ.xml:S1:176:4	pain	NN	I-AdverseReaction	B-AdverseReaction
(	NEURACEQ.xml:S1:181:1	(	(	O	O
3.9	NEURACEQ.xml:S1:182:3	3.9	CD	O	O
)	NEURACEQ.xml:S1:187:1	)	)	O	O
.	NEURACEQ.xml:S1:188:1	.	.	O	O

To	NEURACEQ.xml:S1:196:2	To	TO	O	O
report	NEURACEQ.xml:S1:199:6	report	VB	O	O
SUSPECTED	NEURACEQ.xml:S1:206:9	suspect	NNP	O	O
ADVERSE	NEURACEQ.xml:S1:216:7	advers	NNP	O	O
REACTIONS	NEURACEQ.xml:S1:224:9	reaction	NNP	O	O
,	NEURACEQ.xml:S1:233:1	,	,	O	O
contact	NEURACEQ.xml:S1:235:7	contact	NN	O	O
Piramal	NEURACEQ.xml:S1:243:7	piram	NNP	O	O
at	NEURACEQ.xml:S1:251:2	at	IN	O	O
1	NEURACEQ.xml:S1:254:1	1	CD	O	O
-	NEURACEQ.xml:S1:255:1	-	:	O	O
855	NEURACEQ.xml:S1:256:3	855	CD	O	O
-	NEURACEQ.xml:S1:259:1	-	:	O	O
545	NEURACEQ.xml:S1:260:3	545	CD	O	O
-	NEURACEQ.xml:S1:263:1	-	:	O	O
5245	NEURACEQ.xml:S1:264:4	5245	CD	O	O
or	NEURACEQ.xml:S1:269:2	or	CC	O	O
FDA	NEURACEQ.xml:S1:272:3	fda	NNP	O	O
at	NEURACEQ.xml:S1:276:2	at	IN	O	O
1	NEURACEQ.xml:S1:279:1	1	CD	O	O
-	NEURACEQ.xml:S1:280:1	-	:	O	O
800	NEURACEQ.xml:S1:281:3	800	CD	O	O
-	NEURACEQ.xml:S1:284:1	-	:	O	O
FDA	NEURACEQ.xml:S1:285:3	fda	NNP	O	O
-	NEURACEQ.xml:S1:288:1	-	:	O	O
1088	NEURACEQ.xml:S1:289:4	1088	CD	O	O
or	NEURACEQ.xml:S1:294:2	or	CC	O	O
www	NEURACEQ.xml:S1:297:3	www	VB	O	O
.	NEURACEQ.xml:S1:300:1	.	.	O	O
fda	NEURACEQ.xml:S1:301:3	fda	NN	O	O
.	NEURACEQ.xml:S1:304:1	.	.	O	O
gov	NEURACEQ.xml:S1:305:3	gov	JJ	O	O
medwatch	NEURACEQ.xml:S1:309:8	medwatch	NN	O	O
.	NEURACEQ.xml:S1:317:1	.	.	O	O

6.1	NEURACEQ.xml:S1:329:3	6.1	CD	O	O

Clinical	NEURACEQ.xml:S1:333:8	clinic	JJ	O	O
Trials	NEURACEQ.xml:S1:342:6	trial	NNS	O	O
Experience	NEURACEQ.xml:S1:349:10	experi	NN	O	O

Because	NEURACEQ.xml:S1:363:7	becaus	IN	O	O
clinical	NEURACEQ.xml:S1:371:8	clinic	JJ	O	O
trials	NEURACEQ.xml:S1:380:6	trial	NNS	O	O
are	NEURACEQ.xml:S1:387:3	are	VBP	O	O
conducted	NEURACEQ.xml:S1:391:9	conduct	VBN	O	O
under	NEURACEQ.xml:S1:401:5	under	IN	O	O
widely	NEURACEQ.xml:S1:407:6	wide	RB	O	O
varying	NEURACEQ.xml:S1:414:7	vari	VBG	O	O
conditions	NEURACEQ.xml:S1:422:10	condit	NNS	O	O
,	NEURACEQ.xml:S1:432:1	,	,	O	O
adverse	NEURACEQ.xml:S1:434:7	advers	JJ	O	O
reaction	NEURACEQ.xml:S1:442:8	reaction	NN	O	O
rates	NEURACEQ.xml:S1:451:5	rate	NNS	O	O
observed	NEURACEQ.xml:S1:457:8	observ	VBD	O	O
in	NEURACEQ.xml:S1:466:2	in	IN	O	O
the	NEURACEQ.xml:S1:469:3	the	DT	O	O
clinical	NEURACEQ.xml:S1:473:8	clinic	JJ	O	O
trials	NEURACEQ.xml:S1:482:6	trial	NNS	O	O
of	NEURACEQ.xml:S1:489:2	of	IN	O	O
a	NEURACEQ.xml:S1:492:1	a	DT	O	O
drug	NEURACEQ.xml:S1:494:4	drug	NN	O	O
cannot	NEURACEQ.xml:S1:499:6	cannot	NN	O	O
be	NEURACEQ.xml:S1:506:2	be	VB	O	O
directly	NEURACEQ.xml:S1:509:8	directli	RB	O	O
compared	NEURACEQ.xml:S1:518:8	compar	VBN	O	O
to	NEURACEQ.xml:S1:527:2	to	TO	O	O
rates	NEURACEQ.xml:S1:530:5	rate	NNS	O	O
in	NEURACEQ.xml:S1:536:2	in	IN	O	O
the	NEURACEQ.xml:S1:539:3	the	DT	O	O
clinical	NEURACEQ.xml:S1:543:8	clinic	JJ	O	O
trials	NEURACEQ.xml:S1:552:6	trial	NNS	O	O
of	NEURACEQ.xml:S1:559:2	of	IN	O	O
another	NEURACEQ.xml:S1:562:7	anoth	DT	O	O
drug	NEURACEQ.xml:S1:570:4	drug	NN	O	O
and	NEURACEQ.xml:S1:575:3	and	CC	O	O
may	NEURACEQ.xml:S1:579:3	may	MD	O	O
not	NEURACEQ.xml:S1:583:3	not	RB	O	O
reflect	NEURACEQ.xml:S1:587:7	reflect	VB	O	O
the	NEURACEQ.xml:S1:595:3	the	DT	O	O
rate	NEURACEQ.xml:S1:599:4	rate	NN	O	O
observed	NEURACEQ.xml:S1:604:8	observ	VBN	O	O
in	NEURACEQ.xml:S1:613:2	in	IN	O	O
clinical	NEURACEQ.xml:S1:616:8	clinic	JJ	O	O
practice	NEURACEQ.xml:S1:625:8	practic	NN	O	O
.	NEURACEQ.xml:S1:633:1	.	.	O	O

The	NEURACEQ.xml:S1:639:3	the	DT	O	O
overall	NEURACEQ.xml:S1:643:7	overal	JJ	O	O
safety	NEURACEQ.xml:S1:651:6	safeti	NN	O	O
profile	NEURACEQ.xml:S1:658:7	profil	NN	O	O
of	NEURACEQ.xml:S1:666:2	of	IN	O	O
Neuraceq	NEURACEQ.xml:S1:669:8	neuraceq	NNP	O	O
is	NEURACEQ.xml:S1:678:2	is	VBZ	O	O
based	NEURACEQ.xml:S1:681:5	base	VBN	O	O
on	NEURACEQ.xml:S1:687:2	on	IN	O	O
data	NEURACEQ.xml:S1:690:4	data	NNS	O	O
from	NEURACEQ.xml:S1:695:4	from	IN	O	O
978	NEURACEQ.xml:S1:700:3	978	CD	O	O
administrations	NEURACEQ.xml:S1:704:15	administr	NNS	O	O
of	NEURACEQ.xml:S1:720:2	of	IN	O	O
Neuraceq	NEURACEQ.xml:S1:723:8	neuraceq	NNP	O	O
to	NEURACEQ.xml:S1:732:2	to	TO	O	O
872	NEURACEQ.xml:S1:735:3	872	CD	O	O
subjects	NEURACEQ.xml:S1:739:8	subject	NNS	O	O
and	NEURACEQ.xml:S1:748:3	and	CC	O	O
12	NEURACEQ.xml:S1:752:2	12	CD	O	O
subjects	NEURACEQ.xml:S1:755:8	subject	NNS	O	O
who	NEURACEQ.xml:S1:764:3	who	WP	O	O
received	NEURACEQ.xml:S1:768:8	receiv	VBD	O	O
vehicle	NEURACEQ.xml:S1:777:7	vehicl	NN	O	O
only	NEURACEQ.xml:S1:785:4	onli	RB	O	O
.	NEURACEQ.xml:S1:789:1	.	.	O	O

No	NEURACEQ.xml:S1:791:2	No	DT	O	O
serious	NEURACEQ.xml:S1:794:7	seriou	JJ	O	O
adverse	NEURACEQ.xml:S1:802:7	advers	JJ	O	O
reactions	NEURACEQ.xml:S1:810:9	reaction	NNS	O	O
related	NEURACEQ.xml:S1:820:7	relat	VBN	O	O
to	NEURACEQ.xml:S1:828:2	to	TO	O	O
Neuraceq	NEURACEQ.xml:S1:831:8	neuraceq	NNP	O	O
administration	NEURACEQ.xml:S1:840:14	administr	NN	O	O
have	NEURACEQ.xml:S1:855:4	have	VBP	O	O
been	NEURACEQ.xml:S1:860:4	been	VBN	O	O
reported	NEURACEQ.xml:S1:865:8	report	VBN	O	O
.	NEURACEQ.xml:S1:873:1	.	.	O	O

The	NEURACEQ.xml:S1:875:3	the	DT	O	O
most	NEURACEQ.xml:S1:879:4	most	RBS	O	O
frequently	NEURACEQ.xml:S1:884:10	frequent	RB	O	O
observed	NEURACEQ.xml:S1:895:8	observ	JJ	O	O
adverse	NEURACEQ.xml:S1:904:7	advers	JJ	O	O
drug	NEURACEQ.xml:S1:912:4	drug	NN	O	O
reactions	NEURACEQ.xml:S1:917:9	reaction	NNS	O	O
in	NEURACEQ.xml:S1:927:2	in	IN	O	O
subjects	NEURACEQ.xml:S1:930:8	subject	NNS	O	O
receiving	NEURACEQ.xml:S1:939:9	receiv	VBG	O	O
Neuraceq	NEURACEQ.xml:S1:949:8	neuraceq	NNP	O	O
were	NEURACEQ.xml:S1:958:4	were	VBD	O	O
injection	NEURACEQ.xml:S1:963:9	inject	JJ	B-AdverseReaction	B-AdverseReaction
site	NEURACEQ.xml:S1:973:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactions	NEURACEQ.xml:S1:978:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
consisting	NEURACEQ.xml:S1:988:10	consist	VBG	O	O
of	NEURACEQ.xml:S1:999:2	of	IN	O	O
erythema	NEURACEQ.xml:S1:1002:8	erythema	NN	I-AdverseReaction	B-AdverseReaction
,	NEURACEQ.xml:S1:1010:1	,	,	O	O
irritation	NEURACEQ.xml:S1:1012:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
and	NEURACEQ.xml:S1:1023:3	and	CC	O	O
pain	NEURACEQ.xml:S1:1027:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	NEURACEQ.xml:S1:1031:1	.	.	O	O

All	NEURACEQ.xml:S1:1033:3	all	DT	O	O
adverse	NEURACEQ.xml:S1:1037:7	advers	JJ	O	O
reactions	NEURACEQ.xml:S1:1045:9	reaction	NNS	O	O
were	NEURACEQ.xml:S1:1055:4	were	VBD	O	O
mild	NEURACEQ.xml:S1:1060:4	mild	JJ	O	O
to	NEURACEQ.xml:S1:1065:2	to	TO	O	O
moderate	NEURACEQ.xml:S1:1068:8	moder	VB	O	O
in	NEURACEQ.xml:S1:1077:2	in	IN	O	O
severity	NEURACEQ.xml:S1:1080:8	sever	NN	O	O
and	NEURACEQ.xml:S1:1089:3	and	CC	O	O
of	NEURACEQ.xml:S1:1093:2	of	IN	O	O
short	NEURACEQ.xml:S1:1096:5	short	JJ	O	O
duration	NEURACEQ.xml:S1:1102:8	durat	NN	O	O
.	NEURACEQ.xml:S1:1110:1	.	.	O	O

The	NEURACEQ.xml:S1:1112:3	the	DT	O	O
most	NEURACEQ.xml:S1:1116:4	most	RBS	O	O
commonly	NEURACEQ.xml:S1:1121:8	commonli	RB	O	O
reported	NEURACEQ.xml:S1:1130:8	report	VBD	O	O
adverse	NEURACEQ.xml:S1:1139:7	advers	JJ	O	O
reactions	NEURACEQ.xml:S1:1147:9	reaction	NNS	O	O
(	NEURACEQ.xml:S1:1157:1	(	(	O	O
occurring	NEURACEQ.xml:S1:1158:9	occur	VBG	O	O
in	NEURACEQ.xml:S1:1168:2	in	IN	O	O
at	NEURACEQ.xml:S1:1171:2	at	IN	O	O
least	NEURACEQ.xml:S1:1174:5	least	JJS	O	O
0.5%	NEURACEQ.xml:S1:1180:4	0.5%	CD	O	O
of	NEURACEQ.xml:S1:1185:2	of	IN	O	O
subjects	NEURACEQ.xml:S1:1188:8	subject	NNS	O	O
)	NEURACEQ.xml:S1:1196:1	)	)	O	O
during	NEURACEQ.xml:S1:1198:6	dure	IN	O	O
Neuraceq	NEURACEQ.xml:S1:1205:8	neuraceq	NNP	O	O
clinical	NEURACEQ.xml:S1:1214:8	clinic	JJ	O	O
trials	NEURACEQ.xml:S1:1223:6	trial	NNS	O	O
are	NEURACEQ.xml:S1:1230:3	are	VBP	O	O
shown	NEURACEQ.xml:S1:1234:5	shown	VBN	O	O
in	NEURACEQ.xml:S1:1240:2	in	IN	O	O
Table	NEURACEQ.xml:S1:1243:5	tabl	JJ	O	O
2	NEURACEQ.xml:S1:1249:1	2	CD	O	O
.	NEURACEQ.xml:S1:1250:1	.	.	O	O

Table	NEURACEQ.xml:S1:1256:5	tabl	JJ	O	O
2	NEURACEQ.xml:S1:1262:1	2	CD	O	O
Adverse	NEURACEQ.xml:S1:1264:7	advers	JJ	O	O
Reactions	NEURACEQ.xml:S1:1272:9	reaction	NNS	O	O
with	NEURACEQ.xml:S1:1282:4	with	IN	O	O
a	NEURACEQ.xml:S1:1287:1	a	DT	O	O
Frequency	NEURACEQ.xml:S1:1289:9	frequenc	NN	O	O
0.5%	NEURACEQ.xml:S1:1301:4	0.5%	CD	O	O
Reported	NEURACEQ.xml:S1:1306:8	report	VBN	O	O
in	NEURACEQ.xml:S1:1315:2	in	IN	O	O
Clinical	NEURACEQ.xml:S1:1318:8	clinic	JJ	O	O
Trials	NEURACEQ.xml:S1:1327:6	trial	NNS	O	O
(	NEURACEQ.xml:S1:1334:1	(	(	O	O
n	NEURACEQ.xml:S1:1335:1	n	JJ	O	O
978	NEURACEQ.xml:S1:1339:3	978	CD	O	O
Administrations	NEURACEQ.xml:S1:1343:15	administr	NNPS	O	O
in	NEURACEQ.xml:S1:1359:2	in	IN	O	O
872	NEURACEQ.xml:S1:1362:3	872	CD	O	O
Subjects	NEURACEQ.xml:S1:1366:8	subject	NNS	O	O
)	NEURACEQ.xml:S1:1374:1	)	)	O	O

Adverse	NEURACEQ.xml:S1:1380:7	advers	JJ	O	O
drug	NEURACEQ.xml:S1:1388:4	drug	NN	O	O
reaction	NEURACEQ.xml:S1:1393:8	reaction	NN	O	O
n	NEURACEQ.xml:S1:1407:1	n	FW	O	O
(	NEURACEQ.xml:S1:1409:1	(	(	O	O
)	NEURACEQ.xml:S1:1411:1	)	)	O	O

Injection	NEURACEQ.xml:S1:1435:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
application	NEURACEQ.xml:S1:1447:11	applic	NN	B-AdverseReaction	I-AdverseReaction
site	NEURACEQ.xml:S1:1459:4	site	NN	I-AdverseReaction	I-AdverseReaction
erythema	NEURACEQ.xml:S1:1464:8	erythema	NN	I-AdverseReaction	I-AdverseReaction
17	NEURACEQ.xml:S1:1474:2	17	CD	O	O
(	NEURACEQ.xml:S1:1477:1	(	(	O	O
1.7	NEURACEQ.xml:S1:1478:3	1.7	CD	O	O
)	NEURACEQ.xml:S1:1481:1	)	)	O	O

Injection	NEURACEQ.xml:S1:1504:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	NEURACEQ.xml:S1:1514:4	site	NN	I-AdverseReaction	I-AdverseReaction
irritation	NEURACEQ.xml:S1:1519:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
12	NEURACEQ.xml:S1:1531:2	12	CD	O	O
(	NEURACEQ.xml:S1:1534:1	(	(	O	O
1.2	NEURACEQ.xml:S1:1535:3	1.2	CD	O	O
)	NEURACEQ.xml:S1:1538:1	)	)	O	O

Injection	NEURACEQ.xml:S1:1561:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	NEURACEQ.xml:S1:1571:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	NEURACEQ.xml:S1:1576:4	pain	NN	I-AdverseReaction	I-AdverseReaction
38	NEURACEQ.xml:S1:1588:2	38	CD	O	O
(	NEURACEQ.xml:S1:1591:1	(	(	O	O
3.9	NEURACEQ.xml:S1:1592:3	3.9	CD	O	O
)	NEURACEQ.xml:S1:1595:1	)	)	O	O
5	NEURACEQ.xml:S2:4:1	5	CD	O	O
WARNINGS	NEURACEQ.xml:S2:6:8	warn	NNP	O	O
AND	NEURACEQ.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	NEURACEQ.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	NEURACEQ.xml:S2:43:7	excerpt	NN	O	O

:	NEURACEQ.xml:S2:50:1	:	:	O	O
Image	NEURACEQ.xml:S2:55:5	imag	NN	O	O
interpretation	NEURACEQ.xml:S2:61:14	interpret	NN	O	O
errors	NEURACEQ.xml:S2:76:6	error	NNS	O	O
(	NEURACEQ.xml:S2:83:1	(	(	O	O
especially	NEURACEQ.xml:S2:84:10	especi	RB	O	O
false	NEURACEQ.xml:S2:95:5	fals	JJ	O	O
positives	NEURACEQ.xml:S2:101:9	posit	NNS	O	O
)	NEURACEQ.xml:S2:110:1	)	)	O	O
have	NEURACEQ.xml:S2:112:4	have	VBP	O	O
been	NEURACEQ.xml:S2:117:4	been	VBN	O	O
observed	NEURACEQ.xml:S2:122:8	observ	VBN	O	O
(	NEURACEQ.xml:S2:131:1	(	(	O	O
5.1	NEURACEQ.xml:S2:134:3	5.1	CD	O	O
)	NEURACEQ.xml:S2:139:1	)	)	O	O
.	NEURACEQ.xml:S2:140:1	.	.	O	O

Neuraceq	NEURACEQ.xml:S2:147:8	neuraceq	NNP	O	O
,	NEURACEQ.xml:S2:155:1	,	,	O	O
like	NEURACEQ.xml:S2:157:4	like	IN	O	O
all	NEURACEQ.xml:S2:162:3	all	DT	O	O
radiopharmaceuticals	NEURACEQ.xml:S2:166:20	radiopharmaceut	NNS	O	O
,	NEURACEQ.xml:S2:186:1	,	,	O	O
contributes	NEURACEQ.xml:S2:188:11	contribut	NNS	O	O
to	NEURACEQ.xml:S2:200:2	to	TO	O	O
a	NEURACEQ.xml:S2:203:1	a	DT	O	O
patient	NEURACEQ.xml:S2:205:7	patient	NN	O	O
's	NEURACEQ.xml:S2:212:2	's	POS	O	O
long	NEURACEQ.xml:S2:215:4	long	JJ	B-AdverseReaction	O
-	NEURACEQ.xml:S2:219:1	-	:	I-AdverseReaction	O
term	NEURACEQ.xml:S2:220:4	term	NN	I-AdverseReaction	O
cumulative	NEURACEQ.xml:S2:225:10	cumul	JJ	I-AdverseReaction	O
radiation	NEURACEQ.xml:S2:236:9	radiat	NN	I-AdverseReaction	O
exposure	NEURACEQ.xml:S2:246:8	exposur	NN	I-AdverseReaction	O
.	NEURACEQ.xml:S2:254:1	.	.	O	O

Ensure	NEURACEQ.xml:S2:256:6	ensur	NN	O	O
safe	NEURACEQ.xml:S2:263:4	safe	JJ	O	O
handling	NEURACEQ.xml:S2:268:8	handl	NN	O	O
to	NEURACEQ.xml:S2:277:2	to	TO	O	O
protect	NEURACEQ.xml:S2:280:7	protect	VB	O	O
patients	NEURACEQ.xml:S2:288:8	patient	NNS	O	O
and	NEURACEQ.xml:S2:297:3	and	CC	O	O
health	NEURACEQ.xml:S2:301:6	health	NN	O	O
care	NEURACEQ.xml:S2:308:4	care	NN	O	O
workers	NEURACEQ.xml:S2:313:7	worker	NNS	O	O
from	NEURACEQ.xml:S2:321:4	from	IN	O	O
unintentional	NEURACEQ.xml:S2:326:13	unintent	JJ	O	O
radiation	NEURACEQ.xml:S2:340:9	radiat	NN	O	O
exposure	NEURACEQ.xml:S2:350:8	exposur	NN	O	O
(	NEURACEQ.xml:S2:359:1	(	(	O	O
5.2	NEURACEQ.xml:S2:362:3	5.2	CD	O	O
)	NEURACEQ.xml:S2:367:1	)	)	O	O
.	NEURACEQ.xml:S2:368:1	.	.	O	O

5.1	NEURACEQ.xml:S2:381:3	5.1	CD	O	O

Risk	NEURACEQ.xml:S2:385:4	risk	NN	O	O
for	NEURACEQ.xml:S2:390:3	for	IN	O	O
Image	NEURACEQ.xml:S2:394:5	imag	NNP	O	O
Misinterpretation	NEURACEQ.xml:S2:400:17	misinterpret	NNP	O	O
and	NEURACEQ.xml:S2:418:3	and	CC	O	O
Other	NEURACEQ.xml:S2:422:5	other	JJ	O	O
Errors	NEURACEQ.xml:S2:428:6	error	NNS	O	O

Errors	NEURACEQ.xml:S2:440:6	error	NNS	O	O
may	NEURACEQ.xml:S2:447:3	may	MD	O	O
occur	NEURACEQ.xml:S2:451:5	occur	VB	O	O
in	NEURACEQ.xml:S2:457:2	in	IN	O	O
the	NEURACEQ.xml:S2:460:3	the	DT	O	O
Neuraceq	NEURACEQ.xml:S2:464:8	neuraceq	NNP	O	O
estimation	NEURACEQ.xml:S2:473:10	estim	NN	O	O
of	NEURACEQ.xml:S2:484:2	of	IN	O	O
brain	NEURACEQ.xml:S2:487:5	brain	NN	O	O
neuritic	NEURACEQ.xml:S2:493:8	neurit	JJ	O	O
beta	NEURACEQ.xml:S2:502:4	beta	NN	O	O
-	NEURACEQ.xml:S2:506:1	-	:	O	O
amyloid	NEURACEQ.xml:S2:507:7	amyloid	NN	O	O
plaque	NEURACEQ.xml:S2:515:6	plaqu	NN	O	O
density	NEURACEQ.xml:S2:522:7	densiti	NN	O	O
during	NEURACEQ.xml:S2:530:6	dure	IN	O	O
image	NEURACEQ.xml:S2:537:5	imag	NN	O	O
interpretation	NEURACEQ.xml:S2:543:14	interpret	NN	O	O
[	NEURACEQ.xml:S2:558:1	[	NNP	O	O
see	NEURACEQ.xml:S2:560:3	see	VBP	O	O
Clinical	NEURACEQ.xml:S2:565:8	clinic	JJ	O	O
Studies	NEURACEQ.xml:S2:574:7	studi	NNP	O	O
(	NEURACEQ.xml:S2:582:1	(	(	O	O
14	NEURACEQ.xml:S2:583:2	14	CD	O	O
)	NEURACEQ.xml:S2:585:1	)	)	O	O
]	NEURACEQ.xml:S2:590:1	]	NN	O	O
.	NEURACEQ.xml:S2:591:1	.	.	O	O

Image	NEURACEQ.xml:S2:593:5	imag	NN	O	O
interpretation	NEURACEQ.xml:S2:599:14	interpret	NN	O	O
should	NEURACEQ.xml:S2:614:6	should	MD	O	O
be	NEURACEQ.xml:S2:621:2	be	VB	O	O
performed	NEURACEQ.xml:S2:624:9	perform	VBN	O	O
independently	NEURACEQ.xml:S2:634:13	independ	RB	O	O
of	NEURACEQ.xml:S2:648:2	of	IN	O	O
the	NEURACEQ.xml:S2:651:3	the	DT	O	O
patient	NEURACEQ.xml:S2:655:7	patient	NN	O	O
's	NEURACEQ.xml:S2:662:2	's	POS	O	O
clinical	NEURACEQ.xml:S2:665:8	clinic	JJ	O	O
information	NEURACEQ.xml:S2:674:11	inform	NN	O	O
.	NEURACEQ.xml:S2:685:1	.	.	O	O

The	NEURACEQ.xml:S2:687:3	the	DT	O	O
use	NEURACEQ.xml:S2:691:3	use	NN	O	O
of	NEURACEQ.xml:S2:695:2	of	IN	O	O
clinical	NEURACEQ.xml:S2:698:8	clinic	JJ	O	O
information	NEURACEQ.xml:S2:707:11	inform	NN	O	O
in	NEURACEQ.xml:S2:719:2	in	IN	O	O
the	NEURACEQ.xml:S2:722:3	the	DT	O	O
interpretation	NEURACEQ.xml:S2:726:14	interpret	NN	O	O
of	NEURACEQ.xml:S2:741:2	of	IN	O	O
Neuraceq	NEURACEQ.xml:S2:744:8	neuraceq	NNP	O	O
images	NEURACEQ.xml:S2:753:6	imag	NNS	O	O
has	NEURACEQ.xml:S2:760:3	ha	VBZ	O	O
not	NEURACEQ.xml:S2:764:3	not	RB	O	O
been	NEURACEQ.xml:S2:768:4	been	VBN	O	O
evaluated	NEURACEQ.xml:S2:773:9	evalu	VBN	O	O
and	NEURACEQ.xml:S2:783:3	and	CC	O	O
may	NEURACEQ.xml:S2:787:3	may	MD	O	O
lead	NEURACEQ.xml:S2:791:4	lead	VB	O	O
to	NEURACEQ.xml:S2:796:2	to	TO	O	O
errors	NEURACEQ.xml:S2:799:6	error	NNS	O	O
.	NEURACEQ.xml:S2:805:1	.	.	O	O

Errors	NEURACEQ.xml:S2:807:6	error	NNS	O	O
may	NEURACEQ.xml:S2:814:3	may	MD	O	O
also	NEURACEQ.xml:S2:818:4	also	RB	O	O
occur	NEURACEQ.xml:S2:823:5	occur	VB	O	O
in	NEURACEQ.xml:S2:829:2	in	IN	O	O
cases	NEURACEQ.xml:S2:832:5	case	NNS	O	O
with	NEURACEQ.xml:S2:838:4	with	IN	O	O
severe	NEURACEQ.xml:S2:843:6	sever	JJ	O	O
brain	NEURACEQ.xml:S2:850:5	brain	NN	O	O
atrophy	NEURACEQ.xml:S2:856:7	atrophi	NN	O	O
that	NEURACEQ.xml:S2:864:4	that	WDT	O	O
limits	NEURACEQ.xml:S2:869:6	limit	VBZ	O	O
the	NEURACEQ.xml:S2:876:3	the	DT	O	O
ability	NEURACEQ.xml:S2:880:7	abil	NN	O	O
to	NEURACEQ.xml:S2:888:2	to	TO	O	O
distinguish	NEURACEQ.xml:S2:891:11	distinguish	VB	O	O
gray	NEURACEQ.xml:S2:903:4	gray	JJ	O	O
and	NEURACEQ.xml:S2:908:3	and	CC	O	O
white	NEURACEQ.xml:S2:912:5	white	JJ	O	O
matter	NEURACEQ.xml:S2:918:6	matter	NN	O	O
on	NEURACEQ.xml:S2:925:2	on	IN	O	O
the	NEURACEQ.xml:S2:928:3	the	DT	O	O
Neuraceq	NEURACEQ.xml:S2:932:8	neuraceq	NNP	O	O
scan	NEURACEQ.xml:S2:941:4	scan	NN	O	O
.	NEURACEQ.xml:S2:945:1	.	.	O	O

Errors	NEURACEQ.xml:S2:947:6	error	NNS	O	O
may	NEURACEQ.xml:S2:954:3	may	MD	O	O
also	NEURACEQ.xml:S2:958:4	also	RB	O	O
occur	NEURACEQ.xml:S2:963:5	occur	VB	O	O
due	NEURACEQ.xml:S2:969:3	due	JJ	O	O
to	NEURACEQ.xml:S2:973:2	to	TO	O	O
motion	NEURACEQ.xml:S2:976:6	motion	NN	O	O
artifacts	NEURACEQ.xml:S2:983:9	artifact	NNS	O	O
that	NEURACEQ.xml:S2:993:4	that	WDT	O	O
result	NEURACEQ.xml:S2:998:6	result	VBP	O	O
in	NEURACEQ.xml:S2:1005:2	in	IN	O	O
image	NEURACEQ.xml:S2:1008:5	imag	NN	O	O
distortion	NEURACEQ.xml:S2:1014:10	distort	NN	O	O
.	NEURACEQ.xml:S2:1024:1	.	.	O	O

Neuraceq	NEURACEQ.xml:S2:1026:8	neuraceq	JJ	O	O
scan	NEURACEQ.xml:S2:1035:4	scan	JJ	O	O
results	NEURACEQ.xml:S2:1040:7	result	NNS	O	O
are	NEURACEQ.xml:S2:1048:3	are	VBP	O	O
indicative	NEURACEQ.xml:S2:1052:10	indic	JJ	O	O
of	NEURACEQ.xml:S2:1063:2	of	IN	O	O
the	NEURACEQ.xml:S2:1066:3	the	DT	O	O
presence	NEURACEQ.xml:S2:1070:8	presenc	NN	O	O
of	NEURACEQ.xml:S2:1079:2	of	IN	O	O
brain	NEURACEQ.xml:S2:1082:5	brain	NN	O	O
neuritic	NEURACEQ.xml:S2:1088:8	neurit	JJ	O	O
beta	NEURACEQ.xml:S2:1097:4	beta	NN	O	O
-	NEURACEQ.xml:S2:1101:1	-	:	O	O
amyloid	NEURACEQ.xml:S2:1102:7	amyloid	NN	O	O
plaques	NEURACEQ.xml:S2:1110:7	plaqu	VBZ	O	O
only	NEURACEQ.xml:S2:1118:4	onli	RB	O	O
at	NEURACEQ.xml:S2:1123:2	at	IN	O	O
the	NEURACEQ.xml:S2:1126:3	the	DT	O	O
time	NEURACEQ.xml:S2:1130:4	time	NN	O	O
of	NEURACEQ.xml:S2:1135:2	of	IN	O	O
image	NEURACEQ.xml:S2:1138:5	imag	NN	O	O
acquisition	NEURACEQ.xml:S2:1144:11	acquisit	NN	O	O
and	NEURACEQ.xml:S2:1156:3	and	CC	O	O
a	NEURACEQ.xml:S2:1160:1	a	DT	O	O
negative	NEURACEQ.xml:S2:1162:8	neg	JJ	O	O
scan	NEURACEQ.xml:S2:1171:4	scan	JJ	O	O
result	NEURACEQ.xml:S2:1176:6	result	NN	O	O
does	NEURACEQ.xml:S2:1183:4	doe	VBZ	O	O
not	NEURACEQ.xml:S2:1188:3	not	RB	O	O
preclude	NEURACEQ.xml:S2:1192:8	preclud	VB	O	O
the	NEURACEQ.xml:S2:1201:3	the	DT	O	O
development	NEURACEQ.xml:S2:1205:11	develop	NN	O	O
of	NEURACEQ.xml:S2:1217:2	of	IN	O	O
brain	NEURACEQ.xml:S2:1220:5	brain	NN	O	O
neuritic	NEURACEQ.xml:S2:1226:8	neurit	JJ	O	O
beta	NEURACEQ.xml:S2:1235:4	beta	NN	O	O
-	NEURACEQ.xml:S2:1239:1	-	:	O	O
amyloid	NEURACEQ.xml:S2:1240:7	amyloid	NN	O	O
plaques	NEURACEQ.xml:S2:1248:7	plaqu	NNS	O	O
in	NEURACEQ.xml:S2:1256:2	in	IN	O	O
the	NEURACEQ.xml:S2:1259:3	the	DT	O	O
future	NEURACEQ.xml:S2:1263:6	futur	NN	O	O
.	NEURACEQ.xml:S2:1269:1	.	.	O	O

5.2	NEURACEQ.xml:S2:1278:3	5.2	CD	O	O
Radiation	NEURACEQ.xml:S2:1282:9	radiat	NNP	O	O
Risk	NEURACEQ.xml:S2:1292:4	risk	NN	O	O

Neuraceq	NEURACEQ.xml:S2:1302:8	neuraceq	NNP	O	O
,	NEURACEQ.xml:S2:1310:1	,	,	O	O
similar	NEURACEQ.xml:S2:1312:7	similar	JJ	O	O
to	NEURACEQ.xml:S2:1320:2	to	TO	O	O
other	NEURACEQ.xml:S2:1323:5	other	JJ	O	O
radiopharmaceuticals	NEURACEQ.xml:S2:1329:20	radiopharmaceut	NNS	O	O
,	NEURACEQ.xml:S2:1349:1	,	,	O	O
contributes	NEURACEQ.xml:S2:1351:11	contribut	NNS	O	O
to	NEURACEQ.xml:S2:1363:2	to	TO	O	O
a	NEURACEQ.xml:S2:1366:1	a	DT	O	O
patient	NEURACEQ.xml:S2:1368:7	patient	NN	O	O
's	NEURACEQ.xml:S2:1375:2	's	POS	O	O
overall	NEURACEQ.xml:S2:1378:7	overal	JJ	O	O
long	NEURACEQ.xml:S2:1386:4	long	JJ	B-AdverseReaction	O
-	NEURACEQ.xml:S2:1390:1	-	:	I-AdverseReaction	O
term	NEURACEQ.xml:S2:1391:4	term	NN	I-AdverseReaction	O
cumulative	NEURACEQ.xml:S2:1396:10	cumul	JJ	I-AdverseReaction	O
radiation	NEURACEQ.xml:S2:1407:9	radiat	NN	I-AdverseReaction	O
exposure	NEURACEQ.xml:S2:1417:8	exposur	NN	I-AdverseReaction	O
.	NEURACEQ.xml:S2:1425:1	.	.	O	O

Long	NEURACEQ.xml:S2:1427:4	long	NNP	B-AdverseReaction	O
-	NEURACEQ.xml:S2:1431:1	-	:	I-AdverseReaction	O
term	NEURACEQ.xml:S2:1432:4	term	NN	I-AdverseReaction	O
cumulative	NEURACEQ.xml:S2:1437:10	cumul	JJ	I-AdverseReaction	O
radiation	NEURACEQ.xml:S2:1448:9	radiat	NN	I-AdverseReaction	O
exposure	NEURACEQ.xml:S2:1458:8	exposur	NN	I-AdverseReaction	O
is	NEURACEQ.xml:S2:1467:2	is	VBZ	O	O
associated	NEURACEQ.xml:S2:1470:10	associ	VBN	O	O
with	NEURACEQ.xml:S2:1481:4	with	IN	O	O
an	NEURACEQ.xml:S2:1486:2	an	DT	O	O
increased	NEURACEQ.xml:S2:1489:9	increas	VBN	O	O
risk	NEURACEQ.xml:S2:1499:4	risk	NN	O	O
of	NEURACEQ.xml:S2:1504:2	of	IN	O	O
cancer	NEURACEQ.xml:S2:1507:6	cancer	NN	B-AdverseReaction	B-AdverseReaction
.	NEURACEQ.xml:S2:1513:1	.	.	O	O

Ensure	NEURACEQ.xml:S2:1515:6	ensur	NN	O	O
safe	NEURACEQ.xml:S2:1522:4	safe	JJ	O	O
handling	NEURACEQ.xml:S2:1527:8	handl	NN	O	O
to	NEURACEQ.xml:S2:1536:2	to	TO	O	O
protect	NEURACEQ.xml:S2:1539:7	protect	VB	O	O
patients	NEURACEQ.xml:S2:1547:8	patient	NNS	O	O
and	NEURACEQ.xml:S2:1556:3	and	CC	O	O
health	NEURACEQ.xml:S2:1560:6	health	NN	O	O
care	NEURACEQ.xml:S2:1567:4	care	NN	O	O
workers	NEURACEQ.xml:S2:1572:7	worker	NNS	O	O
from	NEURACEQ.xml:S2:1580:4	from	IN	O	O
unintentional	NEURACEQ.xml:S2:1585:13	unintent	JJ	O	O
radiation	NEURACEQ.xml:S2:1599:9	radiat	NN	O	O
exposure	NEURACEQ.xml:S2:1609:8	exposur	NN	O	O
[	NEURACEQ.xml:S2:1618:1	[	NNP	O	O
see	NEURACEQ.xml:S2:1620:3	see	VBP	O	O
Dosage	NEURACEQ.xml:S2:1625:6	dosag	NNP	O	O
and	NEURACEQ.xml:S2:1632:3	and	CC	O	O
Administration	NEURACEQ.xml:S2:1636:14	administr	NNP	O	O
(	NEURACEQ.xml:S2:1651:1	(	(	O	O
2.1	NEURACEQ.xml:S2:1652:3	2.1	CD	O	O
)	NEURACEQ.xml:S2:1655:1	)	)	O	O
]	NEURACEQ.xml:S2:1660:1	]	NN	O	O
.	NEURACEQ.xml:S2:1661:1	.	.	O	O
6	NORTHERA.xml:S1:4:1	6	CD	O	O
ADVERSE	NORTHERA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	NORTHERA.xml:S1:14:9	reaction	NN	O	O

The	NORTHERA.xml:S1:27:3	the	DT	O	O
following	NORTHERA.xml:S1:31:9	follow	JJ	O	O
adverse	NORTHERA.xml:S1:41:7	advers	JJ	O	O
reactions	NORTHERA.xml:S1:49:9	reaction	NNS	O	O
with	NORTHERA.xml:S1:59:4	with	IN	O	O
NORTHERA	NORTHERA.xml:S1:64:8	northera	NNP	O	O
are	NORTHERA.xml:S1:73:3	are	VBP	O	O
included	NORTHERA.xml:S1:77:8	includ	VBN	O	O
in	NORTHERA.xml:S1:86:2	in	IN	O	O
more	NORTHERA.xml:S1:89:4	more	JJR	O	O
detail	NORTHERA.xml:S1:94:6	detail	NN	O	O
in	NORTHERA.xml:S1:101:2	in	IN	O	O
the	NORTHERA.xml:S1:104:3	the	DT	O	O
Warnings	NORTHERA.xml:S1:108:8	warn	NNP	O	O
and	NORTHERA.xml:S1:117:3	and	CC	O	O
Precautions	NORTHERA.xml:S1:121:11	precaut	NNP	O	O
section	NORTHERA.xml:S1:133:7	section	NN	O	O
of	NORTHERA.xml:S1:141:2	of	IN	O	O
the	NORTHERA.xml:S1:144:3	the	DT	O	O
label	NORTHERA.xml:S1:148:5	label	NN	O	O
:	NORTHERA.xml:S1:153:1	:	:	O	O

Supine	NORTHERA.xml:S1:162:6	supin	NNP	B-AdverseReaction	B-AdverseReaction
Hypertension	NORTHERA.xml:S1:169:12	hypertens	NNP	I-AdverseReaction	I-AdverseReaction
[	NORTHERA.xml:S1:182:1	[	NNP	O	O
see	NORTHERA.xml:S1:183:3	see	VBP	O	O
Warnings	NORTHERA.xml:S1:187:8	warn	NNP	O	O
and	NORTHERA.xml:S1:196:3	and	CC	O	O
Precautions	NORTHERA.xml:S1:200:11	precaut	NNP	O	O
(	NORTHERA.xml:S1:212:1	(	(	O	O
5.1	NORTHERA.xml:S1:215:3	5.1	CD	O	O
)]	NORTHERA.xml:S1:220:2	)]	NN	O	O

Hyperpyrexia	NORTHERA.xml:S1:229:12	hyperpyrexia	NNP	B-AdverseReaction	O
and	NORTHERA.xml:S1:242:3	and	CC	O	O
Confusion	NORTHERA.xml:S1:246:9	confus	NNP	B-AdverseReaction	O
[	NORTHERA.xml:S1:256:1	[	NNP	O	O
see	NORTHERA.xml:S1:257:3	see	VBP	O	O
Warnings	NORTHERA.xml:S1:261:8	warn	NNP	O	O
and	NORTHERA.xml:S1:270:3	and	CC	O	O
Precautions	NORTHERA.xml:S1:274:11	precaut	NNP	O	O
(	NORTHERA.xml:S1:286:1	(	(	O	O
5.2	NORTHERA.xml:S1:289:3	5.2	CD	O	O
)]	NORTHERA.xml:S1:294:2	)]	NN	O	O

May	NORTHERA.xml:S1:303:3	may	NNP	O	O
exacerbate	NORTHERA.xml:S1:307:10	exacerb	VB	B-AdverseReaction	B-AdverseReaction
existing	NORTHERA.xml:S1:318:8	exist	VBG	O	O
ischemic	NORTHERA.xml:S1:327:8	ischem	JJ	I-AdverseReaction	O
heart	NORTHERA.xml:S1:336:5	heart	NN	I-AdverseReaction	O
disease	NORTHERA.xml:S1:342:7	diseas	NN	I-AdverseReaction	O
,	NORTHERA.xml:S1:349:1	,	,	O	O
arrhythmias	NORTHERA.xml:S1:351:11	arrhythmia	NN	I-AdverseReaction	B-AdverseReaction
,	NORTHERA.xml:S1:362:1	,	,	O	O
and	NORTHERA.xml:S1:364:3	and	CC	O	O
congestive	NORTHERA.xml:S1:368:10	congest	JJ	I-AdverseReaction	B-AdverseReaction
heart	NORTHERA.xml:S1:379:5	heart	NN	I-AdverseReaction	I-AdverseReaction
failure	NORTHERA.xml:S1:385:7	failur	NN	I-AdverseReaction	I-AdverseReaction
[	NORTHERA.xml:S1:393:1	[	NNP	O	O
see	NORTHERA.xml:S1:394:3	see	VBP	O	O
Warnings	NORTHERA.xml:S1:398:8	warn	NNP	O	O
and	NORTHERA.xml:S1:407:3	and	CC	O	O
Precautions	NORTHERA.xml:S1:411:11	precaut	NNP	O	O
(	NORTHERA.xml:S1:423:1	(	(	O	O
5.3	NORTHERA.xml:S1:426:3	5.3	CD	O	O
)]	NORTHERA.xml:S1:431:2	)]	NN	O	O

EXCERPT	NORTHERA.xml:S1:442:7	excerpt	NN	O	O
:	NORTHERA.xml:S1:449:1	:	:	O	O
Headache	NORTHERA.xml:S1:453:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
,	NORTHERA.xml:S1:461:1	,	,	O	O
dizziness	NORTHERA.xml:S1:463:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	NORTHERA.xml:S1:472:1	,	,	O	O
nausea	NORTHERA.xml:S1:474:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	NORTHERA.xml:S1:480:1	,	,	O	O
hypertension	NORTHERA.xml:S1:482:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	NORTHERA.xml:S1:494:1	,	,	O	O
and	NORTHERA.xml:S1:496:3	and	CC	O	O
fatigue	NORTHERA.xml:S1:500:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
(	NORTHERA.xml:S1:508:1	(	(	O	O
greater	NORTHERA.xml:S1:509:7	greater	JJR	O	O
than	NORTHERA.xml:S1:517:4	than	IN	O	O
5%	NORTHERA.xml:S1:522:2	5%	CD	O	O
)	NORTHERA.xml:S1:524:1	)	)	O	O
(	NORTHERA.xml:S1:526:1	(	(	O	O
6.1	NORTHERA.xml:S1:529:3	6.1	CD	O	O
)	NORTHERA.xml:S1:534:1	)	)	O	O

To	NORTHERA.xml:S1:542:2	To	TO	O	O

report	NORTHERA.xml:S1:545:6	report	NN	O	O
SUSPECTED	NORTHERA.xml:S1:552:9	suspect	NNP	O	O
ADVERSE	NORTHERA.xml:S1:562:7	advers	NNP	O	O
REACTIONS	NORTHERA.xml:S1:570:9	reaction	NNP	O	O
,	NORTHERA.xml:S1:579:1	,	,	O	O
contact	NORTHERA.xml:S1:581:7	contact	NN	O	O
Lundbeck	NORTHERA.xml:S1:589:8	lundbeck	NNP	O	O
at	NORTHERA.xml:S1:598:2	at	IN	O	O
1	NORTHERA.xml:S1:601:1	1	CD	O	O
-	NORTHERA.xml:S1:602:1	-	:	O	O
800	NORTHERA.xml:S1:603:3	800	CD	O	O
-	NORTHERA.xml:S1:606:1	-	:	O	O
455	NORTHERA.xml:S1:607:3	455	CD	O	O
-	NORTHERA.xml:S1:610:1	-	:	O	O
1141	NORTHERA.xml:S1:611:4	1141	CD	O	O
or	NORTHERA.xml:S1:616:2	or	CC	O	O
FDA	NORTHERA.xml:S1:619:3	fda	NNP	O	O
at	NORTHERA.xml:S1:623:2	at	IN	O	O
1	NORTHERA.xml:S1:626:1	1	CD	O	O
-	NORTHERA.xml:S1:627:1	-	:	O	O
800	NORTHERA.xml:S1:628:3	800	CD	O	O
-	NORTHERA.xml:S1:631:1	-	:	O	O
FDA	NORTHERA.xml:S1:632:3	fda	NNP	O	O
-	NORTHERA.xml:S1:635:1	-	:	O	O
1088	NORTHERA.xml:S1:636:4	1088	CD	O	O
or	NORTHERA.xml:S1:641:2	or	CC	O	O
www	NORTHERA.xml:S1:645:3	www	VB	O	O
.	NORTHERA.xml:S1:648:1	.	.	O	O
fda	NORTHERA.xml:S1:649:3	fda	NN	O	O
.	NORTHERA.xml:S1:652:1	.	.	O	O
gov	NORTHERA.xml:S1:653:3	gov	JJ	O	O
medwatch	NORTHERA.xml:S1:657:8	medwatch	NN	O	O
.	NORTHERA.xml:S1:665:1	.	.	O	O

6.1	NORTHERA.xml:S1:681:3	6.1	CD	O	O

Clinical	NORTHERA.xml:S1:685:8	clinic	JJ	O	O
Trials	NORTHERA.xml:S1:694:6	trial	NNS	O	O
Experience	NORTHERA.xml:S1:701:10	experi	NN	O	O

Because	NORTHERA.xml:S1:715:7	becaus	IN	O	O
clinical	NORTHERA.xml:S1:723:8	clinic	JJ	O	O
trials	NORTHERA.xml:S1:732:6	trial	NNS	O	O
are	NORTHERA.xml:S1:739:3	are	VBP	O	O
conducted	NORTHERA.xml:S1:743:9	conduct	VBN	O	O
under	NORTHERA.xml:S1:753:5	under	IN	O	O
widely	NORTHERA.xml:S1:759:6	wide	RB	O	O
varying	NORTHERA.xml:S1:766:7	vari	VBG	O	O
conditions	NORTHERA.xml:S1:774:10	condit	NNS	O	O
,	NORTHERA.xml:S1:784:1	,	,	O	O
adverse	NORTHERA.xml:S1:786:7	advers	JJ	O	O
reaction	NORTHERA.xml:S1:794:8	reaction	NN	O	O
rates	NORTHERA.xml:S1:803:5	rate	NNS	O	O
observed	NORTHERA.xml:S1:809:8	observ	VBD	O	O
in	NORTHERA.xml:S1:818:2	in	IN	O	O
the	NORTHERA.xml:S1:821:3	the	DT	O	O
clinical	NORTHERA.xml:S1:825:8	clinic	JJ	O	O
trials	NORTHERA.xml:S1:834:6	trial	NNS	O	O
of	NORTHERA.xml:S1:841:2	of	IN	O	O
a	NORTHERA.xml:S1:844:1	a	DT	O	O
drug	NORTHERA.xml:S1:846:4	drug	NN	O	O
cannot	NORTHERA.xml:S1:851:6	cannot	NN	O	O
be	NORTHERA.xml:S1:858:2	be	VB	O	O
directly	NORTHERA.xml:S1:861:8	directli	RB	O	O
compared	NORTHERA.xml:S1:870:8	compar	VBN	O	O
to	NORTHERA.xml:S1:879:2	to	TO	O	O
rates	NORTHERA.xml:S1:882:5	rate	NNS	O	O
in	NORTHERA.xml:S1:888:2	in	IN	O	O
the	NORTHERA.xml:S1:891:3	the	DT	O	O
clinical	NORTHERA.xml:S1:895:8	clinic	JJ	O	O
trials	NORTHERA.xml:S1:904:6	trial	NNS	O	O
of	NORTHERA.xml:S1:911:2	of	IN	O	O
another	NORTHERA.xml:S1:914:7	anoth	DT	O	O
drug	NORTHERA.xml:S1:922:4	drug	NN	O	O
and	NORTHERA.xml:S1:927:3	and	CC	O	O
may	NORTHERA.xml:S1:931:3	may	MD	O	O
not	NORTHERA.xml:S1:935:3	not	RB	O	O
reflect	NORTHERA.xml:S1:939:7	reflect	VB	O	O
the	NORTHERA.xml:S1:947:3	the	DT	O	O
rates	NORTHERA.xml:S1:951:5	rate	NNS	O	O
observed	NORTHERA.xml:S1:957:8	observ	VBD	O	O
in	NORTHERA.xml:S1:966:2	in	IN	O	O
clinical	NORTHERA.xml:S1:969:8	clinic	JJ	O	O
practice	NORTHERA.xml:S1:978:8	practic	NN	O	O
.	NORTHERA.xml:S1:986:1	.	.	O	O

The	NORTHERA.xml:S1:992:3	the	DT	O	O
safety	NORTHERA.xml:S1:996:6	safeti	NN	O	O
evaluation	NORTHERA.xml:S1:1003:10	evalu	NN	O	O
of	NORTHERA.xml:S1:1014:2	of	IN	O	O
NORTHERA	NORTHERA.xml:S1:1017:8	northera	NNP	O	O
is	NORTHERA.xml:S1:1026:2	is	VBZ	O	O
based	NORTHERA.xml:S1:1029:5	base	VBN	O	O
on	NORTHERA.xml:S1:1035:2	on	IN	O	O
two	NORTHERA.xml:S1:1038:3	two	CD	O	O
placebo	NORTHERA.xml:S1:1042:7	placebo	NN	O	O
-	NORTHERA.xml:S1:1049:1	-	:	O	O
controlled	NORTHERA.xml:S1:1050:10	control	VBN	O	O
studies	NORTHERA.xml:S1:1061:7	studi	NNS	O	O
1	NORTHERA.xml:S1:1069:1	1	CD	O	O
to	NORTHERA.xml:S1:1071:2	to	TO	O	O
2	NORTHERA.xml:S1:1074:1	2	CD	O	O
weeks	NORTHERA.xml:S1:1076:5	week	NNS	O	O
in	NORTHERA.xml:S1:1082:2	in	IN	O	O
duration	NORTHERA.xml:S1:1085:8	durat	NN	O	O
(	NORTHERA.xml:S1:1094:1	(	(	O	O
Studies	NORTHERA.xml:S1:1095:7	studi	NNPS	O	O
301	NORTHERA.xml:S1:1103:3	301	CD	O	O
and	NORTHERA.xml:S1:1107:3	and	CC	O	O
302	NORTHERA.xml:S1:1111:3	302	CD	O	O
)	NORTHERA.xml:S1:1114:1	)	)	O	O
,	NORTHERA.xml:S1:1115:1	,	,	O	O
one	NORTHERA.xml:S1:1117:3	one	CD	O	O
8	NORTHERA.xml:S1:1121:1	8	CD	O	O
-	NORTHERA.xml:S1:1122:1	-	:	O	O
week	NORTHERA.xml:S1:1123:4	week	NN	O	O
placebo	NORTHERA.xml:S1:1128:7	placebo	NN	O	O
-	NORTHERA.xml:S1:1135:1	-	:	O	O
controlled	NORTHERA.xml:S1:1136:10	control	VBN	O	O
study	NORTHERA.xml:S1:1147:5	studi	NN	O	O
(	NORTHERA.xml:S1:1153:1	(	(	O	O
Study	NORTHERA.xml:S1:1154:5	studi	NNP	O	O
306	NORTHERA.xml:S1:1160:3	306	CD	O	O
)	NORTHERA.xml:S1:1163:1	)	)	O	O
,	NORTHERA.xml:S1:1164:1	,	,	O	O
and	NORTHERA.xml:S1:1166:3	and	CC	O	O
two	NORTHERA.xml:S1:1170:3	two	CD	O	O
long	NORTHERA.xml:S1:1174:4	long	JJ	O	O
-	NORTHERA.xml:S1:1178:1	-	:	O	O
term	NORTHERA.xml:S1:1179:4	term	NN	O	O
,	NORTHERA.xml:S1:1183:1	,	,	O	O
open	NORTHERA.xml:S1:1185:4	open	JJ	O	O
-	NORTHERA.xml:S1:1189:1	-	:	O	O
label	NORTHERA.xml:S1:1190:5	label	NN	O	O
extension	NORTHERA.xml:S1:1196:9	extens	NN	O	O
studies	NORTHERA.xml:S1:1206:7	studi	NNS	O	O
(	NORTHERA.xml:S1:1214:1	(	(	O	O
Studies	NORTHERA.xml:S1:1215:7	studi	NNPS	O	O
303	NORTHERA.xml:S1:1223:3	303	CD	O	O
and	NORTHERA.xml:S1:1227:3	and	CC	O	O
304	NORTHERA.xml:S1:1231:3	304	CD	O	O
)	NORTHERA.xml:S1:1234:1	)	)	O	O
.	NORTHERA.xml:S1:1235:1	.	.	O	O

In	NORTHERA.xml:S1:1238:2	In	IN	O	O
the	NORTHERA.xml:S1:1241:3	the	DT	O	O
placebo	NORTHERA.xml:S1:1245:7	placebo	NN	O	O
-	NORTHERA.xml:S1:1252:1	-	:	O	O
controlled	NORTHERA.xml:S1:1253:10	control	JJ	O	O
studies	NORTHERA.xml:S1:1264:7	studi	NNS	O	O
,	NORTHERA.xml:S1:1271:1	,	,	O	O
a	NORTHERA.xml:S1:1273:1	a	DT	O	O
total	NORTHERA.xml:S1:1275:5	total	NN	O	O
of	NORTHERA.xml:S1:1281:2	of	IN	O	O
485	NORTHERA.xml:S1:1284:3	485	CD	O	O
patients	NORTHERA.xml:S1:1288:8	patient	NNS	O	O
with	NORTHERA.xml:S1:1297:4	with	IN	O	O
Parkinson	NORTHERA.xml:S1:1302:9	parkinson	NNP	O	O
's	NORTHERA.xml:S1:1311:2	's	POS	O	O
disease	NORTHERA.xml:S1:1314:7	diseas	NN	O	O
,	NORTHERA.xml:S1:1321:1	,	,	O	O
multiple	NORTHERA.xml:S1:1323:8	multipl	JJ	O	O
system	NORTHERA.xml:S1:1332:6	system	NN	O	O
atrophy	NORTHERA.xml:S1:1339:7	atrophi	NN	O	O
,	NORTHERA.xml:S1:1346:1	,	,	O	O
pure	NORTHERA.xml:S1:1348:4	pure	JJ	O	B-AdverseReaction
autonomic	NORTHERA.xml:S1:1353:9	autonom	JJ	O	I-AdverseReaction
failure	NORTHERA.xml:S1:1363:7	failur	NN	O	I-AdverseReaction
,	NORTHERA.xml:S1:1370:1	,	,	O	O
dopamine	NORTHERA.xml:S1:1372:8	dopamin	NN	O	O
beta	NORTHERA.xml:S1:1381:4	beta	SYM	O	O
-	NORTHERA.xml:S1:1385:1	-	:	O	O
hydroxylase	NORTHERA.xml:S1:1386:11	hydroxylas	NN	O	O
deficiency	NORTHERA.xml:S1:1398:10	defici	NN	O	O
,	NORTHERA.xml:S1:1408:1	,	,	O	O
or	NORTHERA.xml:S1:1410:2	or	CC	O	O
non	NORTHERA.xml:S1:1413:3	non	SYM	O	O
-	NORTHERA.xml:S1:1416:1	-	:	O	O
diabetic	NORTHERA.xml:S1:1417:8	diabet	JJ	O	O
autonomic	NORTHERA.xml:S1:1426:9	autonom	JJ	O	B-AdverseReaction
neuropathy	NORTHERA.xml:S1:1436:10	neuropathi	NN	O	I-AdverseReaction
were	NORTHERA.xml:S1:1447:4	were	VBD	O	O
randomized	NORTHERA.xml:S1:1452:10	random	VBN	O	O
and	NORTHERA.xml:S1:1463:3	and	CC	O	O
treated	NORTHERA.xml:S1:1467:7	treat	VBN	O	O
,	NORTHERA.xml:S1:1474:1	,	,	O	O
245	NORTHERA.xml:S1:1476:3	245	CD	O	O
with	NORTHERA.xml:S1:1480:4	with	IN	O	O
NORTHERA	NORTHERA.xml:S1:1485:8	northera	NNP	O	O
and	NORTHERA.xml:S1:1494:3	and	CC	O	O
240	NORTHERA.xml:S1:1498:3	240	CD	O	O
with	NORTHERA.xml:S1:1502:4	with	IN	O	O
placebo	NORTHERA.xml:S1:1507:7	placebo	NN	O	O
[	NORTHERA.xml:S1:1516:1	[	NNP	O	O
see	NORTHERA.xml:S1:1517:3	see	VBP	O	O
Clinical	NORTHERA.xml:S1:1521:8	clinic	JJ	O	O
Studies	NORTHERA.xml:S1:1530:7	studi	NNP	O	O
(	NORTHERA.xml:S1:1538:1	(	(	O	O
14	NORTHERA.xml:S1:1541:2	14	CD	O	O
)]	NORTHERA.xml:S1:1545:2	)]	NN	O	O
.	NORTHERA.xml:S1:1549:1	.	.	O	O

Placebo	NORTHERA.xml:S1:1560:7	placebo	NNP	O	O
-	NORTHERA.xml:S1:1567:1	-	:	O	O
Controlled	NORTHERA.xml:S1:1568:10	control	VBD	O	O
Experience	NORTHERA.xml:S1:1586:10	experi	NN	O	O

The	NORTHERA.xml:S1:1605:3	the	DT	O	O
most	NORTHERA.xml:S1:1609:4	most	RBS	O	O
commonly	NORTHERA.xml:S1:1614:8	commonli	RB	O	O
observed	NORTHERA.xml:S1:1623:8	observ	JJ	O	O
adverse	NORTHERA.xml:S1:1632:7	advers	JJ	O	O
reactions	NORTHERA.xml:S1:1640:9	reaction	NNS	O	O
(	NORTHERA.xml:S1:1650:1	(	(	O	O
those	NORTHERA.xml:S1:1651:5	those	DT	O	O
occurring	NORTHERA.xml:S1:1657:9	occur	VBG	O	O
at	NORTHERA.xml:S1:1667:2	at	IN	O	O
an	NORTHERA.xml:S1:1670:2	an	DT	O	O
incidence	NORTHERA.xml:S1:1673:9	incid	NN	O	O
of	NORTHERA.xml:S1:1683:2	of	IN	O	O
greater	NORTHERA.xml:S1:1686:7	greater	JJR	O	O
than	NORTHERA.xml:S1:1694:4	than	IN	O	O
5%	NORTHERA.xml:S1:1699:2	5%	CD	O	O
in	NORTHERA.xml:S1:1703:2	in	IN	O	O
the	NORTHERA.xml:S1:1706:3	the	DT	O	O
NORTHERA	NORTHERA.xml:S1:1710:8	northera	NNP	O	O
group	NORTHERA.xml:S1:1719:5	group	NN	O	O
and	NORTHERA.xml:S1:1725:3	and	CC	O	O
with	NORTHERA.xml:S1:1729:4	with	IN	O	O
at	NORTHERA.xml:S1:1734:2	at	IN	O	O
least	NORTHERA.xml:S1:1737:5	least	JJS	O	O
a	NORTHERA.xml:S1:1743:1	a	DT	O	O
3%	NORTHERA.xml:S1:1745:2	3%	CD	O	O
greater	NORTHERA.xml:S1:1748:7	greater	JJR	O	O
incidence	NORTHERA.xml:S1:1756:9	incid	NN	O	O
in	NORTHERA.xml:S1:1766:2	in	IN	O	O
the	NORTHERA.xml:S1:1769:3	the	DT	O	O
NORTHERA	NORTHERA.xml:S1:1773:8	northera	NNP	O	O
group	NORTHERA.xml:S1:1782:5	group	NN	O	O
than	NORTHERA.xml:S1:1788:4	than	IN	O	O
in	NORTHERA.xml:S1:1793:2	in	IN	O	O
the	NORTHERA.xml:S1:1796:3	the	DT	O	O
placebo	NORTHERA.xml:S1:1800:7	placebo	NN	O	O
group	NORTHERA.xml:S1:1808:5	group	NN	O	O
)	NORTHERA.xml:S1:1813:1	)	)	O	O
in	NORTHERA.xml:S1:1815:2	in	IN	O	O
NORTHERA	NORTHERA.xml:S1:1818:8	northera	NNP	O	O
-	NORTHERA.xml:S1:1826:1	-	:	O	O
treated	NORTHERA.xml:S1:1827:7	treat	VBD	O	O
patients	NORTHERA.xml:S1:1835:8	patient	NNS	O	O
during	NORTHERA.xml:S1:1844:6	dure	IN	O	O
the	NORTHERA.xml:S1:1851:3	the	DT	O	O
three	NORTHERA.xml:S1:1855:5	three	CD	O	O
placebo	NORTHERA.xml:S1:1861:7	placebo	NN	O	O
-	NORTHERA.xml:S1:1868:1	-	:	O	O
controlled	NORTHERA.xml:S1:1869:10	control	VBN	O	O
trials	NORTHERA.xml:S1:1880:6	trial	NNS	O	O
were	NORTHERA.xml:S1:1887:4	were	VBD	O	O
headache	NORTHERA.xml:S1:1892:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	NORTHERA.xml:S1:1900:1	,	,	O	O
dizziness	NORTHERA.xml:S1:1902:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	NORTHERA.xml:S1:1911:1	,	,	O	O
nausea	NORTHERA.xml:S1:1913:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	NORTHERA.xml:S1:1919:1	,	,	O	O
hypertension	NORTHERA.xml:S1:1921:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
.	NORTHERA.xml:S1:1933:1	.	.	O	O

The	NORTHERA.xml:S1:1936:3	the	DT	O	O
most	NORTHERA.xml:S1:1940:4	most	RBS	O	O
common	NORTHERA.xml:S1:1945:6	common	JJ	O	O
adverse	NORTHERA.xml:S1:1952:7	advers	JJ	O	O
reactions	NORTHERA.xml:S1:1960:9	reaction	NNS	O	O
leading	NORTHERA.xml:S1:1970:7	lead	VBG	O	O
to	NORTHERA.xml:S1:1978:2	to	TO	O	O
discontinuation	NORTHERA.xml:S1:1981:15	discontinu	NN	O	O
from	NORTHERA.xml:S1:1997:4	from	IN	O	O
NORTHERA	NORTHERA.xml:S1:2002:8	northera	NNP	O	O
were	NORTHERA.xml:S1:2011:4	were	VBD	O	O
hypertension	NORTHERA.xml:S1:2016:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
or	NORTHERA.xml:S1:2029:2	or	CC	O	O
increased	NORTHERA.xml:S1:2032:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
blood	NORTHERA.xml:S1:2042:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	NORTHERA.xml:S1:2048:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
and	NORTHERA.xml:S1:2057:3	and	CC	O	O
nausea	NORTHERA.xml:S1:2061:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
.	NORTHERA.xml:S1:2067:1	.	.	O	O

Table	NORTHERA.xml:S1:2073:5	tabl	JJ	O	O
1	NORTHERA.xml:S1:2079:1	1	CD	O	O
.	NORTHERA.xml:S1:2080:1	.	.	O	O

Most	NORTHERA.xml:S1:2082:4	most	JJS	O	O
Common	NORTHERA.xml:S1:2087:6	common	JJ	O	O
Adverse	NORTHERA.xml:S1:2094:7	advers	JJ	O	O
Reactions	NORTHERA.xml:S1:2102:9	reaction	NNPS	O	O
Occurring	NORTHERA.xml:S1:2112:9	occur	VBG	O	O
More	NORTHERA.xml:S1:2122:4	more	RBR	O	O
Frequently	NORTHERA.xml:S1:2127:10	frequent	RB	O	O
in	NORTHERA.xml:S1:2138:2	in	IN	O	O
the	NORTHERA.xml:S1:2141:3	the	DT	O	O
NORTHERA	NORTHERA.xml:S1:2145:8	northera	NNP	O	O
Group	NORTHERA.xml:S1:2154:5	group	NNP	O	O

Study	NORTHERA.xml:S1:2183:5	studi	NNP	O	O
301	NORTHERA.xml:S1:2189:3	301	CD	O	O
and	NORTHERA.xml:S1:2193:3	and	CC	O	O
Study	NORTHERA.xml:S1:2197:5	studi	NNP	O	O
302	NORTHERA.xml:S1:2203:3	302	CD	O	O
(	NORTHERA.xml:S1:2210:1	(	(	O	O
1	NORTHERA.xml:S1:2211:1	1	CD	O	O
to	NORTHERA.xml:S1:2213:2	to	TO	O	O
2	NORTHERA.xml:S1:2216:1	2	CD	O	O
Weeks	NORTHERA.xml:S1:2218:5	week	NNP	O	O
Randomized	NORTHERA.xml:S1:2224:10	random	NNP	O	O
Treatment	NORTHERA.xml:S1:2235:9	treatment	NNP	O	O
)	NORTHERA.xml:S1:2244:1	)	)	O	O
Study	NORTHERA.xml:S1:2253:5	studi	NNP	O	O
306	NORTHERA.xml:S1:2259:3	306	CD	O	O
(	NORTHERA.xml:S1:2266:1	(	(	O	O
8	NORTHERA.xml:S1:2267:1	8	CD	O	O
to	NORTHERA.xml:S1:2269:2	to	TO	O	O
10	NORTHERA.xml:S1:2272:2	10	CD	O	O
Weeks	NORTHERA.xml:S1:2275:5	week	NNP	O	O
Randomized	NORTHERA.xml:S1:2281:10	random	NNP	O	O
Treatment	NORTHERA.xml:S1:2292:9	treatment	NNP	O	O
)	NORTHERA.xml:S1:2301:1	)	)	O	O

Placebo	NORTHERA.xml:S1:2313:7	placebo	NNP	O	O
(	NORTHERA.xml:S1:2324:1	(	(	O	O
N	NORTHERA.xml:S1:2325:1	N	NNP	O	O
132	NORTHERA.xml:S1:2327:3	132	CD	O	O
)	NORTHERA.xml:S1:2330:1	)	)	O	O
n	NORTHERA.xml:S1:2337:1	n	FW	O	O
(	NORTHERA.xml:S1:2339:1	(	(	O	O
)	NORTHERA.xml:S1:2341:1	)	)	O	O
NORTHERA	NORTHERA.xml:S1:2350:8	northera	NNP	O	O
(	NORTHERA.xml:S1:2362:1	(	(	O	O
N	NORTHERA.xml:S1:2363:1	N	NNP	O	O
131	NORTHERA.xml:S1:2365:3	131	CD	O	O
)	NORTHERA.xml:S1:2368:1	)	)	O	O
n	NORTHERA.xml:S1:2375:1	n	FW	O	O
(	NORTHERA.xml:S1:2377:1	(	(	O	O
)	NORTHERA.xml:S1:2379:1	)	)	O	O
Placebo	NORTHERA.xml:S1:2388:7	placebo	NNP	O	O
(	NORTHERA.xml:S1:2399:1	(	(	O	O
N	NORTHERA.xml:S1:2400:1	N	NNP	O	O
108	NORTHERA.xml:S1:2402:3	108	CD	O	O
)	NORTHERA.xml:S1:2405:1	)	)	O	O
n	NORTHERA.xml:S1:2412:1	n	FW	O	O
(	NORTHERA.xml:S1:2414:1	(	(	O	O
)	NORTHERA.xml:S1:2416:1	)	)	O	O
NORTHERA	NORTHERA.xml:S1:2425:8	northera	NNP	O	O
(	NORTHERA.xml:S1:2437:1	(	(	O	O
N	NORTHERA.xml:S1:2438:1	N	NNP	O	O
114	NORTHERA.xml:S1:2440:3	114	CD	O	O
)	NORTHERA.xml:S1:2443:1	)	)	O	O

n	NORTHERA.xml:S1:2455:1	n	RB	O	O
(	NORTHERA.xml:S1:2457:1	(	(	O	O
)	NORTHERA.xml:S1:2459:1	)	)	O	O

Headache	NORTHERA.xml:S1:2474:8	headach	$	B-AdverseReaction	B-AdverseReaction
4	NORTHERA.xml:S1:2491:1	4	CD	O	O
(	NORTHERA.xml:S1:2493:1	(	(	O	O
3.0	NORTHERA.xml:S1:2494:3	3.0	CD	O	O
)	NORTHERA.xml:S1:2497:1	)	)	O	O
8	NORTHERA.xml:S1:2508:1	8	CD	O	O
(	NORTHERA.xml:S1:2510:1	(	(	O	O
6.1	NORTHERA.xml:S1:2511:3	6.1	CD	O	O
)	NORTHERA.xml:S1:2514:1	)	)	O	O
8	NORTHERA.xml:S1:2525:1	8	CD	O	O
(	NORTHERA.xml:S1:2527:1	(	(	O	O
7.4	NORTHERA.xml:S1:2528:3	7.4	CD	O	O
)	NORTHERA.xml:S1:2531:1	)	)	O	O
15	NORTHERA.xml:S1:2542:2	15	CD	O	O
(	NORTHERA.xml:S1:2545:1	(	(	O	O
13.2	NORTHERA.xml:S1:2546:4	13.2	CD	O	O
)	NORTHERA.xml:S1:2550:1	)	)	O	O

Dizziness	NORTHERA.xml:S1:2562:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
2	NORTHERA.xml:S1:2579:1	2	CD	O	O
(	NORTHERA.xml:S1:2581:1	(	(	O	O
1.5	NORTHERA.xml:S1:2582:3	1.5	CD	O	O
)	NORTHERA.xml:S1:2585:1	)	)	O	O
5	NORTHERA.xml:S1:2596:1	5	CD	O	O
(	NORTHERA.xml:S1:2598:1	(	(	O	O
3.8	NORTHERA.xml:S1:2599:3	3.8	CD	O	O
)	NORTHERA.xml:S1:2602:1	)	)	O	O
5	NORTHERA.xml:S1:2613:1	5	CD	O	O
(	NORTHERA.xml:S1:2615:1	(	(	O	O
4.6	NORTHERA.xml:S1:2616:3	4.6	CD	O	O
)	NORTHERA.xml:S1:2619:1	)	)	O	O
11	NORTHERA.xml:S1:2630:2	11	CD	O	O
(	NORTHERA.xml:S1:2633:1	(	(	O	O
9.6	NORTHERA.xml:S1:2634:3	9.6	CD	O	O
)	NORTHERA.xml:S1:2637:1	)	)	O	O

Nausea	NORTHERA.xml:S1:2650:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
2	NORTHERA.xml:S1:2667:1	2	CD	O	O
(	NORTHERA.xml:S1:2669:1	(	(	O	O
1.5	NORTHERA.xml:S1:2670:3	1.5	CD	O	O
)	NORTHERA.xml:S1:2673:1	)	)	O	O
2	NORTHERA.xml:S1:2684:1	2	CD	O	O
(	NORTHERA.xml:S1:2686:1	(	(	O	O
1.5	NORTHERA.xml:S1:2687:3	1.5	CD	O	O
)	NORTHERA.xml:S1:2690:1	)	)	O	O
5	NORTHERA.xml:S1:2701:1	5	CD	O	O
(	NORTHERA.xml:S1:2703:1	(	(	O	O
4.6	NORTHERA.xml:S1:2704:3	4.6	CD	O	O
)	NORTHERA.xml:S1:2707:1	)	)	O	O
10	NORTHERA.xml:S1:2718:2	10	CD	O	O
(	NORTHERA.xml:S1:2721:1	(	(	O	O
8.8	NORTHERA.xml:S1:2722:3	8.8	CD	O	O
)	NORTHERA.xml:S1:2725:1	)	)	O	O

Hypertension	NORTHERA.xml:S1:2738:12	hypertens	NNP	B-AdverseReaction	B-AdverseReaction
0	NORTHERA.xml:S1:2755:1	0	CD	O	O
2	NORTHERA.xml:S1:2772:1	2	CD	O	O
(	NORTHERA.xml:S1:2774:1	(	(	O	O
1.5	NORTHERA.xml:S1:2775:3	1.5	CD	O	O
)	NORTHERA.xml:S1:2778:1	)	)	O	O
1	NORTHERA.xml:S1:2789:1	1	CD	O	O
(	NORTHERA.xml:S1:2791:1	(	(	O	O
0.9	NORTHERA.xml:S1:2792:3	0.9	CD	O	O
)	NORTHERA.xml:S1:2795:1	)	)	O	O
8	NORTHERA.xml:S1:2806:1	8	CD	O	O
(	NORTHERA.xml:S1:2808:1	(	(	O	O
7.0	NORTHERA.xml:S1:2809:3	7.0	CD	O	O
)	NORTHERA.xml:S1:2812:1	)	)	O	O

Note	NORTHERA.xml:S1:2833:4	note	NN	O	O
:	NORTHERA.xml:S1:2837:1	:	:	O	O
n	NORTHERA.xml:S1:2839:1	n	JJ	O	O
number	NORTHERA.xml:S1:2841:6	number	NN	O	O
of	NORTHERA.xml:S1:2848:2	of	IN	O	O
patients	NORTHERA.xml:S1:2851:8	patient	NNS	O	O
.	NORTHERA.xml:S1:2859:1	.	.	O	O

Table	NORTHERA.xml:S1:2862:5	tabl	JJ	O	O
displays	NORTHERA.xml:S1:2868:8	display	NNS	O	O
adverse	NORTHERA.xml:S1:2877:7	advers	JJ	O	O
reactions	NORTHERA.xml:S1:2885:9	reaction	NNS	O	O
that	NORTHERA.xml:S1:2895:4	that	WDT	O	O
were	NORTHERA.xml:S1:2900:4	were	VBD	O	O
reported	NORTHERA.xml:S1:2905:8	report	VBN	O	O
in	NORTHERA.xml:S1:2914:2	in	IN	O	O
greater	NORTHERA.xml:S1:2917:7	greater	JJR	O	O
than	NORTHERA.xml:S1:2925:4	than	IN	O	O
5%	NORTHERA.xml:S1:2930:2	5%	CD	O	O
of	NORTHERA.xml:S1:2933:2	of	IN	O	O
patients	NORTHERA.xml:S1:2936:8	patient	NNS	O	O
in	NORTHERA.xml:S1:2945:2	in	IN	O	O
the	NORTHERA.xml:S1:2948:3	the	DT	O	O
NORTHERA	NORTHERA.xml:S1:2952:8	northera	NNP	O	O
group	NORTHERA.xml:S1:2961:5	group	NN	O	O
and	NORTHERA.xml:S1:2967:3	and	CC	O	O
with	NORTHERA.xml:S1:2971:4	with	IN	O	O
at	NORTHERA.xml:S1:2976:2	at	IN	O	O
least	NORTHERA.xml:S1:2979:5	least	JJS	O	O
a	NORTHERA.xml:S1:2985:1	a	DT	O	O
3%	NORTHERA.xml:S1:2987:2	3%	CD	O	O
greater	NORTHERA.xml:S1:2990:7	greater	JJR	O	O
incidence	NORTHERA.xml:S1:2998:9	incid	NN	O	O
in	NORTHERA.xml:S1:3008:2	in	IN	O	O
the	NORTHERA.xml:S1:3011:3	the	DT	O	O
NORTHERA	NORTHERA.xml:S1:3015:8	northera	NNP	O	O
group	NORTHERA.xml:S1:3024:5	group	NN	O	O
than	NORTHERA.xml:S1:3030:4	than	IN	O	O
in	NORTHERA.xml:S1:3035:2	in	IN	O	O
the	NORTHERA.xml:S1:3038:3	the	DT	O	O
placebo	NORTHERA.xml:S1:3042:7	placebo	NN	O	O
group	NORTHERA.xml:S1:3050:5	group	NN	O	O
.	NORTHERA.xml:S1:3055:1	.	.	O	O

Long	NORTHERA.xml:S1:3065:4	long	RB	O	O

-	NORTHERA.xml:S1:3069:1	-	:	O	O
Term	NORTHERA.xml:S1:3070:4	term	NN	O	O
,	NORTHERA.xml:S1:3074:1	,	,	O	O
Open	NORTHERA.xml:S1:3076:4	open	NNP	O	O
-	NORTHERA.xml:S1:3080:1	-	:	O	O
Label	NORTHERA.xml:S1:3081:5	label	NN	O	O
Trials	NORTHERA.xml:S1:3087:6	trial	NNS	O	O
with	NORTHERA.xml:S1:3094:4	with	IN	O	O
NORTHERA	NORTHERA.xml:S1:3099:8	northera	NNP	O	O
In	NORTHERA.xml:S1:3111:2	In	IN	O	O
the	NORTHERA.xml:S1:3114:3	the	DT	O	O
long	NORTHERA.xml:S1:3118:4	long	JJ	O	O
-	NORTHERA.xml:S1:3122:1	-	:	O	O
term	NORTHERA.xml:S1:3123:4	term	NN	O	O
,	NORTHERA.xml:S1:3127:1	,	,	O	O
open	NORTHERA.xml:S1:3129:4	open	JJ	O	O
-	NORTHERA.xml:S1:3133:1	-	:	O	O
label	NORTHERA.xml:S1:3134:5	label	NN	O	O
extension	NORTHERA.xml:S1:3140:9	extens	NN	O	O
studies	NORTHERA.xml:S1:3150:7	studi	NNS	O	O
,	NORTHERA.xml:S1:3157:1	,	,	O	O
a	NORTHERA.xml:S1:3159:1	a	DT	O	O
total	NORTHERA.xml:S1:3161:5	total	NN	O	O
of	NORTHERA.xml:S1:3167:2	of	IN	O	O
422	NORTHERA.xml:S1:3170:3	422	CD	O	O
patients	NORTHERA.xml:S1:3174:8	patient	NNS	O	O
,	NORTHERA.xml:S1:3182:1	,	,	O	O
mean	NORTHERA.xml:S1:3184:4	mean	JJ	O	O
age	NORTHERA.xml:S1:3189:3	age	NN	O	O
65	NORTHERA.xml:S1:3193:2	65	CD	O	O
years	NORTHERA.xml:S1:3196:5	year	NNS	O	O
,	NORTHERA.xml:S1:3201:1	,	,	O	O
were	NORTHERA.xml:S1:3203:4	were	VBD	O	O
treated	NORTHERA.xml:S1:3208:7	treat	VBN	O	O
with	NORTHERA.xml:S1:3216:4	with	IN	O	O
NORTHERA	NORTHERA.xml:S1:3221:8	northera	NNP	O	O
for	NORTHERA.xml:S1:3230:3	for	IN	O	O
a	NORTHERA.xml:S1:3234:1	a	DT	O	O
mean	NORTHERA.xml:S1:3236:4	mean	JJ	O	O
total	NORTHERA.xml:S1:3241:5	total	JJ	O	O
exposure	NORTHERA.xml:S1:3247:8	exposur	NN	O	O
of	NORTHERA.xml:S1:3256:2	of	IN	O	O
approximately	NORTHERA.xml:S1:3259:13	approxim	RB	O	O
one	NORTHERA.xml:S1:3273:3	one	CD	O	O
year	NORTHERA.xml:S1:3277:4	year	NN	O	O
.	NORTHERA.xml:S1:3281:1	.	.	O	O

The	NORTHERA.xml:S1:3283:3	the	DT	O	O
commonly	NORTHERA.xml:S1:3287:8	commonli	RB	O	O
reported	NORTHERA.xml:S1:3296:8	report	JJ	O	O
adverse	NORTHERA.xml:S1:3305:7	advers	JJ	O	O
events	NORTHERA.xml:S1:3313:6	event	NNS	O	O
were	NORTHERA.xml:S1:3320:4	were	VBD	O	O
falls	NORTHERA.xml:S1:3325:5	fall	NNS	B-AdverseReaction	B-AdverseReaction
(	NORTHERA.xml:S1:3331:1	(	(	O	O
24%	NORTHERA.xml:S1:3332:3	24%	CD	O	O
)	NORTHERA.xml:S1:3335:1	)	)	O	O
,	NORTHERA.xml:S1:3336:1	,	,	O	O
urinary	NORTHERA.xml:S1:3338:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	NORTHERA.xml:S1:3346:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infections	NORTHERA.xml:S1:3352:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
(	NORTHERA.xml:S1:3363:1	(	(	O	O
15%	NORTHERA.xml:S1:3364:3	15%	CD	O	O
)	NORTHERA.xml:S1:3367:1	)	)	O	O
,	NORTHERA.xml:S1:3368:1	,	,	O	O
headache	NORTHERA.xml:S1:3370:8	headach	NN	B-AdverseReaction	B-AdverseReaction
(	NORTHERA.xml:S1:3379:1	(	(	O	O
13%	NORTHERA.xml:S1:3380:3	13%	CD	O	O
)	NORTHERA.xml:S1:3383:1	)	)	O	O
,	NORTHERA.xml:S1:3384:1	,	,	O	O
syncope	NORTHERA.xml:S1:3386:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
(	NORTHERA.xml:S1:3394:1	(	(	O	O
13%	NORTHERA.xml:S1:3395:3	13%	CD	O	O
)	NORTHERA.xml:S1:3398:1	)	)	O	O
,	NORTHERA.xml:S1:3399:1	,	,	O	O
and	NORTHERA.xml:S1:3401:3	and	CC	O	O
dizziness	NORTHERA.xml:S1:3405:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
(	NORTHERA.xml:S1:3415:1	(	(	O	O
10%	NORTHERA.xml:S1:3416:3	10%	CD	O	O
)	NORTHERA.xml:S1:3419:1	)	)	O	O
.	NORTHERA.xml:S1:3420:1	.	.	O	O
\n\n	NORTHERA.xml:S2:0:2	\n\n	$	O	O
BOXED	NORTHERA.xml:S2:6:5	box	NNP	O	O
WARNING	NORTHERA.xml:S2:12:7	warn	NN	O	O
:	NORTHERA.xml:S2:19:1	:	:	O	O
WARNING	NORTHERA.xml:S2:21:7	warn	NN	O	O
:	NORTHERA.xml:S2:28:1	:	:	O	O
SUPINE	NORTHERA.xml:S2:30:6	supin	NNP	B-AdverseReaction	O
HYPERTENSION	NORTHERA.xml:S2:37:12	hypertens	NNP	I-AdverseReaction	B-AdverseReaction
\n\n	NORTHERA.xml:S2:49:2	\n\n	NNP	O	O
WARNING	NORTHERA.xml:S2:55:7	warn	NN	O	O
:	NORTHERA.xml:S2:62:1	:	:	O	O
SUPINE	NORTHERA.xml:S2:64:6	supin	NNP	B-AdverseReaction	O
HYPERTENSION	NORTHERA.xml:S2:71:12	hypertens	NNP	I-AdverseReaction	B-AdverseReaction
\n\n	NORTHERA.xml:S2:85:2	\n\n	NNP	O	O
Monitor	NORTHERA.xml:S2:91:7	monitor	NNP	O	O
supine	NORTHERA.xml:S2:99:6	supin	JJ	O	O
blood	NORTHERA.xml:S2:106:5	blood	NN	O	O
pressure	NORTHERA.xml:S2:112:8	pressur	NN	O	O
prior	NORTHERA.xml:S2:121:5	prior	RB	O	O
to	NORTHERA.xml:S2:127:2	to	TO	O	O
and	NORTHERA.xml:S2:130:3	and	CC	O	O
during	NORTHERA.xml:S2:134:6	dure	IN	O	O
treatment	NORTHERA.xml:S2:141:9	treatment	NN	O	O
and	NORTHERA.xml:S2:151:3	and	CC	O	O
more	NORTHERA.xml:S2:155:4	more	RBR	O	O
frequently	NORTHERA.xml:S2:160:10	frequent	RB	O	O
when	NORTHERA.xml:S2:171:4	when	WRB	O	O
increasing	NORTHERA.xml:S2:176:10	increas	VBG	O	O
doses	NORTHERA.xml:S2:187:5	dose	NNS	O	O
.	NORTHERA.xml:S2:192:1	.	.	O	O

Elevating	NORTHERA.xml:S2:195:9	elev	VBG	O	O
the	NORTHERA.xml:S2:205:3	the	DT	O	O
head	NORTHERA.xml:S2:209:4	head	NN	O	O
of	NORTHERA.xml:S2:214:2	of	IN	O	O
the	NORTHERA.xml:S2:217:3	the	DT	O	O
bed	NORTHERA.xml:S2:221:3	bed	NN	O	O
lessens	NORTHERA.xml:S2:225:7	lessen	VBZ	O	O
the	NORTHERA.xml:S2:233:3	the	DT	O	O
risk	NORTHERA.xml:S2:237:4	risk	NN	O	O
of	NORTHERA.xml:S2:242:2	of	IN	O	O
supine	NORTHERA.xml:S2:245:6	supin	JJ	O	B-AdverseReaction
hypertension	NORTHERA.xml:S2:252:12	hypertens	NN	O	I-AdverseReaction
,	NORTHERA.xml:S2:264:1	,	,	O	O
and	NORTHERA.xml:S2:266:3	and	CC	O	O
blood	NORTHERA.xml:S2:270:5	blood	NN	O	O
pressure	NORTHERA.xml:S2:276:8	pressur	NN	O	O
should	NORTHERA.xml:S2:285:6	should	MD	O	O
be	NORTHERA.xml:S2:292:2	be	VB	O	O
measured	NORTHERA.xml:S2:295:8	measur	VBN	O	O
in	NORTHERA.xml:S2:304:2	in	IN	O	O
this	NORTHERA.xml:S2:307:4	thi	DT	O	O
position	NORTHERA.xml:S2:312:8	posit	NN	O	O
.	NORTHERA.xml:S2:320:1	.	.	O	O

If	NORTHERA.xml:S2:323:2	If	IN	O	O
supine	NORTHERA.xml:S2:326:6	supin	JJ	O	O
hypertension	NORTHERA.xml:S2:333:12	hypertens	NN	O	O
cannot	NORTHERA.xml:S2:346:6	cannot	NN	O	O
be	NORTHERA.xml:S2:353:2	be	VB	O	O
managed	NORTHERA.xml:S2:356:7	manag	VBN	O	O
by	NORTHERA.xml:S2:364:2	by	IN	O	O
elevation	NORTHERA.xml:S2:367:9	elev	NN	O	O
of	NORTHERA.xml:S2:377:2	of	IN	O	O
the	NORTHERA.xml:S2:380:3	the	DT	O	O
head	NORTHERA.xml:S2:384:4	head	NN	O	O
of	NORTHERA.xml:S2:389:2	of	IN	O	O
the	NORTHERA.xml:S2:392:3	the	DT	O	O
bed	NORTHERA.xml:S2:396:3	bed	NN	O	O
,	NORTHERA.xml:S2:399:1	,	,	O	O
reduce	NORTHERA.xml:S2:401:6	reduc	VB	O	O
or	NORTHERA.xml:S2:408:2	or	CC	O	O
discontinue	NORTHERA.xml:S2:411:11	discontinu	VB	O	O
NORTHERA	NORTHERA.xml:S2:423:8	northera	NNP	O	O
[	NORTHERA.xml:S2:438:1	[	NNP	O	O
see	NORTHERA.xml:S2:439:3	see	VBP	O	O
Warnings	NORTHERA.xml:S2:443:8	warn	NNP	O	O
and	NORTHERA.xml:S2:452:3	and	CC	O	O
Precautions	NORTHERA.xml:S2:456:11	precaut	NNP	O	O
(	NORTHERA.xml:S2:468:1	(	(	O	O
5.1	NORTHERA.xml:S2:471:3	5.1	CD	O	O
)]	NORTHERA.xml:S2:476:2	)]	NN	O	O
.	NORTHERA.xml:S2:478:1	.	.	O	O

EXCERPT	NORTHERA.xml:S2:490:7	excerpt	NN	O	O
:	NORTHERA.xml:S2:497:1	:	:	O	O
WARNING	NORTHERA.xml:S2:505:7	warn	NN	O	O
:	NORTHERA.xml:S2:512:1	:	:	O	O
SUPINE	NORTHERA.xml:S2:514:6	supin	JJ	B-AdverseReaction	O
HYPERTENSION	NORTHERA.xml:S2:521:12	hypertens	NNP	I-AdverseReaction	O
See	NORTHERA.xml:S2:541:3	see	NNP	O	O
full	NORTHERA.xml:S2:545:4	full	JJ	O	O
prescribing	NORTHERA.xml:S2:550:11	prescrib	VBG	O	O
information	NORTHERA.xml:S2:562:11	inform	NN	O	O
for	NORTHERA.xml:S2:574:3	for	IN	O	O
complete	NORTHERA.xml:S2:578:8	complet	JJ	O	O
boxed	NORTHERA.xml:S2:587:5	box	JJ	O	O
warning	NORTHERA.xml:S2:593:7	warn	NN	O	O
.	NORTHERA.xml:S2:600:1	.	.	O	O

Monitor	NORTHERA.xml:S2:626:7	monitor	NNP	O	O
supine	NORTHERA.xml:S2:634:6	supin	JJ	O	O
blood	NORTHERA.xml:S2:641:5	blood	NN	O	O
pressure	NORTHERA.xml:S2:647:8	pressur	NN	O	O
prior	NORTHERA.xml:S2:656:5	prior	RB	O	O
to	NORTHERA.xml:S2:662:2	to	TO	O	O
and	NORTHERA.xml:S2:665:3	and	CC	O	O
during	NORTHERA.xml:S2:669:6	dure	IN	O	O
treatment	NORTHERA.xml:S2:676:9	treatment	NN	O	O
and	NORTHERA.xml:S2:686:3	and	CC	O	O
more	NORTHERA.xml:S2:690:4	more	RBR	O	O
frequently	NORTHERA.xml:S2:695:10	frequent	RB	O	O
when	NORTHERA.xml:S2:706:4	when	WRB	O	O
increasing	NORTHERA.xml:S2:711:10	increas	VBG	O	O
doses	NORTHERA.xml:S2:722:5	dose	NNS	O	O
.	NORTHERA.xml:S2:727:1	.	.	O	O

Elevating	NORTHERA.xml:S2:730:9	elev	VBG	O	O
the	NORTHERA.xml:S2:740:3	the	DT	O	O
head	NORTHERA.xml:S2:744:4	head	NN	O	O
of	NORTHERA.xml:S2:749:2	of	IN	O	O
the	NORTHERA.xml:S2:752:3	the	DT	O	O
bed	NORTHERA.xml:S2:756:3	bed	NN	O	O
lessens	NORTHERA.xml:S2:760:7	lessen	VBZ	O	O
the	NORTHERA.xml:S2:768:3	the	DT	O	O
risk	NORTHERA.xml:S2:772:4	risk	NN	O	O
of	NORTHERA.xml:S2:777:2	of	IN	O	O
supine	NORTHERA.xml:S2:780:6	supin	JJ	O	B-AdverseReaction
hypertension	NORTHERA.xml:S2:791:12	hypertens	NN	O	I-AdverseReaction
,	NORTHERA.xml:S2:803:1	,	,	O	O
and	NORTHERA.xml:S2:805:3	and	CC	O	O
blood	NORTHERA.xml:S2:809:5	blood	NN	O	O
pressure	NORTHERA.xml:S2:815:8	pressur	NN	O	O
should	NORTHERA.xml:S2:824:6	should	MD	O	O
be	NORTHERA.xml:S2:831:2	be	VB	O	O
measured	NORTHERA.xml:S2:834:8	measur	VBN	O	O
in	NORTHERA.xml:S2:843:2	in	IN	O	O
this	NORTHERA.xml:S2:846:4	thi	DT	O	O
position	NORTHERA.xml:S2:851:8	posit	NN	O	O
.	NORTHERA.xml:S2:859:1	.	.	O	O

If	NORTHERA.xml:S2:862:2	If	IN	O	O
supine	NORTHERA.xml:S2:865:6	supin	JJ	O	O
hypertension	NORTHERA.xml:S2:872:12	hypertens	NN	O	O
cannot	NORTHERA.xml:S2:885:6	cannot	NN	O	O
be	NORTHERA.xml:S2:892:2	be	VB	O	O
managed	NORTHERA.xml:S2:895:7	manag	VBN	O	O
by	NORTHERA.xml:S2:903:2	by	IN	O	O
elevation	NORTHERA.xml:S2:906:9	elev	NN	O	O
of	NORTHERA.xml:S2:916:2	of	IN	O	O
the	NORTHERA.xml:S2:919:3	the	DT	O	O
head	NORTHERA.xml:S2:923:4	head	NN	O	O
of	NORTHERA.xml:S2:928:2	of	IN	O	O
the	NORTHERA.xml:S2:931:3	the	DT	O	O
bed	NORTHERA.xml:S2:935:3	bed	NN	O	O
,	NORTHERA.xml:S2:938:1	,	,	O	O
reduce	NORTHERA.xml:S2:940:6	reduc	VB	O	O
or	NORTHERA.xml:S2:947:2	or	CC	O	O
discontinue	NORTHERA.xml:S2:950:11	discontinu	VB	O	O
NORTHERA	NORTHERA.xml:S2:962:8	northera	NNP	O	O
[	NORTHERA.xml:S2:973:1	[	NNP	O	O
see	NORTHERA.xml:S2:974:3	see	VBP	O	O
Warnings	NORTHERA.xml:S2:978:8	warn	NNP	O	O
and	NORTHERA.xml:S2:987:3	and	CC	O	O
Precautions	NORTHERA.xml:S2:999:11	precaut	NNP	O	O
(	NORTHERA.xml:S2:1011:1	(	(	O	O
5.1	NORTHERA.xml:S2:1014:3	5.1	CD	O	O
)]	NORTHERA.xml:S2:1019:2	)]	NN	O	O
.	NORTHERA.xml:S2:1021:1	.	.	O	O
\n	NORTHERA.xml:S2:1026:1	\n	CC	O	O
5	NORTHERA.xml:S3:4:1	5	CD	O	O
WARNINGS	NORTHERA.xml:S3:6:8	warn	NNP	O	O
AND	NORTHERA.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	NORTHERA.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	NORTHERA.xml:S3:37:7	excerpt	NN	O	O
:	NORTHERA.xml:S3:44:1	:	:	O	O
NORTHERA	NORTHERA.xml:S3:52:8	northera	NN	O	O
can	NORTHERA.xml:S3:61:3	can	MD	O	O
cause	NORTHERA.xml:S3:65:5	caus	VB	O	O
supine	NORTHERA.xml:S3:71:6	supin	JJ	B-AdverseReaction	B-AdverseReaction
hypertension	NORTHERA.xml:S3:78:12	hypertens	NN	I-AdverseReaction	I-AdverseReaction
and	NORTHERA.xml:S3:91:3	and	CC	O	O
may	NORTHERA.xml:S3:95:3	may	MD	O	O
increase	NORTHERA.xml:S3:99:8	increas	VB	O	O
cardiovascular	NORTHERA.xml:S3:108:14	cardiovascular	NN	B-AdverseReaction	O
risk	NORTHERA.xml:S3:123:4	risk	NN	I-AdverseReaction	O
if	NORTHERA.xml:S3:128:2	if	IN	O	O
supine	NORTHERA.xml:S3:131:6	supin	JJ	B-AdverseReaction	O
hypertension	NORTHERA.xml:S3:138:12	hypertens	NN	I-AdverseReaction	O
is	NORTHERA.xml:S3:151:2	is	VBZ	O	O
not	NORTHERA.xml:S3:154:3	not	RB	O	O
well	NORTHERA.xml:S3:158:4	well	RB	O	O
-	NORTHERA.xml:S3:162:1	-	:	O	O
managed	NORTHERA.xml:S3:163:7	manag	VBN	O	O
(	NORTHERA.xml:S3:171:1	(	(	O	O
5.1	NORTHERA.xml:S3:174:3	5.1	CD	O	O
)	NORTHERA.xml:S3:179:1	)	)	O	O
.	NORTHERA.xml:S3:180:1	.	.	O	O

Hyperpyrexia	NORTHERA.xml:S3:187:12	hyperpyrexia	NNP	B-AdverseReaction	O
and	NORTHERA.xml:S3:200:3	and	CC	O	O
confusion	NORTHERA.xml:S3:204:9	confus	NN	B-AdverseReaction	O
(	NORTHERA.xml:S3:214:1	(	(	O	O
5.2	NORTHERA.xml:S3:217:3	5.2	CD	O	O
)	NORTHERA.xml:S3:222:1	)	)	O	O

May	NORTHERA.xml:S3:229:3	may	NNP	O	B-AdverseReaction
exacerbate	NORTHERA.xml:S3:233:10	exacerb	NN	B-AdverseReaction	I-AdverseReaction
symptoms	NORTHERA.xml:S3:244:8	symptom	NNS	O	I-AdverseReaction
in	NORTHERA.xml:S3:253:2	in	IN	O	O
patients	NORTHERA.xml:S3:256:8	patient	NNS	O	O
with	NORTHERA.xml:S3:265:4	with	IN	O	O
existing	NORTHERA.xml:S3:270:8	exist	VBG	O	O
ischemic	NORTHERA.xml:S3:279:8	ischem	JJ	I-AdverseReaction	O
heart	NORTHERA.xml:S3:288:5	heart	NN	I-AdverseReaction	O
disease	NORTHERA.xml:S3:294:7	diseas	NN	I-AdverseReaction	O
,	NORTHERA.xml:S3:301:1	,	,	O	O
arrhythmias	NORTHERA.xml:S3:303:11	arrhythmia	NN	I-AdverseReaction	B-AdverseReaction
,	NORTHERA.xml:S3:314:1	,	,	O	O
and	NORTHERA.xml:S3:316:3	and	CC	O	O
congestive	NORTHERA.xml:S3:320:10	congest	JJ	I-AdverseReaction	B-AdverseReaction
heart	NORTHERA.xml:S3:331:5	heart	NN	I-AdverseReaction	I-AdverseReaction
failure	NORTHERA.xml:S3:337:7	failur	NN	I-AdverseReaction	I-AdverseReaction
(	NORTHERA.xml:S3:345:1	(	(	O	O
5.3	NORTHERA.xml:S3:348:3	5.3	CD	O	O
)	NORTHERA.xml:S3:353:1	)	)	O	O

Allergic	NORTHERA.xml:S3:360:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
reactions	NORTHERA.xml:S3:369:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
(	NORTHERA.xml:S3:379:1	(	(	O	O
5.4	NORTHERA.xml:S3:382:3	5.4	CD	O	O
)	NORTHERA.xml:S3:387:1	)	)	O	O

5.1	NORTHERA.xml:S3:401:3	5.1	CD	O	O

Supine	NORTHERA.xml:S3:405:6	supin	NN	O	O

Hypertension	NORTHERA.xml:S3:412:12	hypertens	NN	O	O

NORTHERA	NORTHERA.xml:S3:430:8	northera	NNP	O	O
therapy	NORTHERA.xml:S3:439:7	therapi	NN	O	O
may	NORTHERA.xml:S3:447:3	may	MD	O	O
cause	NORTHERA.xml:S3:451:5	caus	VB	O	O
or	NORTHERA.xml:S3:457:2	or	CC	O	O
exacerbate	NORTHERA.xml:S3:460:10	exacerb	VB	O	B-AdverseReaction
supine	NORTHERA.xml:S3:471:6	supin	JJ	B-AdverseReaction	I-AdverseReaction
hypertension	NORTHERA.xml:S3:478:12	hypertens	NN	I-AdverseReaction	I-AdverseReaction
in	NORTHERA.xml:S3:491:2	in	IN	O	O
patients	NORTHERA.xml:S3:494:8	patient	NNS	O	O
with	NORTHERA.xml:S3:503:4	with	IN	O	O
NOH	NORTHERA.xml:S3:508:3	noh	NNP	O	O
.	NORTHERA.xml:S3:511:1	.	.	O	O

Patients	NORTHERA.xml:S3:513:8	patient	NNS	O	O
should	NORTHERA.xml:S3:522:6	should	MD	O	O
be	NORTHERA.xml:S3:529:2	be	VB	O	O
advised	NORTHERA.xml:S3:532:7	advis	VBN	O	O
to	NORTHERA.xml:S3:540:2	to	TO	O	O
elevate	NORTHERA.xml:S3:543:7	elev	VB	O	O
the	NORTHERA.xml:S3:551:3	the	DT	O	O
head	NORTHERA.xml:S3:555:4	head	NN	O	O
of	NORTHERA.xml:S3:560:2	of	IN	O	O
the	NORTHERA.xml:S3:563:3	the	DT	O	O
bed	NORTHERA.xml:S3:567:3	bed	NN	O	O
when	NORTHERA.xml:S3:571:4	when	WRB	O	O
resting	NORTHERA.xml:S3:576:7	rest	NN	O	O
or	NORTHERA.xml:S3:584:2	or	CC	O	O
sleeping	NORTHERA.xml:S3:587:8	sleep	NN	O	O
.	NORTHERA.xml:S3:595:1	.	.	O	O

Monitor	NORTHERA.xml:S3:597:7	monitor	NNP	O	O
blood	NORTHERA.xml:S3:605:5	blood	NN	O	O
pressure	NORTHERA.xml:S3:611:8	pressur	NN	O	O
,	NORTHERA.xml:S3:619:1	,	,	O	O
both	NORTHERA.xml:S3:621:4	both	DT	O	O
in	NORTHERA.xml:S3:626:2	in	IN	O	O
the	NORTHERA.xml:S3:629:3	the	DT	O	O
supine	NORTHERA.xml:S3:633:6	supin	JJ	O	O
position	NORTHERA.xml:S3:640:8	posit	NN	O	O
and	NORTHERA.xml:S3:649:3	and	CC	O	O
in	NORTHERA.xml:S3:653:2	in	IN	O	O
the	NORTHERA.xml:S3:656:3	the	DT	O	O
recommended	NORTHERA.xml:S3:660:11	recommend	VBN	O	O
head	NORTHERA.xml:S3:672:4	head	NN	O	O
-	NORTHERA.xml:S3:676:1	-	:	O	O
elevated	NORTHERA.xml:S3:677:8	elev	VBD	O	O
sleeping	NORTHERA.xml:S3:686:8	sleep	JJ	O	O
position	NORTHERA.xml:S3:695:8	posit	NN	O	O
.	NORTHERA.xml:S3:703:1	.	.	O	O

Reduce	NORTHERA.xml:S3:705:6	reduc	NNP	O	O
or	NORTHERA.xml:S3:712:2	or	CC	O	O
discontinue	NORTHERA.xml:S3:715:11	discontinu	VB	O	O
NORTHERA	NORTHERA.xml:S3:727:8	northera	NNP	O	O
if	NORTHERA.xml:S3:736:2	if	IN	O	O
supine	NORTHERA.xml:S3:739:6	supin	JJ	O	O
hypertension	NORTHERA.xml:S3:746:12	hypertens	NN	O	O
persists	NORTHERA.xml:S3:759:8	persist	NNS	O	O
.	NORTHERA.xml:S3:767:1	.	.	O	O

If	NORTHERA.xml:S3:769:2	If	IN	O	O
supine	NORTHERA.xml:S3:772:6	supin	JJ	O	O
hypertension	NORTHERA.xml:S3:779:12	hypertens	NN	O	O
is	NORTHERA.xml:S3:792:2	is	VBZ	O	O
not	NORTHERA.xml:S3:795:3	not	RB	O	O
well	NORTHERA.xml:S3:799:4	well	RB	O	O
-	NORTHERA.xml:S3:803:1	-	:	O	O
managed	NORTHERA.xml:S3:804:7	manag	VBN	O	O
,	NORTHERA.xml:S3:811:1	,	,	O	O
NORTHERA	NORTHERA.xml:S3:813:8	northera	NNP	O	O
may	NORTHERA.xml:S3:822:3	may	MD	O	O
increase	NORTHERA.xml:S3:826:8	increas	VB	O	O
the	NORTHERA.xml:S3:835:3	the	DT	O	O
risk	NORTHERA.xml:S3:839:4	risk	NN	O	O
of	NORTHERA.xml:S3:844:2	of	IN	O	O
cardiovascular	NORTHERA.xml:S3:847:14	cardiovascular	JJ	O	B-AdverseReaction
events	NORTHERA.xml:S3:862:6	event	NNS	O	I-AdverseReaction
.	NORTHERA.xml:S3:868:1	.	.	O	O

5.2	NORTHERA.xml:S3:877:3	5.2	CD	O	O
Hyperpyrexia	NORTHERA.xml:S3:881:12	hyperpyrexia	NNP	O	O
and	NORTHERA.xml:S3:894:3	and	CC	O	O
Confusion	NORTHERA.xml:S3:898:9	confus	NNP	O	O

Post	NORTHERA.xml:S3:913:4	post	NNP	O	O
-	NORTHERA.xml:S3:917:1	-	:	O	O
marketing	NORTHERA.xml:S3:918:9	market	NN	O	O
cases	NORTHERA.xml:S3:928:5	case	NNS	O	O
of	NORTHERA.xml:S3:934:2	of	IN	O	O
a	NORTHERA.xml:S3:937:1	a	DT	O	O
symptom	NORTHERA.xml:S3:939:7	symptom	NN	O	O
complex	NORTHERA.xml:S3:947:7	complex	JJ	O	O
resembling	NORTHERA.xml:S3:955:10	resembl	VBG	O	O
neuroleptic	NORTHERA.xml:S3:966:11	neurolept	JJ	B-AdverseReaction	B-AdverseReaction
malignant	NORTHERA.xml:S3:978:9	malign	JJ	I-AdverseReaction	I-AdverseReaction
syndrome	NORTHERA.xml:S3:988:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
(	NORTHERA.xml:S3:997:1	(	(	O	O
NMS	NORTHERA.xml:S3:998:3	nm	NNP	B-AdverseReaction	B-AdverseReaction
)	NORTHERA.xml:S3:1001:1	)	)	O	O
have	NORTHERA.xml:S3:1003:4	have	VBP	O	O
been	NORTHERA.xml:S3:1008:4	been	VBN	O	O
reported	NORTHERA.xml:S3:1013:8	report	VBN	O	O
with	NORTHERA.xml:S3:1022:4	with	IN	O	O
NORTHERA	NORTHERA.xml:S3:1027:8	northera	NNP	O	O
use	NORTHERA.xml:S3:1036:3	use	NN	O	O
during	NORTHERA.xml:S3:1040:6	dure	IN	O	O
post	NORTHERA.xml:S3:1047:4	post	NN	O	O
-	NORTHERA.xml:S3:1051:1	-	:	O	O
marketing	NORTHERA.xml:S3:1052:9	market	NN	O	O
surveillance	NORTHERA.xml:S3:1062:12	surveil	NN	O	O
in	NORTHERA.xml:S3:1075:2	in	IN	O	O
Japan	NORTHERA.xml:S3:1078:5	japan	NNP	O	O
.	NORTHERA.xml:S3:1083:1	.	.	O	O

Observe	NORTHERA.xml:S3:1086:7	observ	NN	O	O
patients	NORTHERA.xml:S3:1094:8	patient	NNS	O	O
carefully	NORTHERA.xml:S3:1103:9	care	RB	O	O
when	NORTHERA.xml:S3:1113:4	when	WRB	O	O
the	NORTHERA.xml:S3:1118:3	the	DT	O	O
dosage	NORTHERA.xml:S3:1122:6	dosag	NN	O	O
of	NORTHERA.xml:S3:1129:2	of	IN	O	O
NORTHERA	NORTHERA.xml:S3:1132:8	northera	NNP	O	O
is	NORTHERA.xml:S3:1141:2	is	VBZ	O	O
changed	NORTHERA.xml:S3:1144:7	chang	VBN	O	O
or	NORTHERA.xml:S3:1152:2	or	CC	O	O
when	NORTHERA.xml:S3:1155:4	when	WRB	O	O
concomitant	NORTHERA.xml:S3:1160:11	concomit	JJ	O	O
levodopa	NORTHERA.xml:S3:1172:8	levodopa	NN	O	O
is	NORTHERA.xml:S3:1181:2	is	VBZ	O	O
reduced	NORTHERA.xml:S3:1184:7	reduc	VBN	O	O
abruptly	NORTHERA.xml:S3:1192:8	abruptli	RB	O	O
or	NORTHERA.xml:S3:1201:2	or	CC	O	O
discontinued	NORTHERA.xml:S3:1204:12	discontinu	VBN	O	O
,	NORTHERA.xml:S3:1216:1	,	,	O	O
especially	NORTHERA.xml:S3:1218:10	especi	RB	O	O
if	NORTHERA.xml:S3:1229:2	if	IN	O	O
the	NORTHERA.xml:S3:1232:3	the	DT	O	O
patient	NORTHERA.xml:S3:1236:7	patient	NN	O	O
is	NORTHERA.xml:S3:1244:2	is	VBZ	O	O
receiving	NORTHERA.xml:S3:1247:9	receiv	VBG	O	O
neuroleptics	NORTHERA.xml:S3:1257:12	neurolept	NNS	O	O
.	NORTHERA.xml:S3:1269:1	.	.	O	O

NMS	NORTHERA.xml:S3:1275:3	nm	NNP	B-AdverseReaction	O
is	NORTHERA.xml:S3:1279:2	is	VBZ	O	O
an	NORTHERA.xml:S3:1282:2	an	DT	O	O
uncommon	NORTHERA.xml:S3:1285:8	uncommon	JJ	O	O
but	NORTHERA.xml:S3:1294:3	but	CC	O	O
life	NORTHERA.xml:S3:1298:4	life	NN	O	O
-	NORTHERA.xml:S3:1302:1	-	:	O	O
threatening	NORTHERA.xml:S3:1303:11	threaten	JJ	O	O
syndrome	NORTHERA.xml:S3:1315:8	syndrom	JJ	O	O
characterized	NORTHERA.xml:S3:1324:13	character	VBN	O	O
by	NORTHERA.xml:S3:1338:2	by	IN	O	O
fever	NORTHERA.xml:S3:1341:5	fever	NN	B-AdverseReaction	O
or	NORTHERA.xml:S3:1347:2	or	CC	O	O
hyperthermia	NORTHERA.xml:S3:1350:12	hyperthermia	NN	B-AdverseReaction	O
,	NORTHERA.xml:S3:1362:1	,	,	O	O
muscle	NORTHERA.xml:S3:1364:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
rigidity	NORTHERA.xml:S3:1371:8	rigid	NN	I-AdverseReaction	I-AdverseReaction
,	NORTHERA.xml:S3:1379:1	,	,	O	O
involuntary	NORTHERA.xml:S3:1381:11	involuntari	JJ	B-AdverseReaction	B-AdverseReaction
movements	NORTHERA.xml:S3:1393:9	movement	NNS	I-AdverseReaction	I-AdverseReaction
,	NORTHERA.xml:S3:1402:1	,	,	O	O
altered	NORTHERA.xml:S3:1404:7	alter	VBD	B-AdverseReaction	O
consciousness	NORTHERA.xml:S3:1412:13	conscious	NN	I-AdverseReaction	O
,	NORTHERA.xml:S3:1425:1	,	,	O	O
and	NORTHERA.xml:S3:1427:3	and	CC	O	O
mental	NORTHERA.xml:S3:1431:6	mental	JJ	B-AdverseReaction	O
status	NORTHERA.xml:S3:1438:6	statu	NN	I-AdverseReaction	O
changes	NORTHERA.xml:S3:1445:7	chang	NNS	I-AdverseReaction	O
.	NORTHERA.xml:S3:1452:1	.	.	O	O

The	NORTHERA.xml:S3:1455:3	the	DT	O	O
early	NORTHERA.xml:S3:1459:5	earli	JJ	O	O
diagnosis	NORTHERA.xml:S3:1465:9	diagnosi	NN	O	O
of	NORTHERA.xml:S3:1475:2	of	IN	O	O
this	NORTHERA.xml:S3:1478:4	thi	DT	O	O
condition	NORTHERA.xml:S3:1483:9	condit	NN	O	O
is	NORTHERA.xml:S3:1493:2	is	VBZ	O	O
important	NORTHERA.xml:S3:1496:9	import	JJ	O	O
for	NORTHERA.xml:S3:1506:3	for	IN	O	O
the	NORTHERA.xml:S3:1510:3	the	DT	O	O
appropriate	NORTHERA.xml:S3:1514:11	appropri	JJ	O	O
management	NORTHERA.xml:S3:1526:10	manag	NN	O	O
of	NORTHERA.xml:S3:1537:2	of	IN	O	O
these	NORTHERA.xml:S3:1540:5	these	DT	O	O
patients	NORTHERA.xml:S3:1546:8	patient	NNS	O	O
.	NORTHERA.xml:S3:1554:1	.	.	O	O

5.3	NORTHERA.xml:S3:1563:3	5.3	CD	O	O
Ischemic	NORTHERA.xml:S3:1567:8	ischem	NNP	O	O
Heart	NORTHERA.xml:S3:1576:5	heart	NNP	O	O
Disease	NORTHERA.xml:S3:1582:7	diseas	NNP	O	O
,	NORTHERA.xml:S3:1589:1	,	,	O	O
Arrhythmias	NORTHERA.xml:S3:1591:11	arrhythmia	NNP	O	O
,	NORTHERA.xml:S3:1602:1	,	,	O	O
and	NORTHERA.xml:S3:1604:3	and	CC	O	O
Congestive	NORTHERA.xml:S3:1608:10	congest	NNP	O	O
Heart	NORTHERA.xml:S3:1619:5	heart	NNP	O	O
Failure	NORTHERA.xml:S3:1625:7	failur	NN	O	O

NORTHERA	NORTHERA.xml:S3:1638:8	northera	NNP	O	O
may	NORTHERA.xml:S3:1647:3	may	MD	O	O
exacerbate	NORTHERA.xml:S3:1651:10	exacerb	VB	B-AdverseReaction	B-AdverseReaction
existing	NORTHERA.xml:S3:1662:8	exist	VBG	O	O
ischemic	NORTHERA.xml:S3:1671:8	ischem	JJ	I-AdverseReaction	O
heart	NORTHERA.xml:S3:1680:5	heart	NN	I-AdverseReaction	O
disease	NORTHERA.xml:S3:1686:7	diseas	NN	I-AdverseReaction	O
,	NORTHERA.xml:S3:1693:1	,	,	O	O
arrhythmias	NORTHERA.xml:S3:1695:11	arrhythmia	NN	I-AdverseReaction	B-AdverseReaction
,	NORTHERA.xml:S3:1706:1	,	,	O	O
and	NORTHERA.xml:S3:1708:3	and	CC	O	O
congestive	NORTHERA.xml:S3:1712:10	congest	JJ	I-AdverseReaction	B-AdverseReaction
heart	NORTHERA.xml:S3:1723:5	heart	NN	I-AdverseReaction	I-AdverseReaction
failure	NORTHERA.xml:S3:1729:7	failur	NN	I-AdverseReaction	I-AdverseReaction
.	NORTHERA.xml:S3:1736:1	.	.	O	O

Careful	NORTHERA.xml:S3:1739:7	care	JJ	O	O
consideration	NORTHERA.xml:S3:1747:13	consider	NN	O	O
should	NORTHERA.xml:S3:1761:6	should	MD	O	O
be	NORTHERA.xml:S3:1768:2	be	VB	O	O
given	NORTHERA.xml:S3:1771:5	given	VBN	O	O
to	NORTHERA.xml:S3:1777:2	to	TO	O	O
this	NORTHERA.xml:S3:1780:4	thi	DT	O	O
potential	NORTHERA.xml:S3:1785:9	potenti	JJ	O	O
risk	NORTHERA.xml:S3:1795:4	risk	NN	O	O
prior	NORTHERA.xml:S3:1800:5	prior	RB	O	O
to	NORTHERA.xml:S3:1806:2	to	TO	O	O
initiating	NORTHERA.xml:S3:1809:10	initi	VBG	O	O
therapy	NORTHERA.xml:S3:1820:7	therapi	NN	O	O
in	NORTHERA.xml:S3:1828:2	in	IN	O	O
patients	NORTHERA.xml:S3:1831:8	patient	NNS	O	O
with	NORTHERA.xml:S3:1840:4	with	IN	O	O
these	NORTHERA.xml:S3:1845:5	these	DT	O	O
conditions	NORTHERA.xml:S3:1851:10	condit	NNS	O	O
.	NORTHERA.xml:S3:1861:1	.	.	O	O

5.4	NORTHERA.xml:S3:1870:3	5.4	CD	O	O
Allergic	NORTHERA.xml:S3:1874:8	allerg	NNP	O	O
Reactions	NORTHERA.xml:S3:1883:9	reaction	NNS	O	O

This	NORTHERA.xml:S3:1898:4	thi	DT	O	O
product	NORTHERA.xml:S3:1903:7	product	NN	O	O
contains	NORTHERA.xml:S3:1911:8	contain	VBZ	O	O
FD	NORTHERA.xml:S3:1920:2	FD	NNP	O	O
C	NORTHERA.xml:S3:1923:1	C	NNP	O	O
Yellow	NORTHERA.xml:S3:1925:6	yellow	NNP	O	O
No	NORTHERA.xml:S3:1932:2	No	NNP	O	O
.	NORTHERA.xml:S3:1934:1	.	.	O	O

5	NORTHERA.xml:S3:1936:1	5	CD	O	O
(	NORTHERA.xml:S3:1938:1	(	(	O	O
tartrazine	NORTHERA.xml:S3:1939:10	tartrazin	NN	O	O
)	NORTHERA.xml:S3:1949:1	)	)	O	O
which	NORTHERA.xml:S3:1951:5	which	WDT	O	O
may	NORTHERA.xml:S3:1957:3	may	MD	O	O
cause	NORTHERA.xml:S3:1961:5	caus	VB	O	O
allergic	NORTHERA.xml:S3:1967:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
-	NORTHERA.xml:S3:1975:1	-	:	I-AdverseReaction	I-AdverseReaction
type	NORTHERA.xml:S3:1976:4	type	NN	I-AdverseReaction	I-AdverseReaction
reactions	NORTHERA.xml:S3:1981:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
(	NORTHERA.xml:S3:1991:1	(	(	O	O
including	NORTHERA.xml:S3:1992:9	includ	VBG	O	O
bronchial	NORTHERA.xml:S3:2002:9	bronchial	JJ	B-AdverseReaction	O
asthma	NORTHERA.xml:S3:2012:6	asthma	NN	I-AdverseReaction	O
)	NORTHERA.xml:S3:2018:1	)	)	O	O
in	NORTHERA.xml:S3:2020:2	in	IN	O	O
certain	NORTHERA.xml:S3:2023:7	certain	JJ	O	O
susceptible	NORTHERA.xml:S3:2031:11	suscept	JJ	O	O
persons	NORTHERA.xml:S3:2043:7	person	NNS	O	O
.	NORTHERA.xml:S3:2050:1	.	.	O	O

Although	NORTHERA.xml:S3:2052:8	although	IN	O	O
the	NORTHERA.xml:S3:2061:3	the	DT	O	O
overall	NORTHERA.xml:S3:2065:7	overal	JJ	O	O
incidence	NORTHERA.xml:S3:2073:9	incid	NN	O	O
of	NORTHERA.xml:S3:2083:2	of	IN	O	O
FD	NORTHERA.xml:S3:2086:2	FD	NNP	O	O
C	NORTHERA.xml:S3:2089:1	C	NNP	O	O
Yellow	NORTHERA.xml:S3:2091:6	yellow	NNP	O	O
No	NORTHERA.xml:S3:2098:2	No	NNP	O	O
.	NORTHERA.xml:S3:2100:1	.	.	O	O

5	NORTHERA.xml:S3:2102:1	5	CD	O	O
(	NORTHERA.xml:S3:2104:1	(	(	O	O
tartrazine	NORTHERA.xml:S3:2105:10	tartrazin	NN	O	O
)	NORTHERA.xml:S3:2115:1	)	)	O	O
sensitivity	NORTHERA.xml:S3:2117:11	sensit	NN	O	O
in	NORTHERA.xml:S3:2129:2	in	IN	O	O
the	NORTHERA.xml:S3:2132:3	the	DT	O	O
general	NORTHERA.xml:S3:2136:7	gener	JJ	O	O
population	NORTHERA.xml:S3:2144:10	popul	NN	O	O
is	NORTHERA.xml:S3:2155:2	is	VBZ	O	O
low	NORTHERA.xml:S3:2158:3	low	JJ	O	O
,	NORTHERA.xml:S3:2161:1	,	,	O	O
it	NORTHERA.xml:S3:2163:2	it	PRP	O	O
is	NORTHERA.xml:S3:2166:2	is	VBZ	O	O
frequently	NORTHERA.xml:S3:2169:10	frequent	RB	O	O
seen	NORTHERA.xml:S3:2180:4	seen	VBN	O	O
in	NORTHERA.xml:S3:2185:2	in	IN	O	O
patients	NORTHERA.xml:S3:2188:8	patient	NNS	O	O
who	NORTHERA.xml:S3:2197:3	who	WP	O	O
also	NORTHERA.xml:S3:2201:4	also	RB	O	O
have	NORTHERA.xml:S3:2206:4	have	VBP	O	O
aspirin	NORTHERA.xml:S3:2211:7	aspirin	VBN	O	O
hypersensitivity	NORTHERA.xml:S3:2219:16	hypersensit	NN	O	O
.	NORTHERA.xml:S3:2235:1	.	.	O	O
6	NULOJIX.xml:S1:4:1	6	CD	O	O
ADVERSE	NULOJIX.xml:S1:6:7	advers	JJ	O	O
REACTIONS	NULOJIX.xml:S1:14:9	reaction	NN	O	O

The	NULOJIX.xml:S1:27:3	the	DT	O	O
most	NULOJIX.xml:S1:31:4	most	RBS	O	O
serious	NULOJIX.xml:S1:36:7	seriou	JJ	O	O
adverse	NULOJIX.xml:S1:44:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:52:9	reaction	NNS	O	O
reported	NULOJIX.xml:S1:62:8	report	VBN	O	O
with	NULOJIX.xml:S1:71:4	with	IN	O	O
NULOJIX	NULOJIX.xml:S1:76:7	nulojix	NNP	O	O
are	NULOJIX.xml:S1:84:3	are	VBP	O	O
:	NULOJIX.xml:S1:87:1	:	:	O	O

PTLD	NULOJIX.xml:S1:98:4	ptld	NNP	B-AdverseReaction	O
,	NULOJIX.xml:S1:102:1	,	,	O	O
predominantly	NULOJIX.xml:S1:104:13	predominantli	RB	O	O
CNS	NULOJIX.xml:S1:118:3	cn	NNP	B-AdverseReaction	O
PTLD	NULOJIX.xml:S1:122:4	ptld	NNP	I-AdverseReaction	O
,	NULOJIX.xml:S1:126:1	,	,	O	O
and	NULOJIX.xml:S1:128:3	and	CC	O	O
other	NULOJIX.xml:S1:132:5	other	JJ	O	O
malignancies	NULOJIX.xml:S1:138:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
[	NULOJIX.xml:S1:151:1	[	VBP	O	O
see	NULOJIX.xml:S1:152:3	see	VB	O	O
Boxed	NULOJIX.xml:S1:158:5	box	NNP	O	O
Warning	NULOJIX.xml:S1:164:7	warn	NNP	O	O
and	NULOJIX.xml:S1:174:3	and	CC	O	O
Warnings	NULOJIX.xml:S1:180:8	warn	NNP	O	O
and	NULOJIX.xml:S1:189:3	and	CC	O	O
Precautions	NULOJIX.xml:S1:193:11	precaut	NNP	O	O
(	NULOJIX.xml:S1:205:1	(	(	O	O
5.1	NULOJIX.xml:S1:206:3	5.1	CD	O	O
,	NULOJIX.xml:S1:211:1	,	,	O	O
5.3	NULOJIX.xml:S1:214:3	5.3	CD	O	O
)	NULOJIX.xml:S1:217:1	)	)	O	O
]	NULOJIX.xml:S1:221:1	]	NN	O	O

Serious	NULOJIX.xml:S1:230:7	seriou	JJ	O	O
infections	NULOJIX.xml:S1:238:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:248:1	,	,	O	O
including	NULOJIX.xml:S1:250:9	includ	VBG	O	O
JC	NULOJIX.xml:S1:260:2	JC	NNP	B-AdverseReaction	B-AdverseReaction
virus	NULOJIX.xml:S1:263:5	viru	NN	I-AdverseReaction	I-AdverseReaction
-	NULOJIX.xml:S1:268:1	-	:	O	O
associated	NULOJIX.xml:S1:269:10	associ	VBN	O	O
PML	NULOJIX.xml:S1:280:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
and	NULOJIX.xml:S1:284:3	and	CC	O	O
polyoma	NULOJIX.xml:S1:288:7	polyoma	VB	B-AdverseReaction	B-AdverseReaction
virus	NULOJIX.xml:S1:296:5	viru	NN	I-AdverseReaction	I-AdverseReaction
nephropathy	NULOJIX.xml:S1:302:11	nephropathi	JJ	I-AdverseReaction	I-AdverseReaction
[	NULOJIX.xml:S1:314:1	[	NNP	O	O
see	NULOJIX.xml:S1:315:3	see	VBP	O	O
Warnings	NULOJIX.xml:S1:321:8	warn	NNP	O	O
and	NULOJIX.xml:S1:330:3	and	CC	O	O
Precautions	NULOJIX.xml:S1:334:11	precaut	NNP	O	O
(	NULOJIX.xml:S1:346:1	(	(	O	O
5.4	NULOJIX.xml:S1:347:3	5.4	CD	O	O
,	NULOJIX.xml:S1:352:1	,	,	O	O
5.5	NULOJIX.xml:S1:355:3	5.5	CD	O	O
,	NULOJIX.xml:S1:360:1	,	,	O	O
5.6	NULOJIX.xml:S1:363:3	5.6	CD	O	O
)	NULOJIX.xml:S1:366:1	)	)	O	O
]	NULOJIX.xml:S1:370:1	]	NN	O	O

EXCERPT	NULOJIX.xml:S1:379:7	excerpt	NNS	O	O
:	NULOJIX.xml:S1:386:1	:	:	O	O
Most	NULOJIX.xml:S1:390:4	most	JJS	O	O
common	NULOJIX.xml:S1:395:6	common	JJ	O	O
adverse	NULOJIX.xml:S1:402:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:410:9	reaction	NNS	O	O
(	NULOJIX.xml:S1:420:1	(	(	O	O
20%	NULOJIX.xml:S1:423:3	20%	CD	O	O
on	NULOJIX.xml:S1:427:2	on	IN	O	O
NULOJIX	NULOJIX.xml:S1:430:7	nulojix	NNP	O	O
treatment	NULOJIX.xml:S1:438:9	treatment	NN	O	O
)	NULOJIX.xml:S1:447:1	)	)	O	O
are	NULOJIX.xml:S1:449:3	are	VBP	O	O
anemia	NULOJIX.xml:S1:453:6	anemia	JJ	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:459:1	,	,	O	O
diarrhea	NULOJIX.xml:S1:461:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:469:1	,	,	O	O
urinary	NULOJIX.xml:S1:471:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	NULOJIX.xml:S1:479:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	NULOJIX.xml:S1:485:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:494:1	,	,	O	O
peripheral	NULOJIX.xml:S1:496:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
edema	NULOJIX.xml:S1:507:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:512:1	,	,	O	O
constipation	NULOJIX.xml:S1:514:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:526:1	,	,	O	O
hypertension	NULOJIX.xml:S1:528:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:540:1	,	,	O	O
pyrexia	NULOJIX.xml:S1:542:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:549:1	,	,	O	O
graft	NULOJIX.xml:S1:551:5	graft	NN	B-AdverseReaction	B-AdverseReaction
dysfunction	NULOJIX.xml:S1:557:11	dysfunct	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:568:1	,	,	O	O
cough	NULOJIX.xml:S1:570:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:575:1	,	,	O	O
nausea	NULOJIX.xml:S1:577:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:583:1	,	,	O	O
vomiting	NULOJIX.xml:S1:585:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:593:1	,	,	O	O
headache	NULOJIX.xml:S1:595:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:603:1	,	,	O	O
hypokalemia	NULOJIX.xml:S1:605:11	hypokalemia	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:616:1	,	,	O	O
hyperkalemia	NULOJIX.xml:S1:618:12	hyperkalemia	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:630:1	,	,	O	O
and	NULOJIX.xml:S1:632:3	and	CC	O	O
leukopenia	NULOJIX.xml:S1:636:10	leukopenia	NN	B-AdverseReaction	B-AdverseReaction
.	NULOJIX.xml:S1:646:1	.	.	O	O

(	NULOJIX.xml:S1:649:1	(	(	O	O
6.1	NULOJIX.xml:S1:650:3	6.1	CD	O	O
)	NULOJIX.xml:S1:653:1	)	)	O	O

To	NULOJIX.xml:S1:663:2	To	TO	O	O

report	NULOJIX.xml:S1:666:6	report	NN	O	O
SUSPECTED	NULOJIX.xml:S1:673:9	suspect	NNP	O	O
ADVERSE	NULOJIX.xml:S1:683:7	advers	NNP	O	O
REACTIONS	NULOJIX.xml:S1:691:9	reaction	NNP	O	O
,	NULOJIX.xml:S1:700:1	,	,	O	O
contact	NULOJIX.xml:S1:702:7	contact	NN	O	O
Bristol	NULOJIX.xml:S1:710:7	bristol	NNP	O	O
-	NULOJIX.xml:S1:717:1	-	:	O	O
Myers	NULOJIX.xml:S1:718:5	myer	NNS	O	O
Squibb	NULOJIX.xml:S1:724:6	squibb	VBP	O	O
at	NULOJIX.xml:S1:731:2	at	IN	O	O
1	NULOJIX.xml:S1:734:1	1	CD	O	O
-	NULOJIX.xml:S1:735:1	-	:	O	O
800	NULOJIX.xml:S1:736:3	800	CD	O	O
-	NULOJIX.xml:S1:739:1	-	:	O	O
721	NULOJIX.xml:S1:740:3	721	CD	O	O
-	NULOJIX.xml:S1:743:1	-	:	O	O
5072	NULOJIX.xml:S1:744:4	5072	CD	O	O
or	NULOJIX.xml:S1:749:2	or	CC	O	O
FDA	NULOJIX.xml:S1:752:3	fda	NNP	O	O
at	NULOJIX.xml:S1:756:2	at	IN	O	O
1	NULOJIX.xml:S1:759:1	1	CD	O	O
-	NULOJIX.xml:S1:760:1	-	:	O	O
800	NULOJIX.xml:S1:761:3	800	CD	O	O
-	NULOJIX.xml:S1:764:1	-	:	O	O
FDA	NULOJIX.xml:S1:765:3	fda	NNP	O	O
-	NULOJIX.xml:S1:768:1	-	:	O	O
1088	NULOJIX.xml:S1:769:4	1088	CD	O	O
or	NULOJIX.xml:S1:774:2	or	CC	O	O
www	NULOJIX.xml:S1:780:3	www	VB	O	O
.	NULOJIX.xml:S1:783:1	.	.	O	O
fda	NULOJIX.xml:S1:784:3	fda	NN	O	O
.	NULOJIX.xml:S1:787:1	.	.	O	O
gov	NULOJIX.xml:S1:788:3	gov	JJ	O	O
medwatch	NULOJIX.xml:S1:792:8	medwatch	NN	O	O
.	NULOJIX.xml:S1:804:1	.	.	O	O

6.1	NULOJIX.xml:S1:816:3	6.1	CD	O	O

Clinical	NULOJIX.xml:S1:820:8	clinic	JJ	O	O
Studies	NULOJIX.xml:S1:829:7	studi	NNS	O	O
Experience	NULOJIX.xml:S1:837:10	experi	NN	O	O

The	NULOJIX.xml:S1:851:3	the	DT	O	O
data	NULOJIX.xml:S1:855:4	data	NNS	O	O
described	NULOJIX.xml:S1:860:9	describ	VBD	O	O
below	NULOJIX.xml:S1:870:5	below	IN	O	O
primarily	NULOJIX.xml:S1:876:9	primarili	RB	O	O
derive	NULOJIX.xml:S1:886:6	deriv	JJ	O	O
from	NULOJIX.xml:S1:893:4	from	IN	O	O
two	NULOJIX.xml:S1:898:3	two	CD	O	O
randomized	NULOJIX.xml:S1:902:10	random	NNS	O	O
,	NULOJIX.xml:S1:912:1	,	,	O	O
active	NULOJIX.xml:S1:914:6	activ	JJ	O	O
-	NULOJIX.xml:S1:920:1	-	:	O	O
controlled	NULOJIX.xml:S1:921:10	control	VBD	O	O
three	NULOJIX.xml:S1:932:5	three	CD	O	O
-	NULOJIX.xml:S1:937:1	-	:	O	O
year	NULOJIX.xml:S1:938:4	year	NN	O	O
trials	NULOJIX.xml:S1:943:6	trial	NNS	O	O
of	NULOJIX.xml:S1:950:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:953:7	nulojix	NNP	O	O
in	NULOJIX.xml:S1:961:2	in	IN	O	O
de	NULOJIX.xml:S1:965:2	de	NNP	O	O
novo	NULOJIX.xml:S1:968:4	novo	FW	O	O
kidney	NULOJIX.xml:S1:974:6	kidney	NN	O	O
transplant	NULOJIX.xml:S1:981:10	transplant	NN	O	O
patients	NULOJIX.xml:S1:992:8	patient	NNS	O	O
.	NULOJIX.xml:S1:1000:1	.	.	O	O

In	NULOJIX.xml:S1:1002:2	In	IN	O	O
Study	NULOJIX.xml:S1:1005:5	studi	NNP	O	O
1	NULOJIX.xml:S1:1011:1	1	CD	O	O
and	NULOJIX.xml:S1:1013:3	and	CC	O	O
Study	NULOJIX.xml:S1:1017:5	studi	NNP	O	O
2	NULOJIX.xml:S1:1023:1	2	CD	O	O
,	NULOJIX.xml:S1:1024:1	,	,	O	O
NULOJIX	NULOJIX.xml:S1:1026:7	nulojix	NNP	O	O
was	NULOJIX.xml:S1:1034:3	wa	VBD	O	O
studied	NULOJIX.xml:S1:1038:7	studi	VBN	O	O
at	NULOJIX.xml:S1:1046:2	at	IN	O	O
the	NULOJIX.xml:S1:1049:3	the	DT	O	O
recommended	NULOJIX.xml:S1:1053:11	recommend	VBN	O	O
dose	NULOJIX.xml:S1:1065:4	dose	NN	O	O
and	NULOJIX.xml:S1:1070:3	and	CC	O	O
frequency	NULOJIX.xml:S1:1074:9	frequenc	NN	O	O
[	NULOJIX.xml:S1:1084:1	[	NNP	O	O
see	NULOJIX.xml:S1:1085:3	see	VBP	O	O
Dosage	NULOJIX.xml:S1:1092:6	dosag	NNP	O	O
and	NULOJIX.xml:S1:1099:3	and	CC	O	O
Administration	NULOJIX.xml:S1:1103:14	administr	NNP	O	O
(	NULOJIX.xml:S1:1118:1	(	(	O	O
2.1	NULOJIX.xml:S1:1119:3	2.1	CD	O	O
)	NULOJIX.xml:S1:1122:1	)	)	O	O
]	NULOJIX.xml:S1:1127:1	]	NN	O	O
in	NULOJIX.xml:S1:1129:2	in	IN	O	O
a	NULOJIX.xml:S1:1132:1	a	DT	O	O
total	NULOJIX.xml:S1:1134:5	total	NN	O	O
of	NULOJIX.xml:S1:1140:2	of	IN	O	O
401	NULOJIX.xml:S1:1143:3	401	CD	O	O
patients	NULOJIX.xml:S1:1147:8	patient	NNS	O	O
compared	NULOJIX.xml:S1:1156:8	compar	VBN	O	O
to	NULOJIX.xml:S1:1165:2	to	TO	O	O
a	NULOJIX.xml:S1:1168:1	a	DT	O	O
cyclosporine	NULOJIX.xml:S1:1170:12	cyclosporin	NN	O	O
control	NULOJIX.xml:S1:1183:7	control	NN	O	O
regimen	NULOJIX.xml:S1:1191:7	regimen	NNS	O	O
in	NULOJIX.xml:S1:1199:2	in	IN	O	O
a	NULOJIX.xml:S1:1202:1	a	DT	O	O
total	NULOJIX.xml:S1:1204:5	total	NN	O	O
of	NULOJIX.xml:S1:1210:2	of	IN	O	O
405	NULOJIX.xml:S1:1213:3	405	CD	O	O
patients	NULOJIX.xml:S1:1217:8	patient	NNS	O	O
.	NULOJIX.xml:S1:1225:1	.	.	O	O

These	NULOJIX.xml:S1:1227:5	these	DT	O	O
two	NULOJIX.xml:S1:1233:3	two	CD	O	O
trials	NULOJIX.xml:S1:1237:6	trial	NNS	O	O
also	NULOJIX.xml:S1:1244:4	also	RB	O	O
included	NULOJIX.xml:S1:1249:8	includ	VBD	O	O
a	NULOJIX.xml:S1:1258:1	a	DT	O	O
total	NULOJIX.xml:S1:1260:5	total	NN	O	O
of	NULOJIX.xml:S1:1266:2	of	IN	O	O
403	NULOJIX.xml:S1:1269:3	403	CD	O	O
patients	NULOJIX.xml:S1:1273:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:1282:7	treat	VBN	O	O
with	NULOJIX.xml:S1:1290:4	with	IN	O	O
a	NULOJIX.xml:S1:1295:1	a	DT	O	O
NULOJIX	NULOJIX.xml:S1:1297:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:1305:7	regimen	NN	O	O
of	NULOJIX.xml:S1:1313:2	of	IN	O	O
higher	NULOJIX.xml:S1:1316:6	higher	JJR	O	O
cumulative	NULOJIX.xml:S1:1323:10	cumul	JJ	O	O
dose	NULOJIX.xml:S1:1334:4	dose	NN	O	O
and	NULOJIX.xml:S1:1339:3	and	CC	O	O
more	NULOJIX.xml:S1:1343:4	more	RBR	O	O
frequent	NULOJIX.xml:S1:1348:8	frequent	JJ	O	O
dosing	NULOJIX.xml:S1:1357:6	dose	NN	O	O
than	NULOJIX.xml:S1:1364:4	than	IN	O	O
recommended	NULOJIX.xml:S1:1369:11	recommend	JJ	O	O
[	NULOJIX.xml:S1:1381:1	[	NN	O	O
see	NULOJIX.xml:S1:1382:3	see	VBP	O	O
Clinical	NULOJIX.xml:S1:1389:8	clinic	JJ	O	O
Studies	NULOJIX.xml:S1:1398:7	studi	NNP	O	O
(	NULOJIX.xml:S1:1406:1	(	(	O	O
14.1	NULOJIX.xml:S1:1407:4	14.1	CD	O	O
)	NULOJIX.xml:S1:1411:1	)	)	O	O
]	NULOJIX.xml:S1:1416:1	]	NN	O	O
.	NULOJIX.xml:S1:1417:1	.	.	O	O

All	NULOJIX.xml:S1:1419:3	all	DT	O	O
patients	NULOJIX.xml:S1:1423:8	patient	NNS	O	O
also	NULOJIX.xml:S1:1432:4	also	RB	O	O
received	NULOJIX.xml:S1:1437:8	receiv	VBD	O	O
basiliximab	NULOJIX.xml:S1:1446:11	basiliximab	JJ	O	O
induction	NULOJIX.xml:S1:1458:9	induct	NN	O	O
,	NULOJIX.xml:S1:1467:1	,	,	O	O
mycophenolate	NULOJIX.xml:S1:1469:13	mycophenol	NN	O	O
mofetil	NULOJIX.xml:S1:1483:7	mofetil	NN	O	O
,	NULOJIX.xml:S1:1490:1	,	,	O	O
and	NULOJIX.xml:S1:1492:3	and	CC	O	O
corticosteroids	NULOJIX.xml:S1:1496:15	corticosteroid	NNS	O	O
.	NULOJIX.xml:S1:1511:1	.	.	O	O

Patients	NULOJIX.xml:S1:1513:8	patient	NNS	O	O
were	NULOJIX.xml:S1:1522:4	were	VBD	O	O
treated	NULOJIX.xml:S1:1527:7	treat	VBN	O	O
and	NULOJIX.xml:S1:1535:3	and	CC	O	O
followed	NULOJIX.xml:S1:1539:8	follow	VBN	O	O
for	NULOJIX.xml:S1:1548:3	for	IN	O	O
3	NULOJIX.xml:S1:1552:1	3	CD	O	O
years	NULOJIX.xml:S1:1554:5	year	NNS	O	O
.	NULOJIX.xml:S1:1559:1	.	.	O	O

CNS	NULOJIX.xml:S1:1565:3	cn	NNP	B-AdverseReaction	O
PTLD	NULOJIX.xml:S1:1569:4	ptld	NNP	I-AdverseReaction	O
,	NULOJIX.xml:S1:1573:1	,	,	O	O
PML	NULOJIX.xml:S1:1575:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:1578:1	,	,	O	O
and	NULOJIX.xml:S1:1580:3	and	CC	O	O
other	NULOJIX.xml:S1:1584:5	other	JJ	O	O
CNS	NULOJIX.xml:S1:1590:3	cn	NNP	B-AdverseReaction	O
infections	NULOJIX.xml:S1:1594:10	infect	NNS	I-AdverseReaction	O
were	NULOJIX.xml:S1:1605:4	were	VBD	O	O
more	NULOJIX.xml:S1:1610:4	more	RBR	O	O
frequently	NULOJIX.xml:S1:1615:10	frequent	RB	O	O
observed	NULOJIX.xml:S1:1626:8	observ	VBN	O	O
in	NULOJIX.xml:S1:1635:2	in	IN	O	O
association	NULOJIX.xml:S1:1638:11	associ	NN	O	O
with	NULOJIX.xml:S1:1650:4	with	IN	O	O
a	NULOJIX.xml:S1:1655:1	a	DT	O	O
NULOJIX	NULOJIX.xml:S1:1657:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:1665:7	regimen	NN	O	O
of	NULOJIX.xml:S1:1673:2	of	IN	O	O
higher	NULOJIX.xml:S1:1676:6	higher	JJR	O	O
cumulative	NULOJIX.xml:S1:1683:10	cumul	JJ	O	O
dose	NULOJIX.xml:S1:1694:4	dose	NN	O	O
and	NULOJIX.xml:S1:1699:3	and	CC	O	O
more	NULOJIX.xml:S1:1703:4	more	RBR	O	O
frequent	NULOJIX.xml:S1:1708:8	frequent	JJ	O	O
dosing	NULOJIX.xml:S1:1717:6	dose	NN	O	O
compared	NULOJIX.xml:S1:1724:8	compar	VBN	O	O
to	NULOJIX.xml:S1:1733:2	to	TO	O	O
the	NULOJIX.xml:S1:1736:3	the	DT	O	O
recommended	NULOJIX.xml:S1:1740:11	recommend	JJ	O	O
regimen	NULOJIX.xml:S1:1752:7	regimen	NNS	O	O
;	NULOJIX.xml:S1:1759:1	;	:	O	O
therefore	NULOJIX.xml:S1:1761:9	therefor	RB	O	O
,	NULOJIX.xml:S1:1770:1	,	,	O	O
administration	NULOJIX.xml:S1:1772:14	administr	NN	O	O
of	NULOJIX.xml:S1:1787:2	of	IN	O	O
higher	NULOJIX.xml:S1:1790:6	higher	JJR	O	O
than	NULOJIX.xml:S1:1797:4	than	IN	O	O
the	NULOJIX.xml:S1:1802:3	the	DT	O	O
recommended	NULOJIX.xml:S1:1806:11	recommend	JJ	O	O
doses	NULOJIX.xml:S1:1818:5	dose	NNS	O	O
and	NULOJIX.xml:S1:1824:3	and	CC	O	O
or	NULOJIX.xml:S1:1828:2	or	CC	O	O
more	NULOJIX.xml:S1:1831:4	more	JJR	O	O
frequent	NULOJIX.xml:S1:1836:8	frequent	JJ	O	O
dosing	NULOJIX.xml:S1:1845:6	dose	NN	O	O
of	NULOJIX.xml:S1:1852:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:1855:7	nulojix	NNP	O	O
is	NULOJIX.xml:S1:1863:2	is	VBZ	O	O
not	NULOJIX.xml:S1:1866:3	not	RB	O	O
recommended	NULOJIX.xml:S1:1870:11	recommend	JJ	O	O
[	NULOJIX.xml:S1:1882:1	[	NNS	O	O
see	NULOJIX.xml:S1:1883:3	see	VBP	O	O
Dosage	NULOJIX.xml:S1:1890:6	dosag	NNP	O	O
and	NULOJIX.xml:S1:1897:3	and	CC	O	O
Administration	NULOJIX.xml:S1:1901:14	administr	NNP	O	O
(	NULOJIX.xml:S1:1916:1	(	(	O	O
2.1	NULOJIX.xml:S1:1917:3	2.1	CD	O	O
)	NULOJIX.xml:S1:1920:1	)	)	O	O
]	NULOJIX.xml:S1:1925:1	]	NN	O	O
.	NULOJIX.xml:S1:1926:1	.	.	O	O

The	NULOJIX.xml:S1:1932:3	the	DT	O	O
average	NULOJIX.xml:S1:1936:7	averag	JJ	O	O
age	NULOJIX.xml:S1:1944:3	age	NN	O	O
of	NULOJIX.xml:S1:1948:2	of	IN	O	O
patients	NULOJIX.xml:S1:1951:8	patient	NNS	O	O
in	NULOJIX.xml:S1:1960:2	in	IN	O	O
Studies	NULOJIX.xml:S1:1963:7	studi	NNP	O	O
1	NULOJIX.xml:S1:1971:1	1	CD	O	O
and	NULOJIX.xml:S1:1973:3	and	CC	O	O
2	NULOJIX.xml:S1:1977:1	2	CD	O	O
in	NULOJIX.xml:S1:1979:2	in	IN	O	O
the	NULOJIX.xml:S1:1982:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:1986:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:1994:11	recommend	VBD	O	O
dose	NULOJIX.xml:S1:2006:4	dose	NN	O	O
and	NULOJIX.xml:S1:2011:3	and	CC	O	O
cyclosporine	NULOJIX.xml:S1:2015:12	cyclosporin	VB	O	O
control	NULOJIX.xml:S1:2028:7	control	NN	O	O
regimens	NULOJIX.xml:S1:2036:8	regimen	NNS	O	O
was	NULOJIX.xml:S1:2045:3	wa	VBD	O	O
49	NULOJIX.xml:S1:2049:2	49	CD	O	O
years	NULOJIX.xml:S1:2052:5	year	NNS	O	O
,	NULOJIX.xml:S1:2057:1	,	,	O	O
ranging	NULOJIX.xml:S1:2059:7	rang	VBG	O	O
from	NULOJIX.xml:S1:2067:4	from	IN	O	O
18	NULOJIX.xml:S1:2072:2	18	CD	O	O
to	NULOJIX.xml:S1:2075:2	to	TO	O	O
79	NULOJIX.xml:S1:2078:2	79	CD	O	O
years	NULOJIX.xml:S1:2081:5	year	NNS	O	O
.	NULOJIX.xml:S1:2086:1	.	.	O	O

Approximately	NULOJIX.xml:S1:2088:13	approxim	RB	O	O
70%	NULOJIX.xml:S1:2102:3	70%	CD	O	O
of	NULOJIX.xml:S1:2106:2	of	IN	O	O
patients	NULOJIX.xml:S1:2109:8	patient	NNS	O	O
were	NULOJIX.xml:S1:2118:4	were	VBD	O	O
male	NULOJIX.xml:S1:2123:4	male	JJ	O	O
;	NULOJIX.xml:S1:2127:1	;	:	O	O
67%	NULOJIX.xml:S1:2129:3	67%	CD	O	O
were	NULOJIX.xml:S1:2133:4	were	VBD	O	O
white	NULOJIX.xml:S1:2138:5	white	JJ	O	O
,	NULOJIX.xml:S1:2143:1	,	,	O	O
11%	NULOJIX.xml:S1:2145:3	11%	CD	O	O
were	NULOJIX.xml:S1:2149:4	were	VBD	O	O
black	NULOJIX.xml:S1:2154:5	black	JJ	O	O
,	NULOJIX.xml:S1:2159:1	,	,	O	O
and	NULOJIX.xml:S1:2161:3	and	CC	O	O
22%	NULOJIX.xml:S1:2165:3	22%	CD	O	O
other	NULOJIX.xml:S1:2169:5	other	JJ	O	O
races	NULOJIX.xml:S1:2175:5	race	NNS	O	O
.	NULOJIX.xml:S1:2180:1	.	.	O	O

About	NULOJIX.xml:S1:2182:5	about	IN	O	O
25%	NULOJIX.xml:S1:2188:3	25%	CD	O	O
of	NULOJIX.xml:S1:2192:2	of	IN	O	O
patients	NULOJIX.xml:S1:2195:8	patient	NNS	O	O
were	NULOJIX.xml:S1:2204:4	were	VBD	O	O
from	NULOJIX.xml:S1:2209:4	from	IN	O	O
the	NULOJIX.xml:S1:2214:3	the	DT	O	O
United	NULOJIX.xml:S1:2218:6	unit	NNP	O	O
States	NULOJIX.xml:S1:2225:6	state	NNPS	O	O
and	NULOJIX.xml:S1:2232:3	and	CC	O	O
75%	NULOJIX.xml:S1:2236:3	75%	CD	O	O
from	NULOJIX.xml:S1:2240:4	from	IN	O	O
other	NULOJIX.xml:S1:2245:5	other	JJ	O	O
countries	NULOJIX.xml:S1:2251:9	countri	NNS	O	O
.	NULOJIX.xml:S1:2260:1	.	.	O	O

Because	NULOJIX.xml:S1:2266:7	becaus	IN	O	O
clinical	NULOJIX.xml:S1:2274:8	clinic	JJ	O	O
trials	NULOJIX.xml:S1:2283:6	trial	NNS	O	O
are	NULOJIX.xml:S1:2290:3	are	VBP	O	O
conducted	NULOJIX.xml:S1:2294:9	conduct	VBN	O	O
under	NULOJIX.xml:S1:2304:5	under	IN	O	O
widely	NULOJIX.xml:S1:2310:6	wide	RB	O	O
varying	NULOJIX.xml:S1:2317:7	vari	VBG	O	O
conditions	NULOJIX.xml:S1:2325:10	condit	NNS	O	O
,	NULOJIX.xml:S1:2335:1	,	,	O	O
the	NULOJIX.xml:S1:2337:3	the	DT	O	O
adverse	NULOJIX.xml:S1:2341:7	advers	JJ	O	O
reaction	NULOJIX.xml:S1:2349:8	reaction	NN	O	O
rates	NULOJIX.xml:S1:2358:5	rate	NNS	O	O
observed	NULOJIX.xml:S1:2364:8	observ	VBD	O	O
cannot	NULOJIX.xml:S1:2373:6	cannot	JJ	O	O
be	NULOJIX.xml:S1:2380:2	be	VB	O	O
directly	NULOJIX.xml:S1:2383:8	directli	RB	O	O
compared	NULOJIX.xml:S1:2392:8	compar	VBN	O	O
to	NULOJIX.xml:S1:2401:2	to	TO	O	O
rates	NULOJIX.xml:S1:2404:5	rate	NNS	O	O
in	NULOJIX.xml:S1:2410:2	in	IN	O	O
other	NULOJIX.xml:S1:2413:5	other	JJ	O	O
trials	NULOJIX.xml:S1:2419:6	trial	NNS	O	O
and	NULOJIX.xml:S1:2426:3	and	CC	O	O
may	NULOJIX.xml:S1:2430:3	may	MD	O	O
not	NULOJIX.xml:S1:2434:3	not	RB	O	O
reflect	NULOJIX.xml:S1:2438:7	reflect	VB	O	O
the	NULOJIX.xml:S1:2446:3	the	DT	O	O
rates	NULOJIX.xml:S1:2450:5	rate	NNS	O	O
observed	NULOJIX.xml:S1:2456:8	observ	VBD	O	O
in	NULOJIX.xml:S1:2465:2	in	IN	O	O
clinical	NULOJIX.xml:S1:2468:8	clinic	JJ	O	O
practice	NULOJIX.xml:S1:2477:8	practic	NN	O	O
.	NULOJIX.xml:S1:2485:1	.	.	O	O

The	NULOJIX.xml:S1:2491:3	the	DT	O	O
most	NULOJIX.xml:S1:2495:4	most	RBS	O	O
commonly	NULOJIX.xml:S1:2500:8	commonli	RB	O	O
reported	NULOJIX.xml:S1:2509:8	report	VBD	O	O
adverse	NULOJIX.xml:S1:2518:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:2526:9	reaction	NNS	O	O
occurring	NULOJIX.xml:S1:2536:9	occur	VBG	O	O
in	NULOJIX.xml:S1:2546:2	in	IN	O	O
20%	NULOJIX.xml:S1:2551:3	20%	CD	O	O
of	NULOJIX.xml:S1:2555:2	of	IN	O	O
patients	NULOJIX.xml:S1:2558:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:2567:7	treat	VBN	O	O
with	NULOJIX.xml:S1:2575:4	with	IN	O	O
the	NULOJIX.xml:S1:2580:3	the	DT	O	O
recommended	NULOJIX.xml:S1:2584:11	recommend	VBN	O	O
dose	NULOJIX.xml:S1:2596:4	dose	NN	O	O
and	NULOJIX.xml:S1:2601:3	and	CC	O	O
frequency	NULOJIX.xml:S1:2605:9	frequenc	NN	O	O
of	NULOJIX.xml:S1:2615:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:2618:7	nulojix	NNP	O	O
were	NULOJIX.xml:S1:2626:4	were	VBD	O	O
anemia	NULOJIX.xml:S1:2631:6	anemia	RB	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2637:1	,	,	O	O
diarrhea	NULOJIX.xml:S1:2639:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2647:1	,	,	O	O
urinary	NULOJIX.xml:S1:2649:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	NULOJIX.xml:S1:2657:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	NULOJIX.xml:S1:2663:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:2672:1	,	,	O	O
peripheral	NULOJIX.xml:S1:2674:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
edema	NULOJIX.xml:S1:2685:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:2690:1	,	,	O	O
constipation	NULOJIX.xml:S1:2692:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2704:1	,	,	O	O
hypertension	NULOJIX.xml:S1:2706:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2718:1	,	,	O	O
pyrexia	NULOJIX.xml:S1:2720:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2727:1	,	,	O	O
graft	NULOJIX.xml:S1:2729:5	graft	NN	B-AdverseReaction	B-AdverseReaction
dysfunction	NULOJIX.xml:S1:2735:11	dysfunct	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:2746:1	,	,	O	O
cough	NULOJIX.xml:S1:2748:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2753:1	,	,	O	O
nausea	NULOJIX.xml:S1:2755:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2761:1	,	,	O	O
vomiting	NULOJIX.xml:S1:2763:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2771:1	,	,	O	O
headache	NULOJIX.xml:S1:2773:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2781:1	,	,	O	O
hypokalemia	NULOJIX.xml:S1:2783:11	hypokalemia	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2794:1	,	,	O	O
hyperkalemia	NULOJIX.xml:S1:2796:12	hyperkalemia	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:2808:1	,	,	O	O
and	NULOJIX.xml:S1:2810:3	and	CC	O	O
leukopenia	NULOJIX.xml:S1:2814:10	leukopenia	NN	B-AdverseReaction	B-AdverseReaction
.	NULOJIX.xml:S1:2824:1	.	.	O	O

The	NULOJIX.xml:S1:2830:3	the	DT	O	O
proportion	NULOJIX.xml:S1:2834:10	proport	NN	O	O
of	NULOJIX.xml:S1:2845:2	of	IN	O	O
patients	NULOJIX.xml:S1:2848:8	patient	NNS	O	O
who	NULOJIX.xml:S1:2857:3	who	WP	O	O
discontinued	NULOJIX.xml:S1:2861:12	discontinu	VBD	O	O
treatment	NULOJIX.xml:S1:2874:9	treatment	NN	O	O
due	NULOJIX.xml:S1:2884:3	due	JJ	O	O
to	NULOJIX.xml:S1:2888:2	to	TO	O	O
adverse	NULOJIX.xml:S1:2891:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:2899:9	reaction	NNS	O	O
was	NULOJIX.xml:S1:2909:3	wa	VBD	O	O
13%	NULOJIX.xml:S1:2913:3	13%	CD	O	O
for	NULOJIX.xml:S1:2917:3	for	IN	O	O
the	NULOJIX.xml:S1:2921:3	the	DT	O	O
recommended	NULOJIX.xml:S1:2925:11	recommend	JJ	O	O
NULOJIX	NULOJIX.xml:S1:2937:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:2945:7	regimen	NNS	O	O
and	NULOJIX.xml:S1:2953:3	and	CC	O	O
19%	NULOJIX.xml:S1:2957:3	19%	CD	O	O
for	NULOJIX.xml:S1:2961:3	for	IN	O	O
the	NULOJIX.xml:S1:2965:3	the	DT	O	O
cyclosporine	NULOJIX.xml:S1:2969:12	cyclosporin	NN	O	O
control	NULOJIX.xml:S1:2982:7	control	NN	O	O
arm	NULOJIX.xml:S1:2990:3	arm	NN	O	O
through	NULOJIX.xml:S1:2994:7	through	IN	O	O
three	NULOJIX.xml:S1:3002:5	three	CD	O	O
years	NULOJIX.xml:S1:3008:5	year	NNS	O	O
of	NULOJIX.xml:S1:3014:2	of	IN	O	O
treatment	NULOJIX.xml:S1:3017:9	treatment	NN	O	O
.	NULOJIX.xml:S1:3026:1	.	.	O	O

The	NULOJIX.xml:S1:3028:3	the	DT	O	O
most	NULOJIX.xml:S1:3032:4	most	RBS	O	O
common	NULOJIX.xml:S1:3037:6	common	JJ	O	O
adverse	NULOJIX.xml:S1:3044:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:3052:9	reaction	NNS	O	O
leading	NULOJIX.xml:S1:3062:7	lead	VBG	O	O
to	NULOJIX.xml:S1:3070:2	to	TO	O	O
discontinuation	NULOJIX.xml:S1:3073:15	discontinu	NN	O	O
in	NULOJIX.xml:S1:3089:2	in	IN	O	O
NULOJIX	NULOJIX.xml:S1:3092:7	nulojix	NNP	O	O
-	NULOJIX.xml:S1:3099:1	-	:	O	O
treated	NULOJIX.xml:S1:3100:7	treat	VBD	O	O
patients	NULOJIX.xml:S1:3108:8	patient	NNS	O	O
were	NULOJIX.xml:S1:3117:4	were	VBD	O	O
cytomegalovirus	NULOJIX.xml:S1:3122:15	cytomegaloviru	JJ	B-AdverseReaction	B-AdverseReaction
infection	NULOJIX.xml:S1:3138:9	infect	NN	I-AdverseReaction	I-AdverseReaction
(	NULOJIX.xml:S1:3148:1	(	(	O	O
1.5%	NULOJIX.xml:S1:3149:4	1.5%	CD	O	O
)	NULOJIX.xml:S1:3153:1	)	)	O	O
and	NULOJIX.xml:S1:3155:3	and	CC	O	O
complications	NULOJIX.xml:S1:3159:13	complic	NNS	B-AdverseReaction	O
of	NULOJIX.xml:S1:3173:2	of	IN	I-AdverseReaction	O
transplanted	NULOJIX.xml:S1:3176:12	transplant	JJ	I-AdverseReaction	O
kidney	NULOJIX.xml:S1:3189:6	kidney	NN	I-AdverseReaction	O
(	NULOJIX.xml:S1:3196:1	(	(	O	O
1.5%	NULOJIX.xml:S1:3197:4	1.5%	CD	O	O
)	NULOJIX.xml:S1:3201:1	)	)	O	O
.	NULOJIX.xml:S1:3202:1	.	.	O	O

Information	NULOJIX.xml:S1:3208:11	inform	NN	O	O
on	NULOJIX.xml:S1:3220:2	on	IN	O	O
selected	NULOJIX.xml:S1:3223:8	select	VBN	O	O
significant	NULOJIX.xml:S1:3232:11	signific	JJ	O	O
adverse	NULOJIX.xml:S1:3244:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:3252:9	reaction	NNS	O	O
observed	NULOJIX.xml:S1:3262:8	observ	VBD	O	O
during	NULOJIX.xml:S1:3271:6	dure	IN	O	O
clinical	NULOJIX.xml:S1:3278:8	clinic	JJ	O	O
trials	NULOJIX.xml:S1:3287:6	trial	NNS	O	O
is	NULOJIX.xml:S1:3294:2	is	VBZ	O	O
summarized	NULOJIX.xml:S1:3297:10	summar	VBN	O	O
below	NULOJIX.xml:S1:3308:5	below	IN	O	O
.	NULOJIX.xml:S1:3313:1	.	.	O	O

Post	NULOJIX.xml:S1:3321:4	post	NNP	O	O
-	NULOJIX.xml:S1:3325:1	-	:	O	O
Transplant	NULOJIX.xml:S1:3326:10	transplant	NN	O	O
Lymphoproliferative	NULOJIX.xml:S1:3337:19	lymphoprolif	JJ	O	O
Disorder	NULOJIX.xml:S1:3357:8	disord	NN	O	O

Reported	NULOJIX.xml:S1:3369:8	report	VBN	O	O
cases	NULOJIX.xml:S1:3378:5	case	NNS	O	O
of	NULOJIX.xml:S1:3384:2	of	IN	O	O
post	NULOJIX.xml:S1:3387:4	post	NN	B-AdverseReaction	O
-	NULOJIX.xml:S1:3391:1	-	:	I-AdverseReaction	O
transplant	NULOJIX.xml:S1:3392:10	transplant	NN	I-AdverseReaction	O
lymphoproliferative	NULOJIX.xml:S1:3403:19	lymphoprolif	JJ	I-AdverseReaction	O
disorder	NULOJIX.xml:S1:3423:8	disord	NN	I-AdverseReaction	O
(	NULOJIX.xml:S1:3432:1	(	(	O	O
PTLD	NULOJIX.xml:S1:3433:4	ptld	NNP	B-AdverseReaction	O
)	NULOJIX.xml:S1:3437:1	)	)	O	O
up	NULOJIX.xml:S1:3439:2	up	RB	O	O
to	NULOJIX.xml:S1:3442:2	to	TO	O	O
36	NULOJIX.xml:S1:3445:2	36	CD	O	O
months	NULOJIX.xml:S1:3448:6	month	NNS	O	O
post	NULOJIX.xml:S1:3455:4	post	VBN	O	O
transplant	NULOJIX.xml:S1:3460:10	transplant	NN	O	O
were	NULOJIX.xml:S1:3471:4	were	VBD	O	O
obtained	NULOJIX.xml:S1:3476:8	obtain	VBN	O	O
for	NULOJIX.xml:S1:3485:3	for	IN	O	O
NULOJIX	NULOJIX.xml:S1:3489:7	nulojix	NNP	O	O
by	NULOJIX.xml:S1:3497:2	by	IN	O	O
pooling	NULOJIX.xml:S1:3500:7	pool	VBG	O	O
both	NULOJIX.xml:S1:3508:4	both	DT	O	O
dosage	NULOJIX.xml:S1:3513:6	dosag	NN	O	O
regimens	NULOJIX.xml:S1:3520:8	regimen	NNS	O	O
of	NULOJIX.xml:S1:3529:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:3532:7	nulojix	NNP	O	O
in	NULOJIX.xml:S1:3540:2	in	IN	O	O
Studies	NULOJIX.xml:S1:3543:7	studi	NNP	O	O
1	NULOJIX.xml:S1:3551:1	1	CD	O	O
and	NULOJIX.xml:S1:3553:3	and	CC	O	O
2	NULOJIX.xml:S1:3557:1	2	CD	O	O
(	NULOJIX.xml:S1:3559:1	(	(	O	O
804	NULOJIX.xml:S1:3560:3	804	CD	O	O
patients	NULOJIX.xml:S1:3564:8	patient	NNS	O	O
)	NULOJIX.xml:S1:3572:1	)	)	O	O
with	NULOJIX.xml:S1:3574:4	with	IN	O	O
data	NULOJIX.xml:S1:3579:4	data	NNS	O	O
from	NULOJIX.xml:S1:3584:4	from	IN	O	O
a	NULOJIX.xml:S1:3589:1	a	DT	O	O
third	NULOJIX.xml:S1:3591:5	third	JJ	O	O
study	NULOJIX.xml:S1:3597:5	studi	NN	O	O
in	NULOJIX.xml:S1:3603:2	in	IN	O	O
kidney	NULOJIX.xml:S1:3606:6	kidney	NN	O	O
transplantation	NULOJIX.xml:S1:3613:15	transplant	NN	O	O
(	NULOJIX.xml:S1:3629:1	(	(	O	O
Study	NULOJIX.xml:S1:3630:5	studi	NNP	O	O
3	NULOJIX.xml:S1:3636:1	3	CD	O	O
,	NULOJIX.xml:S1:3637:1	,	,	O	O
145	NULOJIX.xml:S1:3639:3	145	CD	O	O
patients	NULOJIX.xml:S1:3643:8	patient	NNS	O	O
)	NULOJIX.xml:S1:3651:1	)	)	O	O
which	NULOJIX.xml:S1:3653:5	which	WDT	O	O
evaluated	NULOJIX.xml:S1:3659:9	evalu	VBD	O	O
two	NULOJIX.xml:S1:3669:3	two	CD	O	O
NULOJIX	NULOJIX.xml:S1:3673:7	nulojix	NNP	O	O
dosage	NULOJIX.xml:S1:3681:6	dosag	NN	O	O
regimens	NULOJIX.xml:S1:3688:8	regimen	VBZ	O	O
similar	NULOJIX.xml:S1:3697:7	similar	JJ	O	O
,	NULOJIX.xml:S1:3704:1	,	,	O	O
but	NULOJIX.xml:S1:3706:3	but	CC	O	O
slightly	NULOJIX.xml:S1:3710:8	slightli	RB	O	O
different	NULOJIX.xml:S1:3719:9	differ	JJ	O	O
,	NULOJIX.xml:S1:3728:1	,	,	O	O
from	NULOJIX.xml:S1:3730:4	from	IN	O	O
those	NULOJIX.xml:S1:3735:5	those	DT	O	O
of	NULOJIX.xml:S1:3741:2	of	IN	O	O
Studies	NULOJIX.xml:S1:3744:7	studi	NNS	O	O
1	NULOJIX.xml:S1:3752:1	1	CD	O	O
and	NULOJIX.xml:S1:3754:3	and	CC	O	O
2	NULOJIX.xml:S1:3758:1	2	CD	O	O
(	NULOJIX.xml:S1:3760:1	(	(	O	O
see	NULOJIX.xml:S1:3761:3	see	VB	O	O
Table	NULOJIX.xml:S1:3765:5	tabl	NNP	O	O
2	NULOJIX.xml:S1:3771:1	2	CD	O	O
)	NULOJIX.xml:S1:3772:1	)	)	O	O
.	NULOJIX.xml:S1:3773:1	.	.	O	O

The	NULOJIX.xml:S1:3775:3	the	DT	O	O
total	NULOJIX.xml:S1:3779:5	total	JJ	O	O
number	NULOJIX.xml:S1:3785:6	number	NN	O	O
of	NULOJIX.xml:S1:3792:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:3795:7	nulojix	NNP	O	O
patients	NULOJIX.xml:S1:3803:8	patient	NNS	O	O
from	NULOJIX.xml:S1:3812:4	from	IN	O	O
these	NULOJIX.xml:S1:3817:5	these	DT	O	O
three	NULOJIX.xml:S1:3823:5	three	CD	O	O
studies	NULOJIX.xml:S1:3829:7	studi	NNS	O	O
(	NULOJIX.xml:S1:3837:1	(	(	O	O
949	NULOJIX.xml:S1:3838:3	949	CD	O	O
)	NULOJIX.xml:S1:3841:1	)	)	O	O
was	NULOJIX.xml:S1:3843:3	wa	VBD	O	O
compared	NULOJIX.xml:S1:3847:8	compar	VBN	O	O
to	NULOJIX.xml:S1:3856:2	to	TO	O	O
the	NULOJIX.xml:S1:3859:3	the	DT	O	O
pooled	NULOJIX.xml:S1:3863:6	pool	JJ	O	O
cyclosporine	NULOJIX.xml:S1:3870:12	cyclosporin	NN	O	O
control	NULOJIX.xml:S1:3883:7	control	NN	O	O
groups	NULOJIX.xml:S1:3891:6	group	NNS	O	O
from	NULOJIX.xml:S1:3898:4	from	IN	O	O
all	NULOJIX.xml:S1:3903:3	all	DT	O	O
three	NULOJIX.xml:S1:3907:5	three	CD	O	O
studies	NULOJIX.xml:S1:3913:7	studi	NNS	O	O
(	NULOJIX.xml:S1:3921:1	(	(	O	O
476	NULOJIX.xml:S1:3922:3	476	CD	O	O
patients	NULOJIX.xml:S1:3926:8	patient	NNS	O	O
)	NULOJIX.xml:S1:3934:1	)	)	O	O
.	NULOJIX.xml:S1:3935:1	.	.	O	O

Among	NULOJIX.xml:S1:3941:5	among	IN	O	O
401	NULOJIX.xml:S1:3947:3	401	CD	O	O
patients	NULOJIX.xml:S1:3951:8	patient	NNS	O	O
in	NULOJIX.xml:S1:3960:2	in	IN	O	O
Studies	NULOJIX.xml:S1:3963:7	studi	NNP	O	O
1	NULOJIX.xml:S1:3971:1	1	CD	O	O
and	NULOJIX.xml:S1:3973:3	and	CC	O	O
2	NULOJIX.xml:S1:3977:1	2	CD	O	O
treated	NULOJIX.xml:S1:3979:7	treat	VBN	O	O
with	NULOJIX.xml:S1:3987:4	with	IN	O	O
the	NULOJIX.xml:S1:3992:3	the	DT	O	O
recommended	NULOJIX.xml:S1:3996:11	recommend	JJ	O	O
regimen	NULOJIX.xml:S1:4008:7	regimen	NNS	O	O
of	NULOJIX.xml:S1:4016:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:4019:7	nulojix	NNP	O	O
and	NULOJIX.xml:S1:4027:3	and	CC	O	O
the	NULOJIX.xml:S1:4031:3	the	DT	O	O
71	NULOJIX.xml:S1:4035:2	71	CD	O	O
patients	NULOJIX.xml:S1:4038:8	patient	NNS	O	O
in	NULOJIX.xml:S1:4047:2	in	IN	O	O
Study	NULOJIX.xml:S1:4050:5	studi	NNP	O	O
3	NULOJIX.xml:S1:4056:1	3	CD	O	O
treated	NULOJIX.xml:S1:4058:7	treat	VBD	O	O
with	NULOJIX.xml:S1:4066:4	with	IN	O	O
a	NULOJIX.xml:S1:4071:1	a	DT	O	O
very	NULOJIX.xml:S1:4073:4	veri	RB	O	O
similar	NULOJIX.xml:S1:4078:7	similar	JJ	O	O
(	NULOJIX.xml:S1:4086:1	(	(	O	O
but	NULOJIX.xml:S1:4087:3	but	CC	O	O
non	NULOJIX.xml:S1:4091:3	non	SYM	O	O
-	NULOJIX.xml:S1:4094:1	-	:	O	O
identical	NULOJIX.xml:S1:4095:9	ident	JJ	O	O
)	NULOJIX.xml:S1:4104:1	)	)	O	O
NULOJIX	NULOJIX.xml:S1:4106:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:4114:7	regimen	NNS	O	O
,	NULOJIX.xml:S1:4121:1	,	,	O	O
there	NULOJIX.xml:S1:4123:5	there	EX	O	O
were	NULOJIX.xml:S1:4129:4	were	VBD	O	O
5	NULOJIX.xml:S1:4134:1	5	CD	O	O
cases	NULOJIX.xml:S1:4136:5	case	NNS	O	O
of	NULOJIX.xml:S1:4142:2	of	IN	O	O
PTLD	NULOJIX.xml:S1:4145:4	ptld	NNP	B-AdverseReaction	B-AdverseReaction
:	NULOJIX.xml:S1:4149:1	:	:	O	O
3	NULOJIX.xml:S1:4151:1	3	CD	O	O
in	NULOJIX.xml:S1:4153:2	in	IN	O	O
EBV	NULOJIX.xml:S1:4156:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S1:4160:12	seroposit	JJ	O	O
patients	NULOJIX.xml:S1:4173:8	patient	NNS	O	O
and	NULOJIX.xml:S1:4182:3	and	CC	O	O
2	NULOJIX.xml:S1:4186:1	2	CD	O	O
in	NULOJIX.xml:S1:4188:2	in	IN	O	O
EBV	NULOJIX.xml:S1:4191:3	ebv	NNP	O	O
seronegative	NULOJIX.xml:S1:4195:12	seroneg	JJ	O	O
patients	NULOJIX.xml:S1:4208:8	patient	NNS	O	O
.	NULOJIX.xml:S1:4216:1	.	.	O	O

Two	NULOJIX.xml:S1:4218:3	two	CD	O	O
of	NULOJIX.xml:S1:4222:2	of	IN	O	O
the	NULOJIX.xml:S1:4225:3	the	DT	O	O
5	NULOJIX.xml:S1:4229:1	5	CD	O	O
cases	NULOJIX.xml:S1:4231:5	case	NNS	O	O
presented	NULOJIX.xml:S1:4237:9	present	VBN	O	O
with	NULOJIX.xml:S1:4247:4	with	IN	O	O
CNS	NULOJIX.xml:S1:4252:3	cn	NNP	O	O
involvement	NULOJIX.xml:S1:4256:11	involv	NN	O	O
.	NULOJIX.xml:S1:4267:1	.	.	O	O

Among	NULOJIX.xml:S1:4273:5	among	IN	O	O
the	NULOJIX.xml:S1:4279:3	the	DT	O	O
477	NULOJIX.xml:S1:4283:3	477	CD	O	O
patients	NULOJIX.xml:S1:4287:8	patient	NNS	O	O
in	NULOJIX.xml:S1:4296:2	in	IN	O	O
Studies	NULOJIX.xml:S1:4299:7	studi	NNP	O	O
1	NULOJIX.xml:S1:4307:1	1	CD	O	O
,	NULOJIX.xml:S1:4308:1	,	,	O	O
2	NULOJIX.xml:S1:4310:1	2	CD	O	O
,	NULOJIX.xml:S1:4311:1	,	,	O	O
and	NULOJIX.xml:S1:4313:3	and	CC	O	O
3	NULOJIX.xml:S1:4317:1	3	CD	O	O
treated	NULOJIX.xml:S1:4319:7	treat	VBN	O	O
with	NULOJIX.xml:S1:4327:4	with	IN	O	O
the	NULOJIX.xml:S1:4332:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:4336:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:4344:7	regimen	NNS	O	O
of	NULOJIX.xml:S1:4352:2	of	IN	O	O
higher	NULOJIX.xml:S1:4355:6	higher	JJR	O	O
cumulative	NULOJIX.xml:S1:4362:10	cumul	JJ	O	O
dose	NULOJIX.xml:S1:4373:4	dose	NN	O	O
and	NULOJIX.xml:S1:4378:3	and	CC	O	O
more	NULOJIX.xml:S1:4382:4	more	RBR	O	O
frequent	NULOJIX.xml:S1:4387:8	frequent	JJ	O	O
dosing	NULOJIX.xml:S1:4396:6	dose	NN	O	O
than	NULOJIX.xml:S1:4403:4	than	IN	O	O
recommended	NULOJIX.xml:S1:4408:11	recommend	VBN	O	O
,	NULOJIX.xml:S1:4419:1	,	,	O	O
there	NULOJIX.xml:S1:4421:5	there	EX	O	O
were	NULOJIX.xml:S1:4427:4	were	VBD	O	O
8	NULOJIX.xml:S1:4432:1	8	CD	O	O
cases	NULOJIX.xml:S1:4434:5	case	NNS	O	O
of	NULOJIX.xml:S1:4440:2	of	IN	O	O
PTLD	NULOJIX.xml:S1:4443:4	ptld	NNP	B-AdverseReaction	O
:	NULOJIX.xml:S1:4447:1	:	:	O	O
2	NULOJIX.xml:S1:4449:1	2	CD	O	O
in	NULOJIX.xml:S1:4451:2	in	IN	O	O
EBV	NULOJIX.xml:S1:4454:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S1:4458:12	seroposit	JJ	O	O
patients	NULOJIX.xml:S1:4471:8	patient	NNS	O	O
and	NULOJIX.xml:S1:4480:3	and	CC	O	O
6	NULOJIX.xml:S1:4484:1	6	CD	O	O
in	NULOJIX.xml:S1:4486:2	in	IN	O	O
EBV	NULOJIX.xml:S1:4489:3	ebv	NNP	O	O
seronegative	NULOJIX.xml:S1:4493:12	seroneg	NN	O	O
or	NULOJIX.xml:S1:4506:2	or	CC	O	O
serostatus	NULOJIX.xml:S1:4509:10	serostatu	VB	O	O
unknown	NULOJIX.xml:S1:4520:7	unknown	JJ	O	O
patients	NULOJIX.xml:S1:4528:8	patient	NNS	O	O
.	NULOJIX.xml:S1:4536:1	.	.	O	O

Six	NULOJIX.xml:S1:4538:3	six	CD	O	O
of	NULOJIX.xml:S1:4542:2	of	IN	O	O
the	NULOJIX.xml:S1:4545:3	the	DT	O	O
8	NULOJIX.xml:S1:4549:1	8	CD	O	O
cases	NULOJIX.xml:S1:4551:5	case	NNS	O	O
presented	NULOJIX.xml:S1:4557:9	present	VBN	O	O
with	NULOJIX.xml:S1:4567:4	with	IN	O	O
CNS	NULOJIX.xml:S1:4572:3	cn	NNP	O	O
involvement	NULOJIX.xml:S1:4576:11	involv	NN	O	O
.	NULOJIX.xml:S1:4587:1	.	.	O	O

Therefore	NULOJIX.xml:S1:4589:9	therefor	RB	O	O
,	NULOJIX.xml:S1:4598:1	,	,	O	O
administration	NULOJIX.xml:S1:4600:14	administr	NN	O	O
of	NULOJIX.xml:S1:4615:2	of	IN	O	O
higher	NULOJIX.xml:S1:4618:6	higher	JJR	O	O
than	NULOJIX.xml:S1:4625:4	than	IN	O	O
the	NULOJIX.xml:S1:4630:3	the	DT	O	O
recommended	NULOJIX.xml:S1:4634:11	recommend	JJ	O	O
doses	NULOJIX.xml:S1:4646:5	dose	NNS	O	O
or	NULOJIX.xml:S1:4652:2	or	CC	O	O
more	NULOJIX.xml:S1:4655:4	more	JJR	O	O
frequent	NULOJIX.xml:S1:4660:8	frequent	JJ	O	O
dosing	NULOJIX.xml:S1:4669:6	dose	NN	O	O
of	NULOJIX.xml:S1:4676:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:4679:7	nulojix	NNP	O	O
is	NULOJIX.xml:S1:4687:2	is	VBZ	O	O
not	NULOJIX.xml:S1:4690:3	not	RB	O	O
recommended	NULOJIX.xml:S1:4694:11	recommend	VBN	O	O
.	NULOJIX.xml:S1:4705:1	.	.	O	O

[	NULOJIX.xml:S1:4707:1	[	NNS	O	O
See	NULOJIX.xml:S1:4708:3	see	NNP	O	O
Dosage	NULOJIX.xml:S1:4715:6	dosag	NNP	O	O
and	NULOJIX.xml:S1:4722:3	and	CC	O	O
Administration	NULOJIX.xml:S1:4726:14	administr	NNP	O	O
(	NULOJIX.xml:S1:4741:1	(	(	O	O
2.1	NULOJIX.xml:S1:4742:3	2.1	CD	O	O
)	NULOJIX.xml:S1:4745:1	)	)	O	O
and	NULOJIX.xml:S1:4750:3	and	CC	O	O
Warnings	NULOJIX.xml:S1:4757:8	warn	NNP	O	O
and	NULOJIX.xml:S1:4766:3	and	CC	O	O
Precautions	NULOJIX.xml:S1:4770:11	precaut	NNP	O	O
(	NULOJIX.xml:S1:4782:1	(	(	O	O
5.1	NULOJIX.xml:S1:4783:3	5.1	CD	O	O
)	NULOJIX.xml:S1:4786:1	)	)	O	O
.	NULOJIX.xml:S1:4791:1	.	.	O	O
]	NULOJIX.xml:S1:4792:1	]	NN	O	O

One	NULOJIX.xml:S1:4798:3	one	CD	O	O
of	NULOJIX.xml:S1:4802:2	of	IN	O	O
the	NULOJIX.xml:S1:4805:3	the	DT	O	O
476	NULOJIX.xml:S1:4809:3	476	CD	O	O
patients	NULOJIX.xml:S1:4813:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:4822:7	treat	VBN	O	O
with	NULOJIX.xml:S1:4830:4	with	IN	O	O
cyclosporine	NULOJIX.xml:S1:4835:12	cyclosporin	NN	O	O
developed	NULOJIX.xml:S1:4848:9	develop	VBN	O	O
PTLD	NULOJIX.xml:S1:4858:4	ptld	NNP	B-AdverseReaction	O
,	NULOJIX.xml:S1:4862:1	,	,	O	O
without	NULOJIX.xml:S1:4864:7	without	IN	O	O
CNS	NULOJIX.xml:S1:4872:3	cn	NNP	O	O
involvement	NULOJIX.xml:S1:4876:11	involv	NN	O	O
.	NULOJIX.xml:S1:4887:1	.	.	O	O

All	NULOJIX.xml:S1:4893:3	all	DT	O	O
cases	NULOJIX.xml:S1:4897:5	case	NNS	O	O
of	NULOJIX.xml:S1:4903:2	of	IN	O	O
PTLD	NULOJIX.xml:S1:4906:4	ptld	NNP	B-AdverseReaction	O
reported	NULOJIX.xml:S1:4911:8	report	VBD	O	O
up	NULOJIX.xml:S1:4920:2	up	RB	O	O
to	NULOJIX.xml:S1:4923:2	to	TO	O	O
36	NULOJIX.xml:S1:4926:2	36	CD	O	O
months	NULOJIX.xml:S1:4929:6	month	NNS	O	O
post	NULOJIX.xml:S1:4936:4	post	VBN	O	O
transplant	NULOJIX.xml:S1:4941:10	transplant	NN	O	O
in	NULOJIX.xml:S1:4952:2	in	IN	O	O
NULOJIX	NULOJIX.xml:S1:4955:7	nulojix	NNP	O	O
-	NULOJIX.xml:S1:4962:1	-	:	O	O
or	NULOJIX.xml:S1:4964:2	or	CC	O	O
cyclosporine	NULOJIX.xml:S1:4967:12	cyclosporin	VB	O	O
-	NULOJIX.xml:S1:4979:1	-	:	O	O
treated	NULOJIX.xml:S1:4980:7	treat	JJ	O	O
patients	NULOJIX.xml:S1:4988:8	patient	NNS	O	O
presented	NULOJIX.xml:S1:4997:9	present	VBD	O	O
within	NULOJIX.xml:S1:5007:6	within	IN	O	O
18	NULOJIX.xml:S1:5014:2	18	CD	O	O
months	NULOJIX.xml:S1:5017:6	month	NNS	O	O
of	NULOJIX.xml:S1:5024:2	of	IN	O	O
transplantation	NULOJIX.xml:S1:5027:15	transplant	NN	O	O
.	NULOJIX.xml:S1:5042:1	.	.	O	O

Overall	NULOJIX.xml:S1:5048:7	overal	JJ	O	O
,	NULOJIX.xml:S1:5055:1	,	,	O	O
the	NULOJIX.xml:S1:5057:3	the	DT	O	O
rate	NULOJIX.xml:S1:5061:4	rate	NN	O	O
of	NULOJIX.xml:S1:5066:2	of	IN	O	O
PTLD	NULOJIX.xml:S1:5069:4	ptld	NNP	B-AdverseReaction	O
in	NULOJIX.xml:S1:5074:2	in	IN	O	O
949	NULOJIX.xml:S1:5077:3	949	CD	O	O
patients	NULOJIX.xml:S1:5081:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:5090:7	treat	VBN	O	O
with	NULOJIX.xml:S1:5098:4	with	IN	O	O
any	NULOJIX.xml:S1:5103:3	ani	DT	O	O
of	NULOJIX.xml:S1:5107:2	of	IN	O	O
the	NULOJIX.xml:S1:5110:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:5114:7	nulojix	NNP	O	O
regimens	NULOJIX.xml:S1:5122:8	regimen	NNS	O	O
was	NULOJIX.xml:S1:5131:3	wa	VBD	O	O
9	NULOJIX.xml:S1:5135:1	9	CD	O	O
-	NULOJIX.xml:S1:5136:1	-	:	O	O
fold	NULOJIX.xml:S1:5137:4	fold	NN	O	O
higher	NULOJIX.xml:S1:5142:6	higher	RBR	O	O
in	NULOJIX.xml:S1:5149:2	in	IN	O	O
those	NULOJIX.xml:S1:5152:5	those	DT	O	O
who	NULOJIX.xml:S1:5158:3	who	WP	O	O
were	NULOJIX.xml:S1:5162:4	were	VBD	O	O
EBV	NULOJIX.xml:S1:5167:3	ebv	NNP	O	O
seronegative	NULOJIX.xml:S1:5171:12	seroneg	JJ	O	O
or	NULOJIX.xml:S1:5184:2	or	CC	O	O
EBV	NULOJIX.xml:S1:5187:3	ebv	NNP	O	O
serostatus	NULOJIX.xml:S1:5191:10	serostatu	VBP	O	O
unknown	NULOJIX.xml:S1:5202:7	unknown	JJ	O	O
(	NULOJIX.xml:S1:5210:1	(	(	O	O
8	NULOJIX.xml:S1:5211:1	8	CD	O	O
139	NULOJIX.xml:S1:5213:3	139	CD	O	O
)	NULOJIX.xml:S1:5216:1	)	)	O	O
compared	NULOJIX.xml:S1:5218:8	compar	VBN	O	O
to	NULOJIX.xml:S1:5227:2	to	TO	O	O
those	NULOJIX.xml:S1:5230:5	those	DT	O	O
who	NULOJIX.xml:S1:5236:3	who	WP	O	O
were	NULOJIX.xml:S1:5240:4	were	VBD	O	O
EBV	NULOJIX.xml:S1:5245:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S1:5249:12	seroposit	JJ	O	O
(	NULOJIX.xml:S1:5262:1	(	(	O	O
5	NULOJIX.xml:S1:5263:1	5	CD	O	O
810	NULOJIX.xml:S1:5265:3	810	CD	O	O
patients	NULOJIX.xml:S1:5269:8	patient	NNS	O	O
)	NULOJIX.xml:S1:5277:1	)	)	O	O
.	NULOJIX.xml:S1:5278:1	.	.	O	O

Therefore	NULOJIX.xml:S1:5280:9	therefor	RB	O	O
NULOJIX	NULOJIX.xml:S1:5290:7	nulojix	NNP	O	O
is	NULOJIX.xml:S1:5298:2	is	VBZ	O	O
recommended	NULOJIX.xml:S1:5301:11	recommend	VBN	O	O
for	NULOJIX.xml:S1:5313:3	for	IN	O	O
use	NULOJIX.xml:S1:5317:3	use	NN	O	O
only	NULOJIX.xml:S1:5321:4	onli	RB	O	O
in	NULOJIX.xml:S1:5326:2	in	IN	O	O
patients	NULOJIX.xml:S1:5329:8	patient	NNS	O	O
who	NULOJIX.xml:S1:5338:3	who	WP	O	O
are	NULOJIX.xml:S1:5342:3	are	VBP	O	O
EBV	NULOJIX.xml:S1:5346:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S1:5350:12	seroposit	JJ	O	O
[	NULOJIX.xml:S1:5363:1	[	NNP	O	O
see	NULOJIX.xml:S1:5364:3	see	NN	O	O
Boxed	NULOJIX.xml:S1:5371:5	box	NNP	O	O
Warning	NULOJIX.xml:S1:5377:7	warn	NNP	O	O
and	NULOJIX.xml:S1:5388:3	and	CC	O	O
Contraindications	NULOJIX.xml:S1:5395:17	contraind	NNP	O	O
(	NULOJIX.xml:S1:5413:1	(	(	O	O
4	NULOJIX.xml:S1:5414:1	4	CD	O	O
)	NULOJIX.xml:S1:5415:1	)	)	O	O
]	NULOJIX.xml:S1:5420:1	]	NN	O	O
.	NULOJIX.xml:S1:5421:1	.	.	O	O

Table	NULOJIX.xml:S1:5427:5	tabl	JJ	O	O
2	NULOJIX.xml:S1:5433:1	2	CD	O	O
:	NULOJIX.xml:S1:5434:1	:	:	O	O
Summary	NULOJIX.xml:S1:5436:7	summari	NN	O	O
of	NULOJIX.xml:S1:5444:2	of	IN	O	O
PTLD	NULOJIX.xml:S1:5447:4	ptld	NNP	B-AdverseReaction	O
Reported	NULOJIX.xml:S1:5452:8	report	NNP	O	O
in	NULOJIX.xml:S1:5461:2	in	IN	O	O
Studies	NULOJIX.xml:S1:5464:7	studi	NNP	O	O
1	NULOJIX.xml:S1:5472:1	1	CD	O	O
,	NULOJIX.xml:S1:5473:1	,	,	O	O
2	NULOJIX.xml:S1:5475:1	2	CD	O	O
,	NULOJIX.xml:S1:5476:1	,	,	O	O
and	NULOJIX.xml:S1:5478:3	and	CC	O	O
3	NULOJIX.xml:S1:5482:1	3	CD	O	O
Through	NULOJIX.xml:S1:5484:7	through	IN	O	O
Three	NULOJIX.xml:S1:5492:5	three	CD	O	O
Years	NULOJIX.xml:S1:5498:5	year	NNS	O	O
of	NULOJIX.xml:S1:5504:2	of	IN	O	O
Treatment	NULOJIX.xml:S1:5507:9	treatment	NN	O	O

NULOJIX	NULOJIX.xml:S1:5538:7	nulojix	NNP	O	O
Non	NULOJIX.xml:S1:5549:3	non	NNP	O	O
-	NULOJIX.xml:S1:5552:1	-	:	O	O
Recommended	NULOJIX.xml:S1:5553:11	recommend	VBN	O	O
Regimen	NULOJIX.xml:S1:5568:7	regimen	NNP	O	O
(	NULOJIX.xml:S1:5580:1	(	(	O	O
N	NULOJIX.xml:S1:5581:1	N	NNP	O	O
477	NULOJIX.xml:S1:5583:3	477	CD	O	O
)	NULOJIX.xml:S1:5586:1	)	)	O	O
NULOJIX	NULOJIX.xml:S1:5593:7	nulojix	NNP	O	O
Recommended	NULOJIX.xml:S1:5604:11	recommend	NNP	O	O
Regimen	NULOJIX.xml:S1:5619:7	regimen	NNP	O	O
(	NULOJIX.xml:S1:5634:1	(	(	O	O
N	NULOJIX.xml:S1:5635:1	N	NNP	O	O
472	NULOJIX.xml:S1:5637:3	472	CD	O	O
)	NULOJIX.xml:S1:5640:1	)	)	O	O
Cyclosporine	NULOJIX.xml:S1:5647:12	cyclosporin	NNP	O	O
(	NULOJIX.xml:S1:5663:1	(	(	O	O
N	NULOJIX.xml:S1:5664:1	N	NNP	O	O
476	NULOJIX.xml:S1:5666:3	476	CD	O	O
)	NULOJIX.xml:S1:5669:1	)	)	O	O

Trial	NULOJIX.xml:S1:5679:5	trial	JJ	O	O
EBV	NULOJIX.xml:S1:5696:3	ebv	NNP	O	O
Positive	NULOJIX.xml:S1:5703:8	posit	NNP	O	O
(	NULOJIX.xml:S1:5715:1	(	(	O	O
n	NULOJIX.xml:S1:5716:1	n	JJ	O	O
406	NULOJIX.xml:S1:5718:3	406	CD	O	O
)	NULOJIX.xml:S1:5721:1	)	)	O	O
EBV	NULOJIX.xml:S1:5728:3	ebv	NNP	O	O
Negative	NULOJIX.xml:S1:5735:8	neg	NNP	O	O
(	NULOJIX.xml:S1:5747:1	(	(	O	O
n	NULOJIX.xml:S1:5748:1	n	JJ	O	O
43	NULOJIX.xml:S1:5750:2	43	CD	O	O
)	NULOJIX.xml:S1:5752:1	)	)	O	O
EBV	NULOJIX.xml:S1:5759:3	ebv	NNP	O	O
Unknown	NULOJIX.xml:S1:5766:7	unknown	NNP	O	O
(	NULOJIX.xml:S1:5777:1	(	(	O	O
n	NULOJIX.xml:S1:5778:1	n	JJ	O	O
28	NULOJIX.xml:S1:5780:2	28	CD	O	O
)	NULOJIX.xml:S1:5782:1	)	)	O	O
EBV	NULOJIX.xml:S1:5789:3	ebv	NNP	O	O
Positive	NULOJIX.xml:S1:5796:8	posit	NNP	O	O
(	NULOJIX.xml:S1:5808:1	(	(	O	O
n	NULOJIX.xml:S1:5809:1	n	JJ	O	O
404	NULOJIX.xml:S1:5811:3	404	CD	O	O
)	NULOJIX.xml:S1:5814:1	)	)	O	O
EBV	NULOJIX.xml:S1:5821:3	ebv	NNP	O	O
Negative	NULOJIX.xml:S1:5828:8	neg	NNP	O	O
(	NULOJIX.xml:S1:5840:1	(	(	O	O
n	NULOJIX.xml:S1:5841:1	n	JJ	O	O
48	NULOJIX.xml:S1:5843:2	48	CD	O	O
)	NULOJIX.xml:S1:5845:1	)	)	O	O
EBV	NULOJIX.xml:S1:5852:3	ebv	NNP	O	O
Unknown	NULOJIX.xml:S1:5859:7	unknown	NNP	O	O
(	NULOJIX.xml:S1:5870:1	(	(	O	O
n	NULOJIX.xml:S1:5871:1	n	JJ	O	O
20	NULOJIX.xml:S1:5873:2	20	CD	O	O
)	NULOJIX.xml:S1:5875:1	)	)	O	O
EBV	NULOJIX.xml:S1:5882:3	ebv	NNP	O	O
Positive	NULOJIX.xml:S1:5889:8	posit	NNP	O	O
(	NULOJIX.xml:S1:5901:1	(	(	O	O
n	NULOJIX.xml:S1:5902:1	n	JJ	O	O
399	NULOJIX.xml:S1:5904:3	399	CD	O	O
)	NULOJIX.xml:S1:5907:1	)	)	O	O
EBV	NULOJIX.xml:S1:5914:3	ebv	NNP	O	O
Negative	NULOJIX.xml:S1:5921:8	neg	NNP	O	O
(	NULOJIX.xml:S1:5933:1	(	(	O	O
n	NULOJIX.xml:S1:5934:1	n	JJ	O	O
57	NULOJIX.xml:S1:5936:2	57	CD	O	O
)	NULOJIX.xml:S1:5938:1	)	)	O	O
EBV	NULOJIX.xml:S1:5945:3	ebv	NNP	O	O
Unknown	NULOJIX.xml:S1:5952:7	unknown	NNP	O	O
(	NULOJIX.xml:S1:5963:1	(	(	O	O
n	NULOJIX.xml:S1:5964:1	n	JJ	O	O
20	NULOJIX.xml:S1:5966:2	20	CD	O	O
)	NULOJIX.xml:S1:5968:1	)	)	O	O

Regimen	NULOJIX.xml:S1:5982:7	regimen	NNS	O	O

with	NULOJIX.xml:S1:5990:4	with	IN	O	O
higher	NULOJIX.xml:S1:5995:6	higher	JJR	O	O
cumulative	NULOJIX.xml:S1:6002:10	cumul	NN	O	O
dose	NULOJIX.xml:S1:6013:4	dose	NN	O	O
and	NULOJIX.xml:S1:6018:3	and	CC	O	O
more	NULOJIX.xml:S1:6022:4	more	RBR	O	O
frequent	NULOJIX.xml:S1:6027:8	frequent	JJ	O	O
dosing	NULOJIX.xml:S1:6036:6	dose	NN	O	O
than	NULOJIX.xml:S1:6043:4	than	IN	O	O
the	NULOJIX.xml:S1:6048:3	the	DT	O	O
recommended	NULOJIX.xml:S1:6052:11	recommend	JJ	O	O
NULOJIX	NULOJIX.xml:S1:6064:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:6072:7	regimen	NNS	O	O
.	NULOJIX.xml:S1:6079:1	.	.	O	O

In	NULOJIX.xml:S1:6086:2	In	IN	O	O
Studies	NULOJIX.xml:S1:6089:7	studi	NNP	O	O
1	NULOJIX.xml:S1:6097:1	1	CD	O	O
and	NULOJIX.xml:S1:6099:3	and	CC	O	O
2	NULOJIX.xml:S1:6103:1	2	CD	O	O
the	NULOJIX.xml:S1:6105:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:6109:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:6117:7	regimen	NNS	O	O
is	NULOJIX.xml:S1:6125:2	is	VBZ	O	O
identical	NULOJIX.xml:S1:6128:9	ident	JJ	O	O
to	NULOJIX.xml:S1:6138:2	to	TO	O	O
the	NULOJIX.xml:S1:6141:3	the	DT	O	O
recommended	NULOJIX.xml:S1:6145:11	recommend	VBN	O	O
regimen	NULOJIX.xml:S1:6157:7	regimen	NNS	O	O
,	NULOJIX.xml:S1:6164:1	,	,	O	O
but	NULOJIX.xml:S1:6166:3	but	CC	O	O
is	NULOJIX.xml:S1:6170:2	is	VBZ	O	O
slightly	NULOJIX.xml:S1:6173:8	slightli	RB	O	O
different	NULOJIX.xml:S1:6182:9	differ	JJ	O	O
in	NULOJIX.xml:S1:6192:2	in	IN	O	O
Study	NULOJIX.xml:S1:6195:5	studi	NNP	O	O
3	NULOJIX.xml:S1:6201:1	3	CD	O	O
.	NULOJIX.xml:S1:6202:1	.	.	O	O

Study	NULOJIX.xml:S1:6212:5	studi	NN	O	O

1	NULOJIX.xml:S1:6218:1	1	CD	O	O

CNS	NULOJIX.xml:S1:6232:3	cn	NNP	B-AdverseReaction	B-AdverseReaction
PTLD	NULOJIX.xml:S1:6236:4	ptld	NNP	I-AdverseReaction	I-AdverseReaction
1	NULOJIX.xml:S1:6249:1	1	CD	O	O
1	NULOJIX.xml:S1:6261:1	1	CD	O	O

Non	NULOJIX.xml:S1:6355:3	non	NNP	B-AdverseReaction	B-AdverseReaction
-	NULOJIX.xml:S1:6358:1	-	:	I-AdverseReaction	I-AdverseReaction
CNSPTLD	NULOJIX.xml:S1:6359:7	cnsptld	NNP	I-AdverseReaction	I-AdverseReaction
1	NULOJIX.xml:S1:6384:1	1	CD	O	O
2	NULOJIX.xml:S1:6407:1	2	CD	O	O
1	NULOJIX.xml:S1:6453:1	1	CD	O	O

Study	NULOJIX.xml:S1:6478:5	studi	NNP	O	O
2	NULOJIX.xml:S1:6484:1	2	CD	O	O

CNS	NULOJIX.xml:S1:6498:3	cn	NNP	B-AdverseReaction	B-AdverseReaction
PTLD	NULOJIX.xml:S1:6502:4	ptld	NNP	I-AdverseReaction	I-AdverseReaction
1	NULOJIX.xml:S1:6515:1	1	CD	O	O
1	NULOJIX.xml:S1:6527:1	1	CD	O	O
1	NULOJIX.xml:S1:6550:1	1	CD	O	O
1	NULOJIX.xml:S1:6562:1	1	CD	O	O

Non	NULOJIX.xml:S1:6621:3	non	NNP	B-AdverseReaction	O
-	NULOJIX.xml:S1:6624:1	-	:	I-AdverseReaction	O
CNSPTLD	NULOJIX.xml:S1:6625:7	cnsptld	NN	I-AdverseReaction	O
1	NULOJIX.xml:S1:6685:1	1	CD	O	O

Study	NULOJIX.xml:S1:6744:5	studi	NNP	O	O
3	NULOJIX.xml:S1:6750:1	3	CD	O	O

CNS	NULOJIX.xml:S1:6764:3	cn	NNP	B-AdverseReaction	O
PTLD	NULOJIX.xml:S1:6768:4	ptld	NNP	I-AdverseReaction	O
2	NULOJIX.xml:S1:6793:1	2	CD	O	O

Non	NULOJIX.xml:S1:6887:3	non	NNP	B-AdverseReaction	O
-	NULOJIX.xml:S1:6890:1	-	:	I-AdverseReaction	O
CNSPTLD	NULOJIX.xml:S1:6891:7	cnsptld	NN	I-AdverseReaction	O
1	NULOJIX.xml:S1:6927:1	1	CD	O	O

Total	NULOJIX.xml:S1:7010:5	total	NNP	O	O
(	NULOJIX.xml:S1:7016:1	(	(	O	O
)	NULOJIX.xml:S1:7018:1	)	)	O	O
2	NULOJIX.xml:S1:7027:1	2	CD	O	O
(	NULOJIX.xml:S1:7029:1	(	(	O	O
0.5	NULOJIX.xml:S1:7030:3	0.5	CD	O	O
)	NULOJIX.xml:S1:7033:1	)	)	O	O
5	NULOJIX.xml:S1:7039:1	5	CD	O	O
(	NULOJIX.xml:S1:7041:1	(	(	O	O
11.6	NULOJIX.xml:S1:7042:4	11.6	CD	O	O
)	NULOJIX.xml:S1:7046:1	)	)	O	O
1	NULOJIX.xml:S1:7051:1	1	CD	O	O
(	NULOJIX.xml:S1:7053:1	(	(	O	O
3.6	NULOJIX.xml:S1:7054:3	3.6	CD	O	O
)	NULOJIX.xml:S1:7057:1	)	)	O	O
3	NULOJIX.xml:S1:7063:1	3	CD	O	O
(	NULOJIX.xml:S1:7065:1	(	(	O	O
0.7	NULOJIX.xml:S1:7066:3	0.7	CD	O	O
)	NULOJIX.xml:S1:7069:1	)	)	O	O
2	NULOJIX.xml:S1:7075:1	2	CD	O	O
(	NULOJIX.xml:S1:7077:1	(	(	O	O
4.1	NULOJIX.xml:S1:7078:3	4.1	CD	O	O
)	NULOJIX.xml:S1:7081:1	)	)	O	O
0	NULOJIX.xml:S1:7086:1	0	CD	O	O
0	NULOJIX.xml:S1:7098:1	0	CD	O	O
1	NULOJIX.xml:S1:7110:1	1	CD	O	O
(	NULOJIX.xml:S1:7112:1	(	(	O	O
1.8	NULOJIX.xml:S1:7113:3	1.8	CD	O	O
)	NULOJIX.xml:S1:7116:1	)	)	O	O
0	NULOJIX.xml:S1:7121:1	0	CD	O	O

EBV	NULOJIX.xml:S1:7152:3	ebv	NNP	O	O
Seropositive	NULOJIX.xml:S1:7156:12	seroposit	NNP	O	O
Subpopulation	NULOJIX.xml:S1:7169:13	subpopul	NNP	O	O

Among	NULOJIX.xml:S1:7186:5	among	IN	O	O
the	NULOJIX.xml:S1:7192:3	the	DT	O	O
806	NULOJIX.xml:S1:7196:3	806	CD	O	O
EBV	NULOJIX.xml:S1:7200:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S1:7204:12	seroposit	JJ	O	O
patients	NULOJIX.xml:S1:7217:8	patient	NNS	O	O
with	NULOJIX.xml:S1:7226:4	with	IN	O	O
known	NULOJIX.xml:S1:7231:5	known	JJ	O	O
CMV	NULOJIX.xml:S1:7237:3	cmv	NNP	O	O
serostatus	NULOJIX.xml:S1:7241:10	serostatu	NN	O	O
treated	NULOJIX.xml:S1:7252:7	treat	VBD	O	O
with	NULOJIX.xml:S1:7260:4	with	IN	O	O
either	NULOJIX.xml:S1:7265:6	either	DT	O	O
NULOJIX	NULOJIX.xml:S1:7272:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:7280:7	regimen	NNS	O	O
in	NULOJIX.xml:S1:7288:2	in	IN	O	O
Studies	NULOJIX.xml:S1:7291:7	studi	NNP	O	O
1	NULOJIX.xml:S1:7299:1	1	CD	O	O
,	NULOJIX.xml:S1:7300:1	,	,	O	O
2	NULOJIX.xml:S1:7302:1	2	CD	O	O
,	NULOJIX.xml:S1:7303:1	,	,	O	O
and	NULOJIX.xml:S1:7305:3	and	CC	O	O
3	NULOJIX.xml:S1:7309:1	3	CD	O	O
,	NULOJIX.xml:S1:7310:1	,	,	O	O
two	NULOJIX.xml:S1:7312:3	two	CD	O	O
percent	NULOJIX.xml:S1:7316:7	percent	NN	O	O
(	NULOJIX.xml:S1:7324:1	(	(	O	O
2%	NULOJIX.xml:S1:7325:2	2%	CD	O	O
;	NULOJIX.xml:S1:7327:1	;	:	O	O
4	NULOJIX.xml:S1:7329:1	4	CD	O	O
210	NULOJIX.xml:S1:7331:3	210	CD	O	O
)	NULOJIX.xml:S1:7334:1	)	)	O	O
of	NULOJIX.xml:S1:7336:2	of	IN	O	O
CMV	NULOJIX.xml:S1:7339:3	cmv	NNP	O	O
seronegative	NULOJIX.xml:S1:7343:12	seroneg	JJ	O	O
patients	NULOJIX.xml:S1:7356:8	patient	NNS	O	O
developed	NULOJIX.xml:S1:7365:9	develop	VBD	O	O
PTLD	NULOJIX.xml:S1:7375:4	ptld	NNP	B-AdverseReaction	O
compared	NULOJIX.xml:S1:7380:8	compar	VBN	O	O
to	NULOJIX.xml:S1:7389:2	to	TO	O	O
0.2%	NULOJIX.xml:S1:7392:4	0.2%	CD	O	O
(	NULOJIX.xml:S1:7397:1	(	(	O	O
1	NULOJIX.xml:S1:7398:1	1	CD	O	O
596	NULOJIX.xml:S1:7400:3	596	CD	O	O
)	NULOJIX.xml:S1:7403:1	)	)	O	O
of	NULOJIX.xml:S1:7405:2	of	IN	O	O
CMV	NULOJIX.xml:S1:7408:3	cmv	NNP	O	O
seropositive	NULOJIX.xml:S1:7412:12	seroposit	JJ	O	O
patients	NULOJIX.xml:S1:7425:8	patient	NNS	O	O
.	NULOJIX.xml:S1:7433:1	.	.	O	O

Among	NULOJIX.xml:S1:7435:5	among	IN	O	O
the	NULOJIX.xml:S1:7441:3	the	DT	O	O
404	NULOJIX.xml:S1:7445:3	404	CD	O	O
EBV	NULOJIX.xml:S1:7449:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S1:7453:12	seroposit	JJ	O	O
recipients	NULOJIX.xml:S1:7466:10	recipi	NNS	O	O
treated	NULOJIX.xml:S1:7477:7	treat	VBN	O	O
with	NULOJIX.xml:S1:7485:4	with	IN	O	O
the	NULOJIX.xml:S1:7490:3	the	DT	O	O
recommended	NULOJIX.xml:S1:7494:11	recommend	JJ	O	O
dosage	NULOJIX.xml:S1:7506:6	dosag	NN	O	O
regimen	NULOJIX.xml:S1:7513:7	regimen	NNS	O	O
of	NULOJIX.xml:S1:7521:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:7524:7	nulojix	NNP	O	O
,	NULOJIX.xml:S1:7531:1	,	,	O	O
three	NULOJIX.xml:S1:7533:5	three	CD	O	O
PTLD	NULOJIX.xml:S1:7539:4	ptld	NNP	B-AdverseReaction	O
cases	NULOJIX.xml:S1:7544:5	case	NNS	O	O
were	NULOJIX.xml:S1:7550:4	were	VBD	O	O
detected	NULOJIX.xml:S1:7555:8	detect	VBN	O	B-AdverseReaction
among	NULOJIX.xml:S1:7564:5	among	IN	O	O
99	NULOJIX.xml:S1:7570:2	99	CD	O	O
CMV	NULOJIX.xml:S1:7573:3	cmv	NNP	O	O
seronegative	NULOJIX.xml:S1:7577:12	seroneg	JJ	O	O
patients	NULOJIX.xml:S1:7590:8	patient	NNS	O	O
(	NULOJIX.xml:S1:7599:1	(	(	O	O
3%	NULOJIX.xml:S1:7600:2	3%	CD	O	O
)	NULOJIX.xml:S1:7602:1	)	)	O	O
and	NULOJIX.xml:S1:7604:3	and	CC	O	O
there	NULOJIX.xml:S1:7608:5	there	EX	O	O
was	NULOJIX.xml:S1:7614:3	wa	VBD	O	O
no	NULOJIX.xml:S1:7618:2	no	DT	O	O
case	NULOJIX.xml:S1:7621:4	case	NN	O	O
detected	NULOJIX.xml:S1:7626:8	detect	VBD	O	O
among	NULOJIX.xml:S1:7635:5	among	IN	O	O
303	NULOJIX.xml:S1:7641:3	303	CD	O	O
CMV	NULOJIX.xml:S1:7645:3	cmv	NNP	O	O
seropositive	NULOJIX.xml:S1:7649:12	seroposit	JJ	O	O
patients	NULOJIX.xml:S1:7662:8	patient	NNS	O	O
.	NULOJIX.xml:S1:7670:1	.	.	O	O

The	NULOJIX.xml:S1:7672:3	the	DT	O	O
clinical	NULOJIX.xml:S1:7676:8	clinic	JJ	O	O
significance	NULOJIX.xml:S1:7685:12	signific	NN	O	O
of	NULOJIX.xml:S1:7698:2	of	IN	O	O
CMV	NULOJIX.xml:S1:7701:3	cmv	NNP	O	O
serology	NULOJIX.xml:S1:7705:8	serolog	NN	O	O
as	NULOJIX.xml:S1:7714:2	as	IN	O	O
a	NULOJIX.xml:S1:7717:1	a	DT	O	O
risk	NULOJIX.xml:S1:7719:4	risk	NN	O	O
factor	NULOJIX.xml:S1:7724:6	factor	NN	O	O
for	NULOJIX.xml:S1:7731:3	for	IN	O	O
PTLD	NULOJIX.xml:S1:7735:4	ptld	NNP	B-AdverseReaction	O
remains	NULOJIX.xml:S1:7740:7	remain	VBZ	O	O
to	NULOJIX.xml:S1:7748:2	to	TO	O	O
be	NULOJIX.xml:S1:7751:2	be	VB	O	O
determined	NULOJIX.xml:S1:7754:10	determin	VBN	O	O
;	NULOJIX.xml:S1:7764:1	;	:	O	O
however	NULOJIX.xml:S1:7766:7	howev	RB	O	O
,	NULOJIX.xml:S1:7773:1	,	,	O	O
these	NULOJIX.xml:S1:7775:5	these	DT	O	O
findings	NULOJIX.xml:S1:7781:8	find	NNS	O	O
should	NULOJIX.xml:S1:7790:6	should	MD	O	O
be	NULOJIX.xml:S1:7797:2	be	VB	O	O
considered	NULOJIX.xml:S1:7800:10	consid	VBN	O	O
when	NULOJIX.xml:S1:7811:4	when	WRB	O	O
prescribing	NULOJIX.xml:S1:7816:11	prescrib	VBG	O	O
NULOJIX	NULOJIX.xml:S1:7828:7	nulojix	NNP	O	O
[	NULOJIX.xml:S1:7836:1	[	NNP	O	O
see	NULOJIX.xml:S1:7837:3	see	VBP	O	O
Warnings	NULOJIX.xml:S1:7844:8	warn	NNP	O	O
and	NULOJIX.xml:S1:7853:3	and	CC	O	O
Precautions	NULOJIX.xml:S1:7857:11	precaut	NNP	O	O
(	NULOJIX.xml:S1:7869:1	(	(	O	O
5.1	NULOJIX.xml:S1:7870:3	5.1	CD	O	O
)	NULOJIX.xml:S1:7873:1	)	)	O	O
]	NULOJIX.xml:S1:7878:1	]	NN	O	O
.	NULOJIX.xml:S1:7879:1	.	.	O	O

Other	NULOJIX.xml:S1:7887:5	other	JJ	O	O
Malignancies	NULOJIX.xml:S1:7893:12	malign	NNS	O	O

Malignancies	NULOJIX.xml:S1:7909:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:7921:1	,	,	O	O
excluding	NULOJIX.xml:S1:7923:9	exclud	VBG	O	O
non	NULOJIX.xml:S1:7933:3	non	SYM	B-AdverseReaction	B-AdverseReaction
-	NULOJIX.xml:S1:7936:1	-	:	I-AdverseReaction	I-AdverseReaction
melanoma	NULOJIX.xml:S1:7937:8	melanoma	NN	I-AdverseReaction	I-AdverseReaction
skin	NULOJIX.xml:S1:7946:4	skin	NN	I-AdverseReaction	I-AdverseReaction
cancer	NULOJIX.xml:S1:7951:6	cancer	NN	I-AdverseReaction	I-AdverseReaction
and	NULOJIX.xml:S1:7958:3	and	CC	O	O
PTLD	NULOJIX.xml:S1:7962:4	ptld	NNP	B-AdverseReaction	O
,	NULOJIX.xml:S1:7966:1	,	,	O	O
were	NULOJIX.xml:S1:7968:4	were	VBD	O	O
reported	NULOJIX.xml:S1:7973:8	report	VBN	O	O
in	NULOJIX.xml:S1:7982:2	in	IN	O	O
Study	NULOJIX.xml:S1:7985:5	studi	NNP	O	O
1	NULOJIX.xml:S1:7991:1	1	CD	O	O
and	NULOJIX.xml:S1:7993:3	and	CC	O	O
Study	NULOJIX.xml:S1:7997:5	studi	NNP	O	O
2	NULOJIX.xml:S1:8003:1	2	CD	O	O
in	NULOJIX.xml:S1:8005:2	in	IN	O	O
3.5%	NULOJIX.xml:S1:8008:4	3.5%	CD	O	O
(	NULOJIX.xml:S1:8013:1	(	(	O	O
14	NULOJIX.xml:S1:8014:2	14	CD	O	O
401	NULOJIX.xml:S1:8017:3	401	CD	O	O
)	NULOJIX.xml:S1:8020:1	)	)	O	O
of	NULOJIX.xml:S1:8022:2	of	IN	O	O
patients	NULOJIX.xml:S1:8025:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:8034:7	treat	VBN	O	O
with	NULOJIX.xml:S1:8042:4	with	IN	O	O
the	NULOJIX.xml:S1:8047:3	the	DT	O	O
recommended	NULOJIX.xml:S1:8051:11	recommend	VBN	O	O
NULOJIX	NULOJIX.xml:S1:8063:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:8071:7	regimen	NNS	O	O
and	NULOJIX.xml:S1:8079:3	and	CC	O	O
3.7%	NULOJIX.xml:S1:8083:4	3.7%	CD	O	O
(	NULOJIX.xml:S1:8088:1	(	(	O	O
15	NULOJIX.xml:S1:8089:2	15	CD	O	O
405	NULOJIX.xml:S1:8092:3	405	CD	O	O
)	NULOJIX.xml:S1:8095:1	)	)	O	O
of	NULOJIX.xml:S1:8097:2	of	IN	O	O
patients	NULOJIX.xml:S1:8100:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:8109:7	treat	VBN	O	O
with	NULOJIX.xml:S1:8117:4	with	IN	O	O
the	NULOJIX.xml:S1:8122:3	the	DT	O	O
cyclosporine	NULOJIX.xml:S1:8126:12	cyclosporin	NN	O	O
control	NULOJIX.xml:S1:8139:7	control	NN	O	O
regimen	NULOJIX.xml:S1:8147:7	regimen	NNS	O	O
.	NULOJIX.xml:S1:8154:1	.	.	O	O

Non	NULOJIX.xml:S1:8156:3	non	NNP	B-AdverseReaction	B-AdverseReaction
-	NULOJIX.xml:S1:8159:1	-	:	I-AdverseReaction	I-AdverseReaction
melanoma	NULOJIX.xml:S1:8160:8	melanoma	NN	I-AdverseReaction	I-AdverseReaction
skin	NULOJIX.xml:S1:8169:4	skin	NN	I-AdverseReaction	I-AdverseReaction
cancer	NULOJIX.xml:S1:8174:6	cancer	NN	I-AdverseReaction	I-AdverseReaction
was	NULOJIX.xml:S1:8181:3	wa	VBD	O	O
reported	NULOJIX.xml:S1:8185:8	report	VBN	O	O
in	NULOJIX.xml:S1:8194:2	in	IN	O	O
1.5%	NULOJIX.xml:S1:8197:4	1.5%	CD	O	O
(	NULOJIX.xml:S1:8202:1	(	(	O	O
6	NULOJIX.xml:S1:8203:1	6	CD	O	O
401	NULOJIX.xml:S1:8205:3	401	CD	O	O
)	NULOJIX.xml:S1:8208:1	)	)	O	O
of	NULOJIX.xml:S1:8210:2	of	IN	O	O
patients	NULOJIX.xml:S1:8213:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:8222:7	treat	VBN	O	O
with	NULOJIX.xml:S1:8230:4	with	IN	O	O
the	NULOJIX.xml:S1:8235:3	the	DT	O	O
recommended	NULOJIX.xml:S1:8239:11	recommend	VBN	O	O
NULOJIX	NULOJIX.xml:S1:8251:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:8259:7	regimen	NNS	O	O
and	NULOJIX.xml:S1:8267:3	and	CC	O	O
in	NULOJIX.xml:S1:8271:2	in	IN	O	O
3.7%	NULOJIX.xml:S1:8274:4	3.7%	CD	O	O
(	NULOJIX.xml:S1:8279:1	(	(	O	O
15	NULOJIX.xml:S1:8280:2	15	CD	O	O
405	NULOJIX.xml:S1:8283:3	405	CD	O	O
)	NULOJIX.xml:S1:8286:1	)	)	O	O
of	NULOJIX.xml:S1:8288:2	of	IN	O	O
patients	NULOJIX.xml:S1:8291:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:8300:7	treat	VBN	O	O
with	NULOJIX.xml:S1:8308:4	with	IN	O	O
cyclosporine	NULOJIX.xml:S1:8313:12	cyclosporin	JJ	O	O
[	NULOJIX.xml:S1:8326:1	[	NNP	O	O
see	NULOJIX.xml:S1:8327:3	see	VBP	O	O
Warnings	NULOJIX.xml:S1:8334:8	warn	NNP	O	O
and	NULOJIX.xml:S1:8343:3	and	CC	O	O
Precautions	NULOJIX.xml:S1:8347:11	precaut	NNP	O	O
(	NULOJIX.xml:S1:8359:1	(	(	O	O
5.3	NULOJIX.xml:S1:8360:3	5.3	CD	O	O
)	NULOJIX.xml:S1:8363:1	)	)	O	O
]	NULOJIX.xml:S1:8368:1	]	NN	O	O
.	NULOJIX.xml:S1:8369:1	.	.	O	O

Progressive	NULOJIX.xml:S1:8377:11	progress	JJ	O	O
Multifocal	NULOJIX.xml:S1:8389:10	multifoc	NNP	O	O
Leukoencephalopathy	NULOJIX.xml:S1:8400:19	leukoencephalopathi	NNP	O	O

Two	NULOJIX.xml:S1:8423:3	two	CD	O	O
fatal	NULOJIX.xml:S1:8427:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
cases	NULOJIX.xml:S1:8433:5	case	NNS	O	O
of	NULOJIX.xml:S1:8439:2	of	IN	O	O
progressive	NULOJIX.xml:S1:8442:11	progress	JJ	B-AdverseReaction	B-AdverseReaction
multifocal	NULOJIX.xml:S1:8454:10	multifoc	JJ	I-AdverseReaction	I-AdverseReaction
leukoencephalopathy	NULOJIX.xml:S1:8465:19	leukoencephalopathi	NN	I-AdverseReaction	I-AdverseReaction
(	NULOJIX.xml:S1:8485:1	(	(	O	O
PML	NULOJIX.xml:S1:8486:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
)	NULOJIX.xml:S1:8489:1	)	)	O	O
have	NULOJIX.xml:S1:8491:4	have	VBP	O	O
been	NULOJIX.xml:S1:8496:4	been	VBN	O	O
reported	NULOJIX.xml:S1:8501:8	report	VBN	O	O
among	NULOJIX.xml:S1:8510:5	among	IN	O	O
1096	NULOJIX.xml:S1:8516:4	1096	CD	O	O
patients	NULOJIX.xml:S1:8521:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:8530:7	treat	VBN	O	O
with	NULOJIX.xml:S1:8538:4	with	IN	O	O
a	NULOJIX.xml:S1:8543:1	a	DT	O	O
NULOJIX	NULOJIX.xml:S1:8545:7	nulojix	NNP	O	O
-	NULOJIX.xml:S1:8552:1	-	:	O	O
containing	NULOJIX.xml:S1:8553:10	contain	VBG	O	O
regimen	NULOJIX.xml:S1:8564:7	regimen	NNS	O	O
:	NULOJIX.xml:S1:8571:1	:	:	O	O
one	NULOJIX.xml:S1:8573:3	one	CD	O	O
patient	NULOJIX.xml:S1:8577:7	patient	NN	O	O
in	NULOJIX.xml:S1:8585:2	in	IN	O	O
clinical	NULOJIX.xml:S1:8588:8	clinic	JJ	O	O
trials	NULOJIX.xml:S1:8597:6	trial	NNS	O	O
of	NULOJIX.xml:S1:8604:2	of	IN	O	O
kidney	NULOJIX.xml:S1:8607:6	kidney	NN	O	O
transplant	NULOJIX.xml:S1:8614:10	transplant	NN	O	O
(	NULOJIX.xml:S1:8625:1	(	(	O	O
Studies	NULOJIX.xml:S1:8626:7	studi	NNPS	O	O
1	NULOJIX.xml:S1:8634:1	1	CD	O	O
,	NULOJIX.xml:S1:8635:1	,	,	O	O
2	NULOJIX.xml:S1:8637:1	2	CD	O	O
,	NULOJIX.xml:S1:8638:1	,	,	O	O
and	NULOJIX.xml:S1:8640:3	and	CC	O	O
3	NULOJIX.xml:S1:8644:1	3	CD	O	O
described	NULOJIX.xml:S1:8646:9	describ	NNS	O	O
above	NULOJIX.xml:S1:8656:5	abov	IN	O	O
)	NULOJIX.xml:S1:8661:1	)	)	O	O
and	NULOJIX.xml:S1:8663:3	and	CC	O	O
one	NULOJIX.xml:S1:8667:3	one	CD	O	O
patient	NULOJIX.xml:S1:8671:7	patient	NN	O	O
in	NULOJIX.xml:S1:8679:2	in	IN	O	O
a	NULOJIX.xml:S1:8682:1	a	DT	O	O
trial	NULOJIX.xml:S1:8684:5	trial	NN	O	O
of	NULOJIX.xml:S1:8690:2	of	IN	O	O
liver	NULOJIX.xml:S1:8693:5	liver	NN	O	O
transplant	NULOJIX.xml:S1:8699:10	transplant	NN	O	O
(	NULOJIX.xml:S1:8710:1	(	(	O	O
trial	NULOJIX.xml:S1:8711:5	trial	NN	O	O
of	NULOJIX.xml:S1:8717:2	of	IN	O	O
250	NULOJIX.xml:S1:8720:3	250	CD	O	O
patients	NULOJIX.xml:S1:8724:8	patient	NNS	O	O
)	NULOJIX.xml:S1:8732:1	)	)	O	O
.	NULOJIX.xml:S1:8733:1	.	.	O	O

No	NULOJIX.xml:S1:8735:2	No	DT	O	O
cases	NULOJIX.xml:S1:8738:5	case	NNS	O	O
of	NULOJIX.xml:S1:8744:2	of	IN	O	O
PML	NULOJIX.xml:S1:8747:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
were	NULOJIX.xml:S1:8751:4	were	VBD	O	O
reported	NULOJIX.xml:S1:8756:8	report	VBN	O	O
in	NULOJIX.xml:S1:8765:2	in	IN	O	O
patients	NULOJIX.xml:S1:8768:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:8777:7	treat	VBN	O	O
with	NULOJIX.xml:S1:8785:4	with	IN	O	O
the	NULOJIX.xml:S1:8790:3	the	DT	O	O
recommended	NULOJIX.xml:S1:8794:11	recommend	VBN	O	O
NULOJIX	NULOJIX.xml:S1:8806:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:8814:7	regimen	NNS	O	O
or	NULOJIX.xml:S1:8822:2	or	CC	O	O
the	NULOJIX.xml:S1:8825:3	the	DT	O	O
control	NULOJIX.xml:S1:8829:7	control	JJ	O	O
regimen	NULOJIX.xml:S1:8837:7	regimen	NNS	O	O
in	NULOJIX.xml:S1:8845:2	in	IN	O	O
these	NULOJIX.xml:S1:8848:5	these	DT	O	O
trials	NULOJIX.xml:S1:8854:6	trial	NNS	O	O
.	NULOJIX.xml:S1:8860:1	.	.	O	O

The	NULOJIX.xml:S1:8866:3	the	DT	O	O
kidney	NULOJIX.xml:S1:8870:6	kidney	NN	O	O
transplant	NULOJIX.xml:S1:8877:10	transplant	NN	O	O
recipient	NULOJIX.xml:S1:8888:9	recipi	NN	O	O
was	NULOJIX.xml:S1:8898:3	wa	VBD	O	O
treated	NULOJIX.xml:S1:8902:7	treat	VBN	O	O
with	NULOJIX.xml:S1:8910:4	with	IN	O	O
the	NULOJIX.xml:S1:8915:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:8919:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:8927:7	regimen	NNS	O	O
of	NULOJIX.xml:S1:8935:2	of	IN	O	O
higher	NULOJIX.xml:S1:8938:6	higher	JJR	O	O
cumulative	NULOJIX.xml:S1:8945:10	cumul	JJ	O	O
dose	NULOJIX.xml:S1:8956:4	dose	NN	O	O
and	NULOJIX.xml:S1:8961:3	and	CC	O	O
more	NULOJIX.xml:S1:8965:4	more	RBR	O	O
frequent	NULOJIX.xml:S1:8970:8	frequent	JJ	O	O
dosing	NULOJIX.xml:S1:8979:6	dose	NN	O	O
than	NULOJIX.xml:S1:8986:4	than	IN	O	O
recommended	NULOJIX.xml:S1:8991:11	recommend	VBN	O	O
,	NULOJIX.xml:S1:9002:1	,	,	O	O
mycophenolate	NULOJIX.xml:S1:9004:13	mycophenol	VB	O	O
mofetil	NULOJIX.xml:S1:9018:7	mofetil	NN	O	O
(	NULOJIX.xml:S1:9026:1	(	(	O	O
MMF	NULOJIX.xml:S1:9027:3	mmf	NNP	O	O
)	NULOJIX.xml:S1:9030:1	)	)	O	O
,	NULOJIX.xml:S1:9031:1	,	,	O	O
and	NULOJIX.xml:S1:9033:3	and	CC	O	O
corticosteroids	NULOJIX.xml:S1:9037:15	corticosteroid	NNS	O	O
for	NULOJIX.xml:S1:9053:3	for	IN	O	O
2	NULOJIX.xml:S1:9057:1	2	CD	O	O
years	NULOJIX.xml:S1:9059:5	year	NNS	O	O
.	NULOJIX.xml:S1:9064:1	.	.	O	O

The	NULOJIX.xml:S1:9066:3	the	DT	O	O
liver	NULOJIX.xml:S1:9070:5	liver	NN	O	O
transplant	NULOJIX.xml:S1:9076:10	transplant	NN	O	O
recipient	NULOJIX.xml:S1:9087:9	recipi	NN	O	O
was	NULOJIX.xml:S1:9097:3	wa	VBD	O	O
treated	NULOJIX.xml:S1:9101:7	treat	VBN	O	O
with	NULOJIX.xml:S1:9109:4	with	IN	O	O
6	NULOJIX.xml:S1:9114:1	6	CD	O	O
months	NULOJIX.xml:S1:9116:6	month	NNS	O	O
of	NULOJIX.xml:S1:9123:2	of	IN	O	O
a	NULOJIX.xml:S1:9126:1	a	DT	O	O
NULOJIX	NULOJIX.xml:S1:9128:7	nulojix	NNP	O	O
dosage	NULOJIX.xml:S1:9136:6	dosag	NN	O	O
regimen	NULOJIX.xml:S1:9143:7	regimen	NNS	O	O
that	NULOJIX.xml:S1:9151:4	that	WDT	O	O
was	NULOJIX.xml:S1:9156:3	wa	VBD	O	O
more	NULOJIX.xml:S1:9160:4	more	RBR	O	O
intensive	NULOJIX.xml:S1:9165:9	intens	JJ	O	O
than	NULOJIX.xml:S1:9175:4	than	IN	O	O
that	NULOJIX.xml:S1:9180:4	that	DT	O	O
studied	NULOJIX.xml:S1:9185:7	studi	VBN	O	O
in	NULOJIX.xml:S1:9193:2	in	IN	O	O
kidney	NULOJIX.xml:S1:9196:6	kidney	NN	O	O
transplant	NULOJIX.xml:S1:9203:10	transplant	NN	O	O
recipients	NULOJIX.xml:S1:9214:10	recipi	NNS	O	O
,	NULOJIX.xml:S1:9224:1	,	,	O	O
MMF	NULOJIX.xml:S1:9226:3	mmf	NNP	O	O
at	NULOJIX.xml:S1:9230:2	at	IN	O	O
doses	NULOJIX.xml:S1:9233:5	dose	VBZ	O	O
higher	NULOJIX.xml:S1:9239:6	higher	JJR	O	O
than	NULOJIX.xml:S1:9246:4	than	IN	O	O
the	NULOJIX.xml:S1:9251:3	the	DT	O	O
recommended	NULOJIX.xml:S1:9255:11	recommend	VBN	O	O
dose	NULOJIX.xml:S1:9267:4	dose	NN	O	O
,	NULOJIX.xml:S1:9271:1	,	,	O	O
and	NULOJIX.xml:S1:9273:3	and	CC	O	O
corticosteroids	NULOJIX.xml:S1:9277:15	corticosteroid	NNS	O	O
[	NULOJIX.xml:S1:9293:1	[	NNP	O	O
see	NULOJIX.xml:S1:9294:3	see	VBP	O	O
Warnings	NULOJIX.xml:S1:9301:8	warn	NNP	O	O
and	NULOJIX.xml:S1:9310:3	and	CC	O	O
Precautions	NULOJIX.xml:S1:9314:11	precaut	NNP	O	O
(	NULOJIX.xml:S1:9326:1	(	(	O	O
5.4	NULOJIX.xml:S1:9327:3	5.4	CD	O	O
)	NULOJIX.xml:S1:9330:1	)	)	O	O
]	NULOJIX.xml:S1:9335:1	]	NN	O	O
.	NULOJIX.xml:S1:9336:1	.	.	O	O

Bacterial	NULOJIX.xml:S1:9344:9	bacteri	NNP	O	O
,	NULOJIX.xml:S1:9353:1	,	,	O	O
Mycobacterial	NULOJIX.xml:S1:9355:13	mycobacteri	NNP	O	O
,	NULOJIX.xml:S1:9368:1	,	,	O	O
Viral	NULOJIX.xml:S1:9370:5	viral	NNP	O	I-AdverseReaction
,	NULOJIX.xml:S1:9375:1	,	,	O	O
and	NULOJIX.xml:S1:9377:3	and	CC	O	O
Fungal	NULOJIX.xml:S1:9381:6	fungal	NNP	O	O
Infections	NULOJIX.xml:S1:9388:10	infect	NNP	O	O

Adverse	NULOJIX.xml:S1:9402:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:9410:9	reaction	NNS	O	O
of	NULOJIX.xml:S1:9420:2	of	IN	O	O
infectious	NULOJIX.xml:S1:9423:10	infecti	JJ	B-AdverseReaction	B-AdverseReaction
etiology	NULOJIX.xml:S1:9434:8	etiolog	NN	I-AdverseReaction	I-AdverseReaction
were	NULOJIX.xml:S1:9443:4	were	VBD	O	O
reported	NULOJIX.xml:S1:9448:8	report	VBN	O	O
based	NULOJIX.xml:S1:9457:5	base	VBN	O	O
on	NULOJIX.xml:S1:9463:2	on	IN	O	O
clinical	NULOJIX.xml:S1:9466:8	clinic	JJ	O	O
assessment	NULOJIX.xml:S1:9475:10	assess	NN	O	O
by	NULOJIX.xml:S1:9486:2	by	IN	O	O
physicians	NULOJIX.xml:S1:9489:10	physician	NNS	O	O
.	NULOJIX.xml:S1:9499:1	.	.	O	O

The	NULOJIX.xml:S1:9501:3	the	DT	O	O
causative	NULOJIX.xml:S1:9505:9	caus	JJ	O	O
organisms	NULOJIX.xml:S1:9515:9	organ	NNS	O	O
for	NULOJIX.xml:S1:9525:3	for	IN	O	O
these	NULOJIX.xml:S1:9529:5	these	DT	O	O
reactions	NULOJIX.xml:S1:9535:9	reaction	NNS	O	O
are	NULOJIX.xml:S1:9545:3	are	VBP	O	O
identified	NULOJIX.xml:S1:9549:10	identifi	VBN	O	O
when	NULOJIX.xml:S1:9560:4	when	WRB	O	O
provided	NULOJIX.xml:S1:9565:8	provid	VBN	O	O
by	NULOJIX.xml:S1:9574:2	by	IN	O	O
the	NULOJIX.xml:S1:9577:3	the	DT	O	O
physician	NULOJIX.xml:S1:9581:9	physician	NN	O	O
.	NULOJIX.xml:S1:9590:1	.	.	O	O

The	NULOJIX.xml:S1:9592:3	the	DT	O	O
overall	NULOJIX.xml:S1:9596:7	overal	JJ	O	O
number	NULOJIX.xml:S1:9604:6	number	NN	O	O
of	NULOJIX.xml:S1:9611:2	of	IN	O	O
infections	NULOJIX.xml:S1:9614:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:9624:1	,	,	O	O
serious	NULOJIX.xml:S1:9626:7	seriou	JJ	O	O
infections	NULOJIX.xml:S1:9634:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:9644:1	,	,	O	O
and	NULOJIX.xml:S1:9646:3	and	CC	O	O
select	NULOJIX.xml:S1:9650:6	select	JJ	O	B-AdverseReaction
infections	NULOJIX.xml:S1:9657:10	infect	NNS	B-AdverseReaction	I-AdverseReaction
with	NULOJIX.xml:S1:9668:4	with	IN	O	O
identified	NULOJIX.xml:S1:9673:10	identifi	JJ	O	O
etiology	NULOJIX.xml:S1:9684:8	etiolog	NN	O	O
reported	NULOJIX.xml:S1:9693:8	report	VBN	O	O
in	NULOJIX.xml:S1:9702:2	in	IN	O	O
patients	NULOJIX.xml:S1:9705:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:9714:7	treat	VBN	O	O
with	NULOJIX.xml:S1:9722:4	with	IN	O	O
the	NULOJIX.xml:S1:9727:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:9731:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:9739:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:9751:7	regimen	NNS	O	O
or	NULOJIX.xml:S1:9759:2	or	CC	O	O
the	NULOJIX.xml:S1:9762:3	the	DT	O	O
cyclosporine	NULOJIX.xml:S1:9766:12	cyclosporin	NN	O	O
control	NULOJIX.xml:S1:9779:7	control	NN	O	O
in	NULOJIX.xml:S1:9787:2	in	IN	O	O
Studies	NULOJIX.xml:S1:9790:7	studi	NNP	O	O
1	NULOJIX.xml:S1:9798:1	1	CD	O	O
and	NULOJIX.xml:S1:9800:3	and	CC	O	O
2	NULOJIX.xml:S1:9804:1	2	CD	O	O
are	NULOJIX.xml:S1:9806:3	are	VBP	O	O
shown	NULOJIX.xml:S1:9810:5	shown	VBN	O	O
in	NULOJIX.xml:S1:9816:2	in	IN	O	O
Table	NULOJIX.xml:S1:9819:5	tabl	JJ	O	O
3	NULOJIX.xml:S1:9825:1	3	CD	O	O
.	NULOJIX.xml:S1:9826:1	.	.	O	O

Fungal	NULOJIX.xml:S1:9828:6	fungal	JJ	B-AdverseReaction	B-AdverseReaction
infections	NULOJIX.xml:S1:9835:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
were	NULOJIX.xml:S1:9846:4	were	VBD	O	O
reported	NULOJIX.xml:S1:9851:8	report	VBN	O	O
in	NULOJIX.xml:S1:9860:2	in	IN	O	O
18%	NULOJIX.xml:S1:9863:3	18%	CD	O	O
of	NULOJIX.xml:S1:9867:2	of	IN	O	O
patients	NULOJIX.xml:S1:9870:8	patient	NNS	O	O
receiving	NULOJIX.xml:S1:9879:9	receiv	VBG	O	O
NULOJIX	NULOJIX.xml:S1:9889:7	nulojix	NNP	O	O
compared	NULOJIX.xml:S1:9897:8	compar	VBN	O	O
to	NULOJIX.xml:S1:9906:2	to	TO	O	O
22%	NULOJIX.xml:S1:9909:3	22%	CD	O	O
receiving	NULOJIX.xml:S1:9913:9	receiv	VBG	O	O
cyclosporine	NULOJIX.xml:S1:9923:12	cyclosporin	NN	O	O
,	NULOJIX.xml:S1:9935:1	,	,	O	O
primarily	NULOJIX.xml:S1:9937:9	primarili	RB	O	O
due	NULOJIX.xml:S1:9947:3	due	JJ	O	O
to	NULOJIX.xml:S1:9951:2	to	TO	O	O
skin	NULOJIX.xml:S1:9954:4	skin	VB	B-AdverseReaction	O
and	NULOJIX.xml:S1:9959:3	and	CC	O	O
mucocutaneous	NULOJIX.xml:S1:9963:13	mucocutan	JJ	B-AdverseReaction	B-AdverseReaction
fungal	NULOJIX.xml:S1:9977:6	fungal	JJ	I-AdverseReaction	I-AdverseReaction
infections	NULOJIX.xml:S1:9984:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
.	NULOJIX.xml:S1:9994:1	.	.	O	O

Tuberculosis	NULOJIX.xml:S1:9996:12	tuberculosi	NN	B-AdverseReaction	O
and	NULOJIX.xml:S1:10009:3	and	CC	O	O
herpes	NULOJIX.xml:S1:10013:6	herp	NNS	B-AdverseReaction	O
infections	NULOJIX.xml:S1:10020:10	infect	NNS	I-AdverseReaction	B-AdverseReaction
were	NULOJIX.xml:S1:10031:4	were	VBD	O	O
reported	NULOJIX.xml:S1:10036:8	report	VBN	O	O
more	NULOJIX.xml:S1:10045:4	more	RBR	O	O
frequently	NULOJIX.xml:S1:10050:10	frequent	RB	O	O
in	NULOJIX.xml:S1:10061:2	in	IN	O	O
patients	NULOJIX.xml:S1:10064:8	patient	NNS	O	O
receiving	NULOJIX.xml:S1:10073:9	receiv	VBG	O	O
NULOJIX	NULOJIX.xml:S1:10083:7	nulojix	NNP	O	O
than	NULOJIX.xml:S1:10091:4	than	IN	O	O
cyclosporine	NULOJIX.xml:S1:10096:12	cyclosporin	NN	O	O
.	NULOJIX.xml:S1:10108:1	.	.	O	O

Of	NULOJIX.xml:S1:10110:2	Of	IN	O	O
the	NULOJIX.xml:S1:10113:3	the	DT	O	O
patients	NULOJIX.xml:S1:10117:8	patient	NNS	O	O
who	NULOJIX.xml:S1:10126:3	who	WP	O	O
developed	NULOJIX.xml:S1:10130:9	develop	VBD	O	O
tuberculosis	NULOJIX.xml:S1:10140:12	tuberculosi	NN	B-AdverseReaction	O
through	NULOJIX.xml:S1:10153:7	through	IN	O	O
3	NULOJIX.xml:S1:10161:1	3	CD	O	O
years	NULOJIX.xml:S1:10163:5	year	NNS	O	O
,	NULOJIX.xml:S1:10168:1	,	,	O	O
all	NULOJIX.xml:S1:10170:3	all	DT	O	O
but	NULOJIX.xml:S1:10174:3	but	CC	O	O
one	NULOJIX.xml:S1:10178:3	one	CD	O	O
NULOJIX	NULOJIX.xml:S1:10182:7	nulojix	NNP	O	O
patient	NULOJIX.xml:S1:10190:7	patient	NN	O	O
lived	NULOJIX.xml:S1:10198:5	live	VBD	O	O
in	NULOJIX.xml:S1:10204:2	in	IN	O	O
countries	NULOJIX.xml:S1:10207:9	countri	NNS	O	O
with	NULOJIX.xml:S1:10217:4	with	IN	O	O
a	NULOJIX.xml:S1:10222:1	a	DT	O	O
high	NULOJIX.xml:S1:10224:4	high	JJ	O	O
prevalence	NULOJIX.xml:S1:10229:10	preval	NN	O	O
of	NULOJIX.xml:S1:10240:2	of	IN	O	O
tuberculosis	NULOJIX.xml:S1:10243:12	tuberculosi	NN	O	B-AdverseReaction
[	NULOJIX.xml:S1:10256:1	[	NNP	O	O
see	NULOJIX.xml:S1:10257:3	see	VBP	O	O
Warnings	NULOJIX.xml:S1:10264:8	warn	NNP	O	O
and	NULOJIX.xml:S1:10273:3	and	CC	O	O
Precautions	NULOJIX.xml:S1:10277:11	precaut	NNP	O	O
(	NULOJIX.xml:S1:10289:1	(	(	O	O
5.5	NULOJIX.xml:S1:10290:3	5.5	CD	O	O
)	NULOJIX.xml:S1:10293:1	)	)	O	O
]	NULOJIX.xml:S1:10298:1	]	NN	O	O
.	NULOJIX.xml:S1:10299:1	.	.	O	O

Table	NULOJIX.xml:S1:10305:5	tabl	JJ	O	O
3	NULOJIX.xml:S1:10311:1	3	CD	O	O
:	NULOJIX.xml:S1:10312:1	:	:	O	O
Overall	NULOJIX.xml:S1:10314:7	overal	JJ	O	O
Infections	NULOJIX.xml:S1:10322:10	infect	NNS	B-AdverseReaction	O
and	NULOJIX.xml:S1:10333:3	and	CC	O	O
Select	NULOJIX.xml:S1:10337:6	select	NNP	O	O
Infections	NULOJIX.xml:S1:10344:10	infect	NNP	B-AdverseReaction	O
with	NULOJIX.xml:S1:10355:4	with	IN	O	O
Identified	NULOJIX.xml:S1:10360:10	identifi	NNP	O	O
Etiology	NULOJIX.xml:S1:10371:8	etiolog	NNP	O	O
by	NULOJIX.xml:S1:10380:2	by	IN	O	O
Treatment	NULOJIX.xml:S1:10383:9	treatment	NNP	O	O
Group	NULOJIX.xml:S1:10393:5	group	NNP	O	O
following	NULOJIX.xml:S1:10399:9	follow	VBG	O	O
One	NULOJIX.xml:S1:10409:3	one	CD	O	O
and	NULOJIX.xml:S1:10413:3	and	CC	O	O
Three	NULOJIX.xml:S1:10417:5	three	CD	O	O
Years	NULOJIX.xml:S1:10423:5	year	NNS	O	O
of	NULOJIX.xml:S1:10429:2	of	IN	O	O
Treatment	NULOJIX.xml:S1:10432:9	treatment	NNP	O	O
in	NULOJIX.xml:S1:10442:2	in	IN	O	O
Studies	NULOJIX.xml:S1:10445:7	studi	NNP	O	O
1	NULOJIX.xml:S1:10453:1	1	CD	O	O
and	NULOJIX.xml:S1:10455:3	and	CC	O	O
2	NULOJIX.xml:S1:10459:1	2	CD	O	O

Up	NULOJIX.xml:S1:10496:2	Up	RB	O	O
to	NULOJIX.xml:S1:10499:2	to	TO	O	O
Year	NULOJIX.xml:S1:10502:4	year	VB	O	O
1	NULOJIX.xml:S1:10507:1	1	CD	O	O
Up	NULOJIX.xml:S1:10516:2	Up	NNP	O	O
to	NULOJIX.xml:S1:10519:2	to	TO	O	O
Year	NULOJIX.xml:S1:10522:4	year	VB	O	O
3	NULOJIX.xml:S1:10527:1	3	CD	O	O

NULOJIX	NULOJIX.xml:S1:10571:7	nulojix	NNP	O	O
Recommended	NULOJIX.xml:S1:10582:11	recommend	VBD	O	O
Regimen	NULOJIX.xml:S1:10597:7	regimen	NNP	O	O
N	NULOJIX.xml:S1:10608:1	N	NNP	O	O
401	NULOJIX.xml:S1:10610:3	401	CD	O	O
n	NULOJIX.xml:S1:10617:1	n	NN	O	O
(	NULOJIX.xml:S1:10619:1	(	(	O	O
)	NULOJIX.xml:S1:10621:1	)	)	O	O
Cyclosporine	NULOJIX.xml:S1:10628:12	cyclosporin	NNP	O	O
N	NULOJIX.xml:S1:10644:1	N	NNP	O	O
405	NULOJIX.xml:S1:10646:3	405	CD	O	O
n	NULOJIX.xml:S1:10653:1	n	NN	O	O
(	NULOJIX.xml:S1:10655:1	(	(	O	O
)	NULOJIX.xml:S1:10657:1	)	)	O	O
NULOJIX	NULOJIX.xml:S1:10664:7	nulojix	NNP	O	O
Recommended	NULOJIX.xml:S1:10675:11	recommend	NNP	O	O
Regimen	NULOJIX.xml:S1:10690:7	regimen	NNP	O	O
N	NULOJIX.xml:S1:10701:1	N	NNP	O	O
401	NULOJIX.xml:S1:10703:3	401	CD	O	O
n	NULOJIX.xml:S1:10710:1	n	NN	O	O
(	NULOJIX.xml:S1:10712:1	(	(	O	O
)	NULOJIX.xml:S1:10714:1	)	)	O	O
Cyclosporine	NULOJIX.xml:S1:10721:12	cyclosporin	NNP	O	O
N	NULOJIX.xml:S1:10737:1	N	NNP	O	O
405	NULOJIX.xml:S1:10739:3	405	CD	O	O
n	NULOJIX.xml:S1:10746:1	n	NN	O	O
(	NULOJIX.xml:S1:10748:1	(	(	O	O
)	NULOJIX.xml:S1:10750:1	)	)	O	O

Studies	NULOJIX.xml:S1:10764:7	studi	NNS	O	O

1	NULOJIX.xml:S1:10772:1	1	CD	O	O
and	NULOJIX.xml:S1:10774:3	and	CC	O	O
2	NULOJIX.xml:S1:10778:1	2	CD	O	O
were	NULOJIX.xml:S1:10780:4	were	VBD	O	O
not	NULOJIX.xml:S1:10785:3	not	RB	O	O
designed	NULOJIX.xml:S1:10789:8	design	VBN	O	O
to	NULOJIX.xml:S1:10798:2	to	TO	O	O
support	NULOJIX.xml:S1:10801:7	support	VB	O	O
comparative	NULOJIX.xml:S1:10809:11	compar	JJ	O	O
claims	NULOJIX.xml:S1:10821:6	claim	NNS	O	O
for	NULOJIX.xml:S1:10828:3	for	IN	O	O
NULOJIX	NULOJIX.xml:S1:10832:7	nulojix	NNP	O	O
for	NULOJIX.xml:S1:10840:3	for	IN	O	O
the	NULOJIX.xml:S1:10844:3	the	DT	O	O
adverse	NULOJIX.xml:S1:10848:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:10856:9	reaction	NNS	O	O
reported	NULOJIX.xml:S1:10866:8	report	VBN	O	O
in	NULOJIX.xml:S1:10875:2	in	IN	O	O
this	NULOJIX.xml:S1:10878:4	thi	DT	O	O
table	NULOJIX.xml:S1:10883:5	tabl	NN	O	O
.	NULOJIX.xml:S1:10888:1	.	.	O	O

Median	NULOJIX.xml:S1:10895:6	median	JJ	O	O
exposure	NULOJIX.xml:S1:10902:8	exposur	NN	O	O
in	NULOJIX.xml:S1:10911:2	in	IN	O	O
days	NULOJIX.xml:S1:10914:4	day	NNS	O	O
for	NULOJIX.xml:S1:10919:3	for	IN	O	O
pooled	NULOJIX.xml:S1:10923:6	pool	JJ	O	O
studies	NULOJIX.xml:S1:10930:7	studi	NNS	O	O
:	NULOJIX.xml:S1:10937:1	:	:	O	O
1203	NULOJIX.xml:S1:10939:4	1203	CD	O	O
for	NULOJIX.xml:S1:10944:3	for	IN	O	O
NULOJIX	NULOJIX.xml:S1:10948:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:10956:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:10968:7	regimen	NNS	O	O
and	NULOJIX.xml:S1:10976:3	and	CC	O	O
1163	NULOJIX.xml:S1:10980:4	1163	CD	O	O
for	NULOJIX.xml:S1:10985:3	for	IN	O	O
cyclosporine	NULOJIX.xml:S1:10989:12	cyclosporin	NN	O	O
in	NULOJIX.xml:S1:11002:2	in	IN	O	O
Studies	NULOJIX.xml:S1:11005:7	studi	NNP	O	O
1	NULOJIX.xml:S1:11013:1	1	CD	O	O
and	NULOJIX.xml:S1:11015:3	and	CC	O	O
2	NULOJIX.xml:S1:11019:1	2	CD	O	O
.	NULOJIX.xml:S1:11020:1	.	.	O	O
?	NULOJIX.xml:S1:11023:1	?	.	O	O

All	NULOJIX.xml:S1:11028:3	all	DT	O	O
infections	NULOJIX.xml:S1:11032:10	infect	NNS	B-AdverseReaction	O
include	NULOJIX.xml:S1:11043:7	includ	VBP	O	O
bacterial	NULOJIX.xml:S1:11051:9	bacteri	JJ	I-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:11060:1	,	,	O	O
viral	NULOJIX.xml:S1:11062:5	viral	JJ	I-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:11067:1	,	,	O	O
fungal	NULOJIX.xml:S1:11069:6	fungal	JJ	I-AdverseReaction	O
,	NULOJIX.xml:S1:11075:1	,	,	O	O
and	NULOJIX.xml:S1:11077:3	and	CC	O	O
other	NULOJIX.xml:S1:11081:5	other	JJ	O	O
organisms	NULOJIX.xml:S1:11087:9	organ	NNS	O	O
.	NULOJIX.xml:S1:11096:1	.	.	O	O

For	NULOJIX.xml:S1:11098:3	for	IN	O	O
infectious	NULOJIX.xml:S1:11102:10	infecti	JJ	B-AdverseReaction	O
adverse	NULOJIX.xml:S1:11113:7	advers	JJ	I-AdverseReaction	O
reactions	NULOJIX.xml:S1:11121:9	reaction	NNS	I-AdverseReaction	O
,	NULOJIX.xml:S1:11130:1	,	,	O	O
the	NULOJIX.xml:S1:11132:3	the	DT	O	O
causative	NULOJIX.xml:S1:11136:9	caus	JJ	O	O
organism	NULOJIX.xml:S1:11146:8	organ	NN	O	O
is	NULOJIX.xml:S1:11155:2	is	VBZ	O	O
reported	NULOJIX.xml:S1:11158:8	report	VBN	O	O
if	NULOJIX.xml:S1:11167:2	if	IN	O	O
specified	NULOJIX.xml:S1:11170:9	specifi	VBN	O	O
by	NULOJIX.xml:S1:11180:2	by	IN	O	O
the	NULOJIX.xml:S1:11183:3	the	DT	O	O
physician	NULOJIX.xml:S1:11187:9	physician	NN	O	O
in	NULOJIX.xml:S1:11197:2	in	IN	O	O
the	NULOJIX.xml:S1:11200:3	the	DT	O	O
clinical	NULOJIX.xml:S1:11204:8	clinic	JJ	O	O
trials	NULOJIX.xml:S1:11213:6	trial	NNS	O	O
.	NULOJIX.xml:S1:11219:1	.	.	O	O

S	NULOJIX.xml:S1:11222:1	S	VB	O	O
A	NULOJIX.xml:S1:11227:1	A	NNP	O	O
medically	NULOJIX.xml:S1:11229:9	medic	RB	O	O
important	NULOJIX.xml:S1:11239:9	import	JJ	O	O
event	NULOJIX.xml:S1:11249:5	event	NN	O	O
that	NULOJIX.xml:S1:11255:4	that	WDT	O	O
may	NULOJIX.xml:S1:11260:3	may	MD	O	O
be	NULOJIX.xml:S1:11264:2	be	VB	O	O
life	NULOJIX.xml:S1:11267:4	life	NN	O	O
-	NULOJIX.xml:S1:11271:1	-	:	O	O
threatening	NULOJIX.xml:S1:11272:11	threaten	NN	O	O
or	NULOJIX.xml:S1:11284:2	or	CC	O	O
result	NULOJIX.xml:S1:11287:6	result	NN	O	O
in	NULOJIX.xml:S1:11294:2	in	IN	O	O
death	NULOJIX.xml:S1:11297:5	death	NN	B-AdverseReaction	B-AdverseReaction
or	NULOJIX.xml:S1:11303:2	or	CC	O	O
hospitalization	NULOJIX.xml:S1:11306:15	hospit	NN	O	O
or	NULOJIX.xml:S1:11322:2	or	CC	O	O
prolongation	NULOJIX.xml:S1:11325:12	prolong	NN	O	O
of	NULOJIX.xml:S1:11338:2	of	IN	O	O
existing	NULOJIX.xml:S1:11341:8	exist	VBG	O	O
hospitalization	NULOJIX.xml:S1:11350:15	hospit	NN	O	O
.	NULOJIX.xml:S1:11365:1	.	.	O	O

Infections	NULOJIX.xml:S1:11367:10	infect	NNS	B-AdverseReaction	O
not	NULOJIX.xml:S1:11378:3	not	RB	O	O
meeting	NULOJIX.xml:S1:11382:7	meet	VBG	O	O
these	NULOJIX.xml:S1:11390:5	these	DT	O	O
criteria	NULOJIX.xml:S1:11396:8	criteria	NNS	O	O
are	NULOJIX.xml:S1:11405:3	are	VBP	O	O
considered	NULOJIX.xml:S1:11409:10	consid	VBN	O	O
non	NULOJIX.xml:S1:11420:3	non	JJ	O	O
-	NULOJIX.xml:S1:11423:1	-	:	O	O
serious	NULOJIX.xml:S1:11424:7	seriou	JJ	O	O
.	NULOJIX.xml:S1:11431:1	.	.	O	O

BK	NULOJIX.xml:S1:11439:2	BK	NNP	B-AdverseReaction	B-AdverseReaction
virus	NULOJIX.xml:S1:11442:5	viru	NN	I-AdverseReaction	I-AdverseReaction
-	NULOJIX.xml:S1:11447:1	-	:	I-AdverseReaction	I-AdverseReaction
associated	NULOJIX.xml:S1:11448:10	associ	VBN	I-AdverseReaction	I-AdverseReaction
nephropathy	NULOJIX.xml:S1:11459:11	nephropathi	NN	I-AdverseReaction	I-AdverseReaction
was	NULOJIX.xml:S1:11471:3	wa	VBD	O	O
reported	NULOJIX.xml:S1:11475:8	report	VBN	O	O
in	NULOJIX.xml:S1:11484:2	in	IN	O	O
6	NULOJIX.xml:S1:11487:1	6	CD	O	O
NULOJIX	NULOJIX.xml:S1:11489:7	nulojix	JJ	O	O
patients	NULOJIX.xml:S1:11497:8	patient	NNS	O	O
(	NULOJIX.xml:S1:11506:1	(	(	O	O
4	NULOJIX.xml:S1:11507:1	4	CD	O	O
of	NULOJIX.xml:S1:11509:2	of	IN	O	O
which	NULOJIX.xml:S1:11512:5	which	WDT	O	O
resulted	NULOJIX.xml:S1:11518:8	result	VBD	O	O
in	NULOJIX.xml:S1:11527:2	in	IN	O	O
graft	NULOJIX.xml:S1:11530:5	graft	JJ	O	B-AdverseReaction
loss	NULOJIX.xml:S1:11536:4	loss	NN	O	I-AdverseReaction
)	NULOJIX.xml:S1:11540:1	)	)	O	O
and	NULOJIX.xml:S1:11542:3	and	CC	O	O
6	NULOJIX.xml:S1:11546:1	6	CD	O	O
cyclosporine	NULOJIX.xml:S1:11548:12	cyclosporin	NN	O	O
patients	NULOJIX.xml:S1:11561:8	patient	NNS	O	O
(	NULOJIX.xml:S1:11570:1	(	(	O	O
none	NULOJIX.xml:S1:11571:4	none	NN	O	O
of	NULOJIX.xml:S1:11576:2	of	IN	O	O
which	NULOJIX.xml:S1:11579:5	which	WDT	O	O
resulted	NULOJIX.xml:S1:11585:8	result	VBD	O	O
in	NULOJIX.xml:S1:11594:2	in	IN	O	O
graft	NULOJIX.xml:S1:11597:5	graft	JJ	O	O
loss	NULOJIX.xml:S1:11603:4	loss	NN	O	O
)	NULOJIX.xml:S1:11607:1	)	)	O	O
by	NULOJIX.xml:S1:11609:2	by	IN	O	O
Year	NULOJIX.xml:S1:11612:4	year	$	O	O
3	NULOJIX.xml:S1:11617:1	3	CD	O	O
.	NULOJIX.xml:S1:11618:1	.	.	O	O

Most	NULOJIX.xml:S1:11626:4	most	JJS	O	O
herpes	NULOJIX.xml:S1:11631:6	herp	NNS	B-AdverseReaction	O
infections	NULOJIX.xml:S1:11638:10	infect	NNS	I-AdverseReaction	B-AdverseReaction
were	NULOJIX.xml:S1:11649:4	were	VBD	O	O
non	NULOJIX.xml:S1:11654:3	non	JJ	O	O
-	NULOJIX.xml:S1:11657:1	-	:	O	O
serious	NULOJIX.xml:S1:11658:7	seriou	JJ	O	O
and	NULOJIX.xml:S1:11666:3	and	CC	O	O
1	NULOJIX.xml:S1:11670:1	1	CD	O	O
led	NULOJIX.xml:S1:11672:3	led	VBD	O	O
to	NULOJIX.xml:S1:11676:2	to	TO	O	O
treatment	NULOJIX.xml:S1:11679:9	treatment	NN	O	O
discontinuation	NULOJIX.xml:S1:11689:15	discontinu	NN	O	O
.	NULOJIX.xml:S1:11704:1	.	.	O	O

All	NULOJIX.xml:S1:11714:3	all	DT	O	O

infections	NULOJIX.xml:S1:11718:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
?	NULOJIX.xml:S1:11728:1	?	.	O	O

287	NULOJIX.xml:S1:11744:3	287	CD	O	O
(	NULOJIX.xml:S1:11748:1	(	(	O	O
72	NULOJIX.xml:S1:11749:2	72	CD	O	O
)	NULOJIX.xml:S1:11751:1	)	)	O	O
299	NULOJIX.xml:S1:11764:3	299	CD	O	O
(	NULOJIX.xml:S1:11768:1	(	(	O	O
74	NULOJIX.xml:S1:11769:2	74	CD	O	O
)	NULOJIX.xml:S1:11771:1	)	)	O	O
329	NULOJIX.xml:S1:11784:3	329	CD	O	O
(	NULOJIX.xml:S1:11788:1	(	(	O	O
82	NULOJIX.xml:S1:11789:2	82	CD	O	O
)	NULOJIX.xml:S1:11791:1	)	)	O	O
327	NULOJIX.xml:S1:11804:3	327	CD	O	O
(	NULOJIX.xml:S1:11808:1	(	(	O	O
81	NULOJIX.xml:S1:11809:2	81	CD	O	O
)	NULOJIX.xml:S1:11811:1	)	)	O	O

Serious	NULOJIX.xml:S1:11830:7	seriou	JJ	O	O
infectionsS	NULOJIX.xml:S1:11838:11	infectionss	NN	B-AdverseReaction	O
98	NULOJIX.xml:S1:11857:2	98	CD	O	O
(	NULOJIX.xml:S1:11860:1	(	(	O	O
24	NULOJIX.xml:S1:11861:2	24	CD	O	O
)	NULOJIX.xml:S1:11863:1	)	)	O	O
113	NULOJIX.xml:S1:11877:3	113	CD	O	O
(	NULOJIX.xml:S1:11881:1	(	(	O	O
28	NULOJIX.xml:S1:11882:2	28	CD	O	O
)	NULOJIX.xml:S1:11884:1	)	)	O	O
144	NULOJIX.xml:S1:11897:3	144	CD	O	O
(	NULOJIX.xml:S1:11901:1	(	(	O	O
36	NULOJIX.xml:S1:11902:2	36	CD	O	O
)	NULOJIX.xml:S1:11904:1	)	)	O	O
157	NULOJIX.xml:S1:11917:3	157	CD	O	O
(	NULOJIX.xml:S1:11921:1	(	(	O	O
39	NULOJIX.xml:S1:11922:2	39	CD	O	O
)	NULOJIX.xml:S1:11924:1	)	)	O	O

CMV	NULOJIX.xml:S1:11940:3	cmv	NNP	I-AdverseReaction	B-AdverseReaction
44	NULOJIX.xml:S1:11970:2	44	CD	O	O
(	NULOJIX.xml:S1:11973:1	(	(	O	O
11	NULOJIX.xml:S1:11974:2	11	CD	O	O
)	NULOJIX.xml:S1:11976:1	)	)	O	O
52	NULOJIX.xml:S1:11990:2	52	CD	O	O
(	NULOJIX.xml:S1:11993:1	(	(	O	O
13	NULOJIX.xml:S1:11994:2	13	CD	O	O
)	NULOJIX.xml:S1:11996:1	)	)	O	O
53	NULOJIX.xml:S1:12010:2	53	CD	O	O
(	NULOJIX.xml:S1:12013:1	(	(	O	O
13	NULOJIX.xml:S1:12014:2	13	CD	O	O
)	NULOJIX.xml:S1:12016:1	)	)	O	O
56	NULOJIX.xml:S1:12030:2	56	CD	O	O
(	NULOJIX.xml:S1:12033:1	(	(	O	O
14	NULOJIX.xml:S1:12034:2	14	CD	O	O
)	NULOJIX.xml:S1:12036:1	)	)	O	O

Polyoma	NULOJIX.xml:S1:12053:7	polyoma	NNP	I-AdverseReaction	B-AdverseReaction
virus	NULOJIX.xml:S1:12061:5	viru	NN	I-AdverseReaction	I-AdverseReaction
10	NULOJIX.xml:S1:12083:2	10	CD	O	O
(	NULOJIX.xml:S1:12086:1	(	(	O	O
3	NULOJIX.xml:S1:12087:1	3	CD	O	O
)	NULOJIX.xml:S1:12088:1	)	)	O	O
23	NULOJIX.xml:S1:12103:2	23	CD	O	O
(	NULOJIX.xml:S1:12106:1	(	(	O	O
6	NULOJIX.xml:S1:12107:1	6	CD	O	O
)	NULOJIX.xml:S1:12108:1	)	)	O	O
17	NULOJIX.xml:S1:12123:2	17	CD	O	O
(	NULOJIX.xml:S1:12126:1	(	(	O	O
4	NULOJIX.xml:S1:12127:1	4	CD	O	O
)	NULOJIX.xml:S1:12128:1	)	)	O	O
27	NULOJIX.xml:S1:12143:2	27	CD	O	O
(	NULOJIX.xml:S1:12146:1	(	(	O	O
7	NULOJIX.xml:S1:12147:1	7	CD	O	O
)	NULOJIX.xml:S1:12148:1	)	)	O	O

Herpes	NULOJIX.xml:S1:12166:6	herp	$	I-AdverseReaction	B-AdverseReaction
27	NULOJIX.xml:S1:12196:2	27	CD	O	O
(	NULOJIX.xml:S1:12199:1	(	(	O	O
7	NULOJIX.xml:S1:12200:1	7	CD	O	O
)	NULOJIX.xml:S1:12201:1	)	)	O	O
26	NULOJIX.xml:S1:12216:2	26	CD	O	O
(	NULOJIX.xml:S1:12219:1	(	(	O	O
6	NULOJIX.xml:S1:12220:1	6	CD	O	O
)	NULOJIX.xml:S1:12221:1	)	)	O	O
55	NULOJIX.xml:S1:12236:2	55	CD	O	O
(	NULOJIX.xml:S1:12239:1	(	(	O	O
14	NULOJIX.xml:S1:12240:2	14	CD	O	O
)	NULOJIX.xml:S1:12242:1	)	)	O	O
46	NULOJIX.xml:S1:12256:2	46	CD	O	O
(	NULOJIX.xml:S1:12259:1	(	(	O	O
11	NULOJIX.xml:S1:12260:2	11	CD	O	O
)	NULOJIX.xml:S1:12262:1	)	)	O	O

Tuberculosis	NULOJIX.xml:S1:12279:12	tuberculosi	NN	B-AdverseReaction	B-AdverseReaction
2	NULOJIX.xml:S1:12309:1	2	CD	O	O
(	NULOJIX.xml:S1:12311:1	(	(	O	O
1	NULOJIX.xml:S1:12312:1	1	CD	O	O
)	NULOJIX.xml:S1:12313:1	)	)	O	O
1	NULOJIX.xml:S1:12329:1	1	CD	O	O
(	NULOJIX.xml:S1:12331:1	(	(	O	O
1	NULOJIX.xml:S1:12333:1	1	CD	O	O
)	NULOJIX.xml:S1:12334:1	)	)	O	O
6	NULOJIX.xml:S1:12349:1	6	CD	O	O
(	NULOJIX.xml:S1:12351:1	(	(	O	O
2	NULOJIX.xml:S1:12352:1	2	CD	O	O
)	NULOJIX.xml:S1:12353:1	)	)	O	O
1	NULOJIX.xml:S1:12369:1	1	CD	O	O
(	NULOJIX.xml:S1:12371:1	(	(	O	O
1	NULOJIX.xml:S1:12373:1	1	CD	O	O
)	NULOJIX.xml:S1:12374:1	)	)	O	O

Infections	NULOJIX.xml:S1:12403:10	infect	NNS	O	O
Reported	NULOJIX.xml:S1:12414:8	report	VBN	O	O
in	NULOJIX.xml:S1:12423:2	in	IN	O	O
the	NULOJIX.xml:S1:12426:3	the	DT	O	O
CNS	NULOJIX.xml:S1:12430:3	cn	NNP	O	O

Following	NULOJIX.xml:S1:12437:9	follow	VBG	O	O
three	NULOJIX.xml:S1:12447:5	three	CD	O	O
years	NULOJIX.xml:S1:12453:5	year	NNS	O	O
of	NULOJIX.xml:S1:12459:2	of	IN	O	O
treatment	NULOJIX.xml:S1:12462:9	treatment	NN	O	O
in	NULOJIX.xml:S1:12472:2	in	IN	O	O
Studies	NULOJIX.xml:S1:12475:7	studi	NNP	O	O
1	NULOJIX.xml:S1:12483:1	1	CD	O	O
and	NULOJIX.xml:S1:12485:3	and	CC	O	O
2	NULOJIX.xml:S1:12489:1	2	CD	O	O
,	NULOJIX.xml:S1:12490:1	,	,	O	O
cryptococcal	NULOJIX.xml:S1:12492:12	cryptococc	JJ	B-AdverseReaction	B-AdverseReaction
meningitis	NULOJIX.xml:S1:12505:10	mening	NN	I-AdverseReaction	I-AdverseReaction
was	NULOJIX.xml:S1:12516:3	wa	VBD	O	O
reported	NULOJIX.xml:S1:12520:8	report	VBN	O	O
in	NULOJIX.xml:S1:12529:2	in	IN	O	O
one	NULOJIX.xml:S1:12532:3	one	CD	O	O
patient	NULOJIX.xml:S1:12536:7	patient	NN	O	O
out	NULOJIX.xml:S1:12544:3	out	IN	O	O
of	NULOJIX.xml:S1:12548:2	of	IN	O	O
401	NULOJIX.xml:S1:12551:3	401	CD	O	O
patients	NULOJIX.xml:S1:12555:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:12564:7	treat	VBN	O	O
with	NULOJIX.xml:S1:12572:4	with	IN	O	O
the	NULOJIX.xml:S1:12577:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:12581:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:12589:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:12601:7	regimen	NNS	O	O
(	NULOJIX.xml:S1:12609:1	(	(	O	O
0.2%	NULOJIX.xml:S1:12610:4	0.2%	CD	O	O
)	NULOJIX.xml:S1:12614:1	)	)	O	O
and	NULOJIX.xml:S1:12616:3	and	CC	O	O
one	NULOJIX.xml:S1:12620:3	one	CD	O	O
patient	NULOJIX.xml:S1:12624:7	patient	NN	O	O
out	NULOJIX.xml:S1:12632:3	out	IN	O	O
of	NULOJIX.xml:S1:12636:2	of	IN	O	O
the	NULOJIX.xml:S1:12639:3	the	DT	O	O
405	NULOJIX.xml:S1:12643:3	405	CD	O	O
treated	NULOJIX.xml:S1:12647:7	treat	VBN	O	O
with	NULOJIX.xml:S1:12655:4	with	IN	O	O
the	NULOJIX.xml:S1:12660:3	the	DT	O	O
cyclosporine	NULOJIX.xml:S1:12664:12	cyclosporin	NN	O	O
control	NULOJIX.xml:S1:12677:7	control	NN	O	O
(	NULOJIX.xml:S1:12685:1	(	(	O	O
0.2%	NULOJIX.xml:S1:12686:4	0.2%	CD	O	O
)	NULOJIX.xml:S1:12690:1	)	)	O	O
.	NULOJIX.xml:S1:12691:1	.	.	O	O

Six	NULOJIX.xml:S1:12697:3	six	CD	O	O
patients	NULOJIX.xml:S1:12701:8	patient	NNS	O	O
out	NULOJIX.xml:S1:12710:3	out	IN	O	O
of	NULOJIX.xml:S1:12714:2	of	IN	O	O
the	NULOJIX.xml:S1:12717:3	the	DT	O	O
403	NULOJIX.xml:S1:12721:3	403	NNS	O	O
who	NULOJIX.xml:S1:12725:3	who	WP	O	O
were	NULOJIX.xml:S1:12729:4	were	VBD	O	O
treated	NULOJIX.xml:S1:12734:7	treat	VBN	O	O
with	NULOJIX.xml:S1:12742:4	with	IN	O	O
the	NULOJIX.xml:S1:12747:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:12751:7	nulojix	NNP	O	O
regimen	NULOJIX.xml:S1:12759:7	regimen	NNS	O	O
of	NULOJIX.xml:S1:12767:2	of	IN	O	O
higher	NULOJIX.xml:S1:12770:6	higher	JJR	O	O
cumulative	NULOJIX.xml:S1:12777:10	cumul	JJ	O	O
dose	NULOJIX.xml:S1:12788:4	dose	NN	O	O
and	NULOJIX.xml:S1:12793:3	and	CC	O	O
more	NULOJIX.xml:S1:12797:4	more	RBR	O	O
frequent	NULOJIX.xml:S1:12802:8	frequent	JJ	O	O
dosing	NULOJIX.xml:S1:12811:6	dose	NN	O	O
than	NULOJIX.xml:S1:12818:4	than	IN	O	O
recommended	NULOJIX.xml:S1:12823:11	recommend	VBN	O	O
in	NULOJIX.xml:S1:12835:2	in	IN	O	O
Studies	NULOJIX.xml:S1:12838:7	studi	NNP	O	O
1	NULOJIX.xml:S1:12846:1	1	CD	O	O
and	NULOJIX.xml:S1:12848:3	and	CC	O	O
2	NULOJIX.xml:S1:12852:1	2	CD	O	O
(	NULOJIX.xml:S1:12854:1	(	(	O	O
1.5%	NULOJIX.xml:S1:12855:4	1.5%	CD	O	O
)	NULOJIX.xml:S1:12859:1	)	)	O	O
were	NULOJIX.xml:S1:12861:4	were	VBD	O	O
reported	NULOJIX.xml:S1:12866:8	report	VBN	O	O
to	NULOJIX.xml:S1:12875:2	to	TO	O	O
have	NULOJIX.xml:S1:12878:4	have	VB	O	O
developed	NULOJIX.xml:S1:12883:9	develop	VBN	O	O
CNS	NULOJIX.xml:S1:12893:3	cn	NNP	B-AdverseReaction	O
infections	NULOJIX.xml:S1:12897:10	infect	NNS	I-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:12907:1	,	,	O	O
including	NULOJIX.xml:S1:12909:9	includ	VBG	O	O
2	NULOJIX.xml:S1:12919:1	2	CD	O	O
cases	NULOJIX.xml:S1:12921:5	case	NNS	O	O
of	NULOJIX.xml:S1:12927:2	of	IN	O	O
cryptococcal	NULOJIX.xml:S1:12930:12	cryptococc	JJ	B-AdverseReaction	B-AdverseReaction
meningitis	NULOJIX.xml:S1:12943:10	mening	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:12953:1	,	,	O	O
one	NULOJIX.xml:S1:12955:3	one	CD	O	O
case	NULOJIX.xml:S1:12959:4	case	NN	O	O
of	NULOJIX.xml:S1:12964:2	of	IN	O	O
Chagas	NULOJIX.xml:S1:12967:6	chaga	NNP	B-AdverseReaction	O
encephalitis	NULOJIX.xml:S1:12974:12	enceph	NN	I-AdverseReaction	O
with	NULOJIX.xml:S1:12987:4	with	IN	O	O
cryptococcal	NULOJIX.xml:S1:12992:12	cryptococc	JJ	B-AdverseReaction	O
meningitis	NULOJIX.xml:S1:13005:10	mening	NN	I-AdverseReaction	O
,	NULOJIX.xml:S1:13015:1	,	,	O	O
one	NULOJIX.xml:S1:13017:3	one	CD	O	O
case	NULOJIX.xml:S1:13021:4	case	NN	O	O
of	NULOJIX.xml:S1:13026:2	of	IN	O	O
cerebral	NULOJIX.xml:S1:13029:8	cerebr	JJ	B-AdverseReaction	B-AdverseReaction
aspergillosis	NULOJIX.xml:S1:13038:13	aspergillosi	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:13051:1	,	,	O	O
one	NULOJIX.xml:S1:13053:3	one	CD	O	O
case	NULOJIX.xml:S1:13057:4	case	NN	O	O
of	NULOJIX.xml:S1:13062:2	of	IN	O	O
West	NULOJIX.xml:S1:13065:4	west	NNP	B-AdverseReaction	O
Nile	NULOJIX.xml:S1:13070:4	nile	NNP	I-AdverseReaction	O
encephalitis	NULOJIX.xml:S1:13075:12	enceph	NN	I-AdverseReaction	O
,	NULOJIX.xml:S1:13087:1	,	,	O	O
and	NULOJIX.xml:S1:13089:3	and	CC	O	O
one	NULOJIX.xml:S1:13093:3	one	CD	O	O
case	NULOJIX.xml:S1:13097:4	case	NN	O	O
of	NULOJIX.xml:S1:13102:2	of	IN	O	O
PML	NULOJIX.xml:S1:13105:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
(	NULOJIX.xml:S1:13109:1	(	(	O	O
discussed	NULOJIX.xml:S1:13110:9	discuss	VBN	O	O
above	NULOJIX.xml:S1:13120:5	abov	RB	O	O
)	NULOJIX.xml:S1:13125:1	)	)	O	O
.	NULOJIX.xml:S1:13126:1	.	.	O	O

Infusion	NULOJIX.xml:S1:13134:8	infus	NN	O	O
Reactions	NULOJIX.xml:S1:13143:9	reaction	NNS	O	O

There	NULOJIX.xml:S1:13156:5	there	EX	O	O
were	NULOJIX.xml:S1:13162:4	were	VBD	O	O
no	NULOJIX.xml:S1:13167:2	no	DT	O	O
reports	NULOJIX.xml:S1:13170:7	report	NNS	O	O
of	NULOJIX.xml:S1:13178:2	of	IN	O	O
anaphylaxis	NULOJIX.xml:S1:13181:11	anaphylaxi	NN	B-AdverseReaction	O
or	NULOJIX.xml:S1:13193:2	or	CC	O	O
drug	NULOJIX.xml:S1:13196:4	drug	NN	B-AdverseReaction	O
hypersensitivity	NULOJIX.xml:S1:13201:16	hypersensit	NN	I-AdverseReaction	O
in	NULOJIX.xml:S1:13218:2	in	IN	O	O
patients	NULOJIX.xml:S1:13221:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:13230:7	treat	VBN	O	O
with	NULOJIX.xml:S1:13238:4	with	IN	O	O
NULOJIX	NULOJIX.xml:S1:13243:7	nulojix	NNP	O	O
in	NULOJIX.xml:S1:13251:2	in	IN	O	O
Studies	NULOJIX.xml:S1:13254:7	studi	NNP	O	O
1	NULOJIX.xml:S1:13262:1	1	CD	O	O
and	NULOJIX.xml:S1:13264:3	and	CC	O	O
2	NULOJIX.xml:S1:13268:1	2	CD	O	O
through	NULOJIX.xml:S1:13270:7	through	IN	O	O
three	NULOJIX.xml:S1:13278:5	three	CD	O	O
years	NULOJIX.xml:S1:13284:5	year	NNS	O	O
.	NULOJIX.xml:S1:13289:1	.	.	O	O

Infusion	NULOJIX.xml:S1:13295:8	infus	NNP	B-AdverseReaction	B-AdverseReaction
-	NULOJIX.xml:S1:13303:1	-	:	I-AdverseReaction	I-AdverseReaction
related	NULOJIX.xml:S1:13304:7	relat	JJ	I-AdverseReaction	I-AdverseReaction
reactions	NULOJIX.xml:S1:13312:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
within	NULOJIX.xml:S1:13322:6	within	IN	O	O
one	NULOJIX.xml:S1:13329:3	one	CD	O	O
hour	NULOJIX.xml:S1:13333:4	hour	NN	O	O
of	NULOJIX.xml:S1:13338:2	of	IN	O	O
infusion	NULOJIX.xml:S1:13341:8	infus	NN	O	O
were	NULOJIX.xml:S1:13350:4	were	VBD	O	O
reported	NULOJIX.xml:S1:13355:8	report	VBN	O	O
in	NULOJIX.xml:S1:13364:2	in	IN	O	O
5%	NULOJIX.xml:S1:13367:2	5%	CD	O	O
of	NULOJIX.xml:S1:13370:2	of	IN	O	O
patients	NULOJIX.xml:S1:13373:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:13382:7	treat	VBN	O	O
with	NULOJIX.xml:S1:13390:4	with	IN	O	O
the	NULOJIX.xml:S1:13395:3	the	DT	O	O
recommended	NULOJIX.xml:S1:13399:11	recommend	VBN	O	O
dose	NULOJIX.xml:S1:13411:4	dose	NN	O	O
of	NULOJIX.xml:S1:13416:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:13419:7	nulojix	NNP	O	O
,	NULOJIX.xml:S1:13426:1	,	,	O	O
similar	NULOJIX.xml:S1:13428:7	similar	JJ	O	O
to	NULOJIX.xml:S1:13436:2	to	TO	O	O
the	NULOJIX.xml:S1:13439:3	the	DT	O	O
placebo	NULOJIX.xml:S1:13443:7	placebo	NN	O	O
rate	NULOJIX.xml:S1:13451:4	rate	NN	O	O
.	NULOJIX.xml:S1:13455:1	.	.	O	O

No	NULOJIX.xml:S1:13457:2	No	DT	O	O
serious	NULOJIX.xml:S1:13460:7	seriou	JJ	O	O
events	NULOJIX.xml:S1:13468:6	event	NNS	O	O
were	NULOJIX.xml:S1:13475:4	were	VBD	O	O
reported	NULOJIX.xml:S1:13480:8	report	VBN	O	O
through	NULOJIX.xml:S1:13489:7	through	IN	O	O
Year	NULOJIX.xml:S1:13497:4	year	NN	O	O
3	NULOJIX.xml:S1:13502:1	3	CD	O	O
.	NULOJIX.xml:S1:13503:1	.	.	O	O

The	NULOJIX.xml:S1:13505:3	the	DT	O	O
most	NULOJIX.xml:S1:13509:4	most	RBS	O	O
frequent	NULOJIX.xml:S1:13514:8	frequent	JJ	O	O
reactions	NULOJIX.xml:S1:13523:9	reaction	NNS	O	O
were	NULOJIX.xml:S1:13533:4	were	VBD	O	O
hypotension	NULOJIX.xml:S1:13538:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
and	NULOJIX.xml:S1:13550:3	and	CC	O	O
hypertension	NULOJIX.xml:S1:13554:12	hypertens	NN	B-AdverseReaction	O
.	NULOJIX.xml:S1:13566:1	.	.	O	O

Proteinuria	NULOJIX.xml:S1:13574:11	proteinuria	NNS	O	O

At	NULOJIX.xml:S1:13589:2	At	IN	O	O
Month	NULOJIX.xml:S1:13592:5	month	NNP	O	O
1	NULOJIX.xml:S1:13598:1	1	CD	O	O
after	NULOJIX.xml:S1:13600:5	after	IN	O	O
transplantation	NULOJIX.xml:S1:13606:15	transplant	NN	O	O
in	NULOJIX.xml:S1:13622:2	in	IN	O	O
Studies	NULOJIX.xml:S1:13625:7	studi	NNP	O	O
1	NULOJIX.xml:S1:13633:1	1	CD	O	O
and	NULOJIX.xml:S1:13635:3	and	CC	O	O
2	NULOJIX.xml:S1:13639:1	2	CD	O	O
,	NULOJIX.xml:S1:13640:1	,	,	O	O
the	NULOJIX.xml:S1:13642:3	the	DT	O	O
frequency	NULOJIX.xml:S1:13646:9	frequenc	NN	O	O
of	NULOJIX.xml:S1:13656:2	of	IN	O	O
2	NULOJIX.xml:S1:13659:1	2	CD	O	O
proteinuria	NULOJIX.xml:S1:13662:11	proteinuria	NNS	B-AdverseReaction	O
on	NULOJIX.xml:S1:13674:2	on	IN	O	O
urine	NULOJIX.xml:S1:13677:5	urin	JJ	O	O
dipstick	NULOJIX.xml:S1:13683:8	dipstick	NN	O	O
in	NULOJIX.xml:S1:13692:2	in	IN	O	O
patients	NULOJIX.xml:S1:13695:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:13704:7	treat	VBN	O	O
with	NULOJIX.xml:S1:13712:4	with	IN	O	O
the	NULOJIX.xml:S1:13717:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:13721:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:13729:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:13741:7	regimen	NNS	O	O
was	NULOJIX.xml:S1:13749:3	wa	VBD	O	O
33%	NULOJIX.xml:S1:13753:3	33%	CD	O	O
(	NULOJIX.xml:S1:13757:1	(	(	O	O
130	NULOJIX.xml:S1:13758:3	130	CD	O	O
390	NULOJIX.xml:S1:13762:3	390	CD	O	O
)	NULOJIX.xml:S1:13765:1	)	)	O	O
and	NULOJIX.xml:S1:13767:3	and	CC	O	O
28%	NULOJIX.xml:S1:13771:3	28%	CD	O	O
(	NULOJIX.xml:S1:13775:1	(	(	O	O
107	NULOJIX.xml:S1:13776:3	107	CD	O	O
384	NULOJIX.xml:S1:13780:3	384	CD	O	O
)	NULOJIX.xml:S1:13783:1	)	)	O	O
in	NULOJIX.xml:S1:13785:2	in	IN	O	O
patients	NULOJIX.xml:S1:13788:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:13797:7	treat	VBN	O	O
with	NULOJIX.xml:S1:13805:4	with	IN	O	O
the	NULOJIX.xml:S1:13810:3	the	DT	O	O
cyclosporine	NULOJIX.xml:S1:13814:12	cyclosporin	NN	O	O
control	NULOJIX.xml:S1:13827:7	control	NN	O	O
regimen	NULOJIX.xml:S1:13835:7	regimen	NNS	O	O
.	NULOJIX.xml:S1:13842:1	.	.	O	O

The	NULOJIX.xml:S1:13844:3	the	DT	O	O
frequency	NULOJIX.xml:S1:13848:9	frequenc	NN	O	O
of	NULOJIX.xml:S1:13858:2	of	IN	O	O
2	NULOJIX.xml:S1:13861:1	2	CD	O	O
proteinuria	NULOJIX.xml:S1:13864:11	proteinuria	NN	B-AdverseReaction	O
was	NULOJIX.xml:S1:13876:3	wa	VBD	O	O
similar	NULOJIX.xml:S1:13880:7	similar	JJ	O	O
between	NULOJIX.xml:S1:13888:7	between	IN	O	O
the	NULOJIX.xml:S1:13896:3	the	DT	O	O
two	NULOJIX.xml:S1:13900:3	two	CD	O	O
treatment	NULOJIX.xml:S1:13904:9	treatment	NN	O	O
groups	NULOJIX.xml:S1:13914:6	group	NNS	O	O
between	NULOJIX.xml:S1:13921:7	between	IN	O	O
one	NULOJIX.xml:S1:13929:3	one	CD	O	O
and	NULOJIX.xml:S1:13933:3	and	CC	O	O
three	NULOJIX.xml:S1:13937:5	three	CD	O	O
years	NULOJIX.xml:S1:13943:5	year	NNS	O	O
after	NULOJIX.xml:S1:13949:5	after	IN	O	O
transplantation	NULOJIX.xml:S1:13955:15	transplant	NN	O	O
(	NULOJIX.xml:S1:13971:1	(	(	O	O
10%	NULOJIX.xml:S1:13973:3	10%	CD	O	O
in	NULOJIX.xml:S1:13977:2	in	IN	O	O
both	NULOJIX.xml:S1:13980:4	both	DT	O	O
studies	NULOJIX.xml:S1:13985:7	studi	NNS	O	O
)	NULOJIX.xml:S1:13992:1	)	)	O	O
.	NULOJIX.xml:S1:13993:1	.	.	O	O

There	NULOJIX.xml:S1:13995:5	there	EX	O	O
were	NULOJIX.xml:S1:14001:4	were	VBD	O	O
no	NULOJIX.xml:S1:14006:2	no	DT	O	O
differences	NULOJIX.xml:S1:14009:11	differ	NNS	O	O
in	NULOJIX.xml:S1:14021:2	in	IN	O	O
the	NULOJIX.xml:S1:14024:3	the	DT	O	O
occurrence	NULOJIX.xml:S1:14028:10	occurr	NN	O	O
of	NULOJIX.xml:S1:14039:2	of	IN	O	O
3	NULOJIX.xml:S1:14042:1	3	CD	O	O
proteinuria	NULOJIX.xml:S1:14045:11	proteinuria	NNS	B-AdverseReaction	O
(	NULOJIX.xml:S1:14057:1	(	(	O	O
4%	NULOJIX.xml:S1:14059:2	4%	CD	O	O
in	NULOJIX.xml:S1:14062:2	in	IN	O	O
both	NULOJIX.xml:S1:14065:4	both	DT	O	O
studies	NULOJIX.xml:S1:14070:7	studi	NNS	O	O
)	NULOJIX.xml:S1:14077:1	)	)	O	O
at	NULOJIX.xml:S1:14079:2	at	IN	O	O
any	NULOJIX.xml:S1:14082:3	ani	DT	O	O
time	NULOJIX.xml:S1:14086:4	time	NN	O	O
point	NULOJIX.xml:S1:14091:5	point	NN	O	O
,	NULOJIX.xml:S1:14096:1	,	,	O	O
and	NULOJIX.xml:S1:14098:3	and	CC	O	O
no	NULOJIX.xml:S1:14102:2	no	DT	O	O
patients	NULOJIX.xml:S1:14105:8	patient	NNS	O	O
experienced	NULOJIX.xml:S1:14114:11	experienc	VBD	O	O
4	NULOJIX.xml:S1:14126:1	4	CD	O	O
proteinuria	NULOJIX.xml:S1:14129:11	proteinuria	NNS	B-AdverseReaction	B-AdverseReaction
.	NULOJIX.xml:S1:14140:1	.	.	O	O

The	NULOJIX.xml:S1:14142:3	the	DT	O	O
clinical	NULOJIX.xml:S1:14146:8	clinic	JJ	O	O
significance	NULOJIX.xml:S1:14155:12	signific	NN	O	O
of	NULOJIX.xml:S1:14168:2	of	IN	O	O
this	NULOJIX.xml:S1:14171:4	thi	DT	O	O
increase	NULOJIX.xml:S1:14176:8	increas	NN	O	O
in	NULOJIX.xml:S1:14185:2	in	IN	O	O
early	NULOJIX.xml:S1:14188:5	earli	JJ	B-AdverseReaction	O
proteinuria	NULOJIX.xml:S1:14194:11	proteinuria	NN	I-AdverseReaction	O
is	NULOJIX.xml:S1:14206:2	is	VBZ	O	O
unknown	NULOJIX.xml:S1:14209:7	unknown	JJ	O	O
.	NULOJIX.xml:S1:14216:1	.	.	O	O

Immunogenicity	NULOJIX.xml:S1:14224:14	immunogen	NN	O	O

Antibodies	NULOJIX.xml:S1:14242:10	antibodi	NNS	O	O
directed	NULOJIX.xml:S1:14253:8	direct	VBN	O	O
against	NULOJIX.xml:S1:14262:7	against	IN	O	O
the	NULOJIX.xml:S1:14270:3	the	DT	O	O
belatacept	NULOJIX.xml:S1:14274:10	belatacept	NN	O	O
molecule	NULOJIX.xml:S1:14285:8	molecul	NN	O	O
were	NULOJIX.xml:S1:14294:4	were	VBD	O	O
assessed	NULOJIX.xml:S1:14299:8	assess	VBN	O	O
in	NULOJIX.xml:S1:14308:2	in	IN	O	O
398	NULOJIX.xml:S1:14311:3	398	CD	O	O
patients	NULOJIX.xml:S1:14315:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:14324:7	treat	VBN	O	O
with	NULOJIX.xml:S1:14332:4	with	IN	O	O
the	NULOJIX.xml:S1:14337:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:14341:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:14349:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:14361:7	regimen	NNS	O	O
in	NULOJIX.xml:S1:14369:2	in	IN	O	O
Studies	NULOJIX.xml:S1:14372:7	studi	NNP	O	O
1	NULOJIX.xml:S1:14380:1	1	CD	O	O
and	NULOJIX.xml:S1:14382:3	and	CC	O	O
2	NULOJIX.xml:S1:14386:1	2	CD	O	O
(	NULOJIX.xml:S1:14388:1	(	(	O	O
212	NULOJIX.xml:S1:14389:3	212	CD	O	O
of	NULOJIX.xml:S1:14393:2	of	IN	O	O
these	NULOJIX.xml:S1:14396:5	these	DT	O	O
patients	NULOJIX.xml:S1:14402:8	patient	NNS	O	O
were	NULOJIX.xml:S1:14411:4	were	VBD	O	O
treated	NULOJIX.xml:S1:14416:7	treat	VBN	O	O
for	NULOJIX.xml:S1:14424:3	for	IN	O	O
at	NULOJIX.xml:S1:14428:2	at	IN	O	O
least	NULOJIX.xml:S1:14431:5	least	JJS	O	O
2	NULOJIX.xml:S1:14437:1	2	CD	O	O
years	NULOJIX.xml:S1:14439:5	year	NNS	O	O
)	NULOJIX.xml:S1:14444:1	)	)	O	O
.	NULOJIX.xml:S1:14445:1	.	.	O	O

Of	NULOJIX.xml:S1:14447:2	Of	IN	O	O
the	NULOJIX.xml:S1:14450:3	the	DT	O	O
372	NULOJIX.xml:S1:14454:3	372	CD	O	O
patients	NULOJIX.xml:S1:14458:8	patient	NNS	O	O
with	NULOJIX.xml:S1:14467:4	with	IN	O	O
immunogenicity	NULOJIX.xml:S1:14472:14	immunogen	JJ	O	O
assessment	NULOJIX.xml:S1:14487:10	assess	NN	O	O
at	NULOJIX.xml:S1:14498:2	at	IN	O	O
baseline	NULOJIX.xml:S1:14501:8	baselin	NN	O	O
(	NULOJIX.xml:S1:14510:1	(	(	O	O
prior	NULOJIX.xml:S1:14511:5	prior	JJ	O	O
to	NULOJIX.xml:S1:14517:2	to	TO	O	O
receiving	NULOJIX.xml:S1:14520:9	receiv	VBG	O	O
belatacept	NULOJIX.xml:S1:14530:10	belatacept	JJ	O	O
treatment	NULOJIX.xml:S1:14541:9	treatment	NN	O	O
)	NULOJIX.xml:S1:14550:1	)	)	O	O
,	NULOJIX.xml:S1:14551:1	,	,	O	O
29	NULOJIX.xml:S1:14553:2	29	CD	O	O
patients	NULOJIX.xml:S1:14556:8	patient	NNS	O	O
tested	NULOJIX.xml:S1:14565:6	test	VBD	O	O
positive	NULOJIX.xml:S1:14572:8	posit	JJ	O	O
for	NULOJIX.xml:S1:14581:3	for	IN	O	O
anti	NULOJIX.xml:S1:14585:4	anti	JJ	O	O
-	NULOJIX.xml:S1:14589:1	-	:	O	O
belatacept	NULOJIX.xml:S1:14590:10	belatacept	NN	O	O
antibodies	NULOJIX.xml:S1:14601:10	antibodi	NNS	O	O
;	NULOJIX.xml:S1:14611:1	;	:	O	O
13	NULOJIX.xml:S1:14613:2	13	CD	O	O
of	NULOJIX.xml:S1:14616:2	of	IN	O	O
these	NULOJIX.xml:S1:14619:5	these	DT	O	O
patients	NULOJIX.xml:S1:14625:8	patient	NNS	O	O
had	NULOJIX.xml:S1:14634:3	had	VBD	O	O
antibodies	NULOJIX.xml:S1:14638:10	antibodi	NNS	O	O
to	NULOJIX.xml:S1:14649:2	to	TO	O	O
the	NULOJIX.xml:S1:14652:3	the	DT	O	O
modified	NULOJIX.xml:S1:14656:8	modifi	VBN	O	O
cytotoxic	NULOJIX.xml:S1:14665:9	cytotox	NN	O	B-AdverseReaction
T	NULOJIX.xml:S1:14675:1	T	NNP	O	I-AdverseReaction
-	NULOJIX.xml:S1:14676:1	-	:	O	I-AdverseReaction
lymphocyte	NULOJIX.xml:S1:14677:10	lymphocyt	NN	O	I-AdverseReaction
-	NULOJIX.xml:S1:14687:1	-	:	O	I-AdverseReaction
associated	NULOJIX.xml:S1:14688:10	associ	VBN	O	I-AdverseReaction
antigen	NULOJIX.xml:S1:14699:7	antigen	NN	O	I-AdverseReaction
4	NULOJIX.xml:S1:14707:1	4	CD	O	O
(	NULOJIX.xml:S1:14709:1	(	(	O	O
CTLA	NULOJIX.xml:S1:14710:4	ctla	NNP	O	O
-	NULOJIX.xml:S1:14714:1	-	:	O	O
4	NULOJIX.xml:S1:14715:1	4	CD	O	O
)	NULOJIX.xml:S1:14716:1	)	)	O	O
.	NULOJIX.xml:S1:14717:1	.	.	O	O

Anti	NULOJIX.xml:S1:14719:4	anti	NNP	O	O
-	NULOJIX.xml:S1:14723:1	-	:	O	O
belatacept	NULOJIX.xml:S1:14724:10	belatacept	NN	O	O
antibody	NULOJIX.xml:S1:14735:8	antibodi	NN	O	O
titers	NULOJIX.xml:S1:14744:6	titer	NNS	O	O
did	NULOJIX.xml:S1:14751:3	did	VBD	O	O
not	NULOJIX.xml:S1:14755:3	not	RB	O	O
increase	NULOJIX.xml:S1:14759:8	increas	VB	O	O
during	NULOJIX.xml:S1:14768:6	dure	IN	O	O
treatment	NULOJIX.xml:S1:14775:9	treatment	NN	O	O
in	NULOJIX.xml:S1:14785:2	in	IN	O	O
these	NULOJIX.xml:S1:14788:5	these	DT	O	O
29	NULOJIX.xml:S1:14794:2	29	CD	O	O
patients	NULOJIX.xml:S1:14797:8	patient	NNS	O	O
.	NULOJIX.xml:S1:14805:1	.	.	O	O

Eight	NULOJIX.xml:S1:14811:5	eight	NNP	O	O
(	NULOJIX.xml:S1:14817:1	(	(	O	O
2%	NULOJIX.xml:S1:14818:2	2%	CD	O	O
)	NULOJIX.xml:S1:14820:1	)	)	O	O
patients	NULOJIX.xml:S1:14822:8	patient	NNS	O	O
developed	NULOJIX.xml:S1:14831:9	develop	JJ	O	O
antibodies	NULOJIX.xml:S1:14841:10	antibodi	NNS	O	O
during	NULOJIX.xml:S1:14852:6	dure	IN	O	O
treatment	NULOJIX.xml:S1:14859:9	treatment	NN	O	O
with	NULOJIX.xml:S1:14869:4	with	IN	O	O
the	NULOJIX.xml:S1:14874:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:14878:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:14886:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:14898:7	regimen	NNS	O	O
.	NULOJIX.xml:S1:14905:1	.	.	O	O

In	NULOJIX.xml:S1:14907:2	In	IN	O	O
the	NULOJIX.xml:S1:14910:3	the	DT	O	O
patients	NULOJIX.xml:S1:14914:8	patient	NNS	O	O
who	NULOJIX.xml:S1:14923:3	who	WP	O	O
developed	NULOJIX.xml:S1:14927:9	develop	VBD	O	O
antibodies	NULOJIX.xml:S1:14937:10	antibodi	NNS	O	O
during	NULOJIX.xml:S1:14948:6	dure	IN	O	O
treatment	NULOJIX.xml:S1:14955:9	treatment	NN	O	O
,	NULOJIX.xml:S1:14964:1	,	,	O	O
the	NULOJIX.xml:S1:14966:3	the	DT	O	O
median	NULOJIX.xml:S1:14970:6	median	JJ	O	O
titer	NULOJIX.xml:S1:14977:5	titer	NN	O	O
(	NULOJIX.xml:S1:14983:1	(	(	O	O
by	NULOJIX.xml:S1:14984:2	by	IN	O	O
dilution	NULOJIX.xml:S1:14987:8	dilut	NN	O	O
method	NULOJIX.xml:S1:14996:6	method	NN	O	O
)	NULOJIX.xml:S1:15002:1	)	)	O	O
was	NULOJIX.xml:S1:15004:3	wa	VBD	O	O
8	NULOJIX.xml:S1:15008:1	8	CD	O	O
,	NULOJIX.xml:S1:15009:1	,	,	O	O
with	NULOJIX.xml:S1:15011:4	with	IN	O	O
a	NULOJIX.xml:S1:15016:1	a	DT	O	O
range	NULOJIX.xml:S1:15018:5	rang	NN	O	O
of	NULOJIX.xml:S1:15024:2	of	IN	O	O
5	NULOJIX.xml:S1:15027:1	5	CD	O	O
to	NULOJIX.xml:S1:15029:2	to	TO	O	O
80	NULOJIX.xml:S1:15032:2	80	CD	O	O
.	NULOJIX.xml:S1:15034:1	.	.	O	O

Of	NULOJIX.xml:S1:15036:2	Of	IN	O	O
56	NULOJIX.xml:S1:15039:2	56	CD	O	O
patients	NULOJIX.xml:S1:15042:8	patient	NNS	O	O
who	NULOJIX.xml:S1:15051:3	who	WP	O	O
tested	NULOJIX.xml:S1:15055:6	test	VBD	O	O
negative	NULOJIX.xml:S1:15062:8	neg	JJ	O	O
for	NULOJIX.xml:S1:15071:3	for	IN	O	O
antibodies	NULOJIX.xml:S1:15075:10	antibodi	NNS	O	O
during	NULOJIX.xml:S1:15086:6	dure	IN	O	O
treatment	NULOJIX.xml:S1:15093:9	treatment	NN	O	O
and	NULOJIX.xml:S1:15103:3	and	CC	O	O
reassessed	NULOJIX.xml:S1:15107:10	reassess	VBD	O	O
approximately	NULOJIX.xml:S1:15118:13	approxim	RB	O	O
7	NULOJIX.xml:S1:15132:1	7	CD	O	O
half	NULOJIX.xml:S1:15134:4	half	NN	O	O
-	NULOJIX.xml:S1:15138:1	-	:	O	O
lives	NULOJIX.xml:S1:15139:5	live	NNS	O	O
after	NULOJIX.xml:S1:15145:5	after	IN	O	O
discontinuation	NULOJIX.xml:S1:15151:15	discontinu	NN	O	O
of	NULOJIX.xml:S1:15167:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:15170:7	nulojix	NNP	O	O
,	NULOJIX.xml:S1:15177:1	,	,	O	O
1	NULOJIX.xml:S1:15179:1	1	CD	O	O
tested	NULOJIX.xml:S1:15181:6	test	VBD	O	O
antibody	NULOJIX.xml:S1:15188:8	antibodi	NN	O	O
positive	NULOJIX.xml:S1:15197:8	posit	JJ	O	O
.	NULOJIX.xml:S1:15205:1	.	.	O	O

Anti	NULOJIX.xml:S1:15207:4	anti	NNP	O	O
-	NULOJIX.xml:S1:15211:1	-	:	O	O
belatacept	NULOJIX.xml:S1:15212:10	belatacept	NN	O	O
antibody	NULOJIX.xml:S1:15223:8	antibodi	NN	O	O
development	NULOJIX.xml:S1:15232:11	develop	NN	O	O
was	NULOJIX.xml:S1:15244:3	wa	VBD	O	O
not	NULOJIX.xml:S1:15248:3	not	RB	O	O
associated	NULOJIX.xml:S1:15252:10	associ	VBN	O	O
with	NULOJIX.xml:S1:15263:4	with	IN	O	O
altered	NULOJIX.xml:S1:15268:7	alter	JJ	O	O
clearance	NULOJIX.xml:S1:15276:9	clearanc	NN	O	O
of	NULOJIX.xml:S1:15286:2	of	IN	O	O
belatacept	NULOJIX.xml:S1:15289:10	belatacept	NN	O	O
.	NULOJIX.xml:S1:15299:1	.	.	O	O

Samples	NULOJIX.xml:S1:15305:7	sampl	NNS	O	O
from	NULOJIX.xml:S1:15313:4	from	IN	O	O
6	NULOJIX.xml:S1:15318:1	6	CD	O	O
patients	NULOJIX.xml:S1:15320:8	patient	NNS	O	O
with	NULOJIX.xml:S1:15329:4	with	IN	O	O
confirmed	NULOJIX.xml:S1:15334:9	confirm	JJ	O	O
binding	NULOJIX.xml:S1:15344:7	bind	VBG	O	O
activity	NULOJIX.xml:S1:15352:8	activ	NN	O	O
to	NULOJIX.xml:S1:15361:2	to	TO	O	O
the	NULOJIX.xml:S1:15364:3	the	DT	O	O
modified	NULOJIX.xml:S1:15368:8	modifi	VBN	O	O
cytotoxic	NULOJIX.xml:S1:15377:9	cytotox	NN	O	B-AdverseReaction
T	NULOJIX.xml:S1:15387:1	T	NNP	O	I-AdverseReaction
-	NULOJIX.xml:S1:15388:1	-	:	O	I-AdverseReaction
lymphocyte	NULOJIX.xml:S1:15389:10	lymphocyt	NN	O	I-AdverseReaction
-	NULOJIX.xml:S1:15399:1	-	:	O	I-AdverseReaction
associated	NULOJIX.xml:S1:15400:10	associ	VBN	O	I-AdverseReaction
antigen	NULOJIX.xml:S1:15411:7	antigen	NN	O	I-AdverseReaction
4	NULOJIX.xml:S1:15419:1	4	CD	O	O
(	NULOJIX.xml:S1:15421:1	(	(	O	O
CTLA	NULOJIX.xml:S1:15422:4	ctla	NNP	O	O
-	NULOJIX.xml:S1:15426:1	-	:	O	O
4	NULOJIX.xml:S1:15427:1	4	CD	O	O
)	NULOJIX.xml:S1:15428:1	)	)	O	O
region	NULOJIX.xml:S1:15430:6	region	NN	O	O
of	NULOJIX.xml:S1:15437:2	of	IN	O	O
the	NULOJIX.xml:S1:15440:3	the	DT	O	O
belatacept	NULOJIX.xml:S1:15444:10	belatacept	NN	O	O
molecule	NULOJIX.xml:S1:15455:8	molecul	NN	O	O
were	NULOJIX.xml:S1:15464:4	were	VBD	O	O
assessed	NULOJIX.xml:S1:15469:8	assess	VBN	O	O
by	NULOJIX.xml:S1:15478:2	by	IN	O	O
an	NULOJIX.xml:S1:15481:2	an	DT	O	O
in	NULOJIX.xml:S1:15485:2	in	IN	O	O
vitro	NULOJIX.xml:S1:15488:5	vitro	NN	O	O
bioassay	NULOJIX.xml:S1:15495:8	bioassay	NN	O	O
for	NULOJIX.xml:S1:15504:3	for	IN	O	O
the	NULOJIX.xml:S1:15508:3	the	DT	O	O
presence	NULOJIX.xml:S1:15512:8	presenc	NN	O	O
of	NULOJIX.xml:S1:15521:2	of	IN	O	O
neutralizing	NULOJIX.xml:S1:15524:12	neutral	VBG	O	O
antibodies	NULOJIX.xml:S1:15537:10	antibodi	NNS	O	O
.	NULOJIX.xml:S1:15547:1	.	.	O	O

Three	NULOJIX.xml:S1:15549:5	three	CD	O	O
of	NULOJIX.xml:S1:15555:2	of	IN	O	O
these	NULOJIX.xml:S1:15558:5	these	DT	O	O
6	NULOJIX.xml:S1:15564:1	6	CD	O	O
patients	NULOJIX.xml:S1:15566:8	patient	NNS	O	O
tested	NULOJIX.xml:S1:15575:6	test	VBD	O	O
positive	NULOJIX.xml:S1:15582:8	posit	JJ	O	O
for	NULOJIX.xml:S1:15591:3	for	IN	O	O
neutralizing	NULOJIX.xml:S1:15595:12	neutral	VBG	O	O
antibodies	NULOJIX.xml:S1:15608:10	antibodi	NNS	O	O
.	NULOJIX.xml:S1:15618:1	.	.	O	O

However	NULOJIX.xml:S1:15620:7	howev	RB	O	O
,	NULOJIX.xml:S1:15627:1	,	,	O	O
the	NULOJIX.xml:S1:15629:3	the	DT	O	O
development	NULOJIX.xml:S1:15633:11	develop	NN	O	O
of	NULOJIX.xml:S1:15645:2	of	IN	O	O
neutralizing	NULOJIX.xml:S1:15648:12	neutral	VBG	O	O
antibodies	NULOJIX.xml:S1:15661:10	antibodi	NNS	O	O
may	NULOJIX.xml:S1:15672:3	may	MD	O	O
be	NULOJIX.xml:S1:15676:2	be	VB	O	O
underreported	NULOJIX.xml:S1:15679:13	underreport	VBN	O	O
due	NULOJIX.xml:S1:15693:3	due	JJ	O	O
to	NULOJIX.xml:S1:15697:2	to	TO	O	O
lack	NULOJIX.xml:S1:15700:4	lack	VB	O	O
of	NULOJIX.xml:S1:15705:2	of	IN	O	O
assay	NULOJIX.xml:S1:15708:5	assay	JJ	O	O
sensitivity	NULOJIX.xml:S1:15714:11	sensit	NN	O	O
.	NULOJIX.xml:S1:15725:1	.	.	O	O

The	NULOJIX.xml:S1:15731:3	the	DT	O	O
clinical	NULOJIX.xml:S1:15735:8	clinic	JJ	O	O
impact	NULOJIX.xml:S1:15744:6	impact	NN	O	O
of	NULOJIX.xml:S1:15751:2	of	IN	O	O
anti	NULOJIX.xml:S1:15754:4	anti	JJ	O	O
-	NULOJIX.xml:S1:15758:1	-	:	O	O
belatacept	NULOJIX.xml:S1:15759:10	belatacept	NN	O	O
antibodies	NULOJIX.xml:S1:15770:10	antibodi	NNS	O	O
(	NULOJIX.xml:S1:15781:1	(	(	O	O
including	NULOJIX.xml:S1:15782:9	includ	VBG	O	O
neutralizing	NULOJIX.xml:S1:15792:12	neutral	VBG	O	O
anti	NULOJIX.xml:S1:15805:4	anti	JJ	O	O
-	NULOJIX.xml:S1:15809:1	-	:	O	O
belatacept	NULOJIX.xml:S1:15810:10	belatacept	IN	O	O
antibodies	NULOJIX.xml:S1:15821:10	antibodi	NNS	O	O
)	NULOJIX.xml:S1:15831:1	)	)	O	O
could	NULOJIX.xml:S1:15833:5	could	MD	O	O
not	NULOJIX.xml:S1:15839:3	not	RB	O	O
be	NULOJIX.xml:S1:15843:2	be	VB	O	O
determined	NULOJIX.xml:S1:15846:10	determin	VBN	O	O
in	NULOJIX.xml:S1:15857:2	in	IN	O	O
the	NULOJIX.xml:S1:15860:3	the	DT	O	O
studies	NULOJIX.xml:S1:15864:7	studi	NNS	O	O
.	NULOJIX.xml:S1:15871:1	.	.	O	O

The	NULOJIX.xml:S1:15877:3	the	DT	O	O
data	NULOJIX.xml:S1:15881:4	data	NNS	O	O
reflect	NULOJIX.xml:S1:15886:7	reflect	VBP	O	O
the	NULOJIX.xml:S1:15894:3	the	DT	O	O
percentage	NULOJIX.xml:S1:15898:10	percentag	NN	O	O
of	NULOJIX.xml:S1:15909:2	of	IN	O	O
patients	NULOJIX.xml:S1:15912:8	patient	NNS	O	O
whose	NULOJIX.xml:S1:15921:5	whose	WP$	O	O
test	NULOJIX.xml:S1:15927:4	test	NN	O	O
results	NULOJIX.xml:S1:15932:7	result	NNS	O	O
were	NULOJIX.xml:S1:15940:4	were	VBD	O	O
positive	NULOJIX.xml:S1:15945:8	posit	JJ	O	O
for	NULOJIX.xml:S1:15954:3	for	IN	O	O
antibodies	NULOJIX.xml:S1:15958:10	antibodi	NNS	O	O
to	NULOJIX.xml:S1:15969:2	to	TO	O	O
belatacept	NULOJIX.xml:S1:15972:10	belatacept	VB	O	O
in	NULOJIX.xml:S1:15983:2	in	IN	O	O
specific	NULOJIX.xml:S1:15986:8	specif	JJ	O	O
assays	NULOJIX.xml:S1:15995:6	assay	NNS	O	O
.	NULOJIX.xml:S1:16001:1	.	.	O	O

The	NULOJIX.xml:S1:16003:3	the	DT	O	O
observed	NULOJIX.xml:S1:16007:8	observ	JJ	O	O
incidence	NULOJIX.xml:S1:16016:9	incid	NN	O	O
of	NULOJIX.xml:S1:16026:2	of	IN	O	O
antibody	NULOJIX.xml:S1:16029:8	antibodi	NN	O	O
(	NULOJIX.xml:S1:16038:1	(	(	O	O
including	NULOJIX.xml:S1:16039:9	includ	VBG	O	O
neutralizing	NULOJIX.xml:S1:16049:12	neutral	VBG	O	O
antibody	NULOJIX.xml:S1:16062:8	antibodi	NN	O	O
)	NULOJIX.xml:S1:16070:1	)	)	O	O
positivity	NULOJIX.xml:S1:16072:10	posit	NN	O	O
in	NULOJIX.xml:S1:16083:2	in	IN	O	O
an	NULOJIX.xml:S1:16086:2	an	DT	O	O
assay	NULOJIX.xml:S1:16089:5	assay	NN	O	O
may	NULOJIX.xml:S1:16095:3	may	MD	O	O
be	NULOJIX.xml:S1:16099:2	be	VB	O	O
influenced	NULOJIX.xml:S1:16102:10	influenc	VBN	O	O
by	NULOJIX.xml:S1:16113:2	by	IN	O	O
several	NULOJIX.xml:S1:16116:7	sever	JJ	O	O
factors	NULOJIX.xml:S1:16124:7	factor	NNS	O	O
including	NULOJIX.xml:S1:16132:9	includ	VBG	O	O
assay	NULOJIX.xml:S1:16142:5	assay	JJ	O	O
sensitivity	NULOJIX.xml:S1:16148:11	sensit	NN	O	O
and	NULOJIX.xml:S1:16160:3	and	CC	O	O
specificity	NULOJIX.xml:S1:16164:11	specif	NN	O	O
,	NULOJIX.xml:S1:16175:1	,	,	O	O
assay	NULOJIX.xml:S1:16177:5	assay	VBP	O	O
methodology	NULOJIX.xml:S1:16183:11	methodolog	NN	O	O
,	NULOJIX.xml:S1:16194:1	,	,	O	O
sample	NULOJIX.xml:S1:16196:6	sampl	NN	O	O
handling	NULOJIX.xml:S1:16203:8	handl	NN	O	O
,	NULOJIX.xml:S1:16211:1	,	,	O	O
timing	NULOJIX.xml:S1:16213:6	time	NN	O	O
of	NULOJIX.xml:S1:16220:2	of	IN	O	O
sample	NULOJIX.xml:S1:16223:6	sampl	JJ	O	O
collection	NULOJIX.xml:S1:16230:10	collect	NN	O	O
,	NULOJIX.xml:S1:16240:1	,	,	O	O
concomitant	NULOJIX.xml:S1:16242:11	concomit	JJ	O	O
medications	NULOJIX.xml:S1:16254:11	medic	NNS	O	O
,	NULOJIX.xml:S1:16265:1	,	,	O	O
and	NULOJIX.xml:S1:16267:3	and	CC	O	O
underlying	NULOJIX.xml:S1:16271:10	underli	JJ	O	O
disease	NULOJIX.xml:S1:16282:7	diseas	NN	O	O
.	NULOJIX.xml:S1:16289:1	.	.	O	O

For	NULOJIX.xml:S1:16291:3	for	IN	O	O
these	NULOJIX.xml:S1:16295:5	these	DT	O	O
reasons	NULOJIX.xml:S1:16301:7	reason	NNS	O	O
,	NULOJIX.xml:S1:16308:1	,	,	O	O
comparison	NULOJIX.xml:S1:16310:10	comparison	NN	O	O
of	NULOJIX.xml:S1:16321:2	of	IN	O	O
the	NULOJIX.xml:S1:16324:3	the	DT	O	O
incidence	NULOJIX.xml:S1:16328:9	incid	NN	O	O
of	NULOJIX.xml:S1:16338:2	of	IN	O	O
antibodies	NULOJIX.xml:S1:16341:10	antibodi	NNS	O	O
to	NULOJIX.xml:S1:16352:2	to	TO	O	O
belatacept	NULOJIX.xml:S1:16355:10	belatacept	VB	O	O
with	NULOJIX.xml:S1:16366:4	with	IN	O	O
the	NULOJIX.xml:S1:16371:3	the	DT	O	O
incidence	NULOJIX.xml:S1:16375:9	incid	NN	O	O
of	NULOJIX.xml:S1:16385:2	of	IN	O	O
antibodies	NULOJIX.xml:S1:16388:10	antibodi	NNS	O	O
to	NULOJIX.xml:S1:16399:2	to	TO	O	O
other	NULOJIX.xml:S1:16402:5	other	JJ	O	O
products	NULOJIX.xml:S1:16408:8	product	NNS	O	O
may	NULOJIX.xml:S1:16417:3	may	MD	O	O
be	NULOJIX.xml:S1:16421:2	be	VB	O	O
misleading	NULOJIX.xml:S1:16424:10	mislead	VBG	O	O
.	NULOJIX.xml:S1:16434:1	.	.	O	O

New	NULOJIX.xml:S1:16442:3	new	NNP	O	O
-	NULOJIX.xml:S1:16445:1	-	:	O	O
Onset	NULOJIX.xml:S1:16446:5	onset	NN	O	O
Diabetes	NULOJIX.xml:S1:16452:8	diabet	VBZ	O	O
After	NULOJIX.xml:S1:16461:5	after	IN	O	O
Transplantation	NULOJIX.xml:S1:16467:15	transplant	NN	O	O

The	NULOJIX.xml:S1:16486:3	the	DT	O	O
incidence	NULOJIX.xml:S1:16490:9	incid	NN	O	O
of	NULOJIX.xml:S1:16500:2	of	IN	O	O
new	NULOJIX.xml:S1:16503:3	new	JJ	B-AdverseReaction	O
-	NULOJIX.xml:S1:16506:1	-	:	I-AdverseReaction	O
onset	NULOJIX.xml:S1:16507:5	onset	NN	I-AdverseReaction	O
diabetes	NULOJIX.xml:S1:16513:8	diabet	NNS	I-AdverseReaction	O
after	NULOJIX.xml:S1:16522:5	after	IN	I-AdverseReaction	O
transplantation	NULOJIX.xml:S1:16528:15	transplant	NN	I-AdverseReaction	O
(	NULOJIX.xml:S1:16544:1	(	(	O	O
NODAT	NULOJIX.xml:S1:16545:5	nodat	NNP	B-AdverseReaction	O
)	NULOJIX.xml:S1:16550:1	)	)	O	O
was	NULOJIX.xml:S1:16552:3	wa	VBD	O	O
defined	NULOJIX.xml:S1:16556:7	defin	VBN	O	O
in	NULOJIX.xml:S1:16564:2	in	IN	O	O
Studies	NULOJIX.xml:S1:16567:7	studi	NNP	O	O
1	NULOJIX.xml:S1:16575:1	1	CD	O	O
and	NULOJIX.xml:S1:16577:3	and	CC	O	O
2	NULOJIX.xml:S1:16581:1	2	CD	O	O
as	NULOJIX.xml:S1:16583:2	as	IN	O	O
use	NULOJIX.xml:S1:16586:3	use	NN	O	O
of	NULOJIX.xml:S1:16590:2	of	IN	O	O
an	NULOJIX.xml:S1:16593:2	an	DT	O	O
antidiabetic	NULOJIX.xml:S1:16596:12	antidiabet	JJ	O	O
agent	NULOJIX.xml:S1:16609:5	agent	NN	O	O
for	NULOJIX.xml:S1:16615:3	for	IN	O	O
30	NULOJIX.xml:S1:16621:2	30	CD	O	O
days	NULOJIX.xml:S1:16624:4	day	NNS	O	O
or	NULOJIX.xml:S1:16629:2	or	CC	O	O
2	NULOJIX.xml:S1:16634:1	2	CD	O	O
fasting	NULOJIX.xml:S1:16636:7	fast	VBG	O	O
plasma	NULOJIX.xml:S1:16644:6	plasma	NN	O	B-AdverseReaction
glucose	NULOJIX.xml:S1:16651:7	glucos	NN	O	I-AdverseReaction
values	NULOJIX.xml:S1:16659:6	valu	NNS	O	I-AdverseReaction
126	NULOJIX.xml:S1:16668:3	126	CD	O	I-AdverseReaction
mg	NULOJIX.xml:S1:16672:2	mg	NNS	O	I-AdverseReaction
dL	NULOJIX.xml:S1:16675:2	dL	NN	O	I-AdverseReaction
(	NULOJIX.xml:S1:16678:1	(	(	O	O
7.0	NULOJIX.xml:S1:16679:3	7.0	CD	O	O
mmol	NULOJIX.xml:S1:16683:4	mmol	RB	O	O
L	NULOJIX.xml:S1:16688:1	L	NNP	O	O
)	NULOJIX.xml:S1:16689:1	)	)	O	O
post	NULOJIX.xml:S1:16691:4	post	NN	O	O
-	NULOJIX.xml:S1:16695:1	-	:	O	O
transplantation	NULOJIX.xml:S1:16696:15	transplant	NN	O	O
.	NULOJIX.xml:S1:16711:1	.	.	O	O

Of	NULOJIX.xml:S1:16713:2	Of	IN	O	O
the	NULOJIX.xml:S1:16716:3	the	DT	O	O
patients	NULOJIX.xml:S1:16720:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:16729:7	treat	VBN	O	O
with	NULOJIX.xml:S1:16737:4	with	IN	O	O
the	NULOJIX.xml:S1:16742:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:16746:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:16754:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:16766:7	regimen	NNS	O	O
,	NULOJIX.xml:S1:16773:1	,	,	O	O
5%	NULOJIX.xml:S1:16775:2	5%	CD	O	O
(	NULOJIX.xml:S1:16778:1	(	(	O	O
14	NULOJIX.xml:S1:16779:2	14	CD	O	O
304	NULOJIX.xml:S1:16782:3	304	CD	O	O
)	NULOJIX.xml:S1:16785:1	)	)	O	O
developed	NULOJIX.xml:S1:16787:9	develop	VBN	O	O
NODAT	NULOJIX.xml:S1:16797:5	nodat	NNP	B-AdverseReaction	O
by	NULOJIX.xml:S1:16803:2	by	IN	O	O
the	NULOJIX.xml:S1:16806:3	the	DT	O	O
end	NULOJIX.xml:S1:16810:3	end	NN	O	O
of	NULOJIX.xml:S1:16814:2	of	IN	O	O
one	NULOJIX.xml:S1:16817:3	one	CD	O	O
year	NULOJIX.xml:S1:16821:4	year	NN	O	O
compared	NULOJIX.xml:S1:16826:8	compar	VBN	O	O
to	NULOJIX.xml:S1:16835:2	to	TO	O	O
10%	NULOJIX.xml:S1:16838:3	10%	CD	O	O
(	NULOJIX.xml:S1:16842:1	(	(	O	O
27	NULOJIX.xml:S1:16843:2	27	CD	O	O
280	NULOJIX.xml:S1:16846:3	280	CD	O	O
)	NULOJIX.xml:S1:16849:1	)	)	O	O
of	NULOJIX.xml:S1:16851:2	of	IN	O	O
patients	NULOJIX.xml:S1:16854:8	patient	NNS	O	O
on	NULOJIX.xml:S1:16863:2	on	IN	O	O
the	NULOJIX.xml:S1:16866:3	the	DT	O	O
cyclosporine	NULOJIX.xml:S1:16870:12	cyclosporin	NN	O	O
control	NULOJIX.xml:S1:16883:7	control	NN	O	O
regimen	NULOJIX.xml:S1:16891:7	regimen	NNS	O	O
.	NULOJIX.xml:S1:16898:1	.	.	O	O

However	NULOJIX.xml:S1:16900:7	howev	RB	O	O
,	NULOJIX.xml:S1:16907:1	,	,	O	O
by	NULOJIX.xml:S1:16909:2	by	IN	O	O
the	NULOJIX.xml:S1:16912:3	the	DT	O	O
end	NULOJIX.xml:S1:16916:3	end	NN	O	O
of	NULOJIX.xml:S1:16920:2	of	IN	O	O
the	NULOJIX.xml:S1:16923:3	the	DT	O	O
third	NULOJIX.xml:S1:16927:5	third	JJ	O	O
year	NULOJIX.xml:S1:16933:4	year	NN	O	O
,	NULOJIX.xml:S1:16937:1	,	,	O	O
the	NULOJIX.xml:S1:16939:3	the	DT	O	O
cumulative	NULOJIX.xml:S1:16943:10	cumul	JJ	O	O
incidence	NULOJIX.xml:S1:16954:9	incid	NN	O	O
of	NULOJIX.xml:S1:16964:2	of	IN	O	O
NODAT	NULOJIX.xml:S1:16967:5	nodat	NNP	B-AdverseReaction	O
was	NULOJIX.xml:S1:16973:3	wa	VBD	O	O
8%	NULOJIX.xml:S1:16977:2	8%	CD	O	O
(	NULOJIX.xml:S1:16980:1	(	(	O	O
24	NULOJIX.xml:S1:16981:2	24	CD	O	O
304	NULOJIX.xml:S1:16984:3	304	CD	O	O
)	NULOJIX.xml:S1:16987:1	)	)	O	O
in	NULOJIX.xml:S1:16989:2	in	IN	O	O
patients	NULOJIX.xml:S1:16992:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:17001:7	treat	VBN	O	O
with	NULOJIX.xml:S1:17009:4	with	IN	O	O
the	NULOJIX.xml:S1:17014:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:17018:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:17026:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:17038:7	regimen	NNS	O	O
and	NULOJIX.xml:S1:17046:3	and	CC	O	O
10%	NULOJIX.xml:S1:17050:3	10%	CD	O	O
(	NULOJIX.xml:S1:17054:1	(	(	O	O
29	NULOJIX.xml:S1:17055:2	29	CD	O	O
280	NULOJIX.xml:S1:17058:3	280	CD	O	O
)	NULOJIX.xml:S1:17061:1	)	)	O	O
in	NULOJIX.xml:S1:17063:2	in	IN	O	O
patients	NULOJIX.xml:S1:17066:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:17075:7	treat	VBN	O	O
with	NULOJIX.xml:S1:17083:4	with	IN	O	O
the	NULOJIX.xml:S1:17088:3	the	DT	O	O
cyclosporine	NULOJIX.xml:S1:17092:12	cyclosporin	NN	O	O
regimen	NULOJIX.xml:S1:17105:7	regimen	NNS	O	O
.	NULOJIX.xml:S1:17112:1	.	.	O	O

Hypertension	NULOJIX.xml:S1:17120:12	hypertens	NN	O	O

Blood	NULOJIX.xml:S1:17136:5	blood	NNP	O	O
pressure	NULOJIX.xml:S1:17142:8	pressur	NN	O	O
and	NULOJIX.xml:S1:17151:3	and	CC	O	O
use	NULOJIX.xml:S1:17155:3	use	NN	O	O
of	NULOJIX.xml:S1:17159:2	of	IN	O	O
antihypertensive	NULOJIX.xml:S1:17162:16	antihypertens	JJ	O	O
medications	NULOJIX.xml:S1:17179:11	medic	NNS	O	O
were	NULOJIX.xml:S1:17191:4	were	VBD	O	O
reported	NULOJIX.xml:S1:17196:8	report	VBN	O	O
in	NULOJIX.xml:S1:17205:2	in	IN	O	O
Studies	NULOJIX.xml:S1:17208:7	studi	NNS	O	O
1	NULOJIX.xml:S1:17216:1	1	CD	O	O
and	NULOJIX.xml:S1:17218:3	and	CC	O	O
2	NULOJIX.xml:S1:17222:1	2	CD	O	O
.	NULOJIX.xml:S1:17223:1	.	.	O	O

By	NULOJIX.xml:S1:17225:2	By	IN	O	O
Year	NULOJIX.xml:S1:17228:4	year	NNP	O	O
3	NULOJIX.xml:S1:17233:1	3	CD	O	O
,	NULOJIX.xml:S1:17234:1	,	,	O	O
one	NULOJIX.xml:S1:17236:3	one	CD	O	O
or	NULOJIX.xml:S1:17240:2	or	CC	O	O
more	NULOJIX.xml:S1:17243:4	more	JJR	O	O
antihypertensive	NULOJIX.xml:S1:17248:16	antihypertens	JJ	O	O
medications	NULOJIX.xml:S1:17265:11	medic	NNS	O	O
were	NULOJIX.xml:S1:17277:4	were	VBD	O	O
used	NULOJIX.xml:S1:17282:4	use	VBN	O	O
in	NULOJIX.xml:S1:17287:2	in	IN	O	O
85%	NULOJIX.xml:S1:17290:3	85%	CD	O	O
of	NULOJIX.xml:S1:17294:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:17297:7	nulojix	NNP	O	O
-	NULOJIX.xml:S1:17304:1	-	:	O	O
treated	NULOJIX.xml:S1:17305:7	treat	VBD	O	O
patients	NULOJIX.xml:S1:17313:8	patient	NNS	O	O
and	NULOJIX.xml:S1:17322:3	and	CC	O	O
92%	NULOJIX.xml:S1:17326:3	92%	CD	O	O
of	NULOJIX.xml:S1:17330:2	of	IN	O	O
cyclosporine	NULOJIX.xml:S1:17333:12	cyclosporin	NN	O	O
-	NULOJIX.xml:S1:17345:1	-	:	O	O
treated	NULOJIX.xml:S1:17346:7	treat	JJ	O	O
patients	NULOJIX.xml:S1:17354:8	patient	NNS	O	O
.	NULOJIX.xml:S1:17362:1	.	.	O	O

At	NULOJIX.xml:S1:17364:2	At	IN	O	O
one	NULOJIX.xml:S1:17367:3	one	CD	O	O
year	NULOJIX.xml:S1:17371:4	year	NN	O	O
after	NULOJIX.xml:S1:17376:5	after	IN	O	O
transplantation	NULOJIX.xml:S1:17382:15	transplant	NN	O	O
,	NULOJIX.xml:S1:17397:1	,	,	O	O
systolic	NULOJIX.xml:S1:17399:8	systol	JJ	O	B-AdverseReaction
blood	NULOJIX.xml:S1:17408:5	blood	NN	O	I-AdverseReaction
pressures	NULOJIX.xml:S1:17414:9	pressur	NNS	O	I-AdverseReaction
were	NULOJIX.xml:S1:17424:4	were	VBD	O	O
8	NULOJIX.xml:S1:17429:1	8	CD	O	O
mmHg	NULOJIX.xml:S1:17431:4	mmhg	NNS	O	O
lower	NULOJIX.xml:S1:17436:5	lower	JJR	O	O
and	NULOJIX.xml:S1:17442:3	and	CC	O	O
diastolic	NULOJIX.xml:S1:17446:9	diastol	JJ	O	B-AdverseReaction
blood	NULOJIX.xml:S1:17456:5	blood	NN	O	I-AdverseReaction
pressures	NULOJIX.xml:S1:17462:9	pressur	NNS	O	I-AdverseReaction
were	NULOJIX.xml:S1:17472:4	were	VBD	O	O
3	NULOJIX.xml:S1:17477:1	3	CD	O	O
mmHg	NULOJIX.xml:S1:17479:4	mmhg	NNS	O	O
lower	NULOJIX.xml:S1:17484:5	lower	JJR	O	O
in	NULOJIX.xml:S1:17490:2	in	IN	O	O
patients	NULOJIX.xml:S1:17493:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:17502:7	treat	VBN	O	O
with	NULOJIX.xml:S1:17510:4	with	IN	O	O
the	NULOJIX.xml:S1:17515:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:17519:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:17527:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:17539:7	regimen	NNS	O	O
compared	NULOJIX.xml:S1:17547:8	compar	VBN	O	O
to	NULOJIX.xml:S1:17556:2	to	TO	O	O
the	NULOJIX.xml:S1:17559:3	the	DT	O	O
cyclosporine	NULOJIX.xml:S1:17563:12	cyclosporin	NN	O	O
control	NULOJIX.xml:S1:17576:7	control	NN	O	O
regimen	NULOJIX.xml:S1:17584:7	regimen	NNS	O	O
.	NULOJIX.xml:S1:17591:1	.	.	O	O

At	NULOJIX.xml:S1:17593:2	At	IN	O	O
three	NULOJIX.xml:S1:17596:5	three	CD	O	O
years	NULOJIX.xml:S1:17602:5	year	NNS	O	O
after	NULOJIX.xml:S1:17608:5	after	IN	O	O
transplantation	NULOJIX.xml:S1:17614:15	transplant	NN	O	O
,	NULOJIX.xml:S1:17629:1	,	,	O	O
systolic	NULOJIX.xml:S1:17631:8	systol	JJ	O	B-AdverseReaction
blood	NULOJIX.xml:S1:17640:5	blood	NN	O	I-AdverseReaction
pressures	NULOJIX.xml:S1:17646:9	pressur	NNS	O	I-AdverseReaction
were	NULOJIX.xml:S1:17656:4	were	VBD	O	O
6	NULOJIX.xml:S1:17661:1	6	CD	O	O
mmHg	NULOJIX.xml:S1:17663:4	mmhg	NNS	O	O
lower	NULOJIX.xml:S1:17668:5	lower	JJR	O	O
and	NULOJIX.xml:S1:17674:3	and	CC	O	O
diastolic	NULOJIX.xml:S1:17678:9	diastol	JJ	O	B-AdverseReaction
blood	NULOJIX.xml:S1:17688:5	blood	NN	O	I-AdverseReaction
pressures	NULOJIX.xml:S1:17694:9	pressur	NNS	O	I-AdverseReaction
were	NULOJIX.xml:S1:17704:4	were	VBD	O	O
3	NULOJIX.xml:S1:17709:1	3	CD	O	O
mmHg	NULOJIX.xml:S1:17711:4	mmhg	NNS	O	O
lower	NULOJIX.xml:S1:17716:5	lower	JJR	O	O
in	NULOJIX.xml:S1:17722:2	in	IN	O	O
NULOJIX	NULOJIX.xml:S1:17725:7	nulojix	NNP	O	O
-	NULOJIX.xml:S1:17732:1	-	:	O	O
treated	NULOJIX.xml:S1:17733:7	treat	VBD	O	O
patients	NULOJIX.xml:S1:17741:8	patient	NNS	O	O
compared	NULOJIX.xml:S1:17750:8	compar	VBN	O	O
to	NULOJIX.xml:S1:17759:2	to	TO	O	O
cyclosporine	NULOJIX.xml:S1:17762:12	cyclosporin	VB	O	O
-	NULOJIX.xml:S1:17774:1	-	:	O	O
treated	NULOJIX.xml:S1:17775:7	treat	JJ	O	O
patients	NULOJIX.xml:S1:17783:8	patient	NNS	O	O
.	NULOJIX.xml:S1:17791:1	.	.	O	O

Hypertension	NULOJIX.xml:S1:17793:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
was	NULOJIX.xml:S1:17806:3	wa	VBD	O	O
reported	NULOJIX.xml:S1:17810:8	report	VBN	O	O
as	NULOJIX.xml:S1:17819:2	as	IN	O	O
an	NULOJIX.xml:S1:17822:2	an	DT	O	O
adverse	NULOJIX.xml:S1:17825:7	advers	JJ	O	O
reaction	NULOJIX.xml:S1:17833:8	reaction	NN	O	O
in	NULOJIX.xml:S1:17842:2	in	IN	O	O
32%	NULOJIX.xml:S1:17845:3	32%	CD	O	O
of	NULOJIX.xml:S1:17849:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S1:17852:7	nulojix	NNP	O	O
-	NULOJIX.xml:S1:17859:1	-	:	O	O
treated	NULOJIX.xml:S1:17860:7	treat	VBD	O	O
patients	NULOJIX.xml:S1:17868:8	patient	NNS	O	O
and	NULOJIX.xml:S1:17877:3	and	CC	O	O
37%	NULOJIX.xml:S1:17881:3	37%	CD	O	O
of	NULOJIX.xml:S1:17885:2	of	IN	O	O
cyclosporine	NULOJIX.xml:S1:17888:12	cyclosporin	NN	O	O
-	NULOJIX.xml:S1:17900:1	-	:	O	O
treated	NULOJIX.xml:S1:17901:7	treat	JJ	O	O
patients	NULOJIX.xml:S1:17909:8	patient	NNS	O	O
(	NULOJIX.xml:S1:17918:1	(	(	O	O
see	NULOJIX.xml:S1:17919:3	see	VB	O	O
Table	NULOJIX.xml:S1:17923:5	tabl	NNP	O	O
4	NULOJIX.xml:S1:17929:1	4	CD	O	O
)	NULOJIX.xml:S1:17930:1	)	)	O	O
.	NULOJIX.xml:S1:17931:1	.	.	O	O

Dyslipidemia	NULOJIX.xml:S1:17939:12	dyslipidemia	NN	O	O

Mean	NULOJIX.xml:S1:17955:4	mean	JJ	O	O
values	NULOJIX.xml:S1:17960:6	valu	NNS	O	O
of	NULOJIX.xml:S1:17967:2	of	IN	O	I-AdverseReaction
total	NULOJIX.xml:S1:17970:5	total	JJ	O	I-AdverseReaction
cholesterol	NULOJIX.xml:S1:17976:11	cholesterol	NN	O	I-AdverseReaction
,	NULOJIX.xml:S1:17987:1	,	,	O	O
HDL	NULOJIX.xml:S1:17989:3	hdl	NNP	O	O
,	NULOJIX.xml:S1:17992:1	,	,	O	O
LDL	NULOJIX.xml:S1:17994:3	ldl	NNP	O	O
,	NULOJIX.xml:S1:17997:1	,	,	O	O
and	NULOJIX.xml:S1:17999:3	and	CC	O	O
triglycerides	NULOJIX.xml:S1:18003:13	triglycerid	NNS	O	B-AdverseReaction
were	NULOJIX.xml:S1:18017:4	were	VBD	O	O
reported	NULOJIX.xml:S1:18022:8	report	VBN	O	O
in	NULOJIX.xml:S1:18031:2	in	IN	O	O
Studies	NULOJIX.xml:S1:18034:7	studi	NNS	O	O
1	NULOJIX.xml:S1:18042:1	1	CD	O	O
and	NULOJIX.xml:S1:18044:3	and	CC	O	O
2	NULOJIX.xml:S1:18048:1	2	CD	O	O
.	NULOJIX.xml:S1:18049:1	.	.	O	O

At	NULOJIX.xml:S1:18051:2	At	IN	O	O
one	NULOJIX.xml:S1:18054:3	one	CD	O	O
year	NULOJIX.xml:S1:18058:4	year	NN	O	O
after	NULOJIX.xml:S1:18063:5	after	IN	O	O
transplantation	NULOJIX.xml:S1:18069:15	transplant	NN	O	O
these	NULOJIX.xml:S1:18085:5	these	DT	O	O
values	NULOJIX.xml:S1:18091:6	valu	NNS	O	O
were	NULOJIX.xml:S1:18098:4	were	VBD	O	O
183	NULOJIX.xml:S1:18103:3	183	CD	O	O
mg	NULOJIX.xml:S1:18107:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18110:2	dL	NN	O	O
,	NULOJIX.xml:S1:18112:1	,	,	O	O
50	NULOJIX.xml:S1:18114:2	50	CD	O	O
mg	NULOJIX.xml:S1:18117:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18120:2	dL	NN	O	O
,	NULOJIX.xml:S1:18122:1	,	,	O	O
102	NULOJIX.xml:S1:18124:3	102	CD	O	O
mg	NULOJIX.xml:S1:18128:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18131:2	dL	NN	O	O
,	NULOJIX.xml:S1:18133:1	,	,	O	O
and	NULOJIX.xml:S1:18135:3	and	CC	O	O
151	NULOJIX.xml:S1:18139:3	151	CD	O	O
mg	NULOJIX.xml:S1:18143:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18146:2	dL	NN	O	O
,	NULOJIX.xml:S1:18148:1	,	,	O	O
respectively	NULOJIX.xml:S1:18150:12	respect	RB	O	O
,	NULOJIX.xml:S1:18162:1	,	,	O	O
in	NULOJIX.xml:S1:18164:2	in	IN	O	O
401	NULOJIX.xml:S1:18167:3	401	CD	O	O
patients	NULOJIX.xml:S1:18171:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:18180:7	treat	VBN	O	O
with	NULOJIX.xml:S1:18188:4	with	IN	O	O
the	NULOJIX.xml:S1:18193:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:18197:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:18205:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:18217:7	regimen	NNS	O	O
and	NULOJIX.xml:S1:18225:3	and	CC	O	O
196	NULOJIX.xml:S1:18229:3	196	CD	O	O
mg	NULOJIX.xml:S1:18233:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18236:2	dL	NN	O	O
,	NULOJIX.xml:S1:18238:1	,	,	O	O
48	NULOJIX.xml:S1:18240:2	48	CD	O	O
mg	NULOJIX.xml:S1:18243:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18246:2	dL	NN	O	O
,	NULOJIX.xml:S1:18248:1	,	,	O	O
108	NULOJIX.xml:S1:18250:3	108	CD	O	O
mg	NULOJIX.xml:S1:18254:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18257:2	dL	NN	O	O
,	NULOJIX.xml:S1:18259:1	,	,	O	O
and	NULOJIX.xml:S1:18261:3	and	CC	O	O
195	NULOJIX.xml:S1:18265:3	195	CD	O	O
mg	NULOJIX.xml:S1:18269:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18272:2	dL	NN	O	O
,	NULOJIX.xml:S1:18274:1	,	,	O	O
respectively	NULOJIX.xml:S1:18276:12	respect	RB	O	O
,	NULOJIX.xml:S1:18288:1	,	,	O	O
in	NULOJIX.xml:S1:18290:2	in	IN	O	O
405	NULOJIX.xml:S1:18293:3	405	CD	O	O
patients	NULOJIX.xml:S1:18297:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:18306:7	treat	VBN	O	O
with	NULOJIX.xml:S1:18314:4	with	IN	O	O
the	NULOJIX.xml:S1:18319:3	the	DT	O	O
cyclosporine	NULOJIX.xml:S1:18323:12	cyclosporin	NN	O	O
control	NULOJIX.xml:S1:18336:7	control	NN	O	O
regimen	NULOJIX.xml:S1:18344:7	regimen	NNS	O	O
.	NULOJIX.xml:S1:18351:1	.	.	O	O

At	NULOJIX.xml:S1:18353:2	At	IN	O	O
three	NULOJIX.xml:S1:18356:5	three	CD	O	O
years	NULOJIX.xml:S1:18362:5	year	NNS	O	O
after	NULOJIX.xml:S1:18368:5	after	IN	O	O
transplantation	NULOJIX.xml:S1:18374:15	transplant	NN	O	O
,	NULOJIX.xml:S1:18389:1	,	,	O	O
the	NULOJIX.xml:S1:18391:3	the	DT	O	O
total	NULOJIX.xml:S1:18395:5	total	JJ	O	O
cholesterol	NULOJIX.xml:S1:18401:11	cholesterol	NN	O	O
,	NULOJIX.xml:S1:18412:1	,	,	O	O
HDL	NULOJIX.xml:S1:18414:3	hdl	NNP	O	O
,	NULOJIX.xml:S1:18417:1	,	,	O	O
LDL	NULOJIX.xml:S1:18419:3	ldl	NNP	O	O
,	NULOJIX.xml:S1:18422:1	,	,	O	O
and	NULOJIX.xml:S1:18424:3	and	CC	O	O
triglycerides	NULOJIX.xml:S1:18428:13	triglycerid	NNS	O	O
were	NULOJIX.xml:S1:18442:4	were	VBD	O	O
176	NULOJIX.xml:S1:18447:3	176	CD	O	O
mg	NULOJIX.xml:S1:18451:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18454:2	dL	NN	O	O
,	NULOJIX.xml:S1:18456:1	,	,	O	O
49	NULOJIX.xml:S1:18458:2	49	CD	O	O
mg	NULOJIX.xml:S1:18461:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18464:2	dL	NN	O	O
,	NULOJIX.xml:S1:18466:1	,	,	O	O
100	NULOJIX.xml:S1:18468:3	100	CD	O	O
mg	NULOJIX.xml:S1:18472:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18475:2	dL	NN	O	O
,	NULOJIX.xml:S1:18477:1	,	,	O	O
and	NULOJIX.xml:S1:18479:3	and	CC	O	O
141	NULOJIX.xml:S1:18483:3	141	CD	O	O
mg	NULOJIX.xml:S1:18487:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18490:2	dL	NN	O	O
,	NULOJIX.xml:S1:18492:1	,	,	O	O
respectively	NULOJIX.xml:S1:18494:12	respect	RB	O	O
,	NULOJIX.xml:S1:18506:1	,	,	O	O
in	NULOJIX.xml:S1:18508:2	in	IN	O	O
NULOJIX	NULOJIX.xml:S1:18511:7	nulojix	NNP	O	O
-	NULOJIX.xml:S1:18518:1	-	:	O	O
treated	NULOJIX.xml:S1:18519:7	treat	VBD	O	O
patients	NULOJIX.xml:S1:18527:8	patient	NNS	O	O
compared	NULOJIX.xml:S1:18536:8	compar	VBN	O	O
to	NULOJIX.xml:S1:18545:2	to	TO	O	O
193	NULOJIX.xml:S1:18548:3	193	CD	O	O
mg	NULOJIX.xml:S1:18552:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18555:2	dL	NN	O	O
,	NULOJIX.xml:S1:18557:1	,	,	O	O
48	NULOJIX.xml:S1:18559:2	48	CD	O	O
mg	NULOJIX.xml:S1:18562:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18565:2	dL	NN	O	O
,	NULOJIX.xml:S1:18567:1	,	,	O	O
106	NULOJIX.xml:S1:18569:3	106	CD	O	O
mg	NULOJIX.xml:S1:18573:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18576:2	dL	NN	O	O
,	NULOJIX.xml:S1:18578:1	,	,	O	O
and	NULOJIX.xml:S1:18580:3	and	CC	O	O
180	NULOJIX.xml:S1:18584:3	180	CD	O	O
mg	NULOJIX.xml:S1:18588:2	mg	NN	O	O
dL	NULOJIX.xml:S1:18591:2	dL	NN	O	O
in	NULOJIX.xml:S1:18594:2	in	IN	O	O
cyclosporine	NULOJIX.xml:S1:18597:12	cyclosporin	NN	O	O
-	NULOJIX.xml:S1:18609:1	-	:	O	O
treated	NULOJIX.xml:S1:18610:7	treat	JJ	O	O
patients	NULOJIX.xml:S1:18618:8	patient	NNS	O	O
.	NULOJIX.xml:S1:18626:1	.	.	O	O

The	NULOJIX.xml:S1:18632:3	the	DT	O	O
clinical	NULOJIX.xml:S1:18636:8	clinic	JJ	O	O
significance	NULOJIX.xml:S1:18645:12	signific	NN	O	O
of	NULOJIX.xml:S1:18658:2	of	IN	O	O
the	NULOJIX.xml:S1:18661:3	the	DT	O	O
lower	NULOJIX.xml:S1:18665:5	lower	JJR	O	O
mean	NULOJIX.xml:S1:18671:4	mean	JJ	O	O
triglyceride	NULOJIX.xml:S1:18676:12	triglycerid	NN	O	O
values	NULOJIX.xml:S1:18689:6	valu	NNS	O	O
in	NULOJIX.xml:S1:18696:2	in	IN	O	O
NULOJIX	NULOJIX.xml:S1:18699:7	nulojix	NNP	O	O
-	NULOJIX.xml:S1:18706:1	-	:	O	O
treated	NULOJIX.xml:S1:18707:7	treat	VBD	O	O
patients	NULOJIX.xml:S1:18715:8	patient	NNS	O	O
at	NULOJIX.xml:S1:18724:2	at	IN	O	O
one	NULOJIX.xml:S1:18727:3	one	CD	O	O
and	NULOJIX.xml:S1:18731:3	and	CC	O	O
three	NULOJIX.xml:S1:18735:5	three	CD	O	O
years	NULOJIX.xml:S1:18741:5	year	NNS	O	O
is	NULOJIX.xml:S1:18747:2	is	VBZ	O	O
unknown	NULOJIX.xml:S1:18750:7	unknown	JJ	O	O
.	NULOJIX.xml:S1:18757:1	.	.	O	O

Other	NULOJIX.xml:S1:18765:5	other	JJ	O	O
Adverse	NULOJIX.xml:S1:18771:7	advers	NNP	O	O
Reactions	NULOJIX.xml:S1:18779:9	reaction	NNP	O	O

Adverse	NULOJIX.xml:S1:18792:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:18800:9	reaction	NNS	O	O
that	NULOJIX.xml:S1:18810:4	that	WDT	O	O
occurred	NULOJIX.xml:S1:18815:8	occur	VBD	O	O
at	NULOJIX.xml:S1:18824:2	at	IN	O	O
a	NULOJIX.xml:S1:18827:1	a	DT	O	O
frequency	NULOJIX.xml:S1:18829:9	frequenc	NN	O	O
of	NULOJIX.xml:S1:18839:2	of	IN	O	O
10%	NULOJIX.xml:S1:18844:3	10%	CD	O	O
in	NULOJIX.xml:S1:18848:2	in	IN	O	O
patients	NULOJIX.xml:S1:18851:8	patient	NNS	O	O
treated	NULOJIX.xml:S1:18860:7	treat	VBN	O	O
with	NULOJIX.xml:S1:18868:4	with	IN	O	O
the	NULOJIX.xml:S1:18873:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:18877:7	nulojix	NNP	O	O
recommended	NULOJIX.xml:S1:18885:11	recommend	VBD	O	O
regimen	NULOJIX.xml:S1:18897:7	regimen	NNS	O	O
or	NULOJIX.xml:S1:18905:2	or	CC	O	O
cyclosporine	NULOJIX.xml:S1:18908:12	cyclosporin	VB	O	O
control	NULOJIX.xml:S1:18921:7	control	NN	O	O
regimen	NULOJIX.xml:S1:18929:7	regimen	NNS	O	O
in	NULOJIX.xml:S1:18937:2	in	IN	O	O
Studies	NULOJIX.xml:S1:18940:7	studi	NNP	O	O
1	NULOJIX.xml:S1:18948:1	1	CD	O	O
and	NULOJIX.xml:S1:18950:3	and	CC	O	O
2	NULOJIX.xml:S1:18954:1	2	CD	O	O
through	NULOJIX.xml:S1:18956:7	through	IN	O	O
three	NULOJIX.xml:S1:18964:5	three	CD	O	O
years	NULOJIX.xml:S1:18970:5	year	NNS	O	O
are	NULOJIX.xml:S1:18976:3	are	VBP	O	O
summarized	NULOJIX.xml:S1:18980:10	summar	VBN	O	O
by	NULOJIX.xml:S1:18991:2	by	IN	O	O
preferred	NULOJIX.xml:S1:18994:9	prefer	JJ	O	O
term	NULOJIX.xml:S1:19004:4	term	NN	O	O
in	NULOJIX.xml:S1:19009:2	in	IN	O	O
decreasing	NULOJIX.xml:S1:19012:10	decreas	VBG	O	O
order	NULOJIX.xml:S1:19023:5	order	NN	O	O
of	NULOJIX.xml:S1:19029:2	of	IN	O	O
frequency	NULOJIX.xml:S1:19032:9	frequenc	NN	O	O
within	NULOJIX.xml:S1:19042:6	within	IN	O	O
Table	NULOJIX.xml:S1:19049:5	tabl	JJ	O	O
4	NULOJIX.xml:S1:19055:1	4	CD	O	O
.	NULOJIX.xml:S1:19056:1	.	.	O	O

Table	NULOJIX.xml:S1:19062:5	tabl	JJ	O	O
4	NULOJIX.xml:S1:19068:1	4	CD	O	O
:	NULOJIX.xml:S1:19069:1	:	:	O	O
Adverse	NULOJIX.xml:S1:19071:7	advers	JJ	O	O
Reactions	NULOJIX.xml:S1:19079:9	reaction	NNS	O	O
Reported	NULOJIX.xml:S1:19089:8	report	VBN	O	O
by	NULOJIX.xml:S1:19098:2	by	IN	O	O
10%	NULOJIX.xml:S1:19103:3	10%	CD	O	O
of	NULOJIX.xml:S1:19107:2	of	IN	O	O
Patients	NULOJIX.xml:S1:19110:8	patient	NNS	O	O
Treated	NULOJIX.xml:S1:19119:7	treat	VBN	O	O
with	NULOJIX.xml:S1:19127:4	with	IN	O	O
Either	NULOJIX.xml:S1:19132:6	either	NNP	O	O
the	NULOJIX.xml:S1:19139:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S1:19143:7	nulojix	NNP	O	O
Recommended	NULOJIX.xml:S1:19151:11	recommend	NNP	O	O
Regimen	NULOJIX.xml:S1:19163:7	regimen	NNP	O	O
or	NULOJIX.xml:S1:19171:2	or	CC	O	O
Control	NULOJIX.xml:S1:19174:7	control	NNP	O	O
in	NULOJIX.xml:S1:19182:2	in	IN	O	O
Studies	NULOJIX.xml:S1:19185:7	studi	NNP	O	O
1	NULOJIX.xml:S1:19193:1	1	CD	O	O
and	NULOJIX.xml:S1:19195:3	and	CC	O	O
2	NULOJIX.xml:S1:19199:1	2	CD	O	O
Through	NULOJIX.xml:S1:19201:7	through	IN	O	O
Three	NULOJIX.xml:S1:19209:5	three	CD	O	O
Years	NULOJIX.xml:S1:19215:5	year	NNS	O	O
,	NULOJIX.xml:S1:19221:1	,	,	O	O

Adverse	NULOJIX.xml:S1:19227:7	advers	JJ	O	O
Reaction	NULOJIX.xml:S1:19235:8	reaction	NNP	O	O
NULOJIX	NULOJIX.xml:S1:19275:7	nulojix	NNP	O	O
Recommended	NULOJIX.xml:S1:19286:11	recommend	NNP	O	O
Regimen	NULOJIX.xml:S1:19298:7	regimen	NNP	O	O
N	NULOJIX.xml:S1:19309:1	N	NNP	O	O
401	NULOJIX.xml:S1:19311:3	401	CD	O	O
Cyclosporine	NULOJIX.xml:S1:19325:12	cyclosporin	NNP	O	O
N	NULOJIX.xml:S1:19341:1	N	NNP	O	O
405	NULOJIX.xml:S1:19343:3	405	CD	O	O

All	NULOJIX.xml:S1:19363:3	all	DT	O	O

randomized	NULOJIX.xml:S1:19367:10	random	VBN	O	O
and	NULOJIX.xml:S1:19378:3	and	CC	O	O
transplanted	NULOJIX.xml:S1:19382:12	transplant	VBN	O	O
patients	NULOJIX.xml:S1:19395:8	patient	NNS	O	O
in	NULOJIX.xml:S1:19404:2	in	IN	O	O
Studies	NULOJIX.xml:S1:19407:7	studi	NNP	O	O
1	NULOJIX.xml:S1:19415:1	1	CD	O	O
and	NULOJIX.xml:S1:19417:3	and	CC	O	O
2	NULOJIX.xml:S1:19421:1	2	CD	O	O
.	NULOJIX.xml:S1:19422:1	.	.	O	O

Studies	NULOJIX.xml:S1:19427:7	studi	NNS	O	O
1	NULOJIX.xml:S1:19435:1	1	CD	O	O
and	NULOJIX.xml:S1:19437:3	and	CC	O	O
2	NULOJIX.xml:S1:19441:1	2	CD	O	O
were	NULOJIX.xml:S1:19443:4	were	VBD	O	O
not	NULOJIX.xml:S1:19448:3	not	RB	O	O
designed	NULOJIX.xml:S1:19452:8	design	VBN	O	O
to	NULOJIX.xml:S1:19461:2	to	TO	O	O
support	NULOJIX.xml:S1:19464:7	support	VB	O	O
comparative	NULOJIX.xml:S1:19472:11	compar	JJ	O	O
claims	NULOJIX.xml:S1:19484:6	claim	NNS	O	O
for	NULOJIX.xml:S1:19491:3	for	IN	O	O
NULOJIX	NULOJIX.xml:S1:19495:7	nulojix	NNP	O	O
for	NULOJIX.xml:S1:19503:3	for	IN	O	O
the	NULOJIX.xml:S1:19507:3	the	DT	O	O
adverse	NULOJIX.xml:S1:19511:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:19519:9	reaction	NNS	O	O
reported	NULOJIX.xml:S1:19529:8	report	VBN	O	O
in	NULOJIX.xml:S1:19538:2	in	IN	O	O
this	NULOJIX.xml:S1:19541:4	thi	DT	O	O
table	NULOJIX.xml:S1:19546:5	tabl	NN	O	O
.	NULOJIX.xml:S1:19551:1	.	.	O	O

Infections	NULOJIX.xml:S1:19561:10	infect	NNS	O	O

and	NULOJIX.xml:S1:19572:3	and	CC	O	O
Infestations	NULOJIX.xml:S1:19576:12	infest	NNS	O	O

Urinary	NULOJIX.xml:S1:19674:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	NULOJIX.xml:S1:19682:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	NULOJIX.xml:S1:19688:9	infect	NN	I-AdverseReaction	I-AdverseReaction
37	NULOJIX.xml:S1:19718:2	37	CD	O	O
36	NULOJIX.xml:S1:19747:2	36	CD	O	O

Upper	NULOJIX.xml:S1:19783:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	NULOJIX.xml:S1:19789:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
infection	NULOJIX.xml:S1:19801:9	infect	NN	I-AdverseReaction	I-AdverseReaction
15	NULOJIX.xml:S1:19827:2	15	CD	O	O
16	NULOJIX.xml:S1:19856:2	16	CD	O	O

Nasopharyngitis	NULOJIX.xml:S1:19892:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
13	NULOJIX.xml:S1:19936:2	13	CD	O	O
16	NULOJIX.xml:S1:19965:2	16	CD	O	O

Cytomegalovirus	NULOJIX.xml:S1:20001:15	cytomegaloviru	NNP	B-AdverseReaction	B-AdverseReaction
infection	NULOJIX.xml:S1:20017:9	infect	NN	I-AdverseReaction	I-AdverseReaction
12	NULOJIX.xml:S1:20045:2	12	CD	O	O
12	NULOJIX.xml:S1:20074:2	12	CD	O	O

Influenza	NULOJIX.xml:S1:20110:9	influenza	NNP	B-AdverseReaction	B-AdverseReaction
11	NULOJIX.xml:S1:20154:2	11	CD	O	O
8	NULOJIX.xml:S1:20183:1	8	CD	O	O

Bronchitis	NULOJIX.xml:S1:20219:10	bronchiti	NNP	B-AdverseReaction	B-AdverseReaction
10	NULOJIX.xml:S1:20263:2	10	CD	O	O
7	NULOJIX.xml:S1:20292:1	7	CD	O	O

Gastrointestinal	NULOJIX.xml:S1:20324:16	gastrointestin	JJ	O	O
Disorders	NULOJIX.xml:S1:20341:9	disord	NNS	O	O

Diarrhea	NULOJIX.xml:S1:20437:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
39	NULOJIX.xml:S1:20481:2	39	CD	O	O
36	NULOJIX.xml:S1:20510:2	36	CD	O	O

Constipation	NULOJIX.xml:S1:20546:12	constip	NN	B-AdverseReaction	B-AdverseReaction
33	NULOJIX.xml:S1:20590:2	33	CD	O	O
35	NULOJIX.xml:S1:20619:2	35	CD	O	O

Nausea	NULOJIX.xml:S1:20655:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
24	NULOJIX.xml:S1:20699:2	24	CD	O	O
27	NULOJIX.xml:S1:20728:2	27	CD	O	O

Vomiting	NULOJIX.xml:S1:20764:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
22	NULOJIX.xml:S1:20808:2	22	CD	O	O
20	NULOJIX.xml:S1:20837:2	20	CD	O	O

Abdominal	NULOJIX.xml:S1:20873:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	NULOJIX.xml:S1:20883:4	pain	NN	I-AdverseReaction	I-AdverseReaction
19	NULOJIX.xml:S1:20917:2	19	CD	O	O
16	NULOJIX.xml:S1:20946:2	16	CD	O	O

Abdominal	NULOJIX.xml:S1:20982:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	NULOJIX.xml:S1:20992:4	pain	NN	I-AdverseReaction	I-AdverseReaction
upper	NULOJIX.xml:S1:20997:5	upper	JJ	I-AdverseReaction	I-AdverseReaction
9	NULOJIX.xml:S1:21026:1	9	CD	O	O
10	NULOJIX.xml:S1:21055:2	10	CD	O	O

Metabolism	NULOJIX.xml:S1:21087:10	metabol	NN	O	O
and	NULOJIX.xml:S1:21098:3	and	CC	O	O
Nutrition	NULOJIX.xml:S1:21102:9	nutrit	NN	O	O
Disorders	NULOJIX.xml:S1:21112:9	disord	NNS	O	O

Hyperkalemia	NULOJIX.xml:S1:21200:12	hyperkalemia	NNP	B-AdverseReaction	B-AdverseReaction
20	NULOJIX.xml:S1:21244:2	20	CD	O	O
20	NULOJIX.xml:S1:21273:2	20	CD	O	O

Hypokalemia	NULOJIX.xml:S1:21309:11	hypokalemia	NNP	B-AdverseReaction	B-AdverseReaction
21	NULOJIX.xml:S1:21353:2	21	CD	O	O
14	NULOJIX.xml:S1:21382:2	14	CD	O	O

Hypophosphatemia	NULOJIX.xml:S1:21418:16	hypophosphatemia	NNP	B-AdverseReaction	B-AdverseReaction
19	NULOJIX.xml:S1:21462:2	19	CD	O	O
13	NULOJIX.xml:S1:21491:2	13	CD	O	O

Dyslipidemia	NULOJIX.xml:S1:21527:12	dyslipidemia	NNP	B-AdverseReaction	B-AdverseReaction
19	NULOJIX.xml:S1:21571:2	19	CD	O	O
24	NULOJIX.xml:S1:21600:2	24	CD	O	O

Hyperglycemia	NULOJIX.xml:S1:21636:13	hyperglycemia	NNP	B-AdverseReaction	B-AdverseReaction
16	NULOJIX.xml:S1:21680:2	16	CD	O	O
17	NULOJIX.xml:S1:21709:2	17	CD	O	O

Hypocalcemia	NULOJIX.xml:S1:21745:12	hypocalcemia	NNP	B-AdverseReaction	B-AdverseReaction
13	NULOJIX.xml:S1:21789:2	13	CD	O	O
11	NULOJIX.xml:S1:21818:2	11	CD	O	O

Hypercholesterolemia	NULOJIX.xml:S1:21854:20	hypercholesterolemia	NNP	B-AdverseReaction	B-AdverseReaction
11	NULOJIX.xml:S1:21898:2	11	CD	O	O
11	NULOJIX.xml:S1:21927:2	11	CD	O	O

Hypomagnesemia	NULOJIX.xml:S1:21963:14	hypomagnesemia	NNP	B-AdverseReaction	B-AdverseReaction
7	NULOJIX.xml:S1:22007:1	7	CD	O	O
10	NULOJIX.xml:S1:22036:2	10	CD	O	O

Hyperuricemia	NULOJIX.xml:S1:22072:13	hyperuricemia	NNP	B-AdverseReaction	B-AdverseReaction
5	NULOJIX.xml:S1:22116:1	5	CD	O	O
12	NULOJIX.xml:S1:22145:2	12	CD	O	O

Procedural	NULOJIX.xml:S1:22177:10	procedur	JJ	O	O
Complications	NULOJIX.xml:S1:22188:13	complic	NNS	O	O

Graft	NULOJIX.xml:S1:22290:5	graft	NNP	B-AdverseReaction	B-AdverseReaction
dysfunction	NULOJIX.xml:S1:22296:11	dysfunct	NN	I-AdverseReaction	I-AdverseReaction
25	NULOJIX.xml:S1:22334:2	25	CD	O	O
34	NULOJIX.xml:S1:22363:2	34	CD	O	O

General	NULOJIX.xml:S1:22395:7	gener	NNP	O	O
Disorders	NULOJIX.xml:S1:22403:9	disord	NNP	O	O

Peripheral	NULOJIX.xml:S1:22508:10	peripher	NNP	B-AdverseReaction	B-AdverseReaction
edema	NULOJIX.xml:S1:22519:5	edema	VBD	I-AdverseReaction	I-AdverseReaction
34	NULOJIX.xml:S1:22552:2	34	CD	O	O
42	NULOJIX.xml:S1:22581:2	42	CD	O	O

Pyrexia	NULOJIX.xml:S1:22617:7	pyrexia	NNP	B-AdverseReaction	B-AdverseReaction
28	NULOJIX.xml:S1:22661:2	28	CD	O	O
26	NULOJIX.xml:S1:22690:2	26	CD	O	O

Blood	NULOJIX.xml:S1:22722:5	blood	NN	O	O
and	NULOJIX.xml:S1:22728:3	and	CC	O	O
Lymphatic	NULOJIX.xml:S1:22732:9	lymphat	NNP	O	O
System	NULOJIX.xml:S1:22742:6	system	NNP	O	O
Disorders	NULOJIX.xml:S1:22749:9	disord	NNP	O	O

Anemia	NULOJIX.xml:S1:22835:6	anemia	NNP	B-AdverseReaction	B-AdverseReaction
45	NULOJIX.xml:S1:22879:2	45	CD	O	O
44	NULOJIX.xml:S1:22908:2	44	CD	O	O

Leukopenia	NULOJIX.xml:S1:22944:10	leukopenia	NNP	B-AdverseReaction	B-AdverseReaction
20	NULOJIX.xml:S1:22988:2	20	CD	O	O
23	NULOJIX.xml:S1:23017:2	23	CD	O	O

Renal	NULOJIX.xml:S1:23049:5	renal	NNP	O	O
and	NULOJIX.xml:S1:23055:3	and	CC	O	O
Urinary	NULOJIX.xml:S1:23059:7	urinari	NNP	O	O
Disorders	NULOJIX.xml:S1:23067:9	disord	NNS	O	O

Hematuria	NULOJIX.xml:S1:23162:9	hematuria	NNP	B-AdverseReaction	B-AdverseReaction
16	NULOJIX.xml:S1:23206:2	16	CD	O	O
18	NULOJIX.xml:S1:23235:2	18	CD	O	O

Proteinuria	NULOJIX.xml:S1:23271:11	proteinuria	NNP	B-AdverseReaction	B-AdverseReaction
16	NULOJIX.xml:S1:23315:2	16	CD	O	O
12	NULOJIX.xml:S1:23344:2	12	CD	O	O

Dysuria	NULOJIX.xml:S1:23380:7	dysuria	NNP	B-AdverseReaction	B-AdverseReaction
11	NULOJIX.xml:S1:23424:2	11	CD	O	O
11	NULOJIX.xml:S1:23453:2	11	CD	O	O

Renal	NULOJIX.xml:S1:23489:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
tubular	NULOJIX.xml:S1:23495:7	tubular	JJ	I-AdverseReaction	I-AdverseReaction
necrosis	NULOJIX.xml:S1:23503:8	necrosi	NN	I-AdverseReaction	I-AdverseReaction
9	NULOJIX.xml:S1:23533:1	9	CD	O	O
13	NULOJIX.xml:S1:23562:2	13	CD	O	O

Vascular	NULOJIX.xml:S1:23594:8	vascular	JJ	O	O
Disorders	NULOJIX.xml:S1:23603:9	disord	NNS	O	O

Hypertension	NULOJIX.xml:S1:23707:12	hypertens	NNP	B-AdverseReaction	B-AdverseReaction
32	NULOJIX.xml:S1:23751:2	32	CD	O	O
37	NULOJIX.xml:S1:23780:2	37	CD	O	O

Hypotension	NULOJIX.xml:S1:23816:11	hypotens	NNP	B-AdverseReaction	B-AdverseReaction
18	NULOJIX.xml:S1:23860:2	18	CD	O	O
12	NULOJIX.xml:S1:23889:2	12	CD	O	O

Respiratory	NULOJIX.xml:S1:23921:11	respiratori	NNP	O	O
,	NULOJIX.xml:S1:23932:1	,	,	O	O
Thoracic	NULOJIX.xml:S1:23934:8	thorac	NNP	O	O
,	NULOJIX.xml:S1:23942:1	,	,	O	O
and	NULOJIX.xml:S1:23944:3	and	CC	O	O
Mediastinal	NULOJIX.xml:S1:23948:11	mediastin	NNP	O	O
Disorders	NULOJIX.xml:S1:23960:9	disord	NNP	O	O

Cough	NULOJIX.xml:S1:24038:5	cough	NNP	B-AdverseReaction	B-AdverseReaction
24	NULOJIX.xml:S1:24082:2	24	CD	O	O
18	NULOJIX.xml:S1:24111:2	18	CD	O	O

Dyspnea	NULOJIX.xml:S1:24147:7	dyspnea	NNP	B-AdverseReaction	B-AdverseReaction
12	NULOJIX.xml:S1:24191:2	12	CD	O	O
15	NULOJIX.xml:S1:24220:2	15	CD	O	O

Investigations	NULOJIX.xml:S1:24252:14	investig	NNS	O	O

Blood	NULOJIX.xml:S1:24365:5	blood	NNP	B-AdverseReaction	B-AdverseReaction
creatinine	NULOJIX.xml:S1:24371:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
increased	NULOJIX.xml:S1:24382:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
15	NULOJIX.xml:S1:24409:2	15	CD	O	O
20	NULOJIX.xml:S1:24438:2	20	CD	O	O

Musculoskeletal	NULOJIX.xml:S1:24470:15	musculoskelet	NNP	O	O
and	NULOJIX.xml:S1:24486:3	and	CC	O	O
Connective	NULOJIX.xml:S1:24490:10	connect	NNP	O	O
Tissue	NULOJIX.xml:S1:24501:6	tissu	NNP	O	O
Disorders	NULOJIX.xml:S1:24508:9	disord	NNP	O	O

Arthralgia	NULOJIX.xml:S1:24586:10	arthralgia	NNP	B-AdverseReaction	B-AdverseReaction
17	NULOJIX.xml:S1:24630:2	17	CD	O	O
13	NULOJIX.xml:S1:24659:2	13	CD	O	O

Back	NULOJIX.xml:S1:24695:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	NULOJIX.xml:S1:24700:4	pain	NN	I-AdverseReaction	I-AdverseReaction
13	NULOJIX.xml:S1:24739:2	13	CD	O	O
13	NULOJIX.xml:S1:24768:2	13	CD	O	O

Nervous	NULOJIX.xml:S1:24800:7	nervou	JJ	O	O
System	NULOJIX.xml:S1:24808:6	system	NNP	O	O
Disorders	NULOJIX.xml:S1:24815:9	disord	NNP	O	O

Headache	NULOJIX.xml:S1:24913:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
21	NULOJIX.xml:S1:24957:2	21	CD	O	O
18	NULOJIX.xml:S1:24986:2	18	CD	O	O

Dizziness	NULOJIX.xml:S1:25022:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
9	NULOJIX.xml:S1:25066:1	9	CD	O	O
10	NULOJIX.xml:S1:25095:2	10	CD	O	O

Tremor	NULOJIX.xml:S1:25131:6	tremor	NNP	B-AdverseReaction	B-AdverseReaction
8	NULOJIX.xml:S1:25175:1	8	CD	O	O
17	NULOJIX.xml:S1:25204:2	17	CD	O	O

Skin	NULOJIX.xml:S1:25236:4	skin	NNP	O	O
and	NULOJIX.xml:S1:25241:3	and	CC	O	O
Subcutaneous	NULOJIX.xml:S1:25245:12	subcutan	NNP	O	O
Tissue	NULOJIX.xml:S1:25258:6	tissu	NNP	O	O
Disorders	NULOJIX.xml:S1:25265:9	disord	NNP	O	O

Acne	NULOJIX.xml:S1:25349:4	acn	NNP	B-AdverseReaction	B-AdverseReaction
8	NULOJIX.xml:S1:25393:1	8	CD	O	O
11	NULOJIX.xml:S1:25422:2	11	CD	O	O

Psychiatric	NULOJIX.xml:S1:25454:11	psychiatr	JJ	O	O
Disorders	NULOJIX.xml:S1:25466:9	disord	NNS	O	O

Insomnia	NULOJIX.xml:S1:25567:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
15	NULOJIX.xml:S1:25611:2	15	CD	O	O
18	NULOJIX.xml:S1:25640:2	18	CD	O	O

Anxiety	NULOJIX.xml:S1:25676:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
10	NULOJIX.xml:S1:25720:2	10	CD	O	O
11	NULOJIX.xml:S1:25749:2	11	CD	O	O

Selected	NULOJIX.xml:S1:25788:8	select	VBN	O	O
adverse	NULOJIX.xml:S1:25797:7	advers	JJ	O	O
reactions	NULOJIX.xml:S1:25805:9	reaction	NNS	O	O
occurring	NULOJIX.xml:S1:25815:9	occur	VBG	O	O
in	NULOJIX.xml:S1:25825:2	in	IN	O	O
10%	NULOJIX.xml:S1:25829:3	10%	CD	O	O
from	NULOJIX.xml:S1:25833:4	from	IN	O	O
NULOJIX	NULOJIX.xml:S1:25838:7	nulojix	NNP	O	O
-	NULOJIX.xml:S1:25845:1	-	:	O	O
treated	NULOJIX.xml:S1:25846:7	treat	VBD	O	O
patients	NULOJIX.xml:S1:25854:8	patient	NNS	O	O
in	NULOJIX.xml:S1:25863:2	in	IN	O	O
either	NULOJIX.xml:S1:25866:6	either	DT	O	O
regimen	NULOJIX.xml:S1:25873:7	regimen	NNS	O	O
through	NULOJIX.xml:S1:25881:7	through	IN	O	O
three	NULOJIX.xml:S1:25889:5	three	CD	O	O
years	NULOJIX.xml:S1:25895:5	year	NNS	O	O
in	NULOJIX.xml:S1:25901:2	in	IN	O	O
Studies	NULOJIX.xml:S1:25904:7	studi	NNP	O	O
1	NULOJIX.xml:S1:25912:1	1	CD	O	O
and	NULOJIX.xml:S1:25914:3	and	CC	O	O
2	NULOJIX.xml:S1:25918:1	2	CD	O	O
are	NULOJIX.xml:S1:25920:3	are	VBP	O	O
listed	NULOJIX.xml:S1:25924:6	list	VBN	O	O
below	NULOJIX.xml:S1:25931:5	below	IN	O	O
:	NULOJIX.xml:S1:25936:1	:	:	O	O

Immune	NULOJIX.xml:S1:25944:6	immun	NN	O	O

System	NULOJIX.xml:S1:25951:6	system	NN	O	O
Disorders	NULOJIX.xml:S1:25958:9	disord	NNS	O	O
:	NULOJIX.xml:S1:25967:1	:	:	O	O
Guillain	NULOJIX.xml:S1:25970:8	guillain	NNP	B-AdverseReaction	B-AdverseReaction
-	NULOJIX.xml:S1:25978:1	-	:	I-AdverseReaction	I-AdverseReaction
Barre	NULOJIX.xml:S1:25979:5	barr	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	NULOJIX.xml:S1:25985:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction

Infections	NULOJIX.xml:S1:26000:10	infect	NNS	O	O
and	NULOJIX.xml:S1:26011:3	and	CC	O	O
Infestations	NULOJIX.xml:S1:26015:12	infest	NNS	O	O
:	NULOJIX.xml:S1:26027:1	:	:	O	O
see	NULOJIX.xml:S1:26030:3	see	VB	O	O
Table	NULOJIX.xml:S1:26034:5	tabl	JJ	O	O
3	NULOJIX.xml:S1:26040:1	3	CD	O	O

Gastrointestinal	NULOJIX.xml:S1:26048:16	gastrointestin	JJ	O	O
Disorders	NULOJIX.xml:S1:26065:9	disord	NNS	O	O
:	NULOJIX.xml:S1:26074:1	:	:	O	O
stomatitis	NULOJIX.xml:S1:26077:10	stomat	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:26087:1	,	,	O	O
including	NULOJIX.xml:S1:26089:9	includ	VBG	O	O
aphthous	NULOJIX.xml:S1:26099:8	aphthou	JJ	B-AdverseReaction	B-AdverseReaction
stomatitis	NULOJIX.xml:S1:26108:10	stomat	NN	I-AdverseReaction	I-AdverseReaction

Injury	NULOJIX.xml:S1:26125:6	injuri	NNP	O	O
,	NULOJIX.xml:S1:26131:1	,	,	O	O
Poisoning	NULOJIX.xml:S1:26133:9	poison	NNP	O	O
,	NULOJIX.xml:S1:26142:1	,	,	O	O
and	NULOJIX.xml:S1:26144:3	and	CC	O	O
Procedural	NULOJIX.xml:S1:26148:10	procedur	JJ	O	O
Complications	NULOJIX.xml:S1:26159:13	complic	NNS	O	O
:	NULOJIX.xml:S1:26172:1	:	:	O	O
chronic	NULOJIX.xml:S1:26175:7	chronic	NN	B-AdverseReaction	O
allograft	NULOJIX.xml:S1:26183:9	allograft	NN	I-AdverseReaction	O
nephropathy	NULOJIX.xml:S1:26193:11	nephropathi	NN	I-AdverseReaction	O
,	NULOJIX.xml:S1:26204:1	,	,	O	O
complications	NULOJIX.xml:S1:26206:13	complic	NNS	B-AdverseReaction	O
of	NULOJIX.xml:S1:26220:2	of	IN	I-AdverseReaction	O
transplanted	NULOJIX.xml:S1:26223:12	transplant	JJ	I-AdverseReaction	O
kidney	NULOJIX.xml:S1:26236:6	kidney	NN	I-AdverseReaction	O
,	NULOJIX.xml:S1:26242:1	,	,	O	O
including	NULOJIX.xml:S1:26244:9	includ	VBG	O	O
wound	NULOJIX.xml:S1:26254:5	wound	NN	B-AdverseReaction	B-AdverseReaction
dehiscence	NULOJIX.xml:S1:26260:10	dehisc	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:26270:1	,	,	O	O
arteriovenous	NULOJIX.xml:S1:26272:13	arterioven	JJ	B-AdverseReaction	B-AdverseReaction
fistula	NULOJIX.xml:S1:26286:7	fistula	NN	I-AdverseReaction	I-AdverseReaction
thrombosis	NULOJIX.xml:S1:26294:10	thrombosi	NN	I-AdverseReaction	I-AdverseReaction

Blood	NULOJIX.xml:S1:26311:5	blood	NN	O	O
and	NULOJIX.xml:S1:26317:3	and	CC	O	O
Lymphatic	NULOJIX.xml:S1:26321:9	lymphat	NNP	O	O
System	NULOJIX.xml:S1:26331:6	system	NNP	O	O
Disorders	NULOJIX.xml:S1:26338:9	disord	NNPS	O	O
:	NULOJIX.xml:S1:26347:1	:	:	O	O
neutropenia	NULOJIX.xml:S1:26350:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction

Renal	NULOJIX.xml:S1:26368:5	renal	NNP	O	O
and	NULOJIX.xml:S1:26374:3	and	CC	O	O
Urinary	NULOJIX.xml:S1:26378:7	urinari	JJ	O	O
Disorders	NULOJIX.xml:S1:26386:9	disord	NNS	O	O
:	NULOJIX.xml:S1:26395:1	:	:	O	O
renal	NULOJIX.xml:S1:26398:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
impairment	NULOJIX.xml:S1:26404:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:26414:1	,	,	O	O
including	NULOJIX.xml:S1:26416:9	includ	VBG	O	O
acute	NULOJIX.xml:S1:26426:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
renal	NULOJIX.xml:S1:26432:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	NULOJIX.xml:S1:26438:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:26445:1	,	,	O	O
renal	NULOJIX.xml:S1:26447:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
artery	NULOJIX.xml:S1:26453:6	arteri	NN	I-AdverseReaction	I-AdverseReaction
stenosis	NULOJIX.xml:S1:26460:8	stenosi	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:26468:1	,	,	O	O
urinary	NULOJIX.xml:S1:26470:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
incontinence	NULOJIX.xml:S1:26478:12	incontin	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S1:26490:1	,	,	O	O
hydronephrosis	NULOJIX.xml:S1:26492:14	hydronephrosi	NN	B-AdverseReaction	O

Vascular	NULOJIX.xml:S1:26513:8	vascular	JJ	O	O
Disorders	NULOJIX.xml:S1:26522:9	disord	NNS	O	O
:	NULOJIX.xml:S1:26531:1	:	:	O	O
hematoma	NULOJIX.xml:S1:26534:8	hematoma	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:26542:1	,	,	O	O
lymphocele	NULOJIX.xml:S1:26544:10	lymphocel	NN	B-AdverseReaction	B-AdverseReaction

Musculoskeletal	NULOJIX.xml:S1:26561:15	musculoskelet	NNP	O	O
and	NULOJIX.xml:S1:26577:3	and	CC	O	O
Connective	NULOJIX.xml:S1:26581:10	connect	NNP	O	O
Tissue	NULOJIX.xml:S1:26592:6	tissu	NNP	O	O
Disorders	NULOJIX.xml:S1:26599:9	disord	NNP	O	O
:	NULOJIX.xml:S1:26608:1	:	:	O	O
musculoskeletal	NULOJIX.xml:S1:26611:15	musculoskelet	NN	B-AdverseReaction	B-AdverseReaction
pain	NULOJIX.xml:S1:26627:4	pain	NN	I-AdverseReaction	I-AdverseReaction

Skin	NULOJIX.xml:S1:26638:4	skin	NNP	O	O
and	NULOJIX.xml:S1:26643:3	and	CC	O	O
Subcutaneous	NULOJIX.xml:S1:26647:12	subcutan	NNP	O	O
Tissue	NULOJIX.xml:S1:26660:6	tissu	NNP	O	O
Disorders	NULOJIX.xml:S1:26667:9	disord	NNP	O	O
:	NULOJIX.xml:S1:26676:1	:	:	O	O
alopecia	NULOJIX.xml:S1:26679:8	alopecia	NN	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S1:26687:1	,	,	O	O
hyperhidrosis	NULOJIX.xml:S1:26689:13	hyperhidrosi	NN	B-AdverseReaction	B-AdverseReaction

Cardiac	NULOJIX.xml:S1:26709:7	cardiac	JJ	O	O
Disorders	NULOJIX.xml:S1:26717:9	disord	NNS	O	O
:	NULOJIX.xml:S1:26726:1	:	:	O	O
atrial	NULOJIX.xml:S1:26729:6	atrial	JJ	B-AdverseReaction	B-AdverseReaction
fibrillation	NULOJIX.xml:S1:26736:12	fibril	NN	I-AdverseReaction	I-AdverseReaction
\n\n	NULOJIX.xml:S2:0:2	\n\n	NNP	O	O
BOXED	NULOJIX.xml:S2:6:5	box	NNP	O	O
WARNING	NULOJIX.xml:S2:12:7	warn	NN	O	O
:	NULOJIX.xml:S2:19:1	:	:	O	O
WARNING	NULOJIX.xml:S2:21:7	warn	NN	O	O
:	NULOJIX.xml:S2:28:1	:	:	O	O
POST	NULOJIX.xml:S2:30:4	post	NNP	B-AdverseReaction	O
-	NULOJIX.xml:S2:34:1	-	:	I-AdverseReaction	O
TRANSPLANT	NULOJIX.xml:S2:35:10	transplant	NNP	I-AdverseReaction	O
LYMPHOPROLIFERATIVE	NULOJIX.xml:S2:46:19	lymphoprolif	NNP	I-AdverseReaction	O
DISORDER	NULOJIX.xml:S2:66:8	disord	NNP	I-AdverseReaction	O
,	NULOJIX.xml:S2:74:1	,	,	O	O
OTHER	NULOJIX.xml:S2:76:5	other	NNP	O	O
MALIGNANCIES	NULOJIX.xml:S2:82:12	malign	NNP	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S2:94:1	,	,	O	O
AND	NULOJIX.xml:S2:96:3	and	NNP	O	O
SERIOUS	NULOJIX.xml:S2:100:7	seriou	NNP	O	O
INFECTIONS	NULOJIX.xml:S2:108:10	infect	NNP	B-AdverseReaction	B-AdverseReaction
\n\n	NULOJIX.xml:S2:118:2	\n\n	NNP	O	O
WARNING	NULOJIX.xml:S2:122:7	warn	NNP	O	O
:	NULOJIX.xml:S2:129:1	:	:	O	O
POST	NULOJIX.xml:S2:131:4	post	NNP	B-AdverseReaction	O
-	NULOJIX.xml:S2:135:1	-	:	I-AdverseReaction	O
TRANSPLANT	NULOJIX.xml:S2:136:10	transplant	NNP	I-AdverseReaction	O
LYMPHOPROLIFERATIVE	NULOJIX.xml:S2:147:19	lymphoprolif	NNP	I-AdverseReaction	O
DISORDER	NULOJIX.xml:S2:167:8	disord	NNP	I-AdverseReaction	O
,	NULOJIX.xml:S2:175:1	,	,	O	O
OTHER	NULOJIX.xml:S2:177:5	other	NNP	O	O
MALIGNANCIES	NULOJIX.xml:S2:183:12	malign	NNP	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S2:195:1	,	,	O	O
AND	NULOJIX.xml:S2:197:3	and	NNP	O	O
SERIOUS	NULOJIX.xml:S2:201:7	seriou	NNP	O	O
INFECTIONS	NULOJIX.xml:S2:209:10	infect	NNP	B-AdverseReaction	B-AdverseReaction
\n\n	NULOJIX.xml:S2:219:2	\n\n	NNP	O	O
Increased	NULOJIX.xml:S2:225:9	increas	VBD	O	O
risk	NULOJIX.xml:S2:235:4	risk	NN	O	O
for	NULOJIX.xml:S2:240:3	for	IN	O	O
developing	NULOJIX.xml:S2:244:10	develop	VBG	O	O
post	NULOJIX.xml:S2:255:4	post	NN	B-AdverseReaction	O
-	NULOJIX.xml:S2:259:1	-	:	I-AdverseReaction	O
transplant	NULOJIX.xml:S2:260:10	transplant	NN	I-AdverseReaction	O
lymphoproliferative	NULOJIX.xml:S2:271:19	lymphoprolif	JJ	I-AdverseReaction	O
disorder	NULOJIX.xml:S2:291:8	disord	NN	I-AdverseReaction	O
(	NULOJIX.xml:S2:300:1	(	(	O	O
PTLD	NULOJIX.xml:S2:301:4	ptld	NNP	B-AdverseReaction	O
)	NULOJIX.xml:S2:305:1	)	)	O	O
,	NULOJIX.xml:S2:306:1	,	,	O	O
predominantly	NULOJIX.xml:S2:308:13	predominantli	RB	O	O
involving	NULOJIX.xml:S2:322:9	involv	VBG	O	O
the	NULOJIX.xml:S2:332:3	the	DT	O	O
central	NULOJIX.xml:S2:336:7	central	JJ	O	O
nervous	NULOJIX.xml:S2:344:7	nervou	JJ	O	O
system	NULOJIX.xml:S2:352:6	system	NN	O	O
(	NULOJIX.xml:S2:359:1	(	(	O	O
CNS	NULOJIX.xml:S2:360:3	cn	NNP	O	O
)	NULOJIX.xml:S2:363:1	)	)	O	O
.	NULOJIX.xml:S2:364:1	.	.	O	O

Recipients	NULOJIX.xml:S2:366:10	recipi	NNS	O	O
without	NULOJIX.xml:S2:377:7	without	IN	O	O
immunity	NULOJIX.xml:S2:385:8	immun	NN	O	O
to	NULOJIX.xml:S2:394:2	to	TO	O	O
Epstein	NULOJIX.xml:S2:397:7	epstein	NNP	O	O
-	NULOJIX.xml:S2:404:1	-	:	O	O
Barr	NULOJIX.xml:S2:405:4	barr	NNP	O	O
virus	NULOJIX.xml:S2:410:5	viru	NN	O	O
(	NULOJIX.xml:S2:416:1	(	(	O	O
EBV	NULOJIX.xml:S2:417:3	ebv	NNP	O	O
)	NULOJIX.xml:S2:420:1	)	)	O	O
are	NULOJIX.xml:S2:422:3	are	VBP	O	O
at	NULOJIX.xml:S2:426:2	at	IN	O	O
a	NULOJIX.xml:S2:429:1	a	DT	O	O
particularly	NULOJIX.xml:S2:431:12	particularli	RB	O	O
increased	NULOJIX.xml:S2:444:9	increas	VBN	O	O
risk	NULOJIX.xml:S2:454:4	risk	NN	O	O
;	NULOJIX.xml:S2:458:1	;	:	O	O
therefore	NULOJIX.xml:S2:460:9	therefor	RB	O	O
,	NULOJIX.xml:S2:469:1	,	,	O	O
use	NULOJIX.xml:S2:471:3	use	NN	O	O
in	NULOJIX.xml:S2:475:2	in	IN	O	O
EBV	NULOJIX.xml:S2:478:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S2:482:12	seroposit	JJ	O	O
patients	NULOJIX.xml:S2:495:8	patient	NNS	O	O
only	NULOJIX.xml:S2:504:4	onli	RB	O	O
.	NULOJIX.xml:S2:508:1	.	.	O	O

Do	NULOJIX.xml:S2:510:2	Do	NNP	O	O
not	NULOJIX.xml:S2:513:3	not	RB	O	O
use	NULOJIX.xml:S2:517:3	use	VB	O	O
NULOJIX	NULOJIX.xml:S2:521:7	nulojix	NNP	O	O
in	NULOJIX.xml:S2:529:2	in	IN	O	O
transplant	NULOJIX.xml:S2:532:10	transplant	JJ	O	O
recipients	NULOJIX.xml:S2:543:10	recipi	NNS	O	O
who	NULOJIX.xml:S2:554:3	who	WP	O	O
are	NULOJIX.xml:S2:558:3	are	VBP	O	O
EBV	NULOJIX.xml:S2:562:3	ebv	NNP	O	O
seronegative	NULOJIX.xml:S2:566:12	seroneg	JJ	O	O
or	NULOJIX.xml:S2:579:2	or	CC	O	O
with	NULOJIX.xml:S2:582:4	with	IN	O	O
unknown	NULOJIX.xml:S2:587:7	unknown	JJ	O	O
EBV	NULOJIX.xml:S2:595:3	ebv	NNP	O	O
serostatus	NULOJIX.xml:S2:599:10	serostatu	NN	O	O
[	NULOJIX.xml:S2:610:1	[	NNP	O	O
see	NULOJIX.xml:S2:611:3	see	VBP	O	O
Contraindications	NULOJIX.xml:S2:619:17	contraind	NNP	O	O
(	NULOJIX.xml:S2:637:1	(	(	O	O
4	NULOJIX.xml:S2:638:1	4	CD	O	O
)	NULOJIX.xml:S2:639:1	)	)	O	O
and	NULOJIX.xml:S2:645:3	and	CC	O	O
Warnings	NULOJIX.xml:S2:653:8	warn	NNP	O	O
and	NULOJIX.xml:S2:662:3	and	CC	O	O
Precautions	NULOJIX.xml:S2:666:11	precaut	NNP	O	O
(	NULOJIX.xml:S2:678:1	(	(	O	O
5.1	NULOJIX.xml:S2:679:3	5.1	CD	O	O
)	NULOJIX.xml:S2:682:1	)	)	O	O
]	NULOJIX.xml:S2:687:1	]	NN	O	O
.	NULOJIX.xml:S2:688:1	.	.	O	O

Only	NULOJIX.xml:S2:698:4	onli	RB	O	O
physicians	NULOJIX.xml:S2:703:10	physician	NNS	O	O
experienced	NULOJIX.xml:S2:714:11	experienc	VBD	O	O
in	NULOJIX.xml:S2:726:2	in	IN	O	O
immunosuppressive	NULOJIX.xml:S2:729:17	immunosuppress	JJ	O	O
therapy	NULOJIX.xml:S2:747:7	therapi	NN	O	O
and	NULOJIX.xml:S2:755:3	and	CC	O	O
management	NULOJIX.xml:S2:759:10	manag	NN	O	O
of	NULOJIX.xml:S2:770:2	of	IN	O	O
kidney	NULOJIX.xml:S2:773:6	kidney	NN	O	O
transplant	NULOJIX.xml:S2:780:10	transplant	NN	O	O
patients	NULOJIX.xml:S2:791:8	patient	NNS	O	O
should	NULOJIX.xml:S2:800:6	should	MD	O	O
prescribe	NULOJIX.xml:S2:807:9	prescrib	VB	O	O
NULOJIX	NULOJIX.xml:S2:817:7	nulojix	NNP	O	O
.	NULOJIX.xml:S2:824:1	.	.	O	O

Patients	NULOJIX.xml:S2:826:8	patient	NNS	O	O
receiving	NULOJIX.xml:S2:835:9	receiv	VBG	O	O
the	NULOJIX.xml:S2:845:3	the	DT	O	O
drug	NULOJIX.xml:S2:849:4	drug	NN	O	O
should	NULOJIX.xml:S2:854:6	should	MD	O	O
be	NULOJIX.xml:S2:861:2	be	VB	O	O
managed	NULOJIX.xml:S2:864:7	manag	VBN	O	O
in	NULOJIX.xml:S2:872:2	in	IN	O	O
facilities	NULOJIX.xml:S2:875:10	facil	NNS	O	O
equipped	NULOJIX.xml:S2:886:8	equip	VBN	O	O
and	NULOJIX.xml:S2:895:3	and	CC	O	O
staffed	NULOJIX.xml:S2:899:7	staf	VBN	O	O
with	NULOJIX.xml:S2:907:4	with	IN	O	O
adequate	NULOJIX.xml:S2:912:8	adequ	JJ	O	O
laboratory	NULOJIX.xml:S2:921:10	laboratori	NN	O	O
and	NULOJIX.xml:S2:932:3	and	CC	O	O
supportive	NULOJIX.xml:S2:936:10	support	JJ	O	O
medical	NULOJIX.xml:S2:947:7	medic	JJ	O	O
resources	NULOJIX.xml:S2:955:9	resourc	NNS	O	O
.	NULOJIX.xml:S2:964:1	.	.	O	O

The	NULOJIX.xml:S2:966:3	the	DT	O	O
physician	NULOJIX.xml:S2:970:9	physician	NN	O	O
responsible	NULOJIX.xml:S2:980:11	respons	JJ	O	O
for	NULOJIX.xml:S2:992:3	for	IN	O	O
maintenance	NULOJIX.xml:S2:996:11	mainten	NN	O	O
therapy	NULOJIX.xml:S2:1008:7	therapi	NN	O	O
should	NULOJIX.xml:S2:1016:6	should	MD	O	O
have	NULOJIX.xml:S2:1023:4	have	VB	O	O
complete	NULOJIX.xml:S2:1028:8	complet	JJ	O	O
information	NULOJIX.xml:S2:1037:11	inform	NN	O	O
requisite	NULOJIX.xml:S2:1049:9	requisit	NN	O	O
for	NULOJIX.xml:S2:1059:3	for	IN	O	O
the	NULOJIX.xml:S2:1063:3	the	DT	O	O
follow	NULOJIX.xml:S2:1067:6	follow	NN	O	O
-	NULOJIX.xml:S2:1073:1	-	:	O	O
up	NULOJIX.xml:S2:1074:2	up	IN	O	O
of	NULOJIX.xml:S2:1077:2	of	IN	O	O
the	NULOJIX.xml:S2:1080:3	the	DT	O	O
patient	NULOJIX.xml:S2:1084:7	patient	NN	O	O
[	NULOJIX.xml:S2:1092:1	[	NNP	O	O
see	NULOJIX.xml:S2:1093:3	see	VBP	O	O
Warnings	NULOJIX.xml:S2:1101:8	warn	NNP	O	O
and	NULOJIX.xml:S2:1110:3	and	CC	O	O
Precautions	NULOJIX.xml:S2:1114:11	precaut	NNP	O	O
(	NULOJIX.xml:S2:1126:1	(	(	O	O
5.2	NULOJIX.xml:S2:1127:3	5.2	CD	O	O
)	NULOJIX.xml:S2:1130:1	)	)	O	O
]	NULOJIX.xml:S2:1135:1	]	NN	O	O
.	NULOJIX.xml:S2:1136:1	.	.	O	O

Increased	NULOJIX.xml:S2:1146:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
susceptibility	NULOJIX.xml:S2:1156:14	suscept	NN	I-AdverseReaction	I-AdverseReaction
to	NULOJIX.xml:S2:1171:2	to	TO	I-AdverseReaction	I-AdverseReaction
infection	NULOJIX.xml:S2:1174:9	infect	NN	I-AdverseReaction	I-AdverseReaction
and	NULOJIX.xml:S2:1184:3	and	CC	O	O
the	NULOJIX.xml:S2:1188:3	the	DT	O	O
possible	NULOJIX.xml:S2:1192:8	possibl	JJ	O	O
development	NULOJIX.xml:S2:1201:11	develop	NN	O	O
of	NULOJIX.xml:S2:1213:2	of	IN	O	O
malignancies	NULOJIX.xml:S2:1216:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
may	NULOJIX.xml:S2:1229:3	may	MD	O	O
result	NULOJIX.xml:S2:1233:6	result	VB	O	O
from	NULOJIX.xml:S2:1240:4	from	IN	O	O
immunosuppression	NULOJIX.xml:S2:1245:17	immunosuppress	NN	O	B-AdverseReaction
[	NULOJIX.xml:S2:1263:1	[	NNP	O	O
see	NULOJIX.xml:S2:1264:3	see	VBP	O	O
Warnings	NULOJIX.xml:S2:1272:8	warn	NNP	O	O
and	NULOJIX.xml:S2:1281:3	and	CC	O	O
Precautions	NULOJIX.xml:S2:1285:11	precaut	NNP	O	O
(	NULOJIX.xml:S2:1297:1	(	(	O	O
5.1	NULOJIX.xml:S2:1298:3	5.1	CD	O	O
,	NULOJIX.xml:S2:1303:1	,	,	O	O
5.3	NULOJIX.xml:S2:1307:3	5.3	CD	O	O
,	NULOJIX.xml:S2:1312:1	,	,	O	O
5.4	NULOJIX.xml:S2:1316:3	5.4	CD	O	O
,	NULOJIX.xml:S2:1321:1	,	,	O	O
5.5	NULOJIX.xml:S2:1325:3	5.5	CD	O	O
)	NULOJIX.xml:S2:1328:1	)	)	O	O
]	NULOJIX.xml:S2:1333:1	]	NN	O	O
.	NULOJIX.xml:S2:1334:1	.	.	O	O

Use	NULOJIX.xml:S2:1344:3	use	NNP	O	O
in	NULOJIX.xml:S2:1348:2	in	IN	O	O
liver	NULOJIX.xml:S2:1351:5	liver	NN	O	O
transplant	NULOJIX.xml:S2:1357:10	transplant	NN	O	O
patients	NULOJIX.xml:S2:1368:8	patient	NNS	O	O
is	NULOJIX.xml:S2:1377:2	is	VBZ	O	O
not	NULOJIX.xml:S2:1380:3	not	RB	O	O
recommended	NULOJIX.xml:S2:1384:11	recommend	VBN	O	O
due	NULOJIX.xml:S2:1396:3	due	JJ	O	O
to	NULOJIX.xml:S2:1400:2	to	TO	O	O
an	NULOJIX.xml:S2:1403:2	an	DT	O	O
increased	NULOJIX.xml:S2:1406:9	increas	VBN	O	O
risk	NULOJIX.xml:S2:1416:4	risk	NN	O	O
of	NULOJIX.xml:S2:1421:2	of	IN	O	O
graft	NULOJIX.xml:S2:1424:5	graft	NN	O	O
loss	NULOJIX.xml:S2:1430:4	loss	NN	O	O
and	NULOJIX.xml:S2:1435:3	and	CC	O	O
death	NULOJIX.xml:S2:1439:5	death	NN	O	B-AdverseReaction
[	NULOJIX.xml:S2:1445:1	[	NN	O	O
see	NULOJIX.xml:S2:1446:3	see	VBP	O	O
Warnings	NULOJIX.xml:S2:1454:8	warn	NNS	O	O
and	NULOJIX.xml:S2:1463:3	and	CC	O	O
Precautions	NULOJIX.xml:S2:1467:11	precaut	NNP	O	O
(	NULOJIX.xml:S2:1479:1	(	(	O	O
5.6	NULOJIX.xml:S2:1480:3	5.6	CD	O	O
)	NULOJIX.xml:S2:1483:1	)	)	O	O
]	NULOJIX.xml:S2:1488:1	]	NN	O	O
.	NULOJIX.xml:S2:1489:1	.	.	O	O

EXCERPT	NULOJIX.xml:S2:1499:7	excerpt	NN	O	O
:	NULOJIX.xml:S2:1506:1	:	:	O	O
WARNING	NULOJIX.xml:S2:1510:7	warn	NN	O	O
:	NULOJIX.xml:S2:1517:1	:	:	O	O
POST	NULOJIX.xml:S2:1519:4	post	NNP	B-AdverseReaction	O
-	NULOJIX.xml:S2:1523:1	-	:	I-AdverseReaction	O
TRANSPLANT	NULOJIX.xml:S2:1524:10	transplant	NNP	I-AdverseReaction	O
LYMPHOPROLIFERATIVE	NULOJIX.xml:S2:1535:19	lymphoprolif	NNP	I-AdverseReaction	O
DISORDER	NULOJIX.xml:S2:1555:8	disord	NNP	I-AdverseReaction	O
,	NULOJIX.xml:S2:1563:1	,	,	O	O
OTHER	NULOJIX.xml:S2:1565:5	other	NNP	O	O
MALIGNANCIES	NULOJIX.xml:S2:1571:12	malign	NNP	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S2:1583:1	,	,	O	O
AND	NULOJIX.xml:S2:1585:3	and	NNP	O	O
SERIOUS	NULOJIX.xml:S2:1589:7	seriou	NNP	O	O
INFECTIONS	NULOJIX.xml:S2:1597:10	infect	NNP	B-AdverseReaction	B-AdverseReaction
\n\n\n\n	NULOJIX.xml:S2:1607:4	\n\n\n\n	NNP	O	O
See	NULOJIX.xml:S2:1616:3	see	NNP	O	O
full	NULOJIX.xml:S2:1620:4	full	JJ	O	O
prescribing	NULOJIX.xml:S2:1625:11	prescrib	VBG	O	O
information	NULOJIX.xml:S2:1637:11	inform	NN	O	O
for	NULOJIX.xml:S2:1649:3	for	IN	O	O
complete	NULOJIX.xml:S2:1653:8	complet	JJ	O	O
boxed	NULOJIX.xml:S2:1662:5	box	JJ	O	O
warning	NULOJIX.xml:S2:1668:7	warn	NN	O	O
.	NULOJIX.xml:S2:1675:1	.	.	O	O

Increased	NULOJIX.xml:S2:1688:9	increas	VBN	O	O
risk	NULOJIX.xml:S2:1698:4	risk	NN	O	O
for	NULOJIX.xml:S2:1703:3	for	IN	O	O
developing	NULOJIX.xml:S2:1707:10	develop	VBG	O	O
post	NULOJIX.xml:S2:1718:4	post	NN	B-AdverseReaction	O
-	NULOJIX.xml:S2:1722:1	-	:	I-AdverseReaction	O
transplant	NULOJIX.xml:S2:1723:10	transplant	NN	I-AdverseReaction	O
lymphoproliferative	NULOJIX.xml:S2:1734:19	lymphoprolif	JJ	I-AdverseReaction	O
disorder	NULOJIX.xml:S2:1754:8	disord	NN	I-AdverseReaction	O
(	NULOJIX.xml:S2:1763:1	(	(	O	O
PTLD	NULOJIX.xml:S2:1764:4	ptld	NNP	B-AdverseReaction	O
)	NULOJIX.xml:S2:1768:1	)	)	O	O
,	NULOJIX.xml:S2:1769:1	,	,	O	O
predominantly	NULOJIX.xml:S2:1771:13	predominantli	RB	O	O
involving	NULOJIX.xml:S2:1785:9	involv	VBG	O	O
the	NULOJIX.xml:S2:1795:3	the	DT	O	O
central	NULOJIX.xml:S2:1799:7	central	JJ	O	O
nervous	NULOJIX.xml:S2:1807:7	nervou	JJ	O	O
system	NULOJIX.xml:S2:1815:6	system	NN	O	O
(	NULOJIX.xml:S2:1822:1	(	(	O	O
CNS	NULOJIX.xml:S2:1823:3	cn	NNP	O	O
)	NULOJIX.xml:S2:1826:1	)	)	O	O
.	NULOJIX.xml:S2:1827:1	.	.	O	O

Recipients	NULOJIX.xml:S2:1829:10	recipi	NNS	O	O
without	NULOJIX.xml:S2:1840:7	without	IN	O	O
immunity	NULOJIX.xml:S2:1848:8	immun	NN	O	O
to	NULOJIX.xml:S2:1857:2	to	TO	O	O
Epstein	NULOJIX.xml:S2:1860:7	epstein	NNP	O	O
-	NULOJIX.xml:S2:1867:1	-	:	O	O
Barr	NULOJIX.xml:S2:1868:4	barr	NNP	O	O
virus	NULOJIX.xml:S2:1873:5	viru	NN	O	O
(	NULOJIX.xml:S2:1879:1	(	(	O	O
EBV	NULOJIX.xml:S2:1880:3	ebv	NNP	O	O
)	NULOJIX.xml:S2:1883:1	)	)	O	O
are	NULOJIX.xml:S2:1885:3	are	VBP	O	O
at	NULOJIX.xml:S2:1889:2	at	IN	O	O
a	NULOJIX.xml:S2:1892:1	a	DT	O	O
particularly	NULOJIX.xml:S2:1894:12	particularli	RB	O	O
increased	NULOJIX.xml:S2:1907:9	increas	VBN	O	O
risk	NULOJIX.xml:S2:1917:4	risk	NN	O	O
;	NULOJIX.xml:S2:1921:1	;	:	O	O
therefore	NULOJIX.xml:S2:1923:9	therefor	RB	O	O
,	NULOJIX.xml:S2:1932:1	,	,	O	O
use	NULOJIX.xml:S2:1934:3	use	NN	O	O
in	NULOJIX.xml:S2:1938:2	in	IN	O	O
EBV	NULOJIX.xml:S2:1941:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S2:1945:12	seroposit	JJ	O	O
patients	NULOJIX.xml:S2:1958:8	patient	NNS	O	O
only	NULOJIX.xml:S2:1967:4	onli	RB	O	O
.	NULOJIX.xml:S2:1971:1	.	.	O	O

Do	NULOJIX.xml:S2:1973:2	Do	NNP	O	O
not	NULOJIX.xml:S2:1976:3	not	RB	O	O
use	NULOJIX.xml:S2:1980:3	use	VB	O	O
NULOJIX	NULOJIX.xml:S2:1984:7	nulojix	NNP	O	O
in	NULOJIX.xml:S2:1992:2	in	IN	O	O
transplant	NULOJIX.xml:S2:1995:10	transplant	JJ	O	O
recipients	NULOJIX.xml:S2:2006:10	recipi	NNS	O	O
who	NULOJIX.xml:S2:2017:3	who	WP	O	O
are	NULOJIX.xml:S2:2021:3	are	VBP	O	O
EBV	NULOJIX.xml:S2:2025:3	ebv	NNP	O	O
seronegative	NULOJIX.xml:S2:2029:12	seroneg	JJ	O	O
or	NULOJIX.xml:S2:2042:2	or	CC	O	O
with	NULOJIX.xml:S2:2045:4	with	IN	O	O
unknown	NULOJIX.xml:S2:2050:7	unknown	JJ	O	O
serostatus	NULOJIX.xml:S2:2058:10	serostatu	NN	O	O
.	NULOJIX.xml:S2:2068:1	.	.	O	O

(	NULOJIX.xml:S2:2070:1	(	(	O	O
4	NULOJIX.xml:S2:2071:1	4	CD	O	O
,	NULOJIX.xml:S2:2072:1	,	,	O	O
5.1	NULOJIX.xml:S2:2074:3	5.1	CD	O	O
)	NULOJIX.xml:S2:2077:1	)	)	O	O
\n	NULOJIX.xml:S2:2079:1	\n	FW	O	O
Only	NULOJIX.xml:S2:2084:4	onli	RB	O	O
physicians	NULOJIX.xml:S2:2089:10	physician	VBZ	O	O
experienced	NULOJIX.xml:S2:2100:11	experienc	VBN	O	O
in	NULOJIX.xml:S2:2112:2	in	IN	O	O
immunosuppressive	NULOJIX.xml:S2:2115:17	immunosuppress	JJ	O	O
therapy	NULOJIX.xml:S2:2133:7	therapi	NN	O	O
and	NULOJIX.xml:S2:2141:3	and	CC	O	O
management	NULOJIX.xml:S2:2145:10	manag	NN	O	O
of	NULOJIX.xml:S2:2156:2	of	IN	O	O
kidney	NULOJIX.xml:S2:2159:6	kidney	NN	O	O
transplant	NULOJIX.xml:S2:2166:10	transplant	NN	O	O
patients	NULOJIX.xml:S2:2177:8	patient	NNS	O	O
should	NULOJIX.xml:S2:2186:6	should	MD	O	O
prescribe	NULOJIX.xml:S2:2193:9	prescrib	VB	O	O
NULOJIX	NULOJIX.xml:S2:2203:7	nulojix	NNP	O	O
.	NULOJIX.xml:S2:2210:1	.	.	O	O

(	NULOJIX.xml:S2:2212:1	(	(	O	O
5.2	NULOJIX.xml:S2:2213:3	5.2	CD	O	O
)	NULOJIX.xml:S2:2216:1	)	)	O	O
\n	NULOJIX.xml:S2:2218:1	\n	NN	O	O
Increased	NULOJIX.xml:S2:2223:9	increas	VBD	B-AdverseReaction	O
susceptibility	NULOJIX.xml:S2:2233:14	suscept	NN	I-AdverseReaction	O
to	NULOJIX.xml:S2:2248:2	to	TO	I-AdverseReaction	O
infection	NULOJIX.xml:S2:2251:9	infect	NN	I-AdverseReaction	O
and	NULOJIX.xml:S2:2261:3	and	CC	O	O
the	NULOJIX.xml:S2:2265:3	the	DT	O	O
possible	NULOJIX.xml:S2:2269:8	possibl	JJ	O	O
development	NULOJIX.xml:S2:2278:11	develop	NN	O	O
of	NULOJIX.xml:S2:2290:2	of	IN	O	O
malignancies	NULOJIX.xml:S2:2293:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
may	NULOJIX.xml:S2:2306:3	may	MD	O	O
result	NULOJIX.xml:S2:2310:6	result	VB	O	O
from	NULOJIX.xml:S2:2317:4	from	IN	O	O
immunosuppression	NULOJIX.xml:S2:2322:17	immunosuppress	NN	O	O
.	NULOJIX.xml:S2:2339:1	.	.	O	O

(	NULOJIX.xml:S2:2341:1	(	(	O	O
5.1	NULOJIX.xml:S2:2342:3	5.1	CD	O	O
,	NULOJIX.xml:S2:2345:1	,	,	O	O
5.3	NULOJIX.xml:S2:2347:3	5.3	CD	O	O
,	NULOJIX.xml:S2:2350:1	,	,	O	O
5.4	NULOJIX.xml:S2:2352:3	5.4	CD	O	O
,	NULOJIX.xml:S2:2355:1	,	,	O	O
5.5	NULOJIX.xml:S2:2357:3	5.5	CD	O	O
)	NULOJIX.xml:S2:2360:1	)	)	O	O
\n	NULOJIX.xml:S2:2362:1	\n	NN	O	O
Use	NULOJIX.xml:S2:2367:3	use	NNP	O	O
in	NULOJIX.xml:S2:2371:2	in	IN	O	O
liver	NULOJIX.xml:S2:2374:5	liver	NN	O	O
transplant	NULOJIX.xml:S2:2380:10	transplant	NN	O	O
patients	NULOJIX.xml:S2:2391:8	patient	NNS	O	O
is	NULOJIX.xml:S2:2400:2	is	VBZ	O	O
not	NULOJIX.xml:S2:2403:3	not	RB	O	O
recommended	NULOJIX.xml:S2:2407:11	recommend	VBN	O	O
due	NULOJIX.xml:S2:2419:3	due	JJ	O	O
to	NULOJIX.xml:S2:2423:2	to	TO	O	O
an	NULOJIX.xml:S2:2426:2	an	DT	O	O
increased	NULOJIX.xml:S2:2429:9	increas	VBN	O	O
risk	NULOJIX.xml:S2:2439:4	risk	NN	O	O
of	NULOJIX.xml:S2:2444:2	of	IN	O	O
graft	NULOJIX.xml:S2:2447:5	graft	NN	O	O
loss	NULOJIX.xml:S2:2453:4	loss	NN	O	O
and	NULOJIX.xml:S2:2458:3	and	CC	O	O
death	NULOJIX.xml:S2:2462:5	death	NN	O	B-AdverseReaction
.	NULOJIX.xml:S2:2467:1	.	.	O	O

(	NULOJIX.xml:S2:2469:1	(	(	O	O
5.6	NULOJIX.xml:S2:2470:3	5.6	CD	O	O
)	NULOJIX.xml:S2:2473:1	)	)	O	O
\n	NULOJIX.xml:S2:2475:1	\n	VBD	O	O
5	NULOJIX.xml:S3:4:1	5	CD	O	O
WARNINGS	NULOJIX.xml:S3:6:8	warn	NNP	O	O
AND	NULOJIX.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	NULOJIX.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	NULOJIX.xml:S3:37:7	excerpt	NN	O	O
:	NULOJIX.xml:S3:44:1	:	:	O	O
Post	NULOJIX.xml:S3:55:4	post	NNP	B-AdverseReaction	O
-	NULOJIX.xml:S3:59:1	-	:	I-AdverseReaction	O
Transplant	NULOJIX.xml:S3:60:10	transplant	NN	I-AdverseReaction	O
Lymphoproliferative	NULOJIX.xml:S3:71:19	lymphoprolif	JJ	I-AdverseReaction	O
Disorder	NULOJIX.xml:S3:91:8	disord	NNP	I-AdverseReaction	O
(	NULOJIX.xml:S3:100:1	(	(	O	O
PTLD	NULOJIX.xml:S3:101:4	ptld	NNP	B-AdverseReaction	B-AdverseReaction
)	NULOJIX.xml:S3:105:1	)	)	O	O
:	NULOJIX.xml:S3:107:1	:	:	O	O
increased	NULOJIX.xml:S3:109:9	increas	VBN	O	B-AdverseReaction
risk	NULOJIX.xml:S3:119:4	risk	NN	O	I-AdverseReaction
,	NULOJIX.xml:S3:123:1	,	,	O	O
predominantly	NULOJIX.xml:S3:125:13	predominantli	RB	O	O
involving	NULOJIX.xml:S3:139:9	involv	VBG	O	O
the	NULOJIX.xml:S3:149:3	the	DT	O	O
CNS	NULOJIX.xml:S3:153:3	cn	NNP	O	O
;	NULOJIX.xml:S3:156:1	;	:	O	O
monitor	NULOJIX.xml:S3:158:7	monitor	NN	O	O
for	NULOJIX.xml:S3:166:3	for	IN	O	O
new	NULOJIX.xml:S3:170:3	new	JJ	O	O
or	NULOJIX.xml:S3:174:2	or	CC	O	O
worsening	NULOJIX.xml:S3:177:9	worsen	JJ	O	O
neurological	NULOJIX.xml:S3:187:12	neurolog	JJ	O	O
,	NULOJIX.xml:S3:199:1	,	,	O	O
cognitive	NULOJIX.xml:S3:201:9	cognit	JJ	O	O
,	NULOJIX.xml:S3:210:1	,	,	O	O
or	NULOJIX.xml:S3:212:2	or	CC	O	O
behavioral	NULOJIX.xml:S3:215:10	behavior	JJ	O	O
signs	NULOJIX.xml:S3:226:5	sign	NNS	O	O
and	NULOJIX.xml:S3:232:3	and	CC	O	O
symptoms	NULOJIX.xml:S3:236:8	symptom	NNS	O	O
.	NULOJIX.xml:S3:244:1	.	.	O	O

(	NULOJIX.xml:S3:247:1	(	(	O	O
Boxed	NULOJIX.xml:S3:248:5	box	NNP	O	O
Warning	NULOJIX.xml:S3:254:7	warn	NNP	O	O
,	NULOJIX.xml:S3:263:1	,	,	O	O
4	NULOJIX.xml:S3:266:1	4	CD	O	O
,	NULOJIX.xml:S3:269:1	,	,	O	O
5.1	NULOJIX.xml:S3:272:3	5.1	CD	O	O
,	NULOJIX.xml:S3:277:1	,	,	O	O
5.6	NULOJIX.xml:S3:280:3	5.6	CD	O	O
)	NULOJIX.xml:S3:283:1	)	)	O	O

Other	NULOJIX.xml:S3:295:5	other	JJ	O	O
malignancies	NULOJIX.xml:S3:301:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
:	NULOJIX.xml:S3:314:1	:	:	O	O
increased	NULOJIX.xml:S3:316:9	increas	VBN	O	O
risk	NULOJIX.xml:S3:326:4	risk	NN	O	O
with	NULOJIX.xml:S3:331:4	with	IN	O	O
all	NULOJIX.xml:S3:336:3	all	DT	O	O
immunosuppressants	NULOJIX.xml:S3:340:18	immunosuppress	NNS	O	O
;	NULOJIX.xml:S3:358:1	;	:	O	O
appears	NULOJIX.xml:S3:360:7	appear	VBZ	O	O
related	NULOJIX.xml:S3:368:7	relat	VBN	O	O
to	NULOJIX.xml:S3:376:2	to	TO	O	O
intensity	NULOJIX.xml:S3:379:9	intens	NN	O	O
and	NULOJIX.xml:S3:389:3	and	CC	O	O
duration	NULOJIX.xml:S3:393:8	durat	NN	O	O
of	NULOJIX.xml:S3:402:2	of	IN	O	O
use	NULOJIX.xml:S3:405:3	use	NN	O	O
.	NULOJIX.xml:S3:408:1	.	.	O	O

Avoid	NULOJIX.xml:S3:410:5	avoid	NNP	O	O
prolonged	NULOJIX.xml:S3:416:9	prolong	VBD	O	O
exposure	NULOJIX.xml:S3:426:8	exposur	NN	O	O
to	NULOJIX.xml:S3:435:2	to	TO	O	O
UV	NULOJIX.xml:S3:438:2	UV	NNP	O	O
light	NULOJIX.xml:S3:441:5	light	NN	O	O
and	NULOJIX.xml:S3:447:3	and	CC	O	O
sunlight	NULOJIX.xml:S3:451:8	sunlight	NN	O	O
.	NULOJIX.xml:S3:459:1	.	.	O	O

(	NULOJIX.xml:S3:462:1	(	(	O	O
5.3	NULOJIX.xml:S3:463:3	5.3	CD	O	O
)	NULOJIX.xml:S3:466:1	)	)	O	O

Progressive	NULOJIX.xml:S3:478:11	progress	JJ	B-AdverseReaction	B-AdverseReaction
Multifocal	NULOJIX.xml:S3:490:10	multifoc	NNP	I-AdverseReaction	I-AdverseReaction
Leukoencephalopathy	NULOJIX.xml:S3:501:19	leukoencephalopathi	NNP	I-AdverseReaction	I-AdverseReaction
(	NULOJIX.xml:S3:521:1	(	(	O	O
PML	NULOJIX.xml:S3:522:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
)	NULOJIX.xml:S3:525:1	)	)	O	O
:	NULOJIX.xml:S3:527:1	:	:	O	O
increased	NULOJIX.xml:S3:529:9	increas	VBN	O	O
risk	NULOJIX.xml:S3:539:4	risk	NN	O	O
;	NULOJIX.xml:S3:543:1	;	:	O	O
consider	NULOJIX.xml:S3:545:8	consid	VB	O	O
in	NULOJIX.xml:S3:554:2	in	IN	O	O
the	NULOJIX.xml:S3:557:3	the	DT	O	O
diagnosis	NULOJIX.xml:S3:561:9	diagnosi	NN	O	O
of	NULOJIX.xml:S3:571:2	of	IN	O	O
patients	NULOJIX.xml:S3:574:8	patient	NNS	O	O
reporting	NULOJIX.xml:S3:583:9	report	VBG	O	O
new	NULOJIX.xml:S3:593:3	new	JJ	O	O
or	NULOJIX.xml:S3:597:2	or	CC	O	O
worsening	NULOJIX.xml:S3:600:9	worsen	JJ	O	O
neurological	NULOJIX.xml:S3:610:12	neurolog	JJ	O	O
,	NULOJIX.xml:S3:622:1	,	,	O	O
cognitive	NULOJIX.xml:S3:624:9	cognit	JJ	O	O
,	NULOJIX.xml:S3:633:1	,	,	O	O
or	NULOJIX.xml:S3:635:2	or	CC	O	O
behavioral	NULOJIX.xml:S3:638:10	behavior	JJ	O	O
signs	NULOJIX.xml:S3:649:5	sign	NNS	O	O
and	NULOJIX.xml:S3:655:3	and	CC	O	O
symptoms	NULOJIX.xml:S3:659:8	symptom	NNS	O	O
.	NULOJIX.xml:S3:667:1	.	.	O	O

Recommended	NULOJIX.xml:S3:669:11	recommend	JJ	O	O
doses	NULOJIX.xml:S3:681:5	dose	NNS	O	O
of	NULOJIX.xml:S3:687:2	of	IN	O	O
immunosuppressants	NULOJIX.xml:S3:690:18	immunosuppress	NNS	O	O
should	NULOJIX.xml:S3:709:6	should	MD	O	O
not	NULOJIX.xml:S3:716:3	not	RB	O	O
be	NULOJIX.xml:S3:720:2	be	VB	O	O
exceeded	NULOJIX.xml:S3:723:8	exceed	VBN	O	O
.	NULOJIX.xml:S3:731:1	.	.	O	O

(	NULOJIX.xml:S3:734:1	(	(	O	O
5.4	NULOJIX.xml:S3:735:3	5.4	CD	O	O
)	NULOJIX.xml:S3:738:1	)	)	O	O

Other	NULOJIX.xml:S3:750:5	other	JJ	O	O
serious	NULOJIX.xml:S3:756:7	seriou	JJ	O	O
infections	NULOJIX.xml:S3:764:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
:	NULOJIX.xml:S3:775:1	:	:	O	O
increased	NULOJIX.xml:S3:777:9	increas	VBN	O	O
risk	NULOJIX.xml:S3:787:4	risk	NN	O	O
of	NULOJIX.xml:S3:792:2	of	IN	O	O
bacterial	NULOJIX.xml:S3:795:9	bacteri	JJ	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S3:804:1	,	,	O	O
viral	NULOJIX.xml:S3:806:5	viral	JJ	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S3:811:1	,	,	O	O
fungal	NULOJIX.xml:S3:813:6	fungal	JJ	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S3:819:1	,	,	O	O
and	NULOJIX.xml:S3:821:3	and	CC	O	O
protozoal	NULOJIX.xml:S3:825:9	protozo	NN	B-AdverseReaction	B-AdverseReaction
infections	NULOJIX.xml:S3:835:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S3:845:1	,	,	O	O
including	NULOJIX.xml:S3:847:9	includ	VBG	O	O
opportunistic	NULOJIX.xml:S3:857:13	opportunist	JJ	B-AdverseReaction	B-AdverseReaction
infections	NULOJIX.xml:S3:871:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
and	NULOJIX.xml:S3:882:3	and	CC	O	O
tuberculosis	NULOJIX.xml:S3:886:12	tuberculosi	NN	B-AdverseReaction	B-AdverseReaction
.	NULOJIX.xml:S3:898:1	.	.	O	O

Some	NULOJIX.xml:S3:900:4	some	DT	O	O
infections	NULOJIX.xml:S3:905:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
were	NULOJIX.xml:S3:916:4	were	VBD	O	O
fatal	NULOJIX.xml:S3:921:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
.	NULOJIX.xml:S3:926:1	.	.	O	O

Polyoma	NULOJIX.xml:S3:928:7	polyoma	NNP	B-AdverseReaction	O
virus	NULOJIX.xml:S3:936:5	viru	NN	I-AdverseReaction	O
-	NULOJIX.xml:S3:941:1	-	:	I-AdverseReaction	O
associated	NULOJIX.xml:S3:942:10	associ	VBN	I-AdverseReaction	O
nephropathy	NULOJIX.xml:S3:953:11	nephropathi	JJ	I-AdverseReaction	O
can	NULOJIX.xml:S3:965:3	can	MD	O	O
lead	NULOJIX.xml:S3:969:4	lead	VB	O	O
to	NULOJIX.xml:S3:974:2	to	TO	O	O
kidney	NULOJIX.xml:S3:977:6	kidney	VB	B-AdverseReaction	O
graft	NULOJIX.xml:S3:984:5	graft	JJ	I-AdverseReaction	O
loss	NULOJIX.xml:S3:990:4	loss	NN	I-AdverseReaction	O
;	NULOJIX.xml:S3:994:1	;	:	O	O
consider	NULOJIX.xml:S3:996:8	consid	VB	O	O
reduction	NULOJIX.xml:S3:1005:9	reduct	NN	O	O
in	NULOJIX.xml:S3:1015:2	in	IN	O	O
immunosuppression	NULOJIX.xml:S3:1018:17	immunosuppress	NN	O	O
.	NULOJIX.xml:S3:1035:1	.	.	O	O

Evaluate	NULOJIX.xml:S3:1037:8	evalu	NNP	O	O
for	NULOJIX.xml:S3:1046:3	for	IN	O	O
tuberculosis	NULOJIX.xml:S3:1050:12	tuberculosi	NN	O	O
and	NULOJIX.xml:S3:1063:3	and	CC	O	O
initiate	NULOJIX.xml:S3:1067:8	initi	VB	O	O
treatment	NULOJIX.xml:S3:1076:9	treatment	NN	O	O
for	NULOJIX.xml:S3:1086:3	for	IN	O	O
latent	NULOJIX.xml:S3:1090:6	latent	JJ	O	O
infection	NULOJIX.xml:S3:1097:9	infect	NN	O	O
prior	NULOJIX.xml:S3:1107:5	prior	RB	O	O
to	NULOJIX.xml:S3:1113:2	to	TO	O	O
NULOJIX	NULOJIX.xml:S3:1116:7	nulojix	NNP	O	O
use	NULOJIX.xml:S3:1124:3	use	NN	O	O
.	NULOJIX.xml:S3:1127:1	.	.	O	O

Cytomegalovirus	NULOJIX.xml:S3:1129:15	cytomegaloviru	NNP	O	O
and	NULOJIX.xml:S3:1145:3	and	CC	O	O
pneumocystis	NULOJIX.xml:S3:1149:12	pneumocysti	NN	O	O
prophylaxis	NULOJIX.xml:S3:1162:11	prophylaxi	NN	O	O
are	NULOJIX.xml:S3:1174:3	are	VBP	O	O
recommended	NULOJIX.xml:S3:1178:11	recommend	VBN	O	O
after	NULOJIX.xml:S3:1190:5	after	IN	O	O
transplantation	NULOJIX.xml:S3:1196:15	transplant	NN	O	O
.	NULOJIX.xml:S3:1211:1	.	.	O	O

(	NULOJIX.xml:S3:1214:1	(	(	O	O
5.1	NULOJIX.xml:S3:1215:3	5.1	CD	O	O
,	NULOJIX.xml:S3:1220:1	,	,	O	O
5.4	NULOJIX.xml:S3:1223:3	5.4	CD	O	O
,	NULOJIX.xml:S3:1228:1	,	,	O	O
5.5	NULOJIX.xml:S3:1231:3	5.5	CD	O	O
)	NULOJIX.xml:S3:1234:1	)	)	O	O

Liver	NULOJIX.xml:S3:1246:5	liver	NNP	O	B-AdverseReaction
transplant	NULOJIX.xml:S3:1252:10	transplant	NN	O	I-AdverseReaction
:	NULOJIX.xml:S3:1263:1	:	:	O	O
use	NULOJIX.xml:S3:1265:3	use	NN	O	O
is	NULOJIX.xml:S3:1269:2	is	VBZ	O	O
not	NULOJIX.xml:S3:1272:3	not	RB	O	O
recommended	NULOJIX.xml:S3:1276:11	recommend	VBN	O	O
.	NULOJIX.xml:S3:1287:1	.	.	O	O

(	NULOJIX.xml:S3:1290:1	(	(	O	O
5.6	NULOJIX.xml:S3:1291:3	5.6	CD	O	O
)	NULOJIX.xml:S3:1294:1	)	)	O	O

Acute	NULOJIX.xml:S3:1306:5	acut	NNP	B-AdverseReaction	O
Rejection	NULOJIX.xml:S3:1312:9	reject	NNP	I-AdverseReaction	O
and	NULOJIX.xml:S3:1322:3	and	CC	O	O
Graft	NULOJIX.xml:S3:1326:5	graft	NNP	I-AdverseReaction	O
Loss	NULOJIX.xml:S3:1332:4	loss	NNP	I-AdverseReaction	O
with	NULOJIX.xml:S3:1337:4	with	IN	O	O
Corticosteroid	NULOJIX.xml:S3:1342:14	corticosteroid	NNP	O	O
Minimization	NULOJIX.xml:S3:1357:12	minim	NNP	O	O
:	NULOJIX.xml:S3:1370:1	:	:	O	O
corticosteroid	NULOJIX.xml:S3:1372:14	corticosteroid	JJ	O	O
utilization	NULOJIX.xml:S3:1387:11	util	NN	O	O
should	NULOJIX.xml:S3:1399:6	should	MD	O	O
be	NULOJIX.xml:S3:1406:2	be	VB	O	O
consistent	NULOJIX.xml:S3:1409:10	consist	JJ	O	O
with	NULOJIX.xml:S3:1420:4	with	IN	O	O
the	NULOJIX.xml:S3:1425:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S3:1429:7	nulojix	NNP	O	O
clinical	NULOJIX.xml:S3:1437:8	clinic	JJ	O	O
trial	NULOJIX.xml:S3:1446:5	trial	NN	O	O
experience	NULOJIX.xml:S3:1452:10	experi	NN	O	O
.	NULOJIX.xml:S3:1462:1	.	.	O	O

(	NULOJIX.xml:S3:1465:1	(	(	O	O
2.1	NULOJIX.xml:S3:1466:3	2.1	CD	O	O
,	NULOJIX.xml:S3:1471:1	,	,	O	O
5.7	NULOJIX.xml:S3:1474:3	5.7	CD	O	O
,	NULOJIX.xml:S3:1479:1	,	,	O	O
14.1	NULOJIX.xml:S3:1482:4	14.1	CD	O	O
)	NULOJIX.xml:S3:1486:1	)	)	O	O

Immunizations	NULOJIX.xml:S3:1498:13	immun	NNS	O	O
:	NULOJIX.xml:S3:1512:1	:	:	O	O
avoid	NULOJIX.xml:S3:1514:5	avoid	NN	O	O
use	NULOJIX.xml:S3:1520:3	use	NN	O	O
of	NULOJIX.xml:S3:1524:2	of	IN	O	O
live	NULOJIX.xml:S3:1527:4	live	JJ	O	O
vaccines	NULOJIX.xml:S3:1532:8	vaccin	NNS	O	O
during	NULOJIX.xml:S3:1541:6	dure	IN	O	O
treatment	NULOJIX.xml:S3:1548:9	treatment	NN	O	O
.	NULOJIX.xml:S3:1557:1	.	.	O	O

(	NULOJIX.xml:S3:1560:1	(	(	O	O
5.8	NULOJIX.xml:S3:1561:3	5.8	CD	O	O
)	NULOJIX.xml:S3:1564:1	)	)	O	O

5.1	NULOJIX.xml:S3:1580:3	5.1	CD	O	O

Post	NULOJIX.xml:S3:1584:4	post	NN	O	O

-	NULOJIX.xml:S3:1588:1	-	:	O	O
Transplant	NULOJIX.xml:S3:1589:10	transplant	NN	O	O
Lymphoproliferative	NULOJIX.xml:S3:1600:19	lymphoprolif	JJ	O	O
Disorder	NULOJIX.xml:S3:1620:8	disord	NN	O	O

NULOJIX	NULOJIX.xml:S3:1634:7	nulojix	NNP	O	O
-	NULOJIX.xml:S3:1641:1	-	:	O	O
treated	NULOJIX.xml:S3:1642:7	treat	VBD	O	O
patients	NULOJIX.xml:S3:1650:8	patient	NNS	O	O
have	NULOJIX.xml:S3:1659:4	have	VBP	O	O
an	NULOJIX.xml:S3:1664:2	an	DT	O	O
increased	NULOJIX.xml:S3:1667:9	increas	VBN	O	O
risk	NULOJIX.xml:S3:1677:4	risk	NN	O	O
for	NULOJIX.xml:S3:1682:3	for	IN	O	O
developing	NULOJIX.xml:S3:1686:10	develop	VBG	O	O
post	NULOJIX.xml:S3:1697:4	post	NN	B-AdverseReaction	O
-	NULOJIX.xml:S3:1701:1	-	:	I-AdverseReaction	O
transplant	NULOJIX.xml:S3:1702:10	transplant	NN	I-AdverseReaction	O
lymphoproliferative	NULOJIX.xml:S3:1713:19	lymphoprolif	JJ	I-AdverseReaction	O
disorder	NULOJIX.xml:S3:1733:8	disord	NN	I-AdverseReaction	O
(	NULOJIX.xml:S3:1742:1	(	(	O	O
PTLD	NULOJIX.xml:S3:1743:4	ptld	NNP	B-AdverseReaction	O
)	NULOJIX.xml:S3:1747:1	)	)	O	O
,	NULOJIX.xml:S3:1748:1	,	,	O	O
predominantly	NULOJIX.xml:S3:1750:13	predominantli	RB	O	O
involving	NULOJIX.xml:S3:1764:9	involv	VBG	O	O
the	NULOJIX.xml:S3:1774:3	the	DT	O	O
CNS	NULOJIX.xml:S3:1778:3	cn	NNP	O	O
,	NULOJIX.xml:S3:1781:1	,	,	O	O
compared	NULOJIX.xml:S3:1783:8	compar	VBN	O	O
to	NULOJIX.xml:S3:1792:2	to	TO	O	O
patients	NULOJIX.xml:S3:1795:8	patient	NNS	O	O
on	NULOJIX.xml:S3:1804:2	on	IN	O	O
a	NULOJIX.xml:S3:1807:1	a	DT	O	O
cyclosporine	NULOJIX.xml:S3:1809:12	cyclosporin	NN	O	O
-	NULOJIX.xml:S3:1821:1	-	:	O	O
based	NULOJIX.xml:S3:1822:5	base	VBN	O	O
regimen	NULOJIX.xml:S3:1828:7	regimen	NNS	O	O
[	NULOJIX.xml:S3:1836:1	[	NNP	O	O
see	NULOJIX.xml:S3:1837:3	see	VBP	O	O
Adverse	NULOJIX.xml:S3:1843:7	advers	JJ	O	O
Reactions	NULOJIX.xml:S3:1851:9	reaction	NNP	O	O
(	NULOJIX.xml:S3:1861:1	(	(	O	O
6.1	NULOJIX.xml:S3:1862:3	6.1	CD	O	O
)	NULOJIX.xml:S3:1865:1	)	)	O	O
and	NULOJIX.xml:S3:1870:3	and	CC	O	O
Table	NULOJIX.xml:S3:1874:5	tabl	JJ	O	O
2	NULOJIX.xml:S3:1880:1	2	CD	O	O
]	NULOJIX.xml:S3:1883:1	]	NN	O	O
.	NULOJIX.xml:S3:1884:1	.	.	O	O

As	NULOJIX.xml:S3:1886:2	As	IN	O	O
the	NULOJIX.xml:S3:1889:3	the	DT	O	O
total	NULOJIX.xml:S3:1893:5	total	JJ	O	O
burden	NULOJIX.xml:S3:1899:6	burden	NN	O	O
of	NULOJIX.xml:S3:1906:2	of	IN	O	O
immunosuppression	NULOJIX.xml:S3:1909:17	immunosuppress	NN	O	O
is	NULOJIX.xml:S3:1927:2	is	VBZ	O	O
a	NULOJIX.xml:S3:1930:1	a	DT	O	O
risk	NULOJIX.xml:S3:1932:4	risk	NN	O	O
factor	NULOJIX.xml:S3:1937:6	factor	NN	O	O
for	NULOJIX.xml:S3:1944:3	for	IN	O	O
PTLD	NULOJIX.xml:S3:1948:4	ptld	NNP	O	O
,	NULOJIX.xml:S3:1952:1	,	,	O	O
higher	NULOJIX.xml:S3:1954:6	higher	JJR	O	O
than	NULOJIX.xml:S3:1961:4	than	IN	O	O
the	NULOJIX.xml:S3:1966:3	the	DT	O	O
recommended	NULOJIX.xml:S3:1970:11	recommend	JJ	O	O
doses	NULOJIX.xml:S3:1982:5	dose	NNS	O	O
or	NULOJIX.xml:S3:1988:2	or	CC	O	O
more	NULOJIX.xml:S3:1991:4	more	JJR	O	O
frequent	NULOJIX.xml:S3:1996:8	frequent	JJ	O	O
dosing	NULOJIX.xml:S3:2005:6	dose	NN	O	O
of	NULOJIX.xml:S3:2012:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S3:2015:7	nulojix	NNP	O	O
and	NULOJIX.xml:S3:2023:3	and	CC	O	O
higher	NULOJIX.xml:S3:2027:6	higher	JJR	O	O
than	NULOJIX.xml:S3:2034:4	than	IN	O	O
recommended	NULOJIX.xml:S3:2039:11	recommend	JJ	O	O
doses	NULOJIX.xml:S3:2051:5	dose	NNS	O	O
of	NULOJIX.xml:S3:2057:2	of	IN	O	O
concomitant	NULOJIX.xml:S3:2060:11	concomit	JJ	O	O
immunosuppressive	NULOJIX.xml:S3:2072:17	immunosuppress	JJ	O	O
agents	NULOJIX.xml:S3:2090:6	agent	NNS	O	O
are	NULOJIX.xml:S3:2097:3	are	VBP	O	O
not	NULOJIX.xml:S3:2101:3	not	RB	O	O
recommended	NULOJIX.xml:S3:2105:11	recommend	JJ	O	O
[	NULOJIX.xml:S3:2117:1	[	NNS	O	O
see	NULOJIX.xml:S3:2118:3	see	VBP	O	O
Dosage	NULOJIX.xml:S3:2124:6	dosag	NNP	O	O
and	NULOJIX.xml:S3:2131:3	and	CC	O	O
Administration	NULOJIX.xml:S3:2135:14	administr	NNP	O	O
(	NULOJIX.xml:S3:2150:1	(	(	O	O
2.1	NULOJIX.xml:S3:2151:3	2.1	CD	O	O
)	NULOJIX.xml:S3:2154:1	)	)	O	O
and	NULOJIX.xml:S3:2159:3	and	CC	O	O
Warnings	NULOJIX.xml:S3:2165:8	warn	NNP	O	O
and	NULOJIX.xml:S3:2174:3	and	CC	O	O
Precautions	NULOJIX.xml:S3:2178:11	precaut	NNP	O	O
(	NULOJIX.xml:S3:2190:1	(	(	O	O
5.6	NULOJIX.xml:S3:2191:3	5.6	CD	O	O
)	NULOJIX.xml:S3:2194:1	)	)	O	O
]	NULOJIX.xml:S3:2199:1	]	NN	O	O
.	NULOJIX.xml:S3:2200:1	.	.	O	O

Physicians	NULOJIX.xml:S3:2202:10	physician	NNS	O	O
should	NULOJIX.xml:S3:2213:6	should	MD	O	O
consider	NULOJIX.xml:S3:2220:8	consid	VB	O	O
PTLD	NULOJIX.xml:S3:2229:4	ptld	NNP	O	O
in	NULOJIX.xml:S3:2234:2	in	IN	O	O
patients	NULOJIX.xml:S3:2237:8	patient	NNS	O	O
reporting	NULOJIX.xml:S3:2246:9	report	VBG	O	O
new	NULOJIX.xml:S3:2256:3	new	JJ	O	O
or	NULOJIX.xml:S3:2260:2	or	CC	O	O
worsening	NULOJIX.xml:S3:2263:9	worsen	JJ	O	O
neurological	NULOJIX.xml:S3:2273:12	neurolog	JJ	O	O
,	NULOJIX.xml:S3:2285:1	,	,	O	O
cognitive	NULOJIX.xml:S3:2287:9	cognit	JJ	O	O
,	NULOJIX.xml:S3:2296:1	,	,	O	O
or	NULOJIX.xml:S3:2298:2	or	CC	O	O
behavioral	NULOJIX.xml:S3:2301:10	behavior	JJ	O	O
signs	NULOJIX.xml:S3:2312:5	sign	NNS	O	O
or	NULOJIX.xml:S3:2318:2	or	CC	O	O
symptoms	NULOJIX.xml:S3:2321:8	symptom	NNS	O	O
.	NULOJIX.xml:S3:2329:1	.	.	O	O

EBV	NULOJIX.xml:S3:2338:3	ebv	NNP	O	O
Serostatus	NULOJIX.xml:S3:2342:10	serostatu	NNP	O	O

The	NULOJIX.xml:S3:2358:3	the	DT	O	O
risk	NULOJIX.xml:S3:2362:4	risk	NN	O	O
of	NULOJIX.xml:S3:2367:2	of	IN	O	O
PTLD	NULOJIX.xml:S3:2370:4	ptld	NNP	B-AdverseReaction	O
was	NULOJIX.xml:S3:2375:3	wa	VBD	O	O
higher	NULOJIX.xml:S3:2379:6	higher	RBR	O	O
in	NULOJIX.xml:S3:2386:2	in	IN	O	O
EBV	NULOJIX.xml:S3:2389:3	ebv	NNP	O	O
seronegative	NULOJIX.xml:S3:2393:12	seroneg	JJ	O	O
patients	NULOJIX.xml:S3:2406:8	patient	NNS	O	O
compared	NULOJIX.xml:S3:2415:8	compar	VBN	O	O
to	NULOJIX.xml:S3:2424:2	to	TO	O	O
EBV	NULOJIX.xml:S3:2427:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S3:2431:12	seroposit	JJ	O	O
patients	NULOJIX.xml:S3:2444:8	patient	NNS	O	O
.	NULOJIX.xml:S3:2452:1	.	.	O	O

EBV	NULOJIX.xml:S3:2454:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S3:2458:12	seroposit	JJ	O	O
patients	NULOJIX.xml:S3:2471:8	patient	NNS	O	O
are	NULOJIX.xml:S3:2480:3	are	VBP	O	O
defined	NULOJIX.xml:S3:2484:7	defin	VBN	O	O
as	NULOJIX.xml:S3:2492:2	as	IN	O	O
having	NULOJIX.xml:S3:2495:6	have	VBG	O	O
evidence	NULOJIX.xml:S3:2502:8	evid	NN	O	O
of	NULOJIX.xml:S3:2511:2	of	IN	O	O
acquired	NULOJIX.xml:S3:2514:8	acquir	VBN	O	O
immunity	NULOJIX.xml:S3:2523:8	immun	NN	O	O
shown	NULOJIX.xml:S3:2532:5	shown	VBN	O	O
by	NULOJIX.xml:S3:2538:2	by	IN	O	O
the	NULOJIX.xml:S3:2541:3	the	DT	O	O
presence	NULOJIX.xml:S3:2545:8	presenc	NN	O	O
of	NULOJIX.xml:S3:2554:2	of	IN	O	O
IgG	NULOJIX.xml:S3:2557:3	igg	NNP	O	O
antibodies	NULOJIX.xml:S3:2561:10	antibodi	NNS	O	O
to	NULOJIX.xml:S3:2572:2	to	TO	O	O
viral	NULOJIX.xml:S3:2575:5	viral	JJ	O	B-AdverseReaction
capsid	NULOJIX.xml:S3:2581:6	capsid	NN	O	I-AdverseReaction
antigen	NULOJIX.xml:S3:2588:7	antigen	NN	O	I-AdverseReaction
(	NULOJIX.xml:S3:2596:1	(	(	O	O
VCA	NULOJIX.xml:S3:2597:3	vca	NNP	O	I-AdverseReaction
)	NULOJIX.xml:S3:2600:1	)	)	O	O
and	NULOJIX.xml:S3:2602:3	and	CC	O	O
EBV	NULOJIX.xml:S3:2606:3	ebv	NNP	O	B-AdverseReaction
nuclear	NULOJIX.xml:S3:2610:7	nuclear	JJ	O	I-AdverseReaction
antigen	NULOJIX.xml:S3:2618:7	antigen	NN	O	I-AdverseReaction
(	NULOJIX.xml:S3:2626:1	(	(	O	O
EBNA	NULOJIX.xml:S3:2627:4	ebna	NNP	O	O
)	NULOJIX.xml:S3:2631:1	)	)	O	O
.	NULOJIX.xml:S3:2632:1	.	.	O	O

Epstein	NULOJIX.xml:S3:2638:7	epstein	NNP	O	O
-	NULOJIX.xml:S3:2645:1	-	:	O	O
Barr	NULOJIX.xml:S3:2646:4	barr	NNP	O	O
virus	NULOJIX.xml:S3:2651:5	viru	NN	O	O
serology	NULOJIX.xml:S3:2657:8	serolog	NN	O	O
should	NULOJIX.xml:S3:2666:6	should	MD	O	O
be	NULOJIX.xml:S3:2673:2	be	VB	O	O
ascertained	NULOJIX.xml:S3:2676:11	ascertain	VBN	O	O
before	NULOJIX.xml:S3:2688:6	befor	IN	O	O
starting	NULOJIX.xml:S3:2695:8	start	VBG	O	O
administration	NULOJIX.xml:S3:2704:14	administr	NN	O	O
of	NULOJIX.xml:S3:2719:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S3:2722:7	nulojix	NNP	O	O
,	NULOJIX.xml:S3:2729:1	,	,	O	O
and	NULOJIX.xml:S3:2731:3	and	CC	O	O
only	NULOJIX.xml:S3:2735:4	onli	RB	O	O
patients	NULOJIX.xml:S3:2740:8	patient	NNS	O	O
who	NULOJIX.xml:S3:2749:3	who	WP	O	O
are	NULOJIX.xml:S3:2753:3	are	VBP	O	O
EBV	NULOJIX.xml:S3:2757:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S3:2761:12	seroposit	JJ	O	O
should	NULOJIX.xml:S3:2774:6	should	MD	O	O
receive	NULOJIX.xml:S3:2781:7	receiv	VB	O	O
NULOJIX	NULOJIX.xml:S3:2789:7	nulojix	NNP	O	O
.	NULOJIX.xml:S3:2796:1	.	.	O	O

Transplant	NULOJIX.xml:S3:2798:10	transplant	JJ	O	O
recipients	NULOJIX.xml:S3:2809:10	recipi	NNS	O	O
who	NULOJIX.xml:S3:2820:3	who	WP	O	O
are	NULOJIX.xml:S3:2824:3	are	VBP	O	O
EBV	NULOJIX.xml:S3:2828:3	ebv	NNP	O	O
seronegative	NULOJIX.xml:S3:2832:12	seroneg	JJ	O	O
,	NULOJIX.xml:S3:2844:1	,	,	O	O
or	NULOJIX.xml:S3:2846:2	or	CC	O	O
with	NULOJIX.xml:S3:2849:4	with	IN	O	O
unknown	NULOJIX.xml:S3:2854:7	unknown	JJ	O	O
serostatus	NULOJIX.xml:S3:2862:10	serostatu	NN	O	O
,	NULOJIX.xml:S3:2872:1	,	,	O	O
should	NULOJIX.xml:S3:2874:6	should	MD	O	O
not	NULOJIX.xml:S3:2881:3	not	RB	O	O
receive	NULOJIX.xml:S3:2885:7	receiv	VB	O	O
NULOJIX	NULOJIX.xml:S3:2893:7	nulojix	NNP	O	O
[	NULOJIX.xml:S3:2901:1	[	NNP	O	O
see	NULOJIX.xml:S3:2902:3	see	VBP	O	O
Boxed	NULOJIX.xml:S3:2908:5	box	NNP	O	O
Warning	NULOJIX.xml:S3:2914:7	warn	NNP	O	O
and	NULOJIX.xml:S3:2925:3	and	CC	O	O
Contraindications	NULOJIX.xml:S3:2931:17	contraind	NNP	O	O
(	NULOJIX.xml:S3:2949:1	(	(	O	O
4	NULOJIX.xml:S3:2950:1	4	CD	O	O
)	NULOJIX.xml:S3:2951:1	)	)	O	O
]	NULOJIX.xml:S3:2956:1	]	NN	O	O
.	NULOJIX.xml:S3:2957:1	.	.	O	O

Other	NULOJIX.xml:S3:2966:5	other	JJ	O	O
Risk	NULOJIX.xml:S3:2972:4	risk	NN	O	O
Factors	NULOJIX.xml:S3:2977:7	factor	NNS	O	O

Other	NULOJIX.xml:S3:2990:5	other	JJ	O	O
known	NULOJIX.xml:S3:2996:5	known	VBN	O	O
risk	NULOJIX.xml:S3:3002:4	risk	NN	O	O
factors	NULOJIX.xml:S3:3007:7	factor	NNS	O	O
for	NULOJIX.xml:S3:3015:3	for	IN	O	O
PTLD	NULOJIX.xml:S3:3019:4	ptld	NNP	O	O
include	NULOJIX.xml:S3:3024:7	includ	VBP	O	O
cytomegalovirus	NULOJIX.xml:S3:3032:15	cytomegaloviru	NN	O	O
(	NULOJIX.xml:S3:3048:1	(	(	O	O
CMV	NULOJIX.xml:S3:3049:3	cmv	NNP	O	O
)	NULOJIX.xml:S3:3052:1	)	)	O	O
infection	NULOJIX.xml:S3:3054:9	infect	NN	O	O
and	NULOJIX.xml:S3:3064:3	and	CC	O	O
T	NULOJIX.xml:S3:3068:1	T	NNP	O	O
-	NULOJIX.xml:S3:3069:1	-	:	O	O
cell	NULOJIX.xml:S3:3070:4	cell	NN	O	O
-	NULOJIX.xml:S3:3074:1	-	:	O	O
depleting	NULOJIX.xml:S3:3075:9	deplet	NN	O	O
therapy	NULOJIX.xml:S3:3085:7	therapi	NN	O	O
.	NULOJIX.xml:S3:3092:1	.	.	O	O

T	NULOJIX.xml:S3:3094:1	T	NNP	O	O
-	NULOJIX.xml:S3:3095:1	-	:	O	O
cell	NULOJIX.xml:S3:3096:4	cell	NN	O	O
-	NULOJIX.xml:S3:3100:1	-	:	O	O
depleting	NULOJIX.xml:S3:3101:9	deplet	VBG	O	O
therapies	NULOJIX.xml:S3:3111:9	therapi	NNS	O	O
to	NULOJIX.xml:S3:3121:2	to	TO	O	O
treat	NULOJIX.xml:S3:3124:5	treat	VB	O	O
acute	NULOJIX.xml:S3:3130:5	acut	JJ	O	O
rejection	NULOJIX.xml:S3:3136:9	reject	NN	O	O
should	NULOJIX.xml:S3:3146:6	should	MD	O	O
be	NULOJIX.xml:S3:3153:2	be	VB	O	O
used	NULOJIX.xml:S3:3156:4	use	VBN	O	O
cautiously	NULOJIX.xml:S3:3161:10	cautious	RB	O	O
.	NULOJIX.xml:S3:3171:1	.	.	O	O

CMV	NULOJIX.xml:S3:3173:3	cmv	NNP	O	O
prophylaxis	NULOJIX.xml:S3:3177:11	prophylaxi	NN	O	O
is	NULOJIX.xml:S3:3189:2	is	VBZ	O	O
recommended	NULOJIX.xml:S3:3192:11	recommend	VBN	O	O
for	NULOJIX.xml:S3:3204:3	for	IN	O	O
at	NULOJIX.xml:S3:3208:2	at	IN	O	O
least	NULOJIX.xml:S3:3211:5	least	JJS	O	O
3	NULOJIX.xml:S3:3217:1	3	CD	O	O
months	NULOJIX.xml:S3:3219:6	month	NNS	O	O
after	NULOJIX.xml:S3:3226:5	after	IN	O	O
transplantation	NULOJIX.xml:S3:3232:15	transplant	NN	O	O
[	NULOJIX.xml:S3:3248:1	[	NNP	O	O
see	NULOJIX.xml:S3:3249:3	see	VBP	O	O
Warnings	NULOJIX.xml:S3:3255:8	warn	NNP	O	O
and	NULOJIX.xml:S3:3264:3	and	CC	O	O
Precautions	NULOJIX.xml:S3:3268:11	precaut	NNP	O	O
(	NULOJIX.xml:S3:3280:1	(	(	O	O
5.5	NULOJIX.xml:S3:3281:3	5.5	CD	O	O
)	NULOJIX.xml:S3:3284:1	)	)	O	O
]	NULOJIX.xml:S3:3289:1	]	NN	O	O
.	NULOJIX.xml:S3:3290:1	.	.	O	O

Patients	NULOJIX.xml:S3:3296:8	patient	NNS	O	O
who	NULOJIX.xml:S3:3305:3	who	WP	O	O
are	NULOJIX.xml:S3:3309:3	are	VBP	O	O
EBV	NULOJIX.xml:S3:3313:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S3:3317:12	seroposit	JJ	O	O
and	NULOJIX.xml:S3:3330:3	and	CC	O	O
CMV	NULOJIX.xml:S3:3334:3	cmv	NNP	O	O
seronegative	NULOJIX.xml:S3:3338:12	seroneg	NN	O	O
may	NULOJIX.xml:S3:3351:3	may	MD	O	O
be	NULOJIX.xml:S3:3355:2	be	VB	O	O
at	NULOJIX.xml:S3:3358:2	at	IN	O	O
increased	NULOJIX.xml:S3:3361:9	increas	VBN	O	O
risk	NULOJIX.xml:S3:3371:4	risk	NN	O	O
for	NULOJIX.xml:S3:3376:3	for	IN	O	O
PTLD	NULOJIX.xml:S3:3380:4	ptld	NNP	O	O
compared	NULOJIX.xml:S3:3385:8	compar	VBN	O	O
to	NULOJIX.xml:S3:3394:2	to	TO	O	O
patients	NULOJIX.xml:S3:3397:8	patient	NNS	O	O
who	NULOJIX.xml:S3:3406:3	who	WP	O	O
are	NULOJIX.xml:S3:3410:3	are	VBP	O	O
EBV	NULOJIX.xml:S3:3414:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S3:3418:12	seroposit	JJ	O	O
and	NULOJIX.xml:S3:3431:3	and	CC	O	O
CMV	NULOJIX.xml:S3:3435:3	cmv	NNP	O	O
seropositive	NULOJIX.xml:S3:3439:12	seroposit	JJ	O	O
[	NULOJIX.xml:S3:3452:1	[	NNP	O	O
see	NULOJIX.xml:S3:3453:3	see	VBP	O	O
Adverse	NULOJIX.xml:S3:3459:7	advers	JJ	O	O
Reactions	NULOJIX.xml:S3:3467:9	reaction	NNP	O	O
(	NULOJIX.xml:S3:3477:1	(	(	O	O
6.1	NULOJIX.xml:S3:3478:3	6.1	CD	O	O
)	NULOJIX.xml:S3:3481:1	)	)	O	O
]	NULOJIX.xml:S3:3486:1	]	NN	O	O
.	NULOJIX.xml:S3:3487:1	.	.	O	O

Since	NULOJIX.xml:S3:3489:5	sinc	IN	O	O
CMV	NULOJIX.xml:S3:3495:3	cmv	NNP	O	O
seronegative	NULOJIX.xml:S3:3499:12	seroneg	JJ	O	O
patients	NULOJIX.xml:S3:3512:8	patient	NNS	O	O
are	NULOJIX.xml:S3:3521:3	are	VBP	O	O
at	NULOJIX.xml:S3:3525:2	at	IN	O	O
increased	NULOJIX.xml:S3:3528:9	increas	VBN	O	O
risk	NULOJIX.xml:S3:3538:4	risk	NN	O	O
for	NULOJIX.xml:S3:3543:3	for	IN	O	O
CMV	NULOJIX.xml:S3:3547:3	cmv	NNP	O	O
disease	NULOJIX.xml:S3:3551:7	diseas	NN	O	O
(	NULOJIX.xml:S3:3559:1	(	(	O	O
a	NULOJIX.xml:S3:3560:1	a	DT	O	O
known	NULOJIX.xml:S3:3562:5	known	VBN	O	O
risk	NULOJIX.xml:S3:3568:4	risk	NN	O	O
factor	NULOJIX.xml:S3:3573:6	factor	NN	O	O
for	NULOJIX.xml:S3:3580:3	for	IN	O	O
PTLD	NULOJIX.xml:S3:3584:4	ptld	NNP	O	O
)	NULOJIX.xml:S3:3588:1	)	)	O	O
,	NULOJIX.xml:S3:3589:1	,	,	O	O
the	NULOJIX.xml:S3:3591:3	the	DT	O	O
clinical	NULOJIX.xml:S3:3595:8	clinic	JJ	O	O
significance	NULOJIX.xml:S3:3604:12	signific	NN	O	O
of	NULOJIX.xml:S3:3617:2	of	IN	O	O
CMV	NULOJIX.xml:S3:3620:3	cmv	NNP	O	O
serology	NULOJIX.xml:S3:3624:8	serolog	NN	O	O
for	NULOJIX.xml:S3:3633:3	for	IN	O	O
PTLD	NULOJIX.xml:S3:3637:4	ptld	NNP	O	O
remains	NULOJIX.xml:S3:3642:7	remain	VBZ	O	O
to	NULOJIX.xml:S3:3650:2	to	TO	O	O
be	NULOJIX.xml:S3:3653:2	be	VB	O	O
determined	NULOJIX.xml:S3:3656:10	determin	VBN	O	O
;	NULOJIX.xml:S3:3666:1	;	:	O	O
however	NULOJIX.xml:S3:3668:7	howev	RB	O	O
,	NULOJIX.xml:S3:3675:1	,	,	O	O
these	NULOJIX.xml:S3:3677:5	these	DT	O	O
findings	NULOJIX.xml:S3:3683:8	find	NNS	O	O
should	NULOJIX.xml:S3:3692:6	should	MD	O	O
be	NULOJIX.xml:S3:3699:2	be	VB	O	O
considered	NULOJIX.xml:S3:3702:10	consid	VBN	O	O
when	NULOJIX.xml:S3:3713:4	when	WRB	O	O
prescribing	NULOJIX.xml:S3:3718:11	prescrib	VBG	O	O
NULOJIX	NULOJIX.xml:S3:3730:7	nulojix	NNP	O	O
.	NULOJIX.xml:S3:3737:1	.	.	O	O

5.2	NULOJIX.xml:S3:3746:3	5.2	CD	O	O
Management	NULOJIX.xml:S3:3750:10	manag	NNP	O	O
of	NULOJIX.xml:S3:3761:2	of	IN	O	O
Immunosuppression	NULOJIX.xml:S3:3764:17	immunosuppress	NNP	O	O

Only	NULOJIX.xml:S3:3787:4	onli	RB	O	O
physicians	NULOJIX.xml:S3:3792:10	physician	NNS	O	O
experienced	NULOJIX.xml:S3:3803:11	experienc	VBD	O	O
in	NULOJIX.xml:S3:3815:2	in	IN	O	O
management	NULOJIX.xml:S3:3818:10	manag	NN	O	O
of	NULOJIX.xml:S3:3829:2	of	IN	O	O
systemic	NULOJIX.xml:S3:3832:8	system	JJ	O	O
immunosuppressant	NULOJIX.xml:S3:3841:17	immunosuppress	JJ	O	O
therapy	NULOJIX.xml:S3:3859:7	therapi	NN	O	O
in	NULOJIX.xml:S3:3867:2	in	IN	O	O
transplantation	NULOJIX.xml:S3:3870:15	transplant	NN	O	O
should	NULOJIX.xml:S3:3886:6	should	MD	O	O
prescribe	NULOJIX.xml:S3:3893:9	prescrib	VB	O	O
NULOJIX	NULOJIX.xml:S3:3903:7	nulojix	NNP	O	O
.	NULOJIX.xml:S3:3910:1	.	.	O	O

Patients	NULOJIX.xml:S3:3912:8	patient	NNS	O	O
receiving	NULOJIX.xml:S3:3921:9	receiv	VBG	O	O
the	NULOJIX.xml:S3:3931:3	the	DT	O	O
drug	NULOJIX.xml:S3:3935:4	drug	NN	O	O
should	NULOJIX.xml:S3:3940:6	should	MD	O	O
be	NULOJIX.xml:S3:3947:2	be	VB	O	O
managed	NULOJIX.xml:S3:3950:7	manag	VBN	O	O
in	NULOJIX.xml:S3:3958:2	in	IN	O	O
facilities	NULOJIX.xml:S3:3961:10	facil	NNS	O	O
equipped	NULOJIX.xml:S3:3972:8	equip	VBN	O	O
and	NULOJIX.xml:S3:3981:3	and	CC	O	O
staffed	NULOJIX.xml:S3:3985:7	staf	VBN	O	O
with	NULOJIX.xml:S3:3993:4	with	IN	O	O
adequate	NULOJIX.xml:S3:3998:8	adequ	JJ	O	O
laboratory	NULOJIX.xml:S3:4007:10	laboratori	NN	O	O
and	NULOJIX.xml:S3:4018:3	and	CC	O	O
supportive	NULOJIX.xml:S3:4022:10	support	JJ	O	O
medical	NULOJIX.xml:S3:4033:7	medic	JJ	O	O
resources	NULOJIX.xml:S3:4041:9	resourc	NNS	O	O
.	NULOJIX.xml:S3:4050:1	.	.	O	O

The	NULOJIX.xml:S3:4052:3	the	DT	O	O
physician	NULOJIX.xml:S3:4056:9	physician	NN	O	O
responsible	NULOJIX.xml:S3:4066:11	respons	JJ	O	O
for	NULOJIX.xml:S3:4078:3	for	IN	O	O
the	NULOJIX.xml:S3:4082:3	the	DT	O	O
maintenance	NULOJIX.xml:S3:4086:11	mainten	NN	O	O
therapy	NULOJIX.xml:S3:4098:7	therapi	NN	O	O
should	NULOJIX.xml:S3:4106:6	should	MD	O	O
have	NULOJIX.xml:S3:4113:4	have	VB	O	O
complete	NULOJIX.xml:S3:4118:8	complet	JJ	O	O
information	NULOJIX.xml:S3:4127:11	inform	NN	O	O
requisite	NULOJIX.xml:S3:4139:9	requisit	NN	O	O
for	NULOJIX.xml:S3:4149:3	for	IN	O	O
the	NULOJIX.xml:S3:4153:3	the	DT	O	O
follow	NULOJIX.xml:S3:4157:6	follow	NN	O	O
-	NULOJIX.xml:S3:4163:1	-	:	O	O
up	NULOJIX.xml:S3:4164:2	up	IN	O	O
of	NULOJIX.xml:S3:4167:2	of	IN	O	O
the	NULOJIX.xml:S3:4170:3	the	DT	O	O
patient	NULOJIX.xml:S3:4174:7	patient	NN	O	O
[	NULOJIX.xml:S3:4182:1	[	NNP	O	O
see	NULOJIX.xml:S3:4183:3	see	VBP	O	O
Boxed	NULOJIX.xml:S3:4189:5	box	NNP	O	O
Warning	NULOJIX.xml:S3:4195:7	warn	NNP	O	O
]	NULOJIX.xml:S3:4206:1	]	NNP	O	O
.	NULOJIX.xml:S3:4207:1	.	.	O	O

5.3	NULOJIX.xml:S3:4216:3	5.3	CD	O	O
Other	NULOJIX.xml:S3:4220:5	other	JJ	O	O
Malignancies	NULOJIX.xml:S3:4226:12	malign	NNS	O	O

Patients	NULOJIX.xml:S3:4244:8	patient	NNS	O	O
receiving	NULOJIX.xml:S3:4253:9	receiv	VBG	O	O
immunosuppressants	NULOJIX.xml:S3:4263:18	immunosuppress	NNS	O	O
,	NULOJIX.xml:S3:4281:1	,	,	O	O
including	NULOJIX.xml:S3:4283:9	includ	VBG	O	O
NULOJIX	NULOJIX.xml:S3:4293:7	nulojix	NNP	O	O
,	NULOJIX.xml:S3:4300:1	,	,	O	O
are	NULOJIX.xml:S3:4302:3	are	VBP	O	O
at	NULOJIX.xml:S3:4306:2	at	IN	O	O
increased	NULOJIX.xml:S3:4309:9	increas	JJ	O	O
risk	NULOJIX.xml:S3:4319:4	risk	NN	O	O
of	NULOJIX.xml:S3:4324:2	of	IN	O	O
developing	NULOJIX.xml:S3:4327:10	develop	VBG	O	O
malignancies	NULOJIX.xml:S3:4338:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S3:4350:1	,	,	O	O
in	NULOJIX.xml:S3:4352:2	in	IN	O	O
addition	NULOJIX.xml:S3:4355:8	addit	NN	O	O
to	NULOJIX.xml:S3:4364:2	to	TO	O	O
PTLD	NULOJIX.xml:S3:4367:4	ptld	NNP	B-AdverseReaction	O
,	NULOJIX.xml:S3:4371:1	,	,	O	O
including	NULOJIX.xml:S3:4373:9	includ	VBG	O	O
the	NULOJIX.xml:S3:4383:3	the	DT	O	O
skin	NULOJIX.xml:S3:4387:4	skin	NN	I-AdverseReaction	O
[	NULOJIX.xml:S3:4392:1	[	NNP	O	O
see	NULOJIX.xml:S3:4393:3	see	VBP	O	O
Boxed	NULOJIX.xml:S3:4399:5	box	NNP	O	O
Warning	NULOJIX.xml:S3:4405:7	warn	NNP	O	O
and	NULOJIX.xml:S3:4416:3	and	CC	O	O
Warnings	NULOJIX.xml:S3:4422:8	warn	NNP	O	O
and	NULOJIX.xml:S3:4431:3	and	CC	O	O
Precautions	NULOJIX.xml:S3:4435:11	precaut	NNP	O	O
(	NULOJIX.xml:S3:4447:1	(	(	O	O
5.1	NULOJIX.xml:S3:4448:3	5.1	CD	O	O
)	NULOJIX.xml:S3:4451:1	)	)	O	O
]	NULOJIX.xml:S3:4456:1	]	NN	O	O
.	NULOJIX.xml:S3:4457:1	.	.	O	O

Exposure	NULOJIX.xml:S3:4459:8	exposur	NN	O	O
to	NULOJIX.xml:S3:4468:2	to	TO	O	O
sunlight	NULOJIX.xml:S3:4471:8	sunlight	VB	O	O
and	NULOJIX.xml:S3:4480:3	and	CC	O	O
ultraviolet	NULOJIX.xml:S3:4484:11	ultraviolet	VB	O	O
(	NULOJIX.xml:S3:4496:1	(	(	O	O
UV	NULOJIX.xml:S3:4497:2	UV	NNP	O	O
)	NULOJIX.xml:S3:4499:1	)	)	O	O
light	NULOJIX.xml:S3:4501:5	light	NN	O	O
should	NULOJIX.xml:S3:4507:6	should	MD	O	O
be	NULOJIX.xml:S3:4514:2	be	VB	O	O
limited	NULOJIX.xml:S3:4517:7	limit	VBN	O	O
by	NULOJIX.xml:S3:4525:2	by	IN	O	O
wearing	NULOJIX.xml:S3:4528:7	wear	VBG	O	O
protective	NULOJIX.xml:S3:4536:10	protect	JJ	O	O
clothing	NULOJIX.xml:S3:4547:8	cloth	NN	O	O
and	NULOJIX.xml:S3:4556:3	and	CC	O	O
using	NULOJIX.xml:S3:4560:5	use	VBG	O	O
a	NULOJIX.xml:S3:4566:1	a	DT	O	O
sunscreen	NULOJIX.xml:S3:4568:9	sunscreen	NN	O	O
with	NULOJIX.xml:S3:4578:4	with	IN	O	O
a	NULOJIX.xml:S3:4583:1	a	DT	O	O
high	NULOJIX.xml:S3:4585:4	high	JJ	O	O
protection	NULOJIX.xml:S3:4590:10	protect	NN	O	O
factor	NULOJIX.xml:S3:4601:6	factor	NN	O	O
.	NULOJIX.xml:S3:4607:1	.	.	O	O

5.4	NULOJIX.xml:S3:4616:3	5.4	CD	O	O
Progressive	NULOJIX.xml:S3:4620:11	progress	JJ	O	O
Multifocal	NULOJIX.xml:S3:4632:10	multifoc	NNP	O	O
Leukoencephalopathy	NULOJIX.xml:S3:4643:19	leukoencephalopathi	NNP	O	O

Progressive	NULOJIX.xml:S3:4668:11	progress	JJ	O	B-AdverseReaction
multifocal	NULOJIX.xml:S3:4680:10	multifoc	JJ	O	I-AdverseReaction
leukoencephalopathy	NULOJIX.xml:S3:4691:19	leukoencephalopathi	NN	O	I-AdverseReaction
(	NULOJIX.xml:S3:4711:1	(	(	O	O
PML	NULOJIX.xml:S3:4712:3	pml	NNP	O	B-AdverseReaction
)	NULOJIX.xml:S3:4715:1	)	)	O	O
is	NULOJIX.xml:S3:4717:2	is	VBZ	O	O
an	NULOJIX.xml:S3:4720:2	an	DT	O	O
often	NULOJIX.xml:S3:4723:5	often	RB	O	O
rapidly	NULOJIX.xml:S3:4729:7	rapidli	RB	O	O
progressive	NULOJIX.xml:S3:4737:11	progress	JJ	O	O
and	NULOJIX.xml:S3:4749:3	and	CC	O	O
fatal	NULOJIX.xml:S3:4753:5	fatal	JJ	O	B-AdverseReaction
opportunistic	NULOJIX.xml:S3:4759:13	opportunist	JJ	O	O
infection	NULOJIX.xml:S3:4773:9	infect	NN	O	O
of	NULOJIX.xml:S3:4783:2	of	IN	O	O
the	NULOJIX.xml:S3:4786:3	the	DT	O	O
CNS	NULOJIX.xml:S3:4790:3	cn	NNP	O	O
that	NULOJIX.xml:S3:4794:4	that	WDT	O	O
is	NULOJIX.xml:S3:4799:2	is	VBZ	O	O
caused	NULOJIX.xml:S3:4802:6	caus	VBN	O	O
by	NULOJIX.xml:S3:4809:2	by	IN	O	O
the	NULOJIX.xml:S3:4812:3	the	DT	O	O
JC	NULOJIX.xml:S3:4816:2	JC	NNP	O	O
virus	NULOJIX.xml:S3:4819:5	viru	NN	O	O
,	NULOJIX.xml:S3:4824:1	,	,	O	O
a	NULOJIX.xml:S3:4826:1	a	DT	O	O
human	NULOJIX.xml:S3:4828:5	human	JJ	O	O
polyoma	NULOJIX.xml:S3:4834:7	polyoma	NN	O	O
virus	NULOJIX.xml:S3:4842:5	viru	NN	O	O
.	NULOJIX.xml:S3:4847:1	.	.	O	O

In	NULOJIX.xml:S3:4849:2	In	IN	O	O
clinical	NULOJIX.xml:S3:4852:8	clinic	JJ	O	O
trials	NULOJIX.xml:S3:4861:6	trial	NNS	O	O
with	NULOJIX.xml:S3:4868:4	with	IN	O	O
NULOJIX	NULOJIX.xml:S3:4873:7	nulojix	NNP	O	O
,	NULOJIX.xml:S3:4880:1	,	,	O	O
two	NULOJIX.xml:S3:4882:3	two	CD	O	O
cases	NULOJIX.xml:S3:4886:5	case	NNS	O	O
of	NULOJIX.xml:S3:4892:2	of	IN	O	O
PML	NULOJIX.xml:S3:4895:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
were	NULOJIX.xml:S3:4899:4	were	VBD	O	O
reported	NULOJIX.xml:S3:4904:8	report	VBN	O	O
in	NULOJIX.xml:S3:4913:2	in	IN	O	O
patients	NULOJIX.xml:S3:4916:8	patient	NNS	O	O
receiving	NULOJIX.xml:S3:4925:9	receiv	VBG	O	O
NULOJIX	NULOJIX.xml:S3:4935:7	nulojix	NNP	O	O
at	NULOJIX.xml:S3:4943:2	at	IN	O	O
higher	NULOJIX.xml:S3:4946:6	higher	JJR	O	O
cumulative	NULOJIX.xml:S3:4953:10	cumul	JJ	O	O
doses	NULOJIX.xml:S3:4964:5	dose	NNS	O	O
and	NULOJIX.xml:S3:4970:3	and	CC	O	O
more	NULOJIX.xml:S3:4974:4	more	RBR	O	O
frequently	NULOJIX.xml:S3:4979:10	frequent	RB	O	O
than	NULOJIX.xml:S3:4990:4	than	IN	O	O
the	NULOJIX.xml:S3:4995:3	the	DT	O	O
recommended	NULOJIX.xml:S3:4999:11	recommend	JJ	O	O
regimen	NULOJIX.xml:S3:5011:7	regimen	NNS	O	O
,	NULOJIX.xml:S3:5018:1	,	,	O	O
along	NULOJIX.xml:S3:5020:5	along	IN	O	O
with	NULOJIX.xml:S3:5026:4	with	IN	O	O
mycophenolate	NULOJIX.xml:S3:5031:13	mycophenol	NN	O	O
mofetil	NULOJIX.xml:S3:5045:7	mofetil	NN	O	O
(	NULOJIX.xml:S3:5053:1	(	(	O	O
MMF	NULOJIX.xml:S3:5054:3	mmf	NNP	O	O
)	NULOJIX.xml:S3:5057:1	)	)	O	O
and	NULOJIX.xml:S3:5059:3	and	CC	O	O
corticosteroids	NULOJIX.xml:S3:5063:15	corticosteroid	NNS	O	O
;	NULOJIX.xml:S3:5078:1	;	:	O	O
one	NULOJIX.xml:S3:5080:3	one	CD	O	O
case	NULOJIX.xml:S3:5084:4	case	NN	O	O
occurred	NULOJIX.xml:S3:5089:8	occur	VBD	O	O
in	NULOJIX.xml:S3:5098:2	in	IN	O	O
a	NULOJIX.xml:S3:5101:1	a	DT	O	O
kidney	NULOJIX.xml:S3:5103:6	kidney	NN	O	O
transplant	NULOJIX.xml:S3:5110:10	transplant	NN	O	O
recipient	NULOJIX.xml:S3:5121:9	recipi	NN	O	O
and	NULOJIX.xml:S3:5131:3	and	CC	O	O
the	NULOJIX.xml:S3:5135:3	the	DT	O	O
second	NULOJIX.xml:S3:5139:6	second	JJ	O	O
case	NULOJIX.xml:S3:5146:4	case	NN	O	O
occurred	NULOJIX.xml:S3:5151:8	occur	VBD	O	O
in	NULOJIX.xml:S3:5160:2	in	IN	O	O
a	NULOJIX.xml:S3:5163:1	a	DT	O	O
liver	NULOJIX.xml:S3:5165:5	liver	NN	O	O
transplant	NULOJIX.xml:S3:5171:10	transplant	NN	O	O
recipient	NULOJIX.xml:S3:5182:9	recipi	NN	O	O
[	NULOJIX.xml:S3:5192:1	[	NNP	O	O
see	NULOJIX.xml:S3:5193:3	see	VBP	O	O
Warnings	NULOJIX.xml:S3:5199:8	warn	NNP	O	O
and	NULOJIX.xml:S3:5208:3	and	CC	O	O
Precautions	NULOJIX.xml:S3:5212:11	precaut	NNP	O	O
(	NULOJIX.xml:S3:5224:1	(	(	O	O
5.6	NULOJIX.xml:S3:5225:3	5.6	CD	O	O
)	NULOJIX.xml:S3:5228:1	)	)	O	O
]	NULOJIX.xml:S3:5233:1	]	NN	O	O
.	NULOJIX.xml:S3:5234:1	.	.	O	O

As	NULOJIX.xml:S3:5236:2	As	IN	O	O
PML	NULOJIX.xml:S3:5239:3	pml	NNP	O	B-AdverseReaction
has	NULOJIX.xml:S3:5243:3	ha	VBZ	O	O
been	NULOJIX.xml:S3:5247:4	been	VBN	O	O
associated	NULOJIX.xml:S3:5252:10	associ	VBN	O	O
with	NULOJIX.xml:S3:5263:4	with	IN	O	O
high	NULOJIX.xml:S3:5268:4	high	JJ	O	O
levels	NULOJIX.xml:S3:5273:6	level	NNS	O	O
of	NULOJIX.xml:S3:5280:2	of	IN	O	O
overall	NULOJIX.xml:S3:5283:7	overal	JJ	O	O
immunosuppression	NULOJIX.xml:S3:5291:17	immunosuppress	NN	O	O
,	NULOJIX.xml:S3:5308:1	,	,	O	O
the	NULOJIX.xml:S3:5310:3	the	DT	O	O
recommended	NULOJIX.xml:S3:5314:11	recommend	JJ	O	O
doses	NULOJIX.xml:S3:5326:5	dose	NNS	O	O
and	NULOJIX.xml:S3:5332:3	and	CC	O	O
frequency	NULOJIX.xml:S3:5336:9	frequenc	NN	O	O
of	NULOJIX.xml:S3:5346:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S3:5349:7	nulojix	NNP	O	O
and	NULOJIX.xml:S3:5357:3	and	CC	O	O
concomitant	NULOJIX.xml:S3:5361:11	concomit	JJ	O	O
immunosuppressives	NULOJIX.xml:S3:5373:18	immunosuppress	NNS	O	O
,	NULOJIX.xml:S3:5391:1	,	,	O	O
including	NULOJIX.xml:S3:5393:9	includ	VBG	O	O
MMF	NULOJIX.xml:S3:5403:3	mmf	NNP	O	O
,	NULOJIX.xml:S3:5406:1	,	,	O	O
should	NULOJIX.xml:S3:5408:6	should	MD	O	O
not	NULOJIX.xml:S3:5415:3	not	RB	O	O
be	NULOJIX.xml:S3:5419:2	be	VB	O	O
exceeded	NULOJIX.xml:S3:5422:8	exceed	VBN	O	O
.	NULOJIX.xml:S3:5430:1	.	.	O	O

Physicians	NULOJIX.xml:S3:5436:10	physician	NNS	O	O
should	NULOJIX.xml:S3:5447:6	should	MD	O	O
consider	NULOJIX.xml:S3:5454:8	consid	VB	O	O
PML	NULOJIX.xml:S3:5463:3	pml	NNP	O	O
in	NULOJIX.xml:S3:5467:2	in	IN	O	O
the	NULOJIX.xml:S3:5470:3	the	DT	O	O
differential	NULOJIX.xml:S3:5474:12	differenti	JJ	O	O
diagnosis	NULOJIX.xml:S3:5487:9	diagnosi	NN	O	O
in	NULOJIX.xml:S3:5497:2	in	IN	O	O
patients	NULOJIX.xml:S3:5500:8	patient	NNS	O	O
with	NULOJIX.xml:S3:5509:4	with	IN	O	O
new	NULOJIX.xml:S3:5514:3	new	JJ	O	O
or	NULOJIX.xml:S3:5518:2	or	CC	O	O
worsening	NULOJIX.xml:S3:5521:9	worsen	JJ	O	O
neurological	NULOJIX.xml:S3:5531:12	neurolog	JJ	O	O
,	NULOJIX.xml:S3:5543:1	,	,	O	O
cognitive	NULOJIX.xml:S3:5545:9	cognit	JJ	O	O
,	NULOJIX.xml:S3:5554:1	,	,	O	O
or	NULOJIX.xml:S3:5556:2	or	CC	O	O
behavioral	NULOJIX.xml:S3:5559:10	behavior	JJ	O	O
signs	NULOJIX.xml:S3:5570:5	sign	NNS	O	O
or	NULOJIX.xml:S3:5576:2	or	CC	O	O
symptoms	NULOJIX.xml:S3:5579:8	symptom	NNS	O	O
.	NULOJIX.xml:S3:5587:1	.	.	O	O

PML	NULOJIX.xml:S3:5589:3	pml	NNP	O	B-AdverseReaction
is	NULOJIX.xml:S3:5593:2	is	VBZ	O	O
usually	NULOJIX.xml:S3:5596:7	usual	RB	O	O
diagnosed	NULOJIX.xml:S3:5604:9	diagnos	VBN	O	O
by	NULOJIX.xml:S3:5614:2	by	IN	O	O
brain	NULOJIX.xml:S3:5617:5	brain	NN	O	O
imaging	NULOJIX.xml:S3:5623:7	imag	NN	O	O
,	NULOJIX.xml:S3:5630:1	,	,	O	O
cerebrospinal	NULOJIX.xml:S3:5632:13	cerebrospin	JJ	O	B-AdverseReaction
fluid	NULOJIX.xml:S3:5646:5	fluid	NN	O	I-AdverseReaction
(	NULOJIX.xml:S3:5652:1	(	(	O	O
CSF	NULOJIX.xml:S3:5653:3	csf	NNP	O	O
)	NULOJIX.xml:S3:5656:1	)	)	O	O
testing	NULOJIX.xml:S3:5658:7	test	VBG	O	O
for	NULOJIX.xml:S3:5666:3	for	IN	O	O
JC	NULOJIX.xml:S3:5670:2	JC	NNP	O	O
viral	NULOJIX.xml:S3:5673:5	viral	JJ	O	O
DNA	NULOJIX.xml:S3:5679:3	dna	NNP	O	O
by	NULOJIX.xml:S3:5683:2	by	IN	O	O
polymerase	NULOJIX.xml:S3:5686:10	polymeras	NN	O	O
chain	NULOJIX.xml:S3:5697:5	chain	NN	O	O
reaction	NULOJIX.xml:S3:5703:8	reaction	NN	O	O
(	NULOJIX.xml:S3:5712:1	(	(	O	O
PCR	NULOJIX.xml:S3:5713:3	pcr	NNP	O	O
)	NULOJIX.xml:S3:5716:1	)	)	O	O
,	NULOJIX.xml:S3:5717:1	,	,	O	O
and	NULOJIX.xml:S3:5719:3	and	CC	O	O
or	NULOJIX.xml:S3:5723:2	or	CC	O	O
brain	NULOJIX.xml:S3:5726:5	brain	NN	O	O
biopsy	NULOJIX.xml:S3:5732:6	biopsi	NN	O	O
.	NULOJIX.xml:S3:5738:1	.	.	O	O

Consultation	NULOJIX.xml:S3:5740:12	consult	NN	O	O
with	NULOJIX.xml:S3:5753:4	with	IN	O	O
a	NULOJIX.xml:S3:5758:1	a	DT	O	O
specialist	NULOJIX.xml:S3:5760:10	specialist	NN	O	O
(	NULOJIX.xml:S3:5771:1	(	(	O	O
e	NULOJIX.xml:S3:5772:1	e	NN	O	O
.	NULOJIX.xml:S3:5773:1	.	.	O	O
g	NULOJIX.xml:S3:5774:1	g	NN	O	O
.	NULOJIX.xml:S3:5775:1	.	.	O	O
,	NULOJIX.xml:S3:5776:1	,	,	O	O
neurologist	NULOJIX.xml:S3:5778:11	neurologist	JJ	O	O
and	NULOJIX.xml:S3:5790:3	and	CC	O	O
or	NULOJIX.xml:S3:5794:2	or	CC	O	O
infectious	NULOJIX.xml:S3:5797:10	infecti	JJ	O	O
disease	NULOJIX.xml:S3:5808:7	diseas	NN	O	O
)	NULOJIX.xml:S3:5815:1	)	)	O	O
should	NULOJIX.xml:S3:5817:6	should	MD	O	O
be	NULOJIX.xml:S3:5824:2	be	VB	O	O
considered	NULOJIX.xml:S3:5827:10	consid	VBN	O	O
for	NULOJIX.xml:S3:5838:3	for	IN	O	O
any	NULOJIX.xml:S3:5842:3	ani	DT	O	O
suspected	NULOJIX.xml:S3:5846:9	suspect	JJ	O	O
or	NULOJIX.xml:S3:5856:2	or	CC	O	O
confirmed	NULOJIX.xml:S3:5859:9	confirm	JJ	O	O
cases	NULOJIX.xml:S3:5869:5	case	NNS	O	O
of	NULOJIX.xml:S3:5875:2	of	IN	O	O
PML	NULOJIX.xml:S3:5878:3	pml	NNP	O	B-AdverseReaction
.	NULOJIX.xml:S3:5881:1	.	.	O	O

If	NULOJIX.xml:S3:5887:2	If	IN	O	O
PML	NULOJIX.xml:S3:5890:3	pml	NNP	O	O
is	NULOJIX.xml:S3:5894:2	is	VBZ	O	O
diagnosed	NULOJIX.xml:S3:5897:9	diagnos	VBN	O	O
,	NULOJIX.xml:S3:5906:1	,	,	O	O
consideration	NULOJIX.xml:S3:5908:13	consider	NN	O	O
should	NULOJIX.xml:S3:5922:6	should	MD	O	O
be	NULOJIX.xml:S3:5929:2	be	VB	O	O
given	NULOJIX.xml:S3:5932:5	given	VBN	O	O
to	NULOJIX.xml:S3:5938:2	to	TO	O	O
reduction	NULOJIX.xml:S3:5941:9	reduct	NN	O	O
or	NULOJIX.xml:S3:5951:2	or	CC	O	O
withdrawal	NULOJIX.xml:S3:5954:10	withdraw	NN	O	O
of	NULOJIX.xml:S3:5965:2	of	IN	O	O
immunosuppression	NULOJIX.xml:S3:5968:17	immunosuppress	NN	O	O
taking	NULOJIX.xml:S3:5986:6	take	VBG	O	O
into	NULOJIX.xml:S3:5993:4	into	IN	O	O
account	NULOJIX.xml:S3:5998:7	account	NN	O	O
the	NULOJIX.xml:S3:6006:3	the	DT	O	O
risk	NULOJIX.xml:S3:6010:4	risk	NN	O	O
to	NULOJIX.xml:S3:6015:2	to	TO	O	O
the	NULOJIX.xml:S3:6018:3	the	DT	O	O
allograft	NULOJIX.xml:S3:6022:9	allograft	NN	O	O
.	NULOJIX.xml:S3:6031:1	.	.	O	O

5.5	NULOJIX.xml:S3:6040:3	5.5	CD	O	O
Other	NULOJIX.xml:S3:6044:5	other	JJ	O	O
Serious	NULOJIX.xml:S3:6050:7	seriou	JJ	O	O
Infections	NULOJIX.xml:S3:6058:10	infect	NNS	O	O

Patients	NULOJIX.xml:S3:6074:8	patient	NNS	O	O
receiving	NULOJIX.xml:S3:6083:9	receiv	VBG	O	O
immunosuppressants	NULOJIX.xml:S3:6093:18	immunosuppress	NNS	O	O
,	NULOJIX.xml:S3:6111:1	,	,	O	O
including	NULOJIX.xml:S3:6113:9	includ	VBG	O	O
NULOJIX	NULOJIX.xml:S3:6123:7	nulojix	NNP	O	O
,	NULOJIX.xml:S3:6130:1	,	,	O	O
are	NULOJIX.xml:S3:6132:3	are	VBP	O	O
at	NULOJIX.xml:S3:6136:2	at	IN	O	O
increased	NULOJIX.xml:S3:6139:9	increas	JJ	O	O
risk	NULOJIX.xml:S3:6149:4	risk	NN	O	O
of	NULOJIX.xml:S3:6154:2	of	IN	O	O
developing	NULOJIX.xml:S3:6157:10	develop	VBG	O	O
bacterial	NULOJIX.xml:S3:6168:9	bacteri	JJ	B-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S3:6177:1	,	,	O	O
viral	NULOJIX.xml:S3:6179:5	viral	JJ	B-AdverseReaction	B-AdverseReaction
(	NULOJIX.xml:S3:6185:1	(	(	O	O
cytomegalovirus	NULOJIX.xml:S3:6186:15	cytomegaloviru	JJ	B-AdverseReaction	O
[	NULOJIX.xml:S3:6202:1	[	NNP	O	O
CMV	NULOJIX.xml:S3:6203:3	cmv	NNP	B-AdverseReaction	O
]	NULOJIX.xml:S3:6206:1	]	NNP	O	O
and	NULOJIX.xml:S3:6208:3	and	CC	O	O
herpes	NULOJIX.xml:S3:6212:6	herp	NNS	B-AdverseReaction	O
)	NULOJIX.xml:S3:6218:1	)	)	O	O
,	NULOJIX.xml:S3:6219:1	,	,	O	O
fungal	NULOJIX.xml:S3:6221:6	fungal	JJ	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S3:6227:1	,	,	O	O
and	NULOJIX.xml:S3:6229:3	and	CC	O	O
protozoal	NULOJIX.xml:S3:6233:9	protozo	NN	B-AdverseReaction	B-AdverseReaction
infections	NULOJIX.xml:S3:6243:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S3:6253:1	,	,	O	O
including	NULOJIX.xml:S3:6255:9	includ	VBG	O	O
opportunistic	NULOJIX.xml:S3:6265:13	opportunist	JJ	B-AdverseReaction	B-AdverseReaction
infections	NULOJIX.xml:S3:6279:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
.	NULOJIX.xml:S3:6289:1	.	.	O	O

These	NULOJIX.xml:S3:6291:5	these	DT	O	O
infections	NULOJIX.xml:S3:6297:10	infect	NNS	B-AdverseReaction	O
may	NULOJIX.xml:S3:6308:3	may	MD	O	O
lead	NULOJIX.xml:S3:6312:4	lead	VB	O	O
to	NULOJIX.xml:S3:6317:2	to	TO	O	O
serious	NULOJIX.xml:S3:6320:7	seriou	JJ	O	O
,	NULOJIX.xml:S3:6327:1	,	,	O	O
including	NULOJIX.xml:S3:6329:9	includ	VBG	O	O
fatal	NULOJIX.xml:S3:6339:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
,	NULOJIX.xml:S3:6344:1	,	,	O	O
outcomes	NULOJIX.xml:S3:6346:8	outcom	JJ	O	O
[	NULOJIX.xml:S3:6355:1	[	NNP	O	O
see	NULOJIX.xml:S3:6356:3	see	NN	O	O
Boxed	NULOJIX.xml:S3:6362:5	box	NNP	O	O
Warning	NULOJIX.xml:S3:6368:7	warn	NNP	O	O
and	NULOJIX.xml:S3:6379:3	and	CC	O	O
Adverse	NULOJIX.xml:S3:6385:7	advers	NNP	O	O
Reactions	NULOJIX.xml:S3:6393:9	reaction	NNP	O	O
(	NULOJIX.xml:S3:6403:1	(	(	O	O
6.1	NULOJIX.xml:S3:6404:3	6.1	CD	O	O
)	NULOJIX.xml:S3:6407:1	)	)	O	O
]	NULOJIX.xml:S3:6412:1	]	NN	O	O
.	NULOJIX.xml:S3:6413:1	.	.	O	O

Prophylaxis	NULOJIX.xml:S3:6419:11	prophylaxi	NNP	O	O
for	NULOJIX.xml:S3:6431:3	for	IN	O	O
cytomegalovirus	NULOJIX.xml:S3:6435:15	cytomegaloviru	NN	O	O
is	NULOJIX.xml:S3:6451:2	is	VBZ	O	O
recommended	NULOJIX.xml:S3:6454:11	recommend	VBN	O	O
for	NULOJIX.xml:S3:6466:3	for	IN	O	O
at	NULOJIX.xml:S3:6470:2	at	IN	O	O
least	NULOJIX.xml:S3:6473:5	least	JJS	O	O
3	NULOJIX.xml:S3:6479:1	3	CD	O	O
months	NULOJIX.xml:S3:6481:6	month	NNS	O	O
after	NULOJIX.xml:S3:6488:5	after	IN	O	O
transplantation	NULOJIX.xml:S3:6494:15	transplant	NN	O	O
.	NULOJIX.xml:S3:6509:1	.	.	O	O

Prophylaxis	NULOJIX.xml:S3:6511:11	prophylaxi	NNP	O	O
for	NULOJIX.xml:S3:6523:3	for	IN	O	O
Pneumocystis	NULOJIX.xml:S3:6527:12	pneumocysti	NNP	O	O
jiroveci	NULOJIX.xml:S3:6540:8	jiroveci	NN	O	O
is	NULOJIX.xml:S3:6550:2	is	VBZ	O	O
recommended	NULOJIX.xml:S3:6553:11	recommend	VBN	O	O
after	NULOJIX.xml:S3:6565:5	after	IN	O	O
transplantation	NULOJIX.xml:S3:6571:15	transplant	NN	O	O
.	NULOJIX.xml:S3:6586:1	.	.	O	O

Tuberculosis	NULOJIX.xml:S3:6595:12	tuberculosi	NN	O	O

Tuberculosis	NULOJIX.xml:S3:6613:12	tuberculosi	NN	B-AdverseReaction	B-AdverseReaction
was	NULOJIX.xml:S3:6626:3	wa	VBD	O	O
more	NULOJIX.xml:S3:6630:4	more	RBR	O	O
frequently	NULOJIX.xml:S3:6635:10	frequent	RB	O	O
observed	NULOJIX.xml:S3:6646:8	observ	VBN	O	O
in	NULOJIX.xml:S3:6655:2	in	IN	O	O
patients	NULOJIX.xml:S3:6658:8	patient	NNS	O	O
receiving	NULOJIX.xml:S3:6667:9	receiv	VBG	O	O
NULOJIX	NULOJIX.xml:S3:6677:7	nulojix	NNP	O	O
than	NULOJIX.xml:S3:6685:4	than	IN	O	O
cyclosporine	NULOJIX.xml:S3:6690:12	cyclosporin	NN	O	O
in	NULOJIX.xml:S3:6703:2	in	IN	O	O
clinical	NULOJIX.xml:S3:6706:8	clinic	JJ	O	O
trials	NULOJIX.xml:S3:6715:6	trial	NNS	O	O
[	NULOJIX.xml:S3:6722:1	[	VBP	O	O
see	NULOJIX.xml:S3:6723:3	see	VB	O	O
Adverse	NULOJIX.xml:S3:6729:7	advers	JJ	O	O
Reactions	NULOJIX.xml:S3:6737:9	reaction	NNP	O	O
(	NULOJIX.xml:S3:6747:1	(	(	O	O
6.1	NULOJIX.xml:S3:6748:3	6.1	CD	O	O
)	NULOJIX.xml:S3:6751:1	)	)	O	O
]	NULOJIX.xml:S3:6756:1	]	NN	O	O
.	NULOJIX.xml:S3:6757:1	.	.	O	O

Patients	NULOJIX.xml:S3:6759:8	patient	NNS	O	O
should	NULOJIX.xml:S3:6768:6	should	MD	O	O
be	NULOJIX.xml:S3:6775:2	be	VB	O	O
evaluated	NULOJIX.xml:S3:6778:9	evalu	VBN	O	O
for	NULOJIX.xml:S3:6788:3	for	IN	O	O
tuberculosis	NULOJIX.xml:S3:6792:12	tuberculosi	NN	O	O
and	NULOJIX.xml:S3:6805:3	and	CC	O	O
tested	NULOJIX.xml:S3:6809:6	test	VBN	O	O
for	NULOJIX.xml:S3:6816:3	for	IN	O	O
latent	NULOJIX.xml:S3:6820:6	latent	JJ	O	O
infection	NULOJIX.xml:S3:6827:9	infect	NN	O	O
prior	NULOJIX.xml:S3:6837:5	prior	RB	O	O
to	NULOJIX.xml:S3:6843:2	to	TO	O	O
initiating	NULOJIX.xml:S3:6846:10	initi	VBG	O	O
NULOJIX	NULOJIX.xml:S3:6857:7	nulojix	NNP	O	O
.	NULOJIX.xml:S3:6864:1	.	.	O	O

Treatment	NULOJIX.xml:S3:6866:9	treatment	NN	O	O
of	NULOJIX.xml:S3:6876:2	of	IN	O	O
latent	NULOJIX.xml:S3:6879:6	latent	JJ	O	O
tuberculosis	NULOJIX.xml:S3:6886:12	tuberculosi	NN	O	O
infection	NULOJIX.xml:S3:6899:9	infect	NN	O	O
should	NULOJIX.xml:S3:6909:6	should	MD	O	O
be	NULOJIX.xml:S3:6916:2	be	VB	O	O
initiated	NULOJIX.xml:S3:6919:9	initi	VBN	O	O
prior	NULOJIX.xml:S3:6929:5	prior	RB	O	O
to	NULOJIX.xml:S3:6935:2	to	TO	O	O
NULOJIX	NULOJIX.xml:S3:6938:7	nulojix	NNP	O	O
use	NULOJIX.xml:S3:6946:3	use	NN	O	O
.	NULOJIX.xml:S3:6949:1	.	.	O	O

Polyoma	NULOJIX.xml:S3:6958:7	polyoma	NNP	O	O
Virus	NULOJIX.xml:S3:6966:5	viru	NNP	O	O
Nephropathy	NULOJIX.xml:S3:6972:11	nephropathi	NNP	O	O

In	NULOJIX.xml:S3:6989:2	In	IN	O	O
addition	NULOJIX.xml:S3:6992:8	addit	NN	O	O
to	NULOJIX.xml:S3:7001:2	to	TO	O	O
cases	NULOJIX.xml:S3:7004:5	case	NNS	O	O
of	NULOJIX.xml:S3:7010:2	of	IN	O	O
JC	NULOJIX.xml:S3:7013:2	JC	NNP	B-AdverseReaction	B-AdverseReaction
virus	NULOJIX.xml:S3:7016:5	viru	NN	I-AdverseReaction	I-AdverseReaction
-	NULOJIX.xml:S3:7021:1	-	:	O	I-AdverseReaction
associated	NULOJIX.xml:S3:7022:10	associ	VBN	O	I-AdverseReaction
PML	NULOJIX.xml:S3:7033:3	pml	NNP	B-AdverseReaction	I-AdverseReaction
[	NULOJIX.xml:S3:7037:1	[	NNP	O	O
see	NULOJIX.xml:S3:7038:3	see	VBP	O	O
Warnings	NULOJIX.xml:S3:7044:8	warn	NNP	O	O
and	NULOJIX.xml:S3:7053:3	and	CC	O	O
Precautions	NULOJIX.xml:S3:7057:11	precaut	NNP	O	O
(	NULOJIX.xml:S3:7069:1	(	(	O	O
5.4	NULOJIX.xml:S3:7070:3	5.4	CD	O	O
)	NULOJIX.xml:S3:7073:1	)	)	O	O
]	NULOJIX.xml:S3:7078:1	]	NN	O	O
,	NULOJIX.xml:S3:7079:1	,	,	O	O
cases	NULOJIX.xml:S3:7081:5	case	NNS	O	O
of	NULOJIX.xml:S3:7087:2	of	IN	O	O
polyoma	NULOJIX.xml:S3:7090:7	polyoma	NN	B-AdverseReaction	B-AdverseReaction
virus	NULOJIX.xml:S3:7098:5	viru	NN	I-AdverseReaction	I-AdverseReaction
-	NULOJIX.xml:S3:7103:1	-	:	I-AdverseReaction	I-AdverseReaction
associated	NULOJIX.xml:S3:7104:10	associ	VBN	I-AdverseReaction	I-AdverseReaction
nephropathy	NULOJIX.xml:S3:7115:11	nephropathi	JJ	I-AdverseReaction	I-AdverseReaction
(	NULOJIX.xml:S3:7127:1	(	(	O	O
PVAN	NULOJIX.xml:S3:7128:4	pvan	NNP	B-AdverseReaction	O
)	NULOJIX.xml:S3:7132:1	)	)	O	O
,	NULOJIX.xml:S3:7133:1	,	,	O	O
mostly	NULOJIX.xml:S3:7135:6	mostli	RB	O	O
due	NULOJIX.xml:S3:7142:3	due	JJ	O	O
to	NULOJIX.xml:S3:7146:2	to	TO	O	O
BK	NULOJIX.xml:S3:7149:2	BK	NNP	B-AdverseReaction	B-AdverseReaction
virus	NULOJIX.xml:S3:7152:5	viru	NN	I-AdverseReaction	I-AdverseReaction
infection	NULOJIX.xml:S3:7158:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S3:7167:1	,	,	O	O
have	NULOJIX.xml:S3:7169:4	have	VBP	O	O
been	NULOJIX.xml:S3:7174:4	been	VBN	O	O
reported	NULOJIX.xml:S3:7179:8	report	VBN	O	O
.	NULOJIX.xml:S3:7187:1	.	.	O	O

PVAN	NULOJIX.xml:S3:7189:4	pvan	NNP	B-AdverseReaction	O
is	NULOJIX.xml:S3:7194:2	is	VBZ	O	O
associated	NULOJIX.xml:S3:7197:10	associ	VBN	O	O
with	NULOJIX.xml:S3:7208:4	with	IN	O	O
serious	NULOJIX.xml:S3:7213:7	seriou	JJ	O	O
outcomes	NULOJIX.xml:S3:7221:8	outcom	NNS	O	O
;	NULOJIX.xml:S3:7229:1	;	:	O	O
including	NULOJIX.xml:S3:7231:9	includ	VBG	O	O
deteriorating	NULOJIX.xml:S3:7241:13	deterior	VBG	B-AdverseReaction	O
renal	NULOJIX.xml:S3:7255:5	renal	JJ	I-AdverseReaction	O
function	NULOJIX.xml:S3:7261:8	function	NN	I-AdverseReaction	O
and	NULOJIX.xml:S3:7270:3	and	CC	O	O
kidney	NULOJIX.xml:S3:7274:6	kidney	NN	B-AdverseReaction	O
graft	NULOJIX.xml:S3:7281:5	graft	NN	I-AdverseReaction	O
loss	NULOJIX.xml:S3:7287:4	loss	NN	I-AdverseReaction	O
[	NULOJIX.xml:S3:7292:1	[	NNP	O	O
see	NULOJIX.xml:S3:7293:3	see	VBP	O	O
Adverse	NULOJIX.xml:S3:7299:7	advers	JJ	O	O
Reactions	NULOJIX.xml:S3:7307:9	reaction	NNP	O	O
(	NULOJIX.xml:S3:7317:1	(	(	O	O
6.1	NULOJIX.xml:S3:7318:3	6.1	CD	O	O
)	NULOJIX.xml:S3:7321:1	)	)	O	O
]	NULOJIX.xml:S3:7326:1	]	NN	O	O
.	NULOJIX.xml:S3:7327:1	.	.	O	O

Patient	NULOJIX.xml:S3:7329:7	patient	JJ	O	O
monitoring	NULOJIX.xml:S3:7337:10	monitor	NN	O	O
may	NULOJIX.xml:S3:7348:3	may	MD	O	O
help	NULOJIX.xml:S3:7352:4	help	VB	O	O
detect	NULOJIX.xml:S3:7357:6	detect	VB	O	O
patients	NULOJIX.xml:S3:7364:8	patient	NNS	O	O
at	NULOJIX.xml:S3:7373:2	at	IN	O	O
risk	NULOJIX.xml:S3:7376:4	risk	NN	O	O
for	NULOJIX.xml:S3:7381:3	for	IN	O	O
PVAN	NULOJIX.xml:S3:7385:4	pvan	NNP	O	O
.	NULOJIX.xml:S3:7389:1	.	.	O	O

Reductions	NULOJIX.xml:S3:7391:10	reduct	NNS	O	O
in	NULOJIX.xml:S3:7402:2	in	IN	O	O
immunosuppression	NULOJIX.xml:S3:7405:17	immunosuppress	NN	O	O
should	NULOJIX.xml:S3:7423:6	should	MD	O	O
be	NULOJIX.xml:S3:7430:2	be	VB	O	O
considered	NULOJIX.xml:S3:7433:10	consid	VBN	O	O
for	NULOJIX.xml:S3:7444:3	for	IN	O	O
patients	NULOJIX.xml:S3:7448:8	patient	NNS	O	O
who	NULOJIX.xml:S3:7457:3	who	WP	O	O
develop	NULOJIX.xml:S3:7461:7	develop	VBP	O	O
evidence	NULOJIX.xml:S3:7469:8	evid	NN	O	O
of	NULOJIX.xml:S3:7478:2	of	IN	O	O
PVAN	NULOJIX.xml:S3:7481:4	pvan	NNP	O	O
.	NULOJIX.xml:S3:7485:1	.	.	O	O

Physicians	NULOJIX.xml:S3:7487:10	physician	NNS	O	O
should	NULOJIX.xml:S3:7498:6	should	MD	O	O
also	NULOJIX.xml:S3:7505:4	also	RB	O	O
consider	NULOJIX.xml:S3:7510:8	consid	VB	O	O
the	NULOJIX.xml:S3:7519:3	the	DT	O	O
risk	NULOJIX.xml:S3:7523:4	risk	NN	O	O
that	NULOJIX.xml:S3:7528:4	that	IN	O	O
reduced	NULOJIX.xml:S3:7533:7	reduc	VBD	O	O
immunosuppression	NULOJIX.xml:S3:7541:17	immunosuppress	NN	O	O
represents	NULOJIX.xml:S3:7559:10	repres	VBZ	O	O
to	NULOJIX.xml:S3:7570:2	to	TO	O	O
the	NULOJIX.xml:S3:7573:3	the	DT	O	O
functioning	NULOJIX.xml:S3:7577:11	function	NN	O	O
allograft	NULOJIX.xml:S3:7589:9	allograft	NN	O	O
.	NULOJIX.xml:S3:7598:1	.	.	O	O

5.6	NULOJIX.xml:S3:7607:3	5.6	CD	O	O
Liver	NULOJIX.xml:S3:7611:5	liver	NNP	O	O
Transplant	NULOJIX.xml:S3:7617:10	transplant	NNP	O	O

Use	NULOJIX.xml:S3:7633:3	use	NNP	O	O
of	NULOJIX.xml:S3:7637:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S3:7640:7	nulojix	NNP	O	O
in	NULOJIX.xml:S3:7648:2	in	IN	O	O
liver	NULOJIX.xml:S3:7651:5	liver	NN	O	O
transplant	NULOJIX.xml:S3:7657:10	transplant	NN	O	O
patients	NULOJIX.xml:S3:7668:8	patient	NNS	O	O
is	NULOJIX.xml:S3:7677:2	is	VBZ	O	O
not	NULOJIX.xml:S3:7680:3	not	RB	O	O
recommended	NULOJIX.xml:S3:7684:11	recommend	JJ	O	O
[	NULOJIX.xml:S3:7696:1	[	NNS	O	O
see	NULOJIX.xml:S3:7697:3	see	VBP	O	O
Boxed	NULOJIX.xml:S3:7703:5	box	NNP	O	O
Warning	NULOJIX.xml:S3:7709:7	warn	NNP	O	O
]	NULOJIX.xml:S3:7720:1	]	NNP	O	O
.	NULOJIX.xml:S3:7721:1	.	.	O	O

In	NULOJIX.xml:S3:7723:2	In	IN	O	O
a	NULOJIX.xml:S3:7726:1	a	DT	O	O
clinical	NULOJIX.xml:S3:7728:8	clinic	JJ	O	O
trial	NULOJIX.xml:S3:7737:5	trial	NN	O	O
of	NULOJIX.xml:S3:7743:2	of	IN	O	O
liver	NULOJIX.xml:S3:7746:5	liver	NN	O	O
transplant	NULOJIX.xml:S3:7752:10	transplant	NN	O	O
patients	NULOJIX.xml:S3:7763:8	patient	NNS	O	O
,	NULOJIX.xml:S3:7771:1	,	,	O	O
use	NULOJIX.xml:S3:7773:3	use	NN	O	O
of	NULOJIX.xml:S3:7777:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S3:7780:7	nulojix	NNP	O	O
regimens	NULOJIX.xml:S3:7788:8	regimen	VBZ	O	O
with	NULOJIX.xml:S3:7797:4	with	IN	O	O
more	NULOJIX.xml:S3:7802:4	more	RBR	O	O
frequent	NULOJIX.xml:S3:7807:8	frequent	JJ	O	O
administration	NULOJIX.xml:S3:7816:14	administr	NN	O	O
of	NULOJIX.xml:S3:7831:2	of	IN	O	O
belatacept	NULOJIX.xml:S3:7834:10	belatacept	NNS	O	O
than	NULOJIX.xml:S3:7845:4	than	IN	O	O
any	NULOJIX.xml:S3:7850:3	ani	DT	O	O
of	NULOJIX.xml:S3:7854:2	of	IN	O	O
those	NULOJIX.xml:S3:7857:5	those	DT	O	O
studied	NULOJIX.xml:S3:7863:7	studi	VBN	O	O
in	NULOJIX.xml:S3:7871:2	in	IN	O	O
kidney	NULOJIX.xml:S3:7874:6	kidney	NN	O	O
transplant	NULOJIX.xml:S3:7881:10	transplant	NN	O	O
,	NULOJIX.xml:S3:7891:1	,	,	O	O
along	NULOJIX.xml:S3:7893:5	along	IN	O	O
with	NULOJIX.xml:S3:7899:4	with	IN	O	O
mycophenolate	NULOJIX.xml:S3:7904:13	mycophenol	NN	O	O
mofetil	NULOJIX.xml:S3:7918:7	mofetil	NN	O	O
(	NULOJIX.xml:S3:7926:1	(	(	O	O
MMF	NULOJIX.xml:S3:7927:3	mmf	NNP	O	O
)	NULOJIX.xml:S3:7930:1	)	)	O	O
and	NULOJIX.xml:S3:7932:3	and	CC	O	O
corticosteroids	NULOJIX.xml:S3:7936:15	corticosteroid	NNS	O	O
,	NULOJIX.xml:S3:7951:1	,	,	O	O
was	NULOJIX.xml:S3:7953:3	wa	VBD	O	O
associated	NULOJIX.xml:S3:7957:10	associ	VBN	O	O
with	NULOJIX.xml:S3:7968:4	with	IN	O	O
a	NULOJIX.xml:S3:7973:1	a	DT	O	O
higher	NULOJIX.xml:S3:7975:6	higher	JJR	O	O
rate	NULOJIX.xml:S3:7982:4	rate	NN	O	O
of	NULOJIX.xml:S3:7987:2	of	IN	O	O
graft	NULOJIX.xml:S3:7990:5	graft	NN	B-AdverseReaction	O
loss	NULOJIX.xml:S3:7996:4	loss	NN	I-AdverseReaction	O
and	NULOJIX.xml:S3:8001:3	and	CC	O	O
death	NULOJIX.xml:S3:8005:5	death	NN	B-AdverseReaction	B-AdverseReaction
compared	NULOJIX.xml:S3:8011:8	compar	VBN	O	O
to	NULOJIX.xml:S3:8020:2	to	TO	O	O
the	NULOJIX.xml:S3:8023:3	the	DT	O	O
tacrolimus	NULOJIX.xml:S3:8027:10	tacrolimu	NN	O	O
control	NULOJIX.xml:S3:8038:7	control	NN	O	O
arms	NULOJIX.xml:S3:8046:4	arm	NNS	O	O
.	NULOJIX.xml:S3:8050:1	.	.	O	O

In	NULOJIX.xml:S3:8052:2	In	IN	O	O
addition	NULOJIX.xml:S3:8055:8	addit	NN	O	O
,	NULOJIX.xml:S3:8063:1	,	,	O	O
two	NULOJIX.xml:S3:8065:3	two	CD	O	O
cases	NULOJIX.xml:S3:8069:5	case	NNS	O	O
of	NULOJIX.xml:S3:8075:2	of	IN	O	O
PTLD	NULOJIX.xml:S3:8078:4	ptld	NNP	B-AdverseReaction	O
involving	NULOJIX.xml:S3:8083:9	involv	VBG	O	O
the	NULOJIX.xml:S3:8093:3	the	DT	O	O
liver	NULOJIX.xml:S3:8097:5	liver	NN	O	O
allograft	NULOJIX.xml:S3:8103:9	allograft	NN	O	O
(	NULOJIX.xml:S3:8113:1	(	(	O	O
one	NULOJIX.xml:S3:8114:3	one	CD	O	O
fatal	NULOJIX.xml:S3:8118:5	fatal	NN	B-AdverseReaction	B-AdverseReaction
)	NULOJIX.xml:S3:8123:1	)	)	O	O
and	NULOJIX.xml:S3:8125:3	and	CC	O	O
one	NULOJIX.xml:S3:8129:3	one	CD	O	O
fatal	NULOJIX.xml:S3:8133:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
case	NULOJIX.xml:S3:8139:4	case	NN	O	O
of	NULOJIX.xml:S3:8144:2	of	IN	O	O
PML	NULOJIX.xml:S3:8147:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
were	NULOJIX.xml:S3:8151:4	were	VBD	O	O
observed	NULOJIX.xml:S3:8156:8	observ	VBN	O	O
among	NULOJIX.xml:S3:8165:5	among	IN	O	O
the	NULOJIX.xml:S3:8171:3	the	DT	O	O
147	NULOJIX.xml:S3:8175:3	147	CD	O	O
patients	NULOJIX.xml:S3:8179:8	patient	NNS	O	O
randomized	NULOJIX.xml:S3:8188:10	random	VBN	O	O
to	NULOJIX.xml:S3:8199:2	to	TO	O	O
NULOJIX	NULOJIX.xml:S3:8202:7	nulojix	NNP	O	O
.	NULOJIX.xml:S3:8209:1	.	.	O	O

The	NULOJIX.xml:S3:8211:3	the	DT	O	O
two	NULOJIX.xml:S3:8215:3	two	CD	O	O
cases	NULOJIX.xml:S3:8219:5	case	NNS	O	O
of	NULOJIX.xml:S3:8225:2	of	IN	O	O
PTLD	NULOJIX.xml:S3:8228:4	ptld	NNP	B-AdverseReaction	B-AdverseReaction
were	NULOJIX.xml:S3:8233:4	were	VBD	O	O
reported	NULOJIX.xml:S3:8238:8	report	VBN	O	O
among	NULOJIX.xml:S3:8247:5	among	IN	O	O
the	NULOJIX.xml:S3:8253:3	the	DT	O	O
140	NULOJIX.xml:S3:8257:3	140	CD	O	O
EBV	NULOJIX.xml:S3:8261:3	ebv	NNP	O	O
seropositive	NULOJIX.xml:S3:8265:12	seroposit	JJ	O	O
patients	NULOJIX.xml:S3:8278:8	patient	NNS	O	O
(	NULOJIX.xml:S3:8287:1	(	(	O	O
1.4%	NULOJIX.xml:S3:8288:4	1.4%	CD	O	O
)	NULOJIX.xml:S3:8292:1	)	)	O	O
.	NULOJIX.xml:S3:8293:1	.	.	O	O

The	NULOJIX.xml:S3:8295:3	the	DT	O	O
fatal	NULOJIX.xml:S3:8299:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
case	NULOJIX.xml:S3:8305:4	case	NN	O	O
of	NULOJIX.xml:S3:8310:2	of	IN	O	O
PML	NULOJIX.xml:S3:8313:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
was	NULOJIX.xml:S3:8317:3	wa	VBD	O	O
reported	NULOJIX.xml:S3:8321:8	report	VBN	O	O
in	NULOJIX.xml:S3:8330:2	in	IN	O	O
a	NULOJIX.xml:S3:8333:1	a	DT	O	O
patient	NULOJIX.xml:S3:8335:7	patient	NN	O	O
receiving	NULOJIX.xml:S3:8343:9	receiv	VBG	O	O
higher	NULOJIX.xml:S3:8353:6	higher	JJR	O	O
than	NULOJIX.xml:S3:8360:4	than	IN	O	O
recommended	NULOJIX.xml:S3:8365:11	recommend	JJ	O	O
doses	NULOJIX.xml:S3:8377:5	dose	NNS	O	O
of	NULOJIX.xml:S3:8383:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S3:8386:7	nulojix	NNP	O	O
and	NULOJIX.xml:S3:8394:3	and	CC	O	O
MMF	NULOJIX.xml:S3:8398:3	mmf	NNP	O	O
[	NULOJIX.xml:S3:8402:1	[	NNP	O	O
see	NULOJIX.xml:S3:8403:3	see	VBP	O	O
Warnings	NULOJIX.xml:S3:8409:8	warn	NNP	O	O
and	NULOJIX.xml:S3:8418:3	and	CC	O	O
Precautions	NULOJIX.xml:S3:8422:11	precaut	NNP	O	O
(	NULOJIX.xml:S3:8434:1	(	(	O	O
5.4	NULOJIX.xml:S3:8435:3	5.4	CD	O	O
)	NULOJIX.xml:S3:8438:1	)	)	O	O
]	NULOJIX.xml:S3:8443:1	]	NN	O	O
.	NULOJIX.xml:S3:8444:1	.	.	O	O

5.7	NULOJIX.xml:S3:8453:3	5.7	CD	O	O
Acute	NULOJIX.xml:S3:8457:5	acut	NNP	O	O
Rejection	NULOJIX.xml:S3:8463:9	reject	NNP	O	O
and	NULOJIX.xml:S3:8473:3	and	CC	O	O
Graft	NULOJIX.xml:S3:8477:5	graft	NNP	B-AdverseReaction	O
Loss	NULOJIX.xml:S3:8483:4	loss	NNP	O	O
with	NULOJIX.xml:S3:8488:4	with	IN	O	O
Corticosteroid	NULOJIX.xml:S3:8493:14	corticosteroid	NNP	O	O
Minimization	NULOJIX.xml:S3:8508:12	minim	NNP	O	O

In	NULOJIX.xml:S3:8526:2	In	IN	O	O
postmarketing	NULOJIX.xml:S3:8529:13	postmarket	VBG	O	O
experience	NULOJIX.xml:S3:8543:10	experi	NN	O	O
,	NULOJIX.xml:S3:8553:1	,	,	O	O
use	NULOJIX.xml:S3:8555:3	use	NN	O	O
of	NULOJIX.xml:S3:8559:2	of	IN	O	O
NULOJIX	NULOJIX.xml:S3:8562:7	nulojix	NNP	O	O
in	NULOJIX.xml:S3:8570:2	in	IN	O	O
conjunction	NULOJIX.xml:S3:8573:11	conjunct	NN	O	O
with	NULOJIX.xml:S3:8585:4	with	IN	O	O
basiliximab	NULOJIX.xml:S3:8590:11	basiliximab	JJ	O	O
induction	NULOJIX.xml:S3:8602:9	induct	NN	O	O
,	NULOJIX.xml:S3:8611:1	,	,	O	O
MMF	NULOJIX.xml:S3:8613:3	mmf	NNP	O	O
,	NULOJIX.xml:S3:8616:1	,	,	O	O
and	NULOJIX.xml:S3:8618:3	and	CC	O	O
corticosteroid	NULOJIX.xml:S3:8622:14	corticosteroid	JJ	O	O
minimization	NULOJIX.xml:S3:8637:12	minim	NN	O	O
to	NULOJIX.xml:S3:8650:2	to	TO	O	O
5	NULOJIX.xml:S3:8653:1	5	CD	O	O
mg	NULOJIX.xml:S3:8655:2	mg	NNS	O	O
per	NULOJIX.xml:S3:8658:3	per	IN	O	O
day	NULOJIX.xml:S3:8662:3	day	NN	O	O
between	NULOJIX.xml:S3:8666:7	between	IN	O	O
Day	NULOJIX.xml:S3:8674:3	day	NNP	O	O
3	NULOJIX.xml:S3:8678:1	3	CD	O	O
and	NULOJIX.xml:S3:8680:3	and	CC	O	O
Week	NULOJIX.xml:S3:8684:4	week	NNP	O	O
6	NULOJIX.xml:S3:8689:1	6	CD	O	O
post	NULOJIX.xml:S3:8691:4	post	NN	B-AdverseReaction	O
-	NULOJIX.xml:S3:8695:1	-	:	I-AdverseReaction	O
transplant	NULOJIX.xml:S3:8696:10	transplant	NN	I-AdverseReaction	O
was	NULOJIX.xml:S3:8707:3	wa	VBD	O	O
associated	NULOJIX.xml:S3:8711:10	associ	VBN	O	O
with	NULOJIX.xml:S3:8722:4	with	IN	O	O
an	NULOJIX.xml:S3:8727:2	an	DT	O	O
increased	NULOJIX.xml:S3:8730:9	increas	VBN	O	O
rate	NULOJIX.xml:S3:8740:4	rate	NN	O	O
and	NULOJIX.xml:S3:8745:3	and	CC	O	O
grade	NULOJIX.xml:S3:8749:5	grade	NN	O	O
of	NULOJIX.xml:S3:8755:2	of	IN	O	O
acute	NULOJIX.xml:S3:8758:5	acut	JJ	I-AdverseReaction	B-AdverseReaction
rejection	NULOJIX.xml:S3:8764:9	reject	NN	I-AdverseReaction	I-AdverseReaction
,	NULOJIX.xml:S3:8773:1	,	,	O	O
particularly	NULOJIX.xml:S3:8775:12	particularli	RB	O	O
Grade	NULOJIX.xml:S3:8788:5	grade	NNP	O	O
III	NULOJIX.xml:S3:8794:3	iii	NNP	O	O
rejection	NULOJIX.xml:S3:8798:9	reject	NN	O	O
.	NULOJIX.xml:S3:8807:1	.	.	O	O

These	NULOJIX.xml:S3:8809:5	these	DT	O	O
Grade	NULOJIX.xml:S3:8815:5	grade	NNP	O	O
III	NULOJIX.xml:S3:8821:3	iii	NNP	O	O
rejections	NULOJIX.xml:S3:8825:10	reject	NNS	I-AdverseReaction	O
occurred	NULOJIX.xml:S3:8836:8	occur	VBD	O	O
in	NULOJIX.xml:S3:8845:2	in	IN	O	O
patients	NULOJIX.xml:S3:8848:8	patient	NNS	O	O
with	NULOJIX.xml:S3:8857:4	with	IN	O	O
4	NULOJIX.xml:S3:8862:1	4	CD	O	O
to	NULOJIX.xml:S3:8864:2	to	TO	O	O
6	NULOJIX.xml:S3:8867:1	6	CD	O	O
HLA	NULOJIX.xml:S3:8869:3	hla	NNP	O	O
mismatches	NULOJIX.xml:S3:8873:10	mismatch	NNS	O	O
.	NULOJIX.xml:S3:8883:1	.	.	O	O

Graft	NULOJIX.xml:S3:8885:5	graft	NNP	B-AdverseReaction	O
loss	NULOJIX.xml:S3:8891:4	loss	NN	I-AdverseReaction	O
was	NULOJIX.xml:S3:8896:3	wa	VBD	O	O
a	NULOJIX.xml:S3:8900:1	a	DT	O	O
consequence	NULOJIX.xml:S3:8902:11	consequ	NN	O	O
of	NULOJIX.xml:S3:8914:2	of	IN	O	O
Grade	NULOJIX.xml:S3:8917:5	grade	NNP	O	O
III	NULOJIX.xml:S3:8923:3	iii	NNP	O	O
rejection	NULOJIX.xml:S3:8927:9	reject	NN	I-AdverseReaction	O
in	NULOJIX.xml:S3:8937:2	in	IN	O	O
some	NULOJIX.xml:S3:8940:4	some	DT	O	O
patients	NULOJIX.xml:S3:8945:8	patient	NNS	O	O
.	NULOJIX.xml:S3:8953:1	.	.	O	O

Corticosteroid	NULOJIX.xml:S3:8959:14	corticosteroid	JJ	O	O
utilization	NULOJIX.xml:S3:8974:11	util	NN	O	O
should	NULOJIX.xml:S3:8986:6	should	MD	O	O
be	NULOJIX.xml:S3:8993:2	be	VB	O	O
consistent	NULOJIX.xml:S3:8996:10	consist	JJ	O	O
with	NULOJIX.xml:S3:9007:4	with	IN	O	O
the	NULOJIX.xml:S3:9012:3	the	DT	O	O
NULOJIX	NULOJIX.xml:S3:9016:7	nulojix	NNP	O	O
clinical	NULOJIX.xml:S3:9024:8	clinic	JJ	O	O
trial	NULOJIX.xml:S3:9033:5	trial	NN	O	O
experience	NULOJIX.xml:S3:9039:10	experi	NN	O	O
[	NULOJIX.xml:S3:9050:1	[	NNP	O	O
see	NULOJIX.xml:S3:9051:3	see	NN	O	O
Dosage	NULOJIX.xml:S3:9057:6	dosag	NNP	O	O
and	NULOJIX.xml:S3:9064:3	and	CC	O	O
Administration	NULOJIX.xml:S3:9068:14	administr	NNP	O	O
(	NULOJIX.xml:S3:9083:1	(	(	O	O
2.1	NULOJIX.xml:S3:9084:3	2.1	CD	O	O
)	NULOJIX.xml:S3:9087:1	)	)	O	O
and	NULOJIX.xml:S3:9092:3	and	CC	O	O
Clinical	NULOJIX.xml:S3:9098:8	clinic	JJ	O	O
Studies	NULOJIX.xml:S3:9107:7	studi	NNP	O	O
(	NULOJIX.xml:S3:9115:1	(	(	O	O
14.1	NULOJIX.xml:S3:9116:4	14.1	CD	O	O
)	NULOJIX.xml:S3:9120:1	)	)	O	O
]	NULOJIX.xml:S3:9125:1	]	NN	O	O
.	NULOJIX.xml:S3:9126:1	.	.	O	O

5.8	NULOJIX.xml:S3:9135:3	5.8	CD	O	O
Immunizations	NULOJIX.xml:S3:9139:13	immun	NNS	O	O

The	NULOJIX.xml:S3:9158:3	the	DT	O	O
use	NULOJIX.xml:S3:9162:3	use	NN	O	O
of	NULOJIX.xml:S3:9166:2	of	IN	O	O
live	NULOJIX.xml:S3:9169:4	live	JJ	O	O
vaccines	NULOJIX.xml:S3:9174:8	vaccin	NNS	O	O
should	NULOJIX.xml:S3:9183:6	should	MD	O	O
be	NULOJIX.xml:S3:9190:2	be	VB	O	O
avoided	NULOJIX.xml:S3:9193:7	avoid	VBN	O	O
during	NULOJIX.xml:S3:9201:6	dure	IN	O	O
treatment	NULOJIX.xml:S3:9208:9	treatment	NN	O	O
with	NULOJIX.xml:S3:9218:4	with	IN	O	O
NULOJIX	NULOJIX.xml:S3:9223:7	nulojix	NNP	O	O
,	NULOJIX.xml:S3:9230:1	,	,	O	O
including	NULOJIX.xml:S3:9232:9	includ	VBG	O	O
but	NULOJIX.xml:S3:9242:3	but	CC	O	O
not	NULOJIX.xml:S3:9246:3	not	RB	O	O
limited	NULOJIX.xml:S3:9250:7	limit	JJ	O	O
to	NULOJIX.xml:S3:9258:2	to	TO	O	O
the	NULOJIX.xml:S3:9261:3	the	DT	O	O
following	NULOJIX.xml:S3:9265:9	follow	NN	O	O
:	NULOJIX.xml:S3:9274:1	:	:	O	O
intranasal	NULOJIX.xml:S3:9276:10	intranas	JJ	O	B-AdverseReaction
influenza	NULOJIX.xml:S3:9287:9	influenza	NN	O	I-AdverseReaction
,	NULOJIX.xml:S3:9296:1	,	,	O	O
measles	NULOJIX.xml:S3:9298:7	measl	NNS	O	O
,	NULOJIX.xml:S3:9305:1	,	,	O	O
mumps	NULOJIX.xml:S3:9307:5	mump	NNS	O	O
,	NULOJIX.xml:S3:9312:1	,	,	O	O
rubella	NULOJIX.xml:S3:9314:7	rubella	NN	O	O
,	NULOJIX.xml:S3:9321:1	,	,	O	O
oral	NULOJIX.xml:S3:9323:4	oral	JJ	O	O
polio	NULOJIX.xml:S3:9328:5	polio	NN	O	O
,	NULOJIX.xml:S3:9333:1	,	,	O	O
BCG	NULOJIX.xml:S3:9335:3	bcg	NNP	O	O
,	NULOJIX.xml:S3:9338:1	,	,	O	O
yellow	NULOJIX.xml:S3:9340:6	yellow	JJ	O	O
fever	NULOJIX.xml:S3:9347:5	fever	NN	O	O
,	NULOJIX.xml:S3:9352:1	,	,	O	O
varicella	NULOJIX.xml:S3:9354:9	varicella	NN	O	O
,	NULOJIX.xml:S3:9363:1	,	,	O	O
and	NULOJIX.xml:S3:9365:3	and	CC	O	O
TY21a	NULOJIX.xml:S3:9369:5	ty21a	NNP	O	O
typhoid	NULOJIX.xml:S3:9375:7	typhoid	JJ	O	O
vaccines	NULOJIX.xml:S3:9383:8	vaccin	NNS	O	O
.	NULOJIX.xml:S3:9391:1	.	.	O	O
6	ONFI.xml:S1:6:1	6	CD	O	O
ADVERSE	ONFI.xml:S1:8:7	advers	JJ	O	O
REACTIONS	ONFI.xml:S1:16:9	reaction	NN	O	O

Clinically	ONFI.xml:S1:31:10	clinic	RB	O	O
significant	ONFI.xml:S1:42:11	signific	JJ	O	O
adverse	ONFI.xml:S1:54:7	advers	JJ	O	O
reactions	ONFI.xml:S1:62:9	reaction	NNS	O	O
that	ONFI.xml:S1:72:4	that	WDT	O	O
appear	ONFI.xml:S1:77:6	appear	VBP	O	O
in	ONFI.xml:S1:84:2	in	IN	O	O
other	ONFI.xml:S1:87:5	other	JJ	O	O
sections	ONFI.xml:S1:93:8	section	NNS	O	O
of	ONFI.xml:S1:102:2	of	IN	O	O
the	ONFI.xml:S1:105:3	the	DT	O	O
labeling	ONFI.xml:S1:109:8	label	VBG	O	O
include	ONFI.xml:S1:118:7	includ	VBP	O	O
the	ONFI.xml:S1:126:3	the	DT	O	O
following	ONFI.xml:S1:130:9	follow	NN	O	O
:	ONFI.xml:S1:139:1	:	:	O	O

Somnolence	ONFI.xml:S1:148:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
or	ONFI.xml:S1:159:2	or	CC	O	O
Sedation	ONFI.xml:S1:162:8	sedat	NNP	B-AdverseReaction	O
[	ONFI.xml:S1:171:1	[	NNP	O	O
see	ONFI.xml:S1:172:3	see	VBP	O	O
Warnings	ONFI.xml:S1:176:8	warn	NNP	O	O
and	ONFI.xml:S1:185:3	and	CC	O	O
Precautions	ONFI.xml:S1:189:11	precaut	NNP	O	O
(	ONFI.xml:S1:201:1	(	(	O	O
5.1	ONFI.xml:S1:204:3	5.1	CD	O	O
)]	ONFI.xml:S1:209:2	)]	NN	O	O

Potentiation	ONFI.xml:S1:218:12	potenti	NN	B-AdverseReaction	O
of	ONFI.xml:S1:231:2	of	IN	I-AdverseReaction	O
Sedation	ONFI.xml:S1:234:8	sedat	NN	I-AdverseReaction	O
from	ONFI.xml:S1:243:4	from	IN	O	O
Concomitant	ONFI.xml:S1:248:11	concomit	NNP	O	O
Use	ONFI.xml:S1:260:3	use	NNP	O	O
with	ONFI.xml:S1:264:4	with	IN	O	O
Central	ONFI.xml:S1:269:7	central	NNP	O	O
Nervous	ONFI.xml:S1:277:7	nervou	NNP	O	O
System	ONFI.xml:S1:285:6	system	NNP	O	O
Depressants	ONFI.xml:S1:292:11	depress	NNP	O	O
[	ONFI.xml:S1:304:1	[	NNP	O	O
see	ONFI.xml:S1:305:3	see	VBP	O	O
Warnings	ONFI.xml:S1:309:8	warn	NNP	O	O
and	ONFI.xml:S1:318:3	and	CC	O	O
Precautions	ONFI.xml:S1:322:11	precaut	NNP	O	O
(	ONFI.xml:S1:334:1	(	(	O	O
5.2	ONFI.xml:S1:337:3	5.2	CD	O	O
)]	ONFI.xml:S1:342:2	)]	NN	O	O

Withdrawal	ONFI.xml:S1:351:10	withdraw	NNP	O	O
Symptoms	ONFI.xml:S1:362:8	symptom	NNP	O	O
[	ONFI.xml:S1:371:1	[	NNP	O	O
see	ONFI.xml:S1:372:3	see	VBP	O	O
Warnings	ONFI.xml:S1:376:8	warn	NNP	O	O
and	ONFI.xml:S1:385:3	and	CC	O	O
Precautions	ONFI.xml:S1:389:11	precaut	NNP	O	O
(	ONFI.xml:S1:401:1	(	(	O	O
5.3	ONFI.xml:S1:406:3	5.3	CD	O	O
)]	ONFI.xml:S1:413:2	)]	NN	O	O

Serious	ONFI.xml:S1:422:7	seriou	JJ	O	O
Dermatological	ONFI.xml:S1:430:14	dermatolog	NNP	B-AdverseReaction	O
Reactions	ONFI.xml:S1:445:9	reaction	NNP	I-AdverseReaction	O
[	ONFI.xml:S1:455:1	[	NNP	O	O
see	ONFI.xml:S1:456:3	see	VBP	O	O
Contraindications	ONFI.xml:S1:460:17	contraind	NNP	O	O
(	ONFI.xml:S1:478:1	(	(	O	O
4	ONFI.xml:S1:481:1	4	CD	O	O
)	ONFI.xml:S1:484:1	)	)	O	O
,	ONFI.xml:S1:485:1	,	,	O	O
Warnings	ONFI.xml:S1:487:8	warn	NNP	O	O
and	ONFI.xml:S1:496:3	and	CC	O	O
Precautions	ONFI.xml:S1:500:11	precaut	NNP	O	O
(	ONFI.xml:S1:512:1	(	(	O	O
5.4	ONFI.xml:S1:517:3	5.4	CD	O	O
)]	ONFI.xml:S1:524:2	)]	NN	O	O

Physical	ONFI.xml:S1:533:8	physic	JJ	B-AdverseReaction	O
and	ONFI.xml:S1:542:3	and	CC	O	O
Psychological	ONFI.xml:S1:546:13	psycholog	JJ	B-AdverseReaction	O
Dependence	ONFI.xml:S1:560:10	depend	NNP	I-AdverseReaction	O
[	ONFI.xml:S1:571:1	[	NNP	O	O
see	ONFI.xml:S1:572:3	see	VBP	O	O
Warnings	ONFI.xml:S1:576:8	warn	NNP	O	O
and	ONFI.xml:S1:585:3	and	CC	O	O
Precautions	ONFI.xml:S1:589:11	precaut	NNP	O	O
(	ONFI.xml:S1:601:1	(	(	O	O
5.5	ONFI.xml:S1:604:3	5.5	CD	O	O
)]	ONFI.xml:S1:609:2	)]	NN	O	O

Suicidal	ONFI.xml:S1:618:8	suicid	NNP	B-AdverseReaction	B-AdverseReaction
Behavior	ONFI.xml:S1:627:8	behavior	NNP	I-AdverseReaction	I-AdverseReaction
and	ONFI.xml:S1:636:3	and	CC	O	O
Ideation	ONFI.xml:S1:640:8	ideat	NNP	I-AdverseReaction	I-AdverseReaction
[	ONFI.xml:S1:649:1	[	NNP	O	O
see	ONFI.xml:S1:650:3	see	VBP	O	O
Warnings	ONFI.xml:S1:654:8	warn	NNP	O	O
and	ONFI.xml:S1:663:3	and	CC	O	O
Precautions	ONFI.xml:S1:667:11	precaut	NNP	O	O
(	ONFI.xml:S1:679:1	(	(	O	O
5.6	ONFI.xml:S1:682:3	5.6	CD	O	O
)]	ONFI.xml:S1:687:2	)]	NN	O	O

EXCERPT	ONFI.xml:S1:698:7	excerpt	NN	O	O
:	ONFI.xml:S1:705:1	:	:	O	O
Adverse	ONFI.xml:S1:709:7	advers	JJ	O	O
reactions	ONFI.xml:S1:717:9	reaction	NNS	O	O
that	ONFI.xml:S1:727:4	that	WDT	O	O
occurred	ONFI.xml:S1:732:8	occur	VBD	O	O
at	ONFI.xml:S1:741:2	at	IN	O	O
least	ONFI.xml:S1:744:5	least	JJS	O	O
10%	ONFI.xml:S1:750:3	10%	CD	O	O
more	ONFI.xml:S1:754:4	more	JJR	O	O
frequently	ONFI.xml:S1:759:10	frequent	RB	O	O
than	ONFI.xml:S1:770:4	than	IN	O	O
placebo	ONFI.xml:S1:775:7	placebo	NN	O	O
in	ONFI.xml:S1:783:2	in	IN	O	O
any	ONFI.xml:S1:786:3	ani	DT	O	O
ONFI	ONFI.xml:S1:790:4	onfi	NNP	O	O
dose	ONFI.xml:S1:795:4	dose	NN	O	O
included	ONFI.xml:S1:800:8	includ	VBD	O	O
constipation	ONFI.xml:S1:809:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:821:1	,	,	O	O
somnolence	ONFI.xml:S1:823:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
or	ONFI.xml:S1:834:2	or	CC	O	O
sedation	ONFI.xml:S1:837:8	sedat	NN	B-AdverseReaction	O
,	ONFI.xml:S1:845:1	,	,	O	O
pyrexia	ONFI.xml:S1:847:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:854:1	,	,	O	O
lethargy	ONFI.xml:S1:856:8	lethargi	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:864:1	,	,	O	O
and	ONFI.xml:S1:866:3	and	CC	O	O
drooling	ONFI.xml:S1:870:8	drool	VBG	B-AdverseReaction	O
(	ONFI.xml:S1:879:1	(	(	O	O
6.1	ONFI.xml:S1:882:3	6.1	CD	O	O
)	ONFI.xml:S1:887:1	)	)	O	O

To	ONFI.xml:S1:898:2	To	TO	O	O

report	ONFI.xml:S1:901:6	report	NN	O	O
SUSPECTED	ONFI.xml:S1:908:9	suspect	NNP	O	O
ADVERSE	ONFI.xml:S1:918:7	advers	NNP	O	O
REACTIONS	ONFI.xml:S1:926:9	reaction	NNP	O	O
,	ONFI.xml:S1:935:1	,	,	O	O
contact	ONFI.xml:S1:937:7	contact	NN	O	O
Lundbeck	ONFI.xml:S1:945:8	lundbeck	NNP	O	O
at	ONFI.xml:S1:954:2	at	IN	O	O
1	ONFI.xml:S1:957:1	1	CD	O	O
-	ONFI.xml:S1:958:1	-	:	O	O
800	ONFI.xml:S1:959:3	800	CD	O	O
-	ONFI.xml:S1:962:1	-	:	O	O
455	ONFI.xml:S1:963:3	455	CD	O	O
-	ONFI.xml:S1:966:1	-	:	O	O
1141	ONFI.xml:S1:967:4	1141	CD	O	O
or	ONFI.xml:S1:972:2	or	CC	O	O
FDA	ONFI.xml:S1:975:3	fda	NNP	O	O
at	ONFI.xml:S1:979:2	at	IN	O	O
1	ONFI.xml:S1:982:1	1	CD	O	O
-	ONFI.xml:S1:983:1	-	:	O	O
800	ONFI.xml:S1:984:3	800	CD	O	O
-	ONFI.xml:S1:987:1	-	:	O	O
FDA	ONFI.xml:S1:988:3	fda	NNP	O	O
-	ONFI.xml:S1:991:1	-	:	O	O
1088	ONFI.xml:S1:992:4	1088	CD	O	O
or	ONFI.xml:S1:997:2	or	CC	O	O
www	ONFI.xml:S1:1003:3	www	VB	O	O
.	ONFI.xml:S1:1006:1	.	.	O	O
fda	ONFI.xml:S1:1007:3	fda	NN	O	O
.	ONFI.xml:S1:1010:1	.	.	O	O
gov	ONFI.xml:S1:1011:3	gov	JJ	O	O
medwatch	ONFI.xml:S1:1015:8	medwatch	NN	O	O
.	ONFI.xml:S1:1025:1	.	.	O	O

6.1	ONFI.xml:S1:1037:3	6.1	CD	O	O

Clinical	ONFI.xml:S1:1041:8	clinic	JJ	O	O
Trials	ONFI.xml:S1:1050:6	trial	NNS	O	O
Experience	ONFI.xml:S1:1057:10	experi	NN	O	O

Because	ONFI.xml:S1:1073:7	becaus	IN	O	O
clinical	ONFI.xml:S1:1081:8	clinic	JJ	O	O
trials	ONFI.xml:S1:1090:6	trial	NNS	O	O
are	ONFI.xml:S1:1097:3	are	VBP	O	O
conducted	ONFI.xml:S1:1101:9	conduct	VBN	O	O
under	ONFI.xml:S1:1111:5	under	IN	O	O
widely	ONFI.xml:S1:1117:6	wide	RB	O	O
varying	ONFI.xml:S1:1124:7	vari	VBG	O	O
conditions	ONFI.xml:S1:1132:10	condit	NNS	O	O
,	ONFI.xml:S1:1142:1	,	,	O	O
adverse	ONFI.xml:S1:1144:7	advers	JJ	O	O
reaction	ONFI.xml:S1:1152:8	reaction	NN	O	O
rates	ONFI.xml:S1:1161:5	rate	NNS	O	O
observed	ONFI.xml:S1:1167:8	observ	VBD	O	O
in	ONFI.xml:S1:1176:2	in	IN	O	O
the	ONFI.xml:S1:1179:3	the	DT	O	O
clinical	ONFI.xml:S1:1183:8	clinic	JJ	O	O
trials	ONFI.xml:S1:1192:6	trial	NNS	O	O
of	ONFI.xml:S1:1199:2	of	IN	O	O
a	ONFI.xml:S1:1202:1	a	DT	O	O
drug	ONFI.xml:S1:1204:4	drug	NN	O	O
cannot	ONFI.xml:S1:1209:6	cannot	NN	O	O
be	ONFI.xml:S1:1216:2	be	VB	O	O
directly	ONFI.xml:S1:1219:8	directli	RB	O	O
compared	ONFI.xml:S1:1228:8	compar	VBN	O	O
to	ONFI.xml:S1:1237:2	to	TO	O	O
rates	ONFI.xml:S1:1240:5	rate	NNS	O	O
in	ONFI.xml:S1:1246:2	in	IN	O	O
the	ONFI.xml:S1:1249:3	the	DT	O	O
clinical	ONFI.xml:S1:1253:8	clinic	JJ	O	O
trials	ONFI.xml:S1:1262:6	trial	NNS	O	O
of	ONFI.xml:S1:1269:2	of	IN	O	O
another	ONFI.xml:S1:1272:7	anoth	DT	O	O
drug	ONFI.xml:S1:1280:4	drug	NN	O	O
and	ONFI.xml:S1:1285:3	and	CC	O	O
may	ONFI.xml:S1:1289:3	may	MD	O	O
not	ONFI.xml:S1:1293:3	not	RB	O	O
reflect	ONFI.xml:S1:1297:7	reflect	VB	O	O
the	ONFI.xml:S1:1305:3	the	DT	O	O
rates	ONFI.xml:S1:1309:5	rate	NNS	O	O
observed	ONFI.xml:S1:1315:8	observ	VBD	O	O
in	ONFI.xml:S1:1324:2	in	IN	O	O
practice	ONFI.xml:S1:1327:8	practic	NN	O	O
.	ONFI.xml:S1:1335:1	.	.	O	O

During	ONFI.xml:S1:1341:6	dure	IN	O	O
its	ONFI.xml:S1:1348:3	it	PRP$	O	O
development	ONFI.xml:S1:1352:11	develop	NN	O	O
for	ONFI.xml:S1:1364:3	for	IN	O	O
the	ONFI.xml:S1:1368:3	the	DT	O	O
adjunctive	ONFI.xml:S1:1372:10	adjunct	JJ	O	O
treatment	ONFI.xml:S1:1383:9	treatment	NN	O	O
of	ONFI.xml:S1:1393:2	of	IN	O	O
seizures	ONFI.xml:S1:1396:8	seizur	NNS	O	O
associated	ONFI.xml:S1:1405:10	associ	VBN	O	O
with	ONFI.xml:S1:1416:4	with	IN	O	O
LGS	ONFI.xml:S1:1421:3	lg	NNP	O	O
,	ONFI.xml:S1:1424:1	,	,	O	O
ONFI	ONFI.xml:S1:1426:4	onfi	NNP	O	O
was	ONFI.xml:S1:1431:3	wa	VBD	O	O
administered	ONFI.xml:S1:1435:12	administ	VBN	O	O
to	ONFI.xml:S1:1448:2	to	TO	O	O
333	ONFI.xml:S1:1451:3	333	CD	O	O
healthy	ONFI.xml:S1:1455:7	healthi	JJ	O	O
volunteers	ONFI.xml:S1:1463:10	volunt	NNS	O	O
and	ONFI.xml:S1:1474:3	and	CC	O	O
300	ONFI.xml:S1:1478:3	300	CD	O	O
patients	ONFI.xml:S1:1482:8	patient	NNS	O	O
with	ONFI.xml:S1:1491:4	with	IN	O	O
a	ONFI.xml:S1:1496:1	a	DT	O	O
current	ONFI.xml:S1:1498:7	current	JJ	O	O
or	ONFI.xml:S1:1506:2	or	CC	O	O
prior	ONFI.xml:S1:1509:5	prior	JJ	O	O
diagnosis	ONFI.xml:S1:1515:9	diagnosi	NN	O	O
of	ONFI.xml:S1:1525:2	of	IN	O	O
LGS	ONFI.xml:S1:1528:3	lg	NNP	O	O
,	ONFI.xml:S1:1531:1	,	,	O	O
including	ONFI.xml:S1:1533:9	includ	VBG	O	O
197	ONFI.xml:S1:1543:3	197	CD	O	O
patients	ONFI.xml:S1:1547:8	patient	NNS	O	O
treated	ONFI.xml:S1:1556:7	treat	VBD	O	O
for	ONFI.xml:S1:1564:3	for	IN	O	O
12	ONFI.xml:S1:1568:2	12	CD	O	O
months	ONFI.xml:S1:1571:6	month	NNS	O	O
or	ONFI.xml:S1:1578:2	or	CC	O	O
more	ONFI.xml:S1:1581:4	more	JJR	O	O
.	ONFI.xml:S1:1585:1	.	.	O	O

The	ONFI.xml:S1:1587:3	the	DT	O	O
conditions	ONFI.xml:S1:1591:10	condit	NNS	O	O
and	ONFI.xml:S1:1602:3	and	CC	O	O
duration	ONFI.xml:S1:1606:8	durat	NN	O	O
of	ONFI.xml:S1:1615:2	of	IN	O	O
exposure	ONFI.xml:S1:1618:8	exposur	NN	O	O
varied	ONFI.xml:S1:1627:6	vari	VBN	O	O
greatly	ONFI.xml:S1:1634:7	greatli	RB	O	O
and	ONFI.xml:S1:1642:3	and	CC	O	O
included	ONFI.xml:S1:1646:8	includ	VBD	O	O
single	ONFI.xml:S1:1655:6	singl	JJ	O	O
-	ONFI.xml:S1:1661:1	-	:	O	O
and	ONFI.xml:S1:1663:3	and	CC	O	O
multiple	ONFI.xml:S1:1667:8	multipl	JJ	O	O
-	ONFI.xml:S1:1675:1	-	:	O	O
dose	ONFI.xml:S1:1676:4	dose	JJ	O	O
clinical	ONFI.xml:S1:1681:8	clinic	JJ	O	O
pharmacology	ONFI.xml:S1:1690:12	pharmacolog	NN	O	O
studies	ONFI.xml:S1:1703:7	studi	NNS	O	O
in	ONFI.xml:S1:1711:2	in	IN	O	O
healthy	ONFI.xml:S1:1714:7	healthi	JJ	O	O
volunteers	ONFI.xml:S1:1722:10	volunt	NNS	O	O
and	ONFI.xml:S1:1733:3	and	CC	O	O
two	ONFI.xml:S1:1737:3	two	CD	O	O
double	ONFI.xml:S1:1741:6	doubl	JJ	O	O
-	ONFI.xml:S1:1747:1	-	:	O	O
blind	ONFI.xml:S1:1748:5	blind	NN	O	O
studies	ONFI.xml:S1:1754:7	studi	NNS	O	O
in	ONFI.xml:S1:1762:2	in	IN	O	O
patients	ONFI.xml:S1:1765:8	patient	NNS	O	O
with	ONFI.xml:S1:1774:4	with	IN	O	O
LGS	ONFI.xml:S1:1779:3	lg	NNP	O	O
(	ONFI.xml:S1:1783:1	(	(	O	O
Study	ONFI.xml:S1:1784:5	studi	NNP	O	O
1	ONFI.xml:S1:1790:1	1	CD	O	O
and	ONFI.xml:S1:1792:3	and	CC	O	O
2	ONFI.xml:S1:1796:1	2	CD	O	O
)	ONFI.xml:S1:1797:1	)	)	O	O
[	ONFI.xml:S1:1800:1	[	NN	O	O
see	ONFI.xml:S1:1801:3	see	VBP	O	O
Clinical	ONFI.xml:S1:1805:8	clinic	JJ	O	O
Studies	ONFI.xml:S1:1814:7	studi	NNP	O	O
(	ONFI.xml:S1:1822:1	(	(	O	O
14	ONFI.xml:S1:1825:2	14	CD	O	O
)]	ONFI.xml:S1:1829:2	)]	NN	O	O
.	ONFI.xml:S1:1833:1	.	.	O	O

Only	ONFI.xml:S1:1835:4	onli	RB	O	O
Study	ONFI.xml:S1:1840:5	studi	NNP	O	O
1	ONFI.xml:S1:1846:1	1	CD	O	O
included	ONFI.xml:S1:1848:8	includ	VBD	O	O
a	ONFI.xml:S1:1857:1	a	DT	O	O
placebo	ONFI.xml:S1:1859:7	placebo	NN	O	O
group	ONFI.xml:S1:1867:5	group	NN	O	O
,	ONFI.xml:S1:1872:1	,	,	O	O
allowing	ONFI.xml:S1:1874:8	allow	VBG	O	O
comparison	ONFI.xml:S1:1883:10	comparison	NN	O	O
of	ONFI.xml:S1:1894:2	of	IN	O	O
adverse	ONFI.xml:S1:1897:7	advers	JJ	O	O
reaction	ONFI.xml:S1:1905:8	reaction	NN	O	O
rates	ONFI.xml:S1:1914:5	rate	NNS	O	O
on	ONFI.xml:S1:1920:2	on	IN	O	O
ONFI	ONFI.xml:S1:1923:4	onfi	NNP	O	O
at	ONFI.xml:S1:1928:2	at	IN	O	O
several	ONFI.xml:S1:1931:7	sever	JJ	O	O
doses	ONFI.xml:S1:1939:5	dose	NNS	O	O
to	ONFI.xml:S1:1945:2	to	TO	O	O
placebo	ONFI.xml:S1:1948:7	placebo	VB	O	O
.	ONFI.xml:S1:1955:1	.	.	O	O

Adverse	ONFI.xml:S1:1963:7	advers	JJ	O	O
Reactions	ONFI.xml:S1:1971:9	reaction	NNP	O	O
Leading	ONFI.xml:S1:1981:7	lead	NNP	O	O
to	ONFI.xml:S1:1989:2	to	TO	O	O
Discontinuation	ONFI.xml:S1:1992:15	discontinu	NNP	O	O
in	ONFI.xml:S1:2008:2	in	IN	O	O
an	ONFI.xml:S1:2011:2	an	DT	O	O
LGS	ONFI.xml:S1:2014:3	lg	NNP	O	O
Placebo	ONFI.xml:S1:2018:7	placebo	NNP	O	O
Controlled	ONFI.xml:S1:2026:10	control	NNP	O	O
Clinical	ONFI.xml:S1:2037:8	clinic	NNP	O	O
Trial	ONFI.xml:S1:2046:5	trial	NNP	O	O
(	ONFI.xml:S1:2052:1	(	(	O	O
Study	ONFI.xml:S1:2053:5	studi	NNP	O	O
1	ONFI.xml:S1:2059:1	1	CD	O	O
)	ONFI.xml:S1:2060:1	)	)	O	O
The	ONFI.xml:S1:2063:3	the	DT	O	O
adverse	ONFI.xml:S1:2067:7	advers	JJ	O	O
reactions	ONFI.xml:S1:2075:9	reaction	NNS	O	O
associated	ONFI.xml:S1:2085:10	associ	VBN	O	O
with	ONFI.xml:S1:2096:4	with	IN	O	O
ONFI	ONFI.xml:S1:2101:4	onfi	NNP	O	O
treatment	ONFI.xml:S1:2106:9	treatment	NN	O	O
discontinuation	ONFI.xml:S1:2116:15	discontinu	NN	O	O
in	ONFI.xml:S1:2132:2	in	IN	O	O
1%	ONFI.xml:S1:2137:2	1%	CD	O	O
of	ONFI.xml:S1:2140:2	of	IN	O	O
patients	ONFI.xml:S1:2143:8	patient	NNS	O	O
in	ONFI.xml:S1:2152:2	in	IN	O	O
decreasing	ONFI.xml:S1:2155:10	decreas	VBG	O	O
order	ONFI.xml:S1:2166:5	order	NN	O	O
of	ONFI.xml:S1:2172:2	of	IN	O	O
frequency	ONFI.xml:S1:2175:9	frequenc	NN	O	O
included	ONFI.xml:S1:2185:8	includ	VBD	O	O
lethargy	ONFI.xml:S1:2194:8	lethargi	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:2202:1	,	,	O	O
somnolence	ONFI.xml:S1:2204:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:2214:1	,	,	O	O
ataxia	ONFI.xml:S1:2216:6	ataxia	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:2222:1	,	,	O	O
aggression	ONFI.xml:S1:2224:10	aggress	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:2234:1	,	,	O	O
fatigue	ONFI.xml:S1:2236:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:2243:1	,	,	O	O
and	ONFI.xml:S1:2245:3	and	CC	O	O
insomnia	ONFI.xml:S1:2249:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
.	ONFI.xml:S1:2257:1	.	.	O	O

Most	ONFI.xml:S1:2265:4	most	JJS	O	O
Common	ONFI.xml:S1:2270:6	common	JJ	O	O
Adverse	ONFI.xml:S1:2277:7	advers	JJ	O	O
Reactions	ONFI.xml:S1:2285:9	reaction	NNP	O	O
in	ONFI.xml:S1:2295:2	in	IN	O	O
an	ONFI.xml:S1:2298:2	an	DT	O	O
LGS	ONFI.xml:S1:2301:3	lg	NNP	O	O
Placebo	ONFI.xml:S1:2305:7	placebo	NNP	O	O
Controlled	ONFI.xml:S1:2313:10	control	NNP	O	O
Clinical	ONFI.xml:S1:2324:8	clinic	NNP	O	O
Trial	ONFI.xml:S1:2333:5	trial	NNP	O	O
(	ONFI.xml:S1:2339:1	(	(	O	O
Study	ONFI.xml:S1:2340:5	studi	NNP	O	O
1	ONFI.xml:S1:2346:1	1	CD	O	O
)	ONFI.xml:S1:2347:1	)	)	O	O
Table	ONFI.xml:S1:2350:5	tabl	NN	O	O
3	ONFI.xml:S1:2356:1	3	CD	O	O
lists	ONFI.xml:S1:2358:5	list	VBZ	O	O
the	ONFI.xml:S1:2364:3	the	DT	O	O
adverse	ONFI.xml:S1:2368:7	advers	JJ	O	O
reactions	ONFI.xml:S1:2376:9	reaction	NNS	O	O
that	ONFI.xml:S1:2386:4	that	WDT	O	O
occurred	ONFI.xml:S1:2391:8	occur	VBD	O	O
in	ONFI.xml:S1:2400:2	in	IN	O	O
5%	ONFI.xml:S1:2405:2	5%	CD	O	O
of	ONFI.xml:S1:2408:2	of	IN	O	O
ONFI	ONFI.xml:S1:2411:4	onfi	NNP	O	O
treated	ONFI.xml:S1:2416:7	treat	VBD	O	O
patients	ONFI.xml:S1:2424:8	patient	NNS	O	O
(	ONFI.xml:S1:2433:1	(	(	O	O
at	ONFI.xml:S1:2434:2	at	IN	O	O
any	ONFI.xml:S1:2437:3	ani	DT	O	O
dose	ONFI.xml:S1:2441:4	dose	NN	O	O
)	ONFI.xml:S1:2445:1	)	)	O	O
,	ONFI.xml:S1:2446:1	,	,	O	O
and	ONFI.xml:S1:2448:3	and	CC	O	O
at	ONFI.xml:S1:2452:2	at	IN	O	O
a	ONFI.xml:S1:2455:1	a	DT	O	O
rate	ONFI.xml:S1:2457:4	rate	NN	O	O
greater	ONFI.xml:S1:2462:7	greater	JJR	O	O
than	ONFI.xml:S1:2470:4	than	IN	O	O
placebo	ONFI.xml:S1:2475:7	placebo	NN	O	O
treated	ONFI.xml:S1:2483:7	treat	VBN	O	O
patients	ONFI.xml:S1:2491:8	patient	NNS	O	O
,	ONFI.xml:S1:2499:1	,	,	O	O
in	ONFI.xml:S1:2501:2	in	IN	O	O
the	ONFI.xml:S1:2504:3	the	DT	O	O
randomized	ONFI.xml:S1:2508:10	random	NN	O	O
,	ONFI.xml:S1:2518:1	,	,	O	O
double	ONFI.xml:S1:2520:6	doubl	JJ	O	O
-	ONFI.xml:S1:2526:1	-	:	O	O
blind	ONFI.xml:S1:2527:5	blind	NN	O	O
,	ONFI.xml:S1:2532:1	,	,	O	O
placebo	ONFI.xml:S1:2534:7	placebo	SYM	O	O
-	ONFI.xml:S1:2541:1	-	:	O	O
controlled	ONFI.xml:S1:2542:10	control	VBN	O	O
,	ONFI.xml:S1:2552:1	,	,	O	O
parallel	ONFI.xml:S1:2554:8	parallel	JJ	O	O
group	ONFI.xml:S1:2563:5	group	NN	O	O
clinical	ONFI.xml:S1:2569:8	clinic	JJ	O	O
study	ONFI.xml:S1:2578:5	studi	NN	O	O
of	ONFI.xml:S1:2584:2	of	IN	O	O
adjunctive	ONFI.xml:S1:2587:10	adjunct	JJ	O	O
AED	ONFI.xml:S1:2598:3	a	NNP	O	O
therapy	ONFI.xml:S1:2602:7	therapi	NN	O	O
for	ONFI.xml:S1:2610:3	for	IN	O	O
15	ONFI.xml:S1:2614:2	15	CD	O	O
weeks	ONFI.xml:S1:2617:5	week	NNS	O	O
(	ONFI.xml:S1:2623:1	(	(	O	O
Study	ONFI.xml:S1:2624:5	studi	NNP	O	O
1	ONFI.xml:S1:2630:1	1	CD	O	O
)	ONFI.xml:S1:2631:1	)	)	O	O
.	ONFI.xml:S1:2632:1	.	.	O	O

Table	ONFI.xml:S1:2638:5	tabl	JJ	O	O
3	ONFI.xml:S1:2644:1	3	CD	O	O
.	ONFI.xml:S1:2645:1	.	.	O	O

Adverse	ONFI.xml:S1:2647:7	advers	JJ	O	O
Reactions	ONFI.xml:S1:2655:9	reaction	NNP	O	O
Reported	ONFI.xml:S1:2665:8	report	VBD	O	O
for	ONFI.xml:S1:2674:3	for	IN	O	O
5%	ONFI.xml:S1:2680:2	5%	CD	O	O
of	ONFI.xml:S1:2683:2	of	IN	O	O
Patients	ONFI.xml:S1:2686:8	patient	NNS	O	O
and	ONFI.xml:S1:2695:3	and	CC	O	O
More	ONFI.xml:S1:2699:4	more	JJR	O	O
Frequently	ONFI.xml:S1:2704:10	frequent	RB	O	O
than	ONFI.xml:S1:2715:4	than	IN	O	O
Placebo	ONFI.xml:S1:2720:7	placebo	NNP	O	O
in	ONFI.xml:S1:2728:2	in	IN	O	O
Any	ONFI.xml:S1:2731:3	ani	NNP	O	O
Treatment	ONFI.xml:S1:2735:9	treatment	NNP	O	O
Group	ONFI.xml:S1:2745:5	group	NNP	O	O

a	ONFI.xml:S1:2755:1	a	DT	O	O
Maximum	ONFI.xml:S1:2758:7	maximum	JJ	O	O
daily	ONFI.xml:S1:2766:5	daili	JJ	O	O
dose	ONFI.xml:S1:2772:4	dose	NN	O	O
of	ONFI.xml:S1:2777:2	of	IN	O	O
5	ONFI.xml:S1:2780:1	5	CD	O	O
mg	ONFI.xml:S1:2782:2	mg	NN	O	O
for	ONFI.xml:S1:2785:3	for	IN	O	O
30	ONFI.xml:S1:2791:2	30	CD	O	O
kg	ONFI.xml:S1:2794:2	kg	NNS	O	O
body	ONFI.xml:S1:2797:4	bodi	NN	O	O
weight	ONFI.xml:S1:2802:6	weight	VBD	O	O
;	ONFI.xml:S1:2808:1	;	:	O	O
10	ONFI.xml:S1:2810:2	10	CD	O	O
mg	ONFI.xml:S1:2813:2	mg	NN	O	O
for	ONFI.xml:S1:2816:3	for	IN	O	O
30	ONFI.xml:S1:2821:2	30	CD	O	O
kg	ONFI.xml:S1:2824:2	kg	NNS	O	O
body	ONFI.xml:S1:2827:4	bodi	NN	O	O
weight	ONFI.xml:S1:2832:6	weight	VBD	O	O
b	ONFI.xml:S1:2840:1	b	JJ	O	O
Maximum	ONFI.xml:S1:2843:7	maximum	NNP	O	O
daily	ONFI.xml:S1:2851:5	daili	JJ	O	O
dose	ONFI.xml:S1:2857:4	dose	NN	O	O
of	ONFI.xml:S1:2862:2	of	IN	O	O
10	ONFI.xml:S1:2865:2	10	CD	O	O
mg	ONFI.xml:S1:2868:2	mg	NN	O	O
for	ONFI.xml:S1:2871:3	for	IN	O	O
30	ONFI.xml:S1:2877:2	30	CD	O	O
kg	ONFI.xml:S1:2880:2	kg	NNS	O	O
body	ONFI.xml:S1:2883:4	bodi	NN	O	O
weight	ONFI.xml:S1:2888:6	weight	VBD	O	O
;	ONFI.xml:S1:2894:1	;	:	O	O
20	ONFI.xml:S1:2896:2	20	CD	O	O
mg	ONFI.xml:S1:2899:2	mg	NN	O	O
for	ONFI.xml:S1:2902:3	for	IN	O	O
30	ONFI.xml:S1:2907:2	30	CD	O	O
kg	ONFI.xml:S1:2910:2	kg	NNS	O	O
body	ONFI.xml:S1:2913:4	bodi	NN	O	O
weight	ONFI.xml:S1:2918:6	weight	VBD	O	O
c	ONFI.xml:S1:2926:1	c	JJ	O	O
Maximum	ONFI.xml:S1:2929:7	maximum	NNP	O	O
daily	ONFI.xml:S1:2937:5	daili	JJ	O	O
dose	ONFI.xml:S1:2943:4	dose	NN	O	O
of	ONFI.xml:S1:2948:2	of	IN	O	O
20	ONFI.xml:S1:2951:2	20	CD	O	O
mg	ONFI.xml:S1:2954:2	mg	NN	O	O
for	ONFI.xml:S1:2957:3	for	IN	O	O
30	ONFI.xml:S1:2963:2	30	CD	O	O
kg	ONFI.xml:S1:2966:2	kg	NNS	O	O
body	ONFI.xml:S1:2969:4	bodi	NN	O	O
weight	ONFI.xml:S1:2974:6	weight	VBD	O	O
;	ONFI.xml:S1:2980:1	;	:	O	O
40	ONFI.xml:S1:2982:2	40	CD	O	O
mg	ONFI.xml:S1:2985:2	mg	NN	O	O
for	ONFI.xml:S1:2988:3	for	IN	O	O
30	ONFI.xml:S1:2993:2	30	CD	O	O
kg	ONFI.xml:S1:2996:2	kg	NNS	O	O
body	ONFI.xml:S1:2999:4	bodi	NN	O	O
weight	ONFI.xml:S1:3004:6	weight	VBD	O	O

Placebo	ONFI.xml:S1:3038:7	placebo	NN	O	O

N	ONFI.xml:S1:3049:1	N	NNP	O	O
59	ONFI.xml:S1:3051:2	59	CD	O	O
ONFI	ONFI.xml:S1:3061:4	onfi	NNP	O	O
Dose	ONFI.xml:S1:3066:4	dose	NNP	O	O
Level	ONFI.xml:S1:3071:5	level	NNP	O	O
All	ONFI.xml:S1:3083:3	all	NNP	O	O
ONFI	ONFI.xml:S1:3087:4	onfi	NNP	O	O
N	ONFI.xml:S1:3095:1	N	NNP	O	O
179	ONFI.xml:S1:3097:3	179	CD	O	O

Low	ONFI.xml:S1:3111:3	low	NNP	O	O
a	ONFI.xml:S1:3116:1	a	DT	O	O
N	ONFI.xml:S1:3123:1	N	NNP	O	O
58	ONFI.xml:S1:3125:2	58	CD	O	O
Medium	ONFI.xml:S1:3135:6	medium	NNP	O	O
b	ONFI.xml:S1:3143:1	b	NN	O	O
N	ONFI.xml:S1:3150:1	N	NNP	O	O
62	ONFI.xml:S1:3152:2	62	CD	O	O
High	ONFI.xml:S1:3162:4	high	NNP	O	O
c	ONFI.xml:S1:3168:1	c	NN	O	O
N	ONFI.xml:S1:3175:1	N	NNP	O	O
59	ONFI.xml:S1:3177:2	59	CD	O	O

Gastrointestinal	ONFI.xml:S1:3190:16	gastrointestin	JJ	O	O
Disorders	ONFI.xml:S1:3207:9	disord	NNS	O	O

Vomiting	ONFI.xml:S1:3229:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
5	ONFI.xml:S1:3242:1	5	CD	O	O
9	ONFI.xml:S1:3259:1	9	CD	O	O
5	ONFI.xml:S1:3276:1	5	CD	O	O
7	ONFI.xml:S1:3293:1	7	CD	O	O
7	ONFI.xml:S1:3310:1	7	CD	O	O

Constipation	ONFI.xml:S1:3334:12	constip	NN	B-AdverseReaction	B-AdverseReaction
0	ONFI.xml:S1:3350:1	0	CD	O	O
2	ONFI.xml:S1:3367:1	2	CD	O	O
2	ONFI.xml:S1:3384:1	2	CD	O	O
10	ONFI.xml:S1:3401:2	10	CD	O	O
5	ONFI.xml:S1:3418:1	5	CD	O	O

Dysphagia	ONFI.xml:S1:3442:9	dysphagia	NNP	B-AdverseReaction	B-AdverseReaction
0	ONFI.xml:S1:3455:1	0	CD	O	O
0	ONFI.xml:S1:3472:1	0	CD	O	O
0	ONFI.xml:S1:3489:1	0	CD	O	O
5	ONFI.xml:S1:3506:1	5	CD	O	O
2	ONFI.xml:S1:3523:1	2	CD	O	O

General	ONFI.xml:S1:3544:7	gener	NNP	O	O
Disorders	ONFI.xml:S1:3552:9	disord	NNP	O	O
and	ONFI.xml:S1:3562:3	and	CC	O	O
Administration	ONFI.xml:S1:3566:14	administr	NNP	O	O
Site	ONFI.xml:S1:3581:4	site	NNP	O	O
Conditions	ONFI.xml:S1:3586:10	condit	NNS	O	O

Pyrexia	ONFI.xml:S1:3609:7	pyrexia	NNP	B-AdverseReaction	B-AdverseReaction
3	ONFI.xml:S1:3622:1	3	CD	O	O
17	ONFI.xml:S1:3639:2	17	CD	O	O
10	ONFI.xml:S1:3656:2	10	CD	O	O
12	ONFI.xml:S1:3673:2	12	CD	O	O
13	ONFI.xml:S1:3690:2	13	CD	O	O

Irritability	ONFI.xml:S1:3714:12	irrit	NNP	B-AdverseReaction	B-AdverseReaction
5	ONFI.xml:S1:3730:1	5	CD	O	O
3	ONFI.xml:S1:3747:1	3	CD	O	O
11	ONFI.xml:S1:3764:2	11	CD	O	O
5	ONFI.xml:S1:3781:1	5	CD	O	O
7	ONFI.xml:S1:3798:1	7	CD	O	O

Fatigue	ONFI.xml:S1:3822:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
2	ONFI.xml:S1:3835:1	2	CD	O	O
5	ONFI.xml:S1:3852:1	5	CD	O	O
5	ONFI.xml:S1:3869:1	5	CD	O	O
3	ONFI.xml:S1:3886:1	3	CD	O	O
5	ONFI.xml:S1:3903:1	5	CD	O	O

Infections	ONFI.xml:S1:3924:10	infect	NNS	O	O
and	ONFI.xml:S1:3935:3	and	CC	O	O
Infestations	ONFI.xml:S1:3939:12	infest	NNS	O	O

Upper	ONFI.xml:S1:3964:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	ONFI.xml:S1:3970:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	ONFI.xml:S1:3982:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	ONFI.xml:S1:3988:9	infect	NN	I-AdverseReaction	I-AdverseReaction
10	ONFI.xml:S1:4001:2	10	CD	O	O
10	ONFI.xml:S1:4018:2	10	CD	O	O
13	ONFI.xml:S1:4035:2	13	CD	O	O
14	ONFI.xml:S1:4052:2	14	CD	O	O
12	ONFI.xml:S1:4069:2	12	CD	O	O

Pneumonia	ONFI.xml:S1:4093:9	pneumonia	NNP	B-AdverseReaction	B-AdverseReaction
2	ONFI.xml:S1:4106:1	2	CD	O	O
3	ONFI.xml:S1:4123:1	3	CD	O	O
3	ONFI.xml:S1:4140:1	3	CD	O	O
7	ONFI.xml:S1:4157:1	7	CD	O	O
4	ONFI.xml:S1:4174:1	4	CD	O	O

Urinary	ONFI.xml:S1:4198:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	ONFI.xml:S1:4206:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	ONFI.xml:S1:4212:9	infect	NN	I-AdverseReaction	I-AdverseReaction
0	ONFI.xml:S1:4225:1	0	CD	O	O
2	ONFI.xml:S1:4242:1	2	CD	O	O
5	ONFI.xml:S1:4259:1	5	CD	O	O
5	ONFI.xml:S1:4276:1	5	CD	O	O
4	ONFI.xml:S1:4293:1	4	CD	O	O

Bronchitis	ONFI.xml:S1:4317:10	bronchiti	NNP	B-AdverseReaction	B-AdverseReaction
0	ONFI.xml:S1:4331:1	0	CD	O	O
2	ONFI.xml:S1:4348:1	2	CD	O	O
0	ONFI.xml:S1:4365:1	0	CD	O	O
5	ONFI.xml:S1:4382:1	5	CD	O	O
2	ONFI.xml:S1:4399:1	2	CD	O	O

Metabolism	ONFI.xml:S1:4420:10	metabol	NN	O	O
and	ONFI.xml:S1:4431:3	and	CC	O	O
Nutrition	ONFI.xml:S1:4435:9	nutrit	NN	O	O
Disorders	ONFI.xml:S1:4445:9	disord	NNS	O	O

Decreased	ONFI.xml:S1:4467:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	ONFI.xml:S1:4477:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
3	ONFI.xml:S1:4489:1	3	CD	O	O
3	ONFI.xml:S1:4506:1	3	CD	O	O
0	ONFI.xml:S1:4523:1	0	CD	O	O
7	ONFI.xml:S1:4540:1	7	CD	O	O
3	ONFI.xml:S1:4557:1	3	CD	O	O

Increased	ONFI.xml:S1:4581:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	ONFI.xml:S1:4591:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
0	ONFI.xml:S1:4603:1	0	CD	O	O
2	ONFI.xml:S1:4620:1	2	CD	O	O
3	ONFI.xml:S1:4637:1	3	CD	O	O
5	ONFI.xml:S1:4654:1	5	CD	O	O
3	ONFI.xml:S1:4671:1	3	CD	O	O

Nervous	ONFI.xml:S1:4692:7	nervou	JJ	O	O
System	ONFI.xml:S1:4700:6	system	NNP	O	O
Disorders	ONFI.xml:S1:4707:9	disord	NNP	O	O

Somnolence	ONFI.xml:S1:4729:10	somnol	NN	B-AdverseReaction	O
or	ONFI.xml:S1:4740:2	or	CC	O	O
Sedation	ONFI.xml:S1:4743:8	sedat	NNP	B-AdverseReaction	O
15	ONFI.xml:S1:4755:2	15	CD	O	O
17	ONFI.xml:S1:4772:2	17	CD	O	O
27	ONFI.xml:S1:4789:2	27	CD	O	O
32	ONFI.xml:S1:4806:2	32	CD	O	O
26	ONFI.xml:S1:4823:2	26	CD	O	O

Somnolence	ONFI.xml:S1:4851:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
12	ONFI.xml:S1:4865:2	12	CD	O	O
16	ONFI.xml:S1:4882:2	16	CD	O	O
24	ONFI.xml:S1:4899:2	24	CD	O	O
25	ONFI.xml:S1:4916:2	25	CD	O	O
22	ONFI.xml:S1:4933:2	22	CD	O	O

Sedation	ONFI.xml:S1:4961:8	sedat	NN	B-AdverseReaction	B-AdverseReaction
3	ONFI.xml:S1:4973:1	3	CD	O	O
2	ONFI.xml:S1:4990:1	2	CD	O	O
3	ONFI.xml:S1:5007:1	3	CD	O	O
9	ONFI.xml:S1:5024:1	9	CD	O	O
5	ONFI.xml:S1:5041:1	5	CD	O	O

Lethargy	ONFI.xml:S1:5065:8	lethargi	NNP	B-AdverseReaction	B-AdverseReaction
5	ONFI.xml:S1:5078:1	5	CD	O	O
10	ONFI.xml:S1:5095:2	10	CD	O	O
5	ONFI.xml:S1:5112:1	5	CD	O	O
15	ONFI.xml:S1:5129:2	15	CD	O	O
10	ONFI.xml:S1:5146:2	10	CD	O	O

Drooling	ONFI.xml:S1:5170:8	drool	VBG	B-AdverseReaction	B-AdverseReaction
3	ONFI.xml:S1:5183:1	3	CD	O	O
0	ONFI.xml:S1:5200:1	0	CD	O	O
13	ONFI.xml:S1:5217:2	13	CD	O	O
14	ONFI.xml:S1:5234:2	14	CD	O	O
9	ONFI.xml:S1:5251:1	9	CD	O	O

Ataxia	ONFI.xml:S1:5275:6	ataxia	NNP	B-AdverseReaction	B-AdverseReaction
3	ONFI.xml:S1:5288:1	3	CD	O	O
3	ONFI.xml:S1:5305:1	3	CD	O	O
2	ONFI.xml:S1:5322:1	2	CD	O	O
10	ONFI.xml:S1:5339:2	10	CD	O	O
5	ONFI.xml:S1:5356:1	5	CD	O	O

Psychomotor	ONFI.xml:S1:5380:11	psychomotor	NNP	B-AdverseReaction	B-AdverseReaction
hyperactivity	ONFI.xml:S1:5392:13	hyperact	NN	I-AdverseReaction	I-AdverseReaction
3	ONFI.xml:S1:5409:1	3	CD	O	O
3	ONFI.xml:S1:5426:1	3	CD	O	O
3	ONFI.xml:S1:5443:1	3	CD	O	O
5	ONFI.xml:S1:5460:1	5	CD	O	O
4	ONFI.xml:S1:5477:1	4	CD	O	O

Dysarthria	ONFI.xml:S1:5501:10	dysarthria	NNP	B-AdverseReaction	B-AdverseReaction
0	ONFI.xml:S1:5515:1	0	CD	O	O
2	ONFI.xml:S1:5532:1	2	CD	O	O
2	ONFI.xml:S1:5549:1	2	CD	O	O
5	ONFI.xml:S1:5566:1	5	CD	O	O
3	ONFI.xml:S1:5583:1	3	CD	O	O

Psychiatric	ONFI.xml:S1:5604:11	psychiatr	JJ	O	O
Disorders	ONFI.xml:S1:5616:9	disord	NNS	O	O

Aggression	ONFI.xml:S1:5638:10	aggress	NNP	B-AdverseReaction	B-AdverseReaction
5	ONFI.xml:S1:5652:1	5	CD	O	O
3	ONFI.xml:S1:5669:1	3	CD	O	O
8	ONFI.xml:S1:5686:1	8	CD	O	O
14	ONFI.xml:S1:5703:2	14	CD	O	O
8	ONFI.xml:S1:5720:1	8	CD	O	O

Insomnia	ONFI.xml:S1:5744:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
2	ONFI.xml:S1:5757:1	2	CD	O	O
2	ONFI.xml:S1:5774:1	2	CD	O	O
5	ONFI.xml:S1:5791:1	5	CD	O	O
7	ONFI.xml:S1:5808:1	7	CD	O	O
5	ONFI.xml:S1:5825:1	5	CD	O	O

Respiratory	ONFI.xml:S1:5846:11	respiratori	NN	O	O
Disorders	ONFI.xml:S1:5858:9	disord	NNS	O	O

Cough	ONFI.xml:S1:5880:5	cough	NNP	B-AdverseReaction	B-AdverseReaction
0	ONFI.xml:S1:5893:1	0	CD	O	O
3	ONFI.xml:S1:5910:1	3	CD	O	O
5	ONFI.xml:S1:5927:1	5	CD	O	O
7	ONFI.xml:S1:5944:1	7	CD	O	O
5	ONFI.xml:S1:5961:1	5	CD	O	O

6.2	ONFI.xml:S1:5994:3	6.2	CD	O	O
Post	ONFI.xml:S1:5998:4	post	NNP	O	O
Marketing	ONFI.xml:S1:6003:9	market	NNP	O	O
Experience	ONFI.xml:S1:6013:10	experi	NN	O	O

These	ONFI.xml:S1:6029:5	these	DT	O	O
reactions	ONFI.xml:S1:6035:9	reaction	NNS	O	O
are	ONFI.xml:S1:6045:3	are	VBP	O	O
reported	ONFI.xml:S1:6049:8	report	VBN	O	O
voluntarily	ONFI.xml:S1:6058:11	voluntarili	RB	O	O
from	ONFI.xml:S1:6070:4	from	IN	O	O
a	ONFI.xml:S1:6075:1	a	DT	O	O
population	ONFI.xml:S1:6077:10	popul	NN	O	O
of	ONFI.xml:S1:6088:2	of	IN	O	O
uncertain	ONFI.xml:S1:6091:9	uncertain	JJ	O	O
size	ONFI.xml:S1:6101:4	size	NN	O	O
;	ONFI.xml:S1:6105:1	;	:	O	O
therefore	ONFI.xml:S1:6107:9	therefor	RB	O	O
,	ONFI.xml:S1:6116:1	,	,	O	O
it	ONFI.xml:S1:6118:2	it	PRP	O	O
is	ONFI.xml:S1:6121:2	is	VBZ	O	O
not	ONFI.xml:S1:6124:3	not	RB	O	O
possible	ONFI.xml:S1:6128:8	possibl	JJ	O	O
to	ONFI.xml:S1:6137:2	to	TO	O	O
estimate	ONFI.xml:S1:6140:8	estim	VB	O	O
their	ONFI.xml:S1:6149:5	their	PRP$	O	O
frequency	ONFI.xml:S1:6155:9	frequenc	NN	O	O
or	ONFI.xml:S1:6165:2	or	CC	O	O
establish	ONFI.xml:S1:6168:9	establish	VB	O	O
a	ONFI.xml:S1:6178:1	a	DT	O	O
causal	ONFI.xml:S1:6180:6	causal	NN	O	O
relationship	ONFI.xml:S1:6187:12	relationship	NN	O	O
to	ONFI.xml:S1:6200:2	to	TO	O	O
drug	ONFI.xml:S1:6203:4	drug	NN	O	O
exposure	ONFI.xml:S1:6208:8	exposur	NN	O	O
.	ONFI.xml:S1:6216:1	.	.	O	O

Adverse	ONFI.xml:S1:6218:7	advers	JJ	O	O
reactions	ONFI.xml:S1:6226:9	reaction	NNS	O	O
are	ONFI.xml:S1:6236:3	are	VBP	O	O
categorized	ONFI.xml:S1:6240:11	categor	VBN	O	O
by	ONFI.xml:S1:6252:2	by	IN	O	O
system	ONFI.xml:S1:6255:6	system	NN	O	O
organ	ONFI.xml:S1:6262:5	organ	JJ	O	O
class	ONFI.xml:S1:6268:5	class	NN	O	O
.	ONFI.xml:S1:6273:1	.	.	O	O

Blood	ONFI.xml:S1:6283:5	blood	NN	O	O
Disorders	ONFI.xml:S1:6289:9	disord	NNS	O	O
:	ONFI.xml:S1:6298:1	:	:	O	O
Anemia	ONFI.xml:S1:6303:6	anemia	NNP	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6309:1	,	,	O	O
eosinophilia	ONFI.xml:S1:6311:12	eosinophilia	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6323:1	,	,	O	O
leukopenia	ONFI.xml:S1:6325:10	leukopenia	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6335:1	,	,	O	O
thrombocytopenia	ONFI.xml:S1:6337:16	thrombocytopenia	NN	B-AdverseReaction	B-AdverseReaction
Eye	ONFI.xml:S1:6357:3	eye	NNP	O	O
Disorders	ONFI.xml:S1:6361:9	disord	NNS	O	O
:	ONFI.xml:S1:6370:1	:	:	O	O
Diplopia	ONFI.xml:S1:6375:8	diplopia	NNP	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6383:1	,	,	O	O
vision	ONFI.xml:S1:6385:6	vision	NN	B-AdverseReaction	B-AdverseReaction
blurred	ONFI.xml:S1:6392:7	blur	VBD	I-AdverseReaction	I-AdverseReaction
Gastrointestinal	ONFI.xml:S1:6403:16	gastrointestin	NNP	O	O
Disorders	ONFI.xml:S1:6420:9	disord	NNS	O	O
:	ONFI.xml:S1:6429:1	:	:	O	O
Abdominal	ONFI.xml:S1:6434:9	abdomin	NNP	B-AdverseReaction	O
distention	ONFI.xml:S1:6444:10	distent	NN	I-AdverseReaction	O
General	ONFI.xml:S1:6458:7	gener	NNP	O	O
Disorders	ONFI.xml:S1:6466:9	disord	NNP	O	O
and	ONFI.xml:S1:6476:3	and	CC	O	O
Administration	ONFI.xml:S1:6480:14	administr	NNP	O	O
Site	ONFI.xml:S1:6495:4	site	NNP	O	O
Conditions	ONFI.xml:S1:6500:10	condit	NNS	O	O
:	ONFI.xml:S1:6510:1	:	:	O	O
Hypothermia	ONFI.xml:S1:6515:11	hypothermia	NNP	B-AdverseReaction	O
Investigations	ONFI.xml:S1:6530:14	investig	NNS	O	O
:	ONFI.xml:S1:6544:1	:	:	O	O
Hepatic	ONFI.xml:S1:6549:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
enzyme	ONFI.xml:S1:6557:6	enzym	NN	I-AdverseReaction	I-AdverseReaction
increased	ONFI.xml:S1:6564:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
Musculoskeletal	ONFI.xml:S1:6577:15	musculoskelet	NNP	O	O
:	ONFI.xml:S1:6592:1	:	:	O	O
Muscle	ONFI.xml:S1:6597:6	muscl	NN	B-AdverseReaction	O
spasms	ONFI.xml:S1:6604:6	spasm	NNS	I-AdverseReaction	O
Psychiatric	ONFI.xml:S1:6614:11	psychiatr	JJ	O	O
Disorders	ONFI.xml:S1:6626:9	disord	NNS	O	O
:	ONFI.xml:S1:6635:1	:	:	O	O
Agitation	ONFI.xml:S1:6640:9	agit	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6649:1	,	,	O	O
anxiety	ONFI.xml:S1:6651:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6658:1	,	,	O	O
apathy	ONFI.xml:S1:6660:6	apathi	JJ	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6666:1	,	,	O	O
confusional	ONFI.xml:S1:6668:11	confusion	JJ	B-AdverseReaction	B-AdverseReaction
state	ONFI.xml:S1:6680:5	state	NN	I-AdverseReaction	I-AdverseReaction
,	ONFI.xml:S1:6685:1	,	,	O	O
depression	ONFI.xml:S1:6687:10	depress	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6697:1	,	,	O	O
delirium	ONFI.xml:S1:6699:8	delirium	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6707:1	,	,	O	O
delusion	ONFI.xml:S1:6709:8	delus	NN	B-AdverseReaction	O
,	ONFI.xml:S1:6717:1	,	,	O	O
hallucination	ONFI.xml:S1:6719:13	hallucin	NN	B-AdverseReaction	O
Renal	ONFI.xml:S1:6736:5	renal	NNP	O	O
and	ONFI.xml:S1:6742:3	and	CC	O	O
Urinary	ONFI.xml:S1:6746:7	urinari	JJ	O	O
Disorders	ONFI.xml:S1:6754:9	disord	NNS	O	O
:	ONFI.xml:S1:6763:1	:	:	O	O
Urinary	ONFI.xml:S1:6768:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
retention	ONFI.xml:S1:6776:9	retent	NN	I-AdverseReaction	I-AdverseReaction
Respiratory	ONFI.xml:S1:6789:11	respiratori	NNP	O	O
Disorders	ONFI.xml:S1:6801:9	disord	NNS	O	O
:	ONFI.xml:S1:6810:1	:	:	O	O
Aspiration	ONFI.xml:S1:6815:10	aspir	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6825:1	,	,	O	O
respiratory	ONFI.xml:S1:6827:11	respiratori	JJ	B-AdverseReaction	B-AdverseReaction
depression	ONFI.xml:S1:6839:10	depress	NN	I-AdverseReaction	I-AdverseReaction
Skin	ONFI.xml:S1:6853:4	skin	NNP	O	O
and	ONFI.xml:S1:6858:3	and	CC	O	O
Subcutaneous	ONFI.xml:S1:6862:12	subcutan	NNP	O	O
Tissue	ONFI.xml:S1:6875:6	tissu	NNP	O	O
Disorders	ONFI.xml:S1:6882:9	disord	NNP	O	O
:	ONFI.xml:S1:6891:1	:	:	O	O
Rash	ONFI.xml:S1:6896:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6900:1	,	,	O	O
urticaria	ONFI.xml:S1:6902:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6911:1	,	,	O	O
angioedema	ONFI.xml:S1:6913:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
,	ONFI.xml:S1:6923:1	,	,	O	O
and	ONFI.xml:S1:6925:3	and	CC	O	O
facial	ONFI.xml:S1:6929:6	facial	JJ	B-AdverseReaction	B-AdverseReaction
and	ONFI.xml:S1:6936:3	and	CC	O	O
lip	ONFI.xml:S1:6940:3	lip	JJ	B-AdverseReaction	B-AdverseReaction
edema	ONFI.xml:S1:6944:5	edema	NN	I-AdverseReaction	I-AdverseReaction
5	ONFI.xml:S2:5:1	5	CD	O	O
WARNINGS	ONFI.xml:S2:7:8	warn	NNP	O	O
AND	ONFI.xml:S2:16:3	and	NNP	O	O
PRECAUTIONS	ONFI.xml:S2:20:11	precaut	NNP	O	O

EXCERPT	ONFI.xml:S2:40:7	excerpt	NN	O	O
:	ONFI.xml:S2:47:1	:	:	O	O
Somnolence	ONFI.xml:S2:55:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
or	ONFI.xml:S2:66:2	or	CC	O	O
Sedation	ONFI.xml:S2:69:8	sedat	NN	B-AdverseReaction	B-AdverseReaction
:	ONFI.xml:S2:77:1	:	:	O	O
Monitor	ONFI.xml:S2:79:7	monitor	NN	O	O
for	ONFI.xml:S2:87:3	for	IN	O	O
central	ONFI.xml:S2:91:7	central	JJ	O	O
nervous	ONFI.xml:S2:99:7	nervou	JJ	O	O
system	ONFI.xml:S2:107:6	system	NN	O	O
(	ONFI.xml:S2:114:1	(	(	O	O
CNS	ONFI.xml:S2:115:3	cn	NNP	O	O
)	ONFI.xml:S2:118:1	)	)	O	O
depression	ONFI.xml:S2:120:10	depress	NN	O	O
.	ONFI.xml:S2:130:1	.	.	O	O

Risk	ONFI.xml:S2:132:4	risk	NN	O	O
may	ONFI.xml:S2:137:3	may	MD	O	O
be	ONFI.xml:S2:141:2	be	VB	O	O
increased	ONFI.xml:S2:144:9	increas	VBN	O	O
with	ONFI.xml:S2:154:4	with	IN	O	O
concomitant	ONFI.xml:S2:159:11	concomit	JJ	O	O
use	ONFI.xml:S2:171:3	use	NN	O	O
of	ONFI.xml:S2:175:2	of	IN	O	O
other	ONFI.xml:S2:178:5	other	JJ	O	O
CNS	ONFI.xml:S2:184:3	cn	NNP	O	O
depressants	ONFI.xml:S2:188:11	depress	NNS	O	O
.	ONFI.xml:S2:199:1	.	.	O	O

(	ONFI.xml:S2:201:1	(	(	O	O
5.1	ONFI.xml:S2:204:3	5.1	CD	O	O
,	ONFI.xml:S2:209:1	,	,	O	O
5.2	ONFI.xml:S2:212:3	5.2	CD	O	O
)	ONFI.xml:S2:217:1	)	)	O	O

Withdrawal	ONFI.xml:S2:224:10	withdraw	NN	O	O
:	ONFI.xml:S2:234:1	:	:	O	O
Symptoms	ONFI.xml:S2:236:8	symptom	NNS	O	O
may	ONFI.xml:S2:245:3	may	MD	O	O
occur	ONFI.xml:S2:249:5	occur	VB	O	O
with	ONFI.xml:S2:255:4	with	IN	O	O
rapid	ONFI.xml:S2:260:5	rapid	JJ	O	O
dose	ONFI.xml:S2:266:4	dose	JJ	O	O
reduction	ONFI.xml:S2:271:9	reduct	NN	O	O
or	ONFI.xml:S2:281:2	or	CC	O	O
discontinuation	ONFI.xml:S2:284:15	discontinu	NN	O	O
.	ONFI.xml:S2:299:1	.	.	O	O

Discontinue	ONFI.xml:S2:301:11	discontinu	NNP	O	O
ONFI	ONFI.xml:S2:313:4	onfi	NNP	O	O
gradually	ONFI.xml:S2:318:9	gradual	RB	O	O
.	ONFI.xml:S2:327:1	.	.	O	O

(	ONFI.xml:S2:329:1	(	(	O	O
5.3	ONFI.xml:S2:332:3	5.3	CD	O	O
)	ONFI.xml:S2:337:1	)	)	O	O

Serious	ONFI.xml:S2:344:7	seriou	JJ	O	O
Dermatological	ONFI.xml:S2:352:14	dermatolog	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	ONFI.xml:S2:367:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
(	ONFI.xml:S2:376:1	(	(	O	O
including	ONFI.xml:S2:377:9	includ	VBG	O	O
Stevens	ONFI.xml:S2:387:7	steven	NNP	B-AdverseReaction	B-AdverseReaction
-	ONFI.xml:S2:394:1	-	:	I-AdverseReaction	I-AdverseReaction
Johnson	ONFI.xml:S2:395:7	johnson	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	ONFI.xml:S2:403:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
and	ONFI.xml:S2:412:3	and	CC	O	O
toxic	ONFI.xml:S2:416:5	toxic	NN	B-AdverseReaction	B-AdverseReaction
epidermal	ONFI.xml:S2:422:9	epiderm	JJ	I-AdverseReaction	I-AdverseReaction
necrolysis	ONFI.xml:S2:432:10	necrolysi	NN	I-AdverseReaction	I-AdverseReaction
)	ONFI.xml:S2:442:1	)	)	O	O
:	ONFI.xml:S2:443:1	:	:	O	O
Discontinue	ONFI.xml:S2:444:11	discontinu	NN	O	O
ONFI	ONFI.xml:S2:456:4	onfi	NNP	O	O
at	ONFI.xml:S2:461:2	at	IN	O	O
first	ONFI.xml:S2:464:5	first	JJ	O	O
sign	ONFI.xml:S2:470:4	sign	NN	O	O
of	ONFI.xml:S2:475:2	of	IN	O	O
rash	ONFI.xml:S2:478:4	rash	NN	O	B-AdverseReaction
unless	ONFI.xml:S2:483:6	unless	IN	O	O
the	ONFI.xml:S2:490:3	the	DT	O	O
rash	ONFI.xml:S2:494:4	rash	NN	O	O
is	ONFI.xml:S2:499:2	is	VBZ	O	O
clearly	ONFI.xml:S2:502:7	clearli	RB	O	O
not	ONFI.xml:S2:510:3	not	RB	O	O
drug	ONFI.xml:S2:514:4	drug	NN	O	O
-	ONFI.xml:S2:518:1	-	:	O	O
related	ONFI.xml:S2:519:7	relat	VBN	O	O
.	ONFI.xml:S2:526:1	.	.	O	O

(	ONFI.xml:S2:528:1	(	(	O	O
5.4	ONFI.xml:S2:531:3	5.4	CD	O	O
)	ONFI.xml:S2:536:1	)	)	O	O

Physical	ONFI.xml:S2:543:8	physic	JJ	B-AdverseReaction	O
and	ONFI.xml:S2:552:3	and	CC	O	O
Psychological	ONFI.xml:S2:556:13	psycholog	JJ	B-AdverseReaction	B-AdverseReaction
Dependence	ONFI.xml:S2:570:10	depend	NN	I-AdverseReaction	I-AdverseReaction
:	ONFI.xml:S2:580:1	:	:	O	O
Monitor	ONFI.xml:S2:582:7	monitor	NN	O	O
patients	ONFI.xml:S2:590:8	patient	NNS	O	O
with	ONFI.xml:S2:599:4	with	IN	O	O
a	ONFI.xml:S2:604:1	a	DT	O	O
history	ONFI.xml:S2:606:7	histori	NN	O	O
of	ONFI.xml:S2:614:2	of	IN	O	O
substance	ONFI.xml:S2:617:9	substanc	NN	O	O
abuse	ONFI.xml:S2:627:5	abus	NN	O	O
for	ONFI.xml:S2:633:3	for	IN	O	O
signs	ONFI.xml:S2:637:5	sign	NNS	O	O
of	ONFI.xml:S2:643:2	of	IN	O	O
habituation	ONFI.xml:S2:646:11	habitu	NN	O	O
and	ONFI.xml:S2:658:3	and	CC	O	O
dependence	ONFI.xml:S2:662:10	depend	NN	O	O
(	ONFI.xml:S2:673:1	(	(	O	O
5.5	ONFI.xml:S2:676:3	5.5	CD	O	O
,	ONFI.xml:S2:681:1	,	,	O	O
9	ONFI.xml:S2:684:1	9	CD	O	O
)	ONFI.xml:S2:687:1	)	)	O	O

Suicidal	ONFI.xml:S2:694:8	suicid	NNP	B-AdverseReaction	B-AdverseReaction
Behavior	ONFI.xml:S2:703:8	behavior	NNP	I-AdverseReaction	I-AdverseReaction
and	ONFI.xml:S2:712:3	and	CC	O	O
Ideation	ONFI.xml:S2:716:8	ideat	NNP	I-AdverseReaction	I-AdverseReaction
:	ONFI.xml:S2:724:1	:	:	O	O
Monitor	ONFI.xml:S2:726:7	monitor	NN	O	O
for	ONFI.xml:S2:734:3	for	IN	O	O
suicidal	ONFI.xml:S2:738:8	suicid	JJ	O	O
thoughts	ONFI.xml:S2:747:8	thought	NNS	O	O
or	ONFI.xml:S2:756:2	or	CC	O	O
behaviors	ONFI.xml:S2:759:9	behavior	NNS	O	I-AdverseReaction
(	ONFI.xml:S2:769:1	(	(	O	O
5.6	ONFI.xml:S2:772:3	5.6	CD	O	O
)	ONFI.xml:S2:777:1	)	)	O	O

5.1	ONFI.xml:S2:792:3	5.1	CD	O	O

Somnolence	ONFI.xml:S2:796:10	somnol	NN	O	O

or	ONFI.xml:S2:807:2	or	CC	O	O
Sedation	ONFI.xml:S2:810:8	sedat	NN	O	O

ONFI	ONFI.xml:S2:826:4	onfi	NNP	O	O
causes	ONFI.xml:S2:831:6	caus	VBZ	O	O
somnolence	ONFI.xml:S2:838:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
and	ONFI.xml:S2:849:3	and	CC	O	O
sedation	ONFI.xml:S2:853:8	sedat	NN	B-AdverseReaction	O
.	ONFI.xml:S2:861:1	.	.	O	O

In	ONFI.xml:S2:863:2	In	IN	O	O
clinical	ONFI.xml:S2:866:8	clinic	JJ	O	O
trials	ONFI.xml:S2:875:6	trial	NNS	O	O
,	ONFI.xml:S2:881:1	,	,	O	O
somnolence	ONFI.xml:S2:883:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
or	ONFI.xml:S2:894:2	or	CC	O	O
sedation	ONFI.xml:S2:897:8	sedat	NN	B-AdverseReaction	B-AdverseReaction
was	ONFI.xml:S2:906:3	wa	VBD	O	O
reported	ONFI.xml:S2:910:8	report	VBN	O	O
at	ONFI.xml:S2:919:2	at	IN	O	O
all	ONFI.xml:S2:922:3	all	DT	O	O
effective	ONFI.xml:S2:926:9	effect	JJ	O	O
doses	ONFI.xml:S2:936:5	dose	NNS	O	O
and	ONFI.xml:S2:942:3	and	CC	O	O
was	ONFI.xml:S2:946:3	wa	VBD	O	O
dose	ONFI.xml:S2:950:4	dose	JJ	O	O
-	ONFI.xml:S2:954:1	-	:	O	O
related	ONFI.xml:S2:955:7	relat	VBN	O	O
.	ONFI.xml:S2:962:1	.	.	O	O

In	ONFI.xml:S2:968:2	In	IN	O	O
general	ONFI.xml:S2:971:7	gener	JJ	O	O
,	ONFI.xml:S2:978:1	,	,	O	O
somnolence	ONFI.xml:S2:980:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
and	ONFI.xml:S2:991:3	and	CC	O	O
sedation	ONFI.xml:S2:995:8	sedat	NN	B-AdverseReaction	O
begin	ONFI.xml:S2:1004:5	begin	NN	O	O
within	ONFI.xml:S2:1010:6	within	IN	O	O
the	ONFI.xml:S2:1017:3	the	DT	O	O
first	ONFI.xml:S2:1021:5	first	JJ	O	O
month	ONFI.xml:S2:1027:5	month	NN	O	O
of	ONFI.xml:S2:1033:2	of	IN	O	O
treatment	ONFI.xml:S2:1036:9	treatment	NN	O	O
and	ONFI.xml:S2:1046:3	and	CC	O	O
may	ONFI.xml:S2:1050:3	may	MD	O	O
diminish	ONFI.xml:S2:1054:8	diminish	VB	O	O
with	ONFI.xml:S2:1063:4	with	IN	O	O
continued	ONFI.xml:S2:1068:9	continu	JJ	O	O
treatment	ONFI.xml:S2:1078:9	treatment	NN	O	O
.	ONFI.xml:S2:1087:1	.	.	O	O

Prescribers	ONFI.xml:S2:1089:11	prescrib	NNS	O	O
should	ONFI.xml:S2:1101:6	should	MD	O	O
monitor	ONFI.xml:S2:1108:7	monitor	VB	O	O
patients	ONFI.xml:S2:1116:8	patient	NNS	O	O
for	ONFI.xml:S2:1125:3	for	IN	O	O
somnolence	ONFI.xml:S2:1129:10	somnol	NN	O	O
and	ONFI.xml:S2:1140:3	and	CC	O	O
sedation	ONFI.xml:S2:1144:8	sedat	NN	O	O
,	ONFI.xml:S2:1152:1	,	,	O	O
particularly	ONFI.xml:S2:1154:12	particularli	RB	O	O
with	ONFI.xml:S2:1167:4	with	IN	O	O
concomitant	ONFI.xml:S2:1172:11	concomit	JJ	O	O
use	ONFI.xml:S2:1184:3	use	NN	O	O
of	ONFI.xml:S2:1188:2	of	IN	O	O
other	ONFI.xml:S2:1191:5	other	JJ	O	O
central	ONFI.xml:S2:1197:7	central	JJ	O	O
nervous	ONFI.xml:S2:1205:7	nervou	JJ	O	O
system	ONFI.xml:S2:1213:6	system	NN	O	O
depressants	ONFI.xml:S2:1220:11	depress	NNS	O	O
.	ONFI.xml:S2:1231:1	.	.	O	O

Prescribers	ONFI.xml:S2:1233:11	prescrib	NNS	O	O
should	ONFI.xml:S2:1245:6	should	MD	O	O
caution	ONFI.xml:S2:1252:7	caution	VB	O	O
patients	ONFI.xml:S2:1260:8	patient	NNS	O	O
against	ONFI.xml:S2:1269:7	against	IN	O	O
engaging	ONFI.xml:S2:1277:8	engag	VBG	O	O
in	ONFI.xml:S2:1286:2	in	IN	O	O
hazardous	ONFI.xml:S2:1289:9	hazard	JJ	O	O
activities	ONFI.xml:S2:1299:10	activ	NNS	O	O
requiring	ONFI.xml:S2:1310:9	requir	VBG	O	O
mental	ONFI.xml:S2:1320:6	mental	JJ	O	O
alertness	ONFI.xml:S2:1327:9	alert	NN	O	O
,	ONFI.xml:S2:1336:1	,	,	O	O
such	ONFI.xml:S2:1338:4	such	JJ	O	O
as	ONFI.xml:S2:1343:2	as	IN	O	O
operating	ONFI.xml:S2:1346:9	oper	VBG	O	O
dangerous	ONFI.xml:S2:1356:9	danger	JJ	O	O
machinery	ONFI.xml:S2:1366:9	machineri	NN	O	O
or	ONFI.xml:S2:1376:2	or	CC	O	O
motor	ONFI.xml:S2:1379:5	motor	NN	O	O
vehicles	ONFI.xml:S2:1385:8	vehicl	NNS	O	O
,	ONFI.xml:S2:1393:1	,	,	O	O
until	ONFI.xml:S2:1395:5	until	IN	O	O
the	ONFI.xml:S2:1401:3	the	DT	O	O
effect	ONFI.xml:S2:1405:6	effect	NN	O	O
of	ONFI.xml:S2:1412:2	of	IN	O	O
ONFI	ONFI.xml:S2:1415:4	onfi	NNP	O	O
is	ONFI.xml:S2:1420:2	is	VBZ	O	O
known	ONFI.xml:S2:1423:5	known	VBN	O	O
.	ONFI.xml:S2:1428:1	.	.	O	O

5.2	ONFI.xml:S2:1438:3	5.2	CD	O	O
Potentiation	ONFI.xml:S2:1442:12	potenti	NN	O	O
of	ONFI.xml:S2:1455:2	of	IN	O	O
Sedation	ONFI.xml:S2:1458:8	sedat	NN	O	O
from	ONFI.xml:S2:1467:4	from	IN	O	O
Concomitant	ONFI.xml:S2:1472:11	concomit	NNP	O	O
Use	ONFI.xml:S2:1484:3	use	NNP	O	O
with	ONFI.xml:S2:1488:4	with	IN	O	O
Central	ONFI.xml:S2:1493:7	central	NNP	O	O
Nervous	ONFI.xml:S2:1501:7	nervou	NNP	O	O
System	ONFI.xml:S2:1509:6	system	NNP	O	O
Depressants	ONFI.xml:S2:1516:11	depress	NNP	O	O

Since	ONFI.xml:S2:1535:5	sinc	IN	O	O
ONFI	ONFI.xml:S2:1541:4	onfi	NNP	O	O
has	ONFI.xml:S2:1546:3	ha	VBZ	O	O
a	ONFI.xml:S2:1550:1	a	DT	O	O
central	ONFI.xml:S2:1552:7	central	JJ	O	O
nervous	ONFI.xml:S2:1560:7	nervou	JJ	O	O
system	ONFI.xml:S2:1568:6	system	NN	O	O
(	ONFI.xml:S2:1575:1	(	(	O	O
CNS	ONFI.xml:S2:1576:3	cn	NNP	O	O
)	ONFI.xml:S2:1579:1	)	)	O	O
depressant	ONFI.xml:S2:1581:10	depress	NN	O	O
effect	ONFI.xml:S2:1592:6	effect	NN	O	O
,	ONFI.xml:S2:1598:1	,	,	O	O
patients	ONFI.xml:S2:1600:8	patient	NNS	O	O
or	ONFI.xml:S2:1609:2	or	CC	O	O
their	ONFI.xml:S2:1612:5	their	PRP$	O	O
caregivers	ONFI.xml:S2:1618:10	caregiv	NNS	O	O
should	ONFI.xml:S2:1629:6	should	MD	O	O
be	ONFI.xml:S2:1636:2	be	VB	O	O
cautioned	ONFI.xml:S2:1639:9	caution	VBN	O	O
against	ONFI.xml:S2:1649:7	against	IN	O	O
simultaneous	ONFI.xml:S2:1657:12	simultan	JJ	O	O
use	ONFI.xml:S2:1670:3	use	NN	O	O
with	ONFI.xml:S2:1674:4	with	IN	O	O
other	ONFI.xml:S2:1679:5	other	JJ	O	O
CNS	ONFI.xml:S2:1685:3	cn	NNP	O	O
depressant	ONFI.xml:S2:1689:10	depress	NN	O	O
drugs	ONFI.xml:S2:1700:5	drug	NNS	O	O
or	ONFI.xml:S2:1706:2	or	CC	O	O
alcohol	ONFI.xml:S2:1709:7	alcohol	NN	O	O
,	ONFI.xml:S2:1716:1	,	,	O	O
and	ONFI.xml:S2:1718:3	and	CC	O	O
cautioned	ONFI.xml:S2:1722:9	caution	VBD	O	O
that	ONFI.xml:S2:1732:4	that	IN	O	O
the	ONFI.xml:S2:1737:3	the	DT	O	O
effects	ONFI.xml:S2:1741:7	effect	NNS	O	O
of	ONFI.xml:S2:1749:2	of	IN	O	O
other	ONFI.xml:S2:1752:5	other	JJ	O	O
CNS	ONFI.xml:S2:1758:3	cn	NNP	O	O
depressant	ONFI.xml:S2:1762:10	depress	NN	O	O
drugs	ONFI.xml:S2:1773:5	drug	NNS	O	O
or	ONFI.xml:S2:1779:2	or	CC	O	O
alcohol	ONFI.xml:S2:1782:7	alcohol	NN	O	O
may	ONFI.xml:S2:1790:3	may	MD	O	O
be	ONFI.xml:S2:1794:2	be	VB	O	O
potentiated	ONFI.xml:S2:1797:11	potenti	VBN	O	O
.	ONFI.xml:S2:1808:1	.	.	O	O

5.3	ONFI.xml:S2:1818:3	5.3	CD	O	O
Withdrawal	ONFI.xml:S2:1822:10	withdraw	NNP	O	O
Symptoms	ONFI.xml:S2:1833:8	symptom	NNP	O	O

Abrupt	ONFI.xml:S2:1849:6	abrupt	NNP	O	O
discontinuation	ONFI.xml:S2:1856:15	discontinu	NN	O	O
of	ONFI.xml:S2:1872:2	of	IN	O	O
ONFI	ONFI.xml:S2:1875:4	onfi	NNP	O	O
should	ONFI.xml:S2:1880:6	should	MD	O	O
be	ONFI.xml:S2:1887:2	be	VB	O	O
avoided	ONFI.xml:S2:1890:7	avoid	VBN	O	O
.	ONFI.xml:S2:1897:1	.	.	O	O

ONFI	ONFI.xml:S2:1899:4	onfi	NNP	O	O
should	ONFI.xml:S2:1904:6	should	MD	O	O
be	ONFI.xml:S2:1911:2	be	VB	O	O
tapered	ONFI.xml:S2:1914:7	taper	VBN	O	O
by	ONFI.xml:S2:1922:2	by	IN	O	O
decreasing	ONFI.xml:S2:1925:10	decreas	VBG	O	O
the	ONFI.xml:S2:1936:3	the	DT	O	O
dose	ONFI.xml:S2:1940:4	dose	NN	O	O
every	ONFI.xml:S2:1945:5	everi	DT	O	O
week	ONFI.xml:S2:1951:4	week	NN	O	O
by	ONFI.xml:S2:1956:2	by	IN	O	O
5	ONFI.xml:S2:1959:1	5	CD	O	O
-	ONFI.xml:S2:1960:1	-	:	O	O
10	ONFI.xml:S2:1961:2	10	CD	O	O
mg	ONFI.xml:S2:1964:2	mg	JJ	O	O
day	ONFI.xml:S2:1967:3	day	NN	O	O
until	ONFI.xml:S2:1971:5	until	IN	O	O
discontinuation	ONFI.xml:S2:1977:15	discontinu	NN	O	O
[	ONFI.xml:S2:1993:1	[	NNP	O	O
see	ONFI.xml:S2:1994:3	see	VBP	O	O
Dosage	ONFI.xml:S2:1998:6	dosag	NNP	O	O
and	ONFI.xml:S2:2005:3	and	CC	O	O
Administration	ONFI.xml:S2:2009:14	administr	NNP	O	O
(	ONFI.xml:S2:2024:1	(	(	O	O
2.2	ONFI.xml:S2:2027:3	2.2	CD	O	O
)]	ONFI.xml:S2:2032:2	)]	NN	O	O
.	ONFI.xml:S2:2036:1	.	.	O	O

Withdrawal	ONFI.xml:S2:2042:10	withdraw	NNP	O	O
symptoms	ONFI.xml:S2:2053:8	symptom	NNS	O	O
occurred	ONFI.xml:S2:2062:8	occur	VBD	O	O
following	ONFI.xml:S2:2071:9	follow	VBG	O	O
abrupt	ONFI.xml:S2:2081:6	abrupt	JJ	O	O
discontinuation	ONFI.xml:S2:2088:15	discontinu	NN	O	O
of	ONFI.xml:S2:2104:2	of	IN	O	O
ONFI	ONFI.xml:S2:2107:4	onfi	NNP	O	O
;	ONFI.xml:S2:2111:1	;	:	O	O
the	ONFI.xml:S2:2113:3	the	DT	O	O
risk	ONFI.xml:S2:2117:4	risk	NN	O	O
of	ONFI.xml:S2:2122:2	of	IN	O	O
withdrawal	ONFI.xml:S2:2125:10	withdraw	NN	O	O
symptoms	ONFI.xml:S2:2136:8	symptom	NNS	O	O
is	ONFI.xml:S2:2145:2	is	VBZ	O	O
greater	ONFI.xml:S2:2148:7	greater	JJR	O	O
with	ONFI.xml:S2:2156:4	with	IN	O	O
higher	ONFI.xml:S2:2161:6	higher	JJR	O	O
doses	ONFI.xml:S2:2168:5	dose	NNS	O	O
.	ONFI.xml:S2:2173:1	.	.	O	O

As	ONFI.xml:S2:2179:2	As	IN	O	O
with	ONFI.xml:S2:2182:4	with	IN	O	O
all	ONFI.xml:S2:2187:3	all	DT	O	O
antiepileptic	ONFI.xml:S2:2191:13	antiepilept	JJ	O	O
drugs	ONFI.xml:S2:2205:5	drug	NNS	O	O
,	ONFI.xml:S2:2210:1	,	,	O	O
ONFI	ONFI.xml:S2:2212:4	onfi	NNP	O	O
should	ONFI.xml:S2:2217:6	should	MD	O	O
be	ONFI.xml:S2:2224:2	be	VB	O	O
withdrawn	ONFI.xml:S2:2227:9	withdrawn	VBN	O	O
gradually	ONFI.xml:S2:2237:9	gradual	RB	O	O
to	ONFI.xml:S2:2247:2	to	TO	O	O
minimize	ONFI.xml:S2:2250:8	minim	VB	O	O
the	ONFI.xml:S2:2259:3	the	DT	O	O
risk	ONFI.xml:S2:2263:4	risk	NN	O	O
of	ONFI.xml:S2:2268:2	of	IN	O	O
precipitating	ONFI.xml:S2:2271:13	precipit	VBG	O	O
seizures	ONFI.xml:S2:2285:8	seizur	NNS	O	O
,	ONFI.xml:S2:2293:1	,	,	O	O
seizure	ONFI.xml:S2:2295:7	seizur	NN	O	B-AdverseReaction
exacerbation	ONFI.xml:S2:2303:12	exacerb	NN	O	I-AdverseReaction
,	ONFI.xml:S2:2315:1	,	,	O	O
or	ONFI.xml:S2:2317:2	or	CC	O	O
status	ONFI.xml:S2:2320:6	statu	NN	O	O
epilepticus	ONFI.xml:S2:2327:11	epilepticu	NN	O	O
.	ONFI.xml:S2:2338:1	.	.	O	O

Withdrawal	ONFI.xml:S2:2344:10	withdraw	NN	O	O
symptoms	ONFI.xml:S2:2355:8	symptom	NNS	O	O
(	ONFI.xml:S2:2364:1	(	(	O	O
e	ONFI.xml:S2:2365:1	e	NN	O	O
.	ONFI.xml:S2:2366:1	.	.	O	O
g	ONFI.xml:S2:2367:1	g	NN	O	O
.	ONFI.xml:S2:2368:1	.	.	O	O
,	ONFI.xml:S2:2369:1	,	,	O	O
convulsions	ONFI.xml:S2:2371:11	convuls	NNS	O	O
,	ONFI.xml:S2:2382:1	,	,	O	O
psychosis	ONFI.xml:S2:2384:9	psychosi	NN	O	O
,	ONFI.xml:S2:2393:1	,	,	O	O
hallucinations	ONFI.xml:S2:2395:14	hallucin	NNS	O	O
,	ONFI.xml:S2:2409:1	,	,	O	O
behavioral	ONFI.xml:S2:2411:10	behavior	JJ	O	B-AdverseReaction
disorder	ONFI.xml:S2:2422:8	disord	NN	O	I-AdverseReaction
,	ONFI.xml:S2:2430:1	,	,	O	O
tremor	ONFI.xml:S2:2432:6	tremor	NN	O	B-AdverseReaction
,	ONFI.xml:S2:2438:1	,	,	O	O
and	ONFI.xml:S2:2440:3	and	CC	O	O
anxiety	ONFI.xml:S2:2444:7	anxieti	NN	O	B-AdverseReaction
)	ONFI.xml:S2:2451:1	)	)	O	O
have	ONFI.xml:S2:2453:4	have	VBP	O	O
been	ONFI.xml:S2:2458:4	been	VBN	O	O
reported	ONFI.xml:S2:2463:8	report	VBN	O	O
following	ONFI.xml:S2:2472:9	follow	VBG	O	O
abrupt	ONFI.xml:S2:2482:6	abrupt	JJ	O	O
discontinuance	ONFI.xml:S2:2489:14	discontinu	NN	O	O
of	ONFI.xml:S2:2504:2	of	IN	O	O
benzodiazepines	ONFI.xml:S2:2507:15	benzodiazepin	NNS	O	O
.	ONFI.xml:S2:2522:1	.	.	O	O

The	ONFI.xml:S2:2524:3	the	DT	O	O
more	ONFI.xml:S2:2528:4	more	RBR	O	O
severe	ONFI.xml:S2:2533:6	sever	JJ	O	O
withdrawal	ONFI.xml:S2:2540:10	withdraw	NN	O	O
symptoms	ONFI.xml:S2:2551:8	symptom	NNS	O	O
have	ONFI.xml:S2:2560:4	have	VBP	O	O
usually	ONFI.xml:S2:2565:7	usual	RB	O	O
been	ONFI.xml:S2:2573:4	been	VBN	O	O
limited	ONFI.xml:S2:2578:7	limit	VBN	O	O
to	ONFI.xml:S2:2586:2	to	TO	O	O
patients	ONFI.xml:S2:2589:8	patient	NNS	O	O
who	ONFI.xml:S2:2598:3	who	WP	O	O
received	ONFI.xml:S2:2602:8	receiv	VBD	O	O
excessive	ONFI.xml:S2:2611:9	excess	JJ	O	O
doses	ONFI.xml:S2:2621:5	dose	NNS	O	O
over	ONFI.xml:S2:2627:4	over	IN	O	O
an	ONFI.xml:S2:2632:2	an	DT	O	O
extended	ONFI.xml:S2:2635:8	extend	JJ	O	O
period	ONFI.xml:S2:2644:6	period	NN	O	O
of	ONFI.xml:S2:2651:2	of	IN	O	O
time	ONFI.xml:S2:2654:4	time	NN	O	O
,	ONFI.xml:S2:2658:1	,	,	O	O
followed	ONFI.xml:S2:2660:8	follow	VBN	O	O
by	ONFI.xml:S2:2669:2	by	IN	O	O
an	ONFI.xml:S2:2672:2	an	DT	O	O
abrupt	ONFI.xml:S2:2675:6	abrupt	JJ	O	O
discontinuation	ONFI.xml:S2:2682:15	discontinu	NN	O	O
.	ONFI.xml:S2:2697:1	.	.	O	O

Generally	ONFI.xml:S2:2699:9	gener	RB	O	O
milder	ONFI.xml:S2:2709:6	milder	JJR	O	O
withdrawal	ONFI.xml:S2:2716:10	withdraw	NN	O	O
symptoms	ONFI.xml:S2:2727:8	symptom	NNS	O	O
(	ONFI.xml:S2:2736:1	(	(	O	O
e	ONFI.xml:S2:2737:1	e	NN	O	O
.	ONFI.xml:S2:2738:1	.	.	O	O
g	ONFI.xml:S2:2739:1	g	NN	O	O
.	ONFI.xml:S2:2740:1	.	.	O	O
,	ONFI.xml:S2:2741:1	,	,	O	O
dysphoria	ONFI.xml:S2:2743:9	dysphoria	NN	O	O
,	ONFI.xml:S2:2752:1	,	,	O	O
anxiety	ONFI.xml:S2:2754:7	anxieti	NN	O	B-AdverseReaction
,	ONFI.xml:S2:2761:1	,	,	O	O
and	ONFI.xml:S2:2763:3	and	CC	O	O
insomnia	ONFI.xml:S2:2767:8	insomnia	NN	O	B-AdverseReaction
)	ONFI.xml:S2:2775:1	)	)	O	O
have	ONFI.xml:S2:2777:4	have	VBP	O	O
been	ONFI.xml:S2:2782:4	been	VBN	O	O
reported	ONFI.xml:S2:2787:8	report	VBN	O	O
following	ONFI.xml:S2:2796:9	follow	VBG	O	O
abrupt	ONFI.xml:S2:2806:6	abrupt	JJ	O	O
discontinuance	ONFI.xml:S2:2813:14	discontinu	NN	O	O
of	ONFI.xml:S2:2828:2	of	IN	O	O
benzodiazepines	ONFI.xml:S2:2831:15	benzodiazepin	NNS	O	O
taken	ONFI.xml:S2:2847:5	taken	VBN	O	O
continuously	ONFI.xml:S2:2853:12	continu	RB	O	O
at	ONFI.xml:S2:2866:2	at	IN	O	O
therapeutic	ONFI.xml:S2:2869:11	therapeut	JJ	O	O
doses	ONFI.xml:S2:2881:5	dose	NNS	O	O
for	ONFI.xml:S2:2887:3	for	IN	O	O
several	ONFI.xml:S2:2891:7	sever	JJ	O	O
months	ONFI.xml:S2:2899:6	month	NNS	O	O
.	ONFI.xml:S2:2905:1	.	.	O	O

5.4	ONFI.xml:S2:2915:3	5.4	CD	O	O
Serious	ONFI.xml:S2:2919:7	seriou	JJ	O	O
Dermatological	ONFI.xml:S2:2927:14	dermatolog	NNP	O	O
Reactions	ONFI.xml:S2:2942:9	reaction	NNP	O	O

Serious	ONFI.xml:S2:2959:7	seriou	JJ	O	O
skin	ONFI.xml:S2:2967:4	skin	NN	B-AdverseReaction	B-AdverseReaction
reactions	ONFI.xml:S2:2972:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	ONFI.xml:S2:2981:1	,	,	O	O
including	ONFI.xml:S2:2983:9	includ	VBG	O	O
Stevens	ONFI.xml:S2:2993:7	steven	NNP	B-AdverseReaction	B-AdverseReaction
-	ONFI.xml:S2:3000:1	-	:	I-AdverseReaction	I-AdverseReaction
Johnson	ONFI.xml:S2:3001:7	johnson	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	ONFI.xml:S2:3009:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
(	ONFI.xml:S2:3018:1	(	(	O	O
SJS	ONFI.xml:S2:3019:3	sj	NNP	B-AdverseReaction	B-AdverseReaction
)	ONFI.xml:S2:3022:1	)	)	O	O
and	ONFI.xml:S2:3024:3	and	CC	O	O
toxic	ONFI.xml:S2:3028:5	toxic	JJ	B-AdverseReaction	B-AdverseReaction
epidermal	ONFI.xml:S2:3034:9	epiderm	JJ	I-AdverseReaction	I-AdverseReaction
necrolysis	ONFI.xml:S2:3044:10	necrolysi	NN	I-AdverseReaction	I-AdverseReaction
(	ONFI.xml:S2:3055:1	(	(	O	O
TEN	ONFI.xml:S2:3056:3	ten	NNP	B-AdverseReaction	B-AdverseReaction
)	ONFI.xml:S2:3059:1	)	)	O	O
,	ONFI.xml:S2:3060:1	,	,	O	O
have	ONFI.xml:S2:3062:4	have	VBP	O	O
been	ONFI.xml:S2:3067:4	been	VBN	O	O
reported	ONFI.xml:S2:3072:8	report	VBN	O	O
with	ONFI.xml:S2:3081:4	with	IN	O	O
ONFI	ONFI.xml:S2:3086:4	onfi	NNP	O	O
in	ONFI.xml:S2:3091:2	in	IN	O	O
both	ONFI.xml:S2:3094:4	both	DT	O	O
children	ONFI.xml:S2:3099:8	children	NNS	O	O
and	ONFI.xml:S2:3108:3	and	CC	O	O
adults	ONFI.xml:S2:3112:6	adult	NNS	O	O
during	ONFI.xml:S2:3119:6	dure	IN	O	O
the	ONFI.xml:S2:3126:3	the	DT	O	O
post	ONFI.xml:S2:3130:4	post	NN	O	O
-	ONFI.xml:S2:3134:1	-	:	O	O
marketing	ONFI.xml:S2:3135:9	market	NN	O	O
period	ONFI.xml:S2:3145:6	period	NN	O	O
.	ONFI.xml:S2:3151:1	.	.	O	O

Patients	ONFI.xml:S2:3154:8	patient	NNS	O	O
should	ONFI.xml:S2:3163:6	should	MD	O	O
be	ONFI.xml:S2:3170:2	be	VB	O	O
closely	ONFI.xml:S2:3173:7	close	RB	O	O
monitored	ONFI.xml:S2:3181:9	monitor	VBN	O	O
for	ONFI.xml:S2:3191:3	for	IN	O	O
signs	ONFI.xml:S2:3195:5	sign	NNS	O	O
or	ONFI.xml:S2:3201:2	or	CC	O	O
symptoms	ONFI.xml:S2:3204:8	symptom	NNS	O	O
of	ONFI.xml:S2:3213:2	of	IN	O	O
SJS	ONFI.xml:S2:3216:3	sj	NNP	O	O
TEN	ONFI.xml:S2:3220:3	ten	NNP	O	O
,	ONFI.xml:S2:3223:1	,	,	O	O
especially	ONFI.xml:S2:3225:10	especi	RB	O	O
during	ONFI.xml:S2:3236:6	dure	IN	O	O
the	ONFI.xml:S2:3243:3	the	DT	O	O
first	ONFI.xml:S2:3247:5	first	JJ	O	O
8	ONFI.xml:S2:3253:1	8	CD	O	O
weeks	ONFI.xml:S2:3255:5	week	NNS	O	O
of	ONFI.xml:S2:3261:2	of	IN	O	O
treatment	ONFI.xml:S2:3264:9	treatment	NN	O	O
initiation	ONFI.xml:S2:3274:10	initi	NN	O	O
or	ONFI.xml:S2:3285:2	or	CC	O	O
when	ONFI.xml:S2:3288:4	when	WRB	O	O
re	ONFI.xml:S2:3293:2	re	JJ	O	O
-	ONFI.xml:S2:3295:1	-	:	O	O
introducing	ONFI.xml:S2:3296:11	introduc	NN	O	O
therapy	ONFI.xml:S2:3308:7	therapi	NN	O	O
.	ONFI.xml:S2:3315:1	.	.	O	O

ONFI	ONFI.xml:S2:3317:4	onfi	NNP	O	O
should	ONFI.xml:S2:3322:6	should	MD	O	O
be	ONFI.xml:S2:3329:2	be	VB	O	O
discontinued	ONFI.xml:S2:3332:12	discontinu	VBN	O	O
at	ONFI.xml:S2:3345:2	at	IN	O	O
the	ONFI.xml:S2:3348:3	the	DT	O	O
first	ONFI.xml:S2:3352:5	first	JJ	O	O
sign	ONFI.xml:S2:3358:4	sign	NN	O	O
of	ONFI.xml:S2:3363:2	of	IN	O	O
rash	ONFI.xml:S2:3366:4	rash	NN	O	B-AdverseReaction
,	ONFI.xml:S2:3370:1	,	,	O	O
unless	ONFI.xml:S2:3372:6	unless	IN	O	O
the	ONFI.xml:S2:3379:3	the	DT	O	O
rash	ONFI.xml:S2:3383:4	rash	NN	O	O
is	ONFI.xml:S2:3388:2	is	VBZ	O	O
clearly	ONFI.xml:S2:3391:7	clearli	RB	O	O
not	ONFI.xml:S2:3399:3	not	RB	O	O
drug	ONFI.xml:S2:3403:4	drug	NN	O	O
-	ONFI.xml:S2:3407:1	-	:	O	O
related	ONFI.xml:S2:3408:7	relat	VBN	O	O
.	ONFI.xml:S2:3415:1	.	.	O	O

If	ONFI.xml:S2:3417:2	If	IN	O	O
signs	ONFI.xml:S2:3420:5	sign	NNS	O	O
or	ONFI.xml:S2:3426:2	or	CC	O	O
symptoms	ONFI.xml:S2:3429:8	symptom	NNS	O	O
suggest	ONFI.xml:S2:3438:7	suggest	VBP	O	O
SJS	ONFI.xml:S2:3446:3	sj	NNP	O	O
TEN	ONFI.xml:S2:3450:3	ten	NNP	O	O
,	ONFI.xml:S2:3453:1	,	,	O	O
use	ONFI.xml:S2:3455:3	use	NN	O	O
of	ONFI.xml:S2:3459:2	of	IN	O	O
this	ONFI.xml:S2:3462:4	thi	DT	O	O
drug	ONFI.xml:S2:3467:4	drug	NN	O	O
should	ONFI.xml:S2:3472:6	should	MD	O	O
not	ONFI.xml:S2:3479:3	not	RB	O	O
be	ONFI.xml:S2:3483:2	be	VB	O	O
resumed	ONFI.xml:S2:3486:7	resum	VBN	O	O
and	ONFI.xml:S2:3494:3	and	CC	O	O
alternative	ONFI.xml:S2:3498:11	altern	JJ	O	O
therapy	ONFI.xml:S2:3510:7	therapi	NN	O	O
should	ONFI.xml:S2:3518:6	should	MD	O	O
be	ONFI.xml:S2:3525:2	be	VB	O	O
considered	ONFI.xml:S2:3528:10	consid	VBN	O	O
[	ONFI.xml:S2:3539:1	[	NNP	O	O
see	ONFI.xml:S2:3540:3	see	VBP	O	O
Contraindications	ONFI.xml:S2:3544:17	contraind	NNP	O	O
(	ONFI.xml:S2:3562:1	(	(	O	O
4	ONFI.xml:S2:3565:1	4	CD	O	O
)]	ONFI.xml:S2:3568:2	)]	NN	O	O
.	ONFI.xml:S2:3570:1	.	.	O	O

5.5	ONFI.xml:S2:3582:3	5.5	CD	O	O
Physical	ONFI.xml:S2:3586:8	physic	JJ	O	O
and	ONFI.xml:S2:3595:3	and	CC	O	O
Psychological	ONFI.xml:S2:3599:13	psycholog	JJ	O	O
Dependence	ONFI.xml:S2:3613:10	depend	NN	O	O

Patients	ONFI.xml:S2:3631:8	patient	NNS	O	O
with	ONFI.xml:S2:3640:4	with	IN	O	O
a	ONFI.xml:S2:3645:1	a	DT	O	O
history	ONFI.xml:S2:3647:7	histori	NN	O	O
of	ONFI.xml:S2:3655:2	of	IN	O	O
substance	ONFI.xml:S2:3658:9	substanc	NN	O	O
abuse	ONFI.xml:S2:3668:5	abus	NN	O	O
should	ONFI.xml:S2:3674:6	should	MD	O	O
be	ONFI.xml:S2:3681:2	be	VB	O	O
under	ONFI.xml:S2:3684:5	under	IN	O	O
careful	ONFI.xml:S2:3690:7	care	JJ	O	O
surveillance	ONFI.xml:S2:3698:12	surveil	NN	O	O
when	ONFI.xml:S2:3711:4	when	WRB	O	O
receiving	ONFI.xml:S2:3716:9	receiv	VBG	O	O
ONFI	ONFI.xml:S2:3726:4	onfi	NNP	O	O
or	ONFI.xml:S2:3731:2	or	CC	O	O
other	ONFI.xml:S2:3734:5	other	JJ	O	O
psychotropic	ONFI.xml:S2:3740:12	psychotrop	NN	O	O
agents	ONFI.xml:S2:3753:6	agent	NNS	O	O
because	ONFI.xml:S2:3760:7	becaus	IN	O	O
of	ONFI.xml:S2:3768:2	of	IN	O	O
the	ONFI.xml:S2:3771:3	the	DT	O	O
predisposition	ONFI.xml:S2:3775:14	predisposit	NN	O	O
of	ONFI.xml:S2:3790:2	of	IN	O	O
such	ONFI.xml:S2:3793:4	such	JJ	O	O
patients	ONFI.xml:S2:3798:8	patient	NNS	O	O
to	ONFI.xml:S2:3807:2	to	TO	O	O
habituation	ONFI.xml:S2:3810:11	habitu	NN	O	O
and	ONFI.xml:S2:3822:3	and	CC	O	O
dependence	ONFI.xml:S2:3826:10	depend	NN	O	O
[	ONFI.xml:S2:3837:1	[	NNP	O	O
see	ONFI.xml:S2:3838:3	see	VBP	O	O
Drug	ONFI.xml:S2:3844:4	drug	NNP	O	O
Abuse	ONFI.xml:S2:3849:5	abus	NNP	O	O
and	ONFI.xml:S2:3855:3	and	CC	O	O
Dependence	ONFI.xml:S2:3859:10	depend	NNP	O	O
(	ONFI.xml:S2:3870:1	(	(	O	O
9	ONFI.xml:S2:3873:1	9	CD	O	O
)]	ONFI.xml:S2:3876:2	)]	NN	O	O
.	ONFI.xml:S2:3880:1	.	.	O	O

5.6	ONFI.xml:S2:3890:3	5.6	CD	O	O
Suicidal	ONFI.xml:S2:3894:8	suicid	NNP	O	O
Behavior	ONFI.xml:S2:3903:8	behavior	NNP	O	O
and	ONFI.xml:S2:3912:3	and	CC	O	O
Ideation	ONFI.xml:S2:3916:8	ideat	NNP	O	O

Antiepileptic	ONFI.xml:S2:3932:13	antiepilept	JJ	O	O
drugs	ONFI.xml:S2:3946:5	drug	NNS	O	O
(	ONFI.xml:S2:3952:1	(	(	O	O
AEDs	ONFI.xml:S2:3953:4	a	NNP	O	O
)	ONFI.xml:S2:3957:1	)	)	O	O
,	ONFI.xml:S2:3958:1	,	,	O	O
including	ONFI.xml:S2:3960:9	includ	VBG	O	O
ONFI	ONFI.xml:S2:3970:4	onfi	NNP	O	O
,	ONFI.xml:S2:3974:1	,	,	O	O
increase	ONFI.xml:S2:3976:8	increas	VB	O	O
the	ONFI.xml:S2:3985:3	the	DT	O	O
risk	ONFI.xml:S2:3989:4	risk	NN	O	O
of	ONFI.xml:S2:3994:2	of	IN	O	O
suicidal	ONFI.xml:S2:3997:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thoughts	ONFI.xml:S2:4006:8	thought	NNS	I-AdverseReaction	I-AdverseReaction
or	ONFI.xml:S2:4015:2	or	CC	O	O
behavior	ONFI.xml:S2:4018:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
in	ONFI.xml:S2:4027:2	in	IN	O	O
patients	ONFI.xml:S2:4030:8	patient	NNS	O	O
taking	ONFI.xml:S2:4039:6	take	VBG	O	O
these	ONFI.xml:S2:4046:5	these	DT	O	O
drugs	ONFI.xml:S2:4052:5	drug	NNS	O	O
for	ONFI.xml:S2:4058:3	for	IN	O	O
any	ONFI.xml:S2:4062:3	ani	DT	O	O
indication	ONFI.xml:S2:4066:10	indic	NN	O	O
.	ONFI.xml:S2:4076:1	.	.	O	O

Patients	ONFI.xml:S2:4078:8	patient	NNS	O	O
treated	ONFI.xml:S2:4087:7	treat	VBN	O	O
with	ONFI.xml:S2:4095:4	with	IN	O	O
any	ONFI.xml:S2:4100:3	ani	DT	O	O
AED	ONFI.xml:S2:4104:3	a	NNP	O	O
for	ONFI.xml:S2:4108:3	for	IN	O	O
any	ONFI.xml:S2:4112:3	ani	DT	O	O
indication	ONFI.xml:S2:4116:10	indic	NN	O	O
should	ONFI.xml:S2:4127:6	should	MD	O	O
be	ONFI.xml:S2:4134:2	be	VB	O	O
monitored	ONFI.xml:S2:4137:9	monitor	VBN	O	O
for	ONFI.xml:S2:4147:3	for	IN	O	O
the	ONFI.xml:S2:4151:3	the	DT	O	O
emergence	ONFI.xml:S2:4155:9	emerg	NN	O	O
or	ONFI.xml:S2:4165:2	or	CC	O	O
worsening	ONFI.xml:S2:4168:9	worsen	NN	O	O
of	ONFI.xml:S2:4178:2	of	IN	O	O
depression	ONFI.xml:S2:4181:10	depress	NN	O	O
,	ONFI.xml:S2:4191:1	,	,	O	O
suicidal	ONFI.xml:S2:4193:8	suicid	JJ	O	O
thoughts	ONFI.xml:S2:4202:8	thought	NNS	O	O
or	ONFI.xml:S2:4211:2	or	CC	O	O
behavior	ONFI.xml:S2:4214:8	behavior	NN	O	O
,	ONFI.xml:S2:4222:1	,	,	O	O
and	ONFI.xml:S2:4224:3	and	CC	O	O
or	ONFI.xml:S2:4228:2	or	CC	O	O
any	ONFI.xml:S2:4231:3	ani	DT	O	O
unusual	ONFI.xml:S2:4235:7	unusu	JJ	O	O
changes	ONFI.xml:S2:4243:7	chang	NNS	O	O
in	ONFI.xml:S2:4251:2	in	IN	O	O
mood	ONFI.xml:S2:4254:4	mood	NN	O	O
or	ONFI.xml:S2:4259:2	or	CC	O	O
behavior	ONFI.xml:S2:4262:8	behavior	NN	O	O
.	ONFI.xml:S2:4270:1	.	.	O	O

Pooled	ONFI.xml:S2:4276:6	pool	JJ	O	O
analyses	ONFI.xml:S2:4283:8	analys	NNS	O	O
of	ONFI.xml:S2:4292:2	of	IN	O	O
199	ONFI.xml:S2:4295:3	199	CD	O	O
placebo	ONFI.xml:S2:4299:7	placebo	NN	O	O
-	ONFI.xml:S2:4306:1	-	:	O	O
controlled	ONFI.xml:S2:4307:10	control	VBN	O	O
clinical	ONFI.xml:S2:4318:8	clinic	JJ	O	O
trials	ONFI.xml:S2:4327:6	trial	NNS	O	O
(	ONFI.xml:S2:4334:1	(	(	O	O
mono	ONFI.xml:S2:4335:4	mono	SYM	O	O
-	ONFI.xml:S2:4339:1	-	:	O	O
and	ONFI.xml:S2:4341:3	and	CC	O	O
adjunctive	ONFI.xml:S2:4345:10	adjunct	JJ	O	O
therapy	ONFI.xml:S2:4356:7	therapi	NN	O	O
)	ONFI.xml:S2:4363:1	)	)	O	O
of	ONFI.xml:S2:4365:2	of	IN	O	O
11	ONFI.xml:S2:4368:2	11	CD	O	O
different	ONFI.xml:S2:4371:9	differ	JJ	O	O
AEDs	ONFI.xml:S2:4381:4	a	NNP	O	O
showed	ONFI.xml:S2:4386:6	show	VBD	O	O
that	ONFI.xml:S2:4393:4	that	IN	O	O
patients	ONFI.xml:S2:4398:8	patient	NNS	O	O
randomized	ONFI.xml:S2:4407:10	random	VBN	O	O
to	ONFI.xml:S2:4418:2	to	TO	O	O
one	ONFI.xml:S2:4421:3	one	CD	O	O
of	ONFI.xml:S2:4425:2	of	IN	O	O
the	ONFI.xml:S2:4428:3	the	DT	O	O
AEDs	ONFI.xml:S2:4432:4	a	NNP	O	O
had	ONFI.xml:S2:4437:3	had	VBD	O	O
approximately	ONFI.xml:S2:4441:13	approxim	RB	O	O
twice	ONFI.xml:S2:4455:5	twice	RB	O	O
the	ONFI.xml:S2:4461:3	the	DT	O	O
risk	ONFI.xml:S2:4465:4	risk	NN	O	O
(	ONFI.xml:S2:4470:1	(	(	O	O
adjusted	ONFI.xml:S2:4471:8	adjust	VBN	O	O
relative	ONFI.xml:S2:4480:8	rel	NN	O	O
risk	ONFI.xml:S2:4489:4	risk	NN	O	O
1.8	ONFI.xml:S2:4494:3	1.8	CD	O	O
,	ONFI.xml:S2:4497:1	,	,	O	O
95%	ONFI.xml:S2:4499:3	95%	CD	O	O
confidence	ONFI.xml:S2:4503:10	confid	NN	O	O
interval	ONFI.xml:S2:4514:8	interv	NN	O	O
[	ONFI.xml:S2:4523:1	[	NNP	O	O
CI	ONFI.xml:S2:4524:2	CI	NNP	O	O
]	ONFI.xml:S2:4526:1	]	NN	O	O
:	ONFI.xml:S2:4527:1	:	:	O	O
1.2	ONFI.xml:S2:4529:3	1.2	CD	O	O
,	ONFI.xml:S2:4532:1	,	,	O	O
2.7	ONFI.xml:S2:4534:3	2.7	CD	O	O
)	ONFI.xml:S2:4537:1	)	)	O	O
of	ONFI.xml:S2:4539:2	of	IN	O	O
suicidal	ONFI.xml:S2:4542:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thinking	ONFI.xml:S2:4551:8	think	NN	I-AdverseReaction	I-AdverseReaction
or	ONFI.xml:S2:4560:2	or	CC	O	O
behavior	ONFI.xml:S2:4563:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
compared	ONFI.xml:S2:4572:8	compar	VBN	O	O
to	ONFI.xml:S2:4581:2	to	TO	O	O
patients	ONFI.xml:S2:4584:8	patient	NNS	O	O
randomized	ONFI.xml:S2:4593:10	random	VBN	O	O
to	ONFI.xml:S2:4604:2	to	TO	O	O
placebo	ONFI.xml:S2:4607:7	placebo	VB	O	O
.	ONFI.xml:S2:4614:1	.	.	O	O

In	ONFI.xml:S2:4616:2	In	IN	O	O
these	ONFI.xml:S2:4619:5	these	DT	O	O
trials	ONFI.xml:S2:4625:6	trial	NNS	O	O
,	ONFI.xml:S2:4631:1	,	,	O	O
which	ONFI.xml:S2:4633:5	which	WDT	O	O
had	ONFI.xml:S2:4639:3	had	VBD	O	O
a	ONFI.xml:S2:4643:1	a	DT	O	O
median	ONFI.xml:S2:4645:6	median	JJ	O	O
treatment	ONFI.xml:S2:4652:9	treatment	NN	O	O
duration	ONFI.xml:S2:4662:8	durat	NN	O	O
of	ONFI.xml:S2:4671:2	of	IN	O	O
12	ONFI.xml:S2:4674:2	12	CD	O	O
weeks	ONFI.xml:S2:4677:5	week	NNS	O	O
,	ONFI.xml:S2:4682:1	,	,	O	O
the	ONFI.xml:S2:4684:3	the	DT	O	O
estimated	ONFI.xml:S2:4688:9	estim	VBN	O	O
incidence	ONFI.xml:S2:4698:9	incid	NN	O	O
rate	ONFI.xml:S2:4708:4	rate	NN	O	O
of	ONFI.xml:S2:4713:2	of	IN	O	O
suicidal	ONFI.xml:S2:4716:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
behavior	ONFI.xml:S2:4725:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
or	ONFI.xml:S2:4734:2	or	CC	O	O
ideation	ONFI.xml:S2:4737:8	ideat	NN	I-AdverseReaction	I-AdverseReaction
among	ONFI.xml:S2:4746:5	among	IN	O	O
27	ONFI.xml:S2:4752:2	27	CD	O	O
,	ONFI.xml:S2:4754:1	,	,	O	O
863	ONFI.xml:S2:4755:3	863	CD	O	O
AED	ONFI.xml:S2:4759:3	a	NNP	O	O
treated	ONFI.xml:S2:4763:7	treat	VBD	O	O
patients	ONFI.xml:S2:4771:8	patient	NNS	O	O
was	ONFI.xml:S2:4780:3	wa	VBD	O	O
0.43%	ONFI.xml:S2:4784:5	0.43%	CD	O	O
,	ONFI.xml:S2:4789:1	,	,	O	O
compared	ONFI.xml:S2:4791:8	compar	VBN	O	O
to	ONFI.xml:S2:4800:2	to	TO	O	O
0.24%	ONFI.xml:S2:4803:5	0.24%	CD	O	O
among	ONFI.xml:S2:4809:5	among	IN	O	O
16	ONFI.xml:S2:4815:2	16	CD	O	O
,	ONFI.xml:S2:4817:1	,	,	O	O
029	ONFI.xml:S2:4818:3	029	CD	O	O
placebo	ONFI.xml:S2:4822:7	placebo	NN	O	O
treated	ONFI.xml:S2:4830:7	treat	VBD	O	O
patients	ONFI.xml:S2:4838:8	patient	NNS	O	O
,	ONFI.xml:S2:4846:1	,	,	O	O
representing	ONFI.xml:S2:4848:12	repres	VBG	O	O
an	ONFI.xml:S2:4861:2	an	DT	O	O
increase	ONFI.xml:S2:4864:8	increas	NN	O	O
of	ONFI.xml:S2:4873:2	of	IN	O	O
approximately	ONFI.xml:S2:4876:13	approxim	RB	O	O
one	ONFI.xml:S2:4890:3	one	CD	O	O
case	ONFI.xml:S2:4894:4	case	NN	O	O
of	ONFI.xml:S2:4899:2	of	IN	O	O
suicidal	ONFI.xml:S2:4902:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thinking	ONFI.xml:S2:4911:8	think	NN	I-AdverseReaction	I-AdverseReaction
or	ONFI.xml:S2:4920:2	or	CC	O	O
behavior	ONFI.xml:S2:4923:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
for	ONFI.xml:S2:4932:3	for	IN	O	O
every	ONFI.xml:S2:4936:5	everi	DT	O	O
530	ONFI.xml:S2:4942:3	530	CD	O	O
patients	ONFI.xml:S2:4946:8	patient	NNS	O	O
treated	ONFI.xml:S2:4955:7	treat	VBN	O	O
.	ONFI.xml:S2:4962:1	.	.	O	O

There	ONFI.xml:S2:4964:5	there	EX	O	O
were	ONFI.xml:S2:4970:4	were	VBD	O	O
four	ONFI.xml:S2:4975:4	four	CD	O	O
suicides	ONFI.xml:S2:4980:8	suicid	NNS	B-AdverseReaction	B-AdverseReaction
in	ONFI.xml:S2:4989:2	in	IN	O	O
drug	ONFI.xml:S2:4992:4	drug	NN	O	O
treated	ONFI.xml:S2:4997:7	treat	VBN	O	O
patients	ONFI.xml:S2:5005:8	patient	NNS	O	O
in	ONFI.xml:S2:5014:2	in	IN	O	O
the	ONFI.xml:S2:5017:3	the	DT	O	O
trials	ONFI.xml:S2:5021:6	trial	NNS	O	O
and	ONFI.xml:S2:5028:3	and	CC	O	O
none	ONFI.xml:S2:5032:4	none	NN	O	O
in	ONFI.xml:S2:5037:2	in	IN	O	O
placebo	ONFI.xml:S2:5040:7	placebo	NN	O	O
treated	ONFI.xml:S2:5048:7	treat	VBD	O	O
patients	ONFI.xml:S2:5056:8	patient	NNS	O	O
,	ONFI.xml:S2:5064:1	,	,	O	O
but	ONFI.xml:S2:5066:3	but	CC	O	O
the	ONFI.xml:S2:5070:3	the	DT	O	O
number	ONFI.xml:S2:5074:6	number	NN	O	O
is	ONFI.xml:S2:5081:2	is	VBZ	O	O
too	ONFI.xml:S2:5084:3	too	RB	O	O
small	ONFI.xml:S2:5088:5	small	JJ	O	O
to	ONFI.xml:S2:5094:2	to	TO	O	O
allow	ONFI.xml:S2:5097:5	allow	VB	O	O
any	ONFI.xml:S2:5103:3	ani	DT	O	O
conclusion	ONFI.xml:S2:5107:10	conclus	NN	O	O
about	ONFI.xml:S2:5118:5	about	IN	O	O
drug	ONFI.xml:S2:5124:4	drug	NN	O	O
effect	ONFI.xml:S2:5129:6	effect	NN	O	O
on	ONFI.xml:S2:5136:2	on	IN	O	O
suicide	ONFI.xml:S2:5139:7	suicid	NN	B-AdverseReaction	B-AdverseReaction
.	ONFI.xml:S2:5146:1	.	.	O	O

The	ONFI.xml:S2:5152:3	the	DT	O	O
increased	ONFI.xml:S2:5156:9	increas	VBN	O	O
risk	ONFI.xml:S2:5166:4	risk	NN	O	O
of	ONFI.xml:S2:5171:2	of	IN	O	O
suicidal	ONFI.xml:S2:5174:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thoughts	ONFI.xml:S2:5183:8	thought	NNS	I-AdverseReaction	I-AdverseReaction
or	ONFI.xml:S2:5192:2	or	CC	O	O
behavior	ONFI.xml:S2:5195:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
with	ONFI.xml:S2:5204:4	with	IN	O	O
AEDs	ONFI.xml:S2:5209:4	a	NNP	O	O
was	ONFI.xml:S2:5214:3	wa	VBD	O	O
observed	ONFI.xml:S2:5218:8	observ	VBN	O	O
as	ONFI.xml:S2:5227:2	as	RB	O	O
early	ONFI.xml:S2:5230:5	earli	RB	O	O
as	ONFI.xml:S2:5236:2	as	IN	O	O
one	ONFI.xml:S2:5239:3	one	CD	O	O
week	ONFI.xml:S2:5243:4	week	NN	O	O
after	ONFI.xml:S2:5248:5	after	IN	O	O
starting	ONFI.xml:S2:5254:8	start	VBG	O	O
drug	ONFI.xml:S2:5263:4	drug	NN	O	O
treatment	ONFI.xml:S2:5268:9	treatment	NN	O	O
with	ONFI.xml:S2:5278:4	with	IN	O	O
AEDs	ONFI.xml:S2:5283:4	a	NNP	O	O
and	ONFI.xml:S2:5288:3	and	CC	O	O
persisted	ONFI.xml:S2:5292:9	persist	VBN	O	O
for	ONFI.xml:S2:5302:3	for	IN	O	O
the	ONFI.xml:S2:5306:3	the	DT	O	O
duration	ONFI.xml:S2:5310:8	durat	NN	O	O
of	ONFI.xml:S2:5319:2	of	IN	O	O
treatment	ONFI.xml:S2:5322:9	treatment	NN	O	O
assessed	ONFI.xml:S2:5332:8	assess	VBN	O	O
.	ONFI.xml:S2:5340:1	.	.	O	O

Because	ONFI.xml:S2:5342:7	becaus	IN	O	O
most	ONFI.xml:S2:5350:4	most	JJS	O	O
trials	ONFI.xml:S2:5355:6	trial	NNS	O	O
included	ONFI.xml:S2:5362:8	includ	VBD	O	O
in	ONFI.xml:S2:5371:2	in	IN	O	O
the	ONFI.xml:S2:5374:3	the	DT	O	O
analysis	ONFI.xml:S2:5378:8	analysi	NN	O	O
did	ONFI.xml:S2:5387:3	did	VBD	O	O
not	ONFI.xml:S2:5391:3	not	RB	O	O
extend	ONFI.xml:S2:5395:6	extend	VB	O	O
beyond	ONFI.xml:S2:5402:6	beyond	IN	O	O
24	ONFI.xml:S2:5409:2	24	CD	O	O
weeks	ONFI.xml:S2:5412:5	week	NNS	O	O
,	ONFI.xml:S2:5417:1	,	,	O	O
the	ONFI.xml:S2:5419:3	the	DT	O	O
risk	ONFI.xml:S2:5423:4	risk	NN	O	O
of	ONFI.xml:S2:5428:2	of	IN	O	O
suicidal	ONFI.xml:S2:5431:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thoughts	ONFI.xml:S2:5440:8	thought	NNS	I-AdverseReaction	I-AdverseReaction
or	ONFI.xml:S2:5449:2	or	CC	O	O
behavior	ONFI.xml:S2:5452:8	behavior	JJ	I-AdverseReaction	O
beyond	ONFI.xml:S2:5461:6	beyond	IN	O	O
24	ONFI.xml:S2:5468:2	24	CD	O	O
weeks	ONFI.xml:S2:5471:5	week	NNS	O	O
could	ONFI.xml:S2:5477:5	could	MD	O	O
not	ONFI.xml:S2:5483:3	not	RB	O	O
be	ONFI.xml:S2:5487:2	be	VB	O	O
assessed	ONFI.xml:S2:5490:8	assess	VBN	O	O
.	ONFI.xml:S2:5498:1	.	.	O	O

The	ONFI.xml:S2:5504:3	the	DT	O	O
risk	ONFI.xml:S2:5508:4	risk	NN	O	O
of	ONFI.xml:S2:5513:2	of	IN	O	O
suicidal	ONFI.xml:S2:5516:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thoughts	ONFI.xml:S2:5525:8	thought	NNS	I-AdverseReaction	I-AdverseReaction
or	ONFI.xml:S2:5534:2	or	CC	O	O
behavior	ONFI.xml:S2:5537:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
was	ONFI.xml:S2:5546:3	wa	VBD	O	O
generally	ONFI.xml:S2:5550:9	gener	RB	O	O
consistent	ONFI.xml:S2:5560:10	consist	JJ	O	O
among	ONFI.xml:S2:5571:5	among	IN	O	O
drugs	ONFI.xml:S2:5577:5	drug	NNS	O	O
in	ONFI.xml:S2:5583:2	in	IN	O	O
the	ONFI.xml:S2:5586:3	the	DT	O	O
data	ONFI.xml:S2:5590:4	data	NNS	O	O
analyzed	ONFI.xml:S2:5595:8	analyz	VBD	O	O
.	ONFI.xml:S2:5603:1	.	.	O	O

The	ONFI.xml:S2:5605:3	the	DT	O	O
finding	ONFI.xml:S2:5609:7	find	NN	O	O
of	ONFI.xml:S2:5617:2	of	IN	O	O
increased	ONFI.xml:S2:5620:9	increas	VBN	O	O
risk	ONFI.xml:S2:5630:4	risk	NN	O	O
with	ONFI.xml:S2:5635:4	with	IN	O	O
AEDs	ONFI.xml:S2:5640:4	a	NNP	O	O
of	ONFI.xml:S2:5645:2	of	IN	O	O
varying	ONFI.xml:S2:5648:7	vari	VBG	O	O
mechanisms	ONFI.xml:S2:5656:10	mechan	NNS	O	O
of	ONFI.xml:S2:5667:2	of	IN	O	O
action	ONFI.xml:S2:5670:6	action	NN	O	O
and	ONFI.xml:S2:5677:3	and	CC	O	O
across	ONFI.xml:S2:5681:6	across	IN	O	O
a	ONFI.xml:S2:5688:1	a	DT	O	O
range	ONFI.xml:S2:5690:5	rang	NN	O	O
of	ONFI.xml:S2:5696:2	of	IN	O	O
indications	ONFI.xml:S2:5699:11	indic	NNS	O	O
suggests	ONFI.xml:S2:5711:8	suggest	VBZ	O	O
that	ONFI.xml:S2:5720:4	that	IN	O	O
the	ONFI.xml:S2:5725:3	the	DT	O	O
risk	ONFI.xml:S2:5729:4	risk	NN	O	O
applies	ONFI.xml:S2:5734:7	appli	NNS	O	O
to	ONFI.xml:S2:5742:2	to	TO	O	O
all	ONFI.xml:S2:5745:3	all	DT	O	O
AEDs	ONFI.xml:S2:5749:4	a	NNP	O	O
used	ONFI.xml:S2:5754:4	use	VBN	O	O
for	ONFI.xml:S2:5759:3	for	IN	O	O
any	ONFI.xml:S2:5763:3	ani	DT	O	O
indication	ONFI.xml:S2:5767:10	indic	NN	O	O
.	ONFI.xml:S2:5777:1	.	.	O	O

The	ONFI.xml:S2:5779:3	the	DT	O	O
risk	ONFI.xml:S2:5783:4	risk	NN	O	O
did	ONFI.xml:S2:5788:3	did	VBD	O	O
not	ONFI.xml:S2:5792:3	not	RB	O	O
vary	ONFI.xml:S2:5796:4	vari	JJ	O	O
substantially	ONFI.xml:S2:5801:13	substanti	RB	O	O
by	ONFI.xml:S2:5815:2	by	IN	O	O
age	ONFI.xml:S2:5818:3	age	NN	O	O
(	ONFI.xml:S2:5822:1	(	(	O	O
5	ONFI.xml:S2:5823:1	5	CD	O	O
-	ONFI.xml:S2:5824:1	-	:	O	O
100	ONFI.xml:S2:5825:3	100	CD	O	O
years	ONFI.xml:S2:5829:5	year	NNS	O	O
)	ONFI.xml:S2:5834:1	)	)	O	O
in	ONFI.xml:S2:5836:2	in	IN	O	O
the	ONFI.xml:S2:5839:3	the	DT	O	O
clinical	ONFI.xml:S2:5843:8	clinic	JJ	O	O
trials	ONFI.xml:S2:5852:6	trial	NNS	O	O
analyzed	ONFI.xml:S2:5859:8	analyz	VBD	O	O
.	ONFI.xml:S2:5867:1	.	.	O	O

Table	ONFI.xml:S2:5869:5	tabl	JJ	O	O
2	ONFI.xml:S2:5875:1	2	CD	O	O
shows	ONFI.xml:S2:5877:5	show	NNS	O	O
absolute	ONFI.xml:S2:5883:8	absolut	NN	O	O
and	ONFI.xml:S2:5892:3	and	CC	O	O
relative	ONFI.xml:S2:5896:8	rel	JJ	O	O
risk	ONFI.xml:S2:5905:4	risk	NN	O	O
by	ONFI.xml:S2:5910:2	by	IN	O	O
indication	ONFI.xml:S2:5913:10	indic	NN	O	O
for	ONFI.xml:S2:5924:3	for	IN	O	O
all	ONFI.xml:S2:5928:3	all	DT	O	O
evaluated	ONFI.xml:S2:5932:9	evalu	JJ	O	O
AEDs	ONFI.xml:S2:5942:4	a	NNP	O	O
.	ONFI.xml:S2:5946:1	.	.	O	O

Table	ONFI.xml:S2:5952:5	tabl	JJ	O	O
2	ONFI.xml:S2:5958:1	2	CD	O	O
.	ONFI.xml:S2:5959:1	.	.	O	O

Risk	ONFI.xml:S2:5961:4	risk	NN	O	O
by	ONFI.xml:S2:5966:2	by	IN	O	O
Indication	ONFI.xml:S2:5969:10	indic	NNP	O	O
for	ONFI.xml:S2:5980:3	for	IN	O	O
Antiepileptic	ONFI.xml:S2:5984:13	antiepilept	NNP	O	O
Drugs	ONFI.xml:S2:5998:5	drug	NNP	O	O
in	ONFI.xml:S2:6004:2	in	IN	O	O
the	ONFI.xml:S2:6007:3	the	DT	O	O
Pooled	ONFI.xml:S2:6011:6	pool	NNP	O	O
Analysis	ONFI.xml:S2:6018:8	analysi	NN	O	O

Indication	ONFI.xml:S2:6030:10	indic	NNP	O	O
Placebo	ONFI.xml:S2:6049:7	placebo	NNP	O	O
Patients	ONFI.xml:S2:6057:8	patient	NNPS	O	O
with	ONFI.xml:S2:6066:4	with	IN	O	O
Events	ONFI.xml:S2:6074:6	event	NNS	O	O
per	ONFI.xml:S2:6081:3	per	IN	O	O
1000	ONFI.xml:S2:6085:4	1000	CD	O	O
Patients	ONFI.xml:S2:6090:8	patient	NNS	O	O
Drug	ONFI.xml:S2:6105:4	drug	JJ	O	O
Patients	ONFI.xml:S2:6110:8	patient	NNS	O	O
with	ONFI.xml:S2:6119:4	with	IN	O	O
Events	ONFI.xml:S2:6126:6	event	NNS	O	O
per	ONFI.xml:S2:6133:3	per	IN	O	O
1000	ONFI.xml:S2:6137:4	1000	CD	O	O
Patients	ONFI.xml:S2:6142:8	patient	NNS	O	O
Relative	ONFI.xml:S2:6159:8	rel	JJ	O	O
Risk	ONFI.xml:S2:6168:4	risk	NN	O	O
:	ONFI.xml:S2:6172:1	:	:	O	O
Incidence	ONFI.xml:S2:6174:9	incid	NN	O	O
of	ONFI.xml:S2:6184:2	of	IN	O	O
Drug	ONFI.xml:S2:6187:4	drug	NNP	O	O
Events	ONFI.xml:S2:6193:6	event	NNP	O	O
in	ONFI.xml:S2:6200:2	in	IN	O	O
Drug	ONFI.xml:S2:6203:4	drug	NNP	O	O
Patients	ONFI.xml:S2:6208:8	patient	NNP	O	O
Incidencein	ONFI.xml:S2:6217:11	incidencein	NNP	O	O
Placebo	ONFI.xml:S2:6229:7	placebo	NNP	O	O
Patients	ONFI.xml:S2:6237:8	patient	NNP	O	O
Risk	ONFI.xml:S2:6254:4	risk	NNP	O	O
Difference	ONFI.xml:S2:6259:10	differ	NNP	O	O
:	ONFI.xml:S2:6269:1	:	:	O	O
Additional	ONFI.xml:S2:6271:10	addit	JJ	O	O
Drug	ONFI.xml:S2:6283:4	drug	NN	O	O
Patients	ONFI.xml:S2:6288:8	patient	NNS	O	O
with	ONFI.xml:S2:6297:4	with	IN	O	O
Events	ONFI.xml:S2:6302:6	event	NNS	O	O
per	ONFI.xml:S2:6309:3	per	IN	O	O
1000	ONFI.xml:S2:6313:4	1000	CD	O	O
Patients	ONFI.xml:S2:6318:8	patient	NNS	O	O

Epilepsy	ONFI.xml:S2:6338:8	epilepsi	NNP	O	O
1.0	ONFI.xml:S2:6352:3	1.0	CD	O	O
3.4	ONFI.xml:S2:6369:3	3.4	CD	O	O
3.5	ONFI.xml:S2:6386:3	3.5	CD	O	O
2.4	ONFI.xml:S2:6403:3	2.4	CD	O	O

Psychiatric	ONFI.xml:S2:6426:11	psychiatr	JJ	O	O
5.7	ONFI.xml:S2:6442:3	5.7	CD	O	O
8.5	ONFI.xml:S2:6459:3	8.5	CD	O	O
1.5	ONFI.xml:S2:6476:3	1.5	CD	O	O
2.9	ONFI.xml:S2:6493:3	2.9	CD	O	O

Other	ONFI.xml:S2:6516:5	other	JJ	O	O
1.0	ONFI.xml:S2:6530:3	1.0	CD	O	O
1.8	ONFI.xml:S2:6547:3	1.8	CD	O	O
1.9	ONFI.xml:S2:6564:3	1.9	CD	O	O
0.9	ONFI.xml:S2:6581:3	0.9	CD	O	O

Total	ONFI.xml:S2:6604:5	total	JJ	O	O
2.4	ONFI.xml:S2:6618:3	2.4	CD	O	O
4.3	ONFI.xml:S2:6635:3	4.3	CD	O	O
1.8	ONFI.xml:S2:6652:3	1.8	CD	O	O
1.9	ONFI.xml:S2:6669:3	1.9	CD	O	O

The	ONFI.xml:S2:6699:3	the	DT	O	O
relative	ONFI.xml:S2:6703:8	rel	JJ	O	O
risk	ONFI.xml:S2:6712:4	risk	NN	O	O
for	ONFI.xml:S2:6717:3	for	IN	O	O
suicidal	ONFI.xml:S2:6721:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thoughts	ONFI.xml:S2:6730:8	thought	NNS	I-AdverseReaction	I-AdverseReaction
or	ONFI.xml:S2:6739:2	or	CC	O	O
behavior	ONFI.xml:S2:6742:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
was	ONFI.xml:S2:6751:3	wa	VBD	O	O
higher	ONFI.xml:S2:6755:6	higher	RBR	O	O
in	ONFI.xml:S2:6762:2	in	IN	O	O
clinical	ONFI.xml:S2:6765:8	clinic	JJ	O	O
trials	ONFI.xml:S2:6774:6	trial	NNS	O	O
for	ONFI.xml:S2:6781:3	for	IN	O	O
epilepsy	ONFI.xml:S2:6785:8	epilepsi	NN	O	O
than	ONFI.xml:S2:6794:4	than	IN	O	O
in	ONFI.xml:S2:6799:2	in	IN	O	O
clinical	ONFI.xml:S2:6802:8	clinic	JJ	O	O
trials	ONFI.xml:S2:6811:6	trial	NNS	O	O
for	ONFI.xml:S2:6818:3	for	IN	O	O
psychiatric	ONFI.xml:S2:6822:11	psychiatr	JJ	O	O
or	ONFI.xml:S2:6834:2	or	CC	O	O
other	ONFI.xml:S2:6837:5	other	JJ	O	O
conditions	ONFI.xml:S2:6843:10	condit	NNS	O	O
,	ONFI.xml:S2:6853:1	,	,	O	O
but	ONFI.xml:S2:6855:3	but	CC	O	O
the	ONFI.xml:S2:6859:3	the	DT	O	O
absolute	ONFI.xml:S2:6863:8	absolut	NN	O	O
risk	ONFI.xml:S2:6872:4	risk	NN	O	O
differences	ONFI.xml:S2:6877:11	differ	NNS	O	O
were	ONFI.xml:S2:6889:4	were	VBD	O	O
similar	ONFI.xml:S2:6894:7	similar	JJ	O	O
for	ONFI.xml:S2:6902:3	for	IN	O	O
the	ONFI.xml:S2:6906:3	the	DT	O	O
epilepsy	ONFI.xml:S2:6910:8	epilepsi	NN	O	O
and	ONFI.xml:S2:6919:3	and	CC	O	O
psychiatric	ONFI.xml:S2:6923:11	psychiatr	JJ	O	O
indications	ONFI.xml:S2:6935:11	indic	NNS	O	O
.	ONFI.xml:S2:6946:1	.	.	O	O

Anyone	ONFI.xml:S2:6952:6	anyon	NN	O	O

considering	ONFI.xml:S2:6959:11	consid	VBG	O	O
prescribing	ONFI.xml:S2:6971:11	prescrib	VBG	O	O
ONFI	ONFI.xml:S2:6983:4	onfi	NNP	O	O
or	ONFI.xml:S2:6988:2	or	CC	O	O
any	ONFI.xml:S2:6991:3	ani	DT	O	O
other	ONFI.xml:S2:6995:5	other	JJ	O	O
AED	ONFI.xml:S2:7001:3	a	NNP	O	O
must	ONFI.xml:S2:7005:4	must	MD	O	O
balance	ONFI.xml:S2:7010:7	balanc	VB	O	O
the	ONFI.xml:S2:7018:3	the	DT	O	O
risk	ONFI.xml:S2:7022:4	risk	NN	O	O
of	ONFI.xml:S2:7027:2	of	IN	O	O
suicidal	ONFI.xml:S2:7030:8	suicid	JJ	O	B-AdverseReaction
thoughts	ONFI.xml:S2:7039:8	thought	NNS	O	I-AdverseReaction
or	ONFI.xml:S2:7048:2	or	CC	O	O
behavior	ONFI.xml:S2:7051:8	behavior	NN	O	O
with	ONFI.xml:S2:7060:4	with	IN	O	O
the	ONFI.xml:S2:7065:3	the	DT	O	O
risk	ONFI.xml:S2:7069:4	risk	NN	O	O
of	ONFI.xml:S2:7074:2	of	IN	O	O
untreated	ONFI.xml:S2:7077:9	untreat	JJ	O	O
illness	ONFI.xml:S2:7087:7	ill	NN	O	O
.	ONFI.xml:S2:7094:1	.	.	O	O

Epilepsy	ONFI.xml:S2:7096:8	epilepsi	NNP	O	O
and	ONFI.xml:S2:7105:3	and	CC	O	O
many	ONFI.xml:S2:7109:4	mani	JJ	O	O
other	ONFI.xml:S2:7114:5	other	JJ	O	O
illnesses	ONFI.xml:S2:7120:9	ill	NNS	O	O
for	ONFI.xml:S2:7130:3	for	IN	O	O
which	ONFI.xml:S2:7134:5	which	WDT	O	O
AEDs	ONFI.xml:S2:7140:4	a	NNP	O	O
are	ONFI.xml:S2:7145:3	are	VBP	O	O
prescribed	ONFI.xml:S2:7149:10	prescrib	VBN	O	O
are	ONFI.xml:S2:7160:3	are	VBP	O	O
themselves	ONFI.xml:S2:7164:10	themselv	PRP	O	O
associated	ONFI.xml:S2:7175:10	associ	VBN	O	O
with	ONFI.xml:S2:7186:4	with	IN	O	O
morbidity	ONFI.xml:S2:7191:9	morbid	NN	O	O
and	ONFI.xml:S2:7201:3	and	CC	O	O
mortality	ONFI.xml:S2:7205:9	mortal	NN	O	O
and	ONFI.xml:S2:7215:3	and	CC	O	O
an	ONFI.xml:S2:7219:2	an	DT	O	O
increased	ONFI.xml:S2:7222:9	increas	VBN	O	O
risk	ONFI.xml:S2:7232:4	risk	NN	O	O
of	ONFI.xml:S2:7237:2	of	IN	O	O
suicidal	ONFI.xml:S2:7240:8	suicid	JJ	O	O
thoughts	ONFI.xml:S2:7249:8	thought	NNS	O	O
and	ONFI.xml:S2:7258:3	and	CC	O	O
behavior	ONFI.xml:S2:7262:8	behavior	NN	O	O
.	ONFI.xml:S2:7270:1	.	.	O	O

Should	ONFI.xml:S2:7272:6	should	MD	O	O
suicidal	ONFI.xml:S2:7279:8	suicid	VB	O	O
thoughts	ONFI.xml:S2:7288:8	thought	NNS	O	O
and	ONFI.xml:S2:7297:3	and	CC	O	O
behavior	ONFI.xml:S2:7301:8	behavior	JJ	O	O
emerge	ONFI.xml:S2:7310:6	emerg	NN	O	O
during	ONFI.xml:S2:7317:6	dure	IN	O	O
treatment	ONFI.xml:S2:7324:9	treatment	NN	O	O
,	ONFI.xml:S2:7333:1	,	,	O	O
the	ONFI.xml:S2:7335:3	the	DT	O	O
prescriber	ONFI.xml:S2:7339:10	prescrib	NN	O	O
needs	ONFI.xml:S2:7350:5	need	VBZ	O	O
to	ONFI.xml:S2:7356:2	to	TO	O	O
consider	ONFI.xml:S2:7359:8	consid	VB	O	O
whether	ONFI.xml:S2:7368:7	whether	IN	O	O
the	ONFI.xml:S2:7376:3	the	DT	O	O
emergence	ONFI.xml:S2:7380:9	emerg	NN	O	O
of	ONFI.xml:S2:7390:2	of	IN	O	O
these	ONFI.xml:S2:7393:5	these	DT	O	O
symptoms	ONFI.xml:S2:7399:8	symptom	NNS	O	O
in	ONFI.xml:S2:7408:2	in	IN	O	O
any	ONFI.xml:S2:7411:3	ani	DT	O	O
given	ONFI.xml:S2:7415:5	given	VBN	O	O
patient	ONFI.xml:S2:7421:7	patient	NN	O	O
may	ONFI.xml:S2:7429:3	may	MD	O	O
be	ONFI.xml:S2:7433:2	be	VB	O	O
related	ONFI.xml:S2:7436:7	relat	VBN	O	O
to	ONFI.xml:S2:7444:2	to	TO	O	O
the	ONFI.xml:S2:7447:3	the	DT	O	O
illness	ONFI.xml:S2:7451:7	ill	NN	O	O
being	ONFI.xml:S2:7459:5	be	VBG	O	O
treated	ONFI.xml:S2:7465:7	treat	VBN	O	O
.	ONFI.xml:S2:7472:1	.	.	O	O

Patients	ONFI.xml:S2:7478:8	patient	NNS	O	O
,	ONFI.xml:S2:7486:1	,	,	O	O
their	ONFI.xml:S2:7488:5	their	PRP$	O	O
caregivers	ONFI.xml:S2:7494:10	caregiv	NNS	O	O
,	ONFI.xml:S2:7504:1	,	,	O	O
and	ONFI.xml:S2:7506:3	and	CC	O	O
families	ONFI.xml:S2:7510:8	famili	NNS	O	O
should	ONFI.xml:S2:7519:6	should	MD	O	O
be	ONFI.xml:S2:7526:2	be	VB	O	O
informed	ONFI.xml:S2:7529:8	inform	VBN	O	O
that	ONFI.xml:S2:7538:4	that	IN	O	O
AEDs	ONFI.xml:S2:7543:4	a	NNP	O	O
increase	ONFI.xml:S2:7548:8	increas	VB	O	O
the	ONFI.xml:S2:7557:3	the	DT	O	O
risk	ONFI.xml:S2:7561:4	risk	NN	O	O
of	ONFI.xml:S2:7566:2	of	IN	O	O
suicidal	ONFI.xml:S2:7569:8	suicid	JJ	O	O
thoughts	ONFI.xml:S2:7578:8	thought	NNS	O	O
and	ONFI.xml:S2:7587:3	and	CC	O	O
behavior	ONFI.xml:S2:7591:8	behavior	NN	O	O
and	ONFI.xml:S2:7600:3	and	CC	O	O
should	ONFI.xml:S2:7604:6	should	MD	O	O
be	ONFI.xml:S2:7611:2	be	VB	O	O
advised	ONFI.xml:S2:7614:7	advis	VBN	O	O
of	ONFI.xml:S2:7622:2	of	IN	O	O
the	ONFI.xml:S2:7625:3	the	DT	O	O
need	ONFI.xml:S2:7629:4	need	NN	O	O
to	ONFI.xml:S2:7634:2	to	TO	O	O
be	ONFI.xml:S2:7637:2	be	VB	O	O
alert	ONFI.xml:S2:7640:5	alert	JJ	O	O
for	ONFI.xml:S2:7646:3	for	IN	O	O
the	ONFI.xml:S2:7650:3	the	DT	O	O
emergence	ONFI.xml:S2:7654:9	emerg	NN	O	O
or	ONFI.xml:S2:7664:2	or	CC	O	O
worsening	ONFI.xml:S2:7667:9	worsen	NN	O	O
of	ONFI.xml:S2:7677:2	of	IN	O	O
the	ONFI.xml:S2:7680:3	the	DT	O	O
signs	ONFI.xml:S2:7684:5	sign	NNS	O	O
and	ONFI.xml:S2:7690:3	and	CC	O	O
symptoms	ONFI.xml:S2:7694:8	symptom	NNS	O	O
of	ONFI.xml:S2:7703:2	of	IN	O	O
depression	ONFI.xml:S2:7706:10	depress	NN	O	O
,	ONFI.xml:S2:7716:1	,	,	O	O
any	ONFI.xml:S2:7718:3	ani	DT	O	O
unusual	ONFI.xml:S2:7722:7	unusu	JJ	O	O
changes	ONFI.xml:S2:7730:7	chang	NNS	O	O
in	ONFI.xml:S2:7738:2	in	IN	O	O
mood	ONFI.xml:S2:7741:4	mood	NN	O	O
or	ONFI.xml:S2:7746:2	or	CC	O	O
behavior	ONFI.xml:S2:7749:8	behavior	NN	O	O
,	ONFI.xml:S2:7757:1	,	,	O	O
or	ONFI.xml:S2:7759:2	or	CC	O	O
the	ONFI.xml:S2:7762:3	the	DT	O	O
emergence	ONFI.xml:S2:7766:9	emerg	NN	O	O
of	ONFI.xml:S2:7776:2	of	IN	O	O
suicidal	ONFI.xml:S2:7779:8	suicid	JJ	O	O
thoughts	ONFI.xml:S2:7788:8	thought	NNS	O	O
,	ONFI.xml:S2:7796:1	,	,	O	O
behavior	ONFI.xml:S2:7798:8	behavior	NN	O	O
,	ONFI.xml:S2:7806:1	,	,	O	O
or	ONFI.xml:S2:7808:2	or	CC	O	O
thoughts	ONFI.xml:S2:7811:8	thought	NNS	O	O
about	ONFI.xml:S2:7820:5	about	IN	O	O
self	ONFI.xml:S2:7826:4	self	PRP	O	O
-	ONFI.xml:S2:7830:1	-	:	O	O
harm	ONFI.xml:S2:7831:4	harm	NN	O	O
.	ONFI.xml:S2:7835:1	.	.	O	O

Behaviors	ONFI.xml:S2:7837:9	behavior	NNS	O	O
of	ONFI.xml:S2:7847:2	of	IN	O	O
concern	ONFI.xml:S2:7850:7	concern	NN	O	O
should	ONFI.xml:S2:7858:6	should	MD	O	O
be	ONFI.xml:S2:7865:2	be	VB	O	O
reported	ONFI.xml:S2:7868:8	report	VBN	O	O
immediately	ONFI.xml:S2:7877:11	immedi	RB	O	O
to	ONFI.xml:S2:7889:2	to	TO	O	O
healthcare	ONFI.xml:S2:7892:10	healthcar	VB	O	O
providers	ONFI.xml:S2:7903:9	provid	NNS	O	O
.	ONFI.xml:S2:7912:1	.	.	O	O
6	OTEZLA.xml:S1:4:1	6	CD	O	O
ADVERSE	OTEZLA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	OTEZLA.xml:S1:14:9	reaction	NN	O	O

EXCERPT	OTEZLA.xml:S1:28:7	excerpt	NN	O	O
:	OTEZLA.xml:S1:35:1	:	:	O	O
Psoriatic	OTEZLA.xml:S1:44:9	psoriat	JJ	O	O
Arthritis	OTEZLA.xml:S1:54:9	arthriti	NN	O	O
:	OTEZLA.xml:S1:64:1	:	:	O	O
The	OTEZLA.xml:S1:66:3	the	DT	O	O
most	OTEZLA.xml:S1:70:4	most	RBS	O	O
common	OTEZLA.xml:S1:75:6	common	JJ	O	O
adverse	OTEZLA.xml:S1:82:7	advers	JJ	O	O
reactions	OTEZLA.xml:S1:90:9	reaction	NNS	O	O
(	OTEZLA.xml:S1:100:1	(	(	O	O
5%	OTEZLA.xml:S1:103:2	5%	CD	O	O
)	OTEZLA.xml:S1:105:1	)	)	O	O
are	OTEZLA.xml:S1:107:3	are	VBP	O	O
diarrhea	OTEZLA.xml:S1:111:8	diarrhea	JJ	B-AdverseReaction	B-AdverseReaction
,	OTEZLA.xml:S1:119:1	,	,	O	O
nausea	OTEZLA.xml:S1:121:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	OTEZLA.xml:S1:127:1	,	,	O	O
and	OTEZLA.xml:S1:129:3	and	CC	O	O
headache	OTEZLA.xml:S1:133:8	headach	NN	B-AdverseReaction	B-AdverseReaction
(	OTEZLA.xml:S1:142:1	(	(	O	O
6.1	OTEZLA.xml:S1:143:3	6.1	CD	O	O
)	OTEZLA.xml:S1:146:1	)	)	O	O

Psoriasis	OTEZLA.xml:S1:154:9	psoriasi	NN	O	O
:	OTEZLA.xml:S1:164:1	:	:	O	O
The	OTEZLA.xml:S1:166:3	the	DT	O	O
most	OTEZLA.xml:S1:170:4	most	RBS	O	O
common	OTEZLA.xml:S1:175:6	common	JJ	O	O
adverse	OTEZLA.xml:S1:182:7	advers	JJ	O	O
reactions	OTEZLA.xml:S1:190:9	reaction	NNS	O	O
(	OTEZLA.xml:S1:200:1	(	(	O	O
5%	OTEZLA.xml:S1:203:2	5%	CD	O	O
)	OTEZLA.xml:S1:205:1	)	)	O	O
are	OTEZLA.xml:S1:207:3	are	VBP	O	O
diarrhea	OTEZLA.xml:S1:211:8	diarrhea	JJ	B-AdverseReaction	B-AdverseReaction
,	OTEZLA.xml:S1:219:1	,	,	O	O
nausea	OTEZLA.xml:S1:221:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	OTEZLA.xml:S1:227:1	,	,	O	O
upper	OTEZLA.xml:S1:229:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	OTEZLA.xml:S1:235:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	OTEZLA.xml:S1:247:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	OTEZLA.xml:S1:253:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	OTEZLA.xml:S1:262:1	,	,	O	O
and	OTEZLA.xml:S1:264:3	and	CC	O	O
headache	OTEZLA.xml:S1:268:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	OTEZLA.xml:S1:276:1	,	,	O	O
including	OTEZLA.xml:S1:278:9	includ	VBG	O	O
tension	OTEZLA.xml:S1:288:7	tension	NN	B-AdverseReaction	B-AdverseReaction
headache	OTEZLA.xml:S1:296:8	headach	NN	I-AdverseReaction	I-AdverseReaction
(	OTEZLA.xml:S1:305:1	(	(	O	O
6.1	OTEZLA.xml:S1:306:3	6.1	CD	O	O
)	OTEZLA.xml:S1:309:1	)	)	O	O

To	OTEZLA.xml:S1:316:2	To	TO	O	O
report	OTEZLA.xml:S1:319:6	report	VB	O	O
SUSPECTED	OTEZLA.xml:S1:326:9	suspect	NNP	O	O
ADVERSE	OTEZLA.xml:S1:336:7	advers	NNP	O	O
REACTIONS	OTEZLA.xml:S1:344:9	reaction	NNP	O	O
,	OTEZLA.xml:S1:353:1	,	,	O	O
contact	OTEZLA.xml:S1:355:7	contact	NN	O	O
Celgene	OTEZLA.xml:S1:363:7	celgen	NNP	O	O
Corporation	OTEZLA.xml:S1:371:11	corpor	NNP	O	O
at	OTEZLA.xml:S1:383:2	at	IN	O	O
1	OTEZLA.xml:S1:386:1	1	CD	O	O
-	OTEZLA.xml:S1:387:1	-	:	O	O
888	OTEZLA.xml:S1:388:3	888	CD	O	O
-	OTEZLA.xml:S1:391:1	-	:	O	O
423	OTEZLA.xml:S1:392:3	423	CD	O	O
-	OTEZLA.xml:S1:395:1	-	:	O	O
5436	OTEZLA.xml:S1:396:4	5436	CD	O	O
or	OTEZLA.xml:S1:401:2	or	CC	O	O
FDA	OTEZLA.xml:S1:404:3	fda	NNP	O	O
at	OTEZLA.xml:S1:408:2	at	IN	O	O
1	OTEZLA.xml:S1:411:1	1	CD	O	O
-	OTEZLA.xml:S1:412:1	-	:	O	O
800	OTEZLA.xml:S1:413:3	800	CD	O	O
-	OTEZLA.xml:S1:416:1	-	:	O	O
FDA	OTEZLA.xml:S1:417:3	fda	NNP	O	O
-	OTEZLA.xml:S1:420:1	-	:	O	O
1088	OTEZLA.xml:S1:421:4	1088	CD	O	O
or	OTEZLA.xml:S1:426:2	or	CC	O	O
www	OTEZLA.xml:S1:429:3	www	VB	O	O
.	OTEZLA.xml:S1:432:1	.	.	O	O
fda	OTEZLA.xml:S1:433:3	fda	NN	O	O
.	OTEZLA.xml:S1:436:1	.	.	O	O
gov	OTEZLA.xml:S1:437:3	gov	NN	O	O
medwatch	OTEZLA.xml:S1:441:8	medwatch	NN	O	O

6.1	OTEZLA.xml:S1:458:3	6.1	CD	O	O

Clinical	OTEZLA.xml:S1:462:8	clinic	JJ	O	O

Trials	OTEZLA.xml:S1:471:6	trial	NNS	O	O
Experience	OTEZLA.xml:S1:478:10	experi	NN	O	O

Because	OTEZLA.xml:S1:492:7	becaus	IN	O	O
clinical	OTEZLA.xml:S1:500:8	clinic	JJ	O	O
trials	OTEZLA.xml:S1:509:6	trial	NNS	O	O
are	OTEZLA.xml:S1:516:3	are	VBP	O	O
conducted	OTEZLA.xml:S1:520:9	conduct	VBN	O	O
under	OTEZLA.xml:S1:530:5	under	IN	O	O
widely	OTEZLA.xml:S1:536:6	wide	RB	O	O
varying	OTEZLA.xml:S1:543:7	vari	VBG	O	O
conditions	OTEZLA.xml:S1:551:10	condit	NNS	O	O
,	OTEZLA.xml:S1:561:1	,	,	O	O
adverse	OTEZLA.xml:S1:563:7	advers	JJ	O	O
reaction	OTEZLA.xml:S1:571:8	reaction	NN	O	O
rates	OTEZLA.xml:S1:580:5	rate	NNS	O	O
observed	OTEZLA.xml:S1:586:8	observ	VBD	O	O
in	OTEZLA.xml:S1:595:2	in	IN	O	O
the	OTEZLA.xml:S1:598:3	the	DT	O	O
clinical	OTEZLA.xml:S1:602:8	clinic	JJ	O	O
trial	OTEZLA.xml:S1:611:5	trial	NN	O	O
of	OTEZLA.xml:S1:617:2	of	IN	O	O
a	OTEZLA.xml:S1:620:1	a	DT	O	O
drug	OTEZLA.xml:S1:622:4	drug	NN	O	O
cannot	OTEZLA.xml:S1:627:6	cannot	NN	O	O
be	OTEZLA.xml:S1:634:2	be	VB	O	O
directly	OTEZLA.xml:S1:637:8	directli	RB	O	O
compared	OTEZLA.xml:S1:646:8	compar	VBN	O	O
to	OTEZLA.xml:S1:655:2	to	TO	O	O
rates	OTEZLA.xml:S1:658:5	rate	NNS	O	O
in	OTEZLA.xml:S1:664:2	in	IN	O	O
the	OTEZLA.xml:S1:667:3	the	DT	O	O
clinical	OTEZLA.xml:S1:671:8	clinic	JJ	O	O
trials	OTEZLA.xml:S1:680:6	trial	NNS	O	O
of	OTEZLA.xml:S1:687:2	of	IN	O	O
another	OTEZLA.xml:S1:690:7	anoth	DT	O	O
drug	OTEZLA.xml:S1:698:4	drug	NN	O	O
and	OTEZLA.xml:S1:703:3	and	CC	O	O
may	OTEZLA.xml:S1:707:3	may	MD	O	O
not	OTEZLA.xml:S1:711:3	not	RB	O	O
reflect	OTEZLA.xml:S1:715:7	reflect	VB	O	O
the	OTEZLA.xml:S1:723:3	the	DT	O	O
rates	OTEZLA.xml:S1:727:5	rate	NNS	O	O
observed	OTEZLA.xml:S1:733:8	observ	VBD	O	O
in	OTEZLA.xml:S1:742:2	in	IN	O	O
clinical	OTEZLA.xml:S1:745:8	clinic	JJ	O	O
practice	OTEZLA.xml:S1:754:8	practic	NN	O	O
.	OTEZLA.xml:S1:762:1	.	.	O	O

Psoriatic	OTEZLA.xml:S1:770:9	psoriat	JJ	O	O
Arthritis	OTEZLA.xml:S1:780:9	arthriti	NNP	O	O
Clinical	OTEZLA.xml:S1:790:8	clinic	NNP	O	O
Trials	OTEZLA.xml:S1:799:6	trial	NNP	O	O
OTEZLA	OTEZLA.xml:S1:807:6	otezla	NNP	O	O
was	OTEZLA.xml:S1:814:3	wa	VBD	O	O
evaluated	OTEZLA.xml:S1:818:9	evalu	VBN	O	O
in	OTEZLA.xml:S1:828:2	in	IN	O	O
3	OTEZLA.xml:S1:831:1	3	CD	O	O
multicenter	OTEZLA.xml:S1:833:11	multicent	NN	O	O
,	OTEZLA.xml:S1:844:1	,	,	O	O
randomized	OTEZLA.xml:S1:846:10	random	VBN	O	O
,	OTEZLA.xml:S1:856:1	,	,	O	O
double	OTEZLA.xml:S1:858:6	doubl	JJ	O	O
-	OTEZLA.xml:S1:864:1	-	:	O	O
blind	OTEZLA.xml:S1:865:5	blind	NN	O	O
,	OTEZLA.xml:S1:870:1	,	,	O	O
placebo	OTEZLA.xml:S1:872:7	placebo	SYM	O	O
-	OTEZLA.xml:S1:879:1	-	:	O	O
controlled	OTEZLA.xml:S1:880:10	control	VBN	O	O
trials	OTEZLA.xml:S1:891:6	trial	NNS	O	O
[	OTEZLA.xml:S1:898:1	[	JJ	O	O
Studies	OTEZLA.xml:S1:899:7	studi	NNPS	O	O
PsA	OTEZLA.xml:S1:907:3	psa	NNP	O	O
-	OTEZLA.xml:S1:910:1	-	:	O	O
1	OTEZLA.xml:S1:911:1	1	CD	O	O
,	OTEZLA.xml:S1:912:1	,	,	O	O
PsA	OTEZLA.xml:S1:914:3	psa	NNP	O	O
-	OTEZLA.xml:S1:917:1	-	:	O	O
2	OTEZLA.xml:S1:918:1	2	CD	O	O
,	OTEZLA.xml:S1:919:1	,	,	O	O
and	OTEZLA.xml:S1:921:3	and	CC	O	O
PsA	OTEZLA.xml:S1:925:3	psa	NNP	O	O
-	OTEZLA.xml:S1:928:1	-	:	O	O
3	OTEZLA.xml:S1:929:1	3	CD	O	O
]	OTEZLA.xml:S1:930:1	]	NN	O	O
of	OTEZLA.xml:S1:932:2	of	IN	O	O
similar	OTEZLA.xml:S1:935:7	similar	JJ	O	O
design	OTEZLA.xml:S1:943:6	design	NN	O	O
in	OTEZLA.xml:S1:950:2	in	IN	O	O
adult	OTEZLA.xml:S1:953:5	adult	NN	O	O
patients	OTEZLA.xml:S1:959:8	patient	NNS	O	O
with	OTEZLA.xml:S1:968:4	with	IN	O	O
active	OTEZLA.xml:S1:973:6	activ	JJ	O	O
psoriatic	OTEZLA.xml:S1:980:9	psoriat	JJ	O	O
arthritis	OTEZLA.xml:S1:990:9	arthriti	NN	O	O
[	OTEZLA.xml:S1:1001:1	[	NNP	O	O
see	OTEZLA.xml:S1:1002:3	see	VBP	O	O
Clinical	OTEZLA.xml:S1:1006:8	clinic	JJ	O	O
Studies	OTEZLA.xml:S1:1015:7	studi	NNP	O	O
(	OTEZLA.xml:S1:1023:1	(	(	O	O
14.1	OTEZLA.xml:S1:1024:4	14.1	CD	O	O
)]	OTEZLA.xml:S1:1028:2	)]	NN	O	O
.	OTEZLA.xml:S1:1032:1	.	.	O	O

Across	OTEZLA.xml:S1:1034:6	across	IN	O	O
the	OTEZLA.xml:S1:1041:3	the	DT	O	O
3	OTEZLA.xml:S1:1045:1	3	CD	O	O
studies	OTEZLA.xml:S1:1047:7	studi	NNS	O	O
,	OTEZLA.xml:S1:1054:1	,	,	O	O
there	OTEZLA.xml:S1:1056:5	there	EX	O	O
were	OTEZLA.xml:S1:1062:4	were	VBD	O	O
1493	OTEZLA.xml:S1:1067:4	1493	CD	O	O
patients	OTEZLA.xml:S1:1072:8	patient	NNS	O	O
randomized	OTEZLA.xml:S1:1081:10	random	VBN	O	O
equally	OTEZLA.xml:S1:1092:7	equal	RB	O	O
to	OTEZLA.xml:S1:1100:2	to	TO	O	O
placebo	OTEZLA.xml:S1:1103:7	placebo	VB	O	O
,	OTEZLA.xml:S1:1110:1	,	,	O	O
OTEZLA	OTEZLA.xml:S1:1112:6	otezla	NNP	O	O
20	OTEZLA.xml:S1:1119:2	20	CD	O	O
mg	OTEZLA.xml:S1:1122:2	mg	NN	O	O
twice	OTEZLA.xml:S1:1125:5	twice	RB	O	O
daily	OTEZLA.xml:S1:1131:5	daili	RB	O	O
or	OTEZLA.xml:S1:1137:2	or	CC	O	O
OTEZLA	OTEZLA.xml:S1:1140:6	otezla	NNP	O	O
30	OTEZLA.xml:S1:1147:2	30	CD	O	O
mg	OTEZLA.xml:S1:1150:2	mg	NN	O	O
twice	OTEZLA.xml:S1:1153:5	twice	RB	O	O
daily	OTEZLA.xml:S1:1159:5	daili	RB	O	O
.	OTEZLA.xml:S1:1164:1	.	.	O	O

Titration	OTEZLA.xml:S1:1166:9	titrat	NN	O	O
was	OTEZLA.xml:S1:1176:3	wa	VBD	O	O
used	OTEZLA.xml:S1:1180:4	use	VBN	O	O
over	OTEZLA.xml:S1:1185:4	over	IN	O	O
the	OTEZLA.xml:S1:1190:3	the	DT	O	O
first	OTEZLA.xml:S1:1194:5	first	JJ	O	O
5	OTEZLA.xml:S1:1200:1	5	CD	O	O
days	OTEZLA.xml:S1:1202:4	day	NNS	O	O
[	OTEZLA.xml:S1:1208:1	[	NNP	O	O
see	OTEZLA.xml:S1:1209:3	see	VBP	O	O
Dosage	OTEZLA.xml:S1:1213:6	dosag	NNP	O	O
and	OTEZLA.xml:S1:1220:3	and	CC	O	O
Administration	OTEZLA.xml:S1:1224:14	administr	NNP	O	O
(	OTEZLA.xml:S1:1239:1	(	(	O	O
2.1	OTEZLA.xml:S1:1240:3	2.1	CD	O	O
)	OTEZLA.xml:S1:1243:1	)	)	O	O
]	OTEZLA.xml:S1:1246:1	]	NN	O	O
.	OTEZLA.xml:S1:1247:1	.	.	O	O

Placebo	OTEZLA.xml:S1:1249:7	placebo	NN	O	O
patients	OTEZLA.xml:S1:1257:8	patient	NNS	O	O
whose	OTEZLA.xml:S1:1266:5	whose	WP$	O	O
tender	OTEZLA.xml:S1:1272:6	tender	NN	O	O
and	OTEZLA.xml:S1:1279:3	and	CC	O	O
swollen	OTEZLA.xml:S1:1283:7	swollen	JJ	O	O
joint	OTEZLA.xml:S1:1291:5	joint	NN	O	O
counts	OTEZLA.xml:S1:1297:6	count	NNS	O	O
had	OTEZLA.xml:S1:1304:3	had	VBD	O	O
not	OTEZLA.xml:S1:1308:3	not	RB	O	O
improved	OTEZLA.xml:S1:1312:8	improv	VBN	O	O
by	OTEZLA.xml:S1:1321:2	by	IN	O	O
at	OTEZLA.xml:S1:1324:2	at	IN	O	O
least	OTEZLA.xml:S1:1327:5	least	JJS	O	O
20%	OTEZLA.xml:S1:1333:3	20%	CD	O	O
were	OTEZLA.xml:S1:1337:4	were	VBD	O	O
re	OTEZLA.xml:S1:1342:2	re	VBN	O	O
-	OTEZLA.xml:S1:1344:1	-	:	O	O
randomized	OTEZLA.xml:S1:1345:10	random	VBN	O	O
1	OTEZLA.xml:S1:1356:1	1	CD	O	O
:	OTEZLA.xml:S1:1357:1	:	:	O	O
1	OTEZLA.xml:S1:1358:1	1	CD	O	O
in	OTEZLA.xml:S1:1360:2	in	IN	O	O
a	OTEZLA.xml:S1:1363:1	a	DT	O	O
blinded	OTEZLA.xml:S1:1365:7	blind	JJ	O	O
fashion	OTEZLA.xml:S1:1373:7	fashion	NN	O	O
to	OTEZLA.xml:S1:1381:2	to	TO	O	O
either	OTEZLA.xml:S1:1384:6	either	DT	O	O
OTEZLA	OTEZLA.xml:S1:1391:6	otezla	NNP	O	O
20	OTEZLA.xml:S1:1398:2	20	CD	O	O
mg	OTEZLA.xml:S1:1401:2	mg	NN	O	O
twice	OTEZLA.xml:S1:1404:5	twice	RB	O	O
daily	OTEZLA.xml:S1:1410:5	daili	RB	O	O
or	OTEZLA.xml:S1:1416:2	or	CC	O	O
30	OTEZLA.xml:S1:1419:2	30	CD	O	O
mg	OTEZLA.xml:S1:1422:2	mg	JJ	O	O
twice	OTEZLA.xml:S1:1425:5	twice	RB	O	O
daily	OTEZLA.xml:S1:1431:5	daili	RB	O	O
at	OTEZLA.xml:S1:1437:2	at	IN	O	O
week	OTEZLA.xml:S1:1440:4	week	NN	O	O
16	OTEZLA.xml:S1:1445:2	16	CD	O	O
while	OTEZLA.xml:S1:1448:5	while	IN	O	O
OTEZLA	OTEZLA.xml:S1:1454:6	otezla	NNP	O	O
patients	OTEZLA.xml:S1:1461:8	patient	NNS	O	O
remained	OTEZLA.xml:S1:1470:8	remain	VBD	O	O
on	OTEZLA.xml:S1:1479:2	on	IN	O	O
their	OTEZLA.xml:S1:1482:5	their	PRP$	O	O
initial	OTEZLA.xml:S1:1488:7	initi	JJ	O	O
treatment	OTEZLA.xml:S1:1496:9	treatment	NN	O	O
.	OTEZLA.xml:S1:1505:1	.	.	O	O

Patients	OTEZLA.xml:S1:1507:8	patient	NNS	O	O
ranged	OTEZLA.xml:S1:1516:6	rang	VBD	O	O
in	OTEZLA.xml:S1:1523:2	in	IN	O	O
age	OTEZLA.xml:S1:1526:3	age	NN	O	O
from	OTEZLA.xml:S1:1530:4	from	IN	O	O
18	OTEZLA.xml:S1:1535:2	18	CD	O	O
to	OTEZLA.xml:S1:1538:2	to	TO	O	O
83	OTEZLA.xml:S1:1541:2	83	CD	O	O
years	OTEZLA.xml:S1:1544:5	year	NNS	O	O
,	OTEZLA.xml:S1:1549:1	,	,	O	O
with	OTEZLA.xml:S1:1551:4	with	IN	O	O
an	OTEZLA.xml:S1:1556:2	an	DT	O	O
overall	OTEZLA.xml:S1:1559:7	overal	JJ	O	O
median	OTEZLA.xml:S1:1567:6	median	JJ	O	O
age	OTEZLA.xml:S1:1574:3	age	NN	O	O
of	OTEZLA.xml:S1:1578:2	of	IN	O	O
51	OTEZLA.xml:S1:1581:2	51	CD	O	O
years	OTEZLA.xml:S1:1584:5	year	NNS	O	O
.	OTEZLA.xml:S1:1589:1	.	.	O	O

The	OTEZLA.xml:S1:1595:3	the	DT	O	O
majority	OTEZLA.xml:S1:1599:8	major	NN	O	O
of	OTEZLA.xml:S1:1608:2	of	IN	O	O
the	OTEZLA.xml:S1:1611:3	the	DT	O	O
most	OTEZLA.xml:S1:1615:4	most	RBS	O	O
common	OTEZLA.xml:S1:1620:6	common	JJ	O	O
adverse	OTEZLA.xml:S1:1627:7	advers	JJ	O	O
reactions	OTEZLA.xml:S1:1635:9	reaction	NNS	O	O
presented	OTEZLA.xml:S1:1645:9	present	VBD	O	O
inTable	OTEZLA.xml:S1:1655:7	intabl	JJ	O	O
2	OTEZLA.xml:S1:1663:1	2	CD	O	O
occurred	OTEZLA.xml:S1:1664:8	occur	VBD	O	O
within	OTEZLA.xml:S1:1673:6	within	IN	O	O
the	OTEZLA.xml:S1:1680:3	the	DT	O	O
first	OTEZLA.xml:S1:1684:5	first	JJ	O	O
2	OTEZLA.xml:S1:1690:1	2	CD	O	O
weeks	OTEZLA.xml:S1:1692:5	week	NNS	O	O
of	OTEZLA.xml:S1:1698:2	of	IN	O	O
treatment	OTEZLA.xml:S1:1701:9	treatment	NN	O	O
and	OTEZLA.xml:S1:1711:3	and	CC	O	O
tended	OTEZLA.xml:S1:1715:6	tend	VBD	O	O
to	OTEZLA.xml:S1:1722:2	to	TO	O	O
resolve	OTEZLA.xml:S1:1725:7	resolv	VB	O	O
over	OTEZLA.xml:S1:1733:4	over	IN	O	O
time	OTEZLA.xml:S1:1738:4	time	NN	O	O
with	OTEZLA.xml:S1:1743:4	with	IN	O	O
continued	OTEZLA.xml:S1:1748:9	continu	JJ	O	O
dosing	OTEZLA.xml:S1:1758:6	dose	NN	O	O
.	OTEZLA.xml:S1:1764:1	.	.	O	O

Diarrhea	OTEZLA.xml:S1:1766:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
,	OTEZLA.xml:S1:1774:1	,	,	O	O
headache	OTEZLA.xml:S1:1776:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	OTEZLA.xml:S1:1784:1	,	,	O	O
and	OTEZLA.xml:S1:1786:3	and	CC	O	O
nausea	OTEZLA.xml:S1:1790:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
were	OTEZLA.xml:S1:1797:4	were	VBD	O	O
the	OTEZLA.xml:S1:1802:3	the	DT	O	O
most	OTEZLA.xml:S1:1806:4	most	RBS	O	O
commonly	OTEZLA.xml:S1:1811:8	commonli	RB	O	O
reported	OTEZLA.xml:S1:1820:8	report	VBD	O	O
adverse	OTEZLA.xml:S1:1829:7	advers	JJ	O	O
reactions	OTEZLA.xml:S1:1837:9	reaction	NNS	O	O
.	OTEZLA.xml:S1:1846:1	.	.	O	O

The	OTEZLA.xml:S1:1848:3	the	DT	O	O
most	OTEZLA.xml:S1:1852:4	most	RBS	O	O
common	OTEZLA.xml:S1:1857:6	common	JJ	O	O
adverse	OTEZLA.xml:S1:1864:7	advers	JJ	O	O
reactions	OTEZLA.xml:S1:1872:9	reaction	NNS	O	O
leading	OTEZLA.xml:S1:1882:7	lead	VBG	O	O
to	OTEZLA.xml:S1:1890:2	to	TO	O	O
discontinuation	OTEZLA.xml:S1:1893:15	discontinu	NN	O	O
for	OTEZLA.xml:S1:1909:3	for	IN	O	O
patients	OTEZLA.xml:S1:1913:8	patient	NNS	O	O
taking	OTEZLA.xml:S1:1922:6	take	VBG	O	O
OTEZLA	OTEZLA.xml:S1:1929:6	otezla	NNP	O	O
were	OTEZLA.xml:S1:1936:4	were	VBD	O	O
nausea	OTEZLA.xml:S1:1941:6	nausea	RB	B-AdverseReaction	B-AdverseReaction
(	OTEZLA.xml:S1:1948:1	(	(	O	O
1.8%	OTEZLA.xml:S1:1949:4	1.8%	CD	O	O
)	OTEZLA.xml:S1:1953:1	)	)	O	O
,	OTEZLA.xml:S1:1954:1	,	,	O	O
diarrhea	OTEZLA.xml:S1:1956:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
(	OTEZLA.xml:S1:1965:1	(	(	O	O
1.8%	OTEZLA.xml:S1:1966:4	1.8%	CD	O	O
)	OTEZLA.xml:S1:1970:1	)	)	O	O
,	OTEZLA.xml:S1:1971:1	,	,	O	O
and	OTEZLA.xml:S1:1973:3	and	CC	O	O
headache	OTEZLA.xml:S1:1977:8	headach	NN	B-AdverseReaction	B-AdverseReaction
(	OTEZLA.xml:S1:1986:1	(	(	O	O
1.2%	OTEZLA.xml:S1:1987:4	1.2%	CD	O	O
)	OTEZLA.xml:S1:1991:1	)	)	O	O
.	OTEZLA.xml:S1:1992:1	.	.	O	O

The	OTEZLA.xml:S1:1994:3	the	DT	O	O
proportion	OTEZLA.xml:S1:1998:10	proport	NN	O	O
of	OTEZLA.xml:S1:2009:2	of	IN	O	O
patients	OTEZLA.xml:S1:2012:8	patient	NNS	O	O
with	OTEZLA.xml:S1:2021:4	with	IN	O	O
psoriatic	OTEZLA.xml:S1:2026:9	psoriat	JJ	O	O
arthritis	OTEZLA.xml:S1:2036:9	arthriti	NN	O	O
who	OTEZLA.xml:S1:2046:3	who	WP	O	O
discontinued	OTEZLA.xml:S1:2050:12	discontinu	VBD	O	O
treatment	OTEZLA.xml:S1:2063:9	treatment	NN	O	O
due	OTEZLA.xml:S1:2073:3	due	JJ	O	O
to	OTEZLA.xml:S1:2077:2	to	TO	O	O
any	OTEZLA.xml:S1:2080:3	ani	DT	O	O
adverse	OTEZLA.xml:S1:2084:7	advers	JJ	O	O
reaction	OTEZLA.xml:S1:2092:8	reaction	NN	O	O
was	OTEZLA.xml:S1:2101:3	wa	VBD	O	O
4.6%	OTEZLA.xml:S1:2105:4	4.6%	CD	O	O
for	OTEZLA.xml:S1:2110:3	for	IN	O	O
patients	OTEZLA.xml:S1:2114:8	patient	NNS	O	O
taking	OTEZLA.xml:S1:2123:6	take	VBG	O	O
OTEZLA	OTEZLA.xml:S1:2130:6	otezla	NNP	O	O
30	OTEZLA.xml:S1:2137:2	30	CD	O	O
mg	OTEZLA.xml:S1:2140:2	mg	NN	O	O
twice	OTEZLA.xml:S1:2143:5	twice	RB	O	O
daily	OTEZLA.xml:S1:2149:5	daili	RB	O	O
and	OTEZLA.xml:S1:2155:3	and	CC	O	O
1.2%	OTEZLA.xml:S1:2159:4	1.2%	CD	O	O
for	OTEZLA.xml:S1:2164:3	for	IN	O	O
placebo	OTEZLA.xml:S1:2168:7	placebo	NN	O	O
-	OTEZLA.xml:S1:2175:1	-	:	O	O
treated	OTEZLA.xml:S1:2176:7	treat	JJ	O	O
patients	OTEZLA.xml:S1:2184:8	patient	NNS	O	O
.	OTEZLA.xml:S1:2192:1	.	.	O	O

Table	OTEZLA.xml:S1:2198:5	tabl	JJ	O	O
2	OTEZLA.xml:S1:2204:1	2	CD	O	O
:	OTEZLA.xml:S1:2205:1	:	:	O	O
Adverse	OTEZLA.xml:S1:2207:7	advers	JJ	O	O
Reactions	OTEZLA.xml:S1:2215:9	reaction	NNP	O	O
Reported	OTEZLA.xml:S1:2225:8	report	VBD	O	O
in	OTEZLA.xml:S1:2234:2	in	IN	O	O
2%	OTEZLA.xml:S1:2239:2	2%	CD	O	O
of	OTEZLA.xml:S1:2242:2	of	IN	O	O
Patients	OTEZLA.xml:S1:2245:8	patient	NNS	O	O
on	OTEZLA.xml:S1:2254:2	on	IN	O	O
OTEZLA	OTEZLA.xml:S1:2257:6	otezla	NNP	O	O
30	OTEZLA.xml:S1:2264:2	30	CD	O	O
mg	OTEZLA.xml:S1:2267:2	mg	NN	O	O
Twice	OTEZLA.xml:S1:2270:5	twice	NNP	O	O
Daily	OTEZLA.xml:S1:2276:5	daili	NNP	O	O
and	OTEZLA.xml:S1:2282:3	and	CC	O	O
1%	OTEZLA.xml:S1:2288:2	1%	CD	O	O
Than	OTEZLA.xml:S1:2291:4	than	NNP	O	O
That	OTEZLA.xml:S1:2296:4	that	WDT	O	O
Observed	OTEZLA.xml:S1:2301:8	observ	VBD	O	O
in	OTEZLA.xml:S1:2310:2	in	IN	O	O
Patients	OTEZLA.xml:S1:2313:8	patient	NNS	O	O
on	OTEZLA.xml:S1:2322:2	on	IN	O	O
Placebo	OTEZLA.xml:S1:2325:7	placebo	NNP	O	O
for	OTEZLA.xml:S1:2333:3	for	IN	O	O
up	OTEZLA.xml:S1:2337:2	up	RB	O	O
to	OTEZLA.xml:S1:2340:2	to	TO	O	O
Day	OTEZLA.xml:S1:2343:3	day	NNP	O	O
112	OTEZLA.xml:S1:2347:3	112	CD	O	O
(	OTEZLA.xml:S1:2351:1	(	(	O	O
Week	OTEZLA.xml:S1:2352:4	week	NNP	O	O
16	OTEZLA.xml:S1:2357:2	16	CD	O	O
)	OTEZLA.xml:S1:2359:1	)	)	O	O

a	OTEZLA.xml:S1:2365:1	a	DT	O	O
Of	OTEZLA.xml:S1:2368:2	Of	IN	O	O
the	OTEZLA.xml:S1:2371:3	the	DT	O	O
reported	OTEZLA.xml:S1:2375:8	report	VBN	O	O
gastrointestinal	OTEZLA.xml:S1:2384:16	gastrointestin	JJ	B-AdverseReaction	O
adverse	OTEZLA.xml:S1:2401:7	advers	JJ	I-AdverseReaction	O
reactions	OTEZLA.xml:S1:2409:9	reaction	NNS	I-AdverseReaction	O
,	OTEZLA.xml:S1:2418:1	,	,	O	O
1	OTEZLA.xml:S1:2420:1	1	CD	O	O
subject	OTEZLA.xml:S1:2422:7	subject	NN	O	O
experienced	OTEZLA.xml:S1:2430:11	experienc	VBD	O	O
a	OTEZLA.xml:S1:2442:1	a	DT	O	O
serious	OTEZLA.xml:S1:2444:7	seriou	JJ	O	O
adverse	OTEZLA.xml:S1:2452:7	advers	JJ	O	O
reaction	OTEZLA.xml:S1:2460:8	reaction	NN	O	O
of	OTEZLA.xml:S1:2469:2	of	IN	O	O
nausea	OTEZLA.xml:S1:2472:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
and	OTEZLA.xml:S1:2479:3	and	CC	O	O
vomiting	OTEZLA.xml:S1:2483:8	vomit	NN	B-AdverseReaction	B-AdverseReaction
in	OTEZLA.xml:S1:2492:2	in	IN	O	O
OTEZLA	OTEZLA.xml:S1:2495:6	otezla	NNP	O	O
30	OTEZLA.xml:S1:2502:2	30	CD	O	O
mg	OTEZLA.xml:S1:2505:2	mg	NN	O	O
twice	OTEZLA.xml:S1:2508:5	twice	RB	O	O
daily	OTEZLA.xml:S1:2514:5	daili	RB	O	O
;	OTEZLA.xml:S1:2519:1	;	:	O	O
1	OTEZLA.xml:S1:2521:1	1	CD	O	O
subject	OTEZLA.xml:S1:2523:7	subject	NN	O	O
treated	OTEZLA.xml:S1:2531:7	treat	VBN	O	O
with	OTEZLA.xml:S1:2539:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S1:2544:6	otezla	NNP	O	O
20	OTEZLA.xml:S1:2551:2	20	CD	O	O
mg	OTEZLA.xml:S1:2554:2	mg	NN	O	O
twice	OTEZLA.xml:S1:2557:5	twice	RB	O	O
daily	OTEZLA.xml:S1:2563:5	daili	RB	O	O
experienced	OTEZLA.xml:S1:2569:11	experienc	VBD	O	O
a	OTEZLA.xml:S1:2581:1	a	DT	O	O
serious	OTEZLA.xml:S1:2583:7	seriou	JJ	O	O
adverse	OTEZLA.xml:S1:2591:7	advers	JJ	O	O
reaction	OTEZLA.xml:S1:2599:8	reaction	NN	O	O
of	OTEZLA.xml:S1:2608:2	of	IN	O	O
diarrhea	OTEZLA.xml:S1:2611:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
;	OTEZLA.xml:S1:2619:1	;	:	O	O
1	OTEZLA.xml:S1:2621:1	1	CD	O	O
patient	OTEZLA.xml:S1:2623:7	patient	NN	O	O
treated	OTEZLA.xml:S1:2631:7	treat	VBN	O	O
with	OTEZLA.xml:S1:2639:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S1:2644:6	otezla	NNP	O	O
30	OTEZLA.xml:S1:2651:2	30	CD	O	O
mg	OTEZLA.xml:S1:2654:2	mg	NN	O	O
twice	OTEZLA.xml:S1:2657:5	twice	RB	O	O
daily	OTEZLA.xml:S1:2663:5	daili	RB	O	O
experienced	OTEZLA.xml:S1:2669:11	experienc	VBD	O	O
a	OTEZLA.xml:S1:2681:1	a	DT	O	O
serious	OTEZLA.xml:S1:2683:7	seriou	JJ	O	O
adverse	OTEZLA.xml:S1:2691:7	advers	JJ	O	O
reaction	OTEZLA.xml:S1:2699:8	reaction	NN	O	O
of	OTEZLA.xml:S1:2708:2	of	IN	O	O
headache	OTEZLA.xml:S1:2711:8	headach	NN	B-AdverseReaction	B-AdverseReaction
.	OTEZLA.xml:S1:2719:1	.	.	O	O

b	OTEZLA.xml:S1:2727:1	b	NN	O	O
Of	OTEZLA.xml:S1:2730:2	Of	IN	O	O
the	OTEZLA.xml:S1:2733:3	the	DT	O	O
reported	OTEZLA.xml:S1:2737:8	report	JJ	O	O
adverse	OTEZLA.xml:S1:2746:7	advers	JJ	O	O
drug	OTEZLA.xml:S1:2754:4	drug	NN	O	O
reactions	OTEZLA.xml:S1:2759:9	reaction	NNS	O	O
none	OTEZLA.xml:S1:2769:4	none	NN	O	O
were	OTEZLA.xml:S1:2774:4	were	VBD	O	O
serious	OTEZLA.xml:S1:2779:7	seriou	JJ	O	O
.	OTEZLA.xml:S1:2786:1	.	.	O	O

c	OTEZLA.xml:S1:2794:1	c	NNS	O	O
n	OTEZLA.xml:S1:2797:1	n	RB	O	O
(	OTEZLA.xml:S1:2799:1	(	(	O	O
)	OTEZLA.xml:S1:2801:1	)	)	O	O
indicates	OTEZLA.xml:S1:2803:9	indic	VBZ	O	O
number	OTEZLA.xml:S1:2813:6	number	NN	O	O
of	OTEZLA.xml:S1:2820:2	of	IN	O	O
patients	OTEZLA.xml:S1:2823:8	patient	NNS	O	O
and	OTEZLA.xml:S1:2832:3	and	CC	O	O
percent	OTEZLA.xml:S1:2836:7	percent	NN	O	O
.	OTEZLA.xml:S1:2843:1	.	.	O	O

Placebo	OTEZLA.xml:S1:2879:7	placebo	NN	O	O

OTEZLA	OTEZLA.xml:S1:2906:6	otezla	$	O	O
30	OTEZLA.xml:S1:2913:2	30	CD	O	O
mg	OTEZLA.xml:S1:2916:2	mg	NN	O	O
BID	OTEZLA.xml:S1:2919:3	bid	NN	O	O

Preferred	OTEZLA.xml:S1:2936:9	prefer	JJ	O	O
Term	OTEZLA.xml:S1:2946:4	term	NNP	O	O
Day	OTEZLA.xml:S1:2963:3	day	NNP	O	O
1	OTEZLA.xml:S1:2967:1	1	CD	O	O
to	OTEZLA.xml:S1:2969:2	to	TO	O	O
5	OTEZLA.xml:S1:2972:1	5	CD	O	O
(	OTEZLA.xml:S1:2973:1	(	(	O	O
N	OTEZLA.xml:S1:2974:1	N	NNP	O	O
495	OTEZLA.xml:S1:2976:3	495	CD	O	O
)	OTEZLA.xml:S1:2979:1	)	)	O	O
n	OTEZLA.xml:S1:2980:1	n	FW	O	O
(	OTEZLA.xml:S1:2982:1	(	(	O	O
)	OTEZLA.xml:S1:2984:1	)	)	O	O
c	OTEZLA.xml:S1:2987:1	c	VBP	O	O
Day	OTEZLA.xml:S1:2992:3	day	$	O	O
6	OTEZLA.xml:S1:2996:1	6	CD	O	O
to	OTEZLA.xml:S1:2998:2	to	TO	O	O
Day	OTEZLA.xml:S1:3001:3	day	NNP	O	O
112	OTEZLA.xml:S1:3005:3	112	CD	O	O
(	OTEZLA.xml:S1:3008:1	(	(	O	O
N	OTEZLA.xml:S1:3009:1	N	NNP	O	O
490	OTEZLA.xml:S1:3011:3	490	CD	O	O
)	OTEZLA.xml:S1:3014:1	)	)	O	O
n	OTEZLA.xml:S1:3015:1	n	FW	O	O
(	OTEZLA.xml:S1:3017:1	(	(	O	O
)	OTEZLA.xml:S1:3019:1	)	)	O	O
Day	OTEZLA.xml:S1:3022:3	day	VBZ	O	O
1	OTEZLA.xml:S1:3026:1	1	CD	O	O
to	OTEZLA.xml:S1:3028:2	to	TO	O	O
5	OTEZLA.xml:S1:3031:1	5	CD	O	O
(	OTEZLA.xml:S1:3032:1	(	(	O	O
N	OTEZLA.xml:S1:3033:1	N	NNP	O	O
497	OTEZLA.xml:S1:3035:3	497	CD	O	O
)	OTEZLA.xml:S1:3038:1	)	)	O	O
n	OTEZLA.xml:S1:3039:1	n	FW	O	O
(	OTEZLA.xml:S1:3041:1	(	(	O	O
)	OTEZLA.xml:S1:3043:1	)	)	O	O
Day	OTEZLA.xml:S1:3049:3	day	VBZ	O	O
6	OTEZLA.xml:S1:3053:1	6	CD	O	O
to	OTEZLA.xml:S1:3055:2	to	TO	O	O
Day	OTEZLA.xml:S1:3058:3	day	NNP	O	O
112	OTEZLA.xml:S1:3062:3	112	CD	O	O
(	OTEZLA.xml:S1:3065:1	(	(	O	O
N	OTEZLA.xml:S1:3066:1	N	NNP	O	O
493	OTEZLA.xml:S1:3068:3	493	CD	O	O
)	OTEZLA.xml:S1:3071:1	)	)	O	O
n	OTEZLA.xml:S1:3072:1	n	FW	O	O
(	OTEZLA.xml:S1:3074:1	(	(	O	O
)	OTEZLA.xml:S1:3076:1	)	)	O	O

Diarrhea	OTEZLA.xml:S1:3082:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
a	OTEZLA.xml:S1:3092:1	a	DT	O	O
6	OTEZLA.xml:S1:3109:1	6	CD	O	O
(	OTEZLA.xml:S1:3111:1	(	(	O	O
1.2	OTEZLA.xml:S1:3113:3	1.2	CD	O	O
)	OTEZLA.xml:S1:3116:1	)	)	O	O
8	OTEZLA.xml:S1:3136:1	8	CD	O	O
(	OTEZLA.xml:S1:3138:1	(	(	O	O
1.6	OTEZLA.xml:S1:3140:3	1.6	CD	O	O
)	OTEZLA.xml:S1:3143:1	)	)	O	O
46	OTEZLA.xml:S1:3163:2	46	CD	O	O
(	OTEZLA.xml:S1:3166:1	(	(	O	O
9.3	OTEZLA.xml:S1:3168:3	9.3	CD	O	O
)	OTEZLA.xml:S1:3171:1	)	)	O	O
38	OTEZLA.xml:S1:3190:2	38	CD	O	O
(	OTEZLA.xml:S1:3193:1	(	(	O	O
7.7	OTEZLA.xml:S1:3195:3	7.7	CD	O	O
)	OTEZLA.xml:S1:3198:1	)	)	O	O

Nausea	OTEZLA.xml:S1:3220:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
a	OTEZLA.xml:S1:3228:1	a	DT	O	O
7	OTEZLA.xml:S1:3247:1	7	CD	O	O
(	OTEZLA.xml:S1:3249:1	(	(	O	O
1.4	OTEZLA.xml:S1:3251:3	1.4	CD	O	O
)	OTEZLA.xml:S1:3254:1	)	)	O	O
15	OTEZLA.xml:S1:3274:2	15	CD	O	O
(	OTEZLA.xml:S1:3277:1	(	(	O	O
3.1	OTEZLA.xml:S1:3279:3	3.1	CD	O	O
)	OTEZLA.xml:S1:3282:1	)	)	O	O
37	OTEZLA.xml:S1:3301:2	37	CD	O	O
(	OTEZLA.xml:S1:3304:1	(	(	O	O
7.4	OTEZLA.xml:S1:3306:3	7.4	CD	O	O
)	OTEZLA.xml:S1:3309:1	)	)	O	O
44	OTEZLA.xml:S1:3328:2	44	CD	O	O
(	OTEZLA.xml:S1:3331:1	(	(	O	O
8.9	OTEZLA.xml:S1:3333:3	8.9	CD	O	O
)	OTEZLA.xml:S1:3336:1	)	)	O	O

Headache	OTEZLA.xml:S1:3358:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
a	OTEZLA.xml:S1:3368:1	a	DT	O	O
9	OTEZLA.xml:S1:3385:1	9	CD	O	O
(	OTEZLA.xml:S1:3387:1	(	(	O	O
1.8	OTEZLA.xml:S1:3389:3	1.8	CD	O	O
)	OTEZLA.xml:S1:3392:1	)	)	O	O
11	OTEZLA.xml:S1:3412:2	11	CD	O	O
(	OTEZLA.xml:S1:3415:1	(	(	O	O
2.2	OTEZLA.xml:S1:3417:3	2.2	CD	O	O
)	OTEZLA.xml:S1:3420:1	)	)	O	O
24	OTEZLA.xml:S1:3439:2	24	CD	O	O
(	OTEZLA.xml:S1:3442:1	(	(	O	O
4.8	OTEZLA.xml:S1:3444:3	4.8	CD	O	O
)	OTEZLA.xml:S1:3447:1	)	)	O	O
29	OTEZLA.xml:S1:3466:2	29	CD	O	O
(	OTEZLA.xml:S1:3469:1	(	(	O	O
5.9	OTEZLA.xml:S1:3471:3	5.9	CD	O	O
)	OTEZLA.xml:S1:3474:1	)	)	O	O

Upper	OTEZLA.xml:S1:3496:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	OTEZLA.xml:S1:3502:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tractinfection	OTEZLA.xml:S1:3514:14	tractinfect	NN	I-AdverseReaction	I-AdverseReaction
b	OTEZLA.xml:S1:3530:1	b	NN	O	I-AdverseReaction
3	OTEZLA.xml:S1:3535:1	3	CD	O	O
(	OTEZLA.xml:S1:3537:1	(	(	O	O
0.6	OTEZLA.xml:S1:3539:3	0.6	CD	O	O
)	OTEZLA.xml:S1:3542:1	)	)	O	O
9	OTEZLA.xml:S1:3562:1	9	CD	O	O
(	OTEZLA.xml:S1:3564:1	(	(	O	O
1.8	OTEZLA.xml:S1:3566:3	1.8	CD	O	O
)	OTEZLA.xml:S1:3569:1	)	)	O	O
3	OTEZLA.xml:S1:3589:1	3	CD	O	O
(	OTEZLA.xml:S1:3591:1	(	(	O	O
0.6	OTEZLA.xml:S1:3593:3	0.6	CD	O	O
)	OTEZLA.xml:S1:3596:1	)	)	O	O
19	OTEZLA.xml:S1:3616:2	19	CD	O	O
(	OTEZLA.xml:S1:3619:1	(	(	O	O
3.9	OTEZLA.xml:S1:3621:3	3.9	CD	O	O
)	OTEZLA.xml:S1:3624:1	)	)	O	O

Vomiting	OTEZLA.xml:S1:3646:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
a	OTEZLA.xml:S1:3656:1	a	DT	O	O
2	OTEZLA.xml:S1:3673:1	2	CD	O	O
(	OTEZLA.xml:S1:3675:1	(	(	O	O
0.4	OTEZLA.xml:S1:3677:3	0.4	CD	O	O
)	OTEZLA.xml:S1:3680:1	)	)	O	O
2	OTEZLA.xml:S1:3700:1	2	CD	O	O
(	OTEZLA.xml:S1:3702:1	(	(	O	O
0.4	OTEZLA.xml:S1:3704:3	0.4	CD	O	O
)	OTEZLA.xml:S1:3707:1	)	)	O	O
4	OTEZLA.xml:S1:3727:1	4	CD	O	O
(	OTEZLA.xml:S1:3729:1	(	(	O	O
0.8	OTEZLA.xml:S1:3731:3	0.8	CD	O	O
)	OTEZLA.xml:S1:3734:1	)	)	O	O
16	OTEZLA.xml:S1:3754:2	16	CD	O	O
(	OTEZLA.xml:S1:3757:1	(	(	O	O
3.2	OTEZLA.xml:S1:3759:3	3.2	CD	O	O
)	OTEZLA.xml:S1:3762:1	)	)	O	O

Nasopharyngitis	OTEZLA.xml:S1:3784:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
b	OTEZLA.xml:S1:3801:1	b	NN	O	I-AdverseReaction
1	OTEZLA.xml:S1:3811:1	1	CD	O	O
(	OTEZLA.xml:S1:3813:1	(	(	O	O
0.2	OTEZLA.xml:S1:3815:3	0.2	CD	O	O
)	OTEZLA.xml:S1:3818:1	)	)	O	O
8	OTEZLA.xml:S1:3838:1	8	CD	O	O
(	OTEZLA.xml:S1:3840:1	(	(	O	O
1.6	OTEZLA.xml:S1:3842:3	1.6	CD	O	O
)	OTEZLA.xml:S1:3845:1	)	)	O	O
1	OTEZLA.xml:S1:3865:1	1	CD	O	O
(	OTEZLA.xml:S1:3867:1	(	(	O	O
0.2	OTEZLA.xml:S1:3869:3	0.2	CD	O	O
)	OTEZLA.xml:S1:3872:1	)	)	O	O
13	OTEZLA.xml:S1:3892:2	13	CD	O	O
(	OTEZLA.xml:S1:3895:1	(	(	O	O
2.6	OTEZLA.xml:S1:3897:3	2.6	CD	O	O
)	OTEZLA.xml:S1:3900:1	)	)	O	O

Abdominal	OTEZLA.xml:S1:3922:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	OTEZLA.xml:S1:3932:4	pain	NN	I-AdverseReaction	I-AdverseReaction
upper	OTEZLA.xml:S1:3937:5	upper	JJ	I-AdverseReaction	I-AdverseReaction
b	OTEZLA.xml:S1:3944:1	b	NN	O	I-AdverseReaction
0	OTEZLA.xml:S1:3949:1	0	CD	O	O
(	OTEZLA.xml:S1:3951:1	(	(	O	O
0.0	OTEZLA.xml:S1:3953:3	0.0	CD	O	O
)	OTEZLA.xml:S1:3956:1	)	)	O	O
1	OTEZLA.xml:S1:3976:1	1	CD	O	O
(	OTEZLA.xml:S1:3978:1	(	(	O	O
0.2	OTEZLA.xml:S1:3980:3	0.2	CD	O	O
)	OTEZLA.xml:S1:3983:1	)	)	O	O
3	OTEZLA.xml:S1:4003:1	3	CD	O	O
(	OTEZLA.xml:S1:4005:1	(	(	O	O
0.6	OTEZLA.xml:S1:4007:3	0.6	CD	O	O
)	OTEZLA.xml:S1:4010:1	)	)	O	O
10	OTEZLA.xml:S1:4030:2	10	CD	O	O
(	OTEZLA.xml:S1:4033:1	(	(	O	O
2.0	OTEZLA.xml:S1:4035:3	2.0	CD	O	O
)	OTEZLA.xml:S1:4038:1	)	)	O	O

Other	OTEZLA.xml:S1:4065:5	other	JJ	O	O
adverse	OTEZLA.xml:S1:4071:7	advers	JJ	O	O
reactions	OTEZLA.xml:S1:4079:9	reaction	NNS	O	O
reported	OTEZLA.xml:S1:4089:8	report	VBN	O	O
in	OTEZLA.xml:S1:4098:2	in	IN	O	O
patients	OTEZLA.xml:S1:4101:8	patient	NNS	O	O
on	OTEZLA.xml:S1:4110:2	on	IN	O	O
OTEZLA	OTEZLA.xml:S1:4113:6	otezla	NNP	O	O
in	OTEZLA.xml:S1:4120:2	in	IN	O	O
clinical	OTEZLA.xml:S1:4123:8	clinic	JJ	O	O
studies	OTEZLA.xml:S1:4132:7	studi	NNS	O	O
including	OTEZLA.xml:S1:4140:9	includ	VBG	O	O
extension	OTEZLA.xml:S1:4150:9	extens	NN	O	O
studies	OTEZLA.xml:S1:4160:7	studi	NNS	O	O
:	OTEZLA.xml:S1:4167:1	:	:	O	O
Immune	OTEZLA.xml:S1:4170:6	immun	NNP	O	O
system	OTEZLA.xml:S1:4177:6	system	NN	O	O
disorders	OTEZLA.xml:S1:4184:9	disord	NNS	O	O
:	OTEZLA.xml:S1:4193:1	:	:	O	O
Hypersensitivity	OTEZLA.xml:S1:4196:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
Investigations	OTEZLA.xml:S1:4214:14	investig	NNS	O	I-AdverseReaction
:	OTEZLA.xml:S1:4228:1	:	:	O	O
Weight	OTEZLA.xml:S1:4231:6	weight	NNP	B-AdverseReaction	O
decrease	OTEZLA.xml:S1:4238:8	decreas	VBZ	I-AdverseReaction	O
Gastrointestinal	OTEZLA.xml:S1:4248:16	gastrointestin	NNP	O	O
Disorders	OTEZLA.xml:S1:4265:9	disord	NNPS	O	O
:	OTEZLA.xml:S1:4274:1	:	:	O	O
Frequent	OTEZLA.xml:S1:4277:8	frequent	JJ	B-AdverseReaction	B-AdverseReaction
bowel	OTEZLA.xml:S1:4286:5	bowel	NN	I-AdverseReaction	I-AdverseReaction
movement	OTEZLA.xml:S1:4292:8	movement	NN	I-AdverseReaction	I-AdverseReaction
,	OTEZLA.xml:S1:4300:1	,	,	O	O
gastroesophageal	OTEZLA.xml:S1:4302:16	gastroesophag	JJ	B-AdverseReaction	B-AdverseReaction
reflux	OTEZLA.xml:S1:4319:6	reflux	NN	I-AdverseReaction	I-AdverseReaction
disease	OTEZLA.xml:S1:4326:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
,	OTEZLA.xml:S1:4333:1	,	,	O	O
dyspepsia	OTEZLA.xml:S1:4335:9	dyspepsia	JJ	B-AdverseReaction	O
Metabolism	OTEZLA.xml:S1:4346:10	metabol	NNP	O	O
and	OTEZLA.xml:S1:4357:3	and	CC	O	O
Nutrition	OTEZLA.xml:S1:4361:9	nutrit	NNP	O	O
Disorders	OTEZLA.xml:S1:4371:9	disord	NNS	O	O
:	OTEZLA.xml:S1:4380:1	:	:	O	O
Decreased	OTEZLA.xml:S1:4383:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	OTEZLA.xml:S1:4393:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
Nervous	OTEZLA.xml:S1:4404:7	nervou	JJ	O	O
System	OTEZLA.xml:S1:4412:6	system	NN	O	O
Disorders	OTEZLA.xml:S1:4419:9	disord	NNS	O	O
:	OTEZLA.xml:S1:4428:1	:	:	O	O
Migraine	OTEZLA.xml:S1:4431:8	migrain	NNP	B-AdverseReaction	B-AdverseReaction
Respiratory	OTEZLA.xml:S1:4441:11	respiratori	NNP	O	I-AdverseReaction
,	OTEZLA.xml:S1:4452:1	,	,	O	O
Thoracic	OTEZLA.xml:S1:4454:8	thorac	NNP	O	O
,	OTEZLA.xml:S1:4462:1	,	,	O	O
and	OTEZLA.xml:S1:4464:3	and	CC	O	O
Mediastinal	OTEZLA.xml:S1:4468:11	mediastin	NNP	O	O
Disorders	OTEZLA.xml:S1:4480:9	disord	NNS	O	O
:	OTEZLA.xml:S1:4489:1	:	:	O	O
Cough	OTEZLA.xml:S1:4492:5	cough	NNP	B-AdverseReaction	B-AdverseReaction
Skin	OTEZLA.xml:S1:4499:4	skin	NNP	O	I-AdverseReaction
and	OTEZLA.xml:S1:4504:3	and	CC	O	O
Subcutaneous	OTEZLA.xml:S1:4508:12	subcutan	NNP	O	O
Tissue	OTEZLA.xml:S1:4521:6	tissu	NNP	O	O
Disorders	OTEZLA.xml:S1:4528:9	disord	NNP	O	O
:	OTEZLA.xml:S1:4537:1	:	:	O	O
Rash	OTEZLA.xml:S1:4540:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
1	OTEZLA.xml:S1:4545:1	1	CD	O	O
patient	OTEZLA.xml:S1:4547:7	patient	NN	O	O
treated	OTEZLA.xml:S1:4555:7	treat	VBN	O	O
with	OTEZLA.xml:S1:4563:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S1:4568:6	otezla	NNP	O	O
30	OTEZLA.xml:S1:4575:2	30	CD	O	O
mg	OTEZLA.xml:S1:4578:2	mg	NN	O	O
twice	OTEZLA.xml:S1:4581:5	twice	RB	O	O
daily	OTEZLA.xml:S1:4587:5	daili	RB	O	O
experienced	OTEZLA.xml:S1:4593:11	experienc	VBD	O	O
a	OTEZLA.xml:S1:4605:1	a	DT	O	O
serious	OTEZLA.xml:S1:4607:7	seriou	JJ	O	O
adverse	OTEZLA.xml:S1:4615:7	advers	JJ	O	O
reaction	OTEZLA.xml:S1:4623:8	reaction	NN	O	O
.	OTEZLA.xml:S1:4631:1	.	.	O	O

Psoriasis	OTEZLA.xml:S1:4639:9	psoriasi	NN	O	O

Clinical	OTEZLA.xml:S1:4649:8	clinic	JJ	O	O
Trials	OTEZLA.xml:S1:4658:6	trial	NNS	O	O
The	OTEZLA.xml:S1:4666:3	the	DT	O	O
safety	OTEZLA.xml:S1:4670:6	safeti	NN	O	O
of	OTEZLA.xml:S1:4677:2	of	IN	O	O
OTEZLA	OTEZLA.xml:S1:4680:6	otezla	NNP	O	O
(	OTEZLA.xml:S1:4688:1	(	(	O	O
r	OTEZLA.xml:S1:4689:1	r	NN	O	O
)	OTEZLA.xml:S1:4690:1	)	)	O	O
was	OTEZLA.xml:S1:4693:3	wa	VBD	O	O
assessed	OTEZLA.xml:S1:4697:8	assess	VBN	O	O
in	OTEZLA.xml:S1:4706:2	in	IN	O	O
1426	OTEZLA.xml:S1:4709:4	1426	CD	O	O
subjects	OTEZLA.xml:S1:4714:8	subject	NNS	O	O
in	OTEZLA.xml:S1:4723:2	in	IN	O	O
3	OTEZLA.xml:S1:4726:1	3	CD	O	O
randomized	OTEZLA.xml:S1:4728:10	random	NNS	O	O
,	OTEZLA.xml:S1:4738:1	,	,	O	O
double	OTEZLA.xml:S1:4740:6	doubl	JJ	O	O
-	OTEZLA.xml:S1:4746:1	-	:	O	O
blind	OTEZLA.xml:S1:4747:5	blind	NN	O	O
,	OTEZLA.xml:S1:4752:1	,	,	O	O
placebo	OTEZLA.xml:S1:4754:7	placebo	SYM	O	O
-	OTEZLA.xml:S1:4761:1	-	:	O	O
controlled	OTEZLA.xml:S1:4762:10	control	VBN	O	O
trials	OTEZLA.xml:S1:4773:6	trial	NNS	O	O
in	OTEZLA.xml:S1:4780:2	in	IN	O	O
adult	OTEZLA.xml:S1:4783:5	adult	NN	O	O
subjects	OTEZLA.xml:S1:4789:8	subject	NNS	O	O
with	OTEZLA.xml:S1:4798:4	with	IN	O	O
moderate	OTEZLA.xml:S1:4803:8	moder	JJ	O	O
to	OTEZLA.xml:S1:4812:2	to	TO	O	O
severe	OTEZLA.xml:S1:4815:6	sever	VB	O	O
plaque	OTEZLA.xml:S1:4822:6	plaqu	JJ	O	O
psoriasis	OTEZLA.xml:S1:4829:9	psoriasi	NN	O	O
who	OTEZLA.xml:S1:4839:3	who	WP	O	O
were	OTEZLA.xml:S1:4843:4	were	VBD	O	O
candidates	OTEZLA.xml:S1:4848:10	candid	NNS	O	O
for	OTEZLA.xml:S1:4859:3	for	IN	O	O
phototherapy	OTEZLA.xml:S1:4863:12	phototherapi	NN	O	O
or	OTEZLA.xml:S1:4876:2	or	CC	O	O
systemic	OTEZLA.xml:S1:4879:8	system	JJ	O	O
therapy	OTEZLA.xml:S1:4888:7	therapi	NN	O	O
.	OTEZLA.xml:S1:4895:1	.	.	O	O

Subjects	OTEZLA.xml:S1:4897:8	subject	NNS	O	O
were	OTEZLA.xml:S1:4906:4	were	VBD	O	O
randomized	OTEZLA.xml:S1:4911:10	random	VBN	O	O
to	OTEZLA.xml:S1:4922:2	to	TO	O	O
receive	OTEZLA.xml:S1:4925:7	receiv	VB	O	O
OTEZLA	OTEZLA.xml:S1:4933:6	otezla	NNP	O	O
30	OTEZLA.xml:S1:4940:2	30	CD	O	O
mg	OTEZLA.xml:S1:4943:2	mg	NN	O	O
twice	OTEZLA.xml:S1:4946:5	twice	RB	O	O
daily	OTEZLA.xml:S1:4952:5	daili	RB	O	O
or	OTEZLA.xml:S1:4958:2	or	CC	O	O
placebo	OTEZLA.xml:S1:4961:7	placebo	VB	O	O
twice	OTEZLA.xml:S1:4969:5	twice	JJ	O	O
daily	OTEZLA.xml:S1:4975:5	daili	RB	O	O
.	OTEZLA.xml:S1:4980:1	.	.	O	O

Titration	OTEZLA.xml:S1:4982:9	titrat	NN	O	O
was	OTEZLA.xml:S1:4992:3	wa	VBD	O	O
used	OTEZLA.xml:S1:4996:4	use	VBN	O	O
over	OTEZLA.xml:S1:5001:4	over	IN	O	O
the	OTEZLA.xml:S1:5006:3	the	DT	O	O
first	OTEZLA.xml:S1:5010:5	first	JJ	O	O
5	OTEZLA.xml:S1:5016:1	5	CD	O	O
days	OTEZLA.xml:S1:5018:4	day	NNS	O	O
[	OTEZLA.xml:S1:5024:1	[	NNP	O	O
see	OTEZLA.xml:S1:5025:3	see	VBP	O	O
Dosage	OTEZLA.xml:S1:5029:6	dosag	NNP	O	O
and	OTEZLA.xml:S1:5036:3	and	CC	O	O
Administration	OTEZLA.xml:S1:5040:14	administr	NNP	O	O
(	OTEZLA.xml:S1:5055:1	(	(	O	O
2.1	OTEZLA.xml:S1:5056:3	2.1	CD	O	O
)	OTEZLA.xml:S1:5059:1	)	)	O	O
]	OTEZLA.xml:S1:5062:1	]	NN	O	O
.	OTEZLA.xml:S1:5063:1	.	.	O	O

Subjects	OTEZLA.xml:S1:5065:8	subject	NNS	O	O
ranged	OTEZLA.xml:S1:5074:6	rang	VBD	O	O
in	OTEZLA.xml:S1:5081:2	in	IN	O	O
age	OTEZLA.xml:S1:5084:3	age	NN	O	O
from	OTEZLA.xml:S1:5088:4	from	IN	O	O
18	OTEZLA.xml:S1:5093:2	18	CD	O	O
to	OTEZLA.xml:S1:5096:2	to	TO	O	O
83	OTEZLA.xml:S1:5099:2	83	CD	O	O
years	OTEZLA.xml:S1:5102:5	year	NNS	O	O
,	OTEZLA.xml:S1:5107:1	,	,	O	O
with	OTEZLA.xml:S1:5109:4	with	IN	O	O
an	OTEZLA.xml:S1:5114:2	an	DT	O	O
overall	OTEZLA.xml:S1:5117:7	overal	JJ	O	O
median	OTEZLA.xml:S1:5125:6	median	JJ	O	O
age	OTEZLA.xml:S1:5132:3	age	NN	O	O
of	OTEZLA.xml:S1:5136:2	of	IN	O	O
46	OTEZLA.xml:S1:5139:2	46	CD	O	O
years	OTEZLA.xml:S1:5142:5	year	NNS	O	O
.	OTEZLA.xml:S1:5147:1	.	.	O	O

Diarrhea	OTEZLA.xml:S1:5153:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
,	OTEZLA.xml:S1:5161:1	,	,	O	O
nausea	OTEZLA.xml:S1:5163:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	OTEZLA.xml:S1:5169:1	,	,	O	O
and	OTEZLA.xml:S1:5171:3	and	CC	O	O
upper	OTEZLA.xml:S1:5175:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	OTEZLA.xml:S1:5181:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	OTEZLA.xml:S1:5193:5	tract	JJ	I-AdverseReaction	I-AdverseReaction
infection	OTEZLA.xml:S1:5199:9	infect	NN	I-AdverseReaction	I-AdverseReaction
were	OTEZLA.xml:S1:5209:4	were	VBD	O	O
the	OTEZLA.xml:S1:5214:3	the	DT	O	O
most	OTEZLA.xml:S1:5218:4	most	RBS	O	O
commonly	OTEZLA.xml:S1:5223:8	commonli	RB	O	O
reported	OTEZLA.xml:S1:5232:8	report	VBD	O	O
adverse	OTEZLA.xml:S1:5241:7	advers	JJ	O	O
reactions	OTEZLA.xml:S1:5249:9	reaction	NNS	O	O
.	OTEZLA.xml:S1:5258:1	.	.	O	O

The	OTEZLA.xml:S1:5260:3	the	DT	O	O
most	OTEZLA.xml:S1:5264:4	most	RBS	O	O
common	OTEZLA.xml:S1:5269:6	common	JJ	O	O
adverse	OTEZLA.xml:S1:5276:7	advers	JJ	O	O
reactions	OTEZLA.xml:S1:5284:9	reaction	NNS	O	O
leading	OTEZLA.xml:S1:5294:7	lead	VBG	O	O
to	OTEZLA.xml:S1:5302:2	to	TO	O	O
discontinuation	OTEZLA.xml:S1:5305:15	discontinu	NN	O	O
for	OTEZLA.xml:S1:5321:3	for	IN	O	O
subjects	OTEZLA.xml:S1:5325:8	subject	NNS	O	O
taking	OTEZLA.xml:S1:5334:6	take	VBG	O	O
OTEZLA	OTEZLA.xml:S1:5341:6	otezla	NNP	O	O
were	OTEZLA.xml:S1:5348:4	were	VBD	O	O
nausea	OTEZLA.xml:S1:5353:6	nausea	RB	B-AdverseReaction	B-AdverseReaction
(	OTEZLA.xml:S1:5360:1	(	(	O	O
1.6%	OTEZLA.xml:S1:5361:4	1.6%	CD	O	O
)	OTEZLA.xml:S1:5365:1	)	)	O	O
,	OTEZLA.xml:S1:5366:1	,	,	O	O
diarrhea	OTEZLA.xml:S1:5368:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
(	OTEZLA.xml:S1:5377:1	(	(	O	O
1.0%	OTEZLA.xml:S1:5378:4	1.0%	CD	O	O
)	OTEZLA.xml:S1:5382:1	)	)	O	O
,	OTEZLA.xml:S1:5383:1	,	,	O	O
and	OTEZLA.xml:S1:5385:3	and	CC	O	O
headache	OTEZLA.xml:S1:5389:8	headach	NN	B-AdverseReaction	B-AdverseReaction
(	OTEZLA.xml:S1:5398:1	(	(	O	O
0.8%	OTEZLA.xml:S1:5399:4	0.8%	CD	O	O
)	OTEZLA.xml:S1:5403:1	)	)	O	O
.	OTEZLA.xml:S1:5404:1	.	.	O	O

The	OTEZLA.xml:S1:5406:3	the	DT	O	O
proportion	OTEZLA.xml:S1:5410:10	proport	NN	O	O
of	OTEZLA.xml:S1:5421:2	of	IN	O	O
subjects	OTEZLA.xml:S1:5424:8	subject	NNS	O	O
with	OTEZLA.xml:S1:5433:4	with	IN	O	O
psoriasis	OTEZLA.xml:S1:5438:9	psoriasi	NN	O	O
who	OTEZLA.xml:S1:5448:3	who	WP	O	O
discontinued	OTEZLA.xml:S1:5452:12	discontinu	VBD	O	O
treatment	OTEZLA.xml:S1:5465:9	treatment	NN	O	O
due	OTEZLA.xml:S1:5475:3	due	JJ	O	O
to	OTEZLA.xml:S1:5479:2	to	TO	O	O
any	OTEZLA.xml:S1:5482:3	ani	DT	O	O
adverse	OTEZLA.xml:S1:5486:7	advers	JJ	O	O
reaction	OTEZLA.xml:S1:5494:8	reaction	NN	O	O
was	OTEZLA.xml:S1:5503:3	wa	VBD	O	O
6.1%	OTEZLA.xml:S1:5507:4	6.1%	CD	O	O
for	OTEZLA.xml:S1:5512:3	for	IN	O	O
subjects	OTEZLA.xml:S1:5516:8	subject	NNS	O	O
treated	OTEZLA.xml:S1:5525:7	treat	VBN	O	O
with	OTEZLA.xml:S1:5533:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S1:5538:6	otezla	NNP	O	O
30	OTEZLA.xml:S1:5545:2	30	CD	O	O
mg	OTEZLA.xml:S1:5548:2	mg	NN	O	O
twice	OTEZLA.xml:S1:5551:5	twice	RB	O	O
daily	OTEZLA.xml:S1:5557:5	daili	RB	O	O
and	OTEZLA.xml:S1:5563:3	and	CC	O	O
4.1%	OTEZLA.xml:S1:5567:4	4.1%	CD	O	O
for	OTEZLA.xml:S1:5572:3	for	IN	O	O
placebo	OTEZLA.xml:S1:5576:7	placebo	NN	O	O
-	OTEZLA.xml:S1:5583:1	-	:	O	O
treated	OTEZLA.xml:S1:5584:7	treat	JJ	O	O
subjects	OTEZLA.xml:S1:5592:8	subject	NNS	O	O
.	OTEZLA.xml:S1:5600:1	.	.	O	O

Table	OTEZLA.xml:S1:5606:5	tabl	JJ	O	O
3	OTEZLA.xml:S1:5612:1	3	CD	O	O
:	OTEZLA.xml:S1:5613:1	:	:	O	O
Adverse	OTEZLA.xml:S1:5615:7	advers	JJ	O	O
Reactions	OTEZLA.xml:S1:5623:9	reaction	NNP	O	O
Reported	OTEZLA.xml:S1:5633:8	report	VBD	O	O
in	OTEZLA.xml:S1:5642:2	in	IN	O	O
1%	OTEZLA.xml:S1:5647:2	1%	CD	O	O
of	OTEZLA.xml:S1:5650:2	of	IN	O	O
Subjects	OTEZLA.xml:S1:5653:8	subject	NNS	O	O
on	OTEZLA.xml:S1:5662:2	on	IN	O	O
OTEZLA	OTEZLA.xml:S1:5665:6	otezla	NNP	O	O
and	OTEZLA.xml:S1:5672:3	and	CC	O	O
With	OTEZLA.xml:S1:5676:4	with	IN	O	O
Greater	OTEZLA.xml:S1:5681:7	greater	NNP	O	O
Frequency	OTEZLA.xml:S1:5689:9	frequenc	NNP	O	O
Than	OTEZLA.xml:S1:5699:4	than	NNP	O	O
in	OTEZLA.xml:S1:5704:2	in	IN	O	O
Subjects	OTEZLA.xml:S1:5707:8	subject	NNP	O	O
on	OTEZLA.xml:S1:5716:2	on	IN	O	O
Placebo	OTEZLA.xml:S1:5719:7	placebo	NNP	O	O
;	OTEZLA.xml:S1:5726:1	;	:	O	O
up	OTEZLA.xml:S1:5728:2	up	RB	O	O
to	OTEZLA.xml:S1:5731:2	to	TO	O	O
Day	OTEZLA.xml:S1:5734:3	day	NNP	O	O
112	OTEZLA.xml:S1:5738:3	112	CD	O	O
(	OTEZLA.xml:S1:5742:1	(	(	O	O
Week	OTEZLA.xml:S1:5743:4	week	NNP	O	O
16	OTEZLA.xml:S1:5748:2	16	CD	O	O
)	OTEZLA.xml:S1:5750:1	)	)	O	O

Two	OTEZLA.xml:S1:5759:3	two	CD	O	O
subjects	OTEZLA.xml:S1:5763:8	subject	NNS	O	O
treated	OTEZLA.xml:S1:5772:7	treat	VBN	O	O
with	OTEZLA.xml:S1:5780:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S1:5785:6	otezla	NNP	O	O
experienced	OTEZLA.xml:S1:5792:11	experienc	VBD	O	O
serious	OTEZLA.xml:S1:5804:7	seriou	JJ	O	O
adverse	OTEZLA.xml:S1:5812:7	advers	JJ	O	O
reaction	OTEZLA.xml:S1:5820:8	reaction	NN	O	O
of	OTEZLA.xml:S1:5829:2	of	IN	O	O
abdominal	OTEZLA.xml:S1:5832:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	OTEZLA.xml:S1:5842:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	OTEZLA.xml:S1:5846:1	.	.	O	O

Preferred	OTEZLA.xml:S1:5855:9	prefer	VBN	O	O

Term	OTEZLA.xml:S1:5865:4	term	NNP	O	O
Placebo	OTEZLA.xml:S1:5877:7	placebo	NNP	O	O
(	OTEZLA.xml:S1:5885:1	(	(	O	O
N	OTEZLA.xml:S1:5886:1	N	NNP	O	O
506	OTEZLA.xml:S1:5888:3	506	CD	O	O
)	OTEZLA.xml:S1:5891:1	)	)	O	O
n	OTEZLA.xml:S1:5892:1	n	FW	O	O
(	OTEZLA.xml:S1:5894:1	(	(	O	O
)	OTEZLA.xml:S1:5896:1	)	)	O	O
OTEZLA	OTEZLA.xml:S1:5899:6	otezla	VBP	O	O
30	OTEZLA.xml:S1:5906:2	30	CD	O	O
mg	OTEZLA.xml:S1:5909:2	mg	NNS	O	O
BID	OTEZLA.xml:S1:5912:3	bid	NNP	O	O
(	OTEZLA.xml:S1:5916:1	(	(	O	O
N	OTEZLA.xml:S1:5917:1	N	NNP	O	O
920	OTEZLA.xml:S1:5919:3	920	CD	O	O
)	OTEZLA.xml:S1:5922:1	)	)	O	O
n	OTEZLA.xml:S1:5923:1	n	FW	O	O
(	OTEZLA.xml:S1:5925:1	(	(	O	O
)	OTEZLA.xml:S1:5927:1	)	)	O	O

Diarrhea	OTEZLA.xml:S1:5933:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
32	OTEZLA.xml:S1:5955:2	32	CD	O	O
(	OTEZLA.xml:S1:5958:1	(	(	O	O
6	OTEZLA.xml:S1:5959:1	6	CD	O	O
)	OTEZLA.xml:S1:5960:1	)	)	O	O
160	OTEZLA.xml:S1:5977:3	160	CD	O	O
(	OTEZLA.xml:S1:5981:1	(	(	O	O
17	OTEZLA.xml:S1:5982:2	17	CD	O	O
)	OTEZLA.xml:S1:5984:1	)	)	O	O

Nausea	OTEZLA.xml:S1:6002:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
35	OTEZLA.xml:S1:6024:2	35	CD	O	O
(	OTEZLA.xml:S1:6027:1	(	(	O	O
7	OTEZLA.xml:S1:6028:1	7	CD	O	O
)	OTEZLA.xml:S1:6029:1	)	)	O	O
155	OTEZLA.xml:S1:6046:3	155	CD	O	O
(	OTEZLA.xml:S1:6050:1	(	(	O	O
17	OTEZLA.xml:S1:6051:2	17	CD	O	O
)	OTEZLA.xml:S1:6053:1	)	)	O	O

Upper	OTEZLA.xml:S1:6071:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	OTEZLA.xml:S1:6077:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	OTEZLA.xml:S1:6089:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	OTEZLA.xml:S1:6095:9	infect	NN	I-AdverseReaction	I-AdverseReaction
31	OTEZLA.xml:S1:6106:2	31	CD	O	O
(	OTEZLA.xml:S1:6109:1	(	(	O	O
6	OTEZLA.xml:S1:6110:1	6	CD	O	O
)	OTEZLA.xml:S1:6111:1	)	)	O	O
84	OTEZLA.xml:S1:6128:2	84	CD	O	O
(	OTEZLA.xml:S1:6131:1	(	(	O	O
9	OTEZLA.xml:S1:6132:1	9	CD	O	O
)	OTEZLA.xml:S1:6133:1	)	)	O	O

Tension	OTEZLA.xml:S1:6153:7	tension	NNP	B-AdverseReaction	B-AdverseReaction
headache	OTEZLA.xml:S1:6161:8	headach	NN	I-AdverseReaction	I-AdverseReaction
21	OTEZLA.xml:S1:6175:2	21	CD	O	O
(	OTEZLA.xml:S1:6178:1	(	(	O	O
4	OTEZLA.xml:S1:6179:1	4	CD	O	O
)	OTEZLA.xml:S1:6180:1	)	)	O	O
75	OTEZLA.xml:S1:6197:2	75	CD	O	O
(	OTEZLA.xml:S1:6200:1	(	(	O	O
8	OTEZLA.xml:S1:6201:1	8	CD	O	O
)	OTEZLA.xml:S1:6202:1	)	)	O	O

Headache	OTEZLA.xml:S1:6222:8	headach	$	B-AdverseReaction	B-AdverseReaction
19	OTEZLA.xml:S1:6244:2	19	CD	O	O
(	OTEZLA.xml:S1:6247:1	(	(	O	O
4	OTEZLA.xml:S1:6248:1	4	CD	O	O
)	OTEZLA.xml:S1:6249:1	)	)	O	O
55	OTEZLA.xml:S1:6266:2	55	CD	O	O
(	OTEZLA.xml:S1:6269:1	(	(	O	O
6	OTEZLA.xml:S1:6270:1	6	CD	O	O
)	OTEZLA.xml:S1:6271:1	)	)	O	O

Abdominal	OTEZLA.xml:S1:6291:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	OTEZLA.xml:S1:6301:4	pain	NN	I-AdverseReaction	I-AdverseReaction
11	OTEZLA.xml:S1:6313:2	11	CD	O	O
(	OTEZLA.xml:S1:6316:1	(	(	O	O
2	OTEZLA.xml:S1:6317:1	2	CD	O	O
)	OTEZLA.xml:S1:6318:1	)	)	O	O
39	OTEZLA.xml:S1:6335:2	39	CD	O	O
(	OTEZLA.xml:S1:6338:1	(	(	O	O
4	OTEZLA.xml:S1:6339:1	4	CD	O	O
)	OTEZLA.xml:S1:6340:1	)	)	O	O

Vomiting	OTEZLA.xml:S1:6360:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
8	OTEZLA.xml:S1:6382:1	8	CD	O	O
(	OTEZLA.xml:S1:6384:1	(	(	O	O
2	OTEZLA.xml:S1:6385:1	2	CD	O	O
)	OTEZLA.xml:S1:6386:1	)	)	O	O
35	OTEZLA.xml:S1:6404:2	35	CD	O	O
(	OTEZLA.xml:S1:6407:1	(	(	O	O
4	OTEZLA.xml:S1:6408:1	4	CD	O	O
)	OTEZLA.xml:S1:6409:1	)	)	O	O

Fatigue	OTEZLA.xml:S1:6429:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
9	OTEZLA.xml:S1:6451:1	9	CD	O	O
(	OTEZLA.xml:S1:6453:1	(	(	O	O
2	OTEZLA.xml:S1:6454:1	2	CD	O	O
)	OTEZLA.xml:S1:6455:1	)	)	O	O
29	OTEZLA.xml:S1:6473:2	29	CD	O	O
(	OTEZLA.xml:S1:6476:1	(	(	O	O
3	OTEZLA.xml:S1:6477:1	3	CD	O	O
)	OTEZLA.xml:S1:6478:1	)	)	O	O

Dyspepsia	OTEZLA.xml:S1:6498:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
6	OTEZLA.xml:S1:6520:1	6	CD	O	O
(	OTEZLA.xml:S1:6522:1	(	(	O	O
1	OTEZLA.xml:S1:6523:1	1	CD	O	O
)	OTEZLA.xml:S1:6524:1	)	)	O	O
29	OTEZLA.xml:S1:6542:2	29	CD	O	O
(	OTEZLA.xml:S1:6545:1	(	(	O	O
3	OTEZLA.xml:S1:6546:1	3	CD	O	O
)	OTEZLA.xml:S1:6547:1	)	)	O	O

Decrease	OTEZLA.xml:S1:6567:8	decreas	NNP	B-AdverseReaction	B-AdverseReaction
appetite	OTEZLA.xml:S1:6576:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
5	OTEZLA.xml:S1:6589:1	5	CD	O	O
(	OTEZLA.xml:S1:6591:1	(	(	O	O
1	OTEZLA.xml:S1:6592:1	1	CD	O	O
)	OTEZLA.xml:S1:6593:1	)	)	O	O
26	OTEZLA.xml:S1:6611:2	26	CD	O	O
(	OTEZLA.xml:S1:6614:1	(	(	O	O
3	OTEZLA.xml:S1:6615:1	3	CD	O	O
)	OTEZLA.xml:S1:6616:1	)	)	O	O

Insomnia	OTEZLA.xml:S1:6636:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
4	OTEZLA.xml:S1:6658:1	4	CD	O	O
(	OTEZLA.xml:S1:6660:1	(	(	O	O
1	OTEZLA.xml:S1:6661:1	1	CD	O	O
)	OTEZLA.xml:S1:6662:1	)	)	O	O
21	OTEZLA.xml:S1:6680:2	21	CD	O	O
(	OTEZLA.xml:S1:6683:1	(	(	O	O
2	OTEZLA.xml:S1:6684:1	2	CD	O	O
)	OTEZLA.xml:S1:6685:1	)	)	O	O

Back	OTEZLA.xml:S1:6705:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	OTEZLA.xml:S1:6710:4	pain	NN	I-AdverseReaction	I-AdverseReaction
4	OTEZLA.xml:S1:6727:1	4	CD	O	O
(	OTEZLA.xml:S1:6729:1	(	(	O	O
1	OTEZLA.xml:S1:6730:1	1	CD	O	O
)	OTEZLA.xml:S1:6731:1	)	)	O	O
20	OTEZLA.xml:S1:6749:2	20	CD	O	O
(	OTEZLA.xml:S1:6752:1	(	(	O	O
2	OTEZLA.xml:S1:6753:1	2	CD	O	O
)	OTEZLA.xml:S1:6754:1	)	)	O	O

Migraine	OTEZLA.xml:S1:6774:8	migrain	NN	B-AdverseReaction	B-AdverseReaction
5	OTEZLA.xml:S1:6796:1	5	CD	O	O
(	OTEZLA.xml:S1:6798:1	(	(	O	O
1	OTEZLA.xml:S1:6799:1	1	CD	O	O
)	OTEZLA.xml:S1:6800:1	)	)	O	O
19	OTEZLA.xml:S1:6818:2	19	CD	O	O
(	OTEZLA.xml:S1:6821:1	(	(	O	O
2	OTEZLA.xml:S1:6822:1	2	CD	O	O
)	OTEZLA.xml:S1:6823:1	)	)	O	O

Frequent	OTEZLA.xml:S1:6843:8	frequent	JJ	B-AdverseReaction	O
bowel	OTEZLA.xml:S1:6852:5	bowel	NN	I-AdverseReaction	O
movements	OTEZLA.xml:S1:6858:9	movement	NNS	I-AdverseReaction	O
1	OTEZLA.xml:S1:6869:1	1	CD	O	O
(	OTEZLA.xml:S1:6871:1	(	(	O	O
0	OTEZLA.xml:S1:6872:1	0	CD	O	O
)	OTEZLA.xml:S1:6873:1	)	)	O	O
17	OTEZLA.xml:S1:6891:2	17	CD	O	O
(	OTEZLA.xml:S1:6894:1	(	(	O	O
2	OTEZLA.xml:S1:6895:1	2	CD	O	O
)	OTEZLA.xml:S1:6896:1	)	)	O	O

Depression	OTEZLA.xml:S1:6916:10	depress	NN	B-AdverseReaction	B-AdverseReaction
2	OTEZLA.xml:S1:6938:1	2	CD	O	O
(	OTEZLA.xml:S1:6940:1	(	(	O	O
0	OTEZLA.xml:S1:6941:1	0	CD	O	O
)	OTEZLA.xml:S1:6942:1	)	)	O	O
12	OTEZLA.xml:S1:6960:2	12	CD	O	O
(	OTEZLA.xml:S1:6963:1	(	(	O	O
1	OTEZLA.xml:S1:6964:1	1	CD	O	O
)	OTEZLA.xml:S1:6965:1	)	)	O	O

Bronchitis	OTEZLA.xml:S1:6985:10	bronchiti	NN	B-AdverseReaction	B-AdverseReaction
2	OTEZLA.xml:S1:7007:1	2	CD	O	O
(	OTEZLA.xml:S1:7009:1	(	(	O	O
0	OTEZLA.xml:S1:7010:1	0	CD	O	O
)	OTEZLA.xml:S1:7011:1	)	)	O	O
12	OTEZLA.xml:S1:7029:2	12	CD	O	O
(	OTEZLA.xml:S1:7032:1	(	(	O	O
1	OTEZLA.xml:S1:7033:1	1	CD	O	O
)	OTEZLA.xml:S1:7034:1	)	)	O	O

Tooth	OTEZLA.xml:S1:7054:5	tooth	NNP	B-AdverseReaction	B-AdverseReaction
abscess	OTEZLA.xml:S1:7060:7	abscess	RB	I-AdverseReaction	I-AdverseReaction
0	OTEZLA.xml:S1:7076:1	0	CD	O	O
(	OTEZLA.xml:S1:7078:1	(	(	O	O
0	OTEZLA.xml:S1:7079:1	0	CD	O	O
)	OTEZLA.xml:S1:7080:1	)	)	O	O
10	OTEZLA.xml:S1:7098:2	10	CD	O	O
(	OTEZLA.xml:S1:7101:1	(	(	O	O
1	OTEZLA.xml:S1:7102:1	1	CD	O	O
)	OTEZLA.xml:S1:7103:1	)	)	O	O

Folliculitis	OTEZLA.xml:S1:7123:12	follicul	NN	B-AdverseReaction	B-AdverseReaction
0	OTEZLA.xml:S1:7145:1	0	CD	O	O
(	OTEZLA.xml:S1:7147:1	(	(	O	O
0	OTEZLA.xml:S1:7148:1	0	CD	O	O
)	OTEZLA.xml:S1:7149:1	)	)	O	O
9	OTEZLA.xml:S1:7167:1	9	CD	O	O
(	OTEZLA.xml:S1:7169:1	(	(	O	O
1	OTEZLA.xml:S1:7170:1	1	CD	O	O
)	OTEZLA.xml:S1:7171:1	)	)	O	O

Sinus	OTEZLA.xml:S1:7192:5	sinu	NNP	B-AdverseReaction	B-AdverseReaction
headache	OTEZLA.xml:S1:7198:8	headach	NN	I-AdverseReaction	I-AdverseReaction
0	OTEZLA.xml:S1:7214:1	0	CD	O	O
(	OTEZLA.xml:S1:7216:1	(	(	O	O
0	OTEZLA.xml:S1:7217:1	0	CD	O	O
)	OTEZLA.xml:S1:7218:1	)	)	O	O
9	OTEZLA.xml:S1:7236:1	9	CD	O	O
(	OTEZLA.xml:S1:7238:1	(	(	O	O
1	OTEZLA.xml:S1:7239:1	1	CD	O	O
)	OTEZLA.xml:S1:7240:1	)	)	O	O

Severe	OTEZLA.xml:S1:7269:6	sever	JJ	O	O
worsening	OTEZLA.xml:S1:7276:9	worsen	NN	O	O
of	OTEZLA.xml:S1:7286:2	of	IN	O	O
psoriasis	OTEZLA.xml:S1:7289:9	psoriasi	NN	O	O
(	OTEZLA.xml:S1:7299:1	(	(	O	O
rebound	OTEZLA.xml:S1:7300:7	rebound	NN	O	B-AdverseReaction
)	OTEZLA.xml:S1:7307:1	)	)	O	O
occurred	OTEZLA.xml:S1:7309:8	occur	VBD	O	O
in	OTEZLA.xml:S1:7318:2	in	IN	O	O
0.3%	OTEZLA.xml:S1:7321:4	0.3%	CD	O	O
(	OTEZLA.xml:S1:7326:1	(	(	O	O
4	OTEZLA.xml:S1:7327:1	4	CD	O	O
1184	OTEZLA.xml:S1:7329:4	1184	CD	O	O
)	OTEZLA.xml:S1:7333:1	)	)	O	O
subjects	OTEZLA.xml:S1:7335:8	subject	VBZ	O	O
following	OTEZLA.xml:S1:7344:9	follow	VBG	O	O
discontinuation	OTEZLA.xml:S1:7354:15	discontinu	NN	O	O
of	OTEZLA.xml:S1:7370:2	of	IN	O	O
treatment	OTEZLA.xml:S1:7373:9	treatment	NN	O	O
with	OTEZLA.xml:S1:7383:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S1:7388:6	otezla	NNP	O	O
.	OTEZLA.xml:S1:7394:1	.	.	O	O
5	OTEZLA.xml:S2:4:1	5	CD	O	O
WARNINGS	OTEZLA.xml:S2:6:8	warn	NNP	O	O
AND	OTEZLA.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	OTEZLA.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	OTEZLA.xml:S2:37:7	excerpt	NN	O	O
:	OTEZLA.xml:S2:44:1	:	:	O	O
Depression	OTEZLA.xml:S2:53:10	depress	NN	B-AdverseReaction	B-AdverseReaction
:	OTEZLA.xml:S2:64:1	:	:	O	O
Advise	OTEZLA.xml:S2:66:6	advis	NN	O	O
patients	OTEZLA.xml:S2:73:8	patient	NNS	O	O
,	OTEZLA.xml:S2:81:1	,	,	O	O
their	OTEZLA.xml:S2:83:5	their	PRP$	O	O
caregivers	OTEZLA.xml:S2:89:10	caregiv	NNS	O	O
,	OTEZLA.xml:S2:99:1	,	,	O	O
and	OTEZLA.xml:S2:101:3	and	CC	O	O
families	OTEZLA.xml:S2:105:8	famili	NNS	O	O
to	OTEZLA.xml:S2:114:2	to	TO	O	O
be	OTEZLA.xml:S2:117:2	be	VB	O	O
alert	OTEZLA.xml:S2:120:5	alert	JJ	O	O
for	OTEZLA.xml:S2:126:3	for	IN	O	O
the	OTEZLA.xml:S2:130:3	the	DT	O	O
emergence	OTEZLA.xml:S2:134:9	emerg	NN	O	O
or	OTEZLA.xml:S2:144:2	or	CC	O	O
worsening	OTEZLA.xml:S2:147:9	worsen	NN	O	O
of	OTEZLA.xml:S2:157:2	of	IN	O	O
depression	OTEZLA.xml:S2:160:10	depress	NN	O	O
,	OTEZLA.xml:S2:170:1	,	,	O	O
suicidal	OTEZLA.xml:S2:172:8	suicid	JJ	O	O
thoughts	OTEZLA.xml:S2:181:8	thought	NNS	O	O
or	OTEZLA.xml:S2:190:2	or	CC	O	O
other	OTEZLA.xml:S2:193:5	other	JJ	O	O
mood	OTEZLA.xml:S2:199:4	mood	NN	O	O
changes	OTEZLA.xml:S2:204:7	chang	NNS	O	O
and	OTEZLA.xml:S2:212:3	and	CC	O	O
if	OTEZLA.xml:S2:216:2	if	IN	O	O
such	OTEZLA.xml:S2:219:4	such	JJ	O	O
changes	OTEZLA.xml:S2:224:7	chang	NNS	O	O
occur	OTEZLA.xml:S2:232:5	occur	VBP	O	O
to	OTEZLA.xml:S2:238:2	to	TO	O	O
contact	OTEZLA.xml:S2:241:7	contact	VB	O	O
their	OTEZLA.xml:S2:249:5	their	PRP$	O	O
healthcare	OTEZLA.xml:S2:255:10	healthcar	NN	O	O
provider	OTEZLA.xml:S2:266:8	provid	NN	O	O
.	OTEZLA.xml:S2:274:1	.	.	O	O

Carefully	OTEZLA.xml:S2:276:9	care	RB	O	O
weigh	OTEZLA.xml:S2:286:5	weigh	JJ	O	O
risks	OTEZLA.xml:S2:292:5	risk	NNS	O	O
and	OTEZLA.xml:S2:298:3	and	CC	O	O
benefits	OTEZLA.xml:S2:302:8	benefit	NNS	O	O
of	OTEZLA.xml:S2:311:2	of	IN	O	O
treatment	OTEZLA.xml:S2:314:9	treatment	NN	O	O
with	OTEZLA.xml:S2:324:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:329:6	otezla	NNP	O	O
in	OTEZLA.xml:S2:336:2	in	IN	O	O
patients	OTEZLA.xml:S2:339:8	patient	NNS	O	O
with	OTEZLA.xml:S2:348:4	with	IN	O	O
a	OTEZLA.xml:S2:353:1	a	DT	O	O
history	OTEZLA.xml:S2:355:7	histori	NN	O	O
of	OTEZLA.xml:S2:363:2	of	IN	O	O
depression	OTEZLA.xml:S2:366:10	depress	NN	O	O
and	OTEZLA.xml:S2:377:3	and	CC	O	O
or	OTEZLA.xml:S2:381:2	or	CC	O	O
suicidal	OTEZLA.xml:S2:384:8	suicid	VB	O	O
thoughts	OTEZLA.xml:S2:393:8	thought	NNS	O	O
or	OTEZLA.xml:S2:402:2	or	CC	O	O
behavior	OTEZLA.xml:S2:405:8	behavior	NN	O	O
.	OTEZLA.xml:S2:413:1	.	.	O	O

(	OTEZLA.xml:S2:415:1	(	(	O	O
5.1	OTEZLA.xml:S2:416:3	5.1	CD	O	O
)	OTEZLA.xml:S2:419:1	)	)	O	O

Weight	OTEZLA.xml:S2:427:6	weight	JJ	B-AdverseReaction	B-AdverseReaction
Decrease	OTEZLA.xml:S2:434:8	decreas	NN	I-AdverseReaction	I-AdverseReaction
:	OTEZLA.xml:S2:443:1	:	:	O	O
Monitor	OTEZLA.xml:S2:445:7	monitor	NNP	O	O
weight	OTEZLA.xml:S2:453:6	weight	VBD	O	O
regularly	OTEZLA.xml:S2:460:9	regularli	RB	O	O
.	OTEZLA.xml:S2:469:1	.	.	O	O

If	OTEZLA.xml:S2:471:2	If	IN	O	O
unexplained	OTEZLA.xml:S2:474:11	unexplain	VBN	O	O
or	OTEZLA.xml:S2:486:2	or	CC	O	O
clinically	OTEZLA.xml:S2:489:10	clinic	RB	O	O
significant	OTEZLA.xml:S2:500:11	signific	JJ	O	O
weight	OTEZLA.xml:S2:512:6	weight	JJ	O	O
loss	OTEZLA.xml:S2:519:4	loss	NN	O	O
occurs	OTEZLA.xml:S2:524:6	occur	VBZ	O	O
,	OTEZLA.xml:S2:530:1	,	,	O	O
evaluate	OTEZLA.xml:S2:532:8	evalu	VB	O	O
weight	OTEZLA.xml:S2:541:6	weight	JJ	O	O
loss	OTEZLA.xml:S2:548:4	loss	NN	O	O
and	OTEZLA.xml:S2:553:3	and	CC	O	O
consider	OTEZLA.xml:S2:557:8	consid	VB	O	O
discontinuation	OTEZLA.xml:S2:566:15	discontinu	NN	O	O
of	OTEZLA.xml:S2:582:2	of	IN	O	O
OTEZLA	OTEZLA.xml:S2:585:6	otezla	NNP	O	O
(	OTEZLA.xml:S2:592:1	(	(	O	O
5.2	OTEZLA.xml:S2:593:3	5.2	CD	O	O
)	OTEZLA.xml:S2:596:1	)	)	O	O

Drug	OTEZLA.xml:S2:604:4	drug	NN	O	O
Interactions	OTEZLA.xml:S2:609:12	interact	NNS	O	O
:	OTEZLA.xml:S2:622:1	:	:	O	O
Use	OTEZLA.xml:S2:624:3	use	NN	O	O
with	OTEZLA.xml:S2:628:4	with	IN	O	O
strong	OTEZLA.xml:S2:633:6	strong	JJ	O	O
cytochrome	OTEZLA.xml:S2:640:10	cytochrom	NN	O	O
P450	OTEZLA.xml:S2:651:4	p450	NNP	O	O
enzyme	OTEZLA.xml:S2:656:6	enzym	NN	O	O
inducers	OTEZLA.xml:S2:663:8	induc	NNS	O	O
(	OTEZLA.xml:S2:672:1	(	(	O	O
e	OTEZLA.xml:S2:673:1	e	NN	O	O
.	OTEZLA.xml:S2:674:1	.	.	O	O
g	OTEZLA.xml:S2:675:1	g	NN	O	O
.	OTEZLA.xml:S2:676:1	.	.	O	O
,	OTEZLA.xml:S2:677:1	,	,	O	O
rifampin	OTEZLA.xml:S2:679:8	rifampin	NN	O	O
,	OTEZLA.xml:S2:687:1	,	,	O	O
phenobarbital	OTEZLA.xml:S2:689:13	phenobarbit	NN	O	B-AdverseReaction
,	OTEZLA.xml:S2:702:1	,	,	O	O
carbamazepine	OTEZLA.xml:S2:704:13	carbamazepin	NN	O	O
,	OTEZLA.xml:S2:717:1	,	,	O	O
phenytoin	OTEZLA.xml:S2:719:9	phenytoin	NN	O	O
)	OTEZLA.xml:S2:728:1	)	)	O	O
is	OTEZLA.xml:S2:730:2	is	VBZ	O	O
not	OTEZLA.xml:S2:733:3	not	RB	O	O
recommended	OTEZLA.xml:S2:737:11	recommend	JJ	O	O
because	OTEZLA.xml:S2:749:7	becaus	IN	O	O
loss	OTEZLA.xml:S2:757:4	loss	NN	O	O
of	OTEZLA.xml:S2:762:2	of	IN	O	O
efficacy	OTEZLA.xml:S2:765:8	efficaci	NN	O	O
may	OTEZLA.xml:S2:774:3	may	MD	O	O
occur	OTEZLA.xml:S2:778:5	occur	VB	O	O
(	OTEZLA.xml:S2:784:1	(	(	O	O
5.3	OTEZLA.xml:S2:785:3	5.3	CD	O	O
,	OTEZLA.xml:S2:788:1	,	,	O	O
7.1	OTEZLA.xml:S2:789:3	7.1	CD	O	O
)	OTEZLA.xml:S2:792:1	)	)	O	O

5.1	OTEZLA.xml:S2:803:3	5.1	CD	O	O

Depression	OTEZLA.xml:S2:807:10	depress	NN	O	O

Treatment	OTEZLA.xml:S2:821:9	treatment	NN	O	O
with	OTEZLA.xml:S2:831:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:836:6	otezla	NNP	O	O
is	OTEZLA.xml:S2:843:2	is	VBZ	O	O
associated	OTEZLA.xml:S2:846:10	associ	VBN	O	O
with	OTEZLA.xml:S2:857:4	with	IN	O	O
an	OTEZLA.xml:S2:862:2	an	DT	O	O
increase	OTEZLA.xml:S2:865:8	increas	NN	O	O
in	OTEZLA.xml:S2:874:2	in	IN	O	O
adverse	OTEZLA.xml:S2:877:7	advers	JJ	O	O
reactions	OTEZLA.xml:S2:885:9	reaction	NNS	O	O
of	OTEZLA.xml:S2:895:2	of	IN	O	O
depression	OTEZLA.xml:S2:898:10	depress	NN	B-AdverseReaction	B-AdverseReaction
.	OTEZLA.xml:S2:908:1	.	.	O	O

Before	OTEZLA.xml:S2:910:6	befor	IN	O	O
using	OTEZLA.xml:S2:917:5	use	VBG	O	O
OTEZLA	OTEZLA.xml:S2:923:6	otezla	NNP	O	O
in	OTEZLA.xml:S2:930:2	in	IN	O	O
patients	OTEZLA.xml:S2:933:8	patient	NNS	O	O
with	OTEZLA.xml:S2:942:4	with	IN	O	O
a	OTEZLA.xml:S2:947:1	a	DT	O	O
history	OTEZLA.xml:S2:949:7	histori	NN	O	O
of	OTEZLA.xml:S2:957:2	of	IN	O	O
depression	OTEZLA.xml:S2:960:10	depress	NN	O	O
and	OTEZLA.xml:S2:971:3	and	CC	O	O
or	OTEZLA.xml:S2:975:2	or	CC	O	O
suicidal	OTEZLA.xml:S2:978:8	suicid	VB	O	O
thoughts	OTEZLA.xml:S2:987:8	thought	NNS	O	O
or	OTEZLA.xml:S2:996:2	or	CC	O	O
behavior	OTEZLA.xml:S2:999:8	behavior	JJ	O	O
prescribers	OTEZLA.xml:S2:1008:11	prescrib	NNS	O	O
should	OTEZLA.xml:S2:1020:6	should	MD	O	O
carefully	OTEZLA.xml:S2:1027:9	care	RB	O	O
weigh	OTEZLA.xml:S2:1037:5	weigh	VB	O	O
the	OTEZLA.xml:S2:1043:3	the	DT	O	O
risks	OTEZLA.xml:S2:1047:5	risk	NNS	O	O
and	OTEZLA.xml:S2:1053:3	and	CC	O	O
benefits	OTEZLA.xml:S2:1057:8	benefit	NNS	O	O
of	OTEZLA.xml:S2:1066:2	of	IN	O	O
treatment	OTEZLA.xml:S2:1069:9	treatment	NN	O	O
with	OTEZLA.xml:S2:1079:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:1084:6	otezla	NNP	O	O
in	OTEZLA.xml:S2:1091:2	in	IN	O	O
such	OTEZLA.xml:S2:1094:4	such	JJ	O	O
patients	OTEZLA.xml:S2:1099:8	patient	NNS	O	O
.	OTEZLA.xml:S2:1107:1	.	.	O	O

Patients	OTEZLA.xml:S2:1109:8	patient	NNS	O	O
,	OTEZLA.xml:S2:1117:1	,	,	O	O
their	OTEZLA.xml:S2:1119:5	their	PRP$	O	O
caregivers	OTEZLA.xml:S2:1125:10	caregiv	NNS	O	O
,	OTEZLA.xml:S2:1135:1	,	,	O	O
and	OTEZLA.xml:S2:1137:3	and	CC	O	O
families	OTEZLA.xml:S2:1141:8	famili	NNS	O	O
should	OTEZLA.xml:S2:1150:6	should	MD	O	O
be	OTEZLA.xml:S2:1157:2	be	VB	O	O
advised	OTEZLA.xml:S2:1160:7	advis	VBN	O	O
of	OTEZLA.xml:S2:1168:2	of	IN	O	O
the	OTEZLA.xml:S2:1171:3	the	DT	O	O
need	OTEZLA.xml:S2:1175:4	need	NN	O	O
to	OTEZLA.xml:S2:1180:2	to	TO	O	O
be	OTEZLA.xml:S2:1183:2	be	VB	O	O
alert	OTEZLA.xml:S2:1186:5	alert	JJ	O	O
for	OTEZLA.xml:S2:1192:3	for	IN	O	O
the	OTEZLA.xml:S2:1196:3	the	DT	O	O
emergence	OTEZLA.xml:S2:1200:9	emerg	NN	O	O
or	OTEZLA.xml:S2:1210:2	or	CC	O	O
worsening	OTEZLA.xml:S2:1213:9	worsen	NN	O	O
of	OTEZLA.xml:S2:1223:2	of	IN	O	O
depression	OTEZLA.xml:S2:1226:10	depress	NN	O	O
,	OTEZLA.xml:S2:1236:1	,	,	O	O
suicidal	OTEZLA.xml:S2:1238:8	suicid	JJ	O	O
thoughts	OTEZLA.xml:S2:1247:8	thought	NNS	O	O
or	OTEZLA.xml:S2:1256:2	or	CC	O	O
other	OTEZLA.xml:S2:1259:5	other	JJ	O	O
mood	OTEZLA.xml:S2:1265:4	mood	NN	O	O
changes	OTEZLA.xml:S2:1270:7	chang	NNS	O	O
,	OTEZLA.xml:S2:1277:1	,	,	O	O
and	OTEZLA.xml:S2:1279:3	and	CC	O	O
if	OTEZLA.xml:S2:1283:2	if	IN	O	O
such	OTEZLA.xml:S2:1286:4	such	JJ	O	O
changes	OTEZLA.xml:S2:1291:7	chang	NNS	O	O
occur	OTEZLA.xml:S2:1299:5	occur	VBP	O	O
to	OTEZLA.xml:S2:1305:2	to	TO	O	O
contact	OTEZLA.xml:S2:1308:7	contact	VB	O	O
their	OTEZLA.xml:S2:1316:5	their	PRP$	O	O
healthcare	OTEZLA.xml:S2:1322:10	healthcar	NN	O	O
provider	OTEZLA.xml:S2:1333:8	provid	NN	O	O
.	OTEZLA.xml:S2:1341:1	.	.	O	O

Prescribers	OTEZLA.xml:S2:1343:11	prescrib	NNS	O	O
should	OTEZLA.xml:S2:1355:6	should	MD	O	O
carefully	OTEZLA.xml:S2:1362:9	care	RB	O	O
evaluate	OTEZLA.xml:S2:1372:8	evalu	VB	O	O
the	OTEZLA.xml:S2:1381:3	the	DT	O	O
risks	OTEZLA.xml:S2:1385:5	risk	NNS	O	O
and	OTEZLA.xml:S2:1391:3	and	CC	O	O
benefits	OTEZLA.xml:S2:1395:8	benefit	NNS	O	O
of	OTEZLA.xml:S2:1404:2	of	IN	O	O
continuing	OTEZLA.xml:S2:1407:10	continu	VBG	O	O
treatment	OTEZLA.xml:S2:1418:9	treatment	NN	O	O
with	OTEZLA.xml:S2:1428:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:1433:6	otezla	NNP	O	O
if	OTEZLA.xml:S2:1440:2	if	IN	O	O
such	OTEZLA.xml:S2:1443:4	such	JJ	O	O
events	OTEZLA.xml:S2:1448:6	event	NNS	O	O
occur	OTEZLA.xml:S2:1455:5	occur	VBP	O	O
.	OTEZLA.xml:S2:1460:1	.	.	O	O

Psoriatic	OTEZLA.xml:S2:1468:9	psoriat	JJ	O	O
arthritis	OTEZLA.xml:S2:1478:9	arthriti	NN	O	O
:	OTEZLA.xml:S2:1489:1	:	:	O	O
During	OTEZLA.xml:S2:1491:6	dure	IN	O	O
the	OTEZLA.xml:S2:1498:3	the	DT	O	O
0	OTEZLA.xml:S2:1502:1	0	CD	O	O
to	OTEZLA.xml:S2:1504:2	to	TO	O	O
16	OTEZLA.xml:S2:1507:2	16	CD	O	O
week	OTEZLA.xml:S2:1510:4	week	NN	O	O
placebo	OTEZLA.xml:S2:1515:7	placebo	NN	O	O
-	OTEZLA.xml:S2:1522:1	-	:	O	O
controlled	OTEZLA.xml:S2:1523:10	control	JJ	O	O
period	OTEZLA.xml:S2:1534:6	period	NN	O	O
of	OTEZLA.xml:S2:1541:2	of	IN	O	O
the	OTEZLA.xml:S2:1544:3	the	DT	O	O
3	OTEZLA.xml:S2:1548:1	3	CD	O	O
controlled	OTEZLA.xml:S2:1550:10	control	VBD	O	O
clinical	OTEZLA.xml:S2:1561:8	clinic	JJ	O	O
trials	OTEZLA.xml:S2:1570:6	trial	NNS	O	O
,	OTEZLA.xml:S2:1576:1	,	,	O	O
1.0%	OTEZLA.xml:S2:1578:4	1.0%	CD	O	O
(	OTEZLA.xml:S2:1583:1	(	(	O	O
10	OTEZLA.xml:S2:1584:2	10	CD	O	O
998	OTEZLA.xml:S2:1587:3	998	CD	O	O
)	OTEZLA.xml:S2:1590:1	)	)	O	O
of	OTEZLA.xml:S2:1592:2	of	IN	O	O
subjects	OTEZLA.xml:S2:1595:8	subject	NNS	O	O
treated	OTEZLA.xml:S2:1604:7	treat	VBN	O	O
with	OTEZLA.xml:S2:1612:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:1617:6	otezla	NNP	O	O
reported	OTEZLA.xml:S2:1624:8	report	VBD	O	O
depression	OTEZLA.xml:S2:1633:10	depress	NN	B-AdverseReaction	B-AdverseReaction
or	OTEZLA.xml:S2:1644:2	or	CC	O	O
depressed	OTEZLA.xml:S2:1647:9	depress	VBN	B-AdverseReaction	O
mood	OTEZLA.xml:S2:1657:4	mood	NN	I-AdverseReaction	O
compared	OTEZLA.xml:S2:1662:8	compar	VBN	O	O
to	OTEZLA.xml:S2:1671:2	to	TO	O	O
0.8%	OTEZLA.xml:S2:1674:4	0.8%	CD	O	O
(	OTEZLA.xml:S2:1679:1	(	(	O	O
4	OTEZLA.xml:S2:1680:1	4	CD	O	O
495	OTEZLA.xml:S2:1682:3	495	CD	O	O
)	OTEZLA.xml:S2:1685:1	)	)	O	O
treated	OTEZLA.xml:S2:1687:7	treat	VBN	O	O
with	OTEZLA.xml:S2:1695:4	with	IN	O	O
placebo	OTEZLA.xml:S2:1700:7	placebo	NN	O	O
.	OTEZLA.xml:S2:1707:1	.	.	O	O

During	OTEZLA.xml:S2:1709:6	dure	IN	O	O
the	OTEZLA.xml:S2:1716:3	the	DT	O	O
clinical	OTEZLA.xml:S2:1720:8	clinic	JJ	O	O
trials	OTEZLA.xml:S2:1729:6	trial	NNS	O	O
,	OTEZLA.xml:S2:1735:1	,	,	O	O
0.3%	OTEZLA.xml:S2:1737:4	0.3%	CD	O	O
(	OTEZLA.xml:S2:1742:1	(	(	O	O
4	OTEZLA.xml:S2:1743:1	4	CD	O	O
1441	OTEZLA.xml:S2:1745:4	1441	CD	O	O
)	OTEZLA.xml:S2:1749:1	)	)	O	O
of	OTEZLA.xml:S2:1751:2	of	IN	O	O
subjects	OTEZLA.xml:S2:1754:8	subject	NNS	O	O
treated	OTEZLA.xml:S2:1763:7	treat	VBN	O	O
with	OTEZLA.xml:S2:1771:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:1776:6	otezla	NNP	O	O
discontinued	OTEZLA.xml:S2:1783:12	discontinu	VBD	O	O
treatment	OTEZLA.xml:S2:1796:9	treatment	NN	O	O
due	OTEZLA.xml:S2:1806:3	due	JJ	O	O
to	OTEZLA.xml:S2:1810:2	to	TO	O	O
depression	OTEZLA.xml:S2:1813:10	depress	NN	B-AdverseReaction	B-AdverseReaction
or	OTEZLA.xml:S2:1824:2	or	CC	O	O
depressed	OTEZLA.xml:S2:1827:9	depress	VBN	B-AdverseReaction	O
mood	OTEZLA.xml:S2:1837:4	mood	NN	I-AdverseReaction	O
compared	OTEZLA.xml:S2:1842:8	compar	VBN	O	O
with	OTEZLA.xml:S2:1851:4	with	IN	O	O
none	OTEZLA.xml:S2:1856:4	none	NN	O	O
in	OTEZLA.xml:S2:1861:2	in	IN	O	O
placebo	OTEZLA.xml:S2:1864:7	placebo	NN	O	O
treated	OTEZLA.xml:S2:1872:7	treat	VBN	O	O
subjects	OTEZLA.xml:S2:1880:8	subject	NNS	O	O
(	OTEZLA.xml:S2:1889:1	(	(	O	O
0	OTEZLA.xml:S2:1890:1	0	CD	O	O
495	OTEZLA.xml:S2:1892:3	495	CD	O	O
)	OTEZLA.xml:S2:1895:1	)	)	O	O
.	OTEZLA.xml:S2:1896:1	.	.	O	O

Depression	OTEZLA.xml:S2:1898:10	depress	NN	B-AdverseReaction	B-AdverseReaction
was	OTEZLA.xml:S2:1909:3	wa	VBD	O	O
reported	OTEZLA.xml:S2:1913:8	report	VBN	O	O
as	OTEZLA.xml:S2:1922:2	as	IN	O	O
serious	OTEZLA.xml:S2:1925:7	seriou	JJ	O	O
in	OTEZLA.xml:S2:1933:2	in	IN	O	O
0.2%	OTEZLA.xml:S2:1936:4	0.2%	CD	O	O
(	OTEZLA.xml:S2:1941:1	(	(	O	O
3	OTEZLA.xml:S2:1942:1	3	CD	O	O
1441	OTEZLA.xml:S2:1944:4	1441	CD	O	O
)	OTEZLA.xml:S2:1948:1	)	)	O	O
of	OTEZLA.xml:S2:1950:2	of	IN	O	O
subjects	OTEZLA.xml:S2:1953:8	subject	NNS	O	O
exposed	OTEZLA.xml:S2:1962:7	expos	VBN	O	O
to	OTEZLA.xml:S2:1970:2	to	TO	O	O
OTEZLA	OTEZLA.xml:S2:1973:6	otezla	NNP	O	O
,	OTEZLA.xml:S2:1979:1	,	,	O	O
compared	OTEZLA.xml:S2:1981:8	compar	VBN	O	O
to	OTEZLA.xml:S2:1990:2	to	TO	O	O
none	OTEZLA.xml:S2:1993:4	none	NN	O	O
in	OTEZLA.xml:S2:1998:2	in	IN	O	O
placebo	OTEZLA.xml:S2:2001:7	placebo	NN	O	O
-	OTEZLA.xml:S2:2008:1	-	:	O	O
treated	OTEZLA.xml:S2:2009:7	treat	VBN	O	O
subjects	OTEZLA.xml:S2:2017:8	subject	NNS	O	O
(	OTEZLA.xml:S2:2026:1	(	(	O	O
0	OTEZLA.xml:S2:2027:1	0	CD	O	O
495	OTEZLA.xml:S2:2029:3	495	CD	O	O
)	OTEZLA.xml:S2:2032:1	)	)	O	O
.	OTEZLA.xml:S2:2033:1	.	.	O	O

Instances	OTEZLA.xml:S2:2035:9	instanc	NNS	O	O
of	OTEZLA.xml:S2:2045:2	of	IN	O	O
suicidal	OTEZLA.xml:S2:2048:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
ideation	OTEZLA.xml:S2:2057:8	ideat	NN	I-AdverseReaction	I-AdverseReaction
and	OTEZLA.xml:S2:2066:3	and	CC	O	O
behavior	OTEZLA.xml:S2:2070:8	behavior	NN	I-AdverseReaction	B-AdverseReaction
have	OTEZLA.xml:S2:2079:4	have	VBP	O	O
been	OTEZLA.xml:S2:2084:4	been	VBN	O	O
observed	OTEZLA.xml:S2:2089:8	observ	VBN	O	O
in	OTEZLA.xml:S2:2098:2	in	IN	O	O
0.2%	OTEZLA.xml:S2:2101:4	0.2%	CD	O	O
(	OTEZLA.xml:S2:2106:1	(	(	O	O
3	OTEZLA.xml:S2:2107:1	3	CD	O	O
1441	OTEZLA.xml:S2:2109:4	1441	CD	O	O
)	OTEZLA.xml:S2:2113:1	)	)	O	O
of	OTEZLA.xml:S2:2115:2	of	IN	O	O
subjects	OTEZLA.xml:S2:2118:8	subject	NNS	O	O
while	OTEZLA.xml:S2:2127:5	while	IN	O	O
receiving	OTEZLA.xml:S2:2133:9	receiv	VBG	O	O
OTEZLA	OTEZLA.xml:S2:2143:6	otezla	NNP	O	O
,	OTEZLA.xml:S2:2149:1	,	,	O	O
compared	OTEZLA.xml:S2:2151:8	compar	VBN	O	O
to	OTEZLA.xml:S2:2160:2	to	TO	O	O
none	OTEZLA.xml:S2:2163:4	none	NN	O	O
in	OTEZLA.xml:S2:2168:2	in	IN	O	O
placebo	OTEZLA.xml:S2:2171:7	placebo	NN	O	O
treated	OTEZLA.xml:S2:2179:7	treat	VBN	O	O
subjects	OTEZLA.xml:S2:2187:8	subject	NNS	O	O
(	OTEZLA.xml:S2:2196:1	(	(	O	O
0	OTEZLA.xml:S2:2197:1	0	CD	O	O
495	OTEZLA.xml:S2:2199:3	495	CD	O	O
)	OTEZLA.xml:S2:2202:1	)	)	O	O
.	OTEZLA.xml:S2:2203:1	.	.	O	O

In	OTEZLA.xml:S2:2205:2	In	IN	O	O
the	OTEZLA.xml:S2:2208:3	the	DT	O	O
clinical	OTEZLA.xml:S2:2212:8	clinic	JJ	O	O
trials	OTEZLA.xml:S2:2221:6	trial	NNS	O	O
,	OTEZLA.xml:S2:2227:1	,	,	O	O
2	OTEZLA.xml:S2:2229:1	2	CD	O	O
subjects	OTEZLA.xml:S2:2231:8	subject	NNS	O	O
who	OTEZLA.xml:S2:2240:3	who	WP	O	O
received	OTEZLA.xml:S2:2244:8	receiv	VBD	O	O
placebo	OTEZLA.xml:S2:2253:7	placebo	RB	O	O
committed	OTEZLA.xml:S2:2261:9	commit	VBN	O	O
suicide	OTEZLA.xml:S2:2271:7	suicid	NN	B-AdverseReaction	O
compared	OTEZLA.xml:S2:2279:8	compar	VBN	O	O
to	OTEZLA.xml:S2:2288:2	to	TO	O	O
none	OTEZLA.xml:S2:2291:4	none	NN	O	O
in	OTEZLA.xml:S2:2296:2	in	IN	O	O
OTEZLA	OTEZLA.xml:S2:2299:6	otezla	NNP	O	O
-	OTEZLA.xml:S2:2305:1	-	:	O	O
treated	OTEZLA.xml:S2:2306:7	treat	JJ	O	O
subjects	OTEZLA.xml:S2:2314:8	subject	NNS	O	O
.	OTEZLA.xml:S2:2322:1	.	.	O	O

Psoriasis	OTEZLA.xml:S2:2330:9	psoriasi	NN	O	O
:	OTEZLA.xml:S2:2341:1	:	:	O	O
During	OTEZLA.xml:S2:2343:6	dure	IN	O	O
the	OTEZLA.xml:S2:2350:3	the	DT	O	O
0	OTEZLA.xml:S2:2354:1	0	CD	O	O
to	OTEZLA.xml:S2:2356:2	to	TO	O	O
16	OTEZLA.xml:S2:2359:2	16	CD	O	O
week	OTEZLA.xml:S2:2362:4	week	NN	O	O
placebo	OTEZLA.xml:S2:2367:7	placebo	NN	O	O
-	OTEZLA.xml:S2:2374:1	-	:	O	O
controlled	OTEZLA.xml:S2:2375:10	control	JJ	O	O
period	OTEZLA.xml:S2:2386:6	period	NN	O	O
of	OTEZLA.xml:S2:2393:2	of	IN	O	O
the	OTEZLA.xml:S2:2396:3	the	DT	O	O
3	OTEZLA.xml:S2:2400:1	3	CD	O	O
controlled	OTEZLA.xml:S2:2402:10	control	VBD	O	O
clinical	OTEZLA.xml:S2:2413:8	clinic	JJ	O	O
trials	OTEZLA.xml:S2:2422:6	trial	NNS	O	O
,	OTEZLA.xml:S2:2428:1	,	,	O	O
1.3%	OTEZLA.xml:S2:2430:4	1.3%	CD	O	O
(	OTEZLA.xml:S2:2435:1	(	(	O	O
12	OTEZLA.xml:S2:2436:2	12	CD	O	O
920	OTEZLA.xml:S2:2439:3	920	CD	O	O
)	OTEZLA.xml:S2:2442:1	)	)	O	O
of	OTEZLA.xml:S2:2444:2	of	IN	O	O
subjects	OTEZLA.xml:S2:2447:8	subject	NNS	O	O
treated	OTEZLA.xml:S2:2456:7	treat	VBN	O	O
with	OTEZLA.xml:S2:2464:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:2469:6	otezla	NNP	O	O
reported	OTEZLA.xml:S2:2476:8	report	VBD	O	O
depression	OTEZLA.xml:S2:2485:10	depress	NN	B-AdverseReaction	B-AdverseReaction
compared	OTEZLA.xml:S2:2496:8	compar	VBN	O	O
to	OTEZLA.xml:S2:2505:2	to	TO	O	O
0.4%	OTEZLA.xml:S2:2508:4	0.4%	CD	O	O
(	OTEZLA.xml:S2:2513:1	(	(	O	O
2	OTEZLA.xml:S2:2514:1	2	CD	O	O
506	OTEZLA.xml:S2:2516:3	506	CD	O	O
)	OTEZLA.xml:S2:2519:1	)	)	O	O
treated	OTEZLA.xml:S2:2521:7	treat	VBN	O	O
with	OTEZLA.xml:S2:2529:4	with	IN	O	O
placebo	OTEZLA.xml:S2:2534:7	placebo	NN	O	O
.	OTEZLA.xml:S2:2541:1	.	.	O	O

During	OTEZLA.xml:S2:2543:6	dure	IN	O	O
the	OTEZLA.xml:S2:2550:3	the	DT	O	O
clinical	OTEZLA.xml:S2:2554:8	clinic	JJ	O	O
trials	OTEZLA.xml:S2:2563:6	trial	NNS	O	O
,	OTEZLA.xml:S2:2569:1	,	,	O	O
0.1%	OTEZLA.xml:S2:2571:4	0.1%	CD	O	O
(	OTEZLA.xml:S2:2576:1	(	(	O	O
1	OTEZLA.xml:S2:2577:1	1	CD	O	O
1308	OTEZLA.xml:S2:2579:4	1308	CD	O	O
)	OTEZLA.xml:S2:2583:1	)	)	O	O
of	OTEZLA.xml:S2:2585:2	of	IN	O	O
subjects	OTEZLA.xml:S2:2588:8	subject	NNS	O	O
treated	OTEZLA.xml:S2:2597:7	treat	VBN	O	O
with	OTEZLA.xml:S2:2605:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:2610:6	otezla	NNP	O	O
discontinued	OTEZLA.xml:S2:2617:12	discontinu	VBD	O	O
treatment	OTEZLA.xml:S2:2630:9	treatment	NN	O	O
due	OTEZLA.xml:S2:2640:3	due	JJ	O	O
to	OTEZLA.xml:S2:2644:2	to	TO	O	O
depression	OTEZLA.xml:S2:2647:10	depress	VB	B-AdverseReaction	O
compared	OTEZLA.xml:S2:2658:8	compar	VBN	O	O
with	OTEZLA.xml:S2:2667:4	with	IN	O	O
none	OTEZLA.xml:S2:2672:4	none	NN	O	O
in	OTEZLA.xml:S2:2677:2	in	IN	O	O
placebo	OTEZLA.xml:S2:2680:7	placebo	NN	O	O
-	OTEZLA.xml:S2:2687:1	-	:	O	O
treated	OTEZLA.xml:S2:2688:7	treat	VBN	O	O
subjects	OTEZLA.xml:S2:2696:8	subject	NNS	O	O
(	OTEZLA.xml:S2:2704:1	(	(	O	O
0	OTEZLA.xml:S2:2705:1	0	CD	O	O
506	OTEZLA.xml:S2:2707:3	506	CD	O	O
)	OTEZLA.xml:S2:2710:1	)	)	O	O
.	OTEZLA.xml:S2:2711:1	.	.	O	O

Depression	OTEZLA.xml:S2:2713:10	depress	NN	B-AdverseReaction	B-AdverseReaction
was	OTEZLA.xml:S2:2724:3	wa	VBD	O	O
reported	OTEZLA.xml:S2:2728:8	report	VBN	O	O
as	OTEZLA.xml:S2:2737:2	as	IN	O	O
serious	OTEZLA.xml:S2:2740:7	seriou	JJ	O	O
in	OTEZLA.xml:S2:2748:2	in	IN	O	O
0.1%	OTEZLA.xml:S2:2751:4	0.1%	CD	O	O
(	OTEZLA.xml:S2:2756:1	(	(	O	O
1	OTEZLA.xml:S2:2757:1	1	CD	O	O
1308	OTEZLA.xml:S2:2759:4	1308	CD	O	O
)	OTEZLA.xml:S2:2763:1	)	)	O	O
of	OTEZLA.xml:S2:2765:2	of	IN	O	O
subjects	OTEZLA.xml:S2:2768:8	subject	NNS	O	O
exposed	OTEZLA.xml:S2:2777:7	expos	VBN	O	O
to	OTEZLA.xml:S2:2785:2	to	TO	O	O
OTEZLA	OTEZLA.xml:S2:2788:6	otezla	NNP	O	O
,	OTEZLA.xml:S2:2794:1	,	,	O	O
compared	OTEZLA.xml:S2:2796:8	compar	VBN	O	O
to	OTEZLA.xml:S2:2805:2	to	TO	O	O
none	OTEZLA.xml:S2:2808:4	none	NN	O	O
in	OTEZLA.xml:S2:2813:2	in	IN	O	O
placebo	OTEZLA.xml:S2:2816:7	placebo	NN	O	O
-	OTEZLA.xml:S2:2823:1	-	:	O	O
treated	OTEZLA.xml:S2:2824:7	treat	VBN	O	O
subjects	OTEZLA.xml:S2:2832:8	subject	NNS	O	O
(	OTEZLA.xml:S2:2841:1	(	(	O	O
0	OTEZLA.xml:S2:2842:1	0	CD	O	O
506	OTEZLA.xml:S2:2844:3	506	CD	O	O
)	OTEZLA.xml:S2:2847:1	)	)	O	O
.	OTEZLA.xml:S2:2848:1	.	.	O	O

Instances	OTEZLA.xml:S2:2850:9	instanc	NNS	O	O
of	OTEZLA.xml:S2:2860:2	of	IN	O	O
suicidal	OTEZLA.xml:S2:2863:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
behavior	OTEZLA.xml:S2:2872:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
have	OTEZLA.xml:S2:2881:4	have	VBP	O	O
been	OTEZLA.xml:S2:2886:4	been	VBN	O	O
observed	OTEZLA.xml:S2:2891:8	observ	VBN	O	O
in	OTEZLA.xml:S2:2900:2	in	IN	O	O
0.1%	OTEZLA.xml:S2:2903:4	0.1%	CD	O	O
(	OTEZLA.xml:S2:2908:1	(	(	O	O
1	OTEZLA.xml:S2:2909:1	1	CD	O	O
1308	OTEZLA.xml:S2:2911:4	1308	CD	O	O
)	OTEZLA.xml:S2:2915:1	)	)	O	O
of	OTEZLA.xml:S2:2917:2	of	IN	O	O
subjects	OTEZLA.xml:S2:2920:8	subject	NNS	O	O
while	OTEZLA.xml:S2:2929:5	while	IN	O	O
receiving	OTEZLA.xml:S2:2935:9	receiv	VBG	O	O
OTEZLA	OTEZLA.xml:S2:2945:6	otezla	NNP	O	O
,	OTEZLA.xml:S2:2951:1	,	,	O	O
compared	OTEZLA.xml:S2:2953:8	compar	VBN	O	O
to	OTEZLA.xml:S2:2962:2	to	TO	O	O
0.2%	OTEZLA.xml:S2:2965:4	0.2%	CD	O	O
(	OTEZLA.xml:S2:2970:1	(	(	O	O
1	OTEZLA.xml:S2:2971:1	1	CD	O	O
506	OTEZLA.xml:S2:2973:3	506	CD	O	O
)	OTEZLA.xml:S2:2976:1	)	)	O	O
in	OTEZLA.xml:S2:2978:2	in	IN	O	O
placebo	OTEZLA.xml:S2:2981:7	placebo	NN	O	O
-	OTEZLA.xml:S2:2988:1	-	:	O	O
treated	OTEZLA.xml:S2:2989:7	treat	JJ	O	O
subjects	OTEZLA.xml:S2:2997:8	subject	NNS	O	O
.	OTEZLA.xml:S2:3005:1	.	.	O	O

In	OTEZLA.xml:S2:3007:2	In	IN	O	O
the	OTEZLA.xml:S2:3010:3	the	DT	O	O
clinical	OTEZLA.xml:S2:3014:8	clinic	JJ	O	O
trials	OTEZLA.xml:S2:3023:6	trial	NNS	O	O
,	OTEZLA.xml:S2:3029:1	,	,	O	O
one	OTEZLA.xml:S2:3031:3	one	CD	O	O
subject	OTEZLA.xml:S2:3035:7	subject	NN	O	O
treated	OTEZLA.xml:S2:3043:7	treat	VBN	O	O
with	OTEZLA.xml:S2:3051:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:3056:6	otezla	NNP	O	O
attempted	OTEZLA.xml:S2:3063:9	attempt	VBD	B-AdverseReaction	O
suicide	OTEZLA.xml:S2:3073:7	suicid	RB	I-AdverseReaction	O
while	OTEZLA.xml:S2:3081:5	while	IN	O	O
one	OTEZLA.xml:S2:3087:3	one	CD	O	O
who	OTEZLA.xml:S2:3091:3	who	WP	O	O
received	OTEZLA.xml:S2:3095:8	receiv	VBD	O	O
placebo	OTEZLA.xml:S2:3104:7	placebo	RB	O	O
committed	OTEZLA.xml:S2:3112:9	commit	VBN	O	O
suicide	OTEZLA.xml:S2:3122:7	suicid	NN	B-AdverseReaction	O
.	OTEZLA.xml:S2:3129:1	.	.	O	O

5.2	OTEZLA.xml:S2:3137:3	5.2	CD	O	O
Weight	OTEZLA.xml:S2:3141:6	weight	NNP	O	O
Decrease	OTEZLA.xml:S2:3148:8	decreas	NNP	O	O

During	OTEZLA.xml:S2:3160:6	dure	IN	O	O
the	OTEZLA.xml:S2:3167:3	the	DT	O	O
controlled	OTEZLA.xml:S2:3171:10	control	JJ	O	O
period	OTEZLA.xml:S2:3182:6	period	NN	O	O
of	OTEZLA.xml:S2:3189:2	of	IN	O	O
the	OTEZLA.xml:S2:3192:3	the	DT	O	O
studies	OTEZLA.xml:S2:3196:7	studi	NNS	O	O
in	OTEZLA.xml:S2:3204:2	in	IN	O	O
psoriatic	OTEZLA.xml:S2:3207:9	psoriat	JJ	O	O
arthritis	OTEZLA.xml:S2:3217:9	arthriti	NN	O	O
(	OTEZLA.xml:S2:3227:1	(	(	O	O
PsA	OTEZLA.xml:S2:3228:3	psa	NNP	O	O
)	OTEZLA.xml:S2:3231:1	)	)	O	O
,	OTEZLA.xml:S2:3232:1	,	,	O	O
weight	OTEZLA.xml:S2:3234:6	weight	VBD	B-AdverseReaction	B-AdverseReaction
decrease	OTEZLA.xml:S2:3241:8	decreas	NN	I-AdverseReaction	I-AdverseReaction
between	OTEZLA.xml:S2:3250:7	between	IN	O	O
5%	OTEZLA.xml:S2:3258:2	5%	CD	O	O
-	OTEZLA.xml:S2:3260:1	-	:	O	O
10%	OTEZLA.xml:S2:3261:3	10%	CD	O	O
of	OTEZLA.xml:S2:3265:2	of	IN	O	O
body	OTEZLA.xml:S2:3268:4	bodi	NN	O	B-AdverseReaction
weight	OTEZLA.xml:S2:3273:6	weight	NN	O	I-AdverseReaction
was	OTEZLA.xml:S2:3280:3	wa	VBD	O	O
reported	OTEZLA.xml:S2:3284:8	report	VBN	O	O
in	OTEZLA.xml:S2:3293:2	in	IN	O	O
10%	OTEZLA.xml:S2:3296:3	10%	CD	O	O
(	OTEZLA.xml:S2:3300:1	(	(	O	O
49	OTEZLA.xml:S2:3301:2	49	CD	O	O
497	OTEZLA.xml:S2:3304:3	497	CD	O	O
)	OTEZLA.xml:S2:3307:1	)	)	O	O
of	OTEZLA.xml:S2:3309:2	of	IN	O	O
subjects	OTEZLA.xml:S2:3312:8	subject	NNS	O	O
treated	OTEZLA.xml:S2:3321:7	treat	VBN	O	O
with	OTEZLA.xml:S2:3329:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:3334:6	otezla	NNP	O	O
30	OTEZLA.xml:S2:3341:2	30	CD	O	O
mg	OTEZLA.xml:S2:3344:2	mg	NN	O	O
twice	OTEZLA.xml:S2:3347:5	twice	RB	O	O
daily	OTEZLA.xml:S2:3353:5	daili	RB	O	O
compared	OTEZLA.xml:S2:3359:8	compar	VBN	O	O
to	OTEZLA.xml:S2:3368:2	to	TO	O	O
3.3%	OTEZLA.xml:S2:3371:4	3.3%	CD	O	O
(	OTEZLA.xml:S2:3376:1	(	(	O	O
16	OTEZLA.xml:S2:3377:2	16	CD	O	O
495	OTEZLA.xml:S2:3380:3	495	CD	O	O
)	OTEZLA.xml:S2:3383:1	)	)	O	O
treated	OTEZLA.xml:S2:3385:7	treat	VBN	O	O
with	OTEZLA.xml:S2:3393:4	with	IN	O	O
placebo	OTEZLA.xml:S2:3398:7	placebo	NN	O	O
[	OTEZLA.xml:S2:3406:1	[	NNP	O	O
see	OTEZLA.xml:S2:3409:3	see	VBP	O	O
Adverse	OTEZLA.xml:S2:3413:7	advers	JJ	O	O
Reactions	OTEZLA.xml:S2:3421:9	reaction	NNP	O	O
(	OTEZLA.xml:S2:3431:1	(	(	O	O
6.1	OTEZLA.xml:S2:3432:3	6.1	CD	O	O
)	OTEZLA.xml:S2:3435:1	)	)	O	O
]	OTEZLA.xml:S2:3438:1	]	NN	O	O
.	OTEZLA.xml:S2:3439:1	.	.	O	O

During	OTEZLA.xml:S2:3447:6	dure	IN	O	O
the	OTEZLA.xml:S2:3454:3	the	DT	O	O
controlled	OTEZLA.xml:S2:3458:10	control	JJ	O	O
period	OTEZLA.xml:S2:3469:6	period	NN	O	O
of	OTEZLA.xml:S2:3476:2	of	IN	O	O
the	OTEZLA.xml:S2:3479:3	the	DT	O	O
trials	OTEZLA.xml:S2:3483:6	trial	NNS	O	O
in	OTEZLA.xml:S2:3490:2	in	IN	O	O
psoriasis	OTEZLA.xml:S2:3493:9	psoriasi	NN	O	O
,	OTEZLA.xml:S2:3502:1	,	,	O	O
weight	OTEZLA.xml:S2:3504:6	weight	VBD	B-AdverseReaction	B-AdverseReaction
decrease	OTEZLA.xml:S2:3511:8	decreas	NN	I-AdverseReaction	I-AdverseReaction
between	OTEZLA.xml:S2:3520:7	between	IN	O	O
5%	OTEZLA.xml:S2:3528:2	5%	CD	O	O
-	OTEZLA.xml:S2:3530:1	-	:	O	O
10%	OTEZLA.xml:S2:3531:3	10%	CD	O	O
of	OTEZLA.xml:S2:3535:2	of	IN	O	O
body	OTEZLA.xml:S2:3538:4	bodi	NN	O	B-AdverseReaction
weight	OTEZLA.xml:S2:3543:6	weight	NN	O	I-AdverseReaction
occurred	OTEZLA.xml:S2:3550:8	occur	VBD	O	O
in	OTEZLA.xml:S2:3559:2	in	IN	O	O
12%	OTEZLA.xml:S2:3562:3	12%	CD	O	O
(	OTEZLA.xml:S2:3566:1	(	(	O	O
96	OTEZLA.xml:S2:3567:2	96	CD	O	O
784	OTEZLA.xml:S2:3570:3	784	CD	O	O
)	OTEZLA.xml:S2:3573:1	)	)	O	O
of	OTEZLA.xml:S2:3575:2	of	IN	O	O
subjects	OTEZLA.xml:S2:3578:8	subject	NNS	O	O
treated	OTEZLA.xml:S2:3587:7	treat	VBN	O	O
with	OTEZLA.xml:S2:3595:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:3600:6	otezla	NNP	O	O
compared	OTEZLA.xml:S2:3607:8	compar	VBN	O	O
to	OTEZLA.xml:S2:3616:2	to	TO	O	O
5%	OTEZLA.xml:S2:3619:2	5%	CD	O	O
(	OTEZLA.xml:S2:3622:1	(	(	O	O
19	OTEZLA.xml:S2:3623:2	19	CD	O	O
382	OTEZLA.xml:S2:3626:3	382	CD	O	O
)	OTEZLA.xml:S2:3629:1	)	)	O	O
treated	OTEZLA.xml:S2:3631:7	treat	VBN	O	O
with	OTEZLA.xml:S2:3639:4	with	IN	O	O
placebo	OTEZLA.xml:S2:3644:7	placebo	NN	O	O
.	OTEZLA.xml:S2:3651:1	.	.	O	O

Weight	OTEZLA.xml:S2:3653:6	weight	NNP	B-AdverseReaction	B-AdverseReaction
decrease	OTEZLA.xml:S2:3660:8	decreas	NN	I-AdverseReaction	I-AdverseReaction
of	OTEZLA.xml:S2:3669:2	of	IN	O	O
10%	OTEZLA.xml:S2:3674:3	10%	CD	O	O
of	OTEZLA.xml:S2:3678:2	of	IN	O	O
body	OTEZLA.xml:S2:3681:4	bodi	NN	O	B-AdverseReaction
weight	OTEZLA.xml:S2:3686:6	weight	NN	O	I-AdverseReaction
occurred	OTEZLA.xml:S2:3693:8	occur	VBD	O	O
in	OTEZLA.xml:S2:3702:2	in	IN	O	O
2%	OTEZLA.xml:S2:3705:2	2%	CD	O	O
(	OTEZLA.xml:S2:3708:1	(	(	O	O
16	OTEZLA.xml:S2:3709:2	16	CD	O	O
784	OTEZLA.xml:S2:3712:3	784	CD	O	O
)	OTEZLA.xml:S2:3715:1	)	)	O	O
of	OTEZLA.xml:S2:3717:2	of	IN	O	O
subjects	OTEZLA.xml:S2:3720:8	subject	NNS	O	O
treated	OTEZLA.xml:S2:3729:7	treat	VBN	O	O
with	OTEZLA.xml:S2:3737:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:3742:6	otezla	NNP	O	O
30	OTEZLA.xml:S2:3749:2	30	CD	O	O
mg	OTEZLA.xml:S2:3752:2	mg	NN	O	O
twice	OTEZLA.xml:S2:3755:5	twice	RB	O	O
daily	OTEZLA.xml:S2:3761:5	daili	RB	O	O
compared	OTEZLA.xml:S2:3767:8	compar	VBN	O	O
to	OTEZLA.xml:S2:3776:2	to	TO	O	O
1%	OTEZLA.xml:S2:3779:2	1%	CD	O	O
(	OTEZLA.xml:S2:3782:1	(	(	O	O
3	OTEZLA.xml:S2:3783:1	3	CD	O	O
382	OTEZLA.xml:S2:3785:3	382	CD	O	O
)	OTEZLA.xml:S2:3788:1	)	)	O	O
subjects	OTEZLA.xml:S2:3790:8	subject	NNS	O	O
treated	OTEZLA.xml:S2:3799:7	treat	VBN	O	O
with	OTEZLA.xml:S2:3807:4	with	IN	O	O
placebo	OTEZLA.xml:S2:3812:7	placebo	NN	O	O
.	OTEZLA.xml:S2:3819:1	.	.	O	O

Patients	OTEZLA.xml:S2:3827:8	patient	NNS	O	O
treated	OTEZLA.xml:S2:3836:7	treat	VBN	O	O
with	OTEZLA.xml:S2:3844:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:3849:6	otezla	NNP	O	O
should	OTEZLA.xml:S2:3856:6	should	MD	O	O
have	OTEZLA.xml:S2:3863:4	have	VB	O	O
their	OTEZLA.xml:S2:3868:5	their	PRP$	O	O
weight	OTEZLA.xml:S2:3874:6	weight	NN	O	O
monitored	OTEZLA.xml:S2:3881:9	monitor	VBD	O	O
regularly	OTEZLA.xml:S2:3891:9	regularli	RB	O	O
.	OTEZLA.xml:S2:3900:1	.	.	O	O

If	OTEZLA.xml:S2:3902:2	If	IN	O	O
unexplained	OTEZLA.xml:S2:3905:11	unexplain	VBN	O	O
or	OTEZLA.xml:S2:3917:2	or	CC	O	O
clinically	OTEZLA.xml:S2:3920:10	clinic	RB	O	O
significant	OTEZLA.xml:S2:3931:11	signific	JJ	O	O
weight	OTEZLA.xml:S2:3943:6	weight	JJ	O	O
loss	OTEZLA.xml:S2:3950:4	loss	NN	O	O
occurs	OTEZLA.xml:S2:3955:6	occur	VBZ	O	O
,	OTEZLA.xml:S2:3961:1	,	,	O	O
weight	OTEZLA.xml:S2:3963:6	weight	JJ	O	O
loss	OTEZLA.xml:S2:3970:4	loss	NN	O	O
should	OTEZLA.xml:S2:3975:6	should	MD	O	O
be	OTEZLA.xml:S2:3982:2	be	VB	O	O
evaluated	OTEZLA.xml:S2:3985:9	evalu	VBN	O	O
,	OTEZLA.xml:S2:3994:1	,	,	O	O
and	OTEZLA.xml:S2:3996:3	and	CC	O	O
discontinuation	OTEZLA.xml:S2:4000:15	discontinu	NN	O	O
of	OTEZLA.xml:S2:4016:2	of	IN	O	O
OTEZLA	OTEZLA.xml:S2:4019:6	otezla	NNP	O	O
should	OTEZLA.xml:S2:4026:6	should	MD	O	O
be	OTEZLA.xml:S2:4033:2	be	VB	O	O
considered	OTEZLA.xml:S2:4036:10	consid	VBN	O	O
.	OTEZLA.xml:S2:4046:1	.	.	O	O

5.3	OTEZLA.xml:S2:4054:3	5.3	CD	O	O
Drug	OTEZLA.xml:S2:4058:4	drug	NNP	O	O
Interactions	OTEZLA.xml:S2:4063:12	interact	NNS	O	O

Co	OTEZLA.xml:S2:4079:2	Co	NNP	O	O
-	OTEZLA.xml:S2:4081:1	-	:	O	O
administration	OTEZLA.xml:S2:4082:14	administr	NN	O	O
of	OTEZLA.xml:S2:4097:2	of	IN	O	O
strong	OTEZLA.xml:S2:4100:6	strong	JJ	O	O
cytochrome	OTEZLA.xml:S2:4107:10	cytochrom	NN	O	O
P450	OTEZLA.xml:S2:4118:4	p450	NNP	O	O
enzyme	OTEZLA.xml:S2:4123:6	enzym	NN	O	O
inducer	OTEZLA.xml:S2:4130:7	induc	NN	O	O
,	OTEZLA.xml:S2:4137:1	,	,	O	O
rifampin	OTEZLA.xml:S2:4139:8	rifampin	NN	O	B-AdverseReaction
,	OTEZLA.xml:S2:4147:1	,	,	O	O
resulted	OTEZLA.xml:S2:4149:8	result	VBD	O	O
in	OTEZLA.xml:S2:4158:2	in	IN	O	O
a	OTEZLA.xml:S2:4161:1	a	DT	O	O
reduction	OTEZLA.xml:S2:4163:9	reduct	NN	O	O
of	OTEZLA.xml:S2:4173:2	of	IN	O	O
systemic	OTEZLA.xml:S2:4176:8	system	JJ	O	O
exposure	OTEZLA.xml:S2:4185:8	exposur	NN	O	O
of	OTEZLA.xml:S2:4194:2	of	IN	O	O
apremilast	OTEZLA.xml:S2:4197:10	apremilast	NN	O	O
,	OTEZLA.xml:S2:4207:1	,	,	O	O
which	OTEZLA.xml:S2:4209:5	which	WDT	O	O
may	OTEZLA.xml:S2:4215:3	may	MD	O	O
result	OTEZLA.xml:S2:4219:6	result	VB	O	O
in	OTEZLA.xml:S2:4226:2	in	IN	O	O
a	OTEZLA.xml:S2:4229:1	a	DT	O	O
loss	OTEZLA.xml:S2:4231:4	loss	NN	O	O
of	OTEZLA.xml:S2:4236:2	of	IN	O	O
efficacy	OTEZLA.xml:S2:4239:8	efficaci	NN	O	O
of	OTEZLA.xml:S2:4248:2	of	IN	O	O
OTEZLA	OTEZLA.xml:S2:4251:6	otezla	NNP	O	O
.	OTEZLA.xml:S2:4257:1	.	.	O	O

Therefore	OTEZLA.xml:S2:4259:9	therefor	RB	O	O
,	OTEZLA.xml:S2:4268:1	,	,	O	O
the	OTEZLA.xml:S2:4270:3	the	DT	O	O
use	OTEZLA.xml:S2:4274:3	use	NN	O	O
of	OTEZLA.xml:S2:4278:2	of	IN	O	O
cytochrome	OTEZLA.xml:S2:4281:10	cytochrom	NN	O	O
P450	OTEZLA.xml:S2:4292:4	p450	NNP	O	O
enzyme	OTEZLA.xml:S2:4297:6	enzym	NN	O	O
inducers	OTEZLA.xml:S2:4304:8	induc	NNS	O	O
(	OTEZLA.xml:S2:4313:1	(	(	O	O
e	OTEZLA.xml:S2:4314:1	e	NN	O	O
.	OTEZLA.xml:S2:4315:1	.	.	O	O
g	OTEZLA.xml:S2:4316:1	g	NN	O	O
.	OTEZLA.xml:S2:4317:1	.	.	O	O
,	OTEZLA.xml:S2:4318:1	,	,	O	O
rifampin	OTEZLA.xml:S2:4320:8	rifampin	NN	O	O
,	OTEZLA.xml:S2:4328:1	,	,	O	O
phenobarbital	OTEZLA.xml:S2:4330:13	phenobarbit	NN	O	B-AdverseReaction
,	OTEZLA.xml:S2:4343:1	,	,	O	O
carbamazepine	OTEZLA.xml:S2:4345:13	carbamazepin	NN	O	O
,	OTEZLA.xml:S2:4358:1	,	,	O	O
phenytoin	OTEZLA.xml:S2:4360:9	phenytoin	NN	O	O
)	OTEZLA.xml:S2:4369:1	)	)	O	O
with	OTEZLA.xml:S2:4371:4	with	IN	O	O
OTEZLA	OTEZLA.xml:S2:4376:6	otezla	NNP	O	O
is	OTEZLA.xml:S2:4383:2	is	VBZ	O	O
not	OTEZLA.xml:S2:4386:3	not	RB	O	O
recommended	OTEZLA.xml:S2:4390:11	recommend	JJ	O	O
[	OTEZLA.xml:S2:4402:1	[	NNS	O	O
see	OTEZLA.xml:S2:4403:3	see	VBP	O	O
Drug	OTEZLA.xml:S2:4408:4	drug	JJ	O	O
Interactions	OTEZLA.xml:S2:4413:12	interact	NNP	O	O
(	OTEZLA.xml:S2:4426:1	(	(	O	O
7.1	OTEZLA.xml:S2:4427:3	7.1	CD	O	O
)	OTEZLA.xml:S2:4430:1	)	)	O	O
and	OTEZLA.xml:S2:4433:3	and	CC	O	O
Clinical	OTEZLA.xml:S2:4438:8	clinic	JJ	O	O
Pharmacology	OTEZLA.xml:S2:4447:12	pharmacolog	NNP	O	O
(	OTEZLA.xml:S2:4460:1	(	(	O	O
12.3	OTEZLA.xml:S2:4461:4	12.3	CD	O	O
)	OTEZLA.xml:S2:4465:1	)	)	O	O
]	OTEZLA.xml:S2:4468:1	]	NN	O	O
.	OTEZLA.xml:S2:4469:1	.	.	O	O
6	PICATO.xml:S1:6:1	6	CD	O	O
ADVERSE	PICATO.xml:S1:8:7	advers	JJ	O	O
REACTIONS	PICATO.xml:S1:16:9	reaction	NN	O	O

The	PICATO.xml:S1:40:3	the	DT	O	O

following	PICATO.xml:S1:44:9	follow	VBG	O	O
serious	PICATO.xml:S1:54:7	seriou	JJ	O	O
adverse	PICATO.xml:S1:62:7	advers	JJ	O	O
reactions	PICATO.xml:S1:70:9	reaction	NNS	O	O
are	PICATO.xml:S1:80:3	are	VBP	O	O
discussed	PICATO.xml:S1:84:9	discuss	VBN	O	O
in	PICATO.xml:S1:94:2	in	IN	O	O
more	PICATO.xml:S1:97:4	more	JJR	O	O
detail	PICATO.xml:S1:102:6	detail	NN	O	O
in	PICATO.xml:S1:109:2	in	IN	O	O
other	PICATO.xml:S1:112:5	other	JJ	O	O
sections	PICATO.xml:S1:118:8	section	NNS	O	O
of	PICATO.xml:S1:127:2	of	IN	O	O
the	PICATO.xml:S1:130:3	the	DT	O	O
labeling	PICATO.xml:S1:134:8	label	NN	O	O
:	PICATO.xml:S1:142:1	:	:	O	O

Ophthalmic	PICATO.xml:S1:160:10	ophthalm	NNP	B-AdverseReaction	O

Adverse	PICATO.xml:S1:171:7	advers	JJ	I-AdverseReaction	O
Reaction	PICATO.xml:S1:179:8	reaction	NNP	I-AdverseReaction	O
[	PICATO.xml:S1:188:1	[	NNP	O	O
see	PICATO.xml:S1:189:3	see	VBP	O	O
Warnings	PICATO.xml:S1:193:8	warn	NNP	O	O
and	PICATO.xml:S1:202:3	and	CC	O	O
Precautions	PICATO.xml:S1:206:11	precaut	NNP	O	O
(	PICATO.xml:S1:218:1	(	(	O	O
5.1	PICATO.xml:S1:221:3	5.1	CD	O	O
)]	PICATO.xml:S1:226:2	)]	NN	O	O

Hypersensitivity	PICATO.xml:S1:235:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	PICATO.xml:S1:252:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
[	PICATO.xml:S1:262:1	[	NNP	O	O
see	PICATO.xml:S1:263:3	see	VBP	O	O
Warnings	PICATO.xml:S1:267:8	warn	NNP	O	O
and	PICATO.xml:S1:276:3	and	CC	O	O
Precautions	PICATO.xml:S1:280:11	precaut	NNP	O	O
(	PICATO.xml:S1:292:1	(	(	O	O
5.2	PICATO.xml:S1:295:3	5.2	CD	O	O
)]	PICATO.xml:S1:300:2	)]	NN	O	O

EXCERPT	PICATO.xml:S1:316:7	excerpt	NN	O	O

:	PICATO.xml:S1:323:1	:	:	O	O

The	PICATO.xml:S1:327:3	the	DT	O	O
most	PICATO.xml:S1:331:4	most	RBS	O	O
common	PICATO.xml:S1:336:6	common	JJ	O	O
adverse	PICATO.xml:S1:343:7	advers	JJ	O	O
reactions	PICATO.xml:S1:351:9	reaction	NNS	O	O
(	PICATO.xml:S1:361:1	(	(	O	O
2	PICATO.xml:S1:364:1	2	CD	O	O
)	PICATO.xml:S1:367:1	)	)	O	O
are	PICATO.xml:S1:369:3	are	VBP	O	O
local	PICATO.xml:S1:373:5	local	JJ	B-AdverseReaction	B-AdverseReaction
skin	PICATO.xml:S1:379:4	skin	NN	I-AdverseReaction	I-AdverseReaction
reactions	PICATO.xml:S1:384:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:393:1	,	,	O	O
application	PICATO.xml:S1:395:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	PICATO.xml:S1:407:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	PICATO.xml:S1:412:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:416:1	,	,	O	O
application	PICATO.xml:S1:418:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	PICATO.xml:S1:430:4	site	NN	I-AdverseReaction	I-AdverseReaction
pruritus	PICATO.xml:S1:435:8	pruritu	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:443:1	,	,	O	O
application	PICATO.xml:S1:445:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	PICATO.xml:S1:457:4	site	NN	I-AdverseReaction	I-AdverseReaction
irritation	PICATO.xml:S1:462:10	irrit	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:472:1	,	,	O	O
application	PICATO.xml:S1:474:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	PICATO.xml:S1:486:4	site	NN	I-AdverseReaction	I-AdverseReaction
infection	PICATO.xml:S1:491:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:500:1	,	,	O	O
periorbital	PICATO.xml:S1:502:11	periorbit	JJ	B-AdverseReaction	B-AdverseReaction
edema	PICATO.xml:S1:514:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:519:1	,	,	O	O
nasopharyngitis	PICATO.xml:S1:521:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
and	PICATO.xml:S1:537:3	and	CC	O	O
headache	PICATO.xml:S1:541:8	headach	NN	B-AdverseReaction	B-AdverseReaction
.	PICATO.xml:S1:549:1	.	.	O	O

(	PICATO.xml:S1:551:1	(	(	O	O
6.1	PICATO.xml:S1:556:3	6.1	CD	O	O
)	PICATO.xml:S1:563:1	)	)	O	O

To	PICATO.xml:S1:571:2	To	TO	O	O
report	PICATO.xml:S1:574:6	report	VB	O	O
SUSPECTED	PICATO.xml:S1:581:9	suspect	NNP	O	O
ADVERSE	PICATO.xml:S1:591:7	advers	NNP	O	O
REACTIONS	PICATO.xml:S1:599:9	reaction	NNP	O	O
,	PICATO.xml:S1:608:1	,	,	O	O
contact	PICATO.xml:S1:610:7	contact	NN	O	O
LEO	PICATO.xml:S1:618:3	leo	NNP	O	O
Pharma	PICATO.xml:S1:622:6	pharma	NNP	O	O
Inc	PICATO.xml:S1:629:3	inc	NNP	O	O
.	PICATO.xml:S1:632:1	.	.	O	O

at	PICATO.xml:S1:634:2	at	IN	O	O
1	PICATO.xml:S1:637:1	1	CD	O	O
-	PICATO.xml:S1:638:1	-	:	O	O
877	PICATO.xml:S1:639:3	877	CD	O	O
-	PICATO.xml:S1:642:1	-	:	O	O
494	PICATO.xml:S1:643:3	494	CD	O	O
-	PICATO.xml:S1:646:1	-	:	O	O
4536	PICATO.xml:S1:647:4	4536	CD	O	O
or	PICATO.xml:S1:652:2	or	CC	O	O
FDA	PICATO.xml:S1:655:3	fda	NNP	O	O
at	PICATO.xml:S1:659:2	at	IN	O	O
1	PICATO.xml:S1:662:1	1	CD	O	O
-	PICATO.xml:S1:663:1	-	:	O	O
800	PICATO.xml:S1:664:3	800	CD	O	O
-	PICATO.xml:S1:667:1	-	:	O	O
FDA	PICATO.xml:S1:668:3	fda	NNP	O	O
-	PICATO.xml:S1:671:1	-	:	O	O
1088	PICATO.xml:S1:672:4	1088	CD	O	O
or	PICATO.xml:S1:677:2	or	CC	O	O
www	PICATO.xml:S1:681:3	www	VB	O	O
.	PICATO.xml:S1:684:1	.	.	O	O
fda	PICATO.xml:S1:685:3	fda	NN	O	O
.	PICATO.xml:S1:688:1	.	.	O	O
gov	PICATO.xml:S1:689:3	gov	JJ	O	O
medwatch	PICATO.xml:S1:693:8	medwatch	NN	O	O
.	PICATO.xml:S1:701:1	.	.	O	O

6.1	PICATO.xml:S1:715:3	6.1	CD	O	O

Clinical	PICATO.xml:S1:719:8	clinic	JJ	O	O
Trials	PICATO.xml:S1:728:6	trial	NNS	O	O
Experience	PICATO.xml:S1:735:10	experi	NN	O	O

Because	PICATO.xml:S1:749:7	becaus	IN	O	O
clinical	PICATO.xml:S1:757:8	clinic	JJ	O	O
trials	PICATO.xml:S1:766:6	trial	NNS	O	O
are	PICATO.xml:S1:773:3	are	VBP	O	O
conducted	PICATO.xml:S1:777:9	conduct	VBN	O	O
under	PICATO.xml:S1:787:5	under	IN	O	O
widely	PICATO.xml:S1:793:6	wide	RB	O	O
varying	PICATO.xml:S1:800:7	vari	VBG	O	O
conditions	PICATO.xml:S1:808:10	condit	NNS	O	O
,	PICATO.xml:S1:818:1	,	,	O	O
adverse	PICATO.xml:S1:820:7	advers	JJ	O	O
reaction	PICATO.xml:S1:828:8	reaction	NN	O	O
rates	PICATO.xml:S1:837:5	rate	NNS	O	O
observed	PICATO.xml:S1:843:8	observ	VBD	O	O
in	PICATO.xml:S1:852:2	in	IN	O	O
the	PICATO.xml:S1:855:3	the	DT	O	O
clinical	PICATO.xml:S1:859:8	clinic	JJ	O	O
trials	PICATO.xml:S1:868:6	trial	NNS	O	O
of	PICATO.xml:S1:875:2	of	IN	O	O
a	PICATO.xml:S1:878:1	a	DT	O	O
drug	PICATO.xml:S1:880:4	drug	NN	O	O
cannot	PICATO.xml:S1:885:6	cannot	NN	O	O
be	PICATO.xml:S1:892:2	be	VB	O	O
directly	PICATO.xml:S1:895:8	directli	RB	O	O
compared	PICATO.xml:S1:904:8	compar	VBN	O	O
to	PICATO.xml:S1:913:2	to	TO	O	O
rates	PICATO.xml:S1:916:5	rate	NNS	O	O
in	PICATO.xml:S1:922:2	in	IN	O	O
the	PICATO.xml:S1:925:3	the	DT	O	O
clinical	PICATO.xml:S1:929:8	clinic	JJ	O	O
trials	PICATO.xml:S1:938:6	trial	NNS	O	O
of	PICATO.xml:S1:945:2	of	IN	O	O
another	PICATO.xml:S1:948:7	anoth	DT	O	O
drug	PICATO.xml:S1:956:4	drug	NN	O	O
and	PICATO.xml:S1:961:3	and	CC	O	O
may	PICATO.xml:S1:965:3	may	MD	O	O
not	PICATO.xml:S1:969:3	not	RB	O	O
reflect	PICATO.xml:S1:973:7	reflect	VB	O	O
the	PICATO.xml:S1:981:3	the	DT	O	O
rates	PICATO.xml:S1:985:5	rate	NNS	O	O
observed	PICATO.xml:S1:991:8	observ	VBD	O	O
in	PICATO.xml:S1:1000:2	in	IN	O	O
clinical	PICATO.xml:S1:1003:8	clinic	JJ	O	O
practice	PICATO.xml:S1:1012:8	practic	NN	O	O
.	PICATO.xml:S1:1020:1	.	.	O	O

The	PICATO.xml:S1:1031:3	the	DT	O	O

data	PICATO.xml:S1:1035:4	data	NNS	O	O
described	PICATO.xml:S1:1040:9	describ	VBD	O	O
below	PICATO.xml:S1:1050:5	below	IN	O	O
reflect	PICATO.xml:S1:1056:7	reflect	NN	O	O
exposure	PICATO.xml:S1:1064:8	exposur	NN	O	O
to	PICATO.xml:S1:1073:2	to	TO	O	O
Picato	PICATO.xml:S1:1076:6	picato	NNP	O	O
(	PICATO.xml:S1:1084:1	(	(	O	O
r	PICATO.xml:S1:1085:1	r	NN	O	O
)	PICATO.xml:S1:1086:1	)	)	O	O
gel	PICATO.xml:S1:1089:3	gel	NN	O	O
in	PICATO.xml:S1:1093:2	in	IN	O	O
499	PICATO.xml:S1:1096:3	499	CD	O	O
subjects	PICATO.xml:S1:1100:8	subject	NNS	O	O
with	PICATO.xml:S1:1109:4	with	IN	O	O
actinic	PICATO.xml:S1:1114:7	actin	JJ	O	O
keratosis	PICATO.xml:S1:1122:9	keratosi	NN	O	O
,	PICATO.xml:S1:1131:1	,	,	O	O
including	PICATO.xml:S1:1133:9	includ	VBG	O	O
274	PICATO.xml:S1:1143:3	274	CD	O	O
subjects	PICATO.xml:S1:1147:8	subject	NNS	O	O
exposed	PICATO.xml:S1:1156:7	expos	VBN	O	O
to	PICATO.xml:S1:1164:2	to	TO	O	O
Picato	PICATO.xml:S1:1167:6	picato	NNP	O	O
(	PICATO.xml:S1:1175:1	(	(	O	O
r	PICATO.xml:S1:1176:1	r	NN	O	O
)	PICATO.xml:S1:1177:1	)	)	O	O
gel	PICATO.xml:S1:1180:3	gel	NN	O	O
field	PICATO.xml:S1:1184:5	field	NN	O	O
treatment	PICATO.xml:S1:1190:9	treatment	NN	O	O
(	PICATO.xml:S1:1200:1	(	(	O	O
skin	PICATO.xml:S1:1201:4	skin	JJ	O	O
area	PICATO.xml:S1:1206:4	area	NN	O	O
of	PICATO.xml:S1:1211:2	of	IN	O	O
25	PICATO.xml:S1:1214:2	25	CD	O	O
cm	PICATO.xml:S1:1217:2	cm	NNS	O	O
2	PICATO.xml:S1:1221:1	2	CD	O	O
in	PICATO.xml:S1:1224:2	in	IN	O	O
the	PICATO.xml:S1:1227:3	the	DT	O	O
face	PICATO.xml:S1:1231:4	face	NN	O	O
or	PICATO.xml:S1:1236:2	or	CC	O	O
scalp	PICATO.xml:S1:1239:5	scalp	JJ	O	O
regions	PICATO.xml:S1:1245:7	region	NNS	O	O
)	PICATO.xml:S1:1252:1	)	)	O	O
at	PICATO.xml:S1:1254:2	at	IN	O	O
a	PICATO.xml:S1:1257:1	a	DT	O	O
concentration	PICATO.xml:S1:1259:13	concentr	NN	O	O
of	PICATO.xml:S1:1273:2	of	IN	O	O
0.015%	PICATO.xml:S1:1276:6	0.015%	CD	O	O
once	PICATO.xml:S1:1283:4	onc	RB	O	O
daily	PICATO.xml:S1:1288:5	daili	JJ	O	O
for	PICATO.xml:S1:1294:3	for	IN	O	O
3	PICATO.xml:S1:1298:1	3	CD	O	O
consecutive	PICATO.xml:S1:1300:11	consecut	JJ	O	O
days	PICATO.xml:S1:1312:4	day	NNS	O	O
,	PICATO.xml:S1:1316:1	,	,	O	O
and	PICATO.xml:S1:1318:3	and	CC	O	O
225	PICATO.xml:S1:1322:3	225	CD	O	O
subjects	PICATO.xml:S1:1326:8	subject	NNS	O	O
exposed	PICATO.xml:S1:1335:7	expos	VBN	O	O
to	PICATO.xml:S1:1343:2	to	TO	O	O
Picato	PICATO.xml:S1:1346:6	picato	NNP	O	O
(	PICATO.xml:S1:1354:1	(	(	O	O
r	PICATO.xml:S1:1355:1	r	NN	O	O
)	PICATO.xml:S1:1356:1	)	)	O	O
gel	PICATO.xml:S1:1359:3	gel	NN	O	O
field	PICATO.xml:S1:1363:5	field	NN	O	O
treatment	PICATO.xml:S1:1369:9	treatment	NN	O	O
(	PICATO.xml:S1:1379:1	(	(	O	O
skin	PICATO.xml:S1:1380:4	skin	JJ	O	O
area	PICATO.xml:S1:1385:4	area	NN	O	O
of	PICATO.xml:S1:1390:2	of	IN	O	O
25	PICATO.xml:S1:1393:2	25	CD	O	O
cm	PICATO.xml:S1:1396:2	cm	NNS	O	O
2	PICATO.xml:S1:1400:1	2	CD	O	O
in	PICATO.xml:S1:1403:2	in	IN	O	O
the	PICATO.xml:S1:1406:3	the	DT	O	O
trunk	PICATO.xml:S1:1410:5	trunk	NN	O	O
or	PICATO.xml:S1:1416:2	or	CC	O	O
extremities	PICATO.xml:S1:1419:11	extrem	NNS	O	O
regions	PICATO.xml:S1:1431:7	region	NNS	O	O
)	PICATO.xml:S1:1438:1	)	)	O	O
at	PICATO.xml:S1:1440:2	at	IN	O	O
a	PICATO.xml:S1:1443:1	a	DT	O	O
concentration	PICATO.xml:S1:1445:13	concentr	NN	O	O
of	PICATO.xml:S1:1459:2	of	IN	O	O
0.05%	PICATO.xml:S1:1462:5	0.05%	CD	O	O
once	PICATO.xml:S1:1468:4	onc	RB	O	O
daily	PICATO.xml:S1:1473:5	daili	JJ	O	O
for	PICATO.xml:S1:1479:3	for	IN	O	O
2	PICATO.xml:S1:1483:1	2	CD	O	O
consecutive	PICATO.xml:S1:1485:11	consecut	JJ	O	O
days	PICATO.xml:S1:1497:4	day	NNS	O	O
.	PICATO.xml:S1:1501:1	.	.	O	O

Local	PICATO.xml:S1:1512:5	local	JJ	B-AdverseReaction	O

skin	PICATO.xml:S1:1518:4	skin	JJ	I-AdverseReaction	B-AdverseReaction
reactions	PICATO.xml:S1:1523:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:1532:1	,	,	O	O
including	PICATO.xml:S1:1534:9	includ	VBG	O	O
erythema	PICATO.xml:S1:1544:8	erythema	NN	I-AdverseReaction	B-AdverseReaction
,	PICATO.xml:S1:1552:1	,	,	O	O
flaking	PICATO.xml:S1:1554:7	flake	VBG	I-AdverseReaction	B-AdverseReaction
scaling	PICATO.xml:S1:1562:7	scale	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:1569:1	,	,	O	O
crusting	PICATO.xml:S1:1571:8	crust	VBG	I-AdverseReaction	O
,	PICATO.xml:S1:1579:1	,	,	O	O
swelling	PICATO.xml:S1:1581:8	swell	VBG	I-AdverseReaction	B-AdverseReaction
,	PICATO.xml:S1:1589:1	,	,	O	O
vesiculation	PICATO.xml:S1:1591:12	vesicul	NN	I-AdverseReaction	B-AdverseReaction
pustulation	PICATO.xml:S1:1604:11	pustul	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:1615:1	,	,	O	O
and	PICATO.xml:S1:1617:3	and	CC	O	O
erosion	PICATO.xml:S1:1621:7	eros	NN	I-AdverseReaction	B-AdverseReaction
ulceration	PICATO.xml:S1:1629:10	ulcer	NN	I-AdverseReaction	I-AdverseReaction
were	PICATO.xml:S1:1640:4	were	VBD	O	O
assessed	PICATO.xml:S1:1645:8	assess	VBN	O	O
within	PICATO.xml:S1:1654:6	within	IN	O	O
the	PICATO.xml:S1:1661:3	the	DT	O	O
selected	PICATO.xml:S1:1665:8	select	VBN	O	O
treatment	PICATO.xml:S1:1674:9	treatment	NN	O	O
area	PICATO.xml:S1:1684:4	area	NN	O	O
and	PICATO.xml:S1:1689:3	and	CC	O	O
graded	PICATO.xml:S1:1693:6	grade	VBN	O	O
by	PICATO.xml:S1:1700:2	by	IN	O	O
the	PICATO.xml:S1:1703:3	the	DT	O	O
investigator	PICATO.xml:S1:1707:12	investig	NN	O	O
on	PICATO.xml:S1:1720:2	on	IN	O	O
a	PICATO.xml:S1:1723:1	a	DT	O	O
scale	PICATO.xml:S1:1725:5	scale	NN	O	O
of	PICATO.xml:S1:1731:2	of	IN	O	O
0	PICATO.xml:S1:1734:1	0	CD	O	O
to	PICATO.xml:S1:1736:2	to	TO	O	O
4	PICATO.xml:S1:1739:1	4	CD	O	O
.	PICATO.xml:S1:1740:1	.	.	O	O

A	PICATO.xml:S1:1742:1	A	DT	O	O
grade	PICATO.xml:S1:1744:5	grade	NN	O	O
of	PICATO.xml:S1:1750:2	of	IN	O	O
0	PICATO.xml:S1:1753:1	0	CD	O	O
represented	PICATO.xml:S1:1755:11	repres	VBD	O	O
no	PICATO.xml:S1:1767:2	no	DT	O	O
reaction	PICATO.xml:S1:1770:8	reaction	NN	O	O
present	PICATO.xml:S1:1779:7	present	NN	O	O
in	PICATO.xml:S1:1787:2	in	IN	O	O
the	PICATO.xml:S1:1790:3	the	DT	O	O
treated	PICATO.xml:S1:1794:7	treat	JJ	O	O
area	PICATO.xml:S1:1802:4	area	NN	O	O
,	PICATO.xml:S1:1806:1	,	,	O	O
and	PICATO.xml:S1:1808:3	and	CC	O	O
a	PICATO.xml:S1:1812:1	a	DT	O	O
grade	PICATO.xml:S1:1814:5	grade	NN	O	O
of	PICATO.xml:S1:1820:2	of	IN	O	O
4	PICATO.xml:S1:1823:1	4	CD	O	O
indicated	PICATO.xml:S1:1825:9	indic	VBD	O	O
a	PICATO.xml:S1:1835:1	a	DT	O	O
marked	PICATO.xml:S1:1837:6	mark	JJ	O	O
and	PICATO.xml:S1:1844:3	and	CC	O	O
severe	PICATO.xml:S1:1848:6	sever	JJ	O	O
skin	PICATO.xml:S1:1855:4	skin	NN	O	B-AdverseReaction
reaction	PICATO.xml:S1:1860:8	reaction	NN	O	I-AdverseReaction
that	PICATO.xml:S1:1869:4	that	WDT	O	O
extended	PICATO.xml:S1:1874:8	extend	VBD	O	O
beyond	PICATO.xml:S1:1883:6	beyond	IN	O	O
the	PICATO.xml:S1:1890:3	the	DT	O	O
treated	PICATO.xml:S1:1894:7	treat	JJ	O	O
area	PICATO.xml:S1:1902:4	area	NN	O	O
.	PICATO.xml:S1:1906:1	.	.	O	O

Table	PICATO.xml:S1:1919:5	tabl	NN	O	O

1	PICATO.xml:S1:1925:1	1	CD	O	O
Investigator	PICATO.xml:S1:1927:12	investig	NNP	O	O
Assessment	PICATO.xml:S1:1940:10	assess	NNP	O	O
of	PICATO.xml:S1:1951:2	of	IN	O	O
Maximal	PICATO.xml:S1:1954:7	maxim	NNP	O	O
Local	PICATO.xml:S1:1962:5	local	NNP	B-AdverseReaction	O
Skin	PICATO.xml:S1:1968:4	skin	NNP	I-AdverseReaction	O
Reactions	PICATO.xml:S1:1973:9	reaction	NNP	I-AdverseReaction	O
in	PICATO.xml:S1:1983:2	in	IN	O	O
the	PICATO.xml:S1:1986:3	the	DT	O	O
Treatment	PICATO.xml:S1:1990:9	treatment	NNP	O	O
Area	PICATO.xml:S1:2000:4	area	NNP	O	O
during	PICATO.xml:S1:2005:6	dure	IN	O	O
the	PICATO.xml:S1:2012:3	the	DT	O	O
57	PICATO.xml:S1:2016:2	57	CD	O	O
Days	PICATO.xml:S1:2019:4	day	NNPS	O	O
Post	PICATO.xml:S1:2024:4	post	NNP	O	O
Treatment	PICATO.xml:S1:2029:9	treatment	NNP	O	O
Period	PICATO.xml:S1:2039:6	period	NNP	O	O
(	PICATO.xml:S1:2046:1	(	(	O	O
face	PICATO.xml:S1:2047:4	face	NN	O	O
scalp	PICATO.xml:S1:2052:5	scalp	NN	O	O
trials	PICATO.xml:S1:2058:6	trial	NNS	O	O
)	PICATO.xml:S1:2064:1	)	)	O	O

Face	PICATO.xml:S1:2074:4	face	NN	O	O
and	PICATO.xml:S1:2079:3	and	CC	O	O
Scalp	PICATO.xml:S1:2083:5	scalp	NNP	O	O
(	PICATO.xml:S1:2090:1	(	(	O	O
n	PICATO.xml:S1:2091:1	n	JJ	O	O
545	PICATO.xml:S1:2093:3	545	CD	O	O
)	PICATO.xml:S1:2096:1	)	)	O	O
Picato	PICATO.xml:S1:2099:6	picato	NNP	O	O
(	PICATO.xml:S1:2105:1	(	(	O	O
r	PICATO.xml:S1:2106:1	r	NN	O	O
)	PICATO.xml:S1:2107:1	)	)	O	O
gel	PICATO.xml:S1:2109:3	gel	NN	O	O
,	PICATO.xml:S1:2112:1	,	,	O	O
0.015%	PICATO.xml:S1:2114:6	0.015%	CD	O	O
once	PICATO.xml:S1:2121:4	onc	RB	O	O
daily	PICATO.xml:S1:2126:5	daili	JJ	O	O
for	PICATO.xml:S1:2132:3	for	IN	O	O
3	PICATO.xml:S1:2136:1	3	CD	O	O
days	PICATO.xml:S1:2138:4	day	NNS	O	O

Skin	PICATO.xml:S1:2149:4	skin	NNP	B-AdverseReaction	O
reactions	PICATO.xml:S1:2154:9	reaction	NNS	O	O
Any	PICATO.xml:S1:2176:3	ani	NNP	O	O
Gradea	PICATO.xml:S1:2180:6	gradea	NNP	O	O
Baseline	PICATO.xml:S1:2189:8	baselin	NNP	O	O
Grade	PICATO.xml:S1:2203:5	grade	NNP	O	O
4	PICATO.xml:S1:2209:1	4	CD	O	O

Picato	PICATO.xml:S1:2260:6	picato	NNP	O	O
(	PICATO.xml:S1:2266:1	(	(	O	O
r	PICATO.xml:S1:2267:1	r	NN	O	O
)	PICATO.xml:S1:2268:1	)	)	O	O
gel	PICATO.xml:S1:2270:3	gel	NN	O	O
(	PICATO.xml:S1:2275:1	(	(	O	O
n	PICATO.xml:S1:2276:1	n	JJ	O	O
274	PICATO.xml:S1:2278:3	274	CD	O	O
)	PICATO.xml:S1:2281:1	)	)	O	O
Vehicle	PICATO.xml:S1:2287:7	vehicl	NNP	O	O
(	PICATO.xml:S1:2296:1	(	(	O	O
n	PICATO.xml:S1:2297:1	n	RB	O	O
271	PICATO.xml:S1:2299:3	271	CD	O	O
)	PICATO.xml:S1:2302:1	)	)	O	O
Picato	PICATO.xml:S1:2314:6	picato	NNP	O	O
(	PICATO.xml:S1:2320:1	(	(	O	O
r	PICATO.xml:S1:2321:1	r	NN	O	O
)	PICATO.xml:S1:2322:1	)	)	O	O
gel	PICATO.xml:S1:2324:3	gel	NN	O	O
(	PICATO.xml:S1:2329:1	(	(	O	O
n	PICATO.xml:S1:2330:1	n	JJ	O	O
274	PICATO.xml:S1:2332:3	274	CD	O	O
)	PICATO.xml:S1:2335:1	)	)	O	O
Vehicle	PICATO.xml:S1:2342:7	vehicl	NNP	O	O
(	PICATO.xml:S1:2351:1	(	(	O	O
n	PICATO.xml:S1:2352:1	n	RB	O	O
271	PICATO.xml:S1:2354:3	271	CD	O	O
)	PICATO.xml:S1:2357:1	)	)	O	O

Erythema	PICATO.xml:S1:2372:8	erythema	RB	I-AdverseReaction	B-AdverseReaction
258	PICATO.xml:S1:2399:3	258	CD	O	O
(	PICATO.xml:S1:2403:1	(	(	O	O
94%	PICATO.xml:S1:2404:3	94%	CD	O	O
)	PICATO.xml:S1:2407:1	)	)	O	O
69	PICATO.xml:S1:2426:2	69	CD	O	O
(	PICATO.xml:S1:2429:1	(	(	O	O
25%	PICATO.xml:S1:2430:3	25%	CD	O	O
)	PICATO.xml:S1:2433:1	)	)	O	O
66	PICATO.xml:S1:2453:2	66	CD	O	O
(	PICATO.xml:S1:2456:1	(	(	O	O
24%	PICATO.xml:S1:2457:3	24%	CD	O	O
)	PICATO.xml:S1:2460:1	)	)	O	O
0	PICATO.xml:S1:2480:1	0	CD	O	O
(	PICATO.xml:S1:2482:1	(	(	O	O
0%	PICATO.xml:S1:2483:2	0%	CD	O	O
)	PICATO.xml:S1:2485:1	)	)	O	O

Flaking	PICATO.xml:S1:2510:7	flake	VBG	I-AdverseReaction	O
Scaling	PICATO.xml:S1:2518:7	scale	VBG	I-AdverseReaction	O
233	PICATO.xml:S1:2537:3	233	CD	O	O
(	PICATO.xml:S1:2541:1	(	(	O	O
85%	PICATO.xml:S1:2542:3	85%	CD	O	O
)	PICATO.xml:S1:2545:1	)	)	O	O
67	PICATO.xml:S1:2564:2	67	CD	O	O
(	PICATO.xml:S1:2567:1	(	(	O	O
25%	PICATO.xml:S1:2568:3	25%	CD	O	O
)	PICATO.xml:S1:2571:1	)	)	O	O
25	PICATO.xml:S1:2591:2	25	CD	O	O
(	PICATO.xml:S1:2594:1	(	(	O	O
9%	PICATO.xml:S1:2595:2	9%	CD	O	O
)	PICATO.xml:S1:2597:1	)	)	O	O
0	PICATO.xml:S1:2618:1	0	CD	O	O
(	PICATO.xml:S1:2620:1	(	(	O	O
0%	PICATO.xml:S1:2621:2	0%	CD	O	O
)	PICATO.xml:S1:2623:1	)	)	O	O

Crusting	PICATO.xml:S1:2648:8	crust	VBG	I-AdverseReaction	B-AdverseReaction
220	PICATO.xml:S1:2675:3	220	CD	O	O
(	PICATO.xml:S1:2679:1	(	(	O	O
80%	PICATO.xml:S1:2680:3	80%	CD	O	O
)	PICATO.xml:S1:2683:1	)	)	O	O
46	PICATO.xml:S1:2702:2	46	CD	O	O
(	PICATO.xml:S1:2705:1	(	(	O	O
17%	PICATO.xml:S1:2706:3	17%	CD	O	O
)	PICATO.xml:S1:2709:1	)	)	O	O
16	PICATO.xml:S1:2729:2	16	CD	O	O
(	PICATO.xml:S1:2732:1	(	(	O	O
6%	PICATO.xml:S1:2733:2	6%	CD	O	O
)	PICATO.xml:S1:2735:1	)	)	O	O
0	PICATO.xml:S1:2756:1	0	CD	O	O
(	PICATO.xml:S1:2758:1	(	(	O	O
0%	PICATO.xml:S1:2759:2	0%	CD	O	O
)	PICATO.xml:S1:2761:1	)	)	O	O

Swelling	PICATO.xml:S1:2786:8	swell	VBG	I-AdverseReaction	B-AdverseReaction
217	PICATO.xml:S1:2813:3	217	CD	O	O
(	PICATO.xml:S1:2817:1	(	(	O	O
79%	PICATO.xml:S1:2818:3	79%	CD	O	O
)	PICATO.xml:S1:2821:1	)	)	O	O
11	PICATO.xml:S1:2840:2	11	CD	O	O
(	PICATO.xml:S1:2843:1	(	(	O	O
4%	PICATO.xml:S1:2844:2	4%	CD	O	O
)	PICATO.xml:S1:2846:1	)	)	O	O
14	PICATO.xml:S1:2867:2	14	CD	O	O
(	PICATO.xml:S1:2870:1	(	(	O	O
5%	PICATO.xml:S1:2871:2	5%	CD	O	O
)	PICATO.xml:S1:2873:1	)	)	O	O
0	PICATO.xml:S1:2894:1	0	CD	O	O
(	PICATO.xml:S1:2896:1	(	(	O	O
0%	PICATO.xml:S1:2897:2	0%	CD	O	O
)	PICATO.xml:S1:2899:1	)	)	O	O

Vesiculation	PICATO.xml:S1:2924:12	vesicul	NNP	I-AdverseReaction	O
Pustulation	PICATO.xml:S1:2937:11	pustul	NNP	I-AdverseReaction	O
154	PICATO.xml:S1:2952:3	154	CD	O	O
(	PICATO.xml:S1:2956:1	(	(	O	O
56%	PICATO.xml:S1:2957:3	56%	CD	O	O
)	PICATO.xml:S1:2960:1	)	)	O	O
1	PICATO.xml:S1:2979:1	1	CD	O	O
(	PICATO.xml:S1:2981:1	(	(	O	O
0%	PICATO.xml:S1:2982:2	0%	CD	O	O
)	PICATO.xml:S1:2984:1	)	)	O	O
15	PICATO.xml:S1:3006:2	15	CD	O	O
(	PICATO.xml:S1:3009:1	(	(	O	O
5%	PICATO.xml:S1:3010:2	5%	CD	O	O
)	PICATO.xml:S1:3012:1	)	)	O	O
0	PICATO.xml:S1:3033:1	0	CD	O	O
(	PICATO.xml:S1:3035:1	(	(	O	O
0%	PICATO.xml:S1:3036:2	0%	CD	O	O
)	PICATO.xml:S1:3038:1	)	)	O	O

Erosion	PICATO.xml:S1:3063:7	eros	NNP	I-AdverseReaction	B-AdverseReaction
Ulceration	PICATO.xml:S1:3071:10	ulcer	NNP	I-AdverseReaction	I-AdverseReaction
87	PICATO.xml:S1:3090:2	87	CD	O	O
(	PICATO.xml:S1:3093:1	(	(	O	O
32%	PICATO.xml:S1:3094:3	32%	CD	O	O
)	PICATO.xml:S1:3097:1	)	)	O	O
3	PICATO.xml:S1:3117:1	3	CD	O	O
(	PICATO.xml:S1:3119:1	(	(	O	O
1%	PICATO.xml:S1:3120:2	1%	CD	O	O
)	PICATO.xml:S1:3122:1	)	)	O	O
1	PICATO.xml:S1:3144:1	1	CD	O	O
(	PICATO.xml:S1:3146:1	(	(	O	O
0%	PICATO.xml:S1:3147:2	0%	CD	O	O
)	PICATO.xml:S1:3149:1	)	)	O	O
0	PICATO.xml:S1:3171:1	0	CD	O	O
(	PICATO.xml:S1:3173:1	(	(	O	O
0%	PICATO.xml:S1:3174:2	0%	CD	O	O
)	PICATO.xml:S1:3176:1	)	)	O	O

a	PICATO.xml:S1:3207:1	a	DT	O	O
Mild	PICATO.xml:S1:3210:4	mild	NNP	O	O
(	PICATO.xml:S1:3215:1	(	(	O	O
grade	PICATO.xml:S1:3216:5	grade	VB	O	O
1	PICATO.xml:S1:3222:1	1	CD	O	O
)	PICATO.xml:S1:3223:1	)	)	O	O
,	PICATO.xml:S1:3224:1	,	,	O	O
Moderate	PICATO.xml:S1:3226:8	moder	NNP	O	O
(	PICATO.xml:S1:3235:1	(	(	O	O
grade	PICATO.xml:S1:3236:5	grade	VB	O	O
2	PICATO.xml:S1:3242:1	2	CD	O	O
-	PICATO.xml:S1:3243:1	-	:	O	O
3	PICATO.xml:S1:3244:1	3	CD	O	O
)	PICATO.xml:S1:3245:1	)	)	O	O
or	PICATO.xml:S1:3247:2	or	CC	O	O
Severe	PICATO.xml:S1:3250:6	sever	NNP	O	O
(	PICATO.xml:S1:3257:1	(	(	O	O
grade	PICATO.xml:S1:3258:5	grade	VB	O	O
4	PICATO.xml:S1:3264:1	4	CD	O	O
)	PICATO.xml:S1:3265:1	)	)	O	O
.	PICATO.xml:S1:3266:1	.	.	O	O

Table	PICATO.xml:S1:3279:5	tabl	NN	O	O

2	PICATO.xml:S1:3285:1	2	CD	O	O

Investigator	PICATO.xml:S1:3287:12	investig	NNP	O	O
Assessment	PICATO.xml:S1:3300:10	assess	NNP	O	O
of	PICATO.xml:S1:3311:2	of	IN	O	O
Maximal	PICATO.xml:S1:3314:7	maxim	NNP	O	O
Local	PICATO.xml:S1:3322:5	local	NNP	B-AdverseReaction	O
Skin	PICATO.xml:S1:3328:4	skin	NNP	I-AdverseReaction	O
Reactions	PICATO.xml:S1:3333:9	reaction	NNP	I-AdverseReaction	O
in	PICATO.xml:S1:3343:2	in	IN	O	O
the	PICATO.xml:S1:3346:3	the	DT	O	O
Treatment	PICATO.xml:S1:3350:9	treatment	NNP	O	O
Area	PICATO.xml:S1:3360:4	area	NNP	O	O
during	PICATO.xml:S1:3365:6	dure	IN	O	O
the	PICATO.xml:S1:3372:3	the	DT	O	O
57	PICATO.xml:S1:3376:2	57	CD	O	O
Days	PICATO.xml:S1:3379:4	day	NNPS	O	O
Post	PICATO.xml:S1:3384:4	post	NNP	O	O
Treatment	PICATO.xml:S1:3389:9	treatment	NNP	O	O
Period	PICATO.xml:S1:3399:6	period	NNP	O	O
(	PICATO.xml:S1:3406:1	(	(	O	O
trunk	PICATO.xml:S1:3407:5	trunk	JJ	O	O
extremities	PICATO.xml:S1:3413:11	extrem	NNS	O	O
trials	PICATO.xml:S1:3425:6	trial	NNS	O	O
)	PICATO.xml:S1:3431:1	)	)	O	O

Trunk	PICATO.xml:S1:3441:5	trunk	NN	O	O
and	PICATO.xml:S1:3447:3	and	CC	O	O
Extremities	PICATO.xml:S1:3451:11	extrem	NNP	O	O
(	PICATO.xml:S1:3464:1	(	(	O	O
n	PICATO.xml:S1:3465:1	n	JJ	O	O
457	PICATO.xml:S1:3467:3	457	CD	O	O
)	PICATO.xml:S1:3470:1	)	)	O	O
Picato	PICATO.xml:S1:3473:6	picato	NNP	O	O
(	PICATO.xml:S1:3479:1	(	(	O	O
r	PICATO.xml:S1:3480:1	r	NN	O	O
)	PICATO.xml:S1:3481:1	)	)	O	O
gel	PICATO.xml:S1:3483:3	gel	NN	O	O
,	PICATO.xml:S1:3486:1	,	,	O	O
0.05%	PICATO.xml:S1:3488:5	0.05%	CD	O	O
once	PICATO.xml:S1:3494:4	onc	RB	O	O
daily	PICATO.xml:S1:3499:5	daili	JJ	O	O
for	PICATO.xml:S1:3505:3	for	IN	O	O
2	PICATO.xml:S1:3509:1	2	CD	O	O
days	PICATO.xml:S1:3511:4	day	NNS	O	O

Skin	PICATO.xml:S1:3522:4	skin	NNP	B-AdverseReaction	O
reactions	PICATO.xml:S1:3527:9	reaction	NNS	O	O
Any	PICATO.xml:S1:3549:3	ani	NNP	O	O
Gradea	PICATO.xml:S1:3553:6	gradea	NNP	O	O
Baseline	PICATO.xml:S1:3562:8	baselin	NNP	O	O
Grade	PICATO.xml:S1:3576:5	grade	NNP	O	O
4	PICATO.xml:S1:3582:1	4	CD	O	O

Picato	PICATO.xml:S1:3633:6	picato	NNP	O	O
(	PICATO.xml:S1:3639:1	(	(	O	O
r	PICATO.xml:S1:3640:1	r	NN	O	O
)	PICATO.xml:S1:3641:1	)	)	O	O
gel	PICATO.xml:S1:3643:3	gel	NN	O	O
(	PICATO.xml:S1:3648:1	(	(	O	O
n	PICATO.xml:S1:3649:1	n	JJ	O	O
225	PICATO.xml:S1:3651:3	225	CD	O	O
)	PICATO.xml:S1:3654:1	)	)	O	O
Vehicle	PICATO.xml:S1:3660:7	vehicl	NNP	O	O
(	PICATO.xml:S1:3669:1	(	(	O	O
n	PICATO.xml:S1:3670:1	n	RB	O	O
232	PICATO.xml:S1:3672:3	232	CD	O	O
)	PICATO.xml:S1:3675:1	)	)	O	O
Picato	PICATO.xml:S1:3687:6	picato	NNP	O	O
(	PICATO.xml:S1:3693:1	(	(	O	O
r	PICATO.xml:S1:3694:1	r	NN	O	O
)	PICATO.xml:S1:3695:1	)	)	O	O
gel	PICATO.xml:S1:3697:3	gel	NN	O	O
(	PICATO.xml:S1:3702:1	(	(	O	O
n	PICATO.xml:S1:3703:1	n	JJ	O	O
225	PICATO.xml:S1:3705:3	225	CD	O	O
)	PICATO.xml:S1:3708:1	)	)	O	O
Vehicle	PICATO.xml:S1:3714:7	vehicl	NNP	O	O
(	PICATO.xml:S1:3723:1	(	(	O	O
n	PICATO.xml:S1:3724:1	n	RB	O	O
232	PICATO.xml:S1:3726:3	232	CD	O	O
)	PICATO.xml:S1:3729:1	)	)	O	O

Erythema	PICATO.xml:S1:3744:8	erythema	RB	I-AdverseReaction	B-AdverseReaction
207	PICATO.xml:S1:3771:3	207	CD	O	O
(	PICATO.xml:S1:3775:1	(	(	O	O
92%	PICATO.xml:S1:3776:3	92%	CD	O	O
)	PICATO.xml:S1:3779:1	)	)	O	O
43	PICATO.xml:S1:3798:2	43	CD	O	O
(	PICATO.xml:S1:3801:1	(	(	O	O
19%	PICATO.xml:S1:3802:3	19%	CD	O	O
)	PICATO.xml:S1:3805:1	)	)	O	O
34	PICATO.xml:S1:3825:2	34	CD	O	O
(	PICATO.xml:S1:3828:1	(	(	O	O
15%	PICATO.xml:S1:3829:3	15%	CD	O	O
)	PICATO.xml:S1:3832:1	)	)	O	O
0	PICATO.xml:S1:3852:1	0	CD	O	O
(	PICATO.xml:S1:3854:1	(	(	O	O
0%	PICATO.xml:S1:3855:2	0%	CD	O	O
)	PICATO.xml:S1:3857:1	)	)	O	O

Flaking	PICATO.xml:S1:3882:7	flake	VBG	I-AdverseReaction	O
Scaling	PICATO.xml:S1:3890:7	scale	VBG	I-AdverseReaction	O
203	PICATO.xml:S1:3909:3	203	CD	O	O
(	PICATO.xml:S1:3913:1	(	(	O	O
90%	PICATO.xml:S1:3914:3	90%	CD	O	O
)	PICATO.xml:S1:3917:1	)	)	O	O
44	PICATO.xml:S1:3936:2	44	CD	O	O
(	PICATO.xml:S1:3939:1	(	(	O	O
19%	PICATO.xml:S1:3940:3	19%	CD	O	O
)	PICATO.xml:S1:3943:1	)	)	O	O
18	PICATO.xml:S1:3963:2	18	CD	O	O
(	PICATO.xml:S1:3966:1	(	(	O	O
8%	PICATO.xml:S1:3967:2	8%	CD	O	O
)	PICATO.xml:S1:3969:1	)	)	O	O
0	PICATO.xml:S1:3990:1	0	CD	O	O
(	PICATO.xml:S1:3992:1	(	(	O	O
0%	PICATO.xml:S1:3993:2	0%	CD	O	O
)	PICATO.xml:S1:3995:1	)	)	O	O

Crusting	PICATO.xml:S1:4020:8	crust	VBG	I-AdverseReaction	B-AdverseReaction
167	PICATO.xml:S1:4047:3	167	CD	O	O
(	PICATO.xml:S1:4051:1	(	(	O	O
74%	PICATO.xml:S1:4052:3	74%	CD	O	O
)	PICATO.xml:S1:4055:1	)	)	O	O
23	PICATO.xml:S1:4074:2	23	CD	O	O
(	PICATO.xml:S1:4077:1	(	(	O	O
10%	PICATO.xml:S1:4078:3	10%	CD	O	O
)	PICATO.xml:S1:4081:1	)	)	O	O
8	PICATO.xml:S1:4101:1	8	CD	O	O
(	PICATO.xml:S1:4103:1	(	(	O	O
4%	PICATO.xml:S1:4104:2	4%	CD	O	O
)	PICATO.xml:S1:4106:1	)	)	O	O
0	PICATO.xml:S1:4128:1	0	CD	O	O
(	PICATO.xml:S1:4130:1	(	(	O	O
0%	PICATO.xml:S1:4131:2	0%	CD	O	O
)	PICATO.xml:S1:4133:1	)	)	O	O

Swelling	PICATO.xml:S1:4158:8	swell	VBG	I-AdverseReaction	B-AdverseReaction
143	PICATO.xml:S1:4185:3	143	CD	O	O
(	PICATO.xml:S1:4189:1	(	(	O	O
64%	PICATO.xml:S1:4190:3	64%	CD	O	O
)	PICATO.xml:S1:4193:1	)	)	O	O
13	PICATO.xml:S1:4212:2	13	CD	O	O
(	PICATO.xml:S1:4215:1	(	(	O	O
6%	PICATO.xml:S1:4216:2	6%	CD	O	O
)	PICATO.xml:S1:4218:1	)	)	O	O
7	PICATO.xml:S1:4239:1	7	CD	O	O
(	PICATO.xml:S1:4241:1	(	(	O	O
3%	PICATO.xml:S1:4242:2	3%	CD	O	O
)	PICATO.xml:S1:4244:1	)	)	O	O
0	PICATO.xml:S1:4266:1	0	CD	O	O
(	PICATO.xml:S1:4268:1	(	(	O	O
0%	PICATO.xml:S1:4269:2	0%	CD	O	O
)	PICATO.xml:S1:4271:1	)	)	O	O

Vesiculation	PICATO.xml:S1:4296:12	vesicul	NNP	I-AdverseReaction	O
Pustulation	PICATO.xml:S1:4309:11	pustul	NNP	I-AdverseReaction	O
98	PICATO.xml:S1:4324:2	98	CD	O	O
(	PICATO.xml:S1:4327:1	(	(	O	O
44%	PICATO.xml:S1:4328:3	44%	CD	O	O
)	PICATO.xml:S1:4331:1	)	)	O	O
2	PICATO.xml:S1:4351:1	2	CD	O	O
(	PICATO.xml:S1:4353:1	(	(	O	O
1%	PICATO.xml:S1:4354:2	1%	CD	O	O
)	PICATO.xml:S1:4356:1	)	)	O	O
3	PICATO.xml:S1:4378:1	3	CD	O	O
(	PICATO.xml:S1:4380:1	(	(	O	O
1%	PICATO.xml:S1:4381:2	1%	CD	O	O
)	PICATO.xml:S1:4383:1	)	)	O	O
0	PICATO.xml:S1:4405:1	0	CD	O	O
(	PICATO.xml:S1:4407:1	(	(	O	O
0%	PICATO.xml:S1:4408:2	0%	CD	O	O
)	PICATO.xml:S1:4410:1	)	)	O	O

Erosion	PICATO.xml:S1:4435:7	eros	NNP	I-AdverseReaction	B-AdverseReaction
Ulceration	PICATO.xml:S1:4443:10	ulcer	NNP	I-AdverseReaction	I-AdverseReaction
58	PICATO.xml:S1:4462:2	58	CD	O	O
(	PICATO.xml:S1:4465:1	(	(	O	O
26%	PICATO.xml:S1:4466:3	26%	CD	O	O
)	PICATO.xml:S1:4469:1	)	)	O	O
6	PICATO.xml:S1:4489:1	6	CD	O	O
(	PICATO.xml:S1:4491:1	(	(	O	O
3%	PICATO.xml:S1:4492:2	3%	CD	O	O
)	PICATO.xml:S1:4494:1	)	)	O	O
2	PICATO.xml:S1:4516:1	2	CD	O	O
(	PICATO.xml:S1:4518:1	(	(	O	O
1%	PICATO.xml:S1:4519:2	1%	CD	O	O
)	PICATO.xml:S1:4521:1	)	)	O	O
0	PICATO.xml:S1:4543:1	0	CD	O	O
(	PICATO.xml:S1:4545:1	(	(	O	O
0%	PICATO.xml:S1:4546:2	0%	CD	O	O
)	PICATO.xml:S1:4548:1	)	)	O	O

a	PICATO.xml:S1:4579:1	a	DT	O	O
Mild	PICATO.xml:S1:4582:4	mild	NNP	O	O
(	PICATO.xml:S1:4587:1	(	(	O	O
grade	PICATO.xml:S1:4588:5	grade	VB	O	O
1	PICATO.xml:S1:4594:1	1	CD	O	O
)	PICATO.xml:S1:4595:1	)	)	O	O
,	PICATO.xml:S1:4596:1	,	,	O	O
Moderate	PICATO.xml:S1:4598:8	moder	NNP	O	O
(	PICATO.xml:S1:4607:1	(	(	O	O
grade	PICATO.xml:S1:4608:5	grade	VB	O	O
2	PICATO.xml:S1:4614:1	2	CD	O	O
-	PICATO.xml:S1:4615:1	-	:	O	O
3	PICATO.xml:S1:4616:1	3	CD	O	O
)	PICATO.xml:S1:4617:1	)	)	O	O
or	PICATO.xml:S1:4619:2	or	CC	O	O
Severe	PICATO.xml:S1:4622:6	sever	NNP	O	O
(	PICATO.xml:S1:4629:1	(	(	O	O
grade	PICATO.xml:S1:4630:5	grade	VB	O	O
4	PICATO.xml:S1:4636:1	4	CD	O	O
)	PICATO.xml:S1:4637:1	)	)	O	O
.	PICATO.xml:S1:4638:1	.	.	O	O

Local	PICATO.xml:S1:4649:5	local	JJ	B-AdverseReaction	O

skin	PICATO.xml:S1:4655:4	skin	NN	I-AdverseReaction	O

reactions	PICATO.xml:S1:4660:9	reaction	NNS	I-AdverseReaction	O
typically	PICATO.xml:S1:4670:9	typic	RB	O	O
occurred	PICATO.xml:S1:4680:8	occur	VBD	O	O
within	PICATO.xml:S1:4689:6	within	IN	O	O
1	PICATO.xml:S1:4696:1	1	CD	O	O
day	PICATO.xml:S1:4698:3	day	NN	O	O
of	PICATO.xml:S1:4702:2	of	IN	O	O
treatment	PICATO.xml:S1:4705:9	treatment	NN	O	O
initiation	PICATO.xml:S1:4715:10	initi	NN	O	O
,	PICATO.xml:S1:4725:1	,	,	O	O
peaked	PICATO.xml:S1:4727:6	peak	VBN	O	O
in	PICATO.xml:S1:4734:2	in	IN	O	O
intensity	PICATO.xml:S1:4737:9	intens	NN	O	O
up	PICATO.xml:S1:4747:2	up	RB	O	O
to	PICATO.xml:S1:4750:2	to	TO	O	O
1	PICATO.xml:S1:4753:1	1	CD	O	O
week	PICATO.xml:S1:4755:4	week	NN	O	O
following	PICATO.xml:S1:4760:9	follow	VBG	O	O
completion	PICATO.xml:S1:4770:10	complet	NN	O	O
of	PICATO.xml:S1:4781:2	of	IN	O	O
treatment	PICATO.xml:S1:4784:9	treatment	NN	O	O
,	PICATO.xml:S1:4793:1	,	,	O	O
and	PICATO.xml:S1:4795:3	and	CC	O	O
resolved	PICATO.xml:S1:4799:8	resolv	VBD	O	O
within	PICATO.xml:S1:4808:6	within	IN	O	O
2	PICATO.xml:S1:4815:1	2	CD	O	O
weeks	PICATO.xml:S1:4817:5	week	NNS	O	O
for	PICATO.xml:S1:4823:3	for	IN	O	O
areas	PICATO.xml:S1:4827:5	area	NNS	O	O
treated	PICATO.xml:S1:4833:7	treat	VBN	O	O
on	PICATO.xml:S1:4841:2	on	IN	O	O
the	PICATO.xml:S1:4844:3	the	DT	O	O
face	PICATO.xml:S1:4848:4	face	NN	O	O
and	PICATO.xml:S1:4853:3	and	CC	O	O
scalp	PICATO.xml:S1:4857:5	scalp	NN	O	O
,	PICATO.xml:S1:4862:1	,	,	O	O
and	PICATO.xml:S1:4864:3	and	CC	O	O
within	PICATO.xml:S1:4868:6	within	IN	O	O
4	PICATO.xml:S1:4875:1	4	CD	O	O
weeks	PICATO.xml:S1:4877:5	week	NNS	O	O
for	PICATO.xml:S1:4883:3	for	IN	O	O
areas	PICATO.xml:S1:4887:5	area	NNS	O	O
treated	PICATO.xml:S1:4893:7	treat	VBN	O	O
on	PICATO.xml:S1:4901:2	on	IN	O	O
the	PICATO.xml:S1:4904:3	the	DT	O	O
trunk	PICATO.xml:S1:4908:5	trunk	NN	O	O
and	PICATO.xml:S1:4914:3	and	CC	O	O
extremities	PICATO.xml:S1:4918:11	extrem	NNS	O	O
.	PICATO.xml:S1:4929:1	.	.	O	O

Adverse	PICATO.xml:S1:4940:7	advers	NN	O	O

reactions	PICATO.xml:S1:4948:9	reaction	NNS	O	O
that	PICATO.xml:S1:4958:4	that	WDT	O	O
occurred	PICATO.xml:S1:4963:8	occur	VBD	O	O
in	PICATO.xml:S1:4972:2	in	IN	O	O
2%	PICATO.xml:S1:4977:2	2%	CD	O	O
of	PICATO.xml:S1:4980:2	of	IN	O	O
subjects	PICATO.xml:S1:4983:8	subject	NNS	O	O
treated	PICATO.xml:S1:4992:7	treat	VBN	O	O
with	PICATO.xml:S1:5000:4	with	IN	O	O
Picato	PICATO.xml:S1:5005:6	picato	NNP	O	O
(	PICATO.xml:S1:5013:1	(	(	O	O
r	PICATO.xml:S1:5014:1	r	NN	O	O
)	PICATO.xml:S1:5015:1	)	)	O	O
gel	PICATO.xml:S1:5018:3	gel	NN	O	O
and	PICATO.xml:S1:5022:3	and	CC	O	O
at	PICATO.xml:S1:5026:2	at	IN	O	O
a	PICATO.xml:S1:5029:1	a	DT	O	O
higher	PICATO.xml:S1:5031:6	higher	JJR	O	O
frequency	PICATO.xml:S1:5038:9	frequenc	NN	O	O
than	PICATO.xml:S1:5048:4	than	IN	O	O
the	PICATO.xml:S1:5053:3	the	DT	O	O
vehicle	PICATO.xml:S1:5057:7	vehicl	NN	O	O
are	PICATO.xml:S1:5065:3	are	VBP	O	O
presented	PICATO.xml:S1:5069:9	present	VBN	O	O
in	PICATO.xml:S1:5079:2	in	IN	O	O
Table	PICATO.xml:S1:5082:5	tabl	JJ	O	O
3	PICATO.xml:S1:5088:1	3	CD	O	O
and	PICATO.xml:S1:5090:3	and	CC	O	O
Table	PICATO.xml:S1:5094:5	tabl	JJ	O	O
4	PICATO.xml:S1:5100:1	4	CD	O	O
.	PICATO.xml:S1:5101:1	.	.	O	O

Table	PICATO.xml:S1:5114:5	tabl	NN	O	O

3	PICATO.xml:S1:5120:1	3	CD	O	O
Adverse	PICATO.xml:S1:5122:7	advers	JJ	O	O
reactions	PICATO.xml:S1:5130:9	reaction	NNS	O	O
occurring	PICATO.xml:S1:5140:9	occur	VBG	O	O
in	PICATO.xml:S1:5150:2	in	IN	O	O
2%	PICATO.xml:S1:5156:2	2%	CD	O	O
of	PICATO.xml:S1:5159:2	of	IN	O	O
subjects	PICATO.xml:S1:5162:8	subject	NNS	O	O
treated	PICATO.xml:S1:5171:7	treat	VBN	O	O
with	PICATO.xml:S1:5179:4	with	IN	O	O
Picato	PICATO.xml:S1:5184:6	picato	NNP	O	O
(	PICATO.xml:S1:5192:1	(	(	O	O
r	PICATO.xml:S1:5193:1	r	NN	O	O
)	PICATO.xml:S1:5194:1	)	)	O	O
gel	PICATO.xml:S1:5197:3	gel	NN	O	O
and	PICATO.xml:S1:5201:3	and	CC	O	O
at	PICATO.xml:S1:5205:2	at	IN	O	O
higher	PICATO.xml:S1:5208:6	higher	JJR	O	O
frequency	PICATO.xml:S1:5215:9	frequenc	NN	O	O
than	PICATO.xml:S1:5225:4	than	IN	O	O
vehicle	PICATO.xml:S1:5230:7	vehicl	NN	O	O
(	PICATO.xml:S1:5238:1	(	(	O	O
face	PICATO.xml:S1:5239:4	face	NN	O	O
scalp	PICATO.xml:S1:5244:5	scalp	NN	O	O
trials	PICATO.xml:S1:5250:6	trial	NNS	O	O
)	PICATO.xml:S1:5256:1	)	)	O	O

Face	PICATO.xml:S1:5293:4	face	NN	O	O
Scalp	PICATO.xml:S1:5298:5	scalp	NNP	O	O

Adverse	PICATO.xml:S1:5323:7	advers	JJ	O	O
Reactions	PICATO.xml:S1:5331:9	reaction	NNP	O	O
Picato	PICATO.xml:S1:5350:6	picato	NNP	O	O
(	PICATO.xml:S1:5356:1	(	(	O	O
r	PICATO.xml:S1:5357:1	r	NN	O	O
)	PICATO.xml:S1:5358:1	)	)	O	O
gel	PICATO.xml:S1:5360:3	gel	NN	O	O
,	PICATO.xml:S1:5363:1	,	,	O	O
0.015%	PICATO.xml:S1:5365:6	0.015%	CD	O	O
(	PICATO.xml:S1:5373:1	(	(	O	O
N	PICATO.xml:S1:5374:1	N	NNP	O	O
274	PICATO.xml:S1:5376:3	274	CD	O	O
)	PICATO.xml:S1:5379:1	)	)	O	O
Vehicle	PICATO.xml:S1:5384:7	vehicl	NNP	O	O
(	PICATO.xml:S1:5393:1	(	(	O	O
N	PICATO.xml:S1:5394:1	N	NNP	O	O
271	PICATO.xml:S1:5396:3	271	CD	O	O
)	PICATO.xml:S1:5399:1	)	)	O	O

Application	PICATO.xml:S1:5417:11	applic	NN	B-AdverseReaction	O

Site	PICATO.xml:S1:5429:4	site	NNP	I-AdverseReaction	B-AdverseReaction
Pain	PICATO.xml:S1:5434:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
42	PICATO.xml:S1:5444:2	42	CD	O	O
(	PICATO.xml:S1:5447:1	(	(	O	O
15%	PICATO.xml:S1:5448:3	15%	CD	O	O
)	PICATO.xml:S1:5451:1	)	)	O	O
1	PICATO.xml:S1:5471:1	1	CD	O	O
(	PICATO.xml:S1:5473:1	(	(	O	O
0%	PICATO.xml:S1:5474:2	0%	CD	O	O
)	PICATO.xml:S1:5476:1	)	)	O	O

Application	PICATO.xml:S1:5501:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	PICATO.xml:S1:5513:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Pruritus	PICATO.xml:S1:5518:8	pruritu	NNP	I-AdverseReaction	I-AdverseReaction
22	PICATO.xml:S1:5530:2	22	CD	O	O
(	PICATO.xml:S1:5533:1	(	(	O	O
8%	PICATO.xml:S1:5534:2	8%	CD	O	O
)	PICATO.xml:S1:5536:1	)	)	O	O
3	PICATO.xml:S1:5557:1	3	CD	O	O
(	PICATO.xml:S1:5559:1	(	(	O	O
1%	PICATO.xml:S1:5560:2	1%	CD	O	O
)	PICATO.xml:S1:5562:1	)	)	O	O

Application	PICATO.xml:S1:5587:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	PICATO.xml:S1:5599:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Infection	PICATO.xml:S1:5604:9	infect	NNP	I-AdverseReaction	I-AdverseReaction
7	PICATO.xml:S1:5617:1	7	CD	O	O
(	PICATO.xml:S1:5619:1	(	(	O	O
3%	PICATO.xml:S1:5620:2	3%	CD	O	O
)	PICATO.xml:S1:5622:1	)	)	O	O
0	PICATO.xml:S1:5644:1	0	CD	O	O
(	PICATO.xml:S1:5646:1	(	(	O	O
0%	PICATO.xml:S1:5647:2	0%	CD	O	O
)	PICATO.xml:S1:5649:1	)	)	O	O

Periorbital	PICATO.xml:S1:5674:11	periorbit	NNP	B-AdverseReaction	B-AdverseReaction
Edema	PICATO.xml:S1:5686:5	edema	NNP	I-AdverseReaction	I-AdverseReaction
7	PICATO.xml:S1:5701:1	7	CD	O	O
(	PICATO.xml:S1:5703:1	(	(	O	O
3%	PICATO.xml:S1:5704:2	3%	CD	O	O
)	PICATO.xml:S1:5706:1	)	)	O	O
0	PICATO.xml:S1:5728:1	0	CD	O	O
(	PICATO.xml:S1:5730:1	(	(	O	O
0%	PICATO.xml:S1:5731:2	0%	CD	O	O
)	PICATO.xml:S1:5733:1	)	)	O	O

Headache	PICATO.xml:S1:5758:8	headach	$	B-AdverseReaction	B-AdverseReaction
6	PICATO.xml:S1:5785:1	6	CD	O	O
(	PICATO.xml:S1:5787:1	(	(	O	O
2%	PICATO.xml:S1:5788:2	2%	CD	O	O
)	PICATO.xml:S1:5790:1	)	)	O	O
3	PICATO.xml:S1:5812:1	3	CD	O	O
(	PICATO.xml:S1:5814:1	(	(	O	O
1%	PICATO.xml:S1:5815:2	1%	CD	O	O
)	PICATO.xml:S1:5817:1	)	)	O	O

Table	PICATO.xml:S1:5853:5	tabl	NN	O	O

4	PICATO.xml:S1:5859:1	4	CD	O	O

Adverse	PICATO.xml:S1:5861:7	advers	JJ	O	O
reactions	PICATO.xml:S1:5869:9	reaction	NNS	O	O
occurring	PICATO.xml:S1:5879:9	occur	VBG	O	O
in	PICATO.xml:S1:5889:2	in	IN	O	O
2%	PICATO.xml:S1:5895:2	2%	CD	O	O
of	PICATO.xml:S1:5898:2	of	IN	O	O
subjects	PICATO.xml:S1:5901:8	subject	NNS	O	O
treated	PICATO.xml:S1:5910:7	treat	VBN	O	O
with	PICATO.xml:S1:5918:4	with	IN	O	O
Picato	PICATO.xml:S1:5923:6	picato	NNP	O	O
(	PICATO.xml:S1:5931:1	(	(	O	O
r	PICATO.xml:S1:5932:1	r	NN	O	O
)	PICATO.xml:S1:5933:1	)	)	O	O
gel	PICATO.xml:S1:5936:3	gel	NN	O	O
and	PICATO.xml:S1:5940:3	and	CC	O	O
at	PICATO.xml:S1:5944:2	at	IN	O	O
higher	PICATO.xml:S1:5947:6	higher	JJR	O	O
frequency	PICATO.xml:S1:5954:9	frequenc	NN	O	O
than	PICATO.xml:S1:5964:4	than	IN	O	O
vehicle	PICATO.xml:S1:5969:7	vehicl	NN	O	O
(	PICATO.xml:S1:5977:1	(	(	O	O
trunk	PICATO.xml:S1:5978:5	trunk	JJ	O	O
extremities	PICATO.xml:S1:5984:11	extrem	NNS	O	O
trials	PICATO.xml:S1:5996:6	trial	NNS	O	O
)	PICATO.xml:S1:6002:1	)	)	O	O

Trunk	PICATO.xml:S1:6039:5	trunk	NN	O	O
Extremities	PICATO.xml:S1:6045:11	extrem	NNS	O	O

Adverse	PICATO.xml:S1:6069:7	advers	JJ	O	O
Reactions	PICATO.xml:S1:6077:9	reaction	NNP	O	O
Picato	PICATO.xml:S1:6096:6	picato	NNP	O	O
(	PICATO.xml:S1:6102:1	(	(	O	O
r	PICATO.xml:S1:6103:1	r	NN	O	O
)	PICATO.xml:S1:6104:1	)	)	O	O
gel	PICATO.xml:S1:6106:3	gel	NN	O	O
,	PICATO.xml:S1:6109:1	,	,	O	O
0.05%	PICATO.xml:S1:6111:5	0.05%	CD	O	O
(	PICATO.xml:S1:6118:1	(	(	O	O
N	PICATO.xml:S1:6119:1	N	NNP	O	O
225	PICATO.xml:S1:6121:3	225	CD	O	O
)	PICATO.xml:S1:6124:1	)	)	O	O
Vehicle	PICATO.xml:S1:6129:7	vehicl	NNP	O	O
(	PICATO.xml:S1:6138:1	(	(	O	O
N	PICATO.xml:S1:6139:1	N	NNP	O	O
232	PICATO.xml:S1:6141:3	232	CD	O	O
)	PICATO.xml:S1:6144:1	)	)	O	O

Application	PICATO.xml:S1:6159:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	PICATO.xml:S1:6171:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Pruritus	PICATO.xml:S1:6176:8	pruritu	NNP	I-AdverseReaction	I-AdverseReaction
18	PICATO.xml:S1:6188:2	18	CD	O	O
(	PICATO.xml:S1:6191:1	(	(	O	O
8%	PICATO.xml:S1:6192:2	8%	CD	O	O
)	PICATO.xml:S1:6194:1	)	)	O	O
0	PICATO.xml:S1:6215:1	0	CD	O	O
(	PICATO.xml:S1:6217:1	(	(	O	O
0%	PICATO.xml:S1:6218:2	0%	CD	O	O
)	PICATO.xml:S1:6220:1	)	)	O	O

Application	PICATO.xml:S1:6245:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	PICATO.xml:S1:6257:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Irritation	PICATO.xml:S1:6262:10	irrit	NNP	I-AdverseReaction	I-AdverseReaction
8	PICATO.xml:S1:6276:1	8	CD	O	O
(	PICATO.xml:S1:6278:1	(	(	O	O
4%	PICATO.xml:S1:6279:2	4%	CD	O	O
)	PICATO.xml:S1:6281:1	)	)	O	O
1	PICATO.xml:S1:6303:1	1	CD	O	O
(	PICATO.xml:S1:6305:1	(	(	O	O
0%	PICATO.xml:S1:6306:2	0%	CD	O	O
)	PICATO.xml:S1:6308:1	)	)	O	O

Nasopharyngitis	PICATO.xml:S1:6333:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
4	PICATO.xml:S1:6360:1	4	CD	O	O
(	PICATO.xml:S1:6362:1	(	(	O	O
2%	PICATO.xml:S1:6363:2	2%	CD	O	O
)	PICATO.xml:S1:6365:1	)	)	O	O
2	PICATO.xml:S1:6387:1	2	CD	O	O
(	PICATO.xml:S1:6389:1	(	(	O	O
1%	PICATO.xml:S1:6390:2	1%	CD	O	O
)	PICATO.xml:S1:6392:1	)	)	O	O

Application	PICATO.xml:S1:6417:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	PICATO.xml:S1:6429:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Pain	PICATO.xml:S1:6434:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
5	PICATO.xml:S1:6444:1	5	CD	O	O
(	PICATO.xml:S1:6446:1	(	(	O	O
2%	PICATO.xml:S1:6447:2	2%	CD	O	O
)	PICATO.xml:S1:6449:1	)	)	O	O
0	PICATO.xml:S1:6471:1	0	CD	O	O
(	PICATO.xml:S1:6473:1	(	(	O	O
0%	PICATO.xml:S1:6474:2	0%	CD	O	O
)	PICATO.xml:S1:6476:1	)	)	O	O

Less	PICATO.xml:S1:6510:4	less	JJR	O	O

common	PICATO.xml:S1:6515:6	common	JJ	O	O

adverse	PICATO.xml:S1:6522:7	advers	JJ	O	O
reactions	PICATO.xml:S1:6530:9	reaction	NNS	O	O
in	PICATO.xml:S1:6540:2	in	IN	O	O
subjects	PICATO.xml:S1:6543:8	subject	NNS	O	O
treated	PICATO.xml:S1:6552:7	treat	VBN	O	O
with	PICATO.xml:S1:6560:4	with	IN	O	O
Picato	PICATO.xml:S1:6565:6	picato	NNP	O	O
(	PICATO.xml:S1:6573:1	(	(	O	O
r	PICATO.xml:S1:6574:1	r	NN	O	O
)	PICATO.xml:S1:6575:1	)	)	O	O
included	PICATO.xml:S1:6578:8	includ	VBD	O	O
:	PICATO.xml:S1:6586:1	:	:	O	O
eyelid	PICATO.xml:S1:6588:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
edema	PICATO.xml:S1:6595:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:6600:1	,	,	O	O
eye	PICATO.xml:S1:6602:3	eye	NN	B-AdverseReaction	B-AdverseReaction
pain	PICATO.xml:S1:6606:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:6610:1	,	,	O	O
conjunctivitis	PICATO.xml:S1:6612:14	conjunct	NN	B-AdverseReaction	B-AdverseReaction
.	PICATO.xml:S1:6626:1	.	.	O	O

A	PICATO.xml:S1:6637:1	A	DT	O	O

total	PICATO.xml:S1:6639:5	total	NN	O	O
of	PICATO.xml:S1:6645:2	of	IN	O	O
108	PICATO.xml:S1:6648:3	108	CD	O	O
subjects	PICATO.xml:S1:6652:8	subject	NNS	O	O
treated	PICATO.xml:S1:6661:7	treat	VBN	O	O
with	PICATO.xml:S1:6669:4	with	IN	O	O
Picato	PICATO.xml:S1:6674:6	picato	NNP	O	O
(	PICATO.xml:S1:6682:1	(	(	O	O
r	PICATO.xml:S1:6683:1	r	NN	O	O
)	PICATO.xml:S1:6684:1	)	)	O	O
gel	PICATO.xml:S1:6687:3	gel	NN	O	O
on	PICATO.xml:S1:6691:2	on	IN	O	O
the	PICATO.xml:S1:6694:3	the	DT	O	O
face	PICATO.xml:S1:6698:4	face	NN	O	O
scalp	PICATO.xml:S1:6703:5	scalp	NN	O	O
and	PICATO.xml:S1:6709:3	and	CC	O	O
38	PICATO.xml:S1:6713:2	38	CD	O	O
subjects	PICATO.xml:S1:6716:8	subject	NNS	O	O
treated	PICATO.xml:S1:6725:7	treat	VBN	O	O
on	PICATO.xml:S1:6733:2	on	IN	O	O
the	PICATO.xml:S1:6736:3	the	DT	O	O
trunk	PICATO.xml:S1:6740:5	trunk	NN	O	O
extremities	PICATO.xml:S1:6746:11	extrem	NNS	O	O
were	PICATO.xml:S1:6758:4	were	VBD	O	O
followed	PICATO.xml:S1:6763:8	follow	VBN	O	O
for	PICATO.xml:S1:6772:3	for	IN	O	O
12	PICATO.xml:S1:6776:2	12	CD	O	O
months	PICATO.xml:S1:6779:6	month	NNS	O	O
.	PICATO.xml:S1:6785:1	.	.	O	O

Results	PICATO.xml:S1:6787:7	result	NNS	O	O
from	PICATO.xml:S1:6795:4	from	IN	O	O
these	PICATO.xml:S1:6800:5	these	DT	O	O
studies	PICATO.xml:S1:6806:7	studi	NNS	O	O
did	PICATO.xml:S1:6814:3	did	VBD	O	O
not	PICATO.xml:S1:6818:3	not	RB	O	O
change	PICATO.xml:S1:6822:6	chang	VB	O	O
the	PICATO.xml:S1:6829:3	the	DT	O	O
safety	PICATO.xml:S1:6833:6	safeti	NN	O	O
profile	PICATO.xml:S1:6840:7	profil	NN	O	O
of	PICATO.xml:S1:6848:2	of	IN	O	O
Picato	PICATO.xml:S1:6851:6	picato	NNP	O	O
(	PICATO.xml:S1:6859:1	(	(	O	O
r	PICATO.xml:S1:6860:1	r	NN	O	O
)	PICATO.xml:S1:6861:1	)	)	O	O
gel	PICATO.xml:S1:6864:3	gel	NN	O	O
.	PICATO.xml:S1:6867:1	.	.	O	O

6.2	PICATO.xml:S1:6875:3	6.2	CD	O	O
Postmarketing	PICATO.xml:S1:6879:13	postmarket	VBG	O	O
Experience	PICATO.xml:S1:6893:10	experi	NN	O	O

The	PICATO.xml:S1:6907:3	the	DT	O	O
following	PICATO.xml:S1:6911:9	follow	JJ	O	O
adverse	PICATO.xml:S1:6921:7	advers	JJ	O	O
reactions	PICATO.xml:S1:6929:9	reaction	NNS	O	O
have	PICATO.xml:S1:6939:4	have	VBP	O	O
been	PICATO.xml:S1:6944:4	been	VBN	O	O
identified	PICATO.xml:S1:6949:10	identifi	VBN	O	O
during	PICATO.xml:S1:6960:6	dure	IN	O	O
post	PICATO.xml:S1:6967:4	post	NN	O	O
approval	PICATO.xml:S1:6972:8	approv	NN	O	O
use	PICATO.xml:S1:6981:3	use	NN	O	O
of	PICATO.xml:S1:6985:2	of	IN	O	O
Picato	PICATO.xml:S1:6988:6	picato	NNP	O	O
(	PICATO.xml:S1:6996:1	(	(	O	O
r	PICATO.xml:S1:6997:1	r	NN	O	O
)	PICATO.xml:S1:6998:1	)	)	O	O
(	PICATO.xml:S1:7001:1	(	(	O	O
ingenol	PICATO.xml:S1:7002:7	ingenol	JJ	O	O
mebutate	PICATO.xml:S1:7010:8	mebut	NN	O	O
)	PICATO.xml:S1:7018:1	)	)	O	O
gel	PICATO.xml:S1:7020:3	gel	NN	O	O
,	PICATO.xml:S1:7023:1	,	,	O	O
0.015%	PICATO.xml:S1:7025:6	0.015%	CD	O	O
and	PICATO.xml:S1:7032:3	and	CC	O	O
0.05%	PICATO.xml:S1:7036:5	0.05%	CD	O	O
:	PICATO.xml:S1:7041:1	:	:	O	O
hypersensitivity	PICATO.xml:S1:7043:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
,	PICATO.xml:S1:7059:1	,	,	O	O
allergic	PICATO.xml:S1:7061:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
contact	PICATO.xml:S1:7070:7	contact	NN	I-AdverseReaction	I-AdverseReaction
dermatitis	PICATO.xml:S1:7078:10	dermat	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:7088:1	,	,	O	O
herpes	PICATO.xml:S1:7090:6	herp	NNS	B-AdverseReaction	B-AdverseReaction
zoster	PICATO.xml:S1:7097:6	zoster	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S1:7103:1	,	,	O	O
chemical	PICATO.xml:S1:7105:8	chemic	NN	B-AdverseReaction	O
conjunctivitis	PICATO.xml:S1:7114:14	conjunct	NN	I-AdverseReaction	O
,	PICATO.xml:S1:7128:1	,	,	O	O
and	PICATO.xml:S1:7130:3	and	CC	O	O
corneal	PICATO.xml:S1:7134:7	corneal	JJ	B-AdverseReaction	B-AdverseReaction
burn	PICATO.xml:S1:7142:4	burn	NN	I-AdverseReaction	I-AdverseReaction
.	PICATO.xml:S1:7146:1	.	.	O	O

Because	PICATO.xml:S1:7152:7	becaus	IN	O	O
these	PICATO.xml:S1:7160:5	these	DT	O	O
reactions	PICATO.xml:S1:7166:9	reaction	NNS	O	O
are	PICATO.xml:S1:7176:3	are	VBP	O	O
reported	PICATO.xml:S1:7180:8	report	VBN	O	O
voluntarily	PICATO.xml:S1:7189:11	voluntarili	RB	O	O
from	PICATO.xml:S1:7201:4	from	IN	O	O
a	PICATO.xml:S1:7206:1	a	DT	O	O
population	PICATO.xml:S1:7208:10	popul	NN	O	O
of	PICATO.xml:S1:7219:2	of	IN	O	O
uncertain	PICATO.xml:S1:7222:9	uncertain	JJ	O	O
size	PICATO.xml:S1:7232:4	size	NN	O	O
,	PICATO.xml:S1:7236:1	,	,	O	O
it	PICATO.xml:S1:7238:2	it	PRP	O	O
is	PICATO.xml:S1:7241:2	is	VBZ	O	O
not	PICATO.xml:S1:7244:3	not	RB	O	O
always	PICATO.xml:S1:7248:6	alway	RB	O	O
possible	PICATO.xml:S1:7255:8	possibl	JJ	O	O
to	PICATO.xml:S1:7264:2	to	TO	O	O
reliably	PICATO.xml:S1:7267:8	reliabl	VB	O	O
estimate	PICATO.xml:S1:7276:8	estim	VB	O	O
their	PICATO.xml:S1:7285:5	their	PRP$	O	O
frequency	PICATO.xml:S1:7291:9	frequenc	NN	O	O
or	PICATO.xml:S1:7301:2	or	CC	O	O
establish	PICATO.xml:S1:7304:9	establish	VB	O	O
a	PICATO.xml:S1:7314:1	a	DT	O	O
causal	PICATO.xml:S1:7316:6	causal	NN	O	O
relationship	PICATO.xml:S1:7323:12	relationship	NN	O	O
to	PICATO.xml:S1:7336:2	to	TO	O	O
drug	PICATO.xml:S1:7339:4	drug	NN	O	O
exposure	PICATO.xml:S1:7344:8	exposur	NN	O	O
.	PICATO.xml:S1:7352:1	.	.	O	O
5	PICATO.xml:S2:5:1	5	CD	O	O
WARNINGS	PICATO.xml:S2:7:8	warn	NNP	O	O
AND	PICATO.xml:S2:16:3	and	NNP	O	O
PRECAUTIONS	PICATO.xml:S2:20:11	precaut	NNP	O	O

EXCERPT	PICATO.xml:S2:39:7	excerpt	NN	O	O
:	PICATO.xml:S2:46:1	:	:	O	O
Avoid	PICATO.xml:S2:50:5	avoid	NNP	O	O
treatment	PICATO.xml:S2:56:9	treatment	NN	O	O
in	PICATO.xml:S2:66:2	in	IN	O	O
the	PICATO.xml:S2:69:3	the	DT	O	O
periocular	PICATO.xml:S2:73:10	periocular	JJ	O	O
area	PICATO.xml:S2:84:4	area	NN	O	O
.	PICATO.xml:S2:88:1	.	.	O	O

Eye	PICATO.xml:S2:90:3	eye	NNP	B-AdverseReaction	B-AdverseReaction
disorders	PICATO.xml:S2:94:9	disord	NNS	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:103:1	,	,	O	O
including	PICATO.xml:S2:105:9	includ	VBG	O	O
severe	PICATO.xml:S2:115:6	sever	JJ	O	O
eye	PICATO.xml:S2:122:3	eye	NN	B-AdverseReaction	B-AdverseReaction
pain	PICATO.xml:S2:126:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:130:1	,	,	O	O
chemical	PICATO.xml:S2:132:8	chemic	NN	B-AdverseReaction	B-AdverseReaction
conjunctivitis	PICATO.xml:S2:141:14	conjunct	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:155:1	,	,	O	O
corneal	PICATO.xml:S2:157:7	corneal	JJ	B-AdverseReaction	B-AdverseReaction
burn	PICATO.xml:S2:165:4	burn	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:169:1	,	,	O	O
eyelid	PICATO.xml:S2:171:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
edema	PICATO.xml:S2:178:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:183:1	,	,	O	O
eyelid	PICATO.xml:S2:185:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
ptosis	PICATO.xml:S2:192:6	ptosi	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:198:1	,	,	O	O
periorbital	PICATO.xml:S2:200:11	periorbit	JJ	B-AdverseReaction	B-AdverseReaction
edema	PICATO.xml:S2:212:5	edema	NN	I-AdverseReaction	I-AdverseReaction
can	PICATO.xml:S2:218:3	can	MD	O	O
occur	PICATO.xml:S2:222:5	occur	VB	O	O
after	PICATO.xml:S2:228:5	after	IN	O	O
exposure	PICATO.xml:S2:234:8	exposur	NN	O	O
.	PICATO.xml:S2:242:1	.	.	O	O

Avoid	PICATO.xml:S2:244:5	avoid	NNP	O	O
accidental	PICATO.xml:S2:250:10	accident	JJ	O	O
transfer	PICATO.xml:S2:261:8	transfer	NN	O	O
of	PICATO.xml:S2:270:2	of	IN	O	O
the	PICATO.xml:S2:273:3	the	DT	O	O
drug	PICATO.xml:S2:277:4	drug	NN	O	O
into	PICATO.xml:S2:282:4	into	IN	O	O
the	PICATO.xml:S2:287:3	the	DT	O	O
eyes	PICATO.xml:S2:291:4	eye	NNS	O	O
and	PICATO.xml:S2:296:3	and	CC	O	O
to	PICATO.xml:S2:300:2	to	TO	O	O
the	PICATO.xml:S2:303:3	the	DT	O	O
periocular	PICATO.xml:S2:307:10	periocular	JJ	O	O
area	PICATO.xml:S2:318:4	area	NN	O	O
.	PICATO.xml:S2:322:1	.	.	O	O

If	PICATO.xml:S2:324:2	If	IN	O	O
accidental	PICATO.xml:S2:327:10	accident	JJ	O	O
exposure	PICATO.xml:S2:338:8	exposur	NN	O	O
occurs	PICATO.xml:S2:347:6	occur	VBZ	O	O
,	PICATO.xml:S2:353:1	,	,	O	O
flush	PICATO.xml:S2:355:5	flush	JJ	O	O
eyes	PICATO.xml:S2:361:4	eye	NNS	O	O
with	PICATO.xml:S2:366:4	with	IN	O	O
water	PICATO.xml:S2:371:5	water	NN	O	O
and	PICATO.xml:S2:377:3	and	CC	O	O
seek	PICATO.xml:S2:381:4	seek	VB	O	O
medical	PICATO.xml:S2:386:7	medic	JJ	O	O
care	PICATO.xml:S2:394:4	care	NN	O	O
.	PICATO.xml:S2:398:1	.	.	O	O

(	PICATO.xml:S2:400:1	(	(	O	O
5.1	PICATO.xml:S2:403:3	5.1	CD	O	O
)	PICATO.xml:S2:408:1	)	)	O	O

Local	PICATO.xml:S2:419:5	local	JJ	B-AdverseReaction	O

skin	PICATO.xml:S2:425:4	skin	JJ	I-AdverseReaction	B-AdverseReaction
reactions	PICATO.xml:S2:430:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
can	PICATO.xml:S2:440:3	can	MD	O	O
occur	PICATO.xml:S2:444:5	occur	VB	O	O
including	PICATO.xml:S2:450:9	includ	VBG	O	O
severe	PICATO.xml:S2:460:6	sever	JJ	O	O
reactions	PICATO.xml:S2:467:9	reaction	NNS	O	O
(	PICATO.xml:S2:477:1	(	(	O	O
e	PICATO.xml:S2:478:1	e	NN	O	O
.	PICATO.xml:S2:479:1	.	.	O	O
g	PICATO.xml:S2:480:1	g	NN	O	O
.	PICATO.xml:S2:481:1	.	.	O	O
,	PICATO.xml:S2:482:1	,	,	O	O
vesiculation	PICATO.xml:S2:484:12	vesicul	NN	I-AdverseReaction	O
pustulation	PICATO.xml:S2:497:11	pustul	NN	I-AdverseReaction	O
,	PICATO.xml:S2:508:1	,	,	O	O
erosion	PICATO.xml:S2:510:7	eros	NN	I-AdverseReaction	B-AdverseReaction
ulceration	PICATO.xml:S2:518:10	ulcer	NN	I-AdverseReaction	I-AdverseReaction
)	PICATO.xml:S2:528:1	)	)	O	O
.	PICATO.xml:S2:529:1	.	.	O	O

Administration	PICATO.xml:S2:531:14	administr	NN	O	O
of	PICATO.xml:S2:546:2	of	IN	O	O
Picato	PICATO.xml:S2:549:6	picato	NNP	O	O
(	PICATO.xml:S2:557:1	(	(	O	O
r	PICATO.xml:S2:558:1	r	NN	O	O
)	PICATO.xml:S2:559:1	)	)	O	O
gel	PICATO.xml:S2:562:3	gel	NN	O	O
is	PICATO.xml:S2:566:2	is	VBZ	O	O
not	PICATO.xml:S2:569:3	not	RB	O	O
recommended	PICATO.xml:S2:573:11	recommend	VBN	O	O
until	PICATO.xml:S2:585:5	until	IN	O	O
skin	PICATO.xml:S2:591:4	skin	NN	O	O
is	PICATO.xml:S2:596:2	is	VBZ	O	O
healed	PICATO.xml:S2:599:6	heal	VBN	O	O
from	PICATO.xml:S2:606:4	from	IN	O	O
any	PICATO.xml:S2:611:3	ani	DT	O	O
previous	PICATO.xml:S2:615:8	previou	JJ	O	O
drug	PICATO.xml:S2:624:4	drug	NN	O	O
or	PICATO.xml:S2:629:2	or	CC	O	O
surgical	PICATO.xml:S2:632:8	surgic	JJ	O	O
treatment	PICATO.xml:S2:641:9	treatment	NN	O	O
.	PICATO.xml:S2:650:1	.	.	O	O

(	PICATO.xml:S2:652:1	(	(	O	O
5.3	PICATO.xml:S2:655:3	5.3	CD	O	O
)	PICATO.xml:S2:660:1	)	)	O	O

5.1	PICATO.xml:S2:673:3	5.1	CD	O	O

Ophthalmic	PICATO.xml:S2:677:10	ophthalm	JJ	O	O
Adverse	PICATO.xml:S2:688:7	advers	NNP	O	O
Reactions	PICATO.xml:S2:696:9	reaction	NNP	O	O

Avoid	PICATO.xml:S2:711:5	avoid	NNP	O	O
treatment	PICATO.xml:S2:717:9	treatment	NN	O	O
in	PICATO.xml:S2:727:2	in	IN	O	O
the	PICATO.xml:S2:730:3	the	DT	O	O
periocular	PICATO.xml:S2:734:10	periocular	JJ	O	O
area	PICATO.xml:S2:745:4	area	NN	O	O
.	PICATO.xml:S2:749:1	.	.	O	O

Eye	PICATO.xml:S2:751:3	eye	NNP	B-AdverseReaction	B-AdverseReaction
disorders	PICATO.xml:S2:755:9	disord	NNS	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:764:1	,	,	O	O
including	PICATO.xml:S2:766:9	includ	VBG	O	O
severe	PICATO.xml:S2:776:6	sever	JJ	O	O
eye	PICATO.xml:S2:783:3	eye	NN	B-AdverseReaction	B-AdverseReaction
pain	PICATO.xml:S2:787:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:791:1	,	,	O	O
chemical	PICATO.xml:S2:793:8	chemic	NN	B-AdverseReaction	B-AdverseReaction
conjunctivitis	PICATO.xml:S2:802:14	conjunct	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:816:1	,	,	O	O
corneal	PICATO.xml:S2:818:7	corneal	JJ	B-AdverseReaction	B-AdverseReaction
burn	PICATO.xml:S2:826:4	burn	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:830:1	,	,	O	O
eyelid	PICATO.xml:S2:832:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
edema	PICATO.xml:S2:839:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:844:1	,	,	O	O
eyelid	PICATO.xml:S2:846:6	eyelid	JJ	B-AdverseReaction	B-AdverseReaction
ptosis	PICATO.xml:S2:853:6	ptosi	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:859:1	,	,	O	O
periorbital	PICATO.xml:S2:861:11	periorbit	JJ	B-AdverseReaction	B-AdverseReaction
edema	PICATO.xml:S2:873:5	edema	NN	I-AdverseReaction	I-AdverseReaction
can	PICATO.xml:S2:879:3	can	MD	O	O
occur	PICATO.xml:S2:883:5	occur	VB	O	O
after	PICATO.xml:S2:889:5	after	IN	O	O
exposure	PICATO.xml:S2:895:8	exposur	NN	O	O
[	PICATO.xml:S2:904:1	[	NNP	O	O
see	PICATO.xml:S2:905:3	see	VBP	O	O
Adverse	PICATO.xml:S2:909:7	advers	JJ	O	O
Reactions	PICATO.xml:S2:917:9	reaction	NNP	O	O
(	PICATO.xml:S2:927:1	(	(	O	O
6	PICATO.xml:S2:930:1	6	CD	O	O
)]	PICATO.xml:S2:933:2	)]	NN	O	O
.	PICATO.xml:S2:938:1	.	.	O	O

To	PICATO.xml:S2:951:2	To	TO	O	O

avoid	PICATO.xml:S2:954:5	avoid	JJ	O	O
transfer	PICATO.xml:S2:960:8	transfer	NN	O	O
of	PICATO.xml:S2:969:2	of	IN	O	O
the	PICATO.xml:S2:972:3	the	DT	O	O
drug	PICATO.xml:S2:976:4	drug	NN	O	O
into	PICATO.xml:S2:981:4	into	IN	O	O
the	PICATO.xml:S2:986:3	the	DT	O	O
eyes	PICATO.xml:S2:990:4	eye	NNS	O	O
and	PICATO.xml:S2:995:3	and	CC	O	O
to	PICATO.xml:S2:999:2	to	TO	O	O
the	PICATO.xml:S2:1002:3	the	DT	O	O
periocular	PICATO.xml:S2:1006:10	periocular	JJ	O	O
area	PICATO.xml:S2:1017:4	area	NN	O	O
during	PICATO.xml:S2:1022:6	dure	IN	O	O
and	PICATO.xml:S2:1029:3	and	CC	O	O
after	PICATO.xml:S2:1033:5	after	IN	O	O
application	PICATO.xml:S2:1039:11	applic	NN	O	O
,	PICATO.xml:S2:1050:1	,	,	O	O
patients	PICATO.xml:S2:1052:8	patient	NNS	O	O
should	PICATO.xml:S2:1061:6	should	MD	O	O
wash	PICATO.xml:S2:1068:4	wash	VB	O	O
hands	PICATO.xml:S2:1073:5	hand	NNS	O	O
well	PICATO.xml:S2:1079:4	well	RB	O	O
after	PICATO.xml:S2:1084:5	after	IN	O	O
applying	PICATO.xml:S2:1090:8	appli	VBG	O	O
Picato	PICATO.xml:S2:1099:6	picato	NNP	O	O
(	PICATO.xml:S2:1107:1	(	(	O	O
r	PICATO.xml:S2:1108:1	r	NN	O	O
)	PICATO.xml:S2:1109:1	)	)	O	O
gel	PICATO.xml:S2:1113:3	gel	NN	O	O
.	PICATO.xml:S2:1116:1	.	.	O	O

If	PICATO.xml:S2:1118:2	If	IN	O	O
accidental	PICATO.xml:S2:1121:10	accident	JJ	O	O
exposure	PICATO.xml:S2:1132:8	exposur	NN	O	O
occurs	PICATO.xml:S2:1141:6	occur	VBZ	O	O
,	PICATO.xml:S2:1147:1	,	,	O	O
the	PICATO.xml:S2:1149:3	the	DT	O	O
area	PICATO.xml:S2:1153:4	area	NN	O	O
should	PICATO.xml:S2:1158:6	should	MD	O	O
be	PICATO.xml:S2:1165:2	be	VB	O	O
flushed	PICATO.xml:S2:1168:7	flush	VBN	O	O
with	PICATO.xml:S2:1176:4	with	IN	O	O
water	PICATO.xml:S2:1181:5	water	NN	O	O
and	PICATO.xml:S2:1187:3	and	CC	O	O
the	PICATO.xml:S2:1191:3	the	DT	O	O
patient	PICATO.xml:S2:1195:7	patient	NN	O	O
should	PICATO.xml:S2:1203:6	should	MD	O	O
seek	PICATO.xml:S2:1210:4	seek	VB	O	O
medical	PICATO.xml:S2:1215:7	medic	JJ	O	O
care	PICATO.xml:S2:1223:4	care	NN	O	O
as	PICATO.xml:S2:1228:2	as	RB	O	O
soon	PICATO.xml:S2:1231:4	soon	RB	O	O
as	PICATO.xml:S2:1236:2	as	IN	O	O
possible	PICATO.xml:S2:1239:8	possibl	JJ	O	O
.	PICATO.xml:S2:1247:1	.	.	O	O

5.2	PICATO.xml:S2:1258:3	5.2	CD	O	O
Hypersensitivity	PICATO.xml:S2:1262:16	hypersensit	NNP	O	O
Reactions	PICATO.xml:S2:1279:9	reaction	NNP	O	O

Hypersensitivity	PICATO.xml:S2:1294:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	PICATO.xml:S2:1311:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:1320:1	,	,	O	O
including	PICATO.xml:S2:1322:9	includ	VBG	O	O
anaphylaxis	PICATO.xml:S2:1332:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
and	PICATO.xml:S2:1344:3	and	CC	O	O
allergic	PICATO.xml:S2:1348:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
contact	PICATO.xml:S2:1357:7	contact	NN	I-AdverseReaction	I-AdverseReaction
dermatitis	PICATO.xml:S2:1365:10	dermat	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:1375:1	,	,	O	O
have	PICATO.xml:S2:1377:4	have	VBP	O	O
been	PICATO.xml:S2:1382:4	been	VBN	O	O
reported	PICATO.xml:S2:1387:8	report	VBN	O	O
post	PICATO.xml:S2:1396:4	post	NN	O	O
-	PICATO.xml:S2:1400:1	-	:	O	O
marketing	PICATO.xml:S2:1401:9	market	NN	O	O
[	PICATO.xml:S2:1411:1	[	NN	O	O
see	PICATO.xml:S2:1412:3	see	VBP	O	O
Adverse	PICATO.xml:S2:1416:7	advers	JJ	O	O
Reactions	PICATO.xml:S2:1424:9	reaction	NNP	O	O
(	PICATO.xml:S2:1434:1	(	(	O	O
6.2	PICATO.xml:S2:1437:3	6.2	CD	O	O
)]	PICATO.xml:S2:1442:2	)]	NN	O	O
.	PICATO.xml:S2:1446:1	.	.	O	O

If	PICATO.xml:S2:1448:2	If	IN	O	O
anaphylactic	PICATO.xml:S2:1451:12	anaphylact	JJ	O	O
or	PICATO.xml:S2:1464:2	or	CC	O	O
other	PICATO.xml:S2:1467:5	other	JJ	O	O
clinically	PICATO.xml:S2:1473:10	clinic	RB	O	O
significant	PICATO.xml:S2:1484:11	signific	JJ	O	O
hypersensitivity	PICATO.xml:S2:1496:16	hypersensit	NN	O	O
reactions	PICATO.xml:S2:1513:9	reaction	NNS	O	O
occur	PICATO.xml:S2:1523:5	occur	VBP	O	O
,	PICATO.xml:S2:1528:1	,	,	O	O
discontinue	PICATO.xml:S2:1530:11	discontinu	VBP	O	O
Picato	PICATO.xml:S2:1542:6	picato	NNP	O	O
(	PICATO.xml:S2:1550:1	(	(	O	O
r	PICATO.xml:S2:1551:1	r	NN	O	O
)	PICATO.xml:S2:1552:1	)	)	O	O
immediately	PICATO.xml:S2:1555:11	immedi	RB	O	O
and	PICATO.xml:S2:1567:3	and	CC	O	O
institute	PICATO.xml:S2:1571:9	institut	VB	O	O
appropriate	PICATO.xml:S2:1581:11	appropri	JJ	O	O
medical	PICATO.xml:S2:1593:7	medic	JJ	O	O
therapy	PICATO.xml:S2:1601:7	therapi	NN	O	O
.	PICATO.xml:S2:1608:1	.	.	O	O

5.3	PICATO.xml:S2:1617:3	5.3	CD	O	O
Local	PICATO.xml:S2:1621:5	local	JJ	O	O
Skin	PICATO.xml:S2:1627:4	skin	NNP	O	O
Reactions	PICATO.xml:S2:1632:9	reaction	NNP	O	O

Severe	PICATO.xml:S2:1647:6	sever	JJ	O	O
skin	PICATO.xml:S2:1654:4	skin	NN	B-AdverseReaction	B-AdverseReaction
reactions	PICATO.xml:S2:1659:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
in	PICATO.xml:S2:1669:2	in	IN	I-AdverseReaction	O
the	PICATO.xml:S2:1672:3	the	DT	I-AdverseReaction	O
treated	PICATO.xml:S2:1676:7	treat	JJ	I-AdverseReaction	O
area	PICATO.xml:S2:1684:4	area	NN	I-AdverseReaction	O
,	PICATO.xml:S2:1688:1	,	,	O	O
including	PICATO.xml:S2:1690:9	includ	VBG	O	O
erythema	PICATO.xml:S2:1700:8	erythema	NN	I-AdverseReaction	B-AdverseReaction
,	PICATO.xml:S2:1708:1	,	,	O	O
crusting	PICATO.xml:S2:1710:8	crust	VBG	I-AdverseReaction	B-AdverseReaction
,	PICATO.xml:S2:1718:1	,	,	O	O
swelling	PICATO.xml:S2:1720:8	swell	VBG	I-AdverseReaction	B-AdverseReaction
,	PICATO.xml:S2:1728:1	,	,	O	O
vesiculation	PICATO.xml:S2:1730:12	vesicul	NN	I-AdverseReaction	B-AdverseReaction
postulation	PICATO.xml:S2:1743:11	postul	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:1754:1	,	,	O	O
and	PICATO.xml:S2:1756:3	and	CC	O	O
erosion	PICATO.xml:S2:1760:7	eros	NN	I-AdverseReaction	B-AdverseReaction
ulceration	PICATO.xml:S2:1768:10	ulcer	NN	I-AdverseReaction	I-AdverseReaction
,	PICATO.xml:S2:1778:1	,	,	O	O
can	PICATO.xml:S2:1780:3	can	MD	O	O
occur	PICATO.xml:S2:1784:5	occur	VB	O	O
after	PICATO.xml:S2:1790:5	after	IN	O	O
topical	PICATO.xml:S2:1796:7	topic	JJ	O	O
application	PICATO.xml:S2:1804:11	applic	NN	O	O
of	PICATO.xml:S2:1816:2	of	IN	O	O
Picato	PICATO.xml:S2:1819:6	picato	NNP	O	O
(	PICATO.xml:S2:1827:1	(	(	O	O
r	PICATO.xml:S2:1828:1	r	NN	O	O
)	PICATO.xml:S2:1829:1	)	)	O	O
gel	PICATO.xml:S2:1832:3	gel	NN	O	O
[	PICATO.xml:S2:1836:1	[	NNP	O	O
see	PICATO.xml:S2:1837:3	see	VBP	O	O
Adverse	PICATO.xml:S2:1841:7	advers	JJ	O	O
Reactions	PICATO.xml:S2:1849:9	reaction	NNP	O	O
(	PICATO.xml:S2:1859:1	(	(	O	O
6	PICATO.xml:S2:1862:1	6	CD	O	O
)]	PICATO.xml:S2:1868:2	)]	NN	O	O
.	PICATO.xml:S2:1872:1	.	.	O	O

Administration	PICATO.xml:S2:1874:14	administr	NN	O	O
of	PICATO.xml:S2:1889:2	of	IN	O	O
Picato	PICATO.xml:S2:1892:6	picato	NNP	O	O
(	PICATO.xml:S2:1900:1	(	(	O	O
r	PICATO.xml:S2:1901:1	r	NN	O	O
)	PICATO.xml:S2:1902:1	)	)	O	O
gel	PICATO.xml:S2:1905:3	gel	NN	O	O
is	PICATO.xml:S2:1909:2	is	VBZ	O	O
not	PICATO.xml:S2:1912:3	not	RB	O	O
recommended	PICATO.xml:S2:1916:11	recommend	VBN	O	O
until	PICATO.xml:S2:1928:5	until	IN	O	O
the	PICATO.xml:S2:1934:3	the	DT	O	O
skin	PICATO.xml:S2:1938:4	skin	NN	O	O
is	PICATO.xml:S2:1943:2	is	VBZ	O	O
healed	PICATO.xml:S2:1946:6	heal	VBN	O	O
from	PICATO.xml:S2:1953:4	from	IN	O	O
any	PICATO.xml:S2:1958:3	ani	DT	O	O
previous	PICATO.xml:S2:1962:8	previou	JJ	O	O
drug	PICATO.xml:S2:1971:4	drug	NN	O	O
or	PICATO.xml:S2:1976:2	or	CC	O	O
surgical	PICATO.xml:S2:1979:8	surgic	JJ	O	O
treatment	PICATO.xml:S2:1988:9	treatment	NN	O	O
.	PICATO.xml:S2:1997:1	.	.	O	O
6	POTIGA.xml:S1:4:1	6	CD	O	O
ADVERSE	POTIGA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	POTIGA.xml:S1:14:9	reaction	NN	O	O

The	POTIGA.xml:S1:27:3	the	DT	O	O
following	POTIGA.xml:S1:31:9	follow	JJ	O	O
adverse	POTIGA.xml:S1:41:7	advers	JJ	O	O
reactions	POTIGA.xml:S1:49:9	reaction	NNS	O	O
are	POTIGA.xml:S1:59:3	are	VBP	O	O
described	POTIGA.xml:S1:63:9	describ	VBN	O	O
in	POTIGA.xml:S1:73:2	in	IN	O	O
more	POTIGA.xml:S1:76:4	more	JJR	O	O
detail	POTIGA.xml:S1:81:6	detail	NN	O	O
in	POTIGA.xml:S1:88:2	in	IN	O	O
the	POTIGA.xml:S1:91:3	the	DT	O	O
Warnings	POTIGA.xml:S1:96:8	warn	NNP	O	O
and	POTIGA.xml:S1:105:3	and	CC	O	O
Precautions	POTIGA.xml:S1:109:11	precaut	NNP	O	O
section	POTIGA.xml:S1:122:7	section	NN	O	O
of	POTIGA.xml:S1:130:2	of	IN	O	O
the	POTIGA.xml:S1:133:3	the	DT	O	O
label	POTIGA.xml:S1:137:5	label	NN	O	O
:	POTIGA.xml:S1:142:1	:	:	O	O

Retinal	POTIGA.xml:S1:153:7	retin	JJ	B-AdverseReaction	B-AdverseReaction
abnormalities	POTIGA.xml:S1:161:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
and	POTIGA.xml:S1:175:3	and	CC	O	O
potential	POTIGA.xml:S1:179:9	potenti	JJ	O	B-AdverseReaction
vision	POTIGA.xml:S1:189:6	vision	NN	B-AdverseReaction	I-AdverseReaction
loss	POTIGA.xml:S1:196:4	loss	NN	I-AdverseReaction	I-AdverseReaction
[	POTIGA.xml:S1:201:1	[	NNP	O	O
see	POTIGA.xml:S1:202:3	see	VBP	O	O
Warnings	POTIGA.xml:S1:206:8	warn	NNP	O	O
and	POTIGA.xml:S1:215:3	and	CC	O	O
Precautions	POTIGA.xml:S1:219:11	precaut	NNP	O	O
(	POTIGA.xml:S1:231:1	(	(	O	O
5.1	POTIGA.xml:S1:232:3	5.1	CD	O	O
)]	POTIGA.xml:S1:235:2	)]	NN	O	O

Urinary	POTIGA.xml:S1:246:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
retention	POTIGA.xml:S1:254:9	retent	NN	I-AdverseReaction	I-AdverseReaction
[	POTIGA.xml:S1:264:1	[	NNP	O	O
see	POTIGA.xml:S1:265:3	see	VBP	O	O
Warnings	POTIGA.xml:S1:269:8	warn	NNP	O	O
and	POTIGA.xml:S1:278:3	and	CC	O	O
Precautions	POTIGA.xml:S1:282:11	precaut	NNP	O	O
(	POTIGA.xml:S1:294:1	(	(	O	O
5.2	POTIGA.xml:S1:295:3	5.2	CD	O	O
)]	POTIGA.xml:S1:298:2	)]	NN	O	O

Skin	POTIGA.xml:S1:309:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
discoloration	POTIGA.xml:S1:314:13	discolor	NN	I-AdverseReaction	I-AdverseReaction
[	POTIGA.xml:S1:328:1	[	NNP	O	O
see	POTIGA.xml:S1:329:3	see	VBP	O	O
Warnings	POTIGA.xml:S1:333:8	warn	NNP	O	O
and	POTIGA.xml:S1:342:3	and	CC	O	O
Precautions	POTIGA.xml:S1:346:11	precaut	NNP	O	O
(	POTIGA.xml:S1:358:1	(	(	O	O
5.3	POTIGA.xml:S1:359:3	5.3	CD	O	O
)]	POTIGA.xml:S1:362:2	)]	NN	O	O

Neuropsychiatric	POTIGA.xml:S1:373:16	neuropsychiatr	NNP	B-AdverseReaction	B-AdverseReaction
symptoms	POTIGA.xml:S1:390:8	symptom	NNS	I-AdverseReaction	I-AdverseReaction
[	POTIGA.xml:S1:399:1	[	NNP	O	O
see	POTIGA.xml:S1:400:3	see	VBP	O	O
Warnings	POTIGA.xml:S1:404:8	warn	NNP	O	O
and	POTIGA.xml:S1:413:3	and	CC	O	O
Precautions	POTIGA.xml:S1:417:11	precaut	NNP	O	O
(	POTIGA.xml:S1:429:1	(	(	O	O
5.4	POTIGA.xml:S1:430:3	5.4	CD	O	O
)]	POTIGA.xml:S1:433:2	)]	NN	O	O

Dizziness	POTIGA.xml:S1:444:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
and	POTIGA.xml:S1:454:3	and	CC	O	O
somnolence	POTIGA.xml:S1:458:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
[	POTIGA.xml:S1:469:1	[	NNP	O	O
see	POTIGA.xml:S1:470:3	see	VBP	O	O
Warnings	POTIGA.xml:S1:474:8	warn	NNP	O	O
and	POTIGA.xml:S1:483:3	and	CC	O	O
Precautions	POTIGA.xml:S1:487:11	precaut	NNP	O	O
(	POTIGA.xml:S1:499:1	(	(	O	O
5.5	POTIGA.xml:S1:500:3	5.5	CD	O	O
)]	POTIGA.xml:S1:503:2	)]	NN	O	O

QT	POTIGA.xml:S1:514:2	QT	NNP	B-AdverseReaction	B-AdverseReaction
interval	POTIGA.xml:S1:517:8	interv	JJ	I-AdverseReaction	I-AdverseReaction
effect	POTIGA.xml:S1:526:6	effect	NN	I-AdverseReaction	I-AdverseReaction
[	POTIGA.xml:S1:533:1	[	NNP	O	O
see	POTIGA.xml:S1:534:3	see	VBP	O	O
Warnings	POTIGA.xml:S1:538:8	warn	NNP	O	O
and	POTIGA.xml:S1:547:3	and	CC	O	O
Precautions	POTIGA.xml:S1:551:11	precaut	NNP	O	O
(	POTIGA.xml:S1:563:1	(	(	O	O
5.6	POTIGA.xml:S1:564:3	5.6	CD	O	O
)]	POTIGA.xml:S1:567:2	)]	NN	O	O

Suicidal	POTIGA.xml:S1:578:8	suicid	NNP	B-AdverseReaction	B-AdverseReaction
behavior	POTIGA.xml:S1:587:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
and	POTIGA.xml:S1:596:3	and	CC	O	O
ideation	POTIGA.xml:S1:600:8	ideat	NN	I-AdverseReaction	I-AdverseReaction
[	POTIGA.xml:S1:609:1	[	NNP	O	O
see	POTIGA.xml:S1:610:3	see	VBP	O	O
Warnings	POTIGA.xml:S1:614:8	warn	NNP	O	O
and	POTIGA.xml:S1:623:3	and	CC	O	O
Precautions	POTIGA.xml:S1:627:11	precaut	NNP	O	O
(	POTIGA.xml:S1:639:1	(	(	O	O
5.7	POTIGA.xml:S1:640:3	5.7	CD	O	O
)]	POTIGA.xml:S1:643:2	)]	NN	O	O

Withdrawal	POTIGA.xml:S1:654:10	withdraw	NNP	B-AdverseReaction	B-AdverseReaction
seizures	POTIGA.xml:S1:665:8	seizur	VBZ	I-AdverseReaction	I-AdverseReaction
[	POTIGA.xml:S1:674:1	[	NNP	O	O
see	POTIGA.xml:S1:675:3	see	VBP	O	O
Warnings	POTIGA.xml:S1:679:8	warn	NNP	O	O
and	POTIGA.xml:S1:688:3	and	CC	O	O
Precautions	POTIGA.xml:S1:692:11	precaut	NNP	O	O
(	POTIGA.xml:S1:704:1	(	(	O	O
5.8	POTIGA.xml:S1:705:3	5.8	CD	O	O
)]	POTIGA.xml:S1:708:2	)]	NN	O	O

EXCERPT	POTIGA.xml:S1:719:7	excerpt	NNS	O	O
:	POTIGA.xml:S1:726:1	:	:	O	O
Most	POTIGA.xml:S1:730:4	most	JJS	O	O
common	POTIGA.xml:S1:735:6	common	JJ	O	O
adverse	POTIGA.xml:S1:742:7	advers	JJ	O	O
reactions	POTIGA.xml:S1:750:9	reaction	NNS	O	O
(	POTIGA.xml:S1:760:1	(	(	O	O
incidence	POTIGA.xml:S1:761:9	incid	NN	O	O
4%	POTIGA.xml:S1:773:2	4%	CD	O	O
and	POTIGA.xml:S1:776:3	and	CC	O	O
twice	POTIGA.xml:S1:780:5	twice	RB	O	O
placebo	POTIGA.xml:S1:786:7	placebo	NN	O	O
)	POTIGA.xml:S1:793:1	)	)	O	O
were	POTIGA.xml:S1:795:4	were	VBD	O	O
dizziness	POTIGA.xml:S1:800:9	dizzi	JJ	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:809:1	,	,	O	O
somnolence	POTIGA.xml:S1:811:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:821:1	,	,	O	O
fatigue	POTIGA.xml:S1:823:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:830:1	,	,	O	O
confusional	POTIGA.xml:S1:832:11	confusion	JJ	B-AdverseReaction	B-AdverseReaction
state	POTIGA.xml:S1:844:5	state	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:849:1	,	,	O	O
vertigo	POTIGA.xml:S1:851:7	vertigo	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:858:1	,	,	O	O
tremor	POTIGA.xml:S1:860:6	tremor	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:866:1	,	,	O	O
abnormal	POTIGA.xml:S1:868:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
coordination	POTIGA.xml:S1:877:12	coordin	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:889:1	,	,	O	O
diplopia	POTIGA.xml:S1:891:8	diplopia	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:899:1	,	,	O	O
disturbance	POTIGA.xml:S1:901:11	disturb	NN	B-AdverseReaction	B-AdverseReaction
in	POTIGA.xml:S1:913:2	in	IN	I-AdverseReaction	I-AdverseReaction
attention	POTIGA.xml:S1:916:9	attent	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:925:1	,	,	O	O
memory	POTIGA.xml:S1:927:6	memori	NN	B-AdverseReaction	B-AdverseReaction
impairment	POTIGA.xml:S1:934:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:944:1	,	,	O	O
asthenia	POTIGA.xml:S1:946:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:954:1	,	,	O	O
blurred	POTIGA.xml:S1:956:7	blur	VBN	B-AdverseReaction	B-AdverseReaction
vision	POTIGA.xml:S1:964:6	vision	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:970:1	,	,	O	O
gait	POTIGA.xml:S1:972:4	gait	NN	B-AdverseReaction	B-AdverseReaction
disturbance	POTIGA.xml:S1:977:11	disturb	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:988:1	,	,	O	O
aphasia	POTIGA.xml:S1:990:7	aphasia	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:997:1	,	,	O	O
dysarthria	POTIGA.xml:S1:999:10	dysarthria	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:1009:1	,	,	O	O
and	POTIGA.xml:S1:1011:3	and	CC	O	O
balance	POTIGA.xml:S1:1015:7	balanc	NN	B-AdverseReaction	B-AdverseReaction
disorder	POTIGA.xml:S1:1023:8	disord	NN	I-AdverseReaction	I-AdverseReaction
.	POTIGA.xml:S1:1031:1	.	.	O	O

(	POTIGA.xml:S1:1033:1	(	(	O	O
6.1	POTIGA.xml:S1:1036:3	6.1	CD	O	O
)	POTIGA.xml:S1:1041:1	)	)	O	O

To	POTIGA.xml:S1:1049:2	To	TO	O	O

report	POTIGA.xml:S1:1052:6	report	NN	O	O
SUSPECTED	POTIGA.xml:S1:1059:9	suspect	NNP	O	O
ADVERSE	POTIGA.xml:S1:1069:7	advers	NNP	O	O
REACTIONS	POTIGA.xml:S1:1077:9	reaction	NNP	O	O
,	POTIGA.xml:S1:1086:1	,	,	O	O
contact	POTIGA.xml:S1:1088:7	contact	NN	O	O
GlaxoSmithKline	POTIGA.xml:S1:1096:15	glaxosmithklin	NNP	O	O
at	POTIGA.xml:S1:1112:2	at	IN	O	O
1	POTIGA.xml:S1:1115:1	1	CD	O	O
-	POTIGA.xml:S1:1116:1	-	:	O	O
888	POTIGA.xml:S1:1117:3	888	CD	O	O
-	POTIGA.xml:S1:1120:1	-	:	O	O
825	POTIGA.xml:S1:1121:3	825	CD	O	O
-	POTIGA.xml:S1:1124:1	-	:	O	O
5249	POTIGA.xml:S1:1125:4	5249	CD	O	O
or	POTIGA.xml:S1:1130:2	or	CC	O	O
FDA	POTIGA.xml:S1:1133:3	fda	NNP	O	O
at	POTIGA.xml:S1:1137:2	at	IN	O	O
1	POTIGA.xml:S1:1140:1	1	CD	O	O
-	POTIGA.xml:S1:1141:1	-	:	O	O
800	POTIGA.xml:S1:1142:3	800	CD	O	O
-	POTIGA.xml:S1:1145:1	-	:	O	O
FDA	POTIGA.xml:S1:1146:3	fda	NNP	O	O
-	POTIGA.xml:S1:1149:1	-	:	O	O
1088	POTIGA.xml:S1:1150:4	1088	CD	O	O
or	POTIGA.xml:S1:1155:2	or	CC	O	O
www	POTIGA.xml:S1:1159:3	www	VB	O	O
.	POTIGA.xml:S1:1162:1	.	.	O	O
fda	POTIGA.xml:S1:1163:3	fda	NN	O	O
.	POTIGA.xml:S1:1166:1	.	.	O	O
gov	POTIGA.xml:S1:1167:3	gov	JJ	O	O
medwatch	POTIGA.xml:S1:1171:8	medwatch	NN	O	O
.	POTIGA.xml:S1:1181:1	.	.	O	O

6.1	POTIGA.xml:S1:1193:3	6.1	CD	O	O

Clinical	POTIGA.xml:S1:1197:8	clinic	JJ	O	O
Trials	POTIGA.xml:S1:1206:6	trial	NNS	O	O
Experience	POTIGA.xml:S1:1213:10	experi	NN	O	O

Because	POTIGA.xml:S1:1227:7	becaus	IN	O	O
clinical	POTIGA.xml:S1:1235:8	clinic	JJ	O	O
trials	POTIGA.xml:S1:1244:6	trial	NNS	O	O
are	POTIGA.xml:S1:1251:3	are	VBP	O	O
conducted	POTIGA.xml:S1:1255:9	conduct	VBN	O	O
under	POTIGA.xml:S1:1265:5	under	IN	O	O
widely	POTIGA.xml:S1:1271:6	wide	RB	O	O
varying	POTIGA.xml:S1:1278:7	vari	VBG	O	O
conditions	POTIGA.xml:S1:1286:10	condit	NNS	O	O
,	POTIGA.xml:S1:1296:1	,	,	O	O
adverse	POTIGA.xml:S1:1298:7	advers	JJ	O	O
reaction	POTIGA.xml:S1:1306:8	reaction	NN	O	O
rates	POTIGA.xml:S1:1315:5	rate	NNS	O	O
observed	POTIGA.xml:S1:1321:8	observ	VBD	O	O
in	POTIGA.xml:S1:1330:2	in	IN	O	O
the	POTIGA.xml:S1:1333:3	the	DT	O	O
clinical	POTIGA.xml:S1:1337:8	clinic	JJ	O	O
trials	POTIGA.xml:S1:1346:6	trial	NNS	O	O
of	POTIGA.xml:S1:1353:2	of	IN	O	O
a	POTIGA.xml:S1:1356:1	a	DT	O	O
drug	POTIGA.xml:S1:1358:4	drug	NN	O	O
cannot	POTIGA.xml:S1:1363:6	cannot	NN	O	O
be	POTIGA.xml:S1:1370:2	be	VB	O	O
directly	POTIGA.xml:S1:1373:8	directli	RB	O	O
compared	POTIGA.xml:S1:1382:8	compar	VBN	O	O
with	POTIGA.xml:S1:1391:4	with	IN	O	O
rates	POTIGA.xml:S1:1396:5	rate	NNS	O	O
in	POTIGA.xml:S1:1402:2	in	IN	O	O
the	POTIGA.xml:S1:1405:3	the	DT	O	O
clinical	POTIGA.xml:S1:1409:8	clinic	JJ	O	O
trials	POTIGA.xml:S1:1418:6	trial	NNS	O	O
of	POTIGA.xml:S1:1425:2	of	IN	O	O
another	POTIGA.xml:S1:1428:7	anoth	DT	O	O
drug	POTIGA.xml:S1:1436:4	drug	NN	O	O
and	POTIGA.xml:S1:1441:3	and	CC	O	O
may	POTIGA.xml:S1:1445:3	may	MD	O	O
not	POTIGA.xml:S1:1449:3	not	RB	O	O
reflect	POTIGA.xml:S1:1453:7	reflect	VB	O	O
the	POTIGA.xml:S1:1461:3	the	DT	O	O
rates	POTIGA.xml:S1:1465:5	rate	NNS	O	O
observed	POTIGA.xml:S1:1471:8	observ	VBD	O	O
in	POTIGA.xml:S1:1480:2	in	IN	O	O
practice	POTIGA.xml:S1:1483:8	practic	NN	O	O
.	POTIGA.xml:S1:1491:1	.	.	O	O

POTIGA	POTIGA.xml:S1:1497:6	potiga	NNP	O	O
was	POTIGA.xml:S1:1504:3	wa	VBD	O	O
administered	POTIGA.xml:S1:1508:12	administ	VBN	O	O
as	POTIGA.xml:S1:1521:2	as	IN	O	O
adjunctive	POTIGA.xml:S1:1524:10	adjunct	JJ	O	O
therapy	POTIGA.xml:S1:1535:7	therapi	NN	O	O
to	POTIGA.xml:S1:1543:2	to	TO	O	O
1	POTIGA.xml:S1:1546:1	1	CD	O	O
,	POTIGA.xml:S1:1547:1	,	,	O	O
365	POTIGA.xml:S1:1548:3	365	CD	O	O
patients	POTIGA.xml:S1:1552:8	patient	NNS	O	O
with	POTIGA.xml:S1:1561:4	with	IN	O	O
epilepsy	POTIGA.xml:S1:1566:8	epilepsi	NN	O	O
in	POTIGA.xml:S1:1575:2	in	IN	O	O
all	POTIGA.xml:S1:1578:3	all	DT	O	O
controlled	POTIGA.xml:S1:1582:10	control	VBN	O	O
and	POTIGA.xml:S1:1593:3	and	CC	O	O
uncontrolled	POTIGA.xml:S1:1597:12	uncontrol	JJ	O	O
clinical	POTIGA.xml:S1:1610:8	clinic	JJ	O	O
studies	POTIGA.xml:S1:1619:7	studi	NNS	O	O
during	POTIGA.xml:S1:1627:6	dure	IN	O	O
the	POTIGA.xml:S1:1634:3	the	DT	O	O
premarketing	POTIGA.xml:S1:1638:12	premarket	NN	O	O
development	POTIGA.xml:S1:1651:11	develop	NN	O	O
.	POTIGA.xml:S1:1662:1	.	.	O	O

A	POTIGA.xml:S1:1664:1	A	DT	O	O
total	POTIGA.xml:S1:1666:5	total	NN	O	O
of	POTIGA.xml:S1:1672:2	of	IN	O	O
801	POTIGA.xml:S1:1675:3	801	CD	O	O
patients	POTIGA.xml:S1:1679:8	patient	NNS	O	O
were	POTIGA.xml:S1:1688:4	were	VBD	O	O
treated	POTIGA.xml:S1:1693:7	treat	VBN	O	O
for	POTIGA.xml:S1:1701:3	for	IN	O	O
at	POTIGA.xml:S1:1705:2	at	IN	O	O
least	POTIGA.xml:S1:1708:5	least	JJS	O	O
6	POTIGA.xml:S1:1714:1	6	CD	O	O
months	POTIGA.xml:S1:1716:6	month	NNS	O	O
,	POTIGA.xml:S1:1722:1	,	,	O	O
585	POTIGA.xml:S1:1724:3	585	CD	O	O
patients	POTIGA.xml:S1:1728:8	patient	NNS	O	O
were	POTIGA.xml:S1:1737:4	were	VBD	O	O
treated	POTIGA.xml:S1:1742:7	treat	VBN	O	O
for	POTIGA.xml:S1:1750:3	for	IN	O	O
1	POTIGA.xml:S1:1754:1	1	CD	O	O
year	POTIGA.xml:S1:1756:4	year	NN	O	O
or	POTIGA.xml:S1:1761:2	or	CC	O	O
longer	POTIGA.xml:S1:1764:6	longer	JJR	O	O
,	POTIGA.xml:S1:1770:1	,	,	O	O
and	POTIGA.xml:S1:1772:3	and	CC	O	O
311	POTIGA.xml:S1:1776:3	311	CD	O	O
patients	POTIGA.xml:S1:1780:8	patient	NNS	O	O
were	POTIGA.xml:S1:1789:4	were	VBD	O	O
treated	POTIGA.xml:S1:1794:7	treat	VBN	O	O
for	POTIGA.xml:S1:1802:3	for	IN	O	O
at	POTIGA.xml:S1:1806:2	at	IN	O	O
least	POTIGA.xml:S1:1809:5	least	JJS	O	O
2	POTIGA.xml:S1:1815:1	2	CD	O	O
years	POTIGA.xml:S1:1817:5	year	NNS	O	O
.	POTIGA.xml:S1:1822:1	.	.	O	O

Adverse	POTIGA.xml:S1:1830:7	advers	JJ	O	O
Reactions	POTIGA.xml:S1:1838:9	reaction	NNP	O	O
Leading	POTIGA.xml:S1:1848:7	lead	NNP	O	O
to	POTIGA.xml:S1:1856:2	to	TO	O	O
Discontinuation	POTIGA.xml:S1:1859:15	discontinu	NNP	O	O
in	POTIGA.xml:S1:1875:2	in	IN	O	O
All	POTIGA.xml:S1:1878:3	all	NNP	O	O
Controlled	POTIGA.xml:S1:1882:10	control	NNP	O	O
Clinical	POTIGA.xml:S1:1893:8	clinic	NNP	O	O
Studies	POTIGA.xml:S1:1902:7	studi	NNS	O	O

In	POTIGA.xml:S1:1916:2	In	IN	O	O
the	POTIGA.xml:S1:1919:3	the	DT	O	O
3	POTIGA.xml:S1:1923:1	3	CD	O	O
randomized	POTIGA.xml:S1:1925:10	random	VBN	O	O
,	POTIGA.xml:S1:1935:1	,	,	O	O
double	POTIGA.xml:S1:1937:6	doubl	JJ	O	O
-	POTIGA.xml:S1:1943:1	-	:	O	O
blind	POTIGA.xml:S1:1944:5	blind	NN	O	O
,	POTIGA.xml:S1:1949:1	,	,	O	O
placebo	POTIGA.xml:S1:1951:7	placebo	SYM	O	O
-	POTIGA.xml:S1:1958:1	-	:	O	O
controlled	POTIGA.xml:S1:1959:10	control	VBN	O	O
studies	POTIGA.xml:S1:1970:7	studi	NNS	O	O
,	POTIGA.xml:S1:1977:1	,	,	O	O
199	POTIGA.xml:S1:1979:3	199	CD	O	O
of	POTIGA.xml:S1:1983:2	of	IN	O	O
813	POTIGA.xml:S1:1986:3	813	CD	O	O
patients	POTIGA.xml:S1:1990:8	patient	NNS	O	O
(	POTIGA.xml:S1:1999:1	(	(	O	O
25%	POTIGA.xml:S1:2000:3	25%	CD	O	O
)	POTIGA.xml:S1:2003:1	)	)	O	O
receiving	POTIGA.xml:S1:2005:9	receiv	VBG	O	O
POTIGA	POTIGA.xml:S1:2015:6	potiga	NNP	O	O
and	POTIGA.xml:S1:2022:3	and	CC	O	O
45	POTIGA.xml:S1:2026:2	45	CD	O	O
of	POTIGA.xml:S1:2029:2	of	IN	O	O
427	POTIGA.xml:S1:2032:3	427	CD	O	O
patients	POTIGA.xml:S1:2036:8	patient	NNS	O	O
(	POTIGA.xml:S1:2045:1	(	(	O	O
11%	POTIGA.xml:S1:2046:3	11%	CD	O	O
)	POTIGA.xml:S1:2049:1	)	)	O	O
receiving	POTIGA.xml:S1:2051:9	receiv	VBG	O	O
placebo	POTIGA.xml:S1:2061:7	placebo	NN	O	O
discontinued	POTIGA.xml:S1:2069:12	discontinu	VBN	O	O
treatment	POTIGA.xml:S1:2082:9	treatment	NN	O	O
because	POTIGA.xml:S1:2092:7	becaus	IN	O	O
of	POTIGA.xml:S1:2100:2	of	IN	O	O
adverse	POTIGA.xml:S1:2103:7	advers	JJ	O	O
reactions	POTIGA.xml:S1:2111:9	reaction	NNS	O	O
.	POTIGA.xml:S1:2120:1	.	.	O	O

The	POTIGA.xml:S1:2122:3	the	DT	O	O
most	POTIGA.xml:S1:2126:4	most	RBS	O	O
common	POTIGA.xml:S1:2131:6	common	JJ	O	O
adverse	POTIGA.xml:S1:2138:7	advers	JJ	O	O
reactions	POTIGA.xml:S1:2146:9	reaction	NNS	O	O
leading	POTIGA.xml:S1:2156:7	lead	VBG	O	O
to	POTIGA.xml:S1:2164:2	to	TO	O	O
withdrawal	POTIGA.xml:S1:2167:10	withdraw	VB	O	O
in	POTIGA.xml:S1:2178:2	in	IN	O	O
patients	POTIGA.xml:S1:2181:8	patient	NNS	O	O
receiving	POTIGA.xml:S1:2190:9	receiv	VBG	O	O
POTIGA	POTIGA.xml:S1:2200:6	potiga	NNP	O	O
were	POTIGA.xml:S1:2207:4	were	VBD	O	O
dizziness	POTIGA.xml:S1:2212:9	dizzi	JJ	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2222:1	(	(	O	O
6%	POTIGA.xml:S1:2223:2	6%	CD	O	O
)	POTIGA.xml:S1:2225:1	)	)	O	O
,	POTIGA.xml:S1:2226:1	,	,	O	O
confusional	POTIGA.xml:S1:2228:11	confusion	JJ	B-AdverseReaction	B-AdverseReaction
state	POTIGA.xml:S1:2240:5	state	NN	I-AdverseReaction	I-AdverseReaction
(	POTIGA.xml:S1:2246:1	(	(	O	O
4%	POTIGA.xml:S1:2247:2	4%	CD	O	O
)	POTIGA.xml:S1:2249:1	)	)	O	O
,	POTIGA.xml:S1:2250:1	,	,	O	O
fatigue	POTIGA.xml:S1:2252:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2260:1	(	(	O	O
3%	POTIGA.xml:S1:2261:2	3%	CD	O	O
)	POTIGA.xml:S1:2263:1	)	)	O	O
,	POTIGA.xml:S1:2264:1	,	,	O	O
and	POTIGA.xml:S1:2266:3	and	CC	O	O
somnolence	POTIGA.xml:S1:2270:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2281:1	(	(	O	O
3%	POTIGA.xml:S1:2282:2	3%	CD	O	O
)	POTIGA.xml:S1:2284:1	)	)	O	O
.	POTIGA.xml:S1:2285:1	.	.	O	O

Common	POTIGA.xml:S1:2293:6	common	JJ	O	O
Adverse	POTIGA.xml:S1:2300:7	advers	NNP	O	O
Reactions	POTIGA.xml:S1:2308:9	reaction	NNP	O	O
in	POTIGA.xml:S1:2318:2	in	IN	O	O
All	POTIGA.xml:S1:2321:3	all	NNP	O	O
Controlled	POTIGA.xml:S1:2325:10	control	NNP	O	O
Clinical	POTIGA.xml:S1:2336:8	clinic	NNP	O	O
Studies	POTIGA.xml:S1:2345:7	studi	NNS	O	O

Overall	POTIGA.xml:S1:2359:7	overal	JJ	O	O
,	POTIGA.xml:S1:2366:1	,	,	O	O
the	POTIGA.xml:S1:2368:3	the	DT	O	O
most	POTIGA.xml:S1:2372:4	most	RBS	O	O
frequently	POTIGA.xml:S1:2377:10	frequent	RB	O	O
reported	POTIGA.xml:S1:2388:8	report	VBD	O	O
adverse	POTIGA.xml:S1:2397:7	advers	JJ	O	O
reactions	POTIGA.xml:S1:2405:9	reaction	NNS	O	O
in	POTIGA.xml:S1:2415:2	in	IN	O	O
patients	POTIGA.xml:S1:2418:8	patient	NNS	O	O
receiving	POTIGA.xml:S1:2427:9	receiv	VBG	O	O
POTIGA	POTIGA.xml:S1:2437:6	potiga	NNP	O	O
(	POTIGA.xml:S1:2444:1	(	(	O	O
4%	POTIGA.xml:S1:2447:2	4%	CD	O	O
and	POTIGA.xml:S1:2450:3	and	CC	O	O
occurring	POTIGA.xml:S1:2454:9	occur	VBG	O	O
approximately	POTIGA.xml:S1:2464:13	approxim	RB	O	O
twice	POTIGA.xml:S1:2478:5	twice	RB	O	O
the	POTIGA.xml:S1:2484:3	the	DT	O	O
placebo	POTIGA.xml:S1:2488:7	placebo	NN	O	O
rate	POTIGA.xml:S1:2496:4	rate	NN	O	O
)	POTIGA.xml:S1:2500:1	)	)	O	O
were	POTIGA.xml:S1:2502:4	were	VBD	O	O
dizziness	POTIGA.xml:S1:2507:9	dizzi	JJ	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2517:1	(	(	O	O
23%	POTIGA.xml:S1:2518:3	23%	CD	O	O
)	POTIGA.xml:S1:2521:1	)	)	O	O
,	POTIGA.xml:S1:2522:1	,	,	O	O
somnolence	POTIGA.xml:S1:2524:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2535:1	(	(	O	O
22%	POTIGA.xml:S1:2536:3	22%	CD	O	O
)	POTIGA.xml:S1:2539:1	)	)	O	O
,	POTIGA.xml:S1:2540:1	,	,	O	O
fatigue	POTIGA.xml:S1:2542:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2550:1	(	(	O	O
15%	POTIGA.xml:S1:2551:3	15%	CD	O	O
)	POTIGA.xml:S1:2554:1	)	)	O	O
,	POTIGA.xml:S1:2555:1	,	,	O	O
confusional	POTIGA.xml:S1:2557:11	confusion	JJ	B-AdverseReaction	B-AdverseReaction
state	POTIGA.xml:S1:2569:5	state	NN	I-AdverseReaction	I-AdverseReaction
(	POTIGA.xml:S1:2575:1	(	(	O	O
9%	POTIGA.xml:S1:2576:2	9%	CD	O	O
)	POTIGA.xml:S1:2578:1	)	)	O	O
,	POTIGA.xml:S1:2579:1	,	,	O	O
vertigo	POTIGA.xml:S1:2581:7	vertigo	FW	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2589:1	(	(	O	O
8%	POTIGA.xml:S1:2590:2	8%	CD	O	O
)	POTIGA.xml:S1:2592:1	)	)	O	O
,	POTIGA.xml:S1:2593:1	,	,	O	O
tremor	POTIGA.xml:S1:2595:6	tremor	NN	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2602:1	(	(	O	O
8%	POTIGA.xml:S1:2603:2	8%	CD	O	O
)	POTIGA.xml:S1:2605:1	)	)	O	O
,	POTIGA.xml:S1:2606:1	,	,	O	O
abnormal	POTIGA.xml:S1:2608:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
coordination	POTIGA.xml:S1:2617:12	coordin	NN	I-AdverseReaction	I-AdverseReaction
(	POTIGA.xml:S1:2630:1	(	(	O	O
7%	POTIGA.xml:S1:2631:2	7%	CD	O	O
)	POTIGA.xml:S1:2633:1	)	)	O	O
,	POTIGA.xml:S1:2634:1	,	,	O	O
diplopia	POTIGA.xml:S1:2636:8	diplopia	NN	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2645:1	(	(	O	O
7%	POTIGA.xml:S1:2646:2	7%	CD	O	O
)	POTIGA.xml:S1:2648:1	)	)	O	O
,	POTIGA.xml:S1:2649:1	,	,	O	O
disturbance	POTIGA.xml:S1:2651:11	disturb	NN	B-AdverseReaction	B-AdverseReaction
in	POTIGA.xml:S1:2663:2	in	IN	I-AdverseReaction	I-AdverseReaction
attention	POTIGA.xml:S1:2666:9	attent	NN	I-AdverseReaction	I-AdverseReaction
(	POTIGA.xml:S1:2676:1	(	(	O	O
6%	POTIGA.xml:S1:2677:2	6%	CD	O	O
)	POTIGA.xml:S1:2679:1	)	)	O	O
,	POTIGA.xml:S1:2680:1	,	,	O	O
memory	POTIGA.xml:S1:2682:6	memori	JJ	B-AdverseReaction	B-AdverseReaction
impairment	POTIGA.xml:S1:2689:10	impair	NN	I-AdverseReaction	I-AdverseReaction
(	POTIGA.xml:S1:2700:1	(	(	O	O
6%	POTIGA.xml:S1:2701:2	6%	CD	O	O
)	POTIGA.xml:S1:2703:1	)	)	O	O
,	POTIGA.xml:S1:2704:1	,	,	O	O
asthenia	POTIGA.xml:S1:2706:8	asthenia	RB	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2715:1	(	(	O	O
5%	POTIGA.xml:S1:2716:2	5%	CD	O	O
)	POTIGA.xml:S1:2718:1	)	)	O	O
,	POTIGA.xml:S1:2719:1	,	,	O	O
blurred	POTIGA.xml:S1:2721:7	blur	VBN	B-AdverseReaction	B-AdverseReaction
vision	POTIGA.xml:S1:2729:6	vision	NN	I-AdverseReaction	I-AdverseReaction
(	POTIGA.xml:S1:2736:1	(	(	O	O
5%	POTIGA.xml:S1:2737:2	5%	CD	O	O
)	POTIGA.xml:S1:2739:1	)	)	O	O
,	POTIGA.xml:S1:2740:1	,	,	O	O
gait	POTIGA.xml:S1:2742:4	gait	JJ	B-AdverseReaction	B-AdverseReaction
disturbance	POTIGA.xml:S1:2747:11	disturb	NN	I-AdverseReaction	I-AdverseReaction
(	POTIGA.xml:S1:2759:1	(	(	O	O
4%	POTIGA.xml:S1:2760:2	4%	CD	O	O
)	POTIGA.xml:S1:2762:1	)	)	O	O
,	POTIGA.xml:S1:2763:1	,	,	O	O
aphasia	POTIGA.xml:S1:2765:7	aphasia	NN	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2773:1	(	(	O	O
4%	POTIGA.xml:S1:2774:2	4%	CD	O	O
)	POTIGA.xml:S1:2776:1	)	)	O	O
,	POTIGA.xml:S1:2777:1	,	,	O	O
dysarthria	POTIGA.xml:S1:2779:10	dysarthria	NN	B-AdverseReaction	B-AdverseReaction
(	POTIGA.xml:S1:2790:1	(	(	O	O
4%	POTIGA.xml:S1:2791:2	4%	CD	O	O
)	POTIGA.xml:S1:2793:1	)	)	O	O
,	POTIGA.xml:S1:2794:1	,	,	O	O
and	POTIGA.xml:S1:2796:3	and	CC	O	O
balance	POTIGA.xml:S1:2800:7	balanc	NN	B-AdverseReaction	B-AdverseReaction
disorder	POTIGA.xml:S1:2808:8	disord	NN	I-AdverseReaction	I-AdverseReaction
(	POTIGA.xml:S1:2817:1	(	(	O	O
4%	POTIGA.xml:S1:2818:2	4%	CD	O	O
)	POTIGA.xml:S1:2820:1	)	)	O	O
(	POTIGA.xml:S1:2822:1	(	(	O	O
see	POTIGA.xml:S1:2823:3	see	VB	O	O
Table	POTIGA.xml:S1:2827:5	tabl	NNP	O	O
4	POTIGA.xml:S1:2833:1	4	CD	O	O
)	POTIGA.xml:S1:2834:1	)	)	O	O
.	POTIGA.xml:S1:2835:1	.	.	O	O

In	POTIGA.xml:S1:2837:2	In	IN	O	O
most	POTIGA.xml:S1:2840:4	most	JJS	O	O
cases	POTIGA.xml:S1:2845:5	case	NNS	O	O
the	POTIGA.xml:S1:2851:3	the	DT	O	O
reactions	POTIGA.xml:S1:2855:9	reaction	NNS	O	O
were	POTIGA.xml:S1:2865:4	were	VBD	O	O
of	POTIGA.xml:S1:2870:2	of	IN	O	O
mild	POTIGA.xml:S1:2873:4	mild	NN	O	O
or	POTIGA.xml:S1:2878:2	or	CC	O	O
moderate	POTIGA.xml:S1:2881:8	moder	JJ	O	O
intensity	POTIGA.xml:S1:2890:9	intens	NN	O	O
.	POTIGA.xml:S1:2899:1	.	.	O	O

Table	POTIGA.xml:S1:2907:5	tabl	JJ	O	O
4	POTIGA.xml:S1:2913:1	4	CD	O	O
.	POTIGA.xml:S1:2914:1	.	.	O	O

Adverse	POTIGA.xml:S1:2916:7	advers	JJ	O	O
Reactions	POTIGA.xml:S1:2924:9	reaction	NNP	O	O
Incidence	POTIGA.xml:S1:2934:9	incid	NNP	O	O
in	POTIGA.xml:S1:2944:2	in	IN	O	O
Placebo	POTIGA.xml:S1:2947:7	placebo	NNP	O	O
-	POTIGA.xml:S1:2954:1	-	:	O	O
Controlled	POTIGA.xml:S1:2955:10	control	VBD	O	O
Adjunctive	POTIGA.xml:S1:2966:10	adjunct	JJ	O	O
Trials	POTIGA.xml:S1:2977:6	trial	NNS	O	O
in	POTIGA.xml:S1:2984:2	in	IN	O	O
Adult	POTIGA.xml:S1:2987:5	adult	NNP	O	O
Patients	POTIGA.xml:S1:2993:8	patient	NNPS	O	O
with	POTIGA.xml:S1:3002:4	with	IN	O	O
Partial	POTIGA.xml:S1:3007:7	partial	NNP	O	O
-	POTIGA.xml:S1:3014:1	-	:	O	O
Onset	POTIGA.xml:S1:3015:5	onset	NN	O	O
Seizures	POTIGA.xml:S1:3021:8	seizur	NNP	O	O
(	POTIGA.xml:S1:3030:1	(	(	O	O
Adverse	POTIGA.xml:S1:3031:7	advers	JJ	O	O
reactions	POTIGA.xml:S1:3039:9	reaction	NNS	O	O
in	POTIGA.xml:S1:3049:2	in	IN	O	O
at	POTIGA.xml:S1:3052:2	at	IN	O	O
least	POTIGA.xml:S1:3055:5	least	JJS	O	O
2%	POTIGA.xml:S1:3061:2	2%	CD	O	O
of	POTIGA.xml:S1:3064:2	of	IN	O	O
patients	POTIGA.xml:S1:3067:8	patient	NNS	O	O
treated	POTIGA.xml:S1:3076:7	treat	VBN	O	O
with	POTIGA.xml:S1:3084:4	with	IN	O	O
POTIGA	POTIGA.xml:S1:3089:6	potiga	NNP	O	O
in	POTIGA.xml:S1:3096:2	in	IN	O	O
any	POTIGA.xml:S1:3099:3	ani	DT	O	O
treatment	POTIGA.xml:S1:3103:9	treatment	NN	O	O
group	POTIGA.xml:S1:3113:5	group	NN	O	O
and	POTIGA.xml:S1:3119:3	and	CC	O	O
numerically	POTIGA.xml:S1:3123:11	numer	RB	O	O
more	POTIGA.xml:S1:3135:4	more	RBR	O	O
frequent	POTIGA.xml:S1:3140:8	frequent	JJ	O	O
than	POTIGA.xml:S1:3149:4	than	IN	O	O
in	POTIGA.xml:S1:3154:2	in	IN	O	O
the	POTIGA.xml:S1:3157:3	the	DT	O	O
placebo	POTIGA.xml:S1:3161:7	placebo	NN	O	O
group	POTIGA.xml:S1:3169:5	group	NN	O	O
.	POTIGA.xml:S1:3174:1	.	.	O	O
)	POTIGA.xml:S1:3175:1	)	)	O	O

Body	POTIGA.xml:S1:3185:4	bodi	NN	O	O
System	POTIGA.xml:S1:3190:6	system	NNP	O	O
Adverse	POTIGA.xml:S1:3197:7	advers	NNP	O	O
Reaction	POTIGA.xml:S1:3205:8	reaction	NNP	O	O
Placebo	POTIGA.xml:S1:3217:7	placebo	NNP	O	O
POTIGA	POTIGA.xml:S1:3230:6	potiga	NNP	O	O

600	POTIGA.xml:S1:3249:3	600	CD	O	O
mg	POTIGA.xml:S1:3253:2	mg	JJ	O	O
day	POTIGA.xml:S1:3256:3	day	NN	O	O
900	POTIGA.xml:S1:3278:3	900	CD	O	O
mg	POTIGA.xml:S1:3282:2	mg	NN	O	O
day	POTIGA.xml:S1:3285:3	day	NN	O	O
1	POTIGA.xml:S1:3292:1	1	CD	O	O
,	POTIGA.xml:S1:3293:1	,	,	O	O
200	POTIGA.xml:S1:3294:3	200	CD	O	O
mg	POTIGA.xml:S1:3298:2	mg	NNS	O	O
day	POTIGA.xml:S1:3301:3	day	NN	O	O
All	POTIGA.xml:S1:3308:3	all	DT	O	O

(	POTIGA.xml:S1:3327:1	(	(	O	O
N	POTIGA.xml:S1:3328:1	N	NNP	O	O
427	POTIGA.xml:S1:3332:3	427	CD	O	O
)	POTIGA.xml:S1:3335:1	)	)	O	O
(	POTIGA.xml:S1:3356:1	(	(	O	O
n	POTIGA.xml:S1:3357:1	n	$	O	O
281	POTIGA.xml:S1:3361:3	281	CD	O	O
)	POTIGA.xml:S1:3364:1	)	)	O	O
(	POTIGA.xml:S1:3372:1	(	(	O	O
n	POTIGA.xml:S1:3373:1	n	$	O	O
273	POTIGA.xml:S1:3377:3	273	CD	O	O
)	POTIGA.xml:S1:3380:1	)	)	O	O
(	POTIGA.xml:S1:3388:1	(	(	O	O
n	POTIGA.xml:S1:3389:1	n	$	O	O
259	POTIGA.xml:S1:3393:3	259	CD	O	O
)	POTIGA.xml:S1:3396:1	)	)	O	O
(	POTIGA.xml:S1:3404:1	(	(	O	O
N	POTIGA.xml:S1:3405:1	N	NNP	O	O
813	POTIGA.xml:S1:3409:3	813	CD	O	O
)	POTIGA.xml:S1:3412:1	)	)	O	O

Eye	POTIGA.xml:S1:3452:3	eye	NN	O	O

Diplopia	POTIGA.xml:S1:3647:8	diplopia	NN	B-AdverseReaction	O

2	POTIGA.xml:S1:3736:1	2	CD	O	O

8	POTIGA.xml:S1:3749:1	8	CD	O	O
6	POTIGA.xml:S1:3765:1	6	CD	O	O
7	POTIGA.xml:S1:3781:1	7	CD	O	O
7	POTIGA.xml:S1:3798:1	7	CD	O	O

Blurred	POTIGA.xml:S1:3842:7	blur	VBN	B-AdverseReaction	B-AdverseReaction
vision	POTIGA.xml:S1:3850:6	vision	NN	I-AdverseReaction	I-AdverseReaction

2	POTIGA.xml:S1:3931:1	2	CD	O	O
2	POTIGA.xml:S1:3944:1	2	CD	O	O
4	POTIGA.xml:S1:3960:1	4	CD	O	O
10	POTIGA.xml:S1:3976:2	10	CD	O	O
5	POTIGA.xml:S1:3993:1	5	CD	O	O

Gastrointestinal	POTIGA.xml:S1:4037:16	gastrointestin	JJ	O	O

Nausea	POTIGA.xml:S1:4232:6	nausea	NN	B-AdverseReaction	B-AdverseReaction

5	POTIGA.xml:S1:4321:1	5	CD	O	O

6	POTIGA.xml:S1:4334:1	6	CD	O	O
6	POTIGA.xml:S1:4350:1	6	CD	O	O
9	POTIGA.xml:S1:4366:1	9	CD	O	O
7	POTIGA.xml:S1:4383:1	7	CD	O	O

Constipation	POTIGA.xml:S1:4427:12	constip	NN	B-AdverseReaction	B-AdverseReaction

1	POTIGA.xml:S1:4516:1	1	CD	O	O
1	POTIGA.xml:S1:4529:1	1	CD	O	O
4	POTIGA.xml:S1:4545:1	4	CD	O	O
5	POTIGA.xml:S1:4561:1	5	CD	O	O
3	POTIGA.xml:S1:4578:1	3	CD	O	O

Dyspepsia	POTIGA.xml:S1:4622:9	dyspepsia	NN	B-AdverseReaction	O

2	POTIGA.xml:S1:4711:1	2	CD	O	O
3	POTIGA.xml:S1:4724:1	3	CD	O	O
2	POTIGA.xml:S1:4740:1	2	CD	O	O
3	POTIGA.xml:S1:4756:1	3	CD	O	O
2	POTIGA.xml:S1:4773:1	2	CD	O	O

General	POTIGA.xml:S1:4817:7	gener	NNP	O	O

Fatigue	POTIGA.xml:S1:5012:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction

6	POTIGA.xml:S1:5101:1	6	CD	O	O

16	POTIGA.xml:S1:5114:2	16	CD	O	O
15	POTIGA.xml:S1:5130:2	15	CD	O	O
13	POTIGA.xml:S1:5146:2	13	CD	O	O
15	POTIGA.xml:S1:5163:2	15	CD	O	O

Asthenia	POTIGA.xml:S1:5207:8	asthenia	NNP	B-AdverseReaction	O

2	POTIGA.xml:S1:5296:1	2	CD	O	O
4	POTIGA.xml:S1:5309:1	4	CD	O	O
6	POTIGA.xml:S1:5325:1	6	CD	O	O
4	POTIGA.xml:S1:5341:1	4	CD	O	O
5	POTIGA.xml:S1:5358:1	5	CD	O	O

Infections	POTIGA.xml:S1:5402:10	infect	NNS	O	O
and	POTIGA.xml:S1:5413:3	and	CC	O	O
infestations	POTIGA.xml:S1:5417:12	infest	NNS	O	O

Influenza	POTIGA.xml:S1:5597:9	influenza	NN	B-AdverseReaction	B-AdverseReaction

2	POTIGA.xml:S1:5686:1	2	CD	O	O

4	POTIGA.xml:S1:5699:1	4	CD	O	O
1	POTIGA.xml:S1:5715:1	1	CD	O	O
5	POTIGA.xml:S1:5731:1	5	CD	O	O
3	POTIGA.xml:S1:5748:1	3	CD	O	O

Investigations	POTIGA.xml:S1:5792:14	investig	NNS	O	O

Weight	POTIGA.xml:S1:5987:6	weight	NN	B-AdverseReaction	O

increased	POTIGA.xml:S1:5994:9	increas	VBN	I-AdverseReaction	O

1	POTIGA.xml:S1:6076:1	1	CD	O	O
2	POTIGA.xml:S1:6089:1	2	CD	O	O
3	POTIGA.xml:S1:6105:1	3	CD	O	O
3	POTIGA.xml:S1:6121:1	3	CD	O	O
3	POTIGA.xml:S1:6138:1	3	CD	O	O

Nervous	POTIGA.xml:S1:6182:7	nervou	JJ	O	O
system	POTIGA.xml:S1:6190:6	system	NN	O	O

Dizziness	POTIGA.xml:S1:6377:9	dizzi	NN	B-AdverseReaction	O

9	POTIGA.xml:S1:6466:1	9	CD	O	O

15	POTIGA.xml:S1:6479:2	15	CD	O	O
23	POTIGA.xml:S1:6495:2	23	CD	O	O
32	POTIGA.xml:S1:6511:2	32	CD	O	O
23	POTIGA.xml:S1:6528:2	23	CD	O	O

Somnolence	POTIGA.xml:S1:6572:10	somnol	NN	B-AdverseReaction	O

12	POTIGA.xml:S1:6661:2	12	CD	O	O
15	POTIGA.xml:S1:6674:2	15	CD	O	O
25	POTIGA.xml:S1:6690:2	25	CD	O	O
27	POTIGA.xml:S1:6706:2	27	CD	O	O
22	POTIGA.xml:S1:6723:2	22	CD	O	O

Memory	POTIGA.xml:S1:6767:6	memori	NN	B-AdverseReaction	O
impairment	POTIGA.xml:S1:6774:10	impair	NN	I-AdverseReaction	O

3	POTIGA.xml:S1:6856:1	3	CD	O	O
3	POTIGA.xml:S1:6869:1	3	CD	O	O
6	POTIGA.xml:S1:6885:1	6	CD	O	O
9	POTIGA.xml:S1:6901:1	9	CD	O	O
6	POTIGA.xml:S1:6918:1	6	CD	O	O

Tremor	POTIGA.xml:S1:6962:6	tremor	NN	B-AdverseReaction	B-AdverseReaction

3	POTIGA.xml:S1:7051:1	3	CD	O	O
3	POTIGA.xml:S1:7064:1	3	CD	O	O
10	POTIGA.xml:S1:7080:2	10	CD	O	O
12	POTIGA.xml:S1:7096:2	12	CD	O	O
8	POTIGA.xml:S1:7113:1	8	CD	O	O

Vertigo	POTIGA.xml:S1:7157:7	vertigo	NN	B-AdverseReaction	O

2	POTIGA.xml:S1:7246:1	2	CD	O	O
8	POTIGA.xml:S1:7259:1	8	CD	O	O
8	POTIGA.xml:S1:7275:1	8	CD	O	O
9	POTIGA.xml:S1:7291:1	9	CD	O	O
8	POTIGA.xml:S1:7308:1	8	CD	O	O

Abnormal	POTIGA.xml:S1:7352:8	abnorm	JJ	B-AdverseReaction	O
coordination	POTIGA.xml:S1:7361:12	coordin	NN	I-AdverseReaction	O

3	POTIGA.xml:S1:7441:1	3	CD	O	O
5	POTIGA.xml:S1:7454:1	5	CD	O	O
5	POTIGA.xml:S1:7470:1	5	CD	O	O
12	POTIGA.xml:S1:7486:2	12	CD	O	O
7	POTIGA.xml:S1:7503:1	7	CD	O	O

Disturbance	POTIGA.xml:S1:7547:11	disturb	NN	B-AdverseReaction	O
in	POTIGA.xml:S1:7559:2	in	IN	I-AdverseReaction	O
attention	POTIGA.xml:S1:7562:9	attent	NN	I-AdverseReaction	O

1	POTIGA.xml:S1:7637:1	1	CD	O	O
6	POTIGA.xml:S1:7649:1	6	CD	O	O
6	POTIGA.xml:S1:7665:1	6	CD	O	O
7	POTIGA.xml:S1:7681:1	7	CD	O	O
6	POTIGA.xml:S1:7698:1	6	CD	O	O

Gait	POTIGA.xml:S1:7742:4	gait	NNP	B-AdverseReaction	O
disturbance	POTIGA.xml:S1:7747:11	disturb	NN	I-AdverseReaction	O

1	POTIGA.xml:S1:7831:1	1	CD	O	O
2	POTIGA.xml:S1:7844:1	2	CD	O	O
5	POTIGA.xml:S1:7860:1	5	CD	O	O
6	POTIGA.xml:S1:7876:1	6	CD	O	O
4	POTIGA.xml:S1:7893:1	4	CD	O	O

Aphasia	POTIGA.xml:S1:7937:7	aphasia	NN	B-AdverseReaction	O

1	POTIGA.xml:S1:8027:1	1	CD	O	O
1	POTIGA.xml:S1:8039:1	1	CD	O	O
3	POTIGA.xml:S1:8055:1	3	CD	O	O
7	POTIGA.xml:S1:8071:1	7	CD	O	O
4	POTIGA.xml:S1:8088:1	4	CD	O	O

Dysarthria	POTIGA.xml:S1:8132:10	dysarthria	NNS	B-AdverseReaction	O

1	POTIGA.xml:S1:8222:1	1	CD	O	O
4	POTIGA.xml:S1:8234:1	4	CD	O	O
2	POTIGA.xml:S1:8250:1	2	CD	O	O
8	POTIGA.xml:S1:8266:1	8	CD	O	O
4	POTIGA.xml:S1:8283:1	4	CD	O	O

Balance	POTIGA.xml:S1:8327:7	balanc	NN	B-AdverseReaction	B-AdverseReaction
disorder	POTIGA.xml:S1:8335:8	disord	NN	I-AdverseReaction	I-AdverseReaction

1	POTIGA.xml:S1:8417:1	1	CD	O	O
3	POTIGA.xml:S1:8429:1	3	CD	O	O
3	POTIGA.xml:S1:8445:1	3	CD	O	O
5	POTIGA.xml:S1:8461:1	5	CD	O	O
4	POTIGA.xml:S1:8478:1	4	CD	O	O

Paresthesia	POTIGA.xml:S1:8522:11	paresthesia	NN	B-AdverseReaction	O

2	POTIGA.xml:S1:8611:1	2	CD	O	O
3	POTIGA.xml:S1:8624:1	3	CD	O	O
2	POTIGA.xml:S1:8640:1	2	CD	O	O
5	POTIGA.xml:S1:8656:1	5	CD	O	O
3	POTIGA.xml:S1:8673:1	3	CD	O	O

Amnesia	POTIGA.xml:S1:8717:7	amnesia	NN	B-AdverseReaction	O

1	POTIGA.xml:S1:8807:1	1	CD	O	O
1	POTIGA.xml:S1:8820:1	1	CD	O	O
3	POTIGA.xml:S1:8835:1	3	CD	O	O
3	POTIGA.xml:S1:8851:1	3	CD	O	O
2	POTIGA.xml:S1:8868:1	2	CD	O	O

Dysphasia	POTIGA.xml:S1:8912:9	dysphasia	NN	B-AdverseReaction	O

1	POTIGA.xml:S1:9002:1	1	CD	O	O
1	POTIGA.xml:S1:9014:1	1	CD	O	O
1	POTIGA.xml:S1:9030:1	1	CD	O	O
3	POTIGA.xml:S1:9046:1	3	CD	O	O
2	POTIGA.xml:S1:9063:1	2	CD	O	O

Psychiatric	POTIGA.xml:S1:9107:11	psychiatr	JJ	O	O

Confusional	POTIGA.xml:S1:9302:11	confusion	JJ	B-AdverseReaction	O

state	POTIGA.xml:S1:9314:5	state	NN	I-AdverseReaction	O

3	POTIGA.xml:S1:9391:1	3	CD	O	O
4	POTIGA.xml:S1:9404:1	4	CD	O	O
8	POTIGA.xml:S1:9420:1	8	CD	O	O
16	POTIGA.xml:S1:9436:2	16	CD	O	O
9	POTIGA.xml:S1:9453:1	9	CD	O	O

Anxiety	POTIGA.xml:S1:9497:7	anxieti	NN	B-AdverseReaction	O

2	POTIGA.xml:S1:9586:1	2	CD	O	O
3	POTIGA.xml:S1:9599:1	3	CD	O	O
2	POTIGA.xml:S1:9615:1	2	CD	O	O
5	POTIGA.xml:S1:9631:1	5	CD	O	O
3	POTIGA.xml:S1:9648:1	3	CD	O	O

Disorientation	POTIGA.xml:S1:9692:14	disorient	NN	B-AdverseReaction	O

1	POTIGA.xml:S1:9782:1	1	CD	O	O
1	POTIGA.xml:S1:9795:1	1	CD	O	O
1	POTIGA.xml:S1:9811:1	1	CD	O	O
5	POTIGA.xml:S1:9826:1	5	CD	O	O
2	POTIGA.xml:S1:9843:1	2	CD	O	O

Psychotic	POTIGA.xml:S1:9887:9	psychot	JJ	B-AdverseReaction	O
disorder	POTIGA.xml:S1:9897:8	disord	NN	I-AdverseReaction	O

0	POTIGA.xml:S1:9976:1	0	CD	O	O
0	POTIGA.xml:S1:9989:1	0	CD	O	O
1	POTIGA.xml:S1:10006:1	1	CD	O	O
2	POTIGA.xml:S1:10021:1	2	CD	O	O
1	POTIGA.xml:S1:10039:1	1	CD	O	O

Renal	POTIGA.xml:S1:10082:5	renal	NNP	O	O
and	POTIGA.xml:S1:10088:3	and	CC	O	O
urinary	POTIGA.xml:S1:10092:7	urinari	JJ	O	O

Dysuria	POTIGA.xml:S1:10277:7	dysuria	NNS	B-AdverseReaction	O

1	POTIGA.xml:S1:10367:1	1	CD	O	O

1	POTIGA.xml:S1:10379:1	1	CD	O	O
2	POTIGA.xml:S1:10395:1	2	CD	O	O
4	POTIGA.xml:S1:10411:1	4	CD	O	O
2	POTIGA.xml:S1:10428:1	2	CD	O	O

Urinary	POTIGA.xml:S1:10472:7	urinari	JJ	B-AdverseReaction	O
hesitation	POTIGA.xml:S1:10480:10	hesit	NN	I-AdverseReaction	O

1	POTIGA.xml:S1:10562:1	1	CD	O	O
2	POTIGA.xml:S1:10574:1	2	CD	O	O
1	POTIGA.xml:S1:10590:1	1	CD	O	O
4	POTIGA.xml:S1:10606:1	4	CD	O	O
2	POTIGA.xml:S1:10623:1	2	CD	O	O

Hematuria	POTIGA.xml:S1:10667:9	hematuria	NNS	B-AdverseReaction	O

1	POTIGA.xml:S1:10757:1	1	CD	O	O
2	POTIGA.xml:S1:10769:1	2	CD	O	O
1	POTIGA.xml:S1:10785:1	1	CD	O	O
2	POTIGA.xml:S1:10801:1	2	CD	O	O
2	POTIGA.xml:S1:10818:1	2	CD	O	O

Chromaturia	POTIGA.xml:S1:10862:11	chromaturia	NNS	B-AdverseReaction	B-AdverseReaction

1	POTIGA.xml:S1:10952:1	1	CD	O	O
1	POTIGA.xml:S1:10965:1	1	CD	O	O
2	POTIGA.xml:S1:10980:1	2	CD	O	O
3	POTIGA.xml:S1:10996:1	3	CD	O	O
2	POTIGA.xml:S1:11013:1	2	CD	O	O

Other	POTIGA.xml:S1:11039:5	other	JJ	O	O
adverse	POTIGA.xml:S1:11045:7	advers	JJ	O	O
reactions	POTIGA.xml:S1:11053:9	reaction	NNS	O	O
reported	POTIGA.xml:S1:11063:8	report	VBN	O	O
in	POTIGA.xml:S1:11072:2	in	IN	O	O
these	POTIGA.xml:S1:11075:5	these	DT	O	O
3	POTIGA.xml:S1:11081:1	3	CD	O	O
studies	POTIGA.xml:S1:11083:7	studi	NNS	O	O
in	POTIGA.xml:S1:11091:2	in	IN	O	O
2%	POTIGA.xml:S1:11095:2	2%	CD	O	O
of	POTIGA.xml:S1:11098:2	of	IN	O	O
patients	POTIGA.xml:S1:11101:8	patient	NNS	O	O
treated	POTIGA.xml:S1:11110:7	treat	VBN	O	O
with	POTIGA.xml:S1:11118:4	with	IN	O	O
POTIGA	POTIGA.xml:S1:11123:6	potiga	NNP	O	O
and	POTIGA.xml:S1:11130:3	and	CC	O	O
numerically	POTIGA.xml:S1:11134:11	numer	RB	O	O
greater	POTIGA.xml:S1:11146:7	greater	JJR	O	O
than	POTIGA.xml:S1:11154:4	than	IN	O	O
placebo	POTIGA.xml:S1:11159:7	placebo	NN	O	O
were	POTIGA.xml:S1:11167:4	were	VBD	O	O
increased	POTIGA.xml:S1:11172:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	POTIGA.xml:S1:11182:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:11190:1	,	,	O	O
hallucinations	POTIGA.xml:S1:11192:14	hallucin	NNS	B-AdverseReaction	O
,	POTIGA.xml:S1:11206:1	,	,	O	O
myoclonus	POTIGA.xml:S1:11208:9	myoclonu	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:11217:1	,	,	O	O
peripheral	POTIGA.xml:S1:11219:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
edema	POTIGA.xml:S1:11230:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:11235:1	,	,	O	O
hypokinesia	POTIGA.xml:S1:11237:11	hypokinesia	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:11248:1	,	,	O	O
dry	POTIGA.xml:S1:11250:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	POTIGA.xml:S1:11254:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:11259:1	,	,	O	O
dysphagia	POTIGA.xml:S1:11261:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:11270:1	,	,	O	O
hyperhydrosis	POTIGA.xml:S1:11272:13	hyperhydrosi	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:11285:1	,	,	O	O
urinary	POTIGA.xml:S1:11287:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
retention	POTIGA.xml:S1:11295:9	retent	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:11304:1	,	,	O	O
malaise	POTIGA.xml:S1:11306:7	malais	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:11313:1	,	,	O	O
and	POTIGA.xml:S1:11315:3	and	CC	O	O
increased	POTIGA.xml:S1:11319:9	increas	VBD	B-AdverseReaction	O
liver	POTIGA.xml:S1:11329:5	liver	RB	I-AdverseReaction	O
enzymes	POTIGA.xml:S1:11335:7	enzym	RB	I-AdverseReaction	O
.	POTIGA.xml:S1:11342:1	.	.	O	O

Most	POTIGA.xml:S1:11348:4	most	JJS	O	O

of	POTIGA.xml:S1:11353:2	of	IN	O	O
the	POTIGA.xml:S1:11356:3	the	DT	O	O
adverse	POTIGA.xml:S1:11360:7	advers	JJ	O	O
reactions	POTIGA.xml:S1:11368:9	reaction	NNS	O	O
appear	POTIGA.xml:S1:11378:6	appear	VBP	O	O
to	POTIGA.xml:S1:11385:2	to	TO	O	O
be	POTIGA.xml:S1:11388:2	be	VB	O	O
dose	POTIGA.xml:S1:11391:4	dose	RB	O	O
related	POTIGA.xml:S1:11396:7	relat	VBN	O	O
(	POTIGA.xml:S1:11404:1	(	(	O	O
especially	POTIGA.xml:S1:11405:10	especi	RB	O	O
those	POTIGA.xml:S1:11416:5	those	DT	O	O
classified	POTIGA.xml:S1:11422:10	classifi	VBN	O	O
as	POTIGA.xml:S1:11433:2	as	IN	O	O
psychiatric	POTIGA.xml:S1:11436:11	psychiatr	JJ	O	O
and	POTIGA.xml:S1:11448:3	and	CC	O	O
nervous	POTIGA.xml:S1:11452:7	nervou	JJ	O	O
system	POTIGA.xml:S1:11460:6	system	NN	O	O
symptoms	POTIGA.xml:S1:11467:8	symptom	NNS	O	O
)	POTIGA.xml:S1:11475:1	)	)	O	O
,	POTIGA.xml:S1:11476:1	,	,	O	O
including	POTIGA.xml:S1:11478:9	includ	VBG	O	O
dizziness	POTIGA.xml:S1:11488:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:11497:1	,	,	O	O
somnolence	POTIGA.xml:S1:11499:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:11509:1	,	,	O	O
confusional	POTIGA.xml:S1:11511:11	confusion	JJ	B-AdverseReaction	B-AdverseReaction
state	POTIGA.xml:S1:11523:5	state	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:11528:1	,	,	O	O
tremor	POTIGA.xml:S1:11530:6	tremor	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:11536:1	,	,	O	O
abnormal	POTIGA.xml:S1:11538:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
coordination	POTIGA.xml:S1:11547:12	coordin	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:11559:1	,	,	O	O
memory	POTIGA.xml:S1:11561:6	memori	NN	B-AdverseReaction	B-AdverseReaction
impairment	POTIGA.xml:S1:11568:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:11578:1	,	,	O	O
blurred	POTIGA.xml:S1:11580:7	blur	VBN	B-AdverseReaction	B-AdverseReaction
vision	POTIGA.xml:S1:11588:6	vision	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:11594:1	,	,	O	O
gait	POTIGA.xml:S1:11596:4	gait	NN	B-AdverseReaction	B-AdverseReaction
disturbance	POTIGA.xml:S1:11601:11	disturb	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:11612:1	,	,	O	O
aphasia	POTIGA.xml:S1:11614:7	aphasia	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:11621:1	,	,	O	O
balance	POTIGA.xml:S1:11623:7	balanc	NN	B-AdverseReaction	B-AdverseReaction
disorder	POTIGA.xml:S1:11631:8	disord	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:11639:1	,	,	O	O
constipation	POTIGA.xml:S1:11641:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:11653:1	,	,	O	O
dysuria	POTIGA.xml:S1:11655:7	dysuria	NN	B-AdverseReaction	O
,	POTIGA.xml:S1:11662:1	,	,	O	O
and	POTIGA.xml:S1:11664:3	and	CC	O	O
chromaturia	POTIGA.xml:S1:11668:11	chromaturia	NNS	B-AdverseReaction	B-AdverseReaction
.	POTIGA.xml:S1:11679:1	.	.	O	O

POTIGA	POTIGA.xml:S1:11685:6	potiga	NNP	O	O
was	POTIGA.xml:S1:11692:3	wa	VBD	O	O
associated	POTIGA.xml:S1:11696:10	associ	VBN	O	O
with	POTIGA.xml:S1:11707:4	with	IN	O	O
dose	POTIGA.xml:S1:11712:4	dose	JJ	O	O
-	POTIGA.xml:S1:11716:1	-	:	O	O
related	POTIGA.xml:S1:11717:7	relat	JJ	O	O
weight	POTIGA.xml:S1:11725:6	weight	NN	B-AdverseReaction	O
gain	POTIGA.xml:S1:11732:4	gain	NN	I-AdverseReaction	O
,	POTIGA.xml:S1:11736:1	,	,	O	O
with	POTIGA.xml:S1:11738:4	with	IN	O	O
mean	POTIGA.xml:S1:11743:4	mean	JJ	O	O
weight	POTIGA.xml:S1:11748:6	weight	NN	B-AdverseReaction	O
increasing	POTIGA.xml:S1:11755:10	increas	VBG	I-AdverseReaction	O
by	POTIGA.xml:S1:11766:2	by	IN	O	O
0.2	POTIGA.xml:S1:11769:3	0.2	CD	O	O
kg	POTIGA.xml:S1:11773:2	kg	NNS	O	O
,	POTIGA.xml:S1:11775:1	,	,	O	O
1.2	POTIGA.xml:S1:11777:3	1.2	CD	O	O
kg	POTIGA.xml:S1:11781:2	kg	NN	O	O
,	POTIGA.xml:S1:11783:1	,	,	O	O
1.6	POTIGA.xml:S1:11785:3	1.6	CD	O	O
kg	POTIGA.xml:S1:11789:2	kg	NN	O	O
,	POTIGA.xml:S1:11791:1	,	,	O	O
and	POTIGA.xml:S1:11793:3	and	CC	O	O
2.7	POTIGA.xml:S1:11797:3	2.7	CD	O	O
kg	POTIGA.xml:S1:11801:2	kg	NN	O	O
in	POTIGA.xml:S1:11804:2	in	IN	O	O
the	POTIGA.xml:S1:11807:3	the	DT	O	O
placebo	POTIGA.xml:S1:11811:7	placebo	NN	O	O
,	POTIGA.xml:S1:11818:1	,	,	O	O
600	POTIGA.xml:S1:11820:3	600	CD	O	O
mg	POTIGA.xml:S1:11824:2	mg	NNS	O	O
per	POTIGA.xml:S1:11827:3	per	IN	O	O
day	POTIGA.xml:S1:11831:3	day	NN	O	O
,	POTIGA.xml:S1:11834:1	,	,	O	O
900	POTIGA.xml:S1:11836:3	900	CD	O	O
mg	POTIGA.xml:S1:11840:2	mg	NNS	O	O
per	POTIGA.xml:S1:11843:3	per	IN	O	O
day	POTIGA.xml:S1:11847:3	day	NN	O	O
,	POTIGA.xml:S1:11850:1	,	,	O	O
and	POTIGA.xml:S1:11852:3	and	CC	O	O
1	POTIGA.xml:S1:11856:1	1	CD	O	O
,	POTIGA.xml:S1:11857:1	,	,	O	O
200	POTIGA.xml:S1:11858:3	200	CD	O	O
mg	POTIGA.xml:S1:11862:2	mg	NNS	O	O
per	POTIGA.xml:S1:11865:3	per	IN	O	O
day	POTIGA.xml:S1:11869:3	day	NN	O	O
groups	POTIGA.xml:S1:11873:6	group	NNS	O	O
,	POTIGA.xml:S1:11879:1	,	,	O	O
respectively	POTIGA.xml:S1:11881:12	respect	RB	O	O
.	POTIGA.xml:S1:11893:1	.	.	O	O

Additional	POTIGA.xml:S1:11901:10	addit	JJ	O	O
Adverse	POTIGA.xml:S1:11912:7	advers	NNP	O	O
Reactions	POTIGA.xml:S1:11920:9	reaction	NNP	O	O
Observed	POTIGA.xml:S1:11930:8	observ	NNP	O	O
during	POTIGA.xml:S1:11939:6	dure	IN	O	O
All	POTIGA.xml:S1:11946:3	all	NNP	O	O
Phase	POTIGA.xml:S1:11950:5	phase	NNP	O	O
2	POTIGA.xml:S1:11956:1	2	CD	O	O
and	POTIGA.xml:S1:11958:3	and	CC	O	O
3	POTIGA.xml:S1:11962:1	3	CD	O	O
Clinical	POTIGA.xml:S1:11964:8	clinic	JJ	O	O
Trials	POTIGA.xml:S1:11973:6	trial	NNS	O	O

Following	POTIGA.xml:S1:11986:9	follow	VBG	O	O
is	POTIGA.xml:S1:11996:2	is	VBZ	O	O
a	POTIGA.xml:S1:11999:1	a	DT	O	O
list	POTIGA.xml:S1:12001:4	list	NN	O	O
of	POTIGA.xml:S1:12006:2	of	IN	O	O
adverse	POTIGA.xml:S1:12009:7	advers	JJ	O	O
reactions	POTIGA.xml:S1:12017:9	reaction	NNS	O	O
reported	POTIGA.xml:S1:12027:8	report	VBN	O	O
by	POTIGA.xml:S1:12036:2	by	IN	O	O
patients	POTIGA.xml:S1:12039:8	patient	NNS	O	O
treated	POTIGA.xml:S1:12048:7	treat	VBN	O	O
with	POTIGA.xml:S1:12056:4	with	IN	O	O
POTIGA	POTIGA.xml:S1:12061:6	potiga	NNP	O	O
during	POTIGA.xml:S1:12068:6	dure	IN	O	O
all	POTIGA.xml:S1:12075:3	all	DT	O	O
clinical	POTIGA.xml:S1:12079:8	clinic	JJ	O	O
trials	POTIGA.xml:S1:12088:6	trial	NNS	O	O
:	POTIGA.xml:S1:12094:1	:	:	O	O
rash	POTIGA.xml:S1:12096:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:12100:1	,	,	O	O
nystagmus	POTIGA.xml:S1:12102:9	nystagmu	RB	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:12111:1	,	,	O	O
dyspnea	POTIGA.xml:S1:12113:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:12120:1	,	,	O	O
leukopenia	POTIGA.xml:S1:12122:10	leukopenia	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:12132:1	,	,	O	O
muscle	POTIGA.xml:S1:12134:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
spasms	POTIGA.xml:S1:12141:6	spasm	NNS	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:12147:1	,	,	O	O
alopecia	POTIGA.xml:S1:12149:8	alopecia	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:12157:1	,	,	O	O
nephrolithiasis	POTIGA.xml:S1:12159:15	nephrolithiasi	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:12174:1	,	,	O	O
syncope	POTIGA.xml:S1:12176:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:12183:1	,	,	O	O
neutropenia	POTIGA.xml:S1:12185:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:12196:1	,	,	O	O
thrombocytopenia	POTIGA.xml:S1:12198:16	thrombocytopenia	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:12214:1	,	,	O	O
euphoric	POTIGA.xml:S1:12216:8	euphor	JJ	B-AdverseReaction	B-AdverseReaction
mood	POTIGA.xml:S1:12225:4	mood	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:12229:1	,	,	O	O
renal	POTIGA.xml:S1:12231:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
colic	POTIGA.xml:S1:12237:5	colic	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S1:12242:1	,	,	O	O
coma	POTIGA.xml:S1:12244:4	coma	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S1:12248:1	,	,	O	O
encephalopathy	POTIGA.xml:S1:12250:14	encephalopathi	NN	B-AdverseReaction	O
.	POTIGA.xml:S1:12264:1	.	.	O	O

Comparison	POTIGA.xml:S1:12272:10	comparison	NNP	O	O
of	POTIGA.xml:S1:12283:2	of	IN	O	O
Gender	POTIGA.xml:S1:12286:6	gender	NNP	O	O
,	POTIGA.xml:S1:12292:1	,	,	O	O
Age	POTIGA.xml:S1:12294:3	age	NNP	O	O
,	POTIGA.xml:S1:12297:1	,	,	O	O
and	POTIGA.xml:S1:12299:3	and	CC	O	O
Race	POTIGA.xml:S1:12303:4	race	NNP	O	O

The	POTIGA.xml:S1:12314:3	the	DT	O	O
overall	POTIGA.xml:S1:12318:7	overal	JJ	O	O
adverse	POTIGA.xml:S1:12326:7	advers	JJ	O	O
reaction	POTIGA.xml:S1:12334:8	reaction	NN	O	O
profile	POTIGA.xml:S1:12343:7	profil	NN	O	O
of	POTIGA.xml:S1:12351:2	of	IN	O	O
POTIGA	POTIGA.xml:S1:12354:6	potiga	NNP	O	O
was	POTIGA.xml:S1:12361:3	wa	VBD	O	O
similar	POTIGA.xml:S1:12365:7	similar	JJ	O	O
for	POTIGA.xml:S1:12373:3	for	IN	O	O
females	POTIGA.xml:S1:12377:7	femal	NNS	O	O
and	POTIGA.xml:S1:12385:3	and	CC	O	O
males	POTIGA.xml:S1:12389:5	male	NNS	O	O
.	POTIGA.xml:S1:12394:1	.	.	O	O

There	POTIGA.xml:S1:12400:5	there	EX	O	O
are	POTIGA.xml:S1:12406:3	are	VBP	O	O
insufficient	POTIGA.xml:S1:12410:12	insuffici	JJ	O	O
data	POTIGA.xml:S1:12423:4	data	NNS	O	O
to	POTIGA.xml:S1:12428:2	to	TO	O	O
support	POTIGA.xml:S1:12431:7	support	VB	O	O
meaningful	POTIGA.xml:S1:12439:10	meaning	JJ	O	O
analyses	POTIGA.xml:S1:12450:8	analys	NNS	O	O
of	POTIGA.xml:S1:12459:2	of	IN	O	O
adverse	POTIGA.xml:S1:12462:7	advers	JJ	O	O
reactions	POTIGA.xml:S1:12470:9	reaction	NNS	O	O
by	POTIGA.xml:S1:12480:2	by	IN	O	O
age	POTIGA.xml:S1:12483:3	age	NN	O	O
or	POTIGA.xml:S1:12487:2	or	CC	O	O
race	POTIGA.xml:S1:12490:4	race	NN	O	O
.	POTIGA.xml:S1:12494:1	.	.	O	O

Approximately	POTIGA.xml:S1:12496:13	approxim	RB	O	O
86%	POTIGA.xml:S1:12510:3	86%	CD	O	O
of	POTIGA.xml:S1:12514:2	of	IN	O	O
the	POTIGA.xml:S1:12517:3	the	DT	O	O
population	POTIGA.xml:S1:12521:10	popul	NN	O	O
studied	POTIGA.xml:S1:12532:7	studi	VBD	O	O
was	POTIGA.xml:S1:12540:3	wa	VBD	O	O
Caucasian	POTIGA.xml:S1:12544:9	caucasian	JJ	O	O
,	POTIGA.xml:S1:12553:1	,	,	O	O
and	POTIGA.xml:S1:12555:3	and	CC	O	O
0.8%	POTIGA.xml:S1:12559:4	0.8%	CD	O	O
of	POTIGA.xml:S1:12564:2	of	IN	O	O
the	POTIGA.xml:S1:12567:3	the	DT	O	O
population	POTIGA.xml:S1:12571:10	popul	NN	O	O
was	POTIGA.xml:S1:12582:3	wa	VBD	O	O
aged	POTIGA.xml:S1:12586:4	age	VBN	O	O
65	POTIGA.xml:S1:12591:2	65	CD	O	O
years	POTIGA.xml:S1:12594:5	year	NNS	O	O
or	POTIGA.xml:S1:12600:2	or	CC	O	O
older	POTIGA.xml:S1:12603:5	older	JJR	O	O
.	POTIGA.xml:S1:12608:1	.	.	O	O
\n\n	POTIGA.xml:S2:0:2	\n\n	VB	O	O
BOXED	POTIGA.xml:S2:6:5	box	NNP	O	O
WARNING	POTIGA.xml:S2:12:7	warn	NNP	O	O
:	POTIGA.xml:S2:19:1	:	:	O	O
WARNING	POTIGA.xml:S2:21:7	warn	NN	O	O
:	POTIGA.xml:S2:28:1	:	:	O	O
RETINAL	POTIGA.xml:S2:30:7	retin	JJ	B-AdverseReaction	O
ABNORMALITIES	POTIGA.xml:S2:38:13	abnorm	NNP	I-AdverseReaction	O
AND	POTIGA.xml:S2:52:3	and	NNP	O	O
POTENTIAL	POTIGA.xml:S2:56:9	potenti	NNP	O	O
VISION	POTIGA.xml:S2:66:6	vision	NNP	B-AdverseReaction	O
LOSS	POTIGA.xml:S2:73:4	loss	NNP	I-AdverseReaction	O
\n\n	POTIGA.xml:S2:77:2	\n\n	NNP	O	O
WARNING	POTIGA.xml:S2:81:7	warn	NNP	O	O
:	POTIGA.xml:S2:88:1	:	:	O	O
RETINAL	POTIGA.xml:S2:90:7	retin	JJ	B-AdverseReaction	O
ABNORMALITIES	POTIGA.xml:S2:98:13	abnorm	NNP	I-AdverseReaction	O
AND	POTIGA.xml:S2:112:3	and	NNP	O	O
POTENTIAL	POTIGA.xml:S2:116:9	potenti	NNP	O	O
VISION	POTIGA.xml:S2:126:6	vision	NNP	B-AdverseReaction	O
LOSS	POTIGA.xml:S2:133:4	loss	NNP	I-AdverseReaction	O
\n\n	POTIGA.xml:S2:137:2	\n\n	NNP	O	O
POTIGA	POTIGA.xml:S2:143:6	potiga	NNP	O	O
can	POTIGA.xml:S2:150:3	can	MD	O	O
cause	POTIGA.xml:S2:154:5	caus	VB	O	O
retinal	POTIGA.xml:S2:160:7	retin	JJ	B-AdverseReaction	B-AdverseReaction
abnormalities	POTIGA.xml:S2:168:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
with	POTIGA.xml:S2:182:4	with	IN	O	O
funduscopic	POTIGA.xml:S2:187:11	funduscop	NN	O	O
features	POTIGA.xml:S2:199:8	featur	NNS	O	O
similar	POTIGA.xml:S2:208:7	similar	JJ	I-AdverseReaction	O
to	POTIGA.xml:S2:216:2	to	TO	I-AdverseReaction	O
those	POTIGA.xml:S2:219:5	those	DT	O	O
seen	POTIGA.xml:S2:225:4	seen	VBN	O	O
in	POTIGA.xml:S2:230:2	in	IN	O	O
retinal	POTIGA.xml:S2:233:7	retin	JJ	I-AdverseReaction	O
pigment	POTIGA.xml:S2:241:7	pigment	NN	I-AdverseReaction	O
dystrophies	POTIGA.xml:S2:249:11	dystrophi	NNS	I-AdverseReaction	O
,	POTIGA.xml:S2:260:1	,	,	O	O
which	POTIGA.xml:S2:262:5	which	WDT	O	O
are	POTIGA.xml:S2:268:3	are	VBP	O	O
known	POTIGA.xml:S2:272:5	known	VBN	O	O
to	POTIGA.xml:S2:278:2	to	TO	O	O
result	POTIGA.xml:S2:281:6	result	VB	O	O
in	POTIGA.xml:S2:288:2	in	IN	O	O
damage	POTIGA.xml:S2:291:6	damag	NN	B-AdverseReaction	O
to	POTIGA.xml:S2:298:2	to	TO	I-AdverseReaction	O
the	POTIGA.xml:S2:301:3	the	DT	I-AdverseReaction	O
photoreceptors	POTIGA.xml:S2:305:14	photoreceptor	NNS	I-AdverseReaction	O
and	POTIGA.xml:S2:320:3	and	CC	O	O
vision	POTIGA.xml:S2:324:6	vision	NN	B-AdverseReaction	O
loss	POTIGA.xml:S2:331:4	loss	NN	I-AdverseReaction	O
.	POTIGA.xml:S2:335:1	.	.	O	O

Some	POTIGA.xml:S2:345:4	some	DT	O	O
patients	POTIGA.xml:S2:350:8	patient	NNS	O	O
with	POTIGA.xml:S2:359:4	with	IN	O	O
retinal	POTIGA.xml:S2:364:7	retin	JJ	B-AdverseReaction	O
abnormalities	POTIGA.xml:S2:372:13	abnorm	NNS	I-AdverseReaction	O
have	POTIGA.xml:S2:386:4	have	VBP	O	O
been	POTIGA.xml:S2:391:4	been	VBN	O	O
found	POTIGA.xml:S2:396:5	found	VBN	O	O
to	POTIGA.xml:S2:402:2	to	TO	O	O
have	POTIGA.xml:S2:405:4	have	VB	O	O
abnormal	POTIGA.xml:S2:410:8	abnorm	JJ	B-AdverseReaction	O
visual	POTIGA.xml:S2:419:6	visual	JJ	I-AdverseReaction	O
acuity	POTIGA.xml:S2:426:6	acuiti	NN	I-AdverseReaction	O
.	POTIGA.xml:S2:432:1	.	.	O	O

It	POTIGA.xml:S2:434:2	It	PRP	O	O
is	POTIGA.xml:S2:437:2	is	VBZ	O	O
not	POTIGA.xml:S2:440:3	not	RB	O	O
possible	POTIGA.xml:S2:444:8	possibl	JJ	O	O
to	POTIGA.xml:S2:453:2	to	TO	O	O
determine	POTIGA.xml:S2:456:9	determin	VB	O	O
whether	POTIGA.xml:S2:466:7	whether	IN	O	O
POTIGA	POTIGA.xml:S2:474:6	potiga	NNP	O	O
caused	POTIGA.xml:S2:481:6	caus	VBD	O	O
this	POTIGA.xml:S2:488:4	thi	DT	O	O
decreased	POTIGA.xml:S2:493:9	decreas	JJ	B-AdverseReaction	B-AdverseReaction
visual	POTIGA.xml:S2:503:6	visual	JJ	I-AdverseReaction	I-AdverseReaction
acuity	POTIGA.xml:S2:510:6	acuiti	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S2:516:1	,	,	O	O
as	POTIGA.xml:S2:518:2	as	IN	O	O
baseline	POTIGA.xml:S2:521:8	baselin	NN	O	O
assessments	POTIGA.xml:S2:530:11	assess	NNS	O	O
are	POTIGA.xml:S2:542:3	are	VBP	O	O
not	POTIGA.xml:S2:546:3	not	RB	O	O
available	POTIGA.xml:S2:550:9	avail	JJ	O	O
for	POTIGA.xml:S2:560:3	for	IN	O	O
these	POTIGA.xml:S2:564:5	these	DT	O	O
patients	POTIGA.xml:S2:570:8	patient	NNS	O	O
.	POTIGA.xml:S2:578:1	.	.	O	O

Approximately	POTIGA.xml:S2:588:13	approxim	RB	O	O
one	POTIGA.xml:S2:602:3	one	CD	O	O
third	POTIGA.xml:S2:606:5	third	NN	O	O
of	POTIGA.xml:S2:612:2	of	IN	O	O
the	POTIGA.xml:S2:615:3	the	DT	O	O
patients	POTIGA.xml:S2:619:8	patient	NNS	O	O
who	POTIGA.xml:S2:628:3	who	WP	O	O
had	POTIGA.xml:S2:632:3	had	VBD	O	O
eye	POTIGA.xml:S2:636:3	eye	NN	O	O
examinations	POTIGA.xml:S2:640:12	examin	NNS	O	O
performed	POTIGA.xml:S2:653:9	perform	VBD	O	O
after	POTIGA.xml:S2:663:5	after	IN	O	O
approximately	POTIGA.xml:S2:669:13	approxim	RB	O	O
4	POTIGA.xml:S2:683:1	4	CD	O	O
years	POTIGA.xml:S2:685:5	year	NNS	O	O
of	POTIGA.xml:S2:691:2	of	IN	O	O
treatment	POTIGA.xml:S2:694:9	treatment	NN	O	O
were	POTIGA.xml:S2:704:4	were	VBD	O	O
found	POTIGA.xml:S2:709:5	found	VBN	O	O
to	POTIGA.xml:S2:715:2	to	TO	O	O
have	POTIGA.xml:S2:718:4	have	VB	O	O
retinal	POTIGA.xml:S2:723:7	retin	JJ	B-AdverseReaction	O
pigmentary	POTIGA.xml:S2:731:10	pigmentari	JJ	I-AdverseReaction	O
abnormalities	POTIGA.xml:S2:742:13	abnorm	NNS	I-AdverseReaction	O
.	POTIGA.xml:S2:755:1	.	.	O	O

An	POTIGA.xml:S2:757:2	An	DT	O	O
earlier	POTIGA.xml:S2:760:7	earlier	JJR	O	O
onset	POTIGA.xml:S2:768:5	onset	NN	O	O
cannot	POTIGA.xml:S2:774:6	cannot	NN	O	O
be	POTIGA.xml:S2:781:2	be	VB	O	O
ruled	POTIGA.xml:S2:784:5	rule	VBN	O	O
out	POTIGA.xml:S2:790:3	out	RP	O	O
,	POTIGA.xml:S2:793:1	,	,	O	O
and	POTIGA.xml:S2:795:3	and	CC	O	O
it	POTIGA.xml:S2:799:2	it	PRP	O	O
is	POTIGA.xml:S2:802:2	is	VBZ	O	O
possible	POTIGA.xml:S2:805:8	possibl	JJ	O	O
that	POTIGA.xml:S2:814:4	that	IN	O	O
retinal	POTIGA.xml:S2:819:7	retin	JJ	B-AdverseReaction	O
abnormalities	POTIGA.xml:S2:827:13	abnorm	NNS	I-AdverseReaction	O
were	POTIGA.xml:S2:841:4	were	VBD	O	O
present	POTIGA.xml:S2:846:7	present	JJ	O	O
earlier	POTIGA.xml:S2:854:7	earlier	RBR	O	O
in	POTIGA.xml:S2:862:2	in	IN	O	O
the	POTIGA.xml:S2:865:3	the	DT	O	O
course	POTIGA.xml:S2:869:6	cours	NN	O	O
of	POTIGA.xml:S2:876:2	of	IN	O	O
exposure	POTIGA.xml:S2:879:8	exposur	NN	O	O
to	POTIGA.xml:S2:888:2	to	TO	O	O
POTIGA	POTIGA.xml:S2:891:6	potiga	NNP	O	O
.	POTIGA.xml:S2:897:1	.	.	O	O

The	POTIGA.xml:S2:899:3	the	DT	O	O
rate	POTIGA.xml:S2:903:4	rate	NN	O	O
of	POTIGA.xml:S2:908:2	of	IN	O	O
progression	POTIGA.xml:S2:911:11	progress	NN	O	O
of	POTIGA.xml:S2:923:2	of	IN	O	O
retinal	POTIGA.xml:S2:926:7	retin	JJ	B-AdverseReaction	O
abnormalities	POTIGA.xml:S2:934:13	abnorm	NNS	I-AdverseReaction	O
and	POTIGA.xml:S2:948:3	and	CC	O	O
their	POTIGA.xml:S2:952:5	their	PRP$	O	O
reversibility	POTIGA.xml:S2:958:13	revers	NN	O	O
are	POTIGA.xml:S2:972:3	are	VBP	O	O
unknown	POTIGA.xml:S2:976:7	unknown	JJ	O	O
.	POTIGA.xml:S2:983:1	.	.	O	O

POTIGA	POTIGA.xml:S2:993:6	potiga	NNP	O	O
should	POTIGA.xml:S2:1000:6	should	MD	O	O
only	POTIGA.xml:S2:1007:4	onli	RB	O	O
be	POTIGA.xml:S2:1012:2	be	VB	O	O
used	POTIGA.xml:S2:1015:4	use	VBN	O	O
in	POTIGA.xml:S2:1020:2	in	IN	O	O
patients	POTIGA.xml:S2:1023:8	patient	NNS	O	O
who	POTIGA.xml:S2:1032:3	who	WP	O	O
have	POTIGA.xml:S2:1036:4	have	VBP	O	O
responded	POTIGA.xml:S2:1041:9	respond	VBN	O	O
inadequately	POTIGA.xml:S2:1051:12	inadequ	RB	O	O
to	POTIGA.xml:S2:1064:2	to	TO	O	O
several	POTIGA.xml:S2:1067:7	sever	JJ	O	O
alternative	POTIGA.xml:S2:1075:11	altern	JJ	O	O
treatments	POTIGA.xml:S2:1087:10	treatment	NNS	O	O
and	POTIGA.xml:S2:1098:3	and	CC	O	O
for	POTIGA.xml:S2:1102:3	for	IN	O	O
whom	POTIGA.xml:S2:1106:4	whom	WP	O	O
the	POTIGA.xml:S2:1111:3	the	DT	O	O
benefits	POTIGA.xml:S2:1115:8	benefit	NNS	O	O
outweigh	POTIGA.xml:S2:1124:8	outweigh	VBP	O	O
the	POTIGA.xml:S2:1133:3	the	DT	O	O
potential	POTIGA.xml:S2:1137:9	potenti	JJ	O	O
risk	POTIGA.xml:S2:1147:4	risk	NN	O	O
of	POTIGA.xml:S2:1152:2	of	IN	O	O
vision	POTIGA.xml:S2:1155:6	vision	NN	O	O
loss	POTIGA.xml:S2:1162:4	loss	NN	O	O
.	POTIGA.xml:S2:1166:1	.	.	O	O

Patients	POTIGA.xml:S2:1168:8	patient	NNS	O	O
who	POTIGA.xml:S2:1177:3	who	WP	O	O
fail	POTIGA.xml:S2:1181:4	fail	VBP	O	O
to	POTIGA.xml:S2:1186:2	to	TO	O	O
show	POTIGA.xml:S2:1189:4	show	VB	O	O
substantial	POTIGA.xml:S2:1194:11	substanti	JJ	O	O
clinical	POTIGA.xml:S2:1206:8	clinic	JJ	O	O
benefit	POTIGA.xml:S2:1215:7	benefit	NN	O	O
after	POTIGA.xml:S2:1223:5	after	IN	O	O
adequate	POTIGA.xml:S2:1229:8	adequ	JJ	O	O
titration	POTIGA.xml:S2:1238:9	titrat	NN	O	O
should	POTIGA.xml:S2:1248:6	should	MD	O	O
be	POTIGA.xml:S2:1255:2	be	VB	O	O
discontinued	POTIGA.xml:S2:1258:12	discontinu	VBN	O	O
from	POTIGA.xml:S2:1271:4	from	IN	O	O
POTIGA	POTIGA.xml:S2:1276:6	potiga	NNP	O	O
.	POTIGA.xml:S2:1282:1	.	.	O	O

All	POTIGA.xml:S2:1292:3	all	DT	O	O
patients	POTIGA.xml:S2:1296:8	patient	NNS	O	O
taking	POTIGA.xml:S2:1305:6	take	VBG	O	O
POTIGA	POTIGA.xml:S2:1312:6	potiga	NNP	O	O
should	POTIGA.xml:S2:1319:6	should	MD	O	O
have	POTIGA.xml:S2:1326:4	have	VB	O	O
baseline	POTIGA.xml:S2:1331:8	baselin	NN	O	O
and	POTIGA.xml:S2:1340:3	and	CC	O	O
periodic	POTIGA.xml:S2:1344:8	period	NN	O	O
(	POTIGA.xml:S2:1353:1	(	(	O	O
every	POTIGA.xml:S2:1354:5	everi	DT	O	O
6	POTIGA.xml:S2:1360:1	6	CD	O	O
months	POTIGA.xml:S2:1362:6	month	NNS	O	O
)	POTIGA.xml:S2:1368:1	)	)	O	O
systematic	POTIGA.xml:S2:1370:10	systemat	JJ	O	O
visual	POTIGA.xml:S2:1381:6	visual	JJ	O	O
monitoring	POTIGA.xml:S2:1388:10	monitor	NN	O	O
by	POTIGA.xml:S2:1399:2	by	IN	O	O
an	POTIGA.xml:S2:1402:2	an	DT	O	O
ophthalmic	POTIGA.xml:S2:1405:10	ophthalm	JJ	O	O
professional	POTIGA.xml:S2:1416:12	profession	NN	O	O
.	POTIGA.xml:S2:1428:1	.	.	O	O

Testing	POTIGA.xml:S2:1430:7	test	VBG	O	O
should	POTIGA.xml:S2:1438:6	should	MD	O	O
include	POTIGA.xml:S2:1445:7	includ	VB	O	O
visual	POTIGA.xml:S2:1453:6	visual	JJ	O	B-AdverseReaction
acuity	POTIGA.xml:S2:1460:6	acuiti	NN	O	I-AdverseReaction
and	POTIGA.xml:S2:1467:3	and	CC	O	O
dilated	POTIGA.xml:S2:1471:7	dilat	VBD	O	B-AdverseReaction
fundus	POTIGA.xml:S2:1479:6	fundu	NN	O	I-AdverseReaction
photography	POTIGA.xml:S2:1486:11	photographi	NN	O	I-AdverseReaction
.	POTIGA.xml:S2:1497:1	.	.	O	O

Additional	POTIGA.xml:S2:1499:10	addit	JJ	O	O
testing	POTIGA.xml:S2:1510:7	test	NN	O	O
may	POTIGA.xml:S2:1518:3	may	MD	O	O
include	POTIGA.xml:S2:1522:7	includ	VB	O	O
fluorescein	POTIGA.xml:S2:1530:11	fluorescein	JJ	O	O
angiograms	POTIGA.xml:S2:1542:10	angiogram	NNS	O	O
(	POTIGA.xml:S2:1553:1	(	(	O	O
FA	POTIGA.xml:S2:1554:2	FA	NNP	O	O
)	POTIGA.xml:S2:1556:1	)	)	O	O
,	POTIGA.xml:S2:1557:1	,	,	O	O
optical	POTIGA.xml:S2:1559:7	optic	JJ	O	B-AdverseReaction
coherence	POTIGA.xml:S2:1567:9	coher	NN	O	I-AdverseReaction
tomography	POTIGA.xml:S2:1577:10	tomographi	NN	O	I-AdverseReaction
(	POTIGA.xml:S2:1588:1	(	(	O	O
OCT	POTIGA.xml:S2:1589:3	oct	NNP	O	O
)	POTIGA.xml:S2:1592:1	)	)	O	O
,	POTIGA.xml:S2:1593:1	,	,	O	O
perimetry	POTIGA.xml:S2:1595:9	perimetri	NN	O	O
,	POTIGA.xml:S2:1604:1	,	,	O	O
and	POTIGA.xml:S2:1606:3	and	CC	O	O
electroretinograms	POTIGA.xml:S2:1610:18	electroretinogram	NNS	O	O
(	POTIGA.xml:S2:1629:1	(	(	O	O
ERG	POTIGA.xml:S2:1630:3	erg	NNP	O	O
)	POTIGA.xml:S2:1633:1	)	)	O	O
.	POTIGA.xml:S2:1634:1	.	.	O	O

If	POTIGA.xml:S2:1644:2	If	IN	O	O
retinal	POTIGA.xml:S2:1647:7	retin	JJ	O	O
pigmentary	POTIGA.xml:S2:1655:10	pigmentari	JJ	O	O
abnormalities	POTIGA.xml:S2:1666:13	abnorm	NNS	O	O
or	POTIGA.xml:S2:1680:2	or	CC	O	O
vision	POTIGA.xml:S2:1683:6	vision	NN	O	O
changes	POTIGA.xml:S2:1690:7	chang	NNS	O	O
are	POTIGA.xml:S2:1698:3	are	VBP	O	O
detected	POTIGA.xml:S2:1702:8	detect	VBN	O	O
,	POTIGA.xml:S2:1710:1	,	,	O	O
POTIGA	POTIGA.xml:S2:1712:6	potiga	NNP	O	O
should	POTIGA.xml:S2:1719:6	should	MD	O	O
be	POTIGA.xml:S2:1726:2	be	VB	O	O
discontinued	POTIGA.xml:S2:1729:12	discontinu	VBN	O	O
unless	POTIGA.xml:S2:1742:6	unless	IN	O	O
no	POTIGA.xml:S2:1749:2	no	DT	O	O
other	POTIGA.xml:S2:1752:5	other	JJ	O	O
suitable	POTIGA.xml:S2:1758:8	suitabl	JJ	O	O
treatment	POTIGA.xml:S2:1767:9	treatment	NN	O	O
options	POTIGA.xml:S2:1777:7	option	NNS	O	O
are	POTIGA.xml:S2:1785:3	are	VBP	O	O
available	POTIGA.xml:S2:1789:9	avail	JJ	O	O
and	POTIGA.xml:S2:1799:3	and	CC	O	O
the	POTIGA.xml:S2:1803:3	the	DT	O	O
benefits	POTIGA.xml:S2:1807:8	benefit	NNS	O	O
of	POTIGA.xml:S2:1816:2	of	IN	O	O
treatment	POTIGA.xml:S2:1819:9	treatment	NN	O	O
outweigh	POTIGA.xml:S2:1829:8	outweigh	VBP	O	O
the	POTIGA.xml:S2:1838:3	the	DT	O	O
potential	POTIGA.xml:S2:1842:9	potenti	JJ	O	O
risk	POTIGA.xml:S2:1852:4	risk	NN	O	O
of	POTIGA.xml:S2:1857:2	of	IN	O	O
vision	POTIGA.xml:S2:1860:6	vision	NN	O	O
loss	POTIGA.xml:S2:1867:4	loss	NN	O	O
.	POTIGA.xml:S2:1871:1	.	.	O	O

EXCERPT	POTIGA.xml:S2:1881:7	excerpt	NN	O	O
:	POTIGA.xml:S2:1888:1	:	:	O	O
WARNING	POTIGA.xml:S2:1892:7	warn	NN	O	O
:	POTIGA.xml:S2:1899:1	:	:	O	O
RETINAL	POTIGA.xml:S2:1901:7	retin	JJ	B-AdverseReaction	O
ABNORMALITIES	POTIGA.xml:S2:1909:13	abnorm	NNP	I-AdverseReaction	O
AND	POTIGA.xml:S2:1923:3	and	NNP	O	O
POTENTIAL	POTIGA.xml:S2:1927:9	potenti	NNP	O	O
VISION	POTIGA.xml:S2:1937:6	vision	NNP	B-AdverseReaction	O
LOSS	POTIGA.xml:S2:1944:4	loss	NNP	I-AdverseReaction	O
\n\n\n\n	POTIGA.xml:S2:1948:4	\n\n\n\n	NNP	O	O
See	POTIGA.xml:S2:1955:3	see	NNP	O	O
full	POTIGA.xml:S2:1959:4	full	JJ	O	O
prescribing	POTIGA.xml:S2:1964:11	prescrib	VBG	O	O
information	POTIGA.xml:S2:1976:11	inform	NN	O	O
for	POTIGA.xml:S2:1988:3	for	IN	O	O
complete	POTIGA.xml:S2:1992:8	complet	JJ	O	O
boxed	POTIGA.xml:S2:2001:5	box	JJ	O	O
warning	POTIGA.xml:S2:2007:7	warn	NN	O	O
.	POTIGA.xml:S2:2014:1	.	.	O	O

POTIGA	POTIGA.xml:S2:2025:6	potiga	NNP	O	O
can	POTIGA.xml:S2:2032:3	can	MD	O	O
cause	POTIGA.xml:S2:2036:5	caus	VB	O	O
retinal	POTIGA.xml:S2:2042:7	retin	JJ	B-AdverseReaction	B-AdverseReaction
abnormalities	POTIGA.xml:S2:2050:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
with	POTIGA.xml:S2:2064:4	with	IN	O	O
funduscopic	POTIGA.xml:S2:2069:11	funduscop	NN	O	O
features	POTIGA.xml:S2:2081:8	featur	NNS	O	O
similar	POTIGA.xml:S2:2090:7	similar	JJ	I-AdverseReaction	O
to	POTIGA.xml:S2:2098:2	to	TO	I-AdverseReaction	O
those	POTIGA.xml:S2:2101:5	those	DT	O	O
seen	POTIGA.xml:S2:2107:4	seen	VBN	O	O
in	POTIGA.xml:S2:2112:2	in	IN	O	O
retinal	POTIGA.xml:S2:2115:7	retin	JJ	O	O
pigment	POTIGA.xml:S2:2123:7	pigment	NN	I-AdverseReaction	O
dystrophies	POTIGA.xml:S2:2131:11	dystrophi	NNS	I-AdverseReaction	O
,	POTIGA.xml:S2:2142:1	,	,	O	O
which	POTIGA.xml:S2:2144:5	which	WDT	O	O
are	POTIGA.xml:S2:2150:3	are	VBP	O	O
known	POTIGA.xml:S2:2154:5	known	VBN	O	O
to	POTIGA.xml:S2:2160:2	to	TO	O	O
result	POTIGA.xml:S2:2163:6	result	VB	O	O
in	POTIGA.xml:S2:2170:2	in	IN	O	O
damage	POTIGA.xml:S2:2173:6	damag	NN	B-AdverseReaction	O
to	POTIGA.xml:S2:2180:2	to	TO	I-AdverseReaction	O
the	POTIGA.xml:S2:2183:3	the	DT	I-AdverseReaction	O
photoreceptors	POTIGA.xml:S2:2187:14	photoreceptor	NNS	I-AdverseReaction	O
and	POTIGA.xml:S2:2202:3	and	CC	O	O
vision	POTIGA.xml:S2:2206:6	vision	NN	B-AdverseReaction	O
loss	POTIGA.xml:S2:2213:4	loss	NN	I-AdverseReaction	O
.	POTIGA.xml:S2:2217:1	.	.	O	O

(	POTIGA.xml:S2:2219:1	(	(	O	O
5.1	POTIGA.xml:S2:2220:3	5.1	CD	O	O
)	POTIGA.xml:S2:2223:1	)	)	O	O
\n	POTIGA.xml:S2:2225:1	\n	VB	O	O
Some	POTIGA.xml:S2:2230:4	some	DT	O	O
patients	POTIGA.xml:S2:2235:8	patient	NNS	O	O
with	POTIGA.xml:S2:2244:4	with	IN	O	O
retinal	POTIGA.xml:S2:2249:7	retin	JJ	O	O
abnormalities	POTIGA.xml:S2:2257:13	abnorm	NNS	O	O
have	POTIGA.xml:S2:2271:4	have	VBP	O	O
been	POTIGA.xml:S2:2276:4	been	VBN	O	O
found	POTIGA.xml:S2:2281:5	found	VBN	O	O
to	POTIGA.xml:S2:2287:2	to	TO	O	O
have	POTIGA.xml:S2:2290:4	have	VB	O	O
abnormal	POTIGA.xml:S2:2295:8	abnorm	JJ	O	O
visual	POTIGA.xml:S2:2304:6	visual	JJ	O	O
acuity	POTIGA.xml:S2:2311:6	acuiti	NN	O	O
.	POTIGA.xml:S2:2317:1	.	.	O	O

It	POTIGA.xml:S2:2319:2	It	PRP	O	O
is	POTIGA.xml:S2:2322:2	is	VBZ	O	O
not	POTIGA.xml:S2:2325:3	not	RB	O	O
possible	POTIGA.xml:S2:2329:8	possibl	JJ	O	O
to	POTIGA.xml:S2:2338:2	to	TO	O	O
determine	POTIGA.xml:S2:2341:9	determin	VB	O	O
whether	POTIGA.xml:S2:2351:7	whether	IN	O	O
POTIGA	POTIGA.xml:S2:2359:6	potiga	NNP	O	O
caused	POTIGA.xml:S2:2366:6	caus	VBD	O	O
this	POTIGA.xml:S2:2373:4	thi	DT	O	O
decreased	POTIGA.xml:S2:2378:9	decreas	JJ	B-AdverseReaction	B-AdverseReaction
visual	POTIGA.xml:S2:2388:6	visual	JJ	I-AdverseReaction	I-AdverseReaction
acuity	POTIGA.xml:S2:2395:6	acuiti	NN	I-AdverseReaction	I-AdverseReaction
.	POTIGA.xml:S2:2401:1	.	.	O	O

(	POTIGA.xml:S2:2403:1	(	(	O	O
5.1	POTIGA.xml:S2:2404:3	5.1	CD	O	O
)	POTIGA.xml:S2:2407:1	)	)	O	O
\n	POTIGA.xml:S2:2409:1	\n	VBD	O	O
The	POTIGA.xml:S2:2414:3	the	DT	O	O
rate	POTIGA.xml:S2:2418:4	rate	NN	O	O
of	POTIGA.xml:S2:2423:2	of	IN	O	O
progression	POTIGA.xml:S2:2426:11	progress	NN	O	O
of	POTIGA.xml:S2:2438:2	of	IN	O	O
retinal	POTIGA.xml:S2:2441:7	retin	JJ	O	O
abnormalities	POTIGA.xml:S2:2449:13	abnorm	NNS	O	O
and	POTIGA.xml:S2:2463:3	and	CC	O	O
their	POTIGA.xml:S2:2467:5	their	PRP$	O	O
reversibility	POTIGA.xml:S2:2473:13	revers	NN	O	O
are	POTIGA.xml:S2:2487:3	are	VBP	O	O
unknown	POTIGA.xml:S2:2491:7	unknown	JJ	O	O
.	POTIGA.xml:S2:2498:1	.	.	O	O

(	POTIGA.xml:S2:2500:1	(	(	O	O
5.1	POTIGA.xml:S2:2501:3	5.1	CD	O	O
)	POTIGA.xml:S2:2504:1	)	)	O	O
\n	POTIGA.xml:S2:2506:1	\n	NN	O	O
Patients	POTIGA.xml:S2:2511:8	patient	NNPS	O	O
who	POTIGA.xml:S2:2520:3	who	WP	O	O
fail	POTIGA.xml:S2:2524:4	fail	VBP	O	O
to	POTIGA.xml:S2:2529:2	to	TO	O	O
show	POTIGA.xml:S2:2532:4	show	VB	O	O
substantial	POTIGA.xml:S2:2537:11	substanti	JJ	O	O
clinical	POTIGA.xml:S2:2549:8	clinic	JJ	O	O
benefit	POTIGA.xml:S2:2558:7	benefit	NN	O	O
after	POTIGA.xml:S2:2566:5	after	IN	O	O
adequate	POTIGA.xml:S2:2572:8	adequ	JJ	O	O
titration	POTIGA.xml:S2:2581:9	titrat	NN	O	O
should	POTIGA.xml:S2:2591:6	should	MD	O	O
be	POTIGA.xml:S2:2598:2	be	VB	O	O
discontinued	POTIGA.xml:S2:2601:12	discontinu	VBN	O	O
from	POTIGA.xml:S2:2614:4	from	IN	O	O
POTIGA	POTIGA.xml:S2:2619:6	potiga	NNP	O	O
.	POTIGA.xml:S2:2625:1	.	.	O	O

(	POTIGA.xml:S2:2627:1	(	(	O	O
5.1	POTIGA.xml:S2:2628:3	5.1	CD	O	O
)	POTIGA.xml:S2:2631:1	)	)	O	O
\n	POTIGA.xml:S2:2633:1	\n	FW	O	O
All	POTIGA.xml:S2:2638:3	all	DT	O	O
patients	POTIGA.xml:S2:2642:8	patient	NNS	O	O
taking	POTIGA.xml:S2:2651:6	take	VBG	O	O
POTIGA	POTIGA.xml:S2:2658:6	potiga	NNP	O	O
should	POTIGA.xml:S2:2665:6	should	MD	O	O
have	POTIGA.xml:S2:2672:4	have	VB	O	O
baseline	POTIGA.xml:S2:2677:8	baselin	NN	O	O
and	POTIGA.xml:S2:2686:3	and	CC	O	O
periodic	POTIGA.xml:S2:2690:8	period	NN	O	O
(	POTIGA.xml:S2:2699:1	(	(	O	O
every	POTIGA.xml:S2:2700:5	everi	DT	O	O
6	POTIGA.xml:S2:2706:1	6	CD	O	O
months	POTIGA.xml:S2:2708:6	month	NNS	O	O
)	POTIGA.xml:S2:2714:1	)	)	O	O
systematic	POTIGA.xml:S2:2716:10	systemat	JJ	O	O
visual	POTIGA.xml:S2:2727:6	visual	JJ	O	O
monitoring	POTIGA.xml:S2:2734:10	monitor	NN	O	O
by	POTIGA.xml:S2:2745:2	by	IN	O	O
an	POTIGA.xml:S2:2748:2	an	DT	O	O
ophthalmic	POTIGA.xml:S2:2751:10	ophthalm	JJ	O	O
professional	POTIGA.xml:S2:2762:12	profession	NN	O	O
.	POTIGA.xml:S2:2774:1	.	.	O	O

Testing	POTIGA.xml:S2:2776:7	test	VBG	O	O
should	POTIGA.xml:S2:2784:6	should	MD	O	O
include	POTIGA.xml:S2:2791:7	includ	VB	O	O
visual	POTIGA.xml:S2:2799:6	visual	JJ	O	B-AdverseReaction
acuity	POTIGA.xml:S2:2806:6	acuiti	NN	O	I-AdverseReaction
and	POTIGA.xml:S2:2813:3	and	CC	O	O
dilated	POTIGA.xml:S2:2817:7	dilat	VBD	O	B-AdverseReaction
fundus	POTIGA.xml:S2:2825:6	fundu	NN	O	I-AdverseReaction
photography	POTIGA.xml:S2:2832:11	photographi	NN	O	I-AdverseReaction
.	POTIGA.xml:S2:2843:1	.	.	O	O

(	POTIGA.xml:S2:2845:1	(	(	O	O
5.1	POTIGA.xml:S2:2846:3	5.1	CD	O	O
)	POTIGA.xml:S2:2849:1	)	)	O	O
\n	POTIGA.xml:S2:2851:1	\n	NN	O	O
If	POTIGA.xml:S2:2856:2	If	IN	O	O
retinal	POTIGA.xml:S2:2859:7	retin	JJ	O	O
pigmentary	POTIGA.xml:S2:2867:10	pigmentari	JJ	O	O
abnormalities	POTIGA.xml:S2:2878:13	abnorm	NNS	O	O
or	POTIGA.xml:S2:2892:2	or	CC	O	O
vision	POTIGA.xml:S2:2895:6	vision	NN	O	O
changes	POTIGA.xml:S2:2902:7	chang	NNS	O	O
are	POTIGA.xml:S2:2910:3	are	VBP	O	O
detected	POTIGA.xml:S2:2914:8	detect	VBN	O	O
,	POTIGA.xml:S2:2922:1	,	,	O	O
POTIGA	POTIGA.xml:S2:2924:6	potiga	NNP	O	O
should	POTIGA.xml:S2:2931:6	should	MD	O	O
be	POTIGA.xml:S2:2938:2	be	VB	O	O
discontinued	POTIGA.xml:S2:2941:12	discontinu	VBN	O	O
unless	POTIGA.xml:S2:2954:6	unless	IN	O	O
no	POTIGA.xml:S2:2961:2	no	DT	O	O
other	POTIGA.xml:S2:2964:5	other	JJ	O	O
suitable	POTIGA.xml:S2:2970:8	suitabl	JJ	O	O
treatment	POTIGA.xml:S2:2979:9	treatment	NN	O	O
options	POTIGA.xml:S2:2989:7	option	NNS	O	O
are	POTIGA.xml:S2:2997:3	are	VBP	O	O
available	POTIGA.xml:S2:3001:9	avail	JJ	O	O
and	POTIGA.xml:S2:3011:3	and	CC	O	O
the	POTIGA.xml:S2:3015:3	the	DT	O	O
benefits	POTIGA.xml:S2:3019:8	benefit	NNS	O	O
of	POTIGA.xml:S2:3028:2	of	IN	O	O
treatment	POTIGA.xml:S2:3031:9	treatment	NN	O	O
outweigh	POTIGA.xml:S2:3041:8	outweigh	VBP	O	O
the	POTIGA.xml:S2:3050:3	the	DT	O	O
potential	POTIGA.xml:S2:3054:9	potenti	JJ	O	O
risk	POTIGA.xml:S2:3064:4	risk	NN	O	O
of	POTIGA.xml:S2:3069:2	of	IN	O	O
vision	POTIGA.xml:S2:3072:6	vision	NN	O	O
loss	POTIGA.xml:S2:3079:4	loss	NN	O	O
.	POTIGA.xml:S2:3083:1	.	.	O	O

(	POTIGA.xml:S2:3085:1	(	(	O	O
5.1	POTIGA.xml:S2:3086:3	5.1	CD	O	O
)	POTIGA.xml:S2:3089:1	)	)	O	O
\n	POTIGA.xml:S2:3091:1	\n	VBD	O	O
5	POTIGA.xml:S3:4:1	5	CD	O	O
WARNINGS	POTIGA.xml:S3:6:8	warn	NNP	O	O
AND	POTIGA.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	POTIGA.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	POTIGA.xml:S3:37:7	excerpt	NN	O	O
:	POTIGA.xml:S3:44:1	:	:	O	O
Urinary	POTIGA.xml:S3:54:7	urinari	JJ	B-AdverseReaction	O
retention	POTIGA.xml:S3:62:9	retent	NN	I-AdverseReaction	O
:	POTIGA.xml:S3:71:1	:	:	O	O
Patients	POTIGA.xml:S3:73:8	patient	NNS	O	O
should	POTIGA.xml:S3:82:6	should	MD	O	O
be	POTIGA.xml:S3:89:2	be	VB	O	O
carefully	POTIGA.xml:S3:92:9	care	RB	O	O
monitored	POTIGA.xml:S3:102:9	monitor	VBN	O	O
for	POTIGA.xml:S3:112:3	for	IN	O	O
urologic	POTIGA.xml:S3:116:8	urolog	JJ	O	O
symptoms	POTIGA.xml:S3:125:8	symptom	NNS	O	O
.	POTIGA.xml:S3:133:1	.	.	O	O

(	POTIGA.xml:S3:135:1	(	(	O	O
5.2	POTIGA.xml:S3:138:3	5.2	CD	O	O
)	POTIGA.xml:S3:143:1	)	)	O	O

POTIGA	POTIGA.xml:S3:152:6	potiga	NNP	O	O
can	POTIGA.xml:S3:159:3	can	MD	O	O
cause	POTIGA.xml:S3:163:5	caus	VB	O	O
skin	POTIGA.xml:S3:169:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
discoloration	POTIGA.xml:S3:174:13	discolor	NN	I-AdverseReaction	I-AdverseReaction
.	POTIGA.xml:S3:187:1	.	.	O	O

If	POTIGA.xml:S3:189:2	If	IN	O	O
a	POTIGA.xml:S3:192:1	a	DT	O	O
patient	POTIGA.xml:S3:194:7	patient	NN	O	O
develops	POTIGA.xml:S3:202:8	develop	VBZ	O	O
skin	POTIGA.xml:S3:211:4	skin	JJ	O	O
discoloration	POTIGA.xml:S3:216:13	discolor	NN	O	O
,	POTIGA.xml:S3:229:1	,	,	O	O
serious	POTIGA.xml:S3:231:7	seriou	JJ	O	O
consideration	POTIGA.xml:S3:239:13	consider	NN	O	O
should	POTIGA.xml:S3:253:6	should	MD	O	O
be	POTIGA.xml:S3:260:2	be	VB	O	O
given	POTIGA.xml:S3:263:5	given	VBN	O	O
to	POTIGA.xml:S3:269:2	to	TO	O	O
an	POTIGA.xml:S3:272:2	an	DT	O	O
alternative	POTIGA.xml:S3:275:11	altern	JJ	O	O
treatment	POTIGA.xml:S3:287:9	treatment	NN	O	O
.	POTIGA.xml:S3:296:1	.	.	O	O

(	POTIGA.xml:S3:298:1	(	(	O	O
5.3	POTIGA.xml:S3:301:3	5.3	CD	O	O
)	POTIGA.xml:S3:306:1	)	)	O	O

Neuropsychiatric	POTIGA.xml:S3:315:16	neuropsychiatr	JJ	B-AdverseReaction	B-AdverseReaction
symptoms	POTIGA.xml:S3:332:8	symptom	NNS	I-AdverseReaction	I-AdverseReaction
:	POTIGA.xml:S3:340:1	:	:	O	O
Monitor	POTIGA.xml:S3:342:7	monitor	NNP	O	O
for	POTIGA.xml:S3:350:3	for	IN	O	O
confusional	POTIGA.xml:S3:354:11	confusion	JJ	O	O
state	POTIGA.xml:S3:366:5	state	NN	O	O
,	POTIGA.xml:S3:371:1	,	,	O	O
psychotic	POTIGA.xml:S3:373:9	psychot	JJ	O	O
symptoms	POTIGA.xml:S3:383:8	symptom	NNS	O	O
,	POTIGA.xml:S3:391:1	,	,	O	O
and	POTIGA.xml:S3:393:3	and	CC	O	O
hallucinations	POTIGA.xml:S3:397:14	hallucin	NNS	O	O
.	POTIGA.xml:S3:411:1	.	.	O	O

(	POTIGA.xml:S3:413:1	(	(	O	O
5.4	POTIGA.xml:S3:416:3	5.4	CD	O	O
)	POTIGA.xml:S3:421:1	)	)	O	O

Monitor	POTIGA.xml:S3:430:7	monitor	NNP	O	O
for	POTIGA.xml:S3:438:3	for	IN	O	O
dizziness	POTIGA.xml:S3:442:9	dizzi	NN	O	O
and	POTIGA.xml:S3:452:3	and	CC	O	O
somnolence	POTIGA.xml:S3:456:10	somnol	NN	O	B-AdverseReaction
.	POTIGA.xml:S3:466:1	.	.	O	O

(	POTIGA.xml:S3:468:1	(	(	O	O
5.5	POTIGA.xml:S3:471:3	5.5	CD	O	O
)	POTIGA.xml:S3:476:1	)	)	O	O

QT	POTIGA.xml:S3:485:2	QT	JJ	B-AdverseReaction	B-AdverseReaction
prolongation	POTIGA.xml:S3:488:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
:	POTIGA.xml:S3:500:1	:	:	O	O
QT	POTIGA.xml:S3:502:2	QT	NNP	O	O
interval	POTIGA.xml:S3:505:8	interv	NN	O	O
should	POTIGA.xml:S3:514:6	should	MD	O	O
be	POTIGA.xml:S3:521:2	be	VB	O	O
monitored	POTIGA.xml:S3:524:9	monitor	VBN	O	O
in	POTIGA.xml:S3:534:2	in	IN	O	O
patients	POTIGA.xml:S3:537:8	patient	NNS	O	O
taking	POTIGA.xml:S3:546:6	take	VBG	O	O
concomitant	POTIGA.xml:S3:553:11	concomit	JJ	O	O
medications	POTIGA.xml:S3:565:11	medic	NNS	O	O
known	POTIGA.xml:S3:577:5	known	VBN	O	O
to	POTIGA.xml:S3:583:2	to	TO	O	O
increase	POTIGA.xml:S3:586:8	increas	VB	O	O
the	POTIGA.xml:S3:595:3	the	DT	O	O
QT	POTIGA.xml:S3:599:2	QT	NNP	O	O
interval	POTIGA.xml:S3:602:8	interv	NN	O	O
or	POTIGA.xml:S3:611:2	or	CC	O	O
with	POTIGA.xml:S3:614:4	with	IN	O	O
certain	POTIGA.xml:S3:619:7	certain	JJ	O	O
heart	POTIGA.xml:S3:627:5	heart	NN	O	O
conditions	POTIGA.xml:S3:633:10	condit	NNS	O	O
.	POTIGA.xml:S3:643:1	.	.	O	O

(	POTIGA.xml:S3:645:1	(	(	O	O
5.6	POTIGA.xml:S3:648:3	5.6	CD	O	O
)	POTIGA.xml:S3:653:1	)	)	O	O

Monitor	POTIGA.xml:S3:662:7	monitor	NNP	O	O
for	POTIGA.xml:S3:670:3	for	IN	O	O
suicidal	POTIGA.xml:S3:674:8	suicid	JJ	O	O
thoughts	POTIGA.xml:S3:683:8	thought	NNS	O	O
or	POTIGA.xml:S3:692:2	or	CC	O	O
behaviors	POTIGA.xml:S3:695:9	behavior	NNS	O	I-AdverseReaction
.	POTIGA.xml:S3:704:1	.	.	O	O

(	POTIGA.xml:S3:706:1	(	(	O	O
5.7	POTIGA.xml:S3:709:3	5.7	CD	O	O
)	POTIGA.xml:S3:714:1	)	)	O	O

5.1	POTIGA.xml:S3:728:3	5.1	CD	O	O

Retinal	POTIGA.xml:S3:732:7	retin	JJ	O	O

Abnormalities	POTIGA.xml:S3:740:13	abnorm	NNS	O	O
and	POTIGA.xml:S3:754:3	and	CC	O	O
Potential	POTIGA.xml:S3:758:9	potenti	NNP	O	O
Vision	POTIGA.xml:S3:768:6	vision	NNP	O	O
Loss	POTIGA.xml:S3:775:4	loss	NNP	O	O

POTIGA	POTIGA.xml:S3:785:6	potiga	NNP	O	O
can	POTIGA.xml:S3:792:3	can	MD	O	O
cause	POTIGA.xml:S3:796:5	caus	VB	O	O
abnormalities	POTIGA.xml:S3:802:13	abnorm	NNS	B-AdverseReaction	B-AdverseReaction
of	POTIGA.xml:S3:816:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	POTIGA.xml:S3:819:3	the	DT	I-AdverseReaction	I-AdverseReaction
retina	POTIGA.xml:S3:823:6	retina	NN	I-AdverseReaction	I-AdverseReaction
.	POTIGA.xml:S3:829:1	.	.	O	O

The	POTIGA.xml:S3:831:3	the	DT	O	O
abnormalities	POTIGA.xml:S3:835:13	abnorm	NNS	O	O
seen	POTIGA.xml:S3:849:4	seen	VBN	O	O
in	POTIGA.xml:S3:854:2	in	IN	O	O
patients	POTIGA.xml:S3:857:8	patient	NNS	O	O
treated	POTIGA.xml:S3:866:7	treat	VBN	O	O
with	POTIGA.xml:S3:874:4	with	IN	O	O
POTIGA	POTIGA.xml:S3:879:6	potiga	NNP	O	O
have	POTIGA.xml:S3:886:4	have	VBP	O	O
funduscopic	POTIGA.xml:S3:891:11	funduscop	VBN	B-AdverseReaction	O
features	POTIGA.xml:S3:903:8	featur	NNS	I-AdverseReaction	O
similar	POTIGA.xml:S3:912:7	similar	JJ	I-AdverseReaction	O
to	POTIGA.xml:S3:920:2	to	TO	I-AdverseReaction	O
those	POTIGA.xml:S3:923:5	those	DT	O	O
seen	POTIGA.xml:S3:929:4	seen	VBN	O	O
in	POTIGA.xml:S3:934:2	in	IN	O	O
retinal	POTIGA.xml:S3:937:7	retin	JJ	I-AdverseReaction	O
pigment	POTIGA.xml:S3:945:7	pigment	NN	I-AdverseReaction	O
dystrophies	POTIGA.xml:S3:953:11	dystrophi	NNS	I-AdverseReaction	O
that	POTIGA.xml:S3:965:4	that	WDT	O	O
are	POTIGA.xml:S3:970:3	are	VBP	O	O
known	POTIGA.xml:S3:974:5	known	VBN	O	O
to	POTIGA.xml:S3:980:2	to	TO	O	O
result	POTIGA.xml:S3:983:6	result	VB	O	O
in	POTIGA.xml:S3:990:2	in	IN	O	O
damage	POTIGA.xml:S3:993:6	damag	NN	B-AdverseReaction	O
to	POTIGA.xml:S3:1000:2	to	TO	I-AdverseReaction	O
photoreceptors	POTIGA.xml:S3:1003:14	photoreceptor	NNS	I-AdverseReaction	O
and	POTIGA.xml:S3:1018:3	and	CC	O	O
vision	POTIGA.xml:S3:1022:6	vision	NN	B-AdverseReaction	O
loss	POTIGA.xml:S3:1029:4	loss	NN	I-AdverseReaction	O
.	POTIGA.xml:S3:1033:1	.	.	O	O

The	POTIGA.xml:S3:1039:3	the	DT	O	O
retinal	POTIGA.xml:S3:1043:7	retin	JJ	B-AdverseReaction	O
abnormalities	POTIGA.xml:S3:1051:13	abnorm	NNS	I-AdverseReaction	O
observed	POTIGA.xml:S3:1065:8	observ	VBN	O	O
with	POTIGA.xml:S3:1074:4	with	IN	O	O
POTIGA	POTIGA.xml:S3:1079:6	potiga	NNP	O	O
have	POTIGA.xml:S3:1086:4	have	VBP	O	O
been	POTIGA.xml:S3:1091:4	been	VBN	O	O
reported	POTIGA.xml:S3:1096:8	report	VBN	O	O
in	POTIGA.xml:S3:1105:2	in	IN	O	O
patients	POTIGA.xml:S3:1108:8	patient	NNS	O	O
who	POTIGA.xml:S3:1117:3	who	WP	O	O
were	POTIGA.xml:S3:1121:4	were	VBD	O	O
originally	POTIGA.xml:S3:1126:10	origin	RB	O	O
enrolled	POTIGA.xml:S3:1137:8	enrol	VBN	O	O
in	POTIGA.xml:S3:1146:2	in	IN	O	O
clinical	POTIGA.xml:S3:1149:8	clinic	JJ	O	O
trials	POTIGA.xml:S3:1158:6	trial	NNS	O	O
with	POTIGA.xml:S3:1165:4	with	IN	O	O
POTIGA	POTIGA.xml:S3:1170:6	potiga	NNP	O	O
and	POTIGA.xml:S3:1177:3	and	CC	O	O
who	POTIGA.xml:S3:1181:3	who	WP	O	O
have	POTIGA.xml:S3:1185:4	have	VBP	O	O
generally	POTIGA.xml:S3:1190:9	gener	RB	O	O
taken	POTIGA.xml:S3:1200:5	taken	VBN	O	O
the	POTIGA.xml:S3:1206:3	the	DT	O	O
drug	POTIGA.xml:S3:1210:4	drug	NN	O	O
for	POTIGA.xml:S3:1215:3	for	IN	O	O
a	POTIGA.xml:S3:1219:1	a	DT	O	O
long	POTIGA.xml:S3:1221:4	long	JJ	O	O
period	POTIGA.xml:S3:1226:6	period	NN	O	O
of	POTIGA.xml:S3:1233:2	of	IN	O	O
time	POTIGA.xml:S3:1236:4	time	NN	O	O
in	POTIGA.xml:S3:1241:2	in	IN	O	O
2	POTIGA.xml:S3:1244:1	2	CD	O	O
ongoing	POTIGA.xml:S3:1246:7	ongo	JJ	O	O
extension	POTIGA.xml:S3:1254:9	extens	NN	O	O
trials	POTIGA.xml:S3:1264:6	trial	NNS	O	O
.	POTIGA.xml:S3:1270:1	.	.	O	O

Approximately	POTIGA.xml:S3:1272:13	approxim	RB	O	O
one	POTIGA.xml:S3:1286:3	one	CD	O	O
third	POTIGA.xml:S3:1290:5	third	NN	O	O
of	POTIGA.xml:S3:1296:2	of	IN	O	O
the	POTIGA.xml:S3:1299:3	the	DT	O	O
patients	POTIGA.xml:S3:1303:8	patient	NNS	O	O
who	POTIGA.xml:S3:1312:3	who	WP	O	O
had	POTIGA.xml:S3:1316:3	had	VBD	O	O
eye	POTIGA.xml:S3:1320:3	eye	NN	O	O
examinations	POTIGA.xml:S3:1324:12	examin	NNS	O	O
performed	POTIGA.xml:S3:1337:9	perform	VBD	O	O
after	POTIGA.xml:S3:1347:5	after	IN	O	O
approximately	POTIGA.xml:S3:1353:13	approxim	RB	O	O
4	POTIGA.xml:S3:1367:1	4	CD	O	O
years	POTIGA.xml:S3:1369:5	year	NNS	O	O
of	POTIGA.xml:S3:1375:2	of	IN	O	O
treatment	POTIGA.xml:S3:1378:9	treatment	NN	O	O
were	POTIGA.xml:S3:1388:4	were	VBD	O	O
found	POTIGA.xml:S3:1393:5	found	VBN	O	O
to	POTIGA.xml:S3:1399:2	to	TO	O	O
have	POTIGA.xml:S3:1402:4	have	VB	O	O
retinal	POTIGA.xml:S3:1407:7	retin	JJ	B-AdverseReaction	O
pigmentary	POTIGA.xml:S3:1415:10	pigmentari	JJ	I-AdverseReaction	O
abnormalities	POTIGA.xml:S3:1426:13	abnorm	NNS	I-AdverseReaction	O
.	POTIGA.xml:S3:1439:1	.	.	O	O

However	POTIGA.xml:S3:1441:7	howev	RB	O	O
,	POTIGA.xml:S3:1448:1	,	,	O	O
an	POTIGA.xml:S3:1450:2	an	DT	O	O
earlier	POTIGA.xml:S3:1453:7	earlier	JJR	O	O
onset	POTIGA.xml:S3:1461:5	onset	NN	O	O
cannot	POTIGA.xml:S3:1467:6	cannot	NN	O	O
be	POTIGA.xml:S3:1474:2	be	VB	O	O
ruled	POTIGA.xml:S3:1477:5	rule	VBN	O	O
out	POTIGA.xml:S3:1483:3	out	RP	O	O
,	POTIGA.xml:S3:1486:1	,	,	O	O
and	POTIGA.xml:S3:1488:3	and	CC	O	O
it	POTIGA.xml:S3:1492:2	it	PRP	O	O
is	POTIGA.xml:S3:1495:2	is	VBZ	O	O
possible	POTIGA.xml:S3:1498:8	possibl	JJ	O	O
that	POTIGA.xml:S3:1507:4	that	IN	O	O
retinal	POTIGA.xml:S3:1512:7	retin	JJ	B-AdverseReaction	O
abnormalities	POTIGA.xml:S3:1520:13	abnorm	NNS	I-AdverseReaction	O
were	POTIGA.xml:S3:1534:4	were	VBD	O	O
present	POTIGA.xml:S3:1539:7	present	JJ	O	O
earlier	POTIGA.xml:S3:1547:7	earlier	RBR	O	O
in	POTIGA.xml:S3:1555:2	in	IN	O	O
the	POTIGA.xml:S3:1558:3	the	DT	O	O
course	POTIGA.xml:S3:1562:6	cours	NN	O	O
of	POTIGA.xml:S3:1569:2	of	IN	O	O
exposure	POTIGA.xml:S3:1572:8	exposur	NN	O	O
to	POTIGA.xml:S3:1581:2	to	TO	O	O
POTIGA	POTIGA.xml:S3:1584:6	potiga	NNP	O	O
.	POTIGA.xml:S3:1590:1	.	.	O	O

POTIGA	POTIGA.xml:S3:1592:6	potiga	NNP	O	O
causes	POTIGA.xml:S3:1599:6	caus	VBZ	O	O
skin	POTIGA.xml:S3:1606:4	skin	FW	B-AdverseReaction	O
,	POTIGA.xml:S3:1610:1	,	,	O	O
scleral	POTIGA.xml:S3:1612:7	scleral	JJ	B-AdverseReaction	O
,	POTIGA.xml:S3:1619:1	,	,	O	O
nail	POTIGA.xml:S3:1621:4	nail	JJ	B-AdverseReaction	O
,	POTIGA.xml:S3:1625:1	,	,	O	O
and	POTIGA.xml:S3:1627:3	and	CC	O	O
mucous	POTIGA.xml:S3:1631:6	mucou	JJ	B-AdverseReaction	O
membrane	POTIGA.xml:S3:1638:8	membran	NN	I-AdverseReaction	O
discoloration	POTIGA.xml:S3:1647:13	discolor	NN	I-AdverseReaction	O
and	POTIGA.xml:S3:1661:3	and	CC	O	O
it	POTIGA.xml:S3:1665:2	it	PRP	O	O
is	POTIGA.xml:S3:1668:2	is	VBZ	O	O
not	POTIGA.xml:S3:1671:3	not	RB	O	O
clear	POTIGA.xml:S3:1675:5	clear	JJ	O	O
whether	POTIGA.xml:S3:1681:7	whether	IN	O	O
this	POTIGA.xml:S3:1689:4	thi	DT	O	O
discoloration	POTIGA.xml:S3:1694:13	discolor	NN	B-AdverseReaction	O
is	POTIGA.xml:S3:1708:2	is	VBZ	O	O
related	POTIGA.xml:S3:1711:7	relat	VBN	O	O
to	POTIGA.xml:S3:1719:2	to	TO	O	O
retinal	POTIGA.xml:S3:1722:7	retin	JJ	B-AdverseReaction	B-AdverseReaction
abnormalities	POTIGA.xml:S3:1730:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
[	POTIGA.xml:S3:1744:1	[	VBP	O	O
see	POTIGA.xml:S3:1745:3	see	VBP	O	O
Warnings	POTIGA.xml:S3:1749:8	warn	NNS	O	O
and	POTIGA.xml:S3:1758:3	and	CC	O	O
Precautions	POTIGA.xml:S3:1762:11	precaut	NNP	O	O
(	POTIGA.xml:S3:1774:1	(	(	O	O
5.3	POTIGA.xml:S3:1775:3	5.3	CD	O	O
)]	POTIGA.xml:S3:1778:2	)]	NN	O	O
.	POTIGA.xml:S3:1782:1	.	.	O	O

Approximately	POTIGA.xml:S3:1784:13	approxim	RB	O	O
15%	POTIGA.xml:S3:1798:3	15%	CD	O	O
of	POTIGA.xml:S3:1802:2	of	IN	O	O
patients	POTIGA.xml:S3:1805:8	patient	NNS	O	O
with	POTIGA.xml:S3:1814:4	with	IN	O	O
retinal	POTIGA.xml:S3:1819:7	retin	JJ	B-AdverseReaction	O
pigmentary	POTIGA.xml:S3:1827:10	pigmentari	JJ	I-AdverseReaction	O
abnormalities	POTIGA.xml:S3:1838:13	abnorm	NNS	I-AdverseReaction	O
had	POTIGA.xml:S3:1852:3	had	VBD	O	O
no	POTIGA.xml:S3:1856:2	no	DT	O	O
such	POTIGA.xml:S3:1859:4	such	JJ	O	O
discoloration	POTIGA.xml:S3:1864:13	discolor	NN	B-AdverseReaction	O
.	POTIGA.xml:S3:1877:1	.	.	O	O

Funduscopic	POTIGA.xml:S3:1883:11	funduscop	NNP	B-AdverseReaction	O
abnormalities	POTIGA.xml:S3:1895:13	abnorm	NNS	I-AdverseReaction	O
have	POTIGA.xml:S3:1909:4	have	VBP	O	O
most	POTIGA.xml:S3:1914:4	most	VBN	O	O
commonly	POTIGA.xml:S3:1919:8	commonli	RB	O	O
been	POTIGA.xml:S3:1928:4	been	VBN	O	O
described	POTIGA.xml:S3:1933:9	describ	VBN	O	O
as	POTIGA.xml:S3:1943:2	as	IN	O	O
perivascular	POTIGA.xml:S3:1946:12	perivascular	JJ	B-AdverseReaction	O
pigmentation	POTIGA.xml:S3:1959:12	pigment	NN	I-AdverseReaction	O
(	POTIGA.xml:S3:1972:1	(	(	O	O
bone	POTIGA.xml:S3:1973:4	bone	JJ	I-AdverseReaction	O
spicule	POTIGA.xml:S3:1978:7	spicul	NN	I-AdverseReaction	O
pattern	POTIGA.xml:S3:1986:7	pattern	NN	I-AdverseReaction	O
)	POTIGA.xml:S3:1993:1	)	)	O	O
in	POTIGA.xml:S3:1995:2	in	IN	I-AdverseReaction	O
the	POTIGA.xml:S3:1998:3	the	DT	I-AdverseReaction	O
retinal	POTIGA.xml:S3:2002:7	retin	JJ	I-AdverseReaction	O
periphery	POTIGA.xml:S3:2010:9	peripheri	NN	I-AdverseReaction	O
and	POTIGA.xml:S3:2020:3	and	CC	O	O
or	POTIGA.xml:S3:2024:2	or	CC	O	O
as	POTIGA.xml:S3:2027:2	as	IN	O	O
areas	POTIGA.xml:S3:2030:5	area	NNS	O	O
of	POTIGA.xml:S3:2036:2	of	IN	O	O
focal	POTIGA.xml:S3:2039:5	focal	JJ	B-AdverseReaction	O
retinal	POTIGA.xml:S3:2045:7	retin	JJ	I-AdverseReaction	O
pigment	POTIGA.xml:S3:2053:7	pigment	NN	I-AdverseReaction	O
epithelium	POTIGA.xml:S3:2061:10	epithelium	NN	I-AdverseReaction	O
clumping	POTIGA.xml:S3:2072:8	clump	NN	I-AdverseReaction	O
.	POTIGA.xml:S3:2080:1	.	.	O	O

Although	POTIGA.xml:S3:2082:8	although	IN	O	O
some	POTIGA.xml:S3:2091:4	some	DT	O	O
of	POTIGA.xml:S3:2096:2	of	IN	O	O
the	POTIGA.xml:S3:2099:3	the	DT	O	O
patients	POTIGA.xml:S3:2103:8	patient	NNS	O	O
with	POTIGA.xml:S3:2112:4	with	IN	O	O
retinal	POTIGA.xml:S3:2117:7	retin	JJ	B-AdverseReaction	O
abnormalities	POTIGA.xml:S3:2125:13	abnorm	NNS	I-AdverseReaction	O
have	POTIGA.xml:S3:2139:4	have	VBP	O	O
been	POTIGA.xml:S3:2144:4	been	VBN	O	O
found	POTIGA.xml:S3:2149:5	found	VBN	O	O
to	POTIGA.xml:S3:2155:2	to	TO	O	O
have	POTIGA.xml:S3:2158:4	have	VB	O	O
abnormal	POTIGA.xml:S3:2163:8	abnorm	JJ	B-AdverseReaction	O
visual	POTIGA.xml:S3:2172:6	visual	JJ	I-AdverseReaction	O
acuity	POTIGA.xml:S3:2179:6	acuiti	NN	I-AdverseReaction	O
,	POTIGA.xml:S3:2185:1	,	,	O	O
it	POTIGA.xml:S3:2187:2	it	PRP	O	O
is	POTIGA.xml:S3:2190:2	is	VBZ	O	O
not	POTIGA.xml:S3:2193:3	not	RB	O	O
possible	POTIGA.xml:S3:2197:8	possibl	JJ	O	O
to	POTIGA.xml:S3:2206:2	to	TO	O	O
assess	POTIGA.xml:S3:2209:6	assess	VB	O	O
whether	POTIGA.xml:S3:2216:7	whether	IN	O	O
POTIGA	POTIGA.xml:S3:2224:6	potiga	NNP	O	O
caused	POTIGA.xml:S3:2231:6	caus	VBD	O	O
their	POTIGA.xml:S3:2238:5	their	PRP$	O	O
decreased	POTIGA.xml:S3:2244:9	decreas	JJ	B-AdverseReaction	B-AdverseReaction
visual	POTIGA.xml:S3:2254:6	visual	JJ	I-AdverseReaction	I-AdverseReaction
acuity	POTIGA.xml:S3:2261:6	acuiti	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S3:2267:1	,	,	O	O
as	POTIGA.xml:S3:2269:2	as	IN	O	O
baseline	POTIGA.xml:S3:2272:8	baselin	NN	O	O
assessments	POTIGA.xml:S3:2281:11	assess	NNS	O	O
are	POTIGA.xml:S3:2293:3	are	VBP	O	O
not	POTIGA.xml:S3:2297:3	not	RB	O	O
available	POTIGA.xml:S3:2301:9	avail	JJ	O	O
for	POTIGA.xml:S3:2311:3	for	IN	O	O
these	POTIGA.xml:S3:2315:5	these	DT	O	O
patients	POTIGA.xml:S3:2321:8	patient	NNS	O	O
.	POTIGA.xml:S3:2329:1	.	.	O	O

Two	POTIGA.xml:S3:2331:3	two	CD	O	O
patients	POTIGA.xml:S3:2335:8	patient	NNS	O	O
with	POTIGA.xml:S3:2344:4	with	IN	O	O
retinal	POTIGA.xml:S3:2349:7	retin	JJ	B-AdverseReaction	O
abnormalities	POTIGA.xml:S3:2357:13	abnorm	NNS	I-AdverseReaction	O
have	POTIGA.xml:S3:2371:4	have	VBP	O	O
had	POTIGA.xml:S3:2376:3	had	VBN	O	O
more	POTIGA.xml:S3:2380:4	more	RBR	O	O
extensive	POTIGA.xml:S3:2385:9	extens	JJ	O	O
diagnostic	POTIGA.xml:S3:2395:10	diagnost	JJ	O	O
retinal	POTIGA.xml:S3:2406:7	retin	JJ	O	O
evaluations	POTIGA.xml:S3:2414:11	evalu	NNS	O	O
.	POTIGA.xml:S3:2425:1	.	.	O	O

The	POTIGA.xml:S3:2427:3	the	DT	O	O
results	POTIGA.xml:S3:2431:7	result	NNS	O	O
of	POTIGA.xml:S3:2439:2	of	IN	O	O
these	POTIGA.xml:S3:2442:5	these	DT	O	O
evaluations	POTIGA.xml:S3:2448:11	evalu	NNS	O	O
were	POTIGA.xml:S3:2460:4	were	VBD	O	O
consistent	POTIGA.xml:S3:2465:10	consist	JJ	O	O
with	POTIGA.xml:S3:2476:4	with	IN	O	O
a	POTIGA.xml:S3:2481:1	a	DT	O	O
retinal	POTIGA.xml:S3:2483:7	retin	JJ	B-AdverseReaction	O
dystrophy	POTIGA.xml:S3:2491:9	dystrophi	NN	I-AdverseReaction	O
,	POTIGA.xml:S3:2500:1	,	,	O	O
including	POTIGA.xml:S3:2502:9	includ	VBG	O	O
abnormalities	POTIGA.xml:S3:2512:13	abnorm	NNS	B-AdverseReaction	O
in	POTIGA.xml:S3:2526:2	in	IN	I-AdverseReaction	O
the	POTIGA.xml:S3:2529:3	the	DT	I-AdverseReaction	O
electroretinogram	POTIGA.xml:S3:2533:17	electroretinogram	NN	I-AdverseReaction	O
and	POTIGA.xml:S3:2551:3	and	CC	O	O
electrooculogram	POTIGA.xml:S3:2555:16	electrooculogram	NN	I-AdverseReaction	O
of	POTIGA.xml:S3:2572:2	of	IN	O	O
both	POTIGA.xml:S3:2575:4	both	DT	O	O
patients	POTIGA.xml:S3:2580:8	patient	NNS	O	O
,	POTIGA.xml:S3:2588:1	,	,	O	O
with	POTIGA.xml:S3:2590:4	with	IN	O	O
abnormal	POTIGA.xml:S3:2595:8	abnorm	JJ	B-AdverseReaction	O
fluorescein	POTIGA.xml:S3:2604:11	fluorescein	NN	I-AdverseReaction	O
angiography	POTIGA.xml:S3:2616:11	angiographi	NN	I-AdverseReaction	O
and	POTIGA.xml:S3:2628:3	and	CC	O	O
diminished	POTIGA.xml:S3:2632:10	diminish	JJ	B-AdverseReaction	O
sensitivity	POTIGA.xml:S3:2643:11	sensit	NN	I-AdverseReaction	O
on	POTIGA.xml:S3:2655:2	on	IN	I-AdverseReaction	O
visual	POTIGA.xml:S3:2658:6	visual	JJ	I-AdverseReaction	O
field	POTIGA.xml:S3:2665:5	field	NN	I-AdverseReaction	O
testing	POTIGA.xml:S3:2671:7	test	VBG	O	O
in	POTIGA.xml:S3:2679:2	in	IN	O	O
one	POTIGA.xml:S3:2682:3	one	CD	O	O
patient	POTIGA.xml:S3:2686:7	patient	NN	O	O
.	POTIGA.xml:S3:2693:1	.	.	O	O

The	POTIGA.xml:S3:2699:3	the	DT	O	O
rate	POTIGA.xml:S3:2703:4	rate	NN	O	O
of	POTIGA.xml:S3:2708:2	of	IN	O	O
progression	POTIGA.xml:S3:2711:11	progress	NN	O	O
of	POTIGA.xml:S3:2723:2	of	IN	O	O
retinal	POTIGA.xml:S3:2726:7	retin	JJ	B-AdverseReaction	O
abnormalities	POTIGA.xml:S3:2734:13	abnorm	NNS	I-AdverseReaction	O
and	POTIGA.xml:S3:2748:3	and	CC	O	O
the	POTIGA.xml:S3:2752:3	the	DT	O	O
reversibility	POTIGA.xml:S3:2756:13	revers	NN	O	O
after	POTIGA.xml:S3:2770:5	after	IN	O	O
drug	POTIGA.xml:S3:2776:4	drug	NN	O	O
discontinuation	POTIGA.xml:S3:2781:15	discontinu	NN	O	O
are	POTIGA.xml:S3:2797:3	are	VBP	O	O
unknown	POTIGA.xml:S3:2801:7	unknown	JJ	O	O
.	POTIGA.xml:S3:2808:1	.	.	O	O

Because	POTIGA.xml:S3:2814:7	becaus	IN	O	O
of	POTIGA.xml:S3:2822:2	of	IN	O	O
the	POTIGA.xml:S3:2825:3	the	DT	O	O
observed	POTIGA.xml:S3:2829:8	observ	JJ	O	O
ophthalmologic	POTIGA.xml:S3:2838:14	ophthalmolog	JJ	O	O
adverse	POTIGA.xml:S3:2853:7	advers	JJ	O	O
reactions	POTIGA.xml:S3:2861:9	reaction	NNS	O	O
,	POTIGA.xml:S3:2870:1	,	,	O	O
POTIGA	POTIGA.xml:S3:2872:6	potiga	NNP	O	O
should	POTIGA.xml:S3:2879:6	should	MD	O	O
only	POTIGA.xml:S3:2886:4	onli	RB	O	O
be	POTIGA.xml:S3:2891:2	be	VB	O	O
used	POTIGA.xml:S3:2894:4	use	VBN	O	O
in	POTIGA.xml:S3:2899:2	in	IN	O	O
patients	POTIGA.xml:S3:2902:8	patient	NNS	O	O
who	POTIGA.xml:S3:2911:3	who	WP	O	O
have	POTIGA.xml:S3:2915:4	have	VBP	O	O
responded	POTIGA.xml:S3:2920:9	respond	VBN	O	O
inadequately	POTIGA.xml:S3:2930:12	inadequ	RB	O	O
to	POTIGA.xml:S3:2943:2	to	TO	O	O
several	POTIGA.xml:S3:2946:7	sever	JJ	O	O
alternative	POTIGA.xml:S3:2954:11	altern	JJ	O	O
treatments	POTIGA.xml:S3:2966:10	treatment	NNS	O	O
and	POTIGA.xml:S3:2977:3	and	CC	O	O
for	POTIGA.xml:S3:2981:3	for	IN	O	O
whom	POTIGA.xml:S3:2985:4	whom	WP	O	O
the	POTIGA.xml:S3:2990:3	the	DT	O	O
benefits	POTIGA.xml:S3:2994:8	benefit	NNS	O	O
outweigh	POTIGA.xml:S3:3003:8	outweigh	VBP	O	O
the	POTIGA.xml:S3:3012:3	the	DT	O	O
risk	POTIGA.xml:S3:3016:4	risk	NN	O	O
of	POTIGA.xml:S3:3021:2	of	IN	O	O
retinal	POTIGA.xml:S3:3024:7	retin	JJ	O	B-AdverseReaction
abnormalities	POTIGA.xml:S3:3032:13	abnorm	NNS	O	I-AdverseReaction
and	POTIGA.xml:S3:3046:3	and	CC	O	O
potential	POTIGA.xml:S3:3050:9	potenti	JJ	O	B-AdverseReaction
vision	POTIGA.xml:S3:3060:6	vision	NN	O	I-AdverseReaction
loss	POTIGA.xml:S3:3067:4	loss	NN	O	I-AdverseReaction
.	POTIGA.xml:S3:3071:1	.	.	O	O

Patients	POTIGA.xml:S3:3073:8	patient	NNS	O	O
who	POTIGA.xml:S3:3082:3	who	WP	O	O
fail	POTIGA.xml:S3:3086:4	fail	VBP	O	O
to	POTIGA.xml:S3:3091:2	to	TO	O	O
show	POTIGA.xml:S3:3094:4	show	VB	O	O
substantial	POTIGA.xml:S3:3099:11	substanti	JJ	O	O
clinical	POTIGA.xml:S3:3111:8	clinic	JJ	O	O
benefit	POTIGA.xml:S3:3120:7	benefit	NN	O	O
after	POTIGA.xml:S3:3128:5	after	IN	O	O
adequate	POTIGA.xml:S3:3134:8	adequ	JJ	O	O
titration	POTIGA.xml:S3:3143:9	titrat	NN	O	O
should	POTIGA.xml:S3:3153:6	should	MD	O	O
be	POTIGA.xml:S3:3160:2	be	VB	O	O
discontinued	POTIGA.xml:S3:3163:12	discontinu	VBN	O	O
from	POTIGA.xml:S3:3176:4	from	IN	O	O
POTIGA	POTIGA.xml:S3:3181:6	potiga	NNP	O	O
.	POTIGA.xml:S3:3187:1	.	.	O	O

Patients	POTIGA.xml:S3:3193:8	patient	NNS	O	O
should	POTIGA.xml:S3:3202:6	should	MD	O	O
have	POTIGA.xml:S3:3209:4	have	VB	O	O
baseline	POTIGA.xml:S3:3214:8	baselin	NN	O	O
ophthalmologic	POTIGA.xml:S3:3223:14	ophthalmolog	IN	O	O
testing	POTIGA.xml:S3:3238:7	test	VBG	O	O
by	POTIGA.xml:S3:3246:2	by	IN	O	O
an	POTIGA.xml:S3:3249:2	an	DT	O	O
ophthalmic	POTIGA.xml:S3:3252:10	ophthalm	JJ	O	O
professional	POTIGA.xml:S3:3263:12	profession	NN	O	O
and	POTIGA.xml:S3:3276:3	and	CC	O	O
follow	POTIGA.xml:S3:3280:6	follow	VB	O	O
-	POTIGA.xml:S3:3286:1	-	:	O	O
up	POTIGA.xml:S3:3287:2	up	RP	O	O
testing	POTIGA.xml:S3:3290:7	test	VBG	O	O
every	POTIGA.xml:S3:3298:5	everi	DT	O	O
6	POTIGA.xml:S3:3304:1	6	CD	O	O
months	POTIGA.xml:S3:3306:6	month	NNS	O	O
.	POTIGA.xml:S3:3312:1	.	.	O	O

The	POTIGA.xml:S3:3314:3	the	DT	O	O
best	POTIGA.xml:S3:3318:4	best	JJS	O	O
method	POTIGA.xml:S3:3323:6	method	NN	O	O
of	POTIGA.xml:S3:3330:2	of	IN	O	O
detection	POTIGA.xml:S3:3333:9	detect	NN	O	O
of	POTIGA.xml:S3:3343:2	of	IN	O	O
these	POTIGA.xml:S3:3346:5	these	DT	O	O
abnormalities	POTIGA.xml:S3:3352:13	abnorm	NNS	O	O
and	POTIGA.xml:S3:3366:3	and	CC	O	O
the	POTIGA.xml:S3:3370:3	the	DT	O	O
optimal	POTIGA.xml:S3:3374:7	optim	JJ	O	O
frequency	POTIGA.xml:S3:3382:9	frequenc	NN	O	O
of	POTIGA.xml:S3:3392:2	of	IN	O	O
periodic	POTIGA.xml:S3:3395:8	period	JJ	O	O
ophthalmologic	POTIGA.xml:S3:3404:14	ophthalmolog	JJ	O	O
monitoring	POTIGA.xml:S3:3419:10	monitor	NN	O	O
are	POTIGA.xml:S3:3430:3	are	VBP	O	O
unknown	POTIGA.xml:S3:3434:7	unknown	JJ	O	O
.	POTIGA.xml:S3:3441:1	.	.	O	O

Patients	POTIGA.xml:S3:3443:8	patient	NNS	O	O
who	POTIGA.xml:S3:3452:3	who	WP	O	O
cannot	POTIGA.xml:S3:3456:6	cannot	VBP	O	O
be	POTIGA.xml:S3:3463:2	be	VB	O	O
monitored	POTIGA.xml:S3:3466:9	monitor	VBN	O	O
should	POTIGA.xml:S3:3476:6	should	MD	O	O
usually	POTIGA.xml:S3:3483:7	usual	RB	O	O
not	POTIGA.xml:S3:3491:3	not	RB	O	O
be	POTIGA.xml:S3:3495:2	be	VB	O	O
treated	POTIGA.xml:S3:3498:7	treat	VBN	O	O
with	POTIGA.xml:S3:3506:4	with	IN	O	O
POTIGA	POTIGA.xml:S3:3511:6	potiga	NNP	O	O
.	POTIGA.xml:S3:3517:1	.	.	O	O

The	POTIGA.xml:S3:3519:3	the	DT	O	O
ophthalmologic	POTIGA.xml:S3:3523:14	ophthalmolog	JJ	O	O
monitoring	POTIGA.xml:S3:3538:10	monitor	NN	O	O
program	POTIGA.xml:S3:3549:7	program	NN	O	O
should	POTIGA.xml:S3:3557:6	should	MD	O	O
include	POTIGA.xml:S3:3564:7	includ	VB	O	O
visual	POTIGA.xml:S3:3572:6	visual	JJ	O	B-AdverseReaction
acuity	POTIGA.xml:S3:3579:6	acuiti	NN	O	I-AdverseReaction
testing	POTIGA.xml:S3:3586:7	test	NN	O	I-AdverseReaction
and	POTIGA.xml:S3:3594:3	and	CC	O	O
dilated	POTIGA.xml:S3:3598:7	dilat	VBD	O	O
fundus	POTIGA.xml:S3:3606:6	fundu	NN	O	O
photography	POTIGA.xml:S3:3613:11	photographi	NN	O	O
.	POTIGA.xml:S3:3624:1	.	.	O	O

Additional	POTIGA.xml:S3:3626:10	addit	JJ	O	O
testing	POTIGA.xml:S3:3637:7	test	NN	O	O
may	POTIGA.xml:S3:3645:3	may	MD	O	O
include	POTIGA.xml:S3:3649:7	includ	VB	O	O
fluorescein	POTIGA.xml:S3:3657:11	fluorescein	JJ	O	O
angiograms	POTIGA.xml:S3:3669:10	angiogram	NNS	O	O
(	POTIGA.xml:S3:3680:1	(	(	O	O
FA	POTIGA.xml:S3:3681:2	FA	NNP	O	O
)	POTIGA.xml:S3:3683:1	)	)	O	O
,	POTIGA.xml:S3:3684:1	,	,	O	O
optical	POTIGA.xml:S3:3686:7	optic	JJ	O	B-AdverseReaction
coherence	POTIGA.xml:S3:3694:9	coher	NN	O	I-AdverseReaction
tomography	POTIGA.xml:S3:3704:10	tomographi	NN	O	I-AdverseReaction
(	POTIGA.xml:S3:3715:1	(	(	O	O
OCT	POTIGA.xml:S3:3716:3	oct	NNP	O	O
)	POTIGA.xml:S3:3719:1	)	)	O	O
,	POTIGA.xml:S3:3720:1	,	,	O	O
perimetry	POTIGA.xml:S3:3722:9	perimetri	NN	O	O
,	POTIGA.xml:S3:3731:1	,	,	O	O
and	POTIGA.xml:S3:3733:3	and	CC	O	O
electroretinograms	POTIGA.xml:S3:3737:18	electroretinogram	NNS	O	O
(	POTIGA.xml:S3:3756:1	(	(	O	O
ERG	POTIGA.xml:S3:3757:3	erg	NNP	O	O
)	POTIGA.xml:S3:3760:1	)	)	O	O
.	POTIGA.xml:S3:3761:1	.	.	O	O

If	POTIGA.xml:S3:3763:2	If	IN	O	O
retinal	POTIGA.xml:S3:3766:7	retin	JJ	O	O
pigmentary	POTIGA.xml:S3:3774:10	pigmentari	JJ	O	O
abnormalities	POTIGA.xml:S3:3785:13	abnorm	NNS	O	O
or	POTIGA.xml:S3:3799:2	or	CC	O	O
vision	POTIGA.xml:S3:3802:6	vision	NN	O	O
changes	POTIGA.xml:S3:3809:7	chang	NNS	O	O
are	POTIGA.xml:S3:3817:3	are	VBP	O	O
detected	POTIGA.xml:S3:3821:8	detect	VBN	O	O
,	POTIGA.xml:S3:3829:1	,	,	O	O
POTIGA	POTIGA.xml:S3:3831:6	potiga	NNP	O	O
should	POTIGA.xml:S3:3838:6	should	MD	O	O
be	POTIGA.xml:S3:3845:2	be	VB	O	O
discontinued	POTIGA.xml:S3:3848:12	discontinu	VBN	O	O
unless	POTIGA.xml:S3:3861:6	unless	IN	O	O
no	POTIGA.xml:S3:3868:2	no	DT	O	O
other	POTIGA.xml:S3:3871:5	other	JJ	O	O
suitable	POTIGA.xml:S3:3877:8	suitabl	JJ	O	O
treatment	POTIGA.xml:S3:3886:9	treatment	NN	O	O
options	POTIGA.xml:S3:3896:7	option	NNS	O	O
are	POTIGA.xml:S3:3904:3	are	VBP	O	O
available	POTIGA.xml:S3:3908:9	avail	JJ	O	O
and	POTIGA.xml:S3:3918:3	and	CC	O	O
the	POTIGA.xml:S3:3922:3	the	DT	O	O
benefits	POTIGA.xml:S3:3926:8	benefit	NNS	O	O
of	POTIGA.xml:S3:3935:2	of	IN	O	O
treatment	POTIGA.xml:S3:3938:9	treatment	NN	O	O
outweigh	POTIGA.xml:S3:3948:8	outweigh	VBP	O	O
the	POTIGA.xml:S3:3957:3	the	DT	O	O
potential	POTIGA.xml:S3:3961:9	potenti	JJ	O	O
risk	POTIGA.xml:S3:3971:4	risk	NN	O	O
of	POTIGA.xml:S3:3976:2	of	IN	O	O
vision	POTIGA.xml:S3:3979:6	vision	NN	O	O
loss	POTIGA.xml:S3:3986:4	loss	NN	O	O
.	POTIGA.xml:S3:3990:1	.	.	O	O

5.2	POTIGA.xml:S3:3999:3	5.2	CD	O	O
Urinary	POTIGA.xml:S3:4003:7	urinari	JJ	O	O
Retention	POTIGA.xml:S3:4011:9	retent	NN	O	O

POTIGA	POTIGA.xml:S3:4026:6	potiga	NNP	O	O
caused	POTIGA.xml:S3:4033:6	caus	VBD	O	O
urinary	POTIGA.xml:S3:4040:7	urinari	JJ	B-AdverseReaction	O
retention	POTIGA.xml:S3:4048:9	retent	NN	I-AdverseReaction	O
in	POTIGA.xml:S3:4058:2	in	IN	O	O
clinical	POTIGA.xml:S3:4061:8	clinic	JJ	O	O
trials	POTIGA.xml:S3:4070:6	trial	NNS	O	O
.	POTIGA.xml:S3:4076:1	.	.	O	O

Urinary	POTIGA.xml:S3:4078:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
retention	POTIGA.xml:S3:4086:9	retent	NN	I-AdverseReaction	I-AdverseReaction
was	POTIGA.xml:S3:4096:3	wa	VBD	O	O
generally	POTIGA.xml:S3:4100:9	gener	RB	O	O
reported	POTIGA.xml:S3:4110:8	report	VBN	O	O
within	POTIGA.xml:S3:4119:6	within	IN	O	O
the	POTIGA.xml:S3:4126:3	the	DT	O	O
first	POTIGA.xml:S3:4130:5	first	JJ	O	O
6	POTIGA.xml:S3:4136:1	6	CD	O	O
months	POTIGA.xml:S3:4138:6	month	NNS	O	O
of	POTIGA.xml:S3:4145:2	of	IN	O	O
treatment	POTIGA.xml:S3:4148:9	treatment	NN	O	O
,	POTIGA.xml:S3:4157:1	,	,	O	O
but	POTIGA.xml:S3:4159:3	but	CC	O	O
was	POTIGA.xml:S3:4163:3	wa	VBD	O	O
also	POTIGA.xml:S3:4167:4	also	RB	O	O
observed	POTIGA.xml:S3:4172:8	observ	VBN	O	O
later	POTIGA.xml:S3:4181:5	later	RB	O	O
.	POTIGA.xml:S3:4186:1	.	.	O	O

Urinary	POTIGA.xml:S3:4188:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
retention	POTIGA.xml:S3:4196:9	retent	NN	I-AdverseReaction	I-AdverseReaction
was	POTIGA.xml:S3:4206:3	wa	VBD	O	O
reported	POTIGA.xml:S3:4210:8	report	VBN	O	O
as	POTIGA.xml:S3:4219:2	as	IN	O	O
an	POTIGA.xml:S3:4222:2	an	DT	O	O
adverse	POTIGA.xml:S3:4225:7	advers	JJ	O	O
event	POTIGA.xml:S3:4233:5	event	NN	O	O
in	POTIGA.xml:S3:4239:2	in	IN	O	O
29	POTIGA.xml:S3:4242:2	29	CD	O	O
of	POTIGA.xml:S3:4245:2	of	IN	O	O
1	POTIGA.xml:S3:4248:1	1	CD	O	O
,	POTIGA.xml:S3:4249:1	,	,	O	O
365	POTIGA.xml:S3:4250:3	365	CD	O	O
(	POTIGA.xml:S3:4254:1	(	(	O	O
approximately	POTIGA.xml:S3:4255:13	approxim	RB	O	O
2%	POTIGA.xml:S3:4269:2	2%	CD	O	O
)	POTIGA.xml:S3:4271:1	)	)	O	O
patients	POTIGA.xml:S3:4273:8	patient	NNS	O	O
treated	POTIGA.xml:S3:4282:7	treat	VBN	O	O
with	POTIGA.xml:S3:4290:4	with	IN	O	O
POTIGA	POTIGA.xml:S3:4295:6	potiga	NNP	O	O
in	POTIGA.xml:S3:4302:2	in	IN	O	O
the	POTIGA.xml:S3:4305:3	the	DT	O	O
open	POTIGA.xml:S3:4309:4	open	JJ	O	O
-	POTIGA.xml:S3:4313:1	-	:	O	O
label	POTIGA.xml:S3:4314:5	label	NN	O	O
and	POTIGA.xml:S3:4320:3	and	CC	O	O
placebo	POTIGA.xml:S3:4324:7	placebo	NN	O	O
-	POTIGA.xml:S3:4331:1	-	:	O	O
controlled	POTIGA.xml:S3:4332:10	control	VBN	O	O
epilepsy	POTIGA.xml:S3:4343:8	epilepsi	JJ	O	O
database	POTIGA.xml:S3:4352:8	databas	NN	O	O
[	POTIGA.xml:S3:4361:1	[	NNP	O	O
see	POTIGA.xml:S3:4362:3	see	VBP	O	O
Clinical	POTIGA.xml:S3:4366:8	clinic	JJ	O	O
Studies	POTIGA.xml:S3:4375:7	studi	NNP	O	O
(	POTIGA.xml:S3:4383:1	(	(	O	O
14	POTIGA.xml:S3:4384:2	14	CD	O	O
)]	POTIGA.xml:S3:4386:2	)]	NN	O	O
.	POTIGA.xml:S3:4390:1	.	.	O	O

Of	POTIGA.xml:S3:4392:2	Of	IN	O	O
these	POTIGA.xml:S3:4395:5	these	DT	O	O
29	POTIGA.xml:S3:4401:2	29	CD	O	O
patients	POTIGA.xml:S3:4404:8	patient	NNS	O	O
,	POTIGA.xml:S3:4412:1	,	,	O	O
5	POTIGA.xml:S3:4414:1	5	CD	O	O
(	POTIGA.xml:S3:4416:1	(	(	O	O
17%	POTIGA.xml:S3:4417:3	17%	CD	O	O
)	POTIGA.xml:S3:4420:1	)	)	O	O
required	POTIGA.xml:S3:4422:8	requir	VBN	O	O
catheterization	POTIGA.xml:S3:4431:15	catheter	NN	O	O
,	POTIGA.xml:S3:4446:1	,	,	O	O
with	POTIGA.xml:S3:4448:4	with	IN	O	O
post	POTIGA.xml:S3:4453:4	post	NN	O	O
-	POTIGA.xml:S3:4457:1	-	:	O	O
voiding	POTIGA.xml:S3:4458:7	void	NN	O	O
residuals	POTIGA.xml:S3:4466:9	residu	NNS	O	O
of	POTIGA.xml:S3:4476:2	of	IN	O	O
up	POTIGA.xml:S3:4479:2	up	IN	O	O
to	POTIGA.xml:S3:4482:2	to	TO	O	O
1	POTIGA.xml:S3:4485:1	1	CD	O	O
,	POTIGA.xml:S3:4486:1	,	,	O	O
500	POTIGA.xml:S3:4487:3	500	CD	O	O
mL	POTIGA.xml:S3:4491:2	mL	NN	O	O
.	POTIGA.xml:S3:4493:1	.	.	O	O

POTIGA	POTIGA.xml:S3:4495:6	potiga	NNP	O	O
was	POTIGA.xml:S3:4502:3	wa	VBD	O	O
discontinued	POTIGA.xml:S3:4506:12	discontinu	VBN	O	O
in	POTIGA.xml:S3:4519:2	in	IN	O	O
3	POTIGA.xml:S3:4522:1	3	CD	O	O
of	POTIGA.xml:S3:4524:2	of	IN	O	O
the	POTIGA.xml:S3:4527:3	the	DT	O	O
5	POTIGA.xml:S3:4531:1	5	CD	O	O
patients	POTIGA.xml:S3:4533:8	patient	NNS	O	O
who	POTIGA.xml:S3:4542:3	who	WP	O	O
required	POTIGA.xml:S3:4546:8	requir	VBD	O	O
catheterization	POTIGA.xml:S3:4555:15	catheter	NN	O	O
,	POTIGA.xml:S3:4570:1	,	,	O	O
and	POTIGA.xml:S3:4572:3	and	CC	O	O
all	POTIGA.xml:S3:4576:3	all	DT	O	O
were	POTIGA.xml:S3:4580:4	were	VBD	O	O
able	POTIGA.xml:S3:4585:4	abl	JJ	O	O
to	POTIGA.xml:S3:4590:2	to	TO	O	O
void	POTIGA.xml:S3:4593:4	void	VB	O	O
spontaneously	POTIGA.xml:S3:4598:13	spontan	RB	O	O
;	POTIGA.xml:S3:4611:1	;	:	O	O
however	POTIGA.xml:S3:4613:7	howev	RB	O	O
,	POTIGA.xml:S3:4620:1	,	,	O	O
1	POTIGA.xml:S3:4622:1	1	CD	O	O
of	POTIGA.xml:S3:4624:2	of	IN	O	O
the	POTIGA.xml:S3:4627:3	the	DT	O	O
3	POTIGA.xml:S3:4631:1	3	CD	O	O
patients	POTIGA.xml:S3:4633:8	patient	NNS	O	O
continued	POTIGA.xml:S3:4642:9	continu	JJ	O	O
intermittent	POTIGA.xml:S3:4652:12	intermitt	JJ	O	O
self	POTIGA.xml:S3:4665:4	self	NN	O	O
-	POTIGA.xml:S3:4669:1	-	:	O	O
catheterization	POTIGA.xml:S3:4670:15	catheter	NN	O	O
.	POTIGA.xml:S3:4685:1	.	.	O	O

Two	POTIGA.xml:S3:4687:3	two	CD	O	O
patients	POTIGA.xml:S3:4691:8	patient	NNS	O	O
continued	POTIGA.xml:S3:4700:9	continu	VBD	O	O
treatment	POTIGA.xml:S3:4710:9	treatment	NN	O	O
with	POTIGA.xml:S3:4720:4	with	IN	O	O
POTIGA	POTIGA.xml:S3:4725:6	potiga	NNP	O	O
and	POTIGA.xml:S3:4732:3	and	CC	O	O
were	POTIGA.xml:S3:4736:4	were	VBD	O	O
able	POTIGA.xml:S3:4741:4	abl	JJ	O	O
to	POTIGA.xml:S3:4746:2	to	TO	O	O
void	POTIGA.xml:S3:4749:4	void	VB	O	O
spontaneously	POTIGA.xml:S3:4754:13	spontan	RB	O	O
after	POTIGA.xml:S3:4768:5	after	IN	O	O
catheter	POTIGA.xml:S3:4774:8	cathet	NN	O	O
removal	POTIGA.xml:S3:4783:7	remov	NN	O	O
.	POTIGA.xml:S3:4790:1	.	.	O	O

Hydronephrosis	POTIGA.xml:S3:4792:14	hydronephrosi	NN	B-AdverseReaction	O
occurred	POTIGA.xml:S3:4807:8	occur	VBD	O	O
in	POTIGA.xml:S3:4816:2	in	IN	O	O
2	POTIGA.xml:S3:4819:1	2	CD	O	O
patients	POTIGA.xml:S3:4821:8	patient	NNS	O	O
,	POTIGA.xml:S3:4829:1	,	,	O	O
one	POTIGA.xml:S3:4831:3	one	CD	O	O
of	POTIGA.xml:S3:4835:2	of	IN	O	O
whom	POTIGA.xml:S3:4838:4	whom	WP	O	O
had	POTIGA.xml:S3:4843:3	had	VBD	O	O
associated	POTIGA.xml:S3:4847:10	associ	VBN	O	O
renal	POTIGA.xml:S3:4858:5	renal	JJ	B-AdverseReaction	O
function	POTIGA.xml:S3:4864:8	function	NN	I-AdverseReaction	O
impairment	POTIGA.xml:S3:4873:10	impair	NN	I-AdverseReaction	O
that	POTIGA.xml:S3:4884:4	that	WDT	O	O
resolved	POTIGA.xml:S3:4889:8	resolv	VBD	O	O
upon	POTIGA.xml:S3:4898:4	upon	IN	O	O
discontinuation	POTIGA.xml:S3:4903:15	discontinu	NN	O	O
of	POTIGA.xml:S3:4919:2	of	IN	O	O
POTIGA	POTIGA.xml:S3:4922:6	potiga	NNP	O	O
.	POTIGA.xml:S3:4928:1	.	.	O	O

Hydronephrosis	POTIGA.xml:S3:4930:14	hydronephrosi	NN	B-AdverseReaction	O
was	POTIGA.xml:S3:4945:3	wa	VBD	O	O
not	POTIGA.xml:S3:4949:3	not	RB	O	O
reported	POTIGA.xml:S3:4953:8	report	VBN	O	O
in	POTIGA.xml:S3:4962:2	in	IN	O	O
placebo	POTIGA.xml:S3:4965:7	placebo	NN	O	O
patients	POTIGA.xml:S3:4973:8	patient	NNS	O	O
.	POTIGA.xml:S3:4981:1	.	.	O	O

In	POTIGA.xml:S3:4987:2	In	IN	O	O
the	POTIGA.xml:S3:4990:3	the	DT	O	O
placebo	POTIGA.xml:S3:4994:7	placebo	NN	O	O
-	POTIGA.xml:S3:5001:1	-	:	O	O
controlled	POTIGA.xml:S3:5002:10	control	VBN	O	O
epilepsy	POTIGA.xml:S3:5013:8	epilepsi	NN	O	O
trials	POTIGA.xml:S3:5022:6	trial	NNS	O	O
,	POTIGA.xml:S3:5028:1	,	,	O	O
"	POTIGA.xml:S3:5030:1	"	NNP	O	O
urinary	POTIGA.xml:S3:5031:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
retention	POTIGA.xml:S3:5039:9	retent	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S3:5048:1	,	,	O	O
"	POTIGA.xml:S3:5049:1	"	NNP	O	O
"	POTIGA.xml:S3:5051:1	"	NNP	O	O
urinary	POTIGA.xml:S3:5052:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
hesitation	POTIGA.xml:S3:5060:10	hesit	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S3:5070:1	,	,	O	O
"	POTIGA.xml:S3:5071:1	"	NNP	O	O
and	POTIGA.xml:S3:5073:3	and	CC	O	O
"	POTIGA.xml:S3:5077:1	"	NNP	O	O
dysuria	POTIGA.xml:S3:5078:7	dysuria	NNS	B-AdverseReaction	B-AdverseReaction
"	POTIGA.xml:S3:5085:1	"	NN	O	I-AdverseReaction
were	POTIGA.xml:S3:5087:4	were	VBD	O	O
reported	POTIGA.xml:S3:5092:8	report	VBN	O	O
in	POTIGA.xml:S3:5101:2	in	IN	O	O
0.9%	POTIGA.xml:S3:5104:4	0.9%	CD	O	O
,	POTIGA.xml:S3:5108:1	,	,	O	O
2.2%	POTIGA.xml:S3:5110:4	2.2%	CD	O	O
,	POTIGA.xml:S3:5114:1	,	,	O	O
and	POTIGA.xml:S3:5116:3	and	CC	O	O
2.3%	POTIGA.xml:S3:5120:4	2.3%	CD	O	O
of	POTIGA.xml:S3:5125:2	of	IN	O	O
patients	POTIGA.xml:S3:5128:8	patient	NNS	O	O
on	POTIGA.xml:S3:5137:2	on	IN	O	O
POTIGA	POTIGA.xml:S3:5140:6	potiga	NNP	O	O
,	POTIGA.xml:S3:5146:1	,	,	O	O
respectively	POTIGA.xml:S3:5148:12	respect	RB	O	O
,	POTIGA.xml:S3:5160:1	,	,	O	O
and	POTIGA.xml:S3:5162:3	and	CC	O	O
in	POTIGA.xml:S3:5166:2	in	IN	O	O
0.5%	POTIGA.xml:S3:5169:4	0.5%	CD	O	O
,	POTIGA.xml:S3:5173:1	,	,	O	O
0.9%	POTIGA.xml:S3:5175:4	0.9%	CD	O	O
,	POTIGA.xml:S3:5179:1	,	,	O	O
and	POTIGA.xml:S3:5181:3	and	CC	O	O
0.7%	POTIGA.xml:S3:5185:4	0.7%	CD	O	O
of	POTIGA.xml:S3:5190:2	of	IN	O	O
patients	POTIGA.xml:S3:5193:8	patient	NNS	O	O
on	POTIGA.xml:S3:5202:2	on	IN	O	O
placebo	POTIGA.xml:S3:5205:7	placebo	NN	O	O
,	POTIGA.xml:S3:5212:1	,	,	O	O
respectively	POTIGA.xml:S3:5214:12	respect	RB	O	O
.	POTIGA.xml:S3:5226:1	.	.	O	O

Because	POTIGA.xml:S3:5232:7	becaus	IN	O	O
of	POTIGA.xml:S3:5240:2	of	IN	O	O
the	POTIGA.xml:S3:5243:3	the	DT	O	O
increased	POTIGA.xml:S3:5247:9	increas	VBN	O	O
risk	POTIGA.xml:S3:5257:4	risk	NN	O	O
of	POTIGA.xml:S3:5262:2	of	IN	O	O
urinary	POTIGA.xml:S3:5265:7	urinari	JJ	O	B-AdverseReaction
retention	POTIGA.xml:S3:5273:9	retent	NN	O	I-AdverseReaction
on	POTIGA.xml:S3:5283:2	on	IN	O	O
POTIGA	POTIGA.xml:S3:5286:6	potiga	NNP	O	O
,	POTIGA.xml:S3:5292:1	,	,	O	O
urologic	POTIGA.xml:S3:5294:8	urolog	JJ	O	O
symptoms	POTIGA.xml:S3:5303:8	symptom	NNS	O	O
should	POTIGA.xml:S3:5312:6	should	MD	O	O
be	POTIGA.xml:S3:5319:2	be	VB	O	O
carefully	POTIGA.xml:S3:5322:9	care	RB	O	O
monitored	POTIGA.xml:S3:5332:9	monitor	VBN	O	O
.	POTIGA.xml:S3:5341:1	.	.	O	O

Closer	POTIGA.xml:S3:5343:6	closer	NNP	O	O
monitoring	POTIGA.xml:S3:5350:10	monitor	NN	O	O
is	POTIGA.xml:S3:5361:2	is	VBZ	O	O
recommended	POTIGA.xml:S3:5364:11	recommend	VBN	O	O
for	POTIGA.xml:S3:5376:3	for	IN	O	O
patients	POTIGA.xml:S3:5380:8	patient	NNS	O	O
who	POTIGA.xml:S3:5389:3	who	WP	O	O
have	POTIGA.xml:S3:5393:4	have	VBP	O	O
other	POTIGA.xml:S3:5398:5	other	JJ	O	O
risk	POTIGA.xml:S3:5404:4	risk	NN	O	O
factors	POTIGA.xml:S3:5409:7	factor	NNS	O	O
for	POTIGA.xml:S3:5417:3	for	IN	O	O
urinary	POTIGA.xml:S3:5421:7	urinari	JJ	O	O
retention	POTIGA.xml:S3:5429:9	retent	NN	O	O
(	POTIGA.xml:S3:5439:1	(	(	O	O
e	POTIGA.xml:S3:5440:1	e	NN	O	O
.	POTIGA.xml:S3:5441:1	.	.	O	O
g	POTIGA.xml:S3:5442:1	g	NN	O	O
.	POTIGA.xml:S3:5443:1	.	.	O	O
,	POTIGA.xml:S3:5444:1	,	,	O	O
benign	POTIGA.xml:S3:5446:6	benign	JJ	O	O
prostatic	POTIGA.xml:S3:5453:9	prostat	JJ	O	O
hyperplasia	POTIGA.xml:S3:5463:11	hyperplasia	NN	O	O
[	POTIGA.xml:S3:5475:1	[	NNP	O	O
BPH	POTIGA.xml:S3:5476:3	bph	NNP	O	O
])	POTIGA.xml:S3:5479:2	])	NNP	O	O
,	POTIGA.xml:S3:5481:1	,	,	O	O
patients	POTIGA.xml:S3:5483:8	patient	NNS	O	O
who	POTIGA.xml:S3:5492:3	who	WP	O	O
are	POTIGA.xml:S3:5496:3	are	VBP	O	O
unable	POTIGA.xml:S3:5500:6	unabl	JJ	O	O
to	POTIGA.xml:S3:5507:2	to	TO	O	O
communicate	POTIGA.xml:S3:5510:11	commun	VB	O	O
clinical	POTIGA.xml:S3:5522:8	clinic	JJ	O	O
symptoms	POTIGA.xml:S3:5531:8	symptom	NNS	O	O
(	POTIGA.xml:S3:5540:1	(	(	O	O
e	POTIGA.xml:S3:5541:1	e	NN	O	O
.	POTIGA.xml:S3:5542:1	.	.	O	O
g	POTIGA.xml:S3:5543:1	g	NN	O	O
.	POTIGA.xml:S3:5544:1	.	.	O	O
,	POTIGA.xml:S3:5545:1	,	,	O	O
cognitively	POTIGA.xml:S3:5547:11	cognit	RB	O	O
impaired	POTIGA.xml:S3:5559:8	impair	JJ	O	O
patients	POTIGA.xml:S3:5568:8	patient	NNS	O	O
)	POTIGA.xml:S3:5576:1	)	)	O	O
,	POTIGA.xml:S3:5577:1	,	,	O	O
or	POTIGA.xml:S3:5579:2	or	CC	O	O
patients	POTIGA.xml:S3:5582:8	patient	NNS	O	O
who	POTIGA.xml:S3:5591:3	who	WP	O	O
use	POTIGA.xml:S3:5595:3	use	VBP	O	O
concomitant	POTIGA.xml:S3:5599:11	concomit	JJ	O	O
medications	POTIGA.xml:S3:5611:11	medic	NNS	O	O
that	POTIGA.xml:S3:5623:4	that	WDT	O	O
may	POTIGA.xml:S3:5628:3	may	MD	O	O
affect	POTIGA.xml:S3:5632:6	affect	VB	O	O
voiding	POTIGA.xml:S3:5639:7	void	VBG	O	O
(	POTIGA.xml:S3:5647:1	(	(	O	O
e	POTIGA.xml:S3:5648:1	e	NN	O	O
.	POTIGA.xml:S3:5649:1	.	.	O	O
g	POTIGA.xml:S3:5650:1	g	NN	O	O
.	POTIGA.xml:S3:5651:1	.	.	O	O
,	POTIGA.xml:S3:5652:1	,	,	O	O
anticholinergics	POTIGA.xml:S3:5654:16	anticholinerg	NNS	O	O
)	POTIGA.xml:S3:5670:1	)	)	O	O
.	POTIGA.xml:S3:5671:1	.	.	O	O

In	POTIGA.xml:S3:5673:2	In	IN	O	O
these	POTIGA.xml:S3:5676:5	these	DT	O	O
patients	POTIGA.xml:S3:5682:8	patient	NNS	O	O
,	POTIGA.xml:S3:5690:1	,	,	O	O
a	POTIGA.xml:S3:5692:1	a	DT	O	O
comprehensive	POTIGA.xml:S3:5694:13	comprehens	JJ	O	O
evaluation	POTIGA.xml:S3:5708:10	evalu	NN	O	O
of	POTIGA.xml:S3:5719:2	of	IN	O	O
urologic	POTIGA.xml:S3:5722:8	urolog	JJ	O	O
symptoms	POTIGA.xml:S3:5731:8	symptom	NNS	O	O
prior	POTIGA.xml:S3:5740:5	prior	RB	O	O
to	POTIGA.xml:S3:5746:2	to	TO	O	O
and	POTIGA.xml:S3:5749:3	and	CC	O	O
during	POTIGA.xml:S3:5753:6	dure	IN	O	O
treatment	POTIGA.xml:S3:5760:9	treatment	NN	O	O
with	POTIGA.xml:S3:5770:4	with	IN	O	O
POTIGA	POTIGA.xml:S3:5775:6	potiga	NNP	O	O
may	POTIGA.xml:S3:5782:3	may	MD	O	O
be	POTIGA.xml:S3:5786:2	be	VB	O	O
appropriate	POTIGA.xml:S3:5789:11	appropri	JJ	O	O
.	POTIGA.xml:S3:5800:1	.	.	O	O

5.3	POTIGA.xml:S3:5809:3	5.3	CD	O	O
Skin	POTIGA.xml:S3:5813:4	skin	NNP	O	O
Discoloration	POTIGA.xml:S3:5818:13	discolor	NN	O	O

POTIGA	POTIGA.xml:S3:5837:6	potiga	NNP	O	O
can	POTIGA.xml:S3:5844:3	can	MD	O	O
cause	POTIGA.xml:S3:5848:5	caus	VB	O	O
skin	POTIGA.xml:S3:5854:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
discoloration	POTIGA.xml:S3:5859:13	discolor	NN	I-AdverseReaction	I-AdverseReaction
.	POTIGA.xml:S3:5872:1	.	.	O	O

The	POTIGA.xml:S3:5874:3	the	DT	O	O
skin	POTIGA.xml:S3:5878:4	skin	JJ	B-AdverseReaction	O
discoloration	POTIGA.xml:S3:5883:13	discolor	NN	I-AdverseReaction	O
is	POTIGA.xml:S3:5897:2	is	VBZ	O	O
generally	POTIGA.xml:S3:5900:9	gener	RB	O	O
described	POTIGA.xml:S3:5910:9	describ	VBN	O	O
as	POTIGA.xml:S3:5920:2	as	IN	O	O
blue	POTIGA.xml:S3:5923:4	blue	JJ	O	O
,	POTIGA.xml:S3:5927:1	,	,	O	O
but	POTIGA.xml:S3:5929:3	but	CC	O	O
has	POTIGA.xml:S3:5933:3	ha	VBZ	O	O
also	POTIGA.xml:S3:5937:4	also	RB	O	O
been	POTIGA.xml:S3:5942:4	been	VBN	O	O
described	POTIGA.xml:S3:5947:9	describ	VBN	O	O
as	POTIGA.xml:S3:5957:2	as	IN	O	O
grey	POTIGA.xml:S3:5960:4	grey	JJ	O	O
-	POTIGA.xml:S3:5964:1	-	:	O	O
blue	POTIGA.xml:S3:5965:4	blue	NN	O	O
or	POTIGA.xml:S3:5970:2	or	CC	O	O
brown	POTIGA.xml:S3:5973:5	brown	NN	O	O
.	POTIGA.xml:S3:5978:1	.	.	O	O

It	POTIGA.xml:S3:5980:2	It	PRP	O	O
is	POTIGA.xml:S3:5983:2	is	VBZ	O	O
predominantly	POTIGA.xml:S3:5986:13	predominantli	RB	O	O
on	POTIGA.xml:S3:6000:2	on	IN	O	O
or	POTIGA.xml:S3:6003:2	or	CC	O	O
around	POTIGA.xml:S3:6006:6	around	IN	O	O
the	POTIGA.xml:S3:6013:3	the	DT	O	O
lips	POTIGA.xml:S3:6017:4	lip	NNS	O	O
or	POTIGA.xml:S3:6022:2	or	CC	O	O
in	POTIGA.xml:S3:6025:2	in	IN	O	O
the	POTIGA.xml:S3:6028:3	the	DT	O	O
nail	POTIGA.xml:S3:6032:4	nail	JJ	O	O
beds	POTIGA.xml:S3:6037:4	bed	NNS	O	O
of	POTIGA.xml:S3:6042:2	of	IN	O	O
the	POTIGA.xml:S3:6045:3	the	DT	O	O
fingers	POTIGA.xml:S3:6049:7	finger	NNS	O	O
or	POTIGA.xml:S3:6057:2	or	CC	O	O
toes	POTIGA.xml:S3:6060:4	toe	NNS	O	O
,	POTIGA.xml:S3:6064:1	,	,	O	O
but	POTIGA.xml:S3:6066:3	but	CC	O	O
more	POTIGA.xml:S3:6070:4	more	JJR	O	O
widespread	POTIGA.xml:S3:6075:10	widespread	JJ	O	O
involvement	POTIGA.xml:S3:6086:11	involv	NN	O	O
of	POTIGA.xml:S3:6098:2	of	IN	O	O
the	POTIGA.xml:S3:6101:3	the	DT	O	O
face	POTIGA.xml:S3:6105:4	face	NN	O	O
and	POTIGA.xml:S3:6110:3	and	CC	O	O
legs	POTIGA.xml:S3:6114:4	leg	NN	O	O
has	POTIGA.xml:S3:6119:3	ha	VBZ	O	O
also	POTIGA.xml:S3:6123:4	also	RB	O	O
been	POTIGA.xml:S3:6128:4	been	VBN	O	O
reported	POTIGA.xml:S3:6133:8	report	VBN	O	O
.	POTIGA.xml:S3:6141:1	.	.	O	O

Discoloration	POTIGA.xml:S3:6143:13	discolor	NN	B-AdverseReaction	O
of	POTIGA.xml:S3:6157:2	of	IN	I-AdverseReaction	O
the	POTIGA.xml:S3:6160:3	the	DT	I-AdverseReaction	O
palate	POTIGA.xml:S3:6164:6	palat	NN	I-AdverseReaction	O
,	POTIGA.xml:S3:6170:1	,	,	O	O
sclera	POTIGA.xml:S3:6172:6	sclera	NN	I-AdverseReaction	O
,	POTIGA.xml:S3:6178:1	,	,	O	O
and	POTIGA.xml:S3:6180:3	and	CC	O	O
conjunctiva	POTIGA.xml:S3:6184:11	conjunctiva	NN	I-AdverseReaction	B-AdverseReaction
has	POTIGA.xml:S3:6196:3	ha	VBZ	O	O
also	POTIGA.xml:S3:6200:4	also	RB	O	O
been	POTIGA.xml:S3:6205:4	been	VBN	O	O
reported	POTIGA.xml:S3:6210:8	report	VBN	O	O
.	POTIGA.xml:S3:6218:1	.	.	O	O

Approximately	POTIGA.xml:S3:6224:13	approxim	RB	O	O
10%	POTIGA.xml:S3:6238:3	10%	CD	O	O
of	POTIGA.xml:S3:6242:2	of	IN	O	O
patients	POTIGA.xml:S3:6245:8	patient	NNS	O	O
in	POTIGA.xml:S3:6254:2	in	IN	O	O
long	POTIGA.xml:S3:6257:4	long	JJ	O	O
-	POTIGA.xml:S3:6261:1	-	:	O	O
term	POTIGA.xml:S3:6262:4	term	NN	O	O
clinical	POTIGA.xml:S3:6267:8	clinic	JJ	O	O
trials	POTIGA.xml:S3:6276:6	trial	NNS	O	O
developed	POTIGA.xml:S3:6283:9	develop	VBD	O	O
skin	POTIGA.xml:S3:6293:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
discoloration	POTIGA.xml:S3:6298:13	discolor	NN	I-AdverseReaction	I-AdverseReaction
,	POTIGA.xml:S3:6311:1	,	,	O	O
generally	POTIGA.xml:S3:6313:9	gener	RB	O	O
after	POTIGA.xml:S3:6323:5	after	IN	O	O
2	POTIGA.xml:S3:6329:1	2	CD	O	O
or	POTIGA.xml:S3:6331:2	or	CC	O	O
more	POTIGA.xml:S3:6334:4	more	JJR	O	O
years	POTIGA.xml:S3:6339:5	year	NNS	O	O
of	POTIGA.xml:S3:6345:2	of	IN	O	O
treatment	POTIGA.xml:S3:6348:9	treatment	NN	O	O
and	POTIGA.xml:S3:6358:3	and	CC	O	O
at	POTIGA.xml:S3:6362:2	at	IN	O	O
higher	POTIGA.xml:S3:6365:6	higher	JJR	O	O
doses	POTIGA.xml:S3:6372:5	dose	NNS	O	O
(	POTIGA.xml:S3:6378:1	(	(	O	O
900	POTIGA.xml:S3:6379:3	900	CD	O	O
mg	POTIGA.xml:S3:6383:2	mg	NN	O	O
or	POTIGA.xml:S3:6386:2	or	CC	O	O
greater	POTIGA.xml:S3:6389:7	greater	JJR	O	O
)	POTIGA.xml:S3:6396:1	)	)	O	O
of	POTIGA.xml:S3:6398:2	of	IN	O	O
POTIGA	POTIGA.xml:S3:6401:6	potiga	NNP	O	O
.	POTIGA.xml:S3:6407:1	.	.	O	O

Among	POTIGA.xml:S3:6409:5	among	IN	O	O
patients	POTIGA.xml:S3:6415:8	patient	NNS	O	O
in	POTIGA.xml:S3:6424:2	in	IN	O	O
whom	POTIGA.xml:S3:6427:4	whom	WP	O	O
the	POTIGA.xml:S3:6432:3	the	DT	O	O
status	POTIGA.xml:S3:6436:6	statu	NN	O	O
of	POTIGA.xml:S3:6443:2	of	IN	O	O
both	POTIGA.xml:S3:6446:4	both	DT	O	O
skin	POTIGA.xml:S3:6451:4	skin	FW	B-AdverseReaction	O
,	POTIGA.xml:S3:6455:1	,	,	O	O
nail	POTIGA.xml:S3:6457:4	nail	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S3:6461:1	,	,	O	O
lip	POTIGA.xml:S3:6463:3	lip	NN	B-AdverseReaction	O
,	POTIGA.xml:S3:6466:1	,	,	O	O
or	POTIGA.xml:S3:6468:2	or	CC	O	O
mucous	POTIGA.xml:S3:6471:6	mucou	JJ	B-AdverseReaction	O
membrane	POTIGA.xml:S3:6478:8	membran	NN	I-AdverseReaction	O
discoloration	POTIGA.xml:S3:6487:13	discolor	NN	I-AdverseReaction	O
and	POTIGA.xml:S3:6501:3	and	CC	O	O
retinal	POTIGA.xml:S3:6505:7	retin	JJ	B-AdverseReaction	B-AdverseReaction
pigmentary	POTIGA.xml:S3:6513:10	pigmentari	JJ	I-AdverseReaction	I-AdverseReaction
abnormalities	POTIGA.xml:S3:6524:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
are	POTIGA.xml:S3:6538:3	are	VBP	O	O
reported	POTIGA.xml:S3:6542:8	report	VBN	O	O
,	POTIGA.xml:S3:6550:1	,	,	O	O
approximately	POTIGA.xml:S3:6552:13	approxim	RB	O	O
a	POTIGA.xml:S3:6566:1	a	DT	O	O
quarter	POTIGA.xml:S3:6568:7	quarter	NN	O	O
of	POTIGA.xml:S3:6576:2	of	IN	O	O
those	POTIGA.xml:S3:6579:5	those	DT	O	O
with	POTIGA.xml:S3:6585:4	with	IN	O	O
skin	POTIGA.xml:S3:6590:4	skin	NN	B-AdverseReaction	O
,	POTIGA.xml:S3:6594:1	,	,	O	O
nail	POTIGA.xml:S3:6596:4	nail	NN	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S3:6600:1	,	,	O	O
lip	POTIGA.xml:S3:6602:3	lip	NN	B-AdverseReaction	O
,	POTIGA.xml:S3:6605:1	,	,	O	O
or	POTIGA.xml:S3:6607:2	or	CC	O	O
mucous	POTIGA.xml:S3:6610:6	mucou	JJ	B-AdverseReaction	O
membrane	POTIGA.xml:S3:6617:8	membran	NN	I-AdverseReaction	O
discoloration	POTIGA.xml:S3:6626:13	discolor	NN	I-AdverseReaction	O
had	POTIGA.xml:S3:6640:3	had	VBD	O	O
concurrent	POTIGA.xml:S3:6644:10	concurr	JJ	O	O
retinal	POTIGA.xml:S3:6655:7	retin	JJ	B-AdverseReaction	B-AdverseReaction
pigmentary	POTIGA.xml:S3:6663:10	pigmentari	JJ	I-AdverseReaction	I-AdverseReaction
abnormalities	POTIGA.xml:S3:6674:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
[	POTIGA.xml:S3:6688:1	[	VBP	O	O
see	POTIGA.xml:S3:6689:3	see	VBP	O	O
Warnings	POTIGA.xml:S3:6693:8	warn	NNS	O	O
and	POTIGA.xml:S3:6702:3	and	CC	O	O
Precautions	POTIGA.xml:S3:6706:11	precaut	NNP	O	O
(	POTIGA.xml:S3:6718:1	(	(	O	O
5.1	POTIGA.xml:S3:6719:3	5.1	CD	O	O
)]	POTIGA.xml:S3:6722:2	)]	NN	O	O
.	POTIGA.xml:S3:6726:1	.	.	O	O

Information	POTIGA.xml:S3:6732:11	inform	NN	O	O
on	POTIGA.xml:S3:6744:2	on	IN	O	O
the	POTIGA.xml:S3:6747:3	the	DT	O	O
consequences	POTIGA.xml:S3:6751:12	consequ	NNS	O	O
,	POTIGA.xml:S3:6763:1	,	,	O	O
reversibility	POTIGA.xml:S3:6765:13	revers	NN	O	O
,	POTIGA.xml:S3:6778:1	,	,	O	O
time	POTIGA.xml:S3:6780:4	time	NN	O	O
to	POTIGA.xml:S3:6785:2	to	TO	O	O
onset	POTIGA.xml:S3:6788:5	onset	VB	O	O
,	POTIGA.xml:S3:6793:1	,	,	O	O
and	POTIGA.xml:S3:6795:3	and	CC	O	O
pathophysiology	POTIGA.xml:S3:6799:15	pathophysiolog	NN	O	O
of	POTIGA.xml:S3:6815:2	of	IN	O	O
the	POTIGA.xml:S3:6818:3	the	DT	O	O
skin	POTIGA.xml:S3:6822:4	skin	NN	B-AdverseReaction	O
abnormalities	POTIGA.xml:S3:6827:13	abnorm	VBZ	I-AdverseReaction	O
remains	POTIGA.xml:S3:6841:7	remain	VBZ	O	O
incomplete	POTIGA.xml:S3:6849:10	incomplet	JJ	O	O
.	POTIGA.xml:S3:6859:1	.	.	O	O

The	POTIGA.xml:S3:6861:3	the	DT	O	O
possibility	POTIGA.xml:S3:6865:11	possibl	NN	O	O
of	POTIGA.xml:S3:6877:2	of	IN	O	O
more	POTIGA.xml:S3:6880:4	more	RBR	O	O
extensive	POTIGA.xml:S3:6885:9	extens	JJ	O	O
systemic	POTIGA.xml:S3:6895:8	system	JJ	O	O
involvement	POTIGA.xml:S3:6904:11	involv	NN	O	O
has	POTIGA.xml:S3:6916:3	ha	VBZ	O	O
not	POTIGA.xml:S3:6920:3	not	RB	O	O
been	POTIGA.xml:S3:6924:4	been	VBN	O	O
excluded	POTIGA.xml:S3:6929:8	exclud	VBN	O	O
.	POTIGA.xml:S3:6937:1	.	.	O	O

If	POTIGA.xml:S3:6939:2	If	IN	O	O
a	POTIGA.xml:S3:6942:1	a	DT	O	O
patient	POTIGA.xml:S3:6944:7	patient	NN	O	O
develops	POTIGA.xml:S3:6952:8	develop	VBZ	O	O
skin	POTIGA.xml:S3:6961:4	skin	JJ	O	O
discoloration	POTIGA.xml:S3:6966:13	discolor	NN	O	O
,	POTIGA.xml:S3:6979:1	,	,	O	O
serious	POTIGA.xml:S3:6981:7	seriou	JJ	O	O
consideration	POTIGA.xml:S3:6989:13	consider	NN	O	O
should	POTIGA.xml:S3:7003:6	should	MD	O	O
be	POTIGA.xml:S3:7010:2	be	VB	O	O
given	POTIGA.xml:S3:7013:5	given	VBN	O	O
to	POTIGA.xml:S3:7019:2	to	TO	O	O
changing	POTIGA.xml:S3:7022:8	chang	VBG	O	O
to	POTIGA.xml:S3:7031:2	to	TO	O	O
an	POTIGA.xml:S3:7034:2	an	DT	O	O
alternate	POTIGA.xml:S3:7037:9	altern	JJ	O	O
medication	POTIGA.xml:S3:7047:10	medic	NN	O	O
.	POTIGA.xml:S3:7057:1	.	.	O	O

5.4	POTIGA.xml:S3:7066:3	5.4	CD	O	O
Neuropsychiatric	POTIGA.xml:S3:7070:16	neuropsychiatr	NNP	O	O
Symptoms	POTIGA.xml:S3:7087:8	symptom	NNP	O	O

Confusional	POTIGA.xml:S3:7101:11	confusion	JJ	B-AdverseReaction	O
state	POTIGA.xml:S3:7113:5	state	NN	I-AdverseReaction	O
,	POTIGA.xml:S3:7118:1	,	,	O	O
psychotic	POTIGA.xml:S3:7120:9	psychot	JJ	B-AdverseReaction	O
symptoms	POTIGA.xml:S3:7130:8	symptom	NNS	I-AdverseReaction	O
,	POTIGA.xml:S3:7138:1	,	,	O	O
and	POTIGA.xml:S3:7140:3	and	CC	O	O
hallucinations	POTIGA.xml:S3:7144:14	hallucin	NNS	B-AdverseReaction	B-AdverseReaction
were	POTIGA.xml:S3:7159:4	were	VBD	O	O
reported	POTIGA.xml:S3:7164:8	report	VBN	O	O
more	POTIGA.xml:S3:7173:4	more	RBR	O	O
frequently	POTIGA.xml:S3:7178:10	frequent	RB	O	O
as	POTIGA.xml:S3:7189:2	as	IN	O	O
adverse	POTIGA.xml:S3:7192:7	advers	JJ	O	O
reactions	POTIGA.xml:S3:7200:9	reaction	NNS	O	O
in	POTIGA.xml:S3:7210:2	in	IN	O	O
patients	POTIGA.xml:S3:7213:8	patient	NNS	O	O
treated	POTIGA.xml:S3:7222:7	treat	VBN	O	O
with	POTIGA.xml:S3:7230:4	with	IN	O	O
POTIGA	POTIGA.xml:S3:7235:6	potiga	NNP	O	O
than	POTIGA.xml:S3:7242:4	than	IN	O	O
in	POTIGA.xml:S3:7247:2	in	IN	O	O
those	POTIGA.xml:S3:7250:5	those	DT	O	O
treated	POTIGA.xml:S3:7256:7	treat	VBN	O	O
with	POTIGA.xml:S3:7264:4	with	IN	O	O
placebo	POTIGA.xml:S3:7269:7	placebo	NN	O	O
in	POTIGA.xml:S3:7277:2	in	IN	O	O
placebo	POTIGA.xml:S3:7280:7	placebo	NN	O	O
-	POTIGA.xml:S3:7287:1	-	:	O	O
controlled	POTIGA.xml:S3:7288:10	control	VBN	O	O
epilepsy	POTIGA.xml:S3:7299:8	epilepsi	NN	O	O
trials	POTIGA.xml:S3:7308:6	trial	NNS	O	O
(	POTIGA.xml:S3:7315:1	(	(	O	O
see	POTIGA.xml:S3:7316:3	see	VB	O	O
Table	POTIGA.xml:S3:7320:5	tabl	NNP	O	O
2	POTIGA.xml:S3:7326:1	2	CD	O	O
)	POTIGA.xml:S3:7327:1	)	)	O	O
.	POTIGA.xml:S3:7328:1	.	.	O	O

Discontinuations	POTIGA.xml:S3:7330:16	discontinu	NNS	O	O
resulting	POTIGA.xml:S3:7347:9	result	VBG	O	O
from	POTIGA.xml:S3:7357:4	from	IN	O	O
these	POTIGA.xml:S3:7362:5	these	DT	O	O
reactions	POTIGA.xml:S3:7368:9	reaction	NNS	O	O
were	POTIGA.xml:S3:7378:4	were	VBD	O	O
more	POTIGA.xml:S3:7383:4	more	JJR	O	O
common	POTIGA.xml:S3:7388:6	common	JJ	O	O
in	POTIGA.xml:S3:7395:2	in	IN	O	O
the	POTIGA.xml:S3:7398:3	the	DT	O	O
drug	POTIGA.xml:S3:7402:4	drug	NN	O	O
-	POTIGA.xml:S3:7406:1	-	:	O	O
treated	POTIGA.xml:S3:7407:7	treat	VBN	O	O
group	POTIGA.xml:S3:7415:5	group	NN	O	O
(	POTIGA.xml:S3:7421:1	(	(	O	O
see	POTIGA.xml:S3:7422:3	see	VB	O	O
Table	POTIGA.xml:S3:7426:5	tabl	NNP	O	O
2	POTIGA.xml:S3:7432:1	2	CD	O	O
)	POTIGA.xml:S3:7433:1	)	)	O	O
.	POTIGA.xml:S3:7434:1	.	.	O	O

These	POTIGA.xml:S3:7436:5	these	DT	O	O
effects	POTIGA.xml:S3:7442:7	effect	NNS	O	O
were	POTIGA.xml:S3:7450:4	were	VBD	O	O
dose	POTIGA.xml:S3:7455:4	dose	JJ	O	O
-	POTIGA.xml:S3:7459:1	-	:	O	O
related	POTIGA.xml:S3:7460:7	relat	JJ	O	O
and	POTIGA.xml:S3:7468:3	and	CC	O	O
generally	POTIGA.xml:S3:7472:9	gener	RB	O	O
appeared	POTIGA.xml:S3:7482:8	appear	VBD	O	O
within	POTIGA.xml:S3:7491:6	within	IN	O	O
the	POTIGA.xml:S3:7498:3	the	DT	O	O
first	POTIGA.xml:S3:7502:5	first	JJ	O	O
8	POTIGA.xml:S3:7508:1	8	CD	O	O
weeks	POTIGA.xml:S3:7510:5	week	NNS	O	O
of	POTIGA.xml:S3:7516:2	of	IN	O	O
treatment	POTIGA.xml:S3:7519:9	treatment	NN	O	O
.	POTIGA.xml:S3:7528:1	.	.	O	O

Half	POTIGA.xml:S3:7530:4	half	NN	O	O
of	POTIGA.xml:S3:7535:2	of	IN	O	O
the	POTIGA.xml:S3:7538:3	the	DT	O	O
patients	POTIGA.xml:S3:7542:8	patient	NNS	O	O
in	POTIGA.xml:S3:7551:2	in	IN	O	O
the	POTIGA.xml:S3:7554:3	the	DT	O	O
controlled	POTIGA.xml:S3:7558:10	control	JJ	O	O
trials	POTIGA.xml:S3:7569:6	trial	NNS	O	O
who	POTIGA.xml:S3:7576:3	who	WP	O	O
discontinued	POTIGA.xml:S3:7580:12	discontinu	VBD	O	O
POTIGA	POTIGA.xml:S3:7593:6	potiga	NNP	O	O
due	POTIGA.xml:S3:7600:3	due	JJ	O	O
to	POTIGA.xml:S3:7604:2	to	TO	O	O
hallucinations	POTIGA.xml:S3:7607:14	hallucin	NNS	B-AdverseReaction	O
or	POTIGA.xml:S3:7622:2	or	CC	O	O
psychosis	POTIGA.xml:S3:7625:9	psychosi	NN	B-AdverseReaction	O
required	POTIGA.xml:S3:7635:8	requir	VBN	O	O
hospitalization	POTIGA.xml:S3:7644:15	hospit	NN	O	O
.	POTIGA.xml:S3:7659:1	.	.	O	O

Approximately	POTIGA.xml:S3:7661:13	approxim	RB	O	O
two	POTIGA.xml:S3:7675:3	two	CD	O	O
-	POTIGA.xml:S3:7678:1	-	:	O	O
thirds	POTIGA.xml:S3:7679:6	third	NNS	O	O
of	POTIGA.xml:S3:7686:2	of	IN	O	O
patients	POTIGA.xml:S3:7689:8	patient	NNS	O	O
with	POTIGA.xml:S3:7698:4	with	IN	O	O
psychosis	POTIGA.xml:S3:7703:9	psychosi	NN	B-AdverseReaction	O
in	POTIGA.xml:S3:7713:2	in	IN	O	O
controlled	POTIGA.xml:S3:7716:10	control	JJ	O	O
trials	POTIGA.xml:S3:7727:6	trial	NNS	O	O
had	POTIGA.xml:S3:7734:3	had	VBD	O	O
no	POTIGA.xml:S3:7738:2	no	DT	O	O
prior	POTIGA.xml:S3:7741:5	prior	JJ	O	O
psychiatric	POTIGA.xml:S3:7747:11	psychiatr	JJ	O	O
history	POTIGA.xml:S3:7759:7	histori	NN	O	O
.	POTIGA.xml:S3:7766:1	.	.	O	O

The	POTIGA.xml:S3:7768:3	the	DT	O	O
psychiatric	POTIGA.xml:S3:7772:11	psychiatr	JJ	B-AdverseReaction	O
symptoms	POTIGA.xml:S3:7784:8	symptom	NNS	I-AdverseReaction	O
in	POTIGA.xml:S3:7793:2	in	IN	O	O
the	POTIGA.xml:S3:7796:3	the	DT	O	O
vast	POTIGA.xml:S3:7800:4	vast	JJ	O	O
majority	POTIGA.xml:S3:7805:8	major	NN	O	O
of	POTIGA.xml:S3:7814:2	of	IN	O	O
patients	POTIGA.xml:S3:7817:8	patient	NNS	O	O
in	POTIGA.xml:S3:7826:2	in	IN	O	O
both	POTIGA.xml:S3:7829:4	both	DT	O	O
controlled	POTIGA.xml:S3:7834:10	control	VBN	O	O
and	POTIGA.xml:S3:7845:3	and	CC	O	O
open	POTIGA.xml:S3:7849:4	open	JJ	O	O
-	POTIGA.xml:S3:7853:1	-	:	O	O
label	POTIGA.xml:S3:7854:5	label	NN	O	O
trials	POTIGA.xml:S3:7860:6	trial	NNS	O	O
resolved	POTIGA.xml:S3:7867:8	resolv	VBD	O	O
within	POTIGA.xml:S3:7876:6	within	IN	O	O
7	POTIGA.xml:S3:7883:1	7	CD	O	O
days	POTIGA.xml:S3:7885:4	day	NNS	O	O
of	POTIGA.xml:S3:7890:2	of	IN	O	O
discontinuation	POTIGA.xml:S3:7893:15	discontinu	NN	O	O
of	POTIGA.xml:S3:7909:2	of	IN	O	O
POTIGA	POTIGA.xml:S3:7912:6	potiga	NNP	O	O
.	POTIGA.xml:S3:7918:1	.	.	O	O

Rapid	POTIGA.xml:S3:7920:5	rapid	JJ	O	O
titration	POTIGA.xml:S3:7926:9	titrat	NN	O	O
at	POTIGA.xml:S3:7936:2	at	IN	O	O
greater	POTIGA.xml:S3:7939:7	greater	JJR	O	O
than	POTIGA.xml:S3:7947:4	than	IN	O	O
the	POTIGA.xml:S3:7952:3	the	DT	O	O
recommended	POTIGA.xml:S3:7956:11	recommend	JJ	O	O
doses	POTIGA.xml:S3:7968:5	dose	NNS	O	O
appeared	POTIGA.xml:S3:7974:8	appear	VBD	O	O
to	POTIGA.xml:S3:7983:2	to	TO	O	O
increase	POTIGA.xml:S3:7986:8	increas	VB	O	O
the	POTIGA.xml:S3:7995:3	the	DT	O	O
risk	POTIGA.xml:S3:7999:4	risk	NN	O	O
of	POTIGA.xml:S3:8004:2	of	IN	O	O
psychosis	POTIGA.xml:S3:8007:9	psychosi	NN	B-AdverseReaction	O
and	POTIGA.xml:S3:8017:3	and	CC	O	O
hallucinations	POTIGA.xml:S3:8021:14	hallucin	NNS	B-AdverseReaction	O
.	POTIGA.xml:S3:8035:1	.	.	O	O

Table	POTIGA.xml:S3:8042:5	tabl	JJ	O	O
2	POTIGA.xml:S3:8048:1	2	CD	O	O
.	POTIGA.xml:S3:8049:1	.	.	O	O

Major	POTIGA.xml:S3:8051:5	major	JJ	O	O
Neuropsychiatric	POTIGA.xml:S3:8057:16	neuropsychiatr	NNP	B-AdverseReaction	O
Symptoms	POTIGA.xml:S3:8074:8	symptom	NNP	I-AdverseReaction	O
in	POTIGA.xml:S3:8083:2	in	IN	O	O
Placebo	POTIGA.xml:S3:8086:7	placebo	NNP	O	O
-	POTIGA.xml:S3:8093:1	-	:	O	O
Controlled	POTIGA.xml:S3:8094:10	control	VBD	O	O
Epilepsy	POTIGA.xml:S3:8105:8	epilepsi	NNP	O	O
Trials	POTIGA.xml:S3:8114:6	trial	NNS	O	O

Adverse	POTIGA.xml:S3:8129:7	advers	JJ	O	O
Reaction	POTIGA.xml:S3:8137:8	reaction	NNP	O	O
Number	POTIGA.xml:S3:8151:6	number	NNP	O	O
(	POTIGA.xml:S3:8158:1	(	(	O	O
)	POTIGA.xml:S3:8160:1	)	)	O	O
with	POTIGA.xml:S3:8162:4	with	IN	O	O
Adverse	POTIGA.xml:S3:8167:7	advers	NNP	O	O
Reaction	POTIGA.xml:S3:8175:8	reaction	NNP	O	O
Number	POTIGA.xml:S3:8187:6	number	NNP	O	O
(	POTIGA.xml:S3:8194:1	(	(	O	O
)	POTIGA.xml:S3:8196:1	)	)	O	O
Discontinuing	POTIGA.xml:S3:8198:13	discontinu	VBG	O	O

POTIGA	POTIGA.xml:S3:8218:6	potiga	NNP	O	O
(	POTIGA.xml:S3:8226:1	(	(	O	O
n	POTIGA.xml:S3:8227:1	n	JJ	O	O
813	POTIGA.xml:S3:8231:3	813	CD	O	O
)	POTIGA.xml:S3:8234:1	)	)	O	O
Placebo	POTIGA.xml:S3:8240:7	placebo	NNP	O	O
(	POTIGA.xml:S3:8249:1	(	(	O	O
n	POTIGA.xml:S3:8250:1	n	JJ	O	O
427	POTIGA.xml:S3:8254:3	427	CD	O	O
)	POTIGA.xml:S3:8257:1	)	)	O	O
POTIGA	POTIGA.xml:S3:8262:6	potiga	NNP	O	O
(	POTIGA.xml:S3:8270:1	(	(	O	O
n	POTIGA.xml:S3:8271:1	n	JJ	O	O
813	POTIGA.xml:S3:8275:3	813	CD	O	O
)	POTIGA.xml:S3:8278:1	)	)	O	O
Placebo	POTIGA.xml:S3:8283:7	placebo	NNP	O	O
(	POTIGA.xml:S3:8292:1	(	(	O	O
n	POTIGA.xml:S3:8293:1	n	JJ	O	O
427	POTIGA.xml:S3:8297:3	427	CD	O	O
)	POTIGA.xml:S3:8300:1	)	)	O	O

Confusional	POTIGA.xml:S3:8308:11	confusion	NNP	B-AdverseReaction	B-AdverseReaction
state	POTIGA.xml:S3:8320:5	state	NN	I-AdverseReaction	I-AdverseReaction
75	POTIGA.xml:S3:8330:2	75	CD	O	O
(	POTIGA.xml:S3:8333:1	(	(	O	O
9%	POTIGA.xml:S3:8334:2	9%	CD	O	O
)	POTIGA.xml:S3:8336:1	)	)	O	O
11	POTIGA.xml:S3:8351:2	11	CD	O	O
(	POTIGA.xml:S3:8354:1	(	(	O	O
3%	POTIGA.xml:S3:8355:2	3%	CD	O	O
)	POTIGA.xml:S3:8357:1	)	)	O	O
32	POTIGA.xml:S3:8372:2	32	CD	O	O
(	POTIGA.xml:S3:8375:1	(	(	O	O
4%	POTIGA.xml:S3:8376:2	4%	CD	O	O
)	POTIGA.xml:S3:8378:1	)	)	O	O
4	POTIGA.xml:S3:8389:1	4	CD	O	O
(	POTIGA.xml:S3:8391:1	(	(	O	O
1%	POTIGA.xml:S3:8393:2	1%	CD	O	O
)	POTIGA.xml:S3:8395:1	)	)	O	O

Psychosis	POTIGA.xml:S3:8408:9	psychosi	NN	B-AdverseReaction	B-AdverseReaction
9	POTIGA.xml:S3:8430:1	9	CD	O	O
(	POTIGA.xml:S3:8432:1	(	(	O	O
1%	POTIGA.xml:S3:8433:2	1%	CD	O	O
)	POTIGA.xml:S3:8435:1	)	)	O	O
0	POTIGA.xml:S3:8451:1	0	CD	O	O
6	POTIGA.xml:S3:8472:1	6	CD	O	O
(	POTIGA.xml:S3:8474:1	(	(	O	O
1%	POTIGA.xml:S3:8476:2	1%	CD	O	O
)	POTIGA.xml:S3:8478:1	)	)	O	O
0	POTIGA.xml:S3:8489:1	0	CD	O	O

Hallucinationsa	POTIGA.xml:S3:8508:15	hallucinationsa	$	B-AdverseReaction	B-AdverseReaction
14	POTIGA.xml:S3:8530:2	14	CD	O	O
(	POTIGA.xml:S3:8533:1	(	(	O	O
2%	POTIGA.xml:S3:8534:2	2%	CD	O	O
)	POTIGA.xml:S3:8536:1	)	)	O	O
2	POTIGA.xml:S3:8551:1	2	CD	O	O
(	POTIGA.xml:S3:8553:1	(	(	O	O
1%	POTIGA.xml:S3:8555:2	1%	CD	O	O
)	POTIGA.xml:S3:8557:1	)	)	O	O
6	POTIGA.xml:S3:8572:1	6	CD	O	O
(	POTIGA.xml:S3:8574:1	(	(	O	O
1%	POTIGA.xml:S3:8576:2	1%	CD	O	O
)	POTIGA.xml:S3:8578:1	)	)	O	O
0	POTIGA.xml:S3:8589:1	0	CD	O	O

a	POTIGA.xml:S3:8619:1	a	DT	O	O
Hallucinations	POTIGA.xml:S3:8622:14	hallucin	NNP	B-AdverseReaction	O
includes	POTIGA.xml:S3:8637:8	includ	VBZ	O	O
visual	POTIGA.xml:S3:8646:6	visual	JJ	B-AdverseReaction	B-AdverseReaction
,	POTIGA.xml:S3:8652:1	,	,	O	O
auditory	POTIGA.xml:S3:8654:8	auditori	JJ	B-AdverseReaction	O
,	POTIGA.xml:S3:8662:1	,	,	O	O
and	POTIGA.xml:S3:8664:3	and	CC	O	O
mixed	POTIGA.xml:S3:8668:5	mix	JJ	B-AdverseReaction	O
hallucinations	POTIGA.xml:S3:8674:14	hallucin	NNS	I-AdverseReaction	O
.	POTIGA.xml:S3:8688:1	.	.	O	O

5.5	POTIGA.xml:S3:8697:3	5.5	CD	O	O

Dizziness	POTIGA.xml:S3:8701:9	dizzi	NN	O	B-AdverseReaction
and	POTIGA.xml:S3:8711:3	and	CC	O	O
Somnolence	POTIGA.xml:S3:8715:10	somnol	NN	O	B-AdverseReaction

POTIGA	POTIGA.xml:S3:8731:6	potiga	NNP	O	O
causes	POTIGA.xml:S3:8738:6	caus	VBZ	O	O
dose	POTIGA.xml:S3:8745:4	dose	JJ	O	O
-	POTIGA.xml:S3:8749:1	-	:	O	O
related	POTIGA.xml:S3:8750:7	relat	JJ	O	O
increases	POTIGA.xml:S3:8758:9	increas	NNS	O	O
in	POTIGA.xml:S3:8768:2	in	IN	O	O
dizziness	POTIGA.xml:S3:8771:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
and	POTIGA.xml:S3:8781:3	and	CC	O	O
somnolence	POTIGA.xml:S3:8785:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
[	POTIGA.xml:S3:8796:1	[	NNP	O	O
see	POTIGA.xml:S3:8797:3	see	VBP	O	O
Adverse	POTIGA.xml:S3:8801:7	advers	JJ	O	O
Reactions	POTIGA.xml:S3:8809:9	reaction	NNP	O	O
(	POTIGA.xml:S3:8819:1	(	(	O	O
6.1	POTIGA.xml:S3:8820:3	6.1	CD	O	O
)]	POTIGA.xml:S3:8823:2	)]	NN	O	O
.	POTIGA.xml:S3:8827:1	.	.	O	O

In	POTIGA.xml:S3:8829:2	In	IN	O	O
placebo	POTIGA.xml:S3:8832:7	placebo	NN	O	O
-	POTIGA.xml:S3:8839:1	-	:	O	O
controlled	POTIGA.xml:S3:8840:10	control	VBN	O	O
trials	POTIGA.xml:S3:8851:6	trial	NNS	O	O
in	POTIGA.xml:S3:8858:2	in	IN	O	O
patients	POTIGA.xml:S3:8861:8	patient	NNS	O	O
with	POTIGA.xml:S3:8870:4	with	IN	O	O
epilepsy	POTIGA.xml:S3:8875:8	epilepsi	NN	O	O
,	POTIGA.xml:S3:8883:1	,	,	O	O
dizziness	POTIGA.xml:S3:8885:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
was	POTIGA.xml:S3:8895:3	wa	VBD	O	O
reported	POTIGA.xml:S3:8899:8	report	VBN	O	O
in	POTIGA.xml:S3:8908:2	in	IN	O	O
23%	POTIGA.xml:S3:8911:3	23%	CD	O	O
of	POTIGA.xml:S3:8915:2	of	IN	O	O
patients	POTIGA.xml:S3:8918:8	patient	NNS	O	O
treated	POTIGA.xml:S3:8927:7	treat	VBN	O	O
with	POTIGA.xml:S3:8935:4	with	IN	O	O
POTIGA	POTIGA.xml:S3:8940:6	potiga	NNP	O	O
and	POTIGA.xml:S3:8947:3	and	CC	O	O
9%	POTIGA.xml:S3:8951:2	9%	CD	O	O
of	POTIGA.xml:S3:8954:2	of	IN	O	O
patients	POTIGA.xml:S3:8957:8	patient	NNS	O	O
treated	POTIGA.xml:S3:8966:7	treat	VBN	O	O
with	POTIGA.xml:S3:8974:4	with	IN	O	O
placebo	POTIGA.xml:S3:8979:7	placebo	NN	O	O
.	POTIGA.xml:S3:8986:1	.	.	O	O

Somnolence	POTIGA.xml:S3:8988:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
was	POTIGA.xml:S3:8999:3	wa	VBD	O	O
reported	POTIGA.xml:S3:9003:8	report	VBN	O	O
in	POTIGA.xml:S3:9012:2	in	IN	O	O
22%	POTIGA.xml:S3:9015:3	22%	CD	O	O
of	POTIGA.xml:S3:9019:2	of	IN	O	O
patients	POTIGA.xml:S3:9022:8	patient	NNS	O	O
treated	POTIGA.xml:S3:9031:7	treat	VBN	O	O
with	POTIGA.xml:S3:9039:4	with	IN	O	O
POTIGA	POTIGA.xml:S3:9044:6	potiga	NNP	O	O
and	POTIGA.xml:S3:9051:3	and	CC	O	O
12%	POTIGA.xml:S3:9055:3	12%	CD	O	O
of	POTIGA.xml:S3:9059:2	of	IN	O	O
patients	POTIGA.xml:S3:9062:8	patient	NNS	O	O
treated	POTIGA.xml:S3:9071:7	treat	VBN	O	O
with	POTIGA.xml:S3:9079:4	with	IN	O	O
placebo	POTIGA.xml:S3:9084:7	placebo	NN	O	O
.	POTIGA.xml:S3:9091:1	.	.	O	O

In	POTIGA.xml:S3:9093:2	In	IN	O	O
these	POTIGA.xml:S3:9096:5	these	DT	O	O
trials	POTIGA.xml:S3:9102:6	trial	NNS	O	O
6%	POTIGA.xml:S3:9109:2	6%	CD	O	O
of	POTIGA.xml:S3:9112:2	of	IN	O	O
patients	POTIGA.xml:S3:9115:8	patient	NNS	O	O
on	POTIGA.xml:S3:9124:2	on	IN	O	O
POTIGA	POTIGA.xml:S3:9127:6	potiga	NNP	O	O
and	POTIGA.xml:S3:9134:3	and	CC	O	O
1.2%	POTIGA.xml:S3:9138:4	1.2%	CD	O	O
on	POTIGA.xml:S3:9143:2	on	IN	O	O
placebo	POTIGA.xml:S3:9146:7	placebo	NN	O	O
discontinued	POTIGA.xml:S3:9154:12	discontinu	VBN	O	O
treatment	POTIGA.xml:S3:9167:9	treatment	NN	O	O
because	POTIGA.xml:S3:9177:7	becaus	IN	O	O
of	POTIGA.xml:S3:9185:2	of	IN	O	O
dizziness	POTIGA.xml:S3:9188:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
;	POTIGA.xml:S3:9197:1	;	:	O	O
3%	POTIGA.xml:S3:9199:2	3%	CD	O	O
of	POTIGA.xml:S3:9202:2	of	IN	O	O
patients	POTIGA.xml:S3:9205:8	patient	NNS	O	O
on	POTIGA.xml:S3:9214:2	on	IN	O	O
POTIGA	POTIGA.xml:S3:9217:6	potiga	NNP	O	O
and	POTIGA.xml:S3:9224:3	and	CC	O	O
1.0%	POTIGA.xml:S3:9229:4	1.0%	CD	O	O
on	POTIGA.xml:S3:9234:2	on	IN	O	O
placebo	POTIGA.xml:S3:9237:7	placebo	NN	O	O
discontinued	POTIGA.xml:S3:9245:12	discontinu	VBN	O	O
because	POTIGA.xml:S3:9258:7	becaus	IN	O	O
of	POTIGA.xml:S3:9266:2	of	IN	O	O
somnolence	POTIGA.xml:S3:9269:10	somnol	NN	B-AdverseReaction	O
.	POTIGA.xml:S3:9279:1	.	.	O	O

Most	POTIGA.xml:S3:9285:4	most	JJS	O	O
of	POTIGA.xml:S3:9290:2	of	IN	O	O
these	POTIGA.xml:S3:9293:5	these	DT	O	O
adverse	POTIGA.xml:S3:9299:7	advers	JJ	O	O
reactions	POTIGA.xml:S3:9307:9	reaction	NNS	O	O
were	POTIGA.xml:S3:9317:4	were	VBD	O	O
mild	POTIGA.xml:S3:9322:4	mild	JJ	O	O
to	POTIGA.xml:S3:9327:2	to	TO	O	O
moderate	POTIGA.xml:S3:9330:8	moder	VB	O	O
in	POTIGA.xml:S3:9339:2	in	IN	O	O
intensity	POTIGA.xml:S3:9342:9	intens	NN	O	O
and	POTIGA.xml:S3:9352:3	and	CC	O	O
occurred	POTIGA.xml:S3:9356:8	occur	VBD	O	O
during	POTIGA.xml:S3:9365:6	dure	IN	O	O
the	POTIGA.xml:S3:9372:3	the	DT	O	O
titration	POTIGA.xml:S3:9376:9	titrat	NN	O	O
phase	POTIGA.xml:S3:9386:5	phase	NN	O	O
.	POTIGA.xml:S3:9391:1	.	.	O	O

For	POTIGA.xml:S3:9393:3	for	IN	O	O
those	POTIGA.xml:S3:9397:5	those	DT	O	O
patients	POTIGA.xml:S3:9403:8	patient	NNS	O	O
continued	POTIGA.xml:S3:9412:9	continu	VBD	O	O
on	POTIGA.xml:S3:9422:2	on	IN	O	O
POTIGA	POTIGA.xml:S3:9425:6	potiga	NNP	O	O
,	POTIGA.xml:S3:9431:1	,	,	O	O
dizziness	POTIGA.xml:S3:9433:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
and	POTIGA.xml:S3:9443:3	and	CC	O	O
somnolence	POTIGA.xml:S3:9447:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
appeared	POTIGA.xml:S3:9458:8	appear	VBD	O	O
to	POTIGA.xml:S3:9467:2	to	TO	O	O
diminish	POTIGA.xml:S3:9470:8	diminish	VB	O	O
with	POTIGA.xml:S3:9479:4	with	IN	O	O
continued	POTIGA.xml:S3:9484:9	continu	JJ	O	O
use	POTIGA.xml:S3:9494:3	use	NN	O	O
.	POTIGA.xml:S3:9497:1	.	.	O	O

5.6	POTIGA.xml:S3:9506:3	5.6	CD	O	O
QT	POTIGA.xml:S3:9510:2	QT	NNP	O	O
Interval	POTIGA.xml:S3:9513:8	interv	NNP	O	O
Effect	POTIGA.xml:S3:9522:6	effect	NNP	O	O

A	POTIGA.xml:S3:9534:1	A	DT	O	O
study	POTIGA.xml:S3:9536:5	studi	NN	O	O
of	POTIGA.xml:S3:9542:2	of	IN	O	O
cardiac	POTIGA.xml:S3:9545:7	cardiac	JJ	O	O
conduction	POTIGA.xml:S3:9553:10	conduct	NN	O	O
showed	POTIGA.xml:S3:9564:6	show	VBD	O	O
that	POTIGA.xml:S3:9571:4	that	IN	O	O
POTIGA	POTIGA.xml:S3:9576:6	potiga	NNP	O	O
produced	POTIGA.xml:S3:9583:8	produc	VBD	O	O
a	POTIGA.xml:S3:9592:1	a	DT	O	O
mean	POTIGA.xml:S3:9594:4	mean	JJ	O	O
7.7	POTIGA.xml:S3:9599:3	7.7	CD	O	O
-	POTIGA.xml:S3:9602:1	-	:	O	O
msec	POTIGA.xml:S3:9603:4	msec	NN	O	O
QT	POTIGA.xml:S3:9608:2	QT	NNP	B-AdverseReaction	O
prolongation	POTIGA.xml:S3:9611:12	prolong	NN	I-AdverseReaction	O
in	POTIGA.xml:S3:9624:2	in	IN	O	O
healthy	POTIGA.xml:S3:9627:7	healthi	JJ	O	O
volunteers	POTIGA.xml:S3:9635:10	volunt	NNS	O	O
titrated	POTIGA.xml:S3:9646:8	titrat	VBD	O	O
to	POTIGA.xml:S3:9655:2	to	TO	O	O
400	POTIGA.xml:S3:9658:3	400	CD	O	O
mg	POTIGA.xml:S3:9662:2	mg	NN	O	O
3	POTIGA.xml:S3:9665:1	3	CD	O	O
times	POTIGA.xml:S3:9667:5	time	NNS	O	O
daily	POTIGA.xml:S3:9673:5	daili	RB	O	O
.	POTIGA.xml:S3:9678:1	.	.	O	O

The	POTIGA.xml:S3:9680:3	the	DT	O	O
QT	POTIGA.xml:S3:9684:2	QT	NNP	B-AdverseReaction	O
-	POTIGA.xml:S3:9686:1	-	:	I-AdverseReaction	O
prolonging	POTIGA.xml:S3:9687:10	prolong	VBG	I-AdverseReaction	O
effect	POTIGA.xml:S3:9698:6	effect	NN	O	O
occurred	POTIGA.xml:S3:9705:8	occur	VBD	O	O
within	POTIGA.xml:S3:9714:6	within	IN	O	O
3	POTIGA.xml:S3:9721:1	3	CD	O	O
hours	POTIGA.xml:S3:9723:5	hour	NNS	O	O
.	POTIGA.xml:S3:9728:1	.	.	O	O

The	POTIGA.xml:S3:9730:3	the	DT	O	O
QT	POTIGA.xml:S3:9734:2	QT	NNP	O	O
interval	POTIGA.xml:S3:9737:8	interv	NN	O	O
should	POTIGA.xml:S3:9746:6	should	MD	O	O
be	POTIGA.xml:S3:9753:2	be	VB	O	O
monitored	POTIGA.xml:S3:9756:9	monitor	VBN	O	O
when	POTIGA.xml:S3:9766:4	when	WRB	O	O
POTIGA	POTIGA.xml:S3:9771:6	potiga	NNP	O	O
is	POTIGA.xml:S3:9778:2	is	VBZ	O	O
prescribed	POTIGA.xml:S3:9781:10	prescrib	VBN	O	O
with	POTIGA.xml:S3:9792:4	with	IN	O	O
medicines	POTIGA.xml:S3:9797:9	medicin	NNS	O	O
known	POTIGA.xml:S3:9807:5	known	VBN	O	O
to	POTIGA.xml:S3:9813:2	to	TO	O	O
increase	POTIGA.xml:S3:9816:8	increas	VB	O	O
QT	POTIGA.xml:S3:9825:2	QT	NNP	O	O
interval	POTIGA.xml:S3:9828:8	interv	JJ	O	O
and	POTIGA.xml:S3:9837:3	and	CC	O	O
in	POTIGA.xml:S3:9841:2	in	IN	O	O
patients	POTIGA.xml:S3:9844:8	patient	NNS	O	O
with	POTIGA.xml:S3:9853:4	with	IN	O	O
known	POTIGA.xml:S3:9858:5	known	VBN	O	O
prolonged	POTIGA.xml:S3:9864:9	prolong	JJ	O	O
QT	POTIGA.xml:S3:9874:2	QT	NNP	O	O
interval	POTIGA.xml:S3:9877:8	interv	NN	O	O
,	POTIGA.xml:S3:9885:1	,	,	O	O
congestive	POTIGA.xml:S3:9887:10	congest	JJ	O	B-AdverseReaction
heart	POTIGA.xml:S3:9898:5	heart	NN	O	I-AdverseReaction
failure	POTIGA.xml:S3:9904:7	failur	NN	O	I-AdverseReaction
,	POTIGA.xml:S3:9911:1	,	,	O	O
ventricular	POTIGA.xml:S3:9913:11	ventricular	JJ	O	B-AdverseReaction
hypertrophy	POTIGA.xml:S3:9925:11	hypertrophi	NN	O	I-AdverseReaction
,	POTIGA.xml:S3:9936:1	,	,	O	O
hypokalemia	POTIGA.xml:S3:9938:11	hypokalemia	NN	O	B-AdverseReaction
,	POTIGA.xml:S3:9949:1	,	,	O	O
or	POTIGA.xml:S3:9951:2	or	CC	O	O
hypomagnesemia	POTIGA.xml:S3:9954:14	hypomagnesemia	NN	O	O
[	POTIGA.xml:S3:9969:1	[	NNS	O	O
see	POTIGA.xml:S3:9970:3	see	VBP	O	O
Clinical	POTIGA.xml:S3:9974:8	clinic	JJ	O	O
Pharmacology	POTIGA.xml:S3:9983:12	pharmacolog	NNP	O	O
(	POTIGA.xml:S3:9996:1	(	(	O	O
12.2	POTIGA.xml:S3:9997:4	12.2	CD	O	O
)]	POTIGA.xml:S3:10001:2	)]	NN	O	O
.	POTIGA.xml:S3:10005:1	.	.	O	O

5.7	POTIGA.xml:S3:10014:3	5.7	CD	O	O
Suicidal	POTIGA.xml:S3:10018:8	suicid	NNP	O	O
Behavior	POTIGA.xml:S3:10027:8	behavior	NNP	O	O
and	POTIGA.xml:S3:10036:3	and	CC	O	O
Ideation	POTIGA.xml:S3:10040:8	ideat	NNP	O	O

Antiepileptic	POTIGA.xml:S3:10054:13	antiepilept	JJ	O	O
drugs	POTIGA.xml:S3:10068:5	drug	NNS	O	O
(	POTIGA.xml:S3:10074:1	(	(	O	O
AEDs	POTIGA.xml:S3:10075:4	a	NNP	O	O
)	POTIGA.xml:S3:10079:1	)	)	O	O
,	POTIGA.xml:S3:10080:1	,	,	O	O
including	POTIGA.xml:S3:10082:9	includ	VBG	O	O
POTIGA	POTIGA.xml:S3:10092:6	potiga	NNP	O	O
,	POTIGA.xml:S3:10098:1	,	,	O	O
increase	POTIGA.xml:S3:10100:8	increas	VB	O	O
the	POTIGA.xml:S3:10109:3	the	DT	O	O
risk	POTIGA.xml:S3:10113:4	risk	NN	O	O
of	POTIGA.xml:S3:10118:2	of	IN	O	O
suicidal	POTIGA.xml:S3:10121:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thoughts	POTIGA.xml:S3:10130:8	thought	NNS	I-AdverseReaction	I-AdverseReaction
or	POTIGA.xml:S3:10139:2	or	CC	O	O
behavior	POTIGA.xml:S3:10142:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
in	POTIGA.xml:S3:10151:2	in	IN	O	O
patients	POTIGA.xml:S3:10154:8	patient	NNS	O	O
taking	POTIGA.xml:S3:10163:6	take	VBG	O	O
these	POTIGA.xml:S3:10170:5	these	DT	O	O
drugs	POTIGA.xml:S3:10176:5	drug	NNS	O	O
for	POTIGA.xml:S3:10182:3	for	IN	O	O
any	POTIGA.xml:S3:10186:3	ani	DT	O	O
indication	POTIGA.xml:S3:10190:10	indic	NN	O	O
.	POTIGA.xml:S3:10200:1	.	.	O	O

Patients	POTIGA.xml:S3:10202:8	patient	NNS	O	O
treated	POTIGA.xml:S3:10211:7	treat	VBN	O	O
with	POTIGA.xml:S3:10219:4	with	IN	O	O
any	POTIGA.xml:S3:10224:3	ani	DT	O	O
AED	POTIGA.xml:S3:10228:3	a	NNP	O	O
for	POTIGA.xml:S3:10232:3	for	IN	O	O
any	POTIGA.xml:S3:10236:3	ani	DT	O	O
indication	POTIGA.xml:S3:10240:10	indic	NN	O	O
should	POTIGA.xml:S3:10251:6	should	MD	O	O
be	POTIGA.xml:S3:10258:2	be	VB	O	O
monitored	POTIGA.xml:S3:10261:9	monitor	VBN	O	O
for	POTIGA.xml:S3:10271:3	for	IN	O	O
the	POTIGA.xml:S3:10275:3	the	DT	O	O
emergence	POTIGA.xml:S3:10279:9	emerg	NN	O	O
or	POTIGA.xml:S3:10289:2	or	CC	O	O
worsening	POTIGA.xml:S3:10292:9	worsen	NN	O	O
of	POTIGA.xml:S3:10302:2	of	IN	O	O
depression	POTIGA.xml:S3:10305:10	depress	NN	O	O
,	POTIGA.xml:S3:10315:1	,	,	O	O
suicidal	POTIGA.xml:S3:10317:8	suicid	JJ	O	O
thoughts	POTIGA.xml:S3:10326:8	thought	NNS	O	O
or	POTIGA.xml:S3:10335:2	or	CC	O	O
behavior	POTIGA.xml:S3:10338:8	behavior	NN	O	O
,	POTIGA.xml:S3:10346:1	,	,	O	O
and	POTIGA.xml:S3:10348:3	and	CC	O	O
or	POTIGA.xml:S3:10352:2	or	CC	O	O
any	POTIGA.xml:S3:10355:3	ani	DT	O	O
unusual	POTIGA.xml:S3:10359:7	unusu	JJ	O	O
changes	POTIGA.xml:S3:10367:7	chang	NNS	O	O
in	POTIGA.xml:S3:10375:2	in	IN	O	O
mood	POTIGA.xml:S3:10378:4	mood	NN	O	O
or	POTIGA.xml:S3:10383:2	or	CC	O	O
behavior	POTIGA.xml:S3:10386:8	behavior	NN	O	O
.	POTIGA.xml:S3:10394:1	.	.	O	O

Pooled	POTIGA.xml:S3:10400:6	pool	JJ	O	O
analyses	POTIGA.xml:S3:10407:8	analys	NNS	O	O
of	POTIGA.xml:S3:10416:2	of	IN	O	O
199	POTIGA.xml:S3:10419:3	199	CD	O	O
placebo	POTIGA.xml:S3:10423:7	placebo	NN	O	O
-	POTIGA.xml:S3:10430:1	-	:	O	O
controlled	POTIGA.xml:S3:10431:10	control	VBN	O	O
clinical	POTIGA.xml:S3:10442:8	clinic	JJ	O	O
trials	POTIGA.xml:S3:10451:6	trial	NNS	O	O
(	POTIGA.xml:S3:10458:1	(	(	O	O
mono	POTIGA.xml:S3:10459:4	mono	SYM	O	O
-	POTIGA.xml:S3:10463:1	-	:	O	O
and	POTIGA.xml:S3:10465:3	and	CC	O	O
adjunctive	POTIGA.xml:S3:10469:10	adjunct	JJ	O	O
-	POTIGA.xml:S3:10479:1	-	:	O	O
therapy	POTIGA.xml:S3:10480:7	therapi	NN	O	O
)	POTIGA.xml:S3:10487:1	)	)	O	O
of	POTIGA.xml:S3:10489:2	of	IN	O	O
11	POTIGA.xml:S3:10492:2	11	CD	O	O
different	POTIGA.xml:S3:10495:9	differ	JJ	O	O
AEDs	POTIGA.xml:S3:10505:4	a	NNP	O	O
showed	POTIGA.xml:S3:10510:6	show	VBD	O	O
that	POTIGA.xml:S3:10517:4	that	IN	O	O
patients	POTIGA.xml:S3:10522:8	patient	NNS	O	O
randomized	POTIGA.xml:S3:10531:10	random	VBN	O	O
to	POTIGA.xml:S3:10542:2	to	TO	O	O
one	POTIGA.xml:S3:10545:3	one	CD	O	O
of	POTIGA.xml:S3:10549:2	of	IN	O	O
the	POTIGA.xml:S3:10552:3	the	DT	O	O
AEDs	POTIGA.xml:S3:10556:4	a	NNP	O	O
had	POTIGA.xml:S3:10561:3	had	VBD	O	O
approximately	POTIGA.xml:S3:10565:13	approxim	RB	O	O
twice	POTIGA.xml:S3:10579:5	twice	RB	O	O
the	POTIGA.xml:S3:10585:3	the	DT	O	O
risk	POTIGA.xml:S3:10589:4	risk	NN	O	O
(	POTIGA.xml:S3:10594:1	(	(	O	O
adjusted	POTIGA.xml:S3:10595:8	adjust	VBN	O	O
relative	POTIGA.xml:S3:10604:8	rel	NN	O	O
risk	POTIGA.xml:S3:10613:4	risk	NN	O	O
1.8	POTIGA.xml:S3:10618:3	1.8	CD	O	O
,	POTIGA.xml:S3:10621:1	,	,	O	O
95%	POTIGA.xml:S3:10623:3	95%	CD	O	O
confidence	POTIGA.xml:S3:10627:10	confid	NN	O	O
interval	POTIGA.xml:S3:10638:8	interv	NN	O	O
[	POTIGA.xml:S3:10647:1	[	NNP	O	O
CI	POTIGA.xml:S3:10648:2	CI	NNP	O	O
]	POTIGA.xml:S3:10650:1	]	NN	O	O
:	POTIGA.xml:S3:10651:1	:	:	O	O
1.2	POTIGA.xml:S3:10653:3	1.2	CD	O	O
,	POTIGA.xml:S3:10656:1	,	,	O	O
2.7	POTIGA.xml:S3:10658:3	2.7	CD	O	O
)	POTIGA.xml:S3:10661:1	)	)	O	O
of	POTIGA.xml:S3:10663:2	of	IN	O	O
suicidal	POTIGA.xml:S3:10666:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thinking	POTIGA.xml:S3:10675:8	think	NN	I-AdverseReaction	I-AdverseReaction
or	POTIGA.xml:S3:10684:2	or	CC	O	O
behavior	POTIGA.xml:S3:10687:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
compared	POTIGA.xml:S3:10696:8	compar	VBN	O	O
with	POTIGA.xml:S3:10705:4	with	IN	O	O
patients	POTIGA.xml:S3:10710:8	patient	NNS	O	O
randomized	POTIGA.xml:S3:10719:10	random	VBN	O	O
to	POTIGA.xml:S3:10730:2	to	TO	O	O
placebo	POTIGA.xml:S3:10733:7	placebo	VB	O	O
.	POTIGA.xml:S3:10740:1	.	.	O	O

In	POTIGA.xml:S3:10742:2	In	IN	O	O
these	POTIGA.xml:S3:10745:5	these	DT	O	O
trials	POTIGA.xml:S3:10751:6	trial	NNS	O	O
,	POTIGA.xml:S3:10757:1	,	,	O	O
which	POTIGA.xml:S3:10759:5	which	WDT	O	O
had	POTIGA.xml:S3:10765:3	had	VBD	O	O
a	POTIGA.xml:S3:10769:1	a	DT	O	O
median	POTIGA.xml:S3:10771:6	median	JJ	O	O
treatment	POTIGA.xml:S3:10778:9	treatment	NN	O	O
duration	POTIGA.xml:S3:10788:8	durat	NN	O	O
of	POTIGA.xml:S3:10797:2	of	IN	O	O
12	POTIGA.xml:S3:10800:2	12	CD	O	O
weeks	POTIGA.xml:S3:10803:5	week	NNS	O	O
,	POTIGA.xml:S3:10808:1	,	,	O	O
the	POTIGA.xml:S3:10810:3	the	DT	O	O
estimated	POTIGA.xml:S3:10814:9	estim	VBN	O	O
incidence	POTIGA.xml:S3:10824:9	incid	NN	O	O
of	POTIGA.xml:S3:10834:2	of	IN	O	O
suicidal	POTIGA.xml:S3:10837:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
behavior	POTIGA.xml:S3:10846:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
or	POTIGA.xml:S3:10855:2	or	CC	O	O
ideation	POTIGA.xml:S3:10858:8	ideat	NN	I-AdverseReaction	I-AdverseReaction
among	POTIGA.xml:S3:10867:5	among	IN	O	O
27	POTIGA.xml:S3:10873:2	27	CD	O	O
,	POTIGA.xml:S3:10875:1	,	,	O	O
863	POTIGA.xml:S3:10876:3	863	CD	O	O
AED	POTIGA.xml:S3:10880:3	a	NNP	O	O
-	POTIGA.xml:S3:10883:1	-	:	O	O
treated	POTIGA.xml:S3:10884:7	treat	VBD	O	O
patients	POTIGA.xml:S3:10892:8	patient	NNS	O	O
was	POTIGA.xml:S3:10901:3	wa	VBD	O	O
0.43%	POTIGA.xml:S3:10905:5	0.43%	CD	O	O
compared	POTIGA.xml:S3:10911:8	compar	VBN	O	O
with	POTIGA.xml:S3:10920:4	with	IN	O	O
0.24%	POTIGA.xml:S3:10925:5	0.24%	CD	O	O
among	POTIGA.xml:S3:10931:5	among	IN	O	O
16	POTIGA.xml:S3:10937:2	16	CD	O	O
,	POTIGA.xml:S3:10939:1	,	,	O	O
029	POTIGA.xml:S3:10940:3	029	CD	O	O
placebo	POTIGA.xml:S3:10944:7	placebo	NN	O	O
-	POTIGA.xml:S3:10951:1	-	:	O	O
treated	POTIGA.xml:S3:10952:7	treat	JJ	O	O
patients	POTIGA.xml:S3:10960:8	patient	NNS	O	O
,	POTIGA.xml:S3:10968:1	,	,	O	O
representing	POTIGA.xml:S3:10970:12	repres	VBG	O	O
an	POTIGA.xml:S3:10983:2	an	DT	O	O
increase	POTIGA.xml:S3:10986:8	increas	NN	O	O
of	POTIGA.xml:S3:10995:2	of	IN	O	O
approximately	POTIGA.xml:S3:10998:13	approxim	RB	O	O
1	POTIGA.xml:S3:11012:1	1	CD	O	O
case	POTIGA.xml:S3:11014:4	case	NN	O	O
of	POTIGA.xml:S3:11019:2	of	IN	O	O
suicidal	POTIGA.xml:S3:11022:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thinking	POTIGA.xml:S3:11031:8	think	NN	I-AdverseReaction	I-AdverseReaction
or	POTIGA.xml:S3:11040:2	or	CC	O	O
behavior	POTIGA.xml:S3:11043:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
for	POTIGA.xml:S3:11052:3	for	IN	O	O
every	POTIGA.xml:S3:11056:5	everi	DT	O	O
530	POTIGA.xml:S3:11062:3	530	CD	O	O
patients	POTIGA.xml:S3:11066:8	patient	NNS	O	O
treated	POTIGA.xml:S3:11075:7	treat	VBN	O	O
.	POTIGA.xml:S3:11082:1	.	.	O	O

There	POTIGA.xml:S3:11084:5	there	EX	O	O
were	POTIGA.xml:S3:11090:4	were	VBD	O	O
4	POTIGA.xml:S3:11095:1	4	CD	O	O
suicides	POTIGA.xml:S3:11097:8	suicid	NNS	B-AdverseReaction	B-AdverseReaction
in	POTIGA.xml:S3:11106:2	in	IN	O	O
drug	POTIGA.xml:S3:11109:4	drug	NN	O	O
-	POTIGA.xml:S3:11113:1	-	:	O	O
treated	POTIGA.xml:S3:11114:7	treat	JJ	O	O
patients	POTIGA.xml:S3:11122:8	patient	NNS	O	O
in	POTIGA.xml:S3:11131:2	in	IN	O	O
the	POTIGA.xml:S3:11134:3	the	DT	O	O
trials	POTIGA.xml:S3:11138:6	trial	NNS	O	O
and	POTIGA.xml:S3:11145:3	and	CC	O	O
none	POTIGA.xml:S3:11149:4	none	NN	O	O
in	POTIGA.xml:S3:11154:2	in	IN	O	O
placebo	POTIGA.xml:S3:11157:7	placebo	NN	O	O
-	POTIGA.xml:S3:11164:1	-	:	O	O
treated	POTIGA.xml:S3:11165:7	treat	JJ	O	O
patients	POTIGA.xml:S3:11173:8	patient	NNS	O	O
,	POTIGA.xml:S3:11181:1	,	,	O	O
but	POTIGA.xml:S3:11183:3	but	CC	O	O
the	POTIGA.xml:S3:11187:3	the	DT	O	O
number	POTIGA.xml:S3:11191:6	number	NN	O	O
is	POTIGA.xml:S3:11198:2	is	VBZ	O	O
too	POTIGA.xml:S3:11201:3	too	RB	O	O
small	POTIGA.xml:S3:11205:5	small	JJ	O	O
to	POTIGA.xml:S3:11211:2	to	TO	O	O
allow	POTIGA.xml:S3:11214:5	allow	VB	O	O
any	POTIGA.xml:S3:11220:3	ani	DT	O	O
conclusion	POTIGA.xml:S3:11224:10	conclus	NN	O	O
about	POTIGA.xml:S3:11235:5	about	IN	O	O
drug	POTIGA.xml:S3:11241:4	drug	NN	O	O
effect	POTIGA.xml:S3:11246:6	effect	NN	O	O
on	POTIGA.xml:S3:11253:2	on	IN	O	O
suicide	POTIGA.xml:S3:11256:7	suicid	NN	B-AdverseReaction	B-AdverseReaction
.	POTIGA.xml:S3:11263:1	.	.	O	O

The	POTIGA.xml:S3:11269:3	the	DT	O	O
increased	POTIGA.xml:S3:11273:9	increas	VBN	O	O
risk	POTIGA.xml:S3:11283:4	risk	NN	O	O
of	POTIGA.xml:S3:11288:2	of	IN	O	O
suicidal	POTIGA.xml:S3:11291:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thoughts	POTIGA.xml:S3:11300:8	thought	NNS	I-AdverseReaction	I-AdverseReaction
or	POTIGA.xml:S3:11309:2	or	CC	O	O
behavior	POTIGA.xml:S3:11312:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
with	POTIGA.xml:S3:11321:4	with	IN	O	O
AEDs	POTIGA.xml:S3:11326:4	a	NNP	O	O
was	POTIGA.xml:S3:11331:3	wa	VBD	O	O
observed	POTIGA.xml:S3:11335:8	observ	VBN	O	O
as	POTIGA.xml:S3:11344:2	as	RB	O	O
early	POTIGA.xml:S3:11347:5	earli	JJ	O	O
as	POTIGA.xml:S3:11353:2	as	IN	O	O
1	POTIGA.xml:S3:11356:1	1	CD	O	O
week	POTIGA.xml:S3:11358:4	week	NN	O	O
after	POTIGA.xml:S3:11363:5	after	IN	O	O
starting	POTIGA.xml:S3:11369:8	start	VBG	O	O
treatment	POTIGA.xml:S3:11378:9	treatment	NN	O	O
with	POTIGA.xml:S3:11388:4	with	IN	O	O
AEDs	POTIGA.xml:S3:11393:4	a	NNP	O	O
and	POTIGA.xml:S3:11398:3	and	CC	O	O
persisted	POTIGA.xml:S3:11402:9	persist	VBN	O	O
for	POTIGA.xml:S3:11412:3	for	IN	O	O
the	POTIGA.xml:S3:11416:3	the	DT	O	O
duration	POTIGA.xml:S3:11420:8	durat	NN	O	O
of	POTIGA.xml:S3:11429:2	of	IN	O	O
treatment	POTIGA.xml:S3:11432:9	treatment	NN	O	O
assessed	POTIGA.xml:S3:11442:8	assess	VBN	O	O
.	POTIGA.xml:S3:11450:1	.	.	O	O

Because	POTIGA.xml:S3:11452:7	becaus	IN	O	O
most	POTIGA.xml:S3:11460:4	most	JJS	O	O
trials	POTIGA.xml:S3:11465:6	trial	NNS	O	O
included	POTIGA.xml:S3:11472:8	includ	VBD	O	O
in	POTIGA.xml:S3:11481:2	in	IN	O	O
the	POTIGA.xml:S3:11484:3	the	DT	O	O
analysis	POTIGA.xml:S3:11488:8	analysi	NN	O	O
did	POTIGA.xml:S3:11497:3	did	VBD	O	O
not	POTIGA.xml:S3:11501:3	not	RB	O	O
extend	POTIGA.xml:S3:11505:6	extend	VB	O	O
beyond	POTIGA.xml:S3:11512:6	beyond	IN	O	O
24	POTIGA.xml:S3:11519:2	24	CD	O	O
weeks	POTIGA.xml:S3:11522:5	week	NNS	O	O
,	POTIGA.xml:S3:11527:1	,	,	O	O
the	POTIGA.xml:S3:11529:3	the	DT	O	O
risk	POTIGA.xml:S3:11533:4	risk	NN	O	O
of	POTIGA.xml:S3:11538:2	of	IN	O	O
suicidal	POTIGA.xml:S3:11541:8	suicid	JJ	O	B-AdverseReaction
thoughts	POTIGA.xml:S3:11550:8	thought	NNS	O	I-AdverseReaction
or	POTIGA.xml:S3:11559:2	or	CC	O	O
behavior	POTIGA.xml:S3:11562:8	behavior	JJ	O	O
beyond	POTIGA.xml:S3:11571:6	beyond	IN	O	O
24	POTIGA.xml:S3:11578:2	24	CD	O	O
weeks	POTIGA.xml:S3:11581:5	week	NNS	O	O
could	POTIGA.xml:S3:11587:5	could	MD	O	O
not	POTIGA.xml:S3:11593:3	not	RB	O	O
be	POTIGA.xml:S3:11597:2	be	VB	O	O
assessed	POTIGA.xml:S3:11600:8	assess	VBN	O	O
.	POTIGA.xml:S3:11608:1	.	.	O	O

The	POTIGA.xml:S3:11614:3	the	DT	O	O
risk	POTIGA.xml:S3:11618:4	risk	NN	O	O
of	POTIGA.xml:S3:11623:2	of	IN	O	O
suicidal	POTIGA.xml:S3:11626:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thoughts	POTIGA.xml:S3:11635:8	thought	NNS	I-AdverseReaction	I-AdverseReaction
or	POTIGA.xml:S3:11644:2	or	CC	O	O
behavior	POTIGA.xml:S3:11647:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
was	POTIGA.xml:S3:11656:3	wa	VBD	O	O
generally	POTIGA.xml:S3:11660:9	gener	RB	O	O
consistent	POTIGA.xml:S3:11670:10	consist	JJ	O	O
among	POTIGA.xml:S3:11681:5	among	IN	O	O
drugs	POTIGA.xml:S3:11687:5	drug	NNS	O	O
in	POTIGA.xml:S3:11693:2	in	IN	O	O
the	POTIGA.xml:S3:11696:3	the	DT	O	O
data	POTIGA.xml:S3:11700:4	data	NNS	O	O
analyzed	POTIGA.xml:S3:11705:8	analyz	VBD	O	O
.	POTIGA.xml:S3:11713:1	.	.	O	O

The	POTIGA.xml:S3:11715:3	the	DT	O	O
finding	POTIGA.xml:S3:11719:7	find	NN	O	O
of	POTIGA.xml:S3:11727:2	of	IN	O	O
increased	POTIGA.xml:S3:11730:9	increas	VBN	O	O
risk	POTIGA.xml:S3:11740:4	risk	NN	O	O
with	POTIGA.xml:S3:11745:4	with	IN	O	O
AEDs	POTIGA.xml:S3:11750:4	a	NNP	O	O
of	POTIGA.xml:S3:11755:2	of	IN	O	O
varying	POTIGA.xml:S3:11758:7	vari	VBG	O	O
mechanism	POTIGA.xml:S3:11766:9	mechan	NN	O	O
of	POTIGA.xml:S3:11776:2	of	IN	O	O
action	POTIGA.xml:S3:11779:6	action	NN	O	O
and	POTIGA.xml:S3:11786:3	and	CC	O	O
across	POTIGA.xml:S3:11790:6	across	IN	O	O
a	POTIGA.xml:S3:11797:1	a	DT	O	O
range	POTIGA.xml:S3:11799:5	rang	NN	O	O
of	POTIGA.xml:S3:11805:2	of	IN	O	O
indications	POTIGA.xml:S3:11808:11	indic	NNS	O	O
suggests	POTIGA.xml:S3:11820:8	suggest	VBZ	O	O
that	POTIGA.xml:S3:11829:4	that	IN	O	O
the	POTIGA.xml:S3:11834:3	the	DT	O	O
risk	POTIGA.xml:S3:11838:4	risk	NN	O	O
applies	POTIGA.xml:S3:11843:7	appli	NNS	O	O
to	POTIGA.xml:S3:11851:2	to	TO	O	O
all	POTIGA.xml:S3:11854:3	all	DT	O	O
AEDs	POTIGA.xml:S3:11858:4	a	NNP	O	O
used	POTIGA.xml:S3:11863:4	use	VBN	O	O
for	POTIGA.xml:S3:11868:3	for	IN	O	O
any	POTIGA.xml:S3:11872:3	ani	DT	O	O
indication	POTIGA.xml:S3:11876:10	indic	NN	O	O
.	POTIGA.xml:S3:11886:1	.	.	O	O

The	POTIGA.xml:S3:11888:3	the	DT	O	O
risk	POTIGA.xml:S3:11892:4	risk	NN	O	O
did	POTIGA.xml:S3:11897:3	did	VBD	O	O
not	POTIGA.xml:S3:11901:3	not	RB	O	O
vary	POTIGA.xml:S3:11905:4	vari	JJ	O	O
substantially	POTIGA.xml:S3:11910:13	substanti	RB	O	O
by	POTIGA.xml:S3:11924:2	by	IN	O	O
age	POTIGA.xml:S3:11927:3	age	NN	O	O
(	POTIGA.xml:S3:11931:1	(	(	O	O
5	POTIGA.xml:S3:11932:1	5	CD	O	O
to	POTIGA.xml:S3:11934:2	to	TO	O	O
100	POTIGA.xml:S3:11937:3	100	CD	O	O
years	POTIGA.xml:S3:11941:5	year	NNS	O	O
)	POTIGA.xml:S3:11946:1	)	)	O	O
in	POTIGA.xml:S3:11948:2	in	IN	O	O
the	POTIGA.xml:S3:11951:3	the	DT	O	O
clinical	POTIGA.xml:S3:11955:8	clinic	JJ	O	O
trials	POTIGA.xml:S3:11964:6	trial	NNS	O	O
analyzed	POTIGA.xml:S3:11971:8	analyz	VBD	O	O
.	POTIGA.xml:S3:11979:1	.	.	O	O

Table	POTIGA.xml:S3:11985:5	tabl	JJ	O	O
3	POTIGA.xml:S3:11991:1	3	CD	O	O
shows	POTIGA.xml:S3:11993:5	show	NNS	O	O
absolute	POTIGA.xml:S3:11999:8	absolut	NN	O	O
and	POTIGA.xml:S3:12008:3	and	CC	O	O
relative	POTIGA.xml:S3:12012:8	rel	JJ	O	O
risk	POTIGA.xml:S3:12021:4	risk	NN	O	O
by	POTIGA.xml:S3:12026:2	by	IN	O	O
indication	POTIGA.xml:S3:12029:10	indic	NN	O	O
for	POTIGA.xml:S3:12040:3	for	IN	O	O
all	POTIGA.xml:S3:12044:3	all	DT	O	O
evaluated	POTIGA.xml:S3:12048:9	evalu	JJ	O	O
AEDs	POTIGA.xml:S3:12058:4	a	NNP	O	O
.	POTIGA.xml:S3:12062:1	.	.	O	O

Table	POTIGA.xml:S3:12069:5	tabl	JJ	O	O
3	POTIGA.xml:S3:12075:1	3	CD	O	O
.	POTIGA.xml:S3:12076:1	.	.	O	O

Risk	POTIGA.xml:S3:12078:4	risk	NN	O	O
of	POTIGA.xml:S3:12083:2	of	IN	O	O
Suicidal	POTIGA.xml:S3:12086:8	suicid	NNP	B-AdverseReaction	B-AdverseReaction
Thoughts	POTIGA.xml:S3:12095:8	thought	NNP	I-AdverseReaction	I-AdverseReaction
or	POTIGA.xml:S3:12104:2	or	CC	O	O
Behaviors	POTIGA.xml:S3:12107:9	behavior	NNS	I-AdverseReaction	I-AdverseReaction
by	POTIGA.xml:S3:12117:2	by	IN	O	O
Indication	POTIGA.xml:S3:12120:10	indic	NNP	O	O
for	POTIGA.xml:S3:12131:3	for	IN	O	O
Antiepileptic	POTIGA.xml:S3:12135:13	antiepilept	NNP	O	O
Drugs	POTIGA.xml:S3:12149:5	drug	NNP	O	O
in	POTIGA.xml:S3:12155:2	in	IN	O	O
the	POTIGA.xml:S3:12158:3	the	DT	O	O
Pooled	POTIGA.xml:S3:12162:6	pool	NNP	O	O
Analysis	POTIGA.xml:S3:12169:8	analysi	NN	O	O

Indication	POTIGA.xml:S3:12186:10	indic	NNP	O	O
Placebo	POTIGA.xml:S3:12200:7	placebo	NNP	O	O
Patients	POTIGA.xml:S3:12208:8	patient	NNPS	O	O
with	POTIGA.xml:S3:12217:4	with	IN	O	O
Events	POTIGA.xml:S3:12222:6	event	NNS	O	O
per	POTIGA.xml:S3:12229:3	per	IN	O	O
1	POTIGA.xml:S3:12233:1	1	CD	O	O
,	POTIGA.xml:S3:12234:1	,	,	O	O
000	POTIGA.xml:S3:12235:3	000	CD	O	O
Patients	POTIGA.xml:S3:12239:8	patient	NNS	O	O
Drug	POTIGA.xml:S3:12251:4	drug	JJ	O	O
Patients	POTIGA.xml:S3:12256:8	patient	NNS	O	O
with	POTIGA.xml:S3:12265:4	with	IN	O	O
Events	POTIGA.xml:S3:12270:6	event	NNS	O	O
per	POTIGA.xml:S3:12277:3	per	IN	O	O
1	POTIGA.xml:S3:12281:1	1	CD	O	O
,	POTIGA.xml:S3:12282:1	,	,	O	O
000	POTIGA.xml:S3:12283:3	000	CD	O	O
Patients	POTIGA.xml:S3:12287:8	patient	NNS	O	O
Relative	POTIGA.xml:S3:12299:8	rel	JJ	O	O
Risk	POTIGA.xml:S3:12308:4	risk	NN	O	O
:	POTIGA.xml:S3:12312:1	:	:	O	O
Incidence	POTIGA.xml:S3:12314:9	incid	NN	O	O
of	POTIGA.xml:S3:12324:2	of	IN	O	O
Events	POTIGA.xml:S3:12327:6	event	NNS	O	O
in	POTIGA.xml:S3:12334:2	in	IN	O	O
Drug	POTIGA.xml:S3:12337:4	drug	NNP	O	O
Patients	POTIGA.xml:S3:12342:8	patient	NNPS	O	O
Incidence	POTIGA.xml:S3:12351:9	incid	NNP	O	O
in	POTIGA.xml:S3:12361:2	in	IN	O	O
Placebo	POTIGA.xml:S3:12364:7	placebo	NNP	O	O
Patients	POTIGA.xml:S3:12372:8	patient	NNP	O	O
Risk	POTIGA.xml:S3:12384:4	risk	NNP	O	O
Difference	POTIGA.xml:S3:12389:10	differ	NNP	O	O
:	POTIGA.xml:S3:12399:1	:	:	O	O
Additional	POTIGA.xml:S3:12401:10	addit	JJ	O	O
Drug	POTIGA.xml:S3:12412:4	drug	NN	O	O
Patients	POTIGA.xml:S3:12417:8	patient	NNS	O	O
with	POTIGA.xml:S3:12426:4	with	IN	O	O
Events	POTIGA.xml:S3:12431:6	event	NNS	O	O
per	POTIGA.xml:S3:12438:3	per	IN	O	O
1	POTIGA.xml:S3:12442:1	1	CD	O	O
,	POTIGA.xml:S3:12443:1	,	,	O	O
000	POTIGA.xml:S3:12444:3	000	CD	O	O
Patients	POTIGA.xml:S3:12448:8	patient	NNS	O	O

Epilepsy	POTIGA.xml:S3:12463:8	epilepsi	NNP	O	O
1.0	POTIGA.xml:S3:12476:3	1.0	CD	O	O
3.4	POTIGA.xml:S3:12495:3	3.4	CD	O	O
3.5	POTIGA.xml:S3:12514:3	3.5	CD	O	O
2.4	POTIGA.xml:S3:12547:3	2.4	CD	O	O

Psychiatric	POTIGA.xml:S3:12577:11	psychiatr	JJ	O	O
5.7	POTIGA.xml:S3:12592:3	5.7	CD	O	O
8.5	POTIGA.xml:S3:12611:3	8.5	CD	O	O
1.5	POTIGA.xml:S3:12630:3	1.5	CD	O	O
2.9	POTIGA.xml:S3:12663:3	2.9	CD	O	O

Other	POTIGA.xml:S3:12693:5	other	JJ	O	O
1.0	POTIGA.xml:S3:12706:3	1.0	CD	O	O
1.8	POTIGA.xml:S3:12725:3	1.8	CD	O	O
1.9	POTIGA.xml:S3:12744:3	1.9	CD	O	O
0.9	POTIGA.xml:S3:12777:3	0.9	CD	O	O

Total	POTIGA.xml:S3:12807:5	total	JJ	O	O
2.4	POTIGA.xml:S3:12820:3	2.4	CD	O	O
4.3	POTIGA.xml:S3:12839:3	4.3	CD	O	O
1.8	POTIGA.xml:S3:12858:3	1.8	CD	O	O
1.9	POTIGA.xml:S3:12891:3	1.9	CD	O	O

The	POTIGA.xml:S3:12930:3	the	DT	O	O
relative	POTIGA.xml:S3:12934:8	rel	JJ	O	O
risk	POTIGA.xml:S3:12943:4	risk	NN	O	O
for	POTIGA.xml:S3:12948:3	for	IN	O	O
suicidal	POTIGA.xml:S3:12952:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thoughts	POTIGA.xml:S3:12961:8	thought	NNS	I-AdverseReaction	I-AdverseReaction
or	POTIGA.xml:S3:12970:2	or	CC	O	O
behavior	POTIGA.xml:S3:12973:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
was	POTIGA.xml:S3:12982:3	wa	VBD	O	O
higher	POTIGA.xml:S3:12986:6	higher	RBR	O	O
in	POTIGA.xml:S3:12993:2	in	IN	O	O
clinical	POTIGA.xml:S3:12996:8	clinic	JJ	O	O
trials	POTIGA.xml:S3:13005:6	trial	NNS	O	O
in	POTIGA.xml:S3:13012:2	in	IN	O	O
patients	POTIGA.xml:S3:13015:8	patient	NNS	O	O
with	POTIGA.xml:S3:13024:4	with	IN	O	O
epilepsy	POTIGA.xml:S3:13029:8	epilepsi	NN	O	O
than	POTIGA.xml:S3:13038:4	than	IN	O	O
in	POTIGA.xml:S3:13043:2	in	IN	O	O
clinical	POTIGA.xml:S3:13046:8	clinic	JJ	O	O
trials	POTIGA.xml:S3:13055:6	trial	NNS	O	O
in	POTIGA.xml:S3:13062:2	in	IN	O	O
patients	POTIGA.xml:S3:13065:8	patient	NNS	O	O
with	POTIGA.xml:S3:13074:4	with	IN	O	O
psychiatric	POTIGA.xml:S3:13079:11	psychiatr	JJ	O	O
or	POTIGA.xml:S3:13091:2	or	CC	O	O
other	POTIGA.xml:S3:13094:5	other	JJ	O	O
conditions	POTIGA.xml:S3:13100:10	condit	NNS	O	O
,	POTIGA.xml:S3:13110:1	,	,	O	O
but	POTIGA.xml:S3:13112:3	but	CC	O	O
the	POTIGA.xml:S3:13116:3	the	DT	O	O
absolute	POTIGA.xml:S3:13120:8	absolut	NN	O	O
risk	POTIGA.xml:S3:13129:4	risk	NN	O	O
differences	POTIGA.xml:S3:13134:11	differ	NNS	O	O
were	POTIGA.xml:S3:13146:4	were	VBD	O	O
similar	POTIGA.xml:S3:13151:7	similar	JJ	O	O
for	POTIGA.xml:S3:13159:3	for	IN	O	O
epilepsy	POTIGA.xml:S3:13163:8	epilepsi	NN	O	O
and	POTIGA.xml:S3:13172:3	and	CC	O	O
psychiatric	POTIGA.xml:S3:13176:11	psychiatr	JJ	O	O
indications	POTIGA.xml:S3:13188:11	indic	NNS	O	O
.	POTIGA.xml:S3:13199:1	.	.	O	O

Anyone	POTIGA.xml:S3:13205:6	anyon	NN	O	O

considering	POTIGA.xml:S3:13212:11	consid	VBG	O	O
prescribing	POTIGA.xml:S3:13224:11	prescrib	VBG	O	O
POTIGA	POTIGA.xml:S3:13236:6	potiga	NNP	O	O
or	POTIGA.xml:S3:13243:2	or	CC	O	O
any	POTIGA.xml:S3:13246:3	ani	DT	O	O
other	POTIGA.xml:S3:13250:5	other	JJ	O	O
AED	POTIGA.xml:S3:13256:3	a	NNP	O	O
must	POTIGA.xml:S3:13260:4	must	MD	O	O
balance	POTIGA.xml:S3:13265:7	balanc	VB	O	O
this	POTIGA.xml:S3:13273:4	thi	DT	O	O
risk	POTIGA.xml:S3:13278:4	risk	NN	O	O
with	POTIGA.xml:S3:13283:4	with	IN	O	O
the	POTIGA.xml:S3:13288:3	the	DT	O	O
risk	POTIGA.xml:S3:13292:4	risk	NN	O	O
of	POTIGA.xml:S3:13297:2	of	IN	O	O
untreated	POTIGA.xml:S3:13300:9	untreat	JJ	O	O
illness	POTIGA.xml:S3:13310:7	ill	NN	O	O
.	POTIGA.xml:S3:13317:1	.	.	O	O

Epilepsy	POTIGA.xml:S3:13319:8	epilepsi	NNP	O	O
and	POTIGA.xml:S3:13328:3	and	CC	O	O
many	POTIGA.xml:S3:13332:4	mani	JJ	O	O
other	POTIGA.xml:S3:13337:5	other	JJ	O	O
illnesses	POTIGA.xml:S3:13343:9	ill	NNS	O	O
for	POTIGA.xml:S3:13353:3	for	IN	O	O
which	POTIGA.xml:S3:13357:5	which	WDT	O	O
AEDs	POTIGA.xml:S3:13363:4	a	NNP	O	O
are	POTIGA.xml:S3:13368:3	are	VBP	O	O
prescribed	POTIGA.xml:S3:13372:10	prescrib	VBN	O	O
are	POTIGA.xml:S3:13383:3	are	VBP	O	O
themselves	POTIGA.xml:S3:13387:10	themselv	PRP	O	O
associated	POTIGA.xml:S3:13398:10	associ	VBN	O	O
with	POTIGA.xml:S3:13409:4	with	IN	O	O
morbidity	POTIGA.xml:S3:13414:9	morbid	NN	O	O
and	POTIGA.xml:S3:13424:3	and	CC	O	O
mortality	POTIGA.xml:S3:13428:9	mortal	NN	O	O
and	POTIGA.xml:S3:13438:3	and	CC	O	O
an	POTIGA.xml:S3:13442:2	an	DT	O	O
increased	POTIGA.xml:S3:13445:9	increas	VBN	O	O
risk	POTIGA.xml:S3:13455:4	risk	NN	O	O
of	POTIGA.xml:S3:13460:2	of	IN	O	O
suicidal	POTIGA.xml:S3:13463:8	suicid	JJ	O	O
thoughts	POTIGA.xml:S3:13472:8	thought	NNS	O	O
and	POTIGA.xml:S3:13481:3	and	CC	O	O
behavior	POTIGA.xml:S3:13485:8	behavior	NN	O	O
.	POTIGA.xml:S3:13493:1	.	.	O	O

Should	POTIGA.xml:S3:13495:6	should	MD	O	O
suicidal	POTIGA.xml:S3:13502:8	suicid	VB	O	O
thoughts	POTIGA.xml:S3:13511:8	thought	NNS	O	O
and	POTIGA.xml:S3:13520:3	and	CC	O	O
behavior	POTIGA.xml:S3:13524:8	behavior	JJ	O	O
emerge	POTIGA.xml:S3:13533:6	emerg	NN	O	O
during	POTIGA.xml:S3:13540:6	dure	IN	O	O
treatment	POTIGA.xml:S3:13547:9	treatment	NN	O	O
,	POTIGA.xml:S3:13556:1	,	,	O	O
the	POTIGA.xml:S3:13558:3	the	DT	O	O
prescriber	POTIGA.xml:S3:13562:10	prescrib	NN	O	O
needs	POTIGA.xml:S3:13573:5	need	VBZ	O	O
to	POTIGA.xml:S3:13579:2	to	TO	O	O
consider	POTIGA.xml:S3:13582:8	consid	VB	O	O
whether	POTIGA.xml:S3:13591:7	whether	IN	O	O
the	POTIGA.xml:S3:13599:3	the	DT	O	O
emergence	POTIGA.xml:S3:13603:9	emerg	NN	O	O
of	POTIGA.xml:S3:13613:2	of	IN	O	O
these	POTIGA.xml:S3:13616:5	these	DT	O	O
symptoms	POTIGA.xml:S3:13622:8	symptom	NNS	O	O
in	POTIGA.xml:S3:13631:2	in	IN	O	O
any	POTIGA.xml:S3:13634:3	ani	DT	O	O
given	POTIGA.xml:S3:13638:5	given	VBN	O	O
patient	POTIGA.xml:S3:13644:7	patient	NN	O	O
may	POTIGA.xml:S3:13652:3	may	MD	O	O
be	POTIGA.xml:S3:13656:2	be	VB	O	O
related	POTIGA.xml:S3:13659:7	relat	VBN	O	O
to	POTIGA.xml:S3:13667:2	to	TO	O	O
the	POTIGA.xml:S3:13670:3	the	DT	O	O
illness	POTIGA.xml:S3:13674:7	ill	NN	O	O
being	POTIGA.xml:S3:13682:5	be	VBG	O	O
treated	POTIGA.xml:S3:13688:7	treat	VBN	O	O
.	POTIGA.xml:S3:13695:1	.	.	O	O

Patients	POTIGA.xml:S3:13701:8	patient	NNS	O	O
,	POTIGA.xml:S3:13709:1	,	,	O	O
their	POTIGA.xml:S3:13711:5	their	PRP$	O	O
caregivers	POTIGA.xml:S3:13717:10	caregiv	NNS	O	O
,	POTIGA.xml:S3:13727:1	,	,	O	O
and	POTIGA.xml:S3:13729:3	and	CC	O	O
families	POTIGA.xml:S3:13733:8	famili	NNS	O	O
should	POTIGA.xml:S3:13742:6	should	MD	O	O
be	POTIGA.xml:S3:13749:2	be	VB	O	O
informed	POTIGA.xml:S3:13752:8	inform	VBN	O	O
that	POTIGA.xml:S3:13761:4	that	IN	O	O
AEDs	POTIGA.xml:S3:13766:4	a	NNP	O	O
increase	POTIGA.xml:S3:13771:8	increas	VB	O	O
the	POTIGA.xml:S3:13780:3	the	DT	O	O
risk	POTIGA.xml:S3:13784:4	risk	NN	O	O
of	POTIGA.xml:S3:13789:2	of	IN	O	O
suicidal	POTIGA.xml:S3:13792:8	suicid	JJ	O	O
thoughts	POTIGA.xml:S3:13801:8	thought	NNS	O	O
and	POTIGA.xml:S3:13810:3	and	CC	O	O
behavior	POTIGA.xml:S3:13814:8	behavior	NN	O	O
and	POTIGA.xml:S3:13823:3	and	CC	O	O
should	POTIGA.xml:S3:13827:6	should	MD	O	O
be	POTIGA.xml:S3:13834:2	be	VB	O	O
advised	POTIGA.xml:S3:13837:7	advis	VBN	O	O
of	POTIGA.xml:S3:13845:2	of	IN	O	O
the	POTIGA.xml:S3:13848:3	the	DT	O	O
need	POTIGA.xml:S3:13852:4	need	NN	O	O
to	POTIGA.xml:S3:13857:2	to	TO	O	O
be	POTIGA.xml:S3:13860:2	be	VB	O	O
alert	POTIGA.xml:S3:13863:5	alert	JJ	O	O
for	POTIGA.xml:S3:13869:3	for	IN	O	O
the	POTIGA.xml:S3:13873:3	the	DT	O	O
emergence	POTIGA.xml:S3:13877:9	emerg	NN	O	O
or	POTIGA.xml:S3:13887:2	or	CC	O	O
worsening	POTIGA.xml:S3:13890:9	worsen	NN	O	O
of	POTIGA.xml:S3:13900:2	of	IN	O	O
the	POTIGA.xml:S3:13903:3	the	DT	O	O
signs	POTIGA.xml:S3:13907:5	sign	NNS	O	O
and	POTIGA.xml:S3:13913:3	and	CC	O	O
symptoms	POTIGA.xml:S3:13917:8	symptom	NNS	O	O
of	POTIGA.xml:S3:13926:2	of	IN	O	O
depression	POTIGA.xml:S3:13929:10	depress	NN	O	O
;	POTIGA.xml:S3:13939:1	;	:	O	O
any	POTIGA.xml:S3:13941:3	ani	DT	O	O
unusual	POTIGA.xml:S3:13945:7	unusu	JJ	O	O
changes	POTIGA.xml:S3:13953:7	chang	NNS	O	O
in	POTIGA.xml:S3:13961:2	in	IN	O	O
mood	POTIGA.xml:S3:13964:4	mood	NN	O	O
or	POTIGA.xml:S3:13969:2	or	CC	O	O
behavior	POTIGA.xml:S3:13972:8	behavior	NN	O	O
;	POTIGA.xml:S3:13980:1	;	:	O	O
or	POTIGA.xml:S3:13982:2	or	CC	O	O
the	POTIGA.xml:S3:13985:3	the	DT	O	O
emergence	POTIGA.xml:S3:13989:9	emerg	NN	O	O
of	POTIGA.xml:S3:13999:2	of	IN	O	O
suicidal	POTIGA.xml:S3:14002:8	suicid	JJ	O	O
thoughts	POTIGA.xml:S3:14011:8	thought	NNS	O	O
,	POTIGA.xml:S3:14019:1	,	,	O	O
behavior	POTIGA.xml:S3:14021:8	behavior	NN	O	O
,	POTIGA.xml:S3:14029:1	,	,	O	O
or	POTIGA.xml:S3:14031:2	or	CC	O	O
thoughts	POTIGA.xml:S3:14034:8	thought	NNS	O	O
about	POTIGA.xml:S3:14043:5	about	IN	O	O
self	POTIGA.xml:S3:14049:4	self	PRP	O	O
-	POTIGA.xml:S3:14053:1	-	:	O	O
harm	POTIGA.xml:S3:14054:4	harm	NN	O	O
.	POTIGA.xml:S3:14058:1	.	.	O	O

Behaviors	POTIGA.xml:S3:14060:9	behavior	NNS	O	O
of	POTIGA.xml:S3:14070:2	of	IN	O	O
concern	POTIGA.xml:S3:14073:7	concern	NN	O	O
should	POTIGA.xml:S3:14081:6	should	MD	O	O
be	POTIGA.xml:S3:14088:2	be	VB	O	O
reported	POTIGA.xml:S3:14091:8	report	VBN	O	O
immediately	POTIGA.xml:S3:14100:11	immedi	RB	O	O
to	POTIGA.xml:S3:14112:2	to	TO	O	O
healthcare	POTIGA.xml:S3:14115:10	healthcar	VB	O	O
providers	POTIGA.xml:S3:14126:9	provid	NNS	O	O
.	POTIGA.xml:S3:14135:1	.	.	O	O

5.8	POTIGA.xml:S3:14144:3	5.8	CD	O	O
Withdrawal	POTIGA.xml:S3:14148:10	withdraw	NNP	O	O
Seizures	POTIGA.xml:S3:14159:8	seizur	NNS	O	O

As	POTIGA.xml:S3:14173:2	As	IN	O	O
with	POTIGA.xml:S3:14176:4	with	IN	O	O
all	POTIGA.xml:S3:14181:3	all	DT	O	O
AEDs	POTIGA.xml:S3:14185:4	a	NNP	O	O
,	POTIGA.xml:S3:14189:1	,	,	O	O
when	POTIGA.xml:S3:14191:4	when	WRB	O	O
POTIGA	POTIGA.xml:S3:14196:6	potiga	NNP	O	O
is	POTIGA.xml:S3:14203:2	is	VBZ	O	O
discontinued	POTIGA.xml:S3:14206:12	discontinu	VBN	O	O
,	POTIGA.xml:S3:14218:1	,	,	O	O
it	POTIGA.xml:S3:14220:2	it	PRP	O	O
should	POTIGA.xml:S3:14223:6	should	MD	O	O
be	POTIGA.xml:S3:14230:2	be	VB	O	O
withdrawn	POTIGA.xml:S3:14233:9	withdrawn	VBN	O	O
gradually	POTIGA.xml:S3:14243:9	gradual	RB	O	O
when	POTIGA.xml:S3:14253:4	when	WRB	O	O
possible	POTIGA.xml:S3:14258:8	possibl	JJ	O	O
to	POTIGA.xml:S3:14267:2	to	TO	O	O
minimize	POTIGA.xml:S3:14270:8	minim	VB	O	O
the	POTIGA.xml:S3:14279:3	the	DT	O	O
potential	POTIGA.xml:S3:14283:9	potenti	NN	O	O
of	POTIGA.xml:S3:14293:2	of	IN	O	O
increased	POTIGA.xml:S3:14296:9	increas	JJ	O	O
seizure	POTIGA.xml:S3:14306:7	seizur	NN	O	O
frequency	POTIGA.xml:S3:14314:9	frequenc	NN	O	O
[	POTIGA.xml:S3:14324:1	[	NNP	O	O
see	POTIGA.xml:S3:14325:3	see	VBP	O	O
Dosage	POTIGA.xml:S3:14329:6	dosag	NNP	O	O
and	POTIGA.xml:S3:14336:3	and	CC	O	O
Administration	POTIGA.xml:S3:14340:14	administr	NNP	O	O
(	POTIGA.xml:S3:14355:1	(	(	O	O
2.1	POTIGA.xml:S3:14356:3	2.1	CD	O	O
)]	POTIGA.xml:S3:14359:2	)]	NN	O	O
.	POTIGA.xml:S3:14363:1	.	.	O	O

The	POTIGA.xml:S3:14365:3	the	DT	O	O
dosage	POTIGA.xml:S3:14369:6	dosag	NN	O	O
of	POTIGA.xml:S3:14376:2	of	IN	O	O
POTIGA	POTIGA.xml:S3:14379:6	potiga	NNP	O	O
should	POTIGA.xml:S3:14386:6	should	MD	O	O
be	POTIGA.xml:S3:14393:2	be	VB	O	O
reduced	POTIGA.xml:S3:14396:7	reduc	VBN	O	O
over	POTIGA.xml:S3:14404:4	over	IN	O	O
a	POTIGA.xml:S3:14409:1	a	DT	O	O
period	POTIGA.xml:S3:14411:6	period	NN	O	O
of	POTIGA.xml:S3:14418:2	of	IN	O	O
at	POTIGA.xml:S3:14421:2	at	IN	O	O
least	POTIGA.xml:S3:14424:5	least	JJS	O	O
3	POTIGA.xml:S3:14430:1	3	CD	O	O
weeks	POTIGA.xml:S3:14432:5	week	NNS	O	O
,	POTIGA.xml:S3:14437:1	,	,	O	O
unless	POTIGA.xml:S3:14439:6	unless	IN	O	O
safety	POTIGA.xml:S3:14446:6	safeti	NN	O	O
concerns	POTIGA.xml:S3:14453:8	concern	NNS	O	O
require	POTIGA.xml:S3:14462:7	requir	VBP	O	O
abrupt	POTIGA.xml:S3:14470:6	abrupt	JJ	O	O
withdrawal	POTIGA.xml:S3:14477:10	withdraw	NN	O	O
.	POTIGA.xml:S3:14487:1	.	.	O	O
6	PRADAXA.xml:S1:4:1	6	CD	O	O
ADVERSE	PRADAXA.xml:S1:7:7	advers	JJ	O	O
REACTIONS	PRADAXA.xml:S1:15:9	reaction	NN	O	O

The	PRADAXA.xml:S1:28:3	the	DT	O	O
most	PRADAXA.xml:S1:32:4	most	RBS	O	O
serious	PRADAXA.xml:S1:37:7	seriou	JJ	O	O
adverse	PRADAXA.xml:S1:45:7	advers	JJ	O	O
reactions	PRADAXA.xml:S1:53:9	reaction	NNS	O	O
reported	PRADAXA.xml:S1:63:8	report	VBN	O	O
with	PRADAXA.xml:S1:72:4	with	IN	O	O
PRADAXA	PRADAXA.xml:S1:77:7	pradaxa	NNP	O	O
were	PRADAXA.xml:S1:85:4	were	VBD	O	O
related	PRADAXA.xml:S1:90:7	relat	VBN	O	O
to	PRADAXA.xml:S1:98:2	to	TO	O	O
bleeding	PRADAXA.xml:S1:101:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
[	PRADAXA.xml:S1:111:1	[	JJ	O	O
see	PRADAXA.xml:S1:112:3	see	NN	O	O
Warnings	PRADAXA.xml:S1:116:8	warn	NNS	O	O
and	PRADAXA.xml:S1:125:3	and	CC	O	O
Precautions	PRADAXA.xml:S1:129:11	precaut	NNP	O	O
(	PRADAXA.xml:S1:142:1	(	(	O	O
5.2	PRADAXA.xml:S1:143:3	5.2	CD	O	O
)	PRADAXA.xml:S1:146:1	)	)	O	O
]	PRADAXA.xml:S1:149:1	]	NN	O	O
.	PRADAXA.xml:S1:152:1	.	.	O	O

EXCERPT	PRADAXA.xml:S1:160:7	excerpt	NNS	O	O
:	PRADAXA.xml:S1:167:1	:	:	O	O
Most	PRADAXA.xml:S1:171:4	most	JJS	O	O
common	PRADAXA.xml:S1:176:6	common	JJ	O	O
adverse	PRADAXA.xml:S1:183:7	advers	JJ	O	O
reactions	PRADAXA.xml:S1:191:9	reaction	NNS	O	O
(	PRADAXA.xml:S1:201:1	(	(	O	O
15%	PRADAXA.xml:S1:203:3	15%	CD	O	O
)	PRADAXA.xml:S1:206:1	)	)	O	O
are	PRADAXA.xml:S1:208:3	are	VBP	O	O
gastritis	PRADAXA.xml:S1:212:9	gastriti	JJ	B-AdverseReaction	O
-	PRADAXA.xml:S1:221:1	-	:	O	O
like	PRADAXA.xml:S1:222:4	like	IN	O	O
symptoms	PRADAXA.xml:S1:227:8	symptom	NNS	O	O
and	PRADAXA.xml:S1:236:3	and	CC	O	O
bleeding	PRADAXA.xml:S1:240:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
(	PRADAXA.xml:S1:250:1	(	(	O	O
6.1	PRADAXA.xml:S1:251:3	6.1	CD	O	O
)	PRADAXA.xml:S1:254:1	)	)	O	O

To	PRADAXA.xml:S1:266:2	To	TO	O	O
report	PRADAXA.xml:S1:269:6	report	VB	O	O
SUSPECTED	PRADAXA.xml:S1:276:9	suspect	NNP	O	O
ADVERSE	PRADAXA.xml:S1:286:7	advers	NNP	O	O
REACTIONS	PRADAXA.xml:S1:294:9	reaction	NNP	O	O
,	PRADAXA.xml:S1:303:1	,	,	O	O
contact	PRADAXA.xml:S1:305:7	contact	NN	O	O
Boehringer	PRADAXA.xml:S1:313:10	boehring	NNP	O	O
Ingelheim	PRADAXA.xml:S1:324:9	ingelheim	NNP	O	O
Pharmaceuticals	PRADAXA.xml:S1:334:15	pharmaceut	NNP	O	O
,	PRADAXA.xml:S1:349:1	,	,	O	O
Inc	PRADAXA.xml:S1:351:3	inc	NNP	O	O
.	PRADAXA.xml:S1:354:1	.	.	O	O

at	PRADAXA.xml:S1:356:2	at	IN	O	O
(	PRADAXA.xml:S1:359:1	(	(	O	O
800	PRADAXA.xml:S1:360:3	800	CD	O	O
)	PRADAXA.xml:S1:363:1	)	)	O	O
542	PRADAXA.xml:S1:365:3	542	CD	O	O
-	PRADAXA.xml:S1:368:1	-	:	O	O
6257	PRADAXA.xml:S1:369:4	6257	CD	O	O
or	PRADAXA.xml:S1:374:2	or	CC	O	O
(	PRADAXA.xml:S1:377:1	(	(	O	O
800	PRADAXA.xml:S1:378:3	800	CD	O	O
)	PRADAXA.xml:S1:381:1	)	)	O	O
459	PRADAXA.xml:S1:383:3	459	CD	O	O
-	PRADAXA.xml:S1:386:1	-	:	O	O
9906	PRADAXA.xml:S1:387:4	9906	CD	O	O
TTY	PRADAXA.xml:S1:392:3	tti	NNP	O	O
or	PRADAXA.xml:S1:396:2	or	CC	O	O
FDA	PRADAXA.xml:S1:399:3	fda	NNP	O	O
at	PRADAXA.xml:S1:403:2	at	IN	O	O
1	PRADAXA.xml:S1:406:1	1	CD	O	O
-	PRADAXA.xml:S1:407:1	-	:	O	O
800	PRADAXA.xml:S1:408:3	800	CD	O	O
-	PRADAXA.xml:S1:411:1	-	:	O	O
FDA	PRADAXA.xml:S1:412:3	fda	NNP	O	O
-	PRADAXA.xml:S1:415:1	-	:	O	O
1088	PRADAXA.xml:S1:416:4	1088	CD	O	O
or	PRADAXA.xml:S1:421:2	or	CC	O	O
www	PRADAXA.xml:S1:431:3	www	VB	O	O
.	PRADAXA.xml:S1:434:1	.	.	O	O
fda	PRADAXA.xml:S1:435:3	fda	NN	O	O
.	PRADAXA.xml:S1:438:1	.	.	O	O
gov	PRADAXA.xml:S1:439:3	gov	JJ	O	O
medwatch	PRADAXA.xml:S1:443:8	medwatch	NN	O	O
.	PRADAXA.xml:S1:455:1	.	.	O	O

6.1	PRADAXA.xml:S1:465:3	6.1	CD	O	O

Clinical	PRADAXA.xml:S1:469:8	clinic	JJ	O	O
Trials	PRADAXA.xml:S1:478:6	trial	NNS	O	O
Experience	PRADAXA.xml:S1:485:10	experi	NN	O	O

Because	PRADAXA.xml:S1:499:7	becaus	IN	O	O
clinical	PRADAXA.xml:S1:507:8	clinic	JJ	O	O
trials	PRADAXA.xml:S1:516:6	trial	NNS	O	O
are	PRADAXA.xml:S1:523:3	are	VBP	O	O
conducted	PRADAXA.xml:S1:527:9	conduct	VBN	O	O
under	PRADAXA.xml:S1:537:5	under	IN	O	O
widely	PRADAXA.xml:S1:543:6	wide	RB	O	O
varying	PRADAXA.xml:S1:550:7	vari	VBG	O	O
conditions	PRADAXA.xml:S1:558:10	condit	NNS	O	O
,	PRADAXA.xml:S1:568:1	,	,	O	O
adverse	PRADAXA.xml:S1:570:7	advers	JJ	O	O
reactions	PRADAXA.xml:S1:578:9	reaction	NNS	O	O
rates	PRADAXA.xml:S1:588:5	rate	NNS	O	O
observed	PRADAXA.xml:S1:594:8	observ	VBD	O	O
in	PRADAXA.xml:S1:603:2	in	IN	O	O
the	PRADAXA.xml:S1:606:3	the	DT	O	O
clinical	PRADAXA.xml:S1:610:8	clinic	JJ	O	O
trials	PRADAXA.xml:S1:619:6	trial	NNS	O	O
of	PRADAXA.xml:S1:626:2	of	IN	O	O
a	PRADAXA.xml:S1:629:1	a	DT	O	O
drug	PRADAXA.xml:S1:631:4	drug	NN	O	O
cannot	PRADAXA.xml:S1:636:6	cannot	NN	O	O
be	PRADAXA.xml:S1:643:2	be	VB	O	O
directly	PRADAXA.xml:S1:646:8	directli	RB	O	O
compared	PRADAXA.xml:S1:655:8	compar	VBN	O	O
to	PRADAXA.xml:S1:664:2	to	TO	O	O
rates	PRADAXA.xml:S1:667:5	rate	NNS	O	O
in	PRADAXA.xml:S1:673:2	in	IN	O	O
the	PRADAXA.xml:S1:676:3	the	DT	O	O
clinical	PRADAXA.xml:S1:680:8	clinic	JJ	O	O
trials	PRADAXA.xml:S1:689:6	trial	NNS	O	O
of	PRADAXA.xml:S1:696:2	of	IN	O	O
another	PRADAXA.xml:S1:699:7	anoth	DT	O	O
drug	PRADAXA.xml:S1:707:4	drug	NN	O	O
and	PRADAXA.xml:S1:712:3	and	CC	O	O
may	PRADAXA.xml:S1:716:3	may	MD	O	O
not	PRADAXA.xml:S1:720:3	not	RB	O	O
reflect	PRADAXA.xml:S1:724:7	reflect	VB	O	O
the	PRADAXA.xml:S1:732:3	the	DT	O	O
rates	PRADAXA.xml:S1:736:5	rate	NNS	O	O
observed	PRADAXA.xml:S1:742:8	observ	VBD	O	O
in	PRADAXA.xml:S1:751:2	in	IN	O	O
practice	PRADAXA.xml:S1:754:8	practic	NN	O	O
.	PRADAXA.xml:S1:762:1	.	.	O	O

Reduction	PRADAXA.xml:S1:772:9	reduct	NN	O	O
of	PRADAXA.xml:S1:782:2	of	IN	O	O
Risk	PRADAXA.xml:S1:785:4	risk	NN	O	O
of	PRADAXA.xml:S1:790:2	of	IN	O	O
Stroke	PRADAXA.xml:S1:793:6	stroke	NNP	O	O
and	PRADAXA.xml:S1:800:3	and	CC	O	O
Systemic	PRADAXA.xml:S1:804:8	system	NNP	O	O
Embolism	PRADAXA.xml:S1:813:8	embol	NNP	O	O
in	PRADAXA.xml:S1:822:2	in	IN	O	O
Non	PRADAXA.xml:S1:825:3	non	NNP	O	O
-	PRADAXA.xml:S1:828:1	-	:	O	O
valvular	PRADAXA.xml:S1:829:8	valvular	JJ	O	O
Atrial	PRADAXA.xml:S1:838:6	atrial	NNP	O	O
Fibrillation	PRADAXA.xml:S1:845:12	fibril	NN	O	O

The	PRADAXA.xml:S1:866:3	the	DT	O	O
RE	PRADAXA.xml:S1:870:2	RE	NNP	O	O
-	PRADAXA.xml:S1:872:1	-	:	O	O
LY	PRADAXA.xml:S1:873:2	LY	NNP	O	O
(	PRADAXA.xml:S1:876:1	(	(	O	O
Randomized	PRADAXA.xml:S1:877:10	random	NNP	O	O
Evaluation	PRADAXA.xml:S1:888:10	evalu	NNP	O	O
of	PRADAXA.xml:S1:899:2	of	IN	O	O
Long	PRADAXA.xml:S1:902:4	long	NNP	O	O
-	PRADAXA.xml:S1:906:1	-	:	O	O
term	PRADAXA.xml:S1:907:4	term	NN	O	O
Anticoagulant	PRADAXA.xml:S1:912:13	anticoagul	NNP	O	O
Therapy	PRADAXA.xml:S1:926:7	therapi	NNP	O	O
)	PRADAXA.xml:S1:933:1	)	)	O	O
study	PRADAXA.xml:S1:935:5	studi	NN	O	O
provided	PRADAXA.xml:S1:941:8	provid	VBD	O	O
safety	PRADAXA.xml:S1:950:6	safeti	NN	O	O
information	PRADAXA.xml:S1:957:11	inform	NN	O	O
on	PRADAXA.xml:S1:969:2	on	IN	O	O
the	PRADAXA.xml:S1:972:3	the	DT	O	O
use	PRADAXA.xml:S1:976:3	use	NN	O	O
of	PRADAXA.xml:S1:980:2	of	IN	O	O
two	PRADAXA.xml:S1:983:3	two	CD	O	O
doses	PRADAXA.xml:S1:987:5	dose	NNS	O	O
of	PRADAXA.xml:S1:993:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S1:996:7	pradaxa	NNP	O	O
and	PRADAXA.xml:S1:1004:3	and	CC	O	O
warfarin	PRADAXA.xml:S1:1008:8	warfarin	JJ	O	O
[	PRADAXA.xml:S1:1018:1	[	NNP	O	O
see	PRADAXA.xml:S1:1019:3	see	VBP	O	O
Clinical	PRADAXA.xml:S1:1023:8	clinic	JJ	O	O
Studies	PRADAXA.xml:S1:1032:7	studi	NNP	O	O
(	PRADAXA.xml:S1:1041:1	(	(	O	O
14.1	PRADAXA.xml:S1:1042:4	14.1	CD	O	O
)	PRADAXA.xml:S1:1046:1	)	)	O	O
]	PRADAXA.xml:S1:1049:1	]	NN	O	O
.	PRADAXA.xml:S1:1052:1	.	.	O	O

The	PRADAXA.xml:S1:1054:3	the	DT	O	O
numbers	PRADAXA.xml:S1:1058:7	number	NNS	O	O
of	PRADAXA.xml:S1:1066:2	of	IN	O	O
patients	PRADAXA.xml:S1:1069:8	patient	NNS	O	O
and	PRADAXA.xml:S1:1078:3	and	CC	O	O
their	PRADAXA.xml:S1:1082:5	their	PRP$	O	O
exposures	PRADAXA.xml:S1:1088:9	exposur	NNS	O	O
are	PRADAXA.xml:S1:1098:3	are	VBP	O	O
described	PRADAXA.xml:S1:1102:9	describ	VBN	O	O
in	PRADAXA.xml:S1:1112:2	in	IN	O	O
Table	PRADAXA.xml:S1:1115:5	tabl	JJ	O	O
1	PRADAXA.xml:S1:1121:1	1	CD	O	O
.	PRADAXA.xml:S1:1122:1	.	.	O	O

Limited	PRADAXA.xml:S1:1124:7	limit	JJ	O	O
information	PRADAXA.xml:S1:1132:11	inform	NN	O	O
is	PRADAXA.xml:S1:1144:2	is	VBZ	O	O
presented	PRADAXA.xml:S1:1147:9	present	VBN	O	O
on	PRADAXA.xml:S1:1157:2	on	IN	O	O
the	PRADAXA.xml:S1:1160:3	the	DT	O	O
110	PRADAXA.xml:S1:1164:3	110	CD	O	O
mg	PRADAXA.xml:S1:1168:2	mg	NN	O	O
dosing	PRADAXA.xml:S1:1171:6	dose	NN	O	O
arm	PRADAXA.xml:S1:1178:3	arm	NN	O	O
because	PRADAXA.xml:S1:1182:7	becaus	IN	O	O
this	PRADAXA.xml:S1:1190:4	thi	DT	O	O
dose	PRADAXA.xml:S1:1195:4	dose	NN	O	O
is	PRADAXA.xml:S1:1200:2	is	VBZ	O	O
not	PRADAXA.xml:S1:1203:3	not	RB	O	O
approved	PRADAXA.xml:S1:1207:8	approv	VBN	O	O
.	PRADAXA.xml:S1:1215:1	.	.	O	O

Table	PRADAXA.xml:S1:1221:5	tabl	JJ	O	O
1	PRADAXA.xml:S1:1227:1	1	CD	O	O
Summary	PRADAXA.xml:S1:1229:7	summari	NNP	O	O
of	PRADAXA.xml:S1:1237:2	of	IN	O	O
Treatment	PRADAXA.xml:S1:1240:9	treatment	NNP	O	O
Exposure	PRADAXA.xml:S1:1250:8	exposur	NNP	O	O
in	PRADAXA.xml:S1:1259:2	in	IN	O	O
RE	PRADAXA.xml:S1:1262:2	RE	NNP	O	O
-	PRADAXA.xml:S1:1264:1	-	:	O	O
LY	PRADAXA.xml:S1:1265:2	LY	NN	O	O

PRADAXA	PRADAXA.xml:S1:1283:7	pradaxa	NNP	O	O
110	PRADAXA.xml:S1:1291:3	110	CD	O	O
mg	PRADAXA.xml:S1:1295:2	mg	NN	O	O
twice	PRADAXA.xml:S1:1298:5	twice	RB	O	O
daily	PRADAXA.xml:S1:1304:5	daili	RB	O	O
PRADAXA	PRADAXA.xml:S1:1319:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:1327:3	150	CD	O	O
mg	PRADAXA.xml:S1:1331:2	mg	NN	O	O
twice	PRADAXA.xml:S1:1334:5	twice	RB	O	O
daily	PRADAXA.xml:S1:1340:5	daili	RB	O	O
Warfarin	PRADAXA.xml:S1:1359:8	warfarin	NNP	O	O

Total	PRADAXA.xml:S1:1381:5	total	JJ	O	O
number	PRADAXA.xml:S1:1387:6	number	NN	O	O
treated	PRADAXA.xml:S1:1394:7	treat	VBD	O	O
5983	PRADAXA.xml:S1:1403:4	5983	CD	O	O
6059	PRADAXA.xml:S1:1430:4	6059	CD	O	O
5998	PRADAXA.xml:S1:1457:4	5998	CD	O	O

Exposure	PRADAXA.xml:S1:1477:8	exposur	NN	O	O

12	PRADAXA.xml:S1:1572:2	12	CD	O	O
months	PRADAXA.xml:S1:1575:6	month	NNS	O	O
4936	PRADAXA.xml:S1:1597:4	4936	CD	O	O
4939	PRADAXA.xml:S1:1624:4	4939	CD	O	O
5193	PRADAXA.xml:S1:1651:4	5193	CD	O	O

24	PRADAXA.xml:S1:1682:2	24	CD	O	O
months	PRADAXA.xml:S1:1685:6	month	NNS	O	O
2387	PRADAXA.xml:S1:1707:4	2387	CD	O	O
2405	PRADAXA.xml:S1:1734:4	2405	CD	O	O
2470	PRADAXA.xml:S1:1761:4	2470	CD	O	O

Mean	PRADAXA.xml:S1:1781:4	mean	JJ	O	O
exposure	PRADAXA.xml:S1:1786:8	exposur	NN	O	O
(	PRADAXA.xml:S1:1795:1	(	(	O	O
months	PRADAXA.xml:S1:1796:6	month	NNS	O	O
)	PRADAXA.xml:S1:1802:1	)	)	O	O
20.5	PRADAXA.xml:S1:1805:4	20.5	CD	O	O
20.3	PRADAXA.xml:S1:1832:4	20.3	CD	O	O
21.3	PRADAXA.xml:S1:1859:4	21.3	CD	O	O

Total	PRADAXA.xml:S1:1879:5	total	JJ	O	O
patient	PRADAXA.xml:S1:1885:7	patient	JJ	O	O
-	PRADAXA.xml:S1:1892:1	-	:	O	O
years	PRADAXA.xml:S1:1893:5	year	NNS	O	O
10	PRADAXA.xml:S1:1900:2	10	CD	O	O
,	PRADAXA.xml:S1:1902:1	,	,	O	O
242	PRADAXA.xml:S1:1903:3	242	CD	O	O
10	PRADAXA.xml:S1:1926:2	10	CD	O	O
,	PRADAXA.xml:S1:1928:1	,	,	O	O
261	PRADAXA.xml:S1:1929:3	261	CD	O	O
10	PRADAXA.xml:S1:1953:2	10	CD	O	O
,	PRADAXA.xml:S1:1955:1	,	,	O	O
659	PRADAXA.xml:S1:1956:3	659	CD	O	O

Drug	PRADAXA.xml:S1:1991:4	drug	NN	O	O

Discontinuation	PRADAXA.xml:S1:1996:15	discontinu	NN	O	O
in	PRADAXA.xml:S1:2012:2	in	IN	O	O
RE	PRADAXA.xml:S1:2015:2	RE	NNP	O	O
-	PRADAXA.xml:S1:2017:1	-	:	O	O
LY	PRADAXA.xml:S1:2018:2	LY	NN	O	O

The	PRADAXA.xml:S1:2031:3	the	DT	O	O
rates	PRADAXA.xml:S1:2035:5	rate	NNS	O	O
of	PRADAXA.xml:S1:2041:2	of	IN	O	O
adverse	PRADAXA.xml:S1:2044:7	advers	JJ	O	O
reactions	PRADAXA.xml:S1:2052:9	reaction	NNS	O	O
leading	PRADAXA.xml:S1:2062:7	lead	VBG	O	O
to	PRADAXA.xml:S1:2070:2	to	TO	O	O
treatment	PRADAXA.xml:S1:2073:9	treatment	NN	O	O
discontinuation	PRADAXA.xml:S1:2083:15	discontinu	NN	O	O
were	PRADAXA.xml:S1:2099:4	were	VBD	O	O
21%	PRADAXA.xml:S1:2104:3	21%	CD	O	O
for	PRADAXA.xml:S1:2108:3	for	IN	O	O
PRADAXA	PRADAXA.xml:S1:2112:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:2120:3	150	CD	O	O
mg	PRADAXA.xml:S1:2124:2	mg	NN	O	O
and	PRADAXA.xml:S1:2127:3	and	CC	O	O
16%	PRADAXA.xml:S1:2131:3	16%	CD	O	O
for	PRADAXA.xml:S1:2135:3	for	IN	O	O
warfarin	PRADAXA.xml:S1:2139:8	warfarin	NN	O	O
.	PRADAXA.xml:S1:2147:1	.	.	O	O

The	PRADAXA.xml:S1:2149:3	the	DT	O	O
most	PRADAXA.xml:S1:2153:4	most	RBS	O	O
frequent	PRADAXA.xml:S1:2158:8	frequent	JJ	O	O
adverse	PRADAXA.xml:S1:2167:7	advers	JJ	O	O
reactions	PRADAXA.xml:S1:2175:9	reaction	NNS	O	O
leading	PRADAXA.xml:S1:2185:7	lead	VBG	O	O
to	PRADAXA.xml:S1:2193:2	to	TO	O	O
discontinuation	PRADAXA.xml:S1:2196:15	discontinu	NN	O	O
of	PRADAXA.xml:S1:2212:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S1:2215:7	pradaxa	NNP	O	O
were	PRADAXA.xml:S1:2223:4	were	VBD	O	O
bleeding	PRADAXA.xml:S1:2228:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
and	PRADAXA.xml:S1:2237:3	and	CC	O	O
gastrointestinal	PRADAXA.xml:S1:2241:16	gastrointestin	JJ	B-AdverseReaction	B-AdverseReaction
events	PRADAXA.xml:S1:2258:6	event	NNS	I-AdverseReaction	I-AdverseReaction
(	PRADAXA.xml:S1:2265:1	(	(	O	O
i	PRADAXA.xml:S1:2266:1	i	NN	O	O
.	PRADAXA.xml:S1:2267:1	.	.	O	O
e	PRADAXA.xml:S1:2268:1	e	NN	O	O
.	PRADAXA.xml:S1:2269:1	.	.	O	O
,	PRADAXA.xml:S1:2270:1	,	,	O	O
dyspepsia	PRADAXA.xml:S1:2272:9	dyspepsia	NN	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:2281:1	,	,	O	O
nausea	PRADAXA.xml:S1:2283:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:2289:1	,	,	O	O
upper	PRADAXA.xml:S1:2291:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
abdominal	PRADAXA.xml:S1:2297:9	abdomin	JJ	I-AdverseReaction	I-AdverseReaction
pain	PRADAXA.xml:S1:2307:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:2311:1	,	,	O	O
gastrointestinal	PRADAXA.xml:S1:2313:16	gastrointestin	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:2330:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:2340:1	,	,	O	O
and	PRADAXA.xml:S1:2342:3	and	CC	O	O
diarrhea	PRADAXA.xml:S1:2346:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
)	PRADAXA.xml:S1:2354:1	)	)	O	O
.	PRADAXA.xml:S1:2355:1	.	.	O	O

Bleeding	PRADAXA.xml:S1:2373:8	bleed	VBG	O	B-AdverseReaction

[	PRADAXA.xml:S1:2391:1	[	NNS	O	O
see	PRADAXA.xml:S1:2392:3	see	VBP	O	O
Warnings	PRADAXA.xml:S1:2396:8	warn	NNS	O	O
and	PRADAXA.xml:S1:2405:3	and	CC	O	O
Precautions	PRADAXA.xml:S1:2409:11	precaut	NNP	O	O
(	PRADAXA.xml:S1:2422:1	(	(	O	O
5.2	PRADAXA.xml:S1:2423:3	5.2	CD	O	O
)	PRADAXA.xml:S1:2426:1	)	)	O	O
]	PRADAXA.xml:S1:2429:1	]	NN	O	O

Table	PRADAXA.xml:S1:2439:5	tabl	JJ	O	O
2	PRADAXA.xml:S1:2445:1	2	CD	O	O
shows	PRADAXA.xml:S1:2447:5	show	VBZ	O	O
the	PRADAXA.xml:S1:2453:3	the	DT	O	O
number	PRADAXA.xml:S1:2457:6	number	NN	O	O
of	PRADAXA.xml:S1:2464:2	of	IN	O	O
adjudicated	PRADAXA.xml:S1:2467:11	adjud	JJ	O	O
major	PRADAXA.xml:S1:2479:5	major	JJ	O	O
bleeding	PRADAXA.xml:S1:2485:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
events	PRADAXA.xml:S1:2494:6	event	NNS	O	O
during	PRADAXA.xml:S1:2501:6	dure	IN	O	O
the	PRADAXA.xml:S1:2508:3	the	DT	O	O
treatment	PRADAXA.xml:S1:2512:9	treatment	NN	O	O
period	PRADAXA.xml:S1:2522:6	period	NN	O	O
in	PRADAXA.xml:S1:2529:2	in	IN	O	O
the	PRADAXA.xml:S1:2532:3	the	DT	O	O
RE	PRADAXA.xml:S1:2536:2	RE	NNP	O	O
-	PRADAXA.xml:S1:2538:1	-	:	O	O
LY	PRADAXA.xml:S1:2539:2	LY	NNP	O	O
study	PRADAXA.xml:S1:2542:5	studi	NN	O	O
,	PRADAXA.xml:S1:2547:1	,	,	O	O
with	PRADAXA.xml:S1:2549:4	with	IN	O	O
the	PRADAXA.xml:S1:2554:3	the	DT	O	O
bleeding	PRADAXA.xml:S1:2558:8	bleed	VBG	B-AdverseReaction	O
rate	PRADAXA.xml:S1:2567:4	rate	NN	O	O
per	PRADAXA.xml:S1:2572:3	per	IN	O	O
100	PRADAXA.xml:S1:2576:3	100	CD	O	O
subject	PRADAXA.xml:S1:2580:7	subject	JJ	O	O
-	PRADAXA.xml:S1:2587:1	-	:	O	O
years	PRADAXA.xml:S1:2588:5	year	NNS	O	O
(	PRADAXA.xml:S1:2594:1	(	(	O	O
)	PRADAXA.xml:S1:2596:1	)	)	O	O
.	PRADAXA.xml:S1:2597:1	.	.	O	O

Major	PRADAXA.xml:S1:2599:5	major	JJ	O	O
bleeding	PRADAXA.xml:S1:2605:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
is	PRADAXA.xml:S1:2614:2	is	VBZ	O	O
defined	PRADAXA.xml:S1:2617:7	defin	VBN	O	O
as	PRADAXA.xml:S1:2625:2	as	IN	O	O
bleeding	PRADAXA.xml:S1:2628:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
accompanied	PRADAXA.xml:S1:2637:11	accompani	VBN	O	O
by	PRADAXA.xml:S1:2649:2	by	IN	O	O
one	PRADAXA.xml:S1:2652:3	one	CD	O	O
or	PRADAXA.xml:S1:2656:2	or	CC	O	O
more	PRADAXA.xml:S1:2659:4	more	JJR	O	O
of	PRADAXA.xml:S1:2664:2	of	IN	O	O
the	PRADAXA.xml:S1:2667:3	the	DT	O	O
following	PRADAXA.xml:S1:2671:9	follow	NN	O	O
:	PRADAXA.xml:S1:2680:1	:	:	O	O
a	PRADAXA.xml:S1:2682:1	a	DT	O	O
decrease	PRADAXA.xml:S1:2684:8	decreas	NN	B-AdverseReaction	B-AdverseReaction
in	PRADAXA.xml:S1:2693:2	in	IN	I-AdverseReaction	I-AdverseReaction
hemoglobin	PRADAXA.xml:S1:2696:10	hemoglobin	NN	I-AdverseReaction	I-AdverseReaction
of	PRADAXA.xml:S1:2707:2	of	IN	O	O
2	PRADAXA.xml:S1:2712:1	2	CD	O	O
g	PRADAXA.xml:S1:2714:1	g	NN	O	O
dL	PRADAXA.xml:S1:2716:2	dL	NN	O	O
,	PRADAXA.xml:S1:2718:1	,	,	O	O
a	PRADAXA.xml:S1:2720:1	a	DT	O	O
transfusion	PRADAXA.xml:S1:2722:11	transfus	NN	O	O
of	PRADAXA.xml:S1:2734:2	of	IN	O	O
2	PRADAXA.xml:S1:2739:1	2	CD	O	O
units	PRADAXA.xml:S1:2741:5	unit	NNS	O	O
of	PRADAXA.xml:S1:2747:2	of	IN	O	O
packed	PRADAXA.xml:S1:2750:6	pack	JJ	O	O
red	PRADAXA.xml:S1:2757:3	red	JJ	O	O
blood	PRADAXA.xml:S1:2761:5	blood	NN	O	O
cells	PRADAXA.xml:S1:2767:5	cell	NNS	O	O
,	PRADAXA.xml:S1:2772:1	,	,	O	O
bleeding	PRADAXA.xml:S1:2774:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
at	PRADAXA.xml:S1:2783:2	at	IN	I-AdverseReaction	O
a	PRADAXA.xml:S1:2786:1	a	DT	I-AdverseReaction	O
critical	PRADAXA.xml:S1:2788:8	critic	JJ	I-AdverseReaction	O
site	PRADAXA.xml:S1:2797:4	site	NN	I-AdverseReaction	O
or	PRADAXA.xml:S1:2802:2	or	CC	O	O
with	PRADAXA.xml:S1:2805:4	with	IN	O	O
a	PRADAXA.xml:S1:2810:1	a	DT	O	O
fatal	PRADAXA.xml:S1:2812:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
outcome	PRADAXA.xml:S1:2818:7	outcom	NN	O	O
.	PRADAXA.xml:S1:2825:1	.	.	O	O

Intracranial	PRADAXA.xml:S1:2827:12	intracrani	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:2840:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
included	PRADAXA.xml:S1:2851:8	includ	VBD	O	O
intracerebral	PRADAXA.xml:S1:2860:13	intracerebr	JJ	B-AdverseReaction	B-AdverseReaction
(	PRADAXA.xml:S1:2874:1	(	(	O	O
hemorrhagic	PRADAXA.xml:S1:2875:11	hemorrhag	JJ	B-AdverseReaction	B-AdverseReaction
stroke	PRADAXA.xml:S1:2887:6	stroke	NN	I-AdverseReaction	I-AdverseReaction
)	PRADAXA.xml:S1:2893:1	)	)	O	O
,	PRADAXA.xml:S1:2894:1	,	,	O	O
subarachnoid	PRADAXA.xml:S1:2896:12	subarachnoid	JJ	B-AdverseReaction	O
,	PRADAXA.xml:S1:2908:1	,	,	O	O
and	PRADAXA.xml:S1:2910:3	and	CC	O	O
subdural	PRADAXA.xml:S1:2914:8	subdur	JJ	B-AdverseReaction	B-AdverseReaction
bleeds	PRADAXA.xml:S1:2923:6	bleed	NNS	I-AdverseReaction	I-AdverseReaction
.	PRADAXA.xml:S1:2929:1	.	.	O	O

Table	PRADAXA.xml:S1:2935:5	tabl	JJ	O	O
2	PRADAXA.xml:S1:2941:1	2	CD	O	O
Adjudicated	PRADAXA.xml:S1:2943:11	adjud	NNP	O	O
Major	PRADAXA.xml:S1:2955:5	major	NNP	O	O
Bleeding	PRADAXA.xml:S1:2961:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
Events	PRADAXA.xml:S1:2970:6	event	NNS	O	O
in	PRADAXA.xml:S1:2977:2	in	IN	O	O
Treated	PRADAXA.xml:S1:2980:7	treat	NNP	O	O
Patientsa	PRADAXA.xml:S1:2988:9	patientsa	NNP	O	O

aPatients	PRADAXA.xml:S1:3001:9	apati	NNS	O	O
during	PRADAXA.xml:S1:3011:6	dure	IN	O	O
treatment	PRADAXA.xml:S1:3018:9	treatment	NN	O	O
or	PRADAXA.xml:S1:3028:2	or	CC	O	O
within	PRADAXA.xml:S1:3031:6	within	IN	O	O
2	PRADAXA.xml:S1:3038:1	2	CD	O	O
days	PRADAXA.xml:S1:3040:4	day	NNS	O	O
of	PRADAXA.xml:S1:3045:2	of	IN	O	O
stopping	PRADAXA.xml:S1:3048:8	stop	VBG	O	O
study	PRADAXA.xml:S1:3057:5	studi	NN	O	O
treatment	PRADAXA.xml:S1:3063:9	treatment	NN	O	O
.	PRADAXA.xml:S1:3072:1	.	.	O	O

Major	PRADAXA.xml:S1:3074:5	major	JJ	O	O
bleeding	PRADAXA.xml:S1:3080:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
events	PRADAXA.xml:S1:3089:6	event	NNS	O	O
within	PRADAXA.xml:S1:3096:6	within	IN	O	O
each	PRADAXA.xml:S1:3103:4	each	DT	O	O
subcategory	PRADAXA.xml:S1:3108:11	subcategori	NN	O	O
were	PRADAXA.xml:S1:3120:4	were	VBD	O	O
counted	PRADAXA.xml:S1:3125:7	count	VBN	O	O
once	PRADAXA.xml:S1:3133:4	onc	RB	O	O
per	PRADAXA.xml:S1:3138:3	per	IN	O	O
patient	PRADAXA.xml:S1:3142:7	patient	NN	O	O
,	PRADAXA.xml:S1:3149:1	,	,	O	O
but	PRADAXA.xml:S1:3151:3	but	CC	O	O
patients	PRADAXA.xml:S1:3155:8	patient	NNS	O	O
may	PRADAXA.xml:S1:3164:3	may	MD	O	O
have	PRADAXA.xml:S1:3168:4	have	VB	O	O
contributed	PRADAXA.xml:S1:3173:11	contribut	VBN	O	O
events	PRADAXA.xml:S1:3185:6	event	NNS	O	O
to	PRADAXA.xml:S1:3192:2	to	TO	O	O
multiple	PRADAXA.xml:S1:3195:8	multipl	VB	O	O
subcategories	PRADAXA.xml:S1:3204:13	subcategori	NNS	O	O
.	PRADAXA.xml:S1:3217:1	.	.	O	O

bAnnual	PRADAXA.xml:S1:3220:7	bannual	JJ	O	O
event	PRADAXA.xml:S1:3228:5	event	NN	O	O
rate	PRADAXA.xml:S1:3234:4	rate	NN	O	O
per	PRADAXA.xml:S1:3239:3	per	IN	O	O
100	PRADAXA.xml:S1:3243:3	100	CD	O	O
pt	PRADAXA.xml:S1:3247:2	pt	JJ	O	O
-	PRADAXA.xml:S1:3249:1	-	:	O	O
years	PRADAXA.xml:S1:3250:5	year	NNS	O	O
100	PRADAXA.xml:S1:3258:3	100	CD	O	O
number	PRADAXA.xml:S1:3264:6	number	NN	O	O
of	PRADAXA.xml:S1:3271:2	of	IN	O	O
subjects	PRADAXA.xml:S1:3274:8	subject	NNS	O	O
with	PRADAXA.xml:S1:3283:4	with	IN	O	O
event	PRADAXA.xml:S1:3288:5	event	NN	O	O
subject	PRADAXA.xml:S1:3294:7	subject	JJ	O	O
-	PRADAXA.xml:S1:3301:1	-	:	O	O
years	PRADAXA.xml:S1:3302:5	year	NNS	O	O
.	PRADAXA.xml:S1:3307:1	.	.	O	O

Subject	PRADAXA.xml:S1:3309:7	subject	JJ	O	O
-	PRADAXA.xml:S1:3316:1	-	:	O	O
years	PRADAXA.xml:S1:3317:5	year	NNS	O	O
is	PRADAXA.xml:S1:3323:2	is	VBZ	O	O
defined	PRADAXA.xml:S1:3326:7	defin	VBN	O	O
as	PRADAXA.xml:S1:3334:2	as	IN	O	O
cumulative	PRADAXA.xml:S1:3337:10	cumul	JJ	O	O
number	PRADAXA.xml:S1:3348:6	number	NN	O	O
of	PRADAXA.xml:S1:3355:2	of	IN	O	O
days	PRADAXA.xml:S1:3358:4	day	NNS	O	O
from	PRADAXA.xml:S1:3363:4	from	IN	O	O
first	PRADAXA.xml:S1:3368:5	first	JJ	O	O
drug	PRADAXA.xml:S1:3374:4	drug	NN	O	O
intake	PRADAXA.xml:S1:3379:6	intak	NN	O	O
to	PRADAXA.xml:S1:3386:2	to	TO	O	O
event	PRADAXA.xml:S1:3389:5	event	NN	O	O
date	PRADAXA.xml:S1:3395:4	date	NN	O	O
,	PRADAXA.xml:S1:3399:1	,	,	O	O
date	PRADAXA.xml:S1:3401:4	date	NN	O	O
of	PRADAXA.xml:S1:3406:2	of	IN	O	O
last	PRADAXA.xml:S1:3409:4	last	JJ	O	O
drug	PRADAXA.xml:S1:3414:4	drug	NN	O	O
intake	PRADAXA.xml:S1:3419:6	intak	NN	O	O
2	PRADAXA.xml:S1:3428:1	2	CD	O	O
,	PRADAXA.xml:S1:3429:1	,	,	O	O
death	PRADAXA.xml:S1:3431:5	death	NN	O	B-AdverseReaction
date	PRADAXA.xml:S1:3437:4	date	NN	O	I-AdverseReaction
(	PRADAXA.xml:S1:3442:1	(	(	O	O
whatever	PRADAXA.xml:S1:3443:8	whatev	WDT	O	O
occurred	PRADAXA.xml:S1:3452:8	occur	VBD	O	O
first	PRADAXA.xml:S1:3461:5	first	RB	O	O
)	PRADAXA.xml:S1:3466:1	)	)	O	O
across	PRADAXA.xml:S1:3468:6	across	IN	O	O
all	PRADAXA.xml:S1:3475:3	all	DT	O	O
treated	PRADAXA.xml:S1:3479:7	treat	JJ	O	O
subjects	PRADAXA.xml:S1:3487:8	subject	NNS	O	O
divided	PRADAXA.xml:S1:3496:7	divid	VBN	O	O
by	PRADAXA.xml:S1:3504:2	by	IN	O	O
365.25	PRADAXA.xml:S1:3507:6	365.25	CD	O	O
.	PRADAXA.xml:S1:3513:1	.	.	O	O

In	PRADAXA.xml:S1:3515:2	In	IN	O	O
case	PRADAXA.xml:S1:3518:4	case	NN	O	O
of	PRADAXA.xml:S1:3523:2	of	IN	O	O
recurrent	PRADAXA.xml:S1:3526:9	recurr	JJ	O	O
events	PRADAXA.xml:S1:3536:6	event	NNS	O	O
of	PRADAXA.xml:S1:3543:2	of	IN	O	O
the	PRADAXA.xml:S1:3546:3	the	DT	O	O
same	PRADAXA.xml:S1:3550:4	same	JJ	O	O
category	PRADAXA.xml:S1:3555:8	categori	NN	O	O
,	PRADAXA.xml:S1:3563:1	,	,	O	O
the	PRADAXA.xml:S1:3565:3	the	DT	O	O
first	PRADAXA.xml:S1:3569:5	first	JJ	O	O
event	PRADAXA.xml:S1:3575:5	event	NN	O	O
was	PRADAXA.xml:S1:3581:3	wa	VBD	O	O
considered	PRADAXA.xml:S1:3585:10	consid	VBN	O	O
.	PRADAXA.xml:S1:3595:1	.	.	O	O

cDefined	PRADAXA.xml:S1:3598:8	cdefin	VBN	O	O
as	PRADAXA.xml:S1:3607:2	as	IN	O	O
bleeding	PRADAXA.xml:S1:3610:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
accompanied	PRADAXA.xml:S1:3619:11	accompani	VBN	O	O
by	PRADAXA.xml:S1:3631:2	by	IN	O	O
one	PRADAXA.xml:S1:3634:3	one	CD	O	O
or	PRADAXA.xml:S1:3638:2	or	CC	O	O
more	PRADAXA.xml:S1:3641:4	more	JJR	O	O
of	PRADAXA.xml:S1:3646:2	of	IN	O	O
the	PRADAXA.xml:S1:3649:3	the	DT	O	O
following	PRADAXA.xml:S1:3653:9	follow	NN	O	O
:	PRADAXA.xml:S1:3662:1	:	:	O	O
a	PRADAXA.xml:S1:3664:1	a	DT	O	O
decrease	PRADAXA.xml:S1:3666:8	decreas	NN	B-AdverseReaction	B-AdverseReaction
in	PRADAXA.xml:S1:3675:2	in	IN	I-AdverseReaction	I-AdverseReaction
hemoglobin	PRADAXA.xml:S1:3678:10	hemoglobin	NN	I-AdverseReaction	I-AdverseReaction
of	PRADAXA.xml:S1:3689:2	of	IN	O	O
2	PRADAXA.xml:S1:3694:1	2	CD	O	O
g	PRADAXA.xml:S1:3696:1	g	NN	O	O
dL	PRADAXA.xml:S1:3698:2	dL	NN	O	O
,	PRADAXA.xml:S1:3700:1	,	,	O	O
a	PRADAXA.xml:S1:3702:1	a	DT	O	O
transfusion	PRADAXA.xml:S1:3704:11	transfus	NN	O	O
of	PRADAXA.xml:S1:3716:2	of	IN	O	O
2	PRADAXA.xml:S1:3719:1	2	CD	O	O
or	PRADAXA.xml:S1:3721:2	or	CC	O	O
more	PRADAXA.xml:S1:3724:4	more	JJR	O	O
units	PRADAXA.xml:S1:3729:5	unit	NNS	O	O
of	PRADAXA.xml:S1:3735:2	of	IN	O	O
packed	PRADAXA.xml:S1:3738:6	pack	JJ	O	O
red	PRADAXA.xml:S1:3745:3	red	JJ	O	O
blood	PRADAXA.xml:S1:3749:5	blood	NN	O	O
cells	PRADAXA.xml:S1:3755:5	cell	NNS	O	O
,	PRADAXA.xml:S1:3760:1	,	,	O	O
bleeding	PRADAXA.xml:S1:3762:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
at	PRADAXA.xml:S1:3771:2	at	IN	I-AdverseReaction	I-AdverseReaction
a	PRADAXA.xml:S1:3774:1	a	DT	I-AdverseReaction	I-AdverseReaction
critical	PRADAXA.xml:S1:3776:8	critic	JJ	I-AdverseReaction	I-AdverseReaction
site	PRADAXA.xml:S1:3785:4	site	NN	I-AdverseReaction	I-AdverseReaction
or	PRADAXA.xml:S1:3790:2	or	CC	O	O
with	PRADAXA.xml:S1:3793:4	with	IN	O	O
fatal	PRADAXA.xml:S1:3798:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
outcome	PRADAXA.xml:S1:3804:7	outcom	NN	O	O
.	PRADAXA.xml:S1:3811:1	.	.	O	O

dIntracranial	PRADAXA.xml:S1:3814:13	dintracrani	JJ	B-AdverseReaction	B-AdverseReaction
bleed	PRADAXA.xml:S1:3828:5	bleed	NN	I-AdverseReaction	I-AdverseReaction
included	PRADAXA.xml:S1:3834:8	includ	VBD	O	O
intracerebral	PRADAXA.xml:S1:3843:13	intracerebr	JJ	B-AdverseReaction	B-AdverseReaction
(	PRADAXA.xml:S1:3857:1	(	(	O	O
hemorrhagic	PRADAXA.xml:S1:3858:11	hemorrhag	JJ	B-AdverseReaction	B-AdverseReaction
stroke	PRADAXA.xml:S1:3870:6	stroke	NN	I-AdverseReaction	I-AdverseReaction
)	PRADAXA.xml:S1:3876:1	)	)	O	O
,	PRADAXA.xml:S1:3877:1	,	,	O	O
subarachnoid	PRADAXA.xml:S1:3879:12	subarachnoid	JJ	B-AdverseReaction	O
,	PRADAXA.xml:S1:3891:1	,	,	O	O
and	PRADAXA.xml:S1:3893:3	and	CC	O	O
subdural	PRADAXA.xml:S1:3897:8	subdur	JJ	B-AdverseReaction	B-AdverseReaction
bleeds	PRADAXA.xml:S1:3906:6	bleed	NNS	I-AdverseReaction	I-AdverseReaction
.	PRADAXA.xml:S1:3912:1	.	.	O	O

eOn	PRADAXA.xml:S1:3915:3	eon	SYM	O	O
-	PRADAXA.xml:S1:3918:1	-	:	O	O
treatment	PRADAXA.xml:S1:3919:9	treatment	NN	O	O
analysis	PRADAXA.xml:S1:3929:8	analysi	NN	O	O
based	PRADAXA.xml:S1:3938:5	base	VBN	O	O
on	PRADAXA.xml:S1:3944:2	on	IN	O	O
the	PRADAXA.xml:S1:3947:3	the	DT	O	O
safety	PRADAXA.xml:S1:3951:6	safeti	NN	O	O
population	PRADAXA.xml:S1:3958:10	popul	NN	O	O
,	PRADAXA.xml:S1:3968:1	,	,	O	O
compared	PRADAXA.xml:S1:3970:8	compar	VBN	O	O
to	PRADAXA.xml:S1:3979:2	to	TO	O	O
ITT	PRADAXA.xml:S1:3982:3	itt	NNP	O	O
analysis	PRADAXA.xml:S1:3986:8	analysi	NN	O	O
presented	PRADAXA.xml:S1:3995:9	present	VBN	O	O
in	PRADAXA.xml:S1:4005:2	in	IN	O	O
Section	PRADAXA.xml:S1:4008:7	section	NNP	O	O
14	PRADAXA.xml:S1:4016:2	14	CD	O	O
Clinical	PRADAXA.xml:S1:4019:8	clinic	NNP	O	O
Studies	PRADAXA.xml:S1:4028:7	studi	NNPS	O	O
.	PRADAXA.xml:S1:4035:1	.	.	O	O

fFatal	PRADAXA.xml:S1:4038:6	ffatal	JJ	B-AdverseReaction	B-AdverseReaction
bleed	PRADAXA.xml:S1:4045:5	bleed	NN	B-AdverseReaction	I-AdverseReaction
:	PRADAXA.xml:S1:4050:1	:	:	O	O
Adjudicated	PRADAXA.xml:S1:4052:11	adjud	JJ	O	B-AdverseReaction
major	PRADAXA.xml:S1:4064:5	major	JJ	O	O
bleed	PRADAXA.xml:S1:4070:5	bleed	NN	B-AdverseReaction	O
as	PRADAXA.xml:S1:4076:2	as	IN	O	O
defined	PRADAXA.xml:S1:4079:7	defin	VBN	O	O
above	PRADAXA.xml:S1:4087:5	abov	IN	O	O
with	PRADAXA.xml:S1:4093:4	with	IN	O	O
investigator	PRADAXA.xml:S1:4098:12	investig	NN	O	O
reported	PRADAXA.xml:S1:4111:8	report	VBD	O	O
fatal	PRADAXA.xml:S1:4120:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
outcome	PRADAXA.xml:S1:4126:7	outcom	NN	O	O
and	PRADAXA.xml:S1:4134:3	and	CC	O	O
adjudicated	PRADAXA.xml:S1:4138:11	adjud	VBD	O	O
death	PRADAXA.xml:S1:4150:5	death	NN	B-AdverseReaction	B-AdverseReaction
with	PRADAXA.xml:S1:4156:4	with	IN	O	O
primary	PRADAXA.xml:S1:4161:7	primari	JJ	O	O
cause	PRADAXA.xml:S1:4169:5	caus	NN	O	O
from	PRADAXA.xml:S1:4175:4	from	IN	O	O
bleeding	PRADAXA.xml:S1:4180:8	bleed	VBG	B-AdverseReaction	O
.	PRADAXA.xml:S1:4188:1	.	.	O	O

gNon	PRADAXA.xml:S1:4191:4	gnon	SYM	B-AdverseReaction	O
-	PRADAXA.xml:S1:4195:1	-	:	I-AdverseReaction	O
intracranial	PRADAXA.xml:S1:4196:12	intracrani	JJ	I-AdverseReaction	O
fatal	PRADAXA.xml:S1:4209:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
bleed	PRADAXA.xml:S1:4215:5	bleed	NN	I-AdverseReaction	B-AdverseReaction
:	PRADAXA.xml:S1:4220:1	:	:	O	O
Adjudicated	PRADAXA.xml:S1:4222:11	adjud	JJ	O	B-AdverseReaction
major	PRADAXA.xml:S1:4234:5	major	JJ	O	O
bleed	PRADAXA.xml:S1:4240:5	bleed	NN	B-AdverseReaction	O
as	PRADAXA.xml:S1:4246:2	as	IN	O	O
defined	PRADAXA.xml:S1:4249:7	defin	VBN	O	O
above	PRADAXA.xml:S1:4257:5	abov	IN	O	O
and	PRADAXA.xml:S1:4263:3	and	CC	O	O
adjudicated	PRADAXA.xml:S1:4267:11	adjud	VBD	O	O
death	PRADAXA.xml:S1:4279:5	death	NN	B-AdverseReaction	B-AdverseReaction
with	PRADAXA.xml:S1:4285:4	with	IN	O	O
primary	PRADAXA.xml:S1:4290:7	primari	JJ	O	O
cause	PRADAXA.xml:S1:4298:5	caus	NN	O	O
from	PRADAXA.xml:S1:4304:4	from	IN	O	O
bleeding	PRADAXA.xml:S1:4309:8	bleed	VBG	B-AdverseReaction	O
but	PRADAXA.xml:S1:4318:3	but	CC	O	O
without	PRADAXA.xml:S1:4322:7	without	IN	O	O
symptomatic	PRADAXA.xml:S1:4330:11	symptomat	JJ	B-AdverseReaction	B-AdverseReaction
intracranial	PRADAXA.xml:S1:4342:12	intracrani	JJ	I-AdverseReaction	I-AdverseReaction
bleed	PRADAXA.xml:S1:4355:5	bleed	NN	I-AdverseReaction	I-AdverseReaction
based	PRADAXA.xml:S1:4361:5	base	VBN	O	O
on	PRADAXA.xml:S1:4367:2	on	IN	O	O
investigator	PRADAXA.xml:S1:4370:12	investig	NN	O	O
's	PRADAXA.xml:S1:4382:2	's	POS	O	O
clinical	PRADAXA.xml:S1:4385:8	clinic	JJ	O	O
assessment	PRADAXA.xml:S1:4394:10	assess	NN	O	O
.	PRADAXA.xml:S1:4404:1	.	.	O	O

Event	PRADAXA.xml:S1:4417:5	event	NN	O	O

PRADAXA	PRADAXA.xml:S1:4443:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:4451:3	150	CD	O	O
mgN	PRADAXA.xml:S1:4455:3	mgn	NN	O	O
6059	PRADAXA.xml:S1:4461:4	6059	CD	O	O
n	PRADAXA.xml:S1:4465:1	n	NN	O	O
(	PRADAXA.xml:S1:4468:1	(	(	O	O
year	PRADAXA.xml:S1:4471:4	year	NN	O	O
b	PRADAXA.xml:S1:4477:1	b	NN	O	O
)	PRADAXA.xml:S1:4480:1	)	)	O	O
WarfarinN	PRADAXA.xml:S1:4487:9	warfarinn	IN	O	O
5998	PRADAXA.xml:S1:4499:4	5998	CD	O	O
n	PRADAXA.xml:S1:4503:1	n	NN	O	O
(	PRADAXA.xml:S1:4505:1	(	(	O	O
year	PRADAXA.xml:S1:4508:4	year	NN	O	O
b	PRADAXA.xml:S1:4514:1	b	NN	O	O
)	PRADAXA.xml:S1:4517:1	)	)	O	O
PRADAXA	PRADAXA.xml:S1:4524:7	pradaxa	VBZ	O	O
150	PRADAXA.xml:S1:4532:3	150	CD	O	O
mgvs	PRADAXA.xml:S1:4536:4	mgv	NN	O	O
.	PRADAXA.xml:S1:4540:1	.	.	O	O

WarfarinHR	PRADAXA.xml:S1:4542:10	warfarinhr	NNP	O	O
(	PRADAXA.xml:S1:4553:1	(	(	O	O
95%	PRADAXA.xml:S1:4554:3	95%	CD	O	O
CI	PRADAXA.xml:S1:4558:2	CI	NNP	O	O
)	PRADAXA.xml:S1:4560:1	)	)	O	O

Major	PRADAXA.xml:S1:4568:5	major	JJ	O	O
Bleeding	PRADAXA.xml:S1:4574:8	bleed	NNP	B-AdverseReaction	B-AdverseReaction
c	PRADAXA.xml:S1:4584:1	c	NN	O	I-AdverseReaction
350	PRADAXA.xml:S1:4602:3	350	CD	O	O
(	PRADAXA.xml:S1:4606:1	(	(	O	O
3.47	PRADAXA.xml:S1:4607:4	3.47	CD	O	O
)	PRADAXA.xml:S1:4611:1	)	)	O	O
374	PRADAXA.xml:S1:4629:3	374	CD	O	O
(	PRADAXA.xml:S1:4633:1	(	(	O	O
3.58	PRADAXA.xml:S1:4634:4	3.58	CD	O	O
)	PRADAXA.xml:S1:4638:1	)	)	O	O
0.97	PRADAXA.xml:S1:4653:4	0.97	CD	O	O
(	PRADAXA.xml:S1:4658:1	(	(	O	O
0.84	PRADAXA.xml:S1:4659:4	0.84	CD	O	O
,	PRADAXA.xml:S1:4663:1	,	,	O	O
1.12	PRADAXA.xml:S1:4665:4	1.12	CD	O	O
)	PRADAXA.xml:S1:4669:1	)	)	O	O

Intracranial	PRADAXA.xml:S1:4682:12	intracrani	JJ	B-AdverseReaction	B-AdverseReaction
Hemorrhage	PRADAXA.xml:S1:4695:10	hemorrhag	NNP	I-AdverseReaction	I-AdverseReaction
(	PRADAXA.xml:S1:4706:1	(	(	O	O
ICH	PRADAXA.xml:S1:4707:3	ich	NNP	B-AdverseReaction	B-AdverseReaction
)	PRADAXA.xml:S1:4710:1	)	)	O	O
d	PRADAXA.xml:S1:4713:1	d	VBZ	O	O
23	PRADAXA.xml:S1:4726:2	23	CD	O	O
(	PRADAXA.xml:S1:4729:1	(	(	O	O
0.22	PRADAXA.xml:S1:4730:4	0.22	CD	O	O
)	PRADAXA.xml:S1:4734:1	)	)	O	O
82	PRADAXA.xml:S1:4753:2	82	CD	O	O
(	PRADAXA.xml:S1:4756:1	(	(	O	O
0.77	PRADAXA.xml:S1:4757:4	0.77	CD	O	O
)	PRADAXA.xml:S1:4761:1	)	)	O	O
0.29	PRADAXA.xml:S1:4775:4	0.29	CD	O	O
(	PRADAXA.xml:S1:4780:1	(	(	O	O
0.18	PRADAXA.xml:S1:4781:4	0.18	CD	O	O
,	PRADAXA.xml:S1:4785:1	,	,	O	O
0.46	PRADAXA.xml:S1:4787:4	0.46	CD	O	O
)	PRADAXA.xml:S1:4791:1	)	)	O	O

Hemorrhagic	PRADAXA.xml:S1:4808:11	hemorrhag	NNP	B-AdverseReaction	B-AdverseReaction
Stroke	PRADAXA.xml:S1:4820:6	stroke	NNP	I-AdverseReaction	I-AdverseReaction
e	PRADAXA.xml:S1:4828:1	e	VBZ	O	O
6	PRADAXA.xml:S1:4841:1	6	CD	O	O
(	PRADAXA.xml:S1:4843:1	(	(	O	O
0.06	PRADAXA.xml:S1:4844:4	0.06	CD	O	O
)	PRADAXA.xml:S1:4848:1	)	)	O	O
40	PRADAXA.xml:S1:4868:2	40	CD	O	O
(	PRADAXA.xml:S1:4871:1	(	(	O	O
0.37	PRADAXA.xml:S1:4872:4	0.37	CD	O	O
)	PRADAXA.xml:S1:4876:1	)	)	O	O
0.16	PRADAXA.xml:S1:4890:4	0.16	CD	O	O
(	PRADAXA.xml:S1:4895:1	(	(	O	O
0.07	PRADAXA.xml:S1:4896:4	0.07	CD	O	O
,	PRADAXA.xml:S1:4900:1	,	,	O	O
0.37	PRADAXA.xml:S1:4902:4	0.37	CD	O	O
)	PRADAXA.xml:S1:4906:1	)	)	O	O

Other	PRADAXA.xml:S1:4923:5	other	JJ	O	O
ICH	PRADAXA.xml:S1:4929:3	ich	NNP	B-AdverseReaction	B-AdverseReaction
17	PRADAXA.xml:S1:4952:2	17	CD	O	O
(	PRADAXA.xml:S1:4955:1	(	(	O	O
0.17	PRADAXA.xml:S1:4956:4	0.17	CD	O	O
)	PRADAXA.xml:S1:4960:1	)	)	O	O
46	PRADAXA.xml:S1:4979:2	46	CD	O	O
(	PRADAXA.xml:S1:4982:1	(	(	O	O
0.43	PRADAXA.xml:S1:4983:4	0.43	CD	O	O
)	PRADAXA.xml:S1:4987:1	)	)	O	O
0.38	PRADAXA.xml:S1:5002:4	0.38	CD	O	O
(	PRADAXA.xml:S1:5007:1	(	(	O	O
0.22	PRADAXA.xml:S1:5008:4	0.22	CD	O	O
,	PRADAXA.xml:S1:5012:1	,	,	O	O
0.67	PRADAXA.xml:S1:5014:4	0.67	CD	O	O
)	PRADAXA.xml:S1:5018:1	)	)	O	O

Gastrointestinal	PRADAXA.xml:S1:5031:16	gastrointestin	JJ	O	B-AdverseReaction
162	PRADAXA.xml:S1:5062:3	162	CD	O	O
(	PRADAXA.xml:S1:5066:1	(	(	O	O
1.59	PRADAXA.xml:S1:5067:4	1.59	CD	O	O
)	PRADAXA.xml:S1:5071:1	)	)	O	O
111	PRADAXA.xml:S1:5089:3	111	CD	O	O
(	PRADAXA.xml:S1:5093:1	(	(	O	O
1.05	PRADAXA.xml:S1:5094:4	1.05	CD	O	O
)	PRADAXA.xml:S1:5098:1	)	)	O	O
1.51	PRADAXA.xml:S1:5113:4	1.51	CD	O	O
(	PRADAXA.xml:S1:5118:1	(	(	O	O
1.19	PRADAXA.xml:S1:5119:4	1.19	CD	O	O
,	PRADAXA.xml:S1:5123:1	,	,	O	O
1.92	PRADAXA.xml:S1:5125:4	1.92	CD	O	O
)	PRADAXA.xml:S1:5129:1	)	)	O	O

Fatal	PRADAXA.xml:S1:5142:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
Bleeding	PRADAXA.xml:S1:5148:8	bleed	NNP	B-AdverseReaction	B-AdverseReaction
f	PRADAXA.xml:S1:5158:1	f	NN	O	I-AdverseReaction
7	PRADAXA.xml:S1:5174:1	7	CD	O	O
(	PRADAXA.xml:S1:5176:1	(	(	O	O
0.07	PRADAXA.xml:S1:5177:4	0.07	CD	O	O
)	PRADAXA.xml:S1:5181:1	)	)	O	O
16	PRADAXA.xml:S1:5201:2	16	CD	O	O
(	PRADAXA.xml:S1:5204:1	(	(	O	O
0.15	PRADAXA.xml:S1:5205:4	0.15	CD	O	O
)	PRADAXA.xml:S1:5209:1	)	)	O	O
0.45	PRADAXA.xml:S1:5224:4	0.45	CD	O	O
(	PRADAXA.xml:S1:5229:1	(	(	O	O
0.19	PRADAXA.xml:S1:5230:4	0.19	CD	O	O
,	PRADAXA.xml:S1:5234:1	,	,	O	O
1.10	PRADAXA.xml:S1:5236:4	1.10	CD	O	O
)	PRADAXA.xml:S1:5240:1	)	)	O	O

ICH	PRADAXA.xml:S1:5256:3	ich	NNP	B-AdverseReaction	B-AdverseReaction
3	PRADAXA.xml:S1:5285:1	3	CD	O	O
(	PRADAXA.xml:S1:5287:1	(	(	O	O
0.03	PRADAXA.xml:S1:5288:4	0.03	CD	O	O
)	PRADAXA.xml:S1:5292:1	)	)	O	O
9	PRADAXA.xml:S1:5312:1	9	CD	O	O
(	PRADAXA.xml:S1:5314:1	(	(	O	O
0.08	PRADAXA.xml:S1:5315:4	0.08	CD	O	O
)	PRADAXA.xml:S1:5319:1	)	)	O	O
0.35	PRADAXA.xml:S1:5335:4	0.35	CD	O	O
(	PRADAXA.xml:S1:5340:1	(	(	O	O
0.09	PRADAXA.xml:S1:5341:4	0.09	CD	O	O
,	PRADAXA.xml:S1:5345:1	,	,	O	O
1.28	PRADAXA.xml:S1:5347:4	1.28	CD	O	O
)	PRADAXA.xml:S1:5351:1	)	)	O	O

Non	PRADAXA.xml:S1:5367:3	non	NNP	O	O
-	PRADAXA.xml:S1:5370:1	-	:	O	O
intracranial	PRADAXA.xml:S1:5371:12	intracrani	JJ	O	O
g	PRADAXA.xml:S1:5385:1	g	NN	O	O
4	PRADAXA.xml:S1:5398:1	4	CD	O	O
(	PRADAXA.xml:S1:5400:1	(	(	O	O
0.04	PRADAXA.xml:S1:5401:4	0.04	CD	O	O
)	PRADAXA.xml:S1:5405:1	)	)	O	O
7	PRADAXA.xml:S1:5425:1	7	CD	O	O
(	PRADAXA.xml:S1:5427:1	(	(	O	O
0.07	PRADAXA.xml:S1:5428:4	0.07	CD	O	O
)	PRADAXA.xml:S1:5432:1	)	)	O	O
0.59	PRADAXA.xml:S1:5448:4	0.59	CD	O	O
(	PRADAXA.xml:S1:5453:1	(	(	O	O
0.17	PRADAXA.xml:S1:5454:4	0.17	CD	O	O
,	PRADAXA.xml:S1:5458:1	,	,	O	O
2.02	PRADAXA.xml:S1:5460:4	2.02	CD	O	O
)	PRADAXA.xml:S1:5464:1	)	)	O	O

There	PRADAXA.xml:S1:5479:5	there	EX	O	O
was	PRADAXA.xml:S1:5485:3	wa	VBD	O	O
a	PRADAXA.xml:S1:5489:1	a	DT	O	O
higher	PRADAXA.xml:S1:5491:6	higher	JJR	O	O
rate	PRADAXA.xml:S1:5498:4	rate	NN	O	O
of	PRADAXA.xml:S1:5503:2	of	IN	O	O
any	PRADAXA.xml:S1:5506:3	ani	DT	O	O
gastrointestinal	PRADAXA.xml:S1:5510:16	gastrointestin	JJ	B-AdverseReaction	O
bleeds	PRADAXA.xml:S1:5527:6	bleed	NNS	I-AdverseReaction	O
in	PRADAXA.xml:S1:5534:2	in	IN	O	O
patients	PRADAXA.xml:S1:5537:8	patient	NNS	O	O
receiving	PRADAXA.xml:S1:5546:9	receiv	VBG	O	O
PRADAXA	PRADAXA.xml:S1:5556:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:5564:3	150	CD	O	O
mg	PRADAXA.xml:S1:5568:2	mg	NN	O	O
than	PRADAXA.xml:S1:5571:4	than	IN	O	O
in	PRADAXA.xml:S1:5576:2	in	IN	O	O
patients	PRADAXA.xml:S1:5579:8	patient	NNS	O	O
receiving	PRADAXA.xml:S1:5588:9	receiv	VBG	O	O
warfarin	PRADAXA.xml:S1:5598:8	warfarin	NN	O	O
(	PRADAXA.xml:S1:5607:1	(	(	O	O
6.6%	PRADAXA.xml:S1:5608:4	6.6%	CD	O	O
vs	PRADAXA.xml:S1:5613:2	vs	NN	O	O
.	PRADAXA.xml:S1:5615:1	.	.	O	O

4.2%	PRADAXA.xml:S1:5617:4	4.2%	CD	O	O
,	PRADAXA.xml:S1:5621:1	,	,	O	O
respectively	PRADAXA.xml:S1:5623:12	respect	RB	O	O
)	PRADAXA.xml:S1:5635:1	)	)	O	O
.	PRADAXA.xml:S1:5636:1	.	.	O	O

The	PRADAXA.xml:S1:5642:3	the	DT	O	O

risk	PRADAXA.xml:S1:5646:4	risk	NN	O	O
of	PRADAXA.xml:S1:5651:2	of	IN	O	O
major	PRADAXA.xml:S1:5654:5	major	JJ	O	O
bleeds	PRADAXA.xml:S1:5660:6	bleed	NNS	B-AdverseReaction	O
was	PRADAXA.xml:S1:5667:3	wa	VBD	O	O
similar	PRADAXA.xml:S1:5671:7	similar	JJ	O	O
with	PRADAXA.xml:S1:5679:4	with	IN	O	O
PRADAXA	PRADAXA.xml:S1:5684:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:5692:3	150	CD	O	O
mg	PRADAXA.xml:S1:5696:2	mg	NN	O	O
and	PRADAXA.xml:S1:5699:3	and	CC	O	O
warfarin	PRADAXA.xml:S1:5703:8	warfarin	NN	O	O
across	PRADAXA.xml:S1:5712:6	across	IN	O	O
major	PRADAXA.xml:S1:5719:5	major	JJ	O	O
subgroups	PRADAXA.xml:S1:5725:9	subgroup	NNS	O	O
defined	PRADAXA.xml:S1:5735:7	defin	VBN	O	O
by	PRADAXA.xml:S1:5743:2	by	IN	O	O
baseline	PRADAXA.xml:S1:5746:8	baselin	NN	O	O
characteristics	PRADAXA.xml:S1:5755:15	characterist	NNS	O	O
(	PRADAXA.xml:S1:5771:1	(	(	O	O
see	PRADAXA.xml:S1:5772:3	see	VB	O	O
Figure	PRADAXA.xml:S1:5776:6	figur	NNP	O	O
1	PRADAXA.xml:S1:5783:1	1	CD	O	O
)	PRADAXA.xml:S1:5784:1	)	)	O	O
,	PRADAXA.xml:S1:5785:1	,	,	O	O
with	PRADAXA.xml:S1:5787:4	with	IN	O	O
the	PRADAXA.xml:S1:5792:3	the	DT	O	O
exception	PRADAXA.xml:S1:5796:9	except	NN	O	O
of	PRADAXA.xml:S1:5806:2	of	IN	O	O
age	PRADAXA.xml:S1:5809:3	age	NN	O	O
,	PRADAXA.xml:S1:5812:1	,	,	O	O
where	PRADAXA.xml:S1:5814:5	where	WRB	O	O
there	PRADAXA.xml:S1:5820:5	there	EX	O	O
was	PRADAXA.xml:S1:5826:3	wa	VBD	O	O
a	PRADAXA.xml:S1:5830:1	a	DT	O	O
trend	PRADAXA.xml:S1:5832:5	trend	NN	O	O
towards	PRADAXA.xml:S1:5838:7	toward	VBZ	O	O
a	PRADAXA.xml:S1:5846:1	a	DT	O	O
higher	PRADAXA.xml:S1:5848:6	higher	JJR	O	O
incidence	PRADAXA.xml:S1:5855:9	incid	NN	O	O
of	PRADAXA.xml:S1:5865:2	of	IN	O	O
major	PRADAXA.xml:S1:5868:5	major	JJ	O	O
bleeding	PRADAXA.xml:S1:5874:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
on	PRADAXA.xml:S1:5883:2	on	IN	O	O
PRADAXA	PRADAXA.xml:S1:5886:7	pradaxa	NNP	O	O
(	PRADAXA.xml:S1:5894:1	(	(	O	O
hazard	PRADAXA.xml:S1:5895:6	hazard	JJ	O	O
ratio	PRADAXA.xml:S1:5902:5	ratio	NN	O	O
1.2	PRADAXA.xml:S1:5908:3	1.2	CD	O	O
,	PRADAXA.xml:S1:5911:1	,	,	O	O
95%	PRADAXA.xml:S1:5913:3	95%	CD	O	O
CI	PRADAXA.xml:S1:5917:2	CI	NN	O	O
:	PRADAXA.xml:S1:5919:1	:	:	O	O
1.0	PRADAXA.xml:S1:5921:3	1.0	CD	O	O
to	PRADAXA.xml:S1:5925:2	to	TO	O	O
1.5	PRADAXA.xml:S1:5928:3	1.5	CD	O	O
)	PRADAXA.xml:S1:5931:1	)	)	O	O
for	PRADAXA.xml:S1:5933:3	for	IN	O	O
patients	PRADAXA.xml:S1:5937:8	patient	NNS	O	O
75	PRADAXA.xml:S1:5948:2	75	CD	O	O
years	PRADAXA.xml:S1:5951:5	year	NNS	O	O
of	PRADAXA.xml:S1:5957:2	of	IN	O	O
age	PRADAXA.xml:S1:5960:3	age	NN	O	O
.	PRADAXA.xml:S1:5963:1	.	.	O	O

Figure	PRADAXA.xml:S1:5971:6	figur	NN	O	O
1	PRADAXA.xml:S1:5978:1	1	CD	O	O
Adjudicated	PRADAXA.xml:S1:5980:11	adjud	NNP	O	O
Major	PRADAXA.xml:S1:5992:5	major	NNP	O	O
Bleeding	PRADAXA.xml:S1:5998:8	bleed	NNP	B-AdverseReaction	B-AdverseReaction
by	PRADAXA.xml:S1:6007:2	by	IN	O	O
Baseline	PRADAXA.xml:S1:6010:8	baselin	NNP	O	O
Characteristics	PRADAXA.xml:S1:6019:15	characterist	NNPS	O	O
Including	PRADAXA.xml:S1:6035:9	includ	NNP	O	O
Hemorrhagic	PRADAXA.xml:S1:6045:11	hemorrhag	NNP	O	O
Stroke	PRADAXA.xml:S1:6057:6	stroke	NNP	O	O
Treated	PRADAXA.xml:S1:6064:7	treat	VBD	O	O
Patients	PRADAXA.xml:S1:6072:8	patient	NNS	O	O

Note	PRADAXA.xml:S1:6087:4	note	NN	O	O
:	PRADAXA.xml:S1:6091:1	:	:	O	O
The	PRADAXA.xml:S1:6093:3	the	DT	O	O
figure	PRADAXA.xml:S1:6097:6	figur	NN	O	O
above	PRADAXA.xml:S1:6104:5	abov	IN	O	O
presents	PRADAXA.xml:S1:6110:8	present	NNS	O	O
effects	PRADAXA.xml:S1:6119:7	effect	NNS	O	O
in	PRADAXA.xml:S1:6127:2	in	IN	O	O
various	PRADAXA.xml:S1:6130:7	variou	JJ	O	O
subgroups	PRADAXA.xml:S1:6138:9	subgroup	NNS	O	O
all	PRADAXA.xml:S1:6148:3	all	DT	O	O
of	PRADAXA.xml:S1:6152:2	of	IN	O	O
which	PRADAXA.xml:S1:6155:5	which	WDT	O	O
are	PRADAXA.xml:S1:6161:3	are	VBP	O	O
baseline	PRADAXA.xml:S1:6165:8	baselin	JJ	O	O
characteristics	PRADAXA.xml:S1:6174:15	characterist	NNS	O	O
and	PRADAXA.xml:S1:6190:3	and	CC	O	O
all	PRADAXA.xml:S1:6194:3	all	DT	O	O
of	PRADAXA.xml:S1:6198:2	of	IN	O	O
which	PRADAXA.xml:S1:6201:5	which	WDT	O	O
were	PRADAXA.xml:S1:6207:4	were	VBD	O	O
pre	PRADAXA.xml:S1:6212:3	pre	SYM	O	O
-	PRADAXA.xml:S1:6215:1	-	:	O	O
specified	PRADAXA.xml:S1:6216:9	specifi	VBN	O	O
.	PRADAXA.xml:S1:6225:1	.	.	O	O

The	PRADAXA.xml:S1:6227:3	the	DT	O	O
95%	PRADAXA.xml:S1:6231:3	95%	CD	O	O
confidence	PRADAXA.xml:S1:6235:10	confid	NN	O	O
limits	PRADAXA.xml:S1:6246:6	limit	NNS	O	O
that	PRADAXA.xml:S1:6253:4	that	WDT	O	O
are	PRADAXA.xml:S1:6258:3	are	VBP	O	O
shown	PRADAXA.xml:S1:6262:5	shown	VBN	O	O
do	PRADAXA.xml:S1:6268:2	do	JJ	O	O
not	PRADAXA.xml:S1:6271:3	not	RB	O	O
take	PRADAXA.xml:S1:6275:4	take	VB	O	O
into	PRADAXA.xml:S1:6280:4	into	IN	O	O
account	PRADAXA.xml:S1:6285:7	account	NN	O	O
how	PRADAXA.xml:S1:6293:3	how	WRB	O	O
many	PRADAXA.xml:S1:6297:4	mani	JJ	O	O
comparisons	PRADAXA.xml:S1:6302:11	comparison	NNS	O	O
were	PRADAXA.xml:S1:6314:4	were	VBD	O	O
made	PRADAXA.xml:S1:6319:4	made	VBN	O	O
,	PRADAXA.xml:S1:6323:1	,	,	O	O
nor	PRADAXA.xml:S1:6325:3	nor	CC	O	O
do	PRADAXA.xml:S1:6329:2	do	VBP	O	O
they	PRADAXA.xml:S1:6332:4	they	PRP	O	O
reflect	PRADAXA.xml:S1:6337:7	reflect	VB	O	O
the	PRADAXA.xml:S1:6345:3	the	DT	O	O
effect	PRADAXA.xml:S1:6349:6	effect	NN	O	O
of	PRADAXA.xml:S1:6356:2	of	IN	O	O
a	PRADAXA.xml:S1:6359:1	a	DT	O	O
particular	PRADAXA.xml:S1:6361:10	particular	JJ	O	O
factor	PRADAXA.xml:S1:6372:6	factor	NN	O	O
after	PRADAXA.xml:S1:6379:5	after	IN	O	O
adjustment	PRADAXA.xml:S1:6385:10	adjust	NN	O	O
for	PRADAXA.xml:S1:6396:3	for	IN	O	O
all	PRADAXA.xml:S1:6400:3	all	DT	O	O
other	PRADAXA.xml:S1:6404:5	other	JJ	O	O
factors	PRADAXA.xml:S1:6410:7	factor	NNS	O	O
.	PRADAXA.xml:S1:6417:1	.	.	O	O

Apparent	PRADAXA.xml:S1:6419:8	appar	JJ	O	O
homogeneity	PRADAXA.xml:S1:6428:11	homogen	NN	O	O
or	PRADAXA.xml:S1:6440:2	or	CC	O	O
heterogeneity	PRADAXA.xml:S1:6443:13	heterogen	NN	O	O
among	PRADAXA.xml:S1:6457:5	among	IN	O	O
groups	PRADAXA.xml:S1:6463:6	group	NNS	O	O
should	PRADAXA.xml:S1:6470:6	should	MD	O	O
not	PRADAXA.xml:S1:6477:3	not	RB	O	O
be	PRADAXA.xml:S1:6481:2	be	VB	O	O
over	PRADAXA.xml:S1:6484:4	over	IN	O	O
-	PRADAXA.xml:S1:6488:1	-	:	O	O
interpreted	PRADAXA.xml:S1:6489:11	interpret	VBN	O	O
.	PRADAXA.xml:S1:6500:1	.	.	O	O

Figure	PRADAXA.xml:S1:6507:6	figur	NN	O	O
1	PRADAXA.xml:S1:6514:1	1	CD	O	O

Gastrointestinal	PRADAXA.xml:S1:6528:16	gastrointestin	JJ	O	O
Adverse	PRADAXA.xml:S1:6545:7	advers	NNP	O	O
Reactions	PRADAXA.xml:S1:6553:9	reaction	NNP	O	O

Patients	PRADAXA.xml:S1:6573:8	patient	NNS	O	O
on	PRADAXA.xml:S1:6582:2	on	IN	O	O
PRADAXA	PRADAXA.xml:S1:6585:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:6593:3	150	CD	O	O
mg	PRADAXA.xml:S1:6597:2	mg	NN	O	O
had	PRADAXA.xml:S1:6600:3	had	VBD	O	O
an	PRADAXA.xml:S1:6604:2	an	DT	O	O
increased	PRADAXA.xml:S1:6607:9	increas	VBN	O	O
incidence	PRADAXA.xml:S1:6617:9	incid	NN	O	O
of	PRADAXA.xml:S1:6627:2	of	IN	O	O
gastrointestinal	PRADAXA.xml:S1:6630:16	gastrointestin	JJ	B-AdverseReaction	O
adverse	PRADAXA.xml:S1:6647:7	advers	JJ	I-AdverseReaction	O
reactions	PRADAXA.xml:S1:6655:9	reaction	NNS	I-AdverseReaction	O
(	PRADAXA.xml:S1:6665:1	(	(	O	O
35%	PRADAXA.xml:S1:6666:3	35%	CD	O	O
vs	PRADAXA.xml:S1:6670:2	vs	NN	O	O
.	PRADAXA.xml:S1:6672:1	.	.	O	O

24%	PRADAXA.xml:S1:6674:3	24%	CD	O	O
on	PRADAXA.xml:S1:6678:2	on	IN	O	O
warfarin	PRADAXA.xml:S1:6681:8	warfarin	NN	O	O
)	PRADAXA.xml:S1:6689:1	)	)	O	O
.	PRADAXA.xml:S1:6690:1	.	.	O	O

These	PRADAXA.xml:S1:6692:5	these	DT	O	O
were	PRADAXA.xml:S1:6698:4	were	VBD	O	O
commonly	PRADAXA.xml:S1:6703:8	commonli	RB	O	O
dyspepsia	PRADAXA.xml:S1:6712:9	dyspepsia	JJ	B-AdverseReaction	B-AdverseReaction
(	PRADAXA.xml:S1:6722:1	(	(	O	O
including	PRADAXA.xml:S1:6723:9	includ	VBG	O	O
abdominal	PRADAXA.xml:S1:6733:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	PRADAXA.xml:S1:6743:4	pain	NN	I-AdverseReaction	I-AdverseReaction
upper	PRADAXA.xml:S1:6748:5	upper	JJ	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:6753:1	,	,	O	O
abdominal	PRADAXA.xml:S1:6755:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	PRADAXA.xml:S1:6765:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:6769:1	,	,	O	O
abdominal	PRADAXA.xml:S1:6771:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	PRADAXA.xml:S1:6781:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:6791:1	,	,	O	O
and	PRADAXA.xml:S1:6793:3	and	CC	O	O
epigastric	PRADAXA.xml:S1:6797:10	epigastr	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	PRADAXA.xml:S1:6808:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
)	PRADAXA.xml:S1:6818:1	)	)	O	O
and	PRADAXA.xml:S1:6820:3	and	CC	O	O
gastritis	PRADAXA.xml:S1:6824:9	gastriti	$	B-AdverseReaction	B-AdverseReaction
-	PRADAXA.xml:S1:6833:1	-	:	O	I-AdverseReaction
like	PRADAXA.xml:S1:6834:4	like	IN	O	I-AdverseReaction
symptoms	PRADAXA.xml:S1:6839:8	symptom	NNS	O	I-AdverseReaction
(	PRADAXA.xml:S1:6848:1	(	(	O	O
including	PRADAXA.xml:S1:6849:9	includ	VBG	O	O
GERD	PRADAXA.xml:S1:6859:4	gerd	NNP	B-AdverseReaction	O
,	PRADAXA.xml:S1:6863:1	,	,	O	O
esophagitis	PRADAXA.xml:S1:6865:11	esophag	NN	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:6876:1	,	,	O	O
erosive	PRADAXA.xml:S1:6878:7	eros	JJ	B-AdverseReaction	B-AdverseReaction
gastritis	PRADAXA.xml:S1:6886:9	gastriti	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:6895:1	,	,	O	O
gastric	PRADAXA.xml:S1:6897:7	gastric	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:6905:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:6915:1	,	,	O	O
hemorrhagic	PRADAXA.xml:S1:6917:11	hemorrhag	JJ	B-AdverseReaction	B-AdverseReaction
gastritis	PRADAXA.xml:S1:6929:9	gastriti	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:6938:1	,	,	O	O
hemorrhagic	PRADAXA.xml:S1:6940:11	hemorrhag	JJ	B-AdverseReaction	B-AdverseReaction
erosive	PRADAXA.xml:S1:6952:7	eros	JJ	I-AdverseReaction	I-AdverseReaction
gastritis	PRADAXA.xml:S1:6960:9	gastriti	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:6969:1	,	,	O	O
and	PRADAXA.xml:S1:6971:3	and	CC	O	O
gastrointestinal	PRADAXA.xml:S1:6975:16	gastrointestin	JJ	B-AdverseReaction	B-AdverseReaction
ulcer	PRADAXA.xml:S1:6992:5	ulcer	NN	I-AdverseReaction	I-AdverseReaction
)	PRADAXA.xml:S1:6997:1	)	)	O	O
.	PRADAXA.xml:S1:6998:1	.	.	O	O

Hypersensitivity	PRADAXA.xml:S1:7016:16	hypersensit	NN	O	O

Reactions	PRADAXA.xml:S1:7033:9	reaction	NNS	O	O

In	PRADAXA.xml:S1:7053:2	In	IN	O	O
the	PRADAXA.xml:S1:7056:3	the	DT	O	O
RE	PRADAXA.xml:S1:7060:2	RE	NNP	O	O
-	PRADAXA.xml:S1:7062:1	-	:	O	O
LY	PRADAXA.xml:S1:7063:2	LY	NNP	O	O
study	PRADAXA.xml:S1:7066:5	studi	NN	O	O
,	PRADAXA.xml:S1:7071:1	,	,	O	O
drug	PRADAXA.xml:S1:7073:4	drug	NN	O	B-AdverseReaction
hypersensitivity	PRADAXA.xml:S1:7078:16	hypersensit	NN	B-AdverseReaction	I-AdverseReaction
(	PRADAXA.xml:S1:7095:1	(	(	O	O
including	PRADAXA.xml:S1:7096:9	includ	VBG	O	O
urticaria	PRADAXA.xml:S1:7106:9	urticaria	NNS	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:7115:1	,	,	O	O
rash	PRADAXA.xml:S1:7117:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:7121:1	,	,	O	O
and	PRADAXA.xml:S1:7123:3	and	CC	O	O
pruritus	PRADAXA.xml:S1:7127:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
)	PRADAXA.xml:S1:7135:1	)	)	O	O
,	PRADAXA.xml:S1:7136:1	,	,	O	O
allergic	PRADAXA.xml:S1:7138:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
edema	PRADAXA.xml:S1:7147:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:7152:1	,	,	O	O
anaphylactic	PRADAXA.xml:S1:7154:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reaction	PRADAXA.xml:S1:7167:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:7175:1	,	,	O	O
and	PRADAXA.xml:S1:7177:3	and	CC	O	O
anaphylactic	PRADAXA.xml:S1:7181:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
shock	PRADAXA.xml:S1:7194:5	shock	NN	I-AdverseReaction	I-AdverseReaction
were	PRADAXA.xml:S1:7200:4	were	VBD	O	O
reported	PRADAXA.xml:S1:7205:8	report	VBN	O	O
in	PRADAXA.xml:S1:7214:2	in	IN	O	O
0.1%	PRADAXA.xml:S1:7218:4	0.1%	CD	O	O
of	PRADAXA.xml:S1:7223:2	of	IN	O	O
patients	PRADAXA.xml:S1:7226:8	patient	NNS	O	O
receiving	PRADAXA.xml:S1:7235:9	receiv	VBG	O	O
PRADAXA	PRADAXA.xml:S1:7245:7	pradaxa	NNP	O	O
.	PRADAXA.xml:S1:7252:1	.	.	O	O

Treatment	PRADAXA.xml:S1:7268:9	treatment	NN	O	O

and	PRADAXA.xml:S1:7278:3	and	CC	O	O
Reduction	PRADAXA.xml:S1:7282:9	reduct	NNP	O	O
in	PRADAXA.xml:S1:7292:2	in	IN	O	O
the	PRADAXA.xml:S1:7295:3	the	DT	O	O
Risk	PRADAXA.xml:S1:7299:4	risk	NN	O	O
of	PRADAXA.xml:S1:7304:2	of	IN	O	O
Recurrence	PRADAXA.xml:S1:7307:10	recurr	NNP	O	O
of	PRADAXA.xml:S1:7318:2	of	IN	O	O
Deep	PRADAXA.xml:S1:7321:4	deep	NNP	O	O
Venous	PRADAXA.xml:S1:7326:6	venou	NNP	O	O
Thrombosis	PRADAXA.xml:S1:7333:10	thrombosi	NNP	O	O
and	PRADAXA.xml:S1:7344:3	and	CC	O	O
Pulmonary	PRADAXA.xml:S1:7348:9	pulmonari	NNP	O	B-AdverseReaction
Embolism	PRADAXA.xml:S1:7358:8	embol	NNP	O	I-AdverseReaction

PRADAXA	PRADAXA.xml:S1:7375:7	pradaxa	NNP	O	O
was	PRADAXA.xml:S1:7383:3	wa	VBD	O	O
studied	PRADAXA.xml:S1:7387:7	studi	VBN	O	O
in	PRADAXA.xml:S1:7395:2	in	IN	O	O
4387	PRADAXA.xml:S1:7398:4	4387	CD	O	O
patients	PRADAXA.xml:S1:7403:8	patient	NNS	O	O
in	PRADAXA.xml:S1:7412:2	in	IN	O	O
4	PRADAXA.xml:S1:7415:1	4	CD	O	O
pivotal	PRADAXA.xml:S1:7417:7	pivot	JJ	O	O
,	PRADAXA.xml:S1:7424:1	,	,	O	O
parallel	PRADAXA.xml:S1:7426:8	parallel	JJ	O	O
,	PRADAXA.xml:S1:7434:1	,	,	O	O
randomized	PRADAXA.xml:S1:7436:10	random	JJ	O	O
,	PRADAXA.xml:S1:7446:1	,	,	O	O
double	PRADAXA.xml:S1:7448:6	doubl	JJ	O	O
-	PRADAXA.xml:S1:7454:1	-	:	O	O
blind	PRADAXA.xml:S1:7455:5	blind	NN	O	O
trials	PRADAXA.xml:S1:7461:6	trial	NNS	O	O
.	PRADAXA.xml:S1:7467:1	.	.	O	O

Three	PRADAXA.xml:S1:7469:5	three	CD	O	O
of	PRADAXA.xml:S1:7475:2	of	IN	O	O
these	PRADAXA.xml:S1:7478:5	these	DT	O	O
trials	PRADAXA.xml:S1:7484:6	trial	NNS	O	O
were	PRADAXA.xml:S1:7491:4	were	VBD	O	O
active	PRADAXA.xml:S1:7496:6	activ	JJ	O	O
-	PRADAXA.xml:S1:7502:1	-	:	O	O
controlled	PRADAXA.xml:S1:7503:10	control	VBN	O	O
(	PRADAXA.xml:S1:7514:1	(	(	O	O
warfarin	PRADAXA.xml:S1:7515:8	warfarin	NN	O	O
)	PRADAXA.xml:S1:7523:1	)	)	O	O
(	PRADAXA.xml:S1:7525:1	(	(	O	O
RE	PRADAXA.xml:S1:7526:2	RE	NNP	O	O
-	PRADAXA.xml:S1:7528:1	-	:	O	O
COVER	PRADAXA.xml:S1:7529:5	cover	NNP	O	O
,	PRADAXA.xml:S1:7534:1	,	,	O	O
RE	PRADAXA.xml:S1:7536:2	RE	NNP	O	O
-	PRADAXA.xml:S1:7538:1	-	:	O	O
COVER	PRADAXA.xml:S1:7539:5	cover	NNP	O	O
II	PRADAXA.xml:S1:7545:2	II	NNP	O	O
,	PRADAXA.xml:S1:7547:1	,	,	O	O
and	PRADAXA.xml:S1:7549:3	and	CC	O	O
RE	PRADAXA.xml:S1:7553:2	RE	NNP	O	O
-	PRADAXA.xml:S1:7555:1	-	:	O	O
MEDY	PRADAXA.xml:S1:7556:4	medi	NN	O	O
)	PRADAXA.xml:S1:7560:1	)	)	O	O
,	PRADAXA.xml:S1:7561:1	,	,	O	O
and	PRADAXA.xml:S1:7563:3	and	CC	O	O
one	PRADAXA.xml:S1:7567:3	one	CD	O	O
study	PRADAXA.xml:S1:7571:5	studi	NN	O	O
(	PRADAXA.xml:S1:7577:1	(	(	O	O
RE	PRADAXA.xml:S1:7578:2	RE	NNP	O	O
-	PRADAXA.xml:S1:7580:1	-	:	O	O
SONATE	PRADAXA.xml:S1:7581:6	sonat	NN	O	O
)	PRADAXA.xml:S1:7587:1	)	)	O	O
was	PRADAXA.xml:S1:7589:3	wa	VBD	O	O
placebo	PRADAXA.xml:S1:7593:7	placebo	VBN	O	O
-	PRADAXA.xml:S1:7600:1	-	:	O	O
controlled	PRADAXA.xml:S1:7601:10	control	VBN	O	O
.	PRADAXA.xml:S1:7611:1	.	.	O	O

The	PRADAXA.xml:S1:7613:3	the	DT	O	O
demographic	PRADAXA.xml:S1:7617:11	demograph	JJ	O	O
characteristics	PRADAXA.xml:S1:7629:15	characterist	NNS	O	O
were	PRADAXA.xml:S1:7645:4	were	VBD	O	O
similar	PRADAXA.xml:S1:7650:7	similar	JJ	O	O
among	PRADAXA.xml:S1:7658:5	among	IN	O	O
the	PRADAXA.xml:S1:7664:3	the	DT	O	O
4	PRADAXA.xml:S1:7668:1	4	CD	O	O
pivotal	PRADAXA.xml:S1:7670:7	pivot	JJ	O	O
studies	PRADAXA.xml:S1:7678:7	studi	NNS	O	O
and	PRADAXA.xml:S1:7686:3	and	CC	O	O
between	PRADAXA.xml:S1:7690:7	between	IN	O	O
the	PRADAXA.xml:S1:7698:3	the	DT	O	O
treatment	PRADAXA.xml:S1:7702:9	treatment	NN	O	O
groups	PRADAXA.xml:S1:7712:6	group	NNS	O	O
within	PRADAXA.xml:S1:7719:6	within	IN	O	O
these	PRADAXA.xml:S1:7726:5	these	DT	O	O
studies	PRADAXA.xml:S1:7732:7	studi	NNS	O	O
.	PRADAXA.xml:S1:7739:1	.	.	O	O

Approximately	PRADAXA.xml:S1:7741:13	approxim	RB	O	O
60%	PRADAXA.xml:S1:7755:3	60%	CD	O	O
of	PRADAXA.xml:S1:7759:2	of	IN	O	O
the	PRADAXA.xml:S1:7762:3	the	DT	O	O
treated	PRADAXA.xml:S1:7766:7	treat	JJ	O	O
patients	PRADAXA.xml:S1:7774:8	patient	NNS	O	O
were	PRADAXA.xml:S1:7783:4	were	VBD	O	O
male	PRADAXA.xml:S1:7788:4	male	JJ	O	O
,	PRADAXA.xml:S1:7792:1	,	,	O	O
with	PRADAXA.xml:S1:7794:4	with	IN	O	O
a	PRADAXA.xml:S1:7799:1	a	DT	O	O
mean	PRADAXA.xml:S1:7801:4	mean	JJ	O	O
age	PRADAXA.xml:S1:7806:3	age	NN	O	O
of	PRADAXA.xml:S1:7810:2	of	IN	O	O
55.1	PRADAXA.xml:S1:7813:4	55.1	CD	O	O
years	PRADAXA.xml:S1:7818:5	year	NNS	O	O
.	PRADAXA.xml:S1:7823:1	.	.	O	O

The	PRADAXA.xml:S1:7825:3	the	DT	O	O
majority	PRADAXA.xml:S1:7829:8	major	NN	O	O
of	PRADAXA.xml:S1:7838:2	of	IN	O	O
the	PRADAXA.xml:S1:7841:3	the	DT	O	O
patients	PRADAXA.xml:S1:7845:8	patient	NNS	O	O
were	PRADAXA.xml:S1:7854:4	were	VBD	O	O
white	PRADAXA.xml:S1:7859:5	white	JJ	O	O
(	PRADAXA.xml:S1:7865:1	(	(	O	O
87.7%	PRADAXA.xml:S1:7866:5	87.7%	CD	O	O
)	PRADAXA.xml:S1:7871:1	)	)	O	O
,	PRADAXA.xml:S1:7872:1	,	,	O	O
10.3%	PRADAXA.xml:S1:7874:5	10.3%	CD	O	O
were	PRADAXA.xml:S1:7880:4	were	VBD	O	O
Asian	PRADAXA.xml:S1:7885:5	asian	JJ	O	O
,	PRADAXA.xml:S1:7890:1	,	,	O	O
and	PRADAXA.xml:S1:7892:3	and	CC	O	O
1.9%	PRADAXA.xml:S1:7896:4	1.9%	CD	O	O
were	PRADAXA.xml:S1:7901:4	were	VBD	O	O
black	PRADAXA.xml:S1:7906:5	black	JJ	O	O
with	PRADAXA.xml:S1:7912:4	with	IN	O	O
a	PRADAXA.xml:S1:7917:1	a	DT	O	O
mean	PRADAXA.xml:S1:7919:4	mean	JJ	O	O
CrCl	PRADAXA.xml:S1:7924:4	crcl	NNP	O	O
of	PRADAXA.xml:S1:7929:2	of	IN	O	O
105.6	PRADAXA.xml:S1:7932:5	105.6	CD	O	O
mL	PRADAXA.xml:S1:7938:2	mL	NNS	O	O
min	PRADAXA.xml:S1:7941:3	min	NN	O	O
.	PRADAXA.xml:S1:7944:1	.	.	O	O

Bleeding	PRADAXA.xml:S1:7950:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
events	PRADAXA.xml:S1:7959:6	event	NNS	O	O
for	PRADAXA.xml:S1:7966:3	for	IN	O	O
the	PRADAXA.xml:S1:7970:3	the	DT	O	O
4	PRADAXA.xml:S1:7974:1	4	CD	O	O
pivotal	PRADAXA.xml:S1:7976:7	pivot	JJ	O	O
studies	PRADAXA.xml:S1:7984:7	studi	NNS	O	O
were	PRADAXA.xml:S1:7992:4	were	VBD	O	O
classified	PRADAXA.xml:S1:7997:10	classifi	VBN	O	O
as	PRADAXA.xml:S1:8008:2	as	IN	O	O
major	PRADAXA.xml:S1:8011:5	major	JJ	O	O
bleeding	PRADAXA.xml:S1:8017:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
events	PRADAXA.xml:S1:8026:6	event	NNS	O	O
if	PRADAXA.xml:S1:8033:2	if	IN	O	O
at	PRADAXA.xml:S1:8036:2	at	IN	O	O
least	PRADAXA.xml:S1:8039:5	least	JJS	O	O
one	PRADAXA.xml:S1:8045:3	one	CD	O	O
of	PRADAXA.xml:S1:8049:2	of	IN	O	O
the	PRADAXA.xml:S1:8052:3	the	DT	O	O
following	PRADAXA.xml:S1:8056:9	follow	JJ	O	O
criteria	PRADAXA.xml:S1:8066:8	criteria	NNS	O	O
applied	PRADAXA.xml:S1:8075:7	appli	VBN	O	O
:	PRADAXA.xml:S1:8082:1	:	:	O	O
fatal	PRADAXA.xml:S1:8084:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8090:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:8098:1	,	,	O	O
symptomatic	PRADAXA.xml:S1:8100:11	symptomat	JJ	B-AdverseReaction	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8112:8	bleed	NN	I-AdverseReaction	I-AdverseReaction
in	PRADAXA.xml:S1:8121:2	in	IN	I-AdverseReaction	O
a	PRADAXA.xml:S1:8124:1	a	DT	I-AdverseReaction	O
critical	PRADAXA.xml:S1:8126:8	critic	JJ	I-AdverseReaction	O
area	PRADAXA.xml:S1:8135:4	area	NN	I-AdverseReaction	O
or	PRADAXA.xml:S1:8140:2	or	CC	O	O
organ	PRADAXA.xml:S1:8143:5	organ	NN	I-AdverseReaction	O
(	PRADAXA.xml:S1:8149:1	(	(	O	O
intraocular	PRADAXA.xml:S1:8150:11	intraocular	JJ	I-AdverseReaction	O
,	PRADAXA.xml:S1:8161:1	,	,	O	O
intracranial	PRADAXA.xml:S1:8163:12	intracrani	JJ	I-AdverseReaction	O
,	PRADAXA.xml:S1:8175:1	,	,	O	O
intraspinal	PRADAXA.xml:S1:8177:11	intraspin	JJ	I-AdverseReaction	O
or	PRADAXA.xml:S1:8189:2	or	CC	O	O
intramuscular	PRADAXA.xml:S1:8192:13	intramuscular	JJ	I-AdverseReaction	O
with	PRADAXA.xml:S1:8206:4	with	IN	O	O
compartment	PRADAXA.xml:S1:8211:11	compart	JJ	B-AdverseReaction	B-AdverseReaction
syndrome	PRADAXA.xml:S1:8223:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:8231:1	,	,	O	O
retroperitoneal	PRADAXA.xml:S1:8233:15	retroperiton	NN	B-AdverseReaction	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8249:8	bleed	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:8257:1	,	,	O	O
intra	PRADAXA.xml:S1:8259:5	intra	JJ	B-AdverseReaction	B-AdverseReaction
-	PRADAXA.xml:S1:8264:1	-	:	I-AdverseReaction	I-AdverseReaction
articular	PRADAXA.xml:S1:8265:9	articular	JJ	I-AdverseReaction	I-AdverseReaction
bleeding	PRADAXA.xml:S1:8275:8	bleed	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:8283:1	,	,	O	O
or	PRADAXA.xml:S1:8285:2	or	CC	O	O
pericardial	PRADAXA.xml:S1:8288:11	pericardi	JJ	B-AdverseReaction	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8300:8	bleed	NN	I-AdverseReaction	I-AdverseReaction
)	PRADAXA.xml:S1:8308:1	)	)	O	O
,	PRADAXA.xml:S1:8309:1	,	,	O	O
bleeding	PRADAXA.xml:S1:8311:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
causing	PRADAXA.xml:S1:8320:7	caus	VBG	O	O
a	PRADAXA.xml:S1:8328:1	a	DT	O	O
fall	PRADAXA.xml:S1:8330:4	fall	NN	B-AdverseReaction	O
in	PRADAXA.xml:S1:8335:2	in	IN	I-AdverseReaction	O
hemoglobin	PRADAXA.xml:S1:8338:10	hemoglobin	JJ	I-AdverseReaction	O
level	PRADAXA.xml:S1:8349:5	level	NN	I-AdverseReaction	O
of	PRADAXA.xml:S1:8355:2	of	IN	O	O
2.0	PRADAXA.xml:S1:8358:3	2.0	CD	O	O
g	PRADAXA.xml:S1:8362:1	g	NNS	O	O
dL	PRADAXA.xml:S1:8364:2	dL	NN	O	O
(	PRADAXA.xml:S1:8367:1	(	(	O	O
1.24	PRADAXA.xml:S1:8368:4	1.24	CD	O	O
mmol	PRADAXA.xml:S1:8373:4	mmol	NN	O	O
L	PRADAXA.xml:S1:8378:1	L	NNP	O	O
or	PRADAXA.xml:S1:8380:2	or	CC	O	O
more	PRADAXA.xml:S1:8383:4	more	JJR	O	O
,	PRADAXA.xml:S1:8387:1	,	,	O	O
or	PRADAXA.xml:S1:8389:2	or	CC	O	O
leading	PRADAXA.xml:S1:8392:7	lead	VBG	O	O
to	PRADAXA.xml:S1:8400:2	to	TO	O	O
transfusion	PRADAXA.xml:S1:8403:11	transfus	NN	O	O
of	PRADAXA.xml:S1:8415:2	of	IN	O	O
2	PRADAXA.xml:S1:8418:1	2	CD	O	O
or	PRADAXA.xml:S1:8420:2	or	CC	O	O
more	PRADAXA.xml:S1:8423:4	more	JJR	O	O
units	PRADAXA.xml:S1:8428:5	unit	NNS	O	O
of	PRADAXA.xml:S1:8434:2	of	IN	O	O
whole	PRADAXA.xml:S1:8437:5	whole	JJ	O	O
blood	PRADAXA.xml:S1:8443:5	blood	NN	O	O
or	PRADAXA.xml:S1:8449:2	or	CC	O	O
red	PRADAXA.xml:S1:8452:3	red	JJ	O	O
cells	PRADAXA.xml:S1:8456:5	cell	NNS	O	O
)	PRADAXA.xml:S1:8461:1	)	)	O	O
.	PRADAXA.xml:S1:8462:1	.	.	O	O

RE	PRADAXA.xml:S1:8468:2	RE	NNP	O	O
-	PRADAXA.xml:S1:8470:1	-	:	O	O
COVER	PRADAXA.xml:S1:8471:5	cover	NNP	O	O
and	PRADAXA.xml:S1:8477:3	and	CC	O	O
RE	PRADAXA.xml:S1:8481:2	RE	NNP	O	O
-	PRADAXA.xml:S1:8483:1	-	:	O	O
COVER	PRADAXA.xml:S1:8484:5	cover	NNP	O	O
II	PRADAXA.xml:S1:8490:2	II	NNP	O	O
studies	PRADAXA.xml:S1:8493:7	studi	NNS	O	O
compared	PRADAXA.xml:S1:8501:8	compar	VBN	O	O
PRADAXA	PRADAXA.xml:S1:8510:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:8518:3	150	CD	O	O
mg	PRADAXA.xml:S1:8522:2	mg	NN	O	O
twice	PRADAXA.xml:S1:8525:5	twice	RB	O	O
daily	PRADAXA.xml:S1:8531:5	daili	RB	O	O
and	PRADAXA.xml:S1:8537:3	and	CC	O	O
warfarin	PRADAXA.xml:S1:8541:8	warfarin	VB	O	O
for	PRADAXA.xml:S1:8550:3	for	IN	O	O
the	PRADAXA.xml:S1:8554:3	the	DT	O	O
treatment	PRADAXA.xml:S1:8558:9	treatment	NN	O	O
of	PRADAXA.xml:S1:8568:2	of	IN	O	O
deep	PRADAXA.xml:S1:8571:4	deep	JJ	O	B-AdverseReaction
vein	PRADAXA.xml:S1:8576:4	vein	NN	O	I-AdverseReaction
thrombosis	PRADAXA.xml:S1:8581:10	thrombosi	NN	O	I-AdverseReaction
and	PRADAXA.xml:S1:8592:3	and	CC	O	O
pulmonary	PRADAXA.xml:S1:8596:9	pulmonari	JJ	O	B-AdverseReaction
embolism	PRADAXA.xml:S1:8606:8	embol	NN	O	I-AdverseReaction
.	PRADAXA.xml:S1:8614:1	.	.	O	O

Patients	PRADAXA.xml:S1:8616:8	patient	NNS	O	O
received	PRADAXA.xml:S1:8625:8	receiv	VBD	O	O
5	PRADAXA.xml:S1:8634:1	5	CD	O	O
-	PRADAXA.xml:S1:8635:1	-	:	O	O
10	PRADAXA.xml:S1:8636:2	10	CD	O	O
days	PRADAXA.xml:S1:8639:4	day	NNS	O	O
of	PRADAXA.xml:S1:8644:2	of	IN	O	O
an	PRADAXA.xml:S1:8647:2	an	DT	O	O
approved	PRADAXA.xml:S1:8650:8	approv	JJ	O	O
parenteral	PRADAXA.xml:S1:8659:10	parenter	JJ	O	O
anticoagulant	PRADAXA.xml:S1:8670:13	anticoagul	NN	O	O
therapy	PRADAXA.xml:S1:8684:7	therapi	NN	O	O
followed	PRADAXA.xml:S1:8692:8	follow	VBN	O	O
by	PRADAXA.xml:S1:8701:2	by	IN	O	O
6	PRADAXA.xml:S1:8704:1	6	CD	O	O
months	PRADAXA.xml:S1:8706:6	month	NNS	O	O
,	PRADAXA.xml:S1:8712:1	,	,	O	O
with	PRADAXA.xml:S1:8714:4	with	IN	O	O
mean	PRADAXA.xml:S1:8719:4	mean	JJ	O	O
exposure	PRADAXA.xml:S1:8724:8	exposur	NN	O	O
of	PRADAXA.xml:S1:8733:2	of	IN	O	O
164	PRADAXA.xml:S1:8736:3	164	CD	O	O
days	PRADAXA.xml:S1:8740:4	day	NNS	O	O
,	PRADAXA.xml:S1:8744:1	,	,	O	O
of	PRADAXA.xml:S1:8746:2	of	IN	O	O
oral	PRADAXA.xml:S1:8749:4	oral	JJ	O	O
only	PRADAXA.xml:S1:8754:4	onli	RB	O	O
treatment	PRADAXA.xml:S1:8759:9	treatment	NN	O	O
;	PRADAXA.xml:S1:8768:1	;	:	O	O
warfarin	PRADAXA.xml:S1:8770:8	warfarin	NN	O	O
was	PRADAXA.xml:S1:8779:3	wa	VBD	O	O
overlapped	PRADAXA.xml:S1:8783:10	overlap	VBN	O	O
with	PRADAXA.xml:S1:8794:4	with	IN	O	O
parenteral	PRADAXA.xml:S1:8799:10	parenter	JJ	O	O
therapy	PRADAXA.xml:S1:8810:7	therapi	NN	O	O
.	PRADAXA.xml:S1:8817:1	.	.	O	O

Table	PRADAXA.xml:S1:8819:5	tabl	JJ	O	O
3	PRADAXA.xml:S1:8825:1	3	CD	O	O
shows	PRADAXA.xml:S1:8827:5	show	VBZ	O	O
the	PRADAXA.xml:S1:8833:3	the	DT	O	O
number	PRADAXA.xml:S1:8837:6	number	NN	O	O
of	PRADAXA.xml:S1:8844:2	of	IN	O	O
patients	PRADAXA.xml:S1:8847:8	patient	NNS	O	O
experiencing	PRADAXA.xml:S1:8856:12	experienc	VBG	O	O
bleeding	PRADAXA.xml:S1:8869:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
events	PRADAXA.xml:S1:8878:6	event	NNS	O	O
in	PRADAXA.xml:S1:8885:2	in	IN	O	O
the	PRADAXA.xml:S1:8888:3	the	DT	O	O
pooled	PRADAXA.xml:S1:8892:6	pool	JJ	O	O
analysis	PRADAXA.xml:S1:8899:8	analysi	NN	O	O
of	PRADAXA.xml:S1:8908:2	of	IN	O	O
RE	PRADAXA.xml:S1:8911:2	RE	NNP	O	O
-	PRADAXA.xml:S1:8913:1	-	:	O	O
COVER	PRADAXA.xml:S1:8914:5	cover	NNP	O	O
and	PRADAXA.xml:S1:8920:3	and	CC	O	O
RE	PRADAXA.xml:S1:8924:2	RE	NNP	O	O
-	PRADAXA.xml:S1:8926:1	-	:	O	O
COVER	PRADAXA.xml:S1:8927:5	cover	NNP	O	O
II	PRADAXA.xml:S1:8933:2	II	NNP	O	O
studies	PRADAXA.xml:S1:8936:7	studi	NNS	O	O
during	PRADAXA.xml:S1:8944:6	dure	IN	O	O
the	PRADAXA.xml:S1:8951:3	the	DT	O	O
full	PRADAXA.xml:S1:8955:4	full	JJ	O	O
treatment	PRADAXA.xml:S1:8960:9	treatment	NN	O	O
including	PRADAXA.xml:S1:8970:9	includ	VBG	O	O
parenteral	PRADAXA.xml:S1:8980:10	parenter	JJ	O	O
and	PRADAXA.xml:S1:8991:3	and	CC	O	O
oral	PRADAXA.xml:S1:8995:4	oral	JJ	O	O
only	PRADAXA.xml:S1:9000:4	onli	RB	O	O
treatment	PRADAXA.xml:S1:9005:9	treatment	NN	O	O
periods	PRADAXA.xml:S1:9015:7	period	NNS	O	O
after	PRADAXA.xml:S1:9023:5	after	IN	O	O
randomization	PRADAXA.xml:S1:9029:13	random	NN	O	O
.	PRADAXA.xml:S1:9042:1	.	.	O	O

Table	PRADAXA.xml:S1:9048:5	tabl	JJ	O	O
3	PRADAXA.xml:S1:9054:1	3	CD	O	O
Bleeding	PRADAXA.xml:S1:9056:8	bleed	VBG	B-AdverseReaction	O
Events	PRADAXA.xml:S1:9065:6	event	NNS	O	O
in	PRADAXA.xml:S1:9072:2	in	IN	O	O
RE	PRADAXA.xml:S1:9075:2	RE	NNP	O	O
-	PRADAXA.xml:S1:9077:1	-	:	O	O
COVER	PRADAXA.xml:S1:9078:5	cover	NNP	O	O
and	PRADAXA.xml:S1:9084:3	and	CC	O	O
RE	PRADAXA.xml:S1:9088:2	RE	NNP	O	O
-	PRADAXA.xml:S1:9090:1	-	:	O	O
COVER	PRADAXA.xml:S1:9091:5	cover	NNP	O	O
II	PRADAXA.xml:S1:9097:2	II	NNP	O	O
Treated	PRADAXA.xml:S1:9100:7	treat	VBD	O	O
Patients	PRADAXA.xml:S1:9108:8	patient	NNS	O	O

Note	PRADAXA.xml:S1:9119:4	note	NN	O	O
:	PRADAXA.xml:S1:9123:1	:	:	O	O
MBE	PRADAXA.xml:S1:9125:3	mbe	NN	B-AdverseReaction	O
can	PRADAXA.xml:S1:9129:3	can	MD	O	O
belong	PRADAXA.xml:S1:9133:6	belong	VB	O	O
to	PRADAXA.xml:S1:9140:2	to	TO	O	O
more	PRADAXA.xml:S1:9143:4	more	JJR	O	O
than	PRADAXA.xml:S1:9148:4	than	IN	O	O
one	PRADAXA.xml:S1:9153:3	one	CD	O	O
criterion	PRADAXA.xml:S1:9157:9	criterion	NN	O	O
.	PRADAXA.xml:S1:9166:1	.	.	O	O

a	PRADAXA.xml:S1:9169:1	a	DT	O	O
Patients	PRADAXA.xml:S1:9172:8	patient	NNS	O	O
with	PRADAXA.xml:S1:9181:4	with	IN	O	O
at	PRADAXA.xml:S1:9186:2	at	IN	O	O
least	PRADAXA.xml:S1:9189:5	least	JJS	O	O
one	PRADAXA.xml:S1:9195:3	one	CD	O	O
MBE	PRADAXA.xml:S1:9199:3	mbe	NNP	B-AdverseReaction	O
.	PRADAXA.xml:S1:9202:1	.	.	O	O

b	PRADAXA.xml:S1:9205:1	b	NN	O	O
Bleeding	PRADAXA.xml:S1:9208:8	bleed	NNP	B-AdverseReaction	O
site	PRADAXA.xml:S1:9217:4	site	NN	O	O
based	PRADAXA.xml:S1:9222:5	base	VBN	O	O
on	PRADAXA.xml:S1:9228:2	on	IN	O	O
investigator	PRADAXA.xml:S1:9231:12	investig	NN	O	O
assessment	PRADAXA.xml:S1:9244:10	assess	NN	O	O
.	PRADAXA.xml:S1:9254:1	.	.	O	O

Patients	PRADAXA.xml:S1:9256:8	patient	NNS	O	O
can	PRADAXA.xml:S1:9265:3	can	MD	O	O
have	PRADAXA.xml:S1:9269:4	have	VB	O	O
more	PRADAXA.xml:S1:9274:4	more	JJR	O	O
than	PRADAXA.xml:S1:9279:4	than	IN	O	O
one	PRADAXA.xml:S1:9284:3	one	CD	O	O
site	PRADAXA.xml:S1:9288:4	site	NN	O	O
of	PRADAXA.xml:S1:9293:2	of	IN	O	O
bleeding	PRADAXA.xml:S1:9296:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
.	PRADAXA.xml:S1:9304:1	.	.	O	O

c	PRADAXA.xml:S1:9307:1	c	NNS	O	O
Confidence	PRADAXA.xml:S1:9310:10	confid	NNP	O	O
interval	PRADAXA.xml:S1:9321:8	interv	NN	O	O

Patients	PRADAXA.xml:S1:9380:8	patient	NNS	O	O

Major	PRADAXA.xml:S1:9397:5	major	JJ	O	O

bleeding	PRADAXA.xml:S1:9403:8	bleed	NN	B-AdverseReaction	B-AdverseReaction

event	PRADAXA.xml:S1:9412:5	event	NN	O	O

a	PRADAXA.xml:S1:9419:1	a	DT	O	O

Bleeding	PRADAXA.xml:S1:9487:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction

sites	PRADAXA.xml:S1:9496:5	site	NNS	O	O

for	PRADAXA.xml:S1:9502:3	for	IN	O	O

MBE	PRADAXA.xml:S1:9506:3	mbe	NNP	B-AdverseReaction	O
b	PRADAXA.xml:S1:9511:1	b	NN	O	O

Clinically	PRADAXA.xml:S1:9659:10	clinic	RB	O	O

relevant	PRADAXA.xml:S1:9670:8	relev	NN	O	O

non	PRADAXA.xml:S1:9679:3	non	NN	O	O

-	PRADAXA.xml:S1:9682:1	-	:	O	O

major	PRADAXA.xml:S1:9683:5	major	JJ	O	O

bleeding	PRADAXA.xml:S1:9689:8	bleed	NN	B-AdverseReaction	B-AdverseReaction

Any	PRADAXA.xml:S1:9703:3	ani	DT	O	O

bleeding	PRADAXA.xml:S1:9707:8	bleed	NN	B-AdverseReaction	B-AdverseReaction

The	PRADAXA.xml:S1:9727:3	the	DT	O	O

rate	PRADAXA.xml:S1:9731:4	rate	NN	O	O
of	PRADAXA.xml:S1:9736:2	of	IN	O	O
any	PRADAXA.xml:S1:9739:3	ani	DT	O	O
gastrointestinal	PRADAXA.xml:S1:9743:16	gastrointestin	JJ	B-AdverseReaction	O
bleeds	PRADAXA.xml:S1:9760:6	bleed	NNS	I-AdverseReaction	O
in	PRADAXA.xml:S1:9767:2	in	IN	O	O
patients	PRADAXA.xml:S1:9770:8	patient	NNS	O	O
receiving	PRADAXA.xml:S1:9779:9	receiv	VBG	O	O
PRADAXA	PRADAXA.xml:S1:9789:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:9797:3	150	CD	O	O
mg	PRADAXA.xml:S1:9801:2	mg	NN	O	O
in	PRADAXA.xml:S1:9804:2	in	IN	O	O
the	PRADAXA.xml:S1:9807:3	the	DT	O	O
full	PRADAXA.xml:S1:9811:4	full	JJ	O	O
treatment	PRADAXA.xml:S1:9816:9	treatment	NN	O	O
period	PRADAXA.xml:S1:9826:6	period	NN	O	O
was	PRADAXA.xml:S1:9833:3	wa	VBD	O	O
3.1%	PRADAXA.xml:S1:9837:4	3.1%	CD	O	O
(	PRADAXA.xml:S1:9842:1	(	(	O	O
2.4%	PRADAXA.xml:S1:9843:4	2.4%	CD	O	O
on	PRADAXA.xml:S1:9848:2	on	IN	O	O
warfarin	PRADAXA.xml:S1:9851:8	warfarin	NN	O	O
)	PRADAXA.xml:S1:9859:1	)	)	O	O
.	PRADAXA.xml:S1:9860:1	.	.	O	O

The	PRADAXA.xml:S1:9866:3	the	DT	O	O

RE	PRADAXA.xml:S1:9870:2	RE	NNP	O	O
-	PRADAXA.xml:S1:9872:1	-	:	O	O
MEDY	PRADAXA.xml:S1:9873:4	medi	NN	O	O
and	PRADAXA.xml:S1:9878:3	and	CC	O	O
RE	PRADAXA.xml:S1:9882:2	RE	NNP	O	O
-	PRADAXA.xml:S1:9884:1	-	:	O	O
SONATE	PRADAXA.xml:S1:9885:6	sonat	NN	O	O
studies	PRADAXA.xml:S1:9892:7	studi	NNS	O	O
provided	PRADAXA.xml:S1:9900:8	provid	VBD	O	O
safety	PRADAXA.xml:S1:9909:6	safeti	NN	O	O
information	PRADAXA.xml:S1:9916:11	inform	NN	O	O
on	PRADAXA.xml:S1:9928:2	on	IN	O	O
the	PRADAXA.xml:S1:9931:3	the	DT	O	O
use	PRADAXA.xml:S1:9935:3	use	NN	O	O
of	PRADAXA.xml:S1:9939:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S1:9942:7	pradaxa	NNP	O	O
for	PRADAXA.xml:S1:9950:3	for	IN	O	O
the	PRADAXA.xml:S1:9954:3	the	DT	O	O
reduction	PRADAXA.xml:S1:9958:9	reduct	NN	O	O
in	PRADAXA.xml:S1:9968:2	in	IN	O	O
the	PRADAXA.xml:S1:9971:3	the	DT	O	O
risk	PRADAXA.xml:S1:9975:4	risk	NN	O	O
of	PRADAXA.xml:S1:9980:2	of	IN	O	O
recurrence	PRADAXA.xml:S1:9983:10	recurr	NN	O	O
of	PRADAXA.xml:S1:9994:2	of	IN	O	O
deep	PRADAXA.xml:S1:9997:4	deep	JJ	O	B-AdverseReaction
vein	PRADAXA.xml:S1:10002:4	vein	NN	O	I-AdverseReaction
thrombosis	PRADAXA.xml:S1:10007:10	thrombosi	NN	O	I-AdverseReaction
and	PRADAXA.xml:S1:10018:3	and	CC	O	O
pulmonary	PRADAXA.xml:S1:10022:9	pulmonari	JJ	O	B-AdverseReaction
embolism	PRADAXA.xml:S1:10032:8	embol	NN	O	I-AdverseReaction
.	PRADAXA.xml:S1:10040:1	.	.	O	O

RE	PRADAXA.xml:S1:10046:2	RE	NNP	O	O
-	PRADAXA.xml:S1:10048:1	-	:	O	O
MEDY	PRADAXA.xml:S1:10049:4	medi	NNP	O	O
was	PRADAXA.xml:S1:10054:3	wa	VBD	O	O
an	PRADAXA.xml:S1:10058:2	an	DT	O	O
active	PRADAXA.xml:S1:10061:6	activ	JJ	O	O
-	PRADAXA.xml:S1:10067:1	-	:	O	O
controlled	PRADAXA.xml:S1:10068:10	control	VBN	O	O
study	PRADAXA.xml:S1:10079:5	studi	NN	O	O
(	PRADAXA.xml:S1:10085:1	(	(	O	O
warfarin	PRADAXA.xml:S1:10086:8	warfarin	NN	O	O
)	PRADAXA.xml:S1:10094:1	)	)	O	O
in	PRADAXA.xml:S1:10096:2	in	IN	O	O
which	PRADAXA.xml:S1:10099:5	which	WDT	O	O
1430	PRADAXA.xml:S1:10105:4	1430	CD	O	O
patients	PRADAXA.xml:S1:10110:8	patient	NNS	O	O
received	PRADAXA.xml:S1:10119:8	receiv	VBD	O	O
PRADAXA	PRADAXA.xml:S1:10128:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:10136:3	150	CD	O	O
mg	PRADAXA.xml:S1:10140:2	mg	NN	O	O
twice	PRADAXA.xml:S1:10143:5	twice	RB	O	O
daily	PRADAXA.xml:S1:10149:5	daili	RB	O	O
following	PRADAXA.xml:S1:10155:9	follow	VBG	O	O
3	PRADAXA.xml:S1:10165:1	3	CD	O	O
to	PRADAXA.xml:S1:10167:2	to	TO	O	O
12	PRADAXA.xml:S1:10170:2	12	CD	O	O
months	PRADAXA.xml:S1:10173:6	month	NNS	O	O
of	PRADAXA.xml:S1:10180:2	of	IN	O	O
oral	PRADAXA.xml:S1:10183:4	oral	JJ	O	O
anticoagulant	PRADAXA.xml:S1:10188:13	anticoagul	JJ	O	O
regimen	PRADAXA.xml:S1:10202:7	regimen	NNS	O	O
.	PRADAXA.xml:S1:10209:1	.	.	O	O

Patients	PRADAXA.xml:S1:10211:8	patient	NNS	O	O
in	PRADAXA.xml:S1:10220:2	in	IN	O	O
the	PRADAXA.xml:S1:10223:3	the	DT	O	O
treatment	PRADAXA.xml:S1:10227:9	treatment	NN	O	O
studies	PRADAXA.xml:S1:10237:7	studi	NNS	O	O
who	PRADAXA.xml:S1:10245:3	who	WP	O	O
rolled	PRADAXA.xml:S1:10249:6	roll	VBD	O	O
over	PRADAXA.xml:S1:10256:4	over	RB	O	O
into	PRADAXA.xml:S1:10261:4	into	IN	O	O
the	PRADAXA.xml:S1:10266:3	the	DT	O	O
RE	PRADAXA.xml:S1:10270:2	RE	NNP	O	O
-	PRADAXA.xml:S1:10272:1	-	:	O	O
MEDY	PRADAXA.xml:S1:10273:4	medi	NNP	O	O
study	PRADAXA.xml:S1:10278:5	studi	NN	O	O
had	PRADAXA.xml:S1:10284:3	had	VBD	O	O
a	PRADAXA.xml:S1:10288:1	a	DT	O	O
combined	PRADAXA.xml:S1:10290:8	combin	VBN	O	O
treatment	PRADAXA.xml:S1:10299:9	treatment	NN	O	O
duration	PRADAXA.xml:S1:10309:8	durat	NN	O	O
of	PRADAXA.xml:S1:10318:2	of	IN	O	O
up	PRADAXA.xml:S1:10321:2	up	IN	O	O
to	PRADAXA.xml:S1:10324:2	to	TO	O	O
more	PRADAXA.xml:S1:10327:4	more	JJR	O	O
than	PRADAXA.xml:S1:10332:4	than	IN	O	O
3	PRADAXA.xml:S1:10337:1	3	CD	O	O
years	PRADAXA.xml:S1:10339:5	year	NNS	O	O
,	PRADAXA.xml:S1:10344:1	,	,	O	O
with	PRADAXA.xml:S1:10346:4	with	IN	O	O
mean	PRADAXA.xml:S1:10351:4	mean	JJ	O	O
exposure	PRADAXA.xml:S1:10356:8	exposur	NN	O	O
of	PRADAXA.xml:S1:10365:2	of	IN	O	O
473	PRADAXA.xml:S1:10368:3	473	CD	O	O
days	PRADAXA.xml:S1:10372:4	day	NNS	O	O
.	PRADAXA.xml:S1:10376:1	.	.	O	O

Table	PRADAXA.xml:S1:10378:5	tabl	JJ	O	O
4	PRADAXA.xml:S1:10384:1	4	CD	O	O
shows	PRADAXA.xml:S1:10386:5	show	VBZ	O	O
the	PRADAXA.xml:S1:10392:3	the	DT	O	O
number	PRADAXA.xml:S1:10396:6	number	NN	O	O
of	PRADAXA.xml:S1:10403:2	of	IN	O	O
patients	PRADAXA.xml:S1:10406:8	patient	NNS	O	O
experiencing	PRADAXA.xml:S1:10415:12	experienc	VBG	O	O
bleeding	PRADAXA.xml:S1:10428:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
events	PRADAXA.xml:S1:10437:6	event	NNS	O	O
in	PRADAXA.xml:S1:10444:2	in	IN	O	O
the	PRADAXA.xml:S1:10447:3	the	DT	O	O
study	PRADAXA.xml:S1:10451:5	studi	NN	O	O
.	PRADAXA.xml:S1:10456:1	.	.	O	O

Table	PRADAXA.xml:S1:10462:5	tabl	JJ	O	O
4	PRADAXA.xml:S1:10468:1	4	CD	O	O
Bleeding	PRADAXA.xml:S1:10470:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
Events	PRADAXA.xml:S1:10479:6	event	NNS	O	O
in	PRADAXA.xml:S1:10486:2	in	IN	O	O
RE	PRADAXA.xml:S1:10489:2	RE	NNP	O	O
-	PRADAXA.xml:S1:10491:1	-	:	O	O
MEDY	PRADAXA.xml:S1:10492:4	medi	NNP	O	O
Treated	PRADAXA.xml:S1:10497:7	treat	VBD	O	O
Patients	PRADAXA.xml:S1:10505:8	patient	NNS	O	O

Note	PRADAXA.xml:S1:10516:4	note	NN	O	O
:	PRADAXA.xml:S1:10520:1	:	:	O	O
MBE	PRADAXA.xml:S1:10522:3	mbe	NN	B-AdverseReaction	O
can	PRADAXA.xml:S1:10526:3	can	MD	O	O
belong	PRADAXA.xml:S1:10530:6	belong	VB	O	O
to	PRADAXA.xml:S1:10537:2	to	TO	O	O
more	PRADAXA.xml:S1:10540:4	more	JJR	O	O
than	PRADAXA.xml:S1:10545:4	than	IN	O	O
one	PRADAXA.xml:S1:10550:3	one	CD	O	O
criterion	PRADAXA.xml:S1:10554:9	criterion	NN	O	O
.	PRADAXA.xml:S1:10563:1	.	.	O	O

a	PRADAXA.xml:S1:10566:1	a	DT	O	O
Patients	PRADAXA.xml:S1:10569:8	patient	NNS	O	O
with	PRADAXA.xml:S1:10578:4	with	IN	O	O
at	PRADAXA.xml:S1:10583:2	at	IN	O	O
least	PRADAXA.xml:S1:10586:5	least	JJS	O	O
one	PRADAXA.xml:S1:10592:3	one	CD	O	O
MBE	PRADAXA.xml:S1:10596:3	mbe	NNP	B-AdverseReaction	O
.	PRADAXA.xml:S1:10599:1	.	.	O	O

b	PRADAXA.xml:S1:10602:1	b	NN	O	O
Bleeding	PRADAXA.xml:S1:10605:8	bleed	NNP	B-AdverseReaction	O
site	PRADAXA.xml:S1:10614:4	site	NN	O	O
based	PRADAXA.xml:S1:10619:5	base	VBN	O	O
on	PRADAXA.xml:S1:10625:2	on	IN	O	O
investigator	PRADAXA.xml:S1:10628:12	investig	NN	O	O
assessment	PRADAXA.xml:S1:10641:10	assess	NN	O	O
.	PRADAXA.xml:S1:10651:1	.	.	O	O

Patients	PRADAXA.xml:S1:10653:8	patient	NNS	O	O
can	PRADAXA.xml:S1:10662:3	can	MD	O	O
have	PRADAXA.xml:S1:10666:4	have	VB	O	O
more	PRADAXA.xml:S1:10671:4	more	JJR	O	O
than	PRADAXA.xml:S1:10676:4	than	IN	O	O
one	PRADAXA.xml:S1:10681:3	one	CD	O	O
site	PRADAXA.xml:S1:10685:4	site	NN	O	O
of	PRADAXA.xml:S1:10690:2	of	IN	O	O
bleeding	PRADAXA.xml:S1:10693:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
.	PRADAXA.xml:S1:10701:1	.	.	O	O

c	PRADAXA.xml:S1:10704:1	c	NNS	O	O
Confidence	PRADAXA.xml:S1:10707:10	confid	NNP	O	O
interval	PRADAXA.xml:S1:10718:8	interv	NN	O	O

Patients	PRADAXA.xml:S1:10757:8	patient	NNS	O	O

Major	PRADAXA.xml:S1:10774:5	major	JJ	O	O

bleeding	PRADAXA.xml:S1:10780:8	bleed	NN	B-AdverseReaction	B-AdverseReaction

event	PRADAXA.xml:S1:10789:5	event	NN	O	O
a	PRADAXA.xml:S1:10796:1	a	DT	O	O

Bleeding	PRADAXA.xml:S1:10864:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction

sites	PRADAXA.xml:S1:10873:5	site	NNS	O	O

for	PRADAXA.xml:S1:10879:3	for	IN	O	O

MBE	PRADAXA.xml:S1:10883:3	mbe	NNP	B-AdverseReaction	O
b	PRADAXA.xml:S1:10888:1	b	NN	O	O

Clinically	PRADAXA.xml:S1:11056:10	clinic	RB	O	O

relevant	PRADAXA.xml:S1:11067:8	relev	NN	O	O

non	PRADAXA.xml:S1:11076:3	non	NN	O	O

-	PRADAXA.xml:S1:11079:1	-	:	O	O

major	PRADAXA.xml:S1:11080:5	major	JJ	O	O

bleeding	PRADAXA.xml:S1:11086:8	bleed	NN	B-AdverseReaction	B-AdverseReaction

Any	PRADAXA.xml:S1:11100:3	ani	DT	O	O

bleeding	PRADAXA.xml:S1:11104:8	bleed	NN	B-AdverseReaction	B-AdverseReaction

In	PRADAXA.xml:S1:11124:2	In	IN	O	O

the	PRADAXA.xml:S1:11127:3	the	DT	O	O

RE	PRADAXA.xml:S1:11131:2	RE	NNP	O	O
-	PRADAXA.xml:S1:11133:1	-	:	O	O
MEDY	PRADAXA.xml:S1:11134:4	medi	NNP	O	O
study	PRADAXA.xml:S1:11139:5	studi	NN	O	O
,	PRADAXA.xml:S1:11144:1	,	,	O	O
the	PRADAXA.xml:S1:11146:3	the	DT	O	O
rate	PRADAXA.xml:S1:11150:4	rate	NN	O	O
of	PRADAXA.xml:S1:11155:2	of	IN	O	O
any	PRADAXA.xml:S1:11158:3	ani	DT	O	O
gastrointestinal	PRADAXA.xml:S1:11162:16	gastrointestin	JJ	B-AdverseReaction	O
bleeds	PRADAXA.xml:S1:11179:6	bleed	NNS	I-AdverseReaction	O
in	PRADAXA.xml:S1:11186:2	in	IN	O	O
patients	PRADAXA.xml:S1:11189:8	patient	NNS	O	O
receiving	PRADAXA.xml:S1:11198:9	receiv	VBG	O	O
PRADAXA	PRADAXA.xml:S1:11208:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:11216:3	150	CD	O	O
mg	PRADAXA.xml:S1:11220:2	mg	NN	O	O
was	PRADAXA.xml:S1:11223:3	wa	VBD	O	O
3.1%	PRADAXA.xml:S1:11227:4	3.1%	CD	O	O
(	PRADAXA.xml:S1:11232:1	(	(	O	O
2.2%	PRADAXA.xml:S1:11233:4	2.2%	CD	O	O
on	PRADAXA.xml:S1:11238:2	on	IN	O	O
warfarin	PRADAXA.xml:S1:11241:8	warfarin	NN	O	O
)	PRADAXA.xml:S1:11249:1	)	)	O	O
.	PRADAXA.xml:S1:11250:1	.	.	O	O

RE	PRADAXA.xml:S1:11256:2	RE	NN	O	O

-	PRADAXA.xml:S1:11258:1	-	:	O	O
SONATE	PRADAXA.xml:S1:11259:6	sonat	NN	O	O
was	PRADAXA.xml:S1:11266:3	wa	VBD	O	O
a	PRADAXA.xml:S1:11270:1	a	DT	O	O
placebo	PRADAXA.xml:S1:11272:7	placebo	NN	O	O
-	PRADAXA.xml:S1:11279:1	-	:	O	O
controlled	PRADAXA.xml:S1:11280:10	control	VBN	O	O
study	PRADAXA.xml:S1:11291:5	studi	NN	O	O
in	PRADAXA.xml:S1:11297:2	in	IN	O	O
which	PRADAXA.xml:S1:11300:5	which	WDT	O	O
684	PRADAXA.xml:S1:11306:3	684	CD	O	O
patients	PRADAXA.xml:S1:11310:8	patient	NNS	O	O
received	PRADAXA.xml:S1:11319:8	receiv	VBD	O	O
PRADAXA	PRADAXA.xml:S1:11328:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:11336:3	150	CD	O	O
mg	PRADAXA.xml:S1:11340:2	mg	NN	O	O
twice	PRADAXA.xml:S1:11343:5	twice	RB	O	O
daily	PRADAXA.xml:S1:11349:5	daili	RB	O	O
following	PRADAXA.xml:S1:11355:9	follow	VBG	O	O
6	PRADAXA.xml:S1:11365:1	6	CD	O	O
to	PRADAXA.xml:S1:11367:2	to	TO	O	O
18	PRADAXA.xml:S1:11370:2	18	CD	O	O
months	PRADAXA.xml:S1:11373:6	month	NNS	O	O
of	PRADAXA.xml:S1:11380:2	of	IN	O	O
oral	PRADAXA.xml:S1:11383:4	oral	JJ	O	O
anticoagulant	PRADAXA.xml:S1:11388:13	anticoagul	JJ	O	O
regimen	PRADAXA.xml:S1:11402:7	regimen	NNS	O	O
.	PRADAXA.xml:S1:11409:1	.	.	O	O

Patients	PRADAXA.xml:S1:11411:8	patient	NNS	O	O
in	PRADAXA.xml:S1:11420:2	in	IN	O	O
the	PRADAXA.xml:S1:11423:3	the	DT	O	O
treatment	PRADAXA.xml:S1:11427:9	treatment	NN	O	O
studies	PRADAXA.xml:S1:11437:7	studi	NNS	O	O
who	PRADAXA.xml:S1:11445:3	who	WP	O	O
rolled	PRADAXA.xml:S1:11449:6	roll	VBD	O	O
over	PRADAXA.xml:S1:11456:4	over	RB	O	O
into	PRADAXA.xml:S1:11461:4	into	IN	O	O
the	PRADAXA.xml:S1:11466:3	the	DT	O	O
RE	PRADAXA.xml:S1:11470:2	RE	NNP	O	O
-	PRADAXA.xml:S1:11472:1	-	:	O	O
SONATE	PRADAXA.xml:S1:11473:6	sonat	NN	O	O
study	PRADAXA.xml:S1:11480:5	studi	NN	O	O
had	PRADAXA.xml:S1:11486:3	had	VBD	O	O
combined	PRADAXA.xml:S1:11490:8	combin	VBN	O	O
treatment	PRADAXA.xml:S1:11499:9	treatment	NN	O	O
duration	PRADAXA.xml:S1:11509:8	durat	NN	O	O
up	PRADAXA.xml:S1:11518:2	up	RB	O	O
to	PRADAXA.xml:S1:11521:2	to	TO	O	O
9	PRADAXA.xml:S1:11524:1	9	CD	O	O
months	PRADAXA.xml:S1:11526:6	month	NNS	O	O
,	PRADAXA.xml:S1:11532:1	,	,	O	O
with	PRADAXA.xml:S1:11534:4	with	IN	O	O
mean	PRADAXA.xml:S1:11539:4	mean	JJ	O	O
exposure	PRADAXA.xml:S1:11544:8	exposur	NN	O	O
of	PRADAXA.xml:S1:11553:2	of	IN	O	O
165	PRADAXA.xml:S1:11556:3	165	CD	O	O
days	PRADAXA.xml:S1:11560:4	day	NNS	O	O
.	PRADAXA.xml:S1:11564:1	.	.	O	O

Table	PRADAXA.xml:S1:11566:5	tabl	JJ	O	O
5	PRADAXA.xml:S1:11572:1	5	CD	O	O
shows	PRADAXA.xml:S1:11574:5	show	VBZ	O	O
the	PRADAXA.xml:S1:11580:3	the	DT	O	O
number	PRADAXA.xml:S1:11584:6	number	NN	O	O
of	PRADAXA.xml:S1:11591:2	of	IN	O	O
patients	PRADAXA.xml:S1:11594:8	patient	NNS	O	O
experiencing	PRADAXA.xml:S1:11603:12	experienc	VBG	O	O
bleeding	PRADAXA.xml:S1:11616:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
events	PRADAXA.xml:S1:11625:6	event	NNS	O	O
in	PRADAXA.xml:S1:11632:2	in	IN	O	O
the	PRADAXA.xml:S1:11635:3	the	DT	O	O
study	PRADAXA.xml:S1:11639:5	studi	NN	O	O
.	PRADAXA.xml:S1:11644:1	.	.	O	O

Table	PRADAXA.xml:S1:11650:5	tabl	JJ	O	O
5	PRADAXA.xml:S1:11656:1	5	CD	O	O
Bleeding	PRADAXA.xml:S1:11658:8	bleed	VBG	B-AdverseReaction	O
Events	PRADAXA.xml:S1:11667:6	event	NNS	O	O
in	PRADAXA.xml:S1:11674:2	in	IN	O	O
RE	PRADAXA.xml:S1:11677:2	RE	NNP	O	O
-	PRADAXA.xml:S1:11679:1	-	:	O	O
SONATE	PRADAXA.xml:S1:11680:6	sonat	NN	O	O
Treated	PRADAXA.xml:S1:11687:7	treat	VBD	O	O
Patients	PRADAXA.xml:S1:11695:8	patient	NNS	O	O

Note	PRADAXA.xml:S1:11706:4	note	NN	O	O
:	PRADAXA.xml:S1:11710:1	:	:	O	O
MBE	PRADAXA.xml:S1:11712:3	mbe	NN	B-AdverseReaction	O
can	PRADAXA.xml:S1:11716:3	can	MD	O	O
belong	PRADAXA.xml:S1:11720:6	belong	VB	O	O
to	PRADAXA.xml:S1:11727:2	to	TO	O	O
more	PRADAXA.xml:S1:11730:4	more	JJR	O	O
than	PRADAXA.xml:S1:11735:4	than	IN	O	O
one	PRADAXA.xml:S1:11740:3	one	CD	O	O
criterion	PRADAXA.xml:S1:11744:9	criterion	NN	O	O
.	PRADAXA.xml:S1:11753:1	.	.	O	O

a	PRADAXA.xml:S1:11756:1	a	DT	O	O
Patients	PRADAXA.xml:S1:11759:8	patient	NNS	O	O
with	PRADAXA.xml:S1:11768:4	with	IN	O	O
at	PRADAXA.xml:S1:11773:2	at	IN	O	O
least	PRADAXA.xml:S1:11776:5	least	JJS	O	O
one	PRADAXA.xml:S1:11782:3	one	CD	O	O
MBE	PRADAXA.xml:S1:11786:3	mbe	NNP	B-AdverseReaction	O
.	PRADAXA.xml:S1:11789:1	.	.	O	O

b	PRADAXA.xml:S1:11792:1	b	NN	O	O
Bleeding	PRADAXA.xml:S1:11795:8	bleed	NNP	B-AdverseReaction	O
site	PRADAXA.xml:S1:11804:4	site	NN	O	O
based	PRADAXA.xml:S1:11809:5	base	VBN	O	O
on	PRADAXA.xml:S1:11815:2	on	IN	O	O
investigator	PRADAXA.xml:S1:11818:12	investig	NN	O	O
assessment	PRADAXA.xml:S1:11831:10	assess	NN	O	O
.	PRADAXA.xml:S1:11841:1	.	.	O	O

Patients	PRADAXA.xml:S1:11843:8	patient	NNS	O	O
can	PRADAXA.xml:S1:11852:3	can	MD	O	O
have	PRADAXA.xml:S1:11856:4	have	VB	O	O
more	PRADAXA.xml:S1:11861:4	more	JJR	O	O
than	PRADAXA.xml:S1:11866:4	than	IN	O	O
one	PRADAXA.xml:S1:11871:3	one	CD	O	O
site	PRADAXA.xml:S1:11875:4	site	NN	O	O
of	PRADAXA.xml:S1:11880:2	of	IN	O	O
bleeding	PRADAXA.xml:S1:11883:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
.	PRADAXA.xml:S1:11891:1	.	.	O	O

c	PRADAXA.xml:S1:11894:1	c	NNS	O	O
Confidence	PRADAXA.xml:S1:11897:10	confid	NNP	O	O
interval	PRADAXA.xml:S1:11908:8	interv	NN	O	O

Patients	PRADAXA.xml:S1:11947:8	patient	NNS	O	O

Major	PRADAXA.xml:S1:11964:5	major	JJ	O	O

bleeding	PRADAXA.xml:S1:11970:8	bleed	NN	B-AdverseReaction	B-AdverseReaction

event	PRADAXA.xml:S1:11979:5	event	NN	O	O
a	PRADAXA.xml:S1:11986:1	a	DT	O	O

Clinically	PRADAXA.xml:S1:12034:10	clinic	RB	O	O

relevant	PRADAXA.xml:S1:12045:8	relev	NN	O	O

non	PRADAXA.xml:S1:12054:3	non	SYM	O	B-AdverseReaction
-	PRADAXA.xml:S1:12057:1	-	:	O	I-AdverseReaction
major	PRADAXA.xml:S1:12058:5	major	JJ	O	I-AdverseReaction
bleeding	PRADAXA.xml:S1:12064:8	bleed	NN	B-AdverseReaction	I-AdverseReaction

Any	PRADAXA.xml:S1:12078:3	ani	DT	O	O
bleeding	PRADAXA.xml:S1:12082:8	bleed	NN	B-AdverseReaction	O

In	PRADAXA.xml:S1:12102:2	In	IN	O	O
the	PRADAXA.xml:S1:12105:3	the	DT	O	O
RE	PRADAXA.xml:S1:12109:2	RE	NNP	O	O
-	PRADAXA.xml:S1:12111:1	-	:	O	O
SONATE	PRADAXA.xml:S1:12112:6	sonat	NN	O	O
study	PRADAXA.xml:S1:12119:5	studi	NN	O	O
,	PRADAXA.xml:S1:12124:1	,	,	O	O
the	PRADAXA.xml:S1:12126:3	the	DT	O	O
rate	PRADAXA.xml:S1:12130:4	rate	NN	O	O
of	PRADAXA.xml:S1:12135:2	of	IN	O	O
any	PRADAXA.xml:S1:12138:3	ani	DT	O	O
gastrointestinal	PRADAXA.xml:S1:12142:16	gastrointestin	JJ	B-AdverseReaction	O
bleeds	PRADAXA.xml:S1:12159:6	bleed	NNS	I-AdverseReaction	O
in	PRADAXA.xml:S1:12166:2	in	IN	O	O
patients	PRADAXA.xml:S1:12169:8	patient	NNS	O	O
receiving	PRADAXA.xml:S1:12178:9	receiv	VBG	O	O
PRADAXA	PRADAXA.xml:S1:12188:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:12196:3	150	CD	O	O
mg	PRADAXA.xml:S1:12200:2	mg	NN	O	O
was	PRADAXA.xml:S1:12203:3	wa	VBD	O	O
0.7%	PRADAXA.xml:S1:12207:4	0.7%	CD	O	O
(	PRADAXA.xml:S1:12212:1	(	(	O	O
0.3%	PRADAXA.xml:S1:12213:4	0.3%	CD	O	O
on	PRADAXA.xml:S1:12218:2	on	IN	O	O
placebo	PRADAXA.xml:S1:12221:7	placebo	NN	O	O
)	PRADAXA.xml:S1:12228:1	)	)	O	O
.	PRADAXA.xml:S1:12229:1	.	.	O	O

Clinical	PRADAXA.xml:S1:12237:8	clinic	JJ	O	O

Myocardial	PRADAXA.xml:S1:12246:10	myocardi	JJ	O	B-AdverseReaction
Infarction	PRADAXA.xml:S1:12257:10	infarct	NNP	O	I-AdverseReaction
Events	PRADAXA.xml:S1:12268:6	event	NNS	O	I-AdverseReaction
In	PRADAXA.xml:S1:12276:2	In	IN	O	O
the	PRADAXA.xml:S1:12279:3	the	DT	O	O
active	PRADAXA.xml:S1:12283:6	activ	JJ	O	O
-	PRADAXA.xml:S1:12289:1	-	:	O	O
controlled	PRADAXA.xml:S1:12290:10	control	VBN	O	O
VTE	PRADAXA.xml:S1:12301:3	vte	NNP	O	O
studies	PRADAXA.xml:S1:12305:7	studi	NNS	O	O
,	PRADAXA.xml:S1:12312:1	,	,	O	O
a	PRADAXA.xml:S1:12314:1	a	DT	O	O
higher	PRADAXA.xml:S1:12316:6	higher	JJR	O	O
rate	PRADAXA.xml:S1:12323:4	rate	NN	O	O
of	PRADAXA.xml:S1:12328:2	of	IN	O	O
clinical	PRADAXA.xml:S1:12331:8	clinic	JJ	O	O
myocardial	PRADAXA.xml:S1:12340:10	myocardi	JJ	B-AdverseReaction	B-AdverseReaction
infarction	PRADAXA.xml:S1:12351:10	infarct	NN	I-AdverseReaction	I-AdverseReaction
was	PRADAXA.xml:S1:12362:3	wa	VBD	O	O
reported	PRADAXA.xml:S1:12366:8	report	VBN	O	O
in	PRADAXA.xml:S1:12375:2	in	IN	O	O
patients	PRADAXA.xml:S1:12378:8	patient	NNS	O	O
who	PRADAXA.xml:S1:12387:3	who	WP	O	O
received	PRADAXA.xml:S1:12391:8	receiv	VBD	O	O
PRADAXA	PRADAXA.xml:S1:12400:7	pradaxa	NNP	O	O
[	PRADAXA.xml:S1:12408:1	[	NNP	O	O
20	PRADAXA.xml:S1:12409:2	20	CD	O	O
(	PRADAXA.xml:S1:12412:1	(	(	O	O
0.66	PRADAXA.xml:S1:12413:4	0.66	CD	O	O
per	PRADAXA.xml:S1:12418:3	per	IN	O	O
100	PRADAXA.xml:S1:12422:3	100	CD	O	O
patient	PRADAXA.xml:S1:12426:7	patient	JJ	O	O
-	PRADAXA.xml:S1:12433:1	-	:	O	O
years	PRADAXA.xml:S1:12434:5	year	NNS	O	O
)]	PRADAXA.xml:S1:12439:2	)]	VBP	O	O
than	PRADAXA.xml:S1:12442:4	than	IN	O	O
in	PRADAXA.xml:S1:12447:2	in	IN	O	O
those	PRADAXA.xml:S1:12450:5	those	DT	O	O
who	PRADAXA.xml:S1:12456:3	who	WP	O	O
received	PRADAXA.xml:S1:12460:8	receiv	VBD	O	O
warfarin	PRADAXA.xml:S1:12469:8	warfarin	JJ	O	O
[	PRADAXA.xml:S1:12478:1	[	JJ	O	O
5	PRADAXA.xml:S1:12479:1	5	CD	O	O
(	PRADAXA.xml:S1:12481:1	(	(	O	O
0.17	PRADAXA.xml:S1:12482:4	0.17	CD	O	O
per	PRADAXA.xml:S1:12487:3	per	IN	O	O
100	PRADAXA.xml:S1:12491:3	100	CD	O	O
patient	PRADAXA.xml:S1:12495:7	patient	JJ	O	O
-	PRADAXA.xml:S1:12502:1	-	:	O	O
years	PRADAXA.xml:S1:12503:5	year	NNS	O	O
)]	PRADAXA.xml:S1:12508:2	)]	VBP	O	O
.	PRADAXA.xml:S1:12510:1	.	.	O	O

In	PRADAXA.xml:S1:12512:2	In	IN	O	O
the	PRADAXA.xml:S1:12515:3	the	DT	O	O
placebo	PRADAXA.xml:S1:12519:7	placebo	NN	O	O
-	PRADAXA.xml:S1:12526:1	-	:	O	O
controlled	PRADAXA.xml:S1:12527:10	control	VBN	O	O
study	PRADAXA.xml:S1:12538:5	studi	NN	O	O
,	PRADAXA.xml:S1:12543:1	,	,	O	O
a	PRADAXA.xml:S1:12545:1	a	DT	O	O
similar	PRADAXA.xml:S1:12547:7	similar	JJ	O	O
rate	PRADAXA.xml:S1:12555:4	rate	NN	O	O
of	PRADAXA.xml:S1:12560:2	of	IN	O	O
non	PRADAXA.xml:S1:12563:3	non	JJ	O	O
-	PRADAXA.xml:S1:12566:1	-	:	O	O
fatal	PRADAXA.xml:S1:12567:5	fatal	NN	O	B-AdverseReaction
and	PRADAXA.xml:S1:12573:3	and	CC	O	O
fatal	PRADAXA.xml:S1:12577:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
clinical	PRADAXA.xml:S1:12583:8	clinic	JJ	O	O
myocardial	PRADAXA.xml:S1:12592:10	myocardi	JJ	B-AdverseReaction	B-AdverseReaction
infarction	PRADAXA.xml:S1:12603:10	infarct	NN	I-AdverseReaction	I-AdverseReaction
was	PRADAXA.xml:S1:12614:3	wa	VBD	O	O
reported	PRADAXA.xml:S1:12618:8	report	VBN	O	O
in	PRADAXA.xml:S1:12627:2	in	IN	O	O
patients	PRADAXA.xml:S1:12630:8	patient	NNS	O	O
who	PRADAXA.xml:S1:12639:3	who	WP	O	O
received	PRADAXA.xml:S1:12643:8	receiv	VBD	O	O
PRADAXA	PRADAXA.xml:S1:12652:7	pradaxa	NNP	O	O
[	PRADAXA.xml:S1:12660:1	[	NNP	O	O
1	PRADAXA.xml:S1:12661:1	1	CD	O	O
(	PRADAXA.xml:S1:12663:1	(	(	O	O
0.32	PRADAXA.xml:S1:12664:4	0.32	CD	O	O
per	PRADAXA.xml:S1:12669:3	per	IN	O	O
100	PRADAXA.xml:S1:12673:3	100	CD	O	O
patient	PRADAXA.xml:S1:12677:7	patient	JJ	O	O
-	PRADAXA.xml:S1:12684:1	-	:	O	O
years	PRADAXA.xml:S1:12685:5	year	NNS	O	O
)]	PRADAXA.xml:S1:12690:2	)]	VBP	O	O
and	PRADAXA.xml:S1:12693:3	and	CC	O	O
in	PRADAXA.xml:S1:12697:2	in	IN	O	O
those	PRADAXA.xml:S1:12700:5	those	DT	O	O
who	PRADAXA.xml:S1:12706:3	who	WP	O	O
received	PRADAXA.xml:S1:12710:8	receiv	VBD	O	O
placebo	PRADAXA.xml:S1:12719:7	placebo	NN	O	O
[	PRADAXA.xml:S1:12727:1	[	NN	O	O
1	PRADAXA.xml:S1:12728:1	1	CD	O	O
(	PRADAXA.xml:S1:12730:1	(	(	O	O
0.34	PRADAXA.xml:S1:12731:4	0.34	CD	O	O
per	PRADAXA.xml:S1:12736:3	per	IN	O	O
100	PRADAXA.xml:S1:12740:3	100	CD	O	O
patient	PRADAXA.xml:S1:12744:7	patient	JJ	O	O
-	PRADAXA.xml:S1:12751:1	-	:	O	O
years	PRADAXA.xml:S1:12752:5	year	NNS	O	O
)]	PRADAXA.xml:S1:12757:2	)]	VBP	O	O
.	PRADAXA.xml:S1:12759:1	.	.	O	O

Gastrointestinal	PRADAXA.xml:S1:12767:16	gastrointestin	JJ	O	O
Adverse	PRADAXA.xml:S1:12784:7	advers	NNP	O	O
Reactions	PRADAXA.xml:S1:12792:9	reaction	NNP	O	O
In	PRADAXA.xml:S1:12803:2	In	IN	O	O
the	PRADAXA.xml:S1:12806:3	the	DT	O	O
four	PRADAXA.xml:S1:12810:4	four	CD	O	O
pivotal	PRADAXA.xml:S1:12815:7	pivot	JJ	O	O
studies	PRADAXA.xml:S1:12823:7	studi	NNS	O	O
,	PRADAXA.xml:S1:12830:1	,	,	O	O
patients	PRADAXA.xml:S1:12832:8	patient	NNS	O	O
on	PRADAXA.xml:S1:12841:2	on	IN	O	O
PRADAXA	PRADAXA.xml:S1:12844:7	pradaxa	NNP	O	O
150	PRADAXA.xml:S1:12852:3	150	CD	O	O
mg	PRADAXA.xml:S1:12856:2	mg	NN	O	O
had	PRADAXA.xml:S1:12859:3	had	VBD	O	O
a	PRADAXA.xml:S1:12863:1	a	DT	O	O
similar	PRADAXA.xml:S1:12865:7	similar	JJ	O	O
incidence	PRADAXA.xml:S1:12873:9	incid	NN	O	O
of	PRADAXA.xml:S1:12883:2	of	IN	O	O
gastrointestinal	PRADAXA.xml:S1:12886:16	gastrointestin	JJ	B-AdverseReaction	O
adverse	PRADAXA.xml:S1:12903:7	advers	JJ	I-AdverseReaction	O
reactions	PRADAXA.xml:S1:12911:9	reaction	NNS	I-AdverseReaction	O
(	PRADAXA.xml:S1:12921:1	(	(	O	O
24.7%	PRADAXA.xml:S1:12922:5	24.7%	CD	O	O
vs	PRADAXA.xml:S1:12928:2	vs	NN	O	O
.	PRADAXA.xml:S1:12930:1	.	.	O	O

22.7%	PRADAXA.xml:S1:12932:5	22.7%	CD	O	O
on	PRADAXA.xml:S1:12938:2	on	IN	O	O
warfarin	PRADAXA.xml:S1:12941:8	warfarin	NN	O	O
)	PRADAXA.xml:S1:12949:1	)	)	O	O
.	PRADAXA.xml:S1:12950:1	.	.	O	O

Dyspepsia	PRADAXA.xml:S1:12952:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
(	PRADAXA.xml:S1:12962:1	(	(	O	O
including	PRADAXA.xml:S1:12963:9	includ	VBG	O	O
abdominal	PRADAXA.xml:S1:12973:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	PRADAXA.xml:S1:12983:4	pain	NN	I-AdverseReaction	I-AdverseReaction
upper	PRADAXA.xml:S1:12988:5	upper	JJ	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:12993:1	,	,	O	O
abdominal	PRADAXA.xml:S1:12995:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	PRADAXA.xml:S1:13005:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:13009:1	,	,	O	O
abdominal	PRADAXA.xml:S1:13011:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	PRADAXA.xml:S1:13021:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:13031:1	,	,	O	O
and	PRADAXA.xml:S1:13033:3	and	CC	O	O
epigastric	PRADAXA.xml:S1:13037:10	epigastr	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	PRADAXA.xml:S1:13048:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
)	PRADAXA.xml:S1:13058:1	)	)	O	O
occurred	PRADAXA.xml:S1:13060:8	occur	VBD	O	O
in	PRADAXA.xml:S1:13069:2	in	IN	O	O
patients	PRADAXA.xml:S1:13072:8	patient	NNS	O	O
on	PRADAXA.xml:S1:13081:2	on	IN	O	O
PRADAXA	PRADAXA.xml:S1:13084:7	pradaxa	NNP	O	O
in	PRADAXA.xml:S1:13092:2	in	IN	O	O
7.5%	PRADAXA.xml:S1:13095:4	7.5%	CD	O	O
vs	PRADAXA.xml:S1:13100:2	vs	NN	O	O
.	PRADAXA.xml:S1:13102:1	.	.	O	O

5.5%	PRADAXA.xml:S1:13104:4	5.5%	CD	O	O
on	PRADAXA.xml:S1:13109:2	on	IN	O	O
warfarin	PRADAXA.xml:S1:13112:8	warfarin	NN	O	O
,	PRADAXA.xml:S1:13120:1	,	,	O	O
and	PRADAXA.xml:S1:13122:3	and	CC	O	O
gastritis	PRADAXA.xml:S1:13126:9	gastriti	SYM	B-AdverseReaction	B-AdverseReaction
-	PRADAXA.xml:S1:13135:1	-	:	O	I-AdverseReaction
like	PRADAXA.xml:S1:13136:4	like	IN	O	I-AdverseReaction
symptoms	PRADAXA.xml:S1:13141:8	symptom	NNS	O	I-AdverseReaction
(	PRADAXA.xml:S1:13150:1	(	(	O	O
including	PRADAXA.xml:S1:13151:9	includ	VBG	O	O
gastritis	PRADAXA.xml:S1:13161:9	gastriti	NN	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:13170:1	,	,	O	O
GERD	PRADAXA.xml:S1:13172:4	gerd	NNP	B-AdverseReaction	O
,	PRADAXA.xml:S1:13176:1	,	,	O	O
esophagitis	PRADAXA.xml:S1:13178:11	esophag	NN	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:13189:1	,	,	O	O
erosive	PRADAXA.xml:S1:13191:7	eros	JJ	B-AdverseReaction	B-AdverseReaction
gastritis	PRADAXA.xml:S1:13199:9	gastriti	NN	I-AdverseReaction	I-AdverseReaction
and	PRADAXA.xml:S1:13209:3	and	CC	O	O
gastric	PRADAXA.xml:S1:13213:7	gastric	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:13221:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
)	PRADAXA.xml:S1:13231:1	)	)	O	O
occurred	PRADAXA.xml:S1:13233:8	occur	VBD	O	O
at	PRADAXA.xml:S1:13242:2	at	IN	O	O
3.0%	PRADAXA.xml:S1:13245:4	3.0%	CD	O	O
vs	PRADAXA.xml:S1:13250:2	vs	NN	O	O
.	PRADAXA.xml:S1:13252:1	.	.	O	O

1.7%	PRADAXA.xml:S1:13254:4	1.7%	CD	O	O
,	PRADAXA.xml:S1:13258:1	,	,	O	O
respectively	PRADAXA.xml:S1:13260:12	respect	RB	O	O
.	PRADAXA.xml:S1:13272:1	.	.	O	O

Hypersensitivity	PRADAXA.xml:S1:13280:16	hypersensit	NNP	O	B-AdverseReaction
Reactions	PRADAXA.xml:S1:13297:9	reaction	NNP	O	I-AdverseReaction
In	PRADAXA.xml:S1:13308:2	In	IN	O	O
the	PRADAXA.xml:S1:13311:3	the	DT	O	O
4	PRADAXA.xml:S1:13315:1	4	CD	O	O
pivotal	PRADAXA.xml:S1:13317:7	pivot	JJ	O	O
studies	PRADAXA.xml:S1:13325:7	studi	NNS	O	O
,	PRADAXA.xml:S1:13332:1	,	,	O	O
drug	PRADAXA.xml:S1:13334:4	drug	NN	O	O
hypersensitivity	PRADAXA.xml:S1:13339:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
(	PRADAXA.xml:S1:13356:1	(	(	O	O
including	PRADAXA.xml:S1:13357:9	includ	VBG	O	O
urticaria	PRADAXA.xml:S1:13367:9	urticaria	NNS	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:13376:1	,	,	O	O
rash	PRADAXA.xml:S1:13378:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:13382:1	,	,	O	O
and	PRADAXA.xml:S1:13384:3	and	CC	O	O
pruritus	PRADAXA.xml:S1:13388:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
)	PRADAXA.xml:S1:13396:1	)	)	O	O
,	PRADAXA.xml:S1:13397:1	,	,	O	O
allergic	PRADAXA.xml:S1:13399:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
edema	PRADAXA.xml:S1:13408:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:13413:1	,	,	O	O
anaphylactic	PRADAXA.xml:S1:13415:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reaction	PRADAXA.xml:S1:13428:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S1:13436:1	,	,	O	O
and	PRADAXA.xml:S1:13438:3	and	CC	O	O
anaphylactic	PRADAXA.xml:S1:13442:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
shock	PRADAXA.xml:S1:13455:5	shock	NN	I-AdverseReaction	I-AdverseReaction
were	PRADAXA.xml:S1:13461:4	were	VBD	O	O
reported	PRADAXA.xml:S1:13466:8	report	VBN	O	O
in	PRADAXA.xml:S1:13475:2	in	IN	O	O
0.1%	PRADAXA.xml:S1:13478:4	0.1%	CD	O	O
of	PRADAXA.xml:S1:13483:2	of	IN	O	O
patients	PRADAXA.xml:S1:13486:8	patient	NNS	O	O
receiving	PRADAXA.xml:S1:13495:9	receiv	VBG	O	O
PRADAXA	PRADAXA.xml:S1:13505:7	pradaxa	NNP	O	O
.	PRADAXA.xml:S1:13512:1	.	.	O	O

6.2	PRADAXA.xml:S1:13520:3	6.2	CD	O	O
Postmarketing	PRADAXA.xml:S1:13524:13	postmarket	VBG	O	O
Experience	PRADAXA.xml:S1:13538:10	experi	NN	O	O

The	PRADAXA.xml:S1:13552:3	the	DT	O	O
following	PRADAXA.xml:S1:13556:9	follow	JJ	O	O
adverse	PRADAXA.xml:S1:13566:7	advers	JJ	O	O
reactions	PRADAXA.xml:S1:13574:9	reaction	NNS	O	O
have	PRADAXA.xml:S1:13584:4	have	VBP	O	O
been	PRADAXA.xml:S1:13589:4	been	VBN	O	O
identified	PRADAXA.xml:S1:13594:10	identifi	VBN	O	O
during	PRADAXA.xml:S1:13605:6	dure	IN	O	O
post	PRADAXA.xml:S1:13612:4	post	NN	O	O
approval	PRADAXA.xml:S1:13617:8	approv	NN	O	O
use	PRADAXA.xml:S1:13626:3	use	NN	O	O
of	PRADAXA.xml:S1:13630:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S1:13633:7	pradaxa	NNP	O	O
.	PRADAXA.xml:S1:13640:1	.	.	O	O

Because	PRADAXA.xml:S1:13642:7	becaus	IN	O	O
these	PRADAXA.xml:S1:13650:5	these	DT	O	O
reactions	PRADAXA.xml:S1:13656:9	reaction	NNS	O	O
are	PRADAXA.xml:S1:13666:3	are	VBP	O	O
reported	PRADAXA.xml:S1:13670:8	report	VBN	O	O
voluntarily	PRADAXA.xml:S1:13679:11	voluntarili	RB	O	O
from	PRADAXA.xml:S1:13691:4	from	IN	O	O
a	PRADAXA.xml:S1:13696:1	a	DT	O	O
population	PRADAXA.xml:S1:13698:10	popul	NN	O	O
of	PRADAXA.xml:S1:13709:2	of	IN	O	O
uncertain	PRADAXA.xml:S1:13712:9	uncertain	JJ	O	O
size	PRADAXA.xml:S1:13722:4	size	NN	O	O
,	PRADAXA.xml:S1:13726:1	,	,	O	O
it	PRADAXA.xml:S1:13728:2	it	PRP	O	O
is	PRADAXA.xml:S1:13731:2	is	VBZ	O	O
not	PRADAXA.xml:S1:13734:3	not	RB	O	O
always	PRADAXA.xml:S1:13738:6	alway	RB	O	O
possible	PRADAXA.xml:S1:13745:8	possibl	JJ	O	O
to	PRADAXA.xml:S1:13754:2	to	TO	O	O
reliably	PRADAXA.xml:S1:13757:8	reliabl	VB	O	O
estimate	PRADAXA.xml:S1:13766:8	estim	VB	O	O
their	PRADAXA.xml:S1:13775:5	their	PRP$	O	O
frequency	PRADAXA.xml:S1:13781:9	frequenc	NN	O	O
or	PRADAXA.xml:S1:13791:2	or	CC	O	O
establish	PRADAXA.xml:S1:13794:9	establish	VB	O	O
a	PRADAXA.xml:S1:13804:1	a	DT	O	O
causal	PRADAXA.xml:S1:13806:6	causal	NN	O	O
relationship	PRADAXA.xml:S1:13813:12	relationship	NN	O	O
to	PRADAXA.xml:S1:13826:2	to	TO	O	O
drug	PRADAXA.xml:S1:13829:4	drug	NN	O	O
exposure	PRADAXA.xml:S1:13834:8	exposur	NN	O	O
.	PRADAXA.xml:S1:13842:1	.	.	O	O

The	PRADAXA.xml:S1:13844:3	the	DT	O	O
following	PRADAXA.xml:S1:13848:9	follow	JJ	O	O
adverse	PRADAXA.xml:S1:13858:7	advers	JJ	O	O
reactions	PRADAXA.xml:S1:13866:9	reaction	NNS	O	O
have	PRADAXA.xml:S1:13876:4	have	VBP	O	O
been	PRADAXA.xml:S1:13881:4	been	VBN	O	O
identified	PRADAXA.xml:S1:13886:10	identifi	VBN	O	O
during	PRADAXA.xml:S1:13897:6	dure	IN	O	O
post	PRADAXA.xml:S1:13904:4	post	NN	O	O
approval	PRADAXA.xml:S1:13909:8	approv	NN	O	O
use	PRADAXA.xml:S1:13918:3	use	NN	O	O
of	PRADAXA.xml:S1:13922:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S1:13925:7	pradaxa	NNP	O	O
:	PRADAXA.xml:S1:13932:1	:	:	O	O
angioedema	PRADAXA.xml:S1:13934:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:13944:1	,	,	O	O
thrombocytopenia	PRADAXA.xml:S1:13946:16	thrombocytopenia	NN	B-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S1:13962:1	,	,	O	O
esophageal	PRADAXA.xml:S1:13964:10	esophag	JJ	B-AdverseReaction	B-AdverseReaction
ulcer	PRADAXA.xml:S1:13975:5	ulcer	NN	I-AdverseReaction	I-AdverseReaction
.	PRADAXA.xml:S1:13980:1	.	.	O	O
\n\n	PRADAXA.xml:S2:0:2	\n\n	VB	O	O
BOXED	PRADAXA.xml:S2:6:5	box	NNP	O	O
WARNING	PRADAXA.xml:S2:12:7	warn	NNP	O	O
:	PRADAXA.xml:S2:19:1	:	:	O	O
WARNING	PRADAXA.xml:S2:21:7	warn	NN	O	O
:	PRADAXA.xml:S2:28:1	:	:	O	O
(	PRADAXA.xml:S2:30:1	(	(	O	O
A	PRADAXA.xml:S2:31:1	A	DT	O	O
)	PRADAXA.xml:S2:32:1	)	)	O	O
PREMATURE	PRADAXA.xml:S2:34:9	prematur	NNP	O	O
DISCONTINUATION	PRADAXA.xml:S2:44:15	discontinu	NNP	O	O
OF	PRADAXA.xml:S2:60:2	OF	NNP	O	O
PRADAXA	PRADAXA.xml:S2:63:7	pradaxa	NNP	O	O
INCREASES	PRADAXA.xml:S2:71:9	increas	NNP	O	O
THE	PRADAXA.xml:S2:81:3	the	NNP	O	O
RISK	PRADAXA.xml:S2:85:4	risk	NNP	O	O
\n\n	PRADAXA.xml:S2:89:2	\n\n	NNP	O	O
OF	PRADAXA.xml:S2:91:2	OF	NNP	O	O
THROMBOTIC	PRADAXA.xml:S2:94:10	thrombot	NNP	O	O
EVENTS	PRADAXA.xml:S2:105:6	event	NNP	O	O
,	PRADAXA.xml:S2:111:1	,	,	O	O
(	PRADAXA.xml:S2:113:1	(	(	O	O
B	PRADAXA.xml:S2:114:1	B	NNP	O	O
)	PRADAXA.xml:S2:115:1	)	)	O	O
SPINAL	PRADAXA.xml:S2:117:6	spinal	NNP	B-AdverseReaction	B-AdverseReaction
EPIDURAL	PRADAXA.xml:S2:124:8	epidur	NNP	B-AdverseReaction	B-AdverseReaction
HEMATOMA	PRADAXA.xml:S2:133:8	hematoma	NNP	I-AdverseReaction	I-AdverseReaction
\n\n	PRADAXA.xml:S2:141:2	\n\n	NNP	O	O
WARNING	PRADAXA.xml:S2:145:7	warn	NN	O	O
:	PRADAXA.xml:S2:152:1	:	:	O	O
(	PRADAXA.xml:S2:154:1	(	(	O	O
A	PRADAXA.xml:S2:155:1	A	DT	O	O
)	PRADAXA.xml:S2:156:1	)	)	O	O
PREMATURE	PRADAXA.xml:S2:158:9	prematur	NNP	O	O
DISCONTINUATION	PRADAXA.xml:S2:168:15	discontinu	NNP	O	O
OF	PRADAXA.xml:S2:184:2	OF	NNP	O	O
PRADAXA	PRADAXA.xml:S2:187:7	pradaxa	NNP	O	O
INCREASES	PRADAXA.xml:S2:195:9	increas	NNP	O	O
THE	PRADAXA.xml:S2:205:3	the	NNP	O	O
RISK	PRADAXA.xml:S2:209:4	risk	NNP	O	O
\n\n	PRADAXA.xml:S2:213:2	\n\n	NNP	O	O
OF	PRADAXA.xml:S2:215:2	OF	NNP	O	O
THROMBOTIC	PRADAXA.xml:S2:218:10	thrombot	NNP	O	O
EVENTS	PRADAXA.xml:S2:229:6	event	NNP	O	O
,	PRADAXA.xml:S2:235:1	,	,	O	O
(	PRADAXA.xml:S2:237:1	(	(	O	O
B	PRADAXA.xml:S2:238:1	B	NNP	O	O
)	PRADAXA.xml:S2:239:1	)	)	O	O
SPINAL	PRADAXA.xml:S2:241:6	spinal	NNP	B-AdverseReaction	B-AdverseReaction
EPIDURAL	PRADAXA.xml:S2:248:8	epidur	NNP	B-AdverseReaction	B-AdverseReaction
HEMATOMA	PRADAXA.xml:S2:257:8	hematoma	NNP	I-AdverseReaction	I-AdverseReaction
\n\n	PRADAXA.xml:S2:265:2	\n\n	NNP	O	O
(	PRADAXA.xml:S2:271:1	(	(	O	O
A	PRADAXA.xml:S2:272:1	A	NNP	O	O
)	PRADAXA.xml:S2:273:1	)	)	O	O
PREMATURE	PRADAXA.xml:S2:275:9	prematur	NNP	O	O
DISCONTINUATION	PRADAXA.xml:S2:285:15	discontinu	NNP	O	O
\n\n	PRADAXA.xml:S2:300:2	\n\n	NNP	O	O
OF	PRADAXA.xml:S2:302:2	OF	NNP	O	O
PRADAXA	PRADAXA.xml:S2:305:7	pradaxa	NNP	O	O
INCREASES	PRADAXA.xml:S2:313:9	increas	NNP	O	O
THE	PRADAXA.xml:S2:323:3	the	NNP	O	O
RISK	PRADAXA.xml:S2:327:4	risk	NNP	O	O
OF	PRADAXA.xml:S2:332:2	OF	NNP	O	O
THROMBOTIC	PRADAXA.xml:S2:335:10	thrombot	NNP	O	O
EVENTSPremature	PRADAXA.xml:S2:346:15	eventsprematur	NNP	O	O
\n\n	PRADAXA.xml:S2:361:2	\n\n	NNP	O	O
discontinuation	PRADAXA.xml:S2:363:15	discontinu	NN	O	O
of	PRADAXA.xml:S2:379:2	of	IN	O	O
any	PRADAXA.xml:S2:382:3	ani	DT	O	O
oral	PRADAXA.xml:S2:386:4	oral	JJ	O	O
anticoagulant	PRADAXA.xml:S2:391:13	anticoagul	NN	O	O
,	PRADAXA.xml:S2:404:1	,	,	O	O
including	PRADAXA.xml:S2:406:9	includ	VBG	O	O
PRADAXA	PRADAXA.xml:S2:416:7	pradaxa	NNP	O	O
,	PRADAXA.xml:S2:423:1	,	,	O	O
increases	PRADAXA.xml:S2:425:9	increas	VBZ	O	O
\n\n	PRADAXA.xml:S2:434:2	\n\n	VBP	O	O
the	PRADAXA.xml:S2:436:3	the	DT	O	O
risk	PRADAXA.xml:S2:440:4	risk	NN	O	O
of	PRADAXA.xml:S2:445:2	of	IN	O	O
thrombotic	PRADAXA.xml:S2:448:10	thrombot	JJ	O	B-AdverseReaction
events	PRADAXA.xml:S2:459:6	event	NNS	O	I-AdverseReaction
.	PRADAXA.xml:S2:465:1	.	.	O	O

If	PRADAXA.xml:S2:467:2	If	IN	O	O
anticoagulation	PRADAXA.xml:S2:470:15	anticoagul	NN	O	O
with	PRADAXA.xml:S2:486:4	with	IN	O	O
PRADAXA	PRADAXA.xml:S2:491:7	pradaxa	NNP	O	O
is	PRADAXA.xml:S2:499:2	is	VBZ	O	O
\n\n	PRADAXA.xml:S2:501:2	\n\n	JJ	O	O
discontinued	PRADAXA.xml:S2:503:12	discontinu	VBN	O	O
for	PRADAXA.xml:S2:516:3	for	IN	O	O
a	PRADAXA.xml:S2:520:1	a	DT	O	O
reason	PRADAXA.xml:S2:522:6	reason	NN	O	O
other	PRADAXA.xml:S2:529:5	other	JJ	O	O
than	PRADAXA.xml:S2:535:4	than	IN	O	O
pathological	PRADAXA.xml:S2:540:12	patholog	JJ	O	O
bleeding	PRADAXA.xml:S2:553:8	bleed	NN	O	O
or	PRADAXA.xml:S2:562:2	or	CC	O	O
completion	PRADAXA.xml:S2:565:10	complet	NN	O	O
\n\n	PRADAXA.xml:S2:575:2	\n\n	NN	O	O
of	PRADAXA.xml:S2:577:2	of	IN	O	O
a	PRADAXA.xml:S2:580:1	a	DT	O	O
course	PRADAXA.xml:S2:582:6	cours	NN	O	O
of	PRADAXA.xml:S2:589:2	of	IN	O	O
therapy	PRADAXA.xml:S2:592:7	therapi	NN	O	O
,	PRADAXA.xml:S2:599:1	,	,	O	O
consider	PRADAXA.xml:S2:601:8	consid	VB	O	O
coverage	PRADAXA.xml:S2:610:8	coverag	NN	O	O
with	PRADAXA.xml:S2:619:4	with	IN	O	O
another	PRADAXA.xml:S2:624:7	anoth	DT	O	O
anticoagulant	PRADAXA.xml:S2:632:13	anticoagul	JJ	O	O
[	PRADAXA.xml:S2:648:1	[	NN	O	O
see	PRADAXA.xml:S2:649:3	see	VBP	O	O
Dosage	PRADAXA.xml:S2:653:6	dosag	NNP	O	O
and	PRADAXA.xml:S2:660:3	and	CC	O	O
Administration	PRADAXA.xml:S2:664:14	administr	NNP	O	O
(	PRADAXA.xml:S2:681:1	(	(	O	O
2.4	PRADAXA.xml:S2:682:3	2.4	CD	O	O
,	PRADAXA.xml:S2:687:1	,	,	O	O
2.5	PRADAXA.xml:S2:691:3	2.5	CD	O	O
,	PRADAXA.xml:S2:696:1	,	,	O	O
2.6	PRADAXA.xml:S2:700:3	2.6	CD	O	O
)	PRADAXA.xml:S2:703:1	)	)	O	O
and	PRADAXA.xml:S2:707:3	and	CC	O	O
Warnings	PRADAXA.xml:S2:711:8	warn	NNP	O	O
and	PRADAXA.xml:S2:720:3	and	CC	O	O
Precautions	PRADAXA.xml:S2:724:11	precaut	NNP	O	O
(	PRADAXA.xml:S2:738:1	(	(	O	O
5.1	PRADAXA.xml:S2:739:3	5.1	CD	O	O
)	PRADAXA.xml:S2:742:1	)	)	O	O
]	PRADAXA.xml:S2:745:1	]	NN	O	O
.	PRADAXA.xml:S2:748:1	.	.	O	O

(	PRADAXA.xml:S2:753:1	(	(	O	O
B	PRADAXA.xml:S2:754:1	B	NNP	O	O
)	PRADAXA.xml:S2:755:1	)	)	O	O
SPINAL	PRADAXA.xml:S2:757:6	spinal	NNP	O	O
EPIDURAL	PRADAXA.xml:S2:764:8	epidur	NNP	O	O
\n\n	PRADAXA.xml:S2:772:2	\n\n	NNP	O	O
HEMATOMAEpidural	PRADAXA.xml:S2:774:16	hematomaepidur	NNP	B-AdverseReaction	O
or	PRADAXA.xml:S2:791:2	or	CC	O	O
spinal	PRADAXA.xml:S2:794:6	spinal	JJ	B-AdverseReaction	B-AdverseReaction
hematomas	PRADAXA.xml:S2:801:9	hematoma	NN	I-AdverseReaction	I-AdverseReaction
may	PRADAXA.xml:S2:811:3	may	MD	O	O
occur	PRADAXA.xml:S2:815:5	occur	VB	O	O
in	PRADAXA.xml:S2:821:2	in	IN	O	O
patients	PRADAXA.xml:S2:824:8	patient	NNS	O	O
\n\n	PRADAXA.xml:S2:832:2	\n\n	JJ	O	O
treated	PRADAXA.xml:S2:834:7	treat	VBN	O	O
with	PRADAXA.xml:S2:842:4	with	IN	O	O
PRADAXA	PRADAXA.xml:S2:847:7	pradaxa	NNP	O	O
who	PRADAXA.xml:S2:855:3	who	WP	O	O
are	PRADAXA.xml:S2:859:3	are	VBP	O	O
receiving	PRADAXA.xml:S2:863:9	receiv	VBG	O	O
neuraxial	PRADAXA.xml:S2:873:9	neuraxi	JJ	O	O
anesthesia	PRADAXA.xml:S2:883:10	anesthesia	NN	O	O
or	PRADAXA.xml:S2:894:2	or	CC	O	O
undergoing	PRADAXA.xml:S2:897:10	undergo	JJ	O	O
\n\n	PRADAXA.xml:S2:907:2	\n\n	JJ	O	O
spinal	PRADAXA.xml:S2:909:6	spinal	JJ	O	O
puncture	PRADAXA.xml:S2:916:8	punctur	NN	O	O
.	PRADAXA.xml:S2:924:1	.	.	O	O

These	PRADAXA.xml:S2:926:5	these	DT	O	O
hematomas	PRADAXA.xml:S2:932:9	hematoma	NN	B-AdverseReaction	B-AdverseReaction
may	PRADAXA.xml:S2:942:3	may	MD	O	O
result	PRADAXA.xml:S2:946:6	result	VB	O	O
in	PRADAXA.xml:S2:953:2	in	IN	O	O
long	PRADAXA.xml:S2:956:4	long	JJ	B-AdverseReaction	B-AdverseReaction
-	PRADAXA.xml:S2:960:1	-	:	I-AdverseReaction	I-AdverseReaction
term	PRADAXA.xml:S2:961:4	term	NN	I-AdverseReaction	I-AdverseReaction
or	PRADAXA.xml:S2:966:2	or	CC	O	O
permanent	PRADAXA.xml:S2:969:9	perman	JJ	B-AdverseReaction	O
\n\n	PRADAXA.xml:S2:978:2	\n\n	JJ	I-AdverseReaction	O
paralysis	PRADAXA.xml:S2:980:9	paralysi	NN	I-AdverseReaction	O
.	PRADAXA.xml:S2:989:1	.	.	O	O

Consider	PRADAXA.xml:S2:991:8	consid	VB	O	O
these	PRADAXA.xml:S2:1000:5	these	DT	O	O
risks	PRADAXA.xml:S2:1006:5	risk	NNS	O	O
when	PRADAXA.xml:S2:1012:4	when	WRB	O	O
scheduling	PRADAXA.xml:S2:1017:10	schedul	VBG	O	O
patients	PRADAXA.xml:S2:1028:8	patient	NNS	O	O
for	PRADAXA.xml:S2:1037:3	for	IN	O	O
spinal	PRADAXA.xml:S2:1041:6	spinal	JJ	O	O
\n\n	PRADAXA.xml:S2:1047:2	\n\n	NN	O	O
procedures	PRADAXA.xml:S2:1049:10	procedur	NNS	O	O
.	PRADAXA.xml:S2:1059:1	.	.	O	O

Factors	PRADAXA.xml:S2:1061:7	factor	NNS	O	O
that	PRADAXA.xml:S2:1069:4	that	WDT	O	O
can	PRADAXA.xml:S2:1074:3	can	MD	O	O
increase	PRADAXA.xml:S2:1078:8	increas	VB	O	O
the	PRADAXA.xml:S2:1087:3	the	DT	O	O
risk	PRADAXA.xml:S2:1091:4	risk	NN	O	O
of	PRADAXA.xml:S2:1096:2	of	IN	O	O
developing	PRADAXA.xml:S2:1099:10	develop	VBG	O	O
epidural	PRADAXA.xml:S2:1110:8	epidur	JJ	O	O
\n\n	PRADAXA.xml:S2:1118:2	\n\n	NN	O	O
or	PRADAXA.xml:S2:1120:2	or	CC	O	O
spinal	PRADAXA.xml:S2:1123:6	spinal	JJ	O	B-AdverseReaction
hematomas	PRADAXA.xml:S2:1130:9	hematoma	NN	O	I-AdverseReaction
in	PRADAXA.xml:S2:1140:2	in	IN	O	O
these	PRADAXA.xml:S2:1143:5	these	DT	O	O
patients	PRADAXA.xml:S2:1149:8	patient	NNS	O	O
include	PRADAXA.xml:S2:1158:7	includ	VBP	O	O
:	PRADAXA.xml:S2:1165:1	:	:	O	O
\n\n\n\n	PRADAXA.xml:S2:1168:4	\n\n\n\n	JJ	O	O
use	PRADAXA.xml:S2:1177:3	use	NN	O	O
of	PRADAXA.xml:S2:1181:2	of	IN	O	O
indwelling	PRADAXA.xml:S2:1184:10	indwel	VBG	O	O
epidural	PRADAXA.xml:S2:1195:8	epidur	JJ	O	O
catheters	PRADAXA.xml:S2:1204:9	cathet	NNS	O	O
concomitant	PRADAXA.xml:S2:1215:11	concomit	VBP	O	O
use	PRADAXA.xml:S2:1227:3	use	NN	O	O
of	PRADAXA.xml:S2:1231:2	of	IN	O	O
other	PRADAXA.xml:S2:1234:5	other	JJ	O	O
drugs	PRADAXA.xml:S2:1240:5	drug	NNS	O	O
that	PRADAXA.xml:S2:1246:4	that	IN	O	O
affect	PRADAXA.xml:S2:1251:6	affect	JJ	O	O
hemostasis	PRADAXA.xml:S2:1258:10	hemostasi	NN	O	O
,	PRADAXA.xml:S2:1268:1	,	,	O	O
such	PRADAXA.xml:S2:1270:4	such	JJ	O	O
as	PRADAXA.xml:S2:1275:2	as	IN	O	O
\n\n	PRADAXA.xml:S2:1277:2	\n\n	NNP	O	O
non	PRADAXA.xml:S2:1279:3	non	SYM	O	O
-	PRADAXA.xml:S2:1282:1	-	:	O	O
steroidal	PRADAXA.xml:S2:1283:9	steroid	NN	O	O
anti	PRADAXA.xml:S2:1293:4	anti	SYM	O	O
-	PRADAXA.xml:S2:1297:1	-	:	O	O
inflammatory	PRADAXA.xml:S2:1298:12	inflammatori	NN	O	O
drugs	PRADAXA.xml:S2:1311:5	drug	NNS	O	O
(	PRADAXA.xml:S2:1317:1	(	(	O	O
NSAIDs	PRADAXA.xml:S2:1318:6	nsaid	NNP	O	O
)	PRADAXA.xml:S2:1324:1	)	)	O	O
,	PRADAXA.xml:S2:1325:1	,	,	O	O
platelet	PRADAXA.xml:S2:1327:8	platelet	JJ	O	O
inhibitors	PRADAXA.xml:S2:1336:10	inhibitor	NNS	O	O
,	PRADAXA.xml:S2:1346:1	,	,	O	O
\n\n	PRADAXA.xml:S2:1347:2	\n\n	FW	O	O
other	PRADAXA.xml:S2:1349:5	other	JJ	O	O
anticoagulants	PRADAXA.xml:S2:1355:14	anticoagul	NNS	O	O
a	PRADAXA.xml:S2:1371:1	a	DT	O	O
history	PRADAXA.xml:S2:1373:7	histori	NN	O	O
of	PRADAXA.xml:S2:1381:2	of	IN	O	O
traumatic	PRADAXA.xml:S2:1384:9	traumat	JJ	O	O
or	PRADAXA.xml:S2:1394:2	or	CC	O	O
repeated	PRADAXA.xml:S2:1397:8	repeat	VBN	O	O
\n\n	PRADAXA.xml:S2:1405:2	\n\n	JJ	O	O
epidural	PRADAXA.xml:S2:1407:8	epidur	JJ	O	O
or	PRADAXA.xml:S2:1416:2	or	CC	O	O
spinal	PRADAXA.xml:S2:1419:6	spinal	JJ	O	O
punctures	PRADAXA.xml:S2:1426:9	punctur	NNS	O	O
a	PRADAXA.xml:S2:1437:1	a	DT	O	O
history	PRADAXA.xml:S2:1439:7	histori	NN	O	O
of	PRADAXA.xml:S2:1447:2	of	IN	O	O
spinal	PRADAXA.xml:S2:1450:6	spinal	JJ	O	O
deformity	PRADAXA.xml:S2:1457:9	deform	NN	O	O
\n\n	PRADAXA.xml:S2:1466:2	\n\n	NNP	O	O
or	PRADAXA.xml:S2:1468:2	or	CC	O	O
spinal	PRADAXA.xml:S2:1471:6	spinal	JJ	O	O
surgery	PRADAXA.xml:S2:1478:7	surgeri	NN	O	O
optimal	PRADAXA.xml:S2:1487:7	optim	JJ	O	O
timing	PRADAXA.xml:S2:1495:6	time	NN	O	O
between	PRADAXA.xml:S2:1502:7	between	IN	O	O
the	PRADAXA.xml:S2:1510:3	the	DT	O	O
administration	PRADAXA.xml:S2:1514:14	administr	NN	O	O
\n\n	PRADAXA.xml:S2:1528:2	\n\n	NNP	O	O
of	PRADAXA.xml:S2:1530:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S2:1533:7	pradaxa	NNP	O	O
and	PRADAXA.xml:S2:1541:3	and	CC	O	O
neuraxial	PRADAXA.xml:S2:1545:9	neuraxi	JJ	O	O
procedures	PRADAXA.xml:S2:1555:10	procedur	NNS	O	O
is	PRADAXA.xml:S2:1566:2	is	VBZ	O	O
not	PRADAXA.xml:S2:1569:3	not	RB	O	O
known	PRADAXA.xml:S2:1573:5	known	VBN	O	O
[	PRADAXA.xml:S2:1581:1	[	NNP	O	O
see	PRADAXA.xml:S2:1582:3	see	VBP	O	O
Warnings	PRADAXA.xml:S2:1586:8	warn	NNP	O	O
\n\n	PRADAXA.xml:S2:1594:2	\n\n	NNP	O	O
and	PRADAXA.xml:S2:1596:3	and	CC	O	O
Precautions	PRADAXA.xml:S2:1600:11	precaut	NNP	O	O
(	PRADAXA.xml:S2:1614:1	(	(	O	O
5.3	PRADAXA.xml:S2:1615:3	5.3	CD	O	O
)	PRADAXA.xml:S2:1618:1	)	)	O	O
]	PRADAXA.xml:S2:1621:1	]	NN	O	O
.	PRADAXA.xml:S2:1624:1	.	.	O	O

Monitor	PRADAXA.xml:S2:1634:7	monitor	NN	O	O
patients	PRADAXA.xml:S2:1642:8	patient	NNS	O	O
\n\n	PRADAXA.xml:S2:1650:2	\n\n	VBP	O	O
frequently	PRADAXA.xml:S2:1652:10	frequent	RB	O	O
for	PRADAXA.xml:S2:1663:3	for	IN	O	O
signs	PRADAXA.xml:S2:1667:5	sign	NNS	O	O
and	PRADAXA.xml:S2:1673:3	and	CC	O	O
symptoms	PRADAXA.xml:S2:1677:8	symptom	NNS	O	O
of	PRADAXA.xml:S2:1686:2	of	IN	O	O
neurological	PRADAXA.xml:S2:1689:12	neurolog	JJ	O	O
impairment	PRADAXA.xml:S2:1702:10	impair	NN	O	O
.	PRADAXA.xml:S2:1712:1	.	.	O	O

If	PRADAXA.xml:S2:1714:2	If	IN	O	O
neurological	PRADAXA.xml:S2:1717:12	neurolog	JJ	O	O
\n\n	PRADAXA.xml:S2:1729:2	\n\n	NNP	O	O
compromise	PRADAXA.xml:S2:1731:10	compromis	NN	O	O
is	PRADAXA.xml:S2:1742:2	is	VBZ	O	O
noted	PRADAXA.xml:S2:1745:5	note	VBN	O	O
,	PRADAXA.xml:S2:1750:1	,	,	O	O
urgent	PRADAXA.xml:S2:1752:6	urgent	JJ	O	O
treatment	PRADAXA.xml:S2:1759:9	treatment	NN	O	O
is	PRADAXA.xml:S2:1769:2	is	VBZ	O	O
necessary	PRADAXA.xml:S2:1772:9	necessari	JJ	O	O
[	PRADAXA.xml:S2:1784:1	[	NNP	O	O
see	PRADAXA.xml:S2:1785:3	see	VBP	O	O
Warnings	PRADAXA.xml:S2:1789:8	warn	NNP	O	O
\n\n	PRADAXA.xml:S2:1797:2	\n\n	NNP	O	O
and	PRADAXA.xml:S2:1799:3	and	CC	O	O
Precautions	PRADAXA.xml:S2:1803:11	precaut	NNP	O	O
(	PRADAXA.xml:S2:1817:1	(	(	O	O
5.3	PRADAXA.xml:S2:1818:3	5.3	CD	O	O
)	PRADAXA.xml:S2:1821:1	)	)	O	O
]	PRADAXA.xml:S2:1824:1	]	NN	O	O
.	PRADAXA.xml:S2:1827:1	.	.	O	O
Consider	PRADAXA.xml:S2:1828:8	consid	VB	O	O
the	PRADAXA.xml:S2:1837:3	the	DT	O	O
benefits	PRADAXA.xml:S2:1841:8	benefit	NNS	O	O
and	PRADAXA.xml:S2:1850:3	and	CC	O	O
risks	PRADAXA.xml:S2:1854:5	risk	NNS	O	O
before	PRADAXA.xml:S2:1860:6	befor	IN	O	O
neuraxial	PRADAXA.xml:S2:1867:9	neuraxi	JJ	O	O
intervention	PRADAXA.xml:S2:1877:12	intervent	NN	O	O
\n\n	PRADAXA.xml:S2:1889:2	\n\n	NN	O	O
in	PRADAXA.xml:S2:1891:2	in	IN	O	O
patients	PRADAXA.xml:S2:1894:8	patient	NNS	O	O
anticoagulated	PRADAXA.xml:S2:1903:14	anticoagul	VBD	O	O
or	PRADAXA.xml:S2:1918:2	or	CC	O	O
to	PRADAXA.xml:S2:1921:2	to	TO	O	O
be	PRADAXA.xml:S2:1924:2	be	VB	O	O
anticoagulated	PRADAXA.xml:S2:1927:14	anticoagul	VBN	O	O
[	PRADAXA.xml:S2:1944:1	[	NNP	O	O
see	PRADAXA.xml:S2:1945:3	see	VBP	O	O
Warnings	PRADAXA.xml:S2:1949:8	warn	NNP	O	O
\n\n	PRADAXA.xml:S2:1957:2	\n\n	NNP	O	O
and	PRADAXA.xml:S2:1959:3	and	CC	O	O
Precautions	PRADAXA.xml:S2:1963:11	precaut	NNP	O	O
(	PRADAXA.xml:S2:1977:1	(	(	O	O
5.3	PRADAXA.xml:S2:1978:3	5.3	CD	O	O
)	PRADAXA.xml:S2:1981:1	)	)	O	O
]	PRADAXA.xml:S2:1984:1	]	NN	O	O
.	PRADAXA.xml:S2:1987:1	.	.	O	O

EXCERPT	PRADAXA.xml:S2:1997:7	excerpt	NN	O	O
:	PRADAXA.xml:S2:2004:1	:	:	O	O
WARNING	PRADAXA.xml:S2:2010:7	warn	NN	O	O
:	PRADAXA.xml:S2:2017:1	:	:	O	O
(	PRADAXA.xml:S2:2019:1	(	(	O	O
A	PRADAXA.xml:S2:2020:1	A	DT	O	O
)	PRADAXA.xml:S2:2021:1	)	)	O	O
PREMATURE	PRADAXA.xml:S2:2023:9	prematur	NNP	O	O
DISCONTINUATION	PRADAXA.xml:S2:2033:15	discontinu	NNP	O	O
\n\n	PRADAXA.xml:S2:2048:2	\n\n	NNP	O	O
OF	PRADAXA.xml:S2:2050:2	OF	NNP	O	O
PRADAXA	PRADAXA.xml:S2:2053:7	pradaxa	NNP	O	O
INCREASES	PRADAXA.xml:S2:2061:9	increas	NNP	O	O
THE	PRADAXA.xml:S2:2071:3	the	NNP	O	O
RISK	PRADAXA.xml:S2:2075:4	risk	NNP	O	O
OF	PRADAXA.xml:S2:2080:2	OF	NNP	O	O
THROMBOTIC	PRADAXA.xml:S2:2083:10	thrombot	NNP	O	B-AdverseReaction
EVENTS	PRADAXA.xml:S2:2094:6	event	NNP	O	I-AdverseReaction
,	PRADAXA.xml:S2:2100:1	,	,	O	O
and	PRADAXA.xml:S2:2102:3	and	CC	O	O
(	PRADAXA.xml:S2:2106:1	(	(	O	O
B	PRADAXA.xml:S2:2107:1	B	NNP	O	O
)	PRADAXA.xml:S2:2108:1	)	)	O	O
SPINAL	PRADAXA.xml:S2:2110:6	spinal	NNP	B-AdverseReaction	O
EPIDURAL	PRADAXA.xml:S2:2117:8	epidur	NNP	B-AdverseReaction	O
\n\n	PRADAXA.xml:S2:2125:2	\n\n	NNP	I-AdverseReaction	O
HEMATOMA	PRADAXA.xml:S2:2127:8	hematoma	NNP	I-AdverseReaction	O
See	PRADAXA.xml:S2:2139:3	see	NNP	O	O
full	PRADAXA.xml:S2:2143:4	full	JJ	O	O
prescribing	PRADAXA.xml:S2:2148:11	prescrib	VBG	O	O
information	PRADAXA.xml:S2:2160:11	inform	NN	O	O
\n\n	PRADAXA.xml:S2:2171:2	\n\n	NN	O	O
for	PRADAXA.xml:S2:2173:3	for	IN	O	O
complete	PRADAXA.xml:S2:2177:8	complet	JJ	O	O
boxed	PRADAXA.xml:S2:2186:5	box	NN	O	O
warning	PRADAXA.xml:S2:2192:7	warn	NN	O	O
(	PRADAXA.xml:S2:2203:1	(	(	O	O
A	PRADAXA.xml:S2:2204:1	A	DT	O	O
)\n\n	PRADAXA.xml:S2:2205:3	)\n\n	NN	O	O
PREMATURE	PRADAXA.xml:S2:2208:9	prematur	NNP	O	O
DISCONTINUATION	PRADAXA.xml:S2:2218:15	discontinu	NNP	O	O
OF	PRADAXA.xml:S2:2234:2	OF	NNP	O	O
PRADAXA	PRADAXA.xml:S2:2237:7	pradaxa	NNP	O	O
INCREASES	PRADAXA.xml:S2:2245:9	increas	NNP	O	O
THE	PRADAXA.xml:S2:2255:3	the	NNP	O	O
RISK	PRADAXA.xml:S2:2259:4	risk	NNP	O	O
OF	PRADAXA.xml:S2:2264:2	OF	NNP	O	O
THROMBOTIC	PRADAXA.xml:S2:2267:10	thrombot	NNP	O	B-AdverseReaction
\n\n	PRADAXA.xml:S2:2277:2	\n\n	NNP	O	O
EVENTS	PRADAXA.xml:S2:2279:6	event	NNP	O	O
:	PRADAXA.xml:S2:2285:1	:	:	O	O
Premature	PRADAXA.xml:S2:2287:9	prematur	JJ	O	O
discontinuation	PRADAXA.xml:S2:2297:15	discontinu	NN	O	O
of	PRADAXA.xml:S2:2313:2	of	IN	O	O
any	PRADAXA.xml:S2:2316:3	ani	DT	O	O
oral	PRADAXA.xml:S2:2320:4	oral	JJ	O	O
anticoagulant	PRADAXA.xml:S2:2325:13	anticoagul	NN	O	O
,	PRADAXA.xml:S2:2338:1	,	,	O	O
including	PRADAXA.xml:S2:2340:9	includ	VBG	O	O
\n\n	PRADAXA.xml:S2:2349:2	\n\n	JJ	O	O
PRADAXA	PRADAXA.xml:S2:2351:7	pradaxa	NNP	O	O
,	PRADAXA.xml:S2:2358:1	,	,	O	O
increases	PRADAXA.xml:S2:2360:9	increas	VBZ	O	O
the	PRADAXA.xml:S2:2370:3	the	DT	O	O
risk	PRADAXA.xml:S2:2374:4	risk	NN	O	O
of	PRADAXA.xml:S2:2379:2	of	IN	O	O
thrombotic	PRADAXA.xml:S2:2382:10	thrombot	JJ	O	B-AdverseReaction
events	PRADAXA.xml:S2:2393:6	event	NNS	O	I-AdverseReaction
.	PRADAXA.xml:S2:2399:1	.	.	O	O

To	PRADAXA.xml:S2:2402:2	To	TO	O	O
reduce	PRADAXA.xml:S2:2405:6	reduc	VB	O	O
this	PRADAXA.xml:S2:2412:4	thi	DT	O	O
\n\n	PRADAXA.xml:S2:2416:2	\n\n	NN	O	O
risk	PRADAXA.xml:S2:2418:4	risk	NN	O	O
,	PRADAXA.xml:S2:2422:1	,	,	O	O
consider	PRADAXA.xml:S2:2424:8	consid	VB	O	O
coverage	PRADAXA.xml:S2:2433:8	coverag	NN	O	O
with	PRADAXA.xml:S2:2442:4	with	IN	O	O
another	PRADAXA.xml:S2:2447:7	anoth	DT	O	O
anticoagulant	PRADAXA.xml:S2:2455:13	anticoagul	NN	O	O
if	PRADAXA.xml:S2:2469:2	if	IN	O	O
PRADAXA	PRADAXA.xml:S2:2472:7	pradaxa	NNP	O	O
is	PRADAXA.xml:S2:2480:2	is	VBZ	O	O
discontinued	PRADAXA.xml:S2:2483:12	discontinu	VBN	O	O
\n\n	PRADAXA.xml:S2:2495:2	\n\n	NNP	O	O
for	PRADAXA.xml:S2:2497:3	for	IN	O	O
a	PRADAXA.xml:S2:2501:1	a	DT	O	O
reason	PRADAXA.xml:S2:2503:6	reason	NN	O	O
other	PRADAXA.xml:S2:2510:5	other	JJ	O	O
than	PRADAXA.xml:S2:2516:4	than	IN	O	O
pathological	PRADAXA.xml:S2:2521:12	patholog	JJ	O	O
bleeding	PRADAXA.xml:S2:2534:8	bleed	NN	O	O
or	PRADAXA.xml:S2:2543:2	or	CC	O	O
completion	PRADAXA.xml:S2:2546:10	complet	NN	O	O
of	PRADAXA.xml:S2:2557:2	of	IN	O	O
a	PRADAXA.xml:S2:2560:1	a	DT	O	O
course	PRADAXA.xml:S2:2562:6	cours	NN	O	O
\n\n	PRADAXA.xml:S2:2568:2	\n\n	NN	O	O
of	PRADAXA.xml:S2:2570:2	of	IN	O	O
therapy	PRADAXA.xml:S2:2573:7	therapi	NN	O	O
(	PRADAXA.xml:S2:2581:1	(	(	O	O
2.4	PRADAXA.xml:S2:2584:3	2.4	CD	O	O
,	PRADAXA.xml:S2:2589:1	,	,	O	O
2.5	PRADAXA.xml:S2:2593:3	2.5	CD	O	O
,	PRADAXA.xml:S2:2598:1	,	,	O	O
2.6	PRADAXA.xml:S2:2602:3	2.6	CD	O	O
,	PRADAXA.xml:S2:2607:1	,	,	O	O
5.1	PRADAXA.xml:S2:2611:3	5.1	CD	O	O
)	PRADAXA.xml:S2:2616:1	)	)	O	O
.	PRADAXA.xml:S2:2617:1	.	.	O	O

(	PRADAXA.xml:S2:2622:1	(	(	O	O
B	PRADAXA.xml:S2:2623:1	B	NNP	O	O
)	PRADAXA.xml:S2:2624:1	)	)	O	O
SPINAL	PRADAXA.xml:S2:2626:6	spinal	NNP	O	O
EPIDURAL	PRADAXA.xml:S2:2633:8	epidur	NNP	O	O
HEMATOMA	PRADAXA.xml:S2:2642:8	hematoma	NNP	O	O
:	PRADAXA.xml:S2:2650:1	:	:	O	O
Epidural	PRADAXA.xml:S2:2652:8	epidur	JJ	B-AdverseReaction	B-AdverseReaction
or	PRADAXA.xml:S2:2661:2	or	CC	O	O
spinal	PRADAXA.xml:S2:2664:6	spinal	JJ	B-AdverseReaction	B-AdverseReaction
hematomas	PRADAXA.xml:S2:2671:9	hematoma	NNS	I-AdverseReaction	I-AdverseReaction
\n\n	PRADAXA.xml:S2:2680:2	\n\n	VBP	O	O
may	PRADAXA.xml:S2:2682:3	may	MD	O	O
occur	PRADAXA.xml:S2:2686:5	occur	VB	O	O
in	PRADAXA.xml:S2:2692:2	in	IN	O	O
patients	PRADAXA.xml:S2:2695:8	patient	NNS	O	O
treated	PRADAXA.xml:S2:2704:7	treat	VBN	O	O
with	PRADAXA.xml:S2:2712:4	with	IN	O	O
PRADAXA	PRADAXA.xml:S2:2717:7	pradaxa	NNP	O	O
who	PRADAXA.xml:S2:2725:3	who	WP	O	O
are	PRADAXA.xml:S2:2729:3	are	VBP	O	O
receiving	PRADAXA.xml:S2:2733:9	receiv	VBG	O	O
neuraxial	PRADAXA.xml:S2:2743:9	neuraxi	JJ	O	O
\n\n	PRADAXA.xml:S2:2752:2	\n\n	JJ	O	O
anesthesia	PRADAXA.xml:S2:2754:10	anesthesia	NN	O	O
or	PRADAXA.xml:S2:2765:2	or	CC	O	O
undergoing	PRADAXA.xml:S2:2768:10	undergo	JJ	O	O
spinal	PRADAXA.xml:S2:2779:6	spinal	JJ	O	O
puncture	PRADAXA.xml:S2:2786:8	punctur	NN	O	O
.	PRADAXA.xml:S2:2794:1	.	.	O	O

These	PRADAXA.xml:S2:2796:5	these	DT	O	O
hematomas	PRADAXA.xml:S2:2802:9	hematoma	NN	B-AdverseReaction	B-AdverseReaction
may	PRADAXA.xml:S2:2812:3	may	MD	O	O
result	PRADAXA.xml:S2:2816:6	result	VB	O	O
\n\n	PRADAXA.xml:S2:2822:2	\n\n	NNS	O	O
in	PRADAXA.xml:S2:2824:2	in	IN	O	O
long	PRADAXA.xml:S2:2827:4	long	JJ	B-AdverseReaction	O
-	PRADAXA.xml:S2:2831:1	-	:	I-AdverseReaction	O
term	PRADAXA.xml:S2:2832:4	term	NN	I-AdverseReaction	O
or	PRADAXA.xml:S2:2837:2	or	CC	O	O
permanent	PRADAXA.xml:S2:2840:9	perman	JJ	B-AdverseReaction	B-AdverseReaction
paralysis	PRADAXA.xml:S2:2850:9	paralysi	NN	I-AdverseReaction	I-AdverseReaction
(	PRADAXA.xml:S2:2860:1	(	(	O	O
5.3	PRADAXA.xml:S2:2863:3	5.3	CD	O	O
)	PRADAXA.xml:S2:2868:1	)	)	O	O
.	PRADAXA.xml:S2:2869:1	.	.	O	O

Monitor	PRADAXA.xml:S2:2871:7	monitor	NN	O	O
patients	PRADAXA.xml:S2:2879:8	patient	NNS	O	O
frequently	PRADAXA.xml:S2:2888:10	frequent	RB	O	O
for	PRADAXA.xml:S2:2899:3	for	IN	O	O
signs	PRADAXA.xml:S2:2903:5	sign	NNS	O	O
and	PRADAXA.xml:S2:2909:3	and	CC	O	O
symptoms	PRADAXA.xml:S2:2913:8	symptom	NNS	O	O
of	PRADAXA.xml:S2:2922:2	of	IN	O	O
neurological	PRADAXA.xml:S2:2925:12	neurolog	JJ	O	O
\n\n	PRADAXA.xml:S2:2937:2	\n\n	NNP	O	O
impairment	PRADAXA.xml:S2:2939:10	impair	NN	O	O
and	PRADAXA.xml:S2:2950:3	and	CC	O	O
if	PRADAXA.xml:S2:2954:2	if	IN	O	O
observed	PRADAXA.xml:S2:2957:8	observ	VBN	O	O
,	PRADAXA.xml:S2:2965:1	,	,	O	O
treat	PRADAXA.xml:S2:2967:5	treat	NN	O	O
urgently	PRADAXA.xml:S2:2973:8	urgent	RB	O	O
.	PRADAXA.xml:S2:2981:1	.	.	O	O

Consider	PRADAXA.xml:S2:2983:8	consid	VB	O	O
the	PRADAXA.xml:S2:2992:3	the	DT	O	O
benefits	PRADAXA.xml:S2:2996:8	benefit	NNS	O	O
\n\n	PRADAXA.xml:S2:3004:2	\n\n	NNP	O	O
and	PRADAXA.xml:S2:3006:3	and	CC	O	O
risks	PRADAXA.xml:S2:3010:5	risk	NNS	O	O
before	PRADAXA.xml:S2:3016:6	befor	IN	O	O
neuraxial	PRADAXA.xml:S2:3023:9	neuraxi	JJ	O	O
intervention	PRADAXA.xml:S2:3033:12	intervent	NN	O	O
in	PRADAXA.xml:S2:3046:2	in	IN	O	O
patients	PRADAXA.xml:S2:3049:8	patient	NNS	O	O
who	PRADAXA.xml:S2:3058:3	who	WP	O	O
are	PRADAXA.xml:S2:3062:3	are	VBP	O	O
or	PRADAXA.xml:S2:3066:2	or	CC	O	O
who	PRADAXA.xml:S2:3069:3	who	WP	O	O
\n\n	PRADAXA.xml:S2:3072:2	\n\n	VBP	O	O
need	PRADAXA.xml:S2:3074:4	need	VBP	O	O
to	PRADAXA.xml:S2:3079:2	to	TO	O	O
be	PRADAXA.xml:S2:3082:2	be	VB	O	O
anticoagulated	PRADAXA.xml:S2:3085:14	anticoagul	VBN	O	O
(	PRADAXA.xml:S2:3100:1	(	(	O	O
5.3	PRADAXA.xml:S2:3103:3	5.3	CD	O	O
)	PRADAXA.xml:S2:3108:1	)	)	O	O
.	PRADAXA.xml:S2:3109:1	.	.	O	O
\n	PRADAXA.xml:S2:3112:1	\n	$	O	O
5	PRADAXA.xml:S3:4:1	5	CD	O	O
WARNINGS	PRADAXA.xml:S3:7:8	warn	NNP	O	O
AND	PRADAXA.xml:S3:16:3	and	NNP	O	O
PRECAUTIONS	PRADAXA.xml:S3:20:11	precaut	NNP	O	O

EXCERPT	PRADAXA.xml:S3:38:7	excerpt	NN	O	O
:	PRADAXA.xml:S3:45:1	:	:	O	O
Bleeding	PRADAXA.xml:S3:53:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
:	PRADAXA.xml:S3:61:1	:	:	O	O
PRADAXA	PRADAXA.xml:S3:63:7	pradaxa	NN	O	O
can	PRADAXA.xml:S3:71:3	can	MD	O	O
cause	PRADAXA.xml:S3:75:5	caus	VB	O	O
serious	PRADAXA.xml:S3:81:7	seriou	JJ	O	O
and	PRADAXA.xml:S3:89:3	and	CC	O	O
fatal	PRADAXA.xml:S3:93:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
bleeding	PRADAXA.xml:S3:99:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
(	PRADAXA.xml:S3:109:1	(	(	O	O
5.2	PRADAXA.xml:S3:110:3	5.2	CD	O	O
)	PRADAXA.xml:S3:113:1	)	)	O	O

Bioprosthetic	PRADAXA.xml:S3:122:13	bioprosthet	JJ	O	O
heart	PRADAXA.xml:S3:136:5	heart	NN	O	O
valves	PRADAXA.xml:S3:142:6	valv	NNS	O	O
:	PRADAXA.xml:S3:148:1	:	:	O	O
PRADAXA	PRADAXA.xml:S3:150:7	pradaxa	NNP	O	O
use	PRADAXA.xml:S3:158:3	use	NN	O	O
not	PRADAXA.xml:S3:162:3	not	RB	O	O
recommended	PRADAXA.xml:S3:166:11	recommend	VBD	O	O
(	PRADAXA.xml:S3:179:1	(	(	O	O
5.4	PRADAXA.xml:S3:180:3	5.4	CD	O	O
)	PRADAXA.xml:S3:183:1	)	)	O	O

5.1	PRADAXA.xml:S3:199:3	5.1	CD	O	O

Increased	PRADAXA.xml:S3:203:9	increas	VBN	O	O

Risk	PRADAXA.xml:S3:213:4	risk	NN	O	O
of	PRADAXA.xml:S3:218:2	of	IN	O	O
Thrombotic	PRADAXA.xml:S3:221:10	thrombot	JJ	O	B-AdverseReaction
Events	PRADAXA.xml:S3:232:6	event	NNS	O	I-AdverseReaction
after	PRADAXA.xml:S3:239:5	after	IN	O	O
Premature	PRADAXA.xml:S3:245:9	prematur	NNP	O	O
Discontinuation	PRADAXA.xml:S3:255:15	discontinu	NNP	O	O

Premature	PRADAXA.xml:S3:276:9	prematur	JJ	O	O
discontinuation	PRADAXA.xml:S3:286:15	discontinu	NN	O	O
of	PRADAXA.xml:S3:302:2	of	IN	O	O
any	PRADAXA.xml:S3:305:3	ani	DT	O	O
oral	PRADAXA.xml:S3:309:4	oral	JJ	O	O
anticoagulant	PRADAXA.xml:S3:314:13	anticoagul	NN	O	O
,	PRADAXA.xml:S3:327:1	,	,	O	O
including	PRADAXA.xml:S3:329:9	includ	VBG	O	O
PRADAXA	PRADAXA.xml:S3:339:7	pradaxa	NNP	O	O
,	PRADAXA.xml:S3:346:1	,	,	O	O
in	PRADAXA.xml:S3:348:2	in	IN	O	O
the	PRADAXA.xml:S3:351:3	the	DT	O	O
absence	PRADAXA.xml:S3:355:7	absenc	NN	O	O
of	PRADAXA.xml:S3:363:2	of	IN	O	O
adequate	PRADAXA.xml:S3:366:8	adequ	JJ	O	O
alternative	PRADAXA.xml:S3:375:11	altern	JJ	O	O
anticoagulation	PRADAXA.xml:S3:387:15	anticoagul	NN	O	O
increases	PRADAXA.xml:S3:403:9	increas	VBZ	O	O
the	PRADAXA.xml:S3:413:3	the	DT	O	O
risk	PRADAXA.xml:S3:417:4	risk	NN	O	O
of	PRADAXA.xml:S3:422:2	of	IN	O	O
thrombotic	PRADAXA.xml:S3:425:10	thrombot	JJ	O	B-AdverseReaction
events	PRADAXA.xml:S3:436:6	event	NNS	O	I-AdverseReaction
.	PRADAXA.xml:S3:442:1	.	.	O	O

If	PRADAXA.xml:S3:444:2	If	IN	O	O
PRADAXA	PRADAXA.xml:S3:447:7	pradaxa	NNP	O	O
is	PRADAXA.xml:S3:455:2	is	VBZ	O	O
discontinued	PRADAXA.xml:S3:458:12	discontinu	VBN	O	O
for	PRADAXA.xml:S3:471:3	for	IN	O	O
a	PRADAXA.xml:S3:475:1	a	DT	O	O
reason	PRADAXA.xml:S3:477:6	reason	NN	O	O
other	PRADAXA.xml:S3:484:5	other	JJ	O	O
than	PRADAXA.xml:S3:490:4	than	IN	O	O
pathological	PRADAXA.xml:S3:495:12	patholog	JJ	O	O
bleeding	PRADAXA.xml:S3:508:8	bleed	NN	O	O
or	PRADAXA.xml:S3:517:2	or	CC	O	O
completion	PRADAXA.xml:S3:520:10	complet	NN	O	O
of	PRADAXA.xml:S3:531:2	of	IN	O	O
a	PRADAXA.xml:S3:534:1	a	DT	O	O
course	PRADAXA.xml:S3:536:6	cours	NN	O	O
of	PRADAXA.xml:S3:543:2	of	IN	O	O
therapy	PRADAXA.xml:S3:546:7	therapi	NN	O	O
,	PRADAXA.xml:S3:553:1	,	,	O	O
consider	PRADAXA.xml:S3:555:8	consid	VB	O	O
coverage	PRADAXA.xml:S3:564:8	coverag	NN	O	O
with	PRADAXA.xml:S3:573:4	with	IN	O	O
another	PRADAXA.xml:S3:578:7	anoth	DT	O	O
anticoagulant	PRADAXA.xml:S3:586:13	anticoagul	JJ	O	O
[	PRADAXA.xml:S3:600:1	[	NN	O	O
see	PRADAXA.xml:S3:601:3	see	VBP	O	O
Dosage	PRADAXA.xml:S3:605:6	dosag	NNP	O	O
and	PRADAXA.xml:S3:612:3	and	CC	O	O
Administration	PRADAXA.xml:S3:616:14	administr	NNP	O	O
(	PRADAXA.xml:S3:632:1	(	(	O	O
2.4	PRADAXA.xml:S3:633:3	2.4	CD	O	O
,	PRADAXA.xml:S3:638:1	,	,	O	O
2.5	PRADAXA.xml:S3:641:3	2.5	CD	O	O
,	PRADAXA.xml:S3:646:1	,	,	O	O
2.6	PRADAXA.xml:S3:649:3	2.6	CD	O	O
)	PRADAXA.xml:S3:652:1	)	)	O	O
]	PRADAXA.xml:S3:655:1	]	NN	O	O
.	PRADAXA.xml:S3:656:1	.	.	O	O

5.2	PRADAXA.xml:S3:667:3	5.2	CD	O	O
Risk	PRADAXA.xml:S3:671:4	risk	NN	O	O
of	PRADAXA.xml:S3:676:2	of	IN	O	O
Bleeding	PRADAXA.xml:S3:679:8	bleed	VBG	O	O

PRADAXA	PRADAXA.xml:S3:693:7	pradaxa	NN	O	O
increases	PRADAXA.xml:S3:701:9	increas	VBZ	O	O
the	PRADAXA.xml:S3:711:3	the	DT	O	O
risk	PRADAXA.xml:S3:715:4	risk	NN	O	O
of	PRADAXA.xml:S3:720:2	of	IN	O	O
bleeding	PRADAXA.xml:S3:723:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
and	PRADAXA.xml:S3:732:3	and	CC	O	O
can	PRADAXA.xml:S3:736:3	can	MD	O	O
cause	PRADAXA.xml:S3:740:5	caus	VB	O	O
significant	PRADAXA.xml:S3:746:11	signific	JJ	O	O
and	PRADAXA.xml:S3:758:3	and	CC	O	O
,	PRADAXA.xml:S3:761:1	,	,	O	O
sometimes	PRADAXA.xml:S3:763:9	sometim	RB	O	O
,	PRADAXA.xml:S3:772:1	,	,	O	O
fatal	PRADAXA.xml:S3:774:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
bleeding	PRADAXA.xml:S3:780:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
.	PRADAXA.xml:S3:788:1	.	.	O	O

Promptly	PRADAXA.xml:S3:790:8	promptli	RB	O	O
evaluate	PRADAXA.xml:S3:799:8	evalu	VB	O	O
any	PRADAXA.xml:S3:808:3	ani	DT	O	O
signs	PRADAXA.xml:S3:812:5	sign	NNS	O	O
or	PRADAXA.xml:S3:818:2	or	CC	O	O
symptoms	PRADAXA.xml:S3:821:8	symptom	NNS	O	O
of	PRADAXA.xml:S3:830:2	of	IN	O	O
blood	PRADAXA.xml:S3:833:5	blood	NN	O	O
loss	PRADAXA.xml:S3:839:4	loss	NN	O	O
(	PRADAXA.xml:S3:844:1	(	(	O	O
e	PRADAXA.xml:S3:845:1	e	JJ	O	O
.	PRADAXA.xml:S3:846:1	.	.	O	O
g	PRADAXA.xml:S3:847:1	g	NN	O	O
.	PRADAXA.xml:S3:848:1	.	.	O	O
,	PRADAXA.xml:S3:849:1	,	,	O	O
a	PRADAXA.xml:S3:851:1	a	DT	O	O
drop	PRADAXA.xml:S3:853:4	drop	NN	O	O
in	PRADAXA.xml:S3:858:2	in	IN	O	O
hemoglobin	PRADAXA.xml:S3:861:10	hemoglobin	NN	O	O
and	PRADAXA.xml:S3:872:3	and	CC	O	O
or	PRADAXA.xml:S3:876:2	or	CC	O	O
hematocrit	PRADAXA.xml:S3:879:10	hematocrit	NN	O	O
or	PRADAXA.xml:S3:890:2	or	CC	O	O
hypotension	PRADAXA.xml:S3:893:11	hypotens	NN	O	O
)	PRADAXA.xml:S3:904:1	)	)	O	O
.	PRADAXA.xml:S3:905:1	.	.	O	O

Discontinue	PRADAXA.xml:S3:907:11	discontinu	NNP	O	O
PRADAXA	PRADAXA.xml:S3:919:7	pradaxa	NNP	O	O
in	PRADAXA.xml:S3:927:2	in	IN	O	O
patients	PRADAXA.xml:S3:930:8	patient	NNS	O	O
with	PRADAXA.xml:S3:939:4	with	IN	O	O
active	PRADAXA.xml:S3:944:6	activ	JJ	O	O
pathological	PRADAXA.xml:S3:951:12	patholog	JJ	O	O
bleeding	PRADAXA.xml:S3:964:8	bleed	NN	O	O
[	PRADAXA.xml:S3:974:1	[	NNP	O	O
see	PRADAXA.xml:S3:975:3	see	VBP	O	O
Dosage	PRADAXA.xml:S3:979:6	dosag	NNP	O	O
and	PRADAXA.xml:S3:986:3	and	CC	O	O
Administration	PRADAXA.xml:S3:990:14	administr	NNP	O	O
(	PRADAXA.xml:S3:1006:1	(	(	O	O
2.2	PRADAXA.xml:S3:1007:3	2.2	CD	O	O
)	PRADAXA.xml:S3:1010:1	)	)	O	O
]	PRADAXA.xml:S3:1013:1	]	NN	O	O
.	PRADAXA.xml:S3:1018:1	.	.	O	O

Risk	PRADAXA.xml:S3:1024:4	risk	NN	O	O
factors	PRADAXA.xml:S3:1029:7	factor	NNS	O	O
for	PRADAXA.xml:S3:1037:3	for	IN	O	O
bleeding	PRADAXA.xml:S3:1041:8	bleed	VBG	O	O
include	PRADAXA.xml:S3:1050:7	includ	VBP	O	O
the	PRADAXA.xml:S3:1058:3	the	DT	O	O
concomitant	PRADAXA.xml:S3:1062:11	concomit	JJ	O	O
use	PRADAXA.xml:S3:1074:3	use	NN	O	O
of	PRADAXA.xml:S3:1078:2	of	IN	O	O
other	PRADAXA.xml:S3:1081:5	other	JJ	O	O
drugs	PRADAXA.xml:S3:1087:5	drug	NNS	O	O
that	PRADAXA.xml:S3:1093:4	that	WDT	O	O
increase	PRADAXA.xml:S3:1098:8	increas	VBP	O	O
the	PRADAXA.xml:S3:1107:3	the	DT	O	O
risk	PRADAXA.xml:S3:1111:4	risk	NN	O	O
of	PRADAXA.xml:S3:1116:2	of	IN	O	O
bleeding	PRADAXA.xml:S3:1119:8	bleed	NN	O	B-AdverseReaction
(	PRADAXA.xml:S3:1128:1	(	(	O	O
e	PRADAXA.xml:S3:1129:1	e	NN	O	O
.	PRADAXA.xml:S3:1130:1	.	.	O	O
g	PRADAXA.xml:S3:1131:1	g	NN	O	O
.	PRADAXA.xml:S3:1132:1	.	.	O	O
,	PRADAXA.xml:S3:1133:1	,	,	O	O
anti	PRADAXA.xml:S3:1135:4	anti	JJ	O	O
-	PRADAXA.xml:S3:1139:1	-	:	O	O
platelet	PRADAXA.xml:S3:1140:8	platelet	NN	O	O
agents	PRADAXA.xml:S3:1149:6	agent	NNS	O	O
,	PRADAXA.xml:S3:1155:1	,	,	O	O
heparin	PRADAXA.xml:S3:1157:7	heparin	NN	O	O
,	PRADAXA.xml:S3:1164:1	,	,	O	O
fibrinolytic	PRADAXA.xml:S3:1166:12	fibrinolyt	JJ	O	O
therapy	PRADAXA.xml:S3:1179:7	therapi	NN	O	O
,	PRADAXA.xml:S3:1186:1	,	,	O	O
and	PRADAXA.xml:S3:1188:3	and	CC	O	O
chronic	PRADAXA.xml:S3:1192:7	chronic	JJ	O	O
use	PRADAXA.xml:S3:1200:3	use	NN	O	O
of	PRADAXA.xml:S3:1204:2	of	IN	O	O
NSAIDs	PRADAXA.xml:S3:1207:6	nsaid	NNP	O	O
)	PRADAXA.xml:S3:1213:1	)	)	O	O
.	PRADAXA.xml:S3:1214:1	.	.	O	O

PRADAXA	PRADAXA.xml:S3:1216:7	pradaxa	NNP	O	O
's	PRADAXA.xml:S3:1223:2	's	POS	O	O
anticoagulant	PRADAXA.xml:S3:1226:13	anticoagul	JJ	O	O
activity	PRADAXA.xml:S3:1240:8	activ	NN	O	O
and	PRADAXA.xml:S3:1249:3	and	CC	O	O
half	PRADAXA.xml:S3:1253:4	half	NN	O	O
-	PRADAXA.xml:S3:1257:1	-	:	O	O
life	PRADAXA.xml:S3:1258:4	life	NN	O	O
are	PRADAXA.xml:S3:1263:3	are	VBP	O	O
increased	PRADAXA.xml:S3:1267:9	increas	VBN	O	O
in	PRADAXA.xml:S3:1277:2	in	IN	O	O
patients	PRADAXA.xml:S3:1280:8	patient	NNS	O	O
with	PRADAXA.xml:S3:1289:4	with	IN	O	O
renal	PRADAXA.xml:S3:1294:5	renal	JJ	O	O
impairment	PRADAXA.xml:S3:1300:10	impair	NN	O	O
[	PRADAXA.xml:S3:1312:1	[	NNP	O	O
see	PRADAXA.xml:S3:1313:3	see	VBP	O	O
Clinical	PRADAXA.xml:S3:1317:8	clinic	JJ	O	O
Pharmacology	PRADAXA.xml:S3:1326:12	pharmacolog	NNP	O	O
(	PRADAXA.xml:S3:1340:1	(	(	O	O
12.2	PRADAXA.xml:S3:1341:4	12.2	CD	O	O
)	PRADAXA.xml:S3:1345:1	)	)	O	O
]	PRADAXA.xml:S3:1348:1	]	NN	O	O
.	PRADAXA.xml:S3:1353:1	.	.	O	O

Reversal	PRADAXA.xml:S3:1360:8	revers	NNP	O	O
of	PRADAXA.xml:S3:1369:2	of	IN	O	O
Anticoagulant	PRADAXA.xml:S3:1372:13	anticoagul	NNP	O	O
Effect	PRADAXA.xml:S3:1386:6	effect	NNP	O	O
:	PRADAXA.xml:S3:1392:1	:	:	O	O
A	PRADAXA.xml:S3:1395:1	A	DT	O	O
specific	PRADAXA.xml:S3:1397:8	specif	JJ	O	O
reversal	PRADAXA.xml:S3:1406:8	revers	NN	O	O
agent	PRADAXA.xml:S3:1415:5	agent	NN	O	O
for	PRADAXA.xml:S3:1421:3	for	IN	O	O
dabigatran	PRADAXA.xml:S3:1425:10	dabigatran	NN	O	O
is	PRADAXA.xml:S3:1436:2	is	VBZ	O	O
not	PRADAXA.xml:S3:1439:3	not	RB	O	O
available	PRADAXA.xml:S3:1443:9	avail	JJ	O	O
.	PRADAXA.xml:S3:1452:1	.	.	O	O

Hemodialysis	PRADAXA.xml:S3:1454:12	hemodialysi	NN	O	O
can	PRADAXA.xml:S3:1467:3	can	MD	O	O
remove	PRADAXA.xml:S3:1471:6	remov	VB	O	O
dabigatran	PRADAXA.xml:S3:1478:10	dabigatran	NN	O	O
;	PRADAXA.xml:S3:1488:1	;	:	O	O
however	PRADAXA.xml:S3:1490:7	howev	RB	O	O
the	PRADAXA.xml:S3:1498:3	the	DT	O	O
clinical	PRADAXA.xml:S3:1502:8	clinic	JJ	O	O
experience	PRADAXA.xml:S3:1511:10	experi	NN	O	O
supporting	PRADAXA.xml:S3:1522:10	support	VBG	O	O
the	PRADAXA.xml:S3:1533:3	the	DT	O	O
use	PRADAXA.xml:S3:1537:3	use	NN	O	O
of	PRADAXA.xml:S3:1541:2	of	IN	O	O
hemodialysis	PRADAXA.xml:S3:1544:12	hemodialysi	NN	O	O
as	PRADAXA.xml:S3:1557:2	as	IN	O	O
a	PRADAXA.xml:S3:1560:1	a	DT	O	O
treatment	PRADAXA.xml:S3:1562:9	treatment	NN	O	O
for	PRADAXA.xml:S3:1572:3	for	IN	O	O
bleeding	PRADAXA.xml:S3:1576:8	bleed	NN	O	O
is	PRADAXA.xml:S3:1585:2	is	VBZ	O	O
limited	PRADAXA.xml:S3:1588:7	limit	JJ	O	O
[	PRADAXA.xml:S3:1596:1	[	NNP	O	O
see	PRADAXA.xml:S3:1597:3	see	NN	O	O
Overdosage	PRADAXA.xml:S3:1601:10	overdosag	NNP	O	O
(	PRADAXA.xml:S3:1613:1	(	(	O	O
10	PRADAXA.xml:S3:1614:2	10	CD	O	O
)	PRADAXA.xml:S3:1616:1	)	)	O	O
]	PRADAXA.xml:S3:1619:1	]	NN	O	O
.	PRADAXA.xml:S3:1622:1	.	.	O	O

Activated	PRADAXA.xml:S3:1624:9	activ	NNP	O	O
prothrombin	PRADAXA.xml:S3:1634:11	prothrombin	NN	O	O
complex	PRADAXA.xml:S3:1646:7	complex	NN	O	O
concentrates	PRADAXA.xml:S3:1654:12	concentr	NNS	O	O
(	PRADAXA.xml:S3:1667:1	(	(	O	O
aPCCs	PRADAXA.xml:S3:1668:5	apcc	NN	O	O
,	PRADAXA.xml:S3:1673:1	,	,	O	O
e	PRADAXA.xml:S3:1675:1	e	NN	O	O
.	PRADAXA.xml:S3:1676:1	.	.	O	O
g	PRADAXA.xml:S3:1677:1	g	NN	O	O
.	PRADAXA.xml:S3:1678:1	.	.	O	O
,	PRADAXA.xml:S3:1679:1	,	,	O	O
FEIBA	PRADAXA.xml:S3:1681:5	feiba	NNP	O	O
)	PRADAXA.xml:S3:1686:1	)	)	O	O
,	PRADAXA.xml:S3:1687:1	,	,	O	O
or	PRADAXA.xml:S3:1689:2	or	CC	O	O
recombinant	PRADAXA.xml:S3:1692:11	recombin	JJ	O	O
Factor	PRADAXA.xml:S3:1704:6	factor	NNP	O	O
VIIa	PRADAXA.xml:S3:1711:4	viia	NNP	O	O
,	PRADAXA.xml:S3:1715:1	,	,	O	O
or	PRADAXA.xml:S3:1717:2	or	CC	O	O
concentrates	PRADAXA.xml:S3:1720:12	concentr	NNS	O	O
of	PRADAXA.xml:S3:1733:2	of	IN	O	O
coagulation	PRADAXA.xml:S3:1736:11	coagul	NN	O	O
factors	PRADAXA.xml:S3:1748:7	factor	NNS	O	O
II	PRADAXA.xml:S3:1756:2	II	NNP	O	O
,	PRADAXA.xml:S3:1758:1	,	,	O	O
IX	PRADAXA.xml:S3:1760:2	IX	NNP	O	O
or	PRADAXA.xml:S3:1763:2	or	CC	O	O
X	PRADAXA.xml:S3:1766:1	X	NNP	O	O
may	PRADAXA.xml:S3:1768:3	may	MD	O	O
be	PRADAXA.xml:S3:1772:2	be	VB	O	O
considered	PRADAXA.xml:S3:1775:10	consid	VBN	O	O
but	PRADAXA.xml:S3:1786:3	but	CC	O	O
their	PRADAXA.xml:S3:1790:5	their	PRP$	O	O
use	PRADAXA.xml:S3:1796:3	use	NN	O	O
has	PRADAXA.xml:S3:1800:3	ha	VBZ	O	O
not	PRADAXA.xml:S3:1804:3	not	RB	O	O
been	PRADAXA.xml:S3:1808:4	been	VBN	O	O
evaluated	PRADAXA.xml:S3:1813:9	evalu	VBN	O	O
in	PRADAXA.xml:S3:1823:2	in	IN	O	O
clinical	PRADAXA.xml:S3:1826:8	clinic	JJ	O	O
trials	PRADAXA.xml:S3:1835:6	trial	NNS	O	O
.	PRADAXA.xml:S3:1841:1	.	.	O	O

Protamine	PRADAXA.xml:S3:1843:9	protamin	NNP	O	O
sulfate	PRADAXA.xml:S3:1853:7	sulfat	NN	O	O
and	PRADAXA.xml:S3:1861:3	and	CC	O	O
vitamin	PRADAXA.xml:S3:1865:7	vitamin	NN	O	O
K	PRADAXA.xml:S3:1873:1	K	NNP	O	O
are	PRADAXA.xml:S3:1875:3	are	VBP	O	O
not	PRADAXA.xml:S3:1879:3	not	RB	O	O
expected	PRADAXA.xml:S3:1883:8	expect	VBN	O	O
to	PRADAXA.xml:S3:1892:2	to	TO	O	O
affect	PRADAXA.xml:S3:1895:6	affect	VB	O	O
the	PRADAXA.xml:S3:1902:3	the	DT	O	O
anticoagulant	PRADAXA.xml:S3:1906:13	anticoagul	JJ	O	O
activity	PRADAXA.xml:S3:1920:8	activ	NN	O	O
of	PRADAXA.xml:S3:1929:2	of	IN	O	O
dabigatran	PRADAXA.xml:S3:1932:10	dabigatran	NN	O	O
.	PRADAXA.xml:S3:1942:1	.	.	O	O

Consider	PRADAXA.xml:S3:1944:8	consid	VB	O	O
administration	PRADAXA.xml:S3:1953:14	administr	NN	O	O
of	PRADAXA.xml:S3:1968:2	of	IN	O	O
platelet	PRADAXA.xml:S3:1971:8	platelet	NN	O	O
concentrates	PRADAXA.xml:S3:1980:12	concentr	NNS	O	O
in	PRADAXA.xml:S3:1993:2	in	IN	O	O
cases	PRADAXA.xml:S3:1996:5	case	NNS	O	O
where	PRADAXA.xml:S3:2002:5	where	WRB	O	O
thrombocytopenia	PRADAXA.xml:S3:2008:16	thrombocytopenia	NN	O	B-AdverseReaction
is	PRADAXA.xml:S3:2025:2	is	VBZ	O	O
present	PRADAXA.xml:S3:2028:7	present	JJ	O	O
or	PRADAXA.xml:S3:2036:2	or	CC	O	O
long	PRADAXA.xml:S3:2039:4	long	JJ	O	O
-	PRADAXA.xml:S3:2043:1	-	:	O	O
acting	PRADAXA.xml:S3:2044:6	act	VBG	O	O
antiplatelet	PRADAXA.xml:S3:2051:12	antiplatelet	NN	O	O
drugs	PRADAXA.xml:S3:2064:5	drug	NNS	O	O
have	PRADAXA.xml:S3:2070:4	have	VBP	O	O
been	PRADAXA.xml:S3:2075:4	been	VBN	O	O
used	PRADAXA.xml:S3:2080:4	use	VBN	O	O
.	PRADAXA.xml:S3:2084:1	.	.	O	O

5.3	PRADAXA.xml:S3:2093:3	5.3	CD	O	O
Spinal	PRADAXA.xml:S3:2097:6	spinal	JJ	O	O
Epidural	PRADAXA.xml:S3:2104:8	epidur	NNP	O	O
Anesthesia	PRADAXA.xml:S3:2113:10	anesthesia	NNP	O	O
or	PRADAXA.xml:S3:2124:2	or	CC	O	O
Puncture	PRADAXA.xml:S3:2127:8	punctur	NN	O	O

When	PRADAXA.xml:S3:2141:4	when	WRB	O	O
neuraxial	PRADAXA.xml:S3:2146:9	neuraxi	JJ	O	O
anesthesia	PRADAXA.xml:S3:2156:10	anesthesia	NN	O	O
(	PRADAXA.xml:S3:2167:1	(	(	O	O
spinal	PRADAXA.xml:S3:2168:6	spinal	JJ	O	O
epidural	PRADAXA.xml:S3:2175:8	epidur	JJ	O	O
anesthesia	PRADAXA.xml:S3:2184:10	anesthesia	NN	O	O
)	PRADAXA.xml:S3:2194:1	)	)	O	O
or	PRADAXA.xml:S3:2196:2	or	CC	O	O
spinal	PRADAXA.xml:S3:2199:6	spinal	JJ	O	O
puncture	PRADAXA.xml:S3:2206:8	punctur	NN	O	O
is	PRADAXA.xml:S3:2215:2	is	VBZ	O	O
employed	PRADAXA.xml:S3:2218:8	employ	VBN	O	O
,	PRADAXA.xml:S3:2226:1	,	,	O	O
patients	PRADAXA.xml:S3:2228:8	patient	NNS	O	O
treated	PRADAXA.xml:S3:2237:7	treat	VBD	O	O
with	PRADAXA.xml:S3:2245:4	with	IN	O	O
anticoagulant	PRADAXA.xml:S3:2250:13	anticoagul	JJ	O	O
agents	PRADAXA.xml:S3:2264:6	agent	NNS	O	O
are	PRADAXA.xml:S3:2271:3	are	VBP	O	O
at	PRADAXA.xml:S3:2275:2	at	IN	O	O
risk	PRADAXA.xml:S3:2278:4	risk	NN	O	O
of	PRADAXA.xml:S3:2283:2	of	IN	O	O
developing	PRADAXA.xml:S3:2286:10	develop	VBG	O	O
an	PRADAXA.xml:S3:2297:2	an	DT	O	O
epidural	PRADAXA.xml:S3:2300:8	epidur	JJ	B-AdverseReaction	B-AdverseReaction
or	PRADAXA.xml:S3:2309:2	or	CC	O	O
spinal	PRADAXA.xml:S3:2312:6	spinal	JJ	B-AdverseReaction	B-AdverseReaction
hematoma	PRADAXA.xml:S3:2319:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
which	PRADAXA.xml:S3:2328:5	which	WDT	O	O
can	PRADAXA.xml:S3:2334:3	can	MD	O	O
result	PRADAXA.xml:S3:2338:6	result	VB	O	O
in	PRADAXA.xml:S3:2345:2	in	IN	O	O
long	PRADAXA.xml:S3:2348:4	long	JJ	O	B-AdverseReaction
-	PRADAXA.xml:S3:2352:1	-	:	O	I-AdverseReaction
term	PRADAXA.xml:S3:2353:4	term	NN	O	I-AdverseReaction
or	PRADAXA.xml:S3:2358:2	or	CC	O	O
permanent	PRADAXA.xml:S3:2361:9	perman	JJ	B-AdverseReaction	B-AdverseReaction
paralysis	PRADAXA.xml:S3:2371:9	paralysi	NN	I-AdverseReaction	I-AdverseReaction
[	PRADAXA.xml:S3:2381:1	[	NNP	O	O
see	PRADAXA.xml:S3:2382:3	see	VBP	O	O
Boxed	PRADAXA.xml:S3:2387:5	box	NNP	O	O
Warning	PRADAXA.xml:S3:2393:7	warn	NNP	O	O
]	PRADAXA.xml:S3:2402:1	]	NNP	O	O
.	PRADAXA.xml:S3:2405:1	.	.	O	O

To	PRADAXA.xml:S3:2411:2	To	TO	O	O
reduce	PRADAXA.xml:S3:2414:6	reduc	VB	O	O
the	PRADAXA.xml:S3:2421:3	the	DT	O	O
potential	PRADAXA.xml:S3:2425:9	potenti	JJ	O	O
risk	PRADAXA.xml:S3:2435:4	risk	NN	O	O
of	PRADAXA.xml:S3:2440:2	of	IN	O	O
bleeding	PRADAXA.xml:S3:2443:8	bleed	VBG	O	B-AdverseReaction
associated	PRADAXA.xml:S3:2452:10	associ	VBN	O	O
with	PRADAXA.xml:S3:2463:4	with	IN	O	O
the	PRADAXA.xml:S3:2468:3	the	DT	O	O
concurrent	PRADAXA.xml:S3:2472:10	concurr	NN	O	O
use	PRADAXA.xml:S3:2483:3	use	NN	O	O
of	PRADAXA.xml:S3:2487:2	of	IN	O	O
dabigatran	PRADAXA.xml:S3:2490:10	dabigatran	NN	O	O
and	PRADAXA.xml:S3:2501:3	and	CC	O	O
epidural	PRADAXA.xml:S3:2505:8	epidur	JJ	O	B-AdverseReaction
or	PRADAXA.xml:S3:2514:2	or	CC	O	O
spinal	PRADAXA.xml:S3:2517:6	spinal	JJ	O	O
anesthesia	PRADAXA.xml:S3:2524:10	anesthesia	NN	O	O
analgesia	PRADAXA.xml:S3:2535:9	analgesia	NN	O	O
or	PRADAXA.xml:S3:2545:2	or	CC	O	O
spinal	PRADAXA.xml:S3:2548:6	spinal	JJ	O	O
puncture	PRADAXA.xml:S3:2555:8	punctur	NN	O	O
,	PRADAXA.xml:S3:2563:1	,	,	O	O
consider	PRADAXA.xml:S3:2565:8	consid	VB	O	O
the	PRADAXA.xml:S3:2574:3	the	DT	O	O
pharmacokinetic	PRADAXA.xml:S3:2578:15	pharmacokinet	JJ	O	O
profile	PRADAXA.xml:S3:2594:7	profil	NN	O	O
of	PRADAXA.xml:S3:2602:2	of	IN	O	O
dabigatran	PRADAXA.xml:S3:2605:10	dabigatran	NN	O	O
[	PRADAXA.xml:S3:2616:1	[	NNP	O	O
see	PRADAXA.xml:S3:2617:3	see	VBP	O	O
Clinical	PRADAXA.xml:S3:2621:8	clinic	JJ	O	O
Pharmacology	PRADAXA.xml:S3:2630:12	pharmacolog	NNP	O	O
(	PRADAXA.xml:S3:2644:1	(	(	O	O
12.3	PRADAXA.xml:S3:2645:4	12.3	CD	O	O
)	PRADAXA.xml:S3:2649:1	)	)	O	O
]	PRADAXA.xml:S3:2652:1	]	NN	O	O
.	PRADAXA.xml:S3:2655:1	.	.	O	O

Placement	PRADAXA.xml:S3:2657:9	placement	NN	O	O
or	PRADAXA.xml:S3:2667:2	or	CC	O	O
removal	PRADAXA.xml:S3:2670:7	remov	NN	O	O
of	PRADAXA.xml:S3:2678:2	of	IN	O	O
an	PRADAXA.xml:S3:2681:2	an	DT	O	O
epidural	PRADAXA.xml:S3:2684:8	epidur	JJ	O	O
catheter	PRADAXA.xml:S3:2693:8	cathet	NN	O	O
or	PRADAXA.xml:S3:2702:2	or	CC	O	O
lumbar	PRADAXA.xml:S3:2705:6	lumbar	NN	O	O
puncture	PRADAXA.xml:S3:2712:8	punctur	NN	O	O
is	PRADAXA.xml:S3:2721:2	is	VBZ	O	O
best	PRADAXA.xml:S3:2724:4	best	RBS	O	O
performed	PRADAXA.xml:S3:2729:9	perform	VBN	O	O
when	PRADAXA.xml:S3:2739:4	when	WRB	O	O
the	PRADAXA.xml:S3:2744:3	the	DT	O	O
anticoagulant	PRADAXA.xml:S3:2748:13	anticoagul	JJ	O	O
effect	PRADAXA.xml:S3:2762:6	effect	NN	O	O
of	PRADAXA.xml:S3:2769:2	of	IN	O	O
dabigatran	PRADAXA.xml:S3:2772:10	dabigatran	NN	O	O
is	PRADAXA.xml:S3:2783:2	is	VBZ	O	O
low	PRADAXA.xml:S3:2786:3	low	JJ	O	O
;	PRADAXA.xml:S3:2789:1	;	:	O	O
however	PRADAXA.xml:S3:2791:7	howev	RB	O	O
,	PRADAXA.xml:S3:2798:1	,	,	O	O
the	PRADAXA.xml:S3:2800:3	the	DT	O	O
exact	PRADAXA.xml:S3:2804:5	exact	JJ	O	O
timing	PRADAXA.xml:S3:2810:6	time	NN	O	O
to	PRADAXA.xml:S3:2817:2	to	TO	O	O
reach	PRADAXA.xml:S3:2820:5	reach	VB	O	O
a	PRADAXA.xml:S3:2826:1	a	DT	O	O
sufficiently	PRADAXA.xml:S3:2828:12	suffici	RB	O	O
low	PRADAXA.xml:S3:2841:3	low	JJ	O	O
anticoagulant	PRADAXA.xml:S3:2845:13	anticoagul	JJ	O	O
effect	PRADAXA.xml:S3:2859:6	effect	NN	O	O
in	PRADAXA.xml:S3:2866:2	in	IN	O	O
each	PRADAXA.xml:S3:2869:4	each	DT	O	O
patient	PRADAXA.xml:S3:2874:7	patient	NN	O	O
is	PRADAXA.xml:S3:2882:2	is	VBZ	O	O
not	PRADAXA.xml:S3:2885:3	not	RB	O	O
known	PRADAXA.xml:S3:2889:5	known	VBN	O	O
.	PRADAXA.xml:S3:2894:1	.	.	O	O

Should	PRADAXA.xml:S3:2900:6	should	MD	O	O
the	PRADAXA.xml:S3:2907:3	the	DT	O	O
physician	PRADAXA.xml:S3:2911:9	physician	JJ	O	O
decide	PRADAXA.xml:S3:2921:6	decid	NN	O	O
to	PRADAXA.xml:S3:2928:2	to	TO	O	O
administer	PRADAXA.xml:S3:2931:10	administ	VB	O	O
anticoagulation	PRADAXA.xml:S3:2942:15	anticoagul	NN	O	O
in	PRADAXA.xml:S3:2958:2	in	IN	O	O
the	PRADAXA.xml:S3:2961:3	the	DT	O	O
context	PRADAXA.xml:S3:2965:7	context	NN	O	O
of	PRADAXA.xml:S3:2973:2	of	IN	O	O
epidural	PRADAXA.xml:S3:2976:8	epidur	JJ	O	O
or	PRADAXA.xml:S3:2985:2	or	CC	O	O
spinal	PRADAXA.xml:S3:2988:6	spinal	JJ	O	O
anesthesia	PRADAXA.xml:S3:2995:10	anesthesia	NN	O	O
analgesia	PRADAXA.xml:S3:3006:9	analgesia	NN	O	O
or	PRADAXA.xml:S3:3016:2	or	CC	O	O
lumbar	PRADAXA.xml:S3:3019:6	lumbar	NN	O	O
puncture	PRADAXA.xml:S3:3026:8	punctur	NN	O	O
,	PRADAXA.xml:S3:3034:1	,	,	O	O
monitor	PRADAXA.xml:S3:3036:7	monitor	NN	O	O
frequently	PRADAXA.xml:S3:3044:10	frequent	RB	O	O
to	PRADAXA.xml:S3:3055:2	to	TO	O	O
detect	PRADAXA.xml:S3:3058:6	detect	VB	O	O
any	PRADAXA.xml:S3:3065:3	ani	DT	O	O
signs	PRADAXA.xml:S3:3069:5	sign	NNS	O	O
or	PRADAXA.xml:S3:3075:2	or	CC	O	O
symptoms	PRADAXA.xml:S3:3078:8	symptom	NNS	O	O
of	PRADAXA.xml:S3:3087:2	of	IN	O	O
neurological	PRADAXA.xml:S3:3090:12	neurolog	JJ	O	O
impairment	PRADAXA.xml:S3:3103:10	impair	NN	O	O
,	PRADAXA.xml:S3:3113:1	,	,	O	O
such	PRADAXA.xml:S3:3115:4	such	JJ	O	O
as	PRADAXA.xml:S3:3120:2	as	IN	O	O
midline	PRADAXA.xml:S3:3123:7	midlin	NN	O	O
back	PRADAXA.xml:S3:3131:4	back	RB	O	O
pain	PRADAXA.xml:S3:3136:4	pain	NN	O	O
,	PRADAXA.xml:S3:3140:1	,	,	O	O
sensory	PRADAXA.xml:S3:3142:7	sensori	NN	O	B-AdverseReaction
and	PRADAXA.xml:S3:3150:3	and	CC	O	O
motor	PRADAXA.xml:S3:3154:5	motor	NN	O	O
deficits	PRADAXA.xml:S3:3160:8	deficit	NNS	O	O
(	PRADAXA.xml:S3:3169:1	(	(	O	O
numbness	PRADAXA.xml:S3:3170:8	numb	NN	O	O
,	PRADAXA.xml:S3:3178:1	,	,	O	O
tingling	PRADAXA.xml:S3:3180:8	tingl	VBG	O	O
,	PRADAXA.xml:S3:3188:1	,	,	O	O
or	PRADAXA.xml:S3:3190:2	or	CC	O	O
weakness	PRADAXA.xml:S3:3193:8	weak	NN	O	O
in	PRADAXA.xml:S3:3202:2	in	IN	O	O
lower	PRADAXA.xml:S3:3205:5	lower	JJR	O	O
limbs	PRADAXA.xml:S3:3211:5	limb	NN	O	O
)	PRADAXA.xml:S3:3216:1	)	)	O	O
,	PRADAXA.xml:S3:3217:1	,	,	O	O
bowel	PRADAXA.xml:S3:3219:5	bowel	NN	O	O
and	PRADAXA.xml:S3:3225:3	and	CC	O	O
or	PRADAXA.xml:S3:3229:2	or	CC	O	O
bladder	PRADAXA.xml:S3:3232:7	bladder	JJR	O	O
dysfunction	PRADAXA.xml:S3:3240:11	dysfunct	NN	O	O
.	PRADAXA.xml:S3:3251:1	.	.	O	O

Instruct	PRADAXA.xml:S3:3253:8	instruct	NN	O	O
patients	PRADAXA.xml:S3:3262:8	patient	NNS	O	O
to	PRADAXA.xml:S3:3271:2	to	TO	O	O
immediately	PRADAXA.xml:S3:3274:11	immedi	RB	O	O
report	PRADAXA.xml:S3:3286:6	report	VB	O	O
if	PRADAXA.xml:S3:3293:2	if	IN	O	O
they	PRADAXA.xml:S3:3296:4	they	PRP	O	O
experience	PRADAXA.xml:S3:3301:10	experi	VBP	O	O
any	PRADAXA.xml:S3:3312:3	ani	DT	O	O
of	PRADAXA.xml:S3:3316:2	of	IN	O	O
the	PRADAXA.xml:S3:3319:3	the	DT	O	O
above	PRADAXA.xml:S3:3323:5	abov	JJ	O	O
signs	PRADAXA.xml:S3:3329:5	sign	NNS	O	O
or	PRADAXA.xml:S3:3335:2	or	CC	O	O
symptoms	PRADAXA.xml:S3:3338:8	symptom	NNS	O	O
.	PRADAXA.xml:S3:3346:1	.	.	O	O

If	PRADAXA.xml:S3:3348:2	If	IN	O	O
signs	PRADAXA.xml:S3:3351:5	sign	NNS	O	O
or	PRADAXA.xml:S3:3357:2	or	CC	O	O
symptoms	PRADAXA.xml:S3:3360:8	symptom	NNS	O	O
of	PRADAXA.xml:S3:3369:2	of	IN	O	O
spinal	PRADAXA.xml:S3:3372:6	spinal	JJ	O	O
hematoma	PRADAXA.xml:S3:3379:8	hematoma	NN	O	O
are	PRADAXA.xml:S3:3388:3	are	VBP	O	O
suspected	PRADAXA.xml:S3:3392:9	suspect	VBN	O	O
,	PRADAXA.xml:S3:3401:1	,	,	O	O
initiate	PRADAXA.xml:S3:3403:8	initi	JJ	O	O
urgent	PRADAXA.xml:S3:3412:6	urgent	JJ	O	O
diagnosis	PRADAXA.xml:S3:3419:9	diagnosi	NN	O	O
and	PRADAXA.xml:S3:3429:3	and	CC	O	O
treatment	PRADAXA.xml:S3:3433:9	treatment	NN	O	O
including	PRADAXA.xml:S3:3443:9	includ	VBG	O	O
consideration	PRADAXA.xml:S3:3453:13	consider	NN	O	O
for	PRADAXA.xml:S3:3467:3	for	IN	O	O
spinal	PRADAXA.xml:S3:3471:6	spinal	JJ	O	O
cord	PRADAXA.xml:S3:3478:4	cord	NN	O	O
decompression	PRADAXA.xml:S3:3483:13	decompress	NN	O	O
even	PRADAXA.xml:S3:3497:4	even	RB	O	O
though	PRADAXA.xml:S3:3502:6	though	IN	O	O
such	PRADAXA.xml:S3:3509:4	such	JJ	O	O
treatment	PRADAXA.xml:S3:3514:9	treatment	NN	O	O
may	PRADAXA.xml:S3:3524:3	may	MD	O	O
not	PRADAXA.xml:S3:3528:3	not	RB	O	O
prevent	PRADAXA.xml:S3:3532:7	prevent	VB	O	O
or	PRADAXA.xml:S3:3540:2	or	CC	O	O
reverse	PRADAXA.xml:S3:3543:7	revers	VB	O	O
neurological	PRADAXA.xml:S3:3551:12	neurolog	JJ	O	O
sequelae	PRADAXA.xml:S3:3564:8	sequela	NN	O	O
.	PRADAXA.xml:S3:3572:1	.	.	O	O

5.4	PRADAXA.xml:S3:3581:3	5.4	CD	O	O
Thromboembolic	PRADAXA.xml:S3:3585:14	thromboembol	NNP	O	O
and	PRADAXA.xml:S3:3600:3	and	CC	O	O
Bleeding	PRADAXA.xml:S3:3604:8	bleed	NNP	O	B-AdverseReaction
Events	PRADAXA.xml:S3:3613:6	event	NNS	O	O
in	PRADAXA.xml:S3:3620:2	in	IN	O	O
Patients	PRADAXA.xml:S3:3623:8	patient	NNS	O	O
with	PRADAXA.xml:S3:3632:4	with	IN	O	O
Prosthetic	PRADAXA.xml:S3:3637:10	prosthet	NNP	B-AdverseReaction	O
Heart	PRADAXA.xml:S3:3648:5	heart	NNP	I-AdverseReaction	O
Valves	PRADAXA.xml:S3:3654:6	valv	VBZ	O	O

The	PRADAXA.xml:S3:3666:3	the	DT	O	O
safety	PRADAXA.xml:S3:3670:6	safeti	NN	O	O
and	PRADAXA.xml:S3:3677:3	and	CC	O	O
efficacy	PRADAXA.xml:S3:3681:8	efficaci	NN	O	O
of	PRADAXA.xml:S3:3690:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S3:3693:7	pradaxa	NNP	O	O
in	PRADAXA.xml:S3:3701:2	in	IN	O	O
patients	PRADAXA.xml:S3:3704:8	patient	NNS	O	O
with	PRADAXA.xml:S3:3713:4	with	IN	O	O
bileaflet	PRADAXA.xml:S3:3718:9	bileaflet	JJ	O	O
mechanical	PRADAXA.xml:S3:3728:10	mechan	JJ	O	O
prosthetic	PRADAXA.xml:S3:3739:10	prosthet	JJ	O	O
heart	PRADAXA.xml:S3:3750:5	heart	NN	O	O
valves	PRADAXA.xml:S3:3756:6	valv	NNS	O	O
was	PRADAXA.xml:S3:3763:3	wa	VBD	O	O
evaluated	PRADAXA.xml:S3:3767:9	evalu	VBN	O	O
in	PRADAXA.xml:S3:3777:2	in	IN	O	O
the	PRADAXA.xml:S3:3780:3	the	DT	O	O
RE	PRADAXA.xml:S3:3784:2	RE	NNP	O	O
-	PRADAXA.xml:S3:3786:1	-	:	O	O
ALIGN	PRADAXA.xml:S3:3787:5	align	NNP	O	O
trial	PRADAXA.xml:S3:3793:5	trial	NN	O	O
,	PRADAXA.xml:S3:3798:1	,	,	O	O
in	PRADAXA.xml:S3:3800:2	in	IN	O	O
which	PRADAXA.xml:S3:3803:5	which	WDT	O	O
patients	PRADAXA.xml:S3:3809:8	patient	NNS	O	O
with	PRADAXA.xml:S3:3818:4	with	IN	O	O
bileaflet	PRADAXA.xml:S3:3823:9	bileaflet	JJ	O	O
mechanical	PRADAXA.xml:S3:3833:10	mechan	JJ	O	O
prosthetic	PRADAXA.xml:S3:3844:10	prosthet	JJ	O	O
heart	PRADAXA.xml:S3:3855:5	heart	NN	O	O
valves	PRADAXA.xml:S3:3861:6	valv	NNS	O	O
(	PRADAXA.xml:S3:3868:1	(	(	O	O
recently	PRADAXA.xml:S3:3869:8	recent	RB	O	O
implanted	PRADAXA.xml:S3:3878:9	implant	VBN	O	O
or	PRADAXA.xml:S3:3888:2	or	CC	O	O
implanted	PRADAXA.xml:S3:3891:9	implant	VBN	O	O
more	PRADAXA.xml:S3:3901:4	more	JJR	O	O
than	PRADAXA.xml:S3:3906:4	than	IN	O	O
three	PRADAXA.xml:S3:3911:5	three	CD	O	O
months	PRADAXA.xml:S3:3917:6	month	NNS	O	O
prior	PRADAXA.xml:S3:3924:5	prior	RB	O	O
to	PRADAXA.xml:S3:3930:2	to	TO	O	O
enrollment	PRADAXA.xml:S3:3933:10	enrol	NN	O	O
)	PRADAXA.xml:S3:3943:1	)	)	O	O
were	PRADAXA.xml:S3:3945:4	were	VBD	O	O
randomized	PRADAXA.xml:S3:3950:10	random	VBN	O	O
to	PRADAXA.xml:S3:3961:2	to	TO	O	O
dose	PRADAXA.xml:S3:3964:4	dose	VB	O	O
adjusted	PRADAXA.xml:S3:3969:8	adjust	JJ	O	O
warfarin	PRADAXA.xml:S3:3978:8	warfarin	NN	O	O
or	PRADAXA.xml:S3:3987:2	or	CC	O	O
150	PRADAXA.xml:S3:3990:3	150	CD	O	O
,	PRADAXA.xml:S3:3993:1	,	,	O	O
220	PRADAXA.xml:S3:3995:3	220	CD	O	O
,	PRADAXA.xml:S3:3998:1	,	,	O	O
or	PRADAXA.xml:S3:4000:2	or	CC	O	O
300	PRADAXA.xml:S3:4003:3	300	CD	O	O
mg	PRADAXA.xml:S3:4007:2	mg	NN	O	O
of	PRADAXA.xml:S3:4010:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S3:4013:7	pradaxa	NNP	O	O
twice	PRADAXA.xml:S3:4021:5	twice	RB	O	O
a	PRADAXA.xml:S3:4027:1	a	DT	O	O
day	PRADAXA.xml:S3:4029:3	day	NN	O	O
.	PRADAXA.xml:S3:4032:1	.	.	O	O

RE	PRADAXA.xml:S3:4034:2	RE	NNP	O	O
-	PRADAXA.xml:S3:4036:1	-	:	O	O
ALIGN	PRADAXA.xml:S3:4037:5	align	NNP	O	O
was	PRADAXA.xml:S3:4043:3	wa	VBD	O	O
terminated	PRADAXA.xml:S3:4047:10	termin	VBN	O	O
early	PRADAXA.xml:S3:4058:5	earli	RB	O	O
due	PRADAXA.xml:S3:4064:3	due	JJ	O	O
to	PRADAXA.xml:S3:4068:2	to	TO	O	O
the	PRADAXA.xml:S3:4071:3	the	DT	O	O
occurrence	PRADAXA.xml:S3:4075:10	occurr	NN	O	O
of	PRADAXA.xml:S3:4086:2	of	IN	O	O
significantly	PRADAXA.xml:S3:4089:13	significantli	RB	O	O
more	PRADAXA.xml:S3:4103:4	more	RBR	O	O
thromboembolic	PRADAXA.xml:S3:4108:14	thromboembol	JJ	B-AdverseReaction	B-AdverseReaction
events	PRADAXA.xml:S3:4123:6	event	NNS	I-AdverseReaction	I-AdverseReaction
(	PRADAXA.xml:S3:4130:1	(	(	O	O
valve	PRADAXA.xml:S3:4131:5	valv	JJ	I-AdverseReaction	B-AdverseReaction
thrombosis	PRADAXA.xml:S3:4137:10	thrombosi	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S3:4147:1	,	,	O	O
stroke	PRADAXA.xml:S3:4149:6	stroke	NN	I-AdverseReaction	B-AdverseReaction
,	PRADAXA.xml:S3:4155:1	,	,	O	O
transient	PRADAXA.xml:S3:4157:9	transient	JJ	B-AdverseReaction	B-AdverseReaction
ischemic	PRADAXA.xml:S3:4167:8	ischem	JJ	I-AdverseReaction	I-AdverseReaction
attack	PRADAXA.xml:S3:4176:6	attack	NN	I-AdverseReaction	I-AdverseReaction
,	PRADAXA.xml:S3:4182:1	,	,	O	O
and	PRADAXA.xml:S3:4184:3	and	CC	O	O
myocardial	PRADAXA.xml:S3:4188:10	myocardi	JJ	B-AdverseReaction	B-AdverseReaction
infarction	PRADAXA.xml:S3:4199:10	infarct	NN	I-AdverseReaction	I-AdverseReaction
)	PRADAXA.xml:S3:4209:1	)	)	O	O
and	PRADAXA.xml:S3:4211:3	and	CC	O	O
an	PRADAXA.xml:S3:4215:2	an	DT	O	O
excess	PRADAXA.xml:S3:4218:6	excess	NN	O	O
of	PRADAXA.xml:S3:4225:2	of	IN	O	O
major	PRADAXA.xml:S3:4228:5	major	JJ	O	O
bleeding	PRADAXA.xml:S3:4234:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
(	PRADAXA.xml:S3:4243:1	(	(	O	O
predominantly	PRADAXA.xml:S3:4244:13	predominantli	RB	O	O
post	PRADAXA.xml:S3:4258:4	post	VBN	O	O
-	PRADAXA.xml:S3:4262:1	-	:	O	O
operative	PRADAXA.xml:S3:4263:9	oper	JJ	O	O
pericardial	PRADAXA.xml:S3:4273:11	pericardi	JJ	B-AdverseReaction	O
effusions	PRADAXA.xml:S3:4285:9	effus	NNS	I-AdverseReaction	O
requiring	PRADAXA.xml:S3:4295:9	requir	VBG	O	O
intervention	PRADAXA.xml:S3:4305:12	intervent	NN	O	O
for	PRADAXA.xml:S3:4318:3	for	IN	O	O
hemodynamic	PRADAXA.xml:S3:4322:11	hemodynam	JJ	O	O
compromise	PRADAXA.xml:S3:4334:10	compromis	NN	O	O
)	PRADAXA.xml:S3:4344:1	)	)	O	O
in	PRADAXA.xml:S3:4346:2	in	IN	O	O
the	PRADAXA.xml:S3:4349:3	the	DT	O	O
PRADAXA	PRADAXA.xml:S3:4353:7	pradaxa	NNP	O	O
treatment	PRADAXA.xml:S3:4361:9	treatment	NN	O	O
arm	PRADAXA.xml:S3:4371:3	arm	NN	O	O
as	PRADAXA.xml:S3:4375:2	as	IN	O	O
compared	PRADAXA.xml:S3:4378:8	compar	VBN	O	O
to	PRADAXA.xml:S3:4387:2	to	TO	O	O
the	PRADAXA.xml:S3:4390:3	the	DT	O	O
warfarin	PRADAXA.xml:S3:4394:8	warfarin	NN	O	O
treatment	PRADAXA.xml:S3:4403:9	treatment	NN	O	O
arm	PRADAXA.xml:S3:4413:3	arm	NN	O	O
.	PRADAXA.xml:S3:4416:1	.	.	O	O

These	PRADAXA.xml:S3:4418:5	these	DT	O	O
bleeding	PRADAXA.xml:S3:4424:8	bleed	NN	B-AdverseReaction	B-AdverseReaction
and	PRADAXA.xml:S3:4433:3	and	CC	O	O
thromboembolic	PRADAXA.xml:S3:4437:14	thromboembol	JJ	B-AdverseReaction	B-AdverseReaction
events	PRADAXA.xml:S3:4452:6	event	NNS	I-AdverseReaction	I-AdverseReaction
were	PRADAXA.xml:S3:4459:4	were	VBD	O	O
seen	PRADAXA.xml:S3:4464:4	seen	VBN	O	O
both	PRADAXA.xml:S3:4469:4	both	DT	O	O
in	PRADAXA.xml:S3:4474:2	in	IN	O	O
patients	PRADAXA.xml:S3:4477:8	patient	NNS	O	O
who	PRADAXA.xml:S3:4486:3	who	WP	O	O
were	PRADAXA.xml:S3:4490:4	were	VBD	O	O
initiated	PRADAXA.xml:S3:4495:9	initi	VBN	O	O
on	PRADAXA.xml:S3:4505:2	on	IN	O	O
PRADAXA	PRADAXA.xml:S3:4508:7	pradaxa	NNP	O	O
post	PRADAXA.xml:S3:4516:4	post	NN	O	O
-	PRADAXA.xml:S3:4520:1	-	:	O	O
operatively	PRADAXA.xml:S3:4521:11	oper	RB	O	O
within	PRADAXA.xml:S3:4533:6	within	IN	O	O
three	PRADAXA.xml:S3:4540:5	three	CD	O	O
days	PRADAXA.xml:S3:4546:4	day	NNS	O	O
of	PRADAXA.xml:S3:4551:2	of	IN	O	O
mechanical	PRADAXA.xml:S3:4554:10	mechan	JJ	O	O
bileaflet	PRADAXA.xml:S3:4565:9	bileaflet	NN	O	O
valve	PRADAXA.xml:S3:4575:5	valv	NN	O	O
implantation	PRADAXA.xml:S3:4581:12	implant	NN	O	O
,	PRADAXA.xml:S3:4593:1	,	,	O	O
as	PRADAXA.xml:S3:4595:2	as	RB	O	O
well	PRADAXA.xml:S3:4598:4	well	RB	O	O
as	PRADAXA.xml:S3:4603:2	as	IN	O	O
in	PRADAXA.xml:S3:4606:2	in	IN	O	O
patients	PRADAXA.xml:S3:4609:8	patient	NNS	O	O
whose	PRADAXA.xml:S3:4618:5	whose	WP$	O	O
valves	PRADAXA.xml:S3:4624:6	valv	NNS	O	O
had	PRADAXA.xml:S3:4631:3	had	VBD	O	O
been	PRADAXA.xml:S3:4635:4	been	VBN	O	O
implanted	PRADAXA.xml:S3:4640:9	implant	VBN	O	O
more	PRADAXA.xml:S3:4650:4	more	RBR	O	O
than	PRADAXA.xml:S3:4655:4	than	IN	O	O
three	PRADAXA.xml:S3:4660:5	three	CD	O	O
months	PRADAXA.xml:S3:4666:6	month	NNS	O	O
prior	PRADAXA.xml:S3:4673:5	prior	RB	O	O
to	PRADAXA.xml:S3:4679:2	to	TO	O	O
enrollment	PRADAXA.xml:S3:4682:10	enrol	NN	O	O
.	PRADAXA.xml:S3:4692:1	.	.	O	O

Therefore	PRADAXA.xml:S3:4694:9	therefor	RB	O	O
,	PRADAXA.xml:S3:4703:1	,	,	O	O
the	PRADAXA.xml:S3:4705:3	the	DT	O	O
use	PRADAXA.xml:S3:4709:3	use	NN	O	O
of	PRADAXA.xml:S3:4713:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S3:4716:7	pradaxa	NNP	O	O
is	PRADAXA.xml:S3:4724:2	is	VBZ	O	O
contraindicated	PRADAXA.xml:S3:4727:15	contraind	VBN	O	O
in	PRADAXA.xml:S3:4743:2	in	IN	O	O
patients	PRADAXA.xml:S3:4746:8	patient	NNS	O	O
with	PRADAXA.xml:S3:4755:4	with	IN	O	O
mechanical	PRADAXA.xml:S3:4760:10	mechan	JJ	O	O
prosthetic	PRADAXA.xml:S3:4771:10	prosthet	JJ	O	O
valves	PRADAXA.xml:S3:4782:6	valv	NNS	O	O
[	PRADAXA.xml:S3:4789:1	[	VBP	O	O
see	PRADAXA.xml:S3:4790:3	see	VB	O	O
Contraindications	PRADAXA.xml:S3:4794:17	contraind	NNP	O	O
(	PRADAXA.xml:S3:4813:1	(	(	O	O
4	PRADAXA.xml:S3:4814:1	4	CD	O	O
)	PRADAXA.xml:S3:4815:1	)	)	O	O
]	PRADAXA.xml:S3:4818:1	]	NN	O	O
.	PRADAXA.xml:S3:4819:1	.	.	O	O

The	PRADAXA.xml:S3:4827:3	the	DT	O	O
use	PRADAXA.xml:S3:4831:3	use	NN	O	O
of	PRADAXA.xml:S3:4835:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S3:4838:7	pradaxa	NNP	O	O
for	PRADAXA.xml:S3:4846:3	for	IN	O	O
the	PRADAXA.xml:S3:4850:3	the	DT	O	O
prophylaxis	PRADAXA.xml:S3:4854:11	prophylaxi	NN	O	O
of	PRADAXA.xml:S3:4866:2	of	IN	O	O
thromboembolic	PRADAXA.xml:S3:4869:14	thromboembol	JJ	O	B-AdverseReaction
events	PRADAXA.xml:S3:4884:6	event	NNS	O	I-AdverseReaction
in	PRADAXA.xml:S3:4891:2	in	IN	O	O
patients	PRADAXA.xml:S3:4894:8	patient	NNS	O	O
with	PRADAXA.xml:S3:4903:4	with	IN	O	O
atrial	PRADAXA.xml:S3:4908:6	atrial	JJ	O	O
fibrillation	PRADAXA.xml:S3:4915:12	fibril	NN	O	O
in	PRADAXA.xml:S3:4928:2	in	IN	O	O
the	PRADAXA.xml:S3:4931:3	the	DT	O	O
setting	PRADAXA.xml:S3:4935:7	set	NN	O	O
of	PRADAXA.xml:S3:4943:2	of	IN	O	O
other	PRADAXA.xml:S3:4946:5	other	JJ	O	O
forms	PRADAXA.xml:S3:4952:5	form	NNS	O	O
of	PRADAXA.xml:S3:4958:2	of	IN	O	O
valvular	PRADAXA.xml:S3:4961:8	valvular	JJ	O	O
heart	PRADAXA.xml:S3:4970:5	heart	NN	O	O
disease	PRADAXA.xml:S3:4976:7	diseas	NN	O	O
,	PRADAXA.xml:S3:4983:1	,	,	O	O
including	PRADAXA.xml:S3:4985:9	includ	VBG	O	O
the	PRADAXA.xml:S3:4995:3	the	DT	O	O
presence	PRADAXA.xml:S3:4999:8	presenc	NN	O	O
of	PRADAXA.xml:S3:5008:2	of	IN	O	O
a	PRADAXA.xml:S3:5011:1	a	DT	O	O
bioprosthetic	PRADAXA.xml:S3:5013:13	bioprosthet	JJ	O	O
heart	PRADAXA.xml:S3:5027:5	heart	NN	O	O
valve	PRADAXA.xml:S3:5033:5	valv	NN	O	O
,	PRADAXA.xml:S3:5038:1	,	,	O	O
has	PRADAXA.xml:S3:5040:3	ha	VBZ	O	O
not	PRADAXA.xml:S3:5044:3	not	RB	O	O
been	PRADAXA.xml:S3:5048:4	been	VBN	O	O
studied	PRADAXA.xml:S3:5053:7	studi	VBN	O	O
and	PRADAXA.xml:S3:5061:3	and	CC	O	O
is	PRADAXA.xml:S3:5065:2	is	VBZ	O	O
not	PRADAXA.xml:S3:5068:3	not	RB	O	O
recommended	PRADAXA.xml:S3:5072:11	recommend	VBN	O	O
.	PRADAXA.xml:S3:5083:1	.	.	O	O

5.5	PRADAXA.xml:S3:5092:3	5.5	CD	O	O
Effect	PRADAXA.xml:S3:5096:6	effect	NNP	O	O
of	PRADAXA.xml:S3:5103:2	of	IN	O	O
P	PRADAXA.xml:S3:5106:1	P	NNP	O	O
-	PRADAXA.xml:S3:5107:1	-	:	O	O
gp	PRADAXA.xml:S3:5108:2	gp	NN	O	O
Inducers	PRADAXA.xml:S3:5111:8	induc	NNS	O	O
and	PRADAXA.xml:S3:5120:3	and	CC	O	O
Inhibitors	PRADAXA.xml:S3:5124:10	inhibitor	NNS	O	O
on	PRADAXA.xml:S3:5135:2	on	IN	O	O
Dabigatran	PRADAXA.xml:S3:5138:10	dabigatran	NNP	O	O
Exposure	PRADAXA.xml:S3:5149:8	exposur	NN	O	O

The	PRADAXA.xml:S3:5163:3	the	DT	O	O
concomitant	PRADAXA.xml:S3:5167:11	concomit	NN	O	O
use	PRADAXA.xml:S3:5179:3	use	NN	O	O
of	PRADAXA.xml:S3:5183:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S3:5186:7	pradaxa	NNP	O	O
with	PRADAXA.xml:S3:5194:4	with	IN	O	O
P	PRADAXA.xml:S3:5199:1	P	NNP	O	O
-	PRADAXA.xml:S3:5200:1	-	:	O	O
gp	PRADAXA.xml:S3:5201:2	gp	NN	O	O
inducers	PRADAXA.xml:S3:5204:8	induc	NNS	O	O
(	PRADAXA.xml:S3:5213:1	(	(	O	O
e	PRADAXA.xml:S3:5214:1	e	NN	O	O
.	PRADAXA.xml:S3:5215:1	.	.	O	O
g	PRADAXA.xml:S3:5216:1	g	NN	O	O
.	PRADAXA.xml:S3:5217:1	.	.	O	O
,	PRADAXA.xml:S3:5218:1	,	,	O	O
rifampin	PRADAXA.xml:S3:5220:8	rifampin	NN	O	O
)	PRADAXA.xml:S3:5228:1	)	)	O	O
reduces	PRADAXA.xml:S3:5230:7	reduc	VBZ	O	O
exposure	PRADAXA.xml:S3:5238:8	exposur	NN	O	O
to	PRADAXA.xml:S3:5247:2	to	TO	O	O
dabigatran	PRADAXA.xml:S3:5250:10	dabigatran	VB	O	O
and	PRADAXA.xml:S3:5261:3	and	CC	O	O
should	PRADAXA.xml:S3:5265:6	should	MD	O	O
generally	PRADAXA.xml:S3:5272:9	gener	RB	O	O
be	PRADAXA.xml:S3:5282:2	be	VB	O	O
avoided	PRADAXA.xml:S3:5285:7	avoid	VBN	O	O
[	PRADAXA.xml:S3:5293:1	[	NNP	O	O
see	PRADAXA.xml:S3:5294:3	see	VBP	O	O
Clinical	PRADAXA.xml:S3:5298:8	clinic	JJ	O	O
Pharmacology	PRADAXA.xml:S3:5307:12	pharmacolog	NNP	O	O
(	PRADAXA.xml:S3:5321:1	(	(	O	O
12.3	PRADAXA.xml:S3:5322:4	12.3	CD	O	O
)	PRADAXA.xml:S3:5326:1	)	)	O	O
]	PRADAXA.xml:S3:5329:1	]	NN	O	O
.	PRADAXA.xml:S3:5332:1	.	.	O	O

P	PRADAXA.xml:S3:5338:1	P	NNP	O	O
-	PRADAXA.xml:S3:5339:1	-	:	O	O
gp	PRADAXA.xml:S3:5340:2	gp	NN	O	O
inhibition	PRADAXA.xml:S3:5343:10	inhibit	NN	O	O
and	PRADAXA.xml:S3:5354:3	and	CC	O	O
impaired	PRADAXA.xml:S3:5358:8	impair	JJ	O	B-AdverseReaction
renal	PRADAXA.xml:S3:5367:5	renal	JJ	O	I-AdverseReaction
function	PRADAXA.xml:S3:5373:8	function	NN	O	I-AdverseReaction
are	PRADAXA.xml:S3:5382:3	are	VBP	O	O
the	PRADAXA.xml:S3:5386:3	the	DT	O	O
major	PRADAXA.xml:S3:5390:5	major	JJ	O	O
independent	PRADAXA.xml:S3:5396:11	independ	JJ	O	O
factors	PRADAXA.xml:S3:5408:7	factor	NNS	O	O
that	PRADAXA.xml:S3:5416:4	that	WDT	O	O
result	PRADAXA.xml:S3:5421:6	result	VBP	O	O
in	PRADAXA.xml:S3:5428:2	in	IN	O	O
increased	PRADAXA.xml:S3:5431:9	increas	JJ	O	O
exposure	PRADAXA.xml:S3:5441:8	exposur	NN	O	O
to	PRADAXA.xml:S3:5450:2	to	TO	O	O
dabigatran	PRADAXA.xml:S3:5453:10	dabigatran	VB	O	O
[	PRADAXA.xml:S3:5464:1	[	NNP	O	O
see	PRADAXA.xml:S3:5465:3	see	VB	O	O
Clinical	PRADAXA.xml:S3:5469:8	clinic	JJ	O	O
Pharmacology	PRADAXA.xml:S3:5478:12	pharmacolog	NNP	O	O
(	PRADAXA.xml:S3:5492:1	(	(	O	O
12.3	PRADAXA.xml:S3:5493:4	12.3	CD	O	O
)	PRADAXA.xml:S3:5497:1	)	)	O	O
]	PRADAXA.xml:S3:5500:1	]	NN	O	O
.	PRADAXA.xml:S3:5501:1	.	.	O	O

Concomitant	PRADAXA.xml:S3:5504:11	concomit	NNP	O	O
use	PRADAXA.xml:S3:5516:3	use	NN	O	O
of	PRADAXA.xml:S3:5520:2	of	IN	O	O
P	PRADAXA.xml:S3:5523:1	P	NNP	O	O
-	PRADAXA.xml:S3:5524:1	-	:	O	O
gp	PRADAXA.xml:S3:5525:2	gp	NN	O	O
inhibitors	PRADAXA.xml:S3:5528:10	inhibitor	NNS	O	O
in	PRADAXA.xml:S3:5539:2	in	IN	O	O
patients	PRADAXA.xml:S3:5542:8	patient	NNS	O	O
with	PRADAXA.xml:S3:5551:4	with	IN	O	O
renal	PRADAXA.xml:S3:5556:5	renal	JJ	O	O
impairment	PRADAXA.xml:S3:5562:10	impair	NN	O	O
is	PRADAXA.xml:S3:5573:2	is	VBZ	O	O
expected	PRADAXA.xml:S3:5576:8	expect	VBN	O	O
to	PRADAXA.xml:S3:5585:2	to	TO	O	O
produce	PRADAXA.xml:S3:5588:7	produc	VB	O	O
increased	PRADAXA.xml:S3:5596:9	increas	JJ	O	O
exposure	PRADAXA.xml:S3:5606:8	exposur	NN	O	O
of	PRADAXA.xml:S3:5615:2	of	IN	O	O
dabigatran	PRADAXA.xml:S3:5618:10	dabigatran	NN	O	O
compared	PRADAXA.xml:S3:5629:8	compar	VBN	O	O
to	PRADAXA.xml:S3:5638:2	to	TO	O	O
that	PRADAXA.xml:S3:5641:4	that	DT	O	O
seen	PRADAXA.xml:S3:5646:4	seen	VBN	O	O
with	PRADAXA.xml:S3:5651:4	with	IN	O	O
either	PRADAXA.xml:S3:5656:6	either	DT	O	O
factor	PRADAXA.xml:S3:5663:6	factor	NN	O	O
alone	PRADAXA.xml:S3:5670:5	alon	RB	O	O
.	PRADAXA.xml:S3:5675:1	.	.	O	O

Reduction	PRADAXA.xml:S3:5683:9	reduct	NN	O	O
of	PRADAXA.xml:S3:5693:2	of	IN	O	O
Risk	PRADAXA.xml:S3:5696:4	risk	NN	O	O
of	PRADAXA.xml:S3:5701:2	of	IN	O	O
Stroke	PRADAXA.xml:S3:5704:6	stroke	NNP	O	O
and	PRADAXA.xml:S3:5711:3	and	CC	O	O
Systemic	PRADAXA.xml:S3:5715:8	system	NNP	O	O
Embolism	PRADAXA.xml:S3:5724:8	embol	NNP	O	O
in	PRADAXA.xml:S3:5733:2	in	IN	O	O
Non	PRADAXA.xml:S3:5736:3	non	NNP	O	O
-	PRADAXA.xml:S3:5739:1	-	:	O	O
valvular	PRADAXA.xml:S3:5740:8	valvular	JJ	O	O
Atrial	PRADAXA.xml:S3:5749:6	atrial	NNP	O	O
Fibrillation	PRADAXA.xml:S3:5756:12	fibril	NN	O	O

Reduce	PRADAXA.xml:S3:5777:6	reduc	VB	O	O
the	PRADAXA.xml:S3:5784:3	the	DT	O	O
dose	PRADAXA.xml:S3:5788:4	dose	NN	O	O
of	PRADAXA.xml:S3:5793:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S3:5796:7	pradaxa	NNP	O	O
to	PRADAXA.xml:S3:5804:2	to	TO	O	O
75	PRADAXA.xml:S3:5807:2	75	CD	O	O
mg	PRADAXA.xml:S3:5810:2	mg	NNS	O	O
twice	PRADAXA.xml:S3:5813:5	twice	RB	O	O
daily	PRADAXA.xml:S3:5819:5	daili	RB	O	O
when	PRADAXA.xml:S3:5825:4	when	WRB	O	O
dronedarone	PRADAXA.xml:S3:5830:11	dronedaron	NN	O	O
or	PRADAXA.xml:S3:5842:2	or	CC	O	O
systemic	PRADAXA.xml:S3:5845:8	system	JJ	O	O
ketoconazole	PRADAXA.xml:S3:5854:12	ketoconazol	NN	O	O
is	PRADAXA.xml:S3:5867:2	is	VBZ	O	O
coadministered	PRADAXA.xml:S3:5870:14	coadminist	VBN	O	O
with	PRADAXA.xml:S3:5885:4	with	IN	O	O
PRADAXA	PRADAXA.xml:S3:5890:7	pradaxa	NNP	O	O
in	PRADAXA.xml:S3:5898:2	in	IN	O	O
patients	PRADAXA.xml:S3:5901:8	patient	NNS	O	O
with	PRADAXA.xml:S3:5910:4	with	IN	O	O
moderate	PRADAXA.xml:S3:5915:8	moder	JJ	O	O
renal	PRADAXA.xml:S3:5924:5	renal	JJ	O	O
impairment	PRADAXA.xml:S3:5930:10	impair	NN	O	O
(	PRADAXA.xml:S3:5941:1	(	(	O	O
CrCl	PRADAXA.xml:S3:5942:4	crcl	NNP	O	O
30	PRADAXA.xml:S3:5947:2	30	CD	O	O
-	PRADAXA.xml:S3:5949:1	-	:	O	O
50	PRADAXA.xml:S3:5950:2	50	CD	O	O
mL	PRADAXA.xml:S3:5953:2	mL	NNS	O	O
min	PRADAXA.xml:S3:5956:3	min	NN	O	O
)	PRADAXA.xml:S3:5959:1	)	)	O	O
.	PRADAXA.xml:S3:5960:1	.	.	O	O

Avoid	PRADAXA.xml:S3:5962:5	avoid	NNP	O	O
use	PRADAXA.xml:S3:5968:3	use	NN	O	O
of	PRADAXA.xml:S3:5972:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S3:5975:7	pradaxa	NNP	O	O
and	PRADAXA.xml:S3:5983:3	and	CC	O	O
P	PRADAXA.xml:S3:5987:1	P	NNP	O	O
-	PRADAXA.xml:S3:5988:1	-	:	O	O
gp	PRADAXA.xml:S3:5989:2	gp	NN	O	O
inhibitors	PRADAXA.xml:S3:5992:10	inhibitor	NNS	O	O
in	PRADAXA.xml:S3:6003:2	in	IN	O	O
patients	PRADAXA.xml:S3:6006:8	patient	NNS	O	O
with	PRADAXA.xml:S3:6015:4	with	IN	O	O
severe	PRADAXA.xml:S3:6020:6	sever	JJ	O	O
renal	PRADAXA.xml:S3:6027:5	renal	JJ	O	O
impairment	PRADAXA.xml:S3:6033:10	impair	NN	O	O
(	PRADAXA.xml:S3:6044:1	(	(	O	O
CrCl	PRADAXA.xml:S3:6045:4	crcl	NNP	O	O
15	PRADAXA.xml:S3:6050:2	15	CD	O	O
-	PRADAXA.xml:S3:6052:1	-	:	O	O
30	PRADAXA.xml:S3:6053:2	30	CD	O	O
mL	PRADAXA.xml:S3:6056:2	mL	NNS	O	O
min	PRADAXA.xml:S3:6059:3	min	NN	O	O
)	PRADAXA.xml:S3:6062:1	)	)	O	O
[	PRADAXA.xml:S3:6064:1	[	FW	O	O
see	PRADAXA.xml:S3:6065:3	see	VBP	O	O
Drug	PRADAXA.xml:S3:6069:4	drug	JJ	O	O
Interactions	PRADAXA.xml:S3:6074:12	interact	NNP	O	O
(	PRADAXA.xml:S3:6088:1	(	(	O	O
7.1	PRADAXA.xml:S3:6089:3	7.1	CD	O	O
)	PRADAXA.xml:S3:6092:1	)	)	O	O
and	PRADAXA.xml:S3:6095:3	and	CC	O	O
Use	PRADAXA.xml:S3:6099:3	use	NNP	O	O
in	PRADAXA.xml:S3:6103:2	in	IN	O	O
Specific	PRADAXA.xml:S3:6106:8	specif	NNP	O	O
Populations	PRADAXA.xml:S3:6115:11	popul	NNP	O	O
(	PRADAXA.xml:S3:6128:1	(	(	O	O
8.6	PRADAXA.xml:S3:6129:3	8.6	CD	O	O
)	PRADAXA.xml:S3:6132:1	)	)	O	O
]	PRADAXA.xml:S3:6135:1	]	NN	O	O
.	PRADAXA.xml:S3:6138:1	.	.	O	O

Treatment	PRADAXA.xml:S3:6146:9	treatment	NN	O	O
and	PRADAXA.xml:S3:6156:3	and	CC	O	O
Reduction	PRADAXA.xml:S3:6160:9	reduct	NNP	O	O
in	PRADAXA.xml:S3:6170:2	in	IN	O	O
the	PRADAXA.xml:S3:6173:3	the	DT	O	O
Risk	PRADAXA.xml:S3:6177:4	risk	NN	O	O
of	PRADAXA.xml:S3:6182:2	of	IN	O	O
Recurrence	PRADAXA.xml:S3:6185:10	recurr	NNP	O	O
of	PRADAXA.xml:S3:6196:2	of	IN	O	O
Deep	PRADAXA.xml:S3:6199:4	deep	NNP	O	O
Venous	PRADAXA.xml:S3:6204:6	venou	NNP	O	O
Thrombosis	PRADAXA.xml:S3:6211:10	thrombosi	NNP	O	O
and	PRADAXA.xml:S3:6222:3	and	CC	O	O
Pulmonary	PRADAXA.xml:S3:6226:9	pulmonari	NNP	O	B-AdverseReaction
Embolism	PRADAXA.xml:S3:6236:8	embol	NNP	O	I-AdverseReaction

Avoid	PRADAXA.xml:S3:6253:5	avoid	NNP	O	O
use	PRADAXA.xml:S3:6259:3	use	NN	O	O
of	PRADAXA.xml:S3:6263:2	of	IN	O	O
PRADAXA	PRADAXA.xml:S3:6266:7	pradaxa	NNP	O	O
and	PRADAXA.xml:S3:6274:3	and	CC	O	O
concomitant	PRADAXA.xml:S3:6278:11	concomit	JJ	O	O
P	PRADAXA.xml:S3:6290:1	P	NNP	O	O
-	PRADAXA.xml:S3:6291:1	-	:	O	O
gp	PRADAXA.xml:S3:6292:2	gp	NN	O	O
inhibitors	PRADAXA.xml:S3:6295:10	inhibitor	NNS	O	O
in	PRADAXA.xml:S3:6306:2	in	IN	O	O
patients	PRADAXA.xml:S3:6309:8	patient	NNS	O	O
with	PRADAXA.xml:S3:6318:4	with	IN	O	O
CrCl	PRADAXA.xml:S3:6323:4	crcl	NNP	O	O
50	PRADAXA.xml:S3:6329:2	50	CD	O	O
mL	PRADAXA.xml:S3:6332:2	mL	NN	O	O
min	PRADAXA.xml:S3:6335:3	min	NN	O	O
[	PRADAXA.xml:S3:6339:1	[	NNP	O	O
see	PRADAXA.xml:S3:6340:3	see	VBP	O	O
Drug	PRADAXA.xml:S3:6344:4	drug	NNP	O	O
Interactions	PRADAXA.xml:S3:6349:12	interact	NNP	O	O
(	PRADAXA.xml:S3:6363:1	(	(	O	O
7.2	PRADAXA.xml:S3:6364:3	7.2	CD	O	O
)	PRADAXA.xml:S3:6367:1	)	)	O	O
and	PRADAXA.xml:S3:6370:3	and	CC	O	O
Use	PRADAXA.xml:S3:6374:3	use	NNP	O	O
in	PRADAXA.xml:S3:6378:2	in	IN	O	O
Specific	PRADAXA.xml:S3:6381:8	specif	NNP	O	O
Populations	PRADAXA.xml:S3:6390:11	popul	NNP	O	O
(	PRADAXA.xml:S3:6403:1	(	(	O	O
8.6	PRADAXA.xml:S3:6404:3	8.6	CD	O	O
)	PRADAXA.xml:S3:6407:1	)	)	O	O
]	PRADAXA.xml:S3:6410:1	]	NN	O	O
.	PRADAXA.xml:S3:6413:1	.	.	O	O
6	PRISTIQ.xml:S1:4:1	6	CD	O	O
ADVERSE	PRISTIQ.xml:S1:6:7	advers	JJ	O	O
REACTIONS	PRISTIQ.xml:S1:14:9	reaction	NN	O	O

The	PRISTIQ.xml:S1:27:3	the	DT	O	O
following	PRISTIQ.xml:S1:31:9	follow	JJ	O	O
adverse	PRISTIQ.xml:S1:41:7	advers	JJ	O	O
reactions	PRISTIQ.xml:S1:49:9	reaction	NNS	O	O
are	PRISTIQ.xml:S1:59:3	are	VBP	O	O
discussed	PRISTIQ.xml:S1:63:9	discuss	VBN	O	O
in	PRISTIQ.xml:S1:73:2	in	IN	O	O
greater	PRISTIQ.xml:S1:76:7	greater	JJR	O	O
detail	PRISTIQ.xml:S1:84:6	detail	NN	O	O
in	PRISTIQ.xml:S1:91:2	in	IN	O	O
other	PRISTIQ.xml:S1:94:5	other	JJ	O	O
sections	PRISTIQ.xml:S1:100:8	section	NNS	O	O
of	PRISTIQ.xml:S1:109:2	of	IN	O	O
the	PRISTIQ.xml:S1:112:3	the	DT	O	O
label	PRISTIQ.xml:S1:116:5	label	NN	O	O
.	PRISTIQ.xml:S1:121:1	.	.	O	O

Hypersensitivity	PRISTIQ.xml:S1:132:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
[	PRISTIQ.xml:S1:149:1	[	NNP	O	O
see	PRISTIQ.xml:S1:150:3	see	VBP	O	O
Contraindications	PRISTIQ.xml:S1:155:17	contraind	NNP	O	O
(	PRISTIQ.xml:S1:173:1	(	(	O	O
4	PRISTIQ.xml:S1:174:1	4	CD	O	O
)	PRISTIQ.xml:S1:175:1	)	)	O	O
]	PRISTIQ.xml:S1:178:1	]	NN	O	O

Suicidal	PRISTIQ.xml:S1:188:8	suicid	NNP	B-AdverseReaction	O
Thoughts	PRISTIQ.xml:S1:197:8	thought	NNP	I-AdverseReaction	O
and	PRISTIQ.xml:S1:206:3	and	CC	O	O
Behaviors	PRISTIQ.xml:S1:210:9	behavior	NNPS	I-AdverseReaction	I-AdverseReaction
in	PRISTIQ.xml:S1:220:2	in	IN	O	O
Adolescents	PRISTIQ.xml:S1:223:11	adolesc	NNPS	O	O
and	PRISTIQ.xml:S1:235:3	and	CC	O	O
Young	PRISTIQ.xml:S1:239:5	young	NNP	O	O
Adults	PRISTIQ.xml:S1:245:6	adult	NNP	O	O
[	PRISTIQ.xml:S1:252:1	[	NNP	O	O
see	PRISTIQ.xml:S1:253:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S1:258:8	warn	NNP	O	O
and	PRISTIQ.xml:S1:267:3	and	CC	O	O
Precautions	PRISTIQ.xml:S1:271:11	precaut	NNP	O	O
(	PRISTIQ.xml:S1:283:1	(	(	O	O
5.1	PRISTIQ.xml:S1:284:3	5.1	CD	O	O
)	PRISTIQ.xml:S1:287:1	)	)	O	O
]	PRISTIQ.xml:S1:290:1	]	NN	O	O

Serotonin	PRISTIQ.xml:S1:300:9	serotonin	NNP	B-AdverseReaction	B-AdverseReaction
Syndrome	PRISTIQ.xml:S1:310:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
[	PRISTIQ.xml:S1:319:1	[	NNP	O	O
see	PRISTIQ.xml:S1:320:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S1:325:8	warn	NNP	O	O
and	PRISTIQ.xml:S1:334:3	and	CC	O	O
Precautions	PRISTIQ.xml:S1:338:11	precaut	NNP	O	O
(	PRISTIQ.xml:S1:350:1	(	(	O	O
5.2	PRISTIQ.xml:S1:351:3	5.2	CD	O	O
)	PRISTIQ.xml:S1:354:1	)	)	O	O
]	PRISTIQ.xml:S1:357:1	]	NN	O	O

Elevated	PRISTIQ.xml:S1:367:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
Blood	PRISTIQ.xml:S1:376:5	blood	NNP	I-AdverseReaction	I-AdverseReaction
Pressure	PRISTIQ.xml:S1:382:8	pressur	NNP	I-AdverseReaction	I-AdverseReaction
[	PRISTIQ.xml:S1:391:1	[	NNP	O	O
see	PRISTIQ.xml:S1:392:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S1:397:8	warn	NNP	O	O
and	PRISTIQ.xml:S1:406:3	and	CC	O	O
Precautions	PRISTIQ.xml:S1:410:11	precaut	NNP	O	O
(	PRISTIQ.xml:S1:422:1	(	(	O	O
5.3	PRISTIQ.xml:S1:423:3	5.3	CD	O	O
)	PRISTIQ.xml:S1:426:1	)	)	O	O
]	PRISTIQ.xml:S1:429:1	]	NN	O	O

Abnormal	PRISTIQ.xml:S1:439:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
Bleeding	PRISTIQ.xml:S1:448:8	bleed	NNP	I-AdverseReaction	I-AdverseReaction
[	PRISTIQ.xml:S1:457:1	[	NNP	O	O
see	PRISTIQ.xml:S1:458:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S1:463:8	warn	NNP	O	O
and	PRISTIQ.xml:S1:472:3	and	CC	O	O
Precautions	PRISTIQ.xml:S1:476:11	precaut	NNP	O	O
(	PRISTIQ.xml:S1:488:1	(	(	O	O
5.4	PRISTIQ.xml:S1:489:3	5.4	CD	O	O
)	PRISTIQ.xml:S1:492:1	)	)	O	O
]	PRISTIQ.xml:S1:495:1	]	NN	O	O

Angle	PRISTIQ.xml:S1:505:5	angl	NNP	B-AdverseReaction	B-AdverseReaction
Closure	PRISTIQ.xml:S1:511:7	closur	NNP	I-AdverseReaction	I-AdverseReaction
Glaucoma	PRISTIQ.xml:S1:519:8	glaucoma	NNP	I-AdverseReaction	I-AdverseReaction
[	PRISTIQ.xml:S1:528:1	[	NNP	O	O
see	PRISTIQ.xml:S1:530:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S1:535:8	warn	NNP	O	O
and	PRISTIQ.xml:S1:544:3	and	CC	O	O
Precautions	PRISTIQ.xml:S1:548:11	precaut	NNP	O	O
(	PRISTIQ.xml:S1:560:1	(	(	O	O
5.5	PRISTIQ.xml:S1:561:3	5.5	CD	O	O
)	PRISTIQ.xml:S1:564:1	)	)	O	O
]	PRISTIQ.xml:S1:567:1	]	NN	O	O

Activation	PRISTIQ.xml:S1:577:10	activ	NN	O	O
of	PRISTIQ.xml:S1:588:2	of	IN	O	O
Mania	PRISTIQ.xml:S1:591:5	mania	NNP	B-AdverseReaction	O
Hypomania	PRISTIQ.xml:S1:597:9	hypomania	NNP	B-AdverseReaction	O
[	PRISTIQ.xml:S1:607:1	[	NNP	O	O
see	PRISTIQ.xml:S1:608:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S1:613:8	warn	NNP	O	O
and	PRISTIQ.xml:S1:622:3	and	CC	O	O
Precautions	PRISTIQ.xml:S1:626:11	precaut	NNP	O	O
(	PRISTIQ.xml:S1:638:1	(	(	O	O
5.6	PRISTIQ.xml:S1:639:3	5.6	CD	O	O
)	PRISTIQ.xml:S1:642:1	)	)	O	O
]	PRISTIQ.xml:S1:645:1	]	NN	O	O

Discontinuation	PRISTIQ.xml:S1:655:15	discontinu	NNP	B-AdverseReaction	O
Syndrome	PRISTIQ.xml:S1:671:8	syndrom	NNP	I-AdverseReaction	O
[	PRISTIQ.xml:S1:680:1	[	NNP	O	O
see	PRISTIQ.xml:S1:681:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S1:686:8	warn	NNP	O	O
and	PRISTIQ.xml:S1:695:3	and	CC	O	O
Precautions	PRISTIQ.xml:S1:699:11	precaut	NNP	O	O
(	PRISTIQ.xml:S1:711:1	(	(	O	O
5.7	PRISTIQ.xml:S1:712:3	5.7	CD	O	O
)	PRISTIQ.xml:S1:715:1	)	)	O	O
]	PRISTIQ.xml:S1:718:1	]	NN	O	O

Seizure	PRISTIQ.xml:S1:728:7	seizur	NN	B-AdverseReaction	B-AdverseReaction
[	PRISTIQ.xml:S1:736:1	[	NNP	O	O
see	PRISTIQ.xml:S1:737:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S1:742:8	warn	NNP	O	O
and	PRISTIQ.xml:S1:751:3	and	CC	O	O
Precautions	PRISTIQ.xml:S1:755:11	precaut	NNP	O	O
(	PRISTIQ.xml:S1:767:1	(	(	O	O
5.8	PRISTIQ.xml:S1:768:3	5.8	CD	O	O
)	PRISTIQ.xml:S1:771:1	)	)	O	O
]	PRISTIQ.xml:S1:774:1	]	NN	O	O

Hyponatremia	PRISTIQ.xml:S1:784:12	hyponatremia	NNP	B-AdverseReaction	B-AdverseReaction
[	PRISTIQ.xml:S1:797:1	[	NNP	O	O
see	PRISTIQ.xml:S1:798:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S1:803:8	warn	NNP	O	O
and	PRISTIQ.xml:S1:812:3	and	CC	O	O
Precautions	PRISTIQ.xml:S1:816:11	precaut	NNP	O	O
(	PRISTIQ.xml:S1:828:1	(	(	O	O
5.9	PRISTIQ.xml:S1:829:3	5.9	CD	O	O
)	PRISTIQ.xml:S1:832:1	)	)	O	O
]	PRISTIQ.xml:S1:835:1	]	NN	O	O

Interstitial	PRISTIQ.xml:S1:845:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
Lung	PRISTIQ.xml:S1:858:4	lung	NNP	I-AdverseReaction	I-AdverseReaction
Disease	PRISTIQ.xml:S1:863:7	diseas	NNP	I-AdverseReaction	I-AdverseReaction
and	PRISTIQ.xml:S1:871:3	and	CC	O	O
Eosinophilic	PRISTIQ.xml:S1:875:12	eosinophil	NNP	B-AdverseReaction	O
Pneumonia	PRISTIQ.xml:S1:888:9	pneumonia	NNP	I-AdverseReaction	B-AdverseReaction
[	PRISTIQ.xml:S1:898:1	[	NNP	O	O
see	PRISTIQ.xml:S1:899:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S1:904:8	warn	NNP	O	O
and	PRISTIQ.xml:S1:913:3	and	CC	O	O
Precautions	PRISTIQ.xml:S1:917:11	precaut	NNP	O	O
(	PRISTIQ.xml:S1:929:1	(	(	O	O
5.10	PRISTIQ.xml:S1:930:4	5.10	CD	O	O
)	PRISTIQ.xml:S1:934:1	)	)	O	O
]	PRISTIQ.xml:S1:937:1	]	NN	O	O

EXCERPT	PRISTIQ.xml:S1:947:7	excerpt	NNS	O	O
:	PRISTIQ.xml:S1:954:1	:	:	O	O
Most	PRISTIQ.xml:S1:958:4	most	JJS	O	O
common	PRISTIQ.xml:S1:963:6	common	JJ	O	O
adverse	PRISTIQ.xml:S1:970:7	advers	JJ	O	O
reactions	PRISTIQ.xml:S1:978:9	reaction	NNS	O	O
(	PRISTIQ.xml:S1:988:1	(	(	O	O
incidence	PRISTIQ.xml:S1:989:9	incid	NN	O	O
5%	PRISTIQ.xml:S1:1001:2	5%	CD	O	O
and	PRISTIQ.xml:S1:1004:3	and	CC	O	O
twice	PRISTIQ.xml:S1:1008:5	twice	RB	O	O
the	PRISTIQ.xml:S1:1014:3	the	DT	O	O
rate	PRISTIQ.xml:S1:1018:4	rate	NN	O	O
of	PRISTIQ.xml:S1:1023:2	of	IN	O	O
placebo	PRISTIQ.xml:S1:1026:7	placebo	NN	O	O
in	PRISTIQ.xml:S1:1034:2	in	IN	O	O
the	PRISTIQ.xml:S1:1037:3	the	DT	O	O
50	PRISTIQ.xml:S1:1041:2	50	CD	O	O
or	PRISTIQ.xml:S1:1044:2	or	CC	O	O
100	PRISTIQ.xml:S1:1047:3	100	CD	O	O
mg	PRISTIQ.xml:S1:1051:2	mg	NNS	O	O
dose	PRISTIQ.xml:S1:1054:4	dose	JJ	O	O
groups	PRISTIQ.xml:S1:1059:6	group	NNS	O	O
)	PRISTIQ.xml:S1:1065:1	)	)	O	O
were	PRISTIQ.xml:S1:1067:4	were	VBD	O	O
:	PRISTIQ.xml:S1:1071:1	:	:	O	O
nausea	PRISTIQ.xml:S1:1073:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:1079:1	,	,	O	O
dizziness	PRISTIQ.xml:S1:1081:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:1090:1	,	,	O	O
insomnia	PRISTIQ.xml:S1:1092:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:1100:1	,	,	O	O
hyperhidrosis	PRISTIQ.xml:S1:1102:13	hyperhidrosi	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:1115:1	,	,	O	O
constipation	PRISTIQ.xml:S1:1117:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:1129:1	,	,	O	O
somnolence	PRISTIQ.xml:S1:1131:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:1141:1	,	,	O	O
decreased	PRISTIQ.xml:S1:1143:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	PRISTIQ.xml:S1:1153:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S1:1161:1	,	,	O	O
anxiety	PRISTIQ.xml:S1:1163:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:1170:1	,	,	O	O
and	PRISTIQ.xml:S1:1172:3	and	CC	O	O
specific	PRISTIQ.xml:S1:1176:8	specif	JJ	O	O
male	PRISTIQ.xml:S1:1185:4	male	JJ	B-AdverseReaction	O
sexual	PRISTIQ.xml:S1:1190:6	sexual	JJ	I-AdverseReaction	O
function	PRISTIQ.xml:S1:1197:8	function	NN	I-AdverseReaction	O
disorders	PRISTIQ.xml:S1:1206:9	disord	NNS	I-AdverseReaction	O
(	PRISTIQ.xml:S1:1216:1	(	(	O	O
6.1	PRISTIQ.xml:S1:1219:3	6.1	CD	O	O
)	PRISTIQ.xml:S1:1224:1	)	)	O	O
.	PRISTIQ.xml:S1:1225:1	.	.	O	O

To	PRISTIQ.xml:S1:1233:2	To	TO	O	O

report	PRISTIQ.xml:S1:1236:6	report	NN	O	O
SUSPECTED	PRISTIQ.xml:S1:1243:9	suspect	NNP	O	O
ADVERSE	PRISTIQ.xml:S1:1253:7	advers	NNP	O	O
REACTIONS	PRISTIQ.xml:S1:1261:9	reaction	NNP	O	O
,	PRISTIQ.xml:S1:1270:1	,	,	O	O
contact	PRISTIQ.xml:S1:1272:7	contact	NN	O	O
Wyeth	PRISTIQ.xml:S1:1280:5	wyeth	NNP	O	O
Pharmaceuticals	PRISTIQ.xml:S1:1286:15	pharmaceut	NNP	O	O
Inc	PRISTIQ.xml:S1:1302:3	inc	NNP	O	O
.	PRISTIQ.xml:S1:1305:1	.	.	O	O
,	PRISTIQ.xml:S1:1306:1	,	,	O	O
a	PRISTIQ.xml:S1:1308:1	a	DT	O	O
subsidiary	PRISTIQ.xml:S1:1310:10	subsidiari	NN	O	O
of	PRISTIQ.xml:S1:1321:2	of	IN	O	O
Pfizer	PRISTIQ.xml:S1:1324:6	pfizer	NNP	O	O
Inc	PRISTIQ.xml:S1:1331:3	inc	NNP	O	O
.	PRISTIQ.xml:S1:1334:1	.	.	O	O
,	PRISTIQ.xml:S1:1335:1	,	,	O	O
at	PRISTIQ.xml:S1:1337:2	at	IN	O	O
1	PRISTIQ.xml:S1:1340:1	1	CD	O	O
-	PRISTIQ.xml:S1:1341:1	-	:	O	O
800	PRISTIQ.xml:S1:1342:3	800	CD	O	O
-	PRISTIQ.xml:S1:1345:1	-	:	O	O
438	PRISTIQ.xml:S1:1346:3	438	CD	O	O
-	PRISTIQ.xml:S1:1349:1	-	:	O	O
1985	PRISTIQ.xml:S1:1350:4	1985	CD	O	O
or	PRISTIQ.xml:S1:1355:2	or	CC	O	O
FDA	PRISTIQ.xml:S1:1358:3	fda	NNP	O	O
at	PRISTIQ.xml:S1:1362:2	at	IN	O	O
1	PRISTIQ.xml:S1:1365:1	1	CD	O	O
-	PRISTIQ.xml:S1:1366:1	-	:	O	O
800	PRISTIQ.xml:S1:1367:3	800	CD	O	O
-	PRISTIQ.xml:S1:1370:1	-	:	O	O
FDA	PRISTIQ.xml:S1:1371:3	fda	NNP	O	O
-	PRISTIQ.xml:S1:1374:1	-	:	O	O
1088	PRISTIQ.xml:S1:1375:4	1088	CD	O	O
or	PRISTIQ.xml:S1:1380:2	or	CC	O	O
www	PRISTIQ.xml:S1:1383:3	www	VB	O	O
.	PRISTIQ.xml:S1:1386:1	.	.	O	O
fda	PRISTIQ.xml:S1:1387:3	fda	NN	O	O
.	PRISTIQ.xml:S1:1390:1	.	.	O	O
gov	PRISTIQ.xml:S1:1391:3	gov	NN	O	O
medwatch	PRISTIQ.xml:S1:1395:8	medwatch	NN	O	O

6.1	PRISTIQ.xml:S1:1414:3	6.1	CD	O	O

Clinical	PRISTIQ.xml:S1:1418:8	clinic	JJ	O	O
Studies	PRISTIQ.xml:S1:1427:7	studi	NNS	O	O
Experience	PRISTIQ.xml:S1:1435:10	experi	NN	O	O

Because	PRISTIQ.xml:S1:1449:7	becaus	IN	O	O
clinical	PRISTIQ.xml:S1:1457:8	clinic	JJ	O	O
trials	PRISTIQ.xml:S1:1466:6	trial	NNS	O	O
are	PRISTIQ.xml:S1:1473:3	are	VBP	O	O
conducted	PRISTIQ.xml:S1:1477:9	conduct	VBN	O	O
under	PRISTIQ.xml:S1:1487:5	under	IN	O	O
widely	PRISTIQ.xml:S1:1493:6	wide	RB	O	O
varying	PRISTIQ.xml:S1:1500:7	vari	VBG	O	O
conditions	PRISTIQ.xml:S1:1508:10	condit	NNS	O	O
,	PRISTIQ.xml:S1:1518:1	,	,	O	O
adverse	PRISTIQ.xml:S1:1520:7	advers	JJ	O	O
reaction	PRISTIQ.xml:S1:1528:8	reaction	NN	O	O
rates	PRISTIQ.xml:S1:1537:5	rate	NNS	O	O
observed	PRISTIQ.xml:S1:1543:8	observ	VBD	O	O
in	PRISTIQ.xml:S1:1552:2	in	IN	O	O
the	PRISTIQ.xml:S1:1555:3	the	DT	O	O
clinical	PRISTIQ.xml:S1:1559:8	clinic	JJ	O	O
trials	PRISTIQ.xml:S1:1568:6	trial	NNS	O	O
of	PRISTIQ.xml:S1:1575:2	of	IN	O	O
a	PRISTIQ.xml:S1:1578:1	a	DT	O	O
drug	PRISTIQ.xml:S1:1580:4	drug	NN	O	O
cannot	PRISTIQ.xml:S1:1585:6	cannot	NN	O	O
be	PRISTIQ.xml:S1:1592:2	be	VB	O	O
directly	PRISTIQ.xml:S1:1595:8	directli	RB	O	O
compared	PRISTIQ.xml:S1:1604:8	compar	VBN	O	O
to	PRISTIQ.xml:S1:1613:2	to	TO	O	O
rates	PRISTIQ.xml:S1:1616:5	rate	NNS	O	O
in	PRISTIQ.xml:S1:1622:2	in	IN	O	O
the	PRISTIQ.xml:S1:1625:3	the	DT	O	O
clinical	PRISTIQ.xml:S1:1629:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S1:1638:7	studi	NNS	O	O
of	PRISTIQ.xml:S1:1646:2	of	IN	O	O
another	PRISTIQ.xml:S1:1649:7	anoth	DT	O	O
drug	PRISTIQ.xml:S1:1657:4	drug	NN	O	O
and	PRISTIQ.xml:S1:1662:3	and	CC	O	O
may	PRISTIQ.xml:S1:1666:3	may	MD	O	O
not	PRISTIQ.xml:S1:1670:3	not	RB	O	O
reflect	PRISTIQ.xml:S1:1674:7	reflect	VB	O	O
the	PRISTIQ.xml:S1:1682:3	the	DT	O	O
rates	PRISTIQ.xml:S1:1686:5	rate	NNS	O	O
observed	PRISTIQ.xml:S1:1692:8	observ	VBD	O	O
in	PRISTIQ.xml:S1:1701:2	in	IN	O	O
clinical	PRISTIQ.xml:S1:1704:8	clinic	JJ	O	O
practice	PRISTIQ.xml:S1:1713:8	practic	NN	O	O
.	PRISTIQ.xml:S1:1721:1	.	.	O	O

Patient	PRISTIQ.xml:S1:1731:7	patient	NN	O	O
exposure	PRISTIQ.xml:S1:1739:8	exposur	NN	O	O

PRISTIQ	PRISTIQ.xml:S1:1754:7	pristiq	NNP	O	O
was	PRISTIQ.xml:S1:1762:3	wa	VBD	O	O
evaluated	PRISTIQ.xml:S1:1766:9	evalu	VBN	O	O
for	PRISTIQ.xml:S1:1776:3	for	IN	O	O
safety	PRISTIQ.xml:S1:1780:6	safeti	NN	O	O
in	PRISTIQ.xml:S1:1787:2	in	IN	O	O
8	PRISTIQ.xml:S1:1790:1	8	CD	O	O
,	PRISTIQ.xml:S1:1791:1	,	,	O	O
394	PRISTIQ.xml:S1:1792:3	394	CD	O	O
patients	PRISTIQ.xml:S1:1796:8	patient	NNS	O	O
diagnosed	PRISTIQ.xml:S1:1805:9	diagnos	VBN	O	O
with	PRISTIQ.xml:S1:1815:4	with	IN	O	O
major	PRISTIQ.xml:S1:1820:5	major	JJ	O	O
depressive	PRISTIQ.xml:S1:1826:10	depress	JJ	O	O
disorder	PRISTIQ.xml:S1:1837:8	disord	NN	O	O
who	PRISTIQ.xml:S1:1846:3	who	WP	O	O
participated	PRISTIQ.xml:S1:1850:12	particip	VBD	O	O
in	PRISTIQ.xml:S1:1863:2	in	IN	O	O
multiple	PRISTIQ.xml:S1:1866:8	multipl	JJ	O	O
-	PRISTIQ.xml:S1:1874:1	-	:	O	O
dose	PRISTIQ.xml:S1:1875:4	dose	NN	O	O
pre	PRISTIQ.xml:S1:1880:3	pre	SYM	O	O
-	PRISTIQ.xml:S1:1883:1	-	:	O	O
marketing	PRISTIQ.xml:S1:1884:9	market	NN	O	O
studies	PRISTIQ.xml:S1:1894:7	studi	NNS	O	O
,	PRISTIQ.xml:S1:1901:1	,	,	O	O
representing	PRISTIQ.xml:S1:1903:12	repres	VBG	O	O
2	PRISTIQ.xml:S1:1916:1	2	CD	O	O
,	PRISTIQ.xml:S1:1917:1	,	,	O	O
784	PRISTIQ.xml:S1:1918:3	784	CD	O	O
patient	PRISTIQ.xml:S1:1922:7	patient	JJ	O	O
-	PRISTIQ.xml:S1:1929:1	-	:	O	O
years	PRISTIQ.xml:S1:1930:5	year	NNS	O	O
of	PRISTIQ.xml:S1:1936:2	of	IN	O	O
exposure	PRISTIQ.xml:S1:1939:8	exposur	NN	O	O
.	PRISTIQ.xml:S1:1947:1	.	.	O	O

Of	PRISTIQ.xml:S1:1949:2	Of	IN	O	O
the	PRISTIQ.xml:S1:1952:3	the	DT	O	O
total	PRISTIQ.xml:S1:1956:5	total	JJ	O	O
8	PRISTIQ.xml:S1:1962:1	8	CD	O	O
,	PRISTIQ.xml:S1:1963:1	,	,	O	O
394	PRISTIQ.xml:S1:1964:3	394	CD	O	O
patients	PRISTIQ.xml:S1:1968:8	patient	NNS	O	O
exposed	PRISTIQ.xml:S1:1977:7	expos	VBN	O	O
to	PRISTIQ.xml:S1:1985:2	to	TO	O	O
at	PRISTIQ.xml:S1:1988:2	at	IN	O	O
least	PRISTIQ.xml:S1:1991:5	least	JJS	O	O
one	PRISTIQ.xml:S1:1997:3	one	CD	O	O
dose	PRISTIQ.xml:S1:2001:4	dose	NN	O	O
of	PRISTIQ.xml:S1:2006:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:2009:7	pristiq	NNP	O	O
;	PRISTIQ.xml:S1:2016:1	;	:	O	O
2	PRISTIQ.xml:S1:2018:1	2	CD	O	O
,	PRISTIQ.xml:S1:2019:1	,	,	O	O
116	PRISTIQ.xml:S1:2020:3	116	CD	O	O
were	PRISTIQ.xml:S1:2024:4	were	VBD	O	O
exposed	PRISTIQ.xml:S1:2029:7	expos	VBN	O	O
to	PRISTIQ.xml:S1:2037:2	to	TO	O	O
PRISTIQ	PRISTIQ.xml:S1:2040:7	pristiq	NNP	O	O
for	PRISTIQ.xml:S1:2048:3	for	IN	O	O
6	PRISTIQ.xml:S1:2052:1	6	CD	O	O
months	PRISTIQ.xml:S1:2054:6	month	NNS	O	O
,	PRISTIQ.xml:S1:2060:1	,	,	O	O
representing	PRISTIQ.xml:S1:2062:12	repres	VBG	O	O
1	PRISTIQ.xml:S1:2075:1	1	CD	O	O
,	PRISTIQ.xml:S1:2076:1	,	,	O	O
658	PRISTIQ.xml:S1:2077:3	658	CD	O	O
patient	PRISTIQ.xml:S1:2081:7	patient	JJ	O	O
-	PRISTIQ.xml:S1:2088:1	-	:	O	O
years	PRISTIQ.xml:S1:2089:5	year	NNS	O	O
of	PRISTIQ.xml:S1:2095:2	of	IN	O	O
exposure	PRISTIQ.xml:S1:2098:8	exposur	NN	O	O
,	PRISTIQ.xml:S1:2106:1	,	,	O	O
and	PRISTIQ.xml:S1:2108:3	and	CC	O	O
421	PRISTIQ.xml:S1:2112:3	421	CD	O	O
were	PRISTIQ.xml:S1:2116:4	were	VBD	O	O
exposed	PRISTIQ.xml:S1:2121:7	expos	VBN	O	O
for	PRISTIQ.xml:S1:2129:3	for	IN	O	O
one	PRISTIQ.xml:S1:2133:3	one	CD	O	O
year	PRISTIQ.xml:S1:2137:4	year	NN	O	O
,	PRISTIQ.xml:S1:2141:1	,	,	O	O
representing	PRISTIQ.xml:S1:2143:12	repres	VBG	O	O
416	PRISTIQ.xml:S1:2156:3	416	CD	O	O
patient	PRISTIQ.xml:S1:2160:7	patient	JJ	O	O
-	PRISTIQ.xml:S1:2167:1	-	:	O	O
years	PRISTIQ.xml:S1:2168:5	year	NNS	O	O
of	PRISTIQ.xml:S1:2174:2	of	IN	O	O
exposure	PRISTIQ.xml:S1:2177:8	exposur	NN	O	O
.	PRISTIQ.xml:S1:2185:1	.	.	O	O

Adverse	PRISTIQ.xml:S1:2195:7	advers	JJ	O	O
reactions	PRISTIQ.xml:S1:2203:9	reaction	NNS	O	O
reported	PRISTIQ.xml:S1:2213:8	report	VBD	O	O
as	PRISTIQ.xml:S1:2222:2	as	IN	O	O
reasons	PRISTIQ.xml:S1:2225:7	reason	NNS	O	O
for	PRISTIQ.xml:S1:2233:3	for	IN	O	O
discontinuation	PRISTIQ.xml:S1:2237:15	discontinu	NN	O	O
of	PRISTIQ.xml:S1:2253:2	of	IN	O	O
treatment	PRISTIQ.xml:S1:2256:9	treatment	NN	O	O

In	PRISTIQ.xml:S1:2272:2	In	IN	O	O
the	PRISTIQ.xml:S1:2275:3	the	DT	O	O
pre	PRISTIQ.xml:S1:2279:3	pre	NN	O	O
-	PRISTIQ.xml:S1:2282:1	-	:	O	O
marketing	PRISTIQ.xml:S1:2283:9	market	NN	O	O
pooled	PRISTIQ.xml:S1:2293:6	pool	VBD	O	O
8	PRISTIQ.xml:S1:2300:1	8	CD	O	O
-	PRISTIQ.xml:S1:2301:1	-	:	O	O
week	PRISTIQ.xml:S1:2302:4	week	NN	O	O
placebo	PRISTIQ.xml:S1:2307:7	placebo	NN	O	O
-	PRISTIQ.xml:S1:2314:1	-	:	O	O
controlled	PRISTIQ.xml:S1:2315:10	control	VBN	O	O
studies	PRISTIQ.xml:S1:2326:7	studi	NNS	O	O
in	PRISTIQ.xml:S1:2334:2	in	IN	O	O
patients	PRISTIQ.xml:S1:2337:8	patient	NNS	O	O
with	PRISTIQ.xml:S1:2346:4	with	IN	O	O
MDD	PRISTIQ.xml:S1:2351:3	mdd	NNP	O	O
,	PRISTIQ.xml:S1:2354:1	,	,	O	O
1	PRISTIQ.xml:S1:2356:1	1	CD	O	O
,	PRISTIQ.xml:S1:2357:1	,	,	O	O
834	PRISTIQ.xml:S1:2358:3	834	CD	O	O
patients	PRISTIQ.xml:S1:2362:8	patient	NNS	O	O
were	PRISTIQ.xml:S1:2371:4	were	VBD	O	O
exposed	PRISTIQ.xml:S1:2376:7	expos	VBN	O	O
to	PRISTIQ.xml:S1:2384:2	to	TO	O	O
PRISTIQ	PRISTIQ.xml:S1:2387:7	pristiq	NNP	O	O
(	PRISTIQ.xml:S1:2395:1	(	(	O	O
50	PRISTIQ.xml:S1:2396:2	50	CD	O	O
to	PRISTIQ.xml:S1:2399:2	to	TO	O	O
400	PRISTIQ.xml:S1:2402:3	400	CD	O	O
mg	PRISTIQ.xml:S1:2406:2	mg	NN	O	O
)	PRISTIQ.xml:S1:2408:1	)	)	O	O
.	PRISTIQ.xml:S1:2409:1	.	.	O	O

Of	PRISTIQ.xml:S1:2411:2	Of	IN	O	O
the	PRISTIQ.xml:S1:2414:3	the	DT	O	O
1	PRISTIQ.xml:S1:2418:1	1	CD	O	O
,	PRISTIQ.xml:S1:2419:1	,	,	O	O
834	PRISTIQ.xml:S1:2420:3	834	CD	O	O
patients	PRISTIQ.xml:S1:2424:8	patient	NNS	O	O
,	PRISTIQ.xml:S1:2432:1	,	,	O	O
12%	PRISTIQ.xml:S1:2434:3	12%	CD	O	O
discontinued	PRISTIQ.xml:S1:2438:12	discontinu	VBN	O	O
treatment	PRISTIQ.xml:S1:2451:9	treatment	NN	O	O
due	PRISTIQ.xml:S1:2461:3	due	JJ	O	O
to	PRISTIQ.xml:S1:2465:2	to	TO	O	O
an	PRISTIQ.xml:S1:2468:2	an	DT	O	O
adverse	PRISTIQ.xml:S1:2471:7	advers	JJ	O	O
reaction	PRISTIQ.xml:S1:2479:8	reaction	NN	O	O
,	PRISTIQ.xml:S1:2487:1	,	,	O	O
compared	PRISTIQ.xml:S1:2489:8	compar	VBN	O	O
with	PRISTIQ.xml:S1:2498:4	with	IN	O	O
3%	PRISTIQ.xml:S1:2503:2	3%	CD	O	O
of	PRISTIQ.xml:S1:2506:2	of	IN	O	O
the	PRISTIQ.xml:S1:2509:3	the	DT	O	O
1	PRISTIQ.xml:S1:2513:1	1	CD	O	O
,	PRISTIQ.xml:S1:2514:1	,	,	O	O
116	PRISTIQ.xml:S1:2515:3	116	CD	O	O
placebo	PRISTIQ.xml:S1:2519:7	placebo	NN	O	O
-	PRISTIQ.xml:S1:2526:1	-	:	O	O
treated	PRISTIQ.xml:S1:2527:7	treat	JJ	O	O
patients	PRISTIQ.xml:S1:2535:8	patient	NNS	O	O
.	PRISTIQ.xml:S1:2543:1	.	.	O	O

At	PRISTIQ.xml:S1:2545:2	At	IN	O	O
the	PRISTIQ.xml:S1:2548:3	the	DT	O	O
recommended	PRISTIQ.xml:S1:2552:11	recommend	JJ	O	O
dose	PRISTIQ.xml:S1:2564:4	dose	NN	O	O
of	PRISTIQ.xml:S1:2569:2	of	IN	O	O
50	PRISTIQ.xml:S1:2572:2	50	CD	O	O
mg	PRISTIQ.xml:S1:2575:2	mg	NN	O	O
,	PRISTIQ.xml:S1:2577:1	,	,	O	O
the	PRISTIQ.xml:S1:2579:3	the	DT	O	O
discontinuation	PRISTIQ.xml:S1:2583:15	discontinu	NN	O	O
rate	PRISTIQ.xml:S1:2599:4	rate	NN	O	O
due	PRISTIQ.xml:S1:2604:3	due	JJ	O	O
to	PRISTIQ.xml:S1:2608:2	to	TO	O	O
an	PRISTIQ.xml:S1:2611:2	an	DT	O	O
adverse	PRISTIQ.xml:S1:2614:7	advers	JJ	O	O
reaction	PRISTIQ.xml:S1:2622:8	reaction	NN	O	O
for	PRISTIQ.xml:S1:2631:3	for	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:2635:7	pristiq	NNP	O	O
(	PRISTIQ.xml:S1:2643:1	(	(	O	O
4.1%	PRISTIQ.xml:S1:2644:4	4.1%	CD	O	O
)	PRISTIQ.xml:S1:2648:1	)	)	O	O
was	PRISTIQ.xml:S1:2650:3	wa	VBD	O	O
similar	PRISTIQ.xml:S1:2654:7	similar	JJ	O	O
to	PRISTIQ.xml:S1:2662:2	to	TO	O	O
the	PRISTIQ.xml:S1:2665:3	the	DT	O	O
rate	PRISTIQ.xml:S1:2669:4	rate	NN	O	O
for	PRISTIQ.xml:S1:2674:3	for	IN	O	O
placebo	PRISTIQ.xml:S1:2678:7	placebo	NN	O	O
(	PRISTIQ.xml:S1:2686:1	(	(	O	O
3.8%	PRISTIQ.xml:S1:2687:4	3.8%	CD	O	O
)	PRISTIQ.xml:S1:2691:1	)	)	O	O
.	PRISTIQ.xml:S1:2692:1	.	.	O	O

For	PRISTIQ.xml:S1:2694:3	for	IN	O	O
the	PRISTIQ.xml:S1:2698:3	the	DT	O	O
100	PRISTIQ.xml:S1:2702:3	100	CD	O	O
mg	PRISTIQ.xml:S1:2706:2	mg	NN	O	O
dose	PRISTIQ.xml:S1:2709:4	dose	NN	O	O
of	PRISTIQ.xml:S1:2714:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:2717:7	pristiq	NNP	O	O
the	PRISTIQ.xml:S1:2725:3	the	DT	O	O
discontinuation	PRISTIQ.xml:S1:2729:15	discontinu	NN	O	O
rate	PRISTIQ.xml:S1:2745:4	rate	NN	O	O
due	PRISTIQ.xml:S1:2750:3	due	JJ	O	O
to	PRISTIQ.xml:S1:2754:2	to	TO	O	O
an	PRISTIQ.xml:S1:2757:2	an	DT	O	O
adverse	PRISTIQ.xml:S1:2760:7	advers	JJ	O	O
reaction	PRISTIQ.xml:S1:2768:8	reaction	NN	O	O
was	PRISTIQ.xml:S1:2777:3	wa	VBD	O	O
8.7%	PRISTIQ.xml:S1:2781:4	8.7%	CD	O	O
.	PRISTIQ.xml:S1:2785:1	.	.	O	O

The	PRISTIQ.xml:S1:2791:3	the	DT	O	O
most	PRISTIQ.xml:S1:2795:4	most	RBS	O	O
common	PRISTIQ.xml:S1:2800:6	common	JJ	O	O
adverse	PRISTIQ.xml:S1:2807:7	advers	JJ	O	O
reactions	PRISTIQ.xml:S1:2815:9	reaction	NNS	O	O
leading	PRISTIQ.xml:S1:2825:7	lead	VBG	O	O
to	PRISTIQ.xml:S1:2833:2	to	TO	O	O
discontinuation	PRISTIQ.xml:S1:2836:15	discontinu	NN	O	O
in	PRISTIQ.xml:S1:2852:2	in	IN	O	O
at	PRISTIQ.xml:S1:2855:2	at	IN	O	O
least	PRISTIQ.xml:S1:2858:5	least	JJS	O	O
2%	PRISTIQ.xml:S1:2864:2	2%	CD	O	O
and	PRISTIQ.xml:S1:2867:3	and	CC	O	O
at	PRISTIQ.xml:S1:2871:2	at	IN	O	O
a	PRISTIQ.xml:S1:2874:1	a	DT	O	O
rate	PRISTIQ.xml:S1:2876:4	rate	NN	O	O
greater	PRISTIQ.xml:S1:2881:7	greater	JJR	O	O
than	PRISTIQ.xml:S1:2889:4	than	IN	O	O
placebo	PRISTIQ.xml:S1:2894:7	placebo	NN	O	O
of	PRISTIQ.xml:S1:2902:2	of	IN	O	O
the	PRISTIQ.xml:S1:2905:3	the	DT	O	O
PRISTIQ	PRISTIQ.xml:S1:2909:7	pristiq	NNP	O	O
treated	PRISTIQ.xml:S1:2917:7	treat	VBD	O	O
patients	PRISTIQ.xml:S1:2925:8	patient	NNS	O	O
in	PRISTIQ.xml:S1:2934:2	in	IN	O	O
the	PRISTIQ.xml:S1:2937:3	the	DT	O	O
short	PRISTIQ.xml:S1:2941:5	short	JJ	O	O
-	PRISTIQ.xml:S1:2946:1	-	:	O	O
term	PRISTIQ.xml:S1:2947:4	term	NN	O	O
studies	PRISTIQ.xml:S1:2952:7	studi	NNS	O	O
,	PRISTIQ.xml:S1:2959:1	,	,	O	O
up	PRISTIQ.xml:S1:2961:2	up	RB	O	O
to	PRISTIQ.xml:S1:2964:2	to	TO	O	O
8	PRISTIQ.xml:S1:2967:1	8	CD	O	O
weeks	PRISTIQ.xml:S1:2969:5	week	NNS	O	O
,	PRISTIQ.xml:S1:2974:1	,	,	O	O
were	PRISTIQ.xml:S1:2976:4	were	VBD	O	O
:	PRISTIQ.xml:S1:2980:1	:	:	O	O
nausea	PRISTIQ.xml:S1:2982:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
(	PRISTIQ.xml:S1:2989:1	(	(	O	O
4%	PRISTIQ.xml:S1:2990:2	4%	CD	O	O
)	PRISTIQ.xml:S1:2992:1	)	)	O	O
;	PRISTIQ.xml:S1:2993:1	;	:	O	O
dizziness	PRISTIQ.xml:S1:2995:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:3004:1	,	,	O	O
headache	PRISTIQ.xml:S1:3006:8	headach	NN	B-AdverseReaction	B-AdverseReaction
and	PRISTIQ.xml:S1:3015:3	and	CC	O	O
vomiting	PRISTIQ.xml:S1:3019:8	vomit	NN	B-AdverseReaction	B-AdverseReaction
(	PRISTIQ.xml:S1:3028:1	(	(	O	O
2%	PRISTIQ.xml:S1:3029:2	2%	CD	O	O
each	PRISTIQ.xml:S1:3032:4	each	DT	O	O
)	PRISTIQ.xml:S1:3036:1	)	)	O	O
.	PRISTIQ.xml:S1:3037:1	.	.	O	O

In	PRISTIQ.xml:S1:3039:2	In	IN	O	O
a	PRISTIQ.xml:S1:3042:1	a	DT	O	O
longer	PRISTIQ.xml:S1:3044:6	longer	RBR	O	O
-	PRISTIQ.xml:S1:3050:1	-	:	O	O
term	PRISTIQ.xml:S1:3051:4	term	NN	O	O
study	PRISTIQ.xml:S1:3056:5	studi	NN	O	O
,	PRISTIQ.xml:S1:3061:1	,	,	O	O
up	PRISTIQ.xml:S1:3063:2	up	RB	O	O
to	PRISTIQ.xml:S1:3066:2	to	TO	O	O
9	PRISTIQ.xml:S1:3069:1	9	CD	O	O
months	PRISTIQ.xml:S1:3071:6	month	NNS	O	O
,	PRISTIQ.xml:S1:3077:1	,	,	O	O
the	PRISTIQ.xml:S1:3079:3	the	DT	O	O
most	PRISTIQ.xml:S1:3083:4	most	RBS	O	O
common	PRISTIQ.xml:S1:3088:6	common	JJ	O	O
was	PRISTIQ.xml:S1:3095:3	wa	VBD	O	O
vomiting	PRISTIQ.xml:S1:3099:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
(	PRISTIQ.xml:S1:3108:1	(	(	O	O
2%	PRISTIQ.xml:S1:3109:2	2%	CD	O	O
)	PRISTIQ.xml:S1:3111:1	)	)	O	O
.	PRISTIQ.xml:S1:3112:1	.	.	O	O

Common	PRISTIQ.xml:S1:3122:6	common	JJ	O	O
adverse	PRISTIQ.xml:S1:3129:7	advers	JJ	O	O
reactions	PRISTIQ.xml:S1:3137:9	reaction	NNS	O	O
in	PRISTIQ.xml:S1:3147:2	in	IN	O	O
placebo	PRISTIQ.xml:S1:3150:7	placebo	NN	O	O
-	PRISTIQ.xml:S1:3157:1	-	:	O	O
controlled	PRISTIQ.xml:S1:3158:10	control	VBN	O	O
MDD	PRISTIQ.xml:S1:3169:3	mdd	NNP	O	O
studies	PRISTIQ.xml:S1:3173:7	studi	NNS	O	O

The	PRISTIQ.xml:S1:3187:3	the	DT	O	O
most	PRISTIQ.xml:S1:3191:4	most	RBS	O	O
commonly	PRISTIQ.xml:S1:3196:8	commonli	RB	O	O
observed	PRISTIQ.xml:S1:3205:8	observ	JJ	O	O
adverse	PRISTIQ.xml:S1:3214:7	advers	JJ	O	O
reactions	PRISTIQ.xml:S1:3222:9	reaction	NNS	O	O
in	PRISTIQ.xml:S1:3232:2	in	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:3235:7	pristiq	NNP	O	O
treated	PRISTIQ.xml:S1:3243:7	treat	VBD	O	O
MDD	PRISTIQ.xml:S1:3251:3	mdd	NNP	O	O
patients	PRISTIQ.xml:S1:3255:8	patient	NNS	O	O
in	PRISTIQ.xml:S1:3264:2	in	IN	O	O
pre	PRISTIQ.xml:S1:3267:3	pre	JJ	O	O
-	PRISTIQ.xml:S1:3270:1	-	:	O	O
marketing	PRISTIQ.xml:S1:3271:9	market	NN	O	O
pooled	PRISTIQ.xml:S1:3281:6	pool	VBD	O	O
8	PRISTIQ.xml:S1:3288:1	8	CD	O	O
-	PRISTIQ.xml:S1:3289:1	-	:	O	O
week	PRISTIQ.xml:S1:3290:4	week	NN	O	O
,	PRISTIQ.xml:S1:3294:1	,	,	O	O
placebo	PRISTIQ.xml:S1:3296:7	placebo	SYM	O	O
-	PRISTIQ.xml:S1:3303:1	-	:	O	O
controlled	PRISTIQ.xml:S1:3304:10	control	VBN	O	O
,	PRISTIQ.xml:S1:3314:1	,	,	O	O
fixed	PRISTIQ.xml:S1:3316:5	fix	VBN	O	O
-	PRISTIQ.xml:S1:3321:1	-	:	O	O
dose	PRISTIQ.xml:S1:3322:4	dose	NN	O	O
studies	PRISTIQ.xml:S1:3327:7	studi	NNS	O	O
(	PRISTIQ.xml:S1:3335:1	(	(	O	O
incidence	PRISTIQ.xml:S1:3336:9	incid	NN	O	O
5%	PRISTIQ.xml:S1:3349:2	5%	CD	O	O
and	PRISTIQ.xml:S1:3352:3	and	CC	O	O
at	PRISTIQ.xml:S1:3356:2	at	IN	O	O
least	PRISTIQ.xml:S1:3359:5	least	JJS	O	O
twice	PRISTIQ.xml:S1:3365:5	twice	RB	O	O
the	PRISTIQ.xml:S1:3371:3	the	DT	O	O
rate	PRISTIQ.xml:S1:3375:4	rate	NN	O	O
of	PRISTIQ.xml:S1:3380:2	of	IN	O	O
placebo	PRISTIQ.xml:S1:3383:7	placebo	NN	O	O
in	PRISTIQ.xml:S1:3391:2	in	IN	O	O
the	PRISTIQ.xml:S1:3394:3	the	DT	O	O
50	PRISTIQ.xml:S1:3398:2	50	CD	O	O
or	PRISTIQ.xml:S1:3401:2	or	CC	O	O
100	PRISTIQ.xml:S1:3404:3	100	CD	O	O
mg	PRISTIQ.xml:S1:3408:2	mg	NNS	O	O
dose	PRISTIQ.xml:S1:3411:4	dose	JJ	O	O
groups	PRISTIQ.xml:S1:3416:6	group	NNS	O	O
)	PRISTIQ.xml:S1:3422:1	)	)	O	O
were	PRISTIQ.xml:S1:3424:4	were	VBD	O	O
:	PRISTIQ.xml:S1:3428:1	:	:	O	O
nausea	PRISTIQ.xml:S1:3430:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:3436:1	,	,	O	O
dizziness	PRISTIQ.xml:S1:3438:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:3447:1	,	,	O	O
insomnia	PRISTIQ.xml:S1:3449:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:3457:1	,	,	O	O
hyperhidrosis	PRISTIQ.xml:S1:3459:13	hyperhidrosi	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:3472:1	,	,	O	O
constipation	PRISTIQ.xml:S1:3474:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:3486:1	,	,	O	O
somnolence	PRISTIQ.xml:S1:3488:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:3498:1	,	,	O	O
decreased	PRISTIQ.xml:S1:3500:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	PRISTIQ.xml:S1:3510:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S1:3518:1	,	,	O	O
anxiety	PRISTIQ.xml:S1:3520:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:3527:1	,	,	O	O
and	PRISTIQ.xml:S1:3529:3	and	CC	O	O
specific	PRISTIQ.xml:S1:3533:8	specif	JJ	O	O
male	PRISTIQ.xml:S1:3542:4	male	JJ	B-AdverseReaction	O
sexual	PRISTIQ.xml:S1:3547:6	sexual	JJ	I-AdverseReaction	O
function	PRISTIQ.xml:S1:3554:8	function	NN	I-AdverseReaction	O
disorders	PRISTIQ.xml:S1:3563:9	disord	NNS	I-AdverseReaction	O
.	PRISTIQ.xml:S1:3572:1	.	.	O	O

Table	PRISTIQ.xml:S1:3578:5	tabl	JJ	O	O
2	PRISTIQ.xml:S1:3584:1	2	CD	O	O
shows	PRISTIQ.xml:S1:3586:5	show	VBZ	O	O
the	PRISTIQ.xml:S1:3592:3	the	DT	O	O
incidence	PRISTIQ.xml:S1:3596:9	incid	NN	O	O
of	PRISTIQ.xml:S1:3606:2	of	IN	O	O
common	PRISTIQ.xml:S1:3609:6	common	JJ	O	O
adverse	PRISTIQ.xml:S1:3616:7	advers	JJ	O	O
reactions	PRISTIQ.xml:S1:3624:9	reaction	NNS	O	O
that	PRISTIQ.xml:S1:3634:4	that	WDT	O	O
occurred	PRISTIQ.xml:S1:3639:8	occur	VBD	O	O
in	PRISTIQ.xml:S1:3648:2	in	IN	O	O
2%	PRISTIQ.xml:S1:3654:2	2%	CD	O	O
of	PRISTIQ.xml:S1:3657:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:3660:7	pristiq	NNP	O	O
treated	PRISTIQ.xml:S1:3668:7	treat	VBD	O	O
MDD	PRISTIQ.xml:S1:3676:3	mdd	NNP	O	O
patients	PRISTIQ.xml:S1:3680:8	patient	NNS	O	O
and	PRISTIQ.xml:S1:3689:3	and	CC	O	O
twice	PRISTIQ.xml:S1:3693:5	twice	RB	O	O
the	PRISTIQ.xml:S1:3699:3	the	DT	O	O
rate	PRISTIQ.xml:S1:3703:4	rate	NN	O	O
of	PRISTIQ.xml:S1:3708:2	of	IN	O	O
placebo	PRISTIQ.xml:S1:3711:7	placebo	NN	O	O
at	PRISTIQ.xml:S1:3719:2	at	IN	O	O
any	PRISTIQ.xml:S1:3722:3	ani	DT	O	O
dose	PRISTIQ.xml:S1:3726:4	dose	NN	O	O
in	PRISTIQ.xml:S1:3731:2	in	IN	O	O
the	PRISTIQ.xml:S1:3734:3	the	DT	O	O
pre	PRISTIQ.xml:S1:3738:3	pre	NN	O	O
-	PRISTIQ.xml:S1:3741:1	-	:	O	O
marketing	PRISTIQ.xml:S1:3742:9	market	NN	O	O
pooled	PRISTIQ.xml:S1:3752:6	pool	VBD	O	O
8	PRISTIQ.xml:S1:3759:1	8	CD	O	O
-	PRISTIQ.xml:S1:3760:1	-	:	O	O
week	PRISTIQ.xml:S1:3761:4	week	NN	O	O
,	PRISTIQ.xml:S1:3765:1	,	,	O	O
placebo	PRISTIQ.xml:S1:3767:7	placebo	SYM	O	O
-	PRISTIQ.xml:S1:3774:1	-	:	O	O
controlled	PRISTIQ.xml:S1:3775:10	control	VBN	O	O
,	PRISTIQ.xml:S1:3785:1	,	,	O	O
fixed	PRISTIQ.xml:S1:3787:5	fix	VBN	O	O
dose	PRISTIQ.xml:S1:3793:4	dose	JJ	O	O
clinical	PRISTIQ.xml:S1:3798:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S1:3807:7	studi	NNS	O	O

Table	PRISTIQ.xml:S1:3819:5	tabl	JJ	O	O
2	PRISTIQ.xml:S1:3825:1	2	CD	O	O
:	PRISTIQ.xml:S1:3826:1	:	:	O	O
Common	PRISTIQ.xml:S1:3828:6	common	JJ	O	O
Adverse	PRISTIQ.xml:S1:3835:7	advers	NNP	O	O
Reactions	PRISTIQ.xml:S1:3843:9	reaction	NNP	O	O
(	PRISTIQ.xml:S1:3853:1	(	(	O	O
2%	PRISTIQ.xml:S1:3857:2	2%	CD	O	O
in	PRISTIQ.xml:S1:3860:2	in	IN	O	O
any	PRISTIQ.xml:S1:3863:3	ani	DT	O	O
Fixed	PRISTIQ.xml:S1:3867:5	fix	NNP	O	O
-	PRISTIQ.xml:S1:3872:1	-	:	O	O
Dose	PRISTIQ.xml:S1:3873:4	dose	NNP	O	O
Group	PRISTIQ.xml:S1:3878:5	group	NNP	O	O
and	PRISTIQ.xml:S1:3884:3	and	CC	O	O
Twice	PRISTIQ.xml:S1:3888:5	twice	NNP	O	O
the	PRISTIQ.xml:S1:3894:3	the	DT	O	O
Rate	PRISTIQ.xml:S1:3898:4	rate	NNP	O	O
of	PRISTIQ.xml:S1:3903:2	of	IN	O	O
Placebo	PRISTIQ.xml:S1:3906:7	placebo	NNP	O	O
)	PRISTIQ.xml:S1:3913:1	)	)	O	O
in	PRISTIQ.xml:S1:3915:2	in	IN	O	O
Pre	PRISTIQ.xml:S1:3918:3	pre	NNP	O	O
-	PRISTIQ.xml:S1:3921:1	-	:	O	O
marketing	PRISTIQ.xml:S1:3922:9	market	NN	O	O
Pooled	PRISTIQ.xml:S1:3932:6	pool	VBD	O	O
MDD	PRISTIQ.xml:S1:3939:3	mdd	NNP	O	O
8	PRISTIQ.xml:S1:3943:1	8	CD	O	O
-	PRISTIQ.xml:S1:3944:1	-	:	O	O
Week	PRISTIQ.xml:S1:3945:4	week	NN	O	O
Placebo	PRISTIQ.xml:S1:3950:7	placebo	NNP	O	O
-	PRISTIQ.xml:S1:3957:1	-	:	O	O
Controlled	PRISTIQ.xml:S1:3958:10	control	VBD	O	O
Studies	PRISTIQ.xml:S1:3969:7	studi	NNS	O	O

Percentage	PRISTIQ.xml:S1:4008:10	percentag	NN	O	O
of	PRISTIQ.xml:S1:4019:2	of	IN	O	O
Patients	PRISTIQ.xml:S1:4022:8	patient	NNS	O	O
Reporting	PRISTIQ.xml:S1:4031:9	report	VBG	O	O
Reaction	PRISTIQ.xml:S1:4041:8	reaction	NN	O	O

PRISTIQ	PRISTIQ.xml:S1:4102:7	pristiq	NN	O	O

System	PRISTIQ.xml:S1:4122:6	system	NNP	O	O
Organ	PRISTIQ.xml:S1:4129:5	organ	NNP	O	O
Class	PRISTIQ.xml:S1:4135:5	class	NNP	O	O
Preferred	PRISTIQ.xml:S1:4144:9	prefer	NNP	O	O
Term	PRISTIQ.xml:S1:4154:4	term	NNP	O	O
Placebo	PRISTIQ.xml:S1:4164:7	placebo	NNP	O	O
(	PRISTIQ.xml:S1:4175:1	(	(	O	O
n	PRISTIQ.xml:S1:4176:1	n	JJ	O	O
636	PRISTIQ.xml:S1:4178:3	636	CD	O	O
)	PRISTIQ.xml:S1:4181:1	)	)	O	O
50	PRISTIQ.xml:S1:4188:2	50	CD	O	O
mg	PRISTIQ.xml:S1:4191:2	mg	NN	O	O
(	PRISTIQ.xml:S1:4197:1	(	(	O	O
n	PRISTIQ.xml:S1:4198:1	n	JJ	O	O
317	PRISTIQ.xml:S1:4200:3	317	CD	O	O
)	PRISTIQ.xml:S1:4203:1	)	)	O	O
100	PRISTIQ.xml:S1:4210:3	100	CD	O	O
mg	PRISTIQ.xml:S1:4214:2	mg	NN	O	O
(	PRISTIQ.xml:S1:4220:1	(	(	O	O
n	PRISTIQ.xml:S1:4221:1	n	JJ	O	O
424	PRISTIQ.xml:S1:4223:3	424	CD	O	O
)	PRISTIQ.xml:S1:4226:1	)	)	O	O
200	PRISTIQ.xml:S1:4233:3	200	CD	O	O
mg	PRISTIQ.xml:S1:4237:2	mg	NN	O	O
(	PRISTIQ.xml:S1:4243:1	(	(	O	O
n	PRISTIQ.xml:S1:4244:1	n	JJ	O	O
307	PRISTIQ.xml:S1:4246:3	307	CD	O	O
)	PRISTIQ.xml:S1:4249:1	)	)	O	O
400	PRISTIQ.xml:S1:4256:3	400	CD	O	O
mg	PRISTIQ.xml:S1:4260:2	mg	NN	O	O
(	PRISTIQ.xml:S1:4266:1	(	(	O	O
n	PRISTIQ.xml:S1:4267:1	n	JJ	O	O
317	PRISTIQ.xml:S1:4269:3	317	CD	O	O
)	PRISTIQ.xml:S1:4272:1	)	)	O	O

Cardiac	PRISTIQ.xml:S1:4284:7	cardiac	NN	O	O

disorders	PRISTIQ.xml:S1:4292:9	disord	NNS	O	O

Blood	PRISTIQ.xml:S1:4316:5	blood	NNP	B-AdverseReaction	B-AdverseReaction
pressure	PRISTIQ.xml:S1:4322:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
increased	PRISTIQ.xml:S1:4331:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
1	PRISTIQ.xml:S1:4344:1	1	CD	O	O
1	PRISTIQ.xml:S1:4361:1	1	CD	O	O
1	PRISTIQ.xml:S1:4378:1	1	CD	O	O
2	PRISTIQ.xml:S1:4395:1	2	CD	O	O
2	PRISTIQ.xml:S1:4412:1	2	CD	O	O

Gastrointestinal	PRISTIQ.xml:S1:4432:16	gastrointestin	JJ	O	O
disorders	PRISTIQ.xml:S1:4449:9	disord	NNS	O	O

Nausea	PRISTIQ.xml:S1:4467:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
10	PRISTIQ.xml:S1:4492:2	10	CD	O	O
22	PRISTIQ.xml:S1:4509:2	22	CD	O	O
26	PRISTIQ.xml:S1:4526:2	26	CD	O	O
36	PRISTIQ.xml:S1:4543:2	36	CD	O	O
41	PRISTIQ.xml:S1:4560:2	41	CD	O	O

Dry	PRISTIQ.xml:S1:4582:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
mouth	PRISTIQ.xml:S1:4586:5	mouth	VBD	I-AdverseReaction	I-AdverseReaction
9	PRISTIQ.xml:S1:4607:1	9	CD	O	O
11	PRISTIQ.xml:S1:4624:2	11	CD	O	O
17	PRISTIQ.xml:S1:4641:2	17	CD	O	O
21	PRISTIQ.xml:S1:4658:2	21	CD	O	O
25	PRISTIQ.xml:S1:4675:2	25	CD	O	O

Constipation	PRISTIQ.xml:S1:4697:12	constip	NN	B-AdverseReaction	B-AdverseReaction
4	PRISTIQ.xml:S1:4722:1	4	CD	O	O
9	PRISTIQ.xml:S1:4739:1	9	CD	O	O
9	PRISTIQ.xml:S1:4756:1	9	CD	O	O
10	PRISTIQ.xml:S1:4773:2	10	CD	O	O
14	PRISTIQ.xml:S1:4790:2	14	CD	O	O

Vomiting	PRISTIQ.xml:S1:4812:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
3	PRISTIQ.xml:S1:4837:1	3	CD	O	O
3	PRISTIQ.xml:S1:4854:1	3	CD	O	O
4	PRISTIQ.xml:S1:4871:1	4	CD	O	O
6	PRISTIQ.xml:S1:4888:1	6	CD	O	O
9	PRISTIQ.xml:S1:4905:1	9	CD	O	O

General	PRISTIQ.xml:S1:4925:7	gener	NNP	O	O
disorders	PRISTIQ.xml:S1:4933:9	disord	NNS	O	O
and	PRISTIQ.xml:S1:4943:3	and	CC	O	O
administration	PRISTIQ.xml:S1:4947:14	administr	NN	O	O
site	PRISTIQ.xml:S1:4962:4	site	NN	O	O
conditions	PRISTIQ.xml:S1:4967:10	condit	NNS	O	O

Fatigue	PRISTIQ.xml:S1:4986:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
4	PRISTIQ.xml:S1:5011:1	4	CD	O	O
7	PRISTIQ.xml:S1:5028:1	7	CD	O	O
7	PRISTIQ.xml:S1:5045:1	7	CD	O	O
10	PRISTIQ.xml:S1:5062:2	10	CD	O	O
11	PRISTIQ.xml:S1:5079:2	11	CD	O	O

Chills	PRISTIQ.xml:S1:5101:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
1	PRISTIQ.xml:S1:5126:1	1	CD	O	O
1	PRISTIQ.xml:S1:5143:1	1	CD	O	O
1	PRISTIQ.xml:S1:5161:1	1	CD	O	O
3	PRISTIQ.xml:S1:5177:1	3	CD	O	O
4	PRISTIQ.xml:S1:5194:1	4	CD	O	O

Feeling	PRISTIQ.xml:S1:5216:7	feel	VBG	B-AdverseReaction	B-AdverseReaction
jittery	PRISTIQ.xml:S1:5224:7	jitteri	NN	I-AdverseReaction	I-AdverseReaction
1	PRISTIQ.xml:S1:5241:1	1	CD	O	O
1	PRISTIQ.xml:S1:5258:1	1	CD	O	O
2	PRISTIQ.xml:S1:5275:1	2	CD	O	O
3	PRISTIQ.xml:S1:5292:1	3	CD	O	O
3	PRISTIQ.xml:S1:5309:1	3	CD	O	O

Metabolism	PRISTIQ.xml:S1:5329:10	metabol	NN	O	O
and	PRISTIQ.xml:S1:5340:3	and	CC	O	O
nutrition	PRISTIQ.xml:S1:5344:9	nutrit	NN	O	O
disorders	PRISTIQ.xml:S1:5354:9	disord	NNS	O	O

Decreased	PRISTIQ.xml:S1:5372:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	PRISTIQ.xml:S1:5382:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
2	PRISTIQ.xml:S1:5397:1	2	CD	O	O
5	PRISTIQ.xml:S1:5414:1	5	CD	O	O
8	PRISTIQ.xml:S1:5431:1	8	CD	O	O
10	PRISTIQ.xml:S1:5448:2	10	CD	O	O
10	PRISTIQ.xml:S1:5465:2	10	CD	O	O

Nervous	PRISTIQ.xml:S1:5485:7	nervou	JJ	O	O
system	PRISTIQ.xml:S1:5493:6	system	NN	O	O
disorders	PRISTIQ.xml:S1:5500:9	disord	NNS	O	O

Dizziness	PRISTIQ.xml:S1:5518:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
5	PRISTIQ.xml:S1:5543:1	5	CD	O	O
13	PRISTIQ.xml:S1:5560:2	13	CD	O	O
10	PRISTIQ.xml:S1:5577:2	10	CD	O	O
15	PRISTIQ.xml:S1:5594:2	15	CD	O	O
16	PRISTIQ.xml:S1:5611:2	16	CD	O	O

Somnolence	PRISTIQ.xml:S1:5633:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
4	PRISTIQ.xml:S1:5658:1	4	CD	O	O
4	PRISTIQ.xml:S1:5675:1	4	CD	O	O
9	PRISTIQ.xml:S1:5692:1	9	CD	O	O
12	PRISTIQ.xml:S1:5709:2	12	CD	O	O
12	PRISTIQ.xml:S1:5726:2	12	CD	O	O

Tremor	PRISTIQ.xml:S1:5748:6	tremor	NNP	B-AdverseReaction	B-AdverseReaction
2	PRISTIQ.xml:S1:5773:1	2	CD	O	O
2	PRISTIQ.xml:S1:5790:1	2	CD	O	O
3	PRISTIQ.xml:S1:5807:1	3	CD	O	O
9	PRISTIQ.xml:S1:5824:1	9	CD	O	O
9	PRISTIQ.xml:S1:5841:1	9	CD	O	O

Disturbance	PRISTIQ.xml:S1:5863:11	disturb	NN	B-AdverseReaction	B-AdverseReaction
in	PRISTIQ.xml:S1:5875:2	in	IN	I-AdverseReaction	I-AdverseReaction
attention	PRISTIQ.xml:S1:5878:9	attent	NN	I-AdverseReaction	I-AdverseReaction
1	PRISTIQ.xml:S1:5892:1	1	CD	O	O
1	PRISTIQ.xml:S1:5909:1	1	CD	O	O
1	PRISTIQ.xml:S1:5925:1	1	CD	O	O
2	PRISTIQ.xml:S1:5942:1	2	CD	O	O
1	PRISTIQ.xml:S1:5959:1	1	CD	O	O

Psychiatric	PRISTIQ.xml:S1:5979:11	psychiatr	JJ	O	O
disorders	PRISTIQ.xml:S1:5991:9	disord	NNS	O	O

Insomnia	PRISTIQ.xml:S1:6011:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
6	PRISTIQ.xml:S1:6036:1	6	CD	O	O
9	PRISTIQ.xml:S1:6053:1	9	CD	O	O
12	PRISTIQ.xml:S1:6070:2	12	CD	O	O
14	PRISTIQ.xml:S1:6087:2	14	CD	O	O
15	PRISTIQ.xml:S1:6104:2	15	CD	O	O

Anxiety	PRISTIQ.xml:S1:6126:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
2	PRISTIQ.xml:S1:6151:1	2	CD	O	O
3	PRISTIQ.xml:S1:6168:1	3	CD	O	O
5	PRISTIQ.xml:S1:6185:1	5	CD	O	O
4	PRISTIQ.xml:S1:6202:1	4	CD	O	O
4	PRISTIQ.xml:S1:6219:1	4	CD	O	O

Nervousness	PRISTIQ.xml:S1:6241:11	nervous	RB	B-AdverseReaction	B-AdverseReaction
1	PRISTIQ.xml:S1:6266:1	1	CD	O	O
1	PRISTIQ.xml:S1:6284:1	1	CD	O	O
1	PRISTIQ.xml:S1:6300:1	1	CD	O	O
2	PRISTIQ.xml:S1:6317:1	2	CD	O	O
2	PRISTIQ.xml:S1:6334:1	2	CD	O	O

Abnormal	PRISTIQ.xml:S1:6356:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
dreams	PRISTIQ.xml:S1:6365:6	dream	VBZ	I-AdverseReaction	I-AdverseReaction
1	PRISTIQ.xml:S1:6381:1	1	CD	O	O
2	PRISTIQ.xml:S1:6398:1	2	CD	O	O
3	PRISTIQ.xml:S1:6415:1	3	CD	O	O
2	PRISTIQ.xml:S1:6432:1	2	CD	O	O
4	PRISTIQ.xml:S1:6449:1	4	CD	O	O

Renal	PRISTIQ.xml:S1:6469:5	renal	NNP	O	O
and	PRISTIQ.xml:S1:6475:3	and	CC	O	O
urinary	PRISTIQ.xml:S1:6479:7	urinari	JJ	O	O
disorders	PRISTIQ.xml:S1:6487:9	disord	NNS	O	O

Urinary	PRISTIQ.xml:S1:6505:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
hesitation	PRISTIQ.xml:S1:6513:10	hesit	NN	I-AdverseReaction	I-AdverseReaction
0	PRISTIQ.xml:S1:6530:1	0	CD	O	O
1	PRISTIQ.xml:S1:6548:1	1	CD	O	O
1	PRISTIQ.xml:S1:6564:1	1	CD	O	O
2	PRISTIQ.xml:S1:6581:1	2	CD	O	O
2	PRISTIQ.xml:S1:6598:1	2	CD	O	O

Respiratory	PRISTIQ.xml:S1:6618:11	respiratori	NNP	O	O
,	PRISTIQ.xml:S1:6629:1	,	,	O	O
thoracic	PRISTIQ.xml:S1:6631:8	thorac	NN	O	O
and	PRISTIQ.xml:S1:6640:3	and	CC	O	O
mediastinal	PRISTIQ.xml:S1:6644:11	mediastin	JJ	O	O
disorders	PRISTIQ.xml:S1:6656:9	disord	NNS	O	O

Yawning	PRISTIQ.xml:S1:6674:7	yawn	VBG	B-AdverseReaction	B-AdverseReaction
1	PRISTIQ.xml:S1:6700:1	1	CD	O	O
1	PRISTIQ.xml:S1:6716:1	1	CD	O	O
1	PRISTIQ.xml:S1:6733:1	1	CD	O	O
4	PRISTIQ.xml:S1:6750:1	4	CD	O	O
3	PRISTIQ.xml:S1:6767:1	3	CD	O	O

Skin	PRISTIQ.xml:S1:6787:4	skin	NNP	O	O
and	PRISTIQ.xml:S1:6792:3	and	CC	O	O
subcutaneous	PRISTIQ.xml:S1:6796:12	subcutan	JJ	O	O
tissue	PRISTIQ.xml:S1:6809:6	tissu	NN	O	O
disorders	PRISTIQ.xml:S1:6816:9	disord	NNS	O	O

Hyperhidrosis	PRISTIQ.xml:S1:6834:13	hyperhidrosi	$	B-AdverseReaction	B-AdverseReaction
4	PRISTIQ.xml:S1:6859:1	4	CD	O	O
10	PRISTIQ.xml:S1:6876:2	10	CD	O	O
11	PRISTIQ.xml:S1:6893:2	11	CD	O	O
18	PRISTIQ.xml:S1:6910:2	18	CD	O	O
21	PRISTIQ.xml:S1:6927:2	21	CD	O	O

Special	PRISTIQ.xml:S1:6947:7	special	JJ	O	O
Senses	PRISTIQ.xml:S1:6955:6	sens	NNS	O	O

Vision	PRISTIQ.xml:S1:6979:6	vision	NN	B-AdverseReaction	B-AdverseReaction
blurred	PRISTIQ.xml:S1:6986:7	blur	VBD	I-AdverseReaction	I-AdverseReaction
1	PRISTIQ.xml:S1:7004:1	1	CD	O	O
3	PRISTIQ.xml:S1:7021:1	3	CD	O	O
4	PRISTIQ.xml:S1:7038:1	4	CD	O	O
4	PRISTIQ.xml:S1:7055:1	4	CD	O	O
4	PRISTIQ.xml:S1:7072:1	4	CD	O	O

Mydriasis	PRISTIQ.xml:S1:7094:9	mydriasi	NN	B-AdverseReaction	B-AdverseReaction
1	PRISTIQ.xml:S1:7120:1	1	CD	O	O
2	PRISTIQ.xml:S1:7136:1	2	CD	O	O
2	PRISTIQ.xml:S1:7153:1	2	CD	O	O
6	PRISTIQ.xml:S1:7170:1	6	CD	O	O
6	PRISTIQ.xml:S1:7187:1	6	CD	O	O

Vertigo	PRISTIQ.xml:S1:7209:7	vertigo	NNP	B-AdverseReaction	B-AdverseReaction
1	PRISTIQ.xml:S1:7234:1	1	CD	O	O
2	PRISTIQ.xml:S1:7251:1	2	CD	O	O
1	PRISTIQ.xml:S1:7268:1	1	CD	O	O
5	PRISTIQ.xml:S1:7285:1	5	CD	O	O
3	PRISTIQ.xml:S1:7302:1	3	CD	O	O

Tinnitus	PRISTIQ.xml:S1:7324:8	tinnitu	NNP	B-AdverseReaction	B-AdverseReaction
1	PRISTIQ.xml:S1:7349:1	1	CD	O	O
2	PRISTIQ.xml:S1:7366:1	2	CD	O	O
1	PRISTIQ.xml:S1:7383:1	1	CD	O	O
1	PRISTIQ.xml:S1:7400:1	1	CD	O	O
2	PRISTIQ.xml:S1:7417:1	2	CD	O	O

Dysgeusia	PRISTIQ.xml:S1:7439:9	dysgeusia	NNP	B-AdverseReaction	B-AdverseReaction
1	PRISTIQ.xml:S1:7464:1	1	CD	O	O
1	PRISTIQ.xml:S1:7481:1	1	CD	O	O
1	PRISTIQ.xml:S1:7498:1	1	CD	O	O
1	PRISTIQ.xml:S1:7515:1	1	CD	O	O
2	PRISTIQ.xml:S1:7532:1	2	CD	O	O

Vascular	PRISTIQ.xml:S1:7552:8	vascular	JJ	O	O
disorders	PRISTIQ.xml:S1:7561:9	disord	NNS	O	O

Hot	PRISTIQ.xml:S1:7584:3	hot	NNP	B-AdverseReaction	B-AdverseReaction
flush	PRISTIQ.xml:S1:7588:5	flush	VBD	I-AdverseReaction	I-AdverseReaction
1	PRISTIQ.xml:S1:7610:1	1	CD	O	O
1	PRISTIQ.xml:S1:7626:1	1	CD	O	O
1	PRISTIQ.xml:S1:7643:1	1	CD	O	O
2	PRISTIQ.xml:S1:7660:1	2	CD	O	O
2	PRISTIQ.xml:S1:7677:1	2	CD	O	O

Sexual	PRISTIQ.xml:S1:7711:6	sexual	JJ	O	O
function	PRISTIQ.xml:S1:7718:8	function	NN	O	O
adverse	PRISTIQ.xml:S1:7727:7	advers	JJ	O	O
reactions	PRISTIQ.xml:S1:7735:9	reaction	NNS	O	O

Table	PRISTIQ.xml:S1:7751:5	tabl	NN	O	O

3	PRISTIQ.xml:S1:7757:1	3	CD	O	O
shows	PRISTIQ.xml:S1:7759:5	show	VBZ	O	O
the	PRISTIQ.xml:S1:7765:3	the	DT	O	O
incidence	PRISTIQ.xml:S1:7769:9	incid	NN	O	O
of	PRISTIQ.xml:S1:7779:2	of	IN	O	O
sexual	PRISTIQ.xml:S1:7782:6	sexual	JJ	B-AdverseReaction	O
function	PRISTIQ.xml:S1:7789:8	function	NN	I-AdverseReaction	O
adverse	PRISTIQ.xml:S1:7798:7	advers	JJ	I-AdverseReaction	O
reactions	PRISTIQ.xml:S1:7806:9	reaction	NNS	I-AdverseReaction	O
that	PRISTIQ.xml:S1:7816:4	that	WDT	O	O
occurred	PRISTIQ.xml:S1:7821:8	occur	VBD	O	O
in	PRISTIQ.xml:S1:7830:2	in	IN	O	O
2%	PRISTIQ.xml:S1:7836:2	2%	CD	O	O
of	PRISTIQ.xml:S1:7839:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:7842:7	pristiq	NNP	O	O
treated	PRISTIQ.xml:S1:7850:7	treat	VBD	O	O
MDD	PRISTIQ.xml:S1:7858:3	mdd	NNP	O	O
patients	PRISTIQ.xml:S1:7862:8	patient	NNS	O	O
in	PRISTIQ.xml:S1:7871:2	in	IN	O	O
any	PRISTIQ.xml:S1:7874:3	ani	DT	O	O
fixed	PRISTIQ.xml:S1:7878:5	fix	JJ	O	O
-	PRISTIQ.xml:S1:7883:1	-	:	O	O
dose	PRISTIQ.xml:S1:7884:4	dose	NN	O	O
group	PRISTIQ.xml:S1:7889:5	group	NN	O	O
(	PRISTIQ.xml:S1:7895:1	(	(	O	O
pre	PRISTIQ.xml:S1:7896:3	pre	JJ	O	O
-	PRISTIQ.xml:S1:7899:1	-	:	O	O
marketing	PRISTIQ.xml:S1:7900:9	market	NN	O	O
pooled	PRISTIQ.xml:S1:7910:6	pool	VBD	O	O
8	PRISTIQ.xml:S1:7917:1	8	CD	O	O
-	PRISTIQ.xml:S1:7918:1	-	:	O	O
week	PRISTIQ.xml:S1:7919:4	week	NN	O	O
,	PRISTIQ.xml:S1:7923:1	,	,	O	O
placebo	PRISTIQ.xml:S1:7925:7	placebo	SYM	O	O
-	PRISTIQ.xml:S1:7932:1	-	:	O	O
controlled	PRISTIQ.xml:S1:7933:10	control	VBN	O	O
,	PRISTIQ.xml:S1:7943:1	,	,	O	O
fixed	PRISTIQ.xml:S1:7945:5	fix	VBN	O	O
-	PRISTIQ.xml:S1:7951:1	-	:	O	O
dose	PRISTIQ.xml:S1:7952:4	dose	NN	O	O
,	PRISTIQ.xml:S1:7956:1	,	,	O	O
clinical	PRISTIQ.xml:S1:7958:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S1:7967:7	studi	NNS	O	O
)	PRISTIQ.xml:S1:7974:1	)	)	O	O
.	PRISTIQ.xml:S1:7975:1	.	.	O	O

Table	PRISTIQ.xml:S1:7981:5	tabl	JJ	O	O
3	PRISTIQ.xml:S1:7987:1	3	CD	O	O
:	PRISTIQ.xml:S1:7988:1	:	:	O	O
Sexual	PRISTIQ.xml:S1:7990:6	sexual	JJ	B-AdverseReaction	O
Function	PRISTIQ.xml:S1:7997:8	function	NNP	I-AdverseReaction	O
Adverse	PRISTIQ.xml:S1:8006:7	advers	NNP	I-AdverseReaction	O
Reactions	PRISTIQ.xml:S1:8014:9	reaction	NNP	I-AdverseReaction	O
(	PRISTIQ.xml:S1:8024:1	(	(	O	O
2%	PRISTIQ.xml:S1:8028:2	2%	CD	O	O
in	PRISTIQ.xml:S1:8031:2	in	IN	O	O
Men	PRISTIQ.xml:S1:8034:3	men	NNP	O	O
or	PRISTIQ.xml:S1:8038:2	or	CC	O	O
Women	PRISTIQ.xml:S1:8041:5	women	NNP	O	O
in	PRISTIQ.xml:S1:8047:2	in	IN	O	O
any	PRISTIQ.xml:S1:8050:3	ani	DT	O	O
PRISTIQ	PRISTIQ.xml:S1:8054:7	pristiq	NNP	O	O
Group	PRISTIQ.xml:S1:8062:5	group	NNP	O	O
)	PRISTIQ.xml:S1:8067:1	)	)	O	O
During	PRISTIQ.xml:S1:8069:6	dure	IN	O	O
the	PRISTIQ.xml:S1:8076:3	the	DT	O	O
On	PRISTIQ.xml:S1:8080:2	On	IN	O	O
-	PRISTIQ.xml:S1:8082:1	-	:	O	O
Therapy	PRISTIQ.xml:S1:8083:7	therapi	NN	O	O
Period	PRISTIQ.xml:S1:8091:6	period	NN	O	O

PRISTIQ	PRISTIQ.xml:S1:8141:7	pristiq	NN	O	O

Placebo	PRISTIQ.xml:S1:8184:7	placebo	NNP	O	O
(	PRISTIQ.xml:S1:8191:1	(	(	O	O
n	PRISTIQ.xml:S1:8192:1	n	JJ	O	O
239	PRISTIQ.xml:S1:8194:3	239	CD	O	O
)	PRISTIQ.xml:S1:8197:1	)	)	O	O
50	PRISTIQ.xml:S1:8202:2	50	CD	O	O
mg	PRISTIQ.xml:S1:8205:2	mg	NN	O	O
(	PRISTIQ.xml:S1:8207:1	(	(	O	O
n	PRISTIQ.xml:S1:8208:1	n	JJ	O	O
108	PRISTIQ.xml:S1:8210:3	108	CD	O	O
)	PRISTIQ.xml:S1:8213:1	)	)	O	O
100	PRISTIQ.xml:S1:8220:3	100	CD	O	O
mg	PRISTIQ.xml:S1:8224:2	mg	NN	O	O
(	PRISTIQ.xml:S1:8226:1	(	(	O	O
n	PRISTIQ.xml:S1:8227:1	n	JJ	O	O
157	PRISTIQ.xml:S1:8229:3	157	CD	O	O
)	PRISTIQ.xml:S1:8232:1	)	)	O	O
200	PRISTIQ.xml:S1:8238:3	200	CD	O	O
mg	PRISTIQ.xml:S1:8242:2	mg	NN	O	O
(	PRISTIQ.xml:S1:8244:1	(	(	O	O
n	PRISTIQ.xml:S1:8245:1	n	JJ	O	O
131	PRISTIQ.xml:S1:8247:3	131	CD	O	O
)	PRISTIQ.xml:S1:8250:1	)	)	O	O
400	PRISTIQ.xml:S1:8256:3	400	CD	O	O
mg	PRISTIQ.xml:S1:8260:2	mg	NN	O	O
(	PRISTIQ.xml:S1:8262:1	(	(	O	O
n	PRISTIQ.xml:S1:8263:1	n	JJ	O	O
154	PRISTIQ.xml:S1:8265:3	154	CD	O	O
)	PRISTIQ.xml:S1:8268:1	)	)	O	O

Men	PRISTIQ.xml:S1:8277:3	men	NN	O	O
only	PRISTIQ.xml:S1:8281:4	onli	RB	O	O

Anorgasmia	PRISTIQ.xml:S1:8304:10	anorgasmia	NNP	B-AdverseReaction	B-AdverseReaction
0	PRISTIQ.xml:S1:8324:1	0	CD	O	O
0	PRISTIQ.xml:S1:8342:1	0	CD	O	O
3	PRISTIQ.xml:S1:8360:1	3	CD	O	O
5	PRISTIQ.xml:S1:8378:1	5	CD	O	O
8	PRISTIQ.xml:S1:8396:1	8	CD	O	O

Libido	PRISTIQ.xml:S1:8419:6	libido	NNP	B-AdverseReaction	B-AdverseReaction
decreased	PRISTIQ.xml:S1:8426:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction
1	PRISTIQ.xml:S1:8439:1	1	CD	O	O
4	PRISTIQ.xml:S1:8457:1	4	CD	O	O
5	PRISTIQ.xml:S1:8475:1	5	CD	O	O
6	PRISTIQ.xml:S1:8493:1	6	CD	O	O
3	PRISTIQ.xml:S1:8511:1	3	CD	O	O

Orgasm	PRISTIQ.xml:S1:8534:6	orgasm	NNP	B-AdverseReaction	B-AdverseReaction
abnormal	PRISTIQ.xml:S1:8541:8	abnorm	VBD	I-AdverseReaction	I-AdverseReaction
0	PRISTIQ.xml:S1:8554:1	0	CD	O	O
0	PRISTIQ.xml:S1:8572:1	0	CD	O	O
1	PRISTIQ.xml:S1:8590:1	1	CD	O	O
2	PRISTIQ.xml:S1:8608:1	2	CD	O	O
3	PRISTIQ.xml:S1:8626:1	3	CD	O	O

Ejaculation	PRISTIQ.xml:S1:8649:11	ejacul	NNP	B-AdverseReaction	B-AdverseReaction
delayed	PRISTIQ.xml:S1:8661:7	delay	VBD	I-AdverseReaction	I-AdverseReaction
1	PRISTIQ.xml:S1:8673:1	1	CD	O	O
1	PRISTIQ.xml:S1:8690:1	1	CD	O	O
5	PRISTIQ.xml:S1:8708:1	5	CD	O	O
7	PRISTIQ.xml:S1:8726:1	7	CD	O	O
6	PRISTIQ.xml:S1:8744:1	6	CD	O	O

Erectile	PRISTIQ.xml:S1:8767:8	erectil	NNP	B-AdverseReaction	B-AdverseReaction
dysfunction	PRISTIQ.xml:S1:8776:11	dysfunct	NN	I-AdverseReaction	I-AdverseReaction
1	PRISTIQ.xml:S1:8791:1	1	CD	O	O
3	PRISTIQ.xml:S1:8809:1	3	CD	O	O
6	PRISTIQ.xml:S1:8827:1	6	CD	O	O
8	PRISTIQ.xml:S1:8845:1	8	CD	O	O
11	PRISTIQ.xml:S1:8863:2	11	CD	O	O

Ejaculation	PRISTIQ.xml:S1:8886:11	ejacul	NNP	B-AdverseReaction	B-AdverseReaction
disorder	PRISTIQ.xml:S1:8898:8	disord	VBZ	I-AdverseReaction	I-AdverseReaction
0	PRISTIQ.xml:S1:8910:1	0	CD	O	O
0	PRISTIQ.xml:S1:8928:1	0	CD	O	O
1	PRISTIQ.xml:S1:8946:1	1	CD	O	O
2	PRISTIQ.xml:S1:8964:1	2	CD	O	O
5	PRISTIQ.xml:S1:8982:1	5	CD	O	O

Ejaculation	PRISTIQ.xml:S1:9005:11	ejacul	NNP	B-AdverseReaction	B-AdverseReaction
failure	PRISTIQ.xml:S1:9017:7	failur	NN	I-AdverseReaction	I-AdverseReaction
0	PRISTIQ.xml:S1:9028:1	0	CD	O	O
1	PRISTIQ.xml:S1:9046:1	1	CD	O	O
0	PRISTIQ.xml:S1:9064:1	0	CD	O	O
2	PRISTIQ.xml:S1:9082:1	2	CD	O	O
2	PRISTIQ.xml:S1:9100:1	2	CD	O	O

Sexual	PRISTIQ.xml:S1:9123:6	sexual	JJ	B-AdverseReaction	B-AdverseReaction
dysfunction	PRISTIQ.xml:S1:9130:11	dysfunct	NN	I-AdverseReaction	I-AdverseReaction
0	PRISTIQ.xml:S1:9145:1	0	CD	O	O
1	PRISTIQ.xml:S1:9163:1	1	CD	O	O
0	PRISTIQ.xml:S1:9181:1	0	CD	O	O
0	PRISTIQ.xml:S1:9199:1	0	CD	O	O
2	PRISTIQ.xml:S1:9217:1	2	CD	O	O

PRISTIQ	PRISTIQ.xml:S1:9278:7	pristiq	NN	O	O

Placebo	PRISTIQ.xml:S1:9321:7	placebo	NNP	O	O
(	PRISTIQ.xml:S1:9328:1	(	(	O	O
n	PRISTIQ.xml:S1:9329:1	n	JJ	O	O
397	PRISTIQ.xml:S1:9331:3	397	CD	O	O
)	PRISTIQ.xml:S1:9334:1	)	)	O	O
50	PRISTIQ.xml:S1:9339:2	50	CD	O	O
mg	PRISTIQ.xml:S1:9342:2	mg	NN	O	O
(	PRISTIQ.xml:S1:9344:1	(	(	O	O
n	PRISTIQ.xml:S1:9345:1	n	JJ	O	O
209	PRISTIQ.xml:S1:9347:3	209	CD	O	O
)	PRISTIQ.xml:S1:9350:1	)	)	O	O
100	PRISTIQ.xml:S1:9357:3	100	CD	O	O
mg	PRISTIQ.xml:S1:9361:2	mg	NN	O	O
(	PRISTIQ.xml:S1:9363:1	(	(	O	O
n	PRISTIQ.xml:S1:9364:1	n	JJ	O	O
267	PRISTIQ.xml:S1:9366:3	267	CD	O	O
)	PRISTIQ.xml:S1:9369:1	)	)	O	O
200	PRISTIQ.xml:S1:9375:3	200	CD	O	O
mg	PRISTIQ.xml:S1:9379:2	mg	NN	O	O
(	PRISTIQ.xml:S1:9381:1	(	(	O	O
n	PRISTIQ.xml:S1:9382:1	n	JJ	O	O
176	PRISTIQ.xml:S1:9384:3	176	CD	O	O
)	PRISTIQ.xml:S1:9387:1	)	)	O	O
400	PRISTIQ.xml:S1:9393:3	400	CD	O	O
mg	PRISTIQ.xml:S1:9397:2	mg	NN	O	O
(	PRISTIQ.xml:S1:9399:1	(	(	O	O
n	PRISTIQ.xml:S1:9400:1	n	JJ	O	O
163	PRISTIQ.xml:S1:9402:3	163	CD	O	O
)	PRISTIQ.xml:S1:9405:1	)	)	O	O

Women	PRISTIQ.xml:S1:9416:5	women	NNS	O	O
only	PRISTIQ.xml:S1:9422:4	onli	RB	O	O

Anorgasmia	PRISTIQ.xml:S1:9441:10	anorgasmia	NNP	B-AdverseReaction	B-AdverseReaction
0	PRISTIQ.xml:S1:9461:1	0	CD	O	O
1	PRISTIQ.xml:S1:9479:1	1	CD	O	O
1	PRISTIQ.xml:S1:9497:1	1	CD	O	O
0	PRISTIQ.xml:S1:9515:1	0	CD	O	O
3	PRISTIQ.xml:S1:9533:1	3	CD	O	O

Other	PRISTIQ.xml:S1:9568:5	other	JJ	O	O
adverse	PRISTIQ.xml:S1:9574:7	advers	JJ	O	O
reactions	PRISTIQ.xml:S1:9582:9	reaction	NNS	O	O
observed	PRISTIQ.xml:S1:9592:8	observ	VBN	O	O
in	PRISTIQ.xml:S1:9601:2	in	IN	O	O
premarketing	PRISTIQ.xml:S1:9604:12	premarket	NN	O	O
and	PRISTIQ.xml:S1:9617:3	and	CC	O	O
postmarketing	PRISTIQ.xml:S1:9621:13	postmarket	VBG	O	O
clinical	PRISTIQ.xml:S1:9635:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S1:9644:7	studi	NNS	O	O

Other	PRISTIQ.xml:S1:9658:5	other	JJ	O	O

infrequent	PRISTIQ.xml:S1:9664:10	infrequ	JJ	O	O
adverse	PRISTIQ.xml:S1:9675:7	advers	JJ	O	O
reactions	PRISTIQ.xml:S1:9683:9	reaction	NNS	O	O
,	PRISTIQ.xml:S1:9692:1	,	,	O	O
not	PRISTIQ.xml:S1:9694:3	not	RB	O	O
described	PRISTIQ.xml:S1:9698:9	describ	VBN	O	O
elsewhere	PRISTIQ.xml:S1:9708:9	elsewher	RB	O	O
in	PRISTIQ.xml:S1:9718:2	in	IN	O	O
the	PRISTIQ.xml:S1:9721:3	the	DT	O	O
label	PRISTIQ.xml:S1:9725:5	label	NN	O	O
,	PRISTIQ.xml:S1:9730:1	,	,	O	O
occurring	PRISTIQ.xml:S1:9732:9	occur	VBG	O	O
at	PRISTIQ.xml:S1:9742:2	at	IN	O	O
an	PRISTIQ.xml:S1:9745:2	an	DT	O	O
incidence	PRISTIQ.xml:S1:9748:9	incid	NN	O	O
of	PRISTIQ.xml:S1:9758:2	of	IN	O	O
2%	PRISTIQ.xml:S1:9763:2	2%	CD	O	O
in	PRISTIQ.xml:S1:9766:2	in	IN	O	O
MDD	PRISTIQ.xml:S1:9769:3	mdd	NNP	O	O
patients	PRISTIQ.xml:S1:9773:8	patient	NNS	O	O
treated	PRISTIQ.xml:S1:9782:7	treat	VBD	O	O
with	PRISTIQ.xml:S1:9790:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:9795:7	pristiq	NNP	O	O
were	PRISTIQ.xml:S1:9803:4	were	VBD	O	O
:	PRISTIQ.xml:S1:9807:1	:	:	O	O

Cardiac	PRISTIQ.xml:S1:9817:7	cardiac	NNP	O	O
disorders	PRISTIQ.xml:S1:9825:9	disord	NNS	O	O
-	PRISTIQ.xml:S1:9838:1	-	:	O	O
Tachycardia	PRISTIQ.xml:S1:9840:11	tachycardia	NNP	B-AdverseReaction	B-AdverseReaction
.	PRISTIQ.xml:S1:9851:1	.	.	O	O

General	PRISTIQ.xml:S1:9861:7	gener	NNP	O	O
disorders	PRISTIQ.xml:S1:9869:9	disord	NNS	O	O
and	PRISTIQ.xml:S1:9879:3	and	CC	O	O
administration	PRISTIQ.xml:S1:9883:14	administr	NN	O	O
site	PRISTIQ.xml:S1:9898:4	site	NN	O	O
conditions	PRISTIQ.xml:S1:9903:10	condit	NNS	O	O
-	PRISTIQ.xml:S1:9917:1	-	:	O	O
Asthenia	PRISTIQ.xml:S1:9919:8	asthenia	NNP	B-AdverseReaction	O
.	PRISTIQ.xml:S1:9927:1	.	.	O	O

Investigations	PRISTIQ.xml:S1:9937:14	investig	NNS	O	B-AdverseReaction
-	PRISTIQ.xml:S1:9952:1	-	:	O	I-AdverseReaction
Weight	PRISTIQ.xml:S1:9957:6	weight	NNP	B-AdverseReaction	I-AdverseReaction
increased	PRISTIQ.xml:S1:9964:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S1:9973:1	,	,	O	O
liver	PRISTIQ.xml:S1:9975:5	liver	JJ	B-AdverseReaction	B-AdverseReaction
function	PRISTIQ.xml:S1:9981:8	function	NN	I-AdverseReaction	I-AdverseReaction
test	PRISTIQ.xml:S1:9990:4	test	NN	I-AdverseReaction	I-AdverseReaction
abnormal	PRISTIQ.xml:S1:9995:8	abnorm	NN	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S1:10003:1	,	,	O	O
blood	PRISTIQ.xml:S1:10005:5	blood	NN	B-AdverseReaction	B-AdverseReaction
prolactin	PRISTIQ.xml:S1:10011:9	prolactin	NN	I-AdverseReaction	I-AdverseReaction
increased	PRISTIQ.xml:S1:10021:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
.	PRISTIQ.xml:S1:10030:1	.	.	O	O

Musculoskeletal	PRISTIQ.xml:S1:10040:15	musculoskelet	NNP	O	O
and	PRISTIQ.xml:S1:10056:3	and	CC	O	O
connective	PRISTIQ.xml:S1:10060:10	connect	JJ	O	O
tissue	PRISTIQ.xml:S1:10071:6	tissu	NN	O	O
disorders	PRISTIQ.xml:S1:10078:9	disord	NNS	O	O
-	PRISTIQ.xml:S1:10088:1	-	:	O	O
Musculoskeletal	PRISTIQ.xml:S1:10093:15	musculoskelet	NNP	B-AdverseReaction	O
stiffness	PRISTIQ.xml:S1:10109:9	stiff	NN	I-AdverseReaction	O
.	PRISTIQ.xml:S1:10118:1	.	.	O	O

Nervous	PRISTIQ.xml:S1:10128:7	nervou	JJ	O	O
system	PRISTIQ.xml:S1:10136:6	system	NN	O	O
disorders	PRISTIQ.xml:S1:10143:9	disord	NNS	O	O
-	PRISTIQ.xml:S1:10153:1	-	:	O	O
Syncope	PRISTIQ.xml:S1:10158:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:10165:1	,	,	O	O
convulsion	PRISTIQ.xml:S1:10167:10	convuls	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:10177:1	,	,	O	O
dystonia	PRISTIQ.xml:S1:10179:8	dystonia	NN	B-AdverseReaction	O
.	PRISTIQ.xml:S1:10187:1	.	.	O	O

Psychiatric	PRISTIQ.xml:S1:10197:11	psychiatr	JJ	O	O
disorders	PRISTIQ.xml:S1:10209:9	disord	NNS	O	O
-	PRISTIQ.xml:S1:10219:1	-	:	O	O
Depersonalization	PRISTIQ.xml:S1:10224:17	deperson	NN	B-AdverseReaction	O
,	PRISTIQ.xml:S1:10241:1	,	,	O	O
bruxism	PRISTIQ.xml:S1:10243:7	bruxism	NN	B-AdverseReaction	O
.	PRISTIQ.xml:S1:10250:1	.	.	O	O

Renal	PRISTIQ.xml:S1:10260:5	renal	NNP	O	O
and	PRISTIQ.xml:S1:10266:3	and	CC	O	O
urinary	PRISTIQ.xml:S1:10270:7	urinari	JJ	O	O
disorders	PRISTIQ.xml:S1:10278:9	disord	NNS	O	O
-	PRISTIQ.xml:S1:10291:1	-	:	O	O
Urinary	PRISTIQ.xml:S1:10293:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
retention	PRISTIQ.xml:S1:10301:9	retent	NN	I-AdverseReaction	I-AdverseReaction
.	PRISTIQ.xml:S1:10310:1	.	.	O	O

Skin	PRISTIQ.xml:S1:10320:4	skin	NNP	O	O
and	PRISTIQ.xml:S1:10325:3	and	CC	O	O
subcutaneous	PRISTIQ.xml:S1:10329:12	subcutan	JJ	O	O
tissue	PRISTIQ.xml:S1:10342:6	tissu	NN	O	O
disorders	PRISTIQ.xml:S1:10349:9	disord	NNS	O	O
-	PRISTIQ.xml:S1:10360:1	-	:	O	O
Rash	PRISTIQ.xml:S1:10363:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:10367:1	,	,	O	O
alopecia	PRISTIQ.xml:S1:10369:8	alopecia	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S1:10377:1	,	,	O	O
photosensitivity	PRISTIQ.xml:S1:10379:16	photosensit	NN	B-AdverseReaction	B-AdverseReaction
reaction	PRISTIQ.xml:S1:10396:8	reaction	NN	O	I-AdverseReaction
,	PRISTIQ.xml:S1:10404:1	,	,	O	O
angioedema	PRISTIQ.xml:S1:10406:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
.	PRISTIQ.xml:S1:10416:1	.	.	O	O

In	PRISTIQ.xml:S1:10422:2	In	IN	O	O
clinical	PRISTIQ.xml:S1:10425:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S1:10434:7	studi	NNS	O	O
,	PRISTIQ.xml:S1:10441:1	,	,	O	O
there	PRISTIQ.xml:S1:10443:5	there	EX	O	O
were	PRISTIQ.xml:S1:10449:4	were	VBD	O	O
uncommon	PRISTIQ.xml:S1:10454:8	uncommon	JJ	O	O
reports	PRISTIQ.xml:S1:10463:7	report	NNS	O	O
of	PRISTIQ.xml:S1:10471:2	of	IN	O	O
ischemic	PRISTIQ.xml:S1:10474:8	ischem	JJ	B-AdverseReaction	O
cardiac	PRISTIQ.xml:S1:10483:7	cardiac	JJ	I-AdverseReaction	O
adverse	PRISTIQ.xml:S1:10491:7	advers	JJ	I-AdverseReaction	O
reactions	PRISTIQ.xml:S1:10499:9	reaction	NNS	I-AdverseReaction	O
,	PRISTIQ.xml:S1:10508:1	,	,	O	O
including	PRISTIQ.xml:S1:10510:9	includ	VBG	O	O
myocardial	PRISTIQ.xml:S1:10520:10	myocardi	JJ	B-AdverseReaction	B-AdverseReaction
ischemia	PRISTIQ.xml:S1:10531:8	ischemia	NN	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S1:10539:1	,	,	O	O
myocardial	PRISTIQ.xml:S1:10541:10	myocardi	JJ	B-AdverseReaction	B-AdverseReaction
infarction	PRISTIQ.xml:S1:10552:10	infarct	NN	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S1:10562:1	,	,	O	O
and	PRISTIQ.xml:S1:10564:3	and	CC	O	O
coronary	PRISTIQ.xml:S1:10568:8	coronari	JJ	B-AdverseReaction	B-AdverseReaction
occlusion	PRISTIQ.xml:S1:10577:9	occlus	NN	I-AdverseReaction	I-AdverseReaction
requiring	PRISTIQ.xml:S1:10587:9	requir	VBG	O	O
revascularization	PRISTIQ.xml:S1:10597:17	revascular	NN	O	O
;	PRISTIQ.xml:S1:10614:1	;	:	O	O
these	PRISTIQ.xml:S1:10616:5	these	DT	O	O
patients	PRISTIQ.xml:S1:10622:8	patient	NNS	O	O
had	PRISTIQ.xml:S1:10631:3	had	VBD	O	O
multiple	PRISTIQ.xml:S1:10635:8	multipl	JJ	O	O
underlying	PRISTIQ.xml:S1:10644:10	underli	JJ	O	O
cardiac	PRISTIQ.xml:S1:10655:7	cardiac	NN	O	O
risk	PRISTIQ.xml:S1:10663:4	risk	NN	O	O
factors	PRISTIQ.xml:S1:10668:7	factor	NNS	O	O
.	PRISTIQ.xml:S1:10675:1	.	.	O	O

More	PRISTIQ.xml:S1:10677:4	more	JJR	O	O
patients	PRISTIQ.xml:S1:10682:8	patient	NNS	O	O
experienced	PRISTIQ.xml:S1:10691:11	experienc	VBD	O	O
these	PRISTIQ.xml:S1:10703:5	these	DT	O	O
events	PRISTIQ.xml:S1:10709:6	event	NNS	O	O
during	PRISTIQ.xml:S1:10716:6	dure	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:10723:7	pristiq	NNP	O	O
treatment	PRISTIQ.xml:S1:10731:9	treatment	NN	O	O
as	PRISTIQ.xml:S1:10741:2	as	IN	O	O
compared	PRISTIQ.xml:S1:10744:8	compar	VBN	O	O
to	PRISTIQ.xml:S1:10753:2	to	TO	O	O
placebo	PRISTIQ.xml:S1:10756:7	placebo	VB	O	O
.	PRISTIQ.xml:S1:10763:1	.	.	O	O

Laboratory	PRISTIQ.xml:S1:10775:10	laboratori	NN	O	O
,	PRISTIQ.xml:S1:10785:1	,	,	O	O
ECG	PRISTIQ.xml:S1:10787:3	ecg	NNP	O	O
and	PRISTIQ.xml:S1:10791:3	and	CC	O	O
vital	PRISTIQ.xml:S1:10795:5	vital	JJ	O	O
sign	PRISTIQ.xml:S1:10801:4	sign	NN	O	O
changes	PRISTIQ.xml:S1:10806:7	chang	NNS	O	O
observed	PRISTIQ.xml:S1:10814:8	observ	VBN	O	O
in	PRISTIQ.xml:S1:10823:2	in	IN	O	O
MDD	PRISTIQ.xml:S1:10826:3	mdd	NNP	O	O
clinical	PRISTIQ.xml:S1:10830:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S1:10839:7	studi	NNS	O	O

The	PRISTIQ.xml:S1:10855:3	the	DT	O	O
following	PRISTIQ.xml:S1:10859:9	follow	JJ	O	O
changes	PRISTIQ.xml:S1:10869:7	chang	NNS	O	O
were	PRISTIQ.xml:S1:10877:4	were	VBD	O	O
observed	PRISTIQ.xml:S1:10882:8	observ	VBN	O	O
in	PRISTIQ.xml:S1:10891:2	in	IN	O	O
pre	PRISTIQ.xml:S1:10894:3	pre	NN	O	O
-	PRISTIQ.xml:S1:10897:1	-	:	O	O
marketing	PRISTIQ.xml:S1:10898:9	market	NN	O	O
placebo	PRISTIQ.xml:S1:10908:7	placebo	NN	O	O
-	PRISTIQ.xml:S1:10915:1	-	:	O	O
controlled	PRISTIQ.xml:S1:10916:10	control	VBN	O	O
,	PRISTIQ.xml:S1:10926:1	,	,	O	O
short	PRISTIQ.xml:S1:10928:5	short	JJ	O	O
-	PRISTIQ.xml:S1:10933:1	-	:	O	O
term	PRISTIQ.xml:S1:10934:4	term	NN	O	O
MDD	PRISTIQ.xml:S1:10939:3	mdd	NNP	O	O
studies	PRISTIQ.xml:S1:10943:7	studi	NNS	O	O
with	PRISTIQ.xml:S1:10951:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:10956:7	pristiq	NNP	O	O
.	PRISTIQ.xml:S1:10963:1	.	.	O	O

Lipids	PRISTIQ.xml:S1:10975:6	lipid	NNS	O	O

Elevations	PRISTIQ.xml:S1:10990:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	PRISTIQ.xml:S1:11001:2	in	IN	I-AdverseReaction	I-AdverseReaction
fasting	PRISTIQ.xml:S1:11004:7	fast	VBG	I-AdverseReaction	I-AdverseReaction
serum	PRISTIQ.xml:S1:11012:5	serum	JJ	I-AdverseReaction	I-AdverseReaction
total	PRISTIQ.xml:S1:11018:5	total	JJ	I-AdverseReaction	I-AdverseReaction
cholesterol	PRISTIQ.xml:S1:11024:11	cholesterol	NN	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S1:11035:1	,	,	O	O
LDL	PRISTIQ.xml:S1:11037:3	ldl	NNP	I-AdverseReaction	B-AdverseReaction
(	PRISTIQ.xml:S1:11041:1	(	(	O	O
low	PRISTIQ.xml:S1:11042:3	low	JJ	I-AdverseReaction	O
density	PRISTIQ.xml:S1:11046:7	densiti	NN	I-AdverseReaction	O
lipoproteins	PRISTIQ.xml:S1:11054:12	lipoprotein	NNS	I-AdverseReaction	O
)	PRISTIQ.xml:S1:11066:1	)	)	O	O
cholesterol	PRISTIQ.xml:S1:11068:11	cholesterol	NN	I-AdverseReaction	O
,	PRISTIQ.xml:S1:11079:1	,	,	O	O
and	PRISTIQ.xml:S1:11081:3	and	CC	O	O
triglycerides	PRISTIQ.xml:S1:11085:13	triglycerid	NNS	I-AdverseReaction	B-AdverseReaction
occurred	PRISTIQ.xml:S1:11099:8	occur	VBD	O	O
in	PRISTIQ.xml:S1:11108:2	in	IN	O	O
the	PRISTIQ.xml:S1:11111:3	the	DT	O	O
controlled	PRISTIQ.xml:S1:11115:10	control	JJ	O	O
studies	PRISTIQ.xml:S1:11126:7	studi	NNS	O	O
.	PRISTIQ.xml:S1:11133:1	.	.	O	O

Some	PRISTIQ.xml:S1:11135:4	some	DT	O	O
of	PRISTIQ.xml:S1:11140:2	of	IN	O	O
these	PRISTIQ.xml:S1:11143:5	these	DT	O	O
abnormalities	PRISTIQ.xml:S1:11149:13	abnorm	NNS	O	O
were	PRISTIQ.xml:S1:11163:4	were	VBD	O	O
considered	PRISTIQ.xml:S1:11168:10	consid	VBN	O	O
potentially	PRISTIQ.xml:S1:11179:11	potenti	RB	O	O
clinically	PRISTIQ.xml:S1:11191:10	clinic	RB	O	O
significant	PRISTIQ.xml:S1:11202:11	signific	JJ	O	O
.	PRISTIQ.xml:S1:11213:1	.	.	O	O

The	PRISTIQ.xml:S1:11219:3	the	DT	O	O
percentage	PRISTIQ.xml:S1:11223:10	percentag	NN	O	O
of	PRISTIQ.xml:S1:11234:2	of	IN	O	O
patients	PRISTIQ.xml:S1:11237:8	patient	NNS	O	O
who	PRISTIQ.xml:S1:11246:3	who	WP	O	O
exceeded	PRISTIQ.xml:S1:11250:8	exceed	VBD	O	O
a	PRISTIQ.xml:S1:11259:1	a	DT	O	O
predetermined	PRISTIQ.xml:S1:11261:13	predetermin	VBN	O	O
threshold	PRISTIQ.xml:S1:11275:9	threshold	NN	O	O
value	PRISTIQ.xml:S1:11285:5	valu	NN	O	O
is	PRISTIQ.xml:S1:11291:2	is	VBZ	O	O
shown	PRISTIQ.xml:S1:11294:5	shown	VBN	O	O
in	PRISTIQ.xml:S1:11300:2	in	IN	O	O
Table	PRISTIQ.xml:S1:11303:5	tabl	JJ	O	O
4	PRISTIQ.xml:S1:11309:1	4	CD	O	O
.	PRISTIQ.xml:S1:11310:1	.	.	O	O

Table	PRISTIQ.xml:S1:11316:5	tabl	JJ	O	O
4	PRISTIQ.xml:S1:11322:1	4	CD	O	O
:	PRISTIQ.xml:S1:11323:1	:	:	O	O
Incidence	PRISTIQ.xml:S1:11325:9	incid	NNP	O	O
(	PRISTIQ.xml:S1:11335:1	(	(	O	O
)	PRISTIQ.xml:S1:11337:1	)	)	O	O
of	PRISTIQ.xml:S1:11339:2	of	IN	O	O
Patients	PRISTIQ.xml:S1:11342:8	patient	NNS	O	O
With	PRISTIQ.xml:S1:11351:4	with	IN	O	O
Lipid	PRISTIQ.xml:S1:11356:5	lipid	NNP	B-AdverseReaction	O
Abnormalities	PRISTIQ.xml:S1:11362:13	abnorm	NNP	I-AdverseReaction	O
of	PRISTIQ.xml:S1:11376:2	of	IN	O	O
Potential	PRISTIQ.xml:S1:11379:9	potenti	NNP	O	O
Clinical	PRISTIQ.xml:S1:11389:8	clinic	NNP	O	O
Significance	PRISTIQ.xml:S1:11398:12	signific	NNP	O	O

PRISTIQ	PRISTIQ.xml:S1:11465:7	pristiq	NN	O	O

Placebo	PRISTIQ.xml:S1:11516:7	placebo	NNP	O	O
50	PRISTIQ.xml:S1:11531:2	50	CD	O	O
mg	PRISTIQ.xml:S1:11534:2	mg	NN	O	O
100	PRISTIQ.xml:S1:11545:3	100	CD	O	O
mg	PRISTIQ.xml:S1:11549:2	mg	NN	O	O
200	PRISTIQ.xml:S1:11559:3	200	CD	O	O
mg	PRISTIQ.xml:S1:11563:2	mg	NN	O	O
400	PRISTIQ.xml:S1:11573:3	400	CD	O	O
mg	PRISTIQ.xml:S1:11577:2	mg	NN	O	O

Total	PRISTIQ.xml:S1:11592:5	total	JJ	B-AdverseReaction	O

Cholesterol	PRISTIQ.xml:S1:11598:11	cholesterol	NNP	I-AdverseReaction	O
(	PRISTIQ.xml:S1:11610:1	(	(	O	O
Increase	PRISTIQ.xml:S1:11611:8	increas	NNP	O	O
of	PRISTIQ.xml:S1:11620:2	of	IN	O	O
50	PRISTIQ.xml:S1:11626:2	50	CD	O	O
mg	PRISTIQ.xml:S1:11629:2	mg	NNS	O	O
dl	PRISTIQ.xml:S1:11632:2	dl	NN	O	O
and	PRISTIQ.xml:S1:11635:3	and	CC	O	O
an	PRISTIQ.xml:S1:11639:2	an	DT	O	O
absolute	PRISTIQ.xml:S1:11642:8	absolut	JJ	O	O
value	PRISTIQ.xml:S1:11651:5	valu	NN	O	O
of	PRISTIQ.xml:S1:11657:2	of	IN	O	O
261	PRISTIQ.xml:S1:11663:3	261	CD	I-AdverseReaction	O
mg	PRISTIQ.xml:S1:11667:2	mg	NNS	I-AdverseReaction	O
dl	PRISTIQ.xml:S1:11670:2	dl	NN	I-AdverseReaction	O
)	PRISTIQ.xml:S1:11672:1	)	)	O	O
2	PRISTIQ.xml:S1:11677:1	2	CD	O	O
3	PRISTIQ.xml:S1:11692:1	3	CD	O	O
4	PRISTIQ.xml:S1:11706:1	4	CD	O	O
4	PRISTIQ.xml:S1:11720:1	4	CD	O	O
10	PRISTIQ.xml:S1:11734:2	10	CD	O	O

LDL	PRISTIQ.xml:S1:11751:3	ldl	NNP	B-AdverseReaction	O
Cholesterol	PRISTIQ.xml:S1:11755:11	cholesterol	NNP	I-AdverseReaction	O
(	PRISTIQ.xml:S1:11767:1	(	(	O	O
Increase	PRISTIQ.xml:S1:11768:8	increas	NNP	O	O
50	PRISTIQ.xml:S1:11780:2	50	CD	O	O
mg	PRISTIQ.xml:S1:11783:2	mg	NN	O	O
dl	PRISTIQ.xml:S1:11786:2	dl	NN	O	O
and	PRISTIQ.xml:S1:11789:3	and	CC	O	O
an	PRISTIQ.xml:S1:11793:2	an	DT	O	O
absolute	PRISTIQ.xml:S1:11796:8	absolut	JJ	O	O
value	PRISTIQ.xml:S1:11805:5	valu	NN	O	O
of	PRISTIQ.xml:S1:11811:2	of	IN	O	O
190	PRISTIQ.xml:S1:11817:3	190	CD	I-AdverseReaction	O
mg	PRISTIQ.xml:S1:11821:2	mg	NNS	I-AdverseReaction	O
dl	PRISTIQ.xml:S1:11824:2	dl	NN	I-AdverseReaction	O
)	PRISTIQ.xml:S1:11826:1	)	)	O	O
0	PRISTIQ.xml:S1:11831:1	0	CD	O	O
1	PRISTIQ.xml:S1:11846:1	1	CD	O	O
0	PRISTIQ.xml:S1:11860:1	0	CD	O	O
1	PRISTIQ.xml:S1:11874:1	1	CD	O	O
2	PRISTIQ.xml:S1:11888:1	2	CD	O	O

Triglycerides	PRISTIQ.xml:S1:11905:13	triglycerid	NNS	B-AdverseReaction	O
,	PRISTIQ.xml:S1:11918:1	,	,	I-AdverseReaction	O
fasting	PRISTIQ.xml:S1:11920:7	fast	VBG	I-AdverseReaction	O
(	PRISTIQ.xml:S1:11928:1	(	(	O	O
Fasting	PRISTIQ.xml:S1:11929:7	fast	VBG	O	O
:	PRISTIQ.xml:S1:11936:1	:	:	O	O
327	PRISTIQ.xml:S1:11941:3	327	CD	I-AdverseReaction	O
mg	PRISTIQ.xml:S1:11945:2	mg	NNS	I-AdverseReaction	O
dl	PRISTIQ.xml:S1:11948:2	dl	NN	I-AdverseReaction	O
)	PRISTIQ.xml:S1:11950:1	)	)	O	O
3	PRISTIQ.xml:S1:11955:1	3	CD	O	O
2	PRISTIQ.xml:S1:11970:1	2	CD	O	O
1	PRISTIQ.xml:S1:11984:1	1	CD	O	O
4	PRISTIQ.xml:S1:11998:1	4	CD	O	O
6	PRISTIQ.xml:S1:12012:1	6	CD	O	O

Proteinuria	PRISTIQ.xml:S1:12045:11	proteinuria	NNS	O	O

Proteinuria	PRISTIQ.xml:S1:12065:11	proteinuria	NNS	B-AdverseReaction	O

,	PRISTIQ.xml:S1:12076:1	,	,	O	O
greater	PRISTIQ.xml:S1:12078:7	greater	JJR	O	O
than	PRISTIQ.xml:S1:12086:4	than	IN	O	O
or	PRISTIQ.xml:S1:12091:2	or	CC	O	O
equal	PRISTIQ.xml:S1:12094:5	equal	JJ	O	O
to	PRISTIQ.xml:S1:12100:2	to	TO	O	O
trace	PRISTIQ.xml:S1:12103:5	trace	VB	O	O
,	PRISTIQ.xml:S1:12108:1	,	,	O	O
was	PRISTIQ.xml:S1:12110:3	wa	VBD	O	O
observed	PRISTIQ.xml:S1:12114:8	observ	VBN	O	O
in	PRISTIQ.xml:S1:12123:2	in	IN	O	O
the	PRISTIQ.xml:S1:12126:3	the	DT	O	O
pre	PRISTIQ.xml:S1:12130:3	pre	NN	O	O
-	PRISTIQ.xml:S1:12133:1	-	:	O	O
marketing	PRISTIQ.xml:S1:12134:9	market	NN	O	O
fixed	PRISTIQ.xml:S1:12144:5	fix	VBN	O	O
-	PRISTIQ.xml:S1:12149:1	-	:	O	O
dose	PRISTIQ.xml:S1:12150:4	dose	NN	O	O
controlled	PRISTIQ.xml:S1:12155:10	control	VBN	O	O
studies	PRISTIQ.xml:S1:12166:7	studi	NNS	O	O
(	PRISTIQ.xml:S1:12174:1	(	(	O	O
see	PRISTIQ.xml:S1:12175:3	see	VB	O	O
Table	PRISTIQ.xml:S1:12180:5	tabl	NNP	O	O
5	PRISTIQ.xml:S1:12186:1	5	CD	O	O
)	PRISTIQ.xml:S1:12189:1	)	)	O	O
.	PRISTIQ.xml:S1:12190:1	.	.	O	O

This	PRISTIQ.xml:S1:12192:4	thi	DT	O	O
proteinuria	PRISTIQ.xml:S1:12197:11	proteinuria	NN	B-AdverseReaction	O
was	PRISTIQ.xml:S1:12209:3	wa	VBD	O	O
not	PRISTIQ.xml:S1:12213:3	not	RB	O	O
associated	PRISTIQ.xml:S1:12217:10	associ	VBN	O	O
with	PRISTIQ.xml:S1:12228:4	with	IN	O	O
increases	PRISTIQ.xml:S1:12233:9	increas	NNS	B-AdverseReaction	O
in	PRISTIQ.xml:S1:12243:2	in	IN	I-AdverseReaction	O
BUN	PRISTIQ.xml:S1:12246:3	bun	NNP	I-AdverseReaction	O
or	PRISTIQ.xml:S1:12250:2	or	CC	O	O
creatinine	PRISTIQ.xml:S1:12253:10	creatinin	NN	I-AdverseReaction	O
and	PRISTIQ.xml:S1:12264:3	and	CC	O	O
was	PRISTIQ.xml:S1:12268:3	wa	VBD	O	O
generally	PRISTIQ.xml:S1:12272:9	gener	RB	O	O
transient	PRISTIQ.xml:S1:12282:9	transient	JJ	O	O
.	PRISTIQ.xml:S1:12291:1	.	.	O	O

Table	PRISTIQ.xml:S1:12297:5	tabl	JJ	O	O
5	PRISTIQ.xml:S1:12303:1	5	CD	O	O
:	PRISTIQ.xml:S1:12304:1	:	:	O	O
Incidence	PRISTIQ.xml:S1:12306:9	incid	NNP	O	O
(	PRISTIQ.xml:S1:12316:1	(	(	O	O
)	PRISTIQ.xml:S1:12318:1	)	)	O	O
of	PRISTIQ.xml:S1:12320:2	of	IN	O	O
Patients	PRISTIQ.xml:S1:12323:8	patient	NNS	O	O
with	PRISTIQ.xml:S1:12332:4	with	IN	O	O
Proteinuria	PRISTIQ.xml:S1:12337:11	proteinuria	NNP	B-AdverseReaction	O
in	PRISTIQ.xml:S1:12349:2	in	IN	O	O
the	PRISTIQ.xml:S1:12352:3	the	DT	O	O
Fixed	PRISTIQ.xml:S1:12356:5	fix	NNP	O	O
-	PRISTIQ.xml:S1:12361:1	-	:	O	O
dose	PRISTIQ.xml:S1:12362:4	dose	JJ	O	O
Clinical	PRISTIQ.xml:S1:12367:8	clinic	JJ	O	O
Studies	PRISTIQ.xml:S1:12376:7	studi	NNS	O	O

PRISTIQ	PRISTIQ.xml:S1:12426:7	pristiq	NN	O	O

Placebo	PRISTIQ.xml:S1:12467:7	placebo	NNP	O	O
50	PRISTIQ.xml:S1:12484:2	50	CD	O	O
mg	PRISTIQ.xml:S1:12487:2	mg	NN	O	O
100	PRISTIQ.xml:S1:12501:3	100	CD	O	O
mg	PRISTIQ.xml:S1:12505:2	mg	NN	O	O
200	PRISTIQ.xml:S1:12518:3	200	CD	O	O
mg	PRISTIQ.xml:S1:12522:2	mg	NN	O	O
400	PRISTIQ.xml:S1:12535:3	400	CD	O	O
mg	PRISTIQ.xml:S1:12539:2	mg	NN	O	O

Proteinuria	PRISTIQ.xml:S1:12557:11	proteinuria	NNS	B-AdverseReaction	O

4	PRISTIQ.xml:S1:12578:1	4	CD	O	O
6	PRISTIQ.xml:S1:12595:1	6	CD	O	O
8	PRISTIQ.xml:S1:12612:1	8	CD	O	O
5	PRISTIQ.xml:S1:12629:1	5	CD	O	O
7	PRISTIQ.xml:S1:12646:1	7	CD	O	O

Vital	PRISTIQ.xml:S1:12682:5	vital	NNP	O	O
sign	PRISTIQ.xml:S1:12688:4	sign	NN	O	O
changes	PRISTIQ.xml:S1:12693:7	chang	NNS	O	O

Table	PRISTIQ.xml:S1:12709:5	tabl	NN	O	O

6	PRISTIQ.xml:S1:12715:1	6	CD	O	O
summarizes	PRISTIQ.xml:S1:12717:10	summar	VBZ	O	O
the	PRISTIQ.xml:S1:12728:3	the	DT	O	O
changes	PRISTIQ.xml:S1:12732:7	chang	NNS	O	O
that	PRISTIQ.xml:S1:12740:4	that	WDT	O	O
were	PRISTIQ.xml:S1:12745:4	were	VBD	O	O
observed	PRISTIQ.xml:S1:12750:8	observ	VBN	O	O
in	PRISTIQ.xml:S1:12759:2	in	IN	O	O
placebo	PRISTIQ.xml:S1:12762:7	placebo	NN	O	O
-	PRISTIQ.xml:S1:12769:1	-	:	O	O
controlled	PRISTIQ.xml:S1:12770:10	control	VBN	O	O
,	PRISTIQ.xml:S1:12780:1	,	,	O	O
short	PRISTIQ.xml:S1:12782:5	short	JJ	O	O
-	PRISTIQ.xml:S1:12787:1	-	:	O	O
term	PRISTIQ.xml:S1:12788:4	term	NN	O	O
,	PRISTIQ.xml:S1:12792:1	,	,	O	O
pre	PRISTIQ.xml:S1:12794:3	pre	SYM	O	O
-	PRISTIQ.xml:S1:12797:1	-	:	O	O
marketing	PRISTIQ.xml:S1:12798:9	market	NN	O	O
studies	PRISTIQ.xml:S1:12808:7	studi	NNS	O	O
with	PRISTIQ.xml:S1:12816:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:12821:7	pristiq	NNP	O	O
in	PRISTIQ.xml:S1:12829:2	in	IN	O	O
patients	PRISTIQ.xml:S1:12832:8	patient	NNS	O	O
with	PRISTIQ.xml:S1:12841:4	with	IN	O	O
MDD	PRISTIQ.xml:S1:12846:3	mdd	NNP	O	O
(	PRISTIQ.xml:S1:12850:1	(	(	O	O
doses	PRISTIQ.xml:S1:12851:5	dose	VBZ	O	O
50	PRISTIQ.xml:S1:12857:2	50	CD	O	O
to	PRISTIQ.xml:S1:12860:2	to	TO	O	O
400	PRISTIQ.xml:S1:12863:3	400	CD	O	O
mg	PRISTIQ.xml:S1:12867:2	mg	NN	O	O
)	PRISTIQ.xml:S1:12869:1	)	)	O	O
.	PRISTIQ.xml:S1:12870:1	.	.	O	O

Table	PRISTIQ.xml:S1:12876:5	tabl	JJ	O	O
6	PRISTIQ.xml:S1:12882:1	6	CD	O	O
:	PRISTIQ.xml:S1:12883:1	:	:	O	O
Mean	PRISTIQ.xml:S1:12885:4	mean	JJ	O	O
Changes	PRISTIQ.xml:S1:12890:7	chang	NNS	O	O
in	PRISTIQ.xml:S1:12898:2	in	IN	O	O
Vital	PRISTIQ.xml:S1:12901:5	vital	JJ	O	O
Signs	PRISTIQ.xml:S1:12907:5	sign	NNP	O	O
at	PRISTIQ.xml:S1:12913:2	at	IN	O	O
Final	PRISTIQ.xml:S1:12916:5	final	NNP	O	O
on	PRISTIQ.xml:S1:12922:2	on	IN	O	O
Therapy	PRISTIQ.xml:S1:12925:7	therapi	NNP	O	O
for	PRISTIQ.xml:S1:12933:3	for	IN	O	O
All	PRISTIQ.xml:S1:12937:3	all	NNP	O	O
Short	PRISTIQ.xml:S1:12941:5	short	NNP	O	O
-	PRISTIQ.xml:S1:12946:1	-	:	O	O
term	PRISTIQ.xml:S1:12947:4	term	NN	O	O
,	PRISTIQ.xml:S1:12951:1	,	,	O	O
Fixed	PRISTIQ.xml:S1:12953:5	fix	NNP	O	O
-	PRISTIQ.xml:S1:12958:1	-	:	O	O
dose	PRISTIQ.xml:S1:12959:4	dose	NN	O	O
Controlled	PRISTIQ.xml:S1:12964:10	control	NNP	O	O
Studies	PRISTIQ.xml:S1:12975:7	studi	NNS	O	O

PRISTIQ	PRISTIQ.xml:S1:13025:7	pristiq	NN	O	O

Placebo	PRISTIQ.xml:S1:13066:7	placebo	NNP	O	O
50	PRISTIQ.xml:S1:13083:2	50	CD	O	O
mg	PRISTIQ.xml:S1:13086:2	mg	NN	O	O
100	PRISTIQ.xml:S1:13100:3	100	CD	O	O
mg	PRISTIQ.xml:S1:13104:2	mg	NN	O	O
200	PRISTIQ.xml:S1:13117:3	200	CD	O	O
mg	PRISTIQ.xml:S1:13121:2	mg	NN	O	O
400	PRISTIQ.xml:S1:13134:3	400	CD	O	O
mg	PRISTIQ.xml:S1:13138:2	mg	NN	O	O

Blood	PRISTIQ.xml:S1:13156:5	blood	NN	O	O

pressure	PRISTIQ.xml:S1:13162:8	pressur	NN	O	O

Supine	PRISTIQ.xml:S1:13180:6	supin	NNP	O	O
systolic	PRISTIQ.xml:S1:13187:8	systol	JJ	O	O
bp	PRISTIQ.xml:S1:13196:2	bp	NN	O	O
(	PRISTIQ.xml:S1:13199:1	(	(	O	O
mm	PRISTIQ.xml:S1:13200:2	mm	JJ	O	O
Hg	PRISTIQ.xml:S1:13203:2	Hg	NNP	O	O
)	PRISTIQ.xml:S1:13205:1	)	)	O	O
-	PRISTIQ.xml:S1:13210:1	-	:	O	O
1.4	PRISTIQ.xml:S1:13211:3	1.4	CD	O	O
1.2	PRISTIQ.xml:S1:13227:3	1.2	CD	O	O
2.0	PRISTIQ.xml:S1:13244:3	2.0	CD	O	O
2.5	PRISTIQ.xml:S1:13261:3	2.5	CD	O	O
2.1	PRISTIQ.xml:S1:13278:3	2.1	CD	O	O

Supine	PRISTIQ.xml:S1:13298:6	supin	NNP	O	B-AdverseReaction
diastolic	PRISTIQ.xml:S1:13305:9	diastol	JJ	O	I-AdverseReaction
bp	PRISTIQ.xml:S1:13315:2	bp	NN	O	I-AdverseReaction
(	PRISTIQ.xml:S1:13318:1	(	(	O	O
mm	PRISTIQ.xml:S1:13319:2	mm	JJ	O	O
Hg	PRISTIQ.xml:S1:13322:2	Hg	NNP	O	O
)	PRISTIQ.xml:S1:13324:1	)	)	O	O
-	PRISTIQ.xml:S1:13329:1	-	:	O	O
0.6	PRISTIQ.xml:S1:13330:3	0.6	CD	O	O
0.7	PRISTIQ.xml:S1:13346:3	0.7	CD	O	O
0.8	PRISTIQ.xml:S1:13363:3	0.8	CD	O	O
1.8	PRISTIQ.xml:S1:13380:3	1.8	CD	O	O
2.3	PRISTIQ.xml:S1:13397:3	2.3	CD	O	O

Pulse	PRISTIQ.xml:S1:13417:5	puls	NNP	O	O
rate	PRISTIQ.xml:S1:13423:4	rate	NN	O	O

Supine	PRISTIQ.xml:S1:13441:6	supin	NNP	O	O
pulse	PRISTIQ.xml:S1:13448:5	puls	NN	O	O
(	PRISTIQ.xml:S1:13454:1	(	(	O	O
bpm	PRISTIQ.xml:S1:13455:3	bpm	NN	O	O
)	PRISTIQ.xml:S1:13458:1	)	)	O	O
-	PRISTIQ.xml:S1:13463:1	-	:	O	O
0.3	PRISTIQ.xml:S1:13464:3	0.3	CD	O	O
1.3	PRISTIQ.xml:S1:13480:3	1.3	CD	O	O
1.3	PRISTIQ.xml:S1:13497:3	1.3	CD	O	O
0.9	PRISTIQ.xml:S1:13514:3	0.9	CD	O	O
4.1	PRISTIQ.xml:S1:13531:3	4.1	CD	O	O

Weight	PRISTIQ.xml:S1:13551:6	weight	NNP	O	O
(	PRISTIQ.xml:S1:13558:1	(	(	O	O
kg	PRISTIQ.xml:S1:13559:2	kg	NN	O	O
)	PRISTIQ.xml:S1:13561:1	)	)	O	O
0.0	PRISTIQ.xml:S1:13572:3	0.0	CD	O	O
-	PRISTIQ.xml:S1:13589:1	-	:	O	O
0.4	PRISTIQ.xml:S1:13590:3	0.4	CD	O	O
-	PRISTIQ.xml:S1:13606:1	-	:	O	O
0.6	PRISTIQ.xml:S1:13607:3	0.6	CD	O	O
-	PRISTIQ.xml:S1:13623:1	-	:	O	O
0.9	PRISTIQ.xml:S1:13624:3	0.9	CD	O	O
-	PRISTIQ.xml:S1:13640:1	-	:	O	O
1.1	PRISTIQ.xml:S1:13641:3	1.1	CD	O	O

Treatment	PRISTIQ.xml:S1:13670:9	treatment	NN	O	O
with	PRISTIQ.xml:S1:13680:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:13685:7	pristiq	NNP	O	O
at	PRISTIQ.xml:S1:13693:2	at	IN	O	O
all	PRISTIQ.xml:S1:13696:3	all	DT	O	O
doses	PRISTIQ.xml:S1:13700:5	dose	NNS	O	O
from	PRISTIQ.xml:S1:13706:4	from	IN	O	O
50	PRISTIQ.xml:S1:13711:2	50	CD	O	O
mg	PRISTIQ.xml:S1:13714:2	mg	NNS	O	O
per	PRISTIQ.xml:S1:13717:3	per	IN	O	O
day	PRISTIQ.xml:S1:13721:3	day	NN	O	O
to	PRISTIQ.xml:S1:13725:2	to	TO	O	O
400	PRISTIQ.xml:S1:13728:3	400	CD	O	O
mg	PRISTIQ.xml:S1:13732:2	mg	NNS	O	O
per	PRISTIQ.xml:S1:13735:3	per	IN	O	O
day	PRISTIQ.xml:S1:13739:3	day	NN	O	O
in	PRISTIQ.xml:S1:13743:2	in	IN	O	O
controlled	PRISTIQ.xml:S1:13746:10	control	JJ	O	O
studies	PRISTIQ.xml:S1:13757:7	studi	NNS	O	O
was	PRISTIQ.xml:S1:13765:3	wa	VBD	O	O
associated	PRISTIQ.xml:S1:13769:10	associ	VBN	O	O
with	PRISTIQ.xml:S1:13780:4	with	IN	O	O
sustained	PRISTIQ.xml:S1:13785:9	sustain	JJ	O	B-AdverseReaction
hypertension	PRISTIQ.xml:S1:13795:12	hypertens	NN	B-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S1:13807:1	,	,	O	O
defined	PRISTIQ.xml:S1:13809:7	defin	VBD	O	O
as	PRISTIQ.xml:S1:13817:2	as	IN	O	O
treatment	PRISTIQ.xml:S1:13820:9	treatment	NN	O	O
-	PRISTIQ.xml:S1:13829:1	-	:	O	O
emergent	PRISTIQ.xml:S1:13830:8	emerg	NN	O	O
supine	PRISTIQ.xml:S1:13839:6	supin	NN	B-AdverseReaction	B-AdverseReaction
diastolic	PRISTIQ.xml:S1:13846:9	diastol	JJ	I-AdverseReaction	I-AdverseReaction
blood	PRISTIQ.xml:S1:13856:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	PRISTIQ.xml:S1:13862:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
(	PRISTIQ.xml:S1:13871:1	(	(	O	O
SDBP	PRISTIQ.xml:S1:13872:4	sdbp	NNP	O	O
)	PRISTIQ.xml:S1:13876:1	)	)	O	O
90	PRISTIQ.xml:S1:13880:2	90	CD	I-AdverseReaction	O
mm	PRISTIQ.xml:S1:13883:2	mm	NN	I-AdverseReaction	O
Hg	PRISTIQ.xml:S1:13886:2	Hg	NNP	I-AdverseReaction	O
and	PRISTIQ.xml:S1:13889:3	and	CC	O	O
10	PRISTIQ.xml:S1:13895:2	10	CD	O	O
mm	PRISTIQ.xml:S1:13898:2	mm	NNS	O	O
Hg	PRISTIQ.xml:S1:13901:2	Hg	NNP	O	O
above	PRISTIQ.xml:S1:13904:5	abov	IN	O	O
baseline	PRISTIQ.xml:S1:13910:8	baselin	NN	O	O
for	PRISTIQ.xml:S1:13919:3	for	IN	O	O
3	PRISTIQ.xml:S1:13923:1	3	CD	O	O
consecutive	PRISTIQ.xml:S1:13925:11	consecut	JJ	O	O
on	PRISTIQ.xml:S1:13937:2	on	IN	O	O
-	PRISTIQ.xml:S1:13939:1	-	:	O	O
therapy	PRISTIQ.xml:S1:13940:7	therapi	NN	O	O
visits	PRISTIQ.xml:S1:13948:6	visit	NNS	O	O
(	PRISTIQ.xml:S1:13955:1	(	(	O	O
see	PRISTIQ.xml:S1:13956:3	see	VB	O	O
Table	PRISTIQ.xml:S1:13961:5	tabl	NNP	O	O
7	PRISTIQ.xml:S1:13967:1	7	CD	O	O
)	PRISTIQ.xml:S1:13970:1	)	)	O	O
.	PRISTIQ.xml:S1:13971:1	.	.	O	O

Analyses	PRISTIQ.xml:S1:13973:8	analys	NNS	O	O
of	PRISTIQ.xml:S1:13982:2	of	IN	O	O
patients	PRISTIQ.xml:S1:13985:8	patient	NNS	O	O
in	PRISTIQ.xml:S1:13994:2	in	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:13997:7	pristiq	NNP	O	O
pre	PRISTIQ.xml:S1:14005:3	pre	NN	O	O
-	PRISTIQ.xml:S1:14008:1	-	:	O	O
marketing	PRISTIQ.xml:S1:14009:9	market	NN	O	O
short	PRISTIQ.xml:S1:14019:5	short	JJ	O	O
-	PRISTIQ.xml:S1:14024:1	-	:	O	O
term	PRISTIQ.xml:S1:14025:4	term	NN	O	O
controlled	PRISTIQ.xml:S1:14030:10	control	VBN	O	O
studies	PRISTIQ.xml:S1:14041:7	studi	NNS	O	O
who	PRISTIQ.xml:S1:14049:3	who	WP	O	O
met	PRISTIQ.xml:S1:14053:3	met	VBD	O	O
criteria	PRISTIQ.xml:S1:14057:8	criteria	NNS	O	O
for	PRISTIQ.xml:S1:14066:3	for	IN	O	O
sustained	PRISTIQ.xml:S1:14070:9	sustain	JJ	O	O
hypertension	PRISTIQ.xml:S1:14080:12	hypertens	NN	B-AdverseReaction	O
revealed	PRISTIQ.xml:S1:14093:8	reveal	VBD	O	O
a	PRISTIQ.xml:S1:14102:1	a	DT	O	O
consistent	PRISTIQ.xml:S1:14104:10	consist	JJ	O	O
increase	PRISTIQ.xml:S1:14115:8	increas	NN	O	O
in	PRISTIQ.xml:S1:14124:2	in	IN	O	O
the	PRISTIQ.xml:S1:14127:3	the	DT	O	O
proportion	PRISTIQ.xml:S1:14131:10	proport	NN	O	O
of	PRISTIQ.xml:S1:14142:2	of	IN	O	O
patients	PRISTIQ.xml:S1:14145:8	patient	NNS	O	O
who	PRISTIQ.xml:S1:14154:3	who	WP	O	O
developed	PRISTIQ.xml:S1:14158:9	develop	VBD	O	O
sustained	PRISTIQ.xml:S1:14168:9	sustain	VBN	O	O
hypertension	PRISTIQ.xml:S1:14178:12	hypertens	NN	B-AdverseReaction	O
.	PRISTIQ.xml:S1:14190:1	.	.	O	O

This	PRISTIQ.xml:S1:14192:4	thi	DT	O	O
was	PRISTIQ.xml:S1:14197:3	wa	VBD	O	O
seen	PRISTIQ.xml:S1:14201:4	seen	VBN	O	O
at	PRISTIQ.xml:S1:14206:2	at	IN	O	O
all	PRISTIQ.xml:S1:14209:3	all	DT	O	O
doses	PRISTIQ.xml:S1:14213:5	dose	NNS	O	O
with	PRISTIQ.xml:S1:14219:4	with	IN	O	O
a	PRISTIQ.xml:S1:14224:1	a	DT	O	O
suggestion	PRISTIQ.xml:S1:14226:10	suggest	NN	O	O
of	PRISTIQ.xml:S1:14237:2	of	IN	O	O
a	PRISTIQ.xml:S1:14240:1	a	DT	O	O
higher	PRISTIQ.xml:S1:14242:6	higher	JJR	O	O
rate	PRISTIQ.xml:S1:14249:4	rate	NN	O	O
at	PRISTIQ.xml:S1:14254:2	at	IN	O	O
400	PRISTIQ.xml:S1:14257:3	400	CD	O	O
mg	PRISTIQ.xml:S1:14261:2	mg	NNS	O	O
per	PRISTIQ.xml:S1:14264:3	per	IN	O	O
day	PRISTIQ.xml:S1:14268:3	day	NN	O	O
.	PRISTIQ.xml:S1:14271:1	.	.	O	O

Table	PRISTIQ.xml:S1:14277:5	tabl	NN	O	O

7	PRISTIQ.xml:S1:14283:1	7	CD	O	O
:	PRISTIQ.xml:S1:14284:1	:	:	O	O
Proportion	PRISTIQ.xml:S1:14286:10	proport	NN	O	O
of	PRISTIQ.xml:S1:14297:2	of	IN	O	O
Patients	PRISTIQ.xml:S1:14300:8	patient	NNS	O	O
with	PRISTIQ.xml:S1:14309:4	with	IN	O	O
Sustained	PRISTIQ.xml:S1:14314:9	sustain	JJ	O	O
Elevation	PRISTIQ.xml:S1:14324:9	elev	NNP	B-AdverseReaction	O
of	PRISTIQ.xml:S1:14334:2	of	IN	I-AdverseReaction	O
Supine	PRISTIQ.xml:S1:14337:6	supin	NNP	I-AdverseReaction	O
Diastolic	PRISTIQ.xml:S1:14344:9	diastol	NNP	I-AdverseReaction	O
Blood	PRISTIQ.xml:S1:14354:5	blood	NNP	I-AdverseReaction	O
Pressure	PRISTIQ.xml:S1:14360:8	pressur	NN	I-AdverseReaction	O

Treatment	PRISTIQ.xml:S1:14373:9	treatment	NNP	O	O
Group	PRISTIQ.xml:S1:14383:5	group	NNP	O	O
Proportion	PRISTIQ.xml:S1:14412:10	proport	NNP	O	O
of	PRISTIQ.xml:S1:14423:2	of	IN	O	O
Patients	PRISTIQ.xml:S1:14426:8	patient	NNPS	O	O
with	PRISTIQ.xml:S1:14435:4	with	IN	O	O
Sustained	PRISTIQ.xml:S1:14440:9	sustain	JJ	O	O
Hypertension	PRISTIQ.xml:S1:14450:12	hypertens	NN	O	O

Placebo	PRISTIQ.xml:S1:14474:7	placebo	NN	O	O

0.5%	PRISTIQ.xml:S1:14513:4	0.5%	CD	O	O

PRISTIQ	PRISTIQ.xml:S1:14573:7	pristiq	NNP	O	O
50	PRISTIQ.xml:S1:14581:2	50	CD	O	O
mg	PRISTIQ.xml:S1:14584:2	mg	NN	O	O
per	PRISTIQ.xml:S1:14587:3	per	IN	O	O
day	PRISTIQ.xml:S1:14591:3	day	NN	O	O
1.3%	PRISTIQ.xml:S1:14612:4	1.3%	CD	O	O

PRISTIQ	PRISTIQ.xml:S1:14672:7	pristiq	NNP	O	O
100	PRISTIQ.xml:S1:14680:3	100	CD	O	O
mg	PRISTIQ.xml:S1:14684:2	mg	NN	O	O
per	PRISTIQ.xml:S1:14687:3	per	IN	O	O
day	PRISTIQ.xml:S1:14691:3	day	NN	O	O
0.7%	PRISTIQ.xml:S1:14711:4	0.7%	CD	O	O

PRISTIQ	PRISTIQ.xml:S1:14771:7	pristiq	NNP	O	O
200	PRISTIQ.xml:S1:14779:3	200	CD	O	O
mg	PRISTIQ.xml:S1:14783:2	mg	NN	O	O
per	PRISTIQ.xml:S1:14786:3	per	IN	O	O
day	PRISTIQ.xml:S1:14790:3	day	NN	O	O
1.1%	PRISTIQ.xml:S1:14810:4	1.1%	CD	O	O

PRISTIQ	PRISTIQ.xml:S1:14870:7	pristiq	NNP	O	O
400	PRISTIQ.xml:S1:14878:3	400	CD	O	O
mg	PRISTIQ.xml:S1:14882:2	mg	NN	O	O
per	PRISTIQ.xml:S1:14885:3	per	IN	O	O
day	PRISTIQ.xml:S1:14889:3	day	NN	O	O
2.3%	PRISTIQ.xml:S1:14909:4	2.3%	CD	O	O

Orthostatic	PRISTIQ.xml:S1:14981:11	orthostat	JJ	O	B-AdverseReaction
hypotension	PRISTIQ.xml:S1:14993:11	hypotens	NN	O	I-AdverseReaction

In	PRISTIQ.xml:S1:15013:2	In	IN	O	O

the	PRISTIQ.xml:S1:15016:3	the	DT	O	O
pre	PRISTIQ.xml:S1:15020:3	pre	NN	O	O
-	PRISTIQ.xml:S1:15023:1	-	:	O	O
marketing	PRISTIQ.xml:S1:15024:9	market	NN	O	O
short	PRISTIQ.xml:S1:15034:5	short	JJ	O	O
-	PRISTIQ.xml:S1:15039:1	-	:	O	O
term	PRISTIQ.xml:S1:15040:4	term	NN	O	O
,	PRISTIQ.xml:S1:15044:1	,	,	O	O
placebo	PRISTIQ.xml:S1:15046:7	placebo	SYM	O	O
-	PRISTIQ.xml:S1:15053:1	-	:	O	O
controlled	PRISTIQ.xml:S1:15054:10	control	VBN	O	O
clinical	PRISTIQ.xml:S1:15065:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S1:15074:7	studi	NNS	O	O
with	PRISTIQ.xml:S1:15082:4	with	IN	O	O
doses	PRISTIQ.xml:S1:15087:5	dose	NNS	O	O
of	PRISTIQ.xml:S1:15093:2	of	IN	O	O
50	PRISTIQ.xml:S1:15096:2	50	CD	O	O
to	PRISTIQ.xml:S1:15099:2	to	TO	O	O
400	PRISTIQ.xml:S1:15102:3	400	CD	O	O
mg	PRISTIQ.xml:S1:15106:2	mg	NNS	O	O
,	PRISTIQ.xml:S1:15108:1	,	,	O	O
systolic	PRISTIQ.xml:S1:15110:8	systol	JJ	B-AdverseReaction	B-AdverseReaction
orthostatic	PRISTIQ.xml:S1:15119:11	orthostat	JJ	I-AdverseReaction	I-AdverseReaction
hypotension	PRISTIQ.xml:S1:15131:11	hypotens	NN	I-AdverseReaction	I-AdverseReaction
(	PRISTIQ.xml:S1:15143:1	(	(	O	O
decrease	PRISTIQ.xml:S1:15144:8	decreas	VB	O	O
30	PRISTIQ.xml:S1:15155:2	30	CD	O	O
mm	PRISTIQ.xml:S1:15158:2	mm	NNS	O	O
Hg	PRISTIQ.xml:S1:15161:2	Hg	NNP	O	O
from	PRISTIQ.xml:S1:15164:4	from	IN	O	O
supine	PRISTIQ.xml:S1:15169:6	supin	NN	O	O
to	PRISTIQ.xml:S1:15176:2	to	TO	O	O
standing	PRISTIQ.xml:S1:15179:8	stand	VBG	O	O
position	PRISTIQ.xml:S1:15188:8	posit	NN	O	O
)	PRISTIQ.xml:S1:15196:1	)	)	O	O
occurred	PRISTIQ.xml:S1:15198:8	occur	VBD	O	O
more	PRISTIQ.xml:S1:15207:4	more	RBR	O	O
frequently	PRISTIQ.xml:S1:15212:10	frequent	RB	O	O
in	PRISTIQ.xml:S1:15223:2	in	IN	O	O
patients	PRISTIQ.xml:S1:15226:8	patient	NNS	O	O
65	PRISTIQ.xml:S1:15237:2	65	CD	O	O
years	PRISTIQ.xml:S1:15240:5	year	NNS	O	O
of	PRISTIQ.xml:S1:15246:2	of	IN	O	O
age	PRISTIQ.xml:S1:15249:3	age	NN	O	O
receiving	PRISTIQ.xml:S1:15253:9	receiv	VBG	O	O
PRISTIQ	PRISTIQ.xml:S1:15263:7	pristiq	NNP	O	O
(	PRISTIQ.xml:S1:15271:1	(	(	O	O
8%	PRISTIQ.xml:S1:15272:2	8%	CD	O	O
,	PRISTIQ.xml:S1:15274:1	,	,	O	O
7	PRISTIQ.xml:S1:15276:1	7	CD	O	O
87	PRISTIQ.xml:S1:15278:2	87	CD	O	O
)	PRISTIQ.xml:S1:15280:1	)	)	O	O
versus	PRISTIQ.xml:S1:15282:6	versu	NN	O	O
placebo	PRISTIQ.xml:S1:15289:7	placebo	NN	O	O
(	PRISTIQ.xml:S1:15297:1	(	(	O	O
2.5%	PRISTIQ.xml:S1:15298:4	2.5%	CD	O	O
,	PRISTIQ.xml:S1:15302:1	,	,	O	O
1	PRISTIQ.xml:S1:15304:1	1	CD	O	O
40	PRISTIQ.xml:S1:15306:2	40	CD	O	O
)	PRISTIQ.xml:S1:15308:1	)	)	O	O
,	PRISTIQ.xml:S1:15309:1	,	,	O	O
compared	PRISTIQ.xml:S1:15311:8	compar	VBN	O	O
to	PRISTIQ.xml:S1:15320:2	to	TO	O	O
patients	PRISTIQ.xml:S1:15323:8	patient	NNS	O	O
65	PRISTIQ.xml:S1:15333:2	65	CD	O	O
years	PRISTIQ.xml:S1:15336:5	year	NNS	O	O
of	PRISTIQ.xml:S1:15342:2	of	IN	O	O
age	PRISTIQ.xml:S1:15345:3	age	NN	O	O
receiving	PRISTIQ.xml:S1:15349:9	receiv	VBG	O	O
PRISTIQ	PRISTIQ.xml:S1:15359:7	pristiq	NNP	O	O
(	PRISTIQ.xml:S1:15367:1	(	(	O	O
0.9%	PRISTIQ.xml:S1:15368:4	0.9%	CD	O	O
,	PRISTIQ.xml:S1:15372:1	,	,	O	O
18	PRISTIQ.xml:S1:15374:2	18	CD	O	O
1	PRISTIQ.xml:S1:15377:1	1	CD	O	O
,	PRISTIQ.xml:S1:15378:1	,	,	O	O
937	PRISTIQ.xml:S1:15379:3	937	CD	O	O
)	PRISTIQ.xml:S1:15382:1	)	)	O	O
versus	PRISTIQ.xml:S1:15384:6	versu	NN	O	O
placebo	PRISTIQ.xml:S1:15391:7	placebo	NN	O	O
(	PRISTIQ.xml:S1:15399:1	(	(	O	O
0.7%	PRISTIQ.xml:S1:15400:4	0.7%	CD	O	O
,	PRISTIQ.xml:S1:15404:1	,	,	O	O
8	PRISTIQ.xml:S1:15406:1	8	CD	O	O
1	PRISTIQ.xml:S1:15408:1	1	CD	O	O
,	PRISTIQ.xml:S1:15409:1	,	,	O	O
218	PRISTIQ.xml:S1:15410:3	218	CD	O	O
)	PRISTIQ.xml:S1:15413:1	)	)	O	O
.	PRISTIQ.xml:S1:15414:1	.	.	O	O

6.2	PRISTIQ.xml:S1:15422:3	6.2	CD	O	O
Postmarketing	PRISTIQ.xml:S1:15426:13	postmarket	VBG	O	O
Experience	PRISTIQ.xml:S1:15440:10	experi	NN	O	O

The	PRISTIQ.xml:S1:15454:3	the	DT	O	O
following	PRISTIQ.xml:S1:15458:9	follow	JJ	O	O
adverse	PRISTIQ.xml:S1:15468:7	advers	JJ	O	O
reaction	PRISTIQ.xml:S1:15476:8	reaction	NN	O	O
has	PRISTIQ.xml:S1:15485:3	ha	VBZ	O	O
been	PRISTIQ.xml:S1:15489:4	been	VBN	O	O
identified	PRISTIQ.xml:S1:15494:10	identifi	VBN	O	O
during	PRISTIQ.xml:S1:15505:6	dure	IN	O	O
post	PRISTIQ.xml:S1:15512:4	post	NN	O	O
-	PRISTIQ.xml:S1:15516:1	-	:	O	O
approval	PRISTIQ.xml:S1:15517:8	approv	NN	O	O
use	PRISTIQ.xml:S1:15526:3	use	NN	O	O
of	PRISTIQ.xml:S1:15530:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S1:15533:7	pristiq	NNP	O	O
.	PRISTIQ.xml:S1:15540:1	.	.	O	O

Because	PRISTIQ.xml:S1:15542:7	becaus	IN	O	O
these	PRISTIQ.xml:S1:15550:5	these	DT	O	O
reactions	PRISTIQ.xml:S1:15556:9	reaction	NNS	O	O
are	PRISTIQ.xml:S1:15566:3	are	VBP	O	O
reported	PRISTIQ.xml:S1:15570:8	report	VBN	O	O
voluntarily	PRISTIQ.xml:S1:15579:11	voluntarili	RB	O	O
from	PRISTIQ.xml:S1:15591:4	from	IN	O	O
a	PRISTIQ.xml:S1:15596:1	a	DT	O	O
population	PRISTIQ.xml:S1:15598:10	popul	NN	O	O
of	PRISTIQ.xml:S1:15609:2	of	IN	O	O
uncertain	PRISTIQ.xml:S1:15612:9	uncertain	JJ	O	O
size	PRISTIQ.xml:S1:15622:4	size	NN	O	O
,	PRISTIQ.xml:S1:15626:1	,	,	O	O
it	PRISTIQ.xml:S1:15628:2	it	PRP	O	O
is	PRISTIQ.xml:S1:15631:2	is	VBZ	O	O
not	PRISTIQ.xml:S1:15634:3	not	RB	O	O
always	PRISTIQ.xml:S1:15638:6	alway	RB	O	O
possible	PRISTIQ.xml:S1:15645:8	possibl	JJ	O	O
to	PRISTIQ.xml:S1:15654:2	to	TO	O	O
reliably	PRISTIQ.xml:S1:15657:8	reliabl	VB	O	O
estimate	PRISTIQ.xml:S1:15666:8	estim	VB	O	O
their	PRISTIQ.xml:S1:15675:5	their	PRP$	O	O
frequency	PRISTIQ.xml:S1:15681:9	frequenc	NN	O	O
or	PRISTIQ.xml:S1:15691:2	or	CC	O	O
establish	PRISTIQ.xml:S1:15694:9	establish	VB	O	O
a	PRISTIQ.xml:S1:15704:1	a	DT	O	O
causal	PRISTIQ.xml:S1:15706:6	causal	NN	O	O
relationship	PRISTIQ.xml:S1:15713:12	relationship	NN	O	O
to	PRISTIQ.xml:S1:15726:2	to	TO	O	O
drug	PRISTIQ.xml:S1:15729:4	drug	NN	O	O
exposure	PRISTIQ.xml:S1:15734:8	exposur	NN	O	O
:	PRISTIQ.xml:S1:15742:1	:	:	O	O

Skin	PRISTIQ.xml:S1:15752:4	skin	NNP	O	O
and	PRISTIQ.xml:S1:15757:3	and	CC	O	O
subcutaneous	PRISTIQ.xml:S1:15761:12	subcutan	JJ	O	O
tissue	PRISTIQ.xml:S1:15774:6	tissu	NN	O	O
disorders	PRISTIQ.xml:S1:15781:9	disord	NNS	O	O
-	PRISTIQ.xml:S1:15794:1	-	:	O	O
Stevens	PRISTIQ.xml:S1:15796:7	steven	NNP	B-AdverseReaction	B-AdverseReaction
-	PRISTIQ.xml:S1:15803:1	-	:	I-AdverseReaction	I-AdverseReaction
Johnson	PRISTIQ.xml:S1:15804:7	johnson	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	PRISTIQ.xml:S1:15812:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
.	PRISTIQ.xml:S1:15820:1	.	.	O	O
\n\n	PRISTIQ.xml:S2:0:2	\n\n	VB	O	O
BOXED	PRISTIQ.xml:S2:6:5	box	NNP	O	O
WARNING	PRISTIQ.xml:S2:12:7	warn	NNP	O	O
:	PRISTIQ.xml:S2:19:1	:	:	O	O
WARNING	PRISTIQ.xml:S2:21:7	warn	NN	O	O
:	PRISTIQ.xml:S2:28:1	:	:	O	O
SUICIDAL	PRISTIQ.xml:S2:30:8	suicid	NNP	B-AdverseReaction	B-AdverseReaction
THOUGHTS	PRISTIQ.xml:S2:39:8	thought	NNP	I-AdverseReaction	I-AdverseReaction
AND	PRISTIQ.xml:S2:48:3	and	NNP	O	I-AdverseReaction
BEHAVIORS	PRISTIQ.xml:S2:52:9	behavior	NNP	I-AdverseReaction	I-AdverseReaction
\n\n	PRISTIQ.xml:S2:61:2	\n\n	VBD	O	O
WARNING	PRISTIQ.xml:S2:67:7	warn	NN	O	O
:	PRISTIQ.xml:S2:74:1	:	:	O	O
SUICIDAL	PRISTIQ.xml:S2:76:8	suicid	NNP	B-AdverseReaction	O
THOUGHTS	PRISTIQ.xml:S2:85:8	thought	NNP	I-AdverseReaction	O
AND	PRISTIQ.xml:S2:94:3	and	NNP	O	O
BEHAVIORS	PRISTIQ.xml:S2:98:9	behavior	NNP	I-AdverseReaction	O
\n\n	PRISTIQ.xml:S2:109:2	\n\n	NNP	O	O
Antidepressants	PRISTIQ.xml:S2:115:15	antidepress	NNP	O	O
increased	PRISTIQ.xml:S2:131:9	increas	VBD	O	O
the	PRISTIQ.xml:S2:141:3	the	DT	O	O
risk	PRISTIQ.xml:S2:145:4	risk	NN	O	O
of	PRISTIQ.xml:S2:150:2	of	IN	O	O
suicidal	PRISTIQ.xml:S2:153:8	suicid	JJ	B-AdverseReaction	O
thoughts	PRISTIQ.xml:S2:162:8	thought	NNS	I-AdverseReaction	O
and	PRISTIQ.xml:S2:171:3	and	CC	O	O
behavior	PRISTIQ.xml:S2:175:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
in	PRISTIQ.xml:S2:184:2	in	IN	O	O
children	PRISTIQ.xml:S2:187:8	children	NNS	O	O
,	PRISTIQ.xml:S2:195:1	,	,	O	O
adolescents	PRISTIQ.xml:S2:197:11	adolesc	NNS	O	O
,	PRISTIQ.xml:S2:208:1	,	,	O	O
and	PRISTIQ.xml:S2:210:3	and	CC	O	O
young	PRISTIQ.xml:S2:214:5	young	JJ	O	O
adults	PRISTIQ.xml:S2:220:6	adult	NNS	O	O
in	PRISTIQ.xml:S2:227:2	in	IN	O	O
short	PRISTIQ.xml:S2:230:5	short	JJ	O	O
-	PRISTIQ.xml:S2:235:1	-	:	O	O
term	PRISTIQ.xml:S2:236:4	term	NN	O	O
studies	PRISTIQ.xml:S2:241:7	studi	NNS	O	O
.	PRISTIQ.xml:S2:248:1	.	.	O	O

These	PRISTIQ.xml:S2:250:5	these	DT	O	O
studies	PRISTIQ.xml:S2:256:7	studi	NNS	O	O
did	PRISTIQ.xml:S2:264:3	did	VBD	O	O
not	PRISTIQ.xml:S2:268:3	not	RB	O	O
show	PRISTIQ.xml:S2:272:4	show	VB	O	O
an	PRISTIQ.xml:S2:277:2	an	DT	O	O
increase	PRISTIQ.xml:S2:280:8	increas	NN	O	O
in	PRISTIQ.xml:S2:289:2	in	IN	O	O
the	PRISTIQ.xml:S2:292:3	the	DT	O	O
risk	PRISTIQ.xml:S2:296:4	risk	NN	O	O
of	PRISTIQ.xml:S2:301:2	of	IN	O	O
suicidal	PRISTIQ.xml:S2:304:8	suicid	JJ	B-AdverseReaction	O
thoughts	PRISTIQ.xml:S2:313:8	thought	NNS	I-AdverseReaction	O
and	PRISTIQ.xml:S2:322:3	and	CC	O	O
behavior	PRISTIQ.xml:S2:326:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
with	PRISTIQ.xml:S2:335:4	with	IN	O	O
antidepressant	PRISTIQ.xml:S2:340:14	antidepress	JJ	O	O
use	PRISTIQ.xml:S2:355:3	use	NN	O	O
in	PRISTIQ.xml:S2:359:2	in	IN	O	O
patients	PRISTIQ.xml:S2:362:8	patient	NNS	O	O
over	PRISTIQ.xml:S2:371:4	over	IN	O	O
age	PRISTIQ.xml:S2:376:3	age	NN	O	O
24	PRISTIQ.xml:S2:380:2	24	CD	O	O
;	PRISTIQ.xml:S2:382:1	;	:	O	O
there	PRISTIQ.xml:S2:384:5	there	EX	O	O
was	PRISTIQ.xml:S2:390:3	wa	VBD	O	O
a	PRISTIQ.xml:S2:394:1	a	DT	O	O
reduction	PRISTIQ.xml:S2:396:9	reduct	NN	O	O
in	PRISTIQ.xml:S2:406:2	in	IN	O	O
risk	PRISTIQ.xml:S2:409:4	risk	NN	O	O
with	PRISTIQ.xml:S2:414:4	with	IN	O	O
antidepressant	PRISTIQ.xml:S2:419:14	antidepress	JJ	O	O
use	PRISTIQ.xml:S2:434:3	use	NN	O	O
in	PRISTIQ.xml:S2:438:2	in	IN	O	O
patients	PRISTIQ.xml:S2:441:8	patient	NNS	O	O
aged	PRISTIQ.xml:S2:450:4	age	VBN	O	O
65	PRISTIQ.xml:S2:455:2	65	CD	O	O
and	PRISTIQ.xml:S2:458:3	and	CC	O	O
older	PRISTIQ.xml:S2:462:5	older	JJR	O	O
[	PRISTIQ.xml:S2:468:1	[	NNP	O	O
see	PRISTIQ.xml:S2:471:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S2:477:8	warn	NNP	O	O
and	PRISTIQ.xml:S2:486:3	and	CC	O	O
Precautions	PRISTIQ.xml:S2:490:11	precaut	NNP	O	O
(	PRISTIQ.xml:S2:502:1	(	(	O	O
5.1	PRISTIQ.xml:S2:503:3	5.1	CD	O	O
)	PRISTIQ.xml:S2:506:1	)	)	O	O
]	PRISTIQ.xml:S2:511:1	]	NN	O	O
.	PRISTIQ.xml:S2:512:1	.	.	O	O

In	PRISTIQ.xml:S2:523:2	In	IN	O	O
patients	PRISTIQ.xml:S2:526:8	patient	NNS	O	O
of	PRISTIQ.xml:S2:535:2	of	IN	O	O
all	PRISTIQ.xml:S2:538:3	all	DT	O	O
ages	PRISTIQ.xml:S2:542:4	age	NNS	O	O
who	PRISTIQ.xml:S2:547:3	who	WP	O	O
are	PRISTIQ.xml:S2:551:3	are	VBP	O	O
started	PRISTIQ.xml:S2:555:7	start	VBN	O	O
on	PRISTIQ.xml:S2:563:2	on	IN	O	O
antidepressant	PRISTIQ.xml:S2:566:14	antidepress	JJ	O	O
therapy	PRISTIQ.xml:S2:581:7	therapi	NN	O	O
,	PRISTIQ.xml:S2:588:1	,	,	O	O
monitor	PRISTIQ.xml:S2:590:7	monitor	NN	O	O
closely	PRISTIQ.xml:S2:598:7	close	RB	O	O
for	PRISTIQ.xml:S2:606:3	for	IN	O	O
worsening	PRISTIQ.xml:S2:610:9	worsen	VBG	O	O
,	PRISTIQ.xml:S2:619:1	,	,	O	O
and	PRISTIQ.xml:S2:621:3	and	CC	O	O
for	PRISTIQ.xml:S2:625:3	for	IN	O	O
emergence	PRISTIQ.xml:S2:629:9	emerg	NN	O	O
of	PRISTIQ.xml:S2:639:2	of	IN	O	O
suicidal	PRISTIQ.xml:S2:642:8	suicid	JJ	O	O
thoughts	PRISTIQ.xml:S2:651:8	thought	NNS	O	O
and	PRISTIQ.xml:S2:660:3	and	CC	O	O
behaviors	PRISTIQ.xml:S2:664:9	behavior	NNS	O	I-AdverseReaction
.	PRISTIQ.xml:S2:673:1	.	.	O	O

Advise	PRISTIQ.xml:S2:675:6	advis	NNP	O	O
families	PRISTIQ.xml:S2:682:8	famili	NNS	O	O
and	PRISTIQ.xml:S2:691:3	and	CC	O	O
caregivers	PRISTIQ.xml:S2:695:10	caregiv	NNS	O	O
of	PRISTIQ.xml:S2:706:2	of	IN	O	O
the	PRISTIQ.xml:S2:709:3	the	DT	O	O
need	PRISTIQ.xml:S2:713:4	need	NN	O	O
for	PRISTIQ.xml:S2:718:3	for	IN	O	O
close	PRISTIQ.xml:S2:722:5	close	JJ	O	O
observation	PRISTIQ.xml:S2:728:11	observ	NN	O	O
and	PRISTIQ.xml:S2:740:3	and	CC	O	O
communication	PRISTIQ.xml:S2:744:13	commun	NN	O	O
with	PRISTIQ.xml:S2:758:4	with	IN	O	O
the	PRISTIQ.xml:S2:763:3	the	DT	O	O
prescriber	PRISTIQ.xml:S2:767:10	prescrib	NN	O	O
[	PRISTIQ.xml:S2:778:1	[	NNP	O	O
see	PRISTIQ.xml:S2:781:3	see	VBP	O	O
Warnings	PRISTIQ.xml:S2:787:8	warn	NNP	O	O
and	PRISTIQ.xml:S2:796:3	and	CC	O	O
Precautions	PRISTIQ.xml:S2:800:11	precaut	NNP	O	O
(	PRISTIQ.xml:S2:812:1	(	(	O	O
5.1	PRISTIQ.xml:S2:813:3	5.1	CD	O	O
)	PRISTIQ.xml:S2:816:1	)	)	O	O
]	PRISTIQ.xml:S2:821:1	]	NN	O	O
.	PRISTIQ.xml:S2:822:1	.	.	O	O

PRISTIQ	PRISTIQ.xml:S2:833:7	pristiq	NNP	O	O
is	PRISTIQ.xml:S2:841:2	is	VBZ	O	O
not	PRISTIQ.xml:S2:844:3	not	RB	O	O
approved	PRISTIQ.xml:S2:848:8	approv	VBN	O	O
for	PRISTIQ.xml:S2:857:3	for	IN	O	O
use	PRISTIQ.xml:S2:861:3	use	NN	O	O
in	PRISTIQ.xml:S2:865:2	in	IN	O	O
pediatric	PRISTIQ.xml:S2:868:9	pediatr	JJ	O	O
patients	PRISTIQ.xml:S2:878:8	patient	NNS	O	O
[	PRISTIQ.xml:S2:887:1	[	VBP	O	O
see	PRISTIQ.xml:S2:890:3	see	VBP	O	O
Use	PRISTIQ.xml:S2:896:3	use	NNP	O	O
in	PRISTIQ.xml:S2:900:2	in	IN	O	O
Specific	PRISTIQ.xml:S2:903:8	specif	NNP	O	O
Populations	PRISTIQ.xml:S2:912:11	popul	NNP	O	O
(	PRISTIQ.xml:S2:924:1	(	(	O	O
8.4	PRISTIQ.xml:S2:925:3	8.4	CD	O	O
)	PRISTIQ.xml:S2:928:1	)	)	O	O
]	PRISTIQ.xml:S2:933:1	]	NN	O	O
.	PRISTIQ.xml:S2:934:1	.	.	O	O

EXCERPT	PRISTIQ.xml:S2:944:7	excerpt	NN	O	O
:	PRISTIQ.xml:S2:951:1	:	:	O	O
WARNING	PRISTIQ.xml:S2:955:7	warn	NN	O	O
:	PRISTIQ.xml:S2:962:1	:	:	O	O
SUICIDAL	PRISTIQ.xml:S2:964:8	suicid	NNP	B-AdverseReaction	B-AdverseReaction
THOUGHTS	PRISTIQ.xml:S2:973:8	thought	NNP	I-AdverseReaction	I-AdverseReaction
AND	PRISTIQ.xml:S2:982:3	and	NNP	O	I-AdverseReaction
BEHAVIORS	PRISTIQ.xml:S2:986:9	behavior	NNP	I-AdverseReaction	I-AdverseReaction
\n\n\n\n	PRISTIQ.xml:S2:995:4	\n\n\n\n	NNP	O	O
See	PRISTIQ.xml:S2:1004:3	see	NNP	O	O
full	PRISTIQ.xml:S2:1008:4	full	JJ	O	O
prescribing	PRISTIQ.xml:S2:1013:11	prescrib	VBG	O	O
information	PRISTIQ.xml:S2:1025:11	inform	NN	O	O
for	PRISTIQ.xml:S2:1037:3	for	IN	O	O
complete	PRISTIQ.xml:S2:1041:8	complet	JJ	O	O
boxed	PRISTIQ.xml:S2:1050:5	box	JJ	O	O
warning	PRISTIQ.xml:S2:1056:7	warn	NN	O	O
.	PRISTIQ.xml:S2:1063:1	.	.	O	O

Increased	PRISTIQ.xml:S2:1076:9	increas	VBN	O	O
risk	PRISTIQ.xml:S2:1086:4	risk	NN	O	O
of	PRISTIQ.xml:S2:1091:2	of	IN	O	O
suicidal	PRISTIQ.xml:S2:1094:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thinking	PRISTIQ.xml:S2:1103:8	think	NN	I-AdverseReaction	I-AdverseReaction
and	PRISTIQ.xml:S2:1112:3	and	CC	O	O
behavior	PRISTIQ.xml:S2:1116:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
in	PRISTIQ.xml:S2:1125:2	in	IN	O	O
children	PRISTIQ.xml:S2:1128:8	children	NNS	O	O
,	PRISTIQ.xml:S2:1136:1	,	,	O	O
adolescents	PRISTIQ.xml:S2:1138:11	adolesc	NNS	O	O
and	PRISTIQ.xml:S2:1150:3	and	CC	O	O
young	PRISTIQ.xml:S2:1154:5	young	JJ	O	O
adults	PRISTIQ.xml:S2:1160:6	adult	NNS	O	O
taking	PRISTIQ.xml:S2:1167:6	take	VBG	O	O
antidepressants	PRISTIQ.xml:S2:1174:15	antidepress	NNS	O	O
(	PRISTIQ.xml:S2:1190:1	(	(	O	O
5.1	PRISTIQ.xml:S2:1191:3	5.1	CD	O	O
)	PRISTIQ.xml:S2:1194:1	)	)	O	O
.	PRISTIQ.xml:S2:1195:1	.	.	O	O

Monitor	PRISTIQ.xml:S2:1202:7	monitor	NNP	O	O
for	PRISTIQ.xml:S2:1210:3	for	IN	O	O
worsening	PRISTIQ.xml:S2:1214:9	worsen	VBG	O	O
and	PRISTIQ.xml:S2:1224:3	and	CC	O	O
emergence	PRISTIQ.xml:S2:1228:9	emerg	NN	O	O
of	PRISTIQ.xml:S2:1238:2	of	IN	O	O
suicidal	PRISTIQ.xml:S2:1241:8	suicid	JJ	O	O
thoughts	PRISTIQ.xml:S2:1250:8	thought	NNS	O	O
and	PRISTIQ.xml:S2:1259:3	and	CC	O	O
behaviors	PRISTIQ.xml:S2:1263:9	behavior	NNS	O	O
(	PRISTIQ.xml:S2:1273:1	(	(	O	O
5.1	PRISTIQ.xml:S2:1274:3	5.1	CD	O	O
)	PRISTIQ.xml:S2:1277:1	)	)	O	O
.	PRISTIQ.xml:S2:1278:1	.	.	O	O

PRISTIQ	PRISTIQ.xml:S2:1285:7	pristiq	NNP	O	O
is	PRISTIQ.xml:S2:1293:2	is	VBZ	O	O
not	PRISTIQ.xml:S2:1296:3	not	RB	O	O
approved	PRISTIQ.xml:S2:1300:8	approv	VBN	O	O
for	PRISTIQ.xml:S2:1309:3	for	IN	O	O
use	PRISTIQ.xml:S2:1313:3	use	NN	O	O
in	PRISTIQ.xml:S2:1317:2	in	IN	O	O
pediatric	PRISTIQ.xml:S2:1320:9	pediatr	JJ	O	O
patients	PRISTIQ.xml:S2:1330:8	patient	NNS	O	O
(	PRISTIQ.xml:S2:1339:1	(	(	O	O
8.4	PRISTIQ.xml:S2:1340:3	8.4	CD	O	O
)	PRISTIQ.xml:S2:1343:1	)	)	O	O
.	PRISTIQ.xml:S2:1344:1	.	.	O	O
\n	PRISTIQ.xml:S2:1346:1	\n	$	O	O
5	PRISTIQ.xml:S3:4:1	5	CD	O	O
WARNINGS	PRISTIQ.xml:S3:6:8	warn	NNP	O	O
AND	PRISTIQ.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	PRISTIQ.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	PRISTIQ.xml:S3:37:7	excerpt	NN	O	O
:	PRISTIQ.xml:S3:44:1	:	:	O	O
Clinical	PRISTIQ.xml:S3:55:8	clinic	JJ	B-AdverseReaction	O
Worsening	PRISTIQ.xml:S3:64:9	worsen	NNP	I-AdverseReaction	O
Suicide	PRISTIQ.xml:S3:74:7	suicid	NNP	B-AdverseReaction	B-AdverseReaction
Risk	PRISTIQ.xml:S3:82:4	risk	NNP	I-AdverseReaction	I-AdverseReaction
:	PRISTIQ.xml:S3:86:1	:	:	O	O
Monitor	PRISTIQ.xml:S3:88:7	monitor	NN	O	O
for	PRISTIQ.xml:S3:96:3	for	IN	O	O
clinical	PRISTIQ.xml:S3:100:8	clinic	JJ	O	O
worsening	PRISTIQ.xml:S3:109:9	worsen	NN	O	O
and	PRISTIQ.xml:S3:119:3	and	CC	O	O
suicide	PRISTIQ.xml:S3:123:7	suicid	NN	O	B-AdverseReaction
risk	PRISTIQ.xml:S3:131:4	risk	NN	O	O
(	PRISTIQ.xml:S3:136:1	(	(	O	O
5.1	PRISTIQ.xml:S3:139:3	5.1	CD	O	O
)	PRISTIQ.xml:S3:144:1	)	)	O	O
.	PRISTIQ.xml:S3:145:1	.	.	O	O

Serotonin	PRISTIQ.xml:S3:155:9	serotonin	JJ	B-AdverseReaction	B-AdverseReaction
Syndrome	PRISTIQ.xml:S3:165:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
:	PRISTIQ.xml:S3:173:1	:	:	O	O
Serotonin	PRISTIQ.xml:S3:175:9	serotonin	NNP	B-AdverseReaction	B-AdverseReaction
syndrome	PRISTIQ.xml:S3:185:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
has	PRISTIQ.xml:S3:194:3	ha	VBZ	O	O
been	PRISTIQ.xml:S3:198:4	been	VBN	O	O
reported	PRISTIQ.xml:S3:203:8	report	VBN	O	O
with	PRISTIQ.xml:S3:212:4	with	IN	O	O
SSRIs	PRISTIQ.xml:S3:217:5	ssri	NNP	O	O
and	PRISTIQ.xml:S3:223:3	and	CC	O	O
SNRIs	PRISTIQ.xml:S3:227:5	snri	NNP	O	O
,	PRISTIQ.xml:S3:232:1	,	,	O	O
including	PRISTIQ.xml:S3:234:9	includ	VBG	O	O
with	PRISTIQ.xml:S3:244:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:249:7	pristiq	NNP	O	O
,	PRISTIQ.xml:S3:256:1	,	,	O	O
both	PRISTIQ.xml:S3:258:4	both	DT	O	O
when	PRISTIQ.xml:S3:263:4	when	WRB	O	O
taken	PRISTIQ.xml:S3:268:5	taken	VBN	O	O
alone	PRISTIQ.xml:S3:274:5	alon	RB	O	O
,	PRISTIQ.xml:S3:279:1	,	,	O	O
but	PRISTIQ.xml:S3:281:3	but	CC	O	O
especially	PRISTIQ.xml:S3:285:10	especi	RB	O	O
when	PRISTIQ.xml:S3:296:4	when	WRB	O	O
co	PRISTIQ.xml:S3:301:2	co	JJ	O	O
-	PRISTIQ.xml:S3:303:1	-	:	O	O
administered	PRISTIQ.xml:S3:304:12	administ	VBN	O	O
with	PRISTIQ.xml:S3:317:4	with	IN	O	O
other	PRISTIQ.xml:S3:322:5	other	JJ	O	O
serotonergic	PRISTIQ.xml:S3:328:12	serotonerg	JJ	O	O
agents	PRISTIQ.xml:S3:341:6	agent	NNS	O	O
(	PRISTIQ.xml:S3:348:1	(	(	O	O
including	PRISTIQ.xml:S3:349:9	includ	VBG	O	O
triptans	PRISTIQ.xml:S3:359:8	triptan	NNS	O	O
,	PRISTIQ.xml:S3:367:1	,	,	O	O
tricyclic	PRISTIQ.xml:S3:369:9	tricycl	JJ	O	O
antidepressants	PRISTIQ.xml:S3:379:15	antidepress	NNS	O	O
,	PRISTIQ.xml:S3:394:1	,	,	O	O
fentanyl	PRISTIQ.xml:S3:396:8	fentanyl	NN	O	O
,	PRISTIQ.xml:S3:404:1	,	,	O	O
lithium	PRISTIQ.xml:S3:406:7	lithium	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:413:1	,	,	O	O
tramadol	PRISTIQ.xml:S3:415:8	tramadol	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:423:1	,	,	O	O
tryptophan	PRISTIQ.xml:S3:425:10	tryptophan	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:435:1	,	,	O	O
buspirone	PRISTIQ.xml:S3:437:9	buspiron	NN	O	O
,	PRISTIQ.xml:S3:446:1	,	,	O	O
and	PRISTIQ.xml:S3:448:3	and	CC	O	O
St	PRISTIQ.xml:S3:452:2	St	NNP	O	O
.	PRISTIQ.xml:S3:454:1	.	.	O	O

John	PRISTIQ.xml:S3:456:4	john	NNP	O	O
's	PRISTIQ.xml:S3:460:2	's	POS	O	O
Wort	PRISTIQ.xml:S3:463:4	wort	NNP	O	O
)	PRISTIQ.xml:S3:467:1	)	)	O	O
.	PRISTIQ.xml:S3:468:1	.	.	O	O

If	PRISTIQ.xml:S3:470:2	If	IN	O	O
such	PRISTIQ.xml:S3:473:4	such	JJ	O	O
symptoms	PRISTIQ.xml:S3:478:8	symptom	NNS	O	O
occur	PRISTIQ.xml:S3:487:5	occur	VBP	O	O
,	PRISTIQ.xml:S3:492:1	,	,	O	O
discontinue	PRISTIQ.xml:S3:494:11	discontinu	VBP	O	O
PRISTIQ	PRISTIQ.xml:S3:506:7	pristiq	NNP	O	O
and	PRISTIQ.xml:S3:514:3	and	CC	O	O
initiate	PRISTIQ.xml:S3:518:8	initi	VB	O	O
supportive	PRISTIQ.xml:S3:527:10	support	JJ	O	O
treatment	PRISTIQ.xml:S3:538:9	treatment	NN	O	O
.	PRISTIQ.xml:S3:547:1	.	.	O	O

If	PRISTIQ.xml:S3:549:2	If	IN	O	O
concomitant	PRISTIQ.xml:S3:552:11	concomit	JJ	O	O
use	PRISTIQ.xml:S3:564:3	use	NN	O	O
of	PRISTIQ.xml:S3:568:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:571:7	pristiq	NNP	O	O
with	PRISTIQ.xml:S3:579:4	with	IN	O	O
other	PRISTIQ.xml:S3:584:5	other	JJ	O	O
serotonergic	PRISTIQ.xml:S3:590:12	serotonerg	JJ	O	O
drugs	PRISTIQ.xml:S3:603:5	drug	NNS	O	O
is	PRISTIQ.xml:S3:609:2	is	VBZ	O	O
clinically	PRISTIQ.xml:S3:612:10	clinic	RB	O	O
warranted	PRISTIQ.xml:S3:623:9	warrant	VBN	O	O
,	PRISTIQ.xml:S3:632:1	,	,	O	O
patients	PRISTIQ.xml:S3:634:8	patient	NNS	O	O
should	PRISTIQ.xml:S3:643:6	should	MD	O	O
be	PRISTIQ.xml:S3:650:2	be	VB	O	O
made	PRISTIQ.xml:S3:653:4	made	VBN	O	O
aware	PRISTIQ.xml:S3:658:5	awar	JJ	O	O
of	PRISTIQ.xml:S3:664:2	of	IN	O	O
a	PRISTIQ.xml:S3:667:1	a	DT	O	O
potential	PRISTIQ.xml:S3:669:9	potenti	NN	O	O
increased	PRISTIQ.xml:S3:679:9	increas	VBN	O	O
risk	PRISTIQ.xml:S3:689:4	risk	NN	O	O
for	PRISTIQ.xml:S3:694:3	for	IN	O	O
serotonin	PRISTIQ.xml:S3:698:9	serotonin	JJ	O	B-AdverseReaction
syndrome	PRISTIQ.xml:S3:708:8	syndrom	NN	O	I-AdverseReaction
,	PRISTIQ.xml:S3:716:1	,	,	O	O
particularly	PRISTIQ.xml:S3:718:12	particularli	RB	O	O
during	PRISTIQ.xml:S3:731:6	dure	IN	O	O
treatment	PRISTIQ.xml:S3:738:9	treatment	NN	O	O
initiation	PRISTIQ.xml:S3:748:10	initi	NN	O	O
and	PRISTIQ.xml:S3:759:3	and	CC	O	O
dose	PRISTIQ.xml:S3:763:4	dose	NN	O	O
increases	PRISTIQ.xml:S3:768:9	increas	NNS	O	O
(	PRISTIQ.xml:S3:778:1	(	(	O	O
5.2	PRISTIQ.xml:S3:781:3	5.2	CD	O	O
)	PRISTIQ.xml:S3:786:1	)	)	O	O
.	PRISTIQ.xml:S3:787:1	.	.	O	O

Elevated	PRISTIQ.xml:S3:797:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
Blood	PRISTIQ.xml:S3:806:5	blood	NNP	I-AdverseReaction	I-AdverseReaction
Pressure	PRISTIQ.xml:S3:812:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
:	PRISTIQ.xml:S3:820:1	:	:	O	O
Control	PRISTIQ.xml:S3:822:7	control	NNP	O	O
hypertension	PRISTIQ.xml:S3:830:12	hypertens	NN	O	O
before	PRISTIQ.xml:S3:843:6	befor	IN	O	O
initiating	PRISTIQ.xml:S3:850:10	initi	VBG	O	O
treatment	PRISTIQ.xml:S3:861:9	treatment	NN	O	O
.	PRISTIQ.xml:S3:870:1	.	.	O	O

Monitor	PRISTIQ.xml:S3:872:7	monitor	NNP	O	O
blood	PRISTIQ.xml:S3:880:5	blood	NN	O	O
pressure	PRISTIQ.xml:S3:886:8	pressur	NN	O	O
regularly	PRISTIQ.xml:S3:895:9	regularli	RB	O	O
during	PRISTIQ.xml:S3:905:6	dure	IN	O	O
treatment	PRISTIQ.xml:S3:912:9	treatment	NN	O	O
(	PRISTIQ.xml:S3:922:1	(	(	O	O
5.3	PRISTIQ.xml:S3:925:3	5.3	CD	O	O
)	PRISTIQ.xml:S3:930:1	)	)	O	O
.	PRISTIQ.xml:S3:931:1	.	.	O	O

Abnormal	PRISTIQ.xml:S3:941:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
Bleeding	PRISTIQ.xml:S3:950:8	bleed	NNP	I-AdverseReaction	I-AdverseReaction
:	PRISTIQ.xml:S3:958:1	:	:	O	O
PRISTIQ	PRISTIQ.xml:S3:960:7	pristiq	NN	O	O
may	PRISTIQ.xml:S3:968:3	may	MD	O	O
increase	PRISTIQ.xml:S3:972:8	increas	VB	O	O
risk	PRISTIQ.xml:S3:981:4	risk	NN	O	O
of	PRISTIQ.xml:S3:986:2	of	IN	O	O
bleeding	PRISTIQ.xml:S3:989:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
events	PRISTIQ.xml:S3:998:6	event	NNS	O	O
.	PRISTIQ.xml:S3:1004:1	.	.	O	O

Caution	PRISTIQ.xml:S3:1006:7	caution	NN	O	O
patients	PRISTIQ.xml:S3:1014:8	patient	NNS	O	O
about	PRISTIQ.xml:S3:1023:5	about	IN	O	O
risk	PRISTIQ.xml:S3:1029:4	risk	NN	O	O
of	PRISTIQ.xml:S3:1034:2	of	IN	O	O
bleeding	PRISTIQ.xml:S3:1037:8	bleed	VBG	O	B-AdverseReaction
associated	PRISTIQ.xml:S3:1046:10	associ	VBN	O	O
with	PRISTIQ.xml:S3:1057:4	with	IN	O	O
concomitant	PRISTIQ.xml:S3:1062:11	concomit	JJ	O	O
use	PRISTIQ.xml:S3:1074:3	use	NN	O	O
of	PRISTIQ.xml:S3:1078:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:1081:7	pristiq	NNP	O	O
and	PRISTIQ.xml:S3:1089:3	and	CC	O	O
NSAIDs	PRISTIQ.xml:S3:1093:6	nsaid	NNP	O	O
,	PRISTIQ.xml:S3:1099:1	,	,	O	O
aspirin	PRISTIQ.xml:S3:1101:7	aspirin	NN	O	O
,	PRISTIQ.xml:S3:1108:1	,	,	O	O
or	PRISTIQ.xml:S3:1110:2	or	CC	O	O
other	PRISTIQ.xml:S3:1113:5	other	JJ	O	O
drugs	PRISTIQ.xml:S3:1119:5	drug	NNS	O	O
that	PRISTIQ.xml:S3:1125:4	that	IN	O	O
affect	PRISTIQ.xml:S3:1130:6	affect	JJ	O	O
coagulation	PRISTIQ.xml:S3:1137:11	coagul	NN	O	O
(	PRISTIQ.xml:S3:1149:1	(	(	O	O
5.4	PRISTIQ.xml:S3:1152:3	5.4	CD	O	O
)	PRISTIQ.xml:S3:1157:1	)	)	O	O
.	PRISTIQ.xml:S3:1158:1	.	.	O	O

Angle	PRISTIQ.xml:S3:1168:5	angl	NNP	B-AdverseReaction	O
Closure	PRISTIQ.xml:S3:1174:7	closur	NNP	I-AdverseReaction	O
Glaucoma	PRISTIQ.xml:S3:1182:8	glaucoma	NNP	I-AdverseReaction	O
:	PRISTIQ.xml:S3:1190:1	:	:	O	O
Angle	PRISTIQ.xml:S3:1192:5	angl	NNP	B-AdverseReaction	B-AdverseReaction
closure	PRISTIQ.xml:S3:1198:7	closur	NN	I-AdverseReaction	I-AdverseReaction
glaucoma	PRISTIQ.xml:S3:1206:8	glaucoma	NN	I-AdverseReaction	I-AdverseReaction
has	PRISTIQ.xml:S3:1215:3	ha	VBZ	O	O
occurred	PRISTIQ.xml:S3:1219:8	occur	VBN	O	O
in	PRISTIQ.xml:S3:1228:2	in	IN	O	O
patients	PRISTIQ.xml:S3:1231:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:1240:4	with	IN	O	O
untreated	PRISTIQ.xml:S3:1245:9	untreat	JJ	O	O
anatomically	PRISTIQ.xml:S3:1255:12	anatom	RB	O	O
narrow	PRISTIQ.xml:S3:1268:6	narrow	JJ	O	O
angles	PRISTIQ.xml:S3:1275:6	angl	NNS	O	O
treated	PRISTIQ.xml:S3:1282:7	treat	VBN	O	O
with	PRISTIQ.xml:S3:1290:4	with	IN	O	O
antidepressants	PRISTIQ.xml:S3:1295:15	antidepress	NNS	O	O
.	PRISTIQ.xml:S3:1310:1	.	.	O	O

(	PRISTIQ.xml:S3:1312:1	(	(	O	O
5.5	PRISTIQ.xml:S3:1315:3	5.5	CD	O	O
)	PRISTIQ.xml:S3:1320:1	)	)	O	O

Activation	PRISTIQ.xml:S3:1330:10	activ	NN	B-AdverseReaction	O
of	PRISTIQ.xml:S3:1341:2	of	IN	I-AdverseReaction	O
Mania	PRISTIQ.xml:S3:1344:5	mania	NNP	I-AdverseReaction	O
Hypomania	PRISTIQ.xml:S3:1350:9	hypomania	NNP	I-AdverseReaction	O
:	PRISTIQ.xml:S3:1359:1	:	:	O	O
Use	PRISTIQ.xml:S3:1361:3	use	NNP	O	O
cautiously	PRISTIQ.xml:S3:1365:10	cautious	RB	O	O
in	PRISTIQ.xml:S3:1376:2	in	IN	O	O
patients	PRISTIQ.xml:S3:1379:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:1388:4	with	IN	O	O
Bipolar	PRISTIQ.xml:S3:1393:7	bipolar	NNP	O	O
Disorder	PRISTIQ.xml:S3:1401:8	disord	NNP	O	O
.	PRISTIQ.xml:S3:1409:1	.	.	O	O

Caution	PRISTIQ.xml:S3:1411:7	caution	NN	O	O
patients	PRISTIQ.xml:S3:1419:8	patient	NNS	O	O
about	PRISTIQ.xml:S3:1428:5	about	IN	O	O
risk	PRISTIQ.xml:S3:1434:4	risk	NN	O	O
of	PRISTIQ.xml:S3:1439:2	of	IN	O	O
activation	PRISTIQ.xml:S3:1442:10	activ	NN	O	O
of	PRISTIQ.xml:S3:1453:2	of	IN	O	O
mania	PRISTIQ.xml:S3:1456:5	mania	NN	O	O
hypomania	PRISTIQ.xml:S3:1462:9	hypomania	NN	O	O
(	PRISTIQ.xml:S3:1472:1	(	(	O	O
5.6	PRISTIQ.xml:S3:1475:3	5.6	CD	O	O
)	PRISTIQ.xml:S3:1480:1	)	)	O	O
.	PRISTIQ.xml:S3:1481:1	.	.	O	O

Discontinuation	PRISTIQ.xml:S3:1491:15	discontinu	NNP	B-AdverseReaction	O
Syndrome	PRISTIQ.xml:S3:1507:8	syndrom	NNP	I-AdverseReaction	O
:	PRISTIQ.xml:S3:1515:1	:	:	O	O
Taper	PRISTIQ.xml:S3:1517:5	taper	NNP	O	O
dose	PRISTIQ.xml:S3:1523:4	dose	NN	O	O
when	PRISTIQ.xml:S3:1528:4	when	WRB	O	O
possible	PRISTIQ.xml:S3:1533:8	possibl	JJ	O	O
and	PRISTIQ.xml:S3:1542:3	and	CC	O	O
monitor	PRISTIQ.xml:S3:1546:7	monitor	NN	O	O
for	PRISTIQ.xml:S3:1554:3	for	IN	O	O
discontinuation	PRISTIQ.xml:S3:1558:15	discontinu	NN	O	O
symptoms	PRISTIQ.xml:S3:1574:8	symptom	NNS	O	O
(	PRISTIQ.xml:S3:1583:1	(	(	O	O
5.7	PRISTIQ.xml:S3:1586:3	5.7	CD	O	O
)	PRISTIQ.xml:S3:1591:1	)	)	O	O
.	PRISTIQ.xml:S3:1592:1	.	.	O	O

Seizure	PRISTIQ.xml:S3:1602:7	seizur	NN	B-AdverseReaction	B-AdverseReaction
:	PRISTIQ.xml:S3:1609:1	:	:	O	O
Can	PRISTIQ.xml:S3:1611:3	can	MD	O	O
occur	PRISTIQ.xml:S3:1615:5	occur	VB	O	O
.	PRISTIQ.xml:S3:1620:1	.	.	O	O

Use	PRISTIQ.xml:S3:1622:3	use	NNP	O	O
cautiously	PRISTIQ.xml:S3:1626:10	cautious	RB	O	O
in	PRISTIQ.xml:S3:1637:2	in	IN	O	O
patients	PRISTIQ.xml:S3:1640:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:1649:4	with	IN	O	O
seizure	PRISTIQ.xml:S3:1654:7	seizur	NN	O	O
disorder	PRISTIQ.xml:S3:1662:8	disord	NN	O	O
(	PRISTIQ.xml:S3:1671:1	(	(	O	O
5.8	PRISTIQ.xml:S3:1674:3	5.8	CD	O	O
)	PRISTIQ.xml:S3:1679:1	)	)	O	O
.	PRISTIQ.xml:S3:1680:1	.	.	O	O

Hyponatremia	PRISTIQ.xml:S3:1690:12	hyponatremia	NN	B-AdverseReaction	B-AdverseReaction
:	PRISTIQ.xml:S3:1702:1	:	:	O	O
Can	PRISTIQ.xml:S3:1704:3	can	MD	O	O
occur	PRISTIQ.xml:S3:1708:5	occur	VB	O	O
in	PRISTIQ.xml:S3:1714:2	in	IN	O	O
association	PRISTIQ.xml:S3:1717:11	associ	NN	O	O
with	PRISTIQ.xml:S3:1729:4	with	IN	O	O
SIADH	PRISTIQ.xml:S3:1734:5	siadh	NNP	O	O
(	PRISTIQ.xml:S3:1740:1	(	(	O	O
5.9	PRISTIQ.xml:S3:1743:3	5.9	CD	O	O
)	PRISTIQ.xml:S3:1748:1	)	)	O	O
.	PRISTIQ.xml:S3:1749:1	.	.	O	O

Interstitial	PRISTIQ.xml:S3:1759:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
Lung	PRISTIQ.xml:S3:1772:4	lung	NNP	I-AdverseReaction	I-AdverseReaction
Disease	PRISTIQ.xml:S3:1777:7	diseas	NNP	I-AdverseReaction	I-AdverseReaction
and	PRISTIQ.xml:S3:1785:3	and	CC	O	O
Eosinophilic	PRISTIQ.xml:S3:1789:12	eosinophil	NNP	B-AdverseReaction	O
Pneumonia	PRISTIQ.xml:S3:1802:9	pneumonia	NNP	I-AdverseReaction	B-AdverseReaction
:	PRISTIQ.xml:S3:1811:1	:	:	O	O
Can	PRISTIQ.xml:S3:1813:3	can	MD	O	O
occur	PRISTIQ.xml:S3:1817:5	occur	VB	O	O
(	PRISTIQ.xml:S3:1823:1	(	(	O	O
5.10	PRISTIQ.xml:S3:1826:4	5.10	CD	O	O
)	PRISTIQ.xml:S3:1832:1	)	)	O	O
.	PRISTIQ.xml:S3:1833:1	.	.	O	O

5.1	PRISTIQ.xml:S3:1847:3	5.1	CD	O	O

Suicidal	PRISTIQ.xml:S3:1851:8	suicid	NN	O	O

Thoughts	PRISTIQ.xml:S3:1860:8	thought	NNS	O	O
and	PRISTIQ.xml:S3:1869:3	and	CC	O	O
Behaviors	PRISTIQ.xml:S3:1873:9	behavior	NNS	O	O
in	PRISTIQ.xml:S3:1883:2	in	IN	O	O
Children	PRISTIQ.xml:S3:1886:8	children	NNP	O	O
,	PRISTIQ.xml:S3:1894:1	,	,	O	O
Adolescents	PRISTIQ.xml:S3:1896:11	adolesc	NNP	O	O
and	PRISTIQ.xml:S3:1908:3	and	CC	O	O
Young	PRISTIQ.xml:S3:1912:5	young	NNP	O	O
Adults	PRISTIQ.xml:S3:1918:6	adult	NNP	O	O

Patients	PRISTIQ.xml:S3:1930:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:1939:4	with	IN	O	O
major	PRISTIQ.xml:S3:1944:5	major	JJ	O	O
depressive	PRISTIQ.xml:S3:1950:10	depress	JJ	O	O
disorder	PRISTIQ.xml:S3:1961:8	disord	NN	O	O
(	PRISTIQ.xml:S3:1970:1	(	(	O	O
MDD	PRISTIQ.xml:S3:1971:3	mdd	NNP	O	O
)	PRISTIQ.xml:S3:1974:1	)	)	O	O
,	PRISTIQ.xml:S3:1975:1	,	,	O	O
both	PRISTIQ.xml:S3:1977:4	both	DT	O	O
adult	PRISTIQ.xml:S3:1982:5	adult	NN	O	O
and	PRISTIQ.xml:S3:1988:3	and	CC	O	O
pediatric	PRISTIQ.xml:S3:1992:9	pediatr	JJ	O	O
,	PRISTIQ.xml:S3:2001:1	,	,	O	O
may	PRISTIQ.xml:S3:2003:3	may	MD	O	O
experience	PRISTIQ.xml:S3:2007:10	experi	VB	O	O
worsening	PRISTIQ.xml:S3:2018:9	worsen	VBG	O	O
of	PRISTIQ.xml:S3:2028:2	of	IN	O	O
their	PRISTIQ.xml:S3:2031:5	their	PRP$	O	O
depression	PRISTIQ.xml:S3:2037:10	depress	NN	O	O
and	PRISTIQ.xml:S3:2048:3	and	CC	O	O
or	PRISTIQ.xml:S3:2052:2	or	CC	O	O
the	PRISTIQ.xml:S3:2055:3	the	DT	O	O
emergence	PRISTIQ.xml:S3:2059:9	emerg	NN	O	O
of	PRISTIQ.xml:S3:2069:2	of	IN	O	O
suicidal	PRISTIQ.xml:S3:2072:8	suicid	JJ	O	O
ideation	PRISTIQ.xml:S3:2081:8	ideat	NN	O	O
and	PRISTIQ.xml:S3:2090:3	and	CC	O	O
behavior	PRISTIQ.xml:S3:2094:8	behavior	NN	O	O
(	PRISTIQ.xml:S3:2103:1	(	(	O	O
suicidality	PRISTIQ.xml:S3:2104:11	suicid	NN	O	O
)	PRISTIQ.xml:S3:2115:1	)	)	O	O
or	PRISTIQ.xml:S3:2117:2	or	CC	O	O
unusual	PRISTIQ.xml:S3:2120:7	unusu	JJ	O	O
changes	PRISTIQ.xml:S3:2128:7	chang	NNS	O	O
in	PRISTIQ.xml:S3:2136:2	in	IN	O	O
behavior	PRISTIQ.xml:S3:2139:8	behavior	NN	O	O
,	PRISTIQ.xml:S3:2147:1	,	,	O	O
whether	PRISTIQ.xml:S3:2149:7	whether	IN	O	O
or	PRISTIQ.xml:S3:2157:2	or	CC	O	O
not	PRISTIQ.xml:S3:2160:3	not	RB	O	O
they	PRISTIQ.xml:S3:2164:4	they	PRP	O	O
are	PRISTIQ.xml:S3:2169:3	are	VBP	O	O
taking	PRISTIQ.xml:S3:2173:6	take	VBG	O	O
antidepressant	PRISTIQ.xml:S3:2180:14	antidepress	JJ	O	O
medications	PRISTIQ.xml:S3:2195:11	medic	NNS	O	O
,	PRISTIQ.xml:S3:2206:1	,	,	O	O
and	PRISTIQ.xml:S3:2208:3	and	CC	O	O
this	PRISTIQ.xml:S3:2212:4	thi	DT	O	O
risk	PRISTIQ.xml:S3:2217:4	risk	NN	O	O
may	PRISTIQ.xml:S3:2222:3	may	MD	O	O
persist	PRISTIQ.xml:S3:2226:7	persist	VB	O	O
until	PRISTIQ.xml:S3:2234:5	until	IN	O	O
significant	PRISTIQ.xml:S3:2240:11	signific	JJ	O	O
remission	PRISTIQ.xml:S3:2252:9	remiss	NN	O	O
occurs	PRISTIQ.xml:S3:2262:6	occur	NNS	O	O
.	PRISTIQ.xml:S3:2268:1	.	.	O	O

Suicide	PRISTIQ.xml:S3:2270:7	suicid	NNP	O	B-AdverseReaction
is	PRISTIQ.xml:S3:2278:2	is	VBZ	O	O
a	PRISTIQ.xml:S3:2281:1	a	DT	O	O
known	PRISTIQ.xml:S3:2283:5	known	JJ	O	O
risk	PRISTIQ.xml:S3:2289:4	risk	NN	O	O
of	PRISTIQ.xml:S3:2294:2	of	IN	O	O
depression	PRISTIQ.xml:S3:2297:10	depress	NN	O	B-AdverseReaction
and	PRISTIQ.xml:S3:2308:3	and	CC	O	O
certain	PRISTIQ.xml:S3:2312:7	certain	JJ	O	O
other	PRISTIQ.xml:S3:2320:5	other	JJ	O	O
psychiatric	PRISTIQ.xml:S3:2326:11	psychiatr	JJ	O	O
disorders	PRISTIQ.xml:S3:2338:9	disord	NNS	O	O
,	PRISTIQ.xml:S3:2347:1	,	,	O	O
and	PRISTIQ.xml:S3:2349:3	and	CC	O	O
these	PRISTIQ.xml:S3:2353:5	these	DT	O	O
disorders	PRISTIQ.xml:S3:2359:9	disord	NNS	O	O
themselves	PRISTIQ.xml:S3:2369:10	themselv	PRP	O	O
are	PRISTIQ.xml:S3:2380:3	are	VBP	O	O
the	PRISTIQ.xml:S3:2384:3	the	DT	O	O
strongest	PRISTIQ.xml:S3:2388:9	strongest	JJS	O	O
predictors	PRISTIQ.xml:S3:2398:10	predictor	NNS	O	O
of	PRISTIQ.xml:S3:2409:2	of	IN	O	O
suicide	PRISTIQ.xml:S3:2412:7	suicid	NN	O	B-AdverseReaction
.	PRISTIQ.xml:S3:2419:1	.	.	O	O

There	PRISTIQ.xml:S3:2421:5	there	EX	O	O
has	PRISTIQ.xml:S3:2427:3	ha	VBZ	O	O
been	PRISTIQ.xml:S3:2431:4	been	VBN	O	O
a	PRISTIQ.xml:S3:2436:1	a	DT	O	O
long	PRISTIQ.xml:S3:2438:4	long	JJ	O	O
-	PRISTIQ.xml:S3:2442:1	-	:	O	O
standing	PRISTIQ.xml:S3:2443:8	stand	NN	O	O
concern	PRISTIQ.xml:S3:2452:7	concern	NN	O	O
,	PRISTIQ.xml:S3:2459:1	,	,	O	O
however	PRISTIQ.xml:S3:2461:7	howev	RB	O	O
,	PRISTIQ.xml:S3:2468:1	,	,	O	O
that	PRISTIQ.xml:S3:2470:4	that	IN	O	O
antidepressants	PRISTIQ.xml:S3:2475:15	antidepress	NNS	O	O
may	PRISTIQ.xml:S3:2491:3	may	MD	O	O
have	PRISTIQ.xml:S3:2495:4	have	VB	O	O
a	PRISTIQ.xml:S3:2500:1	a	DT	O	O
role	PRISTIQ.xml:S3:2502:4	role	NN	O	O
in	PRISTIQ.xml:S3:2507:2	in	IN	O	O
inducing	PRISTIQ.xml:S3:2510:8	induc	VBG	O	O
worsening	PRISTIQ.xml:S3:2519:9	worsen	NN	B-AdverseReaction	O
of	PRISTIQ.xml:S3:2529:2	of	IN	I-AdverseReaction	O
depression	PRISTIQ.xml:S3:2532:10	depress	NN	I-AdverseReaction	O
and	PRISTIQ.xml:S3:2543:3	and	CC	O	O
the	PRISTIQ.xml:S3:2547:3	the	DT	O	O
emergence	PRISTIQ.xml:S3:2551:9	emerg	NN	O	O
of	PRISTIQ.xml:S3:2561:2	of	IN	O	O
suicidality	PRISTIQ.xml:S3:2564:11	suicid	NN	B-AdverseReaction	O
in	PRISTIQ.xml:S3:2576:2	in	IN	O	O
certain	PRISTIQ.xml:S3:2579:7	certain	JJ	O	O
patients	PRISTIQ.xml:S3:2587:8	patient	NNS	O	O
during	PRISTIQ.xml:S3:2596:6	dure	IN	O	O
the	PRISTIQ.xml:S3:2603:3	the	DT	O	O
early	PRISTIQ.xml:S3:2607:5	earli	JJ	O	O
phases	PRISTIQ.xml:S3:2613:6	phase	NNS	O	O
of	PRISTIQ.xml:S3:2620:2	of	IN	O	O
treatment	PRISTIQ.xml:S3:2623:9	treatment	NN	O	O
.	PRISTIQ.xml:S3:2632:1	.	.	O	O

Pooled	PRISTIQ.xml:S3:2634:6	pool	JJ	O	O
analyses	PRISTIQ.xml:S3:2641:8	analys	NNS	O	O
of	PRISTIQ.xml:S3:2650:2	of	IN	O	O
short	PRISTIQ.xml:S3:2653:5	short	JJ	O	O
-	PRISTIQ.xml:S3:2658:1	-	:	O	O
term	PRISTIQ.xml:S3:2659:4	term	NN	O	O
placebo	PRISTIQ.xml:S3:2664:7	placebo	NN	O	O
-	PRISTIQ.xml:S3:2671:1	-	:	O	O
controlled	PRISTIQ.xml:S3:2672:10	control	JJ	O	O
studies	PRISTIQ.xml:S3:2683:7	studi	NNS	O	O
of	PRISTIQ.xml:S3:2691:2	of	IN	O	O
antidepressant	PRISTIQ.xml:S3:2694:14	antidepress	JJ	O	O
drugs	PRISTIQ.xml:S3:2709:5	drug	NNS	O	O
(	PRISTIQ.xml:S3:2715:1	(	(	O	O
SSRIs	PRISTIQ.xml:S3:2716:5	ssri	NNP	O	O
and	PRISTIQ.xml:S3:2722:3	and	CC	O	O
others	PRISTIQ.xml:S3:2726:6	other	NNS	O	O
)	PRISTIQ.xml:S3:2732:1	)	)	O	O
showed	PRISTIQ.xml:S3:2734:6	show	VBD	O	O
that	PRISTIQ.xml:S3:2741:4	that	IN	O	O
these	PRISTIQ.xml:S3:2746:5	these	DT	O	O
drugs	PRISTIQ.xml:S3:2752:5	drug	NNS	O	O
increase	PRISTIQ.xml:S3:2758:8	increas	VBP	O	O
the	PRISTIQ.xml:S3:2767:3	the	DT	O	O
risk	PRISTIQ.xml:S3:2771:4	risk	NN	O	O
of	PRISTIQ.xml:S3:2776:2	of	IN	O	O
suicidal	PRISTIQ.xml:S3:2779:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
thinking	PRISTIQ.xml:S3:2788:8	think	NN	I-AdverseReaction	I-AdverseReaction
and	PRISTIQ.xml:S3:2797:3	and	CC	O	O
behavior	PRISTIQ.xml:S3:2801:8	behavior	NN	I-AdverseReaction	I-AdverseReaction
(	PRISTIQ.xml:S3:2810:1	(	(	O	O
suicidality	PRISTIQ.xml:S3:2811:11	suicid	NN	B-AdverseReaction	B-AdverseReaction
)	PRISTIQ.xml:S3:2822:1	)	)	O	O
in	PRISTIQ.xml:S3:2824:2	in	IN	O	O
children	PRISTIQ.xml:S3:2827:8	children	NNS	O	O
,	PRISTIQ.xml:S3:2835:1	,	,	O	O
adolescents	PRISTIQ.xml:S3:2837:11	adolesc	NNS	O	O
,	PRISTIQ.xml:S3:2848:1	,	,	O	O
and	PRISTIQ.xml:S3:2850:3	and	CC	O	O
young	PRISTIQ.xml:S3:2854:5	young	JJ	O	O
adults	PRISTIQ.xml:S3:2860:6	adult	NNS	O	O
(	PRISTIQ.xml:S3:2867:1	(	(	O	O
ages	PRISTIQ.xml:S3:2868:4	age	VBZ	O	O
18	PRISTIQ.xml:S3:2873:2	18	CD	O	O
to	PRISTIQ.xml:S3:2876:2	to	TO	O	O
24	PRISTIQ.xml:S3:2879:2	24	CD	O	O
)	PRISTIQ.xml:S3:2881:1	)	)	O	O
with	PRISTIQ.xml:S3:2883:4	with	IN	O	O
major	PRISTIQ.xml:S3:2888:5	major	JJ	O	O
depressive	PRISTIQ.xml:S3:2894:10	depress	JJ	O	O
disorder	PRISTIQ.xml:S3:2905:8	disord	NN	O	O
(	PRISTIQ.xml:S3:2914:1	(	(	O	O
MDD	PRISTIQ.xml:S3:2915:3	mdd	NNP	O	O
)	PRISTIQ.xml:S3:2918:1	)	)	O	O
and	PRISTIQ.xml:S3:2920:3	and	CC	O	O
other	PRISTIQ.xml:S3:2924:5	other	JJ	O	O
psychiatric	PRISTIQ.xml:S3:2930:11	psychiatr	JJ	O	O
disorders	PRISTIQ.xml:S3:2942:9	disord	NNS	O	O
.	PRISTIQ.xml:S3:2951:1	.	.	O	O

Short	PRISTIQ.xml:S3:2953:5	short	NNP	O	O
-	PRISTIQ.xml:S3:2958:1	-	:	O	O
term	PRISTIQ.xml:S3:2959:4	term	NN	O	O
studies	PRISTIQ.xml:S3:2964:7	studi	NNS	O	O
did	PRISTIQ.xml:S3:2972:3	did	VBD	O	O
not	PRISTIQ.xml:S3:2976:3	not	RB	O	O
show	PRISTIQ.xml:S3:2980:4	show	VB	O	O
an	PRISTIQ.xml:S3:2985:2	an	DT	O	O
increase	PRISTIQ.xml:S3:2988:8	increas	NN	O	O
in	PRISTIQ.xml:S3:2997:2	in	IN	O	O
the	PRISTIQ.xml:S3:3000:3	the	DT	O	O
risk	PRISTIQ.xml:S3:3004:4	risk	NN	O	O
of	PRISTIQ.xml:S3:3009:2	of	IN	O	O
suicidality	PRISTIQ.xml:S3:3012:11	suicid	NN	B-AdverseReaction	O
with	PRISTIQ.xml:S3:3024:4	with	IN	O	O
antidepressants	PRISTIQ.xml:S3:3029:15	antidepress	NNS	O	O
compared	PRISTIQ.xml:S3:3045:8	compar	VBN	O	O
to	PRISTIQ.xml:S3:3054:2	to	TO	O	O
placebo	PRISTIQ.xml:S3:3057:7	placebo	VB	O	O
in	PRISTIQ.xml:S3:3065:2	in	IN	O	O
adults	PRISTIQ.xml:S3:3068:6	adult	NNS	O	O
beyond	PRISTIQ.xml:S3:3075:6	beyond	IN	O	O
age	PRISTIQ.xml:S3:3082:3	age	NN	O	O
24	PRISTIQ.xml:S3:3086:2	24	CD	O	O
;	PRISTIQ.xml:S3:3088:1	;	:	O	O
there	PRISTIQ.xml:S3:3090:5	there	EX	O	O
was	PRISTIQ.xml:S3:3096:3	wa	VBD	O	O
a	PRISTIQ.xml:S3:3100:1	a	DT	O	O
reduction	PRISTIQ.xml:S3:3102:9	reduct	NN	O	O
with	PRISTIQ.xml:S3:3112:4	with	IN	O	O
antidepressants	PRISTIQ.xml:S3:3117:15	antidepress	NNS	O	O
compared	PRISTIQ.xml:S3:3133:8	compar	VBN	O	O
to	PRISTIQ.xml:S3:3142:2	to	TO	O	O
placebo	PRISTIQ.xml:S3:3145:7	placebo	VB	O	O
in	PRISTIQ.xml:S3:3153:2	in	IN	O	O
adults	PRISTIQ.xml:S3:3156:6	adult	NNS	O	O
aged	PRISTIQ.xml:S3:3163:4	age	VBN	O	O
65	PRISTIQ.xml:S3:3168:2	65	CD	O	O
and	PRISTIQ.xml:S3:3171:3	and	CC	O	O
older	PRISTIQ.xml:S3:3175:5	older	JJR	O	O
.	PRISTIQ.xml:S3:3180:1	.	.	O	O

The	PRISTIQ.xml:S3:3186:3	the	DT	O	O
pooled	PRISTIQ.xml:S3:3190:6	pool	JJ	O	O
analyses	PRISTIQ.xml:S3:3197:8	analys	NNS	O	O
of	PRISTIQ.xml:S3:3206:2	of	IN	O	O
placebo	PRISTIQ.xml:S3:3209:7	placebo	NN	O	O
-	PRISTIQ.xml:S3:3216:1	-	:	O	O
controlled	PRISTIQ.xml:S3:3217:10	control	VBN	O	O
studies	PRISTIQ.xml:S3:3228:7	studi	NNS	O	O
in	PRISTIQ.xml:S3:3236:2	in	IN	O	O
children	PRISTIQ.xml:S3:3239:8	children	NNS	O	O
and	PRISTIQ.xml:S3:3248:3	and	CC	O	O
adolescents	PRISTIQ.xml:S3:3252:11	adolesc	NNS	O	O
with	PRISTIQ.xml:S3:3264:4	with	IN	O	O
MDD	PRISTIQ.xml:S3:3269:3	mdd	NNP	O	O
,	PRISTIQ.xml:S3:3272:1	,	,	O	O
obsessive	PRISTIQ.xml:S3:3274:9	obsess	JJ	O	B-AdverseReaction
compulsive	PRISTIQ.xml:S3:3284:10	compuls	JJ	O	I-AdverseReaction
disorder	PRISTIQ.xml:S3:3295:8	disord	NN	O	I-AdverseReaction
(	PRISTIQ.xml:S3:3304:1	(	(	O	O
OCD	PRISTIQ.xml:S3:3305:3	ocd	NNP	O	O
)	PRISTIQ.xml:S3:3308:1	)	)	O	O
,	PRISTIQ.xml:S3:3309:1	,	,	O	O
or	PRISTIQ.xml:S3:3311:2	or	CC	O	O
other	PRISTIQ.xml:S3:3314:5	other	JJ	O	O
psychiatric	PRISTIQ.xml:S3:3320:11	psychiatr	JJ	O	O
disorders	PRISTIQ.xml:S3:3332:9	disord	NNS	O	O
included	PRISTIQ.xml:S3:3342:8	includ	VBD	O	O
a	PRISTIQ.xml:S3:3351:1	a	DT	O	O
total	PRISTIQ.xml:S3:3353:5	total	NN	O	O
of	PRISTIQ.xml:S3:3359:2	of	IN	O	O
24	PRISTIQ.xml:S3:3362:2	24	CD	O	O
short	PRISTIQ.xml:S3:3365:5	short	JJ	O	O
-	PRISTIQ.xml:S3:3370:1	-	:	O	O
term	PRISTIQ.xml:S3:3371:4	term	NN	O	O
studies	PRISTIQ.xml:S3:3376:7	studi	NNS	O	O
of	PRISTIQ.xml:S3:3384:2	of	IN	O	O
9	PRISTIQ.xml:S3:3387:1	9	CD	O	O
antidepressant	PRISTIQ.xml:S3:3389:14	antidepress	JJ	O	O
drugs	PRISTIQ.xml:S3:3404:5	drug	NNS	O	O
in	PRISTIQ.xml:S3:3410:2	in	IN	O	O
over	PRISTIQ.xml:S3:3413:4	over	IN	O	O
4	PRISTIQ.xml:S3:3418:1	4	CD	O	O
,	PRISTIQ.xml:S3:3419:1	,	,	O	O
400	PRISTIQ.xml:S3:3420:3	400	CD	O	O
patients	PRISTIQ.xml:S3:3424:8	patient	NNS	O	O
.	PRISTIQ.xml:S3:3432:1	.	.	O	O

The	PRISTIQ.xml:S3:3434:3	the	DT	O	O
pooled	PRISTIQ.xml:S3:3438:6	pool	JJ	O	O
analyses	PRISTIQ.xml:S3:3445:8	analys	NNS	O	O
of	PRISTIQ.xml:S3:3454:2	of	IN	O	O
placebo	PRISTIQ.xml:S3:3457:7	placebo	NN	O	O
-	PRISTIQ.xml:S3:3464:1	-	:	O	O
controlled	PRISTIQ.xml:S3:3465:10	control	VBN	O	O
studies	PRISTIQ.xml:S3:3476:7	studi	NNS	O	O
in	PRISTIQ.xml:S3:3484:2	in	IN	O	O
adults	PRISTIQ.xml:S3:3487:6	adult	NNS	O	O
with	PRISTIQ.xml:S3:3494:4	with	IN	O	O
MDD	PRISTIQ.xml:S3:3499:3	mdd	NNP	O	O
or	PRISTIQ.xml:S3:3503:2	or	CC	O	O
other	PRISTIQ.xml:S3:3506:5	other	JJ	O	O
psychiatric	PRISTIQ.xml:S3:3512:11	psychiatr	JJ	O	O
disorders	PRISTIQ.xml:S3:3524:9	disord	NNS	O	O
included	PRISTIQ.xml:S3:3534:8	includ	VBD	O	O
a	PRISTIQ.xml:S3:3543:1	a	DT	O	O
total	PRISTIQ.xml:S3:3545:5	total	NN	O	O
of	PRISTIQ.xml:S3:3551:2	of	IN	O	O
295	PRISTIQ.xml:S3:3554:3	295	CD	O	O
short	PRISTIQ.xml:S3:3558:5	short	JJ	O	O
-	PRISTIQ.xml:S3:3563:1	-	:	O	O
term	PRISTIQ.xml:S3:3564:4	term	NN	O	O
studies	PRISTIQ.xml:S3:3569:7	studi	NNS	O	O
(	PRISTIQ.xml:S3:3577:1	(	(	O	O
median	PRISTIQ.xml:S3:3578:6	median	JJ	O	O
duration	PRISTIQ.xml:S3:3585:8	durat	NN	O	O
of	PRISTIQ.xml:S3:3594:2	of	IN	O	O
2	PRISTIQ.xml:S3:3597:1	2	CD	O	O
months	PRISTIQ.xml:S3:3599:6	month	NNS	O	O
)	PRISTIQ.xml:S3:3605:1	)	)	O	O
of	PRISTIQ.xml:S3:3607:2	of	IN	O	O
11	PRISTIQ.xml:S3:3610:2	11	CD	O	O
antidepressant	PRISTIQ.xml:S3:3613:14	antidepress	JJ	O	O
drugs	PRISTIQ.xml:S3:3628:5	drug	NNS	O	O
in	PRISTIQ.xml:S3:3634:2	in	IN	O	O
over	PRISTIQ.xml:S3:3637:4	over	IN	O	O
77	PRISTIQ.xml:S3:3642:2	77	CD	O	O
,	PRISTIQ.xml:S3:3644:1	,	,	O	O
000	PRISTIQ.xml:S3:3645:3	000	CD	O	O
patients	PRISTIQ.xml:S3:3649:8	patient	NNS	O	O
.	PRISTIQ.xml:S3:3657:1	.	.	O	O

There	PRISTIQ.xml:S3:3659:5	there	EX	O	O
was	PRISTIQ.xml:S3:3665:3	wa	VBD	O	O
considerable	PRISTIQ.xml:S3:3669:12	consider	JJ	O	O
variation	PRISTIQ.xml:S3:3682:9	variat	NN	O	O
in	PRISTIQ.xml:S3:3692:2	in	IN	O	O
risk	PRISTIQ.xml:S3:3695:4	risk	NN	O	O
of	PRISTIQ.xml:S3:3700:2	of	IN	O	O
suicidality	PRISTIQ.xml:S3:3703:11	suicid	NN	B-AdverseReaction	B-AdverseReaction
among	PRISTIQ.xml:S3:3715:5	among	IN	O	O
drugs	PRISTIQ.xml:S3:3721:5	drug	NNS	O	O
,	PRISTIQ.xml:S3:3726:1	,	,	O	O
but	PRISTIQ.xml:S3:3728:3	but	CC	O	O
a	PRISTIQ.xml:S3:3732:1	a	DT	O	O
tendency	PRISTIQ.xml:S3:3734:8	tendenc	NN	O	O
toward	PRISTIQ.xml:S3:3743:6	toward	IN	O	O
an	PRISTIQ.xml:S3:3750:2	an	DT	O	O
increase	PRISTIQ.xml:S3:3753:8	increas	NN	O	O
in	PRISTIQ.xml:S3:3762:2	in	IN	O	O
the	PRISTIQ.xml:S3:3765:3	the	DT	O	O
younger	PRISTIQ.xml:S3:3769:7	younger	JJR	O	O
patients	PRISTIQ.xml:S3:3777:8	patient	NNS	O	O
for	PRISTIQ.xml:S3:3786:3	for	IN	O	O
almost	PRISTIQ.xml:S3:3790:6	almost	RB	O	O
all	PRISTIQ.xml:S3:3797:3	all	DT	O	O
drugs	PRISTIQ.xml:S3:3801:5	drug	NNS	O	O
studied	PRISTIQ.xml:S3:3807:7	studi	VBN	O	O
.	PRISTIQ.xml:S3:3814:1	.	.	O	O

There	PRISTIQ.xml:S3:3816:5	there	EX	O	O
were	PRISTIQ.xml:S3:3822:4	were	VBD	O	O
differences	PRISTIQ.xml:S3:3827:11	differ	NNS	O	O
in	PRISTIQ.xml:S3:3839:2	in	IN	O	O
absolute	PRISTIQ.xml:S3:3842:8	absolut	JJ	O	O
risk	PRISTIQ.xml:S3:3851:4	risk	NN	O	O
of	PRISTIQ.xml:S3:3856:2	of	IN	O	O
suicidality	PRISTIQ.xml:S3:3859:11	suicid	NN	B-AdverseReaction	B-AdverseReaction
across	PRISTIQ.xml:S3:3871:6	across	IN	O	O
the	PRISTIQ.xml:S3:3878:3	the	DT	O	O
different	PRISTIQ.xml:S3:3882:9	differ	JJ	O	O
indications	PRISTIQ.xml:S3:3892:11	indic	NNS	O	O
,	PRISTIQ.xml:S3:3903:1	,	,	O	O
with	PRISTIQ.xml:S3:3905:4	with	IN	O	O
the	PRISTIQ.xml:S3:3910:3	the	DT	O	O
highest	PRISTIQ.xml:S3:3914:7	highest	JJS	O	O
incidence	PRISTIQ.xml:S3:3922:9	incid	NN	O	O
in	PRISTIQ.xml:S3:3932:2	in	IN	O	O
MDD	PRISTIQ.xml:S3:3935:3	mdd	NNP	O	O
.	PRISTIQ.xml:S3:3938:1	.	.	O	O

The	PRISTIQ.xml:S3:3940:3	the	DT	O	O
risk	PRISTIQ.xml:S3:3944:4	risk	NN	O	O
differences	PRISTIQ.xml:S3:3949:11	differ	NNS	O	O
(	PRISTIQ.xml:S3:3961:1	(	(	O	O
drug	PRISTIQ.xml:S3:3962:4	drug	NN	O	O
vs	PRISTIQ.xml:S3:3967:2	vs	NN	O	O
.	PRISTIQ.xml:S3:3969:1	.	.	O	O

placebo	PRISTIQ.xml:S3:3971:7	placebo	NN	O	O
)	PRISTIQ.xml:S3:3978:1	)	)	O	O
,	PRISTIQ.xml:S3:3979:1	,	,	O	O
however	PRISTIQ.xml:S3:3981:7	howev	RB	O	O
,	PRISTIQ.xml:S3:3988:1	,	,	O	O
were	PRISTIQ.xml:S3:3990:4	were	VBD	O	O
relatively	PRISTIQ.xml:S3:3995:10	rel	RB	O	O
stable	PRISTIQ.xml:S3:4006:6	stabl	JJ	O	O
within	PRISTIQ.xml:S3:4013:6	within	IN	O	O
age	PRISTIQ.xml:S3:4020:3	age	NN	O	O
strata	PRISTIQ.xml:S3:4024:6	strata	NN	O	O
and	PRISTIQ.xml:S3:4031:3	and	CC	O	O
across	PRISTIQ.xml:S3:4035:6	across	IN	O	O
indications	PRISTIQ.xml:S3:4042:11	indic	NNS	O	O
.	PRISTIQ.xml:S3:4053:1	.	.	O	O

These	PRISTIQ.xml:S3:4055:5	these	DT	O	O
risk	PRISTIQ.xml:S3:4061:4	risk	NN	O	O
differences	PRISTIQ.xml:S3:4066:11	differ	NNS	O	O
(	PRISTIQ.xml:S3:4078:1	(	(	O	O
drug	PRISTIQ.xml:S3:4079:4	drug	NN	O	O
-	PRISTIQ.xml:S3:4083:1	-	:	O	O
placebo	PRISTIQ.xml:S3:4084:7	placebo	NN	O	O
difference	PRISTIQ.xml:S3:4092:10	differ	NN	O	O
in	PRISTIQ.xml:S3:4103:2	in	IN	O	O
the	PRISTIQ.xml:S3:4106:3	the	DT	O	O
number	PRISTIQ.xml:S3:4110:6	number	NN	O	O
of	PRISTIQ.xml:S3:4117:2	of	IN	O	O
cases	PRISTIQ.xml:S3:4120:5	case	NNS	O	O
of	PRISTIQ.xml:S3:4126:2	of	IN	O	O
suicidality	PRISTIQ.xml:S3:4129:11	suicid	NN	B-AdverseReaction	B-AdverseReaction
per	PRISTIQ.xml:S3:4141:3	per	IN	O	O
1	PRISTIQ.xml:S3:4145:1	1	CD	O	O
,	PRISTIQ.xml:S3:4146:1	,	,	O	O
000	PRISTIQ.xml:S3:4147:3	000	CD	O	O
patients	PRISTIQ.xml:S3:4151:8	patient	NNS	O	O
treated	PRISTIQ.xml:S3:4160:7	treat	VBN	O	O
)	PRISTIQ.xml:S3:4167:1	)	)	O	O
are	PRISTIQ.xml:S3:4169:3	are	VBP	O	O
provided	PRISTIQ.xml:S3:4173:8	provid	VBN	O	O
in	PRISTIQ.xml:S3:4182:2	in	IN	O	O
Table	PRISTIQ.xml:S3:4185:5	tabl	JJ	O	O
1	PRISTIQ.xml:S3:4191:1	1	CD	O	O
.	PRISTIQ.xml:S3:4192:1	.	.	O	O

Table	PRISTIQ.xml:S3:4198:5	tabl	JJ	O	O
1	PRISTIQ.xml:S3:4204:1	1	CD	O	O

Age	PRISTIQ.xml:S3:4209:3	age	NNP	O	O
Range	PRISTIQ.xml:S3:4213:5	rang	NNP	O	O
Drug	PRISTIQ.xml:S3:4229:4	drug	NNP	O	O
-	PRISTIQ.xml:S3:4233:1	-	:	O	O
Placebo	PRISTIQ.xml:S3:4234:7	placebo	NN	O	O
Difference	PRISTIQ.xml:S3:4242:10	differ	NNP	O	O
in	PRISTIQ.xml:S3:4253:2	in	IN	O	O
Number	PRISTIQ.xml:S3:4256:6	number	NNP	O	O
of	PRISTIQ.xml:S3:4263:2	of	IN	O	O
Cases	PRISTIQ.xml:S3:4266:5	case	NNP	O	O
of	PRISTIQ.xml:S3:4272:2	of	IN	O	O
Suicidality	PRISTIQ.xml:S3:4275:11	suicid	NNP	B-AdverseReaction	B-AdverseReaction
per	PRISTIQ.xml:S3:4287:3	per	IN	O	O
1	PRISTIQ.xml:S3:4291:1	1	CD	O	O
,	PRISTIQ.xml:S3:4292:1	,	,	O	O
000	PRISTIQ.xml:S3:4293:3	000	CD	O	O
Patients	PRISTIQ.xml:S3:4297:8	patient	NNS	O	O
Treated	PRISTIQ.xml:S3:4306:7	treat	VBD	O	O

Increases	PRISTIQ.xml:S3:4344:9	increas	NNS	O	O

Compared	PRISTIQ.xml:S3:4354:8	compar	VBN	O	O
to	PRISTIQ.xml:S3:4363:2	to	TO	O	O
Placebo	PRISTIQ.xml:S3:4366:7	placebo	VB	O	O

18	PRISTIQ.xml:S3:4419:2	18	CD	O	O
14	PRISTIQ.xml:S3:4438:2	14	CD	O	O
additional	PRISTIQ.xml:S3:4441:10	addit	JJ	O	O
cases	PRISTIQ.xml:S3:4452:5	case	NNS	O	O

18	PRISTIQ.xml:S3:4512:2	18	CD	O	O
to	PRISTIQ.xml:S3:4515:2	to	TO	O	O
24	PRISTIQ.xml:S3:4518:2	24	CD	O	O
5	PRISTIQ.xml:S3:4532:1	5	CD	O	O
additional	PRISTIQ.xml:S3:4534:10	addit	JJ	O	O
cases	PRISTIQ.xml:S3:4545:5	case	NNS	O	O

Decreases	PRISTIQ.xml:S3:4626:9	decreas	NNS	O	O
Compared	PRISTIQ.xml:S3:4636:8	compar	VBD	O	O
to	PRISTIQ.xml:S3:4645:2	to	TO	O	O
Placebo	PRISTIQ.xml:S3:4648:7	placebo	VB	O	O

25	PRISTIQ.xml:S3:4700:2	25	CD	O	O
to	PRISTIQ.xml:S3:4703:2	to	TO	O	O
64	PRISTIQ.xml:S3:4706:2	64	CD	O	O
1	PRISTIQ.xml:S3:4720:1	1	CD	O	O
fewer	PRISTIQ.xml:S3:4722:5	fewer	JJR	O	O
case	PRISTIQ.xml:S3:4728:4	case	NN	O	O

65	PRISTIQ.xml:S3:4796:2	65	CD	O	O
6	PRISTIQ.xml:S3:4814:1	6	CD	O	O
fewer	PRISTIQ.xml:S3:4816:5	fewer	JJR	O	O
cases	PRISTIQ.xml:S3:4822:5	case	NNS	O	O

No	PRISTIQ.xml:S3:4894:2	No	DT	O	O
suicides	PRISTIQ.xml:S3:4897:8	suicid	NNS	B-AdverseReaction	B-AdverseReaction
occurred	PRISTIQ.xml:S3:4906:8	occur	VBD	O	O
in	PRISTIQ.xml:S3:4915:2	in	IN	O	O
any	PRISTIQ.xml:S3:4918:3	ani	DT	O	O
of	PRISTIQ.xml:S3:4922:2	of	IN	O	O
the	PRISTIQ.xml:S3:4925:3	the	DT	O	O
pediatric	PRISTIQ.xml:S3:4929:9	pediatr	JJ	O	O
studies	PRISTIQ.xml:S3:4939:7	studi	NNS	O	O
.	PRISTIQ.xml:S3:4946:1	.	.	O	O

There	PRISTIQ.xml:S3:4948:5	there	EX	O	O
were	PRISTIQ.xml:S3:4954:4	were	VBD	O	O
suicides	PRISTIQ.xml:S3:4959:8	suicid	NNS	B-AdverseReaction	B-AdverseReaction
in	PRISTIQ.xml:S3:4968:2	in	IN	O	O
the	PRISTIQ.xml:S3:4971:3	the	DT	O	O
adult	PRISTIQ.xml:S3:4975:5	adult	NN	O	O
studies	PRISTIQ.xml:S3:4981:7	studi	NNS	O	O
,	PRISTIQ.xml:S3:4988:1	,	,	O	O
but	PRISTIQ.xml:S3:4990:3	but	CC	O	O
the	PRISTIQ.xml:S3:4994:3	the	DT	O	O
number	PRISTIQ.xml:S3:4998:6	number	NN	O	O
was	PRISTIQ.xml:S3:5005:3	wa	VBD	O	O
not	PRISTIQ.xml:S3:5009:3	not	RB	O	O
sufficient	PRISTIQ.xml:S3:5013:10	suffici	JJ	O	O
to	PRISTIQ.xml:S3:5024:2	to	TO	O	O
reach	PRISTIQ.xml:S3:5027:5	reach	VB	O	O
any	PRISTIQ.xml:S3:5033:3	ani	DT	O	O
conclusion	PRISTIQ.xml:S3:5037:10	conclus	NN	O	O
about	PRISTIQ.xml:S3:5048:5	about	IN	O	O
drug	PRISTIQ.xml:S3:5054:4	drug	NN	O	O
effect	PRISTIQ.xml:S3:5059:6	effect	NN	O	O
on	PRISTIQ.xml:S3:5066:2	on	IN	O	O
suicide	PRISTIQ.xml:S3:5069:7	suicid	NN	O	B-AdverseReaction
.	PRISTIQ.xml:S3:5076:1	.	.	O	O

It	PRISTIQ.xml:S3:5082:2	It	PRP	O	O

is	PRISTIQ.xml:S3:5085:2	is	VBZ	O	O
unknown	PRISTIQ.xml:S3:5088:7	unknown	JJ	O	O
whether	PRISTIQ.xml:S3:5096:7	whether	IN	O	O
the	PRISTIQ.xml:S3:5104:3	the	DT	O	O
suicidality	PRISTIQ.xml:S3:5108:11	suicid	NN	B-AdverseReaction	O
risk	PRISTIQ.xml:S3:5120:4	risk	NN	O	O
extends	PRISTIQ.xml:S3:5125:7	extend	VBZ	O	O
to	PRISTIQ.xml:S3:5133:2	to	TO	O	O
longer	PRISTIQ.xml:S3:5136:6	longer	RBR	O	O
-	PRISTIQ.xml:S3:5142:1	-	:	O	O
term	PRISTIQ.xml:S3:5143:4	term	NN	O	O
use	PRISTIQ.xml:S3:5148:3	use	NN	O	O
,	PRISTIQ.xml:S3:5151:1	,	,	O	O
i	PRISTIQ.xml:S3:5153:1	i	NN	O	O
.	PRISTIQ.xml:S3:5154:1	.	.	O	O
e	PRISTIQ.xml:S3:5155:1	e	NN	O	O
.	PRISTIQ.xml:S3:5156:1	.	.	O	O
,	PRISTIQ.xml:S3:5157:1	,	,	O	O
beyond	PRISTIQ.xml:S3:5159:6	beyond	IN	O	O
several	PRISTIQ.xml:S3:5166:7	sever	JJ	O	O
months	PRISTIQ.xml:S3:5174:6	month	NNS	O	O
.	PRISTIQ.xml:S3:5180:1	.	.	O	O

However	PRISTIQ.xml:S3:5182:7	howev	RB	O	O
,	PRISTIQ.xml:S3:5189:1	,	,	O	O
there	PRISTIQ.xml:S3:5191:5	there	EX	O	O
is	PRISTIQ.xml:S3:5197:2	is	VBZ	O	O
substantial	PRISTIQ.xml:S3:5200:11	substanti	JJ	O	O
evidence	PRISTIQ.xml:S3:5212:8	evid	NN	O	O
from	PRISTIQ.xml:S3:5221:4	from	IN	O	O
placebo	PRISTIQ.xml:S3:5226:7	placebo	NN	O	O
-	PRISTIQ.xml:S3:5233:1	-	:	O	O
controlled	PRISTIQ.xml:S3:5234:10	control	VBN	O	O
maintenance	PRISTIQ.xml:S3:5245:11	mainten	NN	O	O
studies	PRISTIQ.xml:S3:5257:7	studi	NNS	O	O
in	PRISTIQ.xml:S3:5265:2	in	IN	O	O
adults	PRISTIQ.xml:S3:5268:6	adult	NNS	O	O
with	PRISTIQ.xml:S3:5275:4	with	IN	O	O
depression	PRISTIQ.xml:S3:5280:10	depress	NN	O	O
that	PRISTIQ.xml:S3:5291:4	that	IN	O	O
the	PRISTIQ.xml:S3:5296:3	the	DT	O	O
use	PRISTIQ.xml:S3:5300:3	use	NN	O	O
of	PRISTIQ.xml:S3:5304:2	of	IN	O	O
antidepressants	PRISTIQ.xml:S3:5307:15	antidepress	NNS	O	O
can	PRISTIQ.xml:S3:5323:3	can	MD	O	O
delay	PRISTIQ.xml:S3:5327:5	delay	VB	O	O
the	PRISTIQ.xml:S3:5333:3	the	DT	O	O
recurrence	PRISTIQ.xml:S3:5337:10	recurr	NN	O	O
of	PRISTIQ.xml:S3:5348:2	of	IN	O	O
depression	PRISTIQ.xml:S3:5351:10	depress	NN	O	O
.	PRISTIQ.xml:S3:5361:1	.	.	O	O

All	PRISTIQ.xml:S3:5368:3	all	DT	O	O
patients	PRISTIQ.xml:S3:5372:8	patient	NNS	O	O
being	PRISTIQ.xml:S3:5381:5	be	VBG	O	O
treated	PRISTIQ.xml:S3:5387:7	treat	VBN	O	O
with	PRISTIQ.xml:S3:5395:4	with	IN	O	O
antidepressants	PRISTIQ.xml:S3:5400:15	antidepress	NNS	O	O
for	PRISTIQ.xml:S3:5416:3	for	IN	O	O
any	PRISTIQ.xml:S3:5420:3	ani	DT	O	O
indication	PRISTIQ.xml:S3:5424:10	indic	NN	O	O
should	PRISTIQ.xml:S3:5435:6	should	MD	O	O
be	PRISTIQ.xml:S3:5442:2	be	VB	O	O
monitored	PRISTIQ.xml:S3:5445:9	monitor	VBN	O	O
appropriately	PRISTIQ.xml:S3:5455:13	appropri	RB	O	O
and	PRISTIQ.xml:S3:5469:3	and	CC	O	O
observed	PRISTIQ.xml:S3:5473:8	observ	VBD	O	O
closely	PRISTIQ.xml:S3:5482:7	close	RB	O	O
for	PRISTIQ.xml:S3:5490:3	for	IN	O	O
clinical	PRISTIQ.xml:S3:5494:8	clinic	JJ	O	O
worsening	PRISTIQ.xml:S3:5503:9	worsen	NN	O	O
,	PRISTIQ.xml:S3:5512:1	,	,	O	O
suicidality	PRISTIQ.xml:S3:5514:11	suicid	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:5525:1	,	,	O	O
and	PRISTIQ.xml:S3:5527:3	and	CC	O	O
unusual	PRISTIQ.xml:S3:5531:7	unusu	JJ	O	B-AdverseReaction
changes	PRISTIQ.xml:S3:5539:7	chang	NNS	O	I-AdverseReaction
in	PRISTIQ.xml:S3:5547:2	in	IN	O	O
behavior	PRISTIQ.xml:S3:5550:8	behavior	NN	O	O
,	PRISTIQ.xml:S3:5558:1	,	,	O	O
especially	PRISTIQ.xml:S3:5560:10	especi	RB	O	O
during	PRISTIQ.xml:S3:5571:6	dure	IN	O	O
the	PRISTIQ.xml:S3:5578:3	the	DT	O	O
initial	PRISTIQ.xml:S3:5582:7	initi	JJ	O	O
few	PRISTIQ.xml:S3:5590:3	few	JJ	O	O
months	PRISTIQ.xml:S3:5594:6	month	NNS	O	O
of	PRISTIQ.xml:S3:5601:2	of	IN	O	O
a	PRISTIQ.xml:S3:5604:1	a	DT	O	O
course	PRISTIQ.xml:S3:5606:6	cours	NN	O	O
of	PRISTIQ.xml:S3:5613:2	of	IN	O	O
drug	PRISTIQ.xml:S3:5616:4	drug	NN	O	O
therapy	PRISTIQ.xml:S3:5621:7	therapi	NN	O	O
,	PRISTIQ.xml:S3:5628:1	,	,	O	O
or	PRISTIQ.xml:S3:5630:2	or	CC	O	O
at	PRISTIQ.xml:S3:5633:2	at	IN	O	O
times	PRISTIQ.xml:S3:5636:5	time	NNS	O	O
of	PRISTIQ.xml:S3:5642:2	of	IN	O	O
dose	PRISTIQ.xml:S3:5645:4	dose	JJ	O	O
changes	PRISTIQ.xml:S3:5650:7	chang	NNS	O	O
,	PRISTIQ.xml:S3:5657:1	,	,	O	O
either	PRISTIQ.xml:S3:5659:6	either	CC	O	O
increases	PRISTIQ.xml:S3:5666:9	increas	VBZ	O	O
or	PRISTIQ.xml:S3:5676:2	or	CC	O	O
decreases	PRISTIQ.xml:S3:5679:9	decreas	NNS	O	O
.	PRISTIQ.xml:S3:5688:1	.	.	O	O

The	PRISTIQ.xml:S3:5696:3	the	DT	O	O
following	PRISTIQ.xml:S3:5700:9	follow	NN	O	O
symptoms	PRISTIQ.xml:S3:5710:8	symptom	NNS	O	O
,	PRISTIQ.xml:S3:5718:1	,	,	O	O
anxiety	PRISTIQ.xml:S3:5720:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:5727:1	,	,	O	O
agitation	PRISTIQ.xml:S3:5729:9	agit	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:5738:1	,	,	O	O
panic	PRISTIQ.xml:S3:5740:5	panic	JJ	B-AdverseReaction	O
attacks	PRISTIQ.xml:S3:5746:7	attack	NNS	I-AdverseReaction	O
,	PRISTIQ.xml:S3:5753:1	,	,	O	O
insomnia	PRISTIQ.xml:S3:5755:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:5763:1	,	,	O	O
irritability	PRISTIQ.xml:S3:5765:12	irrit	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:5777:1	,	,	O	O
hostility	PRISTIQ.xml:S3:5779:9	hostil	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:5788:1	,	,	O	O
aggressiveness	PRISTIQ.xml:S3:5790:14	aggress	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:5804:1	,	,	O	O
impulsivity	PRISTIQ.xml:S3:5806:11	impuls	NN	B-AdverseReaction	O
,	PRISTIQ.xml:S3:5817:1	,	,	O	O
akathisia	PRISTIQ.xml:S3:5819:9	akathisia	NN	B-AdverseReaction	B-AdverseReaction
(	PRISTIQ.xml:S3:5829:1	(	(	O	O
psychomotor	PRISTIQ.xml:S3:5830:11	psychomotor	JJ	B-AdverseReaction	O
restlessness	PRISTIQ.xml:S3:5842:12	restless	NN	I-AdverseReaction	O
)	PRISTIQ.xml:S3:5854:1	)	)	O	O
,	PRISTIQ.xml:S3:5855:1	,	,	O	O
hypomania	PRISTIQ.xml:S3:5857:9	hypomania	UH	B-AdverseReaction	O
,	PRISTIQ.xml:S3:5866:1	,	,	O	O
and	PRISTIQ.xml:S3:5868:3	and	CC	O	O
mania	PRISTIQ.xml:S3:5872:5	mania	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:5877:1	,	,	O	O
have	PRISTIQ.xml:S3:5879:4	have	VBP	O	O
been	PRISTIQ.xml:S3:5884:4	been	VBN	O	O
reported	PRISTIQ.xml:S3:5889:8	report	VBN	O	O
in	PRISTIQ.xml:S3:5898:2	in	IN	O	O
adult	PRISTIQ.xml:S3:5901:5	adult	NN	O	O
and	PRISTIQ.xml:S3:5907:3	and	CC	O	O
pediatric	PRISTIQ.xml:S3:5911:9	pediatr	JJ	O	O
patients	PRISTIQ.xml:S3:5921:8	patient	NNS	O	O
being	PRISTIQ.xml:S3:5930:5	be	VBG	O	O
treated	PRISTIQ.xml:S3:5936:7	treat	VBN	O	O
with	PRISTIQ.xml:S3:5944:4	with	IN	O	O
antidepressants	PRISTIQ.xml:S3:5949:15	antidepress	NNS	O	O
for	PRISTIQ.xml:S3:5965:3	for	IN	O	O
major	PRISTIQ.xml:S3:5969:5	major	JJ	O	O
depressive	PRISTIQ.xml:S3:5975:10	depress	JJ	O	O
disorder	PRISTIQ.xml:S3:5986:8	disord	NN	O	O
as	PRISTIQ.xml:S3:5995:2	as	RB	O	O
well	PRISTIQ.xml:S3:5998:4	well	RB	O	O
as	PRISTIQ.xml:S3:6003:2	as	IN	O	O
for	PRISTIQ.xml:S3:6006:3	for	IN	O	O
other	PRISTIQ.xml:S3:6010:5	other	JJ	O	O
indications	PRISTIQ.xml:S3:6016:11	indic	NNS	O	O
,	PRISTIQ.xml:S3:6027:1	,	,	O	O
both	PRISTIQ.xml:S3:6029:4	both	DT	O	O
psychiatric	PRISTIQ.xml:S3:6034:11	psychiatr	JJ	O	O
and	PRISTIQ.xml:S3:6046:3	and	CC	O	O
nonpsychiatric	PRISTIQ.xml:S3:6050:14	nonpsychiatr	JJ	O	O
.	PRISTIQ.xml:S3:6064:1	.	.	O	O

Although	PRISTIQ.xml:S3:6066:8	although	IN	O	O
a	PRISTIQ.xml:S3:6075:1	a	DT	O	O
causal	PRISTIQ.xml:S3:6077:6	causal	NN	O	O
link	PRISTIQ.xml:S3:6084:4	link	NN	O	O
between	PRISTIQ.xml:S3:6089:7	between	IN	O	O
the	PRISTIQ.xml:S3:6097:3	the	DT	O	O
emergence	PRISTIQ.xml:S3:6101:9	emerg	NN	O	O
of	PRISTIQ.xml:S3:6111:2	of	IN	O	O
such	PRISTIQ.xml:S3:6114:4	such	JJ	O	O
symptoms	PRISTIQ.xml:S3:6119:8	symptom	NNS	O	O
and	PRISTIQ.xml:S3:6128:3	and	CC	O	O
either	PRISTIQ.xml:S3:6132:6	either	CC	O	O
the	PRISTIQ.xml:S3:6139:3	the	DT	O	O
worsening	PRISTIQ.xml:S3:6143:9	worsen	NN	B-AdverseReaction	O
of	PRISTIQ.xml:S3:6153:2	of	IN	I-AdverseReaction	O
depression	PRISTIQ.xml:S3:6156:10	depress	NN	I-AdverseReaction	O
and	PRISTIQ.xml:S3:6167:3	and	CC	O	O
or	PRISTIQ.xml:S3:6171:2	or	CC	O	O
the	PRISTIQ.xml:S3:6174:3	the	DT	O	O
emergence	PRISTIQ.xml:S3:6178:9	emerg	NN	O	O
of	PRISTIQ.xml:S3:6188:2	of	IN	O	O
suicidal	PRISTIQ.xml:S3:6191:8	suicid	NN	B-AdverseReaction	O
impulses	PRISTIQ.xml:S3:6200:8	impuls	NNS	I-AdverseReaction	O
has	PRISTIQ.xml:S3:6209:3	ha	VBZ	O	O
not	PRISTIQ.xml:S3:6213:3	not	RB	O	O
been	PRISTIQ.xml:S3:6217:4	been	VBN	O	O
established	PRISTIQ.xml:S3:6222:11	establish	VBN	O	O
,	PRISTIQ.xml:S3:6233:1	,	,	O	O
there	PRISTIQ.xml:S3:6235:5	there	EX	O	O
is	PRISTIQ.xml:S3:6241:2	is	VBZ	O	O
concern	PRISTIQ.xml:S3:6244:7	concern	NN	O	O
that	PRISTIQ.xml:S3:6252:4	that	IN	O	O
such	PRISTIQ.xml:S3:6257:4	such	JJ	O	O
symptoms	PRISTIQ.xml:S3:6262:8	symptom	NNS	O	O
may	PRISTIQ.xml:S3:6271:3	may	MD	O	O
represent	PRISTIQ.xml:S3:6275:9	repres	VB	O	O
precursors	PRISTIQ.xml:S3:6285:10	precursor	NNS	O	O
to	PRISTIQ.xml:S3:6296:2	to	TO	O	O
emerging	PRISTIQ.xml:S3:6299:8	emerg	VBG	O	O
suicidality	PRISTIQ.xml:S3:6308:11	suicid	NN	B-AdverseReaction	O
.	PRISTIQ.xml:S3:6319:1	.	.	O	O

Consideration	PRISTIQ.xml:S3:6325:13	consider	NN	O	O
should	PRISTIQ.xml:S3:6339:6	should	MD	O	O
be	PRISTIQ.xml:S3:6346:2	be	VB	O	O
given	PRISTIQ.xml:S3:6349:5	given	VBN	O	O
to	PRISTIQ.xml:S3:6355:2	to	TO	O	O
changing	PRISTIQ.xml:S3:6358:8	chang	VBG	O	O
the	PRISTIQ.xml:S3:6367:3	the	DT	O	O
therapeutic	PRISTIQ.xml:S3:6371:11	therapeut	JJ	O	O
regimen	PRISTIQ.xml:S3:6383:7	regimen	NNS	O	O
,	PRISTIQ.xml:S3:6390:1	,	,	O	O
including	PRISTIQ.xml:S3:6392:9	includ	VBG	O	O
possibly	PRISTIQ.xml:S3:6402:8	possibl	RB	O	O
discontinuing	PRISTIQ.xml:S3:6411:13	discontinu	VBG	O	O
the	PRISTIQ.xml:S3:6425:3	the	DT	O	O
medication	PRISTIQ.xml:S3:6429:10	medic	NN	O	O
,	PRISTIQ.xml:S3:6439:1	,	,	O	O
in	PRISTIQ.xml:S3:6441:2	in	IN	O	O
patients	PRISTIQ.xml:S3:6444:8	patient	NNS	O	O
whose	PRISTIQ.xml:S3:6453:5	whose	WP$	O	O
depression	PRISTIQ.xml:S3:6459:10	depress	NN	O	O
is	PRISTIQ.xml:S3:6470:2	is	VBZ	O	O
persistently	PRISTIQ.xml:S3:6473:12	persist	RB	O	O
worse	PRISTIQ.xml:S3:6486:5	wors	JJR	O	O
,	PRISTIQ.xml:S3:6491:1	,	,	O	O
or	PRISTIQ.xml:S3:6493:2	or	CC	O	O
who	PRISTIQ.xml:S3:6496:3	who	WP	O	O
are	PRISTIQ.xml:S3:6500:3	are	VBP	O	O
experiencing	PRISTIQ.xml:S3:6504:12	experienc	VBG	O	O
emergent	PRISTIQ.xml:S3:6517:8	emerg	JJ	O	O
suicidality	PRISTIQ.xml:S3:6526:11	suicid	NN	O	B-AdverseReaction
or	PRISTIQ.xml:S3:6538:2	or	CC	O	O
symptoms	PRISTIQ.xml:S3:6541:8	symptom	NNS	O	O
that	PRISTIQ.xml:S3:6550:4	that	WDT	O	O
might	PRISTIQ.xml:S3:6555:5	might	MD	O	O
be	PRISTIQ.xml:S3:6561:2	be	VB	O	O
precursors	PRISTIQ.xml:S3:6564:10	precursor	NNS	O	O
to	PRISTIQ.xml:S3:6575:2	to	TO	O	O
worsening	PRISTIQ.xml:S3:6578:9	worsen	VBG	O	O
depression	PRISTIQ.xml:S3:6588:10	depress	NN	O	B-AdverseReaction
or	PRISTIQ.xml:S3:6599:2	or	CC	O	O
suicidality	PRISTIQ.xml:S3:6602:11	suicid	NN	O	O
,	PRISTIQ.xml:S3:6613:1	,	,	O	O
especially	PRISTIQ.xml:S3:6615:10	especi	RB	O	O
if	PRISTIQ.xml:S3:6626:2	if	IN	O	O
these	PRISTIQ.xml:S3:6629:5	these	DT	O	O
symptoms	PRISTIQ.xml:S3:6635:8	symptom	NNS	O	O
are	PRISTIQ.xml:S3:6644:3	are	VBP	O	O
severe	PRISTIQ.xml:S3:6648:6	sever	JJ	O	O
,	PRISTIQ.xml:S3:6654:1	,	,	O	O
abrupt	PRISTIQ.xml:S3:6656:6	abrupt	JJ	O	O
in	PRISTIQ.xml:S3:6663:2	in	IN	O	O
onset	PRISTIQ.xml:S3:6666:5	onset	NN	O	O
,	PRISTIQ.xml:S3:6671:1	,	,	O	O
or	PRISTIQ.xml:S3:6673:2	or	CC	O	O
were	PRISTIQ.xml:S3:6676:4	were	VBD	O	O
not	PRISTIQ.xml:S3:6681:3	not	RB	O	O
part	PRISTIQ.xml:S3:6685:4	part	NN	O	O
of	PRISTIQ.xml:S3:6690:2	of	IN	O	O
the	PRISTIQ.xml:S3:6693:3	the	DT	O	O
patient	PRISTIQ.xml:S3:6697:7	patient	NN	O	O
's	PRISTIQ.xml:S3:6704:2	's	POS	O	O
presenting	PRISTIQ.xml:S3:6707:10	present	NN	O	O
symptoms	PRISTIQ.xml:S3:6718:8	symptom	NNS	O	O
.	PRISTIQ.xml:S3:6726:1	.	.	O	O

If	PRISTIQ.xml:S3:6732:2	If	IN	O	O
the	PRISTIQ.xml:S3:6735:3	the	DT	O	O
decision	PRISTIQ.xml:S3:6739:8	decis	NN	O	O
has	PRISTIQ.xml:S3:6748:3	ha	VBZ	O	O
been	PRISTIQ.xml:S3:6752:4	been	VBN	O	O
made	PRISTIQ.xml:S3:6757:4	made	VBN	O	O
to	PRISTIQ.xml:S3:6762:2	to	TO	O	O
discontinue	PRISTIQ.xml:S3:6765:11	discontinu	VB	O	O
treatment	PRISTIQ.xml:S3:6777:9	treatment	NN	O	O
,	PRISTIQ.xml:S3:6786:1	,	,	O	O
medication	PRISTIQ.xml:S3:6788:10	medic	NN	O	O
should	PRISTIQ.xml:S3:6799:6	should	MD	O	O
be	PRISTIQ.xml:S3:6806:2	be	VB	O	O
tapered	PRISTIQ.xml:S3:6809:7	taper	VBN	O	O
,	PRISTIQ.xml:S3:6816:1	,	,	O	O
as	PRISTIQ.xml:S3:6818:2	as	RB	O	O
rapidly	PRISTIQ.xml:S3:6821:7	rapidli	RB	O	O
as	PRISTIQ.xml:S3:6829:2	as	IN	O	O
is	PRISTIQ.xml:S3:6832:2	is	VBZ	O	O
feasible	PRISTIQ.xml:S3:6835:8	feasibl	JJ	O	O
,	PRISTIQ.xml:S3:6843:1	,	,	O	O
but	PRISTIQ.xml:S3:6845:3	but	CC	O	O
with	PRISTIQ.xml:S3:6849:4	with	IN	O	O
recognition	PRISTIQ.xml:S3:6854:11	recognit	NN	O	O
that	PRISTIQ.xml:S3:6866:4	that	IN	O	O
abrupt	PRISTIQ.xml:S3:6871:6	abrupt	JJ	O	O
discontinuation	PRISTIQ.xml:S3:6878:15	discontinu	NN	O	O
can	PRISTIQ.xml:S3:6894:3	can	MD	O	O
be	PRISTIQ.xml:S3:6898:2	be	VB	O	O
associated	PRISTIQ.xml:S3:6901:10	associ	VBN	O	O
with	PRISTIQ.xml:S3:6912:4	with	IN	O	O
certain	PRISTIQ.xml:S3:6917:7	certain	JJ	O	O
symptoms	PRISTIQ.xml:S3:6925:8	symptom	NNS	O	O
[	PRISTIQ.xml:S3:6934:1	[	MD	O	O
see	PRISTIQ.xml:S3:6935:3	see	VB	O	O
Dosage	PRISTIQ.xml:S3:6940:6	dosag	NNP	O	O
and	PRISTIQ.xml:S3:6947:3	and	CC	O	O
Administration	PRISTIQ.xml:S3:6951:14	administr	NNP	O	O
(	PRISTIQ.xml:S3:6966:1	(	(	O	O
2.4	PRISTIQ.xml:S3:6967:3	2.4	CD	O	O
)	PRISTIQ.xml:S3:6970:1	)	)	O	O
and	PRISTIQ.xml:S3:6973:3	and	CC	O	O
Warnings	PRISTIQ.xml:S3:6978:8	warn	NNP	O	O
and	PRISTIQ.xml:S3:6987:3	and	CC	O	O
Precautions	PRISTIQ.xml:S3:6991:11	precaut	NNP	O	O
(	PRISTIQ.xml:S3:7003:1	(	(	O	O
5.7	PRISTIQ.xml:S3:7004:3	5.7	CD	O	O
)	PRISTIQ.xml:S3:7007:1	)	)	O	O
for	PRISTIQ.xml:S3:7010:3	for	IN	O	O
a	PRISTIQ.xml:S3:7014:1	a	DT	O	O
description	PRISTIQ.xml:S3:7016:11	descript	NN	O	O
of	PRISTIQ.xml:S3:7028:2	of	IN	O	O
the	PRISTIQ.xml:S3:7031:3	the	DT	O	O
risks	PRISTIQ.xml:S3:7035:5	risk	NNS	O	O
of	PRISTIQ.xml:S3:7041:2	of	IN	O	O
discontinuation	PRISTIQ.xml:S3:7044:15	discontinu	NN	O	O
of	PRISTIQ.xml:S3:7060:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:7063:7	pristiq	NNP	O	O
]	PRISTIQ.xml:S3:7070:1	]	NNP	O	O
.	PRISTIQ.xml:S3:7073:1	.	.	O	O

Families	PRISTIQ.xml:S3:7080:8	famili	NNS	O	O
and	PRISTIQ.xml:S3:7089:3	and	CC	O	O
caregivers	PRISTIQ.xml:S3:7093:10	caregiv	NNS	O	O
of	PRISTIQ.xml:S3:7104:2	of	IN	O	O
patients	PRISTIQ.xml:S3:7107:8	patient	NNS	O	O
being	PRISTIQ.xml:S3:7116:5	be	VBG	O	O
treated	PRISTIQ.xml:S3:7122:7	treat	VBN	O	O
with	PRISTIQ.xml:S3:7130:4	with	IN	O	O
antidepressants	PRISTIQ.xml:S3:7135:15	antidepress	NNS	O	O
for	PRISTIQ.xml:S3:7151:3	for	IN	O	O
major	PRISTIQ.xml:S3:7155:5	major	JJ	O	O
depressive	PRISTIQ.xml:S3:7161:10	depress	JJ	O	O
disorder	PRISTIQ.xml:S3:7172:8	disord	NN	O	O
or	PRISTIQ.xml:S3:7181:2	or	CC	O	O
other	PRISTIQ.xml:S3:7184:5	other	JJ	O	O
indications	PRISTIQ.xml:S3:7190:11	indic	NNS	O	O
,	PRISTIQ.xml:S3:7201:1	,	,	O	O
both	PRISTIQ.xml:S3:7203:4	both	DT	O	O
psychiatric	PRISTIQ.xml:S3:7208:11	psychiatr	JJ	O	O
and	PRISTIQ.xml:S3:7220:3	and	CC	O	O
nonpsychiatric	PRISTIQ.xml:S3:7224:14	nonpsychiatr	JJ	O	O
,	PRISTIQ.xml:S3:7238:1	,	,	O	O
should	PRISTIQ.xml:S3:7240:6	should	MD	O	O
be	PRISTIQ.xml:S3:7247:2	be	VB	O	O
alerted	PRISTIQ.xml:S3:7250:7	alert	VBN	O	O
about	PRISTIQ.xml:S3:7258:5	about	IN	O	O
the	PRISTIQ.xml:S3:7264:3	the	DT	O	O
need	PRISTIQ.xml:S3:7268:4	need	NN	O	O
to	PRISTIQ.xml:S3:7273:2	to	TO	O	O
monitor	PRISTIQ.xml:S3:7276:7	monitor	VB	O	O
patients	PRISTIQ.xml:S3:7284:8	patient	NNS	O	O
for	PRISTIQ.xml:S3:7293:3	for	IN	O	O
the	PRISTIQ.xml:S3:7297:3	the	DT	O	O
emergence	PRISTIQ.xml:S3:7301:9	emerg	NN	O	O
of	PRISTIQ.xml:S3:7311:2	of	IN	O	O
agitation	PRISTIQ.xml:S3:7314:9	agit	NN	O	O
,	PRISTIQ.xml:S3:7323:1	,	,	O	O
irritability	PRISTIQ.xml:S3:7325:12	irrit	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:7337:1	,	,	O	O
unusual	PRISTIQ.xml:S3:7339:7	unusu	JJ	O	B-AdverseReaction
changes	PRISTIQ.xml:S3:7347:7	chang	NNS	O	I-AdverseReaction
in	PRISTIQ.xml:S3:7355:2	in	IN	O	O
behavior	PRISTIQ.xml:S3:7358:8	behavior	NN	O	O
,	PRISTIQ.xml:S3:7366:1	,	,	O	O
and	PRISTIQ.xml:S3:7368:3	and	CC	O	O
the	PRISTIQ.xml:S3:7372:3	the	DT	O	O
other	PRISTIQ.xml:S3:7376:5	other	JJ	O	O
symptoms	PRISTIQ.xml:S3:7382:8	symptom	NNS	O	O
described	PRISTIQ.xml:S3:7391:9	describ	VBN	O	O
above	PRISTIQ.xml:S3:7401:5	abov	RB	O	O
,	PRISTIQ.xml:S3:7406:1	,	,	O	O
as	PRISTIQ.xml:S3:7408:2	as	RB	O	O
well	PRISTIQ.xml:S3:7411:4	well	RB	O	O
as	PRISTIQ.xml:S3:7416:2	as	IN	O	O
the	PRISTIQ.xml:S3:7419:3	the	DT	O	O
emergence	PRISTIQ.xml:S3:7423:9	emerg	NN	O	O
of	PRISTIQ.xml:S3:7433:2	of	IN	O	O
suicidality	PRISTIQ.xml:S3:7436:11	suicid	NN	O	O
,	PRISTIQ.xml:S3:7447:1	,	,	O	O
and	PRISTIQ.xml:S3:7449:3	and	CC	O	O
to	PRISTIQ.xml:S3:7453:2	to	TO	O	O
report	PRISTIQ.xml:S3:7456:6	report	VB	O	O
such	PRISTIQ.xml:S3:7463:4	such	JJ	O	O
symptoms	PRISTIQ.xml:S3:7468:8	symptom	NNS	O	O
immediately	PRISTIQ.xml:S3:7477:11	immedi	RB	O	O
to	PRISTIQ.xml:S3:7489:2	to	TO	O	O
healthcare	PRISTIQ.xml:S3:7492:10	healthcar	VB	O	O
providers	PRISTIQ.xml:S3:7503:9	provid	NNS	O	O
.	PRISTIQ.xml:S3:7512:1	.	.	O	O

Such	PRISTIQ.xml:S3:7514:4	such	JJ	O	O
monitoring	PRISTIQ.xml:S3:7519:10	monitor	NN	O	O
should	PRISTIQ.xml:S3:7530:6	should	MD	O	O
include	PRISTIQ.xml:S3:7537:7	includ	VB	O	O
daily	PRISTIQ.xml:S3:7545:5	daili	JJ	O	O
observation	PRISTIQ.xml:S3:7551:11	observ	NN	O	O
by	PRISTIQ.xml:S3:7563:2	by	IN	O	O
families	PRISTIQ.xml:S3:7566:8	famili	NNS	O	O
and	PRISTIQ.xml:S3:7575:3	and	CC	O	O
caregivers	PRISTIQ.xml:S3:7579:10	caregiv	NNS	O	O
.	PRISTIQ.xml:S3:7591:1	.	.	O	O

Prescriptions	PRISTIQ.xml:S3:7597:13	prescript	NNS	O	O
for	PRISTIQ.xml:S3:7611:3	for	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:7615:7	pristiq	NNP	O	O
should	PRISTIQ.xml:S3:7623:6	should	MD	O	O
be	PRISTIQ.xml:S3:7630:2	be	VB	O	O
written	PRISTIQ.xml:S3:7633:7	written	VBN	O	O
for	PRISTIQ.xml:S3:7641:3	for	IN	O	O
the	PRISTIQ.xml:S3:7645:3	the	DT	O	O
smallest	PRISTIQ.xml:S3:7649:8	smallest	JJS	O	O
quantity	PRISTIQ.xml:S3:7658:8	quantiti	NN	O	O
of	PRISTIQ.xml:S3:7667:2	of	IN	O	O
tablets	PRISTIQ.xml:S3:7670:7	tablet	NNS	O	O
consistent	PRISTIQ.xml:S3:7678:10	consist	JJ	O	O
with	PRISTIQ.xml:S3:7689:4	with	IN	O	O
good	PRISTIQ.xml:S3:7694:4	good	JJ	O	O
patient	PRISTIQ.xml:S3:7699:7	patient	NN	O	O
management	PRISTIQ.xml:S3:7707:10	manag	NN	O	O
,	PRISTIQ.xml:S3:7717:1	,	,	O	O
in	PRISTIQ.xml:S3:7719:2	in	IN	O	O
order	PRISTIQ.xml:S3:7722:5	order	NN	O	O
to	PRISTIQ.xml:S3:7728:2	to	TO	O	O
reduce	PRISTIQ.xml:S3:7731:6	reduc	VB	O	O
the	PRISTIQ.xml:S3:7738:3	the	DT	O	O
risk	PRISTIQ.xml:S3:7742:4	risk	NN	O	O
of	PRISTIQ.xml:S3:7747:2	of	IN	O	O
overdose	PRISTIQ.xml:S3:7750:8	overdos	NN	O	O
.	PRISTIQ.xml:S3:7758:1	.	.	O	O

Screening	PRISTIQ.xml:S3:7767:9	screen	VBG	O	O
patients	PRISTIQ.xml:S3:7777:8	patient	NNS	O	O
for	PRISTIQ.xml:S3:7786:3	for	IN	O	O
bipolar	PRISTIQ.xml:S3:7790:7	bipolar	JJ	O	O
disorder	PRISTIQ.xml:S3:7798:8	disord	NN	O	O

A	PRISTIQ.xml:S3:7813:1	A	DT	O	O
major	PRISTIQ.xml:S3:7815:5	major	JJ	O	O
depressive	PRISTIQ.xml:S3:7821:10	depress	JJ	O	O
episode	PRISTIQ.xml:S3:7832:7	episod	NN	O	O
may	PRISTIQ.xml:S3:7840:3	may	MD	O	O
be	PRISTIQ.xml:S3:7844:2	be	VB	O	O
the	PRISTIQ.xml:S3:7847:3	the	DT	O	O
initial	PRISTIQ.xml:S3:7851:7	initi	JJ	O	O
presentation	PRISTIQ.xml:S3:7859:12	present	NN	O	O
of	PRISTIQ.xml:S3:7872:2	of	IN	O	O
bipolar	PRISTIQ.xml:S3:7875:7	bipolar	JJ	O	O
disorder	PRISTIQ.xml:S3:7883:8	disord	NN	O	O
.	PRISTIQ.xml:S3:7891:1	.	.	O	O

It	PRISTIQ.xml:S3:7893:2	It	PRP	O	O
is	PRISTIQ.xml:S3:7896:2	is	VBZ	O	O
generally	PRISTIQ.xml:S3:7899:9	gener	RB	O	O
believed	PRISTIQ.xml:S3:7909:8	believ	VBN	O	O
(	PRISTIQ.xml:S3:7918:1	(	(	O	O
though	PRISTIQ.xml:S3:7919:6	though	IN	O	O
not	PRISTIQ.xml:S3:7926:3	not	RB	O	O
established	PRISTIQ.xml:S3:7930:11	establish	VBN	O	O
in	PRISTIQ.xml:S3:7942:2	in	IN	O	O
controlled	PRISTIQ.xml:S3:7945:10	control	JJ	O	O
studies	PRISTIQ.xml:S3:7956:7	studi	NNS	O	O
)	PRISTIQ.xml:S3:7963:1	)	)	O	O
that	PRISTIQ.xml:S3:7965:4	that	IN	O	O
treating	PRISTIQ.xml:S3:7970:8	treat	VBG	O	O
such	PRISTIQ.xml:S3:7979:4	such	PDT	O	O
an	PRISTIQ.xml:S3:7984:2	an	DT	O	O
episode	PRISTIQ.xml:S3:7987:7	episod	NN	O	O
with	PRISTIQ.xml:S3:7995:4	with	IN	O	O
an	PRISTIQ.xml:S3:8000:2	an	DT	O	O
antidepressant	PRISTIQ.xml:S3:8003:14	antidepress	JJ	O	O
alone	PRISTIQ.xml:S3:8018:5	alon	NN	O	O
may	PRISTIQ.xml:S3:8024:3	may	MD	O	O
increase	PRISTIQ.xml:S3:8028:8	increas	VB	O	O
the	PRISTIQ.xml:S3:8037:3	the	DT	O	O
likelihood	PRISTIQ.xml:S3:8041:10	likelihood	NN	O	O
of	PRISTIQ.xml:S3:8052:2	of	IN	O	O
precipitation	PRISTIQ.xml:S3:8055:13	precipit	NN	B-AdverseReaction	O
of	PRISTIQ.xml:S3:8069:2	of	IN	I-AdverseReaction	O
a	PRISTIQ.xml:S3:8072:1	a	DT	I-AdverseReaction	O
mixed	PRISTIQ.xml:S3:8074:5	mix	JJ	I-AdverseReaction	O
manic	PRISTIQ.xml:S3:8080:5	manic	JJ	I-AdverseReaction	O
episode	PRISTIQ.xml:S3:8086:7	episod	NN	I-AdverseReaction	O
in	PRISTIQ.xml:S3:8094:2	in	IN	O	O
patients	PRISTIQ.xml:S3:8097:8	patient	NNS	O	O
at	PRISTIQ.xml:S3:8106:2	at	IN	O	O
risk	PRISTIQ.xml:S3:8109:4	risk	NN	O	O
for	PRISTIQ.xml:S3:8114:3	for	IN	O	O
bipolar	PRISTIQ.xml:S3:8118:7	bipolar	JJ	O	O
disorder	PRISTIQ.xml:S3:8126:8	disord	NN	O	O
.	PRISTIQ.xml:S3:8134:1	.	.	O	O

Whether	PRISTIQ.xml:S3:8136:7	whether	NNP	O	O
any	PRISTIQ.xml:S3:8144:3	ani	DT	O	O
of	PRISTIQ.xml:S3:8148:2	of	IN	O	O
the	PRISTIQ.xml:S3:8151:3	the	DT	O	O
symptoms	PRISTIQ.xml:S3:8155:8	symptom	NNS	O	O
described	PRISTIQ.xml:S3:8164:9	describ	VBN	O	O
above	PRISTIQ.xml:S3:8174:5	abov	IN	O	O
represent	PRISTIQ.xml:S3:8180:9	repres	NN	O	O
such	PRISTIQ.xml:S3:8190:4	such	PDT	O	O
a	PRISTIQ.xml:S3:8195:1	a	DT	O	O
conversion	PRISTIQ.xml:S3:8197:10	convers	NN	O	O
is	PRISTIQ.xml:S3:8208:2	is	VBZ	O	O
unknown	PRISTIQ.xml:S3:8211:7	unknown	JJ	O	O
.	PRISTIQ.xml:S3:8218:1	.	.	O	O

However	PRISTIQ.xml:S3:8220:7	howev	RB	O	O
,	PRISTIQ.xml:S3:8227:1	,	,	O	O
prior	PRISTIQ.xml:S3:8229:5	prior	RB	O	O
to	PRISTIQ.xml:S3:8235:2	to	TO	O	O
initiating	PRISTIQ.xml:S3:8238:10	initi	VBG	O	O
treatment	PRISTIQ.xml:S3:8249:9	treatment	NN	O	O
with	PRISTIQ.xml:S3:8259:4	with	IN	O	O
an	PRISTIQ.xml:S3:8264:2	an	DT	O	O
antidepressant	PRISTIQ.xml:S3:8267:14	antidepress	NN	O	O
,	PRISTIQ.xml:S3:8281:1	,	,	O	O
patients	PRISTIQ.xml:S3:8283:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:8292:4	with	IN	O	O
depressive	PRISTIQ.xml:S3:8297:10	depress	JJ	O	O
symptoms	PRISTIQ.xml:S3:8308:8	symptom	NNS	O	O
should	PRISTIQ.xml:S3:8317:6	should	MD	O	O
be	PRISTIQ.xml:S3:8324:2	be	VB	O	O
adequately	PRISTIQ.xml:S3:8327:10	adequ	RB	O	O
screened	PRISTIQ.xml:S3:8338:8	screen	VBN	O	O
to	PRISTIQ.xml:S3:8347:2	to	TO	O	O
determine	PRISTIQ.xml:S3:8350:9	determin	VB	O	O
if	PRISTIQ.xml:S3:8360:2	if	IN	O	O
they	PRISTIQ.xml:S3:8363:4	they	PRP	O	O
are	PRISTIQ.xml:S3:8368:3	are	VBP	O	O
at	PRISTIQ.xml:S3:8372:2	at	IN	O	O
risk	PRISTIQ.xml:S3:8375:4	risk	NN	O	O
for	PRISTIQ.xml:S3:8380:3	for	IN	O	O
bipolar	PRISTIQ.xml:S3:8384:7	bipolar	JJ	O	O
disorder	PRISTIQ.xml:S3:8392:8	disord	NN	O	O
;	PRISTIQ.xml:S3:8400:1	;	:	O	O
such	PRISTIQ.xml:S3:8402:4	such	JJ	O	O
screening	PRISTIQ.xml:S3:8407:9	screen	NN	O	O
should	PRISTIQ.xml:S3:8417:6	should	MD	O	O
include	PRISTIQ.xml:S3:8424:7	includ	VB	O	O
a	PRISTIQ.xml:S3:8432:1	a	DT	O	O
detailed	PRISTIQ.xml:S3:8434:8	detail	JJ	O	O
psychiatric	PRISTIQ.xml:S3:8443:11	psychiatr	JJ	O	O
history	PRISTIQ.xml:S3:8455:7	histori	NN	O	O
,	PRISTIQ.xml:S3:8462:1	,	,	O	O
including	PRISTIQ.xml:S3:8464:9	includ	VBG	O	O
a	PRISTIQ.xml:S3:8474:1	a	DT	O	O
family	PRISTIQ.xml:S3:8476:6	famili	NN	O	O
history	PRISTIQ.xml:S3:8483:7	histori	NN	O	O
of	PRISTIQ.xml:S3:8491:2	of	IN	O	O
suicide	PRISTIQ.xml:S3:8494:7	suicid	NN	O	O
,	PRISTIQ.xml:S3:8501:1	,	,	O	O
bipolar	PRISTIQ.xml:S3:8503:7	bipolar	JJ	O	B-AdverseReaction
disorder	PRISTIQ.xml:S3:8511:8	disord	NN	O	I-AdverseReaction
,	PRISTIQ.xml:S3:8519:1	,	,	O	O
and	PRISTIQ.xml:S3:8521:3	and	CC	O	O
depression	PRISTIQ.xml:S3:8525:10	depress	NN	O	B-AdverseReaction
.	PRISTIQ.xml:S3:8535:1	.	.	O	O

It	PRISTIQ.xml:S3:8537:2	It	PRP	O	O
should	PRISTIQ.xml:S3:8540:6	should	MD	O	O
be	PRISTIQ.xml:S3:8547:2	be	VB	O	O
noted	PRISTIQ.xml:S3:8550:5	note	VBN	O	O
that	PRISTIQ.xml:S3:8556:4	that	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:8561:7	pristiq	NNP	O	O
is	PRISTIQ.xml:S3:8569:2	is	VBZ	O	O
not	PRISTIQ.xml:S3:8572:3	not	RB	O	O
approved	PRISTIQ.xml:S3:8576:8	approv	VBN	O	O
for	PRISTIQ.xml:S3:8585:3	for	IN	O	O
use	PRISTIQ.xml:S3:8589:3	use	NN	O	O
in	PRISTIQ.xml:S3:8593:2	in	IN	O	O
treating	PRISTIQ.xml:S3:8596:8	treat	VBG	O	O
bipolar	PRISTIQ.xml:S3:8605:7	bipolar	JJ	O	O
depression	PRISTIQ.xml:S3:8613:10	depress	NN	O	O
.	PRISTIQ.xml:S3:8623:1	.	.	O	O

5.2	PRISTIQ.xml:S3:8632:3	5.2	CD	O	O
Serotonin	PRISTIQ.xml:S3:8636:9	serotonin	NNP	O	O
Syndrome	PRISTIQ.xml:S3:8646:8	syndrom	NNP	O	O

The	PRISTIQ.xml:S3:8660:3	the	DT	O	O
development	PRISTIQ.xml:S3:8664:11	develop	NN	O	O
of	PRISTIQ.xml:S3:8676:2	of	IN	O	O
a	PRISTIQ.xml:S3:8679:1	a	DT	O	O
potentially	PRISTIQ.xml:S3:8681:11	potenti	RB	O	O
life	PRISTIQ.xml:S3:8693:4	life	NN	O	O
-	PRISTIQ.xml:S3:8697:1	-	:	O	O
threatening	PRISTIQ.xml:S3:8698:11	threaten	VBG	O	O
serotonin	PRISTIQ.xml:S3:8710:9	serotonin	JJ	B-AdverseReaction	O
syndrome	PRISTIQ.xml:S3:8720:8	syndrom	NN	I-AdverseReaction	O
has	PRISTIQ.xml:S3:8729:3	ha	VBZ	O	O
been	PRISTIQ.xml:S3:8733:4	been	VBN	O	O
reported	PRISTIQ.xml:S3:8738:8	report	VBN	O	O
with	PRISTIQ.xml:S3:8747:4	with	IN	O	O
SNRIs	PRISTIQ.xml:S3:8752:5	snri	NNP	O	O
and	PRISTIQ.xml:S3:8758:3	and	CC	O	O
SSRIs	PRISTIQ.xml:S3:8762:5	ssri	NNP	O	O
,	PRISTIQ.xml:S3:8767:1	,	,	O	O
including	PRISTIQ.xml:S3:8769:9	includ	VBG	O	O
PRISTIQ	PRISTIQ.xml:S3:8779:7	pristiq	NNP	O	O
,	PRISTIQ.xml:S3:8786:1	,	,	O	O
alone	PRISTIQ.xml:S3:8788:5	alon	RB	O	O
but	PRISTIQ.xml:S3:8794:3	but	CC	O	O
particularly	PRISTIQ.xml:S3:8798:12	particularli	RB	O	O
with	PRISTIQ.xml:S3:8811:4	with	IN	O	O
concomitant	PRISTIQ.xml:S3:8816:11	concomit	JJ	O	O
use	PRISTIQ.xml:S3:8828:3	use	NN	O	O
of	PRISTIQ.xml:S3:8832:2	of	IN	O	O
other	PRISTIQ.xml:S3:8835:5	other	JJ	O	O
serotonergic	PRISTIQ.xml:S3:8841:12	serotonerg	JJ	O	O
drugs	PRISTIQ.xml:S3:8854:5	drug	NNS	O	O
(	PRISTIQ.xml:S3:8860:1	(	(	O	O
including	PRISTIQ.xml:S3:8861:9	includ	VBG	O	O
triptans	PRISTIQ.xml:S3:8871:8	triptan	NNS	O	O
,	PRISTIQ.xml:S3:8879:1	,	,	O	O
tricyclic	PRISTIQ.xml:S3:8881:9	tricycl	JJ	O	O
antidepressants	PRISTIQ.xml:S3:8891:15	antidepress	NNS	O	O
,	PRISTIQ.xml:S3:8906:1	,	,	O	O
fentanyl	PRISTIQ.xml:S3:8908:8	fentanyl	NN	O	O
,	PRISTIQ.xml:S3:8916:1	,	,	O	O
lithium	PRISTIQ.xml:S3:8918:7	lithium	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:8925:1	,	,	O	O
tramadol	PRISTIQ.xml:S3:8927:8	tramadol	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:8935:1	,	,	O	O
tryptophan	PRISTIQ.xml:S3:8937:10	tryptophan	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:8947:1	,	,	O	O
buspirone	PRISTIQ.xml:S3:8949:9	buspiron	NN	O	O
,	PRISTIQ.xml:S3:8958:1	,	,	O	O
and	PRISTIQ.xml:S3:8960:3	and	CC	O	O
St	PRISTIQ.xml:S3:8964:2	St	NNP	O	O
.	PRISTIQ.xml:S3:8966:1	.	.	O	O

John	PRISTIQ.xml:S3:8968:4	john	NNP	O	O
's	PRISTIQ.xml:S3:8972:2	's	POS	O	O
Wort	PRISTIQ.xml:S3:8975:4	wort	NNP	O	O
)	PRISTIQ.xml:S3:8979:1	)	)	O	O
,	PRISTIQ.xml:S3:8980:1	,	,	O	O
and	PRISTIQ.xml:S3:8982:3	and	CC	O	O
with	PRISTIQ.xml:S3:8986:4	with	IN	O	O
drugs	PRISTIQ.xml:S3:8991:5	drug	NNS	O	O
that	PRISTIQ.xml:S3:8997:4	that	WDT	O	O
impair	PRISTIQ.xml:S3:9002:6	impair	VBP	O	O
metabolism	PRISTIQ.xml:S3:9009:10	metabol	NN	O	O
of	PRISTIQ.xml:S3:9020:2	of	IN	O	O
serotonin	PRISTIQ.xml:S3:9023:9	serotonin	NN	O	O
(	PRISTIQ.xml:S3:9033:1	(	(	O	O
in	PRISTIQ.xml:S3:9034:2	in	IN	O	O
particular	PRISTIQ.xml:S3:9037:10	particular	NN	O	O
,	PRISTIQ.xml:S3:9047:1	,	,	O	O
MAOIs	PRISTIQ.xml:S3:9049:5	maoi	NNP	O	O
,	PRISTIQ.xml:S3:9054:1	,	,	O	O
both	PRISTIQ.xml:S3:9056:4	both	DT	O	O
those	PRISTIQ.xml:S3:9061:5	those	DT	O	O
intended	PRISTIQ.xml:S3:9067:8	intend	VBN	O	O
to	PRISTIQ.xml:S3:9076:2	to	TO	O	O
treat	PRISTIQ.xml:S3:9079:5	treat	VB	O	O
psychiatric	PRISTIQ.xml:S3:9085:11	psychiatr	JJ	O	O
disorders	PRISTIQ.xml:S3:9097:9	disord	NNS	O	O
and	PRISTIQ.xml:S3:9107:3	and	CC	O	O
also	PRISTIQ.xml:S3:9111:4	also	RB	O	O
others	PRISTIQ.xml:S3:9116:6	other	NNS	O	O
,	PRISTIQ.xml:S3:9122:1	,	,	O	O
such	PRISTIQ.xml:S3:9124:4	such	JJ	O	O
as	PRISTIQ.xml:S3:9129:2	as	IN	O	O
linezolid	PRISTIQ.xml:S3:9132:9	linezolid	JJ	O	O
and	PRISTIQ.xml:S3:9142:3	and	CC	O	O
intravenous	PRISTIQ.xml:S3:9146:11	intraven	JJ	O	O
methylene	PRISTIQ.xml:S3:9158:9	methylen	NN	O	O
blue	PRISTIQ.xml:S3:9168:4	blue	NN	O	O
)	PRISTIQ.xml:S3:9172:1	)	)	O	O
.	PRISTIQ.xml:S3:9173:1	.	.	O	O

Serotonin	PRISTIQ.xml:S3:9179:9	serotonin	NNP	B-AdverseReaction	O
syndrome	PRISTIQ.xml:S3:9189:8	syndrom	NN	I-AdverseReaction	O
symptoms	PRISTIQ.xml:S3:9198:8	symptom	NNS	O	O
may	PRISTIQ.xml:S3:9207:3	may	MD	O	O
include	PRISTIQ.xml:S3:9211:7	includ	VB	O	O
mental	PRISTIQ.xml:S3:9219:6	mental	JJ	B-AdverseReaction	B-AdverseReaction
status	PRISTIQ.xml:S3:9226:6	statu	NN	I-AdverseReaction	I-AdverseReaction
changes	PRISTIQ.xml:S3:9233:7	chang	NNS	I-AdverseReaction	I-AdverseReaction
(	PRISTIQ.xml:S3:9241:1	(	(	O	O
e	PRISTIQ.xml:S3:9242:1	e	NN	O	O
.	PRISTIQ.xml:S3:9243:1	.	.	O	O
g	PRISTIQ.xml:S3:9244:1	g	NN	O	O
.	PRISTIQ.xml:S3:9245:1	.	.	O	O
,	PRISTIQ.xml:S3:9246:1	,	,	O	O
agitation	PRISTIQ.xml:S3:9248:9	agit	NN	B-AdverseReaction	O
,	PRISTIQ.xml:S3:9257:1	,	,	O	O
hallucinations	PRISTIQ.xml:S3:9259:14	hallucin	NNS	B-AdverseReaction	O
,	PRISTIQ.xml:S3:9273:1	,	,	O	O
delirium	PRISTIQ.xml:S3:9275:8	delirium	NN	B-AdverseReaction	O
,	PRISTIQ.xml:S3:9283:1	,	,	O	O
and	PRISTIQ.xml:S3:9285:3	and	CC	O	O
coma	PRISTIQ.xml:S3:9289:4	coma	NN	B-AdverseReaction	B-AdverseReaction
)	PRISTIQ.xml:S3:9293:1	)	)	O	O
,	PRISTIQ.xml:S3:9294:1	,	,	O	O
autonomic	PRISTIQ.xml:S3:9296:9	autonom	JJ	B-AdverseReaction	B-AdverseReaction
instability	PRISTIQ.xml:S3:9306:11	instabl	NN	I-AdverseReaction	I-AdverseReaction
(	PRISTIQ.xml:S3:9318:1	(	(	O	O
e	PRISTIQ.xml:S3:9319:1	e	NN	O	O
.	PRISTIQ.xml:S3:9320:1	.	.	O	O
g	PRISTIQ.xml:S3:9321:1	g	NN	O	O
.	PRISTIQ.xml:S3:9322:1	.	.	O	O
,	PRISTIQ.xml:S3:9323:1	,	,	O	O
tachycardia	PRISTIQ.xml:S3:9325:11	tachycardia	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:9336:1	,	,	O	O
labile	PRISTIQ.xml:S3:9338:6	labil	JJ	B-AdverseReaction	B-AdverseReaction
blood	PRISTIQ.xml:S3:9345:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	PRISTIQ.xml:S3:9351:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S3:9359:1	,	,	O	O
dizziness	PRISTIQ.xml:S3:9361:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:9370:1	,	,	O	O
diaphoresis	PRISTIQ.xml:S3:9372:11	diaphoresi	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:9383:1	,	,	O	O
flushing	PRISTIQ.xml:S3:9385:8	flush	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:9393:1	,	,	O	O
hyperthermia	PRISTIQ.xml:S3:9395:12	hyperthermia	NN	B-AdverseReaction	O
)	PRISTIQ.xml:S3:9407:1	)	)	O	O
,	PRISTIQ.xml:S3:9408:1	,	,	O	O
neuromuscular	PRISTIQ.xml:S3:9410:13	neuromuscular	JJ	B-AdverseReaction	O
symptoms	PRISTIQ.xml:S3:9424:8	symptom	NNS	I-AdverseReaction	O
(	PRISTIQ.xml:S3:9433:1	(	(	O	O
e	PRISTIQ.xml:S3:9434:1	e	NN	O	O
.	PRISTIQ.xml:S3:9435:1	.	.	O	O
g	PRISTIQ.xml:S3:9436:1	g	NN	O	O
.	PRISTIQ.xml:S3:9437:1	.	.	O	O
,	PRISTIQ.xml:S3:9438:1	,	,	O	O
tremor	PRISTIQ.xml:S3:9440:6	tremor	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:9446:1	,	,	O	O
rigidity	PRISTIQ.xml:S3:9448:8	rigid	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:9456:1	,	,	O	O
myoclonus	PRISTIQ.xml:S3:9458:9	myoclonu	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:9467:1	,	,	O	O
hyperreflexia	PRISTIQ.xml:S3:9469:13	hyperreflexia	NN	B-AdverseReaction	O
,	PRISTIQ.xml:S3:9482:1	,	,	O	O
incoordination	PRISTIQ.xml:S3:9484:14	incoordin	NN	B-AdverseReaction	O
)	PRISTIQ.xml:S3:9498:1	)	)	O	O
,	PRISTIQ.xml:S3:9499:1	,	,	O	O
seizures	PRISTIQ.xml:S3:9501:8	seizur	VBZ	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:9509:1	,	,	O	O
and	PRISTIQ.xml:S3:9511:3	and	CC	O	O
or	PRISTIQ.xml:S3:9515:2	or	CC	O	O
gastrointestinal	PRISTIQ.xml:S3:9518:16	gastrointestin	JJ	B-AdverseReaction	O
symptoms	PRISTIQ.xml:S3:9535:8	symptom	NNS	I-AdverseReaction	O
(	PRISTIQ.xml:S3:9544:1	(	(	O	O
e	PRISTIQ.xml:S3:9545:1	e	NN	O	O
.	PRISTIQ.xml:S3:9546:1	.	.	O	O
g	PRISTIQ.xml:S3:9547:1	g	NN	O	O
.	PRISTIQ.xml:S3:9548:1	.	.	O	O
,	PRISTIQ.xml:S3:9549:1	,	,	O	O
nausea	PRISTIQ.xml:S3:9551:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:9557:1	,	,	O	O
vomiting	PRISTIQ.xml:S3:9559:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:9567:1	,	,	O	O
diarrhea	PRISTIQ.xml:S3:9569:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
)	PRISTIQ.xml:S3:9577:1	)	)	O	O
.	PRISTIQ.xml:S3:9578:1	.	.	O	O

Patients	PRISTIQ.xml:S3:9580:8	patient	NNS	O	O
should	PRISTIQ.xml:S3:9589:6	should	MD	O	O
be	PRISTIQ.xml:S3:9596:2	be	VB	O	O
monitored	PRISTIQ.xml:S3:9599:9	monitor	VBN	O	O
for	PRISTIQ.xml:S3:9609:3	for	IN	O	O
the	PRISTIQ.xml:S3:9613:3	the	DT	O	O
emergence	PRISTIQ.xml:S3:9617:9	emerg	NN	O	O
of	PRISTIQ.xml:S3:9627:2	of	IN	O	O
serotonin	PRISTIQ.xml:S3:9630:9	serotonin	JJ	O	O
syndrome	PRISTIQ.xml:S3:9640:8	syndrom	NN	O	O
.	PRISTIQ.xml:S3:9648:1	.	.	O	O

The	PRISTIQ.xml:S3:9654:3	the	DT	O	O
concomitant	PRISTIQ.xml:S3:9658:11	concomit	NN	O	O
use	PRISTIQ.xml:S3:9670:3	use	NN	O	O
of	PRISTIQ.xml:S3:9674:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:9677:7	pristiq	NNP	O	O
with	PRISTIQ.xml:S3:9685:4	with	IN	O	O
MAOIs	PRISTIQ.xml:S3:9690:5	maoi	NNP	O	O
intended	PRISTIQ.xml:S3:9696:8	intend	VBD	O	O
to	PRISTIQ.xml:S3:9705:2	to	TO	O	O
treat	PRISTIQ.xml:S3:9708:5	treat	VB	O	O
psychiatric	PRISTIQ.xml:S3:9714:11	psychiatr	JJ	O	O
disorders	PRISTIQ.xml:S3:9726:9	disord	NNS	O	O
is	PRISTIQ.xml:S3:9736:2	is	VBZ	O	O
contraindicated	PRISTIQ.xml:S3:9739:15	contraind	VBN	O	O
.	PRISTIQ.xml:S3:9754:1	.	.	O	O

PRISTIQ	PRISTIQ.xml:S3:9756:7	pristiq	NNP	O	O
should	PRISTIQ.xml:S3:9764:6	should	MD	O	O
also	PRISTIQ.xml:S3:9771:4	also	RB	O	O
not	PRISTIQ.xml:S3:9776:3	not	RB	O	O
be	PRISTIQ.xml:S3:9780:2	be	VB	O	O
started	PRISTIQ.xml:S3:9783:7	start	VBN	O	O
in	PRISTIQ.xml:S3:9791:2	in	IN	O	O
a	PRISTIQ.xml:S3:9794:1	a	DT	O	O
patient	PRISTIQ.xml:S3:9796:7	patient	NN	O	O
who	PRISTIQ.xml:S3:9804:3	who	WP	O	O
is	PRISTIQ.xml:S3:9808:2	is	VBZ	O	O
being	PRISTIQ.xml:S3:9811:5	be	VBG	O	O
treated	PRISTIQ.xml:S3:9817:7	treat	VBN	O	O
with	PRISTIQ.xml:S3:9825:4	with	IN	O	O
MAOIs	PRISTIQ.xml:S3:9830:5	maoi	NNP	O	O
such	PRISTIQ.xml:S3:9836:4	such	JJ	O	O
as	PRISTIQ.xml:S3:9841:2	as	IN	O	O
linezolid	PRISTIQ.xml:S3:9844:9	linezolid	JJ	O	O
or	PRISTIQ.xml:S3:9854:2	or	CC	O	O
intravenous	PRISTIQ.xml:S3:9857:11	intraven	JJ	O	O
methylene	PRISTIQ.xml:S3:9869:9	methylen	NN	O	O
blue	PRISTIQ.xml:S3:9879:4	blue	NN	O	O
.	PRISTIQ.xml:S3:9883:1	.	.	O	O

All	PRISTIQ.xml:S3:9885:3	all	DT	O	O
reports	PRISTIQ.xml:S3:9889:7	report	NNS	O	O
with	PRISTIQ.xml:S3:9897:4	with	IN	O	O
methylene	PRISTIQ.xml:S3:9902:9	methylen	JJ	O	O
blue	PRISTIQ.xml:S3:9912:4	blue	NN	O	O
that	PRISTIQ.xml:S3:9917:4	that	WDT	O	O
provided	PRISTIQ.xml:S3:9922:8	provid	VBD	O	O
information	PRISTIQ.xml:S3:9931:11	inform	NN	O	O
on	PRISTIQ.xml:S3:9943:2	on	IN	O	O
the	PRISTIQ.xml:S3:9946:3	the	DT	O	O
route	PRISTIQ.xml:S3:9950:5	rout	NN	O	O
of	PRISTIQ.xml:S3:9956:2	of	IN	O	O
administration	PRISTIQ.xml:S3:9959:14	administr	NN	O	O
involved	PRISTIQ.xml:S3:9974:8	involv	VBN	O	O
intravenous	PRISTIQ.xml:S3:9983:11	intraven	JJ	O	O
administration	PRISTIQ.xml:S3:9995:14	administr	NN	O	O
in	PRISTIQ.xml:S3:10010:2	in	IN	O	O
the	PRISTIQ.xml:S3:10013:3	the	DT	O	O
dose	PRISTIQ.xml:S3:10017:4	dose	JJ	O	O
range	PRISTIQ.xml:S3:10022:5	rang	NN	O	O
of	PRISTIQ.xml:S3:10028:2	of	IN	O	O
1	PRISTIQ.xml:S3:10031:1	1	CD	O	O
mg	PRISTIQ.xml:S3:10033:2	mg	NNS	O	O
kg	PRISTIQ.xml:S3:10036:2	kg	VBD	O	O
to	PRISTIQ.xml:S3:10039:2	to	TO	O	O
8	PRISTIQ.xml:S3:10042:1	8	CD	O	O
mg	PRISTIQ.xml:S3:10044:2	mg	NN	O	O
kg	PRISTIQ.xml:S3:10047:2	kg	NN	O	O
.	PRISTIQ.xml:S3:10049:1	.	.	O	O

No	PRISTIQ.xml:S3:10051:2	No	DT	O	O
reports	PRISTIQ.xml:S3:10054:7	report	NNS	O	O
involved	PRISTIQ.xml:S3:10062:8	involv	VBD	O	O
the	PRISTIQ.xml:S3:10071:3	the	DT	O	O
administration	PRISTIQ.xml:S3:10075:14	administr	NN	O	O
of	PRISTIQ.xml:S3:10090:2	of	IN	O	O
methylene	PRISTIQ.xml:S3:10093:9	methylen	JJ	O	O
blue	PRISTIQ.xml:S3:10103:4	blue	NN	O	O
by	PRISTIQ.xml:S3:10108:2	by	IN	O	O
other	PRISTIQ.xml:S3:10111:5	other	JJ	O	O
routes	PRISTIQ.xml:S3:10117:6	rout	NNS	O	O
(	PRISTIQ.xml:S3:10124:1	(	(	O	O
such	PRISTIQ.xml:S3:10125:4	such	JJ	O	O
as	PRISTIQ.xml:S3:10130:2	as	IN	O	O
oral	PRISTIQ.xml:S3:10133:4	oral	JJ	O	O
tablets	PRISTIQ.xml:S3:10138:7	tablet	NNS	O	O
or	PRISTIQ.xml:S3:10146:2	or	CC	O	O
local	PRISTIQ.xml:S3:10149:5	local	JJ	O	O
tissue	PRISTIQ.xml:S3:10155:6	tissu	NN	O	O
injection	PRISTIQ.xml:S3:10162:9	inject	NN	O	O
)	PRISTIQ.xml:S3:10171:1	)	)	O	O
or	PRISTIQ.xml:S3:10173:2	or	CC	O	O
at	PRISTIQ.xml:S3:10176:2	at	IN	O	O
lower	PRISTIQ.xml:S3:10179:5	lower	JJR	O	O
doses	PRISTIQ.xml:S3:10185:5	dose	NNS	O	O
.	PRISTIQ.xml:S3:10190:1	.	.	O	O

There	PRISTIQ.xml:S3:10192:5	there	EX	O	O
may	PRISTIQ.xml:S3:10198:3	may	MD	O	O
be	PRISTIQ.xml:S3:10202:2	be	VB	O	O
circumstances	PRISTIQ.xml:S3:10205:13	circumst	NNS	O	O
when	PRISTIQ.xml:S3:10219:4	when	WRB	O	O
it	PRISTIQ.xml:S3:10224:2	it	PRP	O	O
is	PRISTIQ.xml:S3:10227:2	is	VBZ	O	O
necessary	PRISTIQ.xml:S3:10230:9	necessari	JJ	O	O
to	PRISTIQ.xml:S3:10240:2	to	TO	O	O
initiate	PRISTIQ.xml:S3:10243:8	initi	VB	O	O
treatment	PRISTIQ.xml:S3:10252:9	treatment	NN	O	O
with	PRISTIQ.xml:S3:10262:4	with	IN	O	O
a	PRISTIQ.xml:S3:10267:1	a	DT	O	O
MAOI	PRISTIQ.xml:S3:10269:4	maoi	NNP	O	O
such	PRISTIQ.xml:S3:10274:4	such	JJ	O	O
as	PRISTIQ.xml:S3:10279:2	as	IN	O	O
linezolid	PRISTIQ.xml:S3:10282:9	linezolid	JJ	O	O
or	PRISTIQ.xml:S3:10292:2	or	CC	O	O
intravenous	PRISTIQ.xml:S3:10295:11	intraven	JJ	O	O
methylene	PRISTIQ.xml:S3:10307:9	methylen	NN	O	O
blue	PRISTIQ.xml:S3:10317:4	blue	NN	O	O
in	PRISTIQ.xml:S3:10322:2	in	IN	O	O
a	PRISTIQ.xml:S3:10325:1	a	DT	O	O
patient	PRISTIQ.xml:S3:10327:7	patient	NN	O	O
taking	PRISTIQ.xml:S3:10335:6	take	VBG	O	O
PRISTIQ	PRISTIQ.xml:S3:10342:7	pristiq	NNP	O	O
.	PRISTIQ.xml:S3:10349:1	.	.	O	O

PRISTIQ	PRISTIQ.xml:S3:10351:7	pristiq	NNP	O	O
should	PRISTIQ.xml:S3:10359:6	should	MD	O	O
be	PRISTIQ.xml:S3:10366:2	be	VB	O	O
discontinued	PRISTIQ.xml:S3:10369:12	discontinu	VBN	O	O
before	PRISTIQ.xml:S3:10382:6	befor	IN	O	O
initiating	PRISTIQ.xml:S3:10389:10	initi	VBG	O	O
treatment	PRISTIQ.xml:S3:10400:9	treatment	NN	O	O
with	PRISTIQ.xml:S3:10410:4	with	IN	O	O
the	PRISTIQ.xml:S3:10415:3	the	DT	O	O
MAOI	PRISTIQ.xml:S3:10419:4	maoi	NNP	O	O
[	PRISTIQ.xml:S3:10424:1	[	NNP	O	O
see	PRISTIQ.xml:S3:10425:3	see	VBP	O	O
Contraindications	PRISTIQ.xml:S3:10429:17	contraind	NNP	O	O
(	PRISTIQ.xml:S3:10447:1	(	(	O	O
4.2	PRISTIQ.xml:S3:10448:3	4.2	CD	O	O
)	PRISTIQ.xml:S3:10451:1	)	)	O	O
and	PRISTIQ.xml:S3:10454:3	and	CC	O	O
Dosage	PRISTIQ.xml:S3:10460:6	dosag	NNP	O	O
and	PRISTIQ.xml:S3:10467:3	and	CC	O	O
Administration	PRISTIQ.xml:S3:10471:14	administr	NNP	O	O
(	PRISTIQ.xml:S3:10486:1	(	(	O	O
2.6	PRISTIQ.xml:S3:10487:3	2.6	CD	O	O
)	PRISTIQ.xml:S3:10490:1	)	)	O	O
]	PRISTIQ.xml:S3:10493:1	]	NN	O	O
.	PRISTIQ.xml:S3:10496:1	.	.	O	O

If	PRISTIQ.xml:S3:10502:2	If	IN	O	O
concomitant	PRISTIQ.xml:S3:10505:11	concomit	JJ	O	O
use	PRISTIQ.xml:S3:10517:3	use	NN	O	O
of	PRISTIQ.xml:S3:10521:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:10524:7	pristiq	NNP	O	O
with	PRISTIQ.xml:S3:10532:4	with	IN	O	O
other	PRISTIQ.xml:S3:10537:5	other	JJ	O	O
serotonergic	PRISTIQ.xml:S3:10543:12	serotonerg	JJ	O	O
drugs	PRISTIQ.xml:S3:10556:5	drug	NNS	O	O
,	PRISTIQ.xml:S3:10561:1	,	,	O	O
including	PRISTIQ.xml:S3:10563:9	includ	VBG	O	O
triptans	PRISTIQ.xml:S3:10573:8	triptan	NNS	O	O
,	PRISTIQ.xml:S3:10581:1	,	,	O	O
tricyclic	PRISTIQ.xml:S3:10583:9	tricycl	JJ	O	O
antidepressants	PRISTIQ.xml:S3:10593:15	antidepress	NNS	O	O
,	PRISTIQ.xml:S3:10608:1	,	,	O	O
fentanyl	PRISTIQ.xml:S3:10610:8	fentanyl	NN	O	O
,	PRISTIQ.xml:S3:10618:1	,	,	O	O
lithium	PRISTIQ.xml:S3:10620:7	lithium	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:10627:1	,	,	O	O
tramadol	PRISTIQ.xml:S3:10629:8	tramadol	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:10637:1	,	,	O	O
buspirone	PRISTIQ.xml:S3:10639:9	buspiron	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:10648:1	,	,	O	O
tryptophan	PRISTIQ.xml:S3:10650:10	tryptophan	NN	O	O
,	PRISTIQ.xml:S3:10660:1	,	,	O	O
and	PRISTIQ.xml:S3:10662:3	and	CC	O	O
St	PRISTIQ.xml:S3:10666:2	St	NNP	O	O
.	PRISTIQ.xml:S3:10668:1	.	.	O	O

John	PRISTIQ.xml:S3:10670:4	john	NNP	O	O
's	PRISTIQ.xml:S3:10674:2	's	POS	O	O
Wort	PRISTIQ.xml:S3:10677:4	wort	NNP	O	O
is	PRISTIQ.xml:S3:10682:2	is	VBZ	O	O
clinically	PRISTIQ.xml:S3:10685:10	clinic	RB	O	O
warranted	PRISTIQ.xml:S3:10696:9	warrant	VBN	O	O
,	PRISTIQ.xml:S3:10705:1	,	,	O	O
patients	PRISTIQ.xml:S3:10707:8	patient	NNS	O	O
should	PRISTIQ.xml:S3:10716:6	should	MD	O	O
be	PRISTIQ.xml:S3:10723:2	be	VB	O	O
made	PRISTIQ.xml:S3:10726:4	made	VBN	O	O
aware	PRISTIQ.xml:S3:10731:5	awar	JJ	O	O
of	PRISTIQ.xml:S3:10737:2	of	IN	O	O
a	PRISTIQ.xml:S3:10740:1	a	DT	O	O
potential	PRISTIQ.xml:S3:10742:9	potenti	NN	O	O
increased	PRISTIQ.xml:S3:10752:9	increas	VBN	O	O
risk	PRISTIQ.xml:S3:10762:4	risk	NN	O	O
for	PRISTIQ.xml:S3:10767:3	for	IN	O	O
serotonin	PRISTIQ.xml:S3:10771:9	serotonin	JJ	O	B-AdverseReaction
syndrome	PRISTIQ.xml:S3:10781:8	syndrom	NN	O	I-AdverseReaction
,	PRISTIQ.xml:S3:10789:1	,	,	O	O
particularly	PRISTIQ.xml:S3:10791:12	particularli	RB	O	O
during	PRISTIQ.xml:S3:10804:6	dure	IN	O	O
treatment	PRISTIQ.xml:S3:10811:9	treatment	NN	O	O
initiation	PRISTIQ.xml:S3:10821:10	initi	NN	O	O
and	PRISTIQ.xml:S3:10832:3	and	CC	O	O
dose	PRISTIQ.xml:S3:10836:4	dose	JJ	O	O
increases	PRISTIQ.xml:S3:10841:9	increas	NNS	O	O
.	PRISTIQ.xml:S3:10850:1	.	.	O	O

Treatment	PRISTIQ.xml:S3:10856:9	treatment	NN	O	O
with	PRISTIQ.xml:S3:10866:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:10871:7	pristiq	NNP	O	O
and	PRISTIQ.xml:S3:10879:3	and	CC	O	O
any	PRISTIQ.xml:S3:10883:3	ani	DT	O	O
concomitant	PRISTIQ.xml:S3:10887:11	concomit	JJ	O	O
serotonergic	PRISTIQ.xml:S3:10899:12	serotonerg	JJ	O	O
agents	PRISTIQ.xml:S3:10912:6	agent	NNS	O	O
should	PRISTIQ.xml:S3:10919:6	should	MD	O	O
be	PRISTIQ.xml:S3:10926:2	be	VB	O	O
discontinued	PRISTIQ.xml:S3:10929:12	discontinu	VBN	O	O
immediately	PRISTIQ.xml:S3:10942:11	immedi	RB	O	O
if	PRISTIQ.xml:S3:10954:2	if	IN	O	O
the	PRISTIQ.xml:S3:10957:3	the	DT	O	O
above	PRISTIQ.xml:S3:10961:5	abov	JJ	O	O
events	PRISTIQ.xml:S3:10967:6	event	NNS	O	O
occur	PRISTIQ.xml:S3:10974:5	occur	VBP	O	O
and	PRISTIQ.xml:S3:10980:3	and	CC	O	O
supportive	PRISTIQ.xml:S3:10984:10	support	JJ	O	O
symptomatic	PRISTIQ.xml:S3:10995:11	symptomat	JJ	O	O
treatment	PRISTIQ.xml:S3:11007:9	treatment	NN	O	O
should	PRISTIQ.xml:S3:11017:6	should	MD	O	O
be	PRISTIQ.xml:S3:11024:2	be	VB	O	O
initiated	PRISTIQ.xml:S3:11027:9	initi	VBN	O	O
.	PRISTIQ.xml:S3:11036:1	.	.	O	O

5.3	PRISTIQ.xml:S3:11045:3	5.3	CD	O	O
Elevated	PRISTIQ.xml:S3:11049:8	elev	VBD	O	O
Blood	PRISTIQ.xml:S3:11058:5	blood	NNP	O	O
Pressure	PRISTIQ.xml:S3:11064:8	pressur	NN	O	O

Patients	PRISTIQ.xml:S3:11078:8	patient	NNS	O	O
receiving	PRISTIQ.xml:S3:11087:9	receiv	VBG	O	O
PRISTIQ	PRISTIQ.xml:S3:11097:7	pristiq	NNP	O	O
should	PRISTIQ.xml:S3:11105:6	should	MD	O	O
have	PRISTIQ.xml:S3:11112:4	have	VB	O	O
regular	PRISTIQ.xml:S3:11117:7	regular	JJ	O	O
monitoring	PRISTIQ.xml:S3:11125:10	monitor	NN	O	O
of	PRISTIQ.xml:S3:11136:2	of	IN	O	O
blood	PRISTIQ.xml:S3:11139:5	blood	NN	O	O
pressure	PRISTIQ.xml:S3:11145:8	pressur	NN	O	O
since	PRISTIQ.xml:S3:11154:5	sinc	IN	O	O
increases	PRISTIQ.xml:S3:11160:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	PRISTIQ.xml:S3:11170:2	in	IN	I-AdverseReaction	I-AdverseReaction
blood	PRISTIQ.xml:S3:11173:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	PRISTIQ.xml:S3:11179:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
were	PRISTIQ.xml:S3:11188:4	were	VBD	O	O
observed	PRISTIQ.xml:S3:11193:8	observ	VBN	O	O
in	PRISTIQ.xml:S3:11202:2	in	IN	O	O
clinical	PRISTIQ.xml:S3:11205:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S3:11214:7	studi	NNS	O	O
[	PRISTIQ.xml:S3:11222:1	[	VBP	O	O
see	PRISTIQ.xml:S3:11223:3	see	VBP	O	O
Adverse	PRISTIQ.xml:S3:11228:7	advers	JJ	O	O
Reactions	PRISTIQ.xml:S3:11236:9	reaction	NNP	O	O
(	PRISTIQ.xml:S3:11246:1	(	(	O	O
6.1	PRISTIQ.xml:S3:11247:3	6.1	CD	O	O
)	PRISTIQ.xml:S3:11250:1	)	)	O	O
]	PRISTIQ.xml:S3:11253:1	]	NN	O	O
.	PRISTIQ.xml:S3:11256:1	.	.	O	O

Pre	PRISTIQ.xml:S3:11258:3	pre	NNP	O	O
-	PRISTIQ.xml:S3:11261:1	-	:	O	O
existing	PRISTIQ.xml:S3:11262:8	exist	VBG	O	O
hypertension	PRISTIQ.xml:S3:11271:12	hypertens	NN	O	O
should	PRISTIQ.xml:S3:11284:6	should	MD	O	O
be	PRISTIQ.xml:S3:11291:2	be	VB	O	O
controlled	PRISTIQ.xml:S3:11294:10	control	VBN	O	O
before	PRISTIQ.xml:S3:11305:6	befor	IN	O	O
initiating	PRISTIQ.xml:S3:11312:10	initi	VBG	O	O
treatment	PRISTIQ.xml:S3:11323:9	treatment	NN	O	O
with	PRISTIQ.xml:S3:11333:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:11338:7	pristiq	NNP	O	O
.	PRISTIQ.xml:S3:11345:1	.	.	O	O

Caution	PRISTIQ.xml:S3:11347:7	caution	NN	O	O
should	PRISTIQ.xml:S3:11355:6	should	MD	O	O
be	PRISTIQ.xml:S3:11362:2	be	VB	O	O
exercised	PRISTIQ.xml:S3:11365:9	exercis	VBN	O	O
in	PRISTIQ.xml:S3:11375:2	in	IN	O	O
treating	PRISTIQ.xml:S3:11378:8	treat	VBG	O	O
patients	PRISTIQ.xml:S3:11387:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:11396:4	with	IN	O	O
pre	PRISTIQ.xml:S3:11401:3	pre	JJ	O	O
-	PRISTIQ.xml:S3:11404:1	-	:	O	O
existing	PRISTIQ.xml:S3:11405:8	exist	VBG	O	O
hypertension	PRISTIQ.xml:S3:11414:12	hypertens	NN	O	O
,	PRISTIQ.xml:S3:11426:1	,	,	O	O
cardiovascular	PRISTIQ.xml:S3:11428:14	cardiovascular	JJ	O	O
,	PRISTIQ.xml:S3:11442:1	,	,	O	O
or	PRISTIQ.xml:S3:11444:2	or	CC	O	O
cerebrovascular	PRISTIQ.xml:S3:11447:15	cerebrovascular	JJ	O	O
conditions	PRISTIQ.xml:S3:11463:10	condit	NNS	O	O
that	PRISTIQ.xml:S3:11474:4	that	WDT	O	O
might	PRISTIQ.xml:S3:11479:5	might	MD	O	O
be	PRISTIQ.xml:S3:11485:2	be	VB	O	O
compromised	PRISTIQ.xml:S3:11488:11	compromis	VBN	O	O
by	PRISTIQ.xml:S3:11500:2	by	IN	O	O
increases	PRISTIQ.xml:S3:11503:9	increas	NNS	O	B-AdverseReaction
in	PRISTIQ.xml:S3:11513:2	in	IN	O	I-AdverseReaction
blood	PRISTIQ.xml:S3:11516:5	blood	NN	O	I-AdverseReaction
pressure	PRISTIQ.xml:S3:11522:8	pressur	NN	O	I-AdverseReaction
.	PRISTIQ.xml:S3:11530:1	.	.	O	O

Cases	PRISTIQ.xml:S3:11532:5	case	NNS	O	O
of	PRISTIQ.xml:S3:11538:2	of	IN	O	O
elevated	PRISTIQ.xml:S3:11541:8	elev	JJ	B-AdverseReaction	B-AdverseReaction
blood	PRISTIQ.xml:S3:11550:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	PRISTIQ.xml:S3:11556:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
requiring	PRISTIQ.xml:S3:11565:9	requir	VBG	O	O
immediate	PRISTIQ.xml:S3:11575:9	immedi	JJ	O	O
treatment	PRISTIQ.xml:S3:11585:9	treatment	NN	O	O
have	PRISTIQ.xml:S3:11595:4	have	VBP	O	O
been	PRISTIQ.xml:S3:11600:4	been	VBN	O	O
reported	PRISTIQ.xml:S3:11605:8	report	VBN	O	O
with	PRISTIQ.xml:S3:11614:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:11619:7	pristiq	NNP	O	O
.	PRISTIQ.xml:S3:11626:1	.	.	O	O

Sustained	PRISTIQ.xml:S3:11632:9	sustain	VBN	O	B-AdverseReaction
blood	PRISTIQ.xml:S3:11642:5	blood	NN	B-AdverseReaction	I-AdverseReaction
pressure	PRISTIQ.xml:S3:11648:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
increases	PRISTIQ.xml:S3:11657:9	increas	NNS	I-AdverseReaction	I-AdverseReaction
could	PRISTIQ.xml:S3:11667:5	could	MD	O	O
have	PRISTIQ.xml:S3:11673:4	have	VB	O	O
adverse	PRISTIQ.xml:S3:11678:7	advers	JJ	O	O
consequences	PRISTIQ.xml:S3:11686:12	consequ	NNS	O	O
.	PRISTIQ.xml:S3:11698:1	.	.	O	O

For	PRISTIQ.xml:S3:11700:3	for	IN	O	O
patients	PRISTIQ.xml:S3:11704:8	patient	NNS	O	O
who	PRISTIQ.xml:S3:11713:3	who	WP	O	O
experience	PRISTIQ.xml:S3:11717:10	experi	VBP	O	O
a	PRISTIQ.xml:S3:11728:1	a	DT	O	O
sustained	PRISTIQ.xml:S3:11730:9	sustain	JJ	O	O
increase	PRISTIQ.xml:S3:11740:8	increas	NN	O	O
in	PRISTIQ.xml:S3:11749:2	in	IN	O	O
blood	PRISTIQ.xml:S3:11752:5	blood	NN	O	O
pressure	PRISTIQ.xml:S3:11758:8	pressur	NN	O	O
while	PRISTIQ.xml:S3:11767:5	while	IN	O	O
receiving	PRISTIQ.xml:S3:11773:9	receiv	VBG	O	O
PRISTIQ	PRISTIQ.xml:S3:11783:7	pristiq	NNP	O	O
,	PRISTIQ.xml:S3:11790:1	,	,	O	O
either	PRISTIQ.xml:S3:11792:6	either	RB	O	O
dose	PRISTIQ.xml:S3:11799:4	dose	JJ	O	O
reduction	PRISTIQ.xml:S3:11804:9	reduct	NN	O	O
or	PRISTIQ.xml:S3:11814:2	or	CC	O	O
discontinuation	PRISTIQ.xml:S3:11817:15	discontinu	NN	O	O
should	PRISTIQ.xml:S3:11833:6	should	MD	O	O
be	PRISTIQ.xml:S3:11840:2	be	VB	O	O
considered	PRISTIQ.xml:S3:11843:10	consid	VBN	O	O
[	PRISTIQ.xml:S3:11854:1	[	NNP	O	O
see	PRISTIQ.xml:S3:11855:3	see	VBP	O	O
Adverse	PRISTIQ.xml:S3:11860:7	advers	JJ	O	O
Reactions	PRISTIQ.xml:S3:11868:9	reaction	NNP	O	O
(	PRISTIQ.xml:S3:11878:1	(	(	O	O
6.1	PRISTIQ.xml:S3:11879:3	6.1	CD	O	O
)	PRISTIQ.xml:S3:11882:1	)	)	O	O
]	PRISTIQ.xml:S3:11885:1	]	NN	O	O
.	PRISTIQ.xml:S3:11888:1	.	.	O	O

5.4	PRISTIQ.xml:S3:11897:3	5.4	CD	O	O
Abnormal	PRISTIQ.xml:S3:11901:8	abnorm	JJ	O	O
Bleeding	PRISTIQ.xml:S3:11910:8	bleed	NNP	O	O

SSRIs	PRISTIQ.xml:S3:11924:5	ssri	NNP	O	O
and	PRISTIQ.xml:S3:11930:3	and	CC	O	O
SNRIs	PRISTIQ.xml:S3:11934:5	snri	NNP	O	O
,	PRISTIQ.xml:S3:11939:1	,	,	O	O
including	PRISTIQ.xml:S3:11941:9	includ	VBG	O	O
PRISTIQ	PRISTIQ.xml:S3:11951:7	pristiq	NNP	O	O
,	PRISTIQ.xml:S3:11958:1	,	,	O	O
may	PRISTIQ.xml:S3:11960:3	may	MD	O	O
increase	PRISTIQ.xml:S3:11964:8	increas	VB	O	O
the	PRISTIQ.xml:S3:11973:3	the	DT	O	O
risk	PRISTIQ.xml:S3:11977:4	risk	NN	O	O
of	PRISTIQ.xml:S3:11982:2	of	IN	O	O
bleeding	PRISTIQ.xml:S3:11985:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
events	PRISTIQ.xml:S3:11994:6	event	NNS	O	O
.	PRISTIQ.xml:S3:12000:1	.	.	O	O

Concomitant	PRISTIQ.xml:S3:12002:11	concomit	NNP	O	O
use	PRISTIQ.xml:S3:12014:3	use	NN	O	O
of	PRISTIQ.xml:S3:12018:2	of	IN	O	O
aspirin	PRISTIQ.xml:S3:12021:7	aspirin	NN	O	O
,	PRISTIQ.xml:S3:12028:1	,	,	O	O
nonsteroidal	PRISTIQ.xml:S3:12030:12	nonsteroid	JJ	O	O
anti	PRISTIQ.xml:S3:12043:4	anti	SYM	O	O
-	PRISTIQ.xml:S3:12047:1	-	:	O	O
inflammatory	PRISTIQ.xml:S3:12048:12	inflammatori	NN	O	O
drugs	PRISTIQ.xml:S3:12061:5	drug	NNS	O	O
,	PRISTIQ.xml:S3:12066:1	,	,	O	O
warfarin	PRISTIQ.xml:S3:12068:8	warfarin	NN	O	O
,	PRISTIQ.xml:S3:12076:1	,	,	O	O
and	PRISTIQ.xml:S3:12078:3	and	CC	O	O
other	PRISTIQ.xml:S3:12082:5	other	JJ	O	O
anticoagulants	PRISTIQ.xml:S3:12088:14	anticoagul	NNS	O	O
may	PRISTIQ.xml:S3:12103:3	may	MD	O	O
add	PRISTIQ.xml:S3:12107:3	add	VB	O	O
to	PRISTIQ.xml:S3:12111:2	to	TO	O	O
this	PRISTIQ.xml:S3:12114:4	thi	DT	O	O
risk	PRISTIQ.xml:S3:12119:4	risk	NN	O	O
.	PRISTIQ.xml:S3:12123:1	.	.	O	O

Case	PRISTIQ.xml:S3:12125:4	case	NNP	O	O
reports	PRISTIQ.xml:S3:12130:7	report	NNS	O	O
and	PRISTIQ.xml:S3:12138:3	and	CC	O	O
epidemiological	PRISTIQ.xml:S3:12142:15	epidemiolog	JJ	O	O
studies	PRISTIQ.xml:S3:12158:7	studi	NNS	O	O
(	PRISTIQ.xml:S3:12166:1	(	(	O	O
case	PRISTIQ.xml:S3:12167:4	case	NN	O	O
-	PRISTIQ.xml:S3:12171:1	-	:	O	O
control	PRISTIQ.xml:S3:12172:7	control	NN	O	O
and	PRISTIQ.xml:S3:12180:3	and	CC	O	O
cohort	PRISTIQ.xml:S3:12184:6	cohort	NN	O	B-AdverseReaction
design	PRISTIQ.xml:S3:12191:6	design	NN	O	I-AdverseReaction
)	PRISTIQ.xml:S3:12197:1	)	)	O	O
have	PRISTIQ.xml:S3:12199:4	have	VBP	O	O
demonstrated	PRISTIQ.xml:S3:12204:12	demonstr	VBN	O	O
an	PRISTIQ.xml:S3:12217:2	an	DT	O	O
association	PRISTIQ.xml:S3:12220:11	associ	NN	O	O
between	PRISTIQ.xml:S3:12232:7	between	IN	O	O
use	PRISTIQ.xml:S3:12240:3	use	NN	O	O
of	PRISTIQ.xml:S3:12244:2	of	IN	O	O
drugs	PRISTIQ.xml:S3:12247:5	drug	NNS	O	O
that	PRISTIQ.xml:S3:12253:4	that	WDT	O	O
interfere	PRISTIQ.xml:S3:12258:9	interfer	VBP	O	O
with	PRISTIQ.xml:S3:12268:4	with	IN	O	O
serotonin	PRISTIQ.xml:S3:12273:9	serotonin	JJ	O	O
reuptake	PRISTIQ.xml:S3:12283:8	reuptak	NN	O	O
and	PRISTIQ.xml:S3:12292:3	and	CC	O	O
the	PRISTIQ.xml:S3:12296:3	the	DT	O	O
occurrence	PRISTIQ.xml:S3:12300:10	occurr	NN	O	B-AdverseReaction
of	PRISTIQ.xml:S3:12311:2	of	IN	O	I-AdverseReaction
gastrointestinal	PRISTIQ.xml:S3:12314:16	gastrointestin	JJ	B-AdverseReaction	I-AdverseReaction
bleeding	PRISTIQ.xml:S3:12331:8	bleed	NN	I-AdverseReaction	I-AdverseReaction
.	PRISTIQ.xml:S3:12339:1	.	.	O	O

Bleeding	PRISTIQ.xml:S3:12341:8	bleed	VBG	B-AdverseReaction	B-AdverseReaction
events	PRISTIQ.xml:S3:12350:6	event	NNS	O	O
related	PRISTIQ.xml:S3:12357:7	relat	VBN	O	O
to	PRISTIQ.xml:S3:12365:2	to	TO	O	O
SSRIs	PRISTIQ.xml:S3:12368:5	ssri	NNP	O	O
and	PRISTIQ.xml:S3:12374:3	and	CC	O	O
SNRIs	PRISTIQ.xml:S3:12378:5	snri	NNP	O	O
have	PRISTIQ.xml:S3:12384:4	have	VBP	O	O
ranged	PRISTIQ.xml:S3:12389:6	rang	VBN	O	O
from	PRISTIQ.xml:S3:12396:4	from	IN	O	O
ecchymosis	PRISTIQ.xml:S3:12401:10	ecchymosi	NN	B-AdverseReaction	O
,	PRISTIQ.xml:S3:12411:1	,	,	O	O
hematoma	PRISTIQ.xml:S3:12413:8	hematoma	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:12421:1	,	,	O	O
epistaxis	PRISTIQ.xml:S3:12423:9	epistaxi	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:12432:1	,	,	O	O
and	PRISTIQ.xml:S3:12434:3	and	CC	O	O
petechiae	PRISTIQ.xml:S3:12438:9	petechia	NN	B-AdverseReaction	O
to	PRISTIQ.xml:S3:12448:2	to	TO	O	O
life	PRISTIQ.xml:S3:12451:4	life	NN	O	O
-	PRISTIQ.xml:S3:12455:1	-	:	O	O
threatening	PRISTIQ.xml:S3:12456:11	threaten	NN	O	O
hemorrhages	PRISTIQ.xml:S3:12468:11	hemorrhag	NNS	B-AdverseReaction	O
.	PRISTIQ.xml:S3:12479:1	.	.	O	O

Patients	PRISTIQ.xml:S3:12481:8	patient	NNS	O	O
should	PRISTIQ.xml:S3:12490:6	should	MD	O	O
be	PRISTIQ.xml:S3:12497:2	be	VB	O	O
cautioned	PRISTIQ.xml:S3:12500:9	caution	VBN	O	O
about	PRISTIQ.xml:S3:12510:5	about	IN	O	O
the	PRISTIQ.xml:S3:12516:3	the	DT	O	O
risk	PRISTIQ.xml:S3:12520:4	risk	NN	O	O
of	PRISTIQ.xml:S3:12525:2	of	IN	O	O
bleeding	PRISTIQ.xml:S3:12528:8	bleed	VBG	O	B-AdverseReaction
associated	PRISTIQ.xml:S3:12537:10	associ	VBN	O	O
with	PRISTIQ.xml:S3:12548:4	with	IN	O	O
the	PRISTIQ.xml:S3:12553:3	the	DT	O	O
concomitant	PRISTIQ.xml:S3:12557:11	concomit	NN	O	O
use	PRISTIQ.xml:S3:12569:3	use	NN	O	O
of	PRISTIQ.xml:S3:12573:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:12576:7	pristiq	NNP	O	O
and	PRISTIQ.xml:S3:12584:3	and	CC	O	O
NSAIDs	PRISTIQ.xml:S3:12588:6	nsaid	NNP	O	O
,	PRISTIQ.xml:S3:12594:1	,	,	O	O
aspirin	PRISTIQ.xml:S3:12596:7	aspirin	NN	O	O
,	PRISTIQ.xml:S3:12603:1	,	,	O	O
or	PRISTIQ.xml:S3:12605:2	or	CC	O	O
other	PRISTIQ.xml:S3:12608:5	other	JJ	O	O
drugs	PRISTIQ.xml:S3:12614:5	drug	NNS	O	O
that	PRISTIQ.xml:S3:12620:4	that	IN	O	O
affect	PRISTIQ.xml:S3:12625:6	affect	VBP	O	O
coagulation	PRISTIQ.xml:S3:12632:11	coagul	NN	O	O
or	PRISTIQ.xml:S3:12644:2	or	CC	O	O
bleeding	PRISTIQ.xml:S3:12647:8	bleed	NN	O	B-AdverseReaction
.	PRISTIQ.xml:S3:12655:1	.	.	O	O

5.5	PRISTIQ.xml:S3:12664:3	5.5	CD	O	O
Angle	PRISTIQ.xml:S3:12668:5	angl	NNP	O	O
Closure	PRISTIQ.xml:S3:12674:7	closur	NNP	O	O
Glaucoma	PRISTIQ.xml:S3:12682:8	glaucoma	NNP	O	O

Angle	PRISTIQ.xml:S3:12697:5	angl	NNP	B-AdverseReaction	O
-	PRISTIQ.xml:S3:12702:1	-	:	I-AdverseReaction	O
Closure	PRISTIQ.xml:S3:12703:7	closur	NN	I-AdverseReaction	O
Glaucoma	PRISTIQ.xml:S3:12711:8	glaucoma	NNP	I-AdverseReaction	O
:	PRISTIQ.xml:S3:12719:1	:	:	O	O
The	PRISTIQ.xml:S3:12721:3	the	DT	O	O
pupillary	PRISTIQ.xml:S3:12725:9	pupillari	JJ	O	O
dilation	PRISTIQ.xml:S3:12735:8	dilat	NN	O	O
that	PRISTIQ.xml:S3:12744:4	that	WDT	O	O
occurs	PRISTIQ.xml:S3:12749:6	occur	VBZ	O	O
following	PRISTIQ.xml:S3:12756:9	follow	VBG	O	O
use	PRISTIQ.xml:S3:12766:3	use	NN	O	O
of	PRISTIQ.xml:S3:12770:2	of	IN	O	O
many	PRISTIQ.xml:S3:12773:4	mani	JJ	O	O
antidepressant	PRISTIQ.xml:S3:12778:14	antidepress	JJ	O	O
drugs	PRISTIQ.xml:S3:12793:5	drug	NNS	O	O
including	PRISTIQ.xml:S3:12799:9	includ	VBG	O	O
Pristiq	PRISTIQ.xml:S3:12809:7	pristiq	NNP	O	O
may	PRISTIQ.xml:S3:12817:3	may	MD	O	O
trigger	PRISTIQ.xml:S3:12821:7	trigger	VB	O	O
an	PRISTIQ.xml:S3:12829:2	an	DT	O	O
angle	PRISTIQ.xml:S3:12832:5	angl	JJ	B-AdverseReaction	O
closure	PRISTIQ.xml:S3:12838:7	closur	NN	I-AdverseReaction	O
attack	PRISTIQ.xml:S3:12846:6	attack	NN	I-AdverseReaction	O
in	PRISTIQ.xml:S3:12853:2	in	IN	O	O
a	PRISTIQ.xml:S3:12856:1	a	DT	O	O
patient	PRISTIQ.xml:S3:12858:7	patient	NN	O	O
with	PRISTIQ.xml:S3:12866:4	with	IN	O	O
anatomically	PRISTIQ.xml:S3:12871:12	anatom	RB	O	O
narrow	PRISTIQ.xml:S3:12884:6	narrow	JJ	O	O
angles	PRISTIQ.xml:S3:12891:6	angl	NNS	O	O
who	PRISTIQ.xml:S3:12898:3	who	WP	O	O
does	PRISTIQ.xml:S3:12902:4	doe	VBZ	O	O
not	PRISTIQ.xml:S3:12907:3	not	RB	O	O
have	PRISTIQ.xml:S3:12911:4	have	VB	O	O
a	PRISTIQ.xml:S3:12916:1	a	DT	O	O
patent	PRISTIQ.xml:S3:12918:6	patent	NN	O	O
iridectomy	PRISTIQ.xml:S3:12925:10	iridectomi	NN	O	O
.	PRISTIQ.xml:S3:12935:1	.	.	O	O

5.6	PRISTIQ.xml:S3:12946:3	5.6	CD	O	O
Activation	PRISTIQ.xml:S3:12950:10	activ	NNP	O	O
of	PRISTIQ.xml:S3:12961:2	of	IN	O	O
Mania	PRISTIQ.xml:S3:12964:5	mania	NNP	O	O
Hypomania	PRISTIQ.xml:S3:12970:9	hypomania	NNP	O	O

During	PRISTIQ.xml:S3:12985:6	dure	IN	O	O
all	PRISTIQ.xml:S3:12992:3	all	DT	O	O
MDD	PRISTIQ.xml:S3:12996:3	mdd	NNP	O	O
phase	PRISTIQ.xml:S3:13000:5	phase	NN	O	O
2	PRISTIQ.xml:S3:13006:1	2	CD	O	O
and	PRISTIQ.xml:S3:13008:3	and	CC	O	O
phase	PRISTIQ.xml:S3:13012:5	phase	VB	O	O
3	PRISTIQ.xml:S3:13018:1	3	CD	O	O
studies	PRISTIQ.xml:S3:13020:7	studi	NNS	O	O
,	PRISTIQ.xml:S3:13027:1	,	,	O	O
mania	PRISTIQ.xml:S3:13029:5	mania	NN	B-AdverseReaction	B-AdverseReaction
was	PRISTIQ.xml:S3:13035:3	wa	VBD	O	O
reported	PRISTIQ.xml:S3:13039:8	report	VBN	O	O
for	PRISTIQ.xml:S3:13048:3	for	IN	O	O
approximately	PRISTIQ.xml:S3:13052:13	approxim	RB	O	O
0.02%	PRISTIQ.xml:S3:13066:5	0.02%	CD	O	O
of	PRISTIQ.xml:S3:13072:2	of	IN	O	O
patients	PRISTIQ.xml:S3:13075:8	patient	NNS	O	O
treated	PRISTIQ.xml:S3:13084:7	treat	VBN	O	O
with	PRISTIQ.xml:S3:13092:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:13097:7	pristiq	NNP	O	O
.	PRISTIQ.xml:S3:13104:1	.	.	O	O

Activation	PRISTIQ.xml:S3:13106:10	activ	NN	B-AdverseReaction	O
of	PRISTIQ.xml:S3:13117:2	of	IN	I-AdverseReaction	O
mania	PRISTIQ.xml:S3:13120:5	mania	NN	I-AdverseReaction	O
hypomania	PRISTIQ.xml:S3:13126:9	hypomania	NN	I-AdverseReaction	O
has	PRISTIQ.xml:S3:13136:3	ha	VBZ	O	O
also	PRISTIQ.xml:S3:13140:4	also	RB	O	O
been	PRISTIQ.xml:S3:13145:4	been	VBN	O	O
reported	PRISTIQ.xml:S3:13150:8	report	VBN	O	O
in	PRISTIQ.xml:S3:13159:2	in	IN	O	O
a	PRISTIQ.xml:S3:13162:1	a	DT	O	O
small	PRISTIQ.xml:S3:13164:5	small	JJ	O	O
proportion	PRISTIQ.xml:S3:13170:10	proport	NN	O	O
of	PRISTIQ.xml:S3:13181:2	of	IN	O	O
patients	PRISTIQ.xml:S3:13184:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:13193:4	with	IN	O	O
major	PRISTIQ.xml:S3:13198:5	major	JJ	O	O
affective	PRISTIQ.xml:S3:13204:9	affect	JJ	O	O
disorder	PRISTIQ.xml:S3:13214:8	disord	NN	O	O
who	PRISTIQ.xml:S3:13223:3	who	WP	O	O
were	PRISTIQ.xml:S3:13227:4	were	VBD	O	O
treated	PRISTIQ.xml:S3:13232:7	treat	VBN	O	O
with	PRISTIQ.xml:S3:13240:4	with	IN	O	O
other	PRISTIQ.xml:S3:13245:5	other	JJ	O	O
marketed	PRISTIQ.xml:S3:13251:8	market	JJ	O	O
antidepressants	PRISTIQ.xml:S3:13260:15	antidepress	NNS	O	O
.	PRISTIQ.xml:S3:13275:1	.	.	O	O

As	PRISTIQ.xml:S3:13277:2	As	IN	O	O
with	PRISTIQ.xml:S3:13280:4	with	IN	O	O
all	PRISTIQ.xml:S3:13285:3	all	DT	O	O
antidepressants	PRISTIQ.xml:S3:13289:15	antidepress	NNS	O	O
,	PRISTIQ.xml:S3:13304:1	,	,	O	O
PRISTIQ	PRISTIQ.xml:S3:13306:7	pristiq	NNP	O	O
should	PRISTIQ.xml:S3:13314:6	should	MD	O	O
be	PRISTIQ.xml:S3:13321:2	be	VB	O	O
used	PRISTIQ.xml:S3:13324:4	use	VBN	O	O
cautiously	PRISTIQ.xml:S3:13329:10	cautious	RB	O	O
in	PRISTIQ.xml:S3:13340:2	in	IN	O	O
patients	PRISTIQ.xml:S3:13343:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:13352:4	with	IN	O	O
a	PRISTIQ.xml:S3:13357:1	a	DT	O	O
history	PRISTIQ.xml:S3:13359:7	histori	NN	O	O
or	PRISTIQ.xml:S3:13367:2	or	CC	O	O
family	PRISTIQ.xml:S3:13370:6	famili	NN	O	O
history	PRISTIQ.xml:S3:13377:7	histori	NN	O	O
of	PRISTIQ.xml:S3:13385:2	of	IN	O	O
mania	PRISTIQ.xml:S3:13388:5	mania	NN	O	O
or	PRISTIQ.xml:S3:13394:2	or	CC	O	O
hypomania	PRISTIQ.xml:S3:13397:9	hypomania	NN	O	O
.	PRISTIQ.xml:S3:13406:1	.	.	O	O

5.7	PRISTIQ.xml:S3:13415:3	5.7	CD	O	O
Discontinuation	PRISTIQ.xml:S3:13419:15	discontinu	NNP	O	O
Syndrome	PRISTIQ.xml:S3:13435:8	syndrom	NNP	O	O

Discontinuation	PRISTIQ.xml:S3:13449:15	discontinu	NN	O	O
symptoms	PRISTIQ.xml:S3:13465:8	symptom	NNS	O	O
have	PRISTIQ.xml:S3:13474:4	have	VBP	O	O
been	PRISTIQ.xml:S3:13479:4	been	VBN	O	O
systematically	PRISTIQ.xml:S3:13484:14	systemat	RB	O	O
and	PRISTIQ.xml:S3:13499:3	and	CC	O	O
prospectively	PRISTIQ.xml:S3:13503:13	prospect	RB	O	O
evaluated	PRISTIQ.xml:S3:13517:9	evalu	VBN	O	O
in	PRISTIQ.xml:S3:13527:2	in	IN	O	O
patients	PRISTIQ.xml:S3:13530:8	patient	NNS	O	O
treated	PRISTIQ.xml:S3:13539:7	treat	VBN	O	O
with	PRISTIQ.xml:S3:13547:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:13552:7	pristiq	NNP	O	O
during	PRISTIQ.xml:S3:13560:6	dure	IN	O	O
clinical	PRISTIQ.xml:S3:13567:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S3:13576:7	studi	NNS	O	O
in	PRISTIQ.xml:S3:13584:2	in	IN	O	O
Major	PRISTIQ.xml:S3:13587:5	major	JJ	O	O
Depressive	PRISTIQ.xml:S3:13593:10	depress	JJ	O	O
Disorder	PRISTIQ.xml:S3:13604:8	disord	NNP	O	O
.	PRISTIQ.xml:S3:13612:1	.	.	O	O

Abrupt	PRISTIQ.xml:S3:13614:6	abrupt	JJ	O	O
discontinuation	PRISTIQ.xml:S3:13621:15	discontinu	NN	O	O
or	PRISTIQ.xml:S3:13637:2	or	CC	O	O
dose	PRISTIQ.xml:S3:13640:4	dose	JJ	O	O
reduction	PRISTIQ.xml:S3:13645:9	reduct	NN	O	O
has	PRISTIQ.xml:S3:13655:3	ha	VBZ	O	O
been	PRISTIQ.xml:S3:13659:4	been	VBN	O	O
associated	PRISTIQ.xml:S3:13664:10	associ	VBN	O	O
with	PRISTIQ.xml:S3:13675:4	with	IN	O	O
the	PRISTIQ.xml:S3:13680:3	the	DT	O	O
appearance	PRISTIQ.xml:S3:13684:10	appear	NN	O	O
of	PRISTIQ.xml:S3:13695:2	of	IN	O	O
new	PRISTIQ.xml:S3:13698:3	new	JJ	O	O
symptoms	PRISTIQ.xml:S3:13702:8	symptom	NNS	O	O
that	PRISTIQ.xml:S3:13711:4	that	WDT	O	O
include	PRISTIQ.xml:S3:13716:7	includ	VBP	O	O
dizziness	PRISTIQ.xml:S3:13724:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:13733:1	,	,	O	O
nausea	PRISTIQ.xml:S3:13735:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:13741:1	,	,	O	O
headache	PRISTIQ.xml:S3:13743:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:13751:1	,	,	O	O
irritability	PRISTIQ.xml:S3:13753:12	irrit	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:13765:1	,	,	O	O
insomnia	PRISTIQ.xml:S3:13767:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:13775:1	,	,	O	O
diarrhea	PRISTIQ.xml:S3:13777:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:13785:1	,	,	O	O
anxiety	PRISTIQ.xml:S3:13787:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:13794:1	,	,	O	O
fatigue	PRISTIQ.xml:S3:13796:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:13803:1	,	,	O	O
abnormal	PRISTIQ.xml:S3:13805:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
dreams	PRISTIQ.xml:S3:13814:6	dream	NNS	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S3:13820:1	,	,	O	O
and	PRISTIQ.xml:S3:13822:3	and	CC	O	O
hyperhidrosis	PRISTIQ.xml:S3:13826:13	hyperhidrosi	NN	B-AdverseReaction	B-AdverseReaction
.	PRISTIQ.xml:S3:13839:1	.	.	O	O

In	PRISTIQ.xml:S3:13841:2	In	IN	O	O
general	PRISTIQ.xml:S3:13844:7	gener	JJ	O	O
,	PRISTIQ.xml:S3:13851:1	,	,	O	O
discontinuation	PRISTIQ.xml:S3:13853:15	discontinu	NN	O	O
events	PRISTIQ.xml:S3:13869:6	event	NNS	O	O
occurred	PRISTIQ.xml:S3:13876:8	occur	VBD	O	O
more	PRISTIQ.xml:S3:13885:4	more	RBR	O	O
frequently	PRISTIQ.xml:S3:13890:10	frequent	RB	O	O
with	PRISTIQ.xml:S3:13901:4	with	IN	O	O
longer	PRISTIQ.xml:S3:13906:6	longer	JJR	O	O
duration	PRISTIQ.xml:S3:13913:8	durat	NN	O	O
of	PRISTIQ.xml:S3:13922:2	of	IN	O	O
therapy	PRISTIQ.xml:S3:13925:7	therapi	NN	O	O
.	PRISTIQ.xml:S3:13932:1	.	.	O	O

During	PRISTIQ.xml:S3:13938:6	dure	IN	O	O
marketing	PRISTIQ.xml:S3:13945:9	market	NN	O	O
of	PRISTIQ.xml:S3:13955:2	of	IN	O	O
SNRIs	PRISTIQ.xml:S3:13958:5	snri	NNP	O	O
(	PRISTIQ.xml:S3:13964:1	(	(	O	O
Serotonin	PRISTIQ.xml:S3:13965:9	serotonin	NNP	O	O
and	PRISTIQ.xml:S3:13975:3	and	CC	O	O
Norepinephrine	PRISTIQ.xml:S3:13979:14	norepinephrin	NNP	O	O
Reuptake	PRISTIQ.xml:S3:13994:8	reuptak	NNP	O	O
Inhibitors	PRISTIQ.xml:S3:14003:10	inhibitor	NNP	O	O
)	PRISTIQ.xml:S3:14013:1	)	)	O	O
,	PRISTIQ.xml:S3:14014:1	,	,	O	O
and	PRISTIQ.xml:S3:14016:3	and	CC	O	O
SSRIs	PRISTIQ.xml:S3:14020:5	ssri	NNP	O	O
(	PRISTIQ.xml:S3:14026:1	(	(	O	O
Selective	PRISTIQ.xml:S3:14027:9	select	NNP	O	O
Serotonin	PRISTIQ.xml:S3:14037:9	serotonin	NNP	O	O
Reuptake	PRISTIQ.xml:S3:14047:8	reuptak	NNP	O	O
Inhibitors	PRISTIQ.xml:S3:14056:10	inhibitor	NNP	O	O
)	PRISTIQ.xml:S3:14066:1	)	)	O	O
,	PRISTIQ.xml:S3:14067:1	,	,	O	O
there	PRISTIQ.xml:S3:14069:5	there	EX	O	O
have	PRISTIQ.xml:S3:14075:4	have	VBP	O	O
been	PRISTIQ.xml:S3:14080:4	been	VBN	O	O
spontaneous	PRISTIQ.xml:S3:14085:11	spontan	JJ	O	O
reports	PRISTIQ.xml:S3:14097:7	report	NNS	O	O
of	PRISTIQ.xml:S3:14105:2	of	IN	O	O
adverse	PRISTIQ.xml:S3:14108:7	advers	JJ	O	O
events	PRISTIQ.xml:S3:14116:6	event	NNS	O	O
occurring	PRISTIQ.xml:S3:14123:9	occur	VBG	O	O
upon	PRISTIQ.xml:S3:14133:4	upon	IN	O	O
discontinuation	PRISTIQ.xml:S3:14138:15	discontinu	NN	O	O
of	PRISTIQ.xml:S3:14154:2	of	IN	O	O
these	PRISTIQ.xml:S3:14157:5	these	DT	O	O
drugs	PRISTIQ.xml:S3:14163:5	drug	NNS	O	O
,	PRISTIQ.xml:S3:14168:1	,	,	O	O
particularly	PRISTIQ.xml:S3:14170:12	particularli	RB	O	O
when	PRISTIQ.xml:S3:14183:4	when	WRB	O	O
abrupt	PRISTIQ.xml:S3:14188:6	abrupt	NN	O	O
,	PRISTIQ.xml:S3:14194:1	,	,	O	O
including	PRISTIQ.xml:S3:14196:9	includ	VBG	O	O
the	PRISTIQ.xml:S3:14206:3	the	DT	O	O
following	PRISTIQ.xml:S3:14210:9	follow	NN	O	O
:	PRISTIQ.xml:S3:14219:1	:	:	O	O
dysphoric	PRISTIQ.xml:S3:14221:9	dysphor	JJ	O	B-AdverseReaction
mood	PRISTIQ.xml:S3:14231:4	mood	NN	O	I-AdverseReaction
,	PRISTIQ.xml:S3:14235:1	,	,	O	O
irritability	PRISTIQ.xml:S3:14237:12	irrit	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:14249:1	,	,	O	O
agitation	PRISTIQ.xml:S3:14251:9	agit	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:14260:1	,	,	O	O
dizziness	PRISTIQ.xml:S3:14262:9	dizzi	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:14271:1	,	,	O	O
sensory	PRISTIQ.xml:S3:14273:7	sensori	JJ	O	O
disturbances	PRISTIQ.xml:S3:14281:12	disturb	NNS	O	O
(	PRISTIQ.xml:S3:14294:1	(	(	O	O
e	PRISTIQ.xml:S3:14295:1	e	NN	O	O
.	PRISTIQ.xml:S3:14296:1	.	.	O	O
g	PRISTIQ.xml:S3:14297:1	g	NN	O	O
.	PRISTIQ.xml:S3:14298:1	.	.	O	O
,	PRISTIQ.xml:S3:14299:1	,	,	O	O
paresthesia	PRISTIQ.xml:S3:14301:11	paresthesia	NN	O	O
,	PRISTIQ.xml:S3:14312:1	,	,	O	O
such	PRISTIQ.xml:S3:14314:4	such	JJ	O	O
as	PRISTIQ.xml:S3:14319:2	as	IN	O	O
electric	PRISTIQ.xml:S3:14322:8	electr	JJ	O	B-AdverseReaction
shock	PRISTIQ.xml:S3:14331:5	shock	NN	O	I-AdverseReaction
sensations	PRISTIQ.xml:S3:14337:10	sensat	NNS	O	I-AdverseReaction
)	PRISTIQ.xml:S3:14347:1	)	)	O	O
,	PRISTIQ.xml:S3:14348:1	,	,	O	O
anxiety	PRISTIQ.xml:S3:14350:7	anxieti	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:14357:1	,	,	O	O
confusion	PRISTIQ.xml:S3:14359:9	confus	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:14368:1	,	,	O	O
headache	PRISTIQ.xml:S3:14370:8	headach	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:14378:1	,	,	O	O
lethargy	PRISTIQ.xml:S3:14380:8	lethargi	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:14388:1	,	,	O	O
emotional	PRISTIQ.xml:S3:14390:9	emot	JJ	O	O
lability	PRISTIQ.xml:S3:14400:8	labil	NN	O	O
,	PRISTIQ.xml:S3:14408:1	,	,	O	O
insomnia	PRISTIQ.xml:S3:14410:8	insomnia	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:14418:1	,	,	O	O
hypomania	PRISTIQ.xml:S3:14420:9	hypomania	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:14429:1	,	,	O	O
tinnitus	PRISTIQ.xml:S3:14431:8	tinnitu	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:14439:1	,	,	O	O
and	PRISTIQ.xml:S3:14441:3	and	CC	O	O
seizures	PRISTIQ.xml:S3:14445:8	seizur	NNS	O	B-AdverseReaction
.	PRISTIQ.xml:S3:14453:1	.	.	O	O

While	PRISTIQ.xml:S3:14455:5	while	IN	O	O
these	PRISTIQ.xml:S3:14461:5	these	DT	O	O
events	PRISTIQ.xml:S3:14467:6	event	NNS	O	O
are	PRISTIQ.xml:S3:14474:3	are	VBP	O	O
generally	PRISTIQ.xml:S3:14478:9	gener	RB	O	O
self	PRISTIQ.xml:S3:14488:4	self	JJ	O	O
-	PRISTIQ.xml:S3:14492:1	-	:	O	O
limiting	PRISTIQ.xml:S3:14493:8	limit	NN	O	O
,	PRISTIQ.xml:S3:14501:1	,	,	O	O
there	PRISTIQ.xml:S3:14503:5	there	EX	O	O
have	PRISTIQ.xml:S3:14509:4	have	VBP	O	O
been	PRISTIQ.xml:S3:14514:4	been	VBN	O	O
reports	PRISTIQ.xml:S3:14519:7	report	NNS	O	O
of	PRISTIQ.xml:S3:14527:2	of	IN	O	O
serious	PRISTIQ.xml:S3:14530:7	seriou	JJ	O	O
discontinuation	PRISTIQ.xml:S3:14538:15	discontinu	NN	O	O
symptoms	PRISTIQ.xml:S3:14554:8	symptom	NNS	O	O
.	PRISTIQ.xml:S3:14562:1	.	.	O	O

Patients	PRISTIQ.xml:S3:14568:8	patient	NNS	O	O
should	PRISTIQ.xml:S3:14577:6	should	MD	O	O
be	PRISTIQ.xml:S3:14584:2	be	VB	O	O
monitored	PRISTIQ.xml:S3:14587:9	monitor	VBN	O	O
for	PRISTIQ.xml:S3:14597:3	for	IN	O	O
these	PRISTIQ.xml:S3:14601:5	these	DT	O	O
symptoms	PRISTIQ.xml:S3:14607:8	symptom	NNS	O	O
when	PRISTIQ.xml:S3:14616:4	when	WRB	O	O
discontinuing	PRISTIQ.xml:S3:14621:13	discontinu	VBG	O	O
treatment	PRISTIQ.xml:S3:14635:9	treatment	NN	O	O
with	PRISTIQ.xml:S3:14645:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:14650:7	pristiq	NNP	O	O
.	PRISTIQ.xml:S3:14657:1	.	.	O	O

A	PRISTIQ.xml:S3:14659:1	A	DT	O	O
gradual	PRISTIQ.xml:S3:14661:7	gradual	JJ	O	O
reduction	PRISTIQ.xml:S3:14669:9	reduct	NN	O	O
in	PRISTIQ.xml:S3:14679:2	in	IN	O	O
the	PRISTIQ.xml:S3:14682:3	the	DT	O	O
dose	PRISTIQ.xml:S3:14686:4	dose	NN	O	O
rather	PRISTIQ.xml:S3:14691:6	rather	RB	O	O
than	PRISTIQ.xml:S3:14698:4	than	IN	O	O
abrupt	PRISTIQ.xml:S3:14703:6	abrupt	JJ	O	O
cessation	PRISTIQ.xml:S3:14710:9	cessat	NN	O	O
is	PRISTIQ.xml:S3:14720:2	is	VBZ	O	O
recommended	PRISTIQ.xml:S3:14723:11	recommend	VBN	O	O
whenever	PRISTIQ.xml:S3:14735:8	whenev	WRB	O	O
possible	PRISTIQ.xml:S3:14744:8	possibl	JJ	O	O
.	PRISTIQ.xml:S3:14752:1	.	.	O	O

If	PRISTIQ.xml:S3:14754:2	If	IN	O	O
intolerable	PRISTIQ.xml:S3:14757:11	intoler	JJ	O	O
symptoms	PRISTIQ.xml:S3:14769:8	symptom	NNS	O	O
occur	PRISTIQ.xml:S3:14778:5	occur	VBP	O	O
following	PRISTIQ.xml:S3:14784:9	follow	VBG	O	O
a	PRISTIQ.xml:S3:14794:1	a	DT	O	O
decrease	PRISTIQ.xml:S3:14796:8	decreas	NN	O	O
in	PRISTIQ.xml:S3:14805:2	in	IN	O	O
the	PRISTIQ.xml:S3:14808:3	the	DT	O	O
dose	PRISTIQ.xml:S3:14812:4	dose	NN	O	O
or	PRISTIQ.xml:S3:14817:2	or	CC	O	O
upon	PRISTIQ.xml:S3:14820:4	upon	JJ	O	O
discontinuation	PRISTIQ.xml:S3:14825:15	discontinu	NN	O	O
of	PRISTIQ.xml:S3:14841:2	of	IN	O	O
treatment	PRISTIQ.xml:S3:14844:9	treatment	NN	O	O
,	PRISTIQ.xml:S3:14853:1	,	,	O	O
then	PRISTIQ.xml:S3:14855:4	then	RB	O	O
resuming	PRISTIQ.xml:S3:14860:8	resum	VBG	O	O
the	PRISTIQ.xml:S3:14869:3	the	DT	O	O
previously	PRISTIQ.xml:S3:14873:10	previous	RB	O	O
prescribed	PRISTIQ.xml:S3:14884:10	prescrib	VBN	O	O
dose	PRISTIQ.xml:S3:14895:4	dose	NN	O	O
may	PRISTIQ.xml:S3:14900:3	may	MD	O	O
be	PRISTIQ.xml:S3:14904:2	be	VB	O	O
considered	PRISTIQ.xml:S3:14907:10	consid	VBN	O	O
.	PRISTIQ.xml:S3:14917:1	.	.	O	O

Subsequently	PRISTIQ.xml:S3:14919:12	subsequ	RB	O	O
,	PRISTIQ.xml:S3:14931:1	,	,	O	O
the	PRISTIQ.xml:S3:14933:3	the	DT	O	O
physician	PRISTIQ.xml:S3:14937:9	physician	NN	O	O
may	PRISTIQ.xml:S3:14947:3	may	MD	O	O
continue	PRISTIQ.xml:S3:14951:8	continu	VB	O	O
decreasing	PRISTIQ.xml:S3:14960:10	decreas	VBG	O	O
the	PRISTIQ.xml:S3:14971:3	the	DT	O	O
dose	PRISTIQ.xml:S3:14975:4	dose	NN	O	O
,	PRISTIQ.xml:S3:14979:1	,	,	O	O
but	PRISTIQ.xml:S3:14981:3	but	CC	O	O
at	PRISTIQ.xml:S3:14985:2	at	IN	O	O
a	PRISTIQ.xml:S3:14988:1	a	DT	O	O
more	PRISTIQ.xml:S3:14990:4	more	RBR	O	O
gradual	PRISTIQ.xml:S3:14995:7	gradual	JJ	O	O
rate	PRISTIQ.xml:S3:15003:4	rate	NN	O	O
[	PRISTIQ.xml:S3:15008:1	[	NNS	O	O
see	PRISTIQ.xml:S3:15009:3	see	VBP	O	O
Dosage	PRISTIQ.xml:S3:15014:6	dosag	NNP	O	O
and	PRISTIQ.xml:S3:15021:3	and	CC	O	O
Administration	PRISTIQ.xml:S3:15025:14	administr	NNP	O	O
(	PRISTIQ.xml:S3:15040:1	(	(	O	O
2.4	PRISTIQ.xml:S3:15041:3	2.4	CD	O	O
)	PRISTIQ.xml:S3:15044:1	)	)	O	O
and	PRISTIQ.xml:S3:15047:3	and	CC	O	O
Adverse	PRISTIQ.xml:S3:15052:7	advers	JJ	O	O
Reactions	PRISTIQ.xml:S3:15060:9	reaction	NNP	O	O
(	PRISTIQ.xml:S3:15070:1	(	(	O	O
6.1	PRISTIQ.xml:S3:15071:3	6.1	CD	O	O
)	PRISTIQ.xml:S3:15074:1	)	)	O	O
]	PRISTIQ.xml:S3:15077:1	]	NN	O	O
.	PRISTIQ.xml:S3:15080:1	.	.	O	O

5.8	PRISTIQ.xml:S3:15089:3	5.8	CD	O	O
Seizure	PRISTIQ.xml:S3:15093:7	seizur	NN	O	O

Cases	PRISTIQ.xml:S3:15106:5	case	NNS	O	O
of	PRISTIQ.xml:S3:15112:2	of	IN	O	O
seizure	PRISTIQ.xml:S3:15115:7	seizur	NN	B-AdverseReaction	B-AdverseReaction
have	PRISTIQ.xml:S3:15123:4	have	VBP	O	O
been	PRISTIQ.xml:S3:15128:4	been	VBN	O	O
reported	PRISTIQ.xml:S3:15133:8	report	VBN	O	O
in	PRISTIQ.xml:S3:15142:2	in	IN	O	O
pre	PRISTIQ.xml:S3:15145:3	pre	NN	O	O
-	PRISTIQ.xml:S3:15148:1	-	:	O	O
marketing	PRISTIQ.xml:S3:15149:9	market	NN	O	O
clinical	PRISTIQ.xml:S3:15159:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S3:15168:7	studi	NNS	O	O
with	PRISTIQ.xml:S3:15176:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:15181:7	pristiq	NNP	O	O
.	PRISTIQ.xml:S3:15188:1	.	.	O	O

PRISTIQ	PRISTIQ.xml:S3:15190:7	pristiq	NNP	O	O
has	PRISTIQ.xml:S3:15198:3	ha	VBZ	O	O
not	PRISTIQ.xml:S3:15202:3	not	RB	O	O
been	PRISTIQ.xml:S3:15206:4	been	VBN	O	O
systematically	PRISTIQ.xml:S3:15211:14	systemat	RB	O	O
evaluated	PRISTIQ.xml:S3:15226:9	evalu	VBN	O	O
in	PRISTIQ.xml:S3:15236:2	in	IN	O	O
patients	PRISTIQ.xml:S3:15239:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:15248:4	with	IN	O	O
a	PRISTIQ.xml:S3:15253:1	a	DT	O	O
seizure	PRISTIQ.xml:S3:15255:7	seizur	NN	O	O
disorder	PRISTIQ.xml:S3:15263:8	disord	NN	O	O
.	PRISTIQ.xml:S3:15271:1	.	.	O	O

Patients	PRISTIQ.xml:S3:15273:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:15282:4	with	IN	O	O
a	PRISTIQ.xml:S3:15287:1	a	DT	O	O
history	PRISTIQ.xml:S3:15289:7	histori	NN	O	O
of	PRISTIQ.xml:S3:15297:2	of	IN	O	O
seizures	PRISTIQ.xml:S3:15300:8	seizur	NNS	O	O
were	PRISTIQ.xml:S3:15309:4	were	VBD	O	O
excluded	PRISTIQ.xml:S3:15314:8	exclud	VBN	O	O
from	PRISTIQ.xml:S3:15323:4	from	IN	O	O
pre	PRISTIQ.xml:S3:15328:3	pre	NN	O	O
-	PRISTIQ.xml:S3:15331:1	-	:	O	O
marketing	PRISTIQ.xml:S3:15332:9	market	NN	O	O
clinical	PRISTIQ.xml:S3:15342:8	clinic	JJ	O	O
studies	PRISTIQ.xml:S3:15351:7	studi	NNS	O	O
.	PRISTIQ.xml:S3:15358:1	.	.	O	O

PRISTIQ	PRISTIQ.xml:S3:15360:7	pristiq	NNP	O	O
should	PRISTIQ.xml:S3:15368:6	should	MD	O	O
be	PRISTIQ.xml:S3:15375:2	be	VB	O	O
prescribed	PRISTIQ.xml:S3:15378:10	prescrib	VBN	O	O
with	PRISTIQ.xml:S3:15389:4	with	IN	O	O
caution	PRISTIQ.xml:S3:15394:7	caution	NN	O	O
in	PRISTIQ.xml:S3:15402:2	in	IN	O	O
patients	PRISTIQ.xml:S3:15405:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:15414:4	with	IN	O	O
a	PRISTIQ.xml:S3:15419:1	a	DT	O	O
seizure	PRISTIQ.xml:S3:15421:7	seizur	NN	O	O
disorder	PRISTIQ.xml:S3:15429:8	disord	NN	O	O
.	PRISTIQ.xml:S3:15437:1	.	.	O	O

5.9	PRISTIQ.xml:S3:15446:3	5.9	CD	O	O
Hyponatremia	PRISTIQ.xml:S3:15450:12	hyponatremia	NN	O	O

Hyponatremia	PRISTIQ.xml:S3:15468:12	hyponatremia	NNP	B-AdverseReaction	B-AdverseReaction
may	PRISTIQ.xml:S3:15481:3	may	MD	O	O
occur	PRISTIQ.xml:S3:15485:5	occur	VB	O	O
as	PRISTIQ.xml:S3:15491:2	as	IN	O	O
a	PRISTIQ.xml:S3:15494:1	a	DT	O	O
result	PRISTIQ.xml:S3:15496:6	result	NN	O	O
of	PRISTIQ.xml:S3:15503:2	of	IN	O	O
treatment	PRISTIQ.xml:S3:15506:9	treatment	NN	O	O
with	PRISTIQ.xml:S3:15516:4	with	IN	O	O
SSRIs	PRISTIQ.xml:S3:15521:5	ssri	NNP	O	O
and	PRISTIQ.xml:S3:15527:3	and	CC	O	O
SNRIs	PRISTIQ.xml:S3:15531:5	snri	NNP	O	O
,	PRISTIQ.xml:S3:15536:1	,	,	O	O
including	PRISTIQ.xml:S3:15538:9	includ	VBG	O	O
PRISTIQ	PRISTIQ.xml:S3:15548:7	pristiq	NNP	O	O
.	PRISTIQ.xml:S3:15555:1	.	.	O	O

In	PRISTIQ.xml:S3:15557:2	In	IN	O	O
many	PRISTIQ.xml:S3:15560:4	mani	JJ	O	O
cases	PRISTIQ.xml:S3:15565:5	case	NNS	O	O
,	PRISTIQ.xml:S3:15570:1	,	,	O	O
this	PRISTIQ.xml:S3:15572:4	thi	DT	O	O
hyponatremia	PRISTIQ.xml:S3:15577:12	hyponatremia	NN	B-AdverseReaction	B-AdverseReaction
appears	PRISTIQ.xml:S3:15590:7	appear	VBZ	O	O
to	PRISTIQ.xml:S3:15598:2	to	TO	O	O
be	PRISTIQ.xml:S3:15601:2	be	VB	O	O
the	PRISTIQ.xml:S3:15604:3	the	DT	O	O
result	PRISTIQ.xml:S3:15608:6	result	NN	O	O
of	PRISTIQ.xml:S3:15615:2	of	IN	O	O
the	PRISTIQ.xml:S3:15618:3	the	DT	O	O
syndrome	PRISTIQ.xml:S3:15622:8	syndrom	NN	B-AdverseReaction	O
of	PRISTIQ.xml:S3:15631:2	of	IN	I-AdverseReaction	O
inappropriate	PRISTIQ.xml:S3:15634:13	inappropri	JJ	I-AdverseReaction	B-AdverseReaction
antidiuretic	PRISTIQ.xml:S3:15648:12	antidiuret	JJ	I-AdverseReaction	I-AdverseReaction
hormone	PRISTIQ.xml:S3:15661:7	hormon	NN	I-AdverseReaction	I-AdverseReaction
secretion	PRISTIQ.xml:S3:15669:9	secret	NN	I-AdverseReaction	I-AdverseReaction
(	PRISTIQ.xml:S3:15679:1	(	(	O	O
SIADH	PRISTIQ.xml:S3:15680:5	siadh	NNP	B-AdverseReaction	O
)	PRISTIQ.xml:S3:15685:1	)	)	O	O
.	PRISTIQ.xml:S3:15686:1	.	.	O	O

Cases	PRISTIQ.xml:S3:15688:5	case	NNS	O	O
with	PRISTIQ.xml:S3:15694:4	with	IN	O	O
serum	PRISTIQ.xml:S3:15699:5	serum	JJ	B-AdverseReaction	B-AdverseReaction
sodium	PRISTIQ.xml:S3:15705:6	sodium	NN	I-AdverseReaction	I-AdverseReaction
lower	PRISTIQ.xml:S3:15712:5	lower	JJR	I-AdverseReaction	I-AdverseReaction
than	PRISTIQ.xml:S3:15718:4	than	IN	I-AdverseReaction	I-AdverseReaction
110	PRISTIQ.xml:S3:15723:3	110	CD	I-AdverseReaction	I-AdverseReaction
mmol	PRISTIQ.xml:S3:15727:4	mmol	NN	I-AdverseReaction	I-AdverseReaction
L	PRISTIQ.xml:S3:15732:1	L	NNP	I-AdverseReaction	I-AdverseReaction
have	PRISTIQ.xml:S3:15734:4	have	VBP	O	O
been	PRISTIQ.xml:S3:15739:4	been	VBN	O	O
reported	PRISTIQ.xml:S3:15744:8	report	VBN	O	O
.	PRISTIQ.xml:S3:15752:1	.	.	O	O

Elderly	PRISTIQ.xml:S3:15754:7	elderli	JJ	O	O
patients	PRISTIQ.xml:S3:15762:8	patient	NNS	O	O
may	PRISTIQ.xml:S3:15771:3	may	MD	O	O
be	PRISTIQ.xml:S3:15775:2	be	VB	O	O
at	PRISTIQ.xml:S3:15778:2	at	IN	O	O
greater	PRISTIQ.xml:S3:15781:7	greater	JJR	O	O
risk	PRISTIQ.xml:S3:15789:4	risk	NN	O	O
of	PRISTIQ.xml:S3:15794:2	of	IN	O	O
developing	PRISTIQ.xml:S3:15797:10	develop	VBG	O	O
hyponatremia	PRISTIQ.xml:S3:15808:12	hyponatremia	NN	B-AdverseReaction	B-AdverseReaction
with	PRISTIQ.xml:S3:15821:4	with	IN	O	O
SSRIs	PRISTIQ.xml:S3:15826:5	ssri	NNP	O	O
and	PRISTIQ.xml:S3:15832:3	and	CC	O	O
SNRIs	PRISTIQ.xml:S3:15836:5	snri	NNP	O	O
.	PRISTIQ.xml:S3:15841:1	.	.	O	O

Also	PRISTIQ.xml:S3:15843:4	also	RB	O	O
,	PRISTIQ.xml:S3:15847:1	,	,	O	O
patients	PRISTIQ.xml:S3:15849:8	patient	NNS	O	O
taking	PRISTIQ.xml:S3:15858:6	take	VBG	O	O
diuretics	PRISTIQ.xml:S3:15865:9	diuret	NNS	O	O
or	PRISTIQ.xml:S3:15875:2	or	CC	O	O
who	PRISTIQ.xml:S3:15878:3	who	WP	O	O
are	PRISTIQ.xml:S3:15882:3	are	VBP	O	O
otherwise	PRISTIQ.xml:S3:15886:9	otherwis	RB	O	O
volume	PRISTIQ.xml:S3:15896:6	volum	NN	O	O
depleted	PRISTIQ.xml:S3:15903:8	deplet	VBD	O	O
can	PRISTIQ.xml:S3:15912:3	can	MD	O	O
be	PRISTIQ.xml:S3:15916:2	be	VB	O	O
at	PRISTIQ.xml:S3:15919:2	at	IN	O	O
greater	PRISTIQ.xml:S3:15922:7	greater	JJR	O	O
risk	PRISTIQ.xml:S3:15930:4	risk	NN	O	O
[	PRISTIQ.xml:S3:15935:1	[	NNP	O	O
see	PRISTIQ.xml:S3:15936:3	see	NN	O	O
Use	PRISTIQ.xml:S3:15941:3	use	NNP	O	O
in	PRISTIQ.xml:S3:15945:2	in	IN	O	O
Specific	PRISTIQ.xml:S3:15948:8	specif	NNP	O	O
Populations	PRISTIQ.xml:S3:15957:11	popul	NNP	O	O
(	PRISTIQ.xml:S3:15969:1	(	(	O	O
8.5	PRISTIQ.xml:S3:15970:3	8.5	CD	O	O
)	PRISTIQ.xml:S3:15973:1	)	)	O	O
and	PRISTIQ.xml:S3:15976:3	and	CC	O	O
Clinical	PRISTIQ.xml:S3:15980:8	clinic	JJ	O	O
Pharmacology	PRISTIQ.xml:S3:15989:12	pharmacolog	NNP	O	O
(	PRISTIQ.xml:S3:16002:1	(	(	O	O
12.6	PRISTIQ.xml:S3:16003:4	12.6	CD	O	O
)]	PRISTIQ.xml:S3:16007:2	)]	NN	O	O
.	PRISTIQ.xml:S3:16011:1	.	.	O	O

Discontinuation	PRISTIQ.xml:S3:16013:15	discontinu	NN	O	O
of	PRISTIQ.xml:S3:16029:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:16032:7	pristiq	NNP	O	O
should	PRISTIQ.xml:S3:16040:6	should	MD	O	O
be	PRISTIQ.xml:S3:16047:2	be	VB	O	O
considered	PRISTIQ.xml:S3:16050:10	consid	VBN	O	O
in	PRISTIQ.xml:S3:16061:2	in	IN	O	O
patients	PRISTIQ.xml:S3:16064:8	patient	NNS	O	O
with	PRISTIQ.xml:S3:16073:4	with	IN	O	O
symptomatic	PRISTIQ.xml:S3:16078:11	symptomat	JJ	O	O
hyponatremia	PRISTIQ.xml:S3:16090:12	hyponatremia	NN	O	O
and	PRISTIQ.xml:S3:16103:3	and	CC	O	O
appropriate	PRISTIQ.xml:S3:16107:11	appropri	JJ	O	O
medical	PRISTIQ.xml:S3:16119:7	medic	JJ	O	O
intervention	PRISTIQ.xml:S3:16127:12	intervent	NN	O	O
should	PRISTIQ.xml:S3:16140:6	should	MD	O	O
be	PRISTIQ.xml:S3:16147:2	be	VB	O	O
instituted	PRISTIQ.xml:S3:16150:10	institut	VBN	O	O
.	PRISTIQ.xml:S3:16160:1	.	.	O	O

Signs	PRISTIQ.xml:S3:16166:5	sign	NNS	O	O
and	PRISTIQ.xml:S3:16172:3	and	CC	O	O
symptoms	PRISTIQ.xml:S3:16176:8	symptom	NNS	O	O
of	PRISTIQ.xml:S3:16185:2	of	IN	O	O
hyponatremia	PRISTIQ.xml:S3:16188:12	hyponatremia	NN	B-AdverseReaction	O
include	PRISTIQ.xml:S3:16201:7	includ	VBP	O	O
headache	PRISTIQ.xml:S3:16209:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:16217:1	,	,	O	O
difficulty	PRISTIQ.xml:S3:16219:10	difficulti	NN	B-AdverseReaction	O
concentrating	PRISTIQ.xml:S3:16230:13	concentr	NN	I-AdverseReaction	O
,	PRISTIQ.xml:S3:16243:1	,	,	O	O
memory	PRISTIQ.xml:S3:16245:6	memori	NN	B-AdverseReaction	B-AdverseReaction
impairment	PRISTIQ.xml:S3:16252:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S3:16262:1	,	,	O	O
confusion	PRISTIQ.xml:S3:16264:9	confus	NN	B-AdverseReaction	O
,	PRISTIQ.xml:S3:16273:1	,	,	O	O
weakness	PRISTIQ.xml:S3:16275:8	weak	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:16283:1	,	,	O	O
and	PRISTIQ.xml:S3:16285:3	and	CC	O	O
unsteadiness	PRISTIQ.xml:S3:16289:12	unsteadi	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:16301:1	,	,	O	O
which	PRISTIQ.xml:S3:16303:5	which	WDT	O	O
can	PRISTIQ.xml:S3:16309:3	can	MD	O	O
lead	PRISTIQ.xml:S3:16313:4	lead	VB	O	O
to	PRISTIQ.xml:S3:16318:2	to	TO	O	O
falls	PRISTIQ.xml:S3:16321:5	fall	NNS	B-AdverseReaction	B-AdverseReaction
.	PRISTIQ.xml:S3:16326:1	.	.	O	O

Signs	PRISTIQ.xml:S3:16328:5	sign	NNS	O	O
and	PRISTIQ.xml:S3:16334:3	and	CC	O	O
symptoms	PRISTIQ.xml:S3:16338:8	symptom	NNS	O	O
associated	PRISTIQ.xml:S3:16347:10	associ	VBN	O	O
with	PRISTIQ.xml:S3:16358:4	with	IN	O	O
more	PRISTIQ.xml:S3:16363:4	more	RBR	O	O
severe	PRISTIQ.xml:S3:16368:6	sever	JJ	O	O
and	PRISTIQ.xml:S3:16375:3	and	CC	O	O
or	PRISTIQ.xml:S3:16379:2	or	CC	O	O
acute	PRISTIQ.xml:S3:16382:5	acut	JJ	O	O
cases	PRISTIQ.xml:S3:16388:5	case	NNS	O	O
have	PRISTIQ.xml:S3:16394:4	have	VBP	O	O
included	PRISTIQ.xml:S3:16399:8	includ	VBN	O	O
hallucination	PRISTIQ.xml:S3:16408:13	hallucin	NN	B-AdverseReaction	O
,	PRISTIQ.xml:S3:16421:1	,	,	O	O
syncope	PRISTIQ.xml:S3:16423:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:16430:1	,	,	O	O
seizure	PRISTIQ.xml:S3:16432:7	seizur	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:16439:1	,	,	O	O
coma	PRISTIQ.xml:S3:16441:4	coma	NN	B-AdverseReaction	B-AdverseReaction
,	PRISTIQ.xml:S3:16445:1	,	,	O	O
respiratory	PRISTIQ.xml:S3:16447:11	respiratori	NN	B-AdverseReaction	B-AdverseReaction
arrest	PRISTIQ.xml:S3:16459:6	arrest	NN	I-AdverseReaction	I-AdverseReaction
,	PRISTIQ.xml:S3:16465:1	,	,	O	O
and	PRISTIQ.xml:S3:16467:3	and	CC	O	O
death	PRISTIQ.xml:S3:16471:5	death	NN	B-AdverseReaction	B-AdverseReaction
.	PRISTIQ.xml:S3:16476:1	.	.	O	O

5.10	PRISTIQ.xml:S3:16485:4	5.10	CD	O	O
Interstitial	PRISTIQ.xml:S3:16490:12	interstiti	JJ	O	O
Lung	PRISTIQ.xml:S3:16503:4	lung	NNP	O	O
Disease	PRISTIQ.xml:S3:16508:7	diseas	NNP	O	O
and	PRISTIQ.xml:S3:16516:3	and	CC	O	O
Eosinophilic	PRISTIQ.xml:S3:16520:12	eosinophil	NNP	O	O
Pneumonia	PRISTIQ.xml:S3:16533:9	pneumonia	NNP	O	O

Interstitial	PRISTIQ.xml:S3:16548:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
lung	PRISTIQ.xml:S3:16561:4	lung	NN	I-AdverseReaction	I-AdverseReaction
disease	PRISTIQ.xml:S3:16566:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
and	PRISTIQ.xml:S3:16574:3	and	CC	O	O
eosinophilic	PRISTIQ.xml:S3:16578:12	eosinophil	JJ	B-AdverseReaction	B-AdverseReaction
pneumonia	PRISTIQ.xml:S3:16591:9	pneumonia	NN	I-AdverseReaction	I-AdverseReaction
associated	PRISTIQ.xml:S3:16601:10	associ	VBN	O	O
with	PRISTIQ.xml:S3:16612:4	with	IN	O	O
venlafaxine	PRISTIQ.xml:S3:16617:11	venlafaxin	NN	O	O
(	PRISTIQ.xml:S3:16629:1	(	(	O	O
the	PRISTIQ.xml:S3:16630:3	the	DT	O	O
parent	PRISTIQ.xml:S3:16634:6	parent	NN	O	O
drug	PRISTIQ.xml:S3:16641:4	drug	NN	O	O
of	PRISTIQ.xml:S3:16646:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:16649:7	pristiq	NNP	O	O
)	PRISTIQ.xml:S3:16656:1	)	)	O	O
therapy	PRISTIQ.xml:S3:16658:7	therapi	NN	O	O
have	PRISTIQ.xml:S3:16666:4	have	VBP	O	O
been	PRISTIQ.xml:S3:16671:4	been	VBN	O	O
rarely	PRISTIQ.xml:S3:16676:6	rare	RB	O	O
reported	PRISTIQ.xml:S3:16683:8	report	VBN	O	O
.	PRISTIQ.xml:S3:16691:1	.	.	O	O

The	PRISTIQ.xml:S3:16693:3	the	DT	O	O
possibility	PRISTIQ.xml:S3:16697:11	possibl	NN	O	O
of	PRISTIQ.xml:S3:16709:2	of	IN	O	O
these	PRISTIQ.xml:S3:16712:5	these	DT	O	O
adverse	PRISTIQ.xml:S3:16718:7	advers	JJ	O	O
events	PRISTIQ.xml:S3:16726:6	event	NNS	O	O
should	PRISTIQ.xml:S3:16733:6	should	MD	O	O
be	PRISTIQ.xml:S3:16740:2	be	VB	O	O
considered	PRISTIQ.xml:S3:16743:10	consid	VBN	O	O
in	PRISTIQ.xml:S3:16754:2	in	IN	O	O
patients	PRISTIQ.xml:S3:16757:8	patient	NNS	O	O
treated	PRISTIQ.xml:S3:16766:7	treat	VBN	O	O
with	PRISTIQ.xml:S3:16774:4	with	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:16779:7	pristiq	NNP	O	O
who	PRISTIQ.xml:S3:16787:3	who	WP	O	O
present	PRISTIQ.xml:S3:16791:7	present	VBP	O	O
with	PRISTIQ.xml:S3:16799:4	with	IN	O	O
progressive	PRISTIQ.xml:S3:16804:11	progress	JJ	O	O
dyspnea	PRISTIQ.xml:S3:16816:7	dyspnea	NN	O	O
,	PRISTIQ.xml:S3:16823:1	,	,	O	O
cough	PRISTIQ.xml:S3:16825:5	cough	NN	O	B-AdverseReaction
,	PRISTIQ.xml:S3:16830:1	,	,	O	O
or	PRISTIQ.xml:S3:16832:2	or	CC	O	O
chest	PRISTIQ.xml:S3:16835:5	chest	JJS	O	O
discomfort	PRISTIQ.xml:S3:16841:10	discomfort	NN	O	O
.	PRISTIQ.xml:S3:16851:1	.	.	O	O

Such	PRISTIQ.xml:S3:16853:4	such	JJ	O	O
patients	PRISTIQ.xml:S3:16858:8	patient	NNS	O	O
should	PRISTIQ.xml:S3:16867:6	should	MD	O	O
undergo	PRISTIQ.xml:S3:16874:7	undergo	VB	O	O
a	PRISTIQ.xml:S3:16882:1	a	DT	O	O
prompt	PRISTIQ.xml:S3:16884:6	prompt	JJ	O	O
medical	PRISTIQ.xml:S3:16891:7	medic	JJ	O	O
evaluation	PRISTIQ.xml:S3:16899:10	evalu	NN	O	O
,	PRISTIQ.xml:S3:16909:1	,	,	O	O
and	PRISTIQ.xml:S3:16911:3	and	CC	O	O
discontinuation	PRISTIQ.xml:S3:16915:15	discontinu	NN	O	O
of	PRISTIQ.xml:S3:16931:2	of	IN	O	O
PRISTIQ	PRISTIQ.xml:S3:16934:7	pristiq	NNP	O	O
should	PRISTIQ.xml:S3:16942:6	should	MD	O	O
be	PRISTIQ.xml:S3:16949:2	be	VB	O	O
considered	PRISTIQ.xml:S3:16952:10	consid	VBN	O	O
.	PRISTIQ.xml:S3:16962:1	.	.	O	O
6	PROLIA.xml:S1:4:1	6	CD	O	O
ADVERSE	PROLIA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	PROLIA.xml:S1:14:9	reaction	NN	O	O

The	PROLIA.xml:S1:27:3	the	DT	O	O
following	PROLIA.xml:S1:31:9	follow	VBG	O	O
serious	PROLIA.xml:S1:41:7	seriou	JJ	O	O
adverse	PROLIA.xml:S1:49:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:57:9	reaction	NNS	O	O
are	PROLIA.xml:S1:67:3	are	VBP	O	O
discussed	PROLIA.xml:S1:71:9	discuss	VBN	O	O
below	PROLIA.xml:S1:81:5	below	IN	O	O
and	PROLIA.xml:S1:87:3	and	CC	O	O
also	PROLIA.xml:S1:91:4	also	RB	O	O
elsewhere	PROLIA.xml:S1:96:9	elsewher	RB	O	O
in	PROLIA.xml:S1:106:2	in	IN	O	O
the	PROLIA.xml:S1:109:3	the	DT	O	O
labeling	PROLIA.xml:S1:113:8	label	NN	O	O
:	PROLIA.xml:S1:121:1	:	:	O	O

Hypocalcemia	PROLIA.xml:S1:130:12	hypocalcemia	NNP	B-AdverseReaction	B-AdverseReaction
[	PROLIA.xml:S1:143:1	[	NNP	O	O
see	PROLIA.xml:S1:144:3	see	VBP	O	O
Warnings	PROLIA.xml:S1:148:8	warn	NNP	O	O
and	PROLIA.xml:S1:157:3	and	CC	O	O
Precautions	PROLIA.xml:S1:161:11	precaut	NNP	O	O
(	PROLIA.xml:S1:173:1	(	(	O	O
5.3	PROLIA.xml:S1:176:3	5.3	CD	O	O
)]	PROLIA.xml:S1:181:2	)]	NN	O	O

Serious	PROLIA.xml:S1:190:7	seriou	JJ	O	O
Infections	PROLIA.xml:S1:198:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
[	PROLIA.xml:S1:209:1	[	VBP	O	O
see	PROLIA.xml:S1:210:3	see	VBP	O	O
Warnings	PROLIA.xml:S1:214:8	warn	NNS	O	O
and	PROLIA.xml:S1:223:3	and	CC	O	O
Precautions	PROLIA.xml:S1:227:11	precaut	NNP	O	O
(	PROLIA.xml:S1:239:1	(	(	O	O
5.6	PROLIA.xml:S1:242:3	5.6	CD	O	O
)]	PROLIA.xml:S1:247:2	)]	NN	O	O

Dermatologic	PROLIA.xml:S1:256:12	dermatolog	NNP	B-AdverseReaction	B-AdverseReaction
Adverse	PROLIA.xml:S1:269:7	advers	NNP	I-AdverseReaction	I-AdverseReaction
Reactions	PROLIA.xml:S1:277:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
[	PROLIA.xml:S1:287:1	[	NNP	O	O
see	PROLIA.xml:S1:288:3	see	VBP	O	O
Warnings	PROLIA.xml:S1:292:8	warn	NNP	O	O
and	PROLIA.xml:S1:301:3	and	CC	O	O
Precautions	PROLIA.xml:S1:305:11	precaut	NNP	O	O
(	PROLIA.xml:S1:317:1	(	(	O	O
5.7	PROLIA.xml:S1:320:3	5.7	CD	O	O
)]	PROLIA.xml:S1:325:2	)]	NN	O	O

Osteonecrosis	PROLIA.xml:S1:334:13	osteonecrosi	NN	B-AdverseReaction	B-AdverseReaction
of	PROLIA.xml:S1:348:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	PROLIA.xml:S1:351:3	the	DT	I-AdverseReaction	I-AdverseReaction
Jaw	PROLIA.xml:S1:355:3	jaw	NNP	I-AdverseReaction	I-AdverseReaction
[	PROLIA.xml:S1:359:1	[	NNP	O	O
see	PROLIA.xml:S1:360:3	see	VBP	O	O
Warnings	PROLIA.xml:S1:364:8	warn	NNP	O	O
and	PROLIA.xml:S1:373:3	and	CC	O	O
Precautions	PROLIA.xml:S1:377:11	precaut	NNP	O	O
(	PROLIA.xml:S1:389:1	(	(	O	O
5.4	PROLIA.xml:S1:392:3	5.4	CD	O	O
)]	PROLIA.xml:S1:397:2	)]	NN	O	O

Atypical	PROLIA.xml:S1:406:8	atyp	JJ	B-AdverseReaction	O
Subtrochanteric	PROLIA.xml:S1:415:15	subtrochanter	NNP	I-AdverseReaction	O
and	PROLIA.xml:S1:431:3	and	CC	O	O
Diaphyseal	PROLIA.xml:S1:435:10	diaphys	NNP	I-AdverseReaction	B-AdverseReaction
Femoral	PROLIA.xml:S1:446:7	femor	NNP	I-AdverseReaction	I-AdverseReaction
Fractures	PROLIA.xml:S1:454:9	fractur	NNP	I-AdverseReaction	I-AdverseReaction
[	PROLIA.xml:S1:464:1	[	NNP	O	O
see	PROLIA.xml:S1:465:3	see	VBP	O	O
Warnings	PROLIA.xml:S1:469:8	warn	NNP	O	O
and	PROLIA.xml:S1:478:3	and	CC	O	O
Precautions	PROLIA.xml:S1:482:11	precaut	NNP	O	O
(	PROLIA.xml:S1:494:1	(	(	O	O
5.5	PROLIA.xml:S1:497:3	5.5	CD	O	O
)]	PROLIA.xml:S1:502:2	)]	NN	O	O

The	PROLIA.xml:S1:511:3	the	DT	O	O
most	PROLIA.xml:S1:515:4	most	RBS	O	O
common	PROLIA.xml:S1:520:6	common	JJ	O	O
adverse	PROLIA.xml:S1:527:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:535:9	reaction	NNS	O	O
reported	PROLIA.xml:S1:545:8	report	VBN	O	O
with	PROLIA.xml:S1:554:4	with	IN	O	O
Prolia	PROLIA.xml:S1:559:6	prolia	NNP	O	O
in	PROLIA.xml:S1:566:2	in	IN	O	O
patients	PROLIA.xml:S1:569:8	patient	NNS	O	O
with	PROLIA.xml:S1:578:4	with	IN	O	O
postmenopausal	PROLIA.xml:S1:583:14	postmenopaus	JJ	O	O
osteoporosis	PROLIA.xml:S1:598:12	osteoporosi	NN	O	O
are	PROLIA.xml:S1:611:3	are	VBP	O	O
back	PROLIA.xml:S1:615:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:620:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:624:1	,	,	O	O
pain	PROLIA.xml:S1:626:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	PROLIA.xml:S1:631:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	PROLIA.xml:S1:634:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:643:1	,	,	O	O
musculoskeletal	PROLIA.xml:S1:645:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:661:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:665:1	,	,	O	O
hypercholesterolemia	PROLIA.xml:S1:667:20	hypercholesterolemia	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S1:687:1	,	,	O	O
and	PROLIA.xml:S1:689:3	and	CC	O	O
cystitis	PROLIA.xml:S1:693:8	cystiti	NN	B-AdverseReaction	B-AdverseReaction
.	PROLIA.xml:S1:701:1	.	.	O	O

The	PROLIA.xml:S1:707:3	the	DT	O	O

most	PROLIA.xml:S1:711:4	most	RBS	O	O
common	PROLIA.xml:S1:716:6	common	JJ	O	O
adverse	PROLIA.xml:S1:723:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:731:9	reaction	NNS	O	O
reported	PROLIA.xml:S1:741:8	report	VBN	O	O
with	PROLIA.xml:S1:750:4	with	IN	O	O
Prolia	PROLIA.xml:S1:755:6	prolia	NNP	O	O
in	PROLIA.xml:S1:762:2	in	IN	O	O
men	PROLIA.xml:S1:765:3	men	NNS	O	O
with	PROLIA.xml:S1:769:4	with	IN	O	O
osteoporosis	PROLIA.xml:S1:774:12	osteoporosi	NN	O	O
are	PROLIA.xml:S1:787:3	are	VBP	O	O
back	PROLIA.xml:S1:791:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:796:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:800:1	,	,	O	O
arthralgia	PROLIA.xml:S1:802:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S1:812:1	,	,	O	O
and	PROLIA.xml:S1:814:3	and	CC	O	O
nasopharyngitis	PROLIA.xml:S1:818:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
.	PROLIA.xml:S1:833:1	.	.	O	O

The	PROLIA.xml:S1:839:3	the	DT	O	O
most	PROLIA.xml:S1:843:4	most	RBS	O	O
common	PROLIA.xml:S1:848:6	common	JJ	O	O
(	PROLIA.xml:S1:855:1	(	(	O	O
per	PROLIA.xml:S1:856:3	per	IN	O	O
patient	PROLIA.xml:S1:860:7	patient	NN	O	O
incidence	PROLIA.xml:S1:868:9	incid	NN	O	O
10%	PROLIA.xml:S1:881:3	10%	CD	O	O
)	PROLIA.xml:S1:884:1	)	)	O	O
adverse	PROLIA.xml:S1:886:7	advers	NN	O	O
reactions	PROLIA.xml:S1:894:9	reaction	NNS	O	O
reported	PROLIA.xml:S1:904:8	report	VBD	O	O
with	PROLIA.xml:S1:913:4	with	IN	O	O
Prolia	PROLIA.xml:S1:918:6	prolia	NNP	O	O
in	PROLIA.xml:S1:925:2	in	IN	O	O
patients	PROLIA.xml:S1:928:8	patient	NNS	O	O
with	PROLIA.xml:S1:937:4	with	IN	O	O
bone	PROLIA.xml:S1:942:4	bone	JJ	O	O
loss	PROLIA.xml:S1:947:4	loss	NN	O	O
receiving	PROLIA.xml:S1:952:9	receiv	VBG	O	O
androgen	PROLIA.xml:S1:962:8	androgen	JJ	O	O
deprivation	PROLIA.xml:S1:971:11	depriv	NN	O	O
therapy	PROLIA.xml:S1:983:7	therapi	NN	O	O
for	PROLIA.xml:S1:991:3	for	IN	O	O
prostate	PROLIA.xml:S1:995:8	prostat	NN	O	O
cancer	PROLIA.xml:S1:1004:6	cancer	NN	O	O
or	PROLIA.xml:S1:1011:2	or	CC	O	O
adjuvant	PROLIA.xml:S1:1014:8	adjuv	JJ	O	O
aromatase	PROLIA.xml:S1:1023:9	aromatas	NN	O	O
inhibitor	PROLIA.xml:S1:1033:9	inhibitor	NN	O	O
therapy	PROLIA.xml:S1:1043:7	therapi	NN	O	O
for	PROLIA.xml:S1:1051:3	for	IN	O	O
breast	PROLIA.xml:S1:1055:6	breast	NN	O	O
cancer	PROLIA.xml:S1:1062:6	cancer	NN	O	O
are	PROLIA.xml:S1:1069:3	are	VBP	O	O
arthralgia	PROLIA.xml:S1:1073:10	arthralgia	VBN	B-AdverseReaction	B-AdverseReaction
and	PROLIA.xml:S1:1084:3	and	CC	O	O
back	PROLIA.xml:S1:1088:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:1093:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	PROLIA.xml:S1:1097:1	.	.	O	O

Pain	PROLIA.xml:S1:1100:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	PROLIA.xml:S1:1105:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	PROLIA.xml:S1:1108:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
and	PROLIA.xml:S1:1118:3	and	CC	O	O
musculoskeletal	PROLIA.xml:S1:1122:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:1138:4	pain	NN	I-AdverseReaction	I-AdverseReaction
have	PROLIA.xml:S1:1143:4	have	VBP	O	O
also	PROLIA.xml:S1:1148:4	also	RB	O	O
been	PROLIA.xml:S1:1153:4	been	VBN	O	O
reported	PROLIA.xml:S1:1158:8	report	VBN	O	O
in	PROLIA.xml:S1:1167:2	in	IN	O	O
clinical	PROLIA.xml:S1:1170:8	clinic	JJ	O	O
trials	PROLIA.xml:S1:1179:6	trial	NNS	O	O
.	PROLIA.xml:S1:1185:1	.	.	O	O

The	PROLIA.xml:S1:1192:3	the	DT	O	O
most	PROLIA.xml:S1:1196:4	most	RBS	O	O
common	PROLIA.xml:S1:1201:6	common	JJ	O	O
adverse	PROLIA.xml:S1:1208:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:1216:9	reaction	NNS	O	O
leading	PROLIA.xml:S1:1226:7	lead	VBG	O	O
to	PROLIA.xml:S1:1234:2	to	TO	O	O
discontinuation	PROLIA.xml:S1:1237:15	discontinu	NN	O	O
of	PROLIA.xml:S1:1253:2	of	IN	O	O
Prolia	PROLIA.xml:S1:1256:6	prolia	NNP	O	O
in	PROLIA.xml:S1:1263:2	in	IN	O	O
patients	PROLIA.xml:S1:1266:8	patient	NNS	O	O
with	PROLIA.xml:S1:1275:4	with	IN	O	O
postmenopausal	PROLIA.xml:S1:1280:14	postmenopaus	JJ	O	O
osteoporosis	PROLIA.xml:S1:1295:12	osteoporosi	NN	O	O
are	PROLIA.xml:S1:1308:3	are	VBP	O	O
back	PROLIA.xml:S1:1312:4	back	RB	B-AdverseReaction	O
pain	PROLIA.xml:S1:1317:4	pain	NN	I-AdverseReaction	O
and	PROLIA.xml:S1:1322:3	and	CC	O	O
constipation	PROLIA.xml:S1:1326:12	constip	NN	B-AdverseReaction	B-AdverseReaction
.	PROLIA.xml:S1:1338:1	.	.	O	O

The	PROLIA.xml:S1:1344:3	the	DT	O	O
Prolia	PROLIA.xml:S1:1348:6	prolia	NNP	O	O
Postmarketing	PROLIA.xml:S1:1355:13	postmarket	NNP	O	O
Active	PROLIA.xml:S1:1369:6	activ	NNP	O	O
Safety	PROLIA.xml:S1:1376:6	safeti	NNP	O	O
Surveillance	PROLIA.xml:S1:1383:12	surveil	NNP	O	O
Program	PROLIA.xml:S1:1396:7	program	NNP	O	O
is	PROLIA.xml:S1:1404:2	is	VBZ	O	O
available	PROLIA.xml:S1:1407:9	avail	JJ	O	O
to	PROLIA.xml:S1:1417:2	to	TO	O	O
collect	PROLIA.xml:S1:1420:7	collect	VB	O	O
information	PROLIA.xml:S1:1428:11	inform	NN	O	O
from	PROLIA.xml:S1:1440:4	from	IN	O	O
prescribers	PROLIA.xml:S1:1445:11	prescrib	NNS	O	O
on	PROLIA.xml:S1:1457:2	on	IN	O	O
specific	PROLIA.xml:S1:1460:8	specif	JJ	O	O
adverse	PROLIA.xml:S1:1469:7	advers	JJ	O	O
events	PROLIA.xml:S1:1477:6	event	NNS	O	O
.	PROLIA.xml:S1:1483:1	.	.	O	O

Please	PROLIA.xml:S1:1486:6	pleas	NNP	O	O
see	PROLIA.xml:S1:1493:3	see	VB	O	O
www	PROLIA.xml:S1:1497:3	www	NN	O	O
.	PROLIA.xml:S1:1500:1	.	.	O	O
proliasafety	PROLIA.xml:S1:1501:12	proliasafeti	NN	O	O
.	PROLIA.xml:S1:1513:1	.	.	O	O
com	PROLIA.xml:S1:1514:3	com	NN	O	O
or	PROLIA.xml:S1:1518:2	or	CC	O	O
call	PROLIA.xml:S1:1521:4	call	VB	O	O
1	PROLIA.xml:S1:1526:1	1	CD	O	O
-	PROLIA.xml:S1:1527:1	-	:	O	O
800	PROLIA.xml:S1:1528:3	800	CD	O	O
-	PROLIA.xml:S1:1531:1	-	:	O	O
772	PROLIA.xml:S1:1532:3	772	CD	O	O
-	PROLIA.xml:S1:1535:1	-	:	O	O
6436	PROLIA.xml:S1:1536:4	6436	CD	O	O
for	PROLIA.xml:S1:1541:3	for	IN	O	O
more	PROLIA.xml:S1:1545:4	more	JJR	O	O
information	PROLIA.xml:S1:1550:11	inform	NN	O	O
about	PROLIA.xml:S1:1562:5	about	IN	O	O
this	PROLIA.xml:S1:1568:4	thi	DT	O	O
program	PROLIA.xml:S1:1573:7	program	NN	O	O
.	PROLIA.xml:S1:1580:1	.	.	O	O

EXCERPT	PROLIA.xml:S1:1590:7	excerpt	NN	O	O
:	PROLIA.xml:S1:1597:1	:	:	O	O
Postmenopausal	PROLIA.xml:S1:1605:14	postmenopaus	JJ	O	O
osteoporosis	PROLIA.xml:S1:1620:12	osteoporosi	NN	O	O
:	PROLIA.xml:S1:1632:1	:	:	O	O
Most	PROLIA.xml:S1:1634:4	most	JJS	O	O
common	PROLIA.xml:S1:1639:6	common	JJ	O	O
adverse	PROLIA.xml:S1:1646:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:1654:9	reaction	NNS	O	O
(	PROLIA.xml:S1:1664:1	(	(	O	O
5%	PROLIA.xml:S1:1667:2	5%	CD	O	O
and	PROLIA.xml:S1:1670:3	and	CC	O	O
more	PROLIA.xml:S1:1674:4	more	JJR	O	O
common	PROLIA.xml:S1:1679:6	common	JJ	O	O
than	PROLIA.xml:S1:1686:4	than	IN	O	O
placebo	PROLIA.xml:S1:1691:7	placebo	NN	O	O
)	PROLIA.xml:S1:1698:1	)	)	O	O
were	PROLIA.xml:S1:1700:4	were	VBD	O	O
:	PROLIA.xml:S1:1704:1	:	:	O	O
back	PROLIA.xml:S1:1706:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:1711:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:1715:1	,	,	O	O
pain	PROLIA.xml:S1:1717:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	PROLIA.xml:S1:1722:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	PROLIA.xml:S1:1725:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:1734:1	,	,	O	O
hypercholesterolemia	PROLIA.xml:S1:1736:20	hypercholesterolemia	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S1:1756:1	,	,	O	O
musculoskeletal	PROLIA.xml:S1:1758:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:1774:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:1778:1	,	,	O	O
and	PROLIA.xml:S1:1780:3	and	CC	O	O
cystitis	PROLIA.xml:S1:1784:8	cystiti	NN	B-AdverseReaction	B-AdverseReaction
.	PROLIA.xml:S1:1792:1	.	.	O	O

Pancreatitis	PROLIA.xml:S1:1794:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
has	PROLIA.xml:S1:1807:3	ha	VBZ	O	O
been	PROLIA.xml:S1:1811:4	been	VBN	O	O
reported	PROLIA.xml:S1:1816:8	report	VBN	O	O
in	PROLIA.xml:S1:1825:2	in	IN	O	O
clinical	PROLIA.xml:S1:1828:8	clinic	JJ	O	O
trials	PROLIA.xml:S1:1837:6	trial	NNS	O	O
(	PROLIA.xml:S1:1844:1	(	(	O	O
6.1	PROLIA.xml:S1:1847:3	6.1	CD	O	O
)	PROLIA.xml:S1:1852:1	)	)	O	O

Male	PROLIA.xml:S1:1859:4	male	JJ	O	O
Osteoporosis	PROLIA.xml:S1:1864:12	osteoporosi	NN	O	O
:	PROLIA.xml:S1:1876:1	:	:	O	O
Most	PROLIA.xml:S1:1878:4	most	JJS	O	O
common	PROLIA.xml:S1:1883:6	common	JJ	O	O
adverse	PROLIA.xml:S1:1890:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:1898:9	reaction	NNS	O	O
(	PROLIA.xml:S1:1908:1	(	(	O	O
5%	PROLIA.xml:S1:1911:2	5%	CD	O	O
and	PROLIA.xml:S1:1914:3	and	CC	O	O
more	PROLIA.xml:S1:1918:4	more	JJR	O	O
common	PROLIA.xml:S1:1923:6	common	JJ	O	O
than	PROLIA.xml:S1:1930:4	than	IN	O	O
placebo	PROLIA.xml:S1:1935:7	placebo	NN	O	O
)	PROLIA.xml:S1:1942:1	)	)	O	O
were	PROLIA.xml:S1:1944:4	were	VBD	O	O
:	PROLIA.xml:S1:1948:1	:	:	O	O
back	PROLIA.xml:S1:1950:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:1955:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:1959:1	,	,	O	O
arthralgia	PROLIA.xml:S1:1961:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S1:1971:1	,	,	O	O
and	PROLIA.xml:S1:1973:3	and	CC	O	O
nasopharyngitis	PROLIA.xml:S1:1977:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
(	PROLIA.xml:S1:1993:1	(	(	O	O
6.1	PROLIA.xml:S1:1996:3	6.1	CD	O	O
)	PROLIA.xml:S1:2001:1	)	)	O	O

Bone	PROLIA.xml:S1:2008:4	bone	NNP	O	B-AdverseReaction
loss	PROLIA.xml:S1:2013:4	loss	NN	O	I-AdverseReaction
due	PROLIA.xml:S1:2018:3	due	JJ	O	O
to	PROLIA.xml:S1:2022:2	to	TO	O	O
hormone	PROLIA.xml:S1:2025:7	hormon	VB	O	O
ablation	PROLIA.xml:S1:2033:8	ablat	NN	O	O
for	PROLIA.xml:S1:2042:3	for	IN	O	O
cancer	PROLIA.xml:S1:2046:6	cancer	NN	O	O
:	PROLIA.xml:S1:2052:1	:	:	O	O
Most	PROLIA.xml:S1:2054:4	most	JJS	O	O
common	PROLIA.xml:S1:2059:6	common	JJ	O	O
adverse	PROLIA.xml:S1:2066:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:2074:9	reaction	NNS	O	O
(	PROLIA.xml:S1:2084:1	(	(	O	O
10%	PROLIA.xml:S1:2088:3	10%	CD	O	O
and	PROLIA.xml:S1:2092:3	and	CC	O	O
more	PROLIA.xml:S1:2096:4	more	JJR	O	O
common	PROLIA.xml:S1:2101:6	common	JJ	O	O
than	PROLIA.xml:S1:2108:4	than	IN	O	O
placebo	PROLIA.xml:S1:2113:7	placebo	NN	O	O
)	PROLIA.xml:S1:2120:1	)	)	O	O
were	PROLIA.xml:S1:2122:4	were	VBD	O	O
:	PROLIA.xml:S1:2126:1	:	:	O	O
arthralgia	PROLIA.xml:S1:2128:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
and	PROLIA.xml:S1:2139:3	and	CC	O	O
back	PROLIA.xml:S1:2143:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:2148:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	PROLIA.xml:S1:2152:1	.	.	O	O

Pain	PROLIA.xml:S1:2154:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	PROLIA.xml:S1:2159:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	PROLIA.xml:S1:2162:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
and	PROLIA.xml:S1:2172:3	and	CC	O	O
musculoskeletal	PROLIA.xml:S1:2176:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:2192:4	pain	NN	I-AdverseReaction	I-AdverseReaction
have	PROLIA.xml:S1:2197:4	have	VBP	O	O
also	PROLIA.xml:S1:2202:4	also	RB	O	O
been	PROLIA.xml:S1:2207:4	been	VBN	O	O
reported	PROLIA.xml:S1:2212:8	report	VBN	O	O
in	PROLIA.xml:S1:2221:2	in	IN	O	O
clinical	PROLIA.xml:S1:2224:8	clinic	JJ	O	O
trials	PROLIA.xml:S1:2233:6	trial	NNS	O	O
(	PROLIA.xml:S1:2240:1	(	(	O	O
6.1	PROLIA.xml:S1:2243:3	6.1	CD	O	O
)	PROLIA.xml:S1:2248:1	)	)	O	O

To	PROLIA.xml:S1:2257:2	To	TO	O	O
report	PROLIA.xml:S1:2260:6	report	VB	O	O
SUSPECTED	PROLIA.xml:S1:2267:9	suspect	NNP	O	O
ADVERSE	PROLIA.xml:S1:2277:7	advers	NNP	O	O
REACTIONS	PROLIA.xml:S1:2285:9	reaction	NNP	O	O
,	PROLIA.xml:S1:2294:1	,	,	O	O
contact	PROLIA.xml:S1:2296:7	contact	NN	O	O
Amgen	PROLIA.xml:S1:2304:5	amgen	NNP	O	O
Inc	PROLIA.xml:S1:2310:3	inc	NNP	O	O
.	PROLIA.xml:S1:2313:1	.	.	O	O

at	PROLIA.xml:S1:2315:2	at	IN	O	O
1	PROLIA.xml:S1:2318:1	1	CD	O	O
-	PROLIA.xml:S1:2319:1	-	:	O	O
800	PROLIA.xml:S1:2320:3	800	CD	O	O
-	PROLIA.xml:S1:2323:1	-	:	O	O
77	PROLIA.xml:S1:2324:2	77	CD	O	O
-	PROLIA.xml:S1:2326:1	-	:	O	O
AMGEN	PROLIA.xml:S1:2327:5	amgen	NNP	O	O
(	PROLIA.xml:S1:2333:1	(	(	O	O
1	PROLIA.xml:S1:2334:1	1	CD	O	O
-	PROLIA.xml:S1:2335:1	-	:	O	O
800	PROLIA.xml:S1:2336:3	800	CD	O	O
-	PROLIA.xml:S1:2339:1	-	:	O	O
772	PROLIA.xml:S1:2340:3	772	CD	O	O
-	PROLIA.xml:S1:2343:1	-	:	O	O
6436	PROLIA.xml:S1:2344:4	6436	CD	O	O
)	PROLIA.xml:S1:2348:1	)	)	O	O
or	PROLIA.xml:S1:2350:2	or	CC	O	O
FDA	PROLIA.xml:S1:2353:3	fda	NNP	O	O
at	PROLIA.xml:S1:2357:2	at	IN	O	O
1	PROLIA.xml:S1:2360:1	1	CD	O	O
-	PROLIA.xml:S1:2361:1	-	:	O	O
800	PROLIA.xml:S1:2362:3	800	CD	O	O
-	PROLIA.xml:S1:2365:1	-	:	O	O
FDA	PROLIA.xml:S1:2366:3	fda	NNP	O	O
-	PROLIA.xml:S1:2369:1	-	:	O	O
1088	PROLIA.xml:S1:2370:4	1088	CD	O	O
or	PROLIA.xml:S1:2375:2	or	CC	O	O
www	PROLIA.xml:S1:2381:3	www	VB	O	O
.	PROLIA.xml:S1:2384:1	.	.	O	O
fda	PROLIA.xml:S1:2385:3	fda	NN	O	O
.	PROLIA.xml:S1:2388:1	.	.	O	O
gov	PROLIA.xml:S1:2389:3	gov	JJ	O	O
medwatch	PROLIA.xml:S1:2393:8	medwatch	NN	O	O
.	PROLIA.xml:S1:2407:1	.	.	O	O

6.1	PROLIA.xml:S1:2423:3	6.1	CD	O	O

Clinical	PROLIA.xml:S1:2427:8	clinic	JJ	O	O

Trials	PROLIA.xml:S1:2436:6	trial	NNS	O	O
Experience	PROLIA.xml:S1:2443:10	experi	NN	O	O

Because	PROLIA.xml:S1:2457:7	becaus	IN	O	O
clinical	PROLIA.xml:S1:2465:8	clinic	JJ	O	O
studies	PROLIA.xml:S1:2474:7	studi	NNS	O	O
are	PROLIA.xml:S1:2482:3	are	VBP	O	O
conducted	PROLIA.xml:S1:2486:9	conduct	VBN	O	O
under	PROLIA.xml:S1:2496:5	under	IN	O	O
widely	PROLIA.xml:S1:2502:6	wide	RB	O	O
varying	PROLIA.xml:S1:2509:7	vari	VBG	O	O
conditions	PROLIA.xml:S1:2517:10	condit	NNS	O	O
,	PROLIA.xml:S1:2527:1	,	,	O	O
adverse	PROLIA.xml:S1:2529:7	advers	JJ	O	O
reaction	PROLIA.xml:S1:2537:8	reaction	NN	O	O
rates	PROLIA.xml:S1:2546:5	rate	NNS	O	O
observed	PROLIA.xml:S1:2552:8	observ	VBD	O	O
in	PROLIA.xml:S1:2561:2	in	IN	O	O
the	PROLIA.xml:S1:2564:3	the	DT	O	O
clinical	PROLIA.xml:S1:2568:8	clinic	JJ	O	O
studies	PROLIA.xml:S1:2577:7	studi	NNS	O	O
of	PROLIA.xml:S1:2585:2	of	IN	O	O
a	PROLIA.xml:S1:2588:1	a	DT	O	O
drug	PROLIA.xml:S1:2590:4	drug	NN	O	O
cannot	PROLIA.xml:S1:2595:6	cannot	NN	O	O
be	PROLIA.xml:S1:2602:2	be	VB	O	O
directly	PROLIA.xml:S1:2605:8	directli	RB	O	O
compared	PROLIA.xml:S1:2614:8	compar	VBN	O	O
to	PROLIA.xml:S1:2623:2	to	TO	O	O
rates	PROLIA.xml:S1:2626:5	rate	NNS	O	O
in	PROLIA.xml:S1:2632:2	in	IN	O	O
the	PROLIA.xml:S1:2635:3	the	DT	O	O
clinical	PROLIA.xml:S1:2639:8	clinic	JJ	O	O
studies	PROLIA.xml:S1:2648:7	studi	NNS	O	O
of	PROLIA.xml:S1:2656:2	of	IN	O	O
another	PROLIA.xml:S1:2659:7	anoth	DT	O	O
drug	PROLIA.xml:S1:2667:4	drug	NN	O	O
and	PROLIA.xml:S1:2672:3	and	CC	O	O
may	PROLIA.xml:S1:2676:3	may	MD	O	O
not	PROLIA.xml:S1:2680:3	not	RB	O	O
reflect	PROLIA.xml:S1:2684:7	reflect	VB	O	O
the	PROLIA.xml:S1:2692:3	the	DT	O	O
rates	PROLIA.xml:S1:2696:5	rate	NNS	O	O
observed	PROLIA.xml:S1:2702:8	observ	VBD	O	O
in	PROLIA.xml:S1:2711:2	in	IN	O	O
clinical	PROLIA.xml:S1:2714:8	clinic	JJ	O	O
practice	PROLIA.xml:S1:2723:8	practic	NN	O	O
.	PROLIA.xml:S1:2731:1	.	.	O	O

Treatment	PROLIA.xml:S1:2740:9	treatment	NN	O	O
of	PROLIA.xml:S1:2750:2	of	IN	O	O
Postmenopausal	PROLIA.xml:S1:2753:14	postmenopaus	NNP	O	O
Women	PROLIA.xml:S1:2768:5	women	NNP	O	O
with	PROLIA.xml:S1:2774:4	with	IN	O	O
Osteoporosis	PROLIA.xml:S1:2779:12	osteoporosi	NNP	O	O

The	PROLIA.xml:S1:2798:3	the	DT	O	O
safety	PROLIA.xml:S1:2802:6	safeti	NN	O	O
of	PROLIA.xml:S1:2809:2	of	IN	O	O
Prolia	PROLIA.xml:S1:2812:6	prolia	NNP	O	O
in	PROLIA.xml:S1:2819:2	in	IN	O	O
the	PROLIA.xml:S1:2822:3	the	DT	O	O
treatment	PROLIA.xml:S1:2826:9	treatment	NN	O	O
of	PROLIA.xml:S1:2836:2	of	IN	O	O
postmenopausal	PROLIA.xml:S1:2839:14	postmenopaus	JJ	O	O
osteoporosis	PROLIA.xml:S1:2854:12	osteoporosi	NN	O	O
was	PROLIA.xml:S1:2867:3	wa	VBD	O	O
assessed	PROLIA.xml:S1:2871:8	assess	VBN	O	O
in	PROLIA.xml:S1:2880:2	in	IN	O	O
a	PROLIA.xml:S1:2883:1	a	DT	O	O
3	PROLIA.xml:S1:2885:1	3	CD	O	O
-	PROLIA.xml:S1:2886:1	-	:	O	O
year	PROLIA.xml:S1:2887:4	year	NN	O	O
,	PROLIA.xml:S1:2891:1	,	,	O	O
randomized	PROLIA.xml:S1:2893:10	random	VBN	O	O
,	PROLIA.xml:S1:2903:1	,	,	O	O
double	PROLIA.xml:S1:2905:6	doubl	JJ	O	O
-	PROLIA.xml:S1:2911:1	-	:	O	O
blind	PROLIA.xml:S1:2912:5	blind	NN	O	O
,	PROLIA.xml:S1:2917:1	,	,	O	O
placebo	PROLIA.xml:S1:2919:7	placebo	SYM	O	O
-	PROLIA.xml:S1:2926:1	-	:	O	O
controlled	PROLIA.xml:S1:2927:10	control	VBN	O	O
,	PROLIA.xml:S1:2937:1	,	,	O	O
multinational	PROLIA.xml:S1:2939:13	multin	JJ	O	O
study	PROLIA.xml:S1:2953:5	studi	NN	O	O
of	PROLIA.xml:S1:2959:2	of	IN	O	O
7808	PROLIA.xml:S1:2962:4	7808	CD	O	O
postmenopausal	PROLIA.xml:S1:2967:14	postmenopaus	JJ	O	O
women	PROLIA.xml:S1:2982:5	women	NNS	O	O
aged	PROLIA.xml:S1:2988:4	age	VBD	O	O
60	PROLIA.xml:S1:2993:2	60	CD	O	O
to	PROLIA.xml:S1:2996:2	to	TO	O	O
91	PROLIA.xml:S1:2999:2	91	CD	O	O
years	PROLIA.xml:S1:3002:5	year	NNS	O	O
.	PROLIA.xml:S1:3007:1	.	.	O	O

A	PROLIA.xml:S1:3009:1	A	DT	O	O
total	PROLIA.xml:S1:3011:5	total	NN	O	O
of	PROLIA.xml:S1:3017:2	of	IN	O	O
3876	PROLIA.xml:S1:3020:4	3876	CD	O	O
women	PROLIA.xml:S1:3025:5	women	NNS	O	O
were	PROLIA.xml:S1:3031:4	were	VBD	O	O
exposed	PROLIA.xml:S1:3036:7	expos	VBN	O	O
to	PROLIA.xml:S1:3044:2	to	TO	O	O
placebo	PROLIA.xml:S1:3047:7	placebo	VB	O	O
and	PROLIA.xml:S1:3055:3	and	CC	O	O
3886	PROLIA.xml:S1:3059:4	3886	CD	O	O
women	PROLIA.xml:S1:3064:5	women	NNS	O	O
were	PROLIA.xml:S1:3070:4	were	VBD	O	O
exposed	PROLIA.xml:S1:3075:7	expos	VBN	O	O
to	PROLIA.xml:S1:3083:2	to	TO	O	O
Prolia	PROLIA.xml:S1:3086:6	prolia	NNP	O	O
administered	PROLIA.xml:S1:3093:12	administ	VBD	O	O
subcutaneously	PROLIA.xml:S1:3106:14	subcutan	RB	O	O
once	PROLIA.xml:S1:3121:4	onc	RB	O	O
every	PROLIA.xml:S1:3126:5	everi	DT	O	O
6	PROLIA.xml:S1:3132:1	6	CD	O	O
months	PROLIA.xml:S1:3134:6	month	NNS	O	O
as	PROLIA.xml:S1:3141:2	as	IN	O	O
a	PROLIA.xml:S1:3144:1	a	DT	O	O
single	PROLIA.xml:S1:3146:6	singl	JJ	O	O
60	PROLIA.xml:S1:3153:2	60	CD	O	O
mg	PROLIA.xml:S1:3156:2	mg	NN	O	O
dose	PROLIA.xml:S1:3159:4	dose	NN	O	O
.	PROLIA.xml:S1:3163:1	.	.	O	O

All	PROLIA.xml:S1:3165:3	all	DT	O	O
women	PROLIA.xml:S1:3169:5	women	NNS	O	O
were	PROLIA.xml:S1:3175:4	were	VBD	O	O
instructed	PROLIA.xml:S1:3180:10	instruct	VBN	O	O
to	PROLIA.xml:S1:3191:2	to	TO	O	O
take	PROLIA.xml:S1:3194:4	take	VB	O	O
at	PROLIA.xml:S1:3199:2	at	IN	O	O
least	PROLIA.xml:S1:3202:5	least	JJS	O	O
1000	PROLIA.xml:S1:3208:4	1000	CD	O	O
mg	PROLIA.xml:S1:3213:2	mg	NN	O	O
of	PROLIA.xml:S1:3216:2	of	IN	O	O
calcium	PROLIA.xml:S1:3219:7	calcium	NN	O	O
and	PROLIA.xml:S1:3227:3	and	CC	O	O
400	PROLIA.xml:S1:3231:3	400	CD	O	O
IU	PROLIA.xml:S1:3235:2	IU	NNP	O	O
of	PROLIA.xml:S1:3238:2	of	IN	O	O
vitamin	PROLIA.xml:S1:3241:7	vitamin	NNP	O	O
D	PROLIA.xml:S1:3249:1	D	NNP	O	O
supplementation	PROLIA.xml:S1:3251:15	supplement	NN	O	O
per	PROLIA.xml:S1:3267:3	per	IN	O	O
day	PROLIA.xml:S1:3271:3	day	NN	O	O
.	PROLIA.xml:S1:3274:1	.	.	O	O

The	PROLIA.xml:S1:3280:3	the	DT	O	O
incidence	PROLIA.xml:S1:3284:9	incid	NN	O	O
of	PROLIA.xml:S1:3294:2	of	IN	O	O
all	PROLIA.xml:S1:3297:3	all	DT	O	O
-	PROLIA.xml:S1:3300:1	-	:	O	O
cause	PROLIA.xml:S1:3301:5	caus	NN	O	O
mortality	PROLIA.xml:S1:3307:9	mortal	NN	B-AdverseReaction	O
was	PROLIA.xml:S1:3317:3	wa	VBD	O	O
2.3%	PROLIA.xml:S1:3321:4	2.3%	CD	O	O
(	PROLIA.xml:S1:3326:1	(	(	O	O
n	PROLIA.xml:S1:3327:1	n	JJ	O	O
90	PROLIA.xml:S1:3331:2	90	CD	O	O
)	PROLIA.xml:S1:3333:1	)	)	O	O
in	PROLIA.xml:S1:3335:2	in	IN	O	O
the	PROLIA.xml:S1:3338:3	the	DT	O	O
placebo	PROLIA.xml:S1:3342:7	placebo	NN	O	O
group	PROLIA.xml:S1:3350:5	group	NN	O	O
and	PROLIA.xml:S1:3356:3	and	CC	O	O
1.8%	PROLIA.xml:S1:3360:4	1.8%	CD	O	O
(	PROLIA.xml:S1:3365:1	(	(	O	O
n	PROLIA.xml:S1:3366:1	n	JJ	O	O
70	PROLIA.xml:S1:3370:2	70	CD	O	O
)	PROLIA.xml:S1:3372:1	)	)	O	O
in	PROLIA.xml:S1:3374:2	in	IN	O	O
the	PROLIA.xml:S1:3377:3	the	DT	O	O
Prolia	PROLIA.xml:S1:3381:6	prolia	NNP	O	O
group	PROLIA.xml:S1:3388:5	group	NN	O	O
.	PROLIA.xml:S1:3393:1	.	.	O	O

The	PROLIA.xml:S1:3395:3	the	DT	O	O
incidence	PROLIA.xml:S1:3399:9	incid	NN	O	O
of	PROLIA.xml:S1:3409:2	of	IN	O	O
nonfatal	PROLIA.xml:S1:3412:8	nonfat	JJ	O	O
serious	PROLIA.xml:S1:3421:7	seriou	JJ	O	O
adverse	PROLIA.xml:S1:3429:7	advers	JJ	O	O
events	PROLIA.xml:S1:3437:6	event	NNS	O	O
was	PROLIA.xml:S1:3444:3	wa	VBD	O	O
24.2%	PROLIA.xml:S1:3448:5	24.2%	CD	O	O
in	PROLIA.xml:S1:3454:2	in	IN	O	O
the	PROLIA.xml:S1:3457:3	the	DT	O	O
placebo	PROLIA.xml:S1:3461:7	placebo	NN	O	O
group	PROLIA.xml:S1:3469:5	group	NN	O	O
and	PROLIA.xml:S1:3475:3	and	CC	O	O
25.0%	PROLIA.xml:S1:3479:5	25.0%	CD	O	O
in	PROLIA.xml:S1:3485:2	in	IN	O	O
the	PROLIA.xml:S1:3488:3	the	DT	O	O
Prolia	PROLIA.xml:S1:3492:6	prolia	NNP	O	O
group	PROLIA.xml:S1:3499:5	group	NN	O	O
.	PROLIA.xml:S1:3504:1	.	.	O	O

The	PROLIA.xml:S1:3506:3	the	DT	O	O
percentage	PROLIA.xml:S1:3510:10	percentag	NN	O	O
of	PROLIA.xml:S1:3521:2	of	IN	O	O
patients	PROLIA.xml:S1:3524:8	patient	NNS	O	O
who	PROLIA.xml:S1:3533:3	who	WP	O	O
withdrew	PROLIA.xml:S1:3537:8	withdrew	VBP	O	O
from	PROLIA.xml:S1:3546:4	from	IN	O	O
the	PROLIA.xml:S1:3551:3	the	DT	O	O
study	PROLIA.xml:S1:3555:5	studi	NN	O	O
due	PROLIA.xml:S1:3561:3	due	JJ	O	O
to	PROLIA.xml:S1:3565:2	to	TO	O	O
adverse	PROLIA.xml:S1:3568:7	advers	JJ	O	O
events	PROLIA.xml:S1:3576:6	event	NNS	O	O
was	PROLIA.xml:S1:3583:3	wa	VBD	O	O
2.1%	PROLIA.xml:S1:3587:4	2.1%	CD	O	O
and	PROLIA.xml:S1:3592:3	and	CC	O	O
2.4%	PROLIA.xml:S1:3596:4	2.4%	CD	O	O
for	PROLIA.xml:S1:3601:3	for	IN	O	O
the	PROLIA.xml:S1:3605:3	the	DT	O	O
placebo	PROLIA.xml:S1:3609:7	placebo	NN	O	O
and	PROLIA.xml:S1:3617:3	and	CC	O	O
Prolia	PROLIA.xml:S1:3621:6	prolia	NNP	O	O
groups	PROLIA.xml:S1:3628:6	group	NNS	O	O
,	PROLIA.xml:S1:3634:1	,	,	O	O
respectively	PROLIA.xml:S1:3636:12	respect	RB	O	O
.	PROLIA.xml:S1:3648:1	.	.	O	O

Adverse	PROLIA.xml:S1:3654:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:3662:9	reaction	NNS	O	O
reported	PROLIA.xml:S1:3672:8	report	VBN	O	O
in	PROLIA.xml:S1:3681:2	in	IN	O	O
2%	PROLIA.xml:S1:3687:2	2%	CD	O	O
of	PROLIA.xml:S1:3690:2	of	IN	O	O
postmenopausal	PROLIA.xml:S1:3693:14	postmenopaus	JJ	O	O
women	PROLIA.xml:S1:3708:5	women	NNS	O	O
with	PROLIA.xml:S1:3714:4	with	IN	O	O
osteoporosis	PROLIA.xml:S1:3719:12	osteoporosi	NN	O	O
and	PROLIA.xml:S1:3732:3	and	CC	O	O
more	PROLIA.xml:S1:3736:4	more	RBR	O	O
frequently	PROLIA.xml:S1:3741:10	frequent	RB	O	O
in	PROLIA.xml:S1:3752:2	in	IN	O	O
the	PROLIA.xml:S1:3755:3	the	DT	O	O
Prolia	PROLIA.xml:S1:3759:6	prolia	NNP	O	O
-	PROLIA.xml:S1:3765:1	-	:	O	O
treated	PROLIA.xml:S1:3766:7	treat	VBD	O	O
women	PROLIA.xml:S1:3774:5	women	NNS	O	O
than	PROLIA.xml:S1:3780:4	than	IN	O	O
in	PROLIA.xml:S1:3785:2	in	IN	O	O
the	PROLIA.xml:S1:3788:3	the	DT	O	O
placebo	PROLIA.xml:S1:3792:7	placebo	NN	O	O
-	PROLIA.xml:S1:3799:1	-	:	O	O
treated	PROLIA.xml:S1:3800:7	treat	JJ	O	O
women	PROLIA.xml:S1:3808:5	women	NNS	O	O
are	PROLIA.xml:S1:3814:3	are	VBP	O	O
shown	PROLIA.xml:S1:3818:5	shown	VBN	O	O
in	PROLIA.xml:S1:3824:2	in	IN	O	O
the	PROLIA.xml:S1:3827:3	the	DT	O	O
table	PROLIA.xml:S1:3831:5	tabl	NN	O	O
below	PROLIA.xml:S1:3837:5	below	IN	O	O
.	PROLIA.xml:S1:3842:1	.	.	O	O

Table	PROLIA.xml:S1:3848:5	tabl	JJ	O	O
1	PROLIA.xml:S1:3854:1	1	CD	O	O
.	PROLIA.xml:S1:3855:1	.	.	O	O

Adverse	PROLIA.xml:S1:3857:7	advers	JJ	O	O
Reactions	PROLIA.xml:S1:3865:9	reaction	NNP	O	O
Occurring	PROLIA.xml:S1:3875:9	occur	NNP	O	O
in	PROLIA.xml:S1:3885:2	in	IN	O	O
2%	PROLIA.xml:S1:3891:2	2%	CD	O	O
of	PROLIA.xml:S1:3894:2	of	IN	O	O
Patients	PROLIA.xml:S1:3897:8	patient	NNS	O	O
with	PROLIA.xml:S1:3906:4	with	IN	O	O
Osteoporosis	PROLIA.xml:S1:3911:12	osteoporosi	NNP	O	O
and	PROLIA.xml:S1:3924:3	and	CC	O	O
More	PROLIA.xml:S1:3928:4	more	RBR	O	O
Frequently	PROLIA.xml:S1:3933:10	frequent	RB	O	O
than	PROLIA.xml:S1:3944:4	than	IN	O	O
in	PROLIA.xml:S1:3949:2	in	IN	O	O
Placebo	PROLIA.xml:S1:3952:7	placebo	NNP	O	O
-	PROLIA.xml:S1:3959:1	-	:	O	O
treated	PROLIA.xml:S1:3960:7	treat	VBD	O	O
Patients	PROLIA.xml:S1:3968:8	patient	NNS	O	O

SYSTEM	PROLIA.xml:S1:3981:6	system	NNP	O	O
ORGAN	PROLIA.xml:S1:3988:5	organ	NNP	O	O
CLASS	PROLIA.xml:S1:3994:5	class	NNP	O	O
Preferred	PROLIA.xml:S1:4002:9	prefer	NNP	O	O
Term	PROLIA.xml:S1:4012:4	term	NNP	O	O
Prolia	PROLIA.xml:S1:4023:6	prolia	NNP	O	O
(	PROLIA.xml:S1:4029:1	(	(	O	O
N	PROLIA.xml:S1:4030:1	N	NNP	O	O
3886	PROLIA.xml:S1:4034:4	3886	CD	O	O
)	PROLIA.xml:S1:4038:1	)	)	O	O
n	PROLIA.xml:S1:4039:1	n	FW	O	O
(	PROLIA.xml:S1:4041:1	(	(	O	O
)	PROLIA.xml:S1:4043:1	)	)	O	O
Placebo	PROLIA.xml:S1:4051:7	placebo	NNP	O	O
(	PROLIA.xml:S1:4058:1	(	(	O	O
N	PROLIA.xml:S1:4059:1	N	NNP	O	O
3876	PROLIA.xml:S1:4063:4	3876	CD	O	O
)	PROLIA.xml:S1:4067:1	)	)	O	O
n	PROLIA.xml:S1:4068:1	n	FW	O	O
(	PROLIA.xml:S1:4070:1	(	(	O	O
)	PROLIA.xml:S1:4072:1	)	)	O	O

BLOOD	PROLIA.xml:S1:4083:5	blood	NNP	O	O
AND	PROLIA.xml:S1:4089:3	and	NNP	O	O
LYMPHATIC	PROLIA.xml:S1:4093:9	lymphat	NNP	O	O
SYSTEM	PROLIA.xml:S1:4103:6	system	NNP	O	O
DISORDERS	PROLIA.xml:S1:4110:9	disord	NNP	O	O

Anemia	PROLIA.xml:S1:4130:6	anemia	$	B-AdverseReaction	B-AdverseReaction
129	PROLIA.xml:S1:4139:3	129	CD	O	O
(	PROLIA.xml:S1:4143:1	(	(	O	O
3.3	PROLIA.xml:S1:4144:3	3.3	CD	O	O
)	PROLIA.xml:S1:4147:1	)	)	O	O
107	PROLIA.xml:S1:4151:3	107	CD	O	O
(	PROLIA.xml:S1:4155:1	(	(	O	O
2.8	PROLIA.xml:S1:4156:3	2.8	CD	O	O
)	PROLIA.xml:S1:4159:1	)	)	O	O

CARDIAC	PROLIA.xml:S1:4168:7	cardiac	NNP	O	O
DISORDERS	PROLIA.xml:S1:4176:9	disord	NNP	O	O

Angina	PROLIA.xml:S1:4196:6	angina	NNP	B-AdverseReaction	B-AdverseReaction
pectoris	PROLIA.xml:S1:4203:8	pectori	VBZ	I-AdverseReaction	I-AdverseReaction
101	PROLIA.xml:S1:4214:3	101	CD	O	O
(	PROLIA.xml:S1:4218:1	(	(	O	O
2.6	PROLIA.xml:S1:4219:3	2.6	CD	O	O
)	PROLIA.xml:S1:4222:1	)	)	O	O
87	PROLIA.xml:S1:4226:2	87	CD	O	O
(	PROLIA.xml:S1:4229:1	(	(	O	O
2.2	PROLIA.xml:S1:4230:3	2.2	CD	O	O
)	PROLIA.xml:S1:4233:1	)	)	O	O

Atrial	PROLIA.xml:S1:4243:6	atrial	JJ	B-AdverseReaction	B-AdverseReaction
fibrillation	PROLIA.xml:S1:4250:12	fibril	NN	I-AdverseReaction	I-AdverseReaction
79	PROLIA.xml:S1:4265:2	79	CD	O	O
(	PROLIA.xml:S1:4268:1	(	(	O	O
2.0	PROLIA.xml:S1:4269:3	2.0	CD	O	O
)	PROLIA.xml:S1:4272:1	)	)	O	O
77	PROLIA.xml:S1:4276:2	77	CD	O	O
(	PROLIA.xml:S1:4279:1	(	(	O	O
2.0	PROLIA.xml:S1:4280:3	2.0	CD	O	O
)	PROLIA.xml:S1:4283:1	)	)	O	O

EAR	PROLIA.xml:S1:4292:3	ear	NN	O	O
AND	PROLIA.xml:S1:4296:3	and	CC	O	O
LABYRINTH	PROLIA.xml:S1:4300:9	labyrinth	NNP	O	O
DISORDERS	PROLIA.xml:S1:4310:9	disord	NNP	O	O

Vertigo	PROLIA.xml:S1:4330:7	vertigo	NNP	B-AdverseReaction	B-AdverseReaction
195	PROLIA.xml:S1:4340:3	195	CD	O	O
(	PROLIA.xml:S1:4344:1	(	(	O	O
5.0	PROLIA.xml:S1:4345:3	5.0	CD	O	O
)	PROLIA.xml:S1:4348:1	)	)	O	O
187	PROLIA.xml:S1:4352:3	187	CD	O	O
(	PROLIA.xml:S1:4356:1	(	(	O	O
4.8	PROLIA.xml:S1:4357:3	4.8	CD	O	O
)	PROLIA.xml:S1:4360:1	)	)	O	O

GASTROINTESTINAL	PROLIA.xml:S1:4369:16	gastrointestin	NNP	O	O
DISORDERS	PROLIA.xml:S1:4386:9	disord	NNP	O	O

Abdominal	PROLIA.xml:S1:4406:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:4416:4	pain	NN	I-AdverseReaction	I-AdverseReaction
upper	PROLIA.xml:S1:4421:5	upper	JJ	I-AdverseReaction	I-AdverseReaction
129	PROLIA.xml:S1:4429:3	129	CD	O	O
(	PROLIA.xml:S1:4433:1	(	(	O	O
3.3	PROLIA.xml:S1:4434:3	3.3	CD	O	O
)	PROLIA.xml:S1:4437:1	)	)	O	O
111	PROLIA.xml:S1:4441:3	111	CD	O	O
(	PROLIA.xml:S1:4445:1	(	(	O	O
2.9	PROLIA.xml:S1:4446:3	2.9	CD	O	O
)	PROLIA.xml:S1:4449:1	)	)	O	O

Flatulence	PROLIA.xml:S1:4459:10	flatul	NN	B-AdverseReaction	B-AdverseReaction
84	PROLIA.xml:S1:4472:2	84	CD	O	O
(	PROLIA.xml:S1:4475:1	(	(	O	O
2.2	PROLIA.xml:S1:4476:3	2.2	CD	O	O
)	PROLIA.xml:S1:4479:1	)	)	O	O
53	PROLIA.xml:S1:4483:2	53	CD	O	O
(	PROLIA.xml:S1:4486:1	(	(	O	O
1.4	PROLIA.xml:S1:4487:3	1.4	CD	O	O
)	PROLIA.xml:S1:4490:1	)	)	O	O

Gastroesophageal	PROLIA.xml:S1:4500:16	gastroesophag	NNP	B-AdverseReaction	B-AdverseReaction
reflux	PROLIA.xml:S1:4517:6	reflux	VBZ	I-AdverseReaction	I-AdverseReaction
disease	PROLIA.xml:S1:4524:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
80	PROLIA.xml:S1:4534:2	80	CD	O	O
(	PROLIA.xml:S1:4537:1	(	(	O	O
2.1	PROLIA.xml:S1:4538:3	2.1	CD	O	O
)	PROLIA.xml:S1:4541:1	)	)	O	O
66	PROLIA.xml:S1:4545:2	66	CD	O	O
(	PROLIA.xml:S1:4548:1	(	(	O	O
1.7	PROLIA.xml:S1:4549:3	1.7	CD	O	O
)	PROLIA.xml:S1:4552:1	)	)	O	O

GENERAL	PROLIA.xml:S1:4561:7	gener	NNP	O	O
DISORDERS	PROLIA.xml:S1:4569:9	disord	NNP	O	O
AND	PROLIA.xml:S1:4579:3	and	NNP	O	O
ADMINISTRATION	PROLIA.xml:S1:4583:14	administr	NNP	O	O
SITE	PROLIA.xml:S1:4598:4	site	NNP	O	O
CONDITIONS	PROLIA.xml:S1:4603:10	condit	NNP	O	O

Edema	PROLIA.xml:S1:4624:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
peripheral	PROLIA.xml:S1:4630:10	peripher	JJ	I-AdverseReaction	I-AdverseReaction
189	PROLIA.xml:S1:4643:3	189	CD	O	O
(	PROLIA.xml:S1:4647:1	(	(	O	O
4.9	PROLIA.xml:S1:4648:3	4.9	CD	O	O
)	PROLIA.xml:S1:4651:1	)	)	O	O
155	PROLIA.xml:S1:4655:3	155	CD	O	O
(	PROLIA.xml:S1:4659:1	(	(	O	O
4.0	PROLIA.xml:S1:4660:3	4.0	CD	O	O
)	PROLIA.xml:S1:4663:1	)	)	O	O

Asthenia	PROLIA.xml:S1:4673:8	asthenia	NNP	B-AdverseReaction	B-AdverseReaction
90	PROLIA.xml:S1:4684:2	90	CD	O	O
(	PROLIA.xml:S1:4687:1	(	(	O	O
2.3	PROLIA.xml:S1:4688:3	2.3	CD	O	O
)	PROLIA.xml:S1:4691:1	)	)	O	O
73	PROLIA.xml:S1:4695:2	73	CD	O	O
(	PROLIA.xml:S1:4698:1	(	(	O	O
1.9	PROLIA.xml:S1:4699:3	1.9	CD	O	O
)	PROLIA.xml:S1:4702:1	)	)	O	O

INFECTIONS	PROLIA.xml:S1:4711:10	infect	NNP	O	O
AND	PROLIA.xml:S1:4722:3	and	CC	O	O
INFESTATIONS	PROLIA.xml:S1:4726:12	infest	NNP	O	O

Cystitis	PROLIA.xml:S1:4749:8	cystiti	NN	B-AdverseReaction	B-AdverseReaction
228	PROLIA.xml:S1:4760:3	228	CD	O	O
(	PROLIA.xml:S1:4764:1	(	(	O	O
5.9	PROLIA.xml:S1:4765:3	5.9	CD	O	O
)	PROLIA.xml:S1:4768:1	)	)	O	O
225	PROLIA.xml:S1:4772:3	225	CD	O	O
(	PROLIA.xml:S1:4776:1	(	(	O	O
5.8	PROLIA.xml:S1:4777:3	5.8	CD	O	O
)	PROLIA.xml:S1:4780:1	)	)	O	O

Upper	PROLIA.xml:S1:4790:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	PROLIA.xml:S1:4796:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	PROLIA.xml:S1:4808:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	PROLIA.xml:S1:4814:9	infect	NN	I-AdverseReaction	I-AdverseReaction
190	PROLIA.xml:S1:4826:3	190	CD	O	O
(	PROLIA.xml:S1:4830:1	(	(	O	O
4.9	PROLIA.xml:S1:4831:3	4.9	CD	O	O
)	PROLIA.xml:S1:4834:1	)	)	O	O
167	PROLIA.xml:S1:4838:3	167	CD	O	O
(	PROLIA.xml:S1:4842:1	(	(	O	O
4.3	PROLIA.xml:S1:4843:3	4.3	CD	O	O
)	PROLIA.xml:S1:4846:1	)	)	O	O

Pneumonia	PROLIA.xml:S1:4856:9	pneumonia	NNP	B-AdverseReaction	B-AdverseReaction
152	PROLIA.xml:S1:4868:3	152	CD	O	O
(	PROLIA.xml:S1:4872:1	(	(	O	O
3.9	PROLIA.xml:S1:4873:3	3.9	CD	O	O
)	PROLIA.xml:S1:4876:1	)	)	O	O
150	PROLIA.xml:S1:4880:3	150	CD	O	O
(	PROLIA.xml:S1:4884:1	(	(	O	O
3.9	PROLIA.xml:S1:4885:3	3.9	CD	O	O
)	PROLIA.xml:S1:4888:1	)	)	O	O

Pharyngitis	PROLIA.xml:S1:4898:11	pharyng	NN	B-AdverseReaction	B-AdverseReaction
91	PROLIA.xml:S1:4912:2	91	CD	O	O
(	PROLIA.xml:S1:4915:1	(	(	O	O
2.3	PROLIA.xml:S1:4916:3	2.3	CD	O	O
)	PROLIA.xml:S1:4919:1	)	)	O	O
78	PROLIA.xml:S1:4923:2	78	CD	O	O
(	PROLIA.xml:S1:4926:1	(	(	O	O
2.0	PROLIA.xml:S1:4927:3	2.0	CD	O	O
)	PROLIA.xml:S1:4930:1	)	)	O	O

Herpes	PROLIA.xml:S1:4940:6	herp	NNP	B-AdverseReaction	B-AdverseReaction
zoster	PROLIA.xml:S1:4947:6	zoster	NN	I-AdverseReaction	I-AdverseReaction
79	PROLIA.xml:S1:4956:2	79	CD	O	O
(	PROLIA.xml:S1:4959:1	(	(	O	O
2.0	PROLIA.xml:S1:4960:3	2.0	CD	O	O
)	PROLIA.xml:S1:4963:1	)	)	O	O
72	PROLIA.xml:S1:4967:2	72	CD	O	O
(	PROLIA.xml:S1:4970:1	(	(	O	O
1.9	PROLIA.xml:S1:4971:3	1.9	CD	O	O
)	PROLIA.xml:S1:4974:1	)	)	O	O

METABOLISM	PROLIA.xml:S1:4983:10	metabol	NNP	O	O
AND	PROLIA.xml:S1:4994:3	and	CC	O	O
NUTRITION	PROLIA.xml:S1:4998:9	nutrit	NNP	O	O
DISORDERS	PROLIA.xml:S1:5008:9	disord	NNP	O	O

Hypercholesterolemia	PROLIA.xml:S1:5028:20	hypercholesterolemia	$	B-AdverseReaction	B-AdverseReaction
280	PROLIA.xml:S1:5051:3	280	CD	O	O
(	PROLIA.xml:S1:5055:1	(	(	O	O
7.2	PROLIA.xml:S1:5056:3	7.2	CD	O	O
)	PROLIA.xml:S1:5059:1	)	)	O	O
236	PROLIA.xml:S1:5063:3	236	CD	O	O
(	PROLIA.xml:S1:5067:1	(	(	O	O
6.1	PROLIA.xml:S1:5068:3	6.1	CD	O	O
)	PROLIA.xml:S1:5071:1	)	)	O	O

MUSCULOSKELETAL	PROLIA.xml:S1:5080:15	musculoskelet	NNP	O	O
AND	PROLIA.xml:S1:5096:3	and	NNP	O	O
CONNECTIVE	PROLIA.xml:S1:5100:10	connect	NNP	O	O
TISSUE	PROLIA.xml:S1:5111:6	tissu	NNP	O	O
DISORDERS	PROLIA.xml:S1:5118:9	disord	NNP	O	O

Back	PROLIA.xml:S1:5138:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:5143:4	pain	NN	I-AdverseReaction	I-AdverseReaction
1347	PROLIA.xml:S1:5150:4	1347	CD	O	O
(	PROLIA.xml:S1:5155:1	(	(	O	O
34.7	PROLIA.xml:S1:5156:4	34.7	CD	O	O
)	PROLIA.xml:S1:5160:1	)	)	O	O
1340	PROLIA.xml:S1:5164:4	1340	CD	O	O
(	PROLIA.xml:S1:5169:1	(	(	O	O
34.6	PROLIA.xml:S1:5170:4	34.6	CD	O	O
)	PROLIA.xml:S1:5174:1	)	)	O	O

Pain	PROLIA.xml:S1:5184:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	PROLIA.xml:S1:5189:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	PROLIA.xml:S1:5192:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
453	PROLIA.xml:S1:5204:3	453	CD	O	O
(	PROLIA.xml:S1:5208:1	(	(	O	O
11.7	PROLIA.xml:S1:5209:4	11.7	CD	O	O
)	PROLIA.xml:S1:5213:1	)	)	O	O
430	PROLIA.xml:S1:5217:3	430	CD	O	O
(	PROLIA.xml:S1:5221:1	(	(	O	O
11.1	PROLIA.xml:S1:5222:4	11.1	CD	O	O
)	PROLIA.xml:S1:5226:1	)	)	O	O

Musculoskeletal	PROLIA.xml:S1:5236:15	musculoskelet	NNP	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:5252:4	pain	NN	I-AdverseReaction	I-AdverseReaction
297	PROLIA.xml:S1:5259:3	297	CD	O	O
(	PROLIA.xml:S1:5263:1	(	(	O	O
7.6	PROLIA.xml:S1:5264:3	7.6	CD	O	O
)	PROLIA.xml:S1:5267:1	)	)	O	O
291	PROLIA.xml:S1:5271:3	291	CD	O	O
(	PROLIA.xml:S1:5275:1	(	(	O	O
7.5	PROLIA.xml:S1:5276:3	7.5	CD	O	O
)	PROLIA.xml:S1:5279:1	)	)	O	O

Bone	PROLIA.xml:S1:5289:4	bone	NNP	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:5294:4	pain	NN	I-AdverseReaction	I-AdverseReaction
142	PROLIA.xml:S1:5301:3	142	CD	O	O
(	PROLIA.xml:S1:5305:1	(	(	O	O
3.7	PROLIA.xml:S1:5306:3	3.7	CD	O	O
)	PROLIA.xml:S1:5309:1	)	)	O	O
117	PROLIA.xml:S1:5313:3	117	CD	O	O
(	PROLIA.xml:S1:5317:1	(	(	O	O
3.0	PROLIA.xml:S1:5318:3	3.0	CD	O	O
)	PROLIA.xml:S1:5321:1	)	)	O	O

Myalgia	PROLIA.xml:S1:5331:7	myalgia	NNP	B-AdverseReaction	B-AdverseReaction
114	PROLIA.xml:S1:5341:3	114	CD	O	O
(	PROLIA.xml:S1:5345:1	(	(	O	O
2.9	PROLIA.xml:S1:5346:3	2.9	CD	O	O
)	PROLIA.xml:S1:5349:1	)	)	O	O
94	PROLIA.xml:S1:5353:2	94	CD	O	O
(	PROLIA.xml:S1:5356:1	(	(	O	O
2.4	PROLIA.xml:S1:5357:3	2.4	CD	O	O
)	PROLIA.xml:S1:5360:1	)	)	O	O

Spinal	PROLIA.xml:S1:5370:6	spinal	NNP	B-AdverseReaction	B-AdverseReaction
osteoarthritis	PROLIA.xml:S1:5377:14	osteoarthr	NN	I-AdverseReaction	I-AdverseReaction
82	PROLIA.xml:S1:5394:2	82	CD	O	O
(	PROLIA.xml:S1:5397:1	(	(	O	O
2.1	PROLIA.xml:S1:5398:3	2.1	CD	O	O
)	PROLIA.xml:S1:5401:1	)	)	O	O
64	PROLIA.xml:S1:5405:2	64	CD	O	O
(	PROLIA.xml:S1:5408:1	(	(	O	O
1.7	PROLIA.xml:S1:5409:3	1.7	CD	O	O
)	PROLIA.xml:S1:5412:1	)	)	O	O

NERVOUS	PROLIA.xml:S1:5421:7	nervou	NNP	O	O
SYSTEM	PROLIA.xml:S1:5429:6	system	NNP	O	O
DISORDERS	PROLIA.xml:S1:5436:9	disord	NNP	O	O

Sciatica	PROLIA.xml:S1:5456:8	sciatica	NNP	B-AdverseReaction	B-AdverseReaction
178	PROLIA.xml:S1:5467:3	178	CD	O	O
(	PROLIA.xml:S1:5471:1	(	(	O	O
4.6	PROLIA.xml:S1:5472:3	4.6	CD	O	O
)	PROLIA.xml:S1:5475:1	)	)	O	O
149	PROLIA.xml:S1:5479:3	149	CD	O	O
(	PROLIA.xml:S1:5483:1	(	(	O	O
3.8	PROLIA.xml:S1:5484:3	3.8	CD	O	O
)	PROLIA.xml:S1:5487:1	)	)	O	O

PSYCHIATRIC	PROLIA.xml:S1:5496:11	psychiatr	NN	O	O
DISORDERS	PROLIA.xml:S1:5508:9	disord	NNS	O	O

Insomnia	PROLIA.xml:S1:5528:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
126	PROLIA.xml:S1:5539:3	126	CD	O	O
(	PROLIA.xml:S1:5543:1	(	(	O	O
3.2	PROLIA.xml:S1:5544:3	3.2	CD	O	O
)	PROLIA.xml:S1:5547:1	)	)	O	O
122	PROLIA.xml:S1:5551:3	122	CD	O	O
(	PROLIA.xml:S1:5555:1	(	(	O	O
3.1	PROLIA.xml:S1:5556:3	3.1	CD	O	O
)	PROLIA.xml:S1:5559:1	)	)	O	O

SKIN	PROLIA.xml:S1:5568:4	skin	NNP	O	O
AND	PROLIA.xml:S1:5573:3	and	NNP	O	O
SUBCUTANEOUS	PROLIA.xml:S1:5577:12	subcutan	NNP	O	O
TISSUE	PROLIA.xml:S1:5590:6	tissu	NNP	O	O
DISORDERS	PROLIA.xml:S1:5597:9	disord	NNP	O	O

Rash	PROLIA.xml:S1:5617:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
96	PROLIA.xml:S1:5624:2	96	CD	O	O
(	PROLIA.xml:S1:5627:1	(	(	O	O
2.5	PROLIA.xml:S1:5628:3	2.5	CD	O	O
)	PROLIA.xml:S1:5631:1	)	)	O	O
79	PROLIA.xml:S1:5635:2	79	CD	O	O
(	PROLIA.xml:S1:5638:1	(	(	O	O
2.0	PROLIA.xml:S1:5639:3	2.0	CD	O	O
)	PROLIA.xml:S1:5642:1	)	)	O	O

Pruritus	PROLIA.xml:S1:5652:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
87	PROLIA.xml:S1:5663:2	87	CD	O	O
(	PROLIA.xml:S1:5666:1	(	(	O	O
2.2	PROLIA.xml:S1:5667:3	2.2	CD	O	O
)	PROLIA.xml:S1:5670:1	)	)	O	O
82	PROLIA.xml:S1:5674:2	82	CD	O	O
(	PROLIA.xml:S1:5677:1	(	(	O	O
2.1	PROLIA.xml:S1:5678:3	2.1	CD	O	O
)	PROLIA.xml:S1:5681:1	)	)	O	O

Hypocalcemia	PROLIA.xml:S1:5697:12	hypocalcemia	NNP	B-AdverseReaction	B-AdverseReaction
Decreases	PROLIA.xml:S1:5711:9	decreas	VBZ	B-AdverseReaction	I-AdverseReaction
in	PROLIA.xml:S1:5721:2	in	IN	I-AdverseReaction	O
serum	PROLIA.xml:S1:5724:5	serum	JJ	I-AdverseReaction	O
calcium	PROLIA.xml:S1:5730:7	calcium	NN	I-AdverseReaction	O
levels	PROLIA.xml:S1:5738:6	level	NNS	I-AdverseReaction	O
to	PROLIA.xml:S1:5745:2	to	TO	O	O
less	PROLIA.xml:S1:5748:4	less	JJR	O	O
than	PROLIA.xml:S1:5753:4	than	IN	O	O
8.5	PROLIA.xml:S1:5758:3	8.5	CD	O	O
mg	PROLIA.xml:S1:5762:2	mg	JJ	O	O
dL	PROLIA.xml:S1:5765:2	dL	NN	O	O
at	PROLIA.xml:S1:5768:2	at	IN	O	O
any	PROLIA.xml:S1:5771:3	ani	DT	O	O
visit	PROLIA.xml:S1:5775:5	visit	NN	O	O
were	PROLIA.xml:S1:5781:4	were	VBD	O	O
reported	PROLIA.xml:S1:5786:8	report	VBN	O	O
in	PROLIA.xml:S1:5795:2	in	IN	O	O
0.4%	PROLIA.xml:S1:5798:4	0.4%	CD	O	O
women	PROLIA.xml:S1:5803:5	women	NNS	O	O
in	PROLIA.xml:S1:5809:2	in	IN	O	O
the	PROLIA.xml:S1:5812:3	the	DT	O	O
placebo	PROLIA.xml:S1:5816:7	placebo	NN	O	O
group	PROLIA.xml:S1:5824:5	group	NN	O	O
and	PROLIA.xml:S1:5830:3	and	CC	O	O
1.7%	PROLIA.xml:S1:5834:4	1.7%	CD	O	O
women	PROLIA.xml:S1:5839:5	women	NNS	O	O
in	PROLIA.xml:S1:5845:2	in	IN	O	O
the	PROLIA.xml:S1:5848:3	the	DT	O	O
Prolia	PROLIA.xml:S1:5852:6	prolia	NNP	O	O
group	PROLIA.xml:S1:5859:5	group	NN	O	O
.	PROLIA.xml:S1:5864:1	.	.	O	O

The	PROLIA.xml:S1:5866:3	the	DT	O	O
nadir	PROLIA.xml:S1:5870:5	nadir	NN	O	O
in	PROLIA.xml:S1:5876:2	in	IN	O	O
serum	PROLIA.xml:S1:5879:5	serum	JJ	O	O
calcium	PROLIA.xml:S1:5885:7	calcium	NN	O	O
level	PROLIA.xml:S1:5893:5	level	NN	O	O
occurs	PROLIA.xml:S1:5899:6	occur	VBZ	O	O
at	PROLIA.xml:S1:5906:2	at	IN	O	O
approximately	PROLIA.xml:S1:5909:13	approxim	RB	O	O
day	PROLIA.xml:S1:5923:3	day	NN	O	O
10	PROLIA.xml:S1:5927:2	10	CD	O	O
after	PROLIA.xml:S1:5930:5	after	IN	O	O
Prolia	PROLIA.xml:S1:5936:6	prolia	NNP	O	O
dosing	PROLIA.xml:S1:5943:6	dose	VBG	O	O
in	PROLIA.xml:S1:5950:2	in	IN	O	O
subjects	PROLIA.xml:S1:5953:8	subject	NNS	O	O
with	PROLIA.xml:S1:5962:4	with	IN	O	O
normal	PROLIA.xml:S1:5967:6	normal	JJ	O	O
renal	PROLIA.xml:S1:5974:5	renal	JJ	O	O
function	PROLIA.xml:S1:5980:8	function	NN	O	O
.	PROLIA.xml:S1:5988:1	.	.	O	O

In	PROLIA.xml:S1:5994:2	In	IN	O	O

clinical	PROLIA.xml:S1:5997:8	clinic	JJ	O	O
studies	PROLIA.xml:S1:6006:7	studi	NNS	O	O
,	PROLIA.xml:S1:6013:1	,	,	O	O
subjects	PROLIA.xml:S1:6015:8	subject	NNS	O	O
with	PROLIA.xml:S1:6024:4	with	IN	O	O
impaired	PROLIA.xml:S1:6029:8	impair	JJ	O	O
renal	PROLIA.xml:S1:6038:5	renal	JJ	O	O
function	PROLIA.xml:S1:6044:8	function	NN	O	O
were	PROLIA.xml:S1:6053:4	were	VBD	O	O
more	PROLIA.xml:S1:6058:4	more	RBR	O	O
likely	PROLIA.xml:S1:6063:6	like	JJ	O	O
to	PROLIA.xml:S1:6070:2	to	TO	O	O
have	PROLIA.xml:S1:6073:4	have	VB	O	O
greater	PROLIA.xml:S1:6078:7	greater	JJR	O	O
reductions	PROLIA.xml:S1:6086:10	reduct	NNS	O	B-AdverseReaction
in	PROLIA.xml:S1:6097:2	in	IN	O	I-AdverseReaction
serum	PROLIA.xml:S1:6100:5	serum	JJ	O	I-AdverseReaction
calcium	PROLIA.xml:S1:6106:7	calcium	NN	O	I-AdverseReaction
levels	PROLIA.xml:S1:6114:6	level	NNS	O	I-AdverseReaction
compared	PROLIA.xml:S1:6121:8	compar	VBN	O	O
to	PROLIA.xml:S1:6130:2	to	TO	O	O
subjects	PROLIA.xml:S1:6133:8	subject	NNS	O	O
with	PROLIA.xml:S1:6142:4	with	IN	O	O
normal	PROLIA.xml:S1:6147:6	normal	JJ	O	O
renal	PROLIA.xml:S1:6154:5	renal	JJ	O	O
function	PROLIA.xml:S1:6160:8	function	NN	O	O
.	PROLIA.xml:S1:6168:1	.	.	O	O

In	PROLIA.xml:S1:6170:2	In	IN	O	O
a	PROLIA.xml:S1:6173:1	a	DT	O	O
study	PROLIA.xml:S1:6175:5	studi	NN	O	O
of	PROLIA.xml:S1:6181:2	of	IN	O	O
55	PROLIA.xml:S1:6184:2	55	CD	O	O
subjects	PROLIA.xml:S1:6187:8	subject	NNS	O	O
with	PROLIA.xml:S1:6196:4	with	IN	O	O
varying	PROLIA.xml:S1:6201:7	vari	VBG	O	O
degrees	PROLIA.xml:S1:6209:7	degre	NNS	O	O
of	PROLIA.xml:S1:6217:2	of	IN	O	O
renal	PROLIA.xml:S1:6220:5	renal	JJ	O	O
function	PROLIA.xml:S1:6226:8	function	NN	O	O
,	PROLIA.xml:S1:6234:1	,	,	O	O
serum	PROLIA.xml:S1:6236:5	serum	JJ	O	O
calcium	PROLIA.xml:S1:6242:7	calcium	NN	O	O
levels	PROLIA.xml:S1:6250:6	level	NNS	O	O
7.5	PROLIA.xml:S1:6259:3	7.5	CD	O	O
mg	PROLIA.xml:S1:6263:2	mg	NN	O	O
dL	PROLIA.xml:S1:6266:2	dL	NN	O	O
or	PROLIA.xml:S1:6269:2	or	CC	O	O
symptomatic	PROLIA.xml:S1:6272:11	symptomat	JJ	B-AdverseReaction	O
hypocalcemia	PROLIA.xml:S1:6284:12	hypocalcemia	NN	I-AdverseReaction	O
were	PROLIA.xml:S1:6297:4	were	VBD	O	O
observed	PROLIA.xml:S1:6302:8	observ	VBN	O	O
in	PROLIA.xml:S1:6311:2	in	IN	O	O
5	PROLIA.xml:S1:6314:1	5	CD	O	O
subjects	PROLIA.xml:S1:6316:8	subject	NNS	O	O
.	PROLIA.xml:S1:6324:1	.	.	O	O

These	PROLIA.xml:S1:6326:5	these	DT	O	O
included	PROLIA.xml:S1:6332:8	includ	VBD	O	O
no	PROLIA.xml:S1:6341:2	no	DT	O	O
subjects	PROLIA.xml:S1:6344:8	subject	NNS	O	O
in	PROLIA.xml:S1:6353:2	in	IN	O	O
the	PROLIA.xml:S1:6356:3	the	DT	O	O
normal	PROLIA.xml:S1:6360:6	normal	JJ	O	O
renal	PROLIA.xml:S1:6367:5	renal	JJ	O	O
function	PROLIA.xml:S1:6373:8	function	NN	O	O
group	PROLIA.xml:S1:6382:5	group	NN	O	O
,	PROLIA.xml:S1:6387:1	,	,	O	O
10%	PROLIA.xml:S1:6389:3	10%	CD	O	O
of	PROLIA.xml:S1:6393:2	of	IN	O	O
subjects	PROLIA.xml:S1:6396:8	subject	NNS	O	O
in	PROLIA.xml:S1:6405:2	in	IN	O	O
the	PROLIA.xml:S1:6408:3	the	DT	O	O
creatinine	PROLIA.xml:S1:6412:10	creatinin	JJ	O	O
clearance	PROLIA.xml:S1:6423:9	clearanc	NN	O	O
50	PROLIA.xml:S1:6433:2	50	CD	O	O
to	PROLIA.xml:S1:6436:2	to	TO	O	O
80	PROLIA.xml:S1:6439:2	80	CD	O	O
mL	PROLIA.xml:S1:6442:2	mL	NNS	O	O
min	PROLIA.xml:S1:6445:3	min	JJ	O	O
group	PROLIA.xml:S1:6449:5	group	NN	O	O
,	PROLIA.xml:S1:6454:1	,	,	O	O
29%	PROLIA.xml:S1:6456:3	29%	CD	O	O
of	PROLIA.xml:S1:6460:2	of	IN	O	O
subjects	PROLIA.xml:S1:6463:8	subject	NNS	O	O
in	PROLIA.xml:S1:6472:2	in	IN	O	O
the	PROLIA.xml:S1:6475:3	the	DT	O	O
creatinine	PROLIA.xml:S1:6479:10	creatinin	JJ	O	O
clearance	PROLIA.xml:S1:6490:9	clearanc	NN	O	O
30	PROLIA.xml:S1:6502:2	30	CD	O	O
mL	PROLIA.xml:S1:6505:2	mL	NN	O	O
min	PROLIA.xml:S1:6508:3	min	NN	O	O
group	PROLIA.xml:S1:6512:5	group	NN	O	O
,	PROLIA.xml:S1:6517:1	,	,	O	O
and	PROLIA.xml:S1:6519:3	and	CC	O	O
29%	PROLIA.xml:S1:6523:3	29%	CD	O	O
of	PROLIA.xml:S1:6527:2	of	IN	O	O
subjects	PROLIA.xml:S1:6530:8	subject	NNS	O	O
in	PROLIA.xml:S1:6539:2	in	IN	O	O
the	PROLIA.xml:S1:6542:3	the	DT	O	O
hemodialysis	PROLIA.xml:S1:6546:12	hemodialysi	NN	O	O
group	PROLIA.xml:S1:6559:5	group	NN	O	O
.	PROLIA.xml:S1:6564:1	.	.	O	O

These	PROLIA.xml:S1:6566:5	these	DT	O	O
subjects	PROLIA.xml:S1:6572:8	subject	NNS	O	O
did	PROLIA.xml:S1:6581:3	did	VBD	O	O
not	PROLIA.xml:S1:6585:3	not	RB	O	O
receive	PROLIA.xml:S1:6589:7	receiv	VB	O	O
calcium	PROLIA.xml:S1:6597:7	calcium	NN	O	O
and	PROLIA.xml:S1:6605:3	and	CC	O	O
vitamin	PROLIA.xml:S1:6609:7	vitamin	NN	O	O
D	PROLIA.xml:S1:6617:1	D	NNP	O	O
supplementation	PROLIA.xml:S1:6619:15	supplement	NN	O	O
.	PROLIA.xml:S1:6634:1	.	.	O	O

In	PROLIA.xml:S1:6636:2	In	IN	O	O
a	PROLIA.xml:S1:6639:1	a	DT	O	O
study	PROLIA.xml:S1:6641:5	studi	NN	O	O
of	PROLIA.xml:S1:6647:2	of	IN	O	O
4550	PROLIA.xml:S1:6650:4	4550	CD	O	O
postmenopausal	PROLIA.xml:S1:6655:14	postmenopaus	JJ	O	O
women	PROLIA.xml:S1:6670:5	women	NNS	O	O
with	PROLIA.xml:S1:6676:4	with	IN	O	O
osteoporosis	PROLIA.xml:S1:6681:12	osteoporosi	NN	O	O
,	PROLIA.xml:S1:6693:1	,	,	O	O
the	PROLIA.xml:S1:6695:3	the	DT	O	O
mean	PROLIA.xml:S1:6699:4	mean	JJ	O	O
change	PROLIA.xml:S1:6704:6	chang	NN	O	O
from	PROLIA.xml:S1:6711:4	from	IN	O	O
baseline	PROLIA.xml:S1:6716:8	baselin	NN	O	O
in	PROLIA.xml:S1:6725:2	in	IN	O	O
serum	PROLIA.xml:S1:6728:5	serum	JJ	O	O
calcium	PROLIA.xml:S1:6734:7	calcium	NN	O	O
level	PROLIA.xml:S1:6742:5	level	NN	O	O
10	PROLIA.xml:S1:6748:2	10	CD	O	O
days	PROLIA.xml:S1:6751:4	day	NNS	O	O
after	PROLIA.xml:S1:6756:5	after	IN	O	O
Prolia	PROLIA.xml:S1:6762:6	prolia	NNP	O	O
dosing	PROLIA.xml:S1:6769:6	dose	NN	O	O
was	PROLIA.xml:S1:6776:3	wa	VBD	O	O
-	PROLIA.xml:S1:6780:1	-	:	O	O
5.5%	PROLIA.xml:S1:6781:4	5.5%	CD	O	O
in	PROLIA.xml:S1:6786:2	in	IN	O	O
subjects	PROLIA.xml:S1:6789:8	subject	NNS	O	O
with	PROLIA.xml:S1:6798:4	with	IN	O	O
creatinine	PROLIA.xml:S1:6803:10	creatinin	JJ	O	O
clearance	PROLIA.xml:S1:6814:9	clearanc	NN	O	O
30	PROLIA.xml:S1:6826:2	30	CD	O	O
mL	PROLIA.xml:S1:6829:2	mL	NN	O	O
min	PROLIA.xml:S1:6832:3	min	NN	O	O
vs	PROLIA.xml:S1:6836:2	vs	NN	O	O
.	PROLIA.xml:S1:6838:1	.	.	O	O

-	PROLIA.xml:S1:6840:1	-	:	O	O
3.1%	PROLIA.xml:S1:6841:4	3.1%	CD	O	O
in	PROLIA.xml:S1:6846:2	in	IN	O	O
subjects	PROLIA.xml:S1:6849:8	subject	NNS	O	O
with	PROLIA.xml:S1:6858:4	with	IN	O	O
creatinine	PROLIA.xml:S1:6863:10	creatinin	JJ	O	O
clearance	PROLIA.xml:S1:6874:9	clearanc	NN	O	O
30	PROLIA.xml:S1:6887:2	30	CD	O	O
mL	PROLIA.xml:S1:6890:2	mL	NN	O	O
min	PROLIA.xml:S1:6893:3	min	NN	O	O
.	PROLIA.xml:S1:6896:1	.	.	O	O

Serious	PROLIA.xml:S1:6905:7	seriou	JJ	O	O
Infections	PROLIA.xml:S1:6913:10	infect	NNP	O	O
Receptor	PROLIA.xml:S1:6925:8	receptor	NNP	O	O
activator	PROLIA.xml:S1:6934:9	activ	NN	O	O
of	PROLIA.xml:S1:6944:2	of	IN	O	O
nuclear	PROLIA.xml:S1:6947:7	nuclear	JJ	O	O
factor	PROLIA.xml:S1:6955:6	factor	NN	O	O
kappa	PROLIA.xml:S1:6962:5	kappa	SYM	O	O
-	PROLIA.xml:S1:6967:1	-	:	O	O
B	PROLIA.xml:S1:6968:1	B	NN	O	O
ligand	PROLIA.xml:S1:6970:6	ligand	NN	O	O
(	PROLIA.xml:S1:6977:1	(	(	O	O
RANKL	PROLIA.xml:S1:6978:5	rankl	NNP	O	O
)	PROLIA.xml:S1:6983:1	)	)	O	O
is	PROLIA.xml:S1:6985:2	is	VBZ	O	O
expressed	PROLIA.xml:S1:6988:9	express	VBN	O	O
on	PROLIA.xml:S1:6998:2	on	IN	O	O
activated	PROLIA.xml:S1:7001:9	activ	JJ	O	O
T	PROLIA.xml:S1:7011:1	T	NNP	O	O
and	PROLIA.xml:S1:7013:3	and	CC	O	O
B	PROLIA.xml:S1:7017:1	B	NNP	O	O
lymphocytes	PROLIA.xml:S1:7019:11	lymphocyt	NNS	O	O
and	PROLIA.xml:S1:7031:3	and	CC	O	O
in	PROLIA.xml:S1:7035:2	in	IN	O	O
lymph	PROLIA.xml:S1:7038:5	lymph	JJ	O	O
nodes	PROLIA.xml:S1:7044:5	node	NNS	O	O
.	PROLIA.xml:S1:7049:1	.	.	O	O

Therefore	PROLIA.xml:S1:7051:9	therefor	RB	O	O
,	PROLIA.xml:S1:7060:1	,	,	O	O
a	PROLIA.xml:S1:7062:1	a	DT	O	O
RANKL	PROLIA.xml:S1:7064:5	rankl	NNP	O	O
inhibitor	PROLIA.xml:S1:7070:9	inhibitor	NN	O	O
such	PROLIA.xml:S1:7080:4	such	JJ	O	O
as	PROLIA.xml:S1:7085:2	as	IN	O	O
Prolia	PROLIA.xml:S1:7088:6	prolia	NNP	O	O
may	PROLIA.xml:S1:7095:3	may	MD	O	O
increase	PROLIA.xml:S1:7099:8	increas	VB	O	O
the	PROLIA.xml:S1:7108:3	the	DT	O	O
risk	PROLIA.xml:S1:7112:4	risk	NN	O	O
of	PROLIA.xml:S1:7117:2	of	IN	O	O
infection	PROLIA.xml:S1:7120:9	infect	NN	B-AdverseReaction	O
.	PROLIA.xml:S1:7129:1	.	.	O	O

In	PROLIA.xml:S1:7137:2	In	IN	O	O
the	PROLIA.xml:S1:7140:3	the	DT	O	O
clinical	PROLIA.xml:S1:7144:8	clinic	JJ	O	O
study	PROLIA.xml:S1:7153:5	studi	NN	O	O
of	PROLIA.xml:S1:7159:2	of	IN	O	O
7808	PROLIA.xml:S1:7162:4	7808	CD	O	O
postmenopausal	PROLIA.xml:S1:7167:14	postmenopaus	JJ	O	O
women	PROLIA.xml:S1:7182:5	women	NNS	O	O
with	PROLIA.xml:S1:7188:4	with	IN	O	O
osteoporosis	PROLIA.xml:S1:7193:12	osteoporosi	NN	O	O
,	PROLIA.xml:S1:7205:1	,	,	O	O
the	PROLIA.xml:S1:7207:3	the	DT	O	O
incidence	PROLIA.xml:S1:7211:9	incid	NN	O	O
of	PROLIA.xml:S1:7221:2	of	IN	O	O
infections	PROLIA.xml:S1:7224:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
resulting	PROLIA.xml:S1:7235:9	result	VBG	O	O
in	PROLIA.xml:S1:7245:2	in	IN	O	O
death	PROLIA.xml:S1:7248:5	death	NN	B-AdverseReaction	B-AdverseReaction
was	PROLIA.xml:S1:7254:3	wa	VBD	O	O
0.2%	PROLIA.xml:S1:7258:4	0.2%	CD	O	O
in	PROLIA.xml:S1:7263:2	in	IN	O	O
both	PROLIA.xml:S1:7266:4	both	DT	O	O
placebo	PROLIA.xml:S1:7271:7	placebo	NN	O	O
and	PROLIA.xml:S1:7279:3	and	CC	O	O
Prolia	PROLIA.xml:S1:7283:6	prolia	NNP	O	O
treatment	PROLIA.xml:S1:7290:9	treatment	NN	O	O
groups	PROLIA.xml:S1:7300:6	group	NNS	O	O
.	PROLIA.xml:S1:7306:1	.	.	O	O

However	PROLIA.xml:S1:7308:7	howev	RB	O	O
,	PROLIA.xml:S1:7315:1	,	,	O	O
the	PROLIA.xml:S1:7317:3	the	DT	O	O
incidence	PROLIA.xml:S1:7321:9	incid	NN	O	O
of	PROLIA.xml:S1:7331:2	of	IN	O	O
nonfatal	PROLIA.xml:S1:7334:8	nonfat	JJ	O	O
serious	PROLIA.xml:S1:7343:7	seriou	JJ	O	O
infections	PROLIA.xml:S1:7351:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
was	PROLIA.xml:S1:7362:3	wa	VBD	O	O
3.3%	PROLIA.xml:S1:7366:4	3.3%	CD	O	O
in	PROLIA.xml:S1:7371:2	in	IN	O	O
the	PROLIA.xml:S1:7374:3	the	DT	O	O
placebo	PROLIA.xml:S1:7378:7	placebo	NN	O	O
and	PROLIA.xml:S1:7386:3	and	CC	O	O
4.0%	PROLIA.xml:S1:7390:4	4.0%	CD	O	O
in	PROLIA.xml:S1:7395:2	in	IN	O	O
the	PROLIA.xml:S1:7398:3	the	DT	O	O
Prolia	PROLIA.xml:S1:7402:6	prolia	NNP	O	O
groups	PROLIA.xml:S1:7409:6	group	NNS	O	O
.	PROLIA.xml:S1:7415:1	.	.	O	O

Hospitalizations	PROLIA.xml:S1:7417:16	hospit	NNS	O	O
due	PROLIA.xml:S1:7434:3	due	JJ	O	O
to	PROLIA.xml:S1:7438:2	to	TO	O	O
serious	PROLIA.xml:S1:7441:7	seriou	JJ	O	O
infections	PROLIA.xml:S1:7449:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
in	PROLIA.xml:S1:7460:2	in	IN	I-AdverseReaction	O
the	PROLIA.xml:S1:7463:3	the	DT	I-AdverseReaction	O
abdomen	PROLIA.xml:S1:7467:7	abdomen	NNS	I-AdverseReaction	O
(	PROLIA.xml:S1:7475:1	(	(	O	O
0.7%	PROLIA.xml:S1:7476:4	0.7%	CD	O	O
placebo	PROLIA.xml:S1:7481:7	placebo	NN	O	O
vs	PROLIA.xml:S1:7489:2	vs	NN	O	O
.	PROLIA.xml:S1:7491:1	.	.	O	O

0.9%	PROLIA.xml:S1:7493:4	0.9%	CD	O	O
Prolia	PROLIA.xml:S1:7498:6	prolia	NNP	O	O
)	PROLIA.xml:S1:7504:1	)	)	O	O
,	PROLIA.xml:S1:7505:1	,	,	O	O
urinary	PROLIA.xml:S1:7507:7	urinari	JJ	I-AdverseReaction	B-AdverseReaction
tract	PROLIA.xml:S1:7515:5	tract	NN	I-AdverseReaction	I-AdverseReaction
(	PROLIA.xml:S1:7521:1	(	(	O	O
0.5%	PROLIA.xml:S1:7522:4	0.5%	CD	O	O
placebo	PROLIA.xml:S1:7527:7	placebo	NN	O	O
vs	PROLIA.xml:S1:7535:2	vs	NN	O	O
.	PROLIA.xml:S1:7537:1	.	.	O	O

0.7%	PROLIA.xml:S1:7539:4	0.7%	CD	O	O
Prolia	PROLIA.xml:S1:7544:6	prolia	NNP	O	O
)	PROLIA.xml:S1:7550:1	)	)	O	O
,	PROLIA.xml:S1:7551:1	,	,	O	O
and	PROLIA.xml:S1:7553:3	and	CC	O	O
ear	PROLIA.xml:S1:7557:3	ear	NN	I-AdverseReaction	B-AdverseReaction
(	PROLIA.xml:S1:7561:1	(	(	O	O
0.0%	PROLIA.xml:S1:7562:4	0.0%	CD	O	O
placebo	PROLIA.xml:S1:7567:7	placebo	NN	O	O
vs	PROLIA.xml:S1:7575:2	vs	NN	O	O
.	PROLIA.xml:S1:7577:1	.	.	O	O

0.1%	PROLIA.xml:S1:7579:4	0.1%	CD	O	O
Prolia	PROLIA.xml:S1:7584:6	prolia	NNP	O	O
)	PROLIA.xml:S1:7590:1	)	)	O	O
were	PROLIA.xml:S1:7592:4	were	VBD	O	O
reported	PROLIA.xml:S1:7597:8	report	VBN	O	O
.	PROLIA.xml:S1:7605:1	.	.	O	O

Endocarditis	PROLIA.xml:S1:7607:12	endocard	NN	B-AdverseReaction	B-AdverseReaction
was	PROLIA.xml:S1:7620:3	wa	VBD	O	O
reported	PROLIA.xml:S1:7624:8	report	VBN	O	O
in	PROLIA.xml:S1:7633:2	in	IN	O	O
no	PROLIA.xml:S1:7636:2	no	DT	O	O
placebo	PROLIA.xml:S1:7639:7	placebo	NN	O	O
patients	PROLIA.xml:S1:7647:8	patient	NNS	O	O
and	PROLIA.xml:S1:7656:3	and	CC	O	O
3	PROLIA.xml:S1:7660:1	3	CD	O	O
patients	PROLIA.xml:S1:7662:8	patient	NNS	O	O
receiving	PROLIA.xml:S1:7671:9	receiv	VBG	O	O
Prolia	PROLIA.xml:S1:7681:6	prolia	NNP	O	O
.	PROLIA.xml:S1:7687:1	.	.	O	O

Skin	PROLIA.xml:S1:7693:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
infections	PROLIA.xml:S1:7698:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:7708:1	,	,	O	O
including	PROLIA.xml:S1:7710:9	includ	VBG	O	O
erysipelas	PROLIA.xml:S1:7720:10	erysipela	NNS	B-AdverseReaction	O
and	PROLIA.xml:S1:7731:3	and	CC	O	O
cellulitis	PROLIA.xml:S1:7735:10	cellul	NN	B-AdverseReaction	O
,	PROLIA.xml:S1:7745:1	,	,	O	O
leading	PROLIA.xml:S1:7747:7	lead	VBG	O	O
to	PROLIA.xml:S1:7755:2	to	TO	O	O
hospitalization	PROLIA.xml:S1:7758:15	hospit	NN	O	O
were	PROLIA.xml:S1:7774:4	were	VBD	O	O
reported	PROLIA.xml:S1:7779:8	report	VBN	O	O
more	PROLIA.xml:S1:7788:4	more	RBR	O	O
frequently	PROLIA.xml:S1:7793:10	frequent	RB	O	O
in	PROLIA.xml:S1:7804:2	in	IN	O	O
patients	PROLIA.xml:S1:7807:8	patient	NNS	O	O
treated	PROLIA.xml:S1:7816:7	treat	VBN	O	O
with	PROLIA.xml:S1:7824:4	with	IN	O	O
Prolia	PROLIA.xml:S1:7829:6	prolia	NNP	O	O
(	PROLIA.xml:S1:7836:1	(	(	O	O
0.1%	PROLIA.xml:S1:7839:4	0.1%	CD	O	O
placebo	PROLIA.xml:S1:7844:7	placebo	NN	O	O
vs	PROLIA.xml:S1:7852:2	vs	NN	O	O
.	PROLIA.xml:S1:7854:1	.	.	O	O

0.4%	PROLIA.xml:S1:7856:4	0.4%	CD	O	O
Prolia	PROLIA.xml:S1:7861:6	prolia	NNP	O	O
)	PROLIA.xml:S1:7867:1	)	)	O	O
.	PROLIA.xml:S1:7868:1	.	.	O	O

The	PROLIA.xml:S1:7874:3	the	DT	O	O
incidence	PROLIA.xml:S1:7878:9	incid	NN	O	O
of	PROLIA.xml:S1:7888:2	of	IN	O	O
opportunistic	PROLIA.xml:S1:7891:13	opportunist	JJ	B-AdverseReaction	B-AdverseReaction
infections	PROLIA.xml:S1:7905:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
was	PROLIA.xml:S1:7916:3	wa	VBD	O	O
similar	PROLIA.xml:S1:7920:7	similar	JJ	O	O
to	PROLIA.xml:S1:7928:2	to	TO	O	O
that	PROLIA.xml:S1:7931:4	that	DT	O	O
reported	PROLIA.xml:S1:7936:8	report	VBN	O	O
with	PROLIA.xml:S1:7945:4	with	IN	O	O
placebo	PROLIA.xml:S1:7950:7	placebo	NN	O	O
.	PROLIA.xml:S1:7957:1	.	.	O	O

Dermatologic	PROLIA.xml:S1:7965:12	dermatolog	NNP	O	B-AdverseReaction
Reactions	PROLIA.xml:S1:7978:9	reaction	NNP	O	I-AdverseReaction
A	PROLIA.xml:S1:7989:1	A	NNP	O	O
significantly	PROLIA.xml:S1:7991:13	significantli	RB	O	O
higher	PROLIA.xml:S1:8005:6	higher	JJR	O	O
number	PROLIA.xml:S1:8012:6	number	NN	O	O
of	PROLIA.xml:S1:8019:2	of	IN	O	O
patients	PROLIA.xml:S1:8022:8	patient	NNS	O	O
treated	PROLIA.xml:S1:8031:7	treat	VBN	O	O
with	PROLIA.xml:S1:8039:4	with	IN	O	O
Prolia	PROLIA.xml:S1:8044:6	prolia	NNP	O	O
developed	PROLIA.xml:S1:8051:9	develop	VBD	O	O
epidermal	PROLIA.xml:S1:8061:9	epiderm	JJ	B-AdverseReaction	O
and	PROLIA.xml:S1:8071:3	and	CC	O	O
dermal	PROLIA.xml:S1:8075:6	dermal	JJ	B-AdverseReaction	O
adverse	PROLIA.xml:S1:8082:7	advers	JJ	I-AdverseReaction	O
events	PROLIA.xml:S1:8090:6	event	NNS	I-AdverseReaction	O
(	PROLIA.xml:S1:8097:1	(	(	O	O
such	PROLIA.xml:S1:8098:4	such	JJ	O	O
as	PROLIA.xml:S1:8103:2	as	IN	O	O
dermatitis	PROLIA.xml:S1:8106:10	dermat	NN	B-AdverseReaction	O
,	PROLIA.xml:S1:8116:1	,	,	O	O
eczema	PROLIA.xml:S1:8118:6	eczema	NN	B-AdverseReaction	O
,	PROLIA.xml:S1:8124:1	,	,	O	O
and	PROLIA.xml:S1:8126:3	and	CC	O	O
rashes	PROLIA.xml:S1:8130:6	rash	NNS	B-AdverseReaction	B-AdverseReaction
)	PROLIA.xml:S1:8136:1	)	)	O	O
,	PROLIA.xml:S1:8137:1	,	,	O	O
with	PROLIA.xml:S1:8139:4	with	IN	O	O
these	PROLIA.xml:S1:8144:5	these	DT	O	O
events	PROLIA.xml:S1:8150:6	event	NNS	O	O
reported	PROLIA.xml:S1:8157:8	report	VBD	O	O
in	PROLIA.xml:S1:8166:2	in	IN	O	O
8.2%	PROLIA.xml:S1:8169:4	8.2%	CD	O	O
of	PROLIA.xml:S1:8174:2	of	IN	O	O
the	PROLIA.xml:S1:8177:3	the	DT	O	O
placebo	PROLIA.xml:S1:8181:7	placebo	NN	O	O
and	PROLIA.xml:S1:8189:3	and	CC	O	O
10.8%	PROLIA.xml:S1:8193:5	10.8%	CD	O	O
of	PROLIA.xml:S1:8199:2	of	IN	O	O
the	PROLIA.xml:S1:8202:3	the	DT	O	O
Prolia	PROLIA.xml:S1:8206:6	prolia	NNP	O	O
groups	PROLIA.xml:S1:8213:6	group	NNS	O	O
(	PROLIA.xml:S1:8220:1	(	(	O	O
p	PROLIA.xml:S1:8221:1	p	VB	O	O
0.0001	PROLIA.xml:S1:8225:6	0.0001	CD	O	O
)	PROLIA.xml:S1:8231:1	)	)	O	O
.	PROLIA.xml:S1:8232:1	.	.	O	O

Most	PROLIA.xml:S1:8234:4	most	JJS	O	O
of	PROLIA.xml:S1:8239:2	of	IN	O	O
these	PROLIA.xml:S1:8242:5	these	DT	O	O
events	PROLIA.xml:S1:8248:6	event	NNS	O	O
were	PROLIA.xml:S1:8255:4	were	VBD	O	O
not	PROLIA.xml:S1:8260:3	not	RB	O	O
specific	PROLIA.xml:S1:8264:8	specif	JJ	O	O
to	PROLIA.xml:S1:8273:2	to	TO	O	O
the	PROLIA.xml:S1:8276:3	the	DT	O	O
injection	PROLIA.xml:S1:8280:9	inject	NN	O	O
site	PROLIA.xml:S1:8290:4	site	NN	O	O
[	PROLIA.xml:S1:8296:1	[	NNP	O	O
see	PROLIA.xml:S1:8297:3	see	VBP	O	O
Warnings	PROLIA.xml:S1:8301:8	warn	NNP	O	O
and	PROLIA.xml:S1:8310:3	and	CC	O	O
Precautions	PROLIA.xml:S1:8314:11	precaut	NNP	O	O
(	PROLIA.xml:S1:8326:1	(	(	O	O
5.7	PROLIA.xml:S1:8329:3	5.7	CD	O	O
)]	PROLIA.xml:S1:8334:2	)]	NN	O	O
.	PROLIA.xml:S1:8336:1	.	.	O	O

Osteonecrosis	PROLIA.xml:S1:8346:13	osteonecrosi	NN	B-AdverseReaction	B-AdverseReaction
of	PROLIA.xml:S1:8360:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	PROLIA.xml:S1:8363:3	the	DT	I-AdverseReaction	I-AdverseReaction
Jaw	PROLIA.xml:S1:8367:3	jaw	NNP	I-AdverseReaction	I-AdverseReaction
ONJ	PROLIA.xml:S1:8372:3	onj	NNP	B-AdverseReaction	I-AdverseReaction
has	PROLIA.xml:S1:8376:3	ha	VBZ	O	O
been	PROLIA.xml:S1:8380:4	been	VBN	O	O
reported	PROLIA.xml:S1:8385:8	report	VBN	O	O
in	PROLIA.xml:S1:8394:2	in	IN	O	O
the	PROLIA.xml:S1:8397:3	the	DT	O	O
osteoporosis	PROLIA.xml:S1:8401:12	osteoporosi	NN	O	O
clinical	PROLIA.xml:S1:8414:8	clinic	JJ	O	O
trial	PROLIA.xml:S1:8423:5	trial	NN	O	O
program	PROLIA.xml:S1:8429:7	program	NN	O	O
in	PROLIA.xml:S1:8437:2	in	IN	O	O
patients	PROLIA.xml:S1:8440:8	patient	NNS	O	O
treated	PROLIA.xml:S1:8449:7	treat	VBN	O	O
with	PROLIA.xml:S1:8457:4	with	IN	O	O
Prolia	PROLIA.xml:S1:8462:6	prolia	NNP	O	O
[	PROLIA.xml:S1:8470:1	[	NNP	O	O
see	PROLIA.xml:S1:8471:3	see	VBP	O	O
Warnings	PROLIA.xml:S1:8475:8	warn	NNP	O	O
and	PROLIA.xml:S1:8484:3	and	CC	O	O
Precautions	PROLIA.xml:S1:8488:11	precaut	NNP	O	O
(	PROLIA.xml:S1:8500:1	(	(	O	O
5.4	PROLIA.xml:S1:8503:3	5.4	CD	O	O
)]	PROLIA.xml:S1:8508:2	)]	NN	O	O
.	PROLIA.xml:S1:8510:1	.	.	O	O

Atypical	PROLIA.xml:S1:8520:8	atyp	JJ	O	O
Subtrochanteric	PROLIA.xml:S1:8529:15	subtrochanter	NNP	O	O
and	PROLIA.xml:S1:8545:3	and	CC	O	O
Diaphyseal	PROLIA.xml:S1:8549:10	diaphys	NNP	O	B-AdverseReaction
Fractures	PROLIA.xml:S1:8560:9	fractur	NNP	O	I-AdverseReaction
In	PROLIA.xml:S1:8571:2	In	IN	O	O
the	PROLIA.xml:S1:8574:3	the	DT	O	O
osteoporosis	PROLIA.xml:S1:8578:12	osteoporosi	NN	O	O
clinical	PROLIA.xml:S1:8591:8	clinic	JJ	O	O
trial	PROLIA.xml:S1:8600:5	trial	NN	O	O
program	PROLIA.xml:S1:8606:7	program	NN	O	O
,	PROLIA.xml:S1:8613:1	,	,	O	O
atypical	PROLIA.xml:S1:8615:8	atyp	JJ	B-AdverseReaction	B-AdverseReaction
femoral	PROLIA.xml:S1:8624:7	femor	JJ	I-AdverseReaction	I-AdverseReaction
fractures	PROLIA.xml:S1:8632:9	fractur	NNS	I-AdverseReaction	I-AdverseReaction
were	PROLIA.xml:S1:8642:4	were	VBD	O	O
reported	PROLIA.xml:S1:8647:8	report	VBN	O	O
in	PROLIA.xml:S1:8656:2	in	IN	O	O
patients	PROLIA.xml:S1:8659:8	patient	NNS	O	O
treated	PROLIA.xml:S1:8668:7	treat	VBN	O	O
with	PROLIA.xml:S1:8676:4	with	IN	O	O
Prolia	PROLIA.xml:S1:8681:6	prolia	NNP	O	O
.	PROLIA.xml:S1:8687:1	.	.	O	O

The	PROLIA.xml:S1:8689:3	the	DT	O	O
duration	PROLIA.xml:S1:8693:8	durat	NN	O	O
of	PROLIA.xml:S1:8702:2	of	IN	O	O
Prolia	PROLIA.xml:S1:8705:6	prolia	NNP	O	O
exposure	PROLIA.xml:S1:8712:8	exposur	NN	O	O
to	PROLIA.xml:S1:8721:2	to	TO	O	O
time	PROLIA.xml:S1:8724:4	time	NN	O	O
of	PROLIA.xml:S1:8729:2	of	IN	O	O
atypical	PROLIA.xml:S1:8732:8	atyp	JJ	B-AdverseReaction	O
femoral	PROLIA.xml:S1:8741:7	femor	JJ	I-AdverseReaction	O
fracture	PROLIA.xml:S1:8749:8	fractur	NN	I-AdverseReaction	O
diagnosis	PROLIA.xml:S1:8758:9	diagnosi	NN	O	O
was	PROLIA.xml:S1:8768:3	wa	VBD	O	O
as	PROLIA.xml:S1:8772:2	as	RB	O	O
early	PROLIA.xml:S1:8775:5	earli	JJ	O	O
as	PROLIA.xml:S1:8781:2	as	IN	O	O
21	PROLIA.xml:S1:8784:2	21	CD	O	O
2	PROLIA.xml:S1:8787:1	2	CD	O	O
years	PROLIA.xml:S1:8789:5	year	NNS	O	O
[	PROLIA.xml:S1:8796:1	[	JJ	O	O
see	PROLIA.xml:S1:8797:3	see	VBP	O	O
Warnings	PROLIA.xml:S1:8801:8	warn	NNS	O	O
and	PROLIA.xml:S1:8810:3	and	CC	O	O
Precautions	PROLIA.xml:S1:8814:11	precaut	NNP	O	O
(	PROLIA.xml:S1:8826:1	(	(	O	O
5.5	PROLIA.xml:S1:8829:3	5.5	CD	O	O
)]	PROLIA.xml:S1:8834:2	)]	NN	O	O
.	PROLIA.xml:S1:8838:1	.	.	O	O

Pancreatitis	PROLIA.xml:S1:8846:12	pancreat	NNP	O	B-AdverseReaction
Pancreatitis	PROLIA.xml:S1:8860:12	pancreat	NNP	B-AdverseReaction	B-AdverseReaction
was	PROLIA.xml:S1:8873:3	wa	VBD	O	O
reported	PROLIA.xml:S1:8877:8	report	VBN	O	O
in	PROLIA.xml:S1:8886:2	in	IN	O	O
4	PROLIA.xml:S1:8889:1	4	CD	O	O
patients	PROLIA.xml:S1:8891:8	patient	NNS	O	O
(	PROLIA.xml:S1:8900:1	(	(	O	O
0.1%	PROLIA.xml:S1:8901:4	0.1%	CD	O	O
)	PROLIA.xml:S1:8905:1	)	)	O	O
in	PROLIA.xml:S1:8907:2	in	IN	O	O
the	PROLIA.xml:S1:8910:3	the	DT	O	O
placebo	PROLIA.xml:S1:8914:7	placebo	NN	O	O
and	PROLIA.xml:S1:8922:3	and	CC	O	O
8	PROLIA.xml:S1:8926:1	8	CD	O	O
patients	PROLIA.xml:S1:8928:8	patient	NNS	O	O
(	PROLIA.xml:S1:8937:1	(	(	O	O
0.2%	PROLIA.xml:S1:8938:4	0.2%	CD	O	O
)	PROLIA.xml:S1:8942:1	)	)	O	O
in	PROLIA.xml:S1:8944:2	in	IN	O	O
the	PROLIA.xml:S1:8947:3	the	DT	O	O
Prolia	PROLIA.xml:S1:8951:6	prolia	NNP	O	O
groups	PROLIA.xml:S1:8958:6	group	NNS	O	O
.	PROLIA.xml:S1:8964:1	.	.	O	O

Of	PROLIA.xml:S1:8966:2	Of	IN	O	O
these	PROLIA.xml:S1:8969:5	these	DT	O	O
reports	PROLIA.xml:S1:8975:7	report	NNS	O	O
,	PROLIA.xml:S1:8982:1	,	,	O	O
1	PROLIA.xml:S1:8984:1	1	CD	O	O
patient	PROLIA.xml:S1:8986:7	patient	NN	O	O
in	PROLIA.xml:S1:8994:2	in	IN	O	O
the	PROLIA.xml:S1:8997:3	the	DT	O	O
placebo	PROLIA.xml:S1:9001:7	placebo	NN	O	O
group	PROLIA.xml:S1:9009:5	group	NN	O	O
and	PROLIA.xml:S1:9015:3	and	CC	O	O
all	PROLIA.xml:S1:9019:3	all	DT	O	O
8	PROLIA.xml:S1:9023:1	8	CD	O	O
patients	PROLIA.xml:S1:9025:8	patient	NNS	O	O
in	PROLIA.xml:S1:9034:2	in	IN	O	O
the	PROLIA.xml:S1:9037:3	the	DT	O	O
Prolia	PROLIA.xml:S1:9041:6	prolia	NNP	O	O
group	PROLIA.xml:S1:9048:5	group	NN	O	O
had	PROLIA.xml:S1:9054:3	had	VBD	O	O
serious	PROLIA.xml:S1:9058:7	seriou	JJ	O	O
events	PROLIA.xml:S1:9066:6	event	NNS	O	O
,	PROLIA.xml:S1:9072:1	,	,	O	O
including	PROLIA.xml:S1:9074:9	includ	VBG	O	O
one	PROLIA.xml:S1:9084:3	one	CD	O	O
death	PROLIA.xml:S1:9088:5	death	NN	B-AdverseReaction	O
in	PROLIA.xml:S1:9094:2	in	IN	O	O
the	PROLIA.xml:S1:9097:3	the	DT	O	O
Prolia	PROLIA.xml:S1:9101:6	prolia	NNP	O	O
group	PROLIA.xml:S1:9108:5	group	NN	O	O
.	PROLIA.xml:S1:9113:1	.	.	O	O

Several	PROLIA.xml:S1:9115:7	sever	JJ	O	O
patients	PROLIA.xml:S1:9123:8	patient	NNS	O	O
had	PROLIA.xml:S1:9132:3	had	VBD	O	O
a	PROLIA.xml:S1:9136:1	a	DT	O	O
prior	PROLIA.xml:S1:9138:5	prior	JJ	O	O
history	PROLIA.xml:S1:9144:7	histori	NN	O	O
of	PROLIA.xml:S1:9152:2	of	IN	O	O
pancreatitis	PROLIA.xml:S1:9155:12	pancreat	NN	O	O
.	PROLIA.xml:S1:9167:1	.	.	O	O

The	PROLIA.xml:S1:9169:3	the	DT	O	O
time	PROLIA.xml:S1:9173:4	time	NN	O	O
from	PROLIA.xml:S1:9178:4	from	IN	O	O
product	PROLIA.xml:S1:9183:7	product	NN	O	O
administration	PROLIA.xml:S1:9191:14	administr	NN	O	O
to	PROLIA.xml:S1:9206:2	to	TO	O	O
event	PROLIA.xml:S1:9209:5	event	NN	O	O
occurrence	PROLIA.xml:S1:9215:10	occurr	NN	O	O
was	PROLIA.xml:S1:9226:3	wa	VBD	O	O
variable	PROLIA.xml:S1:9230:8	variabl	JJ	O	O
.	PROLIA.xml:S1:9238:1	.	.	O	O

New	PROLIA.xml:S1:9246:3	new	NNP	O	O
Malignancies	PROLIA.xml:S1:9250:12	malign	NNP	O	O
The	PROLIA.xml:S1:9264:3	the	DT	O	O
overall	PROLIA.xml:S1:9268:7	overal	JJ	O	O
incidence	PROLIA.xml:S1:9276:9	incid	NN	O	O
of	PROLIA.xml:S1:9286:2	of	IN	O	O
new	PROLIA.xml:S1:9289:3	new	JJ	O	B-AdverseReaction
malignancies	PROLIA.xml:S1:9293:12	malign	NNS	B-AdverseReaction	I-AdverseReaction
was	PROLIA.xml:S1:9306:3	wa	VBD	O	O
4.3%	PROLIA.xml:S1:9310:4	4.3%	CD	O	O
in	PROLIA.xml:S1:9315:2	in	IN	O	O
the	PROLIA.xml:S1:9318:3	the	DT	O	O
placebo	PROLIA.xml:S1:9322:7	placebo	NN	O	O
and	PROLIA.xml:S1:9330:3	and	CC	O	O
4.8%	PROLIA.xml:S1:9334:4	4.8%	CD	O	O
in	PROLIA.xml:S1:9339:2	in	IN	O	O
the	PROLIA.xml:S1:9342:3	the	DT	O	O
Prolia	PROLIA.xml:S1:9346:6	prolia	NNP	O	O
groups	PROLIA.xml:S1:9353:6	group	NNS	O	O
.	PROLIA.xml:S1:9359:1	.	.	O	O

New	PROLIA.xml:S1:9361:3	new	NNP	O	B-AdverseReaction
malignancies	PROLIA.xml:S1:9365:12	malign	NNS	B-AdverseReaction	I-AdverseReaction
related	PROLIA.xml:S1:9378:7	relat	VBN	O	I-AdverseReaction
to	PROLIA.xml:S1:9386:2	to	TO	I-AdverseReaction	I-AdverseReaction
the	PROLIA.xml:S1:9389:3	the	DT	I-AdverseReaction	I-AdverseReaction
breast	PROLIA.xml:S1:9393:6	breast	NN	I-AdverseReaction	I-AdverseReaction
(	PROLIA.xml:S1:9400:1	(	(	O	O
0.7%	PROLIA.xml:S1:9401:4	0.7%	CD	O	O
placebo	PROLIA.xml:S1:9406:7	placebo	NN	O	O
vs	PROLIA.xml:S1:9414:2	vs	NN	O	O
.	PROLIA.xml:S1:9416:1	.	.	O	O

0.9%	PROLIA.xml:S1:9418:4	0.9%	CD	O	O
Prolia	PROLIA.xml:S1:9423:6	prolia	NNP	O	O
)	PROLIA.xml:S1:9429:1	)	)	O	O
,	PROLIA.xml:S1:9430:1	,	,	O	O
reproductive	PROLIA.xml:S1:9432:12	reproduct	JJ	I-AdverseReaction	O
system	PROLIA.xml:S1:9445:6	system	NN	I-AdverseReaction	O
(	PROLIA.xml:S1:9452:1	(	(	O	O
0.2%	PROLIA.xml:S1:9453:4	0.2%	CD	O	O
placebo	PROLIA.xml:S1:9458:7	placebo	NN	O	O
vs	PROLIA.xml:S1:9466:2	vs	NN	O	O
.	PROLIA.xml:S1:9468:1	.	.	O	O

0.5%	PROLIA.xml:S1:9470:4	0.5%	CD	O	O
Prolia	PROLIA.xml:S1:9475:6	prolia	NNP	O	O
)	PROLIA.xml:S1:9481:1	)	)	O	O
,	PROLIA.xml:S1:9482:1	,	,	O	O
and	PROLIA.xml:S1:9484:3	and	CC	O	O
gastrointestinal	PROLIA.xml:S1:9488:16	gastrointestin	JJ	I-AdverseReaction	B-AdverseReaction
system	PROLIA.xml:S1:9505:6	system	NN	I-AdverseReaction	I-AdverseReaction
(	PROLIA.xml:S1:9512:1	(	(	O	O
0.6%	PROLIA.xml:S1:9513:4	0.6%	CD	O	O
placebo	PROLIA.xml:S1:9518:7	placebo	NN	O	O
vs	PROLIA.xml:S1:9526:2	vs	NN	O	O
.	PROLIA.xml:S1:9528:1	.	.	O	O

0.9%	PROLIA.xml:S1:9530:4	0.9%	CD	O	O
Prolia	PROLIA.xml:S1:9535:6	prolia	NNP	O	O
)	PROLIA.xml:S1:9541:1	)	)	O	O
were	PROLIA.xml:S1:9543:4	were	VBD	O	O
reported	PROLIA.xml:S1:9548:8	report	VBN	O	O
.	PROLIA.xml:S1:9556:1	.	.	O	O

A	PROLIA.xml:S1:9558:1	A	DT	O	O
causal	PROLIA.xml:S1:9560:6	causal	NN	O	O
relationship	PROLIA.xml:S1:9567:12	relationship	NN	O	O
to	PROLIA.xml:S1:9580:2	to	TO	O	O
drug	PROLIA.xml:S1:9583:4	drug	NN	O	O
exposure	PROLIA.xml:S1:9588:8	exposur	NN	O	O
has	PROLIA.xml:S1:9597:3	ha	VBZ	O	O
not	PROLIA.xml:S1:9601:3	not	RB	O	O
been	PROLIA.xml:S1:9605:4	been	VBN	O	O
established	PROLIA.xml:S1:9610:11	establish	VBN	O	O
.	PROLIA.xml:S1:9621:1	.	.	O	O

Treatment	PROLIA.xml:S1:9629:9	treatment	NN	O	O
to	PROLIA.xml:S1:9639:2	to	TO	O	O
Increase	PROLIA.xml:S1:9642:8	increas	NNP	O	O
Bone	PROLIA.xml:S1:9651:4	bone	NNP	O	O
Mass	PROLIA.xml:S1:9656:4	mass	NNP	O	O
in	PROLIA.xml:S1:9661:2	in	IN	O	O
Men	PROLIA.xml:S1:9667:3	men	NNP	O	O
with	PROLIA.xml:S1:9671:4	with	IN	O	O
Osteoporosis	PROLIA.xml:S1:9676:12	osteoporosi	NNP	O	O

The	PROLIA.xml:S1:9695:3	the	DT	O	O
safety	PROLIA.xml:S1:9699:6	safeti	NN	O	O
of	PROLIA.xml:S1:9706:2	of	IN	O	O
Prolia	PROLIA.xml:S1:9709:6	prolia	NNP	O	O
in	PROLIA.xml:S1:9716:2	in	IN	O	O
the	PROLIA.xml:S1:9719:3	the	DT	O	O
treatment	PROLIA.xml:S1:9723:9	treatment	NN	O	O
of	PROLIA.xml:S1:9733:2	of	IN	O	O
men	PROLIA.xml:S1:9736:3	men	NNS	O	O
with	PROLIA.xml:S1:9740:4	with	IN	O	O
osteoporosis	PROLIA.xml:S1:9745:12	osteoporosi	NN	O	O
was	PROLIA.xml:S1:9758:3	wa	VBD	O	O
assessed	PROLIA.xml:S1:9762:8	assess	VBN	O	O
in	PROLIA.xml:S1:9771:2	in	IN	O	O
a	PROLIA.xml:S1:9774:1	a	DT	O	O
1	PROLIA.xml:S1:9776:1	1	CD	O	O
-	PROLIA.xml:S1:9777:1	-	:	O	O
year	PROLIA.xml:S1:9778:4	year	NN	O	O
randomized	PROLIA.xml:S1:9783:10	random	VBN	O	O
,	PROLIA.xml:S1:9793:1	,	,	O	O
double	PROLIA.xml:S1:9795:6	doubl	JJ	O	O
-	PROLIA.xml:S1:9801:1	-	:	O	O
blind	PROLIA.xml:S1:9802:5	blind	NN	O	O
,	PROLIA.xml:S1:9807:1	,	,	O	O
placebo	PROLIA.xml:S1:9809:7	placebo	SYM	O	O
-	PROLIA.xml:S1:9816:1	-	:	O	O
controlled	PROLIA.xml:S1:9817:10	control	VBN	O	O
study	PROLIA.xml:S1:9828:5	studi	NN	O	O
.	PROLIA.xml:S1:9833:1	.	.	O	O

A	PROLIA.xml:S1:9835:1	A	DT	O	O
total	PROLIA.xml:S1:9837:5	total	NN	O	O
of	PROLIA.xml:S1:9843:2	of	IN	O	O
120	PROLIA.xml:S1:9846:3	120	CD	O	O
men	PROLIA.xml:S1:9850:3	men	NNS	O	O
were	PROLIA.xml:S1:9854:4	were	VBD	O	O
exposed	PROLIA.xml:S1:9859:7	expos	VBN	O	O
to	PROLIA.xml:S1:9867:2	to	TO	O	O
placebo	PROLIA.xml:S1:9870:7	placebo	VB	O	O
and	PROLIA.xml:S1:9878:3	and	CC	O	O
120	PROLIA.xml:S1:9882:3	120	CD	O	O
men	PROLIA.xml:S1:9886:3	men	NNS	O	O
were	PROLIA.xml:S1:9890:4	were	VBD	O	O
exposed	PROLIA.xml:S1:9895:7	expos	VBN	O	O
to	PROLIA.xml:S1:9903:2	to	TO	O	O
Prolia	PROLIA.xml:S1:9906:6	prolia	NNP	O	O
administered	PROLIA.xml:S1:9913:12	administ	VBD	O	O
subcutaneously	PROLIA.xml:S1:9926:14	subcutan	RB	O	O
once	PROLIA.xml:S1:9941:4	onc	RB	O	O
every	PROLIA.xml:S1:9946:5	everi	DT	O	O
6	PROLIA.xml:S1:9952:1	6	CD	O	O
months	PROLIA.xml:S1:9954:6	month	NNS	O	O
as	PROLIA.xml:S1:9961:2	as	IN	O	O
a	PROLIA.xml:S1:9964:1	a	DT	O	O
single	PROLIA.xml:S1:9966:6	singl	JJ	O	O
60	PROLIA.xml:S1:9973:2	60	CD	O	O
mg	PROLIA.xml:S1:9976:2	mg	NN	O	O
dose	PROLIA.xml:S1:9979:4	dose	NN	O	O
.	PROLIA.xml:S1:9983:1	.	.	O	O

All	PROLIA.xml:S1:9985:3	all	DT	O	O
men	PROLIA.xml:S1:9989:3	men	NNS	O	O
were	PROLIA.xml:S1:9993:4	were	VBD	O	O
instructed	PROLIA.xml:S1:9998:10	instruct	VBN	O	O
to	PROLIA.xml:S1:10009:2	to	TO	O	O
take	PROLIA.xml:S1:10012:4	take	VB	O	O
at	PROLIA.xml:S1:10017:2	at	IN	O	O
least	PROLIA.xml:S1:10020:5	least	JJS	O	O
1000	PROLIA.xml:S1:10026:4	1000	CD	O	O
mg	PROLIA.xml:S1:10031:2	mg	NN	O	O
of	PROLIA.xml:S1:10034:2	of	IN	O	O
calcium	PROLIA.xml:S1:10037:7	calcium	NN	O	O
and	PROLIA.xml:S1:10045:3	and	CC	O	O
800	PROLIA.xml:S1:10049:3	800	CD	O	O
IU	PROLIA.xml:S1:10053:2	IU	NNP	O	O
of	PROLIA.xml:S1:10056:2	of	IN	O	O
vitamin	PROLIA.xml:S1:10059:7	vitamin	NNP	O	O
D	PROLIA.xml:S1:10067:1	D	NNP	O	O
supplementation	PROLIA.xml:S1:10069:15	supplement	NN	O	O
per	PROLIA.xml:S1:10085:3	per	IN	O	O
day	PROLIA.xml:S1:10089:3	day	NN	O	O
.	PROLIA.xml:S1:10092:1	.	.	O	O

The	PROLIA.xml:S1:10098:3	the	DT	O	O
incidence	PROLIA.xml:S1:10102:9	incid	NN	O	O
of	PROLIA.xml:S1:10112:2	of	IN	O	O
all	PROLIA.xml:S1:10115:3	all	DT	O	O
-	PROLIA.xml:S1:10118:1	-	:	O	O
cause	PROLIA.xml:S1:10119:5	caus	NN	O	O
mortality	PROLIA.xml:S1:10125:9	mortal	NN	B-AdverseReaction	O
was	PROLIA.xml:S1:10135:3	wa	VBD	O	O
0.8%	PROLIA.xml:S1:10139:4	0.8%	CD	O	O
(	PROLIA.xml:S1:10144:1	(	(	O	O
n	PROLIA.xml:S1:10145:1	n	JJ	O	O
1	PROLIA.xml:S1:10149:1	1	CD	O	O
)	PROLIA.xml:S1:10150:1	)	)	O	O
in	PROLIA.xml:S1:10152:2	in	IN	O	O
the	PROLIA.xml:S1:10155:3	the	DT	O	O
placebo	PROLIA.xml:S1:10159:7	placebo	NN	O	O
group	PROLIA.xml:S1:10167:5	group	NN	O	O
and	PROLIA.xml:S1:10173:3	and	CC	O	O
0.8%	PROLIA.xml:S1:10177:4	0.8%	CD	O	O
(	PROLIA.xml:S1:10182:1	(	(	O	O
n	PROLIA.xml:S1:10183:1	n	JJ	O	O
1	PROLIA.xml:S1:10187:1	1	CD	O	O
)	PROLIA.xml:S1:10188:1	)	)	O	O
in	PROLIA.xml:S1:10190:2	in	IN	O	O
the	PROLIA.xml:S1:10193:3	the	DT	O	O
Prolia	PROLIA.xml:S1:10197:6	prolia	NNP	O	O
group	PROLIA.xml:S1:10204:5	group	NN	O	O
.	PROLIA.xml:S1:10209:1	.	.	O	O

The	PROLIA.xml:S1:10211:3	the	DT	O	O
incidence	PROLIA.xml:S1:10215:9	incid	NN	O	O
of	PROLIA.xml:S1:10225:2	of	IN	O	O
nonfatal	PROLIA.xml:S1:10228:8	nonfat	JJ	O	O
serious	PROLIA.xml:S1:10237:7	seriou	JJ	O	O
adverse	PROLIA.xml:S1:10245:7	advers	JJ	O	O
events	PROLIA.xml:S1:10253:6	event	NNS	O	O
was	PROLIA.xml:S1:10260:3	wa	VBD	O	O
7.5%	PROLIA.xml:S1:10264:4	7.5%	CD	O	O
in	PROLIA.xml:S1:10269:2	in	IN	O	O
the	PROLIA.xml:S1:10272:3	the	DT	O	O
placebo	PROLIA.xml:S1:10276:7	placebo	NN	O	O
group	PROLIA.xml:S1:10284:5	group	NN	O	O
and	PROLIA.xml:S1:10290:3	and	CC	O	O
8.3%	PROLIA.xml:S1:10294:4	8.3%	CD	O	O
in	PROLIA.xml:S1:10299:2	in	IN	O	O
the	PROLIA.xml:S1:10302:3	the	DT	O	O
Prolia	PROLIA.xml:S1:10306:6	prolia	NNP	O	O
group	PROLIA.xml:S1:10313:5	group	NN	O	O
.	PROLIA.xml:S1:10318:1	.	.	O	O

The	PROLIA.xml:S1:10320:3	the	DT	O	O
percentage	PROLIA.xml:S1:10324:10	percentag	NN	O	O
of	PROLIA.xml:S1:10335:2	of	IN	O	O
patients	PROLIA.xml:S1:10338:8	patient	NNS	O	O
who	PROLIA.xml:S1:10347:3	who	WP	O	O
withdrew	PROLIA.xml:S1:10351:8	withdrew	VBP	O	O
from	PROLIA.xml:S1:10360:4	from	IN	O	O
the	PROLIA.xml:S1:10365:3	the	DT	O	O
study	PROLIA.xml:S1:10369:5	studi	NN	O	O
due	PROLIA.xml:S1:10375:3	due	JJ	O	O
to	PROLIA.xml:S1:10379:2	to	TO	O	O
adverse	PROLIA.xml:S1:10382:7	advers	JJ	O	O
events	PROLIA.xml:S1:10390:6	event	NNS	O	O
was	PROLIA.xml:S1:10397:3	wa	VBD	O	O
0%	PROLIA.xml:S1:10401:2	0%	CD	O	O
and	PROLIA.xml:S1:10404:3	and	CC	O	O
2.5%	PROLIA.xml:S1:10408:4	2.5%	CD	O	O
for	PROLIA.xml:S1:10413:3	for	IN	O	O
the	PROLIA.xml:S1:10417:3	the	DT	O	O
placebo	PROLIA.xml:S1:10421:7	placebo	NN	O	O
and	PROLIA.xml:S1:10429:3	and	CC	O	O
Prolia	PROLIA.xml:S1:10433:6	prolia	NNP	O	O
groups	PROLIA.xml:S1:10440:6	group	NNS	O	O
,	PROLIA.xml:S1:10446:1	,	,	O	O
respectively	PROLIA.xml:S1:10448:12	respect	RB	O	O
.	PROLIA.xml:S1:10460:1	.	.	O	O

Adverse	PROLIA.xml:S1:10466:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:10474:9	reaction	NNS	O	O
reported	PROLIA.xml:S1:10484:8	report	VBN	O	O
in	PROLIA.xml:S1:10493:2	in	IN	O	O
5%	PROLIA.xml:S1:10499:2	5%	CD	O	O
of	PROLIA.xml:S1:10502:2	of	IN	O	O
men	PROLIA.xml:S1:10505:3	men	NNS	O	O
with	PROLIA.xml:S1:10509:4	with	IN	O	O
osteoporosis	PROLIA.xml:S1:10514:12	osteoporosi	NN	O	O
and	PROLIA.xml:S1:10527:3	and	CC	O	O
more	PROLIA.xml:S1:10531:4	more	RBR	O	O
frequently	PROLIA.xml:S1:10536:10	frequent	RB	O	O
with	PROLIA.xml:S1:10547:4	with	IN	O	O
Prolia	PROLIA.xml:S1:10552:6	prolia	NNP	O	O
than	PROLIA.xml:S1:10559:4	than	IN	O	O
in	PROLIA.xml:S1:10564:2	in	IN	O	O
the	PROLIA.xml:S1:10567:3	the	DT	O	O
placebo	PROLIA.xml:S1:10571:7	placebo	NN	O	O
-	PROLIA.xml:S1:10578:1	-	:	O	O
treated	PROLIA.xml:S1:10579:7	treat	JJ	O	O
patients	PROLIA.xml:S1:10587:8	patient	NNS	O	O
were	PROLIA.xml:S1:10596:4	were	VBD	O	O
:	PROLIA.xml:S1:10600:1	:	:	O	O
back	PROLIA.xml:S1:10602:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:10607:4	pain	NN	I-AdverseReaction	I-AdverseReaction
(	PROLIA.xml:S1:10612:1	(	(	O	O
6.7%	PROLIA.xml:S1:10613:4	6.7%	CD	O	O
placebo	PROLIA.xml:S1:10618:7	placebo	NN	O	O
vs	PROLIA.xml:S1:10626:2	vs	NN	O	O
.	PROLIA.xml:S1:10628:1	.	.	O	O

8.3%	PROLIA.xml:S1:10630:4	8.3%	CD	O	O
Prolia	PROLIA.xml:S1:10635:6	prolia	NNP	O	O
)	PROLIA.xml:S1:10641:1	)	)	O	O
,	PROLIA.xml:S1:10642:1	,	,	O	O
arthralgia	PROLIA.xml:S1:10644:10	arthralgia	RB	B-AdverseReaction	B-AdverseReaction
(	PROLIA.xml:S1:10655:1	(	(	O	O
5.8%	PROLIA.xml:S1:10656:4	5.8%	CD	O	O
placebo	PROLIA.xml:S1:10661:7	placebo	NN	O	O
vs	PROLIA.xml:S1:10669:2	vs	NN	O	O
.	PROLIA.xml:S1:10671:1	.	.	O	O

6.7%	PROLIA.xml:S1:10673:4	6.7%	CD	O	O
Prolia	PROLIA.xml:S1:10678:6	prolia	NNP	O	O
)	PROLIA.xml:S1:10684:1	)	)	O	O
,	PROLIA.xml:S1:10685:1	,	,	O	O
and	PROLIA.xml:S1:10687:3	and	CC	O	O
nasopharyngitis	PROLIA.xml:S1:10691:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
(	PROLIA.xml:S1:10707:1	(	(	O	O
5.8%	PROLIA.xml:S1:10708:4	5.8%	CD	O	O
placebo	PROLIA.xml:S1:10713:7	placebo	NN	O	O
vs	PROLIA.xml:S1:10721:2	vs	NN	O	O
.	PROLIA.xml:S1:10723:1	.	.	O	O

6.7%	PROLIA.xml:S1:10725:4	6.7%	CD	O	O
Prolia	PROLIA.xml:S1:10730:6	prolia	NNP	O	O
)	PROLIA.xml:S1:10736:1	)	)	O	O
.	PROLIA.xml:S1:10737:1	.	.	O	O

Serious	PROLIA.xml:S1:10745:7	seriou	JJ	O	O
Infections	PROLIA.xml:S1:10753:10	infect	NNP	O	B-AdverseReaction
S	PROLIA.xml:S1:10767:1	S	NNP	O	I-AdverseReaction
erious	PROLIA.xml:S1:10770:6	eriou	JJ	O	I-AdverseReaction
infection	PROLIA.xml:S1:10777:9	infect	NN	B-AdverseReaction	I-AdverseReaction
was	PROLIA.xml:S1:10787:3	wa	VBD	O	O
reported	PROLIA.xml:S1:10791:8	report	VBN	O	O
in	PROLIA.xml:S1:10800:2	in	IN	O	O
1	PROLIA.xml:S1:10803:1	1	CD	O	O
patient	PROLIA.xml:S1:10805:7	patient	NN	O	O
(	PROLIA.xml:S1:10813:1	(	(	O	O
0.8%	PROLIA.xml:S1:10814:4	0.8%	CD	O	O
)	PROLIA.xml:S1:10818:1	)	)	O	O
in	PROLIA.xml:S1:10820:2	in	IN	O	O
the	PROLIA.xml:S1:10823:3	the	DT	O	O
placebo	PROLIA.xml:S1:10827:7	placebo	NN	O	O
group	PROLIA.xml:S1:10835:5	group	NN	O	O
and	PROLIA.xml:S1:10841:3	and	CC	O	O
no	PROLIA.xml:S1:10845:2	no	DT	O	O
patients	PROLIA.xml:S1:10848:8	patient	NNS	O	O
in	PROLIA.xml:S1:10857:2	in	IN	O	O
the	PROLIA.xml:S1:10860:3	the	DT	O	O
Prolia	PROLIA.xml:S1:10864:6	prolia	NNP	O	O
group	PROLIA.xml:S1:10871:5	group	NN	O	O
.	PROLIA.xml:S1:10876:1	.	.	O	O

Dermatologic	PROLIA.xml:S1:10884:12	dermatolog	NNP	O	B-AdverseReaction
Reactions	PROLIA.xml:S1:10897:9	reaction	NNP	O	I-AdverseReaction
Epidermal	PROLIA.xml:S1:10908:9	epiderm	NNP	B-AdverseReaction	O
and	PROLIA.xml:S1:10918:3	and	CC	O	O
dermal	PROLIA.xml:S1:10922:6	dermal	JJ	B-AdverseReaction	O
adverse	PROLIA.xml:S1:10929:7	advers	JJ	I-AdverseReaction	O
events	PROLIA.xml:S1:10937:6	event	NNS	I-AdverseReaction	O
(	PROLIA.xml:S1:10944:1	(	(	O	O
such	PROLIA.xml:S1:10945:4	such	JJ	O	O
as	PROLIA.xml:S1:10950:2	as	IN	O	O
dermatitis	PROLIA.xml:S1:10953:10	dermat	NN	B-AdverseReaction	O
,	PROLIA.xml:S1:10963:1	,	,	O	O
eczema	PROLIA.xml:S1:10965:6	eczema	NN	B-AdverseReaction	O
,	PROLIA.xml:S1:10971:1	,	,	O	O
and	PROLIA.xml:S1:10973:3	and	CC	O	O
rashes	PROLIA.xml:S1:10977:6	rash	NNS	B-AdverseReaction	B-AdverseReaction
)	PROLIA.xml:S1:10983:1	)	)	O	O
were	PROLIA.xml:S1:10985:4	were	VBD	O	O
reported	PROLIA.xml:S1:10990:8	report	VBN	O	O
in	PROLIA.xml:S1:10999:2	in	IN	O	O
4	PROLIA.xml:S1:11002:1	4	CD	O	O
patients	PROLIA.xml:S1:11004:8	patient	NNS	O	O
(	PROLIA.xml:S1:11013:1	(	(	O	O
3.3%	PROLIA.xml:S1:11014:4	3.3%	CD	O	O
)	PROLIA.xml:S1:11018:1	)	)	O	O
in	PROLIA.xml:S1:11020:2	in	IN	O	O
the	PROLIA.xml:S1:11023:3	the	DT	O	O
placebo	PROLIA.xml:S1:11027:7	placebo	NN	O	O
group	PROLIA.xml:S1:11035:5	group	NN	O	O
and	PROLIA.xml:S1:11041:3	and	CC	O	O
5	PROLIA.xml:S1:11045:1	5	CD	O	O
patients	PROLIA.xml:S1:11047:8	patient	NNS	O	O
(	PROLIA.xml:S1:11056:1	(	(	O	O
4.2%	PROLIA.xml:S1:11057:4	4.2%	CD	O	O
)	PROLIA.xml:S1:11061:1	)	)	O	O
in	PROLIA.xml:S1:11063:2	in	IN	O	O
the	PROLIA.xml:S1:11066:3	the	DT	O	O
Prolia	PROLIA.xml:S1:11070:6	prolia	NNP	O	O
group	PROLIA.xml:S1:11077:5	group	NN	O	O
.	PROLIA.xml:S1:11082:1	.	.	O	O

Osteonecrosis	PROLIA.xml:S1:11090:13	osteonecrosi	NN	O	O
of	PROLIA.xml:S1:11104:2	of	IN	O	O
the	PROLIA.xml:S1:11107:3	the	DT	O	O
Jaw	PROLIA.xml:S1:11111:3	jaw	NNP	O	O
No	PROLIA.xml:S1:11116:2	No	NNP	O	O
cases	PROLIA.xml:S1:11119:5	case	NNS	O	O
of	PROLIA.xml:S1:11125:2	of	IN	O	O
ONJ	PROLIA.xml:S1:11128:3	onj	NNP	B-AdverseReaction	B-AdverseReaction
were	PROLIA.xml:S1:11132:4	were	VBD	O	O
reported	PROLIA.xml:S1:11137:8	report	VBN	O	O
.	PROLIA.xml:S1:11145:1	.	.	O	O

Pancreatitis	PROLIA.xml:S1:11153:12	pancreat	NNP	O	B-AdverseReaction
Pancreatitis	PROLIA.xml:S1:11167:12	pancreat	NNP	B-AdverseReaction	B-AdverseReaction
was	PROLIA.xml:S1:11180:3	wa	VBD	O	O
reported	PROLIA.xml:S1:11184:8	report	VBN	O	O
in	PROLIA.xml:S1:11193:2	in	IN	O	O
1	PROLIA.xml:S1:11196:1	1	CD	O	O
patient	PROLIA.xml:S1:11198:7	patient	NN	O	O
(	PROLIA.xml:S1:11206:1	(	(	O	O
0.8%	PROLIA.xml:S1:11207:4	0.8%	CD	O	O
)	PROLIA.xml:S1:11211:1	)	)	O	O
in	PROLIA.xml:S1:11213:2	in	IN	O	O
the	PROLIA.xml:S1:11216:3	the	DT	O	O
placebo	PROLIA.xml:S1:11220:7	placebo	NN	O	O
group	PROLIA.xml:S1:11228:5	group	NN	O	O
and	PROLIA.xml:S1:11234:3	and	CC	O	O
1	PROLIA.xml:S1:11238:1	1	CD	O	O
patient	PROLIA.xml:S1:11240:7	patient	NN	O	O
(	PROLIA.xml:S1:11248:1	(	(	O	O
0.8%	PROLIA.xml:S1:11249:4	0.8%	CD	O	O
)	PROLIA.xml:S1:11253:1	)	)	O	O
in	PROLIA.xml:S1:11255:2	in	IN	O	O
the	PROLIA.xml:S1:11258:3	the	DT	O	O
Prolia	PROLIA.xml:S1:11262:6	prolia	NNP	O	O
group	PROLIA.xml:S1:11269:5	group	NN	O	O
.	PROLIA.xml:S1:11274:1	.	.	O	O

New	PROLIA.xml:S1:11283:3	new	NNP	O	B-AdverseReaction
Malignancies	PROLIA.xml:S1:11287:12	malign	NNP	O	I-AdverseReaction
New	PROLIA.xml:S1:11301:3	new	NNP	O	I-AdverseReaction
malignancies	PROLIA.xml:S1:11305:12	malign	NNS	B-AdverseReaction	I-AdverseReaction
were	PROLIA.xml:S1:11318:4	were	VBD	O	O
reported	PROLIA.xml:S1:11323:8	report	VBN	O	O
in	PROLIA.xml:S1:11332:2	in	IN	O	O
no	PROLIA.xml:S1:11335:2	no	DT	O	O
patients	PROLIA.xml:S1:11338:8	patient	NNS	O	O
in	PROLIA.xml:S1:11347:2	in	IN	O	O
the	PROLIA.xml:S1:11350:3	the	DT	O	O
placebo	PROLIA.xml:S1:11354:7	placebo	NN	O	O
group	PROLIA.xml:S1:11362:5	group	NN	O	O
and	PROLIA.xml:S1:11368:3	and	CC	O	O
4	PROLIA.xml:S1:11372:1	4	CD	O	O
(	PROLIA.xml:S1:11374:1	(	(	O	O
3.3%	PROLIA.xml:S1:11375:4	3.3%	CD	O	O
)	PROLIA.xml:S1:11379:1	)	)	O	O
patients	PROLIA.xml:S1:11381:8	patient	NNS	O	O
(	PROLIA.xml:S1:11390:1	(	(	O	O
3	PROLIA.xml:S1:11391:1	3	CD	O	O
prostate	PROLIA.xml:S1:11393:8	prostat	NN	B-AdverseReaction	B-AdverseReaction
cancers	PROLIA.xml:S1:11402:7	cancer	NNS	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:11409:1	,	,	O	O
1	PROLIA.xml:S1:11411:1	1	CD	O	O
basal	PROLIA.xml:S1:11413:5	basal	NN	B-AdverseReaction	O
cell	PROLIA.xml:S1:11419:4	cell	NN	I-AdverseReaction	O
carcinoma	PROLIA.xml:S1:11424:9	carcinoma	NN	I-AdverseReaction	O
)	PROLIA.xml:S1:11433:1	)	)	O	O
in	PROLIA.xml:S1:11435:2	in	IN	O	O
the	PROLIA.xml:S1:11438:3	the	DT	O	O
Prolia	PROLIA.xml:S1:11442:6	prolia	NNP	O	O
group	PROLIA.xml:S1:11449:5	group	NN	O	O
.	PROLIA.xml:S1:11454:1	.	.	O	O

Treatment	PROLIA.xml:S1:11462:9	treatment	NN	O	O
of	PROLIA.xml:S1:11472:2	of	IN	O	O
Bone	PROLIA.xml:S1:11475:4	bone	NNP	O	O
Loss	PROLIA.xml:S1:11480:4	loss	NNP	O	O
in	PROLIA.xml:S1:11485:2	in	IN	O	O
Patients	PROLIA.xml:S1:11488:8	patient	NNP	O	O
Receiving	PROLIA.xml:S1:11497:9	receiv	NNP	O	O
Androgen	PROLIA.xml:S1:11507:8	androgen	NNP	O	O
Deprivation	PROLIA.xml:S1:11516:11	depriv	NNP	O	O
Therapy	PROLIA.xml:S1:11528:7	therapi	NNP	O	O
for	PROLIA.xml:S1:11536:3	for	IN	O	O
Prostate	PROLIA.xml:S1:11540:8	prostat	NNP	O	O
Cancer	PROLIA.xml:S1:11549:6	cancer	NNP	O	O
or	PROLIA.xml:S1:11556:2	or	CC	O	O
Adjuvant	PROLIA.xml:S1:11559:8	adjuv	NNP	O	O
Aromatase	PROLIA.xml:S1:11568:9	aromatas	NNP	O	O
Inhibitor	PROLIA.xml:S1:11578:9	inhibitor	NNP	O	O
Therapy	PROLIA.xml:S1:11588:7	therapi	NNP	O	O
for	PROLIA.xml:S1:11596:3	for	IN	O	O
Breast	PROLIA.xml:S1:11600:6	breast	NNP	O	O
Cancer	PROLIA.xml:S1:11607:6	cancer	NNP	O	O

The	PROLIA.xml:S1:11620:3	the	DT	O	O
safety	PROLIA.xml:S1:11624:6	safeti	NN	O	O
of	PROLIA.xml:S1:11631:2	of	IN	O	O
Prolia	PROLIA.xml:S1:11634:6	prolia	NNP	O	O
in	PROLIA.xml:S1:11641:2	in	IN	O	O
the	PROLIA.xml:S1:11644:3	the	DT	O	O
treatment	PROLIA.xml:S1:11648:9	treatment	NN	O	O
of	PROLIA.xml:S1:11658:2	of	IN	O	O
bone	PROLIA.xml:S1:11661:4	bone	NN	O	O
loss	PROLIA.xml:S1:11666:4	loss	NN	O	O
in	PROLIA.xml:S1:11671:2	in	IN	O	O
men	PROLIA.xml:S1:11674:3	men	NNS	O	O
with	PROLIA.xml:S1:11678:4	with	IN	O	O
nonmetastatic	PROLIA.xml:S1:11683:13	nonmetastat	JJ	O	O
prostate	PROLIA.xml:S1:11697:8	prostat	NN	O	O
cancer	PROLIA.xml:S1:11706:6	cancer	NN	O	O
receiving	PROLIA.xml:S1:11713:9	receiv	VBG	O	O
androgen	PROLIA.xml:S1:11723:8	androgen	JJ	O	O
deprivation	PROLIA.xml:S1:11732:11	depriv	NN	O	O
therapy	PROLIA.xml:S1:11744:7	therapi	NN	O	O
(	PROLIA.xml:S1:11752:1	(	(	O	O
ADT	PROLIA.xml:S1:11753:3	adt	NNP	O	O
)	PROLIA.xml:S1:11756:1	)	)	O	O
was	PROLIA.xml:S1:11758:3	wa	VBD	O	O
assessed	PROLIA.xml:S1:11762:8	assess	VBN	O	O
in	PROLIA.xml:S1:11771:2	in	IN	O	O
a	PROLIA.xml:S1:11774:1	a	DT	O	O
3	PROLIA.xml:S1:11776:1	3	CD	O	O
-	PROLIA.xml:S1:11777:1	-	:	O	O
year	PROLIA.xml:S1:11778:4	year	NN	O	O
,	PROLIA.xml:S1:11782:1	,	,	O	O
randomized	PROLIA.xml:S1:11784:10	random	VBN	O	O
,	PROLIA.xml:S1:11794:1	,	,	O	O
double	PROLIA.xml:S1:11796:6	doubl	JJ	O	O
-	PROLIA.xml:S1:11802:1	-	:	O	O
blind	PROLIA.xml:S1:11803:5	blind	NN	O	O
,	PROLIA.xml:S1:11808:1	,	,	O	O
placebo	PROLIA.xml:S1:11810:7	placebo	SYM	O	O
-	PROLIA.xml:S1:11817:1	-	:	O	O
controlled	PROLIA.xml:S1:11818:10	control	VBN	O	O
,	PROLIA.xml:S1:11828:1	,	,	O	O
multinational	PROLIA.xml:S1:11830:13	multin	JJ	O	O
study	PROLIA.xml:S1:11844:5	studi	NN	O	O
of	PROLIA.xml:S1:11850:2	of	IN	O	O
1468	PROLIA.xml:S1:11853:4	1468	CD	O	O
men	PROLIA.xml:S1:11858:3	men	NNS	O	O
aged	PROLIA.xml:S1:11862:4	age	VBD	O	O
48	PROLIA.xml:S1:11867:2	48	CD	O	O
to	PROLIA.xml:S1:11870:2	to	TO	O	O
97	PROLIA.xml:S1:11873:2	97	CD	O	O
years	PROLIA.xml:S1:11876:5	year	NNS	O	O
.	PROLIA.xml:S1:11881:1	.	.	O	O

A	PROLIA.xml:S1:11883:1	A	DT	O	O
total	PROLIA.xml:S1:11885:5	total	NN	O	O
of	PROLIA.xml:S1:11891:2	of	IN	O	O
725	PROLIA.xml:S1:11894:3	725	CD	O	O
men	PROLIA.xml:S1:11898:3	men	NNS	O	O
were	PROLIA.xml:S1:11902:4	were	VBD	O	O
exposed	PROLIA.xml:S1:11907:7	expos	VBN	O	O
to	PROLIA.xml:S1:11915:2	to	TO	O	O
placebo	PROLIA.xml:S1:11918:7	placebo	VB	O	O
and	PROLIA.xml:S1:11926:3	and	CC	O	O
731	PROLIA.xml:S1:11930:3	731	CD	O	O
men	PROLIA.xml:S1:11934:3	men	NNS	O	O
were	PROLIA.xml:S1:11938:4	were	VBD	O	O
exposed	PROLIA.xml:S1:11943:7	expos	VBN	O	O
to	PROLIA.xml:S1:11951:2	to	TO	O	O
Prolia	PROLIA.xml:S1:11954:6	prolia	NNP	O	O
administered	PROLIA.xml:S1:11961:12	administ	VBD	O	O
once	PROLIA.xml:S1:11974:4	onc	RB	O	O
every	PROLIA.xml:S1:11979:5	everi	DT	O	O
6	PROLIA.xml:S1:11985:1	6	CD	O	O
months	PROLIA.xml:S1:11987:6	month	NNS	O	O
as	PROLIA.xml:S1:11994:2	as	IN	O	O
a	PROLIA.xml:S1:11997:1	a	DT	O	O
single	PROLIA.xml:S1:11999:6	singl	JJ	O	O
60	PROLIA.xml:S1:12006:2	60	CD	O	O
mg	PROLIA.xml:S1:12009:2	mg	NN	O	O
subcutaneous	PROLIA.xml:S1:12012:12	subcutan	JJ	O	O
dose	PROLIA.xml:S1:12025:4	dose	NN	O	O
.	PROLIA.xml:S1:12029:1	.	.	O	O

All	PROLIA.xml:S1:12031:3	all	DT	O	O
men	PROLIA.xml:S1:12035:3	men	NNS	O	O
were	PROLIA.xml:S1:12039:4	were	VBD	O	O
instructed	PROLIA.xml:S1:12044:10	instruct	VBN	O	O
to	PROLIA.xml:S1:12055:2	to	TO	O	O
take	PROLIA.xml:S1:12058:4	take	VB	O	O
at	PROLIA.xml:S1:12063:2	at	IN	O	O
least	PROLIA.xml:S1:12066:5	least	JJS	O	O
1000	PROLIA.xml:S1:12072:4	1000	CD	O	O
mg	PROLIA.xml:S1:12077:2	mg	NN	O	O
of	PROLIA.xml:S1:12080:2	of	IN	O	O
calcium	PROLIA.xml:S1:12083:7	calcium	NN	O	O
and	PROLIA.xml:S1:12091:3	and	CC	O	O
400	PROLIA.xml:S1:12095:3	400	CD	O	O
IU	PROLIA.xml:S1:12099:2	IU	NNP	O	O
of	PROLIA.xml:S1:12102:2	of	IN	O	O
vitamin	PROLIA.xml:S1:12105:7	vitamin	NNP	O	O
D	PROLIA.xml:S1:12113:1	D	NNP	O	O
supplementation	PROLIA.xml:S1:12115:15	supplement	NN	O	O
per	PROLIA.xml:S1:12131:3	per	IN	O	O
day	PROLIA.xml:S1:12135:3	day	NN	O	O
.	PROLIA.xml:S1:12138:1	.	.	O	O

The	PROLIA.xml:S1:12144:3	the	DT	O	O
incidence	PROLIA.xml:S1:12148:9	incid	NN	O	O
of	PROLIA.xml:S1:12158:2	of	IN	O	O
serious	PROLIA.xml:S1:12161:7	seriou	JJ	O	O
adverse	PROLIA.xml:S1:12169:7	advers	JJ	O	O
events	PROLIA.xml:S1:12177:6	event	NNS	O	O
was	PROLIA.xml:S1:12184:3	wa	VBD	O	O
30.6%	PROLIA.xml:S1:12188:5	30.6%	CD	O	O
in	PROLIA.xml:S1:12194:2	in	IN	O	O
the	PROLIA.xml:S1:12197:3	the	DT	O	O
placebo	PROLIA.xml:S1:12201:7	placebo	NN	O	O
group	PROLIA.xml:S1:12209:5	group	NN	O	O
and	PROLIA.xml:S1:12215:3	and	CC	O	O
34.6%	PROLIA.xml:S1:12219:5	34.6%	CD	O	O
in	PROLIA.xml:S1:12225:2	in	IN	O	O
the	PROLIA.xml:S1:12228:3	the	DT	O	O
Prolia	PROLIA.xml:S1:12232:6	prolia	NNP	O	O
group	PROLIA.xml:S1:12239:5	group	NN	O	O
.	PROLIA.xml:S1:12244:1	.	.	O	O

The	PROLIA.xml:S1:12246:3	the	DT	O	O
percentage	PROLIA.xml:S1:12250:10	percentag	NN	O	O
of	PROLIA.xml:S1:12261:2	of	IN	O	O
patients	PROLIA.xml:S1:12264:8	patient	NNS	O	O
who	PROLIA.xml:S1:12273:3	who	WP	O	O
withdrew	PROLIA.xml:S1:12277:8	withdrew	VBP	O	O
from	PROLIA.xml:S1:12286:4	from	IN	O	O
the	PROLIA.xml:S1:12291:3	the	DT	O	O
study	PROLIA.xml:S1:12295:5	studi	NN	O	O
due	PROLIA.xml:S1:12301:3	due	JJ	O	O
to	PROLIA.xml:S1:12305:2	to	TO	O	O
adverse	PROLIA.xml:S1:12308:7	advers	JJ	O	O
events	PROLIA.xml:S1:12316:6	event	NNS	O	O
was	PROLIA.xml:S1:12323:3	wa	VBD	O	O
6.1%	PROLIA.xml:S1:12327:4	6.1%	CD	O	O
and	PROLIA.xml:S1:12332:3	and	CC	O	O
7.0%	PROLIA.xml:S1:12336:4	7.0%	CD	O	O
for	PROLIA.xml:S1:12341:3	for	IN	O	O
the	PROLIA.xml:S1:12345:3	the	DT	O	O
placebo	PROLIA.xml:S1:12349:7	placebo	NN	O	O
and	PROLIA.xml:S1:12357:3	and	CC	O	O
Prolia	PROLIA.xml:S1:12361:6	prolia	NNP	O	O
groups	PROLIA.xml:S1:12368:6	group	NNS	O	O
,	PROLIA.xml:S1:12374:1	,	,	O	O
respectively	PROLIA.xml:S1:12376:12	respect	RB	O	O
.	PROLIA.xml:S1:12388:1	.	.	O	O

The	PROLIA.xml:S1:12394:3	the	DT	O	O
safety	PROLIA.xml:S1:12398:6	safeti	NN	O	O
of	PROLIA.xml:S1:12405:2	of	IN	O	O
Prolia	PROLIA.xml:S1:12408:6	prolia	NNP	O	O
in	PROLIA.xml:S1:12415:2	in	IN	O	O
the	PROLIA.xml:S1:12418:3	the	DT	O	O
treatment	PROLIA.xml:S1:12422:9	treatment	NN	O	O
of	PROLIA.xml:S1:12432:2	of	IN	O	O
bone	PROLIA.xml:S1:12435:4	bone	NN	O	O
loss	PROLIA.xml:S1:12440:4	loss	NN	O	O
in	PROLIA.xml:S1:12445:2	in	IN	O	O
women	PROLIA.xml:S1:12448:5	women	NNS	O	O
with	PROLIA.xml:S1:12454:4	with	IN	O	O
nonmetastatic	PROLIA.xml:S1:12459:13	nonmetastat	JJ	O	O
breast	PROLIA.xml:S1:12473:6	breast	NN	O	O
cancer	PROLIA.xml:S1:12480:6	cancer	NN	O	O
receiving	PROLIA.xml:S1:12487:9	receiv	VBG	O	O
aromatase	PROLIA.xml:S1:12497:9	aromatas	NN	O	O
inhibitor	PROLIA.xml:S1:12507:9	inhibitor	NN	O	O
(	PROLIA.xml:S1:12517:1	(	(	O	O
AI	PROLIA.xml:S1:12518:2	AI	NNP	O	O
)	PROLIA.xml:S1:12520:1	)	)	O	O
therapy	PROLIA.xml:S1:12523:7	therapi	NN	O	O
was	PROLIA.xml:S1:12531:3	wa	VBD	O	O
assessed	PROLIA.xml:S1:12535:8	assess	VBN	O	O
in	PROLIA.xml:S1:12544:2	in	IN	O	O
a	PROLIA.xml:S1:12547:1	a	DT	O	O
2	PROLIA.xml:S1:12549:1	2	CD	O	O
-	PROLIA.xml:S1:12550:1	-	:	O	O
year	PROLIA.xml:S1:12551:4	year	NN	O	O
,	PROLIA.xml:S1:12555:1	,	,	O	O
randomized	PROLIA.xml:S1:12557:10	random	VBN	O	O
,	PROLIA.xml:S1:12567:1	,	,	O	O
double	PROLIA.xml:S1:12569:6	doubl	JJ	O	O
-	PROLIA.xml:S1:12575:1	-	:	O	O
blind	PROLIA.xml:S1:12576:5	blind	NN	O	O
,	PROLIA.xml:S1:12581:1	,	,	O	O
placebo	PROLIA.xml:S1:12583:7	placebo	SYM	O	O
-	PROLIA.xml:S1:12590:1	-	:	O	O
controlled	PROLIA.xml:S1:12591:10	control	VBN	O	O
,	PROLIA.xml:S1:12601:1	,	,	O	O
multinational	PROLIA.xml:S1:12603:13	multin	JJ	O	O
study	PROLIA.xml:S1:12617:5	studi	NN	O	O
of	PROLIA.xml:S1:12623:2	of	IN	O	O
252	PROLIA.xml:S1:12626:3	252	CD	O	O
postmenopausal	PROLIA.xml:S1:12630:14	postmenopaus	JJ	O	O
women	PROLIA.xml:S1:12645:5	women	NNS	O	O
aged	PROLIA.xml:S1:12651:4	age	VBD	O	O
35	PROLIA.xml:S1:12656:2	35	CD	O	O
to	PROLIA.xml:S1:12659:2	to	TO	O	O
84	PROLIA.xml:S1:12662:2	84	CD	O	O
years	PROLIA.xml:S1:12665:5	year	NNS	O	O
.	PROLIA.xml:S1:12670:1	.	.	O	O

A	PROLIA.xml:S1:12672:1	A	DT	O	O
total	PROLIA.xml:S1:12674:5	total	NN	O	O
of	PROLIA.xml:S1:12680:2	of	IN	O	O
120	PROLIA.xml:S1:12683:3	120	CD	O	O
women	PROLIA.xml:S1:12687:5	women	NNS	O	O
were	PROLIA.xml:S1:12693:4	were	VBD	O	O
exposed	PROLIA.xml:S1:12698:7	expos	VBN	O	O
to	PROLIA.xml:S1:12706:2	to	TO	O	O
placebo	PROLIA.xml:S1:12709:7	placebo	VB	O	O
and	PROLIA.xml:S1:12717:3	and	CC	O	O
129	PROLIA.xml:S1:12721:3	129	CD	O	O
women	PROLIA.xml:S1:12725:5	women	NNS	O	O
were	PROLIA.xml:S1:12731:4	were	VBD	O	O
exposed	PROLIA.xml:S1:12736:7	expos	VBN	O	O
to	PROLIA.xml:S1:12744:2	to	TO	O	O
Prolia	PROLIA.xml:S1:12747:6	prolia	NNP	O	O
administered	PROLIA.xml:S1:12754:12	administ	VBD	O	O
once	PROLIA.xml:S1:12767:4	onc	RB	O	O
every	PROLIA.xml:S1:12772:5	everi	DT	O	O
6	PROLIA.xml:S1:12778:1	6	CD	O	O
months	PROLIA.xml:S1:12780:6	month	NNS	O	O
as	PROLIA.xml:S1:12787:2	as	IN	O	O
a	PROLIA.xml:S1:12790:1	a	DT	O	O
single	PROLIA.xml:S1:12792:6	singl	JJ	O	O
60	PROLIA.xml:S1:12799:2	60	CD	O	O
mg	PROLIA.xml:S1:12802:2	mg	NN	O	O
subcutaneous	PROLIA.xml:S1:12805:12	subcutan	JJ	O	O
dose	PROLIA.xml:S1:12818:4	dose	NN	O	O
.	PROLIA.xml:S1:12822:1	.	.	O	O

All	PROLIA.xml:S1:12824:3	all	DT	O	O
women	PROLIA.xml:S1:12828:5	women	NNS	O	O
were	PROLIA.xml:S1:12834:4	were	VBD	O	O
instructed	PROLIA.xml:S1:12839:10	instruct	VBN	O	O
to	PROLIA.xml:S1:12850:2	to	TO	O	O
take	PROLIA.xml:S1:12853:4	take	VB	O	O
at	PROLIA.xml:S1:12858:2	at	IN	O	O
least	PROLIA.xml:S1:12861:5	least	JJS	O	O
1000	PROLIA.xml:S1:12867:4	1000	CD	O	O
mg	PROLIA.xml:S1:12872:2	mg	NN	O	O
of	PROLIA.xml:S1:12875:2	of	IN	O	O
calcium	PROLIA.xml:S1:12878:7	calcium	NN	O	O
and	PROLIA.xml:S1:12886:3	and	CC	O	O
400	PROLIA.xml:S1:12890:3	400	CD	O	O
IU	PROLIA.xml:S1:12894:2	IU	NNP	O	O
of	PROLIA.xml:S1:12897:2	of	IN	O	O
vitamin	PROLIA.xml:S1:12900:7	vitamin	NNP	O	O
D	PROLIA.xml:S1:12908:1	D	NNP	O	O
supplementation	PROLIA.xml:S1:12910:15	supplement	NN	O	O
per	PROLIA.xml:S1:12926:3	per	IN	O	O
day	PROLIA.xml:S1:12930:3	day	NN	O	O
.	PROLIA.xml:S1:12933:1	.	.	O	O

The	PROLIA.xml:S1:12939:3	the	DT	O	O
incidence	PROLIA.xml:S1:12943:9	incid	NN	O	O
of	PROLIA.xml:S1:12953:2	of	IN	O	O
serious	PROLIA.xml:S1:12956:7	seriou	JJ	O	O
adverse	PROLIA.xml:S1:12964:7	advers	JJ	O	O
events	PROLIA.xml:S1:12972:6	event	NNS	O	O
was	PROLIA.xml:S1:12979:3	wa	VBD	O	O
9.2%	PROLIA.xml:S1:12983:4	9.2%	CD	O	O
in	PROLIA.xml:S1:12988:2	in	IN	O	O
the	PROLIA.xml:S1:12991:3	the	DT	O	O
placebo	PROLIA.xml:S1:12995:7	placebo	NN	O	O
group	PROLIA.xml:S1:13003:5	group	NN	O	O
and	PROLIA.xml:S1:13009:3	and	CC	O	O
14.7%	PROLIA.xml:S1:13013:5	14.7%	CD	O	O
in	PROLIA.xml:S1:13019:2	in	IN	O	O
the	PROLIA.xml:S1:13022:3	the	DT	O	O
Prolia	PROLIA.xml:S1:13026:6	prolia	NNP	O	O
group	PROLIA.xml:S1:13033:5	group	NN	O	O
.	PROLIA.xml:S1:13038:1	.	.	O	O

The	PROLIA.xml:S1:13040:3	the	DT	O	O
percentage	PROLIA.xml:S1:13044:10	percentag	NN	O	O
of	PROLIA.xml:S1:13055:2	of	IN	O	O
patients	PROLIA.xml:S1:13058:8	patient	NNS	O	O
who	PROLIA.xml:S1:13067:3	who	WP	O	O
withdrew	PROLIA.xml:S1:13071:8	withdrew	VBP	O	O
from	PROLIA.xml:S1:13080:4	from	IN	O	O
the	PROLIA.xml:S1:13085:3	the	DT	O	O
study	PROLIA.xml:S1:13089:5	studi	NN	O	O
due	PROLIA.xml:S1:13095:3	due	JJ	O	O
to	PROLIA.xml:S1:13099:2	to	TO	O	O
adverse	PROLIA.xml:S1:13102:7	advers	JJ	O	O
events	PROLIA.xml:S1:13110:6	event	NNS	O	O
was	PROLIA.xml:S1:13117:3	wa	VBD	O	O
4.2%	PROLIA.xml:S1:13121:4	4.2%	CD	O	O
and	PROLIA.xml:S1:13126:3	and	CC	O	O
0.8%	PROLIA.xml:S1:13130:4	0.8%	CD	O	O
for	PROLIA.xml:S1:13135:3	for	IN	O	O
the	PROLIA.xml:S1:13139:3	the	DT	O	O
placebo	PROLIA.xml:S1:13143:7	placebo	NN	O	O
and	PROLIA.xml:S1:13151:3	and	CC	O	O
Prolia	PROLIA.xml:S1:13155:6	prolia	NNP	O	O
groups	PROLIA.xml:S1:13162:6	group	NNS	O	O
,	PROLIA.xml:S1:13168:1	,	,	O	O
respectively	PROLIA.xml:S1:13170:12	respect	RB	O	O
.	PROLIA.xml:S1:13182:1	.	.	O	O

Adverse	PROLIA.xml:S1:13188:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:13196:9	reaction	NNS	O	O
reported	PROLIA.xml:S1:13206:8	report	VBN	O	O
in	PROLIA.xml:S1:13215:2	in	IN	O	O
10%	PROLIA.xml:S1:13221:3	10%	CD	O	O
of	PROLIA.xml:S1:13225:2	of	IN	O	O
Prolia	PROLIA.xml:S1:13228:6	prolia	NNP	O	O
-	PROLIA.xml:S1:13234:1	-	:	O	O
treated	PROLIA.xml:S1:13235:7	treat	VBD	O	O
patients	PROLIA.xml:S1:13243:8	patient	NNS	O	O
receiving	PROLIA.xml:S1:13252:9	receiv	VBG	O	O
ADT	PROLIA.xml:S1:13262:3	adt	NNP	O	O
for	PROLIA.xml:S1:13266:3	for	IN	O	O
prostate	PROLIA.xml:S1:13270:8	prostat	NN	O	O
cancer	PROLIA.xml:S1:13279:6	cancer	NN	O	O
or	PROLIA.xml:S1:13286:2	or	CC	O	O
adjuvant	PROLIA.xml:S1:13289:8	adjuv	JJ	O	O
AI	PROLIA.xml:S1:13298:2	AI	NNP	O	O
therapy	PROLIA.xml:S1:13301:7	therapi	NN	O	O
for	PROLIA.xml:S1:13309:3	for	IN	O	O
breast	PROLIA.xml:S1:13313:6	breast	NN	O	O
cancer	PROLIA.xml:S1:13320:6	cancer	NN	O	O
,	PROLIA.xml:S1:13326:1	,	,	O	O
and	PROLIA.xml:S1:13328:3	and	CC	O	O
more	PROLIA.xml:S1:13332:4	more	RBR	O	O
frequently	PROLIA.xml:S1:13337:10	frequent	RB	O	O
than	PROLIA.xml:S1:13348:4	than	IN	O	O
in	PROLIA.xml:S1:13353:2	in	IN	O	O
the	PROLIA.xml:S1:13356:3	the	DT	O	O
placebo	PROLIA.xml:S1:13360:7	placebo	NN	O	O
-	PROLIA.xml:S1:13367:1	-	:	O	O
treated	PROLIA.xml:S1:13368:7	treat	JJ	O	O
patients	PROLIA.xml:S1:13376:8	patient	NNS	O	O
were	PROLIA.xml:S1:13385:4	were	VBD	O	O
:	PROLIA.xml:S1:13389:1	:	:	O	O
arthralgia	PROLIA.xml:S1:13391:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
(	PROLIA.xml:S1:13402:1	(	(	O	O
13.0%	PROLIA.xml:S1:13403:5	13.0%	CD	O	O
placebo	PROLIA.xml:S1:13409:7	placebo	NN	O	O
vs	PROLIA.xml:S1:13417:2	vs	NN	O	O
.	PROLIA.xml:S1:13419:1	.	.	O	O

14.3%	PROLIA.xml:S1:13421:5	14.3%	CD	O	O
Prolia	PROLIA.xml:S1:13427:6	prolia	NNP	O	O
)	PROLIA.xml:S1:13433:1	)	)	O	O
and	PROLIA.xml:S1:13435:3	and	CC	O	O
back	PROLIA.xml:S1:13439:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:13444:4	pain	NN	I-AdverseReaction	I-AdverseReaction
(	PROLIA.xml:S1:13449:1	(	(	O	O
10.5%	PROLIA.xml:S1:13450:5	10.5%	CD	O	O
placebo	PROLIA.xml:S1:13456:7	placebo	NN	O	O
vs	PROLIA.xml:S1:13464:2	vs	NN	O	O
.	PROLIA.xml:S1:13466:1	.	.	O	O

11.5%	PROLIA.xml:S1:13468:5	11.5%	CD	O	O
Prolia	PROLIA.xml:S1:13474:6	prolia	NNP	O	O
)	PROLIA.xml:S1:13480:1	)	)	O	O
.	PROLIA.xml:S1:13481:1	.	.	O	O

Pain	PROLIA.xml:S1:13483:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	PROLIA.xml:S1:13488:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	PROLIA.xml:S1:13491:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
(	PROLIA.xml:S1:13501:1	(	(	O	O
7.7%	PROLIA.xml:S1:13502:4	7.7%	CD	O	O
placebo	PROLIA.xml:S1:13507:7	placebo	NN	O	O
vs	PROLIA.xml:S1:13515:2	vs	NN	O	O
.	PROLIA.xml:S1:13517:1	.	.	O	O

9.9%	PROLIA.xml:S1:13519:4	9.9%	CD	O	O
Prolia	PROLIA.xml:S1:13524:6	prolia	NNP	O	O
)	PROLIA.xml:S1:13530:1	)	)	O	O
and	PROLIA.xml:S1:13532:3	and	CC	O	O
musculoskeletal	PROLIA.xml:S1:13536:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:13552:4	pain	NN	I-AdverseReaction	I-AdverseReaction
(	PROLIA.xml:S1:13557:1	(	(	O	O
3.8%	PROLIA.xml:S1:13558:4	3.8%	CD	O	O
placebo	PROLIA.xml:S1:13563:7	placebo	NN	O	O
vs	PROLIA.xml:S1:13571:2	vs	NN	O	O
.	PROLIA.xml:S1:13573:1	.	.	O	O

6.0%	PROLIA.xml:S1:13575:4	6.0%	CD	O	O
Prolia	PROLIA.xml:S1:13580:6	prolia	NNP	O	O
)	PROLIA.xml:S1:13586:1	)	)	O	O
have	PROLIA.xml:S1:13588:4	have	VBP	O	O
also	PROLIA.xml:S1:13593:4	also	RB	O	O
been	PROLIA.xml:S1:13598:4	been	VBN	O	O
reported	PROLIA.xml:S1:13603:8	report	VBN	O	O
in	PROLIA.xml:S1:13612:2	in	IN	O	O
clinical	PROLIA.xml:S1:13615:8	clinic	JJ	O	O
trials	PROLIA.xml:S1:13624:6	trial	NNS	O	O
.	PROLIA.xml:S1:13630:1	.	.	O	O

Additionally	PROLIA.xml:S1:13632:12	addit	RB	O	O
in	PROLIA.xml:S1:13645:2	in	IN	O	O
Prolia	PROLIA.xml:S1:13648:6	prolia	NNP	O	O
-	PROLIA.xml:S1:13654:1	-	:	O	O
treated	PROLIA.xml:S1:13655:7	treat	VBN	O	O
men	PROLIA.xml:S1:13663:3	men	NNS	O	O
with	PROLIA.xml:S1:13667:4	with	IN	O	O
nonmetastatic	PROLIA.xml:S1:13672:13	nonmetastat	JJ	O	O
prostate	PROLIA.xml:S1:13686:8	prostat	NN	O	O
cancer	PROLIA.xml:S1:13695:6	cancer	NN	O	O
receiving	PROLIA.xml:S1:13702:9	receiv	VBG	O	O
ADT	PROLIA.xml:S1:13712:3	adt	NNP	O	O
,	PROLIA.xml:S1:13715:1	,	,	O	O
a	PROLIA.xml:S1:13717:1	a	DT	O	O
greater	PROLIA.xml:S1:13719:7	greater	JJR	O	O
incidence	PROLIA.xml:S1:13727:9	incid	NN	O	O
of	PROLIA.xml:S1:13737:2	of	IN	O	O
cataracts	PROLIA.xml:S1:13740:9	cataract	NNS	B-AdverseReaction	B-AdverseReaction
was	PROLIA.xml:S1:13750:3	wa	VBD	O	O
observed	PROLIA.xml:S1:13754:8	observ	VBN	O	O
(	PROLIA.xml:S1:13763:1	(	(	O	O
1.2%	PROLIA.xml:S1:13764:4	1.2%	CD	O	O
placebo	PROLIA.xml:S1:13769:7	placebo	NN	O	O
vs	PROLIA.xml:S1:13777:2	vs	NN	O	O
.	PROLIA.xml:S1:13779:1	.	.	O	O

4.7%	PROLIA.xml:S1:13781:4	4.7%	CD	O	O
Prolia	PROLIA.xml:S1:13786:6	prolia	NNP	O	O
)	PROLIA.xml:S1:13792:1	)	)	O	O
.	PROLIA.xml:S1:13793:1	.	.	O	O

Hypocalcemia	PROLIA.xml:S1:13795:12	hypocalcemia	NNP	B-AdverseReaction	O
(	PROLIA.xml:S1:13808:1	(	(	O	O
serum	PROLIA.xml:S1:13809:5	serum	JJ	O	O
calcium	PROLIA.xml:S1:13815:7	calcium	NN	O	O
8.4	PROLIA.xml:S1:13825:3	8.4	CD	O	O
mg	PROLIA.xml:S1:13829:2	mg	NN	O	O
dL	PROLIA.xml:S1:13832:2	dL	NN	O	O
)	PROLIA.xml:S1:13834:1	)	)	O	O
was	PROLIA.xml:S1:13836:3	wa	VBD	O	O
reported	PROLIA.xml:S1:13840:8	report	VBN	O	O
only	PROLIA.xml:S1:13849:4	onli	RB	O	O
in	PROLIA.xml:S1:13854:2	in	IN	O	O
Prolia	PROLIA.xml:S1:13857:6	prolia	NNP	O	O
-	PROLIA.xml:S1:13863:1	-	:	O	O
treated	PROLIA.xml:S1:13864:7	treat	VBD	O	O
patients	PROLIA.xml:S1:13872:8	patient	NNS	O	O
(	PROLIA.xml:S1:13881:1	(	(	O	O
2.4%	PROLIA.xml:S1:13882:4	2.4%	CD	O	O
vs	PROLIA.xml:S1:13887:2	vs	NN	O	O
.	PROLIA.xml:S1:13889:1	.	.	O	O

0%	PROLIA.xml:S1:13891:2	0%	CD	O	O
)	PROLIA.xml:S1:13893:1	)	)	O	O
at	PROLIA.xml:S1:13895:2	at	IN	O	O
the	PROLIA.xml:S1:13898:3	the	DT	O	O
month	PROLIA.xml:S1:13902:5	month	NN	O	O
1	PROLIA.xml:S1:13908:1	1	CD	O	O
visit	PROLIA.xml:S1:13910:5	visit	NN	O	O
.	PROLIA.xml:S1:13915:1	.	.	O	O

6.2	PROLIA.xml:S1:13923:3	6.2	CD	O	O
Postmarketing	PROLIA.xml:S1:13927:13	postmarket	VBG	O	O
Experience	PROLIA.xml:S1:13941:10	experi	NN	O	O

Because	PROLIA.xml:S1:13955:7	becaus	IN	O	O
postmarketing	PROLIA.xml:S1:13963:13	postmarket	VBG	O	O
reactions	PROLIA.xml:S1:13977:9	reaction	NNS	O	O
are	PROLIA.xml:S1:13987:3	are	VBP	O	O
reported	PROLIA.xml:S1:13991:8	report	VBN	O	O
voluntarily	PROLIA.xml:S1:14000:11	voluntarili	RB	O	O
from	PROLIA.xml:S1:14012:4	from	IN	O	O
a	PROLIA.xml:S1:14017:1	a	DT	O	O
population	PROLIA.xml:S1:14019:10	popul	NN	O	O
of	PROLIA.xml:S1:14030:2	of	IN	O	O
uncertain	PROLIA.xml:S1:14033:9	uncertain	JJ	O	O
size	PROLIA.xml:S1:14043:4	size	NN	O	O
,	PROLIA.xml:S1:14047:1	,	,	O	O
it	PROLIA.xml:S1:14049:2	it	PRP	O	O
is	PROLIA.xml:S1:14052:2	is	VBZ	O	O
not	PROLIA.xml:S1:14055:3	not	RB	O	O
always	PROLIA.xml:S1:14059:6	alway	RB	O	O
possible	PROLIA.xml:S1:14066:8	possibl	JJ	O	O
to	PROLIA.xml:S1:14075:2	to	TO	O	O
reliably	PROLIA.xml:S1:14078:8	reliabl	VB	O	O
estimate	PROLIA.xml:S1:14087:8	estim	VB	O	O
their	PROLIA.xml:S1:14096:5	their	PRP$	O	O
frequency	PROLIA.xml:S1:14102:9	frequenc	NN	O	O
or	PROLIA.xml:S1:14112:2	or	CC	O	O
establish	PROLIA.xml:S1:14115:9	establish	VB	O	O
a	PROLIA.xml:S1:14125:1	a	DT	O	O
causal	PROLIA.xml:S1:14127:6	causal	NN	O	O
relationship	PROLIA.xml:S1:14134:12	relationship	NN	O	O
to	PROLIA.xml:S1:14147:2	to	TO	O	O
drug	PROLIA.xml:S1:14150:4	drug	NN	O	O
exposure	PROLIA.xml:S1:14155:8	exposur	NN	O	O
.	PROLIA.xml:S1:14163:1	.	.	O	O

The	PROLIA.xml:S1:14169:3	the	DT	O	O
following	PROLIA.xml:S1:14173:9	follow	JJ	O	O
adverse	PROLIA.xml:S1:14183:7	advers	JJ	O	O
reactions	PROLIA.xml:S1:14191:9	reaction	NNS	O	O
have	PROLIA.xml:S1:14201:4	have	VBP	O	O
been	PROLIA.xml:S1:14206:4	been	VBN	O	O
identified	PROLIA.xml:S1:14211:10	identifi	VBN	O	O
during	PROLIA.xml:S1:14222:6	dure	IN	O	O
post	PROLIA.xml:S1:14229:4	post	NN	O	O
approval	PROLIA.xml:S1:14234:8	approv	NN	O	O
use	PROLIA.xml:S1:14243:3	use	NN	O	O
of	PROLIA.xml:S1:14247:2	of	IN	O	O
Prolia	PROLIA.xml:S1:14250:6	prolia	NNS	O	O
:	PROLIA.xml:S1:14256:1	:	:	O	O

Drug	PROLIA.xml:S1:14265:4	drug	NNP	O	B-AdverseReaction
-	PROLIA.xml:S1:14269:1	-	:	O	I-AdverseReaction
related	PROLIA.xml:S1:14270:7	relat	JJ	O	I-AdverseReaction
hypersensitivity	PROLIA.xml:S1:14278:16	hypersensit	NN	B-AdverseReaction	I-AdverseReaction
reactions	PROLIA.xml:S1:14295:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
:	PROLIA.xml:S1:14304:1	:	:	O	O
anaphylaxis	PROLIA.xml:S1:14306:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S1:14317:1	,	,	O	O
rash	PROLIA.xml:S1:14319:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S1:14323:1	,	,	O	O
urticaria	PROLIA.xml:S1:14325:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S1:14334:1	,	,	O	O
facial	PROLIA.xml:S1:14336:6	facial	JJ	B-AdverseReaction	B-AdverseReaction
swelling	PROLIA.xml:S1:14343:8	swell	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:14351:1	,	,	O	O
and	PROLIA.xml:S1:14353:3	and	CC	O	O
erythema	PROLIA.xml:S1:14357:8	erythema	NN	B-AdverseReaction	B-AdverseReaction

Hypocalcemia	PROLIA.xml:S1:14373:12	hypocalcemia	NN	B-AdverseReaction	B-AdverseReaction
:	PROLIA.xml:S1:14385:1	:	:	O	O
severe	PROLIA.xml:S1:14387:6	sever	JJ	O	O
symptomatic	PROLIA.xml:S1:14394:11	symptomat	JJ	B-AdverseReaction	O
hypocalcemia	PROLIA.xml:S1:14406:12	hypocalcemia	NN	I-AdverseReaction	O

Musculoskeletal	PROLIA.xml:S1:14424:15	musculoskelet	NNP	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S1:14440:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S1:14444:1	,	,	O	O
including	PROLIA.xml:S1:14446:9	includ	VBG	O	O
severe	PROLIA.xml:S1:14456:6	sever	JJ	O	O
cases	PROLIA.xml:S1:14463:5	case	NNS	O	O

Parathyroid	PROLIA.xml:S1:14474:11	parathyroid	NNP	O	O
Hormone	PROLIA.xml:S1:14486:7	hormon	NNP	O	O
(	PROLIA.xml:S1:14494:1	(	(	O	O
PTH	PROLIA.xml:S1:14495:3	pth	NNP	O	O
)	PROLIA.xml:S1:14498:1	)	)	O	O
:	PROLIA.xml:S1:14499:1	:	:	O	O
Marked	PROLIA.xml:S1:14501:6	mark	VBN	O	O
elevation	PROLIA.xml:S1:14508:9	elev	NN	B-AdverseReaction	B-AdverseReaction
in	PROLIA.xml:S1:14518:2	in	IN	I-AdverseReaction	I-AdverseReaction
serum	PROLIA.xml:S1:14521:5	serum	NN	I-AdverseReaction	I-AdverseReaction
PTH	PROLIA.xml:S1:14527:3	pth	NNP	I-AdverseReaction	I-AdverseReaction
in	PROLIA.xml:S1:14531:2	in	IN	O	O
patients	PROLIA.xml:S1:14534:8	patient	NNS	O	O
with	PROLIA.xml:S1:14543:4	with	IN	O	O
severe	PROLIA.xml:S1:14548:6	sever	JJ	O	O
renal	PROLIA.xml:S1:14555:5	renal	JJ	O	O
impairment	PROLIA.xml:S1:14561:10	impair	NN	O	O
(	PROLIA.xml:S1:14572:1	(	(	O	O
creatinine	PROLIA.xml:S1:14573:10	creatinin	JJ	O	O
clearance	PROLIA.xml:S1:14584:9	clearanc	NN	O	O
30	PROLIA.xml:S1:14596:2	30	CD	O	O
mL	PROLIA.xml:S1:14599:2	mL	NN	O	O
min	PROLIA.xml:S1:14602:3	min	NN	O	O
)	PROLIA.xml:S1:14605:1	)	)	O	O
or	PROLIA.xml:S1:14607:2	or	CC	O	O
receiving	PROLIA.xml:S1:14610:9	receiv	VBG	O	O
dialysis	PROLIA.xml:S1:14620:8	dialysi	NN	O	O
.	PROLIA.xml:S1:14628:1	.	.	O	O

6.3	PROLIA.xml:S1:14637:3	6.3	CD	O	O
Immunogenicity	PROLIA.xml:S1:14641:14	immunogen	NN	O	O

Denosumab	PROLIA.xml:S1:14659:9	denosumab	NNP	O	O
is	PROLIA.xml:S1:14669:2	is	VBZ	O	O
a	PROLIA.xml:S1:14672:1	a	DT	O	O
human	PROLIA.xml:S1:14674:5	human	JJ	O	O
monoclonal	PROLIA.xml:S1:14680:10	monoclon	JJ	O	O
antibody	PROLIA.xml:S1:14691:8	antibodi	NN	O	O
.	PROLIA.xml:S1:14699:1	.	.	O	O

As	PROLIA.xml:S1:14701:2	As	IN	O	O
with	PROLIA.xml:S1:14704:4	with	IN	O	O
all	PROLIA.xml:S1:14709:3	all	DT	O	O
therapeutic	PROLIA.xml:S1:14713:11	therapeut	JJ	O	O
proteins	PROLIA.xml:S1:14725:8	protein	NNS	O	O
,	PROLIA.xml:S1:14733:1	,	,	O	O
there	PROLIA.xml:S1:14735:5	there	EX	O	O
is	PROLIA.xml:S1:14741:2	is	VBZ	O	O
potential	PROLIA.xml:S1:14744:9	potenti	JJ	O	O
for	PROLIA.xml:S1:14754:3	for	IN	O	O
immunogenicity	PROLIA.xml:S1:14758:14	immunogen	NN	O	O
.	PROLIA.xml:S1:14772:1	.	.	O	O

Using	PROLIA.xml:S1:14774:5	use	VBG	O	O
an	PROLIA.xml:S1:14780:2	an	DT	O	O
electrochemiluminescent	PROLIA.xml:S1:14783:23	electrochemiluminesc	NN	O	O
bridging	PROLIA.xml:S1:14807:8	bridg	VBG	O	O
immunoassay	PROLIA.xml:S1:14816:11	immunoassay	NN	O	O
,	PROLIA.xml:S1:14827:1	,	,	O	O
less	PROLIA.xml:S1:14829:4	less	JJR	O	O
than	PROLIA.xml:S1:14834:4	than	IN	O	O
1%	PROLIA.xml:S1:14839:2	1%	CD	O	O
(	PROLIA.xml:S1:14842:1	(	(	O	O
55	PROLIA.xml:S1:14843:2	55	CD	O	O
out	PROLIA.xml:S1:14846:3	out	IN	O	O
of	PROLIA.xml:S1:14850:2	of	IN	O	O
8113	PROLIA.xml:S1:14853:4	8113	CD	O	O
)	PROLIA.xml:S1:14857:1	)	)	O	O
of	PROLIA.xml:S1:14859:2	of	IN	O	O
patients	PROLIA.xml:S1:14862:8	patient	NNS	O	O
treated	PROLIA.xml:S1:14871:7	treat	VBN	O	O
with	PROLIA.xml:S1:14879:4	with	IN	O	O
Prolia	PROLIA.xml:S1:14884:6	prolia	NNP	O	O
for	PROLIA.xml:S1:14891:3	for	IN	O	O
up	PROLIA.xml:S1:14895:2	up	RB	O	O
to	PROLIA.xml:S1:14898:2	to	TO	O	O
5	PROLIA.xml:S1:14901:1	5	CD	O	O
years	PROLIA.xml:S1:14903:5	year	NNS	O	O
tested	PROLIA.xml:S1:14909:6	test	VBD	O	O
positive	PROLIA.xml:S1:14916:8	posit	JJ	O	O
for	PROLIA.xml:S1:14925:3	for	IN	O	O
binding	PROLIA.xml:S1:14929:7	bind	VBG	O	O
antibodies	PROLIA.xml:S1:14937:10	antibodi	NNS	O	O
(	PROLIA.xml:S1:14948:1	(	(	O	O
including	PROLIA.xml:S1:14949:9	includ	VBG	O	O
pre	PROLIA.xml:S1:14959:3	pre	SYM	O	O
-	PROLIA.xml:S1:14962:1	-	:	O	O
existing	PROLIA.xml:S1:14963:8	exist	NN	O	O
,	PROLIA.xml:S1:14971:1	,	,	O	O
transient	PROLIA.xml:S1:14973:9	transient	NN	O	O
,	PROLIA.xml:S1:14982:1	,	,	O	O
and	PROLIA.xml:S1:14984:3	and	CC	O	O
developing	PROLIA.xml:S1:14988:10	develop	VBG	O	O
antibodies	PROLIA.xml:S1:14999:10	antibodi	NNS	O	O
)	PROLIA.xml:S1:15009:1	)	)	O	O
.	PROLIA.xml:S1:15010:1	.	.	O	O

None	PROLIA.xml:S1:15012:4	none	NN	O	O
of	PROLIA.xml:S1:15017:2	of	IN	O	O
the	PROLIA.xml:S1:15020:3	the	DT	O	O
patients	PROLIA.xml:S1:15024:8	patient	NNS	O	O
tested	PROLIA.xml:S1:15033:6	test	VBD	O	O
positive	PROLIA.xml:S1:15040:8	posit	JJ	O	O
for	PROLIA.xml:S1:15049:3	for	IN	O	O
neutralizing	PROLIA.xml:S1:15053:12	neutral	VBG	O	O
antibodies	PROLIA.xml:S1:15066:10	antibodi	NNS	O	O
,	PROLIA.xml:S1:15076:1	,	,	O	O
as	PROLIA.xml:S1:15078:2	as	IN	O	O
was	PROLIA.xml:S1:15081:3	wa	VBD	O	O
assessed	PROLIA.xml:S1:15085:8	assess	VBN	O	O
using	PROLIA.xml:S1:15094:5	use	VBG	O	O
a	PROLIA.xml:S1:15100:1	a	DT	O	O
chemiluminescent	PROLIA.xml:S1:15102:16	chemiluminesc	NN	O	O
cell	PROLIA.xml:S1:15119:4	cell	NN	O	O
-	PROLIA.xml:S1:15123:1	-	:	O	O
based	PROLIA.xml:S1:15124:5	base	VBN	O	O
in	PROLIA.xml:S1:15130:2	in	IN	O	O
vitro	PROLIA.xml:S1:15133:5	vitro	JJ	O	O
biological	PROLIA.xml:S1:15139:10	biolog	JJ	O	O
assay	PROLIA.xml:S1:15150:5	assay	NN	O	O
.	PROLIA.xml:S1:15155:1	.	.	O	O

No	PROLIA.xml:S1:15157:2	No	DT	O	O
evidence	PROLIA.xml:S1:15160:8	evid	NN	O	O
of	PROLIA.xml:S1:15169:2	of	IN	O	O
altered	PROLIA.xml:S1:15172:7	alter	JJ	O	O
pharmacokinetic	PROLIA.xml:S1:15180:15	pharmacokinet	JJ	O	O
profile	PROLIA.xml:S1:15196:7	profil	NN	O	O
,	PROLIA.xml:S1:15203:1	,	,	O	O
toxicity	PROLIA.xml:S1:15205:8	toxic	NN	B-AdverseReaction	O
profile	PROLIA.xml:S1:15214:7	profil	NN	O	O
,	PROLIA.xml:S1:15221:1	,	,	O	O
or	PROLIA.xml:S1:15223:2	or	CC	O	O
clinical	PROLIA.xml:S1:15226:8	clinic	JJ	O	O
response	PROLIA.xml:S1:15235:8	respons	NN	O	O
was	PROLIA.xml:S1:15244:3	wa	VBD	O	O
associated	PROLIA.xml:S1:15248:10	associ	VBN	O	O
with	PROLIA.xml:S1:15259:4	with	IN	O	O
binding	PROLIA.xml:S1:15264:7	bind	VBG	O	O
antibody	PROLIA.xml:S1:15272:8	antibodi	NN	O	O
development	PROLIA.xml:S1:15281:11	develop	NN	O	O
.	PROLIA.xml:S1:15292:1	.	.	O	O

The	PROLIA.xml:S1:15298:3	the	DT	O	O
incidence	PROLIA.xml:S1:15302:9	incid	NN	O	O
of	PROLIA.xml:S1:15312:2	of	IN	O	O
antibody	PROLIA.xml:S1:15315:8	antibodi	NN	O	O
formation	PROLIA.xml:S1:15324:9	format	NN	O	O
is	PROLIA.xml:S1:15334:2	is	VBZ	O	O
highly	PROLIA.xml:S1:15337:6	highli	RB	O	O
dependent	PROLIA.xml:S1:15344:9	depend	JJ	O	O
on	PROLIA.xml:S1:15354:2	on	IN	O	O
the	PROLIA.xml:S1:15357:3	the	DT	O	O
sensitivity	PROLIA.xml:S1:15361:11	sensit	NN	O	O
and	PROLIA.xml:S1:15373:3	and	CC	O	O
specificity	PROLIA.xml:S1:15377:11	specif	NN	O	O
of	PROLIA.xml:S1:15389:2	of	IN	O	O
the	PROLIA.xml:S1:15392:3	the	DT	O	O
assay	PROLIA.xml:S1:15396:5	assay	NN	O	O
.	PROLIA.xml:S1:15401:1	.	.	O	O

Additionally	PROLIA.xml:S1:15403:12	addit	RB	O	O
,	PROLIA.xml:S1:15415:1	,	,	O	O
the	PROLIA.xml:S1:15417:3	the	DT	O	O
observed	PROLIA.xml:S1:15421:8	observ	JJ	O	O
incidence	PROLIA.xml:S1:15430:9	incid	NN	O	O
of	PROLIA.xml:S1:15440:2	of	IN	O	O
a	PROLIA.xml:S1:15443:1	a	DT	O	O
positive	PROLIA.xml:S1:15445:8	posit	JJ	O	O
antibody	PROLIA.xml:S1:15454:8	antibodi	NN	O	O
(	PROLIA.xml:S1:15463:1	(	(	O	O
including	PROLIA.xml:S1:15464:9	includ	VBG	O	O
neutralizing	PROLIA.xml:S1:15474:12	neutral	VBG	O	O
antibody	PROLIA.xml:S1:15487:8	antibodi	NN	O	O
)	PROLIA.xml:S1:15495:1	)	)	O	O
test	PROLIA.xml:S1:15497:4	test	NN	O	O
result	PROLIA.xml:S1:15502:6	result	NN	O	O
may	PROLIA.xml:S1:15509:3	may	MD	O	O
be	PROLIA.xml:S1:15513:2	be	VB	O	O
influenced	PROLIA.xml:S1:15516:10	influenc	VBN	O	O
by	PROLIA.xml:S1:15527:2	by	IN	O	O
several	PROLIA.xml:S1:15530:7	sever	JJ	O	O
factors	PROLIA.xml:S1:15538:7	factor	NNS	O	O
,	PROLIA.xml:S1:15545:1	,	,	O	O
including	PROLIA.xml:S1:15547:9	includ	VBG	O	O
assay	PROLIA.xml:S1:15557:5	assay	JJ	O	O
methodology	PROLIA.xml:S1:15563:11	methodolog	NN	O	O
,	PROLIA.xml:S1:15574:1	,	,	O	O
sample	PROLIA.xml:S1:15576:6	sampl	NN	O	O
handling	PROLIA.xml:S1:15583:8	handl	NN	O	O
,	PROLIA.xml:S1:15591:1	,	,	O	O
timing	PROLIA.xml:S1:15593:6	time	NN	O	O
of	PROLIA.xml:S1:15600:2	of	IN	O	O
sample	PROLIA.xml:S1:15603:6	sampl	JJ	O	O
collection	PROLIA.xml:S1:15610:10	collect	NN	O	O
,	PROLIA.xml:S1:15620:1	,	,	O	O
concomitant	PROLIA.xml:S1:15622:11	concomit	JJ	O	O
medications	PROLIA.xml:S1:15634:11	medic	NNS	O	O
,	PROLIA.xml:S1:15645:1	,	,	O	O
and	PROLIA.xml:S1:15647:3	and	CC	O	O
underlying	PROLIA.xml:S1:15651:10	underli	JJ	O	O
disease	PROLIA.xml:S1:15662:7	diseas	NN	O	O
.	PROLIA.xml:S1:15669:1	.	.	O	O

For	PROLIA.xml:S1:15671:3	for	IN	O	O
these	PROLIA.xml:S1:15675:5	these	DT	O	O
reasons	PROLIA.xml:S1:15681:7	reason	NNS	O	O
,	PROLIA.xml:S1:15688:1	,	,	O	O
comparison	PROLIA.xml:S1:15690:10	comparison	NN	O	O
of	PROLIA.xml:S1:15701:2	of	IN	O	O
antibodies	PROLIA.xml:S1:15704:10	antibodi	NNS	O	O
to	PROLIA.xml:S1:15715:2	to	TO	O	O
denosumab	PROLIA.xml:S1:15718:9	denosumab	VB	O	O
with	PROLIA.xml:S1:15728:4	with	IN	O	O
the	PROLIA.xml:S1:15733:3	the	DT	O	O
incidence	PROLIA.xml:S1:15737:9	incid	NN	O	O
of	PROLIA.xml:S1:15747:2	of	IN	O	O
antibodies	PROLIA.xml:S1:15750:10	antibodi	NNS	O	O
to	PROLIA.xml:S1:15761:2	to	TO	O	O
other	PROLIA.xml:S1:15764:5	other	JJ	O	O
products	PROLIA.xml:S1:15770:8	product	NNS	O	O
may	PROLIA.xml:S1:15779:3	may	MD	O	O
be	PROLIA.xml:S1:15783:2	be	VB	O	O
misleading	PROLIA.xml:S1:15786:10	mislead	VBG	O	O
.	PROLIA.xml:S1:15796:1	.	.	O	O
5	PROLIA.xml:S2:4:1	5	CD	O	O
WARNINGS	PROLIA.xml:S2:6:8	warn	NNP	O	O
AND	PROLIA.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	PROLIA.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	PROLIA.xml:S2:37:7	excerpt	NN	O	O
:	PROLIA.xml:S2:44:1	:	:	O	O
Same	PROLIA.xml:S2:52:4	same	NNP	O	O
Active	PROLIA.xml:S2:57:6	activ	NNP	O	O
Ingredient	PROLIA.xml:S2:64:10	ingredi	NNP	O	O
:	PROLIA.xml:S2:74:1	:	:	O	O
Patients	PROLIA.xml:S2:76:8	patient	NNS	O	O
receiving	PROLIA.xml:S2:85:9	receiv	VBG	O	O
Prolia	PROLIA.xml:S2:95:6	prolia	NNP	O	O
should	PROLIA.xml:S2:102:6	should	MD	O	O
not	PROLIA.xml:S2:109:3	not	RB	O	O
receive	PROLIA.xml:S2:113:7	receiv	VB	O	O
XGEVA	PROLIA.xml:S2:121:5	xgeva	NNP	O	O
(	PROLIA.xml:S2:128:1	(	(	O	O
r	PROLIA.xml:S2:129:1	r	NN	O	O
)	PROLIA.xml:S2:130:1	)	)	O	O
(	PROLIA.xml:S2:133:1	(	(	O	O
5.1	PROLIA.xml:S2:136:3	5.1	CD	O	O
)	PROLIA.xml:S2:141:1	)	)	O	O

Hypersensitivity	PROLIA.xml:S2:148:16	hypersensit	NNP	B-AdverseReaction	O
including	PROLIA.xml:S2:165:9	includ	VBG	O	O
anaphylactic	PROLIA.xml:S2:175:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reactions	PROLIA.xml:S2:188:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
may	PROLIA.xml:S2:198:3	may	MD	O	O
occur	PROLIA.xml:S2:202:5	occur	VB	O	O
.	PROLIA.xml:S2:207:1	.	.	O	O

Discontinue	PROLIA.xml:S2:209:11	discontinu	NNP	O	O
permanently	PROLIA.xml:S2:221:11	perman	RB	O	O
if	PROLIA.xml:S2:233:2	if	IN	O	O
a	PROLIA.xml:S2:236:1	a	DT	O	O
clinically	PROLIA.xml:S2:238:10	clinic	RB	O	O
significant	PROLIA.xml:S2:249:11	signific	JJ	O	O
reaction	PROLIA.xml:S2:261:8	reaction	NN	O	O
occurs	PROLIA.xml:S2:270:6	occur	VBZ	O	O
(	PROLIA.xml:S2:277:1	(	(	O	O
5.2	PROLIA.xml:S2:280:3	5.2	CD	O	O
)	PROLIA.xml:S2:285:1	)	)	O	O

Hypocalcemia	PROLIA.xml:S2:292:12	hypocalcemia	NN	B-AdverseReaction	O
:	PROLIA.xml:S2:304:1	:	:	O	O
Must	PROLIA.xml:S2:306:4	must	NN	O	O
be	PROLIA.xml:S2:311:2	be	VB	O	O
corrected	PROLIA.xml:S2:314:9	correct	VBN	O	O
before	PROLIA.xml:S2:324:6	befor	IN	O	O
initiating	PROLIA.xml:S2:331:10	initi	VBG	O	O
Prolia	PROLIA.xml:S2:342:6	prolia	NNP	O	O
.	PROLIA.xml:S2:348:1	.	.	O	O

May	PROLIA.xml:S2:350:3	may	NNP	O	O
worsen	PROLIA.xml:S2:354:6	worsen	NN	O	O
,	PROLIA.xml:S2:360:1	,	,	O	O
especially	PROLIA.xml:S2:362:10	especi	RB	O	O
in	PROLIA.xml:S2:373:2	in	IN	O	O
patients	PROLIA.xml:S2:376:8	patient	NNS	O	O
with	PROLIA.xml:S2:385:4	with	IN	O	O
renal	PROLIA.xml:S2:390:5	renal	JJ	O	O
impairment	PROLIA.xml:S2:396:10	impair	NN	O	O
.	PROLIA.xml:S2:406:1	.	.	O	O

Adequately	PROLIA.xml:S2:408:10	adequ	RB	O	O
supplement	PROLIA.xml:S2:419:10	supplement	JJ	O	O
patients	PROLIA.xml:S2:430:8	patient	NNS	O	O
with	PROLIA.xml:S2:439:4	with	IN	O	O
calcium	PROLIA.xml:S2:444:7	calcium	NN	O	O
and	PROLIA.xml:S2:452:3	and	CC	O	O
vitamin	PROLIA.xml:S2:456:7	vitamin	NN	O	O
D	PROLIA.xml:S2:464:1	D	NNP	O	O
(	PROLIA.xml:S2:466:1	(	(	O	O
5.3	PROLIA.xml:S2:469:3	5.3	CD	O	O
)	PROLIA.xml:S2:474:1	)	)	O	O

Osteonecrosis	PROLIA.xml:S2:481:13	osteonecrosi	NN	B-AdverseReaction	B-AdverseReaction
of	PROLIA.xml:S2:495:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	PROLIA.xml:S2:498:3	the	DT	I-AdverseReaction	I-AdverseReaction
jaw	PROLIA.xml:S2:502:3	jaw	NN	I-AdverseReaction	I-AdverseReaction
:	PROLIA.xml:S2:505:1	:	:	O	O
Has	PROLIA.xml:S2:507:3	ha	NNP	O	O
been	PROLIA.xml:S2:511:4	been	VBN	O	O
reported	PROLIA.xml:S2:516:8	report	VBN	O	O
with	PROLIA.xml:S2:525:4	with	IN	O	O
Prolia	PROLIA.xml:S2:530:6	prolia	NNP	O	O
.	PROLIA.xml:S2:536:1	.	.	O	O

Monitor	PROLIA.xml:S2:538:7	monitor	NNP	O	O
for	PROLIA.xml:S2:546:3	for	IN	O	O
symptoms	PROLIA.xml:S2:550:8	symptom	NNS	O	O
(	PROLIA.xml:S2:559:1	(	(	O	O
5.4	PROLIA.xml:S2:562:3	5.4	CD	O	O
)	PROLIA.xml:S2:567:1	)	)	O	O

Atypical	PROLIA.xml:S2:574:8	atyp	JJ	B-AdverseReaction	B-AdverseReaction
femoral	PROLIA.xml:S2:583:7	femor	JJ	I-AdverseReaction	I-AdverseReaction
fractures	PROLIA.xml:S2:591:9	fractur	NNS	I-AdverseReaction	I-AdverseReaction
:	PROLIA.xml:S2:600:1	:	:	O	O
Have	PROLIA.xml:S2:602:4	have	VBP	O	O
been	PROLIA.xml:S2:607:4	been	VBN	O	O
reported	PROLIA.xml:S2:612:8	report	VBN	O	O
.	PROLIA.xml:S2:620:1	.	.	O	O

Evaluate	PROLIA.xml:S2:622:8	evalu	JJ	O	O
patients	PROLIA.xml:S2:631:8	patient	NNS	O	O
with	PROLIA.xml:S2:640:4	with	IN	O	O
thigh	PROLIA.xml:S2:645:5	thigh	JJ	O	O
or	PROLIA.xml:S2:651:2	or	CC	O	O
groin	PROLIA.xml:S2:654:5	groin	JJ	O	O
pain	PROLIA.xml:S2:660:4	pain	NN	O	O
to	PROLIA.xml:S2:665:2	to	TO	O	O
rule	PROLIA.xml:S2:668:4	rule	VB	O	O
out	PROLIA.xml:S2:673:3	out	RP	O	O
a	PROLIA.xml:S2:677:1	a	DT	O	O
femoral	PROLIA.xml:S2:679:7	femor	JJ	O	B-AdverseReaction
fracture	PROLIA.xml:S2:687:8	fractur	NN	O	I-AdverseReaction
(	PROLIA.xml:S2:696:1	(	(	O	O
5.5	PROLIA.xml:S2:699:3	5.5	CD	O	O
)	PROLIA.xml:S2:704:1	)	)	O	O

Serious	PROLIA.xml:S2:711:7	seriou	JJ	O	O
infections	PROLIA.xml:S2:719:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
including	PROLIA.xml:S2:730:9	includ	VBG	O	O
skin	PROLIA.xml:S2:740:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
infections	PROLIA.xml:S2:745:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
:	PROLIA.xml:S2:755:1	:	:	O	O
May	PROLIA.xml:S2:757:3	may	NNP	O	O
occur	PROLIA.xml:S2:761:5	occur	VB	O	O
,	PROLIA.xml:S2:766:1	,	,	O	O
including	PROLIA.xml:S2:768:9	includ	VBG	O	O
those	PROLIA.xml:S2:778:5	those	DT	O	O
leading	PROLIA.xml:S2:784:7	lead	VBG	O	O
to	PROLIA.xml:S2:792:2	to	TO	O	O
hospitalization	PROLIA.xml:S2:795:15	hospit	NN	O	O
.	PROLIA.xml:S2:810:1	.	.	O	O

Advise	PROLIA.xml:S2:812:6	advis	NN	O	O
patients	PROLIA.xml:S2:819:8	patient	NNS	O	O
to	PROLIA.xml:S2:828:2	to	TO	O	O
seek	PROLIA.xml:S2:831:4	seek	VB	O	O
prompt	PROLIA.xml:S2:836:6	prompt	NN	O	O
medical	PROLIA.xml:S2:843:7	medic	JJ	O	O
attention	PROLIA.xml:S2:851:9	attent	NN	O	O
if	PROLIA.xml:S2:861:2	if	IN	O	O
they	PROLIA.xml:S2:864:4	they	PRP	O	O
develop	PROLIA.xml:S2:869:7	develop	VBP	O	O
signs	PROLIA.xml:S2:877:5	sign	NNS	O	O
or	PROLIA.xml:S2:883:2	or	CC	O	O
symptoms	PROLIA.xml:S2:886:8	symptom	NNS	O	O
of	PROLIA.xml:S2:895:2	of	IN	O	O
infection	PROLIA.xml:S2:898:9	infect	NN	O	O
,	PROLIA.xml:S2:907:1	,	,	O	O
including	PROLIA.xml:S2:909:9	includ	VBG	O	O
cellulitis	PROLIA.xml:S2:919:10	cellul	NN	O	O
(	PROLIA.xml:S2:930:1	(	(	O	O
5.6	PROLIA.xml:S2:933:3	5.6	CD	O	O
)	PROLIA.xml:S2:938:1	)	)	O	O

Dermatologic	PROLIA.xml:S2:945:12	dermatolog	JJ	B-AdverseReaction	B-AdverseReaction
reactions	PROLIA.xml:S2:958:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
:	PROLIA.xml:S2:967:1	:	:	O	O
Dermatitis	PROLIA.xml:S2:969:10	dermat	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S2:979:1	,	,	O	O
rashes	PROLIA.xml:S2:981:6	rash	NNS	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S2:987:1	,	,	O	O
and	PROLIA.xml:S2:989:3	and	CC	O	O
eczema	PROLIA.xml:S2:993:6	eczema	NNS	B-AdverseReaction	B-AdverseReaction
have	PROLIA.xml:S2:1000:4	have	VBP	O	O
been	PROLIA.xml:S2:1005:4	been	VBN	O	O
reported	PROLIA.xml:S2:1010:8	report	VBN	O	O
.	PROLIA.xml:S2:1018:1	.	.	O	O

Consider	PROLIA.xml:S2:1020:8	consid	VB	O	O
discontinuing	PROLIA.xml:S2:1029:13	discontinu	VBG	O	O
Prolia	PROLIA.xml:S2:1043:6	prolia	NNP	O	O
if	PROLIA.xml:S2:1050:2	if	IN	O	O
severe	PROLIA.xml:S2:1053:6	sever	JJ	O	O
symptoms	PROLIA.xml:S2:1060:8	symptom	NNS	O	O
develop	PROLIA.xml:S2:1069:7	develop	VBP	O	O
(	PROLIA.xml:S2:1077:1	(	(	O	O
5.7	PROLIA.xml:S2:1080:3	5.7	CD	O	O
)	PROLIA.xml:S2:1085:1	)	)	O	O

Severe	PROLIA.xml:S2:1092:6	sever	NNP	O	O
Bone	PROLIA.xml:S2:1099:4	bone	NNP	B-AdverseReaction	O
,	PROLIA.xml:S2:1103:1	,	,	O	O
Joint	PROLIA.xml:S2:1105:5	joint	NNP	B-AdverseReaction	O
,	PROLIA.xml:S2:1110:1	,	,	O	O
Muscle	PROLIA.xml:S2:1112:6	muscl	NNP	B-AdverseReaction	B-AdverseReaction
Pain	PROLIA.xml:S2:1119:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
may	PROLIA.xml:S2:1124:3	may	MD	O	O
occur	PROLIA.xml:S2:1128:5	occur	VB	O	O
.	PROLIA.xml:S2:1133:1	.	.	O	O

Discontinue	PROLIA.xml:S2:1135:11	discontinu	NNP	O	O
use	PROLIA.xml:S2:1147:3	use	NN	O	O
if	PROLIA.xml:S2:1151:2	if	IN	O	O
severe	PROLIA.xml:S2:1154:6	sever	JJ	O	O
symptoms	PROLIA.xml:S2:1161:8	symptom	NNS	O	O
develop	PROLIA.xml:S2:1170:7	develop	VBP	O	O
(	PROLIA.xml:S2:1178:1	(	(	O	O
5.8	PROLIA.xml:S2:1181:3	5.8	CD	O	O
)	PROLIA.xml:S2:1186:1	)	)	O	O

Suppression	PROLIA.xml:S2:1193:11	suppress	NN	B-AdverseReaction	B-AdverseReaction
of	PROLIA.xml:S2:1205:2	of	IN	I-AdverseReaction	I-AdverseReaction
bone	PROLIA.xml:S2:1208:4	bone	NN	I-AdverseReaction	I-AdverseReaction
turnover	PROLIA.xml:S2:1213:8	turnov	NN	I-AdverseReaction	I-AdverseReaction
:	PROLIA.xml:S2:1221:1	:	:	O	O
Significant	PROLIA.xml:S2:1223:11	signific	JJ	O	O
suppression	PROLIA.xml:S2:1235:11	suppress	NN	O	O
has	PROLIA.xml:S2:1247:3	ha	VBZ	O	O
been	PROLIA.xml:S2:1251:4	been	VBN	O	O
demonstrated	PROLIA.xml:S2:1256:12	demonstr	VBN	O	O
.	PROLIA.xml:S2:1268:1	.	.	O	O

Monitor	PROLIA.xml:S2:1270:7	monitor	NNP	O	O
for	PROLIA.xml:S2:1278:3	for	IN	O	O
consequences	PROLIA.xml:S2:1282:12	consequ	NNS	O	O
of	PROLIA.xml:S2:1295:2	of	IN	O	O
bone	PROLIA.xml:S2:1298:4	bone	NN	O	O
oversuppression	PROLIA.xml:S2:1303:15	oversuppress	NN	O	O
(	PROLIA.xml:S2:1319:1	(	(	O	O
5.9	PROLIA.xml:S2:1322:3	5.9	CD	O	O
)	PROLIA.xml:S2:1327:1	)	)	O	O

5.1	PROLIA.xml:S2:1341:3	5.1	CD	O	O

Drug	PROLIA.xml:S2:1345:4	drug	NN	O	O

Products	PROLIA.xml:S2:1350:8	product	NNS	O	O
with	PROLIA.xml:S2:1359:4	with	IN	O	O
Same	PROLIA.xml:S2:1364:4	same	NNP	O	O
Active	PROLIA.xml:S2:1369:6	activ	NNP	O	O
Ingredient	PROLIA.xml:S2:1376:10	ingredi	NNP	O	O

Prolia	PROLIA.xml:S2:1392:6	prolia	NNP	O	O
contains	PROLIA.xml:S2:1399:8	contain	VBZ	O	O
the	PROLIA.xml:S2:1408:3	the	DT	O	O
same	PROLIA.xml:S2:1412:4	same	JJ	O	O
active	PROLIA.xml:S2:1417:6	activ	JJ	O	O
ingredient	PROLIA.xml:S2:1424:10	ingredi	NN	O	O
(	PROLIA.xml:S2:1435:1	(	(	O	O
denosumab	PROLIA.xml:S2:1436:9	denosumab	NN	O	O
)	PROLIA.xml:S2:1445:1	)	)	O	O
found	PROLIA.xml:S2:1447:5	found	VBD	O	O
in	PROLIA.xml:S2:1453:2	in	IN	O	O
Xgeva	PROLIA.xml:S2:1456:5	xgeva	NNP	O	O
.	PROLIA.xml:S2:1461:1	.	.	O	O

Patients	PROLIA.xml:S2:1463:8	patient	NNS	O	O
receiving	PROLIA.xml:S2:1472:9	receiv	VBG	O	O
Prolia	PROLIA.xml:S2:1482:6	prolia	NNP	O	O
should	PROLIA.xml:S2:1489:6	should	MD	O	O
not	PROLIA.xml:S2:1496:3	not	RB	O	O
receive	PROLIA.xml:S2:1500:7	receiv	VB	O	O
Xgeva	PROLIA.xml:S2:1508:5	xgeva	NN	O	O
.	PROLIA.xml:S2:1513:1	.	.	O	O

5.2	PROLIA.xml:S2:1522:3	5.2	CD	O	O
Hypersensitivity	PROLIA.xml:S2:1526:16	hypersensit	NN	O	O

Clinically	PROLIA.xml:S2:1548:10	clinic	RB	O	O
significant	PROLIA.xml:S2:1559:11	signific	JJ	O	O
hypersensitivity	PROLIA.xml:S2:1571:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
including	PROLIA.xml:S2:1588:9	includ	VBG	O	O
anaphylaxis	PROLIA.xml:S2:1598:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
has	PROLIA.xml:S2:1610:3	ha	VBZ	O	O
been	PROLIA.xml:S2:1614:4	been	VBN	O	O
reported	PROLIA.xml:S2:1619:8	report	VBN	O	O
with	PROLIA.xml:S2:1628:4	with	IN	O	O
Prolia	PROLIA.xml:S2:1633:6	prolia	NNP	O	O
.	PROLIA.xml:S2:1639:1	.	.	O	O

Symptoms	PROLIA.xml:S2:1641:8	symptom	NNS	O	O
have	PROLIA.xml:S2:1650:4	have	VBP	O	O
included	PROLIA.xml:S2:1655:8	includ	VBN	O	O
hypotension	PROLIA.xml:S2:1664:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S2:1675:1	,	,	O	O
dyspnea	PROLIA.xml:S2:1677:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S2:1684:1	,	,	O	O
throat	PROLIA.xml:S2:1686:6	throat	NN	B-AdverseReaction	B-AdverseReaction
tightness	PROLIA.xml:S2:1693:9	tight	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S2:1702:1	,	,	O	O
facial	PROLIA.xml:S2:1704:6	facial	JJ	B-AdverseReaction	O
and	PROLIA.xml:S2:1711:3	and	CC	O	O
upper	PROLIA.xml:S2:1715:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
airway	PROLIA.xml:S2:1721:6	airway	NN	I-AdverseReaction	I-AdverseReaction
edema	PROLIA.xml:S2:1728:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S2:1733:1	,	,	O	O
pruritus	PROLIA.xml:S2:1735:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
,	PROLIA.xml:S2:1743:1	,	,	O	O
and	PROLIA.xml:S2:1745:3	and	CC	O	O
urticaria	PROLIA.xml:S2:1749:9	urticaria	NNS	B-AdverseReaction	B-AdverseReaction
.	PROLIA.xml:S2:1758:1	.	.	O	O

If	PROLIA.xml:S2:1760:2	If	IN	O	O
an	PROLIA.xml:S2:1763:2	an	DT	O	O
anaphylactic	PROLIA.xml:S2:1766:12	anaphylact	JJ	O	O
or	PROLIA.xml:S2:1779:2	or	CC	O	O
other	PROLIA.xml:S2:1782:5	other	JJ	O	O
clinically	PROLIA.xml:S2:1788:10	clinic	RB	O	O
significant	PROLIA.xml:S2:1799:11	signific	JJ	O	O
allergic	PROLIA.xml:S2:1811:8	allerg	JJ	O	O
reaction	PROLIA.xml:S2:1820:8	reaction	NN	O	O
occurs	PROLIA.xml:S2:1829:6	occur	VBZ	O	O
,	PROLIA.xml:S2:1835:1	,	,	O	O
initiate	PROLIA.xml:S2:1837:8	initi	VB	O	O
appropriate	PROLIA.xml:S2:1846:11	appropri	JJ	O	O
therapy	PROLIA.xml:S2:1858:7	therapi	NN	O	O
and	PROLIA.xml:S2:1866:3	and	CC	O	O
discontinue	PROLIA.xml:S2:1870:11	discontinu	VB	O	O
further	PROLIA.xml:S2:1882:7	further	JJR	O	O
use	PROLIA.xml:S2:1890:3	use	NN	O	O
of	PROLIA.xml:S2:1894:2	of	IN	O	O
Prolia	PROLIA.xml:S2:1897:6	prolia	NNP	O	O
[	PROLIA.xml:S2:1904:1	[	NNP	O	O
see	PROLIA.xml:S2:1905:3	see	VBP	O	O
Contraindications	PROLIA.xml:S2:1909:17	contraind	NNP	O	O
(	PROLIA.xml:S2:1927:1	(	(	O	O
4.3	PROLIA.xml:S2:1930:3	4.3	CD	O	O
)	PROLIA.xml:S2:1935:1	)	)	O	O
,	PROLIA.xml:S2:1936:1	,	,	O	O
Adverse	PROLIA.xml:S2:1938:7	advers	JJ	O	O
Reactions	PROLIA.xml:S2:1946:9	reaction	NNP	O	O
(	PROLIA.xml:S2:1956:1	(	(	O	O
6.2	PROLIA.xml:S2:1959:3	6.2	CD	O	O
)]	PROLIA.xml:S2:1964:2	)]	NN	O	O
.	PROLIA.xml:S2:1968:1	.	.	O	O

5.3	PROLIA.xml:S2:1977:3	5.3	CD	O	O
Hypocalcemia	PROLIA.xml:S2:1981:12	hypocalcemia	NNP	O	O
and	PROLIA.xml:S2:1994:3	and	CC	O	O
Mineral	PROLIA.xml:S2:1998:7	miner	NNP	O	O
Metabolism	PROLIA.xml:S2:2006:10	metabol	NNP	O	O

Hypocalcemia	PROLIA.xml:S2:2023:12	hypocalcemia	NN	B-AdverseReaction	O
may	PROLIA.xml:S2:2036:3	may	MD	O	O
be	PROLIA.xml:S2:2040:2	be	VB	O	O
exacerbated	PROLIA.xml:S2:2043:11	exacerb	VBN	I-AdverseReaction	O
by	PROLIA.xml:S2:2055:2	by	IN	O	O
the	PROLIA.xml:S2:2058:3	the	DT	O	O
use	PROLIA.xml:S2:2062:3	use	NN	O	O
of	PROLIA.xml:S2:2066:2	of	IN	O	O
Prolia	PROLIA.xml:S2:2069:6	prolia	NNP	O	O
.	PROLIA.xml:S2:2075:1	.	.	O	O

Pre	PROLIA.xml:S2:2077:3	pre	NNP	O	O
-	PROLIA.xml:S2:2080:1	-	:	O	O
existing	PROLIA.xml:S2:2081:8	exist	VBG	O	O
hypocalcemia	PROLIA.xml:S2:2090:12	hypocalcemia	NN	O	O
must	PROLIA.xml:S2:2103:4	must	MD	O	O
be	PROLIA.xml:S2:2108:2	be	VB	O	O
corrected	PROLIA.xml:S2:2111:9	correct	VBN	O	O
prior	PROLIA.xml:S2:2121:5	prior	RB	O	O
to	PROLIA.xml:S2:2127:2	to	TO	O	O
initiating	PROLIA.xml:S2:2130:10	initi	VBG	O	O
therapy	PROLIA.xml:S2:2141:7	therapi	NN	O	O
with	PROLIA.xml:S2:2149:4	with	IN	O	O
Prolia	PROLIA.xml:S2:2154:6	prolia	NNP	O	O
.	PROLIA.xml:S2:2160:1	.	.	O	O

In	PROLIA.xml:S2:2162:2	In	IN	O	O
patients	PROLIA.xml:S2:2165:8	patient	NNS	O	O
predisposed	PROLIA.xml:S2:2174:11	predispos	VBN	O	O
to	PROLIA.xml:S2:2186:2	to	TO	O	O
hypocalcemia	PROLIA.xml:S2:2189:12	hypocalcemia	VB	O	O
and	PROLIA.xml:S2:2202:3	and	CC	O	O
disturbances	PROLIA.xml:S2:2206:12	disturb	NNS	O	O
of	PROLIA.xml:S2:2219:2	of	IN	O	O
mineral	PROLIA.xml:S2:2222:7	miner	JJ	O	O
metabolism	PROLIA.xml:S2:2230:10	metabol	NN	O	O
(	PROLIA.xml:S2:2241:1	(	(	O	O
e	PROLIA.xml:S2:2242:1	e	NN	O	O
.	PROLIA.xml:S2:2243:1	.	.	O	O
g	PROLIA.xml:S2:2244:1	g	NN	O	O
.	PROLIA.xml:S2:2245:1	.	.	O	O

history	PROLIA.xml:S2:2247:7	histori	NN	O	O
of	PROLIA.xml:S2:2255:2	of	IN	O	O
hypoparathyroidism	PROLIA.xml:S2:2258:18	hypoparathyroid	NN	O	O
,	PROLIA.xml:S2:2276:1	,	,	O	O
thyroid	PROLIA.xml:S2:2278:7	thyroid	NN	O	B-AdverseReaction
surgery	PROLIA.xml:S2:2286:7	surgeri	NN	O	I-AdverseReaction
,	PROLIA.xml:S2:2293:1	,	,	O	O
parathyroid	PROLIA.xml:S2:2295:11	parathyroid	NN	O	O
surgery	PROLIA.xml:S2:2307:7	surgeri	NN	O	O
,	PROLIA.xml:S2:2314:1	,	,	O	O
malabsorption	PROLIA.xml:S2:2316:13	malabsorpt	NN	O	O
syndromes	PROLIA.xml:S2:2330:9	syndrom	NNS	O	O
,	PROLIA.xml:S2:2339:1	,	,	O	O
excision	PROLIA.xml:S2:2341:8	excis	NN	O	O
of	PROLIA.xml:S2:2350:2	of	IN	O	O
small	PROLIA.xml:S2:2353:5	small	JJ	O	O
intestine	PROLIA.xml:S2:2359:9	intestin	NN	O	O
,	PROLIA.xml:S2:2368:1	,	,	O	O
severe	PROLIA.xml:S2:2370:6	sever	JJ	O	O
renal	PROLIA.xml:S2:2377:5	renal	JJ	O	O
impairment	PROLIA.xml:S2:2383:10	impair	NN	O	O
[	PROLIA.xml:S2:2394:1	[	NNP	O	O
creatinine	PROLIA.xml:S2:2395:10	creatinin	NN	O	O
clearance	PROLIA.xml:S2:2406:9	clearanc	NN	O	O
30	PROLIA.xml:S2:2418:2	30	CD	O	O
mL	PROLIA.xml:S2:2421:2	mL	NN	O	O
min	PROLIA.xml:S2:2424:3	min	NN	O	O
]	PROLIA.xml:S2:2427:1	]	NN	O	O
or	PROLIA.xml:S2:2429:2	or	CC	O	O
receiving	PROLIA.xml:S2:2432:9	receiv	VBG	O	O
dialysis	PROLIA.xml:S2:2442:8	dialysi	NN	O	O
)	PROLIA.xml:S2:2450:1	)	)	O	O
,	PROLIA.xml:S2:2451:1	,	,	O	O
clinical	PROLIA.xml:S2:2453:8	clinic	JJ	O	O
monitoring	PROLIA.xml:S2:2462:10	monitor	NN	O	O
of	PROLIA.xml:S2:2473:2	of	IN	O	O
calcium	PROLIA.xml:S2:2476:7	calcium	NN	O	O
and	PROLIA.xml:S2:2484:3	and	CC	O	O
mineral	PROLIA.xml:S2:2488:7	miner	NN	O	O
levels	PROLIA.xml:S2:2496:6	level	NNS	O	O
(	PROLIA.xml:S2:2503:1	(	(	O	O
phosphorus	PROLIA.xml:S2:2504:10	phosphoru	NN	O	O
and	PROLIA.xml:S2:2515:3	and	CC	O	O
magnesium	PROLIA.xml:S2:2519:9	magnesium	NN	O	O
)	PROLIA.xml:S2:2528:1	)	)	O	O
is	PROLIA.xml:S2:2530:2	is	VBZ	O	O
highly	PROLIA.xml:S2:2533:6	highli	RB	O	O
recommended	PROLIA.xml:S2:2540:11	recommend	VBN	O	O
within	PROLIA.xml:S2:2552:6	within	IN	O	O
14	PROLIA.xml:S2:2559:2	14	CD	O	O
days	PROLIA.xml:S2:2562:4	day	NNS	O	O
of	PROLIA.xml:S2:2567:2	of	IN	O	O
Prolia	PROLIA.xml:S2:2570:6	prolia	NNP	O	O
injection	PROLIA.xml:S2:2577:9	inject	NN	O	O
.	PROLIA.xml:S2:2586:1	.	.	O	O

In	PROLIA.xml:S2:2588:2	In	IN	O	O
some	PROLIA.xml:S2:2591:4	some	DT	O	O
postmarketing	PROLIA.xml:S2:2596:13	postmarket	NN	O	O
cases	PROLIA.xml:S2:2610:5	case	NNS	O	O
,	PROLIA.xml:S2:2615:1	,	,	O	O
hypocalcemia	PROLIA.xml:S2:2617:12	hypocalcemia	NN	B-AdverseReaction	B-AdverseReaction
persisted	PROLIA.xml:S2:2630:9	persist	VBD	O	O
for	PROLIA.xml:S2:2640:3	for	IN	O	O
weeks	PROLIA.xml:S2:2644:5	week	NNS	O	O
or	PROLIA.xml:S2:2650:2	or	CC	O	O
months	PROLIA.xml:S2:2653:6	month	NNS	O	O
and	PROLIA.xml:S2:2660:3	and	CC	O	O
required	PROLIA.xml:S2:2664:8	requir	VBN	O	O
frequent	PROLIA.xml:S2:2673:8	frequent	JJ	O	O
monitoring	PROLIA.xml:S2:2682:10	monitor	NN	O	O
and	PROLIA.xml:S2:2693:3	and	CC	O	O
intravenous	PROLIA.xml:S2:2697:11	intraven	JJ	O	O
and	PROLIA.xml:S2:2709:3	and	CC	O	O
or	PROLIA.xml:S2:2713:2	or	CC	O	O
oral	PROLIA.xml:S2:2716:4	oral	JJ	O	O
calcium	PROLIA.xml:S2:2721:7	calcium	NN	O	O
replacement	PROLIA.xml:S2:2729:11	replac	NN	O	O
,	PROLIA.xml:S2:2740:1	,	,	O	O
with	PROLIA.xml:S2:2742:4	with	IN	O	O
or	PROLIA.xml:S2:2747:2	or	CC	O	O
without	PROLIA.xml:S2:2750:7	without	IN	O	O
vitamin	PROLIA.xml:S2:2758:7	vitamin	JJ	O	O
D.	PROLIA.xml:S2:2766:2	D.	NNP	O	O

Hypocalcemia	PROLIA.xml:S2:2775:12	hypocalcemia	NNP	B-AdverseReaction	O
following	PROLIA.xml:S2:2788:9	follow	VBG	O	O
Prolia	PROLIA.xml:S2:2798:6	prolia	NNP	O	O
administration	PROLIA.xml:S2:2805:14	administr	NN	O	O
is	PROLIA.xml:S2:2820:2	is	VBZ	O	O
a	PROLIA.xml:S2:2823:1	a	DT	O	O
significant	PROLIA.xml:S2:2825:11	signific	JJ	O	O
risk	PROLIA.xml:S2:2837:4	risk	NN	O	O
in	PROLIA.xml:S2:2842:2	in	IN	O	O
patients	PROLIA.xml:S2:2845:8	patient	NNS	O	O
with	PROLIA.xml:S2:2854:4	with	IN	O	O
severe	PROLIA.xml:S2:2859:6	sever	JJ	O	O
renal	PROLIA.xml:S2:2866:5	renal	JJ	O	O
impairment	PROLIA.xml:S2:2872:10	impair	NN	O	O
[	PROLIA.xml:S2:2883:1	[	NNP	O	O
creatinine	PROLIA.xml:S2:2884:10	creatinin	NN	O	O
clearance	PROLIA.xml:S2:2895:9	clearanc	NN	O	O
30	PROLIA.xml:S2:2907:2	30	CD	O	O
mL	PROLIA.xml:S2:2910:2	mL	NN	O	O
min	PROLIA.xml:S2:2913:3	min	NN	O	O
]	PROLIA.xml:S2:2916:1	]	NN	O	O
or	PROLIA.xml:S2:2918:2	or	CC	O	O
receiving	PROLIA.xml:S2:2921:9	receiv	VBG	O	O
dialysis	PROLIA.xml:S2:2931:8	dialysi	NN	O	O
.	PROLIA.xml:S2:2939:1	.	.	O	O

These	PROLIA.xml:S2:2941:5	these	DT	O	O
patients	PROLIA.xml:S2:2947:8	patient	NNS	O	O
may	PROLIA.xml:S2:2956:3	may	MD	O	O
also	PROLIA.xml:S2:2960:4	also	RB	O	O
develop	PROLIA.xml:S2:2965:7	develop	VB	O	O
marked	PROLIA.xml:S2:2973:6	mark	JJ	O	O
elevations	PROLIA.xml:S2:2980:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
of	PROLIA.xml:S2:2991:2	of	IN	I-AdverseReaction	I-AdverseReaction
serum	PROLIA.xml:S2:2994:5	serum	NN	I-AdverseReaction	I-AdverseReaction
parathyroid	PROLIA.xml:S2:3000:11	parathyroid	NN	I-AdverseReaction	I-AdverseReaction
hormone	PROLIA.xml:S2:3012:7	hormon	NN	I-AdverseReaction	I-AdverseReaction
(	PROLIA.xml:S2:3020:1	(	(	O	O
PTH	PROLIA.xml:S2:3021:3	pth	NNP	O	O
)	PROLIA.xml:S2:3024:1	)	)	O	O
.	PROLIA.xml:S2:3025:1	.	.	O	O

Instruct	PROLIA.xml:S2:3029:8	instruct	NNP	O	O
all	PROLIA.xml:S2:3038:3	all	DT	O	O
patients	PROLIA.xml:S2:3042:8	patient	NNS	O	O
with	PROLIA.xml:S2:3051:4	with	IN	O	O
severe	PROLIA.xml:S2:3056:6	sever	JJ	O	O
renal	PROLIA.xml:S2:3063:5	renal	JJ	O	O
impairment	PROLIA.xml:S2:3069:10	impair	NN	O	O
,	PROLIA.xml:S2:3079:1	,	,	O	O
including	PROLIA.xml:S2:3081:9	includ	VBG	O	O
those	PROLIA.xml:S2:3091:5	those	DT	O	O
receiving	PROLIA.xml:S2:3097:9	receiv	VBG	O	O
dialysis	PROLIA.xml:S2:3107:8	dialysi	NN	O	O
,	PROLIA.xml:S2:3115:1	,	,	O	O
about	PROLIA.xml:S2:3117:5	about	IN	O	O
the	PROLIA.xml:S2:3123:3	the	DT	O	O
symptoms	PROLIA.xml:S2:3127:8	symptom	NNS	O	O
of	PROLIA.xml:S2:3136:2	of	IN	O	O
hypocalcemia	PROLIA.xml:S2:3139:12	hypocalcemia	NN	O	O
and	PROLIA.xml:S2:3152:3	and	CC	O	O
the	PROLIA.xml:S2:3156:3	the	DT	O	O
importance	PROLIA.xml:S2:3160:10	import	NN	O	O
of	PROLIA.xml:S2:3171:2	of	IN	O	O
maintaining	PROLIA.xml:S2:3174:11	maintain	VBG	O	O
calcium	PROLIA.xml:S2:3186:7	calcium	NN	O	O
levels	PROLIA.xml:S2:3194:6	level	NNS	O	O
with	PROLIA.xml:S2:3201:4	with	IN	O	O
adequate	PROLIA.xml:S2:3206:8	adequ	JJ	O	O
calcium	PROLIA.xml:S2:3215:7	calcium	NN	O	O
and	PROLIA.xml:S2:3223:3	and	CC	O	O
vitamin	PROLIA.xml:S2:3227:7	vitamin	NN	O	O
D	PROLIA.xml:S2:3235:1	D	NNP	O	O
supplementation	PROLIA.xml:S2:3237:15	supplement	NN	O	O
.	PROLIA.xml:S2:3252:1	.	.	O	O

Adequately	PROLIA.xml:S2:3258:10	adequ	RB	O	O
supplement	PROLIA.xml:S2:3269:10	supplement	JJ	O	O
all	PROLIA.xml:S2:3280:3	all	DT	O	O
patients	PROLIA.xml:S2:3284:8	patient	NNS	O	O
with	PROLIA.xml:S2:3293:4	with	IN	O	O
calcium	PROLIA.xml:S2:3298:7	calcium	NN	O	O
and	PROLIA.xml:S2:3306:3	and	CC	O	O
vitamin	PROLIA.xml:S2:3310:7	vitamin	NN	O	O
D	PROLIA.xml:S2:3318:1	D	NNP	O	O
[	PROLIA.xml:S2:3320:1	[	NNP	O	O
see	PROLIA.xml:S2:3321:3	see	VBP	O	O
Dosage	PROLIA.xml:S2:3325:6	dosag	NNP	O	O
and	PROLIA.xml:S2:3332:3	and	CC	O	O
Administration	PROLIA.xml:S2:3336:14	administr	NNP	O	O
(	PROLIA.xml:S2:3351:1	(	(	O	O
2.1	PROLIA.xml:S2:3354:3	2.1	CD	O	O
)	PROLIA.xml:S2:3359:1	)	)	O	O
,	PROLIA.xml:S2:3360:1	,	,	O	O
Contraindications	PROLIA.xml:S2:3362:17	contraind	NNP	O	O
(	PROLIA.xml:S2:3380:1	(	(	O	O
4.1	PROLIA.xml:S2:3383:3	4.1	CD	O	O
)	PROLIA.xml:S2:3388:1	)	)	O	O
,	PROLIA.xml:S2:3389:1	,	,	O	O
Adverse	PROLIA.xml:S2:3391:7	advers	JJ	O	O
Reactions	PROLIA.xml:S2:3399:9	reaction	NNP	O	O
(	PROLIA.xml:S2:3409:1	(	(	O	O
6.1	PROLIA.xml:S2:3412:3	6.1	CD	O	O
)	PROLIA.xml:S2:3417:1	)	)	O	O
,	PROLIA.xml:S2:3418:1	,	,	O	O
and	PROLIA.xml:S2:3420:3	and	CC	O	O
Patient	PROLIA.xml:S2:3424:7	patient	NNP	O	O
Counseling	PROLIA.xml:S2:3432:10	counsel	NNP	O	O
Information	PROLIA.xml:S2:3443:11	inform	NNP	O	O
(	PROLIA.xml:S2:3455:1	(	(	O	O
17.3	PROLIA.xml:S2:3458:4	17.3	CD	O	O
)]	PROLIA.xml:S2:3464:2	)]	NN	O	O
.	PROLIA.xml:S2:3468:1	.	.	O	O

5.4	PROLIA.xml:S2:3477:3	5.4	CD	O	O
Osteonecrosis	PROLIA.xml:S2:3481:13	osteonecrosi	NN	O	O
of	PROLIA.xml:S2:3495:2	of	IN	O	O
the	PROLIA.xml:S2:3498:3	the	DT	O	O
Jaw	PROLIA.xml:S2:3502:3	jaw	NNP	O	O

Osteonecrosis	PROLIA.xml:S2:3512:13	osteonecrosi	NN	O	B-AdverseReaction
of	PROLIA.xml:S2:3526:2	of	IN	O	I-AdverseReaction
the	PROLIA.xml:S2:3529:3	the	DT	O	I-AdverseReaction
jaw	PROLIA.xml:S2:3533:3	jaw	NN	O	I-AdverseReaction
(	PROLIA.xml:S2:3537:1	(	(	O	O
ONJ	PROLIA.xml:S2:3538:3	onj	NNP	O	B-AdverseReaction
)	PROLIA.xml:S2:3541:1	)	)	O	O
,	PROLIA.xml:S2:3542:1	,	,	O	O
which	PROLIA.xml:S2:3544:5	which	WDT	O	O
can	PROLIA.xml:S2:3550:3	can	MD	O	O
occur	PROLIA.xml:S2:3554:5	occur	VB	O	O
spontaneously	PROLIA.xml:S2:3560:13	spontan	RB	O	O
,	PROLIA.xml:S2:3573:1	,	,	O	O
is	PROLIA.xml:S2:3575:2	is	VBZ	O	O
generally	PROLIA.xml:S2:3578:9	gener	RB	O	O
associated	PROLIA.xml:S2:3588:10	associ	VBN	O	O
with	PROLIA.xml:S2:3599:4	with	IN	O	O
tooth	PROLIA.xml:S2:3604:5	tooth	DT	O	O
extraction	PROLIA.xml:S2:3610:10	extract	NN	O	O
and	PROLIA.xml:S2:3621:3	and	CC	O	O
or	PROLIA.xml:S2:3625:2	or	CC	O	O
local	PROLIA.xml:S2:3628:5	local	JJ	O	B-AdverseReaction
infection	PROLIA.xml:S2:3634:9	infect	NN	O	I-AdverseReaction
with	PROLIA.xml:S2:3644:4	with	IN	O	O
delayed	PROLIA.xml:S2:3649:7	delay	JJ	O	O
healing	PROLIA.xml:S2:3657:7	heal	NN	O	O
.	PROLIA.xml:S2:3664:1	.	.	O	O

ONJ	PROLIA.xml:S2:3666:3	onj	NNP	B-AdverseReaction	B-AdverseReaction
has	PROLIA.xml:S2:3670:3	ha	VBZ	O	O
been	PROLIA.xml:S2:3674:4	been	VBN	O	O
reported	PROLIA.xml:S2:3679:8	report	VBN	O	O
in	PROLIA.xml:S2:3688:2	in	IN	O	O
patients	PROLIA.xml:S2:3691:8	patient	NNS	O	O
receiving	PROLIA.xml:S2:3700:9	receiv	VBG	O	O
denosumab	PROLIA.xml:S2:3710:9	denosumab	JJ	O	O
[	PROLIA.xml:S2:3720:1	[	NNP	O	O
see	PROLIA.xml:S2:3721:3	see	VBP	O	O
Adverse	PROLIA.xml:S2:3725:7	advers	JJ	O	O
Reactions	PROLIA.xml:S2:3733:9	reaction	NNP	O	O
(	PROLIA.xml:S2:3743:1	(	(	O	O
6.1	PROLIA.xml:S2:3746:3	6.1	CD	O	O
)]	PROLIA.xml:S2:3751:2	)]	NN	O	O
.	PROLIA.xml:S2:3753:1	.	.	O	O

A	PROLIA.xml:S2:3756:1	A	DT	O	O
routine	PROLIA.xml:S2:3758:7	routin	JJ	O	O
oral	PROLIA.xml:S2:3766:4	oral	JJ	O	O
exam	PROLIA.xml:S2:3771:4	exam	NN	O	O
should	PROLIA.xml:S2:3776:6	should	MD	O	O
be	PROLIA.xml:S2:3783:2	be	VB	O	O
performed	PROLIA.xml:S2:3786:9	perform	VBN	O	O
by	PROLIA.xml:S2:3796:2	by	IN	O	O
the	PROLIA.xml:S2:3799:3	the	DT	O	O
prescriber	PROLIA.xml:S2:3803:10	prescrib	NN	O	O
prior	PROLIA.xml:S2:3814:5	prior	RB	O	O
to	PROLIA.xml:S2:3820:2	to	TO	O	O
initiation	PROLIA.xml:S2:3823:10	initi	NN	O	O
of	PROLIA.xml:S2:3834:2	of	IN	O	O
Prolia	PROLIA.xml:S2:3837:6	prolia	NNP	O	O
treatment	PROLIA.xml:S2:3844:9	treatment	NN	O	O
.	PROLIA.xml:S2:3853:1	.	.	O	O

A	PROLIA.xml:S2:3855:1	A	DT	O	O
dental	PROLIA.xml:S2:3857:6	dental	JJ	O	O
examination	PROLIA.xml:S2:3864:11	examin	NN	O	O
with	PROLIA.xml:S2:3876:4	with	IN	O	O
appropriate	PROLIA.xml:S2:3881:11	appropri	JJ	O	O
preventive	PROLIA.xml:S2:3893:10	prevent	JJ	O	O
dentistry	PROLIA.xml:S2:3904:9	dentistri	NN	O	O
is	PROLIA.xml:S2:3914:2	is	VBZ	O	O
recommended	PROLIA.xml:S2:3917:11	recommend	VBN	O	O
prior	PROLIA.xml:S2:3929:5	prior	RB	O	O
to	PROLIA.xml:S2:3935:2	to	TO	O	O
treatment	PROLIA.xml:S2:3938:9	treatment	NN	O	O
with	PROLIA.xml:S2:3948:4	with	IN	O	O
Prolia	PROLIA.xml:S2:3953:6	prolia	NNP	O	O
in	PROLIA.xml:S2:3960:2	in	IN	O	O
patients	PROLIA.xml:S2:3963:8	patient	NNS	O	O
with	PROLIA.xml:S2:3972:4	with	IN	O	O
risk	PROLIA.xml:S2:3977:4	risk	NN	O	O
factors	PROLIA.xml:S2:3982:7	factor	NNS	O	O
for	PROLIA.xml:S2:3990:3	for	IN	O	O
ONJ	PROLIA.xml:S2:3994:3	onj	NNP	O	O
such	PROLIA.xml:S2:3998:4	such	JJ	O	O
as	PROLIA.xml:S2:4003:2	as	IN	O	O
invasive	PROLIA.xml:S2:4006:8	invas	JJ	O	O
dental	PROLIA.xml:S2:4015:6	dental	NN	O	O
procedures	PROLIA.xml:S2:4022:10	procedur	NNS	O	O
(	PROLIA.xml:S2:4033:1	(	(	O	O
e	PROLIA.xml:S2:4034:1	e	NN	O	O
.	PROLIA.xml:S2:4035:1	.	.	O	O
g	PROLIA.xml:S2:4036:1	g	NN	O	O
.	PROLIA.xml:S2:4037:1	.	.	O	O

tooth	PROLIA.xml:S2:4039:5	tooth	DT	O	O
extraction	PROLIA.xml:S2:4045:10	extract	NN	O	O
,	PROLIA.xml:S2:4055:1	,	,	O	O
dental	PROLIA.xml:S2:4057:6	dental	JJ	O	O
implants	PROLIA.xml:S2:4064:8	implant	NNS	O	O
,	PROLIA.xml:S2:4072:1	,	,	O	O
oral	PROLIA.xml:S2:4074:4	oral	JJ	O	O
surgery	PROLIA.xml:S2:4079:7	surgeri	NN	O	O
)	PROLIA.xml:S2:4086:1	)	)	O	O
,	PROLIA.xml:S2:4087:1	,	,	O	O
diagnosis	PROLIA.xml:S2:4089:9	diagnosi	NN	O	O
of	PROLIA.xml:S2:4099:2	of	IN	O	O
cancer	PROLIA.xml:S2:4102:6	cancer	NN	O	O
,	PROLIA.xml:S2:4108:1	,	,	O	O
concomitant	PROLIA.xml:S2:4110:11	concomit	JJ	O	O
therapies	PROLIA.xml:S2:4122:9	therapi	NNS	O	O
(	PROLIA.xml:S2:4132:1	(	(	O	O
e	PROLIA.xml:S2:4133:1	e	NN	O	O
.	PROLIA.xml:S2:4134:1	.	.	O	O
g	PROLIA.xml:S2:4135:1	g	NN	O	O
.	PROLIA.xml:S2:4136:1	.	.	O	O

chemotherapy	PROLIA.xml:S2:4138:12	chemotherapi	NN	O	O
,	PROLIA.xml:S2:4150:1	,	,	O	O
corticosteroids	PROLIA.xml:S2:4152:15	corticosteroid	NNS	O	O
,	PROLIA.xml:S2:4167:1	,	,	O	O
angiogenesis	PROLIA.xml:S2:4169:12	angiogenesi	NN	O	O
inhibitors	PROLIA.xml:S2:4182:10	inhibitor	NNS	O	O
)	PROLIA.xml:S2:4192:1	)	)	O	O
,	PROLIA.xml:S2:4193:1	,	,	O	O
poor	PROLIA.xml:S2:4195:4	poor	JJ	O	B-AdverseReaction
oral	PROLIA.xml:S2:4200:4	oral	JJ	O	I-AdverseReaction
hygiene	PROLIA.xml:S2:4205:7	hygien	NN	O	I-AdverseReaction
,	PROLIA.xml:S2:4212:1	,	,	O	O
and	PROLIA.xml:S2:4214:3	and	CC	O	O
co	PROLIA.xml:S2:4218:2	co	SYM	O	O
-	PROLIA.xml:S2:4220:1	-	:	O	O
morbid	PROLIA.xml:S2:4221:6	morbid	NN	O	O
disorders	PROLIA.xml:S2:4228:9	disord	NNS	O	O
(	PROLIA.xml:S2:4238:1	(	(	O	O
e	PROLIA.xml:S2:4239:1	e	NN	O	O
.	PROLIA.xml:S2:4240:1	.	.	O	O
g	PROLIA.xml:S2:4241:1	g	NN	O	O
.	PROLIA.xml:S2:4242:1	.	.	O	O

periodontal	PROLIA.xml:S2:4244:11	periodont	NN	O	O
and	PROLIA.xml:S2:4256:3	and	CC	O	O
or	PROLIA.xml:S2:4260:2	or	CC	O	O
other	PROLIA.xml:S2:4263:5	other	JJ	O	O
pre	PROLIA.xml:S2:4269:3	pre	JJ	O	O
-	PROLIA.xml:S2:4272:1	-	:	O	O
existing	PROLIA.xml:S2:4273:8	exist	VBG	O	O
dental	PROLIA.xml:S2:4282:6	dental	JJ	O	O
disease	PROLIA.xml:S2:4289:7	diseas	NN	O	O
,	PROLIA.xml:S2:4296:1	,	,	O	O
anemia	PROLIA.xml:S2:4298:6	anemia	NN	O	B-AdverseReaction
,	PROLIA.xml:S2:4304:1	,	,	O	O
coagulopathy	PROLIA.xml:S2:4306:12	coagulopathi	NN	O	B-AdverseReaction
,	PROLIA.xml:S2:4318:1	,	,	O	O
infection	PROLIA.xml:S2:4320:9	infect	NN	O	B-AdverseReaction
,	PROLIA.xml:S2:4329:1	,	,	O	O
ill	PROLIA.xml:S2:4331:3	ill	VB	O	O
-	PROLIA.xml:S2:4334:1	-	:	O	O
fitting	PROLIA.xml:S2:4335:7	fit	NN	O	O
dentures	PROLIA.xml:S2:4343:8	dentur	NNS	O	O
)	PROLIA.xml:S2:4351:1	)	)	O	O
.	PROLIA.xml:S2:4352:1	.	.	O	O

Good	PROLIA.xml:S2:4354:4	good	JJ	O	O
oral	PROLIA.xml:S2:4359:4	oral	JJ	O	O
hygiene	PROLIA.xml:S2:4364:7	hygien	NN	O	O
practices	PROLIA.xml:S2:4372:9	practic	NNS	O	O
should	PROLIA.xml:S2:4382:6	should	MD	O	O
be	PROLIA.xml:S2:4389:2	be	VB	O	O
maintained	PROLIA.xml:S2:4392:10	maintain	VBN	O	O
during	PROLIA.xml:S2:4403:6	dure	IN	O	O
treatment	PROLIA.xml:S2:4410:9	treatment	NN	O	O
with	PROLIA.xml:S2:4420:4	with	IN	O	O
Prolia	PROLIA.xml:S2:4425:6	prolia	NNP	O	O
.	PROLIA.xml:S2:4431:1	.	.	O	O

Concomitant	PROLIA.xml:S2:4433:11	concomit	JJ	O	O
administration	PROLIA.xml:S2:4445:14	administr	NN	O	O
of	PROLIA.xml:S2:4460:2	of	IN	O	O
drugs	PROLIA.xml:S2:4463:5	drug	NNS	O	O
associated	PROLIA.xml:S2:4469:10	associ	VBN	O	O
with	PROLIA.xml:S2:4480:4	with	IN	O	O
ONJ	PROLIA.xml:S2:4485:3	onj	NNP	O	O
may	PROLIA.xml:S2:4489:3	may	MD	O	O
increase	PROLIA.xml:S2:4493:8	increas	VB	O	O
the	PROLIA.xml:S2:4502:3	the	DT	O	O
risk	PROLIA.xml:S2:4506:4	risk	NN	O	O
of	PROLIA.xml:S2:4511:2	of	IN	O	O
developing	PROLIA.xml:S2:4514:10	develop	VBG	O	O
ONJ	PROLIA.xml:S2:4525:3	onj	NNP	O	O
.	PROLIA.xml:S2:4528:1	.	.	O	O

For	PROLIA.xml:S2:4536:3	for	IN	O	O
patients	PROLIA.xml:S2:4540:8	patient	NNS	O	O
requiring	PROLIA.xml:S2:4549:9	requir	VBG	O	O
invasive	PROLIA.xml:S2:4559:8	invas	JJ	O	O
dental	PROLIA.xml:S2:4568:6	dental	NN	O	O
procedures	PROLIA.xml:S2:4575:10	procedur	NNS	O	O
,	PROLIA.xml:S2:4585:1	,	,	O	O
clinical	PROLIA.xml:S2:4587:8	clinic	JJ	O	O
judgment	PROLIA.xml:S2:4596:8	judgment	NN	O	O
of	PROLIA.xml:S2:4605:2	of	IN	O	O
the	PROLIA.xml:S2:4608:3	the	DT	O	O
treating	PROLIA.xml:S2:4612:8	treat	NN	O	O
physician	PROLIA.xml:S2:4621:9	physician	NN	O	O
and	PROLIA.xml:S2:4631:3	and	CC	O	O
or	PROLIA.xml:S2:4635:2	or	CC	O	O
oral	PROLIA.xml:S2:4638:4	oral	JJ	O	O
surgeon	PROLIA.xml:S2:4643:7	surgeon	NN	O	O
should	PROLIA.xml:S2:4651:6	should	MD	O	O
guide	PROLIA.xml:S2:4658:5	guid	VB	O	O
the	PROLIA.xml:S2:4664:3	the	DT	O	O
management	PROLIA.xml:S2:4668:10	manag	NN	O	O
plan	PROLIA.xml:S2:4679:4	plan	NN	O	O
of	PROLIA.xml:S2:4684:2	of	IN	O	O
each	PROLIA.xml:S2:4687:4	each	DT	O	O
patient	PROLIA.xml:S2:4692:7	patient	NN	O	O
based	PROLIA.xml:S2:4700:5	base	VBN	O	O
on	PROLIA.xml:S2:4706:2	on	IN	O	O
individual	PROLIA.xml:S2:4709:10	individu	JJ	O	O
benefit	PROLIA.xml:S2:4720:7	benefit	NN	O	O
-	PROLIA.xml:S2:4727:1	-	:	O	O
risk	PROLIA.xml:S2:4728:4	risk	NN	O	O
assessment	PROLIA.xml:S2:4733:10	assess	NN	O	O
.	PROLIA.xml:S2:4743:1	.	.	O	O

Patients	PROLIA.xml:S2:4749:8	patient	NNS	O	O
who	PROLIA.xml:S2:4758:3	who	WP	O	O
are	PROLIA.xml:S2:4762:3	are	VBP	O	O
suspected	PROLIA.xml:S2:4766:9	suspect	VBN	O	O
of	PROLIA.xml:S2:4776:2	of	IN	O	O
having	PROLIA.xml:S2:4779:6	have	VBG	O	O
or	PROLIA.xml:S2:4786:2	or	CC	O	O
who	PROLIA.xml:S2:4789:3	who	WP	O	O
develop	PROLIA.xml:S2:4793:7	develop	VBP	O	O
ONJ	PROLIA.xml:S2:4801:3	onj	NNP	O	O
while	PROLIA.xml:S2:4805:5	while	IN	O	O
on	PROLIA.xml:S2:4811:2	on	IN	O	O
Prolia	PROLIA.xml:S2:4814:6	prolia	NNP	O	O
should	PROLIA.xml:S2:4821:6	should	MD	O	O
receive	PROLIA.xml:S2:4828:7	receiv	VB	O	O
care	PROLIA.xml:S2:4836:4	care	NN	O	O
by	PROLIA.xml:S2:4841:2	by	IN	O	O
a	PROLIA.xml:S2:4844:1	a	DT	O	O
dentist	PROLIA.xml:S2:4846:7	dentist	NN	O	O
or	PROLIA.xml:S2:4854:2	or	CC	O	O
an	PROLIA.xml:S2:4857:2	an	DT	O	O
oral	PROLIA.xml:S2:4860:4	oral	JJ	O	O
surgeon	PROLIA.xml:S2:4865:7	surgeon	NN	O	O
.	PROLIA.xml:S2:4872:1	.	.	O	O

In	PROLIA.xml:S2:4874:2	In	IN	O	O
these	PROLIA.xml:S2:4877:5	these	DT	O	O
patients	PROLIA.xml:S2:4883:8	patient	NNS	O	O
,	PROLIA.xml:S2:4891:1	,	,	O	O
extensive	PROLIA.xml:S2:4893:9	extens	JJ	O	O
dental	PROLIA.xml:S2:4903:6	dental	NN	O	O
surgery	PROLIA.xml:S2:4910:7	surgeri	NN	O	O
to	PROLIA.xml:S2:4918:2	to	TO	O	O
treat	PROLIA.xml:S2:4921:5	treat	VB	O	O
ONJ	PROLIA.xml:S2:4927:3	onj	NNP	O	O
may	PROLIA.xml:S2:4931:3	may	MD	O	O
exacerbate	PROLIA.xml:S2:4935:10	exacerb	VB	O	O
the	PROLIA.xml:S2:4946:3	the	DT	O	O
condition	PROLIA.xml:S2:4950:9	condit	NN	O	O
.	PROLIA.xml:S2:4959:1	.	.	O	O

Discontinuation	PROLIA.xml:S2:4961:15	discontinu	NN	O	O
of	PROLIA.xml:S2:4977:2	of	IN	O	O
Prolia	PROLIA.xml:S2:4980:6	prolia	NNP	O	O
therapy	PROLIA.xml:S2:4987:7	therapi	NN	O	O
should	PROLIA.xml:S2:4995:6	should	MD	O	O
be	PROLIA.xml:S2:5002:2	be	VB	O	O
considered	PROLIA.xml:S2:5005:10	consid	VBN	O	O
based	PROLIA.xml:S2:5016:5	base	VBN	O	O
on	PROLIA.xml:S2:5022:2	on	IN	O	O
individual	PROLIA.xml:S2:5025:10	individu	JJ	O	O
benefit	PROLIA.xml:S2:5036:7	benefit	NN	O	O
-	PROLIA.xml:S2:5043:1	-	:	O	O
risk	PROLIA.xml:S2:5044:4	risk	NN	O	O
assessment	PROLIA.xml:S2:5049:10	assess	NN	O	O
.	PROLIA.xml:S2:5059:1	.	.	O	O

5.5	PROLIA.xml:S2:5068:3	5.5	CD	O	O
Atypical	PROLIA.xml:S2:5072:8	atyp	NNP	O	O
Subtrochanteric	PROLIA.xml:S2:5081:15	subtrochanter	NNP	O	O
and	PROLIA.xml:S2:5097:3	and	CC	O	O
Diaphyseal	PROLIA.xml:S2:5101:10	diaphys	NNP	O	O
Femoral	PROLIA.xml:S2:5112:7	femor	NNP	B-AdverseReaction	O
Fractures	PROLIA.xml:S2:5120:9	fractur	NNP	O	O

Atypical	PROLIA.xml:S2:5135:8	atyp	NNP	I-AdverseReaction	O
low	PROLIA.xml:S2:5144:3	low	JJ	O	O
-	PROLIA.xml:S2:5147:1	-	:	O	O
energy	PROLIA.xml:S2:5148:6	energi	NN	O	O
or	PROLIA.xml:S2:5155:2	or	CC	O	O
low	PROLIA.xml:S2:5158:3	low	JJ	O	O
trauma	PROLIA.xml:S2:5162:6	trauma	NN	O	O
fractures	PROLIA.xml:S2:5169:9	fractur	NNS	I-AdverseReaction	B-AdverseReaction
of	PROLIA.xml:S2:5179:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	PROLIA.xml:S2:5182:3	the	DT	I-AdverseReaction	I-AdverseReaction
shaft	PROLIA.xml:S2:5186:5	shaft	NN	I-AdverseReaction	I-AdverseReaction
have	PROLIA.xml:S2:5192:4	have	VBP	O	O
been	PROLIA.xml:S2:5197:4	been	VBN	O	O
reported	PROLIA.xml:S2:5202:8	report	VBN	O	O
in	PROLIA.xml:S2:5211:2	in	IN	O	O
patients	PROLIA.xml:S2:5214:8	patient	NNS	O	O
receiving	PROLIA.xml:S2:5223:9	receiv	VBG	O	O
Prolia	PROLIA.xml:S2:5233:6	prolia	NNP	O	O
[	PROLIA.xml:S2:5240:1	[	NNP	O	O
see	PROLIA.xml:S2:5241:3	see	VBP	O	O
Adverse	PROLIA.xml:S2:5245:7	advers	JJ	O	O
Reactions	PROLIA.xml:S2:5253:9	reaction	NNP	O	O
(	PROLIA.xml:S2:5263:1	(	(	O	O
6.1	PROLIA.xml:S2:5266:3	6.1	CD	O	O
)]	PROLIA.xml:S2:5271:2	)]	NN	O	O
.	PROLIA.xml:S2:5275:1	.	.	O	O

These	PROLIA.xml:S2:5277:5	these	DT	O	O
fractures	PROLIA.xml:S2:5283:9	fractur	NNS	B-AdverseReaction	B-AdverseReaction
can	PROLIA.xml:S2:5293:3	can	MD	O	O
occur	PROLIA.xml:S2:5297:5	occur	VB	O	O
anywhere	PROLIA.xml:S2:5303:8	anywher	RB	O	O
in	PROLIA.xml:S2:5312:2	in	IN	I-AdverseReaction	O
the	PROLIA.xml:S2:5315:3	the	DT	I-AdverseReaction	O
femoral	PROLIA.xml:S2:5319:7	femor	JJ	I-AdverseReaction	O
shaft	PROLIA.xml:S2:5327:5	shaft	NN	I-AdverseReaction	O
from	PROLIA.xml:S2:5333:4	from	IN	O	O
just	PROLIA.xml:S2:5338:4	just	RB	O	O
below	PROLIA.xml:S2:5343:5	below	IN	O	O
the	PROLIA.xml:S2:5349:3	the	DT	O	O
lesser	PROLIA.xml:S2:5353:6	lesser	JJR	O	O
trochanter	PROLIA.xml:S2:5360:10	trochant	NN	O	O
to	PROLIA.xml:S2:5371:2	to	TO	O	O
above	PROLIA.xml:S2:5374:5	abov	VB	O	O
the	PROLIA.xml:S2:5380:3	the	DT	O	O
supracondylar	PROLIA.xml:S2:5384:13	supracondylar	JJ	O	O
flare	PROLIA.xml:S2:5398:5	flare	NN	O	O
and	PROLIA.xml:S2:5404:3	and	CC	O	O
are	PROLIA.xml:S2:5408:3	are	VBP	O	O
transverse	PROLIA.xml:S2:5412:10	transvers	JJ	O	O
or	PROLIA.xml:S2:5423:2	or	CC	O	O
short	PROLIA.xml:S2:5426:5	short	JJ	O	O
oblique	PROLIA.xml:S2:5432:7	obliqu	NN	O	O
in	PROLIA.xml:S2:5440:2	in	IN	O	O
orientation	PROLIA.xml:S2:5443:11	orient	NN	O	O
without	PROLIA.xml:S2:5455:7	without	IN	O	O
evidence	PROLIA.xml:S2:5463:8	evid	NN	O	O
of	PROLIA.xml:S2:5472:2	of	IN	O	O
comminution	PROLIA.xml:S2:5475:11	comminut	NN	O	O
.	PROLIA.xml:S2:5486:1	.	.	O	O

Causality	PROLIA.xml:S2:5488:9	causal	NNP	O	O
has	PROLIA.xml:S2:5498:3	ha	VBZ	O	O
not	PROLIA.xml:S2:5502:3	not	RB	O	O
been	PROLIA.xml:S2:5506:4	been	VBN	O	O
established	PROLIA.xml:S2:5511:11	establish	VBN	O	O
as	PROLIA.xml:S2:5523:2	as	IN	O	O
these	PROLIA.xml:S2:5526:5	these	DT	O	O
fractures	PROLIA.xml:S2:5532:9	fractur	NNS	O	B-AdverseReaction
also	PROLIA.xml:S2:5542:4	also	RB	O	O
occur	PROLIA.xml:S2:5547:5	occur	VBP	O	O
in	PROLIA.xml:S2:5553:2	in	IN	O	O
osteoporotic	PROLIA.xml:S2:5556:12	osteoporot	JJ	O	O
patients	PROLIA.xml:S2:5569:8	patient	NNS	O	O
who	PROLIA.xml:S2:5578:3	who	WP	O	O
have	PROLIA.xml:S2:5582:4	have	VBP	O	O
not	PROLIA.xml:S2:5587:3	not	RB	O	O
been	PROLIA.xml:S2:5591:4	been	VBN	O	O
treated	PROLIA.xml:S2:5596:7	treat	VBN	O	O
with	PROLIA.xml:S2:5604:4	with	IN	O	O
anti	PROLIA.xml:S2:5609:4	anti	JJ	O	O
-	PROLIA.xml:S2:5613:1	-	:	O	O
resorptive	PROLIA.xml:S2:5614:10	resorpt	JJ	O	O
agents	PROLIA.xml:S2:5625:6	agent	NNS	O	O
.	PROLIA.xml:S2:5631:1	.	.	O	O

Atypical	PROLIA.xml:S2:5637:8	atyp	JJ	B-AdverseReaction	O
femoral	PROLIA.xml:S2:5646:7	femor	JJ	I-AdverseReaction	O
fractures	PROLIA.xml:S2:5654:9	fractur	NNS	I-AdverseReaction	O
most	PROLIA.xml:S2:5664:4	most	RBS	O	O
commonly	PROLIA.xml:S2:5669:8	commonli	RB	O	O
occur	PROLIA.xml:S2:5678:5	occur	VBP	O	O
with	PROLIA.xml:S2:5684:4	with	IN	O	O
minimal	PROLIA.xml:S2:5689:7	minim	JJ	O	O
or	PROLIA.xml:S2:5697:2	or	CC	O	O
no	PROLIA.xml:S2:5700:2	no	DT	O	O
trauma	PROLIA.xml:S2:5703:6	trauma	NN	O	O
to	PROLIA.xml:S2:5710:2	to	TO	O	O
the	PROLIA.xml:S2:5713:3	the	DT	O	O
affected	PROLIA.xml:S2:5717:8	affect	JJ	O	O
area	PROLIA.xml:S2:5726:4	area	NN	O	O
.	PROLIA.xml:S2:5730:1	.	.	O	O

They	PROLIA.xml:S2:5732:4	they	PRP	O	O
may	PROLIA.xml:S2:5737:3	may	MD	O	O
be	PROLIA.xml:S2:5741:2	be	VB	O	O
bilateral	PROLIA.xml:S2:5744:9	bilater	JJ	O	O
and	PROLIA.xml:S2:5754:3	and	CC	O	O
many	PROLIA.xml:S2:5758:4	mani	JJ	O	O
patients	PROLIA.xml:S2:5763:8	patient	NNS	O	O
report	PROLIA.xml:S2:5772:6	report	VBP	O	O
prodromal	PROLIA.xml:S2:5779:9	prodrom	JJ	O	O
pain	PROLIA.xml:S2:5789:4	pain	NN	O	O
in	PROLIA.xml:S2:5794:2	in	IN	O	O
the	PROLIA.xml:S2:5797:3	the	DT	O	O
affected	PROLIA.xml:S2:5801:8	affect	JJ	O	O
area	PROLIA.xml:S2:5810:4	area	NN	O	O
,	PROLIA.xml:S2:5814:1	,	,	O	O
usually	PROLIA.xml:S2:5816:7	usual	RB	O	O
presenting	PROLIA.xml:S2:5824:10	present	VBG	O	O
as	PROLIA.xml:S2:5835:2	as	IN	O	O
dull	PROLIA.xml:S2:5838:4	dull	NN	O	O
,	PROLIA.xml:S2:5842:1	,	,	O	O
aching	PROLIA.xml:S2:5844:6	ach	VBG	O	O
thigh	PROLIA.xml:S2:5851:5	thigh	JJ	B-AdverseReaction	O
pain	PROLIA.xml:S2:5857:4	pain	NN	I-AdverseReaction	O
,	PROLIA.xml:S2:5861:1	,	,	O	O
weeks	PROLIA.xml:S2:5863:5	week	NNS	O	O
to	PROLIA.xml:S2:5869:2	to	TO	O	O
months	PROLIA.xml:S2:5872:6	month	NNS	O	O
before	PROLIA.xml:S2:5879:6	befor	IN	O	O
a	PROLIA.xml:S2:5886:1	a	DT	O	O
complete	PROLIA.xml:S2:5888:8	complet	JJ	O	O
fracture	PROLIA.xml:S2:5897:8	fractur	NN	O	O
occurs	PROLIA.xml:S2:5906:6	occur	VBZ	O	O
.	PROLIA.xml:S2:5912:1	.	.	O	O

A	PROLIA.xml:S2:5915:1	A	DT	O	O
number	PROLIA.xml:S2:5917:6	number	NN	O	O
of	PROLIA.xml:S2:5924:2	of	IN	O	O
reports	PROLIA.xml:S2:5927:7	report	NNS	O	O
note	PROLIA.xml:S2:5935:4	note	VBP	O	O
that	PROLIA.xml:S2:5940:4	that	IN	O	O
patients	PROLIA.xml:S2:5945:8	patient	NNS	O	O
were	PROLIA.xml:S2:5954:4	were	VBD	O	O
also	PROLIA.xml:S2:5959:4	also	RB	O	O
receiving	PROLIA.xml:S2:5964:9	receiv	VBG	O	O
treatment	PROLIA.xml:S2:5974:9	treatment	NN	O	O
with	PROLIA.xml:S2:5984:4	with	IN	O	O
glucocorticoids	PROLIA.xml:S2:5989:15	glucocorticoid	NNS	O	O
(	PROLIA.xml:S2:6005:1	(	(	O	O
e	PROLIA.xml:S2:6006:1	e	NN	O	O
.	PROLIA.xml:S2:6007:1	.	.	O	O
g	PROLIA.xml:S2:6008:1	g	NN	O	O
.	PROLIA.xml:S2:6009:1	.	.	O	O

prednisone	PROLIA.xml:S2:6011:10	prednison	NN	O	O
)	PROLIA.xml:S2:6021:1	)	)	O	O
at	PROLIA.xml:S2:6023:2	at	IN	O	O
the	PROLIA.xml:S2:6026:3	the	DT	O	O
time	PROLIA.xml:S2:6030:4	time	NN	O	O
of	PROLIA.xml:S2:6035:2	of	IN	O	O
fracture	PROLIA.xml:S2:6038:8	fractur	NN	O	O
.	PROLIA.xml:S2:6046:1	.	.	O	O

During	PROLIA.xml:S2:6052:6	dure	IN	O	O
Prolia	PROLIA.xml:S2:6059:6	prolia	NNP	O	O
treatment	PROLIA.xml:S2:6066:9	treatment	NN	O	O
,	PROLIA.xml:S2:6075:1	,	,	O	O
patients	PROLIA.xml:S2:6077:8	patient	NNS	O	O
should	PROLIA.xml:S2:6086:6	should	MD	O	O
be	PROLIA.xml:S2:6093:2	be	VB	O	O
advised	PROLIA.xml:S2:6096:7	advis	VBN	O	O
to	PROLIA.xml:S2:6104:2	to	TO	O	O
report	PROLIA.xml:S2:6107:6	report	VB	O	O
new	PROLIA.xml:S2:6114:3	new	JJ	O	O
or	PROLIA.xml:S2:6118:2	or	CC	O	O
unusual	PROLIA.xml:S2:6121:7	unusu	JJ	O	O
thigh	PROLIA.xml:S2:6129:5	thigh	NN	O	O
,	PROLIA.xml:S2:6134:1	,	,	O	O
hip	PROLIA.xml:S2:6136:3	hip	NN	O	O
,	PROLIA.xml:S2:6139:1	,	,	O	O
or	PROLIA.xml:S2:6141:2	or	CC	O	O
groin	PROLIA.xml:S2:6144:5	groin	NN	O	B-AdverseReaction
pain	PROLIA.xml:S2:6150:4	pain	NN	O	I-AdverseReaction
.	PROLIA.xml:S2:6154:1	.	.	O	O

Any	PROLIA.xml:S2:6156:3	ani	DT	O	O
patient	PROLIA.xml:S2:6160:7	patient	NN	O	O
who	PROLIA.xml:S2:6168:3	who	WP	O	O
presents	PROLIA.xml:S2:6172:8	present	VBZ	O	O
with	PROLIA.xml:S2:6181:4	with	IN	O	O
thigh	PROLIA.xml:S2:6186:5	thigh	JJ	O	O
or	PROLIA.xml:S2:6192:2	or	CC	O	O
groin	PROLIA.xml:S2:6195:5	groin	JJ	O	O
pain	PROLIA.xml:S2:6201:4	pain	NN	O	O
should	PROLIA.xml:S2:6206:6	should	MD	O	O
be	PROLIA.xml:S2:6213:2	be	VB	O	O
suspected	PROLIA.xml:S2:6216:9	suspect	VBN	O	O
of	PROLIA.xml:S2:6226:2	of	IN	O	O
having	PROLIA.xml:S2:6229:6	have	VBG	O	O
an	PROLIA.xml:S2:6236:2	an	DT	O	O
atypical	PROLIA.xml:S2:6239:8	atyp	JJ	O	O
fracture	PROLIA.xml:S2:6248:8	fractur	NN	O	O
and	PROLIA.xml:S2:6257:3	and	CC	O	O
should	PROLIA.xml:S2:6261:6	should	MD	O	O
be	PROLIA.xml:S2:6268:2	be	VB	O	O
evaluated	PROLIA.xml:S2:6271:9	evalu	VBN	O	O
to	PROLIA.xml:S2:6281:2	to	TO	O	O
rule	PROLIA.xml:S2:6284:4	rule	VB	O	O
out	PROLIA.xml:S2:6289:3	out	RP	O	O
an	PROLIA.xml:S2:6293:2	an	DT	O	O
incomplete	PROLIA.xml:S2:6296:10	incomplet	JJ	O	O
femur	PROLIA.xml:S2:6307:5	femur	NN	O	O
fracture	PROLIA.xml:S2:6313:8	fractur	NN	O	O
.	PROLIA.xml:S2:6321:1	.	.	O	O

Patient	PROLIA.xml:S2:6323:7	patient	JJ	O	O
presenting	PROLIA.xml:S2:6331:10	present	VBG	O	O
with	PROLIA.xml:S2:6342:4	with	IN	O	O
an	PROLIA.xml:S2:6347:2	an	DT	O	O
atypical	PROLIA.xml:S2:6350:8	atyp	JJ	O	O
femur	PROLIA.xml:S2:6359:5	femur	NN	O	O
fracture	PROLIA.xml:S2:6365:8	fractur	NN	O	O
should	PROLIA.xml:S2:6374:6	should	MD	O	O
also	PROLIA.xml:S2:6381:4	also	RB	O	O
be	PROLIA.xml:S2:6386:2	be	VB	O	O
assessed	PROLIA.xml:S2:6389:8	assess	VBN	O	O
for	PROLIA.xml:S2:6398:3	for	IN	O	O
symptoms	PROLIA.xml:S2:6402:8	symptom	NNS	O	O
and	PROLIA.xml:S2:6411:3	and	CC	O	O
signs	PROLIA.xml:S2:6415:5	sign	NNS	O	O
of	PROLIA.xml:S2:6421:2	of	IN	O	O
fracture	PROLIA.xml:S2:6424:8	fractur	NN	O	O
in	PROLIA.xml:S2:6433:2	in	IN	O	O
the	PROLIA.xml:S2:6436:3	the	DT	O	O
contralateral	PROLIA.xml:S2:6440:13	contralater	JJ	O	O
limb	PROLIA.xml:S2:6454:4	limb	NN	O	O
.	PROLIA.xml:S2:6458:1	.	.	O	O

Interruption	PROLIA.xml:S2:6460:12	interrupt	NN	O	O
of	PROLIA.xml:S2:6473:2	of	IN	O	O
Prolia	PROLIA.xml:S2:6476:6	prolia	NNP	O	O
therapy	PROLIA.xml:S2:6483:7	therapi	NN	O	O
should	PROLIA.xml:S2:6491:6	should	MD	O	O
be	PROLIA.xml:S2:6498:2	be	VB	O	O
considered	PROLIA.xml:S2:6501:10	consid	VBN	O	O
,	PROLIA.xml:S2:6511:1	,	,	O	O
pending	PROLIA.xml:S2:6513:7	pend	VBG	O	O
a	PROLIA.xml:S2:6521:1	a	DT	O	O
risk	PROLIA.xml:S2:6523:4	risk	NN	O	O
benefit	PROLIA.xml:S2:6528:7	benefit	NN	O	O
assessment	PROLIA.xml:S2:6536:10	assess	NN	O	O
,	PROLIA.xml:S2:6546:1	,	,	O	O
on	PROLIA.xml:S2:6548:2	on	IN	O	O
an	PROLIA.xml:S2:6551:2	an	DT	O	O
individual	PROLIA.xml:S2:6554:10	individu	JJ	O	O
basis	PROLIA.xml:S2:6565:5	basi	NN	O	O
.	PROLIA.xml:S2:6570:1	.	.	O	O

5.6	PROLIA.xml:S2:6579:3	5.6	CD	O	O
Serious	PROLIA.xml:S2:6583:7	seriou	JJ	O	O
Infections	PROLIA.xml:S2:6591:10	infect	NNS	O	O

In	PROLIA.xml:S2:6607:2	In	IN	O	O
a	PROLIA.xml:S2:6610:1	a	DT	O	O
clinical	PROLIA.xml:S2:6612:8	clinic	JJ	O	O
trial	PROLIA.xml:S2:6621:5	trial	NN	O	O
of	PROLIA.xml:S2:6627:2	of	IN	O	O
over	PROLIA.xml:S2:6630:4	over	IN	O	O
7800	PROLIA.xml:S2:6635:4	7800	CD	O	O
women	PROLIA.xml:S2:6640:5	women	NNS	O	O
with	PROLIA.xml:S2:6646:4	with	IN	O	O
postmenopausal	PROLIA.xml:S2:6651:14	postmenopaus	JJ	O	O
osteoporosis	PROLIA.xml:S2:6666:12	osteoporosi	NN	O	O
,	PROLIA.xml:S2:6678:1	,	,	O	O
serious	PROLIA.xml:S2:6680:7	seriou	JJ	O	O
infections	PROLIA.xml:S2:6688:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
leading	PROLIA.xml:S2:6699:7	lead	VBG	O	O
to	PROLIA.xml:S2:6707:2	to	TO	O	O
hospitalization	PROLIA.xml:S2:6710:15	hospit	NN	O	O
were	PROLIA.xml:S2:6726:4	were	VBD	O	O
reported	PROLIA.xml:S2:6731:8	report	VBN	O	O
more	PROLIA.xml:S2:6740:4	more	RBR	O	O
frequently	PROLIA.xml:S2:6745:10	frequent	RB	O	O
in	PROLIA.xml:S2:6756:2	in	IN	O	O
the	PROLIA.xml:S2:6759:3	the	DT	O	O
Prolia	PROLIA.xml:S2:6763:6	prolia	NNP	O	O
group	PROLIA.xml:S2:6770:5	group	NN	O	O
than	PROLIA.xml:S2:6776:4	than	IN	O	O
in	PROLIA.xml:S2:6781:2	in	IN	O	O
the	PROLIA.xml:S2:6784:3	the	DT	O	O
placebo	PROLIA.xml:S2:6788:7	placebo	NN	O	O
group	PROLIA.xml:S2:6796:5	group	NN	O	O
[	PROLIA.xml:S2:6802:1	[	NNP	O	O
see	PROLIA.xml:S2:6803:3	see	VBP	O	O
Adverse	PROLIA.xml:S2:6807:7	advers	JJ	O	O
Reactions	PROLIA.xml:S2:6815:9	reaction	NNP	O	O
(	PROLIA.xml:S2:6825:1	(	(	O	O
6.1	PROLIA.xml:S2:6828:3	6.1	CD	O	O
)]	PROLIA.xml:S2:6833:2	)]	NN	O	O
.	PROLIA.xml:S2:6837:1	.	.	O	O

Serious	PROLIA.xml:S2:6839:7	seriou	JJ	O	O
skin	PROLIA.xml:S2:6847:4	skin	NN	B-AdverseReaction	B-AdverseReaction
infections	PROLIA.xml:S2:6852:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S2:6862:1	,	,	O	O
as	PROLIA.xml:S2:6864:2	as	RB	O	O
well	PROLIA.xml:S2:6867:4	well	RB	O	O
as	PROLIA.xml:S2:6872:2	as	IN	O	O
infections	PROLIA.xml:S2:6875:10	infect	NNS	B-AdverseReaction	O
of	PROLIA.xml:S2:6886:2	of	IN	I-AdverseReaction	O
the	PROLIA.xml:S2:6889:3	the	DT	I-AdverseReaction	O
abdomen	PROLIA.xml:S2:6893:7	abdomen	NNS	I-AdverseReaction	O
,	PROLIA.xml:S2:6900:1	,	,	O	O
urinary	PROLIA.xml:S2:6902:7	urinari	JJ	I-AdverseReaction	B-AdverseReaction
tract	PROLIA.xml:S2:6910:5	tract	NN	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S2:6915:1	,	,	O	O
and	PROLIA.xml:S2:6917:3	and	CC	O	O
ear	PROLIA.xml:S2:6921:3	ear	RB	I-AdverseReaction	O
,	PROLIA.xml:S2:6924:1	,	,	O	O
were	PROLIA.xml:S2:6926:4	were	VBD	O	O
more	PROLIA.xml:S2:6931:4	more	RBR	O	O
frequent	PROLIA.xml:S2:6936:8	frequent	JJ	O	O
in	PROLIA.xml:S2:6945:2	in	IN	O	O
patients	PROLIA.xml:S2:6948:8	patient	NNS	O	O
treated	PROLIA.xml:S2:6957:7	treat	VBN	O	O
with	PROLIA.xml:S2:6965:4	with	IN	O	O
Prolia	PROLIA.xml:S2:6970:6	prolia	NNP	O	O
.	PROLIA.xml:S2:6976:1	.	.	O	O

Endocarditis	PROLIA.xml:S2:6978:12	endocard	NN	B-AdverseReaction	O
was	PROLIA.xml:S2:6991:3	wa	VBD	O	O
also	PROLIA.xml:S2:6995:4	also	RB	O	O
reported	PROLIA.xml:S2:7000:8	report	VBN	O	O
more	PROLIA.xml:S2:7009:4	more	RBR	O	O
frequently	PROLIA.xml:S2:7014:10	frequent	RB	O	O
in	PROLIA.xml:S2:7025:2	in	IN	O	O
Prolia	PROLIA.xml:S2:7028:6	prolia	NNP	O	O
-	PROLIA.xml:S2:7034:1	-	:	O	O
treated	PROLIA.xml:S2:7035:7	treat	VBD	O	O
patients	PROLIA.xml:S2:7043:8	patient	NNS	O	O
.	PROLIA.xml:S2:7051:1	.	.	O	O

The	PROLIA.xml:S2:7053:3	the	DT	O	O
incidence	PROLIA.xml:S2:7057:9	incid	NN	O	O
of	PROLIA.xml:S2:7067:2	of	IN	O	O
opportunistic	PROLIA.xml:S2:7070:13	opportunist	JJ	B-AdverseReaction	B-AdverseReaction
infections	PROLIA.xml:S2:7084:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
was	PROLIA.xml:S2:7095:3	wa	VBD	O	O
similar	PROLIA.xml:S2:7099:7	similar	JJ	O	O
between	PROLIA.xml:S2:7107:7	between	IN	O	O
placebo	PROLIA.xml:S2:7115:7	placebo	NN	O	O
and	PROLIA.xml:S2:7123:3	and	CC	O	O
Prolia	PROLIA.xml:S2:7127:6	prolia	NNP	O	O
groups	PROLIA.xml:S2:7134:6	group	NNS	O	O
,	PROLIA.xml:S2:7140:1	,	,	O	O
and	PROLIA.xml:S2:7142:3	and	CC	O	O
the	PROLIA.xml:S2:7146:3	the	DT	O	O
overall	PROLIA.xml:S2:7150:7	overal	JJ	O	O
incidence	PROLIA.xml:S2:7158:9	incid	NN	O	O
of	PROLIA.xml:S2:7168:2	of	IN	O	O
infections	PROLIA.xml:S2:7171:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
was	PROLIA.xml:S2:7182:3	wa	VBD	O	O
similar	PROLIA.xml:S2:7186:7	similar	JJ	O	O
between	PROLIA.xml:S2:7194:7	between	IN	O	O
the	PROLIA.xml:S2:7202:3	the	DT	O	O
treatment	PROLIA.xml:S2:7206:9	treatment	NN	O	O
groups	PROLIA.xml:S2:7216:6	group	NNS	O	O
.	PROLIA.xml:S2:7222:1	.	.	O	O

Advise	PROLIA.xml:S2:7224:6	advis	NN	O	O
patients	PROLIA.xml:S2:7231:8	patient	NNS	O	O
to	PROLIA.xml:S2:7240:2	to	TO	O	O
seek	PROLIA.xml:S2:7243:4	seek	VB	O	O
prompt	PROLIA.xml:S2:7248:6	prompt	NN	O	O
medical	PROLIA.xml:S2:7255:7	medic	JJ	O	O
attention	PROLIA.xml:S2:7263:9	attent	NN	O	O
if	PROLIA.xml:S2:7273:2	if	IN	O	O
they	PROLIA.xml:S2:7276:4	they	PRP	O	O
develop	PROLIA.xml:S2:7281:7	develop	VBP	O	O
signs	PROLIA.xml:S2:7289:5	sign	NNS	O	O
or	PROLIA.xml:S2:7295:2	or	CC	O	O
symptoms	PROLIA.xml:S2:7298:8	symptom	NNS	O	O
of	PROLIA.xml:S2:7307:2	of	IN	O	O
severe	PROLIA.xml:S2:7310:6	sever	JJ	O	O
infection	PROLIA.xml:S2:7317:9	infect	NN	O	O
,	PROLIA.xml:S2:7326:1	,	,	O	O
including	PROLIA.xml:S2:7328:9	includ	VBG	O	O
cellulitis	PROLIA.xml:S2:7338:10	cellul	NN	O	O
.	PROLIA.xml:S2:7348:1	.	.	O	O

Patients	PROLIA.xml:S2:7355:8	patient	NNS	O	O
on	PROLIA.xml:S2:7364:2	on	IN	O	O
concomitant	PROLIA.xml:S2:7367:11	concomit	JJ	O	O
immunosuppressant	PROLIA.xml:S2:7379:17	immunosuppress	JJ	O	O
agents	PROLIA.xml:S2:7397:6	agent	NNS	O	O
or	PROLIA.xml:S2:7404:2	or	CC	O	O
with	PROLIA.xml:S2:7407:4	with	IN	O	O
impaired	PROLIA.xml:S2:7412:8	impair	JJ	O	O
immune	PROLIA.xml:S2:7421:6	immun	JJ	O	O
systems	PROLIA.xml:S2:7428:7	system	NNS	O	O
may	PROLIA.xml:S2:7436:3	may	MD	O	O
be	PROLIA.xml:S2:7440:2	be	VB	O	O
at	PROLIA.xml:S2:7443:2	at	IN	O	O
increased	PROLIA.xml:S2:7446:9	increas	VBN	O	O
risk	PROLIA.xml:S2:7456:4	risk	NN	O	O
for	PROLIA.xml:S2:7461:3	for	IN	O	O
serious	PROLIA.xml:S2:7465:7	seriou	JJ	O	O
infections	PROLIA.xml:S2:7473:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
.	PROLIA.xml:S2:7483:1	.	.	O	O

Consider	PROLIA.xml:S2:7485:8	consid	VB	O	O
the	PROLIA.xml:S2:7494:3	the	DT	O	O
benefit	PROLIA.xml:S2:7498:7	benefit	NN	O	O
-	PROLIA.xml:S2:7505:1	-	:	O	O
risk	PROLIA.xml:S2:7506:4	risk	NN	O	O
profile	PROLIA.xml:S2:7511:7	profil	NN	O	O
in	PROLIA.xml:S2:7519:2	in	IN	O	O
such	PROLIA.xml:S2:7522:4	such	JJ	O	O
patients	PROLIA.xml:S2:7527:8	patient	NNS	O	O
before	PROLIA.xml:S2:7536:6	befor	IN	O	O
treating	PROLIA.xml:S2:7543:8	treat	VBG	O	O
with	PROLIA.xml:S2:7552:4	with	IN	O	O
Prolia	PROLIA.xml:S2:7557:6	prolia	NNP	O	O
.	PROLIA.xml:S2:7563:1	.	.	O	O

In	PROLIA.xml:S2:7565:2	In	IN	O	O
patients	PROLIA.xml:S2:7568:8	patient	NNS	O	O
who	PROLIA.xml:S2:7577:3	who	WP	O	O
develop	PROLIA.xml:S2:7581:7	develop	VBP	O	O
serious	PROLIA.xml:S2:7589:7	seriou	JJ	O	O
infections	PROLIA.xml:S2:7597:10	infect	NNS	O	B-AdverseReaction
while	PROLIA.xml:S2:7608:5	while	IN	O	O
on	PROLIA.xml:S2:7614:2	on	IN	O	O
Prolia	PROLIA.xml:S2:7617:6	prolia	NNP	O	O
,	PROLIA.xml:S2:7623:1	,	,	O	O
prescribers	PROLIA.xml:S2:7625:11	prescrib	NNS	O	O
should	PROLIA.xml:S2:7637:6	should	MD	O	O
assess	PROLIA.xml:S2:7644:6	assess	VB	O	O
the	PROLIA.xml:S2:7651:3	the	DT	O	O
need	PROLIA.xml:S2:7655:4	need	NN	O	O
for	PROLIA.xml:S2:7660:3	for	IN	O	O
continued	PROLIA.xml:S2:7664:9	continu	JJ	O	O
Prolia	PROLIA.xml:S2:7674:6	prolia	NNP	O	O
therapy	PROLIA.xml:S2:7681:7	therapi	NN	O	O
.	PROLIA.xml:S2:7688:1	.	.	O	O

5.7	PROLIA.xml:S2:7697:3	5.7	CD	O	O
Dermatologic	PROLIA.xml:S2:7701:12	dermatolog	NNP	O	O
Adverse	PROLIA.xml:S2:7714:7	advers	NNP	O	O
Reactions	PROLIA.xml:S2:7722:9	reaction	NNP	O	O

In	PROLIA.xml:S2:7737:2	In	IN	O	O
a	PROLIA.xml:S2:7740:1	a	DT	O	O
large	PROLIA.xml:S2:7742:5	larg	JJ	O	O
clinical	PROLIA.xml:S2:7748:8	clinic	JJ	O	O
trial	PROLIA.xml:S2:7757:5	trial	NN	O	O
of	PROLIA.xml:S2:7763:2	of	IN	O	O
over	PROLIA.xml:S2:7766:4	over	IN	O	O
7800	PROLIA.xml:S2:7771:4	7800	CD	O	O
women	PROLIA.xml:S2:7776:5	women	NNS	O	O
with	PROLIA.xml:S2:7782:4	with	IN	O	O
postmenopausal	PROLIA.xml:S2:7787:14	postmenopaus	JJ	O	O
osteoporosis	PROLIA.xml:S2:7802:12	osteoporosi	NN	O	O
,	PROLIA.xml:S2:7814:1	,	,	O	O
epidermal	PROLIA.xml:S2:7816:9	epiderm	JJ	B-AdverseReaction	O
and	PROLIA.xml:S2:7826:3	and	CC	O	O
dermal	PROLIA.xml:S2:7830:6	dermal	JJ	B-AdverseReaction	O
adverse	PROLIA.xml:S2:7837:7	advers	JJ	I-AdverseReaction	O
events	PROLIA.xml:S2:7845:6	event	NNS	I-AdverseReaction	O
such	PROLIA.xml:S2:7852:4	such	JJ	O	O
as	PROLIA.xml:S2:7857:2	as	IN	O	O
dermatitis	PROLIA.xml:S2:7860:10	dermat	NN	B-AdverseReaction	O
,	PROLIA.xml:S2:7870:1	,	,	O	O
eczema	PROLIA.xml:S2:7872:6	eczema	NN	B-AdverseReaction	O
,	PROLIA.xml:S2:7878:1	,	,	O	O
and	PROLIA.xml:S2:7880:3	and	CC	O	O
rashes	PROLIA.xml:S2:7884:6	rash	NNS	B-AdverseReaction	B-AdverseReaction
occurred	PROLIA.xml:S2:7891:8	occur	VBD	O	O
at	PROLIA.xml:S2:7900:2	at	IN	O	O
a	PROLIA.xml:S2:7903:1	a	DT	O	O
significantly	PROLIA.xml:S2:7905:13	significantli	RB	O	O
higher	PROLIA.xml:S2:7919:6	higher	JJR	O	O
rate	PROLIA.xml:S2:7926:4	rate	NN	O	O
in	PROLIA.xml:S2:7931:2	in	IN	O	O
the	PROLIA.xml:S2:7934:3	the	DT	O	O
Prolia	PROLIA.xml:S2:7938:6	prolia	NNP	O	O
group	PROLIA.xml:S2:7945:5	group	NN	O	O
compared	PROLIA.xml:S2:7951:8	compar	VBN	O	O
to	PROLIA.xml:S2:7960:2	to	TO	O	O
the	PROLIA.xml:S2:7963:3	the	DT	O	O
placebo	PROLIA.xml:S2:7967:7	placebo	NN	O	O
group	PROLIA.xml:S2:7975:5	group	NN	O	O
.	PROLIA.xml:S2:7980:1	.	.	O	O

Most	PROLIA.xml:S2:7982:4	most	JJS	O	O
of	PROLIA.xml:S2:7987:2	of	IN	O	O
these	PROLIA.xml:S2:7990:5	these	DT	O	O
events	PROLIA.xml:S2:7996:6	event	NNS	O	O
were	PROLIA.xml:S2:8003:4	were	VBD	O	O
not	PROLIA.xml:S2:8008:3	not	RB	O	O
specific	PROLIA.xml:S2:8012:8	specif	JJ	O	O
to	PROLIA.xml:S2:8021:2	to	TO	O	O
the	PROLIA.xml:S2:8024:3	the	DT	O	O
injection	PROLIA.xml:S2:8028:9	inject	NN	O	O
site	PROLIA.xml:S2:8038:4	site	NN	O	O
[	PROLIA.xml:S2:8043:1	[	NNP	O	O
see	PROLIA.xml:S2:8044:3	see	VBP	O	O
Adverse	PROLIA.xml:S2:8048:7	advers	JJ	O	O
Reactions	PROLIA.xml:S2:8056:9	reaction	NNP	O	O
(	PROLIA.xml:S2:8066:1	(	(	O	O
6.1	PROLIA.xml:S2:8069:3	6.1	CD	O	O
)]	PROLIA.xml:S2:8074:2	)]	NN	O	O
.	PROLIA.xml:S2:8078:1	.	.	O	O

Consider	PROLIA.xml:S2:8080:8	consid	VB	O	O
discontinuing	PROLIA.xml:S2:8089:13	discontinu	VBG	O	O
Prolia	PROLIA.xml:S2:8103:6	prolia	NNP	O	O
if	PROLIA.xml:S2:8110:2	if	IN	O	O
severe	PROLIA.xml:S2:8113:6	sever	JJ	O	O
symptoms	PROLIA.xml:S2:8120:8	symptom	NNS	O	O
develop	PROLIA.xml:S2:8129:7	develop	VBP	O	O
.	PROLIA.xml:S2:8136:1	.	.	O	O

5.8	PROLIA.xml:S2:8145:3	5.8	CD	O	O
Musculoskeletal	PROLIA.xml:S2:8149:15	musculoskelet	NNP	O	O
Pain	PROLIA.xml:S2:8165:4	pain	NN	O	O

In	PROLIA.xml:S2:8176:2	In	IN	O	O
post	PROLIA.xml:S2:8179:4	post	NN	O	O
-	PROLIA.xml:S2:8183:1	-	:	O	O
marketing	PROLIA.xml:S2:8184:9	market	NN	O	O
experience	PROLIA.xml:S2:8194:10	experi	NN	O	O
,	PROLIA.xml:S2:8204:1	,	,	O	O
severe	PROLIA.xml:S2:8206:6	sever	JJ	O	O
and	PROLIA.xml:S2:8213:3	and	CC	O	O
occasionally	PROLIA.xml:S2:8217:12	occasion	RB	O	O
incapacitating	PROLIA.xml:S2:8230:14	incapacit	VBG	O	O
bone	PROLIA.xml:S2:8245:4	bone	NN	B-AdverseReaction	O
,	PROLIA.xml:S2:8249:1	,	,	O	O
joint	PROLIA.xml:S2:8251:5	joint	NN	B-AdverseReaction	O
,	PROLIA.xml:S2:8256:1	,	,	O	O
and	PROLIA.xml:S2:8258:3	and	CC	O	O
or	PROLIA.xml:S2:8262:2	or	CC	O	O
muscle	PROLIA.xml:S2:8265:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
pain	PROLIA.xml:S2:8272:4	pain	NN	I-AdverseReaction	I-AdverseReaction
has	PROLIA.xml:S2:8277:3	ha	VBZ	O	O
been	PROLIA.xml:S2:8281:4	been	VBN	O	O
reported	PROLIA.xml:S2:8286:8	report	VBN	O	O
in	PROLIA.xml:S2:8295:2	in	IN	O	O
patients	PROLIA.xml:S2:8298:8	patient	NNS	O	O
taking	PROLIA.xml:S2:8307:6	take	VBG	O	O
Prolia	PROLIA.xml:S2:8314:6	prolia	NNP	O	O
[	PROLIA.xml:S2:8321:1	[	NNP	O	O
see	PROLIA.xml:S2:8322:3	see	VBP	O	O
Adverse	PROLIA.xml:S2:8326:7	advers	JJ	O	O
Reactions	PROLIA.xml:S2:8334:9	reaction	NNP	O	O
(	PROLIA.xml:S2:8344:1	(	(	O	O
6.2	PROLIA.xml:S2:8347:3	6.2	CD	O	O
)]	PROLIA.xml:S2:8352:2	)]	NN	O	O
.	PROLIA.xml:S2:8356:1	.	.	O	O

The	PROLIA.xml:S2:8358:3	the	DT	O	O
time	PROLIA.xml:S2:8362:4	time	NN	O	O
to	PROLIA.xml:S2:8367:2	to	TO	O	O
onset	PROLIA.xml:S2:8370:5	onset	VB	O	O
of	PROLIA.xml:S2:8376:2	of	IN	O	O
symptoms	PROLIA.xml:S2:8379:8	symptom	NNS	O	O
varied	PROLIA.xml:S2:8388:6	vari	VBN	O	O
from	PROLIA.xml:S2:8395:4	from	IN	O	O
one	PROLIA.xml:S2:8400:3	one	CD	O	O
day	PROLIA.xml:S2:8404:3	day	NN	O	O
to	PROLIA.xml:S2:8408:2	to	TO	O	O
several	PROLIA.xml:S2:8411:7	sever	JJ	O	O
months	PROLIA.xml:S2:8419:6	month	NNS	O	O
after	PROLIA.xml:S2:8426:5	after	IN	O	O
starting	PROLIA.xml:S2:8432:8	start	VBG	O	O
Prolia	PROLIA.xml:S2:8441:6	prolia	NNP	O	O
.	PROLIA.xml:S2:8447:1	.	.	O	O

Consider	PROLIA.xml:S2:8449:8	consid	VB	O	O
discontinuing	PROLIA.xml:S2:8458:13	discontinu	NN	O	O
use	PROLIA.xml:S2:8472:3	use	NN	O	O
if	PROLIA.xml:S2:8476:2	if	IN	O	O
severe	PROLIA.xml:S2:8479:6	sever	JJ	O	O
symptoms	PROLIA.xml:S2:8486:8	symptom	NNS	O	O
develop	PROLIA.xml:S2:8495:7	develop	VB	O	O
[	PROLIA.xml:S2:8503:1	[	JJ	O	O
see	PROLIA.xml:S2:8504:3	see	VB	O	O
Patient	PROLIA.xml:S2:8508:7	patient	JJ	O	O
Counseling	PROLIA.xml:S2:8516:10	counsel	NNP	O	O
Information	PROLIA.xml:S2:8527:11	inform	NNP	O	O
(	PROLIA.xml:S2:8539:1	(	(	O	O
17.8	PROLIA.xml:S2:8542:4	17.8	CD	O	O
)]	PROLIA.xml:S2:8548:2	)]	NN	O	O
.	PROLIA.xml:S2:8552:1	.	.	O	O

5.9	PROLIA.xml:S2:8563:3	5.9	CD	O	O
Suppression	PROLIA.xml:S2:8567:11	suppress	NN	O	O
of	PROLIA.xml:S2:8579:2	of	IN	O	O
Bone	PROLIA.xml:S2:8582:4	bone	NNP	O	O
Turnover	PROLIA.xml:S2:8587:8	turnov	NNP	O	O

In	PROLIA.xml:S2:8601:2	In	IN	O	O
clinical	PROLIA.xml:S2:8604:8	clinic	JJ	O	O
trials	PROLIA.xml:S2:8613:6	trial	NNS	O	O
in	PROLIA.xml:S2:8620:2	in	IN	O	O
women	PROLIA.xml:S2:8623:5	women	NNS	O	O
with	PROLIA.xml:S2:8629:4	with	IN	O	O
postmenopausal	PROLIA.xml:S2:8634:14	postmenopaus	JJ	O	O
osteoporosis	PROLIA.xml:S2:8649:12	osteoporosi	NN	O	O
,	PROLIA.xml:S2:8661:1	,	,	O	O
treatment	PROLIA.xml:S2:8663:9	treatment	NN	O	O
with	PROLIA.xml:S2:8673:4	with	IN	O	O
Prolia	PROLIA.xml:S2:8678:6	prolia	NNP	O	O
resulted	PROLIA.xml:S2:8685:8	result	VBD	O	O
in	PROLIA.xml:S2:8694:2	in	IN	O	O
significant	PROLIA.xml:S2:8697:11	signific	JJ	O	O
suppression	PROLIA.xml:S2:8709:11	suppress	NN	B-AdverseReaction	O
of	PROLIA.xml:S2:8721:2	of	IN	I-AdverseReaction	O
bone	PROLIA.xml:S2:8724:4	bone	NN	I-AdverseReaction	O
remodeling	PROLIA.xml:S2:8729:10	remodel	NN	I-AdverseReaction	O
as	PROLIA.xml:S2:8740:2	as	IN	O	O
evidenced	PROLIA.xml:S2:8743:9	evidenc	VBN	O	O
by	PROLIA.xml:S2:8753:2	by	IN	O	O
markers	PROLIA.xml:S2:8756:7	marker	NNS	O	O
of	PROLIA.xml:S2:8764:2	of	IN	O	O
bone	PROLIA.xml:S2:8767:4	bone	NN	O	O
turnover	PROLIA.xml:S2:8772:8	turnov	NN	O	O
and	PROLIA.xml:S2:8781:3	and	CC	O	O
bone	PROLIA.xml:S2:8785:4	bone	NN	O	B-AdverseReaction
histomorphometry	PROLIA.xml:S2:8790:16	histomorphometri	NN	O	I-AdverseReaction
[	PROLIA.xml:S2:8807:1	[	NNP	O	O
see	PROLIA.xml:S2:8808:3	see	VBP	O	O
Clinical	PROLIA.xml:S2:8812:8	clinic	JJ	O	O
Pharmacology	PROLIA.xml:S2:8821:12	pharmacolog	NNP	O	O
(	PROLIA.xml:S2:8834:1	(	(	O	O
12.2	PROLIA.xml:S2:8837:4	12.2	CD	O	O
)	PROLIA.xml:S2:8843:1	)	)	O	O
and	PROLIA.xml:S2:8845:3	and	CC	O	O
Clinical	PROLIA.xml:S2:8849:8	clinic	JJ	O	O
Studies	PROLIA.xml:S2:8858:7	studi	NNP	O	O
(	PROLIA.xml:S2:8866:1	(	(	O	O
14.1	PROLIA.xml:S2:8869:4	14.1	CD	O	O
)]	PROLIA.xml:S2:8875:2	)]	NN	O	O
.	PROLIA.xml:S2:8879:1	.	.	O	O

The	PROLIA.xml:S2:8881:3	the	DT	O	O
significance	PROLIA.xml:S2:8885:12	signific	NN	O	O
of	PROLIA.xml:S2:8898:2	of	IN	O	O
these	PROLIA.xml:S2:8901:5	these	DT	O	O
findings	PROLIA.xml:S2:8907:8	find	NNS	O	O
and	PROLIA.xml:S2:8916:3	and	CC	O	O
the	PROLIA.xml:S2:8920:3	the	DT	O	O
effect	PROLIA.xml:S2:8924:6	effect	NN	O	O
of	PROLIA.xml:S2:8931:2	of	IN	O	O
long	PROLIA.xml:S2:8934:4	long	JJ	O	O
-	PROLIA.xml:S2:8938:1	-	:	O	O
term	PROLIA.xml:S2:8939:4	term	NN	O	O
treatment	PROLIA.xml:S2:8944:9	treatment	NN	O	O
with	PROLIA.xml:S2:8954:4	with	IN	O	O
Prolia	PROLIA.xml:S2:8959:6	prolia	NNP	O	O
are	PROLIA.xml:S2:8966:3	are	VBP	O	O
unknown	PROLIA.xml:S2:8970:7	unknown	JJ	O	O
.	PROLIA.xml:S2:8977:1	.	.	O	O

The	PROLIA.xml:S2:8979:3	the	DT	O	O
long	PROLIA.xml:S2:8983:4	long	JJ	O	O
-	PROLIA.xml:S2:8987:1	-	:	O	O
term	PROLIA.xml:S2:8988:4	term	NN	O	O
consequences	PROLIA.xml:S2:8993:12	consequ	NNS	O	O
of	PROLIA.xml:S2:9006:2	of	IN	O	O
the	PROLIA.xml:S2:9009:3	the	DT	O	O
degree	PROLIA.xml:S2:9013:6	degre	NN	O	O
of	PROLIA.xml:S2:9020:2	of	IN	O	O
suppression	PROLIA.xml:S2:9023:11	suppress	NN	B-AdverseReaction	O
of	PROLIA.xml:S2:9035:2	of	IN	I-AdverseReaction	O
bone	PROLIA.xml:S2:9038:4	bone	NN	I-AdverseReaction	O
remodeling	PROLIA.xml:S2:9043:10	remodel	VBG	I-AdverseReaction	O
observed	PROLIA.xml:S2:9054:8	observ	VBN	O	O
with	PROLIA.xml:S2:9063:4	with	IN	O	O
Prolia	PROLIA.xml:S2:9068:6	prolia	NNP	O	O
may	PROLIA.xml:S2:9075:3	may	MD	O	O
contribute	PROLIA.xml:S2:9079:10	contribut	VB	O	O
to	PROLIA.xml:S2:9090:2	to	TO	O	O
adverse	PROLIA.xml:S2:9093:7	advers	VB	O	O
outcomes	PROLIA.xml:S2:9101:8	outcom	NNS	O	O
such	PROLIA.xml:S2:9110:4	such	JJ	O	O
as	PROLIA.xml:S2:9115:2	as	IN	O	O
osteonecrosis	PROLIA.xml:S2:9118:13	osteonecrosi	NN	B-AdverseReaction	O
of	PROLIA.xml:S2:9132:2	of	IN	I-AdverseReaction	O
the	PROLIA.xml:S2:9135:3	the	DT	I-AdverseReaction	O
jaw	PROLIA.xml:S2:9139:3	jaw	NN	I-AdverseReaction	O
,	PROLIA.xml:S2:9142:1	,	,	O	O
atypical	PROLIA.xml:S2:9144:8	atyp	JJ	B-AdverseReaction	B-AdverseReaction
fractures	PROLIA.xml:S2:9153:9	fractur	NNS	I-AdverseReaction	I-AdverseReaction
,	PROLIA.xml:S2:9162:1	,	,	O	O
and	PROLIA.xml:S2:9164:3	and	CC	O	O
delayed	PROLIA.xml:S2:9168:7	delay	JJ	B-AdverseReaction	B-AdverseReaction
fracture	PROLIA.xml:S2:9176:8	fractur	NN	I-AdverseReaction	I-AdverseReaction
healing	PROLIA.xml:S2:9185:7	heal	NN	I-AdverseReaction	I-AdverseReaction
.	PROLIA.xml:S2:9192:1	.	.	O	O

Monitor	PROLIA.xml:S2:9194:7	monitor	NN	O	O
patients	PROLIA.xml:S2:9202:8	patient	NNS	O	O
for	PROLIA.xml:S2:9211:3	for	IN	O	O
these	PROLIA.xml:S2:9215:5	these	DT	O	O
consequences	PROLIA.xml:S2:9221:12	consequ	NNS	O	O
.	PROLIA.xml:S2:9233:1	.	.	O	O
6	PROMACTA.xml:S1:4:1	6	CD	O	O
ADVERSE	PROMACTA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	PROMACTA.xml:S1:14:9	reaction	NN	O	O

The	PROMACTA.xml:S1:27:3	the	DT	O	O
following	PROMACTA.xml:S1:31:9	follow	VBG	O	O
serious	PROMACTA.xml:S1:41:7	seriou	JJ	O	O
adverse	PROMACTA.xml:S1:49:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:57:9	reaction	NNS	O	O
associated	PROMACTA.xml:S1:67:10	associ	VBN	O	O
with	PROMACTA.xml:S1:78:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S1:83:8	promacta	NNP	O	O
are	PROMACTA.xml:S1:92:3	are	VBP	O	O
described	PROMACTA.xml:S1:96:9	describ	VBN	O	O
in	PROMACTA.xml:S1:106:2	in	IN	O	O
other	PROMACTA.xml:S1:109:5	other	JJ	O	O
sections	PROMACTA.xml:S1:115:8	section	NNS	O	O
.	PROMACTA.xml:S1:123:1	.	.	O	O

Hepatic	PROMACTA.xml:S1:134:7	hepat	JJ	B-AdverseReaction	O
Decompensation	PROMACTA.xml:S1:142:14	decompens	NNP	I-AdverseReaction	O
in	PROMACTA.xml:S1:157:2	in	IN	O	O
Patients	PROMACTA.xml:S1:160:8	patient	NNP	O	O
with	PROMACTA.xml:S1:169:4	with	IN	O	O
Chronic	PROMACTA.xml:S1:174:7	chronic	NNP	O	O
Hepatitis	PROMACTA.xml:S1:182:9	hepat	NNP	O	O
C	PROMACTA.xml:S1:192:1	C	NNP	O	O
[	PROMACTA.xml:S1:194:1	[	NNP	O	O
see	PROMACTA.xml:S1:195:3	see	VBP	O	O
Warnings	PROMACTA.xml:S1:199:8	warn	NNP	O	O
and	PROMACTA.xml:S1:208:3	and	CC	O	O
Precautions	PROMACTA.xml:S1:212:11	precaut	NNP	O	O
(	PROMACTA.xml:S1:224:1	(	(	O	O
5.1	PROMACTA.xml:S1:225:3	5.1	CD	O	O
)]	PROMACTA.xml:S1:228:2	)]	NN	O	O

Hepatotoxicity	PROMACTA.xml:S1:239:14	hepatotox	NNP	B-AdverseReaction	B-AdverseReaction
[	PROMACTA.xml:S1:254:1	[	NNP	O	O
see	PROMACTA.xml:S1:255:3	see	VBP	O	O
Warnings	PROMACTA.xml:S1:259:8	warn	NNP	O	O
and	PROMACTA.xml:S1:268:3	and	CC	O	O
Precautions	PROMACTA.xml:S1:272:11	precaut	NNP	O	O
(	PROMACTA.xml:S1:284:1	(	(	O	O
5.2	PROMACTA.xml:S1:285:3	5.2	CD	O	O
)]	PROMACTA.xml:S1:288:2	)]	NN	O	O

Thrombotic	PROMACTA.xml:S1:299:10	thrombot	JJ	B-AdverseReaction	B-AdverseReaction
Thromboembolic	PROMACTA.xml:S1:310:14	thromboembol	NNP	B-AdverseReaction	I-AdverseReaction
Complications	PROMACTA.xml:S1:325:13	complic	NNP	I-AdverseReaction	I-AdverseReaction
[	PROMACTA.xml:S1:339:1	[	NNP	O	O
see	PROMACTA.xml:S1:340:3	see	VBP	O	O
Warnings	PROMACTA.xml:S1:344:8	warn	NNP	O	O
and	PROMACTA.xml:S1:353:3	and	CC	O	O
Precautions	PROMACTA.xml:S1:357:11	precaut	NNP	O	O
(	PROMACTA.xml:S1:369:1	(	(	O	O
5.3	PROMACTA.xml:S1:370:3	5.3	CD	O	O
)]	PROMACTA.xml:S1:373:2	)]	NN	O	O

Cataracts	PROMACTA.xml:S1:384:9	cataract	NNS	B-AdverseReaction	B-AdverseReaction
[	PROMACTA.xml:S1:394:1	[	VBP	O	O
see	PROMACTA.xml:S1:395:3	see	VBP	O	O
Warnings	PROMACTA.xml:S1:399:8	warn	NNS	O	O
and	PROMACTA.xml:S1:408:3	and	CC	O	O
Precautions	PROMACTA.xml:S1:412:11	precaut	NNP	O	O
(	PROMACTA.xml:S1:424:1	(	(	O	O
5.4	PROMACTA.xml:S1:425:3	5.4	CD	O	O
)]	PROMACTA.xml:S1:428:2	)]	NN	O	O

In	PROMACTA.xml:S1:441:2	In	IN	O	O
adult	PROMACTA.xml:S1:444:5	adult	NN	O	O
patients	PROMACTA.xml:S1:450:8	patient	NNS	O	O
with	PROMACTA.xml:S1:459:4	with	IN	O	O
ITP	PROMACTA.xml:S1:464:3	itp	NNP	O	O
,	PROMACTA.xml:S1:467:1	,	,	O	O
the	PROMACTA.xml:S1:469:3	the	DT	O	O
most	PROMACTA.xml:S1:473:4	most	RBS	O	O
common	PROMACTA.xml:S1:478:6	common	JJ	O	O
adverse	PROMACTA.xml:S1:485:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:493:9	reaction	NNS	O	O
(	PROMACTA.xml:S1:503:1	(	(	O	O
greater	PROMACTA.xml:S1:504:7	greater	JJR	O	O
than	PROMACTA.xml:S1:512:4	than	IN	O	O
or	PROMACTA.xml:S1:517:2	or	CC	O	O
equal	PROMACTA.xml:S1:520:5	equal	JJ	O	O
to	PROMACTA.xml:S1:526:2	to	TO	O	O
5%	PROMACTA.xml:S1:529:2	5%	CD	O	O
and	PROMACTA.xml:S1:532:3	and	CC	O	O
greater	PROMACTA.xml:S1:536:7	greater	JJR	O	O
than	PROMACTA.xml:S1:544:4	than	IN	O	O
placebo	PROMACTA.xml:S1:549:7	placebo	NN	O	O
)	PROMACTA.xml:S1:556:1	)	)	O	O
were	PROMACTA.xml:S1:558:4	were	VBD	O	O
:	PROMACTA.xml:S1:562:1	:	:	O	O
nausea	PROMACTA.xml:S1:564:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:570:1	,	,	O	O
diarrhea	PROMACTA.xml:S1:572:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:580:1	,	,	O	O
upper	PROMACTA.xml:S1:582:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	PROMACTA.xml:S1:588:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	PROMACTA.xml:S1:600:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	PROMACTA.xml:S1:606:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	PROMACTA.xml:S1:615:1	,	,	O	O
vomiting	PROMACTA.xml:S1:617:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:625:1	,	,	O	O
increased	PROMACTA.xml:S1:627:9	increas	JJ	B-AdverseReaction	B-AdverseReaction
ALT	PROMACTA.xml:S1:637:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
,	PROMACTA.xml:S1:640:1	,	,	O	O
myalgia	PROMACTA.xml:S1:642:7	myalgia	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:649:1	,	,	O	O
and	PROMACTA.xml:S1:651:3	and	CC	O	O
urinary	PROMACTA.xml:S1:655:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	PROMACTA.xml:S1:663:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	PROMACTA.xml:S1:669:9	infect	NN	I-AdverseReaction	I-AdverseReaction
.	PROMACTA.xml:S1:678:1	.	.	O	O

(	PROMACTA.xml:S1:680:1	(	(	O	O
6.1	PROMACTA.xml:S1:683:3	6.1	CD	O	O
)	PROMACTA.xml:S1:688:1	)	)	O	O

In	PROMACTA.xml:S1:697:2	In	IN	O	O
pediatric	PROMACTA.xml:S1:700:9	pediatr	JJ	O	O
patients	PROMACTA.xml:S1:710:8	patient	NNS	O	O
age	PROMACTA.xml:S1:719:3	age	NN	O	O
6	PROMACTA.xml:S1:723:1	6	CD	O	O
years	PROMACTA.xml:S1:725:5	year	NNS	O	O
and	PROMACTA.xml:S1:731:3	and	CC	O	O
older	PROMACTA.xml:S1:735:5	older	JJR	O	O
with	PROMACTA.xml:S1:741:4	with	IN	O	O
ITP	PROMACTA.xml:S1:746:3	itp	NNP	O	O
,	PROMACTA.xml:S1:749:1	,	,	O	O
the	PROMACTA.xml:S1:751:3	the	DT	O	O
most	PROMACTA.xml:S1:755:4	most	RBS	O	O
common	PROMACTA.xml:S1:760:6	common	JJ	O	O
adverse	PROMACTA.xml:S1:767:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:775:9	reaction	NNS	O	O
(	PROMACTA.xml:S1:785:1	(	(	O	O
greater	PROMACTA.xml:S1:786:7	greater	JJR	O	O
than	PROMACTA.xml:S1:794:4	than	IN	O	O
or	PROMACTA.xml:S1:799:2	or	CC	O	O
equal	PROMACTA.xml:S1:802:5	equal	JJ	O	O
to	PROMACTA.xml:S1:808:2	to	TO	O	O
10%	PROMACTA.xml:S1:811:3	10%	CD	O	O
and	PROMACTA.xml:S1:815:3	and	CC	O	O
greater	PROMACTA.xml:S1:819:7	greater	JJR	O	O
than	PROMACTA.xml:S1:827:4	than	IN	O	O
placebo	PROMACTA.xml:S1:832:7	placebo	NN	O	O
)	PROMACTA.xml:S1:839:1	)	)	O	O
were	PROMACTA.xml:S1:841:4	were	VBD	O	O
upper	PROMACTA.xml:S1:846:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	PROMACTA.xml:S1:852:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	PROMACTA.xml:S1:864:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	PROMACTA.xml:S1:870:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	PROMACTA.xml:S1:879:1	,	,	O	O
nasopharyngitis	PROMACTA.xml:S1:881:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:896:1	,	,	O	O
and	PROMACTA.xml:S1:898:3	and	CC	O	O
rhinitis	PROMACTA.xml:S1:902:8	rhiniti	NN	B-AdverseReaction	B-AdverseReaction
.	PROMACTA.xml:S1:910:1	.	.	O	O

(	PROMACTA.xml:S1:912:1	(	(	O	O
6.1	PROMACTA.xml:S1:915:3	6.1	CD	O	O
)	PROMACTA.xml:S1:920:1	)	)	O	O

In	PROMACTA.xml:S1:929:2	In	IN	O	O
patients	PROMACTA.xml:S1:932:8	patient	NNS	O	O
with	PROMACTA.xml:S1:941:4	with	IN	O	O
chronic	PROMACTA.xml:S1:946:7	chronic	JJ	O	O
hepatitis	PROMACTA.xml:S1:954:9	hepat	NN	O	O
C	PROMACTA.xml:S1:964:1	C	NNP	O	O
-	PROMACTA.xml:S1:965:1	-	:	O	O
associated	PROMACTA.xml:S1:966:10	associ	VBN	O	O
thrombocytopenia	PROMACTA.xml:S1:977:16	thrombocytopenia	NN	O	B-AdverseReaction
,	PROMACTA.xml:S1:993:1	,	,	O	O
the	PROMACTA.xml:S1:995:3	the	DT	O	O
most	PROMACTA.xml:S1:999:4	most	RBS	O	O
common	PROMACTA.xml:S1:1004:6	common	JJ	O	O
adverse	PROMACTA.xml:S1:1011:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:1019:9	reaction	NNS	O	O
(	PROMACTA.xml:S1:1029:1	(	(	O	O
greater	PROMACTA.xml:S1:1030:7	greater	JJR	O	O
than	PROMACTA.xml:S1:1038:4	than	IN	O	O
or	PROMACTA.xml:S1:1043:2	or	CC	O	O
equal	PROMACTA.xml:S1:1046:5	equal	JJ	O	O
to	PROMACTA.xml:S1:1052:2	to	TO	O	O
10%	PROMACTA.xml:S1:1055:3	10%	CD	O	O
and	PROMACTA.xml:S1:1059:3	and	CC	O	O
greater	PROMACTA.xml:S1:1063:7	greater	JJR	O	O
than	PROMACTA.xml:S1:1071:4	than	IN	O	O
placebo	PROMACTA.xml:S1:1076:7	placebo	NN	O	O
)	PROMACTA.xml:S1:1083:1	)	)	O	O
were	PROMACTA.xml:S1:1085:4	were	VBD	O	O
:	PROMACTA.xml:S1:1089:1	:	:	O	O
anemia	PROMACTA.xml:S1:1091:6	anemia	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1097:1	,	,	O	O
pyrexia	PROMACTA.xml:S1:1099:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1106:1	,	,	O	O
fatigue	PROMACTA.xml:S1:1108:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1115:1	,	,	O	O
headache	PROMACTA.xml:S1:1117:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1125:1	,	,	O	O
nausea	PROMACTA.xml:S1:1127:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1133:1	,	,	O	O
diarrhea	PROMACTA.xml:S1:1135:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1143:1	,	,	O	O
decreased	PROMACTA.xml:S1:1145:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	PROMACTA.xml:S1:1155:8	appetit	NN	I-AdverseReaction	I-AdverseReaction
,	PROMACTA.xml:S1:1163:1	,	,	O	O
influenza	PROMACTA.xml:S1:1165:9	influenza	JJ	B-AdverseReaction	B-AdverseReaction
-	PROMACTA.xml:S1:1174:1	-	:	I-AdverseReaction	I-AdverseReaction
like	PROMACTA.xml:S1:1175:4	like	IN	I-AdverseReaction	I-AdverseReaction
illness	PROMACTA.xml:S1:1180:7	ill	NN	I-AdverseReaction	I-AdverseReaction
,	PROMACTA.xml:S1:1187:1	,	,	O	O
asthenia	PROMACTA.xml:S1:1189:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1197:1	,	,	O	O
insomnia	PROMACTA.xml:S1:1199:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1207:1	,	,	O	O
cough	PROMACTA.xml:S1:1209:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1214:1	,	,	O	O
pruritus	PROMACTA.xml:S1:1216:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1224:1	,	,	O	O
chills	PROMACTA.xml:S1:1226:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1232:1	,	,	O	O
myalgia	PROMACTA.xml:S1:1234:7	myalgia	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1241:1	,	,	O	O
alopecia	PROMACTA.xml:S1:1243:8	alopecia	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1251:1	,	,	O	O
and	PROMACTA.xml:S1:1253:3	and	CC	O	O
peripheral	PROMACTA.xml:S1:1257:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
edema	PROMACTA.xml:S1:1268:5	edema	NN	I-AdverseReaction	I-AdverseReaction
.	PROMACTA.xml:S1:1273:1	.	.	O	O

(	PROMACTA.xml:S1:1275:1	(	(	O	O
6.1	PROMACTA.xml:S1:1278:3	6.1	CD	O	O
)	PROMACTA.xml:S1:1283:1	)	)	O	O

In	PROMACTA.xml:S1:1292:2	In	IN	O	O
patients	PROMACTA.xml:S1:1295:8	patient	NNS	O	O
with	PROMACTA.xml:S1:1304:4	with	IN	O	O
severe	PROMACTA.xml:S1:1309:6	sever	JJ	O	O
aplastic	PROMACTA.xml:S1:1316:8	aplast	JJ	O	O
anemia	PROMACTA.xml:S1:1325:6	anemia	NN	O	O
,	PROMACTA.xml:S1:1331:1	,	,	O	O
the	PROMACTA.xml:S1:1333:3	the	DT	O	O
most	PROMACTA.xml:S1:1337:4	most	RBS	O	O
common	PROMACTA.xml:S1:1342:6	common	JJ	O	O
adverse	PROMACTA.xml:S1:1349:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:1357:9	reaction	NNS	O	O
(	PROMACTA.xml:S1:1367:1	(	(	O	O
greater	PROMACTA.xml:S1:1368:7	greater	JJR	O	O
than	PROMACTA.xml:S1:1376:4	than	IN	O	O
or	PROMACTA.xml:S1:1381:2	or	CC	O	O
equal	PROMACTA.xml:S1:1384:5	equal	JJ	O	O
to	PROMACTA.xml:S1:1390:2	to	TO	O	O
20%	PROMACTA.xml:S1:1393:3	20%	CD	O	O
)	PROMACTA.xml:S1:1396:1	)	)	O	O
were	PROMACTA.xml:S1:1398:4	were	VBD	O	O
:	PROMACTA.xml:S1:1402:1	:	:	O	O
nausea	PROMACTA.xml:S1:1404:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1410:1	,	,	O	O
fatigue	PROMACTA.xml:S1:1412:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1419:1	,	,	O	O
cough	PROMACTA.xml:S1:1421:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1426:1	,	,	O	O
diarrhea	PROMACTA.xml:S1:1428:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:1436:1	,	,	O	O
and	PROMACTA.xml:S1:1438:3	and	CC	O	O
headache	PROMACTA.xml:S1:1442:8	headach	NN	B-AdverseReaction	B-AdverseReaction
.	PROMACTA.xml:S1:1450:1	.	.	O	O

(	PROMACTA.xml:S1:1452:1	(	(	O	O
6.1	PROMACTA.xml:S1:1455:3	6.1	CD	O	O
)	PROMACTA.xml:S1:1460:1	)	)	O	O

EXCERPT	PROMACTA.xml:S1:1469:7	excerpt	NN	O	O
:	PROMACTA.xml:S1:1476:1	:	:	O	O
To	PROMACTA.xml:S1:1482:2	To	TO	O	O
report	PROMACTA.xml:S1:1485:6	report	VB	O	O
SUSPECTED	PROMACTA.xml:S1:1492:9	suspect	NNP	O	O
ADVERSE	PROMACTA.xml:S1:1502:7	advers	NNP	O	O
REACTIONS	PROMACTA.xml:S1:1510:9	reaction	NNP	O	O
,	PROMACTA.xml:S1:1519:1	,	,	O	O
contact	PROMACTA.xml:S1:1521:7	contact	NN	O	O
GlaxoSmithKline	PROMACTA.xml:S1:1529:15	glaxosmithklin	NNP	O	O
at	PROMACTA.xml:S1:1545:2	at	IN	O	O
1	PROMACTA.xml:S1:1548:1	1	CD	O	O
-	PROMACTA.xml:S1:1549:1	-	:	O	O
888	PROMACTA.xml:S1:1550:3	888	CD	O	O
-	PROMACTA.xml:S1:1553:1	-	:	O	O
825	PROMACTA.xml:S1:1554:3	825	CD	O	O
-	PROMACTA.xml:S1:1557:1	-	:	O	O
5249	PROMACTA.xml:S1:1558:4	5249	CD	O	O
or	PROMACTA.xml:S1:1563:2	or	CC	O	O
FDA	PROMACTA.xml:S1:1566:3	fda	NNP	O	O
at	PROMACTA.xml:S1:1570:2	at	IN	O	O
1	PROMACTA.xml:S1:1573:1	1	CD	O	O
-	PROMACTA.xml:S1:1574:1	-	:	O	O
800	PROMACTA.xml:S1:1575:3	800	CD	O	O
-	PROMACTA.xml:S1:1578:1	-	:	O	O
FDA	PROMACTA.xml:S1:1579:3	fda	NNP	O	O
-	PROMACTA.xml:S1:1582:1	-	:	O	O
1088	PROMACTA.xml:S1:1583:4	1088	CD	O	O
or	PROMACTA.xml:S1:1588:2	or	CC	O	O
www	PROMACTA.xml:S1:1592:3	www	VB	O	O
.	PROMACTA.xml:S1:1595:1	.	.	O	O
fda	PROMACTA.xml:S1:1596:3	fda	NN	O	O
.	PROMACTA.xml:S1:1599:1	.	.	O	O
gov	PROMACTA.xml:S1:1600:3	gov	JJ	O	O
medwatch	PROMACTA.xml:S1:1604:8	medwatch	NN	O	O
.	PROMACTA.xml:S1:1614:1	.	.	O	O

6.1	PROMACTA.xml:S1:1626:3	6.1	CD	O	O

Clinical	PROMACTA.xml:S1:1630:8	clinic	JJ	O	O

Trials	PROMACTA.xml:S1:1639:6	trial	NNS	O	O
Experience	PROMACTA.xml:S1:1646:10	experi	NN	O	O

Because	PROMACTA.xml:S1:1660:7	becaus	IN	O	O
clinical	PROMACTA.xml:S1:1668:8	clinic	JJ	O	O
trials	PROMACTA.xml:S1:1677:6	trial	NNS	O	O
are	PROMACTA.xml:S1:1684:3	are	VBP	O	O
conducted	PROMACTA.xml:S1:1688:9	conduct	VBN	O	O
under	PROMACTA.xml:S1:1698:5	under	IN	O	O
widely	PROMACTA.xml:S1:1704:6	wide	RB	O	O
varying	PROMACTA.xml:S1:1711:7	vari	VBG	O	O
conditions	PROMACTA.xml:S1:1719:10	condit	NNS	O	O
,	PROMACTA.xml:S1:1729:1	,	,	O	O
adverse	PROMACTA.xml:S1:1731:7	advers	JJ	O	O
reaction	PROMACTA.xml:S1:1739:8	reaction	NN	O	O
rates	PROMACTA.xml:S1:1748:5	rate	NNS	O	O
observed	PROMACTA.xml:S1:1754:8	observ	VBD	O	O
in	PROMACTA.xml:S1:1763:2	in	IN	O	O
the	PROMACTA.xml:S1:1766:3	the	DT	O	O
clinical	PROMACTA.xml:S1:1770:8	clinic	JJ	O	O
trials	PROMACTA.xml:S1:1779:6	trial	NNS	O	O
of	PROMACTA.xml:S1:1786:2	of	IN	O	O
a	PROMACTA.xml:S1:1789:1	a	DT	O	O
drug	PROMACTA.xml:S1:1791:4	drug	NN	O	O
cannot	PROMACTA.xml:S1:1796:6	cannot	NN	O	O
be	PROMACTA.xml:S1:1803:2	be	VB	O	O
directly	PROMACTA.xml:S1:1806:8	directli	RB	O	O
compared	PROMACTA.xml:S1:1815:8	compar	VBN	O	O
with	PROMACTA.xml:S1:1824:4	with	IN	O	O
rates	PROMACTA.xml:S1:1829:5	rate	NNS	O	O
in	PROMACTA.xml:S1:1835:2	in	IN	O	O
the	PROMACTA.xml:S1:1838:3	the	DT	O	O
clinical	PROMACTA.xml:S1:1842:8	clinic	JJ	O	O
trials	PROMACTA.xml:S1:1851:6	trial	NNS	O	O
of	PROMACTA.xml:S1:1858:2	of	IN	O	O
another	PROMACTA.xml:S1:1861:7	anoth	DT	O	O
drug	PROMACTA.xml:S1:1869:4	drug	NN	O	O
and	PROMACTA.xml:S1:1874:3	and	CC	O	O
may	PROMACTA.xml:S1:1878:3	may	MD	O	O
not	PROMACTA.xml:S1:1882:3	not	RB	O	O
reflect	PROMACTA.xml:S1:1886:7	reflect	VB	O	O
the	PROMACTA.xml:S1:1894:3	the	DT	O	O
rates	PROMACTA.xml:S1:1898:5	rate	NNS	O	O
observed	PROMACTA.xml:S1:1904:8	observ	VBD	O	O
in	PROMACTA.xml:S1:1913:2	in	IN	O	O
practice	PROMACTA.xml:S1:1916:8	practic	NN	O	O
.	PROMACTA.xml:S1:1924:1	.	.	O	O

Chronic	PROMACTA.xml:S1:1932:7	chronic	NNP	O	O
Immune	PROMACTA.xml:S1:1940:6	immun	NNP	O	O
(	PROMACTA.xml:S1:1947:1	(	(	O	O
Idiopathic	PROMACTA.xml:S1:1948:10	idiopath	NNP	O	O
)	PROMACTA.xml:S1:1958:1	)	)	O	O
Thrombocytopenia	PROMACTA.xml:S1:1960:16	thrombocytopenia	NNP	O	O
:	PROMACTA.xml:S1:1976:1	:	:	O	O
Adults	PROMACTA.xml:S1:1981:6	adult	NNS	O	O
:	PROMACTA.xml:S1:1987:1	:	:	O	O
In	PROMACTA.xml:S1:1990:2	In	IN	O	O
clinical	PROMACTA.xml:S1:1993:8	clinic	JJ	O	O
trials	PROMACTA.xml:S1:2002:6	trial	NNS	O	O
,	PROMACTA.xml:S1:2008:1	,	,	O	O
hemorrhage	PROMACTA.xml:S1:2010:10	hemorrhag	NN	B-AdverseReaction	B-AdverseReaction
was	PROMACTA.xml:S1:2021:3	wa	VBD	O	O
the	PROMACTA.xml:S1:2025:3	the	DT	O	O
most	PROMACTA.xml:S1:2029:4	most	RBS	O	O
common	PROMACTA.xml:S1:2034:6	common	JJ	O	O
serious	PROMACTA.xml:S1:2041:7	seriou	JJ	O	O
adverse	PROMACTA.xml:S1:2049:7	advers	JJ	O	O
reaction	PROMACTA.xml:S1:2057:8	reaction	NN	O	O
and	PROMACTA.xml:S1:2066:3	and	CC	O	O
most	PROMACTA.xml:S1:2070:4	most	JJS	O	O
hemorrhagic	PROMACTA.xml:S1:2075:11	hemorrhag	JJ	B-AdverseReaction	B-AdverseReaction
reactions	PROMACTA.xml:S1:2087:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
followed	PROMACTA.xml:S1:2097:8	follow	VBD	O	O
discontinuation	PROMACTA.xml:S1:2106:15	discontinu	NN	O	O
of	PROMACTA.xml:S1:2122:2	of	IN	O	O
PROMACTA	PROMACTA.xml:S1:2125:8	promacta	NNP	O	O
.	PROMACTA.xml:S1:2133:1	.	.	O	O

Other	PROMACTA.xml:S1:2135:5	other	JJ	O	O
serious	PROMACTA.xml:S1:2141:7	seriou	JJ	O	O
adverse	PROMACTA.xml:S1:2149:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:2157:9	reaction	NNS	O	O
included	PROMACTA.xml:S1:2167:8	includ	VBD	O	O
thrombotic	PROMACTA.xml:S1:2176:10	thrombot	JJ	B-AdverseReaction	B-AdverseReaction
thromboembolic	PROMACTA.xml:S1:2187:14	thromboembol	JJ	B-AdverseReaction	I-AdverseReaction
complications	PROMACTA.xml:S1:2202:13	complic	NNS	I-AdverseReaction	I-AdverseReaction
[	PROMACTA.xml:S1:2217:1	[	VBP	O	O
see	PROMACTA.xml:S1:2218:3	see	VBP	O	O
Warnings	PROMACTA.xml:S1:2222:8	warn	NNS	O	O
and	PROMACTA.xml:S1:2231:3	and	CC	O	O
Precautions	PROMACTA.xml:S1:2235:11	precaut	NNP	O	O
(	PROMACTA.xml:S1:2247:1	(	(	O	O
5.3	PROMACTA.xml:S1:2248:3	5.3	CD	O	O
)]	PROMACTA.xml:S1:2251:2	)]	NN	O	O
.	PROMACTA.xml:S1:2255:1	.	.	O	O

The	PROMACTA.xml:S1:2257:3	the	DT	O	O
data	PROMACTA.xml:S1:2261:4	data	NNS	O	O
described	PROMACTA.xml:S1:2266:9	describ	VBD	O	O
below	PROMACTA.xml:S1:2276:5	below	IN	O	O
reflect	PROMACTA.xml:S1:2282:7	reflect	JJ	O	O
exposure	PROMACTA.xml:S1:2290:8	exposur	NN	O	O
of	PROMACTA.xml:S1:2299:2	of	IN	O	O
PROMACTA	PROMACTA.xml:S1:2302:8	promacta	NNP	O	O
to	PROMACTA.xml:S1:2311:2	to	TO	O	O
446	PROMACTA.xml:S1:2314:3	446	CD	O	O
patients	PROMACTA.xml:S1:2318:8	patient	NNS	O	O
with	PROMACTA.xml:S1:2327:4	with	IN	O	O
chronic	PROMACTA.xml:S1:2332:7	chronic	JJ	O	O
ITP	PROMACTA.xml:S1:2340:3	itp	NNP	O	O
aged	PROMACTA.xml:S1:2344:4	age	VBD	O	O
18	PROMACTA.xml:S1:2349:2	18	CD	O	O
to	PROMACTA.xml:S1:2352:2	to	TO	O	O
85	PROMACTA.xml:S1:2355:2	85	CD	O	O
years	PROMACTA.xml:S1:2358:5	year	NNS	O	O
,	PROMACTA.xml:S1:2363:1	,	,	O	O
of	PROMACTA.xml:S1:2365:2	of	IN	O	O
whom	PROMACTA.xml:S1:2368:4	whom	WP	O	O
65%	PROMACTA.xml:S1:2373:3	65%	CD	O	O
were	PROMACTA.xml:S1:2377:4	were	VBD	O	O
female	PROMACTA.xml:S1:2382:6	femal	JJ	O	O
,	PROMACTA.xml:S1:2388:1	,	,	O	O
across	PROMACTA.xml:S1:2390:6	across	IN	O	O
the	PROMACTA.xml:S1:2397:3	the	DT	O	O
ITP	PROMACTA.xml:S1:2401:3	itp	NNP	O	O
clinical	PROMACTA.xml:S1:2405:8	clinic	JJ	O	O
development	PROMACTA.xml:S1:2414:11	develop	NN	O	O
program	PROMACTA.xml:S1:2426:7	program	NN	O	O
including	PROMACTA.xml:S1:2434:9	includ	VBG	O	O
three	PROMACTA.xml:S1:2444:5	three	CD	O	O
placebo	PROMACTA.xml:S1:2450:7	placebo	NN	O	O
-	PROMACTA.xml:S1:2457:1	-	:	O	O
controlled	PROMACTA.xml:S1:2458:10	control	VBN	O	O
trials	PROMACTA.xml:S1:2469:6	trial	NNS	O	O
.	PROMACTA.xml:S1:2475:1	.	.	O	O

PROMACTA	PROMACTA.xml:S1:2477:8	promacta	NNP	O	O
was	PROMACTA.xml:S1:2486:3	wa	VBD	O	O
administered	PROMACTA.xml:S1:2490:12	administ	VBN	O	O
to	PROMACTA.xml:S1:2503:2	to	TO	O	O
277	PROMACTA.xml:S1:2506:3	277	CD	O	O
patients	PROMACTA.xml:S1:2510:8	patient	NNS	O	O
for	PROMACTA.xml:S1:2519:3	for	IN	O	O
at	PROMACTA.xml:S1:2523:2	at	IN	O	O
least	PROMACTA.xml:S1:2526:5	least	JJS	O	O
6	PROMACTA.xml:S1:2532:1	6	CD	O	O
months	PROMACTA.xml:S1:2534:6	month	NNS	O	O
and	PROMACTA.xml:S1:2541:3	and	CC	O	O
202	PROMACTA.xml:S1:2545:3	202	CD	O	O
patients	PROMACTA.xml:S1:2549:8	patient	NNS	O	O
for	PROMACTA.xml:S1:2558:3	for	IN	O	O
at	PROMACTA.xml:S1:2562:2	at	IN	O	O
least	PROMACTA.xml:S1:2565:5	least	JJS	O	O
1	PROMACTA.xml:S1:2571:1	1	CD	O	O
year	PROMACTA.xml:S1:2573:4	year	NN	O	O
.	PROMACTA.xml:S1:2577:1	.	.	O	O

Table	PROMACTA.xml:S1:2583:5	tabl	JJ	O	O
4	PROMACTA.xml:S1:2589:1	4	CD	O	O
presents	PROMACTA.xml:S1:2591:8	present	VBZ	O	O
the	PROMACTA.xml:S1:2600:3	the	DT	O	O
most	PROMACTA.xml:S1:2604:4	most	RBS	O	O
common	PROMACTA.xml:S1:2609:6	common	JJ	O	O
adverse	PROMACTA.xml:S1:2616:7	advers	JJ	O	O
drug	PROMACTA.xml:S1:2624:4	drug	NN	O	O
reactions	PROMACTA.xml:S1:2629:9	reaction	NNS	O	O
(	PROMACTA.xml:S1:2639:1	(	(	O	O
experienced	PROMACTA.xml:S1:2640:11	experienc	VBN	O	O
by	PROMACTA.xml:S1:2652:2	by	IN	O	O
greater	PROMACTA.xml:S1:2655:7	greater	JJR	O	O
than	PROMACTA.xml:S1:2663:4	than	IN	O	O
or	PROMACTA.xml:S1:2668:2	or	CC	O	O
equal	PROMACTA.xml:S1:2671:5	equal	JJ	O	O
to	PROMACTA.xml:S1:2677:2	to	TO	O	O
3%	PROMACTA.xml:S1:2680:2	3%	CD	O	O
of	PROMACTA.xml:S1:2683:2	of	IN	O	O
patients	PROMACTA.xml:S1:2686:8	patient	NNS	O	O
receiving	PROMACTA.xml:S1:2695:9	receiv	VBG	O	O
PROMACTA	PROMACTA.xml:S1:2705:8	promacta	NNP	O	O
)	PROMACTA.xml:S1:2713:1	)	)	O	O
from	PROMACTA.xml:S1:2715:4	from	IN	O	O
the	PROMACTA.xml:S1:2720:3	the	DT	O	O
three	PROMACTA.xml:S1:2724:5	three	CD	O	O
placebo	PROMACTA.xml:S1:2730:7	placebo	NN	O	O
-	PROMACTA.xml:S1:2737:1	-	:	O	O
controlled	PROMACTA.xml:S1:2738:10	control	VBN	O	O
trials	PROMACTA.xml:S1:2749:6	trial	NNS	O	O
,	PROMACTA.xml:S1:2755:1	,	,	O	O
with	PROMACTA.xml:S1:2757:4	with	IN	O	O
a	PROMACTA.xml:S1:2762:1	a	DT	O	O
higher	PROMACTA.xml:S1:2764:6	higher	JJR	O	O
incidence	PROMACTA.xml:S1:2771:9	incid	NN	O	O
in	PROMACTA.xml:S1:2781:2	in	IN	O	O
PROMACTA	PROMACTA.xml:S1:2784:8	promacta	NNP	O	O
versus	PROMACTA.xml:S1:2793:6	versu	NN	O	O
placebo	PROMACTA.xml:S1:2800:7	placebo	NN	O	O
.	PROMACTA.xml:S1:2807:1	.	.	O	O

Table	PROMACTA.xml:S1:2813:5	tabl	JJ	O	O
4	PROMACTA.xml:S1:2819:1	4	CD	O	O
.	PROMACTA.xml:S1:2820:1	.	.	O	O

Adverse	PROMACTA.xml:S1:2822:7	advers	JJ	O	O
Reactions	PROMACTA.xml:S1:2830:9	reaction	NNP	O	O
(	PROMACTA.xml:S1:2840:1	(	(	O	O
3%	PROMACTA.xml:S1:2843:2	3%	CD	O	O
)	PROMACTA.xml:S1:2845:1	)	)	O	O
from	PROMACTA.xml:S1:2847:4	from	IN	O	O
Three	PROMACTA.xml:S1:2852:5	three	NNP	O	O
Placebo	PROMACTA.xml:S1:2858:7	placebo	NNP	O	O
-	PROMACTA.xml:S1:2865:1	-	:	O	O
controlled	PROMACTA.xml:S1:2866:10	control	VBN	O	O
Trials	PROMACTA.xml:S1:2877:6	trial	NNS	O	O
in	PROMACTA.xml:S1:2884:2	in	IN	O	O
Adults	PROMACTA.xml:S1:2887:6	adult	NNP	O	O
with	PROMACTA.xml:S1:2894:4	with	IN	O	O
Chronic	PROMACTA.xml:S1:2899:7	chronic	NNP	O	O
Immune	PROMACTA.xml:S1:2907:6	immun	NNP	O	O
(	PROMACTA.xml:S1:2914:1	(	(	O	O
Idiopathic	PROMACTA.xml:S1:2915:10	idiopath	NNP	O	O
)	PROMACTA.xml:S1:2925:1	)	)	O	O
Thrombocytopenia	PROMACTA.xml:S1:2927:16	thrombocytopenia	NNP	O	O

Adverse	PROMACTA.xml:S1:2947:7	advers	JJ	O	O
Reaction	PROMACTA.xml:S1:2955:8	reaction	NNP	O	O
PROMACTA	PROMACTA.xml:S1:2999:8	promacta	NNP	O	O
50	PROMACTA.xml:S1:3008:2	50	CD	O	O
mg	PROMACTA.xml:S1:3011:2	mg	NN	O	O
n	PROMACTA.xml:S1:3015:1	n	RB	O	O
241	PROMACTA.xml:S1:3019:3	241	CD	O	O
(	PROMACTA.xml:S1:3024:1	(	(	O	O
)	PROMACTA.xml:S1:3026:1	)	)	O	O
Placebo	PROMACTA.xml:S1:3036:7	placebo	NNP	O	O
n	PROMACTA.xml:S1:3045:1	n	$	O	O
128	PROMACTA.xml:S1:3049:3	128	CD	O	O
(	PROMACTA.xml:S1:3054:1	(	(	O	O
)	PROMACTA.xml:S1:3056:1	)	)	O	O

Nausea	PROMACTA.xml:S1:3064:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
9	PROMACTA.xml:S1:3116:1	9	CD	O	O
3	PROMACTA.xml:S1:3153:1	3	CD	O	O

Diarrhea	PROMACTA.xml:S1:3173:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
9	PROMACTA.xml:S1:3225:1	9	CD	O	O
7	PROMACTA.xml:S1:3262:1	7	CD	O	O

Upper	PROMACTA.xml:S1:3282:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	PROMACTA.xml:S1:3288:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	PROMACTA.xml:S1:3300:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	PROMACTA.xml:S1:3306:9	infect	NN	I-AdverseReaction	I-AdverseReaction
7	PROMACTA.xml:S1:3334:1	7	CD	O	O
6	PROMACTA.xml:S1:3371:1	6	CD	O	O

Vomiting	PROMACTA.xml:S1:3391:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
6	PROMACTA.xml:S1:3443:1	6	CD	O	O
1	PROMACTA.xml:S1:3481:1	1	CD	O	O

Increased	PROMACTA.xml:S1:3500:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
ALT	PROMACTA.xml:S1:3510:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
5	PROMACTA.xml:S1:3552:1	5	CD	O	O
3	PROMACTA.xml:S1:3589:1	3	CD	O	O

Myalgia	PROMACTA.xml:S1:3609:7	myalgia	NNP	B-AdverseReaction	B-AdverseReaction
5	PROMACTA.xml:S1:3661:1	5	CD	O	O
2	PROMACTA.xml:S1:3698:1	2	CD	O	O

Urinary	PROMACTA.xml:S1:3718:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	PROMACTA.xml:S1:3726:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	PROMACTA.xml:S1:3732:9	infect	NN	I-AdverseReaction	I-AdverseReaction
5	PROMACTA.xml:S1:3770:1	5	CD	O	O
3	PROMACTA.xml:S1:3807:1	3	CD	O	O

Oropharyngeal	PROMACTA.xml:S1:3827:13	oropharyng	NNP	B-AdverseReaction	B-AdverseReaction
pain	PROMACTA.xml:S1:3841:4	pain	NN	I-AdverseReaction	I-AdverseReaction
4	PROMACTA.xml:S1:3879:1	4	CD	O	O
3	PROMACTA.xml:S1:3916:1	3	CD	O	O

Increased	PROMACTA.xml:S1:3936:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
AST	PROMACTA.xml:S1:3946:3	ast	$	I-AdverseReaction	I-AdverseReaction
4	PROMACTA.xml:S1:3988:1	4	CD	O	O
2	PROMACTA.xml:S1:4025:1	2	CD	O	O

Pharyngitis	PROMACTA.xml:S1:4045:11	pharyng	NN	B-AdverseReaction	B-AdverseReaction
4	PROMACTA.xml:S1:4097:1	4	CD	O	O
2	PROMACTA.xml:S1:4134:1	2	CD	O	O

Back	PROMACTA.xml:S1:4154:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	PROMACTA.xml:S1:4159:4	pain	NN	I-AdverseReaction	I-AdverseReaction
3	PROMACTA.xml:S1:4206:1	3	CD	O	O
2	PROMACTA.xml:S1:4243:1	2	CD	O	O

Influenza	PROMACTA.xml:S1:4263:9	influenza	NNP	B-AdverseReaction	B-AdverseReaction
3	PROMACTA.xml:S1:4315:1	3	CD	O	O
2	PROMACTA.xml:S1:4352:1	2	CD	O	O

Paresthesia	PROMACTA.xml:S1:4372:11	paresthesia	NNP	B-AdverseReaction	B-AdverseReaction
3	PROMACTA.xml:S1:4424:1	3	CD	O	O
2	PROMACTA.xml:S1:4461:1	2	CD	O	O

Rash	PROMACTA.xml:S1:4481:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
3	PROMACTA.xml:S1:4533:1	3	CD	O	O
2	PROMACTA.xml:S1:4570:1	2	CD	O	O

In	PROMACTA.xml:S1:4597:2	In	IN	O	O
the	PROMACTA.xml:S1:4600:3	the	DT	O	O
three	PROMACTA.xml:S1:4604:5	three	CD	O	O
controlled	PROMACTA.xml:S1:4610:10	control	VBD	O	O
clinical	PROMACTA.xml:S1:4621:8	clinic	JJ	O	O
chronic	PROMACTA.xml:S1:4630:7	chronic	NN	O	O
ITP	PROMACTA.xml:S1:4638:3	itp	NNP	O	O
trials	PROMACTA.xml:S1:4642:6	trial	NNS	O	O
,	PROMACTA.xml:S1:4648:1	,	,	O	O
alopecia	PROMACTA.xml:S1:4650:8	alopecia	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:4658:1	,	,	O	O
musculoskeletal	PROMACTA.xml:S1:4660:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	PROMACTA.xml:S1:4676:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PROMACTA.xml:S1:4680:1	,	,	O	O
blood	PROMACTA.xml:S1:4682:5	blood	NN	B-AdverseReaction	B-AdverseReaction
alkaline	PROMACTA.xml:S1:4688:8	alkalin	JJ	I-AdverseReaction	I-AdverseReaction
phosphatase	PROMACTA.xml:S1:4697:11	phosphatas	NN	I-AdverseReaction	I-AdverseReaction
increased	PROMACTA.xml:S1:4709:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	PROMACTA.xml:S1:4718:1	,	,	O	O
and	PROMACTA.xml:S1:4720:3	and	CC	O	O
dry	PROMACTA.xml:S1:4724:3	dri	JJ	B-AdverseReaction	B-AdverseReaction
mouth	PROMACTA.xml:S1:4728:5	mouth	NN	I-AdverseReaction	I-AdverseReaction
were	PROMACTA.xml:S1:4734:4	were	VBD	O	O
the	PROMACTA.xml:S1:4739:3	the	DT	O	O
adverse	PROMACTA.xml:S1:4743:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:4751:9	reaction	NNS	O	O
reported	PROMACTA.xml:S1:4761:8	report	VBN	O	O
in	PROMACTA.xml:S1:4770:2	in	IN	O	O
2%	PROMACTA.xml:S1:4773:2	2%	CD	O	O
of	PROMACTA.xml:S1:4776:2	of	IN	O	O
patients	PROMACTA.xml:S1:4779:8	patient	NNS	O	O
treated	PROMACTA.xml:S1:4788:7	treat	VBN	O	O
with	PROMACTA.xml:S1:4796:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S1:4801:8	promacta	NNP	O	O
and	PROMACTA.xml:S1:4810:3	and	CC	O	O
in	PROMACTA.xml:S1:4814:2	in	IN	O	O
no	PROMACTA.xml:S1:4817:2	no	DT	O	O
patients	PROMACTA.xml:S1:4820:8	patient	NNS	O	O
who	PROMACTA.xml:S1:4829:3	who	WP	O	O
received	PROMACTA.xml:S1:4833:8	receiv	VBD	O	O
placebo	PROMACTA.xml:S1:4842:7	placebo	NN	O	O
.	PROMACTA.xml:S1:4849:1	.	.	O	O

Among	PROMACTA.xml:S1:4855:5	among	IN	O	O

299	PROMACTA.xml:S1:4861:3	299	CD	O	O
patients	PROMACTA.xml:S1:4865:8	patient	NNS	O	O
with	PROMACTA.xml:S1:4874:4	with	IN	O	O
chronic	PROMACTA.xml:S1:4879:7	chronic	JJ	O	O
ITP	PROMACTA.xml:S1:4887:3	itp	NNP	O	O
who	PROMACTA.xml:S1:4891:3	who	WP	O	O
received	PROMACTA.xml:S1:4895:8	receiv	VBD	O	O
PROMACTA	PROMACTA.xml:S1:4904:8	promacta	NNP	O	O
in	PROMACTA.xml:S1:4913:2	in	IN	O	O
the	PROMACTA.xml:S1:4916:3	the	DT	O	O
single	PROMACTA.xml:S1:4920:6	singl	JJ	O	O
-	PROMACTA.xml:S1:4926:1	-	:	O	O
arm	PROMACTA.xml:S1:4927:3	arm	NN	O	O
extension	PROMACTA.xml:S1:4931:9	extens	NN	O	O
trial	PROMACTA.xml:S1:4941:5	trial	NN	O	O
,	PROMACTA.xml:S1:4946:1	,	,	O	O
the	PROMACTA.xml:S1:4948:3	the	DT	O	O
adverse	PROMACTA.xml:S1:4952:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:4960:9	reaction	NNS	O	O
occurred	PROMACTA.xml:S1:4970:8	occur	VBD	O	O
in	PROMACTA.xml:S1:4979:2	in	IN	O	O
a	PROMACTA.xml:S1:4982:1	a	DT	O	O
pattern	PROMACTA.xml:S1:4984:7	pattern	NN	O	O
similar	PROMACTA.xml:S1:4992:7	similar	JJ	O	O
to	PROMACTA.xml:S1:5000:2	to	TO	O	O
that	PROMACTA.xml:S1:5003:4	that	DT	O	O
seen	PROMACTA.xml:S1:5008:4	seen	VBN	O	O
in	PROMACTA.xml:S1:5013:2	in	IN	O	O
the	PROMACTA.xml:S1:5016:3	the	DT	O	O
placebo	PROMACTA.xml:S1:5020:7	placebo	NN	O	O
-	PROMACTA.xml:S1:5027:1	-	:	O	O
controlled	PROMACTA.xml:S1:5028:10	control	VBN	O	O
trials	PROMACTA.xml:S1:5039:6	trial	NNS	O	O
.	PROMACTA.xml:S1:5045:1	.	.	O	O

Table	PROMACTA.xml:S1:5047:5	tabl	JJ	O	O
5	PROMACTA.xml:S1:5053:1	5	CD	O	O
presents	PROMACTA.xml:S1:5055:8	present	VBZ	O	O
the	PROMACTA.xml:S1:5064:3	the	DT	O	O
most	PROMACTA.xml:S1:5068:4	most	RBS	O	O
common	PROMACTA.xml:S1:5073:6	common	JJ	O	O
treatment	PROMACTA.xml:S1:5080:9	treatment	NN	O	O
-	PROMACTA.xml:S1:5089:1	-	:	O	O
related	PROMACTA.xml:S1:5090:7	relat	JJ	O	O
adverse	PROMACTA.xml:S1:5098:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:5106:9	reaction	NNS	O	O
(	PROMACTA.xml:S1:5116:1	(	(	O	O
experienced	PROMACTA.xml:S1:5117:11	experienc	VBN	O	O
by	PROMACTA.xml:S1:5129:2	by	IN	O	O
greater	PROMACTA.xml:S1:5132:7	greater	JJR	O	O
than	PROMACTA.xml:S1:5140:4	than	IN	O	O
or	PROMACTA.xml:S1:5145:2	or	CC	O	O
equal	PROMACTA.xml:S1:5148:5	equal	JJ	O	O
to	PROMACTA.xml:S1:5154:2	to	TO	O	O
3%	PROMACTA.xml:S1:5157:2	3%	CD	O	O
of	PROMACTA.xml:S1:5160:2	of	IN	O	O
patients	PROMACTA.xml:S1:5163:8	patient	NNS	O	O
receiving	PROMACTA.xml:S1:5172:9	receiv	VBG	O	O
PROMACTA	PROMACTA.xml:S1:5182:8	promacta	NNP	O	O
)	PROMACTA.xml:S1:5190:1	)	)	O	O
from	PROMACTA.xml:S1:5192:4	from	IN	O	O
the	PROMACTA.xml:S1:5197:3	the	DT	O	O
extension	PROMACTA.xml:S1:5201:9	extens	NN	O	O
trial	PROMACTA.xml:S1:5211:5	trial	NN	O	O
.	PROMACTA.xml:S1:5216:1	.	.	O	O

Table	PROMACTA.xml:S1:5222:5	tabl	JJ	O	O
5	PROMACTA.xml:S1:5228:1	5	CD	O	O
.	PROMACTA.xml:S1:5229:1	.	.	O	O

Treatment	PROMACTA.xml:S1:5231:9	treatment	NNP	O	B-AdverseReaction
-	PROMACTA.xml:S1:5240:1	-	:	O	I-AdverseReaction
related	PROMACTA.xml:S1:5241:7	relat	JJ	O	I-AdverseReaction
Adverse	PROMACTA.xml:S1:5249:7	advers	JJ	O	I-AdverseReaction
Reactions	PROMACTA.xml:S1:5257:9	reaction	NNP	O	I-AdverseReaction
(	PROMACTA.xml:S1:5267:1	(	(	O	O
3%	PROMACTA.xml:S1:5270:2	3%	CD	O	O
)	PROMACTA.xml:S1:5272:1	)	)	O	O
from	PROMACTA.xml:S1:5274:4	from	IN	O	O
Extension	PROMACTA.xml:S1:5279:9	extens	NNP	O	O
Trial	PROMACTA.xml:S1:5289:5	trial	NNP	O	O
in	PROMACTA.xml:S1:5295:2	in	IN	O	O
Adults	PROMACTA.xml:S1:5298:6	adult	NNP	O	O
with	PROMACTA.xml:S1:5305:4	with	IN	O	O
Chronic	PROMACTA.xml:S1:5310:7	chronic	NNP	O	O
Immune	PROMACTA.xml:S1:5318:6	immun	NNP	O	O
(	PROMACTA.xml:S1:5325:1	(	(	O	O
Idiopathic	PROMACTA.xml:S1:5326:10	idiopath	NNP	O	O
)	PROMACTA.xml:S1:5336:1	)	)	O	O
Thrombocytopenia	PROMACTA.xml:S1:5338:16	thrombocytopenia	NNP	O	O

Adverse	PROMACTA.xml:S1:5358:7	advers	JJ	O	O
Reaction	PROMACTA.xml:S1:5366:8	reaction	NNP	O	O
PROMACTA	PROMACTA.xml:S1:5408:8	promacta	NNP	O	O
50	PROMACTA.xml:S1:5417:2	50	CD	O	O
mg	PROMACTA.xml:S1:5420:2	mg	NN	O	O
n	PROMACTA.xml:S1:5424:1	n	RB	O	O
299	PROMACTA.xml:S1:5428:3	299	CD	O	O
(	PROMACTA.xml:S1:5433:1	(	(	O	O
)	PROMACTA.xml:S1:5435:1	)	)	O	O

Headache	PROMACTA.xml:S1:5465:8	headach	$	B-AdverseReaction	B-AdverseReaction
10	PROMACTA.xml:S1:5515:2	10	CD	O	O

Hyperbilirubinemia	PROMACTA.xml:S1:5572:18	hyperbilirubinemia	$	B-AdverseReaction	B-AdverseReaction
6	PROMACTA.xml:S1:5622:1	6	CD	O	O

ALT	PROMACTA.xml:S1:5679:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
increased	PROMACTA.xml:S1:5683:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
6	PROMACTA.xml:S1:5729:1	6	CD	O	O

Cataract	PROMACTA.xml:S1:5786:8	cataract	NN	B-AdverseReaction	B-AdverseReaction
5	PROMACTA.xml:S1:5836:1	5	CD	O	O

AST	PROMACTA.xml:S1:5893:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
increased	PROMACTA.xml:S1:5897:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
4	PROMACTA.xml:S1:5943:1	4	CD	O	O

Fatigue	PROMACTA.xml:S1:6000:7	fatigu	CD	B-AdverseReaction	O
4	PROMACTA.xml:S1:6050:1	4	CD	O	O

Nausea	PROMACTA.xml:S1:6107:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
4	PROMACTA.xml:S1:6157:1	4	CD	O	O

In	PROMACTA.xml:S1:6220:2	In	IN	O	O
the	PROMACTA.xml:S1:6223:3	the	DT	O	O
three	PROMACTA.xml:S1:6227:5	three	CD	O	O
controlled	PROMACTA.xml:S1:6233:10	control	VBD	O	O
chronic	PROMACTA.xml:S1:6244:7	chronic	JJ	O	O
ITP	PROMACTA.xml:S1:6252:3	itp	NNP	O	O
trials	PROMACTA.xml:S1:6256:6	trial	NNS	O	O
,	PROMACTA.xml:S1:6262:1	,	,	O	O
serum	PROMACTA.xml:S1:6264:5	serum	NN	B-AdverseReaction	O
liver	PROMACTA.xml:S1:6270:5	liver	RB	I-AdverseReaction	O
test	PROMACTA.xml:S1:6276:4	test	NN	I-AdverseReaction	O
abnormalities	PROMACTA.xml:S1:6281:13	abnorm	NNS	I-AdverseReaction	O
(	PROMACTA.xml:S1:6295:1	(	(	O	O
predominantly	PROMACTA.xml:S1:6296:13	predominantli	RB	O	O
Grade	PROMACTA.xml:S1:6310:5	grade	VBZ	O	O
2	PROMACTA.xml:S1:6316:1	2	CD	O	O
or	PROMACTA.xml:S1:6318:2	or	CC	O	O
less	PROMACTA.xml:S1:6321:4	less	JJR	O	O
in	PROMACTA.xml:S1:6326:2	in	IN	O	O
severity	PROMACTA.xml:S1:6329:8	sever	NN	O	O
)	PROMACTA.xml:S1:6337:1	)	)	O	O
were	PROMACTA.xml:S1:6339:4	were	VBD	O	O
reported	PROMACTA.xml:S1:6344:8	report	VBN	O	O
in	PROMACTA.xml:S1:6353:2	in	IN	O	O
11%	PROMACTA.xml:S1:6356:3	11%	CD	O	O
and	PROMACTA.xml:S1:6360:3	and	CC	O	O
7%	PROMACTA.xml:S1:6364:2	7%	CD	O	O
of	PROMACTA.xml:S1:6367:2	of	IN	O	O
patients	PROMACTA.xml:S1:6370:8	patient	NNS	O	O
for	PROMACTA.xml:S1:6379:3	for	IN	O	O
PROMACTA	PROMACTA.xml:S1:6383:8	promacta	NNP	O	O
and	PROMACTA.xml:S1:6392:3	and	CC	O	O
placebo	PROMACTA.xml:S1:6396:7	placebo	NN	O	O
,	PROMACTA.xml:S1:6403:1	,	,	O	O
respectively	PROMACTA.xml:S1:6405:12	respect	RB	O	O
.	PROMACTA.xml:S1:6417:1	.	.	O	O

Four	PROMACTA.xml:S1:6419:4	four	CD	O	O
patients	PROMACTA.xml:S1:6424:8	patient	NNS	O	O
(	PROMACTA.xml:S1:6433:1	(	(	O	O
1%	PROMACTA.xml:S1:6434:2	1%	CD	O	O
)	PROMACTA.xml:S1:6436:1	)	)	O	O
treated	PROMACTA.xml:S1:6438:7	treat	VBN	O	O
with	PROMACTA.xml:S1:6446:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S1:6451:8	promacta	NNP	O	O
and	PROMACTA.xml:S1:6460:3	and	CC	O	O
three	PROMACTA.xml:S1:6464:5	three	CD	O	O
patients	PROMACTA.xml:S1:6470:8	patient	NNS	O	O
in	PROMACTA.xml:S1:6479:2	in	IN	O	O
the	PROMACTA.xml:S1:6482:3	the	DT	O	O
placebo	PROMACTA.xml:S1:6486:7	placebo	NN	O	O
group	PROMACTA.xml:S1:6494:5	group	NN	O	O
(	PROMACTA.xml:S1:6500:1	(	(	O	O
2%	PROMACTA.xml:S1:6501:2	2%	CD	O	O
)	PROMACTA.xml:S1:6503:1	)	)	O	O
discontinued	PROMACTA.xml:S1:6505:12	discontinu	VBN	O	O
treatment	PROMACTA.xml:S1:6518:9	treatment	NN	O	O
due	PROMACTA.xml:S1:6528:3	due	JJ	O	O
to	PROMACTA.xml:S1:6532:2	to	TO	O	O
hepatobiliary	PROMACTA.xml:S1:6535:13	hepatobiliari	JJ	B-AdverseReaction	O
laboratory	PROMACTA.xml:S1:6549:10	laboratori	NN	I-AdverseReaction	O
abnormalities	PROMACTA.xml:S1:6560:13	abnorm	NNS	I-AdverseReaction	O
.	PROMACTA.xml:S1:6573:1	.	.	O	O

Seven	PROMACTA.xml:S1:6575:5	seven	CD	O	O
of	PROMACTA.xml:S1:6581:2	of	IN	O	O
the	PROMACTA.xml:S1:6584:3	the	DT	O	O
patients	PROMACTA.xml:S1:6588:8	patient	NNS	O	O
treated	PROMACTA.xml:S1:6597:7	treat	VBN	O	O
with	PROMACTA.xml:S1:6605:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S1:6610:8	promacta	NNP	O	O
in	PROMACTA.xml:S1:6619:2	in	IN	O	O
the	PROMACTA.xml:S1:6622:3	the	DT	O	O
controlled	PROMACTA.xml:S1:6626:10	control	JJ	O	O
trials	PROMACTA.xml:S1:6637:6	trial	NNS	O	O
with	PROMACTA.xml:S1:6644:4	with	IN	O	O
hepatobiliary	PROMACTA.xml:S1:6649:13	hepatobiliari	JJ	B-AdverseReaction	O
laboratory	PROMACTA.xml:S1:6663:10	laboratori	NN	I-AdverseReaction	O
abnormalities	PROMACTA.xml:S1:6674:13	abnorm	NNS	I-AdverseReaction	O
were	PROMACTA.xml:S1:6688:4	were	VBD	O	O
re	PROMACTA.xml:S1:6693:2	re	JJ	O	O
-	PROMACTA.xml:S1:6695:1	-	:	O	O
exposed	PROMACTA.xml:S1:6696:7	expos	VBN	O	O
to	PROMACTA.xml:S1:6704:2	to	TO	O	O
PROMACTA	PROMACTA.xml:S1:6707:8	promacta	NNP	O	O
in	PROMACTA.xml:S1:6716:2	in	IN	O	O
the	PROMACTA.xml:S1:6719:3	the	DT	O	O
extension	PROMACTA.xml:S1:6723:9	extens	NN	O	O
trial	PROMACTA.xml:S1:6733:5	trial	NN	O	O
.	PROMACTA.xml:S1:6738:1	.	.	O	O

Six	PROMACTA.xml:S1:6740:3	six	CD	O	O
of	PROMACTA.xml:S1:6744:2	of	IN	O	O
these	PROMACTA.xml:S1:6747:5	these	DT	O	O
patients	PROMACTA.xml:S1:6753:8	patient	NNS	O	O
again	PROMACTA.xml:S1:6762:5	again	RB	O	O
experienced	PROMACTA.xml:S1:6768:11	experienc	VBD	O	O
liver	PROMACTA.xml:S1:6780:5	liver	JJ	B-AdverseReaction	B-AdverseReaction
test	PROMACTA.xml:S1:6786:4	test	NN	I-AdverseReaction	I-AdverseReaction
abnormalities	PROMACTA.xml:S1:6791:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
(	PROMACTA.xml:S1:6805:1	(	(	O	O
predominantly	PROMACTA.xml:S1:6806:13	predominantli	RB	O	O
Grade	PROMACTA.xml:S1:6820:5	grade	NNP	O	O
1	PROMACTA.xml:S1:6826:1	1	CD	O	O
)	PROMACTA.xml:S1:6827:1	)	)	O	O
resulting	PROMACTA.xml:S1:6829:9	result	VBG	O	O
in	PROMACTA.xml:S1:6839:2	in	IN	O	O
discontinuation	PROMACTA.xml:S1:6842:15	discontinu	NN	O	O
of	PROMACTA.xml:S1:6858:2	of	IN	O	O
PROMACTA	PROMACTA.xml:S1:6861:8	promacta	NNP	O	O
in	PROMACTA.xml:S1:6870:2	in	IN	O	O
one	PROMACTA.xml:S1:6873:3	one	CD	O	O
patient	PROMACTA.xml:S1:6877:7	patient	NN	O	O
.	PROMACTA.xml:S1:6884:1	.	.	O	O

In	PROMACTA.xml:S1:6886:2	In	IN	O	O
the	PROMACTA.xml:S1:6889:3	the	DT	O	O
extension	PROMACTA.xml:S1:6893:9	extens	NN	O	O
chronic	PROMACTA.xml:S1:6903:7	chronic	JJ	O	O
ITP	PROMACTA.xml:S1:6911:3	itp	NNP	O	O
trial	PROMACTA.xml:S1:6915:5	trial	NN	O	O
,	PROMACTA.xml:S1:6920:1	,	,	O	O
one	PROMACTA.xml:S1:6922:3	one	CD	O	O
additional	PROMACTA.xml:S1:6926:10	addit	JJ	O	O
patient	PROMACTA.xml:S1:6937:7	patient	NN	O	O
had	PROMACTA.xml:S1:6945:3	had	VBD	O	O
PROMACTA	PROMACTA.xml:S1:6949:8	promacta	NNP	O	O
discontinued	PROMACTA.xml:S1:6958:12	discontinu	VBN	O	O
due	PROMACTA.xml:S1:6971:3	due	JJ	O	O
to	PROMACTA.xml:S1:6975:2	to	TO	O	O
liver	PROMACTA.xml:S1:6978:5	liver	VB	B-AdverseReaction	B-AdverseReaction
test	PROMACTA.xml:S1:6984:4	test	NN	I-AdverseReaction	I-AdverseReaction
abnormalities	PROMACTA.xml:S1:6989:13	abnorm	NNS	I-AdverseReaction	I-AdverseReaction
(	PROMACTA.xml:S1:7003:1	(	(	O	O
less	PROMACTA.xml:S1:7004:4	less	JJR	O	O
than	PROMACTA.xml:S1:7009:4	than	IN	O	O
or	PROMACTA.xml:S1:7014:2	or	CC	O	O
equal	PROMACTA.xml:S1:7017:5	equal	JJ	O	O
to	PROMACTA.xml:S1:7023:2	to	TO	O	O
Grade	PROMACTA.xml:S1:7026:5	grade	VB	O	O
3	PROMACTA.xml:S1:7032:1	3	CD	O	O
)	PROMACTA.xml:S1:7033:1	)	)	O	O
.	PROMACTA.xml:S1:7034:1	.	.	O	O

In	PROMACTA.xml:S1:7040:2	In	IN	O	O

a	PROMACTA.xml:S1:7043:1	a	DT	O	O
placebo	PROMACTA.xml:S1:7045:7	placebo	NN	O	O
-	PROMACTA.xml:S1:7052:1	-	:	O	O
controlled	PROMACTA.xml:S1:7053:10	control	VBN	O	O
trial	PROMACTA.xml:S1:7064:5	trial	NN	O	O
of	PROMACTA.xml:S1:7070:2	of	IN	O	O
PROMACTA	PROMACTA.xml:S1:7073:8	promacta	NNP	O	O
in	PROMACTA.xml:S1:7082:2	in	IN	O	O
patients	PROMACTA.xml:S1:7085:8	patient	NNS	O	O
with	PROMACTA.xml:S1:7094:4	with	IN	O	O
chronic	PROMACTA.xml:S1:7099:7	chronic	JJ	O	O
liver	PROMACTA.xml:S1:7107:5	liver	NN	O	O
diseaseand	PROMACTA.xml:S1:7113:10	diseaseand	NN	O	O
thrombocytopenia	PROMACTA.xml:S1:7124:16	thrombocytopenia	NN	O	O
not	PROMACTA.xml:S1:7141:3	not	RB	O	O
related	PROMACTA.xml:S1:7145:7	relat	VBN	O	O
to	PROMACTA.xml:S1:7153:2	to	TO	O	O
ITP	PROMACTA.xml:S1:7156:3	itp	NNP	O	O
,	PROMACTA.xml:S1:7159:1	,	,	O	O
six	PROMACTA.xml:S1:7161:3	six	CD	O	O
patients	PROMACTA.xml:S1:7165:8	patient	NNS	O	O
treated	PROMACTA.xml:S1:7174:7	treat	VBN	O	O
with	PROMACTA.xml:S1:7182:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S1:7187:8	promacta	NNP	O	O
and	PROMACTA.xml:S1:7196:3	and	CC	O	O
one	PROMACTA.xml:S1:7200:3	one	CD	O	O
patient	PROMACTA.xml:S1:7204:7	patient	NN	O	O
in	PROMACTA.xml:S1:7212:2	in	IN	O	O
the	PROMACTA.xml:S1:7215:3	the	DT	O	O
placebo	PROMACTA.xml:S1:7219:7	placebo	NN	O	O
group	PROMACTA.xml:S1:7227:5	group	NN	O	O
developed	PROMACTA.xml:S1:7233:9	develop	VBD	O	O
portal	PROMACTA.xml:S1:7243:6	portal	JJ	B-AdverseReaction	B-AdverseReaction
vein	PROMACTA.xml:S1:7250:4	vein	NN	I-AdverseReaction	I-AdverseReaction
thromboses	PROMACTA.xml:S1:7255:10	thrombos	VBZ	I-AdverseReaction	I-AdverseReaction
[	PROMACTA.xml:S1:7267:1	[	NNP	O	O
see	PROMACTA.xml:S1:7268:3	see	VBP	O	O
Warnings	PROMACTA.xml:S1:7272:8	warn	NNP	O	O
and	PROMACTA.xml:S1:7281:3	and	CC	O	O
Precautions	PROMACTA.xml:S1:7285:11	precaut	NNP	O	O
(	PROMACTA.xml:S1:7297:1	(	(	O	O
5.3	PROMACTA.xml:S1:7298:3	5.3	CD	O	O
)]	PROMACTA.xml:S1:7301:2	)]	NN	O	O
.	PROMACTA.xml:S1:7305:1	.	.	O	O

Pediatric	PROMACTA.xml:S1:7313:9	pediatr	JJ	O	O
Patients	PROMACTA.xml:S1:7323:8	patient	NNS	O	O
:	PROMACTA.xml:S1:7331:1	:	:	O	O
The	PROMACTA.xml:S1:7334:3	the	DT	O	O
data	PROMACTA.xml:S1:7338:4	data	NNS	O	O
described	PROMACTA.xml:S1:7343:9	describ	VBD	O	O
below	PROMACTA.xml:S1:7353:5	below	IN	O	O
reflect	PROMACTA.xml:S1:7359:7	reflect	JJ	O	O
median	PROMACTA.xml:S1:7367:6	median	JJ	O	O
exposure	PROMACTA.xml:S1:7374:8	exposur	NN	O	O
to	PROMACTA.xml:S1:7383:2	to	TO	O	O
PROMACTA	PROMACTA.xml:S1:7386:8	promacta	NNP	O	O
of	PROMACTA.xml:S1:7395:2	of	IN	O	O
91	PROMACTA.xml:S1:7398:2	91	CD	O	O
days	PROMACTA.xml:S1:7401:4	day	NNS	O	O
for	PROMACTA.xml:S1:7406:3	for	IN	O	O
82	PROMACTA.xml:S1:7410:2	82	CD	O	O
pediatric	PROMACTA.xml:S1:7413:9	pediatr	JJ	O	O
patients	PROMACTA.xml:S1:7423:8	patient	NNS	O	O
(	PROMACTA.xml:S1:7432:1	(	(	O	O
aged	PROMACTA.xml:S1:7433:4	age	VBN	O	O
6	PROMACTA.xml:S1:7438:1	6	CD	O	O
to	PROMACTA.xml:S1:7440:2	to	TO	O	O
17	PROMACTA.xml:S1:7443:2	17	CD	O	O
years	PROMACTA.xml:S1:7446:5	year	NNS	O	O
)	PROMACTA.xml:S1:7451:1	)	)	O	O
with	PROMACTA.xml:S1:7453:4	with	IN	O	O
chronic	PROMACTA.xml:S1:7458:7	chronic	JJ	O	O
ITP	PROMACTA.xml:S1:7466:3	itp	NNP	O	O
,	PROMACTA.xml:S1:7469:1	,	,	O	O
of	PROMACTA.xml:S1:7471:2	of	IN	O	O
whom	PROMACTA.xml:S1:7474:4	whom	WP	O	O
52%	PROMACTA.xml:S1:7479:3	52%	CD	O	O
were	PROMACTA.xml:S1:7483:4	were	VBD	O	O
female	PROMACTA.xml:S1:7488:6	femal	JJ	O	O
,	PROMACTA.xml:S1:7494:1	,	,	O	O
across	PROMACTA.xml:S1:7496:6	across	IN	O	O
the	PROMACTA.xml:S1:7503:3	the	DT	O	O
randomized	PROMACTA.xml:S1:7507:10	random	JJ	O	O
phase	PROMACTA.xml:S1:7518:5	phase	NN	O	O
of	PROMACTA.xml:S1:7524:2	of	IN	O	O
two	PROMACTA.xml:S1:7527:3	two	CD	O	O
placebo	PROMACTA.xml:S1:7531:7	placebo	NN	O	O
-	PROMACTA.xml:S1:7538:1	-	:	O	O
controlled	PROMACTA.xml:S1:7539:10	control	VBN	O	O
trials	PROMACTA.xml:S1:7550:6	trial	NNS	O	O
.	PROMACTA.xml:S1:7556:1	.	.	O	O

Table	PROMACTA.xml:S1:7562:5	tabl	JJ	O	O
6	PROMACTA.xml:S1:7568:1	6	CD	O	O
presents	PROMACTA.xml:S1:7570:8	present	VBZ	O	O
the	PROMACTA.xml:S1:7579:3	the	DT	O	O
most	PROMACTA.xml:S1:7583:4	most	RBS	O	O
common	PROMACTA.xml:S1:7588:6	common	JJ	O	O
adverse	PROMACTA.xml:S1:7595:7	advers	JJ	O	O
drug	PROMACTA.xml:S1:7603:4	drug	NN	O	O
reactions	PROMACTA.xml:S1:7608:9	reaction	NNS	O	O
(	PROMACTA.xml:S1:7618:1	(	(	O	O
experienced	PROMACTA.xml:S1:7619:11	experienc	VBN	O	O
by	PROMACTA.xml:S1:7631:2	by	IN	O	O
greater	PROMACTA.xml:S1:7634:7	greater	JJR	O	O
than	PROMACTA.xml:S1:7642:4	than	IN	O	O
or	PROMACTA.xml:S1:7647:2	or	CC	O	O
equal	PROMACTA.xml:S1:7650:5	equal	JJ	O	O
to	PROMACTA.xml:S1:7656:2	to	TO	O	O
3%	PROMACTA.xml:S1:7659:2	3%	CD	O	O
of	PROMACTA.xml:S1:7662:2	of	IN	O	O
pediatric	PROMACTA.xml:S1:7665:9	pediatr	JJ	O	O
patients	PROMACTA.xml:S1:7675:8	patient	NNS	O	O
6	PROMACTA.xml:S1:7684:1	6	CD	O	O
years	PROMACTA.xml:S1:7686:5	year	NNS	O	O
and	PROMACTA.xml:S1:7692:3	and	CC	O	O
older	PROMACTA.xml:S1:7696:5	older	JJR	O	O
receiving	PROMACTA.xml:S1:7702:9	receiv	VBG	O	O
PROMACTA	PROMACTA.xml:S1:7712:8	promacta	NNP	O	O
)	PROMACTA.xml:S1:7720:1	)	)	O	O
across	PROMACTA.xml:S1:7722:6	across	IN	O	O
the	PROMACTA.xml:S1:7729:3	the	DT	O	O
two	PROMACTA.xml:S1:7733:3	two	CD	O	O
placebo	PROMACTA.xml:S1:7737:7	placebo	NN	O	O
-	PROMACTA.xml:S1:7744:1	-	:	O	O
controlled	PROMACTA.xml:S1:7745:10	control	VBN	O	O
trials	PROMACTA.xml:S1:7756:6	trial	NNS	O	O
,	PROMACTA.xml:S1:7762:1	,	,	O	O
with	PROMACTA.xml:S1:7764:4	with	IN	O	O
a	PROMACTA.xml:S1:7769:1	a	DT	O	O
higher	PROMACTA.xml:S1:7771:6	higher	JJR	O	O
incidence	PROMACTA.xml:S1:7778:9	incid	NN	O	O
for	PROMACTA.xml:S1:7788:3	for	IN	O	O
PROMACTA	PROMACTA.xml:S1:7792:8	promacta	NNP	O	O
versus	PROMACTA.xml:S1:7801:6	versu	NN	O	O
placebo	PROMACTA.xml:S1:7808:7	placebo	NN	O	O
.	PROMACTA.xml:S1:7815:1	.	.	O	O

Table	PROMACTA.xml:S1:7821:5	tabl	JJ	O	O
6	PROMACTA.xml:S1:7827:1	6	CD	O	O
.	PROMACTA.xml:S1:7828:1	.	.	O	O

Adverse	PROMACTA.xml:S1:7830:7	advers	JJ	O	O
Reactions	PROMACTA.xml:S1:7838:9	reaction	NNP	O	O
(	PROMACTA.xml:S1:7848:1	(	(	O	O
3%	PROMACTA.xml:S1:7851:2	3%	CD	O	O
)	PROMACTA.xml:S1:7853:1	)	)	O	O
with	PROMACTA.xml:S1:7855:4	with	IN	O	O
a	PROMACTA.xml:S1:7860:1	a	DT	O	O
Higher	PROMACTA.xml:S1:7862:6	higher	JJR	O	O
Incidence	PROMACTA.xml:S1:7869:9	incid	NN	O	O
for	PROMACTA.xml:S1:7879:3	for	IN	O	O
PROMACTA	PROMACTA.xml:S1:7883:8	promacta	NNP	O	O
versus	PROMACTA.xml:S1:7892:6	versu	NN	O	O
Placebo	PROMACTA.xml:S1:7899:7	placebo	NNP	O	O
from	PROMACTA.xml:S1:7907:4	from	IN	O	O
Two	PROMACTA.xml:S1:7912:3	two	CD	O	O
Placebo	PROMACTA.xml:S1:7916:7	placebo	NNP	O	O
-	PROMACTA.xml:S1:7923:1	-	:	O	O
controlled	PROMACTA.xml:S1:7924:10	control	VBN	O	O
Trials	PROMACTA.xml:S1:7935:6	trial	NNS	O	O
in	PROMACTA.xml:S1:7942:2	in	IN	O	O
Pediatric	PROMACTA.xml:S1:7945:9	pediatr	NNP	O	O
Patients	PROMACTA.xml:S1:7955:8	patient	NNPS	O	O
6	PROMACTA.xml:S1:7964:1	6	CD	O	O
Years	PROMACTA.xml:S1:7966:5	year	NNS	O	O
and	PROMACTA.xml:S1:7972:3	and	CC	O	O
Older	PROMACTA.xml:S1:7976:5	older	JJR	O	O
with	PROMACTA.xml:S1:7982:4	with	IN	O	O
Chronic	PROMACTA.xml:S1:7987:7	chronic	NNP	O	O
Immune	PROMACTA.xml:S1:7995:6	immun	NNP	O	O
(	PROMACTA.xml:S1:8002:1	(	(	O	O
Idiopathic	PROMACTA.xml:S1:8003:10	idiopath	NNP	O	O
)	PROMACTA.xml:S1:8013:1	)	)	O	O
Thrombocytopenia	PROMACTA.xml:S1:8015:16	thrombocytopenia	NNP	O	O

PROMACTA	PROMACTA.xml:S1:8076:8	promacta	NNP	O	O
Placebo	PROMACTA.xml:S1:8109:7	placebo	NNP	O	O

n	PROMACTA.xml:S1:8186:1	n	RB	O	O
82	PROMACTA.xml:S1:8190:2	82	CD	O	O
n	PROMACTA.xml:S1:8219:1	n	NNS	O	O
40	PROMACTA.xml:S1:8223:2	40	CD	O	O

Adverse	PROMACTA.xml:S1:8255:7	advers	JJ	O	O
Reaction	PROMACTA.xml:S1:8263:8	reaction	NNP	O	O
(	PROMACTA.xml:S1:8296:1	(	(	O	O
)	PROMACTA.xml:S1:8298:1	)	)	O	O
(	PROMACTA.xml:S1:8329:1	(	(	O	O
)	PROMACTA.xml:S1:8331:1	)	)	O	O

Upper	PROMACTA.xml:S1:8365:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	PROMACTA.xml:S1:8371:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	PROMACTA.xml:S1:8383:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	PROMACTA.xml:S1:8389:9	infect	NN	I-AdverseReaction	I-AdverseReaction
16	PROMACTA.xml:S1:8406:2	16	CD	O	O
5	PROMACTA.xml:S1:8439:1	5	CD	O	O

Nasopharyngitis	PROMACTA.xml:S1:8475:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
12	PROMACTA.xml:S1:8516:2	12	CD	O	O
5	PROMACTA.xml:S1:8549:1	5	CD	O	O

Rhinitis	PROMACTA.xml:S1:8585:8	rhiniti	RB	B-AdverseReaction	B-AdverseReaction
11	PROMACTA.xml:S1:8626:2	11	CD	O	O
8	PROMACTA.xml:S1:8659:1	8	CD	O	O

Abdominal	PROMACTA.xml:S1:8695:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	PROMACTA.xml:S1:8705:4	pain	NN	I-AdverseReaction	I-AdverseReaction
9	PROMACTA.xml:S1:8736:1	9	CD	O	O
5	PROMACTA.xml:S1:8769:1	5	CD	O	O

Cough	PROMACTA.xml:S1:8805:5	cough	NNP	B-AdverseReaction	B-AdverseReaction
9	PROMACTA.xml:S1:8846:1	9	CD	O	O
0	PROMACTA.xml:S1:8879:1	0	CD	O	O

Oropharyngeal	PROMACTA.xml:S1:8915:13	oropharyng	NNP	B-AdverseReaction	B-AdverseReaction
pain	PROMACTA.xml:S1:8929:4	pain	NN	I-AdverseReaction	I-AdverseReaction
9	PROMACTA.xml:S1:8956:1	9	CD	O	O
3	PROMACTA.xml:S1:8989:1	3	CD	O	O

Toothache	PROMACTA.xml:S1:9025:9	toothach	NNP	B-AdverseReaction	B-AdverseReaction
6	PROMACTA.xml:S1:9066:1	6	CD	O	O
0	PROMACTA.xml:S1:9099:1	0	CD	O	O

AST	PROMACTA.xml:S1:9135:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
increased	PROMACTA.xml:S1:9139:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
5	PROMACTA.xml:S1:9176:1	5	CD	O	O
0	PROMACTA.xml:S1:9209:1	0	CD	O	O

Diarrhea	PROMACTA.xml:S1:9245:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
5	PROMACTA.xml:S1:9286:1	5	CD	O	O
3	PROMACTA.xml:S1:9319:1	3	CD	O	O

Rash	PROMACTA.xml:S1:9355:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
5	PROMACTA.xml:S1:9396:1	5	CD	O	O
3	PROMACTA.xml:S1:9429:1	3	CD	O	O

ALT	PROMACTA.xml:S1:9465:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
increaseda	PROMACTA.xml:S1:9469:10	increaseda	VBZ	I-AdverseReaction	I-AdverseReaction
6	PROMACTA.xml:S1:9506:1	6	CD	O	O
0	PROMACTA.xml:S1:9539:1	0	CD	O	O

Vitamin	PROMACTA.xml:S1:9575:7	vitamin	NNP	B-AdverseReaction	O
D	PROMACTA.xml:S1:9583:1	D	NNP	I-AdverseReaction	O
deficiency	PROMACTA.xml:S1:9585:10	defici	NN	I-AdverseReaction	O
4	PROMACTA.xml:S1:9616:1	4	CD	O	O
0	PROMACTA.xml:S1:9649:1	0	CD	O	O

a	PROMACTA.xml:S1:9699:1	a	DT	O	O
Includes	PROMACTA.xml:S1:9702:8	includ	NNP	O	O
adverse	PROMACTA.xml:S1:9711:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:9719:9	reaction	NNS	O	O
or	PROMACTA.xml:S1:9729:2	or	CC	O	O
laboratory	PROMACTA.xml:S1:9732:10	laboratori	NN	O	O
abnormalities	PROMACTA.xml:S1:9743:13	abnorm	NNS	O	O
3	PROMACTA.xml:S1:9758:1	3	CD	O	O
x	PROMACTA.xml:S1:9760:1	x	JJ	O	O
ULN	PROMACTA.xml:S1:9762:3	uln	NNP	O	O
.	PROMACTA.xml:S1:9765:1	.	.	O	O

Chronic	PROMACTA.xml:S1:9774:7	chronic	NNP	O	O
Hepatitis	PROMACTA.xml:S1:9782:9	hepat	NNP	O	O
C	PROMACTA.xml:S1:9792:1	C	NNP	O	O
-	PROMACTA.xml:S1:9793:1	-	:	O	O
associated	PROMACTA.xml:S1:9794:10	associ	VBN	O	O
Thrombocytopenia	PROMACTA.xml:S1:9805:16	thrombocytopenia	NNP	O	B-AdverseReaction
:	PROMACTA.xml:S1:9821:1	:	:	O	O
In	PROMACTA.xml:S1:9824:2	In	IN	O	O
the	PROMACTA.xml:S1:9827:3	the	DT	O	O
two	PROMACTA.xml:S1:9831:3	two	CD	O	O
placebo	PROMACTA.xml:S1:9835:7	placebo	NN	O	O
-	PROMACTA.xml:S1:9842:1	-	:	O	O
controlled	PROMACTA.xml:S1:9843:10	control	VBN	O	O
trials	PROMACTA.xml:S1:9854:6	trial	NNS	O	O
,	PROMACTA.xml:S1:9860:1	,	,	O	O
955	PROMACTA.xml:S1:9862:3	955	CD	O	O
patients	PROMACTA.xml:S1:9866:8	patient	NNS	O	O
with	PROMACTA.xml:S1:9875:4	with	IN	O	O
chronic	PROMACTA.xml:S1:9880:7	chronic	JJ	O	O
hepatitis	PROMACTA.xml:S1:9888:9	hepat	NN	O	O
C	PROMACTA.xml:S1:9898:1	C	NNP	O	O
-	PROMACTA.xml:S1:9899:1	-	:	O	O
associated	PROMACTA.xml:S1:9900:10	associ	VBN	O	O
thrombocytopenia	PROMACTA.xml:S1:9911:16	thrombocytopenia	NN	O	B-AdverseReaction
received	PROMACTA.xml:S1:9928:8	receiv	VBD	O	O
PROMACTA	PROMACTA.xml:S1:9937:8	promacta	NNP	O	O
.	PROMACTA.xml:S1:9945:1	.	.	O	O

Table	PROMACTA.xml:S1:9947:5	tabl	JJ	O	O
7	PROMACTA.xml:S1:9953:1	7	CD	O	O
presents	PROMACTA.xml:S1:9955:8	present	VBZ	O	O
the	PROMACTA.xml:S1:9964:3	the	DT	O	O
most	PROMACTA.xml:S1:9968:4	most	RBS	O	O
common	PROMACTA.xml:S1:9973:6	common	JJ	O	O
adverse	PROMACTA.xml:S1:9980:7	advers	JJ	O	O
drug	PROMACTA.xml:S1:9988:4	drug	NN	O	O
reactions	PROMACTA.xml:S1:9993:9	reaction	NNS	O	O
(	PROMACTA.xml:S1:10003:1	(	(	O	O
experienced	PROMACTA.xml:S1:10004:11	experienc	VBN	O	O
by	PROMACTA.xml:S1:10016:2	by	IN	O	O
greater	PROMACTA.xml:S1:10019:7	greater	JJR	O	O
than	PROMACTA.xml:S1:10027:4	than	IN	O	O
or	PROMACTA.xml:S1:10032:2	or	CC	O	O
equal	PROMACTA.xml:S1:10035:5	equal	JJ	O	O
to	PROMACTA.xml:S1:10041:2	to	TO	O	O
10%	PROMACTA.xml:S1:10044:3	10%	CD	O	O
of	PROMACTA.xml:S1:10048:2	of	IN	O	O
patients	PROMACTA.xml:S1:10051:8	patient	NNS	O	O
receiving	PROMACTA.xml:S1:10060:9	receiv	VBG	O	O
PROMACTA	PROMACTA.xml:S1:10070:8	promacta	NNP	O	O
compared	PROMACTA.xml:S1:10079:8	compar	VBN	O	O
with	PROMACTA.xml:S1:10088:4	with	IN	O	O
placebo	PROMACTA.xml:S1:10093:7	placebo	NN	O	O
)	PROMACTA.xml:S1:10100:1	)	)	O	O
.	PROMACTA.xml:S1:10101:1	.	.	O	O

Table	PROMACTA.xml:S1:10107:5	tabl	NN	O	O

7	PROMACTA.xml:S1:10113:1	7	CD	O	O
.	PROMACTA.xml:S1:10114:1	.	.	O	O

Adverse	PROMACTA.xml:S1:10116:7	advers	JJ	O	O
Reactions	PROMACTA.xml:S1:10124:9	reaction	NNP	O	O
(	PROMACTA.xml:S1:10134:1	(	(	O	O
10%	PROMACTA.xml:S1:10137:3	10%	CD	O	O
and	PROMACTA.xml:S1:10141:3	and	CC	O	O
Greater	PROMACTA.xml:S1:10145:7	greater	NNP	O	O
than	PROMACTA.xml:S1:10153:4	than	IN	O	O
Placebo	PROMACTA.xml:S1:10158:7	placebo	NNP	O	O
)	PROMACTA.xml:S1:10165:1	)	)	O	O
from	PROMACTA.xml:S1:10167:4	from	IN	O	O
Two	PROMACTA.xml:S1:10172:3	two	CD	O	O
Placebo	PROMACTA.xml:S1:10176:7	placebo	NNP	O	O
-	PROMACTA.xml:S1:10183:1	-	:	O	O
controlled	PROMACTA.xml:S1:10184:10	control	VBN	O	O
Trials	PROMACTA.xml:S1:10195:6	trial	NNS	O	O
in	PROMACTA.xml:S1:10202:2	in	IN	O	O
Adults	PROMACTA.xml:S1:10205:6	adult	NNP	O	O
with	PROMACTA.xml:S1:10212:4	with	IN	O	O
Chronic	PROMACTA.xml:S1:10217:7	chronic	NNP	O	O
Hepatitis	PROMACTA.xml:S1:10225:9	hepat	NNP	O	O
C	PROMACTA.xml:S1:10235:1	C	NNP	O	O

Adverse	PROMACTA.xml:S1:10240:7	advers	JJ	O	O
Reaction	PROMACTA.xml:S1:10248:8	reaction	NNP	O	O
PROMACTA	PROMACTA.xml:S1:10270:8	promacta	NNP	O	O
Peginterferon	PROMACTA.xml:S1:10282:13	peginterferon	NNP	O	O
Ribavirin	PROMACTA.xml:S1:10296:9	ribavirin	NNP	O	O
n	PROMACTA.xml:S1:10307:1	n	RB	O	O
955	PROMACTA.xml:S1:10311:3	955	CD	O	O
(	PROMACTA.xml:S1:10316:1	(	(	O	O
)	PROMACTA.xml:S1:10318:1	)	)	O	O
Placebo	PROMACTA.xml:S1:10323:7	placebo	NNP	O	O
Peginterferon	PROMACTA.xml:S1:10334:13	peginterferon	NNP	O	O
Ribavirin	PROMACTA.xml:S1:10348:9	ribavirin	NNP	O	O
n	PROMACTA.xml:S1:10359:1	n	RB	O	O
484	PROMACTA.xml:S1:10363:3	484	CD	O	O
(	PROMACTA.xml:S1:10368:1	(	(	O	O
)	PROMACTA.xml:S1:10370:1	)	)	O	O

Anemia	PROMACTA.xml:S1:10378:6	anemia	NNP	B-AdverseReaction	B-AdverseReaction
40	PROMACTA.xml:S1:10408:2	40	CD	O	O
35	PROMACTA.xml:S1:10446:2	35	CD	O	O

Pyrexia	PROMACTA.xml:S1:10487:7	pyrexia	NNP	B-AdverseReaction	B-AdverseReaction
30	PROMACTA.xml:S1:10517:2	30	CD	O	O
24	PROMACTA.xml:S1:10555:2	24	CD	O	O

Fatigue	PROMACTA.xml:S1:10596:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
28	PROMACTA.xml:S1:10626:2	28	CD	O	O
23	PROMACTA.xml:S1:10664:2	23	CD	O	O

Headache	PROMACTA.xml:S1:10705:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
21	PROMACTA.xml:S1:10735:2	21	CD	O	O
20	PROMACTA.xml:S1:10773:2	20	CD	O	O

Nausea	PROMACTA.xml:S1:10814:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
19	PROMACTA.xml:S1:10844:2	19	CD	O	O
14	PROMACTA.xml:S1:10882:2	14	CD	O	O

Diarrhea	PROMACTA.xml:S1:10923:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
19	PROMACTA.xml:S1:10953:2	19	CD	O	O
11	PROMACTA.xml:S1:10991:2	11	CD	O	O

Decreased	PROMACTA.xml:S1:11032:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	PROMACTA.xml:S1:11042:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
18	PROMACTA.xml:S1:11062:2	18	CD	O	O
14	PROMACTA.xml:S1:11100:2	14	CD	O	O

Influenza	PROMACTA.xml:S1:11141:9	influenza	NNP	B-AdverseReaction	B-AdverseReaction
-	PROMACTA.xml:S1:11150:1	-	:	I-AdverseReaction	I-AdverseReaction
like	PROMACTA.xml:S1:11151:4	like	IN	I-AdverseReaction	I-AdverseReaction
illness	PROMACTA.xml:S1:11156:7	ill	NN	I-AdverseReaction	I-AdverseReaction
18	PROMACTA.xml:S1:11171:2	18	CD	O	O
16	PROMACTA.xml:S1:11209:2	16	CD	O	O

Asthenia	PROMACTA.xml:S1:11250:8	asthenia	NNP	B-AdverseReaction	B-AdverseReaction
16	PROMACTA.xml:S1:11280:2	16	CD	O	O
13	PROMACTA.xml:S1:11318:2	13	CD	O	O

Insomnia	PROMACTA.xml:S1:11359:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
16	PROMACTA.xml:S1:11389:2	16	CD	O	O
15	PROMACTA.xml:S1:11427:2	15	CD	O	O

Cough	PROMACTA.xml:S1:11468:5	cough	NNP	B-AdverseReaction	B-AdverseReaction
15	PROMACTA.xml:S1:11498:2	15	CD	O	O
12	PROMACTA.xml:S1:11536:2	12	CD	O	O

Pruritus	PROMACTA.xml:S1:11577:8	pruritu	NNP	B-AdverseReaction	B-AdverseReaction
15	PROMACTA.xml:S1:11607:2	15	CD	O	O
13	PROMACTA.xml:S1:11645:2	13	CD	O	O

Chills	PROMACTA.xml:S1:11686:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
14	PROMACTA.xml:S1:11716:2	14	CD	O	O
9	PROMACTA.xml:S1:11754:1	9	CD	O	O

Myalgia	PROMACTA.xml:S1:11795:7	myalgia	NNP	B-AdverseReaction	B-AdverseReaction
12	PROMACTA.xml:S1:11825:2	12	CD	O	O
10	PROMACTA.xml:S1:11863:2	10	CD	O	O

Alopecia	PROMACTA.xml:S1:11904:8	alopecia	NNP	B-AdverseReaction	B-AdverseReaction
10	PROMACTA.xml:S1:11934:2	10	CD	O	O
6	PROMACTA.xml:S1:11972:1	6	CD	O	O

Peripheral	PROMACTA.xml:S1:12013:10	peripher	NNP	B-AdverseReaction	B-AdverseReaction
edema	PROMACTA.xml:S1:12024:5	edema	VBD	I-AdverseReaction	I-AdverseReaction
10	PROMACTA.xml:S1:12043:2	10	CD	O	O
5	PROMACTA.xml:S1:12081:1	5	CD	O	O

In	PROMACTA.xml:S1:12129:2	In	IN	O	O
the	PROMACTA.xml:S1:12132:3	the	DT	O	O
two	PROMACTA.xml:S1:12136:3	two	CD	O	O
controlled	PROMACTA.xml:S1:12140:10	control	VBD	O	O
clinical	PROMACTA.xml:S1:12151:8	clinic	JJ	O	O
trials	PROMACTA.xml:S1:12160:6	trial	NNS	O	O
in	PROMACTA.xml:S1:12167:2	in	IN	O	O
patients	PROMACTA.xml:S1:12170:8	patient	NNS	O	O
with	PROMACTA.xml:S1:12179:4	with	IN	O	O
chronic	PROMACTA.xml:S1:12184:7	chronic	JJ	O	O
hepatitis	PROMACTA.xml:S1:12192:9	hepat	NN	O	O
C	PROMACTA.xml:S1:12202:1	C	NNP	O	O
,	PROMACTA.xml:S1:12203:1	,	,	O	O
hyperbilirubinemia	PROMACTA.xml:S1:12205:18	hyperbilirubinemia	NN	B-AdverseReaction	B-AdverseReaction
was	PROMACTA.xml:S1:12224:3	wa	VBD	O	O
reported	PROMACTA.xml:S1:12228:8	report	VBN	O	O
in	PROMACTA.xml:S1:12237:2	in	IN	O	O
8%	PROMACTA.xml:S1:12240:2	8%	CD	O	O
of	PROMACTA.xml:S1:12243:2	of	IN	O	O
patients	PROMACTA.xml:S1:12246:8	patient	NNS	O	O
receiving	PROMACTA.xml:S1:12255:9	receiv	VBG	O	O
PROMACTA	PROMACTA.xml:S1:12265:8	promacta	NNP	O	O
compared	PROMACTA.xml:S1:12274:8	compar	VBN	O	O
with	PROMACTA.xml:S1:12283:4	with	IN	O	O
3%	PROMACTA.xml:S1:12288:2	3%	CD	O	O
for	PROMACTA.xml:S1:12291:3	for	IN	O	O
placebo	PROMACTA.xml:S1:12295:7	placebo	NN	O	O
.	PROMACTA.xml:S1:12302:1	.	.	O	O

Total	PROMACTA.xml:S1:12304:5	total	JJ	B-AdverseReaction	B-AdverseReaction
bilirubin	PROMACTA.xml:S1:12310:9	bilirubin	NN	I-AdverseReaction	I-AdverseReaction
greater	PROMACTA.xml:S1:12320:7	greater	JJR	I-AdverseReaction	O
than	PROMACTA.xml:S1:12328:4	than	IN	I-AdverseReaction	O
or	PROMACTA.xml:S1:12333:2	or	CC	I-AdverseReaction	O
equal	PROMACTA.xml:S1:12336:5	equal	JJ	I-AdverseReaction	O
to	PROMACTA.xml:S1:12342:2	to	TO	I-AdverseReaction	O
1.5	PROMACTA.xml:S1:12345:3	1.5	CD	I-AdverseReaction	I-AdverseReaction
x	PROMACTA.xml:S1:12349:1	x	NNS	I-AdverseReaction	I-AdverseReaction
ULN	PROMACTA.xml:S1:12351:3	uln	NNP	I-AdverseReaction	I-AdverseReaction
was	PROMACTA.xml:S1:12355:3	wa	VBD	O	O
reported	PROMACTA.xml:S1:12359:8	report	VBN	O	O
in	PROMACTA.xml:S1:12368:2	in	IN	O	O
76%	PROMACTA.xml:S1:12371:3	76%	CD	O	O
and	PROMACTA.xml:S1:12375:3	and	CC	O	O
50%	PROMACTA.xml:S1:12379:3	50%	CD	O	O
of	PROMACTA.xml:S1:12383:2	of	IN	O	O
patients	PROMACTA.xml:S1:12386:8	patient	NNS	O	O
receiving	PROMACTA.xml:S1:12395:9	receiv	VBG	O	O
PROMACTA	PROMACTA.xml:S1:12405:8	promacta	NNP	O	O
and	PROMACTA.xml:S1:12414:3	and	CC	O	O
placebo	PROMACTA.xml:S1:12418:7	placebo	NN	O	O
,	PROMACTA.xml:S1:12425:1	,	,	O	O
respectively	PROMACTA.xml:S1:12427:12	respect	RB	O	O
.	PROMACTA.xml:S1:12439:1	.	.	O	O

ALT	PROMACTA.xml:S1:12441:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
or	PROMACTA.xml:S1:12445:2	or	CC	O	O
AST	PROMACTA.xml:S1:12448:3	ast	NNP	B-AdverseReaction	I-AdverseReaction
greater	PROMACTA.xml:S1:12452:7	greater	JJR	I-AdverseReaction	O
than	PROMACTA.xml:S1:12460:4	than	IN	I-AdverseReaction	O
or	PROMACTA.xml:S1:12465:2	or	CC	I-AdverseReaction	O
equal	PROMACTA.xml:S1:12468:5	equal	JJ	I-AdverseReaction	I-AdverseReaction
to	PROMACTA.xml:S1:12474:2	to	TO	I-AdverseReaction	I-AdverseReaction
3	PROMACTA.xml:S1:12477:1	3	CD	I-AdverseReaction	I-AdverseReaction
x	PROMACTA.xml:S1:12479:1	x	NNS	I-AdverseReaction	I-AdverseReaction
ULN	PROMACTA.xml:S1:12481:3	uln	NNP	I-AdverseReaction	I-AdverseReaction
was	PROMACTA.xml:S1:12485:3	wa	VBD	O	O
reported	PROMACTA.xml:S1:12489:8	report	VBN	O	O
in	PROMACTA.xml:S1:12498:2	in	IN	O	O
34%	PROMACTA.xml:S1:12501:3	34%	CD	O	O
and	PROMACTA.xml:S1:12505:3	and	CC	O	O
38%	PROMACTA.xml:S1:12509:3	38%	CD	O	O
of	PROMACTA.xml:S1:12513:2	of	IN	O	O
patients	PROMACTA.xml:S1:12516:8	patient	NNS	O	O
for	PROMACTA.xml:S1:12525:3	for	IN	O	O
PROMACTA	PROMACTA.xml:S1:12529:8	promacta	NNP	O	O
and	PROMACTA.xml:S1:12538:3	and	CC	O	O
placebo	PROMACTA.xml:S1:12542:7	placebo	NN	O	O
,	PROMACTA.xml:S1:12549:1	,	,	O	O
respectively	PROMACTA.xml:S1:12551:12	respect	RB	O	O
.	PROMACTA.xml:S1:12563:1	.	.	O	O

Severe	PROMACTA.xml:S1:12571:6	sever	JJ	O	O

Aplastic	PROMACTA.xml:S1:12578:8	aplast	JJ	O	B-AdverseReaction
Anemia	PROMACTA.xml:S1:12587:6	anemia	NN	O	I-AdverseReaction
:	PROMACTA.xml:S1:12593:1	:	:	O	O
In	PROMACTA.xml:S1:12596:2	In	IN	O	O
the	PROMACTA.xml:S1:12599:3	the	DT	O	O
single	PROMACTA.xml:S1:12603:6	singl	JJ	O	O
-	PROMACTA.xml:S1:12609:1	-	:	O	O
arm	PROMACTA.xml:S1:12610:3	arm	NN	O	O
,	PROMACTA.xml:S1:12613:1	,	,	O	O
open	PROMACTA.xml:S1:12615:4	open	JJ	O	O
-	PROMACTA.xml:S1:12619:1	-	:	O	O
label	PROMACTA.xml:S1:12620:5	label	NN	O	O
trial	PROMACTA.xml:S1:12626:5	trial	NN	O	O
,	PROMACTA.xml:S1:12631:1	,	,	O	O
43	PROMACTA.xml:S1:12633:2	43	CD	O	O
patients	PROMACTA.xml:S1:12636:8	patient	NNS	O	O
with	PROMACTA.xml:S1:12645:4	with	IN	O	O
severe	PROMACTA.xml:S1:12650:6	sever	JJ	O	O
aplastic	PROMACTA.xml:S1:12657:8	aplast	JJ	O	O
anemia	PROMACTA.xml:S1:12666:6	anemia	NN	O	O
received	PROMACTA.xml:S1:12673:8	receiv	VBD	O	O
PROMACTA	PROMACTA.xml:S1:12682:8	promacta	NNP	O	O
.	PROMACTA.xml:S1:12690:1	.	.	O	O

Eleven	PROMACTA.xml:S1:12692:6	eleven	JJ	O	O
patients	PROMACTA.xml:S1:12699:8	patient	NNS	O	O
(	PROMACTA.xml:S1:12708:1	(	(	O	O
26%	PROMACTA.xml:S1:12709:3	26%	CD	O	O
)	PROMACTA.xml:S1:12712:1	)	)	O	O
were	PROMACTA.xml:S1:12714:4	were	VBD	O	O
treated	PROMACTA.xml:S1:12719:7	treat	VBN	O	O
for	PROMACTA.xml:S1:12727:3	for	IN	O	O
greater	PROMACTA.xml:S1:12731:7	greater	JJR	O	O
than	PROMACTA.xml:S1:12739:4	than	IN	O	O
6	PROMACTA.xml:S1:12744:1	6	CD	O	O
months	PROMACTA.xml:S1:12746:6	month	NNS	O	O
and	PROMACTA.xml:S1:12753:3	and	CC	O	O
7	PROMACTA.xml:S1:12757:1	7	CD	O	O
patients	PROMACTA.xml:S1:12759:8	patient	NNS	O	O
(	PROMACTA.xml:S1:12768:1	(	(	O	O
16%	PROMACTA.xml:S1:12769:3	16%	CD	O	O
)	PROMACTA.xml:S1:12772:1	)	)	O	O
were	PROMACTA.xml:S1:12774:4	were	VBD	O	O
treated	PROMACTA.xml:S1:12779:7	treat	VBN	O	O
for	PROMACTA.xml:S1:12787:3	for	IN	O	O
greater	PROMACTA.xml:S1:12791:7	greater	JJR	O	O
than	PROMACTA.xml:S1:12799:4	than	IN	O	O
1	PROMACTA.xml:S1:12804:1	1	CD	O	O
year	PROMACTA.xml:S1:12806:4	year	NN	O	O
.	PROMACTA.xml:S1:12810:1	.	.	O	O

The	PROMACTA.xml:S1:12812:3	the	DT	O	O
most	PROMACTA.xml:S1:12816:4	most	RBS	O	O
common	PROMACTA.xml:S1:12821:6	common	JJ	O	O
adverse	PROMACTA.xml:S1:12828:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:12836:9	reaction	NNS	O	O
(	PROMACTA.xml:S1:12846:1	(	(	O	O
greater	PROMACTA.xml:S1:12847:7	greater	JJR	O	O
than	PROMACTA.xml:S1:12855:4	than	IN	O	O
or	PROMACTA.xml:S1:12860:2	or	CC	O	O
equal	PROMACTA.xml:S1:12863:5	equal	JJ	O	O
to	PROMACTA.xml:S1:12869:2	to	TO	O	O
20%	PROMACTA.xml:S1:12872:3	20%	CD	O	O
)	PROMACTA.xml:S1:12875:1	)	)	O	O
were	PROMACTA.xml:S1:12877:4	were	VBD	O	O
nausea	PROMACTA.xml:S1:12882:6	nausea	JJ	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:12888:1	,	,	O	O
fatigue	PROMACTA.xml:S1:12890:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:12897:1	,	,	O	O
cough	PROMACTA.xml:S1:12899:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:12904:1	,	,	O	O
diarrhea	PROMACTA.xml:S1:12906:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S1:12914:1	,	,	O	O
and	PROMACTA.xml:S1:12916:3	and	CC	O	O
headache	PROMACTA.xml:S1:12920:8	headach	NN	B-AdverseReaction	B-AdverseReaction
.	PROMACTA.xml:S1:12928:1	.	.	O	O

Table	PROMACTA.xml:S1:12934:5	tabl	JJ	O	O
8	PROMACTA.xml:S1:12940:1	8	CD	O	O
.	PROMACTA.xml:S1:12941:1	.	.	O	O

Adverse	PROMACTA.xml:S1:12943:7	advers	JJ	O	O
Reactions	PROMACTA.xml:S1:12951:9	reaction	NNP	O	O
(	PROMACTA.xml:S1:12961:1	(	(	O	O
10%	PROMACTA.xml:S1:12964:3	10%	CD	O	O
)	PROMACTA.xml:S1:12967:1	)	)	O	O
from	PROMACTA.xml:S1:12969:4	from	IN	O	O
One	PROMACTA.xml:S1:12974:3	one	CD	O	O
Open	PROMACTA.xml:S1:12978:4	open	NNP	O	O
-	PROMACTA.xml:S1:12982:1	-	:	O	O
label	PROMACTA.xml:S1:12983:5	label	NN	O	O
Trial	PROMACTA.xml:S1:12989:5	trial	NNP	O	O
in	PROMACTA.xml:S1:12995:2	in	IN	O	O
Adults	PROMACTA.xml:S1:12998:6	adult	NNP	O	O
with	PROMACTA.xml:S1:13005:4	with	IN	O	O
Severe	PROMACTA.xml:S1:13010:6	sever	NNP	O	O
Aplastic	PROMACTA.xml:S1:13017:8	aplast	NNP	O	O
Anemia	PROMACTA.xml:S1:13026:6	anemia	NNP	O	O

Adverse	PROMACTA.xml:S1:13036:7	advers	JJ	O	O
Reaction	PROMACTA.xml:S1:13044:8	reaction	NNP	O	O
PROMACTA	PROMACTA.xml:S1:13099:8	promacta	NNP	O	O
(	PROMACTA.xml:S1:13109:1	(	(	O	O
n	PROMACTA.xml:S1:13110:1	n	JJ	O	O
43	PROMACTA.xml:S1:13114:2	43	CD	O	O
)	PROMACTA.xml:S1:13116:1	)	)	O	O
(	PROMACTA.xml:S1:13119:1	(	(	O	O
)	PROMACTA.xml:S1:13121:1	)	)	O	O

Nausea	PROMACTA.xml:S1:13143:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
33	PROMACTA.xml:S1:13206:2	33	CD	O	O

Fatigue	PROMACTA.xml:S1:13250:7	fatigu	CD	B-AdverseReaction	O
28	PROMACTA.xml:S1:13313:2	28	CD	O	O

Cough	PROMACTA.xml:S1:13357:5	cough	IN	B-AdverseReaction	B-AdverseReaction
23	PROMACTA.xml:S1:13420:2	23	CD	O	O

Diarrhea	PROMACTA.xml:S1:13464:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
21	PROMACTA.xml:S1:13527:2	21	CD	O	O

Headache	PROMACTA.xml:S1:13571:8	headach	$	B-AdverseReaction	B-AdverseReaction
21	PROMACTA.xml:S1:13634:2	21	CD	O	O

Pain	PROMACTA.xml:S1:13678:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	PROMACTA.xml:S1:13683:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	PROMACTA.xml:S1:13686:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
19	PROMACTA.xml:S1:13741:2	19	CD	O	O

Dyspnea	PROMACTA.xml:S1:13785:7	dyspnea	NNP	B-AdverseReaction	B-AdverseReaction
14	PROMACTA.xml:S1:13848:2	14	CD	O	O

Pyrexia	PROMACTA.xml:S1:13892:7	pyrexia	$	B-AdverseReaction	B-AdverseReaction
14	PROMACTA.xml:S1:13955:2	14	CD	O	O

Dizziness	PROMACTA.xml:S1:13999:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
14	PROMACTA.xml:S1:14062:2	14	CD	O	O

Oropharyngeal	PROMACTA.xml:S1:14106:13	oropharyng	NNP	B-AdverseReaction	B-AdverseReaction
pain	PROMACTA.xml:S1:14120:4	pain	NN	I-AdverseReaction	I-AdverseReaction
14	PROMACTA.xml:S1:14169:2	14	CD	O	O

Febrile	PROMACTA.xml:S1:14213:7	febril	NNP	B-AdverseReaction	B-AdverseReaction
neutropenia	PROMACTA.xml:S1:14221:11	neutropenia	VBZ	I-AdverseReaction	I-AdverseReaction
14	PROMACTA.xml:S1:14276:2	14	CD	O	O

Abdominal	PROMACTA.xml:S1:14320:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	PROMACTA.xml:S1:14330:4	pain	NN	I-AdverseReaction	I-AdverseReaction
12	PROMACTA.xml:S1:14383:2	12	CD	O	O

Ecchymosis	PROMACTA.xml:S1:14427:10	ecchymosi	NN	B-AdverseReaction	O
12	PROMACTA.xml:S1:14490:2	12	CD	O	O

Muscle	PROMACTA.xml:S1:14534:6	muscl	NNP	B-AdverseReaction	B-AdverseReaction
spasms	PROMACTA.xml:S1:14541:6	spasm	VBD	I-AdverseReaction	I-AdverseReaction
12	PROMACTA.xml:S1:14597:2	12	CD	O	O

Transaminases	PROMACTA.xml:S1:14641:13	transaminas	NNS	B-AdverseReaction	B-AdverseReaction
increased	PROMACTA.xml:S1:14655:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
12	PROMACTA.xml:S1:14704:2	12	CD	O	O

Arthralgia	PROMACTA.xml:S1:14748:10	arthralgia	$	B-AdverseReaction	B-AdverseReaction
12	PROMACTA.xml:S1:14811:2	12	CD	O	O

Rhinorrhea	PROMACTA.xml:S1:14855:10	rhinorrhea	NNP	B-AdverseReaction	B-AdverseReaction
12	PROMACTA.xml:S1:14918:2	12	CD	O	O

In	PROMACTA.xml:S1:14968:2	In	IN	O	O
this	PROMACTA.xml:S1:14971:4	thi	DT	O	O
trial	PROMACTA.xml:S1:14976:5	trial	NN	O	O
,	PROMACTA.xml:S1:14981:1	,	,	O	O
patients	PROMACTA.xml:S1:14983:8	patient	NNS	O	O
had	PROMACTA.xml:S1:14992:3	had	VBD	O	O
bone	PROMACTA.xml:S1:14996:4	bone	VBN	O	O
marrow	PROMACTA.xml:S1:15001:6	marrow	NN	O	O
aspirates	PROMACTA.xml:S1:15008:9	aspir	NNS	O	O
evaluated	PROMACTA.xml:S1:15018:9	evalu	VBD	O	O
for	PROMACTA.xml:S1:15028:3	for	IN	O	O
cytogenetic	PROMACTA.xml:S1:15032:11	cytogenet	JJ	O	O
abnormalities	PROMACTA.xml:S1:15044:13	abnorm	NNS	O	O
.	PROMACTA.xml:S1:15057:1	.	.	O	O

Eight	PROMACTA.xml:S1:15059:5	eight	CD	O	O
patients	PROMACTA.xml:S1:15065:8	patient	NNS	O	O
had	PROMACTA.xml:S1:15074:3	had	VBD	O	O
a	PROMACTA.xml:S1:15078:1	a	DT	O	O
new	PROMACTA.xml:S1:15080:3	new	JJ	O	O
cytogenetic	PROMACTA.xml:S1:15084:11	cytogenet	JJ	B-AdverseReaction	O
abnormality	PROMACTA.xml:S1:15096:11	abnorm	NN	I-AdverseReaction	O
reported	PROMACTA.xml:S1:15108:8	report	VBN	O	O
on	PROMACTA.xml:S1:15117:2	on	IN	O	O
therapy	PROMACTA.xml:S1:15120:7	therapi	NN	O	O
,	PROMACTA.xml:S1:15127:1	,	,	O	O
including	PROMACTA.xml:S1:15129:9	includ	VBG	O	O
5	PROMACTA.xml:S1:15139:1	5	CD	O	O
patients	PROMACTA.xml:S1:15141:8	patient	NNS	O	O
who	PROMACTA.xml:S1:15150:3	who	WP	O	O
had	PROMACTA.xml:S1:15154:3	had	VBD	O	O
complex	PROMACTA.xml:S1:15158:7	complex	JJ	O	O
changes	PROMACTA.xml:S1:15166:7	chang	NNS	B-AdverseReaction	O
in	PROMACTA.xml:S1:15174:2	in	IN	I-AdverseReaction	O
chromosome	PROMACTA.xml:S1:15177:10	chromosom	NN	I-AdverseReaction	O
7	PROMACTA.xml:S1:15188:1	7	CD	I-AdverseReaction	O
.	PROMACTA.xml:S1:15189:1	.	.	O	O

6.2	PROMACTA.xml:S1:15197:3	6.2	CD	O	O

Postmarketing	PROMACTA.xml:S1:15201:13	postmarket	VBG	O	O
Experience	PROMACTA.xml:S1:15215:10	experi	NN	O	O

The	PROMACTA.xml:S1:15229:3	the	DT	O	O
following	PROMACTA.xml:S1:15233:9	follow	JJ	O	O
adverse	PROMACTA.xml:S1:15243:7	advers	JJ	O	O
reactions	PROMACTA.xml:S1:15251:9	reaction	NNS	O	O
have	PROMACTA.xml:S1:15261:4	have	VBP	O	O
been	PROMACTA.xml:S1:15266:4	been	VBN	O	O
identified	PROMACTA.xml:S1:15271:10	identifi	VBN	O	O
during	PROMACTA.xml:S1:15282:6	dure	IN	O	O
post	PROMACTA.xml:S1:15289:4	post	NN	O	O
approval	PROMACTA.xml:S1:15294:8	approv	NN	O	O
use	PROMACTA.xml:S1:15303:3	use	NN	O	O
of	PROMACTA.xml:S1:15307:2	of	IN	O	O
PROMACTA	PROMACTA.xml:S1:15310:8	promacta	NNP	O	O
.	PROMACTA.xml:S1:15318:1	.	.	O	O

Because	PROMACTA.xml:S1:15320:7	becaus	IN	O	O
these	PROMACTA.xml:S1:15328:5	these	DT	O	O
reactions	PROMACTA.xml:S1:15334:9	reaction	NNS	O	O
are	PROMACTA.xml:S1:15344:3	are	VBP	O	O
reported	PROMACTA.xml:S1:15348:8	report	VBN	O	O
voluntarily	PROMACTA.xml:S1:15357:11	voluntarili	RB	O	O
from	PROMACTA.xml:S1:15369:4	from	IN	O	O
a	PROMACTA.xml:S1:15374:1	a	DT	O	O
population	PROMACTA.xml:S1:15376:10	popul	NN	O	O
of	PROMACTA.xml:S1:15387:2	of	IN	O	O
uncertain	PROMACTA.xml:S1:15390:9	uncertain	JJ	O	O
size	PROMACTA.xml:S1:15400:4	size	NN	O	O
,	PROMACTA.xml:S1:15404:1	,	,	O	O
it	PROMACTA.xml:S1:15406:2	it	PRP	O	O
is	PROMACTA.xml:S1:15409:2	is	VBZ	O	O
not	PROMACTA.xml:S1:15412:3	not	RB	O	O
always	PROMACTA.xml:S1:15416:6	alway	RB	O	O
possible	PROMACTA.xml:S1:15423:8	possibl	JJ	O	O
to	PROMACTA.xml:S1:15432:2	to	TO	O	O
reliably	PROMACTA.xml:S1:15435:8	reliabl	VB	O	O
estimate	PROMACTA.xml:S1:15444:8	estim	VB	O	O
the	PROMACTA.xml:S1:15453:3	the	DT	O	O
frequency	PROMACTA.xml:S1:15457:9	frequenc	NN	O	O
or	PROMACTA.xml:S1:15467:2	or	CC	O	O
establish	PROMACTA.xml:S1:15470:9	establish	VB	O	O
a	PROMACTA.xml:S1:15480:1	a	DT	O	O
causal	PROMACTA.xml:S1:15482:6	causal	NN	O	O
relationship	PROMACTA.xml:S1:15489:12	relationship	NN	O	O
to	PROMACTA.xml:S1:15502:2	to	TO	O	O
drug	PROMACTA.xml:S1:15505:4	drug	NN	O	O
exposure	PROMACTA.xml:S1:15510:8	exposur	NN	O	O
.	PROMACTA.xml:S1:15518:1	.	.	O	O

Vascular	PROMACTA.xml:S1:15526:8	vascular	JJ	O	O
Disorders	PROMACTA.xml:S1:15535:9	disord	NNS	O	O
:	PROMACTA.xml:S1:15544:1	:	:	O	O
Thrombotic	PROMACTA.xml:S1:15547:10	thrombot	NNP	B-AdverseReaction	B-AdverseReaction
microangiopathy	PROMACTA.xml:S1:15558:15	microangiopathi	NN	I-AdverseReaction	I-AdverseReaction
with	PROMACTA.xml:S1:15574:4	with	IN	O	I-AdverseReaction
acute	PROMACTA.xml:S1:15579:5	acut	JJ	B-AdverseReaction	I-AdverseReaction
renal	PROMACTA.xml:S1:15585:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	PROMACTA.xml:S1:15591:7	failur	NN	I-AdverseReaction	I-AdverseReaction
.	PROMACTA.xml:S1:15598:1	.	.	O	O
\n\n	PROMACTA.xml:S2:0:2	\n\n	CC	O	O
BOXED	PROMACTA.xml:S2:6:5	box	NNP	O	O
WARNING	PROMACTA.xml:S2:12:7	warn	NNP	O	O
:	PROMACTA.xml:S2:19:1	:	:	O	O
WARNING	PROMACTA.xml:S2:21:7	warn	NN	O	O
:	PROMACTA.xml:S2:28:1	:	:	O	O
RISK	PROMACTA.xml:S2:30:4	risk	NN	O	O
FOR	PROMACTA.xml:S2:35:3	for	NNP	O	O
HEPATIC	PROMACTA.xml:S2:39:7	hepat	NNP	B-AdverseReaction	O
DECOMPENSATION	PROMACTA.xml:S2:47:14	decompens	NNP	I-AdverseReaction	O
IN	PROMACTA.xml:S2:62:2	IN	NNP	O	O
PATIENTS	PROMACTA.xml:S2:65:8	patient	NNP	O	O
WITH	PROMACTA.xml:S2:74:4	with	NNP	O	O
CHRONIC	PROMACTA.xml:S2:79:7	chronic	NNP	O	O
HEPATITIS	PROMACTA.xml:S2:87:9	hepat	NNP	O	O
C	PROMACTA.xml:S2:97:1	C	NNP	O	O
\n\n	PROMACTA.xml:S2:98:2	\n\n	NNP	O	O
WARNING	PROMACTA.xml:S2:102:7	warn	NN	O	O
:	PROMACTA.xml:S2:109:1	:	:	O	O
RISK	PROMACTA.xml:S2:111:4	risk	NN	O	O
FOR	PROMACTA.xml:S2:116:3	for	NNP	O	O
HEPATIC	PROMACTA.xml:S2:120:7	hepat	NNP	B-AdverseReaction	O
DECOMPENSATION	PROMACTA.xml:S2:128:14	decompens	NNP	I-AdverseReaction	O
IN	PROMACTA.xml:S2:143:2	IN	NNP	O	O
PATIENTS	PROMACTA.xml:S2:146:8	patient	NNP	O	O
WITH	PROMACTA.xml:S2:155:4	with	NNP	O	O
CHRONIC	PROMACTA.xml:S2:160:7	chronic	NNP	O	O
HEPATITIS	PROMACTA.xml:S2:168:9	hepat	NNP	O	O
C	PROMACTA.xml:S2:178:1	C	NNP	O	O
\n\n	PROMACTA.xml:S2:179:2	\n\n	NNP	O	O
In	PROMACTA.xml:S2:185:2	In	IN	O	O
patients	PROMACTA.xml:S2:188:8	patient	NNS	O	O
with	PROMACTA.xml:S2:197:4	with	IN	O	O
chronic	PROMACTA.xml:S2:202:7	chronic	JJ	O	O
hepatitis	PROMACTA.xml:S2:210:9	hepat	NN	O	O
C	PROMACTA.xml:S2:220:1	C	NNP	O	O
,	PROMACTA.xml:S2:221:1	,	,	O	O
PROMACTA	PROMACTA.xml:S2:223:8	promacta	NNP	O	O
(	PROMACTA.xml:S2:233:1	(	(	O	O
r	PROMACTA.xml:S2:234:1	r	NN	O	O
)	PROMACTA.xml:S2:235:1	)	)	O	O
in	PROMACTA.xml:S2:239:2	in	IN	O	O
combination	PROMACTA.xml:S2:242:11	combin	NN	O	O
with	PROMACTA.xml:S2:254:4	with	IN	O	O
interferon	PROMACTA.xml:S2:259:10	interferon	NN	O	O
and	PROMACTA.xml:S2:270:3	and	CC	O	O
ribavirin	PROMACTA.xml:S2:274:9	ribavirin	NN	O	O
may	PROMACTA.xml:S2:284:3	may	MD	O	O
increase	PROMACTA.xml:S2:288:8	increas	VB	O	O
the	PROMACTA.xml:S2:297:3	the	DT	O	O
risk	PROMACTA.xml:S2:301:4	risk	NN	O	O
of	PROMACTA.xml:S2:306:2	of	IN	O	O
hepatic	PROMACTA.xml:S2:309:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
decompensation	PROMACTA.xml:S2:317:14	decompens	NN	I-AdverseReaction	I-AdverseReaction
[	PROMACTA.xml:S2:334:1	[	NNP	O	O
see	PROMACTA.xml:S2:335:3	see	VBP	O	O
Warnings	PROMACTA.xml:S2:339:8	warn	NNP	O	O
and	PROMACTA.xml:S2:348:3	and	CC	O	O
Precautions	PROMACTA.xml:S2:352:11	precaut	NNP	O	O
(	PROMACTA.xml:S2:364:1	(	(	O	O
5.1	PROMACTA.xml:S2:365:3	5.1	CD	O	O
)]	PROMACTA.xml:S2:368:2	)]	NN	O	O
.	PROMACTA.xml:S2:372:1	.	.	O	O

EXCERPT	PROMACTA.xml:S2:382:7	excerpt	NN	O	O
:	PROMACTA.xml:S2:389:1	:	:	O	O
WARNING	PROMACTA.xml:S2:393:7	warn	NN	O	O
:	PROMACTA.xml:S2:400:1	:	:	O	O
RISK	PROMACTA.xml:S2:402:4	risk	NN	O	O
FOR	PROMACTA.xml:S2:407:3	for	NNP	O	O
HEPATIC	PROMACTA.xml:S2:411:7	hepat	NNP	B-AdverseReaction	O
DECOMPENSATION	PROMACTA.xml:S2:419:14	decompens	NNP	I-AdverseReaction	O
IN	PROMACTA.xml:S2:434:2	IN	NNP	O	O
PATIENTS	PROMACTA.xml:S2:437:8	patient	NNP	O	O
WITH	PROMACTA.xml:S2:446:4	with	NNP	O	O
CHRONIC	PROMACTA.xml:S2:451:7	chronic	NNP	O	O
HEPATITIS	PROMACTA.xml:S2:459:9	hepat	NNP	O	O
C	PROMACTA.xml:S2:469:1	C	NNP	O	O
\n\n\n\n	PROMACTA.xml:S2:470:4	\n\n\n\n	NNP	O	O
See	PROMACTA.xml:S2:477:3	see	NNP	O	O
full	PROMACTA.xml:S2:481:4	full	JJ	O	O
prescribing	PROMACTA.xml:S2:486:11	prescrib	VBG	O	O
information	PROMACTA.xml:S2:498:11	inform	NN	O	O
for	PROMACTA.xml:S2:510:3	for	IN	O	O
complete	PROMACTA.xml:S2:514:8	complet	JJ	O	O
boxed	PROMACTA.xml:S2:523:5	box	JJ	O	O
warning	PROMACTA.xml:S2:529:7	warn	NN	O	O
.	PROMACTA.xml:S2:536:1	.	.	O	O

In	PROMACTA.xml:S2:546:2	In	IN	O	O
patients	PROMACTA.xml:S2:549:8	patient	NNS	O	O
with	PROMACTA.xml:S2:558:4	with	IN	O	O
chronic	PROMACTA.xml:S2:563:7	chronic	JJ	O	O
hepatitis	PROMACTA.xml:S2:571:9	hepat	NN	O	O
C	PROMACTA.xml:S2:581:1	C	NNP	O	O
,	PROMACTA.xml:S2:582:1	,	,	O	O
PROMACTA	PROMACTA.xml:S2:584:8	promacta	NNP	O	O
in	PROMACTA.xml:S2:593:2	in	IN	O	O
combination	PROMACTA.xml:S2:596:11	combin	NN	O	O
with	PROMACTA.xml:S2:608:4	with	IN	O	O
interferon	PROMACTA.xml:S2:613:10	interferon	NN	O	O
and	PROMACTA.xml:S2:624:3	and	CC	O	O
ribavirin	PROMACTA.xml:S2:628:9	ribavirin	NN	O	O
may	PROMACTA.xml:S2:638:3	may	MD	O	O
increase	PROMACTA.xml:S2:642:8	increas	VB	O	O
the	PROMACTA.xml:S2:651:3	the	DT	O	O
risk	PROMACTA.xml:S2:655:4	risk	NN	O	O
of	PROMACTA.xml:S2:660:2	of	IN	O	O
hepatic	PROMACTA.xml:S2:663:7	hepat	JJ	B-AdverseReaction	O
decompensation	PROMACTA.xml:S2:671:14	decompens	NN	I-AdverseReaction	O
.	PROMACTA.xml:S2:685:1	.	.	O	O

(	PROMACTA.xml:S2:687:1	(	(	O	O
5.1	PROMACTA.xml:S2:690:3	5.1	CD	O	O
)	PROMACTA.xml:S2:695:1	)	)	O	O
\n	PROMACTA.xml:S2:698:1	\n	VBD	O	O
5	PROMACTA.xml:S3:4:1	5	CD	O	O
WARNINGS	PROMACTA.xml:S3:6:8	warn	NNP	O	O
AND	PROMACTA.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	PROMACTA.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	PROMACTA.xml:S3:37:7	excerpt	NN	O	O
:	PROMACTA.xml:S3:44:1	:	:	O	O
Hepatotoxicity	PROMACTA.xml:S3:54:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
:	PROMACTA.xml:S3:68:1	:	:	O	O
Monitor	PROMACTA.xml:S3:70:7	monitor	NNP	O	O
liver	PROMACTA.xml:S3:78:5	liver	WRB	O	O
function	PROMACTA.xml:S3:84:8	function	NN	O	O
before	PROMACTA.xml:S3:93:6	befor	IN	O	O
and	PROMACTA.xml:S3:100:3	and	CC	O	O
during	PROMACTA.xml:S3:104:6	dure	IN	O	O
therapy	PROMACTA.xml:S3:111:7	therapi	NN	O	O
.	PROMACTA.xml:S3:118:1	.	.	O	O

(	PROMACTA.xml:S3:120:1	(	(	O	O
5.2	PROMACTA.xml:S3:123:3	5.2	CD	O	O
)	PROMACTA.xml:S3:128:1	)	)	O	O

Thrombotic	PROMACTA.xml:S3:137:10	thrombot	JJ	B-AdverseReaction	B-AdverseReaction
Thromboembolic	PROMACTA.xml:S3:148:14	thromboembol	NNP	B-AdverseReaction	I-AdverseReaction
Complications	PROMACTA.xml:S3:163:13	complic	NNPS	I-AdverseReaction	I-AdverseReaction
:	PROMACTA.xml:S3:176:1	:	:	O	O
Portal	PROMACTA.xml:S3:178:6	portal	JJ	B-AdverseReaction	B-AdverseReaction
vein	PROMACTA.xml:S3:185:4	vein	NN	I-AdverseReaction	I-AdverseReaction
thrombosis	PROMACTA.xml:S3:190:10	thrombosi	NN	I-AdverseReaction	I-AdverseReaction
has	PROMACTA.xml:S3:201:3	ha	VBZ	O	O
been	PROMACTA.xml:S3:205:4	been	VBN	O	O
reported	PROMACTA.xml:S3:210:8	report	VBN	O	O
in	PROMACTA.xml:S3:219:2	in	IN	O	O
patients	PROMACTA.xml:S3:222:8	patient	NNS	O	O
with	PROMACTA.xml:S3:231:4	with	IN	O	O
chronic	PROMACTA.xml:S3:236:7	chronic	JJ	O	O
liver	PROMACTA.xml:S3:244:5	liver	NN	O	O
disease	PROMACTA.xml:S3:250:7	diseas	NN	O	O
receiving	PROMACTA.xml:S3:258:9	receiv	VBG	O	O
PROMACTA	PROMACTA.xml:S3:268:8	promacta	NNP	O	O
.	PROMACTA.xml:S3:276:1	.	.	O	O

Monitor	PROMACTA.xml:S3:278:7	monitor	NNP	O	O
platelet	PROMACTA.xml:S3:286:8	platelet	NN	O	O
counts	PROMACTA.xml:S3:295:6	count	VBZ	O	O
regularly	PROMACTA.xml:S3:302:9	regularli	RB	O	O
.	PROMACTA.xml:S3:311:1	.	.	O	O

(	PROMACTA.xml:S3:313:1	(	(	O	O
5.3	PROMACTA.xml:S3:316:3	5.3	CD	O	O
)	PROMACTA.xml:S3:321:1	)	)	O	O

5.1	PROMACTA.xml:S3:335:3	5.1	CD	O	O

Hepatic	PROMACTA.xml:S3:339:7	hepat	JJ	O	O

Decompensation	PROMACTA.xml:S3:347:14	decompens	NN	O	O
in	PROMACTA.xml:S3:362:2	in	IN	O	O
Patients	PROMACTA.xml:S3:365:8	patient	NNS	O	O
with	PROMACTA.xml:S3:374:4	with	IN	O	O
Chronic	PROMACTA.xml:S3:379:7	chronic	NNP	O	O
Hepatitis	PROMACTA.xml:S3:387:9	hepat	NNP	O	O
C	PROMACTA.xml:S3:397:1	C	NNP	O	O

In	PROMACTA.xml:S3:404:2	In	IN	O	O
patients	PROMACTA.xml:S3:407:8	patient	NNS	O	O
with	PROMACTA.xml:S3:416:4	with	IN	O	O
chronic	PROMACTA.xml:S3:421:7	chronic	JJ	O	O
hepatitis	PROMACTA.xml:S3:429:9	hepat	NN	O	O
C	PROMACTA.xml:S3:439:1	C	NNP	O	O
,	PROMACTA.xml:S3:440:1	,	,	O	O
PROMACTA	PROMACTA.xml:S3:442:8	promacta	NNP	O	O
in	PROMACTA.xml:S3:451:2	in	IN	O	O
combination	PROMACTA.xml:S3:454:11	combin	NN	O	O
with	PROMACTA.xml:S3:466:4	with	IN	O	O
interferon	PROMACTA.xml:S3:471:10	interferon	NN	O	O
and	PROMACTA.xml:S3:482:3	and	CC	O	O
ribavirin	PROMACTA.xml:S3:486:9	ribavirin	NN	O	O
may	PROMACTA.xml:S3:496:3	may	MD	O	O
increase	PROMACTA.xml:S3:500:8	increas	VB	O	O
the	PROMACTA.xml:S3:509:3	the	DT	O	O
risk	PROMACTA.xml:S3:513:4	risk	NN	O	O
of	PROMACTA.xml:S3:518:2	of	IN	O	O
hepatic	PROMACTA.xml:S3:521:7	hepat	JJ	B-AdverseReaction	O
decompensation	PROMACTA.xml:S3:529:14	decompens	NN	I-AdverseReaction	O
.	PROMACTA.xml:S3:543:1	.	.	O	O

In	PROMACTA.xml:S3:545:2	In	IN	O	O
two	PROMACTA.xml:S3:548:3	two	CD	O	O
controlled	PROMACTA.xml:S3:552:10	control	VBD	O	O
clinical	PROMACTA.xml:S3:563:8	clinic	JJ	O	O
trials	PROMACTA.xml:S3:572:6	trial	NNS	O	O
in	PROMACTA.xml:S3:579:2	in	IN	O	O
patients	PROMACTA.xml:S3:582:8	patient	NNS	O	O
with	PROMACTA.xml:S3:591:4	with	IN	O	O
chronic	PROMACTA.xml:S3:596:7	chronic	JJ	O	O
hepatitis	PROMACTA.xml:S3:604:9	hepat	NN	O	O
C	PROMACTA.xml:S3:614:1	C	NNP	O	O
and	PROMACTA.xml:S3:616:3	and	CC	O	O
thrombocytopenia	PROMACTA.xml:S3:620:16	thrombocytopenia	NN	O	B-AdverseReaction
,	PROMACTA.xml:S3:636:1	,	,	O	O
ascites	PROMACTA.xml:S3:638:7	ascit	NNS	B-AdverseReaction	O
and	PROMACTA.xml:S3:646:3	and	CC	O	O
encephalopathy	PROMACTA.xml:S3:650:14	encephalopathi	VB	B-AdverseReaction	O
occurred	PROMACTA.xml:S3:665:8	occur	VBD	O	O
more	PROMACTA.xml:S3:674:4	more	RBR	O	O
frequently	PROMACTA.xml:S3:679:10	frequent	RB	O	O
on	PROMACTA.xml:S3:690:2	on	IN	O	O
the	PROMACTA.xml:S3:693:3	the	DT	O	O
arm	PROMACTA.xml:S3:697:3	arm	NN	O	O
receiving	PROMACTA.xml:S3:701:9	receiv	NN	O	O
treatment	PROMACTA.xml:S3:711:9	treatment	NN	O	O
with	PROMACTA.xml:S3:721:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S3:726:8	promacta	NNP	O	O
plus	PROMACTA.xml:S3:735:4	plu	CC	O	O
antivirals	PROMACTA.xml:S3:740:10	antivir	NNS	O	O
(	PROMACTA.xml:S3:751:1	(	(	O	O
7%	PROMACTA.xml:S3:752:2	7%	CD	O	O
)	PROMACTA.xml:S3:754:1	)	)	O	O
than	PROMACTA.xml:S3:756:4	than	IN	O	O
the	PROMACTA.xml:S3:761:3	the	DT	O	O
placebo	PROMACTA.xml:S3:765:7	placebo	NN	O	O
plus	PROMACTA.xml:S3:773:4	plu	CC	O	O
antivirals	PROMACTA.xml:S3:778:10	antivir	NNS	O	O
arm	PROMACTA.xml:S3:789:3	arm	NN	O	O
(	PROMACTA.xml:S3:793:1	(	(	O	O
4%	PROMACTA.xml:S3:794:2	4%	CD	O	O
)	PROMACTA.xml:S3:796:1	)	)	O	O
.	PROMACTA.xml:S3:797:1	.	.	O	O

Patients	PROMACTA.xml:S3:799:8	patient	NNS	O	O
with	PROMACTA.xml:S3:808:4	with	IN	O	O
low	PROMACTA.xml:S3:813:3	low	JJ	O	O
albumin	PROMACTA.xml:S3:817:7	albumin	NN	O	O
levels	PROMACTA.xml:S3:825:6	level	NNS	O	O
(	PROMACTA.xml:S3:832:1	(	(	O	O
less	PROMACTA.xml:S3:833:4	less	JJR	O	O
than	PROMACTA.xml:S3:838:4	than	IN	O	O
3.5	PROMACTA.xml:S3:843:3	3.5	CD	O	O
g	PROMACTA.xml:S3:847:1	g	JJ	O	O
dL	PROMACTA.xml:S3:849:2	dL	NN	O	O
)	PROMACTA.xml:S3:851:1	)	)	O	O
or	PROMACTA.xml:S3:853:2	or	CC	O	O
Model	PROMACTA.xml:S3:856:5	model	NNP	O	O
for	PROMACTA.xml:S3:862:3	for	IN	O	O
End	PROMACTA.xml:S3:866:3	end	NNP	O	O
-	PROMACTA.xml:S3:869:1	-	:	O	O
Stage	PROMACTA.xml:S3:870:5	stage	NN	O	O
Liver	PROMACTA.xml:S3:876:5	liver	NNP	O	O
Disease	PROMACTA.xml:S3:882:7	diseas	NNP	O	O
(	PROMACTA.xml:S3:890:1	(	(	O	O
MELD	PROMACTA.xml:S3:891:4	meld	NNP	O	O
)	PROMACTA.xml:S3:895:1	)	)	O	O
score	PROMACTA.xml:S3:897:5	score	NN	O	O
greater	PROMACTA.xml:S3:903:7	greater	JJR	O	O
than	PROMACTA.xml:S3:911:4	than	IN	O	O
or	PROMACTA.xml:S3:916:2	or	CC	O	O
equal	PROMACTA.xml:S3:919:5	equal	JJ	O	O
to	PROMACTA.xml:S3:925:2	to	TO	O	O
10	PROMACTA.xml:S3:928:2	10	CD	O	O
at	PROMACTA.xml:S3:931:2	at	IN	O	O
baseline	PROMACTA.xml:S3:934:8	baselin	NN	O	O
had	PROMACTA.xml:S3:943:3	had	VBD	O	O
a	PROMACTA.xml:S3:947:1	a	DT	O	O
greater	PROMACTA.xml:S3:949:7	greater	JJR	O	O
risk	PROMACTA.xml:S3:957:4	risk	NN	O	O
for	PROMACTA.xml:S3:962:3	for	IN	O	O
hepatic	PROMACTA.xml:S3:966:7	hepat	JJ	B-AdverseReaction	O
decompensation	PROMACTA.xml:S3:974:14	decompens	NN	I-AdverseReaction	O
on	PROMACTA.xml:S3:989:2	on	IN	O	O
the	PROMACTA.xml:S3:992:3	the	DT	O	O
arm	PROMACTA.xml:S3:996:3	arm	NN	O	O
receiving	PROMACTA.xml:S3:1000:9	receiv	NN	O	O
treatment	PROMACTA.xml:S3:1010:9	treatment	NN	O	O
with	PROMACTA.xml:S3:1020:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S3:1025:8	promacta	NNP	O	O
plus	PROMACTA.xml:S3:1034:4	plu	CC	O	O
antivirals	PROMACTA.xml:S3:1039:10	antivir	NNS	O	O
.	PROMACTA.xml:S3:1049:1	.	.	O	O

Discontinue	PROMACTA.xml:S3:1051:11	discontinu	NNP	O	O
PROMACTA	PROMACTA.xml:S3:1063:8	promacta	NNP	O	O
if	PROMACTA.xml:S3:1072:2	if	IN	O	O
antiviral	PROMACTA.xml:S3:1075:9	antivir	JJ	O	O
therapy	PROMACTA.xml:S3:1085:7	therapi	NN	O	O
is	PROMACTA.xml:S3:1093:2	is	VBZ	O	O
discontinued	PROMACTA.xml:S3:1096:12	discontinu	VBN	O	O
.	PROMACTA.xml:S3:1108:1	.	.	O	O

5.2	PROMACTA.xml:S3:1117:3	5.2	CD	O	O
Hepatotoxicity	PROMACTA.xml:S3:1121:14	hepatotox	NN	O	O

PROMACTA	PROMACTA.xml:S3:1141:8	promacta	NNP	O	O
can	PROMACTA.xml:S3:1150:3	can	MD	O	O
cause	PROMACTA.xml:S3:1154:5	caus	VB	O	O
liver	PROMACTA.xml:S3:1160:5	liver	JJ	B-AdverseReaction	B-AdverseReaction
enzyme	PROMACTA.xml:S3:1166:6	enzym	JJ	I-AdverseReaction	I-AdverseReaction
elevations	PROMACTA.xml:S3:1173:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
[	PROMACTA.xml:S3:1184:1	[	VBP	O	O
see	PROMACTA.xml:S3:1185:3	see	VB	O	O
Adverse	PROMACTA.xml:S3:1189:7	advers	JJ	O	O
Reactions	PROMACTA.xml:S3:1197:9	reaction	NNP	O	O
(	PROMACTA.xml:S3:1207:1	(	(	O	O
6.1	PROMACTA.xml:S3:1208:3	6.1	CD	O	O
)]	PROMACTA.xml:S3:1211:2	)]	NN	O	O
.	PROMACTA.xml:S3:1215:1	.	.	O	O

Measure	PROMACTA.xml:S3:1217:7	measur	NN	O	B-AdverseReaction
serum	PROMACTA.xml:S3:1225:5	serum	NN	O	I-AdverseReaction
ALT	PROMACTA.xml:S3:1231:3	alt	NNP	O	I-AdverseReaction
,	PROMACTA.xml:S3:1234:1	,	,	O	O
AST	PROMACTA.xml:S3:1236:3	ast	NNP	O	I-AdverseReaction
,	PROMACTA.xml:S3:1239:1	,	,	O	O
and	PROMACTA.xml:S3:1241:3	and	CC	O	O
bilirubin	PROMACTA.xml:S3:1245:9	bilirubin	RB	O	O
prior	PROMACTA.xml:S3:1255:5	prior	RB	O	O
to	PROMACTA.xml:S3:1261:2	to	TO	O	O
initiation	PROMACTA.xml:S3:1264:10	initi	NN	O	O
of	PROMACTA.xml:S3:1275:2	of	IN	O	O
PROMACTA	PROMACTA.xml:S3:1278:8	promacta	NNP	O	O
,	PROMACTA.xml:S3:1286:1	,	,	O	O
every	PROMACTA.xml:S3:1288:5	everi	DT	O	O
2	PROMACTA.xml:S3:1294:1	2	CD	O	O
weeks	PROMACTA.xml:S3:1296:5	week	NNS	O	O
during	PROMACTA.xml:S3:1302:6	dure	IN	O	O
the	PROMACTA.xml:S3:1309:3	the	DT	O	O
dose	PROMACTA.xml:S3:1313:4	dose	JJ	O	O
adjustment	PROMACTA.xml:S3:1318:10	adjust	NN	O	O
phase	PROMACTA.xml:S3:1329:5	phase	NN	O	O
,	PROMACTA.xml:S3:1334:1	,	,	O	O
and	PROMACTA.xml:S3:1336:3	and	CC	O	O
monthly	PROMACTA.xml:S3:1340:7	monthli	RB	O	O
following	PROMACTA.xml:S3:1348:9	follow	VBG	O	O
establishment	PROMACTA.xml:S3:1358:13	establish	NN	O	O
of	PROMACTA.xml:S3:1372:2	of	IN	O	O
a	PROMACTA.xml:S3:1375:1	a	DT	O	O
stable	PROMACTA.xml:S3:1377:6	stabl	JJ	O	O
dose	PROMACTA.xml:S3:1384:4	dose	NN	O	O
.	PROMACTA.xml:S3:1388:1	.	.	O	O

PROMACTA	PROMACTA.xml:S3:1390:8	promacta	NNP	O	O
inhibits	PROMACTA.xml:S3:1399:8	inhibit	VBZ	O	O
UDP	PROMACTA.xml:S3:1408:3	udp	NNP	O	O
-	PROMACTA.xml:S3:1411:1	-	:	O	O
glucuronosyltransferase	PROMACTA.xml:S3:1412:23	glucuronosyltransferas	NN	O	O
(	PROMACTA.xml:S3:1436:1	(	(	O	O
UGT	PROMACTA.xml:S3:1437:3	ugt	NNP	O	O
)	PROMACTA.xml:S3:1440:1	)	)	O	O
1	PROMACTA.xml:S3:1441:1	1	CD	O	O
A1	PROMACTA.xml:S3:1442:2	A1	NNP	O	O
and	PROMACTA.xml:S3:1445:3	and	CC	O	O
organic	PROMACTA.xml:S3:1449:7	organ	JJ	O	O
anion	PROMACTA.xml:S3:1457:5	anion	NN	O	O
-	PROMACTA.xml:S3:1462:1	-	:	O	O
transporting	PROMACTA.xml:S3:1463:12	transport	NN	O	O
polypeptide	PROMACTA.xml:S3:1476:11	polypeptid	NN	O	O
(	PROMACTA.xml:S3:1488:1	(	(	O	O
OATP	PROMACTA.xml:S3:1489:4	oatp	NNP	O	O
)	PROMACTA.xml:S3:1493:1	)	)	O	O
1	PROMACTA.xml:S3:1494:1	1	CD	O	O
B1	PROMACTA.xml:S3:1495:2	B1	NNP	O	O
,	PROMACTA.xml:S3:1497:1	,	,	O	O
which	PROMACTA.xml:S3:1499:5	which	WDT	O	O
may	PROMACTA.xml:S3:1505:3	may	MD	O	O
lead	PROMACTA.xml:S3:1509:4	lead	VB	O	O
to	PROMACTA.xml:S3:1514:2	to	TO	O	O
indirect	PROMACTA.xml:S3:1517:8	indirect	JJ	B-AdverseReaction	O
hyperbilirubinemia	PROMACTA.xml:S3:1526:18	hyperbilirubinemia	NN	I-AdverseReaction	O
.	PROMACTA.xml:S3:1544:1	.	.	O	O

If	PROMACTA.xml:S3:1546:2	If	IN	O	O
bilirubin	PROMACTA.xml:S3:1549:9	bilirubin	VBN	O	O
is	PROMACTA.xml:S3:1559:2	is	VBZ	O	O
elevated	PROMACTA.xml:S3:1562:8	elev	VBN	O	O
,	PROMACTA.xml:S3:1570:1	,	,	O	O
perform	PROMACTA.xml:S3:1572:7	perform	VB	O	O
fractionation	PROMACTA.xml:S3:1580:13	fraction	NN	O	O
.	PROMACTA.xml:S3:1593:1	.	.	O	O

Evaluate	PROMACTA.xml:S3:1595:8	evalu	NNP	O	O
abnormal	PROMACTA.xml:S3:1604:8	abnorm	JJ	O	O
serum	PROMACTA.xml:S3:1613:5	serum	NN	O	O
liver	PROMACTA.xml:S3:1619:5	liver	NN	O	O
tests	PROMACTA.xml:S3:1625:5	test	NNS	O	O
with	PROMACTA.xml:S3:1631:4	with	IN	O	O
repeat	PROMACTA.xml:S3:1636:6	repeat	NN	O	O
testing	PROMACTA.xml:S3:1643:7	test	VBG	O	O
within	PROMACTA.xml:S3:1651:6	within	IN	O	O
3	PROMACTA.xml:S3:1658:1	3	CD	O	O
to	PROMACTA.xml:S3:1660:2	to	TO	O	O
5	PROMACTA.xml:S3:1663:1	5	CD	O	O
days	PROMACTA.xml:S3:1665:4	day	NNS	O	O
.	PROMACTA.xml:S3:1669:1	.	.	O	O

If	PROMACTA.xml:S3:1671:2	If	IN	O	O
the	PROMACTA.xml:S3:1674:3	the	DT	O	O
abnormalities	PROMACTA.xml:S3:1678:13	abnorm	NNS	O	O
are	PROMACTA.xml:S3:1692:3	are	VBP	O	O
confirmed	PROMACTA.xml:S3:1696:9	confirm	VBN	O	O
,	PROMACTA.xml:S3:1705:1	,	,	O	O
monitor	PROMACTA.xml:S3:1707:7	monitor	NN	O	O
serum	PROMACTA.xml:S3:1715:5	serum	NN	O	O
liver	PROMACTA.xml:S3:1721:5	liver	NN	O	O
tests	PROMACTA.xml:S3:1727:5	test	NNS	O	O
weekly	PROMACTA.xml:S3:1733:6	weekli	RB	O	O
until	PROMACTA.xml:S3:1740:5	until	IN	O	O
resolved	PROMACTA.xml:S3:1746:8	resolv	VBN	O	O
or	PROMACTA.xml:S3:1755:2	or	CC	O	O
stabilized	PROMACTA.xml:S3:1758:10	stabil	VBN	O	O
.	PROMACTA.xml:S3:1768:1	.	.	O	O

Discontinue	PROMACTA.xml:S3:1770:11	discontinu	NNP	O	O
PROMACTA	PROMACTA.xml:S3:1782:8	promacta	NNP	O	O
if	PROMACTA.xml:S3:1791:2	if	IN	O	O
ALT	PROMACTA.xml:S3:1794:3	alt	NNP	O	O
levels	PROMACTA.xml:S3:1798:6	level	NNS	O	O
increase	PROMACTA.xml:S3:1805:8	increas	NN	O	O
to	PROMACTA.xml:S3:1814:2	to	TO	O	O
greater	PROMACTA.xml:S3:1817:7	greater	JJR	O	O
than	PROMACTA.xml:S3:1825:4	than	IN	O	O
or	PROMACTA.xml:S3:1830:2	or	CC	O	O
equal	PROMACTA.xml:S3:1833:5	equal	JJ	O	O
to	PROMACTA.xml:S3:1839:2	to	TO	O	O
3	PROMACTA.xml:S3:1842:1	3	CD	O	O
x	PROMACTA.xml:S3:1844:1	x	NNS	O	O
ULN	PROMACTA.xml:S3:1846:3	uln	NNP	O	O
in	PROMACTA.xml:S3:1850:2	in	IN	O	O
patients	PROMACTA.xml:S3:1853:8	patient	NNS	O	O
with	PROMACTA.xml:S3:1862:4	with	IN	O	O
normal	PROMACTA.xml:S3:1867:6	normal	JJ	O	O
liver	PROMACTA.xml:S3:1874:5	liver	JJ	O	O
function	PROMACTA.xml:S3:1880:8	function	NN	O	O
or	PROMACTA.xml:S3:1889:2	or	CC	O	O
greater	PROMACTA.xml:S3:1892:7	greater	JJR	O	O
than	PROMACTA.xml:S3:1900:4	than	IN	O	O
or	PROMACTA.xml:S3:1905:2	or	CC	O	O
equal	PROMACTA.xml:S3:1908:5	equal	JJ	O	O
to	PROMACTA.xml:S3:1914:2	to	TO	O	O
3	PROMACTA.xml:S3:1917:1	3	CD	O	O
x	PROMACTA.xml:S3:1919:1	x	NNS	O	O
baseline	PROMACTA.xml:S3:1921:8	baselin	NN	O	O
in	PROMACTA.xml:S3:1930:2	in	IN	O	O
patients	PROMACTA.xml:S3:1933:8	patient	NNS	O	O
with	PROMACTA.xml:S3:1942:4	with	IN	O	O
pre	PROMACTA.xml:S3:1947:3	pre	JJ	O	O
-	PROMACTA.xml:S3:1950:1	-	:	O	O
treatment	PROMACTA.xml:S3:1951:9	treatment	NN	O	O
elevations	PROMACTA.xml:S3:1961:10	elev	NNS	O	O
in	PROMACTA.xml:S3:1972:2	in	IN	O	O
transaminases	PROMACTA.xml:S3:1975:13	transaminas	NNS	O	O
and	PROMACTA.xml:S3:1989:3	and	CC	O	O
are	PROMACTA.xml:S3:1993:3	are	VBP	O	O
:	PROMACTA.xml:S3:1996:1	:	:	O	O

progressively	PROMACTA.xml:S3:2007:13	progress	RB	O	O
increasing	PROMACTA.xml:S3:2021:10	increas	VBG	O	O
,	PROMACTA.xml:S3:2031:1	,	,	O	O
or	PROMACTA.xml:S3:2033:2	or	CC	O	O

persistent	PROMACTA.xml:S3:2043:10	persist	NN	O	O
for	PROMACTA.xml:S3:2054:3	for	IN	O	O
greater	PROMACTA.xml:S3:2058:7	greater	JJR	O	O
than	PROMACTA.xml:S3:2066:4	than	IN	O	O
or	PROMACTA.xml:S3:2071:2	or	CC	O	O
equal	PROMACTA.xml:S3:2074:5	equal	JJ	O	O
to	PROMACTA.xml:S3:2080:2	to	TO	O	O
4	PROMACTA.xml:S3:2083:1	4	CD	O	O
weeks	PROMACTA.xml:S3:2085:5	week	NNS	O	O
,	PROMACTA.xml:S3:2090:1	,	,	O	O
or	PROMACTA.xml:S3:2092:2	or	CC	O	O

accompanied	PROMACTA.xml:S3:2102:11	accompani	VBN	O	O
by	PROMACTA.xml:S3:2114:2	by	IN	O	O
increased	PROMACTA.xml:S3:2117:9	increas	JJ	O	O
direct	PROMACTA.xml:S3:2127:6	direct	JJ	O	O
bilirubin	PROMACTA.xml:S3:2134:9	bilirubin	NN	O	O
,	PROMACTA.xml:S3:2143:1	,	,	O	O
or	PROMACTA.xml:S3:2145:2	or	CC	O	O

accompanied	PROMACTA.xml:S3:2155:11	accompani	VBN	O	O
by	PROMACTA.xml:S3:2167:2	by	IN	O	O
clinical	PROMACTA.xml:S3:2170:8	clinic	JJ	O	O
symptoms	PROMACTA.xml:S3:2179:8	symptom	NNS	O	O
of	PROMACTA.xml:S3:2188:2	of	IN	O	O
liver	PROMACTA.xml:S3:2191:5	liver	JJ	O	O
injury	PROMACTA.xml:S3:2197:6	injuri	NN	O	O
or	PROMACTA.xml:S3:2204:2	or	CC	O	O
evidence	PROMACTA.xml:S3:2207:8	evid	NN	O	O
for	PROMACTA.xml:S3:2216:3	for	IN	O	O
hepatic	PROMACTA.xml:S3:2220:7	hepat	JJ	O	O
decompensation	PROMACTA.xml:S3:2228:14	decompens	NN	O	O
.	PROMACTA.xml:S3:2242:1	.	.	O	O

If	PROMACTA.xml:S3:2249:2	If	IN	O	O
the	PROMACTA.xml:S3:2252:3	the	DT	O	O
potential	PROMACTA.xml:S3:2256:9	potenti	JJ	O	O
benefit	PROMACTA.xml:S3:2266:7	benefit	NN	O	O
for	PROMACTA.xml:S3:2274:3	for	IN	O	O
reinitiating	PROMACTA.xml:S3:2278:12	reiniti	VBG	O	O
treatment	PROMACTA.xml:S3:2291:9	treatment	NN	O	O
with	PROMACTA.xml:S3:2301:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S3:2306:8	promacta	NNP	O	O
is	PROMACTA.xml:S3:2315:2	is	VBZ	O	O
considered	PROMACTA.xml:S3:2318:10	consid	VBN	O	O
to	PROMACTA.xml:S3:2329:2	to	TO	O	O
outweigh	PROMACTA.xml:S3:2332:8	outweigh	VB	O	O
the	PROMACTA.xml:S3:2341:3	the	DT	O	O
risk	PROMACTA.xml:S3:2345:4	risk	NN	O	O
for	PROMACTA.xml:S3:2350:3	for	IN	O	O
hepatotoxicity	PROMACTA.xml:S3:2354:14	hepatotox	NN	O	B-AdverseReaction
,	PROMACTA.xml:S3:2368:1	,	,	O	O
then	PROMACTA.xml:S3:2370:4	then	RB	O	O
consider	PROMACTA.xml:S3:2375:8	consid	VB	O	O
cautiously	PROMACTA.xml:S3:2384:10	cautious	RB	O	O
reintroducing	PROMACTA.xml:S3:2395:13	reintroduc	VBG	O	O
PROMACTA	PROMACTA.xml:S3:2409:8	promacta	NNP	O	O
and	PROMACTA.xml:S3:2418:3	and	CC	O	O
measure	PROMACTA.xml:S3:2422:7	measur	NN	O	O
serum	PROMACTA.xml:S3:2430:5	serum	NN	O	O
liver	PROMACTA.xml:S3:2436:5	liver	NN	O	O
tests	PROMACTA.xml:S3:2442:5	test	NNS	O	O
weekly	PROMACTA.xml:S3:2448:6	weekli	VBP	O	O
during	PROMACTA.xml:S3:2455:6	dure	IN	O	O
the	PROMACTA.xml:S3:2462:3	the	DT	O	O
dose	PROMACTA.xml:S3:2466:4	dose	JJ	O	O
adjustment	PROMACTA.xml:S3:2471:10	adjust	NN	O	O
phase	PROMACTA.xml:S3:2482:5	phase	NN	O	O
.	PROMACTA.xml:S3:2487:1	.	.	O	O

Hepatotoxicity	PROMACTA.xml:S3:2489:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
may	PROMACTA.xml:S3:2504:3	may	MD	O	O
reoccur	PROMACTA.xml:S3:2508:7	reoccur	VB	O	O
if	PROMACTA.xml:S3:2516:2	if	IN	O	O
PROMACTA	PROMACTA.xml:S3:2519:8	promacta	NNP	O	O
is	PROMACTA.xml:S3:2528:2	is	VBZ	O	O
reinitiated	PROMACTA.xml:S3:2531:11	reiniti	VBN	O	O
.	PROMACTA.xml:S3:2542:1	.	.	O	O

If	PROMACTA.xml:S3:2544:2	If	IN	O	O
liver	PROMACTA.xml:S3:2547:5	liver	JJ	O	O
test	PROMACTA.xml:S3:2553:4	test	NN	O	O
abnormalities	PROMACTA.xml:S3:2558:13	abnorm	NNS	O	O
persist	PROMACTA.xml:S3:2572:7	persist	VBP	O	O
,	PROMACTA.xml:S3:2579:1	,	,	O	O
worsen	PROMACTA.xml:S3:2581:6	worsen	VBP	O	O
or	PROMACTA.xml:S3:2588:2	or	CC	O	O
recur	PROMACTA.xml:S3:2591:5	recur	VBP	O	O
,	PROMACTA.xml:S3:2596:1	,	,	O	O
then	PROMACTA.xml:S3:2598:4	then	RB	O	O
permanently	PROMACTA.xml:S3:2603:11	perman	RB	O	O
discontinue	PROMACTA.xml:S3:2615:11	discontinu	VBP	O	O
PROMACTA	PROMACTA.xml:S3:2627:8	promacta	NNP	O	O
.	PROMACTA.xml:S3:2635:1	.	.	O	O

5.3	PROMACTA.xml:S3:2644:3	5.3	CD	O	O

Thrombotic	PROMACTA.xml:S3:2648:10	thrombot	JJ	O	O
Thromboembolic	PROMACTA.xml:S3:2659:14	thromboembol	NNP	O	O
Complications	PROMACTA.xml:S3:2674:13	complic	NNP	O	O

In	PROMACTA.xml:S3:2693:2	In	IN	O	O
two	PROMACTA.xml:S3:2696:3	two	CD	O	O
controlled	PROMACTA.xml:S3:2700:10	control	VBD	O	O
clinical	PROMACTA.xml:S3:2711:8	clinic	JJ	O	O
trials	PROMACTA.xml:S3:2720:6	trial	NNS	O	O
in	PROMACTA.xml:S3:2727:2	in	IN	O	O
patients	PROMACTA.xml:S3:2730:8	patient	NNS	O	O
with	PROMACTA.xml:S3:2739:4	with	IN	O	O
chronic	PROMACTA.xml:S3:2744:7	chronic	JJ	O	O
hepatitis	PROMACTA.xml:S3:2752:9	hepat	NN	O	O
C	PROMACTA.xml:S3:2762:1	C	NNP	O	O
and	PROMACTA.xml:S3:2764:3	and	CC	O	O
thrombocytopenia	PROMACTA.xml:S3:2768:16	thrombocytopenia	NN	O	B-AdverseReaction
,	PROMACTA.xml:S3:2784:1	,	,	O	O
3%	PROMACTA.xml:S3:2786:2	3%	CD	O	O
(	PROMACTA.xml:S3:2789:1	(	(	O	O
31	PROMACTA.xml:S3:2790:2	31	CD	O	O
955	PROMACTA.xml:S3:2793:3	955	CD	O	O
)	PROMACTA.xml:S3:2796:1	)	)	O	O
treated	PROMACTA.xml:S3:2798:7	treat	VBN	O	O
with	PROMACTA.xml:S3:2806:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S3:2811:8	promacta	NNP	O	O
experienced	PROMACTA.xml:S3:2820:11	experienc	VBD	O	O
a	PROMACTA.xml:S3:2832:1	a	DT	O	O
thrombotic	PROMACTA.xml:S3:2834:10	thrombot	JJ	B-AdverseReaction	B-AdverseReaction
event	PROMACTA.xml:S3:2845:5	event	NN	I-AdverseReaction	I-AdverseReaction
compared	PROMACTA.xml:S3:2851:8	compar	VBN	O	O
with	PROMACTA.xml:S3:2860:4	with	IN	O	O
1%	PROMACTA.xml:S3:2865:2	1%	CD	O	O
(	PROMACTA.xml:S3:2868:1	(	(	O	O
5	PROMACTA.xml:S3:2869:1	5	CD	O	O
484	PROMACTA.xml:S3:2871:3	484	CD	O	O
)	PROMACTA.xml:S3:2874:1	)	)	O	O
on	PROMACTA.xml:S3:2876:2	on	IN	O	O
placebo	PROMACTA.xml:S3:2879:7	placebo	NN	O	O
.	PROMACTA.xml:S3:2886:1	.	.	O	O

The	PROMACTA.xml:S3:2888:3	the	DT	O	O
majority	PROMACTA.xml:S3:2892:8	major	NN	O	O
of	PROMACTA.xml:S3:2901:2	of	IN	O	O
events	PROMACTA.xml:S3:2904:6	event	NNS	I-AdverseReaction	O
were	PROMACTA.xml:S3:2911:4	were	VBD	O	O
of	PROMACTA.xml:S3:2916:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	PROMACTA.xml:S3:2919:3	the	DT	I-AdverseReaction	I-AdverseReaction
portal	PROMACTA.xml:S3:2923:6	portal	JJ	I-AdverseReaction	I-AdverseReaction
venous	PROMACTA.xml:S3:2930:6	venou	JJ	I-AdverseReaction	I-AdverseReaction
system	PROMACTA.xml:S3:2937:6	system	NN	I-AdverseReaction	I-AdverseReaction
(	PROMACTA.xml:S3:2944:1	(	(	O	O
1%	PROMACTA.xml:S3:2945:2	1%	CD	O	O
in	PROMACTA.xml:S3:2948:2	in	IN	O	O
patients	PROMACTA.xml:S3:2951:8	patient	NNS	O	O
treated	PROMACTA.xml:S3:2960:7	treat	VBN	O	O
with	PROMACTA.xml:S3:2968:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S3:2973:8	promacta	NNP	O	O
versus	PROMACTA.xml:S3:2982:6	versu	NN	O	O
less	PROMACTA.xml:S3:2989:4	less	JJR	O	O
than	PROMACTA.xml:S3:2994:4	than	IN	O	O
1%	PROMACTA.xml:S3:2999:2	1%	CD	O	O
for	PROMACTA.xml:S3:3002:3	for	IN	O	O
placebo	PROMACTA.xml:S3:3006:7	placebo	NN	O	O
)	PROMACTA.xml:S3:3013:1	)	)	O	O
.	PROMACTA.xml:S3:3014:1	.	.	O	O

Thrombotic	PROMACTA.xml:S3:3020:10	thrombot	JJ	B-AdverseReaction	B-AdverseReaction
thromboembolic	PROMACTA.xml:S3:3031:14	thromboembol	JJ	B-AdverseReaction	I-AdverseReaction
complications	PROMACTA.xml:S3:3046:13	complic	NNS	I-AdverseReaction	I-AdverseReaction
may	PROMACTA.xml:S3:3060:3	may	MD	O	O
result	PROMACTA.xml:S3:3064:6	result	VB	O	O
from	PROMACTA.xml:S3:3071:4	from	IN	O	O
increases	PROMACTA.xml:S3:3076:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	PROMACTA.xml:S3:3086:2	in	IN	I-AdverseReaction	I-AdverseReaction
platelet	PROMACTA.xml:S3:3089:8	platelet	NN	I-AdverseReaction	I-AdverseReaction
counts	PROMACTA.xml:S3:3098:6	count	NNS	I-AdverseReaction	I-AdverseReaction
with	PROMACTA.xml:S3:3105:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S3:3110:8	promacta	NNP	O	O
.	PROMACTA.xml:S3:3118:1	.	.	O	O

Reported	PROMACTA.xml:S3:3120:8	report	VBN	O	O
thrombotic	PROMACTA.xml:S3:3129:10	thrombot	JJ	B-AdverseReaction	B-AdverseReaction
thromboembolic	PROMACTA.xml:S3:3140:14	thromboembol	JJ	B-AdverseReaction	I-AdverseReaction
complications	PROMACTA.xml:S3:3155:13	complic	NNS	I-AdverseReaction	I-AdverseReaction
included	PROMACTA.xml:S3:3169:8	includ	VBD	O	O
both	PROMACTA.xml:S3:3178:4	both	DT	O	O
venous	PROMACTA.xml:S3:3183:6	venou	JJ	I-AdverseReaction	O
and	PROMACTA.xml:S3:3190:3	and	CC	O	O
arterial	PROMACTA.xml:S3:3194:8	arteri	JJ	I-AdverseReaction	B-AdverseReaction
events	PROMACTA.xml:S3:3203:6	event	NNS	I-AdverseReaction	I-AdverseReaction
and	PROMACTA.xml:S3:3210:3	and	CC	O	O
were	PROMACTA.xml:S3:3214:4	were	VBD	O	O
observed	PROMACTA.xml:S3:3219:8	observ	VBN	O	O
at	PROMACTA.xml:S3:3228:2	at	IN	O	O
low	PROMACTA.xml:S3:3231:3	low	JJ	O	O
and	PROMACTA.xml:S3:3235:3	and	CC	O	O
at	PROMACTA.xml:S3:3239:2	at	IN	O	O
normal	PROMACTA.xml:S3:3242:6	normal	JJ	O	O
platelet	PROMACTA.xml:S3:3249:8	platelet	NN	O	O
counts	PROMACTA.xml:S3:3258:6	count	NNS	O	O
.	PROMACTA.xml:S3:3264:1	.	.	O	O

Consider	PROMACTA.xml:S3:3270:8	consid	VB	O	O
the	PROMACTA.xml:S3:3279:3	the	DT	O	O
potential	PROMACTA.xml:S3:3283:9	potenti	NN	O	O
for	PROMACTA.xml:S3:3293:3	for	IN	O	O
an	PROMACTA.xml:S3:3297:2	an	DT	O	O
increased	PROMACTA.xml:S3:3300:9	increas	VBN	O	O
risk	PROMACTA.xml:S3:3310:4	risk	NN	O	O
of	PROMACTA.xml:S3:3315:2	of	IN	O	O
thromboembolism	PROMACTA.xml:S3:3318:15	thromboembol	NN	O	O
when	PROMACTA.xml:S3:3334:4	when	WRB	O	O
administering	PROMACTA.xml:S3:3339:13	administ	VBG	O	O
PROMACTA	PROMACTA.xml:S3:3353:8	promacta	NNP	O	O
to	PROMACTA.xml:S3:3362:2	to	TO	O	O
patients	PROMACTA.xml:S3:3365:8	patient	NNS	O	O
with	PROMACTA.xml:S3:3374:4	with	IN	O	O
known	PROMACTA.xml:S3:3379:5	known	VBN	O	O
risk	PROMACTA.xml:S3:3385:4	risk	NN	O	O
factors	PROMACTA.xml:S3:3390:7	factor	NNS	O	O
for	PROMACTA.xml:S3:3398:3	for	IN	O	O
thromboembolism	PROMACTA.xml:S3:3402:15	thromboembol	NN	O	O
(	PROMACTA.xml:S3:3418:1	(	(	O	O
e	PROMACTA.xml:S3:3419:1	e	NN	O	O
.	PROMACTA.xml:S3:3420:1	.	.	O	O
g	PROMACTA.xml:S3:3421:1	g	NN	O	O
.	PROMACTA.xml:S3:3422:1	.	.	O	O
,	PROMACTA.xml:S3:3423:1	,	,	O	O
Factor	PROMACTA.xml:S3:3425:6	factor	NNP	O	O
V	PROMACTA.xml:S3:3432:1	V	NNP	O	O
Leiden	PROMACTA.xml:S3:3434:6	leiden	NNP	O	O
,	PROMACTA.xml:S3:3440:1	,	,	O	O
ATIII	PROMACTA.xml:S3:3442:5	atiii	NNP	O	B-AdverseReaction
deficiency	PROMACTA.xml:S3:3448:10	defici	NN	O	I-AdverseReaction
,	PROMACTA.xml:S3:3458:1	,	,	O	O
antiphospholipid	PROMACTA.xml:S3:3460:16	antiphospholipid	JJ	O	B-AdverseReaction
syndrome	PROMACTA.xml:S3:3477:8	syndrom	NN	O	I-AdverseReaction
,	PROMACTA.xml:S3:3485:1	,	,	O	O
chronic	PROMACTA.xml:S3:3487:7	chronic	JJ	O	B-AdverseReaction
liver	PROMACTA.xml:S3:3495:5	liver	NN	O	I-AdverseReaction
disease	PROMACTA.xml:S3:3501:7	diseas	NN	O	I-AdverseReaction
)	PROMACTA.xml:S3:3508:1	)	)	O	O
.	PROMACTA.xml:S3:3509:1	.	.	O	O

To	PROMACTA.xml:S3:3511:2	To	TO	O	O
minimize	PROMACTA.xml:S3:3514:8	minim	VB	O	O
the	PROMACTA.xml:S3:3523:3	the	DT	O	O
risk	PROMACTA.xml:S3:3527:4	risk	NN	O	O
for	PROMACTA.xml:S3:3532:3	for	IN	O	O
thrombotic	PROMACTA.xml:S3:3536:10	thrombot	JJ	O	O
thromboembolic	PROMACTA.xml:S3:3547:14	thromboembol	JJ	O	O
complications	PROMACTA.xml:S3:3562:13	complic	NNS	O	O
,	PROMACTA.xml:S3:3575:1	,	,	O	O
do	PROMACTA.xml:S3:3577:2	do	VBP	O	O
not	PROMACTA.xml:S3:3580:3	not	RB	O	O
use	PROMACTA.xml:S3:3584:3	use	VB	O	O
PROMACTA	PROMACTA.xml:S3:3588:8	promacta	NNP	O	O
in	PROMACTA.xml:S3:3597:2	in	IN	O	O
an	PROMACTA.xml:S3:3600:2	an	DT	O	O
attempt	PROMACTA.xml:S3:3603:7	attempt	NN	O	O
to	PROMACTA.xml:S3:3611:2	to	TO	O	O
normalize	PROMACTA.xml:S3:3614:9	normal	VB	O	O
platelet	PROMACTA.xml:S3:3624:8	platelet	NN	O	O
counts	PROMACTA.xml:S3:3633:6	count	NNS	O	O
.	PROMACTA.xml:S3:3639:1	.	.	O	O

Follow	PROMACTA.xml:S3:3641:6	follow	IN	O	O
the	PROMACTA.xml:S3:3648:3	the	DT	O	O
dose	PROMACTA.xml:S3:3652:4	dose	JJ	O	O
adjustment	PROMACTA.xml:S3:3657:10	adjust	NN	O	O
guidelines	PROMACTA.xml:S3:3668:10	guidelin	NNS	O	O
to	PROMACTA.xml:S3:3679:2	to	TO	O	O
achieve	PROMACTA.xml:S3:3682:7	achiev	VB	O	O
and	PROMACTA.xml:S3:3690:3	and	CC	O	O
maintain	PROMACTA.xml:S3:3694:8	maintain	VB	O	B-AdverseReaction
target	PROMACTA.xml:S3:3703:6	target	NN	O	I-AdverseReaction
platelet	PROMACTA.xml:S3:3710:8	platelet	NN	O	I-AdverseReaction
counts	PROMACTA.xml:S3:3719:6	count	VBZ	O	O
[	PROMACTA.xml:S3:3726:1	[	JJ	O	O
see	PROMACTA.xml:S3:3727:3	see	NN	O	O
Dosage	PROMACTA.xml:S3:3731:6	dosag	NNP	O	O
and	PROMACTA.xml:S3:3738:3	and	CC	O	O
Administration	PROMACTA.xml:S3:3742:14	administr	NNP	O	O
(	PROMACTA.xml:S3:3757:1	(	(	O	O
2.1	PROMACTA.xml:S3:3758:3	2.1	CD	O	O
,	PROMACTA.xml:S3:3761:1	,	,	O	O
2.2	PROMACTA.xml:S3:3763:3	2.2	CD	O	O
,	PROMACTA.xml:S3:3766:1	,	,	O	O
2.3	PROMACTA.xml:S3:3768:3	2.3	CD	O	O
)]	PROMACTA.xml:S3:3771:2	)]	NN	O	O
.	PROMACTA.xml:S3:3775:1	.	.	O	O

In	PROMACTA.xml:S3:3781:2	In	IN	O	O
a	PROMACTA.xml:S3:3784:1	a	DT	O	O
controlled	PROMACTA.xml:S3:3786:10	control	JJ	O	O
trial	PROMACTA.xml:S3:3797:5	trial	NN	O	O
in	PROMACTA.xml:S3:3803:2	in	IN	O	O
patients	PROMACTA.xml:S3:3806:8	patient	NNS	O	O
with	PROMACTA.xml:S3:3815:4	with	IN	O	O
chronic	PROMACTA.xml:S3:3820:7	chronic	JJ	O	O
liver	PROMACTA.xml:S3:3828:5	liver	NN	O	O
disease	PROMACTA.xml:S3:3834:7	diseas	NN	O	O
and	PROMACTA.xml:S3:3842:3	and	CC	O	O
thrombocytopenia	PROMACTA.xml:S3:3846:16	thrombocytopenia	NN	O	B-AdverseReaction
not	PROMACTA.xml:S3:3863:3	not	RB	O	O
related	PROMACTA.xml:S3:3867:7	relat	VBN	O	O
to	PROMACTA.xml:S3:3875:2	to	TO	O	O
ITP	PROMACTA.xml:S3:3878:3	itp	NNP	O	B-AdverseReaction
undergoing	PROMACTA.xml:S3:3882:10	undergo	VBG	O	O
elective	PROMACTA.xml:S3:3893:8	elect	JJ	O	O
invasive	PROMACTA.xml:S3:3902:8	invas	JJ	O	O
procedures	PROMACTA.xml:S3:3911:10	procedur	NNS	O	O
(	PROMACTA.xml:S3:3922:1	(	(	O	O
N	PROMACTA.xml:S3:3923:1	N	NNP	O	O
292	PROMACTA.xml:S3:3927:3	292	CD	O	O
)	PROMACTA.xml:S3:3930:1	)	)	O	O
,	PROMACTA.xml:S3:3931:1	,	,	O	O
the	PROMACTA.xml:S3:3933:3	the	DT	O	O
risk	PROMACTA.xml:S3:3937:4	risk	NN	O	O
of	PROMACTA.xml:S3:3942:2	of	IN	O	O
thrombotic	PROMACTA.xml:S3:3945:10	thrombot	JJ	B-AdverseReaction	B-AdverseReaction
events	PROMACTA.xml:S3:3956:6	event	NNS	I-AdverseReaction	I-AdverseReaction
was	PROMACTA.xml:S3:3963:3	wa	VBD	O	O
increased	PROMACTA.xml:S3:3967:9	increas	VBN	O	O
in	PROMACTA.xml:S3:3977:2	in	IN	O	O
patients	PROMACTA.xml:S3:3980:8	patient	NNS	O	O
treated	PROMACTA.xml:S3:3989:7	treat	VBN	O	O
with	PROMACTA.xml:S3:3997:4	with	IN	O	O
75	PROMACTA.xml:S3:4002:2	75	CD	O	O
mg	PROMACTA.xml:S3:4005:2	mg	NNS	O	O
of	PROMACTA.xml:S3:4008:2	of	IN	O	O
PROMACTA	PROMACTA.xml:S3:4011:8	promacta	NNP	O	O
once	PROMACTA.xml:S3:4020:4	onc	RB	O	O
daily	PROMACTA.xml:S3:4025:5	daili	RB	O	O
.	PROMACTA.xml:S3:4030:1	.	.	O	O

Seven	PROMACTA.xml:S3:4032:5	seven	NNP	O	B-AdverseReaction
thrombotic	PROMACTA.xml:S3:4038:10	thrombot	JJ	B-AdverseReaction	I-AdverseReaction
complications	PROMACTA.xml:S3:4049:13	complic	NNS	I-AdverseReaction	I-AdverseReaction
(	PROMACTA.xml:S3:4063:1	(	(	O	O
six	PROMACTA.xml:S3:4064:3	six	CD	O	O
patients	PROMACTA.xml:S3:4068:8	patient	NNS	O	O
)	PROMACTA.xml:S3:4076:1	)	)	O	O
were	PROMACTA.xml:S3:4078:4	were	VBD	O	O
reported	PROMACTA.xml:S3:4083:8	report	VBN	O	O
in	PROMACTA.xml:S3:4092:2	in	IN	O	O
the	PROMACTA.xml:S3:4095:3	the	DT	O	O
group	PROMACTA.xml:S3:4099:5	group	NN	O	O
that	PROMACTA.xml:S3:4105:4	that	WDT	O	O
received	PROMACTA.xml:S3:4110:8	receiv	VBD	O	O
PROMACTA	PROMACTA.xml:S3:4119:8	promacta	NNP	O	O
and	PROMACTA.xml:S3:4128:3	and	CC	O	O
three	PROMACTA.xml:S3:4132:5	three	CD	O	O
thrombotic	PROMACTA.xml:S3:4138:10	thrombot	JJ	B-AdverseReaction	O
complications	PROMACTA.xml:S3:4149:13	complic	NNS	I-AdverseReaction	O
were	PROMACTA.xml:S3:4163:4	were	VBD	O	O
reported	PROMACTA.xml:S3:4168:8	report	VBN	O	O
in	PROMACTA.xml:S3:4177:2	in	IN	O	O
the	PROMACTA.xml:S3:4180:3	the	DT	O	O
placebo	PROMACTA.xml:S3:4184:7	placebo	NN	O	O
group	PROMACTA.xml:S3:4192:5	group	NN	O	O
(	PROMACTA.xml:S3:4198:1	(	(	O	O
two	PROMACTA.xml:S3:4199:3	two	CD	O	O
patients	PROMACTA.xml:S3:4203:8	patient	NNS	O	O
)	PROMACTA.xml:S3:4211:1	)	)	O	O
.	PROMACTA.xml:S3:4212:1	.	.	O	O

All	PROMACTA.xml:S3:4214:3	all	DT	O	O
of	PROMACTA.xml:S3:4218:2	of	IN	O	O
the	PROMACTA.xml:S3:4221:3	the	DT	O	O
thrombotic	PROMACTA.xml:S3:4225:10	thrombot	JJ	B-AdverseReaction	O
complications	PROMACTA.xml:S3:4236:13	complic	NNS	I-AdverseReaction	O
reported	PROMACTA.xml:S3:4250:8	report	VBN	O	O
in	PROMACTA.xml:S3:4259:2	in	IN	O	O
the	PROMACTA.xml:S3:4262:3	the	DT	O	O
group	PROMACTA.xml:S3:4266:5	group	NN	O	O
that	PROMACTA.xml:S3:4272:4	that	WDT	O	O
received	PROMACTA.xml:S3:4277:8	receiv	VBD	O	O
PROMACTA	PROMACTA.xml:S3:4286:8	promacta	NNP	O	O
were	PROMACTA.xml:S3:4295:4	were	VBD	O	O
portal	PROMACTA.xml:S3:4300:6	portal	JJ	B-AdverseReaction	B-AdverseReaction
vein	PROMACTA.xml:S3:4307:4	vein	JJ	I-AdverseReaction	I-AdverseReaction
thrombosis	PROMACTA.xml:S3:4312:10	thrombosi	NN	I-AdverseReaction	I-AdverseReaction
(	PROMACTA.xml:S3:4323:1	(	(	O	O
PVT	PROMACTA.xml:S3:4324:3	pvt	NNP	B-AdverseReaction	O
)	PROMACTA.xml:S3:4327:1	)	)	O	O
.	PROMACTA.xml:S3:4328:1	.	.	O	O

Symptoms	PROMACTA.xml:S3:4330:8	symptom	NNS	O	O
of	PROMACTA.xml:S3:4339:2	of	IN	O	O
PVT	PROMACTA.xml:S3:4342:3	pvt	NNP	B-AdverseReaction	O
included	PROMACTA.xml:S3:4346:8	includ	VBD	O	O
abdominal	PROMACTA.xml:S3:4355:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	PROMACTA.xml:S3:4365:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	PROMACTA.xml:S3:4369:1	,	,	O	O
nausea	PROMACTA.xml:S3:4371:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S3:4377:1	,	,	O	O
vomiting	PROMACTA.xml:S3:4379:8	vomit	NN	B-AdverseReaction	B-AdverseReaction
,	PROMACTA.xml:S3:4387:1	,	,	O	O
and	PROMACTA.xml:S3:4389:3	and	CC	O	O
diarrhea	PROMACTA.xml:S3:4393:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
.	PROMACTA.xml:S3:4401:1	.	.	O	O

Five	PROMACTA.xml:S3:4403:4	five	CD	O	O
of	PROMACTA.xml:S3:4408:2	of	IN	O	O
the	PROMACTA.xml:S3:4411:3	the	DT	O	O
six	PROMACTA.xml:S3:4415:3	six	CD	O	O
patients	PROMACTA.xml:S3:4419:8	patient	NNS	O	O
in	PROMACTA.xml:S3:4428:2	in	IN	O	O
the	PROMACTA.xml:S3:4431:3	the	DT	O	O
group	PROMACTA.xml:S3:4435:5	group	NN	O	O
that	PROMACTA.xml:S3:4441:4	that	WDT	O	O
received	PROMACTA.xml:S3:4446:8	receiv	VBD	O	O
PROMACTA	PROMACTA.xml:S3:4455:8	promacta	NNP	O	O
experienced	PROMACTA.xml:S3:4464:11	experienc	VBD	O	O
a	PROMACTA.xml:S3:4476:1	a	DT	O	O
thrombotic	PROMACTA.xml:S3:4478:10	thrombot	JJ	B-AdverseReaction	O
complication	PROMACTA.xml:S3:4489:12	complic	NN	I-AdverseReaction	O
within	PROMACTA.xml:S3:4502:6	within	IN	O	O
30	PROMACTA.xml:S3:4509:2	30	CD	O	O
days	PROMACTA.xml:S3:4512:4	day	NNS	O	O
of	PROMACTA.xml:S3:4517:2	of	IN	O	O
completing	PROMACTA.xml:S3:4520:10	complet	VBG	O	O
treatment	PROMACTA.xml:S3:4531:9	treatment	NN	O	O
with	PROMACTA.xml:S3:4541:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S3:4546:8	promacta	NNP	O	O
and	PROMACTA.xml:S3:4555:3	and	CC	O	O
at	PROMACTA.xml:S3:4559:2	at	IN	O	O
a	PROMACTA.xml:S3:4562:1	a	DT	O	O
platelet	PROMACTA.xml:S3:4564:8	platelet	NN	O	O
count	PROMACTA.xml:S3:4573:5	count	NN	O	O
above	PROMACTA.xml:S3:4579:5	abov	IN	O	O
200	PROMACTA.xml:S3:4585:3	200	CD	O	O
x	PROMACTA.xml:S3:4589:1	x	JJ	O	O
10	PROMACTA.xml:S3:4591:2	10	CD	O	O
9	PROMACTA.xml:S3:4595:1	9	CD	O	O
L.	PROMACTA.xml:S3:4599:2	L.	NNP	O	O

The	PROMACTA.xml:S3:4602:3	the	DT	O	O
risk	PROMACTA.xml:S3:4606:4	risk	NN	O	O
of	PROMACTA.xml:S3:4611:2	of	IN	O	O
portal	PROMACTA.xml:S3:4614:6	portal	JJ	B-AdverseReaction	B-AdverseReaction
venous	PROMACTA.xml:S3:4621:6	venou	JJ	I-AdverseReaction	I-AdverseReaction
thrombosis	PROMACTA.xml:S3:4628:10	thrombosi	NN	I-AdverseReaction	I-AdverseReaction
was	PROMACTA.xml:S3:4639:3	wa	VBD	O	O
increased	PROMACTA.xml:S3:4643:9	increas	VBN	O	O
in	PROMACTA.xml:S3:4653:2	in	IN	O	O
thrombocytopenic	PROMACTA.xml:S3:4656:16	thrombocytopen	JJ	O	O
patients	PROMACTA.xml:S3:4673:8	patient	NNS	O	O
with	PROMACTA.xml:S3:4682:4	with	IN	O	O
chronic	PROMACTA.xml:S3:4687:7	chronic	JJ	O	O
liver	PROMACTA.xml:S3:4695:5	liver	NN	O	O
disease	PROMACTA.xml:S3:4701:7	diseas	NN	O	O
treated	PROMACTA.xml:S3:4709:7	treat	VBD	O	O
with	PROMACTA.xml:S3:4717:4	with	IN	O	O
75	PROMACTA.xml:S3:4722:2	75	CD	O	O
mg	PROMACTA.xml:S3:4725:2	mg	NNS	O	O
of	PROMACTA.xml:S3:4728:2	of	IN	O	O
PROMACTA	PROMACTA.xml:S3:4731:8	promacta	NNP	O	O
once	PROMACTA.xml:S3:4740:4	onc	RB	O	O
daily	PROMACTA.xml:S3:4745:5	daili	RB	O	O
for	PROMACTA.xml:S3:4751:3	for	IN	O	O
2	PROMACTA.xml:S3:4755:1	2	CD	O	O
weeks	PROMACTA.xml:S3:4757:5	week	NNS	O	O
in	PROMACTA.xml:S3:4763:2	in	IN	O	O
preparation	PROMACTA.xml:S3:4766:11	prepar	NN	O	O
for	PROMACTA.xml:S3:4778:3	for	IN	O	O
invasive	PROMACTA.xml:S3:4782:8	invas	JJ	O	O
procedures	PROMACTA.xml:S3:4791:10	procedur	NNS	O	O
.	PROMACTA.xml:S3:4801:1	.	.	O	O

5.4	PROMACTA.xml:S3:4810:3	5.4	CD	O	O
Cataracts	PROMACTA.xml:S3:4814:9	cataract	NNS	O	O

In	PROMACTA.xml:S3:4829:2	In	IN	O	O
the	PROMACTA.xml:S3:4832:3	the	DT	O	O
three	PROMACTA.xml:S3:4836:5	three	CD	O	O
controlled	PROMACTA.xml:S3:4842:10	control	VBD	O	O
clinical	PROMACTA.xml:S3:4853:8	clinic	JJ	O	O
trials	PROMACTA.xml:S3:4862:6	trial	NNS	O	O
in	PROMACTA.xml:S3:4869:2	in	IN	O	O
adults	PROMACTA.xml:S3:4872:6	adult	NNS	O	O
with	PROMACTA.xml:S3:4879:4	with	IN	O	O
chronic	PROMACTA.xml:S3:4884:7	chronic	JJ	O	O
ITP	PROMACTA.xml:S3:4892:3	itp	NNP	O	O
,	PROMACTA.xml:S3:4895:1	,	,	O	O
cataracts	PROMACTA.xml:S3:4897:9	cataract	VBZ	B-AdverseReaction	O
developed	PROMACTA.xml:S3:4907:9	develop	VBN	O	O
or	PROMACTA.xml:S3:4917:2	or	CC	O	O
worsened	PROMACTA.xml:S3:4920:8	worsen	VBN	O	O
in	PROMACTA.xml:S3:4929:2	in	IN	O	O
15	PROMACTA.xml:S3:4932:2	15	CD	O	O
(	PROMACTA.xml:S3:4935:1	(	(	O	O
7%	PROMACTA.xml:S3:4936:2	7%	CD	O	O
)	PROMACTA.xml:S3:4938:1	)	)	O	O
patients	PROMACTA.xml:S3:4940:8	patient	NNS	O	O
who	PROMACTA.xml:S3:4949:3	who	WP	O	O
received	PROMACTA.xml:S3:4953:8	receiv	VBD	O	O
50	PROMACTA.xml:S3:4962:2	50	CD	O	O
mg	PROMACTA.xml:S3:4965:2	mg	NN	O	O
of	PROMACTA.xml:S3:4968:2	of	IN	O	O
PROMACTA	PROMACTA.xml:S3:4971:8	promacta	NNP	O	O
daily	PROMACTA.xml:S3:4980:5	daili	JJ	O	O
and	PROMACTA.xml:S3:4986:3	and	CC	O	O
8	PROMACTA.xml:S3:4990:1	8	CD	O	O
(	PROMACTA.xml:S3:4992:1	(	(	O	O
7%	PROMACTA.xml:S3:4993:2	7%	CD	O	O
)	PROMACTA.xml:S3:4995:1	)	)	O	O
placebo	PROMACTA.xml:S3:4997:7	placebo	NN	O	O
-	PROMACTA.xml:S3:5004:1	-	:	O	O
group	PROMACTA.xml:S3:5005:5	group	NN	O	O
patients	PROMACTA.xml:S3:5011:8	patient	NNS	O	O
.	PROMACTA.xml:S3:5019:1	.	.	O	O

In	PROMACTA.xml:S3:5021:2	In	IN	O	O
the	PROMACTA.xml:S3:5024:3	the	DT	O	O
extension	PROMACTA.xml:S3:5028:9	extens	NN	O	O
trial	PROMACTA.xml:S3:5038:5	trial	NN	O	O
,	PROMACTA.xml:S3:5043:1	,	,	O	O
cataracts	PROMACTA.xml:S3:5045:9	cataract	NNS	B-AdverseReaction	O
developed	PROMACTA.xml:S3:5055:9	develop	VBD	O	O
or	PROMACTA.xml:S3:5065:2	or	CC	O	O
worsened	PROMACTA.xml:S3:5068:8	worsen	VBN	O	O
in	PROMACTA.xml:S3:5077:2	in	IN	O	O
4%	PROMACTA.xml:S3:5080:2	4%	CD	O	O
of	PROMACTA.xml:S3:5083:2	of	IN	O	O
patients	PROMACTA.xml:S3:5086:8	patient	NNS	O	O
who	PROMACTA.xml:S3:5095:3	who	WP	O	O
underwent	PROMACTA.xml:S3:5099:9	underw	VBP	O	O
ocular	PROMACTA.xml:S3:5109:6	ocular	JJ	O	O
examination	PROMACTA.xml:S3:5116:11	examin	NN	O	O
prior	PROMACTA.xml:S3:5128:5	prior	RB	O	O
to	PROMACTA.xml:S3:5134:2	to	TO	O	O
therapy	PROMACTA.xml:S3:5137:7	therapi	VB	O	O
with	PROMACTA.xml:S3:5145:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S3:5150:8	promacta	NNP	O	O
.	PROMACTA.xml:S3:5158:1	.	.	O	O

In	PROMACTA.xml:S3:5160:2	In	IN	O	O
the	PROMACTA.xml:S3:5163:3	the	DT	O	O
two	PROMACTA.xml:S3:5167:3	two	CD	O	O
controlled	PROMACTA.xml:S3:5171:10	control	VBD	O	O
clinical	PROMACTA.xml:S3:5182:8	clinic	JJ	O	O
trials	PROMACTA.xml:S3:5191:6	trial	NNS	O	O
in	PROMACTA.xml:S3:5198:2	in	IN	O	O
patients	PROMACTA.xml:S3:5201:8	patient	NNS	O	O
with	PROMACTA.xml:S3:5210:4	with	IN	O	O
chronic	PROMACTA.xml:S3:5215:7	chronic	JJ	O	O
hepatitis	PROMACTA.xml:S3:5223:9	hepat	NN	O	O
C	PROMACTA.xml:S3:5233:1	C	NNP	O	O
and	PROMACTA.xml:S3:5235:3	and	CC	O	O
thrombocytopenia	PROMACTA.xml:S3:5239:16	thrombocytopenia	NN	O	B-AdverseReaction
,	PROMACTA.xml:S3:5255:1	,	,	O	O
cataracts	PROMACTA.xml:S3:5257:9	cataract	NNS	B-AdverseReaction	O
developed	PROMACTA.xml:S3:5267:9	develop	VBD	O	O
or	PROMACTA.xml:S3:5277:2	or	CC	O	O
worsened	PROMACTA.xml:S3:5280:8	worsen	VBN	O	O
in	PROMACTA.xml:S3:5289:2	in	IN	O	O
8%	PROMACTA.xml:S3:5292:2	8%	CD	O	O
patients	PROMACTA.xml:S3:5295:8	patient	NNS	O	O
treated	PROMACTA.xml:S3:5304:7	treat	VBN	O	O
with	PROMACTA.xml:S3:5312:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S3:5317:8	promacta	NNP	O	O
and	PROMACTA.xml:S3:5326:3	and	CC	O	O
5%	PROMACTA.xml:S3:5330:2	5%	CD	O	O
patients	PROMACTA.xml:S3:5333:8	patient	NNS	O	O
treated	PROMACTA.xml:S3:5342:7	treat	VBN	O	O
with	PROMACTA.xml:S3:5350:4	with	IN	O	O
placebo	PROMACTA.xml:S3:5355:7	placebo	NN	O	O
.	PROMACTA.xml:S3:5362:1	.	.	O	O

Cataracts	PROMACTA.xml:S3:5368:9	cataract	NNS	B-AdverseReaction	B-AdverseReaction
were	PROMACTA.xml:S3:5378:4	were	VBD	O	O
observed	PROMACTA.xml:S3:5383:8	observ	VBN	O	O
in	PROMACTA.xml:S3:5392:2	in	IN	O	O
toxicology	PROMACTA.xml:S3:5395:10	toxicolog	NN	O	O
studies	PROMACTA.xml:S3:5406:7	studi	NNS	O	O
of	PROMACTA.xml:S3:5414:2	of	IN	O	O
eltrombopag	PROMACTA.xml:S3:5417:11	eltrombopag	NN	O	O
in	PROMACTA.xml:S3:5429:2	in	IN	O	O
rodents	PROMACTA.xml:S3:5432:7	rodent	NNS	O	O
[	PROMACTA.xml:S3:5440:1	[	JJ	O	O
see	PROMACTA.xml:S3:5441:3	see	VBP	O	O
Nonclinical	PROMACTA.xml:S3:5445:11	nonclin	JJ	O	O
Toxicology	PROMACTA.xml:S3:5457:10	toxicolog	NNP	O	O
(	PROMACTA.xml:S3:5468:1	(	(	O	O
13.2	PROMACTA.xml:S3:5469:4	13.2	CD	O	O
)]	PROMACTA.xml:S3:5473:2	)]	NN	O	O
.	PROMACTA.xml:S3:5477:1	.	.	O	O

Perform	PROMACTA.xml:S3:5479:7	perform	VB	O	O
a	PROMACTA.xml:S3:5487:1	a	DT	O	O
baseline	PROMACTA.xml:S3:5489:8	baselin	NN	O	O
ocular	PROMACTA.xml:S3:5498:6	ocular	JJ	O	O
examination	PROMACTA.xml:S3:5505:11	examin	NN	O	O
prior	PROMACTA.xml:S3:5517:5	prior	RB	O	O
to	PROMACTA.xml:S3:5523:2	to	TO	O	O
administration	PROMACTA.xml:S3:5526:14	administr	NN	O	O
of	PROMACTA.xml:S3:5541:2	of	IN	O	O
PROMACTA	PROMACTA.xml:S3:5544:8	promacta	NNP	O	O
and	PROMACTA.xml:S3:5553:3	and	CC	O	O
,	PROMACTA.xml:S3:5556:1	,	,	O	O
during	PROMACTA.xml:S3:5558:6	dure	IN	O	O
therapy	PROMACTA.xml:S3:5565:7	therapi	NN	O	O
with	PROMACTA.xml:S3:5573:4	with	IN	O	O
PROMACTA	PROMACTA.xml:S3:5578:8	promacta	NNP	O	O
,	PROMACTA.xml:S3:5586:1	,	,	O	O
regularly	PROMACTA.xml:S3:5588:9	regularli	RB	O	O
monitor	PROMACTA.xml:S3:5598:7	monitor	NN	O	O
patients	PROMACTA.xml:S3:5606:8	patient	NNS	O	O
for	PROMACTA.xml:S3:5615:3	for	IN	O	O
signs	PROMACTA.xml:S3:5619:5	sign	NNS	O	O
and	PROMACTA.xml:S3:5625:3	and	CC	O	O
symptoms	PROMACTA.xml:S3:5629:8	symptom	NNS	O	O
of	PROMACTA.xml:S3:5638:2	of	IN	O	O
cataracts	PROMACTA.xml:S3:5641:9	cataract	NNS	O	O
.	PROMACTA.xml:S3:5650:1	.	.	O	O
6	QUTENZA.xml:S1:4:1	6	CD	O	O
ADVERSE	QUTENZA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	QUTENZA.xml:S1:14:9	reaction	NN	O	O

The	QUTENZA.xml:S1:27:3	the	DT	O	O
following	QUTENZA.xml:S1:31:9	follow	VBG	O	O
serious	QUTENZA.xml:S1:41:7	seriou	JJ	O	O
adverse	QUTENZA.xml:S1:49:7	advers	JJ	O	O
reactions	QUTENZA.xml:S1:57:9	reaction	NNS	O	O
are	QUTENZA.xml:S1:67:3	are	VBP	O	O
discussed	QUTENZA.xml:S1:71:9	discuss	VBN	O	O
elsewhere	QUTENZA.xml:S1:81:9	elsewher	RB	O	O
in	QUTENZA.xml:S1:91:2	in	IN	O	O
the	QUTENZA.xml:S1:94:3	the	DT	O	O
labeling	QUTENZA.xml:S1:98:8	label	NN	O	O
:	QUTENZA.xml:S1:106:1	:	:	O	O

Application	QUTENZA.xml:S1:112:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
-	QUTENZA.xml:S1:123:1	-	:	I-AdverseReaction	I-AdverseReaction
Associated	QUTENZA.xml:S1:124:10	associ	NNP	I-AdverseReaction	I-AdverseReaction
Pain	QUTENZA.xml:S1:135:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
[	QUTENZA.xml:S1:140:1	[	NNP	O	O
see	QUTENZA.xml:S1:143:3	see	VBP	O	O
Warnings	QUTENZA.xml:S1:148:8	warn	NNP	O	O
and	QUTENZA.xml:S1:157:3	and	CC	O	O
Precautions	QUTENZA.xml:S1:161:11	precaut	NNP	O	O
(	QUTENZA.xml:S1:173:1	(	(	O	O
5.4	QUTENZA.xml:S1:174:3	5.4	CD	O	O
)]	QUTENZA.xml:S1:179:2	)]	NN	O	O

Increase	QUTENZA.xml:S1:188:8	increas	NNP	B-AdverseReaction	B-AdverseReaction
in	QUTENZA.xml:S1:197:2	in	IN	I-AdverseReaction	I-AdverseReaction
Blood	QUTENZA.xml:S1:200:5	blood	NNP	I-AdverseReaction	I-AdverseReaction
Pressure	QUTENZA.xml:S1:206:8	pressur	NNP	I-AdverseReaction	I-AdverseReaction
[	QUTENZA.xml:S1:215:1	[	NNP	O	O
see	QUTENZA.xml:S1:218:3	see	VBP	O	O
Warnings	QUTENZA.xml:S1:223:8	warn	NNP	O	O
and	QUTENZA.xml:S1:232:3	and	CC	O	O
Precautions	QUTENZA.xml:S1:236:11	precaut	NNP	O	O
(	QUTENZA.xml:S1:248:1	(	(	O	O
5.5	QUTENZA.xml:S1:249:3	5.5	CD	O	O
)]	QUTENZA.xml:S1:254:2	)]	NN	O	O

EXCERPT	QUTENZA.xml:S1:265:7	excerpt	NN	O	O
:	QUTENZA.xml:S1:272:1	:	:	O	O
The	QUTENZA.xml:S1:276:3	the	DT	O	O
most	QUTENZA.xml:S1:280:4	most	RBS	O	O
common	QUTENZA.xml:S1:285:6	common	JJ	O	O
adverse	QUTENZA.xml:S1:292:7	advers	JJ	O	O
reactions	QUTENZA.xml:S1:300:9	reaction	NNS	O	O
(	QUTENZA.xml:S1:310:1	(	(	O	O
5%	QUTENZA.xml:S1:314:2	5%	CD	O	O
and	QUTENZA.xml:S1:317:3	and	CC	O	O
greater	QUTENZA.xml:S1:321:7	greater	JJR	O	O
than	QUTENZA.xml:S1:329:4	than	IN	O	O
control	QUTENZA.xml:S1:334:7	control	NN	O	O
)	QUTENZA.xml:S1:341:1	)	)	O	O
are	QUTENZA.xml:S1:343:3	are	VBP	O	O
application	QUTENZA.xml:S1:347:11	applic	JJ	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:359:4	site	NN	I-AdverseReaction	I-AdverseReaction
erythema	QUTENZA.xml:S1:364:8	erythema	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:372:1	,	,	O	O
application	QUTENZA.xml:S1:374:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:386:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	QUTENZA.xml:S1:391:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:395:1	,	,	O	O
application	QUTENZA.xml:S1:397:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:409:4	site	NN	I-AdverseReaction	I-AdverseReaction
pruritus	QUTENZA.xml:S1:414:8	pruritu	NN	I-AdverseReaction	I-AdverseReaction
and	QUTENZA.xml:S1:423:3	and	CC	O	O
application	QUTENZA.xml:S1:427:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:439:4	site	NN	I-AdverseReaction	I-AdverseReaction
papules	QUTENZA.xml:S1:444:7	papul	NNS	I-AdverseReaction	I-AdverseReaction
.	QUTENZA.xml:S1:451:1	.	.	O	O

(	QUTENZA.xml:S1:453:1	(	(	O	O
6.1	QUTENZA.xml:S1:456:3	6.1	CD	O	O
)	QUTENZA.xml:S1:461:1	)	)	O	O

To	QUTENZA.xml:S1:469:2	To	TO	O	O
report	QUTENZA.xml:S1:472:6	report	VB	O	O
SUSPECTED	QUTENZA.xml:S1:479:9	suspect	NNP	O	O
ADVERSE	QUTENZA.xml:S1:489:7	advers	NNP	O	O
REACTIONS	QUTENZA.xml:S1:497:9	reaction	NNP	O	O
,	QUTENZA.xml:S1:506:1	,	,	O	O
contact	QUTENZA.xml:S1:508:7	contact	NN	O	O
Acorda	QUTENZA.xml:S1:516:6	acorda	NNP	O	O
Therapeutics	QUTENZA.xml:S1:523:12	therapeut	NNP	O	O
at	QUTENZA.xml:S1:536:2	at	IN	O	O
1	QUTENZA.xml:S1:539:1	1	CD	O	O
-	QUTENZA.xml:S1:540:1	-	:	O	O
877	QUTENZA.xml:S1:541:3	877	CD	O	O
-	QUTENZA.xml:S1:544:1	-	:	O	O
900	QUTENZA.xml:S1:545:3	900	CD	O	O
-	QUTENZA.xml:S1:548:1	-	:	O	O
6479	QUTENZA.xml:S1:549:4	6479	CD	O	O
or	QUTENZA.xml:S1:554:2	or	CC	O	O
FDA	QUTENZA.xml:S1:557:3	fda	NNP	O	O
at	QUTENZA.xml:S1:561:2	at	IN	O	O
1	QUTENZA.xml:S1:564:1	1	CD	O	O
-	QUTENZA.xml:S1:565:1	-	:	O	O
800	QUTENZA.xml:S1:566:3	800	CD	O	O
-	QUTENZA.xml:S1:569:1	-	:	O	O
FDA	QUTENZA.xml:S1:570:3	fda	NNP	O	O
-	QUTENZA.xml:S1:573:1	-	:	O	O
1088	QUTENZA.xml:S1:574:4	1088	CD	O	O
or	QUTENZA.xml:S1:579:2	or	CC	O	O
www	QUTENZA.xml:S1:582:3	www	VB	O	O
.	QUTENZA.xml:S1:585:1	.	.	O	O
fda	QUTENZA.xml:S1:586:3	fda	NN	O	O
.	QUTENZA.xml:S1:589:1	.	.	O	O
gov	QUTENZA.xml:S1:590:3	gov	JJ	O	O
medwatch	QUTENZA.xml:S1:594:8	medwatch	NN	O	O
.	QUTENZA.xml:S1:602:1	.	.	O	O

6.1	QUTENZA.xml:S1:614:3	6.1	CD	O	O

Clinical	QUTENZA.xml:S1:618:8	clinic	JJ	O	O
Trials	QUTENZA.xml:S1:627:6	trial	NNS	O	O
Experience	QUTENZA.xml:S1:634:10	experi	NN	O	O

Because	QUTENZA.xml:S1:648:7	becaus	IN	O	O
clinical	QUTENZA.xml:S1:656:8	clinic	JJ	O	O
trials	QUTENZA.xml:S1:665:6	trial	NNS	O	O
are	QUTENZA.xml:S1:672:3	are	VBP	O	O
conducted	QUTENZA.xml:S1:676:9	conduct	VBN	O	O
under	QUTENZA.xml:S1:686:5	under	IN	O	O
widely	QUTENZA.xml:S1:692:6	wide	RB	O	O
varying	QUTENZA.xml:S1:699:7	vari	VBG	O	O
conditions	QUTENZA.xml:S1:707:10	condit	NNS	O	O
,	QUTENZA.xml:S1:717:1	,	,	O	O
adverse	QUTENZA.xml:S1:719:7	advers	JJ	O	O
reaction	QUTENZA.xml:S1:727:8	reaction	NN	O	O
rates	QUTENZA.xml:S1:736:5	rate	NNS	O	O
observed	QUTENZA.xml:S1:742:8	observ	VBD	O	O
in	QUTENZA.xml:S1:751:2	in	IN	O	O
the	QUTENZA.xml:S1:754:3	the	DT	O	O
clinical	QUTENZA.xml:S1:758:8	clinic	JJ	O	O
trials	QUTENZA.xml:S1:767:6	trial	NNS	O	O
of	QUTENZA.xml:S1:774:2	of	IN	O	O
a	QUTENZA.xml:S1:777:1	a	DT	O	O
drug	QUTENZA.xml:S1:779:4	drug	NN	O	O
cannot	QUTENZA.xml:S1:784:6	cannot	NN	O	O
be	QUTENZA.xml:S1:791:2	be	VB	O	O
directly	QUTENZA.xml:S1:794:8	directli	RB	O	O
compared	QUTENZA.xml:S1:803:8	compar	VBN	O	O
to	QUTENZA.xml:S1:812:2	to	TO	O	O
rates	QUTENZA.xml:S1:815:5	rate	NNS	O	O
in	QUTENZA.xml:S1:821:2	in	IN	O	O
the	QUTENZA.xml:S1:824:3	the	DT	O	O
clinical	QUTENZA.xml:S1:828:8	clinic	JJ	O	O
trials	QUTENZA.xml:S1:837:6	trial	NNS	O	O
of	QUTENZA.xml:S1:844:2	of	IN	O	O
other	QUTENZA.xml:S1:847:5	other	JJ	O	O
drugs	QUTENZA.xml:S1:853:5	drug	NNS	O	O
and	QUTENZA.xml:S1:859:3	and	CC	O	O
may	QUTENZA.xml:S1:863:3	may	MD	O	O
not	QUTENZA.xml:S1:867:3	not	RB	O	O
reflect	QUTENZA.xml:S1:871:7	reflect	VB	O	O
the	QUTENZA.xml:S1:879:3	the	DT	O	O
rates	QUTENZA.xml:S1:883:5	rate	NNS	O	O
observed	QUTENZA.xml:S1:889:8	observ	VBD	O	O
in	QUTENZA.xml:S1:898:2	in	IN	O	O
clinical	QUTENZA.xml:S1:901:8	clinic	JJ	O	O
practice	QUTENZA.xml:S1:910:8	practic	NN	O	O
.	QUTENZA.xml:S1:918:1	.	.	O	O

Across	QUTENZA.xml:S1:924:6	across	IN	O	O
all	QUTENZA.xml:S1:931:3	all	DT	O	O
controlled	QUTENZA.xml:S1:935:10	control	VBN	O	O
and	QUTENZA.xml:S1:946:3	and	CC	O	O
uncontrolled	QUTENZA.xml:S1:950:12	uncontrol	JJ	O	O
trials	QUTENZA.xml:S1:963:6	trial	NNS	O	O
,	QUTENZA.xml:S1:969:1	,	,	O	O
more	QUTENZA.xml:S1:971:4	more	JJR	O	O
than	QUTENZA.xml:S1:976:4	than	IN	O	O
1	QUTENZA.xml:S1:981:1	1	CD	O	O
,	QUTENZA.xml:S1:982:1	,	,	O	O
600	QUTENZA.xml:S1:983:3	600	CD	O	O
patients	QUTENZA.xml:S1:987:8	patient	NNS	O	O
have	QUTENZA.xml:S1:996:4	have	VBP	O	O
received	QUTENZA.xml:S1:1001:8	receiv	VBN	O	O
Qutenza	QUTENZA.xml:S1:1010:7	qutenza	NNP	O	O
.	QUTENZA.xml:S1:1017:1	.	.	O	O

A	QUTENZA.xml:S1:1019:1	A	DT	O	O
total	QUTENZA.xml:S1:1021:5	total	NN	O	O
of	QUTENZA.xml:S1:1027:2	of	IN	O	O
394	QUTENZA.xml:S1:1030:3	394	CD	O	O
patients	QUTENZA.xml:S1:1034:8	patient	NNS	O	O
received	QUTENZA.xml:S1:1043:8	receiv	VBD	O	O
more	QUTENZA.xml:S1:1052:4	more	JJR	O	O
than	QUTENZA.xml:S1:1057:4	than	IN	O	O
one	QUTENZA.xml:S1:1062:3	one	CD	O	O
treatment	QUTENZA.xml:S1:1066:9	treatment	NN	O	O
application	QUTENZA.xml:S1:1076:11	applic	NN	O	O
and	QUTENZA.xml:S1:1088:3	and	CC	O	O
274	QUTENZA.xml:S1:1092:3	274	CD	O	O
patients	QUTENZA.xml:S1:1096:8	patient	NNS	O	O
were	QUTENZA.xml:S1:1105:4	were	VBD	O	O
followed	QUTENZA.xml:S1:1110:8	follow	VBN	O	O
for	QUTENZA.xml:S1:1119:3	for	IN	O	O
48	QUTENZA.xml:S1:1123:2	48	CD	O	O
weeks	QUTENZA.xml:S1:1126:5	week	NNS	O	O
or	QUTENZA.xml:S1:1132:2	or	CC	O	O
longer	QUTENZA.xml:S1:1135:6	longer	JJR	O	O
.	QUTENZA.xml:S1:1141:1	.	.	O	O

In	QUTENZA.xml:S1:1147:2	In	IN	O	O
controlled	QUTENZA.xml:S1:1150:10	control	JJ	O	O
clinical	QUTENZA.xml:S1:1161:8	clinic	JJ	O	O
studies	QUTENZA.xml:S1:1170:7	studi	NNS	O	O
,	QUTENZA.xml:S1:1177:1	,	,	O	O
98%	QUTENZA.xml:S1:1179:3	98%	CD	O	O
of	QUTENZA.xml:S1:1183:2	of	IN	O	O
patients	QUTENZA.xml:S1:1186:8	patient	NNS	O	O
completed	QUTENZA.xml:S1:1195:9	complet	VBN	O	O
90%	QUTENZA.xml:S1:1208:3	90%	CD	O	O
of	QUTENZA.xml:S1:1212:2	of	IN	O	O
the	QUTENZA.xml:S1:1215:3	the	DT	O	O
intended	QUTENZA.xml:S1:1219:8	intend	JJ	O	O
patch	QUTENZA.xml:S1:1228:5	patch	NN	O	O
application	QUTENZA.xml:S1:1234:11	applic	NN	O	O
duration	QUTENZA.xml:S1:1246:8	durat	NN	O	O
.	QUTENZA.xml:S1:1254:1	.	.	O	O

Among	QUTENZA.xml:S1:1256:5	among	IN	O	O
patients	QUTENZA.xml:S1:1262:8	patient	NNS	O	O
treated	QUTENZA.xml:S1:1271:7	treat	VBN	O	O
with	QUTENZA.xml:S1:1279:4	with	IN	O	O
Qutenza	QUTENZA.xml:S1:1284:7	qutenza	NNP	O	O
,	QUTENZA.xml:S1:1291:1	,	,	O	O
1%	QUTENZA.xml:S1:1293:2	1%	CD	O	O
discontinued	QUTENZA.xml:S1:1296:12	discontinu	VBN	O	O
prematurely	QUTENZA.xml:S1:1309:11	prematur	RB	O	O
due	QUTENZA.xml:S1:1321:3	due	JJ	O	O
to	QUTENZA.xml:S1:1325:2	to	TO	O	O
an	QUTENZA.xml:S1:1328:2	an	DT	O	O
adverse	QUTENZA.xml:S1:1331:7	advers	JJ	O	O
event	QUTENZA.xml:S1:1339:5	event	NN	O	O
.	QUTENZA.xml:S1:1344:1	.	.	O	O

Controlled	QUTENZA.xml:S1:1354:10	control	VBN	O	O
Clinical	QUTENZA.xml:S1:1365:8	clinic	JJ	O	O
Studies	QUTENZA.xml:S1:1374:7	studi	NNS	O	O

Common	QUTENZA.xml:S1:1392:6	common	JJ	O	O
Adverse	QUTENZA.xml:S1:1399:7	advers	NNP	O	O
Reactions	QUTENZA.xml:S1:1407:9	reaction	NNP	O	O

Adverse	QUTENZA.xml:S1:1423:7	advers	JJ	O	O
reactions	QUTENZA.xml:S1:1431:9	reaction	NNS	O	O
occurring	QUTENZA.xml:S1:1441:9	occur	VBG	O	O
in	QUTENZA.xml:S1:1451:2	in	IN	O	O
5%	QUTENZA.xml:S1:1457:2	5%	CD	O	O
of	QUTENZA.xml:S1:1460:2	of	IN	O	O
patients	QUTENZA.xml:S1:1463:8	patient	NNS	O	O
in	QUTENZA.xml:S1:1472:2	in	IN	O	O
the	QUTENZA.xml:S1:1475:3	the	DT	O	O
Qutenza	QUTENZA.xml:S1:1479:7	qutenza	NNP	O	O
group	QUTENZA.xml:S1:1487:5	group	NN	O	O
and	QUTENZA.xml:S1:1493:3	and	CC	O	O
at	QUTENZA.xml:S1:1497:2	at	IN	O	O
an	QUTENZA.xml:S1:1500:2	an	DT	O	O
incidence	QUTENZA.xml:S1:1503:9	incid	NN	O	O
greater	QUTENZA.xml:S1:1513:7	greater	JJR	O	O
than	QUTENZA.xml:S1:1521:4	than	IN	O	O
in	QUTENZA.xml:S1:1526:2	in	IN	O	O
the	QUTENZA.xml:S1:1529:3	the	DT	O	O
control	QUTENZA.xml:S1:1533:7	control	NN	O	O
group	QUTENZA.xml:S1:1541:5	group	NN	O	O
were	QUTENZA.xml:S1:1547:4	were	VBD	O	O
application	QUTENZA.xml:S1:1552:11	applic	JJ	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:1564:4	site	NN	I-AdverseReaction	I-AdverseReaction
erythema	QUTENZA.xml:S1:1569:8	erythema	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:1577:1	,	,	O	O
application	QUTENZA.xml:S1:1579:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:1591:4	site	NN	I-AdverseReaction	I-AdverseReaction
pain	QUTENZA.xml:S1:1596:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:1600:1	,	,	O	O
application	QUTENZA.xml:S1:1602:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:1614:4	site	NN	I-AdverseReaction	I-AdverseReaction
pruritus	QUTENZA.xml:S1:1619:8	pruritu	NN	I-AdverseReaction	I-AdverseReaction
and	QUTENZA.xml:S1:1628:3	and	CC	O	O
application	QUTENZA.xml:S1:1632:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:1644:4	site	NN	I-AdverseReaction	I-AdverseReaction
papules	QUTENZA.xml:S1:1649:7	papul	NNS	I-AdverseReaction	I-AdverseReaction
.	QUTENZA.xml:S1:1656:1	.	.	O	O

Table	QUTENZA.xml:S1:1662:5	tabl	JJ	O	O
1	QUTENZA.xml:S1:1668:1	1	CD	O	O
summarizes	QUTENZA.xml:S1:1670:10	summar	VBZ	O	O
all	QUTENZA.xml:S1:1681:3	all	DT	O	O
adverse	QUTENZA.xml:S1:1685:7	advers	JJ	O	O
reactions	QUTENZA.xml:S1:1693:9	reaction	NNS	O	O
,	QUTENZA.xml:S1:1702:1	,	,	O	O
regardless	QUTENZA.xml:S1:1704:10	regardless	RB	O	O
of	QUTENZA.xml:S1:1715:2	of	IN	O	O
causality	QUTENZA.xml:S1:1718:9	causal	NN	O	O
,	QUTENZA.xml:S1:1727:1	,	,	O	O
occurring	QUTENZA.xml:S1:1729:9	occur	VBG	O	O
in	QUTENZA.xml:S1:1739:2	in	IN	O	O
1%	QUTENZA.xml:S1:1745:2	1%	CD	O	O
of	QUTENZA.xml:S1:1748:2	of	IN	O	O
patients	QUTENZA.xml:S1:1751:8	patient	NNS	O	O
with	QUTENZA.xml:S1:1760:4	with	IN	O	O
postherpetic	QUTENZA.xml:S1:1765:12	postherpet	JJ	O	O
neuralgia	QUTENZA.xml:S1:1778:9	neuralgia	NN	O	O
in	QUTENZA.xml:S1:1788:2	in	IN	O	O
the	QUTENZA.xml:S1:1791:3	the	DT	O	O
Qutenza	QUTENZA.xml:S1:1795:7	qutenza	NNP	O	O
group	QUTENZA.xml:S1:1803:5	group	NN	O	O
for	QUTENZA.xml:S1:1809:3	for	IN	O	O
which	QUTENZA.xml:S1:1813:5	which	WDT	O	O
the	QUTENZA.xml:S1:1819:3	the	DT	O	O
incidence	QUTENZA.xml:S1:1823:9	incid	NN	O	O
was	QUTENZA.xml:S1:1833:3	wa	VBD	O	O
greater	QUTENZA.xml:S1:1837:7	greater	JJR	O	O
than	QUTENZA.xml:S1:1845:4	than	IN	O	O
in	QUTENZA.xml:S1:1850:2	in	IN	O	O
the	QUTENZA.xml:S1:1853:3	the	DT	O	O
control	QUTENZA.xml:S1:1857:7	control	NN	O	O
group	QUTENZA.xml:S1:1865:5	group	NN	O	O
.	QUTENZA.xml:S1:1870:1	.	.	O	O

The	QUTENZA.xml:S1:1872:3	the	DT	O	O
majority	QUTENZA.xml:S1:1876:8	major	NN	O	O
of	QUTENZA.xml:S1:1885:2	of	IN	O	O
application	QUTENZA.xml:S1:1888:11	applic	NN	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:1900:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactions	QUTENZA.xml:S1:1905:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
were	QUTENZA.xml:S1:1915:4	were	VBD	O	O
transient	QUTENZA.xml:S1:1920:9	transient	JJ	O	O
and	QUTENZA.xml:S1:1930:3	and	CC	O	O
self	QUTENZA.xml:S1:1934:4	self	PRP	O	O
-	QUTENZA.xml:S1:1938:1	-	:	O	O
limited	QUTENZA.xml:S1:1939:7	limit	VBN	O	O
.	QUTENZA.xml:S1:1946:1	.	.	O	O

Transient	QUTENZA.xml:S1:1948:9	transient	NN	O	O
increases	QUTENZA.xml:S1:1958:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	QUTENZA.xml:S1:1968:2	in	IN	I-AdverseReaction	I-AdverseReaction
pain	QUTENZA.xml:S1:1971:4	pain	NN	I-AdverseReaction	I-AdverseReaction
were	QUTENZA.xml:S1:1976:4	were	VBD	O	O
commonly	QUTENZA.xml:S1:1981:8	commonli	RB	O	O
observed	QUTENZA.xml:S1:1990:8	observ	VBN	O	O
on	QUTENZA.xml:S1:1999:2	on	IN	O	O
the	QUTENZA.xml:S1:2002:3	the	DT	O	O
day	QUTENZA.xml:S1:2006:3	day	NN	O	O
of	QUTENZA.xml:S1:2010:2	of	IN	O	O
treatment	QUTENZA.xml:S1:2013:9	treatment	NN	O	O
in	QUTENZA.xml:S1:2023:2	in	IN	O	O
patients	QUTENZA.xml:S1:2026:8	patient	NNS	O	O
treated	QUTENZA.xml:S1:2035:7	treat	VBN	O	O
with	QUTENZA.xml:S1:2043:4	with	IN	O	O
Qutenza	QUTENZA.xml:S1:2048:7	qutenza	NNP	O	O
.	QUTENZA.xml:S1:2055:1	.	.	O	O

Pain	QUTENZA.xml:S1:2057:4	pain	NN	B-AdverseReaction	B-AdverseReaction
increases	QUTENZA.xml:S1:2062:9	increas	NNS	I-AdverseReaction	I-AdverseReaction
occurring	QUTENZA.xml:S1:2072:9	occur	VBG	O	O
during	QUTENZA.xml:S1:2082:6	dure	IN	O	O
patch	QUTENZA.xml:S1:2089:5	patch	JJ	O	O
application	QUTENZA.xml:S1:2095:11	applic	NN	O	O
usually	QUTENZA.xml:S1:2107:7	usual	RB	O	O
began	QUTENZA.xml:S1:2115:5	began	VBD	O	O
to	QUTENZA.xml:S1:2121:2	to	TO	O	O
resolve	QUTENZA.xml:S1:2124:7	resolv	VB	O	O
after	QUTENZA.xml:S1:2132:5	after	IN	O	O
patch	QUTENZA.xml:S1:2138:5	patch	NN	O	O
removal	QUTENZA.xml:S1:2144:7	remov	NN	O	O
.	QUTENZA.xml:S1:2151:1	.	.	O	O

On	QUTENZA.xml:S1:2153:2	On	IN	O	O
average	QUTENZA.xml:S1:2156:7	averag	NN	O	O
,	QUTENZA.xml:S1:2163:1	,	,	O	O
pain	QUTENZA.xml:S1:2165:4	pain	NN	O	B-AdverseReaction
scores	QUTENZA.xml:S1:2170:6	score	NNS	O	I-AdverseReaction
returned	QUTENZA.xml:S1:2177:8	return	VBD	O	O
to	QUTENZA.xml:S1:2186:2	to	TO	O	O
baseline	QUTENZA.xml:S1:2189:8	baselin	VB	O	O
by	QUTENZA.xml:S1:2198:2	by	IN	O	O
the	QUTENZA.xml:S1:2201:3	the	DT	O	O
end	QUTENZA.xml:S1:2205:3	end	NN	O	O
of	QUTENZA.xml:S1:2209:2	of	IN	O	O
the	QUTENZA.xml:S1:2212:3	the	DT	O	O
treatment	QUTENZA.xml:S1:2216:9	treatment	NN	O	O
day	QUTENZA.xml:S1:2226:3	day	NN	O	O
and	QUTENZA.xml:S1:2230:3	and	CC	O	O
then	QUTENZA.xml:S1:2234:4	then	RB	O	O
remained	QUTENZA.xml:S1:2239:8	remain	VBD	O	O
at	QUTENZA.xml:S1:2248:2	at	IN	O	O
or	QUTENZA.xml:S1:2251:2	or	CC	O	O
below	QUTENZA.xml:S1:2254:5	below	IN	O	O
baseline	QUTENZA.xml:S1:2260:8	baselin	NN	O	O
levels	QUTENZA.xml:S1:2269:6	level	NNS	O	O
.	QUTENZA.xml:S1:2275:1	.	.	O	O

A	QUTENZA.xml:S1:2277:1	A	DT	O	O
majority	QUTENZA.xml:S1:2279:8	major	NN	O	O
of	QUTENZA.xml:S1:2288:2	of	IN	O	O
Qutenza	QUTENZA.xml:S1:2291:7	qutenza	NNP	O	O
-	QUTENZA.xml:S1:2298:1	-	:	O	O
treated	QUTENZA.xml:S1:2299:7	treat	VBD	O	O
patients	QUTENZA.xml:S1:2307:8	patient	NNS	O	O
in	QUTENZA.xml:S1:2316:2	in	IN	O	O
clinical	QUTENZA.xml:S1:2319:8	clinic	JJ	O	O
studies	QUTENZA.xml:S1:2328:7	studi	NNS	O	O
had	QUTENZA.xml:S1:2336:3	had	VBD	O	O
adverse	QUTENZA.xml:S1:2340:7	advers	JJ	O	O
reactions	QUTENZA.xml:S1:2348:9	reaction	NNS	O	O
with	QUTENZA.xml:S1:2358:4	with	IN	O	O
a	QUTENZA.xml:S1:2363:1	a	DT	O	O
maximum	QUTENZA.xml:S1:2365:7	maximum	JJ	O	O
intensity	QUTENZA.xml:S1:2373:9	intens	NN	O	O
of	QUTENZA.xml:S1:2383:2	of	IN	O	O
"	QUTENZA.xml:S1:2386:1	"	NNP	O	O
mild	QUTENZA.xml:S1:2387:4	mild	FW	O	O
"	QUTENZA.xml:S1:2391:1	"	NNP	O	O
or	QUTENZA.xml:S1:2393:2	or	CC	O	O
"	QUTENZA.xml:S1:2396:1	"	VB	O	O
moderate	QUTENZA.xml:S1:2397:8	moder	JJ	O	O
"	QUTENZA.xml:S1:2405:1	"	NN	O	O
.	QUTENZA.xml:S1:2406:1	.	.	O	O

TABLE	QUTENZA.xml:S1:2412:5	tabl	NN	O	O
1	QUTENZA.xml:S1:2418:1	1	CD	O	O
:	QUTENZA.xml:S1:2419:1	:	:	O	O
Treatment	QUTENZA.xml:S1:2421:9	treatment	NN	O	O
-	QUTENZA.xml:S1:2430:1	-	:	O	O
emergent	QUTENZA.xml:S1:2431:8	emerg	JJ	O	O
adverse	QUTENZA.xml:S1:2440:7	advers	JJ	O	O
reaction	QUTENZA.xml:S1:2448:8	reaction	NN	O	O
incidence	QUTENZA.xml:S1:2457:9	incid	NN	O	O
(	QUTENZA.xml:S1:2467:1	(	(	O	O
)	QUTENZA.xml:S1:2469:1	)	)	O	O
in	QUTENZA.xml:S1:2471:2	in	IN	O	O
controlled	QUTENZA.xml:S1:2474:10	control	JJ	O	O
trials	QUTENZA.xml:S1:2485:6	trial	NNS	O	O
in	QUTENZA.xml:S1:2492:2	in	IN	O	O
Postherpetic	QUTENZA.xml:S1:2495:12	postherpet	NNP	O	O
Neuralgia	QUTENZA.xml:S1:2508:9	neuralgia	NNP	O	O
(	QUTENZA.xml:S1:2518:1	(	(	O	O
Events	QUTENZA.xml:S1:2519:6	event	NNS	O	O
in	QUTENZA.xml:S1:2526:2	in	IN	O	O
1%	QUTENZA.xml:S1:2532:2	1%	CD	O	O
of	QUTENZA.xml:S1:2535:2	of	IN	O	O
Qutenza	QUTENZA.xml:S1:2538:7	qutenza	NNP	O	O
-	QUTENZA.xml:S1:2545:1	-	:	O	O
treated	QUTENZA.xml:S1:2546:7	treat	VBD	O	O
patients	QUTENZA.xml:S1:2554:8	patient	NNS	O	O
and	QUTENZA.xml:S1:2563:3	and	CC	O	O
at	QUTENZA.xml:S1:2567:2	at	IN	O	O
least	QUTENZA.xml:S1:2570:5	least	JJS	O	O
1%	QUTENZA.xml:S1:2576:2	1%	CD	O	O
greater	QUTENZA.xml:S1:2579:7	greater	JJR	O	O
in	QUTENZA.xml:S1:2587:2	in	IN	O	O
the	QUTENZA.xml:S1:2590:3	the	DT	O	O
Qutenza	QUTENZA.xml:S1:2594:7	qutenza	NNP	O	O
group	QUTENZA.xml:S1:2602:5	group	NN	O	O
than	QUTENZA.xml:S1:2608:4	than	IN	O	O
in	QUTENZA.xml:S1:2613:2	in	IN	O	O
the	QUTENZA.xml:S1:2616:3	the	DT	O	O
Control	QUTENZA.xml:S1:2620:7	control	NNP	O	O
group	QUTENZA.xml:S1:2628:5	group	NN	O	O
)	QUTENZA.xml:S1:2633:1	)	)	O	O

Body	QUTENZA.xml:S1:2637:4	bodi	NN	O	O
SystemPreferred	QUTENZA.xml:S1:2642:15	systempref	NNP	O	O
Term	QUTENZA.xml:S1:2658:4	term	NNP	O	O
Qutenza60	QUTENZA.xml:S1:2689:9	qutenza60	NNP	O	O
minutes	QUTENZA.xml:S1:2699:7	minut	NNS	O	O
(	QUTENZA.xml:S1:2706:1	(	(	O	O
N	QUTENZA.xml:S1:2707:1	N	NNP	O	O
622	QUTENZA.xml:S1:2711:3	622	CD	O	O
)	QUTENZA.xml:S1:2714:1	)	)	O	O
Control60	QUTENZA.xml:S1:2718:9	control60	NNP	O	O
minutes	QUTENZA.xml:S1:2728:7	minut	NNS	O	O
(	QUTENZA.xml:S1:2735:1	(	(	O	O
N	QUTENZA.xml:S1:2736:1	N	NNP	O	O
495	QUTENZA.xml:S1:2740:3	495	CD	O	O
)	QUTENZA.xml:S1:2743:1	)	)	O	O

General	QUTENZA.xml:S1:2755:7	gener	NNP	O	O

Disorders	QUTENZA.xml:S1:2763:9	disord	NNS	O	O
and	QUTENZA.xml:S1:2773:3	and	CC	O	O
Administration	QUTENZA.xml:S1:2777:14	administr	NNP	O	O
Site	QUTENZA.xml:S1:2792:4	site	NNP	O	O
Conditions	QUTENZA.xml:S1:2797:10	condit	NNS	O	O

Application	QUTENZA.xml:S1:2868:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	QUTENZA.xml:S1:2880:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Erythema	QUTENZA.xml:S1:2885:8	erythema	NNP	I-AdverseReaction	I-AdverseReaction
63	QUTENZA.xml:S1:2931:2	63	CD	O	O
54	QUTENZA.xml:S1:2958:2	54	CD	O	O

Application	QUTENZA.xml:S1:2977:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	QUTENZA.xml:S1:2989:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Pain	QUTENZA.xml:S1:2994:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
42	QUTENZA.xml:S1:3040:2	42	CD	O	O
21	QUTENZA.xml:S1:3067:2	21	CD	O	O

Application	QUTENZA.xml:S1:3086:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	QUTENZA.xml:S1:3098:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Pruritus	QUTENZA.xml:S1:3103:8	pruritu	NNP	I-AdverseReaction	I-AdverseReaction
6	QUTENZA.xml:S1:3150:1	6	CD	O	O
4	QUTENZA.xml:S1:3177:1	4	CD	O	O

Application	QUTENZA.xml:S1:3195:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	QUTENZA.xml:S1:3207:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Papules	QUTENZA.xml:S1:3212:7	papul	NNP	I-AdverseReaction	I-AdverseReaction
6	QUTENZA.xml:S1:3259:1	6	CD	O	O
3	QUTENZA.xml:S1:3286:1	3	CD	O	O

Application	QUTENZA.xml:S1:3304:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	QUTENZA.xml:S1:3316:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Edema	QUTENZA.xml:S1:3321:5	edema	NNP	I-AdverseReaction	I-AdverseReaction
4	QUTENZA.xml:S1:3368:1	4	CD	O	O
1	QUTENZA.xml:S1:3395:1	1	CD	O	O

Application	QUTENZA.xml:S1:3413:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	QUTENZA.xml:S1:3425:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Swelling	QUTENZA.xml:S1:3430:8	swell	VBG	I-AdverseReaction	I-AdverseReaction
2	QUTENZA.xml:S1:3477:1	2	CD	O	O
1	QUTENZA.xml:S1:3504:1	1	CD	O	O

Application	QUTENZA.xml:S1:3522:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
Site	QUTENZA.xml:S1:3534:4	site	NNP	I-AdverseReaction	I-AdverseReaction
Dryness	QUTENZA.xml:S1:3539:7	dryness	NNP	I-AdverseReaction	I-AdverseReaction
2	QUTENZA.xml:S1:3586:1	2	CD	O	O
1	QUTENZA.xml:S1:3613:1	1	CD	O	O

Infections	QUTENZA.xml:S1:3633:10	infect	NNS	O	O
and	QUTENZA.xml:S1:3644:3	and	CC	O	O
Infestations	QUTENZA.xml:S1:3648:12	infest	NNS	O	O

Nasopharyngitis	QUTENZA.xml:S1:3740:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
4	QUTENZA.xml:S1:3804:1	4	CD	O	O
2	QUTENZA.xml:S1:3831:1	2	CD	O	O

Bronchitis	QUTENZA.xml:S1:3849:10	bronchiti	NNP	B-AdverseReaction	B-AdverseReaction
2	QUTENZA.xml:S1:3913:1	2	CD	O	O
1	QUTENZA.xml:S1:3940:1	1	CD	O	O

Sinusitis	QUTENZA.xml:S1:3958:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
3	QUTENZA.xml:S1:4022:1	3	CD	O	O
1	QUTENZA.xml:S1:4049:1	1	CD	O	O

Gastrointestinal	QUTENZA.xml:S1:4069:16	gastrointestin	JJ	O	O
Disorders	QUTENZA.xml:S1:4086:9	disord	NNS	O	O

Nausea	QUTENZA.xml:S1:4176:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
5	QUTENZA.xml:S1:4240:1	5	CD	O	O
2	QUTENZA.xml:S1:4267:1	2	CD	O	O

Vomiting	QUTENZA.xml:S1:4285:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
3	QUTENZA.xml:S1:4349:1	3	CD	O	O
1	QUTENZA.xml:S1:4376:1	1	CD	O	O

Skin	QUTENZA.xml:S1:4396:4	skin	NNP	O	O
and	QUTENZA.xml:S1:4401:3	and	CC	O	O
Subcutaneous	QUTENZA.xml:S1:4405:12	subcutan	NNP	O	O
Tissue	QUTENZA.xml:S1:4418:6	tissu	NNP	O	O
Disorder	QUTENZA.xml:S1:4425:8	disord	NNP	O	O

Pruritus	QUTENZA.xml:S1:4503:8	pruritu	NNP	B-AdverseReaction	B-AdverseReaction
2	QUTENZA.xml:S1:4567:1	2	CD	O	O
1	QUTENZA.xml:S1:4595:1	1	CD	O	O

Vascular	QUTENZA.xml:S1:4614:8	vascular	JJ	O	O
Disorders	QUTENZA.xml:S1:4623:9	disord	NNS	O	O

Hypertension	QUTENZA.xml:S1:4721:12	hypertens	NNP	B-AdverseReaction	B-AdverseReaction
2	QUTENZA.xml:S1:4785:1	2	CD	O	O
1	QUTENZA.xml:S1:4812:1	1	CD	O	O

Other	QUTENZA.xml:S1:4842:5	other	JJ	O	O
Adverse	QUTENZA.xml:S1:4848:7	advers	NNP	O	O
Reactions	QUTENZA.xml:S1:4856:9	reaction	NNP	O	O
Observed	QUTENZA.xml:S1:4866:8	observ	NNP	O	O
During	QUTENZA.xml:S1:4875:6	dure	IN	O	O
the	QUTENZA.xml:S1:4882:3	the	DT	O	O
Clinical	QUTENZA.xml:S1:4886:8	clinic	NNP	O	O
Studies	QUTENZA.xml:S1:4895:7	studi	NNPS	O	O
of	QUTENZA.xml:S1:4903:2	of	IN	O	O
Qutenza	QUTENZA.xml:S1:4906:7	qutenza	NNP	O	O

General	QUTENZA.xml:S1:4920:7	gener	NNP	O	O

Disorders	QUTENZA.xml:S1:4928:9	disord	NNS	O	O
and	QUTENZA.xml:S1:4938:3	and	CC	O	O
Administration	QUTENZA.xml:S1:4942:14	administr	NNP	O	O
Site	QUTENZA.xml:S1:4957:4	site	NNP	O	O
Conditions	QUTENZA.xml:S1:4962:10	condit	NNS	O	O
:	QUTENZA.xml:S1:4972:1	:	:	O	O
Application	QUTENZA.xml:S1:4974:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:4986:4	site	NN	I-AdverseReaction	I-AdverseReaction
urticaria	QUTENZA.xml:S1:4991:9	urticaria	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5000:1	,	,	O	O
Application	QUTENZA.xml:S1:5002:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:5014:4	site	NN	I-AdverseReaction	I-AdverseReaction
paresthesia	QUTENZA.xml:S1:5019:11	paresthesia	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5030:1	,	,	O	O
Application	QUTENZA.xml:S1:5032:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:5044:4	site	NN	I-AdverseReaction	I-AdverseReaction
dermatitis	QUTENZA.xml:S1:5049:10	dermat	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5059:1	,	,	O	O
Application	QUTENZA.xml:S1:5061:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:5073:4	site	NN	I-AdverseReaction	I-AdverseReaction
hyperesthesia	QUTENZA.xml:S1:5078:13	hyperesthesia	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5091:1	,	,	O	O
Application	QUTENZA.xml:S1:5093:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:5105:4	site	NN	I-AdverseReaction	I-AdverseReaction
excoriation	QUTENZA.xml:S1:5110:11	excori	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5121:1	,	,	O	O
Application	QUTENZA.xml:S1:5123:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:5135:4	site	NN	I-AdverseReaction	I-AdverseReaction
warmth	QUTENZA.xml:S1:5140:6	warmth	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5146:1	,	,	O	O
Application	QUTENZA.xml:S1:5148:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:5160:4	site	NN	I-AdverseReaction	I-AdverseReaction
anesthesia	QUTENZA.xml:S1:5165:10	anesthesia	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5175:1	,	,	O	O
Application	QUTENZA.xml:S1:5177:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:5189:4	site	NN	I-AdverseReaction	I-AdverseReaction
bruising	QUTENZA.xml:S1:5194:8	bruis	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5202:1	,	,	O	O
Application	QUTENZA.xml:S1:5204:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:5216:4	site	NN	I-AdverseReaction	I-AdverseReaction
inflammation	QUTENZA.xml:S1:5221:12	inflamm	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5233:1	,	,	O	O
Application	QUTENZA.xml:S1:5235:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	QUTENZA.xml:S1:5247:4	site	NN	I-AdverseReaction	I-AdverseReaction
exfoliation	QUTENZA.xml:S1:5252:11	exfoli	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5263:1	,	,	O	O
Peripheral	QUTENZA.xml:S1:5265:10	peripher	NNP	B-AdverseReaction	B-AdverseReaction
edema	QUTENZA.xml:S1:5276:5	edema	NN	I-AdverseReaction	I-AdverseReaction

Nervous	QUTENZA.xml:S1:5286:7	nervou	JJ	O	O
System	QUTENZA.xml:S1:5294:6	system	NN	O	O
Disorders	QUTENZA.xml:S1:5301:9	disord	NNS	O	O
:	QUTENZA.xml:S1:5310:1	:	:	O	O
Headache	QUTENZA.xml:S1:5312:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
,	QUTENZA.xml:S1:5320:1	,	,	O	O
Burning	QUTENZA.xml:S1:5322:7	burn	NNP	B-AdverseReaction	B-AdverseReaction
sensation	QUTENZA.xml:S1:5330:9	sensat	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5339:1	,	,	O	O
Peripheral	QUTENZA.xml:S1:5341:10	peripher	NNP	B-AdverseReaction	B-AdverseReaction
sensory	QUTENZA.xml:S1:5352:7	sensori	NN	I-AdverseReaction	I-AdverseReaction
neuropathy	QUTENZA.xml:S1:5360:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
,	QUTENZA.xml:S1:5370:1	,	,	O	O
Dizziness	QUTENZA.xml:S1:5372:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
,	QUTENZA.xml:S1:5381:1	,	,	O	O
Dysgeusia	QUTENZA.xml:S1:5383:9	dysgeusia	NNP	B-AdverseReaction	B-AdverseReaction
,	QUTENZA.xml:S1:5392:1	,	,	O	O
Hyperesthesia	QUTENZA.xml:S1:5394:13	hyperesthesia	NNP	B-AdverseReaction	O
,	QUTENZA.xml:S1:5407:1	,	,	O	O
Hypoesthesia	QUTENZA.xml:S1:5409:12	hypoesthesia	NNP	B-AdverseReaction	O

Respiratory	QUTENZA.xml:S1:5426:11	respiratori	NNP	O	O
,	QUTENZA.xml:S1:5437:1	,	,	O	O
Thoracic	QUTENZA.xml:S1:5439:8	thorac	NNP	O	O
and	QUTENZA.xml:S1:5448:3	and	CC	O	O
Mediastinal	QUTENZA.xml:S1:5452:11	mediastin	NNP	O	O
Disorders	QUTENZA.xml:S1:5464:9	disord	NNS	O	O
:	QUTENZA.xml:S1:5473:1	:	:	O	O
Cough	QUTENZA.xml:S1:5475:5	cough	NNP	B-AdverseReaction	B-AdverseReaction
,	QUTENZA.xml:S1:5480:1	,	,	O	O
Throat	QUTENZA.xml:S1:5482:6	throat	NNP	B-AdverseReaction	O
irritation	QUTENZA.xml:S1:5489:10	irrit	NN	I-AdverseReaction	O

Skin	QUTENZA.xml:S1:5504:4	skin	NNP	O	O
and	QUTENZA.xml:S1:5509:3	and	CC	O	O
Subcutaneous	QUTENZA.xml:S1:5513:12	subcutan	NNP	O	O
Tissue	QUTENZA.xml:S1:5526:6	tissu	NNP	O	O
Disorders	QUTENZA.xml:S1:5533:9	disord	NNP	O	O
:	QUTENZA.xml:S1:5542:1	:	:	O	O
Abnormal	QUTENZA.xml:S1:5544:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
skin	QUTENZA.xml:S1:5553:4	skin	NN	I-AdverseReaction	I-AdverseReaction
odor	QUTENZA.xml:S1:5558:4	odor	NN	I-AdverseReaction	I-AdverseReaction
5	QUTENZA.xml:S2:4:1	5	CD	O	O
WARNINGS	QUTENZA.xml:S2:6:8	warn	NNP	O	O
AND	QUTENZA.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	QUTENZA.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	QUTENZA.xml:S2:37:7	excerpt	NN	O	O
:	QUTENZA.xml:S2:44:1	:	:	O	O
Do	QUTENZA.xml:S2:52:2	Do	NNP	O	O
not	QUTENZA.xml:S2:55:3	not	RB	O	O
use	QUTENZA.xml:S2:59:3	use	VB	O	O
near	QUTENZA.xml:S2:63:4	near	JJ	O	O
eyes	QUTENZA.xml:S2:68:4	eye	NNS	O	O
or	QUTENZA.xml:S2:73:2	or	CC	O	O
mucous	QUTENZA.xml:S2:76:6	mucou	JJ	O	O
membranes	QUTENZA.xml:S2:83:9	membran	NNS	O	O
.	QUTENZA.xml:S2:92:1	.	.	O	O

(	QUTENZA.xml:S2:94:1	(	(	O	O
5.1	QUTENZA.xml:S2:97:3	5.1	CD	O	O
)	QUTENZA.xml:S2:102:1	)	)	O	O

Inhalation	QUTENZA.xml:S2:109:10	inhal	NN	O	O
of	QUTENZA.xml:S2:120:2	of	IN	O	O
airborne	QUTENZA.xml:S2:123:8	airborn	JJ	O	O
capsaicin	QUTENZA.xml:S2:132:9	capsaicin	NN	O	O
can	QUTENZA.xml:S2:142:3	can	MD	O	O
result	QUTENZA.xml:S2:146:6	result	VB	O	O
in	QUTENZA.xml:S2:153:2	in	IN	O	O
coughing	QUTENZA.xml:S2:156:8	cough	NN	B-AdverseReaction	B-AdverseReaction
or	QUTENZA.xml:S2:165:2	or	CC	O	O
sneezing	QUTENZA.xml:S2:168:8	sneez	NN	B-AdverseReaction	O
.	QUTENZA.xml:S2:176:1	.	.	O	O

(	QUTENZA.xml:S2:178:1	(	(	O	O
5.2	QUTENZA.xml:S2:181:3	5.2	CD	O	O
)	QUTENZA.xml:S2:186:1	)	)	O	O

If	QUTENZA.xml:S2:193:2	If	IN	O	O
irritation	QUTENZA.xml:S2:196:10	irrit	NN	O	O
of	QUTENZA.xml:S2:207:2	of	IN	O	O
eyes	QUTENZA.xml:S2:210:4	eye	NNS	O	O
or	QUTENZA.xml:S2:215:2	or	CC	O	O
airway	QUTENZA.xml:S2:218:6	airway	NN	O	O
occurs	QUTENZA.xml:S2:225:6	occur	NNS	O	O
,	QUTENZA.xml:S2:231:1	,	,	O	O
remove	QUTENZA.xml:S2:233:6	remov	VB	O	O
the	QUTENZA.xml:S2:240:3	the	DT	O	O
affected	QUTENZA.xml:S2:244:8	affect	JJ	O	O
individual	QUTENZA.xml:S2:253:10	individu	NN	O	O
from	QUTENZA.xml:S2:264:4	from	IN	O	O
the	QUTENZA.xml:S2:269:3	the	DT	O	O
vicinity	QUTENZA.xml:S2:273:8	vicin	NN	O	O
of	QUTENZA.xml:S2:282:2	of	IN	O	O
Qutenza	QUTENZA.xml:S2:285:7	qutenza	NNP	O	O
and	QUTENZA.xml:S2:293:3	and	CC	O	O
flush	QUTENZA.xml:S2:297:5	flush	VB	O	O
the	QUTENZA.xml:S2:303:3	the	DT	O	O
mucous	QUTENZA.xml:S2:307:6	mucou	JJ	O	O
membranes	QUTENZA.xml:S2:314:9	membran	NNS	O	O
or	QUTENZA.xml:S2:324:2	or	CC	O	O
eyes	QUTENZA.xml:S2:327:4	eye	NNS	O	O
with	QUTENZA.xml:S2:332:4	with	IN	O	O
water	QUTENZA.xml:S2:337:5	water	NN	O	O
.	QUTENZA.xml:S2:342:1	.	.	O	O

If	QUTENZA.xml:S2:344:2	If	IN	O	O
skin	QUTENZA.xml:S2:347:4	skin	VBN	O	O
not	QUTENZA.xml:S2:352:3	not	RB	O	O
intended	QUTENZA.xml:S2:356:8	intend	VBN	O	O
to	QUTENZA.xml:S2:365:2	to	TO	O	O
be	QUTENZA.xml:S2:368:2	be	VB	O	O
treated	QUTENZA.xml:S2:371:7	treat	VBN	O	O
comes	QUTENZA.xml:S2:379:5	come	VBZ	O	O
into	QUTENZA.xml:S2:385:4	into	IN	O	O
contact	QUTENZA.xml:S2:390:7	contact	NN	O	O
with	QUTENZA.xml:S2:398:4	with	IN	O	O
Qutenza	QUTENZA.xml:S2:403:7	qutenza	NNP	O	O
,	QUTENZA.xml:S2:410:1	,	,	O	O
apply	QUTENZA.xml:S2:412:5	appli	RB	O	O
Cleansing	QUTENZA.xml:S2:418:9	cleans	VBG	O	O
Gel	QUTENZA.xml:S2:428:3	gel	NNP	O	O
and	QUTENZA.xml:S2:432:3	and	CC	O	O
then	QUTENZA.xml:S2:436:4	then	RB	O	O
wipe	QUTENZA.xml:S2:441:4	wipe	VB	O	O
off	QUTENZA.xml:S2:446:3	off	RP	O	O
with	QUTENZA.xml:S2:450:4	with	IN	O	O
dry	QUTENZA.xml:S2:455:3	dri	JJ	O	O
gauze	QUTENZA.xml:S2:459:5	gauz	NN	O	O
.	QUTENZA.xml:S2:464:1	.	.	O	O

(	QUTENZA.xml:S2:466:1	(	(	O	O
5.2	QUTENZA.xml:S2:469:3	5.2	CD	O	O
,	QUTENZA.xml:S2:474:1	,	,	O	O
5.3	QUTENZA.xml:S2:477:3	5.3	CD	O	O
)	QUTENZA.xml:S2:482:1	)	)	O	O

Transient	QUTENZA.xml:S2:489:9	transient	NN	O	O
increases	QUTENZA.xml:S2:499:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	QUTENZA.xml:S2:509:2	in	IN	I-AdverseReaction	I-AdverseReaction
blood	QUTENZA.xml:S2:512:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	QUTENZA.xml:S2:518:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
may	QUTENZA.xml:S2:527:3	may	MD	O	O
occur	QUTENZA.xml:S2:531:5	occur	VB	O	O
in	QUTENZA.xml:S2:537:2	in	IN	O	O
patients	QUTENZA.xml:S2:540:8	patient	NNS	O	O
during	QUTENZA.xml:S2:549:6	dure	IN	O	O
and	QUTENZA.xml:S2:556:3	and	CC	O	O
shortly	QUTENZA.xml:S2:560:7	shortli	RB	O	O
after	QUTENZA.xml:S2:568:5	after	IN	O	O
the	QUTENZA.xml:S2:574:3	the	DT	O	O
Qutenza	QUTENZA.xml:S2:578:7	qutenza	NNP	O	O
treatment	QUTENZA.xml:S2:586:9	treatment	NN	O	O
.	QUTENZA.xml:S2:595:1	.	.	O	O

Monitor	QUTENZA.xml:S2:597:7	monitor	NNP	O	O
blood	QUTENZA.xml:S2:605:5	blood	NN	O	O
pressure	QUTENZA.xml:S2:611:8	pressur	NN	O	O
during	QUTENZA.xml:S2:620:6	dure	IN	O	O
and	QUTENZA.xml:S2:627:3	and	CC	O	O
following	QUTENZA.xml:S2:631:9	follow	VBG	O	O
the	QUTENZA.xml:S2:641:3	the	DT	O	O
treatment	QUTENZA.xml:S2:645:9	treatment	NN	O	O
procedure	QUTENZA.xml:S2:655:9	procedur	NN	O	O
.	QUTENZA.xml:S2:664:1	.	.	O	O

For	QUTENZA.xml:S2:666:3	for	IN	O	O
those	QUTENZA.xml:S2:670:5	those	DT	O	O
patients	QUTENZA.xml:S2:676:8	patient	NNS	O	O
who	QUTENZA.xml:S2:685:3	who	WP	O	O
require	QUTENZA.xml:S2:689:7	requir	VBP	O	O
the	QUTENZA.xml:S2:697:3	the	DT	O	O
use	QUTENZA.xml:S2:701:3	use	NN	O	O
of	QUTENZA.xml:S2:705:2	of	IN	O	O
opioids	QUTENZA.xml:S2:708:7	opioid	NNS	O	O
to	QUTENZA.xml:S2:716:2	to	TO	O	O
treat	QUTENZA.xml:S2:719:5	treat	VB	O	O
pain	QUTENZA.xml:S2:725:4	pain	NN	O	O
during	QUTENZA.xml:S2:730:6	dure	IN	O	O
or	QUTENZA.xml:S2:737:2	or	CC	O	O
following	QUTENZA.xml:S2:740:9	follow	VBG	O	O
the	QUTENZA.xml:S2:750:3	the	DT	O	O
procedure	QUTENZA.xml:S2:754:9	procedur	NN	O	O
,	QUTENZA.xml:S2:763:1	,	,	O	O
their	QUTENZA.xml:S2:765:5	their	PRP$	O	O
ability	QUTENZA.xml:S2:771:7	abil	NN	O	O
to	QUTENZA.xml:S2:779:2	to	TO	O	O
perform	QUTENZA.xml:S2:782:7	perform	VB	O	O
potentially	QUTENZA.xml:S2:790:11	potenti	RB	O	O
hazardous	QUTENZA.xml:S2:802:9	hazard	JJ	O	O
activities	QUTENZA.xml:S2:812:10	activ	NNS	O	O
such	QUTENZA.xml:S2:823:4	such	JJ	O	O
as	QUTENZA.xml:S2:828:2	as	IN	O	O
driving	QUTENZA.xml:S2:831:7	drive	VBG	O	O
or	QUTENZA.xml:S2:839:2	or	CC	O	O
operating	QUTENZA.xml:S2:842:9	oper	VBG	O	O
machinery	QUTENZA.xml:S2:852:9	machineri	NN	O	O
may	QUTENZA.xml:S2:862:3	may	MD	O	O
be	QUTENZA.xml:S2:866:2	be	VB	O	O
affected	QUTENZA.xml:S2:869:8	affect	VBN	O	O
.	QUTENZA.xml:S2:877:1	.	.	O	O

(	QUTENZA.xml:S2:879:1	(	(	O	O
5.4	QUTENZA.xml:S2:882:3	5.4	CD	O	O
,	QUTENZA.xml:S2:887:1	,	,	O	O
5.5	QUTENZA.xml:S2:890:3	5.5	CD	O	O
)	QUTENZA.xml:S2:895:1	)	)	O	O

5.1	QUTENZA.xml:S2:909:3	5.1	CD	O	O

Eye	QUTENZA.xml:S2:913:3	eye	NN	O	O

and	QUTENZA.xml:S2:917:3	and	CC	O	O
Mucous	QUTENZA.xml:S2:921:6	mucou	NNP	O	O
Membrane	QUTENZA.xml:S2:928:8	membran	NNP	O	O
Exposure	QUTENZA.xml:S2:937:8	exposur	NN	O	O

Do	QUTENZA.xml:S2:951:2	Do	MD	O	O
not	QUTENZA.xml:S2:954:3	not	RB	O	O
apply	QUTENZA.xml:S2:958:5	appli	VB	O	O
Qutenza	QUTENZA.xml:S2:964:7	qutenza	NNP	O	O
to	QUTENZA.xml:S2:972:2	to	TO	O	O
the	QUTENZA.xml:S2:975:3	the	DT	O	O
face	QUTENZA.xml:S2:979:4	face	NN	O	O
or	QUTENZA.xml:S2:984:2	or	CC	O	O
scalp	QUTENZA.xml:S2:987:5	scalp	NN	O	O
to	QUTENZA.xml:S2:993:2	to	TO	O	O
avoid	QUTENZA.xml:S2:996:5	avoid	VB	O	O
risk	QUTENZA.xml:S2:1002:4	risk	NN	O	O
of	QUTENZA.xml:S2:1007:2	of	IN	O	O
exposure	QUTENZA.xml:S2:1010:8	exposur	NN	O	O
to	QUTENZA.xml:S2:1019:2	to	TO	O	O
the	QUTENZA.xml:S2:1022:3	the	DT	O	O
eyes	QUTENZA.xml:S2:1026:4	eye	NNS	O	O
or	QUTENZA.xml:S2:1031:2	or	CC	O	O
mucous	QUTENZA.xml:S2:1034:6	mucou	JJ	O	O
membranes	QUTENZA.xml:S2:1041:9	membran	NNS	O	O
.	QUTENZA.xml:S2:1050:1	.	.	O	O

5.2	QUTENZA.xml:S2:1059:3	5.2	CD	O	O
Aerosolization	QUTENZA.xml:S2:1063:14	aerosol	NNP	O	O
of	QUTENZA.xml:S2:1078:2	of	IN	O	O
Capsaicin	QUTENZA.xml:S2:1081:9	capsaicin	NNP	O	O

Aerosolization	QUTENZA.xml:S2:1096:14	aerosol	NN	O	O
of	QUTENZA.xml:S2:1111:2	of	IN	O	O
capsaicin	QUTENZA.xml:S2:1114:9	capsaicin	NN	O	O
can	QUTENZA.xml:S2:1124:3	can	MD	O	O
occur	QUTENZA.xml:S2:1128:5	occur	VB	O	O
upon	QUTENZA.xml:S2:1134:4	upon	IN	O	O
rapid	QUTENZA.xml:S2:1139:5	rapid	JJ	O	O
removal	QUTENZA.xml:S2:1145:7	remov	NN	O	O
of	QUTENZA.xml:S2:1153:2	of	IN	O	O
Qutenza	QUTENZA.xml:S2:1156:7	qutenza	NNP	O	O
patches	QUTENZA.xml:S2:1164:7	patch	NNS	O	O
.	QUTENZA.xml:S2:1171:1	.	.	O	O

Therefore	QUTENZA.xml:S2:1173:9	therefor	RB	O	O
,	QUTENZA.xml:S2:1182:1	,	,	O	O
remove	QUTENZA.xml:S2:1184:6	remov	VB	O	O
Qutenza	QUTENZA.xml:S2:1191:7	qutenza	NNP	O	O
patches	QUTENZA.xml:S2:1199:7	patch	NNS	O	O
gently	QUTENZA.xml:S2:1207:6	gentli	RB	O	O
and	QUTENZA.xml:S2:1214:3	and	CC	O	O
slowly	QUTENZA.xml:S2:1218:6	slowli	RB	O	O
by	QUTENZA.xml:S2:1225:2	by	IN	O	O
rolling	QUTENZA.xml:S2:1228:7	roll	VBG	O	O
the	QUTENZA.xml:S2:1236:3	the	DT	O	O
adhesive	QUTENZA.xml:S2:1240:8	adhes	JJ	O	O
side	QUTENZA.xml:S2:1249:4	side	NN	O	O
inward	QUTENZA.xml:S2:1254:6	inward	NN	O	O
[	QUTENZA.xml:S2:1261:1	[	NNP	O	O
see	QUTENZA.xml:S2:1262:3	see	VBP	O	O
Dosage	QUTENZA.xml:S2:1267:6	dosag	NNP	O	O
and	QUTENZA.xml:S2:1274:3	and	CC	O	O
Administration	QUTENZA.xml:S2:1278:14	administr	NNP	O	O
(	QUTENZA.xml:S2:1293:1	(	(	O	O
2.3	QUTENZA.xml:S2:1294:3	2.3	CD	O	O
)]	QUTENZA.xml:S2:1299:2	)]	NN	O	O
.	QUTENZA.xml:S2:1303:1	.	.	O	O

If	QUTENZA.xml:S2:1309:2	If	IN	O	O
irritation	QUTENZA.xml:S2:1312:10	irrit	NN	O	O
of	QUTENZA.xml:S2:1323:2	of	IN	O	O
eyes	QUTENZA.xml:S2:1326:4	eye	NNS	O	O
or	QUTENZA.xml:S2:1331:2	or	CC	O	O
airways	QUTENZA.xml:S2:1334:7	airway	NNS	O	O
occurs	QUTENZA.xml:S2:1342:6	occur	NNS	O	O
,	QUTENZA.xml:S2:1348:1	,	,	O	O
remove	QUTENZA.xml:S2:1350:6	remov	VB	O	O
the	QUTENZA.xml:S2:1357:3	the	DT	O	O
affected	QUTENZA.xml:S2:1361:8	affect	JJ	O	O
individual	QUTENZA.xml:S2:1370:10	individu	NN	O	O
from	QUTENZA.xml:S2:1381:4	from	IN	O	O
the	QUTENZA.xml:S2:1386:3	the	DT	O	O
vicinity	QUTENZA.xml:S2:1390:8	vicin	NN	O	O
of	QUTENZA.xml:S2:1399:2	of	IN	O	O
Qutenza	QUTENZA.xml:S2:1402:7	qutenza	NNP	O	O
.	QUTENZA.xml:S2:1409:1	.	.	O	O

Flush	QUTENZA.xml:S2:1411:5	flush	NNP	O	O
eyes	QUTENZA.xml:S2:1417:4	eye	NNS	O	O
and	QUTENZA.xml:S2:1422:3	and	CC	O	O
mucous	QUTENZA.xml:S2:1426:6	mucou	JJ	O	O
membranes	QUTENZA.xml:S2:1433:9	membran	NNS	O	O
with	QUTENZA.xml:S2:1443:4	with	IN	O	O
cool	QUTENZA.xml:S2:1448:4	cool	JJ	O	O
water	QUTENZA.xml:S2:1453:5	water	NN	O	O
.	QUTENZA.xml:S2:1458:1	.	.	O	O

Inhalation	QUTENZA.xml:S2:1464:10	inhal	NN	O	O
of	QUTENZA.xml:S2:1475:2	of	IN	O	O
airborne	QUTENZA.xml:S2:1478:8	airborn	JJ	O	O
capsaicin	QUTENZA.xml:S2:1487:9	capsaicin	NN	O	O
can	QUTENZA.xml:S2:1497:3	can	MD	O	O
result	QUTENZA.xml:S2:1501:6	result	VB	O	O
in	QUTENZA.xml:S2:1508:2	in	IN	O	O
coughing	QUTENZA.xml:S2:1511:8	cough	NN	B-AdverseReaction	B-AdverseReaction
or	QUTENZA.xml:S2:1520:2	or	CC	O	O
sneezing	QUTENZA.xml:S2:1523:8	sneez	NN	B-AdverseReaction	O
.	QUTENZA.xml:S2:1531:1	.	.	O	O

Provide	QUTENZA.xml:S2:1533:7	provid	NNP	O	O
supportive	QUTENZA.xml:S2:1541:10	support	JJ	O	O
medical	QUTENZA.xml:S2:1552:7	medic	JJ	O	O
care	QUTENZA.xml:S2:1560:4	care	NN	O	O
if	QUTENZA.xml:S2:1565:2	if	IN	O	O
shortness	QUTENZA.xml:S2:1568:9	short	NN	O	O
of	QUTENZA.xml:S2:1578:2	of	IN	O	O
breath	QUTENZA.xml:S2:1581:6	breath	NN	O	O
develops	QUTENZA.xml:S2:1588:8	develop	NNS	O	O
.	QUTENZA.xml:S2:1596:1	.	.	O	O

5.3	QUTENZA.xml:S2:1605:3	5.3	CD	O	O
Unintended	QUTENZA.xml:S2:1609:10	unintend	JJ	O	O
Skin	QUTENZA.xml:S2:1620:4	skin	NNP	O	O
Exposure	QUTENZA.xml:S2:1625:8	exposur	NN	O	O

If	QUTENZA.xml:S2:1639:2	If	IN	O	O
skin	QUTENZA.xml:S2:1642:4	skin	VBN	O	O
not	QUTENZA.xml:S2:1647:3	not	RB	O	O
intended	QUTENZA.xml:S2:1651:8	intend	VBN	O	O
to	QUTENZA.xml:S2:1660:2	to	TO	O	O
be	QUTENZA.xml:S2:1663:2	be	VB	O	O
treated	QUTENZA.xml:S2:1666:7	treat	VBN	O	O
comes	QUTENZA.xml:S2:1674:5	come	VBZ	O	O
in	QUTENZA.xml:S2:1680:2	in	IN	O	O
contact	QUTENZA.xml:S2:1683:7	contact	NN	O	O
with	QUTENZA.xml:S2:1691:4	with	IN	O	O
Qutenza	QUTENZA.xml:S2:1696:7	qutenza	NNP	O	O
,	QUTENZA.xml:S2:1703:1	,	,	O	O
apply	QUTENZA.xml:S2:1705:5	appli	RB	O	O
Cleansing	QUTENZA.xml:S2:1711:9	cleans	VBG	O	O
Gel	QUTENZA.xml:S2:1721:3	gel	NNP	O	O
for	QUTENZA.xml:S2:1725:3	for	IN	O	O
one	QUTENZA.xml:S2:1729:3	one	CD	O	O
minute	QUTENZA.xml:S2:1733:6	minut	NN	O	O
and	QUTENZA.xml:S2:1740:3	and	CC	O	O
wipe	QUTENZA.xml:S2:1744:4	wipe	VB	O	O
off	QUTENZA.xml:S2:1749:3	off	RP	O	O
with	QUTENZA.xml:S2:1753:4	with	IN	O	O
dry	QUTENZA.xml:S2:1758:3	dri	JJ	O	O
gauze	QUTENZA.xml:S2:1762:5	gauz	NN	O	O
.	QUTENZA.xml:S2:1767:1	.	.	O	O

After	QUTENZA.xml:S2:1769:5	after	IN	O	O
the	QUTENZA.xml:S2:1775:3	the	DT	O	O
Cleansing	QUTENZA.xml:S2:1779:9	cleans	NNP	O	O
Gel	QUTENZA.xml:S2:1789:3	gel	NNP	O	O
has	QUTENZA.xml:S2:1793:3	ha	VBZ	O	O
been	QUTENZA.xml:S2:1797:4	been	VBN	O	O
wiped	QUTENZA.xml:S2:1802:5	wipe	VBN	O	O
off	QUTENZA.xml:S2:1808:3	off	RP	O	O
,	QUTENZA.xml:S2:1811:1	,	,	O	O
wash	QUTENZA.xml:S2:1813:4	wash	VBZ	O	O
the	QUTENZA.xml:S2:1818:3	the	DT	O	O
area	QUTENZA.xml:S2:1822:4	area	NN	O	O
with	QUTENZA.xml:S2:1827:4	with	IN	O	O
soap	QUTENZA.xml:S2:1832:4	soap	NN	O	O
and	QUTENZA.xml:S2:1837:3	and	CC	O	O
water	QUTENZA.xml:S2:1841:5	water	NN	O	O
.	QUTENZA.xml:S2:1846:1	.	.	O	O

5.4	QUTENZA.xml:S2:1855:3	5.4	CD	O	O
Application	QUTENZA.xml:S2:1859:11	applic	NNP	O	O
Associated	QUTENZA.xml:S2:1871:10	associ	NNP	O	O
Pain	QUTENZA.xml:S2:1882:4	pain	NNP	O	O

Even	QUTENZA.xml:S2:1892:4	even	RB	O	O
following	QUTENZA.xml:S2:1897:9	follow	VBG	O	O
use	QUTENZA.xml:S2:1907:3	use	NN	O	O
of	QUTENZA.xml:S2:1911:2	of	IN	O	O
a	QUTENZA.xml:S2:1914:1	a	DT	O	O
local	QUTENZA.xml:S2:1916:5	local	JJ	O	O
anesthetic	QUTENZA.xml:S2:1922:10	anesthet	JJ	O	O
prior	QUTENZA.xml:S2:1933:5	prior	NN	O	O
to	QUTENZA.xml:S2:1939:2	to	TO	O	O
administration	QUTENZA.xml:S2:1942:14	administr	NN	O	O
of	QUTENZA.xml:S2:1957:2	of	IN	O	O
Qutenza	QUTENZA.xml:S2:1960:7	qutenza	NNP	O	O
,	QUTENZA.xml:S2:1967:1	,	,	O	O
patients	QUTENZA.xml:S2:1969:8	patient	NNS	O	O
may	QUTENZA.xml:S2:1978:3	may	MD	O	O
experience	QUTENZA.xml:S2:1982:10	experi	VB	O	O
substantial	QUTENZA.xml:S2:1993:11	substanti	JJ	O	O
procedural	QUTENZA.xml:S2:2005:10	procedur	JJ	B-AdverseReaction	O
pain	QUTENZA.xml:S2:2016:4	pain	NN	I-AdverseReaction	O
.	QUTENZA.xml:S2:2020:1	.	.	O	O

Prepare	QUTENZA.xml:S2:2022:7	prepar	NNP	O	O
to	QUTENZA.xml:S2:2030:2	to	TO	O	O
treat	QUTENZA.xml:S2:2033:5	treat	VB	O	O
acute	QUTENZA.xml:S2:2039:5	acut	JJ	O	O
pain	QUTENZA.xml:S2:2045:4	pain	NN	O	O
during	QUTENZA.xml:S2:2050:6	dure	IN	O	O
and	QUTENZA.xml:S2:2057:3	and	CC	O	O
following	QUTENZA.xml:S2:2061:9	follow	VBG	O	O
the	QUTENZA.xml:S2:2071:3	the	DT	O	O
application	QUTENZA.xml:S2:2075:11	applic	NN	O	O
procedure	QUTENZA.xml:S2:2087:9	procedur	NN	O	O
with	QUTENZA.xml:S2:2097:4	with	IN	O	O
local	QUTENZA.xml:S2:2102:5	local	JJ	O	O
cooling	QUTENZA.xml:S2:2108:7	cool	VBG	O	O
(	QUTENZA.xml:S2:2116:1	(	(	O	O
such	QUTENZA.xml:S2:2117:4	such	JJ	O	O
as	QUTENZA.xml:S2:2122:2	as	IN	O	O
an	QUTENZA.xml:S2:2125:2	an	DT	O	O
ice	QUTENZA.xml:S2:2128:3	ice	NN	O	O
pack	QUTENZA.xml:S2:2132:4	pack	NN	O	O
)	QUTENZA.xml:S2:2136:1	)	)	O	O
and	QUTENZA.xml:S2:2138:3	and	CC	O	O
or	QUTENZA.xml:S2:2142:2	or	CC	O	O
appropriate	QUTENZA.xml:S2:2145:11	appropri	JJ	O	O
analgesic	QUTENZA.xml:S2:2157:9	analges	JJ	O	O
medication	QUTENZA.xml:S2:2167:10	medic	NN	O	O
,	QUTENZA.xml:S2:2177:1	,	,	O	O
such	QUTENZA.xml:S2:2179:4	such	JJ	O	O
as	QUTENZA.xml:S2:2184:2	as	IN	O	O
opioids	QUTENZA.xml:S2:2187:7	opioid	NNS	O	O
.	QUTENZA.xml:S2:2194:1	.	.	O	O

Opioids	QUTENZA.xml:S2:2196:7	opioid	NNS	O	O
may	QUTENZA.xml:S2:2204:3	may	MD	O	O
affect	QUTENZA.xml:S2:2208:6	affect	VB	O	O
the	QUTENZA.xml:S2:2215:3	the	DT	O	O
ability	QUTENZA.xml:S2:2219:7	abil	NN	O	O
to	QUTENZA.xml:S2:2227:2	to	TO	O	O
perform	QUTENZA.xml:S2:2230:7	perform	VB	O	O
potentially	QUTENZA.xml:S2:2238:11	potenti	RB	O	O
hazardous	QUTENZA.xml:S2:2250:9	hazard	JJ	O	O
activities	QUTENZA.xml:S2:2260:10	activ	NNS	O	O
such	QUTENZA.xml:S2:2271:4	such	JJ	O	O
as	QUTENZA.xml:S2:2276:2	as	IN	O	O
driving	QUTENZA.xml:S2:2279:7	drive	VBG	O	O
or	QUTENZA.xml:S2:2287:2	or	CC	O	O
operating	QUTENZA.xml:S2:2290:9	oper	VBG	O	O
machinery	QUTENZA.xml:S2:2300:9	machineri	NN	O	O
.	QUTENZA.xml:S2:2309:1	.	.	O	O

5.5	QUTENZA.xml:S2:2318:3	5.5	CD	O	O
Increase	QUTENZA.xml:S2:2322:8	increas	NNP	O	O
in	QUTENZA.xml:S2:2331:2	in	IN	O	O
Blood	QUTENZA.xml:S2:2334:5	blood	NNP	O	O
Pressure	QUTENZA.xml:S2:2340:8	pressur	NN	O	O

In	QUTENZA.xml:S2:2354:2	In	IN	O	O
clinical	QUTENZA.xml:S2:2357:8	clinic	JJ	O	O
trials	QUTENZA.xml:S2:2366:6	trial	NNS	O	O
,	QUTENZA.xml:S2:2372:1	,	,	O	O
increases	QUTENZA.xml:S2:2374:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	QUTENZA.xml:S2:2384:2	in	IN	I-AdverseReaction	I-AdverseReaction
blood	QUTENZA.xml:S2:2387:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	QUTENZA.xml:S2:2393:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
occurred	QUTENZA.xml:S2:2402:8	occur	VBD	O	O
during	QUTENZA.xml:S2:2411:6	dure	IN	O	O
or	QUTENZA.xml:S2:2418:2	or	CC	O	O
shortly	QUTENZA.xml:S2:2421:7	shortli	RB	O	O
after	QUTENZA.xml:S2:2429:5	after	IN	O	O
exposure	QUTENZA.xml:S2:2435:8	exposur	NN	O	O
to	QUTENZA.xml:S2:2444:2	to	TO	O	O
Qutenza	QUTENZA.xml:S2:2447:7	qutenza	NNP	O	O
.	QUTENZA.xml:S2:2454:1	.	.	O	O

The	QUTENZA.xml:S2:2456:3	the	DT	O	O
changes	QUTENZA.xml:S2:2460:7	chang	NNS	O	O
averaged	QUTENZA.xml:S2:2468:8	averag	VBD	O	O
less	QUTENZA.xml:S2:2477:4	less	JJR	O	O
than	QUTENZA.xml:S2:2482:4	than	IN	O	O
10	QUTENZA.xml:S2:2487:2	10	CD	O	O
mm	QUTENZA.xml:S2:2490:2	mm	JJ	O	O
Hg	QUTENZA.xml:S2:2493:2	Hg	NNP	O	O
,	QUTENZA.xml:S2:2495:1	,	,	O	O
although	QUTENZA.xml:S2:2497:8	although	IN	O	O
some	QUTENZA.xml:S2:2506:4	some	DT	O	O
patients	QUTENZA.xml:S2:2511:8	patient	NNS	O	O
had	QUTENZA.xml:S2:2520:3	had	VBD	O	O
greater	QUTENZA.xml:S2:2524:7	greater	JJR	O	O
increases	QUTENZA.xml:S2:2532:9	increas	NNS	O	O
and	QUTENZA.xml:S2:2542:3	and	CC	O	O
these	QUTENZA.xml:S2:2546:5	these	DT	O	O
changes	QUTENZA.xml:S2:2552:7	chang	NNS	O	O
lasted	QUTENZA.xml:S2:2560:6	last	VBD	O	O
for	QUTENZA.xml:S2:2567:3	for	IN	O	O
approximately	QUTENZA.xml:S2:2571:13	approxim	RB	O	O
two	QUTENZA.xml:S2:2585:3	two	CD	O	O
hours	QUTENZA.xml:S2:2589:5	hour	NNS	O	O
after	QUTENZA.xml:S2:2595:5	after	IN	O	O
patch	QUTENZA.xml:S2:2601:5	patch	NN	O	O
removal	QUTENZA.xml:S2:2607:7	remov	NN	O	O
.	QUTENZA.xml:S2:2614:1	.	.	O	O

Increases	QUTENZA.xml:S2:2616:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	QUTENZA.xml:S2:2626:2	in	IN	I-AdverseReaction	I-AdverseReaction
blood	QUTENZA.xml:S2:2629:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	QUTENZA.xml:S2:2635:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
were	QUTENZA.xml:S2:2644:4	were	VBD	O	O
unrelated	QUTENZA.xml:S2:2649:9	unrel	JJ	O	O
to	QUTENZA.xml:S2:2659:2	to	TO	O	O
the	QUTENZA.xml:S2:2662:3	the	DT	O	O
pretreatment	QUTENZA.xml:S2:2666:12	pretreat	NN	O	O
blood	QUTENZA.xml:S2:2679:5	blood	NN	O	O
pressure	QUTENZA.xml:S2:2685:8	pressur	NN	O	O
but	QUTENZA.xml:S2:2694:3	but	CC	O	O
were	QUTENZA.xml:S2:2698:4	were	VBD	O	O
related	QUTENZA.xml:S2:2703:7	relat	VBN	O	O
to	QUTENZA.xml:S2:2711:2	to	TO	O	O
treatment	QUTENZA.xml:S2:2714:9	treatment	NN	O	O
-	QUTENZA.xml:S2:2723:1	-	:	O	O
related	QUTENZA.xml:S2:2724:7	relat	JJ	O	O
increases	QUTENZA.xml:S2:2732:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	QUTENZA.xml:S2:2742:2	in	IN	I-AdverseReaction	I-AdverseReaction
pain	QUTENZA.xml:S2:2745:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	QUTENZA.xml:S2:2749:1	.	.	O	O

Monitor	QUTENZA.xml:S2:2751:7	monitor	NNP	O	O
blood	QUTENZA.xml:S2:2759:5	blood	NN	O	O
pressure	QUTENZA.xml:S2:2765:8	pressur	NN	O	O
periodically	QUTENZA.xml:S2:2774:12	period	RB	O	O
during	QUTENZA.xml:S2:2787:6	dure	IN	O	O
the	QUTENZA.xml:S2:2794:3	the	DT	O	O
treatment	QUTENZA.xml:S2:2798:9	treatment	NN	O	O
and	QUTENZA.xml:S2:2808:3	and	CC	O	O
provide	QUTENZA.xml:S2:2812:7	provid	VB	O	O
adequate	QUTENZA.xml:S2:2820:8	adequ	JJ	O	O
support	QUTENZA.xml:S2:2829:7	support	NN	O	O
for	QUTENZA.xml:S2:2837:3	for	IN	O	O
treatment	QUTENZA.xml:S2:2841:9	treatment	NN	O	O
related	QUTENZA.xml:S2:2851:7	relat	VBN	O	O
pain	QUTENZA.xml:S2:2859:4	pain	NN	O	O
.	QUTENZA.xml:S2:2863:1	.	.	O	O

Patients	QUTENZA.xml:S2:2869:8	patient	NNS	O	O
with	QUTENZA.xml:S2:2878:4	with	IN	O	O
unstable	QUTENZA.xml:S2:2883:8	unstabl	JJ	O	O
or	QUTENZA.xml:S2:2892:2	or	CC	O	O
poorly	QUTENZA.xml:S2:2895:6	poorli	RB	O	O
controlled	QUTENZA.xml:S2:2902:10	control	VBN	O	O
hypertension	QUTENZA.xml:S2:2913:12	hypertens	NN	O	O
,	QUTENZA.xml:S2:2925:1	,	,	O	O
a	QUTENZA.xml:S2:2927:1	a	DT	O	O
recent	QUTENZA.xml:S2:2929:6	recent	JJ	O	O
history	QUTENZA.xml:S2:2936:7	histori	NN	O	O
of	QUTENZA.xml:S2:2944:2	of	IN	O	O
cardiovascular	QUTENZA.xml:S2:2947:14	cardiovascular	NN	O	O
or	QUTENZA.xml:S2:2962:2	or	CC	O	O
cerebrovascular	QUTENZA.xml:S2:2965:15	cerebrovascular	JJ	O	B-AdverseReaction
events	QUTENZA.xml:S2:2981:6	event	NNS	O	I-AdverseReaction
may	QUTENZA.xml:S2:2988:3	may	MD	O	O
be	QUTENZA.xml:S2:2992:2	be	VB	O	O
at	QUTENZA.xml:S2:2995:2	at	IN	O	O
an	QUTENZA.xml:S2:2998:2	an	DT	O	O
increased	QUTENZA.xml:S2:3001:9	increas	VBN	O	O
risk	QUTENZA.xml:S2:3011:4	risk	NN	O	O
of	QUTENZA.xml:S2:3016:2	of	IN	O	O
adverse	QUTENZA.xml:S2:3019:7	advers	JJ	B-AdverseReaction	O
cardiovascular	QUTENZA.xml:S2:3027:14	cardiovascular	JJ	I-AdverseReaction	O
effects	QUTENZA.xml:S2:3042:7	effect	NNS	I-AdverseReaction	O
.	QUTENZA.xml:S2:3049:1	.	.	O	O

Consider	QUTENZA.xml:S2:3051:8	consid	VB	O	O
these	QUTENZA.xml:S2:3060:5	these	DT	O	O
factors	QUTENZA.xml:S2:3066:7	factor	NNS	O	O
prior	QUTENZA.xml:S2:3074:5	prior	VBP	O	O
to	QUTENZA.xml:S2:3080:2	to	TO	O	O
initiating	QUTENZA.xml:S2:3083:10	initi	VBG	O	O
Qutenza	QUTENZA.xml:S2:3094:7	qutenza	NNP	O	O
treatment	QUTENZA.xml:S2:3102:9	treatment	NN	O	O
.	QUTENZA.xml:S2:3111:1	.	.	O	O
6	SAPHRIS.xml:S1:4:1	6	CD	O	O
ADVERSE	SAPHRIS.xml:S1:6:7	advers	JJ	O	O
REACTIONS	SAPHRIS.xml:S1:14:9	reaction	NN	O	O

The	SAPHRIS.xml:S1:27:3	the	DT	O	O
following	SAPHRIS.xml:S1:31:9	follow	JJ	O	O
adverse	SAPHRIS.xml:S1:41:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:49:9	reaction	NNS	O	O
are	SAPHRIS.xml:S1:59:3	are	VBP	O	O
discussed	SAPHRIS.xml:S1:63:9	discuss	VBN	O	O
in	SAPHRIS.xml:S1:73:2	in	IN	O	O
more	SAPHRIS.xml:S1:76:4	more	JJR	O	O
detail	SAPHRIS.xml:S1:81:6	detail	NN	O	O
in	SAPHRIS.xml:S1:88:2	in	IN	O	O
other	SAPHRIS.xml:S1:91:5	other	JJ	O	O
sections	SAPHRIS.xml:S1:97:8	section	NNS	O	O
of	SAPHRIS.xml:S1:106:2	of	IN	O	O
the	SAPHRIS.xml:S1:109:3	the	DT	O	O
labeling	SAPHRIS.xml:S1:113:8	label	NN	O	O
:	SAPHRIS.xml:S1:121:1	:	:	O	O

Use	SAPHRIS.xml:S1:130:3	use	NNP	O	O
in	SAPHRIS.xml:S1:134:2	in	IN	O	O
Elderly	SAPHRIS.xml:S1:137:7	elderli	JJ	O	O
Patients	SAPHRIS.xml:S1:145:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:154:4	with	IN	O	O
Dementia	SAPHRIS.xml:S1:159:8	dementia	NNP	O	O
-	SAPHRIS.xml:S1:167:1	-	:	O	O
Related	SAPHRIS.xml:S1:168:7	relat	JJ	O	O
Psychosis	SAPHRIS.xml:S1:176:9	psychosi	NNP	O	O
[	SAPHRIS.xml:S1:186:1	[	NNP	O	O
seeBoxed	SAPHRIS.xml:S1:187:8	seebox	VBD	O	O
Warningand	SAPHRIS.xml:S1:196:10	warningand	NNP	O	O
Warnings	SAPHRIS.xml:S1:207:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:216:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:220:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:232:1	(	(	O	O
5.1	SAPHRIS.xml:S1:233:3	5.1	CD	O	O
and5	SAPHRIS.xml:S1:236:4	and5	NN	O	O
.	SAPHRIS.xml:S1:240:1	.	.	O	O
2	SAPHRIS.xml:S1:241:1	2	CD	O	O
)]	SAPHRIS.xml:S1:242:2	)]	NN	O	O

Neuroleptic	SAPHRIS.xml:S1:251:11	neurolept	JJ	B-AdverseReaction	B-AdverseReaction
Malignant	SAPHRIS.xml:S1:263:9	malign	NNP	I-AdverseReaction	I-AdverseReaction
Syndrome	SAPHRIS.xml:S1:273:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
[	SAPHRIS.xml:S1:282:1	[	NNP	O	O
see	SAPHRIS.xml:S1:283:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:287:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:296:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:300:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:312:1	(	(	O	O
5.3	SAPHRIS.xml:S1:313:3	5.3	CD	O	O
)]	SAPHRIS.xml:S1:316:2	)]	NN	O	O

Tardive	SAPHRIS.xml:S1:325:7	tardiv	JJ	B-AdverseReaction	B-AdverseReaction
Dyskinesia	SAPHRIS.xml:S1:333:10	dyskinesia	NNP	I-AdverseReaction	I-AdverseReaction
[	SAPHRIS.xml:S1:344:1	[	NNP	O	O
see	SAPHRIS.xml:S1:345:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:349:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:358:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:362:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:374:1	(	(	O	O
5.4	SAPHRIS.xml:S1:375:3	5.4	CD	O	O
)]	SAPHRIS.xml:S1:378:2	)]	NN	O	O

Metabolic	SAPHRIS.xml:S1:387:9	metabol	NNP	B-AdverseReaction	B-AdverseReaction
Changes	SAPHRIS.xml:S1:397:7	chang	NNP	I-AdverseReaction	I-AdverseReaction
[	SAPHRIS.xml:S1:405:1	[	NNP	O	O
see	SAPHRIS.xml:S1:406:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:410:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:419:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:423:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:435:1	(	(	O	O
5.5	SAPHRIS.xml:S1:436:3	5.5	CD	O	O
)]	SAPHRIS.xml:S1:439:2	)]	NN	O	O

Hypersensitivity	SAPHRIS.xml:S1:448:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	SAPHRIS.xml:S1:465:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
[	SAPHRIS.xml:S1:475:1	[	NNP	O	O
see	SAPHRIS.xml:S1:476:3	see	VBP	O	O
Contraindications	SAPHRIS.xml:S1:480:17	contraind	NNP	O	O
,	SAPHRIS.xml:S1:497:1	,	,	O	O
Warnings	SAPHRIS.xml:S1:499:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:508:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:512:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:524:1	(	(	O	O
5.6	SAPHRIS.xml:S1:525:3	5.6	CD	O	O
)	SAPHRIS.xml:S1:528:1	)	)	O	O
and	SAPHRIS.xml:S1:530:3	and	CC	O	O
Patient	SAPHRIS.xml:S1:534:7	patient	NNP	O	O
Counseling	SAPHRIS.xml:S1:542:10	counsel	NNP	O	O
Information	SAPHRIS.xml:S1:553:11	inform	NNP	O	O
(	SAPHRIS.xml:S1:565:1	(	(	O	O
17	SAPHRIS.xml:S1:566:2	17	CD	O	O
)]	SAPHRIS.xml:S1:568:2	)]	NN	O	O

Application	SAPHRIS.xml:S1:577:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	SAPHRIS.xml:S1:589:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactions	SAPHRIS.xml:S1:594:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
including	SAPHRIS.xml:S1:604:9	includ	VBG	O	O
oral	SAPHRIS.xml:S1:614:4	oral	JJ	I-AdverseReaction	B-AdverseReaction
ulcers	SAPHRIS.xml:S1:619:6	ulcer	NNS	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:625:1	,	,	O	O
blisters	SAPHRIS.xml:S1:627:8	blister	NNS	I-AdverseReaction	O
,	SAPHRIS.xml:S1:635:1	,	,	O	O
peeling	SAPHRIS.xml:S1:637:7	peel	VBG	I-AdverseReaction	O
sloughing	SAPHRIS.xml:S1:645:9	slough	NN	I-AdverseReaction	O
and	SAPHRIS.xml:S1:655:3	and	CC	O	O
inflammation	SAPHRIS.xml:S1:659:12	inflamm	NN	I-AdverseReaction	O
[	SAPHRIS.xml:S1:672:1	[	NNP	O	O
see	SAPHRIS.xml:S1:673:3	see	VBP	O	O
Adverse	SAPHRIS.xml:S1:677:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:685:9	reaction	NNP	O	O
(	SAPHRIS.xml:S1:695:1	(	(	O	O
6.2	SAPHRIS.xml:S1:696:3	6.2	CD	O	O
)]	SAPHRIS.xml:S1:699:2	)]	NN	O	O

Orthostatic	SAPHRIS.xml:S1:708:11	orthostat	JJ	B-AdverseReaction	B-AdverseReaction
Hypotension	SAPHRIS.xml:S1:720:11	hypotens	NNP	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:731:1	,	,	O	O
Syncope	SAPHRIS.xml:S1:733:7	syncop	NNP	B-AdverseReaction	O
,	SAPHRIS.xml:S1:740:1	,	,	O	O
and	SAPHRIS.xml:S1:742:3	and	CC	O	O
other	SAPHRIS.xml:S1:746:5	other	JJ	O	O
Hemodynamic	SAPHRIS.xml:S1:752:11	hemodynam	NNP	B-AdverseReaction	B-AdverseReaction
Effects	SAPHRIS.xml:S1:764:7	effect	NNPS	I-AdverseReaction	I-AdverseReaction
[	SAPHRIS.xml:S1:772:1	[	NNP	O	O
see	SAPHRIS.xml:S1:773:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:777:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:786:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:790:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:802:1	(	(	O	O
5.7	SAPHRIS.xml:S1:803:3	5.7	CD	O	O
)]	SAPHRIS.xml:S1:806:2	)]	NN	O	O

Leukopenia	SAPHRIS.xml:S1:815:10	leukopenia	NNP	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:825:1	,	,	O	O
Neutropenia	SAPHRIS.xml:S1:827:11	neutropenia	NNP	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:838:1	,	,	O	O
and	SAPHRIS.xml:S1:840:3	and	CC	O	O
Agranulocytosis	SAPHRIS.xml:S1:844:15	agranulocytosi	NNP	B-AdverseReaction	B-AdverseReaction
[	SAPHRIS.xml:S1:860:1	[	NNP	O	O
see	SAPHRIS.xml:S1:861:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:865:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:874:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:878:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:890:1	(	(	O	O
5.8	SAPHRIS.xml:S1:891:3	5.8	CD	O	O
)]	SAPHRIS.xml:S1:894:2	)]	NN	O	O

QT	SAPHRIS.xml:S1:903:2	QT	NNP	B-AdverseReaction	B-AdverseReaction
Interval	SAPHRIS.xml:S1:906:8	interv	NNP	I-AdverseReaction	I-AdverseReaction
Prolongation	SAPHRIS.xml:S1:915:12	prolong	NNP	I-AdverseReaction	I-AdverseReaction
[	SAPHRIS.xml:S1:928:1	[	NNP	O	O
see	SAPHRIS.xml:S1:929:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:933:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:942:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:946:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:958:1	(	(	O	O
5.9	SAPHRIS.xml:S1:959:3	5.9	CD	O	O
)]	SAPHRIS.xml:S1:962:2	)]	NN	O	O

Hyperprolactinemia	SAPHRIS.xml:S1:971:18	hyperprolactinemia	NNP	B-AdverseReaction	B-AdverseReaction
[	SAPHRIS.xml:S1:990:1	[	NNP	O	O
see	SAPHRIS.xml:S1:991:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:995:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:1004:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:1008:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:1020:1	(	(	O	O
5.10	SAPHRIS.xml:S1:1021:4	5.10	CD	O	O
)]	SAPHRIS.xml:S1:1025:2	)]	NN	O	O

Seizures	SAPHRIS.xml:S1:1034:8	seizur	NNS	B-AdverseReaction	B-AdverseReaction
[	SAPHRIS.xml:S1:1043:1	[	VBP	O	O
see	SAPHRIS.xml:S1:1044:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:1048:8	warn	NNS	O	O
and	SAPHRIS.xml:S1:1057:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:1061:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:1073:1	(	(	O	O
5.11	SAPHRIS.xml:S1:1074:4	5.11	CD	O	O
)]	SAPHRIS.xml:S1:1078:2	)]	NN	O	O

Potential	SAPHRIS.xml:S1:1087:9	potenti	NNP	O	O
for	SAPHRIS.xml:S1:1097:3	for	IN	O	O
Cognitive	SAPHRIS.xml:S1:1101:9	cognit	NNP	B-AdverseReaction	O
and	SAPHRIS.xml:S1:1111:3	and	CC	O	O
Motor	SAPHRIS.xml:S1:1115:5	motor	NNP	B-AdverseReaction	B-AdverseReaction
Impairment	SAPHRIS.xml:S1:1121:10	impair	NNP	I-AdverseReaction	I-AdverseReaction
[	SAPHRIS.xml:S1:1132:1	[	NNP	O	O
see	SAPHRIS.xml:S1:1133:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:1137:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:1146:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:1150:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:1162:1	(	(	O	O
5.12	SAPHRIS.xml:S1:1163:4	5.12	CD	O	O
)]	SAPHRIS.xml:S1:1167:2	)]	NN	O	O

Body	SAPHRIS.xml:S1:1176:4	bodi	NN	O	B-AdverseReaction
Temperature	SAPHRIS.xml:S1:1181:11	temperatur	NNP	O	I-AdverseReaction
Regulation	SAPHRIS.xml:S1:1193:10	regul	NNP	O	I-AdverseReaction
[	SAPHRIS.xml:S1:1204:1	[	NNP	O	O
see	SAPHRIS.xml:S1:1205:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:1209:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:1218:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:1222:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:1234:1	(	(	O	O
5.13	SAPHRIS.xml:S1:1235:4	5.13	CD	O	O
)]	SAPHRIS.xml:S1:1239:2	)]	NN	O	O

Suicide	SAPHRIS.xml:S1:1248:7	suicid	NNP	B-AdverseReaction	B-AdverseReaction
[	SAPHRIS.xml:S1:1256:1	[	NNP	O	O
see	SAPHRIS.xml:S1:1257:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:1261:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:1270:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:1274:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:1286:1	(	(	O	O
5.14	SAPHRIS.xml:S1:1287:4	5.14	CD	O	O
)]	SAPHRIS.xml:S1:1291:2	)]	NN	O	O

Dysphagia	SAPHRIS.xml:S1:1300:9	dysphagia	NNP	B-AdverseReaction	B-AdverseReaction
[	SAPHRIS.xml:S1:1310:1	[	NNP	O	O
see	SAPHRIS.xml:S1:1311:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:1315:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:1324:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:1328:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:1340:1	(	(	O	O
5.15	SAPHRIS.xml:S1:1341:4	5.15	CD	O	O
)]	SAPHRIS.xml:S1:1345:2	)]	NN	O	O

Use	SAPHRIS.xml:S1:1354:3	use	NNP	O	O
in	SAPHRIS.xml:S1:1358:2	in	IN	O	O
Patients	SAPHRIS.xml:S1:1361:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:1370:4	with	IN	O	O
Concomitant	SAPHRIS.xml:S1:1375:11	concomit	NNP	O	O
Illness	SAPHRIS.xml:S1:1387:7	ill	NNP	O	O
[	SAPHRIS.xml:S1:1395:1	[	NNP	O	O
see	SAPHRIS.xml:S1:1396:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S1:1400:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:1409:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:1413:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:1425:1	(	(	O	O
5.16	SAPHRIS.xml:S1:1426:4	5.16	CD	O	O
)]	SAPHRIS.xml:S1:1430:2	)]	NN	O	O

The	SAPHRIS.xml:S1:1439:3	the	DT	O	O
most	SAPHRIS.xml:S1:1443:4	most	RBS	O	O
common	SAPHRIS.xml:S1:1448:6	common	JJ	O	O
adverse	SAPHRIS.xml:S1:1455:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:1463:9	reaction	NNS	O	O
(	SAPHRIS.xml:S1:1473:1	(	(	O	O
5%	SAPHRIS.xml:S1:1476:2	5%	CD	O	O
and	SAPHRIS.xml:S1:1479:3	and	CC	O	O
at	SAPHRIS.xml:S1:1483:2	at	IN	O	O
least	SAPHRIS.xml:S1:1486:5	least	JJS	O	O
twice	SAPHRIS.xml:S1:1492:5	twice	RB	O	O
the	SAPHRIS.xml:S1:1498:3	the	DT	O	O
rate	SAPHRIS.xml:S1:1502:4	rate	NN	O	O
of	SAPHRIS.xml:S1:1507:2	of	IN	O	O
placebo	SAPHRIS.xml:S1:1510:7	placebo	NN	O	O
)	SAPHRIS.xml:S1:1517:1	)	)	O	O
reported	SAPHRIS.xml:S1:1519:8	report	VBD	O	O
with	SAPHRIS.xml:S1:1528:4	with	IN	O	O
acute	SAPHRIS.xml:S1:1533:5	acut	JJ	O	O
treatment	SAPHRIS.xml:S1:1539:9	treatment	NN	O	O
in	SAPHRIS.xml:S1:1549:2	in	IN	O	O
adults	SAPHRIS.xml:S1:1552:6	adult	NNS	O	O
with	SAPHRIS.xml:S1:1559:4	with	IN	O	O
schizophrenia	SAPHRIS.xml:S1:1564:13	schizophrenia	NN	O	O
were	SAPHRIS.xml:S1:1578:4	were	VBD	O	O
akathisia	SAPHRIS.xml:S1:1583:9	akathisia	RB	B-AdverseReaction	O
,	SAPHRIS.xml:S1:1592:1	,	,	O	O
oral	SAPHRIS.xml:S1:1594:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:1599:12	hypoesthesia	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:1611:1	,	,	O	O
and	SAPHRIS.xml:S1:1613:3	and	CC	O	O
somnolence	SAPHRIS.xml:S1:1617:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
.	SAPHRIS.xml:S1:1627:1	.	.	O	O

The	SAPHRIS.xml:S1:1629:3	the	DT	O	O
safety	SAPHRIS.xml:S1:1633:6	safeti	NN	O	O
profile	SAPHRIS.xml:S1:1640:7	profil	NN	O	O
of	SAPHRIS.xml:S1:1648:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:1651:7	saphri	NNP	O	O
in	SAPHRIS.xml:S1:1659:2	in	IN	O	O
the	SAPHRIS.xml:S1:1662:3	the	DT	O	O
maintenance	SAPHRIS.xml:S1:1666:11	mainten	NN	O	O
treatment	SAPHRIS.xml:S1:1678:9	treatment	NN	O	O
of	SAPHRIS.xml:S1:1688:2	of	IN	O	O
schizophrenia	SAPHRIS.xml:S1:1691:13	schizophrenia	NN	O	O
in	SAPHRIS.xml:S1:1705:2	in	IN	O	O
adults	SAPHRIS.xml:S1:1708:6	adult	NNS	O	O
was	SAPHRIS.xml:S1:1715:3	wa	VBD	O	O
similar	SAPHRIS.xml:S1:1719:7	similar	JJ	O	O
to	SAPHRIS.xml:S1:1727:2	to	TO	O	O
that	SAPHRIS.xml:S1:1730:4	that	DT	O	O
seen	SAPHRIS.xml:S1:1735:4	seen	VBN	O	O
with	SAPHRIS.xml:S1:1740:4	with	IN	O	O
acute	SAPHRIS.xml:S1:1745:5	acut	JJ	O	O
treatment	SAPHRIS.xml:S1:1751:9	treatment	NN	O	O
.	SAPHRIS.xml:S1:1760:1	.	.	O	O

The	SAPHRIS.xml:S1:1766:3	the	DT	O	O

most	SAPHRIS.xml:S1:1770:4	most	RBS	O	O
common	SAPHRIS.xml:S1:1775:6	common	JJ	O	O
adverse	SAPHRIS.xml:S1:1782:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:1790:9	reaction	NNS	O	O
(	SAPHRIS.xml:S1:1800:1	(	(	O	O
5%	SAPHRIS.xml:S1:1803:2	5%	CD	O	O
and	SAPHRIS.xml:S1:1806:3	and	CC	O	O
at	SAPHRIS.xml:S1:1810:2	at	IN	O	O
least	SAPHRIS.xml:S1:1813:5	least	JJS	O	O
twice	SAPHRIS.xml:S1:1819:5	twice	RB	O	O
the	SAPHRIS.xml:S1:1825:3	the	DT	O	O
rate	SAPHRIS.xml:S1:1829:4	rate	NN	O	O
of	SAPHRIS.xml:S1:1834:2	of	IN	O	O
placebo	SAPHRIS.xml:S1:1837:7	placebo	NN	O	O
)	SAPHRIS.xml:S1:1844:1	)	)	O	O
reported	SAPHRIS.xml:S1:1846:8	report	VBD	O	O
with	SAPHRIS.xml:S1:1855:4	with	IN	O	O
acute	SAPHRIS.xml:S1:1860:5	acut	JJ	O	O
monotherapy	SAPHRIS.xml:S1:1866:11	monotherapi	NN	O	O
treatment	SAPHRIS.xml:S1:1878:9	treatment	NN	O	O
of	SAPHRIS.xml:S1:1888:2	of	IN	O	O
manic	SAPHRIS.xml:S1:1891:5	manic	NN	O	O
or	SAPHRIS.xml:S1:1897:2	or	CC	O	O
mixed	SAPHRIS.xml:S1:1900:5	mix	JJ	O	O
episodes	SAPHRIS.xml:S1:1906:8	episod	NNS	O	O
associated	SAPHRIS.xml:S1:1915:10	associ	VBN	O	O
with	SAPHRIS.xml:S1:1926:4	with	IN	O	O
bipolar	SAPHRIS.xml:S1:1931:7	bipolar	JJ	O	O
I	SAPHRIS.xml:S1:1939:1	I	PRP	O	O
disorder	SAPHRIS.xml:S1:1941:8	disord	VBP	O	O
in	SAPHRIS.xml:S1:1950:2	in	IN	O	O
adults	SAPHRIS.xml:S1:1953:6	adult	NNS	O	O
were	SAPHRIS.xml:S1:1960:4	were	VBD	O	O
somnolence	SAPHRIS.xml:S1:1965:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:1975:1	,	,	O	O
dizziness	SAPHRIS.xml:S1:1977:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:1986:1	,	,	O	O
extrapyramidal	SAPHRIS.xml:S1:1988:14	extrapyramid	NN	B-AdverseReaction	O
symptoms	SAPHRIS.xml:S1:2003:8	symptom	NNS	I-AdverseReaction	O
other	SAPHRIS.xml:S1:2012:5	other	JJ	O	O
than	SAPHRIS.xml:S1:2018:4	than	IN	O	O
akathisia	SAPHRIS.xml:S1:2023:9	akathisia	NN	B-AdverseReaction	O
,	SAPHRIS.xml:S1:2032:1	,	,	O	O
and	SAPHRIS.xml:S1:2034:3	and	CC	O	O
increased	SAPHRIS.xml:S1:2038:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
weight	SAPHRIS.xml:S1:2048:6	weight	NN	I-AdverseReaction	I-AdverseReaction
and	SAPHRIS.xml:S1:2055:3	and	CC	O	O
during	SAPHRIS.xml:S1:2059:6	dure	IN	O	O
the	SAPHRIS.xml:S1:2066:3	the	DT	O	O
adjunctive	SAPHRIS.xml:S1:2070:10	adjunct	JJ	O	O
therapy	SAPHRIS.xml:S1:2081:7	therapi	NN	O	O
trial	SAPHRIS.xml:S1:2089:5	trial	NN	O	O
in	SAPHRIS.xml:S1:2095:2	in	IN	O	O
bipolar	SAPHRIS.xml:S1:2098:7	bipolar	NN	O	O
I	SAPHRIS.xml:S1:2106:1	I	PRP	O	O
disorder	SAPHRIS.xml:S1:2108:8	disord	VBP	O	O
in	SAPHRIS.xml:S1:2117:2	in	IN	O	O
adults	SAPHRIS.xml:S1:2120:6	adult	NNS	O	O
were	SAPHRIS.xml:S1:2127:4	were	VBD	O	O
somnolence	SAPHRIS.xml:S1:2132:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
and	SAPHRIS.xml:S1:2143:3	and	CC	O	O
oral	SAPHRIS.xml:S1:2147:4	oral	JJ	B-AdverseReaction	O
hypoesthesia	SAPHRIS.xml:S1:2152:12	hypoesthesia	NN	I-AdverseReaction	O
.	SAPHRIS.xml:S1:2164:1	.	.	O	O

The	SAPHRIS.xml:S1:2170:3	the	DT	O	O
adult	SAPHRIS.xml:S1:2174:5	adult	NN	O	O
information	SAPHRIS.xml:S1:2180:11	inform	NN	O	O
below	SAPHRIS.xml:S1:2192:5	below	IN	O	O
is	SAPHRIS.xml:S1:2198:2	is	VBZ	O	O
derived	SAPHRIS.xml:S1:2201:7	deriv	VBN	O	O
from	SAPHRIS.xml:S1:2209:4	from	IN	O	O
a	SAPHRIS.xml:S1:2214:1	a	DT	O	O
clinical	SAPHRIS.xml:S1:2216:8	clinic	JJ	O	O
trial	SAPHRIS.xml:S1:2225:5	trial	NN	O	O
database	SAPHRIS.xml:S1:2231:8	databas	NN	O	O
for	SAPHRIS.xml:S1:2240:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:2244:7	saphri	NNP	O	O
consisting	SAPHRIS.xml:S1:2252:10	consist	NN	O	O
of	SAPHRIS.xml:S1:2263:2	of	IN	O	O
over	SAPHRIS.xml:S1:2266:4	over	IN	O	O
4565	SAPHRIS.xml:S1:2271:4	4565	CD	O	O
patients	SAPHRIS.xml:S1:2276:8	patient	NNS	O	O
and	SAPHRIS.xml:S1:2285:3	and	CC	O	O
or	SAPHRIS.xml:S1:2289:2	or	CC	O	O
healthy	SAPHRIS.xml:S1:2292:7	healthi	JJ	O	O
subjects	SAPHRIS.xml:S1:2300:8	subject	NNS	O	O
exposed	SAPHRIS.xml:S1:2309:7	expos	VBN	O	O
to	SAPHRIS.xml:S1:2317:2	to	TO	O	O
one	SAPHRIS.xml:S1:2320:3	one	CD	O	O
or	SAPHRIS.xml:S1:2324:2	or	CC	O	O
more	SAPHRIS.xml:S1:2327:4	more	JJR	O	O
sublingual	SAPHRIS.xml:S1:2332:10	sublingu	JJ	O	O
doses	SAPHRIS.xml:S1:2343:5	dose	NNS	O	O
of	SAPHRIS.xml:S1:2349:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:2352:7	saphri	NNP	O	O
.	SAPHRIS.xml:S1:2359:1	.	.	O	O

A	SAPHRIS.xml:S1:2361:1	A	DT	O	O
total	SAPHRIS.xml:S1:2363:5	total	NN	O	O
of	SAPHRIS.xml:S1:2369:2	of	IN	O	O
1314	SAPHRIS.xml:S1:2372:4	1314	CD	O	O
SAPHRIS	SAPHRIS.xml:S1:2377:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:2384:1	-	:	O	O
treated	SAPHRIS.xml:S1:2385:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:2393:8	patient	NNS	O	O
were	SAPHRIS.xml:S1:2402:4	were	VBD	O	O
treated	SAPHRIS.xml:S1:2407:7	treat	VBN	O	O
for	SAPHRIS.xml:S1:2415:3	for	IN	O	O
at	SAPHRIS.xml:S1:2419:2	at	IN	O	O
least	SAPHRIS.xml:S1:2422:5	least	JJS	O	O
24	SAPHRIS.xml:S1:2428:2	24	CD	O	O
weeks	SAPHRIS.xml:S1:2431:5	week	NNS	O	O
and	SAPHRIS.xml:S1:2437:3	and	CC	O	O
785	SAPHRIS.xml:S1:2441:3	785	CD	O	O
SAPHRIS	SAPHRIS.xml:S1:2445:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:2452:1	-	:	O	O
treated	SAPHRIS.xml:S1:2453:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:2461:8	patient	NNS	O	O
had	SAPHRIS.xml:S1:2470:3	had	VBD	O	O
at	SAPHRIS.xml:S1:2474:2	at	IN	O	O
least	SAPHRIS.xml:S1:2477:5	least	JJS	O	O
52	SAPHRIS.xml:S1:2483:2	52	CD	O	O
weeks	SAPHRIS.xml:S1:2486:5	week	NNS	O	O
of	SAPHRIS.xml:S1:2492:2	of	IN	O	O
exposure	SAPHRIS.xml:S1:2495:8	exposur	NN	O	O
at	SAPHRIS.xml:S1:2504:2	at	IN	O	O
therapeutic	SAPHRIS.xml:S1:2507:11	therapeut	JJ	O	O
doses	SAPHRIS.xml:S1:2519:5	dose	NNS	O	O
.	SAPHRIS.xml:S1:2524:1	.	.	O	O

In	SAPHRIS.xml:S1:2530:2	In	IN	O	O
a	SAPHRIS.xml:S1:2533:1	a	DT	O	O
3	SAPHRIS.xml:S1:2535:1	3	CD	O	O
-	SAPHRIS.xml:S1:2536:1	-	:	O	O
week	SAPHRIS.xml:S1:2537:4	week	NN	O	O
monotherapy	SAPHRIS.xml:S1:2542:11	monotherapi	NN	O	O
trial	SAPHRIS.xml:S1:2554:5	trial	NN	O	O
,	SAPHRIS.xml:S1:2559:1	,	,	O	O
the	SAPHRIS.xml:S1:2561:3	the	DT	O	O
most	SAPHRIS.xml:S1:2565:4	most	RBS	O	O
common	SAPHRIS.xml:S1:2570:6	common	JJ	O	O
adverse	SAPHRIS.xml:S1:2577:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:2585:9	reaction	NNS	O	O
(	SAPHRIS.xml:S1:2595:1	(	(	O	O
5%	SAPHRIS.xml:S1:2598:2	5%	CD	O	O
and	SAPHRIS.xml:S1:2601:3	and	CC	O	O
at	SAPHRIS.xml:S1:2605:2	at	IN	O	O
least	SAPHRIS.xml:S1:2608:5	least	JJS	O	O
twice	SAPHRIS.xml:S1:2614:5	twice	RB	O	O
the	SAPHRIS.xml:S1:2620:3	the	DT	O	O
rate	SAPHRIS.xml:S1:2624:4	rate	NN	O	O
of	SAPHRIS.xml:S1:2629:2	of	IN	O	O
placebo	SAPHRIS.xml:S1:2632:7	placebo	NN	O	O
)	SAPHRIS.xml:S1:2639:1	)	)	O	O
reported	SAPHRIS.xml:S1:2641:8	report	VBD	O	O
in	SAPHRIS.xml:S1:2650:2	in	IN	O	O
pediatric	SAPHRIS.xml:S1:2653:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:2663:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:2672:4	with	IN	O	O
bipolar	SAPHRIS.xml:S1:2677:7	bipolar	JJ	O	O
I	SAPHRIS.xml:S1:2685:1	I	PRP	O	O
disorder	SAPHRIS.xml:S1:2687:8	disord	VBP	O	O
treated	SAPHRIS.xml:S1:2696:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:2704:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:2709:7	saphri	NNP	O	O
were	SAPHRIS.xml:S1:2717:4	were	VBD	O	O
somnolence	SAPHRIS.xml:S1:2722:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:2732:1	,	,	O	O
dizziness	SAPHRIS.xml:S1:2734:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:2743:1	,	,	O	O
dysgeusia	SAPHRIS.xml:S1:2745:9	dysgeusia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:2754:1	,	,	O	O
oral	SAPHRIS.xml:S1:2756:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:2761:11	paresthesia	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:2772:1	,	,	O	O
nausea	SAPHRIS.xml:S1:2774:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:2780:1	,	,	O	O
increased	SAPHRIS.xml:S1:2782:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
appetite	SAPHRIS.xml:S1:2792:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:2800:1	,	,	O	O
fatigue	SAPHRIS.xml:S1:2802:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:2809:1	,	,	O	O
and	SAPHRIS.xml:S1:2811:3	and	CC	O	O
increased	SAPHRIS.xml:S1:2815:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
weight	SAPHRIS.xml:S1:2825:6	weight	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S1:2831:1	.	.	O	O

No	SAPHRIS.xml:S1:2833:2	No	DT	O	O
new	SAPHRIS.xml:S1:2836:3	new	JJ	O	O
major	SAPHRIS.xml:S1:2840:5	major	JJ	O	O
safety	SAPHRIS.xml:S1:2846:6	safeti	NN	O	O
findings	SAPHRIS.xml:S1:2853:8	find	NNS	O	O
were	SAPHRIS.xml:S1:2862:4	were	VBD	O	O
reported	SAPHRIS.xml:S1:2867:8	report	VBN	O	O
from	SAPHRIS.xml:S1:2876:4	from	IN	O	O
a	SAPHRIS.xml:S1:2881:1	a	DT	O	O
50	SAPHRIS.xml:S1:2883:2	50	CD	O	O
-	SAPHRIS.xml:S1:2885:1	-	:	O	O
week	SAPHRIS.xml:S1:2886:4	week	NN	O	O
,	SAPHRIS.xml:S1:2890:1	,	,	O	O
open	SAPHRIS.xml:S1:2892:4	open	JJ	O	O
-	SAPHRIS.xml:S1:2896:1	-	:	O	O
label	SAPHRIS.xml:S1:2897:5	label	NN	O	O
,	SAPHRIS.xml:S1:2902:1	,	,	O	O
uncontrolled	SAPHRIS.xml:S1:2904:12	uncontrol	JJ	O	O
safety	SAPHRIS.xml:S1:2917:6	safeti	NN	O	O
trial	SAPHRIS.xml:S1:2924:5	trial	NN	O	O
.	SAPHRIS.xml:S1:2929:1	.	.	O	O

A	SAPHRIS.xml:S1:2935:1	A	DT	O	O
total	SAPHRIS.xml:S1:2937:5	total	NN	O	O
of	SAPHRIS.xml:S1:2943:2	of	IN	O	O
651	SAPHRIS.xml:S1:2946:3	651	CD	O	O
pediatric	SAPHRIS.xml:S1:2950:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:2960:8	patient	NNS	O	O
were	SAPHRIS.xml:S1:2969:4	were	VBD	O	O
treated	SAPHRIS.xml:S1:2974:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:2982:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:2987:7	saphri	NNP	O	O
.	SAPHRIS.xml:S1:2994:1	.	.	O	O

Of	SAPHRIS.xml:S1:2996:2	Of	IN	O	O
these	SAPHRIS.xml:S1:2999:5	these	DT	O	O
patients	SAPHRIS.xml:S1:3005:8	patient	NNS	O	O
,	SAPHRIS.xml:S1:3013:1	,	,	O	O
352	SAPHRIS.xml:S1:3015:3	352	CD	O	O
pediatric	SAPHRIS.xml:S1:3019:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:3029:8	patient	NNS	O	O
were	SAPHRIS.xml:S1:3038:4	were	VBD	O	O
treated	SAPHRIS.xml:S1:3043:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:3051:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:3056:7	saphri	NNP	O	O
for	SAPHRIS.xml:S1:3064:3	for	IN	O	O
at	SAPHRIS.xml:S1:3068:2	at	IN	O	O
least	SAPHRIS.xml:S1:3071:5	least	JJS	O	O
180	SAPHRIS.xml:S1:3077:3	180	CD	O	O
days	SAPHRIS.xml:S1:3081:4	day	NNS	O	O
and	SAPHRIS.xml:S1:3086:3	and	CC	O	O
58	SAPHRIS.xml:S1:3090:2	58	CD	O	O
pediatric	SAPHRIS.xml:S1:3093:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:3103:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:3112:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:3120:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:3125:7	saphri	NNP	O	O
had	SAPHRIS.xml:S1:3133:3	had	VBD	O	O
at	SAPHRIS.xml:S1:3137:2	at	IN	O	O
least	SAPHRIS.xml:S1:3140:5	least	JJS	O	O
1	SAPHRIS.xml:S1:3146:1	1	CD	O	O
year	SAPHRIS.xml:S1:3148:4	year	NN	O	O
of	SAPHRIS.xml:S1:3153:2	of	IN	O	O
exposure	SAPHRIS.xml:S1:3156:8	exposur	NN	O	O
.	SAPHRIS.xml:S1:3164:1	.	.	O	O

The	SAPHRIS.xml:S1:3166:3	the	DT	O	O
safety	SAPHRIS.xml:S1:3170:6	safeti	NN	O	O
of	SAPHRIS.xml:S1:3177:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:3180:7	saphri	NNP	O	O
was	SAPHRIS.xml:S1:3188:3	wa	VBD	O	O
evaluated	SAPHRIS.xml:S1:3192:9	evalu	VBN	O	O
in	SAPHRIS.xml:S1:3202:2	in	IN	O	O
403	SAPHRIS.xml:S1:3205:3	403	CD	O	O
pediatric	SAPHRIS.xml:S1:3209:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:3219:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:3228:4	with	IN	O	O
bipolar	SAPHRIS.xml:S1:3233:7	bipolar	JJ	O	O
I	SAPHRIS.xml:S1:3241:1	I	PRP	O	O
disorder	SAPHRIS.xml:S1:3243:8	disord	VBP	O	O
who	SAPHRIS.xml:S1:3252:3	who	WP	O	O
participated	SAPHRIS.xml:S1:3256:12	particip	VBD	O	O
in	SAPHRIS.xml:S1:3269:2	in	IN	O	O
a	SAPHRIS.xml:S1:3272:1	a	DT	O	O
3	SAPHRIS.xml:S1:3274:1	3	CD	O	O
-	SAPHRIS.xml:S1:3275:1	-	:	O	O
week	SAPHRIS.xml:S1:3276:4	week	NN	O	O
,	SAPHRIS.xml:S1:3280:1	,	,	O	O
placebo	SAPHRIS.xml:S1:3282:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:3289:1	-	:	O	O
controlled	SAPHRIS.xml:S1:3290:10	control	VBN	O	O
,	SAPHRIS.xml:S1:3300:1	,	,	O	O
double	SAPHRIS.xml:S1:3302:6	doubl	JJ	O	O
-	SAPHRIS.xml:S1:3308:1	-	:	O	O
blind	SAPHRIS.xml:S1:3309:5	blind	NN	O	O
trial	SAPHRIS.xml:S1:3315:5	trial	NN	O	O
,	SAPHRIS.xml:S1:3320:1	,	,	O	O
of	SAPHRIS.xml:S1:3322:2	of	IN	O	O
whom	SAPHRIS.xml:S1:3325:4	whom	WP	O	O
302	SAPHRIS.xml:S1:3330:3	302	CD	O	O
patients	SAPHRIS.xml:S1:3334:8	patient	NNS	O	O
received	SAPHRIS.xml:S1:3343:8	receiv	VBD	O	O
SAPHRIS	SAPHRIS.xml:S1:3352:7	saphri	NNP	O	O
at	SAPHRIS.xml:S1:3360:2	at	IN	O	O
fixed	SAPHRIS.xml:S1:3363:5	fix	JJ	O	O
doses	SAPHRIS.xml:S1:3369:5	dose	NNS	O	O
ranging	SAPHRIS.xml:S1:3375:7	rang	VBG	O	O
from	SAPHRIS.xml:S1:3383:4	from	IN	O	O
2.5	SAPHRIS.xml:S1:3388:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:3392:2	mg	NNS	O	O
to	SAPHRIS.xml:S1:3395:2	to	TO	O	O
10	SAPHRIS.xml:S1:3398:2	10	CD	O	O
mg	SAPHRIS.xml:S1:3401:2	mg	NNS	O	O
twice	SAPHRIS.xml:S1:3404:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:3410:5	daili	RB	O	O
.	SAPHRIS.xml:S1:3415:1	.	.	O	O

The	SAPHRIS.xml:S1:3421:3	the	DT	O	O
stated	SAPHRIS.xml:S1:3425:6	state	JJ	O	O
frequencies	SAPHRIS.xml:S1:3432:11	frequenc	NNS	O	O
of	SAPHRIS.xml:S1:3444:2	of	IN	O	O
adverse	SAPHRIS.xml:S1:3447:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:3455:9	reaction	NNS	O	O
represent	SAPHRIS.xml:S1:3465:9	repres	VBP	O	O
the	SAPHRIS.xml:S1:3475:3	the	DT	O	O
proportion	SAPHRIS.xml:S1:3479:10	proport	NN	O	O
of	SAPHRIS.xml:S1:3490:2	of	IN	O	O
individuals	SAPHRIS.xml:S1:3493:11	individu	NNS	O	O
who	SAPHRIS.xml:S1:3505:3	who	WP	O	O
experienced	SAPHRIS.xml:S1:3509:11	experienc	VBD	O	O
a	SAPHRIS.xml:S1:3521:1	a	DT	O	O
treatment	SAPHRIS.xml:S1:3523:9	treatment	NN	O	O
-	SAPHRIS.xml:S1:3532:1	-	:	O	O
emergent	SAPHRIS.xml:S1:3533:8	emerg	JJ	O	O
adverse	SAPHRIS.xml:S1:3542:7	advers	JJ	O	O
event	SAPHRIS.xml:S1:3550:5	event	NN	O	O
of	SAPHRIS.xml:S1:3556:2	of	IN	O	O
the	SAPHRIS.xml:S1:3559:3	the	DT	O	O
type	SAPHRIS.xml:S1:3563:4	type	NN	O	O
listed	SAPHRIS.xml:S1:3568:6	list	VBN	O	O
.	SAPHRIS.xml:S1:3574:1	.	.	O	O

A	SAPHRIS.xml:S1:3576:1	A	DT	O	O
reaction	SAPHRIS.xml:S1:3578:8	reaction	NN	O	O
was	SAPHRIS.xml:S1:3587:3	wa	VBD	O	O
considered	SAPHRIS.xml:S1:3591:10	consid	VBN	O	O
treatment	SAPHRIS.xml:S1:3602:9	treatment	NN	O	O
emergent	SAPHRIS.xml:S1:3612:8	emerg	NN	O	O
if	SAPHRIS.xml:S1:3621:2	if	IN	O	O
it	SAPHRIS.xml:S1:3624:2	it	PRP	O	O
occurred	SAPHRIS.xml:S1:3627:8	occur	VBD	O	O
for	SAPHRIS.xml:S1:3636:3	for	IN	O	O
the	SAPHRIS.xml:S1:3640:3	the	DT	O	O
first	SAPHRIS.xml:S1:3644:5	first	JJ	O	O
time	SAPHRIS.xml:S1:3650:4	time	NN	O	O
or	SAPHRIS.xml:S1:3655:2	or	CC	O	O
worsened	SAPHRIS.xml:S1:3658:8	worsen	VBN	O	O
while	SAPHRIS.xml:S1:3667:5	while	IN	O	O
receiving	SAPHRIS.xml:S1:3673:9	receiv	VBG	O	O
therapy	SAPHRIS.xml:S1:3683:7	therapi	NN	O	O
following	SAPHRIS.xml:S1:3691:9	follow	VBG	O	O
baseline	SAPHRIS.xml:S1:3701:8	baselin	JJ	O	O
evaluation	SAPHRIS.xml:S1:3710:10	evalu	NN	O	O
.	SAPHRIS.xml:S1:3720:1	.	.	O	O

EXCERPT	SAPHRIS.xml:S1:3728:7	excerpt	NN	O	O
:	SAPHRIS.xml:S1:3735:1	:	:	O	O
Commonly	SAPHRIS.xml:S1:3739:8	commonli	RB	O	O
observed	SAPHRIS.xml:S1:3748:8	observ	VBD	O	O
adverse	SAPHRIS.xml:S1:3757:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:3765:9	reaction	NNS	O	O
(	SAPHRIS.xml:S1:3775:1	(	(	O	O
incidence	SAPHRIS.xml:S1:3776:9	incid	NN	O	O
5%	SAPHRIS.xml:S1:3788:2	5%	CD	O	O
and	SAPHRIS.xml:S1:3791:3	and	CC	O	O
at	SAPHRIS.xml:S1:3795:2	at	IN	O	O
least	SAPHRIS.xml:S1:3798:5	least	JJS	O	O
twice	SAPHRIS.xml:S1:3804:5	twice	NN	O	O
that	SAPHRIS.xml:S1:3810:4	that	DT	O	O
for	SAPHRIS.xml:S1:3815:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:3819:7	placebo	NN	O	O
)	SAPHRIS.xml:S1:3826:1	)	)	O	O
were	SAPHRIS.xml:S1:3828:4	were	VBD	O	O
(	SAPHRIS.xml:S1:3833:1	(	(	O	O
6.1	SAPHRIS.xml:S1:3834:3	6.1	CD	O	O
)	SAPHRIS.xml:S1:3837:1	)	)	O	O
:	SAPHRIS.xml:S1:3838:1	:	:	O	O

Schizophrenia	SAPHRIS.xml:S1:3848:13	schizophrenia	NNP	O	O
Adults	SAPHRIS.xml:S1:3862:6	adult	NNS	O	O
:	SAPHRIS.xml:S1:3868:1	:	:	O	O
akathisia	SAPHRIS.xml:S1:3870:9	akathisia	NN	B-AdverseReaction	O
,	SAPHRIS.xml:S1:3879:1	,	,	O	O
oral	SAPHRIS.xml:S1:3881:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:3886:12	hypoesthesia	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:3898:1	,	,	O	O
somnolence	SAPHRIS.xml:S1:3900:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
.	SAPHRIS.xml:S1:3910:1	.	.	O	O

Bipolar	SAPHRIS.xml:S1:3918:7	bipolar	JJ	O	O
Disorder	SAPHRIS.xml:S1:3926:8	disord	NNP	O	O
Adults	SAPHRIS.xml:S1:3935:6	adult	NNP	O	O
(	SAPHRIS.xml:S1:3942:1	(	(	O	O
Monotherapy	SAPHRIS.xml:S1:3943:11	monotherapi	NNP	O	O
)	SAPHRIS.xml:S1:3954:1	)	)	O	O
:	SAPHRIS.xml:S1:3955:1	:	:	O	O
somnolence	SAPHRIS.xml:S1:3957:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:3967:1	,	,	O	O
dizziness	SAPHRIS.xml:S1:3969:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:3978:1	,	,	O	O
extrapyramidal	SAPHRIS.xml:S1:3980:14	extrapyramid	NN	B-AdverseReaction	O
symptoms	SAPHRIS.xml:S1:3995:8	symptom	NNS	I-AdverseReaction	O
other	SAPHRIS.xml:S1:4004:5	other	JJ	O	O
than	SAPHRIS.xml:S1:4010:4	than	IN	O	O
akathisia	SAPHRIS.xml:S1:4015:9	akathisia	JJ	B-AdverseReaction	O
,	SAPHRIS.xml:S1:4024:1	,	,	O	O
increased	SAPHRIS.xml:S1:4026:9	increas	JJ	B-AdverseReaction	B-AdverseReaction
weight	SAPHRIS.xml:S1:4036:6	weight	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S1:4042:1	.	.	O	O

Bipolar	SAPHRIS.xml:S1:4050:7	bipolar	JJ	O	O
Disorder	SAPHRIS.xml:S1:4058:8	disord	NNP	O	O
Pediatric	SAPHRIS.xml:S1:4067:9	pediatr	NNP	O	O
Patients	SAPHRIS.xml:S1:4077:8	patient	NNP	O	O
(	SAPHRIS.xml:S1:4086:1	(	(	O	O
Monotherapy	SAPHRIS.xml:S1:4087:11	monotherapi	NNP	O	O
)	SAPHRIS.xml:S1:4098:1	)	)	O	O
:	SAPHRIS.xml:S1:4099:1	:	:	O	O
somnolence	SAPHRIS.xml:S1:4101:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:4111:1	,	,	O	O
dizziness	SAPHRIS.xml:S1:4113:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:4122:1	,	,	O	O
dysgeusia	SAPHRIS.xml:S1:4124:9	dysgeusia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:4133:1	,	,	O	O
oral	SAPHRIS.xml:S1:4135:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:4140:11	paresthesia	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:4151:1	,	,	O	O
nausea	SAPHRIS.xml:S1:4153:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:4159:1	,	,	O	O
increased	SAPHRIS.xml:S1:4161:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
appetite	SAPHRIS.xml:S1:4171:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:4179:1	,	,	O	O
fatigue	SAPHRIS.xml:S1:4181:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:4188:1	,	,	O	O
increased	SAPHRIS.xml:S1:4190:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
weight	SAPHRIS.xml:S1:4200:6	weight	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S1:4206:1	.	.	O	O

Bipolar	SAPHRIS.xml:S1:4214:7	bipolar	JJ	O	O
Disorder	SAPHRIS.xml:S1:4222:8	disord	NNP	O	O
Adults	SAPHRIS.xml:S1:4231:6	adult	NNP	O	O
(	SAPHRIS.xml:S1:4238:1	(	(	O	O
Adjunctive	SAPHRIS.xml:S1:4239:10	adjunct	NNP	O	O
)	SAPHRIS.xml:S1:4249:1	)	)	O	O
:	SAPHRIS.xml:S1:4250:1	:	:	O	O
somnolence	SAPHRIS.xml:S1:4252:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:4262:1	,	,	O	O
oral	SAPHRIS.xml:S1:4264:4	oral	JJ	B-AdverseReaction	O
hypoesthesia	SAPHRIS.xml:S1:4269:12	hypoesthesia	NN	I-AdverseReaction	O
.	SAPHRIS.xml:S1:4281:1	.	.	O	O

To	SAPHRIS.xml:S1:4290:2	To	TO	O	O
report	SAPHRIS.xml:S1:4293:6	report	VB	O	O
SUSPECTED	SAPHRIS.xml:S1:4300:9	suspect	NNP	O	O
ADVERSE	SAPHRIS.xml:S1:4310:7	advers	NNP	O	O
REACTIONS	SAPHRIS.xml:S1:4318:9	reaction	NNP	O	O
,	SAPHRIS.xml:S1:4327:1	,	,	O	O
contact	SAPHRIS.xml:S1:4329:7	contact	NN	O	O
Forest	SAPHRIS.xml:S1:4337:6	forest	NNP	O	O
Laboratories	SAPHRIS.xml:S1:4344:12	laboratori	NNPS	O	O
,	SAPHRIS.xml:S1:4356:1	,	,	O	O
LLC	SAPHRIS.xml:S1:4358:3	llc	NNP	O	O
.	SAPHRIS.xml:S1:4361:1	.	.	O	O

at	SAPHRIS.xml:S1:4363:2	at	IN	O	O
1	SAPHRIS.xml:S1:4366:1	1	CD	O	O
-	SAPHRIS.xml:S1:4367:1	-	:	O	O
800	SAPHRIS.xml:S1:4368:3	800	CD	O	O
-	SAPHRIS.xml:S1:4371:1	-	:	O	O
678	SAPHRIS.xml:S1:4372:3	678	CD	O	O
-	SAPHRIS.xml:S1:4375:1	-	:	O	O
1605	SAPHRIS.xml:S1:4376:4	1605	CD	O	O
or	SAPHRIS.xml:S1:4381:2	or	CC	O	O
FDA	SAPHRIS.xml:S1:4384:3	fda	NNP	O	O
at	SAPHRIS.xml:S1:4388:2	at	IN	O	O
1	SAPHRIS.xml:S1:4391:1	1	CD	O	O
-	SAPHRIS.xml:S1:4392:1	-	:	O	O
800	SAPHRIS.xml:S1:4393:3	800	CD	O	O
-	SAPHRIS.xml:S1:4396:1	-	:	O	O
FDA	SAPHRIS.xml:S1:4397:3	fda	NNP	O	O
-	SAPHRIS.xml:S1:4400:1	-	:	O	O
1088	SAPHRIS.xml:S1:4401:4	1088	CD	O	O
or	SAPHRIS.xml:S1:4406:2	or	CC	O	O
www	SAPHRIS.xml:S1:4409:3	www	VB	O	O
.	SAPHRIS.xml:S1:4412:1	.	.	O	O
fda	SAPHRIS.xml:S1:4413:3	fda	NN	O	O
.	SAPHRIS.xml:S1:4416:1	.	.	O	O
gov	SAPHRIS.xml:S1:4417:3	gov	JJ	O	O
medwatch	SAPHRIS.xml:S1:4421:8	medwatch	NN	O	O
.	SAPHRIS.xml:S1:4429:1	.	.	O	O

6.1	SAPHRIS.xml:S1:4441:3	6.1	CD	O	O

Clinical	SAPHRIS.xml:S1:4445:8	clinic	JJ	O	O

Trials	SAPHRIS.xml:S1:4454:6	trial	NNS	O	O
Experience	SAPHRIS.xml:S1:4461:10	experi	NN	O	O

Because	SAPHRIS.xml:S1:4475:7	becaus	IN	O	O
clinical	SAPHRIS.xml:S1:4483:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S1:4492:6	trial	NNS	O	O
are	SAPHRIS.xml:S1:4499:3	are	VBP	O	O
conducted	SAPHRIS.xml:S1:4503:9	conduct	VBN	O	O
under	SAPHRIS.xml:S1:4513:5	under	IN	O	O
widely	SAPHRIS.xml:S1:4519:6	wide	RB	O	O
varying	SAPHRIS.xml:S1:4526:7	vari	VBG	O	O
conditions	SAPHRIS.xml:S1:4534:10	condit	NNS	O	O
,	SAPHRIS.xml:S1:4544:1	,	,	O	O
adverse	SAPHRIS.xml:S1:4546:7	advers	JJ	O	O
reaction	SAPHRIS.xml:S1:4554:8	reaction	NN	O	O
rates	SAPHRIS.xml:S1:4563:5	rate	NNS	O	O
observed	SAPHRIS.xml:S1:4569:8	observ	VBD	O	O
in	SAPHRIS.xml:S1:4578:2	in	IN	O	O
the	SAPHRIS.xml:S1:4581:3	the	DT	O	O
clinical	SAPHRIS.xml:S1:4585:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S1:4594:6	trial	NNS	O	O
of	SAPHRIS.xml:S1:4601:2	of	IN	O	O
a	SAPHRIS.xml:S1:4604:1	a	DT	O	O
drug	SAPHRIS.xml:S1:4606:4	drug	NN	O	O
cannot	SAPHRIS.xml:S1:4611:6	cannot	NN	O	O
be	SAPHRIS.xml:S1:4618:2	be	VB	O	O
directly	SAPHRIS.xml:S1:4621:8	directli	RB	O	O
compared	SAPHRIS.xml:S1:4630:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:4639:2	to	TO	O	O
rates	SAPHRIS.xml:S1:4642:5	rate	NNS	O	O
in	SAPHRIS.xml:S1:4648:2	in	IN	O	O
the	SAPHRIS.xml:S1:4651:3	the	DT	O	O
clinical	SAPHRIS.xml:S1:4655:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S1:4664:6	trial	NNS	O	O
of	SAPHRIS.xml:S1:4671:2	of	IN	O	O
another	SAPHRIS.xml:S1:4674:7	anoth	DT	O	O
drug	SAPHRIS.xml:S1:4682:4	drug	NN	O	O
and	SAPHRIS.xml:S1:4687:3	and	CC	O	O
may	SAPHRIS.xml:S1:4691:3	may	MD	O	O
not	SAPHRIS.xml:S1:4695:3	not	RB	O	O
reflect	SAPHRIS.xml:S1:4699:7	reflect	VB	O	O
the	SAPHRIS.xml:S1:4707:3	the	DT	O	O
rates	SAPHRIS.xml:S1:4711:5	rate	NNS	O	O
observed	SAPHRIS.xml:S1:4717:8	observ	VBD	O	O
in	SAPHRIS.xml:S1:4726:2	in	IN	O	O
practice	SAPHRIS.xml:S1:4729:8	practic	NN	O	O
.	SAPHRIS.xml:S1:4737:1	.	.	O	O

Adult	SAPHRIS.xml:S1:4747:5	adult	NN	O	O
Patients	SAPHRIS.xml:S1:4753:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:4762:4	with	IN	O	O
Schizophrenia	SAPHRIS.xml:S1:4767:13	schizophrenia	NNP	O	O
:	SAPHRIS.xml:S1:4780:1	:	:	O	O
The	SAPHRIS.xml:S1:4783:3	the	DT	O	O
following	SAPHRIS.xml:S1:4787:9	follow	JJ	O	O
findings	SAPHRIS.xml:S1:4797:8	find	NNS	O	O
are	SAPHRIS.xml:S1:4806:3	are	VBP	O	O
based	SAPHRIS.xml:S1:4810:5	base	VBN	O	O
on	SAPHRIS.xml:S1:4816:2	on	IN	O	O
the	SAPHRIS.xml:S1:4819:3	the	DT	O	O
short	SAPHRIS.xml:S1:4823:5	short	JJ	O	O
-	SAPHRIS.xml:S1:4828:1	-	:	O	O
term	SAPHRIS.xml:S1:4829:4	term	NN	O	O
placebo	SAPHRIS.xml:S1:4834:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:4841:1	-	:	O	O
controlled	SAPHRIS.xml:S1:4842:10	control	VBN	O	O
pre	SAPHRIS.xml:S1:4853:3	pre	NN	O	O
-	SAPHRIS.xml:S1:4856:1	-	:	O	O
marketing	SAPHRIS.xml:S1:4857:9	market	NN	O	O
trials	SAPHRIS.xml:S1:4867:6	trial	NNS	O	O
for	SAPHRIS.xml:S1:4874:3	for	IN	O	O
schizophrenia	SAPHRIS.xml:S1:4878:13	schizophrenia	NN	O	O
(	SAPHRIS.xml:S1:4892:1	(	(	O	O
a	SAPHRIS.xml:S1:4893:1	a	DT	O	O
pool	SAPHRIS.xml:S1:4895:4	pool	NN	O	O
of	SAPHRIS.xml:S1:4900:2	of	IN	O	O
three	SAPHRIS.xml:S1:4903:5	three	CD	O	O
6	SAPHRIS.xml:S1:4909:1	6	CD	O	O
-	SAPHRIS.xml:S1:4910:1	-	:	O	O
week	SAPHRIS.xml:S1:4911:4	week	NN	O	O
fixed	SAPHRIS.xml:S1:4916:5	fix	VBN	O	O
-	SAPHRIS.xml:S1:4921:1	-	:	O	O
dose	SAPHRIS.xml:S1:4922:4	dose	NN	O	O
trials	SAPHRIS.xml:S1:4927:6	trial	NNS	O	O
and	SAPHRIS.xml:S1:4934:3	and	CC	O	O
one	SAPHRIS.xml:S1:4938:3	one	CD	O	O
6	SAPHRIS.xml:S1:4942:1	6	CD	O	O
-	SAPHRIS.xml:S1:4943:1	-	:	O	O
week	SAPHRIS.xml:S1:4944:4	week	NN	O	O
flexible	SAPHRIS.xml:S1:4949:8	flexibl	JJ	O	O
-	SAPHRIS.xml:S1:4957:1	-	:	O	O
dose	SAPHRIS.xml:S1:4958:4	dose	JJ	O	O
trial	SAPHRIS.xml:S1:4963:5	trial	NN	O	O
)	SAPHRIS.xml:S1:4968:1	)	)	O	O
in	SAPHRIS.xml:S1:4970:2	in	IN	O	O
which	SAPHRIS.xml:S1:4973:5	which	WDT	O	O
sublingual	SAPHRIS.xml:S1:4979:10	sublingu	JJ	O	O
SAPHRIS	SAPHRIS.xml:S1:4990:7	saphri	NNP	O	O
was	SAPHRIS.xml:S1:4998:3	wa	VBD	O	O
administered	SAPHRIS.xml:S1:5002:12	administ	VBN	O	O
in	SAPHRIS.xml:S1:5015:2	in	IN	O	O
doses	SAPHRIS.xml:S1:5018:5	dose	NNS	O	O
ranging	SAPHRIS.xml:S1:5024:7	rang	VBG	O	O
from	SAPHRIS.xml:S1:5032:4	from	IN	O	O
5	SAPHRIS.xml:S1:5037:1	5	CD	O	O
to	SAPHRIS.xml:S1:5039:2	to	TO	O	O
10	SAPHRIS.xml:S1:5042:2	10	CD	O	O
mg	SAPHRIS.xml:S1:5045:2	mg	NNS	O	O
twice	SAPHRIS.xml:S1:5048:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:5054:5	daili	RB	O	O
.	SAPHRIS.xml:S1:5059:1	.	.	O	O

Adverse	SAPHRIS.xml:S1:5069:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:5077:9	reaction	NNP	O	O
Associated	SAPHRIS.xml:S1:5087:10	associ	NNP	O	O
with	SAPHRIS.xml:S1:5098:4	with	IN	O	O
Discontinuation	SAPHRIS.xml:S1:5103:15	discontinu	NNP	O	O
of	SAPHRIS.xml:S1:5119:2	of	IN	O	O
Treatment	SAPHRIS.xml:S1:5122:9	treatment	NNP	O	O
:	SAPHRIS.xml:S1:5131:1	:	:	O	O
A	SAPHRIS.xml:S1:5134:1	A	DT	O	O
total	SAPHRIS.xml:S1:5136:5	total	NN	O	O
of	SAPHRIS.xml:S1:5142:2	of	IN	O	O
9%	SAPHRIS.xml:S1:5145:2	9%	CD	O	O
of	SAPHRIS.xml:S1:5148:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:5151:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:5158:1	-	:	O	O
treated	SAPHRIS.xml:S1:5159:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:5167:8	patient	NNS	O	O
and	SAPHRIS.xml:S1:5176:3	and	CC	O	O
10%	SAPHRIS.xml:S1:5180:3	10%	CD	O	O
of	SAPHRIS.xml:S1:5184:2	of	IN	O	O
placebo	SAPHRIS.xml:S1:5187:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:5194:1	-	:	O	O
treated	SAPHRIS.xml:S1:5195:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:5203:8	patient	NNS	O	O
discontinued	SAPHRIS.xml:S1:5212:12	discontinu	VBN	O	O
due	SAPHRIS.xml:S1:5225:3	due	JJ	O	O
to	SAPHRIS.xml:S1:5229:2	to	TO	O	O
adverse	SAPHRIS.xml:S1:5232:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:5240:9	reaction	NNS	O	O
.	SAPHRIS.xml:S1:5249:1	.	.	O	O

There	SAPHRIS.xml:S1:5251:5	there	EX	O	O
were	SAPHRIS.xml:S1:5257:4	were	VBD	O	O
no	SAPHRIS.xml:S1:5262:2	no	DT	O	O
drug	SAPHRIS.xml:S1:5265:4	drug	NN	O	O
-	SAPHRIS.xml:S1:5269:1	-	:	O	O
related	SAPHRIS.xml:S1:5270:7	relat	JJ	O	O
adverse	SAPHRIS.xml:S1:5278:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:5286:9	reaction	NNS	O	O
associated	SAPHRIS.xml:S1:5296:10	associ	VBN	O	O
with	SAPHRIS.xml:S1:5307:4	with	IN	O	O
discontinuation	SAPHRIS.xml:S1:5312:15	discontinu	NN	O	O
in	SAPHRIS.xml:S1:5328:2	in	IN	O	O
patients	SAPHRIS.xml:S1:5331:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:5340:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:5348:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:5353:7	saphri	NNP	O	O
at	SAPHRIS.xml:S1:5361:2	at	IN	O	O
the	SAPHRIS.xml:S1:5364:3	the	DT	O	O
rate	SAPHRIS.xml:S1:5368:4	rate	NN	O	O
of	SAPHRIS.xml:S1:5373:2	of	IN	O	O
at	SAPHRIS.xml:S1:5376:2	at	IN	O	O
least	SAPHRIS.xml:S1:5379:5	least	JJS	O	O
1%	SAPHRIS.xml:S1:5385:2	1%	CD	O	O
and	SAPHRIS.xml:S1:5388:3	and	CC	O	O
at	SAPHRIS.xml:S1:5392:2	at	IN	O	O
least	SAPHRIS.xml:S1:5395:5	least	JJS	O	O
twice	SAPHRIS.xml:S1:5401:5	twice	RB	O	O
the	SAPHRIS.xml:S1:5407:3	the	DT	O	O
placebo	SAPHRIS.xml:S1:5411:7	placebo	NN	O	O
rate	SAPHRIS.xml:S1:5419:4	rate	NN	O	O
.	SAPHRIS.xml:S1:5423:1	.	.	O	O

Adverse	SAPHRIS.xml:S1:5433:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:5441:9	reaction	NNP	O	O
Occurring	SAPHRIS.xml:S1:5451:9	occur	NNP	O	O
at	SAPHRIS.xml:S1:5461:2	at	IN	O	O
an	SAPHRIS.xml:S1:5464:2	an	DT	O	O
Incidence	SAPHRIS.xml:S1:5467:9	incid	NN	O	O
of	SAPHRIS.xml:S1:5477:2	of	IN	O	O
2%	SAPHRIS.xml:S1:5480:2	2%	CD	O	O
or	SAPHRIS.xml:S1:5483:2	or	CC	O	O
More	SAPHRIS.xml:S1:5486:4	more	JJR	O	O
in	SAPHRIS.xml:S1:5491:2	in	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:5494:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:5501:1	-	:	O	O
Treated	SAPHRIS.xml:S1:5502:7	treat	VBD	O	O
Patients	SAPHRIS.xml:S1:5510:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:5519:4	with	IN	O	O
Schizophrenia	SAPHRIS.xml:S1:5524:13	schizophrenia	NNP	O	O
:	SAPHRIS.xml:S1:5537:1	:	:	O	O
Adverse	SAPHRIS.xml:S1:5540:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:5548:9	reaction	NNS	O	O
associated	SAPHRIS.xml:S1:5558:10	associ	VBN	O	O
with	SAPHRIS.xml:S1:5569:4	with	IN	O	O
the	SAPHRIS.xml:S1:5574:3	the	DT	O	O
use	SAPHRIS.xml:S1:5578:3	use	NN	O	O
of	SAPHRIS.xml:S1:5582:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:5585:7	saphri	NNP	O	O
(	SAPHRIS.xml:S1:5593:1	(	(	O	O
incidence	SAPHRIS.xml:S1:5594:9	incid	NN	O	O
of	SAPHRIS.xml:S1:5604:2	of	IN	O	O
2%	SAPHRIS.xml:S1:5607:2	2%	CD	O	O
or	SAPHRIS.xml:S1:5610:2	or	CC	O	O
greater	SAPHRIS.xml:S1:5613:7	greater	JJR	O	O
,	SAPHRIS.xml:S1:5620:1	,	,	O	O
rounded	SAPHRIS.xml:S1:5622:7	round	VBD	O	O
to	SAPHRIS.xml:S1:5630:2	to	TO	O	O
the	SAPHRIS.xml:S1:5633:3	the	DT	O	O
nearest	SAPHRIS.xml:S1:5637:7	nearest	JJS	O	O
percent	SAPHRIS.xml:S1:5645:7	percent	NN	O	O
,	SAPHRIS.xml:S1:5652:1	,	,	O	O
and	SAPHRIS.xml:S1:5654:3	and	CC	O	O
SAPHRIS	SAPHRIS.xml:S1:5658:7	saphri	NNP	O	O
incidence	SAPHRIS.xml:S1:5666:9	incid	NN	O	O
greater	SAPHRIS.xml:S1:5676:7	greater	JJR	O	O
than	SAPHRIS.xml:S1:5684:4	than	IN	O	O
placebo	SAPHRIS.xml:S1:5689:7	placebo	NN	O	O
)	SAPHRIS.xml:S1:5696:1	)	)	O	O
that	SAPHRIS.xml:S1:5698:4	that	WDT	O	O
occurred	SAPHRIS.xml:S1:5703:8	occur	VBD	O	O
during	SAPHRIS.xml:S1:5712:6	dure	IN	O	O
acute	SAPHRIS.xml:S1:5719:5	acut	NN	O	O
therapy	SAPHRIS.xml:S1:5725:7	therapi	NN	O	O
(	SAPHRIS.xml:S1:5733:1	(	(	O	O
up	SAPHRIS.xml:S1:5734:2	up	IN	O	O
to	SAPHRIS.xml:S1:5737:2	to	TO	O	O
6	SAPHRIS.xml:S1:5740:1	6	CD	O	O
-	SAPHRIS.xml:S1:5741:1	-	:	O	O
weeks	SAPHRIS.xml:S1:5742:5	week	NNS	O	O
in	SAPHRIS.xml:S1:5748:2	in	IN	O	O
patients	SAPHRIS.xml:S1:5751:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:5760:4	with	IN	O	O
schizophrenia	SAPHRIS.xml:S1:5765:13	schizophrenia	NN	O	O
)	SAPHRIS.xml:S1:5778:1	)	)	O	O
are	SAPHRIS.xml:S1:5780:3	are	VBP	O	O
shown	SAPHRIS.xml:S1:5784:5	shown	VBN	O	O
in	SAPHRIS.xml:S1:5790:2	in	IN	O	O
Table	SAPHRIS.xml:S1:5794:5	tabl	JJ	O	O
8	SAPHRIS.xml:S1:5800:1	8	CD	O	O
.	SAPHRIS.xml:S1:5803:1	.	.	O	O

Table	SAPHRIS.xml:S1:5809:5	tabl	JJ	O	O
8	SAPHRIS.xml:S1:5815:1	8	CD	O	O
:	SAPHRIS.xml:S1:5816:1	:	:	O	O
Adverse	SAPHRIS.xml:S1:5818:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:5826:9	reaction	NNP	O	O
Reported	SAPHRIS.xml:S1:5836:8	report	VBD	O	O
in	SAPHRIS.xml:S1:5845:2	in	IN	O	O
2%	SAPHRIS.xml:S1:5848:2	2%	CD	O	O
or	SAPHRIS.xml:S1:5851:2	or	CC	O	O
More	SAPHRIS.xml:S1:5854:4	more	JJR	O	O
of	SAPHRIS.xml:S1:5859:2	of	IN	O	O
Adult	SAPHRIS.xml:S1:5862:5	adult	NNP	O	O
Patients	SAPHRIS.xml:S1:5868:8	patient	NNPS	O	O
in	SAPHRIS.xml:S1:5877:2	in	IN	O	O
Any	SAPHRIS.xml:S1:5880:3	ani	NNP	O	O
SAPHRIS	SAPHRIS.xml:S1:5884:7	saphri	NNP	O	O
Dose	SAPHRIS.xml:S1:5892:4	dose	NNP	O	O
Group	SAPHRIS.xml:S1:5897:5	group	NNP	O	O
and	SAPHRIS.xml:S1:5903:3	and	CC	O	O
Which	SAPHRIS.xml:S1:5907:5	which	NNP	O	O
Occurred	SAPHRIS.xml:S1:5913:8	occur	VBD	O	O
at	SAPHRIS.xml:S1:5922:2	at	IN	O	O
Greater	SAPHRIS.xml:S1:5925:7	greater	NNP	O	O
Incidence	SAPHRIS.xml:S1:5933:9	incid	NNP	O	O
Than	SAPHRIS.xml:S1:5943:4	than	NNP	O	O
in	SAPHRIS.xml:S1:5948:2	in	IN	O	O
the	SAPHRIS.xml:S1:5951:3	the	DT	O	O
Placebo	SAPHRIS.xml:S1:5955:7	placebo	NNP	O	O
Group	SAPHRIS.xml:S1:5963:5	group	NNP	O	O
in	SAPHRIS.xml:S1:5969:2	in	IN	O	O
6	SAPHRIS.xml:S1:5972:1	6	CD	O	O
-	SAPHRIS.xml:S1:5973:1	-	:	O	O
Week	SAPHRIS.xml:S1:5974:4	week	NN	O	O
Schizophrenia	SAPHRIS.xml:S1:5979:13	schizophrenia	NNP	O	O
Trials	SAPHRIS.xml:S1:5993:6	trial	NNS	O	O

Akathisia	SAPHRIS.xml:S1:6005:9	akathisia	NNP	B-AdverseReaction	O
includes	SAPHRIS.xml:S1:6015:8	includ	VBZ	O	O
:	SAPHRIS.xml:S1:6023:1	:	:	O	O
akathisia	SAPHRIS.xml:S1:6025:9	akathisia	NN	B-AdverseReaction	O
and	SAPHRIS.xml:S1:6035:3	and	CC	O	O
hyperkinesia	SAPHRIS.xml:S1:6039:12	hyperkinesia	NN	B-AdverseReaction	O
.	SAPHRIS.xml:S1:6051:1	.	.	O	O

Extrapyramidal	SAPHRIS.xml:S1:6060:14	extrapyramid	NNP	B-AdverseReaction	O
symptoms	SAPHRIS.xml:S1:6075:8	symptom	NNS	I-AdverseReaction	O
included	SAPHRIS.xml:S1:6084:8	includ	VBD	O	O
dystonia	SAPHRIS.xml:S1:6093:8	dystonia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:6101:1	,	,	O	O
oculogyration	SAPHRIS.xml:S1:6103:13	oculogyr	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:6116:1	,	,	O	O
dyskinesia	SAPHRIS.xml:S1:6118:10	dyskinesia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:6128:1	,	,	O	O
tardive	SAPHRIS.xml:S1:6130:7	tardiv	JJ	B-AdverseReaction	O
dyskinesia	SAPHRIS.xml:S1:6138:10	dyskinesia	NN	I-AdverseReaction	O
,	SAPHRIS.xml:S1:6148:1	,	,	O	O
muscle	SAPHRIS.xml:S1:6150:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
rigidity	SAPHRIS.xml:S1:6157:8	rigid	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:6165:1	,	,	O	O
parkinsonism	SAPHRIS.xml:S1:6167:12	parkinson	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:6179:1	,	,	O	O
tremor	SAPHRIS.xml:S1:6181:6	tremor	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:6187:1	,	,	O	O
and	SAPHRIS.xml:S1:6189:3	and	CC	O	O
extrapyramidal	SAPHRIS.xml:S1:6193:14	extrapyramid	JJ	B-AdverseReaction	B-AdverseReaction
disorder	SAPHRIS.xml:S1:6208:8	disord	NN	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S1:6217:1	(	(	O	O
excluding	SAPHRIS.xml:S1:6218:9	exclud	VBG	O	O
akathisia	SAPHRIS.xml:S1:6228:9	akathisia	NN	B-AdverseReaction	O
)	SAPHRIS.xml:S1:6237:1	)	)	O	O
.	SAPHRIS.xml:S1:6238:1	.	.	O	O

?	SAPHRIS.xml:S1:6246:1	?	.	O	O

Somnolence	SAPHRIS.xml:S1:6248:10	somnol	NNP	B-AdverseReaction	B-AdverseReaction
includes	SAPHRIS.xml:S1:6259:8	includ	VBZ	O	O
the	SAPHRIS.xml:S1:6268:3	the	DT	O	O
following	SAPHRIS.xml:S1:6272:9	follow	JJ	O	O
events	SAPHRIS.xml:S1:6282:6	event	NNS	O	O
:	SAPHRIS.xml:S1:6288:1	:	:	O	O
somnolence	SAPHRIS.xml:S1:6290:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:6300:1	,	,	O	O
sedation	SAPHRIS.xml:S1:6302:8	sedat	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:6310:1	,	,	O	O
and	SAPHRIS.xml:S1:6312:3	and	CC	O	O
hypersomnia	SAPHRIS.xml:S1:6316:11	hypersomnia	NN	B-AdverseReaction	O
.	SAPHRIS.xml:S1:6327:1	.	.	O	O

S	SAPHRIS.xml:S1:6335:1	S	NNP	O	O
Also	SAPHRIS.xml:S1:6337:4	also	RB	O	O
includes	SAPHRIS.xml:S1:6342:8	includ	VBZ	O	O
the	SAPHRIS.xml:S1:6351:3	the	DT	O	O
Flexible	SAPHRIS.xml:S1:6355:8	flexibl	JJ	O	O
-	SAPHRIS.xml:S1:6363:1	-	:	O	O
dose	SAPHRIS.xml:S1:6364:4	dose	JJ	O	O
trial	SAPHRIS.xml:S1:6369:5	trial	NN	O	O
(	SAPHRIS.xml:S1:6375:1	(	(	O	O
N	SAPHRIS.xml:S1:6376:1	N	NNP	O	O
90	SAPHRIS.xml:S1:6378:2	90	CD	O	O
)	SAPHRIS.xml:S1:6380:1	)	)	O	O
.	SAPHRIS.xml:S1:6381:1	.	.	O	O

System	SAPHRIS.xml:S1:6393:6	system	NN	O	O

Organ	SAPHRIS.xml:S1:6400:5	organ	NNP	O	O
Class	SAPHRIS.xml:S1:6406:5	class	NNP	O	O
Preferred	SAPHRIS.xml:S1:6413:9	prefer	NNP	O	O
Term	SAPHRIS.xml:S1:6423:4	term	NNP	O	O
Placebo	SAPHRIS.xml:S1:6433:7	placebo	NNP	O	O
N	SAPHRIS.xml:S1:6444:1	N	NNP	O	O
378	SAPHRIS.xml:S1:6446:3	378	CD	O	O
SAPHRIS	SAPHRIS.xml:S1:6460:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:6468:1	5	CD	O	O
mg	SAPHRIS.xml:S1:6470:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:6473:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:6479:5	daili	RB	O	O
N	SAPHRIS.xml:S1:6488:1	N	NNP	O	O
274	SAPHRIS.xml:S1:6490:3	274	CD	O	O
SAPHRIS	SAPHRIS.xml:S1:6504:7	saphri	NNP	O	O
10	SAPHRIS.xml:S1:6512:2	10	CD	O	O
mg	SAPHRIS.xml:S1:6515:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:6518:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:6524:5	daili	RB	O	O
N	SAPHRIS.xml:S1:6533:1	N	NNP	O	O
208	SAPHRIS.xml:S1:6535:3	208	CD	O	O
All	SAPHRIS.xml:S1:6549:3	all	NNP	O	O
SAPHRIS	SAPHRIS.xml:S1:6553:7	saphri	NNP	O	O
S	SAPHRIS.xml:S1:6564:1	S	NNP	O	O
5	SAPHRIS.xml:S1:6569:1	5	CD	O	O
mg	SAPHRIS.xml:S1:6571:2	mg	NN	O	O
or	SAPHRIS.xml:S1:6574:2	or	CC	O	O
10	SAPHRIS.xml:S1:6580:2	10	CD	O	O
mg	SAPHRIS.xml:S1:6583:2	mg	JJ	O	O
twice	SAPHRIS.xml:S1:6586:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:6592:5	daili	RB	O	O
N	SAPHRIS.xml:S1:6601:1	N	NNP	O	O
572	SAPHRIS.xml:S1:6603:3	572	CD	O	O

Gastrointestinal	SAPHRIS.xml:S1:6620:16	gastrointestin	JJ	O	O
disorders	SAPHRIS.xml:S1:6637:9	disord	NNS	O	O

Constipation	SAPHRIS.xml:S1:6734:12	constip	NN	B-AdverseReaction	B-AdverseReaction
6	SAPHRIS.xml:S1:6769:1	6	CD	O	O
7	SAPHRIS.xml:S1:6785:1	7	CD	O	O
4	SAPHRIS.xml:S1:6800:1	4	CD	O	O
5	SAPHRIS.xml:S1:6817:1	5	CD	O	O

Dry	SAPHRIS.xml:S1:6845:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
mouth	SAPHRIS.xml:S1:6849:5	mouth	VBD	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:6880:1	1	CD	O	O
3	SAPHRIS.xml:S1:6896:1	3	CD	O	O
1	SAPHRIS.xml:S1:6911:1	1	CD	O	O
2	SAPHRIS.xml:S1:6928:1	2	CD	O	O

Oral	SAPHRIS.xml:S1:6956:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:6961:12	hypoesthesia	NN	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:6991:1	1	CD	O	O
6	SAPHRIS.xml:S1:7007:1	6	CD	O	O
7	SAPHRIS.xml:S1:7022:1	7	CD	O	O
5	SAPHRIS.xml:S1:7039:1	5	CD	O	O

Salivary	SAPHRIS.xml:S1:7067:8	salivari	JJ	B-AdverseReaction	B-AdverseReaction
hypersecretion	SAPHRIS.xml:S1:7076:14	hypersecret	NN	I-AdverseReaction	I-AdverseReaction
0	SAPHRIS.xml:S1:7102:1	0	CD	O	O
1	SAPHRIS.xml:S1:7119:1	1	CD	O	O
4	SAPHRIS.xml:S1:7133:1	4	CD	O	O
2	SAPHRIS.xml:S1:7150:1	2	CD	O	O

Stomach	SAPHRIS.xml:S1:7178:7	stomach	NNP	B-AdverseReaction	B-AdverseReaction
discomfort	SAPHRIS.xml:S1:7186:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:7213:1	1	CD	O	O
1	SAPHRIS.xml:S1:7230:1	1	CD	O	O
3	SAPHRIS.xml:S1:7244:1	3	CD	O	O
2	SAPHRIS.xml:S1:7261:1	2	CD	O	O

Vomiting	SAPHRIS.xml:S1:7289:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
5	SAPHRIS.xml:S1:7324:1	5	CD	O	O
4	SAPHRIS.xml:S1:7340:1	4	CD	O	O
7	SAPHRIS.xml:S1:7355:1	7	CD	O	O
5	SAPHRIS.xml:S1:7372:1	5	CD	O	O

General	SAPHRIS.xml:S1:7397:7	gener	NNP	O	O
disorders	SAPHRIS.xml:S1:7405:9	disord	NNS	O	O

Fatigue	SAPHRIS.xml:S1:7511:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
3	SAPHRIS.xml:S1:7546:1	3	CD	O	O
4	SAPHRIS.xml:S1:7562:1	4	CD	O	O
3	SAPHRIS.xml:S1:7577:1	3	CD	O	O
3	SAPHRIS.xml:S1:7594:1	3	CD	O	O

Irritability	SAPHRIS.xml:S1:7622:12	irrit	NNP	B-AdverseReaction	B-AdverseReaction
1	SAPHRIS.xml:S1:7658:1	1	CD	O	O
2	SAPHRIS.xml:S1:7673:1	2	CD	O	O
1	SAPHRIS.xml:S1:7688:1	1	CD	O	O
2	SAPHRIS.xml:S1:7705:1	2	CD	O	O

Investigations	SAPHRIS.xml:S1:7730:14	investig	NNS	O	O

Increased	SAPHRIS.xml:S1:7844:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
weight	SAPHRIS.xml:S1:7854:6	weight	VBD	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:7880:1	1	CD	O	O
2	SAPHRIS.xml:S1:7895:1	2	CD	O	O
2	SAPHRIS.xml:S1:7910:1	2	CD	O	O
3	SAPHRIS.xml:S1:7927:1	3	CD	O	O

Metabolism	SAPHRIS.xml:S1:7952:10	metabol	NN	O	O
disorders	SAPHRIS.xml:S1:7963:9	disord	NNS	O	O

Increased	SAPHRIS.xml:S1:8066:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	SAPHRIS.xml:S1:8076:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:8102:1	1	CD	O	O
3	SAPHRIS.xml:S1:8117:1	3	CD	O	O
0	SAPHRIS.xml:S1:8132:1	0	CD	O	O
2	SAPHRIS.xml:S1:8149:1	2	CD	O	O

Nervous	SAPHRIS.xml:S1:8174:7	nervou	JJ	O	O
system	SAPHRIS.xml:S1:8182:6	system	NN	O	O
disorders	SAPHRIS.xml:S1:8189:9	disord	NNS	O	O

Akathisia	SAPHRIS.xml:S1:8288:9	akathisia	$	B-AdverseReaction	B-AdverseReaction
3	SAPHRIS.xml:S1:8323:1	3	CD	O	O
4	SAPHRIS.xml:S1:8339:1	4	CD	O	O
11	SAPHRIS.xml:S1:8354:2	11	CD	O	O
6	SAPHRIS.xml:S1:8371:1	6	CD	O	O

Dizziness	SAPHRIS.xml:S1:8399:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
4	SAPHRIS.xml:S1:8434:1	4	CD	O	O
7	SAPHRIS.xml:S1:8450:1	7	CD	O	O
3	SAPHRIS.xml:S1:8465:1	3	CD	O	O
5	SAPHRIS.xml:S1:8482:1	5	CD	O	O

Extrapyramidal	SAPHRIS.xml:S1:8510:14	extrapyramid	NNP	B-AdverseReaction	O
symptoms	SAPHRIS.xml:S1:8525:8	symptom	NNS	I-AdverseReaction	O
(	SAPHRIS.xml:S1:8534:1	(	(	O	O
excluding	SAPHRIS.xml:S1:8535:9	exclud	VBG	O	O
akathisia	SAPHRIS.xml:S1:8545:9	akathisia	NN	B-AdverseReaction	O
)	SAPHRIS.xml:S1:8554:1	)	)	O	O
7	SAPHRIS.xml:S1:8561:1	7	CD	O	O
9	SAPHRIS.xml:S1:8577:1	9	CD	O	O
12	SAPHRIS.xml:S1:8592:2	12	CD	O	O
10	SAPHRIS.xml:S1:8609:2	10	CD	O	O

Somnolence	SAPHRIS.xml:S1:8637:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
?	SAPHRIS.xml:S1:8649:1	?	.	O	O

7	SAPHRIS.xml:S1:8672:1	7	CD	O	O
15	SAPHRIS.xml:S1:8688:2	15	CD	O	O
13	SAPHRIS.xml:S1:8703:2	13	CD	O	O
13	SAPHRIS.xml:S1:8720:2	13	CD	O	O

Psychiatric	SAPHRIS.xml:S1:8745:11	psychiatr	JJ	O	O
disorders	SAPHRIS.xml:S1:8757:9	disord	NNS	O	O

Insomnia	SAPHRIS.xml:S1:8859:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
13	SAPHRIS.xml:S1:8894:2	13	CD	O	O
16	SAPHRIS.xml:S1:8910:2	16	CD	O	O
15	SAPHRIS.xml:S1:8925:2	15	CD	O	O
15	SAPHRIS.xml:S1:8942:2	15	CD	O	O

Vascular	SAPHRIS.xml:S1:8967:8	vascular	JJ	O	O
disorders	SAPHRIS.xml:S1:8976:9	disord	NNS	O	O

Hypertension	SAPHRIS.xml:S1:9081:12	hypertens	NNP	B-AdverseReaction	B-AdverseReaction
2	SAPHRIS.xml:S1:9116:1	2	CD	O	O
2	SAPHRIS.xml:S1:9132:1	2	CD	O	O
3	SAPHRIS.xml:S1:9147:1	3	CD	O	O
2	SAPHRIS.xml:S1:9164:1	2	CD	O	O

Dose	SAPHRIS.xml:S1:9201:4	dose	NNP	O	O
-	SAPHRIS.xml:S1:9205:1	-	:	O	O
Related	SAPHRIS.xml:S1:9206:7	relat	JJ	O	O
Adverse	SAPHRIS.xml:S1:9214:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:9222:9	reaction	NNS	O	O
:	SAPHRIS.xml:S1:9231:1	:	:	O	O
In	SAPHRIS.xml:S1:9234:2	In	IN	O	O
the	SAPHRIS.xml:S1:9237:3	the	DT	O	O
short	SAPHRIS.xml:S1:9241:5	short	JJ	O	O
term	SAPHRIS.xml:S1:9247:4	term	NN	O	O
schizophrenia	SAPHRIS.xml:S1:9252:13	schizophrenia	NN	O	O
trials	SAPHRIS.xml:S1:9266:6	trial	VBZ	O	O
the	SAPHRIS.xml:S1:9273:3	the	DT	O	O
incidence	SAPHRIS.xml:S1:9277:9	incid	NN	O	O
of	SAPHRIS.xml:S1:9287:2	of	IN	O	O
akathisia	SAPHRIS.xml:S1:9290:9	akathisia	NN	B-AdverseReaction	B-AdverseReaction
appeared	SAPHRIS.xml:S1:9300:8	appear	VBD	O	O
to	SAPHRIS.xml:S1:9309:2	to	TO	O	O
be	SAPHRIS.xml:S1:9312:2	be	VB	O	O
dose	SAPHRIS.xml:S1:9315:4	dose	JJ	O	O
-	SAPHRIS.xml:S1:9319:1	-	:	O	O
related	SAPHRIS.xml:S1:9320:7	relat	VBN	O	O
(	SAPHRIS.xml:S1:9328:1	(	(	O	O
seeTable	SAPHRIS.xml:S1:9329:8	seetabl	JJ	O	O
8	SAPHRIS.xml:S1:9338:1	8	CD	O	O
)	SAPHRIS.xml:S1:9339:1	)	)	O	O
.	SAPHRIS.xml:S1:9340:1	.	.	O	O

Monotherapy	SAPHRIS.xml:S1:9350:11	monotherapi	NN	O	O

in	SAPHRIS.xml:S1:9362:2	in	IN	O	O
Adult	SAPHRIS.xml:S1:9365:5	adult	NNP	O	O
Patients	SAPHRIS.xml:S1:9371:8	patient	NNPS	O	O
with	SAPHRIS.xml:S1:9380:4	with	IN	O	O
Bipolar	SAPHRIS.xml:S1:9385:7	bipolar	NNP	O	O
Mania	SAPHRIS.xml:S1:9393:5	mania	NNP	O	O
:	SAPHRIS.xml:S1:9398:1	:	:	O	O
The	SAPHRIS.xml:S1:9401:3	the	DT	O	O
following	SAPHRIS.xml:S1:9405:9	follow	JJ	O	O
findings	SAPHRIS.xml:S1:9415:8	find	NNS	O	O
are	SAPHRIS.xml:S1:9424:3	are	VBP	O	O
based	SAPHRIS.xml:S1:9428:5	base	VBN	O	O
on	SAPHRIS.xml:S1:9434:2	on	IN	O	O
the	SAPHRIS.xml:S1:9437:3	the	DT	O	O
short	SAPHRIS.xml:S1:9441:5	short	JJ	O	O
-	SAPHRIS.xml:S1:9446:1	-	:	O	O
term	SAPHRIS.xml:S1:9447:4	term	NN	O	O
placebo	SAPHRIS.xml:S1:9452:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:9459:1	-	:	O	O
controlled	SAPHRIS.xml:S1:9460:10	control	VBN	O	O
trials	SAPHRIS.xml:S1:9471:6	trial	NNS	O	O
for	SAPHRIS.xml:S1:9478:3	for	IN	O	O
bipolar	SAPHRIS.xml:S1:9482:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S1:9490:5	mania	NN	O	O
(	SAPHRIS.xml:S1:9496:1	(	(	O	O
a	SAPHRIS.xml:S1:9497:1	a	DT	O	O
pool	SAPHRIS.xml:S1:9499:4	pool	NN	O	O
of	SAPHRIS.xml:S1:9504:2	of	IN	O	O
two	SAPHRIS.xml:S1:9507:3	two	CD	O	O
3	SAPHRIS.xml:S1:9511:1	3	CD	O	O
-	SAPHRIS.xml:S1:9512:1	-	:	O	O
week	SAPHRIS.xml:S1:9513:4	week	NN	O	O
flexible	SAPHRIS.xml:S1:9518:8	flexibl	JJ	O	O
-	SAPHRIS.xml:S1:9526:1	-	:	O	O
dose	SAPHRIS.xml:S1:9527:4	dose	JJ	O	O
trials	SAPHRIS.xml:S1:9532:6	trial	NNS	O	O
)	SAPHRIS.xml:S1:9538:1	)	)	O	O
in	SAPHRIS.xml:S1:9540:2	in	IN	O	O
which	SAPHRIS.xml:S1:9543:5	which	WDT	O	O
sublingual	SAPHRIS.xml:S1:9549:10	sublingu	JJ	O	O
SAPHRIS	SAPHRIS.xml:S1:9560:7	saphri	NNP	O	O
was	SAPHRIS.xml:S1:9568:3	wa	VBD	O	O
administered	SAPHRIS.xml:S1:9572:12	administ	VBN	O	O
in	SAPHRIS.xml:S1:9585:2	in	IN	O	O
doses	SAPHRIS.xml:S1:9588:5	dose	NNS	O	O
of	SAPHRIS.xml:S1:9594:2	of	IN	O	O
5	SAPHRIS.xml:S1:9597:1	5	CD	O	O
mg	SAPHRIS.xml:S1:9599:2	mg	NNS	O	O
or	SAPHRIS.xml:S1:9602:2	or	CC	O	O
10	SAPHRIS.xml:S1:9605:2	10	CD	O	O
mg	SAPHRIS.xml:S1:9608:2	mg	JJ	O	O
twice	SAPHRIS.xml:S1:9611:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:9617:5	daili	RB	O	O
.	SAPHRIS.xml:S1:9622:1	.	.	O	O

Adverse	SAPHRIS.xml:S1:9632:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:9640:9	reaction	NNP	O	O
Associated	SAPHRIS.xml:S1:9650:10	associ	NNP	O	O
with	SAPHRIS.xml:S1:9661:4	with	IN	O	O
Discontinuation	SAPHRIS.xml:S1:9666:15	discontinu	NNP	O	O
of	SAPHRIS.xml:S1:9682:2	of	IN	O	O
Treatment	SAPHRIS.xml:S1:9685:9	treatment	NNP	O	O
:	SAPHRIS.xml:S1:9694:1	:	:	O	O
Approximately	SAPHRIS.xml:S1:9697:13	approxim	RB	O	O
10%	SAPHRIS.xml:S1:9711:3	10%	CD	O	O
(	SAPHRIS.xml:S1:9715:1	(	(	O	O
38	SAPHRIS.xml:S1:9716:2	38	CD	O	O
379	SAPHRIS.xml:S1:9719:3	379	CD	O	O
)	SAPHRIS.xml:S1:9722:1	)	)	O	O
of	SAPHRIS.xml:S1:9724:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:9727:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:9734:1	-	:	O	O
treated	SAPHRIS.xml:S1:9735:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:9743:8	patient	NNS	O	O
in	SAPHRIS.xml:S1:9752:2	in	IN	O	O
short	SAPHRIS.xml:S1:9755:5	short	JJ	O	O
-	SAPHRIS.xml:S1:9760:1	-	:	O	O
term	SAPHRIS.xml:S1:9761:4	term	NN	O	O
,	SAPHRIS.xml:S1:9765:1	,	,	O	O
placebo	SAPHRIS.xml:S1:9767:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:9774:1	-	:	O	O
controlled	SAPHRIS.xml:S1:9775:10	control	VBN	O	O
trials	SAPHRIS.xml:S1:9786:6	trial	NNS	O	O
discontinued	SAPHRIS.xml:S1:9793:12	discontinu	VBN	O	O
treatment	SAPHRIS.xml:S1:9806:9	treatment	NN	O	O
due	SAPHRIS.xml:S1:9816:3	due	JJ	O	O
to	SAPHRIS.xml:S1:9820:2	to	TO	O	O
an	SAPHRIS.xml:S1:9823:2	an	DT	O	O
adverse	SAPHRIS.xml:S1:9826:7	advers	JJ	O	O
reaction	SAPHRIS.xml:S1:9834:8	reaction	NN	O	O
,	SAPHRIS.xml:S1:9842:1	,	,	O	O
compared	SAPHRIS.xml:S1:9844:8	compar	VBN	O	O
with	SAPHRIS.xml:S1:9853:4	with	IN	O	O
about	SAPHRIS.xml:S1:9858:5	about	RB	O	O
6%	SAPHRIS.xml:S1:9864:2	6%	CD	O	O
(	SAPHRIS.xml:S1:9867:1	(	(	O	O
12	SAPHRIS.xml:S1:9868:2	12	CD	O	O
203	SAPHRIS.xml:S1:9871:3	203	CD	O	O
)	SAPHRIS.xml:S1:9874:1	)	)	O	O
on	SAPHRIS.xml:S1:9876:2	on	IN	O	O
placebo	SAPHRIS.xml:S1:9879:7	placebo	NN	O	O
.	SAPHRIS.xml:S1:9886:1	.	.	O	O

The	SAPHRIS.xml:S1:9888:3	the	DT	O	O
most	SAPHRIS.xml:S1:9892:4	most	RBS	O	O
common	SAPHRIS.xml:S1:9897:6	common	JJ	O	O
adverse	SAPHRIS.xml:S1:9904:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:9912:9	reaction	NNS	O	O
associated	SAPHRIS.xml:S1:9922:10	associ	VBN	O	O
with	SAPHRIS.xml:S1:9933:4	with	IN	O	O
discontinuation	SAPHRIS.xml:S1:9938:15	discontinu	NN	O	O
in	SAPHRIS.xml:S1:9954:2	in	IN	O	O
patients	SAPHRIS.xml:S1:9957:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:9966:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:9974:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:9979:7	saphri	NNP	O	O
(	SAPHRIS.xml:S1:9987:1	(	(	O	O
rates	SAPHRIS.xml:S1:9988:5	rate	NNS	O	O
at	SAPHRIS.xml:S1:9994:2	at	IN	O	O
least	SAPHRIS.xml:S1:9997:5	least	JJS	O	O
1%	SAPHRIS.xml:S1:10003:2	1%	CD	O	O
and	SAPHRIS.xml:S1:10006:3	and	CC	O	O
at	SAPHRIS.xml:S1:10010:2	at	IN	O	O
least	SAPHRIS.xml:S1:10013:5	least	JJS	O	O
twice	SAPHRIS.xml:S1:10019:5	twice	RB	O	O
the	SAPHRIS.xml:S1:10025:3	the	DT	O	O
placebo	SAPHRIS.xml:S1:10029:7	placebo	NN	O	O
rate	SAPHRIS.xml:S1:10037:4	rate	NN	O	O
)	SAPHRIS.xml:S1:10041:1	)	)	O	O
were	SAPHRIS.xml:S1:10043:4	were	VBD	O	O
anxiety	SAPHRIS.xml:S1:10048:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
(	SAPHRIS.xml:S1:10056:1	(	(	O	O
1.1%	SAPHRIS.xml:S1:10057:4	1.1%	CD	O	O
)	SAPHRIS.xml:S1:10061:1	)	)	O	O
and	SAPHRIS.xml:S1:10063:3	and	CC	O	O
oral	SAPHRIS.xml:S1:10067:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:10072:12	hypoesthesia	NN	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S1:10085:1	(	(	O	O
1.1%	SAPHRIS.xml:S1:10086:4	1.1%	CD	O	O
)	SAPHRIS.xml:S1:10090:1	)	)	O	O
compared	SAPHRIS.xml:S1:10092:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:10101:2	to	TO	O	O
placebo	SAPHRIS.xml:S1:10104:7	placebo	VB	O	O
(	SAPHRIS.xml:S1:10112:1	(	(	O	O
0%	SAPHRIS.xml:S1:10113:2	0%	CD	O	O
)	SAPHRIS.xml:S1:10115:1	)	)	O	O
.	SAPHRIS.xml:S1:10116:1	.	.	O	O

Adverse	SAPHRIS.xml:S1:10126:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:10134:9	reaction	NNP	O	O
Occurring	SAPHRIS.xml:S1:10144:9	occur	NNP	O	O
at	SAPHRIS.xml:S1:10154:2	at	IN	O	O
an	SAPHRIS.xml:S1:10157:2	an	DT	O	O
Incidence	SAPHRIS.xml:S1:10160:9	incid	NN	O	O
of	SAPHRIS.xml:S1:10170:2	of	IN	O	O
2%	SAPHRIS.xml:S1:10173:2	2%	CD	O	O
or	SAPHRIS.xml:S1:10176:2	or	CC	O	O
More	SAPHRIS.xml:S1:10179:4	more	JJR	O	O
Among	SAPHRIS.xml:S1:10184:5	among	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:10190:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:10197:1	-	:	O	O
Treated	SAPHRIS.xml:S1:10198:7	treat	VBN	O	O
(	SAPHRIS.xml:S1:10206:1	(	(	O	O
Monotherapy	SAPHRIS.xml:S1:10207:11	monotherapi	NNP	O	O
)	SAPHRIS.xml:S1:10218:1	)	)	O	O
patients	SAPHRIS.xml:S1:10220:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:10229:4	with	IN	O	O
Bipolar	SAPHRIS.xml:S1:10234:7	bipolar	NNP	O	O
I	SAPHRIS.xml:S1:10242:1	I	PRP	O	O
Disorder	SAPHRIS.xml:S1:10244:8	disord	VBP	O	O
:	SAPHRIS.xml:S1:10252:1	:	:	O	O
Adverse	SAPHRIS.xml:S1:10255:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:10263:9	reaction	NNS	O	O
associated	SAPHRIS.xml:S1:10273:10	associ	VBN	O	O
with	SAPHRIS.xml:S1:10284:4	with	IN	O	O
the	SAPHRIS.xml:S1:10289:3	the	DT	O	O
use	SAPHRIS.xml:S1:10293:3	use	NN	O	O
of	SAPHRIS.xml:S1:10297:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:10300:7	saphri	NNP	O	O
(	SAPHRIS.xml:S1:10308:1	(	(	O	O
incidence	SAPHRIS.xml:S1:10309:9	incid	NN	O	O
of	SAPHRIS.xml:S1:10319:2	of	IN	O	O
2%	SAPHRIS.xml:S1:10322:2	2%	CD	O	O
or	SAPHRIS.xml:S1:10325:2	or	CC	O	O
greater	SAPHRIS.xml:S1:10328:7	greater	JJR	O	O
,	SAPHRIS.xml:S1:10335:1	,	,	O	O
rounded	SAPHRIS.xml:S1:10337:7	round	VBD	O	O
to	SAPHRIS.xml:S1:10345:2	to	TO	O	O
the	SAPHRIS.xml:S1:10348:3	the	DT	O	O
nearest	SAPHRIS.xml:S1:10352:7	nearest	JJS	O	O
percent	SAPHRIS.xml:S1:10360:7	percent	NN	O	O
,	SAPHRIS.xml:S1:10367:1	,	,	O	O
and	SAPHRIS.xml:S1:10369:3	and	CC	O	O
SAPHRIS	SAPHRIS.xml:S1:10373:7	saphri	NNP	O	O
incidence	SAPHRIS.xml:S1:10381:9	incid	NN	O	O
greater	SAPHRIS.xml:S1:10391:7	greater	JJR	O	O
than	SAPHRIS.xml:S1:10399:4	than	IN	O	O
placebo	SAPHRIS.xml:S1:10404:7	placebo	NN	O	O
)	SAPHRIS.xml:S1:10411:1	)	)	O	O
that	SAPHRIS.xml:S1:10413:4	that	WDT	O	O
occurred	SAPHRIS.xml:S1:10418:8	occur	VBD	O	O
during	SAPHRIS.xml:S1:10427:6	dure	IN	O	O
acute	SAPHRIS.xml:S1:10434:5	acut	NN	O	O
monotherapy	SAPHRIS.xml:S1:10440:11	monotherapi	NN	O	O
(	SAPHRIS.xml:S1:10452:1	(	(	O	O
up	SAPHRIS.xml:S1:10453:2	up	IN	O	O
to	SAPHRIS.xml:S1:10456:2	to	TO	O	O
3	SAPHRIS.xml:S1:10459:1	3	CD	O	O
-	SAPHRIS.xml:S1:10460:1	-	:	O	O
weeks	SAPHRIS.xml:S1:10461:5	week	NNS	O	O
in	SAPHRIS.xml:S1:10467:2	in	IN	O	O
patients	SAPHRIS.xml:S1:10470:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:10479:4	with	IN	O	O
bipolar	SAPHRIS.xml:S1:10484:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S1:10492:5	mania	NN	O	O
)	SAPHRIS.xml:S1:10497:1	)	)	O	O
are	SAPHRIS.xml:S1:10499:3	are	VBP	O	O
shown	SAPHRIS.xml:S1:10503:5	shown	VBN	O	O
in	SAPHRIS.xml:S1:10509:2	in	IN	O	O
Table	SAPHRIS.xml:S1:10513:5	tabl	JJ	O	O
9	SAPHRIS.xml:S1:10519:1	9	CD	O	O
.	SAPHRIS.xml:S1:10522:1	.	.	O	O

Table	SAPHRIS.xml:S1:10528:5	tabl	JJ	O	O
9	SAPHRIS.xml:S1:10534:1	9	CD	O	O
:	SAPHRIS.xml:S1:10535:1	:	:	O	O
Adverse	SAPHRIS.xml:S1:10537:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:10545:9	reaction	NNP	O	O
Reported	SAPHRIS.xml:S1:10555:8	report	VBD	O	O
in	SAPHRIS.xml:S1:10564:2	in	IN	O	O
2%	SAPHRIS.xml:S1:10567:2	2%	CD	O	O
or	SAPHRIS.xml:S1:10570:2	or	CC	O	O
More	SAPHRIS.xml:S1:10573:4	more	JJR	O	O
of	SAPHRIS.xml:S1:10578:2	of	IN	O	O
Adult	SAPHRIS.xml:S1:10581:5	adult	NNP	O	O
Patients	SAPHRIS.xml:S1:10587:8	patient	NNPS	O	O
in	SAPHRIS.xml:S1:10596:2	in	IN	O	O
Any	SAPHRIS.xml:S1:10599:3	ani	NNP	O	O
SAPHRIS	SAPHRIS.xml:S1:10603:7	saphri	NNP	O	O
Dose	SAPHRIS.xml:S1:10611:4	dose	NNP	O	O
Group	SAPHRIS.xml:S1:10616:5	group	NNP	O	O
and	SAPHRIS.xml:S1:10622:3	and	CC	O	O
Which	SAPHRIS.xml:S1:10626:5	which	NNP	O	O
Occurred	SAPHRIS.xml:S1:10632:8	occur	VBD	O	O
at	SAPHRIS.xml:S1:10641:2	at	IN	O	O
Greater	SAPHRIS.xml:S1:10644:7	greater	NNP	O	O
Incidence	SAPHRIS.xml:S1:10652:9	incid	NNP	O	O
Than	SAPHRIS.xml:S1:10662:4	than	NNP	O	O
in	SAPHRIS.xml:S1:10667:2	in	IN	O	O
the	SAPHRIS.xml:S1:10670:3	the	DT	O	O
Placebo	SAPHRIS.xml:S1:10674:7	placebo	NNP	O	O
Group	SAPHRIS.xml:S1:10682:5	group	NNP	O	O
in	SAPHRIS.xml:S1:10688:2	in	IN	O	O
3	SAPHRIS.xml:S1:10691:1	3	CD	O	O
-	SAPHRIS.xml:S1:10692:1	-	:	O	O
Week	SAPHRIS.xml:S1:10693:4	week	NN	O	O
Bipolar	SAPHRIS.xml:S1:10698:7	bipolar	NNP	O	O
Mania	SAPHRIS.xml:S1:10706:5	mania	NNP	O	O
Trials	SAPHRIS.xml:S1:10712:6	trial	NNP	O	O

SAPHRIS	SAPHRIS.xml:S1:10724:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:10732:1	5	CD	O	O
mg	SAPHRIS.xml:S1:10734:2	mg	NN	O	O
to	SAPHRIS.xml:S1:10737:2	to	TO	O	O
10	SAPHRIS.xml:S1:10740:2	10	CD	O	O
mg	SAPHRIS.xml:S1:10743:2	mg	NNS	O	O
twice	SAPHRIS.xml:S1:10746:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:10752:5	daili	RB	O	O
with	SAPHRIS.xml:S1:10758:4	with	IN	O	O
flexible	SAPHRIS.xml:S1:10763:8	flexibl	JJ	O	O
dosing	SAPHRIS.xml:S1:10772:6	dose	NN	O	O
.	SAPHRIS.xml:S1:10778:1	.	.	O	O

Extrapyramidal	SAPHRIS.xml:S1:10787:14	extrapyramid	NNP	B-AdverseReaction	O
symptoms	SAPHRIS.xml:S1:10802:8	symptom	NNS	I-AdverseReaction	O
included	SAPHRIS.xml:S1:10811:8	includ	VBD	O	O
:	SAPHRIS.xml:S1:10819:1	:	:	O	O
dystonia	SAPHRIS.xml:S1:10821:8	dystonia	NN	B-AdverseReaction	O
,	SAPHRIS.xml:S1:10829:1	,	,	O	O
blepharospasm	SAPHRIS.xml:S1:10831:13	blepharospasm	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:10844:1	,	,	O	O
torticollis	SAPHRIS.xml:S1:10846:11	torticolli	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:10857:1	,	,	O	O
dyskinesia	SAPHRIS.xml:S1:10859:10	dyskinesia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:10869:1	,	,	O	O
tardive	SAPHRIS.xml:S1:10871:7	tardiv	JJ	B-AdverseReaction	O
dyskinesia	SAPHRIS.xml:S1:10879:10	dyskinesia	NN	I-AdverseReaction	O
,	SAPHRIS.xml:S1:10889:1	,	,	O	O
muscle	SAPHRIS.xml:S1:10891:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
rigidity	SAPHRIS.xml:S1:10898:8	rigid	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:10906:1	,	,	O	O
parkinsonism	SAPHRIS.xml:S1:10908:12	parkinson	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:10920:1	,	,	O	O
gait	SAPHRIS.xml:S1:10922:4	gait	NN	B-AdverseReaction	B-AdverseReaction
disturbance	SAPHRIS.xml:S1:10927:11	disturb	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:10938:1	,	,	O	O
masked	SAPHRIS.xml:S1:10940:6	mask	JJ	B-AdverseReaction	B-AdverseReaction
facies	SAPHRIS.xml:S1:10947:6	faci	NNS	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:10953:1	,	,	O	O
and	SAPHRIS.xml:S1:10955:3	and	CC	O	O
tremor	SAPHRIS.xml:S1:10959:6	tremor	NN	B-AdverseReaction	B-AdverseReaction
(	SAPHRIS.xml:S1:10966:1	(	(	O	O
excluding	SAPHRIS.xml:S1:10967:9	exclud	VBG	O	O
akathisia	SAPHRIS.xml:S1:10977:9	akathisia	NN	B-AdverseReaction	O
)	SAPHRIS.xml:S1:10986:1	)	)	O	O
.	SAPHRIS.xml:S1:10987:1	.	.	O	O

?	SAPHRIS.xml:S1:10995:1	?	.	O	O

Somnolence	SAPHRIS.xml:S1:10997:10	somnol	NNP	B-AdverseReaction	B-AdverseReaction
includes	SAPHRIS.xml:S1:11008:8	includ	VBZ	O	O
the	SAPHRIS.xml:S1:11017:3	the	DT	O	O
following	SAPHRIS.xml:S1:11021:9	follow	JJ	O	O
events	SAPHRIS.xml:S1:11031:6	event	NNS	O	O
:	SAPHRIS.xml:S1:11037:1	:	:	O	O
somnolence	SAPHRIS.xml:S1:11039:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:11049:1	,	,	O	O
sedation	SAPHRIS.xml:S1:11051:8	sedat	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:11059:1	,	,	O	O
and	SAPHRIS.xml:S1:11061:3	and	CC	O	O
hypersomnia	SAPHRIS.xml:S1:11065:11	hypersomnia	NN	B-AdverseReaction	O
.	SAPHRIS.xml:S1:11076:1	.	.	O	O

System	SAPHRIS.xml:S1:11088:6	system	NN	O	O

Organ	SAPHRIS.xml:S1:11095:5	organ	NNP	O	O
Class	SAPHRIS.xml:S1:11101:5	class	NNP	O	O
Preferred	SAPHRIS.xml:S1:11107:9	prefer	NNP	O	O
Term	SAPHRIS.xml:S1:11117:4	term	NNP	O	O
Placebo	SAPHRIS.xml:S1:11137:7	placebo	NNP	O	O
N	SAPHRIS.xml:S1:11148:1	N	NNP	O	O
203	SAPHRIS.xml:S1:11150:3	203	CD	O	O
SAPHRIS	SAPHRIS.xml:S1:11164:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:11175:1	5	CD	O	O
mg	SAPHRIS.xml:S1:11177:2	mg	NN	O	O
or	SAPHRIS.xml:S1:11180:2	or	CC	O	O
10	SAPHRIS.xml:S1:11183:2	10	CD	O	O
mg	SAPHRIS.xml:S1:11186:2	mg	JJ	O	O
twice	SAPHRIS.xml:S1:11189:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:11195:5	daili	RB	O	O
N	SAPHRIS.xml:S1:11205:1	N	NNP	O	O
379	SAPHRIS.xml:S1:11207:3	379	CD	O	O

Gastrointestinal	SAPHRIS.xml:S1:11224:16	gastrointestin	JJ	O	O
disorders	SAPHRIS.xml:S1:11241:9	disord	NNS	O	O

Dry	SAPHRIS.xml:S1:11279:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
mouth	SAPHRIS.xml:S1:11283:5	mouth	VBD	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:11323:1	1	CD	O	O
3	SAPHRIS.xml:S1:11346:1	3	CD	O	O

Dyspepsia	SAPHRIS.xml:S1:11386:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
2	SAPHRIS.xml:S1:11430:1	2	CD	O	O
4	SAPHRIS.xml:S1:11453:1	4	CD	O	O

Oral	SAPHRIS.xml:S1:11493:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:11498:12	hypoesthesia	NN	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:11538:1	1	CD	O	O
4	SAPHRIS.xml:S1:11560:1	4	CD	O	O

Toothache	SAPHRIS.xml:S1:11600:9	toothach	NNP	B-AdverseReaction	B-AdverseReaction
2	SAPHRIS.xml:S1:11644:1	2	CD	O	O
3	SAPHRIS.xml:S1:11667:1	3	CD	O	O

General	SAPHRIS.xml:S1:11704:7	gener	NNP	O	O
disorders	SAPHRIS.xml:S1:11712:9	disord	NNS	O	O

Fatigue	SAPHRIS.xml:S1:11759:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
2	SAPHRIS.xml:S1:11803:1	2	CD	O	O
4	SAPHRIS.xml:S1:11826:1	4	CD	O	O

Investigations	SAPHRIS.xml:S1:11863:14	investig	NNS	O	O

Increased	SAPHRIS.xml:S1:11918:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
weight	SAPHRIS.xml:S1:11928:6	weight	VBD	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:11963:1	1	CD	O	O
5	SAPHRIS.xml:S1:11985:1	5	CD	O	O

Metabolism	SAPHRIS.xml:S1:12022:10	metabol	NN	O	O
disorders	SAPHRIS.xml:S1:12033:9	disord	NNS	O	O

Increased	SAPHRIS.xml:S1:12077:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	SAPHRIS.xml:S1:12087:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:12121:1	1	CD	O	O
4	SAPHRIS.xml:S1:12144:1	4	CD	O	O

Musculoskeletal	SAPHRIS.xml:S1:12181:15	musculoskelet	NNP	O	O
and	SAPHRIS.xml:S1:12197:3	and	CC	O	O
connective	SAPHRIS.xml:S1:12201:10	connect	JJ	O	O
tissue	SAPHRIS.xml:S1:12212:6	tissu	NN	O	O
disorders	SAPHRIS.xml:S1:12219:9	disord	NNS	O	O

Arthralgia	SAPHRIS.xml:S1:12240:10	arthralgia	NNP	B-AdverseReaction	B-AdverseReaction
1	SAPHRIS.xml:S1:12284:1	1	CD	O	O
3	SAPHRIS.xml:S1:12307:1	3	CD	O	O

Pain	SAPHRIS.xml:S1:12347:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S1:12352:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	SAPHRIS.xml:S1:12355:9	extrem	NN	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:12392:1	1	CD	O	O
2	SAPHRIS.xml:S1:12414:1	2	CD	O	O

Nervous	SAPHRIS.xml:S1:12451:7	nervou	JJ	O	O
system	SAPHRIS.xml:S1:12459:6	system	NN	O	O
disorders	SAPHRIS.xml:S1:12466:9	disord	NNS	O	O

Akathisia	SAPHRIS.xml:S1:12506:9	akathisia	$	B-AdverseReaction	B-AdverseReaction
2	SAPHRIS.xml:S1:12550:1	2	CD	O	O
4	SAPHRIS.xml:S1:12573:1	4	CD	O	O

Dizziness	SAPHRIS.xml:S1:12613:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
3	SAPHRIS.xml:S1:12657:1	3	CD	O	O
11	SAPHRIS.xml:S1:12680:2	11	CD	O	O

Dysgeusia	SAPHRIS.xml:S1:12720:9	dysgeusia	NNP	B-AdverseReaction	B-AdverseReaction
1	SAPHRIS.xml:S1:12765:1	1	CD	O	O
3	SAPHRIS.xml:S1:12787:1	3	CD	O	O

Headache	SAPHRIS.xml:S1:12827:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
11	SAPHRIS.xml:S1:12871:2	11	CD	O	O
12	SAPHRIS.xml:S1:12894:2	12	CD	O	O

Other	SAPHRIS.xml:S1:12934:5	other	JJ	O	O
extrapyramidal	SAPHRIS.xml:S1:12940:14	extrapyramid	NN	B-AdverseReaction	O
symptoms	SAPHRIS.xml:S1:12955:8	symptom	NNS	I-AdverseReaction	O
(	SAPHRIS.xml:S1:12964:1	(	(	O	O
excluding	SAPHRIS.xml:S1:12965:9	exclud	VBG	O	O
akathisia	SAPHRIS.xml:S1:12975:9	akathisia	NN	B-AdverseReaction	O
)	SAPHRIS.xml:S1:12984:1	)	)	O	O
2	SAPHRIS.xml:S1:12991:1	2	CD	O	O
7	SAPHRIS.xml:S1:13014:1	7	CD	O	O

Somnolence	SAPHRIS.xml:S1:13054:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
?	SAPHRIS.xml:S1:13066:1	?	.	O	O

6	SAPHRIS.xml:S1:13098:1	6	CD	O	O
24	SAPHRIS.xml:S1:13121:2	24	CD	O	O

Psychiatric	SAPHRIS.xml:S1:13158:11	psychiatr	JJ	O	O
disorders	SAPHRIS.xml:S1:13170:9	disord	NNS	O	O

Anxiety	SAPHRIS.xml:S1:13213:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
2	SAPHRIS.xml:S1:13257:1	2	CD	O	O
4	SAPHRIS.xml:S1:13280:1	4	CD	O	O

Depression	SAPHRIS.xml:S1:13320:10	depress	NNP	B-AdverseReaction	B-AdverseReaction
1	SAPHRIS.xml:S1:13364:1	1	CD	O	O
2	SAPHRIS.xml:S1:13387:1	2	CD	O	O

Insomnia	SAPHRIS.xml:S1:13427:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
5	SAPHRIS.xml:S1:13471:1	5	CD	O	O
6	SAPHRIS.xml:S1:13494:1	6	CD	O	O

Monotherapy	SAPHRIS.xml:S1:13541:11	monotherapi	NNP	O	O
in	SAPHRIS.xml:S1:13553:2	in	IN	O	O
Pediatric	SAPHRIS.xml:S1:13556:9	pediatr	NNP	O	O
Patients	SAPHRIS.xml:S1:13566:8	patient	NNPS	O	O
with	SAPHRIS.xml:S1:13575:4	with	IN	O	O
Bipolar	SAPHRIS.xml:S1:13580:7	bipolar	NNP	O	O
Mania	SAPHRIS.xml:S1:13588:5	mania	NNP	O	O
:	SAPHRIS.xml:S1:13593:1	:	:	O	O
The	SAPHRIS.xml:S1:13596:3	the	DT	O	O
following	SAPHRIS.xml:S1:13600:9	follow	JJ	O	O
findings	SAPHRIS.xml:S1:13610:8	find	NNS	O	O
are	SAPHRIS.xml:S1:13619:3	are	VBP	O	O
based	SAPHRIS.xml:S1:13623:5	base	VBN	O	O
on	SAPHRIS.xml:S1:13629:2	on	IN	O	O
a	SAPHRIS.xml:S1:13632:1	a	DT	O	O
3	SAPHRIS.xml:S1:13634:1	3	CD	O	O
-	SAPHRIS.xml:S1:13635:1	-	:	O	O
week	SAPHRIS.xml:S1:13636:4	week	NN	O	O
,	SAPHRIS.xml:S1:13641:1	,	,	O	O
placebo	SAPHRIS.xml:S1:13643:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:13650:1	-	:	O	O
controlled	SAPHRIS.xml:S1:13651:10	control	VBN	O	O
trial	SAPHRIS.xml:S1:13662:5	trial	NN	O	O
for	SAPHRIS.xml:S1:13668:3	for	IN	O	O
bipolar	SAPHRIS.xml:S1:13672:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S1:13680:5	mania	NN	O	O
in	SAPHRIS.xml:S1:13686:2	in	IN	O	O
which	SAPHRIS.xml:S1:13689:5	which	WDT	O	O
SAPHRIS	SAPHRIS.xml:S1:13695:7	saphri	NNP	O	O
was	SAPHRIS.xml:S1:13703:3	wa	VBD	O	O
administered	SAPHRIS.xml:S1:13707:12	administ	VBN	O	O
at	SAPHRIS.xml:S1:13720:2	at	IN	O	O
doses	SAPHRIS.xml:S1:13723:5	dose	NNS	O	O
of	SAPHRIS.xml:S1:13729:2	of	IN	O	O
2.5	SAPHRIS.xml:S1:13732:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:13736:2	mg	NNS	O	O
,	SAPHRIS.xml:S1:13738:1	,	,	O	O
5	SAPHRIS.xml:S1:13740:1	5	CD	O	O
mg	SAPHRIS.xml:S1:13742:2	mg	NN	O	O
,	SAPHRIS.xml:S1:13744:1	,	,	O	O
or	SAPHRIS.xml:S1:13746:2	or	CC	O	O
10	SAPHRIS.xml:S1:13749:2	10	CD	O	O
mg	SAPHRIS.xml:S1:13752:2	mg	JJ	O	O
twice	SAPHRIS.xml:S1:13755:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:13761:5	daili	RB	O	O
.	SAPHRIS.xml:S1:13766:1	.	.	O	O

Adverse	SAPHRIS.xml:S1:13776:7	advers	NN	O	O

Reactions	SAPHRIS.xml:S1:13784:9	reaction	NNS	O	O
Leading	SAPHRIS.xml:S1:13794:7	lead	VBG	O	O
to	SAPHRIS.xml:S1:13802:2	to	TO	O	O
Discontinuation	SAPHRIS.xml:S1:13805:15	discontinu	NNP	O	O
of	SAPHRIS.xml:S1:13821:2	of	IN	O	O
Treatment	SAPHRIS.xml:S1:13824:9	treatment	NNP	O	O
:	SAPHRIS.xml:S1:13833:1	:	:	O	O
A	SAPHRIS.xml:S1:13836:1	A	DT	O	O
total	SAPHRIS.xml:S1:13838:5	total	NN	O	O
of	SAPHRIS.xml:S1:13844:2	of	IN	O	O
6.7%	SAPHRIS.xml:S1:13847:4	6.7%	CD	O	O
(	SAPHRIS.xml:S1:13852:1	(	(	O	O
7	SAPHRIS.xml:S1:13853:1	7	CD	O	O
104	SAPHRIS.xml:S1:13855:3	104	CD	O	O
)	SAPHRIS.xml:S1:13858:1	)	)	O	O
of	SAPHRIS.xml:S1:13860:2	of	IN	O	O
patients	SAPHRIS.xml:S1:13863:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:13872:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:13880:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:13885:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S1:13893:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:13897:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:13900:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:13906:5	daili	RB	O	O
,	SAPHRIS.xml:S1:13911:1	,	,	O	O
5.1%	SAPHRIS.xml:S1:13913:4	5.1%	CD	O	O
(	SAPHRIS.xml:S1:13918:1	(	(	O	O
5	SAPHRIS.xml:S1:13919:1	5	CD	O	O
99	SAPHRIS.xml:S1:13921:2	99	CD	O	O
)	SAPHRIS.xml:S1:13923:1	)	)	O	O
of	SAPHRIS.xml:S1:13925:2	of	IN	O	O
patients	SAPHRIS.xml:S1:13928:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:13937:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:13945:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:13950:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:13958:1	5	CD	O	O
mg	SAPHRIS.xml:S1:13960:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:13963:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:13969:5	daili	RB	O	O
,	SAPHRIS.xml:S1:13974:1	,	,	O	O
and	SAPHRIS.xml:S1:13976:3	and	CC	O	O
5.1%	SAPHRIS.xml:S1:13980:4	5.1%	CD	O	O
(	SAPHRIS.xml:S1:13985:1	(	(	O	O
5	SAPHRIS.xml:S1:13986:1	5	CD	O	O
99	SAPHRIS.xml:S1:13988:2	99	CD	O	O
)	SAPHRIS.xml:S1:13990:1	)	)	O	O
of	SAPHRIS.xml:S1:13992:2	of	IN	O	O
patients	SAPHRIS.xml:S1:13995:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:14004:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:14012:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:14017:7	saphri	NNP	O	O
10	SAPHRIS.xml:S1:14025:2	10	CD	O	O
mg	SAPHRIS.xml:S1:14028:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:14031:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:14037:5	daili	RB	O	O
discontinued	SAPHRIS.xml:S1:14043:12	discontinu	VBN	O	O
treatment	SAPHRIS.xml:S1:14056:9	treatment	NN	O	O
due	SAPHRIS.xml:S1:14066:3	due	JJ	O	O
to	SAPHRIS.xml:S1:14070:2	to	TO	O	O
adverse	SAPHRIS.xml:S1:14073:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:14081:9	reaction	NNS	O	O
compared	SAPHRIS.xml:S1:14091:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:14100:2	to	TO	O	O
4%	SAPHRIS.xml:S1:14103:2	4%	CD	O	O
(	SAPHRIS.xml:S1:14106:1	(	(	O	O
4	SAPHRIS.xml:S1:14107:1	4	CD	O	O
101	SAPHRIS.xml:S1:14109:3	101	CD	O	O
)	SAPHRIS.xml:S1:14112:1	)	)	O	O
on	SAPHRIS.xml:S1:14114:2	on	IN	O	O
placebo	SAPHRIS.xml:S1:14117:7	placebo	NN	O	O
.	SAPHRIS.xml:S1:14124:1	.	.	O	O

The	SAPHRIS.xml:S1:14126:3	the	DT	O	O
most	SAPHRIS.xml:S1:14130:4	most	RBS	O	O
common	SAPHRIS.xml:S1:14135:6	common	JJ	O	O
adverse	SAPHRIS.xml:S1:14142:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:14150:9	reaction	NNS	O	O
that	SAPHRIS.xml:S1:14160:4	that	WDT	O	O
led	SAPHRIS.xml:S1:14165:3	led	VBD	O	O
to	SAPHRIS.xml:S1:14169:2	to	TO	O	O
discontinuation	SAPHRIS.xml:S1:14172:15	discontinu	NN	O	O
in	SAPHRIS.xml:S1:14188:2	in	IN	O	O
pediatric	SAPHRIS.xml:S1:14191:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:14201:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:14210:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:14218:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:14223:7	saphri	NNP	O	O
(	SAPHRIS.xml:S1:14231:1	(	(	O	O
rates	SAPHRIS.xml:S1:14232:5	rate	NNS	O	O
at	SAPHRIS.xml:S1:14238:2	at	IN	O	O
least	SAPHRIS.xml:S1:14241:5	least	JJS	O	O
2%	SAPHRIS.xml:S1:14247:2	2%	CD	O	O
in	SAPHRIS.xml:S1:14250:2	in	IN	O	O
any	SAPHRIS.xml:S1:14253:3	ani	DT	O	O
SAPHRIS	SAPHRIS.xml:S1:14257:7	saphri	NNP	O	O
arm	SAPHRIS.xml:S1:14265:3	arm	NN	O	O
and	SAPHRIS.xml:S1:14269:3	and	CC	O	O
at	SAPHRIS.xml:S1:14273:2	at	IN	O	O
least	SAPHRIS.xml:S1:14276:5	least	JJS	O	O
twice	SAPHRIS.xml:S1:14282:5	twice	RB	O	O
the	SAPHRIS.xml:S1:14288:3	the	DT	O	O
placebo	SAPHRIS.xml:S1:14292:7	placebo	NN	O	O
rate	SAPHRIS.xml:S1:14300:4	rate	NN	O	O
)	SAPHRIS.xml:S1:14304:1	)	)	O	O
were	SAPHRIS.xml:S1:14306:4	were	VBD	O	O
somnolence	SAPHRIS.xml:S1:14311:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
(	SAPHRIS.xml:S1:14322:1	(	(	O	O
3%	SAPHRIS.xml:S1:14323:2	3%	CD	O	O
in	SAPHRIS.xml:S1:14326:2	in	IN	O	O
the	SAPHRIS.xml:S1:14329:3	the	DT	O	O
2.5	SAPHRIS.xml:S1:14333:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:14336:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:14339:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:14345:5	daili	RB	O	O
group	SAPHRIS.xml:S1:14351:5	group	NN	O	O
,	SAPHRIS.xml:S1:14356:1	,	,	O	O
1%	SAPHRIS.xml:S1:14358:2	1%	CD	O	O
in	SAPHRIS.xml:S1:14361:2	in	IN	O	O
the	SAPHRIS.xml:S1:14364:3	the	DT	O	O
5	SAPHRIS.xml:S1:14368:1	5	CD	O	O
mg	SAPHRIS.xml:S1:14369:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:14372:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:14378:5	daili	RB	O	O
group	SAPHRIS.xml:S1:14384:5	group	NN	O	O
,	SAPHRIS.xml:S1:14389:1	,	,	O	O
and	SAPHRIS.xml:S1:14391:3	and	CC	O	O
2%	SAPHRIS.xml:S1:14395:2	2%	CD	O	O
in	SAPHRIS.xml:S1:14398:2	in	IN	O	O
the	SAPHRIS.xml:S1:14401:3	the	DT	O	O
10	SAPHRIS.xml:S1:14405:2	10	CD	O	O
mg	SAPHRIS.xml:S1:14407:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:14410:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:14416:5	daili	RB	O	O
group	SAPHRIS.xml:S1:14422:5	group	NN	O	O
)	SAPHRIS.xml:S1:14427:1	)	)	O	O
,	SAPHRIS.xml:S1:14428:1	,	,	O	O
abdominal	SAPHRIS.xml:S1:14430:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	SAPHRIS.xml:S1:14440:4	pain	NN	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S1:14445:1	(	(	O	O
2%	SAPHRIS.xml:S1:14446:2	2%	CD	O	O
in	SAPHRIS.xml:S1:14449:2	in	IN	O	O
the	SAPHRIS.xml:S1:14452:3	the	DT	O	O
10	SAPHRIS.xml:S1:14456:2	10	CD	O	O
mg	SAPHRIS.xml:S1:14458:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:14461:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:14467:5	daili	RB	O	O
group	SAPHRIS.xml:S1:14473:5	group	NN	O	O
)	SAPHRIS.xml:S1:14478:1	)	)	O	O
,	SAPHRIS.xml:S1:14479:1	,	,	O	O
and	SAPHRIS.xml:S1:14481:3	and	CC	O	O
nausea	SAPHRIS.xml:S1:14485:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
(	SAPHRIS.xml:S1:14492:1	(	(	O	O
2%	SAPHRIS.xml:S1:14493:2	2%	CD	O	O
in	SAPHRIS.xml:S1:14496:2	in	IN	O	O
the	SAPHRIS.xml:S1:14499:3	the	DT	O	O
10	SAPHRIS.xml:S1:14503:2	10	CD	O	O
mg	SAPHRIS.xml:S1:14505:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:14508:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:14514:5	daili	RB	O	O
group	SAPHRIS.xml:S1:14520:5	group	NN	O	O
)	SAPHRIS.xml:S1:14525:1	)	)	O	O
No	SAPHRIS.xml:S1:14527:2	No	DT	O	O
placebo	SAPHRIS.xml:S1:14530:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:14537:1	-	:	O	O
treated	SAPHRIS.xml:S1:14538:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:14546:8	patient	NNS	O	O
dropped	SAPHRIS.xml:S1:14555:7	drop	VBD	O	O
out	SAPHRIS.xml:S1:14563:3	out	RP	O	O
for	SAPHRIS.xml:S1:14567:3	for	IN	O	O
these	SAPHRIS.xml:S1:14571:5	these	DT	O	O
events	SAPHRIS.xml:S1:14577:6	event	NNS	O	O
.	SAPHRIS.xml:S1:14583:1	.	.	O	O

Adverse	SAPHRIS.xml:S1:14593:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:14601:9	reaction	NNP	O	O
Occurring	SAPHRIS.xml:S1:14611:9	occur	VBG	O	O
with	SAPHRIS.xml:S1:14621:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:14626:7	saphri	NNP	O	O
at	SAPHRIS.xml:S1:14634:2	at	IN	O	O
an	SAPHRIS.xml:S1:14637:2	an	DT	O	O
Incidence	SAPHRIS.xml:S1:14640:9	incid	NN	O	O
of	SAPHRIS.xml:S1:14650:2	of	IN	O	O
2%	SAPHRIS.xml:S1:14653:2	2%	CD	O	O
or	SAPHRIS.xml:S1:14656:2	or	CC	O	O
More	SAPHRIS.xml:S1:14659:4	more	JJR	O	O
in	SAPHRIS.xml:S1:14664:2	in	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:14667:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:14674:1	-	:	O	O
treated	SAPHRIS.xml:S1:14675:7	treat	VBD	O	O
Bipolar	SAPHRIS.xml:S1:14683:7	bipolar	JJ	O	O
Patients	SAPHRIS.xml:S1:14691:8	patient	NNS	O	O
:	SAPHRIS.xml:S1:14699:1	:	:	O	O
Adverse	SAPHRIS.xml:S1:14702:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:14710:9	reaction	NNS	O	O
associated	SAPHRIS.xml:S1:14720:10	associ	VBN	O	O
with	SAPHRIS.xml:S1:14731:4	with	IN	O	O
the	SAPHRIS.xml:S1:14736:3	the	DT	O	O
use	SAPHRIS.xml:S1:14740:3	use	NN	O	O
of	SAPHRIS.xml:S1:14744:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:14747:7	saphri	NNP	O	O
(	SAPHRIS.xml:S1:14755:1	(	(	O	O
incidence	SAPHRIS.xml:S1:14756:9	incid	NN	O	O
of	SAPHRIS.xml:S1:14766:2	of	IN	O	O
2%	SAPHRIS.xml:S1:14771:2	2%	CD	O	O
in	SAPHRIS.xml:S1:14774:2	in	IN	O	O
any	SAPHRIS.xml:S1:14777:3	ani	DT	O	O
SAPHRIS	SAPHRIS.xml:S1:14781:7	saphri	NNP	O	O
dose	SAPHRIS.xml:S1:14789:4	dose	NN	O	O
group	SAPHRIS.xml:S1:14794:5	group	NN	O	O
and	SAPHRIS.xml:S1:14800:3	and	CC	O	O
greater	SAPHRIS.xml:S1:14804:7	greater	JJR	O	O
than	SAPHRIS.xml:S1:14812:4	than	IN	O	O
placebo	SAPHRIS.xml:S1:14817:7	placebo	NN	O	O
)	SAPHRIS.xml:S1:14824:1	)	)	O	O
that	SAPHRIS.xml:S1:14826:4	that	WDT	O	O
occurred	SAPHRIS.xml:S1:14831:8	occur	VBD	O	O
during	SAPHRIS.xml:S1:14840:6	dure	IN	O	O
acute	SAPHRIS.xml:S1:14847:5	acut	NN	O	O
therapy	SAPHRIS.xml:S1:14853:7	therapi	NN	O	O
are	SAPHRIS.xml:S1:14861:3	are	VBP	O	O
shown	SAPHRIS.xml:S1:14865:5	shown	VBN	O	O
in	SAPHRIS.xml:S1:14871:2	in	IN	O	O
Table	SAPHRIS.xml:S1:14875:5	tabl	JJ	O	O
10	SAPHRIS.xml:S1:14881:2	10	CD	O	O
.	SAPHRIS.xml:S1:14885:1	.	.	O	O

Table	SAPHRIS.xml:S1:14891:5	tabl	JJ	O	O
10	SAPHRIS.xml:S1:14897:2	10	CD	O	O
:	SAPHRIS.xml:S1:14899:1	:	:	O	O
Adverse	SAPHRIS.xml:S1:14901:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:14909:9	reaction	NNP	O	O
Reported	SAPHRIS.xml:S1:14919:8	report	VBD	O	O
in	SAPHRIS.xml:S1:14928:2	in	IN	O	O
2%	SAPHRIS.xml:S1:14931:2	2%	CD	O	O
or	SAPHRIS.xml:S1:14934:2	or	CC	O	O
More	SAPHRIS.xml:S1:14937:4	more	JJR	O	O
of	SAPHRIS.xml:S1:14942:2	of	IN	O	O
Pediatric	SAPHRIS.xml:S1:14945:9	pediatr	JJ	O	O
Patients	SAPHRIS.xml:S1:14955:8	patient	NNS	O	O
(	SAPHRIS.xml:S1:14964:1	(	(	O	O
Ages	SAPHRIS.xml:S1:14965:4	age	$	O	O
10	SAPHRIS.xml:S1:14970:2	10	CD	O	O
to	SAPHRIS.xml:S1:14973:2	to	TO	O	O
17	SAPHRIS.xml:S1:14976:2	17	CD	O	O
Years	SAPHRIS.xml:S1:14979:5	year	NNS	O	O
)	SAPHRIS.xml:S1:14984:1	)	)	O	O
in	SAPHRIS.xml:S1:14986:2	in	IN	O	O
Any	SAPHRIS.xml:S1:14989:3	ani	NNP	O	O
SAPHRIS	SAPHRIS.xml:S1:14993:7	saphri	NNP	O	O
Dose	SAPHRIS.xml:S1:15001:4	dose	NNP	O	O
Group	SAPHRIS.xml:S1:15006:5	group	NNP	O	O
and	SAPHRIS.xml:S1:15012:3	and	CC	O	O
Which	SAPHRIS.xml:S1:15016:5	which	NNP	O	O
Occurred	SAPHRIS.xml:S1:15022:8	occur	VBD	O	O
at	SAPHRIS.xml:S1:15031:2	at	IN	O	O
Greater	SAPHRIS.xml:S1:15034:7	greater	NNP	O	O
Incidence	SAPHRIS.xml:S1:15042:9	incid	NNP	O	O
Than	SAPHRIS.xml:S1:15052:4	than	NNP	O	O
in	SAPHRIS.xml:S1:15057:2	in	IN	O	O
the	SAPHRIS.xml:S1:15060:3	the	DT	O	O
Placebo	SAPHRIS.xml:S1:15064:7	placebo	NNP	O	O
Group	SAPHRIS.xml:S1:15072:5	group	NNP	O	O
in	SAPHRIS.xml:S1:15078:2	in	IN	O	O
a	SAPHRIS.xml:S1:15081:1	a	DT	O	O
3	SAPHRIS.xml:S1:15083:1	3	CD	O	O
-	SAPHRIS.xml:S1:15084:1	-	:	O	O
Week	SAPHRIS.xml:S1:15085:4	week	NN	O	O
Bipolar	SAPHRIS.xml:S1:15090:7	bipolar	NNP	O	O
Mania	SAPHRIS.xml:S1:15098:5	mania	NNP	O	O
Trial	SAPHRIS.xml:S1:15104:5	trial	NNP	O	O

1	SAPHRIS.xml:S1:15113:1	1	CD	O	O
Includes	SAPHRIS.xml:S1:15114:8	includ	VBZ	O	O
the	SAPHRIS.xml:S1:15123:3	the	DT	O	O
preferred	SAPHRIS.xml:S1:15127:9	prefer	JJ	O	O
terms	SAPHRIS.xml:S1:15137:5	term	NNS	O	O
tachycardia	SAPHRIS.xml:S1:15143:11	tachycardia	NN	B-AdverseReaction	B-AdverseReaction
and	SAPHRIS.xml:S1:15155:3	and	CC	O	O
heart	SAPHRIS.xml:S1:15159:5	heart	NN	B-AdverseReaction	B-AdverseReaction
rate	SAPHRIS.xml:S1:15165:4	rate	NN	I-AdverseReaction	I-AdverseReaction
increased	SAPHRIS.xml:S1:15170:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S1:15179:1	.	.	O	O

2	SAPHRIS.xml:S1:15187:1	2	CD	O	O
Includes	SAPHRIS.xml:S1:15188:8	includ	VBZ	O	O
the	SAPHRIS.xml:S1:15197:3	the	DT	O	O
preferred	SAPHRIS.xml:S1:15201:9	prefer	JJ	O	O
terms	SAPHRIS.xml:S1:15211:5	term	NNS	O	O
oral	SAPHRIS.xml:S1:15217:4	oral	JJ	B-AdverseReaction	O
hypoesthesia	SAPHRIS.xml:S1:15222:12	hypoesthesia	NN	I-AdverseReaction	O
,	SAPHRIS.xml:S1:15234:1	,	,	O	O
oral	SAPHRIS.xml:S1:15236:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:15241:11	paresthesia	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:15252:1	,	,	O	O
and	SAPHRIS.xml:S1:15254:3	and	CC	O	O
oral	SAPHRIS.xml:S1:15258:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
dysesthesia	SAPHRIS.xml:S1:15263:11	dysesthesia	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S1:15274:1	.	.	O	O

3	SAPHRIS.xml:S1:15282:1	3	CD	O	O
Includes	SAPHRIS.xml:S1:15283:8	includ	VBZ	O	O
the	SAPHRIS.xml:S1:15292:3	the	DT	O	O
preferred	SAPHRIS.xml:S1:15296:9	prefer	JJ	O	O
terms	SAPHRIS.xml:S1:15306:5	term	NNS	O	O
abdominal	SAPHRIS.xml:S1:15312:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	SAPHRIS.xml:S1:15322:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:15326:1	,	,	O	O
abdominal	SAPHRIS.xml:S1:15328:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	SAPHRIS.xml:S1:15338:4	pain	NN	I-AdverseReaction	I-AdverseReaction
upper	SAPHRIS.xml:S1:15343:5	upper	JJ	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:15348:1	,	,	O	O
abdominal	SAPHRIS.xml:S1:15350:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	SAPHRIS.xml:S1:15360:4	pain	NN	I-AdverseReaction	I-AdverseReaction
lower	SAPHRIS.xml:S1:15365:5	lower	JJR	I-AdverseReaction	O
,	SAPHRIS.xml:S1:15370:1	,	,	O	O
and	SAPHRIS.xml:S1:15372:3	and	CC	O	O
abdominal	SAPHRIS.xml:S1:15376:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	SAPHRIS.xml:S1:15386:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S1:15396:1	.	.	O	O

4	SAPHRIS.xml:S1:15404:1	4	CD	O	O
Includes	SAPHRIS.xml:S1:15405:8	includ	VBZ	O	O
the	SAPHRIS.xml:S1:15414:3	the	DT	O	O
preferred	SAPHRIS.xml:S1:15418:9	prefer	JJ	O	O
terms	SAPHRIS.xml:S1:15428:5	term	NNS	O	O
fatigue	SAPHRIS.xml:S1:15434:7	fatigu	NN	B-AdverseReaction	O
and	SAPHRIS.xml:S1:15442:3	and	CC	O	O
lethargy	SAPHRIS.xml:S1:15446:8	lethargi	NN	B-AdverseReaction	O
.	SAPHRIS.xml:S1:15454:1	.	.	O	O

5	SAPHRIS.xml:S1:15462:1	5	CD	O	O
Includes	SAPHRIS.xml:S1:15463:8	includ	VBZ	O	O
the	SAPHRIS.xml:S1:15472:3	the	DT	O	O
preferred	SAPHRIS.xml:S1:15476:9	prefer	JJ	O	O
terms	SAPHRIS.xml:S1:15486:5	term	NNS	O	O
hyperinsulinemia	SAPHRIS.xml:S1:15492:16	hyperinsulinemia	NN	B-AdverseReaction	O
and	SAPHRIS.xml:S1:15509:3	and	CC	O	O
blood	SAPHRIS.xml:S1:15513:5	blood	NN	B-AdverseReaction	B-AdverseReaction
insulin	SAPHRIS.xml:S1:15519:7	insulin	NN	I-AdverseReaction	I-AdverseReaction
increased	SAPHRIS.xml:S1:15527:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S1:15536:1	.	.	O	O

6	SAPHRIS.xml:S1:15544:1	6	CD	O	O
Includes	SAPHRIS.xml:S1:15545:8	includ	VBZ	O	O
the	SAPHRIS.xml:S1:15554:3	the	DT	O	O
preferred	SAPHRIS.xml:S1:15558:9	prefer	JJ	O	O
terms	SAPHRIS.xml:S1:15568:5	term	NNS	O	O
somnolence	SAPHRIS.xml:S1:15574:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:15584:1	,	,	O	O
sedation	SAPHRIS.xml:S1:15586:8	sedat	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:15594:1	,	,	O	O
and	SAPHRIS.xml:S1:15596:3	and	CC	O	O
hypersomnia	SAPHRIS.xml:S1:15600:11	hypersomnia	NN	B-AdverseReaction	O
.	SAPHRIS.xml:S1:15611:1	.	.	O	O

System	SAPHRIS.xml:S1:15623:6	system	NN	O	O

Organ	SAPHRIS.xml:S1:15630:5	organ	NNP	O	O
Class	SAPHRIS.xml:S1:15636:5	class	NNP	O	O
AE	SAPHRIS.xml:S1:15646:2	AE	NNP	O	O
Preferred	SAPHRIS.xml:S1:15649:9	prefer	NNP	O	O
Term	SAPHRIS.xml:S1:15659:4	term	NNP	O	O
Placebo	SAPHRIS.xml:S1:15669:7	placebo	NNP	O	O
N	SAPHRIS.xml:S1:15680:1	N	NNP	O	O
101	SAPHRIS.xml:S1:15682:3	101	CD	O	O
Placebo	SAPHRIS.xml:S1:15689:7	placebo	NNP	O	O
SAPHRIS	SAPHRIS.xml:S1:15702:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S1:15713:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:15717:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:15723:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:15729:5	daili	RB	O	O
N	SAPHRIS.xml:S1:15738:1	N	NNP	O	O
104	SAPHRIS.xml:S1:15740:3	104	CD	O	O
2.5	SAPHRIS.xml:S1:15747:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:15750:2	mg	NNS	O	O
SAPHRIS	SAPHRIS.xml:S1:15758:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:15769:1	5	CD	O	O
mg	SAPHRIS.xml:S1:15771:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:15777:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:15783:5	daili	RB	O	O
N	SAPHRIS.xml:S1:15792:1	N	NNP	O	O
99	SAPHRIS.xml:S1:15794:2	99	CD	O	O
5	SAPHRIS.xml:S1:15800:1	5	CD	O	O
mg	SAPHRIS.xml:S1:15801:2	mg	NNS	O	O
SAPHRIS	SAPHRIS.xml:S1:15809:7	saphri	NNP	O	O
10	SAPHRIS.xml:S1:15820:2	10	CD	O	O
mg	SAPHRIS.xml:S1:15823:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:15829:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:15835:5	daili	RB	O	O
N	SAPHRIS.xml:S1:15844:1	N	NNP	O	O
99	SAPHRIS.xml:S1:15846:2	99	CD	O	O
10	SAPHRIS.xml:S1:15852:2	10	CD	O	O
mg	SAPHRIS.xml:S1:15854:2	mg	NN	O	O
All	SAPHRIS.xml:S1:15862:3	all	NNP	O	O
SAPHRIS	SAPHRIS.xml:S1:15866:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S1:15877:3	2.5	CD	O	O
,	SAPHRIS.xml:S1:15880:1	,	,	O	O
5	SAPHRIS.xml:S1:15882:1	5	CD	O	O
,	SAPHRIS.xml:S1:15883:1	,	,	O	O
and	SAPHRIS.xml:S1:15885:3	and	CC	O	O
10	SAPHRIS.xml:S1:15889:2	10	CD	O	O
mg	SAPHRIS.xml:S1:15892:2	mg	NN	O	O

N	SAPHRIS.xml:S1:15903:1	N	NNP	O	O
101	SAPHRIS.xml:S1:15905:3	101	CD	O	O
N	SAPHRIS.xml:S1:15939:1	N	NNP	O	O
104	SAPHRIS.xml:S1:15941:3	104	CD	O	O
N	SAPHRIS.xml:S1:15955:1	N	NNP	O	O
99	SAPHRIS.xml:S1:15957:2	99	CD	O	O
N	SAPHRIS.xml:S1:15970:1	N	NNP	O	O
99	SAPHRIS.xml:S1:15972:2	99	CD	O	O
N	SAPHRIS.xml:S1:15985:1	N	NNP	O	O
302	SAPHRIS.xml:S1:15987:3	302	CD	O	O

Cardiac	SAPHRIS.xml:S1:16004:7	cardiac	JJ	O	O
Disorders	SAPHRIS.xml:S1:16012:9	disord	NNS	O	O

Tachycardia	SAPHRIS.xml:S1:16096:11	tachycardia	NNP	B-AdverseReaction	B-AdverseReaction
1	SAPHRIS.xml:S1:16109:1	1	CD	O	O
0	SAPHRIS.xml:S1:16129:1	0	CD	O	O
3	SAPHRIS.xml:S1:16140:1	3	CD	O	O
0	SAPHRIS.xml:S1:16154:1	0	CD	O	O
1	SAPHRIS.xml:S1:16168:1	1	CD	O	O
1	SAPHRIS.xml:S1:16181:1	1	CD	O	O

Gastrointestinal	SAPHRIS.xml:S1:16208:16	gastrointestin	JJ	O	O
Disorders	SAPHRIS.xml:S1:16225:9	disord	NNS	O	O

Oral	SAPHRIS.xml:S1:16300:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
paraesthesia	SAPHRIS.xml:S1:16305:12	paraesthesia	NN	I-AdverseReaction	I-AdverseReaction
2	SAPHRIS.xml:S1:16319:1	2	CD	O	O
4	SAPHRIS.xml:S1:16333:1	4	CD	O	O
25	SAPHRIS.xml:S1:16344:2	25	CD	O	O
25	SAPHRIS.xml:S1:16358:2	25	CD	O	O
30	SAPHRIS.xml:S1:16372:2	30	CD	O	O
27	SAPHRIS.xml:S1:16385:2	27	CD	O	O

Nausea	SAPHRIS.xml:S1:16413:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
3	SAPHRIS.xml:S1:16446:1	3	CD	O	O
6	SAPHRIS.xml:S1:16457:1	6	CD	O	O
6	SAPHRIS.xml:S1:16471:1	6	CD	O	O
6	SAPHRIS.xml:S1:16485:1	6	CD	O	O
6	SAPHRIS.xml:S1:16498:1	6	CD	O	O

Vomiting	SAPHRIS.xml:S1:16526:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
3	SAPHRIS.xml:S1:16559:1	3	CD	O	O
4	SAPHRIS.xml:S1:16570:1	4	CD	O	O
4	SAPHRIS.xml:S1:16584:1	4	CD	O	O
4	SAPHRIS.xml:S1:16598:1	4	CD	O	O
4	SAPHRIS.xml:S1:16611:1	4	CD	O	O

Abdominal	SAPHRIS.xml:S1:16639:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	SAPHRIS.xml:S1:16649:4	pain	NN	I-AdverseReaction	I-AdverseReaction
3	SAPHRIS.xml:S1:16655:1	3	CD	O	O
7	SAPHRIS.xml:S1:16672:1	7	CD	O	O
9	SAPHRIS.xml:S1:16683:1	9	CD	O	O
3	SAPHRIS.xml:S1:16697:1	3	CD	O	O
5	SAPHRIS.xml:S1:16711:1	5	CD	O	O
6	SAPHRIS.xml:S1:16724:1	6	CD	O	O

Glossodynia	SAPHRIS.xml:S1:16752:11	glossodynia	NNP	B-AdverseReaction	B-AdverseReaction
0	SAPHRIS.xml:S1:16785:1	0	CD	O	O
0	SAPHRIS.xml:S1:16796:1	0	CD	O	O
2	SAPHRIS.xml:S1:16810:1	2	CD	O	O
0	SAPHRIS.xml:S1:16824:1	0	CD	O	O
1	SAPHRIS.xml:S1:16837:1	1	CD	O	O

General	SAPHRIS.xml:S1:16864:7	gener	NNP	O	O
Disorders	SAPHRIS.xml:S1:16872:9	disord	NNPS	O	O
and	SAPHRIS.xml:S1:16882:3	and	CC	O	O
Administrative	SAPHRIS.xml:S1:16886:14	administr	NNP	O	O
Site	SAPHRIS.xml:S1:16901:4	site	NNP	O	O
Disorders	SAPHRIS.xml:S1:16906:9	disord	NNS	O	O

Fatigue	SAPHRIS.xml:S1:16977:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
4	SAPHRIS.xml:S1:16986:1	4	CD	O	O
5	SAPHRIS.xml:S1:17010:1	5	CD	O	O
4	SAPHRIS.xml:S1:17021:1	4	CD	O	O
8	SAPHRIS.xml:S1:17035:1	8	CD	O	O
14	SAPHRIS.xml:S1:17049:2	14	CD	O	O
9	SAPHRIS.xml:S1:17062:1	9	CD	O	O

Irritability	SAPHRIS.xml:S1:17090:12	irrit	NNP	B-AdverseReaction	B-AdverseReaction
1	SAPHRIS.xml:S1:17123:1	1	CD	O	O
1	SAPHRIS.xml:S1:17134:1	1	CD	O	O
1	SAPHRIS.xml:S1:17148:1	1	CD	O	O
2	SAPHRIS.xml:S1:17162:1	2	CD	O	O
1	SAPHRIS.xml:S1:17175:1	1	CD	O	O

Injury	SAPHRIS.xml:S1:17202:6	injuri	NNP	O	O
,	SAPHRIS.xml:S1:17208:1	,	,	O	O
Poisoning	SAPHRIS.xml:S1:17210:9	poison	NNP	O	O
,	SAPHRIS.xml:S1:17219:1	,	,	O	O
and	SAPHRIS.xml:S1:17221:3	and	CC	O	O
Procedural	SAPHRIS.xml:S1:17225:10	procedur	NNP	O	O
Complications	SAPHRIS.xml:S1:17236:13	complic	NNP	O	O

Muscle	SAPHRIS.xml:S1:17311:6	muscl	NNP	B-AdverseReaction	B-AdverseReaction
strain	SAPHRIS.xml:S1:17318:6	strain	VBD	I-AdverseReaction	I-AdverseReaction
0	SAPHRIS.xml:S1:17344:1	0	CD	O	O
0	SAPHRIS.xml:S1:17355:1	0	CD	O	O
0	SAPHRIS.xml:S1:17369:1	0	CD	O	O
2	SAPHRIS.xml:S1:17383:1	2	CD	O	O
1	SAPHRIS.xml:S1:17396:1	1	CD	O	O

Investigations	SAPHRIS.xml:S1:17423:14	investig	NNS	O	O

Increased	SAPHRIS.xml:S1:17537:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
weight	SAPHRIS.xml:S1:17547:6	weight	VBD	I-AdverseReaction	I-AdverseReaction
0	SAPHRIS.xml:S1:17570:1	0	CD	O	O
6	SAPHRIS.xml:S1:17581:1	6	CD	O	O
2	SAPHRIS.xml:S1:17595:1	2	CD	O	O
2	SAPHRIS.xml:S1:17609:1	2	CD	O	O
3	SAPHRIS.xml:S1:17622:1	3	CD	O	O

Hyperinsulinemia	SAPHRIS.xml:S1:17650:16	hyperinsulinemia	NNP	B-AdverseReaction	B-AdverseReaction
5	SAPHRIS.xml:S1:17668:1	5	CD	O	O
0	SAPHRIS.xml:S1:17683:1	0	CD	O	O
1	SAPHRIS.xml:S1:17694:1	1	CD	O	O
3	SAPHRIS.xml:S1:17708:1	3	CD	O	O
1	SAPHRIS.xml:S1:17722:1	1	CD	O	O
2	SAPHRIS.xml:S1:17735:1	2	CD	O	O

ALT	SAPHRIS.xml:S1:17763:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
increased	SAPHRIS.xml:S1:17767:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
0	SAPHRIS.xml:S1:17796:1	0	CD	O	O
0	SAPHRIS.xml:S1:17807:1	0	CD	O	O
0	SAPHRIS.xml:S1:17821:1	0	CD	O	O
2	SAPHRIS.xml:S1:17835:1	2	CD	O	O
1	SAPHRIS.xml:S1:17848:1	1	CD	O	O

AST	SAPHRIS.xml:S1:17876:3	ast	NNP	B-AdverseReaction	B-AdverseReaction
increased	SAPHRIS.xml:S1:17880:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
0	SAPHRIS.xml:S1:17909:1	0	CD	O	O
0	SAPHRIS.xml:S1:17920:1	0	CD	O	O
0	SAPHRIS.xml:S1:17934:1	0	CD	O	O
2	SAPHRIS.xml:S1:17948:1	2	CD	O	O
1	SAPHRIS.xml:S1:17961:1	1	CD	O	O

Metabolism	SAPHRIS.xml:S1:17988:10	metabol	NN	O	O
and	SAPHRIS.xml:S1:17999:3	and	CC	O	O
Nutrition	SAPHRIS.xml:S1:18003:9	nutrit	NN	O	O
Disorders	SAPHRIS.xml:S1:18013:9	disord	NNS	O	O

Increased	SAPHRIS.xml:S1:18106:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	SAPHRIS.xml:S1:18116:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
2	SAPHRIS.xml:S1:18139:1	2	CD	O	O
10	SAPHRIS.xml:S1:18150:2	10	CD	O	O
9	SAPHRIS.xml:S1:18164:1	9	CD	O	O
6	SAPHRIS.xml:S1:18178:1	6	CD	O	O
8	SAPHRIS.xml:S1:18191:1	8	CD	O	O

Dehydration	SAPHRIS.xml:S1:18219:11	dehydr	NN	B-AdverseReaction	B-AdverseReaction
1	SAPHRIS.xml:S1:18252:1	1	CD	O	O
0	SAPHRIS.xml:S1:18263:1	0	CD	O	O
2	SAPHRIS.xml:S1:18277:1	2	CD	O	O
0	SAPHRIS.xml:S1:18291:1	0	CD	O	O
1	SAPHRIS.xml:S1:18304:1	1	CD	O	O

Musculoskeletal	SAPHRIS.xml:S1:18331:15	musculoskelet	NNP	O	O
and	SAPHRIS.xml:S1:18347:3	and	CC	O	O
Connective	SAPHRIS.xml:S1:18351:10	connect	NNP	O	O
Tissue	SAPHRIS.xml:S1:18362:6	tissu	NNP	O	O
Disorders	SAPHRIS.xml:S1:18369:9	disord	NNP	O	O

Myalgia	SAPHRIS.xml:S1:18440:7	myalgia	NNP	B-AdverseReaction	B-AdverseReaction
0	SAPHRIS.xml:S1:18473:1	0	CD	O	O
0	SAPHRIS.xml:S1:18484:1	0	CD	O	O
2	SAPHRIS.xml:S1:18498:1	2	CD	O	O
1	SAPHRIS.xml:S1:18512:1	1	CD	O	O
1	SAPHRIS.xml:S1:18525:1	1	CD	O	O

Nervous	SAPHRIS.xml:S1:18552:7	nervou	JJ	O	O
System	SAPHRIS.xml:S1:18560:6	system	NNP	O	O
Disorders	SAPHRIS.xml:S1:18567:9	disord	NNP	O	O

Somnolence	SAPHRIS.xml:S1:18644:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
6	SAPHRIS.xml:S1:18656:1	6	CD	O	O
12	SAPHRIS.xml:S1:18677:2	12	CD	O	O
46	SAPHRIS.xml:S1:18688:2	46	CD	O	O
53	SAPHRIS.xml:S1:18702:2	53	CD	O	O
49	SAPHRIS.xml:S1:18716:2	49	CD	O	O
49	SAPHRIS.xml:S1:18729:2	49	CD	O	O

Headache	SAPHRIS.xml:S1:18757:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
6	SAPHRIS.xml:S1:18790:1	6	CD	O	O
8	SAPHRIS.xml:S1:18801:1	8	CD	O	O
11	SAPHRIS.xml:S1:18815:2	11	CD	O	O
9	SAPHRIS.xml:S1:18829:1	9	CD	O	O
9	SAPHRIS.xml:S1:18842:1	9	CD	O	O

Dizziness	SAPHRIS.xml:S1:18870:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
3	SAPHRIS.xml:S1:18903:1	3	CD	O	O
6	SAPHRIS.xml:S1:18914:1	6	CD	O	O
10	SAPHRIS.xml:S1:18928:2	10	CD	O	O
5	SAPHRIS.xml:S1:18942:1	5	CD	O	O
7	SAPHRIS.xml:S1:18955:1	7	CD	O	O

Dysgeusia	SAPHRIS.xml:S1:18983:9	dysgeusia	NNP	B-AdverseReaction	B-AdverseReaction
2	SAPHRIS.xml:S1:19016:1	2	CD	O	O
4	SAPHRIS.xml:S1:19027:1	4	CD	O	O
5	SAPHRIS.xml:S1:19041:1	5	CD	O	O
9	SAPHRIS.xml:S1:19055:1	9	CD	O	O
6	SAPHRIS.xml:S1:19068:1	6	CD	O	O

Akathisia	SAPHRIS.xml:S1:19096:9	akathisia	$	B-AdverseReaction	B-AdverseReaction
0	SAPHRIS.xml:S1:19129:1	0	CD	O	O
2	SAPHRIS.xml:S1:19140:1	2	CD	O	O
2	SAPHRIS.xml:S1:19154:1	2	CD	O	O
1	SAPHRIS.xml:S1:19168:1	1	CD	O	O
2	SAPHRIS.xml:S1:19181:1	2	CD	O	O

Parkinsonism	SAPHRIS.xml:S1:19209:12	parkinson	NN	B-AdverseReaction	B-AdverseReaction
0	SAPHRIS.xml:S1:19242:1	0	CD	O	O
1	SAPHRIS.xml:S1:19253:1	1	CD	O	O
0	SAPHRIS.xml:S1:19267:1	0	CD	O	O
2	SAPHRIS.xml:S1:19281:1	2	CD	O	O
1	SAPHRIS.xml:S1:19294:1	1	CD	O	O

Psychiatric	SAPHRIS.xml:S1:19321:11	psychiatr	JJ	O	O
Disorders	SAPHRIS.xml:S1:19333:9	disord	NNS	O	O

Insomnia	SAPHRIS.xml:S1:19413:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
3	SAPHRIS.xml:S1:19446:1	3	CD	O	O
3	SAPHRIS.xml:S1:19457:1	3	CD	O	O
4	SAPHRIS.xml:S1:19471:1	4	CD	O	O
3	SAPHRIS.xml:S1:19485:1	3	CD	O	O
3	SAPHRIS.xml:S1:19498:1	3	CD	O	O

Suicidal	SAPHRIS.xml:S1:19526:8	suicid	NNP	B-AdverseReaction	B-AdverseReaction
ideation	SAPHRIS.xml:S1:19535:8	ideat	NN	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:19559:1	1	CD	O	O
4	SAPHRIS.xml:S1:19570:1	4	CD	O	O
1	SAPHRIS.xml:S1:19584:1	1	CD	O	O
3	SAPHRIS.xml:S1:19598:1	3	CD	O	O
3	SAPHRIS.xml:S1:19611:1	3	CD	O	O

Anger	SAPHRIS.xml:S1:19639:5	anger	NNP	B-AdverseReaction	B-AdverseReaction
0	SAPHRIS.xml:S1:19672:1	0	CD	O	O
0	SAPHRIS.xml:S1:19683:1	0	CD	O	O
0	SAPHRIS.xml:S1:19697:1	0	CD	O	O
2	SAPHRIS.xml:S1:19711:1	2	CD	O	O
1	SAPHRIS.xml:S1:19724:1	1	CD	O	O

Reproductive	SAPHRIS.xml:S1:19751:12	reproduct	JJ	O	O
System	SAPHRIS.xml:S1:19764:6	system	NNP	O	O
and	SAPHRIS.xml:S1:19771:3	and	CC	O	O
Breast	SAPHRIS.xml:S1:19775:6	breast	NNP	O	O
Disorders	SAPHRIS.xml:S1:19782:9	disord	NNP	O	O

Dysmenorrhea	SAPHRIS.xml:S1:19853:12	dysmenorrhea	NNP	B-AdverseReaction	B-AdverseReaction
1	SAPHRIS.xml:S1:19886:1	1	CD	O	O
0	SAPHRIS.xml:S1:19897:1	0	CD	O	O
2	SAPHRIS.xml:S1:19911:1	2	CD	O	O
0	SAPHRIS.xml:S1:19925:1	0	CD	O	O
1	SAPHRIS.xml:S1:19938:1	1	CD	O	O

Respiratory	SAPHRIS.xml:S1:19965:11	respiratori	NNP	O	O
,	SAPHRIS.xml:S1:19976:1	,	,	O	O
Thoracic	SAPHRIS.xml:S1:19978:8	thorac	NNP	O	O
,	SAPHRIS.xml:S1:19986:1	,	,	O	O
and	SAPHRIS.xml:S1:19988:3	and	CC	O	O
Mediastinal	SAPHRIS.xml:S1:19992:11	mediastin	NNP	O	O
Disorders	SAPHRIS.xml:S1:20004:9	disord	NNP	O	O

Oropharyngeal	SAPHRIS.xml:S1:20097:13	oropharyng	NNP	B-AdverseReaction	B-AdverseReaction
pain	SAPHRIS.xml:S1:20111:4	pain	NN	I-AdverseReaction	I-AdverseReaction
2	SAPHRIS.xml:S1:20130:1	2	CD	O	O
0	SAPHRIS.xml:S1:20141:1	0	CD	O	O
3	SAPHRIS.xml:S1:20155:1	3	CD	O	O
1	SAPHRIS.xml:S1:20169:1	1	CD	O	O
1	SAPHRIS.xml:S1:20182:1	1	CD	O	O

Nasal	SAPHRIS.xml:S1:20210:5	nasal	NNP	B-AdverseReaction	B-AdverseReaction
congestion	SAPHRIS.xml:S1:20216:10	congest	NN	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:20243:1	1	CD	O	O
0	SAPHRIS.xml:S1:20254:1	0	CD	O	O
2	SAPHRIS.xml:S1:20268:1	2	CD	O	O
0	SAPHRIS.xml:S1:20282:1	0	CD	O	O
1	SAPHRIS.xml:S1:20295:1	1	CD	O	O

Dyspnea	SAPHRIS.xml:S1:20323:7	dyspnea	NNP	B-AdverseReaction	B-AdverseReaction
0	SAPHRIS.xml:S1:20356:1	0	CD	O	O
0	SAPHRIS.xml:S1:20367:1	0	CD	O	O
2	SAPHRIS.xml:S1:20381:1	2	CD	O	O
0	SAPHRIS.xml:S1:20395:1	0	CD	O	O
1	SAPHRIS.xml:S1:20408:1	1	CD	O	O

Skin	SAPHRIS.xml:S1:20435:4	skin	NNP	O	O
and	SAPHRIS.xml:S1:20440:3	and	CC	O	O
Subcutaneous	SAPHRIS.xml:S1:20444:12	subcutan	NNP	O	O
Tissue	SAPHRIS.xml:S1:20457:6	tissu	NNP	O	O
Disorders	SAPHRIS.xml:S1:20464:9	disord	NNP	O	O

Rash	SAPHRIS.xml:S1:20535:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
1	SAPHRIS.xml:S1:20568:1	1	CD	O	O
0	SAPHRIS.xml:S1:20579:1	0	CD	O	O
1	SAPHRIS.xml:S1:20593:1	1	CD	O	O
2	SAPHRIS.xml:S1:20607:1	2	CD	O	O
1	SAPHRIS.xml:S1:20620:1	1	CD	O	O

Dose	SAPHRIS.xml:S1:20660:4	dose	NNP	O	O
-	SAPHRIS.xml:S1:20664:1	-	:	O	O
Related	SAPHRIS.xml:S1:20665:7	relat	JJ	O	O
Adverse	SAPHRIS.xml:S1:20673:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:20681:9	reaction	NNS	O	O
:	SAPHRIS.xml:S1:20690:1	:	:	O	O
In	SAPHRIS.xml:S1:20693:2	In	IN	O	O
the	SAPHRIS.xml:S1:20696:3	the	DT	O	O
short	SAPHRIS.xml:S1:20700:5	short	JJ	O	O
term	SAPHRIS.xml:S1:20706:4	term	NN	O	O
pediatric	SAPHRIS.xml:S1:20711:9	pediatr	JJ	O	O
bipolar	SAPHRIS.xml:S1:20721:7	bipolar	JJ	O	O
trials	SAPHRIS.xml:S1:20729:6	trial	NNS	O	O
the	SAPHRIS.xml:S1:20736:3	the	DT	O	O
incidence	SAPHRIS.xml:S1:20740:9	incid	NN	O	O
of	SAPHRIS.xml:S1:20750:2	of	IN	O	O
fatigue	SAPHRIS.xml:S1:20753:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
appeared	SAPHRIS.xml:S1:20761:8	appear	VBD	O	O
to	SAPHRIS.xml:S1:20770:2	to	TO	O	O
be	SAPHRIS.xml:S1:20773:2	be	VB	O	O
dose	SAPHRIS.xml:S1:20776:4	dose	JJ	O	O
-	SAPHRIS.xml:S1:20780:1	-	:	O	O
related	SAPHRIS.xml:S1:20781:7	relat	JJ	O	O
(	SAPHRIS.xml:S1:20789:1	(	(	O	O
see	SAPHRIS.xml:S1:20790:3	see	VB	O	O
Table	SAPHRIS.xml:S1:20795:5	tabl	NNP	O	O
10	SAPHRIS.xml:S1:20801:2	10	CD	O	O
)	SAPHRIS.xml:S1:20805:1	)	)	O	O

Adjunctive	SAPHRIS.xml:S1:20815:10	adjunct	JJ	O	O

Therapy	SAPHRIS.xml:S1:20826:7	therapi	NN	O	O
in	SAPHRIS.xml:S1:20834:2	in	IN	O	O
Adult	SAPHRIS.xml:S1:20837:5	adult	NNP	O	O
Patients	SAPHRIS.xml:S1:20843:8	patient	NNPS	O	O
with	SAPHRIS.xml:S1:20852:4	with	IN	O	O
Bipolar	SAPHRIS.xml:S1:20857:7	bipolar	NNP	O	O
Mania	SAPHRIS.xml:S1:20865:5	mania	NNP	O	O
:	SAPHRIS.xml:S1:20870:1	:	:	O	O
The	SAPHRIS.xml:S1:20873:3	the	DT	O	O
following	SAPHRIS.xml:S1:20877:9	follow	JJ	O	O
findings	SAPHRIS.xml:S1:20887:8	find	NNS	O	O
are	SAPHRIS.xml:S1:20896:3	are	VBP	O	O
based	SAPHRIS.xml:S1:20900:5	base	VBN	O	O
on	SAPHRIS.xml:S1:20906:2	on	IN	O	O
a	SAPHRIS.xml:S1:20909:1	a	DT	O	O
12	SAPHRIS.xml:S1:20911:2	12	CD	O	O
week	SAPHRIS.xml:S1:20914:4	week	NN	O	O
placebo	SAPHRIS.xml:S1:20919:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:20926:1	-	:	O	O
controlled	SAPHRIS.xml:S1:20927:10	control	VBN	O	O
trial	SAPHRIS.xml:S1:20938:5	trial	NN	O	O
(	SAPHRIS.xml:S1:20944:1	(	(	O	O
with	SAPHRIS.xml:S1:20945:4	with	IN	O	O
a	SAPHRIS.xml:S1:20950:1	a	DT	O	O
3	SAPHRIS.xml:S1:20952:1	3	CD	O	O
week	SAPHRIS.xml:S1:20954:4	week	NN	O	O
efficacy	SAPHRIS.xml:S1:20959:8	efficaci	NN	O	O
endpoint	SAPHRIS.xml:S1:20968:8	endpoint	NN	O	O
)	SAPHRIS.xml:S1:20976:1	)	)	O	O
in	SAPHRIS.xml:S1:20978:2	in	IN	O	O
adult	SAPHRIS.xml:S1:20981:5	adult	NN	O	O
patients	SAPHRIS.xml:S1:20987:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:20996:4	with	IN	O	O
bipolar	SAPHRIS.xml:S1:21001:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S1:21009:5	mania	NN	O	O
in	SAPHRIS.xml:S1:21015:2	in	IN	O	O
which	SAPHRIS.xml:S1:21018:5	which	WDT	O	O
sublingual	SAPHRIS.xml:S1:21024:10	sublingu	JJ	O	O
SAPHRIS	SAPHRIS.xml:S1:21035:7	saphri	NNP	O	O
was	SAPHRIS.xml:S1:21043:3	wa	VBD	O	O
administered	SAPHRIS.xml:S1:21047:12	administ	VBN	O	O
in	SAPHRIS.xml:S1:21060:2	in	IN	O	O
doses	SAPHRIS.xml:S1:21063:5	dose	NNS	O	O
of	SAPHRIS.xml:S1:21069:2	of	IN	O	O
5	SAPHRIS.xml:S1:21072:1	5	CD	O	O
mg	SAPHRIS.xml:S1:21074:2	mg	NNS	O	O
or	SAPHRIS.xml:S1:21077:2	or	CC	O	O
10	SAPHRIS.xml:S1:21080:2	10	CD	O	O
mg	SAPHRIS.xml:S1:21083:2	mg	JJ	O	O
twice	SAPHRIS.xml:S1:21086:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:21092:5	daili	RB	O	O
as	SAPHRIS.xml:S1:21098:2	as	IN	O	O
adjunctive	SAPHRIS.xml:S1:21101:10	adjunct	JJ	O	O
therapy	SAPHRIS.xml:S1:21112:7	therapi	NN	O	O
with	SAPHRIS.xml:S1:21120:4	with	IN	O	O
lithium	SAPHRIS.xml:S1:21125:7	lithium	NN	O	O
or	SAPHRIS.xml:S1:21133:2	or	CC	O	O
valproate	SAPHRIS.xml:S1:21136:9	valproat	NN	O	O
.	SAPHRIS.xml:S1:21145:1	.	.	O	O

Adverse	SAPHRIS.xml:S1:21155:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:21163:9	reaction	NNP	O	O
Associated	SAPHRIS.xml:S1:21173:10	associ	NNP	O	O
with	SAPHRIS.xml:S1:21184:4	with	IN	O	O
Discontinuation	SAPHRIS.xml:S1:21189:15	discontinu	NNP	O	O
of	SAPHRIS.xml:S1:21205:2	of	IN	O	O
Treatment	SAPHRIS.xml:S1:21208:9	treatment	NNP	O	O
:	SAPHRIS.xml:S1:21217:1	:	:	O	O
Approximately	SAPHRIS.xml:S1:21220:13	approxim	RB	O	O
16%	SAPHRIS.xml:S1:21234:3	16%	CD	O	O
(	SAPHRIS.xml:S1:21238:1	(	(	O	O
25	SAPHRIS.xml:S1:21239:2	25	CD	O	O
158	SAPHRIS.xml:S1:21242:3	158	CD	O	O
)	SAPHRIS.xml:S1:21245:1	)	)	O	O
of	SAPHRIS.xml:S1:21247:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:21250:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:21257:1	-	:	O	O
treated	SAPHRIS.xml:S1:21258:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:21266:8	patient	NNS	O	O
discontinued	SAPHRIS.xml:S1:21275:12	discontinu	VBN	O	O
treatment	SAPHRIS.xml:S1:21288:9	treatment	NN	O	O
due	SAPHRIS.xml:S1:21298:3	due	JJ	O	O
to	SAPHRIS.xml:S1:21302:2	to	TO	O	O
an	SAPHRIS.xml:S1:21305:2	an	DT	O	O
adverse	SAPHRIS.xml:S1:21308:7	advers	JJ	O	O
reaction	SAPHRIS.xml:S1:21316:8	reaction	NN	O	O
,	SAPHRIS.xml:S1:21324:1	,	,	O	O
compared	SAPHRIS.xml:S1:21326:8	compar	VBN	O	O
with	SAPHRIS.xml:S1:21335:4	with	IN	O	O
about	SAPHRIS.xml:S1:21340:5	about	RB	O	O
11%	SAPHRIS.xml:S1:21346:3	11%	CD	O	O
(	SAPHRIS.xml:S1:21350:1	(	(	O	O
18	SAPHRIS.xml:S1:21351:2	18	CD	O	O
166	SAPHRIS.xml:S1:21354:3	166	CD	O	O
)	SAPHRIS.xml:S1:21357:1	)	)	O	O
on	SAPHRIS.xml:S1:21359:2	on	IN	O	O
placebo	SAPHRIS.xml:S1:21362:7	placebo	NN	O	O
.	SAPHRIS.xml:S1:21369:1	.	.	O	O

The	SAPHRIS.xml:S1:21371:3	the	DT	O	O
most	SAPHRIS.xml:S1:21375:4	most	RBS	O	O
common	SAPHRIS.xml:S1:21380:6	common	JJ	O	O
adverse	SAPHRIS.xml:S1:21387:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:21395:9	reaction	NNS	O	O
associated	SAPHRIS.xml:S1:21405:10	associ	VBN	O	O
with	SAPHRIS.xml:S1:21416:4	with	IN	O	O
discontinuation	SAPHRIS.xml:S1:21421:15	discontinu	NN	O	O
in	SAPHRIS.xml:S1:21437:2	in	IN	O	O
subjects	SAPHRIS.xml:S1:21440:8	subject	NNS	O	O
treated	SAPHRIS.xml:S1:21449:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:21457:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:21462:7	saphri	NNP	O	O
(	SAPHRIS.xml:S1:21470:1	(	(	O	O
rates	SAPHRIS.xml:S1:21471:5	rate	NNS	O	O
at	SAPHRIS.xml:S1:21477:2	at	IN	O	O
least	SAPHRIS.xml:S1:21480:5	least	JJS	O	O
1%	SAPHRIS.xml:S1:21486:2	1%	CD	O	O
and	SAPHRIS.xml:S1:21489:3	and	CC	O	O
at	SAPHRIS.xml:S1:21493:2	at	IN	O	O
least	SAPHRIS.xml:S1:21496:5	least	JJS	O	O
twice	SAPHRIS.xml:S1:21502:5	twice	RB	O	O
the	SAPHRIS.xml:S1:21508:3	the	DT	O	O
placebo	SAPHRIS.xml:S1:21512:7	placebo	NN	O	O
rate	SAPHRIS.xml:S1:21520:4	rate	NN	O	O
)	SAPHRIS.xml:S1:21524:1	)	)	O	O
were	SAPHRIS.xml:S1:21526:4	were	VBD	O	O
depression	SAPHRIS.xml:S1:21531:10	depress	NN	B-AdverseReaction	B-AdverseReaction
(	SAPHRIS.xml:S1:21542:1	(	(	O	O
2.5%	SAPHRIS.xml:S1:21543:4	2.5%	CD	O	O
)	SAPHRIS.xml:S1:21547:1	)	)	O	O
,	SAPHRIS.xml:S1:21548:1	,	,	O	O
suicidal	SAPHRIS.xml:S1:21550:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
ideation	SAPHRIS.xml:S1:21559:8	ideat	NN	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S1:21568:1	(	(	O	O
2.5%	SAPHRIS.xml:S1:21569:4	2.5%	CD	O	O
)	SAPHRIS.xml:S1:21573:1	)	)	O	O
,	SAPHRIS.xml:S1:21574:1	,	,	O	O
bipolar	SAPHRIS.xml:S1:21576:7	bipolar	JJ	B-AdverseReaction	O
I	SAPHRIS.xml:S1:21584:1	I	PRP	I-AdverseReaction	O
disorder	SAPHRIS.xml:S1:21586:8	disord	VBP	I-AdverseReaction	O
(	SAPHRIS.xml:S1:21595:1	(	(	O	O
1.9%	SAPHRIS.xml:S1:21596:4	1.9%	CD	O	O
)	SAPHRIS.xml:S1:21600:1	)	)	O	O
,	SAPHRIS.xml:S1:21601:1	,	,	O	O
insomnia	SAPHRIS.xml:S1:21603:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
(	SAPHRIS.xml:S1:21612:1	(	(	O	O
1.9%	SAPHRIS.xml:S1:21613:4	1.9%	CD	O	O
)	SAPHRIS.xml:S1:21617:1	)	)	O	O
and	SAPHRIS.xml:S1:21619:3	and	CC	O	O
depressive	SAPHRIS.xml:S1:21623:10	depress	JJ	B-AdverseReaction	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:21634:8	symptom	NNS	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S1:21643:1	(	(	O	O
1.3%	SAPHRIS.xml:S1:21644:4	1.3%	CD	O	O
)	SAPHRIS.xml:S1:21648:1	)	)	O	O
.	SAPHRIS.xml:S1:21649:1	.	.	O	O

Adverse	SAPHRIS.xml:S1:21659:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:21667:9	reaction	NNP	O	O
Occurring	SAPHRIS.xml:S1:21677:9	occur	NNP	O	O
at	SAPHRIS.xml:S1:21687:2	at	IN	O	O
an	SAPHRIS.xml:S1:21690:2	an	DT	O	O
Incidence	SAPHRIS.xml:S1:21693:9	incid	NN	O	O
of	SAPHRIS.xml:S1:21703:2	of	IN	O	O
2%	SAPHRIS.xml:S1:21706:2	2%	CD	O	O
or	SAPHRIS.xml:S1:21709:2	or	CC	O	O
More	SAPHRIS.xml:S1:21712:4	more	JJR	O	O
Among	SAPHRIS.xml:S1:21717:5	among	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:21723:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:21730:1	-	:	O	O
Treated	SAPHRIS.xml:S1:21731:7	treat	VBN	O	O
(	SAPHRIS.xml:S1:21739:1	(	(	O	O
Adjunctive	SAPHRIS.xml:S1:21740:10	adjunct	NNP	O	O
)	SAPHRIS.xml:S1:21750:1	)	)	O	O
Bipolar	SAPHRIS.xml:S1:21752:7	bipolar	JJ	O	O
Patients	SAPHRIS.xml:S1:21760:8	patient	NNS	O	O
:	SAPHRIS.xml:S1:21768:1	:	:	O	O
Adverse	SAPHRIS.xml:S1:21771:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:21779:9	reaction	NNS	O	O
associated	SAPHRIS.xml:S1:21789:10	associ	VBN	O	O
with	SAPHRIS.xml:S1:21800:4	with	IN	O	O
the	SAPHRIS.xml:S1:21805:3	the	DT	O	O
use	SAPHRIS.xml:S1:21809:3	use	NN	O	O
of	SAPHRIS.xml:S1:21813:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:21816:7	saphri	NNP	O	O
(	SAPHRIS.xml:S1:21824:1	(	(	O	O
incidence	SAPHRIS.xml:S1:21825:9	incid	NN	O	O
of	SAPHRIS.xml:S1:21835:2	of	IN	O	O
2%	SAPHRIS.xml:S1:21838:2	2%	CD	O	O
or	SAPHRIS.xml:S1:21841:2	or	CC	O	O
greater	SAPHRIS.xml:S1:21844:7	greater	JJR	O	O
,	SAPHRIS.xml:S1:21851:1	,	,	O	O
rounded	SAPHRIS.xml:S1:21853:7	round	VBD	O	O
to	SAPHRIS.xml:S1:21861:2	to	TO	O	O
the	SAPHRIS.xml:S1:21864:3	the	DT	O	O
nearest	SAPHRIS.xml:S1:21868:7	nearest	JJS	O	O
percent	SAPHRIS.xml:S1:21876:7	percent	NN	O	O
,	SAPHRIS.xml:S1:21883:1	,	,	O	O
and	SAPHRIS.xml:S1:21885:3	and	CC	O	O
SAPHRIS	SAPHRIS.xml:S1:21889:7	saphri	NNP	O	O
incidence	SAPHRIS.xml:S1:21897:9	incid	NN	O	O
greater	SAPHRIS.xml:S1:21907:7	greater	JJR	O	O
than	SAPHRIS.xml:S1:21915:4	than	IN	O	O
placebo	SAPHRIS.xml:S1:21920:7	placebo	NN	O	O
)	SAPHRIS.xml:S1:21927:1	)	)	O	O
that	SAPHRIS.xml:S1:21929:4	that	WDT	O	O
occurred	SAPHRIS.xml:S1:21934:8	occur	VBD	O	O
during	SAPHRIS.xml:S1:21943:6	dure	IN	O	O
acute	SAPHRIS.xml:S1:21950:5	acut	JJ	O	O
adjunctive	SAPHRIS.xml:S1:21956:10	adjunct	JJ	O	O
therapy	SAPHRIS.xml:S1:21967:7	therapi	NN	O	O
at	SAPHRIS.xml:S1:21975:2	at	IN	O	O
3	SAPHRIS.xml:S1:21978:1	3	CD	O	O
weeks	SAPHRIS.xml:S1:21980:5	week	NNS	O	O
,	SAPHRIS.xml:S1:21985:1	,	,	O	O
a	SAPHRIS.xml:S1:21987:1	a	DT	O	O
time	SAPHRIS.xml:S1:21989:4	time	NN	O	O
when	SAPHRIS.xml:S1:21994:4	when	WRB	O	O
most	SAPHRIS.xml:S1:21999:4	most	JJS	O	O
of	SAPHRIS.xml:S1:22004:2	of	IN	O	O
the	SAPHRIS.xml:S1:22007:3	the	DT	O	O
patients	SAPHRIS.xml:S1:22011:8	patient	NNS	O	O
were	SAPHRIS.xml:S1:22020:4	were	VBD	O	O
still	SAPHRIS.xml:S1:22025:5	still	RB	O	O
participating	SAPHRIS.xml:S1:22031:13	particip	VBG	O	O
in	SAPHRIS.xml:S1:22045:2	in	IN	O	O
the	SAPHRIS.xml:S1:22048:3	the	DT	O	O
trial	SAPHRIS.xml:S1:22052:5	trial	NN	O	O
,	SAPHRIS.xml:S1:22057:1	,	,	O	O
are	SAPHRIS.xml:S1:22059:3	are	VBP	O	O
shown	SAPHRIS.xml:S1:22063:5	shown	VBN	O	O
in	SAPHRIS.xml:S1:22069:2	in	IN	O	O
Table	SAPHRIS.xml:S1:22073:5	tabl	JJ	O	O
11	SAPHRIS.xml:S1:22079:2	11	CD	O	O
.	SAPHRIS.xml:S1:22083:1	.	.	O	O

Table	SAPHRIS.xml:S1:22089:5	tabl	JJ	O	O
11	SAPHRIS.xml:S1:22095:2	11	CD	O	O
:	SAPHRIS.xml:S1:22097:1	:	:	O	O
Adverse	SAPHRIS.xml:S1:22099:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S1:22107:9	reaction	NNP	O	O
Reported	SAPHRIS.xml:S1:22117:8	report	VBD	O	O
in	SAPHRIS.xml:S1:22126:2	in	IN	O	O
2%	SAPHRIS.xml:S1:22129:2	2%	CD	O	O
or	SAPHRIS.xml:S1:22132:2	or	CC	O	O
More	SAPHRIS.xml:S1:22135:4	more	JJR	O	O
of	SAPHRIS.xml:S1:22140:2	of	IN	O	O
Adult	SAPHRIS.xml:S1:22143:5	adult	NNP	O	O
Patients	SAPHRIS.xml:S1:22149:8	patient	NNPS	O	O
In	SAPHRIS.xml:S1:22158:2	In	IN	O	O
Any	SAPHRIS.xml:S1:22161:3	ani	NNP	O	O
SAPHRIS	SAPHRIS.xml:S1:22165:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:22172:1	-	:	O	O
Dose	SAPHRIS.xml:S1:22173:4	dose	NNP	O	O
Group	SAPHRIS.xml:S1:22178:5	group	NNP	O	O
and	SAPHRIS.xml:S1:22184:3	and	CC	O	O
Which	SAPHRIS.xml:S1:22188:5	which	NNP	O	O
Occurred	SAPHRIS.xml:S1:22194:8	occur	VBD	O	O
at	SAPHRIS.xml:S1:22203:2	at	IN	O	O
Greater	SAPHRIS.xml:S1:22206:7	greater	NNP	O	O
Incidence	SAPHRIS.xml:S1:22214:9	incid	NNP	O	O
Than	SAPHRIS.xml:S1:22224:4	than	NNP	O	O
in	SAPHRIS.xml:S1:22229:2	in	IN	O	O
the	SAPHRIS.xml:S1:22232:3	the	DT	O	O
Placebo	SAPHRIS.xml:S1:22236:7	placebo	NNP	O	O
Group	SAPHRIS.xml:S1:22244:5	group	NNP	O	O
at	SAPHRIS.xml:S1:22250:2	at	IN	O	O
3	SAPHRIS.xml:S1:22253:1	3	CD	O	O
Weeks	SAPHRIS.xml:S1:22255:5	week	NNP	O	O
in	SAPHRIS.xml:S1:22261:2	in	IN	O	O
Adjunctive	SAPHRIS.xml:S1:22264:10	adjunct	NNP	O	O
Bipolar	SAPHRIS.xml:S1:22275:7	bipolar	NNP	O	O
Mania	SAPHRIS.xml:S1:22283:5	mania	NNP	O	O
Trials	SAPHRIS.xml:S1:22289:6	trial	NNP	O	O

SAPHRIS	SAPHRIS.xml:S1:22301:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:22309:1	5	CD	O	O
mg	SAPHRIS.xml:S1:22311:2	mg	NN	O	O
to	SAPHRIS.xml:S1:22314:2	to	TO	O	O
10	SAPHRIS.xml:S1:22317:2	10	CD	O	O
mg	SAPHRIS.xml:S1:22320:2	mg	NNS	O	O
twice	SAPHRIS.xml:S1:22323:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:22329:5	daili	RB	O	O
with	SAPHRIS.xml:S1:22335:4	with	IN	O	O
flexible	SAPHRIS.xml:S1:22340:8	flexibl	JJ	O	O
dosing	SAPHRIS.xml:S1:22349:6	dose	NN	O	O
.	SAPHRIS.xml:S1:22355:1	.	.	O	O

Extrapyramidal	SAPHRIS.xml:S1:22364:14	extrapyramid	NNP	B-AdverseReaction	O
symptoms	SAPHRIS.xml:S1:22379:8	symptom	NNS	I-AdverseReaction	O
included	SAPHRIS.xml:S1:22388:8	includ	VBD	O	O
:	SAPHRIS.xml:S1:22396:1	:	:	O	O
dystonia	SAPHRIS.xml:S1:22398:8	dystonia	NN	B-AdverseReaction	O
,	SAPHRIS.xml:S1:22406:1	,	,	O	O
parkinsonism	SAPHRIS.xml:S1:22408:12	parkinson	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:22420:1	,	,	O	O
oculogyration	SAPHRIS.xml:S1:22422:13	oculogyr	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:22435:1	,	,	O	O
and	SAPHRIS.xml:S1:22437:3	and	CC	O	O
tremor	SAPHRIS.xml:S1:22441:6	tremor	NN	B-AdverseReaction	B-AdverseReaction
(	SAPHRIS.xml:S1:22448:1	(	(	O	O
excluding	SAPHRIS.xml:S1:22449:9	exclud	VBG	O	O
akathisia	SAPHRIS.xml:S1:22459:9	akathisia	NN	B-AdverseReaction	O
)	SAPHRIS.xml:S1:22468:1	)	)	O	O
.	SAPHRIS.xml:S1:22469:1	.	.	O	O

?	SAPHRIS.xml:S1:22477:1	?	.	O	O

Somnolence	SAPHRIS.xml:S1:22479:10	somnol	NNP	B-AdverseReaction	B-AdverseReaction
includes	SAPHRIS.xml:S1:22490:8	includ	VBZ	O	O
the	SAPHRIS.xml:S1:22499:3	the	DT	O	O
following	SAPHRIS.xml:S1:22503:9	follow	JJ	O	O
events	SAPHRIS.xml:S1:22513:6	event	NNS	O	O
:	SAPHRIS.xml:S1:22519:1	:	:	O	O
somnolence	SAPHRIS.xml:S1:22521:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
and	SAPHRIS.xml:S1:22532:3	and	CC	O	O
sedation	SAPHRIS.xml:S1:22536:8	sedat	NN	B-AdverseReaction	O
.	SAPHRIS.xml:S1:22544:1	.	.	O	O

System	SAPHRIS.xml:S1:22556:6	system	NN	O	O

Organ	SAPHRIS.xml:S1:22563:5	organ	NNP	O	O
Class	SAPHRIS.xml:S1:22569:5	class	NNP	O	O
Preferred	SAPHRIS.xml:S1:22575:9	prefer	NNP	O	O
Term	SAPHRIS.xml:S1:22585:4	term	NNP	O	O
Placebo	SAPHRIS.xml:S1:22605:7	placebo	NNP	O	O
N	SAPHRIS.xml:S1:22616:1	N	NNP	O	O
166	SAPHRIS.xml:S1:22618:3	166	CD	O	O
SAPHRIS	SAPHRIS.xml:S1:22632:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:22643:1	5	CD	O	O
mg	SAPHRIS.xml:S1:22645:2	mg	NN	O	O
or	SAPHRIS.xml:S1:22648:2	or	CC	O	O
10	SAPHRIS.xml:S1:22651:2	10	CD	O	O
mg	SAPHRIS.xml:S1:22654:2	mg	JJ	O	O
twice	SAPHRIS.xml:S1:22657:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:22663:5	daili	RB	O	O
N	SAPHRIS.xml:S1:22673:1	N	NNP	O	O
158	SAPHRIS.xml:S1:22675:3	158	CD	O	O

Gastrointestinal	SAPHRIS.xml:S1:22692:16	gastrointestin	JJ	O	O
disorders	SAPHRIS.xml:S1:22709:9	disord	NNS	O	O

Dyspepsia	SAPHRIS.xml:S1:22745:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
2	SAPHRIS.xml:S1:22791:1	2	CD	O	O
3	SAPHRIS.xml:S1:22813:1	3	CD	O	O

Oral	SAPHRIS.xml:S1:22853:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:22858:12	hypoesthesia	NN	I-AdverseReaction	I-AdverseReaction
0	SAPHRIS.xml:S1:22899:1	0	CD	O	O
5	SAPHRIS.xml:S1:22921:1	5	CD	O	O

General	SAPHRIS.xml:S1:22960:7	gener	NNP	O	O
disorders	SAPHRIS.xml:S1:22968:9	disord	NNS	O	O

Fatigue	SAPHRIS.xml:S1:23013:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
2	SAPHRIS.xml:S1:23059:1	2	CD	O	O
4	SAPHRIS.xml:S1:23081:1	4	CD	O	O

Edema	SAPHRIS.xml:S1:23121:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
peripheral	SAPHRIS.xml:S1:23127:10	peripher	JJ	I-AdverseReaction	I-AdverseReaction
1	SAPHRIS.xml:S1:23168:1	1	CD	O	O
3	SAPHRIS.xml:S1:23189:1	3	CD	O	O

Investigations	SAPHRIS.xml:S1:23228:14	investig	NNS	O	O

Increased	SAPHRIS.xml:S1:23281:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
weight	SAPHRIS.xml:S1:23291:6	weight	VBD	I-AdverseReaction	I-AdverseReaction
0	SAPHRIS.xml:S1:23327:1	0	CD	O	O
3	SAPHRIS.xml:S1:23349:1	3	CD	O	O

Nervous	SAPHRIS.xml:S1:23388:7	nervou	JJ	O	O
system	SAPHRIS.xml:S1:23396:6	system	NN	O	O
disorders	SAPHRIS.xml:S1:23403:9	disord	NNS	O	O

Dizziness	SAPHRIS.xml:S1:23441:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
2	SAPHRIS.xml:S1:23487:1	2	CD	O	O
4	SAPHRIS.xml:S1:23509:1	4	CD	O	O

Other	SAPHRIS.xml:S1:23549:5	other	JJ	O	O
extrapyramidal	SAPHRIS.xml:S1:23555:14	extrapyramid	NN	B-AdverseReaction	O
symptoms	SAPHRIS.xml:S1:23570:8	symptom	NNS	I-AdverseReaction	O
(	SAPHRIS.xml:S1:23579:1	(	(	O	O
excluding	SAPHRIS.xml:S1:23580:9	exclud	VBG	O	O
akathisia	SAPHRIS.xml:S1:23590:9	akathisia	NN	B-AdverseReaction	O
)	SAPHRIS.xml:S1:23599:1	)	)	O	O
5	SAPHRIS.xml:S1:23606:1	5	CD	O	O
6	SAPHRIS.xml:S1:23628:1	6	CD	O	O

Somnolence	SAPHRIS.xml:S1:23668:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
?	SAPHRIS.xml:S1:23680:1	?	.	O	O

10	SAPHRIS.xml:S1:23714:2	10	CD	O	O
22	SAPHRIS.xml:S1:23736:2	22	CD	O	O

Psychiatric	SAPHRIS.xml:S1:23775:11	psychiatr	JJ	O	O
disorders	SAPHRIS.xml:S1:23787:9	disord	NNS	O	O

Insomnia	SAPHRIS.xml:S1:23828:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
8	SAPHRIS.xml:S1:23874:1	8	CD	O	O
10	SAPHRIS.xml:S1:23896:2	10	CD	O	O

Vascular	SAPHRIS.xml:S1:23935:8	vascular	JJ	O	O
disorders	SAPHRIS.xml:S1:23944:9	disord	NNS	O	O

Hypertension	SAPHRIS.xml:S1:23988:12	hypertens	NNP	B-AdverseReaction	B-AdverseReaction
1	SAPHRIS.xml:S1:24035:1	1	CD	O	O
3	SAPHRIS.xml:S1:24056:1	3	CD	O	O

Dystonia	SAPHRIS.xml:S1:24105:8	dystonia	NN	O	O
:	SAPHRIS.xml:S1:24113:1	:	:	O	O
Symptoms	SAPHRIS.xml:S1:24116:8	symptom	NNS	O	O
of	SAPHRIS.xml:S1:24125:2	of	IN	O	O
dystonia	SAPHRIS.xml:S1:24128:8	dystonia	NN	B-AdverseReaction	O
,	SAPHRIS.xml:S1:24136:1	,	,	O	O
prolonged	SAPHRIS.xml:S1:24138:9	prolong	VBD	B-AdverseReaction	O
abnormal	SAPHRIS.xml:S1:24148:8	abnorm	JJ	I-AdverseReaction	O
contractions	SAPHRIS.xml:S1:24157:12	contract	NNS	I-AdverseReaction	O
of	SAPHRIS.xml:S1:24170:2	of	IN	I-AdverseReaction	O
muscle	SAPHRIS.xml:S1:24173:6	muscl	NN	I-AdverseReaction	O
groups	SAPHRIS.xml:S1:24180:6	group	NNS	I-AdverseReaction	O
,	SAPHRIS.xml:S1:24186:1	,	,	O	O
may	SAPHRIS.xml:S1:24188:3	may	MD	O	O
occur	SAPHRIS.xml:S1:24192:5	occur	VB	O	O
in	SAPHRIS.xml:S1:24198:2	in	IN	O	O
susceptible	SAPHRIS.xml:S1:24201:11	suscept	JJ	O	O
individuals	SAPHRIS.xml:S1:24213:11	individu	NNS	O	O
during	SAPHRIS.xml:S1:24225:6	dure	IN	O	O
the	SAPHRIS.xml:S1:24232:3	the	DT	O	O
first	SAPHRIS.xml:S1:24236:5	first	JJ	O	O
few	SAPHRIS.xml:S1:24242:3	few	JJ	O	O
days	SAPHRIS.xml:S1:24246:4	day	NNS	O	O
of	SAPHRIS.xml:S1:24251:2	of	IN	O	O
treatment	SAPHRIS.xml:S1:24254:9	treatment	NN	O	O
.	SAPHRIS.xml:S1:24263:1	.	.	O	O

Dystonic	SAPHRIS.xml:S1:24265:8	dyston	NNP	B-AdverseReaction	O
symptoms	SAPHRIS.xml:S1:24274:8	symptom	NNS	I-AdverseReaction	O
include	SAPHRIS.xml:S1:24283:7	includ	VBP	O	O
:	SAPHRIS.xml:S1:24290:1	:	:	O	O
spasm	SAPHRIS.xml:S1:24292:5	spasm	NN	B-AdverseReaction	B-AdverseReaction
of	SAPHRIS.xml:S1:24298:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	SAPHRIS.xml:S1:24301:3	the	DT	I-AdverseReaction	I-AdverseReaction
neck	SAPHRIS.xml:S1:24305:4	neck	NN	I-AdverseReaction	I-AdverseReaction
muscles	SAPHRIS.xml:S1:24310:7	muscl	NNS	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:24317:1	,	,	O	O
sometimes	SAPHRIS.xml:S1:24319:9	sometim	RB	O	O
progressing	SAPHRIS.xml:S1:24329:11	progress	VBG	O	O
to	SAPHRIS.xml:S1:24341:2	to	TO	O	O
tightness	SAPHRIS.xml:S1:24344:9	tight	NN	B-AdverseReaction	B-AdverseReaction
of	SAPHRIS.xml:S1:24354:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	SAPHRIS.xml:S1:24357:3	the	DT	I-AdverseReaction	I-AdverseReaction
throat	SAPHRIS.xml:S1:24361:6	throat	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:24367:1	,	,	O	O
swallowing	SAPHRIS.xml:S1:24369:10	swallow	VBG	B-AdverseReaction	B-AdverseReaction
difficulty	SAPHRIS.xml:S1:24380:10	difficulti	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:24390:1	,	,	O	O
difficulty	SAPHRIS.xml:S1:24392:10	difficulti	NN	B-AdverseReaction	B-AdverseReaction
breathing	SAPHRIS.xml:S1:24403:9	breath	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:24412:1	,	,	O	O
and	SAPHRIS.xml:S1:24414:3	and	CC	O	O
or	SAPHRIS.xml:S1:24418:2	or	CC	O	O
protrusion	SAPHRIS.xml:S1:24421:10	protrus	NN	B-AdverseReaction	O
of	SAPHRIS.xml:S1:24432:2	of	IN	I-AdverseReaction	O
the	SAPHRIS.xml:S1:24435:3	the	DT	I-AdverseReaction	O
tongue	SAPHRIS.xml:S1:24439:6	tongu	NN	I-AdverseReaction	O
.	SAPHRIS.xml:S1:24445:1	.	.	O	O

While	SAPHRIS.xml:S1:24447:5	while	IN	O	O
these	SAPHRIS.xml:S1:24453:5	these	DT	O	O
symptoms	SAPHRIS.xml:S1:24459:8	symptom	NNS	O	O
can	SAPHRIS.xml:S1:24468:3	can	MD	O	O
occur	SAPHRIS.xml:S1:24472:5	occur	VB	O	O
at	SAPHRIS.xml:S1:24478:2	at	IN	O	O
low	SAPHRIS.xml:S1:24481:3	low	JJ	O	O
doses	SAPHRIS.xml:S1:24485:5	dose	NNS	O	O
,	SAPHRIS.xml:S1:24490:1	,	,	O	O
they	SAPHRIS.xml:S1:24492:4	they	PRP	O	O
occur	SAPHRIS.xml:S1:24497:5	occur	VBP	O	O
more	SAPHRIS.xml:S1:24503:4	more	RBR	O	O
frequently	SAPHRIS.xml:S1:24508:10	frequent	RB	O	O
and	SAPHRIS.xml:S1:24519:3	and	CC	O	O
with	SAPHRIS.xml:S1:24523:4	with	IN	O	O
greater	SAPHRIS.xml:S1:24528:7	greater	JJR	O	O
severity	SAPHRIS.xml:S1:24536:8	sever	NN	O	O
with	SAPHRIS.xml:S1:24545:4	with	IN	O	O
high	SAPHRIS.xml:S1:24550:4	high	JJ	O	O
potency	SAPHRIS.xml:S1:24555:7	potenc	NN	O	O
and	SAPHRIS.xml:S1:24563:3	and	CC	O	O
at	SAPHRIS.xml:S1:24567:2	at	IN	O	O
higher	SAPHRIS.xml:S1:24570:6	higher	JJR	O	O
doses	SAPHRIS.xml:S1:24577:5	dose	NNS	O	O
of	SAPHRIS.xml:S1:24583:2	of	IN	O	O
first	SAPHRIS.xml:S1:24586:5	first	JJ	O	O
generation	SAPHRIS.xml:S1:24592:10	gener	NN	O	O
antipsychotic	SAPHRIS.xml:S1:24603:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S1:24617:5	drug	NNS	O	O
.	SAPHRIS.xml:S1:24622:1	.	.	O	O

An	SAPHRIS.xml:S1:24624:2	An	DT	O	O
elevated	SAPHRIS.xml:S1:24627:8	elev	JJ	O	O
risk	SAPHRIS.xml:S1:24636:4	risk	NN	O	O
of	SAPHRIS.xml:S1:24641:2	of	IN	O	O
acute	SAPHRIS.xml:S1:24644:5	acut	JJ	B-AdverseReaction	O
dystonia	SAPHRIS.xml:S1:24650:8	dystonia	NN	I-AdverseReaction	O
is	SAPHRIS.xml:S1:24659:2	is	VBZ	O	O
observed	SAPHRIS.xml:S1:24662:8	observ	VBN	O	O
in	SAPHRIS.xml:S1:24671:2	in	IN	O	O
males	SAPHRIS.xml:S1:24674:5	male	NNS	O	O
and	SAPHRIS.xml:S1:24680:3	and	CC	O	O
younger	SAPHRIS.xml:S1:24684:7	younger	JJR	O	O
age	SAPHRIS.xml:S1:24692:3	age	NN	O	O
groups	SAPHRIS.xml:S1:24696:6	group	NNS	O	O
[	SAPHRIS.xml:S1:24704:1	[	VBP	O	O
see	SAPHRIS.xml:S1:24705:3	see	VBP	O	O
Dosage	SAPHRIS.xml:S1:24709:6	dosag	NNP	O	O
and	SAPHRIS.xml:S1:24716:3	and	CC	O	O
Administration	SAPHRIS.xml:S1:24720:14	administr	NNP	O	O
(	SAPHRIS.xml:S1:24735:1	(	(	O	O
2.3	SAPHRIS.xml:S1:24736:3	2.3	CD	O	O
)	SAPHRIS.xml:S1:24739:1	)	)	O	O
,	SAPHRIS.xml:S1:24740:1	,	,	O	O
Use	SAPHRIS.xml:S1:24742:3	use	NNP	O	O
in	SAPHRIS.xml:S1:24746:2	in	IN	O	O
Specific	SAPHRIS.xml:S1:24749:8	specif	NNP	O	O
Populations	SAPHRIS.xml:S1:24758:11	popul	NNP	O	O
(	SAPHRIS.xml:S1:24770:1	(	(	O	O
8.4	SAPHRIS.xml:S1:24771:3	8.4	CD	O	O
)	SAPHRIS.xml:S1:24774:1	)	)	O	O
,	SAPHRIS.xml:S1:24775:1	,	,	O	O
and	SAPHRIS.xml:S1:24777:3	and	CC	O	O
Clinical	SAPHRIS.xml:S1:24781:8	clinic	NNP	O	O
Pharmacology	SAPHRIS.xml:S1:24790:12	pharmacolog	NNP	O	O
(	SAPHRIS.xml:S1:24803:1	(	(	O	O
12.3	SAPHRIS.xml:S1:24804:4	12.3	CD	O	O
)]	SAPHRIS.xml:S1:24808:2	)]	NN	O	O
.	SAPHRIS.xml:S1:24812:1	.	.	O	O

Extrapyramidal	SAPHRIS.xml:S1:24822:14	extrapyramid	NN	O	O

Symptoms	SAPHRIS.xml:S1:24837:8	symptom	NNS	O	O
:	SAPHRIS.xml:S1:24845:1	:	:	O	O
In	SAPHRIS.xml:S1:24848:2	In	IN	O	O
the	SAPHRIS.xml:S1:24851:3	the	DT	O	O
short	SAPHRIS.xml:S1:24855:5	short	JJ	O	O
-	SAPHRIS.xml:S1:24860:1	-	:	O	O
term	SAPHRIS.xml:S1:24861:4	term	NN	O	O
,	SAPHRIS.xml:S1:24865:1	,	,	O	O
placebo	SAPHRIS.xml:S1:24867:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:24874:1	-	:	O	O
controlled	SAPHRIS.xml:S1:24875:10	control	VBN	O	O
schizophrenia	SAPHRIS.xml:S1:24886:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S1:24900:3	and	CC	O	O
bipolar	SAPHRIS.xml:S1:24904:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S1:24912:5	mania	NN	O	O
adult	SAPHRIS.xml:S1:24918:5	adult	NN	O	O
trials	SAPHRIS.xml:S1:24924:6	trial	NNS	O	O
,	SAPHRIS.xml:S1:24930:1	,	,	O	O
data	SAPHRIS.xml:S1:24932:4	data	NNS	O	O
was	SAPHRIS.xml:S1:24937:3	wa	VBD	O	O
objectively	SAPHRIS.xml:S1:24941:11	object	RB	O	O
collected	SAPHRIS.xml:S1:24953:9	collect	VBN	O	O
on	SAPHRIS.xml:S1:24963:2	on	IN	O	O
the	SAPHRIS.xml:S1:24966:3	the	DT	O	O
Simpson	SAPHRIS.xml:S1:24970:7	simpson	NNP	O	O
Angus	SAPHRIS.xml:S1:24978:5	angu	NNP	O	O
Rating	SAPHRIS.xml:S1:24984:6	rate	NNP	O	O
Scale	SAPHRIS.xml:S1:24991:5	scale	NNP	O	O
for	SAPHRIS.xml:S1:24997:3	for	IN	O	O
extrapyramidal	SAPHRIS.xml:S1:25001:14	extrapyramid	NN	B-AdverseReaction	O
symptoms	SAPHRIS.xml:S1:25016:8	symptom	NNS	I-AdverseReaction	O
(	SAPHRIS.xml:S1:25025:1	(	(	O	O
EPS	SAPHRIS.xml:S1:25026:3	ep	NNP	B-AdverseReaction	O
)	SAPHRIS.xml:S1:25029:1	)	)	O	O
,	SAPHRIS.xml:S1:25030:1	,	,	O	O
the	SAPHRIS.xml:S1:25032:3	the	DT	O	O
Barnes	SAPHRIS.xml:S1:25036:6	barn	NNP	O	O
Akathisia	SAPHRIS.xml:S1:25043:9	akathisia	NNP	O	O
Scale	SAPHRIS.xml:S1:25053:5	scale	NNP	O	O
(	SAPHRIS.xml:S1:25059:1	(	(	O	O
for	SAPHRIS.xml:S1:25060:3	for	IN	O	O
akathisia	SAPHRIS.xml:S1:25064:9	akathisia	NN	B-AdverseReaction	O
)	SAPHRIS.xml:S1:25073:1	)	)	O	O
and	SAPHRIS.xml:S1:25075:3	and	CC	O	O
the	SAPHRIS.xml:S1:25079:3	the	DT	O	O
Assessments	SAPHRIS.xml:S1:25083:11	assess	NNS	O	O
of	SAPHRIS.xml:S1:25095:2	of	IN	O	O
Involuntary	SAPHRIS.xml:S1:25098:11	involuntari	NNP	O	O
Movement	SAPHRIS.xml:S1:25110:8	movement	NNP	O	O
Scales	SAPHRIS.xml:S1:25119:6	scale	NNP	O	O
(	SAPHRIS.xml:S1:25126:1	(	(	O	O
for	SAPHRIS.xml:S1:25127:3	for	IN	O	O
dyskinesias	SAPHRIS.xml:S1:25131:11	dyskinesia	NN	B-AdverseReaction	O
)	SAPHRIS.xml:S1:25142:1	)	)	O	O
.	SAPHRIS.xml:S1:25143:1	.	.	O	O

The	SAPHRIS.xml:S1:25145:3	the	DT	O	O
mean	SAPHRIS.xml:S1:25149:4	mean	JJ	O	O
change	SAPHRIS.xml:S1:25154:6	chang	NN	O	O
from	SAPHRIS.xml:S1:25161:4	from	IN	O	O
baseline	SAPHRIS.xml:S1:25166:8	baselin	NN	O	O
for	SAPHRIS.xml:S1:25175:3	for	IN	O	O
the	SAPHRIS.xml:S1:25179:3	the	DT	O	O
all	SAPHRIS.xml:S1:25183:3	all	DT	O	O
-	SAPHRIS.xml:S1:25186:1	-	:	O	O
SAPHRIS	SAPHRIS.xml:S1:25187:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:25195:1	5	CD	O	O
mg	SAPHRIS.xml:S1:25197:2	mg	NN	O	O
or	SAPHRIS.xml:S1:25200:2	or	CC	O	O
10	SAPHRIS.xml:S1:25203:2	10	CD	O	O
mg	SAPHRIS.xml:S1:25206:2	mg	JJ	O	O
twice	SAPHRIS.xml:S1:25209:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:25215:5	daili	RB	O	O
treated	SAPHRIS.xml:S1:25221:7	treat	VBN	O	O
group	SAPHRIS.xml:S1:25229:5	group	NN	O	O
was	SAPHRIS.xml:S1:25235:3	wa	VBD	O	O
comparable	SAPHRIS.xml:S1:25239:10	compar	JJ	O	O
to	SAPHRIS.xml:S1:25250:2	to	TO	O	O
placebo	SAPHRIS.xml:S1:25253:7	placebo	VB	O	O
in	SAPHRIS.xml:S1:25261:2	in	IN	O	O
each	SAPHRIS.xml:S1:25264:4	each	DT	O	O
of	SAPHRIS.xml:S1:25269:2	of	IN	O	O
the	SAPHRIS.xml:S1:25272:3	the	DT	O	O
rating	SAPHRIS.xml:S1:25276:6	rate	NN	O	O
scale	SAPHRIS.xml:S1:25283:5	scale	NN	O	O
scores	SAPHRIS.xml:S1:25289:6	score	NNS	O	O
.	SAPHRIS.xml:S1:25295:1	.	.	O	O

In	SAPHRIS.xml:S1:25301:2	In	IN	O	O
the	SAPHRIS.xml:S1:25304:3	the	DT	O	O
short	SAPHRIS.xml:S1:25308:5	short	JJ	O	O
-	SAPHRIS.xml:S1:25313:1	-	:	O	O
term	SAPHRIS.xml:S1:25314:4	term	NN	O	O
,	SAPHRIS.xml:S1:25318:1	,	,	O	O
placebo	SAPHRIS.xml:S1:25320:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:25327:1	-	:	O	O
controlled	SAPHRIS.xml:S1:25328:10	control	VBN	O	O
schizophrenia	SAPHRIS.xml:S1:25339:13	schizophrenia	NN	O	O
adult	SAPHRIS.xml:S1:25353:5	adult	NN	O	O
trials	SAPHRIS.xml:S1:25359:6	trial	NNS	O	O
,	SAPHRIS.xml:S1:25365:1	,	,	O	O
the	SAPHRIS.xml:S1:25367:3	the	DT	O	O
incidence	SAPHRIS.xml:S1:25371:9	incid	NN	O	O
of	SAPHRIS.xml:S1:25381:2	of	IN	O	O
reported	SAPHRIS.xml:S1:25384:8	report	VBN	O	O
EPS	SAPHRIS.xml:S1:25393:3	ep	NNP	B-AdverseReaction	B-AdverseReaction
-	SAPHRIS.xml:S1:25396:1	-	:	I-AdverseReaction	I-AdverseReaction
related	SAPHRIS.xml:S1:25397:7	relat	JJ	I-AdverseReaction	I-AdverseReaction
events	SAPHRIS.xml:S1:25405:6	event	NNS	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:25411:1	,	,	O	O
excluding	SAPHRIS.xml:S1:25413:9	exclud	VBG	O	B-AdverseReaction
events	SAPHRIS.xml:S1:25423:6	event	NNS	O	I-AdverseReaction
related	SAPHRIS.xml:S1:25430:7	relat	VBN	O	O
to	SAPHRIS.xml:S1:25438:2	to	TO	O	O
akathisia	SAPHRIS.xml:S1:25441:9	akathisia	VB	B-AdverseReaction	O
,	SAPHRIS.xml:S1:25450:1	,	,	O	O
for	SAPHRIS.xml:S1:25452:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:25456:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:25463:1	-	:	O	O
treated	SAPHRIS.xml:S1:25464:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:25472:8	patient	NNS	O	O
was	SAPHRIS.xml:S1:25481:3	wa	VBD	O	O
10%	SAPHRIS.xml:S1:25485:3	10%	CD	O	O
versus	SAPHRIS.xml:S1:25489:6	versu	NN	O	O
7%	SAPHRIS.xml:S1:25496:2	7%	CD	O	O
for	SAPHRIS.xml:S1:25499:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:25503:7	placebo	NN	O	O
;	SAPHRIS.xml:S1:25510:1	;	:	O	O
and	SAPHRIS.xml:S1:25512:3	and	CC	O	O
the	SAPHRIS.xml:S1:25516:3	the	DT	O	O
incidence	SAPHRIS.xml:S1:25520:9	incid	NN	O	O
of	SAPHRIS.xml:S1:25530:2	of	IN	O	O
akathisia	SAPHRIS.xml:S1:25533:9	akathisia	JJ	B-AdverseReaction	B-AdverseReaction
-	SAPHRIS.xml:S1:25542:1	-	:	O	I-AdverseReaction
related	SAPHRIS.xml:S1:25543:7	relat	JJ	O	I-AdverseReaction
events	SAPHRIS.xml:S1:25551:6	event	NNS	O	I-AdverseReaction
for	SAPHRIS.xml:S1:25558:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:25562:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:25569:1	-	:	O	O
treated	SAPHRIS.xml:S1:25570:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:25578:8	patient	NNS	O	O
was	SAPHRIS.xml:S1:25587:3	wa	VBD	O	O
6%	SAPHRIS.xml:S1:25591:2	6%	CD	O	O
versus	SAPHRIS.xml:S1:25594:6	versu	NN	O	O
3%	SAPHRIS.xml:S1:25601:2	3%	CD	O	O
for	SAPHRIS.xml:S1:25604:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:25608:7	placebo	NN	O	O
.	SAPHRIS.xml:S1:25615:1	.	.	O	O

In	SAPHRIS.xml:S1:25617:2	In	IN	O	O
short	SAPHRIS.xml:S1:25620:5	short	JJ	O	O
-	SAPHRIS.xml:S1:25625:1	-	:	O	O
term	SAPHRIS.xml:S1:25626:4	term	NN	O	O
placebo	SAPHRIS.xml:S1:25631:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:25638:1	-	:	O	O
controlled	SAPHRIS.xml:S1:25639:10	control	VBN	O	O
bipolar	SAPHRIS.xml:S1:25650:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S1:25658:5	mania	NN	O	O
adult	SAPHRIS.xml:S1:25664:5	adult	NN	O	O
trials	SAPHRIS.xml:S1:25670:6	trial	NNS	O	O
,	SAPHRIS.xml:S1:25676:1	,	,	O	O
the	SAPHRIS.xml:S1:25678:3	the	DT	O	O
incidence	SAPHRIS.xml:S1:25682:9	incid	NN	O	O
of	SAPHRIS.xml:S1:25692:2	of	IN	O	O
EPS	SAPHRIS.xml:S1:25695:3	ep	NNP	B-AdverseReaction	B-AdverseReaction
-	SAPHRIS.xml:S1:25698:1	-	:	I-AdverseReaction	I-AdverseReaction
related	SAPHRIS.xml:S1:25699:7	relat	JJ	I-AdverseReaction	I-AdverseReaction
events	SAPHRIS.xml:S1:25707:6	event	NNS	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:25713:1	,	,	O	O
excluding	SAPHRIS.xml:S1:25715:9	exclud	VBG	O	B-AdverseReaction
events	SAPHRIS.xml:S1:25725:6	event	NNS	O	I-AdverseReaction
related	SAPHRIS.xml:S1:25732:7	relat	VBN	O	O
to	SAPHRIS.xml:S1:25740:2	to	TO	O	O
akathisia	SAPHRIS.xml:S1:25743:9	akathisia	VB	B-AdverseReaction	O
,	SAPHRIS.xml:S1:25752:1	,	,	O	O
for	SAPHRIS.xml:S1:25754:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:25758:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:25765:1	-	:	O	O
treated	SAPHRIS.xml:S1:25766:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:25774:8	patient	NNS	O	O
was	SAPHRIS.xml:S1:25783:3	wa	VBD	O	O
7%	SAPHRIS.xml:S1:25787:2	7%	CD	O	O
versus	SAPHRIS.xml:S1:25790:6	versu	NN	O	O
2%	SAPHRIS.xml:S1:25797:2	2%	CD	O	O
for	SAPHRIS.xml:S1:25800:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:25804:7	placebo	NN	O	O
;	SAPHRIS.xml:S1:25811:1	;	:	O	O
and	SAPHRIS.xml:S1:25813:3	and	CC	O	O
the	SAPHRIS.xml:S1:25817:3	the	DT	O	O
incidence	SAPHRIS.xml:S1:25821:9	incid	NN	O	O
of	SAPHRIS.xml:S1:25831:2	of	IN	O	O
akathisia	SAPHRIS.xml:S1:25834:9	akathisia	JJ	B-AdverseReaction	B-AdverseReaction
-	SAPHRIS.xml:S1:25843:1	-	:	O	I-AdverseReaction
related	SAPHRIS.xml:S1:25844:7	relat	JJ	O	I-AdverseReaction
events	SAPHRIS.xml:S1:25852:6	event	NNS	O	I-AdverseReaction
for	SAPHRIS.xml:S1:25859:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:25863:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:25870:1	-	:	O	O
treated	SAPHRIS.xml:S1:25871:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:25879:8	patient	NNS	O	O
was	SAPHRIS.xml:S1:25888:3	wa	VBD	O	O
4%	SAPHRIS.xml:S1:25892:2	4%	CD	O	O
versus	SAPHRIS.xml:S1:25895:6	versu	NN	O	O
2%	SAPHRIS.xml:S1:25902:2	2%	CD	O	O
for	SAPHRIS.xml:S1:25905:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:25909:7	placebo	NN	O	O
.	SAPHRIS.xml:S1:25916:1	.	.	O	O

In	SAPHRIS.xml:S1:25922:2	In	IN	O	O
a	SAPHRIS.xml:S1:25925:1	a	DT	O	O
3	SAPHRIS.xml:S1:25927:1	3	CD	O	O
-	SAPHRIS.xml:S1:25928:1	-	:	O	O
week	SAPHRIS.xml:S1:25929:4	week	NN	O	O
,	SAPHRIS.xml:S1:25933:1	,	,	O	O
placebo	SAPHRIS.xml:S1:25935:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:25942:1	-	:	O	O
controlled	SAPHRIS.xml:S1:25943:10	control	VBN	O	O
pediatric	SAPHRIS.xml:S1:25954:9	pediatr	JJ	O	O
trial	SAPHRIS.xml:S1:25964:5	trial	NN	O	O
with	SAPHRIS.xml:S1:25970:4	with	IN	O	O
bipolar	SAPHRIS.xml:S1:25975:7	bipolar	JJ	O	O
I	SAPHRIS.xml:S1:25983:1	I	PRP	O	O
disorder	SAPHRIS.xml:S1:25985:8	disord	VBP	O	O
,	SAPHRIS.xml:S1:25993:1	,	,	O	O
the	SAPHRIS.xml:S1:25995:3	the	DT	O	O
incidences	SAPHRIS.xml:S1:25999:10	incid	NNS	O	O
of	SAPHRIS.xml:S1:26010:2	of	IN	O	O
EPS	SAPHRIS.xml:S1:26013:3	ep	NNP	B-AdverseReaction	B-AdverseReaction
-	SAPHRIS.xml:S1:26016:1	-	:	I-AdverseReaction	I-AdverseReaction
related	SAPHRIS.xml:S1:26017:7	relat	JJ	I-AdverseReaction	I-AdverseReaction
events	SAPHRIS.xml:S1:26025:6	event	NNS	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:26031:1	,	,	O	O
excluding	SAPHRIS.xml:S1:26033:9	exclud	VBG	O	B-AdverseReaction
events	SAPHRIS.xml:S1:26043:6	event	NNS	O	I-AdverseReaction
related	SAPHRIS.xml:S1:26050:7	relat	VBN	O	O
to	SAPHRIS.xml:S1:26058:2	to	TO	O	O
akathisia	SAPHRIS.xml:S1:26061:9	akathisia	NNS	B-AdverseReaction	O
,	SAPHRIS.xml:S1:26070:1	,	,	O	O
were	SAPHRIS.xml:S1:26072:4	were	VBD	O	O
4%	SAPHRIS.xml:S1:26077:2	4%	CD	O	O
,	SAPHRIS.xml:S1:26079:1	,	,	O	O
3%	SAPHRIS.xml:S1:26081:2	3%	CD	O	O
,	SAPHRIS.xml:S1:26083:1	,	,	O	O
and	SAPHRIS.xml:S1:26085:3	and	CC	O	O
5%	SAPHRIS.xml:S1:26089:2	5%	CD	O	O
for	SAPHRIS.xml:S1:26092:3	for	IN	O	O
patients	SAPHRIS.xml:S1:26096:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:26105:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:26113:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:26118:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S1:26126:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:26130:2	mg	NN	O	O
,	SAPHRIS.xml:S1:26132:1	,	,	O	O
5	SAPHRIS.xml:S1:26134:1	5	CD	O	O
mg	SAPHRIS.xml:S1:26136:2	mg	NN	O	O
,	SAPHRIS.xml:S1:26138:1	,	,	O	O
and	SAPHRIS.xml:S1:26140:3	and	CC	O	O
10	SAPHRIS.xml:S1:26144:2	10	CD	O	O
mg	SAPHRIS.xml:S1:26147:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:26150:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:26156:5	daili	RB	O	O
,	SAPHRIS.xml:S1:26161:1	,	,	O	O
respectively	SAPHRIS.xml:S1:26163:12	respect	RB	O	O
,	SAPHRIS.xml:S1:26175:1	,	,	O	O
as	SAPHRIS.xml:S1:26177:2	as	IN	O	O
compared	SAPHRIS.xml:S1:26180:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:26189:2	to	TO	O	O
3%	SAPHRIS.xml:S1:26192:2	3%	CD	O	O
for	SAPHRIS.xml:S1:26195:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:26199:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:26206:1	-	:	O	O
treated	SAPHRIS.xml:S1:26207:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:26215:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:26223:1	.	.	O	O

EPS	SAPHRIS.xml:S1:26225:3	ep	NNP	B-AdverseReaction	B-AdverseReaction
-	SAPHRIS.xml:S1:26228:1	-	:	I-AdverseReaction	I-AdverseReaction
related	SAPHRIS.xml:S1:26229:7	relat	JJ	I-AdverseReaction	I-AdverseReaction
events	SAPHRIS.xml:S1:26237:6	event	NNS	I-AdverseReaction	I-AdverseReaction
include	SAPHRIS.xml:S1:26244:7	includ	VBP	O	O
:	SAPHRIS.xml:S1:26251:1	:	:	O	O
bradykinesia	SAPHRIS.xml:S1:26253:12	bradykinesia	NN	B-AdverseReaction	O
,	SAPHRIS.xml:S1:26265:1	,	,	O	O
dyskinesia	SAPHRIS.xml:S1:26267:10	dyskinesia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:26277:1	,	,	O	O
dystonia	SAPHRIS.xml:S1:26279:8	dystonia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:26287:1	,	,	O	O
oromandibular	SAPHRIS.xml:S1:26289:13	oromandibular	JJ	B-AdverseReaction	O
dystonia	SAPHRIS.xml:S1:26303:8	dystonia	NN	I-AdverseReaction	O
,	SAPHRIS.xml:S1:26311:1	,	,	O	O
muscle	SAPHRIS.xml:S1:26313:6	muscl	NN	B-AdverseReaction	O
contractions	SAPHRIS.xml:S1:26320:12	contract	NNS	I-AdverseReaction	O
involuntary	SAPHRIS.xml:S1:26333:11	involuntari	JJ	I-AdverseReaction	O
,	SAPHRIS.xml:S1:26344:1	,	,	O	O
muscle	SAPHRIS.xml:S1:26346:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
twitching	SAPHRIS.xml:S1:26353:9	twitch	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:26362:1	,	,	O	O
musculoskeletal	SAPHRIS.xml:S1:26364:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
stiffness	SAPHRIS.xml:S1:26380:9	stiff	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:26389:1	,	,	O	O
parkinsonism	SAPHRIS.xml:S1:26391:12	parkinson	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:26403:1	,	,	O	O
protrusion	SAPHRIS.xml:S1:26405:10	protrus	NN	B-AdverseReaction	B-AdverseReaction
tongue	SAPHRIS.xml:S1:26416:6	tongu	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:26422:1	,	,	O	O
resting	SAPHRIS.xml:S1:26424:7	rest	VBG	B-AdverseReaction	B-AdverseReaction
tremor	SAPHRIS.xml:S1:26432:6	tremor	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:26438:1	,	,	O	O
and	SAPHRIS.xml:S1:26440:3	and	CC	O	O
tremor	SAPHRIS.xml:S1:26444:6	tremor	NN	B-AdverseReaction	B-AdverseReaction
.	SAPHRIS.xml:S1:26450:1	.	.	O	O

For	SAPHRIS.xml:S1:26456:3	for	IN	O	O
events	SAPHRIS.xml:S1:26460:6	event	NNS	O	O
of	SAPHRIS.xml:S1:26467:2	of	IN	O	O
akathisia	SAPHRIS.xml:S1:26470:9	akathisia	NN	B-AdverseReaction	O
,	SAPHRIS.xml:S1:26479:1	,	,	O	O
incidences	SAPHRIS.xml:S1:26481:10	incid	NNS	O	O
were	SAPHRIS.xml:S1:26492:4	were	VBD	O	O
2%	SAPHRIS.xml:S1:26497:2	2%	CD	O	O
,	SAPHRIS.xml:S1:26499:1	,	,	O	O
2%	SAPHRIS.xml:S1:26501:2	2%	CD	O	O
,	SAPHRIS.xml:S1:26503:1	,	,	O	O
and	SAPHRIS.xml:S1:26505:3	and	CC	O	O
1%	SAPHRIS.xml:S1:26509:2	1%	CD	O	O
for	SAPHRIS.xml:S1:26512:3	for	IN	O	O
patients	SAPHRIS.xml:S1:26516:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:26525:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:26533:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:26538:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S1:26546:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:26550:2	mg	NN	O	O
,	SAPHRIS.xml:S1:26552:1	,	,	O	O
5	SAPHRIS.xml:S1:26554:1	5	CD	O	O
mg	SAPHRIS.xml:S1:26556:2	mg	NN	O	O
,	SAPHRIS.xml:S1:26558:1	,	,	O	O
and	SAPHRIS.xml:S1:26560:3	and	CC	O	O
10	SAPHRIS.xml:S1:26564:2	10	CD	O	O
mg	SAPHRIS.xml:S1:26567:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:26570:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:26576:5	daili	RB	O	O
,	SAPHRIS.xml:S1:26581:1	,	,	O	O
respectively	SAPHRIS.xml:S1:26583:12	respect	RB	O	O
,	SAPHRIS.xml:S1:26595:1	,	,	O	O
as	SAPHRIS.xml:S1:26597:2	as	IN	O	O
compared	SAPHRIS.xml:S1:26600:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:26609:2	to	TO	O	O
0%	SAPHRIS.xml:S1:26612:2	0%	CD	O	O
for	SAPHRIS.xml:S1:26615:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:26619:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:26626:1	-	:	O	O
treated	SAPHRIS.xml:S1:26627:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:26635:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:26643:1	.	.	O	O

Other	SAPHRIS.xml:S1:26653:5	other	JJ	O	O
Findings	SAPHRIS.xml:S1:26659:8	find	NNS	O	O
:	SAPHRIS.xml:S1:26667:1	:	:	O	O
Oral	SAPHRIS.xml:S1:26670:4	oral	NNP	B-AdverseReaction	O
hypoesthesia	SAPHRIS.xml:S1:26675:12	hypoesthesia	NN	I-AdverseReaction	O
and	SAPHRIS.xml:S1:26688:3	and	CC	O	O
or	SAPHRIS.xml:S1:26692:2	or	CC	O	O
oral	SAPHRIS.xml:S1:26695:4	oral	JJ	B-AdverseReaction	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:26700:11	paresthesia	NN	I-AdverseReaction	I-AdverseReaction
may	SAPHRIS.xml:S1:26712:3	may	MD	O	O
occur	SAPHRIS.xml:S1:26716:5	occur	VB	O	O
directly	SAPHRIS.xml:S1:26722:8	directli	RB	O	O
after	SAPHRIS.xml:S1:26731:5	after	IN	O	O
administration	SAPHRIS.xml:S1:26737:14	administr	NN	O	O
of	SAPHRIS.xml:S1:26752:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:26755:7	saphri	NNP	O	O
and	SAPHRIS.xml:S1:26763:3	and	CC	O	O
usually	SAPHRIS.xml:S1:26767:7	usual	RB	O	O
resolves	SAPHRIS.xml:S1:26775:8	resolv	NNS	O	O
within	SAPHRIS.xml:S1:26784:6	within	IN	O	O
1	SAPHRIS.xml:S1:26791:1	1	CD	O	O
hour	SAPHRIS.xml:S1:26793:4	hour	NN	O	O
.	SAPHRIS.xml:S1:26797:1	.	.	O	O

Laboratory	SAPHRIS.xml:S1:26807:10	laboratori	JJ	O	O
Test	SAPHRIS.xml:S1:26818:4	test	NNP	O	O
Abnormalities	SAPHRIS.xml:S1:26823:13	abnorm	NNS	O	O
:	SAPHRIS.xml:S1:26836:1	:	:	O	O

Transaminases	SAPHRIS.xml:S1:26848:13	transaminas	NNS	O	O
:	SAPHRIS.xml:S1:26861:1	:	:	O	O
Transient	SAPHRIS.xml:S1:26864:9	transient	NN	O	O
elevations	SAPHRIS.xml:S1:26874:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S1:26885:2	in	IN	I-AdverseReaction	I-AdverseReaction
serum	SAPHRIS.xml:S1:26888:5	serum	NN	I-AdverseReaction	I-AdverseReaction
transaminases	SAPHRIS.xml:S1:26894:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S1:26908:1	(	(	O	O
primarily	SAPHRIS.xml:S1:26909:9	primarili	RB	O	O
ALT	SAPHRIS.xml:S1:26919:3	alt	NNP	I-AdverseReaction	O
)	SAPHRIS.xml:S1:26922:1	)	)	O	O
in	SAPHRIS.xml:S1:26924:2	in	IN	O	O
the	SAPHRIS.xml:S1:26927:3	the	DT	O	O
short	SAPHRIS.xml:S1:26931:5	short	JJ	O	O
-	SAPHRIS.xml:S1:26936:1	-	:	O	O
term	SAPHRIS.xml:S1:26937:4	term	NN	O	O
schizophrenia	SAPHRIS.xml:S1:26942:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S1:26956:3	and	CC	O	O
bipolar	SAPHRIS.xml:S1:26960:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S1:26968:5	mania	NN	O	O
adult	SAPHRIS.xml:S1:26974:5	adult	NN	O	O
trials	SAPHRIS.xml:S1:26980:6	trial	NNS	O	O
were	SAPHRIS.xml:S1:26987:4	were	VBD	O	O
more	SAPHRIS.xml:S1:26992:4	more	JJR	O	O
common	SAPHRIS.xml:S1:26997:6	common	JJ	O	O
in	SAPHRIS.xml:S1:27004:2	in	IN	O	O
treated	SAPHRIS.xml:S1:27007:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:27015:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:27023:1	.	.	O	O

In	SAPHRIS.xml:S1:27025:2	In	IN	O	O
short	SAPHRIS.xml:S1:27028:5	short	JJ	O	O
-	SAPHRIS.xml:S1:27033:1	-	:	O	O
term	SAPHRIS.xml:S1:27034:4	term	NN	O	O
,	SAPHRIS.xml:S1:27038:1	,	,	O	O
placebo	SAPHRIS.xml:S1:27040:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:27047:1	-	:	O	O
controlled	SAPHRIS.xml:S1:27048:10	control	VBN	O	O
schizophrenia	SAPHRIS.xml:S1:27059:13	schizophrenia	NN	O	O
adult	SAPHRIS.xml:S1:27073:5	adult	NN	O	O
trials	SAPHRIS.xml:S1:27079:6	trial	NNS	O	O
,	SAPHRIS.xml:S1:27085:1	,	,	O	O
the	SAPHRIS.xml:S1:27087:3	the	DT	O	O
mean	SAPHRIS.xml:S1:27091:4	mean	JJ	O	O
increase	SAPHRIS.xml:S1:27096:8	increas	NN	B-AdverseReaction	O
in	SAPHRIS.xml:S1:27105:2	in	IN	I-AdverseReaction	O
transaminase	SAPHRIS.xml:S1:27108:12	transaminas	NN	I-AdverseReaction	O
levels	SAPHRIS.xml:S1:27121:6	level	NNS	I-AdverseReaction	O
for	SAPHRIS.xml:S1:27128:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:27132:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:27139:1	-	:	O	O
treated	SAPHRIS.xml:S1:27140:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:27148:8	patient	NNS	O	O
was	SAPHRIS.xml:S1:27157:3	wa	VBD	O	O
1.6	SAPHRIS.xml:S1:27161:3	1.6	CD	O	O
units	SAPHRIS.xml:S1:27165:5	unit	NNS	O	O
L	SAPHRIS.xml:S1:27171:1	L	NNP	O	O
compared	SAPHRIS.xml:S1:27173:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:27182:2	to	TO	O	O
a	SAPHRIS.xml:S1:27185:1	a	DT	O	O
decrease	SAPHRIS.xml:S1:27187:8	decreas	NN	O	O
of	SAPHRIS.xml:S1:27196:2	of	IN	O	O
0.4	SAPHRIS.xml:S1:27199:3	0.4	CD	O	O
units	SAPHRIS.xml:S1:27203:5	unit	NNS	O	O
L	SAPHRIS.xml:S1:27209:1	L	NNP	O	O
for	SAPHRIS.xml:S1:27211:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:27215:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:27222:1	-	:	O	O
treated	SAPHRIS.xml:S1:27223:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:27231:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:27239:1	.	.	O	O

The	SAPHRIS.xml:S1:27241:3	the	DT	O	O
proportion	SAPHRIS.xml:S1:27245:10	proport	NN	O	O
of	SAPHRIS.xml:S1:27256:2	of	IN	O	O
patients	SAPHRIS.xml:S1:27259:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:27268:4	with	IN	O	O
transaminase	SAPHRIS.xml:S1:27273:12	transaminas	JJ	B-AdverseReaction	O
elevations	SAPHRIS.xml:S1:27286:10	elev	NNS	I-AdverseReaction	O
3	SAPHRIS.xml:S1:27299:1	3	CD	O	O
times	SAPHRIS.xml:S1:27301:5	time	NNS	O	O
ULN	SAPHRIS.xml:S1:27307:3	uln	NNP	O	O
(	SAPHRIS.xml:S1:27311:1	(	(	O	O
at	SAPHRIS.xml:S1:27312:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S1:27315:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S1:27323:1	)	)	O	O
was	SAPHRIS.xml:S1:27325:3	wa	VBD	O	O
0.9%	SAPHRIS.xml:S1:27329:4	0.9%	CD	O	O
for	SAPHRIS.xml:S1:27334:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:27338:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:27345:1	-	:	O	O
treated	SAPHRIS.xml:S1:27346:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:27354:8	patient	NNS	O	O
versus	SAPHRIS.xml:S1:27363:6	versu	VBP	O	O
1.3%	SAPHRIS.xml:S1:27370:4	1.3%	CD	O	O
for	SAPHRIS.xml:S1:27375:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:27379:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:27386:1	-	:	O	O
treated	SAPHRIS.xml:S1:27387:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:27395:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:27403:1	.	.	O	O

In	SAPHRIS.xml:S1:27405:2	In	IN	O	O
short	SAPHRIS.xml:S1:27408:5	short	JJ	O	O
-	SAPHRIS.xml:S1:27413:1	-	:	O	O
term	SAPHRIS.xml:S1:27414:4	term	NN	O	O
,	SAPHRIS.xml:S1:27418:1	,	,	O	O
placebo	SAPHRIS.xml:S1:27420:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:27427:1	-	:	O	O
controlled	SAPHRIS.xml:S1:27428:10	control	VBN	O	O
bipolar	SAPHRIS.xml:S1:27439:7	bipolar	JJ	O	O
adult	SAPHRIS.xml:S1:27447:5	adult	NN	O	O
mania	SAPHRIS.xml:S1:27453:5	mania	NN	O	O
trials	SAPHRIS.xml:S1:27459:6	trial	NNS	O	O
,	SAPHRIS.xml:S1:27465:1	,	,	O	O
the	SAPHRIS.xml:S1:27467:3	the	DT	O	O
mean	SAPHRIS.xml:S1:27471:4	mean	JJ	O	O
increase	SAPHRIS.xml:S1:27476:8	increas	NN	B-AdverseReaction	O
in	SAPHRIS.xml:S1:27485:2	in	IN	I-AdverseReaction	O
transaminase	SAPHRIS.xml:S1:27488:12	transaminas	NN	I-AdverseReaction	O
levels	SAPHRIS.xml:S1:27501:6	level	NNS	I-AdverseReaction	O
for	SAPHRIS.xml:S1:27508:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:27512:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:27519:1	-	:	O	O
treated	SAPHRIS.xml:S1:27520:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:27528:8	patient	NNS	O	O
was	SAPHRIS.xml:S1:27537:3	wa	VBD	O	O
8.9	SAPHRIS.xml:S1:27541:3	8.9	CD	O	O
units	SAPHRIS.xml:S1:27545:5	unit	NNS	O	O
L	SAPHRIS.xml:S1:27551:1	L	NNP	O	O
compared	SAPHRIS.xml:S1:27553:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:27562:2	to	TO	O	O
a	SAPHRIS.xml:S1:27565:1	a	DT	O	O
decrease	SAPHRIS.xml:S1:27567:8	decreas	NN	O	O
of	SAPHRIS.xml:S1:27576:2	of	IN	O	O
4.9	SAPHRIS.xml:S1:27579:3	4.9	CD	O	O
units	SAPHRIS.xml:S1:27583:5	unit	NNS	O	O
L	SAPHRIS.xml:S1:27589:1	L	NNP	O	O
in	SAPHRIS.xml:S1:27591:2	in	IN	O	O
placebo	SAPHRIS.xml:S1:27594:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:27601:1	-	:	O	O
treated	SAPHRIS.xml:S1:27602:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:27610:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:27618:1	.	.	O	O

The	SAPHRIS.xml:S1:27620:3	the	DT	O	O
proportion	SAPHRIS.xml:S1:27624:10	proport	NN	O	O
of	SAPHRIS.xml:S1:27635:2	of	IN	O	O
patients	SAPHRIS.xml:S1:27638:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:27647:4	with	IN	O	O
transaminase	SAPHRIS.xml:S1:27652:12	transaminas	JJ	B-AdverseReaction	O
elevations	SAPHRIS.xml:S1:27665:10	elev	NNS	I-AdverseReaction	O
3	SAPHRIS.xml:S1:27678:1	3	CD	O	O
times	SAPHRIS.xml:S1:27680:5	time	NNS	O	O
upper	SAPHRIS.xml:S1:27686:5	upper	JJ	O	O
limit	SAPHRIS.xml:S1:27692:5	limit	NN	O	O
of	SAPHRIS.xml:S1:27698:2	of	IN	O	O
normal	SAPHRIS.xml:S1:27701:6	normal	JJ	O	O
(	SAPHRIS.xml:S1:27708:1	(	(	O	O
ULN	SAPHRIS.xml:S1:27709:3	uln	NNP	O	O
)	SAPHRIS.xml:S1:27712:1	)	)	O	O
(	SAPHRIS.xml:S1:27714:1	(	(	O	O
at	SAPHRIS.xml:S1:27715:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S1:27718:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S1:27726:1	)	)	O	O
was	SAPHRIS.xml:S1:27728:3	wa	VBD	O	O
2.5%	SAPHRIS.xml:S1:27732:4	2.5%	CD	O	O
for	SAPHRIS.xml:S1:27737:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:27741:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:27748:1	-	:	O	O
treated	SAPHRIS.xml:S1:27749:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:27757:8	patient	NNS	O	O
versus	SAPHRIS.xml:S1:27766:6	versu	VBP	O	O
0.6%	SAPHRIS.xml:S1:27773:4	0.6%	CD	O	O
for	SAPHRIS.xml:S1:27778:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:27782:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:27789:1	-	:	O	O
treated	SAPHRIS.xml:S1:27790:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:27798:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:27806:1	.	.	O	O

In	SAPHRIS.xml:S1:27812:2	In	IN	O	O
a	SAPHRIS.xml:S1:27815:1	a	DT	O	O
52	SAPHRIS.xml:S1:27817:2	52	CD	O	O
-	SAPHRIS.xml:S1:27819:1	-	:	O	O
week	SAPHRIS.xml:S1:27820:4	week	NN	O	O
,	SAPHRIS.xml:S1:27824:1	,	,	O	O
double	SAPHRIS.xml:S1:27826:6	doubl	JJ	O	O
-	SAPHRIS.xml:S1:27832:1	-	:	O	O
blind	SAPHRIS.xml:S1:27833:5	blind	NN	O	O
,	SAPHRIS.xml:S1:27838:1	,	,	O	O
comparator	SAPHRIS.xml:S1:27840:10	compar	NN	O	O
-	SAPHRIS.xml:S1:27850:1	-	:	O	O
controlled	SAPHRIS.xml:S1:27851:10	control	VBN	O	O
trial	SAPHRIS.xml:S1:27862:5	trial	NN	O	O
that	SAPHRIS.xml:S1:27868:4	that	WDT	O	O
included	SAPHRIS.xml:S1:27873:8	includ	VBD	O	O
primarily	SAPHRIS.xml:S1:27882:9	primarili	RB	O	O
adult	SAPHRIS.xml:S1:27892:5	adult	VBN	O	O
patients	SAPHRIS.xml:S1:27898:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:27907:4	with	IN	O	O
schizophrenia	SAPHRIS.xml:S1:27912:13	schizophrenia	NN	O	O
,	SAPHRIS.xml:S1:27925:1	,	,	O	O
the	SAPHRIS.xml:S1:27927:3	the	DT	O	O
mean	SAPHRIS.xml:S1:27931:4	mean	JJ	O	O
increase	SAPHRIS.xml:S1:27936:8	increas	NN	B-AdverseReaction	O
from	SAPHRIS.xml:S1:27945:4	from	IN	O	O
baseline	SAPHRIS.xml:S1:27950:8	baselin	NN	O	O
of	SAPHRIS.xml:S1:27959:2	of	IN	I-AdverseReaction	O
ALT	SAPHRIS.xml:S1:27962:3	alt	NNP	I-AdverseReaction	O
was	SAPHRIS.xml:S1:27966:3	wa	VBD	O	O
1.7	SAPHRIS.xml:S1:27970:3	1.7	CD	O	O
units	SAPHRIS.xml:S1:27974:5	unit	NNS	O	O
L.	SAPHRIS.xml:S1:27980:2	L.	NNP	O	O

In	SAPHRIS.xml:S1:27987:2	In	IN	O	O
a	SAPHRIS.xml:S1:27990:1	a	DT	O	O
3	SAPHRIS.xml:S1:27992:1	3	CD	O	O
-	SAPHRIS.xml:S1:27993:1	-	:	O	O
week	SAPHRIS.xml:S1:27994:4	week	NN	O	O
,	SAPHRIS.xml:S1:27998:1	,	,	O	O
placebo	SAPHRIS.xml:S1:28000:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:28007:1	-	:	O	O
controlled	SAPHRIS.xml:S1:28008:10	control	VBN	O	O
pediatric	SAPHRIS.xml:S1:28019:9	pediatr	JJ	O	O
trial	SAPHRIS.xml:S1:28029:5	trial	NN	O	O
with	SAPHRIS.xml:S1:28035:4	with	IN	O	O
bipolar	SAPHRIS.xml:S1:28040:7	bipolar	JJ	O	O
I	SAPHRIS.xml:S1:28048:1	I	PRP	O	O
disorder	SAPHRIS.xml:S1:28050:8	disord	VBP	O	O
,	SAPHRIS.xml:S1:28058:1	,	,	O	O
transient	SAPHRIS.xml:S1:28060:9	transient	JJ	O	O
elevations	SAPHRIS.xml:S1:28070:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S1:28081:2	in	IN	I-AdverseReaction	I-AdverseReaction
serum	SAPHRIS.xml:S1:28084:5	serum	NN	I-AdverseReaction	I-AdverseReaction
transaminases	SAPHRIS.xml:S1:28090:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S1:28104:1	(	(	O	O
primarily	SAPHRIS.xml:S1:28105:9	primarili	RB	O	O
ALT	SAPHRIS.xml:S1:28115:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
)	SAPHRIS.xml:S1:28118:1	)	)	O	O
were	SAPHRIS.xml:S1:28120:4	were	VBD	O	O
more	SAPHRIS.xml:S1:28125:4	more	JJR	O	O
common	SAPHRIS.xml:S1:28130:6	common	JJ	O	O
in	SAPHRIS.xml:S1:28137:2	in	IN	O	O
treated	SAPHRIS.xml:S1:28140:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:28148:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:28156:1	.	.	O	O

The	SAPHRIS.xml:S1:28158:3	the	DT	O	O
proportion	SAPHRIS.xml:S1:28162:10	proport	NN	O	O
of	SAPHRIS.xml:S1:28173:2	of	IN	O	O
pediatric	SAPHRIS.xml:S1:28176:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:28186:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:28195:4	with	IN	O	O
ALT	SAPHRIS.xml:S1:28200:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
elevations	SAPHRIS.xml:S1:28204:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
3	SAPHRIS.xml:S1:28217:1	3	CD	O	O
times	SAPHRIS.xml:S1:28219:5	time	NNS	O	O
upper	SAPHRIS.xml:S1:28225:5	upper	JJ	O	O
limit	SAPHRIS.xml:S1:28231:5	limit	NN	O	O
of	SAPHRIS.xml:S1:28237:2	of	IN	O	O
normal	SAPHRIS.xml:S1:28240:6	normal	JJ	O	O
(	SAPHRIS.xml:S1:28247:1	(	(	O	O
ULN	SAPHRIS.xml:S1:28248:3	uln	NNP	O	O
)	SAPHRIS.xml:S1:28251:1	)	)	O	O
was	SAPHRIS.xml:S1:28253:3	wa	VBD	O	O
2.4%	SAPHRIS.xml:S1:28257:4	2.4%	CD	O	O
for	SAPHRIS.xml:S1:28262:3	for	IN	O	O
patients	SAPHRIS.xml:S1:28266:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:28275:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:28283:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:28288:7	saphri	NNP	O	O
10	SAPHRIS.xml:S1:28296:2	10	CD	O	O
mg	SAPHRIS.xml:S1:28299:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:28302:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:28308:5	daili	JJ	O	O
versus	SAPHRIS.xml:S1:28314:6	versu	NN	O	O
none	SAPHRIS.xml:S1:28321:4	none	NN	O	O
for	SAPHRIS.xml:S1:28326:3	for	IN	O	O
the	SAPHRIS.xml:S1:28330:3	the	DT	O	O
other	SAPHRIS.xml:S1:28334:5	other	JJ	O	O
SAPHRIS	SAPHRIS.xml:S1:28340:7	saphri	NNP	O	O
dose	SAPHRIS.xml:S1:28348:4	dose	NN	O	O
groups	SAPHRIS.xml:S1:28353:6	group	NNS	O	O
and	SAPHRIS.xml:S1:28360:3	and	CC	O	O
placebo	SAPHRIS.xml:S1:28364:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:28371:1	-	:	O	O
treated	SAPHRIS.xml:S1:28372:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:28380:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:28388:1	.	.	O	O

Prolactin	SAPHRIS.xml:S1:28398:9	prolactin	NN	O	O
:	SAPHRIS.xml:S1:28407:1	:	:	O	O
In	SAPHRIS.xml:S1:28410:2	In	IN	O	O
short	SAPHRIS.xml:S1:28413:5	short	JJ	O	O
-	SAPHRIS.xml:S1:28418:1	-	:	O	O
term	SAPHRIS.xml:S1:28419:4	term	NN	O	O
,	SAPHRIS.xml:S1:28423:1	,	,	O	O
placebo	SAPHRIS.xml:S1:28425:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:28432:1	-	:	O	O
controlled	SAPHRIS.xml:S1:28433:10	control	VBN	O	O
adult	SAPHRIS.xml:S1:28444:5	adult	NN	O	O
schizophrenia	SAPHRIS.xml:S1:28450:13	schizophrenia	NN	O	O
trials	SAPHRIS.xml:S1:28464:6	trial	NNS	O	O
,	SAPHRIS.xml:S1:28470:1	,	,	O	O
the	SAPHRIS.xml:S1:28472:3	the	DT	O	O
mean	SAPHRIS.xml:S1:28476:4	mean	NN	O	O
decreases	SAPHRIS.xml:S1:28481:9	decreas	VBZ	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S1:28491:2	in	IN	I-AdverseReaction	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:28494:9	prolactin	NN	I-AdverseReaction	I-AdverseReaction
levels	SAPHRIS.xml:S1:28504:6	level	NNS	I-AdverseReaction	I-AdverseReaction
were	SAPHRIS.xml:S1:28511:4	were	VBD	O	O
6.5	SAPHRIS.xml:S1:28516:3	6.5	CD	O	O
ng	SAPHRIS.xml:S1:28520:2	ng	JJ	O	O
mL	SAPHRIS.xml:S1:28523:2	mL	NN	O	O
for	SAPHRIS.xml:S1:28526:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:28530:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:28537:1	-	:	O	O
treated	SAPHRIS.xml:S1:28538:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:28546:8	patient	NNS	O	O
compared	SAPHRIS.xml:S1:28555:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:28564:2	to	TO	O	O
10.7	SAPHRIS.xml:S1:28567:4	10.7	CD	O	O
ng	SAPHRIS.xml:S1:28572:2	ng	NNS	O	O
mL	SAPHRIS.xml:S1:28575:2	mL	NN	O	O
for	SAPHRIS.xml:S1:28578:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:28582:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:28589:1	-	:	O	O
treated	SAPHRIS.xml:S1:28590:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:28598:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:28606:1	.	.	O	O

The	SAPHRIS.xml:S1:28608:3	the	DT	O	O
proportion	SAPHRIS.xml:S1:28612:10	proport	NN	O	O
of	SAPHRIS.xml:S1:28623:2	of	IN	O	O
patients	SAPHRIS.xml:S1:28626:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:28635:4	with	IN	O	O
prolactin	SAPHRIS.xml:S1:28640:9	prolactin	JJ	B-AdverseReaction	O
elevations	SAPHRIS.xml:S1:28650:10	elev	NNS	I-AdverseReaction	O
4	SAPHRIS.xml:S1:28663:1	4	CD	O	O
times	SAPHRIS.xml:S1:28665:5	time	NNS	O	O
ULN	SAPHRIS.xml:S1:28671:3	uln	NNP	O	O
(	SAPHRIS.xml:S1:28675:1	(	(	O	O
at	SAPHRIS.xml:S1:28676:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S1:28679:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S1:28687:1	)	)	O	O
were	SAPHRIS.xml:S1:28689:4	were	VBD	O	O
2.6%	SAPHRIS.xml:S1:28694:4	2.6%	CD	O	O
for	SAPHRIS.xml:S1:28699:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:28703:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:28710:1	-	:	O	O
treated	SAPHRIS.xml:S1:28711:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:28719:8	patient	NNS	O	O
versus	SAPHRIS.xml:S1:28728:6	versu	VBP	O	O
0.6%	SAPHRIS.xml:S1:28735:4	0.6%	CD	O	O
for	SAPHRIS.xml:S1:28740:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:28744:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:28751:1	-	:	O	O
treated	SAPHRIS.xml:S1:28752:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:28760:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:28768:1	.	.	O	O

In	SAPHRIS.xml:S1:28770:2	In	IN	O	O
short	SAPHRIS.xml:S1:28773:5	short	JJ	O	O
-	SAPHRIS.xml:S1:28778:1	-	:	O	O
term	SAPHRIS.xml:S1:28779:4	term	NN	O	O
,	SAPHRIS.xml:S1:28783:1	,	,	O	O
placebo	SAPHRIS.xml:S1:28785:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:28792:1	-	:	O	O
controlled	SAPHRIS.xml:S1:28793:10	control	VBN	O	O
bipolar	SAPHRIS.xml:S1:28804:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S1:28812:5	mania	NN	O	O
adult	SAPHRIS.xml:S1:28818:5	adult	NN	O	O
trials	SAPHRIS.xml:S1:28824:6	trial	NNS	O	O
,	SAPHRIS.xml:S1:28830:1	,	,	O	O
the	SAPHRIS.xml:S1:28832:3	the	DT	O	O
mean	SAPHRIS.xml:S1:28836:4	mean	JJ	O	O
increase	SAPHRIS.xml:S1:28841:8	increas	NN	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S1:28850:2	in	IN	I-AdverseReaction	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:28853:9	prolactin	NN	I-AdverseReaction	I-AdverseReaction
levels	SAPHRIS.xml:S1:28863:6	level	NNS	I-AdverseReaction	I-AdverseReaction
was	SAPHRIS.xml:S1:28870:3	wa	VBD	O	O
4.9	SAPHRIS.xml:S1:28874:3	4.9	CD	O	O
ng	SAPHRIS.xml:S1:28878:2	ng	JJ	O	O
mL	SAPHRIS.xml:S1:28881:2	mL	NN	O	O
for	SAPHRIS.xml:S1:28884:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:28888:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:28895:1	-	:	O	O
treated	SAPHRIS.xml:S1:28896:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:28904:8	patient	NNS	O	O
compared	SAPHRIS.xml:S1:28913:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:28922:2	to	TO	O	O
a	SAPHRIS.xml:S1:28925:1	a	DT	O	O
decrease	SAPHRIS.xml:S1:28927:8	decreas	NN	O	O
of	SAPHRIS.xml:S1:28936:2	of	IN	O	O
0.2	SAPHRIS.xml:S1:28939:3	0.2	CD	O	O
ng	SAPHRIS.xml:S1:28943:2	ng	NNS	O	O
mL	SAPHRIS.xml:S1:28946:2	mL	NN	O	O
for	SAPHRIS.xml:S1:28949:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:28953:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:28960:1	-	:	O	O
treated	SAPHRIS.xml:S1:28961:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:28969:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:28977:1	.	.	O	O

The	SAPHRIS.xml:S1:28979:3	the	DT	O	O
proportion	SAPHRIS.xml:S1:28983:10	proport	NN	O	O
of	SAPHRIS.xml:S1:28994:2	of	IN	O	O
patients	SAPHRIS.xml:S1:28997:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:29006:4	with	IN	O	O
prolactin	SAPHRIS.xml:S1:29011:9	prolactin	JJ	B-AdverseReaction	O
elevations	SAPHRIS.xml:S1:29021:10	elev	NNS	I-AdverseReaction	O
4	SAPHRIS.xml:S1:29034:1	4	CD	O	O
times	SAPHRIS.xml:S1:29036:5	time	NNS	O	O
ULN	SAPHRIS.xml:S1:29042:3	uln	NNP	O	O
(	SAPHRIS.xml:S1:29046:1	(	(	O	O
at	SAPHRIS.xml:S1:29047:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S1:29050:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S1:29058:1	)	)	O	O
were	SAPHRIS.xml:S1:29060:4	were	VBD	O	O
2.3%	SAPHRIS.xml:S1:29065:4	2.3%	CD	O	O
for	SAPHRIS.xml:S1:29070:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:29074:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:29081:1	-	:	O	O
treated	SAPHRIS.xml:S1:29082:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:29090:8	patient	NNS	O	O
versus	SAPHRIS.xml:S1:29099:6	versu	VBP	O	O
0.7%	SAPHRIS.xml:S1:29106:4	0.7%	CD	O	O
for	SAPHRIS.xml:S1:29111:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:29115:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:29122:1	-	:	O	O
treated	SAPHRIS.xml:S1:29123:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:29131:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:29139:1	.	.	O	O

In	SAPHRIS.xml:S1:29145:2	In	IN	O	O
a	SAPHRIS.xml:S1:29148:1	a	DT	O	O
long	SAPHRIS.xml:S1:29150:4	long	JJ	O	O
-	SAPHRIS.xml:S1:29154:1	-	:	O	O
term	SAPHRIS.xml:S1:29155:4	term	NN	O	O
(	SAPHRIS.xml:S1:29160:1	(	(	O	O
52	SAPHRIS.xml:S1:29161:2	52	CD	O	O
-	SAPHRIS.xml:S1:29163:1	-	:	O	O
week	SAPHRIS.xml:S1:29164:4	week	NN	O	O
)	SAPHRIS.xml:S1:29168:1	)	)	O	O
,	SAPHRIS.xml:S1:29169:1	,	,	O	O
double	SAPHRIS.xml:S1:29171:6	doubl	JJ	O	O
-	SAPHRIS.xml:S1:29177:1	-	:	O	O
blind	SAPHRIS.xml:S1:29178:5	blind	NN	O	O
,	SAPHRIS.xml:S1:29183:1	,	,	O	O
comparator	SAPHRIS.xml:S1:29185:10	compar	NN	O	O
-	SAPHRIS.xml:S1:29195:1	-	:	O	O
controlled	SAPHRIS.xml:S1:29196:10	control	VBN	O	O
adult	SAPHRIS.xml:S1:29207:5	adult	NN	O	O
trial	SAPHRIS.xml:S1:29213:5	trial	NN	O	O
that	SAPHRIS.xml:S1:29219:4	that	WDT	O	O
included	SAPHRIS.xml:S1:29224:8	includ	VBD	O	O
primarily	SAPHRIS.xml:S1:29233:9	primarili	RB	O	O
patients	SAPHRIS.xml:S1:29243:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:29252:4	with	IN	O	O
schizophrenia	SAPHRIS.xml:S1:29257:13	schizophrenia	NN	O	O
,	SAPHRIS.xml:S1:29270:1	,	,	O	O
the	SAPHRIS.xml:S1:29272:3	the	DT	O	O
mean	SAPHRIS.xml:S1:29276:4	mean	JJ	O	O
decrease	SAPHRIS.xml:S1:29281:8	decreas	NN	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S1:29290:2	in	IN	I-AdverseReaction	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:29293:9	prolactin	NN	I-AdverseReaction	I-AdverseReaction
from	SAPHRIS.xml:S1:29303:4	from	IN	O	O
baseline	SAPHRIS.xml:S1:29308:8	baselin	NN	O	O
for	SAPHRIS.xml:S1:29317:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:29321:7	saphri	NNP	O	O
-	SAPHRIS.xml:S1:29328:1	-	:	O	O
treated	SAPHRIS.xml:S1:29329:7	treat	VBD	O	O
patients	SAPHRIS.xml:S1:29337:8	patient	NNS	O	O
was	SAPHRIS.xml:S1:29346:3	wa	VBD	O	O
26.9	SAPHRIS.xml:S1:29350:4	26.9	CD	O	O
ng	SAPHRIS.xml:S1:29355:2	ng	JJ	O	O
mL	SAPHRIS.xml:S1:29358:2	mL	NN	O	O
.	SAPHRIS.xml:S1:29360:1	.	.	O	O

In	SAPHRIS.xml:S1:29366:2	In	IN	O	O
a	SAPHRIS.xml:S1:29369:1	a	DT	O	O
3	SAPHRIS.xml:S1:29371:1	3	CD	O	O
-	SAPHRIS.xml:S1:29372:1	-	:	O	O
week	SAPHRIS.xml:S1:29373:4	week	NN	O	O
,	SAPHRIS.xml:S1:29377:1	,	,	O	O
placebo	SAPHRIS.xml:S1:29379:7	placebo	SYM	O	O
-	SAPHRIS.xml:S1:29386:1	-	:	O	O
controlled	SAPHRIS.xml:S1:29387:10	control	VBN	O	O
pediatric	SAPHRIS.xml:S1:29398:9	pediatr	JJ	O	O
trial	SAPHRIS.xml:S1:29408:5	trial	NN	O	O
with	SAPHRIS.xml:S1:29414:4	with	IN	O	O
bipolar	SAPHRIS.xml:S1:29419:7	bipolar	JJ	O	O
I	SAPHRIS.xml:S1:29427:1	I	PRP	O	O
disorder	SAPHRIS.xml:S1:29429:8	disord	VBP	O	O
,	SAPHRIS.xml:S1:29437:1	,	,	O	O
the	SAPHRIS.xml:S1:29439:3	the	DT	O	O
mean	SAPHRIS.xml:S1:29443:4	mean	NN	O	O
increases	SAPHRIS.xml:S1:29448:9	increas	NNS	B-AdverseReaction	O
(	SAPHRIS.xml:S1:29458:1	(	(	O	O
at	SAPHRIS.xml:S1:29459:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S1:29462:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S1:29470:1	)	)	O	O
in	SAPHRIS.xml:S1:29472:2	in	IN	I-AdverseReaction	O
prolactin	SAPHRIS.xml:S1:29475:9	prolactin	NN	I-AdverseReaction	B-AdverseReaction
levels	SAPHRIS.xml:S1:29485:6	level	NNS	I-AdverseReaction	I-AdverseReaction
were	SAPHRIS.xml:S1:29492:4	were	VBD	O	O
3.2	SAPHRIS.xml:S1:29497:3	3.2	CD	O	O
ng	SAPHRIS.xml:S1:29501:2	ng	JJ	O	O
mL	SAPHRIS.xml:S1:29504:2	mL	NN	O	O
for	SAPHRIS.xml:S1:29507:3	for	IN	O	O
patients	SAPHRIS.xml:S1:29511:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:29520:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:29528:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:29533:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S1:29541:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:29545:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:29548:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:29554:5	daili	RB	O	O
,	SAPHRIS.xml:S1:29559:1	,	,	O	O
2.1	SAPHRIS.xml:S1:29561:3	2.1	CD	O	O
ng	SAPHRIS.xml:S1:29565:2	ng	NN	O	O
mL	SAPHRIS.xml:S1:29568:2	mL	NN	O	O
for	SAPHRIS.xml:S1:29571:3	for	IN	O	O
patients	SAPHRIS.xml:S1:29575:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:29584:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:29592:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:29597:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:29605:1	5	CD	O	O
mg	SAPHRIS.xml:S1:29607:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:29610:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:29616:5	daili	RB	O	O
,	SAPHRIS.xml:S1:29621:1	,	,	O	O
and	SAPHRIS.xml:S1:29623:3	and	CC	O	O
6.4	SAPHRIS.xml:S1:29627:3	6.4	CD	O	O
ng	SAPHRIS.xml:S1:29631:2	ng	NNS	O	O
mL	SAPHRIS.xml:S1:29634:2	mL	NN	O	O
for	SAPHRIS.xml:S1:29637:3	for	IN	O	O
patients	SAPHRIS.xml:S1:29641:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:29650:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:29658:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:29663:7	saphri	NNP	O	O
10	SAPHRIS.xml:S1:29671:2	10	CD	O	O
mg	SAPHRIS.xml:S1:29674:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:29677:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:29683:5	daili	RB	O	O
compared	SAPHRIS.xml:S1:29689:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:29698:2	to	TO	O	O
an	SAPHRIS.xml:S1:29701:2	an	DT	O	O
increase	SAPHRIS.xml:S1:29704:8	increas	NN	O	O
of	SAPHRIS.xml:S1:29713:2	of	IN	O	O
2.5	SAPHRIS.xml:S1:29716:3	2.5	CD	O	O
ng	SAPHRIS.xml:S1:29720:2	ng	NNS	O	O
mL	SAPHRIS.xml:S1:29723:2	mL	NN	O	O
for	SAPHRIS.xml:S1:29726:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:29730:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:29737:1	-	:	O	O
treated	SAPHRIS.xml:S1:29738:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:29746:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:29754:1	.	.	O	O

There	SAPHRIS.xml:S1:29756:5	there	EX	O	O
were	SAPHRIS.xml:S1:29762:4	were	VBD	O	O
no	SAPHRIS.xml:S1:29767:2	no	DT	O	O
reports	SAPHRIS.xml:S1:29770:7	report	NNS	O	O
of	SAPHRIS.xml:S1:29778:2	of	IN	O	O
prolactin	SAPHRIS.xml:S1:29781:9	prolactin	JJ	B-AdverseReaction	B-AdverseReaction
elevations	SAPHRIS.xml:S1:29791:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
4	SAPHRIS.xml:S1:29804:1	4	CD	O	O
times	SAPHRIS.xml:S1:29806:5	time	NNS	O	O
ULN	SAPHRIS.xml:S1:29812:3	uln	NNP	O	O
(	SAPHRIS.xml:S1:29816:1	(	(	O	O
at	SAPHRIS.xml:S1:29817:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S1:29820:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S1:29828:1	)	)	O	O
for	SAPHRIS.xml:S1:29830:3	for	IN	O	O
patients	SAPHRIS.xml:S1:29834:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:29843:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:29851:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:29856:7	saphri	NNP	O	O
or	SAPHRIS.xml:S1:29864:2	or	CC	O	O
placebo	SAPHRIS.xml:S1:29867:7	placebo	NN	O	O
.	SAPHRIS.xml:S1:29874:1	.	.	O	O

Galactorrhea	SAPHRIS.xml:S1:29876:12	galactorrhea	NNP	B-AdverseReaction	O
or	SAPHRIS.xml:S1:29889:2	or	CC	O	O
dysmenorrhea	SAPHRIS.xml:S1:29892:12	dysmenorrhea	NN	B-AdverseReaction	O
were	SAPHRIS.xml:S1:29905:4	were	VBD	O	O
reported	SAPHRIS.xml:S1:29910:8	report	VBN	O	O
in	SAPHRIS.xml:S1:29919:2	in	IN	O	O
0%	SAPHRIS.xml:S1:29922:2	0%	CD	O	O
of	SAPHRIS.xml:S1:29925:2	of	IN	O	O
patients	SAPHRIS.xml:S1:29928:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:29937:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:29945:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:29950:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S1:29958:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:29962:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:29965:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:29971:5	daili	RB	O	O
,	SAPHRIS.xml:S1:29976:1	,	,	O	O
2%	SAPHRIS.xml:S1:29978:2	2%	CD	O	O
of	SAPHRIS.xml:S1:29981:2	of	IN	O	O
patients	SAPHRIS.xml:S1:29984:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:29993:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:30001:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:30006:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:30014:1	5	CD	O	O
mg	SAPHRIS.xml:S1:30016:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:30019:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:30025:5	daili	RB	O	O
,	SAPHRIS.xml:S1:30030:1	,	,	O	O
and	SAPHRIS.xml:S1:30032:3	and	CC	O	O
1%	SAPHRIS.xml:S1:30036:2	1%	CD	O	O
of	SAPHRIS.xml:S1:30039:2	of	IN	O	O
patients	SAPHRIS.xml:S1:30042:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:30051:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:30059:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:30064:7	saphri	NNP	O	O
10	SAPHRIS.xml:S1:30072:2	10	CD	O	O
mg	SAPHRIS.xml:S1:30075:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:30078:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:30084:5	daili	RB	O	O
compared	SAPHRIS.xml:S1:30090:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:30099:2	to	TO	O	O
1%	SAPHRIS.xml:S1:30102:2	1%	CD	O	O
of	SAPHRIS.xml:S1:30105:2	of	IN	O	O
placebo	SAPHRIS.xml:S1:30108:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:30115:1	-	:	O	O
treated	SAPHRIS.xml:S1:30116:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:30124:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:30132:1	.	.	O	O

There	SAPHRIS.xml:S1:30134:5	there	EX	O	O
were	SAPHRIS.xml:S1:30140:4	were	VBD	O	O
no	SAPHRIS.xml:S1:30145:2	no	DT	O	O
reports	SAPHRIS.xml:S1:30148:7	report	NNS	O	O
of	SAPHRIS.xml:S1:30156:2	of	IN	O	O
gynecomastia	SAPHRIS.xml:S1:30159:12	gynecomastia	NN	B-AdverseReaction	O
in	SAPHRIS.xml:S1:30172:2	in	IN	O	O
this	SAPHRIS.xml:S1:30175:4	thi	DT	O	O
trial	SAPHRIS.xml:S1:30180:5	trial	NN	O	O
.	SAPHRIS.xml:S1:30185:1	.	.	O	O

Creatine	SAPHRIS.xml:S1:30195:8	creatin	NNP	O	O
Kinase	SAPHRIS.xml:S1:30204:6	kinas	NNP	O	O
(	SAPHRIS.xml:S1:30211:1	(	(	O	O
CK	SAPHRIS.xml:S1:30212:2	CK	NNP	O	O
)	SAPHRIS.xml:S1:30214:1	)	)	O	O
:	SAPHRIS.xml:S1:30215:1	:	:	O	O
The	SAPHRIS.xml:S1:30218:3	the	DT	O	O
proportion	SAPHRIS.xml:S1:30222:10	proport	NN	O	O
of	SAPHRIS.xml:S1:30233:2	of	IN	O	O
adult	SAPHRIS.xml:S1:30236:5	adult	NN	O	O
patients	SAPHRIS.xml:S1:30242:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:30251:4	with	IN	O	O
CK	SAPHRIS.xml:S1:30256:2	CK	NNP	B-AdverseReaction	O
elevations	SAPHRIS.xml:S1:30259:10	elev	NNS	I-AdverseReaction	O
3	SAPHRIS.xml:S1:30271:1	3	CD	O	O
times	SAPHRIS.xml:S1:30273:5	time	NNS	O	O
ULN	SAPHRIS.xml:S1:30279:3	uln	NNP	O	O
at	SAPHRIS.xml:S1:30283:2	at	IN	O	O
any	SAPHRIS.xml:S1:30286:3	ani	DT	O	O
time	SAPHRIS.xml:S1:30290:4	time	NN	O	O
were	SAPHRIS.xml:S1:30295:4	were	VBD	O	O
6.4%	SAPHRIS.xml:S1:30300:4	6.4%	CD	O	O
and	SAPHRIS.xml:S1:30305:3	and	CC	O	O
11.1%	SAPHRIS.xml:S1:30309:5	11.1%	CD	O	O
for	SAPHRIS.xml:S1:30315:3	for	IN	O	O
patients	SAPHRIS.xml:S1:30319:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:30328:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:30336:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:30341:7	saphri	NNP	O	O
5	SAPHRIS.xml:S1:30349:1	5	CD	O	O
mg	SAPHRIS.xml:S1:30351:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:30354:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:30360:5	daili	RB	O	O
and	SAPHRIS.xml:S1:30366:3	and	CC	O	O
10	SAPHRIS.xml:S1:30370:2	10	CD	O	O
mg	SAPHRIS.xml:S1:30373:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:30376:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:30382:5	daili	RB	O	O
,	SAPHRIS.xml:S1:30387:1	,	,	O	O
respectively	SAPHRIS.xml:S1:30389:12	respect	RB	O	O
,	SAPHRIS.xml:S1:30401:1	,	,	O	O
as	SAPHRIS.xml:S1:30403:2	as	IN	O	O
compared	SAPHRIS.xml:S1:30406:8	compar	VBN	O	O
to	SAPHRIS.xml:S1:30415:2	to	TO	O	O
6.7%	SAPHRIS.xml:S1:30418:4	6.7%	CD	O	O
for	SAPHRIS.xml:S1:30423:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:30427:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:30434:1	-	:	O	O
treated	SAPHRIS.xml:S1:30435:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:30443:8	patient	NNS	O	O
in	SAPHRIS.xml:S1:30452:2	in	IN	O	O
short	SAPHRIS.xml:S1:30455:5	short	JJ	O	O
-	SAPHRIS.xml:S1:30460:1	-	:	O	O
term	SAPHRIS.xml:S1:30461:4	term	NN	O	O
,	SAPHRIS.xml:S1:30465:1	,	,	O	O
fixed	SAPHRIS.xml:S1:30467:5	fix	VBN	O	O
-	SAPHRIS.xml:S1:30472:1	-	:	O	O
dose	SAPHRIS.xml:S1:30473:4	dose	NN	O	O
trials	SAPHRIS.xml:S1:30478:6	trial	NNS	O	O
in	SAPHRIS.xml:S1:30485:2	in	IN	O	O
schizophrenia	SAPHRIS.xml:S1:30488:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S1:30502:3	and	CC	O	O
bipolar	SAPHRIS.xml:S1:30506:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S1:30514:5	mania	NN	O	O
.	SAPHRIS.xml:S1:30519:1	.	.	O	O

The	SAPHRIS.xml:S1:30521:3	the	DT	O	O
clinical	SAPHRIS.xml:S1:30525:8	clinic	JJ	O	O
relevance	SAPHRIS.xml:S1:30534:9	relev	NN	O	O
of	SAPHRIS.xml:S1:30544:2	of	IN	O	O
this	SAPHRIS.xml:S1:30547:4	thi	DT	O	O
finding	SAPHRIS.xml:S1:30552:7	find	NN	O	O
is	SAPHRIS.xml:S1:30560:2	is	VBZ	O	O
unknown	SAPHRIS.xml:S1:30563:7	unknown	JJ	O	O
.	SAPHRIS.xml:S1:30570:1	.	.	O	O

The	SAPHRIS.xml:S1:30576:3	the	DT	O	O
proportion	SAPHRIS.xml:S1:30580:10	proport	NN	O	O
of	SAPHRIS.xml:S1:30591:2	of	IN	O	O
patients	SAPHRIS.xml:S1:30594:8	patient	NNS	O	O
with	SAPHRIS.xml:S1:30603:4	with	IN	O	O
CK	SAPHRIS.xml:S1:30608:2	CK	NNP	B-AdverseReaction	O
elevations	SAPHRIS.xml:S1:30611:10	elev	NNS	I-AdverseReaction	O
3	SAPHRIS.xml:S1:30624:1	3	CD	O	O
times	SAPHRIS.xml:S1:30626:5	time	NNS	O	O
ULN	SAPHRIS.xml:S1:30632:3	uln	NNP	O	O
during	SAPHRIS.xml:S1:30636:6	dure	IN	O	O
a	SAPHRIS.xml:S1:30643:1	a	DT	O	O
3	SAPHRIS.xml:S1:30645:1	3	CD	O	O
-	SAPHRIS.xml:S1:30646:1	-	:	O	O
week	SAPHRIS.xml:S1:30647:4	week	NN	O	O
trial	SAPHRIS.xml:S1:30652:5	trial	NN	O	O
in	SAPHRIS.xml:S1:30658:2	in	IN	O	O
pediatric	SAPHRIS.xml:S1:30661:9	pediatr	JJ	O	O
bipolar	SAPHRIS.xml:S1:30671:7	bipolar	NN	O	O
I	SAPHRIS.xml:S1:30679:1	I	PRP	O	O
disorder	SAPHRIS.xml:S1:30681:8	disord	VBP	O	O
at	SAPHRIS.xml:S1:30690:2	at	IN	O	O
any	SAPHRIS.xml:S1:30693:3	ani	DT	O	O
time	SAPHRIS.xml:S1:30697:4	time	NN	O	O
were	SAPHRIS.xml:S1:30702:4	were	VBD	O	O
1%	SAPHRIS.xml:S1:30707:2	1%	CD	O	O
,	SAPHRIS.xml:S1:30709:1	,	,	O	O
0%	SAPHRIS.xml:S1:30711:2	0%	CD	O	O
,	SAPHRIS.xml:S1:30713:1	,	,	O	O
and	SAPHRIS.xml:S1:30715:3	and	CC	O	O
1%	SAPHRIS.xml:S1:30719:2	1%	CD	O	O
for	SAPHRIS.xml:S1:30722:3	for	IN	O	O
patients	SAPHRIS.xml:S1:30726:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:30735:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:30743:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:30748:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S1:30756:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:30760:2	mg	NN	O	O
,	SAPHRIS.xml:S1:30762:1	,	,	O	O
5	SAPHRIS.xml:S1:30764:1	5	CD	O	O
mg	SAPHRIS.xml:S1:30766:2	mg	NN	O	O
,	SAPHRIS.xml:S1:30768:1	,	,	O	O
and	SAPHRIS.xml:S1:30770:3	and	CC	O	O
10	SAPHRIS.xml:S1:30774:2	10	CD	O	O
mg	SAPHRIS.xml:S1:30777:2	mg	NN	O	O
twice	SAPHRIS.xml:S1:30780:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:30786:5	daili	RB	O	O
,	SAPHRIS.xml:S1:30791:1	,	,	O	O
respectively	SAPHRIS.xml:S1:30793:12	respect	RB	O	O
,	SAPHRIS.xml:S1:30805:1	,	,	O	O
versus	SAPHRIS.xml:S1:30807:6	versu	VBZ	O	O
3%	SAPHRIS.xml:S1:30814:2	3%	CD	O	O
for	SAPHRIS.xml:S1:30817:3	for	IN	O	O
placebo	SAPHRIS.xml:S1:30821:7	placebo	NN	O	O
-	SAPHRIS.xml:S1:30828:1	-	:	O	O
treated	SAPHRIS.xml:S1:30829:7	treat	JJ	O	O
patients	SAPHRIS.xml:S1:30837:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:30845:1	.	.	O	O

Other	SAPHRIS.xml:S1:30855:5	other	JJ	O	O
Adverse	SAPHRIS.xml:S1:30861:7	advers	NNP	O	O
Reactions	SAPHRIS.xml:S1:30869:9	reaction	NNP	O	O
Observed	SAPHRIS.xml:S1:30879:8	observ	NNP	O	O
During	SAPHRIS.xml:S1:30888:6	dure	IN	O	O
the	SAPHRIS.xml:S1:30895:3	the	DT	O	O
Premarketing	SAPHRIS.xml:S1:30899:12	premarket	NNP	O	O
Evaluation	SAPHRIS.xml:S1:30912:10	evalu	NNP	O	O
of	SAPHRIS.xml:S1:30923:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:30926:7	saphri	NNP	O	O
:	SAPHRIS.xml:S1:30933:1	:	:	O	O
Following	SAPHRIS.xml:S1:30936:9	follow	NNP	O	O
is	SAPHRIS.xml:S1:30946:2	is	VBZ	O	O
a	SAPHRIS.xml:S1:30949:1	a	DT	O	O
list	SAPHRIS.xml:S1:30951:4	list	NN	O	O
of	SAPHRIS.xml:S1:30956:2	of	IN	O	O
MedDRA	SAPHRIS.xml:S1:30959:6	meddra	NNP	O	O
terms	SAPHRIS.xml:S1:30966:5	term	NNS	O	O
that	SAPHRIS.xml:S1:30972:4	that	WDT	O	O
reflect	SAPHRIS.xml:S1:30977:7	reflect	VBP	O	O
adverse	SAPHRIS.xml:S1:30985:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:30993:9	reaction	NNS	O	O
reported	SAPHRIS.xml:S1:31003:8	report	VBN	O	O
by	SAPHRIS.xml:S1:31012:2	by	IN	O	O
patients	SAPHRIS.xml:S1:31015:8	patient	NNS	O	O
treated	SAPHRIS.xml:S1:31024:7	treat	VBN	O	O
with	SAPHRIS.xml:S1:31032:4	with	IN	O	O
sublingual	SAPHRIS.xml:S1:31037:10	sublingu	JJ	O	O
SAPHRIS	SAPHRIS.xml:S1:31048:7	saphri	NNP	O	O
at	SAPHRIS.xml:S1:31056:2	at	IN	O	O
multiple	SAPHRIS.xml:S1:31059:8	multipl	JJ	O	O
doses	SAPHRIS.xml:S1:31068:5	dose	NNS	O	O
of	SAPHRIS.xml:S1:31074:2	of	IN	O	O
5	SAPHRIS.xml:S1:31079:1	5	CD	O	O
mg	SAPHRIS.xml:S1:31081:2	mg	JJ	O	O
twice	SAPHRIS.xml:S1:31084:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:31090:5	daili	RB	O	O
during	SAPHRIS.xml:S1:31096:6	dure	IN	O	O
any	SAPHRIS.xml:S1:31103:3	ani	DT	O	O
phase	SAPHRIS.xml:S1:31107:5	phase	NN	O	O
of	SAPHRIS.xml:S1:31113:2	of	IN	O	O
a	SAPHRIS.xml:S1:31116:1	a	DT	O	O
trial	SAPHRIS.xml:S1:31118:5	trial	NN	O	O
within	SAPHRIS.xml:S1:31124:6	within	IN	O	O
the	SAPHRIS.xml:S1:31131:3	the	DT	O	O
database	SAPHRIS.xml:S1:31135:8	databas	NN	O	O
of	SAPHRIS.xml:S1:31144:2	of	IN	O	O
adult	SAPHRIS.xml:S1:31147:5	adult	NN	O	O
patients	SAPHRIS.xml:S1:31153:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:31161:1	.	.	O	O

The	SAPHRIS.xml:S1:31163:3	the	DT	O	O
reactions	SAPHRIS.xml:S1:31167:9	reaction	NNS	O	O
listed	SAPHRIS.xml:S1:31177:6	list	VBN	O	O
are	SAPHRIS.xml:S1:31184:3	are	VBP	O	O
those	SAPHRIS.xml:S1:31188:5	those	DT	O	O
that	SAPHRIS.xml:S1:31194:4	that	WDT	O	O
could	SAPHRIS.xml:S1:31199:5	could	MD	O	O
be	SAPHRIS.xml:S1:31205:2	be	VB	O	O
of	SAPHRIS.xml:S1:31208:2	of	IN	O	O
clinical	SAPHRIS.xml:S1:31211:8	clinic	JJ	O	O
importance	SAPHRIS.xml:S1:31220:10	import	NN	O	O
,	SAPHRIS.xml:S1:31230:1	,	,	O	O
as	SAPHRIS.xml:S1:31232:2	as	RB	O	O
well	SAPHRIS.xml:S1:31235:4	well	RB	O	O
as	SAPHRIS.xml:S1:31240:2	as	IN	O	O
reactions	SAPHRIS.xml:S1:31243:9	reaction	NNS	O	O
that	SAPHRIS.xml:S1:31253:4	that	WDT	O	O
are	SAPHRIS.xml:S1:31258:3	are	VBP	O	O
plausibly	SAPHRIS.xml:S1:31262:9	plausibl	RB	O	O
drug	SAPHRIS.xml:S1:31272:4	drug	NN	O	O
-	SAPHRIS.xml:S1:31276:1	-	:	O	O
related	SAPHRIS.xml:S1:31277:7	relat	VBN	O	O
on	SAPHRIS.xml:S1:31285:2	on	IN	O	O
pharmacologic	SAPHRIS.xml:S1:31288:13	pharmacolog	NN	O	O
or	SAPHRIS.xml:S1:31302:2	or	CC	O	O
other	SAPHRIS.xml:S1:31305:5	other	JJ	O	O
grounds	SAPHRIS.xml:S1:31311:7	ground	NNS	O	O
.	SAPHRIS.xml:S1:31318:1	.	.	O	O

Reactions	SAPHRIS.xml:S1:31320:9	reaction	NNS	O	O
already	SAPHRIS.xml:S1:31330:7	alreadi	RB	O	O
listed	SAPHRIS.xml:S1:31338:6	list	VBN	O	O
for	SAPHRIS.xml:S1:31345:3	for	IN	O	O
either	SAPHRIS.xml:S1:31349:6	either	DT	O	O
adults	SAPHRIS.xml:S1:31356:6	adult	NNS	O	O
or	SAPHRIS.xml:S1:31363:2	or	CC	O	O
pediatric	SAPHRIS.xml:S1:31366:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:31376:8	patient	NNS	O	O
in	SAPHRIS.xml:S1:31385:2	in	IN	O	O
other	SAPHRIS.xml:S1:31388:5	other	JJ	O	O
parts	SAPHRIS.xml:S1:31394:5	part	NNS	O	O
of	SAPHRIS.xml:S1:31400:2	of	IN	O	O
Adverse	SAPHRIS.xml:S1:31404:7	advers	NNP	O	O
Reactions	SAPHRIS.xml:S1:31412:9	reaction	NNP	O	O
(	SAPHRIS.xml:S1:31422:1	(	(	O	O
6	SAPHRIS.xml:S1:31423:1	6	CD	O	O
)	SAPHRIS.xml:S1:31424:1	)	)	O	O
,	SAPHRIS.xml:S1:31427:1	,	,	O	O
or	SAPHRIS.xml:S1:31429:2	or	CC	O	O
those	SAPHRIS.xml:S1:31432:5	those	DT	O	O
considered	SAPHRIS.xml:S1:31438:10	consid	VBN	O	O
in	SAPHRIS.xml:S1:31449:2	in	IN	O	O
Contraindications	SAPHRIS.xml:S1:31453:17	contraind	NNP	O	O
(	SAPHRIS.xml:S1:31471:1	(	(	O	O
4	SAPHRIS.xml:S1:31472:1	4	CD	O	O
)	SAPHRIS.xml:S1:31473:1	)	)	O	O
,	SAPHRIS.xml:S1:31474:1	,	,	O	O
Warnings	SAPHRIS.xml:S1:31476:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:31485:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:31489:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:31501:1	(	(	O	O
5	SAPHRIS.xml:S1:31502:1	5	CD	O	O
)	SAPHRIS.xml:S1:31503:1	)	)	O	O
or	SAPHRIS.xml:S1:31506:2	or	CC	O	O
Overdosage	SAPHRIS.xml:S1:31510:10	overdosag	NNP	O	O
(	SAPHRIS.xml:S1:31521:1	(	(	O	O
10	SAPHRIS.xml:S1:31522:2	10	CD	O	O
)	SAPHRIS.xml:S1:31524:1	)	)	O	O
are	SAPHRIS.xml:S1:31527:3	are	VBP	O	O
not	SAPHRIS.xml:S1:31531:3	not	RB	O	O
included	SAPHRIS.xml:S1:31535:8	includ	VBN	O	O
.	SAPHRIS.xml:S1:31543:1	.	.	O	O

Reactions	SAPHRIS.xml:S1:31545:9	reaction	NNS	O	O
are	SAPHRIS.xml:S1:31555:3	are	VBP	O	O
further	SAPHRIS.xml:S1:31559:7	further	JJ	O	O
categorized	SAPHRIS.xml:S1:31567:11	categor	VBN	O	O
by	SAPHRIS.xml:S1:31579:2	by	IN	O	O
MedDRA	SAPHRIS.xml:S1:31582:6	meddra	NNP	O	O
system	SAPHRIS.xml:S1:31589:6	system	NN	O	O
organ	SAPHRIS.xml:S1:31596:5	organ	JJ	O	O
class	SAPHRIS.xml:S1:31602:5	class	NN	O	O
and	SAPHRIS.xml:S1:31608:3	and	CC	O	O
listed	SAPHRIS.xml:S1:31612:6	list	VBN	O	O
in	SAPHRIS.xml:S1:31619:2	in	IN	O	O
order	SAPHRIS.xml:S1:31622:5	order	NN	O	O
of	SAPHRIS.xml:S1:31628:2	of	IN	O	O
decreasing	SAPHRIS.xml:S1:31631:10	decreas	VBG	O	O
frequency	SAPHRIS.xml:S1:31642:9	frequenc	NN	O	O
according	SAPHRIS.xml:S1:31652:9	accord	VBG	O	O
to	SAPHRIS.xml:S1:31662:2	to	TO	O	O
the	SAPHRIS.xml:S1:31665:3	the	DT	O	O
following	SAPHRIS.xml:S1:31669:9	follow	JJ	O	O
definitions	SAPHRIS.xml:S1:31679:11	definit	NNS	O	O
:	SAPHRIS.xml:S1:31690:1	:	:	O	O
those	SAPHRIS.xml:S1:31692:5	those	DT	O	O
occurring	SAPHRIS.xml:S1:31698:9	occur	VBG	O	O
in	SAPHRIS.xml:S1:31708:2	in	IN	O	O
at	SAPHRIS.xml:S1:31711:2	at	IN	O	O
least	SAPHRIS.xml:S1:31714:5	least	JJS	O	O
1	SAPHRIS.xml:S1:31720:1	1	CD	O	O
100	SAPHRIS.xml:S1:31722:3	100	CD	O	O
patients	SAPHRIS.xml:S1:31726:8	patient	NNS	O	O
(	SAPHRIS.xml:S1:31735:1	(	(	O	O
frequent	SAPHRIS.xml:S1:31736:8	frequent	JJ	O	O
)	SAPHRIS.xml:S1:31744:1	)	)	O	O
(	SAPHRIS.xml:S1:31746:1	(	(	O	O
only	SAPHRIS.xml:S1:31747:4	onli	RB	O	O
those	SAPHRIS.xml:S1:31752:5	those	DT	O	O
not	SAPHRIS.xml:S1:31758:3	not	RB	O	O
already	SAPHRIS.xml:S1:31762:7	alreadi	RB	O	O
listed	SAPHRIS.xml:S1:31770:6	list	VBN	O	O
in	SAPHRIS.xml:S1:31777:2	in	IN	O	O
the	SAPHRIS.xml:S1:31780:3	the	DT	O	O
tabulated	SAPHRIS.xml:S1:31784:9	tabul	JJ	O	O
results	SAPHRIS.xml:S1:31794:7	result	NNS	O	O
from	SAPHRIS.xml:S1:31802:4	from	IN	O	O
placebo	SAPHRIS.xml:S1:31807:7	placebo	JJ	O	O
-	SAPHRIS.xml:S1:31814:1	-	:	O	O
controlled	SAPHRIS.xml:S1:31815:10	control	VBN	O	O
trials	SAPHRIS.xml:S1:31826:6	trial	NNS	O	O
appear	SAPHRIS.xml:S1:31833:6	appear	VBP	O	O
in	SAPHRIS.xml:S1:31840:2	in	IN	O	O
this	SAPHRIS.xml:S1:31843:4	thi	DT	O	O
listing	SAPHRIS.xml:S1:31848:7	list	NN	O	O
)	SAPHRIS.xml:S1:31855:1	)	)	O	O
;	SAPHRIS.xml:S1:31856:1	;	:	O	O
those	SAPHRIS.xml:S1:31858:5	those	DT	O	O
occurring	SAPHRIS.xml:S1:31864:9	occur	VBG	O	O
in	SAPHRIS.xml:S1:31874:2	in	IN	O	O
1	SAPHRIS.xml:S1:31877:1	1	CD	O	O
100	SAPHRIS.xml:S1:31879:3	100	CD	O	O
to	SAPHRIS.xml:S1:31883:2	to	TO	O	O
1	SAPHRIS.xml:S1:31886:1	1	CD	O	O
1000	SAPHRIS.xml:S1:31888:4	1000	CD	O	O
patients	SAPHRIS.xml:S1:31893:8	patient	NNS	O	O
(	SAPHRIS.xml:S1:31902:1	(	(	O	O
infrequent	SAPHRIS.xml:S1:31903:10	infrequ	NN	O	O
)	SAPHRIS.xml:S1:31913:1	)	)	O	O
;	SAPHRIS.xml:S1:31914:1	;	:	O	O
and	SAPHRIS.xml:S1:31916:3	and	CC	O	O
those	SAPHRIS.xml:S1:31920:5	those	DT	O	O
occurring	SAPHRIS.xml:S1:31926:9	occur	VBG	O	O
in	SAPHRIS.xml:S1:31936:2	in	IN	O	O
fewer	SAPHRIS.xml:S1:31939:5	fewer	JJR	O	O
than	SAPHRIS.xml:S1:31945:4	than	IN	O	O
1	SAPHRIS.xml:S1:31950:1	1	CD	O	O
1000	SAPHRIS.xml:S1:31952:4	1000	CD	O	O
patients	SAPHRIS.xml:S1:31957:8	patient	NNS	O	O
(	SAPHRIS.xml:S1:31966:1	(	(	O	O
rare	SAPHRIS.xml:S1:31967:4	rare	JJ	O	O
)	SAPHRIS.xml:S1:31971:1	)	)	O	O
.	SAPHRIS.xml:S1:31972:1	.	.	O	O

Blood	SAPHRIS.xml:S1:31985:5	blood	NN	O	O
and	SAPHRIS.xml:S1:31991:3	and	CC	O	O
lymphatic	SAPHRIS.xml:S1:31995:9	lymphat	JJ	O	O
disorders	SAPHRIS.xml:S1:32005:9	disord	NNS	O	O
:	SAPHRIS.xml:S1:32014:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:32017:10	infrequ	NN	O	B-AdverseReaction
:	SAPHRIS.xml:S1:32027:1	:	:	O	O
anemia	SAPHRIS.xml:S1:32029:6	anemia	NN	B-AdverseReaction	B-AdverseReaction
;	SAPHRIS.xml:S1:32035:1	;	:	O	O
rare	SAPHRIS.xml:S1:32037:4	rare	JJ	O	O
:	SAPHRIS.xml:S1:32041:1	:	:	O	O
thrombocytopenia	SAPHRIS.xml:S1:32043:16	thrombocytopenia	NN	B-AdverseReaction	B-AdverseReaction

Cardiac	SAPHRIS.xml:S1:32069:7	cardiac	JJ	O	O
disorders	SAPHRIS.xml:S1:32077:9	disord	NNS	O	O
:	SAPHRIS.xml:S1:32086:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:32089:10	infrequ	NN	O	B-AdverseReaction
:	SAPHRIS.xml:S1:32099:1	:	:	O	O
temporary	SAPHRIS.xml:S1:32101:9	temporari	JJ	B-AdverseReaction	B-AdverseReaction
bundle	SAPHRIS.xml:S1:32111:6	bundl	NN	I-AdverseReaction	I-AdverseReaction
branch	SAPHRIS.xml:S1:32118:6	branch	NN	I-AdverseReaction	I-AdverseReaction
block	SAPHRIS.xml:S1:32125:5	block	NN	I-AdverseReaction	I-AdverseReaction

Eye	SAPHRIS.xml:S1:32140:3	eye	JJ	O	O
disorders	SAPHRIS.xml:S1:32144:9	disord	NNS	O	O
:	SAPHRIS.xml:S1:32153:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:32156:10	infrequ	NN	O	B-AdverseReaction
:	SAPHRIS.xml:S1:32166:1	:	:	O	O
accommodation	SAPHRIS.xml:S1:32168:13	accommod	NN	B-AdverseReaction	B-AdverseReaction
disorder	SAPHRIS.xml:S1:32182:8	disord	NN	I-AdverseReaction	I-AdverseReaction

Gastrointestinal	SAPHRIS.xml:S1:32200:16	gastrointestin	JJ	O	O
disorders	SAPHRIS.xml:S1:32217:9	disord	NNS	O	O
:	SAPHRIS.xml:S1:32226:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:32229:10	infrequ	NN	O	B-AdverseReaction
:	SAPHRIS.xml:S1:32239:1	:	:	O	O
swollen	SAPHRIS.xml:S1:32241:7	swollen	JJ	B-AdverseReaction	B-AdverseReaction
tongue	SAPHRIS.xml:S1:32249:6	tongu	NN	I-AdverseReaction	I-AdverseReaction

General	SAPHRIS.xml:S1:32265:7	gener	JJ	O	O
disorders	SAPHRIS.xml:S1:32273:9	disord	NNS	O	O
:	SAPHRIS.xml:S1:32282:1	:	:	O	O
rare	SAPHRIS.xml:S1:32285:4	rare	NN	O	B-AdverseReaction
:	SAPHRIS.xml:S1:32289:1	:	:	O	O
idiosyncratic	SAPHRIS.xml:S1:32291:13	idiosyncrat	JJ	B-AdverseReaction	B-AdverseReaction
drug	SAPHRIS.xml:S1:32305:4	drug	NN	I-AdverseReaction	I-AdverseReaction
reaction	SAPHRIS.xml:S1:32310:8	reaction	NN	I-AdverseReaction	I-AdverseReaction

Investigations	SAPHRIS.xml:S1:32328:14	investig	NNS	O	O
:	SAPHRIS.xml:S1:32342:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:32345:10	infrequ	NN	O	O
:	SAPHRIS.xml:S1:32355:1	:	:	O	O
hyponatremia	SAPHRIS.xml:S1:32357:12	hyponatremia	NN	B-AdverseReaction	B-AdverseReaction

Nervous	SAPHRIS.xml:S1:32379:7	nervou	JJ	O	O
system	SAPHRIS.xml:S1:32387:6	system	NN	O	O
disorders	SAPHRIS.xml:S1:32394:9	disord	NNS	O	O
:	SAPHRIS.xml:S1:32403:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:32406:10	infrequ	NN	O	B-AdverseReaction
:	SAPHRIS.xml:S1:32416:1	:	:	O	O
dysarthria	SAPHRIS.xml:S1:32418:10	dysarthria	NN	B-AdverseReaction	B-AdverseReaction

Following	SAPHRIS.xml:S1:32434:9	follow	VBG	O	O
is	SAPHRIS.xml:S1:32444:2	is	VBZ	O	O
a	SAPHRIS.xml:S1:32447:1	a	DT	O	O
list	SAPHRIS.xml:S1:32449:4	list	NN	O	O
of	SAPHRIS.xml:S1:32454:2	of	IN	O	O
MedDRA	SAPHRIS.xml:S1:32457:6	meddra	NNP	O	O
terms	SAPHRIS.xml:S1:32464:5	term	NNS	O	O
not	SAPHRIS.xml:S1:32470:3	not	RB	O	O
already	SAPHRIS.xml:S1:32474:7	alreadi	RB	O	O
listed	SAPHRIS.xml:S1:32482:6	list	VBN	O	O
either	SAPHRIS.xml:S1:32489:6	either	RB	O	O
for	SAPHRIS.xml:S1:32496:3	for	IN	O	O
adults	SAPHRIS.xml:S1:32500:6	adult	NNS	O	O
or	SAPHRIS.xml:S1:32507:2	or	CC	O	O
pediatric	SAPHRIS.xml:S1:32510:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:32520:8	patient	NNS	O	O
in	SAPHRIS.xml:S1:32529:2	in	IN	O	O
other	SAPHRIS.xml:S1:32532:5	other	JJ	O	O
parts	SAPHRIS.xml:S1:32538:5	part	NNS	O	O
of	SAPHRIS.xml:S1:32544:2	of	IN	O	O
Adverse	SAPHRIS.xml:S1:32548:7	advers	NNP	O	O
Reactions	SAPHRIS.xml:S1:32556:9	reaction	NNP	O	O
(	SAPHRIS.xml:S1:32566:1	(	(	O	O
6	SAPHRIS.xml:S1:32567:1	6	CD	O	O
)	SAPHRIS.xml:S1:32568:1	)	)	O	O
,	SAPHRIS.xml:S1:32571:1	,	,	O	O
or	SAPHRIS.xml:S1:32573:2	or	CC	O	O
those	SAPHRIS.xml:S1:32576:5	those	DT	O	O
considered	SAPHRIS.xml:S1:32582:10	consid	VBN	O	O
in	SAPHRIS.xml:S1:32593:2	in	IN	O	O
Contraindications	SAPHRIS.xml:S1:32597:17	contraind	NNP	O	O
(	SAPHRIS.xml:S1:32615:1	(	(	O	O
4	SAPHRIS.xml:S1:32616:1	4	CD	O	O
)	SAPHRIS.xml:S1:32617:1	)	)	O	O
,	SAPHRIS.xml:S1:32618:1	,	,	O	O
Warnings	SAPHRIS.xml:S1:32620:8	warn	NNP	O	O
and	SAPHRIS.xml:S1:32629:3	and	CC	O	O
Precautions	SAPHRIS.xml:S1:32633:11	precaut	NNP	O	O
(	SAPHRIS.xml:S1:32645:1	(	(	O	O
5	SAPHRIS.xml:S1:32646:1	5	CD	O	O
)	SAPHRIS.xml:S1:32647:1	)	)	O	O
or	SAPHRIS.xml:S1:32650:2	or	CC	O	O
Overdosage	SAPHRIS.xml:S1:32654:10	overdosag	NNP	O	O
(	SAPHRIS.xml:S1:32665:1	(	(	O	O
10	SAPHRIS.xml:S1:32666:2	10	CD	O	O
)	SAPHRIS.xml:S1:32668:1	)	)	O	O
that	SAPHRIS.xml:S1:32671:4	that	WDT	O	O
reflect	SAPHRIS.xml:S1:32676:7	reflect	VBP	O	O
adverse	SAPHRIS.xml:S1:32684:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:32692:9	reaction	NNS	O	O
reported	SAPHRIS.xml:S1:32702:8	report	VBN	O	O
by	SAPHRIS.xml:S1:32711:2	by	IN	O	O
pediatric	SAPHRIS.xml:S1:32714:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:32724:8	patient	NNS	O	O
(	SAPHRIS.xml:S1:32733:1	(	(	O	O
Ages	SAPHRIS.xml:S1:32734:4	age	$	O	O
10	SAPHRIS.xml:S1:32739:2	10	CD	O	O
to	SAPHRIS.xml:S1:32742:2	to	TO	O	O
17	SAPHRIS.xml:S1:32745:2	17	CD	O	O
years	SAPHRIS.xml:S1:32748:5	year	NNS	O	O
)	SAPHRIS.xml:S1:32753:1	)	)	O	O
treated	SAPHRIS.xml:S1:32755:7	treat	VBD	O	O
with	SAPHRIS.xml:S1:32763:4	with	IN	O	O
sublingual	SAPHRIS.xml:S1:32768:10	sublingu	JJ	O	O
SAPHRIS	SAPHRIS.xml:S1:32779:7	saphri	NNP	O	O
at	SAPHRIS.xml:S1:32787:2	at	IN	O	O
doses	SAPHRIS.xml:S1:32790:5	dose	NNS	O	O
of	SAPHRIS.xml:S1:32796:2	of	IN	O	O
2.5	SAPHRIS.xml:S1:32799:3	2.5	CD	O	O
mg	SAPHRIS.xml:S1:32803:2	mg	NNS	O	O
,	SAPHRIS.xml:S1:32805:1	,	,	O	O
5	SAPHRIS.xml:S1:32807:1	5	CD	O	O
mg	SAPHRIS.xml:S1:32809:2	mg	NN	O	O
,	SAPHRIS.xml:S1:32811:1	,	,	O	O
or	SAPHRIS.xml:S1:32813:2	or	CC	O	O
10	SAPHRIS.xml:S1:32816:2	10	CD	O	O
mg	SAPHRIS.xml:S1:32819:2	mg	JJ	O	O
twice	SAPHRIS.xml:S1:32822:5	twice	RB	O	O
daily	SAPHRIS.xml:S1:32828:5	daili	RB	O	O
during	SAPHRIS.xml:S1:32834:6	dure	IN	O	O
any	SAPHRIS.xml:S1:32841:3	ani	DT	O	O
phase	SAPHRIS.xml:S1:32845:5	phase	NN	O	O
of	SAPHRIS.xml:S1:32851:2	of	IN	O	O
a	SAPHRIS.xml:S1:32854:1	a	DT	O	O
trial	SAPHRIS.xml:S1:32856:5	trial	NN	O	O
within	SAPHRIS.xml:S1:32862:6	within	IN	O	O
the	SAPHRIS.xml:S1:32869:3	the	DT	O	O
database	SAPHRIS.xml:S1:32873:8	databas	NN	O	O
of	SAPHRIS.xml:S1:32882:2	of	IN	O	O
pediatric	SAPHRIS.xml:S1:32885:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S1:32895:8	patient	NNS	O	O
.	SAPHRIS.xml:S1:32903:1	.	.	O	O

Eye	SAPHRIS.xml:S1:32916:3	eye	NN	O	O

disorders	SAPHRIS.xml:S1:32920:9	disord	NNS	O	O
:	SAPHRIS.xml:S1:32929:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:32932:10	infrequ	NN	O	B-AdverseReaction
:	SAPHRIS.xml:S1:32942:1	:	:	O	O
diplopia	SAPHRIS.xml:S1:32944:8	diplopia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S1:32952:1	,	,	O	O
vision	SAPHRIS.xml:S1:32954:6	vision	NN	B-AdverseReaction	B-AdverseReaction
blurred	SAPHRIS.xml:S1:32961:7	blur	VBD	I-AdverseReaction	I-AdverseReaction

Gastrointestinal	SAPHRIS.xml:S1:32978:16	gastrointestin	JJ	O	O
disorders	SAPHRIS.xml:S1:32995:9	disord	NNS	O	O
:	SAPHRIS.xml:S1:33004:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:33007:10	infrequ	NN	O	B-AdverseReaction
:	SAPHRIS.xml:S1:33017:1	:	:	O	O
gastroesophageal	SAPHRIS.xml:S1:33019:16	gastroesophag	NN	B-AdverseReaction	B-AdverseReaction
reflux	SAPHRIS.xml:S1:33036:6	reflux	NN	I-AdverseReaction	I-AdverseReaction
disease	SAPHRIS.xml:S1:33043:7	diseas	NN	I-AdverseReaction	I-AdverseReaction

Injury	SAPHRIS.xml:S1:33060:6	injuri	NNP	O	O
,	SAPHRIS.xml:S1:33066:1	,	,	O	O
Poisoning	SAPHRIS.xml:S1:33068:9	poison	NNP	O	O
,	SAPHRIS.xml:S1:33077:1	,	,	O	O
and	SAPHRIS.xml:S1:33079:3	and	CC	O	O
Procedural	SAPHRIS.xml:S1:33083:10	procedur	JJ	O	O
Complications	SAPHRIS.xml:S1:33094:13	complic	NNS	O	O
:	SAPHRIS.xml:S1:33107:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:33110:10	infrequ	NN	O	O
:	SAPHRIS.xml:S1:33121:1	:	:	O	O
fall	SAPHRIS.xml:S1:33123:4	fall	NN	B-AdverseReaction	B-AdverseReaction

Skin	SAPHRIS.xml:S1:33137:4	skin	NNP	O	O
and	SAPHRIS.xml:S1:33142:3	and	CC	O	O
subcutaneous	SAPHRIS.xml:S1:33146:12	subcutan	JJ	O	O
tissue	SAPHRIS.xml:S1:33159:6	tissu	NN	O	O
disorders	SAPHRIS.xml:S1:33166:9	disord	NNS	O	O
:	SAPHRIS.xml:S1:33175:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:33178:10	infrequ	NN	O	B-AdverseReaction
:	SAPHRIS.xml:S1:33188:1	:	:	O	O
photosensitivity	SAPHRIS.xml:S1:33190:16	photosensit	NN	B-AdverseReaction	B-AdverseReaction
reaction	SAPHRIS.xml:S1:33207:8	reaction	NN	I-AdverseReaction	I-AdverseReaction

Renal	SAPHRIS.xml:S1:33225:5	renal	NNP	O	O
and	SAPHRIS.xml:S1:33231:3	and	CC	O	O
urinary	SAPHRIS.xml:S1:33235:7	urinari	JJ	O	O
disorders	SAPHRIS.xml:S1:33243:9	disord	NNS	O	O
:	SAPHRIS.xml:S1:33252:1	:	:	O	O
infrequent	SAPHRIS.xml:S1:33254:10	infrequ	NN	O	B-AdverseReaction
:	SAPHRIS.xml:S1:33264:1	:	:	O	O
enuresis	SAPHRIS.xml:S1:33267:8	enuresi	NN	B-AdverseReaction	B-AdverseReaction

6.2	SAPHRIS.xml:S1:33284:3	6.2	CD	O	O
Postmarketing	SAPHRIS.xml:S1:33288:13	postmarket	VBG	O	O
Experience	SAPHRIS.xml:S1:33302:10	experi	NN	O	O

The	SAPHRIS.xml:S1:33316:3	the	DT	O	O
following	SAPHRIS.xml:S1:33320:9	follow	JJ	O	O
adverse	SAPHRIS.xml:S1:33330:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:33338:9	reaction	NNS	O	O
have	SAPHRIS.xml:S1:33348:4	have	VBP	O	O
been	SAPHRIS.xml:S1:33353:4	been	VBN	O	O
identified	SAPHRIS.xml:S1:33358:10	identifi	VBN	O	O
during	SAPHRIS.xml:S1:33369:6	dure	IN	O	O
post	SAPHRIS.xml:S1:33376:4	post	NN	O	O
-	SAPHRIS.xml:S1:33380:1	-	:	O	O
approval	SAPHRIS.xml:S1:33381:8	approv	NN	O	O
use	SAPHRIS.xml:S1:33390:3	use	NN	O	O
of	SAPHRIS.xml:S1:33394:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S1:33397:7	saphri	NNP	O	O
.	SAPHRIS.xml:S1:33404:1	.	.	O	O

Because	SAPHRIS.xml:S1:33406:7	becaus	IN	O	O
these	SAPHRIS.xml:S1:33414:5	these	DT	O	O
reactions	SAPHRIS.xml:S1:33420:9	reaction	NNS	O	O
are	SAPHRIS.xml:S1:33430:3	are	VBP	O	O
reported	SAPHRIS.xml:S1:33434:8	report	VBN	O	O
voluntarily	SAPHRIS.xml:S1:33443:11	voluntarili	RB	O	O
from	SAPHRIS.xml:S1:33455:4	from	IN	O	O
a	SAPHRIS.xml:S1:33460:1	a	DT	O	O
population	SAPHRIS.xml:S1:33462:10	popul	NN	O	O
of	SAPHRIS.xml:S1:33473:2	of	IN	O	O
uncertain	SAPHRIS.xml:S1:33476:9	uncertain	JJ	O	O
size	SAPHRIS.xml:S1:33486:4	size	NN	O	O
,	SAPHRIS.xml:S1:33490:1	,	,	O	O
it	SAPHRIS.xml:S1:33492:2	it	PRP	O	O
is	SAPHRIS.xml:S1:33495:2	is	VBZ	O	O
not	SAPHRIS.xml:S1:33498:3	not	RB	O	O
always	SAPHRIS.xml:S1:33502:6	alway	RB	O	O
possible	SAPHRIS.xml:S1:33509:8	possibl	JJ	O	O
to	SAPHRIS.xml:S1:33518:2	to	TO	O	O
establish	SAPHRIS.xml:S1:33521:9	establish	VB	O	O
a	SAPHRIS.xml:S1:33531:1	a	DT	O	O
causal	SAPHRIS.xml:S1:33533:6	causal	NN	O	O
relationship	SAPHRIS.xml:S1:33540:12	relationship	NN	O	O
to	SAPHRIS.xml:S1:33553:2	to	TO	O	O
drug	SAPHRIS.xml:S1:33556:4	drug	NN	O	O
exposure	SAPHRIS.xml:S1:33561:8	exposur	NN	O	O
.	SAPHRIS.xml:S1:33569:1	.	.	O	O

In	SAPHRIS.xml:S1:33571:2	In	IN	O	O
many	SAPHRIS.xml:S1:33574:4	mani	JJ	O	O
cases	SAPHRIS.xml:S1:33579:5	case	NNS	O	O
,	SAPHRIS.xml:S1:33584:1	,	,	O	O
the	SAPHRIS.xml:S1:33586:3	the	DT	O	O
occurrence	SAPHRIS.xml:S1:33590:10	occurr	NN	O	O
of	SAPHRIS.xml:S1:33601:2	of	IN	O	O
these	SAPHRIS.xml:S1:33604:5	these	DT	O	O
adverse	SAPHRIS.xml:S1:33610:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S1:33618:9	reaction	NNS	O	O
led	SAPHRIS.xml:S1:33628:3	led	VBD	O	O
to	SAPHRIS.xml:S1:33632:2	to	TO	O	O
discontinuation	SAPHRIS.xml:S1:33635:15	discontinu	NN	O	O
of	SAPHRIS.xml:S1:33651:2	of	IN	O	O
therapy	SAPHRIS.xml:S1:33654:7	therapi	NN	O	O
.	SAPHRIS.xml:S1:33661:1	.	.	O	O

Application	SAPHRIS.xml:S1:33670:11	applic	NNP	B-AdverseReaction	B-AdverseReaction
site	SAPHRIS.xml:S1:33682:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactions	SAPHRIS.xml:S1:33687:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:33696:1	,	,	O	O
primarily	SAPHRIS.xml:S1:33698:9	primarili	RB	O	O
in	SAPHRIS.xml:S1:33708:2	in	IN	O	O
the	SAPHRIS.xml:S1:33711:3	the	DT	O	O
sublingual	SAPHRIS.xml:S1:33715:10	sublingu	JJ	I-AdverseReaction	O
area	SAPHRIS.xml:S1:33726:4	area	NN	I-AdverseReaction	O
,	SAPHRIS.xml:S1:33730:1	,	,	O	O
have	SAPHRIS.xml:S1:33732:4	have	VBP	O	O
been	SAPHRIS.xml:S1:33737:4	been	VBN	O	O
reported	SAPHRIS.xml:S1:33742:8	report	VBN	O	O
.	SAPHRIS.xml:S1:33750:1	.	.	O	O

These	SAPHRIS.xml:S1:33752:5	these	DT	O	O
application	SAPHRIS.xml:S1:33758:11	applic	NN	B-AdverseReaction	O
site	SAPHRIS.xml:S1:33770:4	site	NN	I-AdverseReaction	O
reactions	SAPHRIS.xml:S1:33775:9	reaction	NNS	I-AdverseReaction	O
included	SAPHRIS.xml:S1:33785:8	includ	VBD	O	O
oral	SAPHRIS.xml:S1:33794:4	oral	JJ	I-AdverseReaction	B-AdverseReaction
ulcers	SAPHRIS.xml:S1:33799:6	ulcer	NNS	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S1:33805:1	,	,	O	O
blisters	SAPHRIS.xml:S1:33807:8	blister	NNS	I-AdverseReaction	O
,	SAPHRIS.xml:S1:33815:1	,	,	O	O
peeling	SAPHRIS.xml:S1:33817:7	peel	VBG	I-AdverseReaction	O
sloughing	SAPHRIS.xml:S1:33825:9	slough	NN	I-AdverseReaction	O
,	SAPHRIS.xml:S1:33834:1	,	,	O	O
and	SAPHRIS.xml:S1:33836:3	and	CC	O	O
inflammation	SAPHRIS.xml:S1:33840:12	inflamm	NN	I-AdverseReaction	O
.	SAPHRIS.xml:S1:33852:1	.	.	O	O

Choking	SAPHRIS.xml:S1:33859:7	choke	NN	B-AdverseReaction	O
has	SAPHRIS.xml:S1:33867:3	ha	VBZ	O	O
been	SAPHRIS.xml:S1:33871:4	been	VBN	O	O
reported	SAPHRIS.xml:S1:33876:8	report	VBN	O	O
by	SAPHRIS.xml:S1:33885:2	by	IN	O	O
patients	SAPHRIS.xml:S1:33888:8	patient	NNS	O	O
,	SAPHRIS.xml:S1:33896:1	,	,	O	O
some	SAPHRIS.xml:S1:33898:4	some	DT	O	O
of	SAPHRIS.xml:S1:33903:2	of	IN	O	O
whom	SAPHRIS.xml:S1:33906:4	whom	WP	O	O
may	SAPHRIS.xml:S1:33911:3	may	MD	O	O
have	SAPHRIS.xml:S1:33915:4	have	VB	O	O
also	SAPHRIS.xml:S1:33920:4	also	RB	O	O
experienced	SAPHRIS.xml:S1:33925:11	experienc	VBN	O	O
oropharyngeal	SAPHRIS.xml:S1:33937:13	oropharyng	JJ	B-AdverseReaction	B-AdverseReaction
muscular	SAPHRIS.xml:S1:33951:8	muscular	JJ	I-AdverseReaction	I-AdverseReaction
dysfunction	SAPHRIS.xml:S1:33960:11	dysfunct	NN	I-AdverseReaction	I-AdverseReaction
or	SAPHRIS.xml:S1:33972:2	or	CC	O	O
hypoesthesia	SAPHRIS.xml:S1:33975:12	hypoesthesia	NN	B-AdverseReaction	O
.	SAPHRIS.xml:S1:33987:1	.	.	O	O
\n\n	SAPHRIS.xml:S2:0:2	\n\n	VB	O	O
BOXED	SAPHRIS.xml:S2:6:5	box	NNP	O	O
WARNING	SAPHRIS.xml:S2:12:7	warn	NNP	O	O
:	SAPHRIS.xml:S2:19:1	:	:	O	O
WARNING	SAPHRIS.xml:S2:21:7	warn	NN	O	O
:	SAPHRIS.xml:S2:28:1	:	:	O	O
INCREASED	SAPHRIS.xml:S2:30:9	increas	NNP	B-AdverseReaction	O
MORTALITY	SAPHRIS.xml:S2:40:9	mortal	NNP	I-AdverseReaction	B-AdverseReaction
IN	SAPHRIS.xml:S2:50:2	IN	NNP	O	O
ELDERLY	SAPHRIS.xml:S2:53:7	elderli	NNP	O	O
PATIENTS	SAPHRIS.xml:S2:61:8	patient	NNP	O	O
WITH	SAPHRIS.xml:S2:70:4	with	NNP	O	O
DEMENTIA	SAPHRIS.xml:S2:75:8	dementia	NNP	O	O
-	SAPHRIS.xml:S2:83:1	-	:	O	O
RELATED	SAPHRIS.xml:S2:84:7	relat	JJ	O	O
PSYCHOSIS	SAPHRIS.xml:S2:92:9	psychosi	NNP	O	O
\n\n\n\n	SAPHRIS.xml:S2:101:4	\n\n\n\n	NN	O	O
WARNING	SAPHRIS.xml:S2:107:7	warn	NN	O	O
:	SAPHRIS.xml:S2:114:1	:	:	O	O
INCREASED	SAPHRIS.xml:S2:116:9	increas	NNP	B-AdverseReaction	O
MORTALITY	SAPHRIS.xml:S2:126:9	mortal	NNP	I-AdverseReaction	B-AdverseReaction
IN	SAPHRIS.xml:S2:136:2	IN	NNP	O	O
ELDERLY	SAPHRIS.xml:S2:139:7	elderli	NNP	O	O
PATIENTS	SAPHRIS.xml:S2:147:8	patient	NNP	O	O
WITH	SAPHRIS.xml:S2:156:4	with	NNP	O	O
DEMENTIA	SAPHRIS.xml:S2:161:8	dementia	NNP	O	O
-	SAPHRIS.xml:S2:169:1	-	:	O	O
RELATED	SAPHRIS.xml:S2:170:7	relat	JJ	O	O
PSYCHOSIS	SAPHRIS.xml:S2:178:9	psychosi	NNP	O	O
\n\n\n\n	SAPHRIS.xml:S2:187:4	\n\n\n\n	NNP	O	O
Elderly	SAPHRIS.xml:S2:195:7	elderli	NNP	O	O
patients	SAPHRIS.xml:S2:203:8	patient	NNS	O	O
with	SAPHRIS.xml:S2:212:4	with	IN	O	O
dementia	SAPHRIS.xml:S2:217:8	dementia	JJ	O	O
-	SAPHRIS.xml:S2:225:1	-	:	O	O
related	SAPHRIS.xml:S2:226:7	relat	JJ	O	O
psychosis	SAPHRIS.xml:S2:234:9	psychosi	NN	O	O
treated	SAPHRIS.xml:S2:244:7	treat	VBN	O	O
with	SAPHRIS.xml:S2:252:4	with	IN	O	O
antipsychotic	SAPHRIS.xml:S2:257:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S2:271:5	drug	NNS	O	O
are	SAPHRIS.xml:S2:277:3	are	VBP	O	O
at	SAPHRIS.xml:S2:281:2	at	IN	O	O
an	SAPHRIS.xml:S2:284:2	an	DT	O	O
increased	SAPHRIS.xml:S2:287:9	increas	VBN	O	O
risk	SAPHRIS.xml:S2:297:4	risk	NN	O	O
of	SAPHRIS.xml:S2:302:2	of	IN	O	O
death	SAPHRIS.xml:S2:305:5	death	NN	B-AdverseReaction	B-AdverseReaction
.	SAPHRIS.xml:S2:310:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S2:312:7	saphri	NNP	O	O
(	SAPHRIS.xml:S2:323:1	(	(	O	O
r	SAPHRIS.xml:S2:324:1	r	NN	O	O
)\n\n	SAPHRIS.xml:S2:325:3	)\n\n	NNP	O	O
(	SAPHRIS.xml:S2:332:1	(	(	O	O
asenapine	SAPHRIS.xml:S2:333:9	asenapin	NN	O	O
)	SAPHRIS.xml:S2:342:1	)	)	O	O
is	SAPHRIS.xml:S2:344:2	is	VBZ	O	O
not	SAPHRIS.xml:S2:347:3	not	RB	O	O
approved	SAPHRIS.xml:S2:351:8	approv	VBN	O	O
for	SAPHRIS.xml:S2:360:3	for	IN	O	O
the	SAPHRIS.xml:S2:364:3	the	DT	O	O
treatment	SAPHRIS.xml:S2:368:9	treatment	NN	O	O
of	SAPHRIS.xml:S2:378:2	of	IN	O	O
patients	SAPHRIS.xml:S2:381:8	patient	NNS	O	O
with	SAPHRIS.xml:S2:390:4	with	IN	O	O
dementia	SAPHRIS.xml:S2:395:8	dementia	JJ	O	O
-	SAPHRIS.xml:S2:403:1	-	:	O	O
related	SAPHRIS.xml:S2:404:7	relat	JJ	O	O
psychosis	SAPHRIS.xml:S2:412:9	psychosi	NN	O	O
\n\n	SAPHRIS.xml:S2:421:2	\n\n	NNP	O	O
[	SAPHRIS.xml:S2:427:1	[	NNP	O	O
see	SAPHRIS.xml:S2:428:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S2:432:8	warn	NNP	O	O
and	SAPHRIS.xml:S2:441:3	and	CC	O	O
Precautions	SAPHRIS.xml:S2:445:11	precaut	NNP	O	O
(	SAPHRIS.xml:S2:457:1	(	(	O	O
5.1	SAPHRIS.xml:S2:458:3	5.1	CD	O	O
,	SAPHRIS.xml:S2:461:1	,	,	O	O
5.2	SAPHRIS.xml:S2:463:3	5.2	CD	O	O
)]	SAPHRIS.xml:S2:466:2	)]	NN	O	O
.	SAPHRIS.xml:S2:470:1	.	.	O	O

WARNING	SAPHRIS.xml:S2:482:7	warn	NN	O	O
:	SAPHRIS.xml:S2:489:1	:	:	O	O
INCREASED	SAPHRIS.xml:S2:491:9	increas	NNP	B-AdverseReaction	O
MORTALITY	SAPHRIS.xml:S2:501:9	mortal	NNP	I-AdverseReaction	B-AdverseReaction
IN	SAPHRIS.xml:S2:511:2	IN	NNP	O	O
ELDERLY	SAPHRIS.xml:S2:514:7	elderli	NNP	O	O
PATIENTS	SAPHRIS.xml:S2:522:8	patient	NNP	O	O
WITH	SAPHRIS.xml:S2:531:4	with	NNP	O	O
DEMENTIA	SAPHRIS.xml:S2:536:8	dementia	NNP	O	O
-	SAPHRIS.xml:S2:544:1	-	:	O	O
RELATED	SAPHRIS.xml:S2:545:7	relat	JJ	O	O
PSYCHOSIS	SAPHRIS.xml:S2:553:9	psychosi	NNP	O	O
\n\n\n\n	SAPHRIS.xml:S2:564:4	\n\n\n\n	NNP	O	O
See	SAPHRIS.xml:S2:571:3	see	NNP	O	O
full	SAPHRIS.xml:S2:575:4	full	JJ	O	O
prescribing	SAPHRIS.xml:S2:580:11	prescrib	VBG	O	O
information	SAPHRIS.xml:S2:592:11	inform	NN	O	O
for	SAPHRIS.xml:S2:604:3	for	IN	O	O
complete	SAPHRIS.xml:S2:608:8	complet	JJ	O	O
boxed	SAPHRIS.xml:S2:617:5	box	JJ	O	O
warning	SAPHRIS.xml:S2:623:7	warn	NN	O	O
.	SAPHRIS.xml:S2:630:1	.	.	O	O

Elderly	SAPHRIS.xml:S2:640:7	elderli	JJ	O	O
patients	SAPHRIS.xml:S2:648:8	patient	NNS	O	O
with	SAPHRIS.xml:S2:657:4	with	IN	O	O
dementia	SAPHRIS.xml:S2:662:8	dementia	JJ	O	O
-	SAPHRIS.xml:S2:670:1	-	:	O	O
related	SAPHRIS.xml:S2:671:7	relat	JJ	O	O
psychosis	SAPHRIS.xml:S2:679:9	psychosi	NN	O	O
treated	SAPHRIS.xml:S2:689:7	treat	VBN	O	O
with	SAPHRIS.xml:S2:697:4	with	IN	O	O
antipsychotic	SAPHRIS.xml:S2:702:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S2:716:5	drug	NNS	O	O
are	SAPHRIS.xml:S2:722:3	are	VBP	O	O
at	SAPHRIS.xml:S2:726:2	at	IN	O	O
an	SAPHRIS.xml:S2:729:2	an	DT	O	O
increased	SAPHRIS.xml:S2:732:9	increas	VBN	O	O
risk	SAPHRIS.xml:S2:742:4	risk	NN	O	O
of	SAPHRIS.xml:S2:747:2	of	IN	O	O
death	SAPHRIS.xml:S2:750:5	death	NN	B-AdverseReaction	B-AdverseReaction
.	SAPHRIS.xml:S2:755:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S2:757:7	saphri	NNP	O	O
is	SAPHRIS.xml:S2:765:2	is	VBZ	O	O
not	SAPHRIS.xml:S2:768:3	not	RB	O	O
approved	SAPHRIS.xml:S2:772:8	approv	VBN	O	O
for	SAPHRIS.xml:S2:781:3	for	IN	O	O
the	SAPHRIS.xml:S2:785:3	the	DT	O	O
treatment	SAPHRIS.xml:S2:789:9	treatment	NN	O	O
of	SAPHRIS.xml:S2:799:2	of	IN	O	O
patients	SAPHRIS.xml:S2:802:8	patient	NNS	O	O
with	SAPHRIS.xml:S2:811:4	with	IN	O	O
dementia	SAPHRIS.xml:S2:816:8	dementia	JJ	O	O
-	SAPHRIS.xml:S2:824:1	-	:	O	O
related	SAPHRIS.xml:S2:825:7	relat	JJ	O	O
psychosis	SAPHRIS.xml:S2:833:9	psychosi	NN	O	O
.	SAPHRIS.xml:S2:842:1	.	.	O	O

(	SAPHRIS.xml:S2:844:1	(	(	O	O
5.1	SAPHRIS.xml:S2:845:3	5.1	CD	O	O
,	SAPHRIS.xml:S2:848:1	,	,	O	O
5.2	SAPHRIS.xml:S2:850:3	5.2	CD	O	O
)	SAPHRIS.xml:S2:853:1	)	)	O	O
\n	SAPHRIS.xml:S2:856:1	\n	VBD	O	O
5	SAPHRIS.xml:S3:8:1	5	CD	O	O
WARNINGS	SAPHRIS.xml:S3:10:8	warn	NNP	O	O
AND	SAPHRIS.xml:S3:19:3	and	NNP	O	O
PRECAUTIONS	SAPHRIS.xml:S3:23:11	precaut	NNP	O	O

EXCERPT	SAPHRIS.xml:S3:39:7	excerpt	NN	O	O
:	SAPHRIS.xml:S3:46:1	:	:	O	O
Cerebrovascular	SAPHRIS.xml:S3:55:15	cerebrovascular	JJ	B-AdverseReaction	B-AdverseReaction
Adverse	SAPHRIS.xml:S3:71:7	advers	JJ	I-AdverseReaction	I-AdverseReaction
Events	SAPHRIS.xml:S3:79:6	event	NNS	I-AdverseReaction	I-AdverseReaction
:	SAPHRIS.xml:S3:85:1	:	:	O	O
An	SAPHRIS.xml:S3:87:2	An	DT	O	O
increased	SAPHRIS.xml:S3:90:9	increas	JJ	O	O
incidence	SAPHRIS.xml:S3:100:9	incid	NN	O	O
of	SAPHRIS.xml:S3:110:2	of	IN	O	O
cerebrovascular	SAPHRIS.xml:S3:113:15	cerebrovascular	JJ	B-AdverseReaction	B-AdverseReaction
adverse	SAPHRIS.xml:S3:129:7	advers	JJ	I-AdverseReaction	I-AdverseReaction
events	SAPHRIS.xml:S3:137:6	event	NNS	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S3:144:1	(	(	O	O
e	SAPHRIS.xml:S3:145:1	e	NN	O	O
.	SAPHRIS.xml:S3:146:1	.	.	O	O
g	SAPHRIS.xml:S3:147:1	g	NN	O	O
.	SAPHRIS.xml:S3:148:1	.	.	O	O
,	SAPHRIS.xml:S3:149:1	,	,	O	O
stroke	SAPHRIS.xml:S3:151:6	stroke	VBD	B-AdverseReaction	O
,	SAPHRIS.xml:S3:157:1	,	,	O	O
transient	SAPHRIS.xml:S3:159:9	transient	JJ	B-AdverseReaction	B-AdverseReaction
ischemic	SAPHRIS.xml:S3:169:8	ischem	JJ	I-AdverseReaction	I-AdverseReaction
attack	SAPHRIS.xml:S3:178:6	attack	NN	I-AdverseReaction	I-AdverseReaction
)	SAPHRIS.xml:S3:184:1	)	)	O	O
has	SAPHRIS.xml:S3:186:3	ha	VBZ	O	O
been	SAPHRIS.xml:S3:190:4	been	VBN	O	O
seen	SAPHRIS.xml:S3:195:4	seen	VBN	O	O
in	SAPHRIS.xml:S3:200:2	in	IN	O	O
elderly	SAPHRIS.xml:S3:203:7	elderli	JJ	O	O
patients	SAPHRIS.xml:S3:211:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:220:4	with	IN	O	O
dementia	SAPHRIS.xml:S3:225:8	dementia	JJ	O	O
-	SAPHRIS.xml:S3:233:1	-	:	O	O
related	SAPHRIS.xml:S3:234:7	relat	JJ	O	O
psychoses	SAPHRIS.xml:S3:242:9	psychos	NNS	O	O
treated	SAPHRIS.xml:S3:252:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:260:4	with	IN	O	O
atypical	SAPHRIS.xml:S3:265:8	atyp	JJ	O	O
antipsychotic	SAPHRIS.xml:S3:274:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:288:5	drug	NNS	O	O
.	SAPHRIS.xml:S3:293:1	.	.	O	O

(	SAPHRIS.xml:S3:295:1	(	(	O	O
5.2	SAPHRIS.xml:S3:296:3	5.2	CD	O	O
)	SAPHRIS.xml:S3:299:1	)	)	O	O

Neuroleptic	SAPHRIS.xml:S3:307:11	neurolept	JJ	B-AdverseReaction	B-AdverseReaction
Malignant	SAPHRIS.xml:S3:319:9	malign	NNP	I-AdverseReaction	I-AdverseReaction
Syndrome	SAPHRIS.xml:S3:329:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
:	SAPHRIS.xml:S3:337:1	:	:	O	O
Manage	SAPHRIS.xml:S3:339:6	manag	NN	O	O
with	SAPHRIS.xml:S3:346:4	with	IN	O	O
immediate	SAPHRIS.xml:S3:351:9	immedi	JJ	O	O
discontinuation	SAPHRIS.xml:S3:361:15	discontinu	NN	O	O
and	SAPHRIS.xml:S3:377:3	and	CC	O	O
close	SAPHRIS.xml:S3:381:5	close	JJ	O	O
monitoring	SAPHRIS.xml:S3:387:10	monitor	NN	O	O
.	SAPHRIS.xml:S3:397:1	.	.	O	O

(	SAPHRIS.xml:S3:399:1	(	(	O	O
5.3	SAPHRIS.xml:S3:400:3	5.3	CD	O	O
)	SAPHRIS.xml:S3:403:1	)	)	O	O

Tardive	SAPHRIS.xml:S3:411:7	tardiv	JJ	B-AdverseReaction	B-AdverseReaction
Dyskinesia	SAPHRIS.xml:S3:419:10	dyskinesia	NN	I-AdverseReaction	I-AdverseReaction
:	SAPHRIS.xml:S3:429:1	:	:	O	O
Discontinue	SAPHRIS.xml:S3:431:11	discontinu	NN	O	O
if	SAPHRIS.xml:S3:443:2	if	IN	O	O
clinically	SAPHRIS.xml:S3:446:10	clinic	RB	O	O
appropriate	SAPHRIS.xml:S3:457:11	appropri	JJ	O	O
.	SAPHRIS.xml:S3:468:1	.	.	O	O

(	SAPHRIS.xml:S3:470:1	(	(	O	O
5.4	SAPHRIS.xml:S3:471:3	5.4	CD	O	O
)	SAPHRIS.xml:S3:474:1	)	)	O	O

dispatch	SAPHRIS.xml:S3:480:8	dispatch	NN	O	O
:	SAPHRIS.xml:S3:488:1	:	:	O	O
unexpected	SAPHRIS.xml:S3:490:10	unexpect	JJ	O	B-AdverseReaction
key	SAPHRIS.xml:S3:501:3	key	NN	O	I-AdverseReaction
:	SAPHRIS.xml:S3:504:1	:	:	O	O
list	SAPHRIS.xml:S3:506:4	list	NN	O	O
in	SAPHRIS.xml:S3:511:2	in	IN	O	O
dispatch	SAPHRIS.xml:S3:514:8	dispatch	NN	O	O
table	SAPHRIS.xml:S3:523:5	tabl	NN	O	O
:	SAPHRIS.xml:S3:528:1	:	:	O	O
caption	SAPHRIS.xml:S3:532:7	caption	NN	O	O
:	SAPHRIS.xml:S3:540:1	:	:	O	O
function	SAPHRIS.xml:S3:543:8	function	NN	O	B-AdverseReaction
print_caption	SAPHRIS.xml:S3:552:13	print_capt	NN	O	I-AdverseReaction
at	SAPHRIS.xml:S3:566:2	at	IN	O	O
0	SAPHRIS.xml:S3:569:1	0	CD	O	O
x1c6c8c0	SAPHRIS.xml:S3:570:8	x1c6c8c0	NN	O	O
,	SAPHRIS.xml:S3:579:1	,	,	O	O
text	SAPHRIS.xml:S3:582:4	text	NN	O	O
:	SAPHRIS.xml:S3:587:1	:	:	O	O
function	SAPHRIS.xml:S3:590:8	function	NN	O	B-AdverseReaction
print_text	SAPHRIS.xml:S3:599:10	print_text	NN	O	I-AdverseReaction
at	SAPHRIS.xml:S3:610:2	at	IN	O	O
0	SAPHRIS.xml:S3:613:1	0	CD	O	O
x1c6c500	SAPHRIS.xml:S3:614:8	x1c6c500	NN	O	O

Metabolic	SAPHRIS.xml:S3:627:9	metabol	JJ	B-AdverseReaction	B-AdverseReaction
Changes	SAPHRIS.xml:S3:637:7	chang	NNS	I-AdverseReaction	I-AdverseReaction
:	SAPHRIS.xml:S3:644:1	:	:	O	O
Atypical	SAPHRIS.xml:S3:646:8	atyp	NNP	O	O
antipsychotic	SAPHRIS.xml:S3:655:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:669:5	drug	NNS	O	O
have	SAPHRIS.xml:S3:675:4	have	VBP	O	O
been	SAPHRIS.xml:S3:680:4	been	VBN	O	O
associated	SAPHRIS.xml:S3:685:10	associ	VBN	O	O
with	SAPHRIS.xml:S3:696:4	with	IN	O	O
metabolic	SAPHRIS.xml:S3:701:9	metabol	JJ	B-AdverseReaction	O
changes	SAPHRIS.xml:S3:711:7	chang	NNS	I-AdverseReaction	O
that	SAPHRIS.xml:S3:719:4	that	WDT	O	O
may	SAPHRIS.xml:S3:724:3	may	MD	O	O
increase	SAPHRIS.xml:S3:728:8	increas	VB	O	B-AdverseReaction
cardiovascular	SAPHRIS.xml:S3:737:14	cardiovascular	JJ	B-AdverseReaction	I-AdverseReaction
cerebrovascular	SAPHRIS.xml:S3:752:15	cerebrovascular	JJ	B-AdverseReaction	I-AdverseReaction
risk	SAPHRIS.xml:S3:768:4	risk	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S3:772:1	.	.	O	O

These	SAPHRIS.xml:S3:774:5	these	DT	O	O
metabolic	SAPHRIS.xml:S3:780:9	metabol	JJ	B-AdverseReaction	O
changes	SAPHRIS.xml:S3:790:7	chang	NNS	I-AdverseReaction	O
include	SAPHRIS.xml:S3:798:7	includ	VBP	O	O
hyperglycemia	SAPHRIS.xml:S3:806:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:819:1	,	,	O	O
dyslipidemia	SAPHRIS.xml:S3:821:12	dyslipidemia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:833:1	,	,	O	O
and	SAPHRIS.xml:S3:835:3	and	CC	O	O
weight	SAPHRIS.xml:S3:839:6	weight	VBD	B-AdverseReaction	B-AdverseReaction
gain	SAPHRIS.xml:S3:846:4	gain	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S3:850:1	.	.	O	O

(	SAPHRIS.xml:S3:852:1	(	(	O	O
5.5	SAPHRIS.xml:S3:853:3	5.5	CD	O	O
)	SAPHRIS.xml:S3:856:1	)	)	O	O

Hypersensitivity	SAPHRIS.xml:S3:864:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	SAPHRIS.xml:S3:881:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
:	SAPHRIS.xml:S3:890:1	:	:	O	O
Hypersensitivity	SAPHRIS.xml:S3:892:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
reactions	SAPHRIS.xml:S3:909:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S3:918:1	,	,	O	O
including	SAPHRIS.xml:S3:920:9	includ	VBG	O	O
anaphylaxis	SAPHRIS.xml:S3:930:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
and	SAPHRIS.xml:S3:942:3	and	CC	O	O
angioedema	SAPHRIS.xml:S3:946:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:956:1	,	,	O	O
have	SAPHRIS.xml:S3:958:4	have	VBP	O	O
been	SAPHRIS.xml:S3:963:4	been	VBN	O	O
observed	SAPHRIS.xml:S3:968:8	observ	VBN	O	O
.	SAPHRIS.xml:S3:976:1	.	.	O	O

(	SAPHRIS.xml:S3:978:1	(	(	O	O
5.6	SAPHRIS.xml:S3:979:3	5.6	CD	O	O
)	SAPHRIS.xml:S3:982:1	)	)	O	O

Orthostatic	SAPHRIS.xml:S3:990:11	orthostat	JJ	B-AdverseReaction	B-AdverseReaction
Hypotension	SAPHRIS.xml:S3:1002:11	hypotens	NNP	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S3:1013:1	,	,	O	O
Syncope	SAPHRIS.xml:S3:1015:7	syncop	NNP	B-AdverseReaction	O
,	SAPHRIS.xml:S3:1022:1	,	,	O	O
and	SAPHRIS.xml:S3:1024:3	and	CC	O	O
Other	SAPHRIS.xml:S3:1028:5	other	JJ	O	O
Hemodynamic	SAPHRIS.xml:S3:1034:11	hemodynam	NNP	B-AdverseReaction	O
Effects	SAPHRIS.xml:S3:1046:7	effect	NNS	I-AdverseReaction	O
:	SAPHRIS.xml:S3:1053:1	:	:	O	O
Dizziness	SAPHRIS.xml:S3:1055:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:1064:1	,	,	O	O
tachycardia	SAPHRIS.xml:S3:1066:11	tachycardia	NN	B-AdverseReaction	B-AdverseReaction
or	SAPHRIS.xml:S3:1078:2	or	CC	O	O
bradycardia	SAPHRIS.xml:S3:1081:11	bradycardia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:1092:1	,	,	O	O
and	SAPHRIS.xml:S3:1094:3	and	CC	O	O
syncope	SAPHRIS.xml:S3:1098:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
may	SAPHRIS.xml:S3:1106:3	may	MD	O	O
occur	SAPHRIS.xml:S3:1110:5	occur	VB	O	O
,	SAPHRIS.xml:S3:1115:1	,	,	O	O
especially	SAPHRIS.xml:S3:1117:10	especi	RB	O	O
early	SAPHRIS.xml:S3:1128:5	earli	JJ	O	O
in	SAPHRIS.xml:S3:1134:2	in	IN	O	O
treatment	SAPHRIS.xml:S3:1137:9	treatment	NN	O	O
.	SAPHRIS.xml:S3:1146:1	.	.	O	O

Use	SAPHRIS.xml:S3:1148:3	use	NN	O	O
with	SAPHRIS.xml:S3:1152:4	with	IN	O	O
caution	SAPHRIS.xml:S3:1157:7	caution	NN	O	O
in	SAPHRIS.xml:S3:1165:2	in	IN	O	O
patients	SAPHRIS.xml:S3:1168:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:1177:4	with	IN	O	O
known	SAPHRIS.xml:S3:1182:5	known	JJ	O	O
cardiovascular	SAPHRIS.xml:S3:1188:14	cardiovascular	NN	O	O
or	SAPHRIS.xml:S3:1203:2	or	CC	O	O
cerebrovascular	SAPHRIS.xml:S3:1206:15	cerebrovascular	JJ	O	B-AdverseReaction
disease	SAPHRIS.xml:S3:1222:7	diseas	NN	O	I-AdverseReaction
,	SAPHRIS.xml:S3:1229:1	,	,	O	O
and	SAPHRIS.xml:S3:1231:3	and	CC	O	O
in	SAPHRIS.xml:S3:1235:2	in	IN	O	O
antipsychotic	SAPHRIS.xml:S3:1238:13	antipsychot	JJ	O	O
-	SAPHRIS.xml:S3:1251:1	-	:	O	O
naive	SAPHRIS.xml:S3:1252:5	naiv	JJ	O	O
patients	SAPHRIS.xml:S3:1258:8	patient	NNS	O	O
.	SAPHRIS.xml:S3:1266:1	.	.	O	O

(	SAPHRIS.xml:S3:1268:1	(	(	O	O
5.7	SAPHRIS.xml:S3:1269:3	5.7	CD	O	O
)	SAPHRIS.xml:S3:1272:1	)	)	O	O

Leukopenia	SAPHRIS.xml:S3:1280:10	leukopenia	NNP	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:1290:1	,	,	O	O
Neutropenia	SAPHRIS.xml:S3:1292:11	neutropenia	NNP	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:1303:1	,	,	O	O
and	SAPHRIS.xml:S3:1305:3	and	CC	O	O
Agranulocytosis	SAPHRIS.xml:S3:1309:15	agranulocytosi	NNP	B-AdverseReaction	B-AdverseReaction
have	SAPHRIS.xml:S3:1325:4	have	VBP	O	O
been	SAPHRIS.xml:S3:1330:4	been	VBN	O	O
reported	SAPHRIS.xml:S3:1335:8	report	VBN	O	O
with	SAPHRIS.xml:S3:1344:4	with	IN	O	O
antipsychotics	SAPHRIS.xml:S3:1349:14	antipsychot	NNS	O	O
.	SAPHRIS.xml:S3:1363:1	.	.	O	O

Patients	SAPHRIS.xml:S3:1365:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:1374:4	with	IN	O	O
a	SAPHRIS.xml:S3:1379:1	a	DT	O	O
pre	SAPHRIS.xml:S3:1381:3	pre	NN	O	O
-	SAPHRIS.xml:S3:1384:1	-	:	O	O
existing	SAPHRIS.xml:S3:1385:8	exist	VBG	O	O
low	SAPHRIS.xml:S3:1394:3	low	JJ	O	O
white	SAPHRIS.xml:S3:1398:5	white	JJ	O	O
blood	SAPHRIS.xml:S3:1404:5	blood	NN	O	O
cell	SAPHRIS.xml:S3:1410:4	cell	NN	O	O
count	SAPHRIS.xml:S3:1415:5	count	NN	O	O
(	SAPHRIS.xml:S3:1421:1	(	(	O	O
WBC	SAPHRIS.xml:S3:1422:3	wbc	NNP	O	O
)	SAPHRIS.xml:S3:1425:1	)	)	O	O
or	SAPHRIS.xml:S3:1427:2	or	CC	O	O
a	SAPHRIS.xml:S3:1430:1	a	DT	O	O
history	SAPHRIS.xml:S3:1432:7	histori	NN	O	O
of	SAPHRIS.xml:S3:1440:2	of	IN	O	O
leukopenia	SAPHRIS.xml:S3:1443:10	leukopenia	NN	O	O
neutropenia	SAPHRIS.xml:S3:1454:11	neutropenia	NN	O	O
should	SAPHRIS.xml:S3:1466:6	should	MD	O	O
have	SAPHRIS.xml:S3:1473:4	have	VB	O	O
their	SAPHRIS.xml:S3:1478:5	their	PRP$	O	O
complete	SAPHRIS.xml:S3:1484:8	complet	JJ	O	O
blood	SAPHRIS.xml:S3:1493:5	blood	NN	O	O
count	SAPHRIS.xml:S3:1499:5	count	NN	O	O
(	SAPHRIS.xml:S3:1505:1	(	(	O	O
CBC	SAPHRIS.xml:S3:1506:3	cbc	NNP	O	O
)	SAPHRIS.xml:S3:1509:1	)	)	O	O
monitored	SAPHRIS.xml:S3:1511:9	monitor	VBD	O	O
frequently	SAPHRIS.xml:S3:1521:10	frequent	RB	O	O
during	SAPHRIS.xml:S3:1532:6	dure	IN	O	O
the	SAPHRIS.xml:S3:1539:3	the	DT	O	O
first	SAPHRIS.xml:S3:1543:5	first	JJ	O	O
few	SAPHRIS.xml:S3:1549:3	few	JJ	O	O
months	SAPHRIS.xml:S3:1553:6	month	NNS	O	O
of	SAPHRIS.xml:S3:1560:2	of	IN	O	O
therapy	SAPHRIS.xml:S3:1563:7	therapi	NN	O	O
and	SAPHRIS.xml:S3:1571:3	and	CC	O	O
SAPHRIS	SAPHRIS.xml:S3:1575:7	saphri	NNP	O	O
should	SAPHRIS.xml:S3:1583:6	should	MD	O	O
be	SAPHRIS.xml:S3:1590:2	be	VB	O	O
discontinued	SAPHRIS.xml:S3:1593:12	discontinu	VBN	O	O
at	SAPHRIS.xml:S3:1606:2	at	IN	O	O
the	SAPHRIS.xml:S3:1609:3	the	DT	O	O
first	SAPHRIS.xml:S3:1613:5	first	JJ	O	O
sign	SAPHRIS.xml:S3:1619:4	sign	NN	O	O
of	SAPHRIS.xml:S3:1624:2	of	IN	O	O
a	SAPHRIS.xml:S3:1627:1	a	DT	O	O
decline	SAPHRIS.xml:S3:1629:7	declin	NN	O	O
in	SAPHRIS.xml:S3:1637:2	in	IN	O	O
WBC	SAPHRIS.xml:S3:1640:3	wbc	NNP	O	O
in	SAPHRIS.xml:S3:1644:2	in	IN	O	O
the	SAPHRIS.xml:S3:1647:3	the	DT	O	O
absence	SAPHRIS.xml:S3:1651:7	absenc	NN	O	O
of	SAPHRIS.xml:S3:1659:2	of	IN	O	O
other	SAPHRIS.xml:S3:1662:5	other	JJ	O	O
causative	SAPHRIS.xml:S3:1668:9	caus	JJ	O	O
factors	SAPHRIS.xml:S3:1678:7	factor	NNS	O	O
.	SAPHRIS.xml:S3:1685:1	.	.	O	O

(	SAPHRIS.xml:S3:1687:1	(	(	O	O
5.8	SAPHRIS.xml:S3:1688:3	5.8	CD	O	O
)	SAPHRIS.xml:S3:1691:1	)	)	O	O

QT	SAPHRIS.xml:S3:1699:2	QT	JJ	B-AdverseReaction	B-AdverseReaction
Prolongation	SAPHRIS.xml:S3:1702:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
:	SAPHRIS.xml:S3:1714:1	:	:	O	O
Increases	SAPHRIS.xml:S3:1716:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S3:1726:2	in	IN	I-AdverseReaction	I-AdverseReaction
QT	SAPHRIS.xml:S3:1729:2	QT	NNP	I-AdverseReaction	I-AdverseReaction
interval	SAPHRIS.xml:S3:1732:8	interv	NN	I-AdverseReaction	I-AdverseReaction
;	SAPHRIS.xml:S3:1740:1	;	:	O	O
avoid	SAPHRIS.xml:S3:1742:5	avoid	CC	O	O
use	SAPHRIS.xml:S3:1748:3	use	NN	O	O
with	SAPHRIS.xml:S3:1752:4	with	IN	O	O
drugs	SAPHRIS.xml:S3:1757:5	drug	NNS	O	O
that	SAPHRIS.xml:S3:1763:4	that	WDT	O	O
also	SAPHRIS.xml:S3:1768:4	also	RB	O	O
increase	SAPHRIS.xml:S3:1773:8	increas	VBP	O	O
the	SAPHRIS.xml:S3:1782:3	the	DT	O	O
QT	SAPHRIS.xml:S3:1786:2	QT	NNP	O	O
interval	SAPHRIS.xml:S3:1789:8	interv	NN	O	O
and	SAPHRIS.xml:S3:1798:3	and	CC	O	O
in	SAPHRIS.xml:S3:1802:2	in	IN	O	O
patients	SAPHRIS.xml:S3:1805:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:1814:4	with	IN	O	O
risk	SAPHRIS.xml:S3:1819:4	risk	NN	O	O
factors	SAPHRIS.xml:S3:1824:7	factor	NNS	O	O
for	SAPHRIS.xml:S3:1832:3	for	IN	O	O
prolonged	SAPHRIS.xml:S3:1836:9	prolong	JJ	O	O
QT	SAPHRIS.xml:S3:1846:2	QT	NNP	O	O
interval	SAPHRIS.xml:S3:1849:8	interv	NN	O	O
.	SAPHRIS.xml:S3:1857:1	.	.	O	O

(	SAPHRIS.xml:S3:1859:1	(	(	O	O
5.9	SAPHRIS.xml:S3:1860:3	5.9	CD	O	O
)	SAPHRIS.xml:S3:1863:1	)	)	O	O

Seizures	SAPHRIS.xml:S3:1871:8	seizur	NNS	B-AdverseReaction	B-AdverseReaction
:	SAPHRIS.xml:S3:1879:1	:	:	O	O
Use	SAPHRIS.xml:S3:1881:3	use	NNP	O	O
cautiously	SAPHRIS.xml:S3:1885:10	cautious	RB	O	O
in	SAPHRIS.xml:S3:1896:2	in	IN	O	O
patients	SAPHRIS.xml:S3:1899:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:1908:4	with	IN	O	O
a	SAPHRIS.xml:S3:1913:1	a	DT	O	O
history	SAPHRIS.xml:S3:1915:7	histori	NN	O	O
of	SAPHRIS.xml:S3:1923:2	of	IN	O	O
seizures	SAPHRIS.xml:S3:1926:8	seizur	NNS	O	O
or	SAPHRIS.xml:S3:1935:2	or	CC	O	O
with	SAPHRIS.xml:S3:1938:4	with	IN	O	O
conditions	SAPHRIS.xml:S3:1943:10	condit	NNS	O	O
that	SAPHRIS.xml:S3:1954:4	that	WDT	O	O
lower	SAPHRIS.xml:S3:1959:5	lower	VBP	O	O
the	SAPHRIS.xml:S3:1965:3	the	DT	O	O
seizure	SAPHRIS.xml:S3:1969:7	seizur	NN	O	O
threshold	SAPHRIS.xml:S3:1977:9	threshold	NN	O	O
.	SAPHRIS.xml:S3:1986:1	.	.	O	O

(	SAPHRIS.xml:S3:1988:1	(	(	O	O
5.11	SAPHRIS.xml:S3:1989:4	5.11	CD	O	O
)	SAPHRIS.xml:S3:1993:1	)	)	O	O

Potential	SAPHRIS.xml:S3:2001:9	potenti	NNP	O	O
for	SAPHRIS.xml:S3:2011:3	for	IN	O	O
Cognitive	SAPHRIS.xml:S3:2015:9	cognit	NNP	B-AdverseReaction	O
and	SAPHRIS.xml:S3:2025:3	and	CC	O	O
Motor	SAPHRIS.xml:S3:2029:5	motor	NNP	B-AdverseReaction	B-AdverseReaction
Impairment	SAPHRIS.xml:S3:2035:10	impair	NNP	I-AdverseReaction	I-AdverseReaction
:	SAPHRIS.xml:S3:2045:1	:	:	O	O
Use	SAPHRIS.xml:S3:2047:3	use	NNP	O	O
caution	SAPHRIS.xml:S3:2051:7	caution	NN	O	O
when	SAPHRIS.xml:S3:2059:4	when	WRB	O	O
operating	SAPHRIS.xml:S3:2064:9	oper	VBG	O	O
machinery	SAPHRIS.xml:S3:2074:9	machineri	NN	O	O
.	SAPHRIS.xml:S3:2083:1	.	.	O	O

(	SAPHRIS.xml:S3:2085:1	(	(	O	O
5.12	SAPHRIS.xml:S3:2086:4	5.12	CD	O	O
)	SAPHRIS.xml:S3:2090:1	)	)	O	O

Suicide	SAPHRIS.xml:S3:2098:7	suicid	NN	B-AdverseReaction	B-AdverseReaction
:	SAPHRIS.xml:S3:2105:1	:	:	O	O
The	SAPHRIS.xml:S3:2107:3	the	DT	O	O
possibility	SAPHRIS.xml:S3:2111:11	possibl	NN	O	O
of	SAPHRIS.xml:S3:2123:2	of	IN	O	O
a	SAPHRIS.xml:S3:2126:1	a	DT	O	O
suicide	SAPHRIS.xml:S3:2128:7	suicid	JJ	O	O
attempt	SAPHRIS.xml:S3:2136:7	attempt	NN	O	O
is	SAPHRIS.xml:S3:2144:2	is	VBZ	O	O
inherent	SAPHRIS.xml:S3:2147:8	inher	JJ	O	O
in	SAPHRIS.xml:S3:2156:2	in	IN	O	O
schizophrenia	SAPHRIS.xml:S3:2159:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S3:2173:3	and	CC	O	O
bipolar	SAPHRIS.xml:S3:2177:7	bipolar	JJ	O	O
disorder	SAPHRIS.xml:S3:2185:8	disord	NN	O	O
.	SAPHRIS.xml:S3:2193:1	.	.	O	O

Closely	SAPHRIS.xml:S3:2195:7	close	RB	O	O
supervise	SAPHRIS.xml:S3:2203:9	supervis	JJ	O	O
high	SAPHRIS.xml:S3:2213:4	high	JJ	O	O
-	SAPHRIS.xml:S3:2217:1	-	:	O	O
risk	SAPHRIS.xml:S3:2218:4	risk	NN	O	O
patients	SAPHRIS.xml:S3:2223:8	patient	NNS	O	O
.	SAPHRIS.xml:S3:2231:1	.	.	O	O

(	SAPHRIS.xml:S3:2233:1	(	(	O	O
5.14	SAPHRIS.xml:S3:2234:4	5.14	CD	O	O
)	SAPHRIS.xml:S3:2238:1	)	)	O	O

5.1	SAPHRIS.xml:S3:2253:3	5.1	CD	O	O

Increased	SAPHRIS.xml:S3:2257:9	increas	VBN	O	O
Mortality	SAPHRIS.xml:S3:2267:9	mortal	NN	O	B-AdverseReaction
in	SAPHRIS.xml:S3:2277:2	in	IN	O	O
Elderly	SAPHRIS.xml:S3:2280:7	elderli	JJ	O	O
Patients	SAPHRIS.xml:S3:2288:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:2297:4	with	IN	O	O
Dementia	SAPHRIS.xml:S3:2302:8	dementia	NNP	O	O
-	SAPHRIS.xml:S3:2310:1	-	:	O	O
Related	SAPHRIS.xml:S3:2311:7	relat	JJ	O	O
Psychosis	SAPHRIS.xml:S3:2319:9	psychosi	NN	O	O

Elderly	SAPHRIS.xml:S3:2336:7	elderli	JJ	O	O
patients	SAPHRIS.xml:S3:2344:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:2353:4	with	IN	O	O
dementia	SAPHRIS.xml:S3:2358:8	dementia	JJ	O	O
-	SAPHRIS.xml:S3:2366:1	-	:	O	O
related	SAPHRIS.xml:S3:2367:7	relat	JJ	O	O
psychosis	SAPHRIS.xml:S3:2375:9	psychosi	NN	O	O
treated	SAPHRIS.xml:S3:2385:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:2393:4	with	IN	O	O
antipsychotic	SAPHRIS.xml:S3:2398:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:2412:5	drug	NNS	O	O
are	SAPHRIS.xml:S3:2418:3	are	VBP	O	O
at	SAPHRIS.xml:S3:2422:2	at	IN	O	O
an	SAPHRIS.xml:S3:2425:2	an	DT	O	O
increased	SAPHRIS.xml:S3:2428:9	increas	VBN	O	O
risk	SAPHRIS.xml:S3:2438:4	risk	NN	O	O
of	SAPHRIS.xml:S3:2443:2	of	IN	O	O
death	SAPHRIS.xml:S3:2446:5	death	NN	B-AdverseReaction	B-AdverseReaction
.	SAPHRIS.xml:S3:2451:1	.	.	O	O

Analyses	SAPHRIS.xml:S3:2453:8	analys	NNS	O	O
of	SAPHRIS.xml:S3:2462:2	of	IN	O	O
17	SAPHRIS.xml:S3:2465:2	17	CD	O	O
placebo	SAPHRIS.xml:S3:2468:7	placebo	NN	O	O
-	SAPHRIS.xml:S3:2475:1	-	:	O	O
controlled	SAPHRIS.xml:S3:2476:10	control	VBN	O	O
trials	SAPHRIS.xml:S3:2487:6	trial	NNS	O	O
(	SAPHRIS.xml:S3:2494:1	(	(	O	O
modal	SAPHRIS.xml:S3:2495:5	modal	JJ	O	O
duration	SAPHRIS.xml:S3:2501:8	durat	NN	O	O
of	SAPHRIS.xml:S3:2510:2	of	IN	O	O
10	SAPHRIS.xml:S3:2513:2	10	CD	O	O
weeks	SAPHRIS.xml:S3:2516:5	week	NNS	O	O
)	SAPHRIS.xml:S3:2521:1	)	)	O	O
,	SAPHRIS.xml:S3:2522:1	,	,	O	O
largely	SAPHRIS.xml:S3:2524:7	larg	RB	O	O
in	SAPHRIS.xml:S3:2532:2	in	IN	O	O
patients	SAPHRIS.xml:S3:2535:8	patient	NNS	O	O
taking	SAPHRIS.xml:S3:2544:6	take	VBG	O	O
atypical	SAPHRIS.xml:S3:2551:8	atyp	JJ	O	O
antipsychotic	SAPHRIS.xml:S3:2560:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:2574:5	drug	NNS	O	O
,	SAPHRIS.xml:S3:2579:1	,	,	O	O
revealed	SAPHRIS.xml:S3:2581:8	reveal	VBD	O	O
a	SAPHRIS.xml:S3:2590:1	a	DT	O	O
risk	SAPHRIS.xml:S3:2592:4	risk	NN	O	O
of	SAPHRIS.xml:S3:2597:2	of	IN	O	O
death	SAPHRIS.xml:S3:2600:5	death	NN	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S3:2606:2	in	IN	O	O
the	SAPHRIS.xml:S3:2609:3	the	DT	O	O
drug	SAPHRIS.xml:S3:2613:4	drug	NN	O	O
-	SAPHRIS.xml:S3:2617:1	-	:	O	O
treated	SAPHRIS.xml:S3:2618:7	treat	JJ	O	O
patients	SAPHRIS.xml:S3:2626:8	patient	NNS	O	O
of	SAPHRIS.xml:S3:2635:2	of	IN	O	O
between	SAPHRIS.xml:S3:2638:7	between	IN	O	O
1.6	SAPHRIS.xml:S3:2646:3	1.6	CD	O	O
to	SAPHRIS.xml:S3:2650:2	to	TO	O	O
1.7	SAPHRIS.xml:S3:2653:3	1.7	CD	O	O
times	SAPHRIS.xml:S3:2657:5	time	NNS	O	O
that	SAPHRIS.xml:S3:2663:4	that	WDT	O	O
seen	SAPHRIS.xml:S3:2668:4	seen	VBN	O	O
in	SAPHRIS.xml:S3:2673:2	in	IN	O	O
placebo	SAPHRIS.xml:S3:2676:7	placebo	JJ	O	O
-	SAPHRIS.xml:S3:2683:1	-	:	O	O
treated	SAPHRIS.xml:S3:2684:7	treat	JJ	O	O
patients	SAPHRIS.xml:S3:2692:8	patient	NNS	O	O
.	SAPHRIS.xml:S3:2700:1	.	.	O	O

Over	SAPHRIS.xml:S3:2702:4	over	IN	O	O
the	SAPHRIS.xml:S3:2707:3	the	DT	O	O
course	SAPHRIS.xml:S3:2711:6	cours	NN	O	O
of	SAPHRIS.xml:S3:2718:2	of	IN	O	O
a	SAPHRIS.xml:S3:2721:1	a	DT	O	O
typical	SAPHRIS.xml:S3:2723:7	typic	JJ	O	O
10	SAPHRIS.xml:S3:2731:2	10	CD	O	O
-	SAPHRIS.xml:S3:2733:1	-	:	O	O
week	SAPHRIS.xml:S3:2734:4	week	NN	O	O
controlled	SAPHRIS.xml:S3:2739:10	control	VBN	O	O
trial	SAPHRIS.xml:S3:2750:5	trial	NN	O	O
,	SAPHRIS.xml:S3:2755:1	,	,	O	O
the	SAPHRIS.xml:S3:2757:3	the	DT	O	O
rate	SAPHRIS.xml:S3:2761:4	rate	NN	O	O
of	SAPHRIS.xml:S3:2766:2	of	IN	O	O
death	SAPHRIS.xml:S3:2769:5	death	NN	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S3:2775:2	in	IN	O	O
drug	SAPHRIS.xml:S3:2778:4	drug	NN	O	O
-	SAPHRIS.xml:S3:2782:1	-	:	O	O
treated	SAPHRIS.xml:S3:2783:7	treat	JJ	O	O
patients	SAPHRIS.xml:S3:2791:8	patient	NNS	O	O
was	SAPHRIS.xml:S3:2800:3	wa	VBD	O	O
about	SAPHRIS.xml:S3:2804:5	about	IN	O	O
4.5%	SAPHRIS.xml:S3:2810:4	4.5%	CD	O	O
,	SAPHRIS.xml:S3:2814:1	,	,	O	O
compared	SAPHRIS.xml:S3:2816:8	compar	VBN	O	O
to	SAPHRIS.xml:S3:2825:2	to	TO	O	O
a	SAPHRIS.xml:S3:2828:1	a	DT	O	O
rate	SAPHRIS.xml:S3:2830:4	rate	NN	O	O
of	SAPHRIS.xml:S3:2835:2	of	IN	O	O
about	SAPHRIS.xml:S3:2838:5	about	IN	O	O
2.6%	SAPHRIS.xml:S3:2844:4	2.6%	CD	O	O
in	SAPHRIS.xml:S3:2849:2	in	IN	O	O
the	SAPHRIS.xml:S3:2852:3	the	DT	O	O
placebo	SAPHRIS.xml:S3:2856:7	placebo	NN	O	O
group	SAPHRIS.xml:S3:2864:5	group	NN	O	O
.	SAPHRIS.xml:S3:2869:1	.	.	O	O

Although	SAPHRIS.xml:S3:2871:8	although	IN	O	O
the	SAPHRIS.xml:S3:2880:3	the	DT	O	O
causes	SAPHRIS.xml:S3:2884:6	caus	NNS	O	O
of	SAPHRIS.xml:S3:2891:2	of	IN	O	O
death	SAPHRIS.xml:S3:2894:5	death	NN	B-AdverseReaction	B-AdverseReaction
were	SAPHRIS.xml:S3:2900:4	were	VBD	O	O
varied	SAPHRIS.xml:S3:2905:6	vari	VBN	O	O
,	SAPHRIS.xml:S3:2911:1	,	,	O	O
most	SAPHRIS.xml:S3:2913:4	most	JJS	O	O
of	SAPHRIS.xml:S3:2918:2	of	IN	O	O
the	SAPHRIS.xml:S3:2921:3	the	DT	O	O
deaths	SAPHRIS.xml:S3:2925:6	death	NNS	B-AdverseReaction	B-AdverseReaction
appeared	SAPHRIS.xml:S3:2932:8	appear	VBD	O	O
to	SAPHRIS.xml:S3:2941:2	to	TO	O	O
be	SAPHRIS.xml:S3:2944:2	be	VB	O	O
either	SAPHRIS.xml:S3:2947:6	either	RB	O	O
cardiovascular	SAPHRIS.xml:S3:2954:14	cardiovascular	JJ	O	O
(	SAPHRIS.xml:S3:2969:1	(	(	O	O
e	SAPHRIS.xml:S3:2970:1	e	NN	O	O
.	SAPHRIS.xml:S3:2971:1	.	.	O	O
g	SAPHRIS.xml:S3:2972:1	g	NN	O	O
.	SAPHRIS.xml:S3:2973:1	.	.	O	O
,	SAPHRIS.xml:S3:2974:1	,	,	O	O
heart	SAPHRIS.xml:S3:2976:5	heart	NN	B-AdverseReaction	B-AdverseReaction
failure	SAPHRIS.xml:S3:2982:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S3:2989:1	,	,	O	O
sudden	SAPHRIS.xml:S3:2991:6	sudden	JJ	B-AdverseReaction	B-AdverseReaction
death	SAPHRIS.xml:S3:2998:5	death	NN	I-AdverseReaction	I-AdverseReaction
)	SAPHRIS.xml:S3:3003:1	)	)	O	O
or	SAPHRIS.xml:S3:3005:2	or	CC	O	O
infectious	SAPHRIS.xml:S3:3008:10	infecti	JJ	O	O
(	SAPHRIS.xml:S3:3019:1	(	(	O	O
e	SAPHRIS.xml:S3:3020:1	e	NN	O	O
.	SAPHRIS.xml:S3:3021:1	.	.	O	O
g	SAPHRIS.xml:S3:3022:1	g	NN	O	O
.	SAPHRIS.xml:S3:3023:1	.	.	O	O
,	SAPHRIS.xml:S3:3024:1	,	,	O	O
pneumonia	SAPHRIS.xml:S3:3026:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
)	SAPHRIS.xml:S3:3035:1	)	)	O	O
in	SAPHRIS.xml:S3:3037:2	in	IN	O	O
nature	SAPHRIS.xml:S3:3040:6	natur	NN	O	O
.	SAPHRIS.xml:S3:3046:1	.	.	O	O

Observational	SAPHRIS.xml:S3:3048:13	observ	JJ	O	O
studies	SAPHRIS.xml:S3:3062:7	studi	NNS	O	O
suggest	SAPHRIS.xml:S3:3070:7	suggest	VBP	O	O
that	SAPHRIS.xml:S3:3078:4	that	IN	O	O
,	SAPHRIS.xml:S3:3082:1	,	,	O	O
similar	SAPHRIS.xml:S3:3084:7	similar	JJ	O	O
to	SAPHRIS.xml:S3:3092:2	to	TO	O	O
atypical	SAPHRIS.xml:S3:3095:8	atyp	JJ	O	O
antipsychotic	SAPHRIS.xml:S3:3104:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:3118:5	drug	NNS	O	O
,	SAPHRIS.xml:S3:3123:1	,	,	O	O
treatment	SAPHRIS.xml:S3:3125:9	treatment	NN	O	O
with	SAPHRIS.xml:S3:3135:4	with	IN	O	O
conventional	SAPHRIS.xml:S3:3140:12	convent	JJ	O	O
antipsychotic	SAPHRIS.xml:S3:3153:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:3167:5	drug	NNS	O	O
may	SAPHRIS.xml:S3:3173:3	may	MD	O	O
increase	SAPHRIS.xml:S3:3177:8	increas	VB	O	O
mortality	SAPHRIS.xml:S3:3186:9	mortal	NN	O	O
.	SAPHRIS.xml:S3:3195:1	.	.	O	O

The	SAPHRIS.xml:S3:3197:3	the	DT	O	O
extent	SAPHRIS.xml:S3:3201:6	extent	NN	O	O
to	SAPHRIS.xml:S3:3208:2	to	TO	O	O
which	SAPHRIS.xml:S3:3211:5	which	WDT	O	O
the	SAPHRIS.xml:S3:3217:3	the	DT	O	O
findings	SAPHRIS.xml:S3:3221:8	find	NNS	O	O
of	SAPHRIS.xml:S3:3230:2	of	IN	O	O
increased	SAPHRIS.xml:S3:3233:9	increas	JJ	B-AdverseReaction	O
mortality	SAPHRIS.xml:S3:3243:9	mortal	NN	I-AdverseReaction	O
in	SAPHRIS.xml:S3:3253:2	in	IN	O	O
observational	SAPHRIS.xml:S3:3256:13	observ	JJ	O	O
studies	SAPHRIS.xml:S3:3270:7	studi	NNS	O	O
may	SAPHRIS.xml:S3:3278:3	may	MD	O	O
be	SAPHRIS.xml:S3:3282:2	be	VB	O	O
attributed	SAPHRIS.xml:S3:3285:10	attribut	VBN	O	O
to	SAPHRIS.xml:S3:3296:2	to	TO	O	O
the	SAPHRIS.xml:S3:3299:3	the	DT	O	O
antipsychotic	SAPHRIS.xml:S3:3303:13	antipsychot	JJ	O	O
drug	SAPHRIS.xml:S3:3317:4	drug	NN	O	O
as	SAPHRIS.xml:S3:3322:2	as	IN	O	O
opposed	SAPHRIS.xml:S3:3325:7	oppos	VBN	O	O
to	SAPHRIS.xml:S3:3333:2	to	TO	O	O
some	SAPHRIS.xml:S3:3336:4	some	DT	O	O
characteristic	SAPHRIS.xml:S3:3341:14	characterist	JJ	O	O
(	SAPHRIS.xml:S3:3355:1	(	(	O	O
s	SAPHRIS.xml:S3:3356:1	s	JJ	O	O
)	SAPHRIS.xml:S3:3357:1	)	)	O	O
of	SAPHRIS.xml:S3:3359:2	of	IN	O	O
the	SAPHRIS.xml:S3:3362:3	the	DT	O	O
patients	SAPHRIS.xml:S3:3366:8	patient	NNS	O	O
is	SAPHRIS.xml:S3:3375:2	is	VBZ	O	O
not	SAPHRIS.xml:S3:3378:3	not	RB	O	O
clear	SAPHRIS.xml:S3:3382:5	clear	JJ	O	O
.	SAPHRIS.xml:S3:3387:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S3:3389:7	saphri	NNP	O	O
is	SAPHRIS.xml:S3:3397:2	is	VBZ	O	O
not	SAPHRIS.xml:S3:3400:3	not	RB	O	O
approved	SAPHRIS.xml:S3:3404:8	approv	VBN	O	O
for	SAPHRIS.xml:S3:3413:3	for	IN	O	O
the	SAPHRIS.xml:S3:3417:3	the	DT	O	O
treatment	SAPHRIS.xml:S3:3421:9	treatment	NN	O	O
of	SAPHRIS.xml:S3:3431:2	of	IN	O	O
patients	SAPHRIS.xml:S3:3434:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:3443:4	with	IN	O	O
dementia	SAPHRIS.xml:S3:3448:8	dementia	JJ	O	O
-	SAPHRIS.xml:S3:3456:1	-	:	O	O
related	SAPHRIS.xml:S3:3457:7	relat	JJ	O	O
psychosis	SAPHRIS.xml:S3:3465:9	psychosi	NN	O	O
[	SAPHRIS.xml:S3:3476:1	[	NNP	O	O
seeBoxed	SAPHRIS.xml:S3:3477:8	seebox	VBD	O	O
Warningand	SAPHRIS.xml:S3:3486:10	warningand	NNP	O	O
Warnings	SAPHRIS.xml:S3:3497:8	warn	NNP	O	O
and	SAPHRIS.xml:S3:3506:3	and	CC	O	O
Precautions	SAPHRIS.xml:S3:3510:11	precaut	NNP	O	O
(	SAPHRIS.xml:S3:3522:1	(	(	O	O
5.2	SAPHRIS.xml:S3:3523:3	5.2	CD	O	O
)]	SAPHRIS.xml:S3:3526:2	)]	NN	O	O
.	SAPHRIS.xml:S3:3530:1	.	.	O	O

5.2	SAPHRIS.xml:S3:3542:3	5.2	CD	O	O
Cerebrovascular	SAPHRIS.xml:S3:3546:15	cerebrovascular	JJ	O	O
Adverse	SAPHRIS.xml:S3:3562:7	advers	JJ	O	O
Events	SAPHRIS.xml:S3:3570:6	event	NNS	O	O
,	SAPHRIS.xml:S3:3576:1	,	,	O	O
Including	SAPHRIS.xml:S3:3578:9	includ	VBG	O	O
Stroke	SAPHRIS.xml:S3:3588:6	stroke	NNP	O	B-AdverseReaction
,	SAPHRIS.xml:S3:3594:1	,	,	O	O
In	SAPHRIS.xml:S3:3596:2	In	IN	O	O
Elderly	SAPHRIS.xml:S3:3599:7	elderli	JJ	O	O
Patients	SAPHRIS.xml:S3:3607:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:3616:4	with	IN	O	O
Dementia	SAPHRIS.xml:S3:3621:8	dementia	NNP	O	O
-	SAPHRIS.xml:S3:3629:1	-	:	O	O
Related	SAPHRIS.xml:S3:3630:7	relat	JJ	O	O
Psychosis	SAPHRIS.xml:S3:3638:9	psychosi	NN	O	O

In	SAPHRIS.xml:S3:3655:2	In	IN	O	O
placebo	SAPHRIS.xml:S3:3658:7	placebo	NN	O	O
-	SAPHRIS.xml:S3:3665:1	-	:	O	O
controlled	SAPHRIS.xml:S3:3666:10	control	VBN	O	O
trials	SAPHRIS.xml:S3:3677:6	trial	NNS	O	O
with	SAPHRIS.xml:S3:3684:4	with	IN	O	O
risperidone	SAPHRIS.xml:S3:3689:11	risperidon	NN	O	O
,	SAPHRIS.xml:S3:3700:1	,	,	O	O
aripiprazole	SAPHRIS.xml:S3:3702:12	aripiprazol	NN	O	O
,	SAPHRIS.xml:S3:3714:1	,	,	O	O
and	SAPHRIS.xml:S3:3716:3	and	CC	O	O
olanzapine	SAPHRIS.xml:S3:3720:10	olanzapin	NN	O	O
in	SAPHRIS.xml:S3:3731:2	in	IN	O	O
elderly	SAPHRIS.xml:S3:3734:7	elderli	JJ	O	O
subjects	SAPHRIS.xml:S3:3742:8	subject	NNS	O	O
with	SAPHRIS.xml:S3:3751:4	with	IN	O	O
dementia	SAPHRIS.xml:S3:3756:8	dementia	NN	O	O
,	SAPHRIS.xml:S3:3764:1	,	,	O	O
there	SAPHRIS.xml:S3:3766:5	there	EX	O	O
was	SAPHRIS.xml:S3:3772:3	wa	VBD	O	O
a	SAPHRIS.xml:S3:3776:1	a	DT	O	O
higher	SAPHRIS.xml:S3:3778:6	higher	JJR	O	O
incidence	SAPHRIS.xml:S3:3785:9	incid	NN	O	O
of	SAPHRIS.xml:S3:3795:2	of	IN	O	O
cerebrovascular	SAPHRIS.xml:S3:3798:15	cerebrovascular	JJ	B-AdverseReaction	B-AdverseReaction
adverse	SAPHRIS.xml:S3:3814:7	advers	JJ	I-AdverseReaction	I-AdverseReaction
reactions	SAPHRIS.xml:S3:3822:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S3:3832:1	(	(	O	O
cerebrovascular	SAPHRIS.xml:S3:3833:15	cerebrovascular	JJ	B-AdverseReaction	B-AdverseReaction
accidents	SAPHRIS.xml:S3:3849:9	accid	NNS	I-AdverseReaction	I-AdverseReaction
and	SAPHRIS.xml:S3:3859:3	and	CC	O	O
transient	SAPHRIS.xml:S3:3863:9	transient	JJ	B-AdverseReaction	B-AdverseReaction
ischemic	SAPHRIS.xml:S3:3873:8	ischem	JJ	I-AdverseReaction	I-AdverseReaction
attacks	SAPHRIS.xml:S3:3882:7	attack	NNS	I-AdverseReaction	I-AdverseReaction
)	SAPHRIS.xml:S3:3889:1	)	)	O	O
including	SAPHRIS.xml:S3:3891:9	includ	VBG	O	O
fatalities	SAPHRIS.xml:S3:3901:10	fatal	NNS	B-AdverseReaction	B-AdverseReaction
compared	SAPHRIS.xml:S3:3912:8	compar	VBN	O	O
to	SAPHRIS.xml:S3:3921:2	to	TO	O	O
placebo	SAPHRIS.xml:S3:3924:7	placebo	VB	O	O
-	SAPHRIS.xml:S3:3931:1	-	:	O	O
treated	SAPHRIS.xml:S3:3932:7	treat	JJ	O	O
subjects	SAPHRIS.xml:S3:3940:8	subject	NNS	O	O
.	SAPHRIS.xml:S3:3948:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S3:3950:7	saphri	NNP	O	O
is	SAPHRIS.xml:S3:3958:2	is	VBZ	O	O
not	SAPHRIS.xml:S3:3961:3	not	RB	O	O
approved	SAPHRIS.xml:S3:3965:8	approv	VBN	O	O
for	SAPHRIS.xml:S3:3974:3	for	IN	O	O
the	SAPHRIS.xml:S3:3978:3	the	DT	O	O
treatment	SAPHRIS.xml:S3:3982:9	treatment	NN	O	O
of	SAPHRIS.xml:S3:3992:2	of	IN	O	O
patients	SAPHRIS.xml:S3:3995:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:4004:4	with	IN	O	O
dementia	SAPHRIS.xml:S3:4009:8	dementia	JJ	O	O
-	SAPHRIS.xml:S3:4017:1	-	:	O	O
related	SAPHRIS.xml:S3:4018:7	relat	JJ	O	O
psychosis	SAPHRIS.xml:S3:4026:9	psychosi	NN	O	O
[	SAPHRIS.xml:S3:4037:1	[	NNP	O	O
see	SAPHRIS.xml:S3:4038:3	see	VBP	O	O
alsoBoxed	SAPHRIS.xml:S3:4042:9	alsobox	JJ	O	O
Warningand	SAPHRIS.xml:S3:4052:10	warningand	NNP	O	O
Warnings	SAPHRIS.xml:S3:4063:8	warn	NNP	O	O
and	SAPHRIS.xml:S3:4072:3	and	CC	O	O
Precautions	SAPHRIS.xml:S3:4076:11	precaut	NNP	O	O
(	SAPHRIS.xml:S3:4088:1	(	(	O	O
5.1	SAPHRIS.xml:S3:4089:3	5.1	CD	O	O
)]	SAPHRIS.xml:S3:4092:2	)]	NN	O	O
.	SAPHRIS.xml:S3:4096:1	.	.	O	O

5.3	SAPHRIS.xml:S3:4108:3	5.3	CD	O	O
Neuroleptic	SAPHRIS.xml:S3:4112:11	neurolept	JJ	O	O
Malignant	SAPHRIS.xml:S3:4124:9	malign	NNP	O	O
Syndrome	SAPHRIS.xml:S3:4134:8	syndrom	NNP	O	O

A	SAPHRIS.xml:S3:4150:1	A	DT	O	O
potentially	SAPHRIS.xml:S3:4152:11	potenti	RB	O	O
fatal	SAPHRIS.xml:S3:4164:5	fatal	JJ	B-AdverseReaction	O
symptom	SAPHRIS.xml:S3:4170:7	symptom	NN	O	O
complex	SAPHRIS.xml:S3:4178:7	complex	JJ	O	O
sometimes	SAPHRIS.xml:S3:4186:9	sometim	RB	O	O
referred	SAPHRIS.xml:S3:4196:8	refer	VBN	O	O
to	SAPHRIS.xml:S3:4205:2	to	TO	O	O
as	SAPHRIS.xml:S3:4208:2	as	IN	O	O
Neuroleptic	SAPHRIS.xml:S3:4211:11	neurolept	NNP	B-AdverseReaction	B-AdverseReaction
Malignant	SAPHRIS.xml:S3:4223:9	malign	NNP	I-AdverseReaction	I-AdverseReaction
Syndrome	SAPHRIS.xml:S3:4233:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S3:4242:1	(	(	O	O
NMS	SAPHRIS.xml:S3:4243:3	nm	NNP	B-AdverseReaction	B-AdverseReaction
)	SAPHRIS.xml:S3:4246:1	)	)	O	O
has	SAPHRIS.xml:S3:4248:3	ha	VBZ	O	O
been	SAPHRIS.xml:S3:4252:4	been	VBN	O	O
reported	SAPHRIS.xml:S3:4257:8	report	VBN	O	O
in	SAPHRIS.xml:S3:4266:2	in	IN	O	O
association	SAPHRIS.xml:S3:4269:11	associ	NN	O	O
with	SAPHRIS.xml:S3:4281:4	with	IN	O	O
administration	SAPHRIS.xml:S3:4286:14	administr	NN	O	O
of	SAPHRIS.xml:S3:4301:2	of	IN	O	O
antipsychotic	SAPHRIS.xml:S3:4304:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:4318:5	drug	NNS	O	O
,	SAPHRIS.xml:S3:4323:1	,	,	O	O
including	SAPHRIS.xml:S3:4325:9	includ	VBG	O	O
SAPHRIS	SAPHRIS.xml:S3:4335:7	saphri	NNP	O	O
.	SAPHRIS.xml:S3:4342:1	.	.	O	O

Clinical	SAPHRIS.xml:S3:4344:8	clinic	JJ	O	O
manifestations	SAPHRIS.xml:S3:4353:14	manifest	NNS	O	O
of	SAPHRIS.xml:S3:4368:2	of	IN	O	O
NMS	SAPHRIS.xml:S3:4371:3	nm	NNP	B-AdverseReaction	O
are	SAPHRIS.xml:S3:4375:3	are	VBP	O	O
hyperpyrexia	SAPHRIS.xml:S3:4379:12	hyperpyrexia	JJ	B-AdverseReaction	O
,	SAPHRIS.xml:S3:4391:1	,	,	O	O
muscle	SAPHRIS.xml:S3:4393:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
rigidity	SAPHRIS.xml:S3:4400:8	rigid	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S3:4408:1	,	,	O	O
altered	SAPHRIS.xml:S3:4410:7	alter	VBD	B-AdverseReaction	B-AdverseReaction
mental	SAPHRIS.xml:S3:4418:6	mental	JJ	I-AdverseReaction	I-AdverseReaction
status	SAPHRIS.xml:S3:4425:6	statu	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S3:4431:1	,	,	O	O
and	SAPHRIS.xml:S3:4433:3	and	CC	O	O
evidence	SAPHRIS.xml:S3:4437:8	evid	NN	O	O
of	SAPHRIS.xml:S3:4446:2	of	IN	O	O
autonomic	SAPHRIS.xml:S3:4449:9	autonom	JJ	B-AdverseReaction	O
instability	SAPHRIS.xml:S3:4459:11	instabl	NN	I-AdverseReaction	O
(	SAPHRIS.xml:S3:4471:1	(	(	O	O
irregular	SAPHRIS.xml:S3:4472:9	irregular	JJ	B-AdverseReaction	B-AdverseReaction
pulse	SAPHRIS.xml:S3:4482:5	puls	NN	I-AdverseReaction	I-AdverseReaction
or	SAPHRIS.xml:S3:4488:2	or	CC	O	O
blood	SAPHRIS.xml:S3:4491:5	blood	NN	I-AdverseReaction	I-AdverseReaction
pressure	SAPHRIS.xml:S3:4497:8	pressur	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S3:4505:1	,	,	O	O
tachycardia	SAPHRIS.xml:S3:4507:11	tachycardia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:4518:1	,	,	O	O
diaphoresis	SAPHRIS.xml:S3:4520:11	diaphoresi	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:4531:1	,	,	O	O
and	SAPHRIS.xml:S3:4533:3	and	CC	O	O
cardiac	SAPHRIS.xml:S3:4537:7	cardiac	JJ	B-AdverseReaction	B-AdverseReaction
dysrhythmia	SAPHRIS.xml:S3:4545:11	dysrhythmia	NN	I-AdverseReaction	I-AdverseReaction
)	SAPHRIS.xml:S3:4556:1	)	)	O	O
.	SAPHRIS.xml:S3:4557:1	.	.	O	O

Additional	SAPHRIS.xml:S3:4559:10	addit	JJ	O	O
signs	SAPHRIS.xml:S3:4570:5	sign	NNS	O	O
may	SAPHRIS.xml:S3:4576:3	may	MD	O	O
include	SAPHRIS.xml:S3:4580:7	includ	VB	O	O
elevated	SAPHRIS.xml:S3:4588:8	elev	JJ	B-AdverseReaction	B-AdverseReaction
creatine	SAPHRIS.xml:S3:4597:8	creatin	JJ	I-AdverseReaction	I-AdverseReaction
phosphokinase	SAPHRIS.xml:S3:4606:13	phosphokinas	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S3:4619:1	,	,	O	O
myoglobinuria	SAPHRIS.xml:S3:4621:13	myoglobinuria	NN	B-AdverseReaction	O
(	SAPHRIS.xml:S3:4635:1	(	(	O	O
rhabdomyolysis	SAPHRIS.xml:S3:4636:14	rhabdomyolysi	NN	B-AdverseReaction	O
)	SAPHRIS.xml:S3:4650:1	)	)	O	O
,	SAPHRIS.xml:S3:4651:1	,	,	O	O
and	SAPHRIS.xml:S3:4653:3	and	CC	O	O
acute	SAPHRIS.xml:S3:4657:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
renal	SAPHRIS.xml:S3:4663:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	SAPHRIS.xml:S3:4669:7	failur	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S3:4676:1	.	.	O	O

The	SAPHRIS.xml:S3:4686:3	the	DT	O	O
diagnostic	SAPHRIS.xml:S3:4690:10	diagnost	JJ	O	O
evaluation	SAPHRIS.xml:S3:4701:10	evalu	NN	O	O
of	SAPHRIS.xml:S3:4712:2	of	IN	O	O
patients	SAPHRIS.xml:S3:4715:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:4724:4	with	IN	O	O
this	SAPHRIS.xml:S3:4729:4	thi	DT	O	O
syndrome	SAPHRIS.xml:S3:4734:8	syndrom	NN	O	O
is	SAPHRIS.xml:S3:4743:2	is	VBZ	O	O
complicated	SAPHRIS.xml:S3:4746:11	complic	VBN	O	O
.	SAPHRIS.xml:S3:4757:1	.	.	O	O

It	SAPHRIS.xml:S3:4759:2	It	PRP	O	O
is	SAPHRIS.xml:S3:4762:2	is	VBZ	O	O
important	SAPHRIS.xml:S3:4765:9	import	JJ	O	O
to	SAPHRIS.xml:S3:4775:2	to	TO	O	O
exclude	SAPHRIS.xml:S3:4778:7	exclud	VB	O	O
cases	SAPHRIS.xml:S3:4786:5	case	NNS	O	O
where	SAPHRIS.xml:S3:4792:5	where	WRB	O	O
the	SAPHRIS.xml:S3:4798:3	the	DT	O	O
clinical	SAPHRIS.xml:S3:4802:8	clinic	JJ	O	O
presentation	SAPHRIS.xml:S3:4811:12	present	NN	O	O
includes	SAPHRIS.xml:S3:4824:8	includ	VBZ	O	O
both	SAPHRIS.xml:S3:4833:4	both	DT	O	O
serious	SAPHRIS.xml:S3:4838:7	seriou	JJ	O	O
medical	SAPHRIS.xml:S3:4846:7	medic	JJ	O	O
illness	SAPHRIS.xml:S3:4854:7	ill	NN	O	O
(	SAPHRIS.xml:S3:4862:1	(	(	O	O
e	SAPHRIS.xml:S3:4863:1	e	NN	O	O
.	SAPHRIS.xml:S3:4864:1	.	.	O	O
g	SAPHRIS.xml:S3:4865:1	g	NN	O	O
.	SAPHRIS.xml:S3:4866:1	.	.	O	O

pneumonia	SAPHRIS.xml:S3:4868:9	pneumonia	NN	O	B-AdverseReaction
,	SAPHRIS.xml:S3:4877:1	,	,	O	O
systemic	SAPHRIS.xml:S3:4879:8	system	JJ	O	B-AdverseReaction
infection	SAPHRIS.xml:S3:4888:9	infect	NN	O	I-AdverseReaction
)	SAPHRIS.xml:S3:4897:1	)	)	O	O
and	SAPHRIS.xml:S3:4899:3	and	CC	O	O
untreated	SAPHRIS.xml:S3:4903:9	untreat	JJ	O	O
or	SAPHRIS.xml:S3:4913:2	or	CC	O	O
inadequately	SAPHRIS.xml:S3:4916:12	inadequ	RB	O	O
treated	SAPHRIS.xml:S3:4929:7	treat	JJ	O	O
extrapyramidal	SAPHRIS.xml:S3:4937:14	extrapyramid	JJ	O	O
signs	SAPHRIS.xml:S3:4952:5	sign	NNS	O	O
and	SAPHRIS.xml:S3:4958:3	and	CC	O	O
symptoms	SAPHRIS.xml:S3:4962:8	symptom	NNS	O	O
(	SAPHRIS.xml:S3:4971:1	(	(	O	O
EPS	SAPHRIS.xml:S3:4972:3	ep	NNP	O	O
)	SAPHRIS.xml:S3:4975:1	)	)	O	O
.	SAPHRIS.xml:S3:4976:1	.	.	O	O

Other	SAPHRIS.xml:S3:4978:5	other	JJ	O	O
important	SAPHRIS.xml:S3:4984:9	import	JJ	O	O
considerations	SAPHRIS.xml:S3:4994:14	consider	NNS	O	O
in	SAPHRIS.xml:S3:5009:2	in	IN	O	O
the	SAPHRIS.xml:S3:5012:3	the	DT	O	O
differential	SAPHRIS.xml:S3:5016:12	differenti	JJ	O	O
diagnosis	SAPHRIS.xml:S3:5029:9	diagnosi	NN	O	O
include	SAPHRIS.xml:S3:5039:7	includ	VBP	O	O
central	SAPHRIS.xml:S3:5047:7	central	JJ	O	O
anticholinergic	SAPHRIS.xml:S3:5055:15	anticholinerg	JJ	O	O
toxicity	SAPHRIS.xml:S3:5071:8	toxic	NN	O	O
,	SAPHRIS.xml:S3:5079:1	,	,	O	O
heat	SAPHRIS.xml:S3:5081:4	heat	NN	O	O
stroke	SAPHRIS.xml:S3:5086:6	stroke	NN	O	O
,	SAPHRIS.xml:S3:5092:1	,	,	O	O
drug	SAPHRIS.xml:S3:5094:4	drug	NN	O	O
fever	SAPHRIS.xml:S3:5099:5	fever	NN	O	O
,	SAPHRIS.xml:S3:5104:1	,	,	O	O
and	SAPHRIS.xml:S3:5106:3	and	CC	O	O
primary	SAPHRIS.xml:S3:5110:7	primari	JJ	O	O
central	SAPHRIS.xml:S3:5118:7	central	JJ	O	O
nervous	SAPHRIS.xml:S3:5126:7	nervou	JJ	O	O
system	SAPHRIS.xml:S3:5134:6	system	NN	O	O
pathology	SAPHRIS.xml:S3:5141:9	patholog	NN	O	O
.	SAPHRIS.xml:S3:5150:1	.	.	O	O

The	SAPHRIS.xml:S3:5160:3	the	DT	O	O
management	SAPHRIS.xml:S3:5164:10	manag	NN	O	O
of	SAPHRIS.xml:S3:5175:2	of	IN	O	O
NMS	SAPHRIS.xml:S3:5178:3	nm	NNP	O	O
should	SAPHRIS.xml:S3:5182:6	should	MD	O	O
include	SAPHRIS.xml:S3:5189:7	includ	VB	O	O
:	SAPHRIS.xml:S3:5196:1	:	:	O	O
1	SAPHRIS.xml:S3:5198:1	1	CD	O	O
)	SAPHRIS.xml:S3:5199:1	)	)	O	O
immediate	SAPHRIS.xml:S3:5201:9	immedi	JJ	O	O
discontinuation	SAPHRIS.xml:S3:5211:15	discontinu	NN	O	O
of	SAPHRIS.xml:S3:5227:2	of	IN	O	O
antipsychotic	SAPHRIS.xml:S3:5230:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:5244:5	drug	NNS	O	O
and	SAPHRIS.xml:S3:5250:3	and	CC	O	O
other	SAPHRIS.xml:S3:5254:5	other	JJ	O	O
drugs	SAPHRIS.xml:S3:5260:5	drug	NNS	O	O
not	SAPHRIS.xml:S3:5266:3	not	RB	O	O
essential	SAPHRIS.xml:S3:5270:9	essenti	JJ	O	O
to	SAPHRIS.xml:S3:5280:2	to	TO	O	O
concurrent	SAPHRIS.xml:S3:5283:10	concurr	JJ	O	O
therapy	SAPHRIS.xml:S3:5294:7	therapi	NN	O	O
;	SAPHRIS.xml:S3:5301:1	;	:	O	O
2	SAPHRIS.xml:S3:5303:1	2	CD	O	O
)	SAPHRIS.xml:S3:5304:1	)	)	O	O
intensive	SAPHRIS.xml:S3:5306:9	intens	JJ	O	O
symptomatic	SAPHRIS.xml:S3:5316:11	symptomat	JJ	O	O
treatment	SAPHRIS.xml:S3:5328:9	treatment	NN	O	O
and	SAPHRIS.xml:S3:5338:3	and	CC	O	O
medical	SAPHRIS.xml:S3:5342:7	medic	JJ	O	O
monitoring	SAPHRIS.xml:S3:5350:10	monitor	NN	O	O
;	SAPHRIS.xml:S3:5360:1	;	:	O	O
and	SAPHRIS.xml:S3:5362:3	and	CC	O	O
3	SAPHRIS.xml:S3:5366:1	3	CD	O	O
)	SAPHRIS.xml:S3:5367:1	)	)	O	O
treatment	SAPHRIS.xml:S3:5369:9	treatment	NN	O	O
of	SAPHRIS.xml:S3:5379:2	of	IN	O	O
any	SAPHRIS.xml:S3:5382:3	ani	DT	O	O
concomitant	SAPHRIS.xml:S3:5386:11	concomit	JJ	O	O
serious	SAPHRIS.xml:S3:5398:7	seriou	JJ	O	O
medical	SAPHRIS.xml:S3:5406:7	medic	JJ	O	O
problems	SAPHRIS.xml:S3:5414:8	problem	NNS	O	O
for	SAPHRIS.xml:S3:5423:3	for	IN	O	O
which	SAPHRIS.xml:S3:5427:5	which	WDT	O	O
specific	SAPHRIS.xml:S3:5433:8	specif	JJ	O	O
treatments	SAPHRIS.xml:S3:5442:10	treatment	NNS	O	O
are	SAPHRIS.xml:S3:5453:3	are	VBP	O	O
available	SAPHRIS.xml:S3:5457:9	avail	JJ	O	O
.	SAPHRIS.xml:S3:5466:1	.	.	O	O

There	SAPHRIS.xml:S3:5468:5	there	EX	O	O
is	SAPHRIS.xml:S3:5474:2	is	VBZ	O	O
no	SAPHRIS.xml:S3:5477:2	no	DT	O	O
general	SAPHRIS.xml:S3:5480:7	gener	JJ	O	O
agreement	SAPHRIS.xml:S3:5488:9	agreement	NN	O	O
about	SAPHRIS.xml:S3:5498:5	about	IN	O	O
specific	SAPHRIS.xml:S3:5504:8	specif	JJ	O	O
pharmacological	SAPHRIS.xml:S3:5513:15	pharmacolog	JJ	O	O
treatment	SAPHRIS.xml:S3:5529:9	treatment	NN	O	O
regimens	SAPHRIS.xml:S3:5539:8	regimen	NNS	O	O
for	SAPHRIS.xml:S3:5548:3	for	IN	O	O
NMS	SAPHRIS.xml:S3:5552:3	nm	NNP	O	O
.	SAPHRIS.xml:S3:5555:1	.	.	O	O

If	SAPHRIS.xml:S3:5565:2	If	IN	O	O
a	SAPHRIS.xml:S3:5568:1	a	DT	O	O
patient	SAPHRIS.xml:S3:5570:7	patient	NN	O	O
requires	SAPHRIS.xml:S3:5578:8	requir	VBZ	O	O
antipsychotic	SAPHRIS.xml:S3:5587:13	antipsychot	JJ	O	O
drug	SAPHRIS.xml:S3:5601:4	drug	NN	O	O
treatment	SAPHRIS.xml:S3:5606:9	treatment	NN	O	O
after	SAPHRIS.xml:S3:5616:5	after	IN	O	O
recovery	SAPHRIS.xml:S3:5622:8	recoveri	NN	O	O
from	SAPHRIS.xml:S3:5631:4	from	IN	O	O
NMS	SAPHRIS.xml:S3:5636:3	nm	NNP	O	O
,	SAPHRIS.xml:S3:5639:1	,	,	O	O
the	SAPHRIS.xml:S3:5641:3	the	DT	O	O
potential	SAPHRIS.xml:S3:5645:9	potenti	JJ	O	O
reintroduction	SAPHRIS.xml:S3:5655:14	reintroduct	NN	O	O
of	SAPHRIS.xml:S3:5670:2	of	IN	O	O
drug	SAPHRIS.xml:S3:5673:4	drug	NN	O	O
therapy	SAPHRIS.xml:S3:5678:7	therapi	NN	O	O
should	SAPHRIS.xml:S3:5686:6	should	MD	O	O
be	SAPHRIS.xml:S3:5693:2	be	VB	O	O
carefully	SAPHRIS.xml:S3:5696:9	care	RB	O	O
considered	SAPHRIS.xml:S3:5706:10	consid	VBN	O	O
.	SAPHRIS.xml:S3:5716:1	.	.	O	O

The	SAPHRIS.xml:S3:5718:3	the	DT	O	O
patient	SAPHRIS.xml:S3:5722:7	patient	NN	O	O
should	SAPHRIS.xml:S3:5730:6	should	MD	O	O
be	SAPHRIS.xml:S3:5737:2	be	VB	O	O
carefully	SAPHRIS.xml:S3:5740:9	care	RB	O	O
monitored	SAPHRIS.xml:S3:5750:9	monitor	VBN	O	O
,	SAPHRIS.xml:S3:5759:1	,	,	O	O
since	SAPHRIS.xml:S3:5761:5	sinc	IN	O	O
recurrences	SAPHRIS.xml:S3:5767:11	recurr	NNS	O	O
of	SAPHRIS.xml:S3:5779:2	of	IN	O	O
NMS	SAPHRIS.xml:S3:5782:3	nm	NNP	O	O
have	SAPHRIS.xml:S3:5786:4	have	VBP	O	O
been	SAPHRIS.xml:S3:5791:4	been	VBN	O	O
reported	SAPHRIS.xml:S3:5796:8	report	VBN	O	O
.	SAPHRIS.xml:S3:5804:1	.	.	O	O

5.4	SAPHRIS.xml:S3:5816:3	5.4	CD	O	O
Tardive	SAPHRIS.xml:S3:5820:7	tardiv	JJ	O	O
Dyskinesia	SAPHRIS.xml:S3:5828:10	dyskinesia	NN	O	O

A	SAPHRIS.xml:S3:5846:1	A	DT	O	O
syndrome	SAPHRIS.xml:S3:5848:8	syndrom	NN	O	O
of	SAPHRIS.xml:S3:5857:2	of	IN	O	O
potentially	SAPHRIS.xml:S3:5860:11	potenti	RB	O	O
irreversible	SAPHRIS.xml:S3:5872:12	irrevers	JJ	O	O
,	SAPHRIS.xml:S3:5884:1	,	,	O	O
involuntary	SAPHRIS.xml:S3:5886:11	involuntari	JJ	B-AdverseReaction	O
,	SAPHRIS.xml:S3:5897:1	,	,	I-AdverseReaction	O
dyskinetic	SAPHRIS.xml:S3:5899:10	dyskinet	JJ	I-AdverseReaction	O
movements	SAPHRIS.xml:S3:5910:9	movement	NNS	I-AdverseReaction	O
can	SAPHRIS.xml:S3:5920:3	can	MD	O	O
develop	SAPHRIS.xml:S3:5924:7	develop	VB	O	O
in	SAPHRIS.xml:S3:5932:2	in	IN	O	O
patients	SAPHRIS.xml:S3:5935:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:5944:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:5952:4	with	IN	O	O
antipsychotic	SAPHRIS.xml:S3:5957:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:5971:5	drug	NNS	O	O
.	SAPHRIS.xml:S3:5976:1	.	.	O	O

Although	SAPHRIS.xml:S3:5978:8	although	IN	O	O
the	SAPHRIS.xml:S3:5987:3	the	DT	O	O
prevalence	SAPHRIS.xml:S3:5991:10	preval	NN	O	O
of	SAPHRIS.xml:S3:6002:2	of	IN	O	O
the	SAPHRIS.xml:S3:6005:3	the	DT	O	O
syndrome	SAPHRIS.xml:S3:6009:8	syndrom	NN	O	O
appears	SAPHRIS.xml:S3:6018:7	appear	VBZ	O	O
to	SAPHRIS.xml:S3:6026:2	to	TO	O	O
be	SAPHRIS.xml:S3:6029:2	be	VB	O	O
highest	SAPHRIS.xml:S3:6032:7	highest	JJS	O	O
among	SAPHRIS.xml:S3:6040:5	among	IN	O	O
the	SAPHRIS.xml:S3:6046:3	the	DT	O	O
elderly	SAPHRIS.xml:S3:6050:7	elderli	JJ	O	O
,	SAPHRIS.xml:S3:6057:1	,	,	O	O
especially	SAPHRIS.xml:S3:6059:10	especi	RB	O	O
elderly	SAPHRIS.xml:S3:6070:7	elderli	JJ	O	O
women	SAPHRIS.xml:S3:6078:5	women	NNS	O	O
,	SAPHRIS.xml:S3:6083:1	,	,	O	O
it	SAPHRIS.xml:S3:6085:2	it	PRP	O	O
is	SAPHRIS.xml:S3:6088:2	is	VBZ	O	O
impossible	SAPHRIS.xml:S3:6091:10	imposs	JJ	O	O
to	SAPHRIS.xml:S3:6102:2	to	TO	O	O
rely	SAPHRIS.xml:S3:6105:4	reli	VB	O	O
upon	SAPHRIS.xml:S3:6110:4	upon	JJ	O	O
prevalence	SAPHRIS.xml:S3:6115:10	preval	NN	O	O
estimates	SAPHRIS.xml:S3:6126:9	estim	NNS	O	O
to	SAPHRIS.xml:S3:6136:2	to	TO	O	O
predict	SAPHRIS.xml:S3:6139:7	predict	VB	O	O
,	SAPHRIS.xml:S3:6146:1	,	,	O	O
at	SAPHRIS.xml:S3:6148:2	at	IN	O	O
the	SAPHRIS.xml:S3:6151:3	the	DT	O	O
inception	SAPHRIS.xml:S3:6155:9	incept	NN	O	O
of	SAPHRIS.xml:S3:6165:2	of	IN	O	O
antipsychotic	SAPHRIS.xml:S3:6168:13	antipsychot	JJ	O	O
treatment	SAPHRIS.xml:S3:6182:9	treatment	NN	O	O
,	SAPHRIS.xml:S3:6191:1	,	,	O	O
which	SAPHRIS.xml:S3:6193:5	which	WDT	O	O
patients	SAPHRIS.xml:S3:6199:8	patient	NNS	O	O
are	SAPHRIS.xml:S3:6208:3	are	VBP	O	O
likely	SAPHRIS.xml:S3:6212:6	like	JJ	O	O
to	SAPHRIS.xml:S3:6219:2	to	TO	O	O
develop	SAPHRIS.xml:S3:6222:7	develop	VB	O	O
the	SAPHRIS.xml:S3:6230:3	the	DT	O	O
syndrome	SAPHRIS.xml:S3:6234:8	syndrom	NN	O	O
.	SAPHRIS.xml:S3:6242:1	.	.	O	O

Whether	SAPHRIS.xml:S3:6244:7	whether	NNP	O	O
antipsychotic	SAPHRIS.xml:S3:6252:13	antipsychot	JJ	O	O
drug	SAPHRIS.xml:S3:6266:4	drug	NN	O	O
products	SAPHRIS.xml:S3:6271:8	product	NNS	O	O
differ	SAPHRIS.xml:S3:6280:6	differ	VBP	O	O
in	SAPHRIS.xml:S3:6287:2	in	IN	O	O
their	SAPHRIS.xml:S3:6290:5	their	PRP$	O	O
potential	SAPHRIS.xml:S3:6296:9	potenti	JJ	O	O
to	SAPHRIS.xml:S3:6306:2	to	TO	O	O
cause	SAPHRIS.xml:S3:6309:5	caus	VB	O	O
Tardive	SAPHRIS.xml:S3:6315:7	tardiv	JJ	B-AdverseReaction	O
Dyskinesia	SAPHRIS.xml:S3:6323:10	dyskinesia	NNP	I-AdverseReaction	O
(	SAPHRIS.xml:S3:6334:1	(	(	O	O
TD	SAPHRIS.xml:S3:6335:2	TD	NNP	B-AdverseReaction	O
)	SAPHRIS.xml:S3:6337:1	)	)	O	O
is	SAPHRIS.xml:S3:6339:2	is	VBZ	O	O
unknown	SAPHRIS.xml:S3:6342:7	unknown	JJ	O	O
.	SAPHRIS.xml:S3:6349:1	.	.	O	O

The	SAPHRIS.xml:S3:6359:3	the	DT	O	O
risk	SAPHRIS.xml:S3:6363:4	risk	NN	O	O
of	SAPHRIS.xml:S3:6368:2	of	IN	O	O
developing	SAPHRIS.xml:S3:6371:10	develop	VBG	O	O
TD	SAPHRIS.xml:S3:6382:2	TD	NNP	B-AdverseReaction	O
and	SAPHRIS.xml:S3:6385:3	and	CC	O	O
the	SAPHRIS.xml:S3:6389:3	the	DT	O	O
likelihood	SAPHRIS.xml:S3:6393:10	likelihood	NN	O	O
that	SAPHRIS.xml:S3:6404:4	that	IN	O	O
it	SAPHRIS.xml:S3:6409:2	it	PRP	O	O
will	SAPHRIS.xml:S3:6412:4	will	MD	O	O
become	SAPHRIS.xml:S3:6417:6	becom	VB	O	O
irreversible	SAPHRIS.xml:S3:6424:12	irrevers	JJ	O	O
are	SAPHRIS.xml:S3:6437:3	are	VBP	O	O
believed	SAPHRIS.xml:S3:6441:8	believ	VBN	O	O
to	SAPHRIS.xml:S3:6450:2	to	TO	O	O
increase	SAPHRIS.xml:S3:6453:8	increas	VB	O	O
as	SAPHRIS.xml:S3:6462:2	as	IN	O	O
the	SAPHRIS.xml:S3:6465:3	the	DT	O	O
duration	SAPHRIS.xml:S3:6469:8	durat	NN	O	O
of	SAPHRIS.xml:S3:6478:2	of	IN	O	O
treatment	SAPHRIS.xml:S3:6481:9	treatment	NN	O	O
and	SAPHRIS.xml:S3:6491:3	and	CC	O	O
the	SAPHRIS.xml:S3:6495:3	the	DT	O	O
total	SAPHRIS.xml:S3:6499:5	total	JJ	O	O
cumulative	SAPHRIS.xml:S3:6505:10	cumul	JJ	O	O
dose	SAPHRIS.xml:S3:6516:4	dose	NN	O	O
of	SAPHRIS.xml:S3:6521:2	of	IN	O	O
antipsychotic	SAPHRIS.xml:S3:6524:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:6538:5	drug	NNS	O	O
administered	SAPHRIS.xml:S3:6544:12	administ	VBN	O	O
to	SAPHRIS.xml:S3:6557:2	to	TO	O	O
the	SAPHRIS.xml:S3:6560:3	the	DT	O	O
patient	SAPHRIS.xml:S3:6564:7	patient	JJ	O	O
increase	SAPHRIS.xml:S3:6572:8	increas	NN	O	O
.	SAPHRIS.xml:S3:6580:1	.	.	O	O

However	SAPHRIS.xml:S3:6582:7	howev	RB	O	O
,	SAPHRIS.xml:S3:6589:1	,	,	O	O
the	SAPHRIS.xml:S3:6591:3	the	DT	O	O
syndrome	SAPHRIS.xml:S3:6595:8	syndrom	NN	O	O
can	SAPHRIS.xml:S3:6604:3	can	MD	O	O
develop	SAPHRIS.xml:S3:6608:7	develop	VB	O	O
,	SAPHRIS.xml:S3:6615:1	,	,	O	O
although	SAPHRIS.xml:S3:6617:8	although	IN	O	O
much	SAPHRIS.xml:S3:6626:4	much	JJ	O	O
less	SAPHRIS.xml:S3:6631:4	less	JJR	O	O
commonly	SAPHRIS.xml:S3:6636:8	commonli	RB	O	O
,	SAPHRIS.xml:S3:6644:1	,	,	O	O
after	SAPHRIS.xml:S3:6646:5	after	IN	O	O
relatively	SAPHRIS.xml:S3:6652:10	rel	RB	O	O
brief	SAPHRIS.xml:S3:6663:5	brief	JJ	O	O
treatment	SAPHRIS.xml:S3:6669:9	treatment	NN	O	O
periods	SAPHRIS.xml:S3:6679:7	period	NNS	O	O
at	SAPHRIS.xml:S3:6687:2	at	IN	O	O
low	SAPHRIS.xml:S3:6690:3	low	JJ	O	O
doses	SAPHRIS.xml:S3:6694:5	dose	NNS	O	O
.	SAPHRIS.xml:S3:6699:1	.	.	O	O

There	SAPHRIS.xml:S3:6709:5	there	EX	O	O
is	SAPHRIS.xml:S3:6715:2	is	VBZ	O	O
no	SAPHRIS.xml:S3:6718:2	no	DT	O	O
known	SAPHRIS.xml:S3:6721:5	known	JJ	O	O
treatment	SAPHRIS.xml:S3:6727:9	treatment	NN	O	O
for	SAPHRIS.xml:S3:6737:3	for	IN	O	O
established	SAPHRIS.xml:S3:6741:11	establish	VBN	O	O
cases	SAPHRIS.xml:S3:6753:5	case	NNS	O	O
of	SAPHRIS.xml:S3:6759:2	of	IN	O	O
TD	SAPHRIS.xml:S3:6762:2	TD	NNP	O	O
,	SAPHRIS.xml:S3:6764:1	,	,	O	O
although	SAPHRIS.xml:S3:6766:8	although	IN	O	O
the	SAPHRIS.xml:S3:6775:3	the	DT	O	O
syndrome	SAPHRIS.xml:S3:6779:8	syndrom	NN	O	O
may	SAPHRIS.xml:S3:6788:3	may	MD	O	O
remit	SAPHRIS.xml:S3:6792:5	remit	VB	O	O
,	SAPHRIS.xml:S3:6797:1	,	,	O	O
partially	SAPHRIS.xml:S3:6799:9	partial	RB	O	O
or	SAPHRIS.xml:S3:6809:2	or	CC	O	O
completely	SAPHRIS.xml:S3:6812:10	complet	RB	O	O
,	SAPHRIS.xml:S3:6822:1	,	,	O	O
if	SAPHRIS.xml:S3:6824:2	if	IN	O	O
antipsychotic	SAPHRIS.xml:S3:6827:13	antipsychot	JJ	O	O
treatment	SAPHRIS.xml:S3:6841:9	treatment	NN	O	O
is	SAPHRIS.xml:S3:6851:2	is	VBZ	O	O
withdrawn	SAPHRIS.xml:S3:6854:9	withdrawn	VBN	O	O
.	SAPHRIS.xml:S3:6863:1	.	.	O	O

Antipsychotic	SAPHRIS.xml:S3:6865:13	antipsychot	JJ	O	O
treatment	SAPHRIS.xml:S3:6879:9	treatment	NN	O	O
,	SAPHRIS.xml:S3:6888:1	,	,	O	O
itself	SAPHRIS.xml:S3:6890:6	itself	PRP	O	O
,	SAPHRIS.xml:S3:6896:1	,	,	O	O
however	SAPHRIS.xml:S3:6898:7	howev	RB	O	O
,	SAPHRIS.xml:S3:6905:1	,	,	O	O
may	SAPHRIS.xml:S3:6907:3	may	MD	O	O
suppress	SAPHRIS.xml:S3:6911:8	suppress	VB	O	O
(	SAPHRIS.xml:S3:6920:1	(	(	O	O
or	SAPHRIS.xml:S3:6921:2	or	CC	O	O
partially	SAPHRIS.xml:S3:6924:9	partial	RB	O	O
suppress	SAPHRIS.xml:S3:6934:8	suppress	JJ	O	O
)	SAPHRIS.xml:S3:6942:1	)	)	O	O
the	SAPHRIS.xml:S3:6944:3	the	DT	O	O
signs	SAPHRIS.xml:S3:6948:5	sign	NNS	O	O
and	SAPHRIS.xml:S3:6954:3	and	CC	O	O
symptoms	SAPHRIS.xml:S3:6958:8	symptom	NNS	O	O
of	SAPHRIS.xml:S3:6967:2	of	IN	O	O
the	SAPHRIS.xml:S3:6970:3	the	DT	O	O
syndrome	SAPHRIS.xml:S3:6974:8	syndrom	NN	O	O
and	SAPHRIS.xml:S3:6983:3	and	CC	O	O
thereby	SAPHRIS.xml:S3:6987:7	therebi	NN	O	O
may	SAPHRIS.xml:S3:6995:3	may	MD	O	O
possibly	SAPHRIS.xml:S3:6999:8	possibl	RB	O	O
mask	SAPHRIS.xml:S3:7008:4	mask	VB	O	O
the	SAPHRIS.xml:S3:7013:3	the	DT	O	O
underlying	SAPHRIS.xml:S3:7017:10	underli	JJ	O	O
process	SAPHRIS.xml:S3:7028:7	process	NN	O	O
.	SAPHRIS.xml:S3:7035:1	.	.	O	O

The	SAPHRIS.xml:S3:7037:3	the	DT	O	O
effect	SAPHRIS.xml:S3:7041:6	effect	NN	O	O
that	SAPHRIS.xml:S3:7048:4	that	IN	O	O
symptomatic	SAPHRIS.xml:S3:7053:11	symptomat	JJ	O	O
suppression	SAPHRIS.xml:S3:7065:11	suppress	NN	O	O
has	SAPHRIS.xml:S3:7077:3	ha	VBZ	O	O
upon	SAPHRIS.xml:S3:7081:4	upon	IN	O	O
the	SAPHRIS.xml:S3:7086:3	the	DT	O	O
long	SAPHRIS.xml:S3:7090:4	long	JJ	O	O
-	SAPHRIS.xml:S3:7094:1	-	:	O	O
term	SAPHRIS.xml:S3:7095:4	term	NN	O	O
course	SAPHRIS.xml:S3:7100:6	cours	NN	O	O
of	SAPHRIS.xml:S3:7107:2	of	IN	O	O
the	SAPHRIS.xml:S3:7110:3	the	DT	O	O
syndrome	SAPHRIS.xml:S3:7114:8	syndrom	NN	O	O
is	SAPHRIS.xml:S3:7123:2	is	VBZ	O	O
unknown	SAPHRIS.xml:S3:7126:7	unknown	JJ	O	O
.	SAPHRIS.xml:S3:7133:1	.	.	O	O

Given	SAPHRIS.xml:S3:7143:5	given	VBN	O	O
these	SAPHRIS.xml:S3:7149:5	these	DT	O	O
considerations	SAPHRIS.xml:S3:7155:14	consider	NNS	O	O
,	SAPHRIS.xml:S3:7169:1	,	,	O	O
SAPHRIS	SAPHRIS.xml:S3:7171:7	saphri	NNP	O	O
should	SAPHRIS.xml:S3:7179:6	should	MD	O	O
be	SAPHRIS.xml:S3:7186:2	be	VB	O	O
prescribed	SAPHRIS.xml:S3:7189:10	prescrib	VBN	O	O
in	SAPHRIS.xml:S3:7200:2	in	IN	O	O
a	SAPHRIS.xml:S3:7203:1	a	DT	O	O
manner	SAPHRIS.xml:S3:7205:6	manner	NN	O	O
that	SAPHRIS.xml:S3:7212:4	that	WDT	O	O
is	SAPHRIS.xml:S3:7217:2	is	VBZ	O	O
most	SAPHRIS.xml:S3:7220:4	most	RBS	O	O
likely	SAPHRIS.xml:S3:7225:6	like	JJ	O	O
to	SAPHRIS.xml:S3:7232:2	to	TO	O	O
minimize	SAPHRIS.xml:S3:7235:8	minim	VB	O	O
the	SAPHRIS.xml:S3:7244:3	the	DT	O	O
occurrence	SAPHRIS.xml:S3:7248:10	occurr	NN	O	O
of	SAPHRIS.xml:S3:7259:2	of	IN	O	O
TD	SAPHRIS.xml:S3:7262:2	TD	NNP	O	O
.	SAPHRIS.xml:S3:7264:1	.	.	O	O

Chronic	SAPHRIS.xml:S3:7266:7	chronic	NNP	O	O
antipsychotic	SAPHRIS.xml:S3:7274:13	antipsychot	JJ	O	O
treatment	SAPHRIS.xml:S3:7288:9	treatment	NN	O	O
should	SAPHRIS.xml:S3:7298:6	should	MD	O	O
generally	SAPHRIS.xml:S3:7305:9	gener	RB	O	O
be	SAPHRIS.xml:S3:7315:2	be	VB	O	O
reserved	SAPHRIS.xml:S3:7318:8	reserv	VBN	O	O
for	SAPHRIS.xml:S3:7327:3	for	IN	O	O
patients	SAPHRIS.xml:S3:7331:8	patient	NNS	O	O
who	SAPHRIS.xml:S3:7340:3	who	WP	O	O
suffer	SAPHRIS.xml:S3:7344:6	suffer	VBP	O	O
from	SAPHRIS.xml:S3:7351:4	from	IN	O	O
a	SAPHRIS.xml:S3:7356:1	a	DT	O	O
chronic	SAPHRIS.xml:S3:7358:7	chronic	JJ	O	O
illness	SAPHRIS.xml:S3:7366:7	ill	NN	O	O
that	SAPHRIS.xml:S3:7374:4	that	WDT	O	O
(	SAPHRIS.xml:S3:7379:1	(	(	O	O
1	SAPHRIS.xml:S3:7380:1	1	CD	O	O
)	SAPHRIS.xml:S3:7381:1	)	)	O	O
is	SAPHRIS.xml:S3:7383:2	is	VBZ	O	O
known	SAPHRIS.xml:S3:7386:5	known	VBN	O	O
to	SAPHRIS.xml:S3:7392:2	to	TO	O	O
respond	SAPHRIS.xml:S3:7395:7	respond	VB	O	O
to	SAPHRIS.xml:S3:7403:2	to	TO	O	O
antipsychotic	SAPHRIS.xml:S3:7406:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:7420:5	drug	NNS	O	O
,	SAPHRIS.xml:S3:7425:1	,	,	O	O
and	SAPHRIS.xml:S3:7427:3	and	CC	O	O
(	SAPHRIS.xml:S3:7431:1	(	(	O	O
2	SAPHRIS.xml:S3:7432:1	2	CD	O	O
)	SAPHRIS.xml:S3:7433:1	)	)	O	O
for	SAPHRIS.xml:S3:7435:3	for	IN	O	O
whom	SAPHRIS.xml:S3:7439:4	whom	WP	O	O
alternative	SAPHRIS.xml:S3:7444:11	altern	JJ	O	O
,	SAPHRIS.xml:S3:7455:1	,	,	O	O
equally	SAPHRIS.xml:S3:7457:7	equal	RB	O	O
effective	SAPHRIS.xml:S3:7465:9	effect	JJ	O	O
,	SAPHRIS.xml:S3:7474:1	,	,	O	O
but	SAPHRIS.xml:S3:7476:3	but	CC	O	O
potentially	SAPHRIS.xml:S3:7480:11	potenti	RB	O	O
less	SAPHRIS.xml:S3:7492:4	less	JJR	O	O
harmful	SAPHRIS.xml:S3:7497:7	harm	JJ	O	O
treatments	SAPHRIS.xml:S3:7505:10	treatment	NNS	O	O
are	SAPHRIS.xml:S3:7516:3	are	VBP	O	O
not	SAPHRIS.xml:S3:7520:3	not	RB	O	O
available	SAPHRIS.xml:S3:7524:9	avail	JJ	O	O
or	SAPHRIS.xml:S3:7534:2	or	CC	O	O
appropriate	SAPHRIS.xml:S3:7537:11	appropri	JJ	O	O
.	SAPHRIS.xml:S3:7548:1	.	.	O	O

In	SAPHRIS.xml:S3:7550:2	In	IN	O	O
patients	SAPHRIS.xml:S3:7553:8	patient	NNS	O	O
who	SAPHRIS.xml:S3:7562:3	who	WP	O	O
do	SAPHRIS.xml:S3:7566:2	do	VBP	O	O
require	SAPHRIS.xml:S3:7569:7	requir	VB	O	O
chronic	SAPHRIS.xml:S3:7577:7	chronic	JJ	O	O
treatment	SAPHRIS.xml:S3:7585:9	treatment	NN	O	O
,	SAPHRIS.xml:S3:7594:1	,	,	O	O
the	SAPHRIS.xml:S3:7596:3	the	DT	O	O
smallest	SAPHRIS.xml:S3:7600:8	smallest	JJS	O	O
dose	SAPHRIS.xml:S3:7609:4	dose	NN	O	O
and	SAPHRIS.xml:S3:7614:3	and	CC	O	O
the	SAPHRIS.xml:S3:7618:3	the	DT	O	O
shortest	SAPHRIS.xml:S3:7622:8	shortest	JJS	O	O
duration	SAPHRIS.xml:S3:7631:8	durat	NN	O	O
of	SAPHRIS.xml:S3:7640:2	of	IN	O	O
treatment	SAPHRIS.xml:S3:7643:9	treatment	NN	O	O
producing	SAPHRIS.xml:S3:7653:9	produc	VBG	O	O
a	SAPHRIS.xml:S3:7663:1	a	DT	O	O
satisfactory	SAPHRIS.xml:S3:7665:12	satisfactori	JJ	O	O
clinical	SAPHRIS.xml:S3:7678:8	clinic	JJ	O	O
response	SAPHRIS.xml:S3:7687:8	respons	NN	O	O
should	SAPHRIS.xml:S3:7696:6	should	MD	O	O
be	SAPHRIS.xml:S3:7703:2	be	VB	O	O
sought	SAPHRIS.xml:S3:7706:6	sought	VBN	O	O
.	SAPHRIS.xml:S3:7712:1	.	.	O	O

The	SAPHRIS.xml:S3:7714:3	the	DT	O	O
need	SAPHRIS.xml:S3:7718:4	need	NN	O	O
for	SAPHRIS.xml:S3:7723:3	for	IN	O	O
continued	SAPHRIS.xml:S3:7727:9	continu	JJ	O	O
treatment	SAPHRIS.xml:S3:7737:9	treatment	NN	O	O
should	SAPHRIS.xml:S3:7747:6	should	MD	O	O
be	SAPHRIS.xml:S3:7754:2	be	VB	O	O
reassessed	SAPHRIS.xml:S3:7757:10	reassess	VBN	O	O
periodically	SAPHRIS.xml:S3:7768:12	period	RB	O	O
.	SAPHRIS.xml:S3:7780:1	.	.	O	O

If	SAPHRIS.xml:S3:7790:2	If	IN	O	O
signs	SAPHRIS.xml:S3:7793:5	sign	NNS	O	O
and	SAPHRIS.xml:S3:7799:3	and	CC	O	O
symptoms	SAPHRIS.xml:S3:7803:8	symptom	NNS	O	O
of	SAPHRIS.xml:S3:7812:2	of	IN	O	O
TD	SAPHRIS.xml:S3:7815:2	TD	NNP	O	O
appear	SAPHRIS.xml:S3:7818:6	appear	VBP	O	O
in	SAPHRIS.xml:S3:7825:2	in	IN	O	O
a	SAPHRIS.xml:S3:7828:1	a	DT	O	O
patient	SAPHRIS.xml:S3:7830:7	patient	NN	O	O
on	SAPHRIS.xml:S3:7838:2	on	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:7841:7	saphri	NNP	O	O
,	SAPHRIS.xml:S3:7848:1	,	,	O	O
drug	SAPHRIS.xml:S3:7850:4	drug	NN	O	O
discontinuation	SAPHRIS.xml:S3:7855:15	discontinu	NN	O	O
should	SAPHRIS.xml:S3:7871:6	should	MD	O	O
be	SAPHRIS.xml:S3:7878:2	be	VB	O	O
considered	SAPHRIS.xml:S3:7881:10	consid	VBN	O	O
.	SAPHRIS.xml:S3:7891:1	.	.	O	O

However	SAPHRIS.xml:S3:7893:7	howev	RB	O	O
,	SAPHRIS.xml:S3:7900:1	,	,	O	O
some	SAPHRIS.xml:S3:7902:4	some	DT	O	O
patients	SAPHRIS.xml:S3:7907:8	patient	NNS	O	O
may	SAPHRIS.xml:S3:7916:3	may	MD	O	O
require	SAPHRIS.xml:S3:7920:7	requir	VB	O	O
treatment	SAPHRIS.xml:S3:7928:9	treatment	NN	O	O
with	SAPHRIS.xml:S3:7938:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:7943:7	saphri	NNP	O	O
despite	SAPHRIS.xml:S3:7951:7	despit	IN	O	O
the	SAPHRIS.xml:S3:7959:3	the	DT	O	O
presence	SAPHRIS.xml:S3:7963:8	presenc	NN	O	O
of	SAPHRIS.xml:S3:7972:2	of	IN	O	O
the	SAPHRIS.xml:S3:7975:3	the	DT	O	O
syndrome	SAPHRIS.xml:S3:7979:8	syndrom	NN	O	O
.	SAPHRIS.xml:S3:7987:1	.	.	O	O

5.5	SAPHRIS.xml:S3:7999:3	5.5	CD	O	O
Metabolic	SAPHRIS.xml:S3:8003:9	metabol	NNP	O	O
Changes	SAPHRIS.xml:S3:8013:7	chang	NNS	O	O

Atypical	SAPHRIS.xml:S3:8028:8	atyp	NNP	O	O
antipsychotic	SAPHRIS.xml:S3:8037:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:8051:5	drug	NNS	O	O
have	SAPHRIS.xml:S3:8057:4	have	VBP	O	O
been	SAPHRIS.xml:S3:8062:4	been	VBN	O	O
associated	SAPHRIS.xml:S3:8067:10	associ	VBN	O	O
with	SAPHRIS.xml:S3:8078:4	with	IN	O	O
metabolic	SAPHRIS.xml:S3:8083:9	metabol	JJ	B-AdverseReaction	O
changes	SAPHRIS.xml:S3:8093:7	chang	NNS	I-AdverseReaction	O
that	SAPHRIS.xml:S3:8101:4	that	WDT	O	O
may	SAPHRIS.xml:S3:8106:3	may	MD	O	O
increase	SAPHRIS.xml:S3:8110:8	increas	VB	B-AdverseReaction	B-AdverseReaction
cardiovascular	SAPHRIS.xml:S3:8119:14	cardiovascular	JJ	I-AdverseReaction	I-AdverseReaction
cerebrovascular	SAPHRIS.xml:S3:8134:15	cerebrovascular	JJ	I-AdverseReaction	I-AdverseReaction
risk	SAPHRIS.xml:S3:8150:4	risk	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S3:8154:1	.	.	O	O

These	SAPHRIS.xml:S3:8156:5	these	DT	O	O
metabolic	SAPHRIS.xml:S3:8162:9	metabol	JJ	B-AdverseReaction	O
changes	SAPHRIS.xml:S3:8172:7	chang	NNS	I-AdverseReaction	O
include	SAPHRIS.xml:S3:8180:7	includ	VBP	O	O
hyperglycemia	SAPHRIS.xml:S3:8188:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:8201:1	,	,	O	O
dyslipidemia	SAPHRIS.xml:S3:8203:12	dyslipidemia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:8215:1	,	,	O	O
and	SAPHRIS.xml:S3:8217:3	and	CC	O	O
body	SAPHRIS.xml:S3:8221:4	bodi	NN	B-AdverseReaction	B-AdverseReaction
weight	SAPHRIS.xml:S3:8226:6	weight	JJ	I-AdverseReaction	I-AdverseReaction
gain	SAPHRIS.xml:S3:8233:4	gain	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S3:8237:1	.	.	O	O

While	SAPHRIS.xml:S3:8239:5	while	IN	O	O
all	SAPHRIS.xml:S3:8245:3	all	DT	O	O
of	SAPHRIS.xml:S3:8249:2	of	IN	O	O
the	SAPHRIS.xml:S3:8252:3	the	DT	O	O
drugs	SAPHRIS.xml:S3:8256:5	drug	NNS	O	O
in	SAPHRIS.xml:S3:8262:2	in	IN	O	O
the	SAPHRIS.xml:S3:8265:3	the	DT	O	O
class	SAPHRIS.xml:S3:8269:5	class	NN	O	O
have	SAPHRIS.xml:S3:8275:4	have	VBP	O	O
been	SAPHRIS.xml:S3:8280:4	been	VBN	O	O
shown	SAPHRIS.xml:S3:8285:5	shown	VBN	O	O
to	SAPHRIS.xml:S3:8291:2	to	TO	O	O
produce	SAPHRIS.xml:S3:8294:7	produc	VB	O	O
some	SAPHRIS.xml:S3:8302:4	some	DT	O	O
metabolic	SAPHRIS.xml:S3:8307:9	metabol	JJ	B-AdverseReaction	O
changes	SAPHRIS.xml:S3:8317:7	chang	NNS	I-AdverseReaction	O
,	SAPHRIS.xml:S3:8324:1	,	,	O	O
each	SAPHRIS.xml:S3:8326:4	each	DT	O	O
drug	SAPHRIS.xml:S3:8331:4	drug	NN	O	O
has	SAPHRIS.xml:S3:8336:3	ha	VBZ	O	O
its	SAPHRIS.xml:S3:8340:3	it	PRP$	O	O
own	SAPHRIS.xml:S3:8344:3	own	JJ	O	O
specific	SAPHRIS.xml:S3:8348:8	specif	JJ	O	O
risk	SAPHRIS.xml:S3:8357:4	risk	NN	O	O
profile	SAPHRIS.xml:S3:8362:7	profil	NN	O	O
.	SAPHRIS.xml:S3:8369:1	.	.	O	O

Hyperglycemia	SAPHRIS.xml:S3:8383:13	hyperglycemia	NNP	O	O
and	SAPHRIS.xml:S3:8397:3	and	CC	O	O
Diabetes	SAPHRIS.xml:S3:8401:8	diabet	NNP	O	O
Mellitus	SAPHRIS.xml:S3:8410:8	mellitu	NNP	O	O

Hyperglycemia	SAPHRIS.xml:S3:8429:13	hyperglycemia	NNP	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:8442:1	,	,	O	O
in	SAPHRIS.xml:S3:8444:2	in	IN	O	O
some	SAPHRIS.xml:S3:8447:4	some	DT	O	O
cases	SAPHRIS.xml:S3:8452:5	case	NNS	O	O
extreme	SAPHRIS.xml:S3:8458:7	extrem	JJ	O	O
and	SAPHRIS.xml:S3:8466:3	and	CC	O	O
associated	SAPHRIS.xml:S3:8470:10	associ	VBN	O	O
with	SAPHRIS.xml:S3:8481:4	with	IN	O	O
ketoacidosis	SAPHRIS.xml:S3:8486:12	ketoacidosi	NN	B-AdverseReaction	B-AdverseReaction
or	SAPHRIS.xml:S3:8499:2	or	CC	O	O
hyperosmolar	SAPHRIS.xml:S3:8502:12	hyperosmolar	JJ	B-AdverseReaction	O
coma	SAPHRIS.xml:S3:8515:4	coma	NN	I-AdverseReaction	O
or	SAPHRIS.xml:S3:8520:2	or	CC	O	O
death	SAPHRIS.xml:S3:8523:5	death	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:8528:1	,	,	O	O
has	SAPHRIS.xml:S3:8530:3	ha	VBZ	O	O
been	SAPHRIS.xml:S3:8534:4	been	VBN	O	O
reported	SAPHRIS.xml:S3:8539:8	report	VBN	O	O
in	SAPHRIS.xml:S3:8548:2	in	IN	O	O
patients	SAPHRIS.xml:S3:8551:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:8560:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:8568:4	with	IN	O	O
atypical	SAPHRIS.xml:S3:8573:8	atyp	JJ	O	O
antipsychotics	SAPHRIS.xml:S3:8582:14	antipsychot	NNS	O	O
.	SAPHRIS.xml:S3:8596:1	.	.	O	O

Assessment	SAPHRIS.xml:S3:8598:10	assess	NN	O	O
of	SAPHRIS.xml:S3:8609:2	of	IN	O	O
the	SAPHRIS.xml:S3:8612:3	the	DT	O	O
relationship	SAPHRIS.xml:S3:8616:12	relationship	NN	O	O
between	SAPHRIS.xml:S3:8629:7	between	IN	O	O
atypical	SAPHRIS.xml:S3:8637:8	atyp	JJ	O	O
antipsychotic	SAPHRIS.xml:S3:8646:13	antipsychot	JJ	O	O
use	SAPHRIS.xml:S3:8660:3	use	NN	O	O
and	SAPHRIS.xml:S3:8664:3	and	CC	O	O
glucose	SAPHRIS.xml:S3:8668:7	glucos	JJ	O	O
abnormalities	SAPHRIS.xml:S3:8676:13	abnorm	NNS	O	O
is	SAPHRIS.xml:S3:8690:2	is	VBZ	O	O
complicated	SAPHRIS.xml:S3:8693:11	complic	VBN	O	O
by	SAPHRIS.xml:S3:8705:2	by	IN	O	O
the	SAPHRIS.xml:S3:8708:3	the	DT	O	O
possibility	SAPHRIS.xml:S3:8712:11	possibl	NN	O	O
of	SAPHRIS.xml:S3:8724:2	of	IN	O	O
an	SAPHRIS.xml:S3:8727:2	an	DT	O	O
increased	SAPHRIS.xml:S3:8730:9	increas	VBN	O	O
background	SAPHRIS.xml:S3:8740:10	background	NN	O	O
risk	SAPHRIS.xml:S3:8751:4	risk	NN	O	O
of	SAPHRIS.xml:S3:8756:2	of	IN	O	O
diabetes	SAPHRIS.xml:S3:8759:8	diabet	NNS	O	O
mellitus	SAPHRIS.xml:S3:8768:8	mellitu	NNS	O	O
in	SAPHRIS.xml:S3:8777:2	in	IN	O	O
patients	SAPHRIS.xml:S3:8780:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:8789:4	with	IN	O	O
schizophrenia	SAPHRIS.xml:S3:8794:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S3:8808:3	and	CC	O	O
the	SAPHRIS.xml:S3:8812:3	the	DT	O	O
increasing	SAPHRIS.xml:S3:8816:10	increas	VBG	O	O
incidence	SAPHRIS.xml:S3:8827:9	incid	NN	O	O
of	SAPHRIS.xml:S3:8837:2	of	IN	O	O
diabetes	SAPHRIS.xml:S3:8840:8	diabet	NNS	O	O
mellitus	SAPHRIS.xml:S3:8849:8	mellitu	VBP	O	O
in	SAPHRIS.xml:S3:8858:2	in	IN	O	O
the	SAPHRIS.xml:S3:8861:3	the	DT	O	O
general	SAPHRIS.xml:S3:8865:7	gener	JJ	O	O
population	SAPHRIS.xml:S3:8873:10	popul	NN	O	O
.	SAPHRIS.xml:S3:8883:1	.	.	O	O

Given	SAPHRIS.xml:S3:8885:5	given	VBN	O	O
these	SAPHRIS.xml:S3:8891:5	these	DT	O	O
confounders	SAPHRIS.xml:S3:8897:11	confound	NNS	O	O
,	SAPHRIS.xml:S3:8908:1	,	,	O	O
the	SAPHRIS.xml:S3:8910:3	the	DT	O	O
relationship	SAPHRIS.xml:S3:8914:12	relationship	NN	O	O
between	SAPHRIS.xml:S3:8927:7	between	IN	O	O
atypical	SAPHRIS.xml:S3:8935:8	atyp	JJ	O	O
antipsychotic	SAPHRIS.xml:S3:8944:13	antipsychot	JJ	O	O
use	SAPHRIS.xml:S3:8958:3	use	NN	O	O
and	SAPHRIS.xml:S3:8962:3	and	CC	O	O
hyperglycemia	SAPHRIS.xml:S3:8966:13	hyperglycemia	NN	B-AdverseReaction	O
-	SAPHRIS.xml:S3:8979:1	-	:	O	O
related	SAPHRIS.xml:S3:8980:7	relat	JJ	O	O
adverse	SAPHRIS.xml:S3:8988:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S3:8996:9	reaction	NNS	O	O
is	SAPHRIS.xml:S3:9006:2	is	VBZ	O	O
not	SAPHRIS.xml:S3:9009:3	not	RB	O	O
completely	SAPHRIS.xml:S3:9013:10	complet	RB	O	O
understood	SAPHRIS.xml:S3:9024:10	understood	JJ	O	O
.	SAPHRIS.xml:S3:9034:1	.	.	O	O

However	SAPHRIS.xml:S3:9036:7	howev	RB	O	O
,	SAPHRIS.xml:S3:9043:1	,	,	O	O
epidemiological	SAPHRIS.xml:S3:9045:15	epidemiolog	JJ	O	O
studies	SAPHRIS.xml:S3:9061:7	studi	NNS	O	O
suggest	SAPHRIS.xml:S3:9069:7	suggest	VBP	O	O
an	SAPHRIS.xml:S3:9077:2	an	DT	O	O
increased	SAPHRIS.xml:S3:9080:9	increas	VBN	O	O
risk	SAPHRIS.xml:S3:9090:4	risk	NN	O	O
of	SAPHRIS.xml:S3:9095:2	of	IN	O	O
treatment	SAPHRIS.xml:S3:9098:9	treatment	NN	O	O
-	SAPHRIS.xml:S3:9107:1	-	:	O	O
emergent	SAPHRIS.xml:S3:9108:8	emerg	NN	O	O
hyperglycemia	SAPHRIS.xml:S3:9117:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
-	SAPHRIS.xml:S3:9130:1	-	:	O	I-AdverseReaction
related	SAPHRIS.xml:S3:9131:7	relat	JJ	O	I-AdverseReaction
adverse	SAPHRIS.xml:S3:9139:7	advers	JJ	O	I-AdverseReaction
events	SAPHRIS.xml:S3:9147:6	event	NNS	O	I-AdverseReaction
in	SAPHRIS.xml:S3:9154:2	in	IN	O	O
patients	SAPHRIS.xml:S3:9157:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:9166:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:9174:4	with	IN	O	O
the	SAPHRIS.xml:S3:9179:3	the	DT	O	O
atypical	SAPHRIS.xml:S3:9183:8	atyp	JJ	O	O
antipsychotics	SAPHRIS.xml:S3:9192:14	antipsychot	NNS	O	O
included	SAPHRIS.xml:S3:9207:8	includ	VBD	O	O
in	SAPHRIS.xml:S3:9216:2	in	IN	O	O
these	SAPHRIS.xml:S3:9219:5	these	DT	O	O
studies	SAPHRIS.xml:S3:9225:7	studi	NNS	O	O
.	SAPHRIS.xml:S3:9232:1	.	.	O	O

Precise	SAPHRIS.xml:S3:9234:7	precis	NNP	O	O
risk	SAPHRIS.xml:S3:9242:4	risk	NN	O	O
estimates	SAPHRIS.xml:S3:9247:9	estim	NNS	O	O
for	SAPHRIS.xml:S3:9257:3	for	IN	O	O
hyperglycemia	SAPHRIS.xml:S3:9261:13	hyperglycemia	NN	B-AdverseReaction	O
-	SAPHRIS.xml:S3:9274:1	-	:	O	O
related	SAPHRIS.xml:S3:9275:7	relat	JJ	O	O
adverse	SAPHRIS.xml:S3:9283:7	advers	JJ	O	O
events	SAPHRIS.xml:S3:9291:6	event	NNS	O	O
in	SAPHRIS.xml:S3:9298:2	in	IN	O	O
patients	SAPHRIS.xml:S3:9301:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:9310:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:9318:4	with	IN	O	O
atypical	SAPHRIS.xml:S3:9323:8	atyp	JJ	O	O
antipsychotics	SAPHRIS.xml:S3:9332:14	antipsychot	NNS	O	O
are	SAPHRIS.xml:S3:9347:3	are	VBP	O	O
not	SAPHRIS.xml:S3:9351:3	not	RB	O	O
available	SAPHRIS.xml:S3:9355:9	avail	JJ	O	O
.	SAPHRIS.xml:S3:9364:1	.	.	O	O

Patients	SAPHRIS.xml:S3:9374:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:9383:4	with	IN	O	O
an	SAPHRIS.xml:S3:9388:2	an	DT	O	O
established	SAPHRIS.xml:S3:9391:11	establish	VBN	O	O
diagnosis	SAPHRIS.xml:S3:9403:9	diagnosi	NN	O	O
of	SAPHRIS.xml:S3:9413:2	of	IN	O	O
diabetes	SAPHRIS.xml:S3:9416:8	diabet	NNS	O	O
mellitus	SAPHRIS.xml:S3:9425:8	mellitu	NNS	O	O
who	SAPHRIS.xml:S3:9434:3	who	WP	O	O
are	SAPHRIS.xml:S3:9438:3	are	VBP	O	O
started	SAPHRIS.xml:S3:9442:7	start	VBN	O	O
on	SAPHRIS.xml:S3:9450:2	on	IN	O	O
atypical	SAPHRIS.xml:S3:9453:8	atyp	JJ	O	O
antipsychotics	SAPHRIS.xml:S3:9462:14	antipsychot	NNS	O	O
should	SAPHRIS.xml:S3:9477:6	should	MD	O	O
be	SAPHRIS.xml:S3:9484:2	be	VB	O	O
monitored	SAPHRIS.xml:S3:9487:9	monitor	VBN	O	O
regularly	SAPHRIS.xml:S3:9497:9	regularli	RB	O	O
for	SAPHRIS.xml:S3:9507:3	for	IN	O	O
worsening	SAPHRIS.xml:S3:9511:9	worsen	VBG	O	O
of	SAPHRIS.xml:S3:9521:2	of	IN	O	O
glucose	SAPHRIS.xml:S3:9524:7	glucos	JJ	O	O
control	SAPHRIS.xml:S3:9532:7	control	NN	O	O
.	SAPHRIS.xml:S3:9539:1	.	.	O	O

Patients	SAPHRIS.xml:S3:9541:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:9550:4	with	IN	O	O
risk	SAPHRIS.xml:S3:9555:4	risk	NN	O	O
factors	SAPHRIS.xml:S3:9560:7	factor	NNS	O	O
for	SAPHRIS.xml:S3:9568:3	for	IN	O	O
diabetes	SAPHRIS.xml:S3:9572:8	diabet	NNS	O	O
mellitus	SAPHRIS.xml:S3:9581:8	mellitu	NNS	O	O
(	SAPHRIS.xml:S3:9590:1	(	(	O	O
e	SAPHRIS.xml:S3:9591:1	e	NN	O	O
.	SAPHRIS.xml:S3:9592:1	.	.	O	O
g	SAPHRIS.xml:S3:9593:1	g	NN	O	O
.	SAPHRIS.xml:S3:9594:1	.	.	O	O
,	SAPHRIS.xml:S3:9595:1	,	,	O	O
obesity	SAPHRIS.xml:S3:9597:7	obes	NN	O	O
,	SAPHRIS.xml:S3:9604:1	,	,	O	O
family	SAPHRIS.xml:S3:9606:6	famili	NN	O	O
history	SAPHRIS.xml:S3:9613:7	histori	NN	O	O
of	SAPHRIS.xml:S3:9621:2	of	IN	O	O
diabetes	SAPHRIS.xml:S3:9624:8	diabet	NNS	O	O
)	SAPHRIS.xml:S3:9632:1	)	)	O	O
who	SAPHRIS.xml:S3:9634:3	who	WP	O	O
are	SAPHRIS.xml:S3:9638:3	are	VBP	O	O
starting	SAPHRIS.xml:S3:9642:8	start	VBG	O	O
treatment	SAPHRIS.xml:S3:9651:9	treatment	NN	O	O
with	SAPHRIS.xml:S3:9661:4	with	IN	O	O
atypical	SAPHRIS.xml:S3:9666:8	atyp	JJ	O	O
antipsychotics	SAPHRIS.xml:S3:9675:14	antipsychot	NNS	O	O
should	SAPHRIS.xml:S3:9690:6	should	MD	O	O
undergo	SAPHRIS.xml:S3:9697:7	undergo	VB	O	O
fasting	SAPHRIS.xml:S3:9705:7	fast	VBG	O	O
blood	SAPHRIS.xml:S3:9713:5	blood	NN	O	O
glucose	SAPHRIS.xml:S3:9719:7	glucos	JJ	O	O
testing	SAPHRIS.xml:S3:9727:7	test	VBG	O	O
at	SAPHRIS.xml:S3:9735:2	at	IN	O	O
the	SAPHRIS.xml:S3:9738:3	the	DT	O	O
beginning	SAPHRIS.xml:S3:9742:9	begin	NN	O	O
of	SAPHRIS.xml:S3:9752:2	of	IN	O	O
treatment	SAPHRIS.xml:S3:9755:9	treatment	NN	O	O
and	SAPHRIS.xml:S3:9765:3	and	CC	O	O
periodically	SAPHRIS.xml:S3:9769:12	period	RB	O	O
during	SAPHRIS.xml:S3:9782:6	dure	IN	O	O
treatment	SAPHRIS.xml:S3:9789:9	treatment	NN	O	O
.	SAPHRIS.xml:S3:9798:1	.	.	O	O

Any	SAPHRIS.xml:S3:9800:3	ani	DT	O	O
patient	SAPHRIS.xml:S3:9804:7	patient	NN	O	O
treated	SAPHRIS.xml:S3:9812:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:9820:4	with	IN	O	O
atypical	SAPHRIS.xml:S3:9825:8	atyp	JJ	O	O
antipsychotics	SAPHRIS.xml:S3:9834:14	antipsychot	NNS	O	O
should	SAPHRIS.xml:S3:9849:6	should	MD	O	O
be	SAPHRIS.xml:S3:9856:2	be	VB	O	O
monitored	SAPHRIS.xml:S3:9859:9	monitor	VBN	O	O
for	SAPHRIS.xml:S3:9869:3	for	IN	O	O
symptoms	SAPHRIS.xml:S3:9873:8	symptom	NNS	O	O
of	SAPHRIS.xml:S3:9882:2	of	IN	O	O
hyperglycemia	SAPHRIS.xml:S3:9885:13	hyperglycemia	NN	O	O
including	SAPHRIS.xml:S3:9899:9	includ	VBG	O	O
polydipsia	SAPHRIS.xml:S3:9909:10	polydipsia	NN	O	O
,	SAPHRIS.xml:S3:9919:1	,	,	O	O
polyuria	SAPHRIS.xml:S3:9921:8	polyuria	NN	O	O
,	SAPHRIS.xml:S3:9929:1	,	,	O	O
polyphagia	SAPHRIS.xml:S3:9931:10	polyphagia	NN	O	O
,	SAPHRIS.xml:S3:9941:1	,	,	O	O
and	SAPHRIS.xml:S3:9943:3	and	CC	O	O
weakness	SAPHRIS.xml:S3:9947:8	weak	NN	O	O
.	SAPHRIS.xml:S3:9955:1	.	.	O	O

Patients	SAPHRIS.xml:S3:9957:8	patient	NNS	O	O
who	SAPHRIS.xml:S3:9966:3	who	WP	O	O
develop	SAPHRIS.xml:S3:9970:7	develop	VBP	O	O
symptoms	SAPHRIS.xml:S3:9978:8	symptom	NNS	O	O
of	SAPHRIS.xml:S3:9987:2	of	IN	O	O
hyperglycemia	SAPHRIS.xml:S3:9990:13	hyperglycemia	NN	O	O
during	SAPHRIS.xml:S3:10004:6	dure	IN	O	O
treatment	SAPHRIS.xml:S3:10011:9	treatment	NN	O	O
with	SAPHRIS.xml:S3:10021:4	with	IN	O	O
atypical	SAPHRIS.xml:S3:10026:8	atyp	JJ	O	O
antipsychotics	SAPHRIS.xml:S3:10035:14	antipsychot	NNS	O	O
should	SAPHRIS.xml:S3:10050:6	should	MD	O	O
undergo	SAPHRIS.xml:S3:10057:7	undergo	VB	O	O
fasting	SAPHRIS.xml:S3:10065:7	fast	VBG	O	O
blood	SAPHRIS.xml:S3:10073:5	blood	NN	O	O
glucose	SAPHRIS.xml:S3:10079:7	glucos	JJ	O	O
testing	SAPHRIS.xml:S3:10087:7	test	NN	O	O
.	SAPHRIS.xml:S3:10094:1	.	.	O	O

In	SAPHRIS.xml:S3:10096:2	In	IN	O	O
some	SAPHRIS.xml:S3:10099:4	some	DT	O	O
cases	SAPHRIS.xml:S3:10104:5	case	NNS	O	O
,	SAPHRIS.xml:S3:10109:1	,	,	O	O
hyperglycemia	SAPHRIS.xml:S3:10111:13	hyperglycemia	NN	O	B-AdverseReaction
has	SAPHRIS.xml:S3:10125:3	ha	VBZ	O	O
resolved	SAPHRIS.xml:S3:10129:8	resolv	VBN	O	O
when	SAPHRIS.xml:S3:10138:4	when	WRB	O	O
the	SAPHRIS.xml:S3:10143:3	the	DT	O	O
atypical	SAPHRIS.xml:S3:10147:8	atyp	JJ	O	O
antipsychotic	SAPHRIS.xml:S3:10156:13	antipsychot	NN	O	O
was	SAPHRIS.xml:S3:10170:3	wa	VBD	O	O
discontinued	SAPHRIS.xml:S3:10174:12	discontinu	VBN	O	O
;	SAPHRIS.xml:S3:10186:1	;	:	O	O
however	SAPHRIS.xml:S3:10188:7	howev	RB	O	O
,	SAPHRIS.xml:S3:10195:1	,	,	O	O
some	SAPHRIS.xml:S3:10197:4	some	DT	O	O
patients	SAPHRIS.xml:S3:10202:8	patient	NNS	O	O
required	SAPHRIS.xml:S3:10211:8	requir	VBN	O	O
continuation	SAPHRIS.xml:S3:10220:12	continu	NN	O	O
of	SAPHRIS.xml:S3:10233:2	of	IN	O	O
anti	SAPHRIS.xml:S3:10236:4	anti	JJ	O	O
-	SAPHRIS.xml:S3:10240:1	-	:	O	O
diabetic	SAPHRIS.xml:S3:10241:8	diabet	JJ	O	O
treatment	SAPHRIS.xml:S3:10250:9	treatment	NN	O	O
despite	SAPHRIS.xml:S3:10260:7	despit	IN	O	O
discontinuation	SAPHRIS.xml:S3:10268:15	discontinu	NN	O	O
of	SAPHRIS.xml:S3:10284:2	of	IN	O	O
the	SAPHRIS.xml:S3:10287:3	the	DT	O	O
antipsychotic	SAPHRIS.xml:S3:10291:13	antipsychot	JJ	O	O
drug	SAPHRIS.xml:S3:10305:4	drug	NN	O	O
.	SAPHRIS.xml:S3:10309:1	.	.	O	O

Adult	SAPHRIS.xml:S3:10321:5	adult	NN	O	O
Patients	SAPHRIS.xml:S3:10327:8	patient	NNS	O	O
:	SAPHRIS.xml:S3:10335:1	:	:	O	O
Pooled	SAPHRIS.xml:S3:10338:6	pool	VBN	O	O
data	SAPHRIS.xml:S3:10345:4	data	NNS	O	O
from	SAPHRIS.xml:S3:10350:4	from	IN	O	O
the	SAPHRIS.xml:S3:10355:3	the	DT	O	O
short	SAPHRIS.xml:S3:10359:5	short	JJ	O	O
-	SAPHRIS.xml:S3:10364:1	-	:	O	O
term	SAPHRIS.xml:S3:10365:4	term	NN	O	O
placebo	SAPHRIS.xml:S3:10370:7	placebo	NN	O	O
-	SAPHRIS.xml:S3:10377:1	-	:	O	O
controlled	SAPHRIS.xml:S3:10378:10	control	VBN	O	O
schizophrenia	SAPHRIS.xml:S3:10389:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S3:10403:3	and	CC	O	O
bipolar	SAPHRIS.xml:S3:10407:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:10415:5	mania	NN	O	O
trials	SAPHRIS.xml:S3:10421:6	trial	NNS	O	O
are	SAPHRIS.xml:S3:10428:3	are	VBP	O	O
presented	SAPHRIS.xml:S3:10432:9	present	VBN	O	O
in	SAPHRIS.xml:S3:10442:2	in	IN	O	O
Table	SAPHRIS.xml:S3:10446:5	tabl	JJ	O	O
1	SAPHRIS.xml:S3:10452:1	1	CD	O	O
.	SAPHRIS.xml:S3:10453:1	.	.	O	O

TABLE	SAPHRIS.xml:S3:10461:5	tabl	NN	O	O
1	SAPHRIS.xml:S3:10467:1	1	CD	O	O
:	SAPHRIS.xml:S3:10468:1	:	:	O	O
Changes	SAPHRIS.xml:S3:10470:7	chang	NNS	O	O
in	SAPHRIS.xml:S3:10478:2	in	IN	O	O
Fasting	SAPHRIS.xml:S3:10481:7	fast	VBG	O	O
Glucose	SAPHRIS.xml:S3:10489:7	glucos	NNP	O	O
in	SAPHRIS.xml:S3:10497:2	in	IN	O	O
Adult	SAPHRIS.xml:S3:10500:5	adult	NNP	O	O
Patients	SAPHRIS.xml:S3:10506:8	patient	NNS	O	O

N	SAPHRIS.xml:S3:10518:1	N	NNP	O	O
Number	SAPHRIS.xml:S3:10523:6	number	NNP	O	O
of	SAPHRIS.xml:S3:10530:2	of	IN	O	O
patients	SAPHRIS.xml:S3:10533:8	patient	NNS	O	O
who	SAPHRIS.xml:S3:10542:3	who	WP	O	O
had	SAPHRIS.xml:S3:10546:3	had	VBD	O	O
assessments	SAPHRIS.xml:S3:10550:11	assess	NNS	O	O
at	SAPHRIS.xml:S3:10562:2	at	IN	O	O
both	SAPHRIS.xml:S3:10565:4	both	DT	O	O
Baseline	SAPHRIS.xml:S3:10570:8	baselin	NNP	O	O
and	SAPHRIS.xml:S3:10579:3	and	CC	O	O
Endpoint	SAPHRIS.xml:S3:10583:8	endpoint	NNP	O	O
.	SAPHRIS.xml:S3:10591:1	.	.	O	O

N	SAPHRIS.xml:S3:10599:1	N	NNP	O	O
Number	SAPHRIS.xml:S3:10605:6	number	NNP	O	O
of	SAPHRIS.xml:S3:10612:2	of	IN	O	O
patients	SAPHRIS.xml:S3:10615:8	patient	NNS	O	O
at	SAPHRIS.xml:S3:10624:2	at	IN	O	O
risk	SAPHRIS.xml:S3:10627:4	risk	NN	O	O
at	SAPHRIS.xml:S3:10632:2	at	IN	O	O
Baseline	SAPHRIS.xml:S3:10635:8	baselin	NNP	O	O
with	SAPHRIS.xml:S3:10644:4	with	IN	O	O
assessments	SAPHRIS.xml:S3:10649:11	assess	NNS	O	O
at	SAPHRIS.xml:S3:10661:2	at	IN	O	O
both	SAPHRIS.xml:S3:10664:4	both	DT	O	O
Baseline	SAPHRIS.xml:S3:10669:8	baselin	NNP	O	O
and	SAPHRIS.xml:S3:10678:3	and	CC	O	O
Endpoint	SAPHRIS.xml:S3:10682:8	endpoint	NNP	O	O
.	SAPHRIS.xml:S3:10690:1	.	.	O	O

S	SAPHRIS.xml:S3:10698:1	S	NNP	O	O
Includes	SAPHRIS.xml:S3:10700:8	includ	NNP	O	O
patients	SAPHRIS.xml:S3:10709:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:10718:7	treat	VBD	O	O
with	SAPHRIS.xml:S3:10726:4	with	IN	O	O
flexible	SAPHRIS.xml:S3:10731:8	flexibl	JJ	O	O
dose	SAPHRIS.xml:S3:10740:4	dose	NN	O	O
of	SAPHRIS.xml:S3:10745:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:10748:7	saphri	NNP	O	O
5	SAPHRIS.xml:S3:10756:1	5	CD	O	O
or	SAPHRIS.xml:S3:10758:2	or	CC	O	O
10	SAPHRIS.xml:S3:10761:2	10	CD	O	O
mg	SAPHRIS.xml:S3:10764:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:10767:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:10773:5	daili	RB	O	O
(	SAPHRIS.xml:S3:10779:1	(	(	O	O
N	SAPHRIS.xml:S3:10780:1	N	NNP	O	O
90	SAPHRIS.xml:S3:10782:2	90	CD	O	O
)	SAPHRIS.xml:S3:10784:1	)	)	O	O
.	SAPHRIS.xml:S3:10785:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S3:10793:7	saphri	NNP	O	O
5	SAPHRIS.xml:S3:10801:1	5	CD	O	O
mg	SAPHRIS.xml:S3:10803:2	mg	NN	O	O
or	SAPHRIS.xml:S3:10806:2	or	CC	O	O
10	SAPHRIS.xml:S3:10809:2	10	CD	O	O
mg	SAPHRIS.xml:S3:10812:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:10815:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:10821:5	daili	RB	O	O
with	SAPHRIS.xml:S3:10827:4	with	IN	O	O
flexible	SAPHRIS.xml:S3:10832:8	flexibl	JJ	O	O
dosing	SAPHRIS.xml:S3:10841:6	dose	NN	O	O
.	SAPHRIS.xml:S3:10847:1	.	.	O	O

Schizophrenia	SAPHRIS.xml:S3:10878:13	schizophrenia	NN	O	O

(	SAPHRIS.xml:S3:10892:1	(	(	O	O
6	SAPHRIS.xml:S3:10893:1	6	CD	O	O
-	SAPHRIS.xml:S3:10894:1	-	:	O	O
weeks	SAPHRIS.xml:S3:10895:5	week	NNS	O	O
)	SAPHRIS.xml:S3:10900:1	)	)	O	O
Bipolar	SAPHRIS.xml:S3:10903:7	bipolar	NNP	O	O
(	SAPHRIS.xml:S3:10911:1	(	(	O	O
3	SAPHRIS.xml:S3:10912:1	3	CD	O	O
-	SAPHRIS.xml:S3:10913:1	-	:	O	O
weeks	SAPHRIS.xml:S3:10914:5	week	NNS	O	O
)	SAPHRIS.xml:S3:10919:1	)	)	O	O

Placebo	SAPHRIS.xml:S3:10925:7	placebo	NNP	O	O
SAPHRIS	SAPHRIS.xml:S3:10946:7	saphri	NNP	O	O
Placebo	SAPHRIS.xml:S3:10960:7	placebo	NNP	O	O
SAPHRIS5	SAPHRIS.xml:S3:10972:8	saphris5	NNP	O	O
or	SAPHRIS.xml:S3:10981:2	or	CC	O	O
10	SAPHRIS.xml:S3:10984:2	10	CD	O	O
mgtwice	SAPHRIS.xml:S3:10987:7	mgtwice	NNS	O	O
daily	SAPHRIS.xml:S3:10995:5	daili	RB	O	O

5	SAPHRIS.xml:S3:11009:1	5	CD	O	O
mgtwice	SAPHRIS.xml:S3:11011:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:11019:5	daili	RB	O	O
10	SAPHRIS.xml:S3:11030:2	10	CD	O	O
mgtwice	SAPHRIS.xml:S3:11033:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:11041:5	daili	RB	O	O
5	SAPHRIS.xml:S3:11048:1	5	CD	O	O
or	SAPHRIS.xml:S3:11050:2	or	CC	O	O
10	SAPHRIS.xml:S3:11053:2	10	CD	O	O
mgtwice	SAPHRIS.xml:S3:11056:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:11064:5	daili	RB	O	O
S	SAPHRIS.xml:S3:11071:1	S	NNP	O	O

Mean	SAPHRIS.xml:S3:11079:4	mean	JJ	O	O
Change	SAPHRIS.xml:S3:11084:6	chang	NNP	O	O
from	SAPHRIS.xml:S3:11091:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:11096:8	baselin	NNP	O	O
in	SAPHRIS.xml:S3:11105:2	in	IN	O	O
Fasting	SAPHRIS.xml:S3:11108:7	fast	VBG	O	O
Glucose	SAPHRIS.xml:S3:11116:7	glucos	NNP	O	O
at	SAPHRIS.xml:S3:11124:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S3:11127:8	endpoint	NNP	O	O

Change	SAPHRIS.xml:S3:11247:6	chang	NN	O	O

from	SAPHRIS.xml:S3:11254:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:11259:8	baselin	NNP	O	O
(	SAPHRIS.xml:S3:11268:1	(	(	O	O
mg	SAPHRIS.xml:S3:11269:2	mg	FW	O	O
dL	SAPHRIS.xml:S3:11272:2	dL	NN	O	O
)	SAPHRIS.xml:S3:11274:1	)	)	O	O
(	SAPHRIS.xml:S3:11276:1	(	(	O	O
N	SAPHRIS.xml:S3:11277:1	N	NNP	O	O
)	SAPHRIS.xml:S3:11279:1	)	)	O	O
-	SAPHRIS.xml:S3:11282:1	-	:	O	O
0.2	SAPHRIS.xml:S3:11283:3	0.2	CD	O	O
(	SAPHRIS.xml:S3:11286:1	(	(	O	O
232	SAPHRIS.xml:S3:11287:3	232	CD	O	O
)	SAPHRIS.xml:S3:11290:1	)	)	O	O
3.8	SAPHRIS.xml:S3:11296:3	3.8	CD	O	O
(	SAPHRIS.xml:S3:11299:1	(	(	O	O
158	SAPHRIS.xml:S3:11300:3	158	CD	O	O
)	SAPHRIS.xml:S3:11303:1	)	)	O	O
1.1	SAPHRIS.xml:S3:11308:3	1.1	CD	O	O
(	SAPHRIS.xml:S3:11311:1	(	(	O	O
153	SAPHRIS.xml:S3:11312:3	153	CD	O	O
)	SAPHRIS.xml:S3:11315:1	)	)	O	O
3.2	SAPHRIS.xml:S3:11323:3	3.2	CD	O	O
(	SAPHRIS.xml:S3:11326:1	(	(	O	O
377	SAPHRIS.xml:S3:11327:3	377	CD	O	O
)	SAPHRIS.xml:S3:11330:1	)	)	O	O
-	SAPHRIS.xml:S3:11335:1	-	:	O	O
0.6	SAPHRIS.xml:S3:11336:3	0.6	CD	O	O
(	SAPHRIS.xml:S3:11339:1	(	(	O	O
89	SAPHRIS.xml:S3:11340:2	89	CD	O	O
)	SAPHRIS.xml:S3:11342:1	)	)	O	O
-	SAPHRIS.xml:S3:11350:1	-	:	O	O
0.6	SAPHRIS.xml:S3:11351:3	0.6	CD	O	O
(	SAPHRIS.xml:S3:11354:1	(	(	O	O
156	SAPHRIS.xml:S3:11355:3	156	CD	O	O
)	SAPHRIS.xml:S3:11358:1	)	)	O	O

Proportion	SAPHRIS.xml:S3:11368:10	proport	NN	O	O
of	SAPHRIS.xml:S3:11379:2	of	IN	O	O
Patients	SAPHRIS.xml:S3:11382:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:11391:4	with	IN	O	O
Shifts	SAPHRIS.xml:S3:11396:6	shift	NNP	O	O
from	SAPHRIS.xml:S3:11403:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:11408:8	baselin	NNP	O	O
to	SAPHRIS.xml:S3:11417:2	to	TO	O	O
Endpoint	SAPHRIS.xml:S3:11420:8	endpoint	VB	O	O

Normal	SAPHRIS.xml:S3:11433:6	normal	NNP	O	O
to	SAPHRIS.xml:S3:11440:2	to	TO	O	O
High	SAPHRIS.xml:S3:11443:4	high	NNP	O	O
100	SAPHRIS.xml:S3:11448:3	100	CD	O	O
to	SAPHRIS.xml:S3:11452:2	to	TO	O	O
126	SAPHRIS.xml:S3:11457:3	126	CD	O	O
mg	SAPHRIS.xml:S3:11461:2	mg	NNS	O	O
dL	SAPHRIS.xml:S3:11464:2	dL	VBD	O	O
4.1%	SAPHRIS.xml:S3:11468:4	4.1%	CD	O	O
4.5%	SAPHRIS.xml:S3:11482:4	4.5%	CD	O	O
4.5%	SAPHRIS.xml:S3:11494:4	4.5%	CD	O	O
5.0%	SAPHRIS.xml:S3:11509:4	5.0%	CD	O	O
3.3%	SAPHRIS.xml:S3:11521:4	3.3%	CD	O	O
2.7%	SAPHRIS.xml:S3:11536:4	2.7%	CD	O	O

(	SAPHRIS.xml:S3:11554:1	(	(	O	O
n	SAPHRIS.xml:S3:11555:1	n	JJ	O	O
N	SAPHRIS.xml:S3:11557:1	N	NNP	O	O
)	SAPHRIS.xml:S3:11560:1	)	)	O	O
(	SAPHRIS.xml:S3:11575:1	(	(	O	O
7	SAPHRIS.xml:S3:11576:1	7	CD	O	O
170	SAPHRIS.xml:S3:11578:3	170	CD	O	O
)	SAPHRIS.xml:S3:11581:1	)	)	O	O
(	SAPHRIS.xml:S3:11589:1	(	(	O	O
5	SAPHRIS.xml:S3:11590:1	5	CD	O	O
111	SAPHRIS.xml:S3:11592:3	111	CD	O	O
)	SAPHRIS.xml:S3:11595:1	)	)	O	O
(	SAPHRIS.xml:S3:11601:1	(	(	O	O
5	SAPHRIS.xml:S3:11602:1	5	CD	O	O
111	SAPHRIS.xml:S3:11604:3	111	CD	O	O
)	SAPHRIS.xml:S3:11607:1	)	)	O	O
(	SAPHRIS.xml:S3:11616:1	(	(	O	O
13	SAPHRIS.xml:S3:11617:2	13	CD	O	O
262	SAPHRIS.xml:S3:11620:3	262	CD	O	O
)	SAPHRIS.xml:S3:11623:1	)	)	O	O
(	SAPHRIS.xml:S3:11628:1	(	(	O	O
2	SAPHRIS.xml:S3:11629:1	2	CD	O	O
61	SAPHRIS.xml:S3:11631:2	61	CD	O	O
)	SAPHRIS.xml:S3:11633:1	)	)	O	O
(	SAPHRIS.xml:S3:11643:1	(	(	O	O
3	SAPHRIS.xml:S3:11644:1	3	CD	O	O
111	SAPHRIS.xml:S3:11646:3	111	CD	O	O
)	SAPHRIS.xml:S3:11649:1	)	)	O	O

Borderline	SAPHRIS.xml:S3:11661:10	borderlin	NNP	O	O
to	SAPHRIS.xml:S3:11672:2	to	TO	O	O
High	SAPHRIS.xml:S3:11675:4	high	NNP	O	O
100	SAPHRIS.xml:S3:11681:3	100	CD	O	O
and	SAPHRIS.xml:S3:11685:3	and	CC	O	O
126	SAPHRIS.xml:S3:11690:3	126	CD	O	O
to	SAPHRIS.xml:S3:11693:2	to	TO	O	O
126	SAPHRIS.xml:S3:11698:3	126	CD	O	O
mg	SAPHRIS.xml:S3:11702:2	mg	NNS	O	O
dL	SAPHRIS.xml:S3:11705:2	dL	VBD	O	O
5.9%	SAPHRIS.xml:S3:11709:4	5.9%	CD	O	O
6.8%	SAPHRIS.xml:S3:11723:4	6.8%	CD	O	O
6.3%	SAPHRIS.xml:S3:11735:4	6.3%	CD	O	O
10.5%	SAPHRIS.xml:S3:11750:5	10.5%	CD	O	O
0.0%	SAPHRIS.xml:S3:11762:4	0.0%	CD	O	O
11.4%	SAPHRIS.xml:S3:11777:5	11.4%	CD	O	O

(	SAPHRIS.xml:S3:11795:1	(	(	O	O
n	SAPHRIS.xml:S3:11796:1	n	JJ	O	O
N	SAPHRIS.xml:S3:11798:1	N	NNP	O	O
)	SAPHRIS.xml:S3:11801:1	)	)	O	O
(	SAPHRIS.xml:S3:11816:1	(	(	O	O
3	SAPHRIS.xml:S3:11817:1	3	CD	O	O
51	SAPHRIS.xml:S3:11819:2	51	CD	O	O
)	SAPHRIS.xml:S3:11821:1	)	)	O	O
(	SAPHRIS.xml:S3:11830:1	(	(	O	O
3	SAPHRIS.xml:S3:11831:1	3	CD	O	O
44	SAPHRIS.xml:S3:11833:2	44	CD	O	O
)	SAPHRIS.xml:S3:11835:1	)	)	O	O
(	SAPHRIS.xml:S3:11842:1	(	(	O	O
2	SAPHRIS.xml:S3:11843:1	2	CD	O	O
32	SAPHRIS.xml:S3:11845:2	32	CD	O	O
)	SAPHRIS.xml:S3:11847:1	)	)	O	O
(	SAPHRIS.xml:S3:11857:1	(	(	O	O
10	SAPHRIS.xml:S3:11858:2	10	CD	O	O
95	SAPHRIS.xml:S3:11861:2	95	CD	O	O
)	SAPHRIS.xml:S3:11863:1	)	)	O	O
(	SAPHRIS.xml:S3:11869:1	(	(	O	O
0	SAPHRIS.xml:S3:11870:1	0	CD	O	O
23	SAPHRIS.xml:S3:11872:2	23	CD	O	O
)	SAPHRIS.xml:S3:11874:1	)	)	O	O
(	SAPHRIS.xml:S3:11884:1	(	(	O	O
4	SAPHRIS.xml:S3:11885:1	4	CD	O	O
35	SAPHRIS.xml:S3:11887:2	35	CD	O	O
)	SAPHRIS.xml:S3:11889:1	)	)	O	O

In	SAPHRIS.xml:S3:11921:2	In	IN	O	O
a	SAPHRIS.xml:S3:11924:1	a	DT	O	O
52	SAPHRIS.xml:S3:11926:2	52	CD	O	O
-	SAPHRIS.xml:S3:11928:1	-	:	O	O
week	SAPHRIS.xml:S3:11929:4	week	NN	O	O
,	SAPHRIS.xml:S3:11933:1	,	,	O	O
double	SAPHRIS.xml:S3:11935:6	doubl	JJ	O	O
-	SAPHRIS.xml:S3:11941:1	-	:	O	O
blind	SAPHRIS.xml:S3:11942:5	blind	NN	O	O
,	SAPHRIS.xml:S3:11947:1	,	,	O	O
comparator	SAPHRIS.xml:S3:11949:10	compar	NN	O	O
-	SAPHRIS.xml:S3:11959:1	-	:	O	O
controlled	SAPHRIS.xml:S3:11960:10	control	VBN	O	O
trial	SAPHRIS.xml:S3:11971:5	trial	NN	O	O
that	SAPHRIS.xml:S3:11977:4	that	WDT	O	O
included	SAPHRIS.xml:S3:11982:8	includ	VBD	O	O
primarily	SAPHRIS.xml:S3:11991:9	primarili	RB	O	O
patients	SAPHRIS.xml:S3:12001:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:12010:4	with	IN	O	O
schizophrenia	SAPHRIS.xml:S3:12015:13	schizophrenia	NN	O	O
,	SAPHRIS.xml:S3:12028:1	,	,	O	O
the	SAPHRIS.xml:S3:12030:3	the	DT	O	O
mean	SAPHRIS.xml:S3:12034:4	mean	JJ	O	O
increase	SAPHRIS.xml:S3:12039:8	increas	NN	B-AdverseReaction	O
from	SAPHRIS.xml:S3:12048:4	from	IN	O	O
baseline	SAPHRIS.xml:S3:12053:8	baselin	NN	O	O
of	SAPHRIS.xml:S3:12062:2	of	IN	I-AdverseReaction	O
fasting	SAPHRIS.xml:S3:12065:7	fast	VBG	I-AdverseReaction	O
glucose	SAPHRIS.xml:S3:12073:7	glucos	NN	I-AdverseReaction	O
was	SAPHRIS.xml:S3:12081:3	wa	VBD	O	O
2.4	SAPHRIS.xml:S3:12085:3	2.4	CD	O	O
mg	SAPHRIS.xml:S3:12089:2	mg	JJ	O	O
dL	SAPHRIS.xml:S3:12092:2	dL	NN	O	O
.	SAPHRIS.xml:S3:12094:1	.	.	O	O

Pediatric	SAPHRIS.xml:S3:12106:9	pediatr	JJ	O	O

Patients	SAPHRIS.xml:S3:12116:8	patient	NNS	O	O
:	SAPHRIS.xml:S3:12124:1	:	:	O	O
Data	SAPHRIS.xml:S3:12127:4	data	NNS	O	O
from	SAPHRIS.xml:S3:12132:4	from	IN	O	O
the	SAPHRIS.xml:S3:12137:3	the	DT	O	O
short	SAPHRIS.xml:S3:12141:5	short	JJ	O	O
-	SAPHRIS.xml:S3:12146:1	-	:	O	O
term	SAPHRIS.xml:S3:12147:4	term	NN	O	O
,	SAPHRIS.xml:S3:12151:1	,	,	O	O
placebo	SAPHRIS.xml:S3:12153:7	placebo	SYM	O	O
-	SAPHRIS.xml:S3:12160:1	-	:	O	O
controlled	SAPHRIS.xml:S3:12161:10	control	VBN	O	O
trial	SAPHRIS.xml:S3:12172:5	trial	NN	O	O
in	SAPHRIS.xml:S3:12178:2	in	IN	O	O
pediatric	SAPHRIS.xml:S3:12181:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S3:12191:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:12200:4	with	IN	O	O
bipolar	SAPHRIS.xml:S3:12205:7	bipolar	JJ	O	O
I	SAPHRIS.xml:S3:12213:1	I	PRP	O	O
disorder	SAPHRIS.xml:S3:12215:8	disord	VBP	O	O
are	SAPHRIS.xml:S3:12224:3	are	VBP	O	O
shown	SAPHRIS.xml:S3:12228:5	shown	VBN	O	O
in	SAPHRIS.xml:S3:12234:2	in	IN	O	O
Table	SAPHRIS.xml:S3:12238:5	tabl	JJ	O	O
2	SAPHRIS.xml:S3:12244:1	2	CD	O	O
.	SAPHRIS.xml:S3:12247:1	.	.	O	O

TABLE	SAPHRIS.xml:S3:12253:5	tabl	NN	O	O
2	SAPHRIS.xml:S3:12259:1	2	CD	O	O
:	SAPHRIS.xml:S3:12260:1	:	:	O	O
Changes	SAPHRIS.xml:S3:12262:7	chang	NNS	O	O
in	SAPHRIS.xml:S3:12270:2	in	IN	O	O
Fasting	SAPHRIS.xml:S3:12273:7	fast	VBG	O	O
Glucose	SAPHRIS.xml:S3:12281:7	glucos	NNP	O	O
in	SAPHRIS.xml:S3:12289:2	in	IN	O	O
Pediatric	SAPHRIS.xml:S3:12292:9	pediatr	NNP	O	O
Subjects	SAPHRIS.xml:S3:12302:8	subject	NNS	O	O

Bipolar	SAPHRIS.xml:S3:12332:7	bipolar	JJ	O	O
I	SAPHRIS.xml:S3:12340:1	I	PRP	O	O
Disorder	SAPHRIS.xml:S3:12342:8	disord	NNP	O	O
(	SAPHRIS.xml:S3:12351:1	(	(	O	O
3	SAPHRIS.xml:S3:12352:1	3	CD	O	O
-	SAPHRIS.xml:S3:12353:1	-	:	O	O
weeks	SAPHRIS.xml:S3:12354:5	week	NNS	O	O
)	SAPHRIS.xml:S3:12359:1	)	)	O	O

Placebo	SAPHRIS.xml:S3:12369:7	placebo	NNP	O	O
SAPHRIS2	SAPHRIS.xml:S3:12384:8	saphris2	NNP	O	O
.	SAPHRIS.xml:S3:12392:1	.	.	O	O
5	SAPHRIS.xml:S3:12393:1	5	CD	O	O
mgtwice	SAPHRIS.xml:S3:12395:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:12403:5	daili	RB	O	O
SAPHRIS5	SAPHRIS.xml:S3:12410:8	saphris5	NNP	O	O
mgtwice	SAPHRIS.xml:S3:12419:7	mgtwice	NN	O	O
daily	SAPHRIS.xml:S3:12427:5	daili	RB	O	O
SAPHRIS10	SAPHRIS.xml:S3:12435:9	saphris10	NNP	O	O
mgtwice	SAPHRIS.xml:S3:12445:7	mgtwice	NN	O	O
daily	SAPHRIS.xml:S3:12453:5	daili	RB	O	O

Mean	SAPHRIS.xml:S3:12482:4	mean	JJ	O	O
Change	SAPHRIS.xml:S3:12487:6	chang	NNP	O	O
from	SAPHRIS.xml:S3:12494:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:12499:8	baselin	NNP	O	O
in	SAPHRIS.xml:S3:12508:2	in	IN	O	O
Fasting	SAPHRIS.xml:S3:12511:7	fast	VBG	O	O
Glucose	SAPHRIS.xml:S3:12519:7	glucos	NNP	O	O
at	SAPHRIS.xml:S3:12527:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S3:12530:8	endpoint	NNP	O	O

Change	SAPHRIS.xml:S3:12547:6	chang	NN	O	O
from	SAPHRIS.xml:S3:12554:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:12559:8	baselin	NNP	O	O
(	SAPHRIS.xml:S3:12568:1	(	(	O	O
mg	SAPHRIS.xml:S3:12569:2	mg	FW	O	O
dL	SAPHRIS.xml:S3:12572:2	dL	NN	O	O
)	SAPHRIS.xml:S3:12574:1	)	)	O	O
(	SAPHRIS.xml:S3:12576:1	(	(	O	O
N	SAPHRIS.xml:S3:12577:1	N	NNP	O	O
)	SAPHRIS.xml:S3:12579:1	)	)	O	O
-	SAPHRIS.xml:S3:12582:1	-	:	O	O
2.24	SAPHRIS.xml:S3:12583:4	2.24	CD	O	O
(	SAPHRIS.xml:S3:12587:1	(	(	O	O
56	SAPHRIS.xml:S3:12588:2	56	CD	O	O
)	SAPHRIS.xml:S3:12590:1	)	)	O	O
1.43	SAPHRIS.xml:S3:12604:4	1.43	CD	O	O
(	SAPHRIS.xml:S3:12608:1	(	(	O	O
51	SAPHRIS.xml:S3:12609:2	51	CD	O	O
)	SAPHRIS.xml:S3:12611:1	)	)	O	O
-	SAPHRIS.xml:S3:12629:1	-	:	O	O
0.45	SAPHRIS.xml:S3:12630:4	0.45	CD	O	O
(	SAPHRIS.xml:S3:12634:1	(	(	O	O
57	SAPHRIS.xml:S3:12635:2	57	CD	O	O
)	SAPHRIS.xml:S3:12637:1	)	)	O	O
0.34	SAPHRIS.xml:S3:12653:4	0.34	CD	O	O
(	SAPHRIS.xml:S3:12657:1	(	(	O	O
52	SAPHRIS.xml:S3:12658:2	52	CD	O	O
)	SAPHRIS.xml:S3:12660:1	)	)	O	O

Proportion	SAPHRIS.xml:S3:12691:10	proport	NN	O	O
of	SAPHRIS.xml:S3:12702:2	of	IN	O	O
Subjects	SAPHRIS.xml:S3:12705:8	subject	NNS	O	O
with	SAPHRIS.xml:S3:12714:4	with	IN	O	O
Shifts	SAPHRIS.xml:S3:12719:6	shift	NNP	O	O
from	SAPHRIS.xml:S3:12726:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:12731:8	baselin	NNP	O	O
to	SAPHRIS.xml:S3:12740:2	to	TO	O	O
Endpoint	SAPHRIS.xml:S3:12743:8	endpoint	VB	O	O

Normal	SAPHRIS.xml:S3:12760:6	normal	NNP	O	O
to	SAPHRIS.xml:S3:12767:2	to	TO	O	O
High	SAPHRIS.xml:S3:12770:4	high	NNP	O	O
45	SAPHRIS.xml:S3:12775:2	45	CD	O	O
100	SAPHRIS.xml:S3:12782:3	100	CD	O	O
to	SAPHRIS.xml:S3:12786:2	to	TO	O	O
126	SAPHRIS.xml:S3:12791:3	126	CD	O	O
mg	SAPHRIS.xml:S3:12795:2	mg	NNS	O	O
dL	SAPHRIS.xml:S3:12798:2	dL	VBD	O	O
0%	SAPHRIS.xml:S3:12802:2	0%	CD	O	O
0%	SAPHRIS.xml:S3:12824:2	0%	CD	O	O
1.8%	SAPHRIS.xml:S3:12849:4	1.8%	CD	O	O
0%	SAPHRIS.xml:S3:12873:2	0%	CD	O	O

(	SAPHRIS.xml:S3:12896:1	(	(	O	O
n	SAPHRIS.xml:S3:12897:1	n	JJ	O	O
N	SAPHRIS.xml:S3:12899:1	N	NNP	O	O
)	SAPHRIS.xml:S3:12901:1	)	)	O	O
(	SAPHRIS.xml:S3:12911:1	(	(	O	O
0	SAPHRIS.xml:S3:12912:1	0	CD	O	O
56	SAPHRIS.xml:S3:12914:2	56	CD	O	O
)	SAPHRIS.xml:S3:12916:1	)	)	O	O
(	SAPHRIS.xml:S3:12933:1	(	(	O	O
0	SAPHRIS.xml:S3:12934:1	0	CD	O	O
51	SAPHRIS.xml:S3:12936:2	51	CD	O	O
)	SAPHRIS.xml:S3:12938:1	)	)	O	O
(	SAPHRIS.xml:S3:12958:1	(	(	O	O
1	SAPHRIS.xml:S3:12959:1	1	CD	O	O
57	SAPHRIS.xml:S3:12961:2	57	CD	O	O
)	SAPHRIS.xml:S3:12963:1	)	)	O	O
(	SAPHRIS.xml:S3:12982:1	(	(	O	O
0	SAPHRIS.xml:S3:12983:1	0	CD	O	O
52	SAPHRIS.xml:S3:12985:2	52	CD	O	O
)	SAPHRIS.xml:S3:12987:1	)	)	O	O

Dyslipidemia	SAPHRIS.xml:S3:13019:12	dyslipidemia	NN	B-AdverseReaction	O

Undesirable	SAPHRIS.xml:S3:13042:11	undesir	JJ	B-AdverseReaction	B-AdverseReaction

alterations	SAPHRIS.xml:S3:13054:11	alter	NNS	I-AdverseReaction	I-AdverseReaction
in	SAPHRIS.xml:S3:13066:2	in	IN	I-AdverseReaction	I-AdverseReaction
lipids	SAPHRIS.xml:S3:13069:6	lipid	NNS	I-AdverseReaction	I-AdverseReaction
have	SAPHRIS.xml:S3:13076:4	have	VBP	O	O
been	SAPHRIS.xml:S3:13081:4	been	VBN	O	O
observed	SAPHRIS.xml:S3:13086:8	observ	VBN	O	O
in	SAPHRIS.xml:S3:13095:2	in	IN	O	O
patients	SAPHRIS.xml:S3:13098:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:13107:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:13115:4	with	IN	O	O
atypical	SAPHRIS.xml:S3:13120:8	atyp	JJ	O	O
antipsychotics	SAPHRIS.xml:S3:13129:14	antipsychot	NNS	O	O
.	SAPHRIS.xml:S3:13143:1	.	.	O	O

Adult	SAPHRIS.xml:S3:13155:5	adult	NN	O	O
Patients	SAPHRIS.xml:S3:13161:8	patient	NNS	O	O
:	SAPHRIS.xml:S3:13169:1	:	:	O	O
Pooled	SAPHRIS.xml:S3:13172:6	pool	VBN	O	O
data	SAPHRIS.xml:S3:13179:4	data	NNS	O	O
from	SAPHRIS.xml:S3:13184:4	from	IN	O	O
the	SAPHRIS.xml:S3:13189:3	the	DT	O	O
short	SAPHRIS.xml:S3:13193:5	short	JJ	O	O
-	SAPHRIS.xml:S3:13198:1	-	:	O	O
term	SAPHRIS.xml:S3:13199:4	term	NN	O	O
,	SAPHRIS.xml:S3:13203:1	,	,	O	O
placebo	SAPHRIS.xml:S3:13205:7	placebo	SYM	O	O
-	SAPHRIS.xml:S3:13212:1	-	:	O	O
controlled	SAPHRIS.xml:S3:13213:10	control	VBN	O	O
schizophrenia	SAPHRIS.xml:S3:13224:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S3:13238:3	and	CC	O	O
bipolar	SAPHRIS.xml:S3:13242:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:13250:5	mania	NN	O	O
trials	SAPHRIS.xml:S3:13256:6	trial	NNS	O	O
are	SAPHRIS.xml:S3:13263:3	are	VBP	O	O
presented	SAPHRIS.xml:S3:13267:9	present	VBN	O	O
in	SAPHRIS.xml:S3:13277:2	in	IN	O	O
Table	SAPHRIS.xml:S3:13281:5	tabl	JJ	O	O
3	SAPHRIS.xml:S3:13287:1	3	CD	O	O
.	SAPHRIS.xml:S3:13288:1	.	.	O	O

TABLE	SAPHRIS.xml:S3:13296:5	tabl	NN	O	O
3	SAPHRIS.xml:S3:13302:1	3	CD	O	O
:	SAPHRIS.xml:S3:13303:1	:	:	O	O
Changes	SAPHRIS.xml:S3:13305:7	chang	NNS	O	O
in	SAPHRIS.xml:S3:13313:2	in	IN	O	O
Lipids	SAPHRIS.xml:S3:13316:6	lipid	NNP	O	O
in	SAPHRIS.xml:S3:13323:2	in	IN	O	O
Adult	SAPHRIS.xml:S3:13326:5	adult	NNP	O	O
Patients	SAPHRIS.xml:S3:13332:8	patient	NNS	O	O

N	SAPHRIS.xml:S3:13344:1	N	NNP	O	O
Number	SAPHRIS.xml:S3:13349:6	number	NNP	O	O
of	SAPHRIS.xml:S3:13356:2	of	IN	O	O
subjects	SAPHRIS.xml:S3:13359:8	subject	NNS	O	O
who	SAPHRIS.xml:S3:13368:3	who	WP	O	O
had	SAPHRIS.xml:S3:13372:3	had	VBD	O	O
assessments	SAPHRIS.xml:S3:13376:11	assess	NNS	O	O
at	SAPHRIS.xml:S3:13388:2	at	IN	O	O
both	SAPHRIS.xml:S3:13391:4	both	DT	O	O
Baseline	SAPHRIS.xml:S3:13396:8	baselin	NNP	O	O
and	SAPHRIS.xml:S3:13405:3	and	CC	O	O
Endpoint	SAPHRIS.xml:S3:13409:8	endpoint	NNP	O	O
.	SAPHRIS.xml:S3:13417:1	.	.	O	O

S	SAPHRIS.xml:S3:13425:1	S	NNP	O	O
Includes	SAPHRIS.xml:S3:13427:8	includ	NNP	O	O
subjects	SAPHRIS.xml:S3:13436:8	subject	NNS	O	O
treated	SAPHRIS.xml:S3:13445:7	treat	VBD	O	O
with	SAPHRIS.xml:S3:13453:4	with	IN	O	O
flexible	SAPHRIS.xml:S3:13458:8	flexibl	JJ	O	O
dose	SAPHRIS.xml:S3:13467:4	dose	NN	O	O
of	SAPHRIS.xml:S3:13472:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:13475:7	saphri	NNP	O	O
5	SAPHRIS.xml:S3:13483:1	5	CD	O	O
or	SAPHRIS.xml:S3:13485:2	or	CC	O	O
10	SAPHRIS.xml:S3:13488:2	10	CD	O	O
mg	SAPHRIS.xml:S3:13491:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:13494:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:13500:5	daili	RB	O	O
(	SAPHRIS.xml:S3:13506:1	(	(	O	O
N	SAPHRIS.xml:S3:13507:1	N	NNP	O	O
90	SAPHRIS.xml:S3:13509:2	90	CD	O	O
)	SAPHRIS.xml:S3:13511:1	)	)	O	O
.	SAPHRIS.xml:S3:13512:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S3:13520:7	saphri	NNP	O	O
5	SAPHRIS.xml:S3:13528:1	5	CD	O	O
mg	SAPHRIS.xml:S3:13530:2	mg	NN	O	O
or	SAPHRIS.xml:S3:13533:2	or	CC	O	O
10	SAPHRIS.xml:S3:13536:2	10	CD	O	O
mg	SAPHRIS.xml:S3:13539:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:13542:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:13548:5	daili	RB	O	O
with	SAPHRIS.xml:S3:13554:4	with	IN	O	O
flexible	SAPHRIS.xml:S3:13559:8	flexibl	JJ	O	O
dosing	SAPHRIS.xml:S3:13568:6	dose	NN	O	O
.	SAPHRIS.xml:S3:13574:1	.	.	O	O

Schizophrenia	SAPHRIS.xml:S3:13603:13	schizophrenia	NN	O	O

(	SAPHRIS.xml:S3:13617:1	(	(	O	O
6	SAPHRIS.xml:S3:13618:1	6	CD	O	O
-	SAPHRIS.xml:S3:13619:1	-	:	O	O
weeks	SAPHRIS.xml:S3:13620:5	week	NNS	O	O
)	SAPHRIS.xml:S3:13625:1	)	)	O	O
Bipolar	SAPHRIS.xml:S3:13628:7	bipolar	NNP	O	O
(	SAPHRIS.xml:S3:13636:1	(	(	O	O
3	SAPHRIS.xml:S3:13637:1	3	CD	O	O
-	SAPHRIS.xml:S3:13638:1	-	:	O	O
weeks	SAPHRIS.xml:S3:13639:5	week	NNS	O	O
)	SAPHRIS.xml:S3:13644:1	)	)	O	O

Placebo	SAPHRIS.xml:S3:13650:7	placebo	NNP	O	O
SAPHRIS	SAPHRIS.xml:S3:13669:7	saphri	NNP	O	O
Placebo	SAPHRIS.xml:S3:13684:7	placebo	NNP	O	O
SAPHRIS5	SAPHRIS.xml:S3:13700:8	saphris5	NNP	O	O
or	SAPHRIS.xml:S3:13709:2	or	CC	O	O
10	SAPHRIS.xml:S3:13712:2	10	CD	O	O
mgtwice	SAPHRIS.xml:S3:13715:7	mgtwice	NNS	O	O
daily	SAPHRIS.xml:S3:13723:5	daili	RB	O	O

5	SAPHRIS.xml:S3:13737:1	5	CD	O	O
mgtwice	SAPHRIS.xml:S3:13739:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:13747:5	daili	RB	O	O
10	SAPHRIS.xml:S3:13756:2	10	CD	O	O
mgtwice	SAPHRIS.xml:S3:13759:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:13767:5	daili	RB	O	O
5	SAPHRIS.xml:S3:13774:1	5	CD	O	O
or	SAPHRIS.xml:S3:13776:2	or	CC	O	O
10	SAPHRIS.xml:S3:13779:2	10	CD	O	O
mgtwice	SAPHRIS.xml:S3:13782:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:13790:5	daili	RB	O	O
S	SAPHRIS.xml:S3:13797:1	S	NNP	O	O

Mean	SAPHRIS.xml:S3:13805:4	mean	JJ	O	O
Change	SAPHRIS.xml:S3:13810:6	chang	NNP	O	O
from	SAPHRIS.xml:S3:13817:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:13822:8	baselin	NNP	O	O
(	SAPHRIS.xml:S3:13831:1	(	(	O	O
mg	SAPHRIS.xml:S3:13832:2	mg	FW	O	O
dL	SAPHRIS.xml:S3:13835:2	dL	NN	O	O
)	SAPHRIS.xml:S3:13837:1	)	)	O	O

Total	SAPHRIS.xml:S3:13843:5	total	JJ	O	O
cholesterol	SAPHRIS.xml:S3:13849:11	cholesterol	NN	O	O
(	SAPHRIS.xml:S3:13860:1	(	(	O	O
N	SAPHRIS.xml:S3:13861:1	N	NNP	O	O
)	SAPHRIS.xml:S3:13863:1	)	)	O	O
-	SAPHRIS.xml:S3:13866:1	-	:	O	O
2.2	SAPHRIS.xml:S3:13867:3	2.2	CD	O	O
(	SAPHRIS.xml:S3:13870:1	(	(	O	O
351	SAPHRIS.xml:S3:13871:3	351	CD	O	O
)	SAPHRIS.xml:S3:13874:1	)	)	O	O
-	SAPHRIS.xml:S3:13881:1	-	:	O	O
2.4	SAPHRIS.xml:S3:13882:3	2.4	CD	O	O
(	SAPHRIS.xml:S3:13885:1	(	(	O	O
258	SAPHRIS.xml:S3:13886:3	258	CD	O	O
)	SAPHRIS.xml:S3:13889:1	)	)	O	O
3.3	SAPHRIS.xml:S3:13897:3	3.3	CD	O	O
(	SAPHRIS.xml:S3:13900:1	(	(	O	O
199	SAPHRIS.xml:S3:13901:3	199	CD	O	O
)	SAPHRIS.xml:S3:13904:1	)	)	O	O
0.4	SAPHRIS.xml:S3:13913:3	0.4	CD	O	O
(	SAPHRIS.xml:S3:13916:1	(	(	O	O
539	SAPHRIS.xml:S3:13917:3	539	CD	O	O
)	SAPHRIS.xml:S3:13920:1	)	)	O	O
-	SAPHRIS.xml:S3:13927:1	-	:	O	O
1.5	SAPHRIS.xml:S3:13928:3	1.5	CD	O	O
(	SAPHRIS.xml:S3:13931:1	(	(	O	O
163	SAPHRIS.xml:S3:13932:3	163	CD	O	O
)	SAPHRIS.xml:S3:13935:1	)	)	O	O
1.1	SAPHRIS.xml:S3:13942:3	1.1	CD	O	O
(	SAPHRIS.xml:S3:13945:1	(	(	O	O
322	SAPHRIS.xml:S3:13946:3	322	CD	O	O
)	SAPHRIS.xml:S3:13949:1	)	)	O	O

LDL	SAPHRIS.xml:S3:13960:3	ldl	NNP	O	O
(	SAPHRIS.xml:S3:13964:1	(	(	O	O
N	SAPHRIS.xml:S3:13965:1	N	NNP	O	O
)	SAPHRIS.xml:S3:13967:1	)	)	O	O
0.1	SAPHRIS.xml:S3:13979:3	0.1	CD	O	O
(	SAPHRIS.xml:S3:13982:1	(	(	O	O
285	SAPHRIS.xml:S3:13983:3	285	CD	O	O
)	SAPHRIS.xml:S3:13986:1	)	)	O	O
-	SAPHRIS.xml:S3:13994:1	-	:	O	O
0.2	SAPHRIS.xml:S3:13995:3	0.2	CD	O	O
(	SAPHRIS.xml:S3:13998:1	(	(	O	O
195	SAPHRIS.xml:S3:13999:3	195	CD	O	O
)	SAPHRIS.xml:S3:14002:1	)	)	O	O
2.6	SAPHRIS.xml:S3:14010:3	2.6	CD	O	O
(	SAPHRIS.xml:S3:14013:1	(	(	O	O
195	SAPHRIS.xml:S3:14014:3	195	CD	O	O
)	SAPHRIS.xml:S3:14017:1	)	)	O	O
1.3	SAPHRIS.xml:S3:14026:3	1.3	CD	O	O
(	SAPHRIS.xml:S3:14029:1	(	(	O	O
465	SAPHRIS.xml:S3:14030:3	465	CD	O	O
)	SAPHRIS.xml:S3:14033:1	)	)	O	O
1.9	SAPHRIS.xml:S3:14040:3	1.9	CD	O	O
(	SAPHRIS.xml:S3:14043:1	(	(	O	O
158	SAPHRIS.xml:S3:14044:3	158	CD	O	O
)	SAPHRIS.xml:S3:14047:1	)	)	O	O
1.6	SAPHRIS.xml:S3:14055:3	1.6	CD	O	O
(	SAPHRIS.xml:S3:14058:1	(	(	O	O
304	SAPHRIS.xml:S3:14059:3	304	CD	O	O
)	SAPHRIS.xml:S3:14062:1	)	)	O	O

HDL	SAPHRIS.xml:S3:14073:3	hdl	NNP	O	O
(	SAPHRIS.xml:S3:14077:1	(	(	O	O
N	SAPHRIS.xml:S3:14078:1	N	NNP	O	O
)	SAPHRIS.xml:S3:14080:1	)	)	O	O
0.5	SAPHRIS.xml:S3:14092:3	0.5	CD	O	O
(	SAPHRIS.xml:S3:14095:1	(	(	O	O
290	SAPHRIS.xml:S3:14096:3	290	CD	O	O
)	SAPHRIS.xml:S3:14099:1	)	)	O	O
0.4	SAPHRIS.xml:S3:14107:3	0.4	CD	O	O
(	SAPHRIS.xml:S3:14110:1	(	(	O	O
199	SAPHRIS.xml:S3:14111:3	199	CD	O	O
)	SAPHRIS.xml:S3:14114:1	)	)	O	O
1.0	SAPHRIS.xml:S3:14123:3	1.0	CD	O	O
(	SAPHRIS.xml:S3:14126:1	(	(	O	O
199	SAPHRIS.xml:S3:14127:3	199	CD	O	O
)	SAPHRIS.xml:S3:14130:1	)	)	O	O
0.5	SAPHRIS.xml:S3:14139:3	0.5	CD	O	O
(	SAPHRIS.xml:S3:14142:1	(	(	O	O
480	SAPHRIS.xml:S3:14143:3	480	CD	O	O
)	SAPHRIS.xml:S3:14146:1	)	)	O	O
0.0	SAPHRIS.xml:S3:14153:3	0.0	CD	O	O
(	SAPHRIS.xml:S3:14156:1	(	(	O	O
163	SAPHRIS.xml:S3:14157:3	163	CD	O	O
)	SAPHRIS.xml:S3:14160:1	)	)	O	O
0.9	SAPHRIS.xml:S3:14168:3	0.9	CD	O	O
(	SAPHRIS.xml:S3:14171:1	(	(	O	O
322	SAPHRIS.xml:S3:14172:3	322	CD	O	O
)	SAPHRIS.xml:S3:14175:1	)	)	O	O

Fasting	SAPHRIS.xml:S3:14186:7	fast	VBG	O	O
triglycerides	SAPHRIS.xml:S3:14194:13	triglycerid	NNS	O	O
(	SAPHRIS.xml:S3:14208:1	(	(	O	O
N	SAPHRIS.xml:S3:14209:1	N	NNP	O	O
)	SAPHRIS.xml:S3:14211:1	)	)	O	O
-	SAPHRIS.xml:S3:14214:1	-	:	O	O
7.6	SAPHRIS.xml:S3:14215:3	7.6	CD	O	O
(	SAPHRIS.xml:S3:14218:1	(	(	O	O
233	SAPHRIS.xml:S3:14219:3	233	CD	O	O
)	SAPHRIS.xml:S3:14222:1	)	)	O	O
-	SAPHRIS.xml:S3:14229:1	-	:	O	O
1.9	SAPHRIS.xml:S3:14230:3	1.9	CD	O	O
(	SAPHRIS.xml:S3:14233:1	(	(	O	O
159	SAPHRIS.xml:S3:14234:3	159	CD	O	O
)	SAPHRIS.xml:S3:14237:1	)	)	O	O
0.1	SAPHRIS.xml:S3:14245:3	0.1	CD	O	O
(	SAPHRIS.xml:S3:14248:1	(	(	O	O
154	SAPHRIS.xml:S3:14249:3	154	CD	O	O
)	SAPHRIS.xml:S3:14252:1	)	)	O	O
3.8	SAPHRIS.xml:S3:14261:3	3.8	CD	O	O
(	SAPHRIS.xml:S3:14264:1	(	(	O	O
380	SAPHRIS.xml:S3:14265:3	380	CD	O	O
)	SAPHRIS.xml:S3:14268:1	)	)	O	O
-	SAPHRIS.xml:S3:14275:1	-	:	O	O
17.9	SAPHRIS.xml:S3:14276:4	17.9	CD	O	O
(	SAPHRIS.xml:S3:14280:1	(	(	O	O
129	SAPHRIS.xml:S3:14281:3	129	CD	O	O
)	SAPHRIS.xml:S3:14284:1	)	)	O	O
-	SAPHRIS.xml:S3:14290:1	-	:	O	O
3.5	SAPHRIS.xml:S3:14291:3	3.5	CD	O	O
(	SAPHRIS.xml:S3:14294:1	(	(	O	O
237	SAPHRIS.xml:S3:14295:3	237	CD	O	O
)	SAPHRIS.xml:S3:14298:1	)	)	O	O

Proportion	SAPHRIS.xml:S3:14308:10	proport	NN	O	O
of	SAPHRIS.xml:S3:14319:2	of	IN	O	O
Patients	SAPHRIS.xml:S3:14322:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:14331:4	with	IN	O	O
Shifts	SAPHRIS.xml:S3:14336:6	shift	NNP	O	O
from	SAPHRIS.xml:S3:14343:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:14348:8	baselin	NNP	O	O
to	SAPHRIS.xml:S3:14357:2	to	TO	O	O
Endpoint	SAPHRIS.xml:S3:14360:8	endpoint	VB	O	O

Total	SAPHRIS.xml:S3:14373:5	total	JJ	O	O
cholesterolNormal	SAPHRIS.xml:S3:14379:17	cholesterolnorm	NN	O	O
to	SAPHRIS.xml:S3:14397:2	to	TO	O	O
High	SAPHRIS.xml:S3:14400:4	high	NNP	O	O
200	SAPHRIS.xml:S3:14405:3	200	CD	O	O
to	SAPHRIS.xml:S3:14409:2	to	TO	O	O
240	SAPHRIS.xml:S3:14414:3	240	CD	O	O
(	SAPHRIS.xml:S3:14417:1	(	(	O	O
mg	SAPHRIS.xml:S3:14418:2	mg	FW	O	O
dL	SAPHRIS.xml:S3:14421:2	dL	NN	O	O
)	SAPHRIS.xml:S3:14423:1	)	)	O	O
(	SAPHRIS.xml:S3:14425:1	(	(	O	O
n	SAPHRIS.xml:S3:14426:1	n	JJ	O	O
N	SAPHRIS.xml:S3:14428:1	N	NNP	O	O
)	SAPHRIS.xml:S3:14430:1	)	)	O	O
1.3%	SAPHRIS.xml:S3:14433:4	1.3%	CD	O	O
(	SAPHRIS.xml:S3:14437:1	(	(	O	O
3	SAPHRIS.xml:S3:14438:1	3	CD	O	O
225	SAPHRIS.xml:S3:14440:3	225	CD	O	O
)	SAPHRIS.xml:S3:14443:1	)	)	O	O
0.6%	SAPHRIS.xml:S3:14448:4	0.6%	CD	O	O
(	SAPHRIS.xml:S3:14452:1	(	(	O	O
1	SAPHRIS.xml:S3:14453:1	1	CD	O	O
161	SAPHRIS.xml:S3:14455:3	161	CD	O	O
)	SAPHRIS.xml:S3:14458:1	)	)	O	O
2.2%	SAPHRIS.xml:S3:14464:4	2.2%	CD	O	O
(	SAPHRIS.xml:S3:14468:1	(	(	O	O
3	SAPHRIS.xml:S3:14469:1	3	CD	O	O
134	SAPHRIS.xml:S3:14471:3	134	CD	O	O
)	SAPHRIS.xml:S3:14474:1	)	)	O	O
1.7%	SAPHRIS.xml:S3:14480:4	1.7%	CD	O	O
(	SAPHRIS.xml:S3:14484:1	(	(	O	O
6	SAPHRIS.xml:S3:14485:1	6	CD	O	O
343	SAPHRIS.xml:S3:14487:3	343	CD	O	O
)	SAPHRIS.xml:S3:14490:1	)	)	O	O
1.1%	SAPHRIS.xml:S3:14494:4	1.1%	CD	O	O
(	SAPHRIS.xml:S3:14498:1	(	(	O	O
1	SAPHRIS.xml:S3:14499:1	1	CD	O	O
95	SAPHRIS.xml:S3:14501:2	95	CD	O	O
)	SAPHRIS.xml:S3:14503:1	)	)	O	O
2.5%	SAPHRIS.xml:S3:14509:4	2.5%	CD	O	O
(	SAPHRIS.xml:S3:14513:1	(	(	O	O
5	SAPHRIS.xml:S3:14514:1	5	CD	O	O
204	SAPHRIS.xml:S3:14516:3	204	CD	O	O
)	SAPHRIS.xml:S3:14519:1	)	)	O	O

LDLNormal	SAPHRIS.xml:S3:14527:9	ldlnormal	NNP	O	O
to	SAPHRIS.xml:S3:14537:2	to	TO	O	O
High	SAPHRIS.xml:S3:14540:4	high	NNP	O	O
100	SAPHRIS.xml:S3:14545:3	100	CD	O	O
to	SAPHRIS.xml:S3:14549:2	to	TO	O	O
160	SAPHRIS.xml:S3:14554:3	160	CD	O	O
(	SAPHRIS.xml:S3:14557:1	(	(	O	O
mg	SAPHRIS.xml:S3:14558:2	mg	FW	O	O
dL	SAPHRIS.xml:S3:14561:2	dL	NN	O	O
)	SAPHRIS.xml:S3:14563:1	)	)	O	O
(	SAPHRIS.xml:S3:14565:1	(	(	O	O
n	SAPHRIS.xml:S3:14566:1	n	JJ	O	O
N	SAPHRIS.xml:S3:14568:1	N	NNP	O	O
)	SAPHRIS.xml:S3:14570:1	)	)	O	O
1.7%	SAPHRIS.xml:S3:14573:4	1.7%	CD	O	O
(	SAPHRIS.xml:S3:14577:1	(	(	O	O
2	SAPHRIS.xml:S3:14578:1	2	CD	O	O
117	SAPHRIS.xml:S3:14580:3	117	CD	O	O
)	SAPHRIS.xml:S3:14583:1	)	)	O	O
0.0%	SAPHRIS.xml:S3:14588:4	0.0%	CD	O	O
(	SAPHRIS.xml:S3:14592:1	(	(	O	O
0	SAPHRIS.xml:S3:14593:1	0	CD	O	O
80	SAPHRIS.xml:S3:14595:2	80	CD	O	O
)	SAPHRIS.xml:S3:14597:1	)	)	O	O
1.2%	SAPHRIS.xml:S3:14604:4	1.2%	CD	O	O
(	SAPHRIS.xml:S3:14608:1	(	(	O	O
1	SAPHRIS.xml:S3:14609:1	1	CD	O	O
86	SAPHRIS.xml:S3:14611:2	86	CD	O	O
)	SAPHRIS.xml:S3:14613:1	)	)	O	O
1.0%	SAPHRIS.xml:S3:14620:4	1.0%	CD	O	O
(	SAPHRIS.xml:S3:14624:1	(	(	O	O
2	SAPHRIS.xml:S3:14625:1	2	CD	O	O
196	SAPHRIS.xml:S3:14627:3	196	CD	O	O
)	SAPHRIS.xml:S3:14630:1	)	)	O	O
1.9%	SAPHRIS.xml:S3:14634:4	1.9%	CD	O	O
(	SAPHRIS.xml:S3:14638:1	(	(	O	O
1	SAPHRIS.xml:S3:14639:1	1	CD	O	O
53	SAPHRIS.xml:S3:14641:2	53	CD	O	O
)	SAPHRIS.xml:S3:14643:1	)	)	O	O
0.0%	SAPHRIS.xml:S3:14649:4	0.0%	CD	O	O
(	SAPHRIS.xml:S3:14653:1	(	(	O	O
0	SAPHRIS.xml:S3:14654:1	0	CD	O	O
141	SAPHRIS.xml:S3:14656:3	141	CD	O	O
)	SAPHRIS.xml:S3:14659:1	)	)	O	O

HDLNormal	SAPHRIS.xml:S3:14667:9	hdlnormal	NNP	O	O
to	SAPHRIS.xml:S3:14677:2	to	TO	O	O
Low	SAPHRIS.xml:S3:14680:3	low	VB	O	O
40	SAPHRIS.xml:S3:14685:2	40	CD	O	O
to	SAPHRIS.xml:S3:14688:2	to	TO	O	O
40	SAPHRIS.xml:S3:14692:2	40	CD	O	O
(	SAPHRIS.xml:S3:14695:1	(	(	O	O
mg	SAPHRIS.xml:S3:14696:2	mg	FW	O	O
dL	SAPHRIS.xml:S3:14699:2	dL	NN	O	O
)	SAPHRIS.xml:S3:14701:1	)	)	O	O
(	SAPHRIS.xml:S3:14703:1	(	(	O	O
n	SAPHRIS.xml:S3:14704:1	n	JJ	O	O
N	SAPHRIS.xml:S3:14706:1	N	NNP	O	O
)	SAPHRIS.xml:S3:14708:1	)	)	O	O
10.7%	SAPHRIS.xml:S3:14711:5	10.7%	CD	O	O
(	SAPHRIS.xml:S3:14716:1	(	(	O	O
21	SAPHRIS.xml:S3:14717:2	21	CD	O	O
196	SAPHRIS.xml:S3:14720:3	196	CD	O	O
)	SAPHRIS.xml:S3:14723:1	)	)	O	O
13.3%	SAPHRIS.xml:S3:14726:5	13.3%	CD	O	O
(	SAPHRIS.xml:S3:14731:1	(	(	O	O
18	SAPHRIS.xml:S3:14732:2	18	CD	O	O
135	SAPHRIS.xml:S3:14735:3	135	CD	O	O
)	SAPHRIS.xml:S3:14738:1	)	)	O	O
14.7%	SAPHRIS.xml:S3:14742:5	14.7%	CD	O	O
(	SAPHRIS.xml:S3:14747:1	(	(	O	O
20	SAPHRIS.xml:S3:14748:2	20	CD	O	O
136	SAPHRIS.xml:S3:14751:3	136	CD	O	O
)	SAPHRIS.xml:S3:14754:1	)	)	O	O
14.0%	SAPHRIS.xml:S3:14758:5	14.0%	CD	O	O
(	SAPHRIS.xml:S3:14763:1	(	(	O	O
45	SAPHRIS.xml:S3:14764:2	45	CD	O	O
322	SAPHRIS.xml:S3:14767:3	322	CD	O	O
)	SAPHRIS.xml:S3:14770:1	)	)	O	O
7.4%	SAPHRIS.xml:S3:14773:4	7.4%	CD	O	O
(	SAPHRIS.xml:S3:14777:1	(	(	O	O
9	SAPHRIS.xml:S3:14778:1	9	CD	O	O
122	SAPHRIS.xml:S3:14780:3	122	CD	O	O
)	SAPHRIS.xml:S3:14783:1	)	)	O	O
8.7%	SAPHRIS.xml:S3:14788:4	8.7%	CD	O	O
(	SAPHRIS.xml:S3:14792:1	(	(	O	O
21	SAPHRIS.xml:S3:14793:2	21	CD	O	O
242	SAPHRIS.xml:S3:14796:3	242	CD	O	O
)	SAPHRIS.xml:S3:14799:1	)	)	O	O

Fasting	SAPHRIS.xml:S3:14806:7	fast	VBG	O	O
triglyceridesNormal	SAPHRIS.xml:S3:14814:19	triglyceridesnorm	NN	O	O
to	SAPHRIS.xml:S3:14834:2	to	TO	O	O
High	SAPHRIS.xml:S3:14837:4	high	NNP	O	O
150	SAPHRIS.xml:S3:14842:3	150	CD	O	O
to	SAPHRIS.xml:S3:14846:2	to	TO	O	O
200	SAPHRIS.xml:S3:14851:3	200	CD	O	O
(	SAPHRIS.xml:S3:14855:1	(	(	O	O
mg	SAPHRIS.xml:S3:14856:2	mg	FW	O	O
dL	SAPHRIS.xml:S3:14859:2	dL	NN	O	O
)	SAPHRIS.xml:S3:14861:1	)	)	O	O
(	SAPHRIS.xml:S3:14863:1	(	(	O	O
n	SAPHRIS.xml:S3:14864:1	n	JJ	O	O
N	SAPHRIS.xml:S3:14866:1	N	NNP	O	O
)	SAPHRIS.xml:S3:14868:1	)	)	O	O
2.4%	SAPHRIS.xml:S3:14871:4	2.4%	CD	O	O
(	SAPHRIS.xml:S3:14875:1	(	(	O	O
4	SAPHRIS.xml:S3:14876:1	4	CD	O	O
167	SAPHRIS.xml:S3:14878:3	167	CD	O	O
)	SAPHRIS.xml:S3:14881:1	)	)	O	O
7.0%	SAPHRIS.xml:S3:14886:4	7.0%	CD	O	O
(	SAPHRIS.xml:S3:14890:1	(	(	O	O
8	SAPHRIS.xml:S3:14891:1	8	CD	O	O
115	SAPHRIS.xml:S3:14893:3	115	CD	O	O
)	SAPHRIS.xml:S3:14896:1	)	)	O	O
8.3%	SAPHRIS.xml:S3:14902:4	8.3%	CD	O	O
(	SAPHRIS.xml:S3:14906:1	(	(	O	O
9	SAPHRIS.xml:S3:14907:1	9	CD	O	O
108	SAPHRIS.xml:S3:14909:3	108	CD	O	O
)	SAPHRIS.xml:S3:14912:1	)	)	O	O
7.7%	SAPHRIS.xml:S3:14918:4	7.7%	CD	O	O
(	SAPHRIS.xml:S3:14922:1	(	(	O	O
20	SAPHRIS.xml:S3:14923:2	20	CD	O	O
260	SAPHRIS.xml:S3:14926:3	260	CD	O	O
)	SAPHRIS.xml:S3:14929:1	)	)	O	O
5.1%	SAPHRIS.xml:S3:14932:4	5.1%	CD	O	O
(	SAPHRIS.xml:S3:14936:1	(	(	O	O
4	SAPHRIS.xml:S3:14937:1	4	CD	O	O
78	SAPHRIS.xml:S3:14939:2	78	CD	O	O
)	SAPHRIS.xml:S3:14941:1	)	)	O	O
7.4%	SAPHRIS.xml:S3:14947:4	7.4%	CD	O	O
(	SAPHRIS.xml:S3:14951:1	(	(	O	O
11	SAPHRIS.xml:S3:14952:2	11	CD	O	O
148	SAPHRIS.xml:S3:14955:3	148	CD	O	O
)	SAPHRIS.xml:S3:14958:1	)	)	O	O

In	SAPHRIS.xml:S3:14981:2	In	IN	O	O
short	SAPHRIS.xml:S3:14984:5	short	JJ	O	O
-	SAPHRIS.xml:S3:14989:1	-	:	O	O
term	SAPHRIS.xml:S3:14990:4	term	NN	O	O
schizophrenia	SAPHRIS.xml:S3:14995:13	schizophrenia	NN	O	O
trials	SAPHRIS.xml:S3:15009:6	trial	NNS	O	O
,	SAPHRIS.xml:S3:15015:1	,	,	O	O
the	SAPHRIS.xml:S3:15017:3	the	DT	O	O
proportion	SAPHRIS.xml:S3:15021:10	proport	NN	O	O
of	SAPHRIS.xml:S3:15032:2	of	IN	O	O
patients	SAPHRIS.xml:S3:15035:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:15044:4	with	IN	O	O
total	SAPHRIS.xml:S3:15049:5	total	JJ	B-AdverseReaction	O
cholesterol	SAPHRIS.xml:S3:15055:11	cholesterol	NN	I-AdverseReaction	O
elevations	SAPHRIS.xml:S3:15067:10	elev	NNS	I-AdverseReaction	O
240	SAPHRIS.xml:S3:15080:3	240	CD	O	O
mg	SAPHRIS.xml:S3:15084:2	mg	NNS	O	O
dL	SAPHRIS.xml:S3:15087:2	dL	NN	O	O
(	SAPHRIS.xml:S3:15090:1	(	(	O	O
at	SAPHRIS.xml:S3:15091:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S3:15094:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S3:15102:1	)	)	O	O
was	SAPHRIS.xml:S3:15104:3	wa	VBD	O	O
8.3%	SAPHRIS.xml:S3:15108:4	8.3%	CD	O	O
for	SAPHRIS.xml:S3:15113:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:15117:7	saphri	NNP	O	O
-	SAPHRIS.xml:S3:15124:1	-	:	O	O
treated	SAPHRIS.xml:S3:15125:7	treat	VBD	O	O
patients	SAPHRIS.xml:S3:15133:8	patient	NNS	O	O
versus	SAPHRIS.xml:S3:15142:6	versu	VBP	O	O
7%	SAPHRIS.xml:S3:15149:2	7%	CD	O	O
for	SAPHRIS.xml:S3:15152:3	for	IN	O	O
placebo	SAPHRIS.xml:S3:15156:7	placebo	NN	O	O
-	SAPHRIS.xml:S3:15163:1	-	:	O	O
treated	SAPHRIS.xml:S3:15164:7	treat	JJ	O	O
patients	SAPHRIS.xml:S3:15172:8	patient	NNS	O	O
.	SAPHRIS.xml:S3:15180:1	.	.	O	O

The	SAPHRIS.xml:S3:15182:3	the	DT	O	O
proportion	SAPHRIS.xml:S3:15186:10	proport	NN	O	O
of	SAPHRIS.xml:S3:15197:2	of	IN	O	O
patients	SAPHRIS.xml:S3:15200:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:15209:4	with	IN	O	O
elevations	SAPHRIS.xml:S3:15214:10	elev	NNS	B-AdverseReaction	O
in	SAPHRIS.xml:S3:15225:2	in	IN	I-AdverseReaction	O
triglycerides	SAPHRIS.xml:S3:15228:13	triglycerid	NNS	I-AdverseReaction	O
200	SAPHRIS.xml:S3:15244:3	200	CD	O	O
mg	SAPHRIS.xml:S3:15248:2	mg	NNS	O	O
dL	SAPHRIS.xml:S3:15251:2	dL	NN	O	O
(	SAPHRIS.xml:S3:15254:1	(	(	O	O
at	SAPHRIS.xml:S3:15255:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S3:15258:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S3:15266:1	)	)	O	O
was	SAPHRIS.xml:S3:15268:3	wa	VBD	O	O
13.2%	SAPHRIS.xml:S3:15272:5	13.2%	CD	O	O
for	SAPHRIS.xml:S3:15278:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:15282:7	saphri	NNP	O	O
-	SAPHRIS.xml:S3:15289:1	-	:	O	O
treated	SAPHRIS.xml:S3:15290:7	treat	VBD	O	O
patients	SAPHRIS.xml:S3:15298:8	patient	NNS	O	O
versus	SAPHRIS.xml:S3:15307:6	versu	VBP	O	O
10.5%	SAPHRIS.xml:S3:15314:5	10.5%	CD	O	O
for	SAPHRIS.xml:S3:15320:3	for	IN	O	O
placebo	SAPHRIS.xml:S3:15324:7	placebo	NN	O	O
-	SAPHRIS.xml:S3:15331:1	-	:	O	O
treated	SAPHRIS.xml:S3:15332:7	treat	JJ	O	O
patients	SAPHRIS.xml:S3:15340:8	patient	NNS	O	O
.	SAPHRIS.xml:S3:15348:1	.	.	O	O

In	SAPHRIS.xml:S3:15350:2	In	IN	O	O
short	SAPHRIS.xml:S3:15353:5	short	JJ	O	O
-	SAPHRIS.xml:S3:15358:1	-	:	O	O
term	SAPHRIS.xml:S3:15359:4	term	NN	O	O
,	SAPHRIS.xml:S3:15363:1	,	,	O	O
placebo	SAPHRIS.xml:S3:15365:7	placebo	SYM	O	O
-	SAPHRIS.xml:S3:15372:1	-	:	O	O
controlled	SAPHRIS.xml:S3:15373:10	control	VBN	O	O
bipolar	SAPHRIS.xml:S3:15384:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:15392:5	mania	NN	O	O
trials	SAPHRIS.xml:S3:15398:6	trial	NNS	O	O
,	SAPHRIS.xml:S3:15404:1	,	,	O	O
the	SAPHRIS.xml:S3:15406:3	the	DT	O	O
proportion	SAPHRIS.xml:S3:15410:10	proport	NN	O	O
of	SAPHRIS.xml:S3:15421:2	of	IN	O	O
patients	SAPHRIS.xml:S3:15424:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:15433:4	with	IN	O	O
total	SAPHRIS.xml:S3:15438:5	total	JJ	B-AdverseReaction	O
cholesterol	SAPHRIS.xml:S3:15444:11	cholesterol	NN	I-AdverseReaction	O
elevations	SAPHRIS.xml:S3:15456:10	elev	NNS	I-AdverseReaction	O
240	SAPHRIS.xml:S3:15469:3	240	CD	O	O
mg	SAPHRIS.xml:S3:15473:2	mg	NNS	O	O
dL	SAPHRIS.xml:S3:15476:2	dL	NN	O	O
(	SAPHRIS.xml:S3:15479:1	(	(	O	O
at	SAPHRIS.xml:S3:15480:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S3:15483:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S3:15491:1	)	)	O	O
was	SAPHRIS.xml:S3:15493:3	wa	VBD	O	O
8.7%	SAPHRIS.xml:S3:15497:4	8.7%	CD	O	O
for	SAPHRIS.xml:S3:15502:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:15506:7	saphri	NNP	O	O
-	SAPHRIS.xml:S3:15513:1	-	:	O	O
treated	SAPHRIS.xml:S3:15514:7	treat	VBD	O	O
patients	SAPHRIS.xml:S3:15522:8	patient	NNS	O	O
versus	SAPHRIS.xml:S3:15531:6	versu	VBP	O	O
8.6%	SAPHRIS.xml:S3:15538:4	8.6%	CD	O	O
for	SAPHRIS.xml:S3:15543:3	for	IN	O	O
placebo	SAPHRIS.xml:S3:15547:7	placebo	NN	O	O
-	SAPHRIS.xml:S3:15554:1	-	:	O	O
treated	SAPHRIS.xml:S3:15555:7	treat	JJ	O	O
patients	SAPHRIS.xml:S3:15563:8	patient	NNS	O	O
.	SAPHRIS.xml:S3:15571:1	.	.	O	O

The	SAPHRIS.xml:S3:15573:3	the	DT	O	O
proportion	SAPHRIS.xml:S3:15577:10	proport	NN	O	O
of	SAPHRIS.xml:S3:15588:2	of	IN	O	O
patients	SAPHRIS.xml:S3:15591:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:15600:4	with	IN	O	O
elevations	SAPHRIS.xml:S3:15605:10	elev	NNS	B-AdverseReaction	O
in	SAPHRIS.xml:S3:15616:2	in	IN	I-AdverseReaction	O
triglycerides	SAPHRIS.xml:S3:15619:13	triglycerid	NNS	I-AdverseReaction	O
200	SAPHRIS.xml:S3:15635:3	200	CD	O	O
mg	SAPHRIS.xml:S3:15639:2	mg	NNS	O	O
dL	SAPHRIS.xml:S3:15642:2	dL	NN	O	O
(	SAPHRIS.xml:S3:15645:1	(	(	O	O
at	SAPHRIS.xml:S3:15646:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S3:15649:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S3:15657:1	)	)	O	O
was	SAPHRIS.xml:S3:15659:3	wa	VBD	O	O
15.2%	SAPHRIS.xml:S3:15663:5	15.2%	CD	O	O
for	SAPHRIS.xml:S3:15669:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:15673:7	saphri	NNP	O	O
-	SAPHRIS.xml:S3:15680:1	-	:	O	O
treated	SAPHRIS.xml:S3:15681:7	treat	VBD	O	O
patients	SAPHRIS.xml:S3:15689:8	patient	NNS	O	O
versus	SAPHRIS.xml:S3:15698:6	versu	VBP	O	O
11.4%	SAPHRIS.xml:S3:15705:5	11.4%	CD	O	O
for	SAPHRIS.xml:S3:15711:3	for	IN	O	O
placebo	SAPHRIS.xml:S3:15715:7	placebo	NN	O	O
-	SAPHRIS.xml:S3:15722:1	-	:	O	O
treated	SAPHRIS.xml:S3:15723:7	treat	JJ	O	O
patients	SAPHRIS.xml:S3:15731:8	patient	NNS	O	O
.	SAPHRIS.xml:S3:15739:1	.	.	O	O

In	SAPHRIS.xml:S3:15749:2	In	IN	O	O

a	SAPHRIS.xml:S3:15752:1	a	DT	O	O
52	SAPHRIS.xml:S3:15754:2	52	CD	O	O
-	SAPHRIS.xml:S3:15756:1	-	:	O	O
week	SAPHRIS.xml:S3:15757:4	week	NN	O	O
,	SAPHRIS.xml:S3:15761:1	,	,	O	O
double	SAPHRIS.xml:S3:15763:6	doubl	JJ	O	O
-	SAPHRIS.xml:S3:15769:1	-	:	O	O
blind	SAPHRIS.xml:S3:15770:5	blind	NN	O	O
,	SAPHRIS.xml:S3:15775:1	,	,	O	O
comparator	SAPHRIS.xml:S3:15777:10	compar	NN	O	O
-	SAPHRIS.xml:S3:15787:1	-	:	O	O
controlled	SAPHRIS.xml:S3:15788:10	control	VBN	O	O
trial	SAPHRIS.xml:S3:15799:5	trial	NN	O	O
that	SAPHRIS.xml:S3:15805:4	that	WDT	O	O
included	SAPHRIS.xml:S3:15810:8	includ	VBD	O	O
primarily	SAPHRIS.xml:S3:15819:9	primarili	RB	O	O
patients	SAPHRIS.xml:S3:15829:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:15838:4	with	IN	O	O
schizophrenia	SAPHRIS.xml:S3:15843:13	schizophrenia	NN	O	O
,	SAPHRIS.xml:S3:15856:1	,	,	O	O
the	SAPHRIS.xml:S3:15858:3	the	DT	O	O
mean	SAPHRIS.xml:S3:15862:4	mean	JJ	O	O
decrease	SAPHRIS.xml:S3:15867:8	decreas	NN	O	O
from	SAPHRIS.xml:S3:15876:4	from	IN	O	O
baseline	SAPHRIS.xml:S3:15881:8	baselin	NN	O	O
of	SAPHRIS.xml:S3:15890:2	of	IN	O	I-AdverseReaction
total	SAPHRIS.xml:S3:15893:5	total	JJ	O	I-AdverseReaction
cholesterol	SAPHRIS.xml:S3:15899:11	cholesterol	NN	O	I-AdverseReaction
was	SAPHRIS.xml:S3:15911:3	wa	VBD	O	O
6	SAPHRIS.xml:S3:15915:1	6	CD	O	O
mg	SAPHRIS.xml:S3:15917:2	mg	NN	O	O
dL	SAPHRIS.xml:S3:15920:2	dL	NN	O	O
and	SAPHRIS.xml:S3:15923:3	and	CC	O	O
the	SAPHRIS.xml:S3:15927:3	the	DT	O	O
mean	SAPHRIS.xml:S3:15931:4	mean	JJ	O	O
decrease	SAPHRIS.xml:S3:15936:8	decreas	NN	O	O
from	SAPHRIS.xml:S3:15945:4	from	IN	O	O
baseline	SAPHRIS.xml:S3:15950:8	baselin	NN	O	O
of	SAPHRIS.xml:S3:15959:2	of	IN	O	O
fasting	SAPHRIS.xml:S3:15962:7	fast	VBG	O	O
triglycerides	SAPHRIS.xml:S3:15970:13	triglycerid	NNS	O	O
was	SAPHRIS.xml:S3:15984:3	wa	VBD	O	O
9.8	SAPHRIS.xml:S3:15988:3	9.8	CD	O	O
mg	SAPHRIS.xml:S3:15992:2	mg	JJ	O	O
dL	SAPHRIS.xml:S3:15995:2	dL	NN	O	O
.	SAPHRIS.xml:S3:15997:1	.	.	O	O

Pediatric	SAPHRIS.xml:S3:16011:9	pediatr	JJ	O	O
Patients	SAPHRIS.xml:S3:16021:8	patient	NNS	O	O
:	SAPHRIS.xml:S3:16029:1	:	:	O	O
Data	SAPHRIS.xml:S3:16032:4	data	NNS	O	O
from	SAPHRIS.xml:S3:16037:4	from	IN	O	O
the	SAPHRIS.xml:S3:16042:3	the	DT	O	O
short	SAPHRIS.xml:S3:16046:5	short	JJ	O	O
-	SAPHRIS.xml:S3:16051:1	-	:	O	O
term	SAPHRIS.xml:S3:16052:4	term	NN	O	O
,	SAPHRIS.xml:S3:16056:1	,	,	O	O
placebo	SAPHRIS.xml:S3:16058:7	placebo	SYM	O	O
-	SAPHRIS.xml:S3:16065:1	-	:	O	O
controlled	SAPHRIS.xml:S3:16066:10	control	VBN	O	O
bipolar	SAPHRIS.xml:S3:16077:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:16085:5	mania	NN	O	O
trial	SAPHRIS.xml:S3:16091:5	trial	NN	O	O
are	SAPHRIS.xml:S3:16097:3	are	VBP	O	O
presented	SAPHRIS.xml:S3:16101:9	present	VBN	O	O
in	SAPHRIS.xml:S3:16111:2	in	IN	O	O
Table	SAPHRIS.xml:S3:16115:5	tabl	JJ	O	O
4	SAPHRIS.xml:S3:16121:1	4	CD	O	O
.	SAPHRIS.xml:S3:16124:1	.	.	O	O

TABLE	SAPHRIS.xml:S3:16130:5	tabl	NN	O	O
4	SAPHRIS.xml:S3:16136:1	4	CD	O	O
:	SAPHRIS.xml:S3:16137:1	:	:	O	O
Changes	SAPHRIS.xml:S3:16139:7	chang	NNS	O	O
in	SAPHRIS.xml:S3:16147:2	in	IN	O	O
Fasting	SAPHRIS.xml:S3:16150:7	fast	VBG	O	O
Lipids	SAPHRIS.xml:S3:16158:6	lipid	NNP	O	O
in	SAPHRIS.xml:S3:16165:2	in	IN	O	O
Pediatric	SAPHRIS.xml:S3:16168:9	pediatr	NNP	O	O
Subjects	SAPHRIS.xml:S3:16178:8	subject	NNS	O	O

N	SAPHRIS.xml:S3:16190:1	N	NNP	O	O
Number	SAPHRIS.xml:S3:16195:6	number	NNP	O	O
of	SAPHRIS.xml:S3:16202:2	of	IN	O	O
patients	SAPHRIS.xml:S3:16205:8	patient	NNS	O	O
who	SAPHRIS.xml:S3:16214:3	who	WP	O	O
had	SAPHRIS.xml:S3:16218:3	had	VBD	O	O
assessments	SAPHRIS.xml:S3:16222:11	assess	NNS	O	O
at	SAPHRIS.xml:S3:16234:2	at	IN	O	O
both	SAPHRIS.xml:S3:16237:4	both	DT	O	O
Baseline	SAPHRIS.xml:S3:16242:8	baselin	NNP	O	O
and	SAPHRIS.xml:S3:16251:3	and	CC	O	O
Endpoint	SAPHRIS.xml:S3:16255:8	endpoint	NNP	O	O

Bipolar	SAPHRIS.xml:S3:16304:7	bipolar	JJ	O	O

I	SAPHRIS.xml:S3:16312:1	I	PRP	O	O
Disorder	SAPHRIS.xml:S3:16314:8	disord	NNP	O	O
(	SAPHRIS.xml:S3:16323:1	(	(	O	O
3	SAPHRIS.xml:S3:16324:1	3	CD	O	O
-	SAPHRIS.xml:S3:16325:1	-	:	O	O
weeks	SAPHRIS.xml:S3:16326:5	week	NNS	O	O
)	SAPHRIS.xml:S3:16331:1	)	)	O	O

Placebo	SAPHRIS.xml:S3:16369:7	placebo	NNP	O	O
SAPHRIS2	SAPHRIS.xml:S3:16385:8	saphris2	NNP	O	O
.	SAPHRIS.xml:S3:16393:1	.	.	O	O
5	SAPHRIS.xml:S3:16394:1	5	CD	O	O
mgtwice	SAPHRIS.xml:S3:16396:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:16404:5	daili	RB	O	O
SAPHRIS5	SAPHRIS.xml:S3:16411:8	saphris5	NNP	O	O
mgtwice	SAPHRIS.xml:S3:16420:7	mgtwice	NN	O	O
daily	SAPHRIS.xml:S3:16428:5	daili	RB	O	O
SAPHRIS10	SAPHRIS.xml:S3:16435:9	saphris10	NNP	O	O
mgtwice	SAPHRIS.xml:S3:16445:7	mgtwice	NN	O	O
daily	SAPHRIS.xml:S3:16453:5	daili	RB	O	O

Mean	SAPHRIS.xml:S3:16463:4	mean	JJ	O	O
Change	SAPHRIS.xml:S3:16468:6	chang	NNP	O	O
from	SAPHRIS.xml:S3:16475:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:16480:8	baselin	NNP	O	O
(	SAPHRIS.xml:S3:16489:1	(	(	O	O
mg	SAPHRIS.xml:S3:16490:2	mg	FW	O	O
dL	SAPHRIS.xml:S3:16493:2	dL	NN	O	O
)	SAPHRIS.xml:S3:16495:1	)	)	O	O

Total	SAPHRIS.xml:S3:16501:5	total	JJ	O	O
fasting	SAPHRIS.xml:S3:16507:7	fast	NN	O	O
cholesterol	SAPHRIS.xml:S3:16515:11	cholesterol	NN	O	O
(	SAPHRIS.xml:S3:16527:1	(	(	O	O
N	SAPHRIS.xml:S3:16528:1	N	NNP	O	O
)	SAPHRIS.xml:S3:16530:1	)	)	O	O
-	SAPHRIS.xml:S3:16533:1	-	:	O	O
2.3	SAPHRIS.xml:S3:16534:3	2.3	CD	O	O
(	SAPHRIS.xml:S3:16537:1	(	(	O	O
57	SAPHRIS.xml:S3:16538:2	57	CD	O	O
)	SAPHRIS.xml:S3:16540:1	)	)	O	O
3.7	SAPHRIS.xml:S3:16549:3	3.7	CD	O	O
(	SAPHRIS.xml:S3:16552:1	(	(	O	O
50	SAPHRIS.xml:S3:16553:2	50	CD	O	O
)	SAPHRIS.xml:S3:16555:1	)	)	O	O
7.2	SAPHRIS.xml:S3:16569:3	7.2	CD	O	O
(	SAPHRIS.xml:S3:16572:1	(	(	O	O
57	SAPHRIS.xml:S3:16573:2	57	CD	O	O
)	SAPHRIS.xml:S3:16575:1	)	)	O	O
9.3	SAPHRIS.xml:S3:16589:3	9.3	CD	O	O
(	SAPHRIS.xml:S3:16592:1	(	(	O	O
52	SAPHRIS.xml:S3:16593:2	52	CD	O	O
)	SAPHRIS.xml:S3:16595:1	)	)	O	O

Fasting	SAPHRIS.xml:S3:16612:7	fast	VBG	O	O
LDL	SAPHRIS.xml:S3:16620:3	ldl	NNP	O	O
(	SAPHRIS.xml:S3:16623:1	(	(	O	O
N	SAPHRIS.xml:S3:16624:1	N	NNP	O	O
)	SAPHRIS.xml:S3:16626:1	)	)	O	O
-	SAPHRIS.xml:S3:16644:1	-	:	O	O
2.5	SAPHRIS.xml:S3:16645:3	2.5	CD	O	O
(	SAPHRIS.xml:S3:16648:1	(	(	O	O
57	SAPHRIS.xml:S3:16649:2	57	CD	O	O
)	SAPHRIS.xml:S3:16651:1	)	)	O	O
-	SAPHRIS.xml:S3:16660:1	-	:	O	O
0.2	SAPHRIS.xml:S3:16661:3	0.2	CD	O	O
(	SAPHRIS.xml:S3:16664:1	(	(	O	O
50	SAPHRIS.xml:S3:16665:2	50	CD	O	O
)	SAPHRIS.xml:S3:16667:1	)	)	O	O
3.0	SAPHRIS.xml:S3:16680:3	3.0	CD	O	O
(	SAPHRIS.xml:S3:16683:1	(	(	O	O
57	SAPHRIS.xml:S3:16684:2	57	CD	O	O
)	SAPHRIS.xml:S3:16686:1	)	)	O	O
4.9	SAPHRIS.xml:S3:16700:3	4.9	CD	O	O
(	SAPHRIS.xml:S3:16703:1	(	(	O	O
51	SAPHRIS.xml:S3:16704:2	51	CD	O	O
)	SAPHRIS.xml:S3:16706:1	)	)	O	O

Fasting	SAPHRIS.xml:S3:16723:7	fast	VBG	O	O
HDL	SAPHRIS.xml:S3:16731:3	hdl	NNP	O	O
(	SAPHRIS.xml:S3:16734:1	(	(	O	O
N	SAPHRIS.xml:S3:16735:1	N	NNP	O	O
)	SAPHRIS.xml:S3:16737:1	)	)	O	O
1.6	SAPHRIS.xml:S3:16755:3	1.6	CD	O	O
(	SAPHRIS.xml:S3:16758:1	(	(	O	O
57	SAPHRIS.xml:S3:16759:2	57	CD	O	O
)	SAPHRIS.xml:S3:16761:1	)	)	O	O
2.3	SAPHRIS.xml:S3:16771:3	2.3	CD	O	O
(	SAPHRIS.xml:S3:16774:1	(	(	O	O
50	SAPHRIS.xml:S3:16775:2	50	CD	O	O
)	SAPHRIS.xml:S3:16777:1	)	)	O	O
1.5	SAPHRIS.xml:S3:16791:3	1.5	CD	O	O
(	SAPHRIS.xml:S3:16794:1	(	(	O	O
57	SAPHRIS.xml:S3:16795:2	57	CD	O	O
)	SAPHRIS.xml:S3:16797:1	)	)	O	O
1.7	SAPHRIS.xml:S3:16811:3	1.7	CD	O	O
(	SAPHRIS.xml:S3:16814:1	(	(	O	O
52	SAPHRIS.xml:S3:16815:2	52	CD	O	O
)	SAPHRIS.xml:S3:16817:1	)	)	O	O

Fasting	SAPHRIS.xml:S3:16834:7	fast	VBG	O	O
triglycerides	SAPHRIS.xml:S3:16842:13	triglycerid	NNS	O	O
(	SAPHRIS.xml:S3:16856:1	(	(	O	O
N	SAPHRIS.xml:S3:16857:1	N	NNP	O	O
)	SAPHRIS.xml:S3:16859:1	)	)	O	O
-	SAPHRIS.xml:S3:16866:1	-	:	O	O
6.6	SAPHRIS.xml:S3:16867:3	6.6	CD	O	O
(	SAPHRIS.xml:S3:16870:1	(	(	O	O
57	SAPHRIS.xml:S3:16871:2	57	CD	O	O
)	SAPHRIS.xml:S3:16873:1	)	)	O	O
8.7	SAPHRIS.xml:S3:16882:3	8.7	CD	O	O
(	SAPHRIS.xml:S3:16885:1	(	(	O	O
50	SAPHRIS.xml:S3:16886:2	50	CD	O	O
)	SAPHRIS.xml:S3:16888:1	)	)	O	O
13.4	SAPHRIS.xml:S3:16902:4	13.4	CD	O	O
(	SAPHRIS.xml:S3:16906:1	(	(	O	O
57	SAPHRIS.xml:S3:16907:2	57	CD	O	O
)	SAPHRIS.xml:S3:16909:1	)	)	O	O
14.7	SAPHRIS.xml:S3:16922:4	14.7	CD	O	O
(	SAPHRIS.xml:S3:16926:1	(	(	O	O
52	SAPHRIS.xml:S3:16927:2	52	CD	O	O
)	SAPHRIS.xml:S3:16929:1	)	)	O	O

Proportion	SAPHRIS.xml:S3:16945:10	proport	NN	O	O
of	SAPHRIS.xml:S3:16956:2	of	IN	O	O
Subjects	SAPHRIS.xml:S3:16959:8	subject	NNS	O	O
with	SAPHRIS.xml:S3:16968:4	with	IN	O	O
Shifts	SAPHRIS.xml:S3:16973:6	shift	NNP	O	O
from	SAPHRIS.xml:S3:16980:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:16985:8	baselin	NNP	O	O
to	SAPHRIS.xml:S3:16994:2	to	TO	O	O
Endpoint	SAPHRIS.xml:S3:16997:8	endpoint	VB	O	O

Total	SAPHRIS.xml:S3:17010:5	total	JJ	O	O
fasting	SAPHRIS.xml:S3:17016:7	fast	VBG	O	O
cholesterolNormal	SAPHRIS.xml:S3:17024:17	cholesterolnorm	NN	O	O
to	SAPHRIS.xml:S3:17042:2	to	TO	O	O
High	SAPHRIS.xml:S3:17045:4	high	NNP	O	O
170	SAPHRIS.xml:S3:17050:3	170	CD	O	O
to	SAPHRIS.xml:S3:17054:2	to	TO	O	O
200	SAPHRIS.xml:S3:17059:3	200	CD	O	O
(	SAPHRIS.xml:S3:17062:1	(	(	O	O
mg	SAPHRIS.xml:S3:17063:2	mg	NN	O	O
dL	SAPHRIS.xml:S3:17066:2	dL	NN	O	O
)(	SAPHRIS.xml:S3:17068:2	)(	NNP	O	O
n	SAPHRIS.xml:S3:17070:1	n	RB	O	O
N	SAPHRIS.xml:S3:17072:1	N	NNP	O	O
)	SAPHRIS.xml:S3:17074:1	)	)	O	O
1.8%	SAPHRIS.xml:S3:17077:4	1.8%	CD	O	O
(	SAPHRIS.xml:S3:17081:1	(	(	O	O
1	SAPHRIS.xml:S3:17082:1	1	CD	O	O
57	SAPHRIS.xml:S3:17084:2	57	CD	O	O
)	SAPHRIS.xml:S3:17086:1	)	)	O	O
0%	SAPHRIS.xml:S3:17093:2	0%	CD	O	O
(	SAPHRIS.xml:S3:17095:1	(	(	O	O
0	SAPHRIS.xml:S3:17096:1	0	CD	O	O
50	SAPHRIS.xml:S3:17098:2	50	CD	O	O
)	SAPHRIS.xml:S3:17100:1	)	)	O	O
1.8%	SAPHRIS.xml:S3:17113:4	1.8%	CD	O	O
(	SAPHRIS.xml:S3:17117:1	(	(	O	O
1	SAPHRIS.xml:S3:17118:1	1	CD	O	O
57	SAPHRIS.xml:S3:17120:2	57	CD	O	O
)	SAPHRIS.xml:S3:17122:1	)	)	O	O
0%	SAPHRIS.xml:S3:17133:2	0%	CD	O	O
(	SAPHRIS.xml:S3:17135:1	(	(	O	O
0	SAPHRIS.xml:S3:17136:1	0	CD	O	O
52	SAPHRIS.xml:S3:17138:2	52	CD	O	O
)	SAPHRIS.xml:S3:17140:1	)	)	O	O

Fasting	SAPHRIS.xml:S3:17156:7	fast	VBG	O	O
LDLNormal	SAPHRIS.xml:S3:17164:9	ldlnormal	NNP	O	O
to	SAPHRIS.xml:S3:17174:2	to	TO	O	O
High	SAPHRIS.xml:S3:17177:4	high	NNP	O	O
110	SAPHRIS.xml:S3:17182:3	110	CD	O	O
to	SAPHRIS.xml:S3:17186:2	to	TO	O	O
130	SAPHRIS.xml:S3:17191:3	130	CD	O	O
(	SAPHRIS.xml:S3:17194:1	(	(	O	O
n	SAPHRIS.xml:S3:17195:1	n	JJ	O	O
N	SAPHRIS.xml:S3:17197:1	N	NNP	O	O
)	SAPHRIS.xml:S3:17199:1	)	)	O	O
1.8%	SAPHRIS.xml:S3:17202:4	1.8%	CD	O	O
(	SAPHRIS.xml:S3:17206:1	(	(	O	O
1	SAPHRIS.xml:S3:17207:1	1	CD	O	O
57	SAPHRIS.xml:S3:17209:2	57	CD	O	O
)	SAPHRIS.xml:S3:17211:1	)	)	O	O
2.0%	SAPHRIS.xml:S3:17218:4	2.0%	CD	O	O
(	SAPHRIS.xml:S3:17222:1	(	(	O	O
1	SAPHRIS.xml:S3:17223:1	1	CD	O	O
50	SAPHRIS.xml:S3:17225:2	50	CD	O	O
)	SAPHRIS.xml:S3:17227:1	)	)	O	O
1.8%	SAPHRIS.xml:S3:17238:4	1.8%	CD	O	O
(	SAPHRIS.xml:S3:17242:1	(	(	O	O
1	SAPHRIS.xml:S3:17243:1	1	CD	O	O
57	SAPHRIS.xml:S3:17245:2	57	CD	O	O
)	SAPHRIS.xml:S3:17247:1	)	)	O	O
0%	SAPHRIS.xml:S3:17258:2	0%	CD	O	O
(	SAPHRIS.xml:S3:17260:1	(	(	O	O
0	SAPHRIS.xml:S3:17261:1	0	CD	O	O
51	SAPHRIS.xml:S3:17263:2	51	CD	O	O
)	SAPHRIS.xml:S3:17265:1	)	)	O	O

Fasting	SAPHRIS.xml:S3:17281:7	fast	VBG	O	O
HDLNormal	SAPHRIS.xml:S3:17289:9	hdlnormal	NNP	O	O
to	SAPHRIS.xml:S3:17299:2	to	TO	O	O
Low	SAPHRIS.xml:S3:17302:3	low	VB	O	O
40	SAPHRIS.xml:S3:17307:2	40	CD	O	O
to	SAPHRIS.xml:S3:17310:2	to	TO	O	O
40	SAPHRIS.xml:S3:17314:2	40	CD	O	O
(	SAPHRIS.xml:S3:17317:1	(	(	O	O
mg	SAPHRIS.xml:S3:17318:2	mg	NN	O	O
dL	SAPHRIS.xml:S3:17321:2	dL	NN	O	O
)(	SAPHRIS.xml:S3:17323:2	)(	NNP	O	O
n	SAPHRIS.xml:S3:17325:1	n	RB	O	O
N	SAPHRIS.xml:S3:17327:1	N	NNP	O	O
)	SAPHRIS.xml:S3:17329:1	)	)	O	O
3.5%	SAPHRIS.xml:S3:17332:4	3.5%	CD	O	O
(	SAPHRIS.xml:S3:17336:1	(	(	O	O
2	SAPHRIS.xml:S3:17337:1	2	CD	O	O
57	SAPHRIS.xml:S3:17339:2	57	CD	O	O
)	SAPHRIS.xml:S3:17341:1	)	)	O	O
6.0%	SAPHRIS.xml:S3:17348:4	6.0%	CD	O	O
(	SAPHRIS.xml:S3:17352:1	(	(	O	O
3	SAPHRIS.xml:S3:17353:1	3	CD	O	O
50	SAPHRIS.xml:S3:17355:2	50	CD	O	O
)	SAPHRIS.xml:S3:17357:1	)	)	O	O
3.5%	SAPHRIS.xml:S3:17368:4	3.5%	CD	O	O
(	SAPHRIS.xml:S3:17372:1	(	(	O	O
2	SAPHRIS.xml:S3:17373:1	2	CD	O	O
57	SAPHRIS.xml:S3:17375:2	57	CD	O	O
)	SAPHRIS.xml:S3:17377:1	)	)	O	O
9.6%	SAPHRIS.xml:S3:17388:4	9.6%	CD	O	O
(	SAPHRIS.xml:S3:17392:1	(	(	O	O
5	SAPHRIS.xml:S3:17393:1	5	CD	O	O
52	SAPHRIS.xml:S3:17395:2	52	CD	O	O
)	SAPHRIS.xml:S3:17397:1	)	)	O	O

Fasting	SAPHRIS.xml:S3:17411:7	fast	VBG	O	O
triglyceridesNormal	SAPHRIS.xml:S3:17419:19	triglyceridesnorm	NN	O	O
to	SAPHRIS.xml:S3:17439:2	to	TO	O	O
High	SAPHRIS.xml:S3:17442:4	high	NNP	O	O
150	SAPHRIS.xml:S3:17447:3	150	CD	O	O
to	SAPHRIS.xml:S3:17451:2	to	TO	O	O
200	SAPHRIS.xml:S3:17456:3	200	CD	O	O
(	SAPHRIS.xml:S3:17460:1	(	(	O	O
mg	SAPHRIS.xml:S3:17461:2	mg	NN	O	O
dL	SAPHRIS.xml:S3:17464:2	dL	NN	O	O
)(	SAPHRIS.xml:S3:17466:2	)(	NNP	O	O
n	SAPHRIS.xml:S3:17468:1	n	RB	O	O
N	SAPHRIS.xml:S3:17470:1	N	NNP	O	O
)	SAPHRIS.xml:S3:17472:1	)	)	O	O
0%	SAPHRIS.xml:S3:17475:2	0%	CD	O	O
(	SAPHRIS.xml:S3:17477:1	(	(	O	O
0	SAPHRIS.xml:S3:17478:1	0	CD	O	O
57	SAPHRIS.xml:S3:17480:2	57	CD	O	O
)	SAPHRIS.xml:S3:17482:1	)	)	O	O
4.0%	SAPHRIS.xml:S3:17491:4	4.0%	CD	O	O
(	SAPHRIS.xml:S3:17495:1	(	(	O	O
2	SAPHRIS.xml:S3:17496:1	2	CD	O	O
50	SAPHRIS.xml:S3:17498:2	50	CD	O	O
)	SAPHRIS.xml:S3:17500:1	)	)	O	O
3.5%	SAPHRIS.xml:S3:17511:4	3.5%	CD	O	O
(	SAPHRIS.xml:S3:17515:1	(	(	O	O
2	SAPHRIS.xml:S3:17516:1	2	CD	O	O
57	SAPHRIS.xml:S3:17518:2	57	CD	O	O
)	SAPHRIS.xml:S3:17520:1	)	)	O	O
1.9%	SAPHRIS.xml:S3:17531:4	1.9%	CD	O	O
(	SAPHRIS.xml:S3:17535:1	(	(	O	O
1	SAPHRIS.xml:S3:17536:1	1	CD	O	O
52	SAPHRIS.xml:S3:17538:2	52	CD	O	O
)	SAPHRIS.xml:S3:17540:1	)	)	O	O

Weight	SAPHRIS.xml:S3:17572:6	weight	NNP	O	O
Gain	SAPHRIS.xml:S3:17579:4	gain	NNP	O	O

Increases	SAPHRIS.xml:S3:17594:9	increas	NNS	B-AdverseReaction	O

in	SAPHRIS.xml:S3:17604:2	in	IN	I-AdverseReaction	O
weight	SAPHRIS.xml:S3:17607:6	weight	NN	I-AdverseReaction	O
have	SAPHRIS.xml:S3:17614:4	have	VBP	O	O
been	SAPHRIS.xml:S3:17619:4	been	VBN	O	O
observed	SAPHRIS.xml:S3:17624:8	observ	VBN	O	O
in	SAPHRIS.xml:S3:17633:2	in	IN	O	O
pre	SAPHRIS.xml:S3:17636:3	pre	NN	O	O
-	SAPHRIS.xml:S3:17639:1	-	:	O	O
marketing	SAPHRIS.xml:S3:17640:9	market	NN	O	O
clinical	SAPHRIS.xml:S3:17650:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S3:17659:6	trial	NNS	O	O
with	SAPHRIS.xml:S3:17666:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:17671:7	saphri	NNP	O	O
.	SAPHRIS.xml:S3:17678:1	.	.	O	O

Patients	SAPHRIS.xml:S3:17680:8	patient	NNS	O	O
receiving	SAPHRIS.xml:S3:17689:9	receiv	VBG	O	O
SAPHRIS	SAPHRIS.xml:S3:17699:7	saphri	NNP	O	O
should	SAPHRIS.xml:S3:17707:6	should	MD	O	O
receive	SAPHRIS.xml:S3:17714:7	receiv	VB	O	O
regular	SAPHRIS.xml:S3:17722:7	regular	JJ	O	O
monitoring	SAPHRIS.xml:S3:17730:10	monitor	NN	O	O
of	SAPHRIS.xml:S3:17741:2	of	IN	O	O
weight	SAPHRIS.xml:S3:17744:6	weight	JJ	O	O
[	SAPHRIS.xml:S3:17752:1	[	NNP	O	O
see	SAPHRIS.xml:S3:17753:3	see	VBP	O	O
Patient	SAPHRIS.xml:S3:17757:7	patient	NNP	O	O
Counseling	SAPHRIS.xml:S3:17765:10	counsel	NNP	O	O
Information	SAPHRIS.xml:S3:17776:11	inform	NNP	O	O
(	SAPHRIS.xml:S3:17788:1	(	(	O	O
17	SAPHRIS.xml:S3:17789:2	17	CD	O	O
)]	SAPHRIS.xml:S3:17791:2	)]	NN	O	O
.	SAPHRIS.xml:S3:17795:1	.	.	O	O

Adult	SAPHRIS.xml:S3:17807:5	adult	NN	O	O
Patients	SAPHRIS.xml:S3:17813:8	patient	NNS	O	O
:	SAPHRIS.xml:S3:17821:1	:	:	O	O
Pooled	SAPHRIS.xml:S3:17824:6	pool	VBN	O	O
data	SAPHRIS.xml:S3:17831:4	data	NNS	O	O
on	SAPHRIS.xml:S3:17836:2	on	IN	O	O
mean	SAPHRIS.xml:S3:17839:4	mean	NN	O	O
changes	SAPHRIS.xml:S3:17844:7	chang	NNS	O	O
in	SAPHRIS.xml:S3:17852:2	in	IN	O	O
body	SAPHRIS.xml:S3:17855:4	bodi	NN	O	O
weight	SAPHRIS.xml:S3:17860:6	weight	NN	O	O
and	SAPHRIS.xml:S3:17867:3	and	CC	O	O
the	SAPHRIS.xml:S3:17871:3	the	DT	O	O
proportion	SAPHRIS.xml:S3:17875:10	proport	NN	O	O
of	SAPHRIS.xml:S3:17886:2	of	IN	O	O
subjects	SAPHRIS.xml:S3:17889:8	subject	NNS	O	O
meeting	SAPHRIS.xml:S3:17898:7	meet	VBG	O	O
a	SAPHRIS.xml:S3:17906:1	a	DT	O	O
weight	SAPHRIS.xml:S3:17908:6	weight	NN	B-AdverseReaction	O
gain	SAPHRIS.xml:S3:17915:4	gain	NN	I-AdverseReaction	O
criterion	SAPHRIS.xml:S3:17920:9	criterion	NN	O	O
of	SAPHRIS.xml:S3:17930:2	of	IN	O	O
7%	SAPHRIS.xml:S3:17935:2	7%	CD	O	O
of	SAPHRIS.xml:S3:17938:2	of	IN	O	O
body	SAPHRIS.xml:S3:17941:4	bodi	NN	O	O
weight	SAPHRIS.xml:S3:17946:6	weight	NN	O	O
from	SAPHRIS.xml:S3:17953:4	from	IN	O	O
the	SAPHRIS.xml:S3:17958:3	the	DT	O	O
short	SAPHRIS.xml:S3:17962:5	short	JJ	O	O
-	SAPHRIS.xml:S3:17967:1	-	:	O	O
term	SAPHRIS.xml:S3:17968:4	term	NN	O	O
,	SAPHRIS.xml:S3:17972:1	,	,	O	O
placebo	SAPHRIS.xml:S3:17974:7	placebo	SYM	O	O
-	SAPHRIS.xml:S3:17981:1	-	:	O	O
controlled	SAPHRIS.xml:S3:17982:10	control	VBN	O	O
schizophrenia	SAPHRIS.xml:S3:17993:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S3:18007:3	and	CC	O	O
bipolar	SAPHRIS.xml:S3:18011:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:18019:5	mania	NN	O	O
trials	SAPHRIS.xml:S3:18025:6	trial	NNS	O	O
are	SAPHRIS.xml:S3:18032:3	are	VBP	O	O
presented	SAPHRIS.xml:S3:18036:9	present	VBN	O	O
in	SAPHRIS.xml:S3:18046:2	in	IN	O	O
Table	SAPHRIS.xml:S3:18050:5	tabl	JJ	O	O
5	SAPHRIS.xml:S3:18056:1	5	CD	O	O
.	SAPHRIS.xml:S3:18057:1	.	.	O	O

Table	SAPHRIS.xml:S3:18065:5	tabl	JJ	O	O
5	SAPHRIS.xml:S3:18071:1	5	CD	O	O
:	SAPHRIS.xml:S3:18072:1	:	:	O	O
Change	SAPHRIS.xml:S3:18074:6	chang	NN	O	O
in	SAPHRIS.xml:S3:18081:2	in	IN	O	O
Body	SAPHRIS.xml:S3:18084:4	bodi	NNP	O	O
Weight	SAPHRIS.xml:S3:18089:6	weight	NNP	O	O
in	SAPHRIS.xml:S3:18096:2	in	IN	O	O
Adult	SAPHRIS.xml:S3:18099:5	adult	NNP	O	O
Patients	SAPHRIS.xml:S3:18105:8	patient	NNS	O	O
from	SAPHRIS.xml:S3:18114:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:18119:8	baselin	NNP	O	O

N	SAPHRIS.xml:S3:18131:1	N	NNP	O	O
Number	SAPHRIS.xml:S3:18136:6	number	NNP	O	O
of	SAPHRIS.xml:S3:18143:2	of	IN	O	O
subjects	SAPHRIS.xml:S3:18146:8	subject	NNS	O	O
who	SAPHRIS.xml:S3:18155:3	who	WP	O	O
had	SAPHRIS.xml:S3:18159:3	had	VBD	O	O
assessments	SAPHRIS.xml:S3:18163:11	assess	NNS	O	O
at	SAPHRIS.xml:S3:18175:2	at	IN	O	O
both	SAPHRIS.xml:S3:18178:4	both	DT	O	O
Baseline	SAPHRIS.xml:S3:18183:8	baselin	NNP	O	O
and	SAPHRIS.xml:S3:18192:3	and	CC	O	O
Endpoint	SAPHRIS.xml:S3:18196:8	endpoint	NNP	O	O
.	SAPHRIS.xml:S3:18204:1	.	.	O	O

S	SAPHRIS.xml:S3:18212:1	S	NNP	O	O
Includes	SAPHRIS.xml:S3:18214:8	includ	NNP	O	O
subjects	SAPHRIS.xml:S3:18223:8	subject	NNS	O	O
treated	SAPHRIS.xml:S3:18232:7	treat	VBD	O	O
with	SAPHRIS.xml:S3:18240:4	with	IN	O	O
flexible	SAPHRIS.xml:S3:18245:8	flexibl	JJ	O	O
dose	SAPHRIS.xml:S3:18254:4	dose	NN	O	O
of	SAPHRIS.xml:S3:18259:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:18262:7	saphri	NNP	O	O
5	SAPHRIS.xml:S3:18270:1	5	CD	O	O
or	SAPHRIS.xml:S3:18272:2	or	CC	O	O
10	SAPHRIS.xml:S3:18275:2	10	CD	O	O
mg	SAPHRIS.xml:S3:18278:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:18281:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:18287:5	daili	RB	O	O
(	SAPHRIS.xml:S3:18293:1	(	(	O	O
N	SAPHRIS.xml:S3:18294:1	N	NNP	O	O
90	SAPHRIS.xml:S3:18296:2	90	CD	O	O
)	SAPHRIS.xml:S3:18298:1	)	)	O	O
.	SAPHRIS.xml:S3:18299:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S3:18307:7	saphri	NNP	O	O
5	SAPHRIS.xml:S3:18315:1	5	CD	O	O
mg	SAPHRIS.xml:S3:18317:2	mg	NN	O	O
or	SAPHRIS.xml:S3:18320:2	or	CC	O	O
10	SAPHRIS.xml:S3:18323:2	10	CD	O	O
mg	SAPHRIS.xml:S3:18326:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:18329:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:18335:5	daili	RB	O	O
with	SAPHRIS.xml:S3:18341:4	with	IN	O	O
flexible	SAPHRIS.xml:S3:18346:8	flexibl	JJ	O	O
dosing	SAPHRIS.xml:S3:18355:6	dose	NN	O	O
.	SAPHRIS.xml:S3:18361:1	.	.	O	O

Schizophrenia	SAPHRIS.xml:S3:18391:13	schizophrenia	NN	O	O

(	SAPHRIS.xml:S3:18405:1	(	(	O	O
6	SAPHRIS.xml:S3:18406:1	6	CD	O	O
-	SAPHRIS.xml:S3:18407:1	-	:	O	O
weeks	SAPHRIS.xml:S3:18408:5	week	NNS	O	O
)	SAPHRIS.xml:S3:18413:1	)	)	O	O
Bipolar	SAPHRIS.xml:S3:18416:7	bipolar	NNP	O	O
(	SAPHRIS.xml:S3:18424:1	(	(	O	O
3	SAPHRIS.xml:S3:18425:1	3	CD	O	O
-	SAPHRIS.xml:S3:18426:1	-	:	O	O
weeks	SAPHRIS.xml:S3:18427:5	week	NNS	O	O
)	SAPHRIS.xml:S3:18432:1	)	)	O	O

Placebo	SAPHRIS.xml:S3:18438:7	placebo	NNP	O	O
SAPHRIS	SAPHRIS.xml:S3:18458:7	saphri	NNP	O	O
Placebo	SAPHRIS.xml:S3:18473:7	placebo	NNP	O	O
SAPHRIS5	SAPHRIS.xml:S3:18487:8	saphris5	NNP	O	O
or	SAPHRIS.xml:S3:18496:2	or	CC	O	O
10	SAPHRIS.xml:S3:18499:2	10	CD	O	O
mgtwice	SAPHRIS.xml:S3:18502:7	mgtwice	NNS	O	O
daily	SAPHRIS.xml:S3:18510:5	daili	RB	O	O

5	SAPHRIS.xml:S3:18524:1	5	CD	O	O
mgtwice	SAPHRIS.xml:S3:18526:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:18534:5	daili	RB	O	O
10	SAPHRIS.xml:S3:18544:2	10	CD	O	O
mgtwice	SAPHRIS.xml:S3:18547:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:18555:5	daili	RB	O	O
5	SAPHRIS.xml:S3:18562:1	5	CD	O	O
or	SAPHRIS.xml:S3:18564:2	or	CC	O	O
10	SAPHRIS.xml:S3:18567:2	10	CD	O	O
mgtwice	SAPHRIS.xml:S3:18570:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:18578:5	daili	RB	O	O
S	SAPHRIS.xml:S3:18585:1	S	NNP	O	O

Change	SAPHRIS.xml:S3:18593:6	chang	NN	O	O
from	SAPHRIS.xml:S3:18600:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:18605:8	baselin	NNP	O	O
(	SAPHRIS.xml:S3:18614:1	(	(	O	O
kg	SAPHRIS.xml:S3:18615:2	kg	NN	O	O
)	SAPHRIS.xml:S3:18617:1	)	)	O	O
(	SAPHRIS.xml:S3:18619:1	(	(	O	O
N	SAPHRIS.xml:S3:18620:1	N	NNP	O	O
)	SAPHRIS.xml:S3:18622:1	)	)	O	O
0.0	SAPHRIS.xml:S3:18625:3	0.0	CD	O	O
(	SAPHRIS.xml:S3:18628:1	(	(	O	O
348	SAPHRIS.xml:S3:18629:3	348	CD	O	O
)	SAPHRIS.xml:S3:18632:1	)	)	O	O
1.0	SAPHRIS.xml:S3:18640:3	1.0	CD	O	O
(	SAPHRIS.xml:S3:18643:1	(	(	O	O
251	SAPHRIS.xml:S3:18644:3	251	CD	O	O
)	SAPHRIS.xml:S3:18647:1	)	)	O	O
0.9	SAPHRIS.xml:S3:18654:3	0.9	CD	O	O
(	SAPHRIS.xml:S3:18657:1	(	(	O	O
200	SAPHRIS.xml:S3:18658:3	200	CD	O	O
)	SAPHRIS.xml:S3:18661:1	)	)	O	O
1.1	SAPHRIS.xml:S3:18670:3	1.1	CD	O	O
(	SAPHRIS.xml:S3:18673:1	(	(	O	O
532	SAPHRIS.xml:S3:18674:3	532	CD	O	O
)	SAPHRIS.xml:S3:18677:1	)	)	O	O
0.2	SAPHRIS.xml:S3:18686:3	0.2	CD	O	O
(	SAPHRIS.xml:S3:18689:1	(	(	O	O
171	SAPHRIS.xml:S3:18690:3	171	CD	O	O
)	SAPHRIS.xml:S3:18693:1	)	)	O	O
1.3	SAPHRIS.xml:S3:18700:3	1.3	CD	O	O
(	SAPHRIS.xml:S3:18703:1	(	(	O	O
336	SAPHRIS.xml:S3:18704:3	336	CD	O	O
)	SAPHRIS.xml:S3:18707:1	)	)	O	O

Proportion	SAPHRIS.xml:S3:18718:10	proport	NN	O	O
of	SAPHRIS.xml:S3:18729:2	of	IN	O	O
Patients	SAPHRIS.xml:S3:18732:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:18741:4	with	IN	O	O
a	SAPHRIS.xml:S3:18746:1	a	DT	O	O
7%	SAPHRIS.xml:S3:18750:2	7%	CD	O	O
Increase	SAPHRIS.xml:S3:18753:8	increas	NNP	B-AdverseReaction	O
in	SAPHRIS.xml:S3:18762:2	in	IN	I-AdverseReaction	O
Body	SAPHRIS.xml:S3:18765:4	bodi	NNP	I-AdverseReaction	O
Weight	SAPHRIS.xml:S3:18770:6	weight	NNP	I-AdverseReaction	O

with	SAPHRIS.xml:S3:18783:4	with	IN	O	O
7%	SAPHRIS.xml:S3:18790:2	7%	CD	O	O
increase	SAPHRIS.xml:S3:18793:8	increas	NN	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S3:18802:2	in	IN	I-AdverseReaction	I-AdverseReaction
body	SAPHRIS.xml:S3:18805:4	bodi	NN	I-AdverseReaction	I-AdverseReaction
weight	SAPHRIS.xml:S3:18810:6	weight	VBD	I-AdverseReaction	I-AdverseReaction
1.6%	SAPHRIS.xml:S3:18818:4	1.6%	CD	O	O
4.4%	SAPHRIS.xml:S3:18833:4	4.4%	CD	O	O
4.8%	SAPHRIS.xml:S3:18847:4	4.8%	CD	O	O
4.9%	SAPHRIS.xml:S3:18863:4	4.9%	CD	O	O
0.5%	SAPHRIS.xml:S3:18879:4	0.5%	CD	O	O
5.8%	SAPHRIS.xml:S3:18893:4	5.8%	CD	O	O

Adult	SAPHRIS.xml:S3:18931:5	adult	NN	O	O
Patients	SAPHRIS.xml:S3:18937:8	patient	NNS	O	O
:	SAPHRIS.xml:S3:18945:1	:	:	O	O
In	SAPHRIS.xml:S3:18948:2	In	IN	O	O
a	SAPHRIS.xml:S3:18951:1	a	DT	O	O
52	SAPHRIS.xml:S3:18953:2	52	CD	O	O
-	SAPHRIS.xml:S3:18955:1	-	:	O	O
week	SAPHRIS.xml:S3:18956:4	week	NN	O	O
,	SAPHRIS.xml:S3:18960:1	,	,	O	O
double	SAPHRIS.xml:S3:18962:6	doubl	JJ	O	O
-	SAPHRIS.xml:S3:18968:1	-	:	O	O
blind	SAPHRIS.xml:S3:18969:5	blind	NN	O	O
,	SAPHRIS.xml:S3:18974:1	,	,	O	O
comparator	SAPHRIS.xml:S3:18976:10	compar	NN	O	O
-	SAPHRIS.xml:S3:18986:1	-	:	O	O
controlled	SAPHRIS.xml:S3:18987:10	control	VBN	O	O
adult	SAPHRIS.xml:S3:18998:5	adult	NN	O	O
trial	SAPHRIS.xml:S3:19004:5	trial	NN	O	O
that	SAPHRIS.xml:S3:19010:4	that	WDT	O	O
included	SAPHRIS.xml:S3:19015:8	includ	VBD	O	O
primarily	SAPHRIS.xml:S3:19024:9	primarili	RB	O	O
patients	SAPHRIS.xml:S3:19034:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:19043:4	with	IN	O	O
schizophrenia	SAPHRIS.xml:S3:19048:13	schizophrenia	NN	O	O
,	SAPHRIS.xml:S3:19061:1	,	,	O	O
the	SAPHRIS.xml:S3:19063:3	the	DT	O	O
mean	SAPHRIS.xml:S3:19067:4	mean	JJ	O	O
weight	SAPHRIS.xml:S3:19072:6	weight	NN	B-AdverseReaction	O
gain	SAPHRIS.xml:S3:19079:4	gain	NN	I-AdverseReaction	O
from	SAPHRIS.xml:S3:19084:4	from	IN	O	O
baseline	SAPHRIS.xml:S3:19089:8	baselin	NN	O	O
was	SAPHRIS.xml:S3:19098:3	wa	VBD	O	O
0.9	SAPHRIS.xml:S3:19102:3	0.9	CD	O	O
kg	SAPHRIS.xml:S3:19106:2	kg	NN	O	O
.	SAPHRIS.xml:S3:19108:1	.	.	O	O

The	SAPHRIS.xml:S3:19110:3	the	DT	O	O
proportion	SAPHRIS.xml:S3:19114:10	proport	NN	O	O
of	SAPHRIS.xml:S3:19125:2	of	IN	O	O
patients	SAPHRIS.xml:S3:19128:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:19137:4	with	IN	O	O
a	SAPHRIS.xml:S3:19142:1	a	DT	O	O
7%	SAPHRIS.xml:S3:19146:2	7%	CD	O	O
increase	SAPHRIS.xml:S3:19149:8	increas	NN	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S3:19158:2	in	IN	I-AdverseReaction	I-AdverseReaction
body	SAPHRIS.xml:S3:19161:4	bodi	NN	I-AdverseReaction	I-AdverseReaction
weight	SAPHRIS.xml:S3:19166:6	weight	NN	I-AdverseReaction	I-AdverseReaction
(	SAPHRIS.xml:S3:19173:1	(	(	O	O
at	SAPHRIS.xml:S3:19174:2	at	IN	O	O
Endpoint	SAPHRIS.xml:S3:19177:8	endpoint	NNP	O	O
)	SAPHRIS.xml:S3:19185:1	)	)	O	O
was	SAPHRIS.xml:S3:19187:3	wa	VBD	O	O
14.7%	SAPHRIS.xml:S3:19191:5	14.7%	CD	O	O
.	SAPHRIS.xml:S3:19196:1	.	.	O	O
Table	SAPHRIS.xml:S3:19197:5	tabl	JJ	O	O
5	SAPHRIS.xml:S3:19203:1	5	CD	O	O
provides	SAPHRIS.xml:S3:19204:8	provid	VBZ	O	O
the	SAPHRIS.xml:S3:19213:3	the	DT	O	O
mean	SAPHRIS.xml:S3:19217:4	mean	JJ	O	O
weight	SAPHRIS.xml:S3:19222:6	weight	NN	B-AdverseReaction	O
change	SAPHRIS.xml:S3:19229:6	chang	NN	I-AdverseReaction	O
from	SAPHRIS.xml:S3:19236:4	from	IN	O	O
baseline	SAPHRIS.xml:S3:19241:8	baselin	NN	O	O
and	SAPHRIS.xml:S3:19250:3	and	CC	O	O
the	SAPHRIS.xml:S3:19254:3	the	DT	O	O
proportion	SAPHRIS.xml:S3:19258:10	proport	NN	O	O
of	SAPHRIS.xml:S3:19269:2	of	IN	O	O
patients	SAPHRIS.xml:S3:19272:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:19281:4	with	IN	O	O
a	SAPHRIS.xml:S3:19286:1	a	DT	O	O
weight	SAPHRIS.xml:S3:19288:6	weight	JJ	B-AdverseReaction	O
gain	SAPHRIS.xml:S3:19295:4	gain	NN	I-AdverseReaction	O
of	SAPHRIS.xml:S3:19300:2	of	IN	O	O
7%	SAPHRIS.xml:S3:19305:2	7%	CD	O	O
categorized	SAPHRIS.xml:S3:19308:11	categor	VBN	O	O
by	SAPHRIS.xml:S3:19320:2	by	IN	O	O
Body	SAPHRIS.xml:S3:19323:4	bodi	NNP	O	O
Mass	SAPHRIS.xml:S3:19328:4	mass	NNP	O	O
Index	SAPHRIS.xml:S3:19333:5	index	NNP	O	O
(	SAPHRIS.xml:S3:19339:1	(	(	O	O
BMI	SAPHRIS.xml:S3:19340:3	bmi	NNP	O	O
)	SAPHRIS.xml:S3:19343:1	)	)	O	O
at	SAPHRIS.xml:S3:19345:2	at	IN	O	O
baseline	SAPHRIS.xml:S3:19348:8	baselin	NN	O	O
.	SAPHRIS.xml:S3:19356:1	.	.	O	O

Table	SAPHRIS.xml:S3:19362:5	tabl	NN	O	O

6	SAPHRIS.xml:S3:19368:1	6	CD	O	O
:	SAPHRIS.xml:S3:19369:1	:	:	O	O
Weight	SAPHRIS.xml:S3:19371:6	weight	JJ	O	O
Change	SAPHRIS.xml:S3:19378:6	chang	NNP	O	O
Results	SAPHRIS.xml:S3:19385:7	result	NNP	O	O
Categorized	SAPHRIS.xml:S3:19393:11	categor	NNP	O	O
by	SAPHRIS.xml:S3:19405:2	by	IN	O	O
BMI	SAPHRIS.xml:S3:19408:3	bmi	NNP	O	O
at	SAPHRIS.xml:S3:19412:2	at	IN	O	O
Baseline	SAPHRIS.xml:S3:19415:8	baselin	NNP	O	O
:	SAPHRIS.xml:S3:19423:1	:	:	O	O
Comparator	SAPHRIS.xml:S3:19425:10	compar	NNP	O	O
-	SAPHRIS.xml:S3:19435:1	-	:	O	O
Controlled	SAPHRIS.xml:S3:19436:10	control	VBD	O	O
52	SAPHRIS.xml:S3:19447:2	52	CD	O	O
-	SAPHRIS.xml:S3:19449:1	-	:	O	O
Week	SAPHRIS.xml:S3:19450:4	week	NN	O	O
Study	SAPHRIS.xml:S3:19455:5	studi	NNP	O	O
in	SAPHRIS.xml:S3:19461:2	in	IN	O	O
Adults	SAPHRIS.xml:S3:19464:6	adult	NNP	O	O
with	SAPHRIS.xml:S3:19471:4	with	IN	O	O
Schizophrenia	SAPHRIS.xml:S3:19476:13	schizophrenia	NNP	O	O

BMI	SAPHRIS.xml:S3:19521:3	bmi	NNP	O	O
23	SAPHRIS.xml:S3:19526:2	23	CD	O	O
SAPHRIS	SAPHRIS.xml:S3:19532:7	saphri	NNP	O	O
N	SAPHRIS.xml:S3:19543:1	N	NNP	O	O
295	SAPHRIS.xml:S3:19545:3	295	CD	O	O
BMI	SAPHRIS.xml:S3:19554:3	bmi	NNP	O	O
23	SAPHRIS.xml:S3:19558:2	23	CD	O	O
-	SAPHRIS.xml:S3:19561:1	-	:	O	O
27	SAPHRIS.xml:S3:19565:2	27	CD	O	O
SAPHRIS	SAPHRIS.xml:S3:19571:7	saphri	NNP	O	O
N	SAPHRIS.xml:S3:19582:1	N	NNP	O	O
290	SAPHRIS.xml:S3:19584:3	290	CD	O	O
BMI	SAPHRIS.xml:S3:19593:3	bmi	NNP	O	O
27	SAPHRIS.xml:S3:19598:2	27	CD	O	O
SAPHRIS	SAPHRIS.xml:S3:19604:7	saphri	NNP	O	O
N	SAPHRIS.xml:S3:19615:1	N	NNP	O	O
302	SAPHRIS.xml:S3:19617:3	302	CD	O	O

Mean	SAPHRIS.xml:S3:19627:4	mean	JJ	O	O
change	SAPHRIS.xml:S3:19632:6	chang	NN	O	O
from	SAPHRIS.xml:S3:19639:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:19644:8	baselin	NNP	O	O
(	SAPHRIS.xml:S3:19653:1	(	(	O	O
kg	SAPHRIS.xml:S3:19654:2	kg	NN	O	O
)	SAPHRIS.xml:S3:19656:1	)	)	O	O
1.7	SAPHRIS.xml:S3:19659:3	1.7	CD	O	O
1	SAPHRIS.xml:S3:19686:1	1	CD	O	O
0	SAPHRIS.xml:S3:19713:1	0	CD	O	O

with	SAPHRIS.xml:S3:19745:4	with	IN	O	O
7%	SAPHRIS.xml:S3:19752:2	7%	CD	O	O
increase	SAPHRIS.xml:S3:19755:8	increas	NN	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S3:19764:2	in	IN	I-AdverseReaction	I-AdverseReaction
body	SAPHRIS.xml:S3:19767:4	bodi	NN	I-AdverseReaction	I-AdverseReaction
weight	SAPHRIS.xml:S3:19772:6	weight	VBD	I-AdverseReaction	I-AdverseReaction
22%	SAPHRIS.xml:S3:19780:3	22%	CD	O	O
13%	SAPHRIS.xml:S3:19807:3	13%	CD	O	O
9%	SAPHRIS.xml:S3:19834:2	9%	CD	O	O

Pediatric	SAPHRIS.xml:S3:19881:9	pediatr	JJ	O	O
Patients	SAPHRIS.xml:S3:19891:8	patient	NNS	O	O
:	SAPHRIS.xml:S3:19899:1	:	:	O	O
Data	SAPHRIS.xml:S3:19902:4	data	NNS	O	O
on	SAPHRIS.xml:S3:19907:2	on	IN	O	O
mean	SAPHRIS.xml:S3:19910:4	mean	NN	O	O
changes	SAPHRIS.xml:S3:19915:7	chang	NNS	B-AdverseReaction	O
in	SAPHRIS.xml:S3:19923:2	in	IN	I-AdverseReaction	O
body	SAPHRIS.xml:S3:19926:4	bodi	NN	I-AdverseReaction	O
weight	SAPHRIS.xml:S3:19931:6	weight	NN	I-AdverseReaction	O
and	SAPHRIS.xml:S3:19938:3	and	CC	O	O
the	SAPHRIS.xml:S3:19942:3	the	DT	O	O
proportion	SAPHRIS.xml:S3:19946:10	proport	NN	O	O
of	SAPHRIS.xml:S3:19957:2	of	IN	O	O
pediatric	SAPHRIS.xml:S3:19960:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S3:19970:8	patient	NNS	O	O
meeting	SAPHRIS.xml:S3:19979:7	meet	VBG	O	O
a	SAPHRIS.xml:S3:19987:1	a	DT	O	O
weight	SAPHRIS.xml:S3:19989:6	weight	NN	B-AdverseReaction	O
gain	SAPHRIS.xml:S3:19996:4	gain	NN	I-AdverseReaction	O
criterion	SAPHRIS.xml:S3:20001:9	criterion	NN	O	O
of	SAPHRIS.xml:S3:20011:2	of	IN	O	O
7%	SAPHRIS.xml:S3:20016:2	7%	CD	O	O
of	SAPHRIS.xml:S3:20019:2	of	IN	O	O
body	SAPHRIS.xml:S3:20022:4	bodi	NN	O	O
weight	SAPHRIS.xml:S3:20027:6	weight	NN	O	O
from	SAPHRIS.xml:S3:20034:4	from	IN	O	O
the	SAPHRIS.xml:S3:20039:3	the	DT	O	O
short	SAPHRIS.xml:S3:20043:5	short	JJ	O	O
-	SAPHRIS.xml:S3:20048:1	-	:	O	O
term	SAPHRIS.xml:S3:20049:4	term	NN	O	O
,	SAPHRIS.xml:S3:20053:1	,	,	O	O
placebo	SAPHRIS.xml:S3:20055:7	placebo	SYM	O	O
-	SAPHRIS.xml:S3:20062:1	-	:	O	O
controlled	SAPHRIS.xml:S3:20063:10	control	VBN	O	O
bipolar	SAPHRIS.xml:S3:20074:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:20082:5	mania	NN	O	O
trial	SAPHRIS.xml:S3:20088:5	trial	NN	O	O
are	SAPHRIS.xml:S3:20094:3	are	VBP	O	O
presented	SAPHRIS.xml:S3:20098:9	present	VBN	O	O
in	SAPHRIS.xml:S3:20108:2	in	IN	O	O
Table	SAPHRIS.xml:S3:20112:5	tabl	JJ	O	O
7	SAPHRIS.xml:S3:20118:1	7	CD	O	O
.	SAPHRIS.xml:S3:20121:1	.	.	O	O

To	SAPHRIS.xml:S3:20123:2	To	TO	O	O
adjust	SAPHRIS.xml:S3:20126:6	adjust	VB	O	O
for	SAPHRIS.xml:S3:20133:3	for	IN	O	O
normal	SAPHRIS.xml:S3:20137:6	normal	JJ	O	O
growth	SAPHRIS.xml:S3:20144:6	growth	NN	O	O
,	SAPHRIS.xml:S3:20150:1	,	,	O	O
z	SAPHRIS.xml:S3:20152:1	z	SYM	O	O
-	SAPHRIS.xml:S3:20153:1	-	:	O	O
scores	SAPHRIS.xml:S3:20154:6	score	NNS	O	O
were	SAPHRIS.xml:S3:20161:4	were	VBD	O	O
derived	SAPHRIS.xml:S3:20166:7	deriv	VBN	O	O
(	SAPHRIS.xml:S3:20174:1	(	(	O	O
measured	SAPHRIS.xml:S3:20175:8	measur	VBN	O	O
in	SAPHRIS.xml:S3:20184:2	in	IN	O	O
standard	SAPHRIS.xml:S3:20187:8	standard	JJ	O	O
deviations	SAPHRIS.xml:S3:20196:10	deviat	NNS	O	O
[	SAPHRIS.xml:S3:20207:1	[	VBP	O	O
SD	SAPHRIS.xml:S3:20208:2	SD	NNP	O	O
])	SAPHRIS.xml:S3:20210:2	])	NNP	O	O
,	SAPHRIS.xml:S3:20212:1	,	,	O	O
which	SAPHRIS.xml:S3:20214:5	which	WDT	O	O
normalize	SAPHRIS.xml:S3:20220:9	normal	VBP	O	O
for	SAPHRIS.xml:S3:20230:3	for	IN	O	O
the	SAPHRIS.xml:S3:20234:3	the	DT	O	O
natural	SAPHRIS.xml:S3:20238:7	natur	JJ	O	O
growth	SAPHRIS.xml:S3:20246:6	growth	NN	O	O
of	SAPHRIS.xml:S3:20253:2	of	IN	O	O
pediatric	SAPHRIS.xml:S3:20256:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S3:20266:8	patient	NNS	O	O
by	SAPHRIS.xml:S3:20275:2	by	IN	O	O
comparisons	SAPHRIS.xml:S3:20278:11	comparison	NNS	O	O
to	SAPHRIS.xml:S3:20290:2	to	TO	O	O
age	SAPHRIS.xml:S3:20293:3	age	NN	O	O
-	SAPHRIS.xml:S3:20296:1	-	:	O	O
and	SAPHRIS.xml:S3:20298:3	and	CC	O	O
sex	SAPHRIS.xml:S3:20302:3	sex	NN	O	O
-	SAPHRIS.xml:S3:20305:1	-	:	O	O
matched	SAPHRIS.xml:S3:20306:7	match	VBN	O	O
population	SAPHRIS.xml:S3:20314:10	popul	NN	O	O
standards	SAPHRIS.xml:S3:20325:9	standard	NNS	O	O
.	SAPHRIS.xml:S3:20334:1	.	.	O	O

The	SAPHRIS.xml:S3:20344:3	the	DT	O	O

distance	SAPHRIS.xml:S3:20348:8	distanc	NN	O	O
of	SAPHRIS.xml:S3:20357:2	of	IN	O	O
a	SAPHRIS.xml:S3:20360:1	a	DT	O	O
z	SAPHRIS.xml:S3:20362:1	z	NN	O	O
-	SAPHRIS.xml:S3:20363:1	-	:	O	O
score	SAPHRIS.xml:S3:20364:5	score	NN	O	O
from	SAPHRIS.xml:S3:20370:4	from	IN	O	O
0	SAPHRIS.xml:S3:20375:1	0	CD	O	O
represents	SAPHRIS.xml:S3:20377:10	repres	VBZ	O	O
the	SAPHRIS.xml:S3:20388:3	the	DT	O	O
distance	SAPHRIS.xml:S3:20392:8	distanc	NN	O	O
of	SAPHRIS.xml:S3:20401:2	of	IN	O	O
a	SAPHRIS.xml:S3:20404:1	a	DT	O	O
percentile	SAPHRIS.xml:S3:20406:10	percentil	NN	O	O
from	SAPHRIS.xml:S3:20417:4	from	IN	O	O
the	SAPHRIS.xml:S3:20422:3	the	DT	O	O
median	SAPHRIS.xml:S3:20426:6	median	NN	O	O
,	SAPHRIS.xml:S3:20432:1	,	,	O	O
measured	SAPHRIS.xml:S3:20434:8	measur	VBN	O	O
in	SAPHRIS.xml:S3:20443:2	in	IN	O	O
standard	SAPHRIS.xml:S3:20446:8	standard	JJ	O	O
deviations	SAPHRIS.xml:S3:20455:10	deviat	NNS	O	O
(	SAPHRIS.xml:S3:20466:1	(	(	O	O
SD	SAPHRIS.xml:S3:20467:2	SD	NNP	O	O
)	SAPHRIS.xml:S3:20469:1	)	)	O	O
.	SAPHRIS.xml:S3:20470:1	.	.	O	O

After	SAPHRIS.xml:S3:20472:5	after	IN	O	O
adjusting	SAPHRIS.xml:S3:20478:9	adjust	VBG	O	O
for	SAPHRIS.xml:S3:20488:3	for	IN	O	O
age	SAPHRIS.xml:S3:20492:3	age	NN	O	O
and	SAPHRIS.xml:S3:20496:3	and	CC	O	O
sex	SAPHRIS.xml:S3:20500:3	sex	NN	O	O
,	SAPHRIS.xml:S3:20503:1	,	,	O	O
the	SAPHRIS.xml:S3:20505:3	the	DT	O	O
mean	SAPHRIS.xml:S3:20509:4	mean	JJ	O	O
change	SAPHRIS.xml:S3:20514:6	chang	NN	O	O
from	SAPHRIS.xml:S3:20521:4	from	IN	O	O
baseline	SAPHRIS.xml:S3:20526:8	baselin	NN	O	O
to	SAPHRIS.xml:S3:20535:2	to	TO	O	O
endpoint	SAPHRIS.xml:S3:20538:8	endpoint	VB	O	O
in	SAPHRIS.xml:S3:20547:2	in	IN	O	O
weight	SAPHRIS.xml:S3:20550:6	weight	NN	O	O
z	SAPHRIS.xml:S3:20557:1	z	SYM	O	O
-	SAPHRIS.xml:S3:20558:1	-	:	O	O
score	SAPHRIS.xml:S3:20559:5	score	NN	O	O
for	SAPHRIS.xml:S3:20565:3	for	IN	O	O
SAPHRS	SAPHRIS.xml:S3:20569:6	saphr	NNP	O	O
2.5	SAPHRIS.xml:S3:20576:3	2.5	CD	O	O
mg	SAPHRIS.xml:S3:20580:2	mg	NN	O	O
,	SAPHRIS.xml:S3:20582:1	,	,	O	O
5	SAPHRIS.xml:S3:20584:1	5	CD	O	O
mg	SAPHRIS.xml:S3:20586:2	mg	NN	O	O
,	SAPHRIS.xml:S3:20588:1	,	,	O	O
and	SAPHRIS.xml:S3:20590:3	and	CC	O	O
10	SAPHRIS.xml:S3:20594:2	10	CD	O	O
mg	SAPHRIS.xml:S3:20597:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:20600:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:20606:5	daili	RB	O	O
,	SAPHRIS.xml:S3:20611:1	,	,	O	O
was	SAPHRIS.xml:S3:20613:3	wa	VBD	O	O
0.11	SAPHRIS.xml:S3:20617:4	0.11	CD	O	O
,	SAPHRIS.xml:S3:20621:1	,	,	O	O
0.08	SAPHRIS.xml:S3:20623:4	0.08	CD	O	O
and	SAPHRIS.xml:S3:20628:3	and	CC	O	O
0.09	SAPHRIS.xml:S3:20632:4	0.09	CD	O	O
SD	SAPHRIS.xml:S3:20637:2	SD	NNP	O	O
versus	SAPHRIS.xml:S3:20640:6	versu	NN	O	O
0.02	SAPHRIS.xml:S3:20647:4	0.02	CD	O	O
SD	SAPHRIS.xml:S3:20652:2	SD	NNP	O	O
for	SAPHRIS.xml:S3:20655:3	for	IN	O	O
placebo	SAPHRIS.xml:S3:20659:7	placebo	NN	O	O
,	SAPHRIS.xml:S3:20666:1	,	,	O	O
respectively	SAPHRIS.xml:S3:20668:12	respect	RB	O	O
.	SAPHRIS.xml:S3:20680:1	.	.	O	O

When	SAPHRIS.xml:S3:20690:4	when	WRB	O	O
treating	SAPHRIS.xml:S3:20695:8	treat	VBG	O	O
pediatric	SAPHRIS.xml:S3:20704:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S3:20714:8	patient	NNS	O	O
,	SAPHRIS.xml:S3:20722:1	,	,	O	O
weight	SAPHRIS.xml:S3:20724:6	weight	VBD	O	O
gain	SAPHRIS.xml:S3:20731:4	gain	NN	O	O
should	SAPHRIS.xml:S3:20736:6	should	MD	O	O
be	SAPHRIS.xml:S3:20743:2	be	VB	O	O
monitored	SAPHRIS.xml:S3:20746:9	monitor	VBN	O	O
and	SAPHRIS.xml:S3:20756:3	and	CC	O	O
assessed	SAPHRIS.xml:S3:20760:8	assess	VBN	O	O
against	SAPHRIS.xml:S3:20769:7	against	IN	O	O
that	SAPHRIS.xml:S3:20777:4	that	DT	O	O
expected	SAPHRIS.xml:S3:20782:8	expect	VBD	O	O
for	SAPHRIS.xml:S3:20791:3	for	IN	O	O
normal	SAPHRIS.xml:S3:20795:6	normal	JJ	O	O
growth	SAPHRIS.xml:S3:20802:6	growth	NN	O	O
.	SAPHRIS.xml:S3:20808:1	.	.	O	O

Table	SAPHRIS.xml:S3:20814:5	tabl	JJ	O	O
7	SAPHRIS.xml:S3:20820:1	7	CD	O	O
:	SAPHRIS.xml:S3:20821:1	:	:	O	O
Change	SAPHRIS.xml:S3:20823:6	chang	NN	O	O
in	SAPHRIS.xml:S3:20830:2	in	IN	O	O
Body	SAPHRIS.xml:S3:20833:4	bodi	NNP	O	O
Weight	SAPHRIS.xml:S3:20838:6	weight	NNP	O	O
in	SAPHRIS.xml:S3:20845:2	in	IN	O	O
Pediatric	SAPHRIS.xml:S3:20848:9	pediatr	NNP	O	O
Subjects	SAPHRIS.xml:S3:20858:8	subject	NNP	O	O
from	SAPHRIS.xml:S3:20867:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:20872:8	baselin	NNP	O	O

N	SAPHRIS.xml:S3:20884:1	N	NNP	O	O
Number	SAPHRIS.xml:S3:20889:6	number	NNP	O	O
of	SAPHRIS.xml:S3:20896:2	of	IN	O	O
subjects	SAPHRIS.xml:S3:20899:8	subject	NNS	O	O
who	SAPHRIS.xml:S3:20908:3	who	WP	O	O
had	SAPHRIS.xml:S3:20912:3	had	VBD	O	O
assessments	SAPHRIS.xml:S3:20916:11	assess	NNS	O	O
at	SAPHRIS.xml:S3:20928:2	at	IN	O	O
both	SAPHRIS.xml:S3:20931:4	both	DT	O	O
Baseline	SAPHRIS.xml:S3:20936:8	baselin	NNP	O	O
and	SAPHRIS.xml:S3:20945:3	and	CC	O	O
Endpoint	SAPHRIS.xml:S3:20949:8	endpoint	NNP	O	O
.	SAPHRIS.xml:S3:20957:1	.	.	O	O

Bipolar	SAPHRIS.xml:S3:20985:7	bipolar	JJ	O	O

I	SAPHRIS.xml:S3:20993:1	I	PRP	O	O
Disorder	SAPHRIS.xml:S3:20995:8	disord	NNP	O	O
(	SAPHRIS.xml:S3:21004:1	(	(	O	O
3	SAPHRIS.xml:S3:21005:1	3	CD	O	O
-	SAPHRIS.xml:S3:21006:1	-	:	O	O
weeks	SAPHRIS.xml:S3:21007:5	week	NNS	O	O
)	SAPHRIS.xml:S3:21012:1	)	)	O	O

Placebo	SAPHRIS.xml:S3:21018:7	placebo	NNP	O	O
SAPHRIS2	SAPHRIS.xml:S3:21036:8	saphris2	NNP	O	O
.	SAPHRIS.xml:S3:21044:1	.	.	O	O
5	SAPHRIS.xml:S3:21045:1	5	CD	O	O
mgtwice	SAPHRIS.xml:S3:21047:7	mgtwice	JJ	O	O
daily	SAPHRIS.xml:S3:21055:5	daili	RB	O	O
SAPHRIS5	SAPHRIS.xml:S3:21062:8	saphris5	NNP	O	O
mgtwice	SAPHRIS.xml:S3:21071:7	mgtwice	NN	O	O
daily	SAPHRIS.xml:S3:21079:5	daili	RB	O	O
SAPHRIS10	SAPHRIS.xml:S3:21086:9	saphris10	NNP	O	O
mgtwice	SAPHRIS.xml:S3:21096:7	mgtwice	NN	O	O
daily	SAPHRIS.xml:S3:21104:5	daili	RB	O	O

Change	SAPHRIS.xml:S3:21114:6	chang	NN	O	O
from	SAPHRIS.xml:S3:21121:4	from	IN	O	O
Baseline	SAPHRIS.xml:S3:21126:8	baselin	NNP	O	O
(	SAPHRIS.xml:S3:21135:1	(	(	O	O
kg	SAPHRIS.xml:S3:21136:2	kg	NN	O	O
)	SAPHRIS.xml:S3:21138:1	)	)	O	O
(	SAPHRIS.xml:S3:21140:1	(	(	O	O
N	SAPHRIS.xml:S3:21141:1	N	NNP	O	O
)	SAPHRIS.xml:S3:21143:1	)	)	O	O
0.5	SAPHRIS.xml:S3:21146:3	0.5	CD	O	O
(	SAPHRIS.xml:S3:21149:1	(	(	O	O
89	SAPHRIS.xml:S3:21150:2	89	CD	O	O
)	SAPHRIS.xml:S3:21152:1	)	)	O	O
1.7	SAPHRIS.xml:S3:21167:3	1.7	CD	O	O
(	SAPHRIS.xml:S3:21170:1	(	(	O	O
92	SAPHRIS.xml:S3:21171:2	92	CD	O	O
)	SAPHRIS.xml:S3:21173:1	)	)	O	O
1.6	SAPHRIS.xml:S3:21190:3	1.6	CD	O	O
(	SAPHRIS.xml:S3:21193:1	(	(	O	O
90	SAPHRIS.xml:S3:21194:2	90	CD	O	O
)	SAPHRIS.xml:S3:21196:1	)	)	O	O
1.4	SAPHRIS.xml:S3:21212:3	1.4	CD	O	O
(	SAPHRIS.xml:S3:21215:1	(	(	O	O
87	SAPHRIS.xml:S3:21216:2	87	CD	O	O
)	SAPHRIS.xml:S3:21218:1	)	)	O	O

Proportion	SAPHRIS.xml:S3:21256:10	proport	NN	O	O
of	SAPHRIS.xml:S3:21267:2	of	IN	O	O
Subjects	SAPHRIS.xml:S3:21270:8	subject	NNS	O	O
with	SAPHRIS.xml:S3:21279:4	with	IN	O	O
a	SAPHRIS.xml:S3:21284:1	a	DT	O	O
7%	SAPHRIS.xml:S3:21288:2	7%	CD	O	O
Increase	SAPHRIS.xml:S3:21291:8	increas	NNP	B-AdverseReaction	O
in	SAPHRIS.xml:S3:21300:2	in	IN	I-AdverseReaction	O
Body	SAPHRIS.xml:S3:21303:4	bodi	NNP	I-AdverseReaction	O
Weight	SAPHRIS.xml:S3:21308:6	weight	NNP	I-AdverseReaction	O

with	SAPHRIS.xml:S3:21321:4	with	IN	O	O
7%	SAPHRIS.xml:S3:21328:2	7%	CD	O	O
increase	SAPHRIS.xml:S3:21331:8	increas	NN	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S3:21340:2	in	IN	I-AdverseReaction	I-AdverseReaction
body	SAPHRIS.xml:S3:21343:4	bodi	NN	I-AdverseReaction	I-AdverseReaction
weight	SAPHRIS.xml:S3:21348:6	weight	VBD	I-AdverseReaction	I-AdverseReaction
1.1%	SAPHRIS.xml:S3:21356:4	1.1%	CD	O	O
12.0%	SAPHRIS.xml:S3:21377:5	12.0%	CD	O	O
8.9%	SAPHRIS.xml:S3:21400:4	8.9%	CD	O	O
8.0%	SAPHRIS.xml:S3:21422:4	8.0%	CD	O	O

5.6	SAPHRIS.xml:S3:21464:3	5.6	CD	O	O
Hypersensitivity	SAPHRIS.xml:S3:21468:16	hypersensit	NNP	O	O
Reactions	SAPHRIS.xml:S3:21485:9	reaction	NNP	O	O

Hypersensitivity	SAPHRIS.xml:S3:21502:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	SAPHRIS.xml:S3:21519:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
have	SAPHRIS.xml:S3:21529:4	have	VBP	O	O
been	SAPHRIS.xml:S3:21534:4	been	VBN	O	O
observed	SAPHRIS.xml:S3:21539:8	observ	VBN	O	O
in	SAPHRIS.xml:S3:21548:2	in	IN	O	O
patients	SAPHRIS.xml:S3:21551:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:21560:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:21568:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:21573:7	saphri	NNP	O	O
.	SAPHRIS.xml:S3:21580:1	.	.	O	O

In	SAPHRIS.xml:S3:21582:2	In	IN	O	O
several	SAPHRIS.xml:S3:21585:7	sever	JJ	O	O
cases	SAPHRIS.xml:S3:21593:5	case	NNS	O	O
,	SAPHRIS.xml:S3:21598:1	,	,	O	O
these	SAPHRIS.xml:S3:21600:5	these	DT	O	O
reactions	SAPHRIS.xml:S3:21606:9	reaction	NNS	O	O
occurred	SAPHRIS.xml:S3:21616:8	occur	VBD	O	O
after	SAPHRIS.xml:S3:21625:5	after	IN	O	O
the	SAPHRIS.xml:S3:21631:3	the	DT	O	O
first	SAPHRIS.xml:S3:21635:5	first	JJ	O	O
dose	SAPHRIS.xml:S3:21641:4	dose	NN	O	O
.	SAPHRIS.xml:S3:21645:1	.	.	O	O

These	SAPHRIS.xml:S3:21647:5	these	DT	O	O
hypersensitivity	SAPHRIS.xml:S3:21653:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
reactions	SAPHRIS.xml:S3:21670:9	reaction	NNS	I-AdverseReaction	O
included	SAPHRIS.xml:S3:21680:8	includ	VBD	O	O
:	SAPHRIS.xml:S3:21688:1	:	:	O	O
anaphylaxis	SAPHRIS.xml:S3:21690:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:21701:1	,	,	O	O
angioedema	SAPHRIS.xml:S3:21703:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:21713:1	,	,	O	O
hypotension	SAPHRIS.xml:S3:21715:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:21726:1	,	,	O	O
tachycardia	SAPHRIS.xml:S3:21728:11	tachycardia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:21739:1	,	,	O	O
swollen	SAPHRIS.xml:S3:21741:7	swollen	JJ	B-AdverseReaction	B-AdverseReaction
tongue	SAPHRIS.xml:S3:21749:6	tongu	NN	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S3:21755:1	,	,	O	O
dyspnea	SAPHRIS.xml:S3:21757:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:21764:1	,	,	O	O
wheezing	SAPHRIS.xml:S3:21766:8	wheez	VBG	B-AdverseReaction	B-AdverseReaction
and	SAPHRIS.xml:S3:21775:3	and	CC	O	O
rash	SAPHRIS.xml:S3:21779:4	rash	NN	B-AdverseReaction	B-AdverseReaction
.	SAPHRIS.xml:S3:21783:1	.	.	O	O

5.7	SAPHRIS.xml:S3:21795:3	5.7	CD	O	O
Orthostatic	SAPHRIS.xml:S3:21799:11	orthostat	JJ	O	O
Hypotension	SAPHRIS.xml:S3:21811:11	hypotens	NNP	O	O
,	SAPHRIS.xml:S3:21822:1	,	,	O	O
Syncope	SAPHRIS.xml:S3:21824:7	syncop	NNP	O	O
,	SAPHRIS.xml:S3:21831:1	,	,	O	O
and	SAPHRIS.xml:S3:21833:3	and	CC	O	O
Other	SAPHRIS.xml:S3:21837:5	other	JJ	O	O
Hemodynamic	SAPHRIS.xml:S3:21843:11	hemodynam	NNP	O	O
Effects	SAPHRIS.xml:S3:21855:7	effect	NNS	O	O

SAPHRIS	SAPHRIS.xml:S3:21870:7	saphri	NNP	O	O
may	SAPHRIS.xml:S3:21878:3	may	MD	O	O
induce	SAPHRIS.xml:S3:21882:6	induc	VB	O	O
orthostatic	SAPHRIS.xml:S3:21889:11	orthostat	JJ	B-AdverseReaction	O
hypotension	SAPHRIS.xml:S3:21901:11	hypotens	NN	I-AdverseReaction	O
and	SAPHRIS.xml:S3:21913:3	and	CC	O	O
syncope	SAPHRIS.xml:S3:21917:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S3:21925:2	in	IN	O	O
some	SAPHRIS.xml:S3:21928:4	some	DT	O	O
patients	SAPHRIS.xml:S3:21933:8	patient	NNS	O	O
,	SAPHRIS.xml:S3:21941:1	,	,	O	O
especially	SAPHRIS.xml:S3:21943:10	especi	RB	O	O
early	SAPHRIS.xml:S3:21954:5	earli	JJ	O	O
in	SAPHRIS.xml:S3:21960:2	in	IN	O	O
treatment	SAPHRIS.xml:S3:21963:9	treatment	NN	O	O
,	SAPHRIS.xml:S3:21972:1	,	,	O	O
because	SAPHRIS.xml:S3:21974:7	becaus	IN	O	O
of	SAPHRIS.xml:S3:21982:2	of	IN	O	O
its	SAPHRIS.xml:S3:21985:3	it	PRP$	O	O
alpha1	SAPHRIS.xml:S3:21989:6	alpha1	JJ	O	O
-	SAPHRIS.xml:S3:21995:1	-	:	O	O
adrenergic	SAPHRIS.xml:S3:21996:10	adrenerg	JJ	O	O
antagonist	SAPHRIS.xml:S3:22007:10	antagonist	NN	O	O
activity	SAPHRIS.xml:S3:22018:8	activ	NN	O	O
.	SAPHRIS.xml:S3:22026:1	.	.	O	O

In	SAPHRIS.xml:S3:22028:2	In	IN	O	O
short	SAPHRIS.xml:S3:22031:5	short	JJ	O	O
-	SAPHRIS.xml:S3:22036:1	-	:	O	O
term	SAPHRIS.xml:S3:22037:4	term	NN	O	O
schizophrenia	SAPHRIS.xml:S3:22042:13	schizophrenia	NN	O	O
adult	SAPHRIS.xml:S3:22056:5	adult	NN	O	O
trials	SAPHRIS.xml:S3:22062:6	trial	NNS	O	O
,	SAPHRIS.xml:S3:22068:1	,	,	O	O
syncope	SAPHRIS.xml:S3:22070:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
was	SAPHRIS.xml:S3:22078:3	wa	VBD	O	O
reported	SAPHRIS.xml:S3:22082:8	report	VBN	O	O
in	SAPHRIS.xml:S3:22091:2	in	IN	O	O
0.2%	SAPHRIS.xml:S3:22094:4	0.2%	CD	O	O
(	SAPHRIS.xml:S3:22099:1	(	(	O	O
1	SAPHRIS.xml:S3:22100:1	1	CD	O	O
572	SAPHRIS.xml:S3:22102:3	572	CD	O	O
)	SAPHRIS.xml:S3:22105:1	)	)	O	O
of	SAPHRIS.xml:S3:22107:2	of	IN	O	O
patients	SAPHRIS.xml:S3:22110:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:22119:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:22127:4	with	IN	O	O
therapeutic	SAPHRIS.xml:S3:22132:11	therapeut	JJ	O	O
doses	SAPHRIS.xml:S3:22144:5	dose	NNS	O	O
(	SAPHRIS.xml:S3:22150:1	(	(	O	O
5	SAPHRIS.xml:S3:22151:1	5	CD	O	O
mg	SAPHRIS.xml:S3:22153:2	mg	NN	O	O
or	SAPHRIS.xml:S3:22156:2	or	CC	O	O
10	SAPHRIS.xml:S3:22159:2	10	CD	O	O
mg	SAPHRIS.xml:S3:22162:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:22165:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:22171:5	daili	RB	O	O
)	SAPHRIS.xml:S3:22176:1	)	)	O	O
of	SAPHRIS.xml:S3:22178:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:22181:7	saphri	NNP	O	O
,	SAPHRIS.xml:S3:22188:1	,	,	O	O
compared	SAPHRIS.xml:S3:22190:8	compar	VBN	O	O
to	SAPHRIS.xml:S3:22199:2	to	TO	O	O
0.3%	SAPHRIS.xml:S3:22202:4	0.3%	CD	O	O
(	SAPHRIS.xml:S3:22207:1	(	(	O	O
1	SAPHRIS.xml:S3:22208:1	1	CD	O	O
378	SAPHRIS.xml:S3:22210:3	378	CD	O	O
)	SAPHRIS.xml:S3:22213:1	)	)	O	O
of	SAPHRIS.xml:S3:22215:2	of	IN	O	O
patients	SAPHRIS.xml:S3:22218:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:22227:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:22235:4	with	IN	O	O
placebo	SAPHRIS.xml:S3:22240:7	placebo	NN	O	O
.	SAPHRIS.xml:S3:22247:1	.	.	O	O

In	SAPHRIS.xml:S3:22249:2	In	IN	O	O
short	SAPHRIS.xml:S3:22252:5	short	JJ	O	O
-	SAPHRIS.xml:S3:22257:1	-	:	O	O
term	SAPHRIS.xml:S3:22258:4	term	NN	O	O
bipolar	SAPHRIS.xml:S3:22263:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:22271:5	mania	NN	O	O
adult	SAPHRIS.xml:S3:22277:5	adult	NN	O	O
trials	SAPHRIS.xml:S3:22283:6	trial	NNS	O	O
,	SAPHRIS.xml:S3:22289:1	,	,	O	O
syncope	SAPHRIS.xml:S3:22291:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
was	SAPHRIS.xml:S3:22299:3	wa	VBD	O	O
reported	SAPHRIS.xml:S3:22303:8	report	VBN	O	O
in	SAPHRIS.xml:S3:22312:2	in	IN	O	O
0.3%	SAPHRIS.xml:S3:22315:4	0.3%	CD	O	O
(	SAPHRIS.xml:S3:22320:1	(	(	O	O
1	SAPHRIS.xml:S3:22321:1	1	CD	O	O
379	SAPHRIS.xml:S3:22323:3	379	CD	O	O
)	SAPHRIS.xml:S3:22326:1	)	)	O	O
of	SAPHRIS.xml:S3:22328:2	of	IN	O	O
patients	SAPHRIS.xml:S3:22331:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:22340:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:22348:4	with	IN	O	O
therapeutic	SAPHRIS.xml:S3:22353:11	therapeut	JJ	O	O
doses	SAPHRIS.xml:S3:22365:5	dose	NNS	O	O
(	SAPHRIS.xml:S3:22371:1	(	(	O	O
5	SAPHRIS.xml:S3:22372:1	5	CD	O	O
mg	SAPHRIS.xml:S3:22374:2	mg	NN	O	O
or	SAPHRIS.xml:S3:22377:2	or	CC	O	O
10	SAPHRIS.xml:S3:22380:2	10	CD	O	O
mg	SAPHRIS.xml:S3:22383:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:22386:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:22392:5	daili	RB	O	O
)	SAPHRIS.xml:S3:22397:1	)	)	O	O
of	SAPHRIS.xml:S3:22399:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:22402:7	saphri	NNP	O	O
,	SAPHRIS.xml:S3:22409:1	,	,	O	O
compared	SAPHRIS.xml:S3:22411:8	compar	VBN	O	O
to	SAPHRIS.xml:S3:22420:2	to	TO	O	O
0%	SAPHRIS.xml:S3:22423:2	0%	CD	O	O
(	SAPHRIS.xml:S3:22426:1	(	(	O	O
0	SAPHRIS.xml:S3:22427:1	0	CD	O	O
203	SAPHRIS.xml:S3:22429:3	203	CD	O	O
)	SAPHRIS.xml:S3:22432:1	)	)	O	O
of	SAPHRIS.xml:S3:22434:2	of	IN	O	O
patients	SAPHRIS.xml:S3:22437:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:22446:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:22454:4	with	IN	O	O
placebo	SAPHRIS.xml:S3:22459:7	placebo	NN	O	O
.	SAPHRIS.xml:S3:22466:1	.	.	O	O

During	SAPHRIS.xml:S3:22468:6	dure	IN	O	O
adult	SAPHRIS.xml:S3:22475:5	adult	NN	O	O
pre	SAPHRIS.xml:S3:22481:3	pre	SYM	O	O
-	SAPHRIS.xml:S3:22484:1	-	:	O	O
marketing	SAPHRIS.xml:S3:22485:9	market	NN	O	O
clinical	SAPHRIS.xml:S3:22495:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S3:22504:6	trial	NNS	O	O
with	SAPHRIS.xml:S3:22511:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:22516:7	saphri	NNP	O	O
,	SAPHRIS.xml:S3:22523:1	,	,	O	O
including	SAPHRIS.xml:S3:22525:9	includ	VBG	O	O
long	SAPHRIS.xml:S3:22535:4	long	JJ	O	O
-	SAPHRIS.xml:S3:22539:1	-	:	O	O
term	SAPHRIS.xml:S3:22540:4	term	NN	O	O
trials	SAPHRIS.xml:S3:22545:6	trial	NNS	O	O
without	SAPHRIS.xml:S3:22552:7	without	IN	O	O
comparison	SAPHRIS.xml:S3:22560:10	comparison	NN	O	O
to	SAPHRIS.xml:S3:22571:2	to	TO	O	O
placebo	SAPHRIS.xml:S3:22574:7	placebo	VB	O	O
,	SAPHRIS.xml:S3:22581:1	,	,	O	O
syncope	SAPHRIS.xml:S3:22583:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
was	SAPHRIS.xml:S3:22591:3	wa	VBD	O	O
reported	SAPHRIS.xml:S3:22595:8	report	VBN	O	O
in	SAPHRIS.xml:S3:22604:2	in	IN	O	O
0.6%	SAPHRIS.xml:S3:22607:4	0.6%	CD	O	O
(	SAPHRIS.xml:S3:22612:1	(	(	O	O
11	SAPHRIS.xml:S3:22613:2	11	CD	O	O
1953	SAPHRIS.xml:S3:22616:4	1953	CD	O	O
)	SAPHRIS.xml:S3:22620:1	)	)	O	O
of	SAPHRIS.xml:S3:22622:2	of	IN	O	O
patients	SAPHRIS.xml:S3:22625:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:22634:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:22642:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:22647:7	saphri	NNP	O	O
.	SAPHRIS.xml:S3:22654:1	.	.	O	O

In	SAPHRIS.xml:S3:22656:2	In	IN	O	O
a	SAPHRIS.xml:S3:22659:1	a	DT	O	O
3	SAPHRIS.xml:S3:22661:1	3	CD	O	O
-	SAPHRIS.xml:S3:22662:1	-	:	O	O
week	SAPHRIS.xml:S3:22663:4	week	NN	O	O
,	SAPHRIS.xml:S3:22667:1	,	,	O	O
bipolar	SAPHRIS.xml:S3:22669:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:22677:5	mania	NN	O	O
pediatric	SAPHRIS.xml:S3:22683:9	pediatr	JJ	O	O
trial	SAPHRIS.xml:S3:22693:5	trial	NN	O	O
,	SAPHRIS.xml:S3:22698:1	,	,	O	O
syncope	SAPHRIS.xml:S3:22700:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
was	SAPHRIS.xml:S3:22708:3	wa	VBD	O	O
reported	SAPHRIS.xml:S3:22712:8	report	VBN	O	O
in	SAPHRIS.xml:S3:22721:2	in	IN	O	O
1%	SAPHRIS.xml:S3:22724:2	1%	CD	O	O
(	SAPHRIS.xml:S3:22727:1	(	(	O	O
1	SAPHRIS.xml:S3:22728:1	1	CD	O	O
104	SAPHRIS.xml:S3:22730:3	104	CD	O	O
)	SAPHRIS.xml:S3:22733:1	)	)	O	O
of	SAPHRIS.xml:S3:22735:2	of	IN	O	O
patients	SAPHRIS.xml:S3:22738:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:22747:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:22755:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:22760:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S3:22768:3	2.5	CD	O	O
mg	SAPHRIS.xml:S3:22772:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:22775:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:22781:5	daili	RB	O	O
,	SAPHRIS.xml:S3:22786:1	,	,	O	O
1%	SAPHRIS.xml:S3:22788:2	1%	CD	O	O
(	SAPHRIS.xml:S3:22791:1	(	(	O	O
1	SAPHRIS.xml:S3:22792:1	1	CD	O	O
99	SAPHRIS.xml:S3:22794:2	99	CD	O	O
)	SAPHRIS.xml:S3:22796:1	)	)	O	O
of	SAPHRIS.xml:S3:22798:2	of	IN	O	O
patients	SAPHRIS.xml:S3:22801:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:22810:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:22818:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:22823:7	saphri	NNP	O	O
5	SAPHRIS.xml:S3:22831:1	5	CD	O	O
mg	SAPHRIS.xml:S3:22833:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:22836:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:22842:5	daili	RB	O	O
,	SAPHRIS.xml:S3:22847:1	,	,	O	O
and	SAPHRIS.xml:S3:22849:3	and	CC	O	O
0%	SAPHRIS.xml:S3:22853:2	0%	CD	O	O
(	SAPHRIS.xml:S3:22856:1	(	(	O	O
0	SAPHRIS.xml:S3:22857:1	0	CD	O	O
99	SAPHRIS.xml:S3:22859:2	99	CD	O	O
)	SAPHRIS.xml:S3:22861:1	)	)	O	O
for	SAPHRIS.xml:S3:22863:3	for	IN	O	O
patients	SAPHRIS.xml:S3:22867:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:22876:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:22884:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:22889:7	saphri	NNP	O	O
10	SAPHRIS.xml:S3:22897:2	10	CD	O	O
mg	SAPHRIS.xml:S3:22900:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:22903:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:22909:5	daili	RB	O	O
compared	SAPHRIS.xml:S3:22915:8	compar	VBN	O	O
to	SAPHRIS.xml:S3:22924:2	to	TO	O	O
0%	SAPHRIS.xml:S3:22927:2	0%	CD	O	O
(	SAPHRIS.xml:S3:22930:1	(	(	O	O
0	SAPHRIS.xml:S3:22931:1	0	CD	O	O
101	SAPHRIS.xml:S3:22933:3	101	CD	O	O
)	SAPHRIS.xml:S3:22936:1	)	)	O	O
for	SAPHRIS.xml:S3:22938:3	for	IN	O	O
patients	SAPHRIS.xml:S3:22942:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:22951:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:22959:4	with	IN	O	O
placebo	SAPHRIS.xml:S3:22964:7	placebo	NN	O	O
.	SAPHRIS.xml:S3:22971:1	.	.	O	O

Patients	SAPHRIS.xml:S3:22981:8	patient	NNS	O	O
should	SAPHRIS.xml:S3:22990:6	should	MD	O	O
be	SAPHRIS.xml:S3:22997:2	be	VB	O	O
instructed	SAPHRIS.xml:S3:23000:10	instruct	VBN	O	O
about	SAPHRIS.xml:S3:23011:5	about	IN	O	O
non	SAPHRIS.xml:S3:23017:3	non	JJ	O	O
-	SAPHRIS.xml:S3:23020:1	-	:	O	O
pharmacologic	SAPHRIS.xml:S3:23021:13	pharmacolog	JJ	O	O
interventions	SAPHRIS.xml:S3:23035:13	intervent	NNS	O	O
that	SAPHRIS.xml:S3:23049:4	that	WDT	O	O
help	SAPHRIS.xml:S3:23054:4	help	VBP	O	O
to	SAPHRIS.xml:S3:23059:2	to	TO	O	O
reduce	SAPHRIS.xml:S3:23062:6	reduc	VB	O	O
the	SAPHRIS.xml:S3:23069:3	the	DT	O	O
occurrence	SAPHRIS.xml:S3:23073:10	occurr	NN	O	O
of	SAPHRIS.xml:S3:23084:2	of	IN	O	O
orthostatic	SAPHRIS.xml:S3:23087:11	orthostat	JJ	O	O
hypotension	SAPHRIS.xml:S3:23099:11	hypotens	NN	O	O
(	SAPHRIS.xml:S3:23111:1	(	(	O	O
e	SAPHRIS.xml:S3:23112:1	e	NN	O	O
.	SAPHRIS.xml:S3:23113:1	.	.	O	O
g	SAPHRIS.xml:S3:23114:1	g	NN	O	O
.	SAPHRIS.xml:S3:23115:1	.	.	O	O
,	SAPHRIS.xml:S3:23116:1	,	,	O	O
sitting	SAPHRIS.xml:S3:23118:7	sit	VBG	O	O
on	SAPHRIS.xml:S3:23126:2	on	IN	O	O
the	SAPHRIS.xml:S3:23129:3	the	DT	O	O
edge	SAPHRIS.xml:S3:23133:4	edg	NN	O	O
of	SAPHRIS.xml:S3:23138:2	of	IN	O	O
the	SAPHRIS.xml:S3:23141:3	the	DT	O	O
bed	SAPHRIS.xml:S3:23145:3	bed	NN	O	O
for	SAPHRIS.xml:S3:23149:3	for	IN	O	O
several	SAPHRIS.xml:S3:23153:7	sever	JJ	O	O
minutes	SAPHRIS.xml:S3:23161:7	minut	NNS	O	O
before	SAPHRIS.xml:S3:23169:6	befor	IN	O	O
attempting	SAPHRIS.xml:S3:23176:10	attempt	VBG	O	O
to	SAPHRIS.xml:S3:23187:2	to	TO	O	O
stand	SAPHRIS.xml:S3:23190:5	stand	VB	O	O
in	SAPHRIS.xml:S3:23196:2	in	IN	O	O
the	SAPHRIS.xml:S3:23199:3	the	DT	O	O
morning	SAPHRIS.xml:S3:23203:7	morn	NN	O	O
and	SAPHRIS.xml:S3:23211:3	and	CC	O	O
slowly	SAPHRIS.xml:S3:23215:6	slowli	RB	O	O
rising	SAPHRIS.xml:S3:23222:6	rise	VBG	O	O
from	SAPHRIS.xml:S3:23229:4	from	IN	O	O
a	SAPHRIS.xml:S3:23234:1	a	DT	O	O
seated	SAPHRIS.xml:S3:23236:6	seat	JJ	O	O
position	SAPHRIS.xml:S3:23243:8	posit	NN	O	O
)	SAPHRIS.xml:S3:23251:1	)	)	O	O
.	SAPHRIS.xml:S3:23252:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S3:23254:7	saphri	NNP	O	O
should	SAPHRIS.xml:S3:23262:6	should	MD	O	O
be	SAPHRIS.xml:S3:23269:2	be	VB	O	O
used	SAPHRIS.xml:S3:23272:4	use	VBN	O	O
with	SAPHRIS.xml:S3:23277:4	with	IN	O	O
caution	SAPHRIS.xml:S3:23282:7	caution	NN	O	O
in	SAPHRIS.xml:S3:23290:2	in	IN	O	O
(	SAPHRIS.xml:S3:23293:1	(	(	O	O
1	SAPHRIS.xml:S3:23294:1	1	CD	O	O
)	SAPHRIS.xml:S3:23295:1	)	)	O	O
patients	SAPHRIS.xml:S3:23297:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:23306:4	with	IN	O	O
known	SAPHRIS.xml:S3:23311:5	known	JJ	O	O
cardiovascular	SAPHRIS.xml:S3:23317:14	cardiovascular	JJ	O	O
disease	SAPHRIS.xml:S3:23332:7	diseas	NN	O	O
(	SAPHRIS.xml:S3:23340:1	(	(	O	O
history	SAPHRIS.xml:S3:23341:7	histori	NN	O	O
of	SAPHRIS.xml:S3:23349:2	of	IN	O	O
myocardial	SAPHRIS.xml:S3:23352:10	myocardi	JJ	O	O
infarction	SAPHRIS.xml:S3:23363:10	infarct	NN	O	O
or	SAPHRIS.xml:S3:23374:2	or	CC	O	O
ischemic	SAPHRIS.xml:S3:23377:8	ischem	JJ	O	O
heart	SAPHRIS.xml:S3:23386:5	heart	NN	O	O
disease	SAPHRIS.xml:S3:23392:7	diseas	NN	O	O
,	SAPHRIS.xml:S3:23399:1	,	,	O	O
heart	SAPHRIS.xml:S3:23401:5	heart	NN	O	B-AdverseReaction
failure	SAPHRIS.xml:S3:23407:7	failur	NN	O	I-AdverseReaction
or	SAPHRIS.xml:S3:23415:2	or	CC	O	O
conduction	SAPHRIS.xml:S3:23418:10	conduct	NN	O	O
abnormalities	SAPHRIS.xml:S3:23429:13	abnorm	NNS	O	O
)	SAPHRIS.xml:S3:23442:1	)	)	O	O
,	SAPHRIS.xml:S3:23443:1	,	,	O	O
cerebrovascular	SAPHRIS.xml:S3:23445:15	cerebrovascular	JJ	O	O
disease	SAPHRIS.xml:S3:23461:7	diseas	NN	O	O
,	SAPHRIS.xml:S3:23468:1	,	,	O	O
or	SAPHRIS.xml:S3:23470:2	or	CC	O	O
conditions	SAPHRIS.xml:S3:23473:10	condit	NNS	O	O
which	SAPHRIS.xml:S3:23484:5	which	WDT	O	O
would	SAPHRIS.xml:S3:23490:5	would	MD	O	O
predispose	SAPHRIS.xml:S3:23496:10	predispos	VB	O	O
patients	SAPHRIS.xml:S3:23507:8	patient	NNS	O	O
to	SAPHRIS.xml:S3:23516:2	to	TO	O	O
hypotension	SAPHRIS.xml:S3:23519:11	hypotens	NN	O	O
(	SAPHRIS.xml:S3:23531:1	(	(	O	O
dehydration	SAPHRIS.xml:S3:23532:11	dehydr	NN	O	O
,	SAPHRIS.xml:S3:23543:1	,	,	O	O
hypovolemia	SAPHRIS.xml:S3:23545:11	hypovolemia	NN	O	O
,	SAPHRIS.xml:S3:23556:1	,	,	O	O
and	SAPHRIS.xml:S3:23558:3	and	CC	O	O
treatment	SAPHRIS.xml:S3:23562:9	treatment	NN	O	O
with	SAPHRIS.xml:S3:23572:4	with	IN	O	O
antihypertensive	SAPHRIS.xml:S3:23577:16	antihypertens	JJ	O	O
medications	SAPHRIS.xml:S3:23594:11	medic	NNS	O	O
)	SAPHRIS.xml:S3:23605:1	)	)	O	O
;	SAPHRIS.xml:S3:23606:1	;	:	O	O
and	SAPHRIS.xml:S3:23608:3	and	CC	O	O
(	SAPHRIS.xml:S3:23612:1	(	(	O	O
2	SAPHRIS.xml:S3:23613:1	2	CD	O	O
)	SAPHRIS.xml:S3:23614:1	)	)	O	O
in	SAPHRIS.xml:S3:23616:2	in	IN	O	O
the	SAPHRIS.xml:S3:23619:3	the	DT	O	O
elderly	SAPHRIS.xml:S3:23623:7	elderli	JJ	O	O
.	SAPHRIS.xml:S3:23630:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S3:23632:7	saphri	NNP	O	O
should	SAPHRIS.xml:S3:23640:6	should	MD	O	O
be	SAPHRIS.xml:S3:23647:2	be	VB	O	O
used	SAPHRIS.xml:S3:23650:4	use	VBN	O	O
cautiously	SAPHRIS.xml:S3:23655:10	cautious	RB	O	O
when	SAPHRIS.xml:S3:23666:4	when	WRB	O	O
treating	SAPHRIS.xml:S3:23671:8	treat	VBG	O	O
patients	SAPHRIS.xml:S3:23680:8	patient	NNS	O	O
who	SAPHRIS.xml:S3:23689:3	who	WP	O	O
receive	SAPHRIS.xml:S3:23693:7	receiv	VBP	O	O
treatment	SAPHRIS.xml:S3:23701:9	treatment	NN	O	O
with	SAPHRIS.xml:S3:23711:4	with	IN	O	O
other	SAPHRIS.xml:S3:23716:5	other	JJ	O	O
drugs	SAPHRIS.xml:S3:23722:5	drug	NNS	O	O
that	SAPHRIS.xml:S3:23728:4	that	WDT	O	O
can	SAPHRIS.xml:S3:23733:3	can	MD	O	O
induce	SAPHRIS.xml:S3:23737:6	induc	VB	O	O
hypotension	SAPHRIS.xml:S3:23744:11	hypotens	NN	O	B-AdverseReaction
,	SAPHRIS.xml:S3:23755:1	,	,	O	O
bradycardia	SAPHRIS.xml:S3:23757:11	bradycardia	NN	O	B-AdverseReaction
,	SAPHRIS.xml:S3:23768:1	,	,	O	O
respiratory	SAPHRIS.xml:S3:23770:11	respiratori	NN	O	O
or	SAPHRIS.xml:S3:23782:2	or	CC	O	O
central	SAPHRIS.xml:S3:23785:7	central	JJ	O	O
nervous	SAPHRIS.xml:S3:23793:7	nervou	JJ	O	O
system	SAPHRIS.xml:S3:23801:6	system	NN	O	O
depression	SAPHRIS.xml:S3:23808:10	depress	NN	O	O
[	SAPHRIS.xml:S3:23820:1	[	NNP	O	O
see	SAPHRIS.xml:S3:23821:3	see	VBP	O	O
Drug	SAPHRIS.xml:S3:23825:4	drug	NNP	O	O
Interactions	SAPHRIS.xml:S3:23830:12	interact	NNP	O	O
(	SAPHRIS.xml:S3:23843:1	(	(	O	O
7.1	SAPHRIS.xml:S3:23844:3	7.1	CD	O	O
)]	SAPHRIS.xml:S3:23847:2	)]	NN	O	O
.	SAPHRIS.xml:S3:23851:1	.	.	O	O

Monitoring	SAPHRIS.xml:S3:23853:10	monitor	NN	O	O
of	SAPHRIS.xml:S3:23864:2	of	IN	O	O
orthostatic	SAPHRIS.xml:S3:23867:11	orthostat	JJ	O	O
vital	SAPHRIS.xml:S3:23879:5	vital	JJ	O	O
signs	SAPHRIS.xml:S3:23885:5	sign	NNS	O	O
should	SAPHRIS.xml:S3:23891:6	should	MD	O	O
be	SAPHRIS.xml:S3:23898:2	be	VB	O	O
considered	SAPHRIS.xml:S3:23901:10	consid	VBN	O	O
in	SAPHRIS.xml:S3:23912:2	in	IN	O	O
all	SAPHRIS.xml:S3:23915:3	all	DT	O	O
such	SAPHRIS.xml:S3:23919:4	such	JJ	O	O
patients	SAPHRIS.xml:S3:23924:8	patient	NNS	O	O
,	SAPHRIS.xml:S3:23932:1	,	,	O	O
and	SAPHRIS.xml:S3:23934:3	and	CC	O	O
a	SAPHRIS.xml:S3:23938:1	a	DT	O	O
dose	SAPHRIS.xml:S3:23940:4	dose	JJ	O	O
reduction	SAPHRIS.xml:S3:23945:9	reduct	NN	O	O
should	SAPHRIS.xml:S3:23955:6	should	MD	O	O
be	SAPHRIS.xml:S3:23962:2	be	VB	O	O
considered	SAPHRIS.xml:S3:23965:10	consid	VBN	O	O
if	SAPHRIS.xml:S3:23976:2	if	IN	O	O
hypotension	SAPHRIS.xml:S3:23979:11	hypotens	NN	O	O
occurs	SAPHRIS.xml:S3:23991:6	occur	VBZ	O	O
.	SAPHRIS.xml:S3:23997:1	.	.	O	O

5.8	SAPHRIS.xml:S3:24009:3	5.8	CD	O	O
Leukopenia	SAPHRIS.xml:S3:24013:10	leukopenia	NNP	O	O
,	SAPHRIS.xml:S3:24023:1	,	,	O	O
Neutropenia	SAPHRIS.xml:S3:24025:11	neutropenia	NNP	O	B-AdverseReaction
,	SAPHRIS.xml:S3:24036:1	,	,	O	O
and	SAPHRIS.xml:S3:24038:3	and	CC	O	O
Agranulocytosis	SAPHRIS.xml:S3:24042:15	agranulocytosi	NNP	O	O

In	SAPHRIS.xml:S3:24065:2	In	IN	O	O
clinical	SAPHRIS.xml:S3:24068:8	clinic	JJ	O	O
trial	SAPHRIS.xml:S3:24077:5	trial	NN	O	O
and	SAPHRIS.xml:S3:24083:3	and	CC	O	O
postmarketing	SAPHRIS.xml:S3:24087:13	postmarket	VBG	O	O
experience	SAPHRIS.xml:S3:24101:10	experi	NN	O	O
,	SAPHRIS.xml:S3:24111:1	,	,	O	O
leukopenia	SAPHRIS.xml:S3:24113:10	leukopenia	NN	B-AdverseReaction	B-AdverseReaction
and	SAPHRIS.xml:S3:24124:3	and	CC	O	O
neutropenia	SAPHRIS.xml:S3:24128:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction
have	SAPHRIS.xml:S3:24140:4	have	VBP	O	O
been	SAPHRIS.xml:S3:24145:4	been	VBN	O	O
reported	SAPHRIS.xml:S3:24150:8	report	VBN	O	O
temporally	SAPHRIS.xml:S3:24159:10	tempor	RB	O	O
related	SAPHRIS.xml:S3:24170:7	relat	VBN	O	O
to	SAPHRIS.xml:S3:24178:2	to	TO	O	O
antipsychotic	SAPHRIS.xml:S3:24181:13	antipsychot	JJ	O	O
agents	SAPHRIS.xml:S3:24195:6	agent	NNS	O	O
,	SAPHRIS.xml:S3:24201:1	,	,	O	O
including	SAPHRIS.xml:S3:24203:9	includ	VBG	O	O
SAPHRIS	SAPHRIS.xml:S3:24213:7	saphri	NNP	O	O
.	SAPHRIS.xml:S3:24220:1	.	.	O	O

Agranulocytosis	SAPHRIS.xml:S3:24222:15	agranulocytosi	NNP	B-AdverseReaction	B-AdverseReaction
(	SAPHRIS.xml:S3:24238:1	(	(	O	O
including	SAPHRIS.xml:S3:24239:9	includ	VBG	O	O
fatal	SAPHRIS.xml:S3:24249:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
cases	SAPHRIS.xml:S3:24255:5	case	NNS	O	O
)	SAPHRIS.xml:S3:24260:1	)	)	O	O
has	SAPHRIS.xml:S3:24262:3	ha	VBZ	O	O
been	SAPHRIS.xml:S3:24266:4	been	VBN	O	O
reported	SAPHRIS.xml:S3:24271:8	report	VBN	O	O
with	SAPHRIS.xml:S3:24280:4	with	IN	O	O
other	SAPHRIS.xml:S3:24285:5	other	JJ	O	O
agents	SAPHRIS.xml:S3:24291:6	agent	NNS	O	O
in	SAPHRIS.xml:S3:24298:2	in	IN	O	O
the	SAPHRIS.xml:S3:24301:3	the	DT	O	O
class	SAPHRIS.xml:S3:24305:5	class	NN	O	O
.	SAPHRIS.xml:S3:24310:1	.	.	O	O

Possible	SAPHRIS.xml:S3:24320:8	possibl	JJ	O	O
risk	SAPHRIS.xml:S3:24329:4	risk	NN	O	O
factors	SAPHRIS.xml:S3:24334:7	factor	NNS	O	O
for	SAPHRIS.xml:S3:24342:3	for	IN	O	O
leukopenia	SAPHRIS.xml:S3:24346:10	leukopenia	NN	O	B-AdverseReaction
neutropenia	SAPHRIS.xml:S3:24357:11	neutropenia	NN	O	B-AdverseReaction
include	SAPHRIS.xml:S3:24369:7	includ	VBP	O	O
pre	SAPHRIS.xml:S3:24377:3	pre	JJ	O	O
-	SAPHRIS.xml:S3:24380:1	-	:	O	O
existing	SAPHRIS.xml:S3:24381:8	exist	VBG	O	O
low	SAPHRIS.xml:S3:24390:3	low	JJ	O	O
white	SAPHRIS.xml:S3:24394:5	white	JJ	O	O
blood	SAPHRIS.xml:S3:24400:5	blood	NN	O	O
cell	SAPHRIS.xml:S3:24406:4	cell	NN	O	O
count	SAPHRIS.xml:S3:24411:5	count	NN	O	O
(	SAPHRIS.xml:S3:24417:1	(	(	O	O
WBC	SAPHRIS.xml:S3:24418:3	wbc	NNP	O	O
)	SAPHRIS.xml:S3:24421:1	)	)	O	O
absolute	SAPHRIS.xml:S3:24423:8	absolut	VBP	O	O
neutrophil	SAPHRIS.xml:S3:24432:10	neutrophil	JJ	O	O
count	SAPHRIS.xml:S3:24443:5	count	NN	O	O
(	SAPHRIS.xml:S3:24449:1	(	(	O	O
ANC	SAPHRIS.xml:S3:24450:3	anc	NNP	O	O
)	SAPHRIS.xml:S3:24453:1	)	)	O	O
and	SAPHRIS.xml:S3:24455:3	and	CC	O	O
history	SAPHRIS.xml:S3:24459:7	histori	NN	O	O
of	SAPHRIS.xml:S3:24467:2	of	IN	O	O
drug	SAPHRIS.xml:S3:24470:4	drug	NN	O	O
induced	SAPHRIS.xml:S3:24475:7	induc	VBN	O	O
leukopenia	SAPHRIS.xml:S3:24483:10	leukopenia	JJ	O	O
neutropenia	SAPHRIS.xml:S3:24494:11	neutropenia	NN	O	O
.	SAPHRIS.xml:S3:24505:1	.	.	O	O

In	SAPHRIS.xml:S3:24507:2	In	IN	O	O
patients	SAPHRIS.xml:S3:24510:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:24519:4	with	IN	O	O
a	SAPHRIS.xml:S3:24524:1	a	DT	O	O
pre	SAPHRIS.xml:S3:24526:3	pre	NN	O	O
-	SAPHRIS.xml:S3:24529:1	-	:	O	O
existing	SAPHRIS.xml:S3:24530:8	exist	VBG	O	O
low	SAPHRIS.xml:S3:24539:3	low	JJ	O	O
WBC	SAPHRIS.xml:S3:24543:3	wbc	NNP	O	O
ANC	SAPHRIS.xml:S3:24547:3	anc	NNP	O	O
or	SAPHRIS.xml:S3:24551:2	or	CC	O	O
drug	SAPHRIS.xml:S3:24554:4	drug	NN	O	O
-	SAPHRIS.xml:S3:24558:1	-	:	O	O
induced	SAPHRIS.xml:S3:24559:7	induc	VBN	O	O
leukopenia	SAPHRIS.xml:S3:24567:10	leukopenia	NN	O	B-AdverseReaction
neutropenia	SAPHRIS.xml:S3:24578:11	neutropenia	NN	O	B-AdverseReaction
,	SAPHRIS.xml:S3:24589:1	,	,	O	O
perform	SAPHRIS.xml:S3:24591:7	perform	VB	O	O
a	SAPHRIS.xml:S3:24599:1	a	DT	O	O
complete	SAPHRIS.xml:S3:24601:8	complet	JJ	O	O
blood	SAPHRIS.xml:S3:24610:5	blood	NN	O	O
count	SAPHRIS.xml:S3:24616:5	count	NN	O	O
(	SAPHRIS.xml:S3:24622:1	(	(	O	O
CBC	SAPHRIS.xml:S3:24623:3	cbc	NNP	O	O
)	SAPHRIS.xml:S3:24626:1	)	)	O	O
frequently	SAPHRIS.xml:S3:24628:10	frequent	RB	O	O
during	SAPHRIS.xml:S3:24639:6	dure	IN	O	O
the	SAPHRIS.xml:S3:24646:3	the	DT	O	O
first	SAPHRIS.xml:S3:24650:5	first	JJ	O	O
few	SAPHRIS.xml:S3:24656:3	few	JJ	O	O
months	SAPHRIS.xml:S3:24660:6	month	NNS	O	O
of	SAPHRIS.xml:S3:24667:2	of	IN	O	O
therapy	SAPHRIS.xml:S3:24670:7	therapi	NN	O	O
.	SAPHRIS.xml:S3:24677:1	.	.	O	O

In	SAPHRIS.xml:S3:24679:2	In	IN	O	O
such	SAPHRIS.xml:S3:24682:4	such	JJ	O	O
patients	SAPHRIS.xml:S3:24687:8	patient	NNS	O	O
,	SAPHRIS.xml:S3:24695:1	,	,	O	O
consider	SAPHRIS.xml:S3:24697:8	consid	VB	O	O
discontinuation	SAPHRIS.xml:S3:24706:15	discontinu	NN	O	O
of	SAPHRIS.xml:S3:24722:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:24725:7	saphri	NNP	O	O
at	SAPHRIS.xml:S3:24733:2	at	IN	O	O
the	SAPHRIS.xml:S3:24736:3	the	DT	O	O
first	SAPHRIS.xml:S3:24740:5	first	JJ	O	O
sign	SAPHRIS.xml:S3:24746:4	sign	NN	O	O
of	SAPHRIS.xml:S3:24751:2	of	IN	O	O
a	SAPHRIS.xml:S3:24754:1	a	DT	O	O
clinically	SAPHRIS.xml:S3:24756:10	clinic	RB	O	O
significant	SAPHRIS.xml:S3:24767:11	signific	JJ	O	O
decline	SAPHRIS.xml:S3:24779:7	declin	NN	O	O
in	SAPHRIS.xml:S3:24787:2	in	IN	O	O
WBC	SAPHRIS.xml:S3:24790:3	wbc	NNP	O	O
in	SAPHRIS.xml:S3:24794:2	in	IN	O	O
the	SAPHRIS.xml:S3:24797:3	the	DT	O	O
absence	SAPHRIS.xml:S3:24801:7	absenc	NN	O	O
of	SAPHRIS.xml:S3:24809:2	of	IN	O	O
other	SAPHRIS.xml:S3:24812:5	other	JJ	O	O
causative	SAPHRIS.xml:S3:24818:9	caus	JJ	O	O
factors	SAPHRIS.xml:S3:24828:7	factor	NNS	O	O
.	SAPHRIS.xml:S3:24835:1	.	.	O	O

Monitor	SAPHRIS.xml:S3:24845:7	monitor	NN	O	O
patients	SAPHRIS.xml:S3:24853:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:24862:4	with	IN	O	O
clinically	SAPHRIS.xml:S3:24867:10	clinic	RB	O	O
significant	SAPHRIS.xml:S3:24878:11	signific	JJ	O	O
neutropenia	SAPHRIS.xml:S3:24890:11	neutropenia	NN	O	O
for	SAPHRIS.xml:S3:24902:3	for	IN	O	O
fever	SAPHRIS.xml:S3:24906:5	fever	NN	O	O
or	SAPHRIS.xml:S3:24912:2	or	CC	O	O
other	SAPHRIS.xml:S3:24915:5	other	JJ	O	O
symptoms	SAPHRIS.xml:S3:24921:8	symptom	NNS	O	O
or	SAPHRIS.xml:S3:24930:2	or	CC	O	O
signs	SAPHRIS.xml:S3:24933:5	sign	NNS	O	O
of	SAPHRIS.xml:S3:24939:2	of	IN	O	O
infection	SAPHRIS.xml:S3:24942:9	infect	NN	O	O
and	SAPHRIS.xml:S3:24952:3	and	CC	O	O
treat	SAPHRIS.xml:S3:24956:5	treat	NN	O	O
promptly	SAPHRIS.xml:S3:24962:8	promptli	RB	O	O
if	SAPHRIS.xml:S3:24971:2	if	IN	O	O
such	SAPHRIS.xml:S3:24974:4	such	JJ	O	O
symptoms	SAPHRIS.xml:S3:24979:8	symptom	NNS	O	O
or	SAPHRIS.xml:S3:24988:2	or	CC	O	O
signs	SAPHRIS.xml:S3:24991:5	sign	NNS	O	O
occur	SAPHRIS.xml:S3:24997:5	occur	VBP	O	O
.	SAPHRIS.xml:S3:25002:1	.	.	O	O

Discontinue	SAPHRIS.xml:S3:25004:11	discontinu	NNP	O	O
SAPHRIS	SAPHRIS.xml:S3:25016:7	saphri	NNP	O	O
in	SAPHRIS.xml:S3:25024:2	in	IN	O	O
patients	SAPHRIS.xml:S3:25027:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:25036:4	with	IN	O	O
severe	SAPHRIS.xml:S3:25041:6	sever	JJ	O	O
neutropenia	SAPHRIS.xml:S3:25048:11	neutropenia	NN	O	O
(	SAPHRIS.xml:S3:25060:1	(	(	O	O
absolute	SAPHRIS.xml:S3:25061:8	absolut	JJ	O	O
neutrophil	SAPHRIS.xml:S3:25070:10	neutrophil	NN	O	O
count	SAPHRIS.xml:S3:25081:5	count	NN	O	O
1000	SAPHRIS.xml:S3:25088:4	1000	CD	O	O
mm	SAPHRIS.xml:S3:25093:2	mm	NN	O	O
3	SAPHRIS.xml:S3:25097:1	3	CD	O	O
)	SAPHRIS.xml:S3:25100:1	)	)	O	O
and	SAPHRIS.xml:S3:25102:3	and	CC	O	O
follow	SAPHRIS.xml:S3:25106:6	follow	VB	O	O
their	SAPHRIS.xml:S3:25113:5	their	PRP$	O	O
WBC	SAPHRIS.xml:S3:25119:3	wbc	NNP	O	O
until	SAPHRIS.xml:S3:25123:5	until	IN	O	O
recovery	SAPHRIS.xml:S3:25129:8	recoveri	NN	O	O
.	SAPHRIS.xml:S3:25137:1	.	.	O	O

5.9	SAPHRIS.xml:S3:25149:3	5.9	CD	O	O
QT	SAPHRIS.xml:S3:25153:2	QT	NNP	O	O
Prolongation	SAPHRIS.xml:S3:25156:12	prolong	NN	O	O

The	SAPHRIS.xml:S3:25176:3	the	DT	O	O
effects	SAPHRIS.xml:S3:25180:7	effect	NNS	O	O
of	SAPHRIS.xml:S3:25188:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:25191:7	saphri	NNP	O	O
on	SAPHRIS.xml:S3:25199:2	on	IN	O	O
the	SAPHRIS.xml:S3:25202:3	the	DT	O	O
QT	SAPHRIS.xml:S3:25206:2	QT	NNP	O	O
QTc	SAPHRIS.xml:S3:25209:3	qtc	NNP	O	O
interval	SAPHRIS.xml:S3:25213:8	interv	NN	O	O
were	SAPHRIS.xml:S3:25222:4	were	VBD	O	O
evaluated	SAPHRIS.xml:S3:25227:9	evalu	VBN	O	O
in	SAPHRIS.xml:S3:25237:2	in	IN	O	O
a	SAPHRIS.xml:S3:25240:1	a	DT	O	O
dedicated	SAPHRIS.xml:S3:25242:9	dedic	JJ	O	O
adult	SAPHRIS.xml:S3:25252:5	adult	NN	O	O
QT	SAPHRIS.xml:S3:25258:2	QT	NNP	O	O
study	SAPHRIS.xml:S3:25261:5	studi	NN	O	O
.	SAPHRIS.xml:S3:25266:1	.	.	O	O

This	SAPHRIS.xml:S3:25268:4	thi	DT	O	O
trial	SAPHRIS.xml:S3:25273:5	trial	NN	O	O
involved	SAPHRIS.xml:S3:25279:8	involv	VBD	O	O
SAPHRIS	SAPHRIS.xml:S3:25288:7	saphri	NNP	O	O
doses	SAPHRIS.xml:S3:25296:5	dose	NNS	O	O
of	SAPHRIS.xml:S3:25302:2	of	IN	O	O
5	SAPHRIS.xml:S3:25305:1	5	CD	O	O
mg	SAPHRIS.xml:S3:25307:2	mg	NNS	O	O
,	SAPHRIS.xml:S3:25309:1	,	,	O	O
10	SAPHRIS.xml:S3:25311:2	10	CD	O	O
mg	SAPHRIS.xml:S3:25314:2	mg	NN	O	O
,	SAPHRIS.xml:S3:25316:1	,	,	O	O
15	SAPHRIS.xml:S3:25318:2	15	CD	O	O
mg	SAPHRIS.xml:S3:25321:2	mg	NN	O	O
,	SAPHRIS.xml:S3:25323:1	,	,	O	O
and	SAPHRIS.xml:S3:25325:3	and	CC	O	O
20	SAPHRIS.xml:S3:25329:2	20	CD	O	O
mg	SAPHRIS.xml:S3:25332:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:25335:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:25341:5	daili	RB	O	O
,	SAPHRIS.xml:S3:25346:1	,	,	O	O
and	SAPHRIS.xml:S3:25348:3	and	CC	O	O
placebo	SAPHRIS.xml:S3:25352:7	placebo	NN	O	O
,	SAPHRIS.xml:S3:25359:1	,	,	O	O
and	SAPHRIS.xml:S3:25361:3	and	CC	O	O
was	SAPHRIS.xml:S3:25365:3	wa	VBD	O	O
conducted	SAPHRIS.xml:S3:25369:9	conduct	VBN	O	O
in	SAPHRIS.xml:S3:25379:2	in	IN	O	O
151	SAPHRIS.xml:S3:25382:3	151	CD	O	O
clinically	SAPHRIS.xml:S3:25386:10	clinic	RB	O	O
stable	SAPHRIS.xml:S3:25397:6	stabl	JJ	O	O
patients	SAPHRIS.xml:S3:25404:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:25413:4	with	IN	O	O
schizophrenia	SAPHRIS.xml:S3:25418:13	schizophrenia	NN	O	O
,	SAPHRIS.xml:S3:25431:1	,	,	O	O
with	SAPHRIS.xml:S3:25433:4	with	IN	O	O
electrocardiographic	SAPHRIS.xml:S3:25438:20	electrocardiograph	JJ	O	O
assessments	SAPHRIS.xml:S3:25459:11	assess	NNS	O	O
throughout	SAPHRIS.xml:S3:25471:10	throughout	IN	O	O
the	SAPHRIS.xml:S3:25482:3	the	DT	O	O
dosing	SAPHRIS.xml:S3:25486:6	dose	NN	O	O
interval	SAPHRIS.xml:S3:25493:8	interv	NN	O	O
at	SAPHRIS.xml:S3:25502:2	at	IN	O	O
baseline	SAPHRIS.xml:S3:25505:8	baselin	NN	O	O
and	SAPHRIS.xml:S3:25514:3	and	CC	O	O
steady	SAPHRIS.xml:S3:25518:6	steadi	JJ	O	O
state	SAPHRIS.xml:S3:25525:5	state	NN	O	O
.	SAPHRIS.xml:S3:25530:1	.	.	O	O

At	SAPHRIS.xml:S3:25532:2	At	IN	O	O
these	SAPHRIS.xml:S3:25535:5	these	DT	O	O
doses	SAPHRIS.xml:S3:25541:5	dose	NNS	O	O
,	SAPHRIS.xml:S3:25546:1	,	,	O	O
SAPHRIS	SAPHRIS.xml:S3:25548:7	saphri	NNP	O	O
was	SAPHRIS.xml:S3:25556:3	wa	VBD	O	O
associated	SAPHRIS.xml:S3:25560:10	associ	VBN	O	O
with	SAPHRIS.xml:S3:25571:4	with	IN	O	O
increases	SAPHRIS.xml:S3:25576:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S3:25586:2	in	IN	I-AdverseReaction	I-AdverseReaction
QTc	SAPHRIS.xml:S3:25589:3	qtc	NNP	I-AdverseReaction	I-AdverseReaction
interval	SAPHRIS.xml:S3:25593:8	interv	NN	I-AdverseReaction	I-AdverseReaction
ranging	SAPHRIS.xml:S3:25602:7	rang	VBG	O	O
from	SAPHRIS.xml:S3:25610:4	from	IN	O	O
2	SAPHRIS.xml:S3:25615:1	2	CD	O	O
to	SAPHRIS.xml:S3:25617:2	to	TO	O	O
5	SAPHRIS.xml:S3:25620:1	5	CD	O	O
msec	SAPHRIS.xml:S3:25622:4	msec	NNS	O	O
compared	SAPHRIS.xml:S3:25627:8	compar	VBN	O	O
to	SAPHRIS.xml:S3:25636:2	to	TO	O	O
placebo	SAPHRIS.xml:S3:25639:7	placebo	VB	O	O
.	SAPHRIS.xml:S3:25646:1	.	.	O	O

No	SAPHRIS.xml:S3:25648:2	No	DT	O	O
patients	SAPHRIS.xml:S3:25651:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:25660:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:25668:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:25673:7	saphri	NNP	O	O
experienced	SAPHRIS.xml:S3:25681:11	experienc	VBD	O	O
QTc	SAPHRIS.xml:S3:25693:3	qtc	NNP	B-AdverseReaction	B-AdverseReaction
increases	SAPHRIS.xml:S3:25697:9	increas	VBZ	I-AdverseReaction	I-AdverseReaction
60	SAPHRIS.xml:S3:25709:2	60	CD	O	O
msec	SAPHRIS.xml:S3:25712:4	msec	NN	O	O
from	SAPHRIS.xml:S3:25717:4	from	IN	O	O
baseline	SAPHRIS.xml:S3:25722:8	baselin	NN	O	O
measurements	SAPHRIS.xml:S3:25731:12	measur	NNS	O	O
,	SAPHRIS.xml:S3:25743:1	,	,	O	O
nor	SAPHRIS.xml:S3:25745:3	nor	CC	O	O
did	SAPHRIS.xml:S3:25749:3	did	VBD	O	O
any	SAPHRIS.xml:S3:25753:3	ani	DT	O	O
patient	SAPHRIS.xml:S3:25757:7	patient	NN	O	O
experience	SAPHRIS.xml:S3:25765:10	experi	NN	O	O
a	SAPHRIS.xml:S3:25776:1	a	DT	O	O
QTc	SAPHRIS.xml:S3:25778:3	qtc	NNP	B-AdverseReaction	O
of	SAPHRIS.xml:S3:25782:2	of	IN	I-AdverseReaction	O
500	SAPHRIS.xml:S3:25787:3	500	CD	I-AdverseReaction	O
msec	SAPHRIS.xml:S3:25791:4	msec	NN	I-AdverseReaction	O
.	SAPHRIS.xml:S3:25795:1	.	.	O	O

Electrocardiogram	SAPHRIS.xml:S3:25805:17	electrocardiogram	NNP	O	O
(	SAPHRIS.xml:S3:25823:1	(	(	O	O
ECG	SAPHRIS.xml:S3:25824:3	ecg	NNP	O	O
)	SAPHRIS.xml:S3:25827:1	)	)	O	O
measurements	SAPHRIS.xml:S3:25829:12	measur	NNS	O	O
were	SAPHRIS.xml:S3:25842:4	were	VBD	O	O
taken	SAPHRIS.xml:S3:25847:5	taken	VBN	O	O
at	SAPHRIS.xml:S3:25853:2	at	IN	O	O
various	SAPHRIS.xml:S3:25856:7	variou	JJ	O	O
time	SAPHRIS.xml:S3:25864:4	time	NN	O	O
points	SAPHRIS.xml:S3:25869:6	point	NNS	O	O
during	SAPHRIS.xml:S3:25876:6	dure	IN	O	O
the	SAPHRIS.xml:S3:25883:3	the	DT	O	O
SAPHRIS	SAPHRIS.xml:S3:25887:7	saphri	NNP	O	O
clinical	SAPHRIS.xml:S3:25895:8	clinic	JJ	O	O
trial	SAPHRIS.xml:S3:25904:5	trial	NN	O	O
program	SAPHRIS.xml:S3:25910:7	program	NN	O	O
(	SAPHRIS.xml:S3:25918:1	(	(	O	O
5	SAPHRIS.xml:S3:25919:1	5	CD	O	O
mg	SAPHRIS.xml:S3:25921:2	mg	NN	O	O
or	SAPHRIS.xml:S3:25924:2	or	CC	O	O
10	SAPHRIS.xml:S3:25927:2	10	CD	O	O
mg	SAPHRIS.xml:S3:25930:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:25933:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:25939:5	daili	JJ	O	O
doses	SAPHRIS.xml:S3:25945:5	dose	NNS	O	O
)	SAPHRIS.xml:S3:25950:1	)	)	O	O
.	SAPHRIS.xml:S3:25951:1	.	.	O	O

Post	SAPHRIS.xml:S3:25953:4	post	NNP	O	O
-	SAPHRIS.xml:S3:25957:1	-	:	O	O
baseline	SAPHRIS.xml:S3:25958:8	baselin	NN	O	O
QT	SAPHRIS.xml:S3:25967:2	QT	NNP	B-AdverseReaction	O
prolongations	SAPHRIS.xml:S3:25970:13	prolong	NNS	I-AdverseReaction	O
exceeding	SAPHRIS.xml:S3:25984:9	exceed	VBG	O	O
500	SAPHRIS.xml:S3:25994:3	500	CD	O	O
msec	SAPHRIS.xml:S3:25998:4	msec	NN	O	O
were	SAPHRIS.xml:S3:26003:4	were	VBD	O	O
reported	SAPHRIS.xml:S3:26008:8	report	VBN	O	O
at	SAPHRIS.xml:S3:26017:2	at	IN	O	O
comparable	SAPHRIS.xml:S3:26020:10	compar	JJ	O	O
rates	SAPHRIS.xml:S3:26031:5	rate	NNS	O	O
for	SAPHRIS.xml:S3:26037:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:26041:7	saphri	NNP	O	O
and	SAPHRIS.xml:S3:26049:3	and	CC	O	O
placebo	SAPHRIS.xml:S3:26053:7	placebo	NN	O	O
in	SAPHRIS.xml:S3:26061:2	in	IN	O	O
these	SAPHRIS.xml:S3:26064:5	these	DT	O	O
short	SAPHRIS.xml:S3:26070:5	short	JJ	O	O
-	SAPHRIS.xml:S3:26075:1	-	:	O	O
term	SAPHRIS.xml:S3:26076:4	term	NN	O	O
trials	SAPHRIS.xml:S3:26081:6	trial	NNS	O	O
.	SAPHRIS.xml:S3:26087:1	.	.	O	O

There	SAPHRIS.xml:S3:26089:5	there	EX	O	O
were	SAPHRIS.xml:S3:26095:4	were	VBD	O	O
no	SAPHRIS.xml:S3:26100:2	no	DT	O	O
reports	SAPHRIS.xml:S3:26103:7	report	NNS	O	O
of	SAPHRIS.xml:S3:26111:2	of	IN	O	O
Torsade	SAPHRIS.xml:S3:26114:7	torsad	NNP	B-AdverseReaction	O
de	SAPHRIS.xml:S3:26122:2	de	FW	I-AdverseReaction	O
Pointes	SAPHRIS.xml:S3:26125:7	point	NNP	I-AdverseReaction	O
or	SAPHRIS.xml:S3:26133:2	or	CC	O	O
any	SAPHRIS.xml:S3:26136:3	ani	DT	O	O
other	SAPHRIS.xml:S3:26140:5	other	JJ	O	O
adverse	SAPHRIS.xml:S3:26146:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S3:26154:9	reaction	NNS	O	O
associated	SAPHRIS.xml:S3:26164:10	associ	VBN	O	O
with	SAPHRIS.xml:S3:26175:4	with	IN	O	O
delayed	SAPHRIS.xml:S3:26180:7	delay	JJ	B-AdverseReaction	O
ventricular	SAPHRIS.xml:S3:26188:11	ventricular	JJ	I-AdverseReaction	O
repolarization	SAPHRIS.xml:S3:26200:14	repolar	NN	I-AdverseReaction	O
.	SAPHRIS.xml:S3:26214:1	.	.	O	O

The	SAPHRIS.xml:S3:26224:3	the	DT	O	O
use	SAPHRIS.xml:S3:26228:3	use	NN	O	O
of	SAPHRIS.xml:S3:26232:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:26235:7	saphri	NNP	O	O
should	SAPHRIS.xml:S3:26243:6	should	MD	O	O
be	SAPHRIS.xml:S3:26250:2	be	VB	O	O
avoided	SAPHRIS.xml:S3:26253:7	avoid	VBN	O	O
in	SAPHRIS.xml:S3:26261:2	in	IN	O	O
combination	SAPHRIS.xml:S3:26264:11	combin	NN	O	O
with	SAPHRIS.xml:S3:26276:4	with	IN	O	O
other	SAPHRIS.xml:S3:26281:5	other	JJ	O	O
drugs	SAPHRIS.xml:S3:26287:5	drug	NNS	O	O
known	SAPHRIS.xml:S3:26293:5	known	VBN	O	O
to	SAPHRIS.xml:S3:26299:2	to	TO	O	O
prolong	SAPHRIS.xml:S3:26302:7	prolong	VB	O	O
QTc	SAPHRIS.xml:S3:26310:3	qtc	NNP	O	O
including	SAPHRIS.xml:S3:26314:9	includ	VBG	O	O
Class	SAPHRIS.xml:S3:26324:5	class	NNP	O	O
1	SAPHRIS.xml:S3:26330:1	1	CD	O	O
A	SAPHRIS.xml:S3:26331:1	A	NNP	O	O
antiarrhythmics	SAPHRIS.xml:S3:26333:15	antiarrhythm	NNS	O	O
(	SAPHRIS.xml:S3:26349:1	(	(	O	O
e	SAPHRIS.xml:S3:26350:1	e	NN	O	O
.	SAPHRIS.xml:S3:26351:1	.	.	O	O
g	SAPHRIS.xml:S3:26352:1	g	NN	O	O
.	SAPHRIS.xml:S3:26353:1	.	.	O	O
,	SAPHRIS.xml:S3:26354:1	,	,	O	O
quinidine	SAPHRIS.xml:S3:26356:9	quinidin	NN	O	O
,	SAPHRIS.xml:S3:26365:1	,	,	O	O
procainamide	SAPHRIS.xml:S3:26367:12	procainamid	NN	O	O
)	SAPHRIS.xml:S3:26379:1	)	)	O	O
or	SAPHRIS.xml:S3:26381:2	or	CC	O	O
Class	SAPHRIS.xml:S3:26384:5	class	$	O	O
3	SAPHRIS.xml:S3:26390:1	3	CD	O	O
antiarrhythmics	SAPHRIS.xml:S3:26392:15	antiarrhythm	NNS	O	O
(	SAPHRIS.xml:S3:26408:1	(	(	O	O
e	SAPHRIS.xml:S3:26409:1	e	NN	O	O
.	SAPHRIS.xml:S3:26410:1	.	.	O	O
g	SAPHRIS.xml:S3:26411:1	g	NN	O	O
.	SAPHRIS.xml:S3:26412:1	.	.	O	O
,	SAPHRIS.xml:S3:26413:1	,	,	O	O
amiodarone	SAPHRIS.xml:S3:26415:10	amiodaron	NN	O	O
,	SAPHRIS.xml:S3:26425:1	,	,	O	O
sotalol	SAPHRIS.xml:S3:26427:7	sotalol	NN	O	O
)	SAPHRIS.xml:S3:26434:1	)	)	O	O
,	SAPHRIS.xml:S3:26435:1	,	,	O	O
antipsychotic	SAPHRIS.xml:S3:26437:13	antipsychot	JJ	O	O
medications	SAPHRIS.xml:S3:26451:11	medic	NNS	O	O
(	SAPHRIS.xml:S3:26463:1	(	(	O	O
e	SAPHRIS.xml:S3:26464:1	e	NN	O	O
.	SAPHRIS.xml:S3:26465:1	.	.	O	O
g	SAPHRIS.xml:S3:26466:1	g	NN	O	O
.	SAPHRIS.xml:S3:26467:1	.	.	O	O
,	SAPHRIS.xml:S3:26468:1	,	,	O	O
ziprasidone	SAPHRIS.xml:S3:26470:11	ziprasidon	NN	O	O
,	SAPHRIS.xml:S3:26481:1	,	,	O	O
chlorpromazine	SAPHRIS.xml:S3:26483:14	chlorpromazin	NN	O	O
,	SAPHRIS.xml:S3:26497:1	,	,	O	O
thioridazine	SAPHRIS.xml:S3:26499:12	thioridazin	NN	O	O
)	SAPHRIS.xml:S3:26511:1	)	)	O	O
,	SAPHRIS.xml:S3:26512:1	,	,	O	O
and	SAPHRIS.xml:S3:26514:3	and	CC	O	O
antibiotics	SAPHRIS.xml:S3:26518:11	antibiot	NNS	O	O
(	SAPHRIS.xml:S3:26530:1	(	(	O	O
e	SAPHRIS.xml:S3:26531:1	e	NN	O	O
.	SAPHRIS.xml:S3:26532:1	.	.	O	O
g	SAPHRIS.xml:S3:26533:1	g	NN	O	O
.	SAPHRIS.xml:S3:26534:1	.	.	O	O
,	SAPHRIS.xml:S3:26535:1	,	,	O	O
gatifloxacin	SAPHRIS.xml:S3:26537:12	gatifloxacin	NN	O	O
,	SAPHRIS.xml:S3:26549:1	,	,	O	O
moxifloxacin	SAPHRIS.xml:S3:26551:12	moxifloxacin	NN	O	O
)	SAPHRIS.xml:S3:26563:1	)	)	O	O
.	SAPHRIS.xml:S3:26564:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S3:26566:7	saphri	NNP	O	O
should	SAPHRIS.xml:S3:26574:6	should	MD	O	O
also	SAPHRIS.xml:S3:26581:4	also	RB	O	O
be	SAPHRIS.xml:S3:26586:2	be	VB	O	O
avoided	SAPHRIS.xml:S3:26589:7	avoid	VBN	O	O
in	SAPHRIS.xml:S3:26597:2	in	IN	O	O
patients	SAPHRIS.xml:S3:26600:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:26609:4	with	IN	O	O
a	SAPHRIS.xml:S3:26614:1	a	DT	O	O
history	SAPHRIS.xml:S3:26616:7	histori	NN	O	O
of	SAPHRIS.xml:S3:26624:2	of	IN	O	O
cardiac	SAPHRIS.xml:S3:26627:7	cardiac	JJ	O	O
arrhythmias	SAPHRIS.xml:S3:26635:11	arrhythmia	NN	O	O
and	SAPHRIS.xml:S3:26647:3	and	CC	O	O
in	SAPHRIS.xml:S3:26651:2	in	IN	O	O
other	SAPHRIS.xml:S3:26654:5	other	JJ	O	O
circumstances	SAPHRIS.xml:S3:26660:13	circumst	NNS	O	O
that	SAPHRIS.xml:S3:26674:4	that	WDT	O	O
may	SAPHRIS.xml:S3:26679:3	may	MD	O	O
increase	SAPHRIS.xml:S3:26683:8	increas	VB	O	O
the	SAPHRIS.xml:S3:26692:3	the	DT	O	O
risk	SAPHRIS.xml:S3:26696:4	risk	NN	O	O
of	SAPHRIS.xml:S3:26701:2	of	IN	O	O
the	SAPHRIS.xml:S3:26704:3	the	DT	O	O
occurrence	SAPHRIS.xml:S3:26708:10	occurr	NN	O	O
of	SAPHRIS.xml:S3:26719:2	of	IN	O	O
torsade	SAPHRIS.xml:S3:26722:7	torsad	NN	O	O
de	SAPHRIS.xml:S3:26730:2	de	FW	O	O
pointes	SAPHRIS.xml:S3:26733:7	point	NNS	O	O
and	SAPHRIS.xml:S3:26741:3	and	CC	O	O
or	SAPHRIS.xml:S3:26745:2	or	CC	O	O
sudden	SAPHRIS.xml:S3:26748:6	sudden	JJ	O	O
death	SAPHRIS.xml:S3:26755:5	death	NN	O	O
in	SAPHRIS.xml:S3:26761:2	in	IN	O	O
association	SAPHRIS.xml:S3:26764:11	associ	NN	O	O
with	SAPHRIS.xml:S3:26776:4	with	IN	O	O
the	SAPHRIS.xml:S3:26781:3	the	DT	O	O
use	SAPHRIS.xml:S3:26785:3	use	NN	O	O
of	SAPHRIS.xml:S3:26789:2	of	IN	O	O
drugs	SAPHRIS.xml:S3:26792:5	drug	NNS	O	O
that	SAPHRIS.xml:S3:26798:4	that	WDT	O	O
prolong	SAPHRIS.xml:S3:26803:7	prolong	VBP	O	O
the	SAPHRIS.xml:S3:26811:3	the	DT	O	O
QTc	SAPHRIS.xml:S3:26815:3	qtc	NNP	O	O
interval	SAPHRIS.xml:S3:26819:8	interv	NN	O	O
,	SAPHRIS.xml:S3:26827:1	,	,	O	O
including	SAPHRIS.xml:S3:26829:9	includ	VBG	O	O
bradycardia	SAPHRIS.xml:S3:26839:11	bradycardia	NN	O	O
;	SAPHRIS.xml:S3:26850:1	;	:	O	O
hypokalemia	SAPHRIS.xml:S3:26852:11	hypokalemia	NN	O	B-AdverseReaction
or	SAPHRIS.xml:S3:26864:2	or	CC	O	O
hypomagnesemia	SAPHRIS.xml:S3:26867:14	hypomagnesemia	NN	O	O
;	SAPHRIS.xml:S3:26881:1	;	:	O	O
and	SAPHRIS.xml:S3:26883:3	and	CC	O	O
presence	SAPHRIS.xml:S3:26887:8	presenc	NN	O	O
of	SAPHRIS.xml:S3:26896:2	of	IN	O	O
congenital	SAPHRIS.xml:S3:26899:10	congenit	JJ	O	O
prolongation	SAPHRIS.xml:S3:26910:12	prolong	NN	O	O
of	SAPHRIS.xml:S3:26923:2	of	IN	O	O
the	SAPHRIS.xml:S3:26926:3	the	DT	O	O
QT	SAPHRIS.xml:S3:26930:2	QT	NNP	O	O
interval	SAPHRIS.xml:S3:26933:8	interv	NN	O	O
.	SAPHRIS.xml:S3:26941:1	.	.	O	O

5.10	SAPHRIS.xml:S3:26953:4	5.10	CD	O	O
Hyperprolactinemia	SAPHRIS.xml:S3:26958:18	hyperprolactinemia	NN	O	O

Like	SAPHRIS.xml:S3:26984:4	like	IN	O	O
other	SAPHRIS.xml:S3:26989:5	other	JJ	O	O
drugs	SAPHRIS.xml:S3:26995:5	drug	NNS	O	O
that	SAPHRIS.xml:S3:27001:4	that	IN	O	O
antagonize	SAPHRIS.xml:S3:27006:10	antagon	VBP	O	O
dopamine	SAPHRIS.xml:S3:27017:8	dopamin	JJ	O	O
D2receptors	SAPHRIS.xml:S3:27026:11	d2receptor	NNS	O	O
,	SAPHRIS.xml:S3:27037:1	,	,	O	O
SAPHRIS	SAPHRIS.xml:S3:27039:7	saphri	NNP	O	O
can	SAPHRIS.xml:S3:27047:3	can	MD	O	O
elevate	SAPHRIS.xml:S3:27051:7	elev	VB	B-AdverseReaction	B-AdverseReaction
prolactin	SAPHRIS.xml:S3:27059:9	prolactin	NN	I-AdverseReaction	I-AdverseReaction
levels	SAPHRIS.xml:S3:27069:6	level	NNS	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S3:27075:1	,	,	O	O
and	SAPHRIS.xml:S3:27077:3	and	CC	O	O
the	SAPHRIS.xml:S3:27081:3	the	DT	O	O
elevation	SAPHRIS.xml:S3:27085:9	elev	NN	O	O
can	SAPHRIS.xml:S3:27095:3	can	MD	O	O
persist	SAPHRIS.xml:S3:27099:7	persist	VB	O	O
during	SAPHRIS.xml:S3:27107:6	dure	IN	O	O
chronic	SAPHRIS.xml:S3:27114:7	chronic	JJ	O	O
administration	SAPHRIS.xml:S3:27122:14	administr	NN	O	O
.	SAPHRIS.xml:S3:27136:1	.	.	O	O

Hyperprolactinemia	SAPHRIS.xml:S3:27138:18	hyperprolactinemia	NNP	B-AdverseReaction	B-AdverseReaction
may	SAPHRIS.xml:S3:27157:3	may	MD	O	O
suppress	SAPHRIS.xml:S3:27161:8	suppress	VB	B-AdverseReaction	B-AdverseReaction
hypothalamic	SAPHRIS.xml:S3:27170:12	hypothalam	JJ	I-AdverseReaction	I-AdverseReaction
GnRH	SAPHRIS.xml:S3:27183:4	gnrh	NNP	I-AdverseReaction	I-AdverseReaction
,	SAPHRIS.xml:S3:27187:1	,	,	O	O
resulting	SAPHRIS.xml:S3:27189:9	result	VBG	O	O
in	SAPHRIS.xml:S3:27199:2	in	IN	O	O
reduced	SAPHRIS.xml:S3:27202:7	reduc	JJ	B-AdverseReaction	B-AdverseReaction
pituitary	SAPHRIS.xml:S3:27210:9	pituitari	JJ	I-AdverseReaction	I-AdverseReaction
gonadotropin	SAPHRIS.xml:S3:27220:12	gonadotropin	NN	I-AdverseReaction	I-AdverseReaction
secretion	SAPHRIS.xml:S3:27233:9	secret	NN	I-AdverseReaction	I-AdverseReaction
.	SAPHRIS.xml:S3:27242:1	.	.	O	O

This	SAPHRIS.xml:S3:27244:4	thi	DT	O	O
,	SAPHRIS.xml:S3:27248:1	,	,	O	O
in	SAPHRIS.xml:S3:27250:2	in	IN	O	O
turn	SAPHRIS.xml:S3:27253:4	turn	NN	O	O
,	SAPHRIS.xml:S3:27257:1	,	,	O	O
may	SAPHRIS.xml:S3:27259:3	may	MD	O	O
inhibit	SAPHRIS.xml:S3:27263:7	inhibit	VB	B-AdverseReaction	O
reproductive	SAPHRIS.xml:S3:27271:12	reproduct	JJ	I-AdverseReaction	O
function	SAPHRIS.xml:S3:27284:8	function	NN	I-AdverseReaction	O
by	SAPHRIS.xml:S3:27293:2	by	IN	O	O
impairing	SAPHRIS.xml:S3:27296:9	impair	VBG	B-AdverseReaction	O
gonadal	SAPHRIS.xml:S3:27306:7	gonad	JJ	I-AdverseReaction	O
steroidogenesis	SAPHRIS.xml:S3:27314:15	steroidogenesi	NN	I-AdverseReaction	O
in	SAPHRIS.xml:S3:27330:2	in	IN	O	O
both	SAPHRIS.xml:S3:27333:4	both	DT	O	O
female	SAPHRIS.xml:S3:27338:6	femal	JJ	O	O
and	SAPHRIS.xml:S3:27345:3	and	CC	O	O
male	SAPHRIS.xml:S3:27349:4	male	JJ	O	O
patients	SAPHRIS.xml:S3:27354:8	patient	NNS	O	O
.	SAPHRIS.xml:S3:27362:1	.	.	O	O

Galactorrhea	SAPHRIS.xml:S3:27364:12	galactorrhea	NNP	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:27376:1	,	,	O	O
amenorrhea	SAPHRIS.xml:S3:27378:10	amenorrhea	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:27388:1	,	,	O	O
gynecomastia	SAPHRIS.xml:S3:27390:12	gynecomastia	NN	B-AdverseReaction	B-AdverseReaction
,	SAPHRIS.xml:S3:27402:1	,	,	O	O
and	SAPHRIS.xml:S3:27404:3	and	CC	O	O
impotence	SAPHRIS.xml:S3:27408:9	impot	NN	B-AdverseReaction	B-AdverseReaction
have	SAPHRIS.xml:S3:27418:4	have	VBP	O	O
been	SAPHRIS.xml:S3:27423:4	been	VBN	O	O
reported	SAPHRIS.xml:S3:27428:8	report	VBN	O	O
in	SAPHRIS.xml:S3:27437:2	in	IN	O	O
patients	SAPHRIS.xml:S3:27440:8	patient	NNS	O	O
receiving	SAPHRIS.xml:S3:27449:9	receiv	VBG	O	O
prolactin	SAPHRIS.xml:S3:27459:9	prolactin	JJ	O	O
-	SAPHRIS.xml:S3:27468:1	-	:	O	O
elevating	SAPHRIS.xml:S3:27469:9	elev	VBG	O	O
compounds	SAPHRIS.xml:S3:27479:9	compound	NNS	O	O
.	SAPHRIS.xml:S3:27488:1	.	.	O	O

Long	SAPHRIS.xml:S3:27490:4	long	NNP	O	B-AdverseReaction
-	SAPHRIS.xml:S3:27494:1	-	:	O	I-AdverseReaction
standing	SAPHRIS.xml:S3:27495:8	stand	NN	O	I-AdverseReaction
hyperprolactinemia	SAPHRIS.xml:S3:27504:18	hyperprolactinemia	NN	B-AdverseReaction	I-AdverseReaction
when	SAPHRIS.xml:S3:27523:4	when	WRB	O	O
associated	SAPHRIS.xml:S3:27528:10	associ	VBN	O	O
with	SAPHRIS.xml:S3:27539:4	with	IN	O	O
hypogonadism	SAPHRIS.xml:S3:27544:12	hypogonad	NN	B-AdverseReaction	O
may	SAPHRIS.xml:S3:27557:3	may	MD	O	O
lead	SAPHRIS.xml:S3:27561:4	lead	VB	O	O
to	SAPHRIS.xml:S3:27566:2	to	TO	O	O
decreased	SAPHRIS.xml:S3:27569:9	decreas	JJ	B-AdverseReaction	B-AdverseReaction
bone	SAPHRIS.xml:S3:27579:4	bone	NN	I-AdverseReaction	I-AdverseReaction
density	SAPHRIS.xml:S3:27584:7	densiti	NN	I-AdverseReaction	I-AdverseReaction
in	SAPHRIS.xml:S3:27592:2	in	IN	O	O
both	SAPHRIS.xml:S3:27595:4	both	DT	O	O
female	SAPHRIS.xml:S3:27600:6	femal	JJ	O	O
and	SAPHRIS.xml:S3:27607:3	and	CC	O	O
male	SAPHRIS.xml:S3:27611:4	male	JJ	O	O
subjects	SAPHRIS.xml:S3:27616:8	subject	NNS	O	O
.	SAPHRIS.xml:S3:27624:1	.	.	O	O

In	SAPHRIS.xml:S3:27626:2	In	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:27629:7	saphri	NNP	O	O
adult	SAPHRIS.xml:S3:27637:5	adult	NN	O	O
clinical	SAPHRIS.xml:S3:27643:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S3:27652:6	trial	NNS	O	O
,	SAPHRIS.xml:S3:27658:1	,	,	O	O
the	SAPHRIS.xml:S3:27660:3	the	DT	O	O
incidences	SAPHRIS.xml:S3:27664:10	incid	NNS	O	O
of	SAPHRIS.xml:S3:27675:2	of	IN	O	O
adverse	SAPHRIS.xml:S3:27678:7	advers	JJ	O	O
events	SAPHRIS.xml:S3:27686:6	event	NNS	O	O
related	SAPHRIS.xml:S3:27693:7	relat	VBN	O	O
to	SAPHRIS.xml:S3:27701:2	to	TO	O	O
abnormal	SAPHRIS.xml:S3:27704:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
prolactin	SAPHRIS.xml:S3:27713:9	prolactin	NN	I-AdverseReaction	I-AdverseReaction
levels	SAPHRIS.xml:S3:27723:6	level	NNS	I-AdverseReaction	I-AdverseReaction
were	SAPHRIS.xml:S3:27730:4	were	VBD	O	O
0.4%	SAPHRIS.xml:S3:27735:4	0.4%	CD	O	O
versus	SAPHRIS.xml:S3:27740:6	versu	NN	O	O
0%	SAPHRIS.xml:S3:27747:2	0%	CD	O	O
for	SAPHRIS.xml:S3:27750:3	for	IN	O	O
placebo	SAPHRIS.xml:S3:27754:7	placebo	NN	O	O
.	SAPHRIS.xml:S3:27761:1	.	.	O	O

In	SAPHRIS.xml:S3:27763:2	In	IN	O	O
a	SAPHRIS.xml:S3:27766:1	a	DT	O	O
3	SAPHRIS.xml:S3:27768:1	3	CD	O	O
-	SAPHRIS.xml:S3:27769:1	-	:	O	O
week	SAPHRIS.xml:S3:27770:4	week	NN	O	O
,	SAPHRIS.xml:S3:27774:1	,	,	O	O
bipolar	SAPHRIS.xml:S3:27776:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:27784:5	mania	NN	O	O
pediatric	SAPHRIS.xml:S3:27790:9	pediatr	JJ	O	O
trial	SAPHRIS.xml:S3:27800:5	trial	NN	O	O
,	SAPHRIS.xml:S3:27805:1	,	,	O	O
the	SAPHRIS.xml:S3:27807:3	the	DT	O	O
incidence	SAPHRIS.xml:S3:27811:9	incid	NN	O	O
of	SAPHRIS.xml:S3:27821:2	of	IN	O	O
adverse	SAPHRIS.xml:S3:27824:7	advers	JJ	O	O
events	SAPHRIS.xml:S3:27832:6	event	NNS	O	O
related	SAPHRIS.xml:S3:27839:7	relat	VBN	O	O
to	SAPHRIS.xml:S3:27847:2	to	TO	O	O
abnormal	SAPHRIS.xml:S3:27850:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
prolactin	SAPHRIS.xml:S3:27859:9	prolactin	NN	I-AdverseReaction	I-AdverseReaction
levels	SAPHRIS.xml:S3:27869:6	level	NNS	I-AdverseReaction	I-AdverseReaction
were	SAPHRIS.xml:S3:27876:4	were	VBD	O	O
0%	SAPHRIS.xml:S3:27881:2	0%	CD	O	O
in	SAPHRIS.xml:S3:27884:2	in	IN	O	O
the	SAPHRIS.xml:S3:27887:3	the	DT	O	O
SAPHRIS	SAPHRIS.xml:S3:27891:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S3:27899:3	2.5	CD	O	O
mg	SAPHRIS.xml:S3:27903:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:27906:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:27912:5	daili	RB	O	O
treatment	SAPHRIS.xml:S3:27918:9	treatment	NN	O	O
group	SAPHRIS.xml:S3:27928:5	group	NN	O	O
,	SAPHRIS.xml:S3:27933:1	,	,	O	O
2%	SAPHRIS.xml:S3:27935:2	2%	CD	O	O
in	SAPHRIS.xml:S3:27938:2	in	IN	O	O
the	SAPHRIS.xml:S3:27941:3	the	DT	O	O
SAPHRIS	SAPHRIS.xml:S3:27945:7	saphri	NNP	O	O
5	SAPHRIS.xml:S3:27953:1	5	CD	O	O
mg	SAPHRIS.xml:S3:27955:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:27958:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:27964:5	daili	RB	O	O
treatment	SAPHRIS.xml:S3:27970:9	treatment	NN	O	O
group	SAPHRIS.xml:S3:27980:5	group	NN	O	O
,	SAPHRIS.xml:S3:27985:1	,	,	O	O
and	SAPHRIS.xml:S3:27987:3	and	CC	O	O
1%	SAPHRIS.xml:S3:27991:2	1%	CD	O	O
in	SAPHRIS.xml:S3:27994:2	in	IN	O	O
the	SAPHRIS.xml:S3:27997:3	the	DT	O	O
SAPHRIS	SAPHRIS.xml:S3:28001:7	saphri	NNP	O	O
10	SAPHRIS.xml:S3:28009:2	10	CD	O	O
mg	SAPHRIS.xml:S3:28012:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:28015:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:28021:5	daili	RB	O	O
treatment	SAPHRIS.xml:S3:28027:9	treatment	NN	O	O
group	SAPHRIS.xml:S3:28037:5	group	NN	O	O
versus	SAPHRIS.xml:S3:28043:6	versu	NN	O	O
to	SAPHRIS.xml:S3:28050:2	to	TO	O	O
1%	SAPHRIS.xml:S3:28053:2	1%	CD	O	O
for	SAPHRIS.xml:S3:28056:3	for	IN	O	O
patients	SAPHRIS.xml:S3:28060:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:28069:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:28077:4	with	IN	O	O
placebo	SAPHRIS.xml:S3:28082:7	placebo	NN	O	O
[	SAPHRIS.xml:S3:28091:1	[	NNP	O	O
see	SAPHRIS.xml:S3:28092:3	see	VBP	O	O
Adverse	SAPHRIS.xml:S3:28096:7	advers	JJ	O	O
Reactions	SAPHRIS.xml:S3:28104:9	reaction	NNP	O	O
(	SAPHRIS.xml:S3:28114:1	(	(	O	O
6.1	SAPHRIS.xml:S3:28115:3	6.1	CD	O	O
)]	SAPHRIS.xml:S3:28118:2	)]	NN	O	O
.	SAPHRIS.xml:S3:28122:1	.	.	O	O

Tissue	SAPHRIS.xml:S3:28132:6	tissu	NN	O	O
culture	SAPHRIS.xml:S3:28139:7	cultur	NN	O	O
experiments	SAPHRIS.xml:S3:28147:11	experi	NNS	O	O
indicate	SAPHRIS.xml:S3:28159:8	indic	VBP	O	O
that	SAPHRIS.xml:S3:28168:4	that	IN	O	O
approximately	SAPHRIS.xml:S3:28173:13	approxim	RB	O	O
one	SAPHRIS.xml:S3:28187:3	one	CD	O	O
-	SAPHRIS.xml:S3:28190:1	-	:	O	O
third	SAPHRIS.xml:S3:28191:5	third	NN	O	O
of	SAPHRIS.xml:S3:28197:2	of	IN	O	O
human	SAPHRIS.xml:S3:28200:5	human	JJ	O	O
breast	SAPHRIS.xml:S3:28206:6	breast	NN	O	O
cancers	SAPHRIS.xml:S3:28213:7	cancer	NNS	O	O
are	SAPHRIS.xml:S3:28221:3	are	VBP	O	O
prolactin	SAPHRIS.xml:S3:28225:9	prolactin	JJ	O	O
-	SAPHRIS.xml:S3:28234:1	-	:	O	O
dependent	SAPHRIS.xml:S3:28235:9	depend	NN	O	O
in	SAPHRIS.xml:S3:28246:2	in	IN	O	O
vitro	SAPHRIS.xml:S3:28249:5	vitro	NN	O	O
,	SAPHRIS.xml:S3:28256:1	,	,	O	O
a	SAPHRIS.xml:S3:28258:1	a	DT	O	O
factor	SAPHRIS.xml:S3:28260:6	factor	NN	O	O
of	SAPHRIS.xml:S3:28267:2	of	IN	O	O
potential	SAPHRIS.xml:S3:28270:9	potenti	JJ	O	O
importance	SAPHRIS.xml:S3:28280:10	import	NN	O	O
if	SAPHRIS.xml:S3:28291:2	if	IN	O	O
the	SAPHRIS.xml:S3:28294:3	the	DT	O	O
prescription	SAPHRIS.xml:S3:28298:12	prescript	NN	O	O
of	SAPHRIS.xml:S3:28311:2	of	IN	O	O
these	SAPHRIS.xml:S3:28314:5	these	DT	O	O
drugs	SAPHRIS.xml:S3:28320:5	drug	NNS	O	O
is	SAPHRIS.xml:S3:28326:2	is	VBZ	O	O
considered	SAPHRIS.xml:S3:28329:10	consid	VBN	O	O
in	SAPHRIS.xml:S3:28340:2	in	IN	O	O
a	SAPHRIS.xml:S3:28343:1	a	DT	O	O
patient	SAPHRIS.xml:S3:28345:7	patient	NN	O	O
with	SAPHRIS.xml:S3:28353:4	with	IN	O	O
previously	SAPHRIS.xml:S3:28358:10	previous	RB	O	O
-	SAPHRIS.xml:S3:28368:1	-	:	O	O
detected	SAPHRIS.xml:S3:28369:8	detect	VBN	O	O
breast	SAPHRIS.xml:S3:28378:6	breast	NN	O	O
cancer	SAPHRIS.xml:S3:28385:6	cancer	NN	O	O
.	SAPHRIS.xml:S3:28391:1	.	.	O	O

Neither	SAPHRIS.xml:S3:28393:7	neither	DT	O	O
clinical	SAPHRIS.xml:S3:28401:8	clinic	JJ	O	O
studies	SAPHRIS.xml:S3:28410:7	studi	NNS	O	O
nor	SAPHRIS.xml:S3:28418:3	nor	CC	O	O
epidemiologic	SAPHRIS.xml:S3:28422:13	epidemiolog	JJ	O	O
studies	SAPHRIS.xml:S3:28436:7	studi	NNS	O	O
conducted	SAPHRIS.xml:S3:28444:9	conduct	VBN	O	O
to	SAPHRIS.xml:S3:28454:2	to	TO	O	O
date	SAPHRIS.xml:S3:28457:4	date	NN	O	O
have	SAPHRIS.xml:S3:28462:4	have	VB	O	O
shown	SAPHRIS.xml:S3:28467:5	shown	VBN	O	O
an	SAPHRIS.xml:S3:28473:2	an	DT	O	O
association	SAPHRIS.xml:S3:28476:11	associ	NN	O	O
between	SAPHRIS.xml:S3:28488:7	between	IN	O	O
chronic	SAPHRIS.xml:S3:28496:7	chronic	JJ	O	O
administration	SAPHRIS.xml:S3:28504:14	administr	NN	O	O
of	SAPHRIS.xml:S3:28519:2	of	IN	O	O
this	SAPHRIS.xml:S3:28522:4	thi	DT	O	O
class	SAPHRIS.xml:S3:28527:5	class	NN	O	O
of	SAPHRIS.xml:S3:28533:2	of	IN	O	O
drugs	SAPHRIS.xml:S3:28536:5	drug	NNS	O	O
and	SAPHRIS.xml:S3:28542:3	and	CC	O	O
tumorigenesis	SAPHRIS.xml:S3:28546:13	tumorigenesi	NN	B-AdverseReaction	O
in	SAPHRIS.xml:S3:28560:2	in	IN	O	O
humans	SAPHRIS.xml:S3:28563:6	human	NNS	O	O
,	SAPHRIS.xml:S3:28569:1	,	,	O	O
but	SAPHRIS.xml:S3:28571:3	but	CC	O	O
the	SAPHRIS.xml:S3:28575:3	the	DT	O	O
available	SAPHRIS.xml:S3:28579:9	avail	JJ	O	O
evidence	SAPHRIS.xml:S3:28589:8	evid	NN	O	O
is	SAPHRIS.xml:S3:28598:2	is	VBZ	O	O
too	SAPHRIS.xml:S3:28601:3	too	RB	O	O
limited	SAPHRIS.xml:S3:28605:7	limit	JJ	O	O
to	SAPHRIS.xml:S3:28613:2	to	TO	O	O
be	SAPHRIS.xml:S3:28616:2	be	VB	O	O
conclusive	SAPHRIS.xml:S3:28619:10	conclus	JJ	O	O
.	SAPHRIS.xml:S3:28629:1	.	.	O	O

5.11	SAPHRIS.xml:S3:28641:4	5.11	CD	O	O
Seizures	SAPHRIS.xml:S3:28646:8	seizur	NNS	O	O

Seizures	SAPHRIS.xml:S3:28662:8	seizur	NNS	B-AdverseReaction	B-AdverseReaction
were	SAPHRIS.xml:S3:28671:4	were	VBD	O	O
reported	SAPHRIS.xml:S3:28676:8	report	VBN	O	O
in	SAPHRIS.xml:S3:28685:2	in	IN	O	O
0%	SAPHRIS.xml:S3:28688:2	0%	CD	O	O
and	SAPHRIS.xml:S3:28691:3	and	CC	O	O
0.3%	SAPHRIS.xml:S3:28695:4	0.3%	CD	O	O
(	SAPHRIS.xml:S3:28700:1	(	(	O	O
0	SAPHRIS.xml:S3:28701:1	0	CD	O	O
572	SAPHRIS.xml:S3:28703:3	572	CD	O	O
,	SAPHRIS.xml:S3:28706:1	,	,	O	O
1	SAPHRIS.xml:S3:28708:1	1	CD	O	O
379	SAPHRIS.xml:S3:28710:3	379	CD	O	O
)	SAPHRIS.xml:S3:28713:1	)	)	O	O
of	SAPHRIS.xml:S3:28715:2	of	IN	O	O
adult	SAPHRIS.xml:S3:28718:5	adult	NN	O	O
patients	SAPHRIS.xml:S3:28724:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:28733:7	treat	VBD	O	O
with	SAPHRIS.xml:S3:28741:4	with	IN	O	O
doses	SAPHRIS.xml:S3:28746:5	dose	NNS	O	O
of	SAPHRIS.xml:S3:28752:2	of	IN	O	O
5	SAPHRIS.xml:S3:28755:1	5	CD	O	O
mg	SAPHRIS.xml:S3:28757:2	mg	NNS	O	O
and	SAPHRIS.xml:S3:28760:3	and	CC	O	O
10	SAPHRIS.xml:S3:28764:2	10	CD	O	O
mg	SAPHRIS.xml:S3:28767:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:28770:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:28776:5	daili	RB	O	O
of	SAPHRIS.xml:S3:28782:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:28785:7	saphri	NNP	O	O
,	SAPHRIS.xml:S3:28792:1	,	,	O	O
respectively	SAPHRIS.xml:S3:28794:12	respect	RB	O	O
,	SAPHRIS.xml:S3:28806:1	,	,	O	O
compared	SAPHRIS.xml:S3:28808:8	compar	VBN	O	O
to	SAPHRIS.xml:S3:28817:2	to	TO	O	O
0%	SAPHRIS.xml:S3:28820:2	0%	CD	O	O
(	SAPHRIS.xml:S3:28823:1	(	(	O	O
0	SAPHRIS.xml:S3:28824:1	0	CD	O	O
503	SAPHRIS.xml:S3:28826:3	503	CD	O	O
,	SAPHRIS.xml:S3:28829:1	,	,	O	O
0	SAPHRIS.xml:S3:28831:1	0	CD	O	O
203	SAPHRIS.xml:S3:28833:3	203	CD	O	O
)	SAPHRIS.xml:S3:28836:1	)	)	O	O
of	SAPHRIS.xml:S3:28838:2	of	IN	O	O
patients	SAPHRIS.xml:S3:28841:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:28850:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:28858:4	with	IN	O	O
placebo	SAPHRIS.xml:S3:28863:7	placebo	NN	O	O
in	SAPHRIS.xml:S3:28871:2	in	IN	O	O
short	SAPHRIS.xml:S3:28874:5	short	JJ	O	O
-	SAPHRIS.xml:S3:28879:1	-	:	O	O
term	SAPHRIS.xml:S3:28880:4	term	NN	O	O
schizophrenia	SAPHRIS.xml:S3:28885:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S3:28899:3	and	CC	O	O
bipolar	SAPHRIS.xml:S3:28903:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:28911:5	mania	NN	O	O
trials	SAPHRIS.xml:S3:28917:6	trial	NNS	O	O
,	SAPHRIS.xml:S3:28923:1	,	,	O	O
respectively	SAPHRIS.xml:S3:28925:12	respect	RB	O	O
.	SAPHRIS.xml:S3:28937:1	.	.	O	O

During	SAPHRIS.xml:S3:28939:6	dure	IN	O	O
adult	SAPHRIS.xml:S3:28946:5	adult	NN	O	O
pre	SAPHRIS.xml:S3:28952:3	pre	SYM	O	O
-	SAPHRIS.xml:S3:28955:1	-	:	O	O
marketing	SAPHRIS.xml:S3:28956:9	market	NN	O	O
clinical	SAPHRIS.xml:S3:28966:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S3:28975:6	trial	NNS	O	O
with	SAPHRIS.xml:S3:28982:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:28987:7	saphri	NNP	O	O
,	SAPHRIS.xml:S3:28994:1	,	,	O	O
including	SAPHRIS.xml:S3:28996:9	includ	VBG	O	O
long	SAPHRIS.xml:S3:29006:4	long	JJ	O	O
-	SAPHRIS.xml:S3:29010:1	-	:	O	O
term	SAPHRIS.xml:S3:29011:4	term	NN	O	O
trials	SAPHRIS.xml:S3:29016:6	trial	NNS	O	O
without	SAPHRIS.xml:S3:29023:7	without	IN	O	O
comparison	SAPHRIS.xml:S3:29031:10	comparison	NN	O	O
to	SAPHRIS.xml:S3:29042:2	to	TO	O	O
placebo	SAPHRIS.xml:S3:29045:7	placebo	VB	O	O
,	SAPHRIS.xml:S3:29052:1	,	,	O	O
seizures	SAPHRIS.xml:S3:29054:8	seizur	NNS	B-AdverseReaction	B-AdverseReaction
were	SAPHRIS.xml:S3:29063:4	were	VBD	O	O
reported	SAPHRIS.xml:S3:29068:8	report	VBN	O	O
in	SAPHRIS.xml:S3:29077:2	in	IN	O	O
0.3%	SAPHRIS.xml:S3:29080:4	0.3%	CD	O	O
(	SAPHRIS.xml:S3:29085:1	(	(	O	O
5	SAPHRIS.xml:S3:29086:1	5	CD	O	O
1953	SAPHRIS.xml:S3:29088:4	1953	CD	O	O
)	SAPHRIS.xml:S3:29092:1	)	)	O	O
of	SAPHRIS.xml:S3:29094:2	of	IN	O	O
patients	SAPHRIS.xml:S3:29097:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:29106:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:29114:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:29119:7	saphri	NNP	O	O
.	SAPHRIS.xml:S3:29126:1	.	.	O	O

There	SAPHRIS.xml:S3:29128:5	there	EX	O	O
were	SAPHRIS.xml:S3:29134:4	were	VBD	O	O
no	SAPHRIS.xml:S3:29139:2	no	DT	O	O
reports	SAPHRIS.xml:S3:29142:7	report	NNS	O	O
of	SAPHRIS.xml:S3:29150:2	of	IN	O	O
seizures	SAPHRIS.xml:S3:29153:8	seizur	NNS	B-AdverseReaction	B-AdverseReaction
in	SAPHRIS.xml:S3:29162:2	in	IN	O	O
pediatric	SAPHRIS.xml:S3:29165:9	pediatr	JJ	O	O
patients	SAPHRIS.xml:S3:29175:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:29184:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:29192:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:29197:7	saphri	NNP	O	O
in	SAPHRIS.xml:S3:29205:2	in	IN	O	O
a	SAPHRIS.xml:S3:29208:1	a	DT	O	O
3	SAPHRIS.xml:S3:29210:1	3	CD	O	O
-	SAPHRIS.xml:S3:29211:1	-	:	O	O
week	SAPHRIS.xml:S3:29212:4	week	NN	O	O
-	SAPHRIS.xml:S3:29216:1	-	:	O	O
term	SAPHRIS.xml:S3:29217:4	term	NN	O	O
,	SAPHRIS.xml:S3:29221:1	,	,	O	O
bipolar	SAPHRIS.xml:S3:29223:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:29231:5	mania	NN	O	O
trial	SAPHRIS.xml:S3:29237:5	trial	NN	O	O
.	SAPHRIS.xml:S3:29242:1	.	.	O	O

As	SAPHRIS.xml:S3:29252:2	As	IN	O	O
with	SAPHRIS.xml:S3:29255:4	with	IN	O	O
other	SAPHRIS.xml:S3:29260:5	other	JJ	O	O
antipsychotic	SAPHRIS.xml:S3:29266:13	antipsychot	JJ	O	O
drugs	SAPHRIS.xml:S3:29280:5	drug	NNS	O	O
,	SAPHRIS.xml:S3:29285:1	,	,	O	O
SAPHRIS	SAPHRIS.xml:S3:29287:7	saphri	NNP	O	O
should	SAPHRIS.xml:S3:29295:6	should	MD	O	O
be	SAPHRIS.xml:S3:29302:2	be	VB	O	O
used	SAPHRIS.xml:S3:29305:4	use	VBN	O	O
with	SAPHRIS.xml:S3:29310:4	with	IN	O	O
caution	SAPHRIS.xml:S3:29315:7	caution	NN	O	O
in	SAPHRIS.xml:S3:29323:2	in	IN	O	O
patients	SAPHRIS.xml:S3:29326:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:29335:4	with	IN	O	O
a	SAPHRIS.xml:S3:29340:1	a	DT	O	O
history	SAPHRIS.xml:S3:29342:7	histori	NN	O	O
of	SAPHRIS.xml:S3:29350:2	of	IN	O	O
seizures	SAPHRIS.xml:S3:29353:8	seizur	NNS	O	O
or	SAPHRIS.xml:S3:29362:2	or	CC	O	O
with	SAPHRIS.xml:S3:29365:4	with	IN	O	O
conditions	SAPHRIS.xml:S3:29370:10	condit	NNS	O	O
that	SAPHRIS.xml:S3:29381:4	that	WDT	O	O
potentially	SAPHRIS.xml:S3:29386:11	potenti	RB	O	O
lower	SAPHRIS.xml:S3:29398:5	lower	JJR	O	O
the	SAPHRIS.xml:S3:29404:3	the	DT	O	O
seizure	SAPHRIS.xml:S3:29408:7	seizur	NN	O	O
threshold	SAPHRIS.xml:S3:29416:9	threshold	NN	O	O
.	SAPHRIS.xml:S3:29425:1	.	.	O	O

Conditions	SAPHRIS.xml:S3:29427:10	condit	NNS	O	O
that	SAPHRIS.xml:S3:29438:4	that	WDT	O	O
lower	SAPHRIS.xml:S3:29443:5	lower	VBP	O	O
the	SAPHRIS.xml:S3:29449:3	the	DT	O	O
seizure	SAPHRIS.xml:S3:29453:7	seizur	NN	O	O
threshold	SAPHRIS.xml:S3:29461:9	threshold	NN	O	O
may	SAPHRIS.xml:S3:29471:3	may	MD	O	O
be	SAPHRIS.xml:S3:29475:2	be	VB	O	O
more	SAPHRIS.xml:S3:29478:4	more	JJR	O	O
prevalent	SAPHRIS.xml:S3:29483:9	preval	JJ	O	O
in	SAPHRIS.xml:S3:29493:2	in	IN	O	O
patients	SAPHRIS.xml:S3:29496:8	patient	NNS	O	O
65	SAPHRIS.xml:S3:29505:2	65	CD	O	O
years	SAPHRIS.xml:S3:29508:5	year	NNS	O	O
or	SAPHRIS.xml:S3:29514:2	or	CC	O	O
older	SAPHRIS.xml:S3:29517:5	older	JJR	O	O
.	SAPHRIS.xml:S3:29522:1	.	.	O	O

5.12	SAPHRIS.xml:S3:29534:4	5.12	CD	O	O
Potential	SAPHRIS.xml:S3:29539:9	potenti	NNP	O	O
for	SAPHRIS.xml:S3:29549:3	for	IN	O	O
Cognitive	SAPHRIS.xml:S3:29553:9	cognit	NNP	O	O
and	SAPHRIS.xml:S3:29563:3	and	CC	O	O
Motor	SAPHRIS.xml:S3:29567:5	motor	NNP	O	O
Impairment	SAPHRIS.xml:S3:29573:10	impair	NNP	O	O

Somnolence	SAPHRIS.xml:S3:29591:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
was	SAPHRIS.xml:S3:29602:3	wa	VBD	O	O
reported	SAPHRIS.xml:S3:29606:8	report	VBN	O	O
in	SAPHRIS.xml:S3:29615:2	in	IN	O	O
patients	SAPHRIS.xml:S3:29618:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:29627:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:29635:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:29640:7	saphri	NNP	O	O
.	SAPHRIS.xml:S3:29647:1	.	.	O	O

It	SAPHRIS.xml:S3:29649:2	It	PRP	O	O
was	SAPHRIS.xml:S3:29652:3	wa	VBD	O	O
usually	SAPHRIS.xml:S3:29656:7	usual	RB	O	O
transient	SAPHRIS.xml:S3:29664:9	transient	JJ	O	O
with	SAPHRIS.xml:S3:29674:4	with	IN	O	O
the	SAPHRIS.xml:S3:29679:3	the	DT	O	O
highest	SAPHRIS.xml:S3:29683:7	highest	JJS	O	O
incidence	SAPHRIS.xml:S3:29691:9	incid	NN	O	O
reported	SAPHRIS.xml:S3:29701:8	report	VBD	O	O
during	SAPHRIS.xml:S3:29710:6	dure	IN	O	O
the	SAPHRIS.xml:S3:29717:3	the	DT	O	O
first	SAPHRIS.xml:S3:29721:5	first	JJ	O	O
week	SAPHRIS.xml:S3:29727:4	week	NN	O	O
of	SAPHRIS.xml:S3:29732:2	of	IN	O	O
treatment	SAPHRIS.xml:S3:29735:9	treatment	NN	O	O
.	SAPHRIS.xml:S3:29744:1	.	.	O	O

In	SAPHRIS.xml:S3:29746:2	In	IN	O	O
short	SAPHRIS.xml:S3:29749:5	short	JJ	O	O
-	SAPHRIS.xml:S3:29754:1	-	:	O	O
term	SAPHRIS.xml:S3:29755:4	term	NN	O	O
,	SAPHRIS.xml:S3:29759:1	,	,	O	O
fixed	SAPHRIS.xml:S3:29761:5	fix	VBN	O	O
-	SAPHRIS.xml:S3:29766:1	-	:	O	O
dose	SAPHRIS.xml:S3:29767:4	dose	NN	O	O
,	SAPHRIS.xml:S3:29771:1	,	,	O	O
placebo	SAPHRIS.xml:S3:29773:7	placebo	SYM	O	O
-	SAPHRIS.xml:S3:29780:1	-	:	O	O
controlled	SAPHRIS.xml:S3:29781:10	control	VBN	O	O
schizophrenia	SAPHRIS.xml:S3:29792:13	schizophrenia	NN	O	O
adult	SAPHRIS.xml:S3:29806:5	adult	NN	O	O
trials	SAPHRIS.xml:S3:29812:6	trial	NNS	O	O
,	SAPHRIS.xml:S3:29818:1	,	,	O	O
somnolence	SAPHRIS.xml:S3:29820:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
was	SAPHRIS.xml:S3:29831:3	wa	VBD	O	O
reported	SAPHRIS.xml:S3:29835:8	report	VBN	O	O
in	SAPHRIS.xml:S3:29844:2	in	IN	O	O
15%	SAPHRIS.xml:S3:29847:3	15%	CD	O	O
(	SAPHRIS.xml:S3:29851:1	(	(	O	O
41	SAPHRIS.xml:S3:29852:2	41	CD	O	O
274	SAPHRIS.xml:S3:29855:3	274	CD	O	O
)	SAPHRIS.xml:S3:29858:1	)	)	O	O
of	SAPHRIS.xml:S3:29860:2	of	IN	O	O
patients	SAPHRIS.xml:S3:29863:8	patient	NNS	O	O
on	SAPHRIS.xml:S3:29872:2	on	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:29875:7	saphri	NNP	O	O
5	SAPHRIS.xml:S3:29883:1	5	CD	O	O
mg	SAPHRIS.xml:S3:29885:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:29888:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:29894:5	daili	RB	O	O
and	SAPHRIS.xml:S3:29900:3	and	CC	O	O
in	SAPHRIS.xml:S3:29904:2	in	IN	O	O
13%	SAPHRIS.xml:S3:29907:3	13%	CD	O	O
(	SAPHRIS.xml:S3:29911:1	(	(	O	O
26	SAPHRIS.xml:S3:29912:2	26	CD	O	O
208	SAPHRIS.xml:S3:29915:3	208	CD	O	O
)	SAPHRIS.xml:S3:29918:1	)	)	O	O
of	SAPHRIS.xml:S3:29920:2	of	IN	O	O
patients	SAPHRIS.xml:S3:29923:8	patient	NNS	O	O
on	SAPHRIS.xml:S3:29932:2	on	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:29935:7	saphri	NNP	O	O
10	SAPHRIS.xml:S3:29943:2	10	CD	O	O
mg	SAPHRIS.xml:S3:29946:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:29949:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:29955:5	daili	RB	O	O
compared	SAPHRIS.xml:S3:29961:8	compar	VBN	O	O
to	SAPHRIS.xml:S3:29970:2	to	TO	O	O
7%	SAPHRIS.xml:S3:29973:2	7%	CD	O	O
(	SAPHRIS.xml:S3:29976:1	(	(	O	O
26	SAPHRIS.xml:S3:29977:2	26	CD	O	O
378	SAPHRIS.xml:S3:29980:3	378	CD	O	O
)	SAPHRIS.xml:S3:29983:1	)	)	O	O
of	SAPHRIS.xml:S3:29985:2	of	IN	O	O
placebo	SAPHRIS.xml:S3:29988:7	placebo	NN	O	O
patients	SAPHRIS.xml:S3:29996:8	patient	NNS	O	O
.	SAPHRIS.xml:S3:30004:1	.	.	O	O

In	SAPHRIS.xml:S3:30006:2	In	IN	O	O
short	SAPHRIS.xml:S3:30009:5	short	JJ	O	O
-	SAPHRIS.xml:S3:30014:1	-	:	O	O
term	SAPHRIS.xml:S3:30015:4	term	NN	O	O
,	SAPHRIS.xml:S3:30019:1	,	,	O	O
placebo	SAPHRIS.xml:S3:30021:7	placebo	SYM	O	O
-	SAPHRIS.xml:S3:30028:1	-	:	O	O
controlled	SAPHRIS.xml:S3:30029:10	control	VBN	O	O
bipolar	SAPHRIS.xml:S3:30040:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:30048:5	mania	NN	O	O
adult	SAPHRIS.xml:S3:30054:5	adult	NN	O	O
trials	SAPHRIS.xml:S3:30060:6	trial	NNS	O	O
of	SAPHRIS.xml:S3:30067:2	of	IN	O	O
therapeutic	SAPHRIS.xml:S3:30070:11	therapeut	JJ	O	O
doses	SAPHRIS.xml:S3:30082:5	dose	NNS	O	O
(	SAPHRIS.xml:S3:30088:1	(	(	O	O
5	SAPHRIS.xml:S3:30089:1	5	CD	O	O
-	SAPHRIS.xml:S3:30090:1	-	:	O	O
10	SAPHRIS.xml:S3:30091:2	10	CD	O	O
mg	SAPHRIS.xml:S3:30094:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:30097:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:30103:5	daili	RB	O	O
)	SAPHRIS.xml:S3:30108:1	)	)	O	O
,	SAPHRIS.xml:S3:30109:1	,	,	O	O
somnolence	SAPHRIS.xml:S3:30111:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
was	SAPHRIS.xml:S3:30122:3	wa	VBD	O	O
reported	SAPHRIS.xml:S3:30126:8	report	VBN	O	O
in	SAPHRIS.xml:S3:30135:2	in	IN	O	O
24%	SAPHRIS.xml:S3:30138:3	24%	CD	O	O
(	SAPHRIS.xml:S3:30142:1	(	(	O	O
90	SAPHRIS.xml:S3:30143:2	90	CD	O	O
379	SAPHRIS.xml:S3:30146:3	379	CD	O	O
)	SAPHRIS.xml:S3:30149:1	)	)	O	O
of	SAPHRIS.xml:S3:30151:2	of	IN	O	O
patients	SAPHRIS.xml:S3:30154:8	patient	NNS	O	O
on	SAPHRIS.xml:S3:30163:2	on	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:30166:7	saphri	NNP	O	O
compared	SAPHRIS.xml:S3:30174:8	compar	VBN	O	O
to	SAPHRIS.xml:S3:30183:2	to	TO	O	O
6%	SAPHRIS.xml:S3:30186:2	6%	CD	O	O
(	SAPHRIS.xml:S3:30189:1	(	(	O	O
13	SAPHRIS.xml:S3:30190:2	13	CD	O	O
203	SAPHRIS.xml:S3:30193:3	203	CD	O	O
)	SAPHRIS.xml:S3:30196:1	)	)	O	O
of	SAPHRIS.xml:S3:30198:2	of	IN	O	O
placebo	SAPHRIS.xml:S3:30201:7	placebo	NN	O	O
patients	SAPHRIS.xml:S3:30209:8	patient	NNS	O	O
.	SAPHRIS.xml:S3:30217:1	.	.	O	O

During	SAPHRIS.xml:S3:30219:6	dure	IN	O	O
adult	SAPHRIS.xml:S3:30226:5	adult	NN	O	O
pre	SAPHRIS.xml:S3:30232:3	pre	SYM	O	O
-	SAPHRIS.xml:S3:30235:1	-	:	O	O
marketing	SAPHRIS.xml:S3:30236:9	market	NN	O	O
clinical	SAPHRIS.xml:S3:30246:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S3:30255:6	trial	NNS	O	O
with	SAPHRIS.xml:S3:30262:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:30267:7	saphri	NNP	O	O
,	SAPHRIS.xml:S3:30274:1	,	,	O	O
including	SAPHRIS.xml:S3:30276:9	includ	VBG	O	O
long	SAPHRIS.xml:S3:30286:4	long	JJ	O	O
-	SAPHRIS.xml:S3:30290:1	-	:	O	O
term	SAPHRIS.xml:S3:30291:4	term	NN	O	O
trials	SAPHRIS.xml:S3:30296:6	trial	NNS	O	O
without	SAPHRIS.xml:S3:30303:7	without	IN	O	O
comparison	SAPHRIS.xml:S3:30311:10	comparison	NN	O	O
to	SAPHRIS.xml:S3:30322:2	to	TO	O	O
placebo	SAPHRIS.xml:S3:30325:7	placebo	VB	O	O
,	SAPHRIS.xml:S3:30332:1	,	,	O	O
somnolence	SAPHRIS.xml:S3:30334:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
was	SAPHRIS.xml:S3:30345:3	wa	VBD	O	O
reported	SAPHRIS.xml:S3:30349:8	report	VBN	O	O
in	SAPHRIS.xml:S3:30358:2	in	IN	O	O
18%	SAPHRIS.xml:S3:30361:3	18%	CD	O	O
(	SAPHRIS.xml:S3:30365:1	(	(	O	O
358	SAPHRIS.xml:S3:30366:3	358	CD	O	O
1953	SAPHRIS.xml:S3:30370:4	1953	CD	O	O
)	SAPHRIS.xml:S3:30374:1	)	)	O	O
of	SAPHRIS.xml:S3:30376:2	of	IN	O	O
patients	SAPHRIS.xml:S3:30379:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:30388:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:30396:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:30401:7	saphri	NNP	O	O
.	SAPHRIS.xml:S3:30408:1	.	.	O	O

Somnolence	SAPHRIS.xml:S3:30410:10	somnol	NNP	B-AdverseReaction	B-AdverseReaction
(	SAPHRIS.xml:S3:30421:1	(	(	O	O
including	SAPHRIS.xml:S3:30422:9	includ	VBG	O	O
sedation	SAPHRIS.xml:S3:30432:8	sedat	NN	B-AdverseReaction	B-AdverseReaction
)	SAPHRIS.xml:S3:30440:1	)	)	O	O
led	SAPHRIS.xml:S3:30442:3	led	VBD	O	O
to	SAPHRIS.xml:S3:30446:2	to	TO	O	O
discontinuation	SAPHRIS.xml:S3:30449:15	discontinu	NN	O	O
in	SAPHRIS.xml:S3:30465:2	in	IN	O	O
0.6%	SAPHRIS.xml:S3:30468:4	0.6%	CD	O	O
(	SAPHRIS.xml:S3:30473:1	(	(	O	O
12	SAPHRIS.xml:S3:30474:2	12	CD	O	O
1953	SAPHRIS.xml:S3:30477:4	1953	CD	O	O
)	SAPHRIS.xml:S3:30481:1	)	)	O	O
of	SAPHRIS.xml:S3:30483:2	of	IN	O	O
patients	SAPHRIS.xml:S3:30486:8	patient	NNS	O	O
in	SAPHRIS.xml:S3:30495:2	in	IN	O	O
short	SAPHRIS.xml:S3:30498:5	short	JJ	O	O
-	SAPHRIS.xml:S3:30503:1	-	:	O	O
term	SAPHRIS.xml:S3:30504:4	term	NN	O	O
,	SAPHRIS.xml:S3:30508:1	,	,	O	O
placebo	SAPHRIS.xml:S3:30510:7	placebo	SYM	O	O
-	SAPHRIS.xml:S3:30517:1	-	:	O	O
controlled	SAPHRIS.xml:S3:30518:10	control	VBN	O	O
trials	SAPHRIS.xml:S3:30529:6	trial	NNS	O	O
.	SAPHRIS.xml:S3:30535:1	.	.	O	O

In	SAPHRIS.xml:S3:30545:2	In	IN	O	O
a	SAPHRIS.xml:S3:30548:1	a	DT	O	O
3	SAPHRIS.xml:S3:30550:1	3	CD	O	O
-	SAPHRIS.xml:S3:30551:1	-	:	O	O
week	SAPHRIS.xml:S3:30552:4	week	NN	O	O
,	SAPHRIS.xml:S3:30556:1	,	,	O	O
placebo	SAPHRIS.xml:S3:30558:7	placebo	SYM	O	O
-	SAPHRIS.xml:S3:30565:1	-	:	O	O
controlled	SAPHRIS.xml:S3:30566:10	control	VBN	O	O
,	SAPHRIS.xml:S3:30576:1	,	,	O	O
bipolar	SAPHRIS.xml:S3:30578:7	bipolar	JJ	O	O
I	SAPHRIS.xml:S3:30586:1	I	PRP	O	O
pediatric	SAPHRIS.xml:S3:30588:9	pediatr	VBP	O	O
trial	SAPHRIS.xml:S3:30598:5	trial	NN	O	O
,	SAPHRIS.xml:S3:30603:1	,	,	O	O
the	SAPHRIS.xml:S3:30605:3	the	DT	O	O
incidence	SAPHRIS.xml:S3:30609:9	incid	NN	O	O
of	SAPHRIS.xml:S3:30619:2	of	IN	O	O
somnolence	SAPHRIS.xml:S3:30622:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
(	SAPHRIS.xml:S3:30633:1	(	(	O	O
including	SAPHRIS.xml:S3:30634:9	includ	VBG	O	O
sedation	SAPHRIS.xml:S3:30644:8	sedat	NN	B-AdverseReaction	B-AdverseReaction
and	SAPHRIS.xml:S3:30653:3	and	CC	O	O
hypersomnia	SAPHRIS.xml:S3:30657:11	hypersomnia	NN	B-AdverseReaction	O
)	SAPHRIS.xml:S3:30668:1	)	)	O	O
for	SAPHRIS.xml:S3:30670:3	for	IN	O	O
placebo	SAPHRIS.xml:S3:30674:7	placebo	NN	O	O
,	SAPHRIS.xml:S3:30681:1	,	,	O	O
SAPHRIS	SAPHRIS.xml:S3:30683:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S3:30691:3	2.5	CD	O	O
mg	SAPHRIS.xml:S3:30695:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:30698:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:30704:5	daili	RB	O	O
,	SAPHRIS.xml:S3:30709:1	,	,	O	O
5	SAPHRIS.xml:S3:30711:1	5	CD	O	O
mg	SAPHRIS.xml:S3:30713:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:30716:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:30722:5	daili	RB	O	O
,	SAPHRIS.xml:S3:30727:1	,	,	O	O
and	SAPHRIS.xml:S3:30729:3	and	CC	O	O
10	SAPHRIS.xml:S3:30733:2	10	CD	O	O
mg	SAPHRIS.xml:S3:30736:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:30739:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:30745:5	daili	RB	O	O
,	SAPHRIS.xml:S3:30750:1	,	,	O	O
was	SAPHRIS.xml:S3:30752:3	wa	VBD	O	O
12%	SAPHRIS.xml:S3:30756:3	12%	CD	O	O
(	SAPHRIS.xml:S3:30760:1	(	(	O	O
12	SAPHRIS.xml:S3:30761:2	12	CD	O	O
101	SAPHRIS.xml:S3:30764:3	101	CD	O	O
)	SAPHRIS.xml:S3:30767:1	)	)	O	O
,	SAPHRIS.xml:S3:30768:1	,	,	O	O
46%	SAPHRIS.xml:S3:30770:3	46%	CD	O	O
(	SAPHRIS.xml:S3:30774:1	(	(	O	O
48	SAPHRIS.xml:S3:30775:2	48	CD	O	O
104	SAPHRIS.xml:S3:30778:3	104	CD	O	O
)	SAPHRIS.xml:S3:30781:1	)	)	O	O
,	SAPHRIS.xml:S3:30782:1	,	,	O	O
53%	SAPHRIS.xml:S3:30784:3	53%	CD	O	O
(	SAPHRIS.xml:S3:30788:1	(	(	O	O
52	SAPHRIS.xml:S3:30789:2	52	CD	O	O
99	SAPHRIS.xml:S3:30792:2	99	CD	O	O
)	SAPHRIS.xml:S3:30794:1	)	)	O	O
,	SAPHRIS.xml:S3:30795:1	,	,	O	O
and	SAPHRIS.xml:S3:30797:3	and	CC	O	O
49%	SAPHRIS.xml:S3:30801:3	49%	CD	O	O
(	SAPHRIS.xml:S3:30805:1	(	(	O	O
49	SAPHRIS.xml:S3:30806:2	49	CD	O	O
99	SAPHRIS.xml:S3:30809:2	99	CD	O	O
)	SAPHRIS.xml:S3:30811:1	)	)	O	O
,	SAPHRIS.xml:S3:30812:1	,	,	O	O
respectively	SAPHRIS.xml:S3:30814:12	respect	RB	O	O
.	SAPHRIS.xml:S3:30826:1	.	.	O	O

Somnolence	SAPHRIS.xml:S3:30828:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
led	SAPHRIS.xml:S3:30839:3	led	VBD	O	O
to	SAPHRIS.xml:S3:30843:2	to	TO	O	O
discontinuation	SAPHRIS.xml:S3:30846:15	discontinu	NN	O	O
in	SAPHRIS.xml:S3:30862:2	in	IN	O	O
0%	SAPHRIS.xml:S3:30865:2	0%	CD	O	O
,	SAPHRIS.xml:S3:30867:1	,	,	O	O
3%	SAPHRIS.xml:S3:30869:2	3%	CD	O	O
,	SAPHRIS.xml:S3:30871:1	,	,	O	O
1%	SAPHRIS.xml:S3:30873:2	1%	CD	O	O
,	SAPHRIS.xml:S3:30875:1	,	,	O	O
and	SAPHRIS.xml:S3:30877:3	and	CC	O	O
2%	SAPHRIS.xml:S3:30881:2	2%	CD	O	O
of	SAPHRIS.xml:S3:30884:2	of	IN	O	O
patients	SAPHRIS.xml:S3:30887:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:30896:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:30904:4	with	IN	O	O
placebo	SAPHRIS.xml:S3:30909:7	placebo	NN	O	O
,	SAPHRIS.xml:S3:30916:1	,	,	O	O
and	SAPHRIS.xml:S3:30918:3	and	CC	O	O
SAPHRIS	SAPHRIS.xml:S3:30922:7	saphri	NNP	O	O
2.5	SAPHRIS.xml:S3:30930:3	2.5	CD	O	O
mg	SAPHRIS.xml:S3:30934:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:30937:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:30943:5	daili	RB	O	O
,	SAPHRIS.xml:S3:30948:1	,	,	O	O
5	SAPHRIS.xml:S3:30950:1	5	CD	O	O
mg	SAPHRIS.xml:S3:30952:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:30955:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:30961:5	daili	RB	O	O
,	SAPHRIS.xml:S3:30966:1	,	,	O	O
and	SAPHRIS.xml:S3:30968:3	and	CC	O	O
10	SAPHRIS.xml:S3:30972:2	10	CD	O	O
mg	SAPHRIS.xml:S3:30975:2	mg	NN	O	O
twice	SAPHRIS.xml:S3:30978:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:30984:5	daili	RB	O	O
,	SAPHRIS.xml:S3:30989:1	,	,	O	O
respectively	SAPHRIS.xml:S3:30991:12	respect	RB	O	O
.	SAPHRIS.xml:S3:31003:1	.	.	O	O

Patients	SAPHRIS.xml:S3:31013:8	patient	NNS	O	O
should	SAPHRIS.xml:S3:31022:6	should	MD	O	O
be	SAPHRIS.xml:S3:31029:2	be	VB	O	O
cautioned	SAPHRIS.xml:S3:31032:9	caution	VBN	O	O
about	SAPHRIS.xml:S3:31042:5	about	IN	O	O
performing	SAPHRIS.xml:S3:31048:10	perform	VBG	O	O
activities	SAPHRIS.xml:S3:31059:10	activ	NNS	O	O
requiring	SAPHRIS.xml:S3:31070:9	requir	VBG	O	O
mental	SAPHRIS.xml:S3:31080:6	mental	JJ	O	O
alertness	SAPHRIS.xml:S3:31087:9	alert	NN	O	O
,	SAPHRIS.xml:S3:31096:1	,	,	O	O
such	SAPHRIS.xml:S3:31098:4	such	JJ	O	O
as	SAPHRIS.xml:S3:31103:2	as	IN	O	O
operating	SAPHRIS.xml:S3:31106:9	oper	VBG	O	O
hazardous	SAPHRIS.xml:S3:31116:9	hazard	JJ	O	O
machinery	SAPHRIS.xml:S3:31126:9	machineri	NN	O	O
or	SAPHRIS.xml:S3:31136:2	or	CC	O	O
operating	SAPHRIS.xml:S3:31139:9	oper	VBG	O	O
a	SAPHRIS.xml:S3:31149:1	a	DT	O	O
motor	SAPHRIS.xml:S3:31151:5	motor	NN	O	O
vehicle	SAPHRIS.xml:S3:31157:7	vehicl	NN	O	O
,	SAPHRIS.xml:S3:31164:1	,	,	O	O
until	SAPHRIS.xml:S3:31166:5	until	IN	O	O
they	SAPHRIS.xml:S3:31172:4	they	PRP	O	O
are	SAPHRIS.xml:S3:31177:3	are	VBP	O	O
reasonably	SAPHRIS.xml:S3:31181:10	reason	RB	O	O
certain	SAPHRIS.xml:S3:31192:7	certain	JJ	O	O
that	SAPHRIS.xml:S3:31200:4	that	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:31205:7	saphri	NNP	O	O
therapy	SAPHRIS.xml:S3:31213:7	therapi	NN	O	O
does	SAPHRIS.xml:S3:31221:4	doe	VBZ	O	O
not	SAPHRIS.xml:S3:31226:3	not	RB	O	O
affect	SAPHRIS.xml:S3:31230:6	affect	VB	O	O
them	SAPHRIS.xml:S3:31237:4	them	PRP	O	O
adversely	SAPHRIS.xml:S3:31242:9	advers	RB	O	O
.	SAPHRIS.xml:S3:31251:1	.	.	O	O

5.13	SAPHRIS.xml:S3:31263:4	5.13	CD	O	O
Body	SAPHRIS.xml:S3:31268:4	bodi	NNP	O	O
Temperature	SAPHRIS.xml:S3:31273:11	temperatur	NNP	O	O
Regulation	SAPHRIS.xml:S3:31285:10	regul	NNP	O	O

Disruption	SAPHRIS.xml:S3:31303:10	disrupt	NN	B-AdverseReaction	B-AdverseReaction
of	SAPHRIS.xml:S3:31314:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	SAPHRIS.xml:S3:31317:3	the	DT	I-AdverseReaction	I-AdverseReaction
body	SAPHRIS.xml:S3:31321:4	bodi	NN	I-AdverseReaction	I-AdverseReaction
's	SAPHRIS.xml:S3:31325:2	's	POS	I-AdverseReaction	I-AdverseReaction
ability	SAPHRIS.xml:S3:31328:7	abil	NN	I-AdverseReaction	I-AdverseReaction
to	SAPHRIS.xml:S3:31336:2	to	TO	I-AdverseReaction	I-AdverseReaction
reduce	SAPHRIS.xml:S3:31339:6	reduc	VB	I-AdverseReaction	I-AdverseReaction
core	SAPHRIS.xml:S3:31346:4	core	NN	I-AdverseReaction	I-AdverseReaction
body	SAPHRIS.xml:S3:31351:4	bodi	NN	I-AdverseReaction	I-AdverseReaction
temperature	SAPHRIS.xml:S3:31356:11	temperatur	NN	I-AdverseReaction	I-AdverseReaction
has	SAPHRIS.xml:S3:31368:3	ha	VBZ	O	O
been	SAPHRIS.xml:S3:31372:4	been	VBN	O	O
attributed	SAPHRIS.xml:S3:31377:10	attribut	VBN	O	O
to	SAPHRIS.xml:S3:31388:2	to	TO	O	O
antipsychotic	SAPHRIS.xml:S3:31391:13	antipsychot	JJ	O	O
agents	SAPHRIS.xml:S3:31405:6	agent	NNS	O	O
.	SAPHRIS.xml:S3:31411:1	.	.	O	O

In	SAPHRIS.xml:S3:31413:2	In	IN	O	O
the	SAPHRIS.xml:S3:31416:3	the	DT	O	O
short	SAPHRIS.xml:S3:31420:5	short	JJ	O	O
-	SAPHRIS.xml:S3:31425:1	-	:	O	O
term	SAPHRIS.xml:S3:31426:4	term	NN	O	O
placebo	SAPHRIS.xml:S3:31431:7	placebo	NN	O	O
-	SAPHRIS.xml:S3:31438:1	-	:	O	O
controlled	SAPHRIS.xml:S3:31439:10	control	VBN	O	O
trials	SAPHRIS.xml:S3:31450:6	trial	NNS	O	O
for	SAPHRIS.xml:S3:31457:3	for	IN	O	O
both	SAPHRIS.xml:S3:31461:4	both	DT	O	O
schizophrenia	SAPHRIS.xml:S3:31466:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S3:31480:3	and	CC	O	O
acute	SAPHRIS.xml:S3:31484:5	acut	JJ	O	B-AdverseReaction
bipolar	SAPHRIS.xml:S3:31490:7	bipolar	NN	O	I-AdverseReaction
disorder	SAPHRIS.xml:S3:31498:8	disord	NN	O	I-AdverseReaction
,	SAPHRIS.xml:S3:31506:1	,	,	O	O
the	SAPHRIS.xml:S3:31508:3	the	DT	O	O
incidence	SAPHRIS.xml:S3:31512:9	incid	NN	O	O
of	SAPHRIS.xml:S3:31522:2	of	IN	O	O
adverse	SAPHRIS.xml:S3:31525:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S3:31533:9	reaction	NNS	O	O
suggestive	SAPHRIS.xml:S3:31543:10	suggest	VBP	O	O
of	SAPHRIS.xml:S3:31554:2	of	IN	O	O
body	SAPHRIS.xml:S3:31557:4	bodi	NN	B-AdverseReaction	O
temperature	SAPHRIS.xml:S3:31562:11	temperatur	NN	I-AdverseReaction	O
increases	SAPHRIS.xml:S3:31574:9	increas	NNS	I-AdverseReaction	O
was	SAPHRIS.xml:S3:31584:3	wa	VBD	O	O
low	SAPHRIS.xml:S3:31588:3	low	JJ	O	O
(	SAPHRIS.xml:S3:31592:1	(	(	O	O
1%	SAPHRIS.xml:S3:31595:2	1%	CD	O	O
)	SAPHRIS.xml:S3:31597:1	)	)	O	O
and	SAPHRIS.xml:S3:31599:3	and	CC	O	O
comparable	SAPHRIS.xml:S3:31603:10	compar	JJ	O	O
to	SAPHRIS.xml:S3:31614:2	to	TO	O	O
placebo	SAPHRIS.xml:S3:31617:7	placebo	VB	O	O
(	SAPHRIS.xml:S3:31625:1	(	(	O	O
0%	SAPHRIS.xml:S3:31626:2	0%	CD	O	O
)	SAPHRIS.xml:S3:31628:1	)	)	O	O
.	SAPHRIS.xml:S3:31629:1	.	.	O	O

During	SAPHRIS.xml:S3:31631:6	dure	IN	O	O
clinical	SAPHRIS.xml:S3:31638:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S3:31647:6	trial	NNS	O	O
with	SAPHRIS.xml:S3:31654:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:31659:7	saphri	NNP	O	O
,	SAPHRIS.xml:S3:31666:1	,	,	O	O
including	SAPHRIS.xml:S3:31668:9	includ	VBG	O	O
long	SAPHRIS.xml:S3:31678:4	long	JJ	O	O
-	SAPHRIS.xml:S3:31682:1	-	:	O	O
term	SAPHRIS.xml:S3:31683:4	term	NN	O	O
trials	SAPHRIS.xml:S3:31688:6	trial	NNS	O	O
without	SAPHRIS.xml:S3:31695:7	without	IN	O	O
comparison	SAPHRIS.xml:S3:31703:10	comparison	NN	O	O
to	SAPHRIS.xml:S3:31714:2	to	TO	O	O
placebo	SAPHRIS.xml:S3:31717:7	placebo	VB	O	O
,	SAPHRIS.xml:S3:31724:1	,	,	O	O
the	SAPHRIS.xml:S3:31726:3	the	DT	O	O
incidence	SAPHRIS.xml:S3:31730:9	incid	NN	O	O
of	SAPHRIS.xml:S3:31740:2	of	IN	O	O
adverse	SAPHRIS.xml:S3:31743:7	advers	JJ	O	O
reactions	SAPHRIS.xml:S3:31751:9	reaction	NNS	O	O
suggestive	SAPHRIS.xml:S3:31761:10	suggest	VBP	O	O
of	SAPHRIS.xml:S3:31772:2	of	IN	O	O
body	SAPHRIS.xml:S3:31775:4	bodi	NN	B-AdverseReaction	O
temperature	SAPHRIS.xml:S3:31780:11	temperatur	NN	I-AdverseReaction	O
increases	SAPHRIS.xml:S3:31792:9	increas	NNS	I-AdverseReaction	O
(	SAPHRIS.xml:S3:31802:1	(	(	O	O
pyrexia	SAPHRIS.xml:S3:31803:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
and	SAPHRIS.xml:S3:31811:3	and	CC	O	O
feeling	SAPHRIS.xml:S3:31815:7	feel	VBG	B-AdverseReaction	B-AdverseReaction
hot	SAPHRIS.xml:S3:31823:3	hot	JJ	I-AdverseReaction	I-AdverseReaction
)	SAPHRIS.xml:S3:31826:1	)	)	O	O
was	SAPHRIS.xml:S3:31828:3	wa	VBD	O	O
1%	SAPHRIS.xml:S3:31834:2	1%	CD	O	O
.	SAPHRIS.xml:S3:31836:1	.	.	O	O

Appropriate	SAPHRIS.xml:S3:31846:11	appropri	NNP	O	O
care	SAPHRIS.xml:S3:31858:4	care	NN	O	O
is	SAPHRIS.xml:S3:31863:2	is	VBZ	O	O
advised	SAPHRIS.xml:S3:31866:7	advis	VBN	O	O
when	SAPHRIS.xml:S3:31874:4	when	WRB	O	O
prescribing	SAPHRIS.xml:S3:31879:11	prescrib	VBG	O	O
SAPHRIS	SAPHRIS.xml:S3:31891:7	saphri	NNP	O	O
for	SAPHRIS.xml:S3:31899:3	for	IN	O	O
patients	SAPHRIS.xml:S3:31903:8	patient	NNS	O	O
who	SAPHRIS.xml:S3:31912:3	who	WP	O	O
will	SAPHRIS.xml:S3:31916:4	will	MD	O	O
be	SAPHRIS.xml:S3:31921:2	be	VB	O	O
experiencing	SAPHRIS.xml:S3:31924:12	experienc	VBG	O	O
conditions	SAPHRIS.xml:S3:31937:10	condit	NNS	O	O
that	SAPHRIS.xml:S3:31948:4	that	WDT	O	O
may	SAPHRIS.xml:S3:31953:3	may	MD	O	O
contribute	SAPHRIS.xml:S3:31957:10	contribut	VB	O	O
to	SAPHRIS.xml:S3:31968:2	to	TO	O	O
an	SAPHRIS.xml:S3:31971:2	an	DT	O	O
elevation	SAPHRIS.xml:S3:31974:9	elev	NN	O	O
in	SAPHRIS.xml:S3:31984:2	in	IN	O	O
core	SAPHRIS.xml:S3:31987:4	core	NN	O	O
body	SAPHRIS.xml:S3:31992:4	bodi	NN	O	O
temperature	SAPHRIS.xml:S3:31997:11	temperatur	NN	O	O
,	SAPHRIS.xml:S3:32008:1	,	,	O	O
e	SAPHRIS.xml:S3:32010:1	e	NN	O	O
.	SAPHRIS.xml:S3:32011:1	.	.	O	O
g	SAPHRIS.xml:S3:32012:1	g	NN	O	O
.	SAPHRIS.xml:S3:32013:1	.	.	O	O
,	SAPHRIS.xml:S3:32014:1	,	,	O	O
exercising	SAPHRIS.xml:S3:32016:10	exercis	VBG	O	O
strenuously	SAPHRIS.xml:S3:32027:11	strenuous	RB	O	O
,	SAPHRIS.xml:S3:32038:1	,	,	O	O
exposure	SAPHRIS.xml:S3:32040:8	exposur	NN	O	O
to	SAPHRIS.xml:S3:32049:2	to	TO	O	O
extreme	SAPHRIS.xml:S3:32052:7	extrem	VB	O	O
heat	SAPHRIS.xml:S3:32060:4	heat	NN	O	O
,	SAPHRIS.xml:S3:32064:1	,	,	O	O
receiving	SAPHRIS.xml:S3:32066:9	receiv	VBG	O	O
concomitant	SAPHRIS.xml:S3:32076:11	concomit	JJ	O	O
medication	SAPHRIS.xml:S3:32088:10	medic	NN	O	O
with	SAPHRIS.xml:S3:32099:4	with	IN	O	O
anticholinergic	SAPHRIS.xml:S3:32104:15	anticholinerg	JJ	O	O
activity	SAPHRIS.xml:S3:32120:8	activ	NN	O	O
,	SAPHRIS.xml:S3:32128:1	,	,	O	O
or	SAPHRIS.xml:S3:32130:2	or	CC	O	O
being	SAPHRIS.xml:S3:32133:5	be	VBG	O	O
subject	SAPHRIS.xml:S3:32139:7	subject	JJ	O	O
to	SAPHRIS.xml:S3:32147:2	to	TO	O	O
dehydration	SAPHRIS.xml:S3:32150:11	dehydr	NN	O	O
.	SAPHRIS.xml:S3:32161:1	.	.	O	O

5.14	SAPHRIS.xml:S3:32173:4	5.14	CD	O	O
Suicide	SAPHRIS.xml:S3:32178:7	suicid	NN	O	O

The	SAPHRIS.xml:S3:32193:3	the	DT	O	O
possibility	SAPHRIS.xml:S3:32197:11	possibl	NN	O	O
of	SAPHRIS.xml:S3:32209:2	of	IN	O	O
a	SAPHRIS.xml:S3:32212:1	a	DT	O	O
suicide	SAPHRIS.xml:S3:32214:7	suicid	JJ	O	O
attempt	SAPHRIS.xml:S3:32222:7	attempt	NN	O	O
is	SAPHRIS.xml:S3:32230:2	is	VBZ	O	O
inherent	SAPHRIS.xml:S3:32233:8	inher	JJ	O	O
in	SAPHRIS.xml:S3:32242:2	in	IN	O	O
psychotic	SAPHRIS.xml:S3:32245:9	psychot	JJ	O	O
illnesses	SAPHRIS.xml:S3:32255:9	ill	NNS	O	O
and	SAPHRIS.xml:S3:32265:3	and	CC	O	O
bipolar	SAPHRIS.xml:S3:32269:7	bipolar	JJ	O	B-AdverseReaction
disorder	SAPHRIS.xml:S3:32277:8	disord	NN	O	I-AdverseReaction
,	SAPHRIS.xml:S3:32285:1	,	,	O	O
and	SAPHRIS.xml:S3:32287:3	and	CC	O	O
close	SAPHRIS.xml:S3:32291:5	close	JJ	O	O
supervision	SAPHRIS.xml:S3:32297:11	supervis	NN	O	O
of	SAPHRIS.xml:S3:32309:2	of	IN	O	O
high	SAPHRIS.xml:S3:32312:4	high	JJ	O	O
-	SAPHRIS.xml:S3:32316:1	-	:	O	O
risk	SAPHRIS.xml:S3:32317:4	risk	NN	O	O
patients	SAPHRIS.xml:S3:32322:8	patient	NNS	O	O
should	SAPHRIS.xml:S3:32331:6	should	MD	O	O
accompany	SAPHRIS.xml:S3:32338:9	accompani	VB	O	O
drug	SAPHRIS.xml:S3:32348:4	drug	NN	O	O
therapy	SAPHRIS.xml:S3:32353:7	therapi	NN	O	O
.	SAPHRIS.xml:S3:32360:1	.	.	O	O

Prescriptions	SAPHRIS.xml:S3:32362:13	prescript	NNS	O	O
for	SAPHRIS.xml:S3:32376:3	for	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:32380:7	saphri	NNP	O	O
should	SAPHRIS.xml:S3:32388:6	should	MD	O	O
be	SAPHRIS.xml:S3:32395:2	be	VB	O	O
written	SAPHRIS.xml:S3:32398:7	written	VBN	O	O
for	SAPHRIS.xml:S3:32406:3	for	IN	O	O
the	SAPHRIS.xml:S3:32410:3	the	DT	O	O
smallest	SAPHRIS.xml:S3:32414:8	smallest	JJS	O	O
quantity	SAPHRIS.xml:S3:32423:8	quantiti	NN	O	O
of	SAPHRIS.xml:S3:32432:2	of	IN	O	O
tablets	SAPHRIS.xml:S3:32435:7	tablet	NNS	O	O
consistent	SAPHRIS.xml:S3:32443:10	consist	JJ	O	O
with	SAPHRIS.xml:S3:32454:4	with	IN	O	O
good	SAPHRIS.xml:S3:32459:4	good	JJ	O	O
patient	SAPHRIS.xml:S3:32464:7	patient	NN	O	O
management	SAPHRIS.xml:S3:32472:10	manag	NN	O	O
in	SAPHRIS.xml:S3:32483:2	in	IN	O	O
order	SAPHRIS.xml:S3:32486:5	order	NN	O	O
to	SAPHRIS.xml:S3:32492:2	to	TO	O	O
reduce	SAPHRIS.xml:S3:32495:6	reduc	VB	O	O
the	SAPHRIS.xml:S3:32502:3	the	DT	O	O
risk	SAPHRIS.xml:S3:32506:4	risk	NN	O	O
of	SAPHRIS.xml:S3:32511:2	of	IN	O	O
overdose	SAPHRIS.xml:S3:32514:8	overdos	NN	O	O
.	SAPHRIS.xml:S3:32522:1	.	.	O	O

5.15	SAPHRIS.xml:S3:32534:4	5.15	CD	O	O
Dysphagia	SAPHRIS.xml:S3:32539:9	dysphagia	NNP	O	O

Esophageal	SAPHRIS.xml:S3:32552:10	esophag	NNP	B-AdverseReaction	O
dysmotility	SAPHRIS.xml:S3:32563:11	dysmotil	NN	I-AdverseReaction	O
and	SAPHRIS.xml:S3:32575:3	and	CC	O	O
aspiration	SAPHRIS.xml:S3:32579:10	aspir	NN	B-AdverseReaction	B-AdverseReaction
have	SAPHRIS.xml:S3:32590:4	have	VBP	O	O
been	SAPHRIS.xml:S3:32595:4	been	VBN	O	O
associated	SAPHRIS.xml:S3:32600:10	associ	VBN	O	O
with	SAPHRIS.xml:S3:32611:4	with	IN	O	O
antipsychotic	SAPHRIS.xml:S3:32616:13	antipsychot	JJ	O	O
drug	SAPHRIS.xml:S3:32630:4	drug	NN	O	O
use	SAPHRIS.xml:S3:32635:3	use	NN	O	O
.	SAPHRIS.xml:S3:32638:1	.	.	O	O

Dysphagia	SAPHRIS.xml:S3:32640:9	dysphagia	NNP	B-AdverseReaction	B-AdverseReaction
was	SAPHRIS.xml:S3:32650:3	wa	VBD	O	O
reported	SAPHRIS.xml:S3:32654:8	report	VBN	O	O
in	SAPHRIS.xml:S3:32663:2	in	IN	O	O
0.2%	SAPHRIS.xml:S3:32666:4	0.2%	CD	O	O
and	SAPHRIS.xml:S3:32671:3	and	CC	O	O
0%	SAPHRIS.xml:S3:32675:2	0%	CD	O	O
(	SAPHRIS.xml:S3:32678:1	(	(	O	O
1	SAPHRIS.xml:S3:32679:1	1	CD	O	O
572	SAPHRIS.xml:S3:32681:3	572	CD	O	O
,	SAPHRIS.xml:S3:32684:1	,	,	O	O
0	SAPHRIS.xml:S3:32686:1	0	CD	O	O
379	SAPHRIS.xml:S3:32688:3	379	CD	O	O
)	SAPHRIS.xml:S3:32691:1	)	)	O	O
of	SAPHRIS.xml:S3:32693:2	of	IN	O	O
patients	SAPHRIS.xml:S3:32696:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:32705:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:32713:4	with	IN	O	O
therapeutic	SAPHRIS.xml:S3:32718:11	therapeut	JJ	O	O
doses	SAPHRIS.xml:S3:32730:5	dose	NNS	O	O
(	SAPHRIS.xml:S3:32736:1	(	(	O	O
5	SAPHRIS.xml:S3:32737:1	5	CD	O	O
-	SAPHRIS.xml:S3:32738:1	-	:	O	O
10	SAPHRIS.xml:S3:32739:2	10	CD	O	O
mg	SAPHRIS.xml:S3:32742:2	mg	JJ	O	O
twice	SAPHRIS.xml:S3:32745:5	twice	RB	O	O
daily	SAPHRIS.xml:S3:32751:5	daili	RB	O	O
)	SAPHRIS.xml:S3:32756:1	)	)	O	O
of	SAPHRIS.xml:S3:32758:2	of	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:32761:7	saphri	NNP	O	O
as	SAPHRIS.xml:S3:32769:2	as	IN	O	O
compared	SAPHRIS.xml:S3:32772:8	compar	VBN	O	O
to	SAPHRIS.xml:S3:32781:2	to	TO	O	O
0%	SAPHRIS.xml:S3:32784:2	0%	CD	O	O
(	SAPHRIS.xml:S3:32787:1	(	(	O	O
0	SAPHRIS.xml:S3:32788:1	0	CD	O	O
378	SAPHRIS.xml:S3:32790:3	378	CD	O	O
,	SAPHRIS.xml:S3:32793:1	,	,	O	O
0	SAPHRIS.xml:S3:32795:1	0	CD	O	O
203	SAPHRIS.xml:S3:32797:3	203	CD	O	O
)	SAPHRIS.xml:S3:32800:1	)	)	O	O
of	SAPHRIS.xml:S3:32802:2	of	IN	O	O
patients	SAPHRIS.xml:S3:32805:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:32814:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:32822:4	with	IN	O	O
placebo	SAPHRIS.xml:S3:32827:7	placebo	NN	O	O
in	SAPHRIS.xml:S3:32835:2	in	IN	O	O
short	SAPHRIS.xml:S3:32838:5	short	JJ	O	O
-	SAPHRIS.xml:S3:32843:1	-	:	O	O
term	SAPHRIS.xml:S3:32844:4	term	NN	O	O
schizophrenia	SAPHRIS.xml:S3:32849:13	schizophrenia	NN	O	O
and	SAPHRIS.xml:S3:32863:3	and	CC	O	O
bipolar	SAPHRIS.xml:S3:32867:7	bipolar	JJ	O	O
mania	SAPHRIS.xml:S3:32875:5	mania	NN	O	O
adult	SAPHRIS.xml:S3:32881:5	adult	NN	O	O
trials	SAPHRIS.xml:S3:32887:6	trial	NNS	O	O
,	SAPHRIS.xml:S3:32893:1	,	,	O	O
respectively	SAPHRIS.xml:S3:32895:12	respect	RB	O	O
.	SAPHRIS.xml:S3:32907:1	.	.	O	O

During	SAPHRIS.xml:S3:32909:6	dure	IN	O	O
adult	SAPHRIS.xml:S3:32916:5	adult	NN	O	O
pre	SAPHRIS.xml:S3:32922:3	pre	SYM	O	O
-	SAPHRIS.xml:S3:32925:1	-	:	O	O
marketing	SAPHRIS.xml:S3:32926:9	market	NN	O	O
clinical	SAPHRIS.xml:S3:32936:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S3:32945:6	trial	NNS	O	O
with	SAPHRIS.xml:S3:32952:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:32957:7	saphri	NNP	O	O
,	SAPHRIS.xml:S3:32964:1	,	,	O	O
including	SAPHRIS.xml:S3:32966:9	includ	VBG	O	O
long	SAPHRIS.xml:S3:32976:4	long	JJ	O	O
-	SAPHRIS.xml:S3:32980:1	-	:	O	O
term	SAPHRIS.xml:S3:32981:4	term	NN	O	O
trials	SAPHRIS.xml:S3:32986:6	trial	NNS	O	O
without	SAPHRIS.xml:S3:32993:7	without	IN	O	O
comparison	SAPHRIS.xml:S3:33001:10	comparison	NN	O	O
to	SAPHRIS.xml:S3:33012:2	to	TO	O	O
placebo	SAPHRIS.xml:S3:33015:7	placebo	VB	O	O
,	SAPHRIS.xml:S3:33022:1	,	,	O	O
dysphagia	SAPHRIS.xml:S3:33024:9	dysphagia	NN	B-AdverseReaction	B-AdverseReaction
was	SAPHRIS.xml:S3:33034:3	wa	VBD	O	O
reported	SAPHRIS.xml:S3:33038:8	report	VBN	O	O
in	SAPHRIS.xml:S3:33047:2	in	IN	O	O
0.1%	SAPHRIS.xml:S3:33050:4	0.1%	CD	O	O
(	SAPHRIS.xml:S3:33055:1	(	(	O	O
2	SAPHRIS.xml:S3:33056:1	2	CD	O	O
1953	SAPHRIS.xml:S3:33058:4	1953	CD	O	O
)	SAPHRIS.xml:S3:33062:1	)	)	O	O
of	SAPHRIS.xml:S3:33064:2	of	IN	O	O
patients	SAPHRIS.xml:S3:33067:8	patient	NNS	O	O
treated	SAPHRIS.xml:S3:33076:7	treat	VBN	O	O
with	SAPHRIS.xml:S3:33084:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:33089:7	saphri	NNP	O	O
.	SAPHRIS.xml:S3:33096:1	.	.	O	O

Aspiration	SAPHRIS.xml:S3:33106:10	aspir	NNP	O	O
pneumonia	SAPHRIS.xml:S3:33117:9	pneumonia	NN	O	O
is	SAPHRIS.xml:S3:33127:2	is	VBZ	O	O
a	SAPHRIS.xml:S3:33130:1	a	DT	O	O
common	SAPHRIS.xml:S3:33132:6	common	JJ	O	O
cause	SAPHRIS.xml:S3:33139:5	caus	NN	O	O
of	SAPHRIS.xml:S3:33145:2	of	IN	O	O
morbidity	SAPHRIS.xml:S3:33148:9	morbid	NN	O	O
and	SAPHRIS.xml:S3:33158:3	and	CC	O	O
mortality	SAPHRIS.xml:S3:33162:9	mortal	NN	O	O
in	SAPHRIS.xml:S3:33172:2	in	IN	O	O
elderly	SAPHRIS.xml:S3:33175:7	elderli	JJ	O	O
patients	SAPHRIS.xml:S3:33183:8	patient	NNS	O	O
,	SAPHRIS.xml:S3:33191:1	,	,	O	O
in	SAPHRIS.xml:S3:33193:2	in	IN	O	O
particular	SAPHRIS.xml:S3:33196:10	particular	JJ	O	O
those	SAPHRIS.xml:S3:33207:5	those	DT	O	O
with	SAPHRIS.xml:S3:33213:4	with	IN	O	O
advanced	SAPHRIS.xml:S3:33218:8	advanc	JJ	O	O
Alzheimer	SAPHRIS.xml:S3:33227:9	alzheim	NNP	O	O
's	SAPHRIS.xml:S3:33236:2	's	POS	O	O
dementia	SAPHRIS.xml:S3:33239:8	dementia	NN	O	O
.	SAPHRIS.xml:S3:33247:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S3:33249:7	saphri	NNP	O	O
is	SAPHRIS.xml:S3:33257:2	is	VBZ	O	O
not	SAPHRIS.xml:S3:33260:3	not	RB	O	O
indicated	SAPHRIS.xml:S3:33264:9	indic	VBN	O	O
for	SAPHRIS.xml:S3:33274:3	for	IN	O	O
the	SAPHRIS.xml:S3:33278:3	the	DT	O	O
treatment	SAPHRIS.xml:S3:33282:9	treatment	NN	O	O
of	SAPHRIS.xml:S3:33292:2	of	IN	O	O
dementia	SAPHRIS.xml:S3:33295:8	dementia	NN	O	O
-	SAPHRIS.xml:S3:33303:1	-	:	O	O
related	SAPHRIS.xml:S3:33304:7	relat	JJ	O	O
psychosis	SAPHRIS.xml:S3:33312:9	psychosi	NN	O	O
,	SAPHRIS.xml:S3:33321:1	,	,	O	O
and	SAPHRIS.xml:S3:33323:3	and	CC	O	O
should	SAPHRIS.xml:S3:33327:6	should	MD	O	O
not	SAPHRIS.xml:S3:33334:3	not	RB	O	O
be	SAPHRIS.xml:S3:33338:2	be	VB	O	O
used	SAPHRIS.xml:S3:33341:4	use	VBN	O	O
in	SAPHRIS.xml:S3:33346:2	in	IN	O	O
patients	SAPHRIS.xml:S3:33349:8	patient	NNS	O	O
at	SAPHRIS.xml:S3:33358:2	at	IN	O	O
risk	SAPHRIS.xml:S3:33361:4	risk	NN	O	O
for	SAPHRIS.xml:S3:33366:3	for	IN	O	O
aspiration	SAPHRIS.xml:S3:33370:10	aspir	NN	O	O
pneumonia	SAPHRIS.xml:S3:33381:9	pneumonia	NN	O	O
[	SAPHRIS.xml:S3:33392:1	[	NNP	O	O
see	SAPHRIS.xml:S3:33393:3	see	NN	O	O
also	SAPHRIS.xml:S3:33397:4	also	RB	O	O
Warnings	SAPHRIS.xml:S3:33402:8	warn	NNP	O	O
and	SAPHRIS.xml:S3:33411:3	and	CC	O	O
Precautions	SAPHRIS.xml:S3:33415:11	precaut	NNP	O	O
(	SAPHRIS.xml:S3:33427:1	(	(	O	O
5.1	SAPHRIS.xml:S3:33428:3	5.1	CD	O	O
)]	SAPHRIS.xml:S3:33431:2	)]	NN	O	O
.	SAPHRIS.xml:S3:33435:1	.	.	O	O

5.16	SAPHRIS.xml:S3:33447:4	5.16	CD	O	O
Use	SAPHRIS.xml:S3:33452:3	use	NNP	O	O
in	SAPHRIS.xml:S3:33456:2	in	IN	O	O
Patients	SAPHRIS.xml:S3:33459:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:33468:4	with	IN	O	O
Concomitant	SAPHRIS.xml:S3:33473:11	concomit	NNP	O	O
Illness	SAPHRIS.xml:S3:33485:7	ill	NNP	O	O

Clinical	SAPHRIS.xml:S3:33500:8	clinic	JJ	O	O
experience	SAPHRIS.xml:S3:33509:10	experi	NN	O	O
with	SAPHRIS.xml:S3:33520:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:33525:7	saphri	NNP	O	O
in	SAPHRIS.xml:S3:33533:2	in	IN	O	O
patients	SAPHRIS.xml:S3:33536:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:33545:4	with	IN	O	O
certain	SAPHRIS.xml:S3:33550:7	certain	JJ	O	O
concomitant	SAPHRIS.xml:S3:33558:11	concomit	JJ	O	O
systemic	SAPHRIS.xml:S3:33570:8	system	JJ	O	O
illnesses	SAPHRIS.xml:S3:33579:9	ill	NNS	O	O
is	SAPHRIS.xml:S3:33589:2	is	VBZ	O	O
limited	SAPHRIS.xml:S3:33592:7	limit	JJ	O	O
[	SAPHRIS.xml:S3:33601:1	[	NNP	O	O
see	SAPHRIS.xml:S3:33602:3	see	VBP	O	O
Clinical	SAPHRIS.xml:S3:33606:8	clinic	JJ	O	O
Pharmacology	SAPHRIS.xml:S3:33615:12	pharmacolog	NNP	O	O
(	SAPHRIS.xml:S3:33628:1	(	(	O	O
12.3	SAPHRIS.xml:S3:33629:4	12.3	CD	O	O
)]	SAPHRIS.xml:S3:33633:2	)]	NN	O	O
.	SAPHRIS.xml:S3:33637:1	.	.	O	O

SAPHRIS	SAPHRIS.xml:S3:33647:7	saphri	NNP	O	O
has	SAPHRIS.xml:S3:33655:3	ha	VBZ	O	O
not	SAPHRIS.xml:S3:33659:3	not	RB	O	O
been	SAPHRIS.xml:S3:33663:4	been	VBN	O	O
evaluated	SAPHRIS.xml:S3:33668:9	evalu	VBN	O	O
in	SAPHRIS.xml:S3:33678:2	in	IN	O	O
patients	SAPHRIS.xml:S3:33681:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:33690:4	with	IN	O	O
a	SAPHRIS.xml:S3:33695:1	a	DT	O	O
recent	SAPHRIS.xml:S3:33697:6	recent	JJ	O	O
history	SAPHRIS.xml:S3:33704:7	histori	NN	O	O
of	SAPHRIS.xml:S3:33712:2	of	IN	O	O
myocardial	SAPHRIS.xml:S3:33715:10	myocardi	JJ	O	O
infarction	SAPHRIS.xml:S3:33726:10	infarct	NN	O	O
or	SAPHRIS.xml:S3:33737:2	or	CC	O	O
unstable	SAPHRIS.xml:S3:33740:8	unstabl	JJ	O	O
heart	SAPHRIS.xml:S3:33749:5	heart	NN	O	O
disease	SAPHRIS.xml:S3:33755:7	diseas	NN	O	O
.	SAPHRIS.xml:S3:33762:1	.	.	O	O

Patients	SAPHRIS.xml:S3:33764:8	patient	NNS	O	O
with	SAPHRIS.xml:S3:33773:4	with	IN	O	O
these	SAPHRIS.xml:S3:33778:5	these	DT	O	O
diagnoses	SAPHRIS.xml:S3:33784:9	diagnos	NNS	O	O
were	SAPHRIS.xml:S3:33794:4	were	VBD	O	O
excluded	SAPHRIS.xml:S3:33799:8	exclud	VBN	O	O
from	SAPHRIS.xml:S3:33808:4	from	IN	O	O
pre	SAPHRIS.xml:S3:33813:3	pre	NN	O	O
-	SAPHRIS.xml:S3:33816:1	-	:	O	O
marketing	SAPHRIS.xml:S3:33817:9	market	NN	O	O
clinical	SAPHRIS.xml:S3:33827:8	clinic	JJ	O	O
trials	SAPHRIS.xml:S3:33836:6	trial	NNS	O	O
.	SAPHRIS.xml:S3:33842:1	.	.	O	O

Because	SAPHRIS.xml:S3:33844:7	becaus	IN	O	O
of	SAPHRIS.xml:S3:33852:2	of	IN	O	O
the	SAPHRIS.xml:S3:33855:3	the	DT	O	O
risk	SAPHRIS.xml:S3:33859:4	risk	NN	O	O
of	SAPHRIS.xml:S3:33864:2	of	IN	O	O
orthostatic	SAPHRIS.xml:S3:33867:11	orthostat	JJ	O	B-AdverseReaction
hypotension	SAPHRIS.xml:S3:33879:11	hypotens	NN	O	I-AdverseReaction
with	SAPHRIS.xml:S3:33891:4	with	IN	O	O
SAPHRIS	SAPHRIS.xml:S3:33896:7	saphri	NNP	O	O
,	SAPHRIS.xml:S3:33903:1	,	,	O	O
caution	SAPHRIS.xml:S3:33905:7	caution	NN	O	O
should	SAPHRIS.xml:S3:33913:6	should	MD	O	O
be	SAPHRIS.xml:S3:33920:2	be	VB	O	O
observed	SAPHRIS.xml:S3:33923:8	observ	VBN	O	O
in	SAPHRIS.xml:S3:33932:2	in	IN	O	O
cardiac	SAPHRIS.xml:S3:33935:7	cardiac	JJ	O	O
patients	SAPHRIS.xml:S3:33943:8	patient	NNS	O	O
[	SAPHRIS.xml:S3:33953:1	[	JJ	O	O
see	SAPHRIS.xml:S3:33954:3	see	VBP	O	O
Warnings	SAPHRIS.xml:S3:33958:8	warn	NNS	O	O
and	SAPHRIS.xml:S3:33967:3	and	CC	O	O
Precautions	SAPHRIS.xml:S3:33971:11	precaut	NNP	O	O
(	SAPHRIS.xml:S3:33983:1	(	(	O	O
5.7	SAPHRIS.xml:S3:33984:3	5.7	CD	O	O
)]	SAPHRIS.xml:S3:33987:2	)]	NN	O	O
.	SAPHRIS.xml:S3:33991:1	.	.	O	O
6	SIMPONI.xml:S1:4:1	6	CD	O	O
ADVERSE	SIMPONI.xml:S1:6:7	advers	JJ	O	O
REACTIONS	SIMPONI.xml:S1:14:9	reaction	NN	O	O

The	SIMPONI.xml:S1:27:3	the	DT	O	O
most	SIMPONI.xml:S1:31:4	most	RBS	O	O
serious	SIMPONI.xml:S1:36:7	seriou	JJ	O	O
adverse	SIMPONI.xml:S1:44:7	advers	JJ	O	O
reactions	SIMPONI.xml:S1:52:9	reaction	NNS	O	O
were	SIMPONI.xml:S1:62:4	were	VBD	O	O
:	SIMPONI.xml:S1:66:1	:	:	O	O

Serious	SIMPONI.xml:S1:75:7	seriou	JJ	O	O
Infections	SIMPONI.xml:S1:83:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
[	SIMPONI.xml:S1:94:1	[	VBP	O	O
see	SIMPONI.xml:S1:95:3	see	VBP	O	O
Warnings	SIMPONI.xml:S1:100:8	warn	NNS	O	O
and	SIMPONI.xml:S1:109:3	and	CC	O	O
Precautions	SIMPONI.xml:S1:113:11	precaut	NNP	O	O
(	SIMPONI.xml:S1:125:1	(	(	O	O
5.1	SIMPONI.xml:S1:126:3	5.1	CD	O	O
)	SIMPONI.xml:S1:129:1	)	)	O	O
]	SIMPONI.xml:S1:132:1	]	NN	O	O

Malignancies	SIMPONI.xml:S1:140:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
[	SIMPONI.xml:S1:153:1	[	VBP	O	O
see	SIMPONI.xml:S1:154:3	see	VBP	O	O
Warnings	SIMPONI.xml:S1:159:8	warn	NNS	O	O
and	SIMPONI.xml:S1:168:3	and	CC	O	O
Precautions	SIMPONI.xml:S1:172:11	precaut	NNP	O	O
(	SIMPONI.xml:S1:184:1	(	(	O	O
5.2	SIMPONI.xml:S1:185:3	5.2	CD	O	O
)	SIMPONI.xml:S1:188:1	)	)	O	O
]	SIMPONI.xml:S1:191:1	]	NN	O	O

EXCERPT	SIMPONI.xml:S1:201:7	excerpt	NNS	O	O
:	SIMPONI.xml:S1:208:1	:	:	O	O
Most	SIMPONI.xml:S1:212:4	most	JJS	O	O
common	SIMPONI.xml:S1:217:6	common	JJ	O	O
adverse	SIMPONI.xml:S1:224:7	advers	JJ	O	O
reactions	SIMPONI.xml:S1:232:9	reaction	NNS	O	O
(	SIMPONI.xml:S1:242:1	(	(	O	O
incidence	SIMPONI.xml:S1:243:9	incid	VB	O	O
3%	SIMPONI.xml:S1:255:2	3%	CD	O	O
)	SIMPONI.xml:S1:257:1	)	)	O	O
are	SIMPONI.xml:S1:259:3	are	VBP	O	O
:	SIMPONI.xml:S1:262:1	:	:	O	O
upper	SIMPONI.xml:S1:264:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	SIMPONI.xml:S1:270:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	SIMPONI.xml:S1:282:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	SIMPONI.xml:S1:288:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S1:297:1	,	,	O	O
viral	SIMPONI.xml:S1:299:5	viral	JJ	B-AdverseReaction	B-AdverseReaction
infection	SIMPONI.xml:S1:305:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S1:314:1	,	,	O	O
bronchitis	SIMPONI.xml:S1:316:10	bronchiti	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:326:1	,	,	O	O
hypertension	SIMPONI.xml:S1:328:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:340:1	,	,	O	O
and	SIMPONI.xml:S1:342:3	and	CC	O	O
rash	SIMPONI.xml:S1:346:4	rash	NN	B-AdverseReaction	B-AdverseReaction
(	SIMPONI.xml:S1:351:1	(	(	O	O
6.1	SIMPONI.xml:S1:354:3	6.1	CD	O	O
)	SIMPONI.xml:S1:359:1	)	)	O	O
.	SIMPONI.xml:S1:360:1	.	.	O	O

To	SIMPONI.xml:S1:368:2	To	TO	O	O

report	SIMPONI.xml:S1:371:6	report	NN	O	O
SUSPECTED	SIMPONI.xml:S1:378:9	suspect	NNP	O	O
ADVERSE	SIMPONI.xml:S1:388:7	advers	NNP	O	O
REACTIONS	SIMPONI.xml:S1:396:9	reaction	NNP	O	O
,	SIMPONI.xml:S1:405:1	,	,	O	O
contactJanssen	SIMPONI.xml:S1:407:14	contactjanssen	NN	O	O
Biotech	SIMPONI.xml:S1:422:7	biotech	NNP	O	O
,	SIMPONI.xml:S1:429:1	,	,	O	O
Inc	SIMPONI.xml:S1:431:3	inc	NNP	O	O
.	SIMPONI.xml:S1:434:1	.	.	O	O

at	SIMPONI.xml:S1:436:2	at	IN	O	O
1	SIMPONI.xml:S1:439:1	1	CD	O	O
-	SIMPONI.xml:S1:440:1	-	:	O	O
800	SIMPONI.xml:S1:441:3	800	CD	O	O
-	SIMPONI.xml:S1:444:1	-	:	O	O
JANSSEN	SIMPONI.xml:S1:445:7	janssen	NNP	O	O
(	SIMPONI.xml:S1:453:1	(	(	O	O
1	SIMPONI.xml:S1:454:1	1	CD	O	O
-	SIMPONI.xml:S1:455:1	-	:	O	O
800	SIMPONI.xml:S1:456:3	800	CD	O	O
-	SIMPONI.xml:S1:459:1	-	:	O	O
526	SIMPONI.xml:S1:460:3	526	CD	O	O
-	SIMPONI.xml:S1:463:1	-	:	O	O
7736	SIMPONI.xml:S1:464:4	7736	CD	O	O
)	SIMPONI.xml:S1:468:1	)	)	O	O
or	SIMPONI.xml:S1:470:2	or	CC	O	O
FDA	SIMPONI.xml:S1:473:3	fda	NNP	O	O
at	SIMPONI.xml:S1:477:2	at	IN	O	O
1	SIMPONI.xml:S1:480:1	1	CD	O	O
-	SIMPONI.xml:S1:481:1	-	:	O	O
800	SIMPONI.xml:S1:482:3	800	CD	O	O
-	SIMPONI.xml:S1:485:1	-	:	O	O
FDA	SIMPONI.xml:S1:486:3	fda	NNP	O	O
-	SIMPONI.xml:S1:489:1	-	:	O	O
1088	SIMPONI.xml:S1:490:4	1088	CD	O	O
or	SIMPONI.xml:S1:495:2	or	CC	O	O
www	SIMPONI.xml:S1:499:3	www	VB	O	O
.	SIMPONI.xml:S1:502:1	.	.	O	O
fda	SIMPONI.xml:S1:503:3	fda	NN	O	O
.	SIMPONI.xml:S1:506:1	.	.	O	O
gov	SIMPONI.xml:S1:507:3	gov	JJ	O	O
medwatch	SIMPONI.xml:S1:511:8	medwatch	NN	O	O
.	SIMPONI.xml:S1:519:1	.	.	O	O

6.1	SIMPONI.xml:S1:533:3	6.1	CD	O	O

Clinical	SIMPONI.xml:S1:537:8	clinic	JJ	O	O
Trials	SIMPONI.xml:S1:546:6	trial	NNS	O	O
Experience	SIMPONI.xml:S1:553:10	experi	NN	O	O

Because	SIMPONI.xml:S1:567:7	becaus	IN	O	O
clinical	SIMPONI.xml:S1:575:8	clinic	JJ	O	O
trials	SIMPONI.xml:S1:584:6	trial	NNS	O	O
are	SIMPONI.xml:S1:591:3	are	VBP	O	O
conducted	SIMPONI.xml:S1:595:9	conduct	VBN	O	O
under	SIMPONI.xml:S1:605:5	under	IN	O	O
widely	SIMPONI.xml:S1:611:6	wide	RB	O	O
varying	SIMPONI.xml:S1:618:7	vari	VBG	O	O
conditions	SIMPONI.xml:S1:626:10	condit	NNS	O	O
,	SIMPONI.xml:S1:636:1	,	,	O	O
adverse	SIMPONI.xml:S1:638:7	advers	JJ	O	O
reaction	SIMPONI.xml:S1:646:8	reaction	NN	O	O
rates	SIMPONI.xml:S1:655:5	rate	NNS	O	O
observed	SIMPONI.xml:S1:661:8	observ	VBD	O	O
in	SIMPONI.xml:S1:670:2	in	IN	O	O
the	SIMPONI.xml:S1:673:3	the	DT	O	O
clinical	SIMPONI.xml:S1:677:8	clinic	JJ	O	O
trials	SIMPONI.xml:S1:686:6	trial	NNS	O	O
of	SIMPONI.xml:S1:693:2	of	IN	O	O
a	SIMPONI.xml:S1:696:1	a	DT	O	O
drug	SIMPONI.xml:S1:698:4	drug	NN	O	O
cannot	SIMPONI.xml:S1:703:6	cannot	NN	O	O
be	SIMPONI.xml:S1:710:2	be	VB	O	O
directly	SIMPONI.xml:S1:713:8	directli	RB	O	O
compared	SIMPONI.xml:S1:722:8	compar	VBN	O	O
to	SIMPONI.xml:S1:731:2	to	TO	O	O
rates	SIMPONI.xml:S1:734:5	rate	NNS	O	O
in	SIMPONI.xml:S1:740:2	in	IN	O	O
the	SIMPONI.xml:S1:743:3	the	DT	O	O
clinical	SIMPONI.xml:S1:747:8	clinic	JJ	O	O
trials	SIMPONI.xml:S1:756:6	trial	NNS	O	O
of	SIMPONI.xml:S1:763:2	of	IN	O	O
another	SIMPONI.xml:S1:766:7	anoth	DT	O	O
drug	SIMPONI.xml:S1:774:4	drug	NN	O	O
and	SIMPONI.xml:S1:779:3	and	CC	O	O
may	SIMPONI.xml:S1:783:3	may	MD	O	O
not	SIMPONI.xml:S1:787:3	not	RB	O	O
reflect	SIMPONI.xml:S1:791:7	reflect	VB	O	O
the	SIMPONI.xml:S1:799:3	the	DT	O	O
rates	SIMPONI.xml:S1:803:5	rate	NNS	O	O
observed	SIMPONI.xml:S1:809:8	observ	VBD	O	O
in	SIMPONI.xml:S1:818:2	in	IN	O	O
clinical	SIMPONI.xml:S1:821:8	clinic	JJ	O	O
practice	SIMPONI.xml:S1:830:8	practic	NN	O	O
.	SIMPONI.xml:S1:838:1	.	.	O	O

The	SIMPONI.xml:S1:844:3	the	DT	O	O
safety	SIMPONI.xml:S1:848:6	safeti	NN	O	O
data	SIMPONI.xml:S1:855:4	data	NNS	O	O
described	SIMPONI.xml:S1:860:9	describ	VBN	O	O
below	SIMPONI.xml:S1:870:5	below	IN	O	O
are	SIMPONI.xml:S1:876:3	are	VBP	O	O
based	SIMPONI.xml:S1:880:5	base	VBN	O	O
on	SIMPONI.xml:S1:886:2	on	IN	O	O
one	SIMPONI.xml:S1:889:3	one	CD	O	O
,	SIMPONI.xml:S1:892:1	,	,	O	O
randomized	SIMPONI.xml:S1:894:10	random	VBN	O	O
,	SIMPONI.xml:S1:904:1	,	,	O	O
double	SIMPONI.xml:S1:906:6	doubl	JJ	O	O
-	SIMPONI.xml:S1:912:1	-	:	O	O
blind	SIMPONI.xml:S1:913:5	blind	NN	O	O
,	SIMPONI.xml:S1:918:1	,	,	O	O
controlled	SIMPONI.xml:S1:920:10	control	VBD	O	O
Phase	SIMPONI.xml:S1:931:5	phase	NNP	O	O
3	SIMPONI.xml:S1:937:1	3	CD	O	O
trial	SIMPONI.xml:S1:939:5	trial	NN	O	O
in	SIMPONI.xml:S1:945:2	in	IN	O	O
patients	SIMPONI.xml:S1:948:8	patient	NNS	O	O
with	SIMPONI.xml:S1:957:4	with	IN	O	O
RA	SIMPONI.xml:S1:962:2	RA	NNP	O	O
receiving	SIMPONI.xml:S1:965:9	receiv	VBG	O	O
SIMPONI	SIMPONI.xml:S1:975:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:983:4	aria	NNP	O	O
by	SIMPONI.xml:S1:988:2	by	IN	O	O
intravenous	SIMPONI.xml:S1:991:11	intraven	JJ	O	O
infusion	SIMPONI.xml:S1:1003:8	infus	NN	O	O
(	SIMPONI.xml:S1:1012:1	(	(	O	O
Trial	SIMPONI.xml:S1:1013:5	trial	JJ	O	O
1	SIMPONI.xml:S1:1019:1	1	CD	O	O
)	SIMPONI.xml:S1:1020:1	)	)	O	O
.	SIMPONI.xml:S1:1021:1	.	.	O	O

The	SIMPONI.xml:S1:1023:3	the	DT	O	O
protocol	SIMPONI.xml:S1:1027:8	protocol	NN	O	O
included	SIMPONI.xml:S1:1036:8	includ	VBD	O	O
provisions	SIMPONI.xml:S1:1045:10	provis	NNS	O	O
for	SIMPONI.xml:S1:1056:3	for	IN	O	O
patients	SIMPONI.xml:S1:1060:8	patient	NNS	O	O
taking	SIMPONI.xml:S1:1069:6	take	VBG	O	O
placebo	SIMPONI.xml:S1:1076:7	placebo	NN	O	O
to	SIMPONI.xml:S1:1084:2	to	TO	O	O
receive	SIMPONI.xml:S1:1087:7	receiv	VB	O	O
treatment	SIMPONI.xml:S1:1095:9	treatment	NN	O	O
with	SIMPONI.xml:S1:1105:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S1:1110:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:1118:4	aria	NNP	O	O
at	SIMPONI.xml:S1:1123:2	at	IN	O	O
Week	SIMPONI.xml:S1:1126:4	week	NNP	O	O
16	SIMPONI.xml:S1:1131:2	16	CD	O	O
or	SIMPONI.xml:S1:1134:2	or	CC	O	O
Week	SIMPONI.xml:S1:1137:4	week	$	O	O
24	SIMPONI.xml:S1:1142:2	24	CD	O	O
either	SIMPONI.xml:S1:1145:6	either	CC	O	O
by	SIMPONI.xml:S1:1152:2	by	IN	O	O
patient	SIMPONI.xml:S1:1155:7	patient	JJ	O	O
response	SIMPONI.xml:S1:1163:8	respons	NN	O	O
(	SIMPONI.xml:S1:1172:1	(	(	O	O
based	SIMPONI.xml:S1:1173:5	base	VBN	O	O
on	SIMPONI.xml:S1:1179:2	on	IN	O	O
uncontrolled	SIMPONI.xml:S1:1182:12	uncontrol	JJ	O	O
disease	SIMPONI.xml:S1:1195:7	diseas	NN	O	O
activity	SIMPONI.xml:S1:1203:8	activ	NN	O	O
)	SIMPONI.xml:S1:1211:1	)	)	O	O
or	SIMPONI.xml:S1:1213:2	or	CC	O	O
by	SIMPONI.xml:S1:1216:2	by	IN	O	O
design	SIMPONI.xml:S1:1219:6	design	NN	O	O
,	SIMPONI.xml:S1:1225:1	,	,	O	O
so	SIMPONI.xml:S1:1227:2	so	IN	O	O
that	SIMPONI.xml:S1:1230:4	that	DT	O	O
adverse	SIMPONI.xml:S1:1235:7	advers	JJ	O	O
events	SIMPONI.xml:S1:1243:6	event	NNS	O	O
cannot	SIMPONI.xml:S1:1250:6	cannot	NN	O	O
always	SIMPONI.xml:S1:1257:6	alway	RB	O	O
be	SIMPONI.xml:S1:1264:2	be	VB	O	O
unambiguously	SIMPONI.xml:S1:1267:13	unambigu	RB	O	O
attributed	SIMPONI.xml:S1:1281:10	attribut	VBN	O	O
to	SIMPONI.xml:S1:1292:2	to	TO	O	O
a	SIMPONI.xml:S1:1295:1	a	DT	O	O
given	SIMPONI.xml:S1:1297:5	given	VBN	O	O
treatment	SIMPONI.xml:S1:1303:9	treatment	NN	O	O
.	SIMPONI.xml:S1:1312:1	.	.	O	O

Comparisons	SIMPONI.xml:S1:1314:11	comparison	NNS	O	O
between	SIMPONI.xml:S1:1326:7	between	IN	O	O
placebo	SIMPONI.xml:S1:1334:7	placebo	NN	O	O
and	SIMPONI.xml:S1:1342:3	and	CC	O	O
SIMPONI	SIMPONI.xml:S1:1346:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:1354:4	aria	NNP	O	O
were	SIMPONI.xml:S1:1359:4	were	VBD	O	O
based	SIMPONI.xml:S1:1364:5	base	VBN	O	O
on	SIMPONI.xml:S1:1370:2	on	IN	O	O
the	SIMPONI.xml:S1:1373:3	the	DT	O	O
first	SIMPONI.xml:S1:1377:5	first	JJ	O	O
24	SIMPONI.xml:S1:1383:2	24	CD	O	O
weeks	SIMPONI.xml:S1:1386:5	week	NNS	O	O
of	SIMPONI.xml:S1:1392:2	of	IN	O	O
exposure	SIMPONI.xml:S1:1395:8	exposur	NN	O	O
.	SIMPONI.xml:S1:1403:1	.	.	O	O

Trial	SIMPONI.xml:S1:1409:5	trial	JJ	O	O
1	SIMPONI.xml:S1:1415:1	1	CD	O	O
included	SIMPONI.xml:S1:1417:8	includ	VBD	O	O
197	SIMPONI.xml:S1:1426:3	197	CD	O	O
control	SIMPONI.xml:S1:1430:7	control	NN	O	O
-	SIMPONI.xml:S1:1437:1	-	:	O	O
treated	SIMPONI.xml:S1:1438:7	treat	VBN	O	O
patients	SIMPONI.xml:S1:1446:8	patient	NNS	O	O
and	SIMPONI.xml:S1:1455:3	and	CC	O	O
463	SIMPONI.xml:S1:1459:3	463	CD	O	O
SIMPONI	SIMPONI.xml:S1:1463:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:1471:4	aria	NNP	O	O
-	SIMPONI.xml:S1:1475:1	-	:	O	O
treated	SIMPONI.xml:S1:1476:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:1484:8	patient	NNS	O	O
(	SIMPONI.xml:S1:1493:1	(	(	O	O
which	SIMPONI.xml:S1:1494:5	which	WDT	O	O
includes	SIMPONI.xml:S1:1500:8	includ	VBZ	O	O
control	SIMPONI.xml:S1:1509:7	control	NN	O	O
-	SIMPONI.xml:S1:1516:1	-	:	O	O
treated	SIMPONI.xml:S1:1517:7	treat	VBN	O	O
patients	SIMPONI.xml:S1:1525:8	patient	NNS	O	O
who	SIMPONI.xml:S1:1534:3	who	WP	O	O
switched	SIMPONI.xml:S1:1538:8	switch	VBD	O	O
to	SIMPONI.xml:S1:1547:2	to	TO	O	O
SIMPONI	SIMPONI.xml:S1:1550:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:1558:4	aria	NNP	O	O
at	SIMPONI.xml:S1:1563:2	at	IN	O	O
Week	SIMPONI.xml:S1:1566:4	week	NNP	O	O
16	SIMPONI.xml:S1:1571:2	16	CD	O	O
)	SIMPONI.xml:S1:1573:1	)	)	O	O
.	SIMPONI.xml:S1:1574:1	.	.	O	O

The	SIMPONI.xml:S1:1576:3	the	DT	O	O
proportion	SIMPONI.xml:S1:1580:10	proport	NN	O	O
of	SIMPONI.xml:S1:1591:2	of	IN	O	O
patients	SIMPONI.xml:S1:1594:8	patient	NNS	O	O
who	SIMPONI.xml:S1:1603:3	who	WP	O	O
discontinued	SIMPONI.xml:S1:1607:12	discontinu	VBD	O	O
treatment	SIMPONI.xml:S1:1620:9	treatment	NN	O	O
due	SIMPONI.xml:S1:1630:3	due	JJ	O	O
to	SIMPONI.xml:S1:1634:2	to	TO	O	O
adverse	SIMPONI.xml:S1:1637:7	advers	JJ	O	O
reactions	SIMPONI.xml:S1:1645:9	reaction	NNS	O	O
in	SIMPONI.xml:S1:1655:2	in	IN	O	O
the	SIMPONI.xml:S1:1658:3	the	DT	O	O
controlled	SIMPONI.xml:S1:1662:10	control	JJ	O	O
phase	SIMPONI.xml:S1:1673:5	phase	NN	O	O
of	SIMPONI.xml:S1:1679:2	of	IN	O	O
Trial	SIMPONI.xml:S1:1682:5	trial	JJ	O	O
1	SIMPONI.xml:S1:1688:1	1	CD	O	O
through	SIMPONI.xml:S1:1690:7	through	IN	O	O
Week	SIMPONI.xml:S1:1698:4	week	JJ	O	O
24	SIMPONI.xml:S1:1703:2	24	CD	O	O
was	SIMPONI.xml:S1:1706:3	wa	VBD	O	O
3.5%	SIMPONI.xml:S1:1710:4	3.5%	CD	O	O
for	SIMPONI.xml:S1:1715:3	for	IN	O	O
SIMPONI	SIMPONI.xml:S1:1719:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:1727:4	aria	NNP	O	O
-	SIMPONI.xml:S1:1731:1	-	:	O	O
treated	SIMPONI.xml:S1:1732:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:1740:8	patient	NNS	O	O
and	SIMPONI.xml:S1:1749:3	and	CC	O	O
0.5%	SIMPONI.xml:S1:1753:4	0.5%	CD	O	O
for	SIMPONI.xml:S1:1758:3	for	IN	O	O
placebo	SIMPONI.xml:S1:1762:7	placebo	NN	O	O
-	SIMPONI.xml:S1:1769:1	-	:	O	O
treated	SIMPONI.xml:S1:1770:7	treat	JJ	O	O
patients	SIMPONI.xml:S1:1778:8	patient	NNS	O	O
.	SIMPONI.xml:S1:1786:1	.	.	O	O

Upper	SIMPONI.xml:S1:1788:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	SIMPONI.xml:S1:1794:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	SIMPONI.xml:S1:1806:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	SIMPONI.xml:S1:1812:9	infect	NN	I-AdverseReaction	I-AdverseReaction
was	SIMPONI.xml:S1:1822:3	wa	VBD	O	O
the	SIMPONI.xml:S1:1826:3	the	DT	O	O
most	SIMPONI.xml:S1:1830:4	most	RBS	O	O
common	SIMPONI.xml:S1:1835:6	common	JJ	O	O
adverse	SIMPONI.xml:S1:1842:7	advers	JJ	O	O
reaction	SIMPONI.xml:S1:1850:8	reaction	NN	O	O
reported	SIMPONI.xml:S1:1859:8	report	VBN	O	O
in	SIMPONI.xml:S1:1868:2	in	IN	O	O
the	SIMPONI.xml:S1:1871:3	the	DT	O	O
trial	SIMPONI.xml:S1:1875:5	trial	NN	O	O
through	SIMPONI.xml:S1:1881:7	through	IN	O	O
Week	SIMPONI.xml:S1:1889:4	week	NNP	O	O
24	SIMPONI.xml:S1:1894:2	24	CD	O	O
occurring	SIMPONI.xml:S1:1897:9	occur	VBG	O	O
in	SIMPONI.xml:S1:1907:2	in	IN	O	O
6.5%	SIMPONI.xml:S1:1910:4	6.5%	CD	O	O
of	SIMPONI.xml:S1:1915:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S1:1918:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:1926:4	aria	NNP	O	O
-	SIMPONI.xml:S1:1930:1	-	:	O	O
treated	SIMPONI.xml:S1:1931:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:1939:8	patient	NNS	O	O
as	SIMPONI.xml:S1:1948:2	as	IN	O	O
compared	SIMPONI.xml:S1:1951:8	compar	VBN	O	O
with	SIMPONI.xml:S1:1960:4	with	IN	O	O
7.6%	SIMPONI.xml:S1:1965:4	7.6%	CD	O	O
of	SIMPONI.xml:S1:1970:2	of	IN	O	O
control	SIMPONI.xml:S1:1973:7	control	NN	O	O
-	SIMPONI.xml:S1:1980:1	-	:	O	O
treated	SIMPONI.xml:S1:1981:7	treat	JJ	O	O
patients	SIMPONI.xml:S1:1989:8	patient	NNS	O	O
,	SIMPONI.xml:S1:1997:1	,	,	O	O
respectively	SIMPONI.xml:S1:1999:12	respect	RB	O	O
.	SIMPONI.xml:S1:2011:1	.	.	O	O

Infections	SIMPONI.xml:S1:2021:10	infect	NNS	O	O

Serious	SIMPONI.xml:S1:2038:7	seriou	JJ	O	O
infections	SIMPONI.xml:S1:2046:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
observed	SIMPONI.xml:S1:2057:8	observ	VBN	O	O
in	SIMPONI.xml:S1:2066:2	in	IN	O	O
SIMPONI	SIMPONI.xml:S1:2069:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:2077:4	aria	NNP	O	O
-	SIMPONI.xml:S1:2081:1	-	:	O	O
treated	SIMPONI.xml:S1:2082:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:2090:8	patient	NNS	O	O
included	SIMPONI.xml:S1:2099:8	includ	JJ	O	O
sepsis	SIMPONI.xml:S1:2108:6	sepsi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:2114:1	,	,	O	O
pneumonia	SIMPONI.xml:S1:2116:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:2125:1	,	,	O	O
cellulitis	SIMPONI.xml:S1:2127:10	cellul	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:2137:1	,	,	O	O
abscess	SIMPONI.xml:S1:2139:7	abscess	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:2146:1	,	,	O	O
opportunistic	SIMPONI.xml:S1:2148:13	opportunist	JJ	B-AdverseReaction	B-AdverseReaction
infections	SIMPONI.xml:S1:2162:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S1:2172:1	,	,	O	O
tuberculosis	SIMPONI.xml:S1:2174:12	tuberculosi	NN	B-AdverseReaction	B-AdverseReaction
(	SIMPONI.xml:S1:2187:1	(	(	O	O
TB	SIMPONI.xml:S1:2188:2	TB	NNP	B-AdverseReaction	O
)	SIMPONI.xml:S1:2190:1	)	)	O	O
,	SIMPONI.xml:S1:2191:1	,	,	O	O
and	SIMPONI.xml:S1:2193:3	and	CC	O	O
invasive	SIMPONI.xml:S1:2197:8	invas	JJ	B-AdverseReaction	B-AdverseReaction
fungal	SIMPONI.xml:S1:2206:6	fungal	JJ	I-AdverseReaction	I-AdverseReaction
infections	SIMPONI.xml:S1:2213:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
.	SIMPONI.xml:S1:2223:1	.	.	O	O

Cases	SIMPONI.xml:S1:2225:5	case	NNS	O	O
of	SIMPONI.xml:S1:2231:2	of	IN	O	O
TB	SIMPONI.xml:S1:2234:2	TB	NNP	B-AdverseReaction	B-AdverseReaction
included	SIMPONI.xml:S1:2237:8	includ	VBD	O	O
pulmonary	SIMPONI.xml:S1:2246:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
and	SIMPONI.xml:S1:2256:3	and	CC	O	O
extrapulmonary	SIMPONI.xml:S1:2260:14	extrapulmonari	JJ	B-AdverseReaction	O
TB	SIMPONI.xml:S1:2275:2	TB	NNP	I-AdverseReaction	O
.	SIMPONI.xml:S1:2277:1	.	.	O	O

The	SIMPONI.xml:S1:2279:3	the	DT	O	O
majority	SIMPONI.xml:S1:2283:8	major	NN	O	O
of	SIMPONI.xml:S1:2292:2	of	IN	O	O
the	SIMPONI.xml:S1:2295:3	the	DT	O	O
TB	SIMPONI.xml:S1:2299:2	TB	NNP	B-AdverseReaction	O
cases	SIMPONI.xml:S1:2302:5	case	NNS	O	O
occurred	SIMPONI.xml:S1:2308:8	occur	VBD	O	O
in	SIMPONI.xml:S1:2317:2	in	IN	O	O
countries	SIMPONI.xml:S1:2320:9	countri	NNS	O	O
with	SIMPONI.xml:S1:2330:4	with	IN	O	O
a	SIMPONI.xml:S1:2335:1	a	DT	O	O
high	SIMPONI.xml:S1:2337:4	high	JJ	O	O
incidence	SIMPONI.xml:S1:2342:9	incid	NN	O	O
rate	SIMPONI.xml:S1:2352:4	rate	NN	O	O
of	SIMPONI.xml:S1:2357:2	of	IN	O	O
TB	SIMPONI.xml:S1:2360:2	TB	NNP	O	B-AdverseReaction
[	SIMPONI.xml:S1:2364:1	[	NNP	O	O
see	SIMPONI.xml:S1:2365:3	see	VBP	O	O
Warnings	SIMPONI.xml:S1:2370:8	warn	NNP	O	O
and	SIMPONI.xml:S1:2379:3	and	CC	O	O
Precautions	SIMPONI.xml:S1:2383:11	precaut	NNP	O	O
(	SIMPONI.xml:S1:2395:1	(	(	O	O
5.1	SIMPONI.xml:S1:2396:3	5.1	CD	O	O
)	SIMPONI.xml:S1:2399:1	)	)	O	O
]	SIMPONI.xml:S1:2402:1	]	NN	O	O
.	SIMPONI.xml:S1:2405:1	.	.	O	O

In	SIMPONI.xml:S1:2411:2	In	IN	O	O
the	SIMPONI.xml:S1:2414:3	the	DT	O	O
controlled	SIMPONI.xml:S1:2418:10	control	JJ	O	O
phase	SIMPONI.xml:S1:2429:5	phase	NN	O	O
of	SIMPONI.xml:S1:2435:2	of	IN	O	O
Trial	SIMPONI.xml:S1:2438:5	trial	JJ	O	O
1	SIMPONI.xml:S1:2444:1	1	CD	O	O
through	SIMPONI.xml:S1:2446:7	through	IN	O	O
Week	SIMPONI.xml:S1:2454:4	week	JJ	O	O
24	SIMPONI.xml:S1:2459:2	24	CD	O	O
,	SIMPONI.xml:S1:2461:1	,	,	O	O
infections	SIMPONI.xml:S1:2463:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
were	SIMPONI.xml:S1:2474:4	were	VBD	O	O
observed	SIMPONI.xml:S1:2479:8	observ	VBN	O	O
in	SIMPONI.xml:S1:2488:2	in	IN	O	O
27%	SIMPONI.xml:S1:2491:3	27%	CD	O	O
of	SIMPONI.xml:S1:2495:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S1:2498:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:2506:4	aria	NNP	O	O
-	SIMPONI.xml:S1:2510:1	-	:	O	O
treated	SIMPONI.xml:S1:2511:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:2519:8	patient	NNS	O	O
compared	SIMPONI.xml:S1:2528:8	compar	VBN	O	O
with	SIMPONI.xml:S1:2537:4	with	IN	O	O
24%	SIMPONI.xml:S1:2542:3	24%	CD	O	O
of	SIMPONI.xml:S1:2546:2	of	IN	O	O
control	SIMPONI.xml:S1:2549:7	control	NN	O	O
-	SIMPONI.xml:S1:2556:1	-	:	O	O
treated	SIMPONI.xml:S1:2557:7	treat	JJ	O	O
patients	SIMPONI.xml:S1:2565:8	patient	NNS	O	O
,	SIMPONI.xml:S1:2573:1	,	,	O	O
and	SIMPONI.xml:S1:2575:3	and	CC	O	O
serious	SIMPONI.xml:S1:2579:7	seriou	JJ	O	O
infections	SIMPONI.xml:S1:2587:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
were	SIMPONI.xml:S1:2598:4	were	VBD	O	O
observed	SIMPONI.xml:S1:2603:8	observ	VBN	O	O
in	SIMPONI.xml:S1:2612:2	in	IN	O	O
0.9%	SIMPONI.xml:S1:2615:4	0.9%	CD	O	O
of	SIMPONI.xml:S1:2620:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S1:2623:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:2631:4	aria	NNP	O	O
-	SIMPONI.xml:S1:2635:1	-	:	O	O
treated	SIMPONI.xml:S1:2636:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:2644:8	patient	NNS	O	O
and	SIMPONI.xml:S1:2653:3	and	CC	O	O
0.0%	SIMPONI.xml:S1:2657:4	0.0%	CD	O	O
of	SIMPONI.xml:S1:2662:2	of	IN	O	O
control	SIMPONI.xml:S1:2665:7	control	NN	O	O
-	SIMPONI.xml:S1:2672:1	-	:	O	O
treated	SIMPONI.xml:S1:2673:7	treat	JJ	O	O
patients	SIMPONI.xml:S1:2681:8	patient	NNS	O	O
.	SIMPONI.xml:S1:2689:1	.	.	O	O

Through	SIMPONI.xml:S1:2691:7	through	IN	O	O
Week	SIMPONI.xml:S1:2699:4	week	NNP	O	O
24	SIMPONI.xml:S1:2704:2	24	CD	O	O
,	SIMPONI.xml:S1:2706:1	,	,	O	O
the	SIMPONI.xml:S1:2708:3	the	DT	O	O
incidence	SIMPONI.xml:S1:2712:9	incid	NN	O	O
of	SIMPONI.xml:S1:2722:2	of	IN	O	O
serious	SIMPONI.xml:S1:2725:7	seriou	JJ	O	O
infections	SIMPONI.xml:S1:2733:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
per	SIMPONI.xml:S1:2744:3	per	IN	O	O
100	SIMPONI.xml:S1:2748:3	100	CD	O	O
patient	SIMPONI.xml:S1:2752:7	patient	JJ	O	O
-	SIMPONI.xml:S1:2759:1	-	:	O	O
years	SIMPONI.xml:S1:2760:5	year	NNS	O	O
of	SIMPONI.xml:S1:2766:2	of	IN	O	O
follow	SIMPONI.xml:S1:2769:6	follow	NN	O	O
-	SIMPONI.xml:S1:2775:1	-	:	O	O
up	SIMPONI.xml:S1:2776:2	up	NN	O	O
was	SIMPONI.xml:S1:2779:3	wa	VBD	O	O
2.2	SIMPONI.xml:S1:2783:3	2.2	CD	O	O
(	SIMPONI.xml:S1:2787:1	(	(	O	O
95%	SIMPONI.xml:S1:2788:3	95%	CD	O	O
CI	SIMPONI.xml:S1:2792:2	CI	NNP	O	O
0.61	SIMPONI.xml:S1:2795:4	0.61	CD	O	O
,	SIMPONI.xml:S1:2799:1	,	,	O	O
5.71	SIMPONI.xml:S1:2801:4	5.71	CD	O	O
)	SIMPONI.xml:S1:2805:1	)	)	O	O
for	SIMPONI.xml:S1:2807:3	for	IN	O	O
the	SIMPONI.xml:S1:2811:3	the	DT	O	O
SIMPONI	SIMPONI.xml:S1:2815:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:2823:4	aria	NNP	O	O
group	SIMPONI.xml:S1:2828:5	group	NN	O	O
,	SIMPONI.xml:S1:2833:1	,	,	O	O
and	SIMPONI.xml:S1:2835:3	and	CC	O	O
0	SIMPONI.xml:S1:2839:1	0	CD	O	O
(	SIMPONI.xml:S1:2841:1	(	(	O	O
0.00	SIMPONI.xml:S1:2842:4	0.00	CD	O	O
,	SIMPONI.xml:S1:2846:1	,	,	O	O
3.79	SIMPONI.xml:S1:2848:4	3.79	CD	O	O
)	SIMPONI.xml:S1:2852:1	)	)	O	O
for	SIMPONI.xml:S1:2854:3	for	IN	O	O
the	SIMPONI.xml:S1:2858:3	the	DT	O	O
placebo	SIMPONI.xml:S1:2862:7	placebo	NN	O	O
group	SIMPONI.xml:S1:2870:5	group	NN	O	O
.	SIMPONI.xml:S1:2875:1	.	.	O	O

In	SIMPONI.xml:S1:2877:2	In	IN	O	O
the	SIMPONI.xml:S1:2880:3	the	DT	O	O
controlled	SIMPONI.xml:S1:2884:10	control	VBN	O	O
and	SIMPONI.xml:S1:2895:3	and	CC	O	O
uncontrolled	SIMPONI.xml:S1:2899:12	uncontrol	JJ	O	O
portions	SIMPONI.xml:S1:2912:8	portion	NNS	O	O
of	SIMPONI.xml:S1:2921:2	of	IN	O	O
Trial	SIMPONI.xml:S1:2924:5	trial	NNP	O	O
1	SIMPONI.xml:S1:2930:1	1	CD	O	O
,	SIMPONI.xml:S1:2931:1	,	,	O	O
958	SIMPONI.xml:S1:2933:3	958	CD	O	O
total	SIMPONI.xml:S1:2937:5	total	JJ	O	O
patient	SIMPONI.xml:S1:2943:7	patient	JJ	O	O
-	SIMPONI.xml:S1:2950:1	-	:	O	O
years	SIMPONI.xml:S1:2951:5	year	NNS	O	O
of	SIMPONI.xml:S1:2957:2	of	IN	O	O
follow	SIMPONI.xml:S1:2960:6	follow	NN	O	O
-	SIMPONI.xml:S1:2966:1	-	:	O	O
up	SIMPONI.xml:S1:2967:2	up	RB	O	O
with	SIMPONI.xml:S1:2970:4	with	IN	O	O
a	SIMPONI.xml:S1:2975:1	a	DT	O	O
median	SIMPONI.xml:S1:2977:6	median	JJ	O	O
follow	SIMPONI.xml:S1:2984:6	follow	NN	O	O
-	SIMPONI.xml:S1:2990:1	-	:	O	O
up	SIMPONI.xml:S1:2991:2	up	IN	O	O
of	SIMPONI.xml:S1:2994:2	of	IN	O	O
approximately	SIMPONI.xml:S1:2997:13	approxim	RB	O	O
92	SIMPONI.xml:S1:3011:2	92	CD	O	O
weeks	SIMPONI.xml:S1:3014:5	week	NNS	O	O
,	SIMPONI.xml:S1:3019:1	,	,	O	O
the	SIMPONI.xml:S1:3021:3	the	DT	O	O
incidence	SIMPONI.xml:S1:3025:9	incid	NN	O	O
per	SIMPONI.xml:S1:3035:3	per	IN	O	O
100	SIMPONI.xml:S1:3039:3	100	CD	O	O
patient	SIMPONI.xml:S1:3043:7	patient	JJ	O	O
-	SIMPONI.xml:S1:3050:1	-	:	O	O
years	SIMPONI.xml:S1:3051:5	year	NNS	O	O
of	SIMPONI.xml:S1:3057:2	of	IN	O	O
all	SIMPONI.xml:S1:3060:3	all	DT	O	O
serious	SIMPONI.xml:S1:3064:7	seriou	JJ	O	O
infections	SIMPONI.xml:S1:3072:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
was	SIMPONI.xml:S1:3083:3	wa	VBD	O	O
4.07	SIMPONI.xml:S1:3087:4	4.07	CD	O	O
(	SIMPONI.xml:S1:3092:1	(	(	O	O
CI	SIMPONI.xml:S1:3093:2	CI	NNP	O	O
:	SIMPONI.xml:S1:3095:1	:	:	O	O
2.90	SIMPONI.xml:S1:3097:4	2.90	CD	O	O
,	SIMPONI.xml:S1:3101:1	,	,	O	O
5.57	SIMPONI.xml:S1:3103:4	5.57	CD	O	O
)	SIMPONI.xml:S1:3107:1	)	)	O	O
in	SIMPONI.xml:S1:3109:2	in	IN	O	O
patients	SIMPONI.xml:S1:3112:8	patient	NNS	O	O
receiving	SIMPONI.xml:S1:3121:9	receiv	VBG	O	O
SIMPONI	SIMPONI.xml:S1:3131:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:3139:4	aria	NNP	O	O
[	SIMPONI.xml:S1:3145:1	[	NNP	O	O
see	SIMPONI.xml:S1:3146:3	see	VBP	O	O
Warnings	SIMPONI.xml:S1:3151:8	warn	NNP	O	O
and	SIMPONI.xml:S1:3160:3	and	CC	O	O
Precautions	SIMPONI.xml:S1:3164:11	precaut	NNP	O	O
(	SIMPONI.xml:S1:3176:1	(	(	O	O
5.1	SIMPONI.xml:S1:3177:3	5.1	CD	O	O
)	SIMPONI.xml:S1:3180:1	)	)	O	O
]	SIMPONI.xml:S1:3183:1	]	NN	O	O
.	SIMPONI.xml:S1:3186:1	.	.	O	O

In	SIMPONI.xml:S1:3188:2	In	IN	O	O
the	SIMPONI.xml:S1:3191:3	the	DT	O	O
controlled	SIMPONI.xml:S1:3195:10	control	VBN	O	O
and	SIMPONI.xml:S1:3206:3	and	CC	O	O
uncontrolled	SIMPONI.xml:S1:3210:12	uncontrol	JJ	O	O
portions	SIMPONI.xml:S1:3223:8	portion	NNS	O	O
of	SIMPONI.xml:S1:3232:2	of	IN	O	O
Trial	SIMPONI.xml:S1:3235:5	trial	NNP	O	O
1	SIMPONI.xml:S1:3241:1	1	CD	O	O
,	SIMPONI.xml:S1:3242:1	,	,	O	O
in	SIMPONI.xml:S1:3244:2	in	IN	O	O
SIMPONI	SIMPONI.xml:S1:3247:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:3255:4	aria	NNP	O	O
treated	SIMPONI.xml:S1:3260:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:3268:8	patient	NNS	O	O
,	SIMPONI.xml:S1:3276:1	,	,	O	O
the	SIMPONI.xml:S1:3278:3	the	DT	O	O
incidence	SIMPONI.xml:S1:3282:9	incid	NN	O	O
of	SIMPONI.xml:S1:3292:2	of	IN	O	O
active	SIMPONI.xml:S1:3295:6	activ	JJ	B-AdverseReaction	O
TB	SIMPONI.xml:S1:3302:2	TB	NNP	I-AdverseReaction	O
per	SIMPONI.xml:S1:3305:3	per	IN	O	O
100	SIMPONI.xml:S1:3309:3	100	CD	O	O
patient	SIMPONI.xml:S1:3313:7	patient	JJ	O	O
-	SIMPONI.xml:S1:3320:1	-	:	O	O
years	SIMPONI.xml:S1:3321:5	year	NNS	O	O
was	SIMPONI.xml:S1:3327:3	wa	VBD	O	O
0.31	SIMPONI.xml:S1:3331:4	0.31	CD	O	O
(	SIMPONI.xml:S1:3336:1	(	(	O	O
95%	SIMPONI.xml:S1:3337:3	95%	CD	O	O
CI	SIMPONI.xml:S1:3341:2	CI	NNP	O	O
:	SIMPONI.xml:S1:3343:1	:	:	O	O
0.06	SIMPONI.xml:S1:3345:4	0.06	CD	O	O
;	SIMPONI.xml:S1:3349:1	;	:	O	O
0.92	SIMPONI.xml:S1:3351:4	0.92	CD	O	O
)	SIMPONI.xml:S1:3355:1	)	)	O	O
and	SIMPONI.xml:S1:3357:3	and	CC	O	O
the	SIMPONI.xml:S1:3361:3	the	DT	O	O
incidence	SIMPONI.xml:S1:3365:9	incid	NN	O	O
of	SIMPONI.xml:S1:3375:2	of	IN	O	O
other	SIMPONI.xml:S1:3378:5	other	JJ	O	O
opportunistic	SIMPONI.xml:S1:3384:13	opportunist	JJ	B-AdverseReaction	B-AdverseReaction
infections	SIMPONI.xml:S1:3398:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
per	SIMPONI.xml:S1:3409:3	per	IN	O	O
100	SIMPONI.xml:S1:3413:3	100	CD	O	O
patient	SIMPONI.xml:S1:3417:7	patient	JJ	O	O
-	SIMPONI.xml:S1:3424:1	-	:	O	O
years	SIMPONI.xml:S1:3425:5	year	NNS	O	O
was	SIMPONI.xml:S1:3431:3	wa	VBD	O	O
0.42	SIMPONI.xml:S1:3435:4	0.42	CD	O	O
(	SIMPONI.xml:S1:3440:1	(	(	O	O
95%	SIMPONI.xml:S1:3441:3	95%	CD	O	O
CI	SIMPONI.xml:S1:3445:2	CI	NNP	O	O
:	SIMPONI.xml:S1:3447:1	:	:	O	O
0.11	SIMPONI.xml:S1:3449:4	0.11	CD	O	O
,	SIMPONI.xml:S1:3453:1	,	,	O	O
1.07	SIMPONI.xml:S1:3455:4	1.07	CD	O	O
)	SIMPONI.xml:S1:3459:1	)	)	O	O
.	SIMPONI.xml:S1:3460:1	.	.	O	O

Malignancies	SIMPONI.xml:S1:3470:12	malign	NNS	O	O

One	SIMPONI.xml:S1:3489:3	one	CD	O	O
case	SIMPONI.xml:S1:3493:4	case	NN	O	O
of	SIMPONI.xml:S1:3498:2	of	IN	O	O
malignancy	SIMPONI.xml:S1:3501:10	malign	NN	B-AdverseReaction	O
other	SIMPONI.xml:S1:3512:5	other	JJ	O	O
than	SIMPONI.xml:S1:3518:4	than	IN	O	O
lymphoma	SIMPONI.xml:S1:3523:8	lymphoma	NN	B-AdverseReaction	B-AdverseReaction
and	SIMPONI.xml:S1:3532:3	and	CC	O	O
NMSC	SIMPONI.xml:S1:3536:4	nmsc	NNP	B-AdverseReaction	O
with	SIMPONI.xml:S1:3541:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S1:3546:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:3554:4	aria	NNP	O	O
was	SIMPONI.xml:S1:3559:3	wa	VBD	O	O
reported	SIMPONI.xml:S1:3563:8	report	VBN	O	O
through	SIMPONI.xml:S1:3572:7	through	IN	O	O
Week	SIMPONI.xml:S1:3580:4	week	JJ	O	O
24	SIMPONI.xml:S1:3585:2	24	CD	O	O
during	SIMPONI.xml:S1:3588:6	dure	IN	O	O
the	SIMPONI.xml:S1:3595:3	the	DT	O	O
controlled	SIMPONI.xml:S1:3599:10	control	JJ	O	O
phase	SIMPONI.xml:S1:3610:5	phase	NN	O	O
of	SIMPONI.xml:S1:3616:2	of	IN	O	O
Trial	SIMPONI.xml:S1:3619:5	trial	JJ	O	O
1	SIMPONI.xml:S1:3625:1	1	CD	O	O
.	SIMPONI.xml:S1:3626:1	.	.	O	O

In	SIMPONI.xml:S1:3628:2	In	IN	O	O
the	SIMPONI.xml:S1:3631:3	the	DT	O	O
controlled	SIMPONI.xml:S1:3635:10	control	VBN	O	O
and	SIMPONI.xml:S1:3646:3	and	CC	O	O
uncontrolled	SIMPONI.xml:S1:3650:12	uncontrol	JJ	O	O
portions	SIMPONI.xml:S1:3663:8	portion	NNS	O	O
through	SIMPONI.xml:S1:3672:7	through	IN	O	O
approximately	SIMPONI.xml:S1:3680:13	approxim	RB	O	O
92	SIMPONI.xml:S1:3694:2	92	CD	O	O
weeks	SIMPONI.xml:S1:3697:5	week	NNS	O	O
,	SIMPONI.xml:S1:3702:1	,	,	O	O
the	SIMPONI.xml:S1:3704:3	the	DT	O	O
incidence	SIMPONI.xml:S1:3708:9	incid	NN	O	O
of	SIMPONI.xml:S1:3718:2	of	IN	O	O
malignancies	SIMPONI.xml:S1:3721:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
per	SIMPONI.xml:S1:3734:3	per	IN	O	O
100	SIMPONI.xml:S1:3738:3	100	CD	O	O
patient	SIMPONI.xml:S1:3742:7	patient	JJ	O	O
-	SIMPONI.xml:S1:3749:1	-	:	O	O
years	SIMPONI.xml:S1:3750:5	year	NNS	O	O
,	SIMPONI.xml:S1:3755:1	,	,	O	O
other	SIMPONI.xml:S1:3757:5	other	JJ	O	O
than	SIMPONI.xml:S1:3763:4	than	IN	O	O
lymphoma	SIMPONI.xml:S1:3768:8	lymphoma	NN	B-AdverseReaction	B-AdverseReaction
and	SIMPONI.xml:S1:3777:3	and	CC	O	O
NMSC	SIMPONI.xml:S1:3781:4	nmsc	NNP	B-AdverseReaction	O
,	SIMPONI.xml:S1:3785:1	,	,	O	O
in	SIMPONI.xml:S1:3787:2	in	IN	O	O
SIMPONI	SIMPONI.xml:S1:3790:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:3798:4	aria	NNP	O	O
-	SIMPONI.xml:S1:3802:1	-	:	O	O
treated	SIMPONI.xml:S1:3803:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:3811:8	patient	NNS	O	O
was	SIMPONI.xml:S1:3820:3	wa	VBD	O	O
0.31	SIMPONI.xml:S1:3824:4	0.31	CD	O	O
(	SIMPONI.xml:S1:3829:1	(	(	O	O
CI	SIMPONI.xml:S1:3830:2	CI	NNP	O	O
:	SIMPONI.xml:S1:3832:1	:	:	O	O
0.06	SIMPONI.xml:S1:3834:4	0.06	CD	O	O
,	SIMPONI.xml:S1:3838:1	,	,	O	O
0.92	SIMPONI.xml:S1:3840:4	0.92	CD	O	O
)	SIMPONI.xml:S1:3844:1	)	)	O	O
and	SIMPONI.xml:S1:3846:3	and	CC	O	O
the	SIMPONI.xml:S1:3850:3	the	DT	O	O
incidence	SIMPONI.xml:S1:3854:9	incid	NN	O	O
of	SIMPONI.xml:S1:3864:2	of	IN	O	O
NMSC	SIMPONI.xml:S1:3867:4	nmsc	NNP	B-AdverseReaction	O
was	SIMPONI.xml:S1:3872:3	wa	VBD	O	O
0.1	SIMPONI.xml:S1:3876:3	0.1	CD	O	O
(	SIMPONI.xml:S1:3880:1	(	(	O	O
95%	SIMPONI.xml:S1:3881:3	95%	CD	O	O
CI	SIMPONI.xml:S1:3885:2	CI	NNP	O	O
:	SIMPONI.xml:S1:3887:1	:	:	O	O
0.00	SIMPONI.xml:S1:3889:4	0.00	CD	O	O
,	SIMPONI.xml:S1:3893:1	,	,	O	O
0.58	SIMPONI.xml:S1:3895:4	0.58	CD	O	O
)	SIMPONI.xml:S1:3899:1	)	)	O	O
.	SIMPONI.xml:S1:3900:1	.	.	O	O

Liver	SIMPONI.xml:S1:3910:5	liver	NNP	O	O
Enzyme	SIMPONI.xml:S1:3916:6	enzym	NNP	O	O
Elevations	SIMPONI.xml:S1:3923:10	elev	NNP	O	O

There	SIMPONI.xml:S1:3940:5	there	EX	O	O
have	SIMPONI.xml:S1:3946:4	have	VBP	O	O
been	SIMPONI.xml:S1:3951:4	been	VBN	O	O
reports	SIMPONI.xml:S1:3956:7	report	NNS	O	O
of	SIMPONI.xml:S1:3964:2	of	IN	O	O
severe	SIMPONI.xml:S1:3967:6	sever	JJ	O	O
hepatic	SIMPONI.xml:S1:3974:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
reactions	SIMPONI.xml:S1:3982:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
including	SIMPONI.xml:S1:3992:9	includ	VBG	O	O
acute	SIMPONI.xml:S1:4002:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
liver	SIMPONI.xml:S1:4008:5	liver	JJ	I-AdverseReaction	I-AdverseReaction
failure	SIMPONI.xml:S1:4014:7	failur	NN	I-AdverseReaction	I-AdverseReaction
in	SIMPONI.xml:S1:4022:2	in	IN	O	O
patients	SIMPONI.xml:S1:4025:8	patient	NNS	O	O
receiving	SIMPONI.xml:S1:4034:9	receiv	VBG	O	O
TNF	SIMPONI.xml:S1:4044:3	tnf	NNP	O	O
-	SIMPONI.xml:S1:4047:1	-	:	O	O
blockers	SIMPONI.xml:S1:4048:8	blocker	NNS	O	O
.	SIMPONI.xml:S1:4056:1	.	.	O	O

In	SIMPONI.xml:S1:4062:2	In	IN	O	O
the	SIMPONI.xml:S1:4065:3	the	DT	O	O
controlled	SIMPONI.xml:S1:4069:10	control	JJ	O	O
phase	SIMPONI.xml:S1:4080:5	phase	NN	O	O
of	SIMPONI.xml:S1:4086:2	of	IN	O	O
Trial	SIMPONI.xml:S1:4089:5	trial	NNP	O	O
1	SIMPONI.xml:S1:4095:1	1	CD	O	O
,	SIMPONI.xml:S1:4096:1	,	,	O	O
through	SIMPONI.xml:S1:4098:7	through	IN	O	O
Week	SIMPONI.xml:S1:4106:4	week	NNP	O	O
24	SIMPONI.xml:S1:4111:2	24	CD	O	O
,	SIMPONI.xml:S1:4113:1	,	,	O	O
ALT	SIMPONI.xml:S1:4115:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
elevations	SIMPONI.xml:S1:4119:10	elev	VBZ	I-AdverseReaction	I-AdverseReaction
5	SIMPONI.xml:S1:4133:1	5	CD	O	O
ULN	SIMPONI.xml:S1:4137:3	uln	NNP	O	O
occurred	SIMPONI.xml:S1:4141:8	occur	VBD	O	O
in	SIMPONI.xml:S1:4150:2	in	IN	O	O
0.8%	SIMPONI.xml:S1:4153:4	0.8%	CD	O	O
of	SIMPONI.xml:S1:4158:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S1:4161:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:4169:4	aria	NNP	O	O
-	SIMPONI.xml:S1:4173:1	-	:	O	O
treated	SIMPONI.xml:S1:4174:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:4182:8	patient	NNS	O	O
and	SIMPONI.xml:S1:4191:3	and	CC	O	O
0%	SIMPONI.xml:S1:4195:2	0%	CD	O	O
of	SIMPONI.xml:S1:4198:2	of	IN	O	O
control	SIMPONI.xml:S1:4201:7	control	NN	O	O
-	SIMPONI.xml:S1:4208:1	-	:	O	O
treated	SIMPONI.xml:S1:4209:7	treat	VBN	O	O
patients	SIMPONI.xml:S1:4217:8	patient	NNS	O	O
and	SIMPONI.xml:S1:4226:3	and	CC	O	O
ALT	SIMPONI.xml:S1:4230:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
elevations	SIMPONI.xml:S1:4234:10	elev	NNS	I-AdverseReaction	I-AdverseReaction
3	SIMPONI.xml:S1:4248:1	3	CD	O	O
ULN	SIMPONI.xml:S1:4252:3	uln	NNP	O	O
occurred	SIMPONI.xml:S1:4256:8	occur	VBD	O	O
in	SIMPONI.xml:S1:4265:2	in	IN	O	O
2.3%	SIMPONI.xml:S1:4268:4	2.3%	CD	O	O
of	SIMPONI.xml:S1:4273:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S1:4276:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:4284:4	aria	NNP	O	O
-	SIMPONI.xml:S1:4288:1	-	:	O	O
treated	SIMPONI.xml:S1:4289:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:4297:8	patient	NNS	O	O
and	SIMPONI.xml:S1:4306:3	and	CC	O	O
2.5%	SIMPONI.xml:S1:4310:4	2.5%	CD	O	O
of	SIMPONI.xml:S1:4315:2	of	IN	O	O
control	SIMPONI.xml:S1:4318:7	control	NN	O	O
-	SIMPONI.xml:S1:4325:1	-	:	O	O
treated	SIMPONI.xml:S1:4326:7	treat	JJ	O	O
patients	SIMPONI.xml:S1:4334:8	patient	NNS	O	O
.	SIMPONI.xml:S1:4342:1	.	.	O	O

Since	SIMPONI.xml:S1:4348:5	sinc	IN	O	O
many	SIMPONI.xml:S1:4354:4	mani	JJ	O	O
of	SIMPONI.xml:S1:4359:2	of	IN	O	O
the	SIMPONI.xml:S1:4362:3	the	DT	O	O
patients	SIMPONI.xml:S1:4366:8	patient	NNS	O	O
in	SIMPONI.xml:S1:4375:2	in	IN	O	O
the	SIMPONI.xml:S1:4378:3	the	DT	O	O
Phase	SIMPONI.xml:S1:4382:5	phase	NNP	O	O
3	SIMPONI.xml:S1:4388:1	3	CD	O	O
trial	SIMPONI.xml:S1:4390:5	trial	NN	O	O
were	SIMPONI.xml:S1:4396:4	were	VBD	O	O
also	SIMPONI.xml:S1:4401:4	also	RB	O	O
taking	SIMPONI.xml:S1:4406:6	take	VBG	O	O
medications	SIMPONI.xml:S1:4413:11	medic	NNS	O	O
that	SIMPONI.xml:S1:4425:4	that	WDT	O	O
cause	SIMPONI.xml:S1:4430:5	caus	VBP	O	O
liver	SIMPONI.xml:S1:4436:5	liver	JJ	O	O
enzyme	SIMPONI.xml:S1:4442:6	enzym	JJ	O	O
elevations	SIMPONI.xml:S1:4449:10	elev	NNS	O	O
(	SIMPONI.xml:S1:4460:1	(	(	O	O
e	SIMPONI.xml:S1:4461:1	e	NN	O	O
.	SIMPONI.xml:S1:4462:1	.	.	O	O
g	SIMPONI.xml:S1:4463:1	g	NN	O	O
.	SIMPONI.xml:S1:4464:1	.	.	O	O
,	SIMPONI.xml:S1:4465:1	,	,	O	O
nonsteroidal	SIMPONI.xml:S1:4467:12	nonsteroid	JJ	O	O
anti	SIMPONI.xml:S1:4480:4	anti	SYM	O	O
-	SIMPONI.xml:S1:4484:1	-	:	O	O
inflammatory	SIMPONI.xml:S1:4485:12	inflammatori	NN	O	O
drugs	SIMPONI.xml:S1:4498:5	drug	NNS	O	O
[	SIMPONI.xml:S1:4504:1	[	VBP	O	O
NSAIDs	SIMPONI.xml:S1:4505:6	nsaid	NNP	O	O
]	SIMPONI.xml:S1:4511:1	]	NNP	O	O
,	SIMPONI.xml:S1:4512:1	,	,	O	O
methotrexate	SIMPONI.xml:S1:4514:12	methotrex	NN	O	O
[	SIMPONI.xml:S1:4527:1	[	NNP	O	O
MTX	SIMPONI.xml:S1:4528:3	mtx	NNP	O	O
]	SIMPONI.xml:S1:4531:1	]	NNP	O	O
,	SIMPONI.xml:S1:4532:1	,	,	O	O
or	SIMPONI.xml:S1:4534:2	or	CC	O	O
isoniazid	SIMPONI.xml:S1:4537:9	isoniazid	VB	O	O
prophylaxis	SIMPONI.xml:S1:4547:11	prophylaxi	NN	O	O
)	SIMPONI.xml:S1:4558:1	)	)	O	O
,	SIMPONI.xml:S1:4559:1	,	,	O	O
the	SIMPONI.xml:S1:4561:3	the	DT	O	O
relationship	SIMPONI.xml:S1:4565:12	relationship	NN	O	O
between	SIMPONI.xml:S1:4578:7	between	IN	O	O
SIMPONI	SIMPONI.xml:S1:4586:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:4594:4	aria	NNP	O	O
and	SIMPONI.xml:S1:4599:3	and	CC	O	O
liver	SIMPONI.xml:S1:4603:5	liver	RB	O	O
enzyme	SIMPONI.xml:S1:4609:6	enzym	JJ	O	O
elevation	SIMPONI.xml:S1:4616:9	elev	NN	O	O
is	SIMPONI.xml:S1:4626:2	is	VBZ	O	O
not	SIMPONI.xml:S1:4629:3	not	RB	O	O
clear	SIMPONI.xml:S1:4633:5	clear	JJ	O	O
.	SIMPONI.xml:S1:4638:1	.	.	O	O

Autoimmune	SIMPONI.xml:S1:4648:10	autoimmun	NNP	O	O
Disorders	SIMPONI.xml:S1:4659:9	disord	NNP	O	O
and	SIMPONI.xml:S1:4669:3	and	CC	O	O
Autoantibodies	SIMPONI.xml:S1:4673:14	autoantibodi	NNS	O	O

The	SIMPONI.xml:S1:4694:3	the	DT	O	O
use	SIMPONI.xml:S1:4698:3	use	NN	O	O
of	SIMPONI.xml:S1:4702:2	of	IN	O	O
TNF	SIMPONI.xml:S1:4705:3	tnf	NNP	O	O
-	SIMPONI.xml:S1:4708:1	-	:	O	O
blockers	SIMPONI.xml:S1:4709:8	blocker	NNS	O	O
,	SIMPONI.xml:S1:4717:1	,	,	O	O
of	SIMPONI.xml:S1:4719:2	of	IN	O	O
which	SIMPONI.xml:S1:4722:5	which	WDT	O	O
SIMPONI	SIMPONI.xml:S1:4728:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:4736:4	aria	NNP	O	O
is	SIMPONI.xml:S1:4741:2	is	VBZ	O	O
a	SIMPONI.xml:S1:4744:1	a	DT	O	O
member	SIMPONI.xml:S1:4746:6	member	NN	O	O
,	SIMPONI.xml:S1:4752:1	,	,	O	O
has	SIMPONI.xml:S1:4754:3	ha	VBZ	O	O
been	SIMPONI.xml:S1:4758:4	been	VBN	O	O
associated	SIMPONI.xml:S1:4763:10	associ	VBN	O	O
with	SIMPONI.xml:S1:4774:4	with	IN	O	O
the	SIMPONI.xml:S1:4779:3	the	DT	O	O
formation	SIMPONI.xml:S1:4783:9	format	NN	B-AdverseReaction	O
of	SIMPONI.xml:S1:4793:2	of	IN	I-AdverseReaction	O
autoantibodies	SIMPONI.xml:S1:4796:14	autoantibodi	NNS	I-AdverseReaction	O
and	SIMPONI.xml:S1:4811:3	and	CC	O	O
,	SIMPONI.xml:S1:4814:1	,	,	O	O
rarely	SIMPONI.xml:S1:4816:6	rare	RB	O	O
,	SIMPONI.xml:S1:4822:1	,	,	O	O
with	SIMPONI.xml:S1:4824:4	with	IN	O	O
the	SIMPONI.xml:S1:4829:3	the	DT	O	O
development	SIMPONI.xml:S1:4833:11	develop	NN	O	O
of	SIMPONI.xml:S1:4845:2	of	IN	O	O
a	SIMPONI.xml:S1:4848:1	a	DT	O	O
lupus	SIMPONI.xml:S1:4850:5	lupu	JJ	B-AdverseReaction	B-AdverseReaction
-	SIMPONI.xml:S1:4855:1	-	:	I-AdverseReaction	I-AdverseReaction
like	SIMPONI.xml:S1:4856:4	like	IN	I-AdverseReaction	I-AdverseReaction
syndrome	SIMPONI.xml:S1:4861:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
.	SIMPONI.xml:S1:4869:1	.	.	O	O

At	SIMPONI.xml:S1:4875:2	At	IN	O	O
Week	SIMPONI.xml:S1:4878:4	week	NNP	O	O
20	SIMPONI.xml:S1:4883:2	20	CD	O	O
in	SIMPONI.xml:S1:4886:2	in	IN	O	O
Trial	SIMPONI.xml:S1:4889:5	trial	JJ	O	O
1	SIMPONI.xml:S1:4895:1	1	CD	O	O
,	SIMPONI.xml:S1:4896:1	,	,	O	O
17%	SIMPONI.xml:S1:4898:3	17%	CD	O	O
of	SIMPONI.xml:S1:4902:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S1:4905:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:4913:4	aria	NNP	O	O
-	SIMPONI.xml:S1:4917:1	-	:	O	O
treated	SIMPONI.xml:S1:4918:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:4926:8	patient	NNS	O	O
and	SIMPONI.xml:S1:4935:3	and	CC	O	O
13%	SIMPONI.xml:S1:4939:3	13%	CD	O	O
of	SIMPONI.xml:S1:4943:2	of	IN	O	O
control	SIMPONI.xml:S1:4946:7	control	NN	O	O
patients	SIMPONI.xml:S1:4954:8	patient	NNS	O	O
were	SIMPONI.xml:S1:4963:4	were	VBD	O	O
newly	SIMPONI.xml:S1:4968:5	newli	RB	B-AdverseReaction	O
ANA	SIMPONI.xml:S1:4974:3	ana	NNP	I-AdverseReaction	O
-	SIMPONI.xml:S1:4977:1	-	:	I-AdverseReaction	O
positive	SIMPONI.xml:S1:4978:8	posit	JJ	I-AdverseReaction	O
(	SIMPONI.xml:S1:4987:1	(	(	O	O
at	SIMPONI.xml:S1:4988:2	at	IN	O	O
titers	SIMPONI.xml:S1:4991:6	titer	NNS	O	O
of	SIMPONI.xml:S1:4998:2	of	IN	O	O
1	SIMPONI.xml:S1:5001:1	1	CD	O	O
:	SIMPONI.xml:S1:5002:1	:	:	O	O
160	SIMPONI.xml:S1:5003:3	160	CD	O	O
or	SIMPONI.xml:S1:5007:2	or	CC	O	O
greater	SIMPONI.xml:S1:5010:7	greater	JJR	O	O
)	SIMPONI.xml:S1:5017:1	)	)	O	O
.	SIMPONI.xml:S1:5018:1	.	.	O	O

Of	SIMPONI.xml:S1:5020:2	Of	IN	O	O
these	SIMPONI.xml:S1:5023:5	these	DT	O	O
patients	SIMPONI.xml:S1:5029:8	patient	NNS	O	O
,	SIMPONI.xml:S1:5037:1	,	,	O	O
one	SIMPONI.xml:S1:5039:3	one	CD	O	O
SIMPONI	SIMPONI.xml:S1:5043:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:5051:4	aria	NNP	O	O
-	SIMPONI.xml:S1:5055:1	-	:	O	O
treated	SIMPONI.xml:S1:5056:7	treat	VBD	O	O
patient	SIMPONI.xml:S1:5064:7	patient	JJ	O	O
and	SIMPONI.xml:S1:5072:3	and	CC	O	O
no	SIMPONI.xml:S1:5076:2	no	DT	O	O
control	SIMPONI.xml:S1:5079:7	control	NN	O	O
-	SIMPONI.xml:S1:5086:1	-	:	O	O
treated	SIMPONI.xml:S1:5087:7	treat	JJ	O	O
patients	SIMPONI.xml:S1:5095:8	patient	NNS	O	O
had	SIMPONI.xml:S1:5104:3	had	VBD	O	O
newly	SIMPONI.xml:S1:5108:5	newli	RB	B-AdverseReaction	O
positive	SIMPONI.xml:S1:5114:8	posit	JJ	I-AdverseReaction	O
anti	SIMPONI.xml:S1:5123:4	anti	SYM	I-AdverseReaction	O
-	SIMPONI.xml:S1:5127:1	-	:	I-AdverseReaction	O
dsDNA	SIMPONI.xml:S1:5128:5	dsdna	NN	I-AdverseReaction	O
antibodies	SIMPONI.xml:S1:5134:10	antibodi	NNS	I-AdverseReaction	O
.	SIMPONI.xml:S1:5144:1	.	.	O	O

Administration	SIMPONI.xml:S1:5154:14	administr	NN	O	O
Reactions	SIMPONI.xml:S1:5169:9	reaction	NNS	O	O

In	SIMPONI.xml:S1:5185:2	In	IN	O	O
the	SIMPONI.xml:S1:5188:3	the	DT	O	O
controlled	SIMPONI.xml:S1:5192:10	control	JJ	O	O
phase	SIMPONI.xml:S1:5203:5	phase	NN	O	O
of	SIMPONI.xml:S1:5209:2	of	IN	O	O
Trial	SIMPONI.xml:S1:5212:5	trial	JJ	O	O
1	SIMPONI.xml:S1:5218:1	1	CD	O	O
through	SIMPONI.xml:S1:5220:7	through	IN	O	O
Week	SIMPONI.xml:S1:5228:4	week	JJ	O	O
24	SIMPONI.xml:S1:5233:2	24	CD	O	O
,	SIMPONI.xml:S1:5235:1	,	,	O	O
1.1%	SIMPONI.xml:S1:5237:4	1.1%	CD	O	O
of	SIMPONI.xml:S1:5242:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S1:5245:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:5253:4	aria	NNP	O	O
infusions	SIMPONI.xml:S1:5258:9	infus	NNS	O	O
were	SIMPONI.xml:S1:5268:4	were	VBD	O	O
associated	SIMPONI.xml:S1:5273:10	associ	VBN	O	O
with	SIMPONI.xml:S1:5284:4	with	IN	O	O
an	SIMPONI.xml:S1:5289:2	an	DT	O	O
infusion	SIMPONI.xml:S1:5292:8	infus	NN	B-AdverseReaction	O
reaction	SIMPONI.xml:S1:5301:8	reaction	NN	I-AdverseReaction	O
compared	SIMPONI.xml:S1:5310:8	compar	VBN	O	O
with	SIMPONI.xml:S1:5319:4	with	IN	O	O
0.2%	SIMPONI.xml:S1:5324:4	0.2%	CD	O	O
of	SIMPONI.xml:S1:5329:2	of	IN	O	O
infusions	SIMPONI.xml:S1:5332:9	infus	NNS	O	O
in	SIMPONI.xml:S1:5342:2	in	IN	O	O
the	SIMPONI.xml:S1:5345:3	the	DT	O	O
control	SIMPONI.xml:S1:5349:7	control	NN	O	O
group	SIMPONI.xml:S1:5357:5	group	NN	O	O
.	SIMPONI.xml:S1:5362:1	.	.	O	O

The	SIMPONI.xml:S1:5364:3	the	DT	O	O
most	SIMPONI.xml:S1:5368:4	most	RBS	O	O
common	SIMPONI.xml:S1:5373:6	common	JJ	O	O
infusion	SIMPONI.xml:S1:5380:8	infus	NN	O	O
reaction	SIMPONI.xml:S1:5389:8	reaction	NN	O	O
in	SIMPONI.xml:S1:5398:2	in	IN	O	O
SIMPONI	SIMPONI.xml:S1:5401:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:5409:4	aria	NNP	O	O
treated	SIMPONI.xml:S1:5414:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:5422:8	patient	NNS	O	O
was	SIMPONI.xml:S1:5431:3	wa	VBD	O	O
rash	SIMPONI.xml:S1:5435:4	rash	NN	B-AdverseReaction	B-AdverseReaction
.	SIMPONI.xml:S1:5439:1	.	.	O	O

No	SIMPONI.xml:S1:5441:2	No	DT	O	O
serious	SIMPONI.xml:S1:5444:7	seriou	JJ	O	O
infusion	SIMPONI.xml:S1:5452:8	infus	NN	B-AdverseReaction	B-AdverseReaction
reactions	SIMPONI.xml:S1:5461:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
were	SIMPONI.xml:S1:5471:4	were	VBD	O	O
reported	SIMPONI.xml:S1:5476:8	report	VBN	O	O
.	SIMPONI.xml:S1:5484:1	.	.	O	O

Immunogenicity	SIMPONI.xml:S1:5494:14	immunogen	NN	O	O

Antibodies	SIMPONI.xml:S1:5515:10	antibodi	NNS	O	O
to	SIMPONI.xml:S1:5526:2	to	TO	O	O
SIMPONI	SIMPONI.xml:S1:5529:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:5537:4	aria	NNP	O	O
were	SIMPONI.xml:S1:5542:4	were	VBD	O	O
detected	SIMPONI.xml:S1:5547:8	detect	VBN	O	O
in	SIMPONI.xml:S1:5556:2	in	IN	O	O
13	SIMPONI.xml:S1:5559:2	13	CD	O	O
(	SIMPONI.xml:S1:5562:1	(	(	O	O
3%	SIMPONI.xml:S1:5563:2	3%	CD	O	O
)	SIMPONI.xml:S1:5565:1	)	)	O	O
golimumab	SIMPONI.xml:S1:5567:9	golimumab	NN	O	O
-	SIMPONI.xml:S1:5576:1	-	:	O	O
treated	SIMPONI.xml:S1:5577:7	treat	JJ	O	O
patients	SIMPONI.xml:S1:5585:8	patient	NNS	O	O
following	SIMPONI.xml:S1:5594:9	follow	VBG	O	O
IV	SIMPONI.xml:S1:5604:2	IV	NNP	O	O
administration	SIMPONI.xml:S1:5607:14	administr	NN	O	O
of	SIMPONI.xml:S1:5622:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S1:5625:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:5633:4	aria	NNP	O	O
in	SIMPONI.xml:S1:5638:2	in	IN	O	O
combination	SIMPONI.xml:S1:5641:11	combin	NN	O	O
with	SIMPONI.xml:S1:5653:4	with	IN	O	O
MTX	SIMPONI.xml:S1:5658:3	mtx	NNP	O	O
through	SIMPONI.xml:S1:5662:7	through	IN	O	O
Week	SIMPONI.xml:S1:5670:4	week	NNP	O	O
24	SIMPONI.xml:S1:5675:2	24	CD	O	O
of	SIMPONI.xml:S1:5678:2	of	IN	O	O
Trial	SIMPONI.xml:S1:5681:5	trial	JJ	O	O
1	SIMPONI.xml:S1:5687:1	1	CD	O	O
.	SIMPONI.xml:S1:5688:1	.	.	O	O

All	SIMPONI.xml:S1:5694:3	all	DT	O	O
patients	SIMPONI.xml:S1:5698:8	patient	NNS	O	O
who	SIMPONI.xml:S1:5707:3	who	WP	O	O
were	SIMPONI.xml:S1:5711:4	were	VBD	O	O
positive	SIMPONI.xml:S1:5716:8	posit	JJ	O	O
for	SIMPONI.xml:S1:5725:3	for	IN	O	O
antibodies	SIMPONI.xml:S1:5729:10	antibodi	NNS	O	O
to	SIMPONI.xml:S1:5740:2	to	TO	O	O
golimumab	SIMPONI.xml:S1:5743:9	golimumab	VB	O	O
had	SIMPONI.xml:S1:5753:3	had	VBD	O	O
neutralizing	SIMPONI.xml:S1:5757:12	neutral	VBG	O	O
antibodies	SIMPONI.xml:S1:5770:10	antibodi	NNS	O	O
based	SIMPONI.xml:S1:5781:5	base	VBN	O	O
on	SIMPONI.xml:S1:5787:2	on	IN	O	O
an	SIMPONI.xml:S1:5790:2	an	DT	O	O
in	SIMPONI.xml:S1:5793:2	in	IN	O	O
vitro	SIMPONI.xml:S1:5796:5	vitro	NN	O	O
cell	SIMPONI.xml:S1:5802:4	cell	NN	O	O
-	SIMPONI.xml:S1:5806:1	-	:	O	O
based	SIMPONI.xml:S1:5807:5	base	VBN	O	O
assay	SIMPONI.xml:S1:5813:5	assay	NN	O	O
.	SIMPONI.xml:S1:5818:1	.	.	O	O

The	SIMPONI.xml:S1:5820:3	the	DT	O	O
small	SIMPONI.xml:S1:5824:5	small	JJ	O	O
number	SIMPONI.xml:S1:5830:6	number	NN	O	O
of	SIMPONI.xml:S1:5837:2	of	IN	O	O
patients	SIMPONI.xml:S1:5840:8	patient	NNS	O	O
positive	SIMPONI.xml:S1:5849:8	posit	JJ	O	O
for	SIMPONI.xml:S1:5858:3	for	IN	O	O
antibodies	SIMPONI.xml:S1:5862:10	antibodi	NNS	O	O
to	SIMPONI.xml:S1:5873:2	to	TO	O	O
SIMPONI	SIMPONI.xml:S1:5876:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:5884:4	aria	NNP	O	O
limits	SIMPONI.xml:S1:5889:6	limit	VBZ	O	O
the	SIMPONI.xml:S1:5896:3	the	DT	O	O
ability	SIMPONI.xml:S1:5900:7	abil	NN	O	O
to	SIMPONI.xml:S1:5908:2	to	TO	O	O
draw	SIMPONI.xml:S1:5911:4	draw	VB	O	O
definitive	SIMPONI.xml:S1:5916:10	definit	JJ	O	O
conclusions	SIMPONI.xml:S1:5927:11	conclus	NNS	O	O
regarding	SIMPONI.xml:S1:5939:9	regard	VBG	O	O
the	SIMPONI.xml:S1:5949:3	the	DT	O	O
relationship	SIMPONI.xml:S1:5953:12	relationship	NN	O	O
between	SIMPONI.xml:S1:5966:7	between	IN	O	O
antibodies	SIMPONI.xml:S1:5974:10	antibodi	NNS	O	O
to	SIMPONI.xml:S1:5985:2	to	TO	O	O
golimumab	SIMPONI.xml:S1:5988:9	golimumab	VB	O	O
and	SIMPONI.xml:S1:5998:3	and	CC	O	O
clinical	SIMPONI.xml:S1:6002:8	clinic	JJ	O	O
efficacy	SIMPONI.xml:S1:6011:8	efficaci	NN	O	O
or	SIMPONI.xml:S1:6020:2	or	CC	O	O
safety	SIMPONI.xml:S1:6023:6	safeti	NN	O	O
measures	SIMPONI.xml:S1:6030:8	measur	NNS	O	O
.	SIMPONI.xml:S1:6038:1	.	.	O	O

The	SIMPONI.xml:S1:6044:3	the	DT	O	O
data	SIMPONI.xml:S1:6048:4	data	NNS	O	O
above	SIMPONI.xml:S1:6053:5	abov	IN	O	O
reflect	SIMPONI.xml:S1:6059:7	reflect	VBP	O	O
the	SIMPONI.xml:S1:6067:3	the	DT	O	O
percentage	SIMPONI.xml:S1:6071:10	percentag	NN	O	O
of	SIMPONI.xml:S1:6082:2	of	IN	O	O
patients	SIMPONI.xml:S1:6085:8	patient	NNS	O	O
whose	SIMPONI.xml:S1:6094:5	whose	WP$	O	O
test	SIMPONI.xml:S1:6100:4	test	NN	O	O
results	SIMPONI.xml:S1:6105:7	result	NNS	O	O
were	SIMPONI.xml:S1:6113:4	were	VBD	O	O
considered	SIMPONI.xml:S1:6118:10	consid	VBN	O	O
positive	SIMPONI.xml:S1:6129:8	posit	JJ	O	O
for	SIMPONI.xml:S1:6138:3	for	IN	O	O
antibodies	SIMPONI.xml:S1:6142:10	antibodi	NNS	O	O
to	SIMPONI.xml:S1:6153:2	to	TO	O	O
SIMPONI	SIMPONI.xml:S1:6156:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:6164:4	aria	NNP	O	O
in	SIMPONI.xml:S1:6169:2	in	IN	O	O
an	SIMPONI.xml:S1:6172:2	an	DT	O	O
ELISA	SIMPONI.xml:S1:6175:5	elisa	NNP	O	O
assay	SIMPONI.xml:S1:6181:5	assay	NN	O	O
.	SIMPONI.xml:S1:6186:1	.	.	O	O

The	SIMPONI.xml:S1:6188:3	the	DT	O	O
ELISA	SIMPONI.xml:S1:6192:5	elisa	NNP	O	O
assay	SIMPONI.xml:S1:6198:5	assay	NN	O	O
is	SIMPONI.xml:S1:6204:2	is	VBZ	O	O
subject	SIMPONI.xml:S1:6207:7	subject	JJ	O	O
to	SIMPONI.xml:S1:6215:2	to	TO	O	O
interference	SIMPONI.xml:S1:6218:12	interfer	VB	O	O
by	SIMPONI.xml:S1:6231:2	by	IN	O	O
co	SIMPONI.xml:S1:6234:2	co	JJ	O	O
-	SIMPONI.xml:S1:6236:1	-	:	O	O
present	SIMPONI.xml:S1:6237:7	present	JJ	O	O
golimumab	SIMPONI.xml:S1:6245:9	golimumab	NN	O	O
and	SIMPONI.xml:S1:6255:3	and	CC	O	O
thus	SIMPONI.xml:S1:6259:4	thu	RB	O	O
the	SIMPONI.xml:S1:6264:3	the	DT	O	O
results	SIMPONI.xml:S1:6268:7	result	NNS	O	O
are	SIMPONI.xml:S1:6276:3	are	VBP	O	O
an	SIMPONI.xml:S1:6280:2	an	DT	O	O
underestimate	SIMPONI.xml:S1:6283:13	underestim	NN	O	O
of	SIMPONI.xml:S1:6297:2	of	IN	O	O
the	SIMPONI.xml:S1:6300:3	the	DT	O	O
rate	SIMPONI.xml:S1:6304:4	rate	NN	O	O
of	SIMPONI.xml:S1:6309:2	of	IN	O	O
product	SIMPONI.xml:S1:6312:7	product	NN	O	O
immunogenicity	SIMPONI.xml:S1:6320:14	immunogen	NN	O	O
and	SIMPONI.xml:S1:6335:3	and	CC	O	O
are	SIMPONI.xml:S1:6339:3	are	VBP	O	O
in	SIMPONI.xml:S1:6343:2	in	IN	O	O
addition	SIMPONI.xml:S1:6346:8	addit	NN	O	O
highly	SIMPONI.xml:S1:6355:6	highli	RB	O	O
dependent	SIMPONI.xml:S1:6362:9	depend	JJ	O	O
on	SIMPONI.xml:S1:6372:2	on	IN	O	O
the	SIMPONI.xml:S1:6375:3	the	DT	O	O
sensitivity	SIMPONI.xml:S1:6379:11	sensit	NN	O	O
and	SIMPONI.xml:S1:6391:3	and	CC	O	O
specificity	SIMPONI.xml:S1:6395:11	specif	NN	O	O
of	SIMPONI.xml:S1:6407:2	of	IN	O	O
the	SIMPONI.xml:S1:6410:3	the	DT	O	O
assay	SIMPONI.xml:S1:6414:5	assay	NN	O	O
.	SIMPONI.xml:S1:6419:1	.	.	O	O

Additionally	SIMPONI.xml:S1:6421:12	addit	RB	O	O
,	SIMPONI.xml:S1:6433:1	,	,	O	O
the	SIMPONI.xml:S1:6435:3	the	DT	O	O
observed	SIMPONI.xml:S1:6439:8	observ	JJ	O	O
incidence	SIMPONI.xml:S1:6448:9	incid	NN	O	O
of	SIMPONI.xml:S1:6458:2	of	IN	O	O
antibody	SIMPONI.xml:S1:6461:8	antibodi	NN	O	O
positivity	SIMPONI.xml:S1:6470:10	posit	NN	O	O
in	SIMPONI.xml:S1:6481:2	in	IN	O	O
an	SIMPONI.xml:S1:6484:2	an	DT	O	O
assay	SIMPONI.xml:S1:6487:5	assay	NN	O	O
may	SIMPONI.xml:S1:6493:3	may	MD	O	O
be	SIMPONI.xml:S1:6497:2	be	VB	O	O
influenced	SIMPONI.xml:S1:6500:10	influenc	VBN	O	O
by	SIMPONI.xml:S1:6511:2	by	IN	O	O
several	SIMPONI.xml:S1:6514:7	sever	JJ	O	O
factors	SIMPONI.xml:S1:6522:7	factor	NNS	O	O
including	SIMPONI.xml:S1:6530:9	includ	VBG	O	O
sample	SIMPONI.xml:S1:6540:6	sampl	NN	O	O
handling	SIMPONI.xml:S1:6547:8	handl	NN	O	O
,	SIMPONI.xml:S1:6555:1	,	,	O	O
timing	SIMPONI.xml:S1:6557:6	time	NN	O	O
of	SIMPONI.xml:S1:6564:2	of	IN	O	O
sample	SIMPONI.xml:S1:6567:6	sampl	JJ	O	O
collection	SIMPONI.xml:S1:6574:10	collect	NN	O	O
,	SIMPONI.xml:S1:6584:1	,	,	O	O
concomitant	SIMPONI.xml:S1:6586:11	concomit	JJ	O	O
medications	SIMPONI.xml:S1:6598:11	medic	NNS	O	O
,	SIMPONI.xml:S1:6609:1	,	,	O	O
and	SIMPONI.xml:S1:6611:3	and	CC	O	O
underlying	SIMPONI.xml:S1:6615:10	underli	JJ	O	O
disease	SIMPONI.xml:S1:6626:7	diseas	NN	O	O
.	SIMPONI.xml:S1:6633:1	.	.	O	O

For	SIMPONI.xml:S1:6635:3	for	IN	O	O
these	SIMPONI.xml:S1:6639:5	these	DT	O	O
reasons	SIMPONI.xml:S1:6645:7	reason	NNS	O	O
,	SIMPONI.xml:S1:6652:1	,	,	O	O
comparison	SIMPONI.xml:S1:6654:10	comparison	NN	O	O
of	SIMPONI.xml:S1:6665:2	of	IN	O	O
the	SIMPONI.xml:S1:6668:3	the	DT	O	O
incidence	SIMPONI.xml:S1:6672:9	incid	NN	O	O
of	SIMPONI.xml:S1:6682:2	of	IN	O	O
antibodies	SIMPONI.xml:S1:6685:10	antibodi	NNS	O	O
to	SIMPONI.xml:S1:6696:2	to	TO	O	O
SIMPONI	SIMPONI.xml:S1:6699:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:6707:4	aria	NNP	O	O
with	SIMPONI.xml:S1:6712:4	with	IN	O	O
the	SIMPONI.xml:S1:6717:3	the	DT	O	O
incidence	SIMPONI.xml:S1:6721:9	incid	NN	O	O
of	SIMPONI.xml:S1:6731:2	of	IN	O	O
antibodies	SIMPONI.xml:S1:6734:10	antibodi	NNS	O	O
to	SIMPONI.xml:S1:6745:2	to	TO	O	O
other	SIMPONI.xml:S1:6748:5	other	JJ	O	O
products	SIMPONI.xml:S1:6754:8	product	NNS	O	O
may	SIMPONI.xml:S1:6763:3	may	MD	O	O
be	SIMPONI.xml:S1:6767:2	be	VB	O	O
misleading	SIMPONI.xml:S1:6770:10	mislead	VBG	O	O
.	SIMPONI.xml:S1:6780:1	.	.	O	O

Other	SIMPONI.xml:S1:6790:5	other	JJ	O	O
Adverse	SIMPONI.xml:S1:6796:7	advers	NNP	O	O
Reactions	SIMPONI.xml:S1:6804:9	reaction	NNP	O	O

Table	SIMPONI.xml:S1:6820:5	tabl	JJ	O	O
1	SIMPONI.xml:S1:6826:1	1	CD	O	O
summarizes	SIMPONI.xml:S1:6828:10	summar	VBZ	O	O
the	SIMPONI.xml:S1:6839:3	the	DT	O	O
adverse	SIMPONI.xml:S1:6843:7	advers	JJ	O	O
drug	SIMPONI.xml:S1:6851:4	drug	NN	O	O
reactions	SIMPONI.xml:S1:6856:9	reaction	NNS	O	O
that	SIMPONI.xml:S1:6866:4	that	WDT	O	O
occurred	SIMPONI.xml:S1:6871:8	occur	VBD	O	O
at	SIMPONI.xml:S1:6880:2	at	IN	O	O
a	SIMPONI.xml:S1:6883:1	a	DT	O	O
rate	SIMPONI.xml:S1:6885:4	rate	NN	O	O
of	SIMPONI.xml:S1:6890:2	of	IN	O	O
at	SIMPONI.xml:S1:6893:2	at	IN	O	O
least	SIMPONI.xml:S1:6896:5	least	JJS	O	O
1%	SIMPONI.xml:S1:6902:2	1%	CD	O	O
in	SIMPONI.xml:S1:6905:2	in	IN	O	O
the	SIMPONI.xml:S1:6908:3	the	DT	O	O
SIMPONI	SIMPONI.xml:S1:6912:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:6920:4	aria	NNP	O	O
MTX	SIMPONI.xml:S1:6927:3	mtx	NNP	O	O
group	SIMPONI.xml:S1:6931:5	group	NN	O	O
with	SIMPONI.xml:S1:6937:4	with	IN	O	O
a	SIMPONI.xml:S1:6942:1	a	DT	O	O
higher	SIMPONI.xml:S1:6944:6	higher	JJR	O	O
incidence	SIMPONI.xml:S1:6951:9	incid	NN	O	O
than	SIMPONI.xml:S1:6961:4	than	IN	O	O
in	SIMPONI.xml:S1:6966:2	in	IN	O	O
the	SIMPONI.xml:S1:6969:3	the	DT	O	O
placebo	SIMPONI.xml:S1:6973:7	placebo	NN	O	O
MTX	SIMPONI.xml:S1:6983:3	mtx	NNP	O	O
group	SIMPONI.xml:S1:6987:5	group	NN	O	O
during	SIMPONI.xml:S1:6993:6	dure	IN	O	O
the	SIMPONI.xml:S1:7000:3	the	DT	O	O
controlled	SIMPONI.xml:S1:7004:10	control	JJ	O	O
period	SIMPONI.xml:S1:7015:6	period	NN	O	O
of	SIMPONI.xml:S1:7022:2	of	IN	O	O
Trial	SIMPONI.xml:S1:7025:5	trial	JJ	O	O
1	SIMPONI.xml:S1:7031:1	1	CD	O	O
through	SIMPONI.xml:S1:7033:7	through	IN	O	O
Week	SIMPONI.xml:S1:7041:4	week	JJ	O	O
24	SIMPONI.xml:S1:7046:2	24	CD	O	O
.	SIMPONI.xml:S1:7048:1	.	.	O	O

Table	SIMPONI.xml:S1:7054:5	tabl	JJ	O	O
1	SIMPONI.xml:S1:7060:1	1	CD	O	O
:	SIMPONI.xml:S1:7061:1	:	:	O	O
Adverse	SIMPONI.xml:S1:7063:7	advers	JJ	O	O
Drug	SIMPONI.xml:S1:7071:4	drug	NNP	O	O
Reactions	SIMPONI.xml:S1:7076:9	reaction	NNP	O	O
Reported	SIMPONI.xml:S1:7086:8	report	NNP	O	O
by	SIMPONI.xml:S1:7095:2	by	IN	O	O
1%	SIMPONI.xml:S1:7101:2	1%	CD	O	O
of	SIMPONI.xml:S1:7104:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S1:7107:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:7115:4	aria	NNP	O	O
-	SIMPONI.xml:S1:7119:1	-	:	O	O
Treated	SIMPONI.xml:S1:7120:7	treat	VBD	O	O
Patients	SIMPONI.xml:S1:7128:8	patient	NNS	O	O
and	SIMPONI.xml:S1:7137:3	and	CC	O	O
with	SIMPONI.xml:S1:7141:4	with	IN	O	O
a	SIMPONI.xml:S1:7146:1	a	DT	O	O
Higher	SIMPONI.xml:S1:7148:6	higher	JJR	O	O
Incidence	SIMPONI.xml:S1:7155:9	incid	NN	O	O
than	SIMPONI.xml:S1:7165:4	than	IN	O	O
Placebo	SIMPONI.xml:S1:7170:7	placebo	NNP	O	O
-	SIMPONI.xml:S1:7177:1	-	:	O	O
Treated	SIMPONI.xml:S1:7178:7	treat	VBD	O	O
Patients	SIMPONI.xml:S1:7186:8	patient	NNS	O	O
in	SIMPONI.xml:S1:7195:2	in	IN	O	O
Trial	SIMPONI.xml:S1:7198:5	trial	JJ	O	O
1	SIMPONI.xml:S1:7204:1	1	CD	O	O
through	SIMPONI.xml:S1:7206:7	through	IN	O	O
Week	SIMPONI.xml:S1:7214:4	week	JJ	O	O
24	SIMPONI.xml:S1:7219:2	24	CD	O	O

Placebo	SIMPONI.xml:S1:7282:7	placebo	NNP	O	O
MTX	SIMPONI.xml:S1:7292:3	mtx	NNP	O	O
SIMPONI	SIMPONI.xml:S1:7306:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:7314:4	aria	NNP	O	O
MTX	SIMPONI.xml:S1:7321:3	mtx	NNP	O	O

Patients	SIMPONI.xml:S1:7336:8	patient	NNS	O	O

treated	SIMPONI.xml:S1:7345:7	treat	VBD	O	O
197	SIMPONI.xml:S1:7399:3	197	CD	O	O
463	SIMPONI.xml:S1:7426:3	463	CD	O	O

Adverse	SIMPONI.xml:S1:7445:7	advers	JJ	O	O
Reaction	SIMPONI.xml:S1:7453:8	reaction	NN	O	O

Infections	SIMPONI.xml:S1:7502:10	infect	NNS	O	O
and	SIMPONI.xml:S1:7513:3	and	CC	O	O
Infestations	SIMPONI.xml:S1:7517:12	infest	NNS	O	O

Upper	SIMPONI.xml:S1:7612:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	SIMPONI.xml:S1:7618:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	SIMPONI.xml:S1:7630:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	SIMPONI.xml:S1:7636:9	infect	NN	I-AdverseReaction	I-AdverseReaction
(	SIMPONI.xml:S1:7646:1	(	(	O	O
such	SIMPONI.xml:S1:7647:4	such	JJ	O	O
as	SIMPONI.xml:S1:7652:2	as	IN	O	O
upper	SIMPONI.xml:S1:7655:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	SIMPONI.xml:S1:7661:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	SIMPONI.xml:S1:7673:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	SIMPONI.xml:S1:7679:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S1:7688:1	,	,	O	O
nasopharyngitis	SIMPONI.xml:S1:7690:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:7705:1	,	,	O	O
pharyngitis	SIMPONI.xml:S1:7707:11	pharyng	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:7718:1	,	,	O	O
laryngitis	SIMPONI.xml:S1:7720:10	laryng	NN	B-AdverseReaction	O
,	SIMPONI.xml:S1:7730:1	,	,	O	O
and	SIMPONI.xml:S1:7732:3	and	CC	O	O
rhinitis	SIMPONI.xml:S1:7736:8	rhiniti	NN	B-AdverseReaction	B-AdverseReaction
)	SIMPONI.xml:S1:7744:1	)	)	O	O
12%	SIMPONI.xml:S1:7758:3	12%	CD	O	O
13%	SIMPONI.xml:S1:7785:3	13%	CD	O	O

Viral	SIMPONI.xml:S1:7807:5	viral	JJ	B-AdverseReaction	B-AdverseReaction
infections	SIMPONI.xml:S1:7813:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
(	SIMPONI.xml:S1:7824:1	(	(	O	O
such	SIMPONI.xml:S1:7825:4	such	JJ	O	O
as	SIMPONI.xml:S1:7830:2	as	IN	O	O
influenza	SIMPONI.xml:S1:7833:9	influenza	NN	B-AdverseReaction	B-AdverseReaction
and	SIMPONI.xml:S1:7843:3	and	CC	O	O
herpes	SIMPONI.xml:S1:7847:6	herp	NNS	B-AdverseReaction	I-AdverseReaction
)	SIMPONI.xml:S1:7853:1	)	)	O	O
3%	SIMPONI.xml:S1:7867:2	3%	CD	O	O
4%	SIMPONI.xml:S1:7894:2	4%	CD	O	O

Bacterial	SIMPONI.xml:S1:7916:9	bacteri	JJ	B-AdverseReaction	B-AdverseReaction
infections	SIMPONI.xml:S1:7926:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
0%	SIMPONI.xml:S1:7976:2	0%	CD	O	O
1%	SIMPONI.xml:S1:8003:2	1%	CD	O	O

Bronchitis	SIMPONI.xml:S1:8025:10	bronchiti	NNP	B-AdverseReaction	B-AdverseReaction
1%	SIMPONI.xml:S1:8085:2	1%	CD	O	O
3%	SIMPONI.xml:S1:8112:2	3%	CD	O	O

Vascular	SIMPONI.xml:S1:8133:8	vascular	JJ	B-AdverseReaction	O
disorders	SIMPONI.xml:S1:8142:9	disord	NNS	I-AdverseReaction	O

Hypertension	SIMPONI.xml:S1:8243:12	hypertens	NNP	B-AdverseReaction	B-AdverseReaction
2%	SIMPONI.xml:S1:8303:2	2%	CD	O	O
3%	SIMPONI.xml:S1:8330:2	3%	CD	O	O

Skin	SIMPONI.xml:S1:8351:4	skin	NNP	O	O
and	SIMPONI.xml:S1:8356:3	and	CC	O	O
subcutaneous	SIMPONI.xml:S1:8360:12	subcutan	JJ	O	O
disorders	SIMPONI.xml:S1:8373:9	disord	NNS	O	O

Rash	SIMPONI.xml:S1:8461:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
1%	SIMPONI.xml:S1:8521:2	1%	CD	O	O
3%	SIMPONI.xml:S1:8548:2	3%	CD	O	O

General	SIMPONI.xml:S1:8569:7	gener	NNP	O	O
disorders	SIMPONI.xml:S1:8577:9	disord	NNS	O	O
and	SIMPONI.xml:S1:8587:3	and	CC	O	O
administration	SIMPONI.xml:S1:8591:14	administr	NN	O	O
site	SIMPONI.xml:S1:8606:4	site	NN	O	O
conditions	SIMPONI.xml:S1:8611:10	condit	NNS	O	O

Pyrexia	SIMPONI.xml:S1:8685:7	pyrexia	NNP	B-AdverseReaction	B-AdverseReaction
1%	SIMPONI.xml:S1:8745:2	1%	CD	O	O
2%	SIMPONI.xml:S1:8772:2	2%	CD	O	O

Blood	SIMPONI.xml:S1:8793:5	blood	NN	B-AdverseReaction	O
and	SIMPONI.xml:S1:8799:3	and	CC	O	O
lymphatic	SIMPONI.xml:S1:8803:9	lymphat	JJ	B-AdverseReaction	O
disorders	SIMPONI.xml:S1:8813:9	disord	NNS	I-AdverseReaction	O

Leukopenia	SIMPONI.xml:S1:8903:10	leukopenia	NNP	B-AdverseReaction	B-AdverseReaction
0%	SIMPONI.xml:S1:8963:2	0%	CD	O	O
1%	SIMPONI.xml:S1:8990:2	1%	CD	O	O

Other	SIMPONI.xml:S1:9021:5	other	JJ	O	O
and	SIMPONI.xml:S1:9027:3	and	CC	O	O
less	SIMPONI.xml:S1:9031:4	less	RBR	O	O
common	SIMPONI.xml:S1:9036:6	common	JJ	O	O
clinical	SIMPONI.xml:S1:9043:8	clinic	JJ	O	O
trial	SIMPONI.xml:S1:9052:5	trial	NN	O	O
adverse	SIMPONI.xml:S1:9058:7	advers	JJ	O	O
drug	SIMPONI.xml:S1:9066:4	drug	NN	O	O
reactions	SIMPONI.xml:S1:9071:9	reaction	NNS	O	O

Adverse	SIMPONI.xml:S1:9087:7	advers	NN	O	O

drug	SIMPONI.xml:S1:9095:4	drug	NN	O	O
reactions	SIMPONI.xml:S1:9100:9	reaction	NNS	O	O
that	SIMPONI.xml:S1:9110:4	that	WDT	O	O
do	SIMPONI.xml:S1:9115:2	do	VBP	O	O
not	SIMPONI.xml:S1:9118:3	not	RB	O	O
appear	SIMPONI.xml:S1:9122:6	appear	VB	O	O
in	SIMPONI.xml:S1:9129:2	in	IN	O	O
Table	SIMPONI.xml:S1:9132:5	tabl	JJ	O	O
1	SIMPONI.xml:S1:9138:1	1	CD	O	O
or	SIMPONI.xml:S1:9140:2	or	CC	O	O
that	SIMPONI.xml:S1:9143:4	that	IN	O	O
occurred	SIMPONI.xml:S1:9148:8	occur	VBD	O	O
1%	SIMPONI.xml:S1:9158:2	1%	CD	O	O
in	SIMPONI.xml:S1:9161:2	in	IN	O	O
SIMPONI	SIMPONI.xml:S1:9164:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:9172:4	aria	NNP	O	O
-	SIMPONI.xml:S1:9176:1	-	:	O	O
treated	SIMPONI.xml:S1:9177:7	treat	VBD	O	O
patients	SIMPONI.xml:S1:9185:8	patient	NNS	O	O
during	SIMPONI.xml:S1:9194:6	dure	IN	O	O
Trial	SIMPONI.xml:S1:9201:5	trial	JJ	O	O
1	SIMPONI.xml:S1:9207:1	1	CD	O	O
through	SIMPONI.xml:S1:9209:7	through	IN	O	O
Week	SIMPONI.xml:S1:9217:4	week	JJ	O	O
24	SIMPONI.xml:S1:9222:2	24	CD	O	O
that	SIMPONI.xml:S1:9225:4	that	WDT	O	O
do	SIMPONI.xml:S1:9230:2	do	VBP	O	O
not	SIMPONI.xml:S1:9233:3	not	RB	O	O
appear	SIMPONI.xml:S1:9237:6	appear	VB	O	O
in	SIMPONI.xml:S1:9244:2	in	IN	O	O
the	SIMPONI.xml:S1:9247:3	the	DT	O	O
Warnings	SIMPONI.xml:S1:9251:8	warn	NNP	O	O
and	SIMPONI.xml:S1:9260:3	and	CC	O	O
Precautions	SIMPONI.xml:S1:9264:11	precaut	NNP	O	O
section	SIMPONI.xml:S1:9276:7	section	NN	O	O
included	SIMPONI.xml:S1:9284:8	includ	VBD	O	O
the	SIMPONI.xml:S1:9293:3	the	DT	O	O
following	SIMPONI.xml:S1:9297:9	follow	JJ	O	O
events	SIMPONI.xml:S1:9307:6	event	NNS	O	O
listed	SIMPONI.xml:S1:9314:6	list	VBN	O	O
by	SIMPONI.xml:S1:9321:2	by	IN	O	O
system	SIMPONI.xml:S1:9324:6	system	NN	O	O
organ	SIMPONI.xml:S1:9331:5	organ	JJ	O	O
class	SIMPONI.xml:S1:9337:5	class	NN	O	O
:	SIMPONI.xml:S1:9342:1	:	:	O	O

Infections	SIMPONI.xml:S1:9350:10	infect	NNS	O	O
and	SIMPONI.xml:S1:9361:3	and	CC	O	O
Infestations	SIMPONI.xml:S1:9365:12	infest	NNS	O	O
:	SIMPONI.xml:S1:9379:1	:	:	O	O
Superficial	SIMPONI.xml:S1:9381:11	superfici	JJ	B-AdverseReaction	B-AdverseReaction
fungal	SIMPONI.xml:S1:9393:6	fungal	JJ	I-AdverseReaction	I-AdverseReaction
infection	SIMPONI.xml:S1:9400:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S1:9409:1	,	,	O	O
sinusitis	SIMPONI.xml:S1:9411:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:9420:1	,	,	O	O
abscess	SIMPONI.xml:S1:9422:7	abscess	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:9429:1	,	,	O	O
lower	SIMPONI.xml:S1:9431:5	lower	JJR	B-AdverseReaction	B-AdverseReaction
respiratory	SIMPONI.xml:S1:9437:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	SIMPONI.xml:S1:9449:5	tract	JJ	I-AdverseReaction	I-AdverseReaction
infection	SIMPONI.xml:S1:9455:9	infect	NN	I-AdverseReaction	I-AdverseReaction
(	SIMPONI.xml:S1:9465:1	(	(	O	O
pneumonia	SIMPONI.xml:S1:9466:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
)	SIMPONI.xml:S1:9475:1	)	)	O	O
,	SIMPONI.xml:S1:9476:1	,	,	O	O
pyelonephritis	SIMPONI.xml:S1:9478:14	pyelonephr	NN	B-AdverseReaction	B-AdverseReaction

Investigations	SIMPONI.xml:S1:9499:14	investig	NNS	O	O
:	SIMPONI.xml:S1:9515:1	:	:	O	O
Alanine	SIMPONI.xml:S1:9517:7	alanin	NNP	B-AdverseReaction	B-AdverseReaction
aminotransferase	SIMPONI.xml:S1:9525:16	aminotransferas	NN	I-AdverseReaction	I-AdverseReaction
increased	SIMPONI.xml:S1:9542:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S1:9551:1	,	,	O	O
aspartate	SIMPONI.xml:S1:9553:9	aspart	JJ	B-AdverseReaction	B-AdverseReaction
aminotransferase	SIMPONI.xml:S1:9563:16	aminotransferas	NN	I-AdverseReaction	I-AdverseReaction
increased	SIMPONI.xml:S1:9580:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S1:9589:1	,	,	O	O
neutrophil	SIMPONI.xml:S1:9591:10	neutrophil	JJ	B-AdverseReaction	B-AdverseReaction
count	SIMPONI.xml:S1:9602:5	count	NN	I-AdverseReaction	I-AdverseReaction
decreased	SIMPONI.xml:S1:9608:9	decreas	VBD	I-AdverseReaction	I-AdverseReaction

Nervous	SIMPONI.xml:S1:9624:7	nervou	JJ	O	O
system	SIMPONI.xml:S1:9632:6	system	NN	O	O
disorders	SIMPONI.xml:S1:9639:9	disord	NNS	O	O
:	SIMPONI.xml:S1:9650:1	:	:	O	O
Dizziness	SIMPONI.xml:S1:9652:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S1:9661:1	,	,	O	O
paresthesia	SIMPONI.xml:S1:9663:11	paresthesia	NN	B-AdverseReaction	B-AdverseReaction

Gastrointestinal	SIMPONI.xml:S1:9681:16	gastrointestin	JJ	O	O
disorders	SIMPONI.xml:S1:9698:9	disord	NNS	O	O
:	SIMPONI.xml:S1:9709:1	:	:	O	O
Constipation	SIMPONI.xml:S1:9711:12	constip	NN	B-AdverseReaction	B-AdverseReaction

6.2	SIMPONI.xml:S1:9730:3	6.2	CD	O	O
Post	SIMPONI.xml:S1:9734:4	post	NNP	O	O
-	SIMPONI.xml:S1:9738:1	-	:	O	O
marketing	SIMPONI.xml:S1:9739:9	market	NN	O	O
Experience	SIMPONI.xml:S1:9749:10	experi	NN	O	O

There	SIMPONI.xml:S1:9763:5	there	EX	O	O
is	SIMPONI.xml:S1:9769:2	is	VBZ	O	O
no	SIMPONI.xml:S1:9772:2	no	DT	O	O
post	SIMPONI.xml:S1:9775:4	post	NN	O	O
-	SIMPONI.xml:S1:9779:1	-	:	O	O
marketing	SIMPONI.xml:S1:9780:9	market	NN	O	O
experience	SIMPONI.xml:S1:9790:10	experi	NN	O	O
available	SIMPONI.xml:S1:9801:9	avail	JJ	O	O
for	SIMPONI.xml:S1:9811:3	for	IN	O	O
SIMPONI	SIMPONI.xml:S1:9815:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S1:9823:4	aria	NNP	O	O
.	SIMPONI.xml:S1:9827:1	.	.	O	O

The	SIMPONI.xml:S1:9829:3	the	DT	O	O
following	SIMPONI.xml:S1:9833:9	follow	JJ	O	O
adverse	SIMPONI.xml:S1:9843:7	advers	JJ	O	O
reactions	SIMPONI.xml:S1:9851:9	reaction	NNS	O	O
have	SIMPONI.xml:S1:9861:4	have	VBP	O	O
been	SIMPONI.xml:S1:9866:4	been	VBN	O	O
identified	SIMPONI.xml:S1:9871:10	identifi	VBN	O	O
during	SIMPONI.xml:S1:9882:6	dure	IN	O	O
post	SIMPONI.xml:S1:9889:4	post	NN	O	O
-	SIMPONI.xml:S1:9893:1	-	:	O	O
approval	SIMPONI.xml:S1:9894:8	approv	NN	O	O
use	SIMPONI.xml:S1:9903:3	use	NN	O	O
of	SIMPONI.xml:S1:9907:2	of	IN	O	O
the	SIMPONI.xml:S1:9910:3	the	DT	O	O
subcutaneous	SIMPONI.xml:S1:9914:12	subcutan	JJ	O	O
formulation	SIMPONI.xml:S1:9927:11	formul	NN	O	O
of	SIMPONI.xml:S1:9939:2	of	IN	O	O
golimumab	SIMPONI.xml:S1:9942:9	golimumab	NN	O	O
.	SIMPONI.xml:S1:9951:1	.	.	O	O

Because	SIMPONI.xml:S1:9953:7	becaus	IN	O	O
these	SIMPONI.xml:S1:9961:5	these	DT	O	O
reactions	SIMPONI.xml:S1:9967:9	reaction	NNS	O	O
are	SIMPONI.xml:S1:9977:3	are	VBP	O	O
reported	SIMPONI.xml:S1:9981:8	report	VBN	O	O
voluntarily	SIMPONI.xml:S1:9990:11	voluntarili	RB	O	O
from	SIMPONI.xml:S1:10002:4	from	IN	O	O
a	SIMPONI.xml:S1:10007:1	a	DT	O	O
population	SIMPONI.xml:S1:10009:10	popul	NN	O	O
of	SIMPONI.xml:S1:10020:2	of	IN	O	O
uncertain	SIMPONI.xml:S1:10023:9	uncertain	JJ	O	O
size	SIMPONI.xml:S1:10033:4	size	NN	O	O
,	SIMPONI.xml:S1:10037:1	,	,	O	O
it	SIMPONI.xml:S1:10039:2	it	PRP	O	O
is	SIMPONI.xml:S1:10042:2	is	VBZ	O	O
not	SIMPONI.xml:S1:10045:3	not	RB	O	O
always	SIMPONI.xml:S1:10049:6	alway	RB	O	O
possible	SIMPONI.xml:S1:10056:8	possibl	JJ	O	O
to	SIMPONI.xml:S1:10065:2	to	TO	O	O
reliably	SIMPONI.xml:S1:10068:8	reliabl	VB	O	O
estimate	SIMPONI.xml:S1:10077:8	estim	VB	O	O
their	SIMPONI.xml:S1:10086:5	their	PRP$	O	O
frequency	SIMPONI.xml:S1:10092:9	frequenc	NN	O	O
or	SIMPONI.xml:S1:10102:2	or	CC	O	O
establish	SIMPONI.xml:S1:10105:9	establish	VB	O	O
a	SIMPONI.xml:S1:10115:1	a	DT	O	O
causal	SIMPONI.xml:S1:10117:6	causal	NN	O	O
relationship	SIMPONI.xml:S1:10124:12	relationship	NN	O	O
to	SIMPONI.xml:S1:10137:2	to	TO	O	O
golimumab	SIMPONI.xml:S1:10140:9	golimumab	VB	O	O
exposure	SIMPONI.xml:S1:10150:8	exposur	NN	O	O
.	SIMPONI.xml:S1:10158:1	.	.	O	O

Neoplasm	SIMPONI.xml:S1:10166:8	neoplasm	NNP	O	O
Benign	SIMPONI.xml:S1:10175:6	benign	NNP	O	O
and	SIMPONI.xml:S1:10182:3	and	CC	O	O
Malignant	SIMPONI.xml:S1:10186:9	malign	NNP	O	O
:	SIMPONI.xml:S1:10197:1	:	:	O	O
Melanoma	SIMPONI.xml:S1:10199:8	melanoma	NNP	B-AdverseReaction	O
[	SIMPONI.xml:S1:10209:1	[	NNP	O	O
see	SIMPONI.xml:S1:10210:3	see	VBP	O	O
Warnings	SIMPONI.xml:S1:10215:8	warn	NNP	O	O
and	SIMPONI.xml:S1:10224:3	and	CC	O	O
Precautions	SIMPONI.xml:S1:10228:11	precaut	NNP	O	O
(	SIMPONI.xml:S1:10240:1	(	(	O	O
5.2	SIMPONI.xml:S1:10241:3	5.2	CD	O	O
)	SIMPONI.xml:S1:10244:1	)	)	O	O
]	SIMPONI.xml:S1:10247:1	]	NN	O	O

Immune	SIMPONI.xml:S1:10257:6	immun	NNP	O	O
System	SIMPONI.xml:S1:10264:6	system	NNP	O	O
Disorders	SIMPONI.xml:S1:10271:9	disord	NNPS	O	O
:	SIMPONI.xml:S1:10282:1	:	:	O	O
Serious	SIMPONI.xml:S1:10284:7	seriou	JJ	O	O
systemic	SIMPONI.xml:S1:10292:8	system	JJ	B-AdverseReaction	B-AdverseReaction
hypersensitivity	SIMPONI.xml:S1:10301:16	hypersensit	NN	I-AdverseReaction	I-AdverseReaction
reactions	SIMPONI.xml:S1:10318:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
(	SIMPONI.xml:S1:10328:1	(	(	O	O
including	SIMPONI.xml:S1:10329:9	includ	VBG	O	O
anaphylactic	SIMPONI.xml:S1:10339:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reaction	SIMPONI.xml:S1:10352:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
)	SIMPONI.xml:S1:10360:1	)	)	O	O
[	SIMPONI.xml:S1:10363:1	[	FW	O	O
see	SIMPONI.xml:S1:10364:3	see	VBP	O	O
Warnings	SIMPONI.xml:S1:10369:8	warn	NNS	O	O
and	SIMPONI.xml:S1:10378:3	and	CC	O	O
Precautions	SIMPONI.xml:S1:10382:11	precaut	NNP	O	O
(	SIMPONI.xml:S1:10394:1	(	(	O	O
5.10	SIMPONI.xml:S1:10395:4	5.10	CD	O	O
)	SIMPONI.xml:S1:10399:1	)	)	O	O
]	SIMPONI.xml:S1:10402:1	]	NN	O	O
,	SIMPONI.xml:S1:10405:1	,	,	O	O
sarcoidosis	SIMPONI.xml:S1:10407:11	sarcoidosi	NN	B-AdverseReaction	B-AdverseReaction

Respiratory	SIMPONI.xml:S1:10425:11	respiratori	NNP	O	O
,	SIMPONI.xml:S1:10436:1	,	,	O	O
thoracic	SIMPONI.xml:S1:10438:8	thorac	NN	O	O
and	SIMPONI.xml:S1:10447:3	and	CC	O	O
mediastinal	SIMPONI.xml:S1:10451:11	mediastin	JJ	O	O
disorders	SIMPONI.xml:S1:10463:9	disord	NNS	O	O
:	SIMPONI.xml:S1:10474:1	:	:	O	O
Interstitial	SIMPONI.xml:S1:10476:12	interstiti	NNP	B-AdverseReaction	B-AdverseReaction
lung	SIMPONI.xml:S1:10489:4	lung	NN	I-AdverseReaction	I-AdverseReaction
disease	SIMPONI.xml:S1:10494:7	diseas	NN	I-AdverseReaction	I-AdverseReaction

Skin	SIMPONI.xml:S1:10508:4	skin	NNP	O	O
and	SIMPONI.xml:S1:10513:3	and	CC	O	O
subcutaneous	SIMPONI.xml:S1:10517:12	subcutan	JJ	O	O
tissue	SIMPONI.xml:S1:10530:6	tissu	NN	O	O
disorders	SIMPONI.xml:S1:10537:9	disord	NNS	O	O
:	SIMPONI.xml:S1:10548:1	:	:	O	O
Skin	SIMPONI.xml:S1:10550:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
exfoliation	SIMPONI.xml:S1:10555:11	exfoli	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S1:10566:1	,	,	O	O
bullous	SIMPONI.xml:S1:10568:7	bullou	JJ	B-AdverseReaction	B-AdverseReaction
skin	SIMPONI.xml:S1:10576:4	skin	NN	I-AdverseReaction	I-AdverseReaction
reactions	SIMPONI.xml:S1:10581:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
\n\n	SIMPONI.xml:S2:0:2	\n\n	VBP	O	O
BOXED	SIMPONI.xml:S2:6:5	box	NNP	O	O
WARNING	SIMPONI.xml:S2:12:7	warn	NN	O	O
:	SIMPONI.xml:S2:19:1	:	:	O	O
WARNING	SIMPONI.xml:S2:21:7	warn	NN	O	O
:	SIMPONI.xml:S2:28:1	:	:	O	O
SERIOUS	SIMPONI.xml:S2:30:7	seriou	JJ	O	O
INFECTIONS	SIMPONI.xml:S2:38:10	infect	NNP	B-AdverseReaction	B-AdverseReaction
AND	SIMPONI.xml:S2:49:3	and	NNP	O	O
MALIGNANCY	SIMPONI.xml:S2:53:10	malign	NNP	B-AdverseReaction	B-AdverseReaction
\n\n	SIMPONI.xml:S2:63:2	\n\n	NNP	O	O
WARNING	SIMPONI.xml:S2:69:7	warn	NN	O	O
:	SIMPONI.xml:S2:76:1	:	:	O	O
SERIOUS	SIMPONI.xml:S2:78:7	seriou	JJ	O	O
INFECTIONS	SIMPONI.xml:S2:86:10	infect	NNP	B-AdverseReaction	B-AdverseReaction
AND	SIMPONI.xml:S2:97:3	and	NNP	O	O
MALIGNANCY	SIMPONI.xml:S2:101:10	malign	NNP	B-AdverseReaction	B-AdverseReaction
\n\n	SIMPONI.xml:S2:113:2	\n\n	NNP	O	O
EXCERPT	SIMPONI.xml:S2:117:7	excerpt	NNP	O	O
:	SIMPONI.xml:S2:124:1	:	:	O	O
WARNING	SIMPONI.xml:S2:128:7	warn	NN	O	O
:	SIMPONI.xml:S2:135:1	:	:	O	O
SERIOUS	SIMPONI.xml:S2:138:7	seriou	JJ	O	O
INFECTIONS	SIMPONI.xml:S2:146:10	infect	NNP	B-AdverseReaction	B-AdverseReaction
AND	SIMPONI.xml:S2:157:3	and	NNP	O	O
MALIGNANCY	SIMPONI.xml:S2:161:10	malign	NNP	B-AdverseReaction	B-AdverseReaction
\n\n\n\n	SIMPONI.xml:S2:171:4	\n\n\n\n	NNP	O	O
See	SIMPONI.xml:S2:178:3	see	NNP	O	O
full	SIMPONI.xml:S2:182:4	full	JJ	O	O
prescribing	SIMPONI.xml:S2:187:11	prescrib	VBG	O	O
information	SIMPONI.xml:S2:199:11	inform	NN	O	O
for	SIMPONI.xml:S2:211:3	for	IN	O	O
complete	SIMPONI.xml:S2:215:8	complet	JJ	O	O
boxed	SIMPONI.xml:S2:224:5	box	JJ	O	O
warning	SIMPONI.xml:S2:230:7	warn	NN	O	O
.	SIMPONI.xml:S2:237:1	.	.	O	O

Serious	SIMPONI.xml:S2:248:7	seriou	JJ	O	O
infections	SIMPONI.xml:S2:256:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
leading	SIMPONI.xml:S2:267:7	lead	VBG	O	O
to	SIMPONI.xml:S2:275:2	to	TO	O	O
hospitalization	SIMPONI.xml:S2:278:15	hospit	NN	O	O
or	SIMPONI.xml:S2:294:2	or	CC	O	O
death	SIMPONI.xml:S2:297:5	death	NN	B-AdverseReaction	B-AdverseReaction
including	SIMPONI.xml:S2:303:9	includ	VBG	O	O
tuberculosis	SIMPONI.xml:S2:313:12	tuberculosi	NN	B-AdverseReaction	B-AdverseReaction
(	SIMPONI.xml:S2:326:1	(	(	O	O
TB	SIMPONI.xml:S2:327:2	TB	NNP	B-AdverseReaction	B-AdverseReaction
)	SIMPONI.xml:S2:329:1	)	)	O	O
,	SIMPONI.xml:S2:330:1	,	,	O	O
bacterial	SIMPONI.xml:S2:332:9	bacteri	JJ	B-AdverseReaction	B-AdverseReaction
sepsis	SIMPONI.xml:S2:342:6	sepsi	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S2:348:1	,	,	O	O
invasive	SIMPONI.xml:S2:350:8	invas	JJ	B-AdverseReaction	B-AdverseReaction
fungal	SIMPONI.xml:S2:359:6	fungal	NN	I-AdverseReaction	I-AdverseReaction
(	SIMPONI.xml:S2:366:1	(	(	O	O
such	SIMPONI.xml:S2:367:4	such	JJ	O	O
as	SIMPONI.xml:S2:372:2	as	IN	O	O
histoplasmosis	SIMPONI.xml:S2:375:14	histoplasmosi	NN	B-AdverseReaction	B-AdverseReaction
)	SIMPONI.xml:S2:389:1	)	)	O	O
,	SIMPONI.xml:S2:390:1	,	,	O	O
and	SIMPONI.xml:S2:392:3	and	CC	O	O
other	SIMPONI.xml:S2:396:5	other	JJ	O	O
opportunistic	SIMPONI.xml:S2:402:13	opportunist	JJ	B-AdverseReaction	B-AdverseReaction
infections	SIMPONI.xml:S2:416:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
have	SIMPONI.xml:S2:427:4	have	VBP	O	O
occurred	SIMPONI.xml:S2:432:8	occur	VBN	O	O
in	SIMPONI.xml:S2:441:2	in	IN	O	O
patients	SIMPONI.xml:S2:444:8	patient	NNS	O	O
receiving	SIMPONI.xml:S2:453:9	receiv	VBG	O	O
SIMPONI	SIMPONI.xml:S2:463:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:471:4	aria	NNP	O	O
(	SIMPONI.xml:S2:476:1	(	(	O	O
5.1	SIMPONI.xml:S2:477:3	5.1	CD	O	O
)	SIMPONI.xml:S2:480:1	)	)	O	O
.	SIMPONI.xml:S2:481:1	.	.	O	O

Discontinue	SIMPONI.xml:S2:488:11	discontinu	NNP	O	O
SIMPONI	SIMPONI.xml:S2:500:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:508:4	aria	NNP	O	O
if	SIMPONI.xml:S2:513:2	if	IN	O	O
a	SIMPONI.xml:S2:516:1	a	DT	O	O
patient	SIMPONI.xml:S2:518:7	patient	NN	O	O
develops	SIMPONI.xml:S2:526:8	develop	VBZ	O	O
a	SIMPONI.xml:S2:535:1	a	DT	O	O
serious	SIMPONI.xml:S2:537:7	seriou	JJ	O	O
infection	SIMPONI.xml:S2:545:9	infect	NN	O	O
or	SIMPONI.xml:S2:555:2	or	CC	O	O
sepsis	SIMPONI.xml:S2:558:6	sepsi	NN	O	O
(	SIMPONI.xml:S2:565:1	(	(	O	O
5.1	SIMPONI.xml:S2:566:3	5.1	CD	O	O
)	SIMPONI.xml:S2:569:1	)	)	O	O
.	SIMPONI.xml:S2:570:1	.	.	O	O

Perform	SIMPONI.xml:S2:577:7	perform	NNP	O	O
test	SIMPONI.xml:S2:585:4	test	NN	O	O
for	SIMPONI.xml:S2:590:3	for	IN	O	O
latent	SIMPONI.xml:S2:594:6	latent	JJ	O	O
TB	SIMPONI.xml:S2:601:2	TB	NNP	O	O
;	SIMPONI.xml:S2:603:1	;	:	O	O
if	SIMPONI.xml:S2:605:2	if	IN	O	O
positive	SIMPONI.xml:S2:608:8	posit	JJ	O	O
,	SIMPONI.xml:S2:616:1	,	,	O	O
start	SIMPONI.xml:S2:618:5	start	JJ	O	O
treatment	SIMPONI.xml:S2:624:9	treatment	NN	O	O
for	SIMPONI.xml:S2:634:3	for	IN	O	O
TB	SIMPONI.xml:S2:638:2	TB	NNP	O	O
prior	SIMPONI.xml:S2:641:5	prior	RB	O	O
to	SIMPONI.xml:S2:647:2	to	TO	O	O
starting	SIMPONI.xml:S2:650:8	start	VBG	O	O
SIMPONI	SIMPONI.xml:S2:659:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:667:4	aria	NNP	O	O
(	SIMPONI.xml:S2:672:1	(	(	O	O
5.1	SIMPONI.xml:S2:673:3	5.1	CD	O	O
)	SIMPONI.xml:S2:676:1	)	)	O	O
.	SIMPONI.xml:S2:677:1	.	.	O	O

Monitor	SIMPONI.xml:S2:684:7	monitor	NNP	O	O
all	SIMPONI.xml:S2:692:3	all	DT	O	O
patients	SIMPONI.xml:S2:696:8	patient	NNS	O	O
for	SIMPONI.xml:S2:705:3	for	IN	O	O
active	SIMPONI.xml:S2:709:6	activ	JJ	O	O
TB	SIMPONI.xml:S2:716:2	TB	NNP	O	O
during	SIMPONI.xml:S2:719:6	dure	IN	O	O
treatment	SIMPONI.xml:S2:726:9	treatment	NN	O	O
,	SIMPONI.xml:S2:735:1	,	,	O	O
even	SIMPONI.xml:S2:737:4	even	RB	O	O
if	SIMPONI.xml:S2:742:2	if	IN	O	O
initial	SIMPONI.xml:S2:745:7	initi	JJ	O	O
latent	SIMPONI.xml:S2:753:6	latent	NN	O	O
TB	SIMPONI.xml:S2:760:2	TB	NNP	O	O
test	SIMPONI.xml:S2:763:4	test	NN	O	O
is	SIMPONI.xml:S2:768:2	is	VBZ	O	O
negative	SIMPONI.xml:S2:771:8	neg	JJ	O	O
(	SIMPONI.xml:S2:780:1	(	(	O	O
5.1	SIMPONI.xml:S2:781:3	5.1	CD	O	O
)	SIMPONI.xml:S2:784:1	)	)	O	O
.	SIMPONI.xml:S2:785:1	.	.	O	O

Lymphoma	SIMPONI.xml:S2:792:8	lymphoma	NNP	B-AdverseReaction	B-AdverseReaction
and	SIMPONI.xml:S2:801:3	and	CC	O	O
other	SIMPONI.xml:S2:805:5	other	JJ	O	O
malignancies	SIMPONI.xml:S2:811:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S2:823:1	,	,	O	O
some	SIMPONI.xml:S2:825:4	some	DT	O	O
fatal	SIMPONI.xml:S2:830:5	fatal	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S2:835:1	,	,	O	O
have	SIMPONI.xml:S2:837:4	have	VBP	O	O
been	SIMPONI.xml:S2:842:4	been	VBN	O	O
reported	SIMPONI.xml:S2:847:8	report	VBN	O	O
in	SIMPONI.xml:S2:856:2	in	IN	O	O
children	SIMPONI.xml:S2:859:8	children	NNS	O	O
and	SIMPONI.xml:S2:868:3	and	CC	O	O
adolescent	SIMPONI.xml:S2:872:10	adolesc	NN	O	O
patients	SIMPONI.xml:S2:883:8	patient	NNS	O	O
treated	SIMPONI.xml:S2:892:7	treat	VBN	O	O
with	SIMPONI.xml:S2:900:4	with	IN	O	O
TNF	SIMPONI.xml:S2:905:3	tnf	NNP	O	O
blockers	SIMPONI.xml:S2:909:8	blocker	NNS	O	O
,	SIMPONI.xml:S2:917:1	,	,	O	O
of	SIMPONI.xml:S2:919:2	of	IN	O	O
which	SIMPONI.xml:S2:922:5	which	WDT	O	O
SIMPONI	SIMPONI.xml:S2:928:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:936:4	aria	NNP	O	O
is	SIMPONI.xml:S2:941:2	is	VBZ	O	O
a	SIMPONI.xml:S2:944:1	a	DT	O	O
member	SIMPONI.xml:S2:946:6	member	NN	O	O
(	SIMPONI.xml:S2:953:1	(	(	O	O
5.2	SIMPONI.xml:S2:954:3	5.2	CD	O	O
)	SIMPONI.xml:S2:957:1	)	)	O	O
.	SIMPONI.xml:S2:958:1	.	.	O	O

SERIOUS	SIMPONI.xml:S2:973:7	seriou	NNP	O	O
INFECTIONS	SIMPONI.xml:S2:981:10	infect	NNP	O	B-AdverseReaction
\n\n\n\n	SIMPONI.xml:S2:993:4	\n\n\n\n	NNP	O	O
Patients	SIMPONI.xml:S2:1000:8	patient	NNP	O	O
treated	SIMPONI.xml:S2:1009:7	treat	VBD	O	O
with	SIMPONI.xml:S2:1017:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S2:1022:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:1030:4	aria	NNP	O	O
are	SIMPONI.xml:S2:1035:3	are	VBP	O	O
at	SIMPONI.xml:S2:1039:2	at	IN	O	O
increased	SIMPONI.xml:S2:1042:9	increas	VBN	O	O
risk	SIMPONI.xml:S2:1052:4	risk	NN	O	O
for	SIMPONI.xml:S2:1057:3	for	IN	O	O
developing	SIMPONI.xml:S2:1061:10	develop	VBG	O	O
serious	SIMPONI.xml:S2:1072:7	seriou	JJ	O	O
infections	SIMPONI.xml:S2:1080:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
that	SIMPONI.xml:S2:1091:4	that	WDT	O	O
may	SIMPONI.xml:S2:1096:3	may	MD	O	O
lead	SIMPONI.xml:S2:1100:4	lead	VB	O	O
to	SIMPONI.xml:S2:1105:2	to	TO	O	O
hospitalization	SIMPONI.xml:S2:1108:15	hospit	NN	O	O
or	SIMPONI.xml:S2:1124:2	or	CC	O	O
death	SIMPONI.xml:S2:1127:5	death	NN	B-AdverseReaction	B-AdverseReaction
[	SIMPONI.xml:S2:1135:1	[	NNS	O	O
see	SIMPONI.xml:S2:1136:3	see	VBP	O	O
Warnings	SIMPONI.xml:S2:1142:8	warn	NNS	O	O
and	SIMPONI.xml:S2:1151:3	and	CC	O	O
Precautions	SIMPONI.xml:S2:1155:11	precaut	NNP	O	O
(	SIMPONI.xml:S2:1167:1	(	(	O	O
5.1	SIMPONI.xml:S2:1168:3	5.1	CD	O	O
)	SIMPONI.xml:S2:1171:1	)	)	O	O
]	SIMPONI.xml:S2:1174:1	]	NN	O	O
.	SIMPONI.xml:S2:1177:1	.	.	O	O

Most	SIMPONI.xml:S2:1180:4	most	JJS	O	O
patients	SIMPONI.xml:S2:1185:8	patient	NNS	O	O
who	SIMPONI.xml:S2:1194:3	who	WP	O	O
developed	SIMPONI.xml:S2:1198:9	develop	VBD	O	O
these	SIMPONI.xml:S2:1208:5	these	DT	O	O
infections	SIMPONI.xml:S2:1214:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
were	SIMPONI.xml:S2:1225:4	were	VBD	O	O
taking	SIMPONI.xml:S2:1230:6	take	VBG	O	O
concomitant	SIMPONI.xml:S2:1237:11	concomit	JJ	O	O
immunosuppressants	SIMPONI.xml:S2:1249:18	immunosuppress	NNS	O	O
such	SIMPONI.xml:S2:1268:4	such	JJ	O	O
as	SIMPONI.xml:S2:1273:2	as	IN	O	O
methotrexate	SIMPONI.xml:S2:1276:12	methotrex	NN	O	O
or	SIMPONI.xml:S2:1289:2	or	CC	O	O
corticosteroids	SIMPONI.xml:S2:1292:15	corticosteroid	NNS	O	O
.	SIMPONI.xml:S2:1307:1	.	.	O	O

Discontinue	SIMPONI.xml:S2:1317:11	discontinu	NNP	O	O
SIMPONI	SIMPONI.xml:S2:1329:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:1337:4	aria	NNP	O	O
if	SIMPONI.xml:S2:1342:2	if	IN	O	O
a	SIMPONI.xml:S2:1345:1	a	DT	O	O
patient	SIMPONI.xml:S2:1347:7	patient	NN	O	O
develops	SIMPONI.xml:S2:1355:8	develop	VBZ	O	O
a	SIMPONI.xml:S2:1364:1	a	DT	O	O
serious	SIMPONI.xml:S2:1366:7	seriou	JJ	O	O
infection	SIMPONI.xml:S2:1374:9	infect	NN	O	O
.	SIMPONI.xml:S2:1383:1	.	.	O	O

Reported	SIMPONI.xml:S2:1393:8	report	VBN	O	O
infections	SIMPONI.xml:S2:1402:10	infect	NNS	O	O
with	SIMPONI.xml:S2:1413:4	with	IN	O	O
TNF	SIMPONI.xml:S2:1418:3	tnf	NNP	O	O
-	SIMPONI.xml:S2:1421:1	-	:	O	O
blockers	SIMPONI.xml:S2:1422:8	blocker	NNS	O	O
,	SIMPONI.xml:S2:1430:1	,	,	O	O
of	SIMPONI.xml:S2:1432:2	of	IN	O	O
which	SIMPONI.xml:S2:1435:5	which	WDT	O	O
SIMPONI	SIMPONI.xml:S2:1441:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:1449:4	aria	NNP	O	O
is	SIMPONI.xml:S2:1454:2	is	VBZ	O	O
a	SIMPONI.xml:S2:1457:1	a	DT	O	O
member	SIMPONI.xml:S2:1459:6	member	NN	O	O
,	SIMPONI.xml:S2:1465:1	,	,	O	O
include	SIMPONI.xml:S2:1467:7	includ	VBP	O	O
:	SIMPONI.xml:S2:1474:1	:	:	O	O
\n\n\n\n	SIMPONI.xml:S2:1477:4	\n\n\n\n	JJ	O	O
Active	SIMPONI.xml:S2:1485:6	activ	NNP	B-AdverseReaction	B-AdverseReaction
tuberculosis	SIMPONI.xml:S2:1492:12	tuberculosi	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S2:1504:1	,	,	O	O
including	SIMPONI.xml:S2:1506:9	includ	VBG	O	O
reactivation	SIMPONI.xml:S2:1516:12	reactiv	NN	B-AdverseReaction	B-AdverseReaction
of	SIMPONI.xml:S2:1529:2	of	IN	I-AdverseReaction	I-AdverseReaction
latent	SIMPONI.xml:S2:1532:6	latent	JJ	I-AdverseReaction	I-AdverseReaction
tuberculosis	SIMPONI.xml:S2:1539:12	tuberculosi	NN	I-AdverseReaction	I-AdverseReaction
.	SIMPONI.xml:S2:1551:1	.	.	O	O

Patients	SIMPONI.xml:S2:1553:8	patient	NNS	O	O
with	SIMPONI.xml:S2:1562:4	with	IN	O	O
tuberculosis	SIMPONI.xml:S2:1567:12	tuberculosi	NN	B-AdverseReaction	B-AdverseReaction
have	SIMPONI.xml:S2:1580:4	have	VBP	O	O
frequently	SIMPONI.xml:S2:1585:10	frequent	RB	O	O
presented	SIMPONI.xml:S2:1596:9	present	VBN	O	O
with	SIMPONI.xml:S2:1606:4	with	IN	O	O
disseminated	SIMPONI.xml:S2:1611:12	dissemin	JJ	I-AdverseReaction	I-AdverseReaction
or	SIMPONI.xml:S2:1624:2	or	CC	O	O
extrapulmonary	SIMPONI.xml:S2:1627:14	extrapulmonari	JJ	I-AdverseReaction	I-AdverseReaction
disease	SIMPONI.xml:S2:1642:7	diseas	NN	O	O
.	SIMPONI.xml:S2:1649:1	.	.	O	O

Test	SIMPONI.xml:S2:1651:4	test	NN	O	O
patients	SIMPONI.xml:S2:1656:8	patient	NNS	O	O
for	SIMPONI.xml:S2:1665:3	for	IN	O	O
latent	SIMPONI.xml:S2:1669:6	latent	JJ	O	O
tuberculosis	SIMPONI.xml:S2:1676:12	tuberculosi	NN	O	O
before	SIMPONI.xml:S2:1689:6	befor	IN	O	O
SIMPONI	SIMPONI.xml:S2:1696:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:1704:4	aria	NNP	O	O
use	SIMPONI.xml:S2:1709:3	use	NN	O	O
and	SIMPONI.xml:S2:1713:3	and	CC	O	O
during	SIMPONI.xml:S2:1717:6	dure	IN	O	O
therapy	SIMPONI.xml:S2:1724:7	therapi	NN	O	O
.	SIMPONI.xml:S2:1731:1	.	.	O	O

Initiate	SIMPONI.xml:S2:1733:8	initi	NNP	O	O
treatment	SIMPONI.xml:S2:1742:9	treatment	NN	O	O
for	SIMPONI.xml:S2:1752:3	for	IN	O	O
latent	SIMPONI.xml:S2:1756:6	latent	JJ	O	O
tuberculosis	SIMPONI.xml:S2:1763:12	tuberculosi	NN	O	O
prior	SIMPONI.xml:S2:1776:5	prior	RB	O	O
to	SIMPONI.xml:S2:1782:2	to	TO	O	O
SIMPONI	SIMPONI.xml:S2:1785:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:1793:4	aria	NNP	O	O
use	SIMPONI.xml:S2:1798:3	use	NN	O	O
.	SIMPONI.xml:S2:1801:1	.	.	O	O

Invasive	SIMPONI.xml:S2:1808:8	invas	JJ	B-AdverseReaction	B-AdverseReaction
fungal	SIMPONI.xml:S2:1817:6	fungal	JJ	I-AdverseReaction	I-AdverseReaction
infections	SIMPONI.xml:S2:1824:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S2:1834:1	,	,	O	O
including	SIMPONI.xml:S2:1836:9	includ	VBG	O	O
histoplasmosis	SIMPONI.xml:S2:1846:14	histoplasmosi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S2:1860:1	,	,	O	O
coccidioidomycosis	SIMPONI.xml:S2:1862:18	coccidioidomycosi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S2:1880:1	,	,	O	O
candidiasis	SIMPONI.xml:S2:1882:11	candidiasi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S2:1893:1	,	,	O	O
aspergillosis	SIMPONI.xml:S2:1895:13	aspergillosi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S2:1908:1	,	,	O	O
blastomycosis	SIMPONI.xml:S2:1910:13	blastomycosi	NN	B-AdverseReaction	B-AdverseReaction
and	SIMPONI.xml:S2:1924:3	and	CC	O	O
pneumocystosis	SIMPONI.xml:S2:1928:14	pneumocystosi	NN	B-AdverseReaction	O
.	SIMPONI.xml:S2:1942:1	.	.	O	O

Patients	SIMPONI.xml:S2:1944:8	patient	NNS	O	O
with	SIMPONI.xml:S2:1953:4	with	IN	O	O
histoplasmosis	SIMPONI.xml:S2:1958:14	histoplasmosi	NN	O	B-AdverseReaction
or	SIMPONI.xml:S2:1973:2	or	CC	O	O
other	SIMPONI.xml:S2:1976:5	other	JJ	O	O
invasive	SIMPONI.xml:S2:1982:8	invas	JJ	O	B-AdverseReaction
fungal	SIMPONI.xml:S2:1991:6	fungal	JJ	O	I-AdverseReaction
infections	SIMPONI.xml:S2:1998:10	infect	NNS	O	I-AdverseReaction
may	SIMPONI.xml:S2:2009:3	may	MD	O	O
present	SIMPONI.xml:S2:2013:7	present	VB	O	O
with	SIMPONI.xml:S2:2021:4	with	IN	O	O
disseminated	SIMPONI.xml:S2:2026:12	dissemin	JJ	O	I-AdverseReaction
,	SIMPONI.xml:S2:2038:1	,	,	O	O
rather	SIMPONI.xml:S2:2040:6	rather	RB	O	O
than	SIMPONI.xml:S2:2047:4	than	IN	O	O
localized	SIMPONI.xml:S2:2052:9	local	VBN	O	O
,	SIMPONI.xml:S2:2061:1	,	,	O	O
disease	SIMPONI.xml:S2:2063:7	diseas	NN	O	O
.	SIMPONI.xml:S2:2070:1	.	.	O	O

Antigen	SIMPONI.xml:S2:2072:7	antigen	NNP	O	O
and	SIMPONI.xml:S2:2080:3	and	CC	O	O
antibody	SIMPONI.xml:S2:2084:8	antibodi	NN	O	O
testing	SIMPONI.xml:S2:2093:7	test	VBG	O	O
for	SIMPONI.xml:S2:2101:3	for	IN	O	O
histoplasmosis	SIMPONI.xml:S2:2105:14	histoplasmosi	NN	O	O
may	SIMPONI.xml:S2:2120:3	may	MD	O	O
be	SIMPONI.xml:S2:2124:2	be	VB	O	O
negative	SIMPONI.xml:S2:2127:8	neg	JJ	O	O
in	SIMPONI.xml:S2:2136:2	in	IN	O	O
some	SIMPONI.xml:S2:2139:4	some	DT	O	O
patients	SIMPONI.xml:S2:2144:8	patient	NNS	O	O
with	SIMPONI.xml:S2:2153:4	with	IN	O	O
active	SIMPONI.xml:S2:2158:6	activ	JJ	O	O
infection	SIMPONI.xml:S2:2165:9	infect	NN	O	O
.	SIMPONI.xml:S2:2174:1	.	.	O	O

Consider	SIMPONI.xml:S2:2176:8	consid	VB	O	O
empiric	SIMPONI.xml:S2:2185:7	empir	JJ	O	O
anti	SIMPONI.xml:S2:2193:4	anti	NN	O	O
-	SIMPONI.xml:S2:2197:1	-	:	O	O
fungal	SIMPONI.xml:S2:2198:6	fungal	JJ	O	O
therapy	SIMPONI.xml:S2:2205:7	therapi	NN	O	O
in	SIMPONI.xml:S2:2213:2	in	IN	O	O
patients	SIMPONI.xml:S2:2216:8	patient	NNS	O	O
at	SIMPONI.xml:S2:2225:2	at	IN	O	O
risk	SIMPONI.xml:S2:2228:4	risk	NN	O	O
for	SIMPONI.xml:S2:2233:3	for	IN	O	O
invasive	SIMPONI.xml:S2:2237:8	invas	JJ	O	O
fungal	SIMPONI.xml:S2:2246:6	fungal	JJ	O	O
infections	SIMPONI.xml:S2:2253:10	infect	NNS	O	O
who	SIMPONI.xml:S2:2264:3	who	WP	O	O
develop	SIMPONI.xml:S2:2268:7	develop	VBP	O	O
severe	SIMPONI.xml:S2:2276:6	sever	JJ	O	O
systemic	SIMPONI.xml:S2:2283:8	system	JJ	O	O
illness	SIMPONI.xml:S2:2292:7	ill	NN	O	O
.	SIMPONI.xml:S2:2299:1	.	.	O	O

Bacterial	SIMPONI.xml:S2:2306:9	bacteri	NNP	B-AdverseReaction	O
,	SIMPONI.xml:S2:2315:1	,	,	O	O
viral	SIMPONI.xml:S2:2317:5	viral	JJ	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S2:2322:1	,	,	O	O
and	SIMPONI.xml:S2:2324:3	and	CC	O	O
other	SIMPONI.xml:S2:2328:5	other	JJ	O	O
infections	SIMPONI.xml:S2:2334:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
due	SIMPONI.xml:S2:2345:3	due	JJ	I-AdverseReaction	O
to	SIMPONI.xml:S2:2349:2	to	TO	I-AdverseReaction	O
opportunistic	SIMPONI.xml:S2:2352:13	opportunist	JJ	I-AdverseReaction	O
pathogens	SIMPONI.xml:S2:2366:9	pathogen	NNS	I-AdverseReaction	O
,	SIMPONI.xml:S2:2375:1	,	,	O	O
including	SIMPONI.xml:S2:2377:9	includ	VBG	O	O
Legionella	SIMPONI.xml:S2:2387:10	legionella	NNP	I-AdverseReaction	O
and	SIMPONI.xml:S2:2398:3	and	CC	O	O
Listeria	SIMPONI.xml:S2:2402:8	listeria	NNP	I-AdverseReaction	O
.	SIMPONI.xml:S2:2410:1	.	.	O	O

Consider	SIMPONI.xml:S2:2419:8	consid	VB	O	O
the	SIMPONI.xml:S2:2428:3	the	DT	O	O
risks	SIMPONI.xml:S2:2432:5	risk	NNS	O	O
and	SIMPONI.xml:S2:2438:3	and	CC	O	O
benefits	SIMPONI.xml:S2:2442:8	benefit	NNS	O	O
of	SIMPONI.xml:S2:2451:2	of	IN	O	O
treatment	SIMPONI.xml:S2:2454:9	treatment	NN	O	O
with	SIMPONI.xml:S2:2464:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S2:2469:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:2477:4	aria	NNP	O	O
prior	SIMPONI.xml:S2:2482:5	prior	RB	O	O
to	SIMPONI.xml:S2:2488:2	to	TO	O	O
initiating	SIMPONI.xml:S2:2491:10	initi	VBG	O	O
therapy	SIMPONI.xml:S2:2502:7	therapi	NN	O	O
in	SIMPONI.xml:S2:2510:2	in	IN	O	O
patients	SIMPONI.xml:S2:2513:8	patient	NNS	O	O
with	SIMPONI.xml:S2:2522:4	with	IN	O	O
chronic	SIMPONI.xml:S2:2527:7	chronic	JJ	O	O
or	SIMPONI.xml:S2:2535:2	or	CC	O	O
recurrent	SIMPONI.xml:S2:2538:9	recurr	JJ	O	O
infection	SIMPONI.xml:S2:2548:9	infect	NN	O	O
.	SIMPONI.xml:S2:2557:1	.	.	O	O

Monitor	SIMPONI.xml:S2:2567:7	monitor	NN	O	O
patients	SIMPONI.xml:S2:2575:8	patient	NNS	O	O
closely	SIMPONI.xml:S2:2584:7	close	RB	O	O
for	SIMPONI.xml:S2:2592:3	for	IN	O	O
the	SIMPONI.xml:S2:2596:3	the	DT	O	O
development	SIMPONI.xml:S2:2600:11	develop	NN	O	O
of	SIMPONI.xml:S2:2612:2	of	IN	O	O
signs	SIMPONI.xml:S2:2615:5	sign	NNS	O	O
and	SIMPONI.xml:S2:2621:3	and	CC	O	O
symptoms	SIMPONI.xml:S2:2625:8	symptom	NNS	O	O
of	SIMPONI.xml:S2:2634:2	of	IN	O	O
infection	SIMPONI.xml:S2:2637:9	infect	NN	O	O
during	SIMPONI.xml:S2:2647:6	dure	IN	O	O
and	SIMPONI.xml:S2:2654:3	and	CC	O	O
after	SIMPONI.xml:S2:2658:5	after	IN	O	O
treatment	SIMPONI.xml:S2:2664:9	treatment	NN	O	O
with	SIMPONI.xml:S2:2674:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S2:2679:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:2687:4	aria	NNP	O	O
,	SIMPONI.xml:S2:2691:1	,	,	O	O
including	SIMPONI.xml:S2:2693:9	includ	VBG	O	O
the	SIMPONI.xml:S2:2703:3	the	DT	O	O
possible	SIMPONI.xml:S2:2707:8	possibl	JJ	O	O
development	SIMPONI.xml:S2:2716:11	develop	NN	O	O
of	SIMPONI.xml:S2:2728:2	of	IN	O	O
tuberculosis	SIMPONI.xml:S2:2731:12	tuberculosi	NN	O	O
in	SIMPONI.xml:S2:2744:2	in	IN	O	O
patients	SIMPONI.xml:S2:2747:8	patient	NNS	O	O
who	SIMPONI.xml:S2:2756:3	who	WP	O	O
tested	SIMPONI.xml:S2:2760:6	test	VBD	O	O
negative	SIMPONI.xml:S2:2767:8	neg	JJ	O	O
for	SIMPONI.xml:S2:2776:3	for	IN	O	O
latent	SIMPONI.xml:S2:2780:6	latent	JJ	O	O
tuberculosis	SIMPONI.xml:S2:2787:12	tuberculosi	NN	O	O
infection	SIMPONI.xml:S2:2800:9	infect	NN	O	O
prior	SIMPONI.xml:S2:2810:5	prior	RB	O	O
to	SIMPONI.xml:S2:2816:2	to	TO	O	O
initiating	SIMPONI.xml:S2:2819:10	initi	VBG	O	O
therapy	SIMPONI.xml:S2:2830:7	therapi	NN	O	O
[	SIMPONI.xml:S2:2840:1	[	NNP	O	O
see	SIMPONI.xml:S2:2841:3	see	VBP	O	O
Warnings	SIMPONI.xml:S2:2847:8	warn	NNP	O	O
and	SIMPONI.xml:S2:2856:3	and	CC	O	O
Precautions	SIMPONI.xml:S2:2860:11	precaut	NNP	O	O
(	SIMPONI.xml:S2:2872:1	(	(	O	O
5.1	SIMPONI.xml:S2:2873:3	5.1	CD	O	O
)	SIMPONI.xml:S2:2876:1	)	)	O	O
]	SIMPONI.xml:S2:2879:1	]	NN	O	O
.	SIMPONI.xml:S2:2882:1	.	.	O	O

MALIGNANCY	SIMPONI.xml:S2:2894:10	malign	NNP	O	O
\n\n\n\n	SIMPONI.xml:S2:2906:4	\n\n\n\n	NNP	O	O
Lymphoma	SIMPONI.xml:S2:2913:8	lymphoma	NNP	B-AdverseReaction	B-AdverseReaction
and	SIMPONI.xml:S2:2922:3	and	CC	O	O
other	SIMPONI.xml:S2:2926:5	other	JJ	O	O
malignancies	SIMPONI.xml:S2:2932:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S2:2944:1	,	,	O	O
some	SIMPONI.xml:S2:2946:4	some	DT	O	O
fatal	SIMPONI.xml:S2:2951:5	fatal	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S2:2956:1	,	,	O	O
have	SIMPONI.xml:S2:2958:4	have	VBP	O	O
been	SIMPONI.xml:S2:2963:4	been	VBN	O	O
reported	SIMPONI.xml:S2:2968:8	report	VBN	O	O
in	SIMPONI.xml:S2:2977:2	in	IN	O	O
children	SIMPONI.xml:S2:2980:8	children	NNS	O	O
and	SIMPONI.xml:S2:2989:3	and	CC	O	O
adolescent	SIMPONI.xml:S2:2993:10	adolesc	NN	O	O
patients	SIMPONI.xml:S2:3004:8	patient	NNS	O	O
treated	SIMPONI.xml:S2:3013:7	treat	VBN	O	O
with	SIMPONI.xml:S2:3021:4	with	IN	O	O
TNF	SIMPONI.xml:S2:3026:3	tnf	NNP	O	O
blockers	SIMPONI.xml:S2:3030:8	blocker	NNS	O	O
,	SIMPONI.xml:S2:3038:1	,	,	O	O
of	SIMPONI.xml:S2:3040:2	of	IN	O	O
which	SIMPONI.xml:S2:3043:5	which	WDT	O	O
SIMPONI	SIMPONI.xml:S2:3049:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S2:3057:4	aria	NNP	O	O
is	SIMPONI.xml:S2:3062:2	is	VBZ	O	O
a	SIMPONI.xml:S2:3065:1	a	DT	O	O
member	SIMPONI.xml:S2:3067:6	member	NN	O	O
[	SIMPONI.xml:S2:3076:1	[	NNP	O	O
see	SIMPONI.xml:S2:3077:3	see	VBP	O	O
Warnings	SIMPONI.xml:S2:3083:8	warn	NNP	O	O
and	SIMPONI.xml:S2:3092:3	and	CC	O	O
Precautions	SIMPONI.xml:S2:3096:11	precaut	NNP	O	O
(	SIMPONI.xml:S2:3108:1	(	(	O	O
5.2	SIMPONI.xml:S2:3109:3	5.2	CD	O	O
)	SIMPONI.xml:S2:3112:1	)	)	O	O
]	SIMPONI.xml:S2:3115:1	]	NN	O	O
.	SIMPONI.xml:S2:3118:1	.	.	O	O
\n	SIMPONI.xml:S2:3121:1	\n	CC	O	O
5	SIMPONI.xml:S3:4:1	5	CD	O	O
WARNINGS	SIMPONI.xml:S3:6:8	warn	NNP	O	O
AND	SIMPONI.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	SIMPONI.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	SIMPONI.xml:S3:37:7	excerpt	NN	O	O
:	SIMPONI.xml:S3:44:1	:	:	O	O
Serious	SIMPONI.xml:S3:52:7	seriou	JJ	O	O
infections	SIMPONI.xml:S3:60:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
-	SIMPONI.xml:S3:71:1	-	:	O	O
Do	SIMPONI.xml:S3:73:2	Do	VBP	O	O
not	SIMPONI.xml:S3:76:3	not	RB	O	O
start	SIMPONI.xml:S3:80:5	start	VB	O	O
SIMPONI	SIMPONI.xml:S3:86:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:94:4	aria	NNP	O	O
during	SIMPONI.xml:S3:99:6	dure	IN	O	O
an	SIMPONI.xml:S3:106:2	an	DT	O	O
active	SIMPONI.xml:S3:109:6	activ	JJ	O	O
infection	SIMPONI.xml:S3:116:9	infect	NN	O	O
.	SIMPONI.xml:S3:125:1	.	.	O	O

If	SIMPONI.xml:S3:127:2	If	IN	O	O
an	SIMPONI.xml:S3:130:2	an	DT	O	O
infection	SIMPONI.xml:S3:133:9	infect	NN	O	O
develops	SIMPONI.xml:S3:143:8	develop	VBZ	O	O
,	SIMPONI.xml:S3:151:1	,	,	O	O
monitor	SIMPONI.xml:S3:153:7	monitor	NN	O	O
carefully	SIMPONI.xml:S3:161:9	care	RB	O	O
,	SIMPONI.xml:S3:170:1	,	,	O	O
and	SIMPONI.xml:S3:172:3	and	CC	O	O
stop	SIMPONI.xml:S3:176:4	stop	VB	O	O
SIMPONI	SIMPONI.xml:S3:181:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:189:4	aria	NNP	O	O
if	SIMPONI.xml:S3:194:2	if	IN	O	O
infection	SIMPONI.xml:S3:197:9	infect	NN	O	O
becomes	SIMPONI.xml:S3:207:7	becom	VBZ	O	O
serious	SIMPONI.xml:S3:215:7	seriou	JJ	O	O
(	SIMPONI.xml:S3:223:1	(	(	O	O
5.1	SIMPONI.xml:S3:226:3	5.1	CD	O	O
)	SIMPONI.xml:S3:231:1	)	)	O	O
.	SIMPONI.xml:S3:232:1	.	.	O	O

Invasive	SIMPONI.xml:S3:239:8	invas	JJ	B-AdverseReaction	B-AdverseReaction
fungal	SIMPONI.xml:S3:248:6	fungal	NN	I-AdverseReaction	I-AdverseReaction
infections	SIMPONI.xml:S3:255:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
-	SIMPONI.xml:S3:266:1	-	:	O	O
For	SIMPONI.xml:S3:268:3	for	IN	O	O
patients	SIMPONI.xml:S3:272:8	patient	NNS	O	O
who	SIMPONI.xml:S3:281:3	who	WP	O	O
develop	SIMPONI.xml:S3:285:7	develop	VBP	O	O
a	SIMPONI.xml:S3:293:1	a	DT	O	O
systemic	SIMPONI.xml:S3:295:8	system	JJ	O	O
illness	SIMPONI.xml:S3:304:7	ill	NN	O	O
on	SIMPONI.xml:S3:312:2	on	IN	O	O
SIMPONI	SIMPONI.xml:S3:315:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:323:4	aria	NNP	O	O
,	SIMPONI.xml:S3:327:1	,	,	O	O
consider	SIMPONI.xml:S3:329:8	consid	VB	O	O
empiric	SIMPONI.xml:S3:338:7	empir	JJ	O	O
antifungal	SIMPONI.xml:S3:346:10	antifung	NN	O	O
therapy	SIMPONI.xml:S3:357:7	therapi	NN	O	O
for	SIMPONI.xml:S3:365:3	for	IN	O	O
those	SIMPONI.xml:S3:369:5	those	DT	O	O
who	SIMPONI.xml:S3:375:3	who	WP	O	O
reside	SIMPONI.xml:S3:379:6	resid	VBP	O	O
in	SIMPONI.xml:S3:386:2	in	IN	O	O
or	SIMPONI.xml:S3:389:2	or	CC	O	O
travel	SIMPONI.xml:S3:392:6	travel	NN	O	O
to	SIMPONI.xml:S3:399:2	to	TO	O	O
regions	SIMPONI.xml:S3:402:7	region	NNS	O	O
where	SIMPONI.xml:S3:410:5	where	WRB	O	O
mycoses	SIMPONI.xml:S3:416:7	mycos	NNS	O	O
are	SIMPONI.xml:S3:424:3	are	VBP	O	O
endemic	SIMPONI.xml:S3:428:7	endem	JJ	O	O
(	SIMPONI.xml:S3:436:1	(	(	O	O
5.1	SIMPONI.xml:S3:439:3	5.1	CD	O	O
)	SIMPONI.xml:S3:444:1	)	)	O	O
.	SIMPONI.xml:S3:445:1	.	.	O	O

Hepatitis	SIMPONI.xml:S3:452:9	hepat	NN	B-AdverseReaction	O
B	SIMPONI.xml:S3:462:1	B	NNP	I-AdverseReaction	O
reactivation	SIMPONI.xml:S3:464:12	reactiv	NN	I-AdverseReaction	O
-	SIMPONI.xml:S3:477:1	-	:	O	O
Monitor	SIMPONI.xml:S3:479:7	monitor	NNP	O	O
HBV	SIMPONI.xml:S3:487:3	hbv	NNP	O	O
carriers	SIMPONI.xml:S3:491:8	carrier	NNS	O	O
during	SIMPONI.xml:S3:500:6	dure	IN	O	O
and	SIMPONI.xml:S3:507:3	and	CC	O	O
several	SIMPONI.xml:S3:511:7	sever	JJ	O	O
months	SIMPONI.xml:S3:519:6	month	NNS	O	O
after	SIMPONI.xml:S3:526:5	after	IN	O	O
therapy	SIMPONI.xml:S3:532:7	therapi	NN	O	O
.	SIMPONI.xml:S3:539:1	.	.	O	O

If	SIMPONI.xml:S3:541:2	If	IN	O	O
reactivation	SIMPONI.xml:S3:544:12	reactiv	NN	O	O
occurs	SIMPONI.xml:S3:557:6	occur	VBZ	O	O
,	SIMPONI.xml:S3:563:1	,	,	O	O
stop	SIMPONI.xml:S3:565:4	stop	VB	O	O
SIMPONI	SIMPONI.xml:S3:570:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:578:4	aria	NNP	O	O
and	SIMPONI.xml:S3:583:3	and	CC	O	O
begin	SIMPONI.xml:S3:587:5	begin	VB	O	O
anti	SIMPONI.xml:S3:593:4	anti	SYM	O	O
-	SIMPONI.xml:S3:597:1	-	:	O	O
viral	SIMPONI.xml:S3:598:5	viral	JJ	O	O
therapy	SIMPONI.xml:S3:604:7	therapi	NN	O	O
(	SIMPONI.xml:S3:612:1	(	(	O	O
5.1	SIMPONI.xml:S3:615:3	5.1	CD	O	O
)	SIMPONI.xml:S3:620:1	)	)	O	O
.	SIMPONI.xml:S3:621:1	.	.	O	O

Malignancies	SIMPONI.xml:S3:628:12	malign	NNS	B-AdverseReaction	O
-	SIMPONI.xml:S3:641:1	-	:	O	O
More	SIMPONI.xml:S3:643:4	more	JJR	O	O
cases	SIMPONI.xml:S3:648:5	case	NNS	O	O
of	SIMPONI.xml:S3:654:2	of	IN	O	O
lymphoma	SIMPONI.xml:S3:657:8	lymphoma	NN	B-AdverseReaction	B-AdverseReaction
have	SIMPONI.xml:S3:666:4	have	VBP	O	O
been	SIMPONI.xml:S3:671:4	been	VBN	O	O
observed	SIMPONI.xml:S3:676:8	observ	VBN	O	O
among	SIMPONI.xml:S3:685:5	among	IN	O	O
patients	SIMPONI.xml:S3:691:8	patient	NNS	O	O
receiving	SIMPONI.xml:S3:700:9	receiv	VBG	O	O
TNF	SIMPONI.xml:S3:710:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:713:1	-	:	O	O
blockers	SIMPONI.xml:S3:714:8	blocker	NNS	O	O
compared	SIMPONI.xml:S3:723:8	compar	VBN	O	O
with	SIMPONI.xml:S3:732:4	with	IN	O	O
patients	SIMPONI.xml:S3:737:8	patient	NNS	O	O
in	SIMPONI.xml:S3:746:2	in	IN	O	O
the	SIMPONI.xml:S3:749:3	the	DT	O	O
control	SIMPONI.xml:S3:753:7	control	NN	O	O
groups	SIMPONI.xml:S3:761:6	group	NNS	O	O
.	SIMPONI.xml:S3:767:1	.	.	O	O

Cases	SIMPONI.xml:S3:769:5	case	NNS	O	O
of	SIMPONI.xml:S3:775:2	of	IN	O	O
other	SIMPONI.xml:S3:778:5	other	JJ	O	O
malignancies	SIMPONI.xml:S3:784:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
have	SIMPONI.xml:S3:797:4	have	VBP	O	O
been	SIMPONI.xml:S3:802:4	been	VBN	O	O
observed	SIMPONI.xml:S3:807:8	observ	VBN	O	O
among	SIMPONI.xml:S3:816:5	among	IN	O	O
patients	SIMPONI.xml:S3:822:8	patient	NNS	O	O
receiving	SIMPONI.xml:S3:831:9	receiv	VBG	O	O
TNF	SIMPONI.xml:S3:841:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:844:1	-	:	O	O
blockers	SIMPONI.xml:S3:845:8	blocker	NNS	O	O
(	SIMPONI.xml:S3:854:1	(	(	O	O
5.2	SIMPONI.xml:S3:857:3	5.2	CD	O	O
)	SIMPONI.xml:S3:862:1	)	)	O	O
.	SIMPONI.xml:S3:863:1	.	.	O	O

Heart	SIMPONI.xml:S3:870:5	heart	NNP	B-AdverseReaction	B-AdverseReaction
failure	SIMPONI.xml:S3:876:7	failur	NN	I-AdverseReaction	I-AdverseReaction
-	SIMPONI.xml:S3:884:1	-	:	O	I-AdverseReaction
Worsening	SIMPONI.xml:S3:886:9	worsen	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S3:895:1	,	,	O	O
or	SIMPONI.xml:S3:897:2	or	CC	O	O
new	SIMPONI.xml:S3:900:3	new	JJ	I-AdverseReaction	O
onset	SIMPONI.xml:S3:904:5	onset	NN	I-AdverseReaction	O
,	SIMPONI.xml:S3:909:1	,	,	O	O
may	SIMPONI.xml:S3:911:3	may	MD	O	O
occur	SIMPONI.xml:S3:915:5	occur	VB	O	O
.	SIMPONI.xml:S3:920:1	.	.	O	O

Stop	SIMPONI.xml:S3:922:4	stop	NNP	O	O
SIMPONI	SIMPONI.xml:S3:927:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:935:4	aria	NNP	O	O
if	SIMPONI.xml:S3:940:2	if	IN	O	O
new	SIMPONI.xml:S3:943:3	new	JJ	O	O
or	SIMPONI.xml:S3:947:2	or	CC	O	O
worsening	SIMPONI.xml:S3:950:9	worsen	VBG	O	O
symptoms	SIMPONI.xml:S3:960:8	symptom	NNS	O	O
occur	SIMPONI.xml:S3:969:5	occur	VBP	O	O
(	SIMPONI.xml:S3:975:1	(	(	O	O
5.3	SIMPONI.xml:S3:978:3	5.3	CD	O	O
)	SIMPONI.xml:S3:983:1	)	)	O	O
.	SIMPONI.xml:S3:984:1	.	.	O	O

Demyelinating	SIMPONI.xml:S3:991:13	demyelin	VBG	B-AdverseReaction	B-AdverseReaction
disease	SIMPONI.xml:S3:1005:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S3:1012:1	,	,	O	O
exacerbation	SIMPONI.xml:S3:1014:12	exacerb	NN	I-AdverseReaction	O
or	SIMPONI.xml:S3:1027:2	or	CC	O	O
new	SIMPONI.xml:S3:1030:3	new	JJ	I-AdverseReaction	O
onset	SIMPONI.xml:S3:1034:5	onset	NN	I-AdverseReaction	O
,	SIMPONI.xml:S3:1039:1	,	,	O	O
may	SIMPONI.xml:S3:1041:3	may	MD	O	O
occur	SIMPONI.xml:S3:1045:5	occur	VB	O	O
(	SIMPONI.xml:S3:1051:1	(	(	O	O
5.4	SIMPONI.xml:S3:1054:3	5.4	CD	O	O
)	SIMPONI.xml:S3:1059:1	)	)	O	O
.	SIMPONI.xml:S3:1060:1	.	.	O	O

Hypersensitivity	SIMPONI.xml:S3:1067:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
reactions	SIMPONI.xml:S3:1084:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
:	SIMPONI.xml:S3:1093:1	:	:	O	O
Serious	SIMPONI.xml:S3:1095:7	seriou	JJ	O	O
systemic	SIMPONI.xml:S3:1103:8	system	JJ	B-AdverseReaction	O
hypersensitivity	SIMPONI.xml:S3:1112:16	hypersensit	NN	I-AdverseReaction	O
reactions	SIMPONI.xml:S3:1129:9	reaction	NNS	I-AdverseReaction	O
including	SIMPONI.xml:S3:1139:9	includ	VBG	O	O
anaphylaxis	SIMPONI.xml:S3:1149:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
may	SIMPONI.xml:S3:1161:3	may	MD	O	O
occur	SIMPONI.xml:S3:1165:5	occur	VB	O	O
(	SIMPONI.xml:S3:1171:1	(	(	O	O
5.10	SIMPONI.xml:S3:1174:4	5.10	CD	O	O
)	SIMPONI.xml:S3:1180:1	)	)	O	O
.	SIMPONI.xml:S3:1181:1	.	.	O	O

5.1	SIMPONI.xml:S3:1195:3	5.1	CD	O	O

Serious	SIMPONI.xml:S3:1199:7	seriou	JJ	O	O

Infections	SIMPONI.xml:S3:1207:10	infect	NNS	O	O

Patients	SIMPONI.xml:S3:1223:8	patient	NNS	O	O
treated	SIMPONI.xml:S3:1232:7	treat	VBN	O	O
with	SIMPONI.xml:S3:1240:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S3:1245:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:1253:4	aria	NNP	O	O
are	SIMPONI.xml:S3:1258:3	are	VBP	O	O
at	SIMPONI.xml:S3:1262:2	at	IN	O	O
increased	SIMPONI.xml:S3:1265:9	increas	VBN	O	O
risk	SIMPONI.xml:S3:1275:4	risk	NN	O	O
for	SIMPONI.xml:S3:1280:3	for	IN	O	O
developing	SIMPONI.xml:S3:1284:10	develop	VBG	O	O
serious	SIMPONI.xml:S3:1295:7	seriou	JJ	O	O
infections	SIMPONI.xml:S3:1303:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
involving	SIMPONI.xml:S3:1314:9	involv	VBG	O	O
various	SIMPONI.xml:S3:1324:7	variou	JJ	O	O
organ	SIMPONI.xml:S3:1332:5	organ	JJ	O	O
systems	SIMPONI.xml:S3:1338:7	system	NNS	O	O
and	SIMPONI.xml:S3:1346:3	and	CC	O	O
sites	SIMPONI.xml:S3:1350:5	site	NNS	O	O
that	SIMPONI.xml:S3:1356:4	that	WDT	O	O
may	SIMPONI.xml:S3:1361:3	may	MD	O	O
lead	SIMPONI.xml:S3:1365:4	lead	VB	O	O
to	SIMPONI.xml:S3:1370:2	to	TO	O	O
hospitalization	SIMPONI.xml:S3:1373:15	hospit	NN	O	O
or	SIMPONI.xml:S3:1389:2	or	CC	O	O
death	SIMPONI.xml:S3:1392:5	death	NN	B-AdverseReaction	B-AdverseReaction
.	SIMPONI.xml:S3:1397:1	.	.	O	O

Opportunistic	SIMPONI.xml:S3:1403:13	opportunist	JJ	B-AdverseReaction	B-AdverseReaction
infections	SIMPONI.xml:S3:1417:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
due	SIMPONI.xml:S3:1428:3	due	JJ	O	O
to	SIMPONI.xml:S3:1432:2	to	TO	O	O
bacterial	SIMPONI.xml:S3:1435:9	bacteri	JJ	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S3:1444:1	,	,	O	O
mycobacterial	SIMPONI.xml:S3:1446:13	mycobacteri	JJ	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S3:1459:1	,	,	O	O
invasive	SIMPONI.xml:S3:1461:8	invas	JJ	I-AdverseReaction	B-AdverseReaction
fungal	SIMPONI.xml:S3:1470:6	fungal	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S3:1476:1	,	,	O	O
viral	SIMPONI.xml:S3:1478:5	viral	JJ	I-AdverseReaction	O
,	SIMPONI.xml:S3:1483:1	,	,	O	O
or	SIMPONI.xml:S3:1485:2	or	CC	O	O
parasitic	SIMPONI.xml:S3:1488:9	parasit	JJ	I-AdverseReaction	O
organisms	SIMPONI.xml:S3:1498:9	organ	NNS	O	O
including	SIMPONI.xml:S3:1508:9	includ	VBG	O	O
aspergillosis	SIMPONI.xml:S3:1518:13	aspergillosi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:1531:1	,	,	O	O
blastomycosis	SIMPONI.xml:S3:1533:13	blastomycosi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:1546:1	,	,	O	O
candidiasis	SIMPONI.xml:S3:1548:11	candidiasi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:1559:1	,	,	O	O
coccidioidomycosis	SIMPONI.xml:S3:1561:18	coccidioidomycosi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:1579:1	,	,	O	O
histoplasmosis	SIMPONI.xml:S3:1581:14	histoplasmosi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:1595:1	,	,	O	O
legionellosis	SIMPONI.xml:S3:1597:13	legionellosi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:1610:1	,	,	O	O
listeriosis	SIMPONI.xml:S3:1612:11	listeriosi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:1623:1	,	,	O	O
pneumocystosis	SIMPONI.xml:S3:1625:14	pneumocystosi	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:1639:1	,	,	O	O
and	SIMPONI.xml:S3:1641:3	and	CC	O	O
tuberculosis	SIMPONI.xml:S3:1645:12	tuberculosi	NN	B-AdverseReaction	B-AdverseReaction
have	SIMPONI.xml:S3:1658:4	have	VBP	O	O
been	SIMPONI.xml:S3:1663:4	been	VBN	O	O
reported	SIMPONI.xml:S3:1668:8	report	VBN	O	O
with	SIMPONI.xml:S3:1677:4	with	IN	O	O
TNF	SIMPONI.xml:S3:1682:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:1685:1	-	:	O	O
blockers	SIMPONI.xml:S3:1686:8	blocker	NNS	O	O
.	SIMPONI.xml:S3:1694:1	.	.	O	O

Patients	SIMPONI.xml:S3:1696:8	patient	NNS	O	O
have	SIMPONI.xml:S3:1705:4	have	VBP	O	O
frequently	SIMPONI.xml:S3:1710:10	frequent	RB	O	O
presented	SIMPONI.xml:S3:1721:9	present	VBN	O	O
with	SIMPONI.xml:S3:1731:4	with	IN	O	O
disseminated	SIMPONI.xml:S3:1736:12	dissemin	JJ	O	O
rather	SIMPONI.xml:S3:1749:6	rather	RB	O	O
than	SIMPONI.xml:S3:1756:4	than	IN	O	O
localized	SIMPONI.xml:S3:1761:9	local	JJ	O	O
disease	SIMPONI.xml:S3:1771:7	diseas	NN	O	O
.	SIMPONI.xml:S3:1778:1	.	.	O	O

The	SIMPONI.xml:S3:1780:3	the	DT	O	O
concomitant	SIMPONI.xml:S3:1784:11	concomit	NN	O	O
use	SIMPONI.xml:S3:1796:3	use	NN	O	O
of	SIMPONI.xml:S3:1800:2	of	IN	O	O
a	SIMPONI.xml:S3:1803:1	a	DT	O	O
TNF	SIMPONI.xml:S3:1805:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:1808:1	-	:	O	O
blocker	SIMPONI.xml:S3:1809:7	blocker	NN	O	O
and	SIMPONI.xml:S3:1817:3	and	CC	O	O
abatacept	SIMPONI.xml:S3:1821:9	abatacept	NN	O	O
or	SIMPONI.xml:S3:1831:2	or	CC	O	O
anakinra	SIMPONI.xml:S3:1834:8	anakinra	NN	O	O
was	SIMPONI.xml:S3:1843:3	wa	VBD	O	O
associated	SIMPONI.xml:S3:1847:10	associ	VBN	O	O
with	SIMPONI.xml:S3:1858:4	with	IN	O	O
a	SIMPONI.xml:S3:1863:1	a	DT	O	O
higher	SIMPONI.xml:S3:1865:6	higher	JJR	O	O
risk	SIMPONI.xml:S3:1872:4	risk	NN	O	O
of	SIMPONI.xml:S3:1877:2	of	IN	O	O
serious	SIMPONI.xml:S3:1880:7	seriou	JJ	O	O
infections	SIMPONI.xml:S3:1888:10	infect	NNS	O	B-AdverseReaction
;	SIMPONI.xml:S3:1898:1	;	:	O	O
therefore	SIMPONI.xml:S3:1900:9	therefor	RB	O	O
,	SIMPONI.xml:S3:1909:1	,	,	O	O
the	SIMPONI.xml:S3:1911:3	the	DT	O	O
concomitant	SIMPONI.xml:S3:1915:11	concomit	NN	O	O
use	SIMPONI.xml:S3:1927:3	use	NN	O	O
of	SIMPONI.xml:S3:1931:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S3:1934:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:1942:4	aria	NNP	O	O
and	SIMPONI.xml:S3:1947:3	and	CC	O	O
these	SIMPONI.xml:S3:1951:5	these	DT	O	O
biologic	SIMPONI.xml:S3:1957:8	biolog	JJ	O	O
products	SIMPONI.xml:S3:1966:8	product	NNS	O	O
is	SIMPONI.xml:S3:1975:2	is	VBZ	O	O
not	SIMPONI.xml:S3:1978:3	not	RB	O	O
recommended	SIMPONI.xml:S3:1982:11	recommend	JJ	O	O
[	SIMPONI.xml:S3:1994:1	[	NNS	O	O
see	SIMPONI.xml:S3:1995:3	see	VBP	O	O
Warnings	SIMPONI.xml:S3:2000:8	warn	NNS	O	O
and	SIMPONI.xml:S3:2009:3	and	CC	O	O
Precautions	SIMPONI.xml:S3:2013:11	precaut	NNP	O	O
(	SIMPONI.xml:S3:2025:1	(	(	O	O
5.5	SIMPONI.xml:S3:2026:3	5.5	CD	O	O
,	SIMPONI.xml:S3:2031:1	,	,	O	O
5.6	SIMPONI.xml:S3:2034:3	5.6	CD	O	O
)	SIMPONI.xml:S3:2039:1	)	)	O	O
and	SIMPONI.xml:S3:2041:3	and	CC	O	O
Drug	SIMPONI.xml:S3:2046:4	drug	NNP	O	O
Interactions	SIMPONI.xml:S3:2051:12	interact	NNP	O	O
(	SIMPONI.xml:S3:2064:1	(	(	O	O
7.2	SIMPONI.xml:S3:2065:3	7.2	CD	O	O
)	SIMPONI.xml:S3:2068:1	)	)	O	O
]	SIMPONI.xml:S3:2071:1	]	NN	O	O
.	SIMPONI.xml:S3:2074:1	.	.	O	O

Treatment	SIMPONI.xml:S3:2080:9	treatment	NN	O	O
with	SIMPONI.xml:S3:2090:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S3:2095:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:2103:4	aria	NNP	O	O
should	SIMPONI.xml:S3:2108:6	should	MD	O	O
not	SIMPONI.xml:S3:2115:3	not	RB	O	O
be	SIMPONI.xml:S3:2119:2	be	VB	O	O
initiated	SIMPONI.xml:S3:2122:9	initi	VBN	O	O
in	SIMPONI.xml:S3:2132:2	in	IN	O	O
patients	SIMPONI.xml:S3:2135:8	patient	NNS	O	O
with	SIMPONI.xml:S3:2144:4	with	IN	O	O
an	SIMPONI.xml:S3:2149:2	an	DT	O	O
active	SIMPONI.xml:S3:2152:6	activ	JJ	O	O
infection	SIMPONI.xml:S3:2159:9	infect	NN	O	O
,	SIMPONI.xml:S3:2168:1	,	,	O	O
including	SIMPONI.xml:S3:2170:9	includ	VBG	O	O
clinically	SIMPONI.xml:S3:2180:10	clinic	RB	O	O
important	SIMPONI.xml:S3:2191:9	import	JJ	O	O
localized	SIMPONI.xml:S3:2201:9	local	VBN	O	O
infections	SIMPONI.xml:S3:2211:10	infect	NNS	O	O
.	SIMPONI.xml:S3:2221:1	.	.	O	O

Patients	SIMPONI.xml:S3:2223:8	patient	NNS	O	O
greater	SIMPONI.xml:S3:2232:7	greater	JJR	O	O
than	SIMPONI.xml:S3:2240:4	than	IN	O	O
65	SIMPONI.xml:S3:2245:2	65	CD	O	O
years	SIMPONI.xml:S3:2248:5	year	NNS	O	O
of	SIMPONI.xml:S3:2254:2	of	IN	O	O
age	SIMPONI.xml:S3:2257:3	age	NN	O	O
,	SIMPONI.xml:S3:2260:1	,	,	O	O
patients	SIMPONI.xml:S3:2262:8	patient	NNS	O	O
with	SIMPONI.xml:S3:2271:4	with	IN	O	O
co	SIMPONI.xml:S3:2276:2	co	JJ	O	O
-	SIMPONI.xml:S3:2278:1	-	:	O	O
morbid	SIMPONI.xml:S3:2279:6	morbid	NN	O	O
conditions	SIMPONI.xml:S3:2286:10	condit	NNS	O	O
and	SIMPONI.xml:S3:2297:3	and	CC	O	O
or	SIMPONI.xml:S3:2301:2	or	CC	O	O
patients	SIMPONI.xml:S3:2304:8	patient	NNS	O	O
taking	SIMPONI.xml:S3:2313:6	take	VBG	O	O
concomitant	SIMPONI.xml:S3:2320:11	concomit	JJ	O	O
immunosuppressants	SIMPONI.xml:S3:2332:18	immunosuppress	NNS	O	O
such	SIMPONI.xml:S3:2351:4	such	JJ	O	O
as	SIMPONI.xml:S3:2356:2	as	IN	O	O
corticosteroids	SIMPONI.xml:S3:2359:15	corticosteroid	NNS	O	O
or	SIMPONI.xml:S3:2375:2	or	CC	O	O
methotrexate	SIMPONI.xml:S3:2378:12	methotrex	NN	O	O
may	SIMPONI.xml:S3:2391:3	may	MD	O	O
be	SIMPONI.xml:S3:2395:2	be	VB	O	O
at	SIMPONI.xml:S3:2398:2	at	IN	O	O
greater	SIMPONI.xml:S3:2401:7	greater	JJR	O	O
risk	SIMPONI.xml:S3:2409:4	risk	NN	O	O
of	SIMPONI.xml:S3:2414:2	of	IN	O	O
infection	SIMPONI.xml:S3:2417:9	infect	NN	O	O
.	SIMPONI.xml:S3:2426:1	.	.	O	O

Consider	SIMPONI.xml:S3:2428:8	consid	VB	O	O
the	SIMPONI.xml:S3:2437:3	the	DT	O	O
risks	SIMPONI.xml:S3:2441:5	risk	NNS	O	O
and	SIMPONI.xml:S3:2447:3	and	CC	O	O
benefits	SIMPONI.xml:S3:2451:8	benefit	NNS	O	O
of	SIMPONI.xml:S3:2460:2	of	IN	O	O
treatment	SIMPONI.xml:S3:2463:9	treatment	NN	O	O
prior	SIMPONI.xml:S3:2473:5	prior	RB	O	O
to	SIMPONI.xml:S3:2479:2	to	TO	O	O
initiating	SIMPONI.xml:S3:2482:10	initi	VBG	O	O
SIMPONI	SIMPONI.xml:S3:2493:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:2501:4	aria	NNP	O	O
in	SIMPONI.xml:S3:2506:2	in	IN	O	O
patients	SIMPONI.xml:S3:2509:8	patient	NNS	O	O
:	SIMPONI.xml:S3:2517:1	:	:	O	O

with	SIMPONI.xml:S3:2526:4	with	IN	O	O
chronic	SIMPONI.xml:S3:2531:7	chronic	JJ	O	O
or	SIMPONI.xml:S3:2539:2	or	CC	O	O
recurrent	SIMPONI.xml:S3:2542:9	recurr	JJ	O	O
infection	SIMPONI.xml:S3:2552:9	infect	NN	O	O
;	SIMPONI.xml:S3:2561:1	;	:	O	O

who	SIMPONI.xml:S3:2568:3	who	WP	O	O
have	SIMPONI.xml:S3:2572:4	have	VBP	O	O
been	SIMPONI.xml:S3:2577:4	been	VBN	O	O
exposed	SIMPONI.xml:S3:2582:7	expos	VBN	O	O
to	SIMPONI.xml:S3:2590:2	to	TO	O	O
tuberculosis	SIMPONI.xml:S3:2593:12	tuberculosi	NN	O	O
;	SIMPONI.xml:S3:2605:1	;	:	O	O

with	SIMPONI.xml:S3:2612:4	with	IN	O	O
a	SIMPONI.xml:S3:2617:1	a	DT	O	O
history	SIMPONI.xml:S3:2619:7	histori	NN	O	O
of	SIMPONI.xml:S3:2627:2	of	IN	O	O
an	SIMPONI.xml:S3:2630:2	an	DT	O	O
opportunistic	SIMPONI.xml:S3:2633:13	opportunist	JJ	O	O
infection	SIMPONI.xml:S3:2647:9	infect	NN	O	O
;	SIMPONI.xml:S3:2656:1	;	:	O	O

who	SIMPONI.xml:S3:2663:3	who	WP	O	O
have	SIMPONI.xml:S3:2667:4	have	VBP	O	O
resided	SIMPONI.xml:S3:2672:7	resid	VBN	O	O
or	SIMPONI.xml:S3:2680:2	or	CC	O	O
traveled	SIMPONI.xml:S3:2683:8	travel	VBN	O	O
in	SIMPONI.xml:S3:2692:2	in	IN	O	O
areas	SIMPONI.xml:S3:2695:5	area	NNS	O	O
of	SIMPONI.xml:S3:2701:2	of	IN	O	O
endemic	SIMPONI.xml:S3:2704:7	endem	JJ	O	O
tuberculosis	SIMPONI.xml:S3:2712:12	tuberculosi	NN	O	O
or	SIMPONI.xml:S3:2725:2	or	CC	O	O
endemic	SIMPONI.xml:S3:2728:7	endem	JJ	O	O
mycoses	SIMPONI.xml:S3:2736:7	mycos	NNS	O	O
,	SIMPONI.xml:S3:2743:1	,	,	O	O
such	SIMPONI.xml:S3:2745:4	such	JJ	O	O
as	SIMPONI.xml:S3:2750:2	as	IN	O	O
histoplasmosis	SIMPONI.xml:S3:2753:14	histoplasmosi	NN	O	B-AdverseReaction
,	SIMPONI.xml:S3:2767:1	,	,	O	O
coccidioidomycosis	SIMPONI.xml:S3:2769:18	coccidioidomycosi	NN	O	O
,	SIMPONI.xml:S3:2787:1	,	,	O	O
or	SIMPONI.xml:S3:2789:2	or	CC	O	O
blastomycosis	SIMPONI.xml:S3:2792:13	blastomycosi	NN	O	O
;	SIMPONI.xml:S3:2805:1	;	:	O	O
or	SIMPONI.xml:S3:2807:2	or	CC	O	O

with	SIMPONI.xml:S3:2815:4	with	IN	O	O
underlying	SIMPONI.xml:S3:2820:10	underli	JJ	O	O
conditions	SIMPONI.xml:S3:2831:10	condit	NNS	O	O
that	SIMPONI.xml:S3:2842:4	that	WDT	O	O
may	SIMPONI.xml:S3:2847:3	may	MD	O	O
predispose	SIMPONI.xml:S3:2851:10	predispos	VB	O	O
them	SIMPONI.xml:S3:2862:4	them	PRP	O	O
to	SIMPONI.xml:S3:2867:2	to	TO	O	O
infection	SIMPONI.xml:S3:2870:9	infect	NN	O	O
.	SIMPONI.xml:S3:2879:1	.	.	O	O

Monitoring	SIMPONI.xml:S3:2889:10	monitor	VBG	O	O

Closely	SIMPONI.xml:S3:2906:7	close	RB	O	O

monitor	SIMPONI.xml:S3:2914:7	monitor	NN	O	O
patients	SIMPONI.xml:S3:2922:8	patient	NNS	O	O
for	SIMPONI.xml:S3:2931:3	for	IN	O	O
the	SIMPONI.xml:S3:2935:3	the	DT	O	O
development	SIMPONI.xml:S3:2939:11	develop	NN	O	O
of	SIMPONI.xml:S3:2951:2	of	IN	O	O
signs	SIMPONI.xml:S3:2954:5	sign	NNS	O	O
and	SIMPONI.xml:S3:2960:3	and	CC	O	O
symptoms	SIMPONI.xml:S3:2964:8	symptom	NNS	O	O
of	SIMPONI.xml:S3:2973:2	of	IN	O	O
infection	SIMPONI.xml:S3:2976:9	infect	NN	O	O
during	SIMPONI.xml:S3:2986:6	dure	IN	O	O
and	SIMPONI.xml:S3:2993:3	and	CC	O	O
after	SIMPONI.xml:S3:2997:5	after	IN	O	O
treatment	SIMPONI.xml:S3:3003:9	treatment	NN	O	O
with	SIMPONI.xml:S3:3013:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S3:3018:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:3026:4	aria	NNP	O	O
.	SIMPONI.xml:S3:3030:1	.	.	O	O

Discontinue	SIMPONI.xml:S3:3032:11	discontinu	NNP	O	O
SIMPONI	SIMPONI.xml:S3:3044:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:3052:4	aria	NNP	O	O
if	SIMPONI.xml:S3:3057:2	if	IN	O	O
a	SIMPONI.xml:S3:3060:1	a	DT	O	O
patient	SIMPONI.xml:S3:3062:7	patient	NN	O	O
develops	SIMPONI.xml:S3:3070:8	develop	VBZ	O	O
a	SIMPONI.xml:S3:3079:1	a	DT	O	O
serious	SIMPONI.xml:S3:3081:7	seriou	JJ	O	O
infection	SIMPONI.xml:S3:3089:9	infect	NN	O	B-AdverseReaction
,	SIMPONI.xml:S3:3098:1	,	,	O	O
an	SIMPONI.xml:S3:3100:2	an	DT	O	O
opportunistic	SIMPONI.xml:S3:3103:13	opportunist	JJ	O	B-AdverseReaction
infection	SIMPONI.xml:S3:3117:9	infect	NN	O	I-AdverseReaction
,	SIMPONI.xml:S3:3126:1	,	,	O	O
or	SIMPONI.xml:S3:3128:2	or	CC	O	O
sepsis	SIMPONI.xml:S3:3131:6	sepsi	NN	O	O
.	SIMPONI.xml:S3:3137:1	.	.	O	O

For	SIMPONI.xml:S3:3139:3	for	IN	O	O
patients	SIMPONI.xml:S3:3143:8	patient	NNS	O	O
who	SIMPONI.xml:S3:3152:3	who	WP	O	O
develop	SIMPONI.xml:S3:3156:7	develop	VBP	O	O
a	SIMPONI.xml:S3:3164:1	a	DT	O	O
new	SIMPONI.xml:S3:3166:3	new	JJ	O	O
infection	SIMPONI.xml:S3:3170:9	infect	NN	O	O
during	SIMPONI.xml:S3:3180:6	dure	IN	O	O
treatment	SIMPONI.xml:S3:3187:9	treatment	NN	O	O
with	SIMPONI.xml:S3:3197:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S3:3202:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:3210:4	aria	NNP	O	O
,	SIMPONI.xml:S3:3214:1	,	,	O	O
perform	SIMPONI.xml:S3:3216:7	perform	VB	O	O
a	SIMPONI.xml:S3:3224:1	a	DT	O	O
prompt	SIMPONI.xml:S3:3226:6	prompt	NN	O	O
and	SIMPONI.xml:S3:3233:3	and	CC	O	O
complete	SIMPONI.xml:S3:3237:8	complet	JJ	O	O
diagnostic	SIMPONI.xml:S3:3246:10	diagnost	JJ	O	O
workup	SIMPONI.xml:S3:3257:6	workup	NN	O	O
appropriate	SIMPONI.xml:S3:3264:11	appropri	NN	O	O
for	SIMPONI.xml:S3:3276:3	for	IN	O	O
an	SIMPONI.xml:S3:3280:2	an	DT	O	O
immunocompromised	SIMPONI.xml:S3:3283:17	immunocompromis	JJ	O	O
patient	SIMPONI.xml:S3:3301:7	patient	NN	O	O
and	SIMPONI.xml:S3:3309:3	and	CC	O	O
initiate	SIMPONI.xml:S3:3313:8	initi	VB	O	O
appropriate	SIMPONI.xml:S3:3322:11	appropri	JJ	O	O
antimicrobial	SIMPONI.xml:S3:3334:13	antimicrobi	JJ	O	O
therapy	SIMPONI.xml:S3:3348:7	therapi	NN	O	O
and	SIMPONI.xml:S3:3356:3	and	CC	O	O
closely	SIMPONI.xml:S3:3360:7	close	RB	O	O
monitor	SIMPONI.xml:S3:3368:7	monitor	VB	O	O
them	SIMPONI.xml:S3:3376:4	them	PRP	O	O
.	SIMPONI.xml:S3:3380:1	.	.	O	O

Tuberculosis	SIMPONI.xml:S3:3389:12	tuberculosi	NN	O	O

Cases	SIMPONI.xml:S3:3408:5	case	NNS	O	O
of	SIMPONI.xml:S3:3414:2	of	IN	O	O
reactivation	SIMPONI.xml:S3:3417:12	reactiv	NN	B-AdverseReaction	B-AdverseReaction
of	SIMPONI.xml:S3:3430:2	of	IN	I-AdverseReaction	I-AdverseReaction
tuberculosis	SIMPONI.xml:S3:3433:12	tuberculosi	NN	I-AdverseReaction	I-AdverseReaction
or	SIMPONI.xml:S3:3446:2	or	CC	O	O
new	SIMPONI.xml:S3:3449:3	new	JJ	B-AdverseReaction	O
tuberculosis	SIMPONI.xml:S3:3453:12	tuberculosi	NN	I-AdverseReaction	B-AdverseReaction
infections	SIMPONI.xml:S3:3466:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
have	SIMPONI.xml:S3:3477:4	have	VBP	O	O
been	SIMPONI.xml:S3:3482:4	been	VBN	O	O
observed	SIMPONI.xml:S3:3487:8	observ	VBN	O	O
in	SIMPONI.xml:S3:3496:2	in	IN	O	O
patients	SIMPONI.xml:S3:3499:8	patient	NNS	O	O
receiving	SIMPONI.xml:S3:3508:9	receiv	VBG	O	O
TNF	SIMPONI.xml:S3:3518:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:3521:1	-	:	O	O
blockers	SIMPONI.xml:S3:3522:8	blocker	NNS	O	O
,	SIMPONI.xml:S3:3530:1	,	,	O	O
including	SIMPONI.xml:S3:3532:9	includ	VBG	O	O
patients	SIMPONI.xml:S3:3542:8	patient	NNS	O	O
who	SIMPONI.xml:S3:3551:3	who	WP	O	O
have	SIMPONI.xml:S3:3555:4	have	VBP	O	O
previously	SIMPONI.xml:S3:3560:10	previous	RB	O	O
received	SIMPONI.xml:S3:3571:8	receiv	VBN	O	O
treatment	SIMPONI.xml:S3:3580:9	treatment	NN	O	O
for	SIMPONI.xml:S3:3590:3	for	IN	O	O
latent	SIMPONI.xml:S3:3594:6	latent	NN	O	O
or	SIMPONI.xml:S3:3601:2	or	CC	O	O
active	SIMPONI.xml:S3:3604:6	activ	JJ	O	O
tuberculosis	SIMPONI.xml:S3:3611:12	tuberculosi	NN	O	O
.	SIMPONI.xml:S3:3623:1	.	.	O	O

Evaluate	SIMPONI.xml:S3:3625:8	evalu	NN	O	O
patients	SIMPONI.xml:S3:3634:8	patient	NNS	O	O
for	SIMPONI.xml:S3:3643:3	for	IN	O	O
tuberculosis	SIMPONI.xml:S3:3647:12	tuberculosi	NN	O	O
risk	SIMPONI.xml:S3:3660:4	risk	NN	O	O
factors	SIMPONI.xml:S3:3665:7	factor	NNS	O	O
and	SIMPONI.xml:S3:3673:3	and	CC	O	O
test	SIMPONI.xml:S3:3677:4	test	NN	O	O
for	SIMPONI.xml:S3:3682:3	for	IN	O	O
latent	SIMPONI.xml:S3:3686:6	latent	JJ	O	O
infection	SIMPONI.xml:S3:3693:9	infect	NN	O	O
prior	SIMPONI.xml:S3:3703:5	prior	RB	O	O
to	SIMPONI.xml:S3:3709:2	to	TO	O	O
initiating	SIMPONI.xml:S3:3712:10	initi	VBG	O	O
SIMPONI	SIMPONI.xml:S3:3723:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:3731:4	aria	NNP	O	O
and	SIMPONI.xml:S3:3736:3	and	CC	O	O
periodically	SIMPONI.xml:S3:3740:12	period	RB	O	O
during	SIMPONI.xml:S3:3753:6	dure	IN	O	O
therapy	SIMPONI.xml:S3:3760:7	therapi	NN	O	O
.	SIMPONI.xml:S3:3767:1	.	.	O	O

Treatment	SIMPONI.xml:S3:3773:9	treatment	NN	O	O
of	SIMPONI.xml:S3:3783:2	of	IN	O	O
latent	SIMPONI.xml:S3:3786:6	latent	JJ	O	O
tuberculosis	SIMPONI.xml:S3:3793:12	tuberculosi	NN	O	O
infection	SIMPONI.xml:S3:3806:9	infect	NN	O	O
prior	SIMPONI.xml:S3:3816:5	prior	RB	O	O
to	SIMPONI.xml:S3:3822:2	to	TO	O	O
therapy	SIMPONI.xml:S3:3825:7	therapi	VB	O	O
with	SIMPONI.xml:S3:3833:4	with	IN	O	O
TNF	SIMPONI.xml:S3:3838:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:3841:1	-	:	O	O
blockers	SIMPONI.xml:S3:3842:8	blocker	NNS	O	O
has	SIMPONI.xml:S3:3851:3	ha	VBZ	O	O
been	SIMPONI.xml:S3:3855:4	been	VBN	O	O
shown	SIMPONI.xml:S3:3860:5	shown	VBN	O	O
to	SIMPONI.xml:S3:3866:2	to	TO	O	O
reduce	SIMPONI.xml:S3:3869:6	reduc	VB	O	O
the	SIMPONI.xml:S3:3876:3	the	DT	O	O
risk	SIMPONI.xml:S3:3880:4	risk	NN	O	O
of	SIMPONI.xml:S3:3885:2	of	IN	O	O
tuberculosis	SIMPONI.xml:S3:3888:12	tuberculosi	NN	O	O
reactivation	SIMPONI.xml:S3:3901:12	reactiv	NN	O	O
during	SIMPONI.xml:S3:3914:6	dure	IN	O	O
therapy	SIMPONI.xml:S3:3921:7	therapi	NN	O	O
.	SIMPONI.xml:S3:3928:1	.	.	O	O

Prior	SIMPONI.xml:S3:3930:5	prior	RB	O	O
to	SIMPONI.xml:S3:3936:2	to	TO	O	O
initiating	SIMPONI.xml:S3:3939:10	initi	VBG	O	O
SIMPONI	SIMPONI.xml:S3:3950:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:3958:4	aria	NNP	O	O
,	SIMPONI.xml:S3:3962:1	,	,	O	O
assess	SIMPONI.xml:S3:3964:6	assess	NN	O	O
if	SIMPONI.xml:S3:3971:2	if	IN	O	O
treatment	SIMPONI.xml:S3:3974:9	treatment	NN	O	O
for	SIMPONI.xml:S3:3984:3	for	IN	O	O
latent	SIMPONI.xml:S3:3988:6	latent	JJ	O	O
tuberculosis	SIMPONI.xml:S3:3995:12	tuberculosi	NN	O	O
is	SIMPONI.xml:S3:4008:2	is	VBZ	O	O
needed	SIMPONI.xml:S3:4011:6	need	VBN	O	O
;	SIMPONI.xml:S3:4017:1	;	:	O	O
An	SIMPONI.xml:S3:4019:2	An	DT	O	O
induration	SIMPONI.xml:S3:4022:10	indur	NN	O	O
of	SIMPONI.xml:S3:4033:2	of	IN	O	O
5	SIMPONI.xml:S3:4036:1	5	CD	O	O
mm	SIMPONI.xml:S3:4038:2	mm	NN	O	O
or	SIMPONI.xml:S3:4041:2	or	CC	O	O
greater	SIMPONI.xml:S3:4044:7	greater	JJR	O	O
is	SIMPONI.xml:S3:4052:2	is	VBZ	O	O
a	SIMPONI.xml:S3:4055:1	a	DT	O	O
positive	SIMPONI.xml:S3:4057:8	posit	JJ	O	O
tuberculin	SIMPONI.xml:S3:4066:10	tuberculin	NN	O	O
skin	SIMPONI.xml:S3:4077:4	skin	JJ	O	O
test	SIMPONI.xml:S3:4082:4	test	NN	O	O
,	SIMPONI.xml:S3:4086:1	,	,	O	O
even	SIMPONI.xml:S3:4088:4	even	RB	O	O
for	SIMPONI.xml:S3:4093:3	for	IN	O	O
patients	SIMPONI.xml:S3:4097:8	patient	NNS	O	O
previously	SIMPONI.xml:S3:4106:10	previous	RB	O	O
vaccinated	SIMPONI.xml:S3:4117:10	vaccin	VBN	O	O
with	SIMPONI.xml:S3:4128:4	with	IN	O	O
Bacille	SIMPONI.xml:S3:4133:7	bacil	NNP	O	O
Calmette	SIMPONI.xml:S3:4141:8	calmett	NNP	O	O
-	SIMPONI.xml:S3:4149:1	-	:	O	O
Guerin	SIMPONI.xml:S3:4150:6	guerin	NNP	O	O
(	SIMPONI.xml:S3:4157:1	(	(	O	O
BCG	SIMPONI.xml:S3:4158:3	bcg	NNP	O	O
)	SIMPONI.xml:S3:4161:1	)	)	O	O
.	SIMPONI.xml:S3:4162:1	.	.	O	O

Consider	SIMPONI.xml:S3:4168:8	consid	VB	O	O
anti	SIMPONI.xml:S3:4177:4	anti	SYM	O	O
-	SIMPONI.xml:S3:4181:1	-	:	O	O
tuberculosis	SIMPONI.xml:S3:4182:12	tuberculosi	NN	O	O
therapy	SIMPONI.xml:S3:4195:7	therapi	NN	O	O
prior	SIMPONI.xml:S3:4203:5	prior	RB	O	O
to	SIMPONI.xml:S3:4209:2	to	TO	O	O
initiation	SIMPONI.xml:S3:4212:10	initi	NN	O	O
of	SIMPONI.xml:S3:4223:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S3:4226:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:4234:4	aria	NNP	O	O
in	SIMPONI.xml:S3:4239:2	in	IN	O	O
patients	SIMPONI.xml:S3:4242:8	patient	NNS	O	O
with	SIMPONI.xml:S3:4251:4	with	IN	O	O
a	SIMPONI.xml:S3:4256:1	a	DT	O	O
past	SIMPONI.xml:S3:4258:4	past	JJ	O	O
history	SIMPONI.xml:S3:4263:7	histori	NN	O	O
of	SIMPONI.xml:S3:4271:2	of	IN	O	O
latent	SIMPONI.xml:S3:4274:6	latent	NN	O	O
or	SIMPONI.xml:S3:4281:2	or	CC	O	O
active	SIMPONI.xml:S3:4284:6	activ	JJ	O	O
tuberculosis	SIMPONI.xml:S3:4291:12	tuberculosi	NN	O	O
in	SIMPONI.xml:S3:4304:2	in	IN	O	O
whom	SIMPONI.xml:S3:4307:4	whom	WP	O	O
an	SIMPONI.xml:S3:4312:2	an	DT	O	O
adequate	SIMPONI.xml:S3:4315:8	adequ	JJ	O	O
course	SIMPONI.xml:S3:4324:6	cours	NN	O	O
of	SIMPONI.xml:S3:4331:2	of	IN	O	O
treatment	SIMPONI.xml:S3:4334:9	treatment	NN	O	O
cannot	SIMPONI.xml:S3:4344:6	cannot	NN	O	O
be	SIMPONI.xml:S3:4351:2	be	VB	O	O
confirmed	SIMPONI.xml:S3:4354:9	confirm	VBN	O	O
,	SIMPONI.xml:S3:4363:1	,	,	O	O
and	SIMPONI.xml:S3:4365:3	and	CC	O	O
for	SIMPONI.xml:S3:4369:3	for	IN	O	O
patients	SIMPONI.xml:S3:4373:8	patient	NNS	O	O
with	SIMPONI.xml:S3:4382:4	with	IN	O	O
a	SIMPONI.xml:S3:4387:1	a	DT	O	O
negative	SIMPONI.xml:S3:4389:8	neg	JJ	O	O
test	SIMPONI.xml:S3:4398:4	test	NN	O	O
for	SIMPONI.xml:S3:4403:3	for	IN	O	O
latent	SIMPONI.xml:S3:4407:6	latent	JJ	O	O
tuberculosis	SIMPONI.xml:S3:4414:12	tuberculosi	NN	O	O
but	SIMPONI.xml:S3:4427:3	but	CC	O	O
having	SIMPONI.xml:S3:4431:6	have	VBG	O	O
risk	SIMPONI.xml:S3:4438:4	risk	NN	O	O
factors	SIMPONI.xml:S3:4443:7	factor	NNS	O	O
for	SIMPONI.xml:S3:4451:3	for	IN	O	O
tuberculosis	SIMPONI.xml:S3:4455:12	tuberculosi	NN	O	O
infection	SIMPONI.xml:S3:4468:9	infect	NN	O	O
.	SIMPONI.xml:S3:4477:1	.	.	O	O

Consultation	SIMPONI.xml:S3:4479:12	consult	NN	O	O
with	SIMPONI.xml:S3:4492:4	with	IN	O	O
a	SIMPONI.xml:S3:4497:1	a	DT	O	O
physician	SIMPONI.xml:S3:4499:9	physician	NN	O	O
with	SIMPONI.xml:S3:4509:4	with	IN	O	O
expertise	SIMPONI.xml:S3:4514:9	expertis	NN	O	O
in	SIMPONI.xml:S3:4524:2	in	IN	O	O
the	SIMPONI.xml:S3:4527:3	the	DT	O	O
treatment	SIMPONI.xml:S3:4531:9	treatment	NN	O	O
of	SIMPONI.xml:S3:4541:2	of	IN	O	O
tuberculosis	SIMPONI.xml:S3:4544:12	tuberculosi	NN	O	O
is	SIMPONI.xml:S3:4557:2	is	VBZ	O	O
recommended	SIMPONI.xml:S3:4560:11	recommend	VBN	O	O
to	SIMPONI.xml:S3:4572:2	to	TO	O	O
aid	SIMPONI.xml:S3:4575:3	aid	NN	O	O
in	SIMPONI.xml:S3:4579:2	in	IN	O	O
the	SIMPONI.xml:S3:4582:3	the	DT	O	O
decision	SIMPONI.xml:S3:4586:8	decis	NN	O	O
whether	SIMPONI.xml:S3:4595:7	whether	IN	O	O
initiating	SIMPONI.xml:S3:4603:10	initi	VBG	O	O
anti	SIMPONI.xml:S3:4614:4	anti	SYM	O	O
-	SIMPONI.xml:S3:4618:1	-	:	O	O
tuberculosis	SIMPONI.xml:S3:4619:12	tuberculosi	NN	O	O
therapy	SIMPONI.xml:S3:4632:7	therapi	NN	O	O
is	SIMPONI.xml:S3:4640:2	is	VBZ	O	O
appropriate	SIMPONI.xml:S3:4643:11	appropri	JJ	O	O
for	SIMPONI.xml:S3:4655:3	for	IN	O	O
an	SIMPONI.xml:S3:4659:2	an	DT	O	O
individual	SIMPONI.xml:S3:4662:10	individu	JJ	O	O
patient	SIMPONI.xml:S3:4673:7	patient	NN	O	O
.	SIMPONI.xml:S3:4680:1	.	.	O	O

Cases	SIMPONI.xml:S3:4687:5	case	NNS	O	O
of	SIMPONI.xml:S3:4693:2	of	IN	O	O
active	SIMPONI.xml:S3:4696:6	activ	JJ	O	B-AdverseReaction
tuberculosis	SIMPONI.xml:S3:4703:12	tuberculosi	NN	O	I-AdverseReaction
have	SIMPONI.xml:S3:4716:4	have	VBP	O	O
occurred	SIMPONI.xml:S3:4721:8	occur	VBN	O	O
in	SIMPONI.xml:S3:4730:2	in	IN	O	O
patients	SIMPONI.xml:S3:4733:8	patient	NNS	O	O
treated	SIMPONI.xml:S3:4742:7	treat	VBN	O	O
with	SIMPONI.xml:S3:4750:4	with	IN	O	O
the	SIMPONI.xml:S3:4755:3	the	DT	O	O
subcutaneous	SIMPONI.xml:S3:4759:12	subcutan	JJ	O	O
formulation	SIMPONI.xml:S3:4772:11	formul	NN	O	O
of	SIMPONI.xml:S3:4784:2	of	IN	O	O
golimumab	SIMPONI.xml:S3:4787:9	golimumab	NN	O	O
during	SIMPONI.xml:S3:4797:6	dure	IN	O	O
and	SIMPONI.xml:S3:4804:3	and	CC	O	O
after	SIMPONI.xml:S3:4808:5	after	IN	O	O
treatment	SIMPONI.xml:S3:4814:9	treatment	NN	O	O
for	SIMPONI.xml:S3:4824:3	for	IN	O	O
latent	SIMPONI.xml:S3:4828:6	latent	JJ	O	O
tuberculosis	SIMPONI.xml:S3:4835:12	tuberculosi	NN	O	O
.	SIMPONI.xml:S3:4847:1	.	.	O	O

Monitor	SIMPONI.xml:S3:4849:7	monitor	NN	O	O
patients	SIMPONI.xml:S3:4857:8	patient	NNS	O	O
for	SIMPONI.xml:S3:4866:3	for	IN	O	O
the	SIMPONI.xml:S3:4870:3	the	DT	O	O
development	SIMPONI.xml:S3:4874:11	develop	NN	O	O
of	SIMPONI.xml:S3:4886:2	of	IN	O	O
signs	SIMPONI.xml:S3:4889:5	sign	NNS	O	O
and	SIMPONI.xml:S3:4895:3	and	CC	O	O
symptoms	SIMPONI.xml:S3:4899:8	symptom	NNS	O	O
of	SIMPONI.xml:S3:4908:2	of	IN	O	O
tuberculosis	SIMPONI.xml:S3:4911:12	tuberculosi	NN	O	O
including	SIMPONI.xml:S3:4924:9	includ	VBG	O	O
patients	SIMPONI.xml:S3:4934:8	patient	NNS	O	O
who	SIMPONI.xml:S3:4943:3	who	WP	O	O
tested	SIMPONI.xml:S3:4947:6	test	VBD	O	O
negative	SIMPONI.xml:S3:4954:8	neg	JJ	O	O
for	SIMPONI.xml:S3:4963:3	for	IN	O	O
latent	SIMPONI.xml:S3:4967:6	latent	JJ	O	O
tuberculosis	SIMPONI.xml:S3:4974:12	tuberculosi	NN	O	O
infection	SIMPONI.xml:S3:4987:9	infect	NN	O	O
prior	SIMPONI.xml:S3:4997:5	prior	RB	O	O
to	SIMPONI.xml:S3:5003:2	to	TO	O	O
initiating	SIMPONI.xml:S3:5006:10	initi	VBG	O	O
therapy	SIMPONI.xml:S3:5017:7	therapi	NN	O	O
,	SIMPONI.xml:S3:5024:1	,	,	O	O
patients	SIMPONI.xml:S3:5026:8	patient	NNS	O	O
who	SIMPONI.xml:S3:5035:3	who	WP	O	O
are	SIMPONI.xml:S3:5039:3	are	VBP	O	O
on	SIMPONI.xml:S3:5043:2	on	IN	O	O
treatment	SIMPONI.xml:S3:5046:9	treatment	NN	O	O
for	SIMPONI.xml:S3:5056:3	for	IN	O	O
latent	SIMPONI.xml:S3:5060:6	latent	JJ	O	O
tuberculosis	SIMPONI.xml:S3:5067:12	tuberculosi	NN	O	O
,	SIMPONI.xml:S3:5079:1	,	,	O	O
or	SIMPONI.xml:S3:5081:2	or	CC	O	O
patients	SIMPONI.xml:S3:5084:8	patient	NNS	O	O
who	SIMPONI.xml:S3:5093:3	who	WP	O	O
were	SIMPONI.xml:S3:5097:4	were	VBD	O	O
previously	SIMPONI.xml:S3:5102:10	previous	RB	O	O
treated	SIMPONI.xml:S3:5113:7	treat	VBN	O	O
for	SIMPONI.xml:S3:5121:3	for	IN	O	O
tuberculosis	SIMPONI.xml:S3:5125:12	tuberculosi	NN	O	O
infection	SIMPONI.xml:S3:5138:9	infect	NN	O	O
.	SIMPONI.xml:S3:5147:1	.	.	O	O

Consider	SIMPONI.xml:S3:5155:8	consid	VB	O	O
tuberculosis	SIMPONI.xml:S3:5164:12	tuberculosi	NN	O	O
in	SIMPONI.xml:S3:5177:2	in	IN	O	O
the	SIMPONI.xml:S3:5180:3	the	DT	O	O
differential	SIMPONI.xml:S3:5184:12	differenti	JJ	O	O
diagnosis	SIMPONI.xml:S3:5197:9	diagnosi	NN	O	O
in	SIMPONI.xml:S3:5207:2	in	IN	O	O
patients	SIMPONI.xml:S3:5210:8	patient	NNS	O	O
who	SIMPONI.xml:S3:5219:3	who	WP	O	O
develop	SIMPONI.xml:S3:5223:7	develop	VBP	O	O
a	SIMPONI.xml:S3:5231:1	a	DT	O	O
new	SIMPONI.xml:S3:5233:3	new	JJ	O	O
infection	SIMPONI.xml:S3:5237:9	infect	NN	O	O
during	SIMPONI.xml:S3:5247:6	dure	IN	O	O
SIMPONI	SIMPONI.xml:S3:5254:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:5262:4	aria	NNP	O	O
treatment	SIMPONI.xml:S3:5267:9	treatment	NN	O	O
,	SIMPONI.xml:S3:5276:1	,	,	O	O
especially	SIMPONI.xml:S3:5278:10	especi	RB	O	O
in	SIMPONI.xml:S3:5289:2	in	IN	O	O
patients	SIMPONI.xml:S3:5292:8	patient	NNS	O	O
who	SIMPONI.xml:S3:5301:3	who	WP	O	O
have	SIMPONI.xml:S3:5305:4	have	VBP	O	O
previously	SIMPONI.xml:S3:5310:10	previous	RB	O	O
or	SIMPONI.xml:S3:5321:2	or	CC	O	O
recently	SIMPONI.xml:S3:5324:8	recent	RB	O	O
traveled	SIMPONI.xml:S3:5333:8	travel	VBD	O	O
to	SIMPONI.xml:S3:5342:2	to	TO	O	O
countries	SIMPONI.xml:S3:5345:9	countri	NNS	O	O
with	SIMPONI.xml:S3:5355:4	with	IN	O	O
a	SIMPONI.xml:S3:5360:1	a	DT	O	O
high	SIMPONI.xml:S3:5362:4	high	JJ	O	O
prevalence	SIMPONI.xml:S3:5367:10	preval	NN	O	O
of	SIMPONI.xml:S3:5378:2	of	IN	O	O
tuberculosis	SIMPONI.xml:S3:5381:12	tuberculosi	NN	O	O
,	SIMPONI.xml:S3:5393:1	,	,	O	O
or	SIMPONI.xml:S3:5395:2	or	CC	O	O
who	SIMPONI.xml:S3:5398:3	who	WP	O	O
have	SIMPONI.xml:S3:5402:4	have	VBP	O	O
had	SIMPONI.xml:S3:5407:3	had	VBN	O	O
close	SIMPONI.xml:S3:5411:5	close	JJ	O	O
contact	SIMPONI.xml:S3:5417:7	contact	NN	O	O
with	SIMPONI.xml:S3:5425:4	with	IN	O	O
a	SIMPONI.xml:S3:5430:1	a	DT	O	O
person	SIMPONI.xml:S3:5432:6	person	NN	O	O
with	SIMPONI.xml:S3:5439:4	with	IN	O	O
active	SIMPONI.xml:S3:5444:6	activ	JJ	O	O
tuberculosis	SIMPONI.xml:S3:5451:12	tuberculosi	NN	O	O
.	SIMPONI.xml:S3:5463:1	.	.	O	O

Invasive	SIMPONI.xml:S3:5472:8	invas	JJ	O	O
Fungal	SIMPONI.xml:S3:5481:6	fungal	NNP	O	O
Infections	SIMPONI.xml:S3:5488:10	infect	NNS	O	O

If	SIMPONI.xml:S3:5505:2	If	IN	O	O
patients	SIMPONI.xml:S3:5508:8	patient	NNS	O	O
develop	SIMPONI.xml:S3:5517:7	develop	VBP	O	O
a	SIMPONI.xml:S3:5525:1	a	DT	O	O
serious	SIMPONI.xml:S3:5527:7	seriou	JJ	O	O
systemic	SIMPONI.xml:S3:5535:8	system	JJ	O	O
illness	SIMPONI.xml:S3:5544:7	ill	NN	O	O
and	SIMPONI.xml:S3:5552:3	and	CC	O	O
they	SIMPONI.xml:S3:5556:4	they	PRP	O	O
reside	SIMPONI.xml:S3:5561:6	resid	VBP	O	O
or	SIMPONI.xml:S3:5568:2	or	CC	O	O
travel	SIMPONI.xml:S3:5571:6	travel	VBP	O	O
in	SIMPONI.xml:S3:5578:2	in	IN	O	O
regions	SIMPONI.xml:S3:5581:7	region	NNS	O	O
where	SIMPONI.xml:S3:5589:5	where	WRB	O	O
mycoses	SIMPONI.xml:S3:5595:7	mycos	NNS	O	O
are	SIMPONI.xml:S3:5603:3	are	VBP	O	O
endemic	SIMPONI.xml:S3:5607:7	endem	JJ	O	O
,	SIMPONI.xml:S3:5614:1	,	,	O	O
consider	SIMPONI.xml:S3:5616:8	consid	VB	O	O
invasive	SIMPONI.xml:S3:5625:8	invas	JJ	O	O
fungal	SIMPONI.xml:S3:5634:6	fungal	JJ	O	O
infection	SIMPONI.xml:S3:5641:9	infect	NN	O	O
in	SIMPONI.xml:S3:5651:2	in	IN	O	O
the	SIMPONI.xml:S3:5654:3	the	DT	O	O
differential	SIMPONI.xml:S3:5658:12	differenti	JJ	O	O
diagnosis	SIMPONI.xml:S3:5671:9	diagnosi	NN	O	O
.	SIMPONI.xml:S3:5680:1	.	.	O	O

Consider	SIMPONI.xml:S3:5682:8	consid	VB	O	O
appropriate	SIMPONI.xml:S3:5691:11	appropri	JJ	O	O
empiric	SIMPONI.xml:S3:5703:7	empir	JJ	O	O
antifungal	SIMPONI.xml:S3:5711:10	antifung	JJ	O	O
therapy	SIMPONI.xml:S3:5722:7	therapi	NN	O	O
and	SIMPONI.xml:S3:5730:3	and	CC	O	O
take	SIMPONI.xml:S3:5734:4	take	VB	O	O
into	SIMPONI.xml:S3:5739:4	into	IN	O	O
account	SIMPONI.xml:S3:5744:7	account	NN	O	O
both	SIMPONI.xml:S3:5752:4	both	CC	O	O
the	SIMPONI.xml:S3:5757:3	the	DT	O	O
risk	SIMPONI.xml:S3:5761:4	risk	NN	O	O
for	SIMPONI.xml:S3:5766:3	for	IN	O	O
severe	SIMPONI.xml:S3:5770:6	sever	JJ	O	O
fungal	SIMPONI.xml:S3:5777:6	fungal	JJ	O	O
infection	SIMPONI.xml:S3:5784:9	infect	NN	O	O
and	SIMPONI.xml:S3:5794:3	and	CC	O	O
the	SIMPONI.xml:S3:5798:3	the	DT	O	O
risks	SIMPONI.xml:S3:5802:5	risk	NNS	O	O
of	SIMPONI.xml:S3:5808:2	of	IN	O	O
antifungal	SIMPONI.xml:S3:5811:10	antifung	JJ	O	O
therapy	SIMPONI.xml:S3:5822:7	therapi	NN	O	O
while	SIMPONI.xml:S3:5830:5	while	IN	O	O
a	SIMPONI.xml:S3:5836:1	a	DT	O	O
diagnostic	SIMPONI.xml:S3:5838:10	diagnost	JJ	O	O
workup	SIMPONI.xml:S3:5849:6	workup	NN	O	O
is	SIMPONI.xml:S3:5856:2	is	VBZ	O	O
being	SIMPONI.xml:S3:5859:5	be	VBG	O	O
performed	SIMPONI.xml:S3:5865:9	perform	VBN	O	O
.	SIMPONI.xml:S3:5874:1	.	.	O	O

Antigen	SIMPONI.xml:S3:5876:7	antigen	NNP	O	O
and	SIMPONI.xml:S3:5884:3	and	CC	O	O
antibody	SIMPONI.xml:S3:5888:8	antibodi	NN	O	O
testing	SIMPONI.xml:S3:5897:7	test	VBG	O	O
for	SIMPONI.xml:S3:5905:3	for	IN	O	O
histoplasmosis	SIMPONI.xml:S3:5909:14	histoplasmosi	NN	O	O
may	SIMPONI.xml:S3:5924:3	may	MD	O	O
be	SIMPONI.xml:S3:5928:2	be	VB	O	O
negative	SIMPONI.xml:S3:5931:8	neg	JJ	O	O
in	SIMPONI.xml:S3:5940:2	in	IN	O	O
some	SIMPONI.xml:S3:5943:4	some	DT	O	O
patients	SIMPONI.xml:S3:5948:8	patient	NNS	O	O
with	SIMPONI.xml:S3:5957:4	with	IN	O	O
active	SIMPONI.xml:S3:5962:6	activ	JJ	O	O
infection	SIMPONI.xml:S3:5969:9	infect	NN	O	O
.	SIMPONI.xml:S3:5978:1	.	.	O	O

To	SIMPONI.xml:S3:5980:2	To	TO	O	O
aid	SIMPONI.xml:S3:5983:3	aid	NN	O	O
in	SIMPONI.xml:S3:5987:2	in	IN	O	O
the	SIMPONI.xml:S3:5990:3	the	DT	O	O
management	SIMPONI.xml:S3:5994:10	manag	NN	O	O
of	SIMPONI.xml:S3:6005:2	of	IN	O	O
such	SIMPONI.xml:S3:6008:4	such	JJ	O	O
patients	SIMPONI.xml:S3:6013:8	patient	NNS	O	O
,	SIMPONI.xml:S3:6021:1	,	,	O	O
consider	SIMPONI.xml:S3:6023:8	consid	VB	O	O
consultation	SIMPONI.xml:S3:6032:12	consult	NN	O	O
with	SIMPONI.xml:S3:6045:4	with	IN	O	O
a	SIMPONI.xml:S3:6050:1	a	DT	O	O
physician	SIMPONI.xml:S3:6052:9	physician	NN	O	O
with	SIMPONI.xml:S3:6062:4	with	IN	O	O
expertise	SIMPONI.xml:S3:6067:9	expertis	NN	O	O
in	SIMPONI.xml:S3:6077:2	in	IN	O	O
the	SIMPONI.xml:S3:6080:3	the	DT	O	O
diagnosis	SIMPONI.xml:S3:6084:9	diagnosi	NN	O	O
and	SIMPONI.xml:S3:6094:3	and	CC	O	O
treatment	SIMPONI.xml:S3:6098:9	treatment	NN	O	O
of	SIMPONI.xml:S3:6108:2	of	IN	O	O
invasive	SIMPONI.xml:S3:6111:8	invas	JJ	O	B-AdverseReaction
fungal	SIMPONI.xml:S3:6120:6	fungal	JJ	O	I-AdverseReaction
infections	SIMPONI.xml:S3:6127:10	infect	NNS	O	I-AdverseReaction
.	SIMPONI.xml:S3:6137:1	.	.	O	O

Hepatitis	SIMPONI.xml:S3:6146:9	hepat	NN	O	O
B	SIMPONI.xml:S3:6156:1	B	NNP	O	O
Virus	SIMPONI.xml:S3:6158:5	viru	NNP	O	O
Reactivation	SIMPONI.xml:S3:6164:12	reactiv	NNP	O	O

The	SIMPONI.xml:S3:6183:3	the	DT	O	O
use	SIMPONI.xml:S3:6187:3	use	NN	O	O
of	SIMPONI.xml:S3:6191:2	of	IN	O	O
TNF	SIMPONI.xml:S3:6194:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:6197:1	-	:	O	O
blockers	SIMPONI.xml:S3:6198:8	blocker	NNS	O	O
,	SIMPONI.xml:S3:6206:1	,	,	O	O
of	SIMPONI.xml:S3:6208:2	of	IN	O	O
which	SIMPONI.xml:S3:6211:5	which	WDT	O	O
SIMPONI	SIMPONI.xml:S3:6217:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:6225:4	aria	NNP	O	O
is	SIMPONI.xml:S3:6230:2	is	VBZ	O	O
a	SIMPONI.xml:S3:6233:1	a	DT	O	O
member	SIMPONI.xml:S3:6235:6	member	NN	O	O
,	SIMPONI.xml:S3:6241:1	,	,	O	O
has	SIMPONI.xml:S3:6243:3	ha	VBZ	O	O
been	SIMPONI.xml:S3:6247:4	been	VBN	O	O
associated	SIMPONI.xml:S3:6252:10	associ	VBN	O	O
with	SIMPONI.xml:S3:6263:4	with	IN	O	O
reactivation	SIMPONI.xml:S3:6268:12	reactiv	NN	B-AdverseReaction	B-AdverseReaction
of	SIMPONI.xml:S3:6281:2	of	IN	I-AdverseReaction	I-AdverseReaction
hepatitis	SIMPONI.xml:S3:6284:9	hepat	NN	I-AdverseReaction	I-AdverseReaction
B	SIMPONI.xml:S3:6294:1	B	NNP	I-AdverseReaction	I-AdverseReaction
virus	SIMPONI.xml:S3:6296:5	viru	NN	I-AdverseReaction	I-AdverseReaction
(	SIMPONI.xml:S3:6302:1	(	(	O	O
HBV	SIMPONI.xml:S3:6303:3	hbv	NNP	I-AdverseReaction	O
)	SIMPONI.xml:S3:6306:1	)	)	O	O
in	SIMPONI.xml:S3:6308:2	in	IN	O	O
patients	SIMPONI.xml:S3:6311:8	patient	NNS	O	O
who	SIMPONI.xml:S3:6320:3	who	WP	O	O
are	SIMPONI.xml:S3:6324:3	are	VBP	O	O
chronic	SIMPONI.xml:S3:6328:7	chronic	JJ	O	O
hepatitis	SIMPONI.xml:S3:6336:9	hepat	NN	O	O
B	SIMPONI.xml:S3:6346:1	B	NNP	O	O
carriers	SIMPONI.xml:S3:6348:8	carrier	NNS	O	O
(	SIMPONI.xml:S3:6357:1	(	(	O	O
i	SIMPONI.xml:S3:6358:1	i	NN	O	O
.	SIMPONI.xml:S3:6359:1	.	.	O	O
e	SIMPONI.xml:S3:6360:1	e	NN	O	O
.	SIMPONI.xml:S3:6361:1	.	.	O	O
,	SIMPONI.xml:S3:6362:1	,	,	O	O
surface	SIMPONI.xml:S3:6364:7	surfac	NN	O	O
antigen	SIMPONI.xml:S3:6372:7	antigen	RB	O	O
positive	SIMPONI.xml:S3:6380:8	posit	JJ	O	O
)	SIMPONI.xml:S3:6388:1	)	)	O	O
.	SIMPONI.xml:S3:6389:1	.	.	O	O

In	SIMPONI.xml:S3:6391:2	In	IN	O	O
some	SIMPONI.xml:S3:6394:4	some	DT	O	O
instances	SIMPONI.xml:S3:6399:9	instanc	NNS	O	O
,	SIMPONI.xml:S3:6408:1	,	,	O	O
HBV	SIMPONI.xml:S3:6410:3	hbv	NNP	B-AdverseReaction	B-AdverseReaction
reactivation	SIMPONI.xml:S3:6414:12	reactiv	NN	I-AdverseReaction	I-AdverseReaction
occurring	SIMPONI.xml:S3:6427:9	occur	VBG	O	O
in	SIMPONI.xml:S3:6437:2	in	IN	O	O
conjunction	SIMPONI.xml:S3:6440:11	conjunct	NN	O	O
with	SIMPONI.xml:S3:6452:4	with	IN	O	O
TNF	SIMPONI.xml:S3:6457:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:6460:1	-	:	O	O
blocker	SIMPONI.xml:S3:6461:7	blocker	NN	O	O
therapy	SIMPONI.xml:S3:6469:7	therapi	NN	O	O
has	SIMPONI.xml:S3:6477:3	ha	VBZ	O	O
been	SIMPONI.xml:S3:6481:4	been	VBN	O	O
fatal	SIMPONI.xml:S3:6486:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
.	SIMPONI.xml:S3:6491:1	.	.	O	O

The	SIMPONI.xml:S3:6493:3	the	DT	O	O
majority	SIMPONI.xml:S3:6497:8	major	NN	O	O
of	SIMPONI.xml:S3:6506:2	of	IN	O	O
these	SIMPONI.xml:S3:6509:5	these	DT	O	O
reports	SIMPONI.xml:S3:6515:7	report	NNS	O	O
have	SIMPONI.xml:S3:6523:4	have	VBP	O	O
occurred	SIMPONI.xml:S3:6528:8	occur	VBN	O	O
in	SIMPONI.xml:S3:6537:2	in	IN	O	O
patients	SIMPONI.xml:S3:6540:8	patient	NNS	O	O
who	SIMPONI.xml:S3:6549:3	who	WP	O	O
received	SIMPONI.xml:S3:6553:8	receiv	VBD	O	O
concomitant	SIMPONI.xml:S3:6562:11	concomit	JJ	O	O
immunosuppressants	SIMPONI.xml:S3:6574:18	immunosuppress	NNS	O	O
.	SIMPONI.xml:S3:6592:1	.	.	O	O

All	SIMPONI.xml:S3:6598:3	all	DT	O	O
patients	SIMPONI.xml:S3:6602:8	patient	NNS	O	O
should	SIMPONI.xml:S3:6611:6	should	MD	O	O
be	SIMPONI.xml:S3:6618:2	be	VB	O	O
tested	SIMPONI.xml:S3:6621:6	test	VBN	O	O
for	SIMPONI.xml:S3:6628:3	for	IN	O	O
HBV	SIMPONI.xml:S3:6632:3	hbv	NNP	O	O
infection	SIMPONI.xml:S3:6636:9	infect	NN	O	O
before	SIMPONI.xml:S3:6646:6	befor	IN	O	O
initiating	SIMPONI.xml:S3:6653:10	initi	VBG	O	O
TNF	SIMPONI.xml:S3:6664:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:6667:1	-	:	O	O
blocker	SIMPONI.xml:S3:6668:7	blocker	NN	O	O
therapy	SIMPONI.xml:S3:6676:7	therapi	NN	O	O
.	SIMPONI.xml:S3:6683:1	.	.	O	O

For	SIMPONI.xml:S3:6685:3	for	IN	O	O
patients	SIMPONI.xml:S3:6689:8	patient	NNS	O	O
who	SIMPONI.xml:S3:6698:3	who	WP	O	O
test	SIMPONI.xml:S3:6702:4	test	VBP	O	O
positive	SIMPONI.xml:S3:6707:8	posit	JJ	O	O
for	SIMPONI.xml:S3:6716:3	for	IN	O	O
hepatitis	SIMPONI.xml:S3:6720:9	hepat	NN	O	O
B	SIMPONI.xml:S3:6730:1	B	NNP	O	O
surface	SIMPONI.xml:S3:6732:7	surfac	NN	O	O
antigen	SIMPONI.xml:S3:6740:7	antigen	NN	O	O
,	SIMPONI.xml:S3:6747:1	,	,	O	O
consultation	SIMPONI.xml:S3:6749:12	consult	NN	O	O
with	SIMPONI.xml:S3:6762:4	with	IN	O	O
a	SIMPONI.xml:S3:6767:1	a	DT	O	O
physician	SIMPONI.xml:S3:6769:9	physician	NN	O	O
with	SIMPONI.xml:S3:6779:4	with	IN	O	O
expertise	SIMPONI.xml:S3:6784:9	expertis	NN	O	O
in	SIMPONI.xml:S3:6794:2	in	IN	O	O
the	SIMPONI.xml:S3:6797:3	the	DT	O	O
treatment	SIMPONI.xml:S3:6801:9	treatment	NN	O	O
of	SIMPONI.xml:S3:6811:2	of	IN	O	O
hepatitis	SIMPONI.xml:S3:6814:9	hepat	NN	O	O
B	SIMPONI.xml:S3:6824:1	B	NNP	O	O
is	SIMPONI.xml:S3:6826:2	is	VBZ	O	O
recommended	SIMPONI.xml:S3:6829:11	recommend	VBN	O	O
before	SIMPONI.xml:S3:6841:6	befor	IN	O	O
initiating	SIMPONI.xml:S3:6848:10	initi	VBG	O	O
TNF	SIMPONI.xml:S3:6859:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:6862:1	-	:	O	O
blocker	SIMPONI.xml:S3:6863:7	blocker	NN	O	O
therapy	SIMPONI.xml:S3:6871:7	therapi	NN	O	O
.	SIMPONI.xml:S3:6878:1	.	.	O	O

The	SIMPONI.xml:S3:6880:3	the	DT	O	O
risks	SIMPONI.xml:S3:6884:5	risk	NNS	O	O
and	SIMPONI.xml:S3:6890:3	and	CC	O	O
benefits	SIMPONI.xml:S3:6894:8	benefit	NNS	O	O
of	SIMPONI.xml:S3:6903:2	of	IN	O	O
treatment	SIMPONI.xml:S3:6906:9	treatment	NN	O	O
should	SIMPONI.xml:S3:6916:6	should	MD	O	O
be	SIMPONI.xml:S3:6923:2	be	VB	O	O
considered	SIMPONI.xml:S3:6926:10	consid	VBN	O	O
prior	SIMPONI.xml:S3:6937:5	prior	JJ	O	O
to	SIMPONI.xml:S3:6943:2	to	TO	O	O
prescribing	SIMPONI.xml:S3:6946:11	prescrib	VBG	O	O
TNF	SIMPONI.xml:S3:6958:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:6961:1	-	:	O	O
blockers	SIMPONI.xml:S3:6962:8	blocker	NNS	O	O
,	SIMPONI.xml:S3:6970:1	,	,	O	O
including	SIMPONI.xml:S3:6972:9	includ	VBG	O	O
SIMPONI	SIMPONI.xml:S3:6982:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:6990:4	aria	NNP	O	O
,	SIMPONI.xml:S3:6994:1	,	,	O	O
to	SIMPONI.xml:S3:6996:2	to	TO	O	O
patients	SIMPONI.xml:S3:6999:8	patient	NNS	O	O
who	SIMPONI.xml:S3:7008:3	who	WP	O	O
are	SIMPONI.xml:S3:7012:3	are	VBP	O	O
carriers	SIMPONI.xml:S3:7016:8	carrier	NNS	O	O
of	SIMPONI.xml:S3:7025:2	of	IN	O	O
HBV	SIMPONI.xml:S3:7028:3	hbv	NNP	O	O
.	SIMPONI.xml:S3:7031:1	.	.	O	O

Adequate	SIMPONI.xml:S3:7033:8	adequ	NNP	O	O
data	SIMPONI.xml:S3:7042:4	data	NNS	O	O
are	SIMPONI.xml:S3:7047:3	are	VBP	O	O
not	SIMPONI.xml:S3:7051:3	not	RB	O	O
available	SIMPONI.xml:S3:7055:9	avail	JJ	O	O
on	SIMPONI.xml:S3:7065:2	on	IN	O	O
whether	SIMPONI.xml:S3:7068:7	whether	IN	O	O
anti	SIMPONI.xml:S3:7076:4	anti	JJ	O	O
-	SIMPONI.xml:S3:7080:1	-	:	O	O
viral	SIMPONI.xml:S3:7081:5	viral	JJ	O	O
therapy	SIMPONI.xml:S3:7087:7	therapi	NN	O	O
can	SIMPONI.xml:S3:7095:3	can	MD	O	O
reduce	SIMPONI.xml:S3:7099:6	reduc	VB	O	O
the	SIMPONI.xml:S3:7106:3	the	DT	O	O
risk	SIMPONI.xml:S3:7110:4	risk	NN	O	O
of	SIMPONI.xml:S3:7115:2	of	IN	O	O
HBV	SIMPONI.xml:S3:7118:3	hbv	NNP	O	O
reactivation	SIMPONI.xml:S3:7122:12	reactiv	NN	O	O
in	SIMPONI.xml:S3:7135:2	in	IN	O	O
HBV	SIMPONI.xml:S3:7138:3	hbv	NNP	O	O
carriers	SIMPONI.xml:S3:7142:8	carrier	NNS	O	O
who	SIMPONI.xml:S3:7151:3	who	WP	O	O
are	SIMPONI.xml:S3:7155:3	are	VBP	O	O
treated	SIMPONI.xml:S3:7159:7	treat	VBN	O	O
with	SIMPONI.xml:S3:7167:4	with	IN	O	O
TNF	SIMPONI.xml:S3:7172:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:7175:1	-	:	O	O
blockers	SIMPONI.xml:S3:7176:8	blocker	NNS	O	O
.	SIMPONI.xml:S3:7184:1	.	.	O	O

Patients	SIMPONI.xml:S3:7186:8	patient	NNS	O	O
who	SIMPONI.xml:S3:7195:3	who	WP	O	O
are	SIMPONI.xml:S3:7199:3	are	VBP	O	O
carriers	SIMPONI.xml:S3:7203:8	carrier	NNS	O	O
of	SIMPONI.xml:S3:7212:2	of	IN	O	O
HBV	SIMPONI.xml:S3:7215:3	hbv	NNP	O	O
and	SIMPONI.xml:S3:7219:3	and	CC	O	O
require	SIMPONI.xml:S3:7223:7	requir	VB	O	O
treatment	SIMPONI.xml:S3:7231:9	treatment	NN	O	O
with	SIMPONI.xml:S3:7241:4	with	IN	O	O
TNF	SIMPONI.xml:S3:7246:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:7249:1	-	:	O	O
blockers	SIMPONI.xml:S3:7250:8	blocker	NNS	O	O
should	SIMPONI.xml:S3:7259:6	should	MD	O	O
be	SIMPONI.xml:S3:7266:2	be	VB	O	O
closely	SIMPONI.xml:S3:7269:7	close	RB	O	O
monitored	SIMPONI.xml:S3:7277:9	monitor	VBN	O	O
for	SIMPONI.xml:S3:7287:3	for	IN	O	O
clinical	SIMPONI.xml:S3:7291:8	clinic	JJ	O	O
and	SIMPONI.xml:S3:7300:3	and	CC	O	O
laboratory	SIMPONI.xml:S3:7304:10	laboratori	JJ	O	O
signs	SIMPONI.xml:S3:7315:5	sign	NNS	O	O
of	SIMPONI.xml:S3:7321:2	of	IN	O	O
active	SIMPONI.xml:S3:7324:6	activ	JJ	O	O
HBV	SIMPONI.xml:S3:7331:3	hbv	NNP	O	O
infection	SIMPONI.xml:S3:7335:9	infect	NN	O	O
throughout	SIMPONI.xml:S3:7345:10	throughout	IN	O	O
therapy	SIMPONI.xml:S3:7356:7	therapi	NN	O	O
and	SIMPONI.xml:S3:7364:3	and	CC	O	O
for	SIMPONI.xml:S3:7368:3	for	IN	O	O
several	SIMPONI.xml:S3:7372:7	sever	JJ	O	O
months	SIMPONI.xml:S3:7380:6	month	NNS	O	O
following	SIMPONI.xml:S3:7387:9	follow	VBG	O	O
termination	SIMPONI.xml:S3:7397:11	termin	NN	O	O
of	SIMPONI.xml:S3:7409:2	of	IN	O	O
therapy	SIMPONI.xml:S3:7412:7	therapi	NN	O	O
.	SIMPONI.xml:S3:7419:1	.	.	O	O

In	SIMPONI.xml:S3:7425:2	In	IN	O	O
patients	SIMPONI.xml:S3:7428:8	patient	NNS	O	O
who	SIMPONI.xml:S3:7437:3	who	WP	O	O
develop	SIMPONI.xml:S3:7441:7	develop	VBP	O	O
HBV	SIMPONI.xml:S3:7449:3	hbv	NNP	O	O
reactivation	SIMPONI.xml:S3:7453:12	reactiv	NN	O	O
,	SIMPONI.xml:S3:7465:1	,	,	O	O
TNF	SIMPONI.xml:S3:7467:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:7470:1	-	:	O	O
blockers	SIMPONI.xml:S3:7471:8	blocker	NNS	O	O
should	SIMPONI.xml:S3:7480:6	should	MD	O	O
be	SIMPONI.xml:S3:7487:2	be	VB	O	O
stopped	SIMPONI.xml:S3:7490:7	stop	VBN	O	O
and	SIMPONI.xml:S3:7498:3	and	CC	O	O
antiviral	SIMPONI.xml:S3:7502:9	antivir	JJ	O	O
therapy	SIMPONI.xml:S3:7512:7	therapi	NN	O	O
with	SIMPONI.xml:S3:7520:4	with	IN	O	O
appropriate	SIMPONI.xml:S3:7525:11	appropri	JJ	O	O
supportive	SIMPONI.xml:S3:7537:10	support	JJ	O	O
treatment	SIMPONI.xml:S3:7548:9	treatment	NN	O	O
should	SIMPONI.xml:S3:7558:6	should	MD	O	O
be	SIMPONI.xml:S3:7565:2	be	VB	O	O
initiated	SIMPONI.xml:S3:7568:9	initi	VBN	O	O
.	SIMPONI.xml:S3:7577:1	.	.	O	O

The	SIMPONI.xml:S3:7579:3	the	DT	O	O
safety	SIMPONI.xml:S3:7583:6	safeti	NN	O	O
of	SIMPONI.xml:S3:7590:2	of	IN	O	O
resuming	SIMPONI.xml:S3:7593:8	resum	VBG	O	O
TNF	SIMPONI.xml:S3:7602:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:7605:1	-	:	O	O
blockers	SIMPONI.xml:S3:7606:8	blocker	NNS	O	O
after	SIMPONI.xml:S3:7615:5	after	IN	O	O
HBV	SIMPONI.xml:S3:7621:3	hbv	NNP	O	O
reactivation	SIMPONI.xml:S3:7625:12	reactiv	NN	O	O
has	SIMPONI.xml:S3:7638:3	ha	VBZ	O	O
been	SIMPONI.xml:S3:7642:4	been	VBN	O	O
controlled	SIMPONI.xml:S3:7647:10	control	VBN	O	O
is	SIMPONI.xml:S3:7658:2	is	VBZ	O	O
not	SIMPONI.xml:S3:7661:3	not	RB	O	O
known	SIMPONI.xml:S3:7665:5	known	VBN	O	O
.	SIMPONI.xml:S3:7670:1	.	.	O	O

Therefore	SIMPONI.xml:S3:7672:9	therefor	RB	O	O
,	SIMPONI.xml:S3:7681:1	,	,	O	O
prescribers	SIMPONI.xml:S3:7683:11	prescrib	NNS	O	O
should	SIMPONI.xml:S3:7695:6	should	MD	O	O
exercise	SIMPONI.xml:S3:7702:8	exercis	VB	O	O
caution	SIMPONI.xml:S3:7711:7	caution	NN	O	O
when	SIMPONI.xml:S3:7719:4	when	WRB	O	O
considering	SIMPONI.xml:S3:7724:11	consid	VBG	O	O
resumption	SIMPONI.xml:S3:7736:10	resumpt	NN	O	O
of	SIMPONI.xml:S3:7747:2	of	IN	O	O
TNF	SIMPONI.xml:S3:7750:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:7753:1	-	:	O	O
blockers	SIMPONI.xml:S3:7754:8	blocker	NNS	O	O
in	SIMPONI.xml:S3:7763:2	in	IN	O	O
this	SIMPONI.xml:S3:7766:4	thi	DT	O	O
situation	SIMPONI.xml:S3:7771:9	situat	NN	O	O
and	SIMPONI.xml:S3:7781:3	and	CC	O	O
monitor	SIMPONI.xml:S3:7785:7	monitor	NN	O	O
patients	SIMPONI.xml:S3:7793:8	patient	NNS	O	O
closely	SIMPONI.xml:S3:7802:7	close	RB	O	O
.	SIMPONI.xml:S3:7809:1	.	.	O	O

5.2	SIMPONI.xml:S3:7818:3	5.2	CD	O	O
Malignancies	SIMPONI.xml:S3:7822:12	malign	NNS	O	O

Malignancies	SIMPONI.xml:S3:7841:12	malign	NNS	O	O
in	SIMPONI.xml:S3:7854:2	in	IN	O	O
Pediatric	SIMPONI.xml:S3:7857:9	pediatr	NNP	O	O
Patients	SIMPONI.xml:S3:7867:8	patient	NNS	O	O

Malignancies	SIMPONI.xml:S3:7882:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:7894:1	,	,	O	O
some	SIMPONI.xml:S3:7896:4	some	DT	O	O
fatal	SIMPONI.xml:S3:7901:5	fatal	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:7906:1	,	,	O	O
have	SIMPONI.xml:S3:7908:4	have	VBP	O	O
been	SIMPONI.xml:S3:7913:4	been	VBN	O	O
reported	SIMPONI.xml:S3:7918:8	report	VBN	O	O
among	SIMPONI.xml:S3:7927:5	among	IN	O	O
children	SIMPONI.xml:S3:7933:8	children	NNS	O	O
,	SIMPONI.xml:S3:7941:1	,	,	O	O
adolescents	SIMPONI.xml:S3:7943:11	adolesc	NNS	O	O
,	SIMPONI.xml:S3:7954:1	,	,	O	O
and	SIMPONI.xml:S3:7956:3	and	CC	O	O
young	SIMPONI.xml:S3:7960:5	young	JJ	O	O
adults	SIMPONI.xml:S3:7966:6	adult	NNS	O	O
who	SIMPONI.xml:S3:7973:3	who	WP	O	O
received	SIMPONI.xml:S3:7977:8	receiv	VBD	O	O
treatment	SIMPONI.xml:S3:7986:9	treatment	NN	O	O
with	SIMPONI.xml:S3:7996:4	with	IN	O	O
TNF	SIMPONI.xml:S3:8001:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:8004:1	-	:	O	O
blocking	SIMPONI.xml:S3:8005:8	block	VBG	O	O
agents	SIMPONI.xml:S3:8014:6	agent	NNS	O	O
(	SIMPONI.xml:S3:8021:1	(	(	O	O
initiation	SIMPONI.xml:S3:8022:10	initi	NN	O	O
of	SIMPONI.xml:S3:8033:2	of	IN	O	O
therapy	SIMPONI.xml:S3:8036:7	therapi	NN	O	O
18	SIMPONI.xml:S3:8047:2	18	CD	O	O
years	SIMPONI.xml:S3:8050:5	year	NNS	O	O
of	SIMPONI.xml:S3:8056:2	of	IN	O	O
age	SIMPONI.xml:S3:8059:3	age	NN	O	O
)	SIMPONI.xml:S3:8062:1	)	)	O	O
,	SIMPONI.xml:S3:8063:1	,	,	O	O
of	SIMPONI.xml:S3:8065:2	of	IN	O	O
which	SIMPONI.xml:S3:8068:5	which	WDT	O	O
SIMPONI	SIMPONI.xml:S3:8074:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:8082:4	aria	NNP	O	O
is	SIMPONI.xml:S3:8087:2	is	VBZ	O	O
a	SIMPONI.xml:S3:8090:1	a	DT	O	O
member	SIMPONI.xml:S3:8092:6	member	NN	O	O
.	SIMPONI.xml:S3:8098:1	.	.	O	O

Approximately	SIMPONI.xml:S3:8100:13	approxim	RB	O	O
half	SIMPONI.xml:S3:8114:4	half	PDT	O	O
the	SIMPONI.xml:S3:8119:3	the	DT	O	O
cases	SIMPONI.xml:S3:8123:5	case	NNS	O	O
were	SIMPONI.xml:S3:8129:4	were	VBD	O	O
lymphomas	SIMPONI.xml:S3:8134:9	lymphoma	JJ	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:8143:1	,	,	O	O
including	SIMPONI.xml:S3:8145:9	includ	VBG	O	O
Hodgkin	SIMPONI.xml:S3:8155:7	hodgkin	NNP	B-AdverseReaction	B-AdverseReaction
's	SIMPONI.xml:S3:8162:2	's	POS	I-AdverseReaction	O
and	SIMPONI.xml:S3:8165:3	and	CC	O	O
non	SIMPONI.xml:S3:8169:3	non	JJ	B-AdverseReaction	B-AdverseReaction
-	SIMPONI.xml:S3:8172:1	-	:	I-AdverseReaction	I-AdverseReaction
Hodgkin	SIMPONI.xml:S3:8173:7	hodgkin	NNP	I-AdverseReaction	I-AdverseReaction
's	SIMPONI.xml:S3:8180:2	's	POS	I-AdverseReaction	I-AdverseReaction
lymphoma	SIMPONI.xml:S3:8183:8	lymphoma	NN	I-AdverseReaction	I-AdverseReaction
.	SIMPONI.xml:S3:8191:1	.	.	O	O

The	SIMPONI.xml:S3:8193:3	the	DT	O	O
other	SIMPONI.xml:S3:8197:5	other	JJ	O	O
cases	SIMPONI.xml:S3:8203:5	case	NNS	O	O
represented	SIMPONI.xml:S3:8209:11	repres	VBD	O	O
a	SIMPONI.xml:S3:8221:1	a	DT	O	O
variety	SIMPONI.xml:S3:8223:7	varieti	NN	O	O
of	SIMPONI.xml:S3:8231:2	of	IN	O	O
malignancies	SIMPONI.xml:S3:8234:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:8246:1	,	,	O	O
including	SIMPONI.xml:S3:8248:9	includ	VBG	O	O
rare	SIMPONI.xml:S3:8258:4	rare	JJ	B-AdverseReaction	B-AdverseReaction
malignancies	SIMPONI.xml:S3:8263:12	malign	NNS	I-AdverseReaction	I-AdverseReaction
that	SIMPONI.xml:S3:8276:4	that	WDT	O	O
are	SIMPONI.xml:S3:8281:3	are	VBP	O	O
usually	SIMPONI.xml:S3:8285:7	usual	RB	O	O
associated	SIMPONI.xml:S3:8293:10	associ	VBN	O	O
with	SIMPONI.xml:S3:8304:4	with	IN	O	O
immunosuppression	SIMPONI.xml:S3:8309:17	immunosuppress	NN	B-AdverseReaction	O
,	SIMPONI.xml:S3:8326:1	,	,	O	O
and	SIMPONI.xml:S3:8328:3	and	CC	O	O
malignancies	SIMPONI.xml:S3:8332:12	malign	NNS	O	B-AdverseReaction
that	SIMPONI.xml:S3:8345:4	that	WDT	O	O
are	SIMPONI.xml:S3:8350:3	are	VBP	O	O
not	SIMPONI.xml:S3:8354:3	not	RB	O	O
usually	SIMPONI.xml:S3:8358:7	usual	RB	O	O
observed	SIMPONI.xml:S3:8366:8	observ	VBN	O	O
in	SIMPONI.xml:S3:8375:2	in	IN	O	O
children	SIMPONI.xml:S3:8378:8	children	NNS	O	O
and	SIMPONI.xml:S3:8387:3	and	CC	O	O
adolescents	SIMPONI.xml:S3:8391:11	adolesc	NNS	O	O
.	SIMPONI.xml:S3:8402:1	.	.	O	O

The	SIMPONI.xml:S3:8404:3	the	DT	O	O
malignancies	SIMPONI.xml:S3:8408:12	malign	NNS	O	B-AdverseReaction
occurred	SIMPONI.xml:S3:8421:8	occur	VBD	O	O
after	SIMPONI.xml:S3:8430:5	after	IN	O	O
a	SIMPONI.xml:S3:8436:1	a	DT	O	O
median	SIMPONI.xml:S3:8438:6	median	NN	O	O
of	SIMPONI.xml:S3:8445:2	of	IN	O	O
30	SIMPONI.xml:S3:8448:2	30	CD	O	O
months	SIMPONI.xml:S3:8451:6	month	NNS	O	O
(	SIMPONI.xml:S3:8458:1	(	(	O	O
range	SIMPONI.xml:S3:8459:5	rang	VB	O	O
1	SIMPONI.xml:S3:8465:1	1	CD	O	O
to	SIMPONI.xml:S3:8467:2	to	TO	O	O
84	SIMPONI.xml:S3:8470:2	84	CD	O	O
months	SIMPONI.xml:S3:8473:6	month	NNS	O	O
)	SIMPONI.xml:S3:8479:1	)	)	O	O
after	SIMPONI.xml:S3:8481:5	after	IN	O	O
the	SIMPONI.xml:S3:8487:3	the	DT	O	O
first	SIMPONI.xml:S3:8491:5	first	JJ	O	O
dose	SIMPONI.xml:S3:8497:4	dose	NN	O	O
of	SIMPONI.xml:S3:8502:2	of	IN	O	O
TNF	SIMPONI.xml:S3:8505:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:8508:1	-	:	O	O
blocker	SIMPONI.xml:S3:8509:7	blocker	NN	O	O
therapy	SIMPONI.xml:S3:8517:7	therapi	NN	O	O
.	SIMPONI.xml:S3:8524:1	.	.	O	O

Most	SIMPONI.xml:S3:8526:4	most	JJS	O	O
of	SIMPONI.xml:S3:8531:2	of	IN	O	O
the	SIMPONI.xml:S3:8534:3	the	DT	O	O
patients	SIMPONI.xml:S3:8538:8	patient	NNS	O	O
were	SIMPONI.xml:S3:8547:4	were	VBD	O	O
receiving	SIMPONI.xml:S3:8552:9	receiv	VBG	O	O
concomitant	SIMPONI.xml:S3:8562:11	concomit	JJ	O	O
immunosuppressants	SIMPONI.xml:S3:8574:18	immunosuppress	NNS	O	O
.	SIMPONI.xml:S3:8592:1	.	.	O	O

These	SIMPONI.xml:S3:8594:5	these	DT	O	O
cases	SIMPONI.xml:S3:8600:5	case	NNS	O	O
were	SIMPONI.xml:S3:8606:4	were	VBD	O	O
reported	SIMPONI.xml:S3:8611:8	report	VBN	O	O
post	SIMPONI.xml:S3:8620:4	post	NN	O	O
-	SIMPONI.xml:S3:8624:1	-	:	O	O
marketing	SIMPONI.xml:S3:8625:9	market	NN	O	O
and	SIMPONI.xml:S3:8635:3	and	CC	O	O
are	SIMPONI.xml:S3:8639:3	are	VBP	O	O
derived	SIMPONI.xml:S3:8643:7	deriv	VBN	O	O
from	SIMPONI.xml:S3:8651:4	from	IN	O	O
a	SIMPONI.xml:S3:8656:1	a	DT	O	O
variety	SIMPONI.xml:S3:8658:7	varieti	NN	O	O
of	SIMPONI.xml:S3:8666:2	of	IN	O	O
sources	SIMPONI.xml:S3:8669:7	sourc	NNS	O	O
,	SIMPONI.xml:S3:8676:1	,	,	O	O
including	SIMPONI.xml:S3:8678:9	includ	VBG	O	O
registries	SIMPONI.xml:S3:8688:10	registri	NNS	O	O
and	SIMPONI.xml:S3:8699:3	and	CC	O	O
spontaneous	SIMPONI.xml:S3:8703:11	spontan	JJ	O	O
post	SIMPONI.xml:S3:8715:4	post	NN	O	O
-	SIMPONI.xml:S3:8719:1	-	:	O	O
marketing	SIMPONI.xml:S3:8720:9	market	NN	O	O
reports	SIMPONI.xml:S3:8730:7	report	NNS	O	O
.	SIMPONI.xml:S3:8737:1	.	.	O	O

Use	SIMPONI.xml:S3:8739:3	use	NNP	O	O
of	SIMPONI.xml:S3:8743:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S3:8746:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:8754:4	aria	NNP	O	O
in	SIMPONI.xml:S3:8759:2	in	IN	O	O
patients	SIMPONI.xml:S3:8762:8	patient	NNS	O	O
under	SIMPONI.xml:S3:8771:5	under	IN	O	O
18	SIMPONI.xml:S3:8777:2	18	CD	O	O
years	SIMPONI.xml:S3:8780:5	year	NNS	O	O
of	SIMPONI.xml:S3:8786:2	of	IN	O	O
age	SIMPONI.xml:S3:8789:3	age	NN	O	O
has	SIMPONI.xml:S3:8793:3	ha	VBZ	O	O
not	SIMPONI.xml:S3:8797:3	not	RB	O	O
been	SIMPONI.xml:S3:8801:4	been	VBN	O	O
established	SIMPONI.xml:S3:8806:11	establish	VBN	O	O
.	SIMPONI.xml:S3:8817:1	.	.	O	O

Malignancies	SIMPONI.xml:S3:8826:12	malign	NNS	O	O
in	SIMPONI.xml:S3:8839:2	in	IN	O	O
Adult	SIMPONI.xml:S3:8842:5	adult	NNP	O	O
Patients	SIMPONI.xml:S3:8848:8	patient	NNS	O	O

The	SIMPONI.xml:S3:8863:3	the	DT	O	O
risks	SIMPONI.xml:S3:8867:5	risk	NNS	O	O
and	SIMPONI.xml:S3:8873:3	and	CC	O	O
benefits	SIMPONI.xml:S3:8877:8	benefit	NNS	O	O
of	SIMPONI.xml:S3:8886:2	of	IN	O	O
TNF	SIMPONI.xml:S3:8889:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:8892:1	-	:	O	O
blocker	SIMPONI.xml:S3:8893:7	blocker	NN	O	O
treatment	SIMPONI.xml:S3:8901:9	treatment	NN	O	O
including	SIMPONI.xml:S3:8911:9	includ	VBG	O	O
SIMPONI	SIMPONI.xml:S3:8921:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:8929:4	aria	NNP	O	O
should	SIMPONI.xml:S3:8934:6	should	MD	O	O
be	SIMPONI.xml:S3:8941:2	be	VB	O	O
considered	SIMPONI.xml:S3:8944:10	consid	VBN	O	O
prior	SIMPONI.xml:S3:8955:5	prior	JJ	O	O
to	SIMPONI.xml:S3:8961:2	to	TO	O	O
initiating	SIMPONI.xml:S3:8964:10	initi	VBG	O	O
therapy	SIMPONI.xml:S3:8975:7	therapi	NN	O	O
in	SIMPONI.xml:S3:8983:2	in	IN	O	O
patients	SIMPONI.xml:S3:8986:8	patient	NNS	O	O
with	SIMPONI.xml:S3:8995:4	with	IN	O	O
a	SIMPONI.xml:S3:9000:1	a	DT	O	O
known	SIMPONI.xml:S3:9002:5	known	VBN	O	O
malignancy	SIMPONI.xml:S3:9008:10	malign	NN	O	O
other	SIMPONI.xml:S3:9019:5	other	JJ	O	O
than	SIMPONI.xml:S3:9025:4	than	IN	O	O
a	SIMPONI.xml:S3:9030:1	a	DT	O	O
successfully	SIMPONI.xml:S3:9032:12	success	RB	O	O
treated	SIMPONI.xml:S3:9045:7	treat	VBN	O	O
non	SIMPONI.xml:S3:9053:3	non	JJ	O	O
-	SIMPONI.xml:S3:9056:1	-	:	O	O
melanoma	SIMPONI.xml:S3:9057:8	melanoma	NN	O	O
skin	SIMPONI.xml:S3:9066:4	skin	NN	O	O
cancer	SIMPONI.xml:S3:9071:6	cancer	NN	O	O
(	SIMPONI.xml:S3:9078:1	(	(	O	O
NMSC	SIMPONI.xml:S3:9079:4	nmsc	NNP	O	O
)	SIMPONI.xml:S3:9083:1	)	)	O	O
or	SIMPONI.xml:S3:9085:2	or	CC	O	O
when	SIMPONI.xml:S3:9088:4	when	WRB	O	O
considering	SIMPONI.xml:S3:9093:11	consid	VBG	O	O
continuing	SIMPONI.xml:S3:9105:10	continu	VBG	O	O
a	SIMPONI.xml:S3:9116:1	a	DT	O	O
TNF	SIMPONI.xml:S3:9118:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:9121:1	-	:	O	O
blocker	SIMPONI.xml:S3:9122:7	blocker	NN	O	O
in	SIMPONI.xml:S3:9130:2	in	IN	O	O
patients	SIMPONI.xml:S3:9133:8	patient	NNS	O	O
who	SIMPONI.xml:S3:9142:3	who	WP	O	O
develop	SIMPONI.xml:S3:9146:7	develop	VBP	O	O
a	SIMPONI.xml:S3:9154:1	a	DT	O	O
malignancy	SIMPONI.xml:S3:9156:10	malign	NN	O	O
.	SIMPONI.xml:S3:9166:1	.	.	O	O

In	SIMPONI.xml:S3:9172:2	In	IN	O	O
the	SIMPONI.xml:S3:9175:3	the	DT	O	O
controlled	SIMPONI.xml:S3:9179:10	control	JJ	O	O
portions	SIMPONI.xml:S3:9190:8	portion	NNS	O	O
of	SIMPONI.xml:S3:9199:2	of	IN	O	O
clinical	SIMPONI.xml:S3:9202:8	clinic	JJ	O	O
trials	SIMPONI.xml:S3:9211:6	trial	NNS	O	O
of	SIMPONI.xml:S3:9218:2	of	IN	O	O
TNF	SIMPONI.xml:S3:9221:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:9224:1	-	:	O	O
blockers	SIMPONI.xml:S3:9225:8	blocker	NNS	O	O
including	SIMPONI.xml:S3:9234:9	includ	VBG	O	O
the	SIMPONI.xml:S3:9244:3	the	DT	O	O
subcutaneous	SIMPONI.xml:S3:9248:12	subcutan	JJ	O	O
formulation	SIMPONI.xml:S3:9261:11	formul	NN	O	O
of	SIMPONI.xml:S3:9273:2	of	IN	O	O
golimumab	SIMPONI.xml:S3:9276:9	golimumab	NN	O	O
more	SIMPONI.xml:S3:9286:4	more	RBR	O	O
cases	SIMPONI.xml:S3:9291:5	case	NNS	O	O
of	SIMPONI.xml:S3:9297:2	of	IN	O	O
lymphoma	SIMPONI.xml:S3:9300:8	lymphoma	NN	B-AdverseReaction	B-AdverseReaction
have	SIMPONI.xml:S3:9309:4	have	VBP	O	O
been	SIMPONI.xml:S3:9314:4	been	VBN	O	O
observed	SIMPONI.xml:S3:9319:8	observ	VBN	O	O
among	SIMPONI.xml:S3:9328:5	among	IN	O	O
patients	SIMPONI.xml:S3:9334:8	patient	NNS	O	O
receiving	SIMPONI.xml:S3:9343:9	receiv	VBG	O	O
anti	SIMPONI.xml:S3:9353:4	anti	JJ	O	O
-	SIMPONI.xml:S3:9357:1	-	:	O	O
TNF	SIMPONI.xml:S3:9358:3	tnf	NNP	O	O
treatment	SIMPONI.xml:S3:9362:9	treatment	NN	O	O
compared	SIMPONI.xml:S3:9372:8	compar	VBN	O	O
with	SIMPONI.xml:S3:9381:4	with	IN	O	O
patients	SIMPONI.xml:S3:9386:8	patient	NNS	O	O
in	SIMPONI.xml:S3:9395:2	in	IN	O	O
the	SIMPONI.xml:S3:9398:3	the	DT	O	O
control	SIMPONI.xml:S3:9402:7	control	NN	O	O
groups	SIMPONI.xml:S3:9410:6	group	NNS	O	O
.	SIMPONI.xml:S3:9416:1	.	.	O	O

Patients	SIMPONI.xml:S3:9418:8	patient	NNS	O	O
with	SIMPONI.xml:S3:9427:4	with	IN	O	O
RA	SIMPONI.xml:S3:9432:2	RA	NNP	O	O
and	SIMPONI.xml:S3:9435:3	and	CC	O	O
other	SIMPONI.xml:S3:9439:5	other	JJ	O	O
chronic	SIMPONI.xml:S3:9445:7	chronic	JJ	O	O
inflammatory	SIMPONI.xml:S3:9453:12	inflammatori	NN	O	O
diseases	SIMPONI.xml:S3:9466:8	diseas	NNS	O	O
,	SIMPONI.xml:S3:9474:1	,	,	O	O
particularly	SIMPONI.xml:S3:9476:12	particularli	RB	O	O
patients	SIMPONI.xml:S3:9489:8	patient	NNS	O	O
with	SIMPONI.xml:S3:9498:4	with	IN	O	O
highly	SIMPONI.xml:S3:9503:6	highli	RB	O	O
active	SIMPONI.xml:S3:9510:6	activ	JJ	O	O
disease	SIMPONI.xml:S3:9517:7	diseas	NN	O	O
and	SIMPONI.xml:S3:9525:3	and	CC	O	O
or	SIMPONI.xml:S3:9529:2	or	CC	O	O
chronic	SIMPONI.xml:S3:9532:7	chronic	JJ	O	O
exposure	SIMPONI.xml:S3:9540:8	exposur	NN	O	O
to	SIMPONI.xml:S3:9549:2	to	TO	O	O
immunosuppressant	SIMPONI.xml:S3:9552:17	immunosuppress	VB	O	O
therapies	SIMPONI.xml:S3:9570:9	therapi	NNS	O	O
,	SIMPONI.xml:S3:9579:1	,	,	O	O
may	SIMPONI.xml:S3:9581:3	may	MD	O	O
be	SIMPONI.xml:S3:9585:2	be	VB	O	O
at	SIMPONI.xml:S3:9588:2	at	IN	O	O
higher	SIMPONI.xml:S3:9591:6	higher	JJR	O	O
risk	SIMPONI.xml:S3:9598:4	risk	NN	O	O
(	SIMPONI.xml:S3:9603:1	(	(	O	O
up	SIMPONI.xml:S3:9604:2	up	IN	O	O
to	SIMPONI.xml:S3:9607:2	to	TO	O	O
several	SIMPONI.xml:S3:9610:7	sever	JJ	O	O
fold	SIMPONI.xml:S3:9618:4	fold	NN	O	O
)	SIMPONI.xml:S3:9622:1	)	)	O	O
than	SIMPONI.xml:S3:9624:4	than	IN	O	O
the	SIMPONI.xml:S3:9629:3	the	DT	O	O
general	SIMPONI.xml:S3:9633:7	gener	JJ	O	O
population	SIMPONI.xml:S3:9641:10	popul	NN	O	O
for	SIMPONI.xml:S3:9652:3	for	IN	O	O
the	SIMPONI.xml:S3:9656:3	the	DT	O	O
development	SIMPONI.xml:S3:9660:11	develop	NN	O	O
of	SIMPONI.xml:S3:9672:2	of	IN	O	O
lymphoma	SIMPONI.xml:S3:9675:8	lymphoma	NN	B-AdverseReaction	O
,	SIMPONI.xml:S3:9683:1	,	,	O	O
even	SIMPONI.xml:S3:9685:4	even	RB	O	O
in	SIMPONI.xml:S3:9690:2	in	IN	O	O
the	SIMPONI.xml:S3:9693:3	the	DT	O	O
absence	SIMPONI.xml:S3:9697:7	absenc	NN	O	O
of	SIMPONI.xml:S3:9705:2	of	IN	O	O
TNF	SIMPONI.xml:S3:9708:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:9711:1	-	:	O	O
blocking	SIMPONI.xml:S3:9712:8	block	VBG	O	O
therapy	SIMPONI.xml:S3:9721:7	therapi	NN	O	O
.	SIMPONI.xml:S3:9728:1	.	.	O	O

Cases	SIMPONI.xml:S3:9730:5	case	NNS	O	O
of	SIMPONI.xml:S3:9736:2	of	IN	O	O
acute	SIMPONI.xml:S3:9739:5	acut	NN	B-AdverseReaction	B-AdverseReaction
and	SIMPONI.xml:S3:9745:3	and	CC	O	O
chronic	SIMPONI.xml:S3:9749:7	chronic	JJ	B-AdverseReaction	B-AdverseReaction
leukemia	SIMPONI.xml:S3:9757:8	leukemia	NN	I-AdverseReaction	I-AdverseReaction
have	SIMPONI.xml:S3:9766:4	have	VBP	O	O
been	SIMPONI.xml:S3:9771:4	been	VBN	O	O
reported	SIMPONI.xml:S3:9776:8	report	VBN	O	O
with	SIMPONI.xml:S3:9785:4	with	IN	O	O
post	SIMPONI.xml:S3:9790:4	post	NN	O	O
-	SIMPONI.xml:S3:9794:1	-	:	O	O
marketing	SIMPONI.xml:S3:9795:9	market	NN	O	O
TNF	SIMPONI.xml:S3:9805:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:9808:1	-	:	O	O
blocker	SIMPONI.xml:S3:9809:7	blocker	NN	O	O
use	SIMPONI.xml:S3:9817:3	use	NN	O	O
in	SIMPONI.xml:S3:9821:2	in	IN	O	O
rheumatoid	SIMPONI.xml:S3:9824:10	rheumatoid	JJ	O	O
arthritis	SIMPONI.xml:S3:9835:9	arthriti	NN	O	O
and	SIMPONI.xml:S3:9845:3	and	CC	O	O
other	SIMPONI.xml:S3:9849:5	other	JJ	O	O
indications	SIMPONI.xml:S3:9855:11	indic	NNS	O	O
.	SIMPONI.xml:S3:9866:1	.	.	O	O

Even	SIMPONI.xml:S3:9868:4	even	RB	O	O
in	SIMPONI.xml:S3:9873:2	in	IN	O	O
the	SIMPONI.xml:S3:9876:3	the	DT	O	O
absence	SIMPONI.xml:S3:9880:7	absenc	NN	O	O
of	SIMPONI.xml:S3:9888:2	of	IN	O	O
TNF	SIMPONI.xml:S3:9891:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:9894:1	-	:	O	O
blocker	SIMPONI.xml:S3:9895:7	blocker	NN	O	O
therapy	SIMPONI.xml:S3:9903:7	therapi	NN	O	O
,	SIMPONI.xml:S3:9910:1	,	,	O	O
patients	SIMPONI.xml:S3:9912:8	patient	NNS	O	O
with	SIMPONI.xml:S3:9921:4	with	IN	O	O
rheumatoid	SIMPONI.xml:S3:9926:10	rheumatoid	JJ	O	O
arthritis	SIMPONI.xml:S3:9937:9	arthriti	NN	O	O
may	SIMPONI.xml:S3:9947:3	may	MD	O	O
be	SIMPONI.xml:S3:9951:2	be	VB	O	O
at	SIMPONI.xml:S3:9954:2	at	IN	O	O
a	SIMPONI.xml:S3:9957:1	a	DT	O	O
higher	SIMPONI.xml:S3:9959:6	higher	JJR	O	O
risk	SIMPONI.xml:S3:9966:4	risk	NN	O	O
(	SIMPONI.xml:S3:9971:1	(	(	O	O
approximately	SIMPONI.xml:S3:9972:13	approxim	RB	O	O
2	SIMPONI.xml:S3:9986:1	2	CD	O	O
-	SIMPONI.xml:S3:9987:1	-	:	O	O
fold	SIMPONI.xml:S3:9988:4	fold	NN	O	O
)	SIMPONI.xml:S3:9992:1	)	)	O	O
than	SIMPONI.xml:S3:9994:4	than	IN	O	O
the	SIMPONI.xml:S3:9999:3	the	DT	O	O
general	SIMPONI.xml:S3:10003:7	gener	JJ	O	O
population	SIMPONI.xml:S3:10011:10	popul	NN	O	O
for	SIMPONI.xml:S3:10022:3	for	IN	O	O
the	SIMPONI.xml:S3:10026:3	the	DT	O	O
development	SIMPONI.xml:S3:10030:11	develop	NN	O	O
of	SIMPONI.xml:S3:10042:2	of	IN	O	O
leukemia	SIMPONI.xml:S3:10045:8	leukemia	NN	O	O
.	SIMPONI.xml:S3:10053:1	.	.	O	O

Rare	SIMPONI.xml:S3:10060:4	rare	JJ	O	O
post	SIMPONI.xml:S3:10065:4	post	NN	O	O
-	SIMPONI.xml:S3:10069:1	-	:	O	O
marketing	SIMPONI.xml:S3:10070:9	market	NN	O	O
cases	SIMPONI.xml:S3:10080:5	case	NNS	O	O
of	SIMPONI.xml:S3:10086:2	of	IN	O	O
hepatosplenic	SIMPONI.xml:S3:10089:13	hepatosplen	JJ	B-AdverseReaction	B-AdverseReaction
T	SIMPONI.xml:S3:10103:1	T	NNP	I-AdverseReaction	I-AdverseReaction
-	SIMPONI.xml:S3:10104:1	-	:	I-AdverseReaction	I-AdverseReaction
cell	SIMPONI.xml:S3:10105:4	cell	NN	I-AdverseReaction	I-AdverseReaction
lymphoma	SIMPONI.xml:S3:10110:8	lymphoma	NN	I-AdverseReaction	I-AdverseReaction
(	SIMPONI.xml:S3:10119:1	(	(	O	O
HSTCL	SIMPONI.xml:S3:10120:5	hstcl	NNP	B-AdverseReaction	B-AdverseReaction
)	SIMPONI.xml:S3:10125:1	)	)	O	O
have	SIMPONI.xml:S3:10127:4	have	VBP	O	O
been	SIMPONI.xml:S3:10132:4	been	VBN	O	O
reported	SIMPONI.xml:S3:10137:8	report	VBN	O	O
in	SIMPONI.xml:S3:10146:2	in	IN	O	O
patients	SIMPONI.xml:S3:10149:8	patient	NNS	O	O
treated	SIMPONI.xml:S3:10158:7	treat	VBN	O	O
with	SIMPONI.xml:S3:10166:4	with	IN	O	O
TNF	SIMPONI.xml:S3:10171:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:10174:1	-	:	O	O
blocking	SIMPONI.xml:S3:10175:8	block	VBG	O	O
agents	SIMPONI.xml:S3:10184:6	agent	NNS	O	O
.	SIMPONI.xml:S3:10190:1	.	.	O	O

This	SIMPONI.xml:S3:10192:4	thi	DT	O	O
rare	SIMPONI.xml:S3:10197:4	rare	JJ	B-AdverseReaction	O
type	SIMPONI.xml:S3:10202:4	type	NN	I-AdverseReaction	O
of	SIMPONI.xml:S3:10207:2	of	IN	I-AdverseReaction	O
T	SIMPONI.xml:S3:10210:1	T	NNP	I-AdverseReaction	O
-	SIMPONI.xml:S3:10211:1	-	:	I-AdverseReaction	O
cell	SIMPONI.xml:S3:10212:4	cell	NN	I-AdverseReaction	O
lymphoma	SIMPONI.xml:S3:10217:8	lymphoma	NN	I-AdverseReaction	O
has	SIMPONI.xml:S3:10226:3	ha	VBZ	O	O
a	SIMPONI.xml:S3:10230:1	a	DT	O	O
very	SIMPONI.xml:S3:10232:4	veri	RB	O	O
aggressive	SIMPONI.xml:S3:10237:10	aggress	JJ	O	O
disease	SIMPONI.xml:S3:10248:7	diseas	NN	O	O
course	SIMPONI.xml:S3:10256:6	cours	NN	O	O
and	SIMPONI.xml:S3:10263:3	and	CC	O	O
is	SIMPONI.xml:S3:10267:2	is	VBZ	O	O
usually	SIMPONI.xml:S3:10270:7	usual	RB	O	O
fatal	SIMPONI.xml:S3:10278:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
.	SIMPONI.xml:S3:10283:1	.	.	O	O

Nearly	SIMPONI.xml:S3:10285:6	nearli	RB	O	O
all	SIMPONI.xml:S3:10292:3	all	DT	O	O
of	SIMPONI.xml:S3:10296:2	of	IN	O	O
the	SIMPONI.xml:S3:10299:3	the	DT	O	O
reported	SIMPONI.xml:S3:10303:8	report	VBN	O	O
TNF	SIMPONI.xml:S3:10312:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:10315:1	-	:	O	O
blocker	SIMPONI.xml:S3:10316:7	blocker	NN	O	O
associated	SIMPONI.xml:S3:10324:10	associ	VBN	O	O
cases	SIMPONI.xml:S3:10335:5	case	NNS	O	O
have	SIMPONI.xml:S3:10341:4	have	VBP	O	O
occurred	SIMPONI.xml:S3:10346:8	occur	VBN	O	O
in	SIMPONI.xml:S3:10355:2	in	IN	O	O
patients	SIMPONI.xml:S3:10358:8	patient	NNS	O	O
with	SIMPONI.xml:S3:10367:4	with	IN	O	O
Crohn	SIMPONI.xml:S3:10372:5	crohn	NNP	O	O
's	SIMPONI.xml:S3:10377:2	's	POS	O	O
disease	SIMPONI.xml:S3:10380:7	diseas	NN	O	O
or	SIMPONI.xml:S3:10388:2	or	CC	O	O
ulcerative	SIMPONI.xml:S3:10391:10	ulcer	JJ	O	O
colitis	SIMPONI.xml:S3:10402:7	coliti	NN	O	O
.	SIMPONI.xml:S3:10409:1	.	.	O	O

The	SIMPONI.xml:S3:10411:3	the	DT	O	O
majority	SIMPONI.xml:S3:10415:8	major	NN	O	O
were	SIMPONI.xml:S3:10424:4	were	VBD	O	O
in	SIMPONI.xml:S3:10429:2	in	IN	O	O
adolescent	SIMPONI.xml:S3:10432:10	adolesc	NN	O	O
and	SIMPONI.xml:S3:10443:3	and	CC	O	O
young	SIMPONI.xml:S3:10447:5	young	JJ	O	O
adult	SIMPONI.xml:S3:10453:5	adult	NN	O	O
males	SIMPONI.xml:S3:10459:5	male	NNS	O	O
.	SIMPONI.xml:S3:10464:1	.	.	O	O

Almost	SIMPONI.xml:S3:10466:6	almost	RB	O	O
all	SIMPONI.xml:S3:10473:3	all	PDT	O	O
these	SIMPONI.xml:S3:10477:5	these	DT	O	O
patients	SIMPONI.xml:S3:10483:8	patient	NNS	O	O
had	SIMPONI.xml:S3:10492:3	had	VBD	O	O
received	SIMPONI.xml:S3:10496:8	receiv	VBN	O	O
treatment	SIMPONI.xml:S3:10505:9	treatment	NN	O	O
with	SIMPONI.xml:S3:10515:4	with	IN	O	O
azathioprine	SIMPONI.xml:S3:10520:12	azathioprin	NN	O	O
(	SIMPONI.xml:S3:10533:1	(	(	O	O
AZA	SIMPONI.xml:S3:10534:3	aza	NNP	O	O
)	SIMPONI.xml:S3:10537:1	)	)	O	O
or	SIMPONI.xml:S3:10539:2	or	CC	O	O
6	SIMPONI.xml:S3:10542:1	6	CD	O	O
-	SIMPONI.xml:S3:10543:1	-	:	O	O
mercaptopurine	SIMPONI.xml:S3:10544:14	mercaptopurin	NN	O	O
(	SIMPONI.xml:S3:10559:1	(	(	O	O
6	SIMPONI.xml:S3:10560:1	6	CD	O	O
-	SIMPONI.xml:S3:10561:1	-	:	O	O
MP	SIMPONI.xml:S3:10562:2	MP	NN	O	O
)	SIMPONI.xml:S3:10564:1	)	)	O	O
concomitantly	SIMPONI.xml:S3:10566:13	concomitantli	RB	O	O
with	SIMPONI.xml:S3:10580:4	with	IN	O	O
a	SIMPONI.xml:S3:10585:1	a	DT	O	O
TNF	SIMPONI.xml:S3:10587:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:10590:1	-	:	O	O
blocker	SIMPONI.xml:S3:10591:7	blocker	NN	O	O
at	SIMPONI.xml:S3:10599:2	at	IN	O	O
or	SIMPONI.xml:S3:10602:2	or	CC	O	O
prior	SIMPONI.xml:S3:10605:5	prior	VB	O	O
to	SIMPONI.xml:S3:10611:2	to	TO	O	O
diagnosis	SIMPONI.xml:S3:10614:9	diagnosi	VB	O	O
.	SIMPONI.xml:S3:10623:1	.	.	O	O

A	SIMPONI.xml:S3:10625:1	A	DT	O	O
risk	SIMPONI.xml:S3:10627:4	risk	NN	O	O
for	SIMPONI.xml:S3:10632:3	for	IN	O	O
the	SIMPONI.xml:S3:10636:3	the	DT	O	O
development	SIMPONI.xml:S3:10640:11	develop	NN	O	O
for	SIMPONI.xml:S3:10652:3	for	IN	O	O
hepatosplenic	SIMPONI.xml:S3:10656:13	hepatosplen	JJ	O	O
T	SIMPONI.xml:S3:10670:1	T	NNP	O	O
-	SIMPONI.xml:S3:10671:1	-	:	O	O
cell	SIMPONI.xml:S3:10672:4	cell	NN	O	O
lymphoma	SIMPONI.xml:S3:10677:8	lymphoma	NN	O	O
in	SIMPONI.xml:S3:10686:2	in	IN	O	O
patients	SIMPONI.xml:S3:10689:8	patient	NNS	O	O
treated	SIMPONI.xml:S3:10698:7	treat	VBN	O	O
with	SIMPONI.xml:S3:10706:4	with	IN	O	O
TNF	SIMPONI.xml:S3:10711:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:10714:1	-	:	O	O
blockers	SIMPONI.xml:S3:10715:8	blocker	NNS	O	O
cannot	SIMPONI.xml:S3:10724:6	cannot	VBP	O	O
be	SIMPONI.xml:S3:10731:2	be	VB	O	O
excluded	SIMPONI.xml:S3:10734:8	exclud	VBN	O	O
.	SIMPONI.xml:S3:10742:1	.	.	O	O

Melanoma	SIMPONI.xml:S3:10750:8	melanoma	NNP	B-AdverseReaction	O
has	SIMPONI.xml:S3:10759:3	ha	VBZ	O	O
been	SIMPONI.xml:S3:10763:4	been	VBN	O	O
reported	SIMPONI.xml:S3:10768:8	report	VBN	O	O
in	SIMPONI.xml:S3:10777:2	in	IN	O	O
patients	SIMPONI.xml:S3:10780:8	patient	NNS	O	O
treated	SIMPONI.xml:S3:10789:7	treat	VBN	O	O
with	SIMPONI.xml:S3:10797:4	with	IN	O	O
TNF	SIMPONI.xml:S3:10802:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:10805:1	-	:	O	O
blocking	SIMPONI.xml:S3:10806:8	block	VBG	O	O
agents	SIMPONI.xml:S3:10815:6	agent	NNS	O	O
,	SIMPONI.xml:S3:10821:1	,	,	O	O
including	SIMPONI.xml:S3:10823:9	includ	VBG	O	O
the	SIMPONI.xml:S3:10833:3	the	DT	O	O
subcutaneous	SIMPONI.xml:S3:10837:12	subcutan	JJ	O	O
formulation	SIMPONI.xml:S3:10850:11	formul	NN	O	O
of	SIMPONI.xml:S3:10862:2	of	IN	O	O
golimumab	SIMPONI.xml:S3:10865:9	golimumab	NN	O	O
.	SIMPONI.xml:S3:10874:1	.	.	O	O

Merkel	SIMPONI.xml:S3:10876:6	merkel	NNP	B-AdverseReaction	B-AdverseReaction
cell	SIMPONI.xml:S3:10883:4	cell	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	SIMPONI.xml:S3:10888:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
has	SIMPONI.xml:S3:10898:3	ha	VBZ	O	O
been	SIMPONI.xml:S3:10902:4	been	VBN	O	O
reported	SIMPONI.xml:S3:10907:8	report	VBN	O	O
in	SIMPONI.xml:S3:10916:2	in	IN	O	O
patients	SIMPONI.xml:S3:10919:8	patient	NNS	O	O
treated	SIMPONI.xml:S3:10928:7	treat	VBN	O	O
with	SIMPONI.xml:S3:10936:4	with	IN	O	O
TNF	SIMPONI.xml:S3:10941:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:10944:1	-	:	O	O
blocking	SIMPONI.xml:S3:10945:8	block	VBG	O	O
agents	SIMPONI.xml:S3:10954:6	agent	NNS	O	O
.	SIMPONI.xml:S3:10960:1	.	.	O	O

Periodic	SIMPONI.xml:S3:10962:8	period	JJ	O	O
skin	SIMPONI.xml:S3:10971:4	skin	NN	O	O
examination	SIMPONI.xml:S3:10976:11	examin	NN	O	O
is	SIMPONI.xml:S3:10988:2	is	VBZ	O	O
recommended	SIMPONI.xml:S3:10991:11	recommend	VBN	O	O
for	SIMPONI.xml:S3:11003:3	for	IN	O	O
all	SIMPONI.xml:S3:11007:3	all	DT	O	O
patients	SIMPONI.xml:S3:11011:8	patient	NNS	O	O
,	SIMPONI.xml:S3:11019:1	,	,	O	O
particularly	SIMPONI.xml:S3:11021:12	particularli	RB	O	O
those	SIMPONI.xml:S3:11034:5	those	DT	O	O
with	SIMPONI.xml:S3:11040:4	with	IN	O	O
risk	SIMPONI.xml:S3:11045:4	risk	NN	O	O
factors	SIMPONI.xml:S3:11050:7	factor	NNS	O	O
for	SIMPONI.xml:S3:11058:3	for	IN	O	O
skin	SIMPONI.xml:S3:11062:4	skin	JJ	O	O
cancer	SIMPONI.xml:S3:11067:6	cancer	NN	O	O
.	SIMPONI.xml:S3:11073:1	.	.	O	O

In	SIMPONI.xml:S3:11079:2	In	IN	O	O
controlled	SIMPONI.xml:S3:11082:10	control	JJ	O	O
trials	SIMPONI.xml:S3:11093:6	trial	NNS	O	O
of	SIMPONI.xml:S3:11100:2	of	IN	O	O
other	SIMPONI.xml:S3:11103:5	other	JJ	O	O
TNF	SIMPONI.xml:S3:11109:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:11112:1	-	:	O	O
blockers	SIMPONI.xml:S3:11113:8	blocker	NNS	O	O
in	SIMPONI.xml:S3:11122:2	in	IN	O	O
patients	SIMPONI.xml:S3:11125:8	patient	NNS	O	O
at	SIMPONI.xml:S3:11134:2	at	IN	O	O
higher	SIMPONI.xml:S3:11137:6	higher	JJR	O	O
risk	SIMPONI.xml:S3:11144:4	risk	NN	O	O
for	SIMPONI.xml:S3:11149:3	for	IN	O	O
malignancies	SIMPONI.xml:S3:11153:12	malign	NNS	O	B-AdverseReaction
(	SIMPONI.xml:S3:11166:1	(	(	O	O
e	SIMPONI.xml:S3:11167:1	e	NN	O	O
.	SIMPONI.xml:S3:11168:1	.	.	O	O
g	SIMPONI.xml:S3:11169:1	g	NN	O	O
.	SIMPONI.xml:S3:11170:1	.	.	O	O
,	SIMPONI.xml:S3:11171:1	,	,	O	O
patients	SIMPONI.xml:S3:11173:8	patient	NNS	O	O
with	SIMPONI.xml:S3:11182:4	with	IN	O	O
COPD	SIMPONI.xml:S3:11187:4	copd	NNP	O	O
,	SIMPONI.xml:S3:11191:1	,	,	O	O
patients	SIMPONI.xml:S3:11193:8	patient	NNS	O	O
with	SIMPONI.xml:S3:11202:4	with	IN	O	O
Wegener	SIMPONI.xml:S3:11207:7	wegen	NNP	O	O
's	SIMPONI.xml:S3:11214:2	's	POS	O	O
granulomatosis	SIMPONI.xml:S3:11217:14	granulomatosi	NN	O	O
treated	SIMPONI.xml:S3:11232:7	treat	VBD	O	O
with	SIMPONI.xml:S3:11240:4	with	IN	O	O
concomitant	SIMPONI.xml:S3:11245:11	concomit	JJ	O	O
cyclophosphamide	SIMPONI.xml:S3:11257:16	cyclophosphamid	NN	O	O
)	SIMPONI.xml:S3:11273:1	)	)	O	O
a	SIMPONI.xml:S3:11275:1	a	DT	O	O
greater	SIMPONI.xml:S3:11277:7	greater	JJR	O	O
portion	SIMPONI.xml:S3:11285:7	portion	NN	O	O
of	SIMPONI.xml:S3:11293:2	of	IN	O	O
malignancies	SIMPONI.xml:S3:11296:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
occurred	SIMPONI.xml:S3:11309:8	occur	VBN	O	O
in	SIMPONI.xml:S3:11318:2	in	IN	O	O
the	SIMPONI.xml:S3:11321:3	the	DT	O	O
TNF	SIMPONI.xml:S3:11325:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:11328:1	-	:	O	O
blocker	SIMPONI.xml:S3:11329:7	blocker	NN	O	O
group	SIMPONI.xml:S3:11337:5	group	NN	O	O
compared	SIMPONI.xml:S3:11343:8	compar	VBN	O	O
to	SIMPONI.xml:S3:11352:2	to	TO	O	O
the	SIMPONI.xml:S3:11355:3	the	DT	O	O
controlled	SIMPONI.xml:S3:11359:10	control	VBN	O	O
group	SIMPONI.xml:S3:11370:5	group	NN	O	O
.	SIMPONI.xml:S3:11375:1	.	.	O	O

In	SIMPONI.xml:S3:11377:2	In	IN	O	O
an	SIMPONI.xml:S3:11380:2	an	DT	O	O
exploratory	SIMPONI.xml:S3:11383:11	exploratori	JJ	O	O
clinical	SIMPONI.xml:S3:11395:8	clinic	JJ	O	O
trial	SIMPONI.xml:S3:11404:5	trial	NN	O	O
evaluating	SIMPONI.xml:S3:11410:10	evalu	VBG	O	O
the	SIMPONI.xml:S3:11421:3	the	DT	O	O
use	SIMPONI.xml:S3:11425:3	use	NN	O	O
of	SIMPONI.xml:S3:11429:2	of	IN	O	O
the	SIMPONI.xml:S3:11432:3	the	DT	O	O
subcutaneous	SIMPONI.xml:S3:11436:12	subcutan	JJ	O	O
formulation	SIMPONI.xml:S3:11449:11	formul	NN	O	O
of	SIMPONI.xml:S3:11461:2	of	IN	O	O
golimumab	SIMPONI.xml:S3:11464:9	golimumab	NN	O	O
in	SIMPONI.xml:S3:11474:2	in	IN	O	O
patients	SIMPONI.xml:S3:11477:8	patient	NNS	O	O
with	SIMPONI.xml:S3:11486:4	with	IN	O	O
severe	SIMPONI.xml:S3:11491:6	sever	JJ	O	O
persistent	SIMPONI.xml:S3:11498:10	persist	NN	O	O
asthma	SIMPONI.xml:S3:11509:6	asthma	NN	O	O
,	SIMPONI.xml:S3:11515:1	,	,	O	O
more	SIMPONI.xml:S3:11517:4	more	JJR	O	O
patients	SIMPONI.xml:S3:11522:8	patient	NNS	O	O
treated	SIMPONI.xml:S3:11531:7	treat	VBN	O	O
with	SIMPONI.xml:S3:11539:4	with	IN	O	O
golimumab	SIMPONI.xml:S3:11544:9	golimumab	NN	O	O
reported	SIMPONI.xml:S3:11554:8	report	VBN	O	O
malignancies	SIMPONI.xml:S3:11563:12	malign	NNS	B-AdverseReaction	O
compared	SIMPONI.xml:S3:11576:8	compar	VBN	O	O
with	SIMPONI.xml:S3:11585:4	with	IN	O	O
control	SIMPONI.xml:S3:11590:7	control	NN	O	O
patients	SIMPONI.xml:S3:11598:8	patient	NNS	O	O
.	SIMPONI.xml:S3:11606:1	.	.	O	O

The	SIMPONI.xml:S3:11608:3	the	DT	O	O
significance	SIMPONI.xml:S3:11612:12	signific	NN	O	O
of	SIMPONI.xml:S3:11625:2	of	IN	O	O
this	SIMPONI.xml:S3:11628:4	thi	DT	O	O
finding	SIMPONI.xml:S3:11633:7	find	NN	O	O
is	SIMPONI.xml:S3:11641:2	is	VBZ	O	O
unknown	SIMPONI.xml:S3:11644:7	unknown	JJ	O	O
.	SIMPONI.xml:S3:11651:1	.	.	O	O

During	SIMPONI.xml:S3:11657:6	dure	IN	O	O
the	SIMPONI.xml:S3:11664:3	the	DT	O	O
controlled	SIMPONI.xml:S3:11668:10	control	JJ	O	O
portion	SIMPONI.xml:S3:11679:7	portion	NN	O	O
of	SIMPONI.xml:S3:11687:2	of	IN	O	O
the	SIMPONI.xml:S3:11690:3	the	DT	O	O
Phase	SIMPONI.xml:S3:11694:5	phase	NNP	O	O
3	SIMPONI.xml:S3:11700:1	3	CD	O	O
trial	SIMPONI.xml:S3:11702:5	trial	NN	O	O
in	SIMPONI.xml:S3:11708:2	in	IN	O	O
RA	SIMPONI.xml:S3:11711:2	RA	NNP	O	O
for	SIMPONI.xml:S3:11714:3	for	IN	O	O
SIMPONI	SIMPONI.xml:S3:11718:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:11726:4	aria	NNP	O	O
,	SIMPONI.xml:S3:11730:1	,	,	O	O
the	SIMPONI.xml:S3:11732:3	the	DT	O	O
incidence	SIMPONI.xml:S3:11736:9	incid	NN	O	O
of	SIMPONI.xml:S3:11746:2	of	IN	O	O
malignancies	SIMPONI.xml:S3:11749:12	malign	NNS	B-AdverseReaction	B-AdverseReaction
other	SIMPONI.xml:S3:11762:5	other	JJ	O	I-AdverseReaction
than	SIMPONI.xml:S3:11768:4	than	IN	O	I-AdverseReaction
lymphoma	SIMPONI.xml:S3:11773:8	lymphoma	NN	O	I-AdverseReaction
and	SIMPONI.xml:S3:11782:3	and	CC	O	O
NMSC	SIMPONI.xml:S3:11786:4	nmsc	NNP	O	O
per	SIMPONI.xml:S3:11791:3	per	IN	O	O
100	SIMPONI.xml:S3:11795:3	100	CD	O	O
-	SIMPONI.xml:S3:11798:1	-	:	O	O
patient	SIMPONI.xml:S3:11799:7	patient	NN	O	O
-	SIMPONI.xml:S3:11806:1	-	:	O	O
years	SIMPONI.xml:S3:11807:5	year	NNS	O	O
of	SIMPONI.xml:S3:11813:2	of	IN	O	O
follow	SIMPONI.xml:S3:11816:6	follow	NN	O	O
-	SIMPONI.xml:S3:11822:1	-	:	O	O
up	SIMPONI.xml:S3:11823:2	up	NN	O	O
was	SIMPONI.xml:S3:11826:3	wa	VBD	O	O
0.56	SIMPONI.xml:S3:11830:4	0.56	CD	O	O
(	SIMPONI.xml:S3:11835:1	(	(	O	O
95%	SIMPONI.xml:S3:11836:3	95%	CD	O	O
CI	SIMPONI.xml:S3:11840:2	CI	NNP	O	O
:	SIMPONI.xml:S3:11842:1	:	:	O	O
0.01	SIMPONI.xml:S3:11844:4	0.01	CD	O	O
,	SIMPONI.xml:S3:11848:1	,	,	O	O
3.11	SIMPONI.xml:S3:11850:4	3.11	CD	O	O
)	SIMPONI.xml:S3:11854:1	)	)	O	O
in	SIMPONI.xml:S3:11856:2	in	IN	O	O
the	SIMPONI.xml:S3:11859:3	the	DT	O	O
SIMPONI	SIMPONI.xml:S3:11863:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:11871:4	aria	NNP	O	O
group	SIMPONI.xml:S3:11876:5	group	NN	O	O
compared	SIMPONI.xml:S3:11882:8	compar	VBN	O	O
with	SIMPONI.xml:S3:11891:4	with	IN	O	O
an	SIMPONI.xml:S3:11896:2	an	DT	O	O
incidence	SIMPONI.xml:S3:11899:9	incid	NN	O	O
of	SIMPONI.xml:S3:11909:2	of	IN	O	O
0	SIMPONI.xml:S3:11912:1	0	CD	O	O
(	SIMPONI.xml:S3:11914:1	(	(	O	O
95%	SIMPONI.xml:S3:11915:3	95%	CD	O	O
CI	SIMPONI.xml:S3:11919:2	CI	NNP	O	O
:	SIMPONI.xml:S3:11921:1	:	:	O	O
0.00	SIMPONI.xml:S3:11923:4	0.00	CD	O	O
,	SIMPONI.xml:S3:11927:1	,	,	O	O
3.79	SIMPONI.xml:S3:11929:4	3.79	CD	O	O
)	SIMPONI.xml:S3:11933:1	)	)	O	O
in	SIMPONI.xml:S3:11935:2	in	IN	O	O
the	SIMPONI.xml:S3:11938:3	the	DT	O	O
placebo	SIMPONI.xml:S3:11942:7	placebo	NN	O	O
group	SIMPONI.xml:S3:11950:5	group	NN	O	O
.	SIMPONI.xml:S3:11955:1	.	.	O	O

5.3	SIMPONI.xml:S3:11964:3	5.3	CD	O	O
Congestive	SIMPONI.xml:S3:11968:10	congest	JJ	O	O
Heart	SIMPONI.xml:S3:11979:5	heart	NNP	O	O
Failure	SIMPONI.xml:S3:11985:7	failur	NN	O	O

Cases	SIMPONI.xml:S3:11998:5	case	NNS	O	O
of	SIMPONI.xml:S3:12004:2	of	IN	O	O
worsening	SIMPONI.xml:S3:12007:9	worsen	VBG	B-AdverseReaction	B-AdverseReaction
congestive	SIMPONI.xml:S3:12017:10	congest	JJ	I-AdverseReaction	I-AdverseReaction
heart	SIMPONI.xml:S3:12028:5	heart	NN	I-AdverseReaction	I-AdverseReaction
failure	SIMPONI.xml:S3:12034:7	failur	NN	I-AdverseReaction	I-AdverseReaction
(	SIMPONI.xml:S3:12042:1	(	(	O	O
CHF	SIMPONI.xml:S3:12043:3	chf	NNP	I-AdverseReaction	I-AdverseReaction
)	SIMPONI.xml:S3:12046:1	)	)	O	O
and	SIMPONI.xml:S3:12048:3	and	CC	O	O
new	SIMPONI.xml:S3:12052:3	new	JJ	B-AdverseReaction	B-AdverseReaction
onset	SIMPONI.xml:S3:12056:5	onset	NN	I-AdverseReaction	I-AdverseReaction
CHF	SIMPONI.xml:S3:12062:3	chf	NNP	I-AdverseReaction	I-AdverseReaction
have	SIMPONI.xml:S3:12066:4	have	VBP	O	O
been	SIMPONI.xml:S3:12071:4	been	VBN	O	O
reported	SIMPONI.xml:S3:12076:8	report	VBN	O	O
with	SIMPONI.xml:S3:12085:4	with	IN	O	O
TNF	SIMPONI.xml:S3:12090:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:12093:1	-	:	O	O
blockers	SIMPONI.xml:S3:12094:8	blocker	NNS	O	O
,	SIMPONI.xml:S3:12102:1	,	,	O	O
including	SIMPONI.xml:S3:12104:9	includ	VBG	O	O
SIMPONI	SIMPONI.xml:S3:12114:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:12122:4	aria	NNP	O	O
.	SIMPONI.xml:S3:12126:1	.	.	O	O

In	SIMPONI.xml:S3:12128:2	In	IN	O	O
several	SIMPONI.xml:S3:12131:7	sever	JJ	O	O
exploratory	SIMPONI.xml:S3:12139:11	exploratori	JJ	O	O
trials	SIMPONI.xml:S3:12151:6	trial	NNS	O	O
of	SIMPONI.xml:S3:12158:2	of	IN	O	O
other	SIMPONI.xml:S3:12161:5	other	JJ	O	O
TNF	SIMPONI.xml:S3:12167:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:12170:1	-	:	O	O
blockers	SIMPONI.xml:S3:12171:8	blocker	NNS	O	O
in	SIMPONI.xml:S3:12180:2	in	IN	O	O
the	SIMPONI.xml:S3:12183:3	the	DT	O	O
treatment	SIMPONI.xml:S3:12187:9	treatment	NN	O	O
of	SIMPONI.xml:S3:12197:2	of	IN	O	O
CHF	SIMPONI.xml:S3:12200:3	chf	NNP	O	O
,	SIMPONI.xml:S3:12203:1	,	,	O	O
there	SIMPONI.xml:S3:12205:5	there	EX	O	O
were	SIMPONI.xml:S3:12211:4	were	VBD	O	O
greater	SIMPONI.xml:S3:12216:7	greater	JJR	O	O
proportions	SIMPONI.xml:S3:12224:11	proport	NNS	O	O
of	SIMPONI.xml:S3:12236:2	of	IN	O	O
TNF	SIMPONI.xml:S3:12239:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:12242:1	-	:	O	O
blocker	SIMPONI.xml:S3:12243:7	blocker	NN	O	O
treated	SIMPONI.xml:S3:12251:7	treat	VBD	O	O
patients	SIMPONI.xml:S3:12259:8	patient	NNS	O	O
who	SIMPONI.xml:S3:12268:3	who	WP	O	O
had	SIMPONI.xml:S3:12272:3	had	VBD	O	O
CHF	SIMPONI.xml:S3:12276:3	chf	NNP	B-AdverseReaction	B-AdverseReaction
exacerbations	SIMPONI.xml:S3:12280:13	exacerb	NNS	I-AdverseReaction	I-AdverseReaction
requiring	SIMPONI.xml:S3:12294:9	requir	VBG	O	O
hospitalization	SIMPONI.xml:S3:12304:15	hospit	NN	O	O
or	SIMPONI.xml:S3:12320:2	or	CC	O	O
increased	SIMPONI.xml:S3:12323:9	increas	JJ	B-AdverseReaction	O
mortality	SIMPONI.xml:S3:12333:9	mortal	NN	I-AdverseReaction	O
.	SIMPONI.xml:S3:12342:1	.	.	O	O

SIMPONI	SIMPONI.xml:S3:12344:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:12352:4	aria	NNP	O	O
has	SIMPONI.xml:S3:12357:3	ha	VBZ	O	O
not	SIMPONI.xml:S3:12361:3	not	RB	O	O
been	SIMPONI.xml:S3:12365:4	been	VBN	O	O
studied	SIMPONI.xml:S3:12370:7	studi	VBN	O	O
in	SIMPONI.xml:S3:12378:2	in	IN	O	O
patients	SIMPONI.xml:S3:12381:8	patient	NNS	O	O
with	SIMPONI.xml:S3:12390:4	with	IN	O	O
a	SIMPONI.xml:S3:12395:1	a	DT	O	O
history	SIMPONI.xml:S3:12397:7	histori	NN	O	O
of	SIMPONI.xml:S3:12405:2	of	IN	O	O
CHF	SIMPONI.xml:S3:12408:3	chf	NNP	O	O
and	SIMPONI.xml:S3:12412:3	and	CC	O	O
SIMPONI	SIMPONI.xml:S3:12416:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:12424:4	aria	NNP	O	O
should	SIMPONI.xml:S3:12429:6	should	MD	O	O
be	SIMPONI.xml:S3:12436:2	be	VB	O	O
used	SIMPONI.xml:S3:12439:4	use	VBN	O	O
with	SIMPONI.xml:S3:12444:4	with	IN	O	O
caution	SIMPONI.xml:S3:12449:7	caution	NN	O	O
in	SIMPONI.xml:S3:12457:2	in	IN	O	O
patients	SIMPONI.xml:S3:12460:8	patient	NNS	O	O
with	SIMPONI.xml:S3:12469:4	with	IN	O	O
CHF	SIMPONI.xml:S3:12474:3	chf	NNP	O	O
.	SIMPONI.xml:S3:12477:1	.	.	O	O

If	SIMPONI.xml:S3:12479:2	If	IN	O	O
a	SIMPONI.xml:S3:12482:1	a	DT	O	O
decision	SIMPONI.xml:S3:12484:8	decis	NN	O	O
is	SIMPONI.xml:S3:12493:2	is	VBZ	O	O
made	SIMPONI.xml:S3:12496:4	made	VBN	O	O
to	SIMPONI.xml:S3:12501:2	to	TO	O	O
administer	SIMPONI.xml:S3:12504:10	administ	VB	O	O
SIMPONI	SIMPONI.xml:S3:12515:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:12523:4	aria	NNP	O	O
to	SIMPONI.xml:S3:12528:2	to	TO	O	O
RA	SIMPONI.xml:S3:12531:2	RA	NNP	O	O
patients	SIMPONI.xml:S3:12534:8	patient	NNS	O	O
with	SIMPONI.xml:S3:12543:4	with	IN	O	O
CHF	SIMPONI.xml:S3:12548:3	chf	NNP	O	O
,	SIMPONI.xml:S3:12551:1	,	,	O	O
these	SIMPONI.xml:S3:12553:5	these	DT	O	O
patients	SIMPONI.xml:S3:12559:8	patient	NNS	O	O
should	SIMPONI.xml:S3:12568:6	should	MD	O	O
be	SIMPONI.xml:S3:12575:2	be	VB	O	O
closely	SIMPONI.xml:S3:12578:7	close	RB	O	O
monitored	SIMPONI.xml:S3:12586:9	monitor	VBN	O	O
during	SIMPONI.xml:S3:12596:6	dure	IN	O	O
therapy	SIMPONI.xml:S3:12603:7	therapi	NN	O	O
,	SIMPONI.xml:S3:12610:1	,	,	O	O
and	SIMPONI.xml:S3:12612:3	and	CC	O	O
SIMPONI	SIMPONI.xml:S3:12616:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:12624:4	aria	NNP	O	O
should	SIMPONI.xml:S3:12629:6	should	MD	O	O
be	SIMPONI.xml:S3:12636:2	be	VB	O	O
discontinued	SIMPONI.xml:S3:12639:12	discontinu	VBN	O	O
if	SIMPONI.xml:S3:12652:2	if	IN	O	O
new	SIMPONI.xml:S3:12655:3	new	JJ	O	O
or	SIMPONI.xml:S3:12659:2	or	CC	O	O
worsening	SIMPONI.xml:S3:12662:9	worsen	VBG	O	O
symptoms	SIMPONI.xml:S3:12672:8	symptom	NNS	O	O
of	SIMPONI.xml:S3:12681:2	of	IN	O	O
CHF	SIMPONI.xml:S3:12684:3	chf	NNP	O	O
appear	SIMPONI.xml:S3:12688:6	appear	VBP	O	O
.	SIMPONI.xml:S3:12694:1	.	.	O	O

5.4	SIMPONI.xml:S3:12703:3	5.4	CD	O	O
Demyelinating	SIMPONI.xml:S3:12707:13	demyelin	VBG	O	O
Disorders	SIMPONI.xml:S3:12721:9	disord	NNS	O	O

Use	SIMPONI.xml:S3:12736:3	use	NNP	O	O
of	SIMPONI.xml:S3:12740:2	of	IN	O	O
TNF	SIMPONI.xml:S3:12743:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:12746:1	-	:	O	O
blockers	SIMPONI.xml:S3:12747:8	blocker	NNS	O	O
,	SIMPONI.xml:S3:12755:1	,	,	O	O
of	SIMPONI.xml:S3:12757:2	of	IN	O	O
which	SIMPONI.xml:S3:12760:5	which	WDT	O	O
SIMPONI	SIMPONI.xml:S3:12766:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:12774:4	aria	NNP	O	O
is	SIMPONI.xml:S3:12779:2	is	VBZ	O	O
a	SIMPONI.xml:S3:12782:1	a	DT	O	O
member	SIMPONI.xml:S3:12784:6	member	NN	O	O
,	SIMPONI.xml:S3:12790:1	,	,	O	O
has	SIMPONI.xml:S3:12792:3	ha	VBZ	O	O
been	SIMPONI.xml:S3:12796:4	been	VBN	O	O
associated	SIMPONI.xml:S3:12801:10	associ	VBN	O	O
with	SIMPONI.xml:S3:12812:4	with	IN	O	O
rare	SIMPONI.xml:S3:12817:4	rare	JJ	O	O
cases	SIMPONI.xml:S3:12822:5	case	NNS	O	O
of	SIMPONI.xml:S3:12828:2	of	IN	O	O
new	SIMPONI.xml:S3:12831:3	new	JJ	B-AdverseReaction	O
onset	SIMPONI.xml:S3:12835:5	onset	NN	I-AdverseReaction	O
or	SIMPONI.xml:S3:12841:2	or	CC	O	O
exacerbation	SIMPONI.xml:S3:12844:12	exacerb	NN	B-AdverseReaction	O
of	SIMPONI.xml:S3:12857:2	of	IN	I-AdverseReaction	O
central	SIMPONI.xml:S3:12860:7	central	JJ	I-AdverseReaction	O
nervous	SIMPONI.xml:S3:12868:7	nervou	JJ	I-AdverseReaction	O
system	SIMPONI.xml:S3:12876:6	system	NN	I-AdverseReaction	O
(	SIMPONI.xml:S3:12883:1	(	(	O	O
CNS	SIMPONI.xml:S3:12884:3	cn	NNP	I-AdverseReaction	O
)	SIMPONI.xml:S3:12887:1	)	)	O	O
demyelinating	SIMPONI.xml:S3:12889:13	demyelin	VBG	I-AdverseReaction	O
disorders	SIMPONI.xml:S3:12903:9	disord	NNS	I-AdverseReaction	O
,	SIMPONI.xml:S3:12912:1	,	,	O	O
including	SIMPONI.xml:S3:12914:9	includ	VBG	O	O
multiple	SIMPONI.xml:S3:12924:8	multipl	JJ	B-AdverseReaction	O
sclerosis	SIMPONI.xml:S3:12933:9	sclerosi	NN	I-AdverseReaction	O
(	SIMPONI.xml:S3:12943:1	(	(	O	O
MS	SIMPONI.xml:S3:12944:2	MS	NNP	B-AdverseReaction	O
)	SIMPONI.xml:S3:12946:1	)	)	O	O
and	SIMPONI.xml:S3:12948:3	and	CC	O	O
peripheral	SIMPONI.xml:S3:12952:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
demyelinating	SIMPONI.xml:S3:12963:13	demyelin	NN	I-AdverseReaction	I-AdverseReaction
disorders	SIMPONI.xml:S3:12977:9	disord	NNS	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S3:12986:1	,	,	O	O
including	SIMPONI.xml:S3:12988:9	includ	VBG	O	O
Guillain	SIMPONI.xml:S3:12998:8	guillain	NNP	B-AdverseReaction	B-AdverseReaction
-	SIMPONI.xml:S3:13006:1	-	:	I-AdverseReaction	I-AdverseReaction
Barre	SIMPONI.xml:S3:13007:5	barr	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	SIMPONI.xml:S3:13013:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
.	SIMPONI.xml:S3:13021:1	.	.	O	O

Cases	SIMPONI.xml:S3:13023:5	case	NNS	O	O
of	SIMPONI.xml:S3:13029:2	of	IN	O	O
central	SIMPONI.xml:S3:13032:7	central	JJ	B-AdverseReaction	B-AdverseReaction
demyelination	SIMPONI.xml:S3:13040:13	demyelin	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S3:13053:1	,	,	O	O
MS	SIMPONI.xml:S3:13055:2	MS	NNP	B-AdverseReaction	O
,	SIMPONI.xml:S3:13057:1	,	,	O	O
optic	SIMPONI.xml:S3:13059:5	optic	JJ	B-AdverseReaction	B-AdverseReaction
neuritis	SIMPONI.xml:S3:13065:8	neuriti	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S3:13073:1	,	,	O	O
and	SIMPONI.xml:S3:13075:3	and	CC	O	O
peripheral	SIMPONI.xml:S3:13079:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
demyelinating	SIMPONI.xml:S3:13090:13	demyelin	NN	I-AdverseReaction	I-AdverseReaction
polyneuropathy	SIMPONI.xml:S3:13104:14	polyneuropathi	NNS	I-AdverseReaction	I-AdverseReaction
have	SIMPONI.xml:S3:13119:4	have	VBP	O	O
rarely	SIMPONI.xml:S3:13124:6	rare	RB	O	O
been	SIMPONI.xml:S3:13131:4	been	VBN	O	O
reported	SIMPONI.xml:S3:13136:8	report	VBN	O	O
in	SIMPONI.xml:S3:13145:2	in	IN	O	O
patients	SIMPONI.xml:S3:13148:8	patient	NNS	O	O
treated	SIMPONI.xml:S3:13157:7	treat	VBN	O	O
with	SIMPONI.xml:S3:13165:4	with	IN	O	O
the	SIMPONI.xml:S3:13170:3	the	DT	O	O
subcutaneous	SIMPONI.xml:S3:13174:12	subcutan	JJ	O	O
formulation	SIMPONI.xml:S3:13187:11	formul	NN	O	O
of	SIMPONI.xml:S3:13199:2	of	IN	O	O
golimumab	SIMPONI.xml:S3:13202:9	golimumab	NN	O	O
.	SIMPONI.xml:S3:13211:1	.	.	O	O

Prescribers	SIMPONI.xml:S3:13213:11	prescrib	NNS	O	O
should	SIMPONI.xml:S3:13225:6	should	MD	O	O
exercise	SIMPONI.xml:S3:13232:8	exercis	VB	O	O
caution	SIMPONI.xml:S3:13241:7	caution	NN	O	O
in	SIMPONI.xml:S3:13249:2	in	IN	O	O
considering	SIMPONI.xml:S3:13252:11	consid	VBG	O	O
the	SIMPONI.xml:S3:13264:3	the	DT	O	O
use	SIMPONI.xml:S3:13268:3	use	NN	O	O
of	SIMPONI.xml:S3:13272:2	of	IN	O	O
TNF	SIMPONI.xml:S3:13275:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:13278:1	-	:	O	O
blockers	SIMPONI.xml:S3:13279:8	blocker	NNS	O	O
,	SIMPONI.xml:S3:13287:1	,	,	O	O
including	SIMPONI.xml:S3:13289:9	includ	VBG	O	O
SIMPONI	SIMPONI.xml:S3:13299:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:13307:4	aria	NNP	O	O
,	SIMPONI.xml:S3:13311:1	,	,	O	O
in	SIMPONI.xml:S3:13313:2	in	IN	O	O
patients	SIMPONI.xml:S3:13316:8	patient	NNS	O	O
with	SIMPONI.xml:S3:13325:4	with	IN	O	O
central	SIMPONI.xml:S3:13330:7	central	JJ	O	O
or	SIMPONI.xml:S3:13338:2	or	CC	O	O
peripheral	SIMPONI.xml:S3:13341:10	peripher	JJ	O	O
nervous	SIMPONI.xml:S3:13352:7	nervou	JJ	O	O
system	SIMPONI.xml:S3:13360:6	system	NN	O	O
demyelinating	SIMPONI.xml:S3:13367:13	demyelin	VBG	O	O
disorders	SIMPONI.xml:S3:13381:9	disord	NNS	O	O
.	SIMPONI.xml:S3:13390:1	.	.	O	O

Discontinuation	SIMPONI.xml:S3:13392:15	discontinu	NN	O	O
of	SIMPONI.xml:S3:13408:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S3:13411:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:13419:4	aria	NNP	O	O
should	SIMPONI.xml:S3:13424:6	should	MD	O	O
be	SIMPONI.xml:S3:13431:2	be	VB	O	O
considered	SIMPONI.xml:S3:13434:10	consid	VBN	O	O
if	SIMPONI.xml:S3:13445:2	if	IN	O	O
these	SIMPONI.xml:S3:13448:5	these	DT	O	O
disorders	SIMPONI.xml:S3:13454:9	disord	NNS	O	O
develop	SIMPONI.xml:S3:13464:7	develop	VBP	O	O
.	SIMPONI.xml:S3:13471:1	.	.	O	O

5.5	SIMPONI.xml:S3:13480:3	5.5	CD	O	O
Use	SIMPONI.xml:S3:13484:3	use	NNP	O	O
with	SIMPONI.xml:S3:13488:4	with	IN	O	O
Abatacept	SIMPONI.xml:S3:13493:9	abatacept	NNP	O	O

In	SIMPONI.xml:S3:13508:2	In	IN	O	O
controlled	SIMPONI.xml:S3:13511:10	control	JJ	O	O
trials	SIMPONI.xml:S3:13522:6	trial	NNS	O	O
,	SIMPONI.xml:S3:13528:1	,	,	O	O
the	SIMPONI.xml:S3:13530:3	the	DT	O	O
concurrent	SIMPONI.xml:S3:13534:10	concurr	JJ	O	O
administration	SIMPONI.xml:S3:13545:14	administr	NN	O	O
of	SIMPONI.xml:S3:13560:2	of	IN	O	O
another	SIMPONI.xml:S3:13563:7	anoth	DT	O	O
TNF	SIMPONI.xml:S3:13571:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:13574:1	-	:	O	O
blocker	SIMPONI.xml:S3:13575:7	blocker	NN	O	O
and	SIMPONI.xml:S3:13583:3	and	CC	O	O
abatacept	SIMPONI.xml:S3:13587:9	abatacept	NN	O	O
was	SIMPONI.xml:S3:13597:3	wa	VBD	O	O
associated	SIMPONI.xml:S3:13601:10	associ	VBN	O	O
with	SIMPONI.xml:S3:13612:4	with	IN	O	O
a	SIMPONI.xml:S3:13617:1	a	DT	O	O
greater	SIMPONI.xml:S3:13619:7	greater	JJR	O	O
proportion	SIMPONI.xml:S3:13627:10	proport	NN	O	O
of	SIMPONI.xml:S3:13638:2	of	IN	O	O
serious	SIMPONI.xml:S3:13641:7	seriou	JJ	O	O
infections	SIMPONI.xml:S3:13649:10	infect	NNS	O	B-AdverseReaction
than	SIMPONI.xml:S3:13660:4	than	IN	O	O
the	SIMPONI.xml:S3:13665:3	the	DT	O	O
use	SIMPONI.xml:S3:13669:3	use	NN	O	O
of	SIMPONI.xml:S3:13673:2	of	IN	O	O
a	SIMPONI.xml:S3:13676:1	a	DT	O	O
TNF	SIMPONI.xml:S3:13678:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:13681:1	-	:	O	O
blocker	SIMPONI.xml:S3:13682:7	blocker	NN	O	O
alone	SIMPONI.xml:S3:13690:5	alon	RB	O	O
;	SIMPONI.xml:S3:13695:1	;	:	O	O
and	SIMPONI.xml:S3:13697:3	and	CC	O	O
the	SIMPONI.xml:S3:13701:3	the	DT	O	O
combination	SIMPONI.xml:S3:13705:11	combin	NN	O	O
therapy	SIMPONI.xml:S3:13717:7	therapi	NN	O	O
,	SIMPONI.xml:S3:13724:1	,	,	O	O
compared	SIMPONI.xml:S3:13726:8	compar	VBN	O	O
to	SIMPONI.xml:S3:13735:2	to	TO	O	O
the	SIMPONI.xml:S3:13738:3	the	DT	O	O
use	SIMPONI.xml:S3:13742:3	use	NN	O	O
of	SIMPONI.xml:S3:13746:2	of	IN	O	O
a	SIMPONI.xml:S3:13749:1	a	DT	O	O
TNF	SIMPONI.xml:S3:13751:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:13754:1	-	:	O	O
blocker	SIMPONI.xml:S3:13755:7	blocker	NN	O	O
alone	SIMPONI.xml:S3:13763:5	alon	RB	O	O
,	SIMPONI.xml:S3:13768:1	,	,	O	O
has	SIMPONI.xml:S3:13770:3	ha	VBZ	O	O
not	SIMPONI.xml:S3:13774:3	not	RB	O	O
demonstrated	SIMPONI.xml:S3:13778:12	demonstr	VBN	O	O
improved	SIMPONI.xml:S3:13791:8	improv	JJ	O	O
clinical	SIMPONI.xml:S3:13800:8	clinic	JJ	O	O
benefit	SIMPONI.xml:S3:13809:7	benefit	NN	O	O
in	SIMPONI.xml:S3:13817:2	in	IN	O	O
the	SIMPONI.xml:S3:13820:3	the	DT	O	O
treatment	SIMPONI.xml:S3:13824:9	treatment	NN	O	O
of	SIMPONI.xml:S3:13834:2	of	IN	O	O
RA	SIMPONI.xml:S3:13837:2	RA	NNP	O	O
.	SIMPONI.xml:S3:13839:1	.	.	O	O

Therefore	SIMPONI.xml:S3:13841:9	therefor	RB	O	O
,	SIMPONI.xml:S3:13850:1	,	,	O	O
the	SIMPONI.xml:S3:13852:3	the	DT	O	O
combination	SIMPONI.xml:S3:13856:11	combin	NN	O	O
of	SIMPONI.xml:S3:13868:2	of	IN	O	O
TNF	SIMPONI.xml:S3:13871:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:13874:1	-	:	O	O
blockers	SIMPONI.xml:S3:13875:8	blocker	NNS	O	O
including	SIMPONI.xml:S3:13884:9	includ	VBG	O	O
SIMPONI	SIMPONI.xml:S3:13894:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:13902:4	aria	NNP	O	O
and	SIMPONI.xml:S3:13907:3	and	CC	O	O
abatacept	SIMPONI.xml:S3:13911:9	abatacept	NN	O	O
is	SIMPONI.xml:S3:13921:2	is	VBZ	O	O
not	SIMPONI.xml:S3:13924:3	not	RB	O	O
recommended	SIMPONI.xml:S3:13928:11	recommend	JJ	O	O
[	SIMPONI.xml:S3:13940:1	[	NNS	O	O
see	SIMPONI.xml:S3:13941:3	see	VBP	O	O
Drug	SIMPONI.xml:S3:13946:4	drug	JJ	O	O
Interactions	SIMPONI.xml:S3:13951:12	interact	NNP	O	O
(	SIMPONI.xml:S3:13964:1	(	(	O	O
7.2	SIMPONI.xml:S3:13965:3	7.2	CD	O	O
)	SIMPONI.xml:S3:13968:1	)	)	O	O
]	SIMPONI.xml:S3:13971:1	]	NN	O	O
.	SIMPONI.xml:S3:13974:1	.	.	O	O

5.6	SIMPONI.xml:S3:13983:3	5.6	CD	O	O
Use	SIMPONI.xml:S3:13987:3	use	NNP	O	O
with	SIMPONI.xml:S3:13991:4	with	IN	O	O
Anakinra	SIMPONI.xml:S3:13996:8	anakinra	NNP	O	O

Concurrent	SIMPONI.xml:S3:14010:10	concurr	JJ	O	O
administration	SIMPONI.xml:S3:14021:14	administr	NN	O	O
of	SIMPONI.xml:S3:14036:2	of	IN	O	O
anakinra	SIMPONI.xml:S3:14039:8	anakinra	NN	O	O
(	SIMPONI.xml:S3:14048:1	(	(	O	O
an	SIMPONI.xml:S3:14049:2	an	DT	O	O
interleukin	SIMPONI.xml:S3:14052:11	interleukin	NN	O	O
-	SIMPONI.xml:S3:14063:1	-	:	O	O
1	SIMPONI.xml:S3:14064:1	1	CD	O	O
antagonist	SIMPONI.xml:S3:14066:10	antagonist	NN	O	O
)	SIMPONI.xml:S3:14076:1	)	)	O	O
and	SIMPONI.xml:S3:14078:3	and	CC	O	O
another	SIMPONI.xml:S3:14082:7	anoth	DT	O	O
TNF	SIMPONI.xml:S3:14090:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:14093:1	-	:	O	O
blocker	SIMPONI.xml:S3:14094:7	blocker	NN	O	O
,	SIMPONI.xml:S3:14101:1	,	,	O	O
was	SIMPONI.xml:S3:14103:3	wa	VBD	O	O
associated	SIMPONI.xml:S3:14107:10	associ	VBN	O	O
with	SIMPONI.xml:S3:14118:4	with	IN	O	O
a	SIMPONI.xml:S3:14123:1	a	DT	O	O
greater	SIMPONI.xml:S3:14125:7	greater	JJR	O	O
portion	SIMPONI.xml:S3:14133:7	portion	NN	O	O
of	SIMPONI.xml:S3:14141:2	of	IN	O	O
serious	SIMPONI.xml:S3:14144:7	seriou	JJ	O	O
infections	SIMPONI.xml:S3:14152:10	infect	NNS	O	B-AdverseReaction
and	SIMPONI.xml:S3:14163:3	and	CC	O	O
neutropenia	SIMPONI.xml:S3:14167:11	neutropenia	NN	O	B-AdverseReaction
and	SIMPONI.xml:S3:14179:3	and	CC	O	O
no	SIMPONI.xml:S3:14183:2	no	DT	O	O
additional	SIMPONI.xml:S3:14186:10	addit	JJ	O	O
benefits	SIMPONI.xml:S3:14197:8	benefit	NNS	O	O
compared	SIMPONI.xml:S3:14206:8	compar	VBN	O	O
with	SIMPONI.xml:S3:14215:4	with	IN	O	O
the	SIMPONI.xml:S3:14220:3	the	DT	O	O
TNF	SIMPONI.xml:S3:14224:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:14227:1	-	:	O	O
blocker	SIMPONI.xml:S3:14228:7	blocker	NN	O	O
alone	SIMPONI.xml:S3:14236:5	alon	RB	O	O
.	SIMPONI.xml:S3:14241:1	.	.	O	O

Therefore	SIMPONI.xml:S3:14243:9	therefor	RB	O	O
,	SIMPONI.xml:S3:14252:1	,	,	O	O
the	SIMPONI.xml:S3:14254:3	the	DT	O	O
combination	SIMPONI.xml:S3:14258:11	combin	NN	O	O
of	SIMPONI.xml:S3:14270:2	of	IN	O	O
anakinra	SIMPONI.xml:S3:14273:8	anakinra	NN	O	O
with	SIMPONI.xml:S3:14282:4	with	IN	O	O
TNF	SIMPONI.xml:S3:14287:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:14290:1	-	:	O	O
blockers	SIMPONI.xml:S3:14291:8	blocker	NNS	O	O
,	SIMPONI.xml:S3:14299:1	,	,	O	O
including	SIMPONI.xml:S3:14301:9	includ	VBG	O	O
SIMPONI	SIMPONI.xml:S3:14311:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:14319:4	aria	NNP	O	O
,	SIMPONI.xml:S3:14323:1	,	,	O	O
is	SIMPONI.xml:S3:14325:2	is	VBZ	O	O
not	SIMPONI.xml:S3:14328:3	not	RB	O	O
recommended	SIMPONI.xml:S3:14332:11	recommend	JJ	O	O
[	SIMPONI.xml:S3:14344:1	[	NNS	O	O
see	SIMPONI.xml:S3:14345:3	see	VBP	O	O
Drug	SIMPONI.xml:S3:14350:4	drug	JJ	O	O
Interactions	SIMPONI.xml:S3:14355:12	interact	NNP	O	O
(	SIMPONI.xml:S3:14368:1	(	(	O	O
7.2	SIMPONI.xml:S3:14369:3	7.2	CD	O	O
)	SIMPONI.xml:S3:14372:1	)	)	O	O
]	SIMPONI.xml:S3:14375:1	]	NN	O	O
.	SIMPONI.xml:S3:14378:1	.	.	O	O

5.7	SIMPONI.xml:S3:14387:3	5.7	CD	O	O
Switching	SIMPONI.xml:S3:14391:9	switch	VBG	O	O
Between	SIMPONI.xml:S3:14401:7	between	NNP	O	O
Biological	SIMPONI.xml:S3:14409:10	biolog	NNP	O	O
Disease	SIMPONI.xml:S3:14420:7	diseas	NNP	O	O
Modifying	SIMPONI.xml:S3:14428:9	modifi	NNP	O	O
Antirheumatic	SIMPONI.xml:S3:14438:13	antirheumat	NNP	O	O
Drugs	SIMPONI.xml:S3:14452:5	drug	NNP	O	O
(	SIMPONI.xml:S3:14458:1	(	(	O	O
DMARDs	SIMPONI.xml:S3:14459:6	dmard	NNP	O	O
)	SIMPONI.xml:S3:14465:1	)	)	O	O

Care	SIMPONI.xml:S3:14472:4	care	NN	O	O
should	SIMPONI.xml:S3:14477:6	should	MD	O	O
be	SIMPONI.xml:S3:14484:2	be	VB	O	O
taken	SIMPONI.xml:S3:14487:5	taken	VBN	O	O
when	SIMPONI.xml:S3:14493:4	when	WRB	O	O
switching	SIMPONI.xml:S3:14498:9	switch	VBG	O	O
from	SIMPONI.xml:S3:14508:4	from	IN	O	O
one	SIMPONI.xml:S3:14513:3	one	CD	O	O
biologic	SIMPONI.xml:S3:14517:8	biolog	JJ	O	O
product	SIMPONI.xml:S3:14526:7	product	NN	O	O
to	SIMPONI.xml:S3:14534:2	to	TO	O	O
another	SIMPONI.xml:S3:14537:7	anoth	DT	O	O
biologic	SIMPONI.xml:S3:14545:8	biolog	NN	O	O
product	SIMPONI.xml:S3:14554:7	product	NN	O	O
since	SIMPONI.xml:S3:14562:5	sinc	IN	O	O
overlapping	SIMPONI.xml:S3:14568:11	overlap	VBG	O	O
biological	SIMPONI.xml:S3:14580:10	biolog	JJ	O	O
activity	SIMPONI.xml:S3:14591:8	activ	NN	O	O
may	SIMPONI.xml:S3:14600:3	may	MD	O	O
further	SIMPONI.xml:S3:14604:7	further	RBR	O	O
increase	SIMPONI.xml:S3:14612:8	increas	VB	O	O
the	SIMPONI.xml:S3:14621:3	the	DT	O	O
risk	SIMPONI.xml:S3:14625:4	risk	NN	O	O
of	SIMPONI.xml:S3:14630:2	of	IN	O	O
infection	SIMPONI.xml:S3:14633:9	infect	NN	O	O
.	SIMPONI.xml:S3:14642:1	.	.	O	O

5.8	SIMPONI.xml:S3:14651:3	5.8	CD	O	O
Hematologic	SIMPONI.xml:S3:14655:11	hematolog	NNP	O	O
Cytopenias	SIMPONI.xml:S3:14667:10	cytopenia	NNP	O	O

There	SIMPONI.xml:S3:14683:5	there	EX	O	O
have	SIMPONI.xml:S3:14689:4	have	VBP	O	O
been	SIMPONI.xml:S3:14694:4	been	VBN	O	O
post	SIMPONI.xml:S3:14699:4	post	VBN	O	O
-	SIMPONI.xml:S3:14703:1	-	:	O	O
marketing	SIMPONI.xml:S3:14704:9	market	NN	O	O
reports	SIMPONI.xml:S3:14714:7	report	NNS	O	O
of	SIMPONI.xml:S3:14722:2	of	IN	O	O
pancytopenia	SIMPONI.xml:S3:14725:12	pancytopenia	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:14737:1	,	,	O	O
leukopenia	SIMPONI.xml:S3:14739:10	leukopenia	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:14749:1	,	,	O	O
neutropenia	SIMPONI.xml:S3:14751:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:14762:1	,	,	O	O
aplastic	SIMPONI.xml:S3:14764:8	aplast	JJ	B-AdverseReaction	B-AdverseReaction
anemia	SIMPONI.xml:S3:14773:6	anemia	NN	I-AdverseReaction	I-AdverseReaction
,	SIMPONI.xml:S3:14779:1	,	,	O	O
and	SIMPONI.xml:S3:14781:3	and	CC	O	O
thrombocytopenia	SIMPONI.xml:S3:14785:16	thrombocytopenia	NN	B-AdverseReaction	B-AdverseReaction
in	SIMPONI.xml:S3:14802:2	in	IN	O	O
patients	SIMPONI.xml:S3:14805:8	patient	NNS	O	O
receiving	SIMPONI.xml:S3:14814:9	receiv	VBG	O	O
TNF	SIMPONI.xml:S3:14824:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:14827:1	-	:	O	O
blockers	SIMPONI.xml:S3:14828:8	blocker	NNS	O	O
.	SIMPONI.xml:S3:14836:1	.	.	O	O

In	SIMPONI.xml:S3:14838:2	In	IN	O	O
clinical	SIMPONI.xml:S3:14841:8	clinic	JJ	O	O
studies	SIMPONI.xml:S3:14850:7	studi	NNS	O	O
,	SIMPONI.xml:S3:14857:1	,	,	O	O
cases	SIMPONI.xml:S3:14859:5	case	NNS	O	O
of	SIMPONI.xml:S3:14865:2	of	IN	O	O
pancytopenia	SIMPONI.xml:S3:14868:12	pancytopenia	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:14880:1	,	,	O	O
leukopenia	SIMPONI.xml:S3:14882:10	leukopenia	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:14892:1	,	,	O	O
neutropenia	SIMPONI.xml:S3:14894:11	neutropenia	NN	B-AdverseReaction	B-AdverseReaction
,	SIMPONI.xml:S3:14905:1	,	,	O	O
and	SIMPONI.xml:S3:14907:3	and	CC	O	O
thrombocytopenia	SIMPONI.xml:S3:14911:16	thrombocytopenia	NNS	B-AdverseReaction	B-AdverseReaction
have	SIMPONI.xml:S3:14928:4	have	VBP	O	O
also	SIMPONI.xml:S3:14933:4	also	RB	O	O
occurred	SIMPONI.xml:S3:14938:8	occur	VBN	O	O
in	SIMPONI.xml:S3:14947:2	in	IN	O	O
SIMPONI	SIMPONI.xml:S3:14950:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:14958:4	aria	NNP	O	O
-	SIMPONI.xml:S3:14962:1	-	:	O	O
treated	SIMPONI.xml:S3:14963:7	treat	VBD	O	O
patients	SIMPONI.xml:S3:14971:8	patient	NNS	O	O
.	SIMPONI.xml:S3:14979:1	.	.	O	O

Caution	SIMPONI.xml:S3:14981:7	caution	NN	O	O
should	SIMPONI.xml:S3:14989:6	should	MD	O	O
be	SIMPONI.xml:S3:14996:2	be	VB	O	O
exercised	SIMPONI.xml:S3:14999:9	exercis	VBN	O	O
when	SIMPONI.xml:S3:15009:4	when	WRB	O	O
using	SIMPONI.xml:S3:15014:5	use	VBG	O	O
TNF	SIMPONI.xml:S3:15020:3	tnf	NNP	O	O
-	SIMPONI.xml:S3:15023:1	-	:	O	O
blockers	SIMPONI.xml:S3:15024:8	blocker	NNS	O	O
,	SIMPONI.xml:S3:15032:1	,	,	O	O
including	SIMPONI.xml:S3:15034:9	includ	VBG	O	O
SIMPONI	SIMPONI.xml:S3:15044:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:15052:4	aria	NNP	O	O
,	SIMPONI.xml:S3:15056:1	,	,	O	O
in	SIMPONI.xml:S3:15058:2	in	IN	O	O
patients	SIMPONI.xml:S3:15061:8	patient	NNS	O	O
who	SIMPONI.xml:S3:15070:3	who	WP	O	O
have	SIMPONI.xml:S3:15074:4	have	VBP	O	O
or	SIMPONI.xml:S3:15079:2	or	CC	O	O
have	SIMPONI.xml:S3:15082:4	have	VBP	O	O
had	SIMPONI.xml:S3:15087:3	had	VBN	O	O
significant	SIMPONI.xml:S3:15091:11	signific	JJ	O	O
cytopenias	SIMPONI.xml:S3:15103:10	cytopenia	NNS	O	O
.	SIMPONI.xml:S3:15113:1	.	.	O	O

5.9	SIMPONI.xml:S3:15122:3	5.9	CD	O	O
Vaccinations	SIMPONI.xml:S3:15126:12	vaccin	NNP	O	O
Therapeutic	SIMPONI.xml:S3:15139:11	therapeut	NNP	O	O
Infectious	SIMPONI.xml:S3:15151:10	infecti	NNP	O	O
Agents	SIMPONI.xml:S3:15162:6	agent	NNS	O	O

Live	SIMPONI.xml:S3:15176:4	live	JJ	O	O
Vaccines	SIMPONI.xml:S3:15181:8	vaccin	NNS	O	O

Patients	SIMPONI.xml:S3:15199:8	patient	NNS	O	O
treated	SIMPONI.xml:S3:15208:7	treat	VBN	O	O
with	SIMPONI.xml:S3:15216:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S3:15221:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:15229:4	aria	NNP	O	O
may	SIMPONI.xml:S3:15234:3	may	MD	O	O
receive	SIMPONI.xml:S3:15238:7	receiv	VB	O	O
vaccinations	SIMPONI.xml:S3:15246:12	vaccin	NNS	O	O
,	SIMPONI.xml:S3:15258:1	,	,	O	O
except	SIMPONI.xml:S3:15260:6	except	IN	O	O
for	SIMPONI.xml:S3:15267:3	for	IN	O	O
live	SIMPONI.xml:S3:15271:4	live	JJ	O	O
vaccines	SIMPONI.xml:S3:15276:8	vaccin	NNS	O	O
.	SIMPONI.xml:S3:15284:1	.	.	O	O

In	SIMPONI.xml:S3:15286:2	In	IN	O	O
patients	SIMPONI.xml:S3:15289:8	patient	NNS	O	O
receiving	SIMPONI.xml:S3:15298:9	receiv	VBG	O	O
anti	SIMPONI.xml:S3:15308:4	anti	JJ	O	O
-	SIMPONI.xml:S3:15312:1	-	:	O	O
TNF	SIMPONI.xml:S3:15313:3	tnf	NN	O	O
therapy	SIMPONI.xml:S3:15317:7	therapi	NN	O	O
,	SIMPONI.xml:S3:15324:1	,	,	O	O
limited	SIMPONI.xml:S3:15326:7	limit	VBN	O	O
data	SIMPONI.xml:S3:15334:4	data	NNS	O	O
are	SIMPONI.xml:S3:15339:3	are	VBP	O	O
available	SIMPONI.xml:S3:15343:9	avail	JJ	O	O
on	SIMPONI.xml:S3:15353:2	on	IN	O	O
the	SIMPONI.xml:S3:15356:3	the	DT	O	O
response	SIMPONI.xml:S3:15360:8	respons	NN	O	O
to	SIMPONI.xml:S3:15369:2	to	TO	O	O
live	SIMPONI.xml:S3:15372:4	live	VB	O	O
vaccination	SIMPONI.xml:S3:15377:11	vaccin	NN	O	O
,	SIMPONI.xml:S3:15388:1	,	,	O	O
or	SIMPONI.xml:S3:15390:2	or	CC	O	O
on	SIMPONI.xml:S3:15393:2	on	IN	O	O
the	SIMPONI.xml:S3:15396:3	the	DT	O	O
secondary	SIMPONI.xml:S3:15400:9	secondari	JJ	O	O
transmission	SIMPONI.xml:S3:15410:12	transmiss	NN	O	O
of	SIMPONI.xml:S3:15423:2	of	IN	O	O
infection	SIMPONI.xml:S3:15426:9	infect	NN	O	O
by	SIMPONI.xml:S3:15436:2	by	IN	O	O
live	SIMPONI.xml:S3:15439:4	live	JJ	O	O
vaccines	SIMPONI.xml:S3:15444:8	vaccin	NNS	O	O
.	SIMPONI.xml:S3:15452:1	.	.	O	O

Use	SIMPONI.xml:S3:15454:3	use	NNP	O	O
of	SIMPONI.xml:S3:15458:2	of	IN	O	O
live	SIMPONI.xml:S3:15461:4	live	JJ	O	O
vaccines	SIMPONI.xml:S3:15466:8	vaccin	NNS	O	O
could	SIMPONI.xml:S3:15475:5	could	MD	O	O
result	SIMPONI.xml:S3:15481:6	result	VB	O	O
in	SIMPONI.xml:S3:15488:2	in	IN	O	O
clinical	SIMPONI.xml:S3:15491:8	clinic	JJ	O	O
infections	SIMPONI.xml:S3:15500:10	infect	NNS	O	O
,	SIMPONI.xml:S3:15510:1	,	,	O	O
including	SIMPONI.xml:S3:15512:9	includ	VBG	O	O
disseminated	SIMPONI.xml:S3:15522:12	dissemin	JJ	O	B-AdverseReaction
infections	SIMPONI.xml:S3:15535:10	infect	NNS	O	I-AdverseReaction
.	SIMPONI.xml:S3:15545:1	.	.	O	O

Therapeutic	SIMPONI.xml:S3:15557:11	therapeut	JJ	O	O
Infectious	SIMPONI.xml:S3:15569:10	infecti	NNP	O	O
Agents	SIMPONI.xml:S3:15580:6	agent	NNS	O	O

Other	SIMPONI.xml:S3:15596:5	other	JJ	O	O
uses	SIMPONI.xml:S3:15602:4	use	NNS	O	O
of	SIMPONI.xml:S3:15607:2	of	IN	O	O
therapeutic	SIMPONI.xml:S3:15610:11	therapeut	JJ	O	O
infectious	SIMPONI.xml:S3:15622:10	infecti	JJ	O	O
agents	SIMPONI.xml:S3:15633:6	agent	NNS	O	O
such	SIMPONI.xml:S3:15640:4	such	JJ	O	O
as	SIMPONI.xml:S3:15645:2	as	IN	O	O
live	SIMPONI.xml:S3:15648:4	live	JJ	O	O
attenuated	SIMPONI.xml:S3:15653:10	attenu	VBN	O	O
bacteria	SIMPONI.xml:S3:15664:8	bacteria	NNS	O	O
(	SIMPONI.xml:S3:15673:1	(	(	O	O
e	SIMPONI.xml:S3:15674:1	e	NN	O	O
.	SIMPONI.xml:S3:15675:1	.	.	O	O
g	SIMPONI.xml:S3:15676:1	g	NN	O	O
.	SIMPONI.xml:S3:15677:1	.	.	O	O
,	SIMPONI.xml:S3:15678:1	,	,	O	O
BCG	SIMPONI.xml:S3:15680:3	bcg	NNP	O	O
bladder	SIMPONI.xml:S3:15684:7	bladder	NN	O	O
instillation	SIMPONI.xml:S3:15692:12	instil	NN	O	O
for	SIMPONI.xml:S3:15705:3	for	IN	O	O
the	SIMPONI.xml:S3:15709:3	the	DT	O	O
treatment	SIMPONI.xml:S3:15713:9	treatment	NN	O	O
of	SIMPONI.xml:S3:15723:2	of	IN	O	O
cancer	SIMPONI.xml:S3:15726:6	cancer	NN	O	O
)	SIMPONI.xml:S3:15732:1	)	)	O	O
could	SIMPONI.xml:S3:15734:5	could	MD	O	O
result	SIMPONI.xml:S3:15740:6	result	VB	O	O
in	SIMPONI.xml:S3:15747:2	in	IN	O	O
clinical	SIMPONI.xml:S3:15750:8	clinic	JJ	O	O
infections	SIMPONI.xml:S3:15759:10	infect	NNS	O	O
,	SIMPONI.xml:S3:15769:1	,	,	O	O
including	SIMPONI.xml:S3:15771:9	includ	VBG	O	O
disseminated	SIMPONI.xml:S3:15781:12	dissemin	JJ	O	B-AdverseReaction
infections	SIMPONI.xml:S3:15794:10	infect	NNS	O	I-AdverseReaction
.	SIMPONI.xml:S3:15804:1	.	.	O	O

It	SIMPONI.xml:S3:15806:2	It	PRP	O	O
is	SIMPONI.xml:S3:15809:2	is	VBZ	O	O
recommended	SIMPONI.xml:S3:15812:11	recommend	VBN	O	O
that	SIMPONI.xml:S3:15824:4	that	IN	O	O
therapeutic	SIMPONI.xml:S3:15829:11	therapeut	JJ	O	O
infectious	SIMPONI.xml:S3:15841:10	infecti	JJ	O	O
agents	SIMPONI.xml:S3:15852:6	agent	NNS	O	O
not	SIMPONI.xml:S3:15859:3	not	RB	O	O
be	SIMPONI.xml:S3:15863:2	be	VB	O	O
given	SIMPONI.xml:S3:15866:5	given	VBN	O	O
concurrently	SIMPONI.xml:S3:15872:12	concurr	RB	O	O
with	SIMPONI.xml:S3:15885:4	with	IN	O	O
SIMPONI	SIMPONI.xml:S3:15890:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:15898:4	aria	NNP	O	O
.	SIMPONI.xml:S3:15902:1	.	.	O	O

5.10	SIMPONI.xml:S3:15913:4	5.10	CD	O	O
Hypersensitivity	SIMPONI.xml:S3:15918:16	hypersensit	NNP	O	O
Reactions	SIMPONI.xml:S3:15935:9	reaction	NNP	O	O

In	SIMPONI.xml:S3:15950:2	In	IN	O	O
post	SIMPONI.xml:S3:15953:4	post	NN	O	O
-	SIMPONI.xml:S3:15957:1	-	:	O	O
marketing	SIMPONI.xml:S3:15958:9	market	NN	O	O
experience	SIMPONI.xml:S3:15968:10	experi	NN	O	O
,	SIMPONI.xml:S3:15978:1	,	,	O	O
serious	SIMPONI.xml:S3:15980:7	seriou	JJ	O	O
systemic	SIMPONI.xml:S3:15988:8	system	JJ	O	B-AdverseReaction
hypersensitivity	SIMPONI.xml:S3:15997:16	hypersensit	NN	B-AdverseReaction	I-AdverseReaction
reactions	SIMPONI.xml:S3:16014:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
(	SIMPONI.xml:S3:16024:1	(	(	O	O
including	SIMPONI.xml:S3:16025:9	includ	VBG	O	O
anaphylactic	SIMPONI.xml:S3:16035:12	anaphylact	JJ	B-AdverseReaction	B-AdverseReaction
reaction	SIMPONI.xml:S3:16048:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
)	SIMPONI.xml:S3:16056:1	)	)	O	O
have	SIMPONI.xml:S3:16058:4	have	VBP	O	O
been	SIMPONI.xml:S3:16063:4	been	VBN	O	O
reported	SIMPONI.xml:S3:16068:8	report	VBN	O	O
following	SIMPONI.xml:S3:16077:9	follow	VBG	O	O
administration	SIMPONI.xml:S3:16087:14	administr	NN	O	O
of	SIMPONI.xml:S3:16102:2	of	IN	O	O
the	SIMPONI.xml:S3:16105:3	the	DT	O	O
subcutaneous	SIMPONI.xml:S3:16109:12	subcutan	JJ	O	O
formulation	SIMPONI.xml:S3:16122:11	formul	NN	O	O
of	SIMPONI.xml:S3:16134:2	of	IN	O	O
golimumab	SIMPONI.xml:S3:16137:9	golimumab	NN	O	O
.	SIMPONI.xml:S3:16146:1	.	.	O	O

Some	SIMPONI.xml:S3:16148:4	some	DT	O	O
of	SIMPONI.xml:S3:16153:2	of	IN	O	O
these	SIMPONI.xml:S3:16156:5	these	DT	O	O
reactions	SIMPONI.xml:S3:16162:9	reaction	NNS	O	O
occurred	SIMPONI.xml:S3:16172:8	occur	VBD	O	O
after	SIMPONI.xml:S3:16181:5	after	IN	O	O
the	SIMPONI.xml:S3:16187:3	the	DT	O	O
first	SIMPONI.xml:S3:16191:5	first	JJ	O	O
administration	SIMPONI.xml:S3:16197:14	administr	NN	O	O
of	SIMPONI.xml:S3:16212:2	of	IN	O	O
golimumab	SIMPONI.xml:S3:16215:9	golimumab	NN	O	O
.	SIMPONI.xml:S3:16224:1	.	.	O	O

If	SIMPONI.xml:S3:16226:2	If	IN	O	O
an	SIMPONI.xml:S3:16229:2	an	DT	O	O
anaphylactic	SIMPONI.xml:S3:16232:12	anaphylact	JJ	O	O
or	SIMPONI.xml:S3:16245:2	or	CC	O	O
other	SIMPONI.xml:S3:16248:5	other	JJ	O	O
serious	SIMPONI.xml:S3:16254:7	seriou	JJ	O	O
allergic	SIMPONI.xml:S3:16262:8	allerg	JJ	O	O
reaction	SIMPONI.xml:S3:16271:8	reaction	NN	O	O
occurs	SIMPONI.xml:S3:16280:6	occur	NNS	O	O
,	SIMPONI.xml:S3:16286:1	,	,	O	O
administration	SIMPONI.xml:S3:16288:14	administr	NN	O	O
of	SIMPONI.xml:S3:16303:2	of	IN	O	O
SIMPONI	SIMPONI.xml:S3:16306:7	simponi	NNP	O	O
ARIA	SIMPONI.xml:S3:16314:4	aria	NNP	O	O
should	SIMPONI.xml:S3:16319:6	should	MD	O	O
be	SIMPONI.xml:S3:16326:2	be	VB	O	O
discontinued	SIMPONI.xml:S3:16329:12	discontinu	VBN	O	O
immediately	SIMPONI.xml:S3:16342:11	immedi	RB	O	O
and	SIMPONI.xml:S3:16354:3	and	CC	O	O
appropriate	SIMPONI.xml:S3:16358:11	appropri	JJ	O	O
therapy	SIMPONI.xml:S3:16370:7	therapi	NN	O	O
instituted	SIMPONI.xml:S3:16378:10	institut	VBD	O	O
.	SIMPONI.xml:S3:16388:1	.	.	O	O
6	SIRTURO.xml:S1:4:1	6	CD	O	O
ADVERSE	SIRTURO.xml:S1:6:7	advers	JJ	O	O
REACTIONS	SIRTURO.xml:S1:14:9	reaction	NN	O	O

The	SIRTURO.xml:S1:27:3	the	DT	O	O
following	SIRTURO.xml:S1:31:9	follow	VBG	O	O
serious	SIRTURO.xml:S1:41:7	seriou	JJ	O	O
adverse	SIRTURO.xml:S1:49:7	advers	JJ	O	O
reactions	SIRTURO.xml:S1:57:9	reaction	NNS	O	O
are	SIRTURO.xml:S1:67:3	are	VBP	O	O
discussed	SIRTURO.xml:S1:71:9	discuss	VBN	O	O
elsewhere	SIRTURO.xml:S1:81:9	elsewher	RB	O	O
in	SIRTURO.xml:S1:91:2	in	IN	O	O
the	SIRTURO.xml:S1:94:3	the	DT	O	O
labeling	SIRTURO.xml:S1:98:8	label	NN	O	O
:	SIRTURO.xml:S1:106:1	:	:	O	O

Increased	SIRTURO.xml:S1:115:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
mortality	SIRTURO.xml:S1:125:9	mortal	NN	I-AdverseReaction	I-AdverseReaction
[	SIRTURO.xml:S1:135:1	[	NNP	O	O
see	SIRTURO.xml:S1:136:3	see	VBP	O	O
Warnings	SIRTURO.xml:S1:141:8	warn	NNP	O	O
and	SIRTURO.xml:S1:150:3	and	CC	O	O
Precautions	SIRTURO.xml:S1:154:11	precaut	NNP	O	O
(	SIRTURO.xml:S1:166:1	(	(	O	O
5.1	SIRTURO.xml:S1:167:3	5.1	CD	O	O
)	SIRTURO.xml:S1:170:1	)	)	O	O
]	SIRTURO.xml:S1:173:1	]	NN	O	O

QT	SIRTURO.xml:S1:181:2	QT	NNP	B-AdverseReaction	B-AdverseReaction
Prolongation	SIRTURO.xml:S1:184:12	prolong	NNP	I-AdverseReaction	I-AdverseReaction
[	SIRTURO.xml:S1:197:1	[	NNP	O	O
see	SIRTURO.xml:S1:198:3	see	VBP	O	O
Warnings	SIRTURO.xml:S1:203:8	warn	NNP	O	O
and	SIRTURO.xml:S1:212:3	and	CC	O	O
Precautions	SIRTURO.xml:S1:216:11	precaut	NNP	O	O
(	SIRTURO.xml:S1:228:1	(	(	O	O
5.2	SIRTURO.xml:S1:229:3	5.2	CD	O	O
)	SIRTURO.xml:S1:232:1	)	)	O	O
and	SIRTURO.xml:S1:236:3	and	CC	O	O
Clinical	SIRTURO.xml:S1:242:8	clinic	JJ	O	O
Pharmacology	SIRTURO.xml:S1:251:12	pharmacolog	NNP	O	O
(	SIRTURO.xml:S1:264:1	(	(	O	O
12.2	SIRTURO.xml:S1:265:4	12.2	CD	O	O
)	SIRTURO.xml:S1:269:1	)	)	O	O
]	SIRTURO.xml:S1:272:1	]	NN	O	O

Hepatotoxicity	SIRTURO.xml:S1:280:14	hepatotox	NNP	B-AdverseReaction	B-AdverseReaction
[	SIRTURO.xml:S1:295:1	[	NNP	O	O
see	SIRTURO.xml:S1:296:3	see	VBP	O	O
Warnings	SIRTURO.xml:S1:301:8	warn	NNP	O	O
and	SIRTURO.xml:S1:310:3	and	CC	O	O
Precautions	SIRTURO.xml:S1:314:11	precaut	NNP	O	O
(	SIRTURO.xml:S1:326:1	(	(	O	O
5.3	SIRTURO.xml:S1:327:3	5.3	CD	O	O
)	SIRTURO.xml:S1:330:1	)	)	O	O
]	SIRTURO.xml:S1:333:1	]	NN	O	O

Drug	SIRTURO.xml:S1:341:4	drug	NN	O	B-AdverseReaction
Interactions	SIRTURO.xml:S1:346:12	interact	NNS	O	I-AdverseReaction
[	SIRTURO.xml:S1:359:1	[	VBP	O	O
see	SIRTURO.xml:S1:360:3	see	VBP	O	O
Warnings	SIRTURO.xml:S1:365:8	warn	NNS	O	O
and	SIRTURO.xml:S1:374:3	and	CC	O	O
Precautions	SIRTURO.xml:S1:378:11	precaut	NNP	O	O
(	SIRTURO.xml:S1:390:1	(	(	O	O
5.4	SIRTURO.xml:S1:391:3	5.4	CD	O	O
)	SIRTURO.xml:S1:394:1	)	)	O	O
]	SIRTURO.xml:S1:397:1	]	NN	O	O

The	SIRTURO.xml:S1:407:3	the	DT	O	O
most	SIRTURO.xml:S1:411:4	most	RBS	O	O
common	SIRTURO.xml:S1:416:6	common	JJ	O	O
adverse	SIRTURO.xml:S1:423:7	advers	JJ	O	O
reactions	SIRTURO.xml:S1:431:9	reaction	NNS	O	O
reported	SIRTURO.xml:S1:441:8	report	VBN	O	O
in	SIRTURO.xml:S1:450:2	in	IN	O	O
10%	SIRTURO.xml:S1:453:3	10%	CD	O	O
or	SIRTURO.xml:S1:457:2	or	CC	O	O
more	SIRTURO.xml:S1:460:4	more	JJR	O	O
of	SIRTURO.xml:S1:465:2	of	IN	O	O
patients	SIRTURO.xml:S1:468:8	patient	NNS	O	O
treated	SIRTURO.xml:S1:477:7	treat	VBN	O	O
with	SIRTURO.xml:S1:485:4	with	IN	O	O
SIRTURO	SIRTURO.xml:S1:490:7	sirturo	NNP	O	O
were	SIRTURO.xml:S1:498:4	were	VBD	O	O
nausea	SIRTURO.xml:S1:503:6	nausea	RB	B-AdverseReaction	B-AdverseReaction
,	SIRTURO.xml:S1:509:1	,	,	O	O
arthralgia	SIRTURO.xml:S1:511:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	SIRTURO.xml:S1:521:1	,	,	O	O
headache	SIRTURO.xml:S1:523:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	SIRTURO.xml:S1:531:1	,	,	O	O
hemoptysis	SIRTURO.xml:S1:533:10	hemoptysi	NN	B-AdverseReaction	B-AdverseReaction
and	SIRTURO.xml:S1:544:3	and	CC	O	O
chest	SIRTURO.xml:S1:548:5	chest	NN	B-AdverseReaction	B-AdverseReaction
pain	SIRTURO.xml:S1:554:4	pain	NN	I-AdverseReaction	I-AdverseReaction
.	SIRTURO.xml:S1:558:1	.	.	O	O

(	SIRTURO.xml:S1:560:1	(	(	O	O
6.1	SIRTURO.xml:S1:563:3	6.1	CD	O	O
)	SIRTURO.xml:S1:568:1	)	)	O	O

EXCERPT	SIRTURO.xml:S1:577:7	excerpt	NN	O	O
:	SIRTURO.xml:S1:584:1	:	:	O	O
To	SIRTURO.xml:S1:590:2	To	TO	O	O
report	SIRTURO.xml:S1:593:6	report	VB	O	O
SUSPECTED	SIRTURO.xml:S1:600:9	suspect	NNP	O	O
ADVERSE	SIRTURO.xml:S1:610:7	advers	NNP	O	O
REACTIONS	SIRTURO.xml:S1:618:9	reaction	NNP	O	O
,	SIRTURO.xml:S1:627:1	,	,	O	O
contact	SIRTURO.xml:S1:629:7	contact	NN	O	O
Janssen	SIRTURO.xml:S1:637:7	janssen	NNP	O	O
Therapeutics	SIRTURO.xml:S1:645:12	therapeut	NNP	O	O
,	SIRTURO.xml:S1:657:1	,	,	O	O
Division	SIRTURO.xml:S1:659:8	divis	NNP	O	O
of	SIRTURO.xml:S1:668:2	of	IN	O	O
Janssen	SIRTURO.xml:S1:671:7	janssen	NNP	O	O
Products	SIRTURO.xml:S1:679:8	product	NNP	O	O
,	SIRTURO.xml:S1:687:1	,	,	O	O
LP	SIRTURO.xml:S1:689:2	LP	NNP	O	O
at	SIRTURO.xml:S1:695:2	at	IN	O	O
1	SIRTURO.xml:S1:698:1	1	CD	O	O
-	SIRTURO.xml:S1:699:1	-	:	O	O
800	SIRTURO.xml:S1:700:3	800	CD	O	O
-	SIRTURO.xml:S1:703:1	-	:	O	O
JANSSEN	SIRTURO.xml:S1:704:7	janssen	NNP	O	O
(	SIRTURO.xml:S1:712:1	(	(	O	O
1	SIRTURO.xml:S1:713:1	1	CD	O	O
-	SIRTURO.xml:S1:714:1	-	:	O	O
800	SIRTURO.xml:S1:715:3	800	CD	O	O
-	SIRTURO.xml:S1:718:1	-	:	O	O
526	SIRTURO.xml:S1:719:3	526	CD	O	O
-	SIRTURO.xml:S1:722:1	-	:	O	O
7736	SIRTURO.xml:S1:723:4	7736	CD	O	O
)	SIRTURO.xml:S1:731:1	)	)	O	O
or	SIRTURO.xml:S1:733:2	or	CC	O	O
FDA	SIRTURO.xml:S1:736:3	fda	NNP	O	O
at	SIRTURO.xml:S1:740:2	at	IN	O	O
1	SIRTURO.xml:S1:743:1	1	CD	O	O
-	SIRTURO.xml:S1:744:1	-	:	O	O
800	SIRTURO.xml:S1:745:3	800	CD	O	O
-	SIRTURO.xml:S1:748:1	-	:	O	O
FDA	SIRTURO.xml:S1:749:3	fda	NNP	O	O
-	SIRTURO.xml:S1:752:1	-	:	O	O
1088	SIRTURO.xml:S1:753:4	1088	CD	O	O
or	SIRTURO.xml:S1:758:2	or	CC	O	O
www	SIRTURO.xml:S1:764:3	www	VB	O	O
.	SIRTURO.xml:S1:767:1	.	.	O	O
fda	SIRTURO.xml:S1:768:3	fda	NN	O	O
.	SIRTURO.xml:S1:771:1	.	.	O	O
gov	SIRTURO.xml:S1:772:3	gov	JJ	O	O
medwatch	SIRTURO.xml:S1:776:8	medwatch	NN	O	O
.	SIRTURO.xml:S1:786:1	.	.	O	O

6.1	SIRTURO.xml:S1:800:3	6.1	CD	O	O

Clinical	SIRTURO.xml:S1:804:8	clinic	JJ	O	O

Studies	SIRTURO.xml:S1:813:7	studi	NNS	O	O
Experience	SIRTURO.xml:S1:821:10	experi	NNP	O	O

Because	SIRTURO.xml:S1:835:7	becaus	IN	O	O
clinical	SIRTURO.xml:S1:843:8	clinic	JJ	O	O
studies	SIRTURO.xml:S1:852:7	studi	NNS	O	O
are	SIRTURO.xml:S1:860:3	are	VBP	O	O
conducted	SIRTURO.xml:S1:864:9	conduct	VBN	O	O
under	SIRTURO.xml:S1:874:5	under	IN	O	O
widely	SIRTURO.xml:S1:880:6	wide	RB	O	O
varying	SIRTURO.xml:S1:887:7	vari	VBG	O	O
conditions	SIRTURO.xml:S1:895:10	condit	NNS	O	O
,	SIRTURO.xml:S1:905:1	,	,	O	O
adverse	SIRTURO.xml:S1:907:7	advers	JJ	O	O
reaction	SIRTURO.xml:S1:915:8	reaction	NN	O	O
rates	SIRTURO.xml:S1:924:5	rate	NNS	O	O
observed	SIRTURO.xml:S1:930:8	observ	VBD	O	O
in	SIRTURO.xml:S1:939:2	in	IN	O	O
the	SIRTURO.xml:S1:942:3	the	DT	O	O
clinical	SIRTURO.xml:S1:946:8	clinic	JJ	O	O
studies	SIRTURO.xml:S1:955:7	studi	NNS	O	O
of	SIRTURO.xml:S1:963:2	of	IN	O	O
a	SIRTURO.xml:S1:966:1	a	DT	O	O
drug	SIRTURO.xml:S1:968:4	drug	NN	O	O
cannot	SIRTURO.xml:S1:973:6	cannot	NN	O	O
be	SIRTURO.xml:S1:980:2	be	VB	O	O
directly	SIRTURO.xml:S1:983:8	directli	RB	O	O
compared	SIRTURO.xml:S1:992:8	compar	VBN	O	O
to	SIRTURO.xml:S1:1001:2	to	TO	O	O
the	SIRTURO.xml:S1:1004:3	the	DT	O	O
rates	SIRTURO.xml:S1:1008:5	rate	NNS	O	O
in	SIRTURO.xml:S1:1014:2	in	IN	O	O
the	SIRTURO.xml:S1:1017:3	the	DT	O	O
clinical	SIRTURO.xml:S1:1021:8	clinic	JJ	O	O
studies	SIRTURO.xml:S1:1030:7	studi	NNS	O	O
of	SIRTURO.xml:S1:1038:2	of	IN	O	O
another	SIRTURO.xml:S1:1041:7	anoth	DT	O	O
drug	SIRTURO.xml:S1:1049:4	drug	NN	O	O
and	SIRTURO.xml:S1:1054:3	and	CC	O	O
may	SIRTURO.xml:S1:1058:3	may	MD	O	O
not	SIRTURO.xml:S1:1062:3	not	RB	O	O
reflect	SIRTURO.xml:S1:1066:7	reflect	VB	O	O
the	SIRTURO.xml:S1:1074:3	the	DT	O	O
rates	SIRTURO.xml:S1:1078:5	rate	NNS	O	O
observed	SIRTURO.xml:S1:1084:8	observ	VBD	O	O
in	SIRTURO.xml:S1:1093:2	in	IN	O	O
clinical	SIRTURO.xml:S1:1096:8	clinic	JJ	O	O
practice	SIRTURO.xml:S1:1105:8	practic	NN	O	O
.	SIRTURO.xml:S1:1113:1	.	.	O	O

Adverse	SIRTURO.xml:S1:1119:7	advers	JJ	O	O
drug	SIRTURO.xml:S1:1127:4	drug	NN	O	O
reactions	SIRTURO.xml:S1:1132:9	reaction	NNS	O	O
for	SIRTURO.xml:S1:1142:3	for	IN	O	O
SIRTURO	SIRTURO.xml:S1:1146:7	sirturo	NNP	O	O
were	SIRTURO.xml:S1:1154:4	were	VBD	O	O
identified	SIRTURO.xml:S1:1159:10	identifi	VBN	O	O
from	SIRTURO.xml:S1:1170:4	from	IN	O	O
the	SIRTURO.xml:S1:1175:3	the	DT	O	O
pooled	SIRTURO.xml:S1:1179:6	pool	JJ	O	O
safety	SIRTURO.xml:S1:1186:6	safeti	NN	O	O
data	SIRTURO.xml:S1:1193:4	data	NNS	O	O
from	SIRTURO.xml:S1:1198:4	from	IN	O	O
335	SIRTURO.xml:S1:1203:3	335	CD	O	O
SIRTURO	SIRTURO.xml:S1:1207:7	sirturo	NNP	O	O
-	SIRTURO.xml:S1:1214:1	-	:	O	O
exposed	SIRTURO.xml:S1:1215:7	expos	JJ	O	O
patients	SIRTURO.xml:S1:1223:8	patient	NNS	O	O
who	SIRTURO.xml:S1:1232:3	who	WP	O	O
received	SIRTURO.xml:S1:1236:8	receiv	VBD	O	O
8	SIRTURO.xml:S1:1245:1	8	CD	O	O
weeks	SIRTURO.xml:S1:1247:5	week	NNS	O	O
(	SIRTURO.xml:S1:1253:1	(	(	O	O
Study	SIRTURO.xml:S1:1254:5	studi	NNP	O	O
2	SIRTURO.xml:S1:1260:1	2	CD	O	O
)	SIRTURO.xml:S1:1261:1	)	)	O	O
and	SIRTURO.xml:S1:1263:3	and	CC	O	O
24	SIRTURO.xml:S1:1267:2	24	CD	O	O
weeks	SIRTURO.xml:S1:1270:5	week	NNS	O	O
(	SIRTURO.xml:S1:1276:1	(	(	O	O
Studies	SIRTURO.xml:S1:1277:7	studi	NNPS	O	O
1	SIRTURO.xml:S1:1285:1	1	CD	O	O
and	SIRTURO.xml:S1:1287:3	and	CC	O	O
3	SIRTURO.xml:S1:1291:1	3	CD	O	O
)	SIRTURO.xml:S1:1292:1	)	)	O	O
at	SIRTURO.xml:S1:1294:2	at	IN	O	O
the	SIRTURO.xml:S1:1297:3	the	DT	O	O
proposed	SIRTURO.xml:S1:1301:8	propos	VBN	O	O
dose	SIRTURO.xml:S1:1310:4	dose	NN	O	O
.	SIRTURO.xml:S1:1314:1	.	.	O	O

Studies	SIRTURO.xml:S1:1316:7	studi	NNS	O	O
1	SIRTURO.xml:S1:1324:1	1	CD	O	O
and	SIRTURO.xml:S1:1326:3	and	CC	O	O
2	SIRTURO.xml:S1:1330:1	2	CD	O	O
were	SIRTURO.xml:S1:1332:4	were	VBD	O	O
randomized	SIRTURO.xml:S1:1337:10	random	VBN	O	O
,	SIRTURO.xml:S1:1347:1	,	,	O	O
double	SIRTURO.xml:S1:1349:6	doubl	JJ	O	O
-	SIRTURO.xml:S1:1355:1	-	:	O	O
blind	SIRTURO.xml:S1:1356:5	blind	NN	O	O
,	SIRTURO.xml:S1:1361:1	,	,	O	O
placebo	SIRTURO.xml:S1:1363:7	placebo	SYM	O	O
-	SIRTURO.xml:S1:1370:1	-	:	O	O
controlled	SIRTURO.xml:S1:1371:10	control	VBN	O	O
trial	SIRTURO.xml:S1:1382:5	trial	NN	O	O
in	SIRTURO.xml:S1:1388:2	in	IN	O	O
newly	SIRTURO.xml:S1:1391:5	newli	RB	O	O
diagnosed	SIRTURO.xml:S1:1397:9	diagnos	VBN	O	O
patients	SIRTURO.xml:S1:1407:8	patient	NNS	O	O
with	SIRTURO.xml:S1:1416:4	with	IN	O	O
pulmonary	SIRTURO.xml:S1:1421:9	pulmonari	JJ	O	O
MDR	SIRTURO.xml:S1:1431:3	mdr	NNP	O	O
-	SIRTURO.xml:S1:1434:1	-	:	O	O
TB	SIRTURO.xml:S1:1435:2	TB	NN	O	O
.	SIRTURO.xml:S1:1437:1	.	.	O	O

In	SIRTURO.xml:S1:1439:2	In	IN	O	O
both	SIRTURO.xml:S1:1442:4	both	DT	O	O
treatment	SIRTURO.xml:S1:1447:9	treatment	NN	O	O
arms	SIRTURO.xml:S1:1457:4	arm	NNS	O	O
,	SIRTURO.xml:S1:1461:1	,	,	O	O
patients	SIRTURO.xml:S1:1463:8	patient	NNS	O	O
received	SIRTURO.xml:S1:1472:8	receiv	VBD	O	O
SIRTURO	SIRTURO.xml:S1:1481:7	sirturo	NNP	O	O
or	SIRTURO.xml:S1:1489:2	or	CC	O	O
placebo	SIRTURO.xml:S1:1492:7	placebo	NN	O	O
in	SIRTURO.xml:S1:1500:2	in	IN	O	O
combination	SIRTURO.xml:S1:1503:11	combin	NN	O	O
with	SIRTURO.xml:S1:1515:4	with	IN	O	O
other	SIRTURO.xml:S1:1520:5	other	JJ	O	O
drugs	SIRTURO.xml:S1:1526:5	drug	NNS	O	O
used	SIRTURO.xml:S1:1532:4	use	VBN	O	O
to	SIRTURO.xml:S1:1537:2	to	TO	O	O
treat	SIRTURO.xml:S1:1540:5	treat	VB	O	O
MDR	SIRTURO.xml:S1:1546:3	mdr	NNP	O	O
-	SIRTURO.xml:S1:1549:1	-	:	O	O
TB	SIRTURO.xml:S1:1550:2	TB	NN	O	O
.	SIRTURO.xml:S1:1552:1	.	.	O	O

Study	SIRTURO.xml:S1:1554:5	studi	NNP	O	O
3	SIRTURO.xml:S1:1560:1	3	CD	O	O
was	SIRTURO.xml:S1:1562:3	wa	VBD	O	O
an	SIRTURO.xml:S1:1566:2	an	DT	O	O
open	SIRTURO.xml:S1:1569:4	open	JJ	O	O
-	SIRTURO.xml:S1:1573:1	-	:	O	O
label	SIRTURO.xml:S1:1574:5	label	NN	O	O
,	SIRTURO.xml:S1:1579:1	,	,	O	O
noncomparative	SIRTURO.xml:S1:1581:14	noncompar	JJ	O	O
study	SIRTURO.xml:S1:1596:5	studi	NN	O	O
with	SIRTURO.xml:S1:1602:4	with	IN	O	O
SIRTURO	SIRTURO.xml:S1:1607:7	sirturo	NNP	O	O
administered	SIRTURO.xml:S1:1615:12	administ	VBD	O	O
as	SIRTURO.xml:S1:1628:2	as	IN	O	O
part	SIRTURO.xml:S1:1631:4	part	NN	O	O
of	SIRTURO.xml:S1:1636:2	of	IN	O	O
an	SIRTURO.xml:S1:1639:2	an	DT	O	O
individualized	SIRTURO.xml:S1:1642:14	individu	JJ	O	O
pulmonary	SIRTURO.xml:S1:1657:9	pulmonari	NN	O	O
MDR	SIRTURO.xml:S1:1667:3	mdr	NNP	O	O
-	SIRTURO.xml:S1:1670:1	-	:	O	O
TB	SIRTURO.xml:S1:1671:2	TB	NN	O	O
treatment	SIRTURO.xml:S1:1674:9	treatment	NN	O	O
regimen	SIRTURO.xml:S1:1684:7	regimen	NNS	O	O
in	SIRTURO.xml:S1:1692:2	in	IN	O	O
previously	SIRTURO.xml:S1:1695:10	previous	RB	O	O
treated	SIRTURO.xml:S1:1706:7	treat	VBN	O	O
patients	SIRTURO.xml:S1:1714:8	patient	NNS	O	O
.	SIRTURO.xml:S1:1722:1	.	.	O	O

In	SIRTURO.xml:S1:1728:2	In	IN	O	O
Study	SIRTURO.xml:S1:1731:5	studi	NNP	O	O
1	SIRTURO.xml:S1:1737:1	1	CD	O	O
,	SIRTURO.xml:S1:1738:1	,	,	O	O
35%	SIRTURO.xml:S1:1740:3	35%	CD	O	O
were	SIRTURO.xml:S1:1744:4	were	VBD	O	O
Black	SIRTURO.xml:S1:1749:5	black	NNP	O	O
,	SIRTURO.xml:S1:1754:1	,	,	O	O
17.5%	SIRTURO.xml:S1:1756:5	17.5%	CD	O	O
were	SIRTURO.xml:S1:1762:4	were	VBD	O	O
Hispanic	SIRTURO.xml:S1:1767:8	hispan	NNP	O	O
,	SIRTURO.xml:S1:1775:1	,	,	O	O
12.5%	SIRTURO.xml:S1:1777:5	12.5%	CD	O	O
were	SIRTURO.xml:S1:1783:4	were	VBD	O	O
White	SIRTURO.xml:S1:1788:5	white	NNP	O	O
,	SIRTURO.xml:S1:1793:1	,	,	O	O
9.4%	SIRTURO.xml:S1:1795:4	9.4%	CD	O	O
were	SIRTURO.xml:S1:1800:4	were	VBD	O	O
Asian	SIRTURO.xml:S1:1805:5	asian	JJ	O	O
,	SIRTURO.xml:S1:1810:1	,	,	O	O
and	SIRTURO.xml:S1:1812:3	and	CC	O	O
25.6%	SIRTURO.xml:S1:1816:5	25.6%	CD	O	O
were	SIRTURO.xml:S1:1822:4	were	VBD	O	O
of	SIRTURO.xml:S1:1827:2	of	IN	O	O
another	SIRTURO.xml:S1:1830:7	anoth	DT	O	O
race	SIRTURO.xml:S1:1838:4	race	NN	O	O
.	SIRTURO.xml:S1:1842:1	.	.	O	O

Eight	SIRTURO.xml:S1:1844:5	eight	CD	O	O
of	SIRTURO.xml:S1:1850:2	of	IN	O	O
79	SIRTURO.xml:S1:1853:2	79	CD	O	O
(	SIRTURO.xml:S1:1856:1	(	(	O	O
10.1%	SIRTURO.xml:S1:1857:5	10.1%	CD	O	O
)	SIRTURO.xml:S1:1862:1	)	)	O	O
patients	SIRTURO.xml:S1:1864:8	patient	NNS	O	O
in	SIRTURO.xml:S1:1873:2	in	IN	O	O
the	SIRTURO.xml:S1:1876:3	the	DT	O	O
SIRTURO	SIRTURO.xml:S1:1880:7	sirturo	NNP	O	O
group	SIRTURO.xml:S1:1888:5	group	NN	O	O
and	SIRTURO.xml:S1:1894:3	and	CC	O	O
16	SIRTURO.xml:S1:1898:2	16	CD	O	O
of	SIRTURO.xml:S1:1901:2	of	IN	O	O
81	SIRTURO.xml:S1:1904:2	81	CD	O	O
(	SIRTURO.xml:S1:1907:1	(	(	O	O
19.8%	SIRTURO.xml:S1:1908:5	19.8%	CD	O	O
)	SIRTURO.xml:S1:1913:1	)	)	O	O
patients	SIRTURO.xml:S1:1915:8	patient	NNS	O	O
in	SIRTURO.xml:S1:1924:2	in	IN	O	O
the	SIRTURO.xml:S1:1927:3	the	DT	O	O
placebo	SIRTURO.xml:S1:1931:7	placebo	NN	O	O
treatment	SIRTURO.xml:S1:1939:9	treatment	NN	O	O
group	SIRTURO.xml:S1:1949:5	group	NN	O	O
were	SIRTURO.xml:S1:1955:4	were	VBD	O	O
HIV	SIRTURO.xml:S1:1960:3	hiv	NNP	O	O
-	SIRTURO.xml:S1:1963:1	-	:	O	O
infected	SIRTURO.xml:S1:1964:8	infect	VBN	O	O
.	SIRTURO.xml:S1:1972:1	.	.	O	O

Seven	SIRTURO.xml:S1:1974:5	seven	NNP	O	O
(	SIRTURO.xml:S1:1980:1	(	(	O	O
8.9%	SIRTURO.xml:S1:1981:4	8.9%	CD	O	O
)	SIRTURO.xml:S1:1985:1	)	)	O	O
SIRTURO	SIRTURO.xml:S1:1987:7	sirturo	NNP	O	O
-	SIRTURO.xml:S1:1994:1	-	:	O	O
treated	SIRTURO.xml:S1:1995:7	treat	VBD	O	O
patients	SIRTURO.xml:S1:2003:8	patient	NNS	O	O
and	SIRTURO.xml:S1:2012:3	and	CC	O	O
six	SIRTURO.xml:S1:2016:3	six	CD	O	O
(	SIRTURO.xml:S1:2020:1	(	(	O	O
7.4%	SIRTURO.xml:S1:2021:4	7.4%	CD	O	O
)	SIRTURO.xml:S1:2025:1	)	)	O	O
placebo	SIRTURO.xml:S1:2027:7	placebo	NN	O	O
-	SIRTURO.xml:S1:2034:1	-	:	O	O
treated	SIRTURO.xml:S1:2035:7	treat	JJ	O	O
patients	SIRTURO.xml:S1:2043:8	patient	NNS	O	O
discontinued	SIRTURO.xml:S1:2052:12	discontinu	VBN	O	O
Study	SIRTURO.xml:S1:2065:5	studi	NNP	O	O
1	SIRTURO.xml:S1:2071:1	1	CD	O	O
because	SIRTURO.xml:S1:2073:7	becaus	IN	O	O
of	SIRTURO.xml:S1:2081:2	of	IN	O	O
an	SIRTURO.xml:S1:2084:2	an	DT	O	O
adverse	SIRTURO.xml:S1:2087:7	advers	JJ	O	O
reaction	SIRTURO.xml:S1:2095:8	reaction	NN	O	O
.	SIRTURO.xml:S1:2103:1	.	.	O	O

Table	SIRTURO.xml:S1:2109:5	tabl	JJ	O	O
1	SIRTURO.xml:S1:2115:1	1	CD	O	O
:	SIRTURO.xml:S1:2116:1	:	:	O	O
Select	SIRTURO.xml:S1:2118:6	select	JJ	O	O
Adverse	SIRTURO.xml:S1:2125:7	advers	NNP	O	O
Reactions	SIRTURO.xml:S1:2133:9	reaction	NNP	O	O
from	SIRTURO.xml:S1:2143:4	from	IN	O	O
Study	SIRTURO.xml:S1:2148:5	studi	NNP	O	O
1	SIRTURO.xml:S1:2154:1	1	CD	O	O
That	SIRTURO.xml:S1:2156:4	that	WDT	O	O
Occurred	SIRTURO.xml:S1:2161:8	occur	VBD	O	O
More	SIRTURO.xml:S1:2170:4	more	RBR	O	O
Frequently	SIRTURO.xml:S1:2175:10	frequent	RB	O	O
Than	SIRTURO.xml:S1:2186:4	than	NNP	O	O
Placebo	SIRTURO.xml:S1:2191:7	placebo	NNP	O	O
During	SIRTURO.xml:S1:2199:6	dure	IN	O	O
Treatment	SIRTURO.xml:S1:2206:9	treatment	NNP	O	O
with	SIRTURO.xml:S1:2216:4	with	IN	O	O
SIRTURO	SIRTURO.xml:S1:2221:7	sirturo	NNP	O	O

Adverse	SIRTURO.xml:S1:2231:7	advers	JJ	O	O
Reactions	SIRTURO.xml:S1:2239:9	reaction	NNP	O	O
SIRTURO	SIRTURO.xml:S1:2267:7	sirturo	NNP	O	O
Treatment	SIRTURO.xml:S1:2275:9	treatment	NNP	O	O
GroupN	SIRTURO.xml:S1:2285:6	groupn	NNP	O	O
79	SIRTURO.xml:S1:2292:2	79	CD	O	O
n	SIRTURO.xml:S1:2294:1	n	NN	O	O
(	SIRTURO.xml:S1:2296:1	(	(	O	O
)	SIRTURO.xml:S1:2298:1	)	)	O	O
Placebo	SIRTURO.xml:S1:2302:7	placebo	NNP	O	O
Treatment	SIRTURO.xml:S1:2310:9	treatment	NNP	O	O
GroupN	SIRTURO.xml:S1:2320:6	groupn	NNP	O	O
81	SIRTURO.xml:S1:2327:2	81	CD	O	O
n	SIRTURO.xml:S1:2329:1	n	NN	O	O
(	SIRTURO.xml:S1:2331:1	(	(	O	O
)	SIRTURO.xml:S1:2333:1	)	)	O	O

Nausea	SIRTURO.xml:S1:2343:6	nausea	NN	B-AdverseReaction	B-AdverseReaction

30	SIRTURO.xml:S1:2391:2	30	CD	O	O
(	SIRTURO.xml:S1:2394:1	(	(	O	O
38	SIRTURO.xml:S1:2395:2	38	CD	O	O
)	SIRTURO.xml:S1:2397:1	)	)	O	O
26	SIRTURO.xml:S1:2427:2	26	CD	O	O
(	SIRTURO.xml:S1:2430:1	(	(	O	O
32	SIRTURO.xml:S1:2431:2	32	CD	O	O
)	SIRTURO.xml:S1:2433:1	)	)	O	O

Arthralgia	SIRTURO.xml:S1:2452:10	arthralgia	$	B-AdverseReaction	B-AdverseReaction
26	SIRTURO.xml:S1:2500:2	26	CD	O	O
(	SIRTURO.xml:S1:2503:1	(	(	O	O
33	SIRTURO.xml:S1:2504:2	33	CD	O	O
)	SIRTURO.xml:S1:2506:1	)	)	O	O
18	SIRTURO.xml:S1:2536:2	18	CD	O	O
(	SIRTURO.xml:S1:2539:1	(	(	O	O
22	SIRTURO.xml:S1:2540:2	22	CD	O	O
)	SIRTURO.xml:S1:2542:1	)	)	O	O

Headache	SIRTURO.xml:S1:2561:8	headach	$	B-AdverseReaction	B-AdverseReaction
22	SIRTURO.xml:S1:2609:2	22	CD	O	O
(	SIRTURO.xml:S1:2612:1	(	(	O	O
28	SIRTURO.xml:S1:2613:2	28	CD	O	O
)	SIRTURO.xml:S1:2615:1	)	)	O	O
10	SIRTURO.xml:S1:2645:2	10	CD	O	O
(	SIRTURO.xml:S1:2648:1	(	(	O	O
12	SIRTURO.xml:S1:2649:2	12	CD	O	O
)	SIRTURO.xml:S1:2651:1	)	)	O	O

Hemoptysis	SIRTURO.xml:S1:2670:10	hemoptysi	NN	B-AdverseReaction	B-AdverseReaction
14	SIRTURO.xml:S1:2718:2	14	CD	O	O
(	SIRTURO.xml:S1:2721:1	(	(	O	O
18	SIRTURO.xml:S1:2722:2	18	CD	O	O
)	SIRTURO.xml:S1:2724:1	)	)	O	O
9	SIRTURO.xml:S1:2754:1	9	CD	O	O
(	SIRTURO.xml:S1:2756:1	(	(	O	O
11	SIRTURO.xml:S1:2757:2	11	CD	O	O
)	SIRTURO.xml:S1:2759:1	)	)	O	O

Chest	SIRTURO.xml:S1:2779:5	chest	NNP	B-AdverseReaction	B-AdverseReaction
Pain	SIRTURO.xml:S1:2785:4	pain	NNP	I-AdverseReaction	I-AdverseReaction
9	SIRTURO.xml:S1:2828:1	9	CD	O	O
(	SIRTURO.xml:S1:2830:1	(	(	O	O
11	SIRTURO.xml:S1:2831:2	11	CD	O	O
)	SIRTURO.xml:S1:2833:1	)	)	O	O
6	SIRTURO.xml:S1:2864:1	6	CD	O	O
(	SIRTURO.xml:S1:2866:1	(	(	O	O
7	SIRTURO.xml:S1:2867:1	7	CD	O	O
)	SIRTURO.xml:S1:2868:1	)	)	O	O

Anorexia	SIRTURO.xml:S1:2888:8	anorexia	$	B-AdverseReaction	B-AdverseReaction
7	SIRTURO.xml:S1:2937:1	7	CD	O	O
(	SIRTURO.xml:S1:2939:1	(	(	O	O
9	SIRTURO.xml:S1:2940:1	9	CD	O	O
)	SIRTURO.xml:S1:2941:1	)	)	O	O
3	SIRTURO.xml:S1:2973:1	3	CD	O	O
(	SIRTURO.xml:S1:2975:1	(	(	O	O
4	SIRTURO.xml:S1:2976:1	4	CD	O	O
)	SIRTURO.xml:S1:2977:1	)	)	O	O

Transaminases	SIRTURO.xml:S1:2997:13	transaminas	NNS	B-AdverseReaction	B-AdverseReaction
Increased	SIRTURO.xml:S1:3011:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
7	SIRTURO.xml:S1:3046:1	7	CD	O	O
(	SIRTURO.xml:S1:3048:1	(	(	O	O
9	SIRTURO.xml:S1:3049:1	9	CD	O	O
)	SIRTURO.xml:S1:3050:1	)	)	O	O
1	SIRTURO.xml:S1:3082:1	1	CD	O	O
(	SIRTURO.xml:S1:3084:1	(	(	O	O
1	SIRTURO.xml:S1:3085:1	1	CD	O	O
)	SIRTURO.xml:S1:3086:1	)	)	O	O

Rash	SIRTURO.xml:S1:3106:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
6	SIRTURO.xml:S1:3155:1	6	CD	O	O
(	SIRTURO.xml:S1:3157:1	(	(	O	O
8	SIRTURO.xml:S1:3158:1	8	CD	O	O
)	SIRTURO.xml:S1:3159:1	)	)	O	O
3	SIRTURO.xml:S1:3191:1	3	CD	O	O
(	SIRTURO.xml:S1:3193:1	(	(	O	O
4	SIRTURO.xml:S1:3194:1	4	CD	O	O
)	SIRTURO.xml:S1:3195:1	)	)	O	O

Blood	SIRTURO.xml:S1:3215:5	blood	NNP	B-AdverseReaction	B-AdverseReaction
Amylase	SIRTURO.xml:S1:3221:7	amylas	NNP	I-AdverseReaction	I-AdverseReaction
Increased	SIRTURO.xml:S1:3229:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
2	SIRTURO.xml:S1:3264:1	2	CD	O	O
(	SIRTURO.xml:S1:3266:1	(	(	O	O
3	SIRTURO.xml:S1:3267:1	3	CD	O	O
)	SIRTURO.xml:S1:3268:1	)	)	O	O
1	SIRTURO.xml:S1:3300:1	1	CD	O	O
(	SIRTURO.xml:S1:3302:1	(	(	O	O
1	SIRTURO.xml:S1:3303:1	1	CD	O	O
)	SIRTURO.xml:S1:3304:1	)	)	O	O

No	SIRTURO.xml:S1:3332:2	No	DT	O	O
additional	SIRTURO.xml:S1:3335:10	addit	JJ	O	O
unique	SIRTURO.xml:S1:3346:6	uniqu	JJ	O	O
Adverse	SIRTURO.xml:S1:3353:7	advers	JJ	O	O
Reactions	SIRTURO.xml:S1:3361:9	reaction	NNPS	O	O
were	SIRTURO.xml:S1:3371:4	were	VBD	O	O
identified	SIRTURO.xml:S1:3376:10	identifi	VBN	O	O
from	SIRTURO.xml:S1:3387:4	from	IN	O	O
the	SIRTURO.xml:S1:3392:3	the	DT	O	O
uncontrolled	SIRTURO.xml:S1:3396:12	uncontrol	JJ	O	O
Study	SIRTURO.xml:S1:3409:5	studi	NNP	O	O
3	SIRTURO.xml:S1:3415:1	3	CD	O	O
.	SIRTURO.xml:S1:3416:1	.	.	O	O

In	SIRTURO.xml:S1:3422:2	In	IN	O	O

both	SIRTURO.xml:S1:3425:4	both	DT	O	O
Studies	SIRTURO.xml:S1:3430:7	studi	NNP	O	O
1	SIRTURO.xml:S1:3438:1	1	CD	O	O
and	SIRTURO.xml:S1:3440:3	and	CC	O	O
2	SIRTURO.xml:S1:3444:1	2	CD	O	O
,	SIRTURO.xml:S1:3445:1	,	,	O	O
aminotransferase	SIRTURO.xml:S1:3447:16	aminotransferas	JJ	B-AdverseReaction	O
elevations	SIRTURO.xml:S1:3464:10	elev	NNS	I-AdverseReaction	O
of	SIRTURO.xml:S1:3475:2	of	IN	O	O
at	SIRTURO.xml:S1:3478:2	at	IN	O	O
least	SIRTURO.xml:S1:3481:5	least	JJS	O	O
3	SIRTURO.xml:S1:3487:1	3	CD	O	O
times	SIRTURO.xml:S1:3489:5	time	NNS	O	O
the	SIRTURO.xml:S1:3495:3	the	DT	O	O
upper	SIRTURO.xml:S1:3499:5	upper	JJ	O	O
limit	SIRTURO.xml:S1:3505:5	limit	NN	O	O
of	SIRTURO.xml:S1:3511:2	of	IN	O	O
normal	SIRTURO.xml:S1:3514:6	normal	JJ	O	O
developed	SIRTURO.xml:S1:3521:9	develop	VBD	O	O
more	SIRTURO.xml:S1:3531:4	more	RBR	O	O
frequently	SIRTURO.xml:S1:3536:10	frequent	RB	O	O
in	SIRTURO.xml:S1:3547:2	in	IN	O	O
the	SIRTURO.xml:S1:3550:3	the	DT	O	O
SIRTURO	SIRTURO.xml:S1:3554:7	sirturo	NNP	O	O
treatment	SIRTURO.xml:S1:3562:9	treatment	NN	O	O
group	SIRTURO.xml:S1:3572:5	group	NN	O	O
(	SIRTURO.xml:S1:3578:1	(	(	O	O
11	SIRTURO.xml:S1:3579:2	11	CD	O	O
102	SIRTURO.xml:S1:3582:3	102	CD	O	O
[	SIRTURO.xml:S1:3586:1	[	JJ	O	O
10.8%	SIRTURO.xml:S1:3587:5	10.8%	CD	O	O
]	SIRTURO.xml:S1:3592:1	]	JJ	O	O
vs	SIRTURO.xml:S1:3594:2	vs	NN	O	O
6	SIRTURO.xml:S1:3597:1	6	CD	O	O
105	SIRTURO.xml:S1:3599:3	105	CD	O	O
[	SIRTURO.xml:S1:3603:1	[	JJ	O	O
5.7%	SIRTURO.xml:S1:3604:4	5.7%	CD	O	O
])	SIRTURO.xml:S1:3608:2	])	NN	O	O
than	SIRTURO.xml:S1:3611:4	than	IN	O	O
in	SIRTURO.xml:S1:3616:2	in	IN	O	O
the	SIRTURO.xml:S1:3619:3	the	DT	O	O
placebo	SIRTURO.xml:S1:3623:7	placebo	NN	O	O
treatment	SIRTURO.xml:S1:3631:9	treatment	NN	O	O
group	SIRTURO.xml:S1:3641:5	group	NN	O	O
.	SIRTURO.xml:S1:3646:1	.	.	O	O

In	SIRTURO.xml:S1:3648:2	In	IN	O	O
Study	SIRTURO.xml:S1:3651:5	studi	NNP	O	O
3	SIRTURO.xml:S1:3657:1	3	CD	O	O
,	SIRTURO.xml:S1:3658:1	,	,	O	O
22	SIRTURO.xml:S1:3660:2	22	CD	O	O
230	SIRTURO.xml:S1:3663:3	230	CD	O	O
(	SIRTURO.xml:S1:3667:1	(	(	O	O
9.6%	SIRTURO.xml:S1:3668:4	9.6%	CD	O	O
)	SIRTURO.xml:S1:3672:1	)	)	O	O
patients	SIRTURO.xml:S1:3674:8	patient	NNS	O	O
had	SIRTURO.xml:S1:3683:3	had	VBD	O	O
alanine	SIRTURO.xml:S1:3687:7	alanin	JJ	B-AdverseReaction	O
aminotransferase	SIRTURO.xml:S1:3695:16	aminotransferas	NN	I-AdverseReaction	O
or	SIRTURO.xml:S1:3712:2	or	CC	O	O
aspartate	SIRTURO.xml:S1:3715:9	aspart	VB	B-AdverseReaction	O
aminotransferase	SIRTURO.xml:S1:3725:16	aminotransferas	NN	I-AdverseReaction	O
greater	SIRTURO.xml:S1:3742:7	greater	JJR	O	O
than	SIRTURO.xml:S1:3750:4	than	IN	O	O
or	SIRTURO.xml:S1:3755:2	or	CC	O	O
equal	SIRTURO.xml:S1:3758:5	equal	JJ	O	O
to	SIRTURO.xml:S1:3764:2	to	TO	O	O
3	SIRTURO.xml:S1:3767:1	3	CD	I-AdverseReaction	O
times	SIRTURO.xml:S1:3769:5	time	NNS	I-AdverseReaction	O
the	SIRTURO.xml:S1:3775:3	the	DT	I-AdverseReaction	O
upper	SIRTURO.xml:S1:3779:5	upper	JJ	I-AdverseReaction	O
limit	SIRTURO.xml:S1:3785:5	limit	NN	I-AdverseReaction	O
of	SIRTURO.xml:S1:3791:2	of	IN	I-AdverseReaction	O
normal	SIRTURO.xml:S1:3794:6	normal	JJ	I-AdverseReaction	O
during	SIRTURO.xml:S1:3801:6	dure	IN	O	O
the	SIRTURO.xml:S1:3808:3	the	DT	O	O
overall	SIRTURO.xml:S1:3812:7	overal	JJ	O	O
treatment	SIRTURO.xml:S1:3820:9	treatment	NN	O	O
period	SIRTURO.xml:S1:3830:6	period	NN	O	O
.	SIRTURO.xml:S1:3836:1	.	.	O	O

Increased	SIRTURO.xml:S1:3846:9	increas	VBN	O	O
Mortality	SIRTURO.xml:S1:3856:9	mortal	NN	O	O

In	SIRTURO.xml:S1:3872:2	In	IN	O	O
Study	SIRTURO.xml:S1:3875:5	studi	NNP	O	O
1	SIRTURO.xml:S1:3881:1	1	CD	O	O
,	SIRTURO.xml:S1:3882:1	,	,	O	O
there	SIRTURO.xml:S1:3884:5	there	EX	O	O
was	SIRTURO.xml:S1:3890:3	wa	VBD	O	O
a	SIRTURO.xml:S1:3894:1	a	DT	O	O
statistically	SIRTURO.xml:S1:3896:13	statist	RB	O	O
significant	SIRTURO.xml:S1:3910:11	signific	JJ	O	O
increased	SIRTURO.xml:S1:3922:9	increas	VBN	B-AdverseReaction	O
mortality	SIRTURO.xml:S1:3932:9	mortal	NN	I-AdverseReaction	O
risk	SIRTURO.xml:S1:3942:4	risk	NN	O	O
by	SIRTURO.xml:S1:3947:2	by	IN	O	O
Week	SIRTURO.xml:S1:3950:4	week	NNP	O	O
120	SIRTURO.xml:S1:3955:3	120	CD	O	O
in	SIRTURO.xml:S1:3959:2	in	IN	O	O
the	SIRTURO.xml:S1:3962:3	the	DT	O	O
SIRTURO	SIRTURO.xml:S1:3966:7	sirturo	NNP	O	O
treatment	SIRTURO.xml:S1:3974:9	treatment	NN	O	O
group	SIRTURO.xml:S1:3984:5	group	NN	O	O
compared	SIRTURO.xml:S1:3990:8	compar	VBN	O	O
to	SIRTURO.xml:S1:3999:2	to	TO	O	O
the	SIRTURO.xml:S1:4002:3	the	DT	O	O
placebo	SIRTURO.xml:S1:4006:7	placebo	NN	O	O
treatment	SIRTURO.xml:S1:4014:9	treatment	NN	O	O
group	SIRTURO.xml:S1:4024:5	group	NN	O	O
(	SIRTURO.xml:S1:4030:1	(	(	O	O
9	SIRTURO.xml:S1:4031:1	9	CD	O	O
79	SIRTURO.xml:S1:4033:2	79	CD	O	O
(	SIRTURO.xml:S1:4036:1	(	(	O	O
11.4%	SIRTURO.xml:S1:4037:5	11.4%	CD	O	O
)	SIRTURO.xml:S1:4042:1	)	)	O	O
versus	SIRTURO.xml:S1:4044:6	versu	NN	O	O
2	SIRTURO.xml:S1:4051:1	2	CD	O	O
81	SIRTURO.xml:S1:4053:2	81	CD	O	O
(	SIRTURO.xml:S1:4056:1	(	(	O	O
2.5%	SIRTURO.xml:S1:4057:4	2.5%	CD	O	O
)	SIRTURO.xml:S1:4061:1	)	)	O	O
,	SIRTURO.xml:S1:4062:1	,	,	O	O
p	SIRTURO.xml:S1:4064:1	p	SYM	O	O
-	SIRTURO.xml:S1:4065:1	-	:	O	O
value	SIRTURO.xml:S1:4066:5	valu	NN	O	O
0.03	SIRTURO.xml:S1:4072:4	0.03	CD	O	O
,	SIRTURO.xml:S1:4076:1	,	,	O	O
an	SIRTURO.xml:S1:4078:2	an	DT	O	O
exact	SIRTURO.xml:S1:4081:5	exact	JJ	O	O
95%	SIRTURO.xml:S1:4087:3	95%	CD	O	O
confidence	SIRTURO.xml:S1:4091:10	confid	NN	O	O
interval	SIRTURO.xml:S1:4102:8	interv	NN	O	O
of	SIRTURO.xml:S1:4111:2	of	IN	O	O
the	SIRTURO.xml:S1:4114:3	the	DT	O	O
difference	SIRTURO.xml:S1:4118:10	differ	NN	O	O
[	SIRTURO.xml:S1:4129:1	[	VBD	O	O
1.1%	SIRTURO.xml:S1:4130:4	1.1%	CD	O	O
,	SIRTURO.xml:S1:4134:1	,	,	O	O
18.2%	SIRTURO.xml:S1:4136:5	18.2%	CD	O	O
])	SIRTURO.xml:S1:4141:2	])	NN	O	O
.	SIRTURO.xml:S1:4143:1	.	.	O	O

Five	SIRTURO.xml:S1:4145:4	five	CD	O	O
of	SIRTURO.xml:S1:4150:2	of	IN	O	O
the	SIRTURO.xml:S1:4153:3	the	DT	O	O
9	SIRTURO.xml:S1:4157:1	9	CD	O	O
SIRTURO	SIRTURO.xml:S1:4159:7	sirturo	NNP	O	O
deaths	SIRTURO.xml:S1:4167:6	death	NNS	B-AdverseReaction	B-AdverseReaction
and	SIRTURO.xml:S1:4174:3	and	CC	O	O
the	SIRTURO.xml:S1:4178:3	the	DT	O	O
2	SIRTURO.xml:S1:4182:1	2	CD	O	O
placebo	SIRTURO.xml:S1:4184:7	placebo	NN	O	O
deaths	SIRTURO.xml:S1:4192:6	death	NNS	B-AdverseReaction	O
were	SIRTURO.xml:S1:4199:4	were	VBD	O	O
tuberculosis	SIRTURO.xml:S1:4204:12	tuberculosi	JJ	O	O
-	SIRTURO.xml:S1:4216:1	-	:	O	O
related	SIRTURO.xml:S1:4217:7	relat	VBN	O	O
.	SIRTURO.xml:S1:4224:1	.	.	O	O

One	SIRTURO.xml:S1:4226:3	one	CD	O	O
death	SIRTURO.xml:S1:4230:5	death	NN	B-AdverseReaction	B-AdverseReaction
occurred	SIRTURO.xml:S1:4236:8	occur	VBD	O	O
during	SIRTURO.xml:S1:4245:6	dure	IN	O	O
the	SIRTURO.xml:S1:4252:3	the	DT	O	O
24	SIRTURO.xml:S1:4256:2	24	CD	O	O
-	SIRTURO.xml:S1:4258:1	-	:	O	O
week	SIRTURO.xml:S1:4259:4	week	NN	O	O
SIRTURO	SIRTURO.xml:S1:4264:7	sirturo	NNP	O	O
treatment	SIRTURO.xml:S1:4272:9	treatment	NN	O	O
period	SIRTURO.xml:S1:4282:6	period	NN	O	O
.	SIRTURO.xml:S1:4288:1	.	.	O	O

The	SIRTURO.xml:S1:4290:3	the	DT	O	O
median	SIRTURO.xml:S1:4294:6	median	JJ	O	O
time	SIRTURO.xml:S1:4301:4	time	NN	O	O
to	SIRTURO.xml:S1:4306:2	to	TO	O	O
death	SIRTURO.xml:S1:4309:5	death	NN	B-AdverseReaction	B-AdverseReaction
for	SIRTURO.xml:S1:4315:3	for	IN	O	O
the	SIRTURO.xml:S1:4319:3	the	DT	O	O
remaining	SIRTURO.xml:S1:4323:9	remain	VBG	O	O
eight	SIRTURO.xml:S1:4333:5	eight	CD	O	O
subjects	SIRTURO.xml:S1:4339:8	subject	NNS	O	O
in	SIRTURO.xml:S1:4348:2	in	IN	O	O
the	SIRTURO.xml:S1:4351:3	the	DT	O	O
SIRTURO	SIRTURO.xml:S1:4355:7	sirturo	NNP	O	O
treatment	SIRTURO.xml:S1:4363:9	treatment	NN	O	O
group	SIRTURO.xml:S1:4373:5	group	NN	O	O
was	SIRTURO.xml:S1:4379:3	wa	VBD	O	O
329	SIRTURO.xml:S1:4383:3	329	CD	O	O
days	SIRTURO.xml:S1:4387:4	day	NNS	O	O
after	SIRTURO.xml:S1:4392:5	after	IN	O	O
last	SIRTURO.xml:S1:4398:4	last	JJ	O	O
intake	SIRTURO.xml:S1:4403:6	intak	NN	O	O
of	SIRTURO.xml:S1:4410:2	of	IN	O	O
SIRTURO	SIRTURO.xml:S1:4413:7	sirturo	NNP	O	O
.	SIRTURO.xml:S1:4420:1	.	.	O	O

The	SIRTURO.xml:S1:4422:3	the	DT	O	O
imbalance	SIRTURO.xml:S1:4426:9	imbal	NN	O	O
in	SIRTURO.xml:S1:4436:2	in	IN	O	O
deaths	SIRTURO.xml:S1:4439:6	death	NNS	B-AdverseReaction	B-AdverseReaction
is	SIRTURO.xml:S1:4446:2	is	VBZ	O	O
unexplained	SIRTURO.xml:S1:4449:11	unexplain	JJ	O	O
;	SIRTURO.xml:S1:4460:1	;	:	O	O
no	SIRTURO.xml:S1:4462:2	no	DT	O	O
discernible	SIRTURO.xml:S1:4465:11	discern	JJ	O	O
pattern	SIRTURO.xml:S1:4477:7	pattern	NN	O	O
between	SIRTURO.xml:S1:4485:7	between	IN	O	O
death	SIRTURO.xml:S1:4493:5	death	NN	B-AdverseReaction	B-AdverseReaction
and	SIRTURO.xml:S1:4499:3	and	CC	O	O
sputum	SIRTURO.xml:S1:4503:6	sputum	NN	O	B-AdverseReaction
conversion	SIRTURO.xml:S1:4510:10	convers	NN	O	I-AdverseReaction
,	SIRTURO.xml:S1:4520:1	,	,	O	O
relapse	SIRTURO.xml:S1:4522:7	relaps	NN	O	O
,	SIRTURO.xml:S1:4529:1	,	,	O	O
sensitivity	SIRTURO.xml:S1:4531:11	sensit	NN	O	O
to	SIRTURO.xml:S1:4543:2	to	TO	O	O
other	SIRTURO.xml:S1:4546:5	other	JJ	O	O
drugs	SIRTURO.xml:S1:4552:5	drug	NNS	O	O
used	SIRTURO.xml:S1:4558:4	use	VBN	O	O
to	SIRTURO.xml:S1:4563:2	to	TO	O	O
treat	SIRTURO.xml:S1:4566:5	treat	VB	O	O
tuberculosis	SIRTURO.xml:S1:4572:12	tuberculosi	NN	O	O
,	SIRTURO.xml:S1:4584:1	,	,	O	O
HIV	SIRTURO.xml:S1:4586:3	hiv	NNP	O	O
status	SIRTURO.xml:S1:4590:6	statu	NN	O	O
,	SIRTURO.xml:S1:4596:1	,	,	O	O
and	SIRTURO.xml:S1:4598:3	and	CC	O	O
severity	SIRTURO.xml:S1:4602:8	sever	NN	O	O
of	SIRTURO.xml:S1:4611:2	of	IN	O	O
disease	SIRTURO.xml:S1:4614:7	diseas	NN	O	O
was	SIRTURO.xml:S1:4622:3	wa	VBD	O	O
observed	SIRTURO.xml:S1:4626:8	observ	VBN	O	O
.	SIRTURO.xml:S1:4634:1	.	.	O	O

In	SIRTURO.xml:S1:4640:2	In	IN	O	O
the	SIRTURO.xml:S1:4643:3	the	DT	O	O
open	SIRTURO.xml:S1:4647:4	open	JJ	O	O
-	SIRTURO.xml:S1:4651:1	-	:	O	O
label	SIRTURO.xml:S1:4652:5	label	NN	O	O
Study	SIRTURO.xml:S1:4658:5	studi	NNP	O	O
3	SIRTURO.xml:S1:4664:1	3	CD	O	O
,	SIRTURO.xml:S1:4665:1	,	,	O	O
6.9%	SIRTURO.xml:S1:4667:4	6.9%	CD	O	O
(	SIRTURO.xml:S1:4672:1	(	(	O	O
16	SIRTURO.xml:S1:4673:2	16	CD	O	O
233	SIRTURO.xml:S1:4676:3	233	CD	O	O
)	SIRTURO.xml:S1:4679:1	)	)	O	O
subjects	SIRTURO.xml:S1:4681:8	subject	NNS	O	O
died	SIRTURO.xml:S1:4690:4	die	VBD	B-AdverseReaction	B-AdverseReaction
.	SIRTURO.xml:S1:4694:1	.	.	O	O

The	SIRTURO.xml:S1:4696:3	the	DT	O	O
most	SIRTURO.xml:S1:4700:4	most	RBS	O	O
common	SIRTURO.xml:S1:4705:6	common	JJ	O	O
cause	SIRTURO.xml:S1:4712:5	caus	NN	O	O
of	SIRTURO.xml:S1:4718:2	of	IN	O	O
death	SIRTURO.xml:S1:4721:5	death	NN	B-AdverseReaction	B-AdverseReaction
as	SIRTURO.xml:S1:4727:2	as	IN	O	O
reported	SIRTURO.xml:S1:4730:8	report	VBN	O	O
by	SIRTURO.xml:S1:4739:2	by	IN	O	O
the	SIRTURO.xml:S1:4742:3	the	DT	O	O
investigator	SIRTURO.xml:S1:4746:12	investig	NN	O	O
was	SIRTURO.xml:S1:4759:3	wa	VBD	O	O
TB	SIRTURO.xml:S1:4763:2	TB	NNP	O	B-AdverseReaction
(	SIRTURO.xml:S1:4766:1	(	(	O	O
9	SIRTURO.xml:S1:4767:1	9	CD	O	O
subjects	SIRTURO.xml:S1:4769:8	subject	NNS	O	O
)	SIRTURO.xml:S1:4777:1	)	)	O	O
.	SIRTURO.xml:S1:4778:1	.	.	O	O

All	SIRTURO.xml:S1:4780:3	all	DT	O	O
but	SIRTURO.xml:S1:4784:3	but	CC	O	O
one	SIRTURO.xml:S1:4788:3	one	CD	O	O
subject	SIRTURO.xml:S1:4792:7	subject	NN	O	O
who	SIRTURO.xml:S1:4800:3	who	WP	O	O
died	SIRTURO.xml:S1:4804:4	die	VBD	B-AdverseReaction	B-AdverseReaction
of	SIRTURO.xml:S1:4809:2	of	IN	O	O
TB	SIRTURO.xml:S1:4812:2	TB	NNP	O	B-AdverseReaction
had	SIRTURO.xml:S1:4815:3	had	VBD	O	O
not	SIRTURO.xml:S1:4819:3	not	RB	O	O
converted	SIRTURO.xml:S1:4823:9	convert	VBN	O	O
or	SIRTURO.xml:S1:4833:2	or	CC	O	O
had	SIRTURO.xml:S1:4836:3	had	VBD	O	O
relapsed	SIRTURO.xml:S1:4840:8	relaps	VBN	O	O
.	SIRTURO.xml:S1:4848:1	.	.	O	O

The	SIRTURO.xml:S1:4850:3	the	DT	O	O
causes	SIRTURO.xml:S1:4854:6	caus	NNS	O	O
of	SIRTURO.xml:S1:4861:2	of	IN	O	O
death	SIRTURO.xml:S1:4864:5	death	NN	B-AdverseReaction	B-AdverseReaction
in	SIRTURO.xml:S1:4870:2	in	IN	O	O
the	SIRTURO.xml:S1:4873:3	the	DT	O	O
remaining	SIRTURO.xml:S1:4877:9	remain	VBG	O	O
subjects	SIRTURO.xml:S1:4887:8	subject	NNS	O	O
varied	SIRTURO.xml:S1:4896:6	vari	VBN	O	O
.	SIRTURO.xml:S1:4902:1	.	.	O	O
\n\n	SIRTURO.xml:S2:0:2	\n\n	VB	O	O
BOXED	SIRTURO.xml:S2:6:5	box	NNP	O	O
WARNING	SIRTURO.xml:S2:12:7	warn	NNP	O	O
:	SIRTURO.xml:S2:19:1	:	:	O	O
WARNINGS	SIRTURO.xml:S2:21:8	warn	NN	O	O
:	SIRTURO.xml:S2:29:1	:	:	O	O
INCREASED	SIRTURO.xml:S2:31:9	increas	NNP	B-AdverseReaction	O
MORTALITY	SIRTURO.xml:S2:41:9	mortal	NNP	I-AdverseReaction	B-AdverseReaction
;	SIRTURO.xml:S2:50:1	;	:	O	O
QT	SIRTURO.xml:S2:52:2	QT	NNP	B-AdverseReaction	O
PROLONGATION	SIRTURO.xml:S2:55:12	prolong	NNP	I-AdverseReaction	O
\n\n	SIRTURO.xml:S2:67:2	\n\n	NNP	O	O
WARNINGS	SIRTURO.xml:S2:71:8	warn	NNP	O	O
:	SIRTURO.xml:S2:79:1	:	:	O	O
INCREASED	SIRTURO.xml:S2:81:9	increas	NNP	B-AdverseReaction	O
MORTALITY	SIRTURO.xml:S2:91:9	mortal	NNP	I-AdverseReaction	B-AdverseReaction
;	SIRTURO.xml:S2:100:1	;	:	O	O
QT	SIRTURO.xml:S2:102:2	QT	NNP	B-AdverseReaction	O
PROLONGATION	SIRTURO.xml:S2:105:12	prolong	NNP	I-AdverseReaction	O
\n\n	SIRTURO.xml:S2:117:2	\n\n	NNP	O	O
EXCERPT	SIRTURO.xml:S2:121:7	excerpt	NNP	O	O
:	SIRTURO.xml:S2:128:1	:	:	O	O
WARNINGS	SIRTURO.xml:S2:132:8	warn	NN	O	O
:	SIRTURO.xml:S2:140:1	:	:	O	O
INCREASED	SIRTURO.xml:S2:142:9	increas	NNP	B-AdverseReaction	O
MORTALITY	SIRTURO.xml:S2:152:9	mortal	NNP	I-AdverseReaction	B-AdverseReaction
;	SIRTURO.xml:S2:161:1	;	:	O	O
QT	SIRTURO.xml:S2:163:2	QT	NNP	B-AdverseReaction	O
PROLONGATION	SIRTURO.xml:S2:166:12	prolong	NNP	I-AdverseReaction	O
\n\n\n\n	SIRTURO.xml:S2:178:4	\n\n\n\n	NNP	O	O
See	SIRTURO.xml:S2:185:3	see	NNP	O	O
full	SIRTURO.xml:S2:189:4	full	JJ	O	O
prescribing	SIRTURO.xml:S2:194:11	prescrib	VBG	O	O
information	SIRTURO.xml:S2:206:11	inform	NN	O	O
for	SIRTURO.xml:S2:218:3	for	IN	O	O
complete	SIRTURO.xml:S2:222:8	complet	JJ	O	O
boxed	SIRTURO.xml:S2:231:5	box	JJ	O	O
warning	SIRTURO.xml:S2:237:7	warn	NN	O	O
.	SIRTURO.xml:S2:244:1	.	.	O	O

Increased	SIRTURO.xml:S2:254:9	increas	VBN	O	O
Mortality	SIRTURO.xml:S2:264:9	mortal	NNP	O	O
\n\n\n\n	SIRTURO.xml:S2:275:4	\n\n\n\n	NNP	O	O
An	SIRTURO.xml:S2:283:2	An	DT	O	O
increased	SIRTURO.xml:S2:286:9	increas	VBN	O	O
risk	SIRTURO.xml:S2:296:4	risk	NN	O	O
of	SIRTURO.xml:S2:301:2	of	IN	O	O
death	SIRTURO.xml:S2:304:5	death	NN	B-AdverseReaction	B-AdverseReaction
was	SIRTURO.xml:S2:310:3	wa	VBD	O	O
seen	SIRTURO.xml:S2:314:4	seen	VBN	O	O
in	SIRTURO.xml:S2:319:2	in	IN	O	O
the	SIRTURO.xml:S2:322:3	the	DT	O	O
SIRTURO	SIRTURO.xml:S2:326:7	sirturo	NNP	O	O
treatment	SIRTURO.xml:S2:334:9	treatment	NN	O	O
group	SIRTURO.xml:S2:344:5	group	NN	O	O
(	SIRTURO.xml:S2:350:1	(	(	O	O
9	SIRTURO.xml:S2:351:1	9	CD	O	O
79	SIRTURO.xml:S2:353:2	79	CD	O	O
,	SIRTURO.xml:S2:355:1	,	,	O	O
11.4%	SIRTURO.xml:S2:357:5	11.4%	CD	O	O
)	SIRTURO.xml:S2:362:1	)	)	O	O
compared	SIRTURO.xml:S2:364:8	compar	VBN	O	O
to	SIRTURO.xml:S2:373:2	to	TO	O	O
the	SIRTURO.xml:S2:376:3	the	DT	O	O
placebo	SIRTURO.xml:S2:380:7	placebo	NN	O	O
treatment	SIRTURO.xml:S2:388:9	treatment	NN	O	O
group	SIRTURO.xml:S2:398:5	group	NN	O	O
(	SIRTURO.xml:S2:404:1	(	(	O	O
2	SIRTURO.xml:S2:405:1	2	CD	O	O
81	SIRTURO.xml:S2:407:2	81	CD	O	O
,	SIRTURO.xml:S2:409:1	,	,	O	O
2.5%	SIRTURO.xml:S2:411:4	2.5%	CD	O	O
)	SIRTURO.xml:S2:415:1	)	)	O	O
in	SIRTURO.xml:S2:417:2	in	IN	O	O
one	SIRTURO.xml:S2:420:3	one	CD	O	O
placebo	SIRTURO.xml:S2:424:7	placebo	NN	O	O
-	SIRTURO.xml:S2:431:1	-	:	O	O
controlled	SIRTURO.xml:S2:432:10	control	VBN	O	O
trial	SIRTURO.xml:S2:443:5	trial	NN	O	O
.	SIRTURO.xml:S2:448:1	.	.	O	O

Only	SIRTURO.xml:S2:450:4	onli	RB	O	O
use	SIRTURO.xml:S2:455:3	use	NN	O	O
SIRTURO	SIRTURO.xml:S2:459:7	sirturo	NNP	O	O
when	SIRTURO.xml:S2:467:4	when	WRB	O	O
an	SIRTURO.xml:S2:472:2	an	DT	O	O
effective	SIRTURO.xml:S2:475:9	effect	JJ	O	O
treatment	SIRTURO.xml:S2:485:9	treatment	NN	O	O
regimen	SIRTURO.xml:S2:495:7	regimen	NNS	O	O
cannot	SIRTURO.xml:S2:503:6	cannot	VBP	O	O
otherwise	SIRTURO.xml:S2:510:9	otherwis	RB	O	O
be	SIRTURO.xml:S2:520:2	be	VB	O	O
provided	SIRTURO.xml:S2:523:8	provid	VBN	O	O
.	SIRTURO.xml:S2:531:1	.	.	O	O

(	SIRTURO.xml:S2:533:1	(	(	O	O
5.1	SIRTURO.xml:S2:534:3	5.1	CD	O	O
)	SIRTURO.xml:S2:537:1	)	)	O	O
\n	SIRTURO.xml:S2:539:1	\n	FW	O	O
QT	SIRTURO.xml:S2:546:2	QT	NNP	O	O
Prolongation	SIRTURO.xml:S2:549:12	prolong	NNP	O	O
\n	SIRTURO.xml:S2:563:1	\n	NNP	O	O
\n\n	SIRTURO.xml:S2:565:2	\n\n	NNP	O	O
QT	SIRTURO.xml:S2:571:2	QT	NNP	B-AdverseReaction	B-AdverseReaction
prolongation	SIRTURO.xml:S2:574:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
can	SIRTURO.xml:S2:587:3	can	MD	O	O
occur	SIRTURO.xml:S2:591:5	occur	VB	O	O
with	SIRTURO.xml:S2:597:4	with	IN	O	O
SIRTURO	SIRTURO.xml:S2:602:7	sirturo	NNP	O	O
.	SIRTURO.xml:S2:609:1	.	.	O	O

Use	SIRTURO.xml:S2:611:3	use	NNP	O	O
with	SIRTURO.xml:S2:615:4	with	IN	O	O
drugs	SIRTURO.xml:S2:620:5	drug	NNS	O	O
that	SIRTURO.xml:S2:626:4	that	WDT	O	O
prolong	SIRTURO.xml:S2:631:7	prolong	VBP	O	O
the	SIRTURO.xml:S2:639:3	the	DT	O	O
QT	SIRTURO.xml:S2:643:2	QT	NNP	O	O
interval	SIRTURO.xml:S2:646:8	interv	NN	O	O
may	SIRTURO.xml:S2:655:3	may	MD	O	O
cause	SIRTURO.xml:S2:659:5	caus	VB	O	O
additive	SIRTURO.xml:S2:665:8	addit	JJ	O	O
QT	SIRTURO.xml:S2:674:2	QT	NNP	B-AdverseReaction	O
prolongation	SIRTURO.xml:S2:677:12	prolong	NN	I-AdverseReaction	O
.	SIRTURO.xml:S2:689:1	.	.	O	O

Monitor	SIRTURO.xml:S2:691:7	monitor	NNP	O	O
ECGs	SIRTURO.xml:S2:699:4	ecg	NNP	O	O
.	SIRTURO.xml:S2:703:1	.	.	O	O

Discontinue	SIRTURO.xml:S2:705:11	discontinu	NNP	O	O
SIRTURO	SIRTURO.xml:S2:717:7	sirturo	NNP	O	O
if	SIRTURO.xml:S2:725:2	if	IN	O	O
significant	SIRTURO.xml:S2:728:11	signific	JJ	O	O
ventricular	SIRTURO.xml:S2:740:11	ventricular	JJ	O	O
arrhythmia	SIRTURO.xml:S2:752:10	arrhythmia	NN	O	O
or	SIRTURO.xml:S2:763:2	or	CC	O	O
QTcF	SIRTURO.xml:S2:766:4	qtcf	NNP	O	O
interval	SIRTURO.xml:S2:771:8	interv	JJ	O	O
500	SIRTURO.xml:S2:781:3	500	CD	O	O
ms	SIRTURO.xml:S2:785:2	ms	NN	O	O
develops	SIRTURO.xml:S2:788:8	develop	NNS	O	O
.	SIRTURO.xml:S2:796:1	.	.	O	O

(	SIRTURO.xml:S2:798:1	(	(	O	O
5.2	SIRTURO.xml:S2:799:3	5.2	CD	O	O
)	SIRTURO.xml:S2:802:1	)	)	O	O
\n	SIRTURO.xml:S2:804:1	\n	FW	O	O
\n	SIRTURO.xml:S2:809:1	\n	JJ	O	O
\n\n	SIRTURO.xml:S2:811:2	\n\n	NN	O	O
Increased	SIRTURO.xml:S2:817:9	increas	VBD	O	O
Mortality	SIRTURO.xml:S2:827:9	mortal	NNP	O	O
\n\n\n\n	SIRTURO.xml:S2:838:4	\n\n\n\n	NNP	O	O
An	SIRTURO.xml:S2:846:2	An	DT	O	O
increased	SIRTURO.xml:S2:849:9	increas	VBN	O	O
risk	SIRTURO.xml:S2:859:4	risk	NN	O	O
of	SIRTURO.xml:S2:864:2	of	IN	O	O
death	SIRTURO.xml:S2:867:5	death	NN	B-AdverseReaction	B-AdverseReaction
was	SIRTURO.xml:S2:873:3	wa	VBD	O	O
seen	SIRTURO.xml:S2:877:4	seen	VBN	O	O
in	SIRTURO.xml:S2:882:2	in	IN	O	O
the	SIRTURO.xml:S2:885:3	the	DT	O	O
SIRTURO	SIRTURO.xml:S2:889:7	sirturo	NNP	O	O
treatment	SIRTURO.xml:S2:897:9	treatment	NN	O	O
group	SIRTURO.xml:S2:907:5	group	NN	O	O
(	SIRTURO.xml:S2:913:1	(	(	O	O
9	SIRTURO.xml:S2:914:1	9	CD	O	O
79	SIRTURO.xml:S2:916:2	79	CD	O	O
,	SIRTURO.xml:S2:918:1	,	,	O	O
11.4%	SIRTURO.xml:S2:920:5	11.4%	CD	O	O
)	SIRTURO.xml:S2:925:1	)	)	O	O
compared	SIRTURO.xml:S2:927:8	compar	VBN	O	O
to	SIRTURO.xml:S2:936:2	to	TO	O	O
the	SIRTURO.xml:S2:939:3	the	DT	O	O
placebo	SIRTURO.xml:S2:943:7	placebo	NN	O	O
treatment	SIRTURO.xml:S2:951:9	treatment	NN	O	O
group	SIRTURO.xml:S2:961:5	group	NN	O	O
(	SIRTURO.xml:S2:967:1	(	(	O	O
2	SIRTURO.xml:S2:968:1	2	CD	O	O
81	SIRTURO.xml:S2:970:2	81	CD	O	O
,	SIRTURO.xml:S2:972:1	,	,	O	O
2.5%	SIRTURO.xml:S2:974:4	2.5%	CD	O	O
)	SIRTURO.xml:S2:978:1	)	)	O	O
in	SIRTURO.xml:S2:980:2	in	IN	O	O
one	SIRTURO.xml:S2:983:3	one	CD	O	O
placebo	SIRTURO.xml:S2:987:7	placebo	NN	O	O
-	SIRTURO.xml:S2:994:1	-	:	O	O
controlled	SIRTURO.xml:S2:995:10	control	VBN	O	O
trial	SIRTURO.xml:S2:1006:5	trial	NN	O	O
.	SIRTURO.xml:S2:1011:1	.	.	O	O

Only	SIRTURO.xml:S2:1013:4	onli	RB	O	O
use	SIRTURO.xml:S2:1018:3	use	NN	O	O
SIRTURO	SIRTURO.xml:S2:1022:7	sirturo	NNP	O	O
when	SIRTURO.xml:S2:1030:4	when	WRB	O	O
an	SIRTURO.xml:S2:1035:2	an	DT	O	O
effective	SIRTURO.xml:S2:1038:9	effect	JJ	O	O
treatment	SIRTURO.xml:S2:1048:9	treatment	NN	O	O
regimen	SIRTURO.xml:S2:1058:7	regimen	NNS	O	O
cannot	SIRTURO.xml:S2:1066:6	cannot	VBP	O	O
otherwise	SIRTURO.xml:S2:1073:9	otherwis	RB	O	O
be	SIRTURO.xml:S2:1083:2	be	VB	O	O
provided	SIRTURO.xml:S2:1086:8	provid	VBN	O	O
[	SIRTURO.xml:S2:1095:1	[	NNP	O	O
see	SIRTURO.xml:S2:1096:3	see	VBP	O	O
Indications	SIRTURO.xml:S2:1100:11	indic	NNP	O	O
and	SIRTURO.xml:S2:1112:3	and	CC	O	O
Usage	SIRTURO.xml:S2:1116:5	usag	NNP	O	O
(	SIRTURO.xml:S2:1122:1	(	(	O	O
1	SIRTURO.xml:S2:1123:1	1	CD	O	O
)	SIRTURO.xml:S2:1124:1	)	)	O	O
and	SIRTURO.xml:S2:1126:3	and	CC	O	O
Warnings	SIRTURO.xml:S2:1130:8	warn	NNP	O	O
and	SIRTURO.xml:S2:1139:3	and	CC	O	O
Precautions	SIRTURO.xml:S2:1143:11	precaut	NNP	O	O
(	SIRTURO.xml:S2:1155:1	(	(	O	O
5.1	SIRTURO.xml:S2:1156:3	5.1	CD	O	O
)]	SIRTURO.xml:S2:1159:2	)]	NN	O	O
.	SIRTURO.xml:S2:1161:1	.	.	O	O

QT	SIRTURO.xml:S2:1172:2	QT	NNP	O	O
Prolongation	SIRTURO.xml:S2:1175:12	prolong	NNP	O	O
\n	SIRTURO.xml:S2:1189:1	\n	NNP	O	O
\n\n	SIRTURO.xml:S2:1191:2	\n\n	NNP	O	O
QT	SIRTURO.xml:S2:1197:2	QT	NNP	B-AdverseReaction	B-AdverseReaction
prolongation	SIRTURO.xml:S2:1200:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
can	SIRTURO.xml:S2:1213:3	can	MD	O	O
occur	SIRTURO.xml:S2:1217:5	occur	VB	O	O
with	SIRTURO.xml:S2:1223:4	with	IN	O	O
SIRTURO	SIRTURO.xml:S2:1228:7	sirturo	NNP	O	O
.	SIRTURO.xml:S2:1235:1	.	.	O	O

Use	SIRTURO.xml:S2:1237:3	use	NNP	O	O
with	SIRTURO.xml:S2:1241:4	with	IN	O	O
drugs	SIRTURO.xml:S2:1246:5	drug	NNS	O	O
that	SIRTURO.xml:S2:1252:4	that	WDT	O	O
prolong	SIRTURO.xml:S2:1257:7	prolong	VBP	O	O
the	SIRTURO.xml:S2:1265:3	the	DT	O	O
QT	SIRTURO.xml:S2:1269:2	QT	NNP	O	O
interval	SIRTURO.xml:S2:1272:8	interv	NN	O	O
may	SIRTURO.xml:S2:1281:3	may	MD	O	O
cause	SIRTURO.xml:S2:1285:5	caus	VB	O	O
additive	SIRTURO.xml:S2:1291:8	addit	JJ	B-AdverseReaction	O
QT	SIRTURO.xml:S2:1300:2	QT	NNP	I-AdverseReaction	O
prolongation	SIRTURO.xml:S2:1303:12	prolong	NN	I-AdverseReaction	O
.	SIRTURO.xml:S2:1315:1	.	.	O	O

Monitor	SIRTURO.xml:S2:1317:7	monitor	NNP	O	O
ECGs	SIRTURO.xml:S2:1325:4	ecg	NNP	O	O
.	SIRTURO.xml:S2:1329:1	.	.	O	O

Discontinue	SIRTURO.xml:S2:1331:11	discontinu	NNP	O	O
SIRTURO	SIRTURO.xml:S2:1343:7	sirturo	NNP	O	O
if	SIRTURO.xml:S2:1351:2	if	IN	O	O
significant	SIRTURO.xml:S2:1354:11	signific	JJ	O	O
ventricular	SIRTURO.xml:S2:1366:11	ventricular	JJ	O	O
arrhythmia	SIRTURO.xml:S2:1378:10	arrhythmia	NN	O	O
or	SIRTURO.xml:S2:1389:2	or	CC	O	O
if	SIRTURO.xml:S2:1392:2	if	IN	O	O
QTcF	SIRTURO.xml:S2:1395:4	qtcf	NNP	O	O
interval	SIRTURO.xml:S2:1400:8	interv	JJ	O	O
prolongation	SIRTURO.xml:S2:1409:12	prolong	NN	O	O
of	SIRTURO.xml:S2:1422:2	of	IN	O	O
greater	SIRTURO.xml:S2:1425:7	greater	JJR	O	O
than	SIRTURO.xml:S2:1433:4	than	IN	O	O
500	SIRTURO.xml:S2:1438:3	500	CD	O	O
ms	SIRTURO.xml:S2:1442:2	ms	JJ	O	O
develops	SIRTURO.xml:S2:1445:8	develop	NNS	O	O
[	SIRTURO.xml:S2:1454:1	[	VBP	O	O
see	SIRTURO.xml:S2:1455:3	see	VBP	O	O
Warnings	SIRTURO.xml:S2:1459:8	warn	NNS	O	O
and	SIRTURO.xml:S2:1468:3	and	CC	O	O
Precautions	SIRTURO.xml:S2:1472:11	precaut	NNP	O	O
(	SIRTURO.xml:S2:1484:1	(	(	O	O
5.2	SIRTURO.xml:S2:1485:3	5.2	CD	O	O
)]	SIRTURO.xml:S2:1488:2	)]	NN	O	O
.	SIRTURO.xml:S2:1490:1	.	.	O	O
\n	SIRTURO.xml:S2:1492:1	\n	CC	O	O
5	SIRTURO.xml:S3:4:1	5	CD	O	O
WARNINGS	SIRTURO.xml:S3:6:8	warn	NNP	O	O
AND	SIRTURO.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	SIRTURO.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	SIRTURO.xml:S3:37:7	excerpt	NN	O	O
:	SIRTURO.xml:S3:44:1	:	:	O	O
QT	SIRTURO.xml:S3:52:2	QT	JJ	B-AdverseReaction	B-AdverseReaction
prolongation	SIRTURO.xml:S3:55:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
can	SIRTURO.xml:S3:68:3	can	MD	O	O
occur	SIRTURO.xml:S3:72:5	occur	VB	O	O
with	SIRTURO.xml:S3:78:4	with	IN	O	O
SIRTURO	SIRTURO.xml:S3:83:7	sirturo	NNP	O	O
.	SIRTURO.xml:S3:90:1	.	.	O	O

Monitor	SIRTURO.xml:S3:92:7	monitor	NNP	O	O
ECGs	SIRTURO.xml:S3:100:4	ecg	NNP	O	O
and	SIRTURO.xml:S3:105:3	and	CC	O	O
discontinue	SIRTURO.xml:S3:109:11	discontinu	VB	O	O
SIRTURO	SIRTURO.xml:S3:121:7	sirturo	NNP	O	O
if	SIRTURO.xml:S3:129:2	if	IN	O	O
significant	SIRTURO.xml:S3:132:11	signific	JJ	O	O
ventricular	SIRTURO.xml:S3:144:11	ventricular	JJ	O	O
arrhythmia	SIRTURO.xml:S3:156:10	arrhythmia	NN	O	O
or	SIRTURO.xml:S3:167:2	or	CC	O	O
QTcF	SIRTURO.xml:S3:170:4	qtcf	NNP	O	O
interval	SIRTURO.xml:S3:175:8	interv	JJ	O	O
500	SIRTURO.xml:S3:186:3	500	CD	O	O
ms	SIRTURO.xml:S3:190:2	ms	NN	O	O
develops	SIRTURO.xml:S3:193:8	develop	NNS	O	O
.	SIRTURO.xml:S3:201:1	.	.	O	O

(	SIRTURO.xml:S3:203:1	(	(	O	O
5.2	SIRTURO.xml:S3:206:3	5.2	CD	O	O
)	SIRTURO.xml:S3:211:1	)	)	O	O

Hepatotoxicity	SIRTURO.xml:S3:218:14	hepatotox	NN	B-AdverseReaction	B-AdverseReaction
may	SIRTURO.xml:S3:233:3	may	MD	O	O
occur	SIRTURO.xml:S3:237:5	occur	VB	O	O
with	SIRTURO.xml:S3:243:4	with	IN	O	O
use	SIRTURO.xml:S3:248:3	use	NN	O	O
of	SIRTURO.xml:S3:252:2	of	IN	O	O
SIRTURO	SIRTURO.xml:S3:255:7	sirturo	NNP	O	O
.	SIRTURO.xml:S3:262:1	.	.	O	O

Monitor	SIRTURO.xml:S3:264:7	monitor	NNP	O	O
liver	SIRTURO.xml:S3:272:5	liver	SYM	O	O
-	SIRTURO.xml:S3:277:1	-	:	O	O
related	SIRTURO.xml:S3:278:7	relat	JJ	O	O
laboratory	SIRTURO.xml:S3:286:10	laboratori	NN	O	O
tests	SIRTURO.xml:S3:297:5	test	NNS	O	O
.	SIRTURO.xml:S3:302:1	.	.	O	O

Discontinue	SIRTURO.xml:S3:304:11	discontinu	NN	O	O
if	SIRTURO.xml:S3:316:2	if	IN	O	O
evidence	SIRTURO.xml:S3:319:8	evid	NN	O	O
of	SIRTURO.xml:S3:328:2	of	IN	O	O
liver	SIRTURO.xml:S3:331:5	liver	JJ	O	O
injury	SIRTURO.xml:S3:337:6	injuri	NN	O	O
.	SIRTURO.xml:S3:343:1	.	.	O	O

(	SIRTURO.xml:S3:345:1	(	(	O	O
5.3	SIRTURO.xml:S3:348:3	5.3	CD	O	O
)	SIRTURO.xml:S3:353:1	)	)	O	O

5.1	SIRTURO.xml:S3:367:3	5.1	CD	O	O

Increased	SIRTURO.xml:S3:371:9	increas	VBN	O	O

Mortality	SIRTURO.xml:S3:381:9	mortal	NN	O	O

An	SIRTURO.xml:S3:396:2	An	DT	O	O
increased	SIRTURO.xml:S3:399:9	increas	VBN	O	O
risk	SIRTURO.xml:S3:409:4	risk	NN	O	O
of	SIRTURO.xml:S3:414:2	of	IN	O	O
death	SIRTURO.xml:S3:417:5	death	NN	B-AdverseReaction	B-AdverseReaction
was	SIRTURO.xml:S3:423:3	wa	VBD	O	O
seen	SIRTURO.xml:S3:427:4	seen	VBN	O	O
in	SIRTURO.xml:S3:432:2	in	IN	O	O
the	SIRTURO.xml:S3:435:3	the	DT	O	O
SIRTURO	SIRTURO.xml:S3:439:7	sirturo	NNP	O	O
treatment	SIRTURO.xml:S3:447:9	treatment	NN	O	O
group	SIRTURO.xml:S3:457:5	group	NN	O	O
(	SIRTURO.xml:S3:463:1	(	(	O	O
9	SIRTURO.xml:S3:464:1	9	CD	O	O
79	SIRTURO.xml:S3:466:2	79	CD	O	O
,	SIRTURO.xml:S3:468:1	,	,	O	O
11.4%	SIRTURO.xml:S3:470:5	11.4%	CD	O	O
)	SIRTURO.xml:S3:475:1	)	)	O	O
compared	SIRTURO.xml:S3:477:8	compar	VBN	O	O
to	SIRTURO.xml:S3:486:2	to	TO	O	O
the	SIRTURO.xml:S3:489:3	the	DT	O	O
placebo	SIRTURO.xml:S3:493:7	placebo	NN	O	O
treatment	SIRTURO.xml:S3:501:9	treatment	NN	O	O
group	SIRTURO.xml:S3:511:5	group	NN	O	O
(	SIRTURO.xml:S3:517:1	(	(	O	O
2	SIRTURO.xml:S3:518:1	2	CD	O	O
81	SIRTURO.xml:S3:520:2	81	CD	O	O
,	SIRTURO.xml:S3:522:1	,	,	O	O
2.5%	SIRTURO.xml:S3:524:4	2.5%	CD	O	O
)	SIRTURO.xml:S3:528:1	)	)	O	O
in	SIRTURO.xml:S3:530:2	in	IN	O	O
one	SIRTURO.xml:S3:533:3	one	CD	O	O
placebo	SIRTURO.xml:S3:537:7	placebo	NN	O	O
-	SIRTURO.xml:S3:544:1	-	:	O	O
controlled	SIRTURO.xml:S3:545:10	control	VBN	O	O
trial	SIRTURO.xml:S3:556:5	trial	NN	O	O
(	SIRTURO.xml:S3:562:1	(	(	O	O
based	SIRTURO.xml:S3:563:5	base	VBN	O	O
on	SIRTURO.xml:S3:569:2	on	IN	O	O
the	SIRTURO.xml:S3:572:3	the	DT	O	O
120	SIRTURO.xml:S3:576:3	120	CD	O	O
-	SIRTURO.xml:S3:579:1	-	:	O	O
week	SIRTURO.xml:S3:580:4	week	NN	O	O
visit	SIRTURO.xml:S3:585:5	visit	NN	O	O
window	SIRTURO.xml:S3:591:6	window	NN	O	O
)	SIRTURO.xml:S3:597:1	)	)	O	O
.	SIRTURO.xml:S3:598:1	.	.	O	O

One	SIRTURO.xml:S3:600:3	one	CD	O	O
death	SIRTURO.xml:S3:604:5	death	NN	B-AdverseReaction	B-AdverseReaction
occurred	SIRTURO.xml:S3:610:8	occur	VBD	O	O
during	SIRTURO.xml:S3:619:6	dure	IN	O	O
the	SIRTURO.xml:S3:626:3	the	DT	O	O
24	SIRTURO.xml:S3:630:2	24	CD	O	O
weeks	SIRTURO.xml:S3:633:5	week	NNS	O	O
of	SIRTURO.xml:S3:639:2	of	IN	O	O
administration	SIRTURO.xml:S3:642:14	administr	NN	O	O
of	SIRTURO.xml:S3:657:2	of	IN	O	O
SIRTURO	SIRTURO.xml:S3:660:7	sirturo	NNP	O	O
.	SIRTURO.xml:S3:667:1	.	.	O	O

The	SIRTURO.xml:S3:669:3	the	DT	O	O
imbalance	SIRTURO.xml:S3:673:9	imbal	NN	O	O
in	SIRTURO.xml:S3:683:2	in	IN	O	O
deaths	SIRTURO.xml:S3:686:6	death	NNS	B-AdverseReaction	B-AdverseReaction
is	SIRTURO.xml:S3:693:2	is	VBZ	O	O
unexplained	SIRTURO.xml:S3:696:11	unexplain	JJ	O	O
.	SIRTURO.xml:S3:707:1	.	.	O	O

No	SIRTURO.xml:S3:709:2	No	DT	O	O
discernible	SIRTURO.xml:S3:712:11	discern	JJ	O	O
pattern	SIRTURO.xml:S3:724:7	pattern	NN	O	O
between	SIRTURO.xml:S3:732:7	between	IN	O	O
death	SIRTURO.xml:S3:740:5	death	NN	B-AdverseReaction	B-AdverseReaction
and	SIRTURO.xml:S3:746:3	and	CC	O	O
sputum	SIRTURO.xml:S3:750:6	sputum	JJ	O	B-AdverseReaction
culture	SIRTURO.xml:S3:757:7	cultur	NN	O	I-AdverseReaction
conversion	SIRTURO.xml:S3:765:10	convers	NN	O	I-AdverseReaction
,	SIRTURO.xml:S3:775:1	,	,	O	O
relapse	SIRTURO.xml:S3:777:7	relaps	NN	O	O
,	SIRTURO.xml:S3:784:1	,	,	O	O
sensitivity	SIRTURO.xml:S3:786:11	sensit	NN	O	O
to	SIRTURO.xml:S3:798:2	to	TO	O	O
other	SIRTURO.xml:S3:801:5	other	JJ	O	O
drugs	SIRTURO.xml:S3:807:5	drug	NNS	O	O
used	SIRTURO.xml:S3:813:4	use	VBN	O	O
to	SIRTURO.xml:S3:818:2	to	TO	O	O
treat	SIRTURO.xml:S3:821:5	treat	VB	O	O
tuberculosis	SIRTURO.xml:S3:827:12	tuberculosi	NN	O	O
,	SIRTURO.xml:S3:839:1	,	,	O	O
HIV	SIRTURO.xml:S3:841:3	hiv	NNP	O	O
status	SIRTURO.xml:S3:845:6	statu	NN	O	O
,	SIRTURO.xml:S3:851:1	,	,	O	O
or	SIRTURO.xml:S3:853:2	or	CC	O	O
severity	SIRTURO.xml:S3:856:8	sever	NN	O	O
of	SIRTURO.xml:S3:865:2	of	IN	O	O
disease	SIRTURO.xml:S3:868:7	diseas	NN	O	O
could	SIRTURO.xml:S3:876:5	could	MD	O	O
be	SIRTURO.xml:S3:882:2	be	VB	O	O
observed	SIRTURO.xml:S3:885:8	observ	VBN	O	O
.	SIRTURO.xml:S3:893:1	.	.	O	O

Only	SIRTURO.xml:S3:895:4	onli	RB	O	O
use	SIRTURO.xml:S3:900:3	use	NN	O	O
SIRTURO	SIRTURO.xml:S3:904:7	sirturo	NNP	O	O
when	SIRTURO.xml:S3:912:4	when	WRB	O	O
an	SIRTURO.xml:S3:917:2	an	DT	O	O
effective	SIRTURO.xml:S3:920:9	effect	JJ	O	O
treatment	SIRTURO.xml:S3:930:9	treatment	NN	O	O
regimen	SIRTURO.xml:S3:940:7	regimen	NNS	O	O
cannot	SIRTURO.xml:S3:948:6	cannot	VBP	O	O
otherwise	SIRTURO.xml:S3:955:9	otherwis	RB	O	O
be	SIRTURO.xml:S3:965:2	be	VB	O	O
provided	SIRTURO.xml:S3:968:8	provid	VBN	O	O
[	SIRTURO.xml:S3:977:1	[	NNP	O	O
see	SIRTURO.xml:S3:978:3	see	VBP	O	O
Adverse	SIRTURO.xml:S3:983:7	advers	JJ	O	O
Reactions	SIRTURO.xml:S3:991:9	reaction	NNP	O	O
(	SIRTURO.xml:S3:1001:1	(	(	O	O
6	SIRTURO.xml:S3:1002:1	6	CD	O	O
)	SIRTURO.xml:S3:1003:1	)	)	O	O
]	SIRTURO.xml:S3:1006:1	]	NN	O	O
.	SIRTURO.xml:S3:1009:1	.	.	O	O

5.2	SIRTURO.xml:S3:1018:3	5.2	CD	O	O
QT	SIRTURO.xml:S3:1022:2	QT	NNP	O	O
Prolongation	SIRTURO.xml:S3:1025:12	prolong	NN	O	O

SIRTURO	SIRTURO.xml:S3:1043:7	sirturo	NNP	O	O
prolongs	SIRTURO.xml:S3:1051:8	prolong	VBZ	B-AdverseReaction	O
the	SIRTURO.xml:S3:1060:3	the	DT	I-AdverseReaction	O
QT	SIRTURO.xml:S3:1064:2	QT	NNP	I-AdverseReaction	O
interval	SIRTURO.xml:S3:1067:8	interv	NN	I-AdverseReaction	O
.	SIRTURO.xml:S3:1075:1	.	.	O	O

Obtain	SIRTURO.xml:S3:1077:6	obtain	NNP	O	O
an	SIRTURO.xml:S3:1084:2	an	DT	O	O
ECG	SIRTURO.xml:S3:1087:3	ecg	NNP	O	O
before	SIRTURO.xml:S3:1091:6	befor	IN	O	O
initiation	SIRTURO.xml:S3:1098:10	initi	NN	O	O
of	SIRTURO.xml:S3:1109:2	of	IN	O	O
treatment	SIRTURO.xml:S3:1112:9	treatment	NN	O	O
,	SIRTURO.xml:S3:1121:1	,	,	O	O
and	SIRTURO.xml:S3:1123:3	and	CC	O	O
at	SIRTURO.xml:S3:1127:2	at	IN	O	O
least	SIRTURO.xml:S3:1130:5	least	JJS	O	O
2	SIRTURO.xml:S3:1136:1	2	CD	O	O
,	SIRTURO.xml:S3:1137:1	,	,	O	O
12	SIRTURO.xml:S3:1139:2	12	CD	O	O
,	SIRTURO.xml:S3:1141:1	,	,	O	O
and	SIRTURO.xml:S3:1143:3	and	CC	O	O
24	SIRTURO.xml:S3:1147:2	24	CD	O	O
weeks	SIRTURO.xml:S3:1150:5	week	NNS	O	O
after	SIRTURO.xml:S3:1156:5	after	IN	O	O
starting	SIRTURO.xml:S3:1162:8	start	VBG	O	O
treatment	SIRTURO.xml:S3:1171:9	treatment	NN	O	O
with	SIRTURO.xml:S3:1181:4	with	IN	O	O
SIRTURO	SIRTURO.xml:S3:1186:7	sirturo	NNP	O	O
.	SIRTURO.xml:S3:1193:1	.	.	O	O

Obtain	SIRTURO.xml:S3:1195:6	obtain	NNP	O	B-AdverseReaction
serum	SIRTURO.xml:S3:1202:5	serum	JJ	O	I-AdverseReaction
potassium	SIRTURO.xml:S3:1208:9	potassium	NN	O	I-AdverseReaction
,	SIRTURO.xml:S3:1217:1	,	,	O	O
calcium	SIRTURO.xml:S3:1219:7	calcium	NN	O	O
,	SIRTURO.xml:S3:1226:1	,	,	O	O
and	SIRTURO.xml:S3:1228:3	and	CC	O	O
magnesium	SIRTURO.xml:S3:1232:9	magnesium	NN	O	O
at	SIRTURO.xml:S3:1242:2	at	IN	O	O
baseline	SIRTURO.xml:S3:1245:8	baselin	NN	O	O
and	SIRTURO.xml:S3:1254:3	and	CC	O	O
correct	SIRTURO.xml:S3:1258:7	correct	VB	O	O
if	SIRTURO.xml:S3:1266:2	if	IN	O	O
abnormal	SIRTURO.xml:S3:1269:8	abnorm	JJ	O	O
.	SIRTURO.xml:S3:1277:1	.	.	O	O

Monitor	SIRTURO.xml:S3:1279:7	monitor	NNP	O	O
electrolytes	SIRTURO.xml:S3:1287:12	electrolyt	VBZ	O	O
if	SIRTURO.xml:S3:1300:2	if	IN	O	O
QT	SIRTURO.xml:S3:1303:2	QT	NNP	O	O
prolongation	SIRTURO.xml:S3:1306:12	prolong	NN	O	O
is	SIRTURO.xml:S3:1319:2	is	VBZ	O	O
detected	SIRTURO.xml:S3:1322:8	detect	VBN	O	O
[	SIRTURO.xml:S3:1331:1	[	JJ	O	O
see	SIRTURO.xml:S3:1332:3	see	VBP	O	O
Adverse	SIRTURO.xml:S3:1337:7	advers	JJ	O	O
Reactions	SIRTURO.xml:S3:1345:9	reaction	NNP	O	O
(	SIRTURO.xml:S3:1355:1	(	(	O	O
6.1	SIRTURO.xml:S3:1356:3	6.1	CD	O	O
)	SIRTURO.xml:S3:1359:1	)	)	O	O
and	SIRTURO.xml:S3:1364:3	and	CC	O	O
Drug	SIRTURO.xml:S3:1370:4	drug	NNP	O	O
Interactions	SIRTURO.xml:S3:1375:12	interact	NNP	O	O
(	SIRTURO.xml:S3:1388:1	(	(	O	O
7.4	SIRTURO.xml:S3:1389:3	7.4	CD	O	O
)	SIRTURO.xml:S3:1392:1	)	)	O	O
]	SIRTURO.xml:S3:1395:1	]	NN	O	O
.	SIRTURO.xml:S3:1398:1	.	.	O	O

SIRTURO	SIRTURO.xml:S3:1400:7	sirturo	NNP	O	O
has	SIRTURO.xml:S3:1408:3	ha	VBZ	O	O
not	SIRTURO.xml:S3:1412:3	not	RB	O	O
been	SIRTURO.xml:S3:1416:4	been	VBN	O	O
studied	SIRTURO.xml:S3:1421:7	studi	VBN	O	O
in	SIRTURO.xml:S3:1429:2	in	IN	O	O
patients	SIRTURO.xml:S3:1432:8	patient	NNS	O	O
with	SIRTURO.xml:S3:1441:4	with	IN	O	O
ventricular	SIRTURO.xml:S3:1446:11	ventricular	JJ	O	O
arrhythmias	SIRTURO.xml:S3:1458:11	arrhythmia	NNS	O	O
or	SIRTURO.xml:S3:1470:2	or	CC	O	O
recent	SIRTURO.xml:S3:1473:6	recent	JJ	O	O
myocardial	SIRTURO.xml:S3:1480:10	myocardi	JJ	O	O
infarction	SIRTURO.xml:S3:1491:10	infarct	NN	O	O
.	SIRTURO.xml:S3:1501:1	.	.	O	O

The	SIRTURO.xml:S3:1507:3	the	DT	O	O
following	SIRTURO.xml:S3:1511:9	follow	NN	O	O
may	SIRTURO.xml:S3:1521:3	may	MD	O	O
increase	SIRTURO.xml:S3:1525:8	increas	VB	O	O
the	SIRTURO.xml:S3:1534:3	the	DT	O	O
risk	SIRTURO.xml:S3:1538:4	risk	NN	O	O
for	SIRTURO.xml:S3:1543:3	for	IN	O	O
QT	SIRTURO.xml:S3:1547:2	QT	NNP	B-AdverseReaction	O
prolongation	SIRTURO.xml:S3:1550:12	prolong	NN	I-AdverseReaction	O
when	SIRTURO.xml:S3:1563:4	when	WRB	O	O
patients	SIRTURO.xml:S3:1568:8	patient	NNS	O	O
are	SIRTURO.xml:S3:1577:3	are	VBP	O	O
receiving	SIRTURO.xml:S3:1581:9	receiv	VBG	O	O
SIRTURO	SIRTURO.xml:S3:1591:7	sirturo	NNP	O	O
:	SIRTURO.xml:S3:1598:1	:	:	O	O

use	SIRTURO.xml:S3:1607:3	use	NN	O	O
with	SIRTURO.xml:S3:1611:4	with	IN	O	O
other	SIRTURO.xml:S3:1616:5	other	JJ	O	O
QT	SIRTURO.xml:S3:1622:2	QT	NNP	O	O
prolonging	SIRTURO.xml:S3:1625:10	prolong	VBG	O	O
drugs	SIRTURO.xml:S3:1636:5	drug	NNS	O	O
including	SIRTURO.xml:S3:1642:9	includ	VBG	O	O
fluoroquinolones	SIRTURO.xml:S3:1652:16	fluoroquinolon	NNS	O	O
and	SIRTURO.xml:S3:1669:3	and	CC	O	O
macrolide	SIRTURO.xml:S3:1673:9	macrolid	VB	O	O
antibacterial	SIRTURO.xml:S3:1683:13	antibacteri	JJ	O	O
drugs	SIRTURO.xml:S3:1697:5	drug	NNS	O	O
and	SIRTURO.xml:S3:1703:3	and	CC	O	O
the	SIRTURO.xml:S3:1707:3	the	DT	O	O
antimycobacterial	SIRTURO.xml:S3:1711:17	antimycobacteri	JJ	O	O
drug	SIRTURO.xml:S3:1729:4	drug	NN	O	O
,	SIRTURO.xml:S3:1733:1	,	,	O	O
clofazimine	SIRTURO.xml:S3:1735:11	clofazimin	NN	O	O

a	SIRTURO.xml:S3:1752:1	a	DT	O	O
history	SIRTURO.xml:S3:1754:7	histori	NN	O	O
of	SIRTURO.xml:S3:1762:2	of	IN	O	O
Torsade	SIRTURO.xml:S3:1765:7	torsad	NNP	O	O
de	SIRTURO.xml:S3:1773:2	de	FW	O	O
Pointes	SIRTURO.xml:S3:1776:7	point	NNP	O	O

a	SIRTURO.xml:S3:1789:1	a	DT	O	O
history	SIRTURO.xml:S3:1791:7	histori	NN	O	O
of	SIRTURO.xml:S3:1799:2	of	IN	O	O
congenital	SIRTURO.xml:S3:1802:10	congenit	NN	O	O
long	SIRTURO.xml:S3:1813:4	long	JJ	O	O
QT	SIRTURO.xml:S3:1818:2	QT	NNP	O	O
syndrome	SIRTURO.xml:S3:1821:8	syndrom	NN	O	O

a	SIRTURO.xml:S3:1835:1	a	DT	O	O
history	SIRTURO.xml:S3:1837:7	histori	NN	O	O
of	SIRTURO.xml:S3:1845:2	of	IN	O	O
or	SIRTURO.xml:S3:1848:2	or	CC	O	O
ongoing	SIRTURO.xml:S3:1851:7	ongo	VBG	O	O
hypothyroidism	SIRTURO.xml:S3:1859:14	hypothyroid	NN	O	O

a	SIRTURO.xml:S3:1879:1	a	DT	O	O
history	SIRTURO.xml:S3:1881:7	histori	NN	O	O
of	SIRTURO.xml:S3:1889:2	of	IN	O	O
or	SIRTURO.xml:S3:1892:2	or	CC	O	O
ongoing	SIRTURO.xml:S3:1895:7	ongo	VBG	O	O
bradyarrhythmias	SIRTURO.xml:S3:1903:16	bradyarrhythmia	NNS	O	O

a	SIRTURO.xml:S3:1925:1	a	DT	O	O
history	SIRTURO.xml:S3:1927:7	histori	NN	O	O
of	SIRTURO.xml:S3:1935:2	of	IN	O	O
uncompensated	SIRTURO.xml:S3:1938:13	uncompens	JJ	O	O
heart	SIRTURO.xml:S3:1952:5	heart	NN	O	O
failure	SIRTURO.xml:S3:1958:7	failur	NN	O	O

serum	SIRTURO.xml:S3:1971:5	serum	NN	O	O
calcium	SIRTURO.xml:S3:1977:7	calcium	NN	O	O
,	SIRTURO.xml:S3:1984:1	,	,	O	O
magnesium	SIRTURO.xml:S3:1986:9	magnesium	NN	O	O
,	SIRTURO.xml:S3:1995:1	,	,	O	O
or	SIRTURO.xml:S3:1997:2	or	CC	O	O
potassium	SIRTURO.xml:S3:2000:9	potassium	NN	O	O
levels	SIRTURO.xml:S3:2010:6	level	NNS	O	O
below	SIRTURO.xml:S3:2017:5	below	IN	O	O
the	SIRTURO.xml:S3:2023:3	the	DT	O	O
lower	SIRTURO.xml:S3:2027:5	lower	JJR	O	O
limits	SIRTURO.xml:S3:2033:6	limit	NNS	O	O
of	SIRTURO.xml:S3:2040:2	of	IN	O	O
normal	SIRTURO.xml:S3:2043:6	normal	JJ	O	O

If	SIRTURO.xml:S3:2055:2	If	IN	O	O
necessary	SIRTURO.xml:S3:2058:9	necessari	JJ	O	O
,	SIRTURO.xml:S3:2067:1	,	,	O	O
bedaquiline	SIRTURO.xml:S3:2069:11	bedaquilin	JJ	O	O
treatment	SIRTURO.xml:S3:2081:9	treatment	NN	O	O
initiation	SIRTURO.xml:S3:2091:10	initi	NN	O	O
could	SIRTURO.xml:S3:2102:5	could	MD	O	O
be	SIRTURO.xml:S3:2108:2	be	VB	O	O
considered	SIRTURO.xml:S3:2111:10	consid	VBN	O	O
in	SIRTURO.xml:S3:2122:2	in	IN	O	O
these	SIRTURO.xml:S3:2125:5	these	DT	O	O
patients	SIRTURO.xml:S3:2131:8	patient	NNS	O	O
after	SIRTURO.xml:S3:2140:5	after	IN	O	O
a	SIRTURO.xml:S3:2146:1	a	DT	O	O
favorable	SIRTURO.xml:S3:2148:9	favor	JJ	O	O
benefit	SIRTURO.xml:S3:2158:7	benefit	NN	O	O
risk	SIRTURO.xml:S3:2166:4	risk	NN	O	O
assessment	SIRTURO.xml:S3:2171:10	assess	NN	O	O
and	SIRTURO.xml:S3:2182:3	and	CC	O	O
with	SIRTURO.xml:S3:2186:4	with	IN	O	O
frequent	SIRTURO.xml:S3:2191:8	frequent	JJ	O	O
ECG	SIRTURO.xml:S3:2200:3	ecg	NNP	O	O
monitoring	SIRTURO.xml:S3:2204:10	monitor	NN	O	O
.	SIRTURO.xml:S3:2214:1	.	.	O	O

Discontinue	SIRTURO.xml:S3:2220:11	discontinu	NN	O	O

SIRTURO	SIRTURO.xml:S3:2232:7	sirturo	NNP	O	O
and	SIRTURO.xml:S3:2240:3	and	CC	O	O
all	SIRTURO.xml:S3:2244:3	all	DT	O	O
other	SIRTURO.xml:S3:2248:5	other	JJ	O	O
QT	SIRTURO.xml:S3:2254:2	QT	NNP	O	O
prolonging	SIRTURO.xml:S3:2257:10	prolong	VBG	O	O
drugs	SIRTURO.xml:S3:2268:5	drug	NNS	O	O
if	SIRTURO.xml:S3:2274:2	if	IN	O	O
the	SIRTURO.xml:S3:2277:3	the	DT	O	O
patient	SIRTURO.xml:S3:2281:7	patient	NN	O	O
develops	SIRTURO.xml:S3:2289:8	develop	VBZ	O	O
:	SIRTURO.xml:S3:2297:1	:	:	O	O

Clinically	SIRTURO.xml:S3:2306:10	clinic	RB	O	O
significant	SIRTURO.xml:S3:2317:11	signific	JJ	O	O
ventricular	SIRTURO.xml:S3:2329:11	ventricular	JJ	O	O
arrhythmia	SIRTURO.xml:S3:2341:10	arrhythmia	NN	O	O

A	SIRTURO.xml:S3:2357:1	A	DT	O	O
QTcF	SIRTURO.xml:S3:2359:4	qtcf	NNP	O	O
interval	SIRTURO.xml:S3:2364:8	interv	NN	O	O
of	SIRTURO.xml:S3:2373:2	of	IN	O	O
greater	SIRTURO.xml:S3:2376:7	greater	JJR	O	O
than	SIRTURO.xml:S3:2384:4	than	IN	O	O
500	SIRTURO.xml:S3:2389:3	500	CD	O	O
ms	SIRTURO.xml:S3:2393:2	ms	NN	O	O
(	SIRTURO.xml:S3:2396:1	(	(	O	O
confirmed	SIRTURO.xml:S3:2397:9	confirm	VBN	O	O
by	SIRTURO.xml:S3:2407:2	by	IN	O	O
repeat	SIRTURO.xml:S3:2410:6	repeat	NN	O	O
ECG	SIRTURO.xml:S3:2417:3	ecg	NNP	O	O
)	SIRTURO.xml:S3:2420:1	)	)	O	O

If	SIRTURO.xml:S3:2427:2	If	IN	O	O
syncope	SIRTURO.xml:S3:2430:7	syncop	NN	O	O
occurs	SIRTURO.xml:S3:2438:6	occur	VBZ	O	O
,	SIRTURO.xml:S3:2444:1	,	,	O	O
obtain	SIRTURO.xml:S3:2446:6	obtain	VB	O	O
an	SIRTURO.xml:S3:2453:2	an	DT	O	O
ECG	SIRTURO.xml:S3:2456:3	ecg	NNP	O	O
to	SIRTURO.xml:S3:2460:2	to	TO	O	O
detect	SIRTURO.xml:S3:2463:6	detect	VB	O	O
QT	SIRTURO.xml:S3:2470:2	QT	NNP	O	O
prolongation	SIRTURO.xml:S3:2473:12	prolong	NN	O	O
.	SIRTURO.xml:S3:2485:1	.	.	O	O

5.3	SIRTURO.xml:S3:2494:3	5.3	CD	O	O

Hepatotoxicity	SIRTURO.xml:S3:2498:14	hepatotox	NN	O	O

More	SIRTURO.xml:S3:2518:4	more	RBR	O	O
hepatic	SIRTURO.xml:S3:2523:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
-	SIRTURO.xml:S3:2530:1	-	:	I-AdverseReaction	I-AdverseReaction
related	SIRTURO.xml:S3:2531:7	relat	JJ	I-AdverseReaction	I-AdverseReaction
adverse	SIRTURO.xml:S3:2539:7	advers	JJ	I-AdverseReaction	I-AdverseReaction
reactions	SIRTURO.xml:S3:2547:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
were	SIRTURO.xml:S3:2557:4	were	VBD	O	O
reported	SIRTURO.xml:S3:2562:8	report	VBN	O	O
with	SIRTURO.xml:S3:2571:4	with	IN	O	O
the	SIRTURO.xml:S3:2576:3	the	DT	O	O
use	SIRTURO.xml:S3:2580:3	use	NN	O	O
of	SIRTURO.xml:S3:2584:2	of	IN	O	O
SIRTURO	SIRTURO.xml:S3:2587:7	sirturo	NNP	O	O
plus	SIRTURO.xml:S3:2595:4	plu	CC	O	O
other	SIRTURO.xml:S3:2600:5	other	JJ	O	O
drugs	SIRTURO.xml:S3:2606:5	drug	NNS	O	O
used	SIRTURO.xml:S3:2612:4	use	VBN	O	O
to	SIRTURO.xml:S3:2617:2	to	TO	O	O
treat	SIRTURO.xml:S3:2620:5	treat	VB	O	O
tuberculosis	SIRTURO.xml:S3:2626:12	tuberculosi	NN	O	O
compared	SIRTURO.xml:S3:2639:8	compar	VBN	O	O
to	SIRTURO.xml:S3:2648:2	to	TO	O	O
other	SIRTURO.xml:S3:2651:5	other	JJ	O	O
drugs	SIRTURO.xml:S3:2657:5	drug	NNS	O	O
used	SIRTURO.xml:S3:2663:4	use	VBN	O	O
to	SIRTURO.xml:S3:2668:2	to	TO	O	O
treat	SIRTURO.xml:S3:2671:5	treat	VB	O	O
tuberculosis	SIRTURO.xml:S3:2677:12	tuberculosi	NN	O	O
without	SIRTURO.xml:S3:2690:7	without	IN	O	O
the	SIRTURO.xml:S3:2698:3	the	DT	O	O
addition	SIRTURO.xml:S3:2702:8	addit	NN	O	O
of	SIRTURO.xml:S3:2711:2	of	IN	O	O
SIRTURO	SIRTURO.xml:S3:2714:7	sirturo	NNP	O	O
.	SIRTURO.xml:S3:2721:1	.	.	O	O

Alcohol	SIRTURO.xml:S3:2723:7	alcohol	NNP	O	O
and	SIRTURO.xml:S3:2731:3	and	CC	O	O
other	SIRTURO.xml:S3:2735:5	other	JJ	O	O
hepatotoxic	SIRTURO.xml:S3:2741:11	hepatotox	NN	O	O
drugs	SIRTURO.xml:S3:2753:5	drug	NNS	O	O
should	SIRTURO.xml:S3:2759:6	should	MD	O	O
be	SIRTURO.xml:S3:2766:2	be	VB	O	O
avoided	SIRTURO.xml:S3:2769:7	avoid	VBN	O	O
while	SIRTURO.xml:S3:2777:5	while	IN	O	O
on	SIRTURO.xml:S3:2783:2	on	IN	O	O
SIRTURO	SIRTURO.xml:S3:2786:7	sirturo	NNP	O	O
,	SIRTURO.xml:S3:2793:1	,	,	O	O
especially	SIRTURO.xml:S3:2795:10	especi	RB	O	O
in	SIRTURO.xml:S3:2806:2	in	IN	O	O
patients	SIRTURO.xml:S3:2809:8	patient	NNS	O	O
with	SIRTURO.xml:S3:2818:4	with	IN	O	O
impaired	SIRTURO.xml:S3:2823:8	impair	JJ	O	O
hepatic	SIRTURO.xml:S3:2832:7	hepat	JJ	O	O
function	SIRTURO.xml:S3:2840:8	function	NN	O	O
.	SIRTURO.xml:S3:2848:1	.	.	O	O

Monitor	SIRTURO.xml:S3:2854:7	monitor	NN	O	O
symptoms	SIRTURO.xml:S3:2862:8	symptom	NNS	O	O
(	SIRTURO.xml:S3:2871:1	(	(	O	O
such	SIRTURO.xml:S3:2872:4	such	JJ	O	O
as	SIRTURO.xml:S3:2877:2	as	IN	O	O
fatigue	SIRTURO.xml:S3:2880:7	fatigu	NN	O	O
,	SIRTURO.xml:S3:2887:1	,	,	O	O
anorexia	SIRTURO.xml:S3:2889:8	anorexia	NN	O	B-AdverseReaction
,	SIRTURO.xml:S3:2897:1	,	,	O	O
nausea	SIRTURO.xml:S3:2899:6	nausea	NN	O	B-AdverseReaction
,	SIRTURO.xml:S3:2905:1	,	,	O	O
jaundice	SIRTURO.xml:S3:2907:8	jaundic	NN	O	O
,	SIRTURO.xml:S3:2915:1	,	,	O	O
dark	SIRTURO.xml:S3:2917:4	dark	JJ	O	B-AdverseReaction
urine	SIRTURO.xml:S3:2922:5	urin	NN	O	I-AdverseReaction
,	SIRTURO.xml:S3:2927:1	,	,	O	O
liver	SIRTURO.xml:S3:2929:5	liver	NN	O	B-AdverseReaction
tenderness	SIRTURO.xml:S3:2935:10	tender	NN	O	I-AdverseReaction
and	SIRTURO.xml:S3:2946:3	and	CC	O	O
hepatomegaly	SIRTURO.xml:S3:2950:12	hepatomegali	NN	O	O
)	SIRTURO.xml:S3:2962:1	)	)	O	O
and	SIRTURO.xml:S3:2964:3	and	CC	O	O
laboratory	SIRTURO.xml:S3:2968:10	laboratori	JJ	O	O
tests	SIRTURO.xml:S3:2979:5	test	NNS	O	O
(	SIRTURO.xml:S3:2985:1	(	(	O	O
ALT	SIRTURO.xml:S3:2986:3	alt	NNP	O	I-AdverseReaction
,	SIRTURO.xml:S3:2989:1	,	,	O	O
AST	SIRTURO.xml:S3:2991:3	ast	NNP	O	I-AdverseReaction
,	SIRTURO.xml:S3:2994:1	,	,	O	O
alkaline	SIRTURO.xml:S3:2996:8	alkalin	JJ	O	O
phosphatase	SIRTURO.xml:S3:3005:11	phosphatas	NN	O	O
,	SIRTURO.xml:S3:3016:1	,	,	O	O
and	SIRTURO.xml:S3:3018:3	and	CC	O	O
bilirubin	SIRTURO.xml:S3:3022:9	bilirubin	NN	O	O
)	SIRTURO.xml:S3:3031:1	)	)	O	O
at	SIRTURO.xml:S3:3033:2	at	IN	O	O
baseline	SIRTURO.xml:S3:3036:8	baselin	NN	O	O
,	SIRTURO.xml:S3:3044:1	,	,	O	O
monthly	SIRTURO.xml:S3:3046:7	monthli	RB	O	O
while	SIRTURO.xml:S3:3054:5	while	IN	O	O
on	SIRTURO.xml:S3:3060:2	on	IN	O	O
treatment	SIRTURO.xml:S3:3063:9	treatment	NN	O	O
,	SIRTURO.xml:S3:3072:1	,	,	O	O
and	SIRTURO.xml:S3:3074:3	and	CC	O	O
as	SIRTURO.xml:S3:3078:2	as	IN	O	O
needed	SIRTURO.xml:S3:3081:6	need	VBN	O	O
.	SIRTURO.xml:S3:3087:1	.	.	O	O

Test	SIRTURO.xml:S3:3089:4	test	NN	O	O
for	SIRTURO.xml:S3:3094:3	for	IN	O	O
viral	SIRTURO.xml:S3:3098:5	viral	JJ	O	O
hepatitis	SIRTURO.xml:S3:3104:9	hepat	NN	O	O
and	SIRTURO.xml:S3:3114:3	and	CC	O	O
discontinue	SIRTURO.xml:S3:3118:11	discontinu	VB	O	O
other	SIRTURO.xml:S3:3130:5	other	JJ	O	O
hepatotoxic	SIRTURO.xml:S3:3136:11	hepatotox	JJ	O	O
medications	SIRTURO.xml:S3:3148:11	medic	NNS	O	O
if	SIRTURO.xml:S3:3160:2	if	IN	O	O
evidence	SIRTURO.xml:S3:3163:8	evid	NN	O	O
of	SIRTURO.xml:S3:3172:2	of	IN	O	O
new	SIRTURO.xml:S3:3175:3	new	JJ	O	O
or	SIRTURO.xml:S3:3179:2	or	CC	O	O
worsening	SIRTURO.xml:S3:3182:9	worsen	VBG	O	O
liver	SIRTURO.xml:S3:3192:5	liver	JJ	O	O
dysfunction	SIRTURO.xml:S3:3198:11	dysfunct	NN	O	O
occurs	SIRTURO.xml:S3:3210:6	occur	NNS	O	O
.	SIRTURO.xml:S3:3216:1	.	.	O	O

Discontinue	SIRTURO.xml:S3:3218:11	discontinu	NNP	O	O
SIRTURO	SIRTURO.xml:S3:3230:7	sirturo	NNP	O	O
if	SIRTURO.xml:S3:3238:2	if	IN	O	O
:	SIRTURO.xml:S3:3240:1	:	:	O	O

aminotransferase	SIRTURO.xml:S3:3249:16	aminotransferas	NN	O	O
elevations	SIRTURO.xml:S3:3266:10	elev	NNS	O	O
are	SIRTURO.xml:S3:3277:3	are	VBP	O	O
accompanied	SIRTURO.xml:S3:3281:11	accompani	VBN	O	O
by	SIRTURO.xml:S3:3293:2	by	IN	O	O
total	SIRTURO.xml:S3:3296:5	total	JJ	O	O
bilirubin	SIRTURO.xml:S3:3302:9	bilirubin	NN	O	O
elevation	SIRTURO.xml:S3:3312:9	elev	NN	O	O
greater	SIRTURO.xml:S3:3322:7	greater	JJR	O	O
than	SIRTURO.xml:S3:3330:4	than	IN	O	O
two	SIRTURO.xml:S3:3335:3	two	CD	O	O
times	SIRTURO.xml:S3:3339:5	time	NNS	O	O
the	SIRTURO.xml:S3:3345:3	the	DT	O	O
upper	SIRTURO.xml:S3:3349:5	upper	JJ	O	O
limit	SIRTURO.xml:S3:3355:5	limit	NN	O	O
of	SIRTURO.xml:S3:3361:2	of	IN	O	O
normal	SIRTURO.xml:S3:3364:6	normal	JJ	O	O

aminotransferase	SIRTURO.xml:S3:3376:16	aminotransferas	NN	O	O
elevations	SIRTURO.xml:S3:3393:10	elev	NNS	O	O
are	SIRTURO.xml:S3:3404:3	are	VBP	O	O
greater	SIRTURO.xml:S3:3408:7	greater	JJR	O	O
than	SIRTURO.xml:S3:3416:4	than	IN	O	O
eight	SIRTURO.xml:S3:3421:5	eight	CD	O	O
times	SIRTURO.xml:S3:3427:5	time	NNS	O	O
the	SIRTURO.xml:S3:3433:3	the	DT	O	O
upper	SIRTURO.xml:S3:3437:5	upper	JJ	O	O
limit	SIRTURO.xml:S3:3443:5	limit	NN	O	O
of	SIRTURO.xml:S3:3449:2	of	IN	O	O
normal	SIRTURO.xml:S3:3452:6	normal	JJ	O	O

aminotransferase	SIRTURO.xml:S3:3464:16	aminotransferas	NN	O	O
elevations	SIRTURO.xml:S3:3481:10	elev	NNS	O	O
are	SIRTURO.xml:S3:3492:3	are	VBP	O	O
greater	SIRTURO.xml:S3:3496:7	greater	JJR	O	O
than	SIRTURO.xml:S3:3504:4	than	IN	O	O
five	SIRTURO.xml:S3:3509:4	five	CD	O	O
times	SIRTURO.xml:S3:3514:5	time	NNS	O	O
the	SIRTURO.xml:S3:3520:3	the	DT	O	O
upper	SIRTURO.xml:S3:3524:5	upper	JJ	O	O
limit	SIRTURO.xml:S3:3530:5	limit	NN	O	O
of	SIRTURO.xml:S3:3536:2	of	IN	O	O
normal	SIRTURO.xml:S3:3539:6	normal	JJ	O	O
and	SIRTURO.xml:S3:3546:3	and	CC	O	O
persist	SIRTURO.xml:S3:3550:7	persist	JJ	O	O
beyond	SIRTURO.xml:S3:3558:6	beyond	IN	O	O
two	SIRTURO.xml:S3:3565:3	two	CD	O	O
weeks	SIRTURO.xml:S3:3569:5	week	NNS	O	O

5.4	SIRTURO.xml:S3:3583:3	5.4	CD	O	O
Drug	SIRTURO.xml:S3:3587:4	drug	NNP	O	O
Interactions	SIRTURO.xml:S3:3592:12	interact	NNS	O	O

CYP3A4	SIRTURO.xml:S3:3611:6	cyp3a4	NN	O	O

inducers	SIRTURO.xml:S3:3618:8	induc	NNS	O	O
inhibitors	SIRTURO.xml:S3:3627:10	inhibitor	NNS	O	O

Bedaquiline	SIRTURO.xml:S3:3644:11	bedaquilin	NNP	O	O
is	SIRTURO.xml:S3:3656:2	is	VBZ	O	O
metabolized	SIRTURO.xml:S3:3659:11	metabol	VBN	O	O
by	SIRTURO.xml:S3:3671:2	by	IN	O	O
CYP3A4	SIRTURO.xml:S3:3674:6	cyp3a4	NNP	O	O
and	SIRTURO.xml:S3:3681:3	and	CC	O	O
its	SIRTURO.xml:S3:3685:3	it	PRP$	O	O
systemic	SIRTURO.xml:S3:3689:8	system	JJ	O	O
exposure	SIRTURO.xml:S3:3698:8	exposur	NN	O	O
and	SIRTURO.xml:S3:3707:3	and	CC	O	O
therapeutic	SIRTURO.xml:S3:3711:11	therapeut	JJ	O	O
effect	SIRTURO.xml:S3:3723:6	effect	NN	O	O
may	SIRTURO.xml:S3:3730:3	may	MD	O	O
therefore	SIRTURO.xml:S3:3734:9	therefor	RB	O	O
be	SIRTURO.xml:S3:3744:2	be	VB	O	O
reduced	SIRTURO.xml:S3:3747:7	reduc	VBN	O	O
during	SIRTURO.xml:S3:3755:6	dure	IN	O	O
co	SIRTURO.xml:S3:3762:2	co	NN	O	O
-	SIRTURO.xml:S3:3764:1	-	:	O	O
administration	SIRTURO.xml:S3:3765:14	administr	NN	O	O
with	SIRTURO.xml:S3:3780:4	with	IN	O	O
inducers	SIRTURO.xml:S3:3785:8	induc	NNS	O	O
of	SIRTURO.xml:S3:3794:2	of	IN	O	O
CYP3A4	SIRTURO.xml:S3:3797:6	cyp3a4	NNP	O	O
.	SIRTURO.xml:S3:3803:1	.	.	O	O

Avoid	SIRTURO.xml:S3:3805:5	avoid	NNP	O	O
co	SIRTURO.xml:S3:3811:2	co	SYM	O	O
-	SIRTURO.xml:S3:3813:1	-	:	O	O
administration	SIRTURO.xml:S3:3814:14	administr	NN	O	O
of	SIRTURO.xml:S3:3829:2	of	IN	O	O
strong	SIRTURO.xml:S3:3832:6	strong	JJ	O	O
CYP3A4	SIRTURO.xml:S3:3839:6	cyp3a4	NNP	O	O
inducers	SIRTURO.xml:S3:3846:8	induc	NNS	O	O
,	SIRTURO.xml:S3:3854:1	,	,	O	O
such	SIRTURO.xml:S3:3856:4	such	JJ	O	O
as	SIRTURO.xml:S3:3861:2	as	IN	O	O
rifamycins	SIRTURO.xml:S3:3864:10	rifamycin	NNS	O	O
(	SIRTURO.xml:S3:3875:1	(	(	O	O
i	SIRTURO.xml:S3:3876:1	i	NN	O	O
.	SIRTURO.xml:S3:3877:1	.	.	O	O
e	SIRTURO.xml:S3:3878:1	e	NN	O	O
.	SIRTURO.xml:S3:3879:1	.	.	O	O
,	SIRTURO.xml:S3:3880:1	,	,	O	O
rifampin	SIRTURO.xml:S3:3882:8	rifampin	NN	O	O
,	SIRTURO.xml:S3:3890:1	,	,	O	O
rifapentine	SIRTURO.xml:S3:3892:11	rifapentin	NN	O	O
and	SIRTURO.xml:S3:3904:3	and	CC	O	O
rifabutin	SIRTURO.xml:S3:3908:9	rifabutin	NN	O	O
)	SIRTURO.xml:S3:3917:1	)	)	O	O
,	SIRTURO.xml:S3:3918:1	,	,	O	O
or	SIRTURO.xml:S3:3920:2	or	CC	O	O
moderate	SIRTURO.xml:S3:3923:8	moder	JJ	O	O
CYP3A4	SIRTURO.xml:S3:3932:6	cyp3a4	NNP	O	O
inducers	SIRTURO.xml:S3:3939:8	induc	NNS	O	O
,	SIRTURO.xml:S3:3947:1	,	,	O	O
such	SIRTURO.xml:S3:3949:4	such	JJ	O	O
as	SIRTURO.xml:S3:3954:2	as	IN	O	O
efavirenz	SIRTURO.xml:S3:3957:9	efavirenz	NN	O	O
,	SIRTURO.xml:S3:3966:1	,	,	O	O
during	SIRTURO.xml:S3:3968:6	dure	IN	O	O
treatment	SIRTURO.xml:S3:3975:9	treatment	NN	O	O
with	SIRTURO.xml:S3:3985:4	with	IN	O	O
SIRTURO	SIRTURO.xml:S3:3990:7	sirturo	NNP	O	O
[	SIRTURO.xml:S3:3998:1	[	NNP	O	O
see	SIRTURO.xml:S3:3999:3	see	VBP	O	O
Drug	SIRTURO.xml:S3:4004:4	drug	NNP	O	O
Interactions	SIRTURO.xml:S3:4009:12	interact	NNP	O	O
(	SIRTURO.xml:S3:4022:1	(	(	O	O
7.1	SIRTURO.xml:S3:4023:3	7.1	CD	O	O
)	SIRTURO.xml:S3:4026:1	)	)	O	O
]	SIRTURO.xml:S3:4029:1	]	NN	O	O
.	SIRTURO.xml:S3:4032:1	.	.	O	O

Co	SIRTURO.xml:S3:4038:2	Co	NNP	O	O
-	SIRTURO.xml:S3:4040:1	-	:	O	O
administration	SIRTURO.xml:S3:4041:14	administr	NN	O	O
of	SIRTURO.xml:S3:4056:2	of	IN	O	O
SIRTURO	SIRTURO.xml:S3:4059:7	sirturo	NNP	O	O
with	SIRTURO.xml:S3:4067:4	with	IN	O	O
strong	SIRTURO.xml:S3:4072:6	strong	JJ	O	O
CYP3A4	SIRTURO.xml:S3:4079:6	cyp3a4	NNP	O	O
inhibitors	SIRTURO.xml:S3:4086:10	inhibitor	NNS	O	O
may	SIRTURO.xml:S3:4097:3	may	MD	O	O
increase	SIRTURO.xml:S3:4101:8	increas	VB	O	O
the	SIRTURO.xml:S3:4110:3	the	DT	O	O
systemic	SIRTURO.xml:S3:4114:8	system	JJ	O	O
exposure	SIRTURO.xml:S3:4123:8	exposur	NN	O	O
to	SIRTURO.xml:S3:4132:2	to	TO	O	O
bedaquiline	SIRTURO.xml:S3:4135:11	bedaquilin	VB	O	O
,	SIRTURO.xml:S3:4146:1	,	,	O	O
which	SIRTURO.xml:S3:4148:5	which	WDT	O	O
could	SIRTURO.xml:S3:4154:5	could	MD	O	O
potentially	SIRTURO.xml:S3:4160:11	potenti	RB	O	O
increase	SIRTURO.xml:S3:4172:8	increas	VB	O	O
the	SIRTURO.xml:S3:4181:3	the	DT	O	O
risk	SIRTURO.xml:S3:4185:4	risk	NN	O	O
of	SIRTURO.xml:S3:4190:2	of	IN	O	O
adverse	SIRTURO.xml:S3:4193:7	advers	JJ	O	O
reactions	SIRTURO.xml:S3:4201:9	reaction	NNS	O	O
.	SIRTURO.xml:S3:4210:1	.	.	O	O

Therefore	SIRTURO.xml:S3:4212:9	therefor	RB	O	O
,	SIRTURO.xml:S3:4221:1	,	,	O	O
avoid	SIRTURO.xml:S3:4223:5	avoid	VBP	O	O
the	SIRTURO.xml:S3:4229:3	the	DT	O	O
use	SIRTURO.xml:S3:4233:3	use	NN	O	O
of	SIRTURO.xml:S3:4237:2	of	IN	O	O
strong	SIRTURO.xml:S3:4240:6	strong	JJ	O	O
CYP3A4	SIRTURO.xml:S3:4247:6	cyp3a4	NNP	O	O
inhibitors	SIRTURO.xml:S3:4254:10	inhibitor	NNS	O	O
for	SIRTURO.xml:S3:4265:3	for	IN	O	O
more	SIRTURO.xml:S3:4269:4	more	JJR	O	O
than	SIRTURO.xml:S3:4274:4	than	IN	O	O
14	SIRTURO.xml:S3:4279:2	14	CD	O	O
consecutive	SIRTURO.xml:S3:4282:11	consecut	JJ	O	O
days	SIRTURO.xml:S3:4294:4	day	NNS	O	O
while	SIRTURO.xml:S3:4299:5	while	IN	O	O
on	SIRTURO.xml:S3:4305:2	on	IN	O	O
SIRTURO	SIRTURO.xml:S3:4308:7	sirturo	NNP	O	O
,	SIRTURO.xml:S3:4315:1	,	,	O	O
unless	SIRTURO.xml:S3:4317:6	unless	IN	O	O
the	SIRTURO.xml:S3:4324:3	the	DT	O	O
benefit	SIRTURO.xml:S3:4328:7	benefit	NN	O	O
of	SIRTURO.xml:S3:4336:2	of	IN	O	O
treatment	SIRTURO.xml:S3:4339:9	treatment	NN	O	O
with	SIRTURO.xml:S3:4349:4	with	IN	O	O
the	SIRTURO.xml:S3:4354:3	the	DT	O	O
drug	SIRTURO.xml:S3:4358:4	drug	NN	O	O
combination	SIRTURO.xml:S3:4363:11	combin	NN	O	O
outweighs	SIRTURO.xml:S3:4375:9	outweigh	VBZ	O	O
the	SIRTURO.xml:S3:4385:3	the	DT	O	O
risk	SIRTURO.xml:S3:4389:4	risk	NN	O	O
[	SIRTURO.xml:S3:4394:1	[	NNP	O	O
see	SIRTURO.xml:S3:4395:3	see	VBP	O	O
Drug	SIRTURO.xml:S3:4400:4	drug	NNP	O	O
Interactions	SIRTURO.xml:S3:4405:12	interact	NNP	O	O
(	SIRTURO.xml:S3:4418:1	(	(	O	O
7.1	SIRTURO.xml:S3:4419:3	7.1	CD	O	O
)	SIRTURO.xml:S3:4422:1	)	)	O	O
]	SIRTURO.xml:S3:4425:1	]	NN	O	O
.	SIRTURO.xml:S3:4428:1	.	.	O	O

Appropriate	SIRTURO.xml:S3:4430:11	appropri	NNP	O	O
clinical	SIRTURO.xml:S3:4442:8	clinic	JJ	O	O
monitoring	SIRTURO.xml:S3:4451:10	monitor	NN	O	O
for	SIRTURO.xml:S3:4462:3	for	IN	O	O
SIRTURO	SIRTURO.xml:S3:4466:7	sirturo	NNP	O	O
-	SIRTURO.xml:S3:4473:1	-	:	O	O
related	SIRTURO.xml:S3:4474:7	relat	JJ	O	O
adverse	SIRTURO.xml:S3:4482:7	advers	JJ	O	O
reactions	SIRTURO.xml:S3:4490:9	reaction	NNS	O	O
is	SIRTURO.xml:S3:4500:2	is	VBZ	O	O
recommended	SIRTURO.xml:S3:4503:11	recommend	VBN	O	O
.	SIRTURO.xml:S3:4514:1	.	.	O	O
6	STENDRA.xml:S1:4:1	6	CD	O	O
ADVERSE	STENDRA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	STENDRA.xml:S1:14:9	reaction	NN	O	O

EXCERPT	STENDRA.xml:S1:27:7	excerpt	NNS	O	O
:	STENDRA.xml:S1:34:1	:	:	O	O
Most	STENDRA.xml:S1:38:4	most	JJS	O	O
common	STENDRA.xml:S1:43:6	common	JJ	O	O
adverse	STENDRA.xml:S1:50:7	advers	JJ	O	O
reactions	STENDRA.xml:S1:58:9	reaction	NNS	O	O
(	STENDRA.xml:S1:68:1	(	(	O	O
greater	STENDRA.xml:S1:69:7	greater	JJR	O	O
than	STENDRA.xml:S1:77:4	than	IN	O	O
or	STENDRA.xml:S1:82:2	or	CC	O	O
equal	STENDRA.xml:S1:85:5	equal	JJ	O	O
to	STENDRA.xml:S1:91:2	to	TO	O	O
2%	STENDRA.xml:S1:94:2	2%	CD	O	O
)	STENDRA.xml:S1:96:1	)	)	O	O
include	STENDRA.xml:S1:98:7	includ	VBP	O	O
headache	STENDRA.xml:S1:106:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:114:1	,	,	O	O
flushing	STENDRA.xml:S1:116:8	flush	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:124:1	,	,	O	O
nasal	STENDRA.xml:S1:126:5	nasal	JJ	B-AdverseReaction	B-AdverseReaction
congestion	STENDRA.xml:S1:132:10	congest	NN	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:142:1	,	,	O	O
nasopharyngitis	STENDRA.xml:S1:144:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:159:1	,	,	O	O
and	STENDRA.xml:S1:161:3	and	CC	O	O
back	STENDRA.xml:S1:165:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	STENDRA.xml:S1:170:4	pain	NN	I-AdverseReaction	I-AdverseReaction
(	STENDRA.xml:S1:175:1	(	(	O	O
6.1	STENDRA.xml:S1:176:3	6.1	CD	O	O
)	STENDRA.xml:S1:179:1	)	)	O	O

To	STENDRA.xml:S1:187:2	To	TO	O	O
report	STENDRA.xml:S1:190:6	report	VB	O	O
SUSPECTED	STENDRA.xml:S1:197:9	suspect	NNP	O	O
ADVERSE	STENDRA.xml:S1:207:7	advers	NNP	O	O
REACTIONS	STENDRA.xml:S1:215:9	reaction	NNP	O	O
,	STENDRA.xml:S1:224:1	,	,	O	O
contact	STENDRA.xml:S1:226:7	contact	NN	O	O
1	STENDRA.xml:S1:234:1	1	CD	O	O
-	STENDRA.xml:S1:235:1	-	:	O	O
877	STENDRA.xml:S1:236:3	877	CD	O	O
-	STENDRA.xml:S1:239:1	-	:	O	O
663	STENDRA.xml:S1:240:3	663	CD	O	O
-	STENDRA.xml:S1:243:1	-	:	O	O
0412	STENDRA.xml:S1:244:4	0412	CD	O	O
or	STENDRA.xml:S1:249:2	or	CC	O	O
FDA	STENDRA.xml:S1:252:3	fda	NNP	O	O
at	STENDRA.xml:S1:256:2	at	IN	O	O
1	STENDRA.xml:S1:259:1	1	CD	O	O
-	STENDRA.xml:S1:260:1	-	:	O	O
800	STENDRA.xml:S1:261:3	800	CD	O	O
-	STENDRA.xml:S1:264:1	-	:	O	O
FDA	STENDRA.xml:S1:265:3	fda	NNP	O	O
-	STENDRA.xml:S1:268:1	-	:	O	O
1088	STENDRA.xml:S1:269:4	1088	CD	O	O
or	STENDRA.xml:S1:274:2	or	CC	O	O
www	STENDRA.xml:S1:278:3	www	VB	O	O
.	STENDRA.xml:S1:281:1	.	.	O	O
fda	STENDRA.xml:S1:282:3	fda	NN	O	O
.	STENDRA.xml:S1:285:1	.	.	O	O
gov	STENDRA.xml:S1:286:3	gov	JJ	O	O
medwatch	STENDRA.xml:S1:290:8	medwatch	NN	O	O
.	STENDRA.xml:S1:298:1	.	.	O	O

6.1	STENDRA.xml:S1:312:3	6.1	CD	O	O

Clinical	STENDRA.xml:S1:316:8	clinic	JJ	O	O
Trials	STENDRA.xml:S1:325:6	trial	NNS	O	O
Experience	STENDRA.xml:S1:332:10	experi	NN	O	O

Because	STENDRA.xml:S1:346:7	becaus	IN	O	O
clinical	STENDRA.xml:S1:354:8	clinic	JJ	O	O
trials	STENDRA.xml:S1:363:6	trial	NNS	O	O
are	STENDRA.xml:S1:370:3	are	VBP	O	O
conducted	STENDRA.xml:S1:374:9	conduct	VBN	O	O
under	STENDRA.xml:S1:384:5	under	IN	O	O
widely	STENDRA.xml:S1:390:6	wide	RB	O	O
varying	STENDRA.xml:S1:397:7	vari	VBG	O	O
conditions	STENDRA.xml:S1:405:10	condit	NNS	O	O
,	STENDRA.xml:S1:415:1	,	,	O	O
adverse	STENDRA.xml:S1:417:7	advers	JJ	O	O
reaction	STENDRA.xml:S1:425:8	reaction	NN	O	O
rates	STENDRA.xml:S1:434:5	rate	NNS	O	O
observed	STENDRA.xml:S1:440:8	observ	VBD	O	O
in	STENDRA.xml:S1:449:2	in	IN	O	O
the	STENDRA.xml:S1:452:3	the	DT	O	O
clinical	STENDRA.xml:S1:456:8	clinic	JJ	O	O
trials	STENDRA.xml:S1:465:6	trial	NNS	O	O
of	STENDRA.xml:S1:472:2	of	IN	O	O
a	STENDRA.xml:S1:475:1	a	DT	O	O
drug	STENDRA.xml:S1:477:4	drug	NN	O	O
cannot	STENDRA.xml:S1:482:6	cannot	NN	O	O
be	STENDRA.xml:S1:489:2	be	VB	O	O
directly	STENDRA.xml:S1:492:8	directli	RB	O	O
compared	STENDRA.xml:S1:501:8	compar	VBN	O	O
to	STENDRA.xml:S1:510:2	to	TO	O	O
rates	STENDRA.xml:S1:513:5	rate	NNS	O	O
in	STENDRA.xml:S1:519:2	in	IN	O	O
the	STENDRA.xml:S1:522:3	the	DT	O	O
clinical	STENDRA.xml:S1:526:8	clinic	JJ	O	O
trials	STENDRA.xml:S1:535:6	trial	NNS	O	O
of	STENDRA.xml:S1:542:2	of	IN	O	O
another	STENDRA.xml:S1:545:7	anoth	DT	O	O
drug	STENDRA.xml:S1:553:4	drug	NN	O	O
and	STENDRA.xml:S1:558:3	and	CC	O	O
may	STENDRA.xml:S1:562:3	may	MD	O	O
not	STENDRA.xml:S1:566:3	not	RB	O	O
reflect	STENDRA.xml:S1:570:7	reflect	VB	O	O
the	STENDRA.xml:S1:578:3	the	DT	O	O
rates	STENDRA.xml:S1:582:5	rate	NNS	O	O
observed	STENDRA.xml:S1:588:8	observ	VBD	O	O
in	STENDRA.xml:S1:597:2	in	IN	O	O
practice	STENDRA.xml:S1:600:8	practic	NN	O	O
.	STENDRA.xml:S1:608:1	.	.	O	O

STENDRA	STENDRA.xml:S1:614:7	stendra	NNP	O	O
was	STENDRA.xml:S1:622:3	wa	VBD	O	O
administered	STENDRA.xml:S1:626:12	administ	VBN	O	O
to	STENDRA.xml:S1:639:2	to	TO	O	O
2215	STENDRA.xml:S1:642:4	2215	CD	O	O
men	STENDRA.xml:S1:647:3	men	NNS	O	O
during	STENDRA.xml:S1:651:6	dure	IN	O	O
clinical	STENDRA.xml:S1:658:8	clinic	JJ	O	O
trials	STENDRA.xml:S1:667:6	trial	NNS	O	O
.	STENDRA.xml:S1:673:1	.	.	O	O

In	STENDRA.xml:S1:675:2	In	IN	O	O
trials	STENDRA.xml:S1:678:6	trial	NNS	O	O
of	STENDRA.xml:S1:685:2	of	IN	O	O
STENDRA	STENDRA.xml:S1:688:7	stendra	NNP	O	O
for	STENDRA.xml:S1:696:3	for	IN	O	O
use	STENDRA.xml:S1:700:3	use	NN	O	O
as	STENDRA.xml:S1:704:2	as	IN	O	O
needed	STENDRA.xml:S1:707:6	need	VBN	O	O
,	STENDRA.xml:S1:713:1	,	,	O	O
a	STENDRA.xml:S1:715:1	a	DT	O	O
total	STENDRA.xml:S1:717:5	total	NN	O	O
of	STENDRA.xml:S1:723:2	of	IN	O	O
493	STENDRA.xml:S1:726:3	493	CD	O	O
patients	STENDRA.xml:S1:730:8	patient	NNS	O	O
were	STENDRA.xml:S1:739:4	were	VBD	O	O
exposed	STENDRA.xml:S1:744:7	expos	VBN	O	O
for	STENDRA.xml:S1:752:3	for	IN	O	O
greater	STENDRA.xml:S1:756:7	greater	JJR	O	O
than	STENDRA.xml:S1:764:4	than	IN	O	O
or	STENDRA.xml:S1:769:2	or	CC	O	O
equal	STENDRA.xml:S1:772:5	equal	JJ	O	O
to	STENDRA.xml:S1:778:2	to	TO	O	O
6	STENDRA.xml:S1:781:1	6	CD	O	O
months	STENDRA.xml:S1:783:6	month	NNS	O	O
,	STENDRA.xml:S1:789:1	,	,	O	O
and	STENDRA.xml:S1:791:3	and	CC	O	O
153	STENDRA.xml:S1:795:3	153	CD	O	O
patients	STENDRA.xml:S1:799:8	patient	NNS	O	O
were	STENDRA.xml:S1:808:4	were	VBD	O	O
treated	STENDRA.xml:S1:813:7	treat	VBN	O	O
for	STENDRA.xml:S1:821:3	for	IN	O	O
greater	STENDRA.xml:S1:825:7	greater	JJR	O	O
than	STENDRA.xml:S1:833:4	than	IN	O	O
or	STENDRA.xml:S1:838:2	or	CC	O	O
equal	STENDRA.xml:S1:841:5	equal	JJ	O	O
to	STENDRA.xml:S1:847:2	to	TO	O	O
12	STENDRA.xml:S1:850:2	12	CD	O	O
months	STENDRA.xml:S1:853:6	month	NNS	O	O
.	STENDRA.xml:S1:859:1	.	.	O	O

In	STENDRA.xml:S1:865:2	In	IN	O	O
three	STENDRA.xml:S1:868:5	three	CD	O	O
randomized	STENDRA.xml:S1:874:10	random	NNS	O	O
,	STENDRA.xml:S1:884:1	,	,	O	O
double	STENDRA.xml:S1:886:6	doubl	JJ	O	O
-	STENDRA.xml:S1:892:1	-	:	O	O
blind	STENDRA.xml:S1:893:5	blind	NN	O	O
,	STENDRA.xml:S1:898:1	,	,	O	O
placebo	STENDRA.xml:S1:900:7	placebo	SYM	O	O
-	STENDRA.xml:S1:907:1	-	:	O	O
controlled	STENDRA.xml:S1:908:10	control	VBN	O	O
trials	STENDRA.xml:S1:919:6	trial	NNS	O	O
lasting	STENDRA.xml:S1:926:7	last	VBG	O	O
up	STENDRA.xml:S1:934:2	up	RB	O	O
to	STENDRA.xml:S1:937:2	to	TO	O	O
3	STENDRA.xml:S1:940:1	3	CD	O	O
months	STENDRA.xml:S1:942:6	month	NNS	O	O
in	STENDRA.xml:S1:949:2	in	IN	O	O
duration	STENDRA.xml:S1:952:8	durat	NN	O	O
,	STENDRA.xml:S1:960:1	,	,	O	O
the	STENDRA.xml:S1:962:3	the	DT	O	O
mean	STENDRA.xml:S1:966:4	mean	JJ	O	O
age	STENDRA.xml:S1:971:3	age	NN	O	O
of	STENDRA.xml:S1:975:2	of	IN	O	O
patients	STENDRA.xml:S1:978:8	patient	NNS	O	O
was	STENDRA.xml:S1:987:3	wa	VBD	O	O
56.4	STENDRA.xml:S1:991:4	56.4	CD	O	O
years	STENDRA.xml:S1:996:5	year	NNS	O	O
(	STENDRA.xml:S1:1002:1	(	(	O	O
range	STENDRA.xml:S1:1003:5	rang	NN	O	O
from	STENDRA.xml:S1:1009:4	from	IN	O	O
23	STENDRA.xml:S1:1014:2	23	CD	O	O
to	STENDRA.xml:S1:1017:2	to	TO	O	O
88	STENDRA.xml:S1:1020:2	88	CD	O	O
years	STENDRA.xml:S1:1023:5	year	NNS	O	O
)	STENDRA.xml:S1:1028:1	)	)	O	O
.	STENDRA.xml:S1:1029:1	.	.	O	O

83.9%	STENDRA.xml:S1:1031:5	83.9%	CD	O	O
of	STENDRA.xml:S1:1037:2	of	IN	O	O
patients	STENDRA.xml:S1:1040:8	patient	NNS	O	O
were	STENDRA.xml:S1:1049:4	were	VBD	O	O
White	STENDRA.xml:S1:1054:5	white	NNP	O	O
,	STENDRA.xml:S1:1059:1	,	,	O	O
13.8%	STENDRA.xml:S1:1061:5	13.8%	CD	O	O
were	STENDRA.xml:S1:1067:4	were	VBD	O	O
Black	STENDRA.xml:S1:1072:5	black	NNP	O	O
,	STENDRA.xml:S1:1077:1	,	,	O	O
1.4%	STENDRA.xml:S1:1079:4	1.4%	CD	O	O
Asian	STENDRA.xml:S1:1084:5	asian	JJ	O	O
,	STENDRA.xml:S1:1089:1	,	,	O	O
and	STENDRA.xml:S1:1091:3	and	CC	O	O
1%	STENDRA.xml:S1:1097:2	1%	CD	O	O
Hispanic	STENDRA.xml:S1:1100:8	hispan	NNP	O	O
.	STENDRA.xml:S1:1108:1	.	.	O	O

41.1%	STENDRA.xml:S1:1110:5	41.1%	CD	O	O
were	STENDRA.xml:S1:1116:4	were	VBD	O	O
current	STENDRA.xml:S1:1121:7	current	JJ	O	O
or	STENDRA.xml:S1:1129:2	or	CC	O	O
previous	STENDRA.xml:S1:1132:8	previou	JJ	O	O
smokers	STENDRA.xml:S1:1141:7	smoker	NNS	O	O
.	STENDRA.xml:S1:1148:1	.	.	O	O

30.6%	STENDRA.xml:S1:1150:5	30.6%	CD	O	O
had	STENDRA.xml:S1:1156:3	had	VBD	O	O
diabetes	STENDRA.xml:S1:1160:8	diabet	NNS	O	O
mellitus	STENDRA.xml:S1:1169:8	mellitu	NNS	O	O
.	STENDRA.xml:S1:1177:1	.	.	O	O

The	STENDRA.xml:S1:1183:3	the	DT	O	O
discontinuation	STENDRA.xml:S1:1187:15	discontinu	NN	O	O
rate	STENDRA.xml:S1:1203:4	rate	NN	O	O
due	STENDRA.xml:S1:1208:3	due	JJ	O	O
to	STENDRA.xml:S1:1212:2	to	TO	O	O
adverse	STENDRA.xml:S1:1215:7	advers	JJ	O	O
reactions	STENDRA.xml:S1:1223:9	reaction	NNS	O	O
for	STENDRA.xml:S1:1233:3	for	IN	O	O
patients	STENDRA.xml:S1:1237:8	patient	NNS	O	O
treated	STENDRA.xml:S1:1246:7	treat	VBN	O	O
with	STENDRA.xml:S1:1254:4	with	IN	O	O
STENDRA	STENDRA.xml:S1:1259:7	stendra	NNP	O	O
50	STENDRA.xml:S1:1267:2	50	CD	O	O
mg	STENDRA.xml:S1:1270:2	mg	NN	O	O
,	STENDRA.xml:S1:1272:1	,	,	O	O
100	STENDRA.xml:S1:1274:3	100	CD	O	O
mg	STENDRA.xml:S1:1278:2	mg	NN	O	O
,	STENDRA.xml:S1:1280:1	,	,	O	O
or	STENDRA.xml:S1:1282:2	or	CC	O	O
200	STENDRA.xml:S1:1285:3	200	CD	O	O
mg	STENDRA.xml:S1:1289:2	mg	NN	O	O
was	STENDRA.xml:S1:1292:3	wa	VBD	O	O
1.4%	STENDRA.xml:S1:1296:4	1.4%	CD	O	O
,	STENDRA.xml:S1:1300:1	,	,	O	O
2.0%	STENDRA.xml:S1:1302:4	2.0%	CD	O	O
,	STENDRA.xml:S1:1306:1	,	,	O	O
and	STENDRA.xml:S1:1308:3	and	CC	O	O
2.0%	STENDRA.xml:S1:1312:4	2.0%	CD	O	O
,	STENDRA.xml:S1:1316:1	,	,	O	O
respectively	STENDRA.xml:S1:1318:12	respect	RB	O	O
,	STENDRA.xml:S1:1330:1	,	,	O	O
compared	STENDRA.xml:S1:1332:8	compar	VBN	O	O
to	STENDRA.xml:S1:1341:2	to	TO	O	O
1.7%	STENDRA.xml:S1:1344:4	1.7%	CD	O	O
for	STENDRA.xml:S1:1349:3	for	IN	O	O
placebo	STENDRA.xml:S1:1353:7	placebo	NN	O	O
-	STENDRA.xml:S1:1360:1	-	:	O	O
treated	STENDRA.xml:S1:1361:7	treat	JJ	O	O
patients	STENDRA.xml:S1:1369:8	patient	NNS	O	O
.	STENDRA.xml:S1:1377:1	.	.	O	O

Table	STENDRA.xml:S1:1383:5	tabl	JJ	O	O
1	STENDRA.xml:S1:1389:1	1	CD	O	O
presents	STENDRA.xml:S1:1391:8	present	VBZ	O	O
the	STENDRA.xml:S1:1400:3	the	DT	O	O
adverse	STENDRA.xml:S1:1404:7	advers	JJ	O	O
reactions	STENDRA.xml:S1:1412:9	reaction	NNS	O	O
reported	STENDRA.xml:S1:1422:8	report	VBD	O	O
when	STENDRA.xml:S1:1431:4	when	WRB	O	O
STENDRA	STENDRA.xml:S1:1436:7	stendra	NNP	O	O
was	STENDRA.xml:S1:1444:3	wa	VBD	O	O
taken	STENDRA.xml:S1:1448:5	taken	VBN	O	O
as	STENDRA.xml:S1:1454:2	as	RB	O	O
recommended	STENDRA.xml:S1:1457:11	recommend	JJ	O	O
(	STENDRA.xml:S1:1469:1	(	(	O	O
on	STENDRA.xml:S1:1470:2	on	IN	O	O
an	STENDRA.xml:S1:1473:2	an	DT	O	O
as	STENDRA.xml:S1:1476:2	as	IN	O	O
-	STENDRA.xml:S1:1478:1	-	:	O	O
needed	STENDRA.xml:S1:1479:6	need	JJ	O	O
basis	STENDRA.xml:S1:1486:5	basi	NN	O	O
)	STENDRA.xml:S1:1491:1	)	)	O	O
from	STENDRA.xml:S1:1493:4	from	IN	O	O
these	STENDRA.xml:S1:1498:5	these	DT	O	O
3	STENDRA.xml:S1:1504:1	3	CD	O	O
clinical	STENDRA.xml:S1:1506:8	clinic	JJ	O	O
trials	STENDRA.xml:S1:1515:6	trial	NNS	O	O
.	STENDRA.xml:S1:1521:1	.	.	O	O

Table	STENDRA.xml:S1:1527:5	tabl	JJ	O	O
1	STENDRA.xml:S1:1533:1	1	CD	O	O
:	STENDRA.xml:S1:1534:1	:	:	O	O
Adverse	STENDRA.xml:S1:1536:7	advers	JJ	O	O
Reactions	STENDRA.xml:S1:1544:9	reaction	NNS	O	O
Reported	STENDRA.xml:S1:1554:8	report	VBN	O	O
by	STENDRA.xml:S1:1563:2	by	IN	O	O
Greater	STENDRA.xml:S1:1566:7	greater	NNP	O	O
Than	STENDRA.xml:S1:1574:4	than	NNP	O	O
or	STENDRA.xml:S1:1579:2	or	CC	O	O
Equal	STENDRA.xml:S1:1582:5	equal	NNP	O	O
to	STENDRA.xml:S1:1588:2	to	TO	O	O
2%	STENDRA.xml:S1:1591:2	2%	CD	O	O
of	STENDRA.xml:S1:1594:2	of	IN	O	O
Patients	STENDRA.xml:S1:1597:8	patient	NNS	O	O
Treated	STENDRA.xml:S1:1606:7	treat	VBN	O	O
with	STENDRA.xml:S1:1614:4	with	IN	O	O
STENDRA	STENDRA.xml:S1:1619:7	stendra	NNP	O	O
From	STENDRA.xml:S1:1627:4	from	NNP	O	O
3	STENDRA.xml:S1:1632:1	3	CD	O	O
Placebo	STENDRA.xml:S1:1634:7	placebo	NNP	O	O
-	STENDRA.xml:S1:1641:1	-	:	O	O
Controlled	STENDRA.xml:S1:1642:10	control	VBD	O	O
Clinical	STENDRA.xml:S1:1653:8	clinic	JJ	O	O
Trials	STENDRA.xml:S1:1662:6	trial	NNS	O	O
Lasting	STENDRA.xml:S1:1669:7	last	VBG	O	O
3	STENDRA.xml:S1:1677:1	3	CD	O	O
Months	STENDRA.xml:S1:1679:6	month	NNS	O	O
for	STENDRA.xml:S1:1686:3	for	IN	O	O
STENDRA	STENDRA.xml:S1:1690:7	stendra	NNP	O	O
Use	STENDRA.xml:S1:1698:3	use	NNP	O	O
as	STENDRA.xml:S1:1702:2	as	IN	O	O
Needed	STENDRA.xml:S1:1705:6	need	NNP	O	O

Adverse	STENDRA.xml:S1:1714:7	advers	JJ	O	O
Reaction	STENDRA.xml:S1:1722:8	reaction	NNP	O	O
Placebo	STENDRA.xml:S1:1741:7	placebo	NNP	O	O
(	STENDRA.xml:S1:1748:1	(	(	O	O
N	STENDRA.xml:S1:1749:1	N	NNP	O	O
349	STENDRA.xml:S1:1753:3	349	CD	O	O
)	STENDRA.xml:S1:1756:1	)	)	O	O
STENDRA	STENDRA.xml:S1:1759:7	stendra	NNP	O	O
50	STENDRA.xml:S1:1767:2	50	CD	O	O
mg	STENDRA.xml:S1:1770:2	mg	NN	O	O
(	STENDRA.xml:S1:1772:1	(	(	O	O
N	STENDRA.xml:S1:1773:1	N	NNP	O	O
217	STENDRA.xml:S1:1777:3	217	CD	O	O
)	STENDRA.xml:S1:1780:1	)	)	O	O
STENDRA	STENDRA.xml:S1:1783:7	stendra	NNP	O	O
100	STENDRA.xml:S1:1791:3	100	CD	O	O
mg	STENDRA.xml:S1:1795:2	mg	NN	O	O
(	STENDRA.xml:S1:1797:1	(	(	O	O
N	STENDRA.xml:S1:1798:1	N	NNP	O	O
349	STENDRA.xml:S1:1802:3	349	CD	O	O
)	STENDRA.xml:S1:1805:1	)	)	O	O
STENDRA	STENDRA.xml:S1:1808:7	stendra	NNP	O	O
200	STENDRA.xml:S1:1816:3	200	CD	O	O
mg	STENDRA.xml:S1:1820:2	mg	NN	O	O
(	STENDRA.xml:S1:1822:1	(	(	O	O
N	STENDRA.xml:S1:1823:1	N	NNP	O	O
352	STENDRA.xml:S1:1827:3	352	CD	O	O
)	STENDRA.xml:S1:1830:1	)	)	O	O

Headache	STENDRA.xml:S1:1839:8	headach	NN	B-AdverseReaction	B-AdverseReaction

1.7%	STENDRA.xml:S1:1871:4	1.7%	CD	O	O
5.1%	STENDRA.xml:S1:1891:4	5.1%	CD	O	O
6.9%	STENDRA.xml:S1:1913:4	6.9%	CD	O	O
10.5%	STENDRA.xml:S1:1934:5	10.5%	CD	O	O

Flushing	STENDRA.xml:S1:1952:8	flush	VBG	B-AdverseReaction	B-AdverseReaction
0.0%	STENDRA.xml:S1:1984:4	0.0%	CD	O	O
3.2%	STENDRA.xml:S1:2004:4	3.2%	CD	O	O
4.3%	STENDRA.xml:S1:2026:4	4.3%	CD	O	O
4.0%	STENDRA.xml:S1:2048:4	4.0%	CD	O	O

Nasal	STENDRA.xml:S1:2065:5	nasal	NNP	B-AdverseReaction	B-AdverseReaction
congestion	STENDRA.xml:S1:2071:10	congest	NN	I-AdverseReaction	I-AdverseReaction
1.1%	STENDRA.xml:S1:2097:4	1.1%	CD	O	O
1.8%	STENDRA.xml:S1:2117:4	1.8%	CD	O	O
2.9%	STENDRA.xml:S1:2139:4	2.9%	CD	O	O
2.0%	STENDRA.xml:S1:2161:4	2.0%	CD	O	O

Nasopharyngitis	STENDRA.xml:S1:2178:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
2.9%	STENDRA.xml:S1:2210:4	2.9%	CD	O	O
0.9%	STENDRA.xml:S1:2230:4	0.9%	CD	O	O
2.6%	STENDRA.xml:S1:2252:4	2.6%	CD	O	O
3.4%	STENDRA.xml:S1:2274:4	3.4%	CD	O	O

Back	STENDRA.xml:S1:2291:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	STENDRA.xml:S1:2296:4	pain	NN	I-AdverseReaction	I-AdverseReaction
1.1%	STENDRA.xml:S1:2323:4	1.1%	CD	O	O
3.2%	STENDRA.xml:S1:2343:4	3.2%	CD	O	O
2.0%	STENDRA.xml:S1:2365:4	2.0%	CD	O	O
1.1%	STENDRA.xml:S1:2387:4	1.1%	CD	O	O

Adverse	STENDRA.xml:S1:2414:7	advers	JJ	O	O
reactions	STENDRA.xml:S1:2422:9	reaction	NNS	O	O
reported	STENDRA.xml:S1:2432:8	report	VBN	O	O
by	STENDRA.xml:S1:2441:2	by	IN	O	O
greater	STENDRA.xml:S1:2444:7	greater	JJR	O	O
than	STENDRA.xml:S1:2452:4	than	IN	O	O
or	STENDRA.xml:S1:2457:2	or	CC	O	O
equal	STENDRA.xml:S1:2460:5	equal	JJ	O	O
to	STENDRA.xml:S1:2466:2	to	TO	O	O
1%	STENDRA.xml:S1:2469:2	1%	CD	O	O
,	STENDRA.xml:S1:2471:1	,	,	O	O
but	STENDRA.xml:S1:2473:3	but	CC	O	O
less	STENDRA.xml:S1:2477:4	less	JJR	O	O
than	STENDRA.xml:S1:2482:4	than	IN	O	O
2%	STENDRA.xml:S1:2487:2	2%	CD	O	O
of	STENDRA.xml:S1:2490:2	of	IN	O	O
patients	STENDRA.xml:S1:2493:8	patient	NNS	O	O
in	STENDRA.xml:S1:2502:2	in	IN	O	O
any	STENDRA.xml:S1:2505:3	ani	DT	O	O
STENDRA	STENDRA.xml:S1:2509:7	stendra	NNP	O	O
dose	STENDRA.xml:S1:2517:4	dose	NN	O	O
group	STENDRA.xml:S1:2522:5	group	NN	O	O
,	STENDRA.xml:S1:2527:1	,	,	O	O
and	STENDRA.xml:S1:2529:3	and	CC	O	O
greater	STENDRA.xml:S1:2533:7	greater	JJR	O	O
than	STENDRA.xml:S1:2541:4	than	IN	O	O
placebo	STENDRA.xml:S1:2546:7	placebo	NN	O	O
included	STENDRA.xml:S1:2554:8	includ	VBD	O	O
:	STENDRA.xml:S1:2562:1	:	:	O	O
upper	STENDRA.xml:S1:2564:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	STENDRA.xml:S1:2570:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
infection	STENDRA.xml:S1:2582:9	infect	NN	I-AdverseReaction	I-AdverseReaction
(	STENDRA.xml:S1:2592:1	(	(	O	O
URI	STENDRA.xml:S1:2593:3	uri	NNP	B-AdverseReaction	O
)	STENDRA.xml:S1:2596:1	)	)	O	O
,	STENDRA.xml:S1:2597:1	,	,	O	O
bronchitis	STENDRA.xml:S1:2599:10	bronchiti	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:2609:1	,	,	O	O
influenza	STENDRA.xml:S1:2611:9	influenza	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:2620:1	,	,	O	O
sinusitis	STENDRA.xml:S1:2622:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:2631:1	,	,	O	O
sinus	STENDRA.xml:S1:2633:5	sinu	JJ	B-AdverseReaction	B-AdverseReaction
congestion	STENDRA.xml:S1:2639:10	congest	NN	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:2649:1	,	,	O	O
hypertension	STENDRA.xml:S1:2651:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:2663:1	,	,	O	O
dyspepsia	STENDRA.xml:S1:2665:9	dyspepsia	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:2674:1	,	,	O	O
nausea	STENDRA.xml:S1:2676:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:2682:1	,	,	O	O
constipation	STENDRA.xml:S1:2684:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:2696:1	,	,	O	O
and	STENDRA.xml:S1:2698:3	and	CC	O	O
rash	STENDRA.xml:S1:2702:4	rash	NN	B-AdverseReaction	B-AdverseReaction
.	STENDRA.xml:S1:2706:1	.	.	O	O

In	STENDRA.xml:S1:2712:2	In	IN	O	O

an	STENDRA.xml:S1:2715:2	an	DT	O	O
open	STENDRA.xml:S1:2718:4	open	JJ	O	O
-	STENDRA.xml:S1:2722:1	-	:	O	O
label	STENDRA.xml:S1:2723:5	label	NN	O	O
,	STENDRA.xml:S1:2728:1	,	,	O	O
long	STENDRA.xml:S1:2730:4	long	JJ	O	O
-	STENDRA.xml:S1:2734:1	-	:	O	O
term	STENDRA.xml:S1:2735:4	term	NN	O	O
extension	STENDRA.xml:S1:2740:9	extens	NN	O	O
study	STENDRA.xml:S1:2750:5	studi	NN	O	O
of	STENDRA.xml:S1:2756:2	of	IN	O	O
two	STENDRA.xml:S1:2759:3	two	CD	O	O
of	STENDRA.xml:S1:2763:2	of	IN	O	O
these	STENDRA.xml:S1:2766:5	these	DT	O	O
randomized	STENDRA.xml:S1:2772:10	random	VBN	O	O
,	STENDRA.xml:S1:2782:1	,	,	O	O
double	STENDRA.xml:S1:2784:6	doubl	JJ	O	O
-	STENDRA.xml:S1:2790:1	-	:	O	O
blind	STENDRA.xml:S1:2791:5	blind	NN	O	O
,	STENDRA.xml:S1:2796:1	,	,	O	O
placebo	STENDRA.xml:S1:2798:7	placebo	SYM	O	O
-	STENDRA.xml:S1:2805:1	-	:	O	O
controlled	STENDRA.xml:S1:2806:10	control	VBN	O	O
trials	STENDRA.xml:S1:2817:6	trial	NNS	O	O
,	STENDRA.xml:S1:2823:1	,	,	O	O
the	STENDRA.xml:S1:2825:3	the	DT	O	O
total	STENDRA.xml:S1:2829:5	total	JJ	O	O
duration	STENDRA.xml:S1:2835:8	durat	NN	O	O
of	STENDRA.xml:S1:2844:2	of	IN	O	O
treatment	STENDRA.xml:S1:2847:9	treatment	NN	O	O
was	STENDRA.xml:S1:2857:3	wa	VBD	O	O
up	STENDRA.xml:S1:2861:2	up	RB	O	O
to	STENDRA.xml:S1:2864:2	to	TO	O	O
52	STENDRA.xml:S1:2867:2	52	CD	O	O
weeks	STENDRA.xml:S1:2870:5	week	NNS	O	O
.	STENDRA.xml:S1:2875:1	.	.	O	O

Among	STENDRA.xml:S1:2877:5	among	IN	O	O
the	STENDRA.xml:S1:2883:3	the	DT	O	O
712	STENDRA.xml:S1:2887:3	712	CD	O	O
patients	STENDRA.xml:S1:2891:8	patient	NNS	O	O
who	STENDRA.xml:S1:2900:3	who	WP	O	O
participated	STENDRA.xml:S1:2904:12	particip	VBD	O	O
in	STENDRA.xml:S1:2917:2	in	IN	O	O
this	STENDRA.xml:S1:2920:4	thi	DT	O	O
open	STENDRA.xml:S1:2925:4	open	JJ	O	O
-	STENDRA.xml:S1:2929:1	-	:	O	O
label	STENDRA.xml:S1:2930:5	label	NN	O	O
extension	STENDRA.xml:S1:2936:9	extens	NN	O	O
study	STENDRA.xml:S1:2946:5	studi	NN	O	O
,	STENDRA.xml:S1:2951:1	,	,	O	O
the	STENDRA.xml:S1:2953:3	the	DT	O	O
mean	STENDRA.xml:S1:2957:4	mean	JJ	O	O
age	STENDRA.xml:S1:2962:3	age	NN	O	O
of	STENDRA.xml:S1:2966:2	of	IN	O	O
the	STENDRA.xml:S1:2969:3	the	DT	O	O
population	STENDRA.xml:S1:2973:10	popul	NN	O	O
was	STENDRA.xml:S1:2984:3	wa	VBD	O	O
56.4	STENDRA.xml:S1:2988:4	56.4	CD	O	O
years	STENDRA.xml:S1:2993:5	year	NNS	O	O
(	STENDRA.xml:S1:2999:1	(	(	O	O
range	STENDRA.xml:S1:3000:5	rang	NN	O	O
from	STENDRA.xml:S1:3006:4	from	IN	O	O
23	STENDRA.xml:S1:3011:2	23	CD	O	O
to	STENDRA.xml:S1:3014:2	to	TO	O	O
88	STENDRA.xml:S1:3017:2	88	CD	O	O
years	STENDRA.xml:S1:3020:5	year	NNS	O	O
)	STENDRA.xml:S1:3025:1	)	)	O	O
.	STENDRA.xml:S1:3026:1	.	.	O	O

The	STENDRA.xml:S1:3028:3	the	DT	O	O
discontinuation	STENDRA.xml:S1:3032:15	discontinu	NN	O	O
rate	STENDRA.xml:S1:3048:4	rate	NN	O	O
due	STENDRA.xml:S1:3053:3	due	JJ	O	O
to	STENDRA.xml:S1:3057:2	to	TO	O	O
adverse	STENDRA.xml:S1:3060:7	advers	JJ	O	O
reactions	STENDRA.xml:S1:3068:9	reaction	NNS	O	O
for	STENDRA.xml:S1:3078:3	for	IN	O	O
patients	STENDRA.xml:S1:3082:8	patient	NNS	O	O
treated	STENDRA.xml:S1:3091:7	treat	VBN	O	O
with	STENDRA.xml:S1:3099:4	with	IN	O	O
STENDRA	STENDRA.xml:S1:3104:7	stendra	NNP	O	O
(	STENDRA.xml:S1:3112:1	(	(	O	O
50	STENDRA.xml:S1:3113:2	50	CD	O	O
mg	STENDRA.xml:S1:3116:2	mg	NN	O	O
,	STENDRA.xml:S1:3118:1	,	,	O	O
100	STENDRA.xml:S1:3120:3	100	CD	O	O
mg	STENDRA.xml:S1:3124:2	mg	NN	O	O
,	STENDRA.xml:S1:3126:1	,	,	O	O
or	STENDRA.xml:S1:3128:2	or	CC	O	O
200	STENDRA.xml:S1:3131:3	200	CD	O	O
mg	STENDRA.xml:S1:3135:2	mg	NN	O	O
)	STENDRA.xml:S1:3137:1	)	)	O	O
was	STENDRA.xml:S1:3139:3	wa	VBD	O	O
2.8%	STENDRA.xml:S1:3143:4	2.8%	CD	O	O
.	STENDRA.xml:S1:3147:1	.	.	O	O

In	STENDRA.xml:S1:3153:2	In	IN	O	O
this	STENDRA.xml:S1:3156:4	thi	DT	O	O
extension	STENDRA.xml:S1:3161:9	extens	NN	O	O
trial	STENDRA.xml:S1:3171:5	trial	NN	O	O
,	STENDRA.xml:S1:3176:1	,	,	O	O
all	STENDRA.xml:S1:3178:3	all	DT	O	O
eligible	STENDRA.xml:S1:3182:8	elig	JJ	O	O
patients	STENDRA.xml:S1:3191:8	patient	NNS	O	O
were	STENDRA.xml:S1:3200:4	were	VBD	O	O
initially	STENDRA.xml:S1:3205:9	initi	RB	O	O
assigned	STENDRA.xml:S1:3215:8	assign	VBN	O	O
to	STENDRA.xml:S1:3224:2	to	TO	O	O
STENDRA	STENDRA.xml:S1:3227:7	stendra	NNP	O	O
100	STENDRA.xml:S1:3235:3	100	CD	O	O
mg	STENDRA.xml:S1:3239:2	mg	NN	O	O
.	STENDRA.xml:S1:3241:1	.	.	O	O

At	STENDRA.xml:S1:3243:2	At	IN	O	O
any	STENDRA.xml:S1:3246:3	ani	DT	O	O
point	STENDRA.xml:S1:3250:5	point	NN	O	O
during	STENDRA.xml:S1:3256:6	dure	IN	O	O
the	STENDRA.xml:S1:3263:3	the	DT	O	O
trial	STENDRA.xml:S1:3267:5	trial	NN	O	O
,	STENDRA.xml:S1:3272:1	,	,	O	O
patients	STENDRA.xml:S1:3274:8	patient	NNS	O	O
could	STENDRA.xml:S1:3283:5	could	MD	O	O
request	STENDRA.xml:S1:3289:7	request	VB	O	O
to	STENDRA.xml:S1:3297:2	to	TO	O	O
have	STENDRA.xml:S1:3300:4	have	VB	O	O
their	STENDRA.xml:S1:3305:5	their	PRP$	O	O
dose	STENDRA.xml:S1:3311:4	dose	NN	O	O
of	STENDRA.xml:S1:3316:2	of	IN	O	O
STENDRA	STENDRA.xml:S1:3319:7	stendra	NNP	O	O
increased	STENDRA.xml:S1:3327:9	increas	VBD	O	O
to	STENDRA.xml:S1:3337:2	to	TO	O	O
200	STENDRA.xml:S1:3340:3	200	CD	O	O
mg	STENDRA.xml:S1:3344:2	mg	NN	O	O
or	STENDRA.xml:S1:3347:2	or	CC	O	O
decreased	STENDRA.xml:S1:3350:9	decreas	VBN	O	O
to	STENDRA.xml:S1:3360:2	to	TO	O	O
50	STENDRA.xml:S1:3363:2	50	CD	O	O
mg	STENDRA.xml:S1:3366:2	mg	NNS	O	O
based	STENDRA.xml:S1:3369:5	base	VBN	O	O
on	STENDRA.xml:S1:3375:2	on	IN	O	O
their	STENDRA.xml:S1:3378:5	their	PRP$	O	O
individual	STENDRA.xml:S1:3384:10	individu	JJ	O	O
response	STENDRA.xml:S1:3395:8	respons	NN	O	O
to	STENDRA.xml:S1:3404:2	to	TO	O	O
treatment	STENDRA.xml:S1:3407:9	treatment	NN	O	O
.	STENDRA.xml:S1:3416:1	.	.	O	O

In	STENDRA.xml:S1:3418:2	In	IN	O	O
total	STENDRA.xml:S1:3421:5	total	JJ	O	O
,	STENDRA.xml:S1:3426:1	,	,	O	O
536	STENDRA.xml:S1:3428:3	536	CD	O	O
(	STENDRA.xml:S1:3432:1	(	(	O	O
approximately	STENDRA.xml:S1:3433:13	approxim	RB	O	O
75%	STENDRA.xml:S1:3447:3	75%	CD	O	O
)	STENDRA.xml:S1:3450:1	)	)	O	O
patients	STENDRA.xml:S1:3452:8	patient	NNS	O	O
increased	STENDRA.xml:S1:3461:9	increas	VBD	O	O
their	STENDRA.xml:S1:3471:5	their	PRP$	O	O
dose	STENDRA.xml:S1:3477:4	dose	NN	O	O
to	STENDRA.xml:S1:3482:2	to	TO	O	O
200	STENDRA.xml:S1:3485:3	200	CD	O	O
mg	STENDRA.xml:S1:3489:2	mg	NNS	O	O
and	STENDRA.xml:S1:3492:3	and	CC	O	O
5	STENDRA.xml:S1:3496:1	5	CD	O	O
(	STENDRA.xml:S1:3498:1	(	(	O	O
less	STENDRA.xml:S1:3499:4	less	JJR	O	O
than	STENDRA.xml:S1:3504:4	than	IN	O	O
1%	STENDRA.xml:S1:3509:2	1%	CD	O	O
)	STENDRA.xml:S1:3511:1	)	)	O	O
patients	STENDRA.xml:S1:3513:8	patient	NNS	O	O
reduced	STENDRA.xml:S1:3522:7	reduc	VBD	O	O
their	STENDRA.xml:S1:3530:5	their	PRP$	O	O
dose	STENDRA.xml:S1:3536:4	dose	NN	O	O
to	STENDRA.xml:S1:3541:2	to	TO	O	O
50	STENDRA.xml:S1:3544:2	50	CD	O	O
mg	STENDRA.xml:S1:3547:2	mg	NNS	O	O
.	STENDRA.xml:S1:3549:1	.	.	O	O

Table	STENDRA.xml:S1:3555:5	tabl	JJ	O	O
2	STENDRA.xml:S1:3561:1	2	CD	O	O
presents	STENDRA.xml:S1:3563:8	present	VBZ	O	O
the	STENDRA.xml:S1:3572:3	the	DT	O	O
adverse	STENDRA.xml:S1:3576:7	advers	JJ	O	O
reactions	STENDRA.xml:S1:3584:9	reaction	NNS	O	O
reported	STENDRA.xml:S1:3594:8	report	VBD	O	O
when	STENDRA.xml:S1:3603:4	when	WRB	O	O
STENDRA	STENDRA.xml:S1:3608:7	stendra	NNP	O	O
was	STENDRA.xml:S1:3616:3	wa	VBD	O	O
taken	STENDRA.xml:S1:3620:5	taken	VBN	O	O
as	STENDRA.xml:S1:3626:2	as	RB	O	O
recommended	STENDRA.xml:S1:3629:11	recommend	JJ	O	O
(	STENDRA.xml:S1:3641:1	(	(	O	O
on	STENDRA.xml:S1:3642:2	on	IN	O	O
an	STENDRA.xml:S1:3645:2	an	DT	O	O
as	STENDRA.xml:S1:3648:2	as	IN	O	O
-	STENDRA.xml:S1:3650:1	-	:	O	O
needed	STENDRA.xml:S1:3651:6	need	JJ	O	O
basis	STENDRA.xml:S1:3658:5	basi	NN	O	O
)	STENDRA.xml:S1:3663:1	)	)	O	O
in	STENDRA.xml:S1:3665:2	in	IN	O	O
this	STENDRA.xml:S1:3668:4	thi	DT	O	O
open	STENDRA.xml:S1:3673:4	open	JJ	O	O
-	STENDRA.xml:S1:3677:1	-	:	O	O
label	STENDRA.xml:S1:3678:5	label	NN	O	O
extension	STENDRA.xml:S1:3684:9	extens	NN	O	O
trial	STENDRA.xml:S1:3694:5	trial	NN	O	O
.	STENDRA.xml:S1:3699:1	.	.	O	O

Table	STENDRA.xml:S1:3705:5	tabl	JJ	O	O
2	STENDRA.xml:S1:3711:1	2	CD	O	O
:	STENDRA.xml:S1:3712:1	:	:	O	O
Adverse	STENDRA.xml:S1:3714:7	advers	JJ	O	O
Reactions	STENDRA.xml:S1:3722:9	reaction	NNS	O	O
Reported	STENDRA.xml:S1:3732:8	report	VBN	O	O
by	STENDRA.xml:S1:3741:2	by	IN	O	O
Greater	STENDRA.xml:S1:3744:7	greater	NNP	O	O
Than	STENDRA.xml:S1:3752:4	than	NNP	O	O
or	STENDRA.xml:S1:3757:2	or	CC	O	O
Equal	STENDRA.xml:S1:3760:5	equal	NNP	O	O
to	STENDRA.xml:S1:3766:2	to	TO	O	O
2%	STENDRA.xml:S1:3769:2	2%	CD	O	O
of	STENDRA.xml:S1:3772:2	of	IN	O	O
Patients	STENDRA.xml:S1:3775:8	patient	NNS	O	O
Treated	STENDRA.xml:S1:3784:7	treat	VBN	O	O
With	STENDRA.xml:S1:3792:4	with	IN	O	O
STENDRA	STENDRA.xml:S1:3797:7	stendra	NNP	O	O
in	STENDRA.xml:S1:3805:2	in	IN	O	O
an	STENDRA.xml:S1:3808:2	an	DT	O	O
Open	STENDRA.xml:S1:3811:4	open	JJ	O	O
-	STENDRA.xml:S1:3815:1	-	:	O	O
Label	STENDRA.xml:S1:3816:5	label	NNP	O	O
Extension	STENDRA.xml:S1:3822:9	extens	NNP	O	O
Trial	STENDRA.xml:S1:3832:5	trial	NNP	O	O

Adverse	STENDRA.xml:S1:3840:7	advers	JJ	O	O
Reaction	STENDRA.xml:S1:3848:8	reaction	NNP	O	O
STENDRA	STENDRA.xml:S1:3909:7	stendra	NNP	O	O
(	STENDRA.xml:S1:3916:1	(	(	O	O
N	STENDRA.xml:S1:3917:1	N	NNP	O	O
711	STENDRA.xml:S1:3921:3	711	CD	O	O
)	STENDRA.xml:S1:3924:1	)	)	O	O

Headache	STENDRA.xml:S1:3950:8	headach	NN	B-AdverseReaction	B-AdverseReaction

5.6%	STENDRA.xml:S1:4025:4	5.6%	CD	O	O

Flushing	STENDRA.xml:S1:4057:8	flush	VBG	B-AdverseReaction	B-AdverseReaction
3.5%	STENDRA.xml:S1:4132:4	3.5%	CD	O	O

Nasopharyngitis	STENDRA.xml:S1:4164:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
3.4%	STENDRA.xml:S1:4239:4	3.4%	CD	O	O

Nasal	STENDRA.xml:S1:4271:5	nasal	NNP	B-AdverseReaction	B-AdverseReaction
congestion	STENDRA.xml:S1:4277:10	congest	NN	I-AdverseReaction	I-AdverseReaction
2.1%	STENDRA.xml:S1:4346:4	2.1%	CD	O	O

Adverse	STENDRA.xml:S1:4385:7	advers	JJ	O	O
reactions	STENDRA.xml:S1:4393:9	reaction	NNS	O	O
reported	STENDRA.xml:S1:4403:8	report	VBN	O	O
by	STENDRA.xml:S1:4412:2	by	IN	O	O
greater	STENDRA.xml:S1:4415:7	greater	JJR	O	O
than	STENDRA.xml:S1:4423:4	than	IN	O	O
or	STENDRA.xml:S1:4428:2	or	CC	O	O
equal	STENDRA.xml:S1:4431:5	equal	JJ	O	O
to	STENDRA.xml:S1:4437:2	to	TO	O	O
1%	STENDRA.xml:S1:4440:2	1%	CD	O	O
,	STENDRA.xml:S1:4442:1	,	,	O	O
but	STENDRA.xml:S1:4444:3	but	CC	O	O
less	STENDRA.xml:S1:4448:4	less	JJR	O	O
than	STENDRA.xml:S1:4453:4	than	IN	O	O
2%	STENDRA.xml:S1:4458:2	2%	CD	O	O
of	STENDRA.xml:S1:4461:2	of	IN	O	O
patients	STENDRA.xml:S1:4464:8	patient	NNS	O	O
in	STENDRA.xml:S1:4473:2	in	IN	O	O
the	STENDRA.xml:S1:4476:3	the	DT	O	O
open	STENDRA.xml:S1:4480:4	open	JJ	O	O
-	STENDRA.xml:S1:4484:1	-	:	O	O
label	STENDRA.xml:S1:4485:5	label	NN	O	O
extension	STENDRA.xml:S1:4491:9	extens	NN	O	O
study	STENDRA.xml:S1:4501:5	studi	NN	O	O
included	STENDRA.xml:S1:4507:8	includ	VBD	O	O
:	STENDRA.xml:S1:4515:1	:	:	O	O
upper	STENDRA.xml:S1:4517:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	STENDRA.xml:S1:4523:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
infection	STENDRA.xml:S1:4535:9	infect	NN	I-AdverseReaction	I-AdverseReaction
(	STENDRA.xml:S1:4545:1	(	(	O	O
URI	STENDRA.xml:S1:4546:3	uri	NNP	B-AdverseReaction	O
)	STENDRA.xml:S1:4549:1	)	)	O	O
,	STENDRA.xml:S1:4550:1	,	,	O	O
influenza	STENDRA.xml:S1:4552:9	influenza	JJ	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:4561:1	,	,	O	O
sinusitis	STENDRA.xml:S1:4563:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:4572:1	,	,	O	O
bronchitis	STENDRA.xml:S1:4574:10	bronchiti	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:4584:1	,	,	O	O
dizziness	STENDRA.xml:S1:4586:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:4595:1	,	,	O	O
back	STENDRA.xml:S1:4597:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	STENDRA.xml:S1:4602:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:4606:1	,	,	O	O
arthralgia	STENDRA.xml:S1:4608:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:4618:1	,	,	O	O
hypertension	STENDRA.xml:S1:4620:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:4632:1	,	,	O	O
and	STENDRA.xml:S1:4634:3	and	CC	O	O
diarrhea	STENDRA.xml:S1:4638:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
.	STENDRA.xml:S1:4646:1	.	.	O	O

The	STENDRA.xml:S1:4652:3	the	DT	O	O

following	STENDRA.xml:S1:4656:9	follow	VBG	O	O
events	STENDRA.xml:S1:4666:6	event	NNS	O	O
occurred	STENDRA.xml:S1:4673:8	occur	VBD	O	O
in	STENDRA.xml:S1:4682:2	in	IN	O	O
less	STENDRA.xml:S1:4685:4	less	JJR	O	O
than	STENDRA.xml:S1:4690:4	than	IN	O	O
1%	STENDRA.xml:S1:4695:2	1%	CD	O	O
of	STENDRA.xml:S1:4698:2	of	IN	O	O
patients	STENDRA.xml:S1:4701:8	patient	NNS	O	O
in	STENDRA.xml:S1:4710:2	in	IN	O	O
the	STENDRA.xml:S1:4713:3	the	DT	O	O
three	STENDRA.xml:S1:4717:5	three	CD	O	O
placebo	STENDRA.xml:S1:4723:7	placebo	NN	O	O
-	STENDRA.xml:S1:4730:1	-	:	O	O
controlled	STENDRA.xml:S1:4731:10	control	VBD	O	O
3	STENDRA.xml:S1:4742:1	3	CD	O	O
-	STENDRA.xml:S1:4743:1	-	:	O	O
month	STENDRA.xml:S1:4744:5	month	NN	O	O
clinical	STENDRA.xml:S1:4750:8	clinic	JJ	O	O
trials	STENDRA.xml:S1:4759:6	trial	NNS	O	O
and	STENDRA.xml:S1:4766:3	and	CC	O	O
or	STENDRA.xml:S1:4770:2	or	CC	O	O
the	STENDRA.xml:S1:4773:3	the	DT	O	O
open	STENDRA.xml:S1:4777:4	open	JJ	O	O
-	STENDRA.xml:S1:4781:1	-	:	O	O
label	STENDRA.xml:S1:4782:5	label	NN	O	O
,	STENDRA.xml:S1:4787:1	,	,	O	O
long	STENDRA.xml:S1:4789:4	long	JJ	O	O
-	STENDRA.xml:S1:4793:1	-	:	O	O
term	STENDRA.xml:S1:4794:4	term	NN	O	O
extension	STENDRA.xml:S1:4799:9	extens	NN	O	O
study	STENDRA.xml:S1:4809:5	studi	NN	O	O
lasting	STENDRA.xml:S1:4815:7	last	VBG	O	O
12	STENDRA.xml:S1:4823:2	12	CD	O	O
months	STENDRA.xml:S1:4826:6	month	NNS	O	O
.	STENDRA.xml:S1:4832:1	.	.	O	O

A	STENDRA.xml:S1:4834:1	A	DT	O	O
causal	STENDRA.xml:S1:4836:6	causal	NN	O	O
relationship	STENDRA.xml:S1:4843:12	relationship	NN	O	O
to	STENDRA.xml:S1:4856:2	to	TO	O	O
STENDRA	STENDRA.xml:S1:4859:7	stendra	NNP	O	O
is	STENDRA.xml:S1:4867:2	is	VBZ	O	O
uncertain	STENDRA.xml:S1:4870:9	uncertain	JJ	O	O
.	STENDRA.xml:S1:4879:1	.	.	O	O

Excluded	STENDRA.xml:S1:4881:8	exclud	VBN	O	O
from	STENDRA.xml:S1:4890:4	from	IN	O	O
this	STENDRA.xml:S1:4895:4	thi	DT	O	O
list	STENDRA.xml:S1:4900:4	list	NN	O	O
are	STENDRA.xml:S1:4905:3	are	VBP	O	O
those	STENDRA.xml:S1:4909:5	those	DT	O	O
events	STENDRA.xml:S1:4915:6	event	NNS	O	O
that	STENDRA.xml:S1:4922:4	that	WDT	O	O
were	STENDRA.xml:S1:4927:4	were	VBD	O	O
minor	STENDRA.xml:S1:4932:5	minor	JJ	O	O
,	STENDRA.xml:S1:4937:1	,	,	O	O
those	STENDRA.xml:S1:4939:5	those	DT	O	O
with	STENDRA.xml:S1:4945:4	with	IN	O	O
no	STENDRA.xml:S1:4950:2	no	DT	O	O
plausible	STENDRA.xml:S1:4953:9	plausibl	JJ	O	O
relation	STENDRA.xml:S1:4963:8	relat	NN	O	O
to	STENDRA.xml:S1:4972:2	to	TO	O	O
drug	STENDRA.xml:S1:4975:4	drug	NN	O	O
use	STENDRA.xml:S1:4980:3	use	NN	O	O
,	STENDRA.xml:S1:4983:1	,	,	O	O
and	STENDRA.xml:S1:4985:3	and	CC	O	O
reports	STENDRA.xml:S1:4989:7	report	NNS	O	O
too	STENDRA.xml:S1:4997:3	too	RB	O	O
imprecise	STENDRA.xml:S1:5001:9	imprecis	VBP	O	O
to	STENDRA.xml:S1:5011:2	to	TO	O	O
be	STENDRA.xml:S1:5014:2	be	VB	O	O
meaningful	STENDRA.xml:S1:5017:10	meaning	JJ	O	O
.	STENDRA.xml:S1:5027:1	.	.	O	O

Body	STENDRA.xml:S1:5035:4	bodi	NN	O	O
as	STENDRA.xml:S1:5040:2	as	IN	O	O
a	STENDRA.xml:S1:5043:1	a	DT	O	O
whole	STENDRA.xml:S1:5045:5	whole	JJ	O	O
-	STENDRA.xml:S1:5052:1	-	:	O	O
edema	STENDRA.xml:S1:5054:5	edema	JJ	B-AdverseReaction	O
peripheral	STENDRA.xml:S1:5060:10	peripher	JJ	I-AdverseReaction	O
,	STENDRA.xml:S1:5070:1	,	,	O	O
fatigue	STENDRA.xml:S1:5072:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction

Cardiovascular	STENDRA.xml:S1:5086:14	cardiovascular	JJ	O	B-AdverseReaction
-	STENDRA.xml:S1:5102:1	-	:	O	I-AdverseReaction
angina	STENDRA.xml:S1:5104:6	angina	NN	B-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5110:1	,	,	O	O
unstable	STENDRA.xml:S1:5112:8	unstabl	JJ	B-AdverseReaction	B-AdverseReaction
angina	STENDRA.xml:S1:5121:6	angina	NN	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5127:1	,	,	O	O
deep	STENDRA.xml:S1:5129:4	deep	JJ	B-AdverseReaction	B-AdverseReaction
vein	STENDRA.xml:S1:5134:4	vein	NN	I-AdverseReaction	I-AdverseReaction
thrombosis	STENDRA.xml:S1:5139:10	thrombosi	NN	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5149:1	,	,	O	O
palpitations	STENDRA.xml:S1:5151:12	palpit	NNS	B-AdverseReaction	B-AdverseReaction

Digestive	STENDRA.xml:S1:5170:9	digest	NNP	O	O
-	STENDRA.xml:S1:5181:1	-	:	O	O
gastritis	STENDRA.xml:S1:5183:9	gastriti	NN	B-AdverseReaction	O
,	STENDRA.xml:S1:5192:1	,	,	O	O
gastroesophageal	STENDRA.xml:S1:5194:16	gastroesophag	JJ	B-AdverseReaction	B-AdverseReaction
reflux	STENDRA.xml:S1:5211:6	reflux	NN	I-AdverseReaction	I-AdverseReaction
disease	STENDRA.xml:S1:5218:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5225:1	,	,	O	O
hypoglycemia	STENDRA.xml:S1:5227:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:5239:1	,	,	O	O
blood	STENDRA.xml:S1:5241:5	blood	NN	B-AdverseReaction	B-AdverseReaction
glucose	STENDRA.xml:S1:5247:7	glucos	NN	I-AdverseReaction	I-AdverseReaction
increased	STENDRA.xml:S1:5255:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5264:1	,	,	O	O
alanine	STENDRA.xml:S1:5266:7	alanin	JJ	B-AdverseReaction	B-AdverseReaction
aminotransferase	STENDRA.xml:S1:5274:16	aminotransferas	NN	I-AdverseReaction	I-AdverseReaction
increased	STENDRA.xml:S1:5291:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5300:1	,	,	O	O
oropharyngeal	STENDRA.xml:S1:5302:13	oropharyng	JJ	B-AdverseReaction	B-AdverseReaction
pain	STENDRA.xml:S1:5316:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5320:1	,	,	O	O
stomach	STENDRA.xml:S1:5322:7	stomach	NN	B-AdverseReaction	B-AdverseReaction
discomfort	STENDRA.xml:S1:5330:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5340:1	,	,	O	O
vomiting	STENDRA.xml:S1:5342:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction

Musculoskeletal	STENDRA.xml:S1:5357:15	musculoskelet	NNP	O	B-AdverseReaction
-	STENDRA.xml:S1:5374:1	-	:	O	I-AdverseReaction
muscle	STENDRA.xml:S1:5376:6	muscl	NN	B-AdverseReaction	I-AdverseReaction
spasms	STENDRA.xml:S1:5383:6	spasm	NNS	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5389:1	,	,	O	O
musculoskeletal	STENDRA.xml:S1:5391:15	musculoskelet	JJ	B-AdverseReaction	B-AdverseReaction
pain	STENDRA.xml:S1:5407:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5411:1	,	,	O	O
myalgia	STENDRA.xml:S1:5413:7	myalgia	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:5420:1	,	,	O	O
pain	STENDRA.xml:S1:5422:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	STENDRA.xml:S1:5427:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	STENDRA.xml:S1:5430:9	extrem	NN	I-AdverseReaction	I-AdverseReaction

Nervous	STENDRA.xml:S1:5446:7	nervou	JJ	O	O
-	STENDRA.xml:S1:5455:1	-	:	O	O
depression	STENDRA.xml:S1:5457:10	depress	NN	B-AdverseReaction	O
,	STENDRA.xml:S1:5467:1	,	,	O	O
insomnia	STENDRA.xml:S1:5469:8	insomnia	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:5477:1	,	,	O	O
somnolence	STENDRA.xml:S1:5479:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:5489:1	,	,	O	O
vertigo	STENDRA.xml:S1:5491:7	vertigo	NN	B-AdverseReaction	B-AdverseReaction

Respiratory	STENDRA.xml:S1:5505:11	respiratori	NNP	O	O
-	STENDRA.xml:S1:5517:1	-	:	O	O
cough	STENDRA.xml:S1:5520:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:5525:1	,	,	O	O
dyspnea	STENDRA.xml:S1:5527:7	dyspnea	JJ	B-AdverseReaction	B-AdverseReaction
exertional	STENDRA.xml:S1:5535:10	exert	JJ	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5545:1	,	,	O	O
epistaxis	STENDRA.xml:S1:5547:9	epistaxi	JJ	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:5556:1	,	,	O	O
wheezing	STENDRA.xml:S1:5558:8	wheez	VBG	B-AdverseReaction	B-AdverseReaction

Skin	STENDRA.xml:S1:5573:4	skin	NNP	O	O
and	STENDRA.xml:S1:5578:3	and	CC	O	O
Appendages	STENDRA.xml:S1:5582:10	appendag	NNP	O	O
-	STENDRA.xml:S1:5594:1	-	:	O	O
pruritus	STENDRA.xml:S1:5596:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction

Urogenital	STENDRA.xml:S1:5611:10	urogenit	JJ	O	B-AdverseReaction
-	STENDRA.xml:S1:5623:1	-	:	O	I-AdverseReaction
balanitis	STENDRA.xml:S1:5625:9	balan	NN	B-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5634:1	,	,	O	O
erection	STENDRA.xml:S1:5636:8	erect	NN	B-AdverseReaction	B-AdverseReaction
increased	STENDRA.xml:S1:5645:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
,	STENDRA.xml:S1:5654:1	,	,	O	O
hematuria	STENDRA.xml:S1:5656:9	hematuria	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:5665:1	,	,	O	O
nephrolithiasis	STENDRA.xml:S1:5667:15	nephrolithiasi	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:5682:1	,	,	O	O
pollakiuria	STENDRA.xml:S1:5684:11	pollakiuria	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S1:5695:1	,	,	O	O
urinary	STENDRA.xml:S1:5697:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	STENDRA.xml:S1:5705:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	STENDRA.xml:S1:5711:9	infect	NN	I-AdverseReaction	I-AdverseReaction

In	STENDRA.xml:S1:5725:2	In	IN	O	O
an	STENDRA.xml:S1:5728:2	an	DT	O	O
additional	STENDRA.xml:S1:5731:10	addit	JJ	O	O
randomized	STENDRA.xml:S1:5742:10	random	NN	O	O
,	STENDRA.xml:S1:5752:1	,	,	O	O
double	STENDRA.xml:S1:5754:6	doubl	JJ	O	O
-	STENDRA.xml:S1:5760:1	-	:	O	O
blind	STENDRA.xml:S1:5761:5	blind	NN	O	O
,	STENDRA.xml:S1:5766:1	,	,	O	O
placebo	STENDRA.xml:S1:5768:7	placebo	SYM	O	O
-	STENDRA.xml:S1:5775:1	-	:	O	O
controlled	STENDRA.xml:S1:5776:10	control	VBN	O	O
study	STENDRA.xml:S1:5787:5	studi	NN	O	O
lasting	STENDRA.xml:S1:5793:7	last	VBG	O	O
up	STENDRA.xml:S1:5801:2	up	RP	O	O
to	STENDRA.xml:S1:5804:2	to	TO	O	O
3	STENDRA.xml:S1:5807:1	3	CD	O	O
months	STENDRA.xml:S1:5809:6	month	NNS	O	O
in	STENDRA.xml:S1:5816:2	in	IN	O	O
298	STENDRA.xml:S1:5819:3	298	CD	O	O
men	STENDRA.xml:S1:5823:3	men	NNS	O	O
who	STENDRA.xml:S1:5827:3	who	WP	O	O
had	STENDRA.xml:S1:5831:3	had	VBD	O	O
undergone	STENDRA.xml:S1:5835:9	undergon	JJ	O	O
bilateral	STENDRA.xml:S1:5845:9	bilater	JJ	O	O
nerve	STENDRA.xml:S1:5855:5	nerv	NN	O	O
-	STENDRA.xml:S1:5860:1	-	:	O	O
sparing	STENDRA.xml:S1:5861:7	spare	VBG	O	O
radical	STENDRA.xml:S1:5869:7	radic	JJ	O	O
prostatectomy	STENDRA.xml:S1:5877:13	prostatectomi	NN	O	O
for	STENDRA.xml:S1:5891:3	for	IN	O	O
prostate	STENDRA.xml:S1:5895:8	prostat	NN	O	O
cancer	STENDRA.xml:S1:5904:6	cancer	NN	O	O
,	STENDRA.xml:S1:5910:1	,	,	O	O
the	STENDRA.xml:S1:5912:3	the	DT	O	O
mean	STENDRA.xml:S1:5916:4	mean	JJ	O	O
age	STENDRA.xml:S1:5921:3	age	NN	O	O
of	STENDRA.xml:S1:5925:2	of	IN	O	O
patients	STENDRA.xml:S1:5928:8	patient	NNS	O	O
was	STENDRA.xml:S1:5937:3	wa	VBD	O	O
58.4	STENDRA.xml:S1:5941:4	58.4	CD	O	O
years	STENDRA.xml:S1:5946:5	year	NNS	O	O
(	STENDRA.xml:S1:5952:1	(	(	O	O
range	STENDRA.xml:S1:5953:5	rang	NN	O	O
40	STENDRA.xml:S1:5959:2	40	CD	O	O
-	STENDRA.xml:S1:5962:1	-	:	O	O
70	STENDRA.xml:S1:5964:2	70	CD	O	O
)	STENDRA.xml:S1:5966:1	)	)	O	O
.	STENDRA.xml:S1:5967:1	.	.	O	O

Table	STENDRA.xml:S1:5969:5	tabl	JJ	O	O
3	STENDRA.xml:S1:5975:1	3	CD	O	O
presents	STENDRA.xml:S1:5977:8	present	VBZ	O	O
the	STENDRA.xml:S1:5986:3	the	DT	O	O
adverse	STENDRA.xml:S1:5990:7	advers	JJ	O	O
reactions	STENDRA.xml:S1:5998:9	reaction	NNS	O	O
reported	STENDRA.xml:S1:6008:8	report	VBN	O	O
in	STENDRA.xml:S1:6017:2	in	IN	O	O
this	STENDRA.xml:S1:6020:4	thi	DT	O	O
study	STENDRA.xml:S1:6025:5	studi	NN	O	O
.	STENDRA.xml:S1:6030:1	.	.	O	O

Table	STENDRA.xml:S1:6036:5	tabl	JJ	O	O
3	STENDRA.xml:S1:6042:1	3	CD	O	O
:	STENDRA.xml:S1:6043:1	:	:	O	O
Adverse	STENDRA.xml:S1:6045:7	advers	JJ	O	O
Reactions	STENDRA.xml:S1:6053:9	reaction	NNS	O	O
Reported	STENDRA.xml:S1:6063:8	report	VBN	O	O
by	STENDRA.xml:S1:6072:2	by	IN	O	O
Greater	STENDRA.xml:S1:6075:7	greater	NNP	O	O
than	STENDRA.xml:S1:6083:4	than	IN	O	O
or	STENDRA.xml:S1:6088:2	or	CC	O	O
Equal	STENDRA.xml:S1:6091:5	equal	JJ	O	O
to	STENDRA.xml:S1:6097:2	to	TO	O	O
2%	STENDRA.xml:S1:6100:2	2%	CD	O	O
of	STENDRA.xml:S1:6103:2	of	IN	O	O
Patients	STENDRA.xml:S1:6106:8	patient	NNS	O	O
Treated	STENDRA.xml:S1:6115:7	treat	VBN	O	O
with	STENDRA.xml:S1:6123:4	with	IN	O	O
STENDRA	STENDRA.xml:S1:6128:7	stendra	NNP	O	O
in	STENDRA.xml:S1:6136:2	in	IN	O	O
a	STENDRA.xml:S1:6139:1	a	DT	O	O
Placebo	STENDRA.xml:S1:6141:7	placebo	NNP	O	O
-	STENDRA.xml:S1:6148:1	-	:	O	O
Controlled	STENDRA.xml:S1:6149:10	control	VBD	O	O
Clinical	STENDRA.xml:S1:6160:8	clinic	JJ	O	O
Trial	STENDRA.xml:S1:6169:5	trial	NNP	O	O
Lasting	STENDRA.xml:S1:6175:7	last	NNP	O	O
3	STENDRA.xml:S1:6183:1	3	CD	O	O
Months	STENDRA.xml:S1:6185:6	month	NNP	O	O
in	STENDRA.xml:S1:6192:2	in	IN	O	O
Patients	STENDRA.xml:S1:6195:8	patient	NNPS	O	O
Who	STENDRA.xml:S1:6204:3	who	NNP	O	O
Underwent	STENDRA.xml:S1:6208:9	underw	NNP	O	O
Bilateral	STENDRA.xml:S1:6218:9	bilater	NNP	O	O
Nerve	STENDRA.xml:S1:6228:5	nerv	NNP	O	O
-	STENDRA.xml:S1:6233:1	-	:	O	O
Sparing	STENDRA.xml:S1:6234:7	spare	VBG	O	O
Radical	STENDRA.xml:S1:6242:7	radic	JJ	O	O
Prostatectomy	STENDRA.xml:S1:6250:13	prostatectomi	NN	O	O

Adverse	STENDRA.xml:S1:6266:7	advers	JJ	O	O
Reaction	STENDRA.xml:S1:6274:8	reaction	NNP	O	O
Placebo	STENDRA.xml:S1:6310:7	placebo	NNP	O	O
(	STENDRA.xml:S1:6317:1	(	(	O	O
N	STENDRA.xml:S1:6318:1	N	NNP	O	O
100	STENDRA.xml:S1:6322:3	100	CD	O	O
)	STENDRA.xml:S1:6325:1	)	)	O	O
STENDRA	STENDRA.xml:S1:6328:7	stendra	NNP	O	O
100	STENDRA.xml:S1:6336:3	100	CD	O	O
mg	STENDRA.xml:S1:6340:2	mg	NN	O	O
(	STENDRA.xml:S1:6342:1	(	(	O	O
N	STENDRA.xml:S1:6343:1	N	NNP	O	O
99	STENDRA.xml:S1:6347:2	99	CD	O	O
)	STENDRA.xml:S1:6349:1	)	)	O	O
STENDRA	STENDRA.xml:S1:6352:7	stendra	NNP	O	O
200	STENDRA.xml:S1:6360:3	200	CD	O	O
mg	STENDRA.xml:S1:6364:2	mg	NN	O	O
(	STENDRA.xml:S1:6366:1	(	(	O	O
N	STENDRA.xml:S1:6367:1	N	NNP	O	O
99	STENDRA.xml:S1:6371:2	99	CD	O	O
)	STENDRA.xml:S1:6373:1	)	)	O	O

Headache	STENDRA.xml:S1:6382:8	headach	NN	B-AdverseReaction	B-AdverseReaction

1.0%	STENDRA.xml:S1:6431:4	1.0%	CD	O	O
8.1%	STENDRA.xml:S1:6451:4	8.1%	CD	O	O
12.1%	STENDRA.xml:S1:6474:5	12.1%	CD	O	O

Flushing	STENDRA.xml:S1:6493:8	flush	VBG	B-AdverseReaction	B-AdverseReaction
0.0%	STENDRA.xml:S1:6542:4	0.0%	CD	O	O
5.1%	STENDRA.xml:S1:6562:4	5.1%	CD	O	O
10.1%	STENDRA.xml:S1:6585:5	10.1%	CD	O	O

Nasopharyngitis	STENDRA.xml:S1:6604:15	nasopharyng	RB	B-AdverseReaction	B-AdverseReaction
0.0%	STENDRA.xml:S1:6653:4	0.0%	CD	O	O
3.0%	STENDRA.xml:S1:6673:4	3.0%	CD	O	O
5.1%	STENDRA.xml:S1:6697:4	5.1%	CD	O	O

Upper	STENDRA.xml:S1:6715:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	STENDRA.xml:S1:6721:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
infection	STENDRA.xml:S1:6733:9	infect	NN	I-AdverseReaction	I-AdverseReaction
0.0%	STENDRA.xml:S1:6764:4	0.0%	CD	O	O
2.0%	STENDRA.xml:S1:6784:4	2.0%	CD	O	O
3.0%	STENDRA.xml:S1:6808:4	3.0%	CD	O	O

Nasal	STENDRA.xml:S1:6826:5	nasal	NNP	B-AdverseReaction	B-AdverseReaction
congestion	STENDRA.xml:S1:6832:10	congest	NN	I-AdverseReaction	I-AdverseReaction
1.0%	STENDRA.xml:S1:6875:4	1.0%	CD	O	O
3.0%	STENDRA.xml:S1:6895:4	3.0%	CD	O	O
1.0%	STENDRA.xml:S1:6919:4	1.0%	CD	O	O

Back	STENDRA.xml:S1:6937:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	STENDRA.xml:S1:6942:4	pain	NN	I-AdverseReaction	I-AdverseReaction
1.0%	STENDRA.xml:S1:6986:4	1.0%	CD	O	O
3.0%	STENDRA.xml:S1:7006:4	3.0%	CD	O	O
2.0%	STENDRA.xml:S1:7030:4	2.0%	CD	O	O

Electrocardiogram	STENDRA.xml:S1:7048:17	electrocardiogram	NNP	B-AdverseReaction	B-AdverseReaction
abnormal	STENDRA.xml:S1:7066:8	abnorm	JJ	I-AdverseReaction	I-AdverseReaction
0.0%	STENDRA.xml:S1:7097:4	0.0%	CD	O	O
1.0%	STENDRA.xml:S1:7117:4	1.0%	CD	O	O
3.0%	STENDRA.xml:S1:7141:4	3.0%	CD	O	O

Dizziness	STENDRA.xml:S1:7159:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
0.0%	STENDRA.xml:S1:7208:4	0.0%	CD	O	O
1.0%	STENDRA.xml:S1:7228:4	1.0%	CD	O	O
2.0%	STENDRA.xml:S1:7252:4	2.0%	CD	O	O

A	STENDRA.xml:S1:7279:1	A	DT	O	O
randomized	STENDRA.xml:S1:7281:10	random	JJ	O	O
,	STENDRA.xml:S1:7291:1	,	,	O	O
double	STENDRA.xml:S1:7293:6	doubl	JJ	O	O
-	STENDRA.xml:S1:7299:1	-	:	O	O
blind	STENDRA.xml:S1:7300:5	blind	NN	O	O
,	STENDRA.xml:S1:7305:1	,	,	O	O
placebo	STENDRA.xml:S1:7307:7	placebo	SYM	O	O
-	STENDRA.xml:S1:7314:1	-	:	O	O
controlled	STENDRA.xml:S1:7315:10	control	VBD	O	O
2	STENDRA.xml:S1:7326:1	2	CD	O	O
months	STENDRA.xml:S1:7328:6	month	NNS	O	O
study	STENDRA.xml:S1:7335:5	studi	NN	O	O
was	STENDRA.xml:S1:7341:3	wa	VBD	O	O
conducted	STENDRA.xml:S1:7345:9	conduct	VBN	O	O
in	STENDRA.xml:S1:7355:2	in	IN	O	O
435	STENDRA.xml:S1:7358:3	435	CD	O	O
subjects	STENDRA.xml:S1:7362:8	subject	NNS	O	O
with	STENDRA.xml:S1:7371:4	with	IN	O	O
a	STENDRA.xml:S1:7376:1	a	DT	O	O
mean	STENDRA.xml:S1:7378:4	mean	JJ	O	O
age	STENDRA.xml:S1:7383:3	age	NN	O	O
of	STENDRA.xml:S1:7387:2	of	IN	O	O
58.2	STENDRA.xml:S1:7390:4	58.2	CD	O	O
years	STENDRA.xml:S1:7395:5	year	NNS	O	O
(	STENDRA.xml:S1:7401:1	(	(	O	O
range	STENDRA.xml:S1:7402:5	rang	VB	O	O
24	STENDRA.xml:S1:7408:2	24	CD	O	O
to	STENDRA.xml:S1:7411:2	to	TO	O	O
86	STENDRA.xml:S1:7414:2	86	CD	O	O
years	STENDRA.xml:S1:7417:5	year	NNS	O	O
)	STENDRA.xml:S1:7422:1	)	)	O	O
to	STENDRA.xml:S1:7424:2	to	TO	O	O
determine	STENDRA.xml:S1:7427:9	determin	VB	O	O
the	STENDRA.xml:S1:7437:3	the	DT	O	O
time	STENDRA.xml:S1:7441:4	time	NN	O	O
to	STENDRA.xml:S1:7446:2	to	TO	O	O
onset	STENDRA.xml:S1:7449:5	onset	VB	O	O
of	STENDRA.xml:S1:7455:2	of	IN	O	O
effect	STENDRA.xml:S1:7458:6	effect	NN	O	O
of	STENDRA.xml:S1:7465:2	of	IN	O	O
STENDRA	STENDRA.xml:S1:7468:7	stendra	NNP	O	O
,	STENDRA.xml:S1:7475:1	,	,	O	O
defined	STENDRA.xml:S1:7477:7	defin	VBD	O	O
as	STENDRA.xml:S1:7485:2	as	IN	O	O
the	STENDRA.xml:S1:7488:3	the	DT	O	O
time	STENDRA.xml:S1:7492:4	time	NN	O	O
to	STENDRA.xml:S1:7497:2	to	TO	O	O
the	STENDRA.xml:S1:7500:3	the	DT	O	O
first	STENDRA.xml:S1:7504:5	first	JJ	O	O
occurrence	STENDRA.xml:S1:7510:10	occurr	NN	O	O
of	STENDRA.xml:S1:7521:2	of	IN	O	O
an	STENDRA.xml:S1:7524:2	an	DT	O	O
erection	STENDRA.xml:S1:7527:8	erect	NN	O	O
sufficient	STENDRA.xml:S1:7536:10	suffici	NN	O	O
for	STENDRA.xml:S1:7547:3	for	IN	O	O
sexual	STENDRA.xml:S1:7551:6	sexual	JJ	O	O
intercourse	STENDRA.xml:S1:7558:11	intercours	NN	O	O
.	STENDRA.xml:S1:7569:1	.	.	O	O

Table	STENDRA.xml:S1:7571:5	tabl	JJ	O	O
4	STENDRA.xml:S1:7577:1	4	CD	O	O
presents	STENDRA.xml:S1:7579:8	present	VBZ	O	O
the	STENDRA.xml:S1:7588:3	the	DT	O	O
adverse	STENDRA.xml:S1:7592:7	advers	JJ	O	O
reactions	STENDRA.xml:S1:7600:9	reaction	NNS	O	O
occurring	STENDRA.xml:S1:7610:9	occur	VBG	O	O
in	STENDRA.xml:S1:7620:2	in	IN	O	O
2%	STENDRA.xml:S1:7626:2	2%	CD	O	O
of	STENDRA.xml:S1:7629:2	of	IN	O	O
subjects	STENDRA.xml:S1:7632:8	subject	NNS	O	O
treated	STENDRA.xml:S1:7641:7	treat	VBN	O	O
with	STENDRA.xml:S1:7649:4	with	IN	O	O
STENDRA	STENDRA.xml:S1:7654:7	stendra	NNP	O	O
.	STENDRA.xml:S1:7661:1	.	.	O	O

Table	STENDRA.xml:S1:7667:5	tabl	NN	O	O

4	STENDRA.xml:S1:7673:1	4	CD	O	O
:	STENDRA.xml:S1:7674:1	:	:	O	O
Adverse	STENDRA.xml:S1:7676:7	advers	JJ	O	O
Reactions	STENDRA.xml:S1:7684:9	reaction	NNS	O	O
Reported	STENDRA.xml:S1:7694:8	report	VBN	O	O
by	STENDRA.xml:S1:7703:2	by	IN	O	O
2%	STENDRA.xml:S1:7709:2	2%	CD	O	O
of	STENDRA.xml:S1:7712:2	of	IN	O	O
Patients	STENDRA.xml:S1:7715:8	patient	NNS	O	O
Treated	STENDRA.xml:S1:7724:7	treat	VBN	O	O
with	STENDRA.xml:S1:7732:4	with	IN	O	O
STENDRA	STENDRA.xml:S1:7737:7	stendra	NNP	O	O
in	STENDRA.xml:S1:7745:2	in	IN	O	O
a	STENDRA.xml:S1:7748:1	a	DT	O	O
Placebo	STENDRA.xml:S1:7750:7	placebo	NNP	O	O
-	STENDRA.xml:S1:7757:1	-	:	O	O
Controlled	STENDRA.xml:S1:7758:10	control	VBD	O	O
Clinical	STENDRA.xml:S1:7769:8	clinic	JJ	O	O
Trial	STENDRA.xml:S1:7778:5	trial	NNP	O	O
Lasting	STENDRA.xml:S1:7784:7	last	NNP	O	O
2	STENDRA.xml:S1:7792:1	2	CD	O	O
Months	STENDRA.xml:S1:7794:6	month	NNP	O	O
to	STENDRA.xml:S1:7801:2	to	TO	O	O
Determine	STENDRA.xml:S1:7804:9	determin	VB	O	O
the	STENDRA.xml:S1:7814:3	the	DT	O	O
Time	STENDRA.xml:S1:7818:4	time	NNP	O	O
to	STENDRA.xml:S1:7823:2	to	TO	O	O
Onset	STENDRA.xml:S1:7826:5	onset	NNP	O	O
of	STENDRA.xml:S1:7832:2	of	IN	O	O
Effect	STENDRA.xml:S1:7835:6	effect	NNP	O	O
(	STENDRA.xml:S1:7842:1	(	(	O	O
Study	STENDRA.xml:S1:7843:5	studi	NNP	O	O
3	STENDRA.xml:S1:7849:1	3	CD	O	O
)	STENDRA.xml:S1:7850:1	)	)	O	O

Adverse	STENDRA.xml:S1:7854:7	advers	JJ	O	O
Reaction	STENDRA.xml:S1:7862:8	reaction	NNP	O	O
Placebon	STENDRA.xml:S1:7900:8	placebon	NNP	O	O
143	STENDRA.xml:S1:7909:3	143	CD	O	O
STENDRA	STENDRA.xml:S1:7918:7	stendra	NNP	O	O
100	STENDRA.xml:S1:7926:3	100	CD	O	O
mgn	STENDRA.xml:S1:7930:3	mgn	NN	O	O
146	STENDRA.xml:S1:7934:3	146	CD	O	O
STENDRA	STENDRA.xml:S1:7940:7	stendra	NNP	O	O
200	STENDRA.xml:S1:7948:3	200	CD	O	O
mgn	STENDRA.xml:S1:7952:3	mgn	NN	O	O
146	STENDRA.xml:S1:7956:3	146	CD	O	O

Headache	STENDRA.xml:S1:7968:8	headach	NN	B-AdverseReaction	B-AdverseReaction

0.7%	STENDRA.xml:S1:8018:4	0.7%	CD	O	O
1.4%	STENDRA.xml:S1:8040:4	1.4%	CD	O	O
8.9%	STENDRA.xml:S1:8062:4	8.9%	CD	O	O

Nasal	STENDRA.xml:S1:8079:5	nasal	NNP	B-AdverseReaction	B-AdverseReaction
congestion	STENDRA.xml:S1:8085:10	congest	NN	I-AdverseReaction	I-AdverseReaction
0.0%	STENDRA.xml:S1:8129:4	0.0%	CD	O	O
0.7%	STENDRA.xml:S1:8151:4	0.7%	CD	O	O
4.1%	STENDRA.xml:S1:8173:4	4.1%	CD	O	O

Gastroenteritis	STENDRA.xml:S1:8190:15	gastroenter	NNP	B-AdverseReaction	B-AdverseReaction
viral	STENDRA.xml:S1:8206:5	viral	JJ	I-AdverseReaction	I-AdverseReaction
0.0%	STENDRA.xml:S1:8240:4	0.0%	CD	O	O
0.0%	STENDRA.xml:S1:8262:4	0.0%	CD	O	O
2.1%	STENDRA.xml:S1:8284:4	2.1%	CD	O	O

Across	STENDRA.xml:S1:8310:6	across	IN	O	O
all	STENDRA.xml:S1:8317:3	all	DT	O	O
trials	STENDRA.xml:S1:8321:6	trial	NNS	O	O
with	STENDRA.xml:S1:8328:4	with	IN	O	O
any	STENDRA.xml:S1:8333:3	ani	DT	O	O
STENDRA	STENDRA.xml:S1:8337:7	stendra	NNP	O	O
dose	STENDRA.xml:S1:8345:4	dose	NN	O	O
,	STENDRA.xml:S1:8349:1	,	,	O	O
1	STENDRA.xml:S1:8351:1	1	CD	O	O
subject	STENDRA.xml:S1:8353:7	subject	NN	O	O
reported	STENDRA.xml:S1:8361:8	report	VBD	O	O
a	STENDRA.xml:S1:8370:1	a	DT	O	O
change	STENDRA.xml:S1:8372:6	chang	NN	B-AdverseReaction	O
in	STENDRA.xml:S1:8379:2	in	IN	I-AdverseReaction	O
color	STENDRA.xml:S1:8382:5	color	NN	I-AdverseReaction	O
vision	STENDRA.xml:S1:8388:6	vision	NN	I-AdverseReaction	O
.	STENDRA.xml:S1:8394:1	.	.	O	O

6.2	STENDRA.xml:S1:8402:3	6.2	CD	O	O

Postmarketing	STENDRA.xml:S1:8406:13	postmarket	VBG	O	O
Experience	STENDRA.xml:S1:8420:10	experi	NN	O	O

Ophthalmologic	STENDRA.xml:S1:8434:14	ophthalmolog	NN	O	O
:	STENDRA.xml:S1:8448:1	:	:	O	O

Non	STENDRA.xml:S1:8454:3	non	NNP	B-AdverseReaction	B-AdverseReaction
-	STENDRA.xml:S1:8457:1	-	:	I-AdverseReaction	I-AdverseReaction
arteritic	STENDRA.xml:S1:8458:9	arterit	JJ	I-AdverseReaction	I-AdverseReaction
anterior	STENDRA.xml:S1:8468:8	anterior	JJ	I-AdverseReaction	I-AdverseReaction
ischemic	STENDRA.xml:S1:8477:8	ischem	JJ	I-AdverseReaction	I-AdverseReaction
optic	STENDRA.xml:S1:8486:5	optic	JJ	I-AdverseReaction	I-AdverseReaction
neuropathy	STENDRA.xml:S1:8492:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
(	STENDRA.xml:S1:8503:1	(	(	O	O
NAION	STENDRA.xml:S1:8504:5	naion	NNP	B-AdverseReaction	O
)	STENDRA.xml:S1:8509:1	)	)	O	O
,	STENDRA.xml:S1:8510:1	,	,	O	O
a	STENDRA.xml:S1:8512:1	a	DT	O	O
cause	STENDRA.xml:S1:8514:5	caus	NN	O	O
of	STENDRA.xml:S1:8520:2	of	IN	O	O
decreased	STENDRA.xml:S1:8523:9	decreas	JJ	B-AdverseReaction	B-AdverseReaction
vision	STENDRA.xml:S1:8533:6	vision	NN	I-AdverseReaction	I-AdverseReaction
including	STENDRA.xml:S1:8540:9	includ	VBG	O	O
permanent	STENDRA.xml:S1:8550:9	perman	JJ	B-AdverseReaction	O
loss	STENDRA.xml:S1:8560:4	loss	NN	I-AdverseReaction	O
of	STENDRA.xml:S1:8565:2	of	IN	I-AdverseReaction	O
vision	STENDRA.xml:S1:8568:6	vision	NN	I-AdverseReaction	O
,	STENDRA.xml:S1:8574:1	,	,	O	O
has	STENDRA.xml:S1:8576:3	ha	VBZ	O	O
been	STENDRA.xml:S1:8580:4	been	VBN	O	O
reported	STENDRA.xml:S1:8585:8	report	VBN	O	O
rarely	STENDRA.xml:S1:8594:6	rare	RB	O	O
post	STENDRA.xml:S1:8601:4	post	NN	O	O
-	STENDRA.xml:S1:8605:1	-	:	O	O
marketing	STENDRA.xml:S1:8606:9	market	NN	O	O
in	STENDRA.xml:S1:8616:2	in	IN	O	O
temporal	STENDRA.xml:S1:8619:8	tempor	JJ	O	O
association	STENDRA.xml:S1:8628:11	associ	NN	O	O
with	STENDRA.xml:S1:8640:4	with	IN	O	O
the	STENDRA.xml:S1:8645:3	the	DT	O	O
use	STENDRA.xml:S1:8649:3	use	NN	O	O
of	STENDRA.xml:S1:8653:2	of	IN	O	O
phosphodiesterase	STENDRA.xml:S1:8656:17	phosphodiesteras	NN	O	O
type	STENDRA.xml:S1:8674:4	type	NN	O	O
5	STENDRA.xml:S1:8679:1	5	CD	O	O
(	STENDRA.xml:S1:8681:1	(	(	O	O
PDE5	STENDRA.xml:S1:8682:4	pde5	NNP	O	O
)	STENDRA.xml:S1:8686:1	)	)	O	O
inhibitors	STENDRA.xml:S1:8688:10	inhibitor	NNS	O	O
.	STENDRA.xml:S1:8698:1	.	.	O	O

Most	STENDRA.xml:S1:8700:4	most	JJS	O	O
,	STENDRA.xml:S1:8704:1	,	,	O	O
but	STENDRA.xml:S1:8706:3	but	CC	O	O
not	STENDRA.xml:S1:8710:3	not	RB	O	O
all	STENDRA.xml:S1:8714:3	all	DT	O	O
,	STENDRA.xml:S1:8717:1	,	,	O	O
of	STENDRA.xml:S1:8719:2	of	IN	O	O
these	STENDRA.xml:S1:8722:5	these	DT	O	O
patients	STENDRA.xml:S1:8728:8	patient	NNS	O	O
had	STENDRA.xml:S1:8737:3	had	VBD	O	O
underlying	STENDRA.xml:S1:8741:10	underli	JJ	O	O
anatomic	STENDRA.xml:S1:8752:8	anatom	JJ	O	O
or	STENDRA.xml:S1:8761:2	or	CC	O	O
vascular	STENDRA.xml:S1:8764:8	vascular	JJ	O	O
risk	STENDRA.xml:S1:8773:4	risk	NN	O	O
factors	STENDRA.xml:S1:8778:7	factor	NNS	O	O
for	STENDRA.xml:S1:8786:3	for	IN	O	O
developing	STENDRA.xml:S1:8790:10	develop	VBG	O	O
NAION	STENDRA.xml:S1:8801:5	naion	NNP	O	O
,	STENDRA.xml:S1:8806:1	,	,	O	O
including	STENDRA.xml:S1:8808:9	includ	VBG	O	O
but	STENDRA.xml:S1:8818:3	but	CC	O	O
not	STENDRA.xml:S1:8822:3	not	RB	O	O
necessarily	STENDRA.xml:S1:8826:11	necessarili	RB	O	O
limited	STENDRA.xml:S1:8838:7	limit	VBN	O	O
to	STENDRA.xml:S1:8846:2	to	TO	O	O
:	STENDRA.xml:S1:8848:1	:	:	O	O
low	STENDRA.xml:S1:8850:3	low	JJ	O	O
cup	STENDRA.xml:S1:8854:3	cup	NN	O	O
to	STENDRA.xml:S1:8858:2	to	TO	O	O
disc	STENDRA.xml:S1:8861:4	disc	VB	O	O
ratio	STENDRA.xml:S1:8866:5	ratio	NN	O	O
(	STENDRA.xml:S1:8872:1	(	(	O	O
"	STENDRA.xml:S1:8873:1	"	NNP	O	O
crowded	STENDRA.xml:S1:8874:7	crowd	VBD	O	O
disc	STENDRA.xml:S1:8882:4	disc	JJ	O	O
"	STENDRA.xml:S1:8886:1	"	NNP	O	O
)	STENDRA.xml:S1:8887:1	)	)	O	O
,	STENDRA.xml:S1:8888:1	,	,	O	O
age	STENDRA.xml:S1:8890:3	age	NN	O	O
over	STENDRA.xml:S1:8894:4	over	IN	O	O
50	STENDRA.xml:S1:8899:2	50	CD	O	O
,	STENDRA.xml:S1:8901:1	,	,	O	O
diabetes	STENDRA.xml:S1:8903:8	diabet	NNS	O	O
,	STENDRA.xml:S1:8911:1	,	,	O	O
hypertension	STENDRA.xml:S1:8913:12	hypertens	NN	O	B-AdverseReaction
,	STENDRA.xml:S1:8925:1	,	,	O	O
coronary	STENDRA.xml:S1:8927:8	coronari	JJ	O	B-AdverseReaction
artery	STENDRA.xml:S1:8936:6	arteri	NN	O	I-AdverseReaction
disease	STENDRA.xml:S1:8943:7	diseas	NN	O	I-AdverseReaction
,	STENDRA.xml:S1:8950:1	,	,	O	O
hyperlipidemia	STENDRA.xml:S1:8952:14	hyperlipidemia	NN	O	O
,	STENDRA.xml:S1:8966:1	,	,	O	O
and	STENDRA.xml:S1:8968:3	and	CC	O	O
smoking	STENDRA.xml:S1:8972:7	smoke	NN	O	O
.	STENDRA.xml:S1:8979:1	.	.	O	O

It	STENDRA.xml:S1:8981:2	It	PRP	O	O
is	STENDRA.xml:S1:8984:2	is	VBZ	O	O
not	STENDRA.xml:S1:8987:3	not	RB	O	O
possible	STENDRA.xml:S1:8991:8	possibl	JJ	O	O
to	STENDRA.xml:S1:9000:2	to	TO	O	O
determine	STENDRA.xml:S1:9003:9	determin	VB	O	O
whether	STENDRA.xml:S1:9013:7	whether	IN	O	O
these	STENDRA.xml:S1:9021:5	these	DT	O	O
events	STENDRA.xml:S1:9027:6	event	NNS	O	O
are	STENDRA.xml:S1:9034:3	are	VBP	O	O
related	STENDRA.xml:S1:9038:7	relat	VBN	O	O
directly	STENDRA.xml:S1:9046:8	directli	RB	O	O
to	STENDRA.xml:S1:9055:2	to	TO	O	O
the	STENDRA.xml:S1:9058:3	the	DT	O	O
use	STENDRA.xml:S1:9062:3	use	NN	O	O
of	STENDRA.xml:S1:9066:2	of	IN	O	O
PDE5	STENDRA.xml:S1:9069:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S1:9074:10	inhibitor	NNS	O	O
,	STENDRA.xml:S1:9084:1	,	,	O	O
to	STENDRA.xml:S1:9086:2	to	TO	O	O
the	STENDRA.xml:S1:9089:3	the	DT	O	O
patient	STENDRA.xml:S1:9093:7	patient	NN	O	O
's	STENDRA.xml:S1:9100:2	's	POS	O	O
underlying	STENDRA.xml:S1:9103:10	underli	JJ	O	O
vascular	STENDRA.xml:S1:9114:8	vascular	JJ	O	O
risk	STENDRA.xml:S1:9123:4	risk	NN	O	O
factors	STENDRA.xml:S1:9128:7	factor	NNS	O	O
or	STENDRA.xml:S1:9136:2	or	CC	O	O
anatomical	STENDRA.xml:S1:9139:10	anatom	JJ	O	O
defects	STENDRA.xml:S1:9150:7	defect	NNS	O	O
,	STENDRA.xml:S1:9157:1	,	,	O	O
to	STENDRA.xml:S1:9159:2	to	TO	O	O
a	STENDRA.xml:S1:9162:1	a	DT	O	O
combination	STENDRA.xml:S1:9164:11	combin	NN	O	O
of	STENDRA.xml:S1:9176:2	of	IN	O	O
these	STENDRA.xml:S1:9179:5	these	DT	O	O
factors	STENDRA.xml:S1:9185:7	factor	NNS	O	O
,	STENDRA.xml:S1:9192:1	,	,	O	O
or	STENDRA.xml:S1:9194:2	or	CC	O	O
to	STENDRA.xml:S1:9197:2	to	TO	O	O
other	STENDRA.xml:S1:9200:5	other	JJ	O	O
factors	STENDRA.xml:S1:9206:7	factor	NNS	O	O
[	STENDRA.xml:S1:9214:1	[	VBP	O	O
see	STENDRA.xml:S1:9215:3	see	VBP	O	O
Warnings	STENDRA.xml:S1:9220:8	warn	NNS	O	O
and	STENDRA.xml:S1:9229:3	and	CC	O	O
Precautions	STENDRA.xml:S1:9233:11	precaut	NNP	O	O
(	STENDRA.xml:S1:9245:1	(	(	O	O
5.4	STENDRA.xml:S1:9246:3	5.4	CD	O	O
)	STENDRA.xml:S1:9249:1	)	)	O	O
andPatient	STENDRA.xml:S1:9250:10	andpati	NN	O	O
Counseling	STENDRA.xml:S1:9261:10	counsel	VBG	O	O
Information	STENDRA.xml:S1:9272:11	inform	NNP	O	O
(	STENDRA.xml:S1:9284:1	(	(	O	O
17.6	STENDRA.xml:S1:9285:4	17.6	CD	O	O
)	STENDRA.xml:S1:9289:1	)	)	O	O
]	STENDRA.xml:S1:9292:1	]	NN	O	O
.	STENDRA.xml:S1:9293:1	.	.	O	O
5	STENDRA.xml:S2:4:1	5	CD	O	O
WARNINGS	STENDRA.xml:S2:6:8	warn	NNP	O	O
AND	STENDRA.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	STENDRA.xml:S2:19:11	precaut	NNP	O	O

Evaluation	STENDRA.xml:S2:34:10	evalu	NN	O	O
of	STENDRA.xml:S2:45:2	of	IN	O	O
erectile	STENDRA.xml:S2:48:8	erectil	JJ	O	O
dysfunction	STENDRA.xml:S2:57:11	dysfunct	NN	O	O
(	STENDRA.xml:S2:69:1	(	(	O	O
ED	STENDRA.xml:S2:70:2	ED	NNP	O	O
)	STENDRA.xml:S2:72:1	)	)	O	O
should	STENDRA.xml:S2:74:6	should	MD	O	O
include	STENDRA.xml:S2:81:7	includ	VB	O	O
an	STENDRA.xml:S2:89:2	an	DT	O	O
appropriate	STENDRA.xml:S2:92:11	appropri	JJ	O	O
medical	STENDRA.xml:S2:104:7	medic	JJ	O	O
assessment	STENDRA.xml:S2:112:10	assess	NN	O	O
to	STENDRA.xml:S2:123:2	to	TO	O	O
identify	STENDRA.xml:S2:126:8	identifi	VB	O	O
potential	STENDRA.xml:S2:135:9	potenti	JJ	O	O
underlying	STENDRA.xml:S2:145:10	underli	JJ	O	O
causes	STENDRA.xml:S2:156:6	caus	NNS	O	O
,	STENDRA.xml:S2:162:1	,	,	O	O
as	STENDRA.xml:S2:164:2	as	RB	O	O
well	STENDRA.xml:S2:167:4	well	RB	O	O
as	STENDRA.xml:S2:172:2	as	IN	O	O
treatment	STENDRA.xml:S2:175:9	treatment	NN	O	O
options	STENDRA.xml:S2:185:7	option	NNS	O	O
.	STENDRA.xml:S2:192:1	.	.	O	O

Before	STENDRA.xml:S2:198:6	befor	IN	O	O
prescribing	STENDRA.xml:S2:205:11	prescrib	VBG	O	O
STENDRA	STENDRA.xml:S2:217:7	stendra	NNP	O	O
,	STENDRA.xml:S2:224:1	,	,	O	O
it	STENDRA.xml:S2:226:2	it	PRP	O	O
is	STENDRA.xml:S2:229:2	is	VBZ	O	O
important	STENDRA.xml:S2:232:9	import	JJ	O	O
to	STENDRA.xml:S2:242:2	to	TO	O	O
note	STENDRA.xml:S2:245:4	note	VB	O	O
the	STENDRA.xml:S2:250:3	the	DT	O	O
following	STENDRA.xml:S2:254:9	follow	NN	O	O
:	STENDRA.xml:S2:263:1	:	:	O	O

EXCERPT	STENDRA.xml:S2:272:7	excerpt	NNS	O	O
:	STENDRA.xml:S2:279:1	:	:	O	O
Patients	STENDRA.xml:S2:287:8	patient	NNS	O	O
should	STENDRA.xml:S2:296:6	should	MD	O	O
not	STENDRA.xml:S2:303:3	not	RB	O	O
use	STENDRA.xml:S2:307:3	use	VB	O	O
STENDRA	STENDRA.xml:S2:311:7	stendra	NNP	O	O
if	STENDRA.xml:S2:319:2	if	IN	O	O
sexual	STENDRA.xml:S2:322:6	sexual	JJ	O	O
activity	STENDRA.xml:S2:329:8	activ	NN	O	O
is	STENDRA.xml:S2:338:2	is	VBZ	O	O
inadvisable	STENDRA.xml:S2:341:11	inadvis	JJ	O	O
due	STENDRA.xml:S2:353:3	due	JJ	O	O
to	STENDRA.xml:S2:357:2	to	TO	O	O
cardiovascular	STENDRA.xml:S2:360:14	cardiovascular	JJ	O	O
status	STENDRA.xml:S2:375:6	statu	NN	O	O
or	STENDRA.xml:S2:382:2	or	CC	O	O
any	STENDRA.xml:S2:385:3	ani	DT	O	O
other	STENDRA.xml:S2:389:5	other	JJ	O	O
reason	STENDRA.xml:S2:395:6	reason	NN	O	O
(	STENDRA.xml:S2:402:1	(	(	O	O
5.1	STENDRA.xml:S2:403:3	5.1	CD	O	O
)	STENDRA.xml:S2:406:1	)	)	O	O

Use	STENDRA.xml:S2:413:3	use	NNP	O	O
of	STENDRA.xml:S2:417:2	of	IN	O	O
STENDRA	STENDRA.xml:S2:420:7	stendra	NNP	O	O
with	STENDRA.xml:S2:428:4	with	IN	O	O
alpha	STENDRA.xml:S2:433:5	alpha	JJ	O	O
-	STENDRA.xml:S2:438:1	-	:	O	O
blockers	STENDRA.xml:S2:439:8	blocker	NNS	O	O
,	STENDRA.xml:S2:447:1	,	,	O	O
other	STENDRA.xml:S2:449:5	other	JJ	O	O
antihypertensives	STENDRA.xml:S2:455:17	antihypertens	NNS	O	O
,	STENDRA.xml:S2:472:1	,	,	O	O
or	STENDRA.xml:S2:474:2	or	CC	O	O
substantial	STENDRA.xml:S2:477:11	substanti	JJ	O	O
amounts	STENDRA.xml:S2:489:7	amount	NNS	O	O
of	STENDRA.xml:S2:497:2	of	IN	O	O
alcohol	STENDRA.xml:S2:500:7	alcohol	NN	O	O
(	STENDRA.xml:S2:508:1	(	(	O	O
greater	STENDRA.xml:S2:509:7	greater	JJR	O	O
than	STENDRA.xml:S2:517:4	than	IN	O	O
3	STENDRA.xml:S2:522:1	3	CD	O	O
units	STENDRA.xml:S2:524:5	unit	NNS	O	O
)	STENDRA.xml:S2:529:1	)	)	O	O
may	STENDRA.xml:S2:531:3	may	MD	O	O
lead	STENDRA.xml:S2:535:4	lead	VB	O	O
to	STENDRA.xml:S2:540:2	to	TO	O	O
hypotension	STENDRA.xml:S2:543:11	hypotens	NN	B-AdverseReaction	B-AdverseReaction
(	STENDRA.xml:S2:555:1	(	(	O	O
2.3	STENDRA.xml:S2:556:3	2.3	CD	O	O
,	STENDRA.xml:S2:559:1	,	,	O	O
5.6	STENDRA.xml:S2:560:3	5.6	CD	O	O
,	STENDRA.xml:S2:563:1	,	,	O	O
5.7	STENDRA.xml:S2:564:3	5.7	CD	O	O
)	STENDRA.xml:S2:567:1	)	)	O	O

Patients	STENDRA.xml:S2:574:8	patient	NNS	O	O
should	STENDRA.xml:S2:583:6	should	MD	O	O
seek	STENDRA.xml:S2:590:4	seek	VB	O	O
emergency	STENDRA.xml:S2:595:9	emerg	NN	O	O
treatment	STENDRA.xml:S2:605:9	treatment	NN	O	O
if	STENDRA.xml:S2:615:2	if	IN	O	O
an	STENDRA.xml:S2:618:2	an	DT	O	O
erection	STENDRA.xml:S2:621:8	erect	NN	O	O
lasts	STENDRA.xml:S2:630:5	last	VBZ	O	O
greater	STENDRA.xml:S2:636:7	greater	JJR	O	O
than	STENDRA.xml:S2:644:4	than	IN	O	O
4	STENDRA.xml:S2:649:1	4	CD	O	O
hours	STENDRA.xml:S2:651:5	hour	NNS	O	O
(	STENDRA.xml:S2:657:1	(	(	O	O
5.3	STENDRA.xml:S2:658:3	5.3	CD	O	O
)	STENDRA.xml:S2:661:1	)	)	O	O

Patients	STENDRA.xml:S2:668:8	patient	NNS	O	O
should	STENDRA.xml:S2:677:6	should	MD	O	O
stop	STENDRA.xml:S2:684:4	stop	VB	O	O
STENDRA	STENDRA.xml:S2:689:7	stendra	NNP	O	O
and	STENDRA.xml:S2:697:3	and	CC	O	O
seek	STENDRA.xml:S2:701:4	seek	VB	O	O
medical	STENDRA.xml:S2:706:7	medic	JJ	O	O
care	STENDRA.xml:S2:714:4	care	NN	O	O
if	STENDRA.xml:S2:719:2	if	IN	O	O
a	STENDRA.xml:S2:722:1	a	DT	O	O
sudden	STENDRA.xml:S2:724:6	sudden	JJ	O	O
loss	STENDRA.xml:S2:731:4	loss	NN	O	O
of	STENDRA.xml:S2:736:2	of	IN	O	O
vision	STENDRA.xml:S2:739:6	vision	NN	O	O
occurs	STENDRA.xml:S2:746:6	occur	NNS	O	O
in	STENDRA.xml:S2:753:2	in	IN	O	O
one	STENDRA.xml:S2:756:3	one	CD	O	O
or	STENDRA.xml:S2:760:2	or	CC	O	O
both	STENDRA.xml:S2:763:4	both	DT	O	O
eyes	STENDRA.xml:S2:768:4	eye	NNS	O	O
,	STENDRA.xml:S2:772:1	,	,	O	O
which	STENDRA.xml:S2:774:5	which	WDT	O	O
could	STENDRA.xml:S2:780:5	could	MD	O	O
be	STENDRA.xml:S2:786:2	be	VB	O	O
a	STENDRA.xml:S2:789:1	a	DT	O	O
sign	STENDRA.xml:S2:791:4	sign	NN	O	O
of	STENDRA.xml:S2:796:2	of	IN	O	O
Non	STENDRA.xml:S2:799:3	non	NNP	O	O
Arteritic	STENDRA.xml:S2:803:9	arterit	NNP	O	O
Ischemic	STENDRA.xml:S2:813:8	ischem	NNP	O	O
Optic	STENDRA.xml:S2:822:5	optic	NNP	O	O
Neuropathy	STENDRA.xml:S2:828:10	neuropathi	NNP	O	O
(	STENDRA.xml:S2:839:1	(	(	O	O
NAION	STENDRA.xml:S2:840:5	naion	NNP	O	O
)	STENDRA.xml:S2:845:1	)	)	O	O
.	STENDRA.xml:S2:846:1	.	.	O	O

STENDRA	STENDRA.xml:S2:848:7	stendra	NNP	O	O
should	STENDRA.xml:S2:856:6	should	MD	O	O
be	STENDRA.xml:S2:863:2	be	VB	O	O
used	STENDRA.xml:S2:866:4	use	VBN	O	O
with	STENDRA.xml:S2:871:4	with	IN	O	O
caution	STENDRA.xml:S2:876:7	caution	NN	O	O
,	STENDRA.xml:S2:883:1	,	,	O	O
and	STENDRA.xml:S2:885:3	and	CC	O	O
only	STENDRA.xml:S2:889:4	onli	RB	O	O
when	STENDRA.xml:S2:894:4	when	WRB	O	O
the	STENDRA.xml:S2:899:3	the	DT	O	O
anticipated	STENDRA.xml:S2:903:11	anticip	JJ	O	O
benefits	STENDRA.xml:S2:915:8	benefit	NNS	O	O
outweigh	STENDRA.xml:S2:924:8	outweigh	VBP	O	O
the	STENDRA.xml:S2:933:3	the	DT	O	O
risks	STENDRA.xml:S2:937:5	risk	NNS	O	O
,	STENDRA.xml:S2:942:1	,	,	O	O
in	STENDRA.xml:S2:944:2	in	IN	O	O
patients	STENDRA.xml:S2:947:8	patient	NNS	O	O
with	STENDRA.xml:S2:956:4	with	IN	O	O
a	STENDRA.xml:S2:961:1	a	DT	O	O
history	STENDRA.xml:S2:963:7	histori	NN	O	O
of	STENDRA.xml:S2:971:2	of	IN	O	O
NAION	STENDRA.xml:S2:974:5	naion	NNP	O	O
.	STENDRA.xml:S2:979:1	.	.	O	O

Patients	STENDRA.xml:S2:981:8	patient	NNS	O	O
with	STENDRA.xml:S2:990:4	with	IN	O	O
a	STENDRA.xml:S2:995:1	a	DT	O	O
"	STENDRA.xml:S2:997:1	"	NN	O	O
crowded	STENDRA.xml:S2:998:7	crowd	VBN	O	O
"	STENDRA.xml:S2:1005:1	"	NNP	O	O
optic	STENDRA.xml:S2:1007:5	optic	JJ	O	O
disc	STENDRA.xml:S2:1013:4	disc	NN	O	O
may	STENDRA.xml:S2:1018:3	may	MD	O	O
also	STENDRA.xml:S2:1022:4	also	RB	O	O
be	STENDRA.xml:S2:1027:2	be	VB	O	O
at	STENDRA.xml:S2:1030:2	at	IN	O	O
an	STENDRA.xml:S2:1033:2	an	DT	O	O
increased	STENDRA.xml:S2:1036:9	increas	VBN	O	O
risk	STENDRA.xml:S2:1046:4	risk	NN	O	O
of	STENDRA.xml:S2:1051:2	of	IN	O	O
NAION	STENDRA.xml:S2:1054:5	naion	NNP	O	O
(	STENDRA.xml:S2:1060:1	(	(	O	O
5.4	STENDRA.xml:S2:1061:3	5.4	CD	O	O
,	STENDRA.xml:S2:1064:1	,	,	O	O
6.2	STENDRA.xml:S2:1065:3	6.2	CD	O	O
)	STENDRA.xml:S2:1068:1	)	)	O	O

Patients	STENDRA.xml:S2:1075:8	patient	NNS	O	O
should	STENDRA.xml:S2:1084:6	should	MD	O	O
stop	STENDRA.xml:S2:1091:4	stop	VB	O	O
taking	STENDRA.xml:S2:1096:6	take	VBG	O	O
STENDRA	STENDRA.xml:S2:1103:7	stendra	NNP	O	O
and	STENDRA.xml:S2:1111:3	and	CC	O	O
seek	STENDRA.xml:S2:1115:4	seek	JJ	O	O
prompt	STENDRA.xml:S2:1120:6	prompt	NN	O	O
medical	STENDRA.xml:S2:1127:7	medic	JJ	O	O
attention	STENDRA.xml:S2:1135:9	attent	NN	O	O
in	STENDRA.xml:S2:1145:2	in	IN	O	O
the	STENDRA.xml:S2:1148:3	the	DT	O	O
event	STENDRA.xml:S2:1152:5	event	NN	O	O
of	STENDRA.xml:S2:1158:2	of	IN	O	O
sudden	STENDRA.xml:S2:1161:6	sudden	JJ	O	O
decrease	STENDRA.xml:S2:1168:8	decreas	NN	O	O
or	STENDRA.xml:S2:1177:2	or	CC	O	O
loss	STENDRA.xml:S2:1180:4	loss	NN	O	B-AdverseReaction
of	STENDRA.xml:S2:1185:2	of	IN	O	I-AdverseReaction
hearing	STENDRA.xml:S2:1188:7	hear	NN	O	I-AdverseReaction
(	STENDRA.xml:S2:1196:1	(	(	O	O
5.5	STENDRA.xml:S2:1197:3	5.5	CD	O	O
)	STENDRA.xml:S2:1200:1	)	)	O	O

5.1	STENDRA.xml:S2:1211:3	5.1	CD	O	O

Cardiovascular	STENDRA.xml:S2:1215:14	cardiovascular	JJ	O	O
Risks	STENDRA.xml:S2:1230:5	risk	NNS	O	O

There	STENDRA.xml:S2:1239:5	there	EX	O	O
is	STENDRA.xml:S2:1245:2	is	VBZ	O	O
a	STENDRA.xml:S2:1248:1	a	DT	O	O
potential	STENDRA.xml:S2:1250:9	potenti	JJ	O	O
for	STENDRA.xml:S2:1260:3	for	IN	O	O
cardiac	STENDRA.xml:S2:1264:7	cardiac	JJ	B-AdverseReaction	O
risk	STENDRA.xml:S2:1272:4	risk	NN	I-AdverseReaction	O
during	STENDRA.xml:S2:1277:6	dure	IN	O	O
sexual	STENDRA.xml:S2:1284:6	sexual	JJ	O	O
activity	STENDRA.xml:S2:1291:8	activ	NN	O	O
in	STENDRA.xml:S2:1300:2	in	IN	O	O
patients	STENDRA.xml:S2:1303:8	patient	NNS	O	O
with	STENDRA.xml:S2:1312:4	with	IN	O	O
pre	STENDRA.xml:S2:1317:3	pre	JJ	O	O
-	STENDRA.xml:S2:1320:1	-	:	O	O
existing	STENDRA.xml:S2:1321:8	exist	VBG	O	O
cardiovascular	STENDRA.xml:S2:1330:14	cardiovascular	JJ	O	O
disease	STENDRA.xml:S2:1345:7	diseas	NN	O	O
.	STENDRA.xml:S2:1352:1	.	.	O	O

Therefore	STENDRA.xml:S2:1354:9	therefor	RB	O	O
,	STENDRA.xml:S2:1363:1	,	,	O	O
treatments	STENDRA.xml:S2:1365:10	treatment	NNS	O	O
for	STENDRA.xml:S2:1376:3	for	IN	O	O
ED	STENDRA.xml:S2:1380:2	ED	NNP	O	O
,	STENDRA.xml:S2:1382:1	,	,	O	O
including	STENDRA.xml:S2:1384:9	includ	VBG	O	O
STENDRA	STENDRA.xml:S2:1394:7	stendra	NNP	O	O
,	STENDRA.xml:S2:1401:1	,	,	O	O
should	STENDRA.xml:S2:1403:6	should	MD	O	O
not	STENDRA.xml:S2:1410:3	not	RB	O	O
be	STENDRA.xml:S2:1414:2	be	VB	O	O
used	STENDRA.xml:S2:1417:4	use	VBN	O	O
in	STENDRA.xml:S2:1422:2	in	IN	O	O
men	STENDRA.xml:S2:1425:3	men	NNS	O	O
for	STENDRA.xml:S2:1429:3	for	IN	O	O
whom	STENDRA.xml:S2:1433:4	whom	WP	O	O
sexual	STENDRA.xml:S2:1438:6	sexual	JJ	O	O
activity	STENDRA.xml:S2:1445:8	activ	NN	O	O
is	STENDRA.xml:S2:1454:2	is	VBZ	O	O
inadvisable	STENDRA.xml:S2:1457:11	inadvis	JJ	O	O
because	STENDRA.xml:S2:1469:7	becaus	IN	O	O
of	STENDRA.xml:S2:1477:2	of	IN	O	O
their	STENDRA.xml:S2:1480:5	their	PRP$	O	O
underlying	STENDRA.xml:S2:1486:10	underli	JJ	O	O
cardiovascular	STENDRA.xml:S2:1497:14	cardiovascular	JJ	O	O
status	STENDRA.xml:S2:1512:6	statu	NN	O	O
.	STENDRA.xml:S2:1518:1	.	.	O	O

Patients	STENDRA.xml:S2:1524:8	patient	NNS	O	O
with	STENDRA.xml:S2:1533:4	with	IN	O	O
left	STENDRA.xml:S2:1538:4	left	JJ	O	O
ventricular	STENDRA.xml:S2:1543:11	ventricular	JJ	O	O
outflow	STENDRA.xml:S2:1555:7	outflow	JJ	O	O
obstruction	STENDRA.xml:S2:1563:11	obstruct	NN	O	O
(	STENDRA.xml:S2:1575:1	(	(	O	O
e	STENDRA.xml:S2:1576:1	e	NN	O	O
.	STENDRA.xml:S2:1577:1	.	.	O	O
g	STENDRA.xml:S2:1578:1	g	NN	O	O
.	STENDRA.xml:S2:1579:1	.	.	O	O
,	STENDRA.xml:S2:1580:1	,	,	O	O
aortic	STENDRA.xml:S2:1582:6	aortic	JJ	O	O
stenosis	STENDRA.xml:S2:1589:8	stenosi	NN	O	O
,	STENDRA.xml:S2:1597:1	,	,	O	O
idiopathic	STENDRA.xml:S2:1599:10	idiopath	JJ	O	O
hypertrophic	STENDRA.xml:S2:1610:12	hypertroph	JJ	O	O
subaortic	STENDRA.xml:S2:1623:9	subaort	JJ	O	O
stenosis	STENDRA.xml:S2:1633:8	stenosi	NN	O	O
)	STENDRA.xml:S2:1641:1	)	)	O	O
and	STENDRA.xml:S2:1643:3	and	CC	O	O
those	STENDRA.xml:S2:1647:5	those	DT	O	O
with	STENDRA.xml:S2:1653:4	with	IN	O	O
severely	STENDRA.xml:S2:1658:8	sever	RB	O	O
impaired	STENDRA.xml:S2:1667:8	impair	JJ	O	O
autonomic	STENDRA.xml:S2:1676:9	autonom	JJ	O	O
control	STENDRA.xml:S2:1686:7	control	NN	O	O
of	STENDRA.xml:S2:1694:2	of	IN	O	O
blood	STENDRA.xml:S2:1697:5	blood	NN	O	O
pressure	STENDRA.xml:S2:1703:8	pressur	NN	O	O
can	STENDRA.xml:S2:1712:3	can	MD	O	O
be	STENDRA.xml:S2:1716:2	be	VB	O	O
particularly	STENDRA.xml:S2:1719:12	particularli	RB	O	O
sensitive	STENDRA.xml:S2:1732:9	sensit	JJ	O	O
to	STENDRA.xml:S2:1742:2	to	TO	O	O
the	STENDRA.xml:S2:1745:3	the	DT	O	O
actions	STENDRA.xml:S2:1749:7	action	NNS	O	O
of	STENDRA.xml:S2:1757:2	of	IN	O	O
vasodilators	STENDRA.xml:S2:1760:12	vasodil	NNS	O	O
,	STENDRA.xml:S2:1772:1	,	,	O	O
including	STENDRA.xml:S2:1774:9	includ	VBG	O	O
STENDRA	STENDRA.xml:S2:1784:7	stendra	NNP	O	O
.	STENDRA.xml:S2:1791:1	.	.	O	O

The	STENDRA.xml:S2:1797:3	the	DT	O	O
following	STENDRA.xml:S2:1801:9	follow	VBG	O	O
groups	STENDRA.xml:S2:1811:6	group	NNS	O	O
of	STENDRA.xml:S2:1818:2	of	IN	O	O
patients	STENDRA.xml:S2:1821:8	patient	NNS	O	O
were	STENDRA.xml:S2:1830:4	were	VBD	O	O
not	STENDRA.xml:S2:1835:3	not	RB	O	O
included	STENDRA.xml:S2:1839:8	includ	VBN	O	O
in	STENDRA.xml:S2:1848:2	in	IN	O	O
clinical	STENDRA.xml:S2:1851:8	clinic	JJ	O	O
safety	STENDRA.xml:S2:1860:6	safeti	NN	O	O
and	STENDRA.xml:S2:1867:3	and	CC	O	O
efficacy	STENDRA.xml:S2:1871:8	efficaci	NN	O	O
trials	STENDRA.xml:S2:1880:6	trial	NNS	O	O
for	STENDRA.xml:S2:1887:3	for	IN	O	O
STENDRA	STENDRA.xml:S2:1891:7	stendra	NNP	O	O
,	STENDRA.xml:S2:1898:1	,	,	O	O
and	STENDRA.xml:S2:1900:3	and	CC	O	O
therefore	STENDRA.xml:S2:1904:9	therefor	RB	O	O
until	STENDRA.xml:S2:1914:5	until	IN	O	O
further	STENDRA.xml:S2:1920:7	further	JJ	O	O
information	STENDRA.xml:S2:1928:11	inform	NN	O	O
is	STENDRA.xml:S2:1940:2	is	VBZ	O	O
available	STENDRA.xml:S2:1943:9	avail	JJ	O	O
,	STENDRA.xml:S2:1952:1	,	,	O	O
STENDRA	STENDRA.xml:S2:1954:7	stendra	NNP	O	O
is	STENDRA.xml:S2:1962:2	is	VBZ	O	O
not	STENDRA.xml:S2:1965:3	not	RB	O	O
recommended	STENDRA.xml:S2:1969:11	recommend	VBN	O	O
for	STENDRA.xml:S2:1981:3	for	IN	O	O
the	STENDRA.xml:S2:1985:3	the	DT	O	O
following	STENDRA.xml:S2:1989:9	follow	JJ	O	O
groups	STENDRA.xml:S2:1999:6	group	NNS	O	O
:	STENDRA.xml:S2:2005:1	:	:	O	O

Patients	STENDRA.xml:S2:2014:8	patient	NNS	O	O
who	STENDRA.xml:S2:2023:3	who	WP	O	O
have	STENDRA.xml:S2:2027:4	have	VBP	O	O
suffered	STENDRA.xml:S2:2032:8	suffer	VBN	O	O
a	STENDRA.xml:S2:2041:1	a	DT	O	O
myocardial	STENDRA.xml:S2:2043:10	myocardi	JJ	O	O
infarction	STENDRA.xml:S2:2054:10	infarct	NN	O	O
,	STENDRA.xml:S2:2064:1	,	,	O	O
stroke	STENDRA.xml:S2:2066:6	stroke	NN	O	B-AdverseReaction
,	STENDRA.xml:S2:2072:1	,	,	O	O
life	STENDRA.xml:S2:2074:4	life	NN	O	O
-	STENDRA.xml:S2:2078:1	-	:	O	O
threatening	STENDRA.xml:S2:2079:11	threaten	NN	O	O
arrhythmia	STENDRA.xml:S2:2091:10	arrhythmia	NN	O	O
,	STENDRA.xml:S2:2101:1	,	,	O	O
or	STENDRA.xml:S2:2103:2	or	CC	O	O
coronary	STENDRA.xml:S2:2106:8	coronari	JJ	O	O
revascularization	STENDRA.xml:S2:2115:17	revascular	NN	O	O
within	STENDRA.xml:S2:2133:6	within	IN	O	O
the	STENDRA.xml:S2:2140:3	the	DT	O	O
last	STENDRA.xml:S2:2144:4	last	JJ	O	O
6	STENDRA.xml:S2:2149:1	6	CD	O	O
months	STENDRA.xml:S2:2151:6	month	NNS	O	O
;	STENDRA.xml:S2:2157:1	;	:	O	O

Patients	STENDRA.xml:S2:2164:8	patient	NNS	O	O
with	STENDRA.xml:S2:2173:4	with	IN	O	O
resting	STENDRA.xml:S2:2178:7	rest	VBG	O	O
hypotension	STENDRA.xml:S2:2186:11	hypotens	NN	O	O
(	STENDRA.xml:S2:2198:1	(	(	O	O
blood	STENDRA.xml:S2:2199:5	blood	JJ	O	I-AdverseReaction
pressure	STENDRA.xml:S2:2205:8	pressur	NN	O	I-AdverseReaction
less	STENDRA.xml:S2:2214:4	less	JJR	O	O
than	STENDRA.xml:S2:2219:4	than	IN	O	O
90	STENDRA.xml:S2:2224:2	90	CD	O	O
50	STENDRA.xml:S2:2227:2	50	CD	O	O
mmHg	STENDRA.xml:S2:2230:4	mmhg	NN	O	O
)	STENDRA.xml:S2:2234:1	)	)	O	O
or	STENDRA.xml:S2:2236:2	or	CC	O	O
hypertension	STENDRA.xml:S2:2239:12	hypertens	NN	O	B-AdverseReaction
(	STENDRA.xml:S2:2252:1	(	(	O	O
blood	STENDRA.xml:S2:2253:5	blood	NN	O	B-AdverseReaction
pressure	STENDRA.xml:S2:2259:8	pressur	NN	O	I-AdverseReaction
greater	STENDRA.xml:S2:2268:7	greater	JJR	O	I-AdverseReaction
than	STENDRA.xml:S2:2276:4	than	IN	O	I-AdverseReaction
170	STENDRA.xml:S2:2281:3	170	CD	O	I-AdverseReaction
100	STENDRA.xml:S2:2285:3	100	CD	O	I-AdverseReaction
mmHg	STENDRA.xml:S2:2289:4	mmhg	NN	O	I-AdverseReaction
)	STENDRA.xml:S2:2293:1	)	)	O	O
;	STENDRA.xml:S2:2294:1	;	:	O	O

Patients	STENDRA.xml:S2:2301:8	patient	NNS	O	O
with	STENDRA.xml:S2:2310:4	with	IN	O	O
unstable	STENDRA.xml:S2:2315:8	unstabl	JJ	O	O
angina	STENDRA.xml:S2:2324:6	angina	NN	O	O
,	STENDRA.xml:S2:2330:1	,	,	O	O
angina	STENDRA.xml:S2:2332:6	angina	NN	O	B-AdverseReaction
with	STENDRA.xml:S2:2339:4	with	IN	O	O
sexual	STENDRA.xml:S2:2344:6	sexual	JJ	O	O
intercourse	STENDRA.xml:S2:2351:11	intercours	NN	O	O
,	STENDRA.xml:S2:2362:1	,	,	O	O
or	STENDRA.xml:S2:2364:2	or	CC	O	O
New	STENDRA.xml:S2:2367:3	new	NNP	O	O
York	STENDRA.xml:S2:2371:4	york	NNP	O	O
Heart	STENDRA.xml:S2:2376:5	heart	NNP	O	O
Association	STENDRA.xml:S2:2382:11	associ	NNP	O	O
Class	STENDRA.xml:S2:2394:5	class	NNP	O	O
2	STENDRA.xml:S2:2400:1	2	CD	O	O
or	STENDRA.xml:S2:2402:2	or	CC	O	O
greater	STENDRA.xml:S2:2405:7	greater	JJR	O	O
congestive	STENDRA.xml:S2:2413:10	congest	JJ	O	O
heart	STENDRA.xml:S2:2424:5	heart	NN	O	O
failure	STENDRA.xml:S2:2430:7	failur	NN	O	O
.	STENDRA.xml:S2:2437:1	.	.	O	O

As	STENDRA.xml:S2:2444:2	As	IN	O	O
with	STENDRA.xml:S2:2447:4	with	IN	O	O
other	STENDRA.xml:S2:2452:5	other	JJ	O	O
PDE5	STENDRA.xml:S2:2458:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:2463:10	inhibitor	NNS	O	O
STENDRA	STENDRA.xml:S2:2474:7	stendra	NNP	O	O
has	STENDRA.xml:S2:2482:3	ha	VBZ	O	O
systemic	STENDRA.xml:S2:2486:8	system	JJ	O	O
vasodilatory	STENDRA.xml:S2:2495:12	vasodilatori	NN	O	O
properties	STENDRA.xml:S2:2508:10	properti	NNS	O	O
and	STENDRA.xml:S2:2519:3	and	CC	O	O
may	STENDRA.xml:S2:2523:3	may	MD	O	O
augment	STENDRA.xml:S2:2527:7	augment	VB	O	O
the	STENDRA.xml:S2:2535:3	the	DT	O	O
blood	STENDRA.xml:S2:2539:5	blood	NN	O	O
pressure	STENDRA.xml:S2:2545:8	pressur	NN	O	O
-	STENDRA.xml:S2:2553:1	-	:	O	O
lowering	STENDRA.xml:S2:2554:8	lower	VBG	O	O
effect	STENDRA.xml:S2:2563:6	effect	NN	O	O
of	STENDRA.xml:S2:2570:2	of	IN	O	O
other	STENDRA.xml:S2:2573:5	other	JJ	O	O
anti	STENDRA.xml:S2:2579:4	anti	JJ	O	O
-	STENDRA.xml:S2:2583:1	-	:	O	O
hypertensive	STENDRA.xml:S2:2584:12	hypertens	JJ	O	O
medications	STENDRA.xml:S2:2597:11	medic	NNS	O	O
.	STENDRA.xml:S2:2608:1	.	.	O	O

STENDRA	STENDRA.xml:S2:2610:7	stendra	NNP	O	O
200	STENDRA.xml:S2:2618:3	200	CD	O	O
mg	STENDRA.xml:S2:2622:2	mg	NN	O	O
resulted	STENDRA.xml:S2:2625:8	result	VBD	O	O
in	STENDRA.xml:S2:2634:2	in	IN	O	O
transient	STENDRA.xml:S2:2637:9	transient	NN	B-AdverseReaction	B-AdverseReaction
decreases	STENDRA.xml:S2:2647:9	decreas	NNS	I-AdverseReaction	I-AdverseReaction
in	STENDRA.xml:S2:2657:2	in	IN	I-AdverseReaction	O
sitting	STENDRA.xml:S2:2660:7	sit	VBG	I-AdverseReaction	O
blood	STENDRA.xml:S2:2668:5	blood	NN	I-AdverseReaction	O
pressure	STENDRA.xml:S2:2674:8	pressur	NN	I-AdverseReaction	O
in	STENDRA.xml:S2:2683:2	in	IN	O	O
healthy	STENDRA.xml:S2:2686:7	healthi	JJ	O	O
volunteers	STENDRA.xml:S2:2694:10	volunt	NNS	O	O
of	STENDRA.xml:S2:2705:2	of	IN	O	O
8.0	STENDRA.xml:S2:2708:3	8.0	CD	O	O
mmHg	STENDRA.xml:S2:2712:4	mmhg	NNS	O	O
systolic	STENDRA.xml:S2:2717:8	systol	JJ	O	O
and	STENDRA.xml:S2:2726:3	and	CC	O	O
3.3	STENDRA.xml:S2:2730:3	3.3	CD	O	O
mmHg	STENDRA.xml:S2:2734:4	mmhg	NNS	O	O
diastolic	STENDRA.xml:S2:2739:9	diastol	JJ	O	O
[	STENDRA.xml:S2:2750:1	[	NNP	O	O
seeClinical	STENDRA.xml:S2:2751:11	seeclin	JJ	O	O
Pharmacology	STENDRA.xml:S2:2763:12	pharmacolog	NNP	O	O
(	STENDRA.xml:S2:2776:1	(	(	O	O
12.2	STENDRA.xml:S2:2777:4	12.2	CD	O	O
)]	STENDRA.xml:S2:2781:2	)]	NN	O	O
,	STENDRA.xml:S2:2785:1	,	,	O	O
with	STENDRA.xml:S2:2787:4	with	IN	O	O
the	STENDRA.xml:S2:2792:3	the	DT	O	O
maximum	STENDRA.xml:S2:2796:7	maximum	JJ	O	O
decrease	STENDRA.xml:S2:2804:8	decreas	NN	O	O
observed	STENDRA.xml:S2:2813:8	observ	VBD	O	O
at	STENDRA.xml:S2:2822:2	at	IN	O	O
1	STENDRA.xml:S2:2825:1	1	CD	O	O
hour	STENDRA.xml:S2:2827:4	hour	NN	O	O
after	STENDRA.xml:S2:2832:5	after	IN	O	O
dosing	STENDRA.xml:S2:2838:6	dose	VBG	O	O
.	STENDRA.xml:S2:2844:1	.	.	O	O

While	STENDRA.xml:S2:2846:5	while	IN	O	O
this	STENDRA.xml:S2:2852:4	thi	DT	O	O
normally	STENDRA.xml:S2:2857:8	normal	RB	O	O
would	STENDRA.xml:S2:2866:5	would	MD	O	O
be	STENDRA.xml:S2:2872:2	be	VB	O	O
expected	STENDRA.xml:S2:2875:8	expect	VBN	O	O
to	STENDRA.xml:S2:2884:2	to	TO	O	O
be	STENDRA.xml:S2:2887:2	be	VB	O	O
of	STENDRA.xml:S2:2890:2	of	IN	O	O
little	STENDRA.xml:S2:2893:6	littl	JJ	O	O
consequence	STENDRA.xml:S2:2900:11	consequ	NN	O	O
in	STENDRA.xml:S2:2912:2	in	IN	O	O
most	STENDRA.xml:S2:2915:4	most	JJS	O	O
patients	STENDRA.xml:S2:2920:8	patient	NNS	O	O
,	STENDRA.xml:S2:2928:1	,	,	O	O
prior	STENDRA.xml:S2:2930:5	prior	RB	O	O
to	STENDRA.xml:S2:2936:2	to	TO	O	O
prescribing	STENDRA.xml:S2:2939:11	prescrib	VBG	O	O
STENDRA	STENDRA.xml:S2:2951:7	stendra	NNP	O	O
,	STENDRA.xml:S2:2958:1	,	,	O	O
physicians	STENDRA.xml:S2:2960:10	physician	NNS	O	O
should	STENDRA.xml:S2:2971:6	should	MD	O	O
carefully	STENDRA.xml:S2:2978:9	care	RB	O	O
consider	STENDRA.xml:S2:2988:8	consid	VB	O	O
whether	STENDRA.xml:S2:2997:7	whether	IN	O	O
patients	STENDRA.xml:S2:3005:8	patient	NNS	O	O
with	STENDRA.xml:S2:3014:4	with	IN	O	O
underlying	STENDRA.xml:S2:3019:10	underli	JJ	O	O
cardiovascular	STENDRA.xml:S2:3030:14	cardiovascular	JJ	O	O
disease	STENDRA.xml:S2:3045:7	diseas	NN	O	O
could	STENDRA.xml:S2:3053:5	could	MD	O	O
be	STENDRA.xml:S2:3059:2	be	VB	O	O
affected	STENDRA.xml:S2:3062:8	affect	VBN	O	O
adversely	STENDRA.xml:S2:3071:9	advers	RB	O	O
by	STENDRA.xml:S2:3081:2	by	IN	O	O
such	STENDRA.xml:S2:3084:4	such	JJ	O	O
vasodilatory	STENDRA.xml:S2:3089:12	vasodilatori	JJ	O	O
effects	STENDRA.xml:S2:3102:7	effect	NNS	O	O
,	STENDRA.xml:S2:3109:1	,	,	O	O
especially	STENDRA.xml:S2:3111:10	especi	RB	O	O
in	STENDRA.xml:S2:3122:2	in	IN	O	O
combination	STENDRA.xml:S2:3125:11	combin	NN	O	O
with	STENDRA.xml:S2:3137:4	with	IN	O	O
sexual	STENDRA.xml:S2:3142:6	sexual	JJ	O	O
activity	STENDRA.xml:S2:3149:8	activ	NN	O	O
.	STENDRA.xml:S2:3157:1	.	.	O	O

5.2	STENDRA.xml:S2:3165:3	5.2	CD	O	O

Concomitant	STENDRA.xml:S2:3169:11	concomit	NNP	O	O
Use	STENDRA.xml:S2:3181:3	use	NNP	O	O
of	STENDRA.xml:S2:3185:2	of	IN	O	O
CYP3A4	STENDRA.xml:S2:3188:6	cyp3a4	NNP	O	O
Inhibitors	STENDRA.xml:S2:3195:10	inhibitor	NNS	O	O

STENDRA	STENDRA.xml:S2:3209:7	stendra	NNP	O	O
metabolism	STENDRA.xml:S2:3217:10	metabol	NN	O	O
is	STENDRA.xml:S2:3228:2	is	VBZ	O	O
principally	STENDRA.xml:S2:3231:11	princip	RB	O	O
mediated	STENDRA.xml:S2:3243:8	mediat	VBN	O	O
by	STENDRA.xml:S2:3252:2	by	IN	O	O
the	STENDRA.xml:S2:3255:3	the	DT	O	O
CYP450	STENDRA.xml:S2:3259:6	cyp450	NNP	O	O
isoform	STENDRA.xml:S2:3266:7	isoform	NN	O	O
3	STENDRA.xml:S2:3274:1	3	CD	O	O
A4	STENDRA.xml:S2:3275:2	A4	NNP	O	O
(	STENDRA.xml:S2:3278:1	(	(	O	O
CYP3A4	STENDRA.xml:S2:3279:6	cyp3a4	NNP	O	O
)	STENDRA.xml:S2:3285:1	)	)	O	O
.	STENDRA.xml:S2:3286:1	.	.	O	O

Inhibitors	STENDRA.xml:S2:3288:10	inhibitor	NNS	O	O
of	STENDRA.xml:S2:3299:2	of	IN	O	O
CYP3A4	STENDRA.xml:S2:3302:6	cyp3a4	NNP	O	O
may	STENDRA.xml:S2:3309:3	may	MD	O	O
reduce	STENDRA.xml:S2:3313:6	reduc	VB	O	O
STENDRA	STENDRA.xml:S2:3320:7	stendra	NNP	O	O
clearance	STENDRA.xml:S2:3328:9	clearanc	NN	O	O
and	STENDRA.xml:S2:3338:3	and	CC	O	O
increase	STENDRA.xml:S2:3342:8	increas	VB	O	O
plasma	STENDRA.xml:S2:3351:6	plasma	JJ	O	O
concentrations	STENDRA.xml:S2:3358:14	concentr	NNS	O	O
of	STENDRA.xml:S2:3373:2	of	IN	O	O
avanafil	STENDRA.xml:S2:3376:8	avanafil	NN	O	O
.	STENDRA.xml:S2:3384:1	.	.	O	O

For	STENDRA.xml:S2:3390:3	for	IN	O	O
patients	STENDRA.xml:S2:3394:8	patient	NNS	O	O
taking	STENDRA.xml:S2:3403:6	take	VBG	O	O
concomitant	STENDRA.xml:S2:3410:11	concomit	JJ	O	O
strong	STENDRA.xml:S2:3422:6	strong	JJ	O	O
CYP3A4	STENDRA.xml:S2:3429:6	cyp3a4	NNP	O	O
inhibitors	STENDRA.xml:S2:3436:10	inhibitor	NNS	O	O
(	STENDRA.xml:S2:3447:1	(	(	O	O
including	STENDRA.xml:S2:3448:9	includ	VBG	O	O
ketoconazole	STENDRA.xml:S2:3458:12	ketoconazol	NN	O	O
,	STENDRA.xml:S2:3470:1	,	,	O	O
ritonavir	STENDRA.xml:S2:3472:9	ritonavir	NN	O	B-AdverseReaction
,	STENDRA.xml:S2:3481:1	,	,	O	O
atazanavir	STENDRA.xml:S2:3483:10	atazanavir	NN	O	B-AdverseReaction
,	STENDRA.xml:S2:3493:1	,	,	O	O
clarithromycin	STENDRA.xml:S2:3495:14	clarithromycin	NN	O	O
,	STENDRA.xml:S2:3509:1	,	,	O	O
indinavir	STENDRA.xml:S2:3511:9	indinavir	NN	O	O
,	STENDRA.xml:S2:3520:1	,	,	O	O
itraconazole	STENDRA.xml:S2:3522:12	itraconazol	NN	O	O
,	STENDRA.xml:S2:3534:1	,	,	O	O
nefazodone	STENDRA.xml:S2:3536:10	nefazodon	NN	O	O
,	STENDRA.xml:S2:3546:1	,	,	O	O
nelfinavir	STENDRA.xml:S2:3548:10	nelfinavir	RB	O	O
,	STENDRA.xml:S2:3558:1	,	,	O	O
saquinavir	STENDRA.xml:S2:3560:10	saquinavir	NN	O	O
,	STENDRA.xml:S2:3570:1	,	,	O	O
and	STENDRA.xml:S2:3572:3	and	CC	O	O
telithromycin	STENDRA.xml:S2:3576:13	telithromycin	NN	O	O
)	STENDRA.xml:S2:3589:1	)	)	O	O
,	STENDRA.xml:S2:3590:1	,	,	O	O
do	STENDRA.xml:S2:3592:2	do	VBP	O	O
not	STENDRA.xml:S2:3595:3	not	RB	O	O
use	STENDRA.xml:S2:3599:3	use	VB	O	O
STENDRA	STENDRA.xml:S2:3603:7	stendra	NNP	O	O
[	STENDRA.xml:S2:3612:1	[	NNP	O	O
seeDrug	STENDRA.xml:S2:3613:7	seedrug	JJ	O	O
Interactions	STENDRA.xml:S2:3621:12	interact	NNP	O	O
(	STENDRA.xml:S2:3634:1	(	(	O	O
7.2	STENDRA.xml:S2:3635:3	7.2	CD	O	O
)]	STENDRA.xml:S2:3638:2	)]	NN	O	O
.	STENDRA.xml:S2:3640:1	.	.	O	O

For	STENDRA.xml:S2:3648:3	for	IN	O	O
patients	STENDRA.xml:S2:3652:8	patient	NNS	O	O
taking	STENDRA.xml:S2:3661:6	take	VBG	O	O
concomitant	STENDRA.xml:S2:3668:11	concomit	JJ	O	O
moderate	STENDRA.xml:S2:3680:8	moder	JJ	O	O
CYP3A4	STENDRA.xml:S2:3689:6	cyp3a4	NNP	O	O
inhibitors	STENDRA.xml:S2:3696:10	inhibitor	NNS	O	O
(	STENDRA.xml:S2:3707:1	(	(	O	O
including	STENDRA.xml:S2:3708:9	includ	VBG	O	O
erythromycin	STENDRA.xml:S2:3718:12	erythromycin	NN	O	O
,	STENDRA.xml:S2:3730:1	,	,	O	O
amprenavir	STENDRA.xml:S2:3732:10	amprenavir	NN	O	B-AdverseReaction
,	STENDRA.xml:S2:3742:1	,	,	O	O
aprepitant	STENDRA.xml:S2:3744:10	aprepit	NN	O	B-AdverseReaction
,	STENDRA.xml:S2:3754:1	,	,	O	O
diltiazem	STENDRA.xml:S2:3756:9	diltiazem	NN	O	B-AdverseReaction
,	STENDRA.xml:S2:3765:1	,	,	O	O
fluconazole	STENDRA.xml:S2:3767:11	fluconazol	NN	O	B-AdverseReaction
,	STENDRA.xml:S2:3778:1	,	,	O	O
fosamprenavir	STENDRA.xml:S2:3780:13	fosamprenavir	NN	O	O
,	STENDRA.xml:S2:3793:1	,	,	O	O
and	STENDRA.xml:S2:3795:3	and	CC	O	O
verapamil	STENDRA.xml:S2:3799:9	verapamil	NN	O	O
)	STENDRA.xml:S2:3808:1	)	)	O	O
,	STENDRA.xml:S2:3809:1	,	,	O	O
the	STENDRA.xml:S2:3811:3	the	DT	O	O
maximum	STENDRA.xml:S2:3815:7	maximum	NN	O	O
recommended	STENDRA.xml:S2:3823:11	recommend	VBD	O	O
dose	STENDRA.xml:S2:3835:4	dose	NN	O	O
of	STENDRA.xml:S2:3840:2	of	IN	O	O
STENDRA	STENDRA.xml:S2:3843:7	stendra	NNP	O	O
is	STENDRA.xml:S2:3851:2	is	VBZ	O	O
50	STENDRA.xml:S2:3854:2	50	CD	O	O
mg	STENDRA.xml:S2:3857:2	mg	NN	O	O
,	STENDRA.xml:S2:3859:1	,	,	O	O
not	STENDRA.xml:S2:3861:3	not	RB	O	O
to	STENDRA.xml:S2:3865:2	to	TO	O	O
exceed	STENDRA.xml:S2:3868:6	exceed	VB	O	O
once	STENDRA.xml:S2:3875:4	onc	RB	O	O
every	STENDRA.xml:S2:3880:5	everi	DT	O	O
24	STENDRA.xml:S2:3886:2	24	CD	O	O
hours	STENDRA.xml:S2:3889:5	hour	NNS	O	O
[	STENDRA.xml:S2:3896:1	[	JJ	O	O
seeDrug	STENDRA.xml:S2:3897:7	seedrug	JJ	O	O
Interactions	STENDRA.xml:S2:3905:12	interact	NNP	O	O
(	STENDRA.xml:S2:3918:1	(	(	O	O
7.2	STENDRA.xml:S2:3919:3	7.2	CD	O	O
)]	STENDRA.xml:S2:3922:2	)]	NN	O	O
.	STENDRA.xml:S2:3924:1	.	.	O	O

5.3	STENDRA.xml:S2:3934:3	5.3	CD	O	O
Prolonged	STENDRA.xml:S2:3938:9	prolong	JJ	O	O
Erection	STENDRA.xml:S2:3948:8	erect	NN	O	O

Prolonged	STENDRA.xml:S2:3960:9	prolong	VBN	B-AdverseReaction	O
erection	STENDRA.xml:S2:3970:8	erect	NN	I-AdverseReaction	O
greater	STENDRA.xml:S2:3979:7	greater	JJR	O	O
than	STENDRA.xml:S2:3987:4	than	IN	O	O
4	STENDRA.xml:S2:3992:1	4	CD	O	O
hours	STENDRA.xml:S2:3994:5	hour	NNS	O	O
and	STENDRA.xml:S2:4000:3	and	CC	O	O
priapism	STENDRA.xml:S2:4004:8	priapism	NN	B-AdverseReaction	B-AdverseReaction
(	STENDRA.xml:S2:4013:1	(	(	O	O
painful	STENDRA.xml:S2:4014:7	pain	JJ	B-AdverseReaction	O
erections	STENDRA.xml:S2:4022:9	erect	NNS	I-AdverseReaction	O
greater	STENDRA.xml:S2:4032:7	greater	JJR	O	O
than	STENDRA.xml:S2:4040:4	than	IN	O	O
6	STENDRA.xml:S2:4045:1	6	CD	O	O
hours	STENDRA.xml:S2:4047:5	hour	NNS	O	O
in	STENDRA.xml:S2:4053:2	in	IN	O	O
duration	STENDRA.xml:S2:4056:8	durat	NN	O	O
)	STENDRA.xml:S2:4064:1	)	)	O	O
have	STENDRA.xml:S2:4066:4	have	VBP	O	O
been	STENDRA.xml:S2:4071:4	been	VBN	O	O
reported	STENDRA.xml:S2:4076:8	report	VBN	O	O
with	STENDRA.xml:S2:4085:4	with	IN	O	O
other	STENDRA.xml:S2:4090:5	other	JJ	O	O
PDE5	STENDRA.xml:S2:4096:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:4101:10	inhibitor	NNS	O	O
.	STENDRA.xml:S2:4111:1	.	.	O	O

In	STENDRA.xml:S2:4113:2	In	IN	O	O
the	STENDRA.xml:S2:4116:3	the	DT	O	O
event	STENDRA.xml:S2:4120:5	event	NN	O	O
of	STENDRA.xml:S2:4126:2	of	IN	O	O
an	STENDRA.xml:S2:4129:2	an	DT	O	O
erection	STENDRA.xml:S2:4132:8	erect	NN	O	O
that	STENDRA.xml:S2:4141:4	that	WDT	O	O
persists	STENDRA.xml:S2:4146:8	persist	VBZ	O	O
longer	STENDRA.xml:S2:4155:6	longer	JJR	O	O
than	STENDRA.xml:S2:4162:4	than	IN	O	O
4	STENDRA.xml:S2:4167:1	4	CD	O	O
hours	STENDRA.xml:S2:4169:5	hour	NNS	O	O
,	STENDRA.xml:S2:4174:1	,	,	O	O
the	STENDRA.xml:S2:4176:3	the	DT	O	O
patient	STENDRA.xml:S2:4180:7	patient	NN	O	O
should	STENDRA.xml:S2:4188:6	should	MD	O	O
seek	STENDRA.xml:S2:4195:4	seek	VB	O	O
immediate	STENDRA.xml:S2:4200:9	immedi	JJ	O	O
medical	STENDRA.xml:S2:4210:7	medic	JJ	O	O
assistance	STENDRA.xml:S2:4218:10	assist	NN	O	O
.	STENDRA.xml:S2:4228:1	.	.	O	O

If	STENDRA.xml:S2:4230:2	If	IN	O	O
not	STENDRA.xml:S2:4233:3	not	RB	O	O
treated	STENDRA.xml:S2:4237:7	treat	VBN	O	O
immediately	STENDRA.xml:S2:4245:11	immedi	RB	O	O
,	STENDRA.xml:S2:4256:1	,	,	O	O
penile	STENDRA.xml:S2:4258:6	penil	JJ	O	B-AdverseReaction
tissue	STENDRA.xml:S2:4265:6	tissu	NN	O	I-AdverseReaction
damage	STENDRA.xml:S2:4272:6	damag	NN	O	I-AdverseReaction
and	STENDRA.xml:S2:4279:3	and	CC	O	O
permanent	STENDRA.xml:S2:4283:9	perman	JJ	O	O
loss	STENDRA.xml:S2:4293:4	loss	NN	O	O
of	STENDRA.xml:S2:4298:2	of	IN	O	O
potency	STENDRA.xml:S2:4301:7	potenc	NN	O	O
could	STENDRA.xml:S2:4309:5	could	MD	O	O
result	STENDRA.xml:S2:4315:6	result	VB	O	O
.	STENDRA.xml:S2:4321:1	.	.	O	O

STENDRA	STENDRA.xml:S2:4327:7	stendra	NNP	O	O
should	STENDRA.xml:S2:4335:6	should	MD	O	O
be	STENDRA.xml:S2:4342:2	be	VB	O	O
used	STENDRA.xml:S2:4345:4	use	VBN	O	O
with	STENDRA.xml:S2:4350:4	with	IN	O	O
caution	STENDRA.xml:S2:4355:7	caution	NN	O	O
in	STENDRA.xml:S2:4363:2	in	IN	O	O
patients	STENDRA.xml:S2:4366:8	patient	NNS	O	O
with	STENDRA.xml:S2:4375:4	with	IN	O	O
anatomical	STENDRA.xml:S2:4380:10	anatom	JJ	O	O
deformation	STENDRA.xml:S2:4391:11	deform	NN	O	O
of	STENDRA.xml:S2:4403:2	of	IN	O	O
the	STENDRA.xml:S2:4406:3	the	DT	O	O
penis	STENDRA.xml:S2:4410:5	peni	NN	O	O
(	STENDRA.xml:S2:4416:1	(	(	O	O
such	STENDRA.xml:S2:4417:4	such	JJ	O	O
as	STENDRA.xml:S2:4422:2	as	IN	O	O
angulation	STENDRA.xml:S2:4425:10	angul	NN	O	O
,	STENDRA.xml:S2:4435:1	,	,	O	O
cavernosal	STENDRA.xml:S2:4437:10	cavernos	JJ	O	B-AdverseReaction
fibrosis	STENDRA.xml:S2:4448:8	fibrosi	NN	O	I-AdverseReaction
,	STENDRA.xml:S2:4456:1	,	,	O	O
or	STENDRA.xml:S2:4458:2	or	CC	O	O
Peyronie	STENDRA.xml:S2:4461:8	peyroni	NNP	O	O
's	STENDRA.xml:S2:4469:2	's	POS	O	O
disease	STENDRA.xml:S2:4472:7	diseas	NN	O	O
)	STENDRA.xml:S2:4479:1	)	)	O	O
,	STENDRA.xml:S2:4480:1	,	,	O	O
or	STENDRA.xml:S2:4482:2	or	CC	O	O
in	STENDRA.xml:S2:4485:2	in	IN	O	O
patients	STENDRA.xml:S2:4488:8	patient	NNS	O	O
who	STENDRA.xml:S2:4497:3	who	WP	O	O
have	STENDRA.xml:S2:4501:4	have	VBP	O	O
conditions	STENDRA.xml:S2:4506:10	condit	NNS	O	O
which	STENDRA.xml:S2:4517:5	which	WDT	O	O
may	STENDRA.xml:S2:4523:3	may	MD	O	O
predispose	STENDRA.xml:S2:4527:10	predispos	VB	O	O
them	STENDRA.xml:S2:4538:4	them	PRP	O	O
to	STENDRA.xml:S2:4543:2	to	TO	O	O
priapism	STENDRA.xml:S2:4546:8	priapism	VB	O	O
(	STENDRA.xml:S2:4555:1	(	(	O	O
such	STENDRA.xml:S2:4556:4	such	JJ	O	O
as	STENDRA.xml:S2:4561:2	as	IN	O	O
sickle	STENDRA.xml:S2:4564:6	sickl	NN	O	B-AdverseReaction
cell	STENDRA.xml:S2:4571:4	cell	NN	O	I-AdverseReaction
anemia	STENDRA.xml:S2:4576:6	anemia	NN	O	I-AdverseReaction
,	STENDRA.xml:S2:4582:1	,	,	O	O
multiple	STENDRA.xml:S2:4584:8	multipl	JJ	O	B-AdverseReaction
myeloma	STENDRA.xml:S2:4593:7	myeloma	NN	O	I-AdverseReaction
,	STENDRA.xml:S2:4600:1	,	,	O	O
or	STENDRA.xml:S2:4602:2	or	CC	O	O
leukemia	STENDRA.xml:S2:4605:8	leukemia	NN	O	O
)	STENDRA.xml:S2:4613:1	)	)	O	O
.	STENDRA.xml:S2:4614:1	.	.	O	O

5.4	STENDRA.xml:S2:4622:3	5.4	CD	O	O
Effects	STENDRA.xml:S2:4626:7	effect	NNS	O	O
on	STENDRA.xml:S2:4634:2	on	IN	O	O
Eye	STENDRA.xml:S2:4637:3	eye	NNP	O	O

Physicians	STENDRA.xml:S2:4646:10	physician	NNS	O	O
should	STENDRA.xml:S2:4657:6	should	MD	O	O
advise	STENDRA.xml:S2:4664:6	advis	VB	O	O
patients	STENDRA.xml:S2:4671:8	patient	NNS	O	O
to	STENDRA.xml:S2:4680:2	to	TO	O	O
stop	STENDRA.xml:S2:4683:4	stop	VB	O	O
use	STENDRA.xml:S2:4688:3	use	NN	O	O
of	STENDRA.xml:S2:4692:2	of	IN	O	O
all	STENDRA.xml:S2:4695:3	all	DT	O	O
PDE5	STENDRA.xml:S2:4699:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:4704:10	inhibitor	NNS	O	O
,	STENDRA.xml:S2:4714:1	,	,	O	O
including	STENDRA.xml:S2:4716:9	includ	VBG	O	O
STENDRA	STENDRA.xml:S2:4726:7	stendra	NNP	O	O
,	STENDRA.xml:S2:4733:1	,	,	O	O
and	STENDRA.xml:S2:4735:3	and	CC	O	O
seek	STENDRA.xml:S2:4739:4	seek	VB	O	O
medical	STENDRA.xml:S2:4744:7	medic	JJ	O	O
attention	STENDRA.xml:S2:4752:9	attent	NN	O	O
in	STENDRA.xml:S2:4762:2	in	IN	O	O
the	STENDRA.xml:S2:4765:3	the	DT	O	O
event	STENDRA.xml:S2:4769:5	event	NN	O	O
of	STENDRA.xml:S2:4775:2	of	IN	O	O
a	STENDRA.xml:S2:4778:1	a	DT	O	O
sudden	STENDRA.xml:S2:4780:6	sudden	JJ	O	O
loss	STENDRA.xml:S2:4787:4	loss	NN	O	O
of	STENDRA.xml:S2:4792:2	of	IN	O	O
vision	STENDRA.xml:S2:4795:6	vision	NN	O	O
in	STENDRA.xml:S2:4802:2	in	IN	O	O
one	STENDRA.xml:S2:4805:3	one	CD	O	O
or	STENDRA.xml:S2:4809:2	or	CC	O	O
both	STENDRA.xml:S2:4812:4	both	DT	O	O
eyes	STENDRA.xml:S2:4817:4	eye	NNS	O	O
.	STENDRA.xml:S2:4821:1	.	.	O	O

Such	STENDRA.xml:S2:4823:4	such	JJ	O	O
an	STENDRA.xml:S2:4828:2	an	DT	O	O
event	STENDRA.xml:S2:4831:5	event	NN	O	O
may	STENDRA.xml:S2:4837:3	may	MD	O	O
be	STENDRA.xml:S2:4841:2	be	VB	O	O
a	STENDRA.xml:S2:4844:1	a	DT	O	O
sign	STENDRA.xml:S2:4846:4	sign	NN	O	O
of	STENDRA.xml:S2:4851:2	of	IN	O	O
non	STENDRA.xml:S2:4854:3	non	JJ	B-AdverseReaction	O
-	STENDRA.xml:S2:4857:1	-	:	I-AdverseReaction	O
arteritic	STENDRA.xml:S2:4858:9	arterit	JJ	I-AdverseReaction	O
anterior	STENDRA.xml:S2:4868:8	anterior	JJ	I-AdverseReaction	B-AdverseReaction
ischemic	STENDRA.xml:S2:4877:8	ischem	JJ	I-AdverseReaction	I-AdverseReaction
optic	STENDRA.xml:S2:4886:5	optic	JJ	I-AdverseReaction	I-AdverseReaction
neuropathy	STENDRA.xml:S2:4892:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
(	STENDRA.xml:S2:4903:1	(	(	O	O
NAION	STENDRA.xml:S2:4904:5	naion	NNP	B-AdverseReaction	O
)	STENDRA.xml:S2:4909:1	)	)	O	O
,	STENDRA.xml:S2:4910:1	,	,	O	O
a	STENDRA.xml:S2:4912:1	a	DT	O	O
rare	STENDRA.xml:S2:4914:4	rare	JJ	O	O
condition	STENDRA.xml:S2:4919:9	condit	NN	O	O
and	STENDRA.xml:S2:4929:3	and	CC	O	O
a	STENDRA.xml:S2:4933:1	a	DT	O	O
cause	STENDRA.xml:S2:4935:5	caus	NN	O	O
of	STENDRA.xml:S2:4941:2	of	IN	O	O
decreased	STENDRA.xml:S2:4944:9	decreas	JJ	B-AdverseReaction	B-AdverseReaction
vision	STENDRA.xml:S2:4954:6	vision	NN	I-AdverseReaction	I-AdverseReaction
including	STENDRA.xml:S2:4961:9	includ	VBG	O	O
permanent	STENDRA.xml:S2:4971:9	perman	JJ	B-AdverseReaction	O
loss	STENDRA.xml:S2:4981:4	loss	NN	I-AdverseReaction	O
of	STENDRA.xml:S2:4986:2	of	IN	I-AdverseReaction	O
vision	STENDRA.xml:S2:4989:6	vision	NN	I-AdverseReaction	O
that	STENDRA.xml:S2:4996:4	that	WDT	O	O
has	STENDRA.xml:S2:5001:3	ha	VBZ	O	O
been	STENDRA.xml:S2:5005:4	been	VBN	O	O
reported	STENDRA.xml:S2:5010:8	report	VBN	O	O
rarely	STENDRA.xml:S2:5019:6	rare	RB	O	O
postmarketing	STENDRA.xml:S2:5026:13	postmarket	VBG	O	O
in	STENDRA.xml:S2:5040:2	in	IN	O	O
temporal	STENDRA.xml:S2:5043:8	tempor	JJ	O	O
association	STENDRA.xml:S2:5052:11	associ	NN	O	O
with	STENDRA.xml:S2:5064:4	with	IN	O	O
the	STENDRA.xml:S2:5069:3	the	DT	O	O
use	STENDRA.xml:S2:5073:3	use	NN	O	O
of	STENDRA.xml:S2:5077:2	of	IN	O	O
all	STENDRA.xml:S2:5080:3	all	DT	O	O
PDE5	STENDRA.xml:S2:5084:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:5089:10	inhibitor	NNS	O	O
.	STENDRA.xml:S2:5099:1	.	.	O	O

Based	STENDRA.xml:S2:5107:5	base	VBN	O	O
on	STENDRA.xml:S2:5113:2	on	IN	O	O
published	STENDRA.xml:S2:5116:9	publish	JJ	O	O
literature	STENDRA.xml:S2:5126:10	literatur	NN	O	O
,	STENDRA.xml:S2:5136:1	,	,	O	O
the	STENDRA.xml:S2:5138:3	the	DT	O	O
annual	STENDRA.xml:S2:5142:6	annual	JJ	O	O
incidence	STENDRA.xml:S2:5149:9	incid	NN	O	O
of	STENDRA.xml:S2:5159:2	of	IN	O	O
NAION	STENDRA.xml:S2:5162:5	naion	NNP	O	O
is	STENDRA.xml:S2:5168:2	is	VBZ	O	O
2.5	STENDRA.xml:S2:5171:3	2.5	CD	O	O
-	STENDRA.xml:S2:5174:1	-	:	O	O
11.8	STENDRA.xml:S2:5175:4	11.8	CD	O	O
cases	STENDRA.xml:S2:5180:5	case	NNS	O	O
per	STENDRA.xml:S2:5186:3	per	IN	O	O
100	STENDRA.xml:S2:5190:3	100	CD	O	O
,	STENDRA.xml:S2:5193:1	,	,	O	O
000	STENDRA.xml:S2:5194:3	000	CD	O	O
in	STENDRA.xml:S2:5198:2	in	IN	O	O
males	STENDRA.xml:S2:5201:5	male	NNS	O	O
aged	STENDRA.xml:S2:5207:4	age	VBN	O	O
50	STENDRA.xml:S2:5215:2	50	CD	O	O
.	STENDRA.xml:S2:5217:1	.	.	O	O

An	STENDRA.xml:S2:5219:2	An	DT	O	O
observational	STENDRA.xml:S2:5222:13	observ	JJ	O	O
study	STENDRA.xml:S2:5236:5	studi	NN	O	O
evaluated	STENDRA.xml:S2:5242:9	evalu	VBD	O	O
whether	STENDRA.xml:S2:5252:7	whether	IN	O	O
recent	STENDRA.xml:S2:5260:6	recent	JJ	O	O
use	STENDRA.xml:S2:5267:3	use	NN	O	O
of	STENDRA.xml:S2:5271:2	of	IN	O	O
PDE5	STENDRA.xml:S2:5274:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:5279:10	inhibitor	NNS	O	O
,	STENDRA.xml:S2:5289:1	,	,	O	O
as	STENDRA.xml:S2:5291:2	as	IN	O	O
a	STENDRA.xml:S2:5294:1	a	DT	O	O
class	STENDRA.xml:S2:5296:5	class	NN	O	O
,	STENDRA.xml:S2:5301:1	,	,	O	O
was	STENDRA.xml:S2:5303:3	wa	VBD	O	O
associated	STENDRA.xml:S2:5307:10	associ	VBN	O	O
with	STENDRA.xml:S2:5318:4	with	IN	O	O
acute	STENDRA.xml:S2:5323:5	acut	JJ	O	O
onset	STENDRA.xml:S2:5329:5	onset	NN	O	O
of	STENDRA.xml:S2:5335:2	of	IN	O	O
NAION	STENDRA.xml:S2:5338:5	naion	NNP	B-AdverseReaction	O
.	STENDRA.xml:S2:5343:1	.	.	O	O

The	STENDRA.xml:S2:5345:3	the	DT	O	O
results	STENDRA.xml:S2:5349:7	result	NNS	O	O
suggest	STENDRA.xml:S2:5357:7	suggest	VBP	O	O
an	STENDRA.xml:S2:5365:2	an	DT	O	O
approximate	STENDRA.xml:S2:5368:11	approxim	JJ	O	O
2	STENDRA.xml:S2:5380:1	2	CD	O	O
-	STENDRA.xml:S2:5381:1	-	:	O	O
fold	STENDRA.xml:S2:5382:4	fold	JJ	O	O
increase	STENDRA.xml:S2:5387:8	increas	NN	O	O
in	STENDRA.xml:S2:5396:2	in	IN	O	O
the	STENDRA.xml:S2:5399:3	the	DT	O	O
risk	STENDRA.xml:S2:5403:4	risk	NN	O	O
of	STENDRA.xml:S2:5408:2	of	IN	O	O
NAION	STENDRA.xml:S2:5411:5	naion	NNP	B-AdverseReaction	O
within	STENDRA.xml:S2:5417:6	within	IN	O	O
5	STENDRA.xml:S2:5424:1	5	CD	O	O
half	STENDRA.xml:S2:5426:4	half	NN	O	O
-	STENDRA.xml:S2:5430:1	-	:	O	O
lives	STENDRA.xml:S2:5431:5	live	NNS	O	O
of	STENDRA.xml:S2:5437:2	of	IN	O	O
PDE5	STENDRA.xml:S2:5440:4	pde5	NNP	O	O
inhibitor	STENDRA.xml:S2:5445:9	inhibitor	NN	O	O
use	STENDRA.xml:S2:5455:3	use	NN	O	O
.	STENDRA.xml:S2:5458:1	.	.	O	O

From	STENDRA.xml:S2:5460:4	from	IN	O	O
this	STENDRA.xml:S2:5465:4	thi	DT	O	O
information	STENDRA.xml:S2:5470:11	inform	NN	O	O
,	STENDRA.xml:S2:5481:1	,	,	O	O
it	STENDRA.xml:S2:5483:2	it	PRP	O	O
is	STENDRA.xml:S2:5486:2	is	VBZ	O	O
not	STENDRA.xml:S2:5489:3	not	RB	O	O
possible	STENDRA.xml:S2:5493:8	possibl	JJ	O	O
to	STENDRA.xml:S2:5502:2	to	TO	O	O
determine	STENDRA.xml:S2:5505:9	determin	VB	O	O
whether	STENDRA.xml:S2:5515:7	whether	IN	O	O
these	STENDRA.xml:S2:5523:5	these	DT	O	O
events	STENDRA.xml:S2:5529:6	event	NNS	O	O
are	STENDRA.xml:S2:5536:3	are	VBP	O	O
related	STENDRA.xml:S2:5540:7	relat	VBN	O	O
directly	STENDRA.xml:S2:5548:8	directli	RB	O	O
to	STENDRA.xml:S2:5557:2	to	TO	O	O
the	STENDRA.xml:S2:5560:3	the	DT	O	O
use	STENDRA.xml:S2:5564:3	use	NN	O	O
of	STENDRA.xml:S2:5568:2	of	IN	O	O
PDE5	STENDRA.xml:S2:5571:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:5576:10	inhibitor	NNS	O	O
or	STENDRA.xml:S2:5587:2	or	CC	O	O
to	STENDRA.xml:S2:5590:2	to	TO	O	O
other	STENDRA.xml:S2:5593:5	other	JJ	O	O
factors	STENDRA.xml:S2:5599:7	factor	NNS	O	O
[	STENDRA.xml:S2:5607:1	[	VBP	O	O
seeAdverse	STENDRA.xml:S2:5610:10	seeadvers	JJ	O	O
Reactions	STENDRA.xml:S2:5621:9	reaction	NNP	O	O
(	STENDRA.xml:S2:5631:1	(	(	O	O
6.2	STENDRA.xml:S2:5632:3	6.2	CD	O	O
)	STENDRA.xml:S2:5635:1	)	)	O	O
]	STENDRA.xml:S2:5638:1	]	NN	O	O
.	STENDRA.xml:S2:5639:1	.	.	O	O

Physicians	STENDRA.xml:S2:5645:10	physician	NNS	O	O
should	STENDRA.xml:S2:5656:6	should	MD	O	O
consider	STENDRA.xml:S2:5663:8	consid	VB	O	O
whether	STENDRA.xml:S2:5672:7	whether	IN	O	O
their	STENDRA.xml:S2:5680:5	their	PRP$	O	O
patients	STENDRA.xml:S2:5686:8	patient	NNS	O	O
with	STENDRA.xml:S2:5695:4	with	IN	O	O
underlying	STENDRA.xml:S2:5700:10	underli	JJ	O	O
NAION	STENDRA.xml:S2:5711:5	naion	NNP	O	O
risk	STENDRA.xml:S2:5717:4	risk	NN	O	O
factors	STENDRA.xml:S2:5722:7	factor	NNS	O	O
could	STENDRA.xml:S2:5730:5	could	MD	O	O
be	STENDRA.xml:S2:5736:2	be	VB	O	O
adversely	STENDRA.xml:S2:5739:9	advers	RB	O	O
affected	STENDRA.xml:S2:5749:8	affect	VBN	O	O
by	STENDRA.xml:S2:5758:2	by	IN	O	O
use	STENDRA.xml:S2:5761:3	use	NN	O	O
of	STENDRA.xml:S2:5765:2	of	IN	O	O
PDE5	STENDRA.xml:S2:5768:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:5773:10	inhibitor	NNS	O	O
.	STENDRA.xml:S2:5783:1	.	.	O	O

Individuals	STENDRA.xml:S2:5785:11	individu	NNS	O	O
who	STENDRA.xml:S2:5797:3	who	WP	O	O
have	STENDRA.xml:S2:5801:4	have	VBP	O	O
already	STENDRA.xml:S2:5806:7	alreadi	RB	O	O
experienced	STENDRA.xml:S2:5814:11	experienc	VBN	O	O
NAION	STENDRA.xml:S2:5826:5	naion	NNP	O	O
are	STENDRA.xml:S2:5832:3	are	VBP	O	O
at	STENDRA.xml:S2:5836:2	at	IN	O	O
increased	STENDRA.xml:S2:5839:9	increas	JJ	O	O
risk	STENDRA.xml:S2:5849:4	risk	NN	O	O
of	STENDRA.xml:S2:5854:2	of	IN	O	O
NAION	STENDRA.xml:S2:5857:5	naion	NNP	O	O
recurrence	STENDRA.xml:S2:5863:10	recurr	NN	O	O
.	STENDRA.xml:S2:5873:1	.	.	O	O

Therefore	STENDRA.xml:S2:5875:9	therefor	RB	O	O
,	STENDRA.xml:S2:5884:1	,	,	O	O
PDE5	STENDRA.xml:S2:5886:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:5891:10	inhibitor	NNS	O	O
,	STENDRA.xml:S2:5901:1	,	,	O	O
including	STENDRA.xml:S2:5903:9	includ	VBG	O	O
STENDRA	STENDRA.xml:S2:5913:7	stendra	NNP	O	O
,	STENDRA.xml:S2:5920:1	,	,	O	O
should	STENDRA.xml:S2:5922:6	should	MD	O	O
be	STENDRA.xml:S2:5929:2	be	VB	O	O
used	STENDRA.xml:S2:5932:4	use	VBN	O	O
with	STENDRA.xml:S2:5937:4	with	IN	O	O
caution	STENDRA.xml:S2:5942:7	caution	NN	O	O
in	STENDRA.xml:S2:5950:2	in	IN	O	O
these	STENDRA.xml:S2:5953:5	these	DT	O	O
patients	STENDRA.xml:S2:5959:8	patient	NNS	O	O
and	STENDRA.xml:S2:5968:3	and	CC	O	O
only	STENDRA.xml:S2:5972:4	onli	RB	O	O
when	STENDRA.xml:S2:5977:4	when	WRB	O	O
the	STENDRA.xml:S2:5982:3	the	DT	O	O
anticipated	STENDRA.xml:S2:5986:11	anticip	JJ	O	O
benefits	STENDRA.xml:S2:5998:8	benefit	NNS	O	O
outweigh	STENDRA.xml:S2:6007:8	outweigh	VBP	O	O
the	STENDRA.xml:S2:6016:3	the	DT	O	O
risks	STENDRA.xml:S2:6020:5	risk	NNS	O	O
.	STENDRA.xml:S2:6025:1	.	.	O	O

Individuals	STENDRA.xml:S2:6027:11	individu	NNS	O	O
with	STENDRA.xml:S2:6039:4	with	IN	O	O
"	STENDRA.xml:S2:6044:1	"	NNP	O	O
crowded	STENDRA.xml:S2:6045:7	crowd	VBD	O	O
"	STENDRA.xml:S2:6052:1	"	NNP	O	O
optic	STENDRA.xml:S2:6054:5	optic	JJ	O	O
disc	STENDRA.xml:S2:6060:4	disc	NN	O	O
are	STENDRA.xml:S2:6065:3	are	VBP	O	O
also	STENDRA.xml:S2:6069:4	also	RB	O	O
considered	STENDRA.xml:S2:6074:10	consid	VBN	O	O
at	STENDRA.xml:S2:6085:2	at	IN	O	O
greater	STENDRA.xml:S2:6088:7	greater	JJR	O	O
risk	STENDRA.xml:S2:6096:4	risk	NN	O	O
for	STENDRA.xml:S2:6101:3	for	IN	O	O
NAION	STENDRA.xml:S2:6105:5	naion	NNP	O	O
compared	STENDRA.xml:S2:6111:8	compar	VBN	O	O
to	STENDRA.xml:S2:6120:2	to	TO	O	O
the	STENDRA.xml:S2:6123:3	the	DT	O	O
general	STENDRA.xml:S2:6127:7	gener	JJ	O	O
population	STENDRA.xml:S2:6135:10	popul	NN	O	O
,	STENDRA.xml:S2:6145:1	,	,	O	O
however	STENDRA.xml:S2:6147:7	howev	RB	O	O
,	STENDRA.xml:S2:6154:1	,	,	O	O
evidence	STENDRA.xml:S2:6156:8	evid	NN	O	O
is	STENDRA.xml:S2:6165:2	is	VBZ	O	O
insufficient	STENDRA.xml:S2:6168:12	insuffici	JJ	O	O
to	STENDRA.xml:S2:6181:2	to	TO	O	O
support	STENDRA.xml:S2:6184:7	support	VB	O	O
screening	STENDRA.xml:S2:6192:9	screen	NN	O	O
of	STENDRA.xml:S2:6202:2	of	IN	O	O
prospective	STENDRA.xml:S2:6205:11	prospect	JJ	O	O
users	STENDRA.xml:S2:6217:5	user	NNS	O	O
of	STENDRA.xml:S2:6223:2	of	IN	O	O
PDE5	STENDRA.xml:S2:6226:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:6231:10	inhibitor	NNS	O	O
,	STENDRA.xml:S2:6241:1	,	,	O	O
including	STENDRA.xml:S2:6243:9	includ	VBG	O	O
STENDRA	STENDRA.xml:S2:6253:7	stendra	NNP	O	O
,	STENDRA.xml:S2:6260:1	,	,	O	O
for	STENDRA.xml:S2:6262:3	for	IN	O	O
this	STENDRA.xml:S2:6266:4	thi	DT	O	O
uncommon	STENDRA.xml:S2:6271:8	uncommon	JJ	O	O
condition	STENDRA.xml:S2:6280:9	condit	NN	O	O
.	STENDRA.xml:S2:6289:1	.	.	O	O

5.5	STENDRA.xml:S2:6297:3	5.5	CD	O	O
Sudden	STENDRA.xml:S2:6301:6	sudden	JJ	O	O
Hearing	STENDRA.xml:S2:6308:7	hear	NNP	O	O
Loss	STENDRA.xml:S2:6316:4	loss	NNP	O	O

Use	STENDRA.xml:S2:6324:3	use	NNP	O	O
of	STENDRA.xml:S2:6328:2	of	IN	O	O
PDE5	STENDRA.xml:S2:6331:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:6336:10	inhibitor	NNS	O	O
has	STENDRA.xml:S2:6347:3	ha	VBZ	O	O
been	STENDRA.xml:S2:6351:4	been	VBN	O	O
associated	STENDRA.xml:S2:6356:10	associ	VBN	O	O
with	STENDRA.xml:S2:6367:4	with	IN	O	O
sudden	STENDRA.xml:S2:6372:6	sudden	JJ	B-AdverseReaction	B-AdverseReaction
decrease	STENDRA.xml:S2:6379:8	decreas	NN	I-AdverseReaction	I-AdverseReaction
or	STENDRA.xml:S2:6388:2	or	CC	O	O
loss	STENDRA.xml:S2:6391:4	loss	NN	B-AdverseReaction	O
of	STENDRA.xml:S2:6396:2	of	IN	I-AdverseReaction	O
hearing	STENDRA.xml:S2:6399:7	hear	NN	I-AdverseReaction	O
,	STENDRA.xml:S2:6406:1	,	,	O	O
which	STENDRA.xml:S2:6408:5	which	WDT	O	O
may	STENDRA.xml:S2:6414:3	may	MD	O	O
be	STENDRA.xml:S2:6418:2	be	VB	O	O
accompanied	STENDRA.xml:S2:6421:11	accompani	VBN	O	O
by	STENDRA.xml:S2:6433:2	by	IN	O	O
tinnitus	STENDRA.xml:S2:6436:8	tinnitu	NN	B-AdverseReaction	O
or	STENDRA.xml:S2:6445:2	or	CC	O	O
dizziness	STENDRA.xml:S2:6448:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
.	STENDRA.xml:S2:6457:1	.	.	O	O

It	STENDRA.xml:S2:6459:2	It	PRP	O	O
is	STENDRA.xml:S2:6462:2	is	VBZ	O	O
not	STENDRA.xml:S2:6465:3	not	RB	O	O
possible	STENDRA.xml:S2:6469:8	possibl	JJ	O	O
to	STENDRA.xml:S2:6478:2	to	TO	O	O
determine	STENDRA.xml:S2:6481:9	determin	VB	O	O
whether	STENDRA.xml:S2:6491:7	whether	IN	O	O
these	STENDRA.xml:S2:6499:5	these	DT	O	O
events	STENDRA.xml:S2:6505:6	event	NNS	O	O
are	STENDRA.xml:S2:6512:3	are	VBP	O	O
related	STENDRA.xml:S2:6516:7	relat	VBN	O	O
directly	STENDRA.xml:S2:6524:8	directli	RB	O	O
to	STENDRA.xml:S2:6533:2	to	TO	O	O
the	STENDRA.xml:S2:6536:3	the	DT	O	O
use	STENDRA.xml:S2:6540:3	use	NN	O	O
of	STENDRA.xml:S2:6544:2	of	IN	O	O
PDE5	STENDRA.xml:S2:6547:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:6552:10	inhibitor	NNS	O	O
or	STENDRA.xml:S2:6563:2	or	CC	O	O
to	STENDRA.xml:S2:6566:2	to	TO	O	O
other	STENDRA.xml:S2:6569:5	other	JJ	O	O
factors	STENDRA.xml:S2:6575:7	factor	NNS	O	O
[	STENDRA.xml:S2:6584:1	[	VBP	O	O
seeAdverse	STENDRA.xml:S2:6585:10	seeadvers	JJ	O	O
Reactions	STENDRA.xml:S2:6596:9	reaction	NNP	O	O
(	STENDRA.xml:S2:6606:1	(	(	O	O
6	STENDRA.xml:S2:6607:1	6	CD	O	O
)]	STENDRA.xml:S2:6608:2	)]	NN	O	O
.	STENDRA.xml:S2:6612:1	.	.	O	O

Patients	STENDRA.xml:S2:6614:8	patient	NNS	O	O
experiencing	STENDRA.xml:S2:6623:12	experienc	VBG	O	O
these	STENDRA.xml:S2:6636:5	these	DT	O	O
symptoms	STENDRA.xml:S2:6642:8	symptom	NNS	O	O
should	STENDRA.xml:S2:6651:6	should	MD	O	O
be	STENDRA.xml:S2:6658:2	be	VB	O	O
advised	STENDRA.xml:S2:6661:7	advis	VBN	O	O
to	STENDRA.xml:S2:6669:2	to	TO	O	O
stop	STENDRA.xml:S2:6672:4	stop	VB	O	O
taking	STENDRA.xml:S2:6677:6	take	VBG	O	O
STENDRA	STENDRA.xml:S2:6684:7	stendra	NNP	O	O
and	STENDRA.xml:S2:6692:3	and	CC	O	O
seek	STENDRA.xml:S2:6696:4	seek	JJ	O	O
prompt	STENDRA.xml:S2:6701:6	prompt	NN	O	O
medical	STENDRA.xml:S2:6708:7	medic	JJ	O	O
attention	STENDRA.xml:S2:6716:9	attent	NN	O	O
.	STENDRA.xml:S2:6725:1	.	.	O	O

5.6	STENDRA.xml:S2:6733:3	5.6	CD	O	O
Alpha	STENDRA.xml:S2:6737:5	alpha	NNP	O	O
-	STENDRA.xml:S2:6742:1	-	:	O	O
Blockers	STENDRA.xml:S2:6743:8	blocker	NNS	O	O
and	STENDRA.xml:S2:6752:3	and	CC	O	O
Other	STENDRA.xml:S2:6756:5	other	JJ	O	O
Antihypertensives	STENDRA.xml:S2:6762:17	antihypertens	NNS	O	O

Physicians	STENDRA.xml:S2:6783:10	physician	NNS	O	O
should	STENDRA.xml:S2:6794:6	should	MD	O	O
discuss	STENDRA.xml:S2:6801:7	discuss	VB	O	O
with	STENDRA.xml:S2:6809:4	with	IN	O	O
patients	STENDRA.xml:S2:6814:8	patient	NNS	O	O
the	STENDRA.xml:S2:6823:3	the	DT	O	O
potential	STENDRA.xml:S2:6827:9	potenti	JJ	O	O
for	STENDRA.xml:S2:6837:3	for	IN	O	O
STENDRA	STENDRA.xml:S2:6841:7	stendra	NNP	O	O
to	STENDRA.xml:S2:6849:2	to	TO	O	O
augment	STENDRA.xml:S2:6852:7	augment	VB	O	O
the	STENDRA.xml:S2:6860:3	the	DT	O	O
blood	STENDRA.xml:S2:6864:5	blood	NN	O	O
pressure	STENDRA.xml:S2:6870:8	pressur	NN	O	O
-	STENDRA.xml:S2:6878:1	-	:	O	O
lowering	STENDRA.xml:S2:6879:8	lower	VBG	O	O
effect	STENDRA.xml:S2:6888:6	effect	NN	O	O
of	STENDRA.xml:S2:6895:2	of	IN	O	O
alpha	STENDRA.xml:S2:6898:5	alpha	NN	O	O
-	STENDRA.xml:S2:6903:1	-	:	O	O
blockers	STENDRA.xml:S2:6904:8	blocker	NNS	O	O
and	STENDRA.xml:S2:6913:3	and	CC	O	O
other	STENDRA.xml:S2:6917:5	other	JJ	O	O
antihypertensive	STENDRA.xml:S2:6923:16	antihypertens	JJ	O	O
medications	STENDRA.xml:S2:6940:11	medic	NNS	O	O
[	STENDRA.xml:S2:6953:1	[	VBP	O	O
seeDrug	STENDRA.xml:S2:6954:7	seedrug	JJ	O	O
Interactions	STENDRA.xml:S2:6962:12	interact	NNP	O	O
(	STENDRA.xml:S2:6975:1	(	(	O	O
7.1	STENDRA.xml:S2:6976:3	7.1	CD	O	O
)	STENDRA.xml:S2:6979:1	)	)	O	O
andClinical	STENDRA.xml:S2:6980:11	andclin	JJ	O	O
Pharmacology	STENDRA.xml:S2:6992:12	pharmacolog	NNP	O	O
(	STENDRA.xml:S2:7005:1	(	(	O	O
12.2	STENDRA.xml:S2:7006:4	12.2	CD	O	O
)]	STENDRA.xml:S2:7010:2	)]	NN	O	O
.	STENDRA.xml:S2:7012:1	.	.	O	O

Caution	STENDRA.xml:S2:7020:7	caution	NN	O	O
is	STENDRA.xml:S2:7028:2	is	VBZ	O	O
advised	STENDRA.xml:S2:7031:7	advis	VBN	O	O
when	STENDRA.xml:S2:7039:4	when	WRB	O	O
PDE5	STENDRA.xml:S2:7044:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:7049:10	inhibitor	NNS	O	O
are	STENDRA.xml:S2:7060:3	are	VBP	O	O
co	STENDRA.xml:S2:7064:2	co	JJ	O	O
-	STENDRA.xml:S2:7066:1	-	:	O	O
administered	STENDRA.xml:S2:7067:12	administ	VBN	O	O
with	STENDRA.xml:S2:7080:4	with	IN	O	O
alpha	STENDRA.xml:S2:7085:5	alpha	JJ	O	O
-	STENDRA.xml:S2:7090:1	-	:	O	O
blockers	STENDRA.xml:S2:7091:8	blocker	NNS	O	O
.	STENDRA.xml:S2:7099:1	.	.	O	O

Phosphodiesterase	STENDRA.xml:S2:7101:17	phosphodiesteras	NNP	O	O
type	STENDRA.xml:S2:7119:4	type	VBD	O	O
5	STENDRA.xml:S2:7124:1	5	CD	O	O
inhibitors	STENDRA.xml:S2:7126:10	inhibitor	NNS	O	O
,	STENDRA.xml:S2:7136:1	,	,	O	O
including	STENDRA.xml:S2:7138:9	includ	VBG	O	O
STENDRA	STENDRA.xml:S2:7148:7	stendra	NNP	O	O
,	STENDRA.xml:S2:7155:1	,	,	O	O
and	STENDRA.xml:S2:7157:3	and	CC	O	O
alpha	STENDRA.xml:S2:7161:5	alpha	SYM	O	O
-	STENDRA.xml:S2:7166:1	-	:	O	O
adrenergic	STENDRA.xml:S2:7167:10	adrenerg	JJ	O	O
blocking	STENDRA.xml:S2:7178:8	block	NN	O	O
agents	STENDRA.xml:S2:7187:6	agent	NNS	O	O
are	STENDRA.xml:S2:7194:3	are	VBP	O	O
both	STENDRA.xml:S2:7198:4	both	DT	O	O
vasodilators	STENDRA.xml:S2:7203:12	vasodil	NNS	O	O
with	STENDRA.xml:S2:7216:4	with	IN	O	O
blood	STENDRA.xml:S2:7221:5	blood	NN	O	O
pressure	STENDRA.xml:S2:7227:8	pressur	NN	O	O
-	STENDRA.xml:S2:7235:1	-	:	O	O
lowering	STENDRA.xml:S2:7236:8	lower	NN	O	O
effects	STENDRA.xml:S2:7245:7	effect	NNS	O	O
.	STENDRA.xml:S2:7252:1	.	.	O	O

When	STENDRA.xml:S2:7254:4	when	WRB	O	O
vasodilators	STENDRA.xml:S2:7259:12	vasodil	NNS	O	O
are	STENDRA.xml:S2:7272:3	are	VBP	O	O
used	STENDRA.xml:S2:7276:4	use	VBN	O	O
in	STENDRA.xml:S2:7281:2	in	IN	O	O
combination	STENDRA.xml:S2:7284:11	combin	NN	O	O
,	STENDRA.xml:S2:7295:1	,	,	O	O
an	STENDRA.xml:S2:7297:2	an	DT	O	O
additive	STENDRA.xml:S2:7300:8	addit	JJ	O	O
effect	STENDRA.xml:S2:7309:6	effect	NN	O	O
on	STENDRA.xml:S2:7316:2	on	IN	O	O
blood	STENDRA.xml:S2:7319:5	blood	NN	O	O
pressure	STENDRA.xml:S2:7325:8	pressur	NN	O	O
may	STENDRA.xml:S2:7334:3	may	MD	O	O
be	STENDRA.xml:S2:7338:2	be	VB	O	O
anticipated	STENDRA.xml:S2:7341:11	anticip	VBN	O	O
.	STENDRA.xml:S2:7352:1	.	.	O	O

In	STENDRA.xml:S2:7354:2	In	IN	O	O
some	STENDRA.xml:S2:7357:4	some	DT	O	O
patients	STENDRA.xml:S2:7362:8	patient	NNS	O	O
,	STENDRA.xml:S2:7370:1	,	,	O	O
concomitant	STENDRA.xml:S2:7372:11	concomit	JJ	O	O
use	STENDRA.xml:S2:7384:3	use	NN	O	O
of	STENDRA.xml:S2:7388:2	of	IN	O	O
these	STENDRA.xml:S2:7391:5	these	DT	O	O
two	STENDRA.xml:S2:7397:3	two	CD	O	O
drug	STENDRA.xml:S2:7401:4	drug	NN	O	O
classes	STENDRA.xml:S2:7406:7	class	NNS	O	O
can	STENDRA.xml:S2:7414:3	can	MD	O	O
lower	STENDRA.xml:S2:7418:5	lower	VB	O	O
blood	STENDRA.xml:S2:7424:5	blood	NN	O	O
pressure	STENDRA.xml:S2:7430:8	pressur	NN	O	O
significantly	STENDRA.xml:S2:7439:13	significantli	RB	O	O
leading	STENDRA.xml:S2:7453:7	lead	VBG	O	O
to	STENDRA.xml:S2:7461:2	to	TO	O	O
symptomatic	STENDRA.xml:S2:7464:11	symptomat	JJ	B-AdverseReaction	B-AdverseReaction
hypotension	STENDRA.xml:S2:7476:11	hypotens	NN	I-AdverseReaction	I-AdverseReaction
(	STENDRA.xml:S2:7488:1	(	(	O	O
e	STENDRA.xml:S2:7489:1	e	NN	O	O
.	STENDRA.xml:S2:7490:1	.	.	O	O
g	STENDRA.xml:S2:7491:1	g	NN	O	O
.	STENDRA.xml:S2:7492:1	.	.	O	O
,	STENDRA.xml:S2:7493:1	,	,	O	O
dizziness	STENDRA.xml:S2:7495:9	dizzi	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S2:7504:1	,	,	O	O
lightheadedness	STENDRA.xml:S2:7506:15	lightheaded	NN	B-AdverseReaction	B-AdverseReaction
,	STENDRA.xml:S2:7521:1	,	,	O	O
fainting	STENDRA.xml:S2:7523:8	faint	VBG	B-AdverseReaction	O
)	STENDRA.xml:S2:7531:1	)	)	O	O
.	STENDRA.xml:S2:7532:1	.	.	O	O

Consideration	STENDRA.xml:S2:7538:13	consider	NN	O	O
should	STENDRA.xml:S2:7552:6	should	MD	O	O
be	STENDRA.xml:S2:7559:2	be	VB	O	O
given	STENDRA.xml:S2:7562:5	given	VBN	O	O
to	STENDRA.xml:S2:7568:2	to	TO	O	O
the	STENDRA.xml:S2:7571:3	the	DT	O	O
following	STENDRA.xml:S2:7575:9	follow	NN	O	O
:	STENDRA.xml:S2:7584:1	:	:	O	O

Patients	STENDRA.xml:S2:7593:8	patient	NNS	O	O
should	STENDRA.xml:S2:7602:6	should	MD	O	O
be	STENDRA.xml:S2:7609:2	be	VB	O	O
stable	STENDRA.xml:S2:7612:6	stabl	JJ	O	O
on	STENDRA.xml:S2:7619:2	on	IN	O	O
alpha	STENDRA.xml:S2:7622:5	alpha	JJ	O	O
-	STENDRA.xml:S2:7627:1	-	:	O	O
blocker	STENDRA.xml:S2:7628:7	blocker	NN	O	O
therapy	STENDRA.xml:S2:7636:7	therapi	NN	O	O
prior	STENDRA.xml:S2:7644:5	prior	RB	O	O
to	STENDRA.xml:S2:7650:2	to	TO	O	O
initiating	STENDRA.xml:S2:7653:10	initi	VBG	O	O
treatment	STENDRA.xml:S2:7664:9	treatment	NN	O	O
with	STENDRA.xml:S2:7674:4	with	IN	O	O
a	STENDRA.xml:S2:7679:1	a	DT	O	O
PDE5	STENDRA.xml:S2:7681:4	pde5	NNP	O	O
inhibitor	STENDRA.xml:S2:7686:9	inhibitor	NN	O	O
.	STENDRA.xml:S2:7695:1	.	.	O	O

Patients	STENDRA.xml:S2:7697:8	patient	NNS	O	O
who	STENDRA.xml:S2:7706:3	who	WP	O	O
demonstrate	STENDRA.xml:S2:7710:11	demonstr	VBP	O	O
hemodynamic	STENDRA.xml:S2:7722:11	hemodynam	JJ	O	O
instability	STENDRA.xml:S2:7734:11	instabl	NN	O	O
on	STENDRA.xml:S2:7746:2	on	IN	O	O
alpha	STENDRA.xml:S2:7749:5	alpha	JJ	O	O
-	STENDRA.xml:S2:7754:1	-	:	O	O
blocker	STENDRA.xml:S2:7755:7	blocker	NN	O	O
therapy	STENDRA.xml:S2:7763:7	therapi	NN	O	O
alone	STENDRA.xml:S2:7771:5	alon	RB	O	O
are	STENDRA.xml:S2:7777:3	are	VBP	O	O
at	STENDRA.xml:S2:7781:2	at	IN	O	O
increased	STENDRA.xml:S2:7784:9	increas	JJ	O	O
risk	STENDRA.xml:S2:7794:4	risk	NN	O	O
of	STENDRA.xml:S2:7799:2	of	IN	O	O
symptomatic	STENDRA.xml:S2:7802:11	symptomat	JJ	B-AdverseReaction	B-AdverseReaction
hypotension	STENDRA.xml:S2:7814:11	hypotens	NN	I-AdverseReaction	I-AdverseReaction
with	STENDRA.xml:S2:7826:4	with	IN	O	O
concomitant	STENDRA.xml:S2:7831:11	concomit	JJ	O	O
use	STENDRA.xml:S2:7843:3	use	NN	O	O
of	STENDRA.xml:S2:7847:2	of	IN	O	O
PDE5	STENDRA.xml:S2:7850:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:7855:10	inhibitor	NNS	O	O
.	STENDRA.xml:S2:7865:1	.	.	O	O

In	STENDRA.xml:S2:7872:2	In	IN	O	O
those	STENDRA.xml:S2:7875:5	those	DT	O	O
patients	STENDRA.xml:S2:7881:8	patient	NNS	O	O
who	STENDRA.xml:S2:7890:3	who	WP	O	O
are	STENDRA.xml:S2:7894:3	are	VBP	O	O
stable	STENDRA.xml:S2:7898:6	stabl	JJ	O	O
on	STENDRA.xml:S2:7905:2	on	IN	O	O
alpha	STENDRA.xml:S2:7908:5	alpha	JJ	O	O
-	STENDRA.xml:S2:7913:1	-	:	O	O
blocker	STENDRA.xml:S2:7914:7	blocker	NN	O	O
therapy	STENDRA.xml:S2:7922:7	therapi	NN	O	O
,	STENDRA.xml:S2:7929:1	,	,	O	O
PDE5	STENDRA.xml:S2:7931:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:7936:10	inhibitor	NNS	O	O
should	STENDRA.xml:S2:7947:6	should	MD	O	O
be	STENDRA.xml:S2:7954:2	be	VB	O	O
initiated	STENDRA.xml:S2:7957:9	initi	VBN	O	O
at	STENDRA.xml:S2:7967:2	at	IN	O	O
the	STENDRA.xml:S2:7970:3	the	DT	O	O
lowest	STENDRA.xml:S2:7974:6	lowest	JJS	O	O
dose	STENDRA.xml:S2:7981:4	dose	NN	O	O
(	STENDRA.xml:S2:7986:1	(	(	O	O
STENDRA	STENDRA.xml:S2:7987:7	stendra	NNP	O	O
50	STENDRA.xml:S2:7995:2	50	CD	O	O
mg	STENDRA.xml:S2:7998:2	mg	NN	O	O
)	STENDRA.xml:S2:8000:1	)	)	O	O
.	STENDRA.xml:S2:8001:1	.	.	O	O

In	STENDRA.xml:S2:8008:2	In	IN	O	O
those	STENDRA.xml:S2:8011:5	those	DT	O	O
patients	STENDRA.xml:S2:8017:8	patient	NNS	O	O
already	STENDRA.xml:S2:8026:7	alreadi	RB	O	O
taking	STENDRA.xml:S2:8034:6	take	VBG	O	O
an	STENDRA.xml:S2:8041:2	an	DT	O	O
optimized	STENDRA.xml:S2:8044:9	optim	VBN	O	O
dose	STENDRA.xml:S2:8054:4	dose	NN	O	O
of	STENDRA.xml:S2:8059:2	of	IN	O	O
a	STENDRA.xml:S2:8062:1	a	DT	O	O
PDE5	STENDRA.xml:S2:8064:4	pde5	NNP	O	O
inhibitor	STENDRA.xml:S2:8069:9	inhibitor	NN	O	O
,	STENDRA.xml:S2:8078:1	,	,	O	O
alpha	STENDRA.xml:S2:8080:5	alpha	SYM	O	O
-	STENDRA.xml:S2:8085:1	-	:	O	O
blocker	STENDRA.xml:S2:8086:7	blocker	NN	O	O
therapy	STENDRA.xml:S2:8094:7	therapi	NN	O	O
should	STENDRA.xml:S2:8102:6	should	MD	O	O
be	STENDRA.xml:S2:8109:2	be	VB	O	O
initiated	STENDRA.xml:S2:8112:9	initi	VBN	O	O
at	STENDRA.xml:S2:8122:2	at	IN	O	O
the	STENDRA.xml:S2:8125:3	the	DT	O	O
lowest	STENDRA.xml:S2:8129:6	lowest	JJS	O	O
dose	STENDRA.xml:S2:8136:4	dose	NN	O	O
.	STENDRA.xml:S2:8140:1	.	.	O	O

Stepwise	STENDRA.xml:S2:8142:8	stepwis	NNP	O	B-AdverseReaction
increase	STENDRA.xml:S2:8151:8	increas	NN	O	I-AdverseReaction
in	STENDRA.xml:S2:8160:2	in	IN	O	O
alpha	STENDRA.xml:S2:8163:5	alpha	JJ	O	O
-	STENDRA.xml:S2:8168:1	-	:	O	O
blocker	STENDRA.xml:S2:8169:7	blocker	NN	O	O
dose	STENDRA.xml:S2:8177:4	dose	NN	O	O
may	STENDRA.xml:S2:8182:3	may	MD	O	O
be	STENDRA.xml:S2:8186:2	be	VB	O	O
associated	STENDRA.xml:S2:8189:10	associ	VBN	O	O
with	STENDRA.xml:S2:8200:4	with	IN	O	O
further	STENDRA.xml:S2:8205:7	further	JJ	O	O
lowering	STENDRA.xml:S2:8213:8	lower	NN	O	O
of	STENDRA.xml:S2:8222:2	of	IN	O	O
blood	STENDRA.xml:S2:8225:5	blood	NN	O	O
pressure	STENDRA.xml:S2:8231:8	pressur	NN	O	O
when	STENDRA.xml:S2:8240:4	when	WRB	O	O
taking	STENDRA.xml:S2:8245:6	take	VBG	O	O
a	STENDRA.xml:S2:8252:1	a	DT	O	O
PDE5	STENDRA.xml:S2:8254:4	pde5	NNP	O	O
inhibitor	STENDRA.xml:S2:8259:9	inhibitor	NN	O	O
.	STENDRA.xml:S2:8268:1	.	.	O	O

Safety	STENDRA.xml:S2:8275:6	safeti	NN	O	O
of	STENDRA.xml:S2:8282:2	of	IN	O	O
combined	STENDRA.xml:S2:8285:8	combin	JJ	O	O
use	STENDRA.xml:S2:8294:3	use	NN	O	O
of	STENDRA.xml:S2:8298:2	of	IN	O	O
PDE5	STENDRA.xml:S2:8301:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:8306:10	inhibitor	NNS	O	O
and	STENDRA.xml:S2:8317:3	and	CC	O	O
alpha	STENDRA.xml:S2:8321:5	alpha	SYM	O	O
-	STENDRA.xml:S2:8326:1	-	:	O	O
blockers	STENDRA.xml:S2:8327:8	blocker	NNS	O	O
may	STENDRA.xml:S2:8336:3	may	MD	O	O
be	STENDRA.xml:S2:8340:2	be	VB	O	O
affected	STENDRA.xml:S2:8343:8	affect	VBN	O	O
by	STENDRA.xml:S2:8352:2	by	IN	O	O
other	STENDRA.xml:S2:8355:5	other	JJ	O	O
variables	STENDRA.xml:S2:8361:9	variabl	NNS	O	O
,	STENDRA.xml:S2:8370:1	,	,	O	O
including	STENDRA.xml:S2:8372:9	includ	VBG	O	O
intravascular	STENDRA.xml:S2:8382:13	intravascular	JJ	O	B-AdverseReaction
volume	STENDRA.xml:S2:8396:6	volum	NN	O	I-AdverseReaction
depletion	STENDRA.xml:S2:8403:9	deplet	NN	O	I-AdverseReaction
and	STENDRA.xml:S2:8413:3	and	CC	O	O
other	STENDRA.xml:S2:8417:5	other	JJ	O	O
anti	STENDRA.xml:S2:8423:4	anti	JJ	O	O
-	STENDRA.xml:S2:8427:1	-	:	O	O
hypertensive	STENDRA.xml:S2:8428:12	hypertens	JJ	O	O
drugs	STENDRA.xml:S2:8441:5	drug	NNS	O	O
[	STENDRA.xml:S2:8447:1	[	VBP	O	O
see	STENDRA.xml:S2:8448:3	see	VBP	O	O
Dosage	STENDRA.xml:S2:8453:6	dosag	NNP	O	O
and	STENDRA.xml:S2:8460:3	and	CC	O	O
Administration	STENDRA.xml:S2:8464:14	administr	NNP	O	O
(	STENDRA.xml:S2:8479:1	(	(	O	O
2	STENDRA.xml:S2:8480:1	2	CD	O	O
)	STENDRA.xml:S2:8481:1	)	)	O	O
and	STENDRA.xml:S2:8484:3	and	CC	O	O
Drug	STENDRA.xml:S2:8489:4	drug	NNP	O	O
Interactions	STENDRA.xml:S2:8494:12	interact	NNP	O	O
(	STENDRA.xml:S2:8507:1	(	(	O	O
7.1	STENDRA.xml:S2:8508:3	7.1	CD	O	O
)	STENDRA.xml:S2:8511:1	)	)	O	O
]	STENDRA.xml:S2:8514:1	]	NN	O	O
.	STENDRA.xml:S2:8515:1	.	.	O	O

5.7	STENDRA.xml:S2:8523:3	5.7	CD	O	O

Alcohol	STENDRA.xml:S2:8527:7	alcohol	NN	O	O

Patients	STENDRA.xml:S2:8538:8	patient	NNS	O	O
should	STENDRA.xml:S2:8547:6	should	MD	O	O
be	STENDRA.xml:S2:8554:2	be	VB	O	O
made	STENDRA.xml:S2:8557:4	made	VBN	O	O
aware	STENDRA.xml:S2:8562:5	awar	JJ	O	O
that	STENDRA.xml:S2:8568:4	that	IN	O	O
both	STENDRA.xml:S2:8573:4	both	DT	O	O
alcohol	STENDRA.xml:S2:8578:7	alcohol	NN	O	O
and	STENDRA.xml:S2:8586:3	and	CC	O	O
PDE5	STENDRA.xml:S2:8590:4	pde5	NNP	O	O
inhibitors	STENDRA.xml:S2:8595:10	inhibitor	NNS	O	O
including	STENDRA.xml:S2:8606:9	includ	VBG	O	O
STENDRA	STENDRA.xml:S2:8616:7	stendra	NNP	O	O
act	STENDRA.xml:S2:8624:3	act	NN	O	O
as	STENDRA.xml:S2:8628:2	as	IN	O	O
vasodilators	STENDRA.xml:S2:8631:12	vasodil	NNS	O	O
.	STENDRA.xml:S2:8643:1	.	.	O	O

When	STENDRA.xml:S2:8645:4	when	WRB	O	O
vasodilators	STENDRA.xml:S2:8650:12	vasodil	NNS	O	O
are	STENDRA.xml:S2:8663:3	are	VBP	O	O
taken	STENDRA.xml:S2:8667:5	taken	VBN	O	O
in	STENDRA.xml:S2:8673:2	in	IN	O	O
combination	STENDRA.xml:S2:8676:11	combin	NN	O	O
,	STENDRA.xml:S2:8687:1	,	,	O	O
blood	STENDRA.xml:S2:8689:5	blood	NN	O	O
-	STENDRA.xml:S2:8694:1	-	:	O	O
pressure	STENDRA.xml:S2:8695:8	pressur	NN	O	O
-	STENDRA.xml:S2:8703:1	-	:	O	O
lowering	STENDRA.xml:S2:8704:8	lower	VBG	O	O
effects	STENDRA.xml:S2:8713:7	effect	NNS	O	O
of	STENDRA.xml:S2:8721:2	of	IN	O	O
each	STENDRA.xml:S2:8724:4	each	DT	O	O
individual	STENDRA.xml:S2:8729:10	individu	JJ	O	O
compound	STENDRA.xml:S2:8740:8	compound	NN	O	O
may	STENDRA.xml:S2:8749:3	may	MD	O	O
be	STENDRA.xml:S2:8753:2	be	VB	O	O
increased	STENDRA.xml:S2:8756:9	increas	VBN	O	O
.	STENDRA.xml:S2:8765:1	.	.	O	O

Therefore	STENDRA.xml:S2:8767:9	therefor	RB	O	O
,	STENDRA.xml:S2:8776:1	,	,	O	O
physicians	STENDRA.xml:S2:8778:10	physician	NNS	O	O
should	STENDRA.xml:S2:8789:6	should	MD	O	O
inform	STENDRA.xml:S2:8796:6	inform	VB	O	O
patients	STENDRA.xml:S2:8803:8	patient	NNS	O	O
that	STENDRA.xml:S2:8812:4	that	IN	O	O
substantial	STENDRA.xml:S2:8817:11	substanti	JJ	O	O
consumption	STENDRA.xml:S2:8829:11	consumpt	NN	O	O
of	STENDRA.xml:S2:8841:2	of	IN	O	O
alcohol	STENDRA.xml:S2:8844:7	alcohol	NN	O	O
(	STENDRA.xml:S2:8852:1	(	(	O	O
e	STENDRA.xml:S2:8853:1	e	NN	O	O
.	STENDRA.xml:S2:8854:1	.	.	O	O
g	STENDRA.xml:S2:8855:1	g	NN	O	O
.	STENDRA.xml:S2:8856:1	.	.	O	O
,	STENDRA.xml:S2:8857:1	,	,	O	O
greater	STENDRA.xml:S2:8859:7	greater	JJR	O	O
than	STENDRA.xml:S2:8867:4	than	IN	O	O
3	STENDRA.xml:S2:8872:1	3	CD	O	O
units	STENDRA.xml:S2:8874:5	unit	NNS	O	O
)	STENDRA.xml:S2:8879:1	)	)	O	O
in	STENDRA.xml:S2:8881:2	in	IN	O	O
combination	STENDRA.xml:S2:8884:11	combin	NN	O	O
with	STENDRA.xml:S2:8896:4	with	IN	O	O
STENDRA	STENDRA.xml:S2:8901:7	stendra	NNP	O	O
may	STENDRA.xml:S2:8909:3	may	MD	O	O
increase	STENDRA.xml:S2:8913:8	increas	VB	O	O
the	STENDRA.xml:S2:8922:3	the	DT	O	O
potential	STENDRA.xml:S2:8926:9	potenti	JJ	O	O
for	STENDRA.xml:S2:8936:3	for	IN	O	O
orthostatic	STENDRA.xml:S2:8940:11	orthostat	JJ	O	O
signs	STENDRA.xml:S2:8952:5	sign	NNS	O	O
and	STENDRA.xml:S2:8958:3	and	CC	O	O
symptoms	STENDRA.xml:S2:8962:8	symptom	NNS	O	O
,	STENDRA.xml:S2:8970:1	,	,	O	O
including	STENDRA.xml:S2:8972:9	includ	VBG	O	O
increase	STENDRA.xml:S2:8982:8	increas	NN	O	B-AdverseReaction
in	STENDRA.xml:S2:8991:2	in	IN	O	I-AdverseReaction
heart	STENDRA.xml:S2:8994:5	heart	NN	O	I-AdverseReaction
rate	STENDRA.xml:S2:9000:4	rate	NN	O	I-AdverseReaction
,	STENDRA.xml:S2:9004:1	,	,	O	O
decrease	STENDRA.xml:S2:9006:8	decreas	NN	O	B-AdverseReaction
in	STENDRA.xml:S2:9015:2	in	IN	O	I-AdverseReaction
standing	STENDRA.xml:S2:9018:8	stand	VBG	O	I-AdverseReaction
blood	STENDRA.xml:S2:9027:5	blood	NN	O	I-AdverseReaction
pressure	STENDRA.xml:S2:9033:8	pressur	NN	O	I-AdverseReaction
,	STENDRA.xml:S2:9041:1	,	,	O	O
dizziness	STENDRA.xml:S2:9043:9	dizzi	NN	O	B-AdverseReaction
,	STENDRA.xml:S2:9052:1	,	,	O	O
and	STENDRA.xml:S2:9054:3	and	CC	O	O
headache	STENDRA.xml:S2:9058:8	headach	NN	O	B-AdverseReaction
[	STENDRA.xml:S2:9068:1	[	NNP	O	O
seeDrug	STENDRA.xml:S2:9069:7	seedrug	NN	O	O
Interactions	STENDRA.xml:S2:9077:12	interact	NNP	O	O
(	STENDRA.xml:S2:9090:1	(	(	O	O
7.1	STENDRA.xml:S2:9091:3	7.1	CD	O	O
)	STENDRA.xml:S2:9094:1	)	)	O	O
andClinical	STENDRA.xml:S2:9095:11	andclin	JJ	O	O
Pharmacology	STENDRA.xml:S2:9107:12	pharmacolog	NNP	O	O
(	STENDRA.xml:S2:9120:1	(	(	O	O
12.2	STENDRA.xml:S2:9121:4	12.2	CD	O	O
)]	STENDRA.xml:S2:9125:2	)]	NN	O	O
.	STENDRA.xml:S2:9129:1	.	.	O	O

5.8	STENDRA.xml:S2:9137:3	5.8	CD	O	O
Combination	STENDRA.xml:S2:9141:11	combin	NN	O	O
with	STENDRA.xml:S2:9153:4	with	IN	O	O
Other	STENDRA.xml:S2:9158:5	other	JJ	O	O
PDE5	STENDRA.xml:S2:9164:4	pde5	NNP	O	O
Inhibitors	STENDRA.xml:S2:9169:10	inhibitor	NNPS	O	O
or	STENDRA.xml:S2:9180:2	or	CC	O	O
Erectile	STENDRA.xml:S2:9183:8	erectil	NNP	O	O
Dysfunction	STENDRA.xml:S2:9192:11	dysfunct	NNP	O	O
Therapies	STENDRA.xml:S2:9204:9	therapi	NNP	O	O

The	STENDRA.xml:S2:9217:3	the	DT	O	O
safety	STENDRA.xml:S2:9221:6	safeti	NN	O	O
and	STENDRA.xml:S2:9228:3	and	CC	O	O
efficacy	STENDRA.xml:S2:9232:8	efficaci	NN	O	O
of	STENDRA.xml:S2:9241:2	of	IN	O	O
combinations	STENDRA.xml:S2:9244:12	combin	NNS	O	O
of	STENDRA.xml:S2:9257:2	of	IN	O	O
STENDRA	STENDRA.xml:S2:9260:7	stendra	NNP	O	O
with	STENDRA.xml:S2:9268:4	with	IN	O	O
other	STENDRA.xml:S2:9273:5	other	JJ	O	O
treatments	STENDRA.xml:S2:9279:10	treatment	NNS	O	O
for	STENDRA.xml:S2:9290:3	for	IN	O	O
ED	STENDRA.xml:S2:9294:2	ED	NNP	O	O
has	STENDRA.xml:S2:9297:3	ha	VBZ	O	O
not	STENDRA.xml:S2:9301:3	not	RB	O	O
been	STENDRA.xml:S2:9305:4	been	VBN	O	O
studied	STENDRA.xml:S2:9310:7	studi	VBN	O	O
.	STENDRA.xml:S2:9317:1	.	.	O	O

Therefore	STENDRA.xml:S2:9319:9	therefor	RB	O	O
,	STENDRA.xml:S2:9328:1	,	,	O	O
the	STENDRA.xml:S2:9330:3	the	DT	O	O
use	STENDRA.xml:S2:9334:3	use	NN	O	O
of	STENDRA.xml:S2:9338:2	of	IN	O	O
such	STENDRA.xml:S2:9341:4	such	JJ	O	O
combinations	STENDRA.xml:S2:9346:12	combin	NNS	O	O
is	STENDRA.xml:S2:9359:2	is	VBZ	O	O
not	STENDRA.xml:S2:9362:3	not	RB	O	O
recommended	STENDRA.xml:S2:9366:11	recommend	VBN	O	O
.	STENDRA.xml:S2:9377:1	.	.	O	O

5.9	STENDRA.xml:S2:9385:3	5.9	CD	O	O
Effects	STENDRA.xml:S2:9389:7	effect	NNS	O	O
on	STENDRA.xml:S2:9397:2	on	IN	O	O
Bleeding	STENDRA.xml:S2:9400:8	bleed	VBG	O	O

The	STENDRA.xml:S2:9412:3	the	DT	O	O
safety	STENDRA.xml:S2:9416:6	safeti	NN	O	O
of	STENDRA.xml:S2:9423:2	of	IN	O	O
STENDRA	STENDRA.xml:S2:9426:7	stendra	NNP	O	O
is	STENDRA.xml:S2:9434:2	is	VBZ	O	O
unknown	STENDRA.xml:S2:9437:7	unknown	JJ	O	O
in	STENDRA.xml:S2:9445:2	in	IN	O	O
patients	STENDRA.xml:S2:9448:8	patient	NNS	O	O
with	STENDRA.xml:S2:9457:4	with	IN	O	O
bleeding	STENDRA.xml:S2:9462:8	bleed	VBG	O	O
disorders	STENDRA.xml:S2:9471:9	disord	NNS	O	O
and	STENDRA.xml:S2:9481:3	and	CC	O	O
patients	STENDRA.xml:S2:9485:8	patient	NNS	O	O
with	STENDRA.xml:S2:9494:4	with	IN	O	O
active	STENDRA.xml:S2:9499:6	activ	JJ	O	O
peptic	STENDRA.xml:S2:9506:6	peptic	JJ	O	O
ulceration	STENDRA.xml:S2:9513:10	ulcer	NN	O	O
.	STENDRA.xml:S2:9523:1	.	.	O	O

In	STENDRA.xml:S2:9526:2	In	IN	O	O
vitro	STENDRA.xml:S2:9529:5	vitro	JJ	O	O
studies	STENDRA.xml:S2:9536:7	studi	NNS	O	O
with	STENDRA.xml:S2:9544:4	with	IN	O	O
human	STENDRA.xml:S2:9549:5	human	JJ	O	O
platelets	STENDRA.xml:S2:9555:9	platelet	NNS	O	O
indicate	STENDRA.xml:S2:9565:8	indic	VBP	O	O
that	STENDRA.xml:S2:9574:4	that	IN	O	O
STENDRA	STENDRA.xml:S2:9579:7	stendra	NNP	O	O
potentiates	STENDRA.xml:S2:9587:11	potenti	VBZ	B-AdverseReaction	O
the	STENDRA.xml:S2:9599:3	the	DT	I-AdverseReaction	O
anti	STENDRA.xml:S2:9603:4	anti	JJ	I-AdverseReaction	O
-	STENDRA.xml:S2:9607:1	-	:	I-AdverseReaction	O
aggregatory	STENDRA.xml:S2:9608:11	aggregatori	JJ	I-AdverseReaction	O
effect	STENDRA.xml:S2:9620:6	effect	NN	I-AdverseReaction	O
of	STENDRA.xml:S2:9627:2	of	IN	I-AdverseReaction	O
sodium	STENDRA.xml:S2:9630:6	sodium	NN	I-AdverseReaction	O
nitroprusside	STENDRA.xml:S2:9637:13	nitroprussid	NN	I-AdverseReaction	O
(	STENDRA.xml:S2:9651:1	(	(	O	O
a	STENDRA.xml:S2:9652:1	a	DT	O	O
nitric	STENDRA.xml:S2:9654:6	nitric	JJ	O	O
oxide	STENDRA.xml:S2:9661:5	oxid	NN	O	O
[	STENDRA.xml:S2:9667:1	[	NNP	O	O
NO	STENDRA.xml:S2:9668:2	NO	NNP	O	O
]	STENDRA.xml:S2:9670:1	]	NNP	O	O
donor	STENDRA.xml:S2:9672:5	donor	NN	O	O
)	STENDRA.xml:S2:9677:1	)	)	O	O
.	STENDRA.xml:S2:9678:1	.	.	O	O

5.10	STENDRA.xml:S2:9686:4	5.10	CD	O	O
Counseling	STENDRA.xml:S2:9691:10	counsel	JJ	O	O
Patients	STENDRA.xml:S2:9702:8	patient	NNS	O	O
about	STENDRA.xml:S2:9711:5	about	IN	O	O
Sexually	STENDRA.xml:S2:9717:8	sexual	NNP	O	O
Transmitted	STENDRA.xml:S2:9726:11	transmit	NNP	O	O
Diseases	STENDRA.xml:S2:9738:8	diseas	NNP	O	O

The	STENDRA.xml:S2:9750:3	the	DT	O	O
use	STENDRA.xml:S2:9754:3	use	NN	O	O
of	STENDRA.xml:S2:9758:2	of	IN	O	O
STENDRA	STENDRA.xml:S2:9761:7	stendra	NNP	O	O
offers	STENDRA.xml:S2:9769:6	offer	VBZ	O	O
no	STENDRA.xml:S2:9776:2	no	DT	O	O
protection	STENDRA.xml:S2:9779:10	protect	NN	O	O
against	STENDRA.xml:S2:9790:7	against	IN	O	O
sexually	STENDRA.xml:S2:9798:8	sexual	RB	O	O
transmitted	STENDRA.xml:S2:9807:11	transmit	JJ	O	O
diseases	STENDRA.xml:S2:9819:8	diseas	NNS	O	O
.	STENDRA.xml:S2:9827:1	.	.	O	O

Counseling	STENDRA.xml:S2:9829:10	counsel	VBG	O	O
patients	STENDRA.xml:S2:9840:8	patient	NNS	O	O
about	STENDRA.xml:S2:9849:5	about	IN	O	O
the	STENDRA.xml:S2:9855:3	the	DT	O	O
protective	STENDRA.xml:S2:9859:10	protect	JJ	O	O
measures	STENDRA.xml:S2:9870:8	measur	NNS	O	O
necessary	STENDRA.xml:S2:9879:9	necessari	JJ	O	O
to	STENDRA.xml:S2:9889:2	to	TO	O	O
guard	STENDRA.xml:S2:9892:5	guard	VB	O	O
against	STENDRA.xml:S2:9898:7	against	IN	O	O
sexually	STENDRA.xml:S2:9906:8	sexual	RB	O	O
transmitted	STENDRA.xml:S2:9915:11	transmit	JJ	O	O
diseases	STENDRA.xml:S2:9927:8	diseas	NNS	O	O
,	STENDRA.xml:S2:9935:1	,	,	O	O
including	STENDRA.xml:S2:9937:9	includ	VBG	O	O
Human	STENDRA.xml:S2:9947:5	human	NNP	O	O
Immunodeficiency	STENDRA.xml:S2:9953:16	immunodefici	NNP	O	O
Virus	STENDRA.xml:S2:9970:5	viru	NNP	O	O
(	STENDRA.xml:S2:9976:1	(	(	O	O
HIV	STENDRA.xml:S2:9977:3	hiv	NNP	O	O
)	STENDRA.xml:S2:9980:1	)	)	O	O
,	STENDRA.xml:S2:9981:1	,	,	O	O
should	STENDRA.xml:S2:9983:6	should	MD	O	O
be	STENDRA.xml:S2:9990:2	be	VB	O	O
considered	STENDRA.xml:S2:9993:10	consid	VBN	O	O
.	STENDRA.xml:S2:10003:1	.	.	O	O
6	STRIBILD.xml:S1:4:1	6	CD	O	O
ADVERSE	STRIBILD.xml:S1:6:7	advers	JJ	O	O
REACTIONS	STRIBILD.xml:S1:14:9	reaction	NN	O	O

The	STRIBILD.xml:S1:27:3	the	DT	O	O
following	STRIBILD.xml:S1:31:9	follow	JJ	O	O
adverse	STRIBILD.xml:S1:41:7	advers	JJ	O	O
drug	STRIBILD.xml:S1:49:4	drug	NN	O	O
reactions	STRIBILD.xml:S1:54:9	reaction	NNS	O	O
are	STRIBILD.xml:S1:64:3	are	VBP	O	O
discussed	STRIBILD.xml:S1:68:9	discuss	VBN	O	O
in	STRIBILD.xml:S1:78:2	in	IN	O	O
other	STRIBILD.xml:S1:81:5	other	JJ	O	O
sections	STRIBILD.xml:S1:87:8	section	NNS	O	O
of	STRIBILD.xml:S1:96:2	of	IN	O	O
the	STRIBILD.xml:S1:99:3	the	DT	O	O
labeling	STRIBILD.xml:S1:103:8	label	NN	O	O
:	STRIBILD.xml:S1:111:1	:	:	O	O

Lactic	STRIBILD.xml:S1:120:6	lactic	JJ	B-AdverseReaction	O
Acidosis	STRIBILD.xml:S1:127:8	acidosi	NNP	I-AdverseReaction	O
Severe	STRIBILD.xml:S1:136:6	sever	NNP	O	O
Hepatomegaly	STRIBILD.xml:S1:143:12	hepatomegali	NNP	B-AdverseReaction	O
with	STRIBILD.xml:S1:156:4	with	IN	O	O
Steatosis	STRIBILD.xml:S1:161:9	steatosi	NNP	B-AdverseReaction	O
[	STRIBILD.xml:S1:171:1	[	NNP	O	O
see	STRIBILD.xml:S1:172:3	see	VBP	O	O
Boxed	STRIBILD.xml:S1:177:5	box	NNP	O	O
Warning	STRIBILD.xml:S1:183:7	warn	NNP	O	O
,	STRIBILD.xml:S1:192:1	,	,	O	O
Warnings	STRIBILD.xml:S1:195:8	warn	NNP	O	O
and	STRIBILD.xml:S1:204:3	and	CC	O	O
Precautions	STRIBILD.xml:S1:208:11	precaut	NNP	O	O
(	STRIBILD.xml:S1:220:1	(	(	O	O
5.1	STRIBILD.xml:S1:221:3	5.1	CD	O	O
)	STRIBILD.xml:S1:224:1	)	)	O	O
]	STRIBILD.xml:S1:227:1	]	NN	O	O
.	STRIBILD.xml:S1:229:1	.	.	O	O

Severe	STRIBILD.xml:S1:236:6	sever	NNP	O	O
Acute	STRIBILD.xml:S1:243:5	acut	NNP	B-AdverseReaction	O
Exacerbations	STRIBILD.xml:S1:249:13	exacerb	NNP	I-AdverseReaction	O
of	STRIBILD.xml:S1:263:2	of	IN	I-AdverseReaction	O
Hepatitis	STRIBILD.xml:S1:266:9	hepat	NNP	I-AdverseReaction	O
B	STRIBILD.xml:S1:276:1	B	NNP	I-AdverseReaction	O
[	STRIBILD.xml:S1:278:1	[	NNP	O	O
see	STRIBILD.xml:S1:279:3	see	VBP	O	O
Boxed	STRIBILD.xml:S1:284:5	box	NNP	O	O
Warning	STRIBILD.xml:S1:290:7	warn	NNP	O	O
,	STRIBILD.xml:S1:299:1	,	,	O	O
Warnings	STRIBILD.xml:S1:302:8	warn	NNP	O	O
and	STRIBILD.xml:S1:311:3	and	CC	O	O
Precautions	STRIBILD.xml:S1:315:11	precaut	NNP	O	O
(	STRIBILD.xml:S1:327:1	(	(	O	O
5.2	STRIBILD.xml:S1:328:3	5.2	CD	O	O
)	STRIBILD.xml:S1:331:1	)	)	O	O
]	STRIBILD.xml:S1:334:1	]	NN	O	O
.	STRIBILD.xml:S1:336:1	.	.	O	O

New	STRIBILD.xml:S1:343:3	new	NNP	B-AdverseReaction	B-AdverseReaction
Onset	STRIBILD.xml:S1:347:5	onset	NNP	I-AdverseReaction	I-AdverseReaction
or	STRIBILD.xml:S1:353:2	or	CC	O	O
Worsening	STRIBILD.xml:S1:356:9	worsen	NNP	B-AdverseReaction	O
Renal	STRIBILD.xml:S1:366:5	renal	NNP	I-AdverseReaction	O
Impairment	STRIBILD.xml:S1:372:10	impair	NNP	I-AdverseReaction	O
[	STRIBILD.xml:S1:383:1	[	NNP	O	O
see	STRIBILD.xml:S1:384:3	see	VBP	O	O
Warnings	STRIBILD.xml:S1:389:8	warn	NNP	O	O
and	STRIBILD.xml:S1:398:3	and	CC	O	O
Precautions	STRIBILD.xml:S1:402:11	precaut	NNP	O	O
(	STRIBILD.xml:S1:414:1	(	(	O	O
5.3	STRIBILD.xml:S1:415:3	5.3	CD	O	O
)	STRIBILD.xml:S1:418:1	)	)	O	O
]	STRIBILD.xml:S1:421:1	]	NN	O	O
.	STRIBILD.xml:S1:423:1	.	.	O	O

Bone	STRIBILD.xml:S1:430:4	bone	NNP	B-AdverseReaction	O
Effects	STRIBILD.xml:S1:435:7	effect	NNPS	I-AdverseReaction	O
of	STRIBILD.xml:S1:443:2	of	IN	O	O
Tenofovir	STRIBILD.xml:S1:446:9	tenofovir	NNP	O	O
DF	STRIBILD.xml:S1:456:2	DF	NNP	O	O
[	STRIBILD.xml:S1:459:1	[	NNP	O	O
see	STRIBILD.xml:S1:460:3	see	VBP	O	O
Warnings	STRIBILD.xml:S1:465:8	warn	NNP	O	O
and	STRIBILD.xml:S1:474:3	and	CC	O	O
Precautions	STRIBILD.xml:S1:478:11	precaut	NNP	O	O
(	STRIBILD.xml:S1:490:1	(	(	O	O
5.6	STRIBILD.xml:S1:491:3	5.6	CD	O	O
)	STRIBILD.xml:S1:494:1	)	)	O	O
]	STRIBILD.xml:S1:497:1	]	NN	O	O
.	STRIBILD.xml:S1:499:1	.	.	O	O

Immune	STRIBILD.xml:S1:506:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
Reconstitution	STRIBILD.xml:S1:513:14	reconstitut	NNP	I-AdverseReaction	I-AdverseReaction
Syndrome	STRIBILD.xml:S1:528:8	syndrom	NNP	I-AdverseReaction	I-AdverseReaction
[	STRIBILD.xml:S1:537:1	[	NNP	O	O
see	STRIBILD.xml:S1:538:3	see	VBP	O	O
Warnings	STRIBILD.xml:S1:543:8	warn	NNP	O	O
and	STRIBILD.xml:S1:552:3	and	CC	O	O
Precautions	STRIBILD.xml:S1:556:11	precaut	NNP	O	O
(	STRIBILD.xml:S1:568:1	(	(	O	O
5.8	STRIBILD.xml:S1:569:3	5.8	CD	O	O
)	STRIBILD.xml:S1:572:1	)	)	O	O
]	STRIBILD.xml:S1:575:1	]	NN	O	O
.	STRIBILD.xml:S1:577:1	.	.	O	O

EXCERPT	STRIBILD.xml:S1:586:7	excerpt	NNS	O	O
:	STRIBILD.xml:S1:593:1	:	:	O	O
Most	STRIBILD.xml:S1:597:4	most	JJS	O	O
common	STRIBILD.xml:S1:602:6	common	JJ	O	O
adverse	STRIBILD.xml:S1:609:7	advers	JJ	O	O
drug	STRIBILD.xml:S1:617:4	drug	NN	O	O
reactions	STRIBILD.xml:S1:622:9	reaction	NNS	O	O
to	STRIBILD.xml:S1:632:2	to	TO	O	O
STRIBILD	STRIBILD.xml:S1:635:8	stribild	NNP	O	O
(	STRIBILD.xml:S1:644:1	(	(	O	O
incidence	STRIBILD.xml:S1:645:9	incid	NN	O	O
greater	STRIBILD.xml:S1:655:7	greater	JJR	O	O
than	STRIBILD.xml:S1:663:4	than	IN	O	O
or	STRIBILD.xml:S1:668:2	or	CC	O	O
equal	STRIBILD.xml:S1:671:5	equal	JJ	O	O
to	STRIBILD.xml:S1:677:2	to	TO	O	O
10%	STRIBILD.xml:S1:680:3	10%	CD	O	O
,	STRIBILD.xml:S1:683:1	,	,	O	O
all	STRIBILD.xml:S1:685:3	all	DT	O	O
grades	STRIBILD.xml:S1:689:6	grade	NNS	O	O
)	STRIBILD.xml:S1:695:1	)	)	O	O
are	STRIBILD.xml:S1:697:3	are	VBP	O	O
nausea	STRIBILD.xml:S1:701:6	nausea	JJ	B-AdverseReaction	B-AdverseReaction
and	STRIBILD.xml:S1:708:3	and	CC	O	O
diarrhea	STRIBILD.xml:S1:712:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
.	STRIBILD.xml:S1:720:1	.	.	O	O

(	STRIBILD.xml:S1:722:1	(	(	O	O
6.1	STRIBILD.xml:S1:725:3	6.1	CD	O	O
)	STRIBILD.xml:S1:730:1	)	)	O	O

To	STRIBILD.xml:S1:738:2	To	TO	O	O

report	STRIBILD.xml:S1:741:6	report	NN	O	O
SUSPECTED	STRIBILD.xml:S1:748:9	suspect	NNP	O	O
ADVERSE	STRIBILD.xml:S1:758:7	advers	NNP	O	O
REACTIONS	STRIBILD.xml:S1:766:9	reaction	NNP	O	O
,	STRIBILD.xml:S1:775:1	,	,	O	O
contact	STRIBILD.xml:S1:777:7	contact	NN	O	O
Gilead	STRIBILD.xml:S1:785:6	gilead	NNP	O	O
Sciences	STRIBILD.xml:S1:792:8	scienc	NNPS	O	O
,	STRIBILD.xml:S1:800:1	,	,	O	O
Inc	STRIBILD.xml:S1:802:3	inc	NNP	O	O
.	STRIBILD.xml:S1:805:1	.	.	O	O

at	STRIBILD.xml:S1:807:2	at	IN	O	O
1	STRIBILD.xml:S1:810:1	1	CD	O	O
-	STRIBILD.xml:S1:811:1	-	:	O	O
800	STRIBILD.xml:S1:812:3	800	CD	O	O
-	STRIBILD.xml:S1:815:1	-	:	O	O
GILEAD	STRIBILD.xml:S1:816:6	gilead	NNP	O	O
-	STRIBILD.xml:S1:822:1	-	:	O	O
5	STRIBILD.xml:S1:823:1	5	CD	O	O
or	STRIBILD.xml:S1:825:2	or	CC	O	O
FDA	STRIBILD.xml:S1:828:3	fda	NNP	O	O
at	STRIBILD.xml:S1:832:2	at	IN	O	O
1	STRIBILD.xml:S1:835:1	1	CD	O	O
-	STRIBILD.xml:S1:836:1	-	:	O	O
800	STRIBILD.xml:S1:837:3	800	CD	O	O
-	STRIBILD.xml:S1:840:1	-	:	O	O
FDA	STRIBILD.xml:S1:841:3	fda	NNP	O	O
-	STRIBILD.xml:S1:844:1	-	:	O	O
1088	STRIBILD.xml:S1:845:4	1088	CD	O	O
or	STRIBILD.xml:S1:850:2	or	CC	O	O
www	STRIBILD.xml:S1:853:3	www	VB	O	O
.	STRIBILD.xml:S1:856:1	.	.	O	O
fda	STRIBILD.xml:S1:857:3	fda	NN	O	O
.	STRIBILD.xml:S1:860:1	.	.	O	O
gov	STRIBILD.xml:S1:861:3	gov	JJ	O	O
medwatch	STRIBILD.xml:S1:865:8	medwatch	NN	O	O
.	STRIBILD.xml:S1:873:1	.	.	O	O

6.1	STRIBILD.xml:S1:885:3	6.1	CD	O	O

Adverse	STRIBILD.xml:S1:889:7	advers	JJ	O	O
Reactions	STRIBILD.xml:S1:897:9	reaction	NNS	O	O
from	STRIBILD.xml:S1:907:4	from	IN	O	O
Clinical	STRIBILD.xml:S1:912:8	clinic	JJ	O	O
Trials	STRIBILD.xml:S1:921:6	trial	NNS	O	O
Experience	STRIBILD.xml:S1:928:10	experi	NN	O	O

Because	STRIBILD.xml:S1:942:7	becaus	IN	O	O
clinical	STRIBILD.xml:S1:950:8	clinic	JJ	O	O
trials	STRIBILD.xml:S1:959:6	trial	NNS	O	O
are	STRIBILD.xml:S1:966:3	are	VBP	O	O
conducted	STRIBILD.xml:S1:970:9	conduct	VBN	O	O
under	STRIBILD.xml:S1:980:5	under	IN	O	O
widely	STRIBILD.xml:S1:986:6	wide	RB	O	O
varying	STRIBILD.xml:S1:993:7	vari	VBG	O	O
conditions	STRIBILD.xml:S1:1001:10	condit	NNS	O	O
,	STRIBILD.xml:S1:1011:1	,	,	O	O
adverse	STRIBILD.xml:S1:1013:7	advers	JJ	O	O
reaction	STRIBILD.xml:S1:1021:8	reaction	NN	O	O
rates	STRIBILD.xml:S1:1030:5	rate	NNS	O	O
observed	STRIBILD.xml:S1:1036:8	observ	VBD	O	O
in	STRIBILD.xml:S1:1045:2	in	IN	O	O
the	STRIBILD.xml:S1:1048:3	the	DT	O	O
clinical	STRIBILD.xml:S1:1052:8	clinic	JJ	O	O
trials	STRIBILD.xml:S1:1061:6	trial	NNS	O	O
of	STRIBILD.xml:S1:1068:2	of	IN	O	O
a	STRIBILD.xml:S1:1071:1	a	DT	O	O
drug	STRIBILD.xml:S1:1073:4	drug	NN	O	O
cannot	STRIBILD.xml:S1:1078:6	cannot	NN	O	O
be	STRIBILD.xml:S1:1085:2	be	VB	O	O
directly	STRIBILD.xml:S1:1088:8	directli	RB	O	O
compared	STRIBILD.xml:S1:1097:8	compar	VBN	O	O
to	STRIBILD.xml:S1:1106:2	to	TO	O	O
rates	STRIBILD.xml:S1:1109:5	rate	NNS	O	O
in	STRIBILD.xml:S1:1115:2	in	IN	O	O
the	STRIBILD.xml:S1:1118:3	the	DT	O	O
clinical	STRIBILD.xml:S1:1122:8	clinic	JJ	O	O
trials	STRIBILD.xml:S1:1131:6	trial	NNS	O	O
of	STRIBILD.xml:S1:1138:2	of	IN	O	O
another	STRIBILD.xml:S1:1141:7	anoth	DT	O	O
drug	STRIBILD.xml:S1:1149:4	drug	NN	O	O
and	STRIBILD.xml:S1:1154:3	and	CC	O	O
may	STRIBILD.xml:S1:1158:3	may	MD	O	O
not	STRIBILD.xml:S1:1162:3	not	RB	O	O
reflect	STRIBILD.xml:S1:1166:7	reflect	VB	O	O
the	STRIBILD.xml:S1:1174:3	the	DT	O	O
rates	STRIBILD.xml:S1:1178:5	rate	NNS	O	O
observed	STRIBILD.xml:S1:1184:8	observ	VBD	O	O
in	STRIBILD.xml:S1:1193:2	in	IN	O	O
practice	STRIBILD.xml:S1:1196:8	practic	NN	O	O
.	STRIBILD.xml:S1:1204:1	.	.	O	O

In	STRIBILD.xml:S1:1214:2	In	IN	O	O
HIV	STRIBILD.xml:S1:1217:3	hiv	NNP	O	O
-	STRIBILD.xml:S1:1220:1	-	:	O	O
1	STRIBILD.xml:S1:1221:1	1	CD	O	O
-	STRIBILD.xml:S1:1222:1	-	:	O	O
Infected	STRIBILD.xml:S1:1223:8	infect	VBN	O	O
Subjects	STRIBILD.xml:S1:1232:8	subject	NNS	O	O
With	STRIBILD.xml:S1:1241:4	with	IN	O	O
No	STRIBILD.xml:S1:1246:2	No	DT	O	O
Antiretroviral	STRIBILD.xml:S1:1249:14	antiretrovir	NNP	O	O
Treatment	STRIBILD.xml:S1:1264:9	treatment	NNP	O	O
History	STRIBILD.xml:S1:1274:7	histori	NNP	O	O

The	STRIBILD.xml:S1:1288:3	the	DT	O	O
safety	STRIBILD.xml:S1:1292:6	safeti	NN	O	O
assessment	STRIBILD.xml:S1:1299:10	assess	NN	O	O
of	STRIBILD.xml:S1:1310:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S1:1313:8	stribild	NNP	O	O
is	STRIBILD.xml:S1:1322:2	is	VBZ	O	O
based	STRIBILD.xml:S1:1325:5	base	VBN	O	O
on	STRIBILD.xml:S1:1331:2	on	IN	O	O
the	STRIBILD.xml:S1:1334:3	the	DT	O	O
Week	STRIBILD.xml:S1:1338:4	week	NNP	O	O
144	STRIBILD.xml:S1:1343:3	144	CD	O	O
pooled	STRIBILD.xml:S1:1347:6	pool	VBD	O	O
data	STRIBILD.xml:S1:1354:4	data	NNS	O	O
from	STRIBILD.xml:S1:1359:4	from	IN	O	O
1408	STRIBILD.xml:S1:1364:4	1408	CD	O	O
subjects	STRIBILD.xml:S1:1369:8	subject	NNS	O	O
in	STRIBILD.xml:S1:1378:2	in	IN	O	O
two	STRIBILD.xml:S1:1381:3	two	CD	O	O
randomized	STRIBILD.xml:S1:1385:10	random	NNS	O	O
,	STRIBILD.xml:S1:1395:1	,	,	O	O
double	STRIBILD.xml:S1:1397:6	doubl	JJ	O	O
-	STRIBILD.xml:S1:1403:1	-	:	O	O
blind	STRIBILD.xml:S1:1404:5	blind	NN	O	O
,	STRIBILD.xml:S1:1409:1	,	,	O	O
active	STRIBILD.xml:S1:1411:6	activ	JJ	O	O
-	STRIBILD.xml:S1:1417:1	-	:	O	O
controlled	STRIBILD.xml:S1:1418:10	control	VBD	O	O
clinical	STRIBILD.xml:S1:1429:8	clinic	JJ	O	O
trials	STRIBILD.xml:S1:1438:6	trial	NNS	O	O
,	STRIBILD.xml:S1:1444:1	,	,	O	O
Study	STRIBILD.xml:S1:1446:5	studi	NNP	O	O
102	STRIBILD.xml:S1:1452:3	102	CD	O	O
and	STRIBILD.xml:S1:1456:3	and	CC	O	O
Study	STRIBILD.xml:S1:1460:5	studi	NNP	O	O
103	STRIBILD.xml:S1:1466:3	103	CD	O	O
,	STRIBILD.xml:S1:1469:1	,	,	O	O
in	STRIBILD.xml:S1:1471:2	in	IN	O	O
antiretroviral	STRIBILD.xml:S1:1474:14	antiretrovir	JJ	O	O
treatment	STRIBILD.xml:S1:1489:9	treatment	NN	O	O
-	STRIBILD.xml:S1:1498:1	-	:	O	O
naive	STRIBILD.xml:S1:1499:5	naiv	JJ	O	O
HIV	STRIBILD.xml:S1:1505:3	hiv	NNP	O	O
-	STRIBILD.xml:S1:1508:1	-	:	O	O
1	STRIBILD.xml:S1:1509:1	1	CD	O	O
infected	STRIBILD.xml:S1:1511:8	infect	JJ	O	O
adult	STRIBILD.xml:S1:1520:5	adult	NN	O	O
subjects	STRIBILD.xml:S1:1526:8	subject	NNS	O	O
[	STRIBILD.xml:S1:1536:1	[	VBP	O	O
see	STRIBILD.xml:S1:1537:3	see	VB	O	O
Clinical	STRIBILD.xml:S1:1542:8	clinic	JJ	O	O
Studies	STRIBILD.xml:S1:1551:7	studi	NNP	O	O
(	STRIBILD.xml:S1:1559:1	(	(	O	O
14	STRIBILD.xml:S1:1560:2	14	CD	O	O
)	STRIBILD.xml:S1:1562:1	)	)	O	O
]	STRIBILD.xml:S1:1565:1	]	NN	O	O
.	STRIBILD.xml:S1:1566:1	.	.	O	O

A	STRIBILD.xml:S1:1569:1	A	DT	O	O
total	STRIBILD.xml:S1:1571:5	total	NN	O	O
of	STRIBILD.xml:S1:1577:2	of	IN	O	O
701	STRIBILD.xml:S1:1580:3	701	CD	O	O
subjects	STRIBILD.xml:S1:1584:8	subject	NNS	O	O
received	STRIBILD.xml:S1:1593:8	receiv	VBN	O	O
STRIBILD	STRIBILD.xml:S1:1602:8	stribild	NNP	O	O
once	STRIBILD.xml:S1:1611:4	onc	RB	O	O
daily	STRIBILD.xml:S1:1616:5	daili	RB	O	O
in	STRIBILD.xml:S1:1622:2	in	IN	O	O
these	STRIBILD.xml:S1:1625:5	these	DT	O	O
two	STRIBILD.xml:S1:1631:3	two	CD	O	O
studies	STRIBILD.xml:S1:1635:7	studi	NNS	O	O
.	STRIBILD.xml:S1:1642:1	.	.	O	O

The	STRIBILD.xml:S1:1648:3	the	DT	O	O
proportion	STRIBILD.xml:S1:1652:10	proport	NN	O	O
of	STRIBILD.xml:S1:1663:2	of	IN	O	O
subjects	STRIBILD.xml:S1:1666:8	subject	NNS	O	O
who	STRIBILD.xml:S1:1675:3	who	WP	O	O
discontinued	STRIBILD.xml:S1:1679:12	discontinu	VBD	O	O
treatment	STRIBILD.xml:S1:1692:9	treatment	NN	O	O
with	STRIBILD.xml:S1:1702:4	with	IN	O	O
STRIBILD	STRIBILD.xml:S1:1707:8	stribild	NNP	O	O
(	STRIBILD.xml:S1:1716:1	(	(	O	O
elvitegravir	STRIBILD.xml:S1:1717:12	elvitegravir	JJ	O	O
150	STRIBILD.xml:S1:1730:3	150	CD	O	O
mg	STRIBILD.xml:S1:1734:2	mg	NN	O	O
cobicistat	STRIBILD.xml:S1:1737:10	cobicistat	NN	O	O
150	STRIBILD.xml:S1:1748:3	150	CD	O	O
mg	STRIBILD.xml:S1:1752:2	mg	NN	O	O
emtricitabine	STRIBILD.xml:S1:1755:13	emtricitabin	NN	O	O
200	STRIBILD.xml:S1:1769:3	200	CD	O	O
mg	STRIBILD.xml:S1:1773:2	mg	NN	O	O
tenofovir	STRIBILD.xml:S1:1776:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S1:1786:2	DF	NNP	O	O
300	STRIBILD.xml:S1:1789:3	300	CD	O	O
mg	STRIBILD.xml:S1:1793:2	mg	NN	O	O
)	STRIBILD.xml:S1:1795:1	)	)	O	O
;	STRIBILD.xml:S1:1796:1	;	:	O	O
ATRIPLA	STRIBILD.xml:S1:1798:7	atripla	NNP	O	O
(	STRIBILD.xml:S1:1806:1	(	(	O	O
efavirenz	STRIBILD.xml:S1:1807:9	efavirenz	VBP	O	O
600	STRIBILD.xml:S1:1817:3	600	CD	O	O
mg	STRIBILD.xml:S1:1821:2	mg	NNS	O	O
emtricitabine	STRIBILD.xml:S1:1824:13	emtricitabin	VBP	O	O
200	STRIBILD.xml:S1:1838:3	200	CD	O	O
mg	STRIBILD.xml:S1:1842:2	mg	NN	O	O
tenofovir	STRIBILD.xml:S1:1845:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S1:1855:2	DF	NNP	O	O
300	STRIBILD.xml:S1:1858:3	300	CD	O	O
mg	STRIBILD.xml:S1:1862:2	mg	NN	O	O
)	STRIBILD.xml:S1:1864:1	)	)	O	O
;	STRIBILD.xml:S1:1865:1	;	:	O	O
or	STRIBILD.xml:S1:1867:2	or	CC	O	O
atazanavir	STRIBILD.xml:S1:1870:10	atazanavir	VB	O	O
(	STRIBILD.xml:S1:1881:1	(	(	O	O
ATV	STRIBILD.xml:S1:1882:3	atv	NNP	O	O
)	STRIBILD.xml:S1:1885:1	)	)	O	O
ritonavir	STRIBILD.xml:S1:1889:9	ritonavir	NN	O	O
(	STRIBILD.xml:S1:1899:1	(	(	O	O
RTV	STRIBILD.xml:S1:1900:3	rtv	NNP	O	O
)	STRIBILD.xml:S1:1903:1	)	)	O	O
TRUVADA	STRIBILD.xml:S1:1907:7	truvada	NNP	O	O
(	STRIBILD.xml:S1:1915:1	(	(	O	O
emtricitabine	STRIBILD.xml:S1:1916:13	emtricitabin	JJ	O	O
200	STRIBILD.xml:S1:1930:3	200	CD	O	O
mg	STRIBILD.xml:S1:1934:2	mg	NN	O	O
tenofovir	STRIBILD.xml:S1:1937:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S1:1947:2	DF	NNP	O	O
300	STRIBILD.xml:S1:1950:3	300	CD	O	O
mg	STRIBILD.xml:S1:1954:2	mg	NN	O	O
)	STRIBILD.xml:S1:1956:1	)	)	O	O
due	STRIBILD.xml:S1:1958:3	due	JJ	O	O
to	STRIBILD.xml:S1:1962:2	to	TO	O	O
adverse	STRIBILD.xml:S1:1965:7	advers	JJ	O	O
events	STRIBILD.xml:S1:1973:6	event	NNS	O	O
,	STRIBILD.xml:S1:1979:1	,	,	O	O
regardless	STRIBILD.xml:S1:1981:10	regardless	RB	O	O
of	STRIBILD.xml:S1:1992:2	of	IN	O	O
severity	STRIBILD.xml:S1:1995:8	sever	NN	O	O
,	STRIBILD.xml:S1:2003:1	,	,	O	O
was	STRIBILD.xml:S1:2005:3	wa	VBD	O	O
6.0%	STRIBILD.xml:S1:2009:4	6.0%	CD	O	O
,	STRIBILD.xml:S1:2013:1	,	,	O	O
7.4%	STRIBILD.xml:S1:2015:4	7.4%	CD	O	O
and	STRIBILD.xml:S1:2020:3	and	CC	O	O
8.5%	STRIBILD.xml:S1:2024:4	8.5%	CD	O	O
,	STRIBILD.xml:S1:2028:1	,	,	O	O
respectively	STRIBILD.xml:S1:2030:12	respect	RB	O	O
.	STRIBILD.xml:S1:2042:1	.	.	O	O

Table	STRIBILD.xml:S1:2044:5	tabl	JJ	O	O
2	STRIBILD.xml:S1:2050:1	2	CD	O	O
displays	STRIBILD.xml:S1:2052:8	display	VBZ	O	O
the	STRIBILD.xml:S1:2061:3	the	DT	O	O
frequency	STRIBILD.xml:S1:2065:9	frequenc	NN	O	O
of	STRIBILD.xml:S1:2075:2	of	IN	O	O
adverse	STRIBILD.xml:S1:2078:7	advers	JJ	O	O
drug	STRIBILD.xml:S1:2086:4	drug	NN	O	O
reactions	STRIBILD.xml:S1:2091:9	reaction	NNS	O	O
greater	STRIBILD.xml:S1:2101:7	greater	JJR	O	O
than	STRIBILD.xml:S1:2109:4	than	IN	O	O
or	STRIBILD.xml:S1:2114:2	or	CC	O	O
equal	STRIBILD.xml:S1:2117:5	equal	JJ	O	O
to	STRIBILD.xml:S1:2123:2	to	TO	O	O
5%	STRIBILD.xml:S1:2126:2	5%	CD	O	O
of	STRIBILD.xml:S1:2129:2	of	IN	O	O
subjects	STRIBILD.xml:S1:2132:8	subject	NNS	O	O
in	STRIBILD.xml:S1:2141:2	in	IN	O	O
any	STRIBILD.xml:S1:2144:3	ani	DT	O	O
treatment	STRIBILD.xml:S1:2148:9	treatment	NN	O	O
arm	STRIBILD.xml:S1:2158:3	arm	NN	O	O
.	STRIBILD.xml:S1:2161:1	.	.	O	O

Table	STRIBILD.xml:S1:2167:5	tabl	JJ	O	O
2	STRIBILD.xml:S1:2173:1	2	CD	O	O
Adverse	STRIBILD.xml:S1:2175:7	advers	JJ	O	O
Drug	STRIBILD.xml:S1:2183:4	drug	NNP	O	O
ReactionsFrequencies	STRIBILD.xml:S1:2188:20	reactionsfrequ	NNP	O	O
of	STRIBILD.xml:S1:2209:2	of	IN	O	O
adverse	STRIBILD.xml:S1:2212:7	advers	JJ	O	O
reactions	STRIBILD.xml:S1:2220:9	reaction	NNS	O	O
are	STRIBILD.xml:S1:2230:3	are	VBP	O	O
based	STRIBILD.xml:S1:2234:5	base	VBN	O	O
on	STRIBILD.xml:S1:2240:2	on	IN	O	O
all	STRIBILD.xml:S1:2243:3	all	DT	O	O
treatment	STRIBILD.xml:S1:2247:9	treatment	NN	O	O
-	STRIBILD.xml:S1:2256:1	-	:	O	O
emergent	STRIBILD.xml:S1:2257:8	emerg	JJ	O	O
adverse	STRIBILD.xml:S1:2266:7	advers	JJ	O	O
events	STRIBILD.xml:S1:2274:6	event	NNS	O	O
,	STRIBILD.xml:S1:2280:1	,	,	O	O
attributed	STRIBILD.xml:S1:2282:10	attribut	VBD	O	O
to	STRIBILD.xml:S1:2293:2	to	TO	O	O
study	STRIBILD.xml:S1:2296:5	studi	VB	O	O
drugs	STRIBILD.xml:S1:2302:5	drug	NNS	O	O
.	STRIBILD.xml:S1:2307:1	.	.	O	O

(	STRIBILD.xml:S1:2309:1	(	(	O	O
all	STRIBILD.xml:S1:2310:3	all	DT	O	O
grades	STRIBILD.xml:S1:2314:6	grade	NNS	O	O
)	STRIBILD.xml:S1:2320:1	)	)	O	O
Reported	STRIBILD.xml:S1:2322:8	report	VBD	O	O
in	STRIBILD.xml:S1:2331:2	in	IN	O	O
5%	STRIBILD.xml:S1:2337:2	5%	CD	O	O
of	STRIBILD.xml:S1:2340:2	of	IN	O	O
Subjects	STRIBILD.xml:S1:2343:8	subject	NNS	O	O
in	STRIBILD.xml:S1:2352:2	in	IN	O	O
Any	STRIBILD.xml:S1:2355:3	ani	NNP	O	O
Treatment	STRIBILD.xml:S1:2359:9	treatment	NNP	O	O
Arm	STRIBILD.xml:S1:2369:3	arm	NNP	O	O
in	STRIBILD.xml:S1:2373:2	in	IN	O	O
Studies	STRIBILD.xml:S1:2376:7	studi	NNP	O	O
102	STRIBILD.xml:S1:2384:3	102	CD	O	O
and	STRIBILD.xml:S1:2388:3	and	CC	O	O
103	STRIBILD.xml:S1:2392:3	103	CD	O	O
(	STRIBILD.xml:S1:2396:1	(	(	O	O
Week	STRIBILD.xml:S1:2397:4	week	JJ	O	O
144	STRIBILD.xml:S1:2402:3	144	CD	O	O
analysis	STRIBILD.xml:S1:2406:8	analysi	NN	O	O
)	STRIBILD.xml:S1:2414:1	)	)	O	O
.	STRIBILD.xml:S1:2415:1	.	.	O	O

STRIBILDN	STRIBILD.xml:S1:2472:9	stribildn	NNP	O	O
701	STRIBILD.xml:S1:2482:3	701	CD	O	O
ATRIPLAN	STRIBILD.xml:S1:2491:8	atriplan	NNP	O	O
352	STRIBILD.xml:S1:2500:3	352	CD	O	O
ATV	STRIBILD.xml:S1:2508:3	atv	NNP	O	O
RTV	STRIBILD.xml:S1:2514:3	rtv	NNP	O	O
TRUVADAN	STRIBILD.xml:S1:2520:8	truvadan	NNP	O	O
355	STRIBILD.xml:S1:2529:3	355	CD	O	O

EYE	STRIBILD.xml:S1:2540:3	eye	NN	O	O

DISORDERS	STRIBILD.xml:S1:2544:9	disord	NNS	O	O

Ocular	STRIBILD.xml:S1:2653:6	ocular	JJ	B-AdverseReaction	B-AdverseReaction
icterus	STRIBILD.xml:S1:2660:7	icteru	NN	I-AdverseReaction	I-AdverseReaction
1%	STRIBILD.xml:S1:2710:2	1%	CD	O	O
0%	STRIBILD.xml:S1:2728:2	0%	CD	O	O
13%	STRIBILD.xml:S1:2747:3	13%	CD	O	O

GASTROINTESTINAL	STRIBILD.xml:S1:2762:16	gastrointestin	NNP	O	O
DISORDERS	STRIBILD.xml:S1:2779:9	disord	NNP	O	O

Diarrhea	STRIBILD.xml:S1:2875:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
12%	STRIBILD.xml:S1:2931:3	12%	CD	O	O
11%	STRIBILD.xml:S1:2950:3	11%	CD	O	O
17%	STRIBILD.xml:S1:2969:3	17%	CD	O	O

Flatulence	STRIBILD.xml:S1:2986:10	flatul	NN	B-AdverseReaction	B-AdverseReaction
2%	STRIBILD.xml:S1:3042:2	2%	CD	O	O
1%	STRIBILD.xml:S1:3062:2	1%	CD	O	O
8%	STRIBILD.xml:S1:3080:2	8%	CD	O	O

Nausea	STRIBILD.xml:S1:3097:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
16%	STRIBILD.xml:S1:3153:3	16%	CD	O	O
9%	STRIBILD.xml:S1:3172:2	9%	CD	O	O
14%	STRIBILD.xml:S1:3191:3	14%	CD	O	O

GENERAL	STRIBILD.xml:S1:3206:7	gener	NNP	O	O
DISORDERS	STRIBILD.xml:S1:3214:9	disord	NNP	O	O
AND	STRIBILD.xml:S1:3224:3	and	NNP	O	O
ADMINISTRATION	STRIBILD.xml:S1:3228:14	administr	NNP	O	O
SITE	STRIBILD.xml:S1:3243:4	site	NNP	O	O
CONDITIONS	STRIBILD.xml:S1:3248:10	condit	NNP	O	O

Fatigue	STRIBILD.xml:S1:3322:7	fatigu	NNP	B-AdverseReaction	B-AdverseReaction
4%	STRIBILD.xml:S1:3378:2	4%	CD	O	O
8%	STRIBILD.xml:S1:3397:2	8%	CD	O	O
6%	STRIBILD.xml:S1:3416:2	6%	CD	O	O

HEPATOBILIARY	STRIBILD.xml:S1:3431:13	hepatobiliari	NNP	O	O
DISORDERS	STRIBILD.xml:S1:3445:9	disord	NNS	O	O

Jaundice	STRIBILD.xml:S1:3544:8	jaundic	NNP	B-AdverseReaction	B-AdverseReaction
0%	STRIBILD.xml:S1:3600:2	0%	CD	O	O
1%	STRIBILD.xml:S1:3620:2	1%	CD	O	O
9%	STRIBILD.xml:S1:3638:2	9%	CD	O	O

NERVOUS	STRIBILD.xml:S1:3653:7	nervou	NNP	O	O
SYSTEM	STRIBILD.xml:S1:3661:6	system	NNP	O	O
DISORDERS	STRIBILD.xml:S1:3668:9	disord	NNP	O	O

Somnolence	STRIBILD.xml:S1:3766:10	somnol	NN	B-AdverseReaction	B-AdverseReaction
1%	STRIBILD.xml:S1:3822:2	1%	CD	O	O
7%	STRIBILD.xml:S1:3841:2	7%	CD	O	O
1%	STRIBILD.xml:S1:3860:2	1%	CD	O	O

Headache	STRIBILD.xml:S1:3877:8	headach	NNP	B-AdverseReaction	B-AdverseReaction
7%	STRIBILD.xml:S1:3933:2	7%	CD	O	O
4%	STRIBILD.xml:S1:3952:2	4%	CD	O	O
6%	STRIBILD.xml:S1:3971:2	6%	CD	O	O

Dizziness	STRIBILD.xml:S1:3988:9	dizzi	NNP	B-AdverseReaction	B-AdverseReaction
3%	STRIBILD.xml:S1:4044:2	3%	CD	O	O
21%	STRIBILD.xml:S1:4063:3	21%	CD	O	O
5%	STRIBILD.xml:S1:4082:2	5%	CD	O	O

PSYCHIATRIC	STRIBILD.xml:S1:4097:11	psychiatr	NN	O	O
DISORDERS	STRIBILD.xml:S1:4109:9	disord	NNS	O	O

Insomnia	STRIBILD.xml:S1:4210:8	insomnia	NNP	B-AdverseReaction	B-AdverseReaction
3%	STRIBILD.xml:S1:4266:2	3%	CD	O	O
9%	STRIBILD.xml:S1:4285:2	9%	CD	O	O
1%	STRIBILD.xml:S1:4304:2	1%	CD	O	O

Abnormal	STRIBILD.xml:S1:4321:8	abnorm	JJ	B-AdverseReaction	B-AdverseReaction
dreams	STRIBILD.xml:S1:4330:6	dream	VBZ	I-AdverseReaction	I-AdverseReaction
9%	STRIBILD.xml:S1:4377:2	9%	CD	O	O
27%	STRIBILD.xml:S1:4396:3	27%	CD	O	O
4%	STRIBILD.xml:S1:4415:2	4%	CD	O	O

SKIN	STRIBILD.xml:S1:4430:4	skin	NNP	O	O
AND	STRIBILD.xml:S1:4435:3	and	NNP	O	O
SUBCUTANEOUS	STRIBILD.xml:S1:4439:12	subcutan	NNP	O	O
TISSUE	STRIBILD.xml:S1:4452:6	tissu	NNP	O	O
DISORDERS	STRIBILD.xml:S1:4459:9	disord	NNP	O	O

Rash	STRIBILD.xml:S1:4543:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
4%	STRIBILD.xml:S1:4599:2	4%	CD	O	O
15%	STRIBILD.xml:S1:4618:3	15%	CD	O	O
6%	STRIBILD.xml:S1:4637:2	6%	CD	O	O

See	STRIBILD.xml:S1:4661:3	see	VB	O	O
Warnings	STRIBILD.xml:S1:4668:8	warn	NNS	O	O
and	STRIBILD.xml:S1:4677:3	and	CC	O	O
Precautions	STRIBILD.xml:S1:4681:11	precaut	NNP	O	O
(	STRIBILD.xml:S1:4693:1	(	(	O	O
5.3	STRIBILD.xml:S1:4694:3	5.3	CD	O	O
)	STRIBILD.xml:S1:4697:1	)	)	O	O
,	STRIBILD.xml:S1:4702:1	,	,	O	O
for	STRIBILD.xml:S1:4704:3	for	IN	O	O
a	STRIBILD.xml:S1:4708:1	a	DT	O	O
discussion	STRIBILD.xml:S1:4710:10	discuss	NN	O	O
of	STRIBILD.xml:S1:4721:2	of	IN	O	O
renal	STRIBILD.xml:S1:4724:5	renal	JJ	B-AdverseReaction	O
adverse	STRIBILD.xml:S1:4730:7	advers	JJ	I-AdverseReaction	O
reactions	STRIBILD.xml:S1:4738:9	reaction	NNS	I-AdverseReaction	O
from	STRIBILD.xml:S1:4748:4	from	IN	O	O
clinical	STRIBILD.xml:S1:4753:8	clinic	JJ	O	O
trials	STRIBILD.xml:S1:4762:6	trial	NNS	O	O
experience	STRIBILD.xml:S1:4769:10	experi	NN	O	O
with	STRIBILD.xml:S1:4780:4	with	IN	O	O
STRIBILD	STRIBILD.xml:S1:4785:8	stribild	NNP	O	O
.	STRIBILD.xml:S1:4793:1	.	.	O	O

Additional	STRIBILD.xml:S1:4799:10	addit	JJ	O	O

adverse	STRIBILD.xml:S1:4810:7	advers	JJ	O	O
drug	STRIBILD.xml:S1:4818:4	drug	NN	O	O
reactions	STRIBILD.xml:S1:4823:9	reaction	NNS	O	O
observed	STRIBILD.xml:S1:4833:8	observ	VBD	O	O
with	STRIBILD.xml:S1:4842:4	with	IN	O	O
STRIBILD	STRIBILD.xml:S1:4847:8	stribild	NNP	O	O
included	STRIBILD.xml:S1:4856:8	includ	VBD	O	O
suicidal	STRIBILD.xml:S1:4865:8	suicid	JJ	B-AdverseReaction	B-AdverseReaction
ideation	STRIBILD.xml:S1:4874:8	ideat	NN	I-AdverseReaction	I-AdverseReaction
and	STRIBILD.xml:S1:4883:3	and	CC	O	O
suicide	STRIBILD.xml:S1:4887:7	suicid	NN	B-AdverseReaction	B-AdverseReaction
attempt	STRIBILD.xml:S1:4895:7	attempt	NN	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S1:4903:1	(	(	O	O
0.3%	STRIBILD.xml:S1:4904:4	0.3%	CD	O	O
)	STRIBILD.xml:S1:4908:1	)	)	O	O
,	STRIBILD.xml:S1:4909:1	,	,	O	O
all	STRIBILD.xml:S1:4911:3	all	DT	O	O
in	STRIBILD.xml:S1:4915:2	in	IN	O	O
subjects	STRIBILD.xml:S1:4918:8	subject	NNS	O	O
with	STRIBILD.xml:S1:4927:4	with	IN	O	O
a	STRIBILD.xml:S1:4932:1	a	DT	O	O
pre	STRIBILD.xml:S1:4934:3	pre	NN	O	O
-	STRIBILD.xml:S1:4937:1	-	:	O	O
existing	STRIBILD.xml:S1:4938:8	exist	VBG	O	O
history	STRIBILD.xml:S1:4947:7	histori	NN	O	O
of	STRIBILD.xml:S1:4955:2	of	IN	O	O
depression	STRIBILD.xml:S1:4958:10	depress	NN	O	O
or	STRIBILD.xml:S1:4969:2	or	CC	O	O
psychiatric	STRIBILD.xml:S1:4972:11	psychiatr	JJ	O	O
illness	STRIBILD.xml:S1:4984:7	ill	NN	O	O
.	STRIBILD.xml:S1:4991:1	.	.	O	O

In	STRIBILD.xml:S1:5001:2	In	IN	O	O
Virologically	STRIBILD.xml:S1:5004:13	virolog	NNP	O	O
-	STRIBILD.xml:S1:5017:1	-	:	O	O
Suppressed	STRIBILD.xml:S1:5018:10	suppress	VBD	O	O
HIV	STRIBILD.xml:S1:5029:3	hiv	NNP	O	O
-	STRIBILD.xml:S1:5032:1	-	:	O	O
1	STRIBILD.xml:S1:5033:1	1	CD	O	O
-	STRIBILD.xml:S1:5034:1	-	:	O	O
Infected	STRIBILD.xml:S1:5035:8	infect	VBN	O	O
Subjects	STRIBILD.xml:S1:5044:8	subject	NNS	O	O

No	STRIBILD.xml:S1:5059:2	No	DT	O	O
new	STRIBILD.xml:S1:5062:3	new	JJ	O	O
adverse	STRIBILD.xml:S1:5066:7	advers	JJ	O	O
reactions	STRIBILD.xml:S1:5074:9	reaction	NNS	O	O
to	STRIBILD.xml:S1:5084:2	to	TO	O	O
STRIBILD	STRIBILD.xml:S1:5087:8	stribild	NNP	O	O
through	STRIBILD.xml:S1:5096:7	through	IN	O	O
Week	STRIBILD.xml:S1:5104:4	week	NNP	O	O
48	STRIBILD.xml:S1:5109:2	48	CD	O	O
were	STRIBILD.xml:S1:5112:4	were	VBD	O	O
identified	STRIBILD.xml:S1:5117:10	identifi	VBN	O	O
in	STRIBILD.xml:S1:5128:2	in	IN	O	O
584	STRIBILD.xml:S1:5131:3	584	CD	O	O
virologically	STRIBILD.xml:S1:5135:13	virolog	RB	O	O
stably	STRIBILD.xml:S1:5149:6	stabli	RB	O	O
suppressed	STRIBILD.xml:S1:5156:10	suppress	JJ	O	O
subjects	STRIBILD.xml:S1:5167:8	subject	NNS	O	O
switching	STRIBILD.xml:S1:5176:9	switch	VBG	O	O
to	STRIBILD.xml:S1:5186:2	to	TO	O	O
STRIBILD	STRIBILD.xml:S1:5189:8	stribild	NNP	O	O
from	STRIBILD.xml:S1:5198:4	from	IN	O	O
a	STRIBILD.xml:S1:5203:1	a	DT	O	O
regimen	STRIBILD.xml:S1:5205:7	regimen	NNS	O	O
containing	STRIBILD.xml:S1:5213:10	contain	VBG	O	O
a	STRIBILD.xml:S1:5224:1	a	DT	O	O
RTV	STRIBILD.xml:S1:5226:3	rtv	NNP	O	O
-	STRIBILD.xml:S1:5229:1	-	:	O	O
boosted	STRIBILD.xml:S1:5230:7	boost	VBD	O	O
protease	STRIBILD.xml:S1:5238:8	proteas	JJ	O	O
inhibitor	STRIBILD.xml:S1:5247:9	inhibitor	NN	O	O
(	STRIBILD.xml:S1:5257:1	(	(	O	O
PI	STRIBILD.xml:S1:5258:2	PI	NNP	O	O
)	STRIBILD.xml:S1:5260:1	)	)	O	O
or	STRIBILD.xml:S1:5262:2	or	CC	O	O
a	STRIBILD.xml:S1:5265:1	a	DT	O	O
non	STRIBILD.xml:S1:5267:3	non	JJ	O	O
-	STRIBILD.xml:S1:5270:1	-	:	O	O
nucleoside	STRIBILD.xml:S1:5271:10	nucleosid	JJ	O	O
reverse	STRIBILD.xml:S1:5282:7	revers	NN	O	O
transcriptase	STRIBILD.xml:S1:5290:13	transcriptas	NN	O	O
inhibitor	STRIBILD.xml:S1:5304:9	inhibitor	NN	O	O
(	STRIBILD.xml:S1:5314:1	(	(	O	O
NNRTI	STRIBILD.xml:S1:5315:5	nnrti	NNP	O	O
)	STRIBILD.xml:S1:5320:1	)	)	O	O
.	STRIBILD.xml:S1:5321:1	.	.	O	O

In	STRIBILD.xml:S1:5323:2	In	IN	O	O
a	STRIBILD.xml:S1:5326:1	a	DT	O	O
combined	STRIBILD.xml:S1:5328:8	combin	JJ	O	O
analysis	STRIBILD.xml:S1:5337:8	analysi	NN	O	O
of	STRIBILD.xml:S1:5346:2	of	IN	O	O
Studies	STRIBILD.xml:S1:5349:7	studi	NNS	O	O
115	STRIBILD.xml:S1:5357:3	115	CD	O	O
and	STRIBILD.xml:S1:5361:3	and	CC	O	O
121	STRIBILD.xml:S1:5365:3	121	CD	O	O
,	STRIBILD.xml:S1:5368:1	,	,	O	O
the	STRIBILD.xml:S1:5370:3	the	DT	O	O
frequency	STRIBILD.xml:S1:5374:9	frequenc	NN	O	O
of	STRIBILD.xml:S1:5384:2	of	IN	O	O
adverse	STRIBILD.xml:S1:5387:7	advers	JJ	O	O
reactions	STRIBILD.xml:S1:5395:9	reaction	NNS	O	O
(	STRIBILD.xml:S1:5405:1	(	(	O	O
all	STRIBILD.xml:S1:5406:3	all	DT	O	O
grades	STRIBILD.xml:S1:5410:6	grade	NNS	O	O
)	STRIBILD.xml:S1:5416:1	)	)	O	O
was	STRIBILD.xml:S1:5418:3	wa	VBD	O	O
24%	STRIBILD.xml:S1:5422:3	24%	CD	O	O
in	STRIBILD.xml:S1:5426:2	in	IN	O	O
subjects	STRIBILD.xml:S1:5429:8	subject	NNS	O	O
switching	STRIBILD.xml:S1:5438:9	switch	VBG	O	O
to	STRIBILD.xml:S1:5448:2	to	TO	O	O
STRIBILD	STRIBILD.xml:S1:5451:8	stribild	NNP	O	O
compared	STRIBILD.xml:S1:5460:8	compar	VBN	O	O
to	STRIBILD.xml:S1:5469:2	to	TO	O	O
6%	STRIBILD.xml:S1:5472:2	6%	CD	O	O
of	STRIBILD.xml:S1:5475:2	of	IN	O	O
subjects	STRIBILD.xml:S1:5478:8	subject	NNS	O	O
in	STRIBILD.xml:S1:5487:2	in	IN	O	O
either	STRIBILD.xml:S1:5490:6	either	DT	O	O
group	STRIBILD.xml:S1:5497:5	group	NN	O	O
who	STRIBILD.xml:S1:5503:3	who	WP	O	O
stayed	STRIBILD.xml:S1:5507:6	stay	VBD	O	O
on	STRIBILD.xml:S1:5514:2	on	IN	O	O
their	STRIBILD.xml:S1:5517:5	their	PRP$	O	O
baseline	STRIBILD.xml:S1:5523:8	baselin	JJ	O	O
antiretroviral	STRIBILD.xml:S1:5532:14	antiretrovir	JJ	O	O
regimen	STRIBILD.xml:S1:5547:7	regimen	NNS	O	O
,	STRIBILD.xml:S1:5554:1	,	,	O	O
RTV	STRIBILD.xml:S1:5556:3	rtv	NNP	O	O
-	STRIBILD.xml:S1:5559:1	-	:	O	O
boosted	STRIBILD.xml:S1:5560:7	boost	VBD	O	O
PI	STRIBILD.xml:S1:5568:2	PI	NNP	O	O
TRUVADA	STRIBILD.xml:S1:5573:7	truvada	NNP	O	O
or	STRIBILD.xml:S1:5581:2	or	CC	O	O
NNRTI	STRIBILD.xml:S1:5584:5	nnrti	NNP	O	O
TRUVADA	STRIBILD.xml:S1:5592:7	truvada	NNP	O	O
.	STRIBILD.xml:S1:5599:1	.	.	O	O

Common	STRIBILD.xml:S1:5601:6	common	JJ	O	O
adverse	STRIBILD.xml:S1:5608:7	advers	JJ	O	O
reactions	STRIBILD.xml:S1:5616:9	reaction	NNS	O	O
that	STRIBILD.xml:S1:5626:4	that	WDT	O	O
occurred	STRIBILD.xml:S1:5631:8	occur	VBD	O	O
in	STRIBILD.xml:S1:5640:2	in	IN	O	O
greater	STRIBILD.xml:S1:5643:7	greater	JJR	O	O
than	STRIBILD.xml:S1:5651:4	than	IN	O	O
or	STRIBILD.xml:S1:5656:2	or	CC	O	O
equal	STRIBILD.xml:S1:5659:5	equal	JJ	O	O
to	STRIBILD.xml:S1:5665:2	to	TO	O	O
2%	STRIBILD.xml:S1:5668:2	2%	CD	O	O
of	STRIBILD.xml:S1:5671:2	of	IN	O	O
subjects	STRIBILD.xml:S1:5674:8	subject	NNS	O	O
switching	STRIBILD.xml:S1:5683:9	switch	VBG	O	O
to	STRIBILD.xml:S1:5693:2	to	TO	O	O
STRIBILD	STRIBILD.xml:S1:5696:8	stribild	NNP	O	O
were	STRIBILD.xml:S1:5705:4	were	VBD	O	O
nausea	STRIBILD.xml:S1:5710:6	nausea	RB	B-AdverseReaction	B-AdverseReaction
(	STRIBILD.xml:S1:5717:1	(	(	O	O
4%	STRIBILD.xml:S1:5718:2	4%	CD	O	O
)	STRIBILD.xml:S1:5720:1	)	)	O	O
,	STRIBILD.xml:S1:5721:1	,	,	O	O
flatulence	STRIBILD.xml:S1:5723:10	flatul	NN	B-AdverseReaction	B-AdverseReaction
(	STRIBILD.xml:S1:5734:1	(	(	O	O
2%	STRIBILD.xml:S1:5735:2	2%	CD	O	O
)	STRIBILD.xml:S1:5737:1	)	)	O	O
,	STRIBILD.xml:S1:5738:1	,	,	O	O
and	STRIBILD.xml:S1:5740:3	and	CC	O	O
headache	STRIBILD.xml:S1:5744:8	headach	NN	B-AdverseReaction	B-AdverseReaction
(	STRIBILD.xml:S1:5753:1	(	(	O	O
2%	STRIBILD.xml:S1:5754:2	2%	CD	O	O
)	STRIBILD.xml:S1:5756:1	)	)	O	O
.	STRIBILD.xml:S1:5757:1	.	.	O	O

The	STRIBILD.xml:S1:5759:3	the	DT	O	O
proportion	STRIBILD.xml:S1:5763:10	proport	NN	O	O
of	STRIBILD.xml:S1:5774:2	of	IN	O	O
subjects	STRIBILD.xml:S1:5777:8	subject	NNS	O	O
who	STRIBILD.xml:S1:5786:3	who	WP	O	O
discontinued	STRIBILD.xml:S1:5790:12	discontinu	VBD	O	O
treatment	STRIBILD.xml:S1:5803:9	treatment	NN	O	O
with	STRIBILD.xml:S1:5813:4	with	IN	O	O
STRIBILD	STRIBILD.xml:S1:5818:8	stribild	NNP	O	O
,	STRIBILD.xml:S1:5826:1	,	,	O	O
the	STRIBILD.xml:S1:5828:3	the	DT	O	O
RTV	STRIBILD.xml:S1:5832:3	rtv	NNP	O	O
-	STRIBILD.xml:S1:5835:1	-	:	O	O
boosted	STRIBILD.xml:S1:5836:7	boost	VBD	O	O
PI	STRIBILD.xml:S1:5844:2	PI	NNP	O	O
,	STRIBILD.xml:S1:5846:1	,	,	O	O
or	STRIBILD.xml:S1:5848:2	or	CC	O	O
the	STRIBILD.xml:S1:5851:3	the	DT	O	O
NNRTI	STRIBILD.xml:S1:5855:5	nnrti	NNP	O	O
due	STRIBILD.xml:S1:5861:3	due	JJ	O	O
to	STRIBILD.xml:S1:5865:2	to	TO	O	O
adverse	STRIBILD.xml:S1:5868:7	advers	JJ	O	O
events	STRIBILD.xml:S1:5876:6	event	NNS	O	O
,	STRIBILD.xml:S1:5882:1	,	,	O	O
was	STRIBILD.xml:S1:5884:3	wa	VBD	O	O
2%	STRIBILD.xml:S1:5888:2	2%	CD	O	O
,	STRIBILD.xml:S1:5890:1	,	,	O	O
3%	STRIBILD.xml:S1:5892:2	3%	CD	O	O
and	STRIBILD.xml:S1:5895:3	and	CC	O	O
1%	STRIBILD.xml:S1:5899:2	1%	CD	O	O
,	STRIBILD.xml:S1:5901:1	,	,	O	O
respectively	STRIBILD.xml:S1:5903:12	respect	RB	O	O
.	STRIBILD.xml:S1:5915:1	.	.	O	O

Adverse	STRIBILD.xml:S1:5925:7	advers	JJ	O	O
Reactions	STRIBILD.xml:S1:5933:9	reaction	NNS	O	O
from	STRIBILD.xml:S1:5943:4	from	IN	O	O
Clinical	STRIBILD.xml:S1:5948:8	clinic	JJ	O	O
Trials	STRIBILD.xml:S1:5957:6	trial	NNS	O	O
of	STRIBILD.xml:S1:5964:2	of	IN	O	O
the	STRIBILD.xml:S1:5967:3	the	DT	O	O
Components	STRIBILD.xml:S1:5971:10	compon	NNS	O	O
of	STRIBILD.xml:S1:5982:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S1:5985:8	stribild	NNP	O	O

Emtricitabine	STRIBILD.xml:S1:6004:13	emtricitabin	NN	O	O
and	STRIBILD.xml:S1:6018:3	and	CC	O	O
Tenofovir	STRIBILD.xml:S1:6022:9	tenofovir	NNP	O	O
Disoproxil	STRIBILD.xml:S1:6032:10	disoproxil	NNP	O	O
Fumarate	STRIBILD.xml:S1:6043:8	fumar	NNP	O	O
:	STRIBILD.xml:S1:6051:1	:	:	O	O
In	STRIBILD.xml:S1:6054:2	In	IN	O	O
addition	STRIBILD.xml:S1:6057:8	addit	NN	O	O
to	STRIBILD.xml:S1:6066:2	to	TO	O	O
the	STRIBILD.xml:S1:6069:3	the	DT	O	O
adverse	STRIBILD.xml:S1:6073:7	advers	JJ	O	O
reactions	STRIBILD.xml:S1:6081:9	reaction	NNS	O	O
observed	STRIBILD.xml:S1:6091:8	observ	VBD	O	O
with	STRIBILD.xml:S1:6100:4	with	IN	O	O
STRIBILD	STRIBILD.xml:S1:6105:8	stribild	NNP	O	O
,	STRIBILD.xml:S1:6113:1	,	,	O	O
the	STRIBILD.xml:S1:6115:3	the	DT	O	O
following	STRIBILD.xml:S1:6119:9	follow	JJ	O	O
adverse	STRIBILD.xml:S1:6129:7	advers	JJ	O	O
reactions	STRIBILD.xml:S1:6137:9	reaction	NNS	O	O
occurred	STRIBILD.xml:S1:6147:8	occur	VBD	O	O
in	STRIBILD.xml:S1:6156:2	in	IN	O	O
at	STRIBILD.xml:S1:6159:2	at	IN	O	O
least	STRIBILD.xml:S1:6162:5	least	JJS	O	O
5%	STRIBILD.xml:S1:6168:2	5%	CD	O	O
of	STRIBILD.xml:S1:6171:2	of	IN	O	O
treatment	STRIBILD.xml:S1:6174:9	treatment	NN	O	O
-	STRIBILD.xml:S1:6183:1	-	:	O	O
experienced	STRIBILD.xml:S1:6184:11	experienc	VBD	O	O
or	STRIBILD.xml:S1:6196:2	or	CC	O	O
treatment	STRIBILD.xml:S1:6199:9	treatment	NN	O	O
-	STRIBILD.xml:S1:6208:1	-	:	O	O
naive	STRIBILD.xml:S1:6209:5	naiv	JJ	O	O
subjects	STRIBILD.xml:S1:6215:8	subject	NNS	O	O
receiving	STRIBILD.xml:S1:6224:9	receiv	VBG	O	O
emtricitabine	STRIBILD.xml:S1:6234:13	emtricitabin	NN	O	O
or	STRIBILD.xml:S1:6248:2	or	CC	O	O
tenofovir	STRIBILD.xml:S1:6251:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S1:6261:2	DF	NNP	O	O
with	STRIBILD.xml:S1:6264:4	with	IN	O	O
other	STRIBILD.xml:S1:6269:5	other	JJ	O	O
antiretroviral	STRIBILD.xml:S1:6275:14	antiretrovir	JJ	O	O
agents	STRIBILD.xml:S1:6290:6	agent	NNS	O	O
in	STRIBILD.xml:S1:6297:2	in	IN	O	O
other	STRIBILD.xml:S1:6300:5	other	JJ	O	O
clinical	STRIBILD.xml:S1:6306:8	clinic	JJ	O	O
trials	STRIBILD.xml:S1:6315:6	trial	NNS	O	O
:	STRIBILD.xml:S1:6321:1	:	:	O	O
depression	STRIBILD.xml:S1:6323:10	depress	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6333:1	,	,	O	O
abdominal	STRIBILD.xml:S1:6335:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	STRIBILD.xml:S1:6345:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:6349:1	,	,	O	O
dyspepsia	STRIBILD.xml:S1:6351:9	dyspepsia	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6360:1	,	,	O	O
vomiting	STRIBILD.xml:S1:6362:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6370:1	,	,	O	O
fever	STRIBILD.xml:S1:6372:5	fever	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6377:1	,	,	O	O
pain	STRIBILD.xml:S1:6379:4	pain	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6383:1	,	,	O	O
nasopharyngitis	STRIBILD.xml:S1:6385:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6400:1	,	,	O	O
pneumonia	STRIBILD.xml:S1:6402:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6411:1	,	,	O	O
sinusitis	STRIBILD.xml:S1:6413:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6422:1	,	,	O	O
upper	STRIBILD.xml:S1:6424:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	STRIBILD.xml:S1:6430:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	STRIBILD.xml:S1:6442:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	STRIBILD.xml:S1:6448:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:6457:1	,	,	O	O
arthralgia	STRIBILD.xml:S1:6459:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6469:1	,	,	O	O
back	STRIBILD.xml:S1:6471:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	STRIBILD.xml:S1:6476:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:6480:1	,	,	O	O
myalgia	STRIBILD.xml:S1:6482:7	myalgia	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6489:1	,	,	O	O
paresthesia	STRIBILD.xml:S1:6491:11	paresthesia	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6502:1	,	,	O	O
peripheral	STRIBILD.xml:S1:6504:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
neuropathy	STRIBILD.xml:S1:6515:10	neuropathi	NN	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S1:6526:1	(	(	O	O
including	STRIBILD.xml:S1:6527:9	includ	VBG	O	O
peripheral	STRIBILD.xml:S1:6537:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
neuritis	STRIBILD.xml:S1:6548:8	neuriti	NN	I-AdverseReaction	I-AdverseReaction
and	STRIBILD.xml:S1:6557:3	and	CC	O	O
neuropathy	STRIBILD.xml:S1:6561:10	neuropathi	NN	I-AdverseReaction	B-AdverseReaction
)	STRIBILD.xml:S1:6571:1	)	)	O	O
,	STRIBILD.xml:S1:6572:1	,	,	O	O
anxiety	STRIBILD.xml:S1:6574:7	anxieti	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:6581:1	,	,	O	O
increased	STRIBILD.xml:S1:6583:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
cough	STRIBILD.xml:S1:6593:5	cough	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:6598:1	,	,	O	O
and	STRIBILD.xml:S1:6600:3	and	CC	O	O
rhinitis	STRIBILD.xml:S1:6604:8	rhiniti	NN	B-AdverseReaction	B-AdverseReaction
.	STRIBILD.xml:S1:6612:1	.	.	O	O

Skin	STRIBILD.xml:S1:6618:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
discoloration	STRIBILD.xml:S1:6623:13	discolor	NN	I-AdverseReaction	I-AdverseReaction
has	STRIBILD.xml:S1:6637:3	ha	VBZ	O	O
been	STRIBILD.xml:S1:6641:4	been	VBN	O	O
reported	STRIBILD.xml:S1:6646:8	report	VBN	O	O
with	STRIBILD.xml:S1:6655:4	with	IN	O	O
higher	STRIBILD.xml:S1:6660:6	higher	JJR	O	O
frequency	STRIBILD.xml:S1:6667:9	frequenc	NN	O	O
among	STRIBILD.xml:S1:6677:5	among	IN	O	O
emtricitabine	STRIBILD.xml:S1:6683:13	emtricitabin	JJ	O	O
-	STRIBILD.xml:S1:6696:1	-	:	O	O
treated	STRIBILD.xml:S1:6697:7	treat	JJ	O	O
subjects	STRIBILD.xml:S1:6705:8	subject	NNS	O	O
;	STRIBILD.xml:S1:6713:1	;	:	O	O
it	STRIBILD.xml:S1:6715:2	it	PRP	O	O
was	STRIBILD.xml:S1:6718:3	wa	VBD	O	O
manifested	STRIBILD.xml:S1:6722:10	manifest	VBN	O	O
by	STRIBILD.xml:S1:6733:2	by	IN	O	O
hyperpigmentation	STRIBILD.xml:S1:6736:17	hyperpigment	NN	B-AdverseReaction	O
on	STRIBILD.xml:S1:6754:2	on	IN	I-AdverseReaction	O
the	STRIBILD.xml:S1:6757:3	the	DT	I-AdverseReaction	O
palms	STRIBILD.xml:S1:6761:5	palm	NN	I-AdverseReaction	O
and	STRIBILD.xml:S1:6767:3	and	CC	O	O
or	STRIBILD.xml:S1:6771:2	or	CC	O	O
soles	STRIBILD.xml:S1:6774:5	sole	NNS	I-AdverseReaction	O
and	STRIBILD.xml:S1:6780:3	and	CC	O	O
was	STRIBILD.xml:S1:6784:3	wa	VBD	O	O
generally	STRIBILD.xml:S1:6788:9	gener	RB	O	O
mild	STRIBILD.xml:S1:6798:4	mild	JJ	O	O
and	STRIBILD.xml:S1:6803:3	and	CC	O	O
asymptomatic	STRIBILD.xml:S1:6807:12	asymptomat	JJ	O	O
.	STRIBILD.xml:S1:6819:1	.	.	O	O

The	STRIBILD.xml:S1:6821:3	the	DT	O	O
mechanism	STRIBILD.xml:S1:6825:9	mechan	NN	O	O
and	STRIBILD.xml:S1:6835:3	and	CC	O	O
clinical	STRIBILD.xml:S1:6839:8	clinic	JJ	O	O
significance	STRIBILD.xml:S1:6848:12	signific	NN	O	O
are	STRIBILD.xml:S1:6861:3	are	VBP	O	O
unknown	STRIBILD.xml:S1:6865:7	unknown	JJ	O	O
.	STRIBILD.xml:S1:6872:1	.	.	O	O

Laboratory	STRIBILD.xml:S1:6882:10	laboratori	NN	O	O
Abnormalities	STRIBILD.xml:S1:6893:13	abnorm	NNS	O	O

The	STRIBILD.xml:S1:6913:3	the	DT	O	O
frequency	STRIBILD.xml:S1:6917:9	frequenc	NN	O	O
of	STRIBILD.xml:S1:6927:2	of	IN	O	O
laboratory	STRIBILD.xml:S1:6930:10	laboratori	NN	O	O
abnormalities	STRIBILD.xml:S1:6941:13	abnorm	NNS	O	O
(	STRIBILD.xml:S1:6955:1	(	(	O	O
Grades	STRIBILD.xml:S1:6956:6	grade	NNP	O	O
3	STRIBILD.xml:S1:6963:1	3	CD	O	O
-	STRIBILD.xml:S1:6964:1	-	:	O	O
4	STRIBILD.xml:S1:6965:1	4	CD	O	O
)	STRIBILD.xml:S1:6966:1	)	)	O	O
occurring	STRIBILD.xml:S1:6968:9	occur	VBG	O	O
in	STRIBILD.xml:S1:6978:2	in	IN	O	O
at	STRIBILD.xml:S1:6981:2	at	IN	O	O
least	STRIBILD.xml:S1:6984:5	least	JJS	O	O
2%	STRIBILD.xml:S1:6990:2	2%	CD	O	O
of	STRIBILD.xml:S1:6993:2	of	IN	O	O
subjects	STRIBILD.xml:S1:6996:8	subject	NNS	O	O
receiving	STRIBILD.xml:S1:7005:9	receiv	VBG	O	O
STRIBILD	STRIBILD.xml:S1:7015:8	stribild	NNP	O	O
in	STRIBILD.xml:S1:7024:2	in	IN	O	O
Studies	STRIBILD.xml:S1:7027:7	studi	NNP	O	O
102	STRIBILD.xml:S1:7035:3	102	CD	O	O
and	STRIBILD.xml:S1:7039:3	and	CC	O	O
103	STRIBILD.xml:S1:7043:3	103	CD	O	O
are	STRIBILD.xml:S1:7047:3	are	VBP	O	O
presented	STRIBILD.xml:S1:7051:9	present	VBN	O	O
in	STRIBILD.xml:S1:7061:2	in	IN	O	O
Table	STRIBILD.xml:S1:7064:5	tabl	JJ	O	O
3	STRIBILD.xml:S1:7070:1	3	CD	O	O
.	STRIBILD.xml:S1:7071:1	.	.	O	O

Table	STRIBILD.xml:S1:7077:5	tabl	JJ	O	O
3	STRIBILD.xml:S1:7083:1	3	CD	O	O
Laboratory	STRIBILD.xml:S1:7085:10	laboratori	NNP	O	O
Abnormalities	STRIBILD.xml:S1:7096:13	abnorm	NNP	O	O
(	STRIBILD.xml:S1:7110:1	(	(	O	O
Grades	STRIBILD.xml:S1:7111:6	grade	NNP	O	O
3	STRIBILD.xml:S1:7118:1	3	CD	O	O
-	STRIBILD.xml:S1:7119:1	-	:	O	O
4	STRIBILD.xml:S1:7120:1	4	CD	O	O
)	STRIBILD.xml:S1:7121:1	)	)	O	O
Reported	STRIBILD.xml:S1:7123:8	report	VBD	O	O
in	STRIBILD.xml:S1:7132:2	in	IN	O	O
2%	STRIBILD.xml:S1:7138:2	2%	CD	O	O
of	STRIBILD.xml:S1:7141:2	of	IN	O	O
Subjects	STRIBILD.xml:S1:7144:8	subject	NNS	O	O
Receiving	STRIBILD.xml:S1:7153:9	receiv	VBG	O	O
STRIBILD	STRIBILD.xml:S1:7163:8	stribild	NNP	O	O
in	STRIBILD.xml:S1:7172:2	in	IN	O	O
Studies	STRIBILD.xml:S1:7175:7	studi	NNP	O	O
102	STRIBILD.xml:S1:7183:3	102	CD	O	O
and	STRIBILD.xml:S1:7187:3	and	CC	O	O
103	STRIBILD.xml:S1:7191:3	103	CD	O	O
(	STRIBILD.xml:S1:7195:1	(	(	O	O
Week	STRIBILD.xml:S1:7196:4	week	JJ	O	O
144	STRIBILD.xml:S1:7201:3	144	CD	O	O
analysis	STRIBILD.xml:S1:7205:8	analysi	NN	O	O
)	STRIBILD.xml:S1:7213:1	)	)	O	O

STRIBILD	STRIBILD.xml:S1:7267:8	stribild	NNP	O	O
ATRIPLA	STRIBILD.xml:S1:7287:7	atripla	NNP	O	O
ATV	STRIBILD.xml:S1:7303:3	atv	NNP	O	O
RTV	STRIBILD.xml:S1:7309:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S1:7315:7	truvada	NNP	O	O

Laboratory	STRIBILD.xml:S1:7333:10	laboratori	NN	O	O

Parameter	STRIBILD.xml:S1:7344:9	paramet	NNP	O	O
Abnormality	STRIBILD.xml:S1:7354:11	abnorm	NNP	O	O
,	STRIBILD.xml:S1:7369:1	,	,	O	O
N	STRIBILD.xml:S1:7382:1	N	NNP	O	O
701	STRIBILD.xml:S1:7384:3	701	CD	O	O
N	STRIBILD.xml:S1:7402:1	N	NNP	O	O
352	STRIBILD.xml:S1:7404:3	352	CD	O	O
N	STRIBILD.xml:S1:7424:1	N	NNP	O	O
355	STRIBILD.xml:S1:7426:3	355	CD	O	O

AST	STRIBILD.xml:S1:7442:3	ast	NNP	B-AdverseReaction	O
(	STRIBILD.xml:S1:7446:1	(	(	O	O
5.0	STRIBILD.xml:S1:7448:3	5.0	CD	I-AdverseReaction	O
ULN	STRIBILD.xml:S1:7454:3	uln	NNP	I-AdverseReaction	O
)	STRIBILD.xml:S1:7457:1	)	)	O	O
3%	STRIBILD.xml:S1:7495:2	3%	CD	O	O
6%	STRIBILD.xml:S1:7515:2	6%	CD	O	O
6%	STRIBILD.xml:S1:7536:2	6%	CD	O	O

ALT	STRIBILD.xml:S1:7553:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
(	STRIBILD.xml:S1:7557:1	(	(	O	O
3.0	STRIBILD.xml:S1:7559:3	3.0	CD	I-AdverseReaction	O
ULN	STRIBILD.xml:S1:7565:3	uln	NNP	I-AdverseReaction	O
)	STRIBILD.xml:S1:7568:1	)	)	O	O
2%	STRIBILD.xml:S1:7606:2	2%	CD	O	O
5%	STRIBILD.xml:S1:7626:2	5%	CD	O	O
4%	STRIBILD.xml:S1:7647:2	4%	CD	O	O

Amylase	STRIBILD.xml:S1:7664:7	amylas	NNP	B-AdverseReaction	O
(	STRIBILD.xml:S1:7671:1	(	(	O	O
2.0	STRIBILD.xml:S1:7673:3	2.0	CD	I-AdverseReaction	O
ULN	STRIBILD.xml:S1:7679:3	uln	NNP	I-AdverseReaction	O
)	STRIBILD.xml:S1:7682:1	)	)	O	O
3%	STRIBILD.xml:S1:7717:2	3%	CD	O	O
3%	STRIBILD.xml:S1:7737:2	3%	CD	O	O
5%	STRIBILD.xml:S1:7758:2	5%	CD	O	O

Creatine	STRIBILD.xml:S1:7775:8	creatin	NNP	B-AdverseReaction	O
Kinase	STRIBILD.xml:S1:7784:6	kinas	NNP	I-AdverseReaction	O
(	STRIBILD.xml:S1:7791:1	(	(	O	O
10.0	STRIBILD.xml:S1:7795:4	10.0	CD	I-AdverseReaction	O
ULN	STRIBILD.xml:S1:7802:3	uln	NNP	I-AdverseReaction	O
)	STRIBILD.xml:S1:7805:1	)	)	O	O
8%	STRIBILD.xml:S1:7828:2	8%	CD	O	O
15%	STRIBILD.xml:S1:7847:3	15%	CD	O	O
11%	STRIBILD.xml:S1:7869:3	11%	CD	O	O

Urine	STRIBILD.xml:S1:7886:5	urin	NNP	B-AdverseReaction	O
RBC	STRIBILD.xml:S1:7892:3	rbc	NNP	I-AdverseReaction	O
(	STRIBILD.xml:S1:7896:1	(	(	O	O
Hematuria	STRIBILD.xml:S1:7897:9	hematuria	NNP	B-AdverseReaction	B-AdverseReaction
)	STRIBILD.xml:S1:7906:1	)	)	O	O
(	STRIBILD.xml:S1:7908:1	(	(	O	O
75	STRIBILD.xml:S1:7911:2	75	CD	O	O
RBC	STRIBILD.xml:S1:7914:3	rbc	NNP	O	O
HPF	STRIBILD.xml:S1:7918:3	hpf	NNP	O	O
)	STRIBILD.xml:S1:7921:1	)	)	O	O
4%	STRIBILD.xml:S1:7939:2	4%	CD	O	O
2%	STRIBILD.xml:S1:7959:2	2%	CD	O	O
4%	STRIBILD.xml:S1:7980:2	4%	CD	O	O

In	STRIBILD.xml:S1:8006:2	In	IN	O	O
Study	STRIBILD.xml:S1:8009:5	studi	NNP	O	O
103	STRIBILD.xml:S1:8015:3	103	CD	O	O
,	STRIBILD.xml:S1:8018:1	,	,	O	O
BMD	STRIBILD.xml:S1:8020:3	bmd	NNP	O	O
was	STRIBILD.xml:S1:8024:3	wa	VBD	O	O
assessed	STRIBILD.xml:S1:8028:8	assess	VBN	O	O
by	STRIBILD.xml:S1:8037:2	by	IN	O	O
DEXA	STRIBILD.xml:S1:8040:4	dexa	NNP	O	O
in	STRIBILD.xml:S1:8045:2	in	IN	O	O
a	STRIBILD.xml:S1:8048:1	a	DT	O	O
non	STRIBILD.xml:S1:8050:3	non	JJ	O	O
-	STRIBILD.xml:S1:8053:1	-	:	O	O
random	STRIBILD.xml:S1:8054:6	random	NN	O	O
subset	STRIBILD.xml:S1:8061:6	subset	NN	O	O
of	STRIBILD.xml:S1:8068:2	of	IN	O	O
120	STRIBILD.xml:S1:8071:3	120	CD	O	O
subjects	STRIBILD.xml:S1:8075:8	subject	NNS	O	O
(	STRIBILD.xml:S1:8084:1	(	(	O	O
STRIBILD	STRIBILD.xml:S1:8085:8	stribild	NNP	O	O
group	STRIBILD.xml:S1:8094:5	group	NN	O	O
N	STRIBILD.xml:S1:8100:1	N	NNP	O	O
54	STRIBILD.xml:S1:8104:2	54	CD	O	O
;	STRIBILD.xml:S1:8106:1	;	:	O	O
ATV	STRIBILD.xml:S1:8108:3	atv	NNP	O	O
RTV	STRIBILD.xml:S1:8114:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S1:8120:7	truvada	NNP	O	O
group	STRIBILD.xml:S1:8128:5	group	NN	O	O
N	STRIBILD.xml:S1:8134:1	N	NNP	O	O
66	STRIBILD.xml:S1:8138:2	66	CD	O	O
)	STRIBILD.xml:S1:8140:1	)	)	O	O
.	STRIBILD.xml:S1:8141:1	.	.	O	O

Mean	STRIBILD.xml:S1:8143:4	mean	JJ	O	O
percentage	STRIBILD.xml:S1:8148:10	percentag	NN	O	O
decreases	STRIBILD.xml:S1:8159:9	decreas	NNS	B-AdverseReaction	O
in	STRIBILD.xml:S1:8169:2	in	IN	I-AdverseReaction	O
BMD	STRIBILD.xml:S1:8172:3	bmd	NNP	I-AdverseReaction	O
from	STRIBILD.xml:S1:8176:4	from	IN	O	O
baseline	STRIBILD.xml:S1:8181:8	baselin	NN	O	O
to	STRIBILD.xml:S1:8190:2	to	TO	O	O
Week	STRIBILD.xml:S1:8193:4	week	VB	O	O
144	STRIBILD.xml:S1:8198:3	144	CD	O	O
in	STRIBILD.xml:S1:8202:2	in	IN	O	O
the	STRIBILD.xml:S1:8205:3	the	DT	O	O
STRIBILD	STRIBILD.xml:S1:8209:8	stribild	NNP	O	O
group	STRIBILD.xml:S1:8218:5	group	NN	O	O
were	STRIBILD.xml:S1:8224:4	were	VBD	O	O
comparable	STRIBILD.xml:S1:8229:10	compar	JJ	O	O
to	STRIBILD.xml:S1:8240:2	to	TO	O	O
the	STRIBILD.xml:S1:8243:3	the	DT	O	O
ATV	STRIBILD.xml:S1:8247:3	atv	NNP	O	O
RTV	STRIBILD.xml:S1:8253:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S1:8259:7	truvada	NNP	O	O
group	STRIBILD.xml:S1:8267:5	group	NN	O	O
at	STRIBILD.xml:S1:8273:2	at	IN	O	O
the	STRIBILD.xml:S1:8276:3	the	DT	O	O
lumbar	STRIBILD.xml:S1:8280:6	lumbar	NN	O	O
spine	STRIBILD.xml:S1:8287:5	spine	NN	O	O
(-	STRIBILD.xml:S1:8293:2	(-	JJ	O	O
1.43%	STRIBILD.xml:S1:8295:5	1.43%	CD	O	O
versus	STRIBILD.xml:S1:8301:6	versu	NN	O	O
-	STRIBILD.xml:S1:8308:1	-	:	O	O
3.68%	STRIBILD.xml:S1:8309:5	3.68%	CD	O	O
,	STRIBILD.xml:S1:8314:1	,	,	O	O
respectively	STRIBILD.xml:S1:8316:12	respect	RB	O	O
)	STRIBILD.xml:S1:8328:1	)	)	O	O
and	STRIBILD.xml:S1:8330:3	and	CC	O	O
at	STRIBILD.xml:S1:8334:2	at	IN	O	O
the	STRIBILD.xml:S1:8337:3	the	DT	O	O
hip	STRIBILD.xml:S1:8341:3	hip	NN	O	O
(-	STRIBILD.xml:S1:8345:2	(-	JJ	O	O
2.83%	STRIBILD.xml:S1:8347:5	2.83%	CD	O	O
versus	STRIBILD.xml:S1:8353:6	versu	NN	O	O
-	STRIBILD.xml:S1:8360:1	-	:	O	O
3.77%	STRIBILD.xml:S1:8361:5	3.77%	CD	O	O
,	STRIBILD.xml:S1:8366:1	,	,	O	O
respectively	STRIBILD.xml:S1:8368:12	respect	RB	O	O
)	STRIBILD.xml:S1:8380:1	)	)	O	O
.	STRIBILD.xml:S1:8381:1	.	.	O	O

In	STRIBILD.xml:S1:8383:2	In	IN	O	O
Studies	STRIBILD.xml:S1:8386:7	studi	NNP	O	O
102	STRIBILD.xml:S1:8394:3	102	CD	O	O
and	STRIBILD.xml:S1:8398:3	and	CC	O	O
103	STRIBILD.xml:S1:8402:3	103	CD	O	O
,	STRIBILD.xml:S1:8405:1	,	,	O	O
bone	STRIBILD.xml:S1:8407:4	bone	NN	B-AdverseReaction	B-AdverseReaction
fractures	STRIBILD.xml:S1:8412:9	fractur	NNS	I-AdverseReaction	I-AdverseReaction
occurred	STRIBILD.xml:S1:8422:8	occur	VBD	O	O
in	STRIBILD.xml:S1:8431:2	in	IN	O	O
27	STRIBILD.xml:S1:8434:2	27	CD	O	O
subjects	STRIBILD.xml:S1:8437:8	subject	NNS	O	O
(	STRIBILD.xml:S1:8446:1	(	(	O	O
3.9%	STRIBILD.xml:S1:8447:4	3.9%	CD	O	O
)	STRIBILD.xml:S1:8451:1	)	)	O	O
in	STRIBILD.xml:S1:8453:2	in	IN	O	O
the	STRIBILD.xml:S1:8456:3	the	DT	O	O
STRIBILD	STRIBILD.xml:S1:8460:8	stribild	NNP	O	O
group	STRIBILD.xml:S1:8469:5	group	NN	O	O
,	STRIBILD.xml:S1:8474:1	,	,	O	O
8	STRIBILD.xml:S1:8476:1	8	CD	O	O
subjects	STRIBILD.xml:S1:8478:8	subject	NNS	O	O
(	STRIBILD.xml:S1:8487:1	(	(	O	O
2.3%	STRIBILD.xml:S1:8488:4	2.3%	CD	O	O
)	STRIBILD.xml:S1:8492:1	)	)	O	O
in	STRIBILD.xml:S1:8494:2	in	IN	O	O
the	STRIBILD.xml:S1:8497:3	the	DT	O	O
ATRIPLA	STRIBILD.xml:S1:8501:7	atripla	NNP	O	O
group	STRIBILD.xml:S1:8509:5	group	NN	O	O
,	STRIBILD.xml:S1:8514:1	,	,	O	O
and	STRIBILD.xml:S1:8516:3	and	CC	O	O
19	STRIBILD.xml:S1:8520:2	19	CD	O	O
subjects	STRIBILD.xml:S1:8523:8	subject	NNS	O	O
(	STRIBILD.xml:S1:8532:1	(	(	O	O
5.4%	STRIBILD.xml:S1:8533:4	5.4%	CD	O	O
)	STRIBILD.xml:S1:8537:1	)	)	O	O
in	STRIBILD.xml:S1:8539:2	in	IN	O	O
the	STRIBILD.xml:S1:8542:3	the	DT	O	O
ATV	STRIBILD.xml:S1:8546:3	atv	NNP	O	O
RTV	STRIBILD.xml:S1:8552:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S1:8558:7	truvada	NNP	O	O
group	STRIBILD.xml:S1:8566:5	group	NN	O	O
.	STRIBILD.xml:S1:8571:1	.	.	O	O

These	STRIBILD.xml:S1:8573:5	these	DT	O	O
findings	STRIBILD.xml:S1:8579:8	find	NNS	O	O
were	STRIBILD.xml:S1:8588:4	were	VBD	O	O
consistent	STRIBILD.xml:S1:8593:10	consist	JJ	O	O
with	STRIBILD.xml:S1:8604:4	with	IN	O	O
data	STRIBILD.xml:S1:8609:4	data	NNS	O	O
from	STRIBILD.xml:S1:8614:4	from	IN	O	O
an	STRIBILD.xml:S1:8619:2	an	DT	O	O
earlier	STRIBILD.xml:S1:8622:7	earlier	JJR	O	O
144	STRIBILD.xml:S1:8630:3	144	CD	O	O
-	STRIBILD.xml:S1:8633:1	-	:	O	O
week	STRIBILD.xml:S1:8634:4	week	NN	O	O
trial	STRIBILD.xml:S1:8639:5	trial	NN	O	O
of	STRIBILD.xml:S1:8645:2	of	IN	O	O
treatment	STRIBILD.xml:S1:8648:9	treatment	NN	O	O
-	STRIBILD.xml:S1:8657:1	-	:	O	O
naive	STRIBILD.xml:S1:8658:5	naiv	JJ	O	O
subjects	STRIBILD.xml:S1:8664:8	subject	NNS	O	O
receiving	STRIBILD.xml:S1:8673:9	receiv	VBG	O	O
tenofovir	STRIBILD.xml:S1:8683:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S1:8693:2	DF	NNP	O	O
lamivudine	STRIBILD.xml:S1:8698:10	lamivudin	NN	O	O
efavirenz	STRIBILD.xml:S1:8711:9	efavirenz	NN	O	O
.	STRIBILD.xml:S1:8720:1	.	.	O	O

Proteinuria	STRIBILD.xml:S1:8726:11	proteinuria	NNS	B-AdverseReaction	O

(	STRIBILD.xml:S1:8738:1	(	(	O	O
all	STRIBILD.xml:S1:8739:3	all	DT	O	O
grades	STRIBILD.xml:S1:8743:6	grade	NNS	O	O
)	STRIBILD.xml:S1:8749:1	)	)	O	O
occurred	STRIBILD.xml:S1:8751:8	occur	VBD	O	O
in	STRIBILD.xml:S1:8760:2	in	IN	O	O
52%	STRIBILD.xml:S1:8763:3	52%	CD	O	O
of	STRIBILD.xml:S1:8767:2	of	IN	O	O
subjects	STRIBILD.xml:S1:8770:8	subject	NNS	O	O
receiving	STRIBILD.xml:S1:8779:9	receiv	VBG	O	O
STRIBILD	STRIBILD.xml:S1:8789:8	stribild	NNP	O	O
,	STRIBILD.xml:S1:8797:1	,	,	O	O
41%	STRIBILD.xml:S1:8799:3	41%	CD	O	O
of	STRIBILD.xml:S1:8803:2	of	IN	O	O
subjects	STRIBILD.xml:S1:8806:8	subject	NNS	O	O
receiving	STRIBILD.xml:S1:8815:9	receiv	VBG	O	O
ATRIPLA	STRIBILD.xml:S1:8825:7	atripla	NNP	O	O
,	STRIBILD.xml:S1:8832:1	,	,	O	O
and	STRIBILD.xml:S1:8834:3	and	CC	O	O
42%	STRIBILD.xml:S1:8838:3	42%	CD	O	O
of	STRIBILD.xml:S1:8842:2	of	IN	O	O
subjects	STRIBILD.xml:S1:8845:8	subject	NNS	O	O
receiving	STRIBILD.xml:S1:8854:9	receiv	VBG	O	O
ATV	STRIBILD.xml:S1:8864:3	atv	NNP	O	O
RTV	STRIBILD.xml:S1:8870:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S1:8876:7	truvada	NNP	O	O
.	STRIBILD.xml:S1:8883:1	.	.	O	O

The	STRIBILD.xml:S1:8889:3	the	DT	O	O
cobicistat	STRIBILD.xml:S1:8893:10	cobicistat	JJ	O	O
component	STRIBILD.xml:S1:8904:9	compon	NN	O	O
of	STRIBILD.xml:S1:8914:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S1:8917:8	stribild	NNP	O	O
has	STRIBILD.xml:S1:8926:3	ha	VBZ	O	O
been	STRIBILD.xml:S1:8930:4	been	VBN	O	O
shown	STRIBILD.xml:S1:8935:5	shown	VBN	O	O
to	STRIBILD.xml:S1:8941:2	to	TO	O	O
increase	STRIBILD.xml:S1:8944:8	increas	VB	B-AdverseReaction	B-AdverseReaction
serum	STRIBILD.xml:S1:8953:5	serum	JJ	I-AdverseReaction	I-AdverseReaction
creatinine	STRIBILD.xml:S1:8959:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
and	STRIBILD.xml:S1:8970:3	and	CC	O	O
decrease	STRIBILD.xml:S1:8974:8	decreas	NN	B-AdverseReaction	B-AdverseReaction
estimated	STRIBILD.xml:S1:8983:9	estim	VBN	I-AdverseReaction	I-AdverseReaction
creatinine	STRIBILD.xml:S1:8993:10	creatinin	JJ	I-AdverseReaction	I-AdverseReaction
clearance	STRIBILD.xml:S1:9004:9	clearanc	NN	I-AdverseReaction	I-AdverseReaction
due	STRIBILD.xml:S1:9014:3	due	JJ	O	O
to	STRIBILD.xml:S1:9018:2	to	TO	O	O
inhibition	STRIBILD.xml:S1:9021:10	inhibit	NN	O	O
of	STRIBILD.xml:S1:9032:2	of	IN	O	O
tubular	STRIBILD.xml:S1:9035:7	tubular	JJ	O	O
secretion	STRIBILD.xml:S1:9043:9	secret	NN	O	O
of	STRIBILD.xml:S1:9053:2	of	IN	O	O
creatinine	STRIBILD.xml:S1:9056:10	creatinin	NN	O	O
without	STRIBILD.xml:S1:9067:7	without	IN	O	O
affecting	STRIBILD.xml:S1:9075:9	affect	VBG	B-AdverseReaction	O
renal	STRIBILD.xml:S1:9085:5	renal	JJ	I-AdverseReaction	O
glomerular	STRIBILD.xml:S1:9091:10	glomerular	JJ	I-AdverseReaction	O
function	STRIBILD.xml:S1:9102:8	function	NN	I-AdverseReaction	O
.	STRIBILD.xml:S1:9110:1	.	.	O	O

In	STRIBILD.xml:S1:9112:2	In	IN	O	O
Studies	STRIBILD.xml:S1:9115:7	studi	NNP	O	O
102	STRIBILD.xml:S1:9123:3	102	CD	O	O
and	STRIBILD.xml:S1:9127:3	and	CC	O	O
103	STRIBILD.xml:S1:9131:3	103	CD	O	O
,	STRIBILD.xml:S1:9134:1	,	,	O	O
increases	STRIBILD.xml:S1:9136:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	STRIBILD.xml:S1:9146:2	in	IN	I-AdverseReaction	I-AdverseReaction
serum	STRIBILD.xml:S1:9149:5	serum	JJ	I-AdverseReaction	I-AdverseReaction
creatinine	STRIBILD.xml:S1:9155:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
and	STRIBILD.xml:S1:9166:3	and	CC	O	O
decreases	STRIBILD.xml:S1:9170:9	decreas	NNS	B-AdverseReaction	B-AdverseReaction
in	STRIBILD.xml:S1:9180:2	in	IN	I-AdverseReaction	I-AdverseReaction
estimated	STRIBILD.xml:S1:9183:9	estim	VBN	I-AdverseReaction	I-AdverseReaction
creatinine	STRIBILD.xml:S1:9193:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
clearance	STRIBILD.xml:S1:9204:9	clearanc	NN	I-AdverseReaction	I-AdverseReaction
occurred	STRIBILD.xml:S1:9214:8	occur	VBD	O	O
early	STRIBILD.xml:S1:9223:5	earli	JJ	O	O
in	STRIBILD.xml:S1:9229:2	in	IN	O	O
treatment	STRIBILD.xml:S1:9232:9	treatment	NN	O	O
with	STRIBILD.xml:S1:9242:4	with	IN	O	O
STRIBILD	STRIBILD.xml:S1:9247:8	stribild	NNP	O	O
,	STRIBILD.xml:S1:9255:1	,	,	O	O
after	STRIBILD.xml:S1:9257:5	after	IN	O	O
which	STRIBILD.xml:S1:9263:5	which	WDT	O	O
they	STRIBILD.xml:S1:9269:4	they	PRP	O	O
stabilized	STRIBILD.xml:S1:9274:10	stabil	VBD	O	O
.	STRIBILD.xml:S1:9284:1	.	.	O	O

Table	STRIBILD.xml:S1:9286:5	tabl	JJ	O	O
4	STRIBILD.xml:S1:9292:1	4	CD	O	O
displays	STRIBILD.xml:S1:9294:8	display	VBZ	O	O
the	STRIBILD.xml:S1:9303:3	the	DT	O	O
mean	STRIBILD.xml:S1:9307:4	mean	JJ	O	O
changes	STRIBILD.xml:S1:9312:7	chang	NNS	O	B-AdverseReaction
in	STRIBILD.xml:S1:9320:2	in	IN	O	I-AdverseReaction
serum	STRIBILD.xml:S1:9323:5	serum	NN	O	I-AdverseReaction
creatinine	STRIBILD.xml:S1:9329:10	creatinin	NN	O	I-AdverseReaction
and	STRIBILD.xml:S1:9340:3	and	CC	O	O
eGFR	STRIBILD.xml:S1:9344:4	egfr	NN	O	O
levels	STRIBILD.xml:S1:9349:6	level	NNS	O	O
at	STRIBILD.xml:S1:9356:2	at	IN	O	O
Week	STRIBILD.xml:S1:9359:4	week	NNP	O	O
144	STRIBILD.xml:S1:9364:3	144	CD	O	O
and	STRIBILD.xml:S1:9368:3	and	CC	O	O
the	STRIBILD.xml:S1:9372:3	the	DT	O	O
percentage	STRIBILD.xml:S1:9376:10	percentag	NN	O	O
of	STRIBILD.xml:S1:9387:2	of	IN	O	O
subjects	STRIBILD.xml:S1:9390:8	subject	NNS	O	O
with	STRIBILD.xml:S1:9399:4	with	IN	O	O
elevations	STRIBILD.xml:S1:9404:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	STRIBILD.xml:S1:9415:2	in	IN	I-AdverseReaction	I-AdverseReaction
serum	STRIBILD.xml:S1:9418:5	serum	JJ	I-AdverseReaction	I-AdverseReaction
creatinine	STRIBILD.xml:S1:9424:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S1:9435:1	(	(	O	O
All	STRIBILD.xml:S1:9436:3	all	NNP	O	O
Grades	STRIBILD.xml:S1:9440:6	grade	NNP	O	O
)	STRIBILD.xml:S1:9446:1	)	)	O	O
.	STRIBILD.xml:S1:9447:1	.	.	O	O

Table	STRIBILD.xml:S1:9453:5	tabl	JJ	O	O
4	STRIBILD.xml:S1:9459:1	4	CD	O	O
Change	STRIBILD.xml:S1:9461:6	chang	NN	O	O
from	STRIBILD.xml:S1:9468:4	from	IN	O	O
Baseline	STRIBILD.xml:S1:9473:8	baselin	NNP	O	O
in	STRIBILD.xml:S1:9482:2	in	IN	O	O
Serum	STRIBILD.xml:S1:9485:5	serum	NNP	O	O
Creatinine	STRIBILD.xml:S1:9491:10	creatinin	NNP	O	O
and	STRIBILD.xml:S1:9502:3	and	CC	O	O
eGFR	STRIBILD.xml:S1:9506:4	egfr	NN	O	O
and	STRIBILD.xml:S1:9511:3	and	CC	O	O
Incidence	STRIBILD.xml:S1:9515:9	incid	NNP	O	O
of	STRIBILD.xml:S1:9525:2	of	IN	O	O
Elevated	STRIBILD.xml:S1:9528:8	elev	NNP	B-AdverseReaction	B-AdverseReaction
Serum	STRIBILD.xml:S1:9537:5	serum	NNP	I-AdverseReaction	I-AdverseReaction
Creatinine	STRIBILD.xml:S1:9543:10	creatinin	NNP	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S1:9554:1	(	(	O	O
All	STRIBILD.xml:S1:9555:3	all	NNP	O	O
Grades	STRIBILD.xml:S1:9559:6	grade	NNP	O	O
)	STRIBILD.xml:S1:9565:1	)	)	O	O
in	STRIBILD.xml:S1:9567:2	in	IN	O	O
Studies	STRIBILD.xml:S1:9570:7	studi	NNP	O	O
102	STRIBILD.xml:S1:9578:3	102	CD	O	O
and	STRIBILD.xml:S1:9582:3	and	CC	O	O
103	STRIBILD.xml:S1:9586:3	103	CD	O	O
at	STRIBILD.xml:S1:9590:2	at	IN	O	O
Week	STRIBILD.xml:S1:9593:4	week	NNP	O	O
144	STRIBILD.xml:S1:9598:3	144	CD	O	O

STRIBILD	STRIBILD.xml:S1:9650:8	stribild	NNP	O	O
(	STRIBILD.xml:S1:9658:1	(	(	O	O
N	STRIBILD.xml:S1:9659:1	N	NNP	O	O
701	STRIBILD.xml:S1:9661:3	701	CD	O	O
)	STRIBILD.xml:S1:9664:1	)	)	O	O
ATRIPLA	STRIBILD.xml:S1:9671:7	atripla	NNP	O	O
(	STRIBILD.xml:S1:9678:1	(	(	O	O
N	STRIBILD.xml:S1:9679:1	N	NNP	O	O
352	STRIBILD.xml:S1:9681:3	352	CD	O	O
)	STRIBILD.xml:S1:9684:1	)	)	O	O
ATV	STRIBILD.xml:S1:9689:3	atv	NNP	O	O
RTV	STRIBILD.xml:S1:9695:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S1:9701:7	truvada	NNP	O	O
(	STRIBILD.xml:S1:9708:1	(	(	O	O
N	STRIBILD.xml:S1:9709:1	N	NNP	O	O
355	STRIBILD.xml:S1:9711:3	355	CD	O	O
)	STRIBILD.xml:S1:9714:1	)	)	O	O

Serum	STRIBILD.xml:S1:9723:5	serum	NN	O	O

Creatinine	STRIBILD.xml:S1:9729:10	creatinin	NNP	O	O
(	STRIBILD.xml:S1:9740:1	(	(	O	O
mg	STRIBILD.xml:S1:9741:2	mg	FW	O	O
dL	STRIBILD.xml:S1:9744:2	dL	NN	O	O
)	STRIBILD.xml:S1:9746:1	)	)	O	O
0.14	STRIBILD.xml:S1:9770:4	0.14	CD	O	O
(	STRIBILD.xml:S1:9775:1	(	(	O	O
-	STRIBILD.xml:S1:9778:1	-	:	O	O
0.14	STRIBILD.xml:S1:9779:4	0.14	CD	O	O
)	STRIBILD.xml:S1:9783:1	)	)	O	O
0.01	STRIBILD.xml:S1:9790:4	0.01	CD	O	O
(	STRIBILD.xml:S1:9795:1	(	(	O	O
-	STRIBILD.xml:S1:9798:1	-	:	O	O
0.12	STRIBILD.xml:S1:9799:4	0.12	CD	O	O
)	STRIBILD.xml:S1:9803:1	)	)	O	O
0.09	STRIBILD.xml:S1:9811:4	0.09	CD	O	O
(	STRIBILD.xml:S1:9816:1	(	(	O	O
-	STRIBILD.xml:S1:9819:1	-	:	O	O
0.15	STRIBILD.xml:S1:9820:4	0.15	CD	O	O
)	STRIBILD.xml:S1:9824:1	)	)	O	O

eGFR	STRIBILD.xml:S1:9834:4	egfr	NN	O	O
by	STRIBILD.xml:S1:9839:2	by	IN	O	O
Cockcroft	STRIBILD.xml:S1:9842:9	cockcroft	NNP	O	O
-	STRIBILD.xml:S1:9851:1	-	:	O	O
Gault	STRIBILD.xml:S1:9852:5	gault	NN	O	O
(	STRIBILD.xml:S1:9858:1	(	(	O	O
mL	STRIBILD.xml:S1:9859:2	mL	JJ	O	O
minute	STRIBILD.xml:S1:9862:6	minut	NN	O	O
)	STRIBILD.xml:S1:9868:1	)	)	O	O
-	STRIBILD.xml:S1:9880:1	-	:	O	O
14.0	STRIBILD.xml:S1:9881:4	14.0	CD	O	O
(	STRIBILD.xml:S1:9886:1	(	(	O	O
-	STRIBILD.xml:S1:9889:1	-	:	O	O
16.6	STRIBILD.xml:S1:9890:4	16.6	CD	O	O
)	STRIBILD.xml:S1:9894:1	)	)	O	O
-	STRIBILD.xml:S1:9901:1	-	:	O	O
1.9	STRIBILD.xml:S1:9902:3	1.9	CD	O	O
(	STRIBILD.xml:S1:9906:1	(	(	O	O
-	STRIBILD.xml:S1:9909:1	-	:	O	O
17.9	STRIBILD.xml:S1:9910:4	17.9	CD	O	O
)	STRIBILD.xml:S1:9914:1	)	)	O	O
-	STRIBILD.xml:S1:9922:1	-	:	O	O
9.8	STRIBILD.xml:S1:9923:3	9.8	CD	O	O
(	STRIBILD.xml:S1:9927:1	(	(	O	O
-	STRIBILD.xml:S1:9930:1	-	:	O	O
19.4	STRIBILD.xml:S1:9931:4	19.4	CD	O	O
)	STRIBILD.xml:S1:9935:1	)	)	O	O

Subjects	STRIBILD.xml:S1:9945:8	subject	NNS	O	O
with	STRIBILD.xml:S1:9954:4	with	IN	O	O
Elevations	STRIBILD.xml:S1:9959:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	STRIBILD.xml:S1:9970:2	in	IN	I-AdverseReaction	I-AdverseReaction
Serum	STRIBILD.xml:S1:9973:5	serum	NNP	I-AdverseReaction	I-AdverseReaction
Creatinine	STRIBILD.xml:S1:9979:10	creatinin	NNP	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S1:9990:1	(	(	O	O
All	STRIBILD.xml:S1:9991:3	all	NNP	O	O
Grades	STRIBILD.xml:S1:9995:6	grade	NNP	O	O
)(	STRIBILD.xml:S1:10001:2	)(	NNP	O	O
)	STRIBILD.xml:S1:10004:1	)	)	O	O
12	STRIBILD.xml:S1:10015:2	12	CD	O	O
2	STRIBILD.xml:S1:10035:1	2	CD	O	O
6	STRIBILD.xml:S1:10057:1	6	CD	O	O

Emtricitabine	STRIBILD.xml:S1:10086:13	emtricitabin	NN	O	O
or	STRIBILD.xml:S1:10100:2	or	CC	O	O
Tenofovir	STRIBILD.xml:S1:10103:9	tenofovir	NNP	O	O
DF	STRIBILD.xml:S1:10113:2	DF	NNP	O	O
:	STRIBILD.xml:S1:10115:1	:	:	O	O
In	STRIBILD.xml:S1:10118:2	In	IN	O	O
addition	STRIBILD.xml:S1:10121:8	addit	NN	O	O
to	STRIBILD.xml:S1:10130:2	to	TO	O	O
the	STRIBILD.xml:S1:10133:3	the	DT	O	O
laboratory	STRIBILD.xml:S1:10137:10	laboratori	NN	O	O
abnormalities	STRIBILD.xml:S1:10148:13	abnorm	NNS	O	O
observed	STRIBILD.xml:S1:10162:8	observ	VBN	O	O
with	STRIBILD.xml:S1:10171:4	with	IN	O	O
STRIBILD	STRIBILD.xml:S1:10176:8	stribild	NNP	O	O
,	STRIBILD.xml:S1:10184:1	,	,	O	O
the	STRIBILD.xml:S1:10186:3	the	DT	O	O
following	STRIBILD.xml:S1:10190:9	follow	JJ	O	O
laboratory	STRIBILD.xml:S1:10200:10	laboratori	NN	O	O
abnormalities	STRIBILD.xml:S1:10211:13	abnorm	NNS	O	O
have	STRIBILD.xml:S1:10225:4	have	VBP	O	O
been	STRIBILD.xml:S1:10230:4	been	VBN	O	O
previously	STRIBILD.xml:S1:10235:10	previous	RB	O	O
reported	STRIBILD.xml:S1:10246:8	report	VBN	O	O
in	STRIBILD.xml:S1:10255:2	in	IN	O	O
subjects	STRIBILD.xml:S1:10258:8	subject	NNS	O	O
treated	STRIBILD.xml:S1:10267:7	treat	VBN	O	O
with	STRIBILD.xml:S1:10275:4	with	IN	O	O
emtricitabine	STRIBILD.xml:S1:10280:13	emtricitabin	NN	O	O
or	STRIBILD.xml:S1:10294:2	or	CC	O	O
tenofovir	STRIBILD.xml:S1:10297:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S1:10307:2	DF	NNP	O	O
with	STRIBILD.xml:S1:10310:4	with	IN	O	O
other	STRIBILD.xml:S1:10315:5	other	JJ	O	O
antiretroviral	STRIBILD.xml:S1:10321:14	antiretrovir	JJ	O	O
agents	STRIBILD.xml:S1:10336:6	agent	NNS	O	O
in	STRIBILD.xml:S1:10343:2	in	IN	O	O
other	STRIBILD.xml:S1:10346:5	other	JJ	O	O
clinical	STRIBILD.xml:S1:10352:8	clinic	JJ	O	O
trials	STRIBILD.xml:S1:10361:6	trial	NNS	O	O
:	STRIBILD.xml:S1:10367:1	:	:	O	O
Grade	STRIBILD.xml:S1:10369:5	grade	VB	O	O
3	STRIBILD.xml:S1:10375:1	3	CD	O	O
or	STRIBILD.xml:S1:10377:2	or	CC	O	O
4	STRIBILD.xml:S1:10380:1	4	CD	O	O
laboratory	STRIBILD.xml:S1:10382:10	laboratori	JJ	O	O
abnormalities	STRIBILD.xml:S1:10393:13	abnorm	NNS	B-AdverseReaction	O
of	STRIBILD.xml:S1:10407:2	of	IN	I-AdverseReaction	O
ALT	STRIBILD.xml:S1:10410:3	alt	NNP	I-AdverseReaction	B-AdverseReaction
(	STRIBILD.xml:S1:10414:1	(	(	O	O
M	STRIBILD.xml:S1:10415:1	M	NNP	O	O
:	STRIBILD.xml:S1:10416:1	:	:	O	O
greater	STRIBILD.xml:S1:10418:7	greater	JJR	O	O
than	STRIBILD.xml:S1:10426:4	than	IN	O	O
215	STRIBILD.xml:S1:10431:3	215	CD	O	O
U	STRIBILD.xml:S1:10435:1	U	NNP	O	O
per	STRIBILD.xml:S1:10437:3	per	IN	O	O
L	STRIBILD.xml:S1:10441:1	L	NNP	O	O
;	STRIBILD.xml:S1:10442:1	;	:	O	O
F	STRIBILD.xml:S1:10444:1	F	NNP	O	O
:	STRIBILD.xml:S1:10445:1	:	:	O	O
greater	STRIBILD.xml:S1:10447:7	greater	JJR	O	O
than	STRIBILD.xml:S1:10455:4	than	IN	O	O
170	STRIBILD.xml:S1:10460:3	170	CD	O	O
U	STRIBILD.xml:S1:10464:1	U	NNP	O	O
per	STRIBILD.xml:S1:10466:3	per	IN	O	O
L	STRIBILD.xml:S1:10470:1	L	NNP	O	O
)	STRIBILD.xml:S1:10471:1	)	)	O	O
,	STRIBILD.xml:S1:10472:1	,	,	O	O
alkaline	STRIBILD.xml:S1:10474:8	alkalin	JJ	I-AdverseReaction	O
phosphatase	STRIBILD.xml:S1:10483:11	phosphatas	NN	I-AdverseReaction	O
(	STRIBILD.xml:S1:10495:1	(	(	O	O
greater	STRIBILD.xml:S1:10496:7	greater	JJR	O	O
than	STRIBILD.xml:S1:10504:4	than	IN	O	O
550	STRIBILD.xml:S1:10509:3	550	CD	O	O
U	STRIBILD.xml:S1:10513:1	U	NNP	O	O
per	STRIBILD.xml:S1:10515:3	per	IN	O	O
L	STRIBILD.xml:S1:10519:1	L	NNP	O	O
)	STRIBILD.xml:S1:10520:1	)	)	O	O
,	STRIBILD.xml:S1:10521:1	,	,	O	O
bilirubin	STRIBILD.xml:S1:10523:9	bilirubin	NN	I-AdverseReaction	B-AdverseReaction
(	STRIBILD.xml:S1:10533:1	(	(	O	O
greater	STRIBILD.xml:S1:10534:7	greater	JJR	O	O
than	STRIBILD.xml:S1:10542:4	than	IN	O	O
2.5	STRIBILD.xml:S1:10547:3	2.5	CD	O	O
ULN	STRIBILD.xml:S1:10553:3	uln	NNP	O	O
)	STRIBILD.xml:S1:10556:1	)	)	O	O
,	STRIBILD.xml:S1:10557:1	,	,	O	O
serum	STRIBILD.xml:S1:10559:5	serum	FW	I-AdverseReaction	B-AdverseReaction
glucose	STRIBILD.xml:S1:10565:7	glucos	FW	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S1:10573:1	(	(	O	O
less	STRIBILD.xml:S1:10574:4	less	JJR	O	O
than	STRIBILD.xml:S1:10579:4	than	IN	O	O
40	STRIBILD.xml:S1:10584:2	40	CD	O	O
or	STRIBILD.xml:S1:10587:2	or	CC	O	O
greater	STRIBILD.xml:S1:10590:7	greater	JJR	O	O
than	STRIBILD.xml:S1:10598:4	than	IN	O	O
250	STRIBILD.xml:S1:10603:3	250	CD	O	O
mg	STRIBILD.xml:S1:10607:2	mg	NNS	O	O
per	STRIBILD.xml:S1:10610:3	per	IN	O	O
dL	STRIBILD.xml:S1:10614:2	dL	NN	O	O
)	STRIBILD.xml:S1:10616:1	)	)	O	O
,	STRIBILD.xml:S1:10617:1	,	,	O	O
glycosuria	STRIBILD.xml:S1:10619:10	glycosuria	FW	I-AdverseReaction	B-AdverseReaction
(	STRIBILD.xml:S1:10630:1	(	(	O	O
greater	STRIBILD.xml:S1:10631:7	greater	JJR	O	O
than	STRIBILD.xml:S1:10639:4	than	IN	O	O
or	STRIBILD.xml:S1:10644:2	or	CC	O	O
equal	STRIBILD.xml:S1:10647:5	equal	JJ	O	O
to	STRIBILD.xml:S1:10653:2	to	TO	O	O
3	STRIBILD.xml:S1:10656:1	3	CD	O	O
)	STRIBILD.xml:S1:10658:1	)	)	O	O
,	STRIBILD.xml:S1:10659:1	,	,	O	O
neutrophils	STRIBILD.xml:S1:10661:11	neutrophil	FW	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S1:10673:1	(	(	O	O
less	STRIBILD.xml:S1:10674:4	less	JJR	O	O
than	STRIBILD.xml:S1:10679:4	than	IN	O	O
750	STRIBILD.xml:S1:10684:3	750	CD	O	O
per	STRIBILD.xml:S1:10688:3	per	IN	O	O
mm	STRIBILD.xml:S1:10692:2	mm	NN	O	O
3	STRIBILD.xml:S1:10696:1	3	CD	O	O
)	STRIBILD.xml:S1:10699:1	)	)	O	O
,	STRIBILD.xml:S1:10700:1	,	,	O	O
fasting	STRIBILD.xml:S1:10702:7	fast	VBG	I-AdverseReaction	O
cholesterol	STRIBILD.xml:S1:10710:11	cholesterol	NN	I-AdverseReaction	O
(	STRIBILD.xml:S1:10722:1	(	(	O	O
greater	STRIBILD.xml:S1:10723:7	greater	JJR	O	O
than	STRIBILD.xml:S1:10731:4	than	IN	O	O
240	STRIBILD.xml:S1:10736:3	240	CD	O	O
mg	STRIBILD.xml:S1:10740:2	mg	NNS	O	O
per	STRIBILD.xml:S1:10743:3	per	IN	O	O
dL	STRIBILD.xml:S1:10747:2	dL	NN	O	O
)	STRIBILD.xml:S1:10749:1	)	)	O	O
,	STRIBILD.xml:S1:10750:1	,	,	O	O
and	STRIBILD.xml:S1:10752:3	and	CC	O	O
fasting	STRIBILD.xml:S1:10756:7	fast	VBG	I-AdverseReaction	O
triglycerides	STRIBILD.xml:S1:10764:13	triglycerid	NNS	I-AdverseReaction	O
(	STRIBILD.xml:S1:10778:1	(	(	O	O
greater	STRIBILD.xml:S1:10779:7	greater	JJR	O	O
than	STRIBILD.xml:S1:10787:4	than	IN	O	O
750	STRIBILD.xml:S1:10792:3	750	CD	O	O
mg	STRIBILD.xml:S1:10796:2	mg	NNS	O	O
per	STRIBILD.xml:S1:10799:3	per	IN	O	O
dL	STRIBILD.xml:S1:10803:2	dL	NN	O	O
)	STRIBILD.xml:S1:10805:1	)	)	O	O
.	STRIBILD.xml:S1:10806:1	.	.	O	O

Serum	STRIBILD.xml:S1:10816:5	serum	NN	O	O

Lipids	STRIBILD.xml:S1:10822:6	lipid	NNS	O	O
:	STRIBILD.xml:S1:10828:1	:	:	O	O
In	STRIBILD.xml:S1:10831:2	In	IN	O	O
the	STRIBILD.xml:S1:10834:3	the	DT	O	O
clinical	STRIBILD.xml:S1:10838:8	clinic	JJ	O	O
trials	STRIBILD.xml:S1:10847:6	trial	NNS	O	O
of	STRIBILD.xml:S1:10854:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S1:10857:8	stribild	NNP	O	O
,	STRIBILD.xml:S1:10865:1	,	,	O	O
a	STRIBILD.xml:S1:10867:1	a	DT	O	O
similar	STRIBILD.xml:S1:10869:7	similar	JJ	O	O
percentage	STRIBILD.xml:S1:10877:10	percentag	NN	O	O
of	STRIBILD.xml:S1:10888:2	of	IN	O	O
subjects	STRIBILD.xml:S1:10891:8	subject	NNS	O	O
receiving	STRIBILD.xml:S1:10900:9	receiv	VBG	O	O
STRIBILD	STRIBILD.xml:S1:10910:8	stribild	NNP	O	O
,	STRIBILD.xml:S1:10918:1	,	,	O	O
ATRIPLA	STRIBILD.xml:S1:10920:7	atripla	NNP	O	O
,	STRIBILD.xml:S1:10927:1	,	,	O	O
and	STRIBILD.xml:S1:10929:3	and	CC	O	O
ATV	STRIBILD.xml:S1:10933:3	atv	NNP	O	O
RTV	STRIBILD.xml:S1:10939:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S1:10945:7	truvada	NNP	O	O
were	STRIBILD.xml:S1:10953:4	were	VBD	O	O
on	STRIBILD.xml:S1:10958:2	on	IN	O	O
lipid	STRIBILD.xml:S1:10961:5	lipid	JJ	O	O
lowering	STRIBILD.xml:S1:10967:8	lower	VBG	O	O
agents	STRIBILD.xml:S1:10976:6	agent	NNS	O	O
at	STRIBILD.xml:S1:10983:2	at	IN	O	O
baseline	STRIBILD.xml:S1:10986:8	baselin	NN	O	O
(	STRIBILD.xml:S1:10995:1	(	(	O	O
12%	STRIBILD.xml:S1:10996:3	12%	CD	O	O
,	STRIBILD.xml:S1:10999:1	,	,	O	O
12%	STRIBILD.xml:S1:11001:3	12%	CD	O	O
,	STRIBILD.xml:S1:11004:1	,	,	O	O
and	STRIBILD.xml:S1:11006:3	and	CC	O	O
13%	STRIBILD.xml:S1:11010:3	13%	CD	O	O
,	STRIBILD.xml:S1:11013:1	,	,	O	O
respectively	STRIBILD.xml:S1:11015:12	respect	RB	O	O
)	STRIBILD.xml:S1:11027:1	)	)	O	O
.	STRIBILD.xml:S1:11028:1	.	.	O	O

While	STRIBILD.xml:S1:11030:5	while	IN	O	O
receiving	STRIBILD.xml:S1:11036:9	receiv	VBG	O	O
study	STRIBILD.xml:S1:11046:5	studi	JJ	O	O
drug	STRIBILD.xml:S1:11052:4	drug	NN	O	O
through	STRIBILD.xml:S1:11057:7	through	IN	O	O
Week	STRIBILD.xml:S1:11065:4	week	NNP	O	O
144	STRIBILD.xml:S1:11070:3	144	CD	O	O
,	STRIBILD.xml:S1:11073:1	,	,	O	O
an	STRIBILD.xml:S1:11075:2	an	DT	O	O
additional	STRIBILD.xml:S1:11078:10	addit	JJ	O	O
11%	STRIBILD.xml:S1:11089:3	11%	CD	O	O
of	STRIBILD.xml:S1:11093:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S1:11096:8	stribild	NNP	O	O
subjects	STRIBILD.xml:S1:11105:8	subject	NNS	O	O
were	STRIBILD.xml:S1:11114:4	were	VBD	O	O
started	STRIBILD.xml:S1:11119:7	start	VBN	O	O
on	STRIBILD.xml:S1:11127:2	on	IN	O	O
lipid	STRIBILD.xml:S1:11130:5	lipid	JJ	O	O
lowering	STRIBILD.xml:S1:11136:8	lower	VBG	O	O
agents	STRIBILD.xml:S1:11145:6	agent	NNS	O	O
,	STRIBILD.xml:S1:11151:1	,	,	O	O
compared	STRIBILD.xml:S1:11153:8	compar	VBN	O	O
to	STRIBILD.xml:S1:11162:2	to	TO	O	O
13%	STRIBILD.xml:S1:11165:3	13%	CD	O	O
of	STRIBILD.xml:S1:11169:2	of	IN	O	O
ATRIPLA	STRIBILD.xml:S1:11172:7	atripla	NNP	O	O
and	STRIBILD.xml:S1:11180:3	and	CC	O	O
12%	STRIBILD.xml:S1:11184:3	12%	CD	O	O
of	STRIBILD.xml:S1:11188:2	of	IN	O	O
ATV	STRIBILD.xml:S1:11191:3	atv	NNP	O	O
RTV	STRIBILD.xml:S1:11197:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S1:11203:7	truvada	NNP	O	O
subjects	STRIBILD.xml:S1:11211:8	subject	NNS	O	O
.	STRIBILD.xml:S1:11219:1	.	.	O	O

Changes	STRIBILD.xml:S1:11225:7	chang	NNS	O	B-AdverseReaction
from	STRIBILD.xml:S1:11233:4	from	IN	O	O
baseline	STRIBILD.xml:S1:11238:8	baselin	NN	O	O
in	STRIBILD.xml:S1:11247:2	in	IN	O	I-AdverseReaction
total	STRIBILD.xml:S1:11250:5	total	JJ	O	I-AdverseReaction
cholesterol	STRIBILD.xml:S1:11256:11	cholesterol	NN	O	I-AdverseReaction
,	STRIBILD.xml:S1:11267:1	,	,	O	O
HDL	STRIBILD.xml:S1:11269:3	hdl	NNP	O	I-AdverseReaction
-	STRIBILD.xml:S1:11272:1	-	:	O	I-AdverseReaction
cholesterol	STRIBILD.xml:S1:11273:11	cholesterol	NN	O	I-AdverseReaction
,	STRIBILD.xml:S1:11284:1	,	,	O	O
LDL	STRIBILD.xml:S1:11286:3	ldl	NNP	O	O
-	STRIBILD.xml:S1:11289:1	-	:	O	O
cholesterol	STRIBILD.xml:S1:11290:11	cholesterol	NN	O	O
,	STRIBILD.xml:S1:11301:1	,	,	O	O
and	STRIBILD.xml:S1:11303:3	and	CC	O	O
triglycerides	STRIBILD.xml:S1:11307:13	triglycerid	NNS	O	O
are	STRIBILD.xml:S1:11321:3	are	VBP	O	O
presented	STRIBILD.xml:S1:11325:9	present	VBN	O	O
in	STRIBILD.xml:S1:11335:2	in	IN	O	O
Table	STRIBILD.xml:S1:11338:5	tabl	JJ	O	O
5	STRIBILD.xml:S1:11344:1	5	CD	O	O
.	STRIBILD.xml:S1:11345:1	.	.	O	O

Table	STRIBILD.xml:S1:11351:5	tabl	JJ	O	O
5	STRIBILD.xml:S1:11357:1	5	CD	O	O
Lipid	STRIBILD.xml:S1:11359:5	lipid	NNP	O	O
Values	STRIBILD.xml:S1:11365:6	valu	NNP	O	O
,	STRIBILD.xml:S1:11371:1	,	,	O	O
Mean	STRIBILD.xml:S1:11373:4	mean	NNP	O	O
Change	STRIBILD.xml:S1:11378:6	chang	NNP	O	O
from	STRIBILD.xml:S1:11385:4	from	IN	O	O
Baseline	STRIBILD.xml:S1:11390:8	baselin	NNP	O	O
at	STRIBILD.xml:S1:11399:2	at	IN	O	O
Week	STRIBILD.xml:S1:11402:4	week	NNP	O	O
144	STRIBILD.xml:S1:11407:3	144	CD	O	O
in	STRIBILD.xml:S1:11411:2	in	IN	O	O
Subjects	STRIBILD.xml:S1:11414:8	subject	NNS	O	O
Receiving	STRIBILD.xml:S1:11423:9	receiv	VBG	O	O
STRIBILD	STRIBILD.xml:S1:11433:8	stribild	NNP	O	O
or	STRIBILD.xml:S1:11442:2	or	CC	O	O
Comparator	STRIBILD.xml:S1:11445:10	compar	NNP	O	O
in	STRIBILD.xml:S1:11456:2	in	IN	O	O
Studies	STRIBILD.xml:S1:11459:7	studi	NNP	O	O
102	STRIBILD.xml:S1:11467:3	102	CD	O	O
and	STRIBILD.xml:S1:11471:3	and	CC	O	O
103	STRIBILD.xml:S1:11475:3	103	CD	O	O

STRIBILDN	STRIBILD.xml:S1:11502:9	stribildn	NNP	O	O
701	STRIBILD.xml:S1:11512:3	701	CD	O	O
ATRIPLAN	STRIBILD.xml:S1:11518:8	atriplan	NNP	O	O
352	STRIBILD.xml:S1:11527:3	352	CD	O	O
ATV	STRIBILD.xml:S1:11533:3	atv	NNP	O	O
RTV	STRIBILD.xml:S1:11539:3	rtv	NNP	O	O
TRUVADAN	STRIBILD.xml:S1:11545:8	truvadan	NNP	O	O
355	STRIBILD.xml:S1:11554:3	355	CD	O	O

Baseline	STRIBILD.xml:S1:11562:8	baselin	NNP	O	O
Week	STRIBILD.xml:S1:11585:4	week	NNP	O	O
144	STRIBILD.xml:S1:11590:3	144	CD	O	O
Baseline	STRIBILD.xml:S1:11601:8	baselin	NNP	O	O
Week	STRIBILD.xml:S1:11616:4	week	NNP	O	O
144	STRIBILD.xml:S1:11621:3	144	CD	O	O
Baseline	STRIBILD.xml:S1:11632:8	baselin	NNP	O	O
Week	STRIBILD.xml:S1:11647:4	week	NNP	O	O
144	STRIBILD.xml:S1:11652:3	144	CD	O	O

mg	STRIBILD.xml:S1:11663:2	mg	NN	O	O
dL	STRIBILD.xml:S1:11666:2	dL	NN	O	O
Change	STRIBILD.xml:S1:11687:6	chang	NNP	O	O
mg	STRIBILD.xml:S1:11703:2	mg	NN	O	O
dL	STRIBILD.xml:S1:11706:2	dL	NN	O	O
Change	STRIBILD.xml:S1:11718:6	chang	NNP	O	O
mg	STRIBILD.xml:S1:11734:2	mg	NN	O	O
dL	STRIBILD.xml:S1:11737:2	dL	NN	O	O
Change	STRIBILD.xml:S1:11749:6	chang	NN	O	O

Total	STRIBILD.xml:S1:11767:5	total	JJ	O	O

Cholesterol	STRIBILD.xml:S1:11773:11	cholesterol	NNP	O	O
(	STRIBILD.xml:S1:11785:1	(	(	O	O
fasted	STRIBILD.xml:S1:11786:6	fast	VBN	O	O
)	STRIBILD.xml:S1:11792:1	)	)	O	O
166	STRIBILD.xml:S1:11796:3	166	CD	O	O
[	STRIBILD.xml:S1:11799:1	[	JJ	O	O
N	STRIBILD.xml:S1:11800:1	N	NNP	O	O
675	STRIBILD.xml:S1:11802:3	675	CD	O	O
]	STRIBILD.xml:S1:11805:1	]	VBD	O	O
17	STRIBILD.xml:S1:11813:2	17	CD	O	O
[	STRIBILD.xml:S1:11815:1	[	NNP	O	O
N	STRIBILD.xml:S1:11816:1	N	NNP	O	O
535	STRIBILD.xml:S1:11818:3	535	CD	O	O
]	STRIBILD.xml:S1:11821:1	]	VBD	O	O
161	STRIBILD.xml:S1:11827:3	161	CD	O	O
[	STRIBILD.xml:S1:11830:1	[	NNP	O	O
N	STRIBILD.xml:S1:11831:1	N	NNP	O	O
343	STRIBILD.xml:S1:11833:3	343	CD	O	O
]	STRIBILD.xml:S1:11836:1	]	VBD	O	O
22	STRIBILD.xml:S1:11844:2	22	CD	O	O
[	STRIBILD.xml:S1:11846:1	[	NNP	O	O
N	STRIBILD.xml:S1:11847:1	N	NNP	O	O
262	STRIBILD.xml:S1:11849:3	262	CD	O	O
]	STRIBILD.xml:S1:11852:1	]	VBD	O	O
168	STRIBILD.xml:S1:11858:3	168	CD	O	O
[	STRIBILD.xml:S1:11861:1	[	NNP	O	O
N	STRIBILD.xml:S1:11862:1	N	NNP	O	O
337	STRIBILD.xml:S1:11864:3	337	CD	O	O
]	STRIBILD.xml:S1:11867:1	]	VBD	O	O
16	STRIBILD.xml:S1:11875:2	16	CD	O	O
[	STRIBILD.xml:S1:11877:1	[	NNP	O	O
N	STRIBILD.xml:S1:11878:1	N	NNP	O	O
243	STRIBILD.xml:S1:11880:3	243	CD	O	O
]	STRIBILD.xml:S1:11883:1	]	NN	O	O

HDL	STRIBILD.xml:S1:11891:3	hdl	NNP	O	O
-	STRIBILD.xml:S1:11894:1	-	:	O	O
cholesterol	STRIBILD.xml:S1:11895:11	cholesterol	NN	O	O
(	STRIBILD.xml:S1:11907:1	(	(	O	O
fasted	STRIBILD.xml:S1:11908:6	fast	VBN	O	O
)	STRIBILD.xml:S1:11914:1	)	)	O	O
43	STRIBILD.xml:S1:11919:2	43	CD	O	O
[	STRIBILD.xml:S1:11921:1	[	JJ	O	O
N	STRIBILD.xml:S1:11922:1	N	NNP	O	O
675	STRIBILD.xml:S1:11924:3	675	CD	O	O
]	STRIBILD.xml:S1:11927:1	]	VBD	O	O
7	STRIBILD.xml:S1:11935:1	7	CD	O	O
[	STRIBILD.xml:S1:11936:1	[	NNP	O	O
N	STRIBILD.xml:S1:11937:1	N	NNP	O	O
535	STRIBILD.xml:S1:11939:3	535	CD	O	O
]	STRIBILD.xml:S1:11942:1	]	VBD	O	O
43	STRIBILD.xml:S1:11950:2	43	CD	O	O
[	STRIBILD.xml:S1:11952:1	[	NNP	O	O
N	STRIBILD.xml:S1:11953:1	N	NNP	O	O
343	STRIBILD.xml:S1:11955:3	343	CD	O	O
]	STRIBILD.xml:S1:11958:1	]	VBD	O	O
9	STRIBILD.xml:S1:11966:1	9	CD	O	O
[	STRIBILD.xml:S1:11967:1	[	NNP	O	O
N	STRIBILD.xml:S1:11968:1	N	NNP	O	O
262	STRIBILD.xml:S1:11970:3	262	CD	O	O
]	STRIBILD.xml:S1:11973:1	]	VBD	O	O
42	STRIBILD.xml:S1:11981:2	42	CD	O	O
[	STRIBILD.xml:S1:11983:1	[	NNP	O	O
N	STRIBILD.xml:S1:11984:1	N	NNP	O	O
335	STRIBILD.xml:S1:11986:3	335	CD	O	O
]	STRIBILD.xml:S1:11989:1	]	VBD	O	O
7	STRIBILD.xml:S1:11997:1	7	CD	O	O
[	STRIBILD.xml:S1:11998:1	[	NNP	O	O
N	STRIBILD.xml:S1:11999:1	N	NNP	O	O
242	STRIBILD.xml:S1:12001:3	242	CD	O	O
]	STRIBILD.xml:S1:12004:1	]	NN	O	O

LDL	STRIBILD.xml:S1:12013:3	ldl	NNP	O	O
-	STRIBILD.xml:S1:12016:1	-	:	O	O
cholesterol	STRIBILD.xml:S1:12017:11	cholesterol	NN	O	O
(	STRIBILD.xml:S1:12029:1	(	(	O	O
fasted	STRIBILD.xml:S1:12030:6	fast	VBN	O	O
)	STRIBILD.xml:S1:12036:1	)	)	O	O
100	STRIBILD.xml:S1:12040:3	100	CD	O	O
[	STRIBILD.xml:S1:12043:1	[	JJ	O	O
N	STRIBILD.xml:S1:12044:1	N	NNP	O	O
675	STRIBILD.xml:S1:12046:3	675	CD	O	O
]	STRIBILD.xml:S1:12049:1	]	VBD	O	O
15	STRIBILD.xml:S1:12057:2	15	CD	O	O
[	STRIBILD.xml:S1:12059:1	[	NNP	O	O
N	STRIBILD.xml:S1:12060:1	N	NNP	O	O
535	STRIBILD.xml:S1:12062:3	535	CD	O	O
]	STRIBILD.xml:S1:12065:1	]	VBD	O	O
97	STRIBILD.xml:S1:12072:2	97	CD	O	O
[	STRIBILD.xml:S1:12074:1	[	NNP	O	O
N	STRIBILD.xml:S1:12075:1	N	NNP	O	O
343	STRIBILD.xml:S1:12077:3	343	CD	O	O
]	STRIBILD.xml:S1:12080:1	]	VBD	O	O
19	STRIBILD.xml:S1:12088:2	19	CD	O	O
[	STRIBILD.xml:S1:12090:1	[	NNP	O	O
N	STRIBILD.xml:S1:12091:1	N	NNP	O	O
262	STRIBILD.xml:S1:12093:3	262	CD	O	O
]	STRIBILD.xml:S1:12096:1	]	VBD	O	O
101	STRIBILD.xml:S1:12102:3	101	CD	O	O
[	STRIBILD.xml:S1:12105:1	[	NNP	O	O
N	STRIBILD.xml:S1:12106:1	N	NNP	O	O
337	STRIBILD.xml:S1:12108:3	337	CD	O	O
]	STRIBILD.xml:S1:12111:1	]	VBD	O	O
18	STRIBILD.xml:S1:12119:2	18	CD	O	O
[	STRIBILD.xml:S1:12121:1	[	NNP	O	O
N	STRIBILD.xml:S1:12122:1	N	NNP	O	O
242	STRIBILD.xml:S1:12124:3	242	CD	O	O
]	STRIBILD.xml:S1:12127:1	]	NN	O	O

Triglycerides	STRIBILD.xml:S1:12135:13	triglycerid	NNP	O	O
(	STRIBILD.xml:S1:12149:1	(	(	O	O
fasted	STRIBILD.xml:S1:12150:6	fast	VBN	O	O
)	STRIBILD.xml:S1:12156:1	)	)	O	O
122	STRIBILD.xml:S1:12160:3	122	CD	O	O
[	STRIBILD.xml:S1:12163:1	[	JJ	O	O
N	STRIBILD.xml:S1:12164:1	N	NNP	O	O
675	STRIBILD.xml:S1:12166:3	675	CD	O	O
]	STRIBILD.xml:S1:12169:1	]	VBD	O	O
12	STRIBILD.xml:S1:12177:2	12	CD	O	O
[	STRIBILD.xml:S1:12179:1	[	NNP	O	O
N	STRIBILD.xml:S1:12180:1	N	NNP	O	O
535	STRIBILD.xml:S1:12182:3	535	CD	O	O
]	STRIBILD.xml:S1:12185:1	]	VBD	O	O
121	STRIBILD.xml:S1:12191:3	121	CD	O	O
[	STRIBILD.xml:S1:12194:1	[	NNP	O	O
N	STRIBILD.xml:S1:12195:1	N	NNP	O	O
343	STRIBILD.xml:S1:12197:3	343	CD	O	O
]	STRIBILD.xml:S1:12200:1	]	VBD	O	O
5	STRIBILD.xml:S1:12208:1	5	CD	O	O
[	STRIBILD.xml:S1:12209:1	[	NNP	O	O
N	STRIBILD.xml:S1:12210:1	N	NNP	O	O
262	STRIBILD.xml:S1:12212:3	262	CD	O	O
]	STRIBILD.xml:S1:12215:1	]	VBD	O	O
132	STRIBILD.xml:S1:12222:3	132	CD	O	O
[	STRIBILD.xml:S1:12225:1	[	NNP	O	O
N	STRIBILD.xml:S1:12226:1	N	NNP	O	O
337	STRIBILD.xml:S1:12228:3	337	CD	O	O
]	STRIBILD.xml:S1:12231:1	]	VBD	O	O
22	STRIBILD.xml:S1:12239:2	22	CD	O	O
[	STRIBILD.xml:S1:12241:1	[	NNP	O	O
N	STRIBILD.xml:S1:12242:1	N	NNP	O	O
242	STRIBILD.xml:S1:12244:3	242	CD	O	O
]	STRIBILD.xml:S1:12247:1	]	NN	O	O

6.2	STRIBILD.xml:S1:12269:3	6.2	CD	O	O
Postmarketing	STRIBILD.xml:S1:12273:13	postmarket	VBG	O	O
Experience	STRIBILD.xml:S1:12287:10	experi	NN	O	O

The	STRIBILD.xml:S1:12301:3	the	DT	O	O
following	STRIBILD.xml:S1:12305:9	follow	JJ	O	O
adverse	STRIBILD.xml:S1:12315:7	advers	JJ	O	O
reactions	STRIBILD.xml:S1:12323:9	reaction	NNS	O	O
have	STRIBILD.xml:S1:12333:4	have	VBP	O	O
been	STRIBILD.xml:S1:12338:4	been	VBN	O	O
identified	STRIBILD.xml:S1:12343:10	identifi	VBN	O	O
during	STRIBILD.xml:S1:12354:6	dure	IN	O	O
post	STRIBILD.xml:S1:12361:4	post	NN	O	O
approval	STRIBILD.xml:S1:12366:8	approv	NN	O	O
use	STRIBILD.xml:S1:12375:3	use	NN	O	O
of	STRIBILD.xml:S1:12379:2	of	IN	O	O
tenofovir	STRIBILD.xml:S1:12382:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S1:12392:2	DF	NNP	O	O
.	STRIBILD.xml:S1:12394:1	.	.	O	O

Because	STRIBILD.xml:S1:12396:7	becaus	IN	O	O
postmarketing	STRIBILD.xml:S1:12404:13	postmarket	VBG	O	O
reactions	STRIBILD.xml:S1:12418:9	reaction	NNS	O	O
are	STRIBILD.xml:S1:12428:3	are	VBP	O	O
reported	STRIBILD.xml:S1:12432:8	report	VBN	O	O
voluntarily	STRIBILD.xml:S1:12441:11	voluntarili	RB	O	O
from	STRIBILD.xml:S1:12453:4	from	IN	O	O
a	STRIBILD.xml:S1:12458:1	a	DT	O	O
population	STRIBILD.xml:S1:12460:10	popul	NN	O	O
of	STRIBILD.xml:S1:12471:2	of	IN	O	O
uncertain	STRIBILD.xml:S1:12474:9	uncertain	JJ	O	O
size	STRIBILD.xml:S1:12484:4	size	NN	O	O
,	STRIBILD.xml:S1:12488:1	,	,	O	O
it	STRIBILD.xml:S1:12490:2	it	PRP	O	O
is	STRIBILD.xml:S1:12493:2	is	VBZ	O	O
not	STRIBILD.xml:S1:12496:3	not	RB	O	O
always	STRIBILD.xml:S1:12500:6	alway	RB	O	O
possible	STRIBILD.xml:S1:12507:8	possibl	JJ	O	O
to	STRIBILD.xml:S1:12516:2	to	TO	O	O
reliably	STRIBILD.xml:S1:12519:8	reliabl	VB	O	O
estimate	STRIBILD.xml:S1:12528:8	estim	VB	O	O
their	STRIBILD.xml:S1:12537:5	their	PRP$	O	O
frequency	STRIBILD.xml:S1:12543:9	frequenc	NN	O	O
or	STRIBILD.xml:S1:12553:2	or	CC	O	O
establish	STRIBILD.xml:S1:12556:9	establish	VB	O	O
a	STRIBILD.xml:S1:12566:1	a	DT	O	O
causal	STRIBILD.xml:S1:12568:6	causal	NN	O	O
relationship	STRIBILD.xml:S1:12575:12	relationship	NN	O	O
to	STRIBILD.xml:S1:12588:2	to	TO	O	O
drug	STRIBILD.xml:S1:12591:4	drug	NN	O	O
exposure	STRIBILD.xml:S1:12596:8	exposur	NN	O	O
.	STRIBILD.xml:S1:12604:1	.	.	O	O

No	STRIBILD.xml:S1:12606:2	No	DT	O	O
additional	STRIBILD.xml:S1:12609:10	addit	JJ	O	O
postmarketing	STRIBILD.xml:S1:12620:13	postmarket	NN	O	O
adverse	STRIBILD.xml:S1:12634:7	advers	JJ	O	O
reactions	STRIBILD.xml:S1:12642:9	reaction	NNS	O	O
specific	STRIBILD.xml:S1:12652:8	specif	VBP	O	O
for	STRIBILD.xml:S1:12661:3	for	IN	O	O
emtricitabine	STRIBILD.xml:S1:12665:13	emtricitabin	NN	O	O
have	STRIBILD.xml:S1:12679:4	have	VBP	O	O
been	STRIBILD.xml:S1:12684:4	been	VBN	O	O
identified	STRIBILD.xml:S1:12689:10	identifi	VBN	O	O
.	STRIBILD.xml:S1:12699:1	.	.	O	O

Immune	STRIBILD.xml:S1:12707:6	immun	NNP	O	O
System	STRIBILD.xml:S1:12714:6	system	NNP	O	O
Disorders	STRIBILD.xml:S1:12721:9	disord	NNP	O	O

allergic	STRIBILD.xml:S1:12737:8	allerg	JJ	B-AdverseReaction	B-AdverseReaction
reaction	STRIBILD.xml:S1:12746:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:12754:1	,	,	O	O
including	STRIBILD.xml:S1:12756:9	includ	VBG	O	O
angioedema	STRIBILD.xml:S1:12766:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction

Metabolism	STRIBILD.xml:S1:12783:10	metabol	NN	O	O
and	STRIBILD.xml:S1:12794:3	and	CC	O	O
Nutrition	STRIBILD.xml:S1:12798:9	nutrit	NN	O	O
Disorders	STRIBILD.xml:S1:12808:9	disord	NNS	O	O

lactic	STRIBILD.xml:S1:12824:6	lactic	JJ	B-AdverseReaction	O
acidosis	STRIBILD.xml:S1:12831:8	acidosi	NN	I-AdverseReaction	O
,	STRIBILD.xml:S1:12839:1	,	,	O	O
hypokalemia	STRIBILD.xml:S1:12841:11	hypokalemia	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:12852:1	,	,	O	O
hypophosphatemia	STRIBILD.xml:S1:12854:16	hypophosphatemia	NN	B-AdverseReaction	B-AdverseReaction

Respiratory	STRIBILD.xml:S1:12877:11	respiratori	NNP	O	O
,	STRIBILD.xml:S1:12888:1	,	,	O	O
Thoracic	STRIBILD.xml:S1:12890:8	thorac	NNP	O	O
,	STRIBILD.xml:S1:12898:1	,	,	O	O
and	STRIBILD.xml:S1:12900:3	and	CC	O	O
Mediastinal	STRIBILD.xml:S1:12904:11	mediastin	NNP	O	O
Disorders	STRIBILD.xml:S1:12916:9	disord	NNP	O	O

dyspnea	STRIBILD.xml:S1:12932:7	dyspnea	NN	B-AdverseReaction	O

Gastrointestinal	STRIBILD.xml:S1:12946:16	gastrointestin	JJ	O	O
Disorders	STRIBILD.xml:S1:12963:9	disord	NNS	O	O

pancreatitis	STRIBILD.xml:S1:12979:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:12991:1	,	,	O	O
increased	STRIBILD.xml:S1:12993:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
amylase	STRIBILD.xml:S1:13003:7	amylas	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13010:1	,	,	O	O
abdominal	STRIBILD.xml:S1:13012:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	STRIBILD.xml:S1:13022:4	pain	NN	I-AdverseReaction	I-AdverseReaction

Hepatobiliary	STRIBILD.xml:S1:13033:13	hepatobiliari	JJ	O	O
Disorders	STRIBILD.xml:S1:13047:9	disord	NNS	O	O

hepatic	STRIBILD.xml:S1:13063:7	hepat	JJ	B-AdverseReaction	B-AdverseReaction
steatosis	STRIBILD.xml:S1:13071:9	steatosi	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13080:1	,	,	O	O
hepatitis	STRIBILD.xml:S1:13082:9	hepat	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:13091:1	,	,	O	O
increased	STRIBILD.xml:S1:13093:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
liver	STRIBILD.xml:S1:13103:5	liver	NN	I-AdverseReaction	I-AdverseReaction
enzymes	STRIBILD.xml:S1:13109:7	enzym	RB	I-AdverseReaction	O
(	STRIBILD.xml:S1:13117:1	(	(	O	O
most	STRIBILD.xml:S1:13118:4	most	JJS	O	O
commonly	STRIBILD.xml:S1:13123:8	commonli	RB	O	O
AST	STRIBILD.xml:S1:13132:3	ast	NNP	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13135:1	,	,	O	O
ALT	STRIBILD.xml:S1:13137:3	alt	NNP	I-AdverseReaction	B-AdverseReaction
gamma	STRIBILD.xml:S1:13141:5	gamma	NNP	I-AdverseReaction	I-AdverseReaction
GT	STRIBILD.xml:S1:13147:2	GT	NNP	I-AdverseReaction	I-AdverseReaction
)	STRIBILD.xml:S1:13149:1	)	)	O	O

Skin	STRIBILD.xml:S1:13157:4	skin	NNP	O	O
and	STRIBILD.xml:S1:13162:3	and	CC	O	O
Subcutaneous	STRIBILD.xml:S1:13166:12	subcutan	NNP	O	O
Tissue	STRIBILD.xml:S1:13179:6	tissu	NNP	O	O
Disorders	STRIBILD.xml:S1:13186:9	disord	NNP	O	O

rash	STRIBILD.xml:S1:13202:4	rash	NN	B-AdverseReaction	B-AdverseReaction

Musculoskeletal	STRIBILD.xml:S1:13213:15	musculoskelet	NNP	O	O
and	STRIBILD.xml:S1:13229:3	and	CC	O	O
Connective	STRIBILD.xml:S1:13233:10	connect	NNP	O	O
Tissue	STRIBILD.xml:S1:13244:6	tissu	NNP	O	O
Disorders	STRIBILD.xml:S1:13251:9	disord	NNP	O	O

rhabdomyolysis	STRIBILD.xml:S1:13267:14	rhabdomyolysi	NN	B-AdverseReaction	O
,	STRIBILD.xml:S1:13281:1	,	,	O	O
osteomalacia	STRIBILD.xml:S1:13283:12	osteomalacia	NN	B-AdverseReaction	O
(	STRIBILD.xml:S1:13296:1	(	(	O	O
manifested	STRIBILD.xml:S1:13297:10	manifest	VBN	O	O
as	STRIBILD.xml:S1:13308:2	as	IN	O	O
bone	STRIBILD.xml:S1:13311:4	bone	NN	B-AdverseReaction	B-AdverseReaction
pain	STRIBILD.xml:S1:13316:4	pain	NN	I-AdverseReaction	I-AdverseReaction
and	STRIBILD.xml:S1:13321:3	and	CC	O	O
which	STRIBILD.xml:S1:13325:5	which	WDT	O	O
may	STRIBILD.xml:S1:13331:3	may	MD	O	O
contribute	STRIBILD.xml:S1:13335:10	contribut	VB	O	O
to	STRIBILD.xml:S1:13346:2	to	TO	O	O
fractures	STRIBILD.xml:S1:13349:9	fractur	NNS	B-AdverseReaction	B-AdverseReaction
)	STRIBILD.xml:S1:13358:1	)	)	O	O
,	STRIBILD.xml:S1:13359:1	,	,	O	O
muscular	STRIBILD.xml:S1:13361:8	muscular	JJ	B-AdverseReaction	B-AdverseReaction
weakness	STRIBILD.xml:S1:13370:8	weak	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13378:1	,	,	O	O
myopathy	STRIBILD.xml:S1:13380:8	myopathi	NN	B-AdverseReaction	O

Renal	STRIBILD.xml:S1:13395:5	renal	NNP	O	O
and	STRIBILD.xml:S1:13401:3	and	CC	O	O
Urinary	STRIBILD.xml:S1:13405:7	urinari	NNP	O	O
Disorders	STRIBILD.xml:S1:13413:9	disord	NNS	O	O

acute	STRIBILD.xml:S1:13429:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
renal	STRIBILD.xml:S1:13435:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	STRIBILD.xml:S1:13441:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13448:1	,	,	O	O
renal	STRIBILD.xml:S1:13450:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	STRIBILD.xml:S1:13456:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13463:1	,	,	O	O
acute	STRIBILD.xml:S1:13465:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
tubular	STRIBILD.xml:S1:13471:7	tubular	JJ	I-AdverseReaction	I-AdverseReaction
necrosis	STRIBILD.xml:S1:13479:8	necrosi	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13487:1	,	,	O	O
Fanconi	STRIBILD.xml:S1:13489:7	fanconi	NNP	B-AdverseReaction	B-AdverseReaction
syndrome	STRIBILD.xml:S1:13497:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13505:1	,	,	O	O
proximal	STRIBILD.xml:S1:13507:8	proxim	JJ	B-AdverseReaction	B-AdverseReaction
renal	STRIBILD.xml:S1:13516:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
tubulopathy	STRIBILD.xml:S1:13522:11	tubulopathi	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13533:1	,	,	O	O
interstitial	STRIBILD.xml:S1:13535:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
nephritis	STRIBILD.xml:S1:13548:9	nephriti	NN	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S1:13558:1	(	(	O	O
including	STRIBILD.xml:S1:13559:9	includ	VBG	O	O
acute	STRIBILD.xml:S1:13569:5	acut	NN	I-AdverseReaction	O
cases	STRIBILD.xml:S1:13575:5	case	NNS	O	O
)	STRIBILD.xml:S1:13580:1	)	)	O	O
,	STRIBILD.xml:S1:13581:1	,	,	O	O
nephrogenic	STRIBILD.xml:S1:13583:11	nephrogen	JJ	B-AdverseReaction	B-AdverseReaction
diabetes	STRIBILD.xml:S1:13595:8	diabet	NNS	I-AdverseReaction	I-AdverseReaction
insipidus	STRIBILD.xml:S1:13604:9	insipidu	VBP	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13613:1	,	,	O	O
renal	STRIBILD.xml:S1:13615:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
insufficiency	STRIBILD.xml:S1:13621:13	insuffici	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13634:1	,	,	O	O
increased	STRIBILD.xml:S1:13636:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
creatinine	STRIBILD.xml:S1:13646:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13656:1	,	,	O	O
proteinuria	STRIBILD.xml:S1:13658:11	proteinuria	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:13669:1	,	,	O	O
polyuria	STRIBILD.xml:S1:13671:8	polyuria	NN	B-AdverseReaction	O

General	STRIBILD.xml:S1:13686:7	gener	NNP	O	O
Disorders	STRIBILD.xml:S1:13694:9	disord	NNP	O	O
and	STRIBILD.xml:S1:13704:3	and	CC	O	O
Administration	STRIBILD.xml:S1:13708:14	administr	NNP	O	O
Site	STRIBILD.xml:S1:13723:4	site	NNP	O	O
Conditions	STRIBILD.xml:S1:13728:10	condit	NNS	O	O

asthenia	STRIBILD.xml:S1:13745:8	asthenia	NN	B-AdverseReaction	B-AdverseReaction

The	STRIBILD.xml:S1:13758:3	the	DT	O	O
following	STRIBILD.xml:S1:13762:9	follow	JJ	O	O
adverse	STRIBILD.xml:S1:13772:7	advers	JJ	O	O
reactions	STRIBILD.xml:S1:13780:9	reaction	NNS	O	O
,	STRIBILD.xml:S1:13789:1	,	,	O	O
listed	STRIBILD.xml:S1:13791:6	list	VBN	O	O
under	STRIBILD.xml:S1:13798:5	under	IN	O	O
the	STRIBILD.xml:S1:13804:3	the	DT	O	O
body	STRIBILD.xml:S1:13808:4	bodi	NN	O	O
system	STRIBILD.xml:S1:13813:6	system	NN	O	O
headings	STRIBILD.xml:S1:13820:8	head	NNS	O	O
above	STRIBILD.xml:S1:13829:5	abov	IN	O	O
,	STRIBILD.xml:S1:13834:1	,	,	O	O
may	STRIBILD.xml:S1:13836:3	may	MD	O	O
occur	STRIBILD.xml:S1:13840:5	occur	VB	O	O
as	STRIBILD.xml:S1:13846:2	as	IN	O	O
a	STRIBILD.xml:S1:13849:1	a	DT	O	O
consequence	STRIBILD.xml:S1:13851:11	consequ	NN	O	O
of	STRIBILD.xml:S1:13863:2	of	IN	O	O
proximal	STRIBILD.xml:S1:13866:8	proxim	JJ	B-AdverseReaction	O
renal	STRIBILD.xml:S1:13875:5	renal	JJ	I-AdverseReaction	O
tubulopathy	STRIBILD.xml:S1:13881:11	tubulopathi	NN	I-AdverseReaction	O
:	STRIBILD.xml:S1:13892:1	:	:	O	O
rhabdomyolysis	STRIBILD.xml:S1:13894:14	rhabdomyolysi	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:13908:1	,	,	O	O
osteomalacia	STRIBILD.xml:S1:13910:12	osteomalacia	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:13922:1	,	,	O	O
hypokalemia	STRIBILD.xml:S1:13924:11	hypokalemia	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S1:13935:1	,	,	O	O
muscular	STRIBILD.xml:S1:13937:8	muscular	JJ	B-AdverseReaction	B-AdverseReaction
weakness	STRIBILD.xml:S1:13946:8	weak	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S1:13954:1	,	,	O	O
myopathy	STRIBILD.xml:S1:13956:8	myopathi	NN	B-AdverseReaction	O
,	STRIBILD.xml:S1:13964:1	,	,	O	O
hypophosphatemia	STRIBILD.xml:S1:13966:16	hypophosphatemia	NN	B-AdverseReaction	B-AdverseReaction
.	STRIBILD.xml:S1:13982:1	.	.	O	O
\n\n	STRIBILD.xml:S2:0:2	\n\n	VB	O	O
BOXED	STRIBILD.xml:S2:6:5	box	NNP	O	O
WARNING	STRIBILD.xml:S2:12:7	warn	NNP	O	O
:	STRIBILD.xml:S2:19:1	:	:	O	O
WARNING	STRIBILD.xml:S2:21:7	warn	NN	O	O
:	STRIBILD.xml:S2:28:1	:	:	O	O
LACTIC	STRIBILD.xml:S2:30:6	lactic	JJ	B-AdverseReaction	O
ACIDOSIS	STRIBILD.xml:S2:37:8	acidosi	NNP	I-AdverseReaction	O
SEVERE	STRIBILD.xml:S2:46:6	sever	NNP	O	O
HEPATOMEGALY	STRIBILD.xml:S2:53:12	hepatomegali	NNP	B-AdverseReaction	O
WITH	STRIBILD.xml:S2:66:4	with	NNP	O	O
STEATOSIS	STRIBILD.xml:S2:71:9	steatosi	NNP	B-AdverseReaction	O
and	STRIBILD.xml:S2:81:3	and	CC	O	O
POST	STRIBILD.xml:S2:85:4	post	NNP	O	O
TREATMENT	STRIBILD.xml:S2:90:9	treatment	NNP	O	O
ACUTE	STRIBILD.xml:S2:100:5	acut	NNP	B-AdverseReaction	O
EXACERBATION	STRIBILD.xml:S2:106:12	exacerb	NNP	I-AdverseReaction	O
OF	STRIBILD.xml:S2:119:2	OF	NNP	I-AdverseReaction	O
HEPATITIS	STRIBILD.xml:S2:122:9	hepat	NNP	I-AdverseReaction	O
B	STRIBILD.xml:S2:132:1	B	NNP	I-AdverseReaction	O
\n\n	STRIBILD.xml:S2:133:2	\n\n	NNP	O	O
WARNING	STRIBILD.xml:S2:139:7	warn	NN	O	O
:	STRIBILD.xml:S2:146:1	:	:	O	O
LACTIC	STRIBILD.xml:S2:148:6	lactic	JJ	B-AdverseReaction	O
ACIDOSIS	STRIBILD.xml:S2:155:8	acidosi	NNP	I-AdverseReaction	O
SEVERE	STRIBILD.xml:S2:164:6	sever	NNP	O	O
HEPATOMEGALY	STRIBILD.xml:S2:171:12	hepatomegali	NNP	B-AdverseReaction	O
WITH	STRIBILD.xml:S2:184:4	with	NNP	O	O
STEATOSIS	STRIBILD.xml:S2:189:9	steatosi	NNP	B-AdverseReaction	O
and	STRIBILD.xml:S2:199:3	and	CC	O	O
POST	STRIBILD.xml:S2:203:4	post	NNP	O	O
TREATMENT	STRIBILD.xml:S2:208:9	treatment	NNP	O	O
ACUTE	STRIBILD.xml:S2:218:5	acut	NNP	B-AdverseReaction	O
EXACERBATION	STRIBILD.xml:S2:224:12	exacerb	NNP	I-AdverseReaction	O
OF	STRIBILD.xml:S2:237:2	OF	NNP	I-AdverseReaction	O
HEPATITIS	STRIBILD.xml:S2:240:9	hepat	NNP	I-AdverseReaction	O
B	STRIBILD.xml:S2:250:1	B	NNP	I-AdverseReaction	O
\n\n	STRIBILD.xml:S2:253:2	\n\n	NNP	O	O
Lactic	STRIBILD.xml:S2:259:6	lactic	NNP	B-AdverseReaction	O
acidosis	STRIBILD.xml:S2:266:8	acidosi	NN	I-AdverseReaction	O
and	STRIBILD.xml:S2:275:3	and	CC	O	O
severe	STRIBILD.xml:S2:279:6	sever	JJ	O	O
hepatomegaly	STRIBILD.xml:S2:286:12	hepatomegali	NN	B-AdverseReaction	O
with	STRIBILD.xml:S2:299:4	with	IN	O	O
steatosis	STRIBILD.xml:S2:304:9	steatosi	NN	B-AdverseReaction	O
,	STRIBILD.xml:S2:313:1	,	,	O	O
including	STRIBILD.xml:S2:315:9	includ	VBG	O	O
fatal	STRIBILD.xml:S2:325:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
cases	STRIBILD.xml:S2:331:5	case	NNS	O	O
,	STRIBILD.xml:S2:336:1	,	,	O	O
have	STRIBILD.xml:S2:338:4	have	VBP	O	O
been	STRIBILD.xml:S2:343:4	been	VBN	O	O
reported	STRIBILD.xml:S2:348:8	report	VBN	O	O
with	STRIBILD.xml:S2:357:4	with	IN	O	O
the	STRIBILD.xml:S2:362:3	the	DT	O	O
use	STRIBILD.xml:S2:366:3	use	NN	O	O
of	STRIBILD.xml:S2:370:2	of	IN	O	O
nucleoside	STRIBILD.xml:S2:373:10	nucleosid	JJ	O	O
analogs	STRIBILD.xml:S2:384:7	analog	NNS	O	O
,	STRIBILD.xml:S2:391:1	,	,	O	O
including	STRIBILD.xml:S2:393:9	includ	VBG	O	O
tenofovir	STRIBILD.xml:S2:403:9	tenofovir	JJ	O	O
disoproxil	STRIBILD.xml:S2:413:10	disoproxil	NN	O	O
fumarate	STRIBILD.xml:S2:424:8	fumar	NN	O	O
,	STRIBILD.xml:S2:432:1	,	,	O	O
a	STRIBILD.xml:S2:434:1	a	DT	O	O
component	STRIBILD.xml:S2:436:9	compon	NN	O	O
of	STRIBILD.xml:S2:446:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S2:449:8	stribild	NNP	O	O
,	STRIBILD.xml:S2:457:1	,	,	O	O
in	STRIBILD.xml:S2:459:2	in	IN	O	O
combination	STRIBILD.xml:S2:462:11	combin	NN	O	O
with	STRIBILD.xml:S2:474:4	with	IN	O	O
other	STRIBILD.xml:S2:479:5	other	JJ	O	O
antiretrovirals	STRIBILD.xml:S2:485:15	antiretrovir	NNS	O	O
[	STRIBILD.xml:S2:503:1	[	VBP	O	O
see	STRIBILD.xml:S2:504:3	see	VBP	O	O
Warnings	STRIBILD.xml:S2:510:8	warn	NNS	O	O
and	STRIBILD.xml:S2:519:3	and	CC	O	O
Precautions	STRIBILD.xml:S2:523:11	precaut	NNP	O	O
(	STRIBILD.xml:S2:535:1	(	(	O	O
5.1	STRIBILD.xml:S2:536:3	5.1	CD	O	O
)	STRIBILD.xml:S2:539:1	)	)	O	O
]	STRIBILD.xml:S2:542:1	]	NN	O	O
.	STRIBILD.xml:S2:545:1	.	.	O	O

STRIBILD	STRIBILD.xml:S2:555:8	stribild	NNP	O	O
is	STRIBILD.xml:S2:564:2	is	VBZ	O	O
not	STRIBILD.xml:S2:567:3	not	RB	O	O
approved	STRIBILD.xml:S2:571:8	approv	VBN	O	O
for	STRIBILD.xml:S2:580:3	for	IN	O	O
the	STRIBILD.xml:S2:584:3	the	DT	O	O
treatment	STRIBILD.xml:S2:588:9	treatment	NN	O	O
of	STRIBILD.xml:S2:598:2	of	IN	O	O
chronic	STRIBILD.xml:S2:601:7	chronic	JJ	O	O
hepatitis	STRIBILD.xml:S2:609:9	hepat	NN	O	O
B	STRIBILD.xml:S2:619:1	B	NNP	O	O
virus	STRIBILD.xml:S2:621:5	viru	NN	O	O
(	STRIBILD.xml:S2:627:1	(	(	O	O
HBV	STRIBILD.xml:S2:628:3	hbv	NNP	O	I-AdverseReaction
)	STRIBILD.xml:S2:631:1	)	)	O	O
infection	STRIBILD.xml:S2:633:9	infect	NN	O	O
and	STRIBILD.xml:S2:643:3	and	CC	O	O
the	STRIBILD.xml:S2:647:3	the	DT	O	O
safety	STRIBILD.xml:S2:651:6	safeti	NN	O	O
and	STRIBILD.xml:S2:658:3	and	CC	O	O
efficacy	STRIBILD.xml:S2:662:8	efficaci	NN	O	O
of	STRIBILD.xml:S2:671:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S2:674:8	stribild	NNP	O	O
have	STRIBILD.xml:S2:683:4	have	VBP	O	O
not	STRIBILD.xml:S2:688:3	not	RB	O	O
been	STRIBILD.xml:S2:692:4	been	VBN	O	O
established	STRIBILD.xml:S2:697:11	establish	VBN	O	O
in	STRIBILD.xml:S2:709:2	in	IN	O	O
patients	STRIBILD.xml:S2:712:8	patient	NNS	O	O
coinfected	STRIBILD.xml:S2:721:10	coinfect	VBN	O	O
with	STRIBILD.xml:S2:732:4	with	IN	O	O
HBV	STRIBILD.xml:S2:737:3	hbv	NNP	O	O
and	STRIBILD.xml:S2:741:3	and	CC	O	O
HIV	STRIBILD.xml:S2:745:3	hiv	NNP	O	O
-	STRIBILD.xml:S2:748:1	-	:	O	O
1	STRIBILD.xml:S2:749:1	1	CD	O	O
.	STRIBILD.xml:S2:750:1	.	.	O	O

Severe	STRIBILD.xml:S2:752:6	sever	NNP	O	O
acute	STRIBILD.xml:S2:759:5	acut	JJ	B-AdverseReaction	O
exacerbations	STRIBILD.xml:S2:765:13	exacerb	NNS	I-AdverseReaction	O
of	STRIBILD.xml:S2:779:2	of	IN	I-AdverseReaction	O
hepatitis	STRIBILD.xml:S2:782:9	hepat	NN	I-AdverseReaction	O
B	STRIBILD.xml:S2:792:1	B	NNP	I-AdverseReaction	O
have	STRIBILD.xml:S2:794:4	have	VBP	O	O
been	STRIBILD.xml:S2:799:4	been	VBN	O	O
reported	STRIBILD.xml:S2:804:8	report	VBN	O	O
in	STRIBILD.xml:S2:813:2	in	IN	O	O
patients	STRIBILD.xml:S2:816:8	patient	NNS	O	O
who	STRIBILD.xml:S2:825:3	who	WP	O	O
are	STRIBILD.xml:S2:829:3	are	VBP	O	O
coinfected	STRIBILD.xml:S2:833:10	coinfect	VBN	O	O
with	STRIBILD.xml:S2:844:4	with	IN	O	O
HBV	STRIBILD.xml:S2:849:3	hbv	NNP	O	O
and	STRIBILD.xml:S2:853:3	and	CC	O	O
human	STRIBILD.xml:S2:857:5	human	JJ	O	O
immunodeficiency	STRIBILD.xml:S2:863:16	immunodefici	NN	O	O
virus	STRIBILD.xml:S2:880:5	viru	NN	O	O
-	STRIBILD.xml:S2:885:1	-	:	O	O
1	STRIBILD.xml:S2:886:1	1	CD	O	O
(	STRIBILD.xml:S2:888:1	(	(	O	O
HIV	STRIBILD.xml:S2:889:3	hiv	NNP	O	O
-	STRIBILD.xml:S2:892:1	-	:	O	O
1	STRIBILD.xml:S2:893:1	1	CD	O	O
)	STRIBILD.xml:S2:894:1	)	)	O	O
and	STRIBILD.xml:S2:896:3	and	CC	O	O
have	STRIBILD.xml:S2:900:4	have	VBP	O	O
discontinued	STRIBILD.xml:S2:905:12	discontinu	VBN	O	O
EMTRIVA	STRIBILD.xml:S2:918:7	emtriva	NNP	O	O
or	STRIBILD.xml:S2:926:2	or	CC	O	O
VIREAD	STRIBILD.xml:S2:929:6	viread	NNP	O	O
,	STRIBILD.xml:S2:935:1	,	,	O	O
which	STRIBILD.xml:S2:937:5	which	WDT	O	O
are	STRIBILD.xml:S2:943:3	are	VBP	O	O
components	STRIBILD.xml:S2:947:10	compon	NNS	O	O
of	STRIBILD.xml:S2:958:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S2:961:8	stribild	NNP	O	O
.	STRIBILD.xml:S2:969:1	.	.	O	O

Hepatic	STRIBILD.xml:S2:971:7	hepat	JJ	O	O
function	STRIBILD.xml:S2:979:8	function	NN	O	O
should	STRIBILD.xml:S2:988:6	should	MD	O	O
be	STRIBILD.xml:S2:995:2	be	VB	O	O
monitored	STRIBILD.xml:S2:998:9	monitor	VBN	O	O
closely	STRIBILD.xml:S2:1008:7	close	RB	O	O
with	STRIBILD.xml:S2:1016:4	with	IN	O	O
both	STRIBILD.xml:S2:1021:4	both	DT	O	O
clinical	STRIBILD.xml:S2:1026:8	clinic	JJ	O	O
and	STRIBILD.xml:S2:1035:3	and	CC	O	O
laboratory	STRIBILD.xml:S2:1039:10	laboratori	JJ	O	O
follow	STRIBILD.xml:S2:1050:6	follow	NN	O	O
-	STRIBILD.xml:S2:1056:1	-	:	O	O
up	STRIBILD.xml:S2:1057:2	up	RB	O	O
for	STRIBILD.xml:S2:1060:3	for	IN	O	O
at	STRIBILD.xml:S2:1064:2	at	IN	O	O
least	STRIBILD.xml:S2:1067:5	least	JJS	O	O
several	STRIBILD.xml:S2:1073:7	sever	JJ	O	O
months	STRIBILD.xml:S2:1081:6	month	NNS	O	O
in	STRIBILD.xml:S2:1088:2	in	IN	O	O
patients	STRIBILD.xml:S2:1091:8	patient	NNS	O	O
who	STRIBILD.xml:S2:1100:3	who	WP	O	O
are	STRIBILD.xml:S2:1104:3	are	VBP	O	O
coinfected	STRIBILD.xml:S2:1108:10	coinfect	VBN	O	O
with	STRIBILD.xml:S2:1119:4	with	IN	O	O
HIV	STRIBILD.xml:S2:1124:3	hiv	NNP	O	O
-	STRIBILD.xml:S2:1127:1	-	:	O	O
1	STRIBILD.xml:S2:1128:1	1	CD	O	O
and	STRIBILD.xml:S2:1130:3	and	CC	O	O
HBV	STRIBILD.xml:S2:1134:3	hbv	NNP	O	O
and	STRIBILD.xml:S2:1138:3	and	CC	O	O
discontinue	STRIBILD.xml:S2:1142:11	discontinu	VB	O	O
STRIBILD	STRIBILD.xml:S2:1154:8	stribild	NNP	O	O
.	STRIBILD.xml:S2:1162:1	.	.	O	O

If	STRIBILD.xml:S2:1164:2	If	IN	O	O
appropriate	STRIBILD.xml:S2:1167:11	appropri	JJ	O	O
,	STRIBILD.xml:S2:1178:1	,	,	O	O
initiation	STRIBILD.xml:S2:1180:10	initi	NN	O	O
of	STRIBILD.xml:S2:1191:2	of	IN	O	O
anti	STRIBILD.xml:S2:1194:4	anti	JJ	O	O
-	STRIBILD.xml:S2:1198:1	-	:	O	O
hepatitis	STRIBILD.xml:S2:1199:9	hepat	NN	O	O
B	STRIBILD.xml:S2:1209:1	B	NNP	O	O
therapy	STRIBILD.xml:S2:1211:7	therapi	NN	O	O
may	STRIBILD.xml:S2:1219:3	may	MD	O	O
be	STRIBILD.xml:S2:1223:2	be	VB	O	O
warranted	STRIBILD.xml:S2:1226:9	warrant	VBN	O	O
[	STRIBILD.xml:S2:1238:1	[	NNP	O	O
see	STRIBILD.xml:S2:1239:3	see	VBP	O	O
Warnings	STRIBILD.xml:S2:1245:8	warn	NNP	O	O
and	STRIBILD.xml:S2:1254:3	and	CC	O	O
Precautions	STRIBILD.xml:S2:1258:11	precaut	NNP	O	O
(	STRIBILD.xml:S2:1270:1	(	(	O	O
5.2	STRIBILD.xml:S2:1271:3	5.2	CD	O	O
)	STRIBILD.xml:S2:1274:1	)	)	O	O
]	STRIBILD.xml:S2:1277:1	]	NN	O	O
.	STRIBILD.xml:S2:1280:1	.	.	O	O

EXCERPT	STRIBILD.xml:S2:1290:7	excerpt	NN	O	O
:	STRIBILD.xml:S2:1297:1	:	:	O	O
WARNING	STRIBILD.xml:S2:1301:7	warn	NN	O	O
:	STRIBILD.xml:S2:1308:1	:	:	O	O
LACTIC	STRIBILD.xml:S2:1310:6	lactic	JJ	B-AdverseReaction	O
ACIDOSIS	STRIBILD.xml:S2:1317:8	acidosi	NNP	I-AdverseReaction	O
SEVERE	STRIBILD.xml:S2:1326:6	sever	NNP	O	O
HEPATOMEGALY	STRIBILD.xml:S2:1333:12	hepatomegali	NNP	B-AdverseReaction	O
WITH	STRIBILD.xml:S2:1346:4	with	NNP	O	O
STEATOSIS	STRIBILD.xml:S2:1351:9	steatosi	NNP	B-AdverseReaction	O
and	STRIBILD.xml:S2:1361:3	and	CC	O	O
POST	STRIBILD.xml:S2:1365:4	post	NNP	O	O
TREATMENT	STRIBILD.xml:S2:1370:9	treatment	NNP	O	O
ACUTE	STRIBILD.xml:S2:1380:5	acut	NNP	B-AdverseReaction	O
EXACERBATION	STRIBILD.xml:S2:1386:12	exacerb	NNP	I-AdverseReaction	O
OF	STRIBILD.xml:S2:1399:2	OF	NNP	I-AdverseReaction	O
HEPATITIS	STRIBILD.xml:S2:1402:9	hepat	NNP	I-AdverseReaction	O
B	STRIBILD.xml:S2:1412:1	B	NNP	I-AdverseReaction	O
\n\n\n\n	STRIBILD.xml:S2:1413:4	\n\n\n\n	NNP	O	O
See	STRIBILD.xml:S2:1420:3	see	NNP	O	O
full	STRIBILD.xml:S2:1424:4	full	JJ	O	O
prescribing	STRIBILD.xml:S2:1429:11	prescrib	VBG	O	O
information	STRIBILD.xml:S2:1441:11	inform	NN	O	O
for	STRIBILD.xml:S2:1453:3	for	IN	O	O
complete	STRIBILD.xml:S2:1457:8	complet	JJ	O	O
boxed	STRIBILD.xml:S2:1466:5	box	JJ	O	O
warning	STRIBILD.xml:S2:1472:7	warn	NN	O	O
.	STRIBILD.xml:S2:1479:1	.	.	O	O

Lactic	STRIBILD.xml:S2:1490:6	lactic	JJ	B-AdverseReaction	O
acidosis	STRIBILD.xml:S2:1497:8	acidosi	NN	I-AdverseReaction	O
and	STRIBILD.xml:S2:1506:3	and	CC	O	O
severe	STRIBILD.xml:S2:1510:6	sever	JJ	O	O
hepatomegaly	STRIBILD.xml:S2:1517:12	hepatomegali	NN	B-AdverseReaction	O
with	STRIBILD.xml:S2:1530:4	with	IN	O	O
steatosis	STRIBILD.xml:S2:1535:9	steatosi	NN	B-AdverseReaction	O
,	STRIBILD.xml:S2:1544:1	,	,	O	O
including	STRIBILD.xml:S2:1546:9	includ	VBG	O	O
fatal	STRIBILD.xml:S2:1556:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
cases	STRIBILD.xml:S2:1562:5	case	NNS	O	O
,	STRIBILD.xml:S2:1567:1	,	,	O	O
have	STRIBILD.xml:S2:1569:4	have	VBP	O	O
been	STRIBILD.xml:S2:1574:4	been	VBN	O	O
reported	STRIBILD.xml:S2:1579:8	report	VBN	O	O
with	STRIBILD.xml:S2:1588:4	with	IN	O	O
the	STRIBILD.xml:S2:1593:3	the	DT	O	O
use	STRIBILD.xml:S2:1597:3	use	NN	O	O
of	STRIBILD.xml:S2:1601:2	of	IN	O	O
nucleoside	STRIBILD.xml:S2:1604:10	nucleosid	JJ	O	O
analogs	STRIBILD.xml:S2:1615:7	analog	NNS	O	O
,	STRIBILD.xml:S2:1622:1	,	,	O	O
including	STRIBILD.xml:S2:1624:9	includ	VBG	O	O
tenofovir	STRIBILD.xml:S2:1634:9	tenofovir	JJ	O	B-AdverseReaction
disoproxil	STRIBILD.xml:S2:1644:10	disoproxil	NN	O	I-AdverseReaction
fumarate	STRIBILD.xml:S2:1655:8	fumar	NN	O	I-AdverseReaction
(	STRIBILD.xml:S2:1664:1	(	(	O	O
DF	STRIBILD.xml:S2:1665:2	DF	NNP	O	O
)	STRIBILD.xml:S2:1667:1	)	)	O	O
,	STRIBILD.xml:S2:1668:1	,	,	O	O
a	STRIBILD.xml:S2:1670:1	a	DT	O	O
component	STRIBILD.xml:S2:1672:9	compon	NN	O	O
of	STRIBILD.xml:S2:1682:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S2:1685:8	stribild	NNP	O	O
.	STRIBILD.xml:S2:1693:1	.	.	O	O

(	STRIBILD.xml:S2:1695:1	(	(	O	O
5.1	STRIBILD.xml:S2:1696:3	5.1	CD	O	O
)	STRIBILD.xml:S2:1699:1	)	)	O	O
\n	STRIBILD.xml:S2:1701:1	\n	FW	O	O
STRIBILD	STRIBILD.xml:S2:1706:8	stribild	NNP	O	O
is	STRIBILD.xml:S2:1715:2	is	VBZ	O	O
not	STRIBILD.xml:S2:1718:3	not	RB	O	O
approved	STRIBILD.xml:S2:1722:8	approv	VBN	O	O
for	STRIBILD.xml:S2:1731:3	for	IN	O	O
the	STRIBILD.xml:S2:1735:3	the	DT	O	O
treatment	STRIBILD.xml:S2:1739:9	treatment	NN	O	O
of	STRIBILD.xml:S2:1749:2	of	IN	O	O
chronic	STRIBILD.xml:S2:1752:7	chronic	JJ	O	O
hepatitis	STRIBILD.xml:S2:1760:9	hepat	NN	O	O
B	STRIBILD.xml:S2:1770:1	B	NNP	O	O
virus	STRIBILD.xml:S2:1772:5	viru	NN	O	O
(	STRIBILD.xml:S2:1778:1	(	(	O	O
HBV	STRIBILD.xml:S2:1779:3	hbv	NNP	O	O
)	STRIBILD.xml:S2:1782:1	)	)	O	O
infection	STRIBILD.xml:S2:1784:9	infect	NN	O	O
.	STRIBILD.xml:S2:1793:1	.	.	O	O

Severe	STRIBILD.xml:S2:1795:6	sever	NNP	O	O
acute	STRIBILD.xml:S2:1802:5	acut	JJ	B-AdverseReaction	O
exacerbations	STRIBILD.xml:S2:1808:13	exacerb	NNS	I-AdverseReaction	O
of	STRIBILD.xml:S2:1822:2	of	IN	I-AdverseReaction	O
hepatitis	STRIBILD.xml:S2:1825:9	hepat	NN	I-AdverseReaction	O
B	STRIBILD.xml:S2:1835:1	B	NNP	I-AdverseReaction	O
have	STRIBILD.xml:S2:1837:4	have	VBP	O	O
been	STRIBILD.xml:S2:1842:4	been	VBN	O	O
reported	STRIBILD.xml:S2:1847:8	report	VBN	O	O
in	STRIBILD.xml:S2:1856:2	in	IN	O	O
patients	STRIBILD.xml:S2:1859:8	patient	NNS	O	O
coinfected	STRIBILD.xml:S2:1868:10	coinfect	VBN	O	O
with	STRIBILD.xml:S2:1879:4	with	IN	O	O
HIV	STRIBILD.xml:S2:1884:3	hiv	NNP	O	O
-	STRIBILD.xml:S2:1887:1	-	:	O	O
1	STRIBILD.xml:S2:1888:1	1	CD	O	O
and	STRIBILD.xml:S2:1890:3	and	CC	O	O
HBV	STRIBILD.xml:S2:1894:3	hbv	NNP	O	O
who	STRIBILD.xml:S2:1898:3	who	WP	O	O
have	STRIBILD.xml:S2:1902:4	have	VBP	O	O
discontinued	STRIBILD.xml:S2:1907:12	discontinu	VBN	O	O
EMTRIVA	STRIBILD.xml:S2:1920:7	emtriva	NNP	O	O
or	STRIBILD.xml:S2:1928:2	or	CC	O	O
VIREAD	STRIBILD.xml:S2:1931:6	viread	NNP	O	O
,	STRIBILD.xml:S2:1937:1	,	,	O	O
two	STRIBILD.xml:S2:1939:3	two	CD	O	O
of	STRIBILD.xml:S2:1943:2	of	IN	O	O
the	STRIBILD.xml:S2:1946:3	the	DT	O	O
components	STRIBILD.xml:S2:1950:10	compon	NNS	O	O
of	STRIBILD.xml:S2:1961:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S2:1964:8	stribild	NNP	O	O
.	STRIBILD.xml:S2:1972:1	.	.	O	O

Hepatic	STRIBILD.xml:S2:1974:7	hepat	JJ	O	O
function	STRIBILD.xml:S2:1982:8	function	NN	O	O
should	STRIBILD.xml:S2:1991:6	should	MD	O	O
be	STRIBILD.xml:S2:1998:2	be	VB	O	O
monitored	STRIBILD.xml:S2:2001:9	monitor	VBN	O	O
closely	STRIBILD.xml:S2:2011:7	close	RB	O	O
in	STRIBILD.xml:S2:2019:2	in	IN	O	O
these	STRIBILD.xml:S2:2022:5	these	DT	O	O
patients	STRIBILD.xml:S2:2028:8	patient	NNS	O	O
.	STRIBILD.xml:S2:2036:1	.	.	O	O

If	STRIBILD.xml:S2:2038:2	If	IN	O	O
appropriate	STRIBILD.xml:S2:2041:11	appropri	JJ	O	O
,	STRIBILD.xml:S2:2052:1	,	,	O	O
initiation	STRIBILD.xml:S2:2054:10	initi	NN	O	O
of	STRIBILD.xml:S2:2065:2	of	IN	O	O
anti	STRIBILD.xml:S2:2068:4	anti	JJ	O	O
-	STRIBILD.xml:S2:2072:1	-	:	O	O
hepatitis	STRIBILD.xml:S2:2073:9	hepat	NN	O	O
B	STRIBILD.xml:S2:2083:1	B	NNP	O	O
therapy	STRIBILD.xml:S2:2085:7	therapi	NN	O	O
may	STRIBILD.xml:S2:2093:3	may	MD	O	O
be	STRIBILD.xml:S2:2097:2	be	VB	O	O
warranted	STRIBILD.xml:S2:2100:9	warrant	VBN	O	O
.	STRIBILD.xml:S2:2109:1	.	.	O	O

(	STRIBILD.xml:S2:2111:1	(	(	O	O
5.2	STRIBILD.xml:S2:2112:3	5.2	CD	O	O
)	STRIBILD.xml:S2:2115:1	)	)	O	O
\n	STRIBILD.xml:S2:2117:1	\n	VBD	O	O
5	STRIBILD.xml:S3:4:1	5	CD	O	O
WARNINGS	STRIBILD.xml:S3:6:8	warn	NNP	O	O
AND	STRIBILD.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	STRIBILD.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	STRIBILD.xml:S3:37:7	excerpt	NNS	O	O
:	STRIBILD.xml:S3:44:1	:	:	O	O
New	STRIBILD.xml:S3:52:3	new	NNP	B-AdverseReaction	O
onset	STRIBILD.xml:S3:56:5	onset	MD	I-AdverseReaction	O
or	STRIBILD.xml:S3:62:2	or	CC	O	O
worsening	STRIBILD.xml:S3:65:9	worsen	VBG	B-AdverseReaction	O
renal	STRIBILD.xml:S3:75:5	renal	JJ	I-AdverseReaction	O
impairment	STRIBILD.xml:S3:81:10	impair	NN	I-AdverseReaction	O
:	STRIBILD.xml:S3:91:1	:	:	O	O
Can	STRIBILD.xml:S3:93:3	can	MD	O	O
include	STRIBILD.xml:S3:97:7	includ	VB	O	O
acute	STRIBILD.xml:S3:105:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
renal	STRIBILD.xml:S3:111:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	STRIBILD.xml:S3:117:7	failur	NN	I-AdverseReaction	I-AdverseReaction
and	STRIBILD.xml:S3:125:3	and	CC	O	O
Fanconi	STRIBILD.xml:S3:129:7	fanconi	NNP	B-AdverseReaction	O
syndrome	STRIBILD.xml:S3:137:8	syndrom	NN	I-AdverseReaction	O
.	STRIBILD.xml:S3:145:1	.	.	O	O

Assess	STRIBILD.xml:S3:147:6	assess	NNP	O	O
creatinine	STRIBILD.xml:S3:154:10	creatinin	NN	O	O
clearance	STRIBILD.xml:S3:165:9	clearanc	NN	O	O
(	STRIBILD.xml:S3:175:1	(	(	O	O
CLcr	STRIBILD.xml:S3:176:4	clcr	NNP	O	O
)	STRIBILD.xml:S3:180:1	)	)	O	O
,	STRIBILD.xml:S3:181:1	,	,	O	O
urine	STRIBILD.xml:S3:183:5	urin	JJ	O	B-AdverseReaction
glucose	STRIBILD.xml:S3:189:7	glucos	NN	O	I-AdverseReaction
and	STRIBILD.xml:S3:197:3	and	CC	O	O
urine	STRIBILD.xml:S3:201:5	urin	JJ	O	O
protein	STRIBILD.xml:S3:207:7	protein	NN	O	O
before	STRIBILD.xml:S3:215:6	befor	IN	O	O
initiating	STRIBILD.xml:S3:222:10	initi	VBG	O	O
treatment	STRIBILD.xml:S3:233:9	treatment	NN	O	O
with	STRIBILD.xml:S3:243:4	with	IN	O	O
STRIBILD	STRIBILD.xml:S3:248:8	stribild	NNP	O	O
.	STRIBILD.xml:S3:256:1	.	.	O	O

Monitor	STRIBILD.xml:S3:258:7	monitor	NNP	O	O
CLcr	STRIBILD.xml:S3:266:4	clcr	NNP	O	O
,	STRIBILD.xml:S3:270:1	,	,	O	O
urine	STRIBILD.xml:S3:272:5	urin	JJ	O	B-AdverseReaction
glucose	STRIBILD.xml:S3:278:7	glucos	NN	O	I-AdverseReaction
,	STRIBILD.xml:S3:285:1	,	,	O	O
and	STRIBILD.xml:S3:287:3	and	CC	O	O
urine	STRIBILD.xml:S3:291:5	urin	JJ	O	O
protein	STRIBILD.xml:S3:297:7	protein	NN	O	O
in	STRIBILD.xml:S3:305:2	in	IN	O	O
all	STRIBILD.xml:S3:308:3	all	DT	O	O
patients	STRIBILD.xml:S3:312:8	patient	NNS	O	O
.	STRIBILD.xml:S3:320:1	.	.	O	O

Monitor	STRIBILD.xml:S3:322:7	monitor	NNP	O	O
serum	STRIBILD.xml:S3:330:5	serum	NN	O	O
phosphorus	STRIBILD.xml:S3:336:10	phosphoru	NN	O	O
in	STRIBILD.xml:S3:347:2	in	IN	O	O
patients	STRIBILD.xml:S3:350:8	patient	NNS	O	O
at	STRIBILD.xml:S3:359:2	at	IN	O	O
risk	STRIBILD.xml:S3:362:4	risk	NN	O	O
for	STRIBILD.xml:S3:367:3	for	IN	O	O
renal	STRIBILD.xml:S3:371:5	renal	JJ	O	O
impairment	STRIBILD.xml:S3:377:10	impair	NN	O	O
.	STRIBILD.xml:S3:387:1	.	.	O	O

Avoid	STRIBILD.xml:S3:389:5	avoid	NNP	O	O
administering	STRIBILD.xml:S3:395:13	administ	VBG	O	O
STRIBILD	STRIBILD.xml:S3:409:8	stribild	NNP	O	O
with	STRIBILD.xml:S3:418:4	with	IN	O	O
concurrent	STRIBILD.xml:S3:423:10	concurr	NN	O	O
or	STRIBILD.xml:S3:434:2	or	CC	O	O
recent	STRIBILD.xml:S3:437:6	recent	JJ	O	O
use	STRIBILD.xml:S3:444:3	use	NN	O	O
of	STRIBILD.xml:S3:448:2	of	IN	O	O
nephrotoxic	STRIBILD.xml:S3:451:11	nephrotox	JJ	O	O
drugs	STRIBILD.xml:S3:463:5	drug	NNS	O	O
.	STRIBILD.xml:S3:468:1	.	.	O	O

(	STRIBILD.xml:S3:470:1	(	(	O	O
5.3	STRIBILD.xml:S3:473:3	5.3	CD	O	O
)	STRIBILD.xml:S3:478:1	)	)	O	O

Avoid	STRIBILD.xml:S3:485:5	avoid	NNP	O	O
coadministration	STRIBILD.xml:S3:491:16	coadministr	NN	O	O
with	STRIBILD.xml:S3:508:4	with	IN	O	O
other	STRIBILD.xml:S3:513:5	other	JJ	O	O
anti	STRIBILD.xml:S3:519:4	anti	JJ	O	O
-	STRIBILD.xml:S3:523:1	-	:	O	O
retroviral	STRIBILD.xml:S3:524:10	retrovir	JJ	O	O
products	STRIBILD.xml:S3:535:8	product	NNS	O	O
:	STRIBILD.xml:S3:543:1	:	:	O	O
Do	STRIBILD.xml:S3:545:2	Do	NNP	O	O
not	STRIBILD.xml:S3:548:3	not	RB	O	O
use	STRIBILD.xml:S3:552:3	use	VB	O	O
with	STRIBILD.xml:S3:556:4	with	IN	O	O
products	STRIBILD.xml:S3:561:8	product	NNS	O	O
containing	STRIBILD.xml:S3:570:10	contain	VBG	O	O
any	STRIBILD.xml:S3:581:3	ani	DT	O	O
of	STRIBILD.xml:S3:585:2	of	IN	O	O
the	STRIBILD.xml:S3:588:3	the	DT	O	O
components	STRIBILD.xml:S3:592:10	compon	NNS	O	O
of	STRIBILD.xml:S3:603:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:606:8	stribild	NNP	O	O
(	STRIBILD.xml:S3:615:1	(	(	O	O
cobicistat	STRIBILD.xml:S3:616:10	cobicistat	NN	O	O
,	STRIBILD.xml:S3:626:1	,	,	O	O
elvitegravir	STRIBILD.xml:S3:628:12	elvitegravir	NN	O	B-AdverseReaction
,	STRIBILD.xml:S3:640:1	,	,	O	O
emtricitabine	STRIBILD.xml:S3:642:13	emtricitabin	NN	O	O
,	STRIBILD.xml:S3:655:1	,	,	O	O
and	STRIBILD.xml:S3:657:3	and	CC	O	O
tenofovir	STRIBILD.xml:S3:661:9	tenofovir	JJ	O	B-AdverseReaction
disoproxil	STRIBILD.xml:S3:671:10	disoproxil	NN	O	I-AdverseReaction
fumarate	STRIBILD.xml:S3:682:8	fumar	NN	O	I-AdverseReaction
)	STRIBILD.xml:S3:690:1	)	)	O	O
,	STRIBILD.xml:S3:691:1	,	,	O	O
including	STRIBILD.xml:S3:693:9	includ	VBG	O	O
ATRIPLA	STRIBILD.xml:S3:703:7	atripla	NNP	O	O
,	STRIBILD.xml:S3:710:1	,	,	O	O
COMPLERA	STRIBILD.xml:S3:712:8	complera	NNP	O	O
,	STRIBILD.xml:S3:720:1	,	,	O	O
EMTRIVA	STRIBILD.xml:S3:722:7	emtriva	NNP	O	O
,	STRIBILD.xml:S3:729:1	,	,	O	O
TRUVADA	STRIBILD.xml:S3:731:7	truvada	NNP	O	O
,	STRIBILD.xml:S3:738:1	,	,	O	O
TYBOST	STRIBILD.xml:S3:740:6	tybost	NNP	O	O
,	STRIBILD.xml:S3:746:1	,	,	O	O
VIREAD	STRIBILD.xml:S3:748:6	viread	NNP	O	O
,	STRIBILD.xml:S3:754:1	,	,	O	O
or	STRIBILD.xml:S3:756:2	or	CC	O	O
VITEKTA	STRIBILD.xml:S3:759:7	vitekta	NNP	O	O
;	STRIBILD.xml:S3:766:1	;	:	O	O
with	STRIBILD.xml:S3:768:4	with	IN	O	O
drugs	STRIBILD.xml:S3:773:5	drug	NNS	O	O
containing	STRIBILD.xml:S3:779:10	contain	VBG	O	O
lamivudine	STRIBILD.xml:S3:790:10	lamivudin	NN	O	O
;	STRIBILD.xml:S3:800:1	;	:	O	O
or	STRIBILD.xml:S3:802:2	or	CC	O	O
with	STRIBILD.xml:S3:805:4	with	IN	O	O
drugs	STRIBILD.xml:S3:810:5	drug	NNS	O	O
or	STRIBILD.xml:S3:816:2	or	CC	O	O
regimens	STRIBILD.xml:S3:819:8	regimen	NNS	O	O
containing	STRIBILD.xml:S3:828:10	contain	VBG	O	O
ritonavir	STRIBILD.xml:S3:839:9	ritonavir	NN	O	O
.	STRIBILD.xml:S3:848:1	.	.	O	O

Do	STRIBILD.xml:S3:850:2	Do	NNP	O	O
not	STRIBILD.xml:S3:853:3	not	RB	O	O
administer	STRIBILD.xml:S3:857:10	administ	VB	O	O
in	STRIBILD.xml:S3:868:2	in	IN	O	O
combination	STRIBILD.xml:S3:871:11	combin	NN	O	O
with	STRIBILD.xml:S3:883:4	with	IN	O	O
HEPSERA	STRIBILD.xml:S3:888:7	hepsera	NNP	O	O
.	STRIBILD.xml:S3:895:1	.	.	O	O

(	STRIBILD.xml:S3:897:1	(	(	O	O
5.4	STRIBILD.xml:S3:900:3	5.4	CD	O	O
)	STRIBILD.xml:S3:905:1	)	)	O	O

Risk	STRIBILD.xml:S3:912:4	risk	NN	O	O
of	STRIBILD.xml:S3:917:2	of	IN	O	O
adverse	STRIBILD.xml:S3:920:7	advers	JJ	O	O
reactions	STRIBILD.xml:S3:928:9	reaction	NNS	O	O
or	STRIBILD.xml:S3:938:2	or	CC	O	O
loss	STRIBILD.xml:S3:941:4	loss	NN	O	B-AdverseReaction
of	STRIBILD.xml:S3:946:2	of	IN	O	I-AdverseReaction
virologic	STRIBILD.xml:S3:949:9	virolog	JJ	O	I-AdverseReaction
response	STRIBILD.xml:S3:959:8	respons	NN	O	I-AdverseReaction
due	STRIBILD.xml:S3:968:3	due	JJ	O	O
to	STRIBILD.xml:S3:972:2	to	TO	O	O
drug	STRIBILD.xml:S3:975:4	drug	NN	O	O
interactions	STRIBILD.xml:S3:980:12	interact	NNS	O	O
:	STRIBILD.xml:S3:992:1	:	:	O	O
The	STRIBILD.xml:S3:994:3	the	DT	O	O
concomitant	STRIBILD.xml:S3:998:11	concomit	NN	O	O
use	STRIBILD.xml:S3:1010:3	use	NN	O	O
of	STRIBILD.xml:S3:1014:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:1017:8	stribild	NNP	O	O
and	STRIBILD.xml:S3:1026:3	and	CC	O	O
other	STRIBILD.xml:S3:1030:5	other	JJ	O	O
drugs	STRIBILD.xml:S3:1036:5	drug	NNS	O	O
may	STRIBILD.xml:S3:1042:3	may	MD	O	O
result	STRIBILD.xml:S3:1046:6	result	VB	O	O
in	STRIBILD.xml:S3:1053:2	in	IN	O	O
known	STRIBILD.xml:S3:1056:5	known	NN	O	O
or	STRIBILD.xml:S3:1062:2	or	CC	O	O
potentially	STRIBILD.xml:S3:1065:11	potenti	RB	O	O
significant	STRIBILD.xml:S3:1077:11	signific	JJ	O	O
drug	STRIBILD.xml:S3:1089:4	drug	NN	O	O
interactions	STRIBILD.xml:S3:1094:12	interact	NNS	O	O
,	STRIBILD.xml:S3:1106:1	,	,	O	O
some	STRIBILD.xml:S3:1108:4	some	DT	O	O
of	STRIBILD.xml:S3:1113:2	of	IN	O	O
which	STRIBILD.xml:S3:1116:5	which	WDT	O	O
may	STRIBILD.xml:S3:1122:3	may	MD	O	O
lead	STRIBILD.xml:S3:1126:4	lead	VB	O	O
to	STRIBILD.xml:S3:1131:2	to	TO	O	O
loss	STRIBILD.xml:S3:1134:4	loss	NN	O	O
of	STRIBILD.xml:S3:1139:2	of	IN	O	O
therapeutic	STRIBILD.xml:S3:1142:11	therapeut	JJ	O	O
effect	STRIBILD.xml:S3:1154:6	effect	NN	O	O
of	STRIBILD.xml:S3:1161:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:1164:8	stribild	NNP	O	O
and	STRIBILD.xml:S3:1173:3	and	CC	O	O
possible	STRIBILD.xml:S3:1177:8	possibl	JJ	O	O
development	STRIBILD.xml:S3:1186:11	develop	NN	O	O
of	STRIBILD.xml:S3:1198:2	of	IN	O	O
resistance	STRIBILD.xml:S3:1201:10	resist	NN	O	O
;	STRIBILD.xml:S3:1211:1	;	:	O	O
and	STRIBILD.xml:S3:1213:3	and	CC	O	O
possible	STRIBILD.xml:S3:1217:8	possibl	JJ	O	O
clinically	STRIBILD.xml:S3:1226:10	clinic	RB	O	O
significant	STRIBILD.xml:S3:1237:11	signific	JJ	O	O
adverse	STRIBILD.xml:S3:1249:7	advers	JJ	O	O
reactions	STRIBILD.xml:S3:1257:9	reaction	NNS	O	O
from	STRIBILD.xml:S3:1267:4	from	IN	O	O
greater	STRIBILD.xml:S3:1272:7	greater	JJR	O	O
exposures	STRIBILD.xml:S3:1280:9	exposur	NNS	O	O
of	STRIBILD.xml:S3:1290:2	of	IN	O	O
concomitant	STRIBILD.xml:S3:1293:11	concomit	JJ	O	O
drugs	STRIBILD.xml:S3:1305:5	drug	NNS	O	O
.	STRIBILD.xml:S3:1310:1	.	.	O	O

(	STRIBILD.xml:S3:1312:1	(	(	O	O
5.5	STRIBILD.xml:S3:1315:3	5.5	CD	O	O
)	STRIBILD.xml:S3:1320:1	)	)	O	O

Decreases	STRIBILD.xml:S3:1327:9	decreas	NNS	B-AdverseReaction	B-AdverseReaction
in	STRIBILD.xml:S3:1337:2	in	IN	I-AdverseReaction	I-AdverseReaction
bone	STRIBILD.xml:S3:1340:4	bone	JJ	I-AdverseReaction	I-AdverseReaction
mineral	STRIBILD.xml:S3:1345:7	miner	JJ	I-AdverseReaction	I-AdverseReaction
density	STRIBILD.xml:S3:1353:7	densiti	NN	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S3:1361:1	(	(	O	O
BMD	STRIBILD.xml:S3:1362:3	bmd	NNP	I-AdverseReaction	O
)	STRIBILD.xml:S3:1365:1	)	)	O	O
:	STRIBILD.xml:S3:1366:1	:	:	O	O
Consider	STRIBILD.xml:S3:1368:8	consid	VB	O	O
monitoring	STRIBILD.xml:S3:1377:10	monitor	VBG	O	O
BMD	STRIBILD.xml:S3:1388:3	bmd	NNP	O	O
in	STRIBILD.xml:S3:1392:2	in	IN	O	O
patients	STRIBILD.xml:S3:1395:8	patient	NNS	O	O
with	STRIBILD.xml:S3:1404:4	with	IN	O	O
a	STRIBILD.xml:S3:1409:1	a	DT	O	O
history	STRIBILD.xml:S3:1411:7	histori	NN	O	O
of	STRIBILD.xml:S3:1419:2	of	IN	O	O
pathologic	STRIBILD.xml:S3:1422:10	patholog	JJ	O	O
fracture	STRIBILD.xml:S3:1433:8	fractur	NN	O	O
or	STRIBILD.xml:S3:1442:2	or	CC	O	O
other	STRIBILD.xml:S3:1445:5	other	JJ	O	O
risk	STRIBILD.xml:S3:1451:4	risk	NN	O	O
factors	STRIBILD.xml:S3:1456:7	factor	NNS	O	O
of	STRIBILD.xml:S3:1464:2	of	IN	O	O
osteoporosis	STRIBILD.xml:S3:1467:12	osteoporosi	NN	O	O
or	STRIBILD.xml:S3:1480:2	or	CC	O	O
bone	STRIBILD.xml:S3:1483:4	bone	NN	O	O
loss	STRIBILD.xml:S3:1488:4	loss	NN	O	O
.	STRIBILD.xml:S3:1492:1	.	.	O	O

(	STRIBILD.xml:S3:1494:1	(	(	O	O
5.6	STRIBILD.xml:S3:1497:3	5.6	CD	O	O
)	STRIBILD.xml:S3:1502:1	)	)	O	O

Redistribution	STRIBILD.xml:S3:1509:14	redistribut	NNP	B-AdverseReaction	B-AdverseReaction
accumulation	STRIBILD.xml:S3:1524:12	accumul	NN	B-AdverseReaction	I-AdverseReaction
of	STRIBILD.xml:S3:1537:2	of	IN	I-AdverseReaction	I-AdverseReaction
body	STRIBILD.xml:S3:1540:4	bodi	NN	I-AdverseReaction	I-AdverseReaction
fat	STRIBILD.xml:S3:1545:3	fat	NN	I-AdverseReaction	I-AdverseReaction
:	STRIBILD.xml:S3:1548:1	:	:	O	O
Observed	STRIBILD.xml:S3:1550:8	observ	VBN	O	O
in	STRIBILD.xml:S3:1559:2	in	IN	O	O
patients	STRIBILD.xml:S3:1562:8	patient	NNS	O	O
receiving	STRIBILD.xml:S3:1571:9	receiv	VBG	O	O
antiretroviral	STRIBILD.xml:S3:1581:14	antiretrovir	JJ	O	O
therapy	STRIBILD.xml:S3:1596:7	therapi	NN	O	O
.	STRIBILD.xml:S3:1603:1	.	.	O	O

(	STRIBILD.xml:S3:1605:1	(	(	O	O
5.7	STRIBILD.xml:S3:1608:3	5.7	CD	O	O
)	STRIBILD.xml:S3:1613:1	)	)	O	O

Immune	STRIBILD.xml:S3:1620:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
reconstitution	STRIBILD.xml:S3:1627:14	reconstitut	NN	I-AdverseReaction	I-AdverseReaction
syndrome	STRIBILD.xml:S3:1642:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
:	STRIBILD.xml:S3:1650:1	:	:	O	O
May	STRIBILD.xml:S3:1652:3	may	NNP	O	O
necessitate	STRIBILD.xml:S3:1656:11	necessit	VB	O	O
further	STRIBILD.xml:S3:1668:7	further	JJ	O	O
evaluation	STRIBILD.xml:S3:1676:10	evalu	NN	O	O
and	STRIBILD.xml:S3:1687:3	and	CC	O	O
treatment	STRIBILD.xml:S3:1691:9	treatment	NN	O	O
.	STRIBILD.xml:S3:1700:1	.	.	O	O

(	STRIBILD.xml:S3:1702:1	(	(	O	O
5.8	STRIBILD.xml:S3:1705:3	5.8	CD	O	O
)	STRIBILD.xml:S3:1710:1	)	)	O	O

5.1	STRIBILD.xml:S3:1724:3	5.1	CD	O	O

Lactic	STRIBILD.xml:S3:1728:6	lactic	JJ	O	O

Acidosis	STRIBILD.xml:S3:1735:8	acidosi	NNP	O	O
Severe	STRIBILD.xml:S3:1744:6	sever	NNP	O	O
Hepatomegaly	STRIBILD.xml:S3:1751:12	hepatomegali	NNP	O	O
with	STRIBILD.xml:S3:1764:4	with	IN	O	O
Steatosis	STRIBILD.xml:S3:1769:9	steatosi	NNP	O	O

Lactic	STRIBILD.xml:S3:1784:6	lactic	JJ	B-AdverseReaction	O
acidosis	STRIBILD.xml:S3:1791:8	acidosi	NN	I-AdverseReaction	O
and	STRIBILD.xml:S3:1800:3	and	CC	O	O
severe	STRIBILD.xml:S3:1804:6	sever	JJ	O	O
hepatomegaly	STRIBILD.xml:S3:1811:12	hepatomegali	NN	B-AdverseReaction	O
with	STRIBILD.xml:S3:1824:4	with	IN	O	O
steatosis	STRIBILD.xml:S3:1829:9	steatosi	NN	B-AdverseReaction	O
,	STRIBILD.xml:S3:1838:1	,	,	O	O
including	STRIBILD.xml:S3:1840:9	includ	VBG	O	O
fatal	STRIBILD.xml:S3:1850:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
cases	STRIBILD.xml:S3:1856:5	case	NNS	O	O
,	STRIBILD.xml:S3:1861:1	,	,	O	O
have	STRIBILD.xml:S3:1863:4	have	VBP	O	O
been	STRIBILD.xml:S3:1868:4	been	VBN	O	O
reported	STRIBILD.xml:S3:1873:8	report	VBN	O	O
with	STRIBILD.xml:S3:1882:4	with	IN	O	O
the	STRIBILD.xml:S3:1887:3	the	DT	O	O
use	STRIBILD.xml:S3:1891:3	use	NN	O	O
of	STRIBILD.xml:S3:1895:2	of	IN	O	O
nucleoside	STRIBILD.xml:S3:1898:10	nucleosid	JJ	O	O
analogs	STRIBILD.xml:S3:1909:7	analog	NNS	O	O
,	STRIBILD.xml:S3:1916:1	,	,	O	O
including	STRIBILD.xml:S3:1918:9	includ	VBG	O	O
tenofovir	STRIBILD.xml:S3:1928:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:1938:2	DF	NNP	O	O
,	STRIBILD.xml:S3:1940:1	,	,	O	O
a	STRIBILD.xml:S3:1942:1	a	DT	O	O
component	STRIBILD.xml:S3:1944:9	compon	NN	O	O
of	STRIBILD.xml:S3:1954:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:1957:8	stribild	NNP	O	O
,	STRIBILD.xml:S3:1965:1	,	,	O	O
in	STRIBILD.xml:S3:1967:2	in	IN	O	O
combination	STRIBILD.xml:S3:1970:11	combin	NN	O	O
with	STRIBILD.xml:S3:1982:4	with	IN	O	O
other	STRIBILD.xml:S3:1987:5	other	JJ	O	O
antiretrovirals	STRIBILD.xml:S3:1993:15	antiretrovir	NNS	O	O
.	STRIBILD.xml:S3:2008:1	.	.	O	O

A	STRIBILD.xml:S3:2010:1	A	DT	O	O
majority	STRIBILD.xml:S3:2012:8	major	NN	O	O
of	STRIBILD.xml:S3:2021:2	of	IN	O	O
these	STRIBILD.xml:S3:2024:5	these	DT	O	O
cases	STRIBILD.xml:S3:2030:5	case	NNS	O	O
have	STRIBILD.xml:S3:2036:4	have	VBP	O	O
been	STRIBILD.xml:S3:2041:4	been	VBN	O	O
in	STRIBILD.xml:S3:2046:2	in	IN	O	O
women	STRIBILD.xml:S3:2049:5	women	NNS	O	O
.	STRIBILD.xml:S3:2054:1	.	.	O	O

Obesity	STRIBILD.xml:S3:2056:7	obes	NN	O	O
and	STRIBILD.xml:S3:2064:3	and	CC	O	O
prolonged	STRIBILD.xml:S3:2068:9	prolong	JJ	O	O
nucleoside	STRIBILD.xml:S3:2078:10	nucleosid	NN	O	O
exposure	STRIBILD.xml:S3:2089:8	exposur	NN	O	O
may	STRIBILD.xml:S3:2098:3	may	MD	O	O
be	STRIBILD.xml:S3:2102:2	be	VB	O	O
risk	STRIBILD.xml:S3:2105:4	risk	JJ	O	O
factors	STRIBILD.xml:S3:2110:7	factor	NNS	O	O
.	STRIBILD.xml:S3:2117:1	.	.	O	O

Particular	STRIBILD.xml:S3:2119:10	particular	JJ	O	O
caution	STRIBILD.xml:S3:2130:7	caution	NN	O	O
should	STRIBILD.xml:S3:2138:6	should	MD	O	O
be	STRIBILD.xml:S3:2145:2	be	VB	O	O
exercised	STRIBILD.xml:S3:2148:9	exercis	VBN	O	O
when	STRIBILD.xml:S3:2158:4	when	WRB	O	O
administering	STRIBILD.xml:S3:2163:13	administ	VBG	O	O
nucleoside	STRIBILD.xml:S3:2177:10	nucleosid	RB	O	O
analogs	STRIBILD.xml:S3:2188:7	analog	NNS	O	O
to	STRIBILD.xml:S3:2196:2	to	TO	O	O
any	STRIBILD.xml:S3:2199:3	ani	DT	O	O
patient	STRIBILD.xml:S3:2203:7	patient	NN	O	O
with	STRIBILD.xml:S3:2211:4	with	IN	O	O
known	STRIBILD.xml:S3:2216:5	known	VBN	O	O
risk	STRIBILD.xml:S3:2222:4	risk	NN	O	O
factors	STRIBILD.xml:S3:2227:7	factor	NNS	O	O
for	STRIBILD.xml:S3:2235:3	for	IN	O	O
liver	STRIBILD.xml:S3:2239:5	liver	JJ	O	O
disease	STRIBILD.xml:S3:2245:7	diseas	NN	O	O
;	STRIBILD.xml:S3:2252:1	;	:	O	O
however	STRIBILD.xml:S3:2254:7	howev	RB	O	O
,	STRIBILD.xml:S3:2261:1	,	,	O	O
cases	STRIBILD.xml:S3:2263:5	case	NNS	O	O
have	STRIBILD.xml:S3:2269:4	have	VBP	O	O
also	STRIBILD.xml:S3:2274:4	also	RB	O	O
been	STRIBILD.xml:S3:2279:4	been	VBN	O	O
reported	STRIBILD.xml:S3:2284:8	report	VBN	O	O
in	STRIBILD.xml:S3:2293:2	in	IN	O	O
patients	STRIBILD.xml:S3:2296:8	patient	NNS	O	O
with	STRIBILD.xml:S3:2305:4	with	IN	O	O
no	STRIBILD.xml:S3:2310:2	no	DT	O	O
known	STRIBILD.xml:S3:2313:5	known	VBN	O	O
risk	STRIBILD.xml:S3:2319:4	risk	NN	O	O
factors	STRIBILD.xml:S3:2324:7	factor	NNS	O	O
.	STRIBILD.xml:S3:2331:1	.	.	O	O

Treatment	STRIBILD.xml:S3:2333:9	treatment	NN	O	O
with	STRIBILD.xml:S3:2343:4	with	IN	O	O
STRIBILD	STRIBILD.xml:S3:2348:8	stribild	NNP	O	O
should	STRIBILD.xml:S3:2357:6	should	MD	O	O
be	STRIBILD.xml:S3:2364:2	be	VB	O	O
suspended	STRIBILD.xml:S3:2367:9	suspend	VBN	O	O
in	STRIBILD.xml:S3:2377:2	in	IN	O	O
any	STRIBILD.xml:S3:2380:3	ani	DT	O	O
patient	STRIBILD.xml:S3:2384:7	patient	NN	O	O
who	STRIBILD.xml:S3:2392:3	who	WP	O	O
develops	STRIBILD.xml:S3:2396:8	develop	VBZ	O	O
clinical	STRIBILD.xml:S3:2405:8	clinic	JJ	O	O
or	STRIBILD.xml:S3:2414:2	or	CC	O	O
laboratory	STRIBILD.xml:S3:2417:10	laboratori	JJ	O	O
findings	STRIBILD.xml:S3:2428:8	find	NNS	O	O
suggestive	STRIBILD.xml:S3:2437:10	suggest	NN	O	O
of	STRIBILD.xml:S3:2448:2	of	IN	O	O
lactic	STRIBILD.xml:S3:2451:6	lactic	JJ	O	O
acidosis	STRIBILD.xml:S3:2458:8	acidosi	NN	O	O
or	STRIBILD.xml:S3:2467:2	or	CC	O	O
pronounced	STRIBILD.xml:S3:2470:10	pronounc	VBN	O	O
hepatotoxicity	STRIBILD.xml:S3:2481:14	hepatotox	NN	O	O
(	STRIBILD.xml:S3:2496:1	(	(	O	O
which	STRIBILD.xml:S3:2497:5	which	WDT	O	O
may	STRIBILD.xml:S3:2503:3	may	MD	O	O
include	STRIBILD.xml:S3:2507:7	includ	VB	O	O
hepatomegaly	STRIBILD.xml:S3:2515:12	hepatomegali	NN	O	B-AdverseReaction
and	STRIBILD.xml:S3:2528:3	and	CC	O	O
steatosis	STRIBILD.xml:S3:2532:9	steatosi	NN	O	O
even	STRIBILD.xml:S3:2542:4	even	RB	O	O
in	STRIBILD.xml:S3:2547:2	in	IN	O	O
the	STRIBILD.xml:S3:2550:3	the	DT	O	O
absence	STRIBILD.xml:S3:2554:7	absenc	NN	O	O
of	STRIBILD.xml:S3:2562:2	of	IN	O	O
marked	STRIBILD.xml:S3:2565:6	mark	JJ	O	O
transaminase	STRIBILD.xml:S3:2572:12	transaminas	NN	O	O
elevations	STRIBILD.xml:S3:2585:10	elev	NNS	O	O
)	STRIBILD.xml:S3:2595:1	)	)	O	O
.	STRIBILD.xml:S3:2596:1	.	.	O	O

5.2	STRIBILD.xml:S3:2605:3	5.2	CD	O	O
Patients	STRIBILD.xml:S3:2609:8	patient	NNS	O	O
Coinfected	STRIBILD.xml:S3:2618:10	coinfect	VBN	O	O
with	STRIBILD.xml:S3:2629:4	with	IN	O	O
HIV	STRIBILD.xml:S3:2634:3	hiv	NNP	O	O
-	STRIBILD.xml:S3:2637:1	-	:	O	O
1	STRIBILD.xml:S3:2638:1	1	CD	O	O
and	STRIBILD.xml:S3:2640:3	and	CC	O	O
HBV	STRIBILD.xml:S3:2644:3	hbv	NNP	O	O

It	STRIBILD.xml:S3:2653:2	It	PRP	O	O
is	STRIBILD.xml:S3:2656:2	is	VBZ	O	O
recommended	STRIBILD.xml:S3:2659:11	recommend	VBN	O	O
that	STRIBILD.xml:S3:2671:4	that	IN	O	O
all	STRIBILD.xml:S3:2676:3	all	DT	O	O
patients	STRIBILD.xml:S3:2680:8	patient	NNS	O	O
with	STRIBILD.xml:S3:2689:4	with	IN	O	O
HIV	STRIBILD.xml:S3:2694:3	hiv	NNP	O	O
-	STRIBILD.xml:S3:2697:1	-	:	O	O
1	STRIBILD.xml:S3:2698:1	1	CD	O	O
be	STRIBILD.xml:S3:2700:2	be	VB	O	O
tested	STRIBILD.xml:S3:2703:6	test	VBN	O	O
for	STRIBILD.xml:S3:2710:3	for	IN	O	O
the	STRIBILD.xml:S3:2714:3	the	DT	O	O
presence	STRIBILD.xml:S3:2718:8	presenc	NN	O	O
of	STRIBILD.xml:S3:2727:2	of	IN	O	O
chronic	STRIBILD.xml:S3:2730:7	chronic	JJ	O	O
hepatitis	STRIBILD.xml:S3:2738:9	hepat	NN	O	O
B	STRIBILD.xml:S3:2748:1	B	NNP	O	O
virus	STRIBILD.xml:S3:2750:5	viru	NN	O	O
(	STRIBILD.xml:S3:2756:1	(	(	O	O
HBV	STRIBILD.xml:S3:2757:3	hbv	NNP	O	I-AdverseReaction
)	STRIBILD.xml:S3:2760:1	)	)	O	O
before	STRIBILD.xml:S3:2762:6	befor	IN	O	O
initiating	STRIBILD.xml:S3:2769:10	initi	VBG	O	O
antiretroviral	STRIBILD.xml:S3:2780:14	antiretrovir	JJ	O	O
therapy	STRIBILD.xml:S3:2795:7	therapi	NN	O	O
.	STRIBILD.xml:S3:2802:1	.	.	O	O

STRIBILD	STRIBILD.xml:S3:2804:8	stribild	NNP	O	O
is	STRIBILD.xml:S3:2813:2	is	VBZ	O	O
not	STRIBILD.xml:S3:2816:3	not	RB	O	O
approved	STRIBILD.xml:S3:2820:8	approv	VBN	O	O
for	STRIBILD.xml:S3:2829:3	for	IN	O	O
the	STRIBILD.xml:S3:2833:3	the	DT	O	O
treatment	STRIBILD.xml:S3:2837:9	treatment	NN	O	O
of	STRIBILD.xml:S3:2847:2	of	IN	O	O
chronic	STRIBILD.xml:S3:2850:7	chronic	JJ	O	O
HBV	STRIBILD.xml:S3:2858:3	hbv	NNP	O	O
infection	STRIBILD.xml:S3:2862:9	infect	NN	O	O
and	STRIBILD.xml:S3:2872:3	and	CC	O	O
the	STRIBILD.xml:S3:2876:3	the	DT	O	O
safety	STRIBILD.xml:S3:2880:6	safeti	NN	O	O
and	STRIBILD.xml:S3:2887:3	and	CC	O	O
efficacy	STRIBILD.xml:S3:2891:8	efficaci	NN	O	O
of	STRIBILD.xml:S3:2900:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:2903:8	stribild	NNP	O	O
have	STRIBILD.xml:S3:2912:4	have	VBP	O	O
not	STRIBILD.xml:S3:2917:3	not	RB	O	O
been	STRIBILD.xml:S3:2921:4	been	VBN	O	O
established	STRIBILD.xml:S3:2926:11	establish	VBN	O	O
in	STRIBILD.xml:S3:2938:2	in	IN	O	O
patients	STRIBILD.xml:S3:2941:8	patient	NNS	O	O
coinfected	STRIBILD.xml:S3:2950:10	coinfect	VBN	O	O
with	STRIBILD.xml:S3:2961:4	with	IN	O	O
HBV	STRIBILD.xml:S3:2966:3	hbv	NNP	O	O
and	STRIBILD.xml:S3:2970:3	and	CC	O	O
HIV	STRIBILD.xml:S3:2974:3	hiv	NNP	O	O
-	STRIBILD.xml:S3:2977:1	-	:	O	O
1	STRIBILD.xml:S3:2978:1	1	CD	O	O
.	STRIBILD.xml:S3:2979:1	.	.	O	O

Severe	STRIBILD.xml:S3:2981:6	sever	NNP	O	O
acute	STRIBILD.xml:S3:2988:5	acut	JJ	O	O
exacerbations	STRIBILD.xml:S3:2994:13	exacerb	NNS	O	O
of	STRIBILD.xml:S3:3008:2	of	IN	O	O
hepatitis	STRIBILD.xml:S3:3011:9	hepat	NN	O	O
B	STRIBILD.xml:S3:3021:1	B	NNP	O	O
have	STRIBILD.xml:S3:3023:4	have	VBP	O	O
been	STRIBILD.xml:S3:3028:4	been	VBN	O	O
reported	STRIBILD.xml:S3:3033:8	report	VBN	O	O
in	STRIBILD.xml:S3:3042:2	in	IN	O	O
patients	STRIBILD.xml:S3:3045:8	patient	NNS	O	O
who	STRIBILD.xml:S3:3054:3	who	WP	O	O
are	STRIBILD.xml:S3:3058:3	are	VBP	O	O
coinfected	STRIBILD.xml:S3:3062:10	coinfect	VBN	O	O
with	STRIBILD.xml:S3:3073:4	with	IN	O	O
HBV	STRIBILD.xml:S3:3078:3	hbv	NNP	O	O
and	STRIBILD.xml:S3:3082:3	and	CC	O	O
HIV	STRIBILD.xml:S3:3086:3	hiv	NNP	O	O
-	STRIBILD.xml:S3:3089:1	-	:	O	O
1	STRIBILD.xml:S3:3090:1	1	CD	O	O
and	STRIBILD.xml:S3:3092:3	and	CC	O	O
have	STRIBILD.xml:S3:3096:4	have	VBP	O	O
discontinued	STRIBILD.xml:S3:3101:12	discontinu	VBN	O	O
emtricitabine	STRIBILD.xml:S3:3114:13	emtricitabin	NN	O	O
or	STRIBILD.xml:S3:3128:2	or	CC	O	O
tenofovir	STRIBILD.xml:S3:3131:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:3141:2	DF	NNP	O	O
,	STRIBILD.xml:S3:3143:1	,	,	O	O
two	STRIBILD.xml:S3:3145:3	two	CD	O	O
of	STRIBILD.xml:S3:3149:2	of	IN	O	O
the	STRIBILD.xml:S3:3152:3	the	DT	O	O
components	STRIBILD.xml:S3:3156:10	compon	NNS	O	O
of	STRIBILD.xml:S3:3167:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:3170:8	stribild	NNP	O	O
.	STRIBILD.xml:S3:3178:1	.	.	O	O

In	STRIBILD.xml:S3:3180:2	In	IN	O	O
some	STRIBILD.xml:S3:3183:4	some	DT	O	O
patients	STRIBILD.xml:S3:3188:8	patient	NNS	O	O
infected	STRIBILD.xml:S3:3197:8	infect	VBN	O	O
with	STRIBILD.xml:S3:3206:4	with	IN	O	O
HBV	STRIBILD.xml:S3:3211:3	hbv	NNP	O	O
and	STRIBILD.xml:S3:3215:3	and	CC	O	O
treated	STRIBILD.xml:S3:3219:7	treat	VBN	O	O
with	STRIBILD.xml:S3:3227:4	with	IN	O	O
EMTRIVA	STRIBILD.xml:S3:3232:7	emtriva	NNP	O	O
,	STRIBILD.xml:S3:3239:1	,	,	O	O
the	STRIBILD.xml:S3:3241:3	the	DT	O	O
exacerbations	STRIBILD.xml:S3:3245:13	exacerb	NNS	B-AdverseReaction	O
of	STRIBILD.xml:S3:3259:2	of	IN	I-AdverseReaction	O
hepatitis	STRIBILD.xml:S3:3262:9	hepat	NN	I-AdverseReaction	O
B	STRIBILD.xml:S3:3272:1	B	NNP	I-AdverseReaction	O
were	STRIBILD.xml:S3:3274:4	were	VBD	O	O
associated	STRIBILD.xml:S3:3279:10	associ	VBN	O	O
with	STRIBILD.xml:S3:3290:4	with	IN	O	O
liver	STRIBILD.xml:S3:3295:5	liver	JJ	B-AdverseReaction	B-AdverseReaction
decompensation	STRIBILD.xml:S3:3301:14	decompens	NN	I-AdverseReaction	I-AdverseReaction
and	STRIBILD.xml:S3:3316:3	and	CC	O	O
liver	STRIBILD.xml:S3:3320:5	liver	JJ	B-AdverseReaction	B-AdverseReaction
failure	STRIBILD.xml:S3:3326:7	failur	NN	I-AdverseReaction	I-AdverseReaction
.	STRIBILD.xml:S3:3333:1	.	.	O	O

Patients	STRIBILD.xml:S3:3335:8	patient	NNS	O	O
who	STRIBILD.xml:S3:3344:3	who	WP	O	O
are	STRIBILD.xml:S3:3348:3	are	VBP	O	O
coinfected	STRIBILD.xml:S3:3352:10	coinfect	VBN	O	O
with	STRIBILD.xml:S3:3363:4	with	IN	O	O
HIV	STRIBILD.xml:S3:3368:3	hiv	NNP	O	O
-	STRIBILD.xml:S3:3371:1	-	:	O	O
1	STRIBILD.xml:S3:3372:1	1	CD	O	O
and	STRIBILD.xml:S3:3374:3	and	CC	O	O
HBV	STRIBILD.xml:S3:3378:3	hbv	NNP	O	O
should	STRIBILD.xml:S3:3382:6	should	MD	O	O
be	STRIBILD.xml:S3:3389:2	be	VB	O	O
closely	STRIBILD.xml:S3:3392:7	close	RB	O	O
monitored	STRIBILD.xml:S3:3400:9	monitor	VBN	O	O
with	STRIBILD.xml:S3:3410:4	with	IN	O	O
both	STRIBILD.xml:S3:3415:4	both	DT	O	O
clinical	STRIBILD.xml:S3:3420:8	clinic	JJ	O	O
and	STRIBILD.xml:S3:3429:3	and	CC	O	O
laboratory	STRIBILD.xml:S3:3433:10	laboratori	JJ	O	O
follow	STRIBILD.xml:S3:3444:6	follow	NN	O	O
-	STRIBILD.xml:S3:3450:1	-	:	O	O
up	STRIBILD.xml:S3:3451:2	up	RB	O	O
for	STRIBILD.xml:S3:3454:3	for	IN	O	O
at	STRIBILD.xml:S3:3458:2	at	IN	O	O
least	STRIBILD.xml:S3:3461:5	least	JJS	O	O
several	STRIBILD.xml:S3:3467:7	sever	JJ	O	O
months	STRIBILD.xml:S3:3475:6	month	NNS	O	O
after	STRIBILD.xml:S3:3482:5	after	IN	O	O
stopping	STRIBILD.xml:S3:3488:8	stop	VBG	O	O
treatment	STRIBILD.xml:S3:3497:9	treatment	NN	O	O
with	STRIBILD.xml:S3:3507:4	with	IN	O	O
STRIBILD	STRIBILD.xml:S3:3512:8	stribild	NNP	O	O
.	STRIBILD.xml:S3:3520:1	.	.	O	O

If	STRIBILD.xml:S3:3522:2	If	IN	O	O
appropriate	STRIBILD.xml:S3:3525:11	appropri	JJ	O	O
,	STRIBILD.xml:S3:3536:1	,	,	O	O
initiation	STRIBILD.xml:S3:3538:10	initi	NN	O	O
of	STRIBILD.xml:S3:3549:2	of	IN	O	O
anti	STRIBILD.xml:S3:3552:4	anti	JJ	O	O
-	STRIBILD.xml:S3:3556:1	-	:	O	O
hepatitis	STRIBILD.xml:S3:3557:9	hepat	NN	O	O
B	STRIBILD.xml:S3:3567:1	B	NNP	O	O
therapy	STRIBILD.xml:S3:3569:7	therapi	NN	O	O
may	STRIBILD.xml:S3:3577:3	may	MD	O	O
be	STRIBILD.xml:S3:3581:2	be	VB	O	O
warranted	STRIBILD.xml:S3:3584:9	warrant	VBN	O	O
.	STRIBILD.xml:S3:3593:1	.	.	O	O

5.3	STRIBILD.xml:S3:3602:3	5.3	CD	O	O
New	STRIBILD.xml:S3:3606:3	new	NNP	O	O
Onset	STRIBILD.xml:S3:3610:5	onset	NNP	O	O
or	STRIBILD.xml:S3:3616:2	or	CC	O	O
Worsening	STRIBILD.xml:S3:3619:9	worsen	NNP	O	O
Renal	STRIBILD.xml:S3:3629:5	renal	NNP	O	O
Impairment	STRIBILD.xml:S3:3635:10	impair	NNP	O	O

Renal	STRIBILD.xml:S3:3651:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
impairment	STRIBILD.xml:S3:3657:10	impair	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S3:3667:1	,	,	O	O
including	STRIBILD.xml:S3:3669:9	includ	VBG	O	O
cases	STRIBILD.xml:S3:3679:5	case	NNS	O	O
of	STRIBILD.xml:S3:3685:2	of	IN	O	O
acute	STRIBILD.xml:S3:3688:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
renal	STRIBILD.xml:S3:3694:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	STRIBILD.xml:S3:3700:7	failur	NN	I-AdverseReaction	I-AdverseReaction
and	STRIBILD.xml:S3:3708:3	and	CC	O	O
Fanconi	STRIBILD.xml:S3:3712:7	fanconi	NNP	B-AdverseReaction	B-AdverseReaction
syndrome	STRIBILD.xml:S3:3720:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S3:3729:1	(	(	O	O
renal	STRIBILD.xml:S3:3730:5	renal	JJ	B-AdverseReaction	O
tubular	STRIBILD.xml:S3:3736:7	tubular	JJ	I-AdverseReaction	O
injury	STRIBILD.xml:S3:3744:6	injuri	NN	I-AdverseReaction	O
with	STRIBILD.xml:S3:3751:4	with	IN	O	O
severe	STRIBILD.xml:S3:3756:6	sever	JJ	O	O
hypophosphatemia	STRIBILD.xml:S3:3763:16	hypophosphatemia	NN	B-AdverseReaction	O
)	STRIBILD.xml:S3:3779:1	)	)	O	O
,	STRIBILD.xml:S3:3780:1	,	,	O	O
has	STRIBILD.xml:S3:3782:3	ha	VBZ	O	O
been	STRIBILD.xml:S3:3786:4	been	VBN	O	O
reported	STRIBILD.xml:S3:3791:8	report	VBN	O	O
with	STRIBILD.xml:S3:3800:4	with	IN	O	O
the	STRIBILD.xml:S3:3805:3	the	DT	O	O
use	STRIBILD.xml:S3:3809:3	use	NN	O	O
of	STRIBILD.xml:S3:3813:2	of	IN	O	O
tenofovir	STRIBILD.xml:S3:3816:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:3826:2	DF	NNP	O	O
,	STRIBILD.xml:S3:3828:1	,	,	O	O
a	STRIBILD.xml:S3:3830:1	a	DT	O	O
component	STRIBILD.xml:S3:3832:9	compon	NN	O	O
of	STRIBILD.xml:S3:3842:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:3845:8	stribild	NNP	O	O
,	STRIBILD.xml:S3:3853:1	,	,	O	O
and	STRIBILD.xml:S3:3855:3	and	CC	O	O
with	STRIBILD.xml:S3:3859:4	with	IN	O	O
the	STRIBILD.xml:S3:3864:3	the	DT	O	O
use	STRIBILD.xml:S3:3868:3	use	NN	O	O
of	STRIBILD.xml:S3:3872:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:3875:8	stribild	NNP	O	O
[	STRIBILD.xml:S3:3884:1	[	NNP	O	O
see	STRIBILD.xml:S3:3885:3	see	VBP	O	O
Adverse	STRIBILD.xml:S3:3890:7	advers	JJ	O	O
Reactions	STRIBILD.xml:S3:3898:9	reaction	NNP	O	O
(	STRIBILD.xml:S3:3908:1	(	(	O	O
6.2	STRIBILD.xml:S3:3909:3	6.2	CD	O	O
)	STRIBILD.xml:S3:3912:1	)	)	O	O
]	STRIBILD.xml:S3:3915:1	]	NN	O	O
.	STRIBILD.xml:S3:3918:1	.	.	O	O

In	STRIBILD.xml:S3:3925:2	In	IN	O	O
the	STRIBILD.xml:S3:3928:3	the	DT	O	O
clinical	STRIBILD.xml:S3:3932:8	clinic	JJ	O	O
trials	STRIBILD.xml:S3:3941:6	trial	NNS	O	O
of	STRIBILD.xml:S3:3948:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:3951:8	stribild	NNP	O	O
over	STRIBILD.xml:S3:3960:4	over	IN	O	O
144	STRIBILD.xml:S3:3965:3	144	CD	O	O
weeks	STRIBILD.xml:S3:3969:5	week	NNS	O	O
,	STRIBILD.xml:S3:3974:1	,	,	O	O
13	STRIBILD.xml:S3:3976:2	13	CD	O	O
(	STRIBILD.xml:S3:3979:1	(	(	O	O
1.9%	STRIBILD.xml:S3:3980:4	1.9%	CD	O	O
)	STRIBILD.xml:S3:3984:1	)	)	O	O
subjects	STRIBILD.xml:S3:3986:8	subject	NNS	O	O
in	STRIBILD.xml:S3:3995:2	in	IN	O	O
the	STRIBILD.xml:S3:3998:3	the	DT	O	O
STRIBILD	STRIBILD.xml:S3:4002:8	stribild	NNP	O	O
group	STRIBILD.xml:S3:4011:5	group	NN	O	O
(	STRIBILD.xml:S3:4017:1	(	(	O	O
N	STRIBILD.xml:S3:4018:1	N	NNP	O	O
701	STRIBILD.xml:S3:4020:3	701	CD	O	O
)	STRIBILD.xml:S3:4023:1	)	)	O	O
,	STRIBILD.xml:S3:4024:1	,	,	O	O
8	STRIBILD.xml:S3:4026:1	8	CD	O	O
(	STRIBILD.xml:S3:4028:1	(	(	O	O
2.3%	STRIBILD.xml:S3:4029:4	2.3%	CD	O	O
)	STRIBILD.xml:S3:4033:1	)	)	O	O
subjects	STRIBILD.xml:S3:4035:8	subject	NNS	O	O
in	STRIBILD.xml:S3:4044:2	in	IN	O	O
the	STRIBILD.xml:S3:4047:3	the	DT	O	O
ATV	STRIBILD.xml:S3:4051:3	atv	NNP	O	O
RTV	STRIBILD.xml:S3:4057:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S3:4063:7	truvada	NNP	O	O
group	STRIBILD.xml:S3:4071:5	group	NN	O	O
(	STRIBILD.xml:S3:4077:1	(	(	O	O
N	STRIBILD.xml:S3:4078:1	N	NNP	O	O
355	STRIBILD.xml:S3:4080:3	355	CD	O	O
)	STRIBILD.xml:S3:4083:1	)	)	O	O
and	STRIBILD.xml:S3:4085:3	and	CC	O	O
no	STRIBILD.xml:S3:4089:2	no	DT	O	O
subjects	STRIBILD.xml:S3:4092:8	subject	NNS	O	O
in	STRIBILD.xml:S3:4101:2	in	IN	O	O
the	STRIBILD.xml:S3:4104:3	the	DT	O	O
ATRIPLA	STRIBILD.xml:S3:4108:7	atripla	NNP	O	O
group	STRIBILD.xml:S3:4116:5	group	NN	O	O
(	STRIBILD.xml:S3:4122:1	(	(	O	O
N	STRIBILD.xml:S3:4123:1	N	NNP	O	O
352	STRIBILD.xml:S3:4127:3	352	CD	O	O
)	STRIBILD.xml:S3:4130:1	)	)	O	O
discontinued	STRIBILD.xml:S3:4132:12	discontinu	VBN	O	O
study	STRIBILD.xml:S3:4145:5	studi	JJ	O	O
drug	STRIBILD.xml:S3:4151:4	drug	NN	O	O
due	STRIBILD.xml:S3:4156:3	due	JJ	O	O
to	STRIBILD.xml:S3:4160:2	to	TO	O	O
a	STRIBILD.xml:S3:4163:1	a	DT	O	O
renal	STRIBILD.xml:S3:4165:5	renal	JJ	B-AdverseReaction	O
adverse	STRIBILD.xml:S3:4171:7	advers	JJ	I-AdverseReaction	O
reaction	STRIBILD.xml:S3:4179:8	reaction	NN	I-AdverseReaction	O
.	STRIBILD.xml:S3:4187:1	.	.	O	O

Of	STRIBILD.xml:S3:4189:2	Of	IN	O	O
these	STRIBILD.xml:S3:4192:5	these	DT	O	O
discontinuations	STRIBILD.xml:S3:4198:16	discontinu	NNS	O	O
,	STRIBILD.xml:S3:4214:1	,	,	O	O
8	STRIBILD.xml:S3:4216:1	8	CD	O	O
in	STRIBILD.xml:S3:4218:2	in	IN	O	O
the	STRIBILD.xml:S3:4221:3	the	DT	O	O
STRIBILD	STRIBILD.xml:S3:4225:8	stribild	NNP	O	O
group	STRIBILD.xml:S3:4234:5	group	NN	O	O
and	STRIBILD.xml:S3:4240:3	and	CC	O	O
1	STRIBILD.xml:S3:4244:1	1	CD	O	O
in	STRIBILD.xml:S3:4246:2	in	IN	O	O
the	STRIBILD.xml:S3:4249:3	the	DT	O	O
ATV	STRIBILD.xml:S3:4253:3	atv	NNP	O	O
RTV	STRIBILD.xml:S3:4259:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S3:4265:7	truvada	NNP	O	O
group	STRIBILD.xml:S3:4273:5	group	NN	O	O
occurred	STRIBILD.xml:S3:4279:8	occur	VBD	O	O
during	STRIBILD.xml:S3:4288:6	dure	IN	O	O
the	STRIBILD.xml:S3:4295:3	the	DT	O	O
first	STRIBILD.xml:S3:4299:5	first	JJ	O	O
48	STRIBILD.xml:S3:4305:2	48	CD	O	O
weeks	STRIBILD.xml:S3:4308:5	week	NNS	O	O
.	STRIBILD.xml:S3:4313:1	.	.	O	O

Four	STRIBILD.xml:S3:4315:4	four	CD	O	O
(	STRIBILD.xml:S3:4320:1	(	(	O	O
0.6%	STRIBILD.xml:S3:4321:4	0.6%	CD	O	O
)	STRIBILD.xml:S3:4325:1	)	)	O	O
subjects	STRIBILD.xml:S3:4327:8	subject	NNS	O	O
who	STRIBILD.xml:S3:4336:3	who	WP	O	O
received	STRIBILD.xml:S3:4340:8	receiv	VBD	O	O
STRIBILD	STRIBILD.xml:S3:4349:8	stribild	NNP	O	O
developed	STRIBILD.xml:S3:4358:9	develop	VBD	O	O
laboratory	STRIBILD.xml:S3:4368:10	laboratori	JJ	O	O
findings	STRIBILD.xml:S3:4379:8	find	NNS	O	O
consistent	STRIBILD.xml:S3:4388:10	consist	JJ	O	O
with	STRIBILD.xml:S3:4399:4	with	IN	O	O
proximal	STRIBILD.xml:S3:4404:8	proxim	JJ	B-AdverseReaction	O
renal	STRIBILD.xml:S3:4413:5	renal	JJ	I-AdverseReaction	O
tubular	STRIBILD.xml:S3:4419:7	tubular	NN	I-AdverseReaction	O
dysfunction	STRIBILD.xml:S3:4427:11	dysfunct	NN	I-AdverseReaction	O
leading	STRIBILD.xml:S3:4439:7	lead	VBG	O	O
to	STRIBILD.xml:S3:4447:2	to	TO	O	O
discontinuation	STRIBILD.xml:S3:4450:15	discontinu	NN	O	O
of	STRIBILD.xml:S3:4466:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:4469:8	stribild	NNP	O	O
during	STRIBILD.xml:S3:4478:6	dure	IN	O	O
the	STRIBILD.xml:S3:4485:3	the	DT	O	O
first	STRIBILD.xml:S3:4489:5	first	JJ	O	O
48	STRIBILD.xml:S3:4495:2	48	CD	O	O
weeks	STRIBILD.xml:S3:4498:5	week	NNS	O	O
of	STRIBILD.xml:S3:4504:2	of	IN	O	O
treatment	STRIBILD.xml:S3:4507:9	treatment	NN	O	O
.	STRIBILD.xml:S3:4516:1	.	.	O	O

Two	STRIBILD.xml:S3:4518:3	two	CD	O	O
of	STRIBILD.xml:S3:4522:2	of	IN	O	O
the	STRIBILD.xml:S3:4525:3	the	DT	O	O
four	STRIBILD.xml:S3:4529:4	four	CD	O	O
subjects	STRIBILD.xml:S3:4534:8	subject	NNS	O	O
had	STRIBILD.xml:S3:4543:3	had	VBD	O	O
renal	STRIBILD.xml:S3:4547:5	renal	JJ	O	B-AdverseReaction
impairment	STRIBILD.xml:S3:4553:10	impair	NN	O	I-AdverseReaction
(	STRIBILD.xml:S3:4564:1	(	(	O	O
i	STRIBILD.xml:S3:4565:1	i	JJ	O	O
.	STRIBILD.xml:S3:4566:1	.	.	O	O
e	STRIBILD.xml:S3:4567:1	e	NN	O	O
.	STRIBILD.xml:S3:4568:1	.	.	O	O

estimated	STRIBILD.xml:S3:4570:9	estim	VBN	O	B-AdverseReaction
creatinine	STRIBILD.xml:S3:4580:10	creatinin	JJ	O	I-AdverseReaction
clearance	STRIBILD.xml:S3:4591:9	clearanc	NN	O	I-AdverseReaction
less	STRIBILD.xml:S3:4601:4	less	JJR	O	I-AdverseReaction
than	STRIBILD.xml:S3:4606:4	than	IN	O	I-AdverseReaction
70	STRIBILD.xml:S3:4611:2	70	CD	O	I-AdverseReaction
mL	STRIBILD.xml:S3:4614:2	mL	NNS	O	I-AdverseReaction
per	STRIBILD.xml:S3:4617:3	per	IN	O	I-AdverseReaction
minute	STRIBILD.xml:S3:4621:6	minut	NN	O	I-AdverseReaction
)	STRIBILD.xml:S3:4627:1	)	)	O	O
at	STRIBILD.xml:S3:4629:2	at	IN	O	O
baseline	STRIBILD.xml:S3:4632:8	baselin	NN	O	O
.	STRIBILD.xml:S3:4640:1	.	.	O	O

The	STRIBILD.xml:S3:4642:3	the	DT	O	O
laboratory	STRIBILD.xml:S3:4646:10	laboratori	NN	O	O
findings	STRIBILD.xml:S3:4657:8	find	NNS	O	O
in	STRIBILD.xml:S3:4666:2	in	IN	O	O
these	STRIBILD.xml:S3:4669:5	these	DT	O	O
4	STRIBILD.xml:S3:4675:1	4	CD	O	O
subjects	STRIBILD.xml:S3:4677:8	subject	NNS	O	O
improved	STRIBILD.xml:S3:4686:8	improv	VBN	O	O
but	STRIBILD.xml:S3:4695:3	but	CC	O	O
did	STRIBILD.xml:S3:4699:3	did	VBD	O	O
not	STRIBILD.xml:S3:4703:3	not	RB	O	O
completely	STRIBILD.xml:S3:4707:10	complet	RB	O	O
resolve	STRIBILD.xml:S3:4718:7	resolv	VB	O	O
in	STRIBILD.xml:S3:4726:2	in	IN	O	O
all	STRIBILD.xml:S3:4729:3	all	DT	O	O
subjects	STRIBILD.xml:S3:4733:8	subject	NNS	O	O
upon	STRIBILD.xml:S3:4742:4	upon	IN	O	O
discontinuation	STRIBILD.xml:S3:4747:15	discontinu	NN	O	O
of	STRIBILD.xml:S3:4763:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:4766:8	stribild	NNP	O	O
.	STRIBILD.xml:S3:4774:1	.	.	O	O

Renal	STRIBILD.xml:S3:4776:5	renal	JJ	O	O
replacement	STRIBILD.xml:S3:4782:11	replac	NN	O	O
therapy	STRIBILD.xml:S3:4794:7	therapi	NN	O	O
was	STRIBILD.xml:S3:4802:3	wa	VBD	O	O
not	STRIBILD.xml:S3:4806:3	not	RB	O	O
required	STRIBILD.xml:S3:4810:8	requir	VBN	O	O
for	STRIBILD.xml:S3:4819:3	for	IN	O	O
these	STRIBILD.xml:S3:4823:5	these	DT	O	O
subjects	STRIBILD.xml:S3:4829:8	subject	NNS	O	O
.	STRIBILD.xml:S3:4837:1	.	.	O	O

One	STRIBILD.xml:S3:4839:3	one	CD	O	O
(	STRIBILD.xml:S3:4843:1	(	(	O	O
0.3%	STRIBILD.xml:S3:4844:4	0.3%	CD	O	O
)	STRIBILD.xml:S3:4848:1	)	)	O	O
subject	STRIBILD.xml:S3:4850:7	subject	NN	O	O
who	STRIBILD.xml:S3:4858:3	who	WP	O	O
received	STRIBILD.xml:S3:4862:8	receiv	VBD	O	O
ATV	STRIBILD.xml:S3:4871:3	atv	NNP	O	O
RTV	STRIBILD.xml:S3:4877:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S3:4883:7	truvada	NNP	O	O
developed	STRIBILD.xml:S3:4891:9	develop	VBD	O	O
laboratory	STRIBILD.xml:S3:4901:10	laboratori	JJ	O	O
findings	STRIBILD.xml:S3:4912:8	find	NNS	O	O
consistent	STRIBILD.xml:S3:4921:10	consist	JJ	O	O
with	STRIBILD.xml:S3:4932:4	with	IN	O	O
proximal	STRIBILD.xml:S3:4937:8	proxim	JJ	B-AdverseReaction	O
renal	STRIBILD.xml:S3:4946:5	renal	JJ	I-AdverseReaction	O
tubular	STRIBILD.xml:S3:4952:7	tubular	NN	I-AdverseReaction	O
dysfunction	STRIBILD.xml:S3:4960:11	dysfunct	NN	I-AdverseReaction	O
leading	STRIBILD.xml:S3:4972:7	lead	VBG	O	O
to	STRIBILD.xml:S3:4980:2	to	TO	O	O
discontinuation	STRIBILD.xml:S3:4983:15	discontinu	NN	O	O
of	STRIBILD.xml:S3:4999:2	of	IN	O	O
ATV	STRIBILD.xml:S3:5002:3	atv	NNP	O	O
RTV	STRIBILD.xml:S3:5008:3	rtv	NNP	O	O
TRUVADA	STRIBILD.xml:S3:5014:7	truvada	NNP	O	O
after	STRIBILD.xml:S3:5022:5	after	IN	O	O
Week	STRIBILD.xml:S3:5028:4	week	NNP	O	O
96	STRIBILD.xml:S3:5033:2	96	CD	O	O
.	STRIBILD.xml:S3:5035:1	.	.	O	O

STRIBILD	STRIBILD.xml:S3:5043:8	stribild	NNP	O	O
should	STRIBILD.xml:S3:5052:6	should	MD	O	O
be	STRIBILD.xml:S3:5059:2	be	VB	O	O
avoided	STRIBILD.xml:S3:5062:7	avoid	VBN	O	O
with	STRIBILD.xml:S3:5070:4	with	IN	O	O
concurrent	STRIBILD.xml:S3:5075:10	concurr	NN	O	O
or	STRIBILD.xml:S3:5086:2	or	CC	O	O
recent	STRIBILD.xml:S3:5089:6	recent	JJ	O	O
use	STRIBILD.xml:S3:5096:3	use	NN	O	O
of	STRIBILD.xml:S3:5100:2	of	IN	O	O
a	STRIBILD.xml:S3:5103:1	a	DT	O	O
nephrotoxic	STRIBILD.xml:S3:5105:11	nephrotox	JJ	O	O
agent	STRIBILD.xml:S3:5117:5	agent	NN	O	O
.	STRIBILD.xml:S3:5122:1	.	.	O	O

(	STRIBILD.xml:S3:5124:1	(	(	O	O
e	STRIBILD.xml:S3:5125:1	e	NN	O	O
.	STRIBILD.xml:S3:5126:1	.	.	O	O
g	STRIBILD.xml:S3:5127:1	g	NN	O	O
.	STRIBILD.xml:S3:5128:1	.	.	O	O
,	STRIBILD.xml:S3:5129:1	,	,	O	O
high	STRIBILD.xml:S3:5131:4	high	JJ	O	O
-	STRIBILD.xml:S3:5135:1	-	:	O	O
dose	STRIBILD.xml:S3:5136:4	dose	NN	O	O
or	STRIBILD.xml:S3:5141:2	or	CC	O	O
multiple	STRIBILD.xml:S3:5144:8	multipl	JJ	O	O
non	STRIBILD.xml:S3:5153:3	non	JJ	O	O
-	STRIBILD.xml:S3:5156:1	-	:	O	O
steroidal	STRIBILD.xml:S3:5157:9	steroid	NN	O	O
anti	STRIBILD.xml:S3:5167:4	anti	SYM	O	O
-	STRIBILD.xml:S3:5171:1	-	:	O	O
inflammatory	STRIBILD.xml:S3:5172:12	inflammatori	NN	O	O
drugs	STRIBILD.xml:S3:5185:5	drug	NNS	O	O
(	STRIBILD.xml:S3:5191:1	(	(	O	O
NSAIDs	STRIBILD.xml:S3:5192:6	nsaid	NNP	O	O
))	STRIBILD.xml:S3:5198:2	))	NNP	O	O
[	STRIBILD.xml:S3:5201:1	[	NNP	O	O
see	STRIBILD.xml:S3:5202:3	see	VBP	O	O
Drug	STRIBILD.xml:S3:5207:4	drug	NNP	O	O
Interactions	STRIBILD.xml:S3:5212:12	interact	NNP	O	O
(	STRIBILD.xml:S3:5225:1	(	(	O	O
7.4	STRIBILD.xml:S3:5226:3	7.4	CD	O	O
)	STRIBILD.xml:S3:5229:1	)	)	O	O
]	STRIBILD.xml:S3:5232:1	]	NN	O	O
.	STRIBILD.xml:S3:5235:1	.	.	O	O

Cases	STRIBILD.xml:S3:5237:5	case	NNS	O	O
of	STRIBILD.xml:S3:5243:2	of	IN	O	O
acute	STRIBILD.xml:S3:5246:5	acut	JJ	O	B-AdverseReaction
renal	STRIBILD.xml:S3:5252:5	renal	JJ	O	I-AdverseReaction
failure	STRIBILD.xml:S3:5258:7	failur	NN	O	I-AdverseReaction
after	STRIBILD.xml:S3:5266:5	after	IN	O	O
initiation	STRIBILD.xml:S3:5272:10	initi	NN	O	O
of	STRIBILD.xml:S3:5283:2	of	IN	O	O
high	STRIBILD.xml:S3:5286:4	high	JJ	O	O
dose	STRIBILD.xml:S3:5291:4	dose	NN	O	O
or	STRIBILD.xml:S3:5296:2	or	CC	O	O
multiple	STRIBILD.xml:S3:5299:8	multipl	JJ	O	O
NSAIDs	STRIBILD.xml:S3:5308:6	nsaid	NNP	O	O
have	STRIBILD.xml:S3:5315:4	have	VBP	O	O
been	STRIBILD.xml:S3:5320:4	been	VBN	O	O
reported	STRIBILD.xml:S3:5325:8	report	VBN	O	O
in	STRIBILD.xml:S3:5334:2	in	IN	O	O
HIV	STRIBILD.xml:S3:5337:3	hiv	NNP	O	O
-	STRIBILD.xml:S3:5340:1	-	:	O	O
infected	STRIBILD.xml:S3:5341:8	infect	VBD	O	O
patients	STRIBILD.xml:S3:5350:8	patient	NNS	O	O
with	STRIBILD.xml:S3:5359:4	with	IN	O	O
risk	STRIBILD.xml:S3:5364:4	risk	NN	O	O
factors	STRIBILD.xml:S3:5369:7	factor	NNS	O	O
for	STRIBILD.xml:S3:5377:3	for	IN	O	O
renal	STRIBILD.xml:S3:5381:5	renal	JJ	O	O
dysfunction	STRIBILD.xml:S3:5387:11	dysfunct	NN	O	O
who	STRIBILD.xml:S3:5399:3	who	WP	O	O
appeared	STRIBILD.xml:S3:5403:8	appear	VBD	O	O
stable	STRIBILD.xml:S3:5412:6	stabl	JJ	O	O
on	STRIBILD.xml:S3:5419:2	on	IN	O	O
tenofovir	STRIBILD.xml:S3:5422:9	tenofovir	JJ	O	O
DF	STRIBILD.xml:S3:5432:2	DF	NNP	O	O
.	STRIBILD.xml:S3:5434:1	.	.	O	O

Some	STRIBILD.xml:S3:5436:4	some	DT	O	O
patients	STRIBILD.xml:S3:5441:8	patient	NNS	O	O
required	STRIBILD.xml:S3:5450:8	requir	VBN	O	O
hospitalization	STRIBILD.xml:S3:5459:15	hospit	NN	O	O
and	STRIBILD.xml:S3:5475:3	and	CC	O	O
renal	STRIBILD.xml:S3:5479:5	renal	JJ	O	O
replacement	STRIBILD.xml:S3:5485:11	replac	NN	O	O
therapy	STRIBILD.xml:S3:5497:7	therapi	NN	O	O
.	STRIBILD.xml:S3:5504:1	.	.	O	O

Alternatives	STRIBILD.xml:S3:5506:12	altern	NNS	O	O
to	STRIBILD.xml:S3:5519:2	to	TO	O	O
NSAIDs	STRIBILD.xml:S3:5522:6	nsaid	NNP	O	O
should	STRIBILD.xml:S3:5529:6	should	MD	O	O
be	STRIBILD.xml:S3:5536:2	be	VB	O	O
considered	STRIBILD.xml:S3:5539:10	consid	VBN	O	O
,	STRIBILD.xml:S3:5549:1	,	,	O	O
if	STRIBILD.xml:S3:5551:2	if	IN	O	O
needed	STRIBILD.xml:S3:5554:6	need	VBN	O	O
,	STRIBILD.xml:S3:5560:1	,	,	O	O
in	STRIBILD.xml:S3:5562:2	in	IN	O	O
patients	STRIBILD.xml:S3:5565:8	patient	NNS	O	O
at	STRIBILD.xml:S3:5574:2	at	IN	O	O
risk	STRIBILD.xml:S3:5577:4	risk	NN	O	O
for	STRIBILD.xml:S3:5582:3	for	IN	O	O
renal	STRIBILD.xml:S3:5586:5	renal	JJ	O	O
dysfunction	STRIBILD.xml:S3:5592:11	dysfunct	NN	O	O
.	STRIBILD.xml:S3:5603:1	.	.	O	O

Persistent	STRIBILD.xml:S3:5609:10	persist	NN	O	O
or	STRIBILD.xml:S3:5620:2	or	CC	O	O
worsening	STRIBILD.xml:S3:5623:9	worsen	VBG	O	O
bone	STRIBILD.xml:S3:5633:4	bone	NN	O	B-AdverseReaction
pain	STRIBILD.xml:S3:5638:4	pain	NN	O	I-AdverseReaction
,	STRIBILD.xml:S3:5642:1	,	,	O	O
pain	STRIBILD.xml:S3:5644:4	pain	NN	O	B-AdverseReaction
in	STRIBILD.xml:S3:5649:2	in	IN	O	I-AdverseReaction
extremities	STRIBILD.xml:S3:5652:11	extrem	NNS	O	I-AdverseReaction
,	STRIBILD.xml:S3:5663:1	,	,	O	O
fractures	STRIBILD.xml:S3:5665:9	fractur	NNS	O	B-AdverseReaction
and	STRIBILD.xml:S3:5675:3	and	CC	O	O
or	STRIBILD.xml:S3:5679:2	or	CC	O	O
muscular	STRIBILD.xml:S3:5682:8	muscular	JJ	O	O
pain	STRIBILD.xml:S3:5691:4	pain	NN	O	O
or	STRIBILD.xml:S3:5696:2	or	CC	O	O
weakness	STRIBILD.xml:S3:5699:8	weak	NN	O	O
may	STRIBILD.xml:S3:5708:3	may	MD	O	O
be	STRIBILD.xml:S3:5712:2	be	VB	O	O
manifestations	STRIBILD.xml:S3:5715:14	manifest	NNS	O	O
of	STRIBILD.xml:S3:5730:2	of	IN	O	O
proximal	STRIBILD.xml:S3:5733:8	proxim	JJ	O	O
renal	STRIBILD.xml:S3:5742:5	renal	JJ	O	O
tubulopathy	STRIBILD.xml:S3:5748:11	tubulopathi	NN	O	O
and	STRIBILD.xml:S3:5760:3	and	CC	O	O
should	STRIBILD.xml:S3:5764:6	should	MD	O	O
prompt	STRIBILD.xml:S3:5771:6	prompt	VB	O	O
an	STRIBILD.xml:S3:5778:2	an	DT	O	O
evaluation	STRIBILD.xml:S3:5781:10	evalu	NN	O	O
of	STRIBILD.xml:S3:5792:2	of	IN	O	O
renal	STRIBILD.xml:S3:5795:5	renal	JJ	O	O
function	STRIBILD.xml:S3:5801:8	function	NN	O	O
in	STRIBILD.xml:S3:5810:2	in	IN	O	O
at	STRIBILD.xml:S3:5813:2	at	IN	O	O
-	STRIBILD.xml:S3:5815:1	-	:	O	O
risk	STRIBILD.xml:S3:5816:4	risk	NN	O	O
patients	STRIBILD.xml:S3:5821:8	patient	NNS	O	O
.	STRIBILD.xml:S3:5829:1	.	.	O	O

Estimated	STRIBILD.xml:S3:5835:9	estim	VBN	O	O
creatinine	STRIBILD.xml:S3:5845:10	creatinin	JJ	O	O
clearance	STRIBILD.xml:S3:5856:9	clearanc	NN	O	O
,	STRIBILD.xml:S3:5865:1	,	,	O	O
urine	STRIBILD.xml:S3:5867:5	urin	JJ	O	B-AdverseReaction
glucose	STRIBILD.xml:S3:5873:7	glucos	NN	O	I-AdverseReaction
and	STRIBILD.xml:S3:5881:3	and	CC	O	O
urine	STRIBILD.xml:S3:5885:5	urin	JJ	O	O
protein	STRIBILD.xml:S3:5891:7	protein	NN	O	O
should	STRIBILD.xml:S3:5899:6	should	MD	O	O
be	STRIBILD.xml:S3:5906:2	be	VB	O	O
documented	STRIBILD.xml:S3:5909:10	document	VBN	O	O
in	STRIBILD.xml:S3:5920:2	in	IN	O	O
all	STRIBILD.xml:S3:5923:3	all	DT	O	O
patients	STRIBILD.xml:S3:5927:8	patient	NNS	O	O
prior	STRIBILD.xml:S3:5936:5	prior	RB	O	O
to	STRIBILD.xml:S3:5942:2	to	TO	O	O
initiating	STRIBILD.xml:S3:5945:10	initi	VBG	O	O
therapy	STRIBILD.xml:S3:5956:7	therapi	NN	O	O
.	STRIBILD.xml:S3:5963:1	.	.	O	O

Initiation	STRIBILD.xml:S3:5965:10	initi	NN	O	O
of	STRIBILD.xml:S3:5976:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:5979:8	stribild	NNP	O	O
in	STRIBILD.xml:S3:5988:2	in	IN	O	O
patients	STRIBILD.xml:S3:5991:8	patient	NNS	O	O
with	STRIBILD.xml:S3:6000:4	with	IN	O	O
estimated	STRIBILD.xml:S3:6005:9	estim	VBN	O	O
creatinine	STRIBILD.xml:S3:6015:10	creatinin	NN	O	O
clearance	STRIBILD.xml:S3:6026:9	clearanc	NN	O	O
below	STRIBILD.xml:S3:6036:5	below	IN	O	O
70	STRIBILD.xml:S3:6042:2	70	CD	O	O
mL	STRIBILD.xml:S3:6045:2	mL	NNS	O	O
per	STRIBILD.xml:S3:6048:3	per	IN	O	O
minute	STRIBILD.xml:S3:6052:6	minut	NN	O	O
is	STRIBILD.xml:S3:6059:2	is	VBZ	O	O
not	STRIBILD.xml:S3:6062:3	not	RB	O	O
recommended	STRIBILD.xml:S3:6066:11	recommend	VBN	O	O
.	STRIBILD.xml:S3:6077:1	.	.	O	O

Routine	STRIBILD.xml:S3:6083:7	routin	JJ	O	O
monitoring	STRIBILD.xml:S3:6091:10	monitor	NN	O	O
of	STRIBILD.xml:S3:6102:2	of	IN	O	O
estimated	STRIBILD.xml:S3:6105:9	estim	VBN	O	O
creatinine	STRIBILD.xml:S3:6115:10	creatinin	NN	O	O
clearance	STRIBILD.xml:S3:6126:9	clearanc	NN	O	O
,	STRIBILD.xml:S3:6135:1	,	,	O	O
urine	STRIBILD.xml:S3:6137:5	urin	JJ	O	B-AdverseReaction
glucose	STRIBILD.xml:S3:6143:7	glucos	NN	O	I-AdverseReaction
,	STRIBILD.xml:S3:6150:1	,	,	O	O
and	STRIBILD.xml:S3:6152:3	and	CC	O	O
urine	STRIBILD.xml:S3:6156:5	urin	JJ	O	O
protein	STRIBILD.xml:S3:6162:7	protein	NN	O	O
should	STRIBILD.xml:S3:6170:6	should	MD	O	O
be	STRIBILD.xml:S3:6177:2	be	VB	O	O
performed	STRIBILD.xml:S3:6180:9	perform	VBN	O	O
during	STRIBILD.xml:S3:6190:6	dure	IN	O	O
STRIBILD	STRIBILD.xml:S3:6197:8	stribild	NNP	O	O
therapy	STRIBILD.xml:S3:6206:7	therapi	NN	O	O
in	STRIBILD.xml:S3:6214:2	in	IN	O	O
all	STRIBILD.xml:S3:6217:3	all	DT	O	O
patients	STRIBILD.xml:S3:6221:8	patient	NNS	O	O
.	STRIBILD.xml:S3:6229:1	.	.	O	O

Additionally	STRIBILD.xml:S3:6231:12	addit	RB	O	O
,	STRIBILD.xml:S3:6243:1	,	,	O	O
serum	STRIBILD.xml:S3:6245:5	serum	JJ	O	O
phosphorus	STRIBILD.xml:S3:6251:10	phosphoru	NN	O	O
should	STRIBILD.xml:S3:6262:6	should	MD	O	O
be	STRIBILD.xml:S3:6269:2	be	VB	O	O
measured	STRIBILD.xml:S3:6272:8	measur	VBN	O	O
in	STRIBILD.xml:S3:6281:2	in	IN	O	O
patients	STRIBILD.xml:S3:6284:8	patient	NNS	O	O
at	STRIBILD.xml:S3:6293:2	at	IN	O	O
risk	STRIBILD.xml:S3:6296:4	risk	NN	O	O
for	STRIBILD.xml:S3:6301:3	for	IN	O	O
renal	STRIBILD.xml:S3:6305:5	renal	JJ	O	O
impairment	STRIBILD.xml:S3:6311:10	impair	NN	O	O
.	STRIBILD.xml:S3:6321:1	.	.	O	O

Although	STRIBILD.xml:S3:6323:8	although	IN	O	O
cobicistat	STRIBILD.xml:S3:6332:10	cobicistat	NN	O	O
(	STRIBILD.xml:S3:6343:1	(	(	O	O
a	STRIBILD.xml:S3:6344:1	a	DT	O	O
component	STRIBILD.xml:S3:6346:9	compon	NN	O	O
of	STRIBILD.xml:S3:6356:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:6359:8	stribild	NNP	O	O
)	STRIBILD.xml:S3:6367:1	)	)	O	O
may	STRIBILD.xml:S3:6369:3	may	MD	O	O
cause	STRIBILD.xml:S3:6373:5	caus	VB	O	O
modest	STRIBILD.xml:S3:6379:6	modest	JJ	O	O
increases	STRIBILD.xml:S3:6386:9	increas	NNS	B-AdverseReaction	B-AdverseReaction
in	STRIBILD.xml:S3:6396:2	in	IN	I-AdverseReaction	I-AdverseReaction
serum	STRIBILD.xml:S3:6399:5	serum	JJ	I-AdverseReaction	I-AdverseReaction
creatinine	STRIBILD.xml:S3:6405:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
and	STRIBILD.xml:S3:6416:3	and	CC	O	O
modest	STRIBILD.xml:S3:6420:6	modest	JJ	O	B-AdverseReaction
declines	STRIBILD.xml:S3:6427:8	declin	NNS	B-AdverseReaction	I-AdverseReaction
in	STRIBILD.xml:S3:6436:2	in	IN	I-AdverseReaction	I-AdverseReaction
estimated	STRIBILD.xml:S3:6439:9	estim	VBN	I-AdverseReaction	I-AdverseReaction
creatinine	STRIBILD.xml:S3:6449:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction
clearance	STRIBILD.xml:S3:6460:9	clearanc	NN	I-AdverseReaction	I-AdverseReaction
without	STRIBILD.xml:S3:6470:7	without	IN	O	O
affecting	STRIBILD.xml:S3:6478:9	affect	VBG	O	O
renal	STRIBILD.xml:S3:6488:5	renal	JJ	O	O
glomerular	STRIBILD.xml:S3:6494:10	glomerular	JJ	O	O
function	STRIBILD.xml:S3:6505:8	function	NN	O	O
[	STRIBILD.xml:S3:6514:1	[	NNP	O	O
see	STRIBILD.xml:S3:6515:3	see	VBP	O	O
Adverse	STRIBILD.xml:S3:6520:7	advers	JJ	O	O
Reactions	STRIBILD.xml:S3:6528:9	reaction	NNP	O	O
(	STRIBILD.xml:S3:6538:1	(	(	O	O
6.1	STRIBILD.xml:S3:6539:3	6.1	CD	O	O
)	STRIBILD.xml:S3:6542:1	)	)	O	O
]	STRIBILD.xml:S3:6545:1	]	NN	O	O
,	STRIBILD.xml:S3:6548:1	,	,	O	O
patients	STRIBILD.xml:S3:6550:8	patient	NNS	O	O
who	STRIBILD.xml:S3:6559:3	who	WP	O	O
experience	STRIBILD.xml:S3:6563:10	experi	VBP	O	O
a	STRIBILD.xml:S3:6574:1	a	DT	O	O
confirmed	STRIBILD.xml:S3:6576:9	confirm	JJ	O	O
increase	STRIBILD.xml:S3:6586:8	increas	NN	O	O
in	STRIBILD.xml:S3:6595:2	in	IN	O	O
serum	STRIBILD.xml:S3:6598:5	serum	JJ	O	O
creatinine	STRIBILD.xml:S3:6604:10	creatinin	NN	O	O
of	STRIBILD.xml:S3:6615:2	of	IN	O	O
greater	STRIBILD.xml:S3:6618:7	greater	JJR	O	O
than	STRIBILD.xml:S3:6626:4	than	IN	O	O
0.4	STRIBILD.xml:S3:6631:3	0.4	CD	O	O
mg	STRIBILD.xml:S3:6635:2	mg	NNS	O	O
per	STRIBILD.xml:S3:6638:3	per	IN	O	O
dL	STRIBILD.xml:S3:6642:2	dL	NN	O	O
from	STRIBILD.xml:S3:6645:4	from	IN	O	O
baseline	STRIBILD.xml:S3:6650:8	baselin	NN	O	O
should	STRIBILD.xml:S3:6659:6	should	MD	O	O
be	STRIBILD.xml:S3:6666:2	be	VB	O	O
closely	STRIBILD.xml:S3:6669:7	close	RB	O	O
monitored	STRIBILD.xml:S3:6677:9	monitor	VBN	O	O
for	STRIBILD.xml:S3:6687:3	for	IN	O	O
renal	STRIBILD.xml:S3:6691:5	renal	JJ	O	O
safety	STRIBILD.xml:S3:6697:6	safeti	NN	O	O
.	STRIBILD.xml:S3:6703:1	.	.	O	O

The	STRIBILD.xml:S3:6709:3	the	DT	O	O
emtricitabine	STRIBILD.xml:S3:6713:13	emtricitabin	NN	O	O
and	STRIBILD.xml:S3:6727:3	and	CC	O	O
tenofovir	STRIBILD.xml:S3:6731:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:6741:2	DF	NNP	O	O
components	STRIBILD.xml:S3:6744:10	compon	NNS	O	O
of	STRIBILD.xml:S3:6755:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:6758:8	stribild	NNP	O	O
are	STRIBILD.xml:S3:6767:3	are	VBP	O	O
primarily	STRIBILD.xml:S3:6771:9	primarili	RB	O	O
excreted	STRIBILD.xml:S3:6781:8	excret	VBN	O	O
by	STRIBILD.xml:S3:6790:2	by	IN	O	O
the	STRIBILD.xml:S3:6793:3	the	DT	O	O
kidney	STRIBILD.xml:S3:6797:6	kidney	NN	O	O
.	STRIBILD.xml:S3:6803:1	.	.	O	O

STRIBILD	STRIBILD.xml:S3:6805:8	stribild	NNP	O	O
should	STRIBILD.xml:S3:6814:6	should	MD	O	O
be	STRIBILD.xml:S3:6821:2	be	VB	O	O
discontinued	STRIBILD.xml:S3:6824:12	discontinu	VBN	O	O
if	STRIBILD.xml:S3:6837:2	if	IN	O	O
estimated	STRIBILD.xml:S3:6840:9	estim	VBN	O	O
creatinine	STRIBILD.xml:S3:6850:10	creatinin	NN	O	O
clearance	STRIBILD.xml:S3:6861:9	clearanc	NN	O	O
declines	STRIBILD.xml:S3:6871:8	declin	NNS	O	O
below	STRIBILD.xml:S3:6880:5	below	IN	O	O
50	STRIBILD.xml:S3:6886:2	50	CD	O	O
mL	STRIBILD.xml:S3:6889:2	mL	NNS	O	O
per	STRIBILD.xml:S3:6892:3	per	IN	O	O
minute	STRIBILD.xml:S3:6896:6	minut	NN	O	O
as	STRIBILD.xml:S3:6903:2	as	IN	O	O
dose	STRIBILD.xml:S3:6906:4	dose	JJ	O	O
interval	STRIBILD.xml:S3:6911:8	interv	JJ	O	O
adjustment	STRIBILD.xml:S3:6920:10	adjust	NN	O	O
required	STRIBILD.xml:S3:6931:8	requir	VBN	O	O
for	STRIBILD.xml:S3:6940:3	for	IN	O	O
emtricitabine	STRIBILD.xml:S3:6944:13	emtricitabin	NN	O	O
and	STRIBILD.xml:S3:6958:3	and	CC	O	O
tenofovir	STRIBILD.xml:S3:6962:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:6972:2	DF	NNP	O	O
cannot	STRIBILD.xml:S3:6975:6	cannot	NN	O	O
be	STRIBILD.xml:S3:6982:2	be	VB	O	O
achieved	STRIBILD.xml:S3:6985:8	achiev	VBN	O	O
with	STRIBILD.xml:S3:6994:4	with	IN	O	O
the	STRIBILD.xml:S3:6999:3	the	DT	O	O
fixed	STRIBILD.xml:S3:7003:5	fix	VBN	O	O
-	STRIBILD.xml:S3:7008:1	-	:	O	O
dose	STRIBILD.xml:S3:7009:4	dose	JJ	O	O
combination	STRIBILD.xml:S3:7014:11	combin	NN	O	O
tablet	STRIBILD.xml:S3:7026:6	tablet	NN	O	O
.	STRIBILD.xml:S3:7032:1	.	.	O	O

5.4	STRIBILD.xml:S3:7041:3	5.4	CD	O	O
Avoid	STRIBILD.xml:S3:7045:5	avoid	NNP	O	O
Use	STRIBILD.xml:S3:7051:3	use	NNP	O	O
with	STRIBILD.xml:S3:7055:4	with	IN	O	O
Other	STRIBILD.xml:S3:7060:5	other	JJ	O	O
Antiretroviral	STRIBILD.xml:S3:7066:14	antiretrovir	JJ	O	O
Products	STRIBILD.xml:S3:7081:8	product	NNS	O	O

STRIBILD	STRIBILD.xml:S3:7095:8	stribild	NNP	O	O
is	STRIBILD.xml:S3:7104:2	is	VBZ	O	O
indicated	STRIBILD.xml:S3:7107:9	indic	VBN	O	O
for	STRIBILD.xml:S3:7117:3	for	IN	O	O
use	STRIBILD.xml:S3:7121:3	use	NN	O	O
as	STRIBILD.xml:S3:7125:2	as	IN	O	O
a	STRIBILD.xml:S3:7128:1	a	DT	O	O
complete	STRIBILD.xml:S3:7130:8	complet	JJ	O	O
regimen	STRIBILD.xml:S3:7139:7	regimen	NN	O	O
for	STRIBILD.xml:S3:7147:3	for	IN	O	O
the	STRIBILD.xml:S3:7151:3	the	DT	O	O
treatment	STRIBILD.xml:S3:7155:9	treatment	NN	O	O
of	STRIBILD.xml:S3:7165:2	of	IN	O	O
HIV	STRIBILD.xml:S3:7168:3	hiv	NNP	O	O
-	STRIBILD.xml:S3:7171:1	-	:	O	O
1	STRIBILD.xml:S3:7172:1	1	CD	O	O
infection	STRIBILD.xml:S3:7174:9	infect	NN	O	O
and	STRIBILD.xml:S3:7184:3	and	CC	O	O
coadministration	STRIBILD.xml:S3:7188:16	coadministr	NN	O	O
with	STRIBILD.xml:S3:7205:4	with	IN	O	O
other	STRIBILD.xml:S3:7210:5	other	JJ	O	O
antiretroviral	STRIBILD.xml:S3:7216:14	antiretrovir	JJ	O	O
products	STRIBILD.xml:S3:7231:8	product	NNS	O	O
is	STRIBILD.xml:S3:7240:2	is	VBZ	O	O
not	STRIBILD.xml:S3:7243:3	not	RB	O	O
recommended	STRIBILD.xml:S3:7247:11	recommend	VBN	O	O
.	STRIBILD.xml:S3:7258:1	.	.	O	O

STRIBILD	STRIBILD.xml:S3:7264:8	stribild	NNP	O	O
is	STRIBILD.xml:S3:7273:2	is	VBZ	O	O
not	STRIBILD.xml:S3:7276:3	not	RB	O	O
recommended	STRIBILD.xml:S3:7280:11	recommend	VBN	O	O
for	STRIBILD.xml:S3:7292:3	for	IN	O	O
coadministration	STRIBILD.xml:S3:7296:16	coadministr	NN	O	O
with	STRIBILD.xml:S3:7313:4	with	IN	O	O
the	STRIBILD.xml:S3:7318:3	the	DT	O	O
following	STRIBILD.xml:S3:7322:9	follow	NN	O	O
:	STRIBILD.xml:S3:7331:1	:	:	O	O

cobicistat	STRIBILD.xml:S3:7341:10	cobicistat	NN	O	O
(	STRIBILD.xml:S3:7352:1	(	(	O	O
TYBOST	STRIBILD.xml:S3:7353:6	tybost	NNP	O	O
)	STRIBILD.xml:S3:7359:1	)	)	O	O
;	STRIBILD.xml:S3:7360:1	;	:	O	O

elvitegravir	STRIBILD.xml:S3:7369:12	elvitegravir	NN	O	O
(	STRIBILD.xml:S3:7382:1	(	(	O	O
VITEKTA	STRIBILD.xml:S3:7383:7	vitekta	NNP	O	O
)	STRIBILD.xml:S3:7390:1	)	)	O	O
;	STRIBILD.xml:S3:7391:1	;	:	O	O

products	STRIBILD.xml:S3:7400:8	product	NNS	O	O
containing	STRIBILD.xml:S3:7409:10	contain	VBG	O	O
emtricitabine	STRIBILD.xml:S3:7420:13	emtricitabin	NN	O	O
or	STRIBILD.xml:S3:7434:2	or	CC	O	O
tenofovir	STRIBILD.xml:S3:7437:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:7447:2	DF	NNP	O	O
(	STRIBILD.xml:S3:7450:1	(	(	O	O
ATRIPLA	STRIBILD.xml:S3:7451:7	atripla	NNP	O	O
,	STRIBILD.xml:S3:7458:1	,	,	O	O
COMPLERA	STRIBILD.xml:S3:7460:8	complera	NNP	O	O
,	STRIBILD.xml:S3:7468:1	,	,	O	O
EMTRIVA	STRIBILD.xml:S3:7470:7	emtriva	NNP	O	O
,	STRIBILD.xml:S3:7477:1	,	,	O	O
TRUVADA	STRIBILD.xml:S3:7479:7	truvada	NNP	O	O
,	STRIBILD.xml:S3:7486:1	,	,	O	O
VIREAD	STRIBILD.xml:S3:7488:6	viread	NNP	O	O
)	STRIBILD.xml:S3:7494:1	)	)	O	O
;	STRIBILD.xml:S3:7495:1	;	:	O	O

products	STRIBILD.xml:S3:7504:8	product	NNS	O	O
containing	STRIBILD.xml:S3:7513:10	contain	VBG	O	O
lamivudine	STRIBILD.xml:S3:7524:10	lamivudin	NN	O	O
(	STRIBILD.xml:S3:7535:1	(	(	O	O
COMBIVIR	STRIBILD.xml:S3:7536:8	combivir	NNP	O	O
,	STRIBILD.xml:S3:7544:1	,	,	O	O
EPIVIR	STRIBILD.xml:S3:7546:6	epivir	NNP	O	O
,	STRIBILD.xml:S3:7552:1	,	,	O	O
EPIVIR	STRIBILD.xml:S3:7554:6	epivir	NNP	O	O
-	STRIBILD.xml:S3:7560:1	-	:	O	O
HBV	STRIBILD.xml:S3:7561:3	hbv	NNP	O	O
,	STRIBILD.xml:S3:7564:1	,	,	O	O
EPZICOM	STRIBILD.xml:S3:7566:7	epzicom	NNP	O	O
,	STRIBILD.xml:S3:7573:1	,	,	O	O
TRIUMEQ	STRIBILD.xml:S3:7575:7	triumeq	NNP	O	O
,	STRIBILD.xml:S3:7582:1	,	,	O	O
TRIZIVIR	STRIBILD.xml:S3:7584:8	trizivir	NNP	O	O
)	STRIBILD.xml:S3:7592:1	)	)	O	O
;	STRIBILD.xml:S3:7593:1	;	:	O	O

adefovir	STRIBILD.xml:S3:7602:8	adefovir	NN	O	O
dipivoxil	STRIBILD.xml:S3:7611:9	dipivoxil	NN	O	O
(	STRIBILD.xml:S3:7621:1	(	(	O	O
HEPSERA	STRIBILD.xml:S3:7622:7	hepsera	NNP	O	O
)	STRIBILD.xml:S3:7629:1	)	)	O	O
;	STRIBILD.xml:S3:7630:1	;	:	O	O

products	STRIBILD.xml:S3:7639:8	product	NNS	O	O
containing	STRIBILD.xml:S3:7648:10	contain	VBG	O	O
ritonavir	STRIBILD.xml:S3:7659:9	ritonavir	NN	O	O
(	STRIBILD.xml:S3:7669:1	(	(	O	O
NORVIR	STRIBILD.xml:S3:7670:6	norvir	NNP	O	O
,	STRIBILD.xml:S3:7676:1	,	,	O	O
KALETRA	STRIBILD.xml:S3:7678:7	kaletra	NNP	O	O
)	STRIBILD.xml:S3:7685:1	)	)	O	O

5.5	STRIBILD.xml:S3:7696:3	5.5	CD	O	O
Risk	STRIBILD.xml:S3:7700:4	risk	NN	O	O
of	STRIBILD.xml:S3:7705:2	of	IN	O	O
Adverse	STRIBILD.xml:S3:7708:7	advers	JJ	O	O
Reactions	STRIBILD.xml:S3:7716:9	reaction	NNPS	O	O
or	STRIBILD.xml:S3:7726:2	or	CC	O	O
Loss	STRIBILD.xml:S3:7729:4	loss	NNP	O	B-AdverseReaction
of	STRIBILD.xml:S3:7734:2	of	IN	O	I-AdverseReaction
Virologic	STRIBILD.xml:S3:7737:9	virolog	NNP	O	I-AdverseReaction
Response	STRIBILD.xml:S3:7747:8	respons	NNP	O	I-AdverseReaction
Due	STRIBILD.xml:S3:7756:3	due	NNP	O	O
to	STRIBILD.xml:S3:7760:2	to	TO	O	O
Drug	STRIBILD.xml:S3:7763:4	drug	NNP	O	O
Interactions	STRIBILD.xml:S3:7768:12	interact	NNP	O	O

The	STRIBILD.xml:S3:7787:3	the	DT	O	O

concomitant	STRIBILD.xml:S3:7791:11	concomit	NN	O	O
use	STRIBILD.xml:S3:7803:3	use	NN	O	O
of	STRIBILD.xml:S3:7807:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:7810:8	stribild	NNP	O	O
and	STRIBILD.xml:S3:7819:3	and	CC	O	O
other	STRIBILD.xml:S3:7823:5	other	JJ	O	O
drugs	STRIBILD.xml:S3:7829:5	drug	NNS	O	O
may	STRIBILD.xml:S3:7835:3	may	MD	O	O
result	STRIBILD.xml:S3:7839:6	result	VB	O	O
in	STRIBILD.xml:S3:7846:2	in	IN	O	O
known	STRIBILD.xml:S3:7849:5	known	NN	O	O
or	STRIBILD.xml:S3:7855:2	or	CC	O	O
potentially	STRIBILD.xml:S3:7858:11	potenti	RB	O	O
significant	STRIBILD.xml:S3:7870:11	signific	JJ	O	O
drug	STRIBILD.xml:S3:7882:4	drug	NN	O	O
interactions	STRIBILD.xml:S3:7887:12	interact	NNS	O	O
,	STRIBILD.xml:S3:7899:1	,	,	O	O
some	STRIBILD.xml:S3:7901:4	some	DT	O	O
of	STRIBILD.xml:S3:7906:2	of	IN	O	O
which	STRIBILD.xml:S3:7909:5	which	WDT	O	O
may	STRIBILD.xml:S3:7915:3	may	MD	O	O
lead	STRIBILD.xml:S3:7919:4	lead	VB	O	O
to	STRIBILD.xml:S3:7924:2	to	TO	O	O
[	STRIBILD.xml:S3:7927:1	[	VB	O	O
see	STRIBILD.xml:S3:7928:3	see	VB	O	O
Contraindications	STRIBILD.xml:S3:7933:17	contraind	NNP	O	O
(	STRIBILD.xml:S3:7951:1	(	(	O	O
4	STRIBILD.xml:S3:7952:1	4	CD	O	O
)	STRIBILD.xml:S3:7953:1	)	)	O	O
,	STRIBILD.xml:S3:7956:1	,	,	O	O
Drug	STRIBILD.xml:S3:7959:4	drug	NNP	O	O
Interactions	STRIBILD.xml:S3:7964:12	interact	NNP	O	O
(	STRIBILD.xml:S3:7977:1	(	(	O	O
7.5	STRIBILD.xml:S3:7978:3	7.5	CD	O	O
)	STRIBILD.xml:S3:7981:1	)	)	O	O
]	STRIBILD.xml:S3:7984:1	]	NN	O	O
:	STRIBILD.xml:S3:7985:1	:	:	O	O

Loss	STRIBILD.xml:S3:7999:4	loss	NNP	O	O
of	STRIBILD.xml:S3:8004:2	of	IN	O	O
therapeutic	STRIBILD.xml:S3:8007:11	therapeut	JJ	O	O
effect	STRIBILD.xml:S3:8019:6	effect	NN	O	O
of	STRIBILD.xml:S3:8026:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:8029:8	stribild	NNP	O	O
and	STRIBILD.xml:S3:8038:3	and	CC	O	O
possible	STRIBILD.xml:S3:8042:8	possibl	JJ	O	O
development	STRIBILD.xml:S3:8051:11	develop	NN	O	O
of	STRIBILD.xml:S3:8063:2	of	IN	O	O
resistance	STRIBILD.xml:S3:8066:10	resist	NN	O	O
.	STRIBILD.xml:S3:8076:1	.	.	O	O

Possible	STRIBILD.xml:S3:8085:8	possibl	JJ	O	O
clinically	STRIBILD.xml:S3:8094:10	clinic	RB	O	O
significant	STRIBILD.xml:S3:8105:11	signific	JJ	O	O
adverse	STRIBILD.xml:S3:8117:7	advers	JJ	O	O
reactions	STRIBILD.xml:S3:8125:9	reaction	NNS	O	O
from	STRIBILD.xml:S3:8135:4	from	IN	O	O
greater	STRIBILD.xml:S3:8140:7	greater	JJR	O	O
exposures	STRIBILD.xml:S3:8148:9	exposur	NNS	O	O
of	STRIBILD.xml:S3:8158:2	of	IN	O	O
concomitant	STRIBILD.xml:S3:8161:11	concomit	JJ	O	O
drugs	STRIBILD.xml:S3:8173:5	drug	NNS	O	O
.	STRIBILD.xml:S3:8178:1	.	.	O	O

See	STRIBILD.xml:S3:8187:3	see	VB	O	O
Table	STRIBILD.xml:S3:8192:5	tabl	JJ	O	O
6	STRIBILD.xml:S3:8198:1	6	CD	O	O
for	STRIBILD.xml:S3:8201:3	for	IN	O	O
steps	STRIBILD.xml:S3:8205:5	step	NNS	O	O
to	STRIBILD.xml:S3:8211:2	to	TO	O	O
prevent	STRIBILD.xml:S3:8214:7	prevent	VB	O	O
or	STRIBILD.xml:S3:8222:2	or	CC	O	O
manage	STRIBILD.xml:S3:8225:6	manag	VB	O	O
these	STRIBILD.xml:S3:8232:5	these	DT	O	O
possible	STRIBILD.xml:S3:8238:8	possibl	JJ	O	O
and	STRIBILD.xml:S3:8247:3	and	CC	O	O
known	STRIBILD.xml:S3:8251:5	known	JJ	O	O
significant	STRIBILD.xml:S3:8257:11	signific	JJ	O	O
drug	STRIBILD.xml:S3:8269:4	drug	NN	O	O
interactions	STRIBILD.xml:S3:8274:12	interact	NNS	O	O
,	STRIBILD.xml:S3:8286:1	,	,	O	O
including	STRIBILD.xml:S3:8288:9	includ	VBG	O	O
dosing	STRIBILD.xml:S3:8298:6	dose	VBG	O	O
recommendations	STRIBILD.xml:S3:8305:15	recommend	NNS	O	O
[	STRIBILD.xml:S3:8321:1	[	NNP	O	O
see	STRIBILD.xml:S3:8322:3	see	VBP	O	O
Drug	STRIBILD.xml:S3:8327:4	drug	NNP	O	O
Interactions	STRIBILD.xml:S3:8332:12	interact	NNP	O	O
(	STRIBILD.xml:S3:8345:1	(	(	O	O
7.5	STRIBILD.xml:S3:8346:3	7.5	CD	O	O
)	STRIBILD.xml:S3:8349:1	)	)	O	O
]	STRIBILD.xml:S3:8352:1	]	NN	O	O
.	STRIBILD.xml:S3:8355:1	.	.	O	O

Consider	STRIBILD.xml:S3:8357:8	consid	VB	O	O
the	STRIBILD.xml:S3:8366:3	the	DT	O	O
potential	STRIBILD.xml:S3:8370:9	potenti	NN	O	O
for	STRIBILD.xml:S3:8380:3	for	IN	O	O
drug	STRIBILD.xml:S3:8384:4	drug	NN	O	O
interactions	STRIBILD.xml:S3:8389:12	interact	NNS	O	O
prior	STRIBILD.xml:S3:8402:5	prior	VBP	O	O
to	STRIBILD.xml:S3:8408:2	to	TO	O	O
and	STRIBILD.xml:S3:8411:3	and	CC	O	O
during	STRIBILD.xml:S3:8415:6	dure	IN	O	O
STRIBILD	STRIBILD.xml:S3:8422:8	stribild	NNP	O	O
therapy	STRIBILD.xml:S3:8431:7	therapi	NN	O	O
;	STRIBILD.xml:S3:8438:1	;	:	O	O
review	STRIBILD.xml:S3:8440:6	review	NN	O	O
concomitant	STRIBILD.xml:S3:8447:11	concomit	JJ	O	O
medications	STRIBILD.xml:S3:8459:11	medic	NNS	O	O
during	STRIBILD.xml:S3:8471:6	dure	IN	O	O
STRIBILD	STRIBILD.xml:S3:8478:8	stribild	NNP	O	O
therapy	STRIBILD.xml:S3:8487:7	therapi	NN	O	O
;	STRIBILD.xml:S3:8494:1	;	:	O	O
and	STRIBILD.xml:S3:8496:3	and	CC	O	O
monitor	STRIBILD.xml:S3:8500:7	monitor	VB	O	O
for	STRIBILD.xml:S3:8508:3	for	IN	O	O
the	STRIBILD.xml:S3:8512:3	the	DT	O	O
adverse	STRIBILD.xml:S3:8516:7	advers	JJ	O	O
reactions	STRIBILD.xml:S3:8524:9	reaction	NNS	O	O
associated	STRIBILD.xml:S3:8534:10	associ	VBN	O	O
with	STRIBILD.xml:S3:8545:4	with	IN	O	O
the	STRIBILD.xml:S3:8550:3	the	DT	O	O
concomitant	STRIBILD.xml:S3:8554:11	concomit	NN	O	O
drugs	STRIBILD.xml:S3:8566:5	drug	NNS	O	O
.	STRIBILD.xml:S3:8571:1	.	.	O	O

5.6	STRIBILD.xml:S3:8582:3	5.6	CD	O	O

Bone	STRIBILD.xml:S3:8586:4	bone	NNP	O	O
Effects	STRIBILD.xml:S3:8591:7	effect	NNPS	O	O
of	STRIBILD.xml:S3:8599:2	of	IN	O	O
Tenofovir	STRIBILD.xml:S3:8602:9	tenofovir	NNP	O	O
DF	STRIBILD.xml:S3:8612:2	DF	NNP	O	O

Bone	STRIBILD.xml:S3:8621:4	bone	NNP	O	O
Mineral	STRIBILD.xml:S3:8626:7	miner	NNP	O	O
Density	STRIBILD.xml:S3:8634:7	densiti	NNP	O	O
:	STRIBILD.xml:S3:8641:1	:	:	O	O

In	STRIBILD.xml:S3:8649:2	In	IN	O	O
clinical	STRIBILD.xml:S3:8652:8	clinic	JJ	O	O
trials	STRIBILD.xml:S3:8661:6	trial	NNS	O	O
in	STRIBILD.xml:S3:8668:2	in	IN	O	O
HIV	STRIBILD.xml:S3:8671:3	hiv	NNP	O	O
-	STRIBILD.xml:S3:8674:1	-	:	O	O
1	STRIBILD.xml:S3:8675:1	1	CD	O	O
infected	STRIBILD.xml:S3:8677:8	infect	JJ	O	O
adults	STRIBILD.xml:S3:8686:6	adult	NNS	O	O
,	STRIBILD.xml:S3:8692:1	,	,	O	O
tenofovir	STRIBILD.xml:S3:8694:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:8704:2	DF	NNP	O	O
(	STRIBILD.xml:S3:8707:1	(	(	O	O
a	STRIBILD.xml:S3:8708:1	a	DT	O	O
component	STRIBILD.xml:S3:8710:9	compon	NN	O	O
of	STRIBILD.xml:S3:8720:2	of	IN	O	O
STRIBILD	STRIBILD.xml:S3:8723:8	stribild	NNP	O	O
)	STRIBILD.xml:S3:8731:1	)	)	O	O
was	STRIBILD.xml:S3:8733:3	wa	VBD	O	O
associated	STRIBILD.xml:S3:8737:10	associ	VBN	O	O
with	STRIBILD.xml:S3:8748:4	with	IN	O	O
slightly	STRIBILD.xml:S3:8753:8	slightli	RB	O	O
greater	STRIBILD.xml:S3:8762:7	greater	JJR	O	O
decreases	STRIBILD.xml:S3:8770:9	decreas	NNS	B-AdverseReaction	B-AdverseReaction
in	STRIBILD.xml:S3:8780:2	in	IN	I-AdverseReaction	I-AdverseReaction
bone	STRIBILD.xml:S3:8783:4	bone	JJ	I-AdverseReaction	I-AdverseReaction
mineral	STRIBILD.xml:S3:8788:7	miner	JJ	I-AdverseReaction	I-AdverseReaction
density	STRIBILD.xml:S3:8796:7	densiti	NN	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S3:8804:1	(	(	O	O
BMD	STRIBILD.xml:S3:8805:3	bmd	NNP	I-AdverseReaction	O
)	STRIBILD.xml:S3:8808:1	)	)	O	O
and	STRIBILD.xml:S3:8810:3	and	CC	O	O
increases	STRIBILD.xml:S3:8814:9	increas	VBZ	B-AdverseReaction	O
in	STRIBILD.xml:S3:8824:2	in	IN	I-AdverseReaction	O
biochemical	STRIBILD.xml:S3:8827:11	biochem	JJ	I-AdverseReaction	O
markers	STRIBILD.xml:S3:8839:7	marker	NNS	I-AdverseReaction	O
of	STRIBILD.xml:S3:8847:2	of	IN	I-AdverseReaction	O
bone	STRIBILD.xml:S3:8850:4	bone	NN	I-AdverseReaction	O
metabolism	STRIBILD.xml:S3:8855:10	metabol	NN	I-AdverseReaction	O
,	STRIBILD.xml:S3:8865:1	,	,	O	O
suggesting	STRIBILD.xml:S3:8867:10	suggest	VBG	O	O
increased	STRIBILD.xml:S3:8878:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
bone	STRIBILD.xml:S3:8888:4	bone	NN	I-AdverseReaction	I-AdverseReaction
turnover	STRIBILD.xml:S3:8893:8	turnov	NN	I-AdverseReaction	I-AdverseReaction
relative	STRIBILD.xml:S3:8902:8	rel	VBP	O	O
to	STRIBILD.xml:S3:8911:2	to	TO	O	O
comparators	STRIBILD.xml:S3:8914:11	compar	NNS	O	O
.	STRIBILD.xml:S3:8925:1	.	.	O	O

Serum	STRIBILD.xml:S3:8927:5	serum	NNP	O	O
parathyroid	STRIBILD.xml:S3:8933:11	parathyroid	VBP	O	O
hormone	STRIBILD.xml:S3:8945:7	hormon	NN	O	O
levels	STRIBILD.xml:S3:8953:6	level	NNS	O	O
and	STRIBILD.xml:S3:8960:3	and	CC	O	O
1.25	STRIBILD.xml:S3:8964:4	1.25	CD	O	O
Vitamin	STRIBILD.xml:S3:8969:7	vitamin	NNP	O	O
D	STRIBILD.xml:S3:8977:1	D	NNP	O	O
levels	STRIBILD.xml:S3:8979:6	level	NNS	O	O
were	STRIBILD.xml:S3:8986:4	were	VBD	O	O
also	STRIBILD.xml:S3:8991:4	also	RB	O	O
higher	STRIBILD.xml:S3:8996:6	higher	JJR	O	O
in	STRIBILD.xml:S3:9003:2	in	IN	O	O
subjects	STRIBILD.xml:S3:9006:8	subject	NNS	O	O
receiving	STRIBILD.xml:S3:9015:9	receiv	VBG	O	O
tenofovir	STRIBILD.xml:S3:9025:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:9035:2	DF	NNP	O	O
.	STRIBILD.xml:S3:9037:1	.	.	O	O

For	STRIBILD.xml:S3:9039:3	for	IN	O	O
additional	STRIBILD.xml:S3:9043:10	addit	JJ	O	O
information	STRIBILD.xml:S3:9054:11	inform	NN	O	O
,	STRIBILD.xml:S3:9065:1	,	,	O	O
see	STRIBILD.xml:S3:9067:3	see	VBP	O	O
Adverse	STRIBILD.xml:S3:9071:7	advers	JJ	O	O
Reactions	STRIBILD.xml:S3:9079:9	reaction	NNP	O	O
(	STRIBILD.xml:S3:9089:1	(	(	O	O
6.1	STRIBILD.xml:S3:9090:3	6.1	CD	O	O
)	STRIBILD.xml:S3:9093:1	)	)	O	O
and	STRIBILD.xml:S3:9095:3	and	CC	O	O
consult	STRIBILD.xml:S3:9099:7	consult	VB	O	O
the	STRIBILD.xml:S3:9107:3	the	DT	O	O
VIREAD	STRIBILD.xml:S3:9111:6	viread	NNP	O	O
prescribing	STRIBILD.xml:S3:9118:11	prescrib	NN	O	O
information	STRIBILD.xml:S3:9130:11	inform	NN	O	O
.	STRIBILD.xml:S3:9141:1	.	.	O	O

The	STRIBILD.xml:S3:9147:3	the	DT	O	O
effects	STRIBILD.xml:S3:9151:7	effect	NNS	O	O
of	STRIBILD.xml:S3:9159:2	of	IN	O	O
tenofovir	STRIBILD.xml:S3:9162:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:9172:2	DF	NNP	O	O
-	STRIBILD.xml:S3:9174:1	-	:	O	O
associated	STRIBILD.xml:S3:9175:10	associ	VBN	O	O
changes	STRIBILD.xml:S3:9186:7	chang	NNS	O	O
in	STRIBILD.xml:S3:9194:2	in	IN	O	O
BMD	STRIBILD.xml:S3:9197:3	bmd	NNP	O	O
and	STRIBILD.xml:S3:9201:3	and	CC	O	O
biochemical	STRIBILD.xml:S3:9205:11	biochem	JJ	O	O
markers	STRIBILD.xml:S3:9217:7	marker	NNS	O	O
on	STRIBILD.xml:S3:9225:2	on	IN	O	O
long	STRIBILD.xml:S3:9228:4	long	JJ	O	O
-	STRIBILD.xml:S3:9232:1	-	:	O	O
term	STRIBILD.xml:S3:9233:4	term	NN	O	O
bone	STRIBILD.xml:S3:9238:4	bone	NN	O	O
health	STRIBILD.xml:S3:9243:6	health	NN	O	O
and	STRIBILD.xml:S3:9250:3	and	CC	O	O
future	STRIBILD.xml:S3:9254:6	futur	JJ	O	O
fracture	STRIBILD.xml:S3:9261:8	fractur	NN	O	O
risk	STRIBILD.xml:S3:9270:4	risk	NN	O	O
are	STRIBILD.xml:S3:9275:3	are	VBP	O	O
unknown	STRIBILD.xml:S3:9279:7	unknown	JJ	O	O
.	STRIBILD.xml:S3:9286:1	.	.	O	O

Assessment	STRIBILD.xml:S3:9288:10	assess	NN	O	O
of	STRIBILD.xml:S3:9299:2	of	IN	O	O
BMD	STRIBILD.xml:S3:9302:3	bmd	NNP	O	O
should	STRIBILD.xml:S3:9306:6	should	MD	O	O
be	STRIBILD.xml:S3:9313:2	be	VB	O	O
considered	STRIBILD.xml:S3:9316:10	consid	VBN	O	O
for	STRIBILD.xml:S3:9327:3	for	IN	O	O
HIV	STRIBILD.xml:S3:9331:3	hiv	NNP	O	O
-	STRIBILD.xml:S3:9334:1	-	:	O	O
1	STRIBILD.xml:S3:9335:1	1	CD	O	O
infected	STRIBILD.xml:S3:9337:8	infect	JJ	O	O
patients	STRIBILD.xml:S3:9346:8	patient	NNS	O	O
who	STRIBILD.xml:S3:9355:3	who	WP	O	O
have	STRIBILD.xml:S3:9359:4	have	VBP	O	O
a	STRIBILD.xml:S3:9364:1	a	DT	O	O
history	STRIBILD.xml:S3:9366:7	histori	NN	O	O
of	STRIBILD.xml:S3:9374:2	of	IN	O	O
pathologic	STRIBILD.xml:S3:9377:10	patholog	JJ	O	O
bone	STRIBILD.xml:S3:9388:4	bone	NN	O	O
fracture	STRIBILD.xml:S3:9393:8	fractur	NN	O	O
or	STRIBILD.xml:S3:9402:2	or	CC	O	O
other	STRIBILD.xml:S3:9405:5	other	JJ	O	O
risk	STRIBILD.xml:S3:9411:4	risk	NN	O	O
factors	STRIBILD.xml:S3:9416:7	factor	NNS	O	O
for	STRIBILD.xml:S3:9424:3	for	IN	O	O
osteoporosis	STRIBILD.xml:S3:9428:12	osteoporosi	NN	O	O
or	STRIBILD.xml:S3:9441:2	or	CC	O	O
bone	STRIBILD.xml:S3:9444:4	bone	NN	O	O
loss	STRIBILD.xml:S3:9449:4	loss	NN	O	O
.	STRIBILD.xml:S3:9453:1	.	.	O	O

Although	STRIBILD.xml:S3:9455:8	although	IN	O	O
the	STRIBILD.xml:S3:9464:3	the	DT	O	O
effect	STRIBILD.xml:S3:9468:6	effect	NN	O	O
of	STRIBILD.xml:S3:9475:2	of	IN	O	O
supplementation	STRIBILD.xml:S3:9478:15	supplement	NN	O	O
with	STRIBILD.xml:S3:9494:4	with	IN	O	O
calcium	STRIBILD.xml:S3:9499:7	calcium	NN	O	O
and	STRIBILD.xml:S3:9507:3	and	CC	O	O
vitamin	STRIBILD.xml:S3:9511:7	vitamin	NN	O	O
D	STRIBILD.xml:S3:9519:1	D	NNP	O	O
was	STRIBILD.xml:S3:9521:3	wa	VBD	O	O
not	STRIBILD.xml:S3:9525:3	not	RB	O	O
studied	STRIBILD.xml:S3:9529:7	studi	VBN	O	O
,	STRIBILD.xml:S3:9536:1	,	,	O	O
such	STRIBILD.xml:S3:9538:4	such	JJ	O	O
supplementation	STRIBILD.xml:S3:9543:15	supplement	NN	O	O
may	STRIBILD.xml:S3:9559:3	may	MD	O	O
be	STRIBILD.xml:S3:9563:2	be	VB	O	O
beneficial	STRIBILD.xml:S3:9566:10	benefici	JJ	O	O
in	STRIBILD.xml:S3:9577:2	in	IN	O	O
all	STRIBILD.xml:S3:9580:3	all	DT	O	O
patients	STRIBILD.xml:S3:9584:8	patient	NNS	O	O
.	STRIBILD.xml:S3:9592:1	.	.	O	O

If	STRIBILD.xml:S3:9594:2	If	IN	O	O
bone	STRIBILD.xml:S3:9597:4	bone	NN	O	O
abnormalities	STRIBILD.xml:S3:9602:13	abnorm	NNS	O	O
are	STRIBILD.xml:S3:9616:3	are	VBP	O	O
suspected	STRIBILD.xml:S3:9620:9	suspect	VBN	O	O
,	STRIBILD.xml:S3:9629:1	,	,	O	O
then	STRIBILD.xml:S3:9631:4	then	RB	O	O
appropriate	STRIBILD.xml:S3:9636:11	appropri	JJ	O	O
consultation	STRIBILD.xml:S3:9648:12	consult	NN	O	O
should	STRIBILD.xml:S3:9661:6	should	MD	O	O
be	STRIBILD.xml:S3:9668:2	be	VB	O	O
obtained	STRIBILD.xml:S3:9671:8	obtain	VBN	O	O
.	STRIBILD.xml:S3:9679:1	.	.	O	O

Mineralization	STRIBILD.xml:S3:9688:14	miner	NN	O	O
Defects	STRIBILD.xml:S3:9703:7	defect	NNS	O	O
:	STRIBILD.xml:S3:9710:1	:	:	O	O

Cases	STRIBILD.xml:S3:9718:5	case	NNS	O	O
of	STRIBILD.xml:S3:9724:2	of	IN	O	O
osteomalacia	STRIBILD.xml:S3:9727:12	osteomalacia	NN	B-AdverseReaction	O
associated	STRIBILD.xml:S3:9740:10	associ	VBN	O	O
with	STRIBILD.xml:S3:9751:4	with	IN	O	O
proximal	STRIBILD.xml:S3:9756:8	proxim	JJ	B-AdverseReaction	O
renal	STRIBILD.xml:S3:9765:5	renal	JJ	I-AdverseReaction	O
tubulopathy	STRIBILD.xml:S3:9771:11	tubulopathi	NN	I-AdverseReaction	O
,	STRIBILD.xml:S3:9782:1	,	,	O	O
manifested	STRIBILD.xml:S3:9784:10	manifest	VBN	O	O
as	STRIBILD.xml:S3:9795:2	as	IN	O	O
bone	STRIBILD.xml:S3:9798:4	bone	NN	B-AdverseReaction	B-AdverseReaction
pain	STRIBILD.xml:S3:9803:4	pain	NN	I-AdverseReaction	I-AdverseReaction
or	STRIBILD.xml:S3:9808:2	or	CC	O	O
pain	STRIBILD.xml:S3:9811:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	STRIBILD.xml:S3:9816:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremities	STRIBILD.xml:S3:9819:11	extrem	NNS	I-AdverseReaction	I-AdverseReaction
and	STRIBILD.xml:S3:9831:3	and	CC	O	O
which	STRIBILD.xml:S3:9835:5	which	WDT	O	O
may	STRIBILD.xml:S3:9841:3	may	MD	O	O
contribute	STRIBILD.xml:S3:9845:10	contribut	VB	O	O
to	STRIBILD.xml:S3:9856:2	to	TO	O	O
fractures	STRIBILD.xml:S3:9859:9	fractur	NNS	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S3:9868:1	,	,	O	O
have	STRIBILD.xml:S3:9870:4	have	VBP	O	O
been	STRIBILD.xml:S3:9875:4	been	VBN	O	O
reported	STRIBILD.xml:S3:9880:8	report	VBN	O	O
in	STRIBILD.xml:S3:9889:2	in	IN	O	O
association	STRIBILD.xml:S3:9892:11	associ	NN	O	O
with	STRIBILD.xml:S3:9904:4	with	IN	O	O
the	STRIBILD.xml:S3:9909:3	the	DT	O	O
use	STRIBILD.xml:S3:9913:3	use	NN	O	O
of	STRIBILD.xml:S3:9917:2	of	IN	O	O
tenofovir	STRIBILD.xml:S3:9920:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:9930:2	DF	NNP	O	O
[	STRIBILD.xml:S3:9933:1	[	NNP	O	O
see	STRIBILD.xml:S3:9934:3	see	VBP	O	O
Adverse	STRIBILD.xml:S3:9939:7	advers	JJ	O	O
Reactions	STRIBILD.xml:S3:9947:9	reaction	NNP	O	O
(	STRIBILD.xml:S3:9957:1	(	(	O	O
6.2	STRIBILD.xml:S3:9958:3	6.2	CD	O	O
)	STRIBILD.xml:S3:9961:1	)	)	O	O
]	STRIBILD.xml:S3:9964:1	]	NN	O	O
.	STRIBILD.xml:S3:9967:1	.	.	O	O

Arthralgias	STRIBILD.xml:S3:9969:11	arthralgia	NNP	B-AdverseReaction	B-AdverseReaction
and	STRIBILD.xml:S3:9981:3	and	CC	O	O
muscle	STRIBILD.xml:S3:9985:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
pain	STRIBILD.xml:S3:9992:4	pain	NN	I-AdverseReaction	I-AdverseReaction
or	STRIBILD.xml:S3:9997:2	or	CC	O	O
weakness	STRIBILD.xml:S3:10000:8	weak	NN	I-AdverseReaction	O
have	STRIBILD.xml:S3:10009:4	have	VBP	O	O
also	STRIBILD.xml:S3:10014:4	also	RB	O	O
been	STRIBILD.xml:S3:10019:4	been	VBN	O	O
reported	STRIBILD.xml:S3:10024:8	report	VBN	O	O
in	STRIBILD.xml:S3:10033:2	in	IN	O	O
cases	STRIBILD.xml:S3:10036:5	case	NNS	O	O
of	STRIBILD.xml:S3:10042:2	of	IN	O	O
proximal	STRIBILD.xml:S3:10045:8	proxim	JJ	B-AdverseReaction	O
renal	STRIBILD.xml:S3:10054:5	renal	JJ	I-AdverseReaction	O
tubulopathy	STRIBILD.xml:S3:10060:11	tubulopathi	NN	I-AdverseReaction	O
.	STRIBILD.xml:S3:10071:1	.	.	O	O

Hypophosphatemia	STRIBILD.xml:S3:10073:16	hypophosphatemia	NNP	O	B-AdverseReaction
and	STRIBILD.xml:S3:10090:3	and	CC	O	O
osteomalacia	STRIBILD.xml:S3:10094:12	osteomalacia	RB	O	O
secondary	STRIBILD.xml:S3:10107:9	secondari	JJ	O	O
to	STRIBILD.xml:S3:10117:2	to	TO	O	O
proximal	STRIBILD.xml:S3:10120:8	proxim	JJ	O	O
renal	STRIBILD.xml:S3:10129:5	renal	JJ	O	O
tubulopathy	STRIBILD.xml:S3:10135:11	tubulopathi	NN	O	O
should	STRIBILD.xml:S3:10147:6	should	MD	O	O
be	STRIBILD.xml:S3:10154:2	be	VB	O	O
considered	STRIBILD.xml:S3:10157:10	consid	VBN	O	O
in	STRIBILD.xml:S3:10168:2	in	IN	O	O
patients	STRIBILD.xml:S3:10171:8	patient	NNS	O	O
at	STRIBILD.xml:S3:10180:2	at	IN	O	O
risk	STRIBILD.xml:S3:10183:4	risk	NN	O	O
of	STRIBILD.xml:S3:10188:2	of	IN	O	O
renal	STRIBILD.xml:S3:10191:5	renal	JJ	O	O
dysfunction	STRIBILD.xml:S3:10197:11	dysfunct	NN	O	O
who	STRIBILD.xml:S3:10209:3	who	WP	O	O
present	STRIBILD.xml:S3:10213:7	present	VBP	O	O
with	STRIBILD.xml:S3:10221:4	with	IN	O	O
persistent	STRIBILD.xml:S3:10226:10	persist	NN	O	O
or	STRIBILD.xml:S3:10237:2	or	CC	O	O
worsening	STRIBILD.xml:S3:10240:9	worsen	VBG	O	O
bone	STRIBILD.xml:S3:10250:4	bone	NN	O	O
or	STRIBILD.xml:S3:10255:2	or	CC	O	O
muscle	STRIBILD.xml:S3:10258:6	muscl	NN	O	O
symptoms	STRIBILD.xml:S3:10265:8	symptom	NNS	O	O
while	STRIBILD.xml:S3:10274:5	while	IN	O	O
receiving	STRIBILD.xml:S3:10280:9	receiv	VBG	O	O
products	STRIBILD.xml:S3:10290:8	product	NNS	O	O
containing	STRIBILD.xml:S3:10299:10	contain	VBG	O	O
tenofovir	STRIBILD.xml:S3:10310:9	tenofovir	NN	O	O
DF	STRIBILD.xml:S3:10320:2	DF	NNP	O	O
[	STRIBILD.xml:S3:10323:1	[	NNP	O	O
see	STRIBILD.xml:S3:10324:3	see	VBP	O	O
Warnings	STRIBILD.xml:S3:10329:8	warn	NNP	O	O
and	STRIBILD.xml:S3:10338:3	and	CC	O	O
Precautions	STRIBILD.xml:S3:10342:11	precaut	NNP	O	O
(	STRIBILD.xml:S3:10354:1	(	(	O	O
5.3	STRIBILD.xml:S3:10355:3	5.3	CD	O	O
)	STRIBILD.xml:S3:10358:1	)	)	O	O
]	STRIBILD.xml:S3:10361:1	]	NN	O	O
.	STRIBILD.xml:S3:10364:1	.	.	O	O

5.7	STRIBILD.xml:S3:10373:3	5.7	CD	O	O
Fat	STRIBILD.xml:S3:10377:3	fat	NNP	O	O
Redistribution	STRIBILD.xml:S3:10381:14	redistribut	NNP	O	O

Redistribution	STRIBILD.xml:S3:10401:14	redistribut	NNP	B-AdverseReaction	O
accumulation	STRIBILD.xml:S3:10416:12	accumul	NN	B-AdverseReaction	O
of	STRIBILD.xml:S3:10429:2	of	IN	I-AdverseReaction	O
body	STRIBILD.xml:S3:10432:4	bodi	NN	I-AdverseReaction	O
fat	STRIBILD.xml:S3:10437:3	fat	JJ	I-AdverseReaction	O
including	STRIBILD.xml:S3:10441:9	includ	VBG	O	O
central	STRIBILD.xml:S3:10451:7	central	JJ	B-AdverseReaction	O
obesity	STRIBILD.xml:S3:10459:7	obes	NN	I-AdverseReaction	O
,	STRIBILD.xml:S3:10466:1	,	,	O	O
dorsocervical	STRIBILD.xml:S3:10468:13	dorsocerv	JJ	B-AdverseReaction	B-AdverseReaction
fat	STRIBILD.xml:S3:10482:3	fat	NN	I-AdverseReaction	I-AdverseReaction
enlargement	STRIBILD.xml:S3:10486:11	enlarg	NN	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S3:10498:1	(	(	O	O
buffalo	STRIBILD.xml:S3:10499:7	buffalo	JJ	B-AdverseReaction	B-AdverseReaction
hump	STRIBILD.xml:S3:10507:4	hump	NN	I-AdverseReaction	I-AdverseReaction
)	STRIBILD.xml:S3:10511:1	)	)	O	O
,	STRIBILD.xml:S3:10512:1	,	,	O	O
peripheral	STRIBILD.xml:S3:10514:10	peripher	JJ	I-AdverseReaction	B-AdverseReaction
wasting	STRIBILD.xml:S3:10525:7	wast	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S3:10532:1	,	,	O	O
facial	STRIBILD.xml:S3:10534:6	facial	JJ	B-AdverseReaction	B-AdverseReaction
wasting	STRIBILD.xml:S3:10541:7	wast	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S3:10548:1	,	,	O	O
breast	STRIBILD.xml:S3:10550:6	breast	NN	B-AdverseReaction	B-AdverseReaction
enlargement	STRIBILD.xml:S3:10557:11	enlarg	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S3:10568:1	,	,	O	O
and	STRIBILD.xml:S3:10570:3	and	CC	O	O
"	STRIBILD.xml:S3:10574:1	"	NNP	O	O
cushingoid	STRIBILD.xml:S3:10575:10	cushingoid	VBP	B-AdverseReaction	B-AdverseReaction
appearance	STRIBILD.xml:S3:10586:10	appear	NN	I-AdverseReaction	I-AdverseReaction
"	STRIBILD.xml:S3:10596:1	"	NNS	O	O
have	STRIBILD.xml:S3:10598:4	have	VBP	O	O
been	STRIBILD.xml:S3:10603:4	been	VBN	O	O
observed	STRIBILD.xml:S3:10608:8	observ	VBN	O	O
in	STRIBILD.xml:S3:10617:2	in	IN	O	O
patients	STRIBILD.xml:S3:10620:8	patient	NNS	O	O
receiving	STRIBILD.xml:S3:10629:9	receiv	VBG	O	O
antiretroviral	STRIBILD.xml:S3:10639:14	antiretrovir	JJ	O	O
therapy	STRIBILD.xml:S3:10654:7	therapi	NN	O	O
.	STRIBILD.xml:S3:10661:1	.	.	O	O

The	STRIBILD.xml:S3:10663:3	the	DT	O	O
mechanism	STRIBILD.xml:S3:10667:9	mechan	NN	O	O
and	STRIBILD.xml:S3:10677:3	and	CC	O	O
long	STRIBILD.xml:S3:10681:4	long	JJ	O	O
-	STRIBILD.xml:S3:10685:1	-	:	O	O
term	STRIBILD.xml:S3:10686:4	term	NN	O	O
consequences	STRIBILD.xml:S3:10691:12	consequ	NNS	O	O
of	STRIBILD.xml:S3:10704:2	of	IN	O	O
these	STRIBILD.xml:S3:10707:5	these	DT	O	O
events	STRIBILD.xml:S3:10713:6	event	NNS	O	O
are	STRIBILD.xml:S3:10720:3	are	VBP	O	O
currently	STRIBILD.xml:S3:10724:9	current	RB	O	O
unknown	STRIBILD.xml:S3:10734:7	unknown	JJ	O	O
.	STRIBILD.xml:S3:10741:1	.	.	O	O

A	STRIBILD.xml:S3:10743:1	A	DT	O	O
causal	STRIBILD.xml:S3:10745:6	causal	NN	O	O
relationship	STRIBILD.xml:S3:10752:12	relationship	NN	O	O
has	STRIBILD.xml:S3:10765:3	ha	VBZ	O	O
not	STRIBILD.xml:S3:10769:3	not	RB	O	O
been	STRIBILD.xml:S3:10773:4	been	VBN	O	O
established	STRIBILD.xml:S3:10778:11	establish	VBN	O	O
.	STRIBILD.xml:S3:10789:1	.	.	O	O

5.8	STRIBILD.xml:S3:10798:3	5.8	CD	O	O
Immune	STRIBILD.xml:S3:10802:6	immun	NNP	O	O
Reconstitution	STRIBILD.xml:S3:10809:14	reconstitut	NNP	O	O
Syndrome	STRIBILD.xml:S3:10824:8	syndrom	NNP	O	O

Immune	STRIBILD.xml:S3:10838:6	immun	NNP	B-AdverseReaction	B-AdverseReaction
reconstitution	STRIBILD.xml:S3:10845:14	reconstitut	NN	I-AdverseReaction	I-AdverseReaction
syndrome	STRIBILD.xml:S3:10860:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
has	STRIBILD.xml:S3:10869:3	ha	VBZ	O	O
been	STRIBILD.xml:S3:10873:4	been	VBN	O	O
reported	STRIBILD.xml:S3:10878:8	report	VBN	O	O
in	STRIBILD.xml:S3:10887:2	in	IN	O	O
patients	STRIBILD.xml:S3:10890:8	patient	NNS	O	O
treated	STRIBILD.xml:S3:10899:7	treat	VBN	O	O
with	STRIBILD.xml:S3:10907:4	with	IN	O	O
combination	STRIBILD.xml:S3:10912:11	combin	NN	O	O
antiretroviral	STRIBILD.xml:S3:10924:14	antiretrovir	JJ	O	O
therapy	STRIBILD.xml:S3:10939:7	therapi	NN	O	O
,	STRIBILD.xml:S3:10946:1	,	,	O	O
including	STRIBILD.xml:S3:10948:9	includ	VBG	O	O
STRIBILD	STRIBILD.xml:S3:10958:8	stribild	NNP	O	O
.	STRIBILD.xml:S3:10966:1	.	.	O	O

During	STRIBILD.xml:S3:10968:6	dure	IN	O	O
the	STRIBILD.xml:S3:10975:3	the	DT	O	O
initial	STRIBILD.xml:S3:10979:7	initi	JJ	O	O
phase	STRIBILD.xml:S3:10987:5	phase	NN	O	O
of	STRIBILD.xml:S3:10993:2	of	IN	O	O
combination	STRIBILD.xml:S3:10996:11	combin	NN	O	O
antiretroviral	STRIBILD.xml:S3:11008:14	antiretrovir	JJ	O	O
treatment	STRIBILD.xml:S3:11023:9	treatment	NN	O	O
,	STRIBILD.xml:S3:11032:1	,	,	O	O
patients	STRIBILD.xml:S3:11034:8	patient	NNS	O	O
whose	STRIBILD.xml:S3:11043:5	whose	WP$	O	O
immune	STRIBILD.xml:S3:11049:6	immun	JJ	O	O
system	STRIBILD.xml:S3:11056:6	system	NN	O	O
responds	STRIBILD.xml:S3:11063:8	respond	NNS	O	O
may	STRIBILD.xml:S3:11072:3	may	MD	O	O
develop	STRIBILD.xml:S3:11076:7	develop	VB	O	O
an	STRIBILD.xml:S3:11084:2	an	DT	O	O
inflammatory	STRIBILD.xml:S3:11087:12	inflammatori	JJ	O	B-AdverseReaction
response	STRIBILD.xml:S3:11100:8	respons	NN	O	I-AdverseReaction
to	STRIBILD.xml:S3:11109:2	to	TO	O	O
indolent	STRIBILD.xml:S3:11112:8	indol	NN	O	O
or	STRIBILD.xml:S3:11121:2	or	CC	O	O
residual	STRIBILD.xml:S3:11124:8	residu	JJ	B-AdverseReaction	B-AdverseReaction
opportunistic	STRIBILD.xml:S3:11133:13	opportunist	JJ	I-AdverseReaction	I-AdverseReaction
infections	STRIBILD.xml:S3:11147:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
[	STRIBILD.xml:S3:11158:1	[	VBP	O	O
such	STRIBILD.xml:S3:11159:4	such	JJ	O	O
as	STRIBILD.xml:S3:11164:2	as	IN	O	O
Mycobacterium	STRIBILD.xml:S3:11167:13	mycobacterium	NNP	B-AdverseReaction	B-AdverseReaction
avium	STRIBILD.xml:S3:11181:5	avium	NN	I-AdverseReaction	I-AdverseReaction
infection	STRIBILD.xml:S3:11188:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	STRIBILD.xml:S3:11197:1	,	,	O	O
cytomegalovirus	STRIBILD.xml:S3:11199:15	cytomegaloviru	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S3:11214:1	,	,	O	O
Pneumocystis	STRIBILD.xml:S3:11216:12	pneumocysti	NNP	B-AdverseReaction	B-AdverseReaction
jirovecii	STRIBILD.xml:S3:11229:9	jirovecii	NN	I-AdverseReaction	I-AdverseReaction
pneumonia	STRIBILD.xml:S3:11240:9	pneumonia	NN	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S3:11250:1	(	(	O	O
PCP	STRIBILD.xml:S3:11251:3	pcp	NNP	B-AdverseReaction	O
)	STRIBILD.xml:S3:11254:1	)	)	O	O
,	STRIBILD.xml:S3:11255:1	,	,	O	O
or	STRIBILD.xml:S3:11257:2	or	CC	O	O
tuberculosis	STRIBILD.xml:S3:11260:12	tuberculosi	NN	B-AdverseReaction	O
]	STRIBILD.xml:S3:11272:1	]	NN	O	O
,	STRIBILD.xml:S3:11273:1	,	,	O	O
which	STRIBILD.xml:S3:11275:5	which	WDT	O	O
may	STRIBILD.xml:S3:11281:3	may	MD	O	O
necessitate	STRIBILD.xml:S3:11285:11	necessit	VB	O	O
further	STRIBILD.xml:S3:11297:7	further	JJ	O	O
evaluation	STRIBILD.xml:S3:11305:10	evalu	NN	O	O
and	STRIBILD.xml:S3:11316:3	and	CC	O	O
treatment	STRIBILD.xml:S3:11320:9	treatment	NN	O	O
.	STRIBILD.xml:S3:11329:1	.	.	O	O

Autoimmune	STRIBILD.xml:S3:11335:10	autoimmun	NNP	B-AdverseReaction	B-AdverseReaction
disorders	STRIBILD.xml:S3:11346:9	disord	NNS	I-AdverseReaction	I-AdverseReaction
(	STRIBILD.xml:S3:11356:1	(	(	O	O
such	STRIBILD.xml:S3:11357:4	such	JJ	O	O
as	STRIBILD.xml:S3:11362:2	as	IN	O	O
Graves	STRIBILD.xml:S3:11365:6	grave	NNS	B-AdverseReaction	O
disease	STRIBILD.xml:S3:11373:7	diseas	NN	I-AdverseReaction	O
,	STRIBILD.xml:S3:11380:1	,	,	O	O
polymyositis	STRIBILD.xml:S3:11382:12	polymyos	NN	B-AdverseReaction	B-AdverseReaction
,	STRIBILD.xml:S3:11394:1	,	,	O	O
and	STRIBILD.xml:S3:11396:3	and	CC	O	O
Guillain	STRIBILD.xml:S3:11400:8	guillain	NNP	B-AdverseReaction	B-AdverseReaction
-	STRIBILD.xml:S3:11408:1	-	:	I-AdverseReaction	I-AdverseReaction
Barre	STRIBILD.xml:S3:11409:5	barr	NNP	I-AdverseReaction	I-AdverseReaction
syndrome	STRIBILD.xml:S3:11415:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
)	STRIBILD.xml:S3:11423:1	)	)	O	O
have	STRIBILD.xml:S3:11425:4	have	VBP	O	O
also	STRIBILD.xml:S3:11430:4	also	RB	O	O
been	STRIBILD.xml:S3:11435:4	been	VBN	O	O
reported	STRIBILD.xml:S3:11440:8	report	VBN	O	O
to	STRIBILD.xml:S3:11449:2	to	TO	O	O
occur	STRIBILD.xml:S3:11452:5	occur	VB	O	O
in	STRIBILD.xml:S3:11458:2	in	IN	O	O
the	STRIBILD.xml:S3:11461:3	the	DT	O	O
setting	STRIBILD.xml:S3:11465:7	set	NN	O	O
of	STRIBILD.xml:S3:11473:2	of	IN	O	O
immune	STRIBILD.xml:S3:11476:6	immun	JJ	O	O
reconstitution	STRIBILD.xml:S3:11483:14	reconstitut	NN	O	O
,	STRIBILD.xml:S3:11497:1	,	,	O	O
however	STRIBILD.xml:S3:11499:7	howev	RB	O	O
,	STRIBILD.xml:S3:11506:1	,	,	O	O
the	STRIBILD.xml:S3:11508:3	the	DT	O	O
time	STRIBILD.xml:S3:11512:4	time	NN	O	O
to	STRIBILD.xml:S3:11517:2	to	TO	O	O
onset	STRIBILD.xml:S3:11520:5	onset	VB	O	O
is	STRIBILD.xml:S3:11526:2	is	VBZ	O	O
more	STRIBILD.xml:S3:11529:4	more	RBR	O	O
variable	STRIBILD.xml:S3:11534:8	variabl	JJ	O	O
,	STRIBILD.xml:S3:11542:1	,	,	O	O
and	STRIBILD.xml:S3:11544:3	and	CC	O	O
can	STRIBILD.xml:S3:11548:3	can	MD	O	O
occur	STRIBILD.xml:S3:11552:5	occur	VB	O	O
many	STRIBILD.xml:S3:11558:4	mani	JJ	O	O
months	STRIBILD.xml:S3:11563:6	month	NNS	O	O
after	STRIBILD.xml:S3:11570:5	after	IN	O	O
initiation	STRIBILD.xml:S3:11576:10	initi	NN	O	O
of	STRIBILD.xml:S3:11587:2	of	IN	O	O
treatment	STRIBILD.xml:S3:11590:9	treatment	NN	O	O
.	STRIBILD.xml:S3:11599:1	.	.	O	O
6	TAFINLAR.xml:S1:4:1	6	CD	O	O
ADVERSE	TAFINLAR.xml:S1:6:7	advers	JJ	O	O
REACTIONS	TAFINLAR.xml:S1:14:9	reaction	NN	O	O

The	TAFINLAR.xml:S1:27:3	the	DT	O	O
following	TAFINLAR.xml:S1:31:9	follow	JJ	O	O
adverse	TAFINLAR.xml:S1:41:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S1:49:9	reaction	NNS	O	O
are	TAFINLAR.xml:S1:59:3	are	VBP	O	O
discussed	TAFINLAR.xml:S1:63:9	discuss	VBN	O	O
in	TAFINLAR.xml:S1:73:2	in	IN	O	O
greater	TAFINLAR.xml:S1:76:7	greater	JJR	O	O
detail	TAFINLAR.xml:S1:84:6	detail	NN	O	O
in	TAFINLAR.xml:S1:91:2	in	IN	O	O
another	TAFINLAR.xml:S1:94:7	anoth	DT	O	O
section	TAFINLAR.xml:S1:102:7	section	NN	O	O
of	TAFINLAR.xml:S1:110:2	of	IN	O	O
the	TAFINLAR.xml:S1:113:3	the	DT	O	O
label	TAFINLAR.xml:S1:117:5	label	NN	O	O
:	TAFINLAR.xml:S1:122:1	:	:	O	O

New	TAFINLAR.xml:S1:133:3	new	NNP	O	B-AdverseReaction
Primary	TAFINLAR.xml:S1:137:7	primari	NNP	B-AdverseReaction	I-AdverseReaction
Malignancies	TAFINLAR.xml:S1:145:12	malign	NNP	I-AdverseReaction	I-AdverseReaction
[	TAFINLAR.xml:S1:158:1	[	NNP	O	O
see	TAFINLAR.xml:S1:159:3	see	VBP	O	O
Warnings	TAFINLAR.xml:S1:163:8	warn	NNP	O	O
and	TAFINLAR.xml:S1:172:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:176:11	precaut	NNP	O	O
(	TAFINLAR.xml:S1:188:1	(	(	O	O
5.1	TAFINLAR.xml:S1:189:3	5.1	CD	O	O
)]	TAFINLAR.xml:S1:192:2	)]	NN	O	O

Tumor	TAFINLAR.xml:S1:203:5	tumor	NN	B-AdverseReaction	O
Promotion	TAFINLAR.xml:S1:209:9	promot	NNP	I-AdverseReaction	O
in	TAFINLAR.xml:S1:219:2	in	IN	I-AdverseReaction	O
BRAF	TAFINLAR.xml:S1:222:4	braf	NNP	I-AdverseReaction	O
Wild	TAFINLAR.xml:S1:227:4	wild	NNP	I-AdverseReaction	O
-	TAFINLAR.xml:S1:231:1	-	:	I-AdverseReaction	O
Type	TAFINLAR.xml:S1:232:4	type	NN	I-AdverseReaction	O
Melanoma	TAFINLAR.xml:S1:237:8	melanoma	NNP	I-AdverseReaction	O
[	TAFINLAR.xml:S1:246:1	[	NNP	O	O
see	TAFINLAR.xml:S1:247:3	see	VBP	O	O
Warnings	TAFINLAR.xml:S1:251:8	warn	NNP	O	O
and	TAFINLAR.xml:S1:260:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:264:11	precaut	NNP	O	O
(	TAFINLAR.xml:S1:276:1	(	(	O	O
5.2	TAFINLAR.xml:S1:277:3	5.2	CD	O	O
)]	TAFINLAR.xml:S1:280:2	)]	NN	O	O

Hemorrhage	TAFINLAR.xml:S1:291:10	hemorrhag	NN	B-AdverseReaction	B-AdverseReaction
[	TAFINLAR.xml:S1:302:1	[	VBD	O	O
see	TAFINLAR.xml:S1:303:3	see	JJ	O	O
Warnings	TAFINLAR.xml:S1:307:8	warn	NNP	O	O
and	TAFINLAR.xml:S1:316:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:320:11	precaut	NNP	O	O
(	TAFINLAR.xml:S1:332:1	(	(	O	O
5.3	TAFINLAR.xml:S1:333:3	5.3	CD	O	O
)]	TAFINLAR.xml:S1:336:2	)]	NN	O	O

Venous	TAFINLAR.xml:S1:347:6	venou	JJ	B-AdverseReaction	B-AdverseReaction
Thromboembolism	TAFINLAR.xml:S1:354:15	thromboembol	NNP	I-AdverseReaction	I-AdverseReaction
[	TAFINLAR.xml:S1:370:1	[	NNP	O	O
see	TAFINLAR.xml:S1:371:3	see	VBP	O	O
Warnings	TAFINLAR.xml:S1:375:8	warn	NNP	O	O
and	TAFINLAR.xml:S1:384:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:388:11	precaut	NNP	O	O
(	TAFINLAR.xml:S1:400:1	(	(	O	O
5.4	TAFINLAR.xml:S1:401:3	5.4	CD	O	O
)]	TAFINLAR.xml:S1:404:2	)]	NN	O	O

Cardiomyopathy	TAFINLAR.xml:S1:415:14	cardiomyopathi	JJ	B-AdverseReaction	O
[	TAFINLAR.xml:S1:430:1	[	NNP	O	O
see	TAFINLAR.xml:S1:431:3	see	VBP	O	O
Warnings	TAFINLAR.xml:S1:435:8	warn	NNP	O	O
and	TAFINLAR.xml:S1:444:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:448:11	precaut	NNP	O	O
(	TAFINLAR.xml:S1:460:1	(	(	O	O
5.5	TAFINLAR.xml:S1:461:3	5.5	CD	O	O
)]	TAFINLAR.xml:S1:464:2	)]	NN	O	O

Ocular	TAFINLAR.xml:S1:475:6	ocular	JJ	B-AdverseReaction	B-AdverseReaction
Toxicities	TAFINLAR.xml:S1:482:10	toxic	NNS	I-AdverseReaction	I-AdverseReaction
[	TAFINLAR.xml:S1:493:1	[	VBP	O	O
see	TAFINLAR.xml:S1:494:3	see	VBP	O	O
Warnings	TAFINLAR.xml:S1:498:8	warn	NNS	O	O
and	TAFINLAR.xml:S1:507:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:511:11	precaut	NNP	O	O
(	TAFINLAR.xml:S1:523:1	(	(	O	O
5.6	TAFINLAR.xml:S1:524:3	5.6	CD	O	O
)]	TAFINLAR.xml:S1:527:2	)]	NN	O	O

Serious	TAFINLAR.xml:S1:538:7	seriou	JJ	O	O
Febrile	TAFINLAR.xml:S1:546:7	febril	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	TAFINLAR.xml:S1:554:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
[	TAFINLAR.xml:S1:564:1	[	NNP	O	O
see	TAFINLAR.xml:S1:565:3	see	VBP	O	O
Warnings	TAFINLAR.xml:S1:569:8	warn	NNP	O	O
and	TAFINLAR.xml:S1:578:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:582:11	precaut	NNP	O	O
(	TAFINLAR.xml:S1:594:1	(	(	O	O
5.7	TAFINLAR.xml:S1:595:3	5.7	CD	O	O
)]	TAFINLAR.xml:S1:598:2	)]	NN	O	O

Serious	TAFINLAR.xml:S1:609:7	seriou	JJ	O	O
Skin	TAFINLAR.xml:S1:617:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
Toxicity	TAFINLAR.xml:S1:622:8	toxic	NNP	I-AdverseReaction	I-AdverseReaction
[	TAFINLAR.xml:S1:631:1	[	NNP	O	O
see	TAFINLAR.xml:S1:632:3	see	VBP	O	O
Warnings	TAFINLAR.xml:S1:636:8	warn	NNP	O	O
and	TAFINLAR.xml:S1:645:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:649:11	precaut	NNP	O	O
(	TAFINLAR.xml:S1:661:1	(	(	O	O
5.8	TAFINLAR.xml:S1:662:3	5.8	CD	O	O
)]	TAFINLAR.xml:S1:665:2	)]	NN	O	O

Hyperglycemia	TAFINLAR.xml:S1:676:13	hyperglycemia	NNP	B-AdverseReaction	B-AdverseReaction
[	TAFINLAR.xml:S1:690:1	[	NNP	O	O
see	TAFINLAR.xml:S1:691:3	see	VBP	O	O
Warnings	TAFINLAR.xml:S1:695:8	warn	NNP	O	O
and	TAFINLAR.xml:S1:704:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:708:11	precaut	NNP	O	O
(	TAFINLAR.xml:S1:720:1	(	(	O	O
5.9	TAFINLAR.xml:S1:721:3	5.9	CD	O	O
)]	TAFINLAR.xml:S1:724:2	)]	NN	O	O

Glucose	TAFINLAR.xml:S1:735:7	glucos	NNP	B-AdverseReaction	B-AdverseReaction
-	TAFINLAR.xml:S1:742:1	-	:	I-AdverseReaction	I-AdverseReaction
6	TAFINLAR.xml:S1:743:1	6	CD	I-AdverseReaction	I-AdverseReaction
-	TAFINLAR.xml:S1:744:1	-	:	I-AdverseReaction	I-AdverseReaction
Phosphate	TAFINLAR.xml:S1:745:9	phosphat	NN	I-AdverseReaction	I-AdverseReaction
Dehydrogenase	TAFINLAR.xml:S1:755:13	dehydrogenas	NNP	I-AdverseReaction	I-AdverseReaction
Deficiency	TAFINLAR.xml:S1:769:10	defici	NNP	I-AdverseReaction	I-AdverseReaction
[	TAFINLAR.xml:S1:780:1	[	NNP	O	O
see	TAFINLAR.xml:S1:781:3	see	VBP	O	O
Warnings	TAFINLAR.xml:S1:785:8	warn	NNP	O	O
and	TAFINLAR.xml:S1:794:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:798:11	precaut	NNP	O	O
(	TAFINLAR.xml:S1:810:1	(	(	O	O
5.10	TAFINLAR.xml:S1:811:4	5.10	CD	O	O
)]	TAFINLAR.xml:S1:815:2	)]	NN	O	O

Most	TAFINLAR.xml:S1:828:4	most	JJS	O	O
common	TAFINLAR.xml:S1:833:6	common	JJ	O	O
adverse	TAFINLAR.xml:S1:840:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S1:848:9	reaction	NNS	O	O
(	TAFINLAR.xml:S1:858:1	(	(	O	O
20%	TAFINLAR.xml:S1:861:3	20%	CD	O	O
)	TAFINLAR.xml:S1:864:1	)	)	O	O
for	TAFINLAR.xml:S1:866:3	for	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:870:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S1:879:2	as	IN	O	O
a	TAFINLAR.xml:S1:882:1	a	DT	O	O
single	TAFINLAR.xml:S1:884:6	singl	JJ	O	O
agent	TAFINLAR.xml:S1:891:5	agent	NN	O	O
are	TAFINLAR.xml:S1:897:3	are	VBP	O	O
hyperkeratosis	TAFINLAR.xml:S1:901:14	hyperkeratosi	NN	B-AdverseReaction	O
,	TAFINLAR.xml:S1:915:1	,	,	O	O
headache	TAFINLAR.xml:S1:917:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:925:1	,	,	O	O
pyrexia	TAFINLAR.xml:S1:927:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:934:1	,	,	O	O
arthralgia	TAFINLAR.xml:S1:936:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:946:1	,	,	O	O
papilloma	TAFINLAR.xml:S1:948:9	papilloma	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:957:1	,	,	O	O
alopecia	TAFINLAR.xml:S1:959:8	alopecia	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:967:1	,	,	O	O
and	TAFINLAR.xml:S1:969:3	and	CC	O	O
palmar	TAFINLAR.xml:S1:973:6	palmar	SYM	B-AdverseReaction	B-AdverseReaction
-	TAFINLAR.xml:S1:979:1	-	:	I-AdverseReaction	I-AdverseReaction
plantar	TAFINLAR.xml:S1:980:7	plantar	NN	I-AdverseReaction	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:988:18	erythrodysesthesia	JJ	I-AdverseReaction	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:1007:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S1:1015:1	.	.	O	O

(	TAFINLAR.xml:S1:1017:1	(	(	O	O
6.1	TAFINLAR.xml:S1:1020:3	6.1	CD	O	O
)	TAFINLAR.xml:S1:1025:1	)	)	O	O

Most	TAFINLAR.xml:S1:1034:4	most	JJS	O	O
common	TAFINLAR.xml:S1:1039:6	common	JJ	O	O
adverse	TAFINLAR.xml:S1:1046:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S1:1054:9	reaction	NNS	O	O
(	TAFINLAR.xml:S1:1064:1	(	(	O	O
20%	TAFINLAR.xml:S1:1067:3	20%	CD	O	O
)	TAFINLAR.xml:S1:1070:1	)	)	O	O
for	TAFINLAR.xml:S1:1072:3	for	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:1076:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S1:1085:2	in	IN	O	O
combination	TAFINLAR.xml:S1:1088:11	combin	NN	O	O
with	TAFINLAR.xml:S1:1100:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:1105:10	trametinib	NNS	O	O
are	TAFINLAR.xml:S1:1116:3	are	VBP	O	O
pyrexia	TAFINLAR.xml:S1:1120:7	pyrexia	JJ	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1127:1	,	,	O	O
chills	TAFINLAR.xml:S1:1129:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1135:1	,	,	O	O
fatigue	TAFINLAR.xml:S1:1137:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1144:1	,	,	O	O
rash	TAFINLAR.xml:S1:1146:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1150:1	,	,	O	O
nausea	TAFINLAR.xml:S1:1152:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1158:1	,	,	O	O
vomiting	TAFINLAR.xml:S1:1160:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1168:1	,	,	O	O
diarrhea	TAFINLAR.xml:S1:1170:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1178:1	,	,	O	O
abdominal	TAFINLAR.xml:S1:1180:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TAFINLAR.xml:S1:1190:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:1194:1	,	,	O	O
peripheral	TAFINLAR.xml:S1:1196:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
edema	TAFINLAR.xml:S1:1207:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:1212:1	,	,	O	O
cough	TAFINLAR.xml:S1:1214:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1219:1	,	,	O	O
headache	TAFINLAR.xml:S1:1221:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1229:1	,	,	O	O
arthralgia	TAFINLAR.xml:S1:1231:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1241:1	,	,	O	O
night	TAFINLAR.xml:S1:1243:5	night	NN	B-AdverseReaction	B-AdverseReaction
sweats	TAFINLAR.xml:S1:1249:6	sweat	NNS	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:1255:1	,	,	O	O
decreased	TAFINLAR.xml:S1:1257:9	decreas	VBD	B-AdverseReaction	B-AdverseReaction
appetite	TAFINLAR.xml:S1:1267:8	appetit	RB	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:1275:1	,	,	O	O
constipation	TAFINLAR.xml:S1:1277:12	constip	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:1289:1	,	,	O	O
and	TAFINLAR.xml:S1:1291:3	and	CC	O	O
myalgia	TAFINLAR.xml:S1:1295:7	myalgia	NN	B-AdverseReaction	B-AdverseReaction
.	TAFINLAR.xml:S1:1302:1	.	.	O	O

(	TAFINLAR.xml:S1:1304:1	(	(	O	O
6.1	TAFINLAR.xml:S1:1307:3	6.1	CD	O	O
)	TAFINLAR.xml:S1:1312:1	)	)	O	O

EXCERPT	TAFINLAR.xml:S1:1321:7	excerpt	NN	O	O
:	TAFINLAR.xml:S1:1328:1	:	:	O	O
To	TAFINLAR.xml:S1:1334:2	To	TO	O	O
report	TAFINLAR.xml:S1:1337:6	report	VB	O	O
SUSPECTED	TAFINLAR.xml:S1:1344:9	suspect	NNP	O	O
ADVERSE	TAFINLAR.xml:S1:1354:7	advers	NNP	O	O
REACTIONS	TAFINLAR.xml:S1:1362:9	reaction	NNP	O	O
,	TAFINLAR.xml:S1:1371:1	,	,	O	O
contact	TAFINLAR.xml:S1:1373:7	contact	NN	O	O
GlaxoSmithKline	TAFINLAR.xml:S1:1381:15	glaxosmithklin	NNP	O	O
at	TAFINLAR.xml:S1:1397:2	at	IN	O	O
1	TAFINLAR.xml:S1:1400:1	1	CD	O	O
-	TAFINLAR.xml:S1:1401:1	-	:	O	O
888	TAFINLAR.xml:S1:1402:3	888	CD	O	O
-	TAFINLAR.xml:S1:1405:1	-	:	O	O
825	TAFINLAR.xml:S1:1406:3	825	CD	O	O
-	TAFINLAR.xml:S1:1409:1	-	:	O	O
5249	TAFINLAR.xml:S1:1410:4	5249	CD	O	O
or	TAFINLAR.xml:S1:1415:2	or	CC	O	O
FDA	TAFINLAR.xml:S1:1418:3	fda	NNP	O	O
at	TAFINLAR.xml:S1:1422:2	at	IN	O	O
1	TAFINLAR.xml:S1:1425:1	1	CD	O	O
-	TAFINLAR.xml:S1:1426:1	-	:	O	O
800	TAFINLAR.xml:S1:1427:3	800	CD	O	O
-	TAFINLAR.xml:S1:1430:1	-	:	O	O
FDA	TAFINLAR.xml:S1:1431:3	fda	NNP	O	O
-	TAFINLAR.xml:S1:1434:1	-	:	O	O
1088	TAFINLAR.xml:S1:1435:4	1088	CD	O	O
or	TAFINLAR.xml:S1:1440:2	or	CC	O	O
www	TAFINLAR.xml:S1:1446:3	www	VB	O	O
.	TAFINLAR.xml:S1:1449:1	.	.	O	O
fda	TAFINLAR.xml:S1:1450:3	fda	NN	O	O
.	TAFINLAR.xml:S1:1453:1	.	.	O	O
gov	TAFINLAR.xml:S1:1454:3	gov	JJ	O	O
medwatch	TAFINLAR.xml:S1:1458:8	medwatch	NN	O	O
.	TAFINLAR.xml:S1:1466:1	.	.	O	O

6.1	TAFINLAR.xml:S1:1478:3	6.1	CD	O	O

Clinical	TAFINLAR.xml:S1:1482:8	clinic	JJ	O	O

Trials	TAFINLAR.xml:S1:1491:6	trial	NNS	O	O
Experience	TAFINLAR.xml:S1:1498:10	experi	NN	O	O

Because	TAFINLAR.xml:S1:1512:7	becaus	IN	O	O
clinical	TAFINLAR.xml:S1:1520:8	clinic	JJ	O	O
trials	TAFINLAR.xml:S1:1529:6	trial	NNS	O	O
are	TAFINLAR.xml:S1:1536:3	are	VBP	O	O
conducted	TAFINLAR.xml:S1:1540:9	conduct	VBN	O	O
under	TAFINLAR.xml:S1:1550:5	under	IN	O	O
widely	TAFINLAR.xml:S1:1556:6	wide	RB	O	O
varying	TAFINLAR.xml:S1:1563:7	vari	VBG	O	O
conditions	TAFINLAR.xml:S1:1571:10	condit	NNS	O	O
,	TAFINLAR.xml:S1:1581:1	,	,	O	O
adverse	TAFINLAR.xml:S1:1583:7	advers	JJ	O	O
reaction	TAFINLAR.xml:S1:1591:8	reaction	NN	O	O
rates	TAFINLAR.xml:S1:1600:5	rate	NNS	O	O
observed	TAFINLAR.xml:S1:1606:8	observ	VBD	O	O
in	TAFINLAR.xml:S1:1615:2	in	IN	O	O
the	TAFINLAR.xml:S1:1618:3	the	DT	O	O
clinical	TAFINLAR.xml:S1:1622:8	clinic	JJ	O	O
trials	TAFINLAR.xml:S1:1631:6	trial	NNS	O	O
of	TAFINLAR.xml:S1:1638:2	of	IN	O	O
a	TAFINLAR.xml:S1:1641:1	a	DT	O	O
drug	TAFINLAR.xml:S1:1643:4	drug	NN	O	O
cannot	TAFINLAR.xml:S1:1648:6	cannot	NN	O	O
be	TAFINLAR.xml:S1:1655:2	be	VB	O	O
directly	TAFINLAR.xml:S1:1658:8	directli	RB	O	O
compared	TAFINLAR.xml:S1:1667:8	compar	VBN	O	O
to	TAFINLAR.xml:S1:1676:2	to	TO	O	O
rates	TAFINLAR.xml:S1:1679:5	rate	NNS	O	O
in	TAFINLAR.xml:S1:1685:2	in	IN	O	O
the	TAFINLAR.xml:S1:1688:3	the	DT	O	O
clinical	TAFINLAR.xml:S1:1692:8	clinic	JJ	O	O
trials	TAFINLAR.xml:S1:1701:6	trial	NNS	O	O
of	TAFINLAR.xml:S1:1708:2	of	IN	O	O
another	TAFINLAR.xml:S1:1711:7	anoth	DT	O	O
drug	TAFINLAR.xml:S1:1719:4	drug	NN	O	O
and	TAFINLAR.xml:S1:1724:3	and	CC	O	O
may	TAFINLAR.xml:S1:1728:3	may	MD	O	O
not	TAFINLAR.xml:S1:1732:3	not	RB	O	O
reflect	TAFINLAR.xml:S1:1736:7	reflect	VB	O	O
the	TAFINLAR.xml:S1:1744:3	the	DT	O	O
rates	TAFINLAR.xml:S1:1748:5	rate	NNS	O	O
observed	TAFINLAR.xml:S1:1754:8	observ	VBD	O	O
in	TAFINLAR.xml:S1:1763:2	in	IN	O	O
practice	TAFINLAR.xml:S1:1766:8	practic	NN	O	O
.	TAFINLAR.xml:S1:1774:1	.	.	O	O

The	TAFINLAR.xml:S1:1780:3	the	DT	O	O
data	TAFINLAR.xml:S1:1784:4	data	NN	O	O
described	TAFINLAR.xml:S1:1789:9	describ	NN	O	O
in	TAFINLAR.xml:S1:1799:2	in	IN	O	O
the	TAFINLAR.xml:S1:1802:3	the	DT	O	O
Warnings	TAFINLAR.xml:S1:1806:8	warn	NNP	O	O
and	TAFINLAR.xml:S1:1815:3	and	CC	O	O
Precautions	TAFINLAR.xml:S1:1819:11	precaut	NNP	O	O
section	TAFINLAR.xml:S1:1831:7	section	NN	O	O
and	TAFINLAR.xml:S1:1839:3	and	CC	O	O
below	TAFINLAR.xml:S1:1843:5	below	IN	O	O
reflect	TAFINLAR.xml:S1:1849:7	reflect	JJ	O	O
exposure	TAFINLAR.xml:S1:1857:8	exposur	NN	O	O
to	TAFINLAR.xml:S1:1866:2	to	TO	O	O
TAFINLAR	TAFINLAR.xml:S1:1869:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S1:1878:2	as	IN	O	O
a	TAFINLAR.xml:S1:1881:1	a	DT	O	O
single	TAFINLAR.xml:S1:1883:6	singl	JJ	O	O
agent	TAFINLAR.xml:S1:1890:5	agent	NN	O	O
and	TAFINLAR.xml:S1:1896:3	and	CC	O	O
in	TAFINLAR.xml:S1:1900:2	in	IN	O	O
combination	TAFINLAR.xml:S1:1903:11	combin	NN	O	O
with	TAFINLAR.xml:S1:1915:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:1920:10	trametinib	NN	O	O
.	TAFINLAR.xml:S1:1930:1	.	.	O	O

BRAF	TAFINLAR.xml:S1:1938:4	braf	NNP	O	O
V600E	TAFINLAR.xml:S1:1943:5	v600e	NNP	O	O
Unresectable	TAFINLAR.xml:S1:1949:12	unresect	NNP	O	O
or	TAFINLAR.xml:S1:1962:2	or	CC	O	O
Metastatic	TAFINLAR.xml:S1:1965:10	metastat	JJ	O	O
Melanoma	TAFINLAR.xml:S1:1976:8	melanoma	NN	O	O
:	TAFINLAR.xml:S1:1984:1	:	:	O	O

The	TAFINLAR.xml:S1:1992:3	the	DT	O	O
safety	TAFINLAR.xml:S1:1996:6	safeti	NN	O	O
of	TAFINLAR.xml:S1:2003:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:2006:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S1:2015:2	as	IN	O	O
a	TAFINLAR.xml:S1:2018:1	a	DT	O	O
single	TAFINLAR.xml:S1:2020:6	singl	JJ	O	O
agent	TAFINLAR.xml:S1:2027:5	agent	NN	O	O
was	TAFINLAR.xml:S1:2033:3	wa	VBD	O	O
evaluated	TAFINLAR.xml:S1:2037:9	evalu	VBN	O	O
in	TAFINLAR.xml:S1:2047:2	in	IN	O	O
586	TAFINLAR.xml:S1:2050:3	586	CD	O	O
patients	TAFINLAR.xml:S1:2054:8	patient	NNS	O	O
with	TAFINLAR.xml:S1:2063:4	with	IN	O	O
BRAF	TAFINLAR.xml:S1:2068:4	braf	NNP	O	O
V600	TAFINLAR.xml:S1:2073:4	v600	NNP	O	O
mutation	TAFINLAR.xml:S1:2078:8	mutat	NN	O	O
-	TAFINLAR.xml:S1:2086:1	-	:	O	O
positive	TAFINLAR.xml:S1:2087:8	posit	JJ	O	O
unresectable	TAFINLAR.xml:S1:2096:12	unresect	JJ	O	O
or	TAFINLAR.xml:S1:2109:2	or	CC	O	O
metastatic	TAFINLAR.xml:S1:2112:10	metastat	JJ	O	O
melanoma	TAFINLAR.xml:S1:2123:8	melanoma	NN	O	O
,	TAFINLAR.xml:S1:2131:1	,	,	O	O
previously	TAFINLAR.xml:S1:2133:10	previous	RB	O	O
treated	TAFINLAR.xml:S1:2144:7	treat	VBD	O	O
or	TAFINLAR.xml:S1:2152:2	or	CC	O	O
untreated	TAFINLAR.xml:S1:2155:9	untreat	JJ	O	O
,	TAFINLAR.xml:S1:2164:1	,	,	O	O
who	TAFINLAR.xml:S1:2166:3	who	WP	O	O
received	TAFINLAR.xml:S1:2170:8	receiv	VBD	O	O
TAFINLAR	TAFINLAR.xml:S1:2179:8	tafinlar	NNP	O	O
150	TAFINLAR.xml:S1:2188:3	150	CD	O	O
mg	TAFINLAR.xml:S1:2192:2	mg	NN	O	O
orally	TAFINLAR.xml:S1:2195:6	oral	RB	O	O
twice	TAFINLAR.xml:S1:2202:5	twice	JJ	O	O
daily	TAFINLAR.xml:S1:2208:5	daili	RB	O	O
until	TAFINLAR.xml:S1:2214:5	until	IN	O	O
disease	TAFINLAR.xml:S1:2220:7	diseas	JJ	O	O
progression	TAFINLAR.xml:S1:2228:11	progress	NN	O	O
or	TAFINLAR.xml:S1:2240:2	or	CC	O	O
unacceptable	TAFINLAR.xml:S1:2243:12	unaccept	JJ	O	O
toxicity	TAFINLAR.xml:S1:2256:8	toxic	NN	O	O
,	TAFINLAR.xml:S1:2264:1	,	,	O	O
including	TAFINLAR.xml:S1:2266:9	includ	VBG	O	O
181	TAFINLAR.xml:S1:2276:3	181	CD	O	O
patients	TAFINLAR.xml:S1:2280:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:2289:7	treat	VBN	O	O
for	TAFINLAR.xml:S1:2297:3	for	IN	O	O
at	TAFINLAR.xml:S1:2301:2	at	IN	O	O
least	TAFINLAR.xml:S1:2304:5	least	JJS	O	O
6	TAFINLAR.xml:S1:2310:1	6	CD	O	O
months	TAFINLAR.xml:S1:2312:6	month	NNS	O	O
and	TAFINLAR.xml:S1:2319:3	and	CC	O	O
86	TAFINLAR.xml:S1:2323:2	86	CD	O	O
additional	TAFINLAR.xml:S1:2326:10	addit	JJ	O	O
patients	TAFINLAR.xml:S1:2337:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:2346:7	treat	VBD	O	O
for	TAFINLAR.xml:S1:2354:3	for	IN	O	O
more	TAFINLAR.xml:S1:2358:4	more	JJR	O	O
than	TAFINLAR.xml:S1:2363:4	than	IN	O	O
12	TAFINLAR.xml:S1:2368:2	12	CD	O	O
months	TAFINLAR.xml:S1:2371:6	month	NNS	O	O
.	TAFINLAR.xml:S1:2377:1	.	.	O	O

TAFINLAR	TAFINLAR.xml:S1:2379:8	tafinlar	NNP	O	O
was	TAFINLAR.xml:S1:2388:3	wa	VBD	O	O
studied	TAFINLAR.xml:S1:2392:7	studi	VBN	O	O
in	TAFINLAR.xml:S1:2400:2	in	IN	O	O
open	TAFINLAR.xml:S1:2403:4	open	JJ	O	O
-	TAFINLAR.xml:S1:2407:1	-	:	O	O
label	TAFINLAR.xml:S1:2408:5	label	NN	O	O
,	TAFINLAR.xml:S1:2413:1	,	,	O	O
single	TAFINLAR.xml:S1:2415:6	singl	JJ	O	O
-	TAFINLAR.xml:S1:2421:1	-	:	O	O
arm	TAFINLAR.xml:S1:2422:3	arm	NN	O	O
trials	TAFINLAR.xml:S1:2426:6	trial	NNS	O	O
and	TAFINLAR.xml:S1:2433:3	and	CC	O	O
in	TAFINLAR.xml:S1:2437:2	in	IN	O	O
an	TAFINLAR.xml:S1:2440:2	an	DT	O	O
open	TAFINLAR.xml:S1:2443:4	open	JJ	O	O
-	TAFINLAR.xml:S1:2447:1	-	:	O	O
label	TAFINLAR.xml:S1:2448:5	label	NN	O	O
,	TAFINLAR.xml:S1:2453:1	,	,	O	O
randomized	TAFINLAR.xml:S1:2455:10	random	VBN	O	O
,	TAFINLAR.xml:S1:2465:1	,	,	O	O
active	TAFINLAR.xml:S1:2467:6	activ	JJ	O	O
-	TAFINLAR.xml:S1:2473:1	-	:	O	O
controlled	TAFINLAR.xml:S1:2474:10	control	VBN	O	O
trial	TAFINLAR.xml:S1:2485:5	trial	NN	O	O
.	TAFINLAR.xml:S1:2490:1	.	.	O	O

The	TAFINLAR.xml:S1:2492:3	the	DT	O	O
median	TAFINLAR.xml:S1:2496:6	median	JJ	O	O
daily	TAFINLAR.xml:S1:2503:5	daili	JJ	O	O
dose	TAFINLAR.xml:S1:2509:4	dose	NN	O	O
of	TAFINLAR.xml:S1:2514:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:2517:8	tafinlar	NNP	O	O
was	TAFINLAR.xml:S1:2526:3	wa	VBD	O	O
300	TAFINLAR.xml:S1:2530:3	300	CD	O	O
mg	TAFINLAR.xml:S1:2534:2	mg	NN	O	O
(	TAFINLAR.xml:S1:2537:1	(	(	O	O
range	TAFINLAR.xml:S1:2538:5	rang	NN	O	O
:	TAFINLAR.xml:S1:2543:1	:	:	O	O
118	TAFINLAR.xml:S1:2545:3	118	CD	O	O
to	TAFINLAR.xml:S1:2549:2	to	TO	O	O
300	TAFINLAR.xml:S1:2552:3	300	CD	O	O
mg	TAFINLAR.xml:S1:2556:2	mg	NN	O	O
)	TAFINLAR.xml:S1:2558:1	)	)	O	O
.	TAFINLAR.xml:S1:2559:1	.	.	O	O

Table	TAFINLAR.xml:S1:2565:5	tabl	JJ	O	O
3	TAFINLAR.xml:S1:2571:1	3	CD	O	O
and	TAFINLAR.xml:S1:2573:3	and	CC	O	O
Table	TAFINLAR.xml:S1:2577:5	tabl	JJ	O	O
4	TAFINLAR.xml:S1:2583:1	4	CD	O	O
present	TAFINLAR.xml:S1:2585:7	present	JJ	O	O
adverse	TAFINLAR.xml:S1:2593:7	advers	JJ	O	O
drug	TAFINLAR.xml:S1:2601:4	drug	NN	O	O
reactions	TAFINLAR.xml:S1:2606:9	reaction	NNS	O	O
and	TAFINLAR.xml:S1:2616:3	and	CC	O	O
laboratory	TAFINLAR.xml:S1:2620:10	laboratori	NN	O	O
abnormalities	TAFINLAR.xml:S1:2631:13	abnorm	NNS	O	O
identified	TAFINLAR.xml:S1:2645:10	identifi	VBN	O	O
from	TAFINLAR.xml:S1:2656:4	from	IN	O	O
analyses	TAFINLAR.xml:S1:2661:8	analys	NNS	O	O
of	TAFINLAR.xml:S1:2670:2	of	IN	O	O
Trial	TAFINLAR.xml:S1:2673:5	trial	NNP	O	O
1	TAFINLAR.xml:S1:2679:1	1	CD	O	O
[	TAFINLAR.xml:S1:2682:1	[	NNP	O	O
see	TAFINLAR.xml:S1:2683:3	see	VBP	O	O
Clinical	TAFINLAR.xml:S1:2687:8	clinic	JJ	O	O
Studies	TAFINLAR.xml:S1:2696:7	studi	NNP	O	O
(	TAFINLAR.xml:S1:2704:1	(	(	O	O
14.1	TAFINLAR.xml:S1:2705:4	14.1	CD	O	O
)]	TAFINLAR.xml:S1:2709:2	)]	NN	O	O
.	TAFINLAR.xml:S1:2711:1	.	.	O	O

Trial	TAFINLAR.xml:S1:2714:5	trial	JJ	O	O
1	TAFINLAR.xml:S1:2720:1	1	CD	O	O
,	TAFINLAR.xml:S1:2721:1	,	,	O	O
a	TAFINLAR.xml:S1:2723:1	a	DT	O	O
multicenter	TAFINLAR.xml:S1:2725:11	multicent	NN	O	O
,	TAFINLAR.xml:S1:2736:1	,	,	O	O
international	TAFINLAR.xml:S1:2738:13	intern	JJ	O	O
,	TAFINLAR.xml:S1:2751:1	,	,	O	O
open	TAFINLAR.xml:S1:2753:4	open	JJ	O	O
-	TAFINLAR.xml:S1:2757:1	-	:	O	O
label	TAFINLAR.xml:S1:2758:5	label	NN	O	O
,	TAFINLAR.xml:S1:2763:1	,	,	O	O
randomized	TAFINLAR.xml:S1:2765:10	random	VBN	O	O
(	TAFINLAR.xml:S1:2776:1	(	(	O	O
3	TAFINLAR.xml:S1:2777:1	3	CD	O	O
:	TAFINLAR.xml:S1:2778:1	:	:	O	O
1	TAFINLAR.xml:S1:2779:1	1	CD	O	O
)	TAFINLAR.xml:S1:2780:1	)	)	O	O
,	TAFINLAR.xml:S1:2781:1	,	,	O	O
controlled	TAFINLAR.xml:S1:2783:10	control	VBN	O	O
trial	TAFINLAR.xml:S1:2794:5	trial	NN	O	O
allocated	TAFINLAR.xml:S1:2800:9	alloc	VBD	O	O
250	TAFINLAR.xml:S1:2810:3	250	CD	O	O
patients	TAFINLAR.xml:S1:2814:8	patient	NNS	O	O
with	TAFINLAR.xml:S1:2823:4	with	IN	O	O
unresectable	TAFINLAR.xml:S1:2828:12	unresect	JJ	O	O
or	TAFINLAR.xml:S1:2841:2	or	CC	O	O
metastatic	TAFINLAR.xml:S1:2844:10	metastat	JJ	O	O
BRAF	TAFINLAR.xml:S1:2855:4	braf	NNP	O	O
V600E	TAFINLAR.xml:S1:2860:5	v600e	NNP	O	O
mutation	TAFINLAR.xml:S1:2866:8	mutat	NN	O	O
-	TAFINLAR.xml:S1:2874:1	-	:	O	O
positive	TAFINLAR.xml:S1:2875:8	posit	JJ	O	O
melanoma	TAFINLAR.xml:S1:2884:8	melanoma	NN	O	O
to	TAFINLAR.xml:S1:2893:2	to	TO	O	O
receive	TAFINLAR.xml:S1:2896:7	receiv	VB	O	O
TAFINLAR	TAFINLAR.xml:S1:2904:8	tafinlar	NNP	O	O
150	TAFINLAR.xml:S1:2913:3	150	CD	O	O
mg	TAFINLAR.xml:S1:2917:2	mg	NN	O	O
orally	TAFINLAR.xml:S1:2920:6	oral	RB	O	O
twice	TAFINLAR.xml:S1:2927:5	twice	JJ	O	O
daily	TAFINLAR.xml:S1:2933:5	daili	RB	O	O
(	TAFINLAR.xml:S1:2939:1	(	(	O	O
n	TAFINLAR.xml:S1:2940:1	n	JJ	O	O
187	TAFINLAR.xml:S1:2944:3	187	CD	O	O
)	TAFINLAR.xml:S1:2947:1	)	)	O	O
or	TAFINLAR.xml:S1:2949:2	or	CC	O	O
dacarbazine	TAFINLAR.xml:S1:2952:11	dacarbazin	JJ	O	O
1	TAFINLAR.xml:S1:2964:1	1	CD	O	O
,	TAFINLAR.xml:S1:2965:1	,	,	O	O
000	TAFINLAR.xml:S1:2966:3	000	CD	O	O
mg	TAFINLAR.xml:S1:2970:2	mg	NN	O	O
m	TAFINLAR.xml:S1:2973:1	m	NN	O	O
2	TAFINLAR.xml:S1:2976:1	2	CD	O	O
intravenously	TAFINLAR.xml:S1:2979:13	intraven	RB	O	O
every	TAFINLAR.xml:S1:2993:5	everi	DT	O	O
3	TAFINLAR.xml:S1:2999:1	3	CD	O	O
weeks	TAFINLAR.xml:S1:3001:5	week	NNS	O	O
(	TAFINLAR.xml:S1:3007:1	(	(	O	O
n	TAFINLAR.xml:S1:3008:1	n	JJ	O	O
63	TAFINLAR.xml:S1:3012:2	63	CD	O	O
)	TAFINLAR.xml:S1:3014:1	)	)	O	O
.	TAFINLAR.xml:S1:3015:1	.	.	O	O

The	TAFINLAR.xml:S1:3017:3	the	DT	O	O
trial	TAFINLAR.xml:S1:3021:5	trial	NN	O	O
excluded	TAFINLAR.xml:S1:3027:8	exclud	VBD	O	O
patients	TAFINLAR.xml:S1:3036:8	patient	NNS	O	O
with	TAFINLAR.xml:S1:3045:4	with	IN	O	O
abnormal	TAFINLAR.xml:S1:3050:8	abnorm	JJ	O	O
left	TAFINLAR.xml:S1:3059:4	left	VBD	O	O
ventricular	TAFINLAR.xml:S1:3064:11	ventricular	JJ	O	O
ejection	TAFINLAR.xml:S1:3076:8	eject	NN	O	O
fraction	TAFINLAR.xml:S1:3085:8	fraction	NN	O	O
or	TAFINLAR.xml:S1:3094:2	or	CC	O	O
cardiac	TAFINLAR.xml:S1:3097:7	cardiac	JJ	O	O
valve	TAFINLAR.xml:S1:3105:5	valv	NN	O	O
morphology	TAFINLAR.xml:S1:3111:10	morpholog	NN	O	O
(	TAFINLAR.xml:S1:3122:1	(	(	O	O
Grade	TAFINLAR.xml:S1:3125:5	grade	NNP	O	O
2	TAFINLAR.xml:S1:3131:1	2	CD	O	O
)	TAFINLAR.xml:S1:3132:1	)	)	O	O
,	TAFINLAR.xml:S1:3133:1	,	,	O	O
corrected	TAFINLAR.xml:S1:3135:9	correct	VBN	O	O
QT	TAFINLAR.xml:S1:3145:2	QT	NNP	O	O
interval	TAFINLAR.xml:S1:3148:8	interv	JJ	O	O
480	TAFINLAR.xml:S1:3159:3	480	CD	O	O
milliseconds	TAFINLAR.xml:S1:3163:12	millisecond	NNS	O	O
on	TAFINLAR.xml:S1:3176:2	on	IN	O	O
electrocardiogram	TAFINLAR.xml:S1:3179:17	electrocardiogram	NN	O	O
,	TAFINLAR.xml:S1:3196:1	,	,	O	O
or	TAFINLAR.xml:S1:3198:2	or	CC	O	O
a	TAFINLAR.xml:S1:3201:1	a	DT	O	O
known	TAFINLAR.xml:S1:3203:5	known	JJ	O	O
history	TAFINLAR.xml:S1:3209:7	histori	NN	O	O
of	TAFINLAR.xml:S1:3217:2	of	IN	O	O
glucose	TAFINLAR.xml:S1:3220:7	glucos	JJ	O	O
-	TAFINLAR.xml:S1:3227:1	-	:	O	O
6	TAFINLAR.xml:S1:3228:1	6	CD	O	O
-	TAFINLAR.xml:S1:3229:1	-	:	O	O
phosphate	TAFINLAR.xml:S1:3230:9	phosphat	NN	O	O
dehydrogenase	TAFINLAR.xml:S1:3240:13	dehydrogenas	NN	O	O
deficiency	TAFINLAR.xml:S1:3254:10	defici	NN	O	O
.	TAFINLAR.xml:S1:3264:1	.	.	O	O

The	TAFINLAR.xml:S1:3266:3	the	DT	O	O
median	TAFINLAR.xml:S1:3270:6	median	JJ	O	O
duration	TAFINLAR.xml:S1:3277:8	durat	NN	O	O
on	TAFINLAR.xml:S1:3286:2	on	IN	O	O
treatment	TAFINLAR.xml:S1:3289:9	treatment	NN	O	O
was	TAFINLAR.xml:S1:3299:3	wa	VBD	O	O
4.9	TAFINLAR.xml:S1:3303:3	4.9	CD	O	O
months	TAFINLAR.xml:S1:3307:6	month	NNS	O	O
for	TAFINLAR.xml:S1:3314:3	for	IN	O	O
patients	TAFINLAR.xml:S1:3318:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:3327:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:3335:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:3340:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S1:3349:3	and	CC	O	O
2.8	TAFINLAR.xml:S1:3353:3	2.8	CD	O	O
months	TAFINLAR.xml:S1:3357:6	month	NNS	O	O
for	TAFINLAR.xml:S1:3364:3	for	IN	O	O
dacarbazine	TAFINLAR.xml:S1:3368:11	dacarbazin	JJ	O	O
-	TAFINLAR.xml:S1:3379:1	-	:	O	O
treated	TAFINLAR.xml:S1:3380:7	treat	JJ	O	O
patients	TAFINLAR.xml:S1:3388:8	patient	NNS	O	O
.	TAFINLAR.xml:S1:3396:1	.	.	O	O

The	TAFINLAR.xml:S1:3398:3	the	DT	O	O
population	TAFINLAR.xml:S1:3402:10	popul	NN	O	O
exposed	TAFINLAR.xml:S1:3413:7	expos	VBD	O	O
to	TAFINLAR.xml:S1:3421:2	to	TO	O	O
TAFINLAR	TAFINLAR.xml:S1:3424:8	tafinlar	NNP	O	O
was	TAFINLAR.xml:S1:3433:3	wa	VBD	O	O
60%	TAFINLAR.xml:S1:3437:3	60%	CD	O	O
male	TAFINLAR.xml:S1:3441:4	male	NN	O	O
,	TAFINLAR.xml:S1:3445:1	,	,	O	O
99%	TAFINLAR.xml:S1:3447:3	99%	CD	O	O
white	TAFINLAR.xml:S1:3451:5	white	JJ	O	O
,	TAFINLAR.xml:S1:3456:1	,	,	O	O
and	TAFINLAR.xml:S1:3458:3	and	CC	O	O
had	TAFINLAR.xml:S1:3462:3	had	VBD	O	O
a	TAFINLAR.xml:S1:3466:1	a	DT	O	O
median	TAFINLAR.xml:S1:3468:6	median	JJ	O	O
age	TAFINLAR.xml:S1:3475:3	age	NN	O	O
of	TAFINLAR.xml:S1:3479:2	of	IN	O	O
53	TAFINLAR.xml:S1:3482:2	53	CD	O	O
years	TAFINLAR.xml:S1:3485:5	year	NNS	O	O
.	TAFINLAR.xml:S1:3490:1	.	.	O	O

The	TAFINLAR.xml:S1:3496:3	the	DT	O	O
most	TAFINLAR.xml:S1:3500:4	most	RBS	O	O
commonly	TAFINLAR.xml:S1:3505:8	commonli	JJ	O	O
occurring	TAFINLAR.xml:S1:3514:9	occur	VBG	O	O
adverse	TAFINLAR.xml:S1:3524:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S1:3532:9	reaction	NNS	O	O
(	TAFINLAR.xml:S1:3542:1	(	(	O	O
20%	TAFINLAR.xml:S1:3545:3	20%	CD	O	O
)	TAFINLAR.xml:S1:3548:1	)	)	O	O
in	TAFINLAR.xml:S1:3550:2	in	IN	O	O
patients	TAFINLAR.xml:S1:3553:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:3562:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:3570:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:3575:8	tafinlar	NNP	O	O
were	TAFINLAR.xml:S1:3584:4	were	VBD	O	O
,	TAFINLAR.xml:S1:3588:1	,	,	O	O
in	TAFINLAR.xml:S1:3590:2	in	IN	O	O
order	TAFINLAR.xml:S1:3593:5	order	NN	O	O
of	TAFINLAR.xml:S1:3599:2	of	IN	O	O
decreasing	TAFINLAR.xml:S1:3602:10	decreas	VBG	O	O
frequency	TAFINLAR.xml:S1:3613:9	frequenc	NN	O	O
:	TAFINLAR.xml:S1:3622:1	:	:	O	O
hyperkeratosis	TAFINLAR.xml:S1:3624:14	hyperkeratosi	NN	B-AdverseReaction	O
,	TAFINLAR.xml:S1:3638:1	,	,	O	O
headache	TAFINLAR.xml:S1:3640:8	headach	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:3648:1	,	,	O	O
pyrexia	TAFINLAR.xml:S1:3650:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:3657:1	,	,	O	O
arthralgia	TAFINLAR.xml:S1:3659:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:3669:1	,	,	O	O
papilloma	TAFINLAR.xml:S1:3671:9	papilloma	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:3680:1	,	,	O	O
alopecia	TAFINLAR.xml:S1:3682:8	alopecia	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:3690:1	,	,	O	O
and	TAFINLAR.xml:S1:3692:3	and	CC	O	O
palmar	TAFINLAR.xml:S1:3696:6	palmar	SYM	B-AdverseReaction	B-AdverseReaction
-	TAFINLAR.xml:S1:3702:1	-	:	I-AdverseReaction	I-AdverseReaction
plantar	TAFINLAR.xml:S1:3703:7	plantar	NN	I-AdverseReaction	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:3711:18	erythrodysesthesia	JJ	I-AdverseReaction	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:3730:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
(	TAFINLAR.xml:S1:3739:1	(	(	O	O
PPES	TAFINLAR.xml:S1:3740:4	ppe	NNP	B-AdverseReaction	B-AdverseReaction
)	TAFINLAR.xml:S1:3744:1	)	)	O	O
.	TAFINLAR.xml:S1:3745:1	.	.	O	O

The	TAFINLAR.xml:S1:3751:3	the	DT	O	O
incidence	TAFINLAR.xml:S1:3755:9	incid	NN	O	O
of	TAFINLAR.xml:S1:3765:2	of	IN	O	O
adverse	TAFINLAR.xml:S1:3768:7	advers	JJ	O	O
events	TAFINLAR.xml:S1:3776:6	event	NNS	O	O
resulting	TAFINLAR.xml:S1:3783:9	result	VBG	O	O
in	TAFINLAR.xml:S1:3793:2	in	IN	O	O
permanent	TAFINLAR.xml:S1:3796:9	perman	JJ	O	O
discontinuation	TAFINLAR.xml:S1:3806:15	discontinu	NN	O	O
of	TAFINLAR.xml:S1:3822:2	of	IN	O	O
study	TAFINLAR.xml:S1:3825:5	studi	NN	O	O
medication	TAFINLAR.xml:S1:3831:10	medic	NN	O	O
in	TAFINLAR.xml:S1:3842:2	in	IN	O	O
Trial	TAFINLAR.xml:S1:3845:5	trial	NNP	O	O
1	TAFINLAR.xml:S1:3851:1	1	CD	O	O
was	TAFINLAR.xml:S1:3853:3	wa	VBD	O	O
3%	TAFINLAR.xml:S1:3857:2	3%	CD	O	O
for	TAFINLAR.xml:S1:3860:3	for	IN	O	O
patients	TAFINLAR.xml:S1:3864:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:3873:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:3881:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:3886:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S1:3895:3	and	CC	O	O
3%	TAFINLAR.xml:S1:3899:2	3%	CD	O	O
for	TAFINLAR.xml:S1:3902:3	for	IN	O	O
patients	TAFINLAR.xml:S1:3906:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:3915:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:3923:4	with	IN	O	O
dacarbazine	TAFINLAR.xml:S1:3928:11	dacarbazin	NN	O	O
.	TAFINLAR.xml:S1:3939:1	.	.	O	O

The	TAFINLAR.xml:S1:3941:3	the	DT	O	O
most	TAFINLAR.xml:S1:3945:4	most	RBS	O	O
frequent	TAFINLAR.xml:S1:3950:8	frequent	JJ	O	O
(	TAFINLAR.xml:S1:3959:1	(	(	O	O
2%	TAFINLAR.xml:S1:3962:2	2%	CD	O	O
)	TAFINLAR.xml:S1:3964:1	)	)	O	O
adverse	TAFINLAR.xml:S1:3966:7	advers	NN	O	O
reactions	TAFINLAR.xml:S1:3974:9	reaction	NNS	O	O
leading	TAFINLAR.xml:S1:3984:7	lead	VBG	O	O
to	TAFINLAR.xml:S1:3992:2	to	TO	O	O
dose	TAFINLAR.xml:S1:3995:4	dose	VB	O	O
reduction	TAFINLAR.xml:S1:4000:9	reduct	NN	O	O
of	TAFINLAR.xml:S1:4010:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:4013:8	tafinlar	NNP	O	O
were	TAFINLAR.xml:S1:4022:4	were	VBD	O	O
pyrexia	TAFINLAR.xml:S1:4027:7	pyrexia	NNS	B-AdverseReaction	B-AdverseReaction
(	TAFINLAR.xml:S1:4035:1	(	(	O	O
9%	TAFINLAR.xml:S1:4036:2	9%	CD	O	O
)	TAFINLAR.xml:S1:4038:1	)	)	O	O
,	TAFINLAR.xml:S1:4039:1	,	,	O	O
PPES	TAFINLAR.xml:S1:4041:4	ppe	NNP	B-AdverseReaction	B-AdverseReaction
(	TAFINLAR.xml:S1:4046:1	(	(	O	O
3%	TAFINLAR.xml:S1:4047:2	3%	CD	O	O
)	TAFINLAR.xml:S1:4049:1	)	)	O	O
,	TAFINLAR.xml:S1:4050:1	,	,	O	O
chills	TAFINLAR.xml:S1:4052:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
(	TAFINLAR.xml:S1:4059:1	(	(	O	O
3%	TAFINLAR.xml:S1:4060:2	3%	CD	O	O
)	TAFINLAR.xml:S1:4062:1	)	)	O	O
,	TAFINLAR.xml:S1:4063:1	,	,	O	O
fatigue	TAFINLAR.xml:S1:4065:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction
(	TAFINLAR.xml:S1:4073:1	(	(	O	O
2%	TAFINLAR.xml:S1:4074:2	2%	CD	O	O
)	TAFINLAR.xml:S1:4076:1	)	)	O	O
,	TAFINLAR.xml:S1:4077:1	,	,	O	O
and	TAFINLAR.xml:S1:4079:3	and	CC	O	O
headache	TAFINLAR.xml:S1:4083:8	headach	NN	B-AdverseReaction	B-AdverseReaction
(	TAFINLAR.xml:S1:4092:1	(	(	O	O
2%	TAFINLAR.xml:S1:4093:2	2%	CD	O	O
)	TAFINLAR.xml:S1:4095:1	)	)	O	O
.	TAFINLAR.xml:S1:4096:1	.	.	O	O

Table	TAFINLAR.xml:S1:4102:5	tabl	JJ	O	O
3	TAFINLAR.xml:S1:4108:1	3	CD	O	O
.	TAFINLAR.xml:S1:4109:1	.	.	O	O

Selected	TAFINLAR.xml:S1:4111:8	select	VBN	O	O
Common	TAFINLAR.xml:S1:4120:6	common	NNP	O	O
Adverse	TAFINLAR.xml:S1:4127:7	advers	NNP	O	O
Reactions	TAFINLAR.xml:S1:4135:9	reaction	NNP	O	O
Occurring	TAFINLAR.xml:S1:4145:9	occur	NNP	O	O
in	TAFINLAR.xml:S1:4155:2	in	IN	O	O
10%	TAFINLAR.xml:S1:4160:3	10%	CD	O	O
(	TAFINLAR.xml:S1:4164:1	(	(	O	O
All	TAFINLAR.xml:S1:4165:3	all	NNP	O	O
Grades	TAFINLAR.xml:S1:4169:6	grade	NNP	O	O
)	TAFINLAR.xml:S1:4175:1	)	)	O	O
or	TAFINLAR.xml:S1:4177:2	or	CC	O	O
2%	TAFINLAR.xml:S1:4182:2	2%	CD	O	O
(	TAFINLAR.xml:S1:4185:1	(	(	O	O
Grades	TAFINLAR.xml:S1:4186:6	grade	NNP	O	O
3	TAFINLAR.xml:S1:4193:1	3	CD	O	O
or	TAFINLAR.xml:S1:4195:2	or	CC	O	O
4	TAFINLAR.xml:S1:4198:1	4	CD	O	O
)	TAFINLAR.xml:S1:4199:1	)	)	O	O
of	TAFINLAR.xml:S1:4201:2	of	IN	O	O
Patients	TAFINLAR.xml:S1:4204:8	patient	NNS	O	O
Treated	TAFINLAR.xml:S1:4213:7	treat	VBN	O	O
With	TAFINLAR.xml:S1:4221:4	with	IN	O	O
TAFINLARa	TAFINLAR.xml:S1:4226:9	tafinlara	NNP	O	O

TAFINLARN	TAFINLAR.xml:S1:4301:9	tafinlarn	$	O	O
187	TAFINLAR.xml:S1:4313:3	187	CD	O	O
Dacarbazine	TAFINLAR.xml:S1:4320:11	dacarbazin	NNP	O	O
N	TAFINLAR.xml:S1:4332:1	N	NNP	O	O
59	TAFINLAR.xml:S1:4336:2	59	CD	O	O

Primary	TAFINLAR.xml:S1:4345:7	primari	JJ	O	O
System	TAFINLAR.xml:S1:4353:6	system	NNP	O	O
Organ	TAFINLAR.xml:S1:4360:5	organ	NNP	O	O
Class	TAFINLAR.xml:S1:4366:5	class	NNP	O	O
Preferred	TAFINLAR.xml:S1:4373:9	prefer	NNP	O	O
Term	TAFINLAR.xml:S1:4383:4	term	NNP	O	O
All	TAFINLAR.xml:S1:4407:3	all	NNP	O	O
Grades	TAFINLAR.xml:S1:4412:6	grade	NNP	O	O
(	TAFINLAR.xml:S1:4419:1	(	(	O	O
)	TAFINLAR.xml:S1:4421:1	)	)	O	O
Grades	TAFINLAR.xml:S1:4426:6	grade	VBZ	O	O
3	TAFINLAR.xml:S1:4434:1	3	CD	O	O
and	TAFINLAR.xml:S1:4436:3	and	CC	O	O
4	TAFINLAR.xml:S1:4440:1	4	CD	O	O
b	TAFINLAR.xml:S1:4441:1	b	NN	O	O
(	TAFINLAR.xml:S1:4444:1	(	(	O	O
)	TAFINLAR.xml:S1:4446:1	)	)	O	O
All	TAFINLAR.xml:S1:4451:3	all	DT	O	O
Grades	TAFINLAR.xml:S1:4456:6	grade	NNP	O	O
(	TAFINLAR.xml:S1:4463:1	(	(	O	O
)	TAFINLAR.xml:S1:4465:1	)	)	O	O
Grades	TAFINLAR.xml:S1:4470:6	grade	VBZ	O	O
3	TAFINLAR.xml:S1:4478:1	3	CD	O	O
and	TAFINLAR.xml:S1:4480:3	and	CC	O	O
4	TAFINLAR.xml:S1:4484:1	4	CD	O	O
(	TAFINLAR.xml:S1:4487:1	(	(	O	O
)	TAFINLAR.xml:S1:4489:1	)	)	O	O

Skin	TAFINLAR.xml:S1:4497:4	skin	NNP	O	O
and	TAFINLAR.xml:S1:4502:3	and	CC	O	O
subcutaneous	TAFINLAR.xml:S1:4506:12	subcutan	JJ	O	O
tissue	TAFINLAR.xml:S1:4519:6	tissu	NN	O	O
disorders	TAFINLAR.xml:S1:4526:9	disord	NNS	O	O

Hyperkeratosis	TAFINLAR.xml:S1:4670:14	hyperkeratosi	NN	B-AdverseReaction	O

37	TAFINLAR.xml:S1:4858:2	37	CD	O	O
1	TAFINLAR.xml:S1:4871:1	1	CD	O	O
0	TAFINLAR.xml:S1:4882:1	0	CD	O	O
0	TAFINLAR.xml:S1:4895:1	0	CD	O	O

Alopecia	TAFINLAR.xml:S1:4969:8	alopecia	NN	B-AdverseReaction	B-AdverseReaction

22	TAFINLAR.xml:S1:5157:2	22	CD	O	O
NAf	TAFINLAR.xml:S1:5170:3	naf	NNP	O	O
2	TAFINLAR.xml:S1:5181:1	2	CD	O	O
NAf	TAFINLAR.xml:S1:5194:3	naf	NNP	O	O

Palmar	TAFINLAR.xml:S1:5268:6	palmar	NNP	B-AdverseReaction	B-AdverseReaction
-	TAFINLAR.xml:S1:5274:1	-	:	I-AdverseReaction	I-AdverseReaction
plantar	TAFINLAR.xml:S1:5275:7	plantar	NN	I-AdverseReaction	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:5283:18	erythrodysesthesia	VBZ	I-AdverseReaction	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:5302:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction

20	TAFINLAR.xml:S1:5456:2	20	CD	O	O
2	TAFINLAR.xml:S1:5469:1	2	CD	O	O
2	TAFINLAR.xml:S1:5480:1	2	CD	O	O
0	TAFINLAR.xml:S1:5493:1	0	CD	O	O

Rash	TAFINLAR.xml:S1:5567:4	rash	NN	B-AdverseReaction	B-AdverseReaction

17	TAFINLAR.xml:S1:5755:2	17	CD	O	O
0	TAFINLAR.xml:S1:5768:1	0	CD	O	O
0	TAFINLAR.xml:S1:5779:1	0	CD	O	O
0	TAFINLAR.xml:S1:5792:1	0	CD	O	O

Nervous	TAFINLAR.xml:S1:5805:7	nervou	JJ	O	O
system	TAFINLAR.xml:S1:5813:6	system	NN	O	O
disorders	TAFINLAR.xml:S1:5820:9	disord	NNS	O	O

Headache	TAFINLAR.xml:S1:5978:8	headach	NN	B-AdverseReaction	B-AdverseReaction

32	TAFINLAR.xml:S1:6166:2	32	CD	O	O
0	TAFINLAR.xml:S1:6179:1	0	CD	O	O
8	TAFINLAR.xml:S1:6190:1	8	CD	O	O
0	TAFINLAR.xml:S1:6203:1	0	CD	O	O

General	TAFINLAR.xml:S1:6216:7	gener	NNP	O	O
disorders	TAFINLAR.xml:S1:6224:9	disord	NNS	O	O
and	TAFINLAR.xml:S1:6234:3	and	CC	O	O
administration	TAFINLAR.xml:S1:6238:14	administr	NN	O	O
site	TAFINLAR.xml:S1:6253:4	site	NN	O	O
conditions	TAFINLAR.xml:S1:6258:10	condit	NNS	O	O

Pyrexia	TAFINLAR.xml:S1:6389:7	pyrexia	NN	B-AdverseReaction	O

28	TAFINLAR.xml:S1:6577:2	28	CD	O	O
3	TAFINLAR.xml:S1:6590:1	3	CD	O	O
10	TAFINLAR.xml:S1:6601:2	10	CD	O	O
0	TAFINLAR.xml:S1:6614:1	0	CD	O	O

Musculoskeletal	TAFINLAR.xml:S1:6627:15	musculoskelet	NNP	O	O
and	TAFINLAR.xml:S1:6643:3	and	CC	O	O
connective	TAFINLAR.xml:S1:6647:10	connect	JJ	O	O
tissue	TAFINLAR.xml:S1:6658:6	tissu	NN	O	O
disorders	TAFINLAR.xml:S1:6665:9	disord	NNS	O	O

Arthralgia	TAFINLAR.xml:S1:6800:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction

27	TAFINLAR.xml:S1:6988:2	27	CD	O	O
1	TAFINLAR.xml:S1:7001:1	1	CD	O	O
2	TAFINLAR.xml:S1:7012:1	2	CD	O	O
0	TAFINLAR.xml:S1:7025:1	0	CD	O	O

Back	TAFINLAR.xml:S1:7099:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	TAFINLAR.xml:S1:7104:4	pain	NN	I-AdverseReaction	I-AdverseReaction

12	TAFINLAR.xml:S1:7287:2	12	CD	O	O
3	TAFINLAR.xml:S1:7300:1	3	CD	O	O
7	TAFINLAR.xml:S1:7311:1	7	CD	O	O
0	TAFINLAR.xml:S1:7324:1	0	CD	O	O

Myalgia	TAFINLAR.xml:S1:7398:7	myalgia	NN	B-AdverseReaction	B-AdverseReaction

11	TAFINLAR.xml:S1:7586:2	11	CD	O	O
0	TAFINLAR.xml:S1:7599:1	0	CD	O	O
0	TAFINLAR.xml:S1:7610:1	0	CD	O	O
0	TAFINLAR.xml:S1:7623:1	0	CD	O	O

Neoplasms	TAFINLAR.xml:S1:7636:9	neoplasm	NNP	O	O
benign	TAFINLAR.xml:S1:7646:6	benign	NN	O	O
,	TAFINLAR.xml:S1:7652:1	,	,	O	O
malignant	TAFINLAR.xml:S1:7654:9	malign	JJ	O	O
,	TAFINLAR.xml:S1:7663:1	,	,	O	O
and	TAFINLAR.xml:S1:7665:3	and	CC	O	O
unspecified	TAFINLAR.xml:S1:7669:11	unspecifi	JJ	O	O
(	TAFINLAR.xml:S1:7681:1	(	(	O	O
including	TAFINLAR.xml:S1:7682:9	includ	VBG	O	O
cysts	TAFINLAR.xml:S1:7692:5	cyst	NNS	O	O
and	TAFINLAR.xml:S1:7698:3	and	CC	O	O
polyps	TAFINLAR.xml:S1:7702:6	polyp	NNS	O	O
)	TAFINLAR.xml:S1:7708:1	)	)	O	O

Papilloma	TAFINLAR.xml:S1:7824:9	papilloma	NNP	B-AdverseReaction	O
c	TAFINLAR.xml:S1:7835:1	c	NN	O	O

27	TAFINLAR.xml:S1:8012:2	27	CD	O	O
0	TAFINLAR.xml:S1:8025:1	0	CD	O	O
2	TAFINLAR.xml:S1:8036:1	2	CD	O	O
0	TAFINLAR.xml:S1:8049:1	0	CD	O	O

cuSCC	TAFINLAR.xml:S1:8123:5	cuscc	NN	B-AdverseReaction	O
d	TAFINLAR.xml:S1:8130:1	d	NN	O	O
,	TAFINLAR.xml:S1:8131:1	,	,	O	O
e	TAFINLAR.xml:S1:8133:1	e	NN	O	O

7	TAFINLAR.xml:S1:8311:1	7	CD	O	O
4	TAFINLAR.xml:S1:8324:1	4	CD	O	O
0	TAFINLAR.xml:S1:8335:1	0	CD	O	O
0	TAFINLAR.xml:S1:8348:1	0	CD	O	O

Respiratory	TAFINLAR.xml:S1:8361:11	respiratori	NNP	O	O
,	TAFINLAR.xml:S1:8372:1	,	,	O	O
thoracic	TAFINLAR.xml:S1:8374:8	thorac	NN	O	O
,	TAFINLAR.xml:S1:8382:1	,	,	O	O
and	TAFINLAR.xml:S1:8384:3	and	CC	O	O
mediastinal	TAFINLAR.xml:S1:8388:11	mediastin	JJ	O	O
disorders	TAFINLAR.xml:S1:8400:9	disord	NNS	O	O

Cough	TAFINLAR.xml:S1:8534:5	cough	NN	B-AdverseReaction	B-AdverseReaction

12	TAFINLAR.xml:S1:8722:2	12	CD	O	O
0	TAFINLAR.xml:S1:8735:1	0	CD	O	O
5	TAFINLAR.xml:S1:8746:1	5	CD	O	O
0	TAFINLAR.xml:S1:8759:1	0	CD	O	O

Gastrointestinal	TAFINLAR.xml:S1:8772:16	gastrointestin	JJ	O	O
disorders	TAFINLAR.xml:S1:8789:9	disord	NNS	O	O

Constipation	TAFINLAR.xml:S1:8945:12	constip	NN	B-AdverseReaction	B-AdverseReaction

11	TAFINLAR.xml:S1:9133:2	11	CD	O	O
2	TAFINLAR.xml:S1:9146:1	2	CD	O	O
14	TAFINLAR.xml:S1:9157:2	14	CD	O	O
0	TAFINLAR.xml:S1:9170:1	0	CD	O	O

Infections	TAFINLAR.xml:S1:9183:10	infect	NNS	O	O
and	TAFINLAR.xml:S1:9194:3	and	CC	O	O
infestations	TAFINLAR.xml:S1:9198:12	infest	NNS	O	O

Nasopharyngitis	TAFINLAR.xml:S1:9356:15	nasopharyng	NN	B-AdverseReaction	B-AdverseReaction

10	TAFINLAR.xml:S1:9544:2	10	CD	O	O
0	TAFINLAR.xml:S1:9557:1	0	CD	O	O
3	TAFINLAR.xml:S1:9568:1	3	CD	O	O
0	TAFINLAR.xml:S1:9581:1	0	CD	O	O

a	TAFINLAR.xml:S1:9605:1	a	DT	O	O
Adverse	TAFINLAR.xml:S1:9608:7	advers	JJ	O	O
drug	TAFINLAR.xml:S1:9616:4	drug	NN	O	O
reactions	TAFINLAR.xml:S1:9621:9	reaction	NNS	O	O
,	TAFINLAR.xml:S1:9630:1	,	,	O	O
reported	TAFINLAR.xml:S1:9632:8	report	VBD	O	O
using	TAFINLAR.xml:S1:9641:5	use	VBG	O	O
MedDRA	TAFINLAR.xml:S1:9647:6	meddra	NNP	O	O
and	TAFINLAR.xml:S1:9654:3	and	CC	O	O
graded	TAFINLAR.xml:S1:9658:6	grade	VBD	O	O
using	TAFINLAR.xml:S1:9665:5	use	VBG	O	O
CTCAE	TAFINLAR.xml:S1:9671:5	ctcae	NNP	O	O
version	TAFINLAR.xml:S1:9677:7	version	NN	O	O
4.0	TAFINLAR.xml:S1:9685:3	4.0	CD	O	O
for	TAFINLAR.xml:S1:9689:3	for	IN	O	O
assessment	TAFINLAR.xml:S1:9693:10	assess	NN	O	O
of	TAFINLAR.xml:S1:9704:2	of	IN	O	O
toxicity	TAFINLAR.xml:S1:9707:8	toxic	NN	O	O
.	TAFINLAR.xml:S1:9715:1	.	.	O	O

b	TAFINLAR.xml:S1:9723:1	b	NN	O	O

Grade	TAFINLAR.xml:S1:9726:5	grade	$	O	O
4	TAFINLAR.xml:S1:9732:1	4	CD	O	O
adverse	TAFINLAR.xml:S1:9734:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S1:9742:9	reaction	NNS	O	O
limited	TAFINLAR.xml:S1:9752:7	limit	VBD	O	O
to	TAFINLAR.xml:S1:9760:2	to	TO	O	O
hyperkeratosis	TAFINLAR.xml:S1:9763:14	hyperkeratosi	NN	B-AdverseReaction	O
(	TAFINLAR.xml:S1:9778:1	(	(	O	O
n	TAFINLAR.xml:S1:9779:1	n	JJ	O	O
1	TAFINLAR.xml:S1:9783:1	1	CD	O	O
)	TAFINLAR.xml:S1:9784:1	)	)	O	O
and	TAFINLAR.xml:S1:9786:3	and	CC	O	O
constipation	TAFINLAR.xml:S1:9790:12	constip	NN	B-AdverseReaction	B-AdverseReaction
(	TAFINLAR.xml:S1:9803:1	(	(	O	O
n	TAFINLAR.xml:S1:9804:1	n	JJ	O	O
1	TAFINLAR.xml:S1:9808:1	1	CD	O	O
)	TAFINLAR.xml:S1:9809:1	)	)	O	O
.	TAFINLAR.xml:S1:9810:1	.	.	O	O

c	TAFINLAR.xml:S1:9818:1	c	SYM	O	O
Includes	TAFINLAR.xml:S1:9821:8	includ	VBZ	O	O
skin	TAFINLAR.xml:S1:9830:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
papilloma	TAFINLAR.xml:S1:9835:9	papilloma	NN	I-AdverseReaction	I-AdverseReaction
and	TAFINLAR.xml:S1:9845:3	and	CC	O	O
papilloma	TAFINLAR.xml:S1:9849:9	papilloma	NN	B-AdverseReaction	O
.	TAFINLAR.xml:S1:9858:1	.	.	O	O

d	TAFINLAR.xml:S1:9866:1	d	NN	O	O
Includes	TAFINLAR.xml:S1:9869:8	includ	NNP	O	O
squamous	TAFINLAR.xml:S1:9878:8	squamou	JJ	B-AdverseReaction	B-AdverseReaction
cell	TAFINLAR.xml:S1:9887:4	cell	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TAFINLAR.xml:S1:9892:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
of	TAFINLAR.xml:S1:9902:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	TAFINLAR.xml:S1:9905:3	the	DT	I-AdverseReaction	I-AdverseReaction
skin	TAFINLAR.xml:S1:9909:4	skin	NN	I-AdverseReaction	I-AdverseReaction
and	TAFINLAR.xml:S1:9914:3	and	CC	O	O
keratoacanthoma	TAFINLAR.xml:S1:9918:15	keratoacanthoma	NN	B-AdverseReaction	O
.	TAFINLAR.xml:S1:9933:1	.	.	O	O

e	TAFINLAR.xml:S1:9941:1	e	NN	O	O
Cases	TAFINLAR.xml:S1:9944:5	case	NNS	O	O
of	TAFINLAR.xml:S1:9950:2	of	IN	O	O
cutaneous	TAFINLAR.xml:S1:9953:9	cutan	JJ	B-AdverseReaction	B-AdverseReaction
squamous	TAFINLAR.xml:S1:9963:8	squamou	JJ	I-AdverseReaction	I-AdverseReaction
cell	TAFINLAR.xml:S1:9972:4	cell	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TAFINLAR.xml:S1:9977:9	carcinoma	NNS	I-AdverseReaction	I-AdverseReaction
were	TAFINLAR.xml:S1:9987:4	were	VBD	O	O
required	TAFINLAR.xml:S1:9992:8	requir	VBN	O	O
to	TAFINLAR.xml:S1:10001:2	to	TO	O	O
be	TAFINLAR.xml:S1:10004:2	be	VB	O	O
reported	TAFINLAR.xml:S1:10007:8	report	VBN	O	O
as	TAFINLAR.xml:S1:10016:2	as	IN	O	O
Grade	TAFINLAR.xml:S1:10019:5	grade	NNP	O	O
3	TAFINLAR.xml:S1:10025:1	3	CD	O	O
per	TAFINLAR.xml:S1:10027:3	per	IN	O	O
protocol	TAFINLAR.xml:S1:10031:8	protocol	NN	O	O
.	TAFINLAR.xml:S1:10039:1	.	.	O	O

f	TAFINLAR.xml:S1:10047:1	f	NNS	O	O
NA	TAFINLAR.xml:S1:10050:2	NA	NNP	O	O
not	TAFINLAR.xml:S1:10055:3	not	RB	O	O
applicable	TAFINLAR.xml:S1:10059:10	applic	JJ	O	O
.	TAFINLAR.xml:S1:10069:1	.	.	O	O

Table	TAFINLAR.xml:S1:10075:5	tabl	JJ	O	O
4	TAFINLAR.xml:S1:10081:1	4	CD	O	O
.	TAFINLAR.xml:S1:10082:1	.	.	O	O

Incidence	TAFINLAR.xml:S1:10084:9	incid	NN	O	O
of	TAFINLAR.xml:S1:10094:2	of	IN	O	O
Laboratory	TAFINLAR.xml:S1:10097:10	laboratori	NNP	O	O
Abnormalities	TAFINLAR.xml:S1:10108:13	abnorm	NNP	O	B-AdverseReaction
Increased	TAFINLAR.xml:S1:10122:9	increas	VBD	O	I-AdverseReaction
From	TAFINLAR.xml:S1:10132:4	from	NNP	O	O
Baseline	TAFINLAR.xml:S1:10137:8	baselin	NNP	O	O
Occurring	TAFINLAR.xml:S1:10146:9	occur	NNP	O	O
at	TAFINLAR.xml:S1:10156:2	at	IN	O	O
a	TAFINLAR.xml:S1:10159:1	a	DT	O	O
Higher	TAFINLAR.xml:S1:10161:6	higher	JJR	O	O
Incidence	TAFINLAR.xml:S1:10168:9	incid	NN	O	O
in	TAFINLAR.xml:S1:10178:2	in	IN	O	O
Patients	TAFINLAR.xml:S1:10181:8	patient	NNS	O	O
Treated	TAFINLAR.xml:S1:10190:7	treat	VBN	O	O
With	TAFINLAR.xml:S1:10198:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:10203:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S1:10212:2	in	IN	O	O
Trial	TAFINLAR.xml:S1:10215:5	trial	NNP	O	O
1	TAFINLAR.xml:S1:10221:1	1	CD	O	O
[	TAFINLAR.xml:S1:10223:1	[	NN	O	O
Between	TAFINLAR.xml:S1:10224:7	between	NNP	O	O
-	TAFINLAR.xml:S1:10231:1	-	:	O	O
Arm	TAFINLAR.xml:S1:10232:3	arm	NNP	O	O
Difference	TAFINLAR.xml:S1:10236:10	differ	NNP	O	O
of	TAFINLAR.xml:S1:10247:2	of	IN	O	O
5%	TAFINLAR.xml:S1:10252:2	5%	CD	O	O
(	TAFINLAR.xml:S1:10255:1	(	(	O	O
All	TAFINLAR.xml:S1:10256:3	all	NNP	O	O
Grades	TAFINLAR.xml:S1:10260:6	grade	NNP	O	O
)	TAFINLAR.xml:S1:10266:1	)	)	O	O
or	TAFINLAR.xml:S1:10268:2	or	CC	O	O
2%	TAFINLAR.xml:S1:10273:2	2%	CD	O	O
(	TAFINLAR.xml:S1:10276:1	(	(	O	O
Grades	TAFINLAR.xml:S1:10277:6	grade	NNP	O	O
3	TAFINLAR.xml:S1:10284:1	3	CD	O	O
or	TAFINLAR.xml:S1:10286:2	or	CC	O	O
4	TAFINLAR.xml:S1:10289:1	4	CD	O	O
)]	TAFINLAR.xml:S1:10290:2	)]	NNS	O	O

Test	TAFINLAR.xml:S1:10296:4	test	NNP	O	O
TAFINLAR	TAFINLAR.xml:S1:10343:8	tafinlar	NNP	O	O
N	TAFINLAR.xml:S1:10353:1	N	NNP	O	O
187	TAFINLAR.xml:S1:10357:3	187	CD	O	O
DTIC	TAFINLAR.xml:S1:10364:4	dtic	NNP	O	O
N	TAFINLAR.xml:S1:10370:1	N	NNP	O	O
59	TAFINLAR.xml:S1:10374:2	59	CD	O	O

All	TAFINLAR.xml:S1:10383:3	all	DT	O	O
Grades	TAFINLAR.xml:S1:10388:6	grade	NNP	O	O
(	TAFINLAR.xml:S1:10396:1	(	(	O	O
)	TAFINLAR.xml:S1:10398:1	)	)	O	O
Grades	TAFINLAR.xml:S1:10430:6	grade	VBZ	O	O
3	TAFINLAR.xml:S1:10438:1	3	CD	O	O
and	TAFINLAR.xml:S1:10440:3	and	CC	O	O
4	TAFINLAR.xml:S1:10444:1	4	CD	O	O
(	TAFINLAR.xml:S1:10447:1	(	(	O	O
)	TAFINLAR.xml:S1:10449:1	)	)	O	O
All	TAFINLAR.xml:S1:10454:3	all	DT	O	O
Grades	TAFINLAR.xml:S1:10459:6	grade	NNP	O	O
(	TAFINLAR.xml:S1:10467:1	(	(	O	O
)	TAFINLAR.xml:S1:10469:1	)	)	O	O
Grades	TAFINLAR.xml:S1:10474:6	grade	VBZ	O	O
3	TAFINLAR.xml:S1:10482:1	3	CD	O	O
and	TAFINLAR.xml:S1:10484:3	and	CC	O	O
4	TAFINLAR.xml:S1:10488:1	4	CD	O	O
(	TAFINLAR.xml:S1:10491:1	(	(	O	O
)	TAFINLAR.xml:S1:10493:1	)	)	O	O

Hyperglycemia	TAFINLAR.xml:S1:10501:13	hyperglycemia	NNP	B-AdverseReaction	B-AdverseReaction
50	TAFINLAR.xml:S1:10548:2	50	CD	O	O
6	TAFINLAR.xml:S1:10564:1	6	CD	O	O
43	TAFINLAR.xml:S1:10580:2	43	CD	O	O
0	TAFINLAR.xml:S1:10596:1	0	CD	O	O

Hypophosphatemia	TAFINLAR.xml:S1:10615:16	hypophosphatemia	NNP	B-AdverseReaction	B-AdverseReaction
37	TAFINLAR.xml:S1:10662:2	37	CD	O	O
6	TAFINLAR.xml:S1:10678:1	6	CD	O	O
a	TAFINLAR.xml:S1:10679:1	a	DT	O	O
14	TAFINLAR.xml:S1:10694:2	14	CD	O	O
2	TAFINLAR.xml:S1:10710:1	2	CD	O	O

Increased	TAFINLAR.xml:S1:10729:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
alkaline	TAFINLAR.xml:S1:10739:8	alkalin	JJ	I-AdverseReaction	I-AdverseReaction
phosphatase	TAFINLAR.xml:S1:10748:11	phosphatas	NN	I-AdverseReaction	I-AdverseReaction
19	TAFINLAR.xml:S1:10776:2	19	CD	O	O
0	TAFINLAR.xml:S1:10792:1	0	CD	O	O
14	TAFINLAR.xml:S1:10808:2	14	CD	O	O
2	TAFINLAR.xml:S1:10824:1	2	CD	O	O

Hyponatremia	TAFINLAR.xml:S1:10843:12	hyponatremia	NNP	B-AdverseReaction	B-AdverseReaction
8	TAFINLAR.xml:S1:10890:1	8	CD	O	O
2	TAFINLAR.xml:S1:10906:1	2	CD	O	O
3	TAFINLAR.xml:S1:10922:1	3	CD	O	O
0	TAFINLAR.xml:S1:10938:1	0	CD	O	O

a	TAFINLAR.xml:S1:10968:1	a	DT	O	O
Grade	TAFINLAR.xml:S1:10971:5	grade	NNP	O	O
4	TAFINLAR.xml:S1:10977:1	4	CD	O	O
laboratory	TAFINLAR.xml:S1:10979:10	laboratori	NN	O	O
abnormality	TAFINLAR.xml:S1:10990:11	abnorm	NN	O	O
limited	TAFINLAR.xml:S1:11002:7	limit	VBD	O	O
to	TAFINLAR.xml:S1:11010:2	to	TO	O	O
hypophosphatemia	TAFINLAR.xml:S1:11013:16	hypophosphatemia	VB	B-AdverseReaction	O
(	TAFINLAR.xml:S1:11030:1	(	(	O	O
n	TAFINLAR.xml:S1:11031:1	n	JJ	O	O
1	TAFINLAR.xml:S1:11035:1	1	CD	O	O
)	TAFINLAR.xml:S1:11036:1	)	)	O	O
.	TAFINLAR.xml:S1:11037:1	.	.	O	O

Other	TAFINLAR.xml:S1:11043:5	other	JJ	O	O

clinically	TAFINLAR.xml:S1:11049:10	clinic	RB	O	O
important	TAFINLAR.xml:S1:11060:9	import	JJ	O	O
adverse	TAFINLAR.xml:S1:11070:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S1:11078:9	reaction	NNS	O	O
observed	TAFINLAR.xml:S1:11088:8	observ	VBD	O	O
in	TAFINLAR.xml:S1:11097:2	in	IN	O	O
10%	TAFINLAR.xml:S1:11101:3	10%	CD	O	O
of	TAFINLAR.xml:S1:11105:2	of	IN	O	O
patients	TAFINLAR.xml:S1:11108:8	patient	NNS	O	O
(	TAFINLAR.xml:S1:11117:1	(	(	O	O
N	TAFINLAR.xml:S1:11118:1	N	NNP	O	O
586	TAFINLAR.xml:S1:11122:3	586	CD	O	O
)	TAFINLAR.xml:S1:11125:1	)	)	O	O
treated	TAFINLAR.xml:S1:11127:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:11135:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:11140:8	tafinlar	NNP	O	O
were	TAFINLAR.xml:S1:11149:4	were	VBD	O	O
:	TAFINLAR.xml:S1:11153:1	:	:	O	O

Gastrointestinal	TAFINLAR.xml:S1:11161:16	gastrointestin	JJ	O	O
Disorders	TAFINLAR.xml:S1:11178:9	disord	NNS	O	O
:	TAFINLAR.xml:S1:11187:1	:	:	O	O
Pancreatitis	TAFINLAR.xml:S1:11190:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
.	TAFINLAR.xml:S1:11202:1	.	.	O	O

Immune	TAFINLAR.xml:S1:11210:6	immun	NNP	O	O
System	TAFINLAR.xml:S1:11217:6	system	NNP	O	O
Disorders	TAFINLAR.xml:S1:11224:9	disord	NNPS	O	O
:	TAFINLAR.xml:S1:11233:1	:	:	O	O
Hypersensitivity	TAFINLAR.xml:S1:11236:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
manifesting	TAFINLAR.xml:S1:11253:11	manifest	NN	O	I-AdverseReaction
as	TAFINLAR.xml:S1:11265:2	as	IN	O	O
bullous	TAFINLAR.xml:S1:11268:7	bullou	JJ	B-AdverseReaction	B-AdverseReaction
rash	TAFINLAR.xml:S1:11276:4	rash	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S1:11280:1	.	.	O	O

Renal	TAFINLAR.xml:S1:11288:5	renal	NNP	O	O
and	TAFINLAR.xml:S1:11294:3	and	CC	O	O
Urinary	TAFINLAR.xml:S1:11298:7	urinari	JJ	O	O
Disorders	TAFINLAR.xml:S1:11306:9	disord	NNS	O	O
:	TAFINLAR.xml:S1:11315:1	:	:	O	O
Interstitial	TAFINLAR.xml:S1:11318:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
nephritis	TAFINLAR.xml:S1:11331:9	nephriti	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S1:11340:1	.	.	O	O

BRAF	TAFINLAR.xml:S1:11348:4	braf	NNP	O	O
V600E	TAFINLAR.xml:S1:11353:5	v600e	NNP	O	O
or	TAFINLAR.xml:S1:11359:2	or	CC	O	O
V600K	TAFINLAR.xml:S1:11362:5	v600k	NNP	O	O
Unresectable	TAFINLAR.xml:S1:11368:12	unresect	NNP	O	O
or	TAFINLAR.xml:S1:11381:2	or	CC	O	O
Metastatic	TAFINLAR.xml:S1:11384:10	metastat	JJ	O	O
Melanoma	TAFINLAR.xml:S1:11395:8	melanoma	NN	O	O
:	TAFINLAR.xml:S1:11403:1	:	:	O	O

The	TAFINLAR.xml:S1:11411:3	the	DT	O	O
safety	TAFINLAR.xml:S1:11415:6	safeti	NN	O	O
of	TAFINLAR.xml:S1:11422:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:11425:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S1:11434:2	in	IN	O	O
combination	TAFINLAR.xml:S1:11437:11	combin	NN	O	O
with	TAFINLAR.xml:S1:11449:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:11454:10	trametinib	NN	O	O
was	TAFINLAR.xml:S1:11465:3	wa	VBD	O	O
evaluated	TAFINLAR.xml:S1:11469:9	evalu	VBN	O	O
in	TAFINLAR.xml:S1:11479:2	in	IN	O	O
Trial	TAFINLAR.xml:S1:11482:5	trial	NNP	O	O
2	TAFINLAR.xml:S1:11488:1	2	CD	O	O
and	TAFINLAR.xml:S1:11490:3	and	CC	O	O
other	TAFINLAR.xml:S1:11494:5	other	JJ	O	O
trials	TAFINLAR.xml:S1:11500:6	trial	NNS	O	O
consisting	TAFINLAR.xml:S1:11507:10	consist	VBG	O	O
of	TAFINLAR.xml:S1:11518:2	of	IN	O	O
a	TAFINLAR.xml:S1:11521:1	a	DT	O	O
total	TAFINLAR.xml:S1:11523:5	total	NN	O	O
of	TAFINLAR.xml:S1:11529:2	of	IN	O	O
202	TAFINLAR.xml:S1:11532:3	202	CD	O	O
patients	TAFINLAR.xml:S1:11536:8	patient	NNS	O	O
with	TAFINLAR.xml:S1:11545:4	with	IN	O	O
BRAF	TAFINLAR.xml:S1:11550:4	braf	NNP	O	O
V600	TAFINLAR.xml:S1:11555:4	v600	NNP	O	O
mutation	TAFINLAR.xml:S1:11560:8	mutat	NN	O	O
-	TAFINLAR.xml:S1:11568:1	-	:	O	O
positive	TAFINLAR.xml:S1:11569:8	posit	JJ	O	O
unresectable	TAFINLAR.xml:S1:11578:12	unresect	JJ	O	O
or	TAFINLAR.xml:S1:11591:2	or	CC	O	O
metastatic	TAFINLAR.xml:S1:11594:10	metastat	JJ	O	O
melanoma	TAFINLAR.xml:S1:11605:8	melanoma	NN	O	O
who	TAFINLAR.xml:S1:11614:3	who	WP	O	O
received	TAFINLAR.xml:S1:11618:8	receiv	VBD	O	O
TAFINLAR	TAFINLAR.xml:S1:11627:8	tafinlar	NNP	O	O
150	TAFINLAR.xml:S1:11636:3	150	CD	O	O
mg	TAFINLAR.xml:S1:11640:2	mg	NN	O	O
orally	TAFINLAR.xml:S1:11643:6	oral	RB	O	O
twice	TAFINLAR.xml:S1:11650:5	twice	JJ	O	O
daily	TAFINLAR.xml:S1:11656:5	daili	RB	O	O
in	TAFINLAR.xml:S1:11662:2	in	IN	O	O
combination	TAFINLAR.xml:S1:11665:11	combin	NN	O	O
with	TAFINLAR.xml:S1:11677:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:11682:10	trametinib	JJ	O	O
2	TAFINLAR.xml:S1:11693:1	2	CD	O	O
mg	TAFINLAR.xml:S1:11695:2	mg	NN	O	O
orally	TAFINLAR.xml:S1:11698:6	oral	RB	O	O
once	TAFINLAR.xml:S1:11705:4	onc	RB	O	O
daily	TAFINLAR.xml:S1:11710:5	daili	JJ	O	O
until	TAFINLAR.xml:S1:11716:5	until	IN	O	O
disease	TAFINLAR.xml:S1:11722:7	diseas	JJ	O	O
progression	TAFINLAR.xml:S1:11730:11	progress	NN	O	O
or	TAFINLAR.xml:S1:11742:2	or	CC	O	O
unacceptable	TAFINLAR.xml:S1:11745:12	unaccept	JJ	O	O
toxicity	TAFINLAR.xml:S1:11758:8	toxic	NN	O	O
.	TAFINLAR.xml:S1:11766:1	.	.	O	O

Among	TAFINLAR.xml:S1:11768:5	among	IN	O	O
these	TAFINLAR.xml:S1:11774:5	these	DT	O	O
202	TAFINLAR.xml:S1:11780:3	202	CD	O	O
patients	TAFINLAR.xml:S1:11784:8	patient	NNS	O	O
,	TAFINLAR.xml:S1:11792:1	,	,	O	O
66	TAFINLAR.xml:S1:11794:2	66	CD	O	O
(	TAFINLAR.xml:S1:11797:1	(	(	O	O
33%	TAFINLAR.xml:S1:11798:3	33%	CD	O	O
)	TAFINLAR.xml:S1:11801:1	)	)	O	O
were	TAFINLAR.xml:S1:11803:4	were	VBD	O	O
exposed	TAFINLAR.xml:S1:11808:7	expos	VBN	O	O
to	TAFINLAR.xml:S1:11816:2	to	TO	O	O
TAFINLAR	TAFINLAR.xml:S1:11819:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S1:11828:3	and	CC	O	O
68	TAFINLAR.xml:S1:11832:2	68	CD	O	O
(	TAFINLAR.xml:S1:11835:1	(	(	O	O
34%	TAFINLAR.xml:S1:11836:3	34%	CD	O	O
)	TAFINLAR.xml:S1:11839:1	)	)	O	O
were	TAFINLAR.xml:S1:11841:4	were	VBD	O	O
exposed	TAFINLAR.xml:S1:11846:7	expos	VBN	O	O
to	TAFINLAR.xml:S1:11854:2	to	TO	O	O
trametinib	TAFINLAR.xml:S1:11857:10	trametinib	VB	O	O
for	TAFINLAR.xml:S1:11868:3	for	IN	O	O
greater	TAFINLAR.xml:S1:11872:7	greater	JJR	O	O
than	TAFINLAR.xml:S1:11880:4	than	IN	O	O
6	TAFINLAR.xml:S1:11885:1	6	CD	O	O
to	TAFINLAR.xml:S1:11887:2	to	TO	O	O
12	TAFINLAR.xml:S1:11890:2	12	CD	O	O
months	TAFINLAR.xml:S1:11893:6	month	NNS	O	O
while	TAFINLAR.xml:S1:11900:5	while	IN	O	O
40	TAFINLAR.xml:S1:11906:2	40	CD	O	O
(	TAFINLAR.xml:S1:11909:1	(	(	O	O
20%	TAFINLAR.xml:S1:11910:3	20%	CD	O	O
)	TAFINLAR.xml:S1:11913:1	)	)	O	O
were	TAFINLAR.xml:S1:11915:4	were	VBD	O	O
exposed	TAFINLAR.xml:S1:11920:7	expos	VBN	O	O
to	TAFINLAR.xml:S1:11928:2	to	TO	O	O
TAFINLAR	TAFINLAR.xml:S1:11931:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S1:11940:3	and	CC	O	O
36	TAFINLAR.xml:S1:11944:2	36	CD	O	O
(	TAFINLAR.xml:S1:11947:1	(	(	O	O
18%	TAFINLAR.xml:S1:11948:3	18%	CD	O	O
)	TAFINLAR.xml:S1:11951:1	)	)	O	O
were	TAFINLAR.xml:S1:11953:4	were	VBD	O	O
exposed	TAFINLAR.xml:S1:11958:7	expos	VBN	O	O
to	TAFINLAR.xml:S1:11966:2	to	TO	O	O
trametinib	TAFINLAR.xml:S1:11969:10	trametinib	VB	O	O
for	TAFINLAR.xml:S1:11980:3	for	IN	O	O
greater	TAFINLAR.xml:S1:11984:7	greater	JJR	O	O
than	TAFINLAR.xml:S1:11992:4	than	IN	O	O
one	TAFINLAR.xml:S1:11997:3	one	CD	O	O
year	TAFINLAR.xml:S1:12001:4	year	NN	O	O
.	TAFINLAR.xml:S1:12005:1	.	.	O	O

The	TAFINLAR.xml:S1:12007:3	the	DT	O	O
median	TAFINLAR.xml:S1:12011:6	median	JJ	O	O
age	TAFINLAR.xml:S1:12018:3	age	NN	O	O
was	TAFINLAR.xml:S1:12022:3	wa	VBD	O	O
54	TAFINLAR.xml:S1:12026:2	54	CD	O	O
years	TAFINLAR.xml:S1:12029:5	year	NNS	O	O
,	TAFINLAR.xml:S1:12034:1	,	,	O	O
57%	TAFINLAR.xml:S1:12036:3	57%	CD	O	O
were	TAFINLAR.xml:S1:12040:4	were	VBD	O	O
male	TAFINLAR.xml:S1:12045:4	male	NN	O	O
,	TAFINLAR.xml:S1:12049:1	,	,	O	O
and	TAFINLAR.xml:S1:12051:3	and	CC	O	O
99%	TAFINLAR.xml:S1:12056:3	99%	CD	O	O
were	TAFINLAR.xml:S1:12060:4	were	VBD	O	O
white	TAFINLAR.xml:S1:12065:5	white	JJ	O	O
.	TAFINLAR.xml:S1:12070:1	.	.	O	O

Table	TAFINLAR.xml:S1:12076:5	tabl	JJ	O	O
5	TAFINLAR.xml:S1:12082:1	5	CD	O	O
presents	TAFINLAR.xml:S1:12084:8	present	NNS	O	O
adverse	TAFINLAR.xml:S1:12093:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S1:12101:9	reaction	NNS	O	O
from	TAFINLAR.xml:S1:12111:4	from	IN	O	O
Trial	TAFINLAR.xml:S1:12116:5	trial	JJ	O	O
2	TAFINLAR.xml:S1:12122:1	2	CD	O	O
,	TAFINLAR.xml:S1:12123:1	,	,	O	O
a	TAFINLAR.xml:S1:12125:1	a	DT	O	O
multicenter	TAFINLAR.xml:S1:12127:11	multicent	NN	O	O
,	TAFINLAR.xml:S1:12138:1	,	,	O	O
open	TAFINLAR.xml:S1:12140:4	open	JJ	O	O
-	TAFINLAR.xml:S1:12144:1	-	:	O	O
label	TAFINLAR.xml:S1:12145:5	label	NN	O	O
,	TAFINLAR.xml:S1:12150:1	,	,	O	O
randomized	TAFINLAR.xml:S1:12152:10	random	VBN	O	O
trial	TAFINLAR.xml:S1:12163:5	trial	NN	O	O
of	TAFINLAR.xml:S1:12169:2	of	IN	O	O
162	TAFINLAR.xml:S1:12172:3	162	CD	O	O
patients	TAFINLAR.xml:S1:12176:8	patient	NNS	O	O
with	TAFINLAR.xml:S1:12185:4	with	IN	O	O
BRAF	TAFINLAR.xml:S1:12190:4	braf	NNP	O	O
V600E	TAFINLAR.xml:S1:12195:5	v600e	NNP	O	O
or	TAFINLAR.xml:S1:12201:2	or	CC	O	O
V600K	TAFINLAR.xml:S1:12204:5	v600k	NNP	O	O
mutation	TAFINLAR.xml:S1:12210:8	mutat	NN	O	O
-	TAFINLAR.xml:S1:12218:1	-	:	O	O
positive	TAFINLAR.xml:S1:12219:8	posit	JJ	O	O
melanoma	TAFINLAR.xml:S1:12228:8	melanoma	NN	O	O
receiving	TAFINLAR.xml:S1:12237:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S1:12247:8	tafinlar	NNP	O	O
150	TAFINLAR.xml:S1:12256:3	150	CD	O	O
mg	TAFINLAR.xml:S1:12260:2	mg	NN	O	O
twice	TAFINLAR.xml:S1:12263:5	twice	RB	O	O
daily	TAFINLAR.xml:S1:12269:5	daili	RB	O	O
in	TAFINLAR.xml:S1:12275:2	in	IN	O	O
combination	TAFINLAR.xml:S1:12278:11	combin	NN	O	O
with	TAFINLAR.xml:S1:12290:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:12295:10	trametinib	JJ	O	O
2	TAFINLAR.xml:S1:12306:1	2	CD	O	O
mg	TAFINLAR.xml:S1:12308:2	mg	NN	O	O
orally	TAFINLAR.xml:S1:12311:6	oral	RB	O	O
once	TAFINLAR.xml:S1:12318:4	onc	RB	O	O
daily	TAFINLAR.xml:S1:12323:5	daili	JJ	O	O
(	TAFINLAR.xml:S1:12329:1	(	(	O	O
n	TAFINLAR.xml:S1:12330:1	n	JJ	O	O
55	TAFINLAR.xml:S1:12334:2	55	CD	O	O
)	TAFINLAR.xml:S1:12336:1	)	)	O	O
,	TAFINLAR.xml:S1:12337:1	,	,	O	O
TAFINLAR	TAFINLAR.xml:S1:12339:8	tafinlar	NNP	O	O
150	TAFINLAR.xml:S1:12348:3	150	CD	O	O
mg	TAFINLAR.xml:S1:12352:2	mg	NN	O	O
orally	TAFINLAR.xml:S1:12355:6	oral	RB	O	O
twice	TAFINLAR.xml:S1:12362:5	twice	JJ	O	O
daily	TAFINLAR.xml:S1:12368:5	daili	RB	O	O
in	TAFINLAR.xml:S1:12374:2	in	IN	O	O
combination	TAFINLAR.xml:S1:12377:11	combin	NN	O	O
with	TAFINLAR.xml:S1:12389:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:12394:10	trametinib	JJ	O	O
1	TAFINLAR.xml:S1:12405:1	1	CD	O	O
mg	TAFINLAR.xml:S1:12407:2	mg	NN	O	O
once	TAFINLAR.xml:S1:12410:4	onc	RB	O	O
daily	TAFINLAR.xml:S1:12415:5	daili	JJ	O	O
(	TAFINLAR.xml:S1:12421:1	(	(	O	O
n	TAFINLAR.xml:S1:12422:1	n	JJ	O	O
54	TAFINLAR.xml:S1:12426:2	54	CD	O	O
)	TAFINLAR.xml:S1:12428:1	)	)	O	O
,	TAFINLAR.xml:S1:12429:1	,	,	O	O
and	TAFINLAR.xml:S1:12431:3	and	CC	O	O
TAFINLAR	TAFINLAR.xml:S1:12435:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S1:12444:2	as	IN	O	O
a	TAFINLAR.xml:S1:12447:1	a	DT	O	O
single	TAFINLAR.xml:S1:12449:6	singl	JJ	O	O
agent	TAFINLAR.xml:S1:12456:5	agent	NN	O	O
150	TAFINLAR.xml:S1:12462:3	150	CD	O	O
mg	TAFINLAR.xml:S1:12466:2	mg	NN	O	O
orally	TAFINLAR.xml:S1:12469:6	oral	RB	O	O
twice	TAFINLAR.xml:S1:12476:5	twice	JJ	O	O
daily	TAFINLAR.xml:S1:12482:5	daili	RB	O	O
(	TAFINLAR.xml:S1:12488:1	(	(	O	O
n	TAFINLAR.xml:S1:12489:1	n	JJ	O	O
53	TAFINLAR.xml:S1:12493:2	53	CD	O	O
)	TAFINLAR.xml:S1:12495:1	)	)	O	O
[	TAFINLAR.xml:S1:12498:1	[	NN	O	O
see	TAFINLAR.xml:S1:12499:3	see	VBP	O	O
Clinical	TAFINLAR.xml:S1:12503:8	clinic	JJ	O	O
Studies	TAFINLAR.xml:S1:12512:7	studi	NNP	O	O
(	TAFINLAR.xml:S1:12520:1	(	(	O	O
14.2	TAFINLAR.xml:S1:12521:4	14.2	CD	O	O
)]	TAFINLAR.xml:S1:12525:2	)]	NN	O	O
.	TAFINLAR.xml:S1:12529:1	.	.	O	O

Patients	TAFINLAR.xml:S1:12531:8	patient	NNS	O	O
with	TAFINLAR.xml:S1:12540:4	with	IN	O	O
abnormal	TAFINLAR.xml:S1:12545:8	abnorm	JJ	O	O
LVEF	TAFINLAR.xml:S1:12554:4	lvef	NNP	O	O
,	TAFINLAR.xml:S1:12558:1	,	,	O	O
history	TAFINLAR.xml:S1:12560:7	histori	NN	O	O
of	TAFINLAR.xml:S1:12568:2	of	IN	O	O
acute	TAFINLAR.xml:S1:12571:5	acut	JJ	O	O
coronary	TAFINLAR.xml:S1:12577:8	coronari	JJ	O	O
syndrome	TAFINLAR.xml:S1:12586:8	syndrom	NN	O	O
within	TAFINLAR.xml:S1:12595:6	within	IN	O	O
6	TAFINLAR.xml:S1:12602:1	6	CD	O	O
months	TAFINLAR.xml:S1:12604:6	month	NNS	O	O
,	TAFINLAR.xml:S1:12610:1	,	,	O	O
current	TAFINLAR.xml:S1:12612:7	current	JJ	O	O
evidence	TAFINLAR.xml:S1:12620:8	evid	NN	O	O
of	TAFINLAR.xml:S1:12629:2	of	IN	O	O
Class	TAFINLAR.xml:S1:12632:5	class	NNP	O	O
II	TAFINLAR.xml:S1:12638:2	II	NNP	O	O
or	TAFINLAR.xml:S1:12641:2	or	CC	O	O
greater	TAFINLAR.xml:S1:12644:7	greater	JJR	O	O
congestive	TAFINLAR.xml:S1:12652:10	congest	JJ	O	B-AdverseReaction
heart	TAFINLAR.xml:S1:12663:5	heart	NN	O	I-AdverseReaction
failure	TAFINLAR.xml:S1:12669:7	failur	NN	O	I-AdverseReaction
(	TAFINLAR.xml:S1:12677:1	(	(	O	O
New	TAFINLAR.xml:S1:12678:3	new	NNP	O	O
York	TAFINLAR.xml:S1:12682:4	york	NNP	O	O
Heart	TAFINLAR.xml:S1:12687:5	heart	NNP	O	O
Association	TAFINLAR.xml:S1:12693:11	associ	NNP	O	O
)	TAFINLAR.xml:S1:12704:1	)	)	O	O
,	TAFINLAR.xml:S1:12705:1	,	,	O	O
history	TAFINLAR.xml:S1:12707:7	histori	NN	O	O
RVO	TAFINLAR.xml:S1:12715:3	rvo	NNP	O	O
or	TAFINLAR.xml:S1:12719:2	or	CC	O	O
RPED	TAFINLAR.xml:S1:12722:4	rped	NNP	O	O
,	TAFINLAR.xml:S1:12726:1	,	,	O	O
QTc	TAFINLAR.xml:S1:12728:3	qtc	NNP	O	B-AdverseReaction
interval	TAFINLAR.xml:S1:12732:8	interv	VBZ	O	I-AdverseReaction
480	TAFINLAR.xml:S1:12743:3	480	CD	O	O
msec	TAFINLAR.xml:S1:12747:4	msec	NN	O	O
,	TAFINLAR.xml:S1:12751:1	,	,	O	O
treatment	TAFINLAR.xml:S1:12753:9	treatment	NN	O	O
refractory	TAFINLAR.xml:S1:12763:10	refractori	NN	O	O
hypertension	TAFINLAR.xml:S1:12774:12	hypertens	NN	O	O
,	TAFINLAR.xml:S1:12786:1	,	,	O	O
uncontrolled	TAFINLAR.xml:S1:12788:12	uncontrol	JJ	O	B-AdverseReaction
arrhythmias	TAFINLAR.xml:S1:12801:11	arrhythmia	NN	O	I-AdverseReaction
,	TAFINLAR.xml:S1:12812:1	,	,	O	O
history	TAFINLAR.xml:S1:12814:7	histori	NN	O	O
of	TAFINLAR.xml:S1:12822:2	of	IN	O	O
pneumonitis	TAFINLAR.xml:S1:12825:11	pneumon	NN	O	O
or	TAFINLAR.xml:S1:12837:2	or	CC	O	O
interstitial	TAFINLAR.xml:S1:12840:12	interstiti	JJ	O	O
lung	TAFINLAR.xml:S1:12853:4	lung	NN	O	O
disease	TAFINLAR.xml:S1:12858:7	diseas	NN	O	O
,	TAFINLAR.xml:S1:12865:1	,	,	O	O
or	TAFINLAR.xml:S1:12867:2	or	CC	O	O
a	TAFINLAR.xml:S1:12870:1	a	DT	O	O
known	TAFINLAR.xml:S1:12872:5	known	JJ	O	O
history	TAFINLAR.xml:S1:12878:7	histori	NN	O	O
of	TAFINLAR.xml:S1:12886:2	of	IN	O	O
G6PD	TAFINLAR.xml:S1:12889:4	g6pd	NNP	O	O
deficiency	TAFINLAR.xml:S1:12894:10	defici	NN	O	O
were	TAFINLAR.xml:S1:12905:4	were	VBD	O	O
excluded	TAFINLAR.xml:S1:12910:8	exclud	VBN	O	O
.	TAFINLAR.xml:S1:12918:1	.	.	O	O

The	TAFINLAR.xml:S1:12920:3	the	DT	O	O
median	TAFINLAR.xml:S1:12924:6	median	JJ	O	O
duration	TAFINLAR.xml:S1:12931:8	durat	NN	O	O
of	TAFINLAR.xml:S1:12940:2	of	IN	O	O
treatment	TAFINLAR.xml:S1:12943:9	treatment	NN	O	O
was	TAFINLAR.xml:S1:12953:3	wa	VBD	O	O
10.9	TAFINLAR.xml:S1:12957:4	10.9	CD	O	O
months	TAFINLAR.xml:S1:12962:6	month	NNS	O	O
for	TAFINLAR.xml:S1:12969:3	for	IN	O	O
both	TAFINLAR.xml:S1:12973:4	both	DT	O	O
TAFINLAR	TAFINLAR.xml:S1:12978:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S1:12987:3	and	CC	O	O
trametinib	TAFINLAR.xml:S1:12991:10	trametinib	NN	O	B-AdverseReaction
(	TAFINLAR.xml:S1:13002:1	(	(	O	O
2	TAFINLAR.xml:S1:13003:1	2	CD	O	O
-	TAFINLAR.xml:S1:13004:1	-	:	O	O
mg	TAFINLAR.xml:S1:13005:2	mg	NN	O	O
orally	TAFINLAR.xml:S1:13008:6	oral	RB	O	O
once	TAFINLAR.xml:S1:13015:4	onc	RB	O	O
-	TAFINLAR.xml:S1:13019:1	-	:	O	O
daily	TAFINLAR.xml:S1:13020:5	daili	JJ	O	O
treatment	TAFINLAR.xml:S1:13026:9	treatment	NN	O	O
group	TAFINLAR.xml:S1:13036:5	group	NN	O	O
)	TAFINLAR.xml:S1:13041:1	)	)	O	O
when	TAFINLAR.xml:S1:13043:4	when	WRB	O	O
used	TAFINLAR.xml:S1:13048:4	use	VBN	O	O
in	TAFINLAR.xml:S1:13053:2	in	IN	O	O
combination	TAFINLAR.xml:S1:13056:11	combin	NN	O	O
,	TAFINLAR.xml:S1:13067:1	,	,	O	O
10.6	TAFINLAR.xml:S1:13069:4	10.6	CD	O	O
months	TAFINLAR.xml:S1:13074:6	month	NNS	O	O
for	TAFINLAR.xml:S1:13081:3	for	IN	O	O
both	TAFINLAR.xml:S1:13085:4	both	DT	O	O
TAFINLAR	TAFINLAR.xml:S1:13090:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S1:13099:3	and	CC	O	O
trametinib	TAFINLAR.xml:S1:13103:10	trametinib	NN	O	O
(	TAFINLAR.xml:S1:13114:1	(	(	O	O
1	TAFINLAR.xml:S1:13115:1	1	CD	O	O
-	TAFINLAR.xml:S1:13116:1	-	:	O	O
mg	TAFINLAR.xml:S1:13117:2	mg	NN	O	O
orally	TAFINLAR.xml:S1:13120:6	oral	RB	O	O
once	TAFINLAR.xml:S1:13127:4	onc	RB	O	O
-	TAFINLAR.xml:S1:13131:1	-	:	O	O
daily	TAFINLAR.xml:S1:13132:5	daili	JJ	O	O
treatment	TAFINLAR.xml:S1:13138:9	treatment	NN	O	O
group	TAFINLAR.xml:S1:13148:5	group	NN	O	O
)	TAFINLAR.xml:S1:13153:1	)	)	O	O
when	TAFINLAR.xml:S1:13155:4	when	WRB	O	O
used	TAFINLAR.xml:S1:13160:4	use	VBN	O	O
in	TAFINLAR.xml:S1:13165:2	in	IN	O	O
combination	TAFINLAR.xml:S1:13168:11	combin	NN	O	O
,	TAFINLAR.xml:S1:13179:1	,	,	O	O
and	TAFINLAR.xml:S1:13181:3	and	CC	O	O
6.1	TAFINLAR.xml:S1:13185:3	6.1	CD	O	O
months	TAFINLAR.xml:S1:13189:6	month	NNS	O	O
for	TAFINLAR.xml:S1:13196:3	for	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:13200:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S1:13209:2	as	IN	O	O
a	TAFINLAR.xml:S1:13212:1	a	DT	O	O
single	TAFINLAR.xml:S1:13214:6	singl	JJ	O	O
agent	TAFINLAR.xml:S1:13221:5	agent	NN	O	O
.	TAFINLAR.xml:S1:13226:1	.	.	O	O

In	TAFINLAR.xml:S1:13232:2	In	IN	O	O
Trial	TAFINLAR.xml:S1:13235:5	trial	NNP	O	O
2	TAFINLAR.xml:S1:13241:1	2	CD	O	O
,	TAFINLAR.xml:S1:13242:1	,	,	O	O
13%	TAFINLAR.xml:S1:13244:3	13%	CD	O	O
of	TAFINLAR.xml:S1:13248:2	of	IN	O	O
patients	TAFINLAR.xml:S1:13251:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S1:13260:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S1:13270:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S1:13279:2	in	IN	O	O
combination	TAFINLAR.xml:S1:13282:11	combin	NN	O	O
with	TAFINLAR.xml:S1:13294:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:13299:10	trametinib	NN	O	O
experienced	TAFINLAR.xml:S1:13310:11	experienc	JJ	O	O
adverse	TAFINLAR.xml:S1:13322:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S1:13330:9	reaction	NNS	O	O
resulting	TAFINLAR.xml:S1:13340:9	result	VBG	O	O
in	TAFINLAR.xml:S1:13350:2	in	IN	O	O
permanent	TAFINLAR.xml:S1:13353:9	perman	JJ	O	O
discontinuation	TAFINLAR.xml:S1:13363:15	discontinu	NN	O	O
of	TAFINLAR.xml:S1:13379:2	of	IN	O	O
trial	TAFINLAR.xml:S1:13382:5	trial	NN	O	O
medication	TAFINLAR.xml:S1:13388:10	medic	NN	O	O
(	TAFINLAR.xml:S1:13398:1	(	(	O	O
s	TAFINLAR.xml:S1:13399:1	s	NN	O	O
)	TAFINLAR.xml:S1:13400:1	)	)	O	O
.	TAFINLAR.xml:S1:13401:1	.	.	O	O

The	TAFINLAR.xml:S1:13403:3	the	DT	O	O
most	TAFINLAR.xml:S1:13407:4	most	RBS	O	O
common	TAFINLAR.xml:S1:13412:6	common	JJ	O	O
adverse	TAFINLAR.xml:S1:13419:7	advers	JJ	O	O
reaction	TAFINLAR.xml:S1:13427:8	reaction	NN	O	O
resulting	TAFINLAR.xml:S1:13436:9	result	VBG	O	O
in	TAFINLAR.xml:S1:13446:2	in	IN	O	O
permanent	TAFINLAR.xml:S1:13449:9	perman	JJ	O	O
discontinuation	TAFINLAR.xml:S1:13459:15	discontinu	NN	O	O
was	TAFINLAR.xml:S1:13475:3	wa	VBD	O	O
pyrexia	TAFINLAR.xml:S1:13479:7	pyrexia	VBN	B-AdverseReaction	B-AdverseReaction
(	TAFINLAR.xml:S1:13487:1	(	(	O	O
4%	TAFINLAR.xml:S1:13488:2	4%	CD	O	O
)	TAFINLAR.xml:S1:13490:1	)	)	O	O
.	TAFINLAR.xml:S1:13491:1	.	.	O	O

Adverse	TAFINLAR.xml:S1:13493:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S1:13501:9	reaction	NNS	O	O
led	TAFINLAR.xml:S1:13511:3	led	VBD	O	O
to	TAFINLAR.xml:S1:13515:2	to	TO	O	O
dose	TAFINLAR.xml:S1:13518:4	dose	VB	O	O
reductions	TAFINLAR.xml:S1:13523:10	reduct	NNS	O	O
in	TAFINLAR.xml:S1:13534:2	in	IN	O	O
49%	TAFINLAR.xml:S1:13537:3	49%	CD	O	O
and	TAFINLAR.xml:S1:13541:3	and	CC	O	O
dose	TAFINLAR.xml:S1:13545:4	dose	JJ	O	O
interruptions	TAFINLAR.xml:S1:13550:13	interrupt	NNS	O	O
in	TAFINLAR.xml:S1:13564:2	in	IN	O	O
67%	TAFINLAR.xml:S1:13567:3	67%	CD	O	O
of	TAFINLAR.xml:S1:13571:2	of	IN	O	O
patients	TAFINLAR.xml:S1:13574:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:13583:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:13591:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:13596:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S1:13605:2	in	IN	O	O
combination	TAFINLAR.xml:S1:13608:11	combin	NN	O	O
with	TAFINLAR.xml:S1:13620:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:13625:10	trametinib	NN	O	O
.	TAFINLAR.xml:S1:13635:1	.	.	O	O

Pyrexia	TAFINLAR.xml:S1:13637:7	pyrexia	NNP	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:13644:1	,	,	O	O
chills	TAFINLAR.xml:S1:13646:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:13652:1	,	,	O	O
and	TAFINLAR.xml:S1:13654:3	and	CC	O	O
nausea	TAFINLAR.xml:S1:13658:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
were	TAFINLAR.xml:S1:13665:4	were	VBD	O	O
the	TAFINLAR.xml:S1:13670:3	the	DT	O	O
most	TAFINLAR.xml:S1:13674:4	most	RBS	O	O
common	TAFINLAR.xml:S1:13679:6	common	JJ	O	O
reasons	TAFINLAR.xml:S1:13686:7	reason	NNS	O	O
cited	TAFINLAR.xml:S1:13694:5	cite	VBD	O	O
for	TAFINLAR.xml:S1:13700:3	for	IN	O	O
dose	TAFINLAR.xml:S1:13704:4	dose	NN	O	O
reductions	TAFINLAR.xml:S1:13709:10	reduct	NNS	O	O
and	TAFINLAR.xml:S1:13720:3	and	CC	O	O
pyrexia	TAFINLAR.xml:S1:13724:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:13731:1	,	,	O	O
chills	TAFINLAR.xml:S1:13733:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:13739:1	,	,	O	O
and	TAFINLAR.xml:S1:13741:3	and	CC	O	O
decreased	TAFINLAR.xml:S1:13745:9	decreas	JJ	B-AdverseReaction	B-AdverseReaction
ejection	TAFINLAR.xml:S1:13755:8	eject	NN	I-AdverseReaction	I-AdverseReaction
fraction	TAFINLAR.xml:S1:13764:8	fraction	NN	I-AdverseReaction	I-AdverseReaction
were	TAFINLAR.xml:S1:13773:4	were	VBD	O	O
the	TAFINLAR.xml:S1:13778:3	the	DT	O	O
most	TAFINLAR.xml:S1:13782:4	most	RBS	O	O
common	TAFINLAR.xml:S1:13787:6	common	JJ	O	O
reasons	TAFINLAR.xml:S1:13794:7	reason	NNS	O	O
cited	TAFINLAR.xml:S1:13802:5	cite	VBD	O	O
for	TAFINLAR.xml:S1:13808:3	for	IN	O	O
dose	TAFINLAR.xml:S1:13812:4	dose	JJ	O	O
interruptions	TAFINLAR.xml:S1:13817:13	interrupt	NNS	O	O
of	TAFINLAR.xml:S1:13831:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:13834:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S1:13843:3	and	CC	O	O
trametinib	TAFINLAR.xml:S1:13847:10	trametinib	NN	O	O
when	TAFINLAR.xml:S1:13858:4	when	WRB	O	O
used	TAFINLAR.xml:S1:13863:4	use	VBN	O	O
in	TAFINLAR.xml:S1:13868:2	in	IN	O	O
combination	TAFINLAR.xml:S1:13871:11	combin	NN	O	O
.	TAFINLAR.xml:S1:13882:1	.	.	O	O

Table	TAFINLAR.xml:S1:13888:5	tabl	JJ	O	O
5	TAFINLAR.xml:S1:13894:1	5	CD	O	O
.	TAFINLAR.xml:S1:13895:1	.	.	O	O

Common	TAFINLAR.xml:S1:13897:6	common	JJ	O	O
Adverse	TAFINLAR.xml:S1:13904:7	advers	NNP	O	O
Drug	TAFINLAR.xml:S1:13912:4	drug	NNP	O	O
Reactions	TAFINLAR.xml:S1:13917:9	reaction	NNP	O	O
Occurring	TAFINLAR.xml:S1:13927:9	occur	NNP	O	O
in	TAFINLAR.xml:S1:13937:2	in	IN	O	O
10%	TAFINLAR.xml:S1:13942:3	10%	CD	O	O
at	TAFINLAR.xml:S1:13946:2	at	IN	O	O
(	TAFINLAR.xml:S1:13949:1	(	(	O	O
All	TAFINLAR.xml:S1:13950:3	all	NNP	O	O
Grades	TAFINLAR.xml:S1:13954:6	grade	NNP	O	O
)	TAFINLAR.xml:S1:13960:1	)	)	O	O
or	TAFINLAR.xml:S1:13962:2	or	CC	O	O
5%	TAFINLAR.xml:S1:13967:2	5%	CD	O	O
(	TAFINLAR.xml:S1:13970:1	(	(	O	O
Grades	TAFINLAR.xml:S1:13971:6	grade	NNP	O	O
3	TAFINLAR.xml:S1:13978:1	3	CD	O	O
or	TAFINLAR.xml:S1:13980:2	or	CC	O	O
4	TAFINLAR.xml:S1:13983:1	4	CD	O	O
)	TAFINLAR.xml:S1:13984:1	)	)	O	O
of	TAFINLAR.xml:S1:13986:2	of	IN	O	O
Patients	TAFINLAR.xml:S1:13989:8	patient	NNS	O	O
Treated	TAFINLAR.xml:S1:13998:7	treat	VBN	O	O
With	TAFINLAR.xml:S1:14006:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:14011:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S1:14020:2	in	IN	O	O
Combination	TAFINLAR.xml:S1:14023:11	combin	NNP	O	O
With	TAFINLAR.xml:S1:14035:4	with	IN	O	O
Trametinib	TAFINLAR.xml:S1:14040:10	trametinib	NNP	O	O
in	TAFINLAR.xml:S1:14051:2	in	IN	O	O
Trial	TAFINLAR.xml:S1:14054:5	trial	NNP	O	O
2	TAFINLAR.xml:S1:14060:1	2	CD	O	O

Adverse	TAFINLAR.xml:S1:14065:7	advers	JJ	O	O
Reactions	TAFINLAR.xml:S1:14073:9	reaction	NNP	O	O
TAFINLAR	TAFINLAR.xml:S1:14092:8	tafinlar	NNP	O	O
plus	TAFINLAR.xml:S1:14101:4	plu	CC	O	O
Trametinib	TAFINLAR.xml:S1:14106:10	trametinib	NNP	O	O
2	TAFINLAR.xml:S1:14117:1	2	CD	O	O
mg	TAFINLAR.xml:S1:14119:2	mg	NN	O	O
N	TAFINLAR.xml:S1:14123:1	N	NNP	O	O
55	TAFINLAR.xml:S1:14127:2	55	CD	O	O
TAFINLAR	TAFINLAR.xml:S1:14133:8	tafinlar	NNP	O	O
plus	TAFINLAR.xml:S1:14142:4	plu	CC	O	O
Trametinib	TAFINLAR.xml:S1:14147:10	trametinib	NNP	O	O
1	TAFINLAR.xml:S1:14158:1	1	CD	O	O
mg	TAFINLAR.xml:S1:14160:2	mg	NN	O	O
N	TAFINLAR.xml:S1:14164:1	N	NNP	O	O
54	TAFINLAR.xml:S1:14168:2	54	CD	O	O
TAFINLAR	TAFINLAR.xml:S1:14174:8	tafinlar	NNP	O	O
N	TAFINLAR.xml:S1:14184:1	N	NNP	O	O
53	TAFINLAR.xml:S1:14188:2	53	CD	O	O

All	TAFINLAR.xml:S1:14197:3	all	DT	O	O
Gradesa	TAFINLAR.xml:S1:14201:7	gradesa	NNP	O	O
Grades	TAFINLAR.xml:S1:14224:6	grade	NNP	O	O
3	TAFINLAR.xml:S1:14232:1	3	CD	O	O
and	TAFINLAR.xml:S1:14234:3	and	CC	O	O
4	TAFINLAR.xml:S1:14238:1	4	CD	O	O
All	TAFINLAR.xml:S1:14243:3	all	DT	O	O
Gradesa	TAFINLAR.xml:S1:14247:7	gradesa	NNP	O	O
Grades	TAFINLAR.xml:S1:14258:6	grade	NNP	O	O
3	TAFINLAR.xml:S1:14266:1	3	CD	O	O
and	TAFINLAR.xml:S1:14268:3	and	CC	O	O
4	TAFINLAR.xml:S1:14272:1	4	CD	O	O
All	TAFINLAR.xml:S1:14277:3	all	DT	O	O
Gradesa	TAFINLAR.xml:S1:14282:7	gradesa	NNP	O	O
Grades	TAFINLAR.xml:S1:14293:6	grade	NNP	O	O
3	TAFINLAR.xml:S1:14301:1	3	CD	O	O
and	TAFINLAR.xml:S1:14303:3	and	CC	O	O
4	TAFINLAR.xml:S1:14307:1	4	CD	O	O

General	TAFINLAR.xml:S1:14315:7	gener	NNP	O	O
disorders	TAFINLAR.xml:S1:14323:9	disord	NNS	O	O
and	TAFINLAR.xml:S1:14333:3	and	CC	O	O
administrative	TAFINLAR.xml:S1:14337:14	administr	JJ	O	O
site	TAFINLAR.xml:S1:14352:4	site	NN	O	O
conditions	TAFINLAR.xml:S1:14357:10	condit	NNS	O	O

Pyrexia	TAFINLAR.xml:S1:14400:7	pyrexia	NN	B-AdverseReaction	O

71	TAFINLAR.xml:S1:14483:2	71	CD	O	O
5	TAFINLAR.xml:S1:14502:1	5	CD	O	O
69	TAFINLAR.xml:S1:14516:2	69	CD	O	O
9	TAFINLAR.xml:S1:14535:1	9	CD	O	O
26	TAFINLAR.xml:S1:14549:2	26	CD	O	O
0	TAFINLAR.xml:S1:14560:1	0	CD	O	O

Chills	TAFINLAR.xml:S1:14599:6	chill	NNS	B-AdverseReaction	O

58	TAFINLAR.xml:S1:14682:2	58	CD	O	O
2	TAFINLAR.xml:S1:14701:1	2	CD	O	O
50	TAFINLAR.xml:S1:14715:2	50	CD	O	O
2	TAFINLAR.xml:S1:14734:1	2	CD	O	O
17	TAFINLAR.xml:S1:14748:2	17	CD	O	O
0	TAFINLAR.xml:S1:14759:1	0	CD	O	O

Fatigue	TAFINLAR.xml:S1:14798:7	fatigu	NN	B-AdverseReaction	B-AdverseReaction

53	TAFINLAR.xml:S1:14881:2	53	CD	O	O
4	TAFINLAR.xml:S1:14900:1	4	CD	O	O
57	TAFINLAR.xml:S1:14914:2	57	CD	O	O
2	TAFINLAR.xml:S1:14933:1	2	CD	O	O
40	TAFINLAR.xml:S1:14947:2	40	CD	O	O
6	TAFINLAR.xml:S1:14958:1	6	CD	O	O

Edema	TAFINLAR.xml:S1:14997:5	edema	NNP	B-AdverseReaction	B-AdverseReaction
peripheral	TAFINLAR.xml:S1:15003:10	peripher	NN	I-AdverseReaction	I-AdverseReaction
b	TAFINLAR.xml:S1:15015:1	b	NN	O	I-AdverseReaction

31	TAFINLAR.xml:S1:15080:2	31	CD	O	O
0	TAFINLAR.xml:S1:15099:1	0	CD	O	O
28	TAFINLAR.xml:S1:15113:2	28	CD	O	O
0	TAFINLAR.xml:S1:15132:1	0	CD	O	O
17	TAFINLAR.xml:S1:15146:2	17	CD	O	O
0	TAFINLAR.xml:S1:15157:1	0	CD	O	O

Skin	TAFINLAR.xml:S1:15170:4	skin	NNP	O	O
and	TAFINLAR.xml:S1:15175:3	and	CC	O	O
subcutaneous	TAFINLAR.xml:S1:15179:12	subcutan	JJ	O	O
tissue	TAFINLAR.xml:S1:15192:6	tissu	NN	O	O
disorders	TAFINLAR.xml:S1:15199:9	disord	NNS	O	O

Rash	TAFINLAR.xml:S1:15241:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
c	TAFINLAR.xml:S1:15247:1	c	NN	O	O

45	TAFINLAR.xml:S1:15324:2	45	CD	O	O
0	TAFINLAR.xml:S1:15343:1	0	CD	O	O
43	TAFINLAR.xml:S1:15357:2	43	CD	O	O
2	TAFINLAR.xml:S1:15376:1	2	CD	O	O
53	TAFINLAR.xml:S1:15390:2	53	CD	O	O
0	TAFINLAR.xml:S1:15401:1	0	CD	O	O

Night	TAFINLAR.xml:S1:15440:5	night	NNP	B-AdverseReaction	O
Sweats	TAFINLAR.xml:S1:15446:6	sweat	NNP	I-AdverseReaction	O

24	TAFINLAR.xml:S1:15523:2	24	CD	O	O
0	TAFINLAR.xml:S1:15542:1	0	CD	O	O
15	TAFINLAR.xml:S1:15556:2	15	CD	O	O
0	TAFINLAR.xml:S1:15575:1	0	CD	O	O
6	TAFINLAR.xml:S1:15589:1	6	CD	O	O
0	TAFINLAR.xml:S1:15600:1	0	CD	O	O

Dry	TAFINLAR.xml:S1:15639:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
skin	TAFINLAR.xml:S1:15643:4	skin	NN	I-AdverseReaction	I-AdverseReaction

18	TAFINLAR.xml:S1:15722:2	18	CD	O	O
0	TAFINLAR.xml:S1:15741:1	0	CD	O	O
9	TAFINLAR.xml:S1:15755:1	9	CD	O	O
0	TAFINLAR.xml:S1:15774:1	0	CD	O	O
6	TAFINLAR.xml:S1:15788:1	6	CD	O	O
0	TAFINLAR.xml:S1:15799:1	0	CD	O	O

Dermatitis	TAFINLAR.xml:S1:15838:10	dermat	NN	B-AdverseReaction	B-AdverseReaction
acneiform	TAFINLAR.xml:S1:15849:9	acneiform	NN	I-AdverseReaction	I-AdverseReaction

16	TAFINLAR.xml:S1:15921:2	16	CD	O	O
0	TAFINLAR.xml:S1:15940:1	0	CD	O	O
11	TAFINLAR.xml:S1:15954:2	11	CD	O	O
0	TAFINLAR.xml:S1:15973:1	0	CD	O	O
4	TAFINLAR.xml:S1:15987:1	4	CD	O	O
0	TAFINLAR.xml:S1:15998:1	0	CD	O	O

Actinic	TAFINLAR.xml:S1:16037:7	actin	JJ	B-AdverseReaction	O
keratosis	TAFINLAR.xml:S1:16045:9	keratosi	NN	I-AdverseReaction	O

15	TAFINLAR.xml:S1:16120:2	15	CD	O	O
0	TAFINLAR.xml:S1:16139:1	0	CD	O	O
7	TAFINLAR.xml:S1:16153:1	7	CD	O	O
0	TAFINLAR.xml:S1:16172:1	0	CD	O	O
9	TAFINLAR.xml:S1:16186:1	9	CD	O	O
0	TAFINLAR.xml:S1:16197:1	0	CD	O	O

Erythema	TAFINLAR.xml:S1:16236:8	erythema	NN	B-AdverseReaction	O

15	TAFINLAR.xml:S1:16319:2	15	CD	O	O
0	TAFINLAR.xml:S1:16338:1	0	CD	O	O
6	TAFINLAR.xml:S1:16352:1	6	CD	O	O
0	TAFINLAR.xml:S1:16371:1	0	CD	O	O
2	TAFINLAR.xml:S1:16385:1	2	CD	O	O
0	TAFINLAR.xml:S1:16396:1	0	CD	O	O

Pruritus	TAFINLAR.xml:S1:16435:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction

11	TAFINLAR.xml:S1:16518:2	11	CD	O	O
0	TAFINLAR.xml:S1:16537:1	0	CD	O	O
11	TAFINLAR.xml:S1:16551:2	11	CD	O	O
0	TAFINLAR.xml:S1:16570:1	0	CD	O	O
13	TAFINLAR.xml:S1:16584:2	13	CD	O	O
0	TAFINLAR.xml:S1:16595:1	0	CD	O	O

Gastrointestinal	TAFINLAR.xml:S1:16608:16	gastrointestin	JJ	O	O
disorders	TAFINLAR.xml:S1:16625:9	disord	NNS	O	O

Nausea	TAFINLAR.xml:S1:16667:6	nausea	NN	B-AdverseReaction	B-AdverseReaction

44	TAFINLAR.xml:S1:16750:2	44	CD	O	O
2	TAFINLAR.xml:S1:16769:1	2	CD	O	O
46	TAFINLAR.xml:S1:16783:2	46	CD	O	O
6	TAFINLAR.xml:S1:16802:1	6	CD	O	O
21	TAFINLAR.xml:S1:16816:2	21	CD	O	O
0	TAFINLAR.xml:S1:16827:1	0	CD	O	O

Vomiting	TAFINLAR.xml:S1:16866:8	vomit	VBG	B-AdverseReaction	O

40	TAFINLAR.xml:S1:16949:2	40	CD	O	O
2	TAFINLAR.xml:S1:16968:1	2	CD	O	O
43	TAFINLAR.xml:S1:16982:2	43	CD	O	O
4	TAFINLAR.xml:S1:17001:1	4	CD	O	O
15	TAFINLAR.xml:S1:17015:2	15	CD	O	O
0	TAFINLAR.xml:S1:17026:1	0	CD	O	O

Diarrhea	TAFINLAR.xml:S1:17065:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction

36	TAFINLAR.xml:S1:17148:2	36	CD	O	O
2	TAFINLAR.xml:S1:17167:1	2	CD	O	O
26	TAFINLAR.xml:S1:17181:2	26	CD	O	O
0	TAFINLAR.xml:S1:17200:1	0	CD	O	O
28	TAFINLAR.xml:S1:17214:2	28	CD	O	O
0	TAFINLAR.xml:S1:17225:1	0	CD	O	O

Abdominal	TAFINLAR.xml:S1:17264:9	abdomin	NNP	B-AdverseReaction	O
pain	TAFINLAR.xml:S1:17274:4	pain	NN	I-AdverseReaction	O
d	TAFINLAR.xml:S1:17280:1	d	NN	O	O

33	TAFINLAR.xml:S1:17347:2	33	CD	O	O
2	TAFINLAR.xml:S1:17366:1	2	CD	O	O
24	TAFINLAR.xml:S1:17380:2	24	CD	O	O
2	TAFINLAR.xml:S1:17399:1	2	CD	O	O
21	TAFINLAR.xml:S1:17413:2	21	CD	O	O
2	TAFINLAR.xml:S1:17424:1	2	CD	O	O

Constipation	TAFINLAR.xml:S1:17463:12	constip	NN	B-AdverseReaction	B-AdverseReaction

22	TAFINLAR.xml:S1:17546:2	22	CD	O	O
0	TAFINLAR.xml:S1:17565:1	0	CD	O	O
17	TAFINLAR.xml:S1:17579:2	17	CD	O	O
2	TAFINLAR.xml:S1:17598:1	2	CD	O	O
11	TAFINLAR.xml:S1:17612:2	11	CD	O	O
0	TAFINLAR.xml:S1:17623:1	0	CD	O	O

Dry	TAFINLAR.xml:S1:17662:3	dri	NNP	B-AdverseReaction	B-AdverseReaction
mouth	TAFINLAR.xml:S1:17666:5	mouth	NN	I-AdverseReaction	I-AdverseReaction

11	TAFINLAR.xml:S1:17745:2	11	CD	O	O
0	TAFINLAR.xml:S1:17764:1	0	CD	O	O
11	TAFINLAR.xml:S1:17778:2	11	CD	O	O
0	TAFINLAR.xml:S1:17797:1	0	CD	O	O
6	TAFINLAR.xml:S1:17811:1	6	CD	O	O
0	TAFINLAR.xml:S1:17822:1	0	CD	O	O

Nervous	TAFINLAR.xml:S1:17835:7	nervou	JJ	O	O
system	TAFINLAR.xml:S1:17843:6	system	NN	O	O
disorders	TAFINLAR.xml:S1:17850:9	disord	NNS	O	O

Headache	TAFINLAR.xml:S1:17892:8	headach	NN	B-AdverseReaction	B-AdverseReaction

29	TAFINLAR.xml:S1:17975:2	29	CD	O	O
0	TAFINLAR.xml:S1:17994:1	0	CD	O	O
37	TAFINLAR.xml:S1:18008:2	37	CD	O	O
2	TAFINLAR.xml:S1:18027:1	2	CD	O	O
28	TAFINLAR.xml:S1:18041:2	28	CD	O	O
0	TAFINLAR.xml:S1:18052:1	0	CD	O	O

Dizziness	TAFINLAR.xml:S1:18091:9	dizzi	NN	B-AdverseReaction	O

16	TAFINLAR.xml:S1:18174:2	16	CD	O	O
0	TAFINLAR.xml:S1:18193:1	0	CD	O	O
13	TAFINLAR.xml:S1:18207:2	13	CD	O	O
0	TAFINLAR.xml:S1:18226:1	0	CD	O	O
9	TAFINLAR.xml:S1:18240:1	9	CD	O	O
0	TAFINLAR.xml:S1:18251:1	0	CD	O	O

Respiratory	TAFINLAR.xml:S1:18264:11	respiratori	NNP	O	O
,	TAFINLAR.xml:S1:18275:1	,	,	O	O
thoracic	TAFINLAR.xml:S1:18277:8	thorac	NN	O	O
,	TAFINLAR.xml:S1:18285:1	,	,	O	O
and	TAFINLAR.xml:S1:18287:3	and	CC	O	O
mediastinal	TAFINLAR.xml:S1:18291:11	mediastin	JJ	O	O
disorders	TAFINLAR.xml:S1:18303:9	disord	NNS	O	O

Cough	TAFINLAR.xml:S1:18345:5	cough	NN	B-AdverseReaction	B-AdverseReaction

29	TAFINLAR.xml:S1:18428:2	29	CD	O	O
0	TAFINLAR.xml:S1:18447:1	0	CD	O	O
11	TAFINLAR.xml:S1:18461:2	11	CD	O	O
0	TAFINLAR.xml:S1:18480:1	0	CD	O	O
21	TAFINLAR.xml:S1:18494:2	21	CD	O	O
0	TAFINLAR.xml:S1:18505:1	0	CD	O	O

Oropharyngeal	TAFINLAR.xml:S1:18544:13	oropharyng	NNP	B-AdverseReaction	B-AdverseReaction
pain	TAFINLAR.xml:S1:18558:4	pain	NN	I-AdverseReaction	I-AdverseReaction

13	TAFINLAR.xml:S1:18627:2	13	CD	O	O
0	TAFINLAR.xml:S1:18646:1	0	CD	O	O
7	TAFINLAR.xml:S1:18660:1	7	CD	O	O
0	TAFINLAR.xml:S1:18679:1	0	CD	O	O
0	TAFINLAR.xml:S1:18693:1	0	CD	O	O
0	TAFINLAR.xml:S1:18704:1	0	CD	O	O

Musculoskeletal	TAFINLAR.xml:S1:18717:15	musculoskelet	NNP	O	O
,	TAFINLAR.xml:S1:18732:1	,	,	O	O
connective	TAFINLAR.xml:S1:18734:10	connect	JJ	O	O
tissue	TAFINLAR.xml:S1:18745:6	tissu	NN	O	O
,	TAFINLAR.xml:S1:18751:1	,	,	O	O
and	TAFINLAR.xml:S1:18753:3	and	CC	O	O
bone	TAFINLAR.xml:S1:18757:4	bone	NN	O	O
disorders	TAFINLAR.xml:S1:18762:9	disord	NNS	O	O

Arthralgia	TAFINLAR.xml:S1:18804:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction

27	TAFINLAR.xml:S1:18887:2	27	CD	O	O
0	TAFINLAR.xml:S1:18906:1	0	CD	O	O
44	TAFINLAR.xml:S1:18920:2	44	CD	O	O
0	TAFINLAR.xml:S1:18939:1	0	CD	O	O
34	TAFINLAR.xml:S1:18953:2	34	CD	O	O
0	TAFINLAR.xml:S1:18964:1	0	CD	O	O

Myalgia	TAFINLAR.xml:S1:19003:7	myalgia	NN	B-AdverseReaction	B-AdverseReaction

22	TAFINLAR.xml:S1:19086:2	22	CD	O	O
2	TAFINLAR.xml:S1:19105:1	2	CD	O	O
24	TAFINLAR.xml:S1:19119:2	24	CD	O	O
0	TAFINLAR.xml:S1:19138:1	0	CD	O	O
23	TAFINLAR.xml:S1:19152:2	23	CD	O	O
2	TAFINLAR.xml:S1:19163:1	2	CD	O	O

Back	TAFINLAR.xml:S1:19202:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	TAFINLAR.xml:S1:19207:4	pain	NN	I-AdverseReaction	I-AdverseReaction

18	TAFINLAR.xml:S1:19285:2	18	CD	O	O
5	TAFINLAR.xml:S1:19304:1	5	CD	O	O
11	TAFINLAR.xml:S1:19318:2	11	CD	O	O
0	TAFINLAR.xml:S1:19337:1	0	CD	O	O
11	TAFINLAR.xml:S1:19351:2	11	CD	O	O
2	TAFINLAR.xml:S1:19362:1	2	CD	O	O

Muscle	TAFINLAR.xml:S1:19401:6	muscl	NN	B-AdverseReaction	B-AdverseReaction
spasms	TAFINLAR.xml:S1:19408:6	spasm	NNS	I-AdverseReaction	I-AdverseReaction

16	TAFINLAR.xml:S1:19484:2	16	CD	O	O
0	TAFINLAR.xml:S1:19503:1	0	CD	O	O
2	TAFINLAR.xml:S1:19517:1	2	CD	O	O
0	TAFINLAR.xml:S1:19536:1	0	CD	O	O
4	TAFINLAR.xml:S1:19550:1	4	CD	O	O
0	TAFINLAR.xml:S1:19561:1	0	CD	O	O

Pain	TAFINLAR.xml:S1:19600:4	pain	NN	B-AdverseReaction	B-AdverseReaction
in	TAFINLAR.xml:S1:19605:2	in	IN	I-AdverseReaction	I-AdverseReaction
extremity	TAFINLAR.xml:S1:19608:9	extrem	NN	I-AdverseReaction	I-AdverseReaction

16	TAFINLAR.xml:S1:19683:2	16	CD	O	O
0	TAFINLAR.xml:S1:19702:1	0	CD	O	O
11	TAFINLAR.xml:S1:19716:2	11	CD	O	O
2	TAFINLAR.xml:S1:19735:1	2	CD	O	O
19	TAFINLAR.xml:S1:19749:2	19	CD	O	O
0	TAFINLAR.xml:S1:19760:1	0	CD	O	O

Metabolism	TAFINLAR.xml:S1:19773:10	metabol	NN	O	O
and	TAFINLAR.xml:S1:19784:3	and	CC	O	O
nutritional	TAFINLAR.xml:S1:19788:11	nutrit	JJ	O	O
disorders	TAFINLAR.xml:S1:19800:9	disord	NNS	O	O

Decreased	TAFINLAR.xml:S1:19842:9	decreas	VBN	B-AdverseReaction	B-AdverseReaction
appetite	TAFINLAR.xml:S1:19852:8	appetit	NN	I-AdverseReaction	I-AdverseReaction

22	TAFINLAR.xml:S1:19925:2	22	CD	O	O
0	TAFINLAR.xml:S1:19944:1	0	CD	O	O
30	TAFINLAR.xml:S1:19958:2	30	CD	O	O
0	TAFINLAR.xml:S1:19977:1	0	CD	O	O
19	TAFINLAR.xml:S1:19991:2	19	CD	O	O
0	TAFINLAR.xml:S1:20002:1	0	CD	O	O

Dehydration	TAFINLAR.xml:S1:20041:11	dehydr	NN	B-AdverseReaction	O

11	TAFINLAR.xml:S1:20124:2	11	CD	O	O
0	TAFINLAR.xml:S1:20143:1	0	CD	O	O
6	TAFINLAR.xml:S1:20157:1	6	CD	O	O
2	TAFINLAR.xml:S1:20176:1	2	CD	O	O
2	TAFINLAR.xml:S1:20190:1	2	CD	O	O
0	TAFINLAR.xml:S1:20201:1	0	CD	O	O

Psychiatric	TAFINLAR.xml:S1:20214:11	psychiatr	JJ	O	O
Disorders	TAFINLAR.xml:S1:20226:9	disord	NNS	O	O

Insomnia	TAFINLAR.xml:S1:20270:8	insomnia	NN	B-AdverseReaction	O

18	TAFINLAR.xml:S1:20353:2	18	CD	O	O
0	TAFINLAR.xml:S1:20372:1	0	CD	O	O
11	TAFINLAR.xml:S1:20386:2	11	CD	O	O
0	TAFINLAR.xml:S1:20405:1	0	CD	O	O
8	TAFINLAR.xml:S1:20419:1	8	CD	O	O
2	TAFINLAR.xml:S1:20430:1	2	CD	O	O

Vascular	TAFINLAR.xml:S1:20443:8	vascular	JJ	O	O
disorders	TAFINLAR.xml:S1:20452:9	disord	NNS	O	O

Hemorrhage	TAFINLAR.xml:S1:20499:10	hemorrhag	NN	B-AdverseReaction	O
e	TAFINLAR.xml:S1:20511:1	e	NN	O	O

16	TAFINLAR.xml:S1:20582:2	16	CD	O	O
5	TAFINLAR.xml:S1:20601:1	5	CD	O	O
11	TAFINLAR.xml:S1:20615:2	11	CD	O	O
0	TAFINLAR.xml:S1:20634:1	0	CD	O	O
2	TAFINLAR.xml:S1:20648:1	2	CD	O	O
0	TAFINLAR.xml:S1:20659:1	0	CD	O	O

Infections	TAFINLAR.xml:S1:20672:10	infect	NNS	O	O
and	TAFINLAR.xml:S1:20683:3	and	CC	O	O
infestations	TAFINLAR.xml:S1:20687:12	infest	NNS	O	O

Urinary	TAFINLAR.xml:S1:20732:7	urinari	JJ	B-AdverseReaction	B-AdverseReaction
tract	TAFINLAR.xml:S1:20740:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	TAFINLAR.xml:S1:20746:9	infect	NN	I-AdverseReaction	I-AdverseReaction

13	TAFINLAR.xml:S1:20815:2	13	CD	O	O
2	TAFINLAR.xml:S1:20834:1	2	CD	O	O
6	TAFINLAR.xml:S1:20848:1	6	CD	O	O
0	TAFINLAR.xml:S1:20867:1	0	CD	O	O
9	TAFINLAR.xml:S1:20881:1	9	CD	O	O
2	TAFINLAR.xml:S1:20892:1	2	CD	O	O

Renal	TAFINLAR.xml:S1:20905:5	renal	NNP	O	O
and	TAFINLAR.xml:S1:20911:3	and	CC	O	O
urinary	TAFINLAR.xml:S1:20915:7	urinari	JJ	O	O
disorders	TAFINLAR.xml:S1:20923:9	disord	NNS	O	O

Renal	TAFINLAR.xml:S1:20965:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	TAFINLAR.xml:S1:20971:7	failur	NN	I-AdverseReaction	I-AdverseReaction
f	TAFINLAR.xml:S1:20980:1	f	NN	O	I-AdverseReaction

7	TAFINLAR.xml:S1:21048:1	7	CD	O	O
7	TAFINLAR.xml:S1:21067:1	7	CD	O	O
2	TAFINLAR.xml:S1:21081:1	2	CD	O	O
0	TAFINLAR.xml:S1:21100:1	0	CD	O	O
0	TAFINLAR.xml:S1:21114:1	0	CD	O	O
0	TAFINLAR.xml:S1:21125:1	0	CD	O	O

a	TAFINLAR.xml:S1:21151:1	a	DT	O	O
National	TAFINLAR.xml:S1:21154:8	nation	NNP	O	O
Cancer	TAFINLAR.xml:S1:21163:6	cancer	NNP	O	O
Institute	TAFINLAR.xml:S1:21170:9	institut	NNP	O	O
Common	TAFINLAR.xml:S1:21180:6	common	NNP	O	O
Terminology	TAFINLAR.xml:S1:21187:11	terminolog	NNP	O	O
Criteria	TAFINLAR.xml:S1:21199:8	criteria	NNP	O	O
for	TAFINLAR.xml:S1:21208:3	for	IN	O	O
Adverse	TAFINLAR.xml:S1:21212:7	advers	NNP	O	O
Events	TAFINLAR.xml:S1:21220:6	event	NNP	O	O
,	TAFINLAR.xml:S1:21226:1	,	,	O	O
version	TAFINLAR.xml:S1:21228:7	version	NN	O	O
4	TAFINLAR.xml:S1:21236:1	4	CD	O	O
.	TAFINLAR.xml:S1:21237:1	.	.	O	O

b	TAFINLAR.xml:S1:21245:1	b	NN	O	O

Includes	TAFINLAR.xml:S1:21248:8	includ	VBZ	O	O
the	TAFINLAR.xml:S1:21257:3	the	DT	O	O
following	TAFINLAR.xml:S1:21261:9	follow	JJ	O	O
terms	TAFINLAR.xml:S1:21271:5	term	NNS	O	O
:	TAFINLAR.xml:S1:21276:1	:	:	O	O
peripheral	TAFINLAR.xml:S1:21278:10	peripher	JJ	B-AdverseReaction	B-AdverseReaction
edema	TAFINLAR.xml:S1:21289:5	edema	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21294:1	,	,	O	O
edema	TAFINLAR.xml:S1:21296:5	edema	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:21301:1	,	,	O	O
and	TAFINLAR.xml:S1:21303:3	and	CC	O	O
lymphedema	TAFINLAR.xml:S1:21307:10	lymphedema	NN	B-AdverseReaction	O
.	TAFINLAR.xml:S1:21317:1	.	.	O	O

c	TAFINLAR.xml:S1:21325:1	c	SYM	O	O
Includes	TAFINLAR.xml:S1:21328:8	includ	VBZ	O	O
the	TAFINLAR.xml:S1:21337:3	the	DT	O	O
following	TAFINLAR.xml:S1:21341:9	follow	JJ	O	O
terms	TAFINLAR.xml:S1:21351:5	term	NNS	O	O
:	TAFINLAR.xml:S1:21356:1	:	:	O	O
rash	TAFINLAR.xml:S1:21358:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:21362:1	,	,	O	O
rash	TAFINLAR.xml:S1:21364:4	rash	NN	B-AdverseReaction	B-AdverseReaction
generalized	TAFINLAR.xml:S1:21369:11	gener	VBD	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21380:1	,	,	O	O
rash	TAFINLAR.xml:S1:21382:4	rash	JJ	B-AdverseReaction	B-AdverseReaction
pruritic	TAFINLAR.xml:S1:21387:8	prurit	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21395:1	,	,	O	O
rash	TAFINLAR.xml:S1:21397:4	rash	VBP	B-AdverseReaction	B-AdverseReaction
erythematous	TAFINLAR.xml:S1:21402:12	erythemat	JJ	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21414:1	,	,	O	O
rash	TAFINLAR.xml:S1:21416:4	rash	JJ	B-AdverseReaction	B-AdverseReaction
papular	TAFINLAR.xml:S1:21421:7	papular	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21428:1	,	,	O	O
rash	TAFINLAR.xml:S1:21430:4	rash	NN	B-AdverseReaction	B-AdverseReaction
vesicular	TAFINLAR.xml:S1:21435:9	vesicular	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21444:1	,	,	O	O
rash	TAFINLAR.xml:S1:21446:4	rash	NN	B-AdverseReaction	B-AdverseReaction
macular	TAFINLAR.xml:S1:21451:7	macular	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21458:1	,	,	O	O
and	TAFINLAR.xml:S1:21460:3	and	CC	O	O
rash	TAFINLAR.xml:S1:21464:4	rash	NN	B-AdverseReaction	B-AdverseReaction
maculo	TAFINLAR.xml:S1:21469:6	maculo	NN	I-AdverseReaction	I-AdverseReaction
-	TAFINLAR.xml:S1:21475:1	-	:	I-AdverseReaction	I-AdverseReaction
papular	TAFINLAR.xml:S1:21476:7	papular	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S1:21483:1	.	.	O	O

d	TAFINLAR.xml:S1:21491:1	d	NN	O	O
Includes	TAFINLAR.xml:S1:21494:8	includ	VBZ	O	O
the	TAFINLAR.xml:S1:21503:3	the	DT	O	O
following	TAFINLAR.xml:S1:21507:9	follow	JJ	O	O
terms	TAFINLAR.xml:S1:21517:5	term	NNS	O	O
:	TAFINLAR.xml:S1:21522:1	:	:	O	O
abdominal	TAFINLAR.xml:S1:21524:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TAFINLAR.xml:S1:21534:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21538:1	,	,	O	O
abdominal	TAFINLAR.xml:S1:21540:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TAFINLAR.xml:S1:21550:4	pain	NN	I-AdverseReaction	I-AdverseReaction
upper	TAFINLAR.xml:S1:21555:5	upper	JJ	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21560:1	,	,	O	O
abdominal	TAFINLAR.xml:S1:21562:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TAFINLAR.xml:S1:21572:4	pain	NN	I-AdverseReaction	I-AdverseReaction
lower	TAFINLAR.xml:S1:21577:5	lower	JJR	I-AdverseReaction	O
,	TAFINLAR.xml:S1:21582:1	,	,	O	O
and	TAFINLAR.xml:S1:21584:3	and	CC	O	O
abdominal	TAFINLAR.xml:S1:21588:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
discomfort	TAFINLAR.xml:S1:21598:10	discomfort	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S1:21608:1	.	.	O	O

e	TAFINLAR.xml:S1:21616:1	e	NN	O	O
Includes	TAFINLAR.xml:S1:21619:8	includ	VBZ	O	O
the	TAFINLAR.xml:S1:21628:3	the	DT	O	O
following	TAFINLAR.xml:S1:21632:9	follow	JJ	O	O
terms	TAFINLAR.xml:S1:21642:5	term	NNS	O	O
:	TAFINLAR.xml:S1:21647:1	:	:	O	O
brain	TAFINLAR.xml:S1:21649:5	brain	NN	B-AdverseReaction	B-AdverseReaction
stem	TAFINLAR.xml:S1:21655:4	stem	NN	I-AdverseReaction	I-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21660:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21670:1	,	,	O	O
cerebral	TAFINLAR.xml:S1:21672:8	cerebr	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21681:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21691:1	,	,	O	O
gastric	TAFINLAR.xml:S1:21693:7	gastric	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21701:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21711:1	,	,	O	O
epistaxis	TAFINLAR.xml:S1:21713:9	epistaxi	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:21722:1	,	,	O	O
gingival	TAFINLAR.xml:S1:21724:8	gingiv	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21733:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21743:1	,	,	O	O
hematuria	TAFINLAR.xml:S1:21745:9	hematuria	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:21754:1	,	,	O	O
vaginal	TAFINLAR.xml:S1:21756:7	vagin	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21764:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21774:1	,	,	O	O
hemorrhage	TAFINLAR.xml:S1:21776:10	hemorrhag	NN	B-AdverseReaction	B-AdverseReaction
intracranial	TAFINLAR.xml:S1:21787:12	intracrani	JJ	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21799:1	,	,	O	O
eye	TAFINLAR.xml:S1:21801:3	eye	NN	B-AdverseReaction	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21805:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:21815:1	,	,	O	O
and	TAFINLAR.xml:S1:21817:3	and	CC	O	O
vitreous	TAFINLAR.xml:S1:21821:8	vitreou	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21830:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S1:21840:1	.	.	O	O

f	TAFINLAR.xml:S1:21848:1	f	NN	O	O
Includes	TAFINLAR.xml:S1:21851:8	includ	VBZ	O	O
the	TAFINLAR.xml:S1:21860:3	the	DT	O	O
following	TAFINLAR.xml:S1:21864:9	follow	JJ	O	O
terms	TAFINLAR.xml:S1:21874:5	term	NNS	O	O
:	TAFINLAR.xml:S1:21879:1	:	:	O	O
renal	TAFINLAR.xml:S1:21881:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	TAFINLAR.xml:S1:21887:7	failur	NN	I-AdverseReaction	I-AdverseReaction
and	TAFINLAR.xml:S1:21895:3	and	CC	O	O
renal	TAFINLAR.xml:S1:21899:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	TAFINLAR.xml:S1:21905:7	failur	NN	I-AdverseReaction	I-AdverseReaction
acute	TAFINLAR.xml:S1:21913:5	acut	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S1:21918:1	.	.	O	O

Other	TAFINLAR.xml:S1:21924:5	other	JJ	O	O
clinically	TAFINLAR.xml:S1:21930:10	clinic	RB	O	O
important	TAFINLAR.xml:S1:21941:9	import	JJ	O	O
adverse	TAFINLAR.xml:S1:21951:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S1:21959:9	reaction	NNS	O	O
(	TAFINLAR.xml:S1:21969:1	(	(	O	O
N	TAFINLAR.xml:S1:21970:1	N	NNP	O	O
202	TAFINLAR.xml:S1:21974:3	202	CD	O	O
)	TAFINLAR.xml:S1:21977:1	)	)	O	O
observed	TAFINLAR.xml:S1:21979:8	observ	VBN	O	O
in	TAFINLAR.xml:S1:21988:2	in	IN	O	O
10%	TAFINLAR.xml:S1:21992:3	10%	CD	O	O
of	TAFINLAR.xml:S1:21996:2	of	IN	O	O
patients	TAFINLAR.xml:S1:21999:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:22008:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:22016:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:22021:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S1:22030:2	in	IN	O	O
combination	TAFINLAR.xml:S1:22033:11	combin	NN	O	O
with	TAFINLAR.xml:S1:22045:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:22050:10	trametinib	NNS	O	O
were	TAFINLAR.xml:S1:22061:4	were	VBD	O	O
:	TAFINLAR.xml:S1:22065:1	:	:	O	O

Eye	TAFINLAR.xml:S1:22073:3	eye	JJ	O	O
Disorders	TAFINLAR.xml:S1:22077:9	disord	NNS	O	O
:	TAFINLAR.xml:S1:22086:1	:	:	O	O
Vision	TAFINLAR.xml:S1:22089:6	vision	NN	B-AdverseReaction	B-AdverseReaction
blurred	TAFINLAR.xml:S1:22096:7	blur	VBD	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:22103:1	,	,	O	O
transient	TAFINLAR.xml:S1:22105:9	transient	JJ	B-AdverseReaction	O
blindness	TAFINLAR.xml:S1:22115:9	blind	NN	I-AdverseReaction	O
.	TAFINLAR.xml:S1:22124:1	.	.	O	O

Gastrointestinal	TAFINLAR.xml:S1:22132:16	gastrointestin	JJ	O	O
Disorders	TAFINLAR.xml:S1:22149:9	disord	NNS	O	O
:	TAFINLAR.xml:S1:22158:1	:	:	O	O
Stomatitis	TAFINLAR.xml:S1:22161:10	stomat	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:22171:1	,	,	O	O
pancreatitis	TAFINLAR.xml:S1:22173:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
.	TAFINLAR.xml:S1:22185:1	.	.	O	O

General	TAFINLAR.xml:S1:22193:7	gener	NNP	O	O
Disorders	TAFINLAR.xml:S1:22201:9	disord	NNP	O	O
and	TAFINLAR.xml:S1:22211:3	and	CC	O	O
Administration	TAFINLAR.xml:S1:22215:14	administr	NNP	O	O
Site	TAFINLAR.xml:S1:22230:4	site	NNP	O	O
Conditions	TAFINLAR.xml:S1:22235:10	condit	NNS	O	O
:	TAFINLAR.xml:S1:22245:1	:	:	O	O
Asthenia	TAFINLAR.xml:S1:22248:8	asthenia	NNP	B-AdverseReaction	B-AdverseReaction
.	TAFINLAR.xml:S1:22256:1	.	.	O	O

Infections	TAFINLAR.xml:S1:22264:10	infect	NNS	O	O
and	TAFINLAR.xml:S1:22275:3	and	CC	O	O
Infestations	TAFINLAR.xml:S1:22279:12	infest	NNS	O	O
:	TAFINLAR.xml:S1:22291:1	:	:	O	O
Cellulitis	TAFINLAR.xml:S1:22294:10	cellul	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:22304:1	,	,	O	O
folliculitis	TAFINLAR.xml:S1:22306:12	follicul	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:22318:1	,	,	O	O
paronychia	TAFINLAR.xml:S1:22320:10	paronychia	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:22330:1	,	,	O	O
rash	TAFINLAR.xml:S1:22332:4	rash	NN	B-AdverseReaction	B-AdverseReaction
pustular	TAFINLAR.xml:S1:22337:8	pustular	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S1:22345:1	.	.	O	O

Neoplasms	TAFINLAR.xml:S1:22353:9	neoplasm	NNP	O	O
Benign	TAFINLAR.xml:S1:22363:6	benign	NNP	O	O
,	TAFINLAR.xml:S1:22369:1	,	,	O	O
Malignant	TAFINLAR.xml:S1:22371:9	malign	NNP	O	O
,	TAFINLAR.xml:S1:22380:1	,	,	O	O
and	TAFINLAR.xml:S1:22382:3	and	CC	O	O
Unspecified	TAFINLAR.xml:S1:22386:11	unspecifi	NNP	O	O
(	TAFINLAR.xml:S1:22398:1	(	(	O	O
including	TAFINLAR.xml:S1:22399:9	includ	VBG	O	O
cysts	TAFINLAR.xml:S1:22409:5	cyst	NNS	O	O
and	TAFINLAR.xml:S1:22415:3	and	CC	O	O
polyps	TAFINLAR.xml:S1:22419:6	polyp	NNS	O	B-AdverseReaction
)	TAFINLAR.xml:S1:22425:1	)	)	O	O
:	TAFINLAR.xml:S1:22426:1	:	:	O	O
Skin	TAFINLAR.xml:S1:22429:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
papilloma	TAFINLAR.xml:S1:22434:9	papilloma	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S1:22443:1	.	.	O	O

Skin	TAFINLAR.xml:S1:22451:4	skin	NNP	O	O
and	TAFINLAR.xml:S1:22456:3	and	CC	O	O
Subcutaneous	TAFINLAR.xml:S1:22460:12	subcutan	NNP	O	O
Tissue	TAFINLAR.xml:S1:22473:6	tissu	NNP	O	O
Disorders	TAFINLAR.xml:S1:22480:9	disord	NNP	O	O
:	TAFINLAR.xml:S1:22489:1	:	:	O	O
Palmar	TAFINLAR.xml:S1:22492:6	palmar	NNP	B-AdverseReaction	B-AdverseReaction
-	TAFINLAR.xml:S1:22498:1	-	:	I-AdverseReaction	I-AdverseReaction
plantar	TAFINLAR.xml:S1:22499:7	plantar	NN	I-AdverseReaction	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:22507:18	erythrodysesthesia	JJ	I-AdverseReaction	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:22526:8	syndrom	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S1:22534:1	,	,	O	O
hyperkeratosis	TAFINLAR.xml:S1:22536:14	hyperkeratosi	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S1:22550:1	,	,	O	O
hyperhidrosis	TAFINLAR.xml:S1:22552:13	hyperhidrosi	NN	B-AdverseReaction	B-AdverseReaction
.	TAFINLAR.xml:S1:22565:1	.	.	O	O

Vascular	TAFINLAR.xml:S1:22573:8	vascular	JJ	O	O
Disorders	TAFINLAR.xml:S1:22582:9	disord	NNS	O	O
:	TAFINLAR.xml:S1:22591:1	:	:	O	O
Hypertension	TAFINLAR.xml:S1:22594:12	hypertens	NN	B-AdverseReaction	B-AdverseReaction
.	TAFINLAR.xml:S1:22606:1	.	.	O	O

Table	TAFINLAR.xml:S1:22612:5	tabl	JJ	O	O
6	TAFINLAR.xml:S1:22618:1	6	CD	O	O
.	TAFINLAR.xml:S1:22619:1	.	.	O	O

Treatment	TAFINLAR.xml:S1:22621:9	treatment	NNP	O	O
-	TAFINLAR.xml:S1:22630:1	-	:	O	O
Emergent	TAFINLAR.xml:S1:22631:8	emerg	JJ	O	O
Laboratory	TAFINLAR.xml:S1:22640:10	laboratori	NNP	O	O
Abnormalities	TAFINLAR.xml:S1:22651:13	abnorm	NNPS	O	O
Occurring	TAFINLAR.xml:S1:22665:9	occur	NNP	O	O
at	TAFINLAR.xml:S1:22675:2	at	IN	O	O
10%	TAFINLAR.xml:S1:22680:3	10%	CD	O	O
(	TAFINLAR.xml:S1:22684:1	(	(	O	O
All	TAFINLAR.xml:S1:22685:3	all	NNP	O	O
Grades	TAFINLAR.xml:S1:22689:6	grade	NNP	O	O
)	TAFINLAR.xml:S1:22695:1	)	)	O	O
or	TAFINLAR.xml:S1:22697:2	or	CC	O	O
2%	TAFINLAR.xml:S1:22702:2	2%	CD	O	O
(	TAFINLAR.xml:S1:22705:1	(	(	O	O
Grades	TAFINLAR.xml:S1:22706:6	grade	NNP	O	O
3	TAFINLAR.xml:S1:22713:1	3	CD	O	O
or	TAFINLAR.xml:S1:22715:2	or	CC	O	O
4	TAFINLAR.xml:S1:22718:1	4	CD	O	O
)]	TAFINLAR.xml:S1:22719:2	)]	NNS	O	O
of	TAFINLAR.xml:S1:22722:2	of	IN	O	O
Patients	TAFINLAR.xml:S1:22725:8	patient	NNS	O	O
Treated	TAFINLAR.xml:S1:22734:7	treat	VBN	O	O
With	TAFINLAR.xml:S1:22742:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:22747:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S1:22756:2	in	IN	O	O
Combination	TAFINLAR.xml:S1:22759:11	combin	NNP	O	O
With	TAFINLAR.xml:S1:22771:4	with	IN	O	O
Trametinib	TAFINLAR.xml:S1:22776:10	trametinib	NNP	O	O
in	TAFINLAR.xml:S1:22787:2	in	IN	O	O
Trial	TAFINLAR.xml:S1:22790:5	trial	NNP	O	O
2	TAFINLAR.xml:S1:22796:1	2	CD	O	O

Tests	TAFINLAR.xml:S1:22801:5	test	NNS	O	O
TAFINLAR	TAFINLAR.xml:S1:22838:8	tafinlar	NNP	O	O
plus	TAFINLAR.xml:S1:22847:4	plu	CC	O	O
Trametinib	TAFINLAR.xml:S1:22852:10	trametinib	NNP	O	O
2	TAFINLAR.xml:S1:22863:1	2	CD	O	O
mg	TAFINLAR.xml:S1:22865:2	mg	NN	O	O
N	TAFINLAR.xml:S1:22869:1	N	NNP	O	O
55	TAFINLAR.xml:S1:22873:2	55	CD	O	O
TAFINLAR	TAFINLAR.xml:S1:22879:8	tafinlar	NNP	O	O
plus	TAFINLAR.xml:S1:22888:4	plu	CC	O	O
Trametinib	TAFINLAR.xml:S1:22893:10	trametinib	NNP	O	O
1	TAFINLAR.xml:S1:22904:1	1	CD	O	O
mg	TAFINLAR.xml:S1:22906:2	mg	NN	O	O
N	TAFINLAR.xml:S1:22910:1	N	NNP	O	O
54	TAFINLAR.xml:S1:22914:2	54	CD	O	O
TAFINLAR	TAFINLAR.xml:S1:22920:8	tafinlar	NNP	O	O
N	TAFINLAR.xml:S1:22930:1	N	NNP	O	O
53	TAFINLAR.xml:S1:22934:2	53	CD	O	O

All	TAFINLAR.xml:S1:22943:3	all	DT	O	O
Grades	TAFINLAR.xml:S1:22948:6	grade	NNP	O	O
Grades	TAFINLAR.xml:S1:22980:6	grade	NNP	O	O
3	TAFINLAR.xml:S1:22988:1	3	CD	O	O
and	TAFINLAR.xml:S1:22990:3	and	CC	O	O
4	TAFINLAR.xml:S1:22994:1	4	CD	O	O
All	TAFINLAR.xml:S1:22999:3	all	NNP	O	O
Grades	TAFINLAR.xml:S1:23004:6	grade	NNP	O	O
Grades	TAFINLAR.xml:S1:23014:6	grade	NNP	O	O
3	TAFINLAR.xml:S1:23022:1	3	CD	O	O
and	TAFINLAR.xml:S1:23024:3	and	CC	O	O
4	TAFINLAR.xml:S1:23028:1	4	CD	O	O
All	TAFINLAR.xml:S1:23033:3	all	NNP	O	O
Grades	TAFINLAR.xml:S1:23038:6	grade	NNP	O	O
Grades	TAFINLAR.xml:S1:23048:6	grade	NNP	O	O
3	TAFINLAR.xml:S1:23056:1	3	CD	O	O
and	TAFINLAR.xml:S1:23058:3	and	CC	O	O
4	TAFINLAR.xml:S1:23062:1	4	CD	O	O
a	TAFINLAR.xml:S1:23063:1	a	DT	O	O

Hematology	TAFINLAR.xml:S1:23071:10	hematolog	NN	O	O

Leukopenia	TAFINLAR.xml:S1:23147:10	leukopenia	NNP	B-AdverseReaction	O

62	TAFINLAR.xml:S1:23260:2	62	CD	O	O
5	TAFINLAR.xml:S1:23274:1	5	CD	O	O
46	TAFINLAR.xml:S1:23288:2	46	CD	O	O
4	TAFINLAR.xml:S1:23302:1	4	CD	O	O
21	TAFINLAR.xml:S1:23316:2	21	CD	O	O
0	TAFINLAR.xml:S1:23326:1	0	CD	O	O

Lymphopenia	TAFINLAR.xml:S1:23376:11	lymphopenia	NNP	B-AdverseReaction	O

55	TAFINLAR.xml:S1:23489:2	55	CD	O	O
22	TAFINLAR.xml:S1:23503:2	22	CD	O	O
59	TAFINLAR.xml:S1:23517:2	59	CD	O	O
19	TAFINLAR.xml:S1:23531:2	19	CD	O	O
40	TAFINLAR.xml:S1:23545:2	40	CD	O	O
6	TAFINLAR.xml:S1:23555:1	6	CD	O	O

Neutropenia	TAFINLAR.xml:S1:23605:11	neutropenia	NN	B-AdverseReaction	O

55	TAFINLAR.xml:S1:23718:2	55	CD	O	O
13	TAFINLAR.xml:S1:23732:2	13	CD	O	O
37	TAFINLAR.xml:S1:23746:2	37	CD	O	O
2	TAFINLAR.xml:S1:23760:1	2	CD	O	O
9	TAFINLAR.xml:S1:23774:1	9	CD	O	O
2	TAFINLAR.xml:S1:23784:1	2	CD	O	O

Anemia	TAFINLAR.xml:S1:23834:6	anemia	NN	B-AdverseReaction	O

55	TAFINLAR.xml:S1:23947:2	55	CD	O	O
4	TAFINLAR.xml:S1:23961:1	4	CD	O	O
46	TAFINLAR.xml:S1:23975:2	46	CD	O	O
7	TAFINLAR.xml:S1:23989:1	7	CD	O	O
28	TAFINLAR.xml:S1:24003:2	28	CD	O	O
0	TAFINLAR.xml:S1:24013:1	0	CD	O	O

Thrombocytopenia	TAFINLAR.xml:S1:24063:16	thrombocytopenia	NN	B-AdverseReaction	O

31	TAFINLAR.xml:S1:24176:2	31	CD	O	O
4	TAFINLAR.xml:S1:24190:1	4	CD	O	O
31	TAFINLAR.xml:S1:24204:2	31	CD	O	O
2	TAFINLAR.xml:S1:24218:1	2	CD	O	O
8	TAFINLAR.xml:S1:24232:1	8	CD	O	O
0	TAFINLAR.xml:S1:24242:1	0	CD	O	O

Liver	TAFINLAR.xml:S1:24256:5	liver	NNP	O	O
Function	TAFINLAR.xml:S1:24262:8	function	NNP	O	O
Tests	TAFINLAR.xml:S1:24271:5	test	NNS	O	O

Increased	TAFINLAR.xml:S1:24332:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
AST	TAFINLAR.xml:S1:24342:3	ast	NN	I-AdverseReaction	I-AdverseReaction

60	TAFINLAR.xml:S1:24445:2	60	CD	O	O
5	TAFINLAR.xml:S1:24459:1	5	CD	O	O
54	TAFINLAR.xml:S1:24473:2	54	CD	O	O
0	TAFINLAR.xml:S1:24487:1	0	CD	O	O
15	TAFINLAR.xml:S1:24501:2	15	CD	O	O
0	TAFINLAR.xml:S1:24511:1	0	CD	O	O

Increased	TAFINLAR.xml:S1:24561:9	increas	VBN	B-AdverseReaction	O
alkaline	TAFINLAR.xml:S1:24571:8	alkalin	JJ	I-AdverseReaction	O
phosphatase	TAFINLAR.xml:S1:24580:11	phosphatas	NN	I-AdverseReaction	O

60	TAFINLAR.xml:S1:24674:2	60	CD	O	O
2	TAFINLAR.xml:S1:24688:1	2	CD	O	O
67	TAFINLAR.xml:S1:24702:2	67	CD	O	O
6	TAFINLAR.xml:S1:24716:1	6	CD	O	O
26	TAFINLAR.xml:S1:24730:2	26	CD	O	O
2	TAFINLAR.xml:S1:24740:1	2	CD	O	O

Increased	TAFINLAR.xml:S1:24790:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
ALT	TAFINLAR.xml:S1:24800:3	alt	NN	I-AdverseReaction	I-AdverseReaction

42	TAFINLAR.xml:S1:24903:2	42	CD	O	O
4	TAFINLAR.xml:S1:24917:1	4	CD	O	O
35	TAFINLAR.xml:S1:24931:2	35	CD	O	O
4	TAFINLAR.xml:S1:24945:1	4	CD	O	O
11	TAFINLAR.xml:S1:24959:2	11	CD	O	O
0	TAFINLAR.xml:S1:24969:1	0	CD	O	O

Hyperbilirubinemia	TAFINLAR.xml:S1:25019:18	hyperbilirubinemia	NN	B-AdverseReaction	O

15	TAFINLAR.xml:S1:25132:2	15	CD	O	O
0	TAFINLAR.xml:S1:25146:1	0	CD	O	O
7	TAFINLAR.xml:S1:25160:1	7	CD	O	O
4	TAFINLAR.xml:S1:25174:1	4	CD	O	O
0	TAFINLAR.xml:S1:25188:1	0	CD	O	O
0	TAFINLAR.xml:S1:25198:1	0	CD	O	O

Chemistry	TAFINLAR.xml:S1:25212:9	chemistri	NN	O	O

Hyperglycemia	TAFINLAR.xml:S1:25288:13	hyperglycemia	NN	B-AdverseReaction	O

58	TAFINLAR.xml:S1:25401:2	58	CD	O	O
5	TAFINLAR.xml:S1:25415:1	5	CD	O	O
67	TAFINLAR.xml:S1:25429:2	67	CD	O	O
6	TAFINLAR.xml:S1:25443:1	6	CD	O	O
49	TAFINLAR.xml:S1:25457:2	49	CD	O	O
2	TAFINLAR.xml:S1:25467:1	2	CD	O	O

Increased	TAFINLAR.xml:S1:25517:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
GGT	TAFINLAR.xml:S1:25527:3	ggt	NN	I-AdverseReaction	I-AdverseReaction

56	TAFINLAR.xml:S1:25630:2	56	CD	O	O
11	TAFINLAR.xml:S1:25644:2	11	CD	O	O
54	TAFINLAR.xml:S1:25658:2	54	CD	O	O
17	TAFINLAR.xml:S1:25672:2	17	CD	O	O
38	TAFINLAR.xml:S1:25686:2	38	CD	O	O
2	TAFINLAR.xml:S1:25696:1	2	CD	O	O

Hyponatremia	TAFINLAR.xml:S1:25746:12	hyponatremia	NN	B-AdverseReaction	O

55	TAFINLAR.xml:S1:25859:2	55	CD	O	O
11	TAFINLAR.xml:S1:25873:2	11	CD	O	O
48	TAFINLAR.xml:S1:25887:2	48	CD	O	O
15	TAFINLAR.xml:S1:25901:2	15	CD	O	O
36	TAFINLAR.xml:S1:25915:2	36	CD	O	O
2	TAFINLAR.xml:S1:25925:1	2	CD	O	O

Hypoalbuminemia	TAFINLAR.xml:S1:25975:15	hypoalbuminemia	NN	B-AdverseReaction	O

53	TAFINLAR.xml:S1:26088:2	53	CD	O	O
0	TAFINLAR.xml:S1:26102:1	0	CD	O	O
43	TAFINLAR.xml:S1:26116:2	43	CD	O	O
2	TAFINLAR.xml:S1:26130:1	2	CD	O	O
23	TAFINLAR.xml:S1:26144:2	23	CD	O	O
0	TAFINLAR.xml:S1:26154:1	0	CD	O	O

Hypophosphatemia	TAFINLAR.xml:S1:26204:16	hypophosphatemia	NN	B-AdverseReaction	O

47	TAFINLAR.xml:S1:26317:2	47	CD	O	O
5	TAFINLAR.xml:S1:26331:1	5	CD	O	O
41	TAFINLAR.xml:S1:26345:2	41	CD	O	O
11	TAFINLAR.xml:S1:26359:2	11	CD	O	O
40	TAFINLAR.xml:S1:26373:2	40	CD	O	O
0	TAFINLAR.xml:S1:26383:1	0	CD	O	O

Hypokalemia	TAFINLAR.xml:S1:26433:11	hypokalemia	NN	B-AdverseReaction	B-AdverseReaction

29	TAFINLAR.xml:S1:26546:2	29	CD	O	O
2	TAFINLAR.xml:S1:26560:1	2	CD	O	O
15	TAFINLAR.xml:S1:26574:2	15	CD	O	O
2	TAFINLAR.xml:S1:26588:1	2	CD	O	O
23	TAFINLAR.xml:S1:26602:2	23	CD	O	O
6	TAFINLAR.xml:S1:26612:1	6	CD	O	O

Increased	TAFINLAR.xml:S1:26662:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
creatinine	TAFINLAR.xml:S1:26672:10	creatinin	NN	I-AdverseReaction	I-AdverseReaction

24	TAFINLAR.xml:S1:26775:2	24	CD	O	O
5	TAFINLAR.xml:S1:26789:1	5	CD	O	O
20	TAFINLAR.xml:S1:26803:2	20	CD	O	O
2	TAFINLAR.xml:S1:26817:1	2	CD	O	O
9	TAFINLAR.xml:S1:26831:1	9	CD	O	O
0	TAFINLAR.xml:S1:26841:1	0	CD	O	O

Hypomagnesemia	TAFINLAR.xml:S1:26891:14	hypomagnesemia	NN	B-AdverseReaction	O

18	TAFINLAR.xml:S1:27004:2	18	CD	O	O
2	TAFINLAR.xml:S1:27018:1	2	CD	O	O
2	TAFINLAR.xml:S1:27032:1	2	CD	O	O
0	TAFINLAR.xml:S1:27046:1	0	CD	O	O
6	TAFINLAR.xml:S1:27060:1	6	CD	O	O
0	TAFINLAR.xml:S1:27070:1	0	CD	O	O

Hyperkalemia	TAFINLAR.xml:S1:27120:12	hyperkalemia	NN	B-AdverseReaction	O

18	TAFINLAR.xml:S1:27233:2	18	CD	O	O
0	TAFINLAR.xml:S1:27247:1	0	CD	O	O
22	TAFINLAR.xml:S1:27261:2	22	CD	O	O
0	TAFINLAR.xml:S1:27275:1	0	CD	O	O
15	TAFINLAR.xml:S1:27289:2	15	CD	O	O
4	TAFINLAR.xml:S1:27299:1	4	CD	O	O

Hypercalcemia	TAFINLAR.xml:S1:27349:13	hypercalcemia	NN	B-AdverseReaction	O

15	TAFINLAR.xml:S1:27462:2	15	CD	O	O
0	TAFINLAR.xml:S1:27476:1	0	CD	O	O
19	TAFINLAR.xml:S1:27490:2	19	CD	O	O
2	TAFINLAR.xml:S1:27504:1	2	CD	O	O
4	TAFINLAR.xml:S1:27518:1	4	CD	O	O
0	TAFINLAR.xml:S1:27528:1	0	CD	O	O

Hypocalcemia	TAFINLAR.xml:S1:27578:12	hypocalcemia	NN	B-AdverseReaction	O

13	TAFINLAR.xml:S1:27691:2	13	CD	O	O
0	TAFINLAR.xml:S1:27705:1	0	CD	O	O
20	TAFINLAR.xml:S1:27719:2	20	CD	O	O
0	TAFINLAR.xml:S1:27733:1	0	CD	O	O
9	TAFINLAR.xml:S1:27747:1	9	CD	O	O
0	TAFINLAR.xml:S1:27757:1	0	CD	O	O

a	TAFINLAR.xml:S1:27784:1	a	DT	O	O
No	TAFINLAR.xml:S1:27787:2	No	NNP	O	O
Grade	TAFINLAR.xml:S1:27790:5	grade	NNP	O	O
4	TAFINLAR.xml:S1:27796:1	4	CD	O	O
events	TAFINLAR.xml:S1:27798:6	event	NNS	O	O
were	TAFINLAR.xml:S1:27805:4	were	VBD	O	O
reported	TAFINLAR.xml:S1:27810:8	report	VBN	O	O
in	TAFINLAR.xml:S1:27819:2	in	IN	O	O
patients	TAFINLAR.xml:S1:27822:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S1:27831:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S1:27841:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S1:27850:2	as	IN	O	O
a	TAFINLAR.xml:S1:27853:1	a	DT	O	O
single	TAFINLAR.xml:S1:27855:6	singl	JJ	O	O
agent	TAFINLAR.xml:S1:27862:5	agent	NN	O	O
.	TAFINLAR.xml:S1:27867:1	.	.	O	O

ALT	TAFINLAR.xml:S1:27873:3	alt	NN	O	O

Alanine	TAFINLAR.xml:S1:27879:7	alanin	NNP	O	O
aminotransferase	TAFINLAR.xml:S1:27887:16	aminotransferas	NN	O	O
;	TAFINLAR.xml:S1:27903:1	;	:	O	O
AST	TAFINLAR.xml:S1:27905:3	ast	NNP	O	O
Aspartate	TAFINLAR.xml:S1:27911:9	aspart	NNP	O	O
aminotransferase	TAFINLAR.xml:S1:27921:16	aminotransferas	NN	O	O
;	TAFINLAR.xml:S1:27937:1	;	:	O	O
GGT	TAFINLAR.xml:S1:27939:3	ggt	NNP	O	O
Gamma	TAFINLAR.xml:S1:27945:5	gamma	NNP	O	O
glutamyltransferase	TAFINLAR.xml:S1:27951:19	glutamyltransferas	NN	O	O
.	TAFINLAR.xml:S1:27970:1	.	.	O	O

QT	TAFINLAR.xml:S1:27978:2	QT	JJ	O	B-AdverseReaction
Prolongation	TAFINLAR.xml:S1:27981:12	prolong	NN	O	I-AdverseReaction
:	TAFINLAR.xml:S1:27993:1	:	:	O	O
In	TAFINLAR.xml:S1:27996:2	In	IN	O	O
Trial	TAFINLAR.xml:S1:27999:5	trial	NNP	O	O
2	TAFINLAR.xml:S1:28005:1	2	CD	O	O
,	TAFINLAR.xml:S1:28006:1	,	,	O	O
QTcF	TAFINLAR.xml:S1:28008:4	qtcf	NNP	B-AdverseReaction	B-AdverseReaction
prolongation	TAFINLAR.xml:S1:28013:12	prolong	NN	I-AdverseReaction	I-AdverseReaction
to	TAFINLAR.xml:S1:28026:2	to	TO	O	O
500	TAFINLAR.xml:S1:28030:3	500	CD	O	O
msec	TAFINLAR.xml:S1:28034:4	msec	NNS	O	O
occurred	TAFINLAR.xml:S1:28039:8	occur	VBD	O	O
in	TAFINLAR.xml:S1:28048:2	in	IN	O	O
4%	TAFINLAR.xml:S1:28051:2	4%	CD	O	O
(	TAFINLAR.xml:S1:28054:1	(	(	O	O
2	TAFINLAR.xml:S1:28055:1	2	CD	O	O
55	TAFINLAR.xml:S1:28057:2	55	CD	O	O
)	TAFINLAR.xml:S1:28059:1	)	)	O	O
of	TAFINLAR.xml:S1:28061:2	of	IN	O	O
patients	TAFINLAR.xml:S1:28064:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:28073:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:28081:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:28086:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S1:28095:2	in	IN	O	O
combination	TAFINLAR.xml:S1:28098:11	combin	NN	O	O
with	TAFINLAR.xml:S1:28110:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:28115:10	trametinib	NN	O	O
and	TAFINLAR.xml:S1:28126:3	and	CC	O	O
in	TAFINLAR.xml:S1:28130:2	in	IN	O	O
2%	TAFINLAR.xml:S1:28133:2	2%	CD	O	O
(	TAFINLAR.xml:S1:28136:1	(	(	O	O
1	TAFINLAR.xml:S1:28137:1	1	CD	O	O
53	TAFINLAR.xml:S1:28139:2	53	CD	O	O
)	TAFINLAR.xml:S1:28141:1	)	)	O	O
of	TAFINLAR.xml:S1:28143:2	of	IN	O	O
patients	TAFINLAR.xml:S1:28146:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:28155:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:28163:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:28168:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S1:28177:2	as	IN	O	O
a	TAFINLAR.xml:S1:28180:1	a	DT	O	O
single	TAFINLAR.xml:S1:28182:6	singl	JJ	O	O
agent	TAFINLAR.xml:S1:28189:5	agent	NN	O	O
.	TAFINLAR.xml:S1:28194:1	.	.	O	O

The	TAFINLAR.xml:S1:28196:3	the	DT	O	O
QTcF	TAFINLAR.xml:S1:28200:4	qtcf	NNP	B-AdverseReaction	O
was	TAFINLAR.xml:S1:28205:3	wa	VBD	I-AdverseReaction	O
increased	TAFINLAR.xml:S1:28209:9	increas	VBN	I-AdverseReaction	O
more	TAFINLAR.xml:S1:28219:4	more	JJR	O	O
than	TAFINLAR.xml:S1:28224:4	than	IN	O	O
60	TAFINLAR.xml:S1:28229:2	60	CD	O	O
msec	TAFINLAR.xml:S1:28232:4	msec	NN	O	O
from	TAFINLAR.xml:S1:28237:4	from	IN	O	O
baseline	TAFINLAR.xml:S1:28242:8	baselin	NN	O	O
in	TAFINLAR.xml:S1:28251:2	in	IN	O	O
13%	TAFINLAR.xml:S1:28254:3	13%	CD	O	O
(	TAFINLAR.xml:S1:28258:1	(	(	O	O
7	TAFINLAR.xml:S1:28259:1	7	CD	O	O
55	TAFINLAR.xml:S1:28261:2	55	CD	O	O
)	TAFINLAR.xml:S1:28263:1	)	)	O	O
of	TAFINLAR.xml:S1:28265:2	of	IN	O	O
patients	TAFINLAR.xml:S1:28268:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:28277:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:28285:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:28290:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S1:28299:2	in	IN	O	O
combination	TAFINLAR.xml:S1:28302:11	combin	NN	O	O
with	TAFINLAR.xml:S1:28314:4	with	IN	O	O
trametinib	TAFINLAR.xml:S1:28319:10	trametinib	NN	O	O
and	TAFINLAR.xml:S1:28330:3	and	CC	O	O
2%	TAFINLAR.xml:S1:28334:2	2%	CD	O	O
(	TAFINLAR.xml:S1:28337:1	(	(	O	O
1	TAFINLAR.xml:S1:28338:1	1	CD	O	O
53	TAFINLAR.xml:S1:28340:2	53	CD	O	O
)	TAFINLAR.xml:S1:28342:1	)	)	O	O
of	TAFINLAR.xml:S1:28344:2	of	IN	O	O
patients	TAFINLAR.xml:S1:28347:8	patient	NNS	O	O
treated	TAFINLAR.xml:S1:28356:7	treat	VBN	O	O
with	TAFINLAR.xml:S1:28364:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S1:28369:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S1:28378:2	as	IN	O	O
a	TAFINLAR.xml:S1:28381:1	a	DT	O	O
single	TAFINLAR.xml:S1:28383:6	singl	JJ	O	O
agent	TAFINLAR.xml:S1:28390:5	agent	NN	O	O
.	TAFINLAR.xml:S1:28395:1	.	.	O	O
5	TAFINLAR.xml:S2:4:1	5	CD	O	O
WARNINGS	TAFINLAR.xml:S2:6:8	warn	NNP	O	O
AND	TAFINLAR.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	TAFINLAR.xml:S2:19:11	precaut	NNP	O	O

Review	TAFINLAR.xml:S2:37:6	review	VB	O	O
the	TAFINLAR.xml:S2:44:3	the	DT	O	O
Full	TAFINLAR.xml:S2:48:4	full	NNP	O	O
Prescribing	TAFINLAR.xml:S2:53:11	prescrib	NNP	O	O
Information	TAFINLAR.xml:S2:65:11	inform	NNP	O	O
for	TAFINLAR.xml:S2:77:3	for	IN	O	O
trametinib	TAFINLAR.xml:S2:81:10	trametinib	NN	O	O
prior	TAFINLAR.xml:S2:92:5	prior	RB	O	O
to	TAFINLAR.xml:S2:98:2	to	TO	O	O
initiation	TAFINLAR.xml:S2:101:10	initi	NN	O	O
of	TAFINLAR.xml:S2:112:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:115:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:124:2	in	IN	O	O
combination	TAFINLAR.xml:S2:127:11	combin	NN	O	O
with	TAFINLAR.xml:S2:139:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:144:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:154:1	.	.	O	O

The	TAFINLAR.xml:S2:156:3	the	DT	O	O
following	TAFINLAR.xml:S2:160:9	follow	VBG	O	O
serious	TAFINLAR.xml:S2:170:7	seriou	JJ	O	O
adverse	TAFINLAR.xml:S2:178:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S2:186:9	reaction	NNS	O	O
of	TAFINLAR.xml:S2:196:2	of	IN	O	O
trametinib	TAFINLAR.xml:S2:199:10	trametinib	NN	O	O
as	TAFINLAR.xml:S2:210:2	as	IN	O	O
a	TAFINLAR.xml:S2:213:1	a	DT	O	O
single	TAFINLAR.xml:S2:215:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:222:5	agent	NN	O	O
,	TAFINLAR.xml:S2:227:1	,	,	O	O
which	TAFINLAR.xml:S2:229:5	which	WDT	O	O
may	TAFINLAR.xml:S2:235:3	may	MD	O	O
occur	TAFINLAR.xml:S2:239:5	occur	VB	O	O
when	TAFINLAR.xml:S2:245:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:250:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:259:2	is	VBZ	O	O
used	TAFINLAR.xml:S2:262:4	use	VBN	O	O
in	TAFINLAR.xml:S2:267:2	in	IN	O	O
combination	TAFINLAR.xml:S2:270:11	combin	NN	O	O
with	TAFINLAR.xml:S2:282:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:287:10	trametinib	NN	O	O
,	TAFINLAR.xml:S2:297:1	,	,	O	O
are	TAFINLAR.xml:S2:299:3	are	VBP	O	O
not	TAFINLAR.xml:S2:303:3	not	RB	O	O
described	TAFINLAR.xml:S2:307:9	describ	VBN	O	O
in	TAFINLAR.xml:S2:317:2	in	IN	O	O
the	TAFINLAR.xml:S2:320:3	the	DT	O	O
Full	TAFINLAR.xml:S2:324:4	full	NNP	O	O
Prescribing	TAFINLAR.xml:S2:329:11	prescrib	NNP	O	O
Information	TAFINLAR.xml:S2:341:11	inform	NNP	O	O
for	TAFINLAR.xml:S2:353:3	for	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:357:8	tafinlar	NNP	O	O
:	TAFINLAR.xml:S2:365:1	:	:	O	O

Retinal	TAFINLAR.xml:S2:379:7	retin	JJ	B-AdverseReaction	O
vein	TAFINLAR.xml:S2:387:4	vein	NN	I-AdverseReaction	O
occlusion	TAFINLAR.xml:S2:392:9	occlus	NN	I-AdverseReaction	O

Interstitial	TAFINLAR.xml:S2:411:12	interstiti	JJ	B-AdverseReaction	B-AdverseReaction
lung	TAFINLAR.xml:S2:424:4	lung	NN	I-AdverseReaction	I-AdverseReaction
disease	TAFINLAR.xml:S2:429:7	diseas	NN	I-AdverseReaction	I-AdverseReaction

New	TAFINLAR.xml:S2:447:3	new	NNP	O	B-AdverseReaction
primary	TAFINLAR.xml:S2:451:7	primari	JJ	B-AdverseReaction	I-AdverseReaction
malignancies	TAFINLAR.xml:S2:459:12	malign	NNS	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S2:471:1	,	,	I-AdverseReaction	O
cutaneous	TAFINLAR.xml:S2:473:9	cutan	JJ	I-AdverseReaction	O
and	TAFINLAR.xml:S2:483:3	and	CC	O	O
non	TAFINLAR.xml:S2:487:3	non	JJ	I-AdverseReaction	O
-	TAFINLAR.xml:S2:490:1	-	:	I-AdverseReaction	O
cutaneous	TAFINLAR.xml:S2:491:9	cutan	JJ	I-AdverseReaction	O
,	TAFINLAR.xml:S2:500:1	,	,	O	O
can	TAFINLAR.xml:S2:502:3	can	MD	O	O
occur	TAFINLAR.xml:S2:506:5	occur	VB	O	O
when	TAFINLAR.xml:S2:512:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:517:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:526:2	is	VBZ	O	O
administered	TAFINLAR.xml:S2:529:12	administ	VBN	O	O
as	TAFINLAR.xml:S2:542:2	as	IN	O	O
a	TAFINLAR.xml:S2:545:1	a	DT	O	O
single	TAFINLAR.xml:S2:547:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:554:5	agent	NN	O	O
or	TAFINLAR.xml:S2:560:2	or	CC	O	O
in	TAFINLAR.xml:S2:563:2	in	IN	O	O
combination	TAFINLAR.xml:S2:566:11	combin	NN	O	O
with	TAFINLAR.xml:S2:578:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:583:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:593:1	.	.	O	O

Monitor	TAFINLAR.xml:S2:595:7	monitor	NN	O	O
patients	TAFINLAR.xml:S2:603:8	patient	NNS	O	O
for	TAFINLAR.xml:S2:612:3	for	IN	O	O
new	TAFINLAR.xml:S2:616:3	new	JJ	O	O
malignancies	TAFINLAR.xml:S2:620:12	malign	NNS	O	O
prior	TAFINLAR.xml:S2:633:5	prior	VBP	O	O
to	TAFINLAR.xml:S2:639:2	to	TO	O	O
initiation	TAFINLAR.xml:S2:642:10	initi	NN	O	O
of	TAFINLAR.xml:S2:653:2	of	IN	O	O
therapy	TAFINLAR.xml:S2:656:7	therapi	NN	O	O
,	TAFINLAR.xml:S2:663:1	,	,	O	O
while	TAFINLAR.xml:S2:665:5	while	IN	O	O
on	TAFINLAR.xml:S2:671:2	on	IN	O	O
therapy	TAFINLAR.xml:S2:674:7	therapi	NN	O	O
,	TAFINLAR.xml:S2:681:1	,	,	O	O
and	TAFINLAR.xml:S2:683:3	and	CC	O	O
following	TAFINLAR.xml:S2:687:9	follow	VBG	O	O
discontinuation	TAFINLAR.xml:S2:697:15	discontinu	NN	O	O
of	TAFINLAR.xml:S2:713:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:716:8	tafinlar	NNP	O	O
or	TAFINLAR.xml:S2:725:2	or	CC	O	O
the	TAFINLAR.xml:S2:728:3	the	DT	O	O
combination	TAFINLAR.xml:S2:732:11	combin	NN	O	O
therapy	TAFINLAR.xml:S2:744:7	therapi	NN	O	O
.	TAFINLAR.xml:S2:751:1	.	.	O	O

(	TAFINLAR.xml:S2:753:1	(	(	O	O
5.1	TAFINLAR.xml:S2:756:3	5.1	CD	O	O
,	TAFINLAR.xml:S2:761:1	,	,	O	O
2.3	TAFINLAR.xml:S2:764:3	2.3	CD	O	O
)	TAFINLAR.xml:S2:769:1	)	)	O	O

Tumor	TAFINLAR.xml:S2:778:5	tumor	NN	B-AdverseReaction	O
Promotion	TAFINLAR.xml:S2:784:9	promot	NNP	I-AdverseReaction	O
in	TAFINLAR.xml:S2:794:2	in	IN	I-AdverseReaction	O
BRAF	TAFINLAR.xml:S2:797:4	braf	NNP	I-AdverseReaction	O
Wild	TAFINLAR.xml:S2:802:4	wild	NNP	I-AdverseReaction	O
-	TAFINLAR.xml:S2:806:1	-	:	I-AdverseReaction	O
Type	TAFINLAR.xml:S2:807:4	type	NN	I-AdverseReaction	O
Melanoma	TAFINLAR.xml:S2:812:8	melanoma	NN	I-AdverseReaction	O
:	TAFINLAR.xml:S2:820:1	:	:	O	O
Increased	TAFINLAR.xml:S2:822:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
cell	TAFINLAR.xml:S2:832:4	cell	NN	I-AdverseReaction	I-AdverseReaction
proliferation	TAFINLAR.xml:S2:837:13	prolifer	NN	I-AdverseReaction	I-AdverseReaction
can	TAFINLAR.xml:S2:851:3	can	MD	O	O
occur	TAFINLAR.xml:S2:855:5	occur	VB	O	O
with	TAFINLAR.xml:S2:861:4	with	IN	O	O
BRAF	TAFINLAR.xml:S2:866:4	braf	NNP	O	O
inhibitors	TAFINLAR.xml:S2:871:10	inhibitor	NNS	O	O
.	TAFINLAR.xml:S2:881:1	.	.	O	O

(	TAFINLAR.xml:S2:883:1	(	(	O	O
5.2	TAFINLAR.xml:S2:886:3	5.2	CD	O	O
)	TAFINLAR.xml:S2:891:1	)	)	O	O

Hemorrhage	TAFINLAR.xml:S2:900:10	hemorrhag	NN	B-AdverseReaction	B-AdverseReaction
:	TAFINLAR.xml:S2:910:1	:	:	O	O
Major	TAFINLAR.xml:S2:912:5	major	JJ	O	O
hemorrhagic	TAFINLAR.xml:S2:918:11	hemorrhag	JJ	B-AdverseReaction	B-AdverseReaction
events	TAFINLAR.xml:S2:930:6	event	NNS	I-AdverseReaction	I-AdverseReaction
can	TAFINLAR.xml:S2:937:3	can	MD	O	O
occur	TAFINLAR.xml:S2:941:5	occur	VB	O	O
in	TAFINLAR.xml:S2:947:2	in	IN	O	O
patients	TAFINLAR.xml:S2:950:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:959:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:969:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:978:2	in	IN	O	O
combination	TAFINLAR.xml:S2:981:11	combin	NN	O	O
with	TAFINLAR.xml:S2:993:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:998:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:1008:1	.	.	O	O

Monitor	TAFINLAR.xml:S2:1010:7	monitor	NNP	O	O
for	TAFINLAR.xml:S2:1018:3	for	IN	O	O
signs	TAFINLAR.xml:S2:1022:5	sign	NNS	O	O
and	TAFINLAR.xml:S2:1028:3	and	CC	O	O
symptoms	TAFINLAR.xml:S2:1032:8	symptom	NNS	O	O
of	TAFINLAR.xml:S2:1041:2	of	IN	O	O
bleeding	TAFINLAR.xml:S2:1044:8	bleed	NN	O	O
.	TAFINLAR.xml:S2:1052:1	.	.	O	O

(	TAFINLAR.xml:S2:1054:1	(	(	O	O
5.3	TAFINLAR.xml:S2:1057:3	5.3	CD	O	O
)	TAFINLAR.xml:S2:1062:1	)	)	O	O

Venous	TAFINLAR.xml:S2:1071:6	venou	JJ	B-AdverseReaction	B-AdverseReaction
Thromboembolism	TAFINLAR.xml:S2:1078:15	thromboembol	NN	I-AdverseReaction	I-AdverseReaction
:	TAFINLAR.xml:S2:1093:1	:	:	O	O
Deep	TAFINLAR.xml:S2:1095:4	deep	JJ	B-AdverseReaction	B-AdverseReaction
vein	TAFINLAR.xml:S2:1100:4	vein	NN	I-AdverseReaction	I-AdverseReaction
thrombosis	TAFINLAR.xml:S2:1105:10	thrombosi	NN	I-AdverseReaction	I-AdverseReaction
and	TAFINLAR.xml:S2:1116:3	and	CC	O	O
pulmonary	TAFINLAR.xml:S2:1120:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
embolism	TAFINLAR.xml:S2:1130:8	embol	NN	I-AdverseReaction	I-AdverseReaction
can	TAFINLAR.xml:S2:1139:3	can	MD	O	O
occur	TAFINLAR.xml:S2:1143:5	occur	VB	O	O
in	TAFINLAR.xml:S2:1149:2	in	IN	O	O
patients	TAFINLAR.xml:S2:1152:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:1161:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:1171:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:1180:2	in	IN	O	O
combination	TAFINLAR.xml:S2:1183:11	combin	NN	O	O
with	TAFINLAR.xml:S2:1195:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:1200:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:1210:1	.	.	O	O

(	TAFINLAR.xml:S2:1212:1	(	(	O	O
5.4	TAFINLAR.xml:S2:1215:3	5.4	CD	O	O
,	TAFINLAR.xml:S2:1220:1	,	,	O	O
2.3	TAFINLAR.xml:S2:1223:3	2.3	CD	O	O
)	TAFINLAR.xml:S2:1228:1	)	)	O	O

Cardiomyopathy	TAFINLAR.xml:S2:1237:14	cardiomyopathi	NN	B-AdverseReaction	O
:	TAFINLAR.xml:S2:1251:1	:	:	O	O
Assess	TAFINLAR.xml:S2:1253:6	assess	NNP	O	O
LVEF	TAFINLAR.xml:S2:1260:4	lvef	NNP	O	O
before	TAFINLAR.xml:S2:1265:6	befor	IN	O	O
treatment	TAFINLAR.xml:S2:1272:9	treatment	NN	O	O
with	TAFINLAR.xml:S2:1282:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:1287:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:1296:2	in	IN	O	O
combination	TAFINLAR.xml:S2:1299:11	combin	NN	O	O
with	TAFINLAR.xml:S2:1311:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:1316:10	trametinib	NN	O	O
,	TAFINLAR.xml:S2:1326:1	,	,	O	O
after	TAFINLAR.xml:S2:1328:5	after	IN	O	O
one	TAFINLAR.xml:S2:1334:3	one	CD	O	O
month	TAFINLAR.xml:S2:1338:5	month	NN	O	O
of	TAFINLAR.xml:S2:1344:2	of	IN	O	O
treatment	TAFINLAR.xml:S2:1347:9	treatment	NN	O	O
,	TAFINLAR.xml:S2:1356:1	,	,	O	O
then	TAFINLAR.xml:S2:1358:4	then	RB	O	O
every	TAFINLAR.xml:S2:1363:5	everi	DT	O	O
2	TAFINLAR.xml:S2:1369:1	2	CD	O	O
to	TAFINLAR.xml:S2:1371:2	to	TO	O	O
3	TAFINLAR.xml:S2:1374:1	3	CD	O	O
months	TAFINLAR.xml:S2:1376:6	month	NNS	O	O
thereafter	TAFINLAR.xml:S2:1383:10	thereaft	RB	O	O
.	TAFINLAR.xml:S2:1393:1	.	.	O	O

(	TAFINLAR.xml:S2:1395:1	(	(	O	O
5.5	TAFINLAR.xml:S2:1398:3	5.5	CD	O	O
,	TAFINLAR.xml:S2:1403:1	,	,	O	O
2.3	TAFINLAR.xml:S2:1406:3	2.3	CD	O	O
)	TAFINLAR.xml:S2:1411:1	)	)	O	O

Ocular	TAFINLAR.xml:S2:1420:6	ocular	JJ	B-AdverseReaction	B-AdverseReaction
Toxicities	TAFINLAR.xml:S2:1427:10	toxic	NNS	I-AdverseReaction	I-AdverseReaction
:	TAFINLAR.xml:S2:1437:1	:	:	O	O
Perform	TAFINLAR.xml:S2:1439:7	perform	NNP	O	O
ophthalmologic	TAFINLAR.xml:S2:1447:14	ophthalmolog	MD	O	O
evaluation	TAFINLAR.xml:S2:1462:10	evalu	VB	O	O
for	TAFINLAR.xml:S2:1473:3	for	IN	O	O
any	TAFINLAR.xml:S2:1477:3	ani	DT	O	O
visual	TAFINLAR.xml:S2:1481:6	visual	JJ	O	O
disturbances	TAFINLAR.xml:S2:1488:12	disturb	NNS	O	O
.	TAFINLAR.xml:S2:1500:1	.	.	O	O

(	TAFINLAR.xml:S2:1502:1	(	(	O	O
5.6	TAFINLAR.xml:S2:1505:3	5.6	CD	O	O
,	TAFINLAR.xml:S2:1510:1	,	,	O	O
2.3	TAFINLAR.xml:S2:1513:3	2.3	CD	O	O
)	TAFINLAR.xml:S2:1518:1	)	)	O	O

Serious	TAFINLAR.xml:S2:1527:7	seriou	JJ	O	O
Febrile	TAFINLAR.xml:S2:1535:7	febril	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	TAFINLAR.xml:S2:1543:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
:	TAFINLAR.xml:S2:1552:1	:	:	O	O
Incidence	TAFINLAR.xml:S2:1554:9	incid	NN	O	O
and	TAFINLAR.xml:S2:1564:3	and	CC	O	O
severity	TAFINLAR.xml:S2:1568:8	sever	NN	O	O
of	TAFINLAR.xml:S2:1577:2	of	IN	O	O
pyrexia	TAFINLAR.xml:S2:1580:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
are	TAFINLAR.xml:S2:1588:3	are	VBP	O	O
increased	TAFINLAR.xml:S2:1592:9	increas	VBN	O	O
with	TAFINLAR.xml:S2:1602:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:1607:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:1616:2	in	IN	O	O
combination	TAFINLAR.xml:S2:1619:11	combin	NN	O	O
with	TAFINLAR.xml:S2:1631:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:1636:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:1646:1	.	.	O	O

(	TAFINLAR.xml:S2:1648:1	(	(	O	O
5.7	TAFINLAR.xml:S2:1651:3	5.7	CD	O	O
,	TAFINLAR.xml:S2:1656:1	,	,	O	O
2.3	TAFINLAR.xml:S2:1659:3	2.3	CD	O	O
)	TAFINLAR.xml:S2:1664:1	)	)	O	O

Serious	TAFINLAR.xml:S2:1673:7	seriou	JJ	O	O
Skin	TAFINLAR.xml:S2:1681:4	skin	NNP	B-AdverseReaction	B-AdverseReaction
Toxicity	TAFINLAR.xml:S2:1686:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
:	TAFINLAR.xml:S2:1694:1	:	:	O	O
Monitor	TAFINLAR.xml:S2:1696:7	monitor	NN	O	O
for	TAFINLAR.xml:S2:1704:3	for	IN	O	O
skin	TAFINLAR.xml:S2:1708:4	skin	NN	O	O
toxicities	TAFINLAR.xml:S2:1713:10	toxic	NNS	O	O
and	TAFINLAR.xml:S2:1724:3	and	CC	O	O
for	TAFINLAR.xml:S2:1728:3	for	IN	O	O
secondary	TAFINLAR.xml:S2:1732:9	secondari	JJ	O	O
infections	TAFINLAR.xml:S2:1742:10	infect	NNS	O	O
.	TAFINLAR.xml:S2:1752:1	.	.	O	O

Discontinue	TAFINLAR.xml:S2:1754:11	discontinu	NNP	O	O
for	TAFINLAR.xml:S2:1766:3	for	IN	O	O
intolerable	TAFINLAR.xml:S2:1770:11	intoler	JJ	O	O
Grade	TAFINLAR.xml:S2:1782:5	grade	NNP	O	O
2	TAFINLAR.xml:S2:1788:1	2	CD	O	O
,	TAFINLAR.xml:S2:1789:1	,	,	O	O
or	TAFINLAR.xml:S2:1791:2	or	CC	O	O
Grade	TAFINLAR.xml:S2:1794:5	grade	VB	O	O
3	TAFINLAR.xml:S2:1800:1	3	CD	O	O
or	TAFINLAR.xml:S2:1802:2	or	CC	O	O
4	TAFINLAR.xml:S2:1805:1	4	CD	O	O
rash	TAFINLAR.xml:S2:1807:4	rash	NN	O	B-AdverseReaction
not	TAFINLAR.xml:S2:1812:3	not	RB	O	O
improving	TAFINLAR.xml:S2:1816:9	improv	VBG	O	O
within	TAFINLAR.xml:S2:1826:6	within	IN	O	O
3	TAFINLAR.xml:S2:1833:1	3	CD	O	O
weeks	TAFINLAR.xml:S2:1835:5	week	NNS	O	O
despite	TAFINLAR.xml:S2:1841:7	despit	IN	O	O
interruption	TAFINLAR.xml:S2:1849:12	interrupt	NN	O	O
of	TAFINLAR.xml:S2:1862:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:1865:8	tafinlar	NNP	O	O
.	TAFINLAR.xml:S2:1873:1	.	.	O	O

(	TAFINLAR.xml:S2:1875:1	(	(	O	O
5.8	TAFINLAR.xml:S2:1878:3	5.8	CD	O	O
,	TAFINLAR.xml:S2:1883:1	,	,	O	O
2.3	TAFINLAR.xml:S2:1886:3	2.3	CD	O	O
)	TAFINLAR.xml:S2:1891:1	)	)	O	O

Hyperglycemia	TAFINLAR.xml:S2:1900:13	hyperglycemia	NN	B-AdverseReaction	B-AdverseReaction
:	TAFINLAR.xml:S2:1913:1	:	:	O	O
Monitor	TAFINLAR.xml:S2:1915:7	monitor	NNP	O	O
serum	TAFINLAR.xml:S2:1923:5	serum	VBD	O	O
glucose	TAFINLAR.xml:S2:1929:7	glucos	JJ	O	O
levels	TAFINLAR.xml:S2:1937:6	level	NNS	O	O
in	TAFINLAR.xml:S2:1944:2	in	IN	O	O
patients	TAFINLAR.xml:S2:1947:8	patient	NNS	O	O
with	TAFINLAR.xml:S2:1956:4	with	IN	O	O
pre	TAFINLAR.xml:S2:1961:3	pre	JJ	O	O
-	TAFINLAR.xml:S2:1964:1	-	:	O	O
existing	TAFINLAR.xml:S2:1965:8	exist	VBG	O	O
diabetes	TAFINLAR.xml:S2:1974:8	diabet	NNS	O	O
or	TAFINLAR.xml:S2:1983:2	or	CC	O	O
hyperglycemia	TAFINLAR.xml:S2:1986:13	hyperglycemia	NN	O	O
.	TAFINLAR.xml:S2:1999:1	.	.	O	O

(	TAFINLAR.xml:S2:2001:1	(	(	O	O
5.9	TAFINLAR.xml:S2:2004:3	5.9	CD	O	O
)	TAFINLAR.xml:S2:2009:1	)	)	O	O

Glucose	TAFINLAR.xml:S2:2018:7	glucos	NNP	B-AdverseReaction	B-AdverseReaction
-	TAFINLAR.xml:S2:2025:1	-	:	I-AdverseReaction	I-AdverseReaction
6	TAFINLAR.xml:S2:2026:1	6	CD	I-AdverseReaction	I-AdverseReaction
-	TAFINLAR.xml:S2:2027:1	-	:	I-AdverseReaction	I-AdverseReaction
Phosphate	TAFINLAR.xml:S2:2028:9	phosphat	NN	I-AdverseReaction	I-AdverseReaction
Dehydrogenase	TAFINLAR.xml:S2:2038:13	dehydrogenas	NNP	I-AdverseReaction	I-AdverseReaction
Deficiency	TAFINLAR.xml:S2:2052:10	defici	NNP	I-AdverseReaction	I-AdverseReaction
:	TAFINLAR.xml:S2:2062:1	:	:	O	O
Closely	TAFINLAR.xml:S2:2064:7	close	RB	O	O
monitor	TAFINLAR.xml:S2:2072:7	monitor	NN	O	O
for	TAFINLAR.xml:S2:2080:3	for	IN	O	O
hemolytic	TAFINLAR.xml:S2:2084:9	hemolyt	JJ	O	O
anemia	TAFINLAR.xml:S2:2094:6	anemia	NN	O	O
.	TAFINLAR.xml:S2:2100:1	.	.	O	O

(	TAFINLAR.xml:S2:2102:1	(	(	O	O
5.10	TAFINLAR.xml:S2:2105:4	5.10	CD	O	O
)	TAFINLAR.xml:S2:2111:1	)	)	O	O

Embryofetal	TAFINLAR.xml:S2:2120:11	embryofet	JJ	B-AdverseReaction	B-AdverseReaction
Toxicity	TAFINLAR.xml:S2:2132:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
:	TAFINLAR.xml:S2:2140:1	:	:	O	O
Can	TAFINLAR.xml:S2:2142:3	can	MD	O	O
cause	TAFINLAR.xml:S2:2146:5	caus	VB	O	O
fetal	TAFINLAR.xml:S2:2152:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
harm	TAFINLAR.xml:S2:2158:4	harm	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S2:2162:1	.	.	O	O

Advise	TAFINLAR.xml:S2:2164:6	advis	NNP	O	O
females	TAFINLAR.xml:S2:2171:7	femal	NNS	O	O
of	TAFINLAR.xml:S2:2179:2	of	IN	O	O
reproductive	TAFINLAR.xml:S2:2182:12	reproduct	JJ	O	O
potential	TAFINLAR.xml:S2:2195:9	potenti	NN	O	O
of	TAFINLAR.xml:S2:2205:2	of	IN	O	O
potential	TAFINLAR.xml:S2:2208:9	potenti	JJ	O	O
risk	TAFINLAR.xml:S2:2218:4	risk	NN	O	O
to	TAFINLAR.xml:S2:2223:2	to	TO	O	O
a	TAFINLAR.xml:S2:2226:1	a	DT	O	O
fetus	TAFINLAR.xml:S2:2228:5	fetu	NN	O	O
.	TAFINLAR.xml:S2:2233:1	.	.	O	O

TAFINLAR	TAFINLAR.xml:S2:2235:8	tafinlar	NNP	O	O
may	TAFINLAR.xml:S2:2244:3	may	MD	O	O
render	TAFINLAR.xml:S2:2248:6	render	VB	O	O
hormonal	TAFINLAR.xml:S2:2255:8	hormon	JJ	O	O
contraceptives	TAFINLAR.xml:S2:2264:14	contracept	NNS	O	O
less	TAFINLAR.xml:S2:2279:4	less	RBR	O	O
effective	TAFINLAR.xml:S2:2284:9	effect	JJ	O	O
and	TAFINLAR.xml:S2:2294:3	and	CC	O	O
an	TAFINLAR.xml:S2:2298:2	an	DT	O	O
alternative	TAFINLAR.xml:S2:2301:11	altern	JJ	O	O
method	TAFINLAR.xml:S2:2313:6	method	NN	O	O
of	TAFINLAR.xml:S2:2320:2	of	IN	O	O
contraception	TAFINLAR.xml:S2:2323:13	contracept	NN	O	O
should	TAFINLAR.xml:S2:2337:6	should	MD	O	O
be	TAFINLAR.xml:S2:2344:2	be	VB	O	O
used	TAFINLAR.xml:S2:2347:4	use	VBN	O	O
.	TAFINLAR.xml:S2:2351:1	.	.	O	O

(	TAFINLAR.xml:S2:2353:1	(	(	O	O
5.11	TAFINLAR.xml:S2:2356:4	5.11	CD	O	O
,	TAFINLAR.xml:S2:2362:1	,	,	O	O
8.1	TAFINLAR.xml:S2:2365:3	8.1	CD	O	O
)	TAFINLAR.xml:S2:2370:1	)	)	O	O

EXCERPT	TAFINLAR.xml:S2:2379:7	excerpt	NN	O	O
:	TAFINLAR.xml:S2:2386:1	:	:	O	O

5.1	TAFINLAR.xml:S2:2397:3	5.1	CD	O	O

New	TAFINLAR.xml:S2:2401:3	new	NNP	O	O
Primary	TAFINLAR.xml:S2:2405:7	primari	NNP	O	O
Malignancies	TAFINLAR.xml:S2:2413:12	malign	NNS	O	O

New	TAFINLAR.xml:S2:2431:3	new	NNP	O	B-AdverseReaction
primary	TAFINLAR.xml:S2:2435:7	primari	JJ	B-AdverseReaction	I-AdverseReaction
malignancies	TAFINLAR.xml:S2:2443:12	malign	NNS	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S2:2455:1	,	,	I-AdverseReaction	O
cutaneous	TAFINLAR.xml:S2:2457:9	cutan	JJ	I-AdverseReaction	O
and	TAFINLAR.xml:S2:2467:3	and	CC	O	O
non	TAFINLAR.xml:S2:2471:3	non	JJ	I-AdverseReaction	O
-	TAFINLAR.xml:S2:2474:1	-	:	I-AdverseReaction	O
cutaneous	TAFINLAR.xml:S2:2475:9	cutan	JJ	I-AdverseReaction	O
,	TAFINLAR.xml:S2:2484:1	,	,	O	O
can	TAFINLAR.xml:S2:2486:3	can	MD	O	O
occur	TAFINLAR.xml:S2:2490:5	occur	VB	O	O
when	TAFINLAR.xml:S2:2496:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:2501:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:2510:2	is	VBZ	O	O
administered	TAFINLAR.xml:S2:2513:12	administ	VBN	O	O
as	TAFINLAR.xml:S2:2526:2	as	IN	O	O
a	TAFINLAR.xml:S2:2529:1	a	DT	O	O
single	TAFINLAR.xml:S2:2531:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:2538:5	agent	NN	O	O
or	TAFINLAR.xml:S2:2544:2	or	CC	O	O
when	TAFINLAR.xml:S2:2547:4	when	WRB	O	O
used	TAFINLAR.xml:S2:2552:4	use	VBN	O	O
in	TAFINLAR.xml:S2:2557:2	in	IN	O	O
combination	TAFINLAR.xml:S2:2560:11	combin	NN	O	O
with	TAFINLAR.xml:S2:2572:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:2577:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:2587:1	.	.	O	O

Cutaneous	TAFINLAR.xml:S2:2594:9	cutan	JJ	O	B-AdverseReaction
Malignancies	TAFINLAR.xml:S2:2604:12	malign	NNS	O	I-AdverseReaction
:	TAFINLAR.xml:S2:2616:1	:	:	O	O

TAFINLAR	TAFINLAR.xml:S2:2624:8	tafinlar	NNP	O	O
results	TAFINLAR.xml:S2:2633:7	result	NNS	O	O
in	TAFINLAR.xml:S2:2641:2	in	IN	O	O
an	TAFINLAR.xml:S2:2644:2	an	DT	O	O
increased	TAFINLAR.xml:S2:2647:9	increas	JJ	O	O
incidence	TAFINLAR.xml:S2:2657:9	incid	NN	O	O
of	TAFINLAR.xml:S2:2667:2	of	IN	O	O
cutaneous	TAFINLAR.xml:S2:2670:9	cutan	JJ	B-AdverseReaction	B-AdverseReaction
squamous	TAFINLAR.xml:S2:2680:8	squamou	JJ	I-AdverseReaction	I-AdverseReaction
cell	TAFINLAR.xml:S2:2689:4	cell	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:2694:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S2:2703:1	,	,	O	O
keratoacanthoma	TAFINLAR.xml:S2:2705:15	keratoacanthoma	NN	B-AdverseReaction	O
,	TAFINLAR.xml:S2:2720:1	,	,	O	O
and	TAFINLAR.xml:S2:2722:3	and	CC	O	O
melanoma	TAFINLAR.xml:S2:2726:8	melanoma	NN	B-AdverseReaction	O
.	TAFINLAR.xml:S2:2734:1	.	.	O	O

TAFINLAR	TAFINLAR.xml:S2:2736:8	tafinlar	NN	O	O
when	TAFINLAR.xml:S2:2745:4	when	WRB	O	O
used	TAFINLAR.xml:S2:2750:4	use	VBN	O	O
in	TAFINLAR.xml:S2:2755:2	in	IN	O	O
combination	TAFINLAR.xml:S2:2758:11	combin	NN	O	O
with	TAFINLAR.xml:S2:2770:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:2775:10	trametinib	JJ	O	O
results	TAFINLAR.xml:S2:2786:7	result	NNS	O	O
in	TAFINLAR.xml:S2:2794:2	in	IN	O	O
an	TAFINLAR.xml:S2:2797:2	an	DT	O	O
increased	TAFINLAR.xml:S2:2800:9	increas	JJ	O	O
incidence	TAFINLAR.xml:S2:2810:9	incid	NN	O	O
of	TAFINLAR.xml:S2:2820:2	of	IN	O	O
basal	TAFINLAR.xml:S2:2823:5	basal	NN	B-AdverseReaction	B-AdverseReaction
cell	TAFINLAR.xml:S2:2829:4	cell	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:2834:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
.	TAFINLAR.xml:S2:2843:1	.	.	O	O

In	TAFINLAR.xml:S2:2851:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:2854:5	trial	NNP	O	O
1	TAFINLAR.xml:S2:2860:1	1	CD	O	O
,	TAFINLAR.xml:S2:2861:1	,	,	O	O
cutaneous	TAFINLAR.xml:S2:2863:9	cutan	JJ	B-AdverseReaction	B-AdverseReaction
squamous	TAFINLAR.xml:S2:2873:8	squamou	JJ	I-AdverseReaction	I-AdverseReaction
cell	TAFINLAR.xml:S2:2882:4	cell	NN	I-AdverseReaction	I-AdverseReaction
carcinomas	TAFINLAR.xml:S2:2887:10	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
and	TAFINLAR.xml:S2:2898:3	and	CC	O	O
keratoacanthomas	TAFINLAR.xml:S2:2902:16	keratoacanthoma	NN	B-AdverseReaction	O
(	TAFINLAR.xml:S2:2919:1	(	(	O	O
cuSCC	TAFINLAR.xml:S2:2920:5	cuscc	NN	B-AdverseReaction	B-AdverseReaction
)	TAFINLAR.xml:S2:2925:1	)	)	O	O
occurred	TAFINLAR.xml:S2:2927:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:2936:2	in	IN	O	O
7%	TAFINLAR.xml:S2:2939:2	7%	CD	O	O
(	TAFINLAR.xml:S2:2942:1	(	(	O	O
14	TAFINLAR.xml:S2:2943:2	14	CD	O	O
187	TAFINLAR.xml:S2:2946:3	187	CD	O	O
)	TAFINLAR.xml:S2:2949:1	)	)	O	O
of	TAFINLAR.xml:S2:2951:2	of	IN	O	O
patients	TAFINLAR.xml:S2:2954:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:2963:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:2971:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:2976:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S2:2985:3	and	CC	O	O
in	TAFINLAR.xml:S2:2989:2	in	IN	O	O
none	TAFINLAR.xml:S2:2992:4	none	NN	O	O
of	TAFINLAR.xml:S2:2997:2	of	IN	O	O
the	TAFINLAR.xml:S2:3000:3	the	DT	O	O
patients	TAFINLAR.xml:S2:3004:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:3013:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:3021:4	with	IN	O	O
dacarbazine	TAFINLAR.xml:S2:3026:11	dacarbazin	NN	O	O
.	TAFINLAR.xml:S2:3037:1	.	.	O	O

Across	TAFINLAR.xml:S2:3043:6	across	IN	O	O
clinical	TAFINLAR.xml:S2:3050:8	clinic	JJ	O	O
trials	TAFINLAR.xml:S2:3059:6	trial	NNS	O	O
of	TAFINLAR.xml:S2:3066:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:3069:8	tafinlar	NNP	O	O
(	TAFINLAR.xml:S2:3078:1	(	(	O	O
N	TAFINLAR.xml:S2:3079:1	N	NNP	O	O
586	TAFINLAR.xml:S2:3083:3	586	CD	O	O
)	TAFINLAR.xml:S2:3086:1	)	)	O	O
,	TAFINLAR.xml:S2:3087:1	,	,	O	O
the	TAFINLAR.xml:S2:3089:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:3093:9	incid	NN	O	O
of	TAFINLAR.xml:S2:3103:2	of	IN	O	O
cuSCC	TAFINLAR.xml:S2:3106:5	cuscc	NN	B-AdverseReaction	O
was	TAFINLAR.xml:S2:3112:3	wa	VBD	O	O
11%	TAFINLAR.xml:S2:3116:3	11%	CD	O	O
.	TAFINLAR.xml:S2:3119:1	.	.	O	O

The	TAFINLAR.xml:S2:3121:3	the	DT	O	O
median	TAFINLAR.xml:S2:3125:6	median	JJ	O	O
time	TAFINLAR.xml:S2:3132:4	time	NN	O	O
to	TAFINLAR.xml:S2:3137:2	to	TO	O	O
first	TAFINLAR.xml:S2:3140:5	first	VB	O	O
cuSCC	TAFINLAR.xml:S2:3146:5	cuscc	NN	B-AdverseReaction	O
was	TAFINLAR.xml:S2:3152:3	wa	VBD	O	O
9	TAFINLAR.xml:S2:3156:1	9	CD	O	O
weeks	TAFINLAR.xml:S2:3158:5	week	NNS	O	O
(	TAFINLAR.xml:S2:3164:1	(	(	O	O
range	TAFINLAR.xml:S2:3165:5	rang	NN	O	O
:	TAFINLAR.xml:S2:3170:1	:	:	O	O
1	TAFINLAR.xml:S2:3172:1	1	CD	O	O
to	TAFINLAR.xml:S2:3174:2	to	TO	O	O
53	TAFINLAR.xml:S2:3177:2	53	CD	O	O
weeks	TAFINLAR.xml:S2:3180:5	week	NNS	O	O
)	TAFINLAR.xml:S2:3185:1	)	)	O	O
.	TAFINLAR.xml:S2:3186:1	.	.	O	O

Of	TAFINLAR.xml:S2:3188:2	Of	IN	O	O
those	TAFINLAR.xml:S2:3191:5	those	DT	O	O
patients	TAFINLAR.xml:S2:3197:8	patient	NNS	O	O
who	TAFINLAR.xml:S2:3206:3	who	WP	O	O
developed	TAFINLAR.xml:S2:3210:9	develop	VBD	O	O
new	TAFINLAR.xml:S2:3220:3	new	JJ	O	O
cuSCC	TAFINLAR.xml:S2:3224:5	cuscc	NN	B-AdverseReaction	O
,	TAFINLAR.xml:S2:3229:1	,	,	O	O
approximately	TAFINLAR.xml:S2:3231:13	approxim	RB	O	O
33%	TAFINLAR.xml:S2:3245:3	33%	CD	O	O
developed	TAFINLAR.xml:S2:3249:9	develop	VBD	O	O
one	TAFINLAR.xml:S2:3259:3	one	CD	O	O
or	TAFINLAR.xml:S2:3263:2	or	CC	O	O
more	TAFINLAR.xml:S2:3266:4	more	JJR	O	O
cuSCC	TAFINLAR.xml:S2:3271:5	cuscc	NNS	B-AdverseReaction	O
with	TAFINLAR.xml:S2:3277:4	with	IN	O	O
continued	TAFINLAR.xml:S2:3282:9	continu	JJ	O	O
administration	TAFINLAR.xml:S2:3292:14	administr	NN	O	O
of	TAFINLAR.xml:S2:3307:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:3310:8	tafinlar	NNP	O	O
.	TAFINLAR.xml:S2:3318:1	.	.	O	O

The	TAFINLAR.xml:S2:3320:3	the	DT	O	O
median	TAFINLAR.xml:S2:3324:6	median	JJ	O	O
time	TAFINLAR.xml:S2:3331:4	time	NN	O	O
between	TAFINLAR.xml:S2:3336:7	between	IN	O	O
diagnosis	TAFINLAR.xml:S2:3344:9	diagnosi	NN	O	O
of	TAFINLAR.xml:S2:3354:2	of	IN	O	O
the	TAFINLAR.xml:S2:3357:3	the	DT	O	O
first	TAFINLAR.xml:S2:3361:5	first	JJ	O	O
cuSCC	TAFINLAR.xml:S2:3367:5	cuscc	NN	B-AdverseReaction	O
and	TAFINLAR.xml:S2:3373:3	and	CC	O	O
the	TAFINLAR.xml:S2:3377:3	the	DT	O	O
second	TAFINLAR.xml:S2:3381:6	second	JJ	O	O
cuSCC	TAFINLAR.xml:S2:3388:5	cuscc	NN	B-AdverseReaction	O
was	TAFINLAR.xml:S2:3394:3	wa	VBD	O	O
6	TAFINLAR.xml:S2:3398:1	6	CD	O	O
weeks	TAFINLAR.xml:S2:3400:5	week	NNS	O	O
.	TAFINLAR.xml:S2:3405:1	.	.	O	O

In	TAFINLAR.xml:S2:3411:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:3414:5	trial	NNP	O	O
1	TAFINLAR.xml:S2:3420:1	1	CD	O	O
,	TAFINLAR.xml:S2:3421:1	,	,	O	O
the	TAFINLAR.xml:S2:3423:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:3427:9	incid	NN	O	O
of	TAFINLAR.xml:S2:3437:2	of	IN	O	O
new	TAFINLAR.xml:S2:3440:3	new	JJ	O	B-AdverseReaction
primary	TAFINLAR.xml:S2:3444:7	primari	JJ	B-AdverseReaction	I-AdverseReaction
malignant	TAFINLAR.xml:S2:3452:9	malign	JJ	I-AdverseReaction	I-AdverseReaction
melanomas	TAFINLAR.xml:S2:3462:9	melanoma	NN	I-AdverseReaction	I-AdverseReaction
was	TAFINLAR.xml:S2:3472:3	wa	VBD	O	O
2%	TAFINLAR.xml:S2:3476:2	2%	CD	O	O
(	TAFINLAR.xml:S2:3479:1	(	(	O	O
3	TAFINLAR.xml:S2:3480:1	3	CD	O	O
187	TAFINLAR.xml:S2:3482:3	187	CD	O	O
)	TAFINLAR.xml:S2:3485:1	)	)	O	O
for	TAFINLAR.xml:S2:3487:3	for	IN	O	O
patients	TAFINLAR.xml:S2:3491:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:3500:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:3510:8	tafinlar	NNP	O	O
while	TAFINLAR.xml:S2:3519:5	while	IN	O	O
no	TAFINLAR.xml:S2:3525:2	no	DT	O	O
dacarbazine	TAFINLAR.xml:S2:3528:11	dacarbazin	NN	O	O
-	TAFINLAR.xml:S2:3539:1	-	:	O	O
treated	TAFINLAR.xml:S2:3540:7	treat	JJ	O	O
patient	TAFINLAR.xml:S2:3548:7	patient	NN	O	O
was	TAFINLAR.xml:S2:3556:3	wa	VBD	O	O
diagnosed	TAFINLAR.xml:S2:3560:9	diagnos	VBN	O	O
with	TAFINLAR.xml:S2:3570:4	with	IN	O	O
new	TAFINLAR.xml:S2:3575:3	new	JJ	O	O
primary	TAFINLAR.xml:S2:3579:7	primari	JJ	O	O
malignant	TAFINLAR.xml:S2:3587:9	malign	JJ	O	O
melanoma	TAFINLAR.xml:S2:3597:8	melanoma	NN	O	O
.	TAFINLAR.xml:S2:3605:1	.	.	O	O

In	TAFINLAR.xml:S2:3612:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:3615:5	trial	NNP	O	O
2	TAFINLAR.xml:S2:3621:1	2	CD	O	O
,	TAFINLAR.xml:S2:3622:1	,	,	O	O
the	TAFINLAR.xml:S2:3624:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:3628:9	incid	NN	O	O
of	TAFINLAR.xml:S2:3638:2	of	IN	O	O
basal	TAFINLAR.xml:S2:3641:5	basal	NN	B-AdverseReaction	B-AdverseReaction
cell	TAFINLAR.xml:S2:3647:4	cell	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:3652:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
was	TAFINLAR.xml:S2:3662:3	wa	VBD	O	O
increased	TAFINLAR.xml:S2:3666:9	increas	VBN	O	O
in	TAFINLAR.xml:S2:3676:2	in	IN	O	O
patients	TAFINLAR.xml:S2:3679:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:3688:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:3698:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:3707:2	in	IN	O	O
combination	TAFINLAR.xml:S2:3710:11	combin	NN	O	O
with	TAFINLAR.xml:S2:3722:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:3727:10	trametinib	NN	O	O
:	TAFINLAR.xml:S2:3737:1	:	:	O	O
9%	TAFINLAR.xml:S2:3739:2	9%	CD	O	O
(	TAFINLAR.xml:S2:3742:1	(	(	O	O
5	TAFINLAR.xml:S2:3743:1	5	CD	O	O
55	TAFINLAR.xml:S2:3745:2	55	CD	O	O
)	TAFINLAR.xml:S2:3747:1	)	)	O	O
of	TAFINLAR.xml:S2:3749:2	of	IN	O	O
patients	TAFINLAR.xml:S2:3752:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:3761:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:3771:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:3780:2	in	IN	O	O
combination	TAFINLAR.xml:S2:3783:11	combin	NN	O	O
with	TAFINLAR.xml:S2:3795:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:3800:10	trametinib	NNS	O	O
compared	TAFINLAR.xml:S2:3811:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:3820:4	with	IN	O	O
2%	TAFINLAR.xml:S2:3825:2	2%	CD	O	O
(	TAFINLAR.xml:S2:3828:1	(	(	O	O
1	TAFINLAR.xml:S2:3829:1	1	CD	O	O
53	TAFINLAR.xml:S2:3831:2	53	CD	O	O
)	TAFINLAR.xml:S2:3833:1	)	)	O	O
of	TAFINLAR.xml:S2:3835:2	of	IN	O	O
patients	TAFINLAR.xml:S2:3838:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:3847:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:3857:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:3866:2	as	IN	O	O
a	TAFINLAR.xml:S2:3869:1	a	DT	O	O
single	TAFINLAR.xml:S2:3871:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:3878:5	agent	NN	O	O
.	TAFINLAR.xml:S2:3883:1	.	.	O	O

The	TAFINLAR.xml:S2:3885:3	the	DT	O	O
range	TAFINLAR.xml:S2:3889:5	rang	NN	O	O
of	TAFINLAR.xml:S2:3895:2	of	IN	O	O
time	TAFINLAR.xml:S2:3898:4	time	NN	O	O
to	TAFINLAR.xml:S2:3903:2	to	TO	O	O
diagnosis	TAFINLAR.xml:S2:3906:9	diagnosi	NN	O	O
of	TAFINLAR.xml:S2:3916:2	of	IN	O	O
basal	TAFINLAR.xml:S2:3919:5	basal	NN	B-AdverseReaction	O
cell	TAFINLAR.xml:S2:3925:4	cell	NN	I-AdverseReaction	O
carcinoma	TAFINLAR.xml:S2:3930:9	carcinoma	NN	I-AdverseReaction	O
was	TAFINLAR.xml:S2:3940:3	wa	VBD	O	O
28	TAFINLAR.xml:S2:3944:2	28	CD	O	O
to	TAFINLAR.xml:S2:3947:2	to	TO	O	O
249	TAFINLAR.xml:S2:3950:3	249	CD	O	O
days	TAFINLAR.xml:S2:3954:4	day	NNS	O	O
in	TAFINLAR.xml:S2:3959:2	in	IN	O	O
patients	TAFINLAR.xml:S2:3962:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:3971:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:3981:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:3990:2	in	IN	O	O
combination	TAFINLAR.xml:S2:3993:11	combin	NN	O	O
with	TAFINLAR.xml:S2:4005:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:4010:10	trametinib	NN	O	O
and	TAFINLAR.xml:S2:4021:3	and	CC	O	O
was	TAFINLAR.xml:S2:4025:3	wa	VBD	O	O
197	TAFINLAR.xml:S2:4029:3	197	CD	O	O
days	TAFINLAR.xml:S2:4033:4	day	NNS	O	O
for	TAFINLAR.xml:S2:4038:3	for	IN	O	O
the	TAFINLAR.xml:S2:4042:3	the	DT	O	O
patient	TAFINLAR.xml:S2:4046:7	patient	NN	O	O
receiving	TAFINLAR.xml:S2:4054:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:4064:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:4073:2	as	IN	O	O
a	TAFINLAR.xml:S2:4076:1	a	DT	O	O
single	TAFINLAR.xml:S2:4078:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:4085:5	agent	NN	O	O
.	TAFINLAR.xml:S2:4090:1	.	.	O	O

Cutaneous	TAFINLAR.xml:S2:4099:9	cutan	JJ	B-AdverseReaction	B-AdverseReaction
squamous	TAFINLAR.xml:S2:4109:8	squamou	JJ	I-AdverseReaction	I-AdverseReaction
cell	TAFINLAR.xml:S2:4118:4	cell	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:4123:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
(	TAFINLAR.xml:S2:4133:1	(	(	O	O
SCC	TAFINLAR.xml:S2:4134:3	scc	NNP	B-AdverseReaction	O
)	TAFINLAR.xml:S2:4137:1	)	)	O	O
,	TAFINLAR.xml:S2:4138:1	,	,	O	O
including	TAFINLAR.xml:S2:4140:9	includ	VBG	O	O
keratoacanthoma	TAFINLAR.xml:S2:4150:15	keratoacanthoma	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S2:4165:1	,	,	O	O
occurred	TAFINLAR.xml:S2:4167:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:4176:2	in	IN	O	O
7%	TAFINLAR.xml:S2:4179:2	7%	CD	O	O
of	TAFINLAR.xml:S2:4182:2	of	IN	O	O
patients	TAFINLAR.xml:S2:4185:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:4194:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:4204:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:4213:2	in	IN	O	O
combination	TAFINLAR.xml:S2:4216:11	combin	NN	O	O
with	TAFINLAR.xml:S2:4228:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:4233:10	trametinib	NN	O	O
and	TAFINLAR.xml:S2:4244:3	and	CC	O	O
19%	TAFINLAR.xml:S2:4248:3	19%	CD	O	O
of	TAFINLAR.xml:S2:4252:2	of	IN	O	O
patients	TAFINLAR.xml:S2:4255:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:4264:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:4274:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:4283:2	as	IN	O	O
a	TAFINLAR.xml:S2:4286:1	a	DT	O	O
single	TAFINLAR.xml:S2:4288:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:4295:5	agent	NN	O	O
.	TAFINLAR.xml:S2:4300:1	.	.	O	O

The	TAFINLAR.xml:S2:4302:3	the	DT	O	O
range	TAFINLAR.xml:S2:4306:5	rang	NN	O	O
of	TAFINLAR.xml:S2:4312:2	of	IN	O	O
time	TAFINLAR.xml:S2:4315:4	time	NN	O	O
to	TAFINLAR.xml:S2:4320:2	to	TO	O	O
diagnosis	TAFINLAR.xml:S2:4323:9	diagnosi	NN	O	O
of	TAFINLAR.xml:S2:4333:2	of	IN	O	O
cuSCC	TAFINLAR.xml:S2:4336:5	cuscc	NN	B-AdverseReaction	O
was	TAFINLAR.xml:S2:4342:3	wa	VBD	O	O
136	TAFINLAR.xml:S2:4346:3	136	CD	O	O
to197	TAFINLAR.xml:S2:4350:5	to197	JJ	O	O
days	TAFINLAR.xml:S2:4356:4	day	NNS	O	O
in	TAFINLAR.xml:S2:4361:2	in	IN	O	O
the	TAFINLAR.xml:S2:4364:3	the	DT	O	O
combination	TAFINLAR.xml:S2:4368:11	combin	NN	O	O
arm	TAFINLAR.xml:S2:4380:3	arm	NN	O	O
and	TAFINLAR.xml:S2:4384:3	and	CC	O	O
was	TAFINLAR.xml:S2:4388:3	wa	VBD	O	O
9	TAFINLAR.xml:S2:4392:1	9	CD	O	O
to	TAFINLAR.xml:S2:4394:2	to	TO	O	O
197	TAFINLAR.xml:S2:4397:3	197	CD	O	O
days	TAFINLAR.xml:S2:4401:4	day	NNS	O	O
in	TAFINLAR.xml:S2:4406:2	in	IN	O	O
the	TAFINLAR.xml:S2:4409:3	the	DT	O	O
arm	TAFINLAR.xml:S2:4413:3	arm	NN	O	O
receiving	TAFINLAR.xml:S2:4417:9	receiv	NN	O	O
TAFINLAR	TAFINLAR.xml:S2:4427:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:4436:2	as	IN	O	O
a	TAFINLAR.xml:S2:4439:1	a	DT	O	O
single	TAFINLAR.xml:S2:4441:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:4448:5	agent	NN	O	O
.	TAFINLAR.xml:S2:4453:1	.	.	O	O

New	TAFINLAR.xml:S2:4462:3	new	NNP	O	B-AdverseReaction
primary	TAFINLAR.xml:S2:4466:7	primari	JJ	B-AdverseReaction	I-AdverseReaction
melanoma	TAFINLAR.xml:S2:4474:8	melanoma	NN	I-AdverseReaction	I-AdverseReaction
occurred	TAFINLAR.xml:S2:4483:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:4492:2	in	IN	O	O
2%	TAFINLAR.xml:S2:4495:2	2%	CD	O	O
(	TAFINLAR.xml:S2:4498:1	(	(	O	O
1	TAFINLAR.xml:S2:4499:1	1	CD	O	O
53	TAFINLAR.xml:S2:4501:2	53	CD	O	O
)	TAFINLAR.xml:S2:4503:1	)	)	O	O
of	TAFINLAR.xml:S2:4505:2	of	IN	O	O
patients	TAFINLAR.xml:S2:4508:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:4517:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:4527:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:4536:2	as	IN	O	O
a	TAFINLAR.xml:S2:4539:1	a	DT	O	O
single	TAFINLAR.xml:S2:4541:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:4548:5	agent	NN	O	O
and	TAFINLAR.xml:S2:4554:3	and	CC	O	O
in	TAFINLAR.xml:S2:4558:2	in	IN	O	O
none	TAFINLAR.xml:S2:4561:4	none	NN	O	O
of	TAFINLAR.xml:S2:4566:2	of	IN	O	O
the	TAFINLAR.xml:S2:4569:3	the	DT	O	O
55	TAFINLAR.xml:S2:4573:2	55	CD	O	O
patients	TAFINLAR.xml:S2:4576:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:4585:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:4595:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:4604:2	in	IN	O	O
combination	TAFINLAR.xml:S2:4607:11	combin	NN	O	O
with	TAFINLAR.xml:S2:4619:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:4624:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:4634:1	.	.	O	O

Perform	TAFINLAR.xml:S2:4643:7	perform	NNP	O	O
dermatologic	TAFINLAR.xml:S2:4651:12	dermatolog	JJ	O	O
evaluations	TAFINLAR.xml:S2:4664:11	evalu	NNS	O	O
prior	TAFINLAR.xml:S2:4676:5	prior	RB	O	O
to	TAFINLAR.xml:S2:4682:2	to	TO	O	O
initiation	TAFINLAR.xml:S2:4685:10	initi	NN	O	O
of	TAFINLAR.xml:S2:4696:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:4699:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:4708:2	as	IN	O	O
a	TAFINLAR.xml:S2:4711:1	a	DT	O	O
single	TAFINLAR.xml:S2:4713:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:4720:5	agent	NN	O	O
or	TAFINLAR.xml:S2:4726:2	or	CC	O	O
in	TAFINLAR.xml:S2:4729:2	in	IN	O	O
combination	TAFINLAR.xml:S2:4732:11	combin	NN	O	O
with	TAFINLAR.xml:S2:4744:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:4749:10	trametinib	NN	O	O
,	TAFINLAR.xml:S2:4759:1	,	,	O	O
every	TAFINLAR.xml:S2:4761:5	everi	DT	O	O
2	TAFINLAR.xml:S2:4767:1	2	CD	O	O
months	TAFINLAR.xml:S2:4769:6	month	NNS	O	O
while	TAFINLAR.xml:S2:4776:5	while	IN	O	O
on	TAFINLAR.xml:S2:4782:2	on	IN	O	O
therapy	TAFINLAR.xml:S2:4785:7	therapi	NN	O	O
,	TAFINLAR.xml:S2:4792:1	,	,	O	O
and	TAFINLAR.xml:S2:4794:3	and	CC	O	O
for	TAFINLAR.xml:S2:4798:3	for	IN	O	O
up	TAFINLAR.xml:S2:4802:2	up	RB	O	O
to	TAFINLAR.xml:S2:4805:2	to	TO	O	O
6	TAFINLAR.xml:S2:4808:1	6	CD	O	O
months	TAFINLAR.xml:S2:4810:6	month	NNS	O	O
following	TAFINLAR.xml:S2:4817:9	follow	VBG	O	O
discontinuation	TAFINLAR.xml:S2:4827:15	discontinu	NN	O	O
of	TAFINLAR.xml:S2:4843:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:4846:8	tafinlar	NNP	O	O
.	TAFINLAR.xml:S2:4854:1	.	.	O	O

No	TAFINLAR.xml:S2:4856:2	No	DT	O	O
dose	TAFINLAR.xml:S2:4859:4	dose	JJ	O	O
modifications	TAFINLAR.xml:S2:4864:13	modif	NNS	O	O
of	TAFINLAR.xml:S2:4878:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:4881:8	tafinlar	NNP	O	O
or	TAFINLAR.xml:S2:4890:2	or	CC	O	O
trametinib	TAFINLAR.xml:S2:4893:10	trametinib	EX	O	O
are	TAFINLAR.xml:S2:4904:3	are	VBP	O	O
required	TAFINLAR.xml:S2:4908:8	requir	VBN	O	O
in	TAFINLAR.xml:S2:4917:2	in	IN	O	O
patients	TAFINLAR.xml:S2:4920:8	patient	NNS	O	O
who	TAFINLAR.xml:S2:4929:3	who	WP	O	O
develop	TAFINLAR.xml:S2:4933:7	develop	VBP	O	O
new	TAFINLAR.xml:S2:4941:3	new	JJ	O	O
primary	TAFINLAR.xml:S2:4945:7	primari	JJ	O	O
cutaneous	TAFINLAR.xml:S2:4953:9	cutan	JJ	O	O
malignancies	TAFINLAR.xml:S2:4963:12	malign	NNS	O	O
.	TAFINLAR.xml:S2:4975:1	.	.	O	O

Non	TAFINLAR.xml:S2:4985:3	non	NNP	O	B-AdverseReaction
-	TAFINLAR.xml:S2:4988:1	-	:	O	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:4989:9	cutan	JJ	O	I-AdverseReaction
Malignancies	TAFINLAR.xml:S2:4999:12	malign	NNS	O	I-AdverseReaction
:	TAFINLAR.xml:S2:5011:1	:	:	O	O

Based	TAFINLAR.xml:S2:5022:5	base	VBN	O	O
on	TAFINLAR.xml:S2:5028:2	on	IN	O	O
its	TAFINLAR.xml:S2:5031:3	it	PRP$	O	O
mechanism	TAFINLAR.xml:S2:5035:9	mechan	NN	O	O
of	TAFINLAR.xml:S2:5045:2	of	IN	O	O
action	TAFINLAR.xml:S2:5048:6	action	NN	O	O
,	TAFINLAR.xml:S2:5054:1	,	,	O	O
TAFINLAR	TAFINLAR.xml:S2:5056:8	tafinlar	NNP	O	O
may	TAFINLAR.xml:S2:5065:3	may	MD	O	O
promote	TAFINLAR.xml:S2:5069:7	promot	VB	O	O
the	TAFINLAR.xml:S2:5077:3	the	DT	O	O
growth	TAFINLAR.xml:S2:5081:6	growth	NN	O	O
and	TAFINLAR.xml:S2:5088:3	and	CC	O	O
development	TAFINLAR.xml:S2:5092:11	develop	NN	O	O
of	TAFINLAR.xml:S2:5104:2	of	IN	O	O
malignancies	TAFINLAR.xml:S2:5107:12	malign	NNS	B-AdverseReaction	O
with	TAFINLAR.xml:S2:5120:4	with	IN	O	O
activation	TAFINLAR.xml:S2:5125:10	activ	NN	O	O
of	TAFINLAR.xml:S2:5136:2	of	IN	O	O
RAS	TAFINLAR.xml:S2:5139:3	ra	NNP	O	O
through	TAFINLAR.xml:S2:5143:7	through	IN	O	O
mutation	TAFINLAR.xml:S2:5151:8	mutat	NN	O	O
or	TAFINLAR.xml:S2:5160:2	or	CC	O	O
other	TAFINLAR.xml:S2:5163:5	other	JJ	O	O
mechanisms	TAFINLAR.xml:S2:5169:10	mechan	NNS	O	O
[	TAFINLAR.xml:S2:5180:1	[	VBP	O	O
see	TAFINLAR.xml:S2:5181:3	see	VBP	O	O
Warnings	TAFINLAR.xml:S2:5185:8	warn	NNS	O	O
and	TAFINLAR.xml:S2:5194:3	and	CC	O	O
Precautions	TAFINLAR.xml:S2:5198:11	precaut	NNP	O	O
(	TAFINLAR.xml:S2:5210:1	(	(	O	O
5.2	TAFINLAR.xml:S2:5211:3	5.2	CD	O	O
)]	TAFINLAR.xml:S2:5214:2	)]	NN	O	O
.	TAFINLAR.xml:S2:5218:1	.	.	O	O

In	TAFINLAR.xml:S2:5220:2	In	IN	O	O
patients	TAFINLAR.xml:S2:5223:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:5232:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:5242:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:5251:2	in	IN	O	O
combination	TAFINLAR.xml:S2:5254:11	combin	NN	O	O
with	TAFINLAR.xml:S2:5266:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:5271:10	trametinib	JJ	O	O
four	TAFINLAR.xml:S2:5282:4	four	CD	O	O
cases	TAFINLAR.xml:S2:5287:5	case	NNS	O	O
of	TAFINLAR.xml:S2:5293:2	of	IN	O	O
non	TAFINLAR.xml:S2:5296:3	non	JJ	B-AdverseReaction	B-AdverseReaction
-	TAFINLAR.xml:S2:5299:1	-	:	I-AdverseReaction	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:5300:9	cutan	JJ	I-AdverseReaction	I-AdverseReaction
malignancies	TAFINLAR.xml:S2:5310:12	malign	NNS	I-AdverseReaction	I-AdverseReaction
were	TAFINLAR.xml:S2:5323:4	were	VBD	O	O
identified	TAFINLAR.xml:S2:5328:10	identifi	VBN	O	O
:	TAFINLAR.xml:S2:5338:1	:	:	O	O
KRAS	TAFINLAR.xml:S2:5340:4	kra	NNP	B-AdverseReaction	O
mutation	TAFINLAR.xml:S2:5345:8	mutat	NN	I-AdverseReaction	O
-	TAFINLAR.xml:S2:5353:1	-	:	I-AdverseReaction	O
positive	TAFINLAR.xml:S2:5354:8	posit	JJ	I-AdverseReaction	O
pancreatic	TAFINLAR.xml:S2:5363:10	pancreat	JJ	I-AdverseReaction	O
adenocarcinoma	TAFINLAR.xml:S2:5374:14	adenocarcinoma	NN	I-AdverseReaction	O
(	TAFINLAR.xml:S2:5389:1	(	(	O	O
n	TAFINLAR.xml:S2:5390:1	n	JJ	O	O
1	TAFINLAR.xml:S2:5394:1	1	CD	O	O
)	TAFINLAR.xml:S2:5395:1	)	)	O	O
,	TAFINLAR.xml:S2:5396:1	,	,	O	O
recurrent	TAFINLAR.xml:S2:5398:9	recurr	JJ	B-AdverseReaction	O
NRAS	TAFINLAR.xml:S2:5408:4	nra	NNP	I-AdverseReaction	O
mutation	TAFINLAR.xml:S2:5413:8	mutat	NN	I-AdverseReaction	O
-	TAFINLAR.xml:S2:5421:1	-	:	I-AdverseReaction	O
positive	TAFINLAR.xml:S2:5422:8	posit	JJ	I-AdverseReaction	O
colorectal	TAFINLAR.xml:S2:5431:10	colorect	JJ	I-AdverseReaction	O
carcinoma	TAFINLAR.xml:S2:5442:9	carcinoma	NN	I-AdverseReaction	O
(	TAFINLAR.xml:S2:5452:1	(	(	O	O
n	TAFINLAR.xml:S2:5453:1	n	JJ	O	O
1	TAFINLAR.xml:S2:5457:1	1	CD	O	O
)	TAFINLAR.xml:S2:5458:1	)	)	O	O
,	TAFINLAR.xml:S2:5459:1	,	,	O	O
head	TAFINLAR.xml:S2:5461:4	head	NN	B-AdverseReaction	B-AdverseReaction
and	TAFINLAR.xml:S2:5466:3	and	CC	I-AdverseReaction	O
neck	TAFINLAR.xml:S2:5470:4	neck	NN	I-AdverseReaction	O
carcinoma	TAFINLAR.xml:S2:5475:9	carcinoma	NN	I-AdverseReaction	O
(	TAFINLAR.xml:S2:5485:1	(	(	O	O
n	TAFINLAR.xml:S2:5486:1	n	JJ	O	O
1	TAFINLAR.xml:S2:5490:1	1	CD	O	O
)	TAFINLAR.xml:S2:5491:1	)	)	O	O
,	TAFINLAR.xml:S2:5492:1	,	,	O	O
and	TAFINLAR.xml:S2:5494:3	and	CC	O	O
glioblastoma	TAFINLAR.xml:S2:5498:12	glioblastoma	NN	B-AdverseReaction	O
(	TAFINLAR.xml:S2:5511:1	(	(	O	O
n	TAFINLAR.xml:S2:5512:1	n	JJ	O	O
1	TAFINLAR.xml:S2:5516:1	1	CD	O	O
)	TAFINLAR.xml:S2:5517:1	)	)	O	O
.	TAFINLAR.xml:S2:5518:1	.	.	O	O

Monitor	TAFINLAR.xml:S2:5520:7	monitor	NN	O	O
patients	TAFINLAR.xml:S2:5528:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:5537:9	receiv	VBG	O	O
the	TAFINLAR.xml:S2:5547:3	the	DT	O	O
combination	TAFINLAR.xml:S2:5551:11	combin	NN	O	O
closely	TAFINLAR.xml:S2:5563:7	close	RB	O	O
for	TAFINLAR.xml:S2:5571:3	for	IN	O	O
signs	TAFINLAR.xml:S2:5575:5	sign	NNS	O	O
or	TAFINLAR.xml:S2:5581:2	or	CC	O	O
symptoms	TAFINLAR.xml:S2:5584:8	symptom	NNS	O	O
of	TAFINLAR.xml:S2:5593:2	of	IN	O	O
non	TAFINLAR.xml:S2:5596:3	non	JJ	O	O
-	TAFINLAR.xml:S2:5599:1	-	:	O	O
cutaneous	TAFINLAR.xml:S2:5600:9	cutan	JJ	O	O
malignancies	TAFINLAR.xml:S2:5610:12	malign	NNS	O	O
.	TAFINLAR.xml:S2:5622:1	.	.	O	O

Permanently	TAFINLAR.xml:S2:5624:11	perman	RB	O	O
discontinue	TAFINLAR.xml:S2:5636:11	discontinu	VBZ	O	O
TAFINLAR	TAFINLAR.xml:S2:5648:8	tafinlar	NNP	O	O
for	TAFINLAR.xml:S2:5657:3	for	IN	O	O
RAS	TAFINLAR.xml:S2:5661:3	ra	NNP	O	O
mutation	TAFINLAR.xml:S2:5665:8	mutat	NN	O	O
-	TAFINLAR.xml:S2:5673:1	-	:	O	O
positive	TAFINLAR.xml:S2:5674:8	posit	JJ	O	O
non	TAFINLAR.xml:S2:5683:3	non	NN	O	O
-	TAFINLAR.xml:S2:5686:1	-	:	O	O
cutaneous	TAFINLAR.xml:S2:5687:9	cutan	JJ	O	O
malignancies	TAFINLAR.xml:S2:5697:12	malign	NNS	O	O
.	TAFINLAR.xml:S2:5709:1	.	.	O	O

If	TAFINLAR.xml:S2:5711:2	If	IN	O	O
used	TAFINLAR.xml:S2:5714:4	use	VBN	O	O
in	TAFINLAR.xml:S2:5719:2	in	IN	O	O
combination	TAFINLAR.xml:S2:5722:11	combin	NN	O	O
with	TAFINLAR.xml:S2:5734:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:5739:10	trametinib	NN	O	O
,	TAFINLAR.xml:S2:5749:1	,	,	O	O
no	TAFINLAR.xml:S2:5751:2	no	DT	O	O
dose	TAFINLAR.xml:S2:5754:4	dose	JJ	O	O
modification	TAFINLAR.xml:S2:5759:12	modif	NN	O	O
of	TAFINLAR.xml:S2:5772:2	of	IN	O	O
trametinib	TAFINLAR.xml:S2:5775:10	trametinib	NN	O	O
is	TAFINLAR.xml:S2:5786:2	is	VBZ	O	O
required	TAFINLAR.xml:S2:5789:8	requir	VBN	O	O
for	TAFINLAR.xml:S2:5798:3	for	IN	O	O
patients	TAFINLAR.xml:S2:5802:8	patient	NNS	O	O
who	TAFINLAR.xml:S2:5811:3	who	WP	O	O
develop	TAFINLAR.xml:S2:5815:7	develop	VBP	O	O
non	TAFINLAR.xml:S2:5823:3	non	JJ	O	B-AdverseReaction
-	TAFINLAR.xml:S2:5826:1	-	:	O	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:5827:9	cutan	JJ	O	I-AdverseReaction
malignancies	TAFINLAR.xml:S2:5837:12	malign	NNS	O	I-AdverseReaction
.	TAFINLAR.xml:S2:5849:1	.	.	O	O

5.2	TAFINLAR.xml:S2:5860:3	5.2	CD	O	O
Tumor	TAFINLAR.xml:S2:5864:5	tumor	NNP	O	O
Promotion	TAFINLAR.xml:S2:5870:9	promot	NNP	O	O
in	TAFINLAR.xml:S2:5880:2	in	IN	O	O
BRAF	TAFINLAR.xml:S2:5883:4	braf	NNP	O	O
Wild	TAFINLAR.xml:S2:5888:4	wild	NNP	O	O
-	TAFINLAR.xml:S2:5892:1	-	:	O	O
Type	TAFINLAR.xml:S2:5893:4	type	NN	O	O
Melanoma	TAFINLAR.xml:S2:5898:8	melanoma	NN	O	O

In	TAFINLAR.xml:S2:5912:2	In	IN	O	O
vitro	TAFINLAR.xml:S2:5915:5	vitro	JJ	O	O
experiments	TAFINLAR.xml:S2:5921:11	experi	NNS	O	O
have	TAFINLAR.xml:S2:5933:4	have	VBP	O	O
demonstrated	TAFINLAR.xml:S2:5938:12	demonstr	VBN	O	O
paradoxical	TAFINLAR.xml:S2:5951:11	paradox	JJ	O	O
activation	TAFINLAR.xml:S2:5963:10	activ	NN	O	O
of	TAFINLAR.xml:S2:5974:2	of	IN	O	O
MAP	TAFINLAR.xml:S2:5977:3	map	NNP	O	O
-	TAFINLAR.xml:S2:5980:1	-	:	O	O
kinase	TAFINLAR.xml:S2:5981:6	kinas	NN	O	O
signaling	TAFINLAR.xml:S2:5988:9	signal	NN	O	O
and	TAFINLAR.xml:S2:5998:3	and	CC	O	O
increased	TAFINLAR.xml:S2:6002:9	increas	VBD	B-AdverseReaction	B-AdverseReaction
cell	TAFINLAR.xml:S2:6012:4	cell	NN	I-AdverseReaction	I-AdverseReaction
proliferation	TAFINLAR.xml:S2:6017:13	prolifer	NN	I-AdverseReaction	I-AdverseReaction
in	TAFINLAR.xml:S2:6031:2	in	IN	O	O
BRAF	TAFINLAR.xml:S2:6034:4	braf	NNP	O	O
wild	TAFINLAR.xml:S2:6039:4	wild	JJ	O	O
-	TAFINLAR.xml:S2:6043:1	-	:	O	O
type	TAFINLAR.xml:S2:6044:4	type	NN	O	O
cells	TAFINLAR.xml:S2:6049:5	cell	NNS	O	O
which	TAFINLAR.xml:S2:6055:5	which	WDT	O	O
are	TAFINLAR.xml:S2:6061:3	are	VBP	O	O
exposed	TAFINLAR.xml:S2:6065:7	expos	VBN	O	O
to	TAFINLAR.xml:S2:6073:2	to	TO	O	O
BRAF	TAFINLAR.xml:S2:6076:4	braf	NNP	O	O
inhibitors	TAFINLAR.xml:S2:6081:10	inhibitor	NNS	O	O
.	TAFINLAR.xml:S2:6091:1	.	.	O	O

Confirm	TAFINLAR.xml:S2:6093:7	confirm	NNP	O	O
evidence	TAFINLAR.xml:S2:6101:8	evid	NN	O	O
of	TAFINLAR.xml:S2:6110:2	of	IN	O	O
BRAF	TAFINLAR.xml:S2:6113:4	braf	NNP	O	O
V600E	TAFINLAR.xml:S2:6118:5	v600e	NNP	O	O
or	TAFINLAR.xml:S2:6124:2	or	CC	O	O
V600K	TAFINLAR.xml:S2:6127:5	v600k	NNP	O	O
mutation	TAFINLAR.xml:S2:6134:8	mutat	NN	O	O
status	TAFINLAR.xml:S2:6143:6	statu	NN	O	O
prior	TAFINLAR.xml:S2:6150:5	prior	RB	O	O
to	TAFINLAR.xml:S2:6156:2	to	TO	O	O
initiation	TAFINLAR.xml:S2:6159:10	initi	NN	O	O
of	TAFINLAR.xml:S2:6170:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:6173:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:6182:2	as	IN	O	O
a	TAFINLAR.xml:S2:6186:1	a	DT	O	O
single	TAFINLAR.xml:S2:6188:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:6195:5	agent	NN	O	O
or	TAFINLAR.xml:S2:6201:2	or	CC	O	O
combination	TAFINLAR.xml:S2:6204:11	combin	NN	O	O
therapy	TAFINLAR.xml:S2:6216:7	therapi	NN	O	O
[	TAFINLAR.xml:S2:6226:1	[	NNP	O	O
see	TAFINLAR.xml:S2:6227:3	see	VBP	O	O
Indications	TAFINLAR.xml:S2:6231:11	indic	NNP	O	O
and	TAFINLAR.xml:S2:6243:3	and	CC	O	O
Usage	TAFINLAR.xml:S2:6247:5	usag	NNP	O	O
(	TAFINLAR.xml:S2:6253:1	(	(	O	O
1	TAFINLAR.xml:S2:6254:1	1	CD	O	O
)	TAFINLAR.xml:S2:6255:1	)	)	O	O
,	TAFINLAR.xml:S2:6256:1	,	,	O	O
Dosage	TAFINLAR.xml:S2:6258:6	dosag	NNP	O	O
and	TAFINLAR.xml:S2:6265:3	and	CC	O	O
Administration	TAFINLAR.xml:S2:6269:14	administr	NNP	O	O
(	TAFINLAR.xml:S2:6284:1	(	(	O	O
2.1	TAFINLAR.xml:S2:6285:3	2.1	CD	O	O
)]	TAFINLAR.xml:S2:6288:2	)]	NN	O	O
.	TAFINLAR.xml:S2:6292:1	.	.	O	O

5.3	TAFINLAR.xml:S2:6302:3	5.3	CD	O	O
Hemorrhage	TAFINLAR.xml:S2:6306:10	hemorrhag	NN	O	O

Hemorrhages	TAFINLAR.xml:S2:6325:11	hemorrhag	NNS	B-AdverseReaction	O
,	TAFINLAR.xml:S2:6336:1	,	,	O	O
including	TAFINLAR.xml:S2:6338:9	includ	VBG	O	O
major	TAFINLAR.xml:S2:6348:5	major	JJ	O	O
hemorrhages	TAFINLAR.xml:S2:6354:11	hemorrhag	NNS	B-AdverseReaction	O
defined	TAFINLAR.xml:S2:6366:7	defin	VBN	O	O
as	TAFINLAR.xml:S2:6374:2	as	IN	O	O
symptomatic	TAFINLAR.xml:S2:6377:11	symptomat	JJ	B-AdverseReaction	O
bleeding	TAFINLAR.xml:S2:6389:8	bleed	NN	I-AdverseReaction	O
in	TAFINLAR.xml:S2:6398:2	in	IN	O	O
a	TAFINLAR.xml:S2:6401:1	a	DT	O	O
critical	TAFINLAR.xml:S2:6403:8	critic	JJ	O	O
area	TAFINLAR.xml:S2:6412:4	area	NN	O	O
or	TAFINLAR.xml:S2:6417:2	or	CC	O	O
organ	TAFINLAR.xml:S2:6420:5	organ	NN	O	O
,	TAFINLAR.xml:S2:6425:1	,	,	O	O
can	TAFINLAR.xml:S2:6427:3	can	MD	O	O
occur	TAFINLAR.xml:S2:6431:5	occur	VB	O	O
when	TAFINLAR.xml:S2:6437:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:6442:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:6451:2	is	VBZ	O	O
used	TAFINLAR.xml:S2:6454:4	use	VBN	O	O
in	TAFINLAR.xml:S2:6459:2	in	IN	O	O
combination	TAFINLAR.xml:S2:6462:11	combin	NN	O	O
with	TAFINLAR.xml:S2:6474:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:6479:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:6489:1	.	.	O	O

In	TAFINLAR.xml:S2:6498:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:6501:5	trial	NNP	O	O
2	TAFINLAR.xml:S2:6507:1	2	CD	O	O
,	TAFINLAR.xml:S2:6508:1	,	,	O	O
treatment	TAFINLAR.xml:S2:6510:9	treatment	NN	O	O
with	TAFINLAR.xml:S2:6520:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:6525:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:6534:2	in	IN	O	O
combination	TAFINLAR.xml:S2:6537:11	combin	NN	O	O
with	TAFINLAR.xml:S2:6549:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:6554:10	trametinib	NN	O	O
resulted	TAFINLAR.xml:S2:6565:8	result	VBD	O	O
in	TAFINLAR.xml:S2:6574:2	in	IN	O	O
an	TAFINLAR.xml:S2:6577:2	an	DT	O	O
increased	TAFINLAR.xml:S2:6580:9	increas	VBN	O	O
incidence	TAFINLAR.xml:S2:6590:9	incid	NN	O	O
and	TAFINLAR.xml:S2:6600:3	and	CC	O	O
severity	TAFINLAR.xml:S2:6604:8	sever	NN	O	O
of	TAFINLAR.xml:S2:6613:2	of	IN	O	O
any	TAFINLAR.xml:S2:6616:3	ani	DT	O	O
hemorrhagic	TAFINLAR.xml:S2:6620:11	hemorrhag	JJ	B-AdverseReaction	B-AdverseReaction
event	TAFINLAR.xml:S2:6632:5	event	NN	I-AdverseReaction	I-AdverseReaction
:	TAFINLAR.xml:S2:6637:1	:	:	O	O
16%	TAFINLAR.xml:S2:6639:3	16%	CD	O	O
(	TAFINLAR.xml:S2:6643:1	(	(	O	O
9	TAFINLAR.xml:S2:6644:1	9	CD	O	O
55	TAFINLAR.xml:S2:6646:2	55	CD	O	O
)	TAFINLAR.xml:S2:6648:1	)	)	O	O
of	TAFINLAR.xml:S2:6650:2	of	IN	O	O
patients	TAFINLAR.xml:S2:6653:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:6662:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:6670:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:6675:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:6684:2	in	IN	O	O
combination	TAFINLAR.xml:S2:6687:11	combin	NN	O	O
with	TAFINLAR.xml:S2:6699:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:6704:10	trametinib	NNS	O	O
compared	TAFINLAR.xml:S2:6715:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:6724:4	with	IN	O	O
2%	TAFINLAR.xml:S2:6729:2	2%	CD	O	O
(	TAFINLAR.xml:S2:6732:1	(	(	O	O
1	TAFINLAR.xml:S2:6733:1	1	CD	O	O
53	TAFINLAR.xml:S2:6735:2	53	CD	O	O
)	TAFINLAR.xml:S2:6737:1	)	)	O	O
of	TAFINLAR.xml:S2:6739:2	of	IN	O	O
patients	TAFINLAR.xml:S2:6742:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:6751:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:6759:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:6764:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:6773:2	as	IN	O	O
a	TAFINLAR.xml:S2:6776:1	a	DT	O	O
single	TAFINLAR.xml:S2:6778:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:6785:5	agent	NN	O	O
.	TAFINLAR.xml:S2:6790:1	.	.	O	O

The	TAFINLAR.xml:S2:6792:3	the	DT	O	O
major	TAFINLAR.xml:S2:6796:5	major	JJ	O	O
hemorrhagic	TAFINLAR.xml:S2:6802:11	hemorrhag	JJ	B-AdverseReaction	O
events	TAFINLAR.xml:S2:6814:6	event	NNS	I-AdverseReaction	O
of	TAFINLAR.xml:S2:6821:2	of	IN	O	O
intracranial	TAFINLAR.xml:S2:6824:12	intracrani	JJ	B-AdverseReaction	O
or	TAFINLAR.xml:S2:6837:2	or	CC	O	O
gastric	TAFINLAR.xml:S2:6840:7	gastric	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S2:6848:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
occurred	TAFINLAR.xml:S2:6859:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:6868:2	in	IN	O	O
5%	TAFINLAR.xml:S2:6871:2	5%	CD	O	O
(	TAFINLAR.xml:S2:6874:1	(	(	O	O
3	TAFINLAR.xml:S2:6875:1	3	CD	O	O
55	TAFINLAR.xml:S2:6877:2	55	CD	O	O
)	TAFINLAR.xml:S2:6879:1	)	)	O	O
of	TAFINLAR.xml:S2:6881:2	of	IN	O	O
patients	TAFINLAR.xml:S2:6884:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:6893:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:6901:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:6906:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:6915:2	in	IN	O	O
combination	TAFINLAR.xml:S2:6918:11	combin	NN	O	O
with	TAFINLAR.xml:S2:6930:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:6935:10	trametinib	NNS	O	O
compared	TAFINLAR.xml:S2:6946:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:6955:4	with	IN	O	O
none	TAFINLAR.xml:S2:6960:4	none	NN	O	O
of	TAFINLAR.xml:S2:6965:2	of	IN	O	O
the	TAFINLAR.xml:S2:6968:3	the	DT	O	O
53	TAFINLAR.xml:S2:6972:2	53	CD	O	O
patients	TAFINLAR.xml:S2:6975:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:6984:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:6992:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:6997:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:7006:2	as	IN	O	O
a	TAFINLAR.xml:S2:7009:1	a	DT	O	O
single	TAFINLAR.xml:S2:7011:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:7018:5	agent	NN	O	O
.	TAFINLAR.xml:S2:7023:1	.	.	O	O

Intracranial	TAFINLAR.xml:S2:7025:12	intracrani	JJ	B-AdverseReaction	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S2:7038:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
was	TAFINLAR.xml:S2:7049:3	wa	VBD	O	O
fatal	TAFINLAR.xml:S2:7053:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
in	TAFINLAR.xml:S2:7059:2	in	IN	O	O
4%	TAFINLAR.xml:S2:7062:2	4%	CD	O	O
(	TAFINLAR.xml:S2:7065:1	(	(	O	O
2	TAFINLAR.xml:S2:7066:1	2	CD	O	O
55	TAFINLAR.xml:S2:7068:2	55	CD	O	O
)	TAFINLAR.xml:S2:7070:1	)	)	O	O
of	TAFINLAR.xml:S2:7072:2	of	IN	O	O
patients	TAFINLAR.xml:S2:7075:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:7084:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:7094:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:7103:2	in	IN	O	O
combination	TAFINLAR.xml:S2:7106:11	combin	NN	O	O
with	TAFINLAR.xml:S2:7118:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:7123:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:7133:1	.	.	O	O

Permanently	TAFINLAR.xml:S2:7142:11	perman	RB	O	O
discontinue	TAFINLAR.xml:S2:7154:11	discontinu	VBZ	O	O
TAFINLAR	TAFINLAR.xml:S2:7166:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S2:7175:3	and	CC	O	O
trametinib	TAFINLAR.xml:S2:7179:10	trametinib	NN	O	O
for	TAFINLAR.xml:S2:7190:3	for	IN	O	O
all	TAFINLAR.xml:S2:7194:3	all	DT	O	O
Grade	TAFINLAR.xml:S2:7198:5	grade	NNP	O	O
4	TAFINLAR.xml:S2:7204:1	4	CD	O	O
hemorrhagic	TAFINLAR.xml:S2:7206:11	hemorrhag	JJ	O	B-AdverseReaction
events	TAFINLAR.xml:S2:7218:6	event	NNS	O	I-AdverseReaction
and	TAFINLAR.xml:S2:7225:3	and	CC	O	O
for	TAFINLAR.xml:S2:7229:3	for	IN	O	O
any	TAFINLAR.xml:S2:7233:3	ani	DT	O	O
Grade	TAFINLAR.xml:S2:7237:5	grade	NNP	O	O
3	TAFINLAR.xml:S2:7243:1	3	CD	O	O
hemorrhagic	TAFINLAR.xml:S2:7245:11	hemorrhag	NN	O	B-AdverseReaction
events	TAFINLAR.xml:S2:7257:6	event	NNS	O	I-AdverseReaction
that	TAFINLAR.xml:S2:7264:4	that	WDT	O	O
do	TAFINLAR.xml:S2:7269:2	do	VBP	O	O
not	TAFINLAR.xml:S2:7272:3	not	RB	O	O
improve	TAFINLAR.xml:S2:7276:7	improv	VB	O	O
.	TAFINLAR.xml:S2:7283:1	.	.	O	O

Withhold	TAFINLAR.xml:S2:7285:8	withhold	NNP	O	O
TAFINLAR	TAFINLAR.xml:S2:7294:8	tafinlar	NNP	O	O
for	TAFINLAR.xml:S2:7303:3	for	IN	O	O
Grade	TAFINLAR.xml:S2:7307:5	grade	NNP	O	O
3	TAFINLAR.xml:S2:7313:1	3	CD	O	O
hemorrhagic	TAFINLAR.xml:S2:7315:11	hemorrhag	JJ	O	B-AdverseReaction
events	TAFINLAR.xml:S2:7327:6	event	NNS	O	I-AdverseReaction
;	TAFINLAR.xml:S2:7333:1	;	:	O	O
if	TAFINLAR.xml:S2:7335:2	if	IN	O	O
improved	TAFINLAR.xml:S2:7338:8	improv	VBN	O	O
resume	TAFINLAR.xml:S2:7347:6	resum	NN	O	O
at	TAFINLAR.xml:S2:7354:2	at	IN	O	O
a	TAFINLAR.xml:S2:7357:1	a	DT	O	O
lower	TAFINLAR.xml:S2:7359:5	lower	JJR	O	O
dose	TAFINLAR.xml:S2:7365:4	dose	JJ	O	O
level	TAFINLAR.xml:S2:7370:5	level	NN	O	O
.	TAFINLAR.xml:S2:7375:1	.	.	O	O

Withhold	TAFINLAR.xml:S2:7377:8	withhold	NNP	O	O
trametinib	TAFINLAR.xml:S2:7386:10	trametinib	NN	O	O
for	TAFINLAR.xml:S2:7397:3	for	IN	O	O
up	TAFINLAR.xml:S2:7401:2	up	IN	O	O
to	TAFINLAR.xml:S2:7404:2	to	TO	O	O
3	TAFINLAR.xml:S2:7407:1	3	CD	O	O
weeks	TAFINLAR.xml:S2:7409:5	week	NNS	O	O
for	TAFINLAR.xml:S2:7415:3	for	IN	O	O
Grade	TAFINLAR.xml:S2:7419:5	grade	NNP	O	O
3	TAFINLAR.xml:S2:7425:1	3	CD	O	O
hemorrhagic	TAFINLAR.xml:S2:7427:11	hemorrhag	JJ	O	B-AdverseReaction
events	TAFINLAR.xml:S2:7439:6	event	NNS	O	I-AdverseReaction
;	TAFINLAR.xml:S2:7445:1	;	:	O	O
if	TAFINLAR.xml:S2:7447:2	if	IN	O	O
improved	TAFINLAR.xml:S2:7450:8	improv	VBN	O	O
,	TAFINLAR.xml:S2:7458:1	,	,	O	O
resume	TAFINLAR.xml:S2:7460:6	resum	VB	O	O
at	TAFINLAR.xml:S2:7467:2	at	IN	O	O
a	TAFINLAR.xml:S2:7470:1	a	DT	O	O
lower	TAFINLAR.xml:S2:7472:5	lower	JJR	O	O
dose	TAFINLAR.xml:S2:7478:4	dose	JJ	O	O
level	TAFINLAR.xml:S2:7483:5	level	NN	O	O
.	TAFINLAR.xml:S2:7488:1	.	.	O	O

5.4	TAFINLAR.xml:S2:7500:3	5.4	CD	O	O
Venous	TAFINLAR.xml:S2:7504:6	venou	JJ	O	O
Thromboembolism	TAFINLAR.xml:S2:7511:15	thromboembol	NN	O	O

Venous	TAFINLAR.xml:S2:7535:6	venou	JJ	B-AdverseReaction	B-AdverseReaction
thromboembolism	TAFINLAR.xml:S2:7542:15	thromboembol	NN	I-AdverseReaction	I-AdverseReaction
can	TAFINLAR.xml:S2:7558:3	can	MD	O	O
occur	TAFINLAR.xml:S2:7562:5	occur	VB	O	O
when	TAFINLAR.xml:S2:7568:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:7573:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:7582:2	is	VBZ	O	O
used	TAFINLAR.xml:S2:7585:4	use	VBN	O	O
in	TAFINLAR.xml:S2:7590:2	in	IN	O	O
combination	TAFINLAR.xml:S2:7593:11	combin	NN	O	O
with	TAFINLAR.xml:S2:7605:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:7610:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:7620:1	.	.	O	O

In	TAFINLAR.xml:S2:7629:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:7632:5	trial	NNP	O	O
2	TAFINLAR.xml:S2:7638:1	2	CD	O	O
,	TAFINLAR.xml:S2:7639:1	,	,	O	O
treatment	TAFINLAR.xml:S2:7641:9	treatment	NN	O	O
with	TAFINLAR.xml:S2:7651:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:7656:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:7665:2	in	IN	O	O
combination	TAFINLAR.xml:S2:7668:11	combin	NN	O	O
with	TAFINLAR.xml:S2:7680:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:7685:10	trametinib	NN	O	O
resulted	TAFINLAR.xml:S2:7696:8	result	VBD	O	O
in	TAFINLAR.xml:S2:7705:2	in	IN	O	O
an	TAFINLAR.xml:S2:7708:2	an	DT	O	O
increased	TAFINLAR.xml:S2:7711:9	increas	JJ	O	O
incidence	TAFINLAR.xml:S2:7721:9	incid	NN	O	O
of	TAFINLAR.xml:S2:7731:2	of	IN	O	O
deep	TAFINLAR.xml:S2:7734:4	deep	JJ	B-AdverseReaction	B-AdverseReaction
venous	TAFINLAR.xml:S2:7739:6	venou	JJ	I-AdverseReaction	I-AdverseReaction
thrombosis	TAFINLAR.xml:S2:7746:10	thrombosi	NN	I-AdverseReaction	I-AdverseReaction
(	TAFINLAR.xml:S2:7757:1	(	(	O	O
DVT	TAFINLAR.xml:S2:7758:3	dvt	NNP	B-AdverseReaction	B-AdverseReaction
)	TAFINLAR.xml:S2:7761:1	)	)	O	O
and	TAFINLAR.xml:S2:7763:3	and	CC	O	O
pulmonary	TAFINLAR.xml:S2:7767:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
embolism	TAFINLAR.xml:S2:7777:8	embol	NN	I-AdverseReaction	I-AdverseReaction
(	TAFINLAR.xml:S2:7786:1	(	(	O	O
PE	TAFINLAR.xml:S2:7787:2	PE	NNP	B-AdverseReaction	O
)	TAFINLAR.xml:S2:7789:1	)	)	O	O
:	TAFINLAR.xml:S2:7790:1	:	:	O	O
7%	TAFINLAR.xml:S2:7792:2	7%	CD	O	O
(	TAFINLAR.xml:S2:7795:1	(	(	O	O
4	TAFINLAR.xml:S2:7796:1	4	CD	O	O
55	TAFINLAR.xml:S2:7798:2	55	CD	O	O
)	TAFINLAR.xml:S2:7800:1	)	)	O	O
of	TAFINLAR.xml:S2:7802:2	of	IN	O	O
patients	TAFINLAR.xml:S2:7805:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:7814:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:7822:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:7827:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:7836:2	in	IN	O	O
combination	TAFINLAR.xml:S2:7839:11	combin	NN	O	O
with	TAFINLAR.xml:S2:7851:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:7856:10	trametinib	NNS	O	O
compared	TAFINLAR.xml:S2:7867:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:7876:4	with	IN	O	O
none	TAFINLAR.xml:S2:7881:4	none	NN	O	O
of	TAFINLAR.xml:S2:7886:2	of	IN	O	O
the	TAFINLAR.xml:S2:7889:3	the	DT	O	O
53	TAFINLAR.xml:S2:7893:2	53	CD	O	O
patients	TAFINLAR.xml:S2:7896:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:7905:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:7913:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:7918:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:7927:2	as	IN	O	O
a	TAFINLAR.xml:S2:7930:1	a	DT	O	O
single	TAFINLAR.xml:S2:7932:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:7939:5	agent	NN	O	O
.	TAFINLAR.xml:S2:7944:1	.	.	O	O

Pulmonary	TAFINLAR.xml:S2:7946:9	pulmonari	JJ	B-AdverseReaction	B-AdverseReaction
embolism	TAFINLAR.xml:S2:7956:8	embol	NN	I-AdverseReaction	I-AdverseReaction
was	TAFINLAR.xml:S2:7965:3	wa	VBD	O	O
fatal	TAFINLAR.xml:S2:7969:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
in	TAFINLAR.xml:S2:7975:2	in	IN	O	O
2%	TAFINLAR.xml:S2:7978:2	2%	CD	O	O
(	TAFINLAR.xml:S2:7981:1	(	(	O	O
1	TAFINLAR.xml:S2:7982:1	1	CD	O	O
55	TAFINLAR.xml:S2:7984:2	55	CD	O	O
)	TAFINLAR.xml:S2:7986:1	)	)	O	O
of	TAFINLAR.xml:S2:7988:2	of	IN	O	O
patients	TAFINLAR.xml:S2:7991:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:8000:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:8010:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:8019:2	in	IN	O	O
combination	TAFINLAR.xml:S2:8022:11	combin	NN	O	O
with	TAFINLAR.xml:S2:8034:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:8039:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:8049:1	.	.	O	O

Advise	TAFINLAR.xml:S2:8058:6	advis	NN	O	O
patients	TAFINLAR.xml:S2:8065:8	patient	NNS	O	O
to	TAFINLAR.xml:S2:8074:2	to	TO	O	O
immediately	TAFINLAR.xml:S2:8077:11	immedi	RB	O	O
seek	TAFINLAR.xml:S2:8089:4	seek	VB	O	O
medical	TAFINLAR.xml:S2:8094:7	medic	JJ	O	O
care	TAFINLAR.xml:S2:8102:4	care	NN	O	O
if	TAFINLAR.xml:S2:8107:2	if	IN	O	O
they	TAFINLAR.xml:S2:8110:4	they	PRP	O	O
develop	TAFINLAR.xml:S2:8115:7	develop	VBP	O	O
symptoms	TAFINLAR.xml:S2:8123:8	symptom	NNS	O	O
of	TAFINLAR.xml:S2:8132:2	of	IN	O	O
DVT	TAFINLAR.xml:S2:8135:3	dvt	NNP	O	O
or	TAFINLAR.xml:S2:8139:2	or	CC	O	O
PE	TAFINLAR.xml:S2:8142:2	PE	NNP	O	O
,	TAFINLAR.xml:S2:8144:1	,	,	O	O
such	TAFINLAR.xml:S2:8146:4	such	JJ	O	O
as	TAFINLAR.xml:S2:8151:2	as	IN	O	O
shortness	TAFINLAR.xml:S2:8154:9	short	NN	O	O
of	TAFINLAR.xml:S2:8164:2	of	IN	O	O
breath	TAFINLAR.xml:S2:8167:6	breath	NN	O	O
,	TAFINLAR.xml:S2:8173:1	,	,	O	O
chest	TAFINLAR.xml:S2:8175:5	chest	NN	O	B-AdverseReaction
pain	TAFINLAR.xml:S2:8181:4	pain	NN	O	I-AdverseReaction
,	TAFINLAR.xml:S2:8185:1	,	,	O	O
or	TAFINLAR.xml:S2:8187:2	or	CC	O	O
arm	TAFINLAR.xml:S2:8190:3	arm	NN	O	O
or	TAFINLAR.xml:S2:8194:2	or	CC	O	O
leg	TAFINLAR.xml:S2:8197:3	leg	NN	O	O
swelling	TAFINLAR.xml:S2:8201:8	swell	NN	O	O
.	TAFINLAR.xml:S2:8209:1	.	.	O	O

Permanently	TAFINLAR.xml:S2:8211:11	perman	RB	O	O
discontinue	TAFINLAR.xml:S2:8223:11	discontinu	VBZ	O	O
TAFINLAR	TAFINLAR.xml:S2:8235:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S2:8244:3	and	CC	O	O
trametinib	TAFINLAR.xml:S2:8248:10	trametinib	NN	O	O
for	TAFINLAR.xml:S2:8259:3	for	IN	O	O
life	TAFINLAR.xml:S2:8263:4	life	NN	O	O
-	TAFINLAR.xml:S2:8267:1	-	:	O	O
threatening	TAFINLAR.xml:S2:8268:11	threaten	NN	O	O
PE	TAFINLAR.xml:S2:8280:2	PE	NNP	O	O
.	TAFINLAR.xml:S2:8282:1	.	.	O	O

Withhold	TAFINLAR.xml:S2:8284:8	withhold	NNP	O	O
trametinib	TAFINLAR.xml:S2:8293:10	trametinib	NN	O	O
and	TAFINLAR.xml:S2:8304:3	and	CC	O	O
continue	TAFINLAR.xml:S2:8308:8	continu	VB	O	O
TAFINLAR	TAFINLAR.xml:S2:8317:8	tafinlar	NNP	O	O
at	TAFINLAR.xml:S2:8326:2	at	IN	O	O
the	TAFINLAR.xml:S2:8329:3	the	DT	O	O
same	TAFINLAR.xml:S2:8333:4	same	JJ	O	O
dose	TAFINLAR.xml:S2:8338:4	dose	NN	O	O
for	TAFINLAR.xml:S2:8343:3	for	IN	O	O
uncomplicated	TAFINLAR.xml:S2:8347:13	uncompl	JJ	O	O
DVT	TAFINLAR.xml:S2:8361:3	dvt	NNP	O	O
or	TAFINLAR.xml:S2:8365:2	or	CC	O	O
PE	TAFINLAR.xml:S2:8368:2	PE	NNP	O	O
;	TAFINLAR.xml:S2:8370:1	;	:	O	O
if	TAFINLAR.xml:S2:8372:2	if	IN	O	O
improved	TAFINLAR.xml:S2:8375:8	improv	VBN	O	O
within	TAFINLAR.xml:S2:8384:6	within	IN	O	O
3	TAFINLAR.xml:S2:8391:1	3	CD	O	O
weeks	TAFINLAR.xml:S2:8393:5	week	NNS	O	O
,	TAFINLAR.xml:S2:8398:1	,	,	O	O
trametinib	TAFINLAR.xml:S2:8400:10	trametinib	NN	O	O
may	TAFINLAR.xml:S2:8411:3	may	MD	O	O
be	TAFINLAR.xml:S2:8415:2	be	VB	O	O
resumed	TAFINLAR.xml:S2:8418:7	resum	VBN	O	O
at	TAFINLAR.xml:S2:8426:2	at	IN	O	O
a	TAFINLAR.xml:S2:8429:1	a	DT	O	O
lower	TAFINLAR.xml:S2:8431:5	lower	JJR	O	O
dose	TAFINLAR.xml:S2:8437:4	dose	JJ	O	O
level	TAFINLAR.xml:S2:8442:5	level	NN	O	O
[	TAFINLAR.xml:S2:8448:1	[	NNP	O	O
see	TAFINLAR.xml:S2:8449:3	see	VBP	O	O
Dosage	TAFINLAR.xml:S2:8453:6	dosag	NNP	O	O
and	TAFINLAR.xml:S2:8460:3	and	CC	O	O
Administration	TAFINLAR.xml:S2:8464:14	administr	NNP	O	O
(	TAFINLAR.xml:S2:8479:1	(	(	O	O
2.3	TAFINLAR.xml:S2:8480:3	2.3	CD	O	O
)]	TAFINLAR.xml:S2:8483:2	)]	NN	O	O
.	TAFINLAR.xml:S2:8489:1	.	.	O	O

5.5	TAFINLAR.xml:S2:8499:3	5.5	CD	O	O
Cardiomyopathy	TAFINLAR.xml:S2:8503:14	cardiomyopathi	NNP	O	O

Cardiomyopathy	TAFINLAR.xml:S2:8526:14	cardiomyopathi	NNP	B-AdverseReaction	O
can	TAFINLAR.xml:S2:8541:3	can	MD	O	O
occur	TAFINLAR.xml:S2:8545:5	occur	VB	O	O
when	TAFINLAR.xml:S2:8551:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:8556:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:8565:2	is	VBZ	O	O
used	TAFINLAR.xml:S2:8568:4	use	VBN	O	O
in	TAFINLAR.xml:S2:8573:2	in	IN	O	O
combination	TAFINLAR.xml:S2:8576:11	combin	NN	O	O
with	TAFINLAR.xml:S2:8588:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:8593:10	trametinib	NN	O	O
and	TAFINLAR.xml:S2:8604:3	and	CC	O	O
with	TAFINLAR.xml:S2:8608:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:8613:10	trametinib	NN	O	O
as	TAFINLAR.xml:S2:8624:2	as	IN	O	O
a	TAFINLAR.xml:S2:8627:1	a	DT	O	O
single	TAFINLAR.xml:S2:8629:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:8636:5	agent	NN	O	O
[	TAFINLAR.xml:S2:8642:1	[	NNP	O	O
refer	TAFINLAR.xml:S2:8643:5	refer	NN	O	O
to	TAFINLAR.xml:S2:8649:2	to	TO	O	O
Full	TAFINLAR.xml:S2:8652:4	full	NNP	O	O
Prescribing	TAFINLAR.xml:S2:8657:11	prescrib	NNP	O	O
Information	TAFINLAR.xml:S2:8669:11	inform	NNP	O	O
for	TAFINLAR.xml:S2:8681:3	for	IN	O	O
trametinib	TAFINLAR.xml:S2:8685:10	trametinib	NN	O	O
]	TAFINLAR.xml:S2:8695:1	]	NN	O	O
.	TAFINLAR.xml:S2:8698:1	.	.	O	O

In	TAFINLAR.xml:S2:8707:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:8710:5	trial	NNP	O	O
2	TAFINLAR.xml:S2:8716:1	2	CD	O	O
,	TAFINLAR.xml:S2:8717:1	,	,	O	O
cardiomyopathy	TAFINLAR.xml:S2:8719:14	cardiomyopathi	NN	B-AdverseReaction	B-AdverseReaction
occurred	TAFINLAR.xml:S2:8734:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:8743:2	in	IN	O	O
9%	TAFINLAR.xml:S2:8746:2	9%	CD	O	O
(	TAFINLAR.xml:S2:8749:1	(	(	O	O
5	TAFINLAR.xml:S2:8750:1	5	CD	O	O
55	TAFINLAR.xml:S2:8752:2	55	CD	O	O
)	TAFINLAR.xml:S2:8754:1	)	)	O	O
of	TAFINLAR.xml:S2:8756:2	of	IN	O	O
patients	TAFINLAR.xml:S2:8759:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:8768:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:8776:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:8781:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:8790:2	in	IN	O	O
combination	TAFINLAR.xml:S2:8793:11	combin	NN	O	O
with	TAFINLAR.xml:S2:8805:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:8810:10	trametinib	NN	O	O
and	TAFINLAR.xml:S2:8821:3	and	CC	O	O
in	TAFINLAR.xml:S2:8825:2	in	IN	O	O
none	TAFINLAR.xml:S2:8828:4	none	NN	O	O
of	TAFINLAR.xml:S2:8833:2	of	IN	O	O
patients	TAFINLAR.xml:S2:8836:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:8845:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:8853:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:8858:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:8867:2	as	IN	O	O
a	TAFINLAR.xml:S2:8870:1	a	DT	O	O
single	TAFINLAR.xml:S2:8872:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:8879:5	agent	NN	O	O
.	TAFINLAR.xml:S2:8884:1	.	.	O	O

The	TAFINLAR.xml:S2:8886:3	the	DT	O	O
median	TAFINLAR.xml:S2:8890:6	median	JJ	O	O
time	TAFINLAR.xml:S2:8897:4	time	NN	O	O
to	TAFINLAR.xml:S2:8902:2	to	TO	O	O
onset	TAFINLAR.xml:S2:8905:5	onset	VB	O	O
of	TAFINLAR.xml:S2:8911:2	of	IN	O	O
cardiomyopathy	TAFINLAR.xml:S2:8914:14	cardiomyopathi	NN	B-AdverseReaction	O
in	TAFINLAR.xml:S2:8929:2	in	IN	O	O
patients	TAFINLAR.xml:S2:8932:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:8941:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:8949:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:8954:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:8963:2	in	IN	O	O
combination	TAFINLAR.xml:S2:8966:11	combin	NN	O	O
with	TAFINLAR.xml:S2:8978:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:8983:10	trametinib	NN	O	O
was	TAFINLAR.xml:S2:8994:3	wa	VBD	O	O
86	TAFINLAR.xml:S2:8998:2	86	CD	O	O
days	TAFINLAR.xml:S2:9001:4	day	NNS	O	O
(	TAFINLAR.xml:S2:9006:1	(	(	O	O
range	TAFINLAR.xml:S2:9007:5	rang	NN	O	O
:	TAFINLAR.xml:S2:9012:1	:	:	O	O
27	TAFINLAR.xml:S2:9014:2	27	CD	O	O
to	TAFINLAR.xml:S2:9017:2	to	TO	O	O
253	TAFINLAR.xml:S2:9020:3	253	CD	O	O
days	TAFINLAR.xml:S2:9024:4	day	NNS	O	O
)	TAFINLAR.xml:S2:9028:1	)	)	O	O
.	TAFINLAR.xml:S2:9029:1	.	.	O	O

Cardiomyopathy	TAFINLAR.xml:S2:9031:14	cardiomyopathi	NNP	B-AdverseReaction	O
was	TAFINLAR.xml:S2:9046:3	wa	VBD	O	O
identified	TAFINLAR.xml:S2:9050:10	identifi	VBN	O	O
within	TAFINLAR.xml:S2:9061:6	within	IN	O	O
the	TAFINLAR.xml:S2:9068:3	the	DT	O	O
first	TAFINLAR.xml:S2:9072:5	first	JJ	O	O
month	TAFINLAR.xml:S2:9078:5	month	NN	O	O
of	TAFINLAR.xml:S2:9084:2	of	IN	O	O
treatment	TAFINLAR.xml:S2:9087:9	treatment	NN	O	O
with	TAFINLAR.xml:S2:9097:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:9102:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:9111:2	in	IN	O	O
combination	TAFINLAR.xml:S2:9114:11	combin	NN	O	O
with	TAFINLAR.xml:S2:9126:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:9131:10	trametinib	NN	O	O
in	TAFINLAR.xml:S2:9142:2	in	IN	O	O
two	TAFINLAR.xml:S2:9145:3	two	CD	O	O
of	TAFINLAR.xml:S2:9149:2	of	IN	O	O
five	TAFINLAR.xml:S2:9152:4	five	CD	O	O
patients	TAFINLAR.xml:S2:9157:8	patient	NNS	O	O
.	TAFINLAR.xml:S2:9165:1	.	.	O	O

Development	TAFINLAR.xml:S2:9167:11	develop	NNP	O	O
of	TAFINLAR.xml:S2:9179:2	of	IN	O	O
cardiomyopathy	TAFINLAR.xml:S2:9182:14	cardiomyopathi	NN	B-AdverseReaction	O
resolved	TAFINLAR.xml:S2:9197:8	resolv	VBN	O	O
in	TAFINLAR.xml:S2:9206:2	in	IN	O	O
all	TAFINLAR.xml:S2:9209:3	all	DT	O	O
five	TAFINLAR.xml:S2:9213:4	five	CD	O	O
patients	TAFINLAR.xml:S2:9218:8	patient	NNS	O	O
following	TAFINLAR.xml:S2:9227:9	follow	VBG	O	O
dose	TAFINLAR.xml:S2:9237:4	dose	JJ	O	O
reduction	TAFINLAR.xml:S2:9242:9	reduct	NN	O	O
(	TAFINLAR.xml:S2:9252:1	(	(	O	O
4	TAFINLAR.xml:S2:9253:1	4	CD	O	O
55	TAFINLAR.xml:S2:9255:2	55	CD	O	O
)	TAFINLAR.xml:S2:9257:1	)	)	O	O
and	TAFINLAR.xml:S2:9259:3	and	CC	O	O
or	TAFINLAR.xml:S2:9263:2	or	CC	O	O
dose	TAFINLAR.xml:S2:9266:4	dose	VB	O	O
interruption	TAFINLAR.xml:S2:9271:12	interrupt	NN	O	O
(	TAFINLAR.xml:S2:9284:1	(	(	O	O
1	TAFINLAR.xml:S2:9285:1	1	CD	O	O
55	TAFINLAR.xml:S2:9287:2	55	CD	O	O
)	TAFINLAR.xml:S2:9289:1	)	)	O	O
.	TAFINLAR.xml:S2:9290:1	.	.	O	O

Across	TAFINLAR.xml:S2:9299:6	across	IN	O	O
clinical	TAFINLAR.xml:S2:9306:8	clinic	JJ	O	O
trials	TAFINLAR.xml:S2:9315:6	trial	NNS	O	O
of	TAFINLAR.xml:S2:9322:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:9325:8	tafinlar	NNP	O	O
administered	TAFINLAR.xml:S2:9334:12	administ	VBD	O	O
in	TAFINLAR.xml:S2:9347:2	in	IN	O	O
combination	TAFINLAR.xml:S2:9350:11	combin	NN	O	O
with	TAFINLAR.xml:S2:9362:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:9367:10	trametinib	NN	O	O
(	TAFINLAR.xml:S2:9378:1	(	(	O	O
N	TAFINLAR.xml:S2:9379:1	N	NNP	O	O
202	TAFINLAR.xml:S2:9383:3	202	CD	O	O
)	TAFINLAR.xml:S2:9386:1	)	)	O	O
,	TAFINLAR.xml:S2:9387:1	,	,	O	O
8%	TAFINLAR.xml:S2:9389:2	8%	CD	O	O
of	TAFINLAR.xml:S2:9392:2	of	IN	O	O
patients	TAFINLAR.xml:S2:9395:8	patient	NNS	O	O
developed	TAFINLAR.xml:S2:9404:9	develop	JJ	O	O
evidence	TAFINLAR.xml:S2:9414:8	evid	NN	O	O
of	TAFINLAR.xml:S2:9423:2	of	IN	O	O
cardiomyopathy	TAFINLAR.xml:S2:9426:14	cardiomyopathi	NN	B-AdverseReaction	O
(	TAFINLAR.xml:S2:9441:1	(	(	O	O
decrease	TAFINLAR.xml:S2:9442:8	decreas	NN	B-AdverseReaction	B-AdverseReaction
in	TAFINLAR.xml:S2:9451:2	in	IN	I-AdverseReaction	I-AdverseReaction
LVEF	TAFINLAR.xml:S2:9454:4	lvef	NNP	I-AdverseReaction	I-AdverseReaction
below	TAFINLAR.xml:S2:9459:5	below	IN	O	O
institutional	TAFINLAR.xml:S2:9465:13	institut	JJ	O	O
lower	TAFINLAR.xml:S2:9479:5	lower	JJR	O	O
limits	TAFINLAR.xml:S2:9485:6	limit	NNS	O	O
of	TAFINLAR.xml:S2:9492:2	of	IN	O	O
normal	TAFINLAR.xml:S2:9495:6	normal	JJ	O	O
with	TAFINLAR.xml:S2:9502:4	with	IN	O	O
an	TAFINLAR.xml:S2:9507:2	an	DT	O	O
absolute	TAFINLAR.xml:S2:9510:8	absolut	JJ	B-AdverseReaction	O
decrease	TAFINLAR.xml:S2:9519:8	decreas	NN	I-AdverseReaction	O
in	TAFINLAR.xml:S2:9528:2	in	IN	I-AdverseReaction	O
LVEF	TAFINLAR.xml:S2:9531:4	lvef	NNP	I-AdverseReaction	O
10%	TAFINLAR.xml:S2:9538:3	10%	CD	O	O
below	TAFINLAR.xml:S2:9542:5	below	IN	O	O
baseline	TAFINLAR.xml:S2:9548:8	baselin	NN	O	O
)	TAFINLAR.xml:S2:9556:1	)	)	O	O
.	TAFINLAR.xml:S2:9557:1	.	.	O	O

Two	TAFINLAR.xml:S2:9559:3	two	CD	O	O
percent	TAFINLAR.xml:S2:9563:7	percent	NN	O	O
demonstrated	TAFINLAR.xml:S2:9571:12	demonstr	VBD	O	O
a	TAFINLAR.xml:S2:9584:1	a	DT	O	O
decrease	TAFINLAR.xml:S2:9586:8	decreas	NN	B-AdverseReaction	O
in	TAFINLAR.xml:S2:9595:2	in	IN	I-AdverseReaction	O
LVEF	TAFINLAR.xml:S2:9598:4	lvef	NNP	I-AdverseReaction	O
below	TAFINLAR.xml:S2:9603:5	below	IN	O	O
institutional	TAFINLAR.xml:S2:9609:13	institut	JJ	O	O
lower	TAFINLAR.xml:S2:9623:5	lower	JJR	O	O
limits	TAFINLAR.xml:S2:9629:6	limit	NNS	O	O
of	TAFINLAR.xml:S2:9636:2	of	IN	O	O
normal	TAFINLAR.xml:S2:9639:6	normal	JJ	O	O
with	TAFINLAR.xml:S2:9646:4	with	IN	O	O
an	TAFINLAR.xml:S2:9651:2	an	DT	O	O
absolute	TAFINLAR.xml:S2:9654:8	absolut	JJ	B-AdverseReaction	O
decrease	TAFINLAR.xml:S2:9663:8	decreas	NN	I-AdverseReaction	O
in	TAFINLAR.xml:S2:9672:2	in	IN	I-AdverseReaction	O
LVEF	TAFINLAR.xml:S2:9675:4	lvef	NNP	I-AdverseReaction	O
of	TAFINLAR.xml:S2:9680:2	of	IN	O	O
20%	TAFINLAR.xml:S2:9685:3	20%	CD	O	O
below	TAFINLAR.xml:S2:9689:5	below	IN	O	O
baseline	TAFINLAR.xml:S2:9695:8	baselin	NN	O	O
.	TAFINLAR.xml:S2:9703:1	.	.	O	O

Assess	TAFINLAR.xml:S2:9712:6	assess	NNP	O	O
LVEF	TAFINLAR.xml:S2:9719:4	lvef	NNP	O	O
by	TAFINLAR.xml:S2:9724:2	by	IN	O	O
echocardiogram	TAFINLAR.xml:S2:9727:14	echocardiogram	NN	O	O
or	TAFINLAR.xml:S2:9742:2	or	CC	O	O
multigated	TAFINLAR.xml:S2:9745:10	multig	VBN	O	O
acquisition	TAFINLAR.xml:S2:9756:11	acquisit	NN	O	O
(	TAFINLAR.xml:S2:9768:1	(	(	O	O
MUGA	TAFINLAR.xml:S2:9769:4	muga	NNP	O	O
)	TAFINLAR.xml:S2:9773:1	)	)	O	O
scan	TAFINLAR.xml:S2:9775:4	scan	VBD	O	O
before	TAFINLAR.xml:S2:9780:6	befor	IN	O	O
initiation	TAFINLAR.xml:S2:9787:10	initi	NN	O	O
of	TAFINLAR.xml:S2:9798:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:9801:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:9810:2	in	IN	O	O
combination	TAFINLAR.xml:S2:9813:11	combin	NN	O	O
with	TAFINLAR.xml:S2:9825:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:9830:10	trametinib	NN	O	O
,	TAFINLAR.xml:S2:9840:1	,	,	O	O
one	TAFINLAR.xml:S2:9842:3	one	CD	O	O
month	TAFINLAR.xml:S2:9846:5	month	NN	O	O
after	TAFINLAR.xml:S2:9852:5	after	IN	O	O
initiation	TAFINLAR.xml:S2:9858:10	initi	NN	O	O
,	TAFINLAR.xml:S2:9868:1	,	,	O	O
and	TAFINLAR.xml:S2:9870:3	and	CC	O	O
then	TAFINLAR.xml:S2:9874:4	then	RB	O	O
at	TAFINLAR.xml:S2:9879:2	at	IN	O	O
2	TAFINLAR.xml:S2:9882:1	2	CD	O	O
-	TAFINLAR.xml:S2:9883:1	-	:	O	O
to	TAFINLAR.xml:S2:9885:2	to	TO	O	O
3	TAFINLAR.xml:S2:9888:1	3	CD	O	O
-	TAFINLAR.xml:S2:9889:1	-	:	O	O
month	TAFINLAR.xml:S2:9890:5	month	NN	O	O
intervals	TAFINLAR.xml:S2:9896:9	interv	NNS	O	O
while	TAFINLAR.xml:S2:9906:5	while	IN	O	O
on	TAFINLAR.xml:S2:9912:2	on	IN	O	O
treatment	TAFINLAR.xml:S2:9915:9	treatment	NN	O	O
with	TAFINLAR.xml:S2:9925:4	with	IN	O	O
the	TAFINLAR.xml:S2:9930:3	the	DT	O	O
combination	TAFINLAR.xml:S2:9934:11	combin	NN	O	O
.	TAFINLAR.xml:S2:9945:1	.	.	O	O

Withhold	TAFINLAR.xml:S2:9947:8	withhold	NNP	O	O
treatment	TAFINLAR.xml:S2:9956:9	treatment	NN	O	O
with	TAFINLAR.xml:S2:9966:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:9971:10	trametinib	NN	O	O
and	TAFINLAR.xml:S2:9982:3	and	CC	O	O
continue	TAFINLAR.xml:S2:9986:8	continu	VB	O	O
TAFINLAR	TAFINLAR.xml:S2:9995:8	tafinlar	NNP	O	O
at	TAFINLAR.xml:S2:10004:2	at	IN	O	O
the	TAFINLAR.xml:S2:10007:3	the	DT	O	O
same	TAFINLAR.xml:S2:10011:4	same	JJ	O	O
dose	TAFINLAR.xml:S2:10016:4	dose	NN	O	O
if	TAFINLAR.xml:S2:10021:2	if	IN	O	O
absolute	TAFINLAR.xml:S2:10024:8	absolut	JJ	O	O
LVEF	TAFINLAR.xml:S2:10033:4	lvef	NNP	O	O
value	TAFINLAR.xml:S2:10038:5	valu	NN	O	O
decreases	TAFINLAR.xml:S2:10044:9	decreas	NNS	O	O
by	TAFINLAR.xml:S2:10054:2	by	IN	O	O
10%	TAFINLAR.xml:S2:10057:3	10%	CD	O	O
from	TAFINLAR.xml:S2:10061:4	from	IN	O	O
pretreatment	TAFINLAR.xml:S2:10066:12	pretreat	NN	O	O
values	TAFINLAR.xml:S2:10079:6	valu	NNS	O	O
and	TAFINLAR.xml:S2:10086:3	and	CC	O	O
is	TAFINLAR.xml:S2:10090:2	is	VBZ	O	O
less	TAFINLAR.xml:S2:10093:4	less	RBR	O	O
than	TAFINLAR.xml:S2:10098:4	than	IN	O	O
the	TAFINLAR.xml:S2:10103:3	the	DT	O	O
lower	TAFINLAR.xml:S2:10107:5	lower	JJR	O	O
limit	TAFINLAR.xml:S2:10113:5	limit	NN	O	O
of	TAFINLAR.xml:S2:10119:2	of	IN	O	O
normal	TAFINLAR.xml:S2:10122:6	normal	JJ	O	O
.	TAFINLAR.xml:S2:10128:1	.	.	O	O

For	TAFINLAR.xml:S2:10130:3	for	IN	O	O
symptomatic	TAFINLAR.xml:S2:10134:11	symptomat	JJ	O	O
cardiomyopathy	TAFINLAR.xml:S2:10146:14	cardiomyopathi	NN	O	O
or	TAFINLAR.xml:S2:10161:2	or	CC	O	O
persistent	TAFINLAR.xml:S2:10164:10	persist	NN	O	I-AdverseReaction
,	TAFINLAR.xml:S2:10174:1	,	,	O	O
asymptomatic	TAFINLAR.xml:S2:10176:12	asymptomat	JJ	O	O
LV	TAFINLAR.xml:S2:10189:2	LV	NNP	O	O
dysfunction	TAFINLAR.xml:S2:10192:11	dysfunct	NN	O	O
that	TAFINLAR.xml:S2:10204:4	that	WDT	O	O
does	TAFINLAR.xml:S2:10209:4	doe	VBZ	O	O
not	TAFINLAR.xml:S2:10214:3	not	RB	O	O
resolve	TAFINLAR.xml:S2:10218:7	resolv	VB	O	O
within	TAFINLAR.xml:S2:10226:6	within	IN	O	O
4	TAFINLAR.xml:S2:10233:1	4	CD	O	O
weeks	TAFINLAR.xml:S2:10235:5	week	NNS	O	O
,	TAFINLAR.xml:S2:10240:1	,	,	O	O
permanently	TAFINLAR.xml:S2:10242:11	perman	RB	O	O
discontinue	TAFINLAR.xml:S2:10254:11	discontinu	VBP	O	O
trametinib	TAFINLAR.xml:S2:10266:10	trametinib	NNS	O	O
and	TAFINLAR.xml:S2:10277:3	and	CC	O	O
withhold	TAFINLAR.xml:S2:10281:8	withhold	JJ	O	O
TAFINLAR	TAFINLAR.xml:S2:10290:8	tafinlar	NNP	O	O
.	TAFINLAR.xml:S2:10298:1	.	.	O	O

Resume	TAFINLAR.xml:S2:10300:6	resum	NNP	O	O
TAFINLAR	TAFINLAR.xml:S2:10307:8	tafinlar	NNP	O	O
at	TAFINLAR.xml:S2:10316:2	at	IN	O	O
the	TAFINLAR.xml:S2:10319:3	the	DT	O	O
same	TAFINLAR.xml:S2:10323:4	same	JJ	O	O
dose	TAFINLAR.xml:S2:10328:4	dose	JJ	O	O
level	TAFINLAR.xml:S2:10333:5	level	NN	O	O
upon	TAFINLAR.xml:S2:10339:4	upon	IN	O	O
recovery	TAFINLAR.xml:S2:10344:8	recoveri	NN	O	O
of	TAFINLAR.xml:S2:10353:2	of	IN	O	O
cardiac	TAFINLAR.xml:S2:10356:7	cardiac	JJ	O	O
function	TAFINLAR.xml:S2:10364:8	function	NN	O	O
[	TAFINLAR.xml:S2:10373:1	[	NNP	O	O
see	TAFINLAR.xml:S2:10374:3	see	VBP	O	O
Dosage	TAFINLAR.xml:S2:10378:6	dosag	NNP	O	O
and	TAFINLAR.xml:S2:10385:3	and	CC	O	O
Administration	TAFINLAR.xml:S2:10389:14	administr	NNP	O	O
(	TAFINLAR.xml:S2:10404:1	(	(	O	O
2.3	TAFINLAR.xml:S2:10405:3	2.3	CD	O	O
)]	TAFINLAR.xml:S2:10408:2	)]	NN	O	O
.	TAFINLAR.xml:S2:10414:1	.	.	O	O

5.6	TAFINLAR.xml:S2:10424:3	5.6	CD	O	O
Ocular	TAFINLAR.xml:S2:10428:6	ocular	JJ	O	O
Toxicities	TAFINLAR.xml:S2:10435:10	toxic	NNS	O	O

Retinal	TAFINLAR.xml:S2:10455:7	retin	JJ	O	O
Pigment	TAFINLAR.xml:S2:10463:7	pigment	NNP	O	O
Epithelial	TAFINLAR.xml:S2:10471:10	epitheli	NNP	O	O
Detachment	TAFINLAR.xml:S2:10482:10	detach	NNP	O	O
(	TAFINLAR.xml:S2:10493:1	(	(	O	O
RPED	TAFINLAR.xml:S2:10494:4	rped	NNP	O	O
)	TAFINLAR.xml:S2:10498:1	)	)	O	O
:	TAFINLAR.xml:S2:10499:1	:	:	O	O

Retinal	TAFINLAR.xml:S2:10510:7	retin	JJ	B-AdverseReaction	B-AdverseReaction
pigment	TAFINLAR.xml:S2:10518:7	pigment	NN	I-AdverseReaction	I-AdverseReaction
epithelial	TAFINLAR.xml:S2:10526:10	epitheli	JJ	I-AdverseReaction	I-AdverseReaction
detachments	TAFINLAR.xml:S2:10537:11	detach	NNS	I-AdverseReaction	I-AdverseReaction
(	TAFINLAR.xml:S2:10549:1	(	(	O	O
RPED	TAFINLAR.xml:S2:10550:4	rped	NNP	B-AdverseReaction	O
)	TAFINLAR.xml:S2:10554:1	)	)	O	O
can	TAFINLAR.xml:S2:10556:3	can	MD	O	O
occur	TAFINLAR.xml:S2:10560:5	occur	VB	O	O
when	TAFINLAR.xml:S2:10566:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:10571:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:10580:2	is	VBZ	O	O
used	TAFINLAR.xml:S2:10583:4	use	VBN	O	O
in	TAFINLAR.xml:S2:10588:2	in	IN	O	O
combination	TAFINLAR.xml:S2:10591:11	combin	NN	O	O
with	TAFINLAR.xml:S2:10603:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:10608:10	trametinib	NN	O	O
and	TAFINLAR.xml:S2:10619:3	and	CC	O	O
with	TAFINLAR.xml:S2:10623:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:10628:10	trametinib	NN	O	O
as	TAFINLAR.xml:S2:10639:2	as	IN	O	O
a	TAFINLAR.xml:S2:10642:1	a	DT	O	O
single	TAFINLAR.xml:S2:10644:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:10651:5	agent	NN	O	O
[	TAFINLAR.xml:S2:10657:1	[	NNP	O	O
refer	TAFINLAR.xml:S2:10658:5	refer	NN	O	O
to	TAFINLAR.xml:S2:10664:2	to	TO	O	O
Full	TAFINLAR.xml:S2:10667:4	full	NNP	O	O
Prescribing	TAFINLAR.xml:S2:10672:11	prescrib	NNP	O	O
Information	TAFINLAR.xml:S2:10684:11	inform	NNP	O	O
for	TAFINLAR.xml:S2:10696:3	for	IN	O	O
trametinib	TAFINLAR.xml:S2:10700:10	trametinib	NN	O	O
]	TAFINLAR.xml:S2:10710:1	]	NN	O	O
.	TAFINLAR.xml:S2:10713:1	.	.	O	O

Retinal	TAFINLAR.xml:S2:10715:7	retin	JJ	B-AdverseReaction	B-AdverseReaction
detachments	TAFINLAR.xml:S2:10723:11	detach	NNS	I-AdverseReaction	I-AdverseReaction
resulting	TAFINLAR.xml:S2:10735:9	result	VBG	O	O
from	TAFINLAR.xml:S2:10745:4	from	IN	O	O
trametinib	TAFINLAR.xml:S2:10750:10	trametinib	NN	O	O
are	TAFINLAR.xml:S2:10761:3	are	VBP	O	O
often	TAFINLAR.xml:S2:10765:5	often	RB	O	O
bilateral	TAFINLAR.xml:S2:10771:9	bilater	JJ	O	O
and	TAFINLAR.xml:S2:10781:3	and	CC	O	O
multifocal	TAFINLAR.xml:S2:10785:10	multifoc	JJ	O	O
,	TAFINLAR.xml:S2:10795:1	,	,	O	O
occurring	TAFINLAR.xml:S2:10797:9	occur	VBG	O	O
in	TAFINLAR.xml:S2:10807:2	in	IN	O	O
the	TAFINLAR.xml:S2:10810:3	the	DT	O	O
macular	TAFINLAR.xml:S2:10814:7	macular	JJ	O	O
region	TAFINLAR.xml:S2:10822:6	region	NN	O	O
of	TAFINLAR.xml:S2:10829:2	of	IN	O	O
the	TAFINLAR.xml:S2:10832:3	the	DT	O	O
retina	TAFINLAR.xml:S2:10836:6	retina	NN	O	O
.	TAFINLAR.xml:S2:10842:1	.	.	O	O

In	TAFINLAR.xml:S2:10851:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:10854:5	trial	NNP	O	O
2	TAFINLAR.xml:S2:10860:1	2	CD	O	O
,	TAFINLAR.xml:S2:10861:1	,	,	O	O
ophthalmologic	TAFINLAR.xml:S2:10863:14	ophthalmolog	JJ	O	O
examinations	TAFINLAR.xml:S2:10878:12	examin	NNS	O	O
including	TAFINLAR.xml:S2:10891:9	includ	VBG	O	O
retinal	TAFINLAR.xml:S2:10901:7	retin	JJ	O	O
evaluation	TAFINLAR.xml:S2:10909:10	evalu	NN	O	O
were	TAFINLAR.xml:S2:10920:4	were	VBD	O	O
performed	TAFINLAR.xml:S2:10925:9	perform	VBN	O	O
pretreatment	TAFINLAR.xml:S2:10935:12	pretreat	NN	O	O
and	TAFINLAR.xml:S2:10948:3	and	CC	O	O
at	TAFINLAR.xml:S2:10952:2	at	IN	O	O
regular	TAFINLAR.xml:S2:10955:7	regular	JJ	O	O
intervals	TAFINLAR.xml:S2:10963:9	interv	NNS	O	O
during	TAFINLAR.xml:S2:10973:6	dure	IN	O	O
treatment	TAFINLAR.xml:S2:10980:9	treatment	NN	O	O
.	TAFINLAR.xml:S2:10989:1	.	.	O	O

RPED	TAFINLAR.xml:S2:10991:4	rped	NNP	B-AdverseReaction	O
occurred	TAFINLAR.xml:S2:10996:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:11005:2	in	IN	O	O
2%	TAFINLAR.xml:S2:11008:2	2%	CD	O	O
(	TAFINLAR.xml:S2:11011:1	(	(	O	O
1	TAFINLAR.xml:S2:11012:1	1	CD	O	O
55	TAFINLAR.xml:S2:11014:2	55	CD	O	O
)	TAFINLAR.xml:S2:11016:1	)	)	O	O
of	TAFINLAR.xml:S2:11018:2	of	IN	O	O
patients	TAFINLAR.xml:S2:11021:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:11030:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:11040:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:11049:2	in	IN	O	O
combination	TAFINLAR.xml:S2:11052:11	combin	NN	O	O
with	TAFINLAR.xml:S2:11064:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:11069:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:11079:1	.	.	O	O

Across	TAFINLAR.xml:S2:11081:6	across	IN	O	O
clinical	TAFINLAR.xml:S2:11088:8	clinic	JJ	O	O
trials	TAFINLAR.xml:S2:11097:6	trial	NNS	O	O
of	TAFINLAR.xml:S2:11104:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:11107:8	tafinlar	NNP	O	O
administered	TAFINLAR.xml:S2:11116:12	administ	VBD	O	O
in	TAFINLAR.xml:S2:11129:2	in	IN	O	O
combination	TAFINLAR.xml:S2:11132:11	combin	NN	O	O
with	TAFINLAR.xml:S2:11144:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:11149:10	trametinib	NN	O	O
(	TAFINLAR.xml:S2:11160:1	(	(	O	O
N	TAFINLAR.xml:S2:11161:1	N	NNP	O	O
202	TAFINLAR.xml:S2:11165:3	202	CD	O	O
)	TAFINLAR.xml:S2:11168:1	)	)	O	O
,	TAFINLAR.xml:S2:11169:1	,	,	O	O
the	TAFINLAR.xml:S2:11171:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:11175:9	incid	NN	O	O
of	TAFINLAR.xml:S2:11185:2	of	IN	O	O
RPED	TAFINLAR.xml:S2:11188:4	rped	NNP	B-AdverseReaction	O
was	TAFINLAR.xml:S2:11193:3	wa	VBD	O	O
1%	TAFINLAR.xml:S2:11197:2	1%	CD	O	O
(	TAFINLAR.xml:S2:11200:1	(	(	O	O
2	TAFINLAR.xml:S2:11201:1	2	CD	O	O
202	TAFINLAR.xml:S2:11203:3	202	CD	O	O
)	TAFINLAR.xml:S2:11206:1	)	)	O	O
.	TAFINLAR.xml:S2:11207:1	.	.	O	O

Perform	TAFINLAR.xml:S2:11216:7	perform	NNP	O	O
ophthalmological	TAFINLAR.xml:S2:11224:16	ophthalmolog	JJ	O	O
evaluation	TAFINLAR.xml:S2:11241:10	evalu	NN	O	O
at	TAFINLAR.xml:S2:11252:2	at	IN	O	O
any	TAFINLAR.xml:S2:11255:3	ani	DT	O	O
time	TAFINLAR.xml:S2:11259:4	time	NN	O	O
a	TAFINLAR.xml:S2:11264:1	a	DT	O	O
patient	TAFINLAR.xml:S2:11266:7	patient	NN	O	O
reports	TAFINLAR.xml:S2:11274:7	report	NNS	O	O
visual	TAFINLAR.xml:S2:11282:6	visual	JJ	O	O
disturbances	TAFINLAR.xml:S2:11289:12	disturb	NNS	O	O
and	TAFINLAR.xml:S2:11302:3	and	CC	O	O
compare	TAFINLAR.xml:S2:11306:7	compar	NN	O	O
with	TAFINLAR.xml:S2:11314:4	with	IN	O	O
baseline	TAFINLAR.xml:S2:11319:8	baselin	NN	O	O
,	TAFINLAR.xml:S2:11327:1	,	,	O	O
if	TAFINLAR.xml:S2:11329:2	if	IN	O	O
available	TAFINLAR.xml:S2:11332:9	avail	JJ	O	O
.	TAFINLAR.xml:S2:11341:1	.	.	O	O

If	TAFINLAR.xml:S2:11343:2	If	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:11346:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:11355:2	is	VBZ	O	O
used	TAFINLAR.xml:S2:11358:4	use	VBN	O	O
in	TAFINLAR.xml:S2:11363:2	in	IN	O	O
combination	TAFINLAR.xml:S2:11366:11	combin	NN	O	O
with	TAFINLAR.xml:S2:11378:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:11383:10	trametinib	NN	O	O
,	TAFINLAR.xml:S2:11393:1	,	,	O	O
do	TAFINLAR.xml:S2:11395:2	do	VBP	O	O
not	TAFINLAR.xml:S2:11398:3	not	RB	O	O
modify	TAFINLAR.xml:S2:11402:6	modifi	VB	O	O
the	TAFINLAR.xml:S2:11409:3	the	DT	O	O
dose	TAFINLAR.xml:S2:11413:4	dose	NN	O	O
of	TAFINLAR.xml:S2:11418:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:11421:8	tafinlar	NNP	O	O
.	TAFINLAR.xml:S2:11429:1	.	.	O	O

Withhold	TAFINLAR.xml:S2:11431:8	withhold	NNP	O	O
trametinib	TAFINLAR.xml:S2:11440:10	trametinib	NN	O	O
if	TAFINLAR.xml:S2:11451:2	if	IN	O	O
RPED	TAFINLAR.xml:S2:11454:4	rped	NNP	O	O
is	TAFINLAR.xml:S2:11459:2	is	VBZ	O	O
diagnosed	TAFINLAR.xml:S2:11462:9	diagnos	VBN	O	O
.	TAFINLAR.xml:S2:11471:1	.	.	O	O

If	TAFINLAR.xml:S2:11473:2	If	IN	O	O
resolution	TAFINLAR.xml:S2:11476:10	resolut	NN	O	O
of	TAFINLAR.xml:S2:11487:2	of	IN	O	O
the	TAFINLAR.xml:S2:11490:3	the	DT	O	O
RPED	TAFINLAR.xml:S2:11494:4	rped	NNP	O	O
is	TAFINLAR.xml:S2:11499:2	is	VBZ	O	O
documented	TAFINLAR.xml:S2:11502:10	document	VBN	O	O
on	TAFINLAR.xml:S2:11513:2	on	IN	O	O
repeat	TAFINLAR.xml:S2:11516:6	repeat	NN	O	O
ophthalmological	TAFINLAR.xml:S2:11523:16	ophthalmolog	JJ	O	O
evaluation	TAFINLAR.xml:S2:11540:10	evalu	NN	O	O
within	TAFINLAR.xml:S2:11551:6	within	IN	O	O
3	TAFINLAR.xml:S2:11558:1	3	CD	O	O
weeks	TAFINLAR.xml:S2:11560:5	week	NNS	O	O
,	TAFINLAR.xml:S2:11565:1	,	,	O	O
resume	TAFINLAR.xml:S2:11567:6	resum	VB	O	O
trametinib	TAFINLAR.xml:S2:11574:10	trametinib	NN	O	O
at	TAFINLAR.xml:S2:11585:2	at	IN	O	O
a	TAFINLAR.xml:S2:11588:1	a	DT	O	O
lower	TAFINLAR.xml:S2:11590:5	lower	JJR	O	O
dose	TAFINLAR.xml:S2:11596:4	dose	JJ	O	O
level	TAFINLAR.xml:S2:11601:5	level	NN	O	O
.	TAFINLAR.xml:S2:11606:1	.	.	O	O

Discontinue	TAFINLAR.xml:S2:11608:11	discontinu	NNP	O	O
trametinib	TAFINLAR.xml:S2:11620:10	trametinib	NN	O	O
if	TAFINLAR.xml:S2:11631:2	if	IN	O	O
no	TAFINLAR.xml:S2:11634:2	no	DT	O	O
improvement	TAFINLAR.xml:S2:11637:11	improv	NN	O	O
after	TAFINLAR.xml:S2:11649:5	after	IN	O	O
3	TAFINLAR.xml:S2:11655:1	3	CD	O	O
weeks	TAFINLAR.xml:S2:11657:5	week	NNS	O	O
[	TAFINLAR.xml:S2:11663:1	[	JJ	O	O
see	TAFINLAR.xml:S2:11664:3	see	VBP	O	O
Dosage	TAFINLAR.xml:S2:11668:6	dosag	NNP	O	O
and	TAFINLAR.xml:S2:11675:3	and	CC	O	O
Administration	TAFINLAR.xml:S2:11679:14	administr	NNP	O	O
(	TAFINLAR.xml:S2:11694:1	(	(	O	O
2.3	TAFINLAR.xml:S2:11695:3	2.3	CD	O	O
)]	TAFINLAR.xml:S2:11698:2	)]	NN	O	O
.	TAFINLAR.xml:S2:11700:1	.	.	O	O

Uveitis	TAFINLAR.xml:S2:11712:7	uveiti	NN	O	O
and	TAFINLAR.xml:S2:11720:3	and	CC	O	O
Iritis	TAFINLAR.xml:S2:11724:6	iriti	NN	O	O
:	TAFINLAR.xml:S2:11730:1	:	:	O	O

Uveitis	TAFINLAR.xml:S2:11741:7	uveiti	NN	B-AdverseReaction	O
and	TAFINLAR.xml:S2:11749:3	and	CC	O	O
iritis	TAFINLAR.xml:S2:11753:6	iriti	NN	B-AdverseReaction	B-AdverseReaction
can	TAFINLAR.xml:S2:11760:3	can	MD	O	O
occur	TAFINLAR.xml:S2:11764:5	occur	VB	O	O
when	TAFINLAR.xml:S2:11770:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:11775:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:11784:2	is	VBZ	O	O
administered	TAFINLAR.xml:S2:11787:12	administ	VBN	O	O
as	TAFINLAR.xml:S2:11800:2	as	IN	O	O
a	TAFINLAR.xml:S2:11803:1	a	DT	O	O
single	TAFINLAR.xml:S2:11805:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:11812:5	agent	NN	O	O
or	TAFINLAR.xml:S2:11818:2	or	CC	O	O
when	TAFINLAR.xml:S2:11821:4	when	WRB	O	O
used	TAFINLAR.xml:S2:11826:4	use	VBN	O	O
in	TAFINLAR.xml:S2:11831:2	in	IN	O	O
combination	TAFINLAR.xml:S2:11834:11	combin	NN	O	O
with	TAFINLAR.xml:S2:11846:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:11851:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:11861:1	.	.	O	O

Uveitis	TAFINLAR.xml:S2:11870:7	uveiti	NN	B-AdverseReaction	O
(	TAFINLAR.xml:S2:11878:1	(	(	O	O
including	TAFINLAR.xml:S2:11879:9	includ	VBG	O	O
iritis	TAFINLAR.xml:S2:11889:6	iriti	NN	B-AdverseReaction	B-AdverseReaction
)	TAFINLAR.xml:S2:11895:1	)	)	O	O
occurred	TAFINLAR.xml:S2:11897:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:11906:2	in	IN	O	O
1%	TAFINLAR.xml:S2:11909:2	1%	CD	O	O
(	TAFINLAR.xml:S2:11912:1	(	(	O	O
6	TAFINLAR.xml:S2:11913:1	6	CD	O	O
586	TAFINLAR.xml:S2:11915:3	586	CD	O	O
)	TAFINLAR.xml:S2:11918:1	)	)	O	O
of	TAFINLAR.xml:S2:11920:2	of	IN	O	O
patients	TAFINLAR.xml:S2:11923:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:11932:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:11940:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:11945:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:11954:2	as	IN	O	O
a	TAFINLAR.xml:S2:11957:1	a	DT	O	O
single	TAFINLAR.xml:S2:11959:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:11966:5	agent	NN	O	O
and	TAFINLAR.xml:S2:11972:3	and	CC	O	O
uveitis	TAFINLAR.xml:S2:11976:7	uveiti	NN	B-AdverseReaction	B-AdverseReaction
occurred	TAFINLAR.xml:S2:11984:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:11993:2	in	IN	O	O
1%	TAFINLAR.xml:S2:11996:2	1%	CD	O	O
(	TAFINLAR.xml:S2:11999:1	(	(	O	O
2	TAFINLAR.xml:S2:12000:1	2	CD	O	O
202	TAFINLAR.xml:S2:12002:3	202	CD	O	O
)	TAFINLAR.xml:S2:12005:1	)	)	O	O
of	TAFINLAR.xml:S2:12007:2	of	IN	O	O
patients	TAFINLAR.xml:S2:12010:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:12019:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:12027:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:12032:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:12041:2	in	IN	O	O
combination	TAFINLAR.xml:S2:12044:11	combin	NN	O	O
with	TAFINLAR.xml:S2:12056:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:12061:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:12071:1	.	.	O	O

Symptomatic	TAFINLAR.xml:S2:12073:11	symptomat	JJ	O	O
treatment	TAFINLAR.xml:S2:12085:9	treatment	NN	O	O
employed	TAFINLAR.xml:S2:12095:8	employ	VBN	O	O
in	TAFINLAR.xml:S2:12104:2	in	IN	O	O
clinical	TAFINLAR.xml:S2:12107:8	clinic	JJ	O	O
trials	TAFINLAR.xml:S2:12116:6	trial	NNS	O	O
included	TAFINLAR.xml:S2:12123:8	includ	VBD	O	O
steroid	TAFINLAR.xml:S2:12132:7	steroid	NN	O	B-AdverseReaction
and	TAFINLAR.xml:S2:12140:3	and	CC	O	O
mydriatic	TAFINLAR.xml:S2:12144:9	mydriat	JJ	O	O
ophthalmic	TAFINLAR.xml:S2:12154:10	ophthalm	JJ	O	O
drops	TAFINLAR.xml:S2:12165:5	drop	NNS	O	O
.	TAFINLAR.xml:S2:12170:1	.	.	O	O

Monitor	TAFINLAR.xml:S2:12172:7	monitor	NN	O	O
patients	TAFINLAR.xml:S2:12180:8	patient	NNS	O	O
for	TAFINLAR.xml:S2:12189:3	for	IN	O	O
visual	TAFINLAR.xml:S2:12193:6	visual	JJ	O	O
signs	TAFINLAR.xml:S2:12200:5	sign	NNS	O	O
and	TAFINLAR.xml:S2:12206:3	and	CC	O	O
symptoms	TAFINLAR.xml:S2:12210:8	symptom	NNS	O	O
of	TAFINLAR.xml:S2:12219:2	of	IN	O	O
uveitis	TAFINLAR.xml:S2:12222:7	uveiti	NN	O	O
(	TAFINLAR.xml:S2:12230:1	(	(	O	O
e	TAFINLAR.xml:S2:12231:1	e	NN	O	O
.	TAFINLAR.xml:S2:12232:1	.	.	O	O
g	TAFINLAR.xml:S2:12233:1	g	NN	O	O
.	TAFINLAR.xml:S2:12234:1	.	.	O	O
,	TAFINLAR.xml:S2:12235:1	,	,	O	O
change	TAFINLAR.xml:S2:12237:6	chang	NN	O	O
in	TAFINLAR.xml:S2:12244:2	in	IN	O	O
vision	TAFINLAR.xml:S2:12247:6	vision	NN	O	O
,	TAFINLAR.xml:S2:12253:1	,	,	O	O
photophobia	TAFINLAR.xml:S2:12255:11	photophobia	NN	O	B-AdverseReaction
,	TAFINLAR.xml:S2:12266:1	,	,	O	O
eye	TAFINLAR.xml:S2:12268:3	eye	NN	O	B-AdverseReaction
pain	TAFINLAR.xml:S2:12272:4	pain	NN	O	I-AdverseReaction
)	TAFINLAR.xml:S2:12276:1	)	)	O	O
.	TAFINLAR.xml:S2:12277:1	.	.	O	O

If	TAFINLAR.xml:S2:12279:2	If	IN	O	O
diagnosed	TAFINLAR.xml:S2:12282:9	diagnos	VBN	O	O
,	TAFINLAR.xml:S2:12291:1	,	,	O	O
withhold	TAFINLAR.xml:S2:12293:8	withhold	JJ	O	O
TAFINLAR	TAFINLAR.xml:S2:12302:8	tafinlar	NN	O	O
for	TAFINLAR.xml:S2:12311:3	for	IN	O	O
up	TAFINLAR.xml:S2:12315:2	up	IN	O	O
to	TAFINLAR.xml:S2:12318:2	to	TO	O	O
6	TAFINLAR.xml:S2:12321:1	6	CD	O	O
weeks	TAFINLAR.xml:S2:12323:5	week	NNS	O	O
until	TAFINLAR.xml:S2:12329:5	until	IN	O	O
uveitis	TAFINLAR.xml:S2:12335:7	uveiti	JJ	O	O
iritis	TAFINLAR.xml:S2:12343:6	iriti	NN	O	O
resolves	TAFINLAR.xml:S2:12350:8	resolv	NNS	O	O
to	TAFINLAR.xml:S2:12359:2	to	TO	O	O
Grade	TAFINLAR.xml:S2:12362:5	grade	VB	O	O
0	TAFINLAR.xml:S2:12368:1	0	CD	O	O
-	TAFINLAR.xml:S2:12369:1	-	:	O	O
1	TAFINLAR.xml:S2:12370:1	1	CD	O	O
.	TAFINLAR.xml:S2:12371:1	.	.	O	O

If	TAFINLAR.xml:S2:12373:2	If	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:12376:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:12385:2	is	VBZ	O	O
used	TAFINLAR.xml:S2:12388:4	use	VBN	O	O
in	TAFINLAR.xml:S2:12393:2	in	IN	O	O
combination	TAFINLAR.xml:S2:12396:11	combin	NN	O	O
with	TAFINLAR.xml:S2:12408:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:12413:10	trametinib	NN	O	O
,	TAFINLAR.xml:S2:12423:1	,	,	O	O
do	TAFINLAR.xml:S2:12425:2	do	VBP	O	O
not	TAFINLAR.xml:S2:12428:3	not	RB	O	O
modify	TAFINLAR.xml:S2:12432:6	modifi	VB	O	O
the	TAFINLAR.xml:S2:12439:3	the	DT	O	O
dose	TAFINLAR.xml:S2:12443:4	dose	NN	O	O
of	TAFINLAR.xml:S2:12448:2	of	IN	O	O
trametinib	TAFINLAR.xml:S2:12451:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:12461:1	.	.	O	O

5.7	TAFINLAR.xml:S2:12472:3	5.7	CD	O	O
Serious	TAFINLAR.xml:S2:12476:7	seriou	JJ	O	O
Febrile	TAFINLAR.xml:S2:12484:7	febril	NNP	O	O
Reactions	TAFINLAR.xml:S2:12492:9	reaction	NNS	O	O

Serious	TAFINLAR.xml:S2:12508:7	seriou	JJ	O	O
febrile	TAFINLAR.xml:S2:12516:7	febril	JJ	B-AdverseReaction	O
reactions	TAFINLAR.xml:S2:12524:9	reaction	NNS	I-AdverseReaction	O
and	TAFINLAR.xml:S2:12534:3	and	CC	O	O
fever	TAFINLAR.xml:S2:12538:5	fever	NN	B-AdverseReaction	O
of	TAFINLAR.xml:S2:12544:2	of	IN	O	O
any	TAFINLAR.xml:S2:12547:3	ani	DT	O	O
severity	TAFINLAR.xml:S2:12551:8	sever	NN	O	O
complicated	TAFINLAR.xml:S2:12560:11	complic	VBN	O	O
by	TAFINLAR.xml:S2:12572:2	by	IN	O	O
hypotension	TAFINLAR.xml:S2:12575:11	hypotens	NN	B-AdverseReaction	O
,	TAFINLAR.xml:S2:12586:1	,	,	O	O
rigors	TAFINLAR.xml:S2:12588:6	rigor	NNS	B-AdverseReaction	O
or	TAFINLAR.xml:S2:12595:2	or	CC	O	O
chills	TAFINLAR.xml:S2:12598:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S2:12604:1	,	,	O	O
dehydration	TAFINLAR.xml:S2:12606:11	dehydr	NN	B-AdverseReaction	B-AdverseReaction
,	TAFINLAR.xml:S2:12617:1	,	,	O	O
or	TAFINLAR.xml:S2:12619:2	or	CC	O	O
renal	TAFINLAR.xml:S2:12622:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	TAFINLAR.xml:S2:12628:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	TAFINLAR.xml:S2:12635:1	,	,	O	O
can	TAFINLAR.xml:S2:12637:3	can	MD	O	O
occur	TAFINLAR.xml:S2:12641:5	occur	VB	O	O
when	TAFINLAR.xml:S2:12647:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:12652:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:12661:2	is	VBZ	O	O
administered	TAFINLAR.xml:S2:12664:12	administ	VBN	O	O
as	TAFINLAR.xml:S2:12677:2	as	IN	O	O
a	TAFINLAR.xml:S2:12680:1	a	DT	O	O
single	TAFINLAR.xml:S2:12682:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:12689:5	agent	NN	O	O
or	TAFINLAR.xml:S2:12695:2	or	CC	O	O
when	TAFINLAR.xml:S2:12698:4	when	WRB	O	O
used	TAFINLAR.xml:S2:12703:4	use	VBN	O	O
in	TAFINLAR.xml:S2:12708:2	in	IN	O	O
combination	TAFINLAR.xml:S2:12711:11	combin	NN	O	O
with	TAFINLAR.xml:S2:12723:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:12728:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:12738:1	.	.	O	O

The	TAFINLAR.xml:S2:12740:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:12744:9	incid	NN	O	O
and	TAFINLAR.xml:S2:12754:3	and	CC	O	O
severity	TAFINLAR.xml:S2:12758:8	sever	NN	O	O
of	TAFINLAR.xml:S2:12767:2	of	IN	O	O
pyrexia	TAFINLAR.xml:S2:12770:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
are	TAFINLAR.xml:S2:12778:3	are	VBP	O	O
increased	TAFINLAR.xml:S2:12782:9	increas	VBN	O	O
when	TAFINLAR.xml:S2:12792:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:12797:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:12806:2	is	VBZ	O	O
used	TAFINLAR.xml:S2:12809:4	use	VBN	O	O
in	TAFINLAR.xml:S2:12814:2	in	IN	O	O
combination	TAFINLAR.xml:S2:12817:11	combin	NN	O	O
with	TAFINLAR.xml:S2:12829:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:12834:10	trametinib	NNS	O	O
compared	TAFINLAR.xml:S2:12845:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:12854:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:12859:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:12868:2	as	IN	O	O
a	TAFINLAR.xml:S2:12871:1	a	DT	O	O
single	TAFINLAR.xml:S2:12873:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:12880:5	agent	NN	O	O
[	TAFINLAR.xml:S2:12886:1	[	NNP	O	O
see	TAFINLAR.xml:S2:12887:3	see	VBP	O	O
Adverse	TAFINLAR.xml:S2:12891:7	advers	JJ	O	O
Reactions	TAFINLAR.xml:S2:12899:9	reaction	NNP	O	O
(	TAFINLAR.xml:S2:12909:1	(	(	O	O
6.1	TAFINLAR.xml:S2:12910:3	6.1	CD	O	O
)]	TAFINLAR.xml:S2:12913:2	)]	NN	O	O
.	TAFINLAR.xml:S2:12915:1	.	.	O	O

In	TAFINLAR.xml:S2:12925:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:12928:5	trial	NNP	O	O
1	TAFINLAR.xml:S2:12934:1	1	CD	O	O
,	TAFINLAR.xml:S2:12935:1	,	,	O	O
the	TAFINLAR.xml:S2:12937:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:12941:9	incid	NN	O	O
of	TAFINLAR.xml:S2:12951:2	of	IN	O	O
fever	TAFINLAR.xml:S2:12954:5	fever	NN	B-AdverseReaction	B-AdverseReaction
(	TAFINLAR.xml:S2:12960:1	(	(	O	O
serious	TAFINLAR.xml:S2:12961:7	seriou	JJ	O	O
and	TAFINLAR.xml:S2:12969:3	and	CC	O	O
non	TAFINLAR.xml:S2:12973:3	non	JJ	O	O
-	TAFINLAR.xml:S2:12976:1	-	:	O	O
serious	TAFINLAR.xml:S2:12977:7	seriou	JJ	O	O
)	TAFINLAR.xml:S2:12984:1	)	)	O	O
was	TAFINLAR.xml:S2:12986:3	wa	VBD	O	O
28%	TAFINLAR.xml:S2:12990:3	28%	CD	O	O
in	TAFINLAR.xml:S2:12994:2	in	IN	O	O
patients	TAFINLAR.xml:S2:12997:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:13006:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:13014:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:13019:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S2:13028:3	and	CC	O	O
10%	TAFINLAR.xml:S2:13032:3	10%	CD	O	O
in	TAFINLAR.xml:S2:13036:2	in	IN	O	O
patients	TAFINLAR.xml:S2:13039:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:13048:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:13056:4	with	IN	O	O
dacarbazine	TAFINLAR.xml:S2:13061:11	dacarbazin	NN	O	O
.	TAFINLAR.xml:S2:13072:1	.	.	O	O

In	TAFINLAR.xml:S2:13074:2	In	IN	O	O
patients	TAFINLAR.xml:S2:13077:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:13086:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:13094:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:13099:8	tafinlar	NNP	O	O
,	TAFINLAR.xml:S2:13107:1	,	,	O	O
the	TAFINLAR.xml:S2:13109:3	the	DT	O	O
median	TAFINLAR.xml:S2:13113:6	median	JJ	O	O
time	TAFINLAR.xml:S2:13120:4	time	NN	O	O
to	TAFINLAR.xml:S2:13125:2	to	TO	O	O
initial	TAFINLAR.xml:S2:13128:7	initi	JJ	O	O
onset	TAFINLAR.xml:S2:13136:5	onset	NN	O	O
of	TAFINLAR.xml:S2:13142:2	of	IN	O	O
fever	TAFINLAR.xml:S2:13145:5	fever	NN	B-AdverseReaction	O
(	TAFINLAR.xml:S2:13151:1	(	(	O	O
any	TAFINLAR.xml:S2:13152:3	ani	DT	O	O
severity	TAFINLAR.xml:S2:13156:8	sever	NN	O	O
)	TAFINLAR.xml:S2:13164:1	)	)	O	O
was	TAFINLAR.xml:S2:13166:3	wa	VBD	O	O
11	TAFINLAR.xml:S2:13170:2	11	CD	O	O
days	TAFINLAR.xml:S2:13173:4	day	NNS	O	O
(	TAFINLAR.xml:S2:13178:1	(	(	O	O
range	TAFINLAR.xml:S2:13179:5	rang	NN	O	O
:	TAFINLAR.xml:S2:13184:1	:	:	O	O
1	TAFINLAR.xml:S2:13186:1	1	CD	O	O
to	TAFINLAR.xml:S2:13188:2	to	TO	O	O
202	TAFINLAR.xml:S2:13191:3	202	CD	O	O
days	TAFINLAR.xml:S2:13195:4	day	NNS	O	O
)	TAFINLAR.xml:S2:13199:1	)	)	O	O
and	TAFINLAR.xml:S2:13201:3	and	CC	O	O
the	TAFINLAR.xml:S2:13205:3	the	DT	O	O
median	TAFINLAR.xml:S2:13209:6	median	JJ	O	O
duration	TAFINLAR.xml:S2:13216:8	durat	NN	O	O
of	TAFINLAR.xml:S2:13225:2	of	IN	O	O
fever	TAFINLAR.xml:S2:13228:5	fever	NN	B-AdverseReaction	O
was	TAFINLAR.xml:S2:13234:3	wa	VBD	O	O
3	TAFINLAR.xml:S2:13238:1	3	CD	O	O
days	TAFINLAR.xml:S2:13240:4	day	NNS	O	O
(	TAFINLAR.xml:S2:13245:1	(	(	O	O
range	TAFINLAR.xml:S2:13246:5	rang	NN	O	O
:	TAFINLAR.xml:S2:13251:1	:	:	O	O
1	TAFINLAR.xml:S2:13253:1	1	CD	O	O
to	TAFINLAR.xml:S2:13255:2	to	TO	O	O
129	TAFINLAR.xml:S2:13258:3	129	CD	O	O
days	TAFINLAR.xml:S2:13262:4	day	NNS	O	O
)	TAFINLAR.xml:S2:13266:1	)	)	O	O
.	TAFINLAR.xml:S2:13267:1	.	.	O	O

Serious	TAFINLAR.xml:S2:13269:7	seriou	JJ	O	O
febrile	TAFINLAR.xml:S2:13277:7	febril	JJ	B-AdverseReaction	O
reactions	TAFINLAR.xml:S2:13285:9	reaction	NNS	I-AdverseReaction	O
and	TAFINLAR.xml:S2:13295:3	and	CC	O	O
fever	TAFINLAR.xml:S2:13299:5	fever	NN	B-AdverseReaction	O
of	TAFINLAR.xml:S2:13305:2	of	IN	O	O
any	TAFINLAR.xml:S2:13308:3	ani	DT	O	O
severity	TAFINLAR.xml:S2:13312:8	sever	NN	O	O
complicated	TAFINLAR.xml:S2:13321:11	complic	VBN	O	O
by	TAFINLAR.xml:S2:13333:2	by	IN	O	O
hypotension	TAFINLAR.xml:S2:13336:11	hypotens	NN	B-AdverseReaction	O
,	TAFINLAR.xml:S2:13347:1	,	,	O	O
rigors	TAFINLAR.xml:S2:13349:6	rigor	NNS	B-AdverseReaction	B-AdverseReaction
or	TAFINLAR.xml:S2:13356:2	or	CC	O	O
chills	TAFINLAR.xml:S2:13359:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
occurred	TAFINLAR.xml:S2:13366:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:13375:2	in	IN	O	O
3.7%	TAFINLAR.xml:S2:13378:4	3.7%	CD	O	O
(	TAFINLAR.xml:S2:13383:1	(	(	O	O
7	TAFINLAR.xml:S2:13384:1	7	CD	O	O
187	TAFINLAR.xml:S2:13386:3	187	CD	O	O
)	TAFINLAR.xml:S2:13389:1	)	)	O	O
of	TAFINLAR.xml:S2:13391:2	of	IN	O	O
patients	TAFINLAR.xml:S2:13394:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:13403:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:13411:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:13416:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S2:13425:3	and	CC	O	O
in	TAFINLAR.xml:S2:13429:2	in	IN	O	O
none	TAFINLAR.xml:S2:13432:4	none	NN	O	O
of	TAFINLAR.xml:S2:13437:2	of	IN	O	O
the	TAFINLAR.xml:S2:13440:3	the	DT	O	O
59	TAFINLAR.xml:S2:13444:2	59	CD	O	O
patients	TAFINLAR.xml:S2:13447:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:13456:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:13464:4	with	IN	O	O
dacarbazine	TAFINLAR.xml:S2:13469:11	dacarbazin	NN	O	O
.	TAFINLAR.xml:S2:13480:1	.	.	O	O

In	TAFINLAR.xml:S2:13489:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:13492:5	trial	NNP	O	O
2	TAFINLAR.xml:S2:13498:1	2	CD	O	O
,	TAFINLAR.xml:S2:13499:1	,	,	O	O
the	TAFINLAR.xml:S2:13501:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:13505:9	incid	NN	O	O
of	TAFINLAR.xml:S2:13515:2	of	IN	O	O
fever	TAFINLAR.xml:S2:13518:5	fever	NN	B-AdverseReaction	B-AdverseReaction
(	TAFINLAR.xml:S2:13524:1	(	(	O	O
serious	TAFINLAR.xml:S2:13525:7	seriou	JJ	O	O
and	TAFINLAR.xml:S2:13533:3	and	CC	O	O
non	TAFINLAR.xml:S2:13537:3	non	JJ	O	O
-	TAFINLAR.xml:S2:13540:1	-	:	O	O
serious	TAFINLAR.xml:S2:13541:7	seriou	JJ	O	O
)	TAFINLAR.xml:S2:13548:1	)	)	O	O
was	TAFINLAR.xml:S2:13550:3	wa	VBD	O	O
71%	TAFINLAR.xml:S2:13554:3	71%	CD	O	O
(	TAFINLAR.xml:S2:13558:1	(	(	O	O
39	TAFINLAR.xml:S2:13559:2	39	CD	O	O
55	TAFINLAR.xml:S2:13562:2	55	CD	O	O
)	TAFINLAR.xml:S2:13564:1	)	)	O	O
in	TAFINLAR.xml:S2:13566:2	in	IN	O	O
patients	TAFINLAR.xml:S2:13569:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:13578:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:13586:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:13591:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:13600:2	in	IN	O	O
combination	TAFINLAR.xml:S2:13603:11	combin	NN	O	O
with	TAFINLAR.xml:S2:13615:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:13620:10	trametinib	NN	O	O
and	TAFINLAR.xml:S2:13631:3	and	CC	O	O
26%	TAFINLAR.xml:S2:13635:3	26%	CD	O	O
(	TAFINLAR.xml:S2:13639:1	(	(	O	O
14	TAFINLAR.xml:S2:13640:2	14	CD	O	O
53	TAFINLAR.xml:S2:13643:2	53	CD	O	O
)	TAFINLAR.xml:S2:13645:1	)	)	O	O
in	TAFINLAR.xml:S2:13647:2	in	IN	O	O
patients	TAFINLAR.xml:S2:13650:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:13659:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:13667:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:13672:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:13681:2	as	IN	O	O
a	TAFINLAR.xml:S2:13684:1	a	DT	O	O
single	TAFINLAR.xml:S2:13686:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:13693:5	agent	NN	O	O
.	TAFINLAR.xml:S2:13698:1	.	.	O	O

Serious	TAFINLAR.xml:S2:13700:7	seriou	JJ	O	O
febrile	TAFINLAR.xml:S2:13708:7	febril	JJ	B-AdverseReaction	O
reactions	TAFINLAR.xml:S2:13716:9	reaction	NNS	I-AdverseReaction	O
and	TAFINLAR.xml:S2:13726:3	and	CC	O	O
fever	TAFINLAR.xml:S2:13730:5	fever	NN	B-AdverseReaction	O
of	TAFINLAR.xml:S2:13736:2	of	IN	O	O
any	TAFINLAR.xml:S2:13739:3	ani	DT	O	O
severity	TAFINLAR.xml:S2:13743:8	sever	NN	O	O
complicated	TAFINLAR.xml:S2:13752:11	complic	VBN	O	O
by	TAFINLAR.xml:S2:13764:2	by	IN	O	O
hypotension	TAFINLAR.xml:S2:13767:11	hypotens	NN	B-AdverseReaction	O
,	TAFINLAR.xml:S2:13778:1	,	,	O	O
rigors	TAFINLAR.xml:S2:13780:6	rigor	NNS	B-AdverseReaction	B-AdverseReaction
or	TAFINLAR.xml:S2:13787:2	or	CC	O	O
chills	TAFINLAR.xml:S2:13790:6	chill	NNS	B-AdverseReaction	B-AdverseReaction
occurred	TAFINLAR.xml:S2:13797:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:13806:2	in	IN	O	O
25%	TAFINLAR.xml:S2:13809:3	25%	CD	O	O
(	TAFINLAR.xml:S2:13813:1	(	(	O	O
14	TAFINLAR.xml:S2:13814:2	14	CD	O	O
55	TAFINLAR.xml:S2:13817:2	55	CD	O	O
)	TAFINLAR.xml:S2:13819:1	)	)	O	O
of	TAFINLAR.xml:S2:13821:2	of	IN	O	O
patients	TAFINLAR.xml:S2:13824:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:13833:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:13841:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:13846:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:13855:2	in	IN	O	O
combination	TAFINLAR.xml:S2:13858:11	combin	NN	O	O
with	TAFINLAR.xml:S2:13870:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:13875:10	trametinib	NNS	O	O
compared	TAFINLAR.xml:S2:13886:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:13895:4	with	IN	O	O
2%	TAFINLAR.xml:S2:13900:2	2%	CD	O	O
(	TAFINLAR.xml:S2:13903:1	(	(	O	O
1	TAFINLAR.xml:S2:13904:1	1	CD	O	O
53	TAFINLAR.xml:S2:13906:2	53	CD	O	O
)	TAFINLAR.xml:S2:13908:1	)	)	O	O
of	TAFINLAR.xml:S2:13910:2	of	IN	O	O
patients	TAFINLAR.xml:S2:13913:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:13922:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:13930:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:13935:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:13944:2	as	IN	O	O
a	TAFINLAR.xml:S2:13947:1	a	DT	O	O
single	TAFINLAR.xml:S2:13949:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:13956:5	agent	NN	O	O
.	TAFINLAR.xml:S2:13961:1	.	.	O	O

Fever	TAFINLAR.xml:S2:13963:5	fever	NNP	B-AdverseReaction	O
was	TAFINLAR.xml:S2:13969:3	wa	VBD	O	O
complicated	TAFINLAR.xml:S2:13973:11	complic	VBN	O	O
with	TAFINLAR.xml:S2:13985:4	with	IN	O	O
chills	TAFINLAR.xml:S2:13990:6	chill	NNS	B-AdverseReaction	O
rigors	TAFINLAR.xml:S2:13997:6	rigor	NNS	B-AdverseReaction	O
in	TAFINLAR.xml:S2:14004:2	in	IN	O	O
51%	TAFINLAR.xml:S2:14007:3	51%	CD	O	O
(	TAFINLAR.xml:S2:14011:1	(	(	O	O
28	TAFINLAR.xml:S2:14012:2	28	CD	O	O
55	TAFINLAR.xml:S2:14015:2	55	CD	O	O
)	TAFINLAR.xml:S2:14017:1	)	)	O	O
,	TAFINLAR.xml:S2:14018:1	,	,	O	O
dehydration	TAFINLAR.xml:S2:14020:11	dehydr	NN	B-AdverseReaction	B-AdverseReaction
in	TAFINLAR.xml:S2:14032:2	in	IN	O	O
9%	TAFINLAR.xml:S2:14035:2	9%	CD	O	O
(	TAFINLAR.xml:S2:14038:1	(	(	O	O
5	TAFINLAR.xml:S2:14039:1	5	CD	O	O
55	TAFINLAR.xml:S2:14041:2	55	CD	O	O
)	TAFINLAR.xml:S2:14043:1	)	)	O	O
,	TAFINLAR.xml:S2:14044:1	,	,	O	O
renal	TAFINLAR.xml:S2:14046:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
failure	TAFINLAR.xml:S2:14052:7	failur	NN	I-AdverseReaction	I-AdverseReaction
in	TAFINLAR.xml:S2:14060:2	in	IN	O	O
4%	TAFINLAR.xml:S2:14063:2	4%	CD	O	O
(	TAFINLAR.xml:S2:14066:1	(	(	O	O
2	TAFINLAR.xml:S2:14067:1	2	CD	O	O
55	TAFINLAR.xml:S2:14069:2	55	CD	O	O
)	TAFINLAR.xml:S2:14071:1	)	)	O	O
,	TAFINLAR.xml:S2:14072:1	,	,	O	O
and	TAFINLAR.xml:S2:14074:3	and	CC	O	O
syncope	TAFINLAR.xml:S2:14078:7	syncop	NN	B-AdverseReaction	B-AdverseReaction
in	TAFINLAR.xml:S2:14086:2	in	IN	O	O
4%	TAFINLAR.xml:S2:14089:2	4%	CD	O	O
(	TAFINLAR.xml:S2:14092:1	(	(	O	O
2	TAFINLAR.xml:S2:14093:1	2	CD	O	O
55	TAFINLAR.xml:S2:14095:2	55	CD	O	O
)	TAFINLAR.xml:S2:14097:1	)	)	O	O
of	TAFINLAR.xml:S2:14099:2	of	IN	O	O
patients	TAFINLAR.xml:S2:14102:8	patient	NNS	O	O
in	TAFINLAR.xml:S2:14111:2	in	IN	O	O
Trial	TAFINLAR.xml:S2:14114:5	trial	JJ	O	O
2	TAFINLAR.xml:S2:14120:1	2	CD	O	O
.	TAFINLAR.xml:S2:14121:1	.	.	O	O

In	TAFINLAR.xml:S2:14130:2	In	IN	O	O
patients	TAFINLAR.xml:S2:14133:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:14142:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:14150:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:14155:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:14164:2	in	IN	O	O
combination	TAFINLAR.xml:S2:14167:11	combin	NN	O	O
with	TAFINLAR.xml:S2:14179:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:14184:10	trametinib	NN	O	O
,	TAFINLAR.xml:S2:14194:1	,	,	O	O
the	TAFINLAR.xml:S2:14196:3	the	DT	O	O
median	TAFINLAR.xml:S2:14200:6	median	JJ	O	O
time	TAFINLAR.xml:S2:14207:4	time	NN	O	O
to	TAFINLAR.xml:S2:14212:2	to	TO	O	O
initial	TAFINLAR.xml:S2:14215:7	initi	JJ	O	O
onset	TAFINLAR.xml:S2:14223:5	onset	NN	O	O
of	TAFINLAR.xml:S2:14229:2	of	IN	O	O
fever	TAFINLAR.xml:S2:14232:5	fever	NN	B-AdverseReaction	O
was	TAFINLAR.xml:S2:14238:3	wa	VBD	O	O
30	TAFINLAR.xml:S2:14242:2	30	CD	O	O
days	TAFINLAR.xml:S2:14245:4	day	NNS	O	O
compared	TAFINLAR.xml:S2:14250:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:14259:4	with	IN	O	O
19	TAFINLAR.xml:S2:14264:2	19	CD	O	O
days	TAFINLAR.xml:S2:14267:4	day	NNS	O	O
in	TAFINLAR.xml:S2:14272:2	in	IN	O	O
patients	TAFINLAR.xml:S2:14275:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:14284:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:14292:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:14297:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:14306:2	as	IN	O	O
a	TAFINLAR.xml:S2:14309:1	a	DT	O	O
single	TAFINLAR.xml:S2:14311:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:14318:5	agent	NN	O	O
;	TAFINLAR.xml:S2:14323:1	;	:	O	O
the	TAFINLAR.xml:S2:14325:3	the	DT	O	O
median	TAFINLAR.xml:S2:14329:6	median	JJ	O	O
duration	TAFINLAR.xml:S2:14336:8	durat	NN	O	O
of	TAFINLAR.xml:S2:14345:2	of	IN	O	O
fever	TAFINLAR.xml:S2:14348:5	fever	NN	B-AdverseReaction	O
was	TAFINLAR.xml:S2:14354:3	wa	VBD	O	O
6	TAFINLAR.xml:S2:14358:1	6	CD	O	O
days	TAFINLAR.xml:S2:14360:4	day	NNS	O	O
with	TAFINLAR.xml:S2:14365:4	with	IN	O	O
the	TAFINLAR.xml:S2:14370:3	the	DT	O	O
combination	TAFINLAR.xml:S2:14374:11	combin	NN	O	O
compared	TAFINLAR.xml:S2:14386:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:14395:4	with	IN	O	O
4	TAFINLAR.xml:S2:14400:1	4	CD	O	O
days	TAFINLAR.xml:S2:14402:4	day	NNS	O	O
with	TAFINLAR.xml:S2:14407:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:14412:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:14421:2	as	IN	O	O
a	TAFINLAR.xml:S2:14424:1	a	DT	O	O
single	TAFINLAR.xml:S2:14426:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:14433:5	agent	NN	O	O
.	TAFINLAR.xml:S2:14438:1	.	.	O	O

Across	TAFINLAR.xml:S2:14447:6	across	IN	O	O
clinical	TAFINLAR.xml:S2:14454:8	clinic	JJ	O	O
trials	TAFINLAR.xml:S2:14463:6	trial	NNS	O	O
of	TAFINLAR.xml:S2:14470:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:14473:8	tafinlar	NNP	O	O
administered	TAFINLAR.xml:S2:14482:12	administ	VBD	O	O
in	TAFINLAR.xml:S2:14495:2	in	IN	O	O
combination	TAFINLAR.xml:S2:14498:11	combin	NN	O	O
with	TAFINLAR.xml:S2:14510:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:14515:10	trametinib	NN	O	O
(	TAFINLAR.xml:S2:14526:1	(	(	O	O
N	TAFINLAR.xml:S2:14527:1	N	NNP	O	O
202	TAFINLAR.xml:S2:14531:3	202	CD	O	O
)	TAFINLAR.xml:S2:14534:1	)	)	O	O
,	TAFINLAR.xml:S2:14535:1	,	,	O	O
the	TAFINLAR.xml:S2:14537:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:14541:9	incid	NN	O	O
of	TAFINLAR.xml:S2:14551:2	of	IN	O	O
pyrexia	TAFINLAR.xml:S2:14554:7	pyrexia	NN	B-AdverseReaction	B-AdverseReaction
was	TAFINLAR.xml:S2:14562:3	wa	VBD	O	O
57%	TAFINLAR.xml:S2:14566:3	57%	CD	O	O
(	TAFINLAR.xml:S2:14570:1	(	(	O	O
116	TAFINLAR.xml:S2:14571:3	116	CD	O	O
202	TAFINLAR.xml:S2:14575:3	202	CD	O	O
)	TAFINLAR.xml:S2:14578:1	)	)	O	O
.	TAFINLAR.xml:S2:14579:1	.	.	O	O

Withhold	TAFINLAR.xml:S2:14587:8	withhold	NNP	O	O
TAFINLAR	TAFINLAR.xml:S2:14596:8	tafinlar	NNP	O	O
for	TAFINLAR.xml:S2:14605:3	for	IN	O	O
fever	TAFINLAR.xml:S2:14609:5	fever	NN	O	O
of	TAFINLAR.xml:S2:14615:2	of	IN	O	O
101.3	TAFINLAR.xml:S2:14618:5	101.3	CD	O	O
oF	TAFINLAR.xml:S2:14623:2	oF	NN	O	O
or	TAFINLAR.xml:S2:14626:2	or	CC	O	O
higher	TAFINLAR.xml:S2:14629:6	higher	JJR	O	O
.	TAFINLAR.xml:S2:14635:1	.	.	O	O

Withhold	TAFINLAR.xml:S2:14637:8	withhold	NNP	O	O
trametinib	TAFINLAR.xml:S2:14646:10	trametinib	NN	O	O
for	TAFINLAR.xml:S2:14657:3	for	IN	O	O
any	TAFINLAR.xml:S2:14661:3	ani	DT	O	O
fever	TAFINLAR.xml:S2:14665:5	fever	NN	O	O
higher	TAFINLAR.xml:S2:14671:6	higher	JJR	O	O
than	TAFINLAR.xml:S2:14678:4	than	IN	O	O
104	TAFINLAR.xml:S2:14683:3	104	CD	O	O
oF	TAFINLAR.xml:S2:14686:2	oF	NN	O	O
.	TAFINLAR.xml:S2:14688:1	.	.	O	O

Withhold	TAFINLAR.xml:S2:14690:8	withhold	NNP	O	O
TAFINLAR	TAFINLAR.xml:S2:14699:8	tafinlar	NNP	O	O
,	TAFINLAR.xml:S2:14707:1	,	,	O	O
and	TAFINLAR.xml:S2:14709:3	and	CC	O	O
trametinib	TAFINLAR.xml:S2:14713:10	trametinib	NN	O	O
if	TAFINLAR.xml:S2:14724:2	if	IN	O	O
used	TAFINLAR.xml:S2:14727:4	use	VBN	O	O
in	TAFINLAR.xml:S2:14732:2	in	IN	O	O
combination	TAFINLAR.xml:S2:14735:11	combin	NN	O	O
,	TAFINLAR.xml:S2:14746:1	,	,	O	O
for	TAFINLAR.xml:S2:14748:3	for	IN	O	O
any	TAFINLAR.xml:S2:14752:3	ani	DT	O	O
serious	TAFINLAR.xml:S2:14756:7	seriou	JJ	O	O
febrile	TAFINLAR.xml:S2:14764:7	febril	JJ	O	O
reaction	TAFINLAR.xml:S2:14772:8	reaction	NN	O	O
or	TAFINLAR.xml:S2:14781:2	or	CC	O	O
fever	TAFINLAR.xml:S2:14784:5	fever	NN	O	O
complicated	TAFINLAR.xml:S2:14790:11	complic	VBN	O	O
by	TAFINLAR.xml:S2:14802:2	by	IN	O	O
hypotension	TAFINLAR.xml:S2:14805:11	hypotens	NN	O	O
,	TAFINLAR.xml:S2:14816:1	,	,	O	O
rigors	TAFINLAR.xml:S2:14818:6	rigor	NNS	O	O
or	TAFINLAR.xml:S2:14825:2	or	CC	O	O
chills	TAFINLAR.xml:S2:14828:6	chill	NNS	O	B-AdverseReaction
,	TAFINLAR.xml:S2:14834:1	,	,	O	O
dehydration	TAFINLAR.xml:S2:14836:11	dehydr	NN	O	B-AdverseReaction
,	TAFINLAR.xml:S2:14847:1	,	,	O	O
or	TAFINLAR.xml:S2:14849:2	or	CC	O	O
renal	TAFINLAR.xml:S2:14852:5	renal	JJ	O	O
failure	TAFINLAR.xml:S2:14858:7	failur	NN	O	O
and	TAFINLAR.xml:S2:14866:3	and	CC	O	O
evaluate	TAFINLAR.xml:S2:14870:8	evalu	NN	O	O
for	TAFINLAR.xml:S2:14879:3	for	IN	O	O
signs	TAFINLAR.xml:S2:14883:5	sign	NNS	O	O
and	TAFINLAR.xml:S2:14889:3	and	CC	O	O
symptoms	TAFINLAR.xml:S2:14893:8	symptom	NNS	O	O
of	TAFINLAR.xml:S2:14902:2	of	IN	O	O
infection	TAFINLAR.xml:S2:14905:9	infect	NN	O	O
.	TAFINLAR.xml:S2:14914:1	.	.	O	O

Refer	TAFINLAR.xml:S2:14916:5	refer	NN	O	O
to	TAFINLAR.xml:S2:14922:2	to	TO	O	O
Table	TAFINLAR.xml:S2:14925:5	tabl	VB	O	O
2	TAFINLAR.xml:S2:14931:1	2	CD	O	O
for	TAFINLAR.xml:S2:14933:3	for	IN	O	O
recommended	TAFINLAR.xml:S2:14937:11	recommend	VBN	O	O
dose	TAFINLAR.xml:S2:14949:4	dose	NN	O	O
modifications	TAFINLAR.xml:S2:14954:13	modif	NNS	O	O
for	TAFINLAR.xml:S2:14968:3	for	IN	O	O
adverse	TAFINLAR.xml:S2:14972:7	advers	JJ	O	O
reactions	TAFINLAR.xml:S2:14980:9	reaction	NNS	O	O
[	TAFINLAR.xml:S2:14990:1	[	VBP	O	O
see	TAFINLAR.xml:S2:14991:3	see	VBP	O	O
Dosage	TAFINLAR.xml:S2:14995:6	dosag	NNP	O	O
and	TAFINLAR.xml:S2:15002:3	and	CC	O	O
Administration	TAFINLAR.xml:S2:15006:14	administr	NNP	O	O
(	TAFINLAR.xml:S2:15021:1	(	(	O	O
2.3	TAFINLAR.xml:S2:15022:3	2.3	CD	O	O
)]	TAFINLAR.xml:S2:15025:2	)]	NN	O	O
.	TAFINLAR.xml:S2:15027:1	.	.	O	O

Prophylaxis	TAFINLAR.xml:S2:15030:11	prophylaxi	NN	O	O
with	TAFINLAR.xml:S2:15042:4	with	IN	O	O
antipyretics	TAFINLAR.xml:S2:15047:12	antipyret	NNS	O	O
may	TAFINLAR.xml:S2:15060:3	may	MD	O	O
be	TAFINLAR.xml:S2:15064:2	be	VB	O	O
required	TAFINLAR.xml:S2:15067:8	requir	VBN	O	O
when	TAFINLAR.xml:S2:15076:4	when	WRB	O	O
resuming	TAFINLAR.xml:S2:15081:8	resum	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:15090:8	tafinlar	NNP	O	O
or	TAFINLAR.xml:S2:15099:2	or	CC	O	O
trametinib	TAFINLAR.xml:S2:15102:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:15112:1	.	.	O	O

5.8	TAFINLAR.xml:S2:15124:3	5.8	CD	O	O
Serious	TAFINLAR.xml:S2:15128:7	seriou	JJ	O	O
Skin	TAFINLAR.xml:S2:15136:4	skin	NNP	O	O
Toxicity	TAFINLAR.xml:S2:15141:8	toxic	NN	O	O

Serious	TAFINLAR.xml:S2:15158:7	seriou	JJ	O	O
skin	TAFINLAR.xml:S2:15166:4	skin	NN	B-AdverseReaction	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15171:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
can	TAFINLAR.xml:S2:15180:3	can	MD	O	O
occur	TAFINLAR.xml:S2:15184:5	occur	VB	O	O
when	TAFINLAR.xml:S2:15190:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:15195:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:15204:2	is	VBZ	O	O
used	TAFINLAR.xml:S2:15207:4	use	VBN	O	O
in	TAFINLAR.xml:S2:15212:2	in	IN	O	O
combination	TAFINLAR.xml:S2:15215:11	combin	NN	O	O
with	TAFINLAR.xml:S2:15227:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:15232:10	trametinib	NN	O	O
and	TAFINLAR.xml:S2:15243:3	and	CC	O	O
with	TAFINLAR.xml:S2:15247:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:15252:10	trametinib	NN	O	O
as	TAFINLAR.xml:S2:15263:2	as	IN	O	O
a	TAFINLAR.xml:S2:15266:1	a	DT	O	O
single	TAFINLAR.xml:S2:15268:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:15275:5	agent	NN	O	O
[	TAFINLAR.xml:S2:15281:1	[	NNP	O	O
refer	TAFINLAR.xml:S2:15282:5	refer	NN	O	O
to	TAFINLAR.xml:S2:15288:2	to	TO	O	O
Full	TAFINLAR.xml:S2:15291:4	full	NNP	O	O
Prescribing	TAFINLAR.xml:S2:15296:11	prescrib	NNP	O	O
Information	TAFINLAR.xml:S2:15308:11	inform	NNP	O	O
for	TAFINLAR.xml:S2:15320:3	for	IN	O	O
trametinib	TAFINLAR.xml:S2:15324:10	trametinib	NN	O	O
]	TAFINLAR.xml:S2:15334:1	]	NN	O	O
.	TAFINLAR.xml:S2:15337:1	.	.	O	O

In	TAFINLAR.xml:S2:15346:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:15349:5	trial	NNP	O	O
2	TAFINLAR.xml:S2:15355:1	2	CD	O	O
,	TAFINLAR.xml:S2:15356:1	,	,	O	O
the	TAFINLAR.xml:S2:15358:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:15362:9	incid	NN	O	O
of	TAFINLAR.xml:S2:15372:2	of	IN	O	O
any	TAFINLAR.xml:S2:15375:3	ani	DT	O	O
skin	TAFINLAR.xml:S2:15379:4	skin	JJ	B-AdverseReaction	O
toxicity	TAFINLAR.xml:S2:15384:8	toxic	NN	I-AdverseReaction	O
was	TAFINLAR.xml:S2:15393:3	wa	VBD	O	O
similar	TAFINLAR.xml:S2:15397:7	similar	JJ	O	O
for	TAFINLAR.xml:S2:15405:3	for	IN	O	O
patients	TAFINLAR.xml:S2:15409:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:15418:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:15428:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:15437:2	in	IN	O	O
combination	TAFINLAR.xml:S2:15440:11	combin	NN	O	O
with	TAFINLAR.xml:S2:15452:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:15457:10	trametinib	NN	O	O
(	TAFINLAR.xml:S2:15468:1	(	(	O	O
65%	TAFINLAR.xml:S2:15469:3	65%	CD	O	O
[	TAFINLAR.xml:S2:15473:1	[	RB	O	O
36	TAFINLAR.xml:S2:15474:2	36	CD	O	O
55	TAFINLAR.xml:S2:15477:2	55	CD	O	O
])	TAFINLAR.xml:S2:15479:2	])	NNS	O	O
compared	TAFINLAR.xml:S2:15482:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:15491:4	with	IN	O	O
patients	TAFINLAR.xml:S2:15496:8	patient	NNS	O	O
receiving	TAFINLAR.xml:S2:15505:9	receiv	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:15515:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:15524:2	as	IN	O	O
a	TAFINLAR.xml:S2:15527:1	a	DT	O	O
single	TAFINLAR.xml:S2:15529:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:15536:5	agent	NN	O	O
(	TAFINLAR.xml:S2:15542:1	(	(	O	O
68%	TAFINLAR.xml:S2:15543:3	68%	CD	O	O
[	TAFINLAR.xml:S2:15547:1	[	RB	O	O
36	TAFINLAR.xml:S2:15548:2	36	CD	O	O
53	TAFINLAR.xml:S2:15551:2	53	CD	O	O
])	TAFINLAR.xml:S2:15553:2	])	NN	O	O
.	TAFINLAR.xml:S2:15555:1	.	.	O	O

The	TAFINLAR.xml:S2:15557:3	the	DT	O	O
median	TAFINLAR.xml:S2:15561:6	median	JJ	O	O
time	TAFINLAR.xml:S2:15568:4	time	NN	O	O
to	TAFINLAR.xml:S2:15573:2	to	TO	O	O
onset	TAFINLAR.xml:S2:15576:5	onset	VB	O	O
of	TAFINLAR.xml:S2:15582:2	of	IN	O	O
skin	TAFINLAR.xml:S2:15585:4	skin	JJ	B-AdverseReaction	O
toxicity	TAFINLAR.xml:S2:15590:8	toxic	NN	I-AdverseReaction	O
in	TAFINLAR.xml:S2:15599:2	in	IN	O	O
patients	TAFINLAR.xml:S2:15602:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:15611:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:15619:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:15624:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:15633:2	in	IN	O	O
combination	TAFINLAR.xml:S2:15636:11	combin	NN	O	O
with	TAFINLAR.xml:S2:15648:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:15653:10	trametinib	NN	O	O
was	TAFINLAR.xml:S2:15664:3	wa	VBD	O	O
37	TAFINLAR.xml:S2:15668:2	37	CD	O	O
days	TAFINLAR.xml:S2:15671:4	day	NNS	O	O
(	TAFINLAR.xml:S2:15676:1	(	(	O	O
range	TAFINLAR.xml:S2:15677:5	rang	NN	O	O
:	TAFINLAR.xml:S2:15682:1	:	:	O	O
1	TAFINLAR.xml:S2:15684:1	1	CD	O	O
to	TAFINLAR.xml:S2:15686:2	to	TO	O	O
225	TAFINLAR.xml:S2:15689:3	225	CD	O	O
days	TAFINLAR.xml:S2:15693:4	day	NNS	O	O
)	TAFINLAR.xml:S2:15697:1	)	)	O	O
and	TAFINLAR.xml:S2:15699:3	and	CC	O	O
median	TAFINLAR.xml:S2:15703:6	median	JJ	O	O
time	TAFINLAR.xml:S2:15710:4	time	NN	O	O
to	TAFINLAR.xml:S2:15715:2	to	TO	O	O
resolution	TAFINLAR.xml:S2:15718:10	resolut	NN	O	O
of	TAFINLAR.xml:S2:15729:2	of	IN	O	O
skin	TAFINLAR.xml:S2:15732:4	skin	JJ	B-AdverseReaction	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15737:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
was	TAFINLAR.xml:S2:15746:3	wa	VBD	O	O
33	TAFINLAR.xml:S2:15750:2	33	CD	O	O
days	TAFINLAR.xml:S2:15753:4	day	NNS	O	O
(	TAFINLAR.xml:S2:15758:1	(	(	O	O
range	TAFINLAR.xml:S2:15759:5	rang	NN	O	O
:	TAFINLAR.xml:S2:15764:1	:	:	O	O
3	TAFINLAR.xml:S2:15766:1	3	CD	O	O
to	TAFINLAR.xml:S2:15768:2	to	TO	O	O
421	TAFINLAR.xml:S2:15771:3	421	CD	O	O
days	TAFINLAR.xml:S2:15775:4	day	NNS	O	O
)	TAFINLAR.xml:S2:15779:1	)	)	O	O
.	TAFINLAR.xml:S2:15780:1	.	.	O	O

No	TAFINLAR.xml:S2:15782:2	No	DT	O	O
patient	TAFINLAR.xml:S2:15785:7	patient	NN	O	O
required	TAFINLAR.xml:S2:15793:8	requir	VBN	O	O
dose	TAFINLAR.xml:S2:15802:4	dose	JJ	O	O
reduction	TAFINLAR.xml:S2:15807:9	reduct	NN	O	O
or	TAFINLAR.xml:S2:15817:2	or	CC	O	O
permanent	TAFINLAR.xml:S2:15820:9	perman	JJ	O	O
discontinuation	TAFINLAR.xml:S2:15830:15	discontinu	NN	O	O
of	TAFINLAR.xml:S2:15846:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:15849:8	tafinlar	NNP	O	O
or	TAFINLAR.xml:S2:15858:2	or	CC	O	O
trametinib	TAFINLAR.xml:S2:15861:10	trametinib	NN	O	O
for	TAFINLAR.xml:S2:15872:3	for	IN	O	O
skin	TAFINLAR.xml:S2:15876:4	skin	JJ	O	O
toxicity	TAFINLAR.xml:S2:15881:8	toxic	NN	O	O
.	TAFINLAR.xml:S2:15889:1	.	.	O	O

Across	TAFINLAR.xml:S2:15898:6	across	IN	O	O
clinical	TAFINLAR.xml:S2:15905:8	clinic	JJ	O	O
trials	TAFINLAR.xml:S2:15914:6	trial	NNS	O	O
of	TAFINLAR.xml:S2:15921:2	of	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:15924:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:15933:2	in	IN	O	O
combination	TAFINLAR.xml:S2:15936:11	combin	NN	O	O
with	TAFINLAR.xml:S2:15948:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:15953:10	trametinib	NN	O	O
(	TAFINLAR.xml:S2:15964:1	(	(	O	O
N	TAFINLAR.xml:S2:15965:1	N	NNP	O	O
202	TAFINLAR.xml:S2:15969:3	202	CD	O	O
)	TAFINLAR.xml:S2:15972:1	)	)	O	O
,	TAFINLAR.xml:S2:15973:1	,	,	O	O
severe	TAFINLAR.xml:S2:15975:6	sever	JJ	O	O
skin	TAFINLAR.xml:S2:15982:4	skin	NN	B-AdverseReaction	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15987:8	toxic	NN	I-AdverseReaction	I-AdverseReaction
and	TAFINLAR.xml:S2:15996:3	and	CC	O	O
secondary	TAFINLAR.xml:S2:16000:9	secondari	JJ	B-AdverseReaction	B-AdverseReaction
infections	TAFINLAR.xml:S2:16010:10	infect	NNS	I-AdverseReaction	I-AdverseReaction
of	TAFINLAR.xml:S2:16021:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	TAFINLAR.xml:S2:16024:3	the	DT	I-AdverseReaction	I-AdverseReaction
skin	TAFINLAR.xml:S2:16028:4	skin	NN	I-AdverseReaction	I-AdverseReaction
requiring	TAFINLAR.xml:S2:16033:9	requir	VBG	O	O
hospitalization	TAFINLAR.xml:S2:16043:15	hospit	NN	O	O
occurred	TAFINLAR.xml:S2:16059:8	occur	VBD	O	O
in	TAFINLAR.xml:S2:16068:2	in	IN	O	O
2.5%	TAFINLAR.xml:S2:16071:4	2.5%	CD	O	O
(	TAFINLAR.xml:S2:16076:1	(	(	O	O
5	TAFINLAR.xml:S2:16077:1	5	CD	O	O
202	TAFINLAR.xml:S2:16079:3	202	CD	O	O
)	TAFINLAR.xml:S2:16082:1	)	)	O	O
of	TAFINLAR.xml:S2:16084:2	of	IN	O	O
patients	TAFINLAR.xml:S2:16087:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:16096:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:16104:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:16109:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:16118:2	in	IN	O	O
combination	TAFINLAR.xml:S2:16121:11	combin	NN	O	O
with	TAFINLAR.xml:S2:16133:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:16138:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:16148:1	.	.	O	O

Withhold	TAFINLAR.xml:S2:16157:8	withhold	NNP	O	O
TAFINLAR	TAFINLAR.xml:S2:16166:8	tafinlar	NNP	O	O
,	TAFINLAR.xml:S2:16174:1	,	,	O	O
and	TAFINLAR.xml:S2:16176:3	and	CC	O	O
trametinib	TAFINLAR.xml:S2:16180:10	trametinib	NN	O	O
if	TAFINLAR.xml:S2:16191:2	if	IN	O	O
used	TAFINLAR.xml:S2:16194:4	use	VBN	O	O
in	TAFINLAR.xml:S2:16199:2	in	IN	O	O
combination	TAFINLAR.xml:S2:16202:11	combin	NN	O	O
,	TAFINLAR.xml:S2:16213:1	,	,	O	O
for	TAFINLAR.xml:S2:16215:3	for	IN	O	O
intolerable	TAFINLAR.xml:S2:16219:11	intoler	JJ	O	O
or	TAFINLAR.xml:S2:16231:2	or	CC	O	O
severe	TAFINLAR.xml:S2:16234:6	sever	JJ	O	O
skin	TAFINLAR.xml:S2:16241:4	skin	JJ	O	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:16246:8	toxic	NN	O	I-AdverseReaction
.	TAFINLAR.xml:S2:16254:1	.	.	O	O

TAFINLAR	TAFINLAR.xml:S2:16256:8	tafinlar	NNP	O	O
and	TAFINLAR.xml:S2:16265:3	and	CC	O	O
trametinib	TAFINLAR.xml:S2:16269:10	trametinib	NN	O	O
may	TAFINLAR.xml:S2:16280:3	may	MD	O	O
be	TAFINLAR.xml:S2:16284:2	be	VB	O	O
resumed	TAFINLAR.xml:S2:16287:7	resum	VBN	O	O
at	TAFINLAR.xml:S2:16295:2	at	IN	O	O
lower	TAFINLAR.xml:S2:16298:5	lower	JJR	O	O
dose	TAFINLAR.xml:S2:16304:4	dose	NN	O	O
levels	TAFINLAR.xml:S2:16309:6	level	NNS	O	O
in	TAFINLAR.xml:S2:16316:2	in	IN	O	O
patients	TAFINLAR.xml:S2:16319:8	patient	NNS	O	O
with	TAFINLAR.xml:S2:16328:4	with	IN	O	O
improvement	TAFINLAR.xml:S2:16333:11	improv	NN	O	O
or	TAFINLAR.xml:S2:16345:2	or	CC	O	O
recovery	TAFINLAR.xml:S2:16348:8	recoveri	NN	O	O
from	TAFINLAR.xml:S2:16357:4	from	IN	O	O
skin	TAFINLAR.xml:S2:16362:4	skin	JJ	O	O
toxicity	TAFINLAR.xml:S2:16367:8	toxic	NN	O	O
within	TAFINLAR.xml:S2:16376:6	within	IN	O	O
3	TAFINLAR.xml:S2:16383:1	3	CD	O	O
weeks	TAFINLAR.xml:S2:16385:5	week	NNS	O	O
[	TAFINLAR.xml:S2:16391:1	[	JJ	O	O
see	TAFINLAR.xml:S2:16392:3	see	VBP	O	O
Dosage	TAFINLAR.xml:S2:16396:6	dosag	NNP	O	O
and	TAFINLAR.xml:S2:16403:3	and	CC	O	O
Administration	TAFINLAR.xml:S2:16407:14	administr	NNP	O	O
(	TAFINLAR.xml:S2:16422:1	(	(	O	O
2.3	TAFINLAR.xml:S2:16423:3	2.3	CD	O	O
)]	TAFINLAR.xml:S2:16426:2	)]	NN	O	O
.	TAFINLAR.xml:S2:16430:1	.	.	O	O

5.9	TAFINLAR.xml:S2:16441:3	5.9	CD	O	O
Hyperglycemia	TAFINLAR.xml:S2:16445:13	hyperglycemia	NN	O	O

Hyperglycemia	TAFINLAR.xml:S2:16465:13	hyperglycemia	NNP	B-AdverseReaction	B-AdverseReaction
can	TAFINLAR.xml:S2:16479:3	can	MD	O	O
occur	TAFINLAR.xml:S2:16483:5	occur	VB	O	O
when	TAFINLAR.xml:S2:16489:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:16494:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:16503:2	is	VBZ	O	O
administered	TAFINLAR.xml:S2:16506:12	administ	VBN	O	O
as	TAFINLAR.xml:S2:16519:2	as	IN	O	O
a	TAFINLAR.xml:S2:16522:1	a	DT	O	O
single	TAFINLAR.xml:S2:16524:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:16531:5	agent	NN	O	O
or	TAFINLAR.xml:S2:16537:2	or	CC	O	O
when	TAFINLAR.xml:S2:16540:4	when	WRB	O	O
used	TAFINLAR.xml:S2:16545:4	use	VBN	O	O
in	TAFINLAR.xml:S2:16550:2	in	IN	O	O
combination	TAFINLAR.xml:S2:16553:11	combin	NN	O	O
with	TAFINLAR.xml:S2:16565:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:16570:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:16582:1	.	.	O	O

In	TAFINLAR.xml:S2:16588:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:16591:5	trial	NNP	O	O
1	TAFINLAR.xml:S2:16597:1	1	CD	O	O
,	TAFINLAR.xml:S2:16598:1	,	,	O	O
5	TAFINLAR.xml:S2:16600:1	5	CD	O	O
of	TAFINLAR.xml:S2:16602:2	of	IN	O	O
12	TAFINLAR.xml:S2:16605:2	12	CD	O	O
patients	TAFINLAR.xml:S2:16608:8	patient	NNS	O	O
with	TAFINLAR.xml:S2:16617:4	with	IN	O	O
a	TAFINLAR.xml:S2:16622:1	a	DT	O	O
history	TAFINLAR.xml:S2:16624:7	histori	NN	O	O
of	TAFINLAR.xml:S2:16632:2	of	IN	O	O
diabetes	TAFINLAR.xml:S2:16635:8	diabet	NNS	O	O
required	TAFINLAR.xml:S2:16644:8	requir	VBN	O	O
more	TAFINLAR.xml:S2:16653:4	more	RBR	O	O
intensive	TAFINLAR.xml:S2:16658:9	intens	JJ	O	O
hypoglycemic	TAFINLAR.xml:S2:16668:12	hypoglycem	JJ	O	O
therapy	TAFINLAR.xml:S2:16681:7	therapi	NN	O	O
while	TAFINLAR.xml:S2:16689:5	while	IN	O	O
taking	TAFINLAR.xml:S2:16695:6	take	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:16702:8	tafinlar	NNP	O	O
.	TAFINLAR.xml:S2:16710:1	.	.	O	O

The	TAFINLAR.xml:S2:16712:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:16716:9	incid	NN	O	O
of	TAFINLAR.xml:S2:16726:2	of	IN	O	O
Grade	TAFINLAR.xml:S2:16729:5	grade	NNP	O	O
3	TAFINLAR.xml:S2:16735:1	3	CD	O	O
hyperglycemia	TAFINLAR.xml:S2:16737:13	hyperglycemia	NN	B-AdverseReaction	O
based	TAFINLAR.xml:S2:16751:5	base	VBN	O	O
on	TAFINLAR.xml:S2:16757:2	on	IN	O	O
laboratory	TAFINLAR.xml:S2:16760:10	laboratori	NN	O	O
values	TAFINLAR.xml:S2:16771:6	valu	NNS	O	O
was	TAFINLAR.xml:S2:16778:3	wa	VBD	O	O
6%	TAFINLAR.xml:S2:16782:2	6%	CD	O	O
(	TAFINLAR.xml:S2:16785:1	(	(	O	O
12	TAFINLAR.xml:S2:16786:2	12	CD	O	O
187	TAFINLAR.xml:S2:16789:3	187	CD	O	O
)	TAFINLAR.xml:S2:16792:1	)	)	O	O
in	TAFINLAR.xml:S2:16794:2	in	IN	O	O
patients	TAFINLAR.xml:S2:16797:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:16806:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:16814:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:16819:8	tafinlar	NNP	O	O
compared	TAFINLAR.xml:S2:16828:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:16837:4	with	IN	O	O
none	TAFINLAR.xml:S2:16842:4	none	NN	O	O
of	TAFINLAR.xml:S2:16847:2	of	IN	O	O
the	TAFINLAR.xml:S2:16850:3	the	DT	O	O
dacarbazine	TAFINLAR.xml:S2:16854:11	dacarbazin	NN	O	O
-	TAFINLAR.xml:S2:16865:1	-	:	O	O
treated	TAFINLAR.xml:S2:16866:7	treat	JJ	O	O
patients	TAFINLAR.xml:S2:16874:8	patient	NNS	O	O
.	TAFINLAR.xml:S2:16882:1	.	.	O	O

In	TAFINLAR.xml:S2:16889:2	In	IN	O	O
Trial	TAFINLAR.xml:S2:16892:5	trial	NNP	O	O
2	TAFINLAR.xml:S2:16898:1	2	CD	O	O
,	TAFINLAR.xml:S2:16899:1	,	,	O	O
the	TAFINLAR.xml:S2:16901:3	the	DT	O	O
incidence	TAFINLAR.xml:S2:16905:9	incid	NN	O	O
of	TAFINLAR.xml:S2:16915:2	of	IN	O	O
Grade	TAFINLAR.xml:S2:16918:5	grade	NNP	O	O
3	TAFINLAR.xml:S2:16924:1	3	CD	O	O
hyperglycemia	TAFINLAR.xml:S2:16926:13	hyperglycemia	NN	B-AdverseReaction	O
based	TAFINLAR.xml:S2:16940:5	base	VBN	O	O
on	TAFINLAR.xml:S2:16946:2	on	IN	O	O
laboratory	TAFINLAR.xml:S2:16949:10	laboratori	NN	O	O
values	TAFINLAR.xml:S2:16960:6	valu	NNS	O	O
was	TAFINLAR.xml:S2:16967:3	wa	VBD	O	O
5%	TAFINLAR.xml:S2:16971:2	5%	CD	O	O
(	TAFINLAR.xml:S2:16974:1	(	(	O	O
3	TAFINLAR.xml:S2:16975:1	3	CD	O	O
55	TAFINLAR.xml:S2:16977:2	55	CD	O	O
)	TAFINLAR.xml:S2:16979:1	)	)	O	O
in	TAFINLAR.xml:S2:16981:2	in	IN	O	O
patients	TAFINLAR.xml:S2:16984:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:16993:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:17001:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:17006:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:17015:2	in	IN	O	O
combination	TAFINLAR.xml:S2:17018:11	combin	NN	O	O
with	TAFINLAR.xml:S2:17030:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:17035:10	trametinib	NNS	O	O
compared	TAFINLAR.xml:S2:17046:8	compar	VBN	O	O
with	TAFINLAR.xml:S2:17055:4	with	IN	O	O
2%	TAFINLAR.xml:S2:17060:2	2%	CD	O	O
(	TAFINLAR.xml:S2:17063:1	(	(	O	O
1	TAFINLAR.xml:S2:17064:1	1	CD	O	O
53	TAFINLAR.xml:S2:17066:2	53	CD	O	O
)	TAFINLAR.xml:S2:17068:1	)	)	O	O
in	TAFINLAR.xml:S2:17070:2	in	IN	O	O
patients	TAFINLAR.xml:S2:17073:8	patient	NNS	O	O
treated	TAFINLAR.xml:S2:17082:7	treat	VBN	O	O
with	TAFINLAR.xml:S2:17090:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:17095:8	tafinlar	NNP	O	O
as	TAFINLAR.xml:S2:17104:2	as	IN	O	O
a	TAFINLAR.xml:S2:17107:1	a	DT	O	O
single	TAFINLAR.xml:S2:17109:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:17116:5	agent	NN	O	O
.	TAFINLAR.xml:S2:17121:1	.	.	O	O

Monitor	TAFINLAR.xml:S2:17130:7	monitor	NNP	O	O
serum	TAFINLAR.xml:S2:17138:5	serum	VBD	O	O
glucose	TAFINLAR.xml:S2:17144:7	glucos	JJ	O	O
levels	TAFINLAR.xml:S2:17152:6	level	NNS	O	O
as	TAFINLAR.xml:S2:17159:2	as	IN	O	O
clinically	TAFINLAR.xml:S2:17162:10	clinic	RB	O	O
appropriate	TAFINLAR.xml:S2:17173:11	appropri	JJ	O	O
when	TAFINLAR.xml:S2:17185:4	when	WRB	O	O
TAFINLAR	TAFINLAR.xml:S2:17190:8	tafinlar	NNP	O	O
is	TAFINLAR.xml:S2:17199:2	is	VBZ	O	O
administered	TAFINLAR.xml:S2:17202:12	administ	VBN	O	O
as	TAFINLAR.xml:S2:17215:2	as	IN	O	O
a	TAFINLAR.xml:S2:17218:1	a	DT	O	O
single	TAFINLAR.xml:S2:17220:6	singl	JJ	O	O
agent	TAFINLAR.xml:S2:17227:5	agent	NN	O	O
or	TAFINLAR.xml:S2:17233:2	or	CC	O	O
when	TAFINLAR.xml:S2:17236:4	when	WRB	O	O
used	TAFINLAR.xml:S2:17241:4	use	VBN	O	O
in	TAFINLAR.xml:S2:17246:2	in	IN	O	O
combination	TAFINLAR.xml:S2:17249:11	combin	NN	O	O
with	TAFINLAR.xml:S2:17261:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:17266:10	trametinib	NN	O	O
in	TAFINLAR.xml:S2:17277:2	in	IN	O	O
patients	TAFINLAR.xml:S2:17280:8	patient	NNS	O	O
with	TAFINLAR.xml:S2:17289:4	with	IN	O	O
pre	TAFINLAR.xml:S2:17294:3	pre	JJ	O	O
-	TAFINLAR.xml:S2:17297:1	-	:	O	O
existing	TAFINLAR.xml:S2:17298:8	exist	VBG	O	O
diabetes	TAFINLAR.xml:S2:17307:8	diabet	NNS	O	O
or	TAFINLAR.xml:S2:17316:2	or	CC	O	O
hyperglycemia	TAFINLAR.xml:S2:17319:13	hyperglycemia	NN	O	O
.	TAFINLAR.xml:S2:17332:1	.	.	O	O

Advise	TAFINLAR.xml:S2:17334:6	advis	NN	O	O
patients	TAFINLAR.xml:S2:17341:8	patient	NNS	O	O
to	TAFINLAR.xml:S2:17350:2	to	TO	O	O
report	TAFINLAR.xml:S2:17353:6	report	VB	O	O
symptoms	TAFINLAR.xml:S2:17360:8	symptom	NNS	O	O
of	TAFINLAR.xml:S2:17369:2	of	IN	O	O
severe	TAFINLAR.xml:S2:17372:6	sever	JJ	O	O
hyperglycemia	TAFINLAR.xml:S2:17379:13	hyperglycemia	NN	O	O
such	TAFINLAR.xml:S2:17393:4	such	JJ	O	O
as	TAFINLAR.xml:S2:17398:2	as	IN	O	O
excessive	TAFINLAR.xml:S2:17401:9	excess	JJ	O	O
thirst	TAFINLAR.xml:S2:17411:6	thirst	NN	O	O
or	TAFINLAR.xml:S2:17418:2	or	CC	O	O
any	TAFINLAR.xml:S2:17421:3	ani	DT	O	O
increase	TAFINLAR.xml:S2:17425:8	increas	NN	O	O
in	TAFINLAR.xml:S2:17434:2	in	IN	O	O
the	TAFINLAR.xml:S2:17437:3	the	DT	O	O
volume	TAFINLAR.xml:S2:17441:6	volum	NN	O	O
or	TAFINLAR.xml:S2:17448:2	or	CC	O	O
frequency	TAFINLAR.xml:S2:17451:9	frequenc	NN	O	O
of	TAFINLAR.xml:S2:17461:2	of	IN	O	O
urination	TAFINLAR.xml:S2:17464:9	urin	NN	O	O
.	TAFINLAR.xml:S2:17475:1	.	.	O	O

5.10	TAFINLAR.xml:S2:17484:4	5.10	CD	O	O
Glucose	TAFINLAR.xml:S2:17489:7	glucos	NNP	O	O
-	TAFINLAR.xml:S2:17496:1	-	:	O	O
6	TAFINLAR.xml:S2:17497:1	6	CD	O	O
-	TAFINLAR.xml:S2:17498:1	-	:	O	O
Phosphate	TAFINLAR.xml:S2:17499:9	phosphat	NN	O	O
Dehydrogenase	TAFINLAR.xml:S2:17509:13	dehydrogenas	NNP	O	O
Deficiency	TAFINLAR.xml:S2:17523:10	defici	NNP	O	O

TAFINLAR	TAFINLAR.xml:S2:17539:8	tafinlar	NNP	O	O
,	TAFINLAR.xml:S2:17547:1	,	,	O	O
which	TAFINLAR.xml:S2:17549:5	which	WDT	O	O
contains	TAFINLAR.xml:S2:17555:8	contain	VBZ	O	O
a	TAFINLAR.xml:S2:17564:1	a	DT	O	O
sulfonamide	TAFINLAR.xml:S2:17566:11	sulfonamid	JJ	O	O
moiety	TAFINLAR.xml:S2:17578:6	moieti	NN	O	O
,	TAFINLAR.xml:S2:17584:1	,	,	O	O
confers	TAFINLAR.xml:S2:17586:7	confer	VBZ	O	O
a	TAFINLAR.xml:S2:17594:1	a	DT	O	O
potential	TAFINLAR.xml:S2:17596:9	potenti	JJ	O	O
risk	TAFINLAR.xml:S2:17606:4	risk	NN	O	O
of	TAFINLAR.xml:S2:17611:2	of	IN	O	O
hemolytic	TAFINLAR.xml:S2:17614:9	hemolyt	JJ	B-AdverseReaction	B-AdverseReaction
anemia	TAFINLAR.xml:S2:17624:6	anemia	NN	I-AdverseReaction	I-AdverseReaction
in	TAFINLAR.xml:S2:17631:2	in	IN	O	O
patients	TAFINLAR.xml:S2:17634:8	patient	NNS	O	O
with	TAFINLAR.xml:S2:17643:4	with	IN	O	O
glucose	TAFINLAR.xml:S2:17648:7	glucos	JJ	O	O
-	TAFINLAR.xml:S2:17655:1	-	:	O	O
6	TAFINLAR.xml:S2:17656:1	6	CD	O	O
-	TAFINLAR.xml:S2:17657:1	-	:	O	O
phosphate	TAFINLAR.xml:S2:17658:9	phosphat	NN	O	O
dehydrogenase	TAFINLAR.xml:S2:17668:13	dehydrogenas	NN	O	O
(	TAFINLAR.xml:S2:17682:1	(	(	O	O
G6PD	TAFINLAR.xml:S2:17683:4	g6pd	NNP	O	O
)	TAFINLAR.xml:S2:17687:1	)	)	O	O
deficiency	TAFINLAR.xml:S2:17689:10	defici	NN	O	O
.	TAFINLAR.xml:S2:17699:1	.	.	O	O

Closely	TAFINLAR.xml:S2:17701:7	close	RB	O	O
observe	TAFINLAR.xml:S2:17709:7	observ	JJ	O	O
patients	TAFINLAR.xml:S2:17717:8	patient	NNS	O	O
with	TAFINLAR.xml:S2:17726:4	with	IN	O	O
G6PD	TAFINLAR.xml:S2:17731:4	g6pd	NNP	O	O
deficiency	TAFINLAR.xml:S2:17736:10	defici	NN	O	O
for	TAFINLAR.xml:S2:17747:3	for	IN	O	O
signs	TAFINLAR.xml:S2:17751:5	sign	NNS	O	O
of	TAFINLAR.xml:S2:17757:2	of	IN	O	O
hemolytic	TAFINLAR.xml:S2:17760:9	hemolyt	JJ	O	O
anemia	TAFINLAR.xml:S2:17770:6	anemia	NN	O	O
.	TAFINLAR.xml:S2:17776:1	.	.	O	O

5.11	TAFINLAR.xml:S2:17785:4	5.11	CD	O	O
Embryofetal	TAFINLAR.xml:S2:17790:11	embryofet	JJ	O	O
Toxicity	TAFINLAR.xml:S2:17802:8	toxic	NN	O	O

Based	TAFINLAR.xml:S2:17816:5	base	VBN	O	O
on	TAFINLAR.xml:S2:17822:2	on	IN	O	O
its	TAFINLAR.xml:S2:17825:3	it	PRP$	O	O
mechanism	TAFINLAR.xml:S2:17829:9	mechan	NN	O	O
of	TAFINLAR.xml:S2:17839:2	of	IN	O	O
action	TAFINLAR.xml:S2:17842:6	action	NN	O	O
,	TAFINLAR.xml:S2:17848:1	,	,	O	O
TAFINLAR	TAFINLAR.xml:S2:17850:8	tafinlar	NNP	O	O
can	TAFINLAR.xml:S2:17859:3	can	MD	O	O
cause	TAFINLAR.xml:S2:17863:5	caus	VB	O	O
fetal	TAFINLAR.xml:S2:17869:5	fetal	JJ	B-AdverseReaction	B-AdverseReaction
harm	TAFINLAR.xml:S2:17875:4	harm	NN	I-AdverseReaction	I-AdverseReaction
when	TAFINLAR.xml:S2:17880:4	when	WRB	O	O
administered	TAFINLAR.xml:S2:17885:12	administ	VBN	O	O
to	TAFINLAR.xml:S2:17898:2	to	TO	O	O
a	TAFINLAR.xml:S2:17901:1	a	DT	O	O
pregnant	TAFINLAR.xml:S2:17903:8	pregnant	JJ	O	O
woman	TAFINLAR.xml:S2:17912:5	woman	NN	O	O
.	TAFINLAR.xml:S2:17917:1	.	.	O	O

Dabrafenib	TAFINLAR.xml:S2:17919:10	dabrafenib	NNP	O	O
was	TAFINLAR.xml:S2:17930:3	wa	VBD	O	O
teratogenic	TAFINLAR.xml:S2:17934:11	teratogen	JJ	B-AdverseReaction	B-AdverseReaction
and	TAFINLAR.xml:S2:17946:3	and	CC	O	O
embryotoxic	TAFINLAR.xml:S2:17950:11	embryotox	NN	B-AdverseReaction	B-AdverseReaction
in	TAFINLAR.xml:S2:17962:2	in	IN	O	O
rats	TAFINLAR.xml:S2:17965:4	rat	NNS	O	O
at	TAFINLAR.xml:S2:17970:2	at	IN	O	O
doses	TAFINLAR.xml:S2:17973:5	dose	NNS	O	O
three	TAFINLAR.xml:S2:17979:5	three	CD	O	O
times	TAFINLAR.xml:S2:17985:5	time	NNS	O	O
greater	TAFINLAR.xml:S2:17991:7	greater	JJR	O	O
than	TAFINLAR.xml:S2:17999:4	than	IN	O	O
the	TAFINLAR.xml:S2:18004:3	the	DT	O	O
human	TAFINLAR.xml:S2:18008:5	human	JJ	O	O
exposure	TAFINLAR.xml:S2:18014:8	exposur	NN	O	O
at	TAFINLAR.xml:S2:18023:2	at	IN	O	O
the	TAFINLAR.xml:S2:18026:3	the	DT	O	O
recommended	TAFINLAR.xml:S2:18030:11	recommend	JJ	O	O
clinical	TAFINLAR.xml:S2:18042:8	clinic	JJ	O	O
dose	TAFINLAR.xml:S2:18051:4	dose	NN	O	O
.	TAFINLAR.xml:S2:18055:1	.	.	O	O

If	TAFINLAR.xml:S2:18057:2	If	IN	O	O
this	TAFINLAR.xml:S2:18060:4	thi	DT	O	O
drug	TAFINLAR.xml:S2:18065:4	drug	NN	O	O
is	TAFINLAR.xml:S2:18070:2	is	VBZ	O	O
used	TAFINLAR.xml:S2:18073:4	use	VBN	O	O
during	TAFINLAR.xml:S2:18078:6	dure	IN	O	O
pregnancy	TAFINLAR.xml:S2:18085:9	pregnanc	NN	O	O
or	TAFINLAR.xml:S2:18095:2	or	CC	O	O
if	TAFINLAR.xml:S2:18098:2	if	IN	O	O
the	TAFINLAR.xml:S2:18101:3	the	DT	O	O
patient	TAFINLAR.xml:S2:18105:7	patient	NN	O	O
becomes	TAFINLAR.xml:S2:18113:7	becom	VBZ	O	O
pregnant	TAFINLAR.xml:S2:18121:8	pregnant	JJ	O	O
while	TAFINLAR.xml:S2:18130:5	while	IN	O	O
taking	TAFINLAR.xml:S2:18136:6	take	VBG	O	O
this	TAFINLAR.xml:S2:18143:4	thi	DT	O	O
drug	TAFINLAR.xml:S2:18148:4	drug	NN	O	O
,	TAFINLAR.xml:S2:18152:1	,	,	O	O
the	TAFINLAR.xml:S2:18154:3	the	DT	O	O
patient	TAFINLAR.xml:S2:18158:7	patient	NN	O	O
should	TAFINLAR.xml:S2:18166:6	should	MD	O	O
be	TAFINLAR.xml:S2:18173:2	be	VB	O	O
apprised	TAFINLAR.xml:S2:18176:8	appris	VBN	O	O
of	TAFINLAR.xml:S2:18185:2	of	IN	O	O
the	TAFINLAR.xml:S2:18188:3	the	DT	O	O
potential	TAFINLAR.xml:S2:18192:9	potenti	JJ	O	O
hazard	TAFINLAR.xml:S2:18202:6	hazard	NN	O	O
to	TAFINLAR.xml:S2:18209:2	to	TO	O	O
a	TAFINLAR.xml:S2:18212:1	a	DT	O	O
fetus	TAFINLAR.xml:S2:18214:5	fetu	NN	O	O
[	TAFINLAR.xml:S2:18220:1	[	NNP	O	O
see	TAFINLAR.xml:S2:18221:3	see	NN	O	O
Use	TAFINLAR.xml:S2:18225:3	use	NNP	O	O
in	TAFINLAR.xml:S2:18229:2	in	IN	O	O
Specific	TAFINLAR.xml:S2:18232:8	specif	NNP	O	O
Populations	TAFINLAR.xml:S2:18241:11	popul	NNP	O	O
(	TAFINLAR.xml:S2:18253:1	(	(	O	O
8.1	TAFINLAR.xml:S2:18254:3	8.1	CD	O	O
)]	TAFINLAR.xml:S2:18257:2	)]	NN	O	O
.	TAFINLAR.xml:S2:18261:1	.	.	O	O

Advise	TAFINLAR.xml:S2:18267:6	advis	NNP	O	O
female	TAFINLAR.xml:S2:18274:6	femal	JJ	O	O
patients	TAFINLAR.xml:S2:18281:8	patient	NNS	O	O
of	TAFINLAR.xml:S2:18290:2	of	IN	O	O
reproductive	TAFINLAR.xml:S2:18293:12	reproduct	JJ	O	O
potential	TAFINLAR.xml:S2:18306:9	potenti	NN	O	O
to	TAFINLAR.xml:S2:18316:2	to	TO	O	O
use	TAFINLAR.xml:S2:18319:3	use	VB	O	O
a	TAFINLAR.xml:S2:18323:1	a	DT	O	O
highly	TAFINLAR.xml:S2:18325:6	highli	RB	O	O
effective	TAFINLAR.xml:S2:18332:9	effect	JJ	O	O
non	TAFINLAR.xml:S2:18342:3	non	NN	O	O
-	TAFINLAR.xml:S2:18345:1	-	:	O	O
hormonal	TAFINLAR.xml:S2:18346:8	hormon	JJ	O	O
method	TAFINLAR.xml:S2:18355:6	method	NN	O	O
of	TAFINLAR.xml:S2:18362:2	of	IN	O	O
contraception	TAFINLAR.xml:S2:18365:13	contracept	NN	O	O
since	TAFINLAR.xml:S2:18379:5	sinc	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:18385:8	tafinlar	NNP	O	O
can	TAFINLAR.xml:S2:18394:3	can	MD	O	O
render	TAFINLAR.xml:S2:18398:6	render	VB	O	O
hormonal	TAFINLAR.xml:S2:18405:8	hormon	JJ	O	O
contraceptives	TAFINLAR.xml:S2:18414:14	contracept	NNS	O	O
ineffective	TAFINLAR.xml:S2:18429:11	ineffect	JJ	O	O
,	TAFINLAR.xml:S2:18441:1	,	,	O	O
during	TAFINLAR.xml:S2:18443:6	dure	IN	O	O
treatment	TAFINLAR.xml:S2:18450:9	treatment	NN	O	O
and	TAFINLAR.xml:S2:18460:3	and	CC	O	O
for	TAFINLAR.xml:S2:18464:3	for	IN	O	O
at	TAFINLAR.xml:S2:18468:2	at	IN	O	O
least	TAFINLAR.xml:S2:18471:5	least	JJS	O	O
2	TAFINLAR.xml:S2:18477:1	2	CD	O	O
weeks	TAFINLAR.xml:S2:18479:5	week	NNS	O	O
after	TAFINLAR.xml:S2:18485:5	after	IN	O	O
treatment	TAFINLAR.xml:S2:18491:9	treatment	NN	O	O
with	TAFINLAR.xml:S2:18501:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:18506:8	tafinlar	NNP	O	O
or	TAFINLAR.xml:S2:18515:2	or	CC	O	O
for	TAFINLAR.xml:S2:18518:3	for	IN	O	O
4	TAFINLAR.xml:S2:18522:1	4	CD	O	O
months	TAFINLAR.xml:S2:18524:6	month	NNS	O	O
after	TAFINLAR.xml:S2:18531:5	after	IN	O	O
treatment	TAFINLAR.xml:S2:18537:9	treatment	NN	O	O
with	TAFINLAR.xml:S2:18547:4	with	IN	O	O
TAFINLAR	TAFINLAR.xml:S2:18552:8	tafinlar	NNP	O	O
in	TAFINLAR.xml:S2:18561:2	in	IN	O	O
combination	TAFINLAR.xml:S2:18564:11	combin	NN	O	O
with	TAFINLAR.xml:S2:18576:4	with	IN	O	O
trametinib	TAFINLAR.xml:S2:18581:10	trametinib	NN	O	O
.	TAFINLAR.xml:S2:18593:1	.	.	O	O

Advise	TAFINLAR.xml:S2:18595:6	advis	NN	O	O
patients	TAFINLAR.xml:S2:18602:8	patient	NNS	O	O
to	TAFINLAR.xml:S2:18611:2	to	TO	O	O
contact	TAFINLAR.xml:S2:18614:7	contact	VB	O	O
their	TAFINLAR.xml:S2:18622:5	their	PRP$	O	O
healthcare	TAFINLAR.xml:S2:18628:10	healthcar	NN	O	O
provider	TAFINLAR.xml:S2:18639:8	provid	NN	O	O
if	TAFINLAR.xml:S2:18648:2	if	IN	O	O
they	TAFINLAR.xml:S2:18651:4	they	PRP	O	O
become	TAFINLAR.xml:S2:18656:6	becom	VBP	O	O
pregnant	TAFINLAR.xml:S2:18663:8	pregnant	JJ	O	O
,	TAFINLAR.xml:S2:18671:1	,	,	O	O
or	TAFINLAR.xml:S2:18673:2	or	CC	O	O
if	TAFINLAR.xml:S2:18676:2	if	IN	O	O
pregnancy	TAFINLAR.xml:S2:18679:9	pregnanc	NN	O	O
is	TAFINLAR.xml:S2:18689:2	is	VBZ	O	O
suspected	TAFINLAR.xml:S2:18692:9	suspect	VBN	O	O
,	TAFINLAR.xml:S2:18701:1	,	,	O	O
while	TAFINLAR.xml:S2:18703:5	while	IN	O	O
taking	TAFINLAR.xml:S2:18709:6	take	VBG	O	O
TAFINLAR	TAFINLAR.xml:S2:18716:8	tafinlar	NNP	O	O
[	TAFINLAR.xml:S2:18725:1	[	NNP	O	O
see	TAFINLAR.xml:S2:18726:3	see	VBP	O	O
Drug	TAFINLAR.xml:S2:18730:4	drug	NNP	O	O
Interactions	TAFINLAR.xml:S2:18735:12	interact	NNP	O	O
(	TAFINLAR.xml:S2:18748:1	(	(	O	O
7.2	TAFINLAR.xml:S2:18749:3	7.2	CD	O	O
)	TAFINLAR.xml:S2:18752:1	)	)	O	O
,	TAFINLAR.xml:S2:18753:1	,	,	O	O
Use	TAFINLAR.xml:S2:18755:3	use	NNP	O	O
in	TAFINLAR.xml:S2:18759:2	in	IN	O	O
Specific	TAFINLAR.xml:S2:18762:8	specif	NNP	O	O
Populations	TAFINLAR.xml:S2:18771:11	popul	NNP	O	O
(	TAFINLAR.xml:S2:18783:1	(	(	O	O
8.6	TAFINLAR.xml:S2:18784:3	8.6	CD	O	O
)]	TAFINLAR.xml:S2:18787:2	)]	NN	O	O
.	TAFINLAR.xml:S2:18789:1	.	.	O	O
6	TANZEUM.xml:S1:4:1	6	CD	O	O
ADVERSE	TANZEUM.xml:S1:6:7	advers	JJ	O	O
REACTIONS	TANZEUM.xml:S1:14:9	reaction	NN	O	O

The	TANZEUM.xml:S1:27:3	the	DT	O	O
following	TANZEUM.xml:S1:31:9	follow	VBG	O	O
serious	TANZEUM.xml:S1:41:7	seriou	JJ	O	O
reactions	TANZEUM.xml:S1:49:9	reaction	NNS	O	O
are	TANZEUM.xml:S1:59:3	are	VBP	O	O
described	TANZEUM.xml:S1:63:9	describ	VBN	O	O
below	TANZEUM.xml:S1:73:5	below	IN	O	O
or	TANZEUM.xml:S1:79:2	or	CC	O	O
elsewhere	TANZEUM.xml:S1:82:9	elsewher	RB	O	O
in	TANZEUM.xml:S1:92:2	in	IN	O	O
the	TANZEUM.xml:S1:95:3	the	DT	O	O
prescribing	TANZEUM.xml:S1:99:11	prescrib	NN	O	O
information	TANZEUM.xml:S1:111:11	inform	NN	O	O
:	TANZEUM.xml:S1:122:1	:	:	O	O

Risk	TANZEUM.xml:S1:133:4	risk	NN	O	O
of	TANZEUM.xml:S1:138:2	of	IN	O	O
Thyroid	TANZEUM.xml:S1:141:7	thyroid	NNP	B-AdverseReaction	O
C	TANZEUM.xml:S1:149:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S1:150:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S1:151:4	cell	NN	I-AdverseReaction	O
Tumors	TANZEUM.xml:S1:156:6	tumor	NNPS	I-AdverseReaction	O
[	TANZEUM.xml:S1:163:1	[	NNP	O	O
see	TANZEUM.xml:S1:164:3	see	VBP	O	O
Warnings	TANZEUM.xml:S1:168:8	warn	NNP	O	O
and	TANZEUM.xml:S1:177:3	and	CC	O	O
Precautions	TANZEUM.xml:S1:181:11	precaut	NNP	O	O
(	TANZEUM.xml:S1:193:1	(	(	O	O
5.1	TANZEUM.xml:S1:194:3	5.1	CD	O	O
)]	TANZEUM.xml:S1:197:2	)]	NN	O	O

Acute	TANZEUM.xml:S1:208:5	acut	NNP	B-AdverseReaction	B-AdverseReaction
Pancreatitis	TANZEUM.xml:S1:214:12	pancreat	NNP	I-AdverseReaction	I-AdverseReaction
[	TANZEUM.xml:S1:227:1	[	NNP	O	O
see	TANZEUM.xml:S1:228:3	see	VBP	O	O
Warnings	TANZEUM.xml:S1:232:8	warn	NNP	O	O
and	TANZEUM.xml:S1:241:3	and	CC	O	O
Precautions	TANZEUM.xml:S1:245:11	precaut	NNP	O	O
(	TANZEUM.xml:S1:257:1	(	(	O	O
5.2	TANZEUM.xml:S1:258:3	5.2	CD	O	O
)]	TANZEUM.xml:S1:261:2	)]	NN	O	O

Hypoglycemia	TANZEUM.xml:S1:272:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
with	TANZEUM.xml:S1:285:4	with	IN	O	O
Concomitant	TANZEUM.xml:S1:290:11	concomit	NNP	O	O
Use	TANZEUM.xml:S1:302:3	use	NNP	O	O
of	TANZEUM.xml:S1:306:2	of	IN	O	O
Insulin	TANZEUM.xml:S1:309:7	insulin	NNP	O	O
Secretagogues	TANZEUM.xml:S1:317:13	secretagogu	NNP	O	O
or	TANZEUM.xml:S1:331:2	or	CC	O	O
Insulin	TANZEUM.xml:S1:334:7	insulin	NNP	O	O
[	TANZEUM.xml:S1:342:1	[	NNP	O	O
see	TANZEUM.xml:S1:343:3	see	VBP	O	O
Warnings	TANZEUM.xml:S1:347:8	warn	NNP	O	O
and	TANZEUM.xml:S1:356:3	and	CC	O	O
Precautions	TANZEUM.xml:S1:360:11	precaut	NNP	O	O
(	TANZEUM.xml:S1:372:1	(	(	O	O
5.3	TANZEUM.xml:S1:373:3	5.3	CD	O	O
)]	TANZEUM.xml:S1:376:2	)]	NN	O	O

Hypersensitivity	TANZEUM.xml:S1:387:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	TANZEUM.xml:S1:404:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
[	TANZEUM.xml:S1:414:1	[	NNP	O	O
see	TANZEUM.xml:S1:415:3	see	VBP	O	O
Warnings	TANZEUM.xml:S1:419:8	warn	NNP	O	O
and	TANZEUM.xml:S1:428:3	and	CC	O	O
Precautions	TANZEUM.xml:S1:432:11	precaut	NNP	O	O
(	TANZEUM.xml:S1:444:1	(	(	O	O
5.4	TANZEUM.xml:S1:445:3	5.4	CD	O	O
)]	TANZEUM.xml:S1:448:2	)]	NN	O	O

Renal	TANZEUM.xml:S1:459:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
Impairment	TANZEUM.xml:S1:465:10	impair	NNP	I-AdverseReaction	I-AdverseReaction
[	TANZEUM.xml:S1:476:1	[	NNP	O	O
see	TANZEUM.xml:S1:477:3	see	VBP	O	O
Warnings	TANZEUM.xml:S1:481:8	warn	NNP	O	O
and	TANZEUM.xml:S1:490:3	and	CC	O	O
Precautions	TANZEUM.xml:S1:494:11	precaut	NNP	O	O
(	TANZEUM.xml:S1:506:1	(	(	O	O
5.5	TANZEUM.xml:S1:507:3	5.5	CD	O	O
)]	TANZEUM.xml:S1:510:2	)]	NN	O	O

EXCERPT	TANZEUM.xml:S1:521:7	excerpt	NN	O	O
:	TANZEUM.xml:S1:528:1	:	:	O	O
Adverse	TANZEUM.xml:S1:532:7	advers	JJ	O	O
reactions	TANZEUM.xml:S1:540:9	reaction	NNS	O	O
,	TANZEUM.xml:S1:549:1	,	,	O	O
reported	TANZEUM.xml:S1:551:8	report	VBD	O	O
in	TANZEUM.xml:S1:560:2	in	IN	O	O
5%	TANZEUM.xml:S1:565:2	5%	CD	O	O
of	TANZEUM.xml:S1:568:2	of	IN	O	O
patients	TANZEUM.xml:S1:571:8	patient	NNS	O	O
treated	TANZEUM.xml:S1:580:7	treat	VBN	O	O
with	TANZEUM.xml:S1:588:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S1:593:7	tanzeum	NNP	O	O
and	TANZEUM.xml:S1:601:3	and	CC	O	O
more	TANZEUM.xml:S1:605:4	more	RBR	O	O
frequently	TANZEUM.xml:S1:610:10	frequent	RB	O	O
than	TANZEUM.xml:S1:621:4	than	IN	O	O
in	TANZEUM.xml:S1:626:2	in	IN	O	O
patients	TANZEUM.xml:S1:629:8	patient	NNS	O	O
on	TANZEUM.xml:S1:638:2	on	IN	O	O
placebo	TANZEUM.xml:S1:641:7	placebo	NN	O	O
,	TANZEUM.xml:S1:648:1	,	,	O	O
were	TANZEUM.xml:S1:650:4	were	VBD	O	O
upper	TANZEUM.xml:S1:655:5	upper	JJ	B-AdverseReaction	B-AdverseReaction
respiratory	TANZEUM.xml:S1:661:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	TANZEUM.xml:S1:673:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	TANZEUM.xml:S1:679:9	infect	NN	I-AdverseReaction	I-AdverseReaction
,	TANZEUM.xml:S1:688:1	,	,	O	O
diarrhea	TANZEUM.xml:S1:690:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	TANZEUM.xml:S1:698:1	,	,	O	O
nausea	TANZEUM.xml:S1:700:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	TANZEUM.xml:S1:706:1	,	,	O	O
injection	TANZEUM.xml:S1:708:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:718:4	site	NN	I-AdverseReaction	I-AdverseReaction
reaction	TANZEUM.xml:S1:723:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
,	TANZEUM.xml:S1:731:1	,	,	O	O
cough	TANZEUM.xml:S1:733:5	cough	NN	B-AdverseReaction	B-AdverseReaction
,	TANZEUM.xml:S1:738:1	,	,	O	O
back	TANZEUM.xml:S1:740:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	TANZEUM.xml:S1:745:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TANZEUM.xml:S1:749:1	,	,	O	O
arthralgia	TANZEUM.xml:S1:751:10	arthralgia	NN	B-AdverseReaction	B-AdverseReaction
,	TANZEUM.xml:S1:761:1	,	,	O	O
sinusitis	TANZEUM.xml:S1:763:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
,	TANZEUM.xml:S1:772:1	,	,	O	O
and	TANZEUM.xml:S1:774:3	and	CC	O	O
influenza	TANZEUM.xml:S1:778:9	influenza	NN	B-AdverseReaction	B-AdverseReaction
.	TANZEUM.xml:S1:787:1	.	.	O	O

(	TANZEUM.xml:S1:789:1	(	(	O	O
6.1	TANZEUM.xml:S1:790:3	6.1	CD	O	O
)	TANZEUM.xml:S1:793:1	)	)	O	O

To	TANZEUM.xml:S1:801:2	To	TO	O	O

report	TANZEUM.xml:S1:804:6	report	NN	O	O
SUSPECTED	TANZEUM.xml:S1:811:9	suspect	NNP	O	O
ADVERSE	TANZEUM.xml:S1:821:7	advers	NNP	O	O
REACTIONS	TANZEUM.xml:S1:829:9	reaction	NNP	O	O
,	TANZEUM.xml:S1:838:1	,	,	O	O
contact	TANZEUM.xml:S1:840:7	contact	NN	O	O
GlaxoSmithKline	TANZEUM.xml:S1:848:15	glaxosmithklin	NNP	O	O
at	TANZEUM.xml:S1:864:2	at	IN	O	O
1	TANZEUM.xml:S1:867:1	1	CD	O	O
-	TANZEUM.xml:S1:868:1	-	:	O	O
888	TANZEUM.xml:S1:869:3	888	CD	O	O
-	TANZEUM.xml:S1:872:1	-	:	O	O
825	TANZEUM.xml:S1:873:3	825	CD	O	O
-	TANZEUM.xml:S1:876:1	-	:	O	O
5249	TANZEUM.xml:S1:877:4	5249	CD	O	O
or	TANZEUM.xml:S1:882:2	or	CC	O	O
FDA	TANZEUM.xml:S1:885:3	fda	NNP	O	O
at	TANZEUM.xml:S1:889:2	at	IN	O	O
1	TANZEUM.xml:S1:892:1	1	CD	O	O
-	TANZEUM.xml:S1:893:1	-	:	O	O
800	TANZEUM.xml:S1:894:3	800	CD	O	O
-	TANZEUM.xml:S1:897:1	-	:	O	O
FDA	TANZEUM.xml:S1:898:3	fda	NNP	O	O
-	TANZEUM.xml:S1:901:1	-	:	O	O
1088	TANZEUM.xml:S1:902:4	1088	CD	O	O
or	TANZEUM.xml:S1:907:2	or	CC	O	O
www	TANZEUM.xml:S1:911:3	www	VB	O	O
.	TANZEUM.xml:S1:914:1	.	.	O	O
fda	TANZEUM.xml:S1:915:3	fda	NN	O	O
.	TANZEUM.xml:S1:918:1	.	.	O	O
gov	TANZEUM.xml:S1:919:3	gov	NN	O	O
medwatch	TANZEUM.xml:S1:923:8	medwatch	NN	O	O

6.1	TANZEUM.xml:S1:940:3	6.1	CD	O	O

Clinical	TANZEUM.xml:S1:944:8	clinic	JJ	O	O
Trials	TANZEUM.xml:S1:953:6	trial	NNS	O	O
Experience	TANZEUM.xml:S1:960:10	experi	NN	O	O

Because	TANZEUM.xml:S1:974:7	becaus	IN	O	O
clinical	TANZEUM.xml:S1:982:8	clinic	JJ	O	O
trials	TANZEUM.xml:S1:991:6	trial	NNS	O	O
are	TANZEUM.xml:S1:998:3	are	VBP	O	O
conducted	TANZEUM.xml:S1:1002:9	conduct	VBN	O	O
under	TANZEUM.xml:S1:1012:5	under	IN	O	O
widely	TANZEUM.xml:S1:1018:6	wide	RB	O	O
varying	TANZEUM.xml:S1:1025:7	vari	VBG	O	O
conditions	TANZEUM.xml:S1:1033:10	condit	NNS	O	O
,	TANZEUM.xml:S1:1043:1	,	,	O	O
adverse	TANZEUM.xml:S1:1045:7	advers	JJ	O	O
reaction	TANZEUM.xml:S1:1053:8	reaction	NN	O	O
rates	TANZEUM.xml:S1:1062:5	rate	NNS	O	O
observed	TANZEUM.xml:S1:1068:8	observ	VBD	O	O
in	TANZEUM.xml:S1:1077:2	in	IN	O	O
the	TANZEUM.xml:S1:1080:3	the	DT	O	O
clinical	TANZEUM.xml:S1:1084:8	clinic	JJ	O	O
trials	TANZEUM.xml:S1:1093:6	trial	NNS	O	O
of	TANZEUM.xml:S1:1100:2	of	IN	O	O
a	TANZEUM.xml:S1:1103:1	a	DT	O	O
drug	TANZEUM.xml:S1:1105:4	drug	NN	O	O
cannot	TANZEUM.xml:S1:1110:6	cannot	NN	O	O
be	TANZEUM.xml:S1:1117:2	be	VB	O	O
directly	TANZEUM.xml:S1:1120:8	directli	RB	O	O
compared	TANZEUM.xml:S1:1129:8	compar	VBN	O	O
with	TANZEUM.xml:S1:1138:4	with	IN	O	O
rates	TANZEUM.xml:S1:1143:5	rate	NNS	O	O
in	TANZEUM.xml:S1:1149:2	in	IN	O	O
the	TANZEUM.xml:S1:1152:3	the	DT	O	O
clinical	TANZEUM.xml:S1:1156:8	clinic	JJ	O	O
trials	TANZEUM.xml:S1:1165:6	trial	NNS	O	O
of	TANZEUM.xml:S1:1172:2	of	IN	O	O
another	TANZEUM.xml:S1:1175:7	anoth	DT	O	O
drug	TANZEUM.xml:S1:1183:4	drug	NN	O	O
and	TANZEUM.xml:S1:1188:3	and	CC	O	O
may	TANZEUM.xml:S1:1192:3	may	MD	O	O
not	TANZEUM.xml:S1:1196:3	not	RB	O	O
reflect	TANZEUM.xml:S1:1200:7	reflect	VB	O	O
the	TANZEUM.xml:S1:1208:3	the	DT	O	O
rates	TANZEUM.xml:S1:1212:5	rate	NNS	O	O
observed	TANZEUM.xml:S1:1218:8	observ	VBD	O	O
in	TANZEUM.xml:S1:1227:2	in	IN	O	O
practice	TANZEUM.xml:S1:1230:8	practic	NN	O	O
.	TANZEUM.xml:S1:1238:1	.	.	O	O

Pool	TANZEUM.xml:S1:1246:4	pool	NN	O	O
of	TANZEUM.xml:S1:1251:2	of	IN	O	O
Placebo	TANZEUM.xml:S1:1254:7	placebo	NNP	O	O
-	TANZEUM.xml:S1:1261:1	-	:	O	O
Controlled	TANZEUM.xml:S1:1262:10	control	VBD	O	O
Trials	TANZEUM.xml:S1:1273:6	trial	NNS	O	O

The	TANZEUM.xml:S1:1286:3	the	DT	O	O
data	TANZEUM.xml:S1:1290:4	data	NN	O	O
in	TANZEUM.xml:S1:1295:2	in	IN	O	O
Table	TANZEUM.xml:S1:1298:5	tabl	JJ	O	O
1	TANZEUM.xml:S1:1304:1	1	CD	O	O
are	TANZEUM.xml:S1:1306:3	are	VBP	O	O
derived	TANZEUM.xml:S1:1310:7	deriv	VBN	O	O
from	TANZEUM.xml:S1:1318:4	from	IN	O	O
4	TANZEUM.xml:S1:1323:1	4	CD	O	O
placebo	TANZEUM.xml:S1:1325:7	placebo	NN	O	O
-	TANZEUM.xml:S1:1332:1	-	:	O	O
controlled	TANZEUM.xml:S1:1333:10	control	VBN	O	O
trials	TANZEUM.xml:S1:1344:6	trial	NNS	O	O
.	TANZEUM.xml:S1:1350:1	.	.	O	O

TANZEUM	TANZEUM.xml:S1:1352:7	tanzeum	NNP	O	O
was	TANZEUM.xml:S1:1360:3	wa	VBD	O	O
used	TANZEUM.xml:S1:1364:4	use	VBN	O	O
as	TANZEUM.xml:S1:1369:2	as	IN	O	O
monotherapy	TANZEUM.xml:S1:1372:11	monotherapi	NN	O	O
in	TANZEUM.xml:S1:1384:2	in	IN	O	O
1	TANZEUM.xml:S1:1387:1	1	CD	O	O
trial	TANZEUM.xml:S1:1389:5	trial	NN	O	O
and	TANZEUM.xml:S1:1395:3	and	CC	O	O
as	TANZEUM.xml:S1:1399:2	as	IN	O	O
add	TANZEUM.xml:S1:1402:3	add	JJ	O	O
-	TANZEUM.xml:S1:1405:1	-	:	O	O
on	TANZEUM.xml:S1:1406:2	on	IN	O	O
therapy	TANZEUM.xml:S1:1409:7	therapi	NN	O	O
in	TANZEUM.xml:S1:1417:2	in	IN	O	O
3	TANZEUM.xml:S1:1420:1	3	CD	O	O
trials	TANZEUM.xml:S1:1422:6	trial	NNS	O	O
[	TANZEUM.xml:S1:1430:1	[	JJ	O	O
see	TANZEUM.xml:S1:1431:3	see	VBP	O	O
Clinical	TANZEUM.xml:S1:1435:8	clinic	JJ	O	O
Studies	TANZEUM.xml:S1:1444:7	studi	NNP	O	O
(	TANZEUM.xml:S1:1452:1	(	(	O	O
14	TANZEUM.xml:S1:1453:2	14	CD	O	O
)]	TANZEUM.xml:S1:1455:2	)]	NN	O	O
.	TANZEUM.xml:S1:1459:1	.	.	O	O

These	TANZEUM.xml:S1:1461:5	these	DT	O	O
data	TANZEUM.xml:S1:1467:4	data	NNS	O	O
reflect	TANZEUM.xml:S1:1472:7	reflect	VBP	O	O
exposure	TANZEUM.xml:S1:1480:8	exposur	NN	O	O
of	TANZEUM.xml:S1:1489:2	of	IN	O	O
923	TANZEUM.xml:S1:1492:3	923	CD	O	O
patients	TANZEUM.xml:S1:1496:8	patient	NNS	O	O
to	TANZEUM.xml:S1:1505:2	to	TO	O	O
TANZEUM	TANZEUM.xml:S1:1508:7	tanzeum	NNP	O	O
and	TANZEUM.xml:S1:1516:3	and	CC	O	O
a	TANZEUM.xml:S1:1520:1	a	DT	O	O
mean	TANZEUM.xml:S1:1522:4	mean	JJ	O	O
duration	TANZEUM.xml:S1:1527:8	durat	NN	O	O
of	TANZEUM.xml:S1:1536:2	of	IN	O	O
exposure	TANZEUM.xml:S1:1539:8	exposur	NN	O	O
to	TANZEUM.xml:S1:1548:2	to	TO	O	O
TANZEUM	TANZEUM.xml:S1:1551:7	tanzeum	NNP	O	O
of	TANZEUM.xml:S1:1559:2	of	IN	O	O
93	TANZEUM.xml:S1:1562:2	93	CD	O	O
weeks	TANZEUM.xml:S1:1565:5	week	NNS	O	O
.	TANZEUM.xml:S1:1570:1	.	.	O	O

The	TANZEUM.xml:S1:1572:3	the	DT	O	O
mean	TANZEUM.xml:S1:1576:4	mean	JJ	O	O
age	TANZEUM.xml:S1:1581:3	age	NN	O	O
of	TANZEUM.xml:S1:1585:2	of	IN	O	O
participants	TANZEUM.xml:S1:1588:12	particip	NNS	O	O
was	TANZEUM.xml:S1:1601:3	wa	VBD	O	O
55	TANZEUM.xml:S1:1605:2	55	CD	O	O
years	TANZEUM.xml:S1:1608:5	year	NNS	O	O
,	TANZEUM.xml:S1:1613:1	,	,	O	O
1%	TANZEUM.xml:S1:1615:2	1%	CD	O	O
of	TANZEUM.xml:S1:1618:2	of	IN	O	O
participants	TANZEUM.xml:S1:1621:12	particip	NNS	O	O
were	TANZEUM.xml:S1:1634:4	were	VBD	O	O
75	TANZEUM.xml:S1:1639:2	75	CD	O	O
years	TANZEUM.xml:S1:1642:5	year	NNS	O	O
or	TANZEUM.xml:S1:1648:2	or	CC	O	O
older	TANZEUM.xml:S1:1651:5	older	JJR	O	O
and	TANZEUM.xml:S1:1657:3	and	CC	O	O
53%	TANZEUM.xml:S1:1661:3	53%	CD	O	O
of	TANZEUM.xml:S1:1665:2	of	IN	O	O
participants	TANZEUM.xml:S1:1668:12	particip	NNS	O	O
were	TANZEUM.xml:S1:1681:4	were	VBD	O	O
male	TANZEUM.xml:S1:1686:4	male	JJ	O	O
.	TANZEUM.xml:S1:1690:1	.	.	O	O

The	TANZEUM.xml:S1:1692:3	the	DT	O	O
population	TANZEUM.xml:S1:1696:10	popul	NN	O	O
in	TANZEUM.xml:S1:1707:2	in	IN	O	O
these	TANZEUM.xml:S1:1710:5	these	DT	O	O
studies	TANZEUM.xml:S1:1716:7	studi	NNS	O	O
was	TANZEUM.xml:S1:1724:3	wa	VBD	O	O
48%	TANZEUM.xml:S1:1728:3	48%	CD	O	O
white	TANZEUM.xml:S1:1732:5	white	JJ	O	O
,	TANZEUM.xml:S1:1737:1	,	,	O	O
13%	TANZEUM.xml:S1:1739:3	13%	CD	O	O
African	TANZEUM.xml:S1:1743:7	african	JJ	O	O
African	TANZEUM.xml:S1:1751:7	african	JJ	O	O
American	TANZEUM.xml:S1:1759:8	american	NNP	O	O
,	TANZEUM.xml:S1:1767:1	,	,	O	O
7%	TANZEUM.xml:S1:1769:2	7%	CD	O	O
Asian	TANZEUM.xml:S1:1772:5	asian	JJ	O	O
,	TANZEUM.xml:S1:1777:1	,	,	O	O
and	TANZEUM.xml:S1:1779:3	and	CC	O	O
29%	TANZEUM.xml:S1:1783:3	29%	CD	O	O
Hispanic	TANZEUM.xml:S1:1787:8	hispan	NNP	O	O
Latino	TANZEUM.xml:S1:1796:6	latino	NNP	O	O
.	TANZEUM.xml:S1:1802:1	.	.	O	O

At	TANZEUM.xml:S1:1804:2	At	IN	O	O
baseline	TANZEUM.xml:S1:1807:8	baselin	NN	O	O
,	TANZEUM.xml:S1:1815:1	,	,	O	O
the	TANZEUM.xml:S1:1817:3	the	DT	O	O
population	TANZEUM.xml:S1:1821:10	popul	NN	O	O
had	TANZEUM.xml:S1:1832:3	had	VBD	O	O
type	TANZEUM.xml:S1:1836:4	type	JJ	O	O
2	TANZEUM.xml:S1:1841:1	2	CD	O	O
diabetes	TANZEUM.xml:S1:1843:8	diabet	NNS	O	O
for	TANZEUM.xml:S1:1852:3	for	IN	O	O
an	TANZEUM.xml:S1:1856:2	an	DT	O	O
average	TANZEUM.xml:S1:1859:7	averag	NN	O	O
of	TANZEUM.xml:S1:1867:2	of	IN	O	O
7	TANZEUM.xml:S1:1870:1	7	CD	O	O
years	TANZEUM.xml:S1:1872:5	year	NNS	O	O
and	TANZEUM.xml:S1:1878:3	and	CC	O	O
had	TANZEUM.xml:S1:1882:3	had	VBD	O	O
a	TANZEUM.xml:S1:1886:1	a	DT	O	O
mean	TANZEUM.xml:S1:1888:4	mean	JJ	O	O
HbA1c	TANZEUM.xml:S1:1893:5	hba1c	NNP	O	O
of	TANZEUM.xml:S1:1899:2	of	IN	O	O
8.1%	TANZEUM.xml:S1:1902:4	8.1%	CD	O	O
.	TANZEUM.xml:S1:1906:1	.	.	O	O

At	TANZEUM.xml:S1:1908:2	At	IN	O	O
baseline	TANZEUM.xml:S1:1911:8	baselin	NN	O	O
,	TANZEUM.xml:S1:1919:1	,	,	O	O
17%	TANZEUM.xml:S1:1921:3	17%	CD	O	O
of	TANZEUM.xml:S1:1925:2	of	IN	O	O
the	TANZEUM.xml:S1:1928:3	the	DT	O	O
population	TANZEUM.xml:S1:1932:10	popul	NN	O	O
in	TANZEUM.xml:S1:1943:2	in	IN	O	O
these	TANZEUM.xml:S1:1946:5	these	DT	O	O
studies	TANZEUM.xml:S1:1952:7	studi	NNS	O	O
reported	TANZEUM.xml:S1:1960:8	report	VBD	O	O
peripheral	TANZEUM.xml:S1:1969:10	peripher	JJ	O	B-AdverseReaction
neuropathy	TANZEUM.xml:S1:1980:10	neuropathi	NN	O	I-AdverseReaction
and	TANZEUM.xml:S1:1991:3	and	CC	O	O
4%	TANZEUM.xml:S1:1995:2	4%	CD	O	O
reported	TANZEUM.xml:S1:1998:8	report	VBD	O	O
retinopathy	TANZEUM.xml:S1:2007:11	retinopathi	NN	O	O
.	TANZEUM.xml:S1:2018:1	.	.	O	O

Baseline	TANZEUM.xml:S1:2020:8	baselin	NNP	O	O
estimated	TANZEUM.xml:S1:2029:9	estim	VBD	O	O
renal	TANZEUM.xml:S1:2039:5	renal	JJ	O	O
function	TANZEUM.xml:S1:2045:8	function	NN	O	O
was	TANZEUM.xml:S1:2054:3	wa	VBD	O	O
normal	TANZEUM.xml:S1:2058:6	normal	JJ	O	O
or	TANZEUM.xml:S1:2065:2	or	CC	O	O
mildly	TANZEUM.xml:S1:2068:6	mildli	RB	O	O
impaired	TANZEUM.xml:S1:2075:8	impair	JJ	O	O
(	TANZEUM.xml:S1:2084:1	(	(	O	O
eGFR	TANZEUM.xml:S1:2085:4	egfr	JJ	O	O
60	TANZEUM.xml:S1:2091:2	60	CD	O	O
mL	TANZEUM.xml:S1:2094:2	mL	NN	O	O
min	TANZEUM.xml:S1:2097:3	min	NN	O	O
1.73	TANZEUM.xml:S1:2101:4	1.73	CD	O	O
m	TANZEUM.xml:S1:2106:1	m	NN	O	O
2	TANZEUM.xml:S1:2109:1	2	CD	O	O
)	TANZEUM.xml:S1:2112:1	)	)	O	O
in	TANZEUM.xml:S1:2114:2	in	IN	O	O
91%	TANZEUM.xml:S1:2117:3	91%	CD	O	O
of	TANZEUM.xml:S1:2121:2	of	IN	O	O
the	TANZEUM.xml:S1:2124:3	the	DT	O	O
study	TANZEUM.xml:S1:2128:5	studi	NN	O	O
population	TANZEUM.xml:S1:2134:10	popul	NN	O	O
and	TANZEUM.xml:S1:2145:3	and	CC	O	O
moderately	TANZEUM.xml:S1:2149:10	moder	RB	O	O
impaired	TANZEUM.xml:S1:2160:8	impair	JJ	O	O
(	TANZEUM.xml:S1:2169:1	(	(	O	O
eGFR	TANZEUM.xml:S1:2170:4	egfr	JJ	O	O
30	TANZEUM.xml:S1:2175:2	30	CD	O	O
to	TANZEUM.xml:S1:2178:2	to	TO	O	O
60	TANZEUM.xml:S1:2181:2	60	CD	O	O
mL	TANZEUM.xml:S1:2184:2	mL	NNS	O	O
min	TANZEUM.xml:S1:2187:3	min	RB	O	O
1.73	TANZEUM.xml:S1:2191:4	1.73	CD	O	O
m	TANZEUM.xml:S1:2196:1	m	NNS	O	O
2	TANZEUM.xml:S1:2199:1	2	CD	O	O
)	TANZEUM.xml:S1:2202:1	)	)	O	O
in	TANZEUM.xml:S1:2204:2	in	IN	O	O
9%	TANZEUM.xml:S1:2207:2	9%	CD	O	O
.	TANZEUM.xml:S1:2209:1	.	.	O	O

Table	TANZEUM.xml:S1:2215:5	tabl	JJ	O	O
1	TANZEUM.xml:S1:2221:1	1	CD	O	O
shows	TANZEUM.xml:S1:2223:5	show	NNS	O	O
common	TANZEUM.xml:S1:2229:6	common	JJ	O	O
adverse	TANZEUM.xml:S1:2236:7	advers	JJ	O	O
reactions	TANZEUM.xml:S1:2244:9	reaction	NNS	O	O
excluding	TANZEUM.xml:S1:2254:9	exclud	VBG	O	O
hypoglycemia	TANZEUM.xml:S1:2264:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
associated	TANZEUM.xml:S1:2277:10	associ	VBN	O	O
with	TANZEUM.xml:S1:2288:4	with	IN	O	O
the	TANZEUM.xml:S1:2293:3	the	DT	O	O
use	TANZEUM.xml:S1:2297:3	use	NN	O	O
of	TANZEUM.xml:S1:2301:2	of	IN	O	O
TANZEUM	TANZEUM.xml:S1:2304:7	tanzeum	NNP	O	O
in	TANZEUM.xml:S1:2312:2	in	IN	O	O
the	TANZEUM.xml:S1:2315:3	the	DT	O	O
pool	TANZEUM.xml:S1:2319:4	pool	NN	O	O
of	TANZEUM.xml:S1:2324:2	of	IN	O	O
placebo	TANZEUM.xml:S1:2327:7	placebo	NN	O	O
-	TANZEUM.xml:S1:2334:1	-	:	O	O
controlled	TANZEUM.xml:S1:2335:10	control	VBN	O	O
trials	TANZEUM.xml:S1:2346:6	trial	NNS	O	O
.	TANZEUM.xml:S1:2352:1	.	.	O	O

These	TANZEUM.xml:S1:2354:5	these	DT	O	O
adverse	TANZEUM.xml:S1:2360:7	advers	JJ	O	O
reactions	TANZEUM.xml:S1:2368:9	reaction	NNS	O	O
were	TANZEUM.xml:S1:2378:4	were	VBD	O	O
not	TANZEUM.xml:S1:2383:3	not	RB	O	O
present	TANZEUM.xml:S1:2387:7	present	JJ	O	O
at	TANZEUM.xml:S1:2395:2	at	IN	O	O
baseline	TANZEUM.xml:S1:2398:8	baselin	NN	O	O
,	TANZEUM.xml:S1:2406:1	,	,	O	O
occurred	TANZEUM.xml:S1:2408:8	occur	VBD	O	O
more	TANZEUM.xml:S1:2417:4	more	JJR	O	O
commonly	TANZEUM.xml:S1:2422:8	commonli	RB	O	O
on	TANZEUM.xml:S1:2431:2	on	IN	O	O
TANZEUM	TANZEUM.xml:S1:2434:7	tanzeum	NNP	O	O
than	TANZEUM.xml:S1:2442:4	than	IN	O	O
on	TANZEUM.xml:S1:2447:2	on	IN	O	O
placebo	TANZEUM.xml:S1:2450:7	placebo	NN	O	O
,	TANZEUM.xml:S1:2457:1	,	,	O	O
and	TANZEUM.xml:S1:2459:3	and	CC	O	O
occurred	TANZEUM.xml:S1:2463:8	occur	VBD	O	O
in	TANZEUM.xml:S1:2472:2	in	IN	O	O
at	TANZEUM.xml:S1:2475:2	at	IN	O	O
least	TANZEUM.xml:S1:2478:5	least	JJS	O	O
5%	TANZEUM.xml:S1:2484:2	5%	CD	O	O
of	TANZEUM.xml:S1:2487:2	of	IN	O	O
patients	TANZEUM.xml:S1:2490:8	patient	NNS	O	O
treated	TANZEUM.xml:S1:2499:7	treat	VBN	O	O
with	TANZEUM.xml:S1:2507:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S1:2512:7	tanzeum	NNP	O	O
.	TANZEUM.xml:S1:2519:1	.	.	O	O

Table	TANZEUM.xml:S1:2527:5	tabl	JJ	O	O
1	TANZEUM.xml:S1:2533:1	1	CD	O	O
.	TANZEUM.xml:S1:2534:1	.	.	O	O

Adverse	TANZEUM.xml:S1:2536:7	advers	JJ	O	O
Reactions	TANZEUM.xml:S1:2544:9	reaction	NNP	O	O
in	TANZEUM.xml:S1:2554:2	in	IN	O	O
Placebo	TANZEUM.xml:S1:2557:7	placebo	NNP	O	O
-	TANZEUM.xml:S1:2564:1	-	:	O	O
controlled	TANZEUM.xml:S1:2565:10	control	VBN	O	O
Trials	TANZEUM.xml:S1:2576:6	trial	NNS	O	O
Reported	TANZEUM.xml:S1:2583:8	report	VBD	O	O
in	TANZEUM.xml:S1:2592:2	in	IN	O	O
5%	TANZEUM.xml:S1:2597:2	5%	CD	O	O
of	TANZEUM.xml:S1:2600:2	of	IN	O	O
Patients	TANZEUM.xml:S1:2603:8	patient	NNS	O	O
Treated	TANZEUM.xml:S1:2612:7	treat	VBN	O	O
with	TANZEUM.xml:S1:2620:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S1:2625:7	tanzeum	NNP	O	O
a	TANZEUM.xml:S1:2634:1	a	DT	O	O

Adverse	TANZEUM.xml:S1:2646:7	advers	JJ	O	O
Reaction	TANZEUM.xml:S1:2654:8	reaction	NNP	O	O
Placebo	TANZEUM.xml:S1:2704:7	placebo	NNP	O	O
(	TANZEUM.xml:S1:2713:1	(	(	O	O
N	TANZEUM.xml:S1:2714:1	N	NNP	O	O
468	TANZEUM.xml:S1:2718:3	468	CD	O	O
)	TANZEUM.xml:S1:2721:1	)	)	O	O
TANZEUM	TANZEUM.xml:S1:2729:7	tanzeum	NNP	O	O
(	TANZEUM.xml:S1:2738:1	(	(	O	O
N	TANZEUM.xml:S1:2739:1	N	NNP	O	O
923	TANZEUM.xml:S1:2743:3	923	CD	O	O
)	TANZEUM.xml:S1:2746:1	)	)	O	O

Upper	TANZEUM.xml:S1:2758:5	upper	NNP	B-AdverseReaction	B-AdverseReaction
respiratory	TANZEUM.xml:S1:2764:11	respiratori	NN	I-AdverseReaction	I-AdverseReaction
tract	TANZEUM.xml:S1:2776:5	tract	NN	I-AdverseReaction	I-AdverseReaction
infection	TANZEUM.xml:S1:2782:9	infect	NN	I-AdverseReaction	I-AdverseReaction
13.0	TANZEUM.xml:S1:2816:4	13.0	CD	O	O
14.2	TANZEUM.xml:S1:2838:4	14.2	CD	O	O

Diarrhea	TANZEUM.xml:S1:2867:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
10.5	TANZEUM.xml:S1:2925:4	10.5	CD	O	O
13.1	TANZEUM.xml:S1:2947:4	13.1	CD	O	O

Nausea	TANZEUM.xml:S1:2976:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
9.6	TANZEUM.xml:S1:3034:3	9.6	CD	O	O
11.1	TANZEUM.xml:S1:3056:4	11.1	CD	O	O

Injection	TANZEUM.xml:S1:3085:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:3095:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactionb	TANZEUM.xml:S1:3100:9	reactionb	VBD	I-AdverseReaction	I-AdverseReaction
2.1	TANZEUM.xml:S1:3143:3	2.1	CD	O	O
10.5	TANZEUM.xml:S1:3165:4	10.5	CD	O	O

Cough	TANZEUM.xml:S1:3194:5	cough	NNP	B-AdverseReaction	B-AdverseReaction
6.2	TANZEUM.xml:S1:3252:3	6.2	CD	O	O
6.9	TANZEUM.xml:S1:3274:3	6.9	CD	O	O

Back	TANZEUM.xml:S1:3303:4	back	RB	B-AdverseReaction	B-AdverseReaction
pain	TANZEUM.xml:S1:3308:4	pain	NN	I-AdverseReaction	I-AdverseReaction
5.8	TANZEUM.xml:S1:3361:3	5.8	CD	O	O
6.7	TANZEUM.xml:S1:3383:3	6.7	CD	O	O

Arthralgia	TANZEUM.xml:S1:3412:10	arthralgia	NNP	B-AdverseReaction	B-AdverseReaction
6.4	TANZEUM.xml:S1:3470:3	6.4	CD	O	O
6.6	TANZEUM.xml:S1:3492:3	6.6	CD	O	O

Sinusitis	TANZEUM.xml:S1:3521:9	sinus	NN	B-AdverseReaction	B-AdverseReaction
5.8	TANZEUM.xml:S1:3579:3	5.8	CD	O	O
6.2	TANZEUM.xml:S1:3601:3	6.2	CD	O	O

Influenza	TANZEUM.xml:S1:3630:9	influenza	NNP	B-AdverseReaction	B-AdverseReaction
3.2	TANZEUM.xml:S1:3688:3	3.2	CD	O	O
5.2	TANZEUM.xml:S1:3710:3	5.2	CD	O	O

a	TANZEUM.xml:S1:3753:1	a	DT	O	O
Adverse	TANZEUM.xml:S1:3756:7	advers	JJ	O	O
reactions	TANZEUM.xml:S1:3764:9	reaction	NNS	O	O
reported	TANZEUM.xml:S1:3774:8	report	VBD	O	O
includes	TANZEUM.xml:S1:3783:8	includ	VBZ	O	O
adverse	TANZEUM.xml:S1:3792:7	advers	JJ	O	O
reactions	TANZEUM.xml:S1:3800:9	reaction	NNS	O	O
occurring	TANZEUM.xml:S1:3810:9	occur	VBG	O	O
with	TANZEUM.xml:S1:3820:4	with	IN	O	O
the	TANZEUM.xml:S1:3825:3	the	DT	O	O
use	TANZEUM.xml:S1:3829:3	use	NN	O	O
of	TANZEUM.xml:S1:3833:2	of	IN	O	O
glycemic	TANZEUM.xml:S1:3836:8	glycem	JJ	O	O
rescue	TANZEUM.xml:S1:3845:6	rescu	NN	O	O
medications	TANZEUM.xml:S1:3852:11	medic	NNS	O	O
which	TANZEUM.xml:S1:3864:5	which	WDT	O	O
included	TANZEUM.xml:S1:3870:8	includ	VBD	O	O
metformin	TANZEUM.xml:S1:3879:9	metformin	NN	O	O
(	TANZEUM.xml:S1:3889:1	(	(	O	O
17%	TANZEUM.xml:S1:3890:3	17%	CD	O	O
for	TANZEUM.xml:S1:3894:3	for	IN	O	O
placebo	TANZEUM.xml:S1:3898:7	placebo	NN	O	O
and	TANZEUM.xml:S1:3906:3	and	CC	O	O
10%	TANZEUM.xml:S1:3910:3	10%	CD	O	O
for	TANZEUM.xml:S1:3914:3	for	IN	O	O
TANZEUM	TANZEUM.xml:S1:3918:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:3925:1	)	)	O	O
and	TANZEUM.xml:S1:3927:3	and	CC	O	O
insulin	TANZEUM.xml:S1:3931:7	insulin	NN	O	O
(	TANZEUM.xml:S1:3939:1	(	(	O	O
24%	TANZEUM.xml:S1:3940:3	24%	CD	O	O
for	TANZEUM.xml:S1:3944:3	for	IN	O	O
placebo	TANZEUM.xml:S1:3948:7	placebo	NN	O	O
and	TANZEUM.xml:S1:3956:3	and	CC	O	O
14%	TANZEUM.xml:S1:3960:3	14%	CD	O	O
for	TANZEUM.xml:S1:3964:3	for	IN	O	O
TANZEUM	TANZEUM.xml:S1:3968:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:3975:1	)	)	O	O
.	TANZEUM.xml:S1:3976:1	.	.	O	O

b	TANZEUM.xml:S1:3988:1	b	NN	O	O
See	TANZEUM.xml:S1:3991:3	see	NNP	O	O
below	TANZEUM.xml:S1:3995:5	below	IN	O	O
for	TANZEUM.xml:S1:4001:3	for	IN	O	O
other	TANZEUM.xml:S1:4005:5	other	JJ	O	O
events	TANZEUM.xml:S1:4011:6	event	NNS	O	O
of	TANZEUM.xml:S1:4018:2	of	IN	O	O
injection	TANZEUM.xml:S1:4021:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:4031:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactions	TANZEUM.xml:S1:4036:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
reported	TANZEUM.xml:S1:4046:8	report	VBD	O	O
.	TANZEUM.xml:S1:4054:1	.	.	O	O

Gastrointestinal	TANZEUM.xml:S1:4063:16	gastrointestin	JJ	O	O
Adverse	TANZEUM.xml:S1:4080:7	advers	NNP	O	O
Reactions	TANZEUM.xml:S1:4088:9	reaction	NNP	O	O

In	TANZEUM.xml:S1:4104:2	In	IN	O	O

the	TANZEUM.xml:S1:4107:3	the	DT	O	O
pool	TANZEUM.xml:S1:4111:4	pool	NN	O	O
of	TANZEUM.xml:S1:4116:2	of	IN	O	O
placebo	TANZEUM.xml:S1:4119:7	placebo	NN	O	O
-	TANZEUM.xml:S1:4126:1	-	:	O	O
controlled	TANZEUM.xml:S1:4127:10	control	VBN	O	O
trials	TANZEUM.xml:S1:4138:6	trial	NNS	O	O
,	TANZEUM.xml:S1:4144:1	,	,	O	O
gastrointestinal	TANZEUM.xml:S1:4146:16	gastrointestin	JJ	B-AdverseReaction	B-AdverseReaction
complaints	TANZEUM.xml:S1:4163:10	complaint	NNS	I-AdverseReaction	I-AdverseReaction
occurred	TANZEUM.xml:S1:4174:8	occur	VBD	O	O
more	TANZEUM.xml:S1:4183:4	more	RBR	O	O
frequently	TANZEUM.xml:S1:4188:10	frequent	RB	O	O
among	TANZEUM.xml:S1:4199:5	among	IN	O	O
patients	TANZEUM.xml:S1:4205:8	patient	NNS	O	O
receiving	TANZEUM.xml:S1:4214:9	receiv	VBG	O	O
TANZEUM	TANZEUM.xml:S1:4224:7	tanzeum	NNP	O	O
(	TANZEUM.xml:S1:4232:1	(	(	O	O
39%	TANZEUM.xml:S1:4233:3	39%	CD	O	O
)	TANZEUM.xml:S1:4236:1	)	)	O	O
than	TANZEUM.xml:S1:4238:4	than	IN	O	O
patients	TANZEUM.xml:S1:4243:8	patient	NNS	O	O
receiving	TANZEUM.xml:S1:4252:9	receiv	VBG	O	O
placebo	TANZEUM.xml:S1:4262:7	placebo	NN	O	O
(	TANZEUM.xml:S1:4270:1	(	(	O	O
33%	TANZEUM.xml:S1:4271:3	33%	CD	O	O
)	TANZEUM.xml:S1:4274:1	)	)	O	O
.	TANZEUM.xml:S1:4275:1	.	.	O	O

In	TANZEUM.xml:S1:4277:2	In	IN	O	O
addition	TANZEUM.xml:S1:4280:8	addit	NN	O	O
to	TANZEUM.xml:S1:4289:2	to	TO	O	O
diarrhea	TANZEUM.xml:S1:4292:8	diarrhea	VB	B-AdverseReaction	O
and	TANZEUM.xml:S1:4301:3	and	CC	O	O
nausea	TANZEUM.xml:S1:4305:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
(	TANZEUM.xml:S1:4312:1	(	(	O	O
see	TANZEUM.xml:S1:4313:3	see	VB	O	O
Table	TANZEUM.xml:S1:4317:5	tabl	NNP	O	O
1	TANZEUM.xml:S1:4323:1	1	CD	O	O
)	TANZEUM.xml:S1:4324:1	)	)	O	O
,	TANZEUM.xml:S1:4325:1	,	,	O	O
the	TANZEUM.xml:S1:4327:3	the	DT	O	O
following	TANZEUM.xml:S1:4331:9	follow	JJ	O	O
gastrointestinal	TANZEUM.xml:S1:4341:16	gastrointestin	JJ	B-AdverseReaction	O
adverse	TANZEUM.xml:S1:4358:7	advers	JJ	I-AdverseReaction	O
reactions	TANZEUM.xml:S1:4366:9	reaction	NNS	I-AdverseReaction	O
also	TANZEUM.xml:S1:4376:4	also	RB	O	O
occurred	TANZEUM.xml:S1:4381:8	occur	VBD	O	O
more	TANZEUM.xml:S1:4390:4	more	RBR	O	O
frequently	TANZEUM.xml:S1:4395:10	frequent	RB	O	O
in	TANZEUM.xml:S1:4406:2	in	IN	O	O
patients	TANZEUM.xml:S1:4409:8	patient	NNS	O	O
receiving	TANZEUM.xml:S1:4418:9	receiv	VBG	O	O
TANZEUM	TANZEUM.xml:S1:4428:7	tanzeum	NN	O	O
:	TANZEUM.xml:S1:4435:1	:	:	O	O
vomiting	TANZEUM.xml:S1:4437:8	vomit	NN	B-AdverseReaction	B-AdverseReaction
(	TANZEUM.xml:S1:4446:1	(	(	O	O
2.6%	TANZEUM.xml:S1:4447:4	2.6%	CD	O	O
versus	TANZEUM.xml:S1:4452:6	versu	NN	O	O
4.2%	TANZEUM.xml:S1:4459:4	4.2%	CD	O	O
for	TANZEUM.xml:S1:4464:3	for	IN	O	O
placebo	TANZEUM.xml:S1:4468:7	placebo	NN	O	O
versus	TANZEUM.xml:S1:4476:6	versu	NN	O	O
TANZEUM	TANZEUM.xml:S1:4483:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:4490:1	)	)	O	O
,	TANZEUM.xml:S1:4491:1	,	,	O	O
gastroesophageal	TANZEUM.xml:S1:4493:16	gastroesophag	JJ	B-AdverseReaction	B-AdverseReaction
reflux	TANZEUM.xml:S1:4510:6	reflux	NN	I-AdverseReaction	I-AdverseReaction
disease	TANZEUM.xml:S1:4517:7	diseas	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:4525:1	(	(	O	O
1.9%	TANZEUM.xml:S1:4526:4	1.9%	CD	O	O
versus	TANZEUM.xml:S1:4531:6	versu	NN	O	O
3.5%	TANZEUM.xml:S1:4538:4	3.5%	CD	O	O
for	TANZEUM.xml:S1:4543:3	for	IN	O	O
placebo	TANZEUM.xml:S1:4547:7	placebo	NN	O	O
versus	TANZEUM.xml:S1:4555:6	versu	NN	O	O
TANZEUM	TANZEUM.xml:S1:4562:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:4569:1	)	)	O	O
,	TANZEUM.xml:S1:4570:1	,	,	O	O
and	TANZEUM.xml:S1:4572:3	and	CC	O	O
dyspepsia	TANZEUM.xml:S1:4576:9	dyspepsia	NN	B-AdverseReaction	B-AdverseReaction
(	TANZEUM.xml:S1:4586:1	(	(	O	O
2.8%	TANZEUM.xml:S1:4587:4	2.8%	CD	O	O
versus	TANZEUM.xml:S1:4592:6	versu	NN	O	O
3.4%	TANZEUM.xml:S1:4599:4	3.4%	CD	O	O
for	TANZEUM.xml:S1:4604:3	for	IN	O	O
placebo	TANZEUM.xml:S1:4608:7	placebo	NN	O	O
versus	TANZEUM.xml:S1:4616:6	versu	NN	O	O
TANZEUM	TANZEUM.xml:S1:4623:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:4630:1	)	)	O	O
.	TANZEUM.xml:S1:4631:1	.	.	O	O

Constipation	TANZEUM.xml:S1:4633:12	constip	NNP	B-AdverseReaction	B-AdverseReaction
also	TANZEUM.xml:S1:4646:4	also	RB	O	O
contributed	TANZEUM.xml:S1:4651:11	contribut	VBD	O	O
to	TANZEUM.xml:S1:4663:2	to	TO	O	O
the	TANZEUM.xml:S1:4666:3	the	DT	O	O
frequently	TANZEUM.xml:S1:4670:10	frequent	RB	O	O
reported	TANZEUM.xml:S1:4681:8	report	VBN	O	O
reactions	TANZEUM.xml:S1:4690:9	reaction	NNS	O	O
.	TANZEUM.xml:S1:4699:1	.	.	O	O

In	TANZEUM.xml:S1:4701:2	In	IN	O	O
the	TANZEUM.xml:S1:4704:3	the	DT	O	O
group	TANZEUM.xml:S1:4708:5	group	NN	O	O
treated	TANZEUM.xml:S1:4714:7	treat	VBD	O	O
with	TANZEUM.xml:S1:4722:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S1:4727:7	tanzeum	NNP	O	O
,	TANZEUM.xml:S1:4734:1	,	,	O	O
investigators	TANZEUM.xml:S1:4736:13	investig	NNS	O	O
graded	TANZEUM.xml:S1:4750:6	grade	VBD	O	O
the	TANZEUM.xml:S1:4757:3	the	DT	O	O
severity	TANZEUM.xml:S1:4761:8	sever	NN	O	O
of	TANZEUM.xml:S1:4770:2	of	IN	O	O
GI	TANZEUM.xml:S1:4773:2	GI	NNP	B-AdverseReaction	O
reactions	TANZEUM.xml:S1:4776:9	reaction	NNS	I-AdverseReaction	O
as	TANZEUM.xml:S1:4786:2	as	IN	O	O
"	TANZEUM.xml:S1:4789:1	"	JJ	O	O
mild	TANZEUM.xml:S1:4790:4	mild	JJ	O	O
"	TANZEUM.xml:S1:4794:1	"	NN	O	O
in	TANZEUM.xml:S1:4796:2	in	IN	O	O
56%	TANZEUM.xml:S1:4799:3	56%	CD	O	O
of	TANZEUM.xml:S1:4803:2	of	IN	O	O
cases	TANZEUM.xml:S1:4806:5	case	NNS	O	O
,	TANZEUM.xml:S1:4811:1	,	,	O	O
"	TANZEUM.xml:S1:4813:1	"	JJ	O	O
moderate	TANZEUM.xml:S1:4814:8	moder	JJ	O	O
"	TANZEUM.xml:S1:4822:1	"	NN	O	O
in	TANZEUM.xml:S1:4824:2	in	IN	O	O
37%	TANZEUM.xml:S1:4827:3	37%	CD	O	O
of	TANZEUM.xml:S1:4831:2	of	IN	O	O
cases	TANZEUM.xml:S1:4834:5	case	NNS	O	O
,	TANZEUM.xml:S1:4839:1	,	,	O	O
and	TANZEUM.xml:S1:4841:3	and	CC	O	O
"	TANZEUM.xml:S1:4845:1	"	NNP	O	O
severe	TANZEUM.xml:S1:4846:6	sever	JJ	O	O
"	TANZEUM.xml:S1:4852:1	"	NN	O	O
in	TANZEUM.xml:S1:4854:2	in	IN	O	O
7%	TANZEUM.xml:S1:4857:2	7%	CD	O	O
of	TANZEUM.xml:S1:4860:2	of	IN	O	O
cases	TANZEUM.xml:S1:4863:5	case	NNS	O	O
.	TANZEUM.xml:S1:4868:1	.	.	O	O

Discontinuation	TANZEUM.xml:S1:4870:15	discontinu	NN	O	O
due	TANZEUM.xml:S1:4886:3	due	JJ	O	O
to	TANZEUM.xml:S1:4890:2	to	TO	O	O
GI	TANZEUM.xml:S1:4893:2	GI	NNP	B-AdverseReaction	O
adverse	TANZEUM.xml:S1:4896:7	advers	JJ	I-AdverseReaction	O
reactions	TANZEUM.xml:S1:4904:9	reaction	NNS	I-AdverseReaction	O
occurred	TANZEUM.xml:S1:4914:8	occur	VBD	O	O
in	TANZEUM.xml:S1:4923:2	in	IN	O	O
2%	TANZEUM.xml:S1:4926:2	2%	CD	O	O
of	TANZEUM.xml:S1:4929:2	of	IN	O	O
individuals	TANZEUM.xml:S1:4932:11	individu	NNS	O	O
on	TANZEUM.xml:S1:4944:2	on	IN	O	O
TANZEUM	TANZEUM.xml:S1:4947:7	tanzeum	NNP	O	O
or	TANZEUM.xml:S1:4955:2	or	CC	O	O
placebo	TANZEUM.xml:S1:4958:7	placebo	NN	O	O
.	TANZEUM.xml:S1:4965:1	.	.	O	O

Injection	TANZEUM.xml:S1:4973:9	inject	NNP	O	O
Site	TANZEUM.xml:S1:4983:4	site	NNP	O	O
Reactions	TANZEUM.xml:S1:4988:9	reaction	NNS	O	O

In	TANZEUM.xml:S1:5004:2	In	IN	O	O
the	TANZEUM.xml:S1:5007:3	the	DT	O	O
pool	TANZEUM.xml:S1:5011:4	pool	NN	O	O
of	TANZEUM.xml:S1:5016:2	of	IN	O	O
placebo	TANZEUM.xml:S1:5019:7	placebo	NN	O	O
-	TANZEUM.xml:S1:5026:1	-	:	O	O
controlled	TANZEUM.xml:S1:5027:10	control	VBN	O	O
trials	TANZEUM.xml:S1:5038:6	trial	NNS	O	O
,	TANZEUM.xml:S1:5044:1	,	,	O	O
injection	TANZEUM.xml:S1:5046:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5056:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactions	TANZEUM.xml:S1:5061:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
occurred	TANZEUM.xml:S1:5071:8	occur	VBD	O	O
more	TANZEUM.xml:S1:5080:4	more	RBR	O	O
frequently	TANZEUM.xml:S1:5085:10	frequent	RB	O	O
on	TANZEUM.xml:S1:5096:2	on	IN	O	O
TANZEUM	TANZEUM.xml:S1:5099:7	tanzeum	NNP	O	O
(	TANZEUM.xml:S1:5107:1	(	(	O	O
18%	TANZEUM.xml:S1:5108:3	18%	CD	O	O
)	TANZEUM.xml:S1:5111:1	)	)	O	O
than	TANZEUM.xml:S1:5113:4	than	IN	O	O
on	TANZEUM.xml:S1:5118:2	on	IN	O	O
placebo	TANZEUM.xml:S1:5121:7	placebo	NN	O	O
(	TANZEUM.xml:S1:5129:1	(	(	O	O
8%	TANZEUM.xml:S1:5130:2	8%	CD	O	O
)	TANZEUM.xml:S1:5132:1	)	)	O	O
.	TANZEUM.xml:S1:5133:1	.	.	O	O

In	TANZEUM.xml:S1:5135:2	In	IN	O	O
addition	TANZEUM.xml:S1:5138:8	addit	NN	O	O
to	TANZEUM.xml:S1:5147:2	to	TO	O	O
the	TANZEUM.xml:S1:5150:3	the	DT	O	O
term	TANZEUM.xml:S1:5154:4	term	NN	O	O
injection	TANZEUM.xml:S1:5159:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5169:4	site	NN	I-AdverseReaction	I-AdverseReaction
reaction	TANZEUM.xml:S1:5174:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:5183:1	(	(	O	O
see	TANZEUM.xml:S1:5184:3	see	VB	O	O
Table	TANZEUM.xml:S1:5188:5	tabl	NNP	O	O
1	TANZEUM.xml:S1:5194:1	1	CD	O	O
)	TANZEUM.xml:S1:5195:1	)	)	O	O
,	TANZEUM.xml:S1:5196:1	,	,	O	O
the	TANZEUM.xml:S1:5198:3	the	DT	O	O
following	TANZEUM.xml:S1:5202:9	follow	VBG	O	O
other	TANZEUM.xml:S1:5212:5	other	JJ	O	O
types	TANZEUM.xml:S1:5218:5	type	NNS	O	O
of	TANZEUM.xml:S1:5224:2	of	IN	O	O
injection	TANZEUM.xml:S1:5227:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5237:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactions	TANZEUM.xml:S1:5242:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
also	TANZEUM.xml:S1:5252:4	also	RB	O	O
occurred	TANZEUM.xml:S1:5257:8	occur	VBD	O	O
more	TANZEUM.xml:S1:5266:4	more	RBR	O	O
frequently	TANZEUM.xml:S1:5271:10	frequent	RB	O	O
on	TANZEUM.xml:S1:5282:2	on	IN	O	O
TANZEUM	TANZEUM.xml:S1:5285:7	tanzeum	NN	O	O
:	TANZEUM.xml:S1:5292:1	:	:	O	O
injection	TANZEUM.xml:S1:5294:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5304:4	site	NN	I-AdverseReaction	I-AdverseReaction
hematoma	TANZEUM.xml:S1:5309:8	hematoma	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:5318:1	(	(	O	O
1.9%	TANZEUM.xml:S1:5319:4	1.9%	CD	O	O
versus	TANZEUM.xml:S1:5324:6	versu	NN	O	O
2.1%	TANZEUM.xml:S1:5331:4	2.1%	CD	O	O
for	TANZEUM.xml:S1:5336:3	for	IN	O	O
placebo	TANZEUM.xml:S1:5340:7	placebo	NN	O	O
versus	TANZEUM.xml:S1:5348:6	versu	NN	O	O
TANZEUM	TANZEUM.xml:S1:5355:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:5363:1	)	)	O	O
,	TANZEUM.xml:S1:5364:1	,	,	O	O
injection	TANZEUM.xml:S1:5366:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5376:4	site	NN	I-AdverseReaction	I-AdverseReaction
erythema	TANZEUM.xml:S1:5381:8	erythema	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:5390:1	(	(	O	O
0.4%	TANZEUM.xml:S1:5391:4	0.4%	CD	O	O
versus	TANZEUM.xml:S1:5396:6	versu	NN	O	O
1.7%	TANZEUM.xml:S1:5403:4	1.7%	CD	O	O
for	TANZEUM.xml:S1:5408:3	for	IN	O	O
placebo	TANZEUM.xml:S1:5412:7	placebo	NN	O	O
versus	TANZEUM.xml:S1:5420:6	versu	NN	O	O
TANZEUM	TANZEUM.xml:S1:5427:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:5434:1	)	)	O	O
,	TANZEUM.xml:S1:5435:1	,	,	O	O
injection	TANZEUM.xml:S1:5437:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5447:4	site	NN	I-AdverseReaction	I-AdverseReaction
rash	TANZEUM.xml:S1:5452:4	rash	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:5457:1	(	(	O	O
0%	TANZEUM.xml:S1:5458:2	0%	CD	O	O
versus	TANZEUM.xml:S1:5461:6	versu	NN	O	O
1.4%	TANZEUM.xml:S1:5468:4	1.4%	CD	O	O
for	TANZEUM.xml:S1:5473:3	for	IN	O	O
placebo	TANZEUM.xml:S1:5477:7	placebo	NN	O	O
versus	TANZEUM.xml:S1:5485:6	versu	NN	O	O
TANZEUM	TANZEUM.xml:S1:5492:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:5499:1	)	)	O	O
,	TANZEUM.xml:S1:5500:1	,	,	O	O
injection	TANZEUM.xml:S1:5502:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5512:4	site	NN	I-AdverseReaction	I-AdverseReaction
hypersensitivity	TANZEUM.xml:S1:5517:16	hypersensit	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:5534:1	(	(	O	O
0%	TANZEUM.xml:S1:5535:2	0%	CD	O	O
versus	TANZEUM.xml:S1:5538:6	versu	NN	O	O
0.8%	TANZEUM.xml:S1:5545:4	0.8%	CD	O	O
for	TANZEUM.xml:S1:5550:3	for	IN	O	O
placebo	TANZEUM.xml:S1:5554:7	placebo	NN	O	O
versus	TANZEUM.xml:S1:5562:6	versu	NN	O	O
TANZEUM	TANZEUM.xml:S1:5569:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:5576:1	)	)	O	O
,	TANZEUM.xml:S1:5577:1	,	,	O	O
and	TANZEUM.xml:S1:5579:3	and	CC	O	O
injection	TANZEUM.xml:S1:5583:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5593:4	site	NN	I-AdverseReaction	I-AdverseReaction
hemorrhage	TANZEUM.xml:S1:5598:10	hemorrhag	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:5609:1	(	(	O	O
0.6%	TANZEUM.xml:S1:5610:4	0.6%	CD	O	O
versus	TANZEUM.xml:S1:5615:6	versu	NN	O	O
0.7%	TANZEUM.xml:S1:5622:4	0.7%	CD	O	O
for	TANZEUM.xml:S1:5627:3	for	IN	O	O
placebo	TANZEUM.xml:S1:5631:7	placebo	NN	O	O
versus	TANZEUM.xml:S1:5639:6	versu	NN	O	O
TANZEUM	TANZEUM.xml:S1:5646:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:5653:1	)	)	O	O
.	TANZEUM.xml:S1:5654:1	.	.	O	O

Injection	TANZEUM.xml:S1:5656:9	inject	NNP	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5666:4	site	NN	I-AdverseReaction	I-AdverseReaction
pruritus	TANZEUM.xml:S1:5671:8	pruritu	NN	I-AdverseReaction	I-AdverseReaction
also	TANZEUM.xml:S1:5680:4	also	RB	O	O
contributed	TANZEUM.xml:S1:5685:11	contribut	VBD	O	O
to	TANZEUM.xml:S1:5697:2	to	TO	O	O
the	TANZEUM.xml:S1:5700:3	the	DT	O	O
frequently	TANZEUM.xml:S1:5704:10	frequent	RB	O	O
reported	TANZEUM.xml:S1:5715:8	report	VBN	O	O
reactions	TANZEUM.xml:S1:5724:9	reaction	NNS	O	O
.	TANZEUM.xml:S1:5733:1	.	.	O	O

The	TANZEUM.xml:S1:5735:3	the	DT	O	O
majority	TANZEUM.xml:S1:5739:8	major	NN	O	O
of	TANZEUM.xml:S1:5748:2	of	IN	O	O
injection	TANZEUM.xml:S1:5751:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5761:4	site	NN	I-AdverseReaction	I-AdverseReaction
reactions	TANZEUM.xml:S1:5766:9	reaction	NNS	I-AdverseReaction	I-AdverseReaction
were	TANZEUM.xml:S1:5776:4	were	VBD	O	O
judged	TANZEUM.xml:S1:5781:6	judg	VBN	O	O
as	TANZEUM.xml:S1:5788:2	as	IN	O	O
"	TANZEUM.xml:S1:5791:1	"	JJ	O	O
mild	TANZEUM.xml:S1:5792:4	mild	NN	O	O
"	TANZEUM.xml:S1:5796:1	"	NN	O	O
by	TANZEUM.xml:S1:5798:2	by	IN	O	O
investigators	TANZEUM.xml:S1:5801:13	investig	NNS	O	O
in	TANZEUM.xml:S1:5815:2	in	IN	O	O
both	TANZEUM.xml:S1:5818:4	both	DT	O	O
groups	TANZEUM.xml:S1:5823:6	group	NNS	O	O
(	TANZEUM.xml:S1:5830:1	(	(	O	O
73%	TANZEUM.xml:S1:5831:3	73%	CD	O	O
for	TANZEUM.xml:S1:5835:3	for	IN	O	O
TANZEUM	TANZEUM.xml:S1:5839:7	tanzeum	NNP	O	O
versus	TANZEUM.xml:S1:5847:6	versu	NN	O	O
94%	TANZEUM.xml:S1:5854:3	94%	CD	O	O
for	TANZEUM.xml:S1:5858:3	for	IN	O	O
placebo	TANZEUM.xml:S1:5862:7	placebo	NN	O	O
)	TANZEUM.xml:S1:5869:1	)	)	O	O
.	TANZEUM.xml:S1:5870:1	.	.	O	O

More	TANZEUM.xml:S1:5872:4	more	JJR	O	O
patients	TANZEUM.xml:S1:5877:8	patient	NNS	O	O
on	TANZEUM.xml:S1:5886:2	on	IN	O	O
TANZEUM	TANZEUM.xml:S1:5889:7	tanzeum	NNP	O	O
than	TANZEUM.xml:S1:5897:4	than	IN	O	O
on	TANZEUM.xml:S1:5902:2	on	IN	O	O
placebo	TANZEUM.xml:S1:5905:7	placebo	NN	O	O
:	TANZEUM.xml:S1:5912:1	:	:	O	O
discontinued	TANZEUM.xml:S1:5914:12	discontinu	VBN	O	O
due	TANZEUM.xml:S1:5927:3	due	JJ	O	O
to	TANZEUM.xml:S1:5931:2	to	TO	O	O
an	TANZEUM.xml:S1:5934:2	an	DT	O	O
injection	TANZEUM.xml:S1:5937:9	inject	NN	B-AdverseReaction	B-AdverseReaction
site	TANZEUM.xml:S1:5947:4	site	NN	I-AdverseReaction	I-AdverseReaction
reaction	TANZEUM.xml:S1:5952:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:5961:1	(	(	O	O
2%	TANZEUM.xml:S1:5962:2	2%	CD	O	O
versus	TANZEUM.xml:S1:5965:6	versu	IN	O	O
0.2%	TANZEUM.xml:S1:5972:4	0.2%	CD	O	O
)	TANZEUM.xml:S1:5976:1	)	)	O	O
,	TANZEUM.xml:S1:5977:1	,	,	O	O
experienced	TANZEUM.xml:S1:5979:11	experienc	VBD	O	B-AdverseReaction
more	TANZEUM.xml:S1:5991:4	more	JJR	O	I-AdverseReaction
than	TANZEUM.xml:S1:5996:4	than	IN	O	I-AdverseReaction
2	TANZEUM.xml:S1:6001:1	2	CD	O	I-AdverseReaction
reactions	TANZEUM.xml:S1:6003:9	reaction	NNS	O	I-AdverseReaction
(	TANZEUM.xml:S1:6013:1	(	(	O	O
38%	TANZEUM.xml:S1:6014:3	38%	CD	O	O
versus	TANZEUM.xml:S1:6018:6	versu	IN	O	O
20%	TANZEUM.xml:S1:6025:3	20%	CD	O	O
)	TANZEUM.xml:S1:6028:1	)	)	O	O
,	TANZEUM.xml:S1:6029:1	,	,	O	O
had	TANZEUM.xml:S1:6031:3	had	VBD	O	O
a	TANZEUM.xml:S1:6035:1	a	DT	O	O
reaction	TANZEUM.xml:S1:6037:8	reaction	NN	O	O
judged	TANZEUM.xml:S1:6046:6	judg	VBN	O	O
by	TANZEUM.xml:S1:6053:2	by	IN	O	O
investigators	TANZEUM.xml:S1:6056:13	investig	NNS	O	O
to	TANZEUM.xml:S1:6070:2	to	TO	O	O
be	TANZEUM.xml:S1:6073:2	be	VB	O	O
"	TANZEUM.xml:S1:6076:1	"	JJ	O	O
moderate	TANZEUM.xml:S1:6077:8	moder	JJ	O	O
"	TANZEUM.xml:S1:6085:1	"	NN	O	O
or	TANZEUM.xml:S1:6087:2	or	CC	O	O
"	TANZEUM.xml:S1:6090:1	"	VB	O	O
severe	TANZEUM.xml:S1:6091:6	sever	JJ	O	O
"	TANZEUM.xml:S1:6097:1	"	NNP	O	O
(	TANZEUM.xml:S1:6099:1	(	(	O	O
27%	TANZEUM.xml:S1:6100:3	27%	CD	O	O
versus	TANZEUM.xml:S1:6104:6	versu	IN	O	O
6%	TANZEUM.xml:S1:6111:2	6%	CD	O	O
)	TANZEUM.xml:S1:6113:1	)	)	O	O
and	TANZEUM.xml:S1:6115:3	and	CC	O	O
required	TANZEUM.xml:S1:6119:8	requir	JJ	O	O
local	TANZEUM.xml:S1:6128:5	local	JJ	O	O
or	TANZEUM.xml:S1:6134:2	or	CC	O	O
systemic	TANZEUM.xml:S1:6137:8	system	JJ	O	O
treatment	TANZEUM.xml:S1:6146:9	treatment	NN	O	O
for	TANZEUM.xml:S1:6156:3	for	IN	O	O
the	TANZEUM.xml:S1:6160:3	the	DT	O	O
reactions	TANZEUM.xml:S1:6164:9	reaction	NNS	O	O
(	TANZEUM.xml:S1:6174:1	(	(	O	O
36%	TANZEUM.xml:S1:6175:3	36%	CD	O	O
versus	TANZEUM.xml:S1:6179:6	versu	IN	O	O
11%	TANZEUM.xml:S1:6186:3	11%	CD	O	O
)	TANZEUM.xml:S1:6189:1	)	)	O	O
.	TANZEUM.xml:S1:6190:1	.	.	O	O

Pool	TANZEUM.xml:S1:6198:4	pool	NN	O	O
of	TANZEUM.xml:S1:6203:2	of	IN	O	O
Placebo	TANZEUM.xml:S1:6206:7	placebo	NNP	O	O
-	TANZEUM.xml:S1:6213:1	-	:	O	O
and	TANZEUM.xml:S1:6215:3	and	CC	O	O
Active	TANZEUM.xml:S1:6219:6	activ	NNP	O	O
-	TANZEUM.xml:S1:6225:1	-	:	O	O
controlled	TANZEUM.xml:S1:6226:10	control	VBD	O	O
Trials	TANZEUM.xml:S1:6237:6	trial	NNS	O	O

The	TANZEUM.xml:S1:6250:3	the	DT	O	O
occurrence	TANZEUM.xml:S1:6254:10	occurr	NN	O	O
of	TANZEUM.xml:S1:6265:2	of	IN	O	O
adverse	TANZEUM.xml:S1:6268:7	advers	JJ	O	O
reactions	TANZEUM.xml:S1:6276:9	reaction	NNS	O	O
was	TANZEUM.xml:S1:6286:3	wa	VBD	O	O
also	TANZEUM.xml:S1:6290:4	also	RB	O	O
evaluated	TANZEUM.xml:S1:6295:9	evalu	VBN	O	O
in	TANZEUM.xml:S1:6305:2	in	IN	O	O
a	TANZEUM.xml:S1:6308:1	a	DT	O	O
larger	TANZEUM.xml:S1:6310:6	larger	JJR	O	O
pool	TANZEUM.xml:S1:6317:4	pool	NN	O	O
of	TANZEUM.xml:S1:6322:2	of	IN	O	O
patients	TANZEUM.xml:S1:6325:8	patient	NNS	O	O
with	TANZEUM.xml:S1:6334:4	with	IN	O	O
type	TANZEUM.xml:S1:6339:4	type	JJ	O	O
2	TANZEUM.xml:S1:6344:1	2	CD	O	O
diabetes	TANZEUM.xml:S1:6346:8	diabet	NNS	O	O
participating	TANZEUM.xml:S1:6355:13	particip	VBG	O	O
in	TANZEUM.xml:S1:6369:2	in	IN	O	O
7	TANZEUM.xml:S1:6372:1	7	CD	O	O
placebo	TANZEUM.xml:S1:6374:7	placebo	NN	O	O
-	TANZEUM.xml:S1:6381:1	-	:	O	O
and	TANZEUM.xml:S1:6383:3	and	CC	O	O
active	TANZEUM.xml:S1:6387:6	activ	JJ	O	O
-	TANZEUM.xml:S1:6393:1	-	:	O	O
controlled	TANZEUM.xml:S1:6394:10	control	VBN	O	O
trials	TANZEUM.xml:S1:6405:6	trial	NNS	O	O
.	TANZEUM.xml:S1:6411:1	.	.	O	O

These	TANZEUM.xml:S1:6413:5	these	DT	O	O
trials	TANZEUM.xml:S1:6419:6	trial	NNS	O	O
evaluated	TANZEUM.xml:S1:6426:9	evalu	VBD	O	O
the	TANZEUM.xml:S1:6436:3	the	DT	O	O
use	TANZEUM.xml:S1:6440:3	use	NN	O	O
of	TANZEUM.xml:S1:6444:2	of	IN	O	O
TANZEUM	TANZEUM.xml:S1:6447:7	tanzeum	NNP	O	O
as	TANZEUM.xml:S1:6455:2	as	IN	O	O
monotherapy	TANZEUM.xml:S1:6458:11	monotherapi	NN	O	O
,	TANZEUM.xml:S1:6469:1	,	,	O	O
and	TANZEUM.xml:S1:6471:3	and	CC	O	O
as	TANZEUM.xml:S1:6475:2	as	IN	O	O
add	TANZEUM.xml:S1:6478:3	add	JJ	O	O
-	TANZEUM.xml:S1:6481:1	-	:	O	O
on	TANZEUM.xml:S1:6482:2	on	IN	O	O
therapy	TANZEUM.xml:S1:6485:7	therapi	NN	O	O
to	TANZEUM.xml:S1:6493:2	to	TO	O	O
oral	TANZEUM.xml:S1:6496:4	oral	JJ	O	O
antidiabetic	TANZEUM.xml:S1:6501:12	antidiabet	JJ	O	O
agents	TANZEUM.xml:S1:6514:6	agent	NNS	O	O
,	TANZEUM.xml:S1:6520:1	,	,	O	O
and	TANZEUM.xml:S1:6522:3	and	CC	O	O
as	TANZEUM.xml:S1:6526:2	as	IN	O	O
add	TANZEUM.xml:S1:6529:3	add	JJ	O	O
-	TANZEUM.xml:S1:6532:1	-	:	O	O
on	TANZEUM.xml:S1:6533:2	on	IN	O	O
therapy	TANZEUM.xml:S1:6536:7	therapi	NN	O	O
to	TANZEUM.xml:S1:6544:2	to	TO	O	O
basal	TANZEUM.xml:S1:6547:5	basal	VB	O	O
insulin	TANZEUM.xml:S1:6553:7	insulin	NN	O	O
[	TANZEUM.xml:S1:6562:1	[	NNP	O	O
see	TANZEUM.xml:S1:6563:3	see	VBP	O	O
Clinical	TANZEUM.xml:S1:6567:8	clinic	JJ	O	O
Studies	TANZEUM.xml:S1:6576:7	studi	NNP	O	O
(	TANZEUM.xml:S1:6584:1	(	(	O	O
14	TANZEUM.xml:S1:6585:2	14	CD	O	O
)]	TANZEUM.xml:S1:6587:2	)]	NN	O	O
.	TANZEUM.xml:S1:6591:1	.	.	O	O

In	TANZEUM.xml:S1:6593:2	In	IN	O	O
this	TANZEUM.xml:S1:6596:4	thi	DT	O	O
pool	TANZEUM.xml:S1:6601:4	pool	NN	O	O
,	TANZEUM.xml:S1:6605:1	,	,	O	O
a	TANZEUM.xml:S1:6607:1	a	DT	O	O
total	TANZEUM.xml:S1:6609:5	total	NN	O	O
of	TANZEUM.xml:S1:6615:2	of	IN	O	O
2	TANZEUM.xml:S1:6618:1	2	CD	O	O
,	TANZEUM.xml:S1:6619:1	,	,	O	O
116	TANZEUM.xml:S1:6620:3	116	CD	O	O
patients	TANZEUM.xml:S1:6624:8	patient	NNS	O	O
with	TANZEUM.xml:S1:6633:4	with	IN	O	O
type	TANZEUM.xml:S1:6638:4	type	JJ	O	O
2	TANZEUM.xml:S1:6643:1	2	CD	O	O
diabetes	TANZEUM.xml:S1:6645:8	diabet	NNS	O	O
were	TANZEUM.xml:S1:6654:4	were	VBD	O	O
treated	TANZEUM.xml:S1:6659:7	treat	VBN	O	O
with	TANZEUM.xml:S1:6667:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S1:6672:7	tanzeum	NNP	O	O
for	TANZEUM.xml:S1:6680:3	for	IN	O	O
a	TANZEUM.xml:S1:6684:1	a	DT	O	O
mean	TANZEUM.xml:S1:6686:4	mean	JJ	O	O
duration	TANZEUM.xml:S1:6691:8	durat	NN	O	O
of	TANZEUM.xml:S1:6700:2	of	IN	O	O
75	TANZEUM.xml:S1:6703:2	75	CD	O	O
weeks	TANZEUM.xml:S1:6706:5	week	NNS	O	O
.	TANZEUM.xml:S1:6711:1	.	.	O	O

The	TANZEUM.xml:S1:6713:3	the	DT	O	O
mean	TANZEUM.xml:S1:6717:4	mean	JJ	O	O
age	TANZEUM.xml:S1:6722:3	age	NN	O	O
of	TANZEUM.xml:S1:6726:2	of	IN	O	O
patients	TANZEUM.xml:S1:6729:8	patient	NNS	O	O
treated	TANZEUM.xml:S1:6738:7	treat	VBN	O	O
with	TANZEUM.xml:S1:6746:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S1:6751:7	tanzeum	NNP	O	O
was	TANZEUM.xml:S1:6759:3	wa	VBD	O	O
55	TANZEUM.xml:S1:6763:2	55	CD	O	O
years	TANZEUM.xml:S1:6766:5	year	NNS	O	O
,	TANZEUM.xml:S1:6771:1	,	,	O	O
1.5%	TANZEUM.xml:S1:6773:4	1.5%	CD	O	O
of	TANZEUM.xml:S1:6778:2	of	IN	O	O
the	TANZEUM.xml:S1:6781:3	the	DT	O	O
population	TANZEUM.xml:S1:6785:10	popul	NN	O	O
in	TANZEUM.xml:S1:6796:2	in	IN	O	O
these	TANZEUM.xml:S1:6799:5	these	DT	O	O
studies	TANZEUM.xml:S1:6805:7	studi	NNS	O	O
was	TANZEUM.xml:S1:6813:3	wa	VBD	O	O
75	TANZEUM.xml:S1:6817:2	75	CD	O	O
years	TANZEUM.xml:S1:6820:5	year	NNS	O	O
or	TANZEUM.xml:S1:6826:2	or	CC	O	O
older	TANZEUM.xml:S1:6829:5	older	JJR	O	O
and	TANZEUM.xml:S1:6835:3	and	CC	O	O
51%	TANZEUM.xml:S1:6839:3	51%	CD	O	O
of	TANZEUM.xml:S1:6843:2	of	IN	O	O
participants	TANZEUM.xml:S1:6846:12	particip	NNS	O	O
were	TANZEUM.xml:S1:6859:4	were	VBD	O	O
male	TANZEUM.xml:S1:6864:4	male	JJ	O	O
.	TANZEUM.xml:S1:6868:1	.	.	O	O

Forty	TANZEUM.xml:S1:6870:5	forti	NNP	O	O
-	TANZEUM.xml:S1:6875:1	-	:	O	O
eight	TANZEUM.xml:S1:6876:5	eight	CD	O	O
percent	TANZEUM.xml:S1:6882:7	percent	NN	O	O
of	TANZEUM.xml:S1:6890:2	of	IN	O	O
patients	TANZEUM.xml:S1:6893:8	patient	NNS	O	O
were	TANZEUM.xml:S1:6902:4	were	VBD	O	O
white	TANZEUM.xml:S1:6907:5	white	JJ	O	O
,	TANZEUM.xml:S1:6912:1	,	,	O	O
15%	TANZEUM.xml:S1:6914:3	15%	CD	O	O
African	TANZEUM.xml:S1:6918:7	african	JJ	O	O
African	TANZEUM.xml:S1:6926:7	african	JJ	O	O
American	TANZEUM.xml:S1:6934:8	american	NNP	O	O
,	TANZEUM.xml:S1:6942:1	,	,	O	O
9%	TANZEUM.xml:S1:6944:2	9%	CD	O	O
Asian	TANZEUM.xml:S1:6947:5	asian	JJ	O	O
,	TANZEUM.xml:S1:6952:1	,	,	O	O
and	TANZEUM.xml:S1:6954:3	and	CC	O	O
26%	TANZEUM.xml:S1:6958:3	26%	CD	O	O
were	TANZEUM.xml:S1:6962:4	were	VBD	O	O
Hispanic	TANZEUM.xml:S1:6967:8	hispan	NNP	O	O
Latino	TANZEUM.xml:S1:6976:6	latino	NNP	O	O
.	TANZEUM.xml:S1:6982:1	.	.	O	O

At	TANZEUM.xml:S1:6984:2	At	IN	O	O
baseline	TANZEUM.xml:S1:6987:8	baselin	NN	O	O
,	TANZEUM.xml:S1:6995:1	,	,	O	O
the	TANZEUM.xml:S1:6997:3	the	DT	O	O
population	TANZEUM.xml:S1:7001:10	popul	NN	O	O
had	TANZEUM.xml:S1:7012:3	had	VBD	O	O
diabetes	TANZEUM.xml:S1:7016:8	diabet	NNS	O	O
for	TANZEUM.xml:S1:7025:3	for	IN	O	O
an	TANZEUM.xml:S1:7029:2	an	DT	O	O
average	TANZEUM.xml:S1:7032:7	averag	NN	O	O
of	TANZEUM.xml:S1:7040:2	of	IN	O	O
8	TANZEUM.xml:S1:7043:1	8	CD	O	O
years	TANZEUM.xml:S1:7045:5	year	NNS	O	O
and	TANZEUM.xml:S1:7051:3	and	CC	O	O
had	TANZEUM.xml:S1:7055:3	had	VBD	O	O
a	TANZEUM.xml:S1:7059:1	a	DT	O	O
mean	TANZEUM.xml:S1:7061:4	mean	JJ	O	O
HbA1c	TANZEUM.xml:S1:7066:5	hba1c	NNP	O	O
of	TANZEUM.xml:S1:7072:2	of	IN	O	O
8.2%	TANZEUM.xml:S1:7075:4	8.2%	CD	O	O
.	TANZEUM.xml:S1:7079:1	.	.	O	O

At	TANZEUM.xml:S1:7081:2	At	IN	O	O
baseline	TANZEUM.xml:S1:7084:8	baselin	NN	O	O
,	TANZEUM.xml:S1:7092:1	,	,	O	O
21%	TANZEUM.xml:S1:7094:3	21%	CD	O	O
of	TANZEUM.xml:S1:7098:2	of	IN	O	O
the	TANZEUM.xml:S1:7101:3	the	DT	O	O
population	TANZEUM.xml:S1:7105:10	popul	NN	O	O
reported	TANZEUM.xml:S1:7116:8	report	VBD	O	O
peripheral	TANZEUM.xml:S1:7125:10	peripher	JJ	O	B-AdverseReaction
neuropathy	TANZEUM.xml:S1:7136:10	neuropathi	NN	O	I-AdverseReaction
and	TANZEUM.xml:S1:7147:3	and	CC	O	O
5%	TANZEUM.xml:S1:7151:2	5%	CD	O	O
reported	TANZEUM.xml:S1:7154:8	report	VBD	O	O
retinopathy	TANZEUM.xml:S1:7163:11	retinopathi	NN	O	O
.	TANZEUM.xml:S1:7174:1	.	.	O	O

Baseline	TANZEUM.xml:S1:7176:8	baselin	NNP	O	O
estimated	TANZEUM.xml:S1:7185:9	estim	VBD	O	O
renal	TANZEUM.xml:S1:7195:5	renal	JJ	O	O
function	TANZEUM.xml:S1:7201:8	function	NN	O	O
was	TANZEUM.xml:S1:7210:3	wa	VBD	O	O
normal	TANZEUM.xml:S1:7214:6	normal	JJ	O	O
or	TANZEUM.xml:S1:7221:2	or	CC	O	O
mildly	TANZEUM.xml:S1:7224:6	mildli	RB	O	O
impaired	TANZEUM.xml:S1:7231:8	impair	JJ	O	O
(	TANZEUM.xml:S1:7240:1	(	(	O	O
eGFR	TANZEUM.xml:S1:7241:4	egfr	JJ	O	O
60	TANZEUM.xml:S1:7247:2	60	CD	O	O
mL	TANZEUM.xml:S1:7250:2	mL	NN	O	O
min	TANZEUM.xml:S1:7253:3	min	NN	O	O
1.73	TANZEUM.xml:S1:7257:4	1.73	CD	O	O
m	TANZEUM.xml:S1:7262:1	m	NN	O	O
2	TANZEUM.xml:S1:7265:1	2	CD	O	O
)	TANZEUM.xml:S1:7268:1	)	)	O	O
in	TANZEUM.xml:S1:7270:2	in	IN	O	O
92%	TANZEUM.xml:S1:7273:3	92%	CD	O	O
of	TANZEUM.xml:S1:7277:2	of	IN	O	O
the	TANZEUM.xml:S1:7280:3	the	DT	O	O
population	TANZEUM.xml:S1:7284:10	popul	NN	O	O
and	TANZEUM.xml:S1:7295:3	and	CC	O	O
moderately	TANZEUM.xml:S1:7299:10	moder	RB	O	O
impaired	TANZEUM.xml:S1:7310:8	impair	JJ	O	O
(	TANZEUM.xml:S1:7319:1	(	(	O	O
eGFR	TANZEUM.xml:S1:7320:4	egfr	JJ	O	O
30	TANZEUM.xml:S1:7325:2	30	CD	O	O
to	TANZEUM.xml:S1:7328:2	to	TO	O	O
60	TANZEUM.xml:S1:7331:2	60	CD	O	O
mL	TANZEUM.xml:S1:7334:2	mL	NNS	O	O
min	TANZEUM.xml:S1:7337:3	min	RB	O	O
1.73	TANZEUM.xml:S1:7341:4	1.73	CD	O	O
m	TANZEUM.xml:S1:7346:1	m	NNS	O	O
2	TANZEUM.xml:S1:7349:1	2	CD	O	O
)	TANZEUM.xml:S1:7352:1	)	)	O	O
in	TANZEUM.xml:S1:7354:2	in	IN	O	O
8%	TANZEUM.xml:S1:7357:2	8%	CD	O	O
of	TANZEUM.xml:S1:7360:2	of	IN	O	O
the	TANZEUM.xml:S1:7363:3	the	DT	O	O
population	TANZEUM.xml:S1:7367:10	popul	NN	O	O
.	TANZEUM.xml:S1:7377:1	.	.	O	O

In	TANZEUM.xml:S1:7383:2	In	IN	O	O
the	TANZEUM.xml:S1:7386:3	the	DT	O	O
pool	TANZEUM.xml:S1:7390:4	pool	NN	O	O
of	TANZEUM.xml:S1:7395:2	of	IN	O	O
placebo	TANZEUM.xml:S1:7398:7	placebo	NN	O	O
-	TANZEUM.xml:S1:7405:1	-	:	O	O
and	TANZEUM.xml:S1:7407:3	and	CC	O	O
active	TANZEUM.xml:S1:7411:6	activ	JJ	O	O
-	TANZEUM.xml:S1:7417:1	-	:	O	O
controlled	TANZEUM.xml:S1:7418:10	control	VBN	O	O
trials	TANZEUM.xml:S1:7429:6	trial	NNS	O	O
,	TANZEUM.xml:S1:7435:1	,	,	O	O
the	TANZEUM.xml:S1:7437:3	the	DT	O	O
types	TANZEUM.xml:S1:7441:5	type	NNS	O	O
and	TANZEUM.xml:S1:7447:3	and	CC	O	O
frequency	TANZEUM.xml:S1:7451:9	frequenc	NN	O	O
of	TANZEUM.xml:S1:7461:2	of	IN	O	O
common	TANZEUM.xml:S1:7464:6	common	JJ	O	O
adverse	TANZEUM.xml:S1:7471:7	advers	JJ	O	O
reactions	TANZEUM.xml:S1:7479:9	reaction	NNS	O	O
excluding	TANZEUM.xml:S1:7489:9	exclud	VBG	O	O
hypoglycemia	TANZEUM.xml:S1:7499:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
were	TANZEUM.xml:S1:7512:4	were	VBD	O	O
similar	TANZEUM.xml:S1:7517:7	similar	JJ	O	O
to	TANZEUM.xml:S1:7525:2	to	TO	O	O
those	TANZEUM.xml:S1:7528:5	those	DT	O	O
listed	TANZEUM.xml:S1:7534:6	list	VBN	O	O
in	TANZEUM.xml:S1:7541:2	in	IN	O	O
Table	TANZEUM.xml:S1:7544:5	tabl	JJ	O	O
1	TANZEUM.xml:S1:7550:1	1	CD	O	O
.	TANZEUM.xml:S1:7551:1	.	.	O	O

Other	TANZEUM.xml:S1:7559:5	other	JJ	O	O
Adverse	TANZEUM.xml:S1:7565:7	advers	NNP	O	O
Reactions	TANZEUM.xml:S1:7573:9	reaction	NNP	O	O

Hypoglycemia	TANZEUM.xml:S1:7591:12	hypoglycemia	NN	O	O

The	TANZEUM.xml:S1:7610:3	the	DT	O	O
proportion	TANZEUM.xml:S1:7614:10	proport	NN	O	O
of	TANZEUM.xml:S1:7625:2	of	IN	O	O
patients	TANZEUM.xml:S1:7628:8	patient	NNS	O	O
experiencing	TANZEUM.xml:S1:7637:12	experienc	VBG	O	O
at	TANZEUM.xml:S1:7650:2	at	IN	O	O
least	TANZEUM.xml:S1:7653:5	least	JJS	O	O
one	TANZEUM.xml:S1:7659:3	one	CD	O	O
documented	TANZEUM.xml:S1:7663:10	document	VBN	O	O
symptomatic	TANZEUM.xml:S1:7674:11	symptomat	JJ	O	O
hypoglycemic	TANZEUM.xml:S1:7686:12	hypoglycem	JJ	B-AdverseReaction	O
episode	TANZEUM.xml:S1:7699:7	episod	NN	I-AdverseReaction	O
on	TANZEUM.xml:S1:7707:2	on	IN	O	O
TANZEUM	TANZEUM.xml:S1:7710:7	tanzeum	NNP	O	O
and	TANZEUM.xml:S1:7718:3	and	CC	O	O
the	TANZEUM.xml:S1:7722:3	the	DT	O	O
proportion	TANZEUM.xml:S1:7726:10	proport	NN	O	O
of	TANZEUM.xml:S1:7737:2	of	IN	O	O
patients	TANZEUM.xml:S1:7740:8	patient	NNS	O	O
experiencing	TANZEUM.xml:S1:7749:12	experienc	VBG	O	O
at	TANZEUM.xml:S1:7762:2	at	IN	O	O
least	TANZEUM.xml:S1:7765:5	least	JJS	O	O
one	TANZEUM.xml:S1:7771:3	one	CD	O	O
severe	TANZEUM.xml:S1:7775:6	sever	JJ	O	O
hypoglycemic	TANZEUM.xml:S1:7782:12	hypoglycem	JJ	B-AdverseReaction	B-AdverseReaction
episode	TANZEUM.xml:S1:7795:7	episod	NN	I-AdverseReaction	I-AdverseReaction
on	TANZEUM.xml:S1:7803:2	on	IN	O	O
TANZEUM	TANZEUM.xml:S1:7806:7	tanzeum	NNP	O	O
in	TANZEUM.xml:S1:7814:2	in	IN	O	O
clinical	TANZEUM.xml:S1:7817:8	clinic	JJ	O	O
trials	TANZEUM.xml:S1:7826:6	trial	NNS	O	O
[	TANZEUM.xml:S1:7834:1	[	VBP	O	O
see	TANZEUM.xml:S1:7835:3	see	VB	O	O
Clinical	TANZEUM.xml:S1:7839:8	clinic	JJ	O	O
Studies	TANZEUM.xml:S1:7848:7	studi	NNP	O	O
(	TANZEUM.xml:S1:7856:1	(	(	O	O
14	TANZEUM.xml:S1:7857:2	14	CD	O	O
)]	TANZEUM.xml:S1:7859:2	)]	NN	O	O
is	TANZEUM.xml:S1:7863:2	is	VBZ	O	O
shown	TANZEUM.xml:S1:7866:5	shown	VBN	O	O
in	TANZEUM.xml:S1:7872:2	in	IN	O	O
Table	TANZEUM.xml:S1:7875:5	tabl	JJ	O	O
2	TANZEUM.xml:S1:7881:1	2	CD	O	O
.	TANZEUM.xml:S1:7882:1	.	.	O	O

Hypoglycemia	TANZEUM.xml:S1:7884:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
was	TANZEUM.xml:S1:7897:3	wa	VBD	O	O
more	TANZEUM.xml:S1:7901:4	more	RBR	O	O
frequent	TANZEUM.xml:S1:7906:8	frequent	JJ	O	O
when	TANZEUM.xml:S1:7915:4	when	WRB	O	O
TANZEUM	TANZEUM.xml:S1:7920:7	tanzeum	NNP	O	O
was	TANZEUM.xml:S1:7928:3	wa	VBD	O	O
added	TANZEUM.xml:S1:7932:5	ad	VBN	O	O
to	TANZEUM.xml:S1:7938:2	to	TO	O	O
sulfonylurea	TANZEUM.xml:S1:7941:12	sulfonylurea	VB	O	O
or	TANZEUM.xml:S1:7954:2	or	CC	O	O
insulin	TANZEUM.xml:S1:7957:7	insulin	VB	O	O
[	TANZEUM.xml:S1:7966:1	[	JJ	O	O
see	TANZEUM.xml:S1:7967:3	see	NN	O	O
Warnings	TANZEUM.xml:S1:7971:8	warn	NNS	O	O
and	TANZEUM.xml:S1:7980:3	and	CC	O	O
Precautions	TANZEUM.xml:S1:7984:11	precaut	NNP	O	O
(	TANZEUM.xml:S1:7996:1	(	(	O	O
5.3	TANZEUM.xml:S1:7997:3	5.3	CD	O	O
)]	TANZEUM.xml:S1:8000:2	)]	NN	O	O
.	TANZEUM.xml:S1:8004:1	.	.	O	O

Table	TANZEUM.xml:S1:8012:5	tabl	JJ	O	O
2	TANZEUM.xml:S1:8018:1	2	CD	O	O
.	TANZEUM.xml:S1:8019:1	.	.	O	O

Incidence	TANZEUM.xml:S1:8021:9	incid	NNP	O	O
(	TANZEUM.xml:S1:8031:1	(	(	O	O
)	TANZEUM.xml:S1:8033:1	)	)	O	O
of	TANZEUM.xml:S1:8035:2	of	IN	O	O
Hypoglycemia	TANZEUM.xml:S1:8038:12	hypoglycemia	NNP	O	O
in	TANZEUM.xml:S1:8051:2	in	IN	O	O
Clinical	TANZEUM.xml:S1:8054:8	clinic	NNP	O	O
Trials	TANZEUM.xml:S1:8063:6	trial	NNP	O	O
of	TANZEUM.xml:S1:8070:2	of	IN	O	O
TANZEUM	TANZEUM.xml:S1:8073:7	tanzeum	NNP	O	O
a	TANZEUM.xml:S1:8082:1	a	DT	O	O

TANZEUM	TANZEUM.xml:S1:8176:7	tanzeum	NN	O	O

Monotherapyb	TANZEUM.xml:S1:8203:12	monotherapyb	NNP	O	O
Placebo	TANZEUM.xml:S1:8258:7	placebo	NNP	O	O
30	TANZEUM.xml:S1:8285:2	30	CD	O	O
mg	TANZEUM.xml:S1:8288:2	mg	NNS	O	O
Weekly	TANZEUM.xml:S1:8291:6	weekli	JJ	O	O

(	TANZEUM.xml:S1:8312:1	(	(	O	O
52	TANZEUM.xml:S1:8313:2	52	CD	O	O
Weeks	TANZEUM.xml:S1:8316:5	week	NNP	O	O
)	TANZEUM.xml:S1:8321:1	)	)	O	O
N	TANZEUM.xml:S1:8367:1	N	NNP	O	O
101	TANZEUM.xml:S1:8371:3	101	CD	O	O
N	TANZEUM.xml:S1:8394:1	N	NNP	O	O
101	TANZEUM.xml:S1:8398:3	101	CD	O	O

Documented	TANZEUM.xml:S1:8421:10	document	VBN	O	B-AdverseReaction
symptomaticc	TANZEUM.xml:S1:8432:12	symptomaticc	VBD	O	I-AdverseReaction
2%	TANZEUM.xml:S1:8476:2	2%	CD	O	O
2%	TANZEUM.xml:S1:8503:2	2%	CD	O	O

Severed	TANZEUM.xml:S1:8530:7	sever	NNP	O	O
-	TANZEUM.xml:S1:8585:1	-	:	O	O
-	TANZEUM.xml:S1:8612:1	-	:	O	O

In	TANZEUM.xml:S1:8639:2	In	IN	O	O
Combination	TANZEUM.xml:S1:8642:11	combin	NNP	O	O
with	TANZEUM.xml:S1:8654:4	with	IN	O	O
Metformin	TANZEUM.xml:S1:8659:9	metformin	NNP	O	O
Trial	TANZEUM.xml:S1:8669:5	trial	NNP	O	O
Placebo	TANZEUM.xml:S1:8694:7	placebo	NNP	O	O
TANZEUM	TANZEUM.xml:S1:8721:7	tanzeum	NNP	O	O

(	TANZEUM.xml:S1:8748:1	(	(	O	O
104	TANZEUM.xml:S1:8749:3	104	CD	O	O
Weeks	TANZEUM.xml:S1:8753:5	week	NNP	O	O
)	TANZEUM.xml:S1:8758:1	)	)	O	O
e	TANZEUM.xml:S1:8759:1	e	VBP	O	O
N	TANZEUM.xml:S1:8803:1	N	$	O	O
101	TANZEUM.xml:S1:8807:3	101	CD	O	O
N	TANZEUM.xml:S1:8830:1	N	NNP	O	O
302	TANZEUM.xml:S1:8834:3	302	CD	O	O

Documented	TANZEUM.xml:S1:8857:10	document	VBN	O	B-AdverseReaction
symptomatic	TANZEUM.xml:S1:8868:11	symptomat	JJ	O	I-AdverseReaction
4%	TANZEUM.xml:S1:8912:2	4%	CD	O	O
3%	TANZEUM.xml:S1:8939:2	3%	CD	O	O

Severe	TANZEUM.xml:S1:8966:6	sever	NNP	O	O
-	TANZEUM.xml:S1:9021:1	-	:	O	O
-	TANZEUM.xml:S1:9048:1	-	:	O	O

In	TANZEUM.xml:S1:9075:2	In	IN	O	O
Combination	TANZEUM.xml:S1:9078:11	combin	NNP	O	O
with	TANZEUM.xml:S1:9090:4	with	IN	O	O
Pioglitazone	TANZEUM.xml:S1:9095:12	pioglitazon	NNP	O	O
-	TANZEUM.xml:S1:9110:1	-	:	O	O
Placebo	TANZEUM.xml:S1:9130:7	placebo	NNP	O	O
TANZEUM	TANZEUM.xml:S1:9157:7	tanzeum	NNP	O	O

Metformin	TANZEUM.xml:S1:9184:9	metformin	NNP	O	O
(	TANZEUM.xml:S1:9194:1	(	(	O	O
52	TANZEUM.xml:S1:9195:2	52	CD	O	O
Weeks	TANZEUM.xml:S1:9198:5	week	NNP	O	O
)	TANZEUM.xml:S1:9203:1	)	)	O	O
N	TANZEUM.xml:S1:9239:1	N	NNP	O	O
151	TANZEUM.xml:S1:9243:3	151	CD	O	O
N	TANZEUM.xml:S1:9266:1	N	NNP	O	O
150	TANZEUM.xml:S1:9270:3	150	CD	O	O

Documented	TANZEUM.xml:S1:9293:10	document	VBN	O	B-AdverseReaction
symptomatic	TANZEUM.xml:S1:9304:11	symptomat	JJ	O	I-AdverseReaction
1%	TANZEUM.xml:S1:9348:2	1%	CD	O	O
3%	TANZEUM.xml:S1:9375:2	3%	CD	O	O

Severe	TANZEUM.xml:S1:9402:6	sever	NNP	O	O
-	TANZEUM.xml:S1:9457:1	-	:	O	O
1%	TANZEUM.xml:S1:9484:2	1%	CD	O	O

In	TANZEUM.xml:S1:9511:2	In	IN	O	O
Combination	TANZEUM.xml:S1:9514:11	combin	NNP	O	O
with	TANZEUM.xml:S1:9526:4	with	IN	O	O
Metformin	TANZEUM.xml:S1:9531:9	metformin	NNP	O	O
and	TANZEUM.xml:S1:9541:3	and	CC	O	O
Placebo	TANZEUM.xml:S1:9566:7	placebo	NNP	O	O
TANZEUM	TANZEUM.xml:S1:9593:7	tanzeum	NNP	O	O

Sulfonylurea	TANZEUM.xml:S1:9620:12	sulfonylurea	NNP	O	O
(	TANZEUM.xml:S1:9633:1	(	(	O	O
52	TANZEUM.xml:S1:9634:2	52	CD	O	O
Weeks	TANZEUM.xml:S1:9637:5	week	NNP	O	O
)	TANZEUM.xml:S1:9642:1	)	)	O	O
N	TANZEUM.xml:S1:9675:1	N	NNP	O	O
115	TANZEUM.xml:S1:9679:3	115	CD	O	O
N	TANZEUM.xml:S1:9702:1	N	NNP	O	O
271	TANZEUM.xml:S1:9706:3	271	CD	O	O

Documented	TANZEUM.xml:S1:9729:10	document	VBN	O	B-AdverseReaction
symptomatic	TANZEUM.xml:S1:9740:11	symptomat	JJ	O	I-AdverseReaction
7%	TANZEUM.xml:S1:9784:2	7%	CD	O	O
13%	TANZEUM.xml:S1:9811:3	13%	CD	O	O

Severe	TANZEUM.xml:S1:9838:6	sever	NNP	O	O
-	TANZEUM.xml:S1:9893:1	-	:	O	O
0.4%	TANZEUM.xml:S1:9920:4	0.4%	CD	O	O

In	TANZEUM.xml:S1:9947:2	In	IN	O	O
Combination	TANZEUM.xml:S1:9950:11	combin	NNP	O	O
with	TANZEUM.xml:S1:9962:4	with	IN	O	O
Insulin	TANZEUM.xml:S1:10002:7	insulin	NNP	O	O
Lispro	TANZEUM.xml:S1:10010:6	lispro	NNP	O	O
TANZEUM	TANZEUM.xml:S1:10029:7	tanzeum	NNP	O	O

Insulin	TANZEUM.xml:S1:10056:7	insulin	NNP	O	O
Glargine	TANZEUM.xml:S1:10064:8	glargin	NNP	O	O
(	TANZEUM.xml:S1:10073:1	(	(	O	O
26	TANZEUM.xml:S1:10074:2	26	CD	O	O
Weeks	TANZEUM.xml:S1:10077:5	week	NNP	O	O
)	TANZEUM.xml:S1:10082:1	)	)	O	O
N	TANZEUM.xml:S1:10111:1	N	NNP	O	O
281	TANZEUM.xml:S1:10115:3	281	CD	O	O
N	TANZEUM.xml:S1:10138:1	N	NNP	O	O
285	TANZEUM.xml:S1:10142:3	285	CD	O	O

Documented	TANZEUM.xml:S1:10165:10	document	VBN	O	B-AdverseReaction
symptomatic	TANZEUM.xml:S1:10176:11	symptomat	JJ	O	I-AdverseReaction
30%	TANZEUM.xml:S1:10220:3	30%	CD	O	O
16%	TANZEUM.xml:S1:10247:3	16%	CD	O	O

Severe	TANZEUM.xml:S1:10274:6	sever	RB	O	O
0.7%	TANZEUM.xml:S1:10329:4	0.7%	CD	O	O
-	TANZEUM.xml:S1:10356:1	-	:	O	O

In	TANZEUM.xml:S1:10383:2	In	IN	O	O
Combination	TANZEUM.xml:S1:10386:11	combin	NNP	O	O
with	TANZEUM.xml:S1:10398:4	with	IN	O	O
Insulin	TANZEUM.xml:S1:10438:7	insulin	NNP	O	O
Glargine	TANZEUM.xml:S1:10446:8	glargin	NNP	O	O
TANZEUM	TANZEUM.xml:S1:10465:7	tanzeum	NNP	O	O

Metformin	TANZEUM.xml:S1:10492:9	metformin	NNP	O	O
-	TANZEUM.xml:S1:10504:1	-	:	O	O
Sulfonylurea	TANZEUM.xml:S1:10506:12	sulfonylurea	NNP	O	O
(	TANZEUM.xml:S1:10519:1	(	(	O	O
52	TANZEUM.xml:S1:10520:2	52	CD	O	O
Weeks	TANZEUM.xml:S1:10523:5	week	NNP	O	O
)	TANZEUM.xml:S1:10528:1	)	)	O	O
N	TANZEUM.xml:S1:10547:1	N	NNP	O	O
241	TANZEUM.xml:S1:10551:3	241	CD	O	O
N	TANZEUM.xml:S1:10574:1	N	NNP	O	O
504	TANZEUM.xml:S1:10578:3	504	CD	O	O

Documented	TANZEUM.xml:S1:10601:10	document	VBN	O	B-AdverseReaction
symptomatic	TANZEUM.xml:S1:10612:11	symptomat	JJ	O	I-AdverseReaction
27%	TANZEUM.xml:S1:10656:3	27%	CD	O	O
17%	TANZEUM.xml:S1:10683:3	17%	CD	O	O

Severe	TANZEUM.xml:S1:10710:6	sever	RB	O	O
0.4%	TANZEUM.xml:S1:10765:4	0.4%	CD	O	O
0.4%	TANZEUM.xml:S1:10792:4	0.4%	CD	O	O

In	TANZEUM.xml:S1:10819:2	In	IN	O	O
Combination	TANZEUM.xml:S1:10822:11	combin	NNP	O	O
with	TANZEUM.xml:S1:10834:4	with	IN	O	O
OADs	TANZEUM.xml:S1:10839:4	oad	NNP	O	O
in	TANZEUM.xml:S1:10844:2	in	IN	O	O
Renal	TANZEUM.xml:S1:10847:5	renal	NNP	O	O
Sitagliptin	TANZEUM.xml:S1:10874:11	sitagliptin	NNP	O	O
TANZEUM	TANZEUM.xml:S1:10901:7	tanzeum	NNP	O	O

Impairment	TANZEUM.xml:S1:10928:10	impair	NNP	O	O
(	TANZEUM.xml:S1:10939:1	(	(	O	O
26	TANZEUM.xml:S1:10940:2	26	CD	O	O
Weeks	TANZEUM.xml:S1:10943:5	week	NNP	O	O
)	TANZEUM.xml:S1:10948:1	)	)	O	O
N	TANZEUM.xml:S1:10983:1	N	NNP	O	O
246	TANZEUM.xml:S1:10987:3	246	CD	O	O
N	TANZEUM.xml:S1:11010:1	N	NNP	O	O
249	TANZEUM.xml:S1:11014:3	249	CD	O	O

Documented	TANZEUM.xml:S1:11037:10	document	VBN	O	B-AdverseReaction
symptomatic	TANZEUM.xml:S1:11048:11	symptomat	JJ	O	I-AdverseReaction
6%	TANZEUM.xml:S1:11092:2	6%	CD	O	O
10%	TANZEUM.xml:S1:11119:3	10%	CD	O	O

Severe	TANZEUM.xml:S1:11146:6	sever	RB	O	O
0.8%	TANZEUM.xml:S1:11201:4	0.8%	CD	O	O
-	TANZEUM.xml:S1:11228:1	-	:	O	O

OAD	TANZEUM.xml:S1:11267:3	oad	NNP	O	O
Oral	TANZEUM.xml:S1:11273:4	oral	NNP	O	O
antidiabetic	TANZEUM.xml:S1:11278:12	antidiabet	JJ	O	O
agents	TANZEUM.xml:S1:11291:6	agent	NNS	O	O
.	TANZEUM.xml:S1:11297:1	.	.	O	O

a	TANZEUM.xml:S1:11309:1	a	DT	O	O
Data	TANZEUM.xml:S1:11312:4	data	NNP	O	O
presented	TANZEUM.xml:S1:11317:9	present	VBN	O	O
are	TANZEUM.xml:S1:11327:3	are	VBP	O	O
to	TANZEUM.xml:S1:11331:2	to	TO	O	O
the	TANZEUM.xml:S1:11334:3	the	DT	O	O
primary	TANZEUM.xml:S1:11338:7	primari	JJ	O	O
endpoint	TANZEUM.xml:S1:11346:8	endpoint	NN	O	O
and	TANZEUM.xml:S1:11355:3	and	CC	O	O
include	TANZEUM.xml:S1:11359:7	includ	VBP	O	O
only	TANZEUM.xml:S1:11367:4	onli	JJ	O	B-AdverseReaction
events	TANZEUM.xml:S1:11372:6	event	NNS	O	I-AdverseReaction
occurring	TANZEUM.xml:S1:11379:9	occur	VBG	O	O
on	TANZEUM.xml:S1:11389:2	on	IN	O	O
-	TANZEUM.xml:S1:11391:1	-	:	O	O
therapy	TANZEUM.xml:S1:11392:7	therapi	NN	O	O
with	TANZEUM.xml:S1:11400:4	with	IN	O	O
randomized	TANZEUM.xml:S1:11405:10	random	JJ	O	O
medications	TANZEUM.xml:S1:11416:11	medic	NNS	O	O
and	TANZEUM.xml:S1:11428:3	and	CC	O	O
excludes	TANZEUM.xml:S1:11432:8	exclud	VBZ	O	B-AdverseReaction
events	TANZEUM.xml:S1:11441:6	event	NNS	O	I-AdverseReaction
occurring	TANZEUM.xml:S1:11448:9	occur	VBG	O	O
after	TANZEUM.xml:S1:11458:5	after	IN	O	O
use	TANZEUM.xml:S1:11464:3	use	NN	O	O
of	TANZEUM.xml:S1:11468:2	of	IN	O	O
glycemic	TANZEUM.xml:S1:11471:8	glycem	JJ	O	O
rescue	TANZEUM.xml:S1:11480:6	rescu	NN	O	O
medications	TANZEUM.xml:S1:11487:11	medic	NNS	O	O
(	TANZEUM.xml:S1:11499:1	(	(	O	O
i	TANZEUM.xml:S1:11500:1	i	NN	O	O
.	TANZEUM.xml:S1:11501:1	.	.	O	O
e	TANZEUM.xml:S1:11502:1	e	NN	O	O
.	TANZEUM.xml:S1:11503:1	.	.	O	O
,	TANZEUM.xml:S1:11504:1	,	,	O	O
primarily	TANZEUM.xml:S1:11506:9	primarili	RB	O	O
metformin	TANZEUM.xml:S1:11516:9	metformin	VBZ	O	O
or	TANZEUM.xml:S1:11526:2	or	CC	O	O
insulin	TANZEUM.xml:S1:11529:7	insulin	NN	O	O
)	TANZEUM.xml:S1:11536:1	)	)	O	O
.	TANZEUM.xml:S1:11537:1	.	.	O	O

b	TANZEUM.xml:S1:11549:1	b	NN	O	O
In	TANZEUM.xml:S1:11552:2	In	IN	O	O
this	TANZEUM.xml:S1:11555:4	thi	DT	O	O
trial	TANZEUM.xml:S1:11560:5	trial	NN	O	O
,	TANZEUM.xml:S1:11565:1	,	,	O	O
no	TANZEUM.xml:S1:11567:2	no	DT	O	O
documented	TANZEUM.xml:S1:11570:10	document	JJ	O	O
symptomatic	TANZEUM.xml:S1:11581:11	symptomat	NN	O	O
or	TANZEUM.xml:S1:11593:2	or	CC	O	O
severe	TANZEUM.xml:S1:11596:6	sever	JJ	O	O
hypoglycemia	TANZEUM.xml:S1:11603:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
were	TANZEUM.xml:S1:11616:4	were	VBD	O	O
reported	TANZEUM.xml:S1:11621:8	report	VBN	O	O
for	TANZEUM.xml:S1:11630:3	for	IN	O	O
TANZEUM	TANZEUM.xml:S1:11634:7	tanzeum	NNP	O	O
50	TANZEUM.xml:S1:11642:2	50	CD	O	O
mg	TANZEUM.xml:S1:11645:2	mg	NN	O	O
and	TANZEUM.xml:S1:11648:3	and	CC	O	O
these	TANZEUM.xml:S1:11652:5	these	DT	O	O
data	TANZEUM.xml:S1:11658:4	data	NNS	O	O
are	TANZEUM.xml:S1:11663:3	are	VBP	O	O
omitted	TANZEUM.xml:S1:11667:7	omit	VBN	O	O
from	TANZEUM.xml:S1:11675:4	from	IN	O	O
the	TANZEUM.xml:S1:11680:3	the	DT	O	O
table	TANZEUM.xml:S1:11684:5	tabl	NN	O	O
.	TANZEUM.xml:S1:11689:1	.	.	O	O

c	TANZEUM.xml:S1:11701:1	c	NNS	O	O
Plasma	TANZEUM.xml:S1:11704:6	plasma	NNP	B-AdverseReaction	B-AdverseReaction
glucose	TANZEUM.xml:S1:11711:7	glucos	VBP	I-AdverseReaction	I-AdverseReaction
concentration	TANZEUM.xml:S1:11719:13	concentr	NN	I-AdverseReaction	I-AdverseReaction
70	TANZEUM.xml:S1:11735:2	70	CD	I-AdverseReaction	I-AdverseReaction
mg	TANZEUM.xml:S1:11738:2	mg	NN	I-AdverseReaction	I-AdverseReaction
dL	TANZEUM.xml:S1:11741:2	dL	NN	I-AdverseReaction	I-AdverseReaction
and	TANZEUM.xml:S1:11744:3	and	CC	O	O
presence	TANZEUM.xml:S1:11748:8	presenc	NN	O	O
of	TANZEUM.xml:S1:11757:2	of	IN	O	O
hypoglycemic	TANZEUM.xml:S1:11760:12	hypoglycem	JJ	B-AdverseReaction	O
symptoms	TANZEUM.xml:S1:11773:8	symptom	NNS	I-AdverseReaction	O
.	TANZEUM.xml:S1:11781:1	.	.	O	O

d	TANZEUM.xml:S1:11793:1	d	JJ	O	O
Event	TANZEUM.xml:S1:11796:5	event	NNP	O	O
requiring	TANZEUM.xml:S1:11802:9	requir	VBG	O	O
another	TANZEUM.xml:S1:11812:7	anoth	DT	O	O
person	TANZEUM.xml:S1:11820:6	person	NN	O	O
to	TANZEUM.xml:S1:11827:2	to	TO	O	O
administer	TANZEUM.xml:S1:11830:10	administ	VB	O	O
a	TANZEUM.xml:S1:11841:1	a	DT	O	O
resuscitative	TANZEUM.xml:S1:11843:13	resuscit	JJ	O	O
action	TANZEUM.xml:S1:11857:6	action	NN	O	O
.	TANZEUM.xml:S1:11863:1	.	.	O	O

e	TANZEUM.xml:S1:11875:1	e	NN	O	O
Rate	TANZEUM.xml:S1:11878:4	rate	NNP	O	O
of	TANZEUM.xml:S1:11883:2	of	IN	O	O
documented	TANZEUM.xml:S1:11886:10	document	VBN	O	O
symptomatic	TANZEUM.xml:S1:11897:11	symptomat	JJ	O	O
hypoglycemia	TANZEUM.xml:S1:11909:12	hypoglycemia	NN	B-AdverseReaction	O
for	TANZEUM.xml:S1:11922:3	for	IN	O	O
active	TANZEUM.xml:S1:11926:6	activ	JJ	O	O
controls	TANZEUM.xml:S1:11933:8	control	NNS	O	O
18%	TANZEUM.xml:S1:11942:3	18%	CD	O	O
(	TANZEUM.xml:S1:11946:1	(	(	O	O
glimepiride	TANZEUM.xml:S1:11947:11	glimepirid	NN	O	O
)	TANZEUM.xml:S1:11958:1	)	)	O	O
and	TANZEUM.xml:S1:11960:3	and	CC	O	O
2%	TANZEUM.xml:S1:11964:2	2%	CD	O	O
(	TANZEUM.xml:S1:11967:1	(	(	O	O
sitagliptin	TANZEUM.xml:S1:11968:11	sitagliptin	NN	O	O
)	TANZEUM.xml:S1:11979:1	)	)	O	O
.	TANZEUM.xml:S1:11980:1	.	.	O	O

Pneumonia	TANZEUM.xml:S1:11989:9	pneumonia	NN	O	O

In	TANZEUM.xml:S1:12005:2	In	IN	O	O

the	TANZEUM.xml:S1:12008:3	the	DT	O	O
pool	TANZEUM.xml:S1:12012:4	pool	NN	O	O
of	TANZEUM.xml:S1:12017:2	of	IN	O	O
7	TANZEUM.xml:S1:12020:1	7	CD	O	O
placebo	TANZEUM.xml:S1:12022:7	placebo	NN	O	O
-	TANZEUM.xml:S1:12029:1	-	:	O	O
and	TANZEUM.xml:S1:12031:3	and	CC	O	O
active	TANZEUM.xml:S1:12035:6	activ	JJ	O	O
-	TANZEUM.xml:S1:12041:1	-	:	O	O
controlled	TANZEUM.xml:S1:12042:10	control	VBN	O	O
trials	TANZEUM.xml:S1:12053:6	trial	NNS	O	O
,	TANZEUM.xml:S1:12059:1	,	,	O	O
the	TANZEUM.xml:S1:12061:3	the	DT	O	O
adverse	TANZEUM.xml:S1:12065:7	advers	JJ	O	O
reaction	TANZEUM.xml:S1:12073:8	reaction	NN	O	O
of	TANZEUM.xml:S1:12082:2	of	IN	O	O
pneumonia	TANZEUM.xml:S1:12085:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
was	TANZEUM.xml:S1:12095:3	wa	VBD	O	O
reported	TANZEUM.xml:S1:12099:8	report	VBN	O	O
more	TANZEUM.xml:S1:12108:4	more	RBR	O	O
frequently	TANZEUM.xml:S1:12113:10	frequent	RB	O	O
in	TANZEUM.xml:S1:12124:2	in	IN	O	O
patients	TANZEUM.xml:S1:12127:8	patient	NNS	O	O
receiving	TANZEUM.xml:S1:12136:9	receiv	VBG	O	O
TANZEUM	TANZEUM.xml:S1:12146:7	tanzeum	NNP	O	O
(	TANZEUM.xml:S1:12154:1	(	(	O	O
1.8%	TANZEUM.xml:S1:12155:4	1.8%	CD	O	O
)	TANZEUM.xml:S1:12159:1	)	)	O	O
than	TANZEUM.xml:S1:12161:4	than	IN	O	O
in	TANZEUM.xml:S1:12166:2	in	IN	O	O
patients	TANZEUM.xml:S1:12169:8	patient	NNS	O	O
in	TANZEUM.xml:S1:12178:2	in	IN	O	O
the	TANZEUM.xml:S1:12181:3	the	DT	O	O
all	TANZEUM.xml:S1:12185:3	all	DT	O	O
-	TANZEUM.xml:S1:12188:1	-	:	O	O
comparators	TANZEUM.xml:S1:12189:11	compar	NNS	O	O
group	TANZEUM.xml:S1:12201:5	group	NN	O	O
(	TANZEUM.xml:S1:12207:1	(	(	O	O
0.8%	TANZEUM.xml:S1:12208:4	0.8%	CD	O	O
)	TANZEUM.xml:S1:12212:1	)	)	O	O
.	TANZEUM.xml:S1:12213:1	.	.	O	O

More	TANZEUM.xml:S1:12215:4	more	RBR	O	O
cases	TANZEUM.xml:S1:12220:5	case	NNS	O	O
of	TANZEUM.xml:S1:12226:2	of	IN	O	O
pneumonia	TANZEUM.xml:S1:12229:9	pneumonia	NN	B-AdverseReaction	B-AdverseReaction
in	TANZEUM.xml:S1:12239:2	in	IN	O	O
the	TANZEUM.xml:S1:12242:3	the	DT	O	O
group	TANZEUM.xml:S1:12246:5	group	NN	O	O
receiving	TANZEUM.xml:S1:12252:9	receiv	VBG	O	O
TANZEUM	TANZEUM.xml:S1:12262:7	tanzeum	NNP	O	O
were	TANZEUM.xml:S1:12270:4	were	VBD	O	O
serious	TANZEUM.xml:S1:12275:7	seriou	JJ	O	O
(	TANZEUM.xml:S1:12283:1	(	(	O	O
0.4%	TANZEUM.xml:S1:12284:4	0.4%	CD	O	O
for	TANZEUM.xml:S1:12289:3	for	IN	O	O
TANZEUM	TANZEUM.xml:S1:12293:7	tanzeum	NNP	O	O
versus	TANZEUM.xml:S1:12301:6	versu	NN	O	O
0.1%	TANZEUM.xml:S1:12308:4	0.1%	CD	O	O
for	TANZEUM.xml:S1:12313:3	for	IN	O	O
all	TANZEUM.xml:S1:12317:3	all	DT	O	O
comparators	TANZEUM.xml:S1:12321:11	compar	NNS	O	O
)	TANZEUM.xml:S1:12332:1	)	)	O	O
.	TANZEUM.xml:S1:12333:1	.	.	O	O

Atrial	TANZEUM.xml:S1:12341:6	atrial	JJ	O	O
Fibrillation	TANZEUM.xml:S1:12348:12	fibril	NNP	O	O
Flutte	TANZEUM.xml:S1:12361:6	flutt	NNP	O	O
r	TANZEUM.xml:S1:12369:1	r	NN	O	O

In	TANZEUM.xml:S1:12375:2	In	IN	O	O
the	TANZEUM.xml:S1:12378:3	the	DT	O	O
pool	TANZEUM.xml:S1:12382:4	pool	NN	O	O
of	TANZEUM.xml:S1:12387:2	of	IN	O	O
7	TANZEUM.xml:S1:12390:1	7	CD	O	O
placebo	TANZEUM.xml:S1:12392:7	placebo	NN	O	O
-	TANZEUM.xml:S1:12399:1	-	:	O	O
and	TANZEUM.xml:S1:12401:3	and	CC	O	O
active	TANZEUM.xml:S1:12405:6	activ	JJ	O	O
-	TANZEUM.xml:S1:12411:1	-	:	O	O
controlled	TANZEUM.xml:S1:12412:10	control	VBN	O	O
trials	TANZEUM.xml:S1:12423:6	trial	NNS	O	O
,	TANZEUM.xml:S1:12429:1	,	,	O	O
adverse	TANZEUM.xml:S1:12431:7	advers	JJ	O	O
reactions	TANZEUM.xml:S1:12439:9	reaction	NNS	O	O
of	TANZEUM.xml:S1:12449:2	of	IN	O	O
atrial	TANZEUM.xml:S1:12452:6	atrial	JJ	B-AdverseReaction	B-AdverseReaction
fibrillation	TANZEUM.xml:S1:12459:12	fibril	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:12472:1	(	(	O	O
1.0%	TANZEUM.xml:S1:12473:4	1.0%	CD	O	O
)	TANZEUM.xml:S1:12477:1	)	)	O	O
and	TANZEUM.xml:S1:12479:3	and	CC	O	O
atrial	TANZEUM.xml:S1:12483:6	atrial	JJ	B-AdverseReaction	B-AdverseReaction
flutter	TANZEUM.xml:S1:12490:7	flutter	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:12498:1	(	(	O	O
0.2%	TANZEUM.xml:S1:12499:4	0.2%	CD	O	O
)	TANZEUM.xml:S1:12503:1	)	)	O	O
were	TANZEUM.xml:S1:12505:4	were	VBD	O	O
reported	TANZEUM.xml:S1:12510:8	report	VBN	O	O
more	TANZEUM.xml:S1:12519:4	more	RBR	O	O
frequently	TANZEUM.xml:S1:12524:10	frequent	RB	O	O
for	TANZEUM.xml:S1:12535:3	for	IN	O	O
TANZEUM	TANZEUM.xml:S1:12539:7	tanzeum	NNP	O	O
than	TANZEUM.xml:S1:12547:4	than	IN	O	O
for	TANZEUM.xml:S1:12552:3	for	IN	O	O
all	TANZEUM.xml:S1:12556:3	all	DT	O	O
comparators	TANZEUM.xml:S1:12560:11	compar	NNS	O	O
(	TANZEUM.xml:S1:12572:1	(	(	O	O
0.5%	TANZEUM.xml:S1:12573:4	0.5%	CD	O	O
and	TANZEUM.xml:S1:12578:3	and	CC	O	O
0%	TANZEUM.xml:S1:12582:2	0%	CD	O	O
,	TANZEUM.xml:S1:12584:1	,	,	O	O
respectively	TANZEUM.xml:S1:12586:12	respect	RB	O	O
)	TANZEUM.xml:S1:12598:1	)	)	O	O
.	TANZEUM.xml:S1:12599:1	.	.	O	O

In	TANZEUM.xml:S1:12601:2	In	IN	O	O
both	TANZEUM.xml:S1:12604:4	both	DT	O	O
groups	TANZEUM.xml:S1:12609:6	group	NNS	O	O
,	TANZEUM.xml:S1:12615:1	,	,	O	O
patients	TANZEUM.xml:S1:12617:8	patient	NNS	O	O
with	TANZEUM.xml:S1:12626:4	with	IN	O	O
events	TANZEUM.xml:S1:12631:6	event	NNS	O	O
were	TANZEUM.xml:S1:12638:4	were	VBD	O	O
generally	TANZEUM.xml:S1:12643:9	gener	RB	O	O
male	TANZEUM.xml:S1:12653:4	male	JJ	O	O
,	TANZEUM.xml:S1:12657:1	,	,	O	O
older	TANZEUM.xml:S1:12659:5	older	JJR	O	O
,	TANZEUM.xml:S1:12664:1	,	,	O	O
and	TANZEUM.xml:S1:12666:3	and	CC	O	O
had	TANZEUM.xml:S1:12670:3	had	VBD	O	O
underlying	TANZEUM.xml:S1:12674:10	underli	JJ	O	O
renal	TANZEUM.xml:S1:12685:5	renal	JJ	O	O
impairment	TANZEUM.xml:S1:12691:10	impair	NN	O	O
or	TANZEUM.xml:S1:12702:2	or	CC	O	O
cardiac	TANZEUM.xml:S1:12705:7	cardiac	JJ	O	O
disease	TANZEUM.xml:S1:12713:7	diseas	NN	O	O
(	TANZEUM.xml:S1:12721:1	(	(	O	O
e	TANZEUM.xml:S1:12722:1	e	NN	O	O
.	TANZEUM.xml:S1:12723:1	.	.	O	O
g	TANZEUM.xml:S1:12724:1	g	NN	O	O
.	TANZEUM.xml:S1:12725:1	.	.	O	O
,	TANZEUM.xml:S1:12726:1	,	,	O	O
history	TANZEUM.xml:S1:12728:7	histori	NN	O	O
of	TANZEUM.xml:S1:12736:2	of	IN	O	O
arrhythmia	TANZEUM.xml:S1:12739:10	arrhythmia	NN	O	O
,	TANZEUM.xml:S1:12749:1	,	,	O	O
palpitations	TANZEUM.xml:S1:12751:12	palpit	NNS	O	B-AdverseReaction
,	TANZEUM.xml:S1:12763:1	,	,	O	O
congestive	TANZEUM.xml:S1:12765:10	congest	JJ	O	B-AdverseReaction
heart	TANZEUM.xml:S1:12776:5	heart	NN	O	I-AdverseReaction
failure	TANZEUM.xml:S1:12782:7	failur	NN	O	I-AdverseReaction
,	TANZEUM.xml:S1:12789:1	,	,	O	O
cardiomyopathy	TANZEUM.xml:S1:12791:14	cardiomyopathi	NN	O	O
,	TANZEUM.xml:S1:12805:1	,	,	O	O
etc	TANZEUM.xml:S1:12807:3	etc	FW	O	O
.	TANZEUM.xml:S1:12810:1	.	.	O	O

)	TANZEUM.xml:S1:12811:1	)	)	O	O
.	TANZEUM.xml:S1:12812:1	.	.	O	O

Appendicitis	TANZEUM.xml:S1:12820:12	append	NN	O	O

In	TANZEUM.xml:S1:12839:2	In	IN	O	O
the	TANZEUM.xml:S1:12842:3	the	DT	O	O
pool	TANZEUM.xml:S1:12846:4	pool	NN	O	O
of	TANZEUM.xml:S1:12851:2	of	IN	O	O
placebo	TANZEUM.xml:S1:12854:7	placebo	NN	O	O
-	TANZEUM.xml:S1:12861:1	-	:	O	O
and	TANZEUM.xml:S1:12863:3	and	CC	O	O
active	TANZEUM.xml:S1:12867:6	activ	JJ	O	O
-	TANZEUM.xml:S1:12873:1	-	:	O	O
controlled	TANZEUM.xml:S1:12874:10	control	VBN	O	O
trials	TANZEUM.xml:S1:12885:6	trial	NNS	O	O
,	TANZEUM.xml:S1:12891:1	,	,	O	O
serious	TANZEUM.xml:S1:12893:7	seriou	JJ	O	O
events	TANZEUM.xml:S1:12901:6	event	NNS	O	O
of	TANZEUM.xml:S1:12908:2	of	IN	O	O
appendicitis	TANZEUM.xml:S1:12911:12	append	NN	B-AdverseReaction	B-AdverseReaction
occurred	TANZEUM.xml:S1:12924:8	occur	VBD	O	O
in	TANZEUM.xml:S1:12933:2	in	IN	O	O
0.3%	TANZEUM.xml:S1:12936:4	0.3%	CD	O	O
of	TANZEUM.xml:S1:12941:2	of	IN	O	O
patients	TANZEUM.xml:S1:12944:8	patient	NNS	O	O
treated	TANZEUM.xml:S1:12953:7	treat	VBN	O	O
with	TANZEUM.xml:S1:12961:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S1:12966:7	tanzeum	NNP	O	O
compared	TANZEUM.xml:S1:12974:8	compar	VBN	O	O
with	TANZEUM.xml:S1:12983:4	with	IN	O	O
0%	TANZEUM.xml:S1:12988:2	0%	CD	O	O
among	TANZEUM.xml:S1:12991:5	among	IN	O	O
all	TANZEUM.xml:S1:12997:3	all	DT	O	O
comparators	TANZEUM.xml:S1:13001:11	compar	NNS	O	O
.	TANZEUM.xml:S1:13012:1	.	.	O	O

Immunogenicity	TANZEUM.xml:S1:13020:14	immunogen	NN	O	O

In	TANZEUM.xml:S1:13041:2	In	IN	O	O
the	TANZEUM.xml:S1:13044:3	the	DT	O	O
pool	TANZEUM.xml:S1:13048:4	pool	NN	O	O
of	TANZEUM.xml:S1:13053:2	of	IN	O	O
7	TANZEUM.xml:S1:13056:1	7	CD	O	O
placebo	TANZEUM.xml:S1:13058:7	placebo	NN	O	O
-	TANZEUM.xml:S1:13065:1	-	:	O	O
and	TANZEUM.xml:S1:13067:3	and	CC	O	O
active	TANZEUM.xml:S1:13071:6	activ	JJ	O	O
-	TANZEUM.xml:S1:13077:1	-	:	O	O
controlled	TANZEUM.xml:S1:13078:10	control	VBN	O	O
trials	TANZEUM.xml:S1:13089:6	trial	NNS	O	O
,	TANZEUM.xml:S1:13095:1	,	,	O	O
116	TANZEUM.xml:S1:13097:3	116	CD	O	O
(	TANZEUM.xml:S1:13101:1	(	(	O	O
5.5%	TANZEUM.xml:S1:13102:4	5.5%	CD	O	O
)	TANZEUM.xml:S1:13106:1	)	)	O	O
of	TANZEUM.xml:S1:13108:2	of	IN	O	O
2	TANZEUM.xml:S1:13111:1	2	CD	O	O
,	TANZEUM.xml:S1:13112:1	,	,	O	O
098	TANZEUM.xml:S1:13113:3	098	CD	O	O
patients	TANZEUM.xml:S1:13117:8	patient	NNS	O	O
exposed	TANZEUM.xml:S1:13126:7	expos	VBN	O	O
to	TANZEUM.xml:S1:13134:2	to	TO	O	O
TANZEUM	TANZEUM.xml:S1:13137:7	tanzeum	NNP	O	O
tested	TANZEUM.xml:S1:13145:6	test	VBD	O	O
positive	TANZEUM.xml:S1:13152:8	posit	JJ	O	O
for	TANZEUM.xml:S1:13161:3	for	IN	O	O
anti	TANZEUM.xml:S1:13165:4	anti	JJ	O	O
-	TANZEUM.xml:S1:13169:1	-	:	O	O
albiglutide	TANZEUM.xml:S1:13170:11	albiglutid	NN	O	O
antibodies	TANZEUM.xml:S1:13182:10	antibodi	NNS	O	O
at	TANZEUM.xml:S1:13193:2	at	IN	O	O
any	TANZEUM.xml:S1:13196:3	ani	DT	O	O
time	TANZEUM.xml:S1:13200:4	time	NN	O	O
during	TANZEUM.xml:S1:13205:6	dure	IN	O	O
the	TANZEUM.xml:S1:13212:3	the	DT	O	O
trials	TANZEUM.xml:S1:13216:6	trial	NNS	O	O
.	TANZEUM.xml:S1:13222:1	.	.	O	O

None	TANZEUM.xml:S1:13224:4	none	NN	O	O
of	TANZEUM.xml:S1:13229:2	of	IN	O	O
these	TANZEUM.xml:S1:13232:5	these	DT	O	O
antibodies	TANZEUM.xml:S1:13238:10	antibodi	NNS	O	O
were	TANZEUM.xml:S1:13249:4	were	VBD	O	O
shown	TANZEUM.xml:S1:13254:5	shown	VBN	O	O
to	TANZEUM.xml:S1:13260:2	to	TO	O	O
neutralize	TANZEUM.xml:S1:13263:10	neutral	VB	O	O
the	TANZEUM.xml:S1:13274:3	the	DT	O	O
activity	TANZEUM.xml:S1:13278:8	activ	NN	O	O
of	TANZEUM.xml:S1:13287:2	of	IN	O	O
albiglutide	TANZEUM.xml:S1:13290:11	albiglutid	NN	O	O
in	TANZEUM.xml:S1:13302:2	in	IN	O	O
an	TANZEUM.xml:S1:13305:2	an	DT	O	O
in	TANZEUM.xml:S1:13308:2	in	IN	O	O
vitro	TANZEUM.xml:S1:13311:5	vitro	NN	O	O
bioassay	TANZEUM.xml:S1:13317:8	bioassay	NN	O	O
.	TANZEUM.xml:S1:13325:1	.	.	O	O

Presence	TANZEUM.xml:S1:13327:8	presenc	NN	O	O
of	TANZEUM.xml:S1:13336:2	of	IN	O	O
antibody	TANZEUM.xml:S1:13339:8	antibodi	NN	O	O
did	TANZEUM.xml:S1:13348:3	did	VBD	O	O
not	TANZEUM.xml:S1:13352:3	not	RB	O	O
correlate	TANZEUM.xml:S1:13356:9	correl	VB	O	O
with	TANZEUM.xml:S1:13366:4	with	IN	O	O
reduced	TANZEUM.xml:S1:13371:7	reduc	JJ	O	O
efficacy	TANZEUM.xml:S1:13379:8	efficaci	NN	O	O
as	TANZEUM.xml:S1:13388:2	as	IN	O	O
measured	TANZEUM.xml:S1:13391:8	measur	VBN	O	O
by	TANZEUM.xml:S1:13400:2	by	IN	O	O
HbA1c	TANZEUM.xml:S1:13403:5	hba1c	NNP	O	O
and	TANZEUM.xml:S1:13409:3	and	CC	O	O
fasting	TANZEUM.xml:S1:13413:7	fast	VBG	O	O
plasma	TANZEUM.xml:S1:13421:6	plasma	NN	O	O
glucose	TANZEUM.xml:S1:13428:7	glucos	NN	O	O
or	TANZEUM.xml:S1:13436:2	or	CC	O	O
specific	TANZEUM.xml:S1:13439:8	specif	JJ	O	O
adverse	TANZEUM.xml:S1:13448:7	advers	JJ	O	O
reactions	TANZEUM.xml:S1:13456:9	reaction	NNS	O	O
.	TANZEUM.xml:S1:13465:1	.	.	O	O

Consistent	TANZEUM.xml:S1:13471:10	consist	JJ	O	O
with	TANZEUM.xml:S1:13482:4	with	IN	O	O
the	TANZEUM.xml:S1:13487:3	the	DT	O	O
high	TANZEUM.xml:S1:13491:4	high	JJ	O	O
homology	TANZEUM.xml:S1:13496:8	homolog	NN	O	O
of	TANZEUM.xml:S1:13505:2	of	IN	O	O
albiglutide	TANZEUM.xml:S1:13508:11	albiglutid	NN	O	O
with	TANZEUM.xml:S1:13520:4	with	IN	O	O
human	TANZEUM.xml:S1:13525:5	human	JJ	O	O
GLP	TANZEUM.xml:S1:13531:3	glp	NNP	O	O
-	TANZEUM.xml:S1:13534:1	-	:	O	O
1	TANZEUM.xml:S1:13535:1	1	CD	O	O
,	TANZEUM.xml:S1:13536:1	,	,	O	O
the	TANZEUM.xml:S1:13538:3	the	DT	O	O
majority	TANZEUM.xml:S1:13542:8	major	NN	O	O
of	TANZEUM.xml:S1:13551:2	of	IN	O	O
patients	TANZEUM.xml:S1:13554:8	patient	NNS	O	O
(	TANZEUM.xml:S1:13563:1	(	(	O	O
approximately	TANZEUM.xml:S1:13564:13	approxim	RB	O	O
79%	TANZEUM.xml:S1:13578:3	79%	CD	O	O
)	TANZEUM.xml:S1:13581:1	)	)	O	O
with	TANZEUM.xml:S1:13583:4	with	IN	O	O
anti	TANZEUM.xml:S1:13588:4	anti	JJ	O	O
-	TANZEUM.xml:S1:13592:1	-	:	O	O
albiglutide	TANZEUM.xml:S1:13593:11	albiglutid	NN	O	O
antibodies	TANZEUM.xml:S1:13605:10	antibodi	NNS	O	O
also	TANZEUM.xml:S1:13616:4	also	RB	O	O
tested	TANZEUM.xml:S1:13621:6	test	VBD	O	O
positive	TANZEUM.xml:S1:13628:8	posit	JJ	O	O
for	TANZEUM.xml:S1:13637:3	for	IN	O	O
anti	TANZEUM.xml:S1:13641:4	anti	JJ	O	O
-	TANZEUM.xml:S1:13645:1	-	:	O	O
GLP	TANZEUM.xml:S1:13646:3	glp	NNP	O	O
-	TANZEUM.xml:S1:13649:1	-	:	O	O
1	TANZEUM.xml:S1:13650:1	1	CD	O	O
antibodies	TANZEUM.xml:S1:13652:10	antibodi	NNS	O	O
;	TANZEUM.xml:S1:13662:1	;	:	O	O
none	TANZEUM.xml:S1:13664:4	none	NN	O	O
were	TANZEUM.xml:S1:13669:4	were	VBD	O	O
neutralizing	TANZEUM.xml:S1:13674:12	neutral	VBG	O	O
.	TANZEUM.xml:S1:13686:1	.	.	O	O

A	TANZEUM.xml:S1:13688:1	A	DT	O	O
minority	TANZEUM.xml:S1:13690:8	minor	NN	O	O
of	TANZEUM.xml:S1:13699:2	of	IN	O	O
patients	TANZEUM.xml:S1:13702:8	patient	NNS	O	O
(	TANZEUM.xml:S1:13711:1	(	(	O	O
approximately	TANZEUM.xml:S1:13712:13	approxim	RB	O	O
17%	TANZEUM.xml:S1:13726:3	17%	CD	O	O
)	TANZEUM.xml:S1:13729:1	)	)	O	O
who	TANZEUM.xml:S1:13731:3	who	WP	O	O
tested	TANZEUM.xml:S1:13735:6	test	VBD	O	O
positive	TANZEUM.xml:S1:13742:8	posit	JJ	O	O
for	TANZEUM.xml:S1:13751:3	for	IN	O	O
anti	TANZEUM.xml:S1:13755:4	anti	JJ	O	O
-	TANZEUM.xml:S1:13759:1	-	:	O	O
albiglutide	TANZEUM.xml:S1:13760:11	albiglutid	NN	O	O
antibodies	TANZEUM.xml:S1:13772:10	antibodi	NNS	O	O
also	TANZEUM.xml:S1:13783:4	also	RB	O	O
transiently	TANZEUM.xml:S1:13788:11	transient	RB	O	O
tested	TANZEUM.xml:S1:13800:6	test	VBN	O	O
positive	TANZEUM.xml:S1:13807:8	posit	JJ	O	O
for	TANZEUM.xml:S1:13816:3	for	IN	O	O
antibodies	TANZEUM.xml:S1:13820:10	antibodi	NNS	O	O
to	TANZEUM.xml:S1:13831:2	to	TO	O	O
human	TANZEUM.xml:S1:13834:5	human	JJ	O	O
albumin	TANZEUM.xml:S1:13840:7	albumin	NN	O	O
.	TANZEUM.xml:S1:13847:1	.	.	O	O

The	TANZEUM.xml:S1:13853:3	the	DT	O	O
detection	TANZEUM.xml:S1:13857:9	detect	NN	O	O
of	TANZEUM.xml:S1:13867:2	of	IN	O	O
antibody	TANZEUM.xml:S1:13870:8	antibodi	NN	O	O
formation	TANZEUM.xml:S1:13879:9	format	NN	O	O
is	TANZEUM.xml:S1:13889:2	is	VBZ	O	O
highly	TANZEUM.xml:S1:13892:6	highli	RB	O	O
dependent	TANZEUM.xml:S1:13899:9	depend	JJ	O	O
on	TANZEUM.xml:S1:13909:2	on	IN	O	O
the	TANZEUM.xml:S1:13912:3	the	DT	O	O
sensitivity	TANZEUM.xml:S1:13916:11	sensit	NN	O	O
and	TANZEUM.xml:S1:13928:3	and	CC	O	O
specificity	TANZEUM.xml:S1:13932:11	specif	NN	O	O
of	TANZEUM.xml:S1:13944:2	of	IN	O	O
the	TANZEUM.xml:S1:13947:3	the	DT	O	O
assay	TANZEUM.xml:S1:13951:5	assay	NN	O	O
.	TANZEUM.xml:S1:13956:1	.	.	O	O

Additionally	TANZEUM.xml:S1:13958:12	addit	RB	O	O
,	TANZEUM.xml:S1:13970:1	,	,	O	O
the	TANZEUM.xml:S1:13972:3	the	DT	O	O
observed	TANZEUM.xml:S1:13976:8	observ	JJ	O	O
incidence	TANZEUM.xml:S1:13985:9	incid	NN	O	O
of	TANZEUM.xml:S1:13995:2	of	IN	O	O
antibody	TANZEUM.xml:S1:13998:8	antibodi	NN	O	O
(	TANZEUM.xml:S1:14007:1	(	(	O	O
including	TANZEUM.xml:S1:14008:9	includ	VBG	O	O
neutralizing	TANZEUM.xml:S1:14018:12	neutral	VBG	O	O
antibody	TANZEUM.xml:S1:14031:8	antibodi	NN	O	O
)	TANZEUM.xml:S1:14039:1	)	)	O	O
positivity	TANZEUM.xml:S1:14041:10	posit	NN	O	O
in	TANZEUM.xml:S1:14052:2	in	IN	O	O
an	TANZEUM.xml:S1:14055:2	an	DT	O	O
assay	TANZEUM.xml:S1:14058:5	assay	NN	O	O
may	TANZEUM.xml:S1:14064:3	may	MD	O	O
be	TANZEUM.xml:S1:14068:2	be	VB	O	O
influenced	TANZEUM.xml:S1:14071:10	influenc	VBN	O	O
by	TANZEUM.xml:S1:14082:2	by	IN	O	O
several	TANZEUM.xml:S1:14085:7	sever	JJ	O	O
factors	TANZEUM.xml:S1:14093:7	factor	NNS	O	O
including	TANZEUM.xml:S1:14101:9	includ	VBG	O	O
assay	TANZEUM.xml:S1:14111:5	assay	JJ	O	O
methodology	TANZEUM.xml:S1:14117:11	methodolog	NN	O	O
,	TANZEUM.xml:S1:14128:1	,	,	O	O
sample	TANZEUM.xml:S1:14130:6	sampl	NN	O	O
handling	TANZEUM.xml:S1:14137:8	handl	NN	O	O
,	TANZEUM.xml:S1:14145:1	,	,	O	O
timing	TANZEUM.xml:S1:14147:6	time	NN	O	O
of	TANZEUM.xml:S1:14154:2	of	IN	O	O
sample	TANZEUM.xml:S1:14157:6	sampl	JJ	O	O
collection	TANZEUM.xml:S1:14164:10	collect	NN	O	O
,	TANZEUM.xml:S1:14174:1	,	,	O	O
concomitant	TANZEUM.xml:S1:14176:11	concomit	JJ	O	O
medications	TANZEUM.xml:S1:14188:11	medic	NNS	O	O
,	TANZEUM.xml:S1:14199:1	,	,	O	O
and	TANZEUM.xml:S1:14201:3	and	CC	O	O
underlying	TANZEUM.xml:S1:14205:10	underli	JJ	O	O
disease	TANZEUM.xml:S1:14216:7	diseas	NN	O	O
.	TANZEUM.xml:S1:14223:1	.	.	O	O

For	TANZEUM.xml:S1:14225:3	for	IN	O	O
these	TANZEUM.xml:S1:14229:5	these	DT	O	O
reasons	TANZEUM.xml:S1:14235:7	reason	NNS	O	O
,	TANZEUM.xml:S1:14242:1	,	,	O	O
the	TANZEUM.xml:S1:14244:3	the	DT	O	O
incidence	TANZEUM.xml:S1:14248:9	incid	NN	O	O
of	TANZEUM.xml:S1:14258:2	of	IN	O	O
antibodies	TANZEUM.xml:S1:14261:10	antibodi	NNS	O	O
to	TANZEUM.xml:S1:14272:2	to	TO	O	O
albiglutide	TANZEUM.xml:S1:14275:11	albiglutid	VB	O	O
cannot	TANZEUM.xml:S1:14287:6	cannot	NN	O	O
be	TANZEUM.xml:S1:14294:2	be	VB	O	O
directly	TANZEUM.xml:S1:14297:8	directli	RB	O	O
compared	TANZEUM.xml:S1:14306:8	compar	VBN	O	O
with	TANZEUM.xml:S1:14315:4	with	IN	O	O
the	TANZEUM.xml:S1:14320:3	the	DT	O	O
incidence	TANZEUM.xml:S1:14324:9	incid	NN	O	O
of	TANZEUM.xml:S1:14334:2	of	IN	O	O
antibodies	TANZEUM.xml:S1:14337:10	antibodi	NNS	O	O
of	TANZEUM.xml:S1:14348:2	of	IN	O	O
other	TANZEUM.xml:S1:14351:5	other	JJ	O	O
products	TANZEUM.xml:S1:14357:8	product	NNS	O	O
.	TANZEUM.xml:S1:14365:1	.	.	O	O

Liver	TANZEUM.xml:S1:14373:5	liver	NNP	O	O
Enzyme	TANZEUM.xml:S1:14379:6	enzym	NNP	O	O
Abnormalities	TANZEUM.xml:S1:14386:13	abnorm	NNP	O	O

In	TANZEUM.xml:S1:14406:2	In	IN	O	O
the	TANZEUM.xml:S1:14409:3	the	DT	O	O
pool	TANZEUM.xml:S1:14413:4	pool	NN	O	O
of	TANZEUM.xml:S1:14418:2	of	IN	O	O
placebo	TANZEUM.xml:S1:14421:7	placebo	NN	O	O
-	TANZEUM.xml:S1:14428:1	-	:	O	O
and	TANZEUM.xml:S1:14430:3	and	CC	O	O
active	TANZEUM.xml:S1:14434:6	activ	JJ	O	O
-	TANZEUM.xml:S1:14440:1	-	:	O	O
controlled	TANZEUM.xml:S1:14441:10	control	VBN	O	O
trials	TANZEUM.xml:S1:14452:6	trial	NNS	O	O
,	TANZEUM.xml:S1:14458:1	,	,	O	O
a	TANZEUM.xml:S1:14460:1	a	DT	O	O
similar	TANZEUM.xml:S1:14462:7	similar	JJ	O	O
proportion	TANZEUM.xml:S1:14470:10	proport	NN	O	O
of	TANZEUM.xml:S1:14481:2	of	IN	O	O
patients	TANZEUM.xml:S1:14484:8	patient	NNS	O	O
experienced	TANZEUM.xml:S1:14493:11	experienc	VBN	O	O
at	TANZEUM.xml:S1:14505:2	at	IN	O	O
least	TANZEUM.xml:S1:14508:5	least	JJS	O	O
one	TANZEUM.xml:S1:14514:3	one	CD	O	O
event	TANZEUM.xml:S1:14518:5	event	NN	O	O
of	TANZEUM.xml:S1:14524:2	of	IN	O	O
alanine	TANZEUM.xml:S1:14527:7	alanin	JJ	B-AdverseReaction	O
aminotransferase	TANZEUM.xml:S1:14535:16	aminotransferas	NN	I-AdverseReaction	O
(	TANZEUM.xml:S1:14552:1	(	(	O	O
ALT	TANZEUM.xml:S1:14553:3	alt	NNP	B-AdverseReaction	O
)	TANZEUM.xml:S1:14556:1	)	)	O	O
increase	TANZEUM.xml:S1:14558:8	increas	NN	I-AdverseReaction	I-AdverseReaction
of	TANZEUM.xml:S1:14567:2	of	IN	O	O
3	TANZEUM.xml:S1:14570:1	3	CD	O	O
-	TANZEUM.xml:S1:14571:1	-	:	O	O
fold	TANZEUM.xml:S1:14572:4	fold	NN	O	O
or	TANZEUM.xml:S1:14577:2	or	CC	O	O
greater	TANZEUM.xml:S1:14580:7	greater	JJR	O	O
above	TANZEUM.xml:S1:14588:5	abov	IN	O	O
the	TANZEUM.xml:S1:14594:3	the	DT	O	O
upper	TANZEUM.xml:S1:14598:5	upper	JJ	O	O
limit	TANZEUM.xml:S1:14604:5	limit	NN	O	O
of	TANZEUM.xml:S1:14610:2	of	IN	O	O
normal	TANZEUM.xml:S1:14613:6	normal	JJ	O	O
(	TANZEUM.xml:S1:14620:1	(	(	O	O
0.9%	TANZEUM.xml:S1:14621:4	0.9%	CD	O	O
and	TANZEUM.xml:S1:14626:3	and	CC	O	O
0.9%	TANZEUM.xml:S1:14630:4	0.9%	CD	O	O
for	TANZEUM.xml:S1:14635:3	for	IN	O	O
all	TANZEUM.xml:S1:14639:3	all	DT	O	O
comparators	TANZEUM.xml:S1:14643:11	compar	NNS	O	O
versus	TANZEUM.xml:S1:14655:6	versu	VBP	O	O
TANZEUM	TANZEUM.xml:S1:14662:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:14669:1	)	)	O	O
.	TANZEUM.xml:S1:14670:1	.	.	O	O

Three	TANZEUM.xml:S1:14672:5	three	CD	O	O
subjects	TANZEUM.xml:S1:14678:8	subject	NNS	O	O
on	TANZEUM.xml:S1:14687:2	on	IN	O	O
TANZEUM	TANZEUM.xml:S1:14690:7	tanzeum	NNP	O	O
and	TANZEUM.xml:S1:14698:3	and	CC	O	O
one	TANZEUM.xml:S1:14702:3	one	CD	O	O
subject	TANZEUM.xml:S1:14706:7	subject	NN	O	O
in	TANZEUM.xml:S1:14714:2	in	IN	O	O
the	TANZEUM.xml:S1:14717:3	the	DT	O	O
all	TANZEUM.xml:S1:14721:3	all	DT	O	O
-	TANZEUM.xml:S1:14724:1	-	:	O	O
comparator	TANZEUM.xml:S1:14725:10	compar	NN	O	O
group	TANZEUM.xml:S1:14736:5	group	NN	O	O
experienced	TANZEUM.xml:S1:14742:11	experienc	VBD	O	O
at	TANZEUM.xml:S1:14754:2	at	IN	O	O
least	TANZEUM.xml:S1:14757:5	least	JJS	O	O
one	TANZEUM.xml:S1:14763:3	one	CD	O	O
event	TANZEUM.xml:S1:14767:5	event	NN	O	O
of	TANZEUM.xml:S1:14773:2	of	IN	O	O
ALT	TANZEUM.xml:S1:14776:3	alt	NNP	B-AdverseReaction	B-AdverseReaction
increase	TANZEUM.xml:S1:14780:8	increas	NN	I-AdverseReaction	I-AdverseReaction
of	TANZEUM.xml:S1:14789:2	of	IN	O	O
10	TANZEUM.xml:S1:14792:2	10	CD	O	O
-	TANZEUM.xml:S1:14794:1	-	:	O	O
fold	TANZEUM.xml:S1:14795:4	fold	NN	O	O
or	TANZEUM.xml:S1:14800:2	or	CC	O	O
greater	TANZEUM.xml:S1:14803:7	greater	JJR	O	O
above	TANZEUM.xml:S1:14811:5	abov	IN	O	O
the	TANZEUM.xml:S1:14817:3	the	DT	O	O
upper	TANZEUM.xml:S1:14821:5	upper	JJ	O	O
limit	TANZEUM.xml:S1:14827:5	limit	NN	O	O
of	TANZEUM.xml:S1:14833:2	of	IN	O	O
normal	TANZEUM.xml:S1:14836:6	normal	JJ	O	O
.	TANZEUM.xml:S1:14844:1	.	.	O	O

In	TANZEUM.xml:S1:14847:2	In	IN	O	O
one	TANZEUM.xml:S1:14850:3	one	CD	O	O
of	TANZEUM.xml:S1:14854:2	of	IN	O	O
the	TANZEUM.xml:S1:14857:3	the	DT	O	O
3	TANZEUM.xml:S1:14861:1	3	CD	O	O
cases	TANZEUM.xml:S1:14863:5	case	NNS	O	O
an	TANZEUM.xml:S1:14869:2	an	DT	O	O
alternate	TANZEUM.xml:S1:14872:9	altern	NN	O	O
etiology	TANZEUM.xml:S1:14882:8	etiolog	NN	O	O
was	TANZEUM.xml:S1:14891:3	wa	VBD	O	O
identified	TANZEUM.xml:S1:14895:10	identifi	VBN	O	O
to	TANZEUM.xml:S1:14906:2	to	TO	O	O
explain	TANZEUM.xml:S1:14909:7	explain	VB	O	O
the	TANZEUM.xml:S1:14917:3	the	DT	O	O
rise	TANZEUM.xml:S1:14921:4	rise	NN	B-AdverseReaction	O
in	TANZEUM.xml:S1:14926:2	in	IN	I-AdverseReaction	O
liver	TANZEUM.xml:S1:14929:5	liver	NN	I-AdverseReaction	O
enzyme	TANZEUM.xml:S1:14935:6	enzym	NN	I-AdverseReaction	O
(	TANZEUM.xml:S1:14942:1	(	(	O	O
acute	TANZEUM.xml:S1:14943:5	acut	JJ	O	B-AdverseReaction
viral	TANZEUM.xml:S1:14949:5	viral	JJ	O	I-AdverseReaction
hepatitis	TANZEUM.xml:S1:14955:9	hepat	NN	O	I-AdverseReaction
)	TANZEUM.xml:S1:14964:1	)	)	O	O
.	TANZEUM.xml:S1:14965:1	.	.	O	O

In	TANZEUM.xml:S1:14967:2	In	IN	O	O
one	TANZEUM.xml:S1:14970:3	one	CD	O	O
case	TANZEUM.xml:S1:14974:4	case	NN	O	O
,	TANZEUM.xml:S1:14978:1	,	,	O	O
insufficient	TANZEUM.xml:S1:14980:12	insuffici	JJ	O	B-AdverseReaction
information	TANZEUM.xml:S1:14993:11	inform	NN	O	I-AdverseReaction
was	TANZEUM.xml:S1:15005:3	wa	VBD	O	O
obtained	TANZEUM.xml:S1:15009:8	obtain	VBN	O	O
to	TANZEUM.xml:S1:15018:2	to	TO	O	O
establish	TANZEUM.xml:S1:15021:9	establish	VB	O	O
or	TANZEUM.xml:S1:15031:2	or	CC	O	O
refute	TANZEUM.xml:S1:15034:6	refut	VB	O	O
a	TANZEUM.xml:S1:15041:1	a	DT	O	O
drug	TANZEUM.xml:S1:15043:4	drug	NN	O	O
-	TANZEUM.xml:S1:15047:1	-	:	O	O
related	TANZEUM.xml:S1:15048:7	relat	JJ	O	O
causality	TANZEUM.xml:S1:15056:9	causal	NN	O	O
.	TANZEUM.xml:S1:15065:1	.	.	O	O

In	TANZEUM.xml:S1:15067:2	In	IN	O	O
the	TANZEUM.xml:S1:15070:3	the	DT	O	O
third	TANZEUM.xml:S1:15074:5	third	JJ	O	O
case	TANZEUM.xml:S1:15080:4	case	NN	O	O
,	TANZEUM.xml:S1:15084:1	,	,	O	O
elevation	TANZEUM.xml:S1:15086:9	elev	NN	B-AdverseReaction	B-AdverseReaction
in	TANZEUM.xml:S1:15096:2	in	IN	I-AdverseReaction	I-AdverseReaction
ALT	TANZEUM.xml:S1:15099:3	alt	NNP	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S1:15103:1	(	(	O	O
10	TANZEUM.xml:S1:15104:2	10	CD	O	O
times	TANZEUM.xml:S1:15107:5	time	NNS	O	O
the	TANZEUM.xml:S1:15113:3	the	DT	O	O
upper	TANZEUM.xml:S1:15117:5	upper	JJ	O	O
limit	TANZEUM.xml:S1:15123:5	limit	NN	O	O
of	TANZEUM.xml:S1:15129:2	of	IN	O	O
normal	TANZEUM.xml:S1:15132:6	normal	JJ	O	O
)	TANZEUM.xml:S1:15138:1	)	)	O	O
was	TANZEUM.xml:S1:15140:3	wa	VBD	O	O
accompanied	TANZEUM.xml:S1:15144:11	accompani	VBN	O	O
by	TANZEUM.xml:S1:15156:2	by	IN	O	O
an	TANZEUM.xml:S1:15159:2	an	DT	O	O
increase	TANZEUM.xml:S1:15162:8	increas	NN	B-AdverseReaction	O
in	TANZEUM.xml:S1:15171:2	in	IN	I-AdverseReaction	O
total	TANZEUM.xml:S1:15174:5	total	JJ	I-AdverseReaction	O
bilirubin	TANZEUM.xml:S1:15180:9	bilirubin	NN	I-AdverseReaction	O
(	TANZEUM.xml:S1:15190:1	(	(	O	O
4	TANZEUM.xml:S1:15191:1	4	CD	O	O
times	TANZEUM.xml:S1:15193:5	time	NNS	O	O
the	TANZEUM.xml:S1:15199:3	the	DT	O	O
upper	TANZEUM.xml:S1:15203:5	upper	JJ	O	O
limit	TANZEUM.xml:S1:15209:5	limit	NN	O	O
of	TANZEUM.xml:S1:15215:2	of	IN	O	O
normal	TANZEUM.xml:S1:15218:6	normal	JJ	O	O
)	TANZEUM.xml:S1:15224:1	)	)	O	O
and	TANZEUM.xml:S1:15226:3	and	CC	O	O
occurred	TANZEUM.xml:S1:15230:8	occur	VBD	O	O
8	TANZEUM.xml:S1:15239:1	8	CD	O	O
days	TANZEUM.xml:S1:15241:4	day	NNS	O	O
after	TANZEUM.xml:S1:15246:5	after	IN	O	O
the	TANZEUM.xml:S1:15252:3	the	DT	O	O
first	TANZEUM.xml:S1:15256:5	first	JJ	O	O
dose	TANZEUM.xml:S1:15262:4	dose	NN	O	O
of	TANZEUM.xml:S1:15267:2	of	IN	O	O
TANZEUM	TANZEUM.xml:S1:15270:7	tanzeum	NNP	O	O
.	TANZEUM.xml:S1:15277:1	.	.	O	O

The	TANZEUM.xml:S1:15279:3	the	DT	O	O
etiology	TANZEUM.xml:S1:15283:8	etiolog	NN	O	O
of	TANZEUM.xml:S1:15292:2	of	IN	O	O
hepatocellular	TANZEUM.xml:S1:15295:14	hepatocellular	JJ	B-AdverseReaction	O
injury	TANZEUM.xml:S1:15310:6	injuri	NN	I-AdverseReaction	O
was	TANZEUM.xml:S1:15317:3	wa	VBD	O	O
possibly	TANZEUM.xml:S1:15321:8	possibl	RB	O	O
related	TANZEUM.xml:S1:15330:7	relat	VBN	O	O
to	TANZEUM.xml:S1:15338:2	to	TO	O	O
TANZEUM	TANZEUM.xml:S1:15341:7	tanzeum	NNP	O	O
but	TANZEUM.xml:S1:15349:3	but	CC	O	O
direct	TANZEUM.xml:S1:15353:6	direct	JJ	O	O
attribution	TANZEUM.xml:S1:15360:11	attribut	NN	O	O
to	TANZEUM.xml:S1:15372:2	to	TO	O	O
TANZEUM	TANZEUM.xml:S1:15375:7	tanzeum	NNP	O	O
was	TANZEUM.xml:S1:15383:3	wa	VBD	O	O
confounded	TANZEUM.xml:S1:15387:10	confound	VBN	O	O
by	TANZEUM.xml:S1:15398:2	by	IN	O	O
the	TANZEUM.xml:S1:15401:3	the	DT	O	O
presence	TANZEUM.xml:S1:15405:8	presenc	NN	O	O
of	TANZEUM.xml:S1:15414:2	of	IN	O	O
gallstone	TANZEUM.xml:S1:15417:9	gallston	NN	O	O
disease	TANZEUM.xml:S1:15427:7	diseas	NN	O	O
diagnosed	TANZEUM.xml:S1:15435:9	diagnos	VBD	O	O
on	TANZEUM.xml:S1:15445:2	on	IN	O	O
ultrasound	TANZEUM.xml:S1:15448:10	ultrasound	IN	O	O
3	TANZEUM.xml:S1:15459:1	3	CD	O	O
weeks	TANZEUM.xml:S1:15461:5	week	NNS	O	O
after	TANZEUM.xml:S1:15467:5	after	IN	O	O
the	TANZEUM.xml:S1:15473:3	the	DT	O	O
event	TANZEUM.xml:S1:15477:5	event	NN	O	O
.	TANZEUM.xml:S1:15484:1	.	.	O	O

Gamma	TANZEUM.xml:S1:15494:5	gamma	NNP	O	O
Glutamyltransferase	TANZEUM.xml:S1:15500:19	glutamyltransferas	NNP	O	O
(	TANZEUM.xml:S1:15520:1	(	(	O	O
GGT	TANZEUM.xml:S1:15521:3	ggt	NNP	O	O
)	TANZEUM.xml:S1:15524:1	)	)	O	O
Increase	TANZEUM.xml:S1:15526:8	increas	NN	O	O

In	TANZEUM.xml:S1:15541:2	In	IN	O	O
the	TANZEUM.xml:S1:15544:3	the	DT	O	O
pool	TANZEUM.xml:S1:15548:4	pool	NN	O	O
of	TANZEUM.xml:S1:15553:2	of	IN	O	O
placebo	TANZEUM.xml:S1:15556:7	placebo	NN	O	O
-	TANZEUM.xml:S1:15563:1	-	:	O	O
controlled	TANZEUM.xml:S1:15564:10	control	VBN	O	O
trials	TANZEUM.xml:S1:15575:6	trial	NNS	O	O
,	TANZEUM.xml:S1:15581:1	,	,	O	O
the	TANZEUM.xml:S1:15583:3	the	DT	O	O
adverse	TANZEUM.xml:S1:15587:7	advers	JJ	O	O
event	TANZEUM.xml:S1:15595:5	event	NN	O	O
of	TANZEUM.xml:S1:15601:2	of	IN	O	O
increased	TANZEUM.xml:S1:15604:9	increas	VBN	B-AdverseReaction	B-AdverseReaction
GGT	TANZEUM.xml:S1:15614:3	ggt	NNP	I-AdverseReaction	I-AdverseReaction
occurred	TANZEUM.xml:S1:15618:8	occur	VBD	O	O
more	TANZEUM.xml:S1:15627:4	more	RBR	O	O
frequently	TANZEUM.xml:S1:15632:10	frequent	RB	O	O
in	TANZEUM.xml:S1:15643:2	in	IN	O	O
the	TANZEUM.xml:S1:15646:3	the	DT	O	O
group	TANZEUM.xml:S1:15650:5	group	NN	O	O
treated	TANZEUM.xml:S1:15656:7	treat	VBD	O	O
with	TANZEUM.xml:S1:15664:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S1:15669:7	tanzeum	NNP	O	O
(	TANZEUM.xml:S1:15677:1	(	(	O	O
0.9%	TANZEUM.xml:S1:15678:4	0.9%	CD	O	O
and	TANZEUM.xml:S1:15683:3	and	CC	O	O
1.5%	TANZEUM.xml:S1:15687:4	1.5%	CD	O	O
for	TANZEUM.xml:S1:15692:3	for	IN	O	O
placebo	TANZEUM.xml:S1:15696:7	placebo	NN	O	O
versus	TANZEUM.xml:S1:15704:6	versu	NN	O	O
TANZEUM	TANZEUM.xml:S1:15711:7	tanzeum	NNP	O	O
)	TANZEUM.xml:S1:15718:1	)	)	O	O
.	TANZEUM.xml:S1:15719:1	.	.	O	O

Heart	TANZEUM.xml:S1:15727:5	heart	NNP	O	B-AdverseReaction
Rate	TANZEUM.xml:S1:15733:4	rate	NNP	O	I-AdverseReaction
Increase	TANZEUM.xml:S1:15738:8	increas	NNP	O	I-AdverseReaction

In	TANZEUM.xml:S1:15753:2	In	IN	O	O
the	TANZEUM.xml:S1:15756:3	the	DT	O	O
pool	TANZEUM.xml:S1:15760:4	pool	NN	O	O
of	TANZEUM.xml:S1:15765:2	of	IN	O	O
placebo	TANZEUM.xml:S1:15768:7	placebo	NN	O	O
-	TANZEUM.xml:S1:15775:1	-	:	O	O
controlled	TANZEUM.xml:S1:15776:10	control	VBN	O	O
trials	TANZEUM.xml:S1:15787:6	trial	NNS	O	O
,	TANZEUM.xml:S1:15793:1	,	,	O	O
mean	TANZEUM.xml:S1:15795:4	mean	JJ	B-AdverseReaction	O
heart	TANZEUM.xml:S1:15800:5	heart	NN	I-AdverseReaction	O
rate	TANZEUM.xml:S1:15806:4	rate	NN	I-AdverseReaction	O
in	TANZEUM.xml:S1:15811:2	in	IN	O	O
patients	TANZEUM.xml:S1:15814:8	patient	NNS	O	O
treated	TANZEUM.xml:S1:15823:7	treat	VBN	O	O
with	TANZEUM.xml:S1:15831:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S1:15836:7	tanzeum	NNP	O	O
was	TANZEUM.xml:S1:15844:3	wa	VBD	O	O
higher	TANZEUM.xml:S1:15848:6	higher	JJR	I-AdverseReaction	O
by	TANZEUM.xml:S1:15855:2	by	IN	I-AdverseReaction	O
an	TANZEUM.xml:S1:15858:2	an	DT	I-AdverseReaction	O
average	TANZEUM.xml:S1:15861:7	averag	NN	I-AdverseReaction	O
of	TANZEUM.xml:S1:15869:2	of	IN	I-AdverseReaction	O
1	TANZEUM.xml:S1:15872:1	1	CD	I-AdverseReaction	O
to	TANZEUM.xml:S1:15874:2	to	TO	I-AdverseReaction	O
2	TANZEUM.xml:S1:15877:1	2	CD	I-AdverseReaction	O
bpm	TANZEUM.xml:S1:15879:3	bpm	NNS	I-AdverseReaction	O
compared	TANZEUM.xml:S1:15883:8	compar	VBN	O	O
with	TANZEUM.xml:S1:15892:4	with	IN	O	O
mean	TANZEUM.xml:S1:15897:4	mean	JJ	O	O
heart	TANZEUM.xml:S1:15902:5	heart	NN	O	O
rate	TANZEUM.xml:S1:15908:4	rate	NN	O	O
in	TANZEUM.xml:S1:15913:2	in	IN	O	O
patients	TANZEUM.xml:S1:15916:8	patient	NNS	O	O
treated	TANZEUM.xml:S1:15925:7	treat	VBN	O	O
with	TANZEUM.xml:S1:15933:4	with	IN	O	O
placebo	TANZEUM.xml:S1:15938:7	placebo	NN	O	O
across	TANZEUM.xml:S1:15946:6	across	IN	O	O
study	TANZEUM.xml:S1:15953:5	studi	NN	O	O
visits	TANZEUM.xml:S1:15959:6	visit	NNS	O	O
.	TANZEUM.xml:S1:15965:1	.	.	O	O

The	TANZEUM.xml:S1:15967:3	the	DT	O	O
long	TANZEUM.xml:S1:15971:4	long	JJ	O	O
-	TANZEUM.xml:S1:15975:1	-	:	O	O
term	TANZEUM.xml:S1:15976:4	term	NN	O	O
clinical	TANZEUM.xml:S1:15981:8	clinic	JJ	O	O
effects	TANZEUM.xml:S1:15990:7	effect	NNS	O	O
of	TANZEUM.xml:S1:15998:2	of	IN	O	O
the	TANZEUM.xml:S1:16001:3	the	DT	O	O
increase	TANZEUM.xml:S1:16005:8	increas	NN	B-AdverseReaction	O
in	TANZEUM.xml:S1:16014:2	in	IN	I-AdverseReaction	O
heart	TANZEUM.xml:S1:16017:5	heart	NN	I-AdverseReaction	O
rate	TANZEUM.xml:S1:16023:4	rate	NN	I-AdverseReaction	O
have	TANZEUM.xml:S1:16028:4	have	VBP	O	O
not	TANZEUM.xml:S1:16033:3	not	RB	O	O
been	TANZEUM.xml:S1:16037:4	been	VBN	O	O
established	TANZEUM.xml:S1:16042:11	establish	VBN	O	O
[	TANZEUM.xml:S1:16055:1	[	NNP	O	O
see	TANZEUM.xml:S1:16056:3	see	VBP	O	O
Warnings	TANZEUM.xml:S1:16060:8	warn	NNP	O	O
and	TANZEUM.xml:S1:16069:3	and	CC	O	O
Precautions	TANZEUM.xml:S1:16073:11	precaut	NNP	O	O
(	TANZEUM.xml:S1:16085:1	(	(	O	O
5.6	TANZEUM.xml:S1:16086:3	5.6	CD	O	O
)]	TANZEUM.xml:S1:16089:2	)]	NN	O	O
.	TANZEUM.xml:S1:16093:1	.	.	O	O
\n\n	TANZEUM.xml:S2:0:2	\n\n	VB	O	O
BOXED	TANZEUM.xml:S2:6:5	box	NNP	O	O
WARNING	TANZEUM.xml:S2:12:7	warn	NNP	O	O
:	TANZEUM.xml:S2:19:1	:	:	O	O
WARNING	TANZEUM.xml:S2:21:7	warn	NN	O	O
:	TANZEUM.xml:S2:28:1	:	:	O	O
RISK	TANZEUM.xml:S2:30:4	risk	NN	O	O
OF	TANZEUM.xml:S2:35:2	OF	IN	O	O
THYROID	TANZEUM.xml:S2:38:7	thyroid	NNP	B-AdverseReaction	O
C	TANZEUM.xml:S2:46:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S2:47:1	-	:	I-AdverseReaction	O
CELL	TANZEUM.xml:S2:48:4	cell	NN	I-AdverseReaction	O
TUMORS	TANZEUM.xml:S2:53:6	tumor	NNP	I-AdverseReaction	B-AdverseReaction
\n\n	TANZEUM.xml:S2:59:2	\n\n	VBD	O	O
WARNING	TANZEUM.xml:S2:63:7	warn	NN	O	O
:	TANZEUM.xml:S2:70:1	:	:	O	O
RISK	TANZEUM.xml:S2:72:4	risk	NN	O	O
OF	TANZEUM.xml:S2:77:2	OF	IN	O	O
THYROID	TANZEUM.xml:S2:80:7	thyroid	NNP	B-AdverseReaction	O
C	TANZEUM.xml:S2:88:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S2:89:1	-	:	I-AdverseReaction	O
CELL	TANZEUM.xml:S2:90:4	cell	NN	I-AdverseReaction	O
TUMORS	TANZEUM.xml:S2:95:6	tumor	NNP	I-AdverseReaction	O
\n\n	TANZEUM.xml:S2:101:2	\n\n	NNP	O	O
Carcinogenicity	TANZEUM.xml:S2:110:15	carcinogen	NNP	O	O
of	TANZEUM.xml:S2:126:2	of	IN	O	O
albiglutide	TANZEUM.xml:S2:129:11	albiglutid	NN	O	O
could	TANZEUM.xml:S2:141:5	could	MD	O	O
not	TANZEUM.xml:S2:147:3	not	RB	O	O
be	TANZEUM.xml:S2:151:2	be	VB	O	O
assessed	TANZEUM.xml:S2:154:8	assess	VBN	O	O
in	TANZEUM.xml:S2:163:2	in	IN	O	O
rodents	TANZEUM.xml:S2:166:7	rodent	NNS	O	O
,	TANZEUM.xml:S2:173:1	,	,	O	O
but	TANZEUM.xml:S2:175:3	but	CC	O	O
other	TANZEUM.xml:S2:179:5	other	JJ	O	O
glucagon	TANZEUM.xml:S2:185:8	glucagon	NN	O	O
-	TANZEUM.xml:S2:193:1	-	:	O	O
like	TANZEUM.xml:S2:194:4	like	IN	O	O
peptide	TANZEUM.xml:S2:199:7	peptid	IN	O	O
-	TANZEUM.xml:S2:206:1	-	:	O	O
1	TANZEUM.xml:S2:207:1	1	CD	O	O
(	TANZEUM.xml:S2:209:1	(	(	O	O
GLP	TANZEUM.xml:S2:210:3	glp	NNP	O	O
-	TANZEUM.xml:S2:213:1	-	:	O	O
1	TANZEUM.xml:S2:214:1	1	CD	O	O
)	TANZEUM.xml:S2:215:1	)	)	O	O
receptor	TANZEUM.xml:S2:217:8	receptor	NN	O	O
agonists	TANZEUM.xml:S2:226:8	agonist	NNS	O	O
have	TANZEUM.xml:S2:235:4	have	VBP	O	O
caused	TANZEUM.xml:S2:240:6	caus	VBN	O	O
thyroid	TANZEUM.xml:S2:247:7	thyroid	JJ	B-AdverseReaction	O
C	TANZEUM.xml:S2:255:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S2:256:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S2:257:4	cell	NN	I-AdverseReaction	O
tumors	TANZEUM.xml:S2:262:6	tumor	NNS	I-AdverseReaction	O
in	TANZEUM.xml:S2:269:2	in	IN	O	O
rodents	TANZEUM.xml:S2:272:7	rodent	NNS	O	O
at	TANZEUM.xml:S2:280:2	at	IN	O	O
clinically	TANZEUM.xml:S2:283:10	clinic	RB	O	O
relevant	TANZEUM.xml:S2:294:8	relev	JJ	O	O
exposures	TANZEUM.xml:S2:303:9	exposur	NNS	O	O
.	TANZEUM.xml:S2:312:1	.	.	O	O

Human	TANZEUM.xml:S2:314:5	human	JJ	O	O
relevance	TANZEUM.xml:S2:320:9	relev	NN	O	O
of	TANZEUM.xml:S2:330:2	of	IN	O	O
GLP	TANZEUM.xml:S2:333:3	glp	NNP	O	O
-	TANZEUM.xml:S2:336:1	-	:	O	O
1	TANZEUM.xml:S2:337:1	1	CD	O	O
receptor	TANZEUM.xml:S2:339:8	receptor	NN	O	O
agonist	TANZEUM.xml:S2:348:7	agonist	NN	O	O
induced	TANZEUM.xml:S2:356:7	induc	VBD	O	O
C	TANZEUM.xml:S2:364:1	C	NNP	B-AdverseReaction	O
-	TANZEUM.xml:S2:365:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S2:366:4	cell	NN	I-AdverseReaction	O
tumors	TANZEUM.xml:S2:371:6	tumor	NNS	I-AdverseReaction	O
in	TANZEUM.xml:S2:378:2	in	IN	O	O
rodents	TANZEUM.xml:S2:381:7	rodent	NNS	O	O
has	TANZEUM.xml:S2:389:3	ha	VBZ	O	O
not	TANZEUM.xml:S2:393:3	not	RB	O	O
been	TANZEUM.xml:S2:397:4	been	VBN	O	O
determined	TANZEUM.xml:S2:402:10	determin	VBN	O	O
.	TANZEUM.xml:S2:412:1	.	.	O	O

It	TANZEUM.xml:S2:414:2	It	PRP	O	O
is	TANZEUM.xml:S2:417:2	is	VBZ	O	O
unknown	TANZEUM.xml:S2:420:7	unknown	JJ	O	O
whether	TANZEUM.xml:S2:428:7	whether	IN	O	O
TANZEUM	TANZEUM.xml:S2:436:7	tanzeum	NNP	O	O
(	TANZEUM.xml:S2:443:1	(	(	O	O
r	TANZEUM.xml:S2:444:1	r	NN	O	O
)	TANZEUM.xml:S2:445:1	)	)	O	O
causes	TANZEUM.xml:S2:447:6	caus	VBZ	O	O
thyroid	TANZEUM.xml:S2:454:7	thyroid	JJ	B-AdverseReaction	O
C	TANZEUM.xml:S2:462:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S2:463:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S2:464:4	cell	NN	I-AdverseReaction	O
tumors	TANZEUM.xml:S2:469:6	tumor	NNS	I-AdverseReaction	O
,	TANZEUM.xml:S2:475:1	,	,	O	O
including	TANZEUM.xml:S2:477:9	includ	VBG	O	O
medullary	TANZEUM.xml:S2:487:9	medullari	JJ	B-AdverseReaction	B-AdverseReaction
thyroid	TANZEUM.xml:S2:497:7	thyroid	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TANZEUM.xml:S2:505:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S2:515:1	(	(	O	O
MTC	TANZEUM.xml:S2:516:3	mtc	NNP	B-AdverseReaction	O
)	TANZEUM.xml:S2:519:1	)	)	O	O
,	TANZEUM.xml:S2:520:1	,	,	O	O
in	TANZEUM.xml:S2:522:2	in	IN	O	O
humans	TANZEUM.xml:S2:525:6	human	NNS	O	O
[	TANZEUM.xml:S2:532:1	[	JJ	O	O
see	TANZEUM.xml:S2:533:3	see	VBP	O	O
Warnings	TANZEUM.xml:S2:537:8	warn	NNS	O	O
and	TANZEUM.xml:S2:546:3	and	CC	O	O
Precautions	TANZEUM.xml:S2:550:11	precaut	NNP	O	O
(	TANZEUM.xml:S2:562:1	(	(	O	O
5.1	TANZEUM.xml:S2:563:3	5.1	CD	O	O
)	TANZEUM.xml:S2:566:1	)	)	O	O
,	TANZEUM.xml:S2:567:1	,	,	O	O
Nonclinical	TANZEUM.xml:S2:569:11	nonclin	NNP	O	O
Toxicology	TANZEUM.xml:S2:581:10	toxicolog	NNP	O	O
(	TANZEUM.xml:S2:592:1	(	(	O	O
13.1	TANZEUM.xml:S2:593:4	13.1	CD	O	O
)]	TANZEUM.xml:S2:597:2	)]	NN	O	O
.	TANZEUM.xml:S2:599:1	.	.	O	O

TANZEUM	TANZEUM.xml:S2:606:7	tanzeum	NNP	O	O
is	TANZEUM.xml:S2:614:2	is	VBZ	O	O
contraindicated	TANZEUM.xml:S2:617:15	contraind	VBN	O	O
in	TANZEUM.xml:S2:633:2	in	IN	O	O
patients	TANZEUM.xml:S2:636:8	patient	NNS	O	O
with	TANZEUM.xml:S2:645:4	with	IN	O	O
a	TANZEUM.xml:S2:650:1	a	DT	O	O
personal	TANZEUM.xml:S2:652:8	person	JJ	O	O
or	TANZEUM.xml:S2:661:2	or	CC	O	O
family	TANZEUM.xml:S2:664:6	famili	NN	O	O
history	TANZEUM.xml:S2:671:7	histori	NN	O	O
of	TANZEUM.xml:S2:679:2	of	IN	O	O
MTC	TANZEUM.xml:S2:682:3	mtc	NNP	O	O
or	TANZEUM.xml:S2:686:2	or	CC	O	O
in	TANZEUM.xml:S2:689:2	in	IN	O	O
patients	TANZEUM.xml:S2:692:8	patient	NNS	O	O
with	TANZEUM.xml:S2:701:4	with	IN	O	O
Multiple	TANZEUM.xml:S2:706:8	multipl	NNP	O	O
Endocrine	TANZEUM.xml:S2:715:9	endocrin	NNP	O	O
Neoplasia	TANZEUM.xml:S2:725:9	neoplasia	NNP	O	O
syndrome	TANZEUM.xml:S2:735:8	syndrom	VBD	O	O
type	TANZEUM.xml:S2:744:4	type	JJ	O	O
2	TANZEUM.xml:S2:749:1	2	CD	O	O
(	TANZEUM.xml:S2:751:1	(	(	O	O
MEN	TANZEUM.xml:S2:752:3	men	NNP	O	O
2	TANZEUM.xml:S2:756:1	2	CD	O	O
)	TANZEUM.xml:S2:757:1	)	)	O	O
.	TANZEUM.xml:S2:758:1	.	.	O	O

Counsel	TANZEUM.xml:S2:760:7	counsel	NNP	O	O
patients	TANZEUM.xml:S2:768:8	patient	NNS	O	O
regarding	TANZEUM.xml:S2:777:9	regard	VBG	O	O
the	TANZEUM.xml:S2:787:3	the	DT	O	O
potential	TANZEUM.xml:S2:791:9	potenti	JJ	O	O
risk	TANZEUM.xml:S2:801:4	risk	NN	O	O
of	TANZEUM.xml:S2:806:2	of	IN	O	O
MTC	TANZEUM.xml:S2:809:3	mtc	NNP	O	O
with	TANZEUM.xml:S2:813:4	with	IN	O	O
the	TANZEUM.xml:S2:818:3	the	DT	O	O
use	TANZEUM.xml:S2:822:3	use	NN	O	O
of	TANZEUM.xml:S2:826:2	of	IN	O	O
TANZEUM	TANZEUM.xml:S2:829:7	tanzeum	NNP	O	O
and	TANZEUM.xml:S2:837:3	and	CC	O	O
inform	TANZEUM.xml:S2:841:6	inform	VB	O	O
them	TANZEUM.xml:S2:848:4	them	PRP	O	O
of	TANZEUM.xml:S2:853:2	of	IN	O	O
the	TANZEUM.xml:S2:856:3	the	DT	O	O
symptoms	TANZEUM.xml:S2:860:8	symptom	NNS	O	O
of	TANZEUM.xml:S2:869:2	of	IN	O	O
thyroid	TANZEUM.xml:S2:872:7	thyroid	JJ	O	O
tumors	TANZEUM.xml:S2:880:6	tumor	NNS	O	O
(	TANZEUM.xml:S2:887:1	(	(	O	O
e	TANZEUM.xml:S2:888:1	e	NN	O	O
.	TANZEUM.xml:S2:889:1	.	.	O	O
g	TANZEUM.xml:S2:890:1	g	NN	O	O
.	TANZEUM.xml:S2:891:1	.	.	O	O
,	TANZEUM.xml:S2:892:1	,	,	O	O
mass	TANZEUM.xml:S2:894:4	mass	NN	O	O
in	TANZEUM.xml:S2:899:2	in	IN	O	O
the	TANZEUM.xml:S2:902:3	the	DT	O	O
neck	TANZEUM.xml:S2:906:4	neck	NN	O	O
,	TANZEUM.xml:S2:910:1	,	,	O	O
dysphagia	TANZEUM.xml:S2:912:9	dysphagia	NN	O	B-AdverseReaction
,	TANZEUM.xml:S2:921:1	,	,	O	O
dyspnea	TANZEUM.xml:S2:923:7	dyspnea	NN	O	B-AdverseReaction
,	TANZEUM.xml:S2:930:1	,	,	O	O
persistent	TANZEUM.xml:S2:932:10	persist	JJ	O	O
hoarseness	TANZEUM.xml:S2:943:10	hoars	NN	O	O
)	TANZEUM.xml:S2:953:1	)	)	O	O
.	TANZEUM.xml:S2:954:1	.	.	O	O

Routine	TANZEUM.xml:S2:956:7	routin	JJ	O	O
monitoring	TANZEUM.xml:S2:964:10	monitor	NN	O	O
of	TANZEUM.xml:S2:975:2	of	IN	O	O
serum	TANZEUM.xml:S2:978:5	serum	JJ	O	O
calcitonin	TANZEUM.xml:S2:984:10	calcitonin	NN	O	O
or	TANZEUM.xml:S2:995:2	or	CC	O	O
using	TANZEUM.xml:S2:998:5	use	VBG	O	O
thyroid	TANZEUM.xml:S2:1004:7	thyroid	JJ	O	O
ultrasound	TANZEUM.xml:S2:1012:10	ultrasound	JJ	O	O
monitoring	TANZEUM.xml:S2:1023:10	monitor	NN	O	O
is	TANZEUM.xml:S2:1034:2	is	VBZ	O	O
of	TANZEUM.xml:S2:1037:2	of	IN	O	O
uncertain	TANZEUM.xml:S2:1040:9	uncertain	JJ	O	O
value	TANZEUM.xml:S2:1050:5	valu	NN	O	O
for	TANZEUM.xml:S2:1056:3	for	IN	O	O
early	TANZEUM.xml:S2:1060:5	earli	JJ	O	O
detection	TANZEUM.xml:S2:1066:9	detect	NN	O	O
of	TANZEUM.xml:S2:1076:2	of	IN	O	O
MTC	TANZEUM.xml:S2:1079:3	mtc	NNP	O	O
in	TANZEUM.xml:S2:1083:2	in	IN	O	O
patients	TANZEUM.xml:S2:1086:8	patient	NNS	O	O
treated	TANZEUM.xml:S2:1095:7	treat	VBN	O	O
with	TANZEUM.xml:S2:1103:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S2:1108:7	tanzeum	NNP	O	O
[	TANZEUM.xml:S2:1116:1	[	NNP	O	O
see	TANZEUM.xml:S2:1117:3	see	VBP	O	O
Contraindications	TANZEUM.xml:S2:1121:17	contraind	NNP	O	O
(	TANZEUM.xml:S2:1139:1	(	(	O	O
4.1	TANZEUM.xml:S2:1140:3	4.1	CD	O	O
)	TANZEUM.xml:S2:1143:1	)	)	O	O
,	TANZEUM.xml:S2:1144:1	,	,	O	O
Warnings	TANZEUM.xml:S2:1146:8	warn	NNP	O	O
and	TANZEUM.xml:S2:1155:3	and	CC	O	O
Precautions	TANZEUM.xml:S2:1159:11	precaut	NNP	O	O
(	TANZEUM.xml:S2:1171:1	(	(	O	O
5.1	TANZEUM.xml:S2:1172:3	5.1	CD	O	O
)]	TANZEUM.xml:S2:1175:2	)]	NN	O	O
.	TANZEUM.xml:S2:1177:1	.	.	O	O

WARNING	TANZEUM.xml:S2:1186:7	warn	NN	O	O
:	TANZEUM.xml:S2:1193:1	:	:	O	O
RISK	TANZEUM.xml:S2:1195:4	risk	NN	O	O
OF	TANZEUM.xml:S2:1200:2	OF	IN	O	O
THYROID	TANZEUM.xml:S2:1203:7	thyroid	NNP	B-AdverseReaction	O
C	TANZEUM.xml:S2:1211:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S2:1212:1	-	:	I-AdverseReaction	O
CELL	TANZEUM.xml:S2:1213:4	cell	NN	I-AdverseReaction	O
TUMORS	TANZEUM.xml:S2:1218:6	tumor	NNP	I-AdverseReaction	O
\n	TANZEUM.xml:S2:1224:1	\n	NNP	O	O
\n\n	TANZEUM.xml:S2:1226:2	\n\n	NNP	O	O
See	TANZEUM.xml:S2:1231:3	see	NNP	O	O
full	TANZEUM.xml:S2:1235:4	full	JJ	O	O
prescribing	TANZEUM.xml:S2:1240:11	prescrib	VBG	O	O
information	TANZEUM.xml:S2:1252:11	inform	NN	O	O
for	TANZEUM.xml:S2:1264:3	for	IN	O	O
complete	TANZEUM.xml:S2:1268:8	complet	JJ	O	O
boxed	TANZEUM.xml:S2:1277:5	box	JJ	O	O
warning	TANZEUM.xml:S2:1283:7	warn	NN	O	O
.	TANZEUM.xml:S2:1290:1	.	.	O	O

Carcinogenicity	TANZEUM.xml:S2:1301:15	carcinogen	NN	O	O
of	TANZEUM.xml:S2:1317:2	of	IN	O	O
albiglutide	TANZEUM.xml:S2:1320:11	albiglutid	NN	O	O
could	TANZEUM.xml:S2:1332:5	could	MD	O	O
not	TANZEUM.xml:S2:1338:3	not	RB	O	O
be	TANZEUM.xml:S2:1342:2	be	VB	O	O
assessed	TANZEUM.xml:S2:1345:8	assess	VBN	O	O
in	TANZEUM.xml:S2:1354:2	in	IN	O	O
rodents	TANZEUM.xml:S2:1357:7	rodent	NNS	O	O
,	TANZEUM.xml:S2:1364:1	,	,	O	O
but	TANZEUM.xml:S2:1366:3	but	CC	O	O
other	TANZEUM.xml:S2:1370:5	other	JJ	O	O
glucagon	TANZEUM.xml:S2:1376:8	glucagon	NN	O	O
-	TANZEUM.xml:S2:1384:1	-	:	O	O
like	TANZEUM.xml:S2:1385:4	like	IN	O	O
peptide	TANZEUM.xml:S2:1390:7	peptid	IN	O	O
-	TANZEUM.xml:S2:1397:1	-	:	O	O
1	TANZEUM.xml:S2:1398:1	1	CD	O	O
(	TANZEUM.xml:S2:1400:1	(	(	O	O
GLP	TANZEUM.xml:S2:1401:3	glp	NNP	O	O
-	TANZEUM.xml:S2:1404:1	-	:	O	O
1	TANZEUM.xml:S2:1405:1	1	CD	O	O
)	TANZEUM.xml:S2:1406:1	)	)	O	O
receptor	TANZEUM.xml:S2:1408:8	receptor	NN	O	O
agonists	TANZEUM.xml:S2:1417:8	agonist	NNS	O	O
have	TANZEUM.xml:S2:1426:4	have	VBP	O	O
caused	TANZEUM.xml:S2:1431:6	caus	VBN	O	O
thyroid	TANZEUM.xml:S2:1438:7	thyroid	JJ	B-AdverseReaction	O
C	TANZEUM.xml:S2:1446:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S2:1447:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S2:1448:4	cell	NN	I-AdverseReaction	O
tumors	TANZEUM.xml:S2:1453:6	tumor	NNS	I-AdverseReaction	O
in	TANZEUM.xml:S2:1460:2	in	IN	O	O
rodents	TANZEUM.xml:S2:1463:7	rodent	NNS	O	O
at	TANZEUM.xml:S2:1471:2	at	IN	O	O
clinically	TANZEUM.xml:S2:1474:10	clinic	RB	O	O
relevant	TANZEUM.xml:S2:1485:8	relev	JJ	O	O
exposures	TANZEUM.xml:S2:1494:9	exposur	NNS	O	O
.	TANZEUM.xml:S2:1503:1	.	.	O	O

Human	TANZEUM.xml:S2:1505:5	human	JJ	O	O
relevance	TANZEUM.xml:S2:1511:9	relev	NN	O	O
of	TANZEUM.xml:S2:1521:2	of	IN	O	O
GLP	TANZEUM.xml:S2:1524:3	glp	NNP	O	O
-	TANZEUM.xml:S2:1527:1	-	:	O	O
1	TANZEUM.xml:S2:1528:1	1	CD	O	O
receptor	TANZEUM.xml:S2:1530:8	receptor	NN	O	O
agonist	TANZEUM.xml:S2:1539:7	agonist	NN	O	O
induced	TANZEUM.xml:S2:1547:7	induc	VBD	O	O
C	TANZEUM.xml:S2:1555:1	C	NNP	B-AdverseReaction	O
-	TANZEUM.xml:S2:1556:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S2:1557:4	cell	NN	I-AdverseReaction	O
tumors	TANZEUM.xml:S2:1562:6	tumor	NNS	I-AdverseReaction	O
in	TANZEUM.xml:S2:1569:2	in	IN	O	O
rodents	TANZEUM.xml:S2:1572:7	rodent	NNS	O	O
has	TANZEUM.xml:S2:1580:3	ha	VBZ	O	O
not	TANZEUM.xml:S2:1584:3	not	RB	O	O
been	TANZEUM.xml:S2:1588:4	been	VBN	O	O
determined	TANZEUM.xml:S2:1593:10	determin	VBN	O	O
.	TANZEUM.xml:S2:1603:1	.	.	O	O

It	TANZEUM.xml:S2:1605:2	It	PRP	O	O
is	TANZEUM.xml:S2:1608:2	is	VBZ	O	O
unknown	TANZEUM.xml:S2:1611:7	unknown	JJ	O	O
whether	TANZEUM.xml:S2:1619:7	whether	IN	O	O
TANZEUM	TANZEUM.xml:S2:1627:7	tanzeum	NNP	O	O
causes	TANZEUM.xml:S2:1635:6	caus	VBZ	O	O
thyroid	TANZEUM.xml:S2:1642:7	thyroid	JJ	B-AdverseReaction	O
C	TANZEUM.xml:S2:1650:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S2:1651:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S2:1652:4	cell	NN	I-AdverseReaction	O
tumors	TANZEUM.xml:S2:1657:6	tumor	NNS	I-AdverseReaction	O
,	TANZEUM.xml:S2:1663:1	,	,	O	O
including	TANZEUM.xml:S2:1665:9	includ	VBG	O	O
medullary	TANZEUM.xml:S2:1675:9	medullari	JJ	B-AdverseReaction	B-AdverseReaction
thyroid	TANZEUM.xml:S2:1685:7	thyroid	NN	I-AdverseReaction	I-AdverseReaction
carcinoma	TANZEUM.xml:S2:1693:9	carcinoma	NN	I-AdverseReaction	I-AdverseReaction
(	TANZEUM.xml:S2:1703:1	(	(	O	O
MTC	TANZEUM.xml:S2:1704:3	mtc	NNP	B-AdverseReaction	O
)	TANZEUM.xml:S2:1707:1	)	)	O	O
,	TANZEUM.xml:S2:1708:1	,	,	O	O
in	TANZEUM.xml:S2:1710:2	in	IN	O	O
humans	TANZEUM.xml:S2:1713:6	human	NNS	O	O
.	TANZEUM.xml:S2:1719:1	.	.	O	O

(	TANZEUM.xml:S2:1721:1	(	(	O	O
5.1	TANZEUM.xml:S2:1722:3	5.1	CD	O	O
,	TANZEUM.xml:S2:1725:1	,	,	O	O
13.1	TANZEUM.xml:S2:1727:4	13.1	CD	O	O
)	TANZEUM.xml:S2:1731:1	)	)	O	O
\n	TANZEUM.xml:S2:1733:1	\n	NN	O	O
TANZEUM	TANZEUM.xml:S2:1738:7	tanzeum	NNP	O	O
is	TANZEUM.xml:S2:1746:2	is	VBZ	O	O
contraindicated	TANZEUM.xml:S2:1749:15	contraind	VBN	O	O
in	TANZEUM.xml:S2:1765:2	in	IN	O	O
patients	TANZEUM.xml:S2:1768:8	patient	NNS	O	O
with	TANZEUM.xml:S2:1777:4	with	IN	O	O
a	TANZEUM.xml:S2:1782:1	a	DT	O	O
personal	TANZEUM.xml:S2:1784:8	person	JJ	O	O
or	TANZEUM.xml:S2:1793:2	or	CC	O	O
family	TANZEUM.xml:S2:1796:6	famili	NN	O	O
history	TANZEUM.xml:S2:1803:7	histori	NN	O	O
of	TANZEUM.xml:S2:1811:2	of	IN	O	O
MTC	TANZEUM.xml:S2:1814:3	mtc	NNP	O	O
or	TANZEUM.xml:S2:1818:2	or	CC	O	O
in	TANZEUM.xml:S2:1821:2	in	IN	O	O
patients	TANZEUM.xml:S2:1824:8	patient	NNS	O	O
with	TANZEUM.xml:S2:1833:4	with	IN	O	O
Multiple	TANZEUM.xml:S2:1838:8	multipl	NNP	O	O
Endocrine	TANZEUM.xml:S2:1847:9	endocrin	NNP	O	O
Neoplasia	TANZEUM.xml:S2:1857:9	neoplasia	NNP	O	O
syndrome	TANZEUM.xml:S2:1867:8	syndrom	VBD	O	O
type	TANZEUM.xml:S2:1876:4	type	JJ	O	O
2	TANZEUM.xml:S2:1881:1	2	CD	O	O
(	TANZEUM.xml:S2:1883:1	(	(	O	O
MEN	TANZEUM.xml:S2:1884:3	men	NNP	O	O
2	TANZEUM.xml:S2:1888:1	2	CD	O	O
)	TANZEUM.xml:S2:1889:1	)	)	O	O
.	TANZEUM.xml:S2:1890:1	.	.	O	O

Counsel	TANZEUM.xml:S2:1892:7	counsel	NNP	O	O
patients	TANZEUM.xml:S2:1900:8	patient	NNS	O	O
regarding	TANZEUM.xml:S2:1909:9	regard	VBG	O	O
the	TANZEUM.xml:S2:1919:3	the	DT	O	O
potential	TANZEUM.xml:S2:1923:9	potenti	JJ	O	O
risk	TANZEUM.xml:S2:1933:4	risk	NN	O	O
of	TANZEUM.xml:S2:1938:2	of	IN	O	O
MTC	TANZEUM.xml:S2:1941:3	mtc	NNP	O	O
and	TANZEUM.xml:S2:1945:3	and	CC	O	O
symptoms	TANZEUM.xml:S2:1949:8	symptom	NNS	O	O
of	TANZEUM.xml:S2:1958:2	of	IN	O	O
thyroid	TANZEUM.xml:S2:1961:7	thyroid	JJ	O	O
tumors	TANZEUM.xml:S2:1969:6	tumor	NNS	O	O
(	TANZEUM.xml:S2:1976:1	(	(	O	O
4.1	TANZEUM.xml:S2:1977:3	4.1	CD	O	O
,	TANZEUM.xml:S2:1980:1	,	,	O	O
5.1	TANZEUM.xml:S2:1982:3	5.1	CD	O	O
)	TANZEUM.xml:S2:1985:1	)	)	O	O
.	TANZEUM.xml:S2:1986:1	.	.	O	O
\n	TANZEUM.xml:S2:1988:1	\n	$	O	O
5	TANZEUM.xml:S3:4:1	5	CD	O	O
WARNINGS	TANZEUM.xml:S3:6:8	warn	NNP	O	O
AND	TANZEUM.xml:S3:15:3	and	NNP	O	O
PRECAUTIONS	TANZEUM.xml:S3:19:11	precaut	NNP	O	O

EXCERPT	TANZEUM.xml:S3:35:7	excerpt	NN	O	O
:	TANZEUM.xml:S3:42:1	:	:	O	O
Thyroid	TANZEUM.xml:S3:53:7	thyroid	NNP	B-AdverseReaction	O
C	TANZEUM.xml:S3:61:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S3:62:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S3:63:4	cell	NN	I-AdverseReaction	O
Tumors	TANZEUM.xml:S3:68:6	tumor	NNS	I-AdverseReaction	O
:	TANZEUM.xml:S3:74:1	:	:	O	O
See	TANZEUM.xml:S3:76:3	see	VB	O	O
Boxed	TANZEUM.xml:S3:80:5	box	NNP	O	O
Warning	TANZEUM.xml:S3:86:7	warn	NNP	O	O
.	TANZEUM.xml:S3:93:1	.	.	O	O

(	TANZEUM.xml:S3:95:1	(	(	O	O
5.1	TANZEUM.xml:S3:96:3	5.1	CD	O	O
)	TANZEUM.xml:S3:99:1	)	)	O	O

Pancreatitis	TANZEUM.xml:S3:109:12	pancreat	NN	B-AdverseReaction	O
:	TANZEUM.xml:S3:121:1	:	:	O	O
Discontinue	TANZEUM.xml:S3:123:11	discontinu	NNP	O	O
promptly	TANZEUM.xml:S3:135:8	promptli	RB	O	O
if	TANZEUM.xml:S3:144:2	if	IN	O	O
suspected	TANZEUM.xml:S3:147:9	suspect	VBN	O	O
.	TANZEUM.xml:S3:156:1	.	.	O	O

Do	TANZEUM.xml:S3:158:2	Do	NNP	O	O
not	TANZEUM.xml:S3:161:3	not	RB	O	O
restart	TANZEUM.xml:S3:165:7	restart	VB	O	O
if	TANZEUM.xml:S3:173:2	if	IN	O	O
confirmed	TANZEUM.xml:S3:176:9	confirm	VBN	O	O
.	TANZEUM.xml:S3:185:1	.	.	O	O

Consider	TANZEUM.xml:S3:187:8	consid	VB	O	O
other	TANZEUM.xml:S3:196:5	other	JJ	O	O
antidiabetic	TANZEUM.xml:S3:202:12	antidiabet	JJ	O	O
therapies	TANZEUM.xml:S3:215:9	therapi	NNS	O	O
in	TANZEUM.xml:S3:225:2	in	IN	O	O
patients	TANZEUM.xml:S3:228:8	patient	NNS	O	O
with	TANZEUM.xml:S3:237:4	with	IN	O	O
a	TANZEUM.xml:S3:242:1	a	DT	O	O
history	TANZEUM.xml:S3:244:7	histori	NN	O	O
of	TANZEUM.xml:S3:252:2	of	IN	O	O
pancreatitis	TANZEUM.xml:S3:255:12	pancreat	NN	O	O
.	TANZEUM.xml:S3:267:1	.	.	O	O

(	TANZEUM.xml:S3:269:1	(	(	O	O
5.2	TANZEUM.xml:S3:270:3	5.2	CD	O	O
)	TANZEUM.xml:S3:273:1	)	)	O	O

Hypoglycemia	TANZEUM.xml:S3:283:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
:	TANZEUM.xml:S3:295:1	:	:	O	O
Can	TANZEUM.xml:S3:297:3	can	MD	O	O
occur	TANZEUM.xml:S3:301:5	occur	VB	O	O
when	TANZEUM.xml:S3:307:4	when	WRB	O	O
used	TANZEUM.xml:S3:312:4	use	VBN	O	O
in	TANZEUM.xml:S3:317:2	in	IN	O	O
combination	TANZEUM.xml:S3:320:11	combin	NN	O	O
with	TANZEUM.xml:S3:332:4	with	IN	O	O
insulin	TANZEUM.xml:S3:337:7	insulin	NN	O	O
secretagogues	TANZEUM.xml:S3:345:13	secretagogu	NNS	O	O
(	TANZEUM.xml:S3:359:1	(	(	O	O
e	TANZEUM.xml:S3:360:1	e	NN	O	O
.	TANZEUM.xml:S3:361:1	.	.	O	O
g	TANZEUM.xml:S3:362:1	g	NN	O	O
.	TANZEUM.xml:S3:363:1	.	.	O	O
,	TANZEUM.xml:S3:364:1	,	,	O	O
sulfonylureas	TANZEUM.xml:S3:366:13	sulfonylurea	JJ	O	O
)	TANZEUM.xml:S3:379:1	)	)	O	O
or	TANZEUM.xml:S3:381:2	or	CC	O	O
insulin	TANZEUM.xml:S3:384:7	insulin	NN	O	O
.	TANZEUM.xml:S3:391:1	.	.	O	O

Consider	TANZEUM.xml:S3:393:8	consid	VB	O	O
lowering	TANZEUM.xml:S3:402:8	lower	VBG	O	O
sulfonylurea	TANZEUM.xml:S3:411:12	sulfonylurea	NN	O	O
or	TANZEUM.xml:S3:424:2	or	CC	O	O
insulin	TANZEUM.xml:S3:427:7	insulin	NN	O	O
dosage	TANZEUM.xml:S3:435:6	dosag	NN	O	O
when	TANZEUM.xml:S3:442:4	when	WRB	O	O
starting	TANZEUM.xml:S3:447:8	start	VBG	O	O
TANZEUM	TANZEUM.xml:S3:456:7	tanzeum	NNP	O	O
.	TANZEUM.xml:S3:463:1	.	.	O	O

(	TANZEUM.xml:S3:465:1	(	(	O	O
5.3	TANZEUM.xml:S3:466:3	5.3	CD	O	O
)	TANZEUM.xml:S3:469:1	)	)	O	O

Hypersensitivity	TANZEUM.xml:S3:479:16	hypersensit	NNP	B-AdverseReaction	B-AdverseReaction
Reactions	TANZEUM.xml:S3:496:9	reaction	NNP	I-AdverseReaction	I-AdverseReaction
:	TANZEUM.xml:S3:505:1	:	:	O	O
Discontinue	TANZEUM.xml:S3:507:11	discontinu	NNP	O	O
TANZEUM	TANZEUM.xml:S3:519:7	tanzeum	NNP	O	O
if	TANZEUM.xml:S3:527:2	if	IN	O	O
suspected	TANZEUM.xml:S3:530:9	suspect	VBN	O	O
.	TANZEUM.xml:S3:539:1	.	.	O	O

Monitor	TANZEUM.xml:S3:541:7	monitor	NNP	O	O
and	TANZEUM.xml:S3:549:3	and	CC	O	O
treat	TANZEUM.xml:S3:553:5	treat	NN	O	O
promptly	TANZEUM.xml:S3:559:8	promptli	RB	O	O
per	TANZEUM.xml:S3:568:3	per	IN	O	O
standard	TANZEUM.xml:S3:572:8	standard	NN	O	O
of	TANZEUM.xml:S3:581:2	of	IN	O	O
care	TANZEUM.xml:S3:584:4	care	NN	O	O
until	TANZEUM.xml:S3:589:5	until	IN	O	O
signs	TANZEUM.xml:S3:595:5	sign	NNS	O	O
and	TANZEUM.xml:S3:601:3	and	CC	O	O
symptoms	TANZEUM.xml:S3:605:8	symptom	NNS	O	O
resolve	TANZEUM.xml:S3:614:7	resolv	VBP	O	O
.	TANZEUM.xml:S3:621:1	.	.	O	O

(	TANZEUM.xml:S3:623:1	(	(	O	O
5.4	TANZEUM.xml:S3:624:3	5.4	CD	O	O
)	TANZEUM.xml:S3:627:1	)	)	O	O

Renal	TANZEUM.xml:S3:637:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
Impairment	TANZEUM.xml:S3:643:10	impair	NN	I-AdverseReaction	I-AdverseReaction
:	TANZEUM.xml:S3:653:1	:	:	O	O
Monitor	TANZEUM.xml:S3:655:7	monitor	NNP	O	O
renal	TANZEUM.xml:S3:663:5	renal	JJ	O	O
function	TANZEUM.xml:S3:669:8	function	NN	O	O
in	TANZEUM.xml:S3:678:2	in	IN	O	O
patients	TANZEUM.xml:S3:681:8	patient	NNS	O	O
with	TANZEUM.xml:S3:690:4	with	IN	O	O
renal	TANZEUM.xml:S3:695:5	renal	JJ	O	O
impairment	TANZEUM.xml:S3:701:10	impair	NN	O	O
reporting	TANZEUM.xml:S3:712:9	report	NN	O	O
severe	TANZEUM.xml:S3:722:6	sever	JJ	O	O
adverse	TANZEUM.xml:S3:729:7	advers	JJ	O	O
gastrointestinal	TANZEUM.xml:S3:737:16	gastrointestin	JJ	O	O
reactions	TANZEUM.xml:S3:754:9	reaction	NNS	O	O
.	TANZEUM.xml:S3:763:1	.	.	O	O

(	TANZEUM.xml:S3:765:1	(	(	O	O
5.5	TANZEUM.xml:S3:766:3	5.5	CD	O	O
)	TANZEUM.xml:S3:769:1	)	)	O	O

Macrovascular	TANZEUM.xml:S3:779:13	macrovascular	JJ	O	O
Outcomes	TANZEUM.xml:S3:793:8	outcom	NNS	O	O
:	TANZEUM.xml:S3:801:1	:	:	O	O
There	TANZEUM.xml:S3:803:5	there	EX	O	O
have	TANZEUM.xml:S3:809:4	have	VBP	O	O
been	TANZEUM.xml:S3:814:4	been	VBN	O	O
no	TANZEUM.xml:S3:819:2	no	DT	O	O
clinical	TANZEUM.xml:S3:822:8	clinic	JJ	O	O
trials	TANZEUM.xml:S3:831:6	trial	NNS	O	O
establishing	TANZEUM.xml:S3:838:12	establish	VBG	O	O
conclusive	TANZEUM.xml:S3:851:10	conclus	JJ	O	O
evidence	TANZEUM.xml:S3:862:8	evid	NN	O	O
of	TANZEUM.xml:S3:871:2	of	IN	O	O
macrovascular	TANZEUM.xml:S3:874:13	macrovascular	JJ	O	O
risk	TANZEUM.xml:S3:888:4	risk	NN	O	O
reduction	TANZEUM.xml:S3:893:9	reduct	NN	O	O
with	TANZEUM.xml:S3:903:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S3:908:7	tanzeum	NNP	O	O
or	TANZEUM.xml:S3:916:2	or	CC	O	O
any	TANZEUM.xml:S3:919:3	ani	DT	O	O
other	TANZEUM.xml:S3:923:5	other	JJ	O	O
antidiabetic	TANZEUM.xml:S3:929:12	antidiabet	JJ	O	O
drug	TANZEUM.xml:S3:942:4	drug	NN	O	O
.	TANZEUM.xml:S3:946:1	.	.	O	O

(	TANZEUM.xml:S3:948:1	(	(	O	O
5.6	TANZEUM.xml:S3:949:3	5.6	CD	O	O
)	TANZEUM.xml:S3:952:1	)	)	O	O

5.1	TANZEUM.xml:S3:963:3	5.1	CD	O	O

Risk	TANZEUM.xml:S3:967:4	risk	NN	O	O
of	TANZEUM.xml:S3:972:2	of	IN	O	O
Thyroid	TANZEUM.xml:S3:975:7	thyroid	NNP	O	O
C	TANZEUM.xml:S3:983:1	C	NNP	O	O
-	TANZEUM.xml:S3:984:1	-	:	O	O
cell	TANZEUM.xml:S3:985:4	cell	NN	O	O
Tumors	TANZEUM.xml:S3:990:6	tumor	NNS	O	O

Carcinogenicity	TANZEUM.xml:S3:1002:15	carcinogen	NN	O	O
of	TANZEUM.xml:S3:1018:2	of	IN	O	O
albiglutide	TANZEUM.xml:S3:1021:11	albiglutid	NN	O	O
could	TANZEUM.xml:S3:1033:5	could	MD	O	O
not	TANZEUM.xml:S3:1039:3	not	RB	O	O
be	TANZEUM.xml:S3:1043:2	be	VB	O	O
assessed	TANZEUM.xml:S3:1046:8	assess	VBN	O	O
in	TANZEUM.xml:S3:1055:2	in	IN	O	O
rodents	TANZEUM.xml:S3:1058:7	rodent	NNS	O	O
due	TANZEUM.xml:S3:1066:3	due	JJ	O	O
to	TANZEUM.xml:S3:1070:2	to	TO	O	O
the	TANZEUM.xml:S3:1073:3	the	DT	O	O
rapid	TANZEUM.xml:S3:1077:5	rapid	JJ	O	O
development	TANZEUM.xml:S3:1083:11	develop	NN	O	O
of	TANZEUM.xml:S3:1095:2	of	IN	O	O
drug	TANZEUM.xml:S3:1098:4	drug	NN	O	O
-	TANZEUM.xml:S3:1102:1	-	:	O	O
clearing	TANZEUM.xml:S3:1103:8	clear	NN	O	O
,	TANZEUM.xml:S3:1111:1	,	,	O	O
anti	TANZEUM.xml:S3:1113:4	anti	JJ	O	O
-	TANZEUM.xml:S3:1117:1	-	:	O	O
drug	TANZEUM.xml:S3:1118:4	drug	NN	O	O
antibodies	TANZEUM.xml:S3:1123:10	antibodi	NNS	O	O
[	TANZEUM.xml:S3:1135:1	[	VBP	O	O
see	TANZEUM.xml:S3:1136:3	see	VB	O	O
Nonclinical	TANZEUM.xml:S3:1140:11	nonclin	JJ	O	O
Toxicology	TANZEUM.xml:S3:1152:10	toxicolog	NNP	O	O
(	TANZEUM.xml:S3:1163:1	(	(	O	O
13.1	TANZEUM.xml:S3:1164:4	13.1	CD	O	O
)]	TANZEUM.xml:S3:1168:2	)]	NN	O	O
.	TANZEUM.xml:S3:1172:1	.	.	O	O

Other	TANZEUM.xml:S3:1174:5	other	JJ	O	O
GLP	TANZEUM.xml:S3:1180:3	glp	NNP	O	O
-	TANZEUM.xml:S3:1183:1	-	:	O	O
1	TANZEUM.xml:S3:1184:1	1	CD	O	O
receptor	TANZEUM.xml:S3:1186:8	receptor	NN	O	O
agonists	TANZEUM.xml:S3:1195:8	agonist	NNS	O	O
have	TANZEUM.xml:S3:1204:4	have	VBP	O	O
caused	TANZEUM.xml:S3:1209:6	caus	VBN	O	O
dose	TANZEUM.xml:S3:1216:4	dose	JJ	O	O
-	TANZEUM.xml:S3:1220:1	-	:	O	O
related	TANZEUM.xml:S3:1221:7	relat	JJ	O	O
and	TANZEUM.xml:S3:1229:3	and	CC	O	O
treatment	TANZEUM.xml:S3:1233:9	treatment	NN	O	O
-	TANZEUM.xml:S3:1242:1	-	:	O	O
duration	TANZEUM.xml:S3:1243:8	durat	NN	O	O
-	TANZEUM.xml:S3:1251:1	-	:	O	O
dependent	TANZEUM.xml:S3:1252:9	depend	JJ	O	O
thyroid	TANZEUM.xml:S3:1262:7	thyroid	NN	B-AdverseReaction	O
C	TANZEUM.xml:S3:1270:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S3:1271:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S3:1272:4	cell	NN	I-AdverseReaction	O
tumors	TANZEUM.xml:S3:1277:6	tumor	NNS	I-AdverseReaction	O
(	TANZEUM.xml:S3:1284:1	(	(	O	O
adenomas	TANZEUM.xml:S3:1285:8	adenoma	NN	I-AdverseReaction	O
or	TANZEUM.xml:S3:1294:2	or	CC	O	O
carcinomas	TANZEUM.xml:S3:1297:10	carcinoma	NN	I-AdverseReaction	O
)	TANZEUM.xml:S3:1307:1	)	)	O	O
in	TANZEUM.xml:S3:1309:2	in	IN	O	O
rodents	TANZEUM.xml:S3:1312:7	rodent	NNS	O	O
.	TANZEUM.xml:S3:1319:1	.	.	O	O

Human	TANZEUM.xml:S3:1321:5	human	JJ	O	O
relevance	TANZEUM.xml:S3:1327:9	relev	NN	O	O
of	TANZEUM.xml:S3:1337:2	of	IN	O	O
GLP	TANZEUM.xml:S3:1340:3	glp	NNP	O	O
-	TANZEUM.xml:S3:1343:1	-	:	O	O
1	TANZEUM.xml:S3:1344:1	1	CD	O	O
receptor	TANZEUM.xml:S3:1346:8	receptor	NN	O	O
agonist	TANZEUM.xml:S3:1355:7	agonist	NN	O	O
induced	TANZEUM.xml:S3:1363:7	induc	VBD	O	O
C	TANZEUM.xml:S3:1371:1	C	NNP	B-AdverseReaction	O
-	TANZEUM.xml:S3:1372:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S3:1373:4	cell	NN	I-AdverseReaction	O
tumors	TANZEUM.xml:S3:1378:6	tumor	NNS	I-AdverseReaction	O
in	TANZEUM.xml:S3:1385:2	in	IN	O	O
rodents	TANZEUM.xml:S3:1388:7	rodent	NNS	O	O
has	TANZEUM.xml:S3:1396:3	ha	VBZ	O	O
not	TANZEUM.xml:S3:1400:3	not	RB	O	O
been	TANZEUM.xml:S3:1404:4	been	VBN	O	O
determined	TANZEUM.xml:S3:1409:10	determin	VBN	O	O
.	TANZEUM.xml:S3:1419:1	.	.	O	O

It	TANZEUM.xml:S3:1421:2	It	PRP	O	O
is	TANZEUM.xml:S3:1424:2	is	VBZ	O	O
unknown	TANZEUM.xml:S3:1427:7	unknown	JJ	O	O
whether	TANZEUM.xml:S3:1435:7	whether	IN	O	O
TANZEUM	TANZEUM.xml:S3:1443:7	tanzeum	NNP	O	O
causes	TANZEUM.xml:S3:1451:6	caus	VBZ	O	O
thyroid	TANZEUM.xml:S3:1458:7	thyroid	JJ	B-AdverseReaction	O
C	TANZEUM.xml:S3:1466:1	C	NNP	I-AdverseReaction	O
-	TANZEUM.xml:S3:1467:1	-	:	I-AdverseReaction	O
cell	TANZEUM.xml:S3:1468:4	cell	NN	I-AdverseReaction	O
tumors	TANZEUM.xml:S3:1473:6	tumor	NNS	I-AdverseReaction	O
,	TANZEUM.xml:S3:1479:1	,	,	O	O
including	TANZEUM.xml:S3:1481:9	includ	VBG	O	O
MTC	TANZEUM.xml:S3:1491:3	mtc	NNP	B-AdverseReaction	O
,	TANZEUM.xml:S3:1494:1	,	,	O	O
in	TANZEUM.xml:S3:1496:2	in	IN	O	O
humans	TANZEUM.xml:S3:1499:6	human	NNS	O	O
[	TANZEUM.xml:S3:1507:1	[	JJ	O	O
see	TANZEUM.xml:S3:1508:3	see	VBP	O	O
Boxed	TANZEUM.xml:S3:1512:5	box	NNP	O	O
Warning	TANZEUM.xml:S3:1518:7	warn	NNP	O	O
,	TANZEUM.xml:S3:1525:1	,	,	O	O
Contraindications	TANZEUM.xml:S3:1527:17	contraind	NNP	O	O
(	TANZEUM.xml:S3:1545:1	(	(	O	O
4.1	TANZEUM.xml:S3:1546:3	4.1	CD	O	O
)]	TANZEUM.xml:S3:1549:2	)]	NN	O	O
.	TANZEUM.xml:S3:1553:1	.	.	O	O

Across	TANZEUM.xml:S3:1563:6	across	IN	O	O
8	TANZEUM.xml:S3:1570:1	8	CD	O	O
Phase	TANZEUM.xml:S3:1572:5	phase	NNP	O	O
III	TANZEUM.xml:S3:1578:3	iii	NNP	O	O
clinical	TANZEUM.xml:S3:1582:8	clinic	JJ	O	O
trials	TANZEUM.xml:S3:1591:6	trial	NNS	O	O
[	TANZEUM.xml:S3:1599:1	[	VBP	O	O
see	TANZEUM.xml:S3:1600:3	see	VB	O	O
Clinical	TANZEUM.xml:S3:1604:8	clinic	JJ	O	O
Studies	TANZEUM.xml:S3:1613:7	studi	NNP	O	O
(	TANZEUM.xml:S3:1621:1	(	(	O	O
14	TANZEUM.xml:S3:1622:2	14	CD	O	O
)]	TANZEUM.xml:S3:1624:2	)]	NN	O	O
,	TANZEUM.xml:S3:1628:1	,	,	O	O
MTC	TANZEUM.xml:S3:1630:3	mtc	NNP	B-AdverseReaction	O
was	TANZEUM.xml:S3:1634:3	wa	VBD	O	O
diagnosed	TANZEUM.xml:S3:1638:9	diagnos	VBN	O	O
in	TANZEUM.xml:S3:1648:2	in	IN	O	O
1	TANZEUM.xml:S3:1651:1	1	CD	O	O
patient	TANZEUM.xml:S3:1653:7	patient	NN	O	O
receiving	TANZEUM.xml:S3:1661:9	receiv	VBG	O	O
TANZEUM	TANZEUM.xml:S3:1671:7	tanzeum	NNP	O	O
and	TANZEUM.xml:S3:1679:3	and	CC	O	O
1	TANZEUM.xml:S3:1683:1	1	CD	O	O
patient	TANZEUM.xml:S3:1685:7	patient	NN	O	O
receiving	TANZEUM.xml:S3:1693:9	receiv	VBG	O	O
placebo	TANZEUM.xml:S3:1703:7	placebo	NN	O	O
.	TANZEUM.xml:S3:1710:1	.	.	O	O

Both	TANZEUM.xml:S3:1712:4	both	DT	O	O
patients	TANZEUM.xml:S3:1717:8	patient	NNS	O	O
had	TANZEUM.xml:S3:1726:3	had	VBD	O	O
markedly	TANZEUM.xml:S3:1730:8	markedli	RB	O	O
elevated	TANZEUM.xml:S3:1739:8	elev	VBN	O	O
serum	TANZEUM.xml:S3:1748:5	serum	NN	O	O
calcitonin	TANZEUM.xml:S3:1754:10	calcitonin	NN	O	O
levels	TANZEUM.xml:S3:1765:6	level	NNS	O	O
at	TANZEUM.xml:S3:1772:2	at	IN	O	O
baseline	TANZEUM.xml:S3:1775:8	baselin	NN	O	O
.	TANZEUM.xml:S3:1783:1	.	.	O	O

Cases	TANZEUM.xml:S3:1785:5	case	NNS	O	O
of	TANZEUM.xml:S3:1791:2	of	IN	O	O
MTC	TANZEUM.xml:S3:1794:3	mtc	NNP	B-AdverseReaction	O
in	TANZEUM.xml:S3:1798:2	in	IN	O	O
patients	TANZEUM.xml:S3:1801:8	patient	NNS	O	O
treated	TANZEUM.xml:S3:1810:7	treat	VBN	O	O
with	TANZEUM.xml:S3:1818:4	with	IN	O	O
liraglutide	TANZEUM.xml:S3:1823:11	liraglutid	NN	O	O
,	TANZEUM.xml:S3:1834:1	,	,	O	O
another	TANZEUM.xml:S3:1836:7	anoth	DT	O	O
GLP	TANZEUM.xml:S3:1844:3	glp	NNP	O	O
-	TANZEUM.xml:S3:1847:1	-	:	O	O
1	TANZEUM.xml:S3:1848:1	1	CD	O	O
receptor	TANZEUM.xml:S3:1850:8	receptor	NN	O	O
agonist	TANZEUM.xml:S3:1859:7	agonist	NN	O	O
,	TANZEUM.xml:S3:1866:1	,	,	O	O
have	TANZEUM.xml:S3:1868:4	have	VBP	O	O
been	TANZEUM.xml:S3:1873:4	been	VBN	O	O
reported	TANZEUM.xml:S3:1878:8	report	VBN	O	O
in	TANZEUM.xml:S3:1887:2	in	IN	O	O
the	TANZEUM.xml:S3:1890:3	the	DT	O	O
postmarketing	TANZEUM.xml:S3:1894:13	postmarket	JJ	O	O
period	TANZEUM.xml:S3:1908:6	period	NN	O	O
;	TANZEUM.xml:S3:1914:1	;	:	O	O
the	TANZEUM.xml:S3:1916:3	the	DT	O	O
data	TANZEUM.xml:S3:1920:4	data	NNS	O	O
in	TANZEUM.xml:S3:1925:2	in	IN	O	O
these	TANZEUM.xml:S3:1928:5	these	DT	O	O
reports	TANZEUM.xml:S3:1934:7	report	NNS	O	O
are	TANZEUM.xml:S3:1942:3	are	VBP	O	O
insufficient	TANZEUM.xml:S3:1946:12	insuffici	JJ	O	O
to	TANZEUM.xml:S3:1959:2	to	TO	O	O
establish	TANZEUM.xml:S3:1962:9	establish	VB	O	O
or	TANZEUM.xml:S3:1972:2	or	CC	O	O
exclude	TANZEUM.xml:S3:1975:7	exclud	VB	O	O
a	TANZEUM.xml:S3:1983:1	a	DT	O	O
causal	TANZEUM.xml:S3:1985:6	causal	NN	O	O
relationship	TANZEUM.xml:S3:1992:12	relationship	NN	O	O
between	TANZEUM.xml:S3:2005:7	between	IN	O	O
MTC	TANZEUM.xml:S3:2013:3	mtc	NNP	B-AdverseReaction	O
and	TANZEUM.xml:S3:2017:3	and	CC	O	O
GLP	TANZEUM.xml:S3:2021:3	glp	NNP	O	O
-	TANZEUM.xml:S3:2024:1	-	:	O	O
1	TANZEUM.xml:S3:2025:1	1	CD	O	O
receptor	TANZEUM.xml:S3:2027:8	receptor	NN	O	O
agonist	TANZEUM.xml:S3:2036:7	agonist	NN	O	O
use	TANZEUM.xml:S3:2044:3	use	NN	O	O
in	TANZEUM.xml:S3:2048:2	in	IN	O	O
humans	TANZEUM.xml:S3:2051:6	human	NNS	O	O
.	TANZEUM.xml:S3:2057:1	.	.	O	O

TANZEUM	TANZEUM.xml:S3:2067:7	tanzeum	NNP	O	O
is	TANZEUM.xml:S3:2075:2	is	VBZ	O	O
contraindicated	TANZEUM.xml:S3:2078:15	contraind	VBN	O	O
in	TANZEUM.xml:S3:2094:2	in	IN	O	O
patients	TANZEUM.xml:S3:2097:8	patient	NNS	O	O
with	TANZEUM.xml:S3:2106:4	with	IN	O	O
a	TANZEUM.xml:S3:2111:1	a	DT	O	O
personal	TANZEUM.xml:S3:2113:8	person	JJ	O	O
or	TANZEUM.xml:S3:2122:2	or	CC	O	O
family	TANZEUM.xml:S3:2125:6	famili	NN	O	O
history	TANZEUM.xml:S3:2132:7	histori	NN	O	O
of	TANZEUM.xml:S3:2140:2	of	IN	O	O
MTC	TANZEUM.xml:S3:2143:3	mtc	NNP	O	O
or	TANZEUM.xml:S3:2147:2	or	CC	O	O
in	TANZEUM.xml:S3:2150:2	in	IN	O	O
patients	TANZEUM.xml:S3:2153:8	patient	NNS	O	O
with	TANZEUM.xml:S3:2162:4	with	IN	O	O
MEN	TANZEUM.xml:S3:2167:3	men	NNP	O	O
2	TANZEUM.xml:S3:2171:1	2	CD	O	O
.	TANZEUM.xml:S3:2172:1	.	.	O	O

Counsel	TANZEUM.xml:S3:2174:7	counsel	NNP	O	O
patients	TANZEUM.xml:S3:2182:8	patient	NNS	O	O
regarding	TANZEUM.xml:S3:2191:9	regard	VBG	O	O
the	TANZEUM.xml:S3:2201:3	the	DT	O	O
potential	TANZEUM.xml:S3:2205:9	potenti	JJ	O	O
risk	TANZEUM.xml:S3:2215:4	risk	NN	O	O
for	TANZEUM.xml:S3:2220:3	for	IN	O	O
MTC	TANZEUM.xml:S3:2224:3	mtc	NNP	O	O
with	TANZEUM.xml:S3:2228:4	with	IN	O	O
the	TANZEUM.xml:S3:2233:3	the	DT	O	O
use	TANZEUM.xml:S3:2237:3	use	NN	O	O
of	TANZEUM.xml:S3:2241:2	of	IN	O	O
TANZEUM	TANZEUM.xml:S3:2244:7	tanzeum	NNP	O	O
and	TANZEUM.xml:S3:2252:3	and	CC	O	O
inform	TANZEUM.xml:S3:2256:6	inform	VB	O	O
them	TANZEUM.xml:S3:2263:4	them	PRP	O	O
of	TANZEUM.xml:S3:2268:2	of	IN	O	O
symptoms	TANZEUM.xml:S3:2271:8	symptom	NNS	O	O
of	TANZEUM.xml:S3:2280:2	of	IN	O	O
thyroid	TANZEUM.xml:S3:2283:7	thyroid	JJ	O	O
tumors	TANZEUM.xml:S3:2291:6	tumor	NNS	O	O
(	TANZEUM.xml:S3:2298:1	(	(	O	O
e	TANZEUM.xml:S3:2299:1	e	NN	O	O
.	TANZEUM.xml:S3:2300:1	.	.	O	O
g	TANZEUM.xml:S3:2301:1	g	NN	O	O
.	TANZEUM.xml:S3:2302:1	.	.	O	O
,	TANZEUM.xml:S3:2303:1	,	,	O	O
a	TANZEUM.xml:S3:2305:1	a	DT	O	O
mass	TANZEUM.xml:S3:2307:4	mass	NN	O	O
in	TANZEUM.xml:S3:2312:2	in	IN	O	O
the	TANZEUM.xml:S3:2315:3	the	DT	O	O
neck	TANZEUM.xml:S3:2319:4	neck	NN	O	O
,	TANZEUM.xml:S3:2323:1	,	,	O	O
dysphagia	TANZEUM.xml:S3:2325:9	dysphagia	NN	O	B-AdverseReaction
,	TANZEUM.xml:S3:2334:1	,	,	O	O
dyspnea	TANZEUM.xml:S3:2336:7	dyspnea	NN	O	B-AdverseReaction
,	TANZEUM.xml:S3:2343:1	,	,	O	O
or	TANZEUM.xml:S3:2345:2	or	CC	O	O
persistent	TANZEUM.xml:S3:2348:10	persist	JJ	O	O
hoarseness	TANZEUM.xml:S3:2359:10	hoars	NN	O	O
)	TANZEUM.xml:S3:2369:1	)	)	O	O
.	TANZEUM.xml:S3:2370:1	.	.	O	O

Routine	TANZEUM.xml:S3:2380:7	routin	JJ	O	O
monitoring	TANZEUM.xml:S3:2388:10	monitor	NN	O	O
of	TANZEUM.xml:S3:2399:2	of	IN	O	O
serum	TANZEUM.xml:S3:2402:5	serum	JJ	O	O
calcitonin	TANZEUM.xml:S3:2408:10	calcitonin	NN	O	O
or	TANZEUM.xml:S3:2419:2	or	CC	O	O
using	TANZEUM.xml:S3:2422:5	use	VBG	O	O
thyroid	TANZEUM.xml:S3:2428:7	thyroid	JJ	O	O
ultrasound	TANZEUM.xml:S3:2436:10	ultrasound	NN	O	O
is	TANZEUM.xml:S3:2447:2	is	VBZ	O	O
of	TANZEUM.xml:S3:2450:2	of	IN	O	O
uncertain	TANZEUM.xml:S3:2453:9	uncertain	JJ	O	O
value	TANZEUM.xml:S3:2463:5	valu	NN	O	O
for	TANZEUM.xml:S3:2469:3	for	IN	O	O
early	TANZEUM.xml:S3:2473:5	earli	JJ	O	O
detection	TANZEUM.xml:S3:2479:9	detect	NN	O	O
of	TANZEUM.xml:S3:2489:2	of	IN	O	O
MTC	TANZEUM.xml:S3:2492:3	mtc	NNP	O	O
in	TANZEUM.xml:S3:2496:2	in	IN	O	O
patients	TANZEUM.xml:S3:2499:8	patient	NNS	O	O
treated	TANZEUM.xml:S3:2508:7	treat	VBN	O	O
with	TANZEUM.xml:S3:2516:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S3:2521:7	tanzeum	NNP	O	O
.	TANZEUM.xml:S3:2528:1	.	.	O	O

Such	TANZEUM.xml:S3:2530:4	such	JJ	O	O
monitoring	TANZEUM.xml:S3:2535:10	monitor	NN	O	O
may	TANZEUM.xml:S3:2546:3	may	MD	O	O
increase	TANZEUM.xml:S3:2550:8	increas	VB	O	O
the	TANZEUM.xml:S3:2559:3	the	DT	O	O
risk	TANZEUM.xml:S3:2563:4	risk	NN	O	O
of	TANZEUM.xml:S3:2568:2	of	IN	O	O
unnecessary	TANZEUM.xml:S3:2571:11	unnecessari	JJ	O	O
procedures	TANZEUM.xml:S3:2583:10	procedur	NNS	O	O
,	TANZEUM.xml:S3:2593:1	,	,	O	O
due	TANZEUM.xml:S3:2595:3	due	JJ	O	O
to	TANZEUM.xml:S3:2599:2	to	TO	O	O
the	TANZEUM.xml:S3:2602:3	the	DT	O	O
low	TANZEUM.xml:S3:2606:3	low	JJ	O	O
specificity	TANZEUM.xml:S3:2610:11	specif	NN	O	O
of	TANZEUM.xml:S3:2622:2	of	IN	O	O
serum	TANZEUM.xml:S3:2625:5	serum	NN	O	O
calcitonin	TANZEUM.xml:S3:2631:10	calcitonin	NN	O	O
testing	TANZEUM.xml:S3:2642:7	test	VBG	O	O
for	TANZEUM.xml:S3:2650:3	for	IN	O	O
MTC	TANZEUM.xml:S3:2654:3	mtc	NNP	O	O
and	TANZEUM.xml:S3:2658:3	and	CC	O	O
a	TANZEUM.xml:S3:2662:1	a	DT	O	O
high	TANZEUM.xml:S3:2664:4	high	JJ	O	O
background	TANZEUM.xml:S3:2669:10	background	NN	O	O
incidence	TANZEUM.xml:S3:2680:9	incid	NN	O	O
of	TANZEUM.xml:S3:2690:2	of	IN	O	O
thyroid	TANZEUM.xml:S3:2693:7	thyroid	JJ	O	O
disease	TANZEUM.xml:S3:2701:7	diseas	NN	O	O
.	TANZEUM.xml:S3:2708:1	.	.	O	O

Significantly	TANZEUM.xml:S3:2710:13	significantli	RB	O	O
elevated	TANZEUM.xml:S3:2724:8	elev	VBN	O	O
serum	TANZEUM.xml:S3:2733:5	serum	JJ	O	O
calcitonin	TANZEUM.xml:S3:2739:10	calcitonin	NN	O	O
may	TANZEUM.xml:S3:2750:3	may	MD	O	O
indicate	TANZEUM.xml:S3:2754:8	indic	VB	O	O
MTC	TANZEUM.xml:S3:2763:3	mtc	NNP	O	O
and	TANZEUM.xml:S3:2767:3	and	CC	O	O
patients	TANZEUM.xml:S3:2771:8	patient	NNS	O	O
with	TANZEUM.xml:S3:2780:4	with	IN	O	O
MTC	TANZEUM.xml:S3:2785:3	mtc	NNP	O	O
usually	TANZEUM.xml:S3:2789:7	usual	RB	O	O
have	TANZEUM.xml:S3:2797:4	have	VBP	O	O
calcitonin	TANZEUM.xml:S3:2802:10	calcitonin	VBN	O	O
values	TANZEUM.xml:S3:2813:6	valu	NNS	O	O
50	TANZEUM.xml:S3:2821:2	50	CD	O	O
ng	TANZEUM.xml:S3:2824:2	ng	NNS	O	O
L.	TANZEUM.xml:S3:2827:2	L.	NNP	O	O

If	TANZEUM.xml:S3:2830:2	If	IN	O	O
serum	TANZEUM.xml:S3:2833:5	serum	JJ	O	O
calcitonin	TANZEUM.xml:S3:2839:10	calcitonin	NN	O	O
is	TANZEUM.xml:S3:2850:2	is	VBZ	O	O
measured	TANZEUM.xml:S3:2853:8	measur	VBN	O	O
and	TANZEUM.xml:S3:2862:3	and	CC	O	O
found	TANZEUM.xml:S3:2866:5	found	VBN	O	O
to	TANZEUM.xml:S3:2872:2	to	TO	O	O
be	TANZEUM.xml:S3:2875:2	be	VB	O	O
elevated	TANZEUM.xml:S3:2878:8	elev	VBN	O	O
,	TANZEUM.xml:S3:2886:1	,	,	O	O
the	TANZEUM.xml:S3:2888:3	the	DT	O	O
patient	TANZEUM.xml:S3:2892:7	patient	NN	O	O
should	TANZEUM.xml:S3:2900:6	should	MD	O	O
be	TANZEUM.xml:S3:2907:2	be	VB	O	O
further	TANZEUM.xml:S3:2910:7	further	RB	O	O
evaluated	TANZEUM.xml:S3:2918:9	evalu	VBN	O	O
.	TANZEUM.xml:S3:2927:1	.	.	O	O

Patients	TANZEUM.xml:S3:2929:8	patient	NNS	O	O
with	TANZEUM.xml:S3:2938:4	with	IN	O	O
thyroid	TANZEUM.xml:S3:2943:7	thyroid	JJ	O	O
nodules	TANZEUM.xml:S3:2951:7	nodul	NNS	O	O
noted	TANZEUM.xml:S3:2959:5	note	VBN	O	O
on	TANZEUM.xml:S3:2965:2	on	IN	O	O
physical	TANZEUM.xml:S3:2968:8	physic	JJ	O	O
examination	TANZEUM.xml:S3:2977:11	examin	NN	O	O
or	TANZEUM.xml:S3:2989:2	or	CC	O	O
neck	TANZEUM.xml:S3:2992:4	neck	NN	O	O
imaging	TANZEUM.xml:S3:2997:7	imag	NN	O	O
should	TANZEUM.xml:S3:3005:6	should	MD	O	O
also	TANZEUM.xml:S3:3012:4	also	RB	O	O
be	TANZEUM.xml:S3:3017:2	be	VB	O	O
further	TANZEUM.xml:S3:3020:7	further	RB	O	O
evaluated	TANZEUM.xml:S3:3028:9	evalu	VBN	O	O
.	TANZEUM.xml:S3:3037:1	.	.	O	O

5.2	TANZEUM.xml:S3:3047:3	5.2	CD	O	O
Acute	TANZEUM.xml:S3:3051:5	acut	NNP	O	O
Pancreatitis	TANZEUM.xml:S3:3057:12	pancreat	NN	O	O

In	TANZEUM.xml:S3:3073:2	In	IN	O	O
clinical	TANZEUM.xml:S3:3076:8	clinic	JJ	O	O
trials	TANZEUM.xml:S3:3085:6	trial	NNS	O	O
,	TANZEUM.xml:S3:3091:1	,	,	O	O
acute	TANZEUM.xml:S3:3093:5	acut	NN	B-AdverseReaction	B-AdverseReaction
pancreatitis	TANZEUM.xml:S3:3099:12	pancreat	NN	I-AdverseReaction	I-AdverseReaction
has	TANZEUM.xml:S3:3112:3	ha	VBZ	O	O
been	TANZEUM.xml:S3:3116:4	been	VBN	O	O
reported	TANZEUM.xml:S3:3121:8	report	VBN	O	O
in	TANZEUM.xml:S3:3130:2	in	IN	O	O
association	TANZEUM.xml:S3:3133:11	associ	NN	O	O
with	TANZEUM.xml:S3:3145:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S3:3150:7	tanzeum	NNP	O	O
.	TANZEUM.xml:S3:3157:1	.	.	O	O

Across	TANZEUM.xml:S3:3163:6	across	IN	O	O
8	TANZEUM.xml:S3:3170:1	8	CD	O	O
Phase	TANZEUM.xml:S3:3172:5	phase	NNP	O	O
III	TANZEUM.xml:S3:3178:3	iii	NNP	O	O
clinical	TANZEUM.xml:S3:3182:8	clinic	JJ	O	O
trials	TANZEUM.xml:S3:3191:6	trial	NNS	O	O
[	TANZEUM.xml:S3:3199:1	[	VBP	O	O
see	TANZEUM.xml:S3:3200:3	see	VB	O	O
Clinical	TANZEUM.xml:S3:3204:8	clinic	JJ	O	O
Studies	TANZEUM.xml:S3:3213:7	studi	NNP	O	O
(	TANZEUM.xml:S3:3221:1	(	(	O	O
14	TANZEUM.xml:S3:3222:2	14	CD	O	O
)]	TANZEUM.xml:S3:3224:2	)]	NN	O	O
,	TANZEUM.xml:S3:3228:1	,	,	O	O
pancreatitis	TANZEUM.xml:S3:3230:12	pancreat	NN	B-AdverseReaction	B-AdverseReaction
adjudicated	TANZEUM.xml:S3:3243:11	adjud	VBD	O	O
as	TANZEUM.xml:S3:3255:2	as	IN	O	O
likely	TANZEUM.xml:S3:3258:6	like	RB	O	O
related	TANZEUM.xml:S3:3265:7	relat	VBN	O	O
to	TANZEUM.xml:S3:3273:2	to	TO	O	O
therapy	TANZEUM.xml:S3:3276:7	therapi	VB	O	O
occurred	TANZEUM.xml:S3:3284:8	occur	PRP	O	O
more	TANZEUM.xml:S3:3293:4	more	RBR	O	O
frequently	TANZEUM.xml:S3:3298:10	frequent	RB	O	O
in	TANZEUM.xml:S3:3309:2	in	IN	O	O
patients	TANZEUM.xml:S3:3312:8	patient	NNS	O	O
receiving	TANZEUM.xml:S3:3321:9	receiv	VBG	O	O
TANZEUM	TANZEUM.xml:S3:3331:7	tanzeum	NNP	O	O
(	TANZEUM.xml:S3:3339:1	(	(	O	O
6	TANZEUM.xml:S3:3340:1	6	CD	O	O
of	TANZEUM.xml:S3:3342:2	of	IN	O	O
2	TANZEUM.xml:S3:3345:1	2	CD	O	O
,	TANZEUM.xml:S3:3346:1	,	,	O	O
365	TANZEUM.xml:S3:3347:3	365	CD	O	O
[	TANZEUM.xml:S3:3351:1	[	NN	O	O
0.3%	TANZEUM.xml:S3:3352:4	0.3%	CD	O	O
])	TANZEUM.xml:S3:3356:2	])	NN	O	O
than	TANZEUM.xml:S3:3359:4	than	IN	O	O
in	TANZEUM.xml:S3:3364:2	in	IN	O	O
patients	TANZEUM.xml:S3:3367:8	patient	NNS	O	O
receiving	TANZEUM.xml:S3:3376:9	receiv	VBG	O	O
placebo	TANZEUM.xml:S3:3386:7	placebo	NN	O	O
(	TANZEUM.xml:S3:3394:1	(	(	O	O
0	TANZEUM.xml:S3:3395:1	0	CD	O	O
of	TANZEUM.xml:S3:3397:2	of	IN	O	O
468	TANZEUM.xml:S3:3400:3	468	CD	O	O
[	TANZEUM.xml:S3:3404:1	[	JJ	O	O
0%	TANZEUM.xml:S3:3405:2	0%	CD	O	O
])	TANZEUM.xml:S3:3407:2	])	NN	O	O
or	TANZEUM.xml:S3:3410:2	or	CC	O	O
active	TANZEUM.xml:S3:3413:6	activ	JJ	O	O
comparators	TANZEUM.xml:S3:3420:11	compar	NNS	O	O
(	TANZEUM.xml:S3:3432:1	(	(	O	O
2	TANZEUM.xml:S3:3433:1	2	CD	O	O
of	TANZEUM.xml:S3:3435:2	of	IN	O	O
2	TANZEUM.xml:S3:3438:1	2	CD	O	O
,	TANZEUM.xml:S3:3439:1	,	,	O	O
065	TANZEUM.xml:S3:3440:3	065	CD	O	O
[	TANZEUM.xml:S3:3444:1	[	NN	O	O
0.1%	TANZEUM.xml:S3:3445:4	0.1%	CD	O	O
])	TANZEUM.xml:S3:3449:2	])	NN	O	O
.	TANZEUM.xml:S3:3451:1	.	.	O	O

After	TANZEUM.xml:S3:3457:5	after	IN	O	O
initiation	TANZEUM.xml:S3:3463:10	initi	NN	O	O
of	TANZEUM.xml:S3:3474:2	of	IN	O	O
TANZEUM	TANZEUM.xml:S3:3477:7	tanzeum	NNP	O	O
,	TANZEUM.xml:S3:3484:1	,	,	O	O
observe	TANZEUM.xml:S3:3486:7	observ	NN	O	O
patients	TANZEUM.xml:S3:3494:8	patient	NNS	O	O
carefully	TANZEUM.xml:S3:3503:9	care	RB	O	O
for	TANZEUM.xml:S3:3513:3	for	IN	O	O
signs	TANZEUM.xml:S3:3517:5	sign	NNS	O	O
and	TANZEUM.xml:S3:3523:3	and	CC	O	O
symptoms	TANZEUM.xml:S3:3527:8	symptom	NNS	O	O
of	TANZEUM.xml:S3:3536:2	of	IN	O	O
pancreatitis	TANZEUM.xml:S3:3539:12	pancreat	NN	O	O
(	TANZEUM.xml:S3:3552:1	(	(	O	O
including	TANZEUM.xml:S3:3553:9	includ	VBG	O	O
persistent	TANZEUM.xml:S3:3563:10	persist	NN	O	O
severe	TANZEUM.xml:S3:3574:6	sever	JJ	O	O
abdominal	TANZEUM.xml:S3:3581:9	abdomin	JJ	O	O
pain	TANZEUM.xml:S3:3591:4	pain	NN	O	O
,	TANZEUM.xml:S3:3595:1	,	,	O	O
sometimes	TANZEUM.xml:S3:3597:9	sometim	RB	O	O
radiating	TANZEUM.xml:S3:3607:9	radiat	VBG	O	O
to	TANZEUM.xml:S3:3617:2	to	TO	O	O
the	TANZEUM.xml:S3:3620:3	the	DT	O	O
back	TANZEUM.xml:S3:3624:4	back	NN	O	O
and	TANZEUM.xml:S3:3629:3	and	CC	O	O
which	TANZEUM.xml:S3:3633:5	which	WDT	O	O
may	TANZEUM.xml:S3:3639:3	may	MD	O	O
or	TANZEUM.xml:S3:3643:2	or	CC	O	O
may	TANZEUM.xml:S3:3646:3	may	MD	O	O
not	TANZEUM.xml:S3:3650:3	not	RB	O	O
be	TANZEUM.xml:S3:3654:2	be	VB	O	O
accompanied	TANZEUM.xml:S3:3657:11	accompani	VBN	O	O
by	TANZEUM.xml:S3:3669:2	by	IN	O	O
vomiting	TANZEUM.xml:S3:3672:8	vomit	VBG	O	O
)	TANZEUM.xml:S3:3680:1	)	)	O	O
.	TANZEUM.xml:S3:3681:1	.	.	O	O

If	TANZEUM.xml:S3:3683:2	If	IN	O	O
pancreatitis	TANZEUM.xml:S3:3686:12	pancreat	NN	O	O
is	TANZEUM.xml:S3:3699:2	is	VBZ	O	O
suspected	TANZEUM.xml:S3:3702:9	suspect	VBN	O	O
,	TANZEUM.xml:S3:3711:1	,	,	O	O
promptly	TANZEUM.xml:S3:3713:8	promptli	RB	O	O
discontinue	TANZEUM.xml:S3:3722:11	discontinu	VBZ	O	O
TANZEUM	TANZEUM.xml:S3:3734:7	tanzeum	NNP	O	O
.	TANZEUM.xml:S3:3741:1	.	.	O	O

If	TANZEUM.xml:S3:3743:2	If	IN	O	O
pancreatitis	TANZEUM.xml:S3:3746:12	pancreat	NN	O	O
is	TANZEUM.xml:S3:3759:2	is	VBZ	O	O
confirmed	TANZEUM.xml:S3:3762:9	confirm	VBN	O	O
,	TANZEUM.xml:S3:3771:1	,	,	O	O
TANZEUM	TANZEUM.xml:S3:3773:7	tanzeum	NNP	O	O
should	TANZEUM.xml:S3:3781:6	should	MD	O	O
not	TANZEUM.xml:S3:3788:3	not	RB	O	O
be	TANZEUM.xml:S3:3792:2	be	VB	O	O
restarted	TANZEUM.xml:S3:3795:9	restart	VBN	O	O
.	TANZEUM.xml:S3:3804:1	.	.	O	O

TANZEUM	TANZEUM.xml:S3:3810:7	tanzeum	NNP	O	O
has	TANZEUM.xml:S3:3818:3	ha	VBZ	O	O
not	TANZEUM.xml:S3:3822:3	not	RB	O	O
been	TANZEUM.xml:S3:3826:4	been	VBN	O	O
studied	TANZEUM.xml:S3:3831:7	studi	VBN	O	O
in	TANZEUM.xml:S3:3839:2	in	IN	O	O
patients	TANZEUM.xml:S3:3842:8	patient	NNS	O	O
with	TANZEUM.xml:S3:3851:4	with	IN	O	O
a	TANZEUM.xml:S3:3856:1	a	DT	O	O
history	TANZEUM.xml:S3:3858:7	histori	NN	O	O
of	TANZEUM.xml:S3:3866:2	of	IN	O	O
pancreatitis	TANZEUM.xml:S3:3869:12	pancreat	NN	O	O
to	TANZEUM.xml:S3:3882:2	to	TO	O	O
determine	TANZEUM.xml:S3:3885:9	determin	VB	O	O
whether	TANZEUM.xml:S3:3895:7	whether	IN	O	O
these	TANZEUM.xml:S3:3903:5	these	DT	O	O
patients	TANZEUM.xml:S3:3909:8	patient	NNS	O	O
are	TANZEUM.xml:S3:3918:3	are	VBP	O	O
at	TANZEUM.xml:S3:3922:2	at	IN	O	O
increased	TANZEUM.xml:S3:3925:9	increas	VBN	O	O
risk	TANZEUM.xml:S3:3935:4	risk	NN	O	O
for	TANZEUM.xml:S3:3940:3	for	IN	O	O
pancreatitis	TANZEUM.xml:S3:3944:12	pancreat	NN	O	O
.	TANZEUM.xml:S3:3956:1	.	.	O	O

Consider	TANZEUM.xml:S3:3958:8	consid	VB	O	O
other	TANZEUM.xml:S3:3967:5	other	JJ	O	O
antidiabetic	TANZEUM.xml:S3:3973:12	antidiabet	JJ	O	O
therapies	TANZEUM.xml:S3:3986:9	therapi	NNS	O	O
in	TANZEUM.xml:S3:3996:2	in	IN	O	O
patients	TANZEUM.xml:S3:3999:8	patient	NNS	O	O
with	TANZEUM.xml:S3:4008:4	with	IN	O	O
a	TANZEUM.xml:S3:4013:1	a	DT	O	O
history	TANZEUM.xml:S3:4015:7	histori	NN	O	O
of	TANZEUM.xml:S3:4023:2	of	IN	O	O
pancreatitis	TANZEUM.xml:S3:4026:12	pancreat	NN	O	O
.	TANZEUM.xml:S3:4038:1	.	.	O	O

5.3	TANZEUM.xml:S3:4046:3	5.3	CD	O	O
Hypoglycemia	TANZEUM.xml:S3:4050:12	hypoglycemia	NNP	O	O
with	TANZEUM.xml:S3:4063:4	with	IN	O	O
Concomitant	TANZEUM.xml:S3:4068:11	concomit	NNP	O	O
Use	TANZEUM.xml:S3:4080:3	use	NNP	O	O
of	TANZEUM.xml:S3:4084:2	of	IN	O	O
Insulin	TANZEUM.xml:S3:4087:7	insulin	NNP	O	O
Secretagogues	TANZEUM.xml:S3:4095:13	secretagogu	NNP	O	O
or	TANZEUM.xml:S3:4109:2	or	CC	O	O
Insulin	TANZEUM.xml:S3:4112:7	insulin	NNP	O	O

The	TANZEUM.xml:S3:4123:3	the	DT	O	O
risk	TANZEUM.xml:S3:4127:4	risk	NN	O	O
of	TANZEUM.xml:S3:4132:2	of	IN	O	O
hypoglycemia	TANZEUM.xml:S3:4135:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
is	TANZEUM.xml:S3:4148:2	is	VBZ	O	O
increased	TANZEUM.xml:S3:4151:9	increas	VBN	O	O
when	TANZEUM.xml:S3:4161:4	when	WRB	O	O
TANZEUM	TANZEUM.xml:S3:4166:7	tanzeum	NNP	O	O
is	TANZEUM.xml:S3:4174:2	is	VBZ	O	O
used	TANZEUM.xml:S3:4177:4	use	VBN	O	O
in	TANZEUM.xml:S3:4182:2	in	IN	O	O
combination	TANZEUM.xml:S3:4185:11	combin	NN	O	O
with	TANZEUM.xml:S3:4197:4	with	IN	O	O
insulin	TANZEUM.xml:S3:4202:7	insulin	NN	O	O
secretagogues	TANZEUM.xml:S3:4210:13	secretagogu	NNS	O	O
(	TANZEUM.xml:S3:4224:1	(	(	O	O
e	TANZEUM.xml:S3:4225:1	e	NN	O	O
.	TANZEUM.xml:S3:4226:1	.	.	O	O
g	TANZEUM.xml:S3:4227:1	g	NN	O	O
.	TANZEUM.xml:S3:4228:1	.	.	O	O
,	TANZEUM.xml:S3:4229:1	,	,	O	O
sulfonylureas	TANZEUM.xml:S3:4231:13	sulfonylurea	JJ	O	O
)	TANZEUM.xml:S3:4244:1	)	)	O	O
or	TANZEUM.xml:S3:4246:2	or	CC	O	O
insulin	TANZEUM.xml:S3:4249:7	insulin	NN	O	O
.	TANZEUM.xml:S3:4256:1	.	.	O	O

Therefore	TANZEUM.xml:S3:4258:9	therefor	RB	O	O
,	TANZEUM.xml:S3:4267:1	,	,	O	O
patients	TANZEUM.xml:S3:4269:8	patient	NNS	O	O
may	TANZEUM.xml:S3:4278:3	may	MD	O	O
require	TANZEUM.xml:S3:4282:7	requir	VB	O	O
a	TANZEUM.xml:S3:4290:1	a	DT	O	O
lower	TANZEUM.xml:S3:4292:5	lower	JJR	O	O
dose	TANZEUM.xml:S3:4298:4	dose	NN	O	O
of	TANZEUM.xml:S3:4303:2	of	IN	O	O
sulfonylurea	TANZEUM.xml:S3:4306:12	sulfonylurea	NN	O	O
or	TANZEUM.xml:S3:4319:2	or	CC	O	O
insulin	TANZEUM.xml:S3:4322:7	insulin	NN	O	O
to	TANZEUM.xml:S3:4330:2	to	TO	O	O
reduce	TANZEUM.xml:S3:4333:6	reduc	VB	O	O
the	TANZEUM.xml:S3:4340:3	the	DT	O	O
risk	TANZEUM.xml:S3:4344:4	risk	NN	O	O
of	TANZEUM.xml:S3:4349:2	of	IN	O	O
hypoglycemia	TANZEUM.xml:S3:4352:12	hypoglycemia	NN	B-AdverseReaction	B-AdverseReaction
in	TANZEUM.xml:S3:4365:2	in	IN	O	O
this	TANZEUM.xml:S3:4368:4	thi	DT	O	O
setting	TANZEUM.xml:S3:4373:7	set	NN	O	O
[	TANZEUM.xml:S3:4382:1	[	NNP	O	O
see	TANZEUM.xml:S3:4383:3	see	VBP	O	O
Dosage	TANZEUM.xml:S3:4387:6	dosag	NNP	O	O
and	TANZEUM.xml:S3:4394:3	and	CC	O	O
Administration	TANZEUM.xml:S3:4398:14	administr	NNP	O	O
(	TANZEUM.xml:S3:4413:1	(	(	O	O
2.2	TANZEUM.xml:S3:4414:3	2.2	CD	O	O
)	TANZEUM.xml:S3:4417:1	)	)	O	O
,	TANZEUM.xml:S3:4418:1	,	,	O	O
Adverse	TANZEUM.xml:S3:4420:7	advers	JJ	O	O
Reactions	TANZEUM.xml:S3:4428:9	reaction	NNP	O	O
(	TANZEUM.xml:S3:4438:1	(	(	O	O
6.1	TANZEUM.xml:S3:4439:3	6.1	CD	O	O
)]	TANZEUM.xml:S3:4442:2	)]	NN	O	O
.	TANZEUM.xml:S3:4446:1	.	.	O	O

5.4	TANZEUM.xml:S3:4454:3	5.4	CD	O	O
Hypersensitivity	TANZEUM.xml:S3:4458:16	hypersensit	NNP	O	O
Reactions	TANZEUM.xml:S3:4475:9	reaction	NNP	O	O

Across	TANZEUM.xml:S3:4488:6	across	IN	O	O
8	TANZEUM.xml:S3:4495:1	8	CD	O	O
Phase	TANZEUM.xml:S3:4497:5	phase	NNP	O	O
III	TANZEUM.xml:S3:4503:3	iii	NNP	O	O
clinical	TANZEUM.xml:S3:4507:8	clinic	JJ	O	O
trials	TANZEUM.xml:S3:4516:6	trial	NNS	O	O
[	TANZEUM.xml:S3:4524:1	[	VBP	O	O
see	TANZEUM.xml:S3:4525:3	see	VB	O	O
Clinical	TANZEUM.xml:S3:4529:8	clinic	JJ	O	O
Studies	TANZEUM.xml:S3:4538:7	studi	NNP	O	O
(	TANZEUM.xml:S3:4546:1	(	(	O	O
14	TANZEUM.xml:S3:4547:2	14	CD	O	O
)]	TANZEUM.xml:S3:4549:2	)]	NN	O	O
,	TANZEUM.xml:S3:4553:1	,	,	O	O
a	TANZEUM.xml:S3:4555:1	a	DT	O	O
serious	TANZEUM.xml:S3:4557:7	seriou	JJ	O	O
hypersensitivity	TANZEUM.xml:S3:4565:16	hypersensit	NN	B-AdverseReaction	B-AdverseReaction
reaction	TANZEUM.xml:S3:4582:8	reaction	NN	I-AdverseReaction	I-AdverseReaction
with	TANZEUM.xml:S3:4591:4	with	IN	O	O
pruritus	TANZEUM.xml:S3:4596:8	pruritu	NN	B-AdverseReaction	B-AdverseReaction
,	TANZEUM.xml:S3:4604:1	,	,	O	O
rash	TANZEUM.xml:S3:4606:4	rash	NN	B-AdverseReaction	B-AdverseReaction
,	TANZEUM.xml:S3:4610:1	,	,	O	O
and	TANZEUM.xml:S3:4612:3	and	CC	O	O
dyspnea	TANZEUM.xml:S3:4616:7	dyspnea	NN	B-AdverseReaction	B-AdverseReaction
occurred	TANZEUM.xml:S3:4624:8	occur	VBD	O	O
in	TANZEUM.xml:S3:4633:2	in	IN	O	O
a	TANZEUM.xml:S3:4636:1	a	DT	O	O
patient	TANZEUM.xml:S3:4638:7	patient	NN	O	O
treated	TANZEUM.xml:S3:4646:7	treat	VBN	O	O
with	TANZEUM.xml:S3:4654:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S3:4659:7	tanzeum	NNP	O	O
.	TANZEUM.xml:S3:4666:1	.	.	O	O

If	TANZEUM.xml:S3:4668:2	If	IN	O	O
hypersensitivity	TANZEUM.xml:S3:4671:16	hypersensit	NN	O	O
reactions	TANZEUM.xml:S3:4688:9	reaction	NNS	O	O
occur	TANZEUM.xml:S3:4698:5	occur	VBP	O	O
,	TANZEUM.xml:S3:4703:1	,	,	O	O
discontinue	TANZEUM.xml:S3:4705:11	discontinu	VBP	O	O
use	TANZEUM.xml:S3:4717:3	use	NN	O	O
of	TANZEUM.xml:S3:4721:2	of	IN	O	O
TANZEUM	TANZEUM.xml:S3:4724:7	tanzeum	NNP	O	O
;	TANZEUM.xml:S3:4731:1	;	:	O	O
treat	TANZEUM.xml:S3:4733:5	treat	NN	O	O
promptly	TANZEUM.xml:S3:4739:8	promptli	RB	O	O
per	TANZEUM.xml:S3:4748:3	per	IN	O	O
standard	TANZEUM.xml:S3:4752:8	standard	NN	O	O
of	TANZEUM.xml:S3:4761:2	of	IN	O	O
care	TANZEUM.xml:S3:4764:4	care	NN	O	O
and	TANZEUM.xml:S3:4769:3	and	CC	O	O
monitor	TANZEUM.xml:S3:4773:7	monitor	NN	O	O
until	TANZEUM.xml:S3:4781:5	until	IN	O	O
signs	TANZEUM.xml:S3:4787:5	sign	NNS	O	O
and	TANZEUM.xml:S3:4793:3	and	CC	O	O
symptoms	TANZEUM.xml:S3:4797:8	symptom	NNS	O	O
resolve	TANZEUM.xml:S3:4806:7	resolv	VBP	O	O
[	TANZEUM.xml:S3:4815:1	[	JJ	O	O
see	TANZEUM.xml:S3:4816:3	see	NN	O	O
Contraindications	TANZEUM.xml:S3:4820:17	contraind	NNP	O	O
(	TANZEUM.xml:S3:4838:1	(	(	O	O
4.2	TANZEUM.xml:S3:4839:3	4.2	CD	O	O
)]	TANZEUM.xml:S3:4842:2	)]	NN	O	O
.	TANZEUM.xml:S3:4846:1	.	.	O	O

5.5	TANZEUM.xml:S3:4854:3	5.5	CD	O	O
Renal	TANZEUM.xml:S3:4858:5	renal	JJ	O	O
Impairment	TANZEUM.xml:S3:4864:10	impair	NN	O	O

In	TANZEUM.xml:S3:4878:2	In	IN	O	O
patients	TANZEUM.xml:S3:4881:8	patient	NNS	O	O
treated	TANZEUM.xml:S3:4890:7	treat	VBN	O	O
with	TANZEUM.xml:S3:4898:4	with	IN	O	O
GLP	TANZEUM.xml:S3:4903:3	glp	NNP	O	O
-	TANZEUM.xml:S3:4906:1	-	:	O	O
1	TANZEUM.xml:S3:4907:1	1	CD	O	O
receptor	TANZEUM.xml:S3:4909:8	receptor	NN	O	O
agonists	TANZEUM.xml:S3:4918:8	agonist	NNS	O	O
,	TANZEUM.xml:S3:4926:1	,	,	O	O
there	TANZEUM.xml:S3:4928:5	there	EX	O	O
have	TANZEUM.xml:S3:4934:4	have	VBP	O	O
been	TANZEUM.xml:S3:4939:4	been	VBN	O	O
postmarketing	TANZEUM.xml:S3:4944:13	postmarket	VBG	O	O
reports	TANZEUM.xml:S3:4958:7	report	NNS	O	O
of	TANZEUM.xml:S3:4966:2	of	IN	O	O
acute	TANZEUM.xml:S3:4969:5	acut	JJ	B-AdverseReaction	B-AdverseReaction
renal	TANZEUM.xml:S3:4975:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	TANZEUM.xml:S3:4981:7	failur	NN	I-AdverseReaction	I-AdverseReaction
and	TANZEUM.xml:S3:4989:3	and	CC	O	O
worsening	TANZEUM.xml:S3:4993:9	worsen	NN	B-AdverseReaction	B-AdverseReaction
of	TANZEUM.xml:S3:5003:2	of	IN	I-AdverseReaction	I-AdverseReaction
chronic	TANZEUM.xml:S3:5006:7	chronic	JJ	I-AdverseReaction	I-AdverseReaction
renal	TANZEUM.xml:S3:5014:5	renal	JJ	I-AdverseReaction	I-AdverseReaction
failure	TANZEUM.xml:S3:5020:7	failur	NN	I-AdverseReaction	I-AdverseReaction
,	TANZEUM.xml:S3:5027:1	,	,	O	O
which	TANZEUM.xml:S3:5029:5	which	WDT	O	O
may	TANZEUM.xml:S3:5035:3	may	MD	O	O
sometimes	TANZEUM.xml:S3:5039:9	sometim	RB	O	O
require	TANZEUM.xml:S3:5049:7	requir	VB	O	O
hemodialysis	TANZEUM.xml:S3:5057:12	hemodialysi	NN	O	O
.	TANZEUM.xml:S3:5069:1	.	.	O	O

Some	TANZEUM.xml:S3:5071:4	some	DT	O	O
of	TANZEUM.xml:S3:5076:2	of	IN	O	O
these	TANZEUM.xml:S3:5079:5	these	DT	O	O
events	TANZEUM.xml:S3:5085:6	event	NNS	O	O
were	TANZEUM.xml:S3:5092:4	were	VBD	O	O
reported	TANZEUM.xml:S3:5097:8	report	VBN	O	O
in	TANZEUM.xml:S3:5106:2	in	IN	O	O
patients	TANZEUM.xml:S3:5109:8	patient	NNS	O	O
without	TANZEUM.xml:S3:5118:7	without	IN	O	O
known	TANZEUM.xml:S3:5126:5	known	VBN	O	O
underlying	TANZEUM.xml:S3:5132:10	underli	JJ	O	O
renal	TANZEUM.xml:S3:5143:5	renal	JJ	O	O
disease	TANZEUM.xml:S3:5149:7	diseas	NN	O	O
.	TANZEUM.xml:S3:5156:1	.	.	O	O

A	TANZEUM.xml:S3:5158:1	A	DT	O	O
majority	TANZEUM.xml:S3:5160:8	major	NN	O	O
of	TANZEUM.xml:S3:5169:2	of	IN	O	O
reported	TANZEUM.xml:S3:5172:8	report	JJ	O	O
events	TANZEUM.xml:S3:5181:6	event	NNS	O	O
occurred	TANZEUM.xml:S3:5188:8	occur	VBD	O	O
in	TANZEUM.xml:S3:5197:2	in	IN	O	O
patients	TANZEUM.xml:S3:5200:8	patient	NNS	O	O
who	TANZEUM.xml:S3:5209:3	who	WP	O	O
had	TANZEUM.xml:S3:5213:3	had	VBD	O	O
experienced	TANZEUM.xml:S3:5217:11	experienc	VBN	O	O
nausea	TANZEUM.xml:S3:5229:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	TANZEUM.xml:S3:5235:1	,	,	O	O
vomiting	TANZEUM.xml:S3:5237:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	TANZEUM.xml:S3:5245:1	,	,	O	O
diarrhea	TANZEUM.xml:S3:5247:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	TANZEUM.xml:S3:5255:1	,	,	O	O
or	TANZEUM.xml:S3:5257:2	or	CC	O	O
dehydration	TANZEUM.xml:S3:5260:11	dehydr	NN	B-AdverseReaction	O
.	TANZEUM.xml:S3:5271:1	.	.	O	O

In	TANZEUM.xml:S3:5273:2	In	IN	O	O
a	TANZEUM.xml:S3:5276:1	a	DT	O	O
trial	TANZEUM.xml:S3:5278:5	trial	NN	O	O
of	TANZEUM.xml:S3:5284:2	of	IN	O	O
TANZEUM	TANZEUM.xml:S3:5287:7	tanzeum	NNP	O	O
in	TANZEUM.xml:S3:5295:2	in	IN	O	O
patients	TANZEUM.xml:S3:5298:8	patient	NNS	O	O
with	TANZEUM.xml:S3:5307:4	with	IN	O	O
renal	TANZEUM.xml:S3:5312:5	renal	JJ	O	O
impairment	TANZEUM.xml:S3:5318:10	impair	NN	O	O
[	TANZEUM.xml:S3:5330:1	[	NNP	O	O
see	TANZEUM.xml:S3:5331:3	see	VBP	O	O
Clinical	TANZEUM.xml:S3:5335:8	clinic	JJ	O	O
Studies	TANZEUM.xml:S3:5344:7	studi	NNP	O	O
(	TANZEUM.xml:S3:5352:1	(	(	O	O
14.3	TANZEUM.xml:S3:5353:4	14.3	CD	O	O
)]	TANZEUM.xml:S3:5357:2	)]	NN	O	O
,	TANZEUM.xml:S3:5361:1	,	,	O	O
the	TANZEUM.xml:S3:5363:3	the	DT	O	O
frequency	TANZEUM.xml:S3:5367:9	frequenc	NN	O	O
of	TANZEUM.xml:S3:5377:2	of	IN	O	O
such	TANZEUM.xml:S3:5380:4	such	JJ	O	O
gastrointestinal	TANZEUM.xml:S3:5385:16	gastrointestin	JJ	B-AdverseReaction	O
reactions	TANZEUM.xml:S3:5402:9	reaction	NNS	I-AdverseReaction	O
increased	TANZEUM.xml:S3:5412:9	increas	VBD	O	O
as	TANZEUM.xml:S3:5422:2	as	IN	O	O
renal	TANZEUM.xml:S3:5425:5	renal	JJ	B-AdverseReaction	B-AdverseReaction
function	TANZEUM.xml:S3:5431:8	function	NN	I-AdverseReaction	I-AdverseReaction
declined	TANZEUM.xml:S3:5440:8	declin	VBD	I-AdverseReaction	I-AdverseReaction
[	TANZEUM.xml:S3:5450:1	[	NNP	O	O
see	TANZEUM.xml:S3:5451:3	see	VB	O	O
Use	TANZEUM.xml:S3:5455:3	use	NNP	O	O
in	TANZEUM.xml:S3:5459:2	in	IN	O	O
Specific	TANZEUM.xml:S3:5462:8	specif	NNP	O	O
Populations	TANZEUM.xml:S3:5471:11	popul	NNP	O	O
(	TANZEUM.xml:S3:5483:1	(	(	O	O
8.6	TANZEUM.xml:S3:5484:3	8.6	CD	O	O
)]	TANZEUM.xml:S3:5487:2	)]	NN	O	O
.	TANZEUM.xml:S3:5491:1	.	.	O	O

Because	TANZEUM.xml:S3:5493:7	becaus	IN	O	O
these	TANZEUM.xml:S3:5501:5	these	DT	O	O
reactions	TANZEUM.xml:S3:5507:9	reaction	NNS	O	O
may	TANZEUM.xml:S3:5517:3	may	MD	O	O
worsen	TANZEUM.xml:S3:5521:6	worsen	VB	O	O
renal	TANZEUM.xml:S3:5528:5	renal	JJ	O	O
function	TANZEUM.xml:S3:5534:8	function	NN	O	O
,	TANZEUM.xml:S3:5542:1	,	,	O	O
use	TANZEUM.xml:S3:5544:3	use	NN	O	O
caution	TANZEUM.xml:S3:5548:7	caution	NN	O	O
when	TANZEUM.xml:S3:5556:4	when	WRB	O	O
initiating	TANZEUM.xml:S3:5561:10	initi	NN	O	O
or	TANZEUM.xml:S3:5572:2	or	CC	O	O
escalating	TANZEUM.xml:S3:5575:10	escal	VBG	O	O
doses	TANZEUM.xml:S3:5586:5	dose	NNS	O	O
of	TANZEUM.xml:S3:5592:2	of	IN	O	O
TANZEUM	TANZEUM.xml:S3:5595:7	tanzeum	NNP	O	O
in	TANZEUM.xml:S3:5603:2	in	IN	O	O
patients	TANZEUM.xml:S3:5606:8	patient	NNS	O	O
with	TANZEUM.xml:S3:5615:4	with	IN	O	O
renal	TANZEUM.xml:S3:5620:5	renal	JJ	O	O
impairment	TANZEUM.xml:S3:5626:10	impair	NN	O	O
[	TANZEUM.xml:S3:5638:1	[	NNP	O	O
see	TANZEUM.xml:S3:5639:3	see	VBP	O	O
Dosage	TANZEUM.xml:S3:5643:6	dosag	NNP	O	O
and	TANZEUM.xml:S3:5650:3	and	CC	O	O
Administration	TANZEUM.xml:S3:5654:14	administr	NNP	O	O
(	TANZEUM.xml:S3:5669:1	(	(	O	O
2.3	TANZEUM.xml:S3:5670:3	2.3	CD	O	O
)	TANZEUM.xml:S3:5673:1	)	)	O	O
,	TANZEUM.xml:S3:5674:1	,	,	O	O
Use	TANZEUM.xml:S3:5676:3	use	NNP	O	O
in	TANZEUM.xml:S3:5680:2	in	IN	O	O
Specific	TANZEUM.xml:S3:5683:8	specif	NNP	O	O
Populations	TANZEUM.xml:S3:5692:11	popul	NNP	O	O
(	TANZEUM.xml:S3:5704:1	(	(	O	O
8.6	TANZEUM.xml:S3:5705:3	8.6	CD	O	O
)]	TANZEUM.xml:S3:5708:2	)]	NN	O	O
.	TANZEUM.xml:S3:5710:1	.	.	O	O

5.6	TANZEUM.xml:S3:5720:3	5.6	CD	O	O
Macrovascular	TANZEUM.xml:S3:5724:13	macrovascular	JJ	O	O
Outcomes	TANZEUM.xml:S3:5738:8	outcom	NNS	O	O

There	TANZEUM.xml:S3:5750:5	there	EX	O	O
have	TANZEUM.xml:S3:5756:4	have	VBP	O	O
been	TANZEUM.xml:S3:5761:4	been	VBN	O	O
no	TANZEUM.xml:S3:5766:2	no	DT	O	O
clinical	TANZEUM.xml:S3:5769:8	clinic	JJ	O	O
trials	TANZEUM.xml:S3:5778:6	trial	NNS	O	O
establishing	TANZEUM.xml:S3:5785:12	establish	VBG	O	O
conclusive	TANZEUM.xml:S3:5798:10	conclus	JJ	O	O
evidence	TANZEUM.xml:S3:5809:8	evid	NN	O	O
of	TANZEUM.xml:S3:5818:2	of	IN	O	O
macrovascular	TANZEUM.xml:S3:5821:13	macrovascular	JJ	O	O
risk	TANZEUM.xml:S3:5835:4	risk	NN	O	O
reduction	TANZEUM.xml:S3:5840:9	reduct	NN	O	O
with	TANZEUM.xml:S3:5850:4	with	IN	O	O
TANZEUM	TANZEUM.xml:S3:5855:7	tanzeum	NNP	O	O
or	TANZEUM.xml:S3:5863:2	or	CC	O	O
any	TANZEUM.xml:S3:5866:3	ani	DT	O	O
other	TANZEUM.xml:S3:5870:5	other	JJ	O	O
antidiabetic	TANZEUM.xml:S3:5876:12	antidiabet	JJ	O	O
drug	TANZEUM.xml:S3:5889:4	drug	NN	O	O
.	TANZEUM.xml:S3:5893:1	.	.	O	O
6	TECFIDERA.xml:S1:4:1	6	CD	O	O
ADVERSE	TECFIDERA.xml:S1:6:7	advers	JJ	O	O
REACTIONS	TECFIDERA.xml:S1:14:9	reaction	NN	O	O

The	TECFIDERA.xml:S1:27:3	the	DT	O	O
following	TECFIDERA.xml:S1:31:9	follow	JJ	O	O
important	TECFIDERA.xml:S1:41:9	import	JJ	O	O
adverse	TECFIDERA.xml:S1:51:7	advers	JJ	O	O
reactions	TECFIDERA.xml:S1:59:9	reaction	NNS	O	O
are	TECFIDERA.xml:S1:69:3	are	VBP	O	O
described	TECFIDERA.xml:S1:73:9	describ	VBN	O	O
elsewhere	TECFIDERA.xml:S1:83:9	elsewher	RB	O	O
in	TECFIDERA.xml:S1:93:2	in	IN	O	O
labeling	TECFIDERA.xml:S1:96:8	label	NN	O	O
:	TECFIDERA.xml:S1:104:1	:	:	O	O

Anaphylaxis	TECFIDERA.xml:S1:113:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
and	TECFIDERA.xml:S1:125:3	and	CC	O	O
Angioedema	TECFIDERA.xml:S1:129:10	angioedema	NNP	B-AdverseReaction	B-AdverseReaction
[	TECFIDERA.xml:S1:140:1	[	NNP	O	O
see	TECFIDERA.xml:S1:141:3	see	VBP	O	O
Warnings	TECFIDERA.xml:S1:145:8	warn	NNP	O	O
and	TECFIDERA.xml:S1:154:3	and	CC	O	O
Precautions	TECFIDERA.xml:S1:158:11	precaut	NNP	O	O
(	TECFIDERA.xml:S1:170:1	(	(	O	O
5.1	TECFIDERA.xml:S1:173:3	5.1	CD	O	O
)]	TECFIDERA.xml:S1:178:2	)]	NN	O	O
.	TECFIDERA.xml:S1:180:1	.	.	O	O

Progressive	TECFIDERA.xml:S1:188:11	progress	JJ	B-AdverseReaction	B-AdverseReaction
multifocal	TECFIDERA.xml:S1:200:10	multifoc	JJ	I-AdverseReaction	I-AdverseReaction
leukoencephalopathy	TECFIDERA.xml:S1:211:19	leukoencephalopathi	NN	I-AdverseReaction	I-AdverseReaction
[	TECFIDERA.xml:S1:231:1	[	NNP	O	O
see	TECFIDERA.xml:S1:232:3	see	VBP	O	O
Warnings	TECFIDERA.xml:S1:236:8	warn	NNP	O	O
and	TECFIDERA.xml:S1:245:3	and	CC	O	O
Precautions	TECFIDERA.xml:S1:249:11	precaut	NNP	O	O
(	TECFIDERA.xml:S1:261:1	(	(	O	O
5.2	TECFIDERA.xml:S1:264:3	5.2	CD	O	O
)]	TECFIDERA.xml:S1:269:2	)]	NN	O	O
.	TECFIDERA.xml:S1:271:1	.	.	O	O

Lymphopenia	TECFIDERA.xml:S1:279:11	lymphopenia	NNP	B-AdverseReaction	B-AdverseReaction
[	TECFIDERA.xml:S1:291:1	[	NNP	O	O
see	TECFIDERA.xml:S1:292:3	see	VBP	O	O
Warnings	TECFIDERA.xml:S1:296:8	warn	NNP	O	O
and	TECFIDERA.xml:S1:305:3	and	CC	O	O
Precautions	TECFIDERA.xml:S1:309:11	precaut	NNP	O	O
(	TECFIDERA.xml:S1:321:1	(	(	O	O
5.3	TECFIDERA.xml:S1:324:3	5.3	CD	O	O
)]	TECFIDERA.xml:S1:329:2	)]	NN	O	O
.	TECFIDERA.xml:S1:331:1	.	.	O	O

Flushing	TECFIDERA.xml:S1:339:8	flush	VBG	B-AdverseReaction	B-AdverseReaction
[	TECFIDERA.xml:S1:348:1	[	NNP	O	O
see	TECFIDERA.xml:S1:349:3	see	VBP	O	O
Warnings	TECFIDERA.xml:S1:353:8	warn	NNP	O	O
and	TECFIDERA.xml:S1:362:3	and	CC	O	O
Precautions	TECFIDERA.xml:S1:366:11	precaut	NNP	O	O
(	TECFIDERA.xml:S1:378:1	(	(	O	O
5.4	TECFIDERA.xml:S1:381:3	5.4	CD	O	O
)]	TECFIDERA.xml:S1:386:2	)]	NN	O	O
.	TECFIDERA.xml:S1:388:1	.	.	O	O

EXCERPT	TECFIDERA.xml:S1:398:7	excerpt	NNS	O	O
:	TECFIDERA.xml:S1:405:1	:	:	O	O
Most	TECFIDERA.xml:S1:409:4	most	JJS	O	O
common	TECFIDERA.xml:S1:414:6	common	JJ	O	O
adverse	TECFIDERA.xml:S1:421:7	advers	JJ	O	O
reactions	TECFIDERA.xml:S1:429:9	reaction	NNS	O	O
(	TECFIDERA.xml:S1:439:1	(	(	O	O
incidence	TECFIDERA.xml:S1:440:9	incid	NN	O	O
10%	TECFIDERA.xml:S1:452:3	10%	CD	O	O
and	TECFIDERA.xml:S1:456:3	and	CC	O	O
2%	TECFIDERA.xml:S1:462:2	2%	CD	O	O
placebo	TECFIDERA.xml:S1:465:7	placebo	NN	O	O
)	TECFIDERA.xml:S1:472:1	)	)	O	O
were	TECFIDERA.xml:S1:474:4	were	VBD	O	O
flushing	TECFIDERA.xml:S1:479:8	flush	VBG	B-AdverseReaction	B-AdverseReaction
,	TECFIDERA.xml:S1:487:1	,	,	O	O
abdominal	TECFIDERA.xml:S1:489:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TECFIDERA.xml:S1:499:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TECFIDERA.xml:S1:503:1	,	,	O	O
diarrhea	TECFIDERA.xml:S1:505:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	TECFIDERA.xml:S1:513:1	,	,	O	O
and	TECFIDERA.xml:S1:515:3	and	CC	O	O
nausea	TECFIDERA.xml:S1:519:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
.	TECFIDERA.xml:S1:525:1	.	.	O	O

(	TECFIDERA.xml:S1:527:1	(	(	O	O
6.1	TECFIDERA.xml:S1:530:3	6.1	CD	O	O
)	TECFIDERA.xml:S1:535:1	)	)	O	O

To	TECFIDERA.xml:S1:543:2	To	TO	O	O

report	TECFIDERA.xml:S1:546:6	report	NN	O	O
SUSPECTED	TECFIDERA.xml:S1:553:9	suspect	NNP	O	O
ADVERSE	TECFIDERA.xml:S1:563:7	advers	NNP	O	O
REACTIONS	TECFIDERA.xml:S1:571:9	reaction	NNP	O	O
,	TECFIDERA.xml:S1:580:1	,	,	O	O
contact	TECFIDERA.xml:S1:582:7	contact	NN	O	O
Biogen	TECFIDERA.xml:S1:590:6	biogen	NNP	O	O
at	TECFIDERA.xml:S1:597:2	at	IN	O	O
1	TECFIDERA.xml:S1:600:1	1	CD	O	O
-	TECFIDERA.xml:S1:601:1	-	:	O	O
800	TECFIDERA.xml:S1:602:3	800	CD	O	O
-	TECFIDERA.xml:S1:605:1	-	:	O	O
456	TECFIDERA.xml:S1:606:3	456	CD	O	O
-	TECFIDERA.xml:S1:609:1	-	:	O	O
2255	TECFIDERA.xml:S1:610:4	2255	CD	O	O
or	TECFIDERA.xml:S1:615:2	or	CC	O	O
FDA	TECFIDERA.xml:S1:618:3	fda	NNP	O	O
at	TECFIDERA.xml:S1:622:2	at	IN	O	O
1	TECFIDERA.xml:S1:625:1	1	CD	O	O
-	TECFIDERA.xml:S1:626:1	-	:	O	O
800	TECFIDERA.xml:S1:627:3	800	CD	O	O
-	TECFIDERA.xml:S1:630:1	-	:	O	O
FDA	TECFIDERA.xml:S1:631:3	fda	NNP	O	O
-	TECFIDERA.xml:S1:634:1	-	:	O	O
1088	TECFIDERA.xml:S1:635:4	1088	CD	O	O
or	TECFIDERA.xml:S1:640:2	or	CC	O	O
www	TECFIDERA.xml:S1:643:3	www	VB	O	O
.	TECFIDERA.xml:S1:646:1	.	.	O	O
fda	TECFIDERA.xml:S1:647:3	fda	NN	O	O
.	TECFIDERA.xml:S1:650:1	.	.	O	O
gov	TECFIDERA.xml:S1:651:3	gov	JJ	O	O
medwatch	TECFIDERA.xml:S1:655:8	medwatch	NN	O	O
.	TECFIDERA.xml:S1:663:1	.	.	O	O

6.1	TECFIDERA.xml:S1:675:3	6.1	CD	O	O

Clinical	TECFIDERA.xml:S1:679:8	clinic	JJ	O	O
Trials	TECFIDERA.xml:S1:688:6	trial	NNS	O	O
Experience	TECFIDERA.xml:S1:695:10	experi	NN	O	O

Because	TECFIDERA.xml:S1:709:7	becaus	IN	O	O
clinical	TECFIDERA.xml:S1:717:8	clinic	JJ	O	O
trials	TECFIDERA.xml:S1:726:6	trial	NNS	O	O
are	TECFIDERA.xml:S1:733:3	are	VBP	O	O
conducted	TECFIDERA.xml:S1:737:9	conduct	VBN	O	O
under	TECFIDERA.xml:S1:747:5	under	IN	O	O
widely	TECFIDERA.xml:S1:753:6	wide	RB	O	O
varying	TECFIDERA.xml:S1:760:7	vari	VBG	O	O
conditions	TECFIDERA.xml:S1:768:10	condit	NNS	O	O
,	TECFIDERA.xml:S1:778:1	,	,	O	O
adverse	TECFIDERA.xml:S1:780:7	advers	JJ	O	O
reaction	TECFIDERA.xml:S1:788:8	reaction	NN	O	O
rates	TECFIDERA.xml:S1:797:5	rate	NNS	O	O
observed	TECFIDERA.xml:S1:803:8	observ	VBD	O	O
in	TECFIDERA.xml:S1:812:2	in	IN	O	O
clinical	TECFIDERA.xml:S1:815:8	clinic	JJ	O	O
trials	TECFIDERA.xml:S1:824:6	trial	NNS	O	O
of	TECFIDERA.xml:S1:831:2	of	IN	O	O
a	TECFIDERA.xml:S1:834:1	a	DT	O	O
drug	TECFIDERA.xml:S1:836:4	drug	NN	O	O
cannot	TECFIDERA.xml:S1:841:6	cannot	NN	O	O
be	TECFIDERA.xml:S1:848:2	be	VB	O	O
directly	TECFIDERA.xml:S1:851:8	directli	RB	O	O
compared	TECFIDERA.xml:S1:860:8	compar	VBN	O	O
to	TECFIDERA.xml:S1:869:2	to	TO	O	O
rates	TECFIDERA.xml:S1:872:5	rate	NNS	O	O
in	TECFIDERA.xml:S1:878:2	in	IN	O	O
the	TECFIDERA.xml:S1:881:3	the	DT	O	O
clinical	TECFIDERA.xml:S1:885:8	clinic	JJ	O	O
trials	TECFIDERA.xml:S1:894:6	trial	NNS	O	O
of	TECFIDERA.xml:S1:901:2	of	IN	O	O
another	TECFIDERA.xml:S1:904:7	anoth	DT	O	O
drug	TECFIDERA.xml:S1:912:4	drug	NN	O	O
and	TECFIDERA.xml:S1:917:3	and	CC	O	O
may	TECFIDERA.xml:S1:921:3	may	MD	O	O
not	TECFIDERA.xml:S1:925:3	not	RB	O	O
reflect	TECFIDERA.xml:S1:929:7	reflect	VB	O	O
the	TECFIDERA.xml:S1:937:3	the	DT	O	O
rates	TECFIDERA.xml:S1:941:5	rate	NNS	O	O
observed	TECFIDERA.xml:S1:947:8	observ	VBD	O	O
in	TECFIDERA.xml:S1:956:2	in	IN	O	O
clinical	TECFIDERA.xml:S1:959:8	clinic	JJ	O	O
practice	TECFIDERA.xml:S1:968:8	practic	NN	O	O
.	TECFIDERA.xml:S1:976:1	.	.	O	O

The	TECFIDERA.xml:S1:982:3	the	DT	O	O
most	TECFIDERA.xml:S1:986:4	most	RBS	O	O
common	TECFIDERA.xml:S1:991:6	common	JJ	O	O
adverse	TECFIDERA.xml:S1:998:7	advers	JJ	O	O
reactions	TECFIDERA.xml:S1:1006:9	reaction	NNS	O	O
(	TECFIDERA.xml:S1:1016:1	(	(	O	O
incidence	TECFIDERA.xml:S1:1017:9	incid	NN	O	O
10%	TECFIDERA.xml:S1:1029:3	10%	CD	O	O
and	TECFIDERA.xml:S1:1033:3	and	CC	O	O
2%	TECFIDERA.xml:S1:1039:2	2%	CD	O	O
more	TECFIDERA.xml:S1:1042:4	more	JJR	O	O
than	TECFIDERA.xml:S1:1047:4	than	IN	O	O
placebo	TECFIDERA.xml:S1:1052:7	placebo	NN	O	O
)	TECFIDERA.xml:S1:1059:1	)	)	O	O
for	TECFIDERA.xml:S1:1061:3	for	IN	O	O
TECFIDERA	TECFIDERA.xml:S1:1065:9	tecfidera	NNP	O	O
were	TECFIDERA.xml:S1:1075:4	were	VBD	O	O
flushing	TECFIDERA.xml:S1:1080:8	flush	VBG	B-AdverseReaction	B-AdverseReaction
,	TECFIDERA.xml:S1:1088:1	,	,	O	O
abdominal	TECFIDERA.xml:S1:1090:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TECFIDERA.xml:S1:1100:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TECFIDERA.xml:S1:1104:1	,	,	O	O
diarrhea	TECFIDERA.xml:S1:1106:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	TECFIDERA.xml:S1:1114:1	,	,	O	O
and	TECFIDERA.xml:S1:1116:3	and	CC	O	O
nausea	TECFIDERA.xml:S1:1120:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
.	TECFIDERA.xml:S1:1126:1	.	.	O	O

Adverse	TECFIDERA.xml:S1:1136:7	advers	JJ	O	O
Reactions	TECFIDERA.xml:S1:1144:9	reaction	NNP	O	O
in	TECFIDERA.xml:S1:1154:2	in	IN	O	O
Placebo	TECFIDERA.xml:S1:1157:7	placebo	NNP	O	O
-	TECFIDERA.xml:S1:1164:1	-	:	O	O
Controlled	TECFIDERA.xml:S1:1165:10	control	VBD	O	O
Trials	TECFIDERA.xml:S1:1176:6	trial	NNS	O	O

In	TECFIDERA.xml:S1:1189:2	In	IN	O	O
the	TECFIDERA.xml:S1:1192:3	the	DT	O	O
two	TECFIDERA.xml:S1:1196:3	two	CD	O	O
well	TECFIDERA.xml:S1:1200:4	well	RB	O	O
-	TECFIDERA.xml:S1:1204:1	-	:	O	O
controlled	TECFIDERA.xml:S1:1205:10	control	VBN	O	O
studies	TECFIDERA.xml:S1:1216:7	studi	NNS	O	O
demonstrating	TECFIDERA.xml:S1:1224:13	demonstr	VBG	O	O
effectiveness	TECFIDERA.xml:S1:1238:13	effect	NN	O	O
,	TECFIDERA.xml:S1:1251:1	,	,	O	O
1529	TECFIDERA.xml:S1:1253:4	1529	CD	O	O
patients	TECFIDERA.xml:S1:1258:8	patient	NNS	O	O
received	TECFIDERA.xml:S1:1267:8	receiv	VBD	O	O
TECFIDERA	TECFIDERA.xml:S1:1276:9	tecfidera	NNP	O	O
with	TECFIDERA.xml:S1:1286:4	with	IN	O	O
an	TECFIDERA.xml:S1:1291:2	an	DT	O	O
overall	TECFIDERA.xml:S1:1294:7	overal	JJ	O	O
exposure	TECFIDERA.xml:S1:1302:8	exposur	NN	O	O
of	TECFIDERA.xml:S1:1311:2	of	IN	O	O
2244	TECFIDERA.xml:S1:1314:4	2244	CD	O	O
person	TECFIDERA.xml:S1:1319:6	person	NN	O	O
-	TECFIDERA.xml:S1:1325:1	-	:	O	O
years	TECFIDERA.xml:S1:1326:5	year	NNS	O	O
[	TECFIDERA.xml:S1:1333:1	[	VBP	O	O
see	TECFIDERA.xml:S1:1334:3	see	VB	O	O
Clinical	TECFIDERA.xml:S1:1338:8	clinic	JJ	O	O
Studies	TECFIDERA.xml:S1:1347:7	studi	NNP	O	O
(	TECFIDERA.xml:S1:1355:1	(	(	O	O
14	TECFIDERA.xml:S1:1358:2	14	CD	O	O
)]	TECFIDERA.xml:S1:1362:2	)]	NN	O	O
.	TECFIDERA.xml:S1:1364:1	.	.	O	O

The	TECFIDERA.xml:S1:1372:3	the	DT	O	O
adverse	TECFIDERA.xml:S1:1376:7	advers	JJ	O	O
reactions	TECFIDERA.xml:S1:1384:9	reaction	NNS	O	O
presented	TECFIDERA.xml:S1:1394:9	present	VBN	O	O
in	TECFIDERA.xml:S1:1404:2	in	IN	O	O
the	TECFIDERA.xml:S1:1407:3	the	DT	O	O
table	TECFIDERA.xml:S1:1411:5	tabl	NN	O	O
below	TECFIDERA.xml:S1:1417:5	below	NN	O	O
are	TECFIDERA.xml:S1:1423:3	are	VBP	O	O
based	TECFIDERA.xml:S1:1427:5	base	VBN	O	O
on	TECFIDERA.xml:S1:1433:2	on	IN	O	O
safety	TECFIDERA.xml:S1:1436:6	safeti	NN	O	O
information	TECFIDERA.xml:S1:1443:11	inform	NN	O	O
from	TECFIDERA.xml:S1:1455:4	from	IN	O	O
769	TECFIDERA.xml:S1:1460:3	769	CD	O	O
patients	TECFIDERA.xml:S1:1464:8	patient	NNS	O	O
treated	TECFIDERA.xml:S1:1473:7	treat	VBN	O	O
with	TECFIDERA.xml:S1:1481:4	with	IN	O	O
TECFIDERA	TECFIDERA.xml:S1:1486:9	tecfidera	NNP	O	O
240	TECFIDERA.xml:S1:1496:3	240	CD	O	O
mg	TECFIDERA.xml:S1:1500:2	mg	NN	O	O
twice	TECFIDERA.xml:S1:1503:5	twice	RB	O	O
a	TECFIDERA.xml:S1:1509:1	a	DT	O	O
day	TECFIDERA.xml:S1:1511:3	day	NN	O	O
and	TECFIDERA.xml:S1:1515:3	and	CC	O	O
771	TECFIDERA.xml:S1:1519:3	771	CD	O	O
placebo	TECFIDERA.xml:S1:1523:7	placebo	NN	O	O
-	TECFIDERA.xml:S1:1530:1	-	:	O	O
treated	TECFIDERA.xml:S1:1531:7	treat	JJ	O	O
patients	TECFIDERA.xml:S1:1539:8	patient	NNS	O	O
.	TECFIDERA.xml:S1:1547:1	.	.	O	O

Table	TECFIDERA.xml:S1:1553:5	tabl	JJ	O	O
1	TECFIDERA.xml:S1:1559:1	1	CD	O	O
:	TECFIDERA.xml:S1:1560:1	:	:	O	O
Adverse	TECFIDERA.xml:S1:1562:7	advers	JJ	O	O
Reactions	TECFIDERA.xml:S1:1570:9	reaction	NNS	O	O
in	TECFIDERA.xml:S1:1580:2	in	IN	O	O
Study	TECFIDERA.xml:S1:1583:5	studi	NNP	O	O
1	TECFIDERA.xml:S1:1589:1	1	CD	O	O
and	TECFIDERA.xml:S1:1591:3	and	CC	O	O
2	TECFIDERA.xml:S1:1595:1	2	CD	O	O
reported	TECFIDERA.xml:S1:1597:8	report	VBD	O	O
for	TECFIDERA.xml:S1:1606:3	for	IN	O	O
TECFIDERA	TECFIDERA.xml:S1:1610:9	tecfidera	NNP	O	O
240	TECFIDERA.xml:S1:1620:3	240	CD	O	O
mg	TECFIDERA.xml:S1:1624:2	mg	NN	O	O
BID	TECFIDERA.xml:S1:1627:3	bid	NNP	O	O
at	TECFIDERA.xml:S1:1631:2	at	IN	O	O
2%	TECFIDERA.xml:S1:1637:2	2%	CD	O	O
higher	TECFIDERA.xml:S1:1640:6	higher	JJR	O	O
incidence	TECFIDERA.xml:S1:1647:9	incid	NN	O	O
than	TECFIDERA.xml:S1:1657:4	than	IN	O	O
placebo	TECFIDERA.xml:S1:1662:7	placebo	NN	O	O

TECFIDERA	TECFIDERA.xml:S1:1723:9	tecfidera	NNP	O	O
N	TECFIDERA.xml:S1:1736:1	N	NNP	O	O
769	TECFIDERA.xml:S1:1738:3	769	CD	O	O
Placebo	TECFIDERA.xml:S1:1752:7	placebo	NNP	O	O
N	TECFIDERA.xml:S1:1763:1	N	NNP	O	O
771	TECFIDERA.xml:S1:1765:3	771	CD	O	O

Flushing	TECFIDERA.xml:S1:1887:8	flush	VBG	B-AdverseReaction	B-AdverseReaction

40	TECFIDERA.xml:S1:1936:2	40	CD	O	O
6	TECFIDERA.xml:S1:1964:1	6	CD	O	O

Abdominal	TECFIDERA.xml:S1:1994:9	abdomin	NNP	B-AdverseReaction	B-AdverseReaction
pain	TECFIDERA.xml:S1:2004:4	pain	NN	I-AdverseReaction	I-AdverseReaction
18	TECFIDERA.xml:S1:2043:2	18	CD	O	O
10	TECFIDERA.xml:S1:2071:2	10	CD	O	O

Diarrhea	TECFIDERA.xml:S1:2101:8	diarrhea	NNP	B-AdverseReaction	B-AdverseReaction
14	TECFIDERA.xml:S1:2150:2	14	CD	O	O
11	TECFIDERA.xml:S1:2178:2	11	CD	O	O

Nausea	TECFIDERA.xml:S1:2208:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
12	TECFIDERA.xml:S1:2257:2	12	CD	O	O
9	TECFIDERA.xml:S1:2285:1	9	CD	O	O

Vomiting	TECFIDERA.xml:S1:2315:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
9	TECFIDERA.xml:S1:2364:1	9	CD	O	O
5	TECFIDERA.xml:S1:2392:1	5	CD	O	O

Pruritus	TECFIDERA.xml:S1:2422:8	pruritu	NNP	B-AdverseReaction	B-AdverseReaction
8	TECFIDERA.xml:S1:2471:1	8	CD	O	O
4	TECFIDERA.xml:S1:2499:1	4	CD	O	O

Rash	TECFIDERA.xml:S1:2529:4	rash	NNP	B-AdverseReaction	B-AdverseReaction
8	TECFIDERA.xml:S1:2578:1	8	CD	O	O
3	TECFIDERA.xml:S1:2606:1	3	CD	O	O

Albumin	TECFIDERA.xml:S1:2636:7	albumin	NNP	B-AdverseReaction	B-AdverseReaction
urine	TECFIDERA.xml:S1:2644:5	urin	JJ	I-AdverseReaction	I-AdverseReaction
present	TECFIDERA.xml:S1:2650:7	present	JJ	I-AdverseReaction	I-AdverseReaction
6	TECFIDERA.xml:S1:2685:1	6	CD	O	O
4	TECFIDERA.xml:S1:2713:1	4	CD	O	O

Erythema	TECFIDERA.xml:S1:2743:8	erythema	NNP	B-AdverseReaction	B-AdverseReaction
5	TECFIDERA.xml:S1:2792:1	5	CD	O	O
1	TECFIDERA.xml:S1:2820:1	1	CD	O	O

Dyspepsia	TECFIDERA.xml:S1:2850:9	dyspepsia	NNP	B-AdverseReaction	B-AdverseReaction
5	TECFIDERA.xml:S1:2899:1	5	CD	O	O
3	TECFIDERA.xml:S1:2927:1	3	CD	O	O

Aspartate	TECFIDERA.xml:S1:2957:9	aspart	NNP	B-AdverseReaction	B-AdverseReaction
aminotransferase	TECFIDERA.xml:S1:2967:16	aminotransferas	NN	I-AdverseReaction	I-AdverseReaction
increased	TECFIDERA.xml:S1:2984:9	increas	VBD	I-AdverseReaction	I-AdverseReaction
4	TECFIDERA.xml:S1:3006:1	4	CD	O	O
2	TECFIDERA.xml:S1:3034:1	2	CD	O	O

Lymphopenia	TECFIDERA.xml:S1:3064:11	lymphopenia	NNP	B-AdverseReaction	B-AdverseReaction
2	TECFIDERA.xml:S1:3113:1	2	CD	O	O
1	TECFIDERA.xml:S1:3142:1	1	CD	O	O

Gastrointestinal	TECFIDERA.xml:S1:3183:16	gastrointestin	JJ	O	O

TECFIDERA	TECFIDERA.xml:S1:3206:9	tecfidera	NN	O	O

caused	TECFIDERA.xml:S1:3216:6	caus	VBN	O	O
GI	TECFIDERA.xml:S1:3223:2	GI	JJ	B-AdverseReaction	O
events	TECFIDERA.xml:S1:3226:6	event	NNS	I-AdverseReaction	O
(	TECFIDERA.xml:S1:3233:1	(	(	O	O
e	TECFIDERA.xml:S1:3234:1	e	NN	O	O
.	TECFIDERA.xml:S1:3235:1	.	.	O	O
g	TECFIDERA.xml:S1:3236:1	g	NN	O	O
.	TECFIDERA.xml:S1:3237:1	.	.	O	O
,	TECFIDERA.xml:S1:3238:1	,	,	O	O
nausea	TECFIDERA.xml:S1:3240:6	nausea	NN	B-AdverseReaction	B-AdverseReaction
,	TECFIDERA.xml:S1:3246:1	,	,	O	O
vomiting	TECFIDERA.xml:S1:3248:8	vomit	VBG	B-AdverseReaction	B-AdverseReaction
,	TECFIDERA.xml:S1:3256:1	,	,	O	O
diarrhea	TECFIDERA.xml:S1:3258:8	diarrhea	NN	B-AdverseReaction	B-AdverseReaction
,	TECFIDERA.xml:S1:3266:1	,	,	O	O
abdominal	TECFIDERA.xml:S1:3268:9	abdomin	JJ	B-AdverseReaction	B-AdverseReaction
pain	TECFIDERA.xml:S1:3278:4	pain	NN	I-AdverseReaction	I-AdverseReaction
,	TECFIDERA.xml:S1:3282:1	,	,	O	O
and	TECFIDERA.xml:S1:3284:3	and	CC	O	O
dyspepsia	TECFIDERA.xml:S1:3288:9	dyspepsia	NN	B-AdverseReaction	B-AdverseReaction
)	TECFIDERA.xml:S1:3297:1	)	)	O	O
.	TECFIDERA.xml:S1:3298:1	.	.	O	O

The	TECFIDERA.xml:S1:3300:3	the	DT	O	O
incidence	TECFIDERA.xml:S1:3304:9	incid	NN	O	O
of	TECFIDERA.xml:S1:3314:2	of	IN	O	O
GI	TECFIDERA.xml:S1:3317:2	GI	NNP	B-AdverseReaction	B-AdverseReaction
events	TECFIDERA.xml:S1:3320:6	event	NNS	I-AdverseReaction	I-AdverseReaction
was	TECFIDERA.xml:S1:3327:3	wa	VBD	O	O
higher	TECFIDERA.xml:S1:3331:6	higher	JJR	O	O
early	TECFIDERA.xml:S1:3338:5	earli	JJ	O	O
in	TECFIDERA.xml:S1:3344:2	in	IN	O	O
the	TECFIDERA.xml:S1:3347:3	the	DT	O	O
course	TECFIDERA.xml:S1:3351:6	cours	NN	O	O
of	TECFIDERA.xml:S1:3358:2	of	IN	O	O
treatment	TECFIDERA.xml:S1:3361:9	treatment	NN	O	O
(	TECFIDERA.xml:S1:3371:1	(	(	O	O
primarily	TECFIDERA.xml:S1:3372:9	primarili	RB	O	O
in	TECFIDERA.xml:S1:3382:2	in	IN	O	O
month	TECFIDERA.xml:S1:3385:5	month	NN	O	O
1	TECFIDERA.xml:S1:3391:1	1	CD	O	O
)	TECFIDERA.xml:S1:3392:1	)	)	O	O
and	TECFIDERA.xml:S1:3394:3	and	CC	O	O
usually	TECFIDERA.xml:S1:3398:7	usual	RB	O	O
decreased	TECFIDERA.xml:S1:3406:9	decreas	VBN	O	I-AdverseReaction
over	TECFIDERA.xml:S1:3416:4	over	RP	O	O
time	TECFIDERA.xml:S1:3421:4	time	NN	O	O
in	TECFIDERA.xml:S1:3426:2	in	IN	O	O
patients	TECFIDERA.xml:S1:3429:8	patient	NNS	O	O
treated	TECFIDERA.xml:S1:3438:7	treat	VBN	O	O
with	TECFIDERA.xml:S1:3446:4	with	IN	O	O
TECFIDERA	TECFIDERA.xml:S1:3451:9	tecfidera	NNP	O	O
compared	TECFIDERA.xml:S1:3461:8	compar	VBN	O	O
with	TECFIDERA.xml:S1:3470:4	with	IN	O	O
placebo	TECFIDERA.xml:S1:3475:7	placebo	NN	O	O
.	TECFIDERA.xml:S1:3482:1	.	.	O	O

Four	TECFIDERA.xml:S1:3484:4	four	CD	O	O
percent	TECFIDERA.xml:S1:3489:7	percent	NN	O	O
(	TECFIDERA.xml:S1:3497:1	(	(	O	O
4%	TECFIDERA.xml:S1:3498:2	4%	CD	O	O
)	TECFIDERA.xml:S1:3500:1	)	)	O	O
of	TECFIDERA.xml:S1:3502:2	of	IN	O	O
patients	TECFIDERA.xml:S1:3505:8	patient	NNS	O	O
treated	TECFIDERA.xml:S1:3514:7	treat	VBN	O	O
with	TECFIDERA.xml:S1:3522:4	with	IN	O	O
TECFIDERA	TECFIDERA.xml:S1:3527:9	tecfidera	NNP	O	O
and	TECFIDERA.xml:S1:3537:3	and	CC	O	O
less	TECFIDERA.xml:S1:3541:4	less	JJR	O	O
than	TECFIDERA.xml:S1:3546:4	than	IN	O	O
1%	TECFIDERA.xml:S1:3551:2	1%	CD	O	O
of	TECFIDERA.xml:S1:3554:2	of	IN	O	O
placebo	TECFIDERA.xml:S1:3557:7	placebo	NN	O	O
patients	TECFIDERA.xml:S1:3565:8	patient	NNS	O	O
discontinued	TECFIDERA.xml:S1:3574:12	discontinu	VBN	O	O
due	TECFIDERA.xml:S1:3587:3	due	JJ	O	O
to	TECFIDERA.xml:S1:3591:2	to	TO	O	O
gastrointestinal	TECFIDERA.xml:S1:3594:16	gastrointestin	JJ	B-AdverseReaction	B-AdverseReaction
events	TECFIDERA.xml:S1:3611:6	event	NNS	I-AdverseReaction	I-AdverseReaction
.	TECFIDERA.xml:S1:3617:1	.	.	O	O

The	TECFIDERA.xml:S1:3619:3	the	DT	O	O
incidence	TECFIDERA.xml:S1:3623:9	incid	NN	O	O
of	TECFIDERA.xml:S1:3633:2	of	IN	O	O
serious	TECFIDERA.xml:S1:3636:7	seriou	JJ	O	O
GI	TECFIDERA.xml:S1:3644:2	GI	NNP	B-AdverseReaction	B-AdverseReaction
events	TECFIDERA.xml:S1:3647:6	event	NNS	I-AdverseReaction	I-AdverseReaction
was	TECFIDERA.xml:S1:3654:3	wa	VBD	O	O
1%	TECFIDERA.xml:S1:3658:2	1%	CD	O	O
in	TECFIDERA.xml:S1:3661:2	in	IN	O	O
patients	TECFIDERA.xml:S1:3664:8	patient	NNS	O	O
treated	TECFIDERA.xml:S1:3673:7	treat	VBN	O	O
with	TECFIDERA.xml:S1:3681:4	with	IN	O	O
TECFIDERA	TECFIDERA.xml:S1:3686:9	tecfidera	NNP	O	O
.	TECFIDERA.xml:S1:3695:1	.	.	O	O

Hepatic	TECFIDERA.xml:S1:3705:7	hepat	JJ	O	O
Transaminases	TECFIDERA.xml:S1:3713:13	transaminas	NNS	O	O

An	TECFIDERA.xml:S1:3733:2	An	DT	O	O
increased	TECFIDERA.xml:S1:3736:9	increas	JJ	O	O
incidence	TECFIDERA.xml:S1:3746:9	incid	NN	O	O
of	TECFIDERA.xml:S1:3756:2	of	IN	O	O
elevations	TECFIDERA.xml:S1:3759:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
of	TECFIDERA.xml:S1:3770:2	of	IN	I-AdverseReaction	I-AdverseReaction
hepatic	TECFIDERA.xml:S1:3773:7	hepat	JJ	I-AdverseReaction	I-AdverseReaction
transaminases	TECFIDERA.xml:S1:3781:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
in	TECFIDERA.xml:S1:3795:2	in	IN	O	O
patients	TECFIDERA.xml:S1:3798:8	patient	NNS	O	O
treated	TECFIDERA.xml:S1:3807:7	treat	VBN	O	O
with	TECFIDERA.xml:S1:3815:4	with	IN	O	O
TECFIDERA	TECFIDERA.xml:S1:3820:9	tecfidera	NNP	O	O
was	TECFIDERA.xml:S1:3830:3	wa	VBD	O	O
seen	TECFIDERA.xml:S1:3834:4	seen	VBN	O	O
primarily	TECFIDERA.xml:S1:3839:9	primarili	RB	O	O
during	TECFIDERA.xml:S1:3849:6	dure	IN	O	O
the	TECFIDERA.xml:S1:3856:3	the	DT	O	O
first	TECFIDERA.xml:S1:3860:5	first	JJ	O	O
six	TECFIDERA.xml:S1:3866:3	six	CD	O	O
months	TECFIDERA.xml:S1:3870:6	month	NNS	O	O
of	TECFIDERA.xml:S1:3877:2	of	IN	O	O
treatment	TECFIDERA.xml:S1:3880:9	treatment	NN	O	O
,	TECFIDERA.xml:S1:3889:1	,	,	O	O
and	TECFIDERA.xml:S1:3891:3	and	CC	O	O
most	TECFIDERA.xml:S1:3895:4	most	JJS	O	O
patients	TECFIDERA.xml:S1:3900:8	patient	NNS	O	O
with	TECFIDERA.xml:S1:3909:4	with	IN	O	O
elevations	TECFIDERA.xml:S1:3914:10	elev	NNS	O	O
had	TECFIDERA.xml:S1:3925:3	had	VBD	O	O
levels	TECFIDERA.xml:S1:3929:6	level	NNS	O	O
3	TECFIDERA.xml:S1:3938:1	3	CD	O	O
times	TECFIDERA.xml:S1:3940:5	time	NNS	O	O
the	TECFIDERA.xml:S1:3946:3	the	DT	O	O
upper	TECFIDERA.xml:S1:3950:5	upper	JJ	O	O
limit	TECFIDERA.xml:S1:3956:5	limit	NN	O	O
of	TECFIDERA.xml:S1:3962:2	of	IN	O	O
normal	TECFIDERA.xml:S1:3965:6	normal	JJ	O	O
(	TECFIDERA.xml:S1:3972:1	(	(	O	O
ULN	TECFIDERA.xml:S1:3973:3	uln	NNP	O	O
)	TECFIDERA.xml:S1:3976:1	)	)	O	O
.	TECFIDERA.xml:S1:3977:1	.	.	O	O

Elevations	TECFIDERA.xml:S1:3979:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
of	TECFIDERA.xml:S1:3990:2	of	IN	I-AdverseReaction	I-AdverseReaction
alanine	TECFIDERA.xml:S1:3993:7	alanin	JJ	I-AdverseReaction	I-AdverseReaction
aminotransferase	TECFIDERA.xml:S1:4001:16	aminotransferas	NN	I-AdverseReaction	I-AdverseReaction
and	TECFIDERA.xml:S1:4018:3	and	CC	O	O
aspartate	TECFIDERA.xml:S1:4022:9	aspart	JJ	I-AdverseReaction	O
aminotransferase	TECFIDERA.xml:S1:4032:16	aminotransferas	NN	I-AdverseReaction	O
to	TECFIDERA.xml:S1:4049:2	to	TO	O	O
3	TECFIDERA.xml:S1:4055:1	3	CD	O	O
times	TECFIDERA.xml:S1:4057:5	time	NNS	O	O
the	TECFIDERA.xml:S1:4063:3	the	DT	O	O
ULN	TECFIDERA.xml:S1:4067:3	uln	NNP	O	O
occurred	TECFIDERA.xml:S1:4071:8	occur	VBD	O	O
in	TECFIDERA.xml:S1:4080:2	in	IN	O	O
a	TECFIDERA.xml:S1:4083:1	a	DT	O	O
small	TECFIDERA.xml:S1:4085:5	small	JJ	O	O
number	TECFIDERA.xml:S1:4091:6	number	NN	O	O
of	TECFIDERA.xml:S1:4098:2	of	IN	O	O
patients	TECFIDERA.xml:S1:4101:8	patient	NNS	O	O
treated	TECFIDERA.xml:S1:4110:7	treat	VBN	O	O
with	TECFIDERA.xml:S1:4118:4	with	IN	O	O
both	TECFIDERA.xml:S1:4123:4	both	DT	O	O
TECFIDERA	TECFIDERA.xml:S1:4128:9	tecfidera	NNP	O	O
and	TECFIDERA.xml:S1:4138:3	and	CC	O	O
placebo	TECFIDERA.xml:S1:4142:7	placebo	NN	O	O
and	TECFIDERA.xml:S1:4150:3	and	CC	O	O
were	TECFIDERA.xml:S1:4154:4	were	VBD	O	O
balanced	TECFIDERA.xml:S1:4159:8	balanc	VBN	O	O
between	TECFIDERA.xml:S1:4168:7	between	IN	O	O
groups	TECFIDERA.xml:S1:4176:6	group	NNS	O	O
.	TECFIDERA.xml:S1:4182:1	.	.	O	O

There	TECFIDERA.xml:S1:4184:5	there	EX	O	O
were	TECFIDERA.xml:S1:4190:4	were	VBD	O	O
no	TECFIDERA.xml:S1:4195:2	no	DT	O	O
elevations	TECFIDERA.xml:S1:4198:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	TECFIDERA.xml:S1:4209:2	in	IN	I-AdverseReaction	I-AdverseReaction
transaminases	TECFIDERA.xml:S1:4212:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
3	TECFIDERA.xml:S1:4229:1	3	CD	O	O
times	TECFIDERA.xml:S1:4231:5	time	NNS	O	O
the	TECFIDERA.xml:S1:4237:3	the	DT	O	O
ULN	TECFIDERA.xml:S1:4241:3	uln	NNP	O	O
with	TECFIDERA.xml:S1:4245:4	with	IN	O	O
concomitant	TECFIDERA.xml:S1:4250:11	concomit	JJ	O	O
elevations	TECFIDERA.xml:S1:4262:10	elev	NNS	B-AdverseReaction	B-AdverseReaction
in	TECFIDERA.xml:S1:4273:2	in	IN	I-AdverseReaction	I-AdverseReaction
total	TECFIDERA.xml:S1:4276:5	total	JJ	I-AdverseReaction	I-AdverseReaction
bilirubin	TECFIDERA.xml:S1:4282:9	bilirubin	NN	I-AdverseReaction	I-AdverseReaction
2	TECFIDERA.xml:S1:4294:1	2	CD	O	O
times	TECFIDERA.xml:S1:4296:5	time	NNS	O	O
the	TECFIDERA.xml:S1:4302:3	the	DT	O	O
ULN	TECFIDERA.xml:S1:4306:3	uln	NNP	O	O
.	TECFIDERA.xml:S1:4309:1	.	.	O	O

Discontinuations	TECFIDERA.xml:S1:4311:16	discontinu	NNS	O	O
due	TECFIDERA.xml:S1:4328:3	due	JJ	O	O
to	TECFIDERA.xml:S1:4332:2	to	TO	O	O
elevated	TECFIDERA.xml:S1:4335:8	elev	VBN	B-AdverseReaction	B-AdverseReaction
hepatic	TECFIDERA.xml:S1:4344:7	hepat	JJ	I-AdverseReaction	I-AdverseReaction
transaminases	TECFIDERA.xml:S1:4352:13	transaminas	NNS	I-AdverseReaction	I-AdverseReaction
were	TECFIDERA.xml:S1:4366:4	were	VBD	O	O
1%	TECFIDERA.xml:S1:4373:2	1%	CD	O	O
and	TECFIDERA.xml:S1:4376:3	and	CC	O	O
were	TECFIDERA.xml:S1:4380:4	were	VBD	O	O
similar	TECFIDERA.xml:S1:4385:7	similar	JJ	O	O
in	TECFIDERA.xml:S1:4393:2	in	IN	O	O
patients	TECFIDERA.xml:S1:4396:8	patient	NNS	O	O
treated	TECFIDERA.xml:S1:4405:7	treat	VBN	O	O
with	TECFIDERA.xml:S1:4413:4	with	IN	O	O
TECFIDERA	TECFIDERA.xml:S1:4418:9	tecfidera	NNP	O	O
or	TECFIDERA.xml:S1:4428:2	or	CC	O	O
placebo	TECFIDERA.xml:S1:4431:7	placebo	NN	O	O
.	TECFIDERA.xml:S1:4438:1	.	.	O	O

Eosinophilia	TECFIDERA.xml:S1:4448:12	eosinophilia	NNS	O	O

A	TECFIDERA.xml:S1:4467:1	A	DT	O	O
transient	TECFIDERA.xml:S1:4469:9	transient	JJ	O	O
increase	TECFIDERA.xml:S1:4479:8	increas	NN	B-AdverseReaction	B-AdverseReaction
in	TECFIDERA.xml:S1:4488:2	in	IN	I-AdverseReaction	I-AdverseReaction
mean	TECFIDERA.xml:S1:4491:4	mean	JJ	I-AdverseReaction	I-AdverseReaction
eosinophil	TECFIDERA.xml:S1:4496:10	eosinophil	NN	I-AdverseReaction	I-AdverseReaction
counts	TECFIDERA.xml:S1:4507:6	count	NNS	I-AdverseReaction	I-AdverseReaction
was	TECFIDERA.xml:S1:4514:3	wa	VBD	O	O
seen	TECFIDERA.xml:S1:4518:4	seen	VBN	O	O
during	TECFIDERA.xml:S1:4523:6	dure	IN	O	O
the	TECFIDERA.xml:S1:4530:3	the	DT	O	O
first	TECFIDERA.xml:S1:4534:5	first	JJ	O	O
2	TECFIDERA.xml:S1:4540:1	2	CD	O	O
months	TECFIDERA.xml:S1:4542:6	month	NNS	O	O
of	TECFIDERA.xml:S1:4549:2	of	IN	O	O
therapy	TECFIDERA.xml:S1:4552:7	therapi	NN	O	O
.	TECFIDERA.xml:S1:4559:1	.	.	O	O

Adverse	TECFIDERA.xml:S1:4569:7	advers	JJ	O	O
Reactions	TECFIDERA.xml:S1:4577:9	reaction	NNP	O	O
in	TECFIDERA.xml:S1:4587:2	in	IN	O	O
Placebo	TECFIDERA.xml:S1:4590:7	placebo	NNP	O	O
-	TECFIDERA.xml:S1:4597:1	-	:	O	O
Controlled	TECFIDERA.xml:S1:4598:10	control	VBD	O	O
and	TECFIDERA.xml:S1:4609:3	and	CC	O	O
Uncontrolled	TECFIDERA.xml:S1:4613:12	uncontrol	VBD	O	O
Studies	TECFIDERA.xml:S1:4626:7	studi	NNS	O	O

In	TECFIDERA.xml:S1:4640:2	In	IN	O	O
placebo	TECFIDERA.xml:S1:4643:7	placebo	NN	O	O
-	TECFIDERA.xml:S1:4650:1	-	:	O	O
controlled	TECFIDERA.xml:S1:4651:10	control	VBN	O	O
and	TECFIDERA.xml:S1:4662:3	and	CC	O	O
uncontrolled	TECFIDERA.xml:S1:4666:12	uncontrol	JJ	O	O
clinical	TECFIDERA.xml:S1:4679:8	clinic	JJ	O	O
studies	TECFIDERA.xml:S1:4688:7	studi	NNS	O	O
,	TECFIDERA.xml:S1:4695:1	,	,	O	O
a	TECFIDERA.xml:S1:4697:1	a	DT	O	O
total	TECFIDERA.xml:S1:4699:5	total	NN	O	O
of	TECFIDERA.xml:S1:4705:2	of	IN	O	O
2513	TECFIDERA.xml:S1:4708:4	2513	CD	O	O
patients	TECFIDERA.xml:S1:4713:8	patient	NNS	O	O
have	TECFIDERA.xml:S1:4722:4	have	VBP	O	O
received	TECFIDERA.xml:S1:4727:8	receiv	VBN	O	O
TECFIDERA	TECFIDERA.xml:S1:4736:9	tecfidera	NNP	O	O
and	TECFIDERA.xml:S1:4746:3	and	CC	O	O
been	TECFIDERA.xml:S1:4750:4	been	VBN	O	O
followed	TECFIDERA.xml:S1:4755:8	follow	VBN	O	O
for	TECFIDERA.xml:S1:4764:3	for	IN	O	O
periods	TECFIDERA.xml:S1:4768:7	period	NNS	O	O
up	TECFIDERA.xml:S1:4776:2	up	RB	O	O
to	TECFIDERA.xml:S1:4779:2	to	TO	O	O
4	TECFIDERA.xml:S1:4782:1	4	CD	O	O
years	TECFIDERA.xml:S1:4784:5	year	NNS	O	O
with	TECFIDERA.xml:S1:4790:4	with	IN	O	O
an	TECFIDERA.xml:S1:4795:2	an	DT	O	O
overall	TECFIDERA.xml:S1:4798:7	overal	JJ	O	O
exposure	TECFIDERA.xml:S1:4806:8	exposur	NN	O	O
of	TECFIDERA.xml:S1:4815:2	of	IN	O	O
4603	TECFIDERA.xml:S1:4818:4	4603	CD	O	O
person	TECFIDERA.xml:S1:4823:6	person	NN	O	O
-	TECFIDERA.xml:S1:4829:1	-	:	O	O
years	TECFIDERA.xml:S1:4830:5	year	NNS	O	O
.	TECFIDERA.xml:S1:4835:1	.	.	O	O

Approximately	TECFIDERA.xml:S1:4837:13	approxim	RB	O	O
1162	TECFIDERA.xml:S1:4851:4	1162	CD	O	O
patients	TECFIDERA.xml:S1:4856:8	patient	NNS	O	O
have	TECFIDERA.xml:S1:4865:4	have	VBP	O	O
received	TECFIDERA.xml:S1:4870:8	receiv	VBN	O	O
more	TECFIDERA.xml:S1:4879:4	more	JJR	O	O
than	TECFIDERA.xml:S1:4884:4	than	IN	O	O
2	TECFIDERA.xml:S1:4889:1	2	CD	O	O
years	TECFIDERA.xml:S1:4891:5	year	NNS	O	O
of	TECFIDERA.xml:S1:4897:2	of	IN	O	O
treatment	TECFIDERA.xml:S1:4900:9	treatment	NN	O	O
with	TECFIDERA.xml:S1:4910:4	with	IN	O	O
TECFIDERA	TECFIDERA.xml:S1:4915:9	tecfidera	NNP	O	O
.	TECFIDERA.xml:S1:4924:1	.	.	O	O

The	TECFIDERA.xml:S1:4926:3	the	DT	O	O
adverse	TECFIDERA.xml:S1:4930:7	advers	JJ	O	O
reaction	TECFIDERA.xml:S1:4938:8	reaction	NN	O	O
profile	TECFIDERA.xml:S1:4947:7	profil	NN	O	O
of	TECFIDERA.xml:S1:4955:2	of	IN	O	O
TECFIDERA	TECFIDERA.xml:S1:4958:9	tecfidera	NNP	O	O
in	TECFIDERA.xml:S1:4968:2	in	IN	O	O
the	TECFIDERA.xml:S1:4971:3	the	DT	O	O
uncontrolled	TECFIDERA.xml:S1:4975:12	uncontrol	JJ	O	O
clinical	TECFIDERA.xml:S1:4988:8	clinic	JJ	O	O
studies	TECFIDERA.xml:S1:4997:7	studi	NNS	O	O
was	TECFIDERA.xml:S1:5005:3	wa	VBD	O	O
consistent	TECFIDERA.xml:S1:5009:10	consist	JJ	O	O
with	TECFIDERA.xml:S1:5020:4	with	IN	O	O
the	TECFIDERA.xml:S1:5025:3	the	DT	O	O
experience	TECFIDERA.xml:S1:5029:10	experi	NN	O	O
in	TECFIDERA.xml:S1:5040:2	in	IN	O	O
the	TECFIDERA.xml:S1:5043:3	the	DT	O	O
placebo	TECFIDERA.xml:S1:5047:7	placebo	NN	O	O
-	TECFIDERA.xml:S1:5054:1	-	:	O	O
controlled	TECFIDERA.xml:S1:5055:10	control	VBN	O	O
clinical	TECFIDERA.xml:S1:5066:8	clinic	JJ	O	O
trials	TECFIDERA.xml:S1:5075:6	trial	NNS	O	O
.	TECFIDERA.xml:S1:5081:1	.	.	O	O
5	TECFIDERA.xml:S2:4:1	5	CD	O	O
WARNINGS	TECFIDERA.xml:S2:6:8	warn	NNP	O	O
AND	TECFIDERA.xml:S2:15:3	and	NNP	O	O
PRECAUTIONS	TECFIDERA.xml:S2:19:11	precaut	NNP	O	O

EXCERPT	TECFIDERA.xml:S2:37:7	excerpt	NN	O	O
:	TECFIDERA.xml:S2:44:1	:	:	O	O
Anaphylaxis	TECFIDERA.xml:S2:52:11	anaphylaxi	NNP	B-AdverseReaction	B-AdverseReaction
and	TECFIDERA.xml:S2:64:3	and	CC	O	O
angioedema	TECFIDERA.xml:S2:68:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
:	TECFIDERA.xml:S2:78:1	:	:	O	O
Discontinue	TECFIDERA.xml:S2:80:11	discontinu	NN	O	O
and	TECFIDERA.xml:S2:92:3	and	CC	O	O
do	TECFIDERA.xml:S2:96:2	do	VBP	O	O
not	TECFIDERA.xml:S2:99:3	not	RB	O	O
restart	TECFIDERA.xml:S2:103:7	restart	VB	O	O
TECFIDERA	TECFIDERA.xml:S2:111:9	tecfidera	NNP	O	O
if	TECFIDERA.xml:S2:121:2	if	IN	O	O
these	TECFIDERA.xml:S2:124:5	these	DT	O	O
occur	TECFIDERA.xml:S2:130:5	occur	NNS	O	O
.	TECFIDERA.xml:S2:135:1	.	.	O	O

(	TECFIDERA.xml:S2:137:1	(	(	O	O
5.1	TECFIDERA.xml:S2:140:3	5.1	CD	O	O
)	TECFIDERA.xml:S2:145:1	)	)	O	O

Progressive	TECFIDERA.xml:S2:152:11	progress	JJ	B-AdverseReaction	B-AdverseReaction
multifocal	TECFIDERA.xml:S2:164:10	multifoc	JJ	I-AdverseReaction	I-AdverseReaction
leukoencephalopathy	TECFIDERA.xml:S2:175:19	leukoencephalopathi	NN	I-AdverseReaction	I-AdverseReaction
(	TECFIDERA.xml:S2:195:1	(	(	O	O
PML	TECFIDERA.xml:S2:196:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
)	TECFIDERA.xml:S2:199:1	)	)	O	O
:	TECFIDERA.xml:S2:200:1	:	:	O	O
Withhold	TECFIDERA.xml:S2:202:8	withhold	JJ	O	O
TECFIDERA	TECFIDERA.xml:S2:211:9	tecfidera	NNP	O	O
at	TECFIDERA.xml:S2:221:2	at	IN	O	O
the	TECFIDERA.xml:S2:224:3	the	DT	O	O
first	TECFIDERA.xml:S2:228:5	first	JJ	O	O
sign	TECFIDERA.xml:S2:234:4	sign	NN	O	O
or	TECFIDERA.xml:S2:239:2	or	CC	O	O
symptom	TECFIDERA.xml:S2:242:7	symptom	JJ	O	O
suggestive	TECFIDERA.xml:S2:250:10	suggest	NN	O	O
of	TECFIDERA.xml:S2:261:2	of	IN	O	O
PML	TECFIDERA.xml:S2:264:3	pml	NNP	O	O
.	TECFIDERA.xml:S2:267:1	.	.	O	O

(	TECFIDERA.xml:S2:269:1	(	(	O	O
5.2	TECFIDERA.xml:S2:272:3	5.2	CD	O	O
)	TECFIDERA.xml:S2:277:1	)	)	O	O

Lymphopenia	TECFIDERA.xml:S2:284:11	lymphopenia	NNP	B-AdverseReaction	B-AdverseReaction
:	TECFIDERA.xml:S2:295:1	:	:	O	O
Obtain	TECFIDERA.xml:S2:297:6	obtain	VBP	O	O
a	TECFIDERA.xml:S2:304:1	a	DT	O	O
CBC	TECFIDERA.xml:S2:306:3	cbc	NNP	O	O
including	TECFIDERA.xml:S2:310:9	includ	VBG	O	O
lymphocyte	TECFIDERA.xml:S2:320:10	lymphocyt	JJ	O	O
count	TECFIDERA.xml:S2:331:5	count	NN	O	O
before	TECFIDERA.xml:S2:337:6	befor	IN	O	O
initiating	TECFIDERA.xml:S2:344:10	initi	VBG	O	O
TECFIDERA	TECFIDERA.xml:S2:355:9	tecfidera	NNP	O	O
,	TECFIDERA.xml:S2:364:1	,	,	O	O
after	TECFIDERA.xml:S2:366:5	after	IN	O	O
6	TECFIDERA.xml:S2:372:1	6	CD	O	O
months	TECFIDERA.xml:S2:374:6	month	NNS	O	O
,	TECFIDERA.xml:S2:380:1	,	,	O	O
and	TECFIDERA.xml:S2:382:3	and	CC	O	O
every	TECFIDERA.xml:S2:386:5	everi	DT	O	O
6	TECFIDERA.xml:S2:392:1	6	CD	O	O
to	TECFIDERA.xml:S2:394:2	to	TO	O	O
12	TECFIDERA.xml:S2:397:2	12	CD	O	O
months	TECFIDERA.xml:S2:400:6	month	NNS	O	O
thereafter	TECFIDERA.xml:S2:407:10	thereaft	RB	O	O
.	TECFIDERA.xml:S2:417:1	.	.	O	O

Consider	TECFIDERA.xml:S2:419:8	consid	VB	O	O
interruption	TECFIDERA.xml:S2:428:12	interrupt	NN	O	O
of	TECFIDERA.xml:S2:441:2	of	IN	O	O
TECFIDERA	TECFIDERA.xml:S2:444:9	tecfidera	NNP	O	O
if	TECFIDERA.xml:S2:454:2	if	IN	O	O
lymphocyte	TECFIDERA.xml:S2:457:10	lymphocyt	JJ	O	O
counts	TECFIDERA.xml:S2:468:6	count	VBZ	O	O
0.5	TECFIDERA.xml:S2:476:3	0.5	CD	O	O
x	TECFIDERA.xml:S2:480:1	x	NN	O	O
10	TECFIDERA.xml:S2:482:2	10	CD	O	O
9	TECFIDERA.xml:S2:486:1	9	CD	O	O
L	TECFIDERA.xml:S2:490:1	L	NNP	O	O
persist	TECFIDERA.xml:S2:492:7	persist	NN	O	O
for	TECFIDERA.xml:S2:500:3	for	IN	O	O
more	TECFIDERA.xml:S2:504:4	more	JJR	O	O
than	TECFIDERA.xml:S2:509:4	than	IN	O	O
six	TECFIDERA.xml:S2:514:3	six	CD	O	O
months	TECFIDERA.xml:S2:518:6	month	NNS	O	O
.	TECFIDERA.xml:S2:524:1	.	.	O	O

(	TECFIDERA.xml:S2:526:1	(	(	O	O
5.3	TECFIDERA.xml:S2:529:3	5.3	CD	O	O
)	TECFIDERA.xml:S2:534:1	)	)	O	O

5.1	TECFIDERA.xml:S2:551:3	5.1	CD	O	O

Anaphylaxis	TECFIDERA.xml:S2:555:11	anaphylaxi	NN	O	O

and	TECFIDERA.xml:S2:567:3	and	CC	O	O
Angioedema	TECFIDERA.xml:S2:571:10	angioedema	NNP	O	O

TECFIDERA	TECFIDERA.xml:S2:590:9	tecfidera	NNP	O	O
can	TECFIDERA.xml:S2:600:3	can	MD	O	O
cause	TECFIDERA.xml:S2:604:5	caus	VB	O	O
anaphylaxis	TECFIDERA.xml:S2:610:11	anaphylaxi	NN	B-AdverseReaction	B-AdverseReaction
and	TECFIDERA.xml:S2:622:3	and	CC	O	O
angioedema	TECFIDERA.xml:S2:626:10	angioedema	NN	B-AdverseReaction	B-AdverseReaction
after	TECFIDERA.xml:S2:637:5	after	IN	O	O
the	TECFIDERA.xml:S2:643:3	the	DT	O	O
first	TECFIDERA.xml:S2:647:5	first	JJ	O	O
dose	TECFIDERA.xml:S2:653:4	dose	NN	O	O
or	TECFIDERA.xml:S2:658:2	or	CC	O	O
at	TECFIDERA.xml:S2:661:2	at	IN	O	O
any	TECFIDERA.xml:S2:664:3	ani	DT	O	O
time	TECFIDERA.xml:S2:668:4	time	NN	O	O
during	TECFIDERA.xml:S2:673:6	dure	IN	O	O
treatment	TECFIDERA.xml:S2:680:9	treatment	NN	O	O
.	TECFIDERA.xml:S2:689:1	.	.	O	O

Signs	TECFIDERA.xml:S2:691:5	sign	NNS	O	O
and	TECFIDERA.xml:S2:697:3	and	CC	O	O
symptoms	TECFIDERA.xml:S2:701:8	symptom	NNS	O	O
have	TECFIDERA.xml:S2:710:4	have	VBP	O	O
included	TECFIDERA.xml:S2:715:8	includ	VBN	O	O
difficulty	TECFIDERA.xml:S2:724:10	difficulti	NN	B-AdverseReaction	B-AdverseReaction
breathing	TECFIDERA.xml:S2:735:9	breath	NN	I-AdverseReaction	I-AdverseReaction
,	TECFIDERA.xml:S2:744:1	,	,	O	O
urticaria	TECFIDERA.xml:S2:746:9	urticaria	NN	B-AdverseReaction	B-AdverseReaction
,	TECFIDERA.xml:S2:755:1	,	,	O	O
and	TECFIDERA.xml:S2:757:3	and	CC	O	O
swelling	TECFIDERA.xml:S2:761:8	swell	VBG	B-AdverseReaction	B-AdverseReaction
of	TECFIDERA.xml:S2:770:2	of	IN	I-AdverseReaction	I-AdverseReaction
the	TECFIDERA.xml:S2:773:3	the	DT	I-AdverseReaction	I-AdverseReaction
throat	TECFIDERA.xml:S2:777:6	throat	NN	I-AdverseReaction	I-AdverseReaction
and	TECFIDERA.xml:S2:784:3	and	CC	O	O
tongue	TECFIDERA.xml:S2:788:6	tongu	NN	I-AdverseReaction	O
.	TECFIDERA.xml:S2:794:1	.	.	O	O

Patients	TECFIDERA.xml:S2:796:8	patient	NNS	O	O
should	TECFIDERA.xml:S2:805:6	should	MD	O	O
be	TECFIDERA.xml:S2:812:2	be	VB	O	O
instructed	TECFIDERA.xml:S2:815:10	instruct	VBN	O	O
to	TECFIDERA.xml:S2:826:2	to	TO	O	O
discontinue	TECFIDERA.xml:S2:829:11	discontinu	VB	O	O
TECFIDERA	TECFIDERA.xml:S2:841:9	tecfidera	NNP	O	O
and	TECFIDERA.xml:S2:851:3	and	CC	O	O
seek	TECFIDERA.xml:S2:855:4	seek	VB	O	O
immediate	TECFIDERA.xml:S2:860:9	immedi	JJ	O	O
medical	TECFIDERA.xml:S2:870:7	medic	JJ	O	O
care	TECFIDERA.xml:S2:878:4	care	NN	O	O
should	TECFIDERA.xml:S2:883:6	should	MD	O	O
they	TECFIDERA.xml:S2:890:4	they	PRP	O	O
experience	TECFIDERA.xml:S2:895:10	experi	VB	O	O
signs	TECFIDERA.xml:S2:906:5	sign	NNS	O	O
and	TECFIDERA.xml:S2:912:3	and	CC	O	O
symptoms	TECFIDERA.xml:S2:916:8	symptom	NNS	O	O
of	TECFIDERA.xml:S2:925:2	of	IN	O	O
anaphylaxis	TECFIDERA.xml:S2:928:11	anaphylaxi	NN	O	O
or	TECFIDERA.xml:S2:940:2	or	CC	O	O
angioedema	TECFIDERA.xml:S2:943:10	angioedema	NN	O	O
.	TECFIDERA.xml:S2:953:1	.	.	O	O

5.2	TECFIDERA.xml:S2:965:3	5.2	CD	O	O
Progressive	TECFIDERA.xml:S2:969:11	progress	JJ	O	O
Multifocal	TECFIDERA.xml:S2:981:10	multifoc	NNP	O	O
Leukoencephalopathy	TECFIDERA.xml:S2:992:19	leukoencephalopathi	NNP	O	O

A	TECFIDERA.xml:S2:1020:1	A	DT	O	O
fatal	TECFIDERA.xml:S2:1022:5	fatal	JJ	B-AdverseReaction	B-AdverseReaction
case	TECFIDERA.xml:S2:1028:4	case	NN	O	O
of	TECFIDERA.xml:S2:1033:2	of	IN	O	O
progressive	TECFIDERA.xml:S2:1036:11	progress	JJ	B-AdverseReaction	B-AdverseReaction
multifocal	TECFIDERA.xml:S2:1048:10	multifoc	JJ	I-AdverseReaction	I-AdverseReaction
leukoencephalopathy	TECFIDERA.xml:S2:1059:19	leukoencephalopathi	NN	I-AdverseReaction	I-AdverseReaction
(	TECFIDERA.xml:S2:1079:1	(	(	O	O
PML	TECFIDERA.xml:S2:1080:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
)	TECFIDERA.xml:S2:1083:1	)	)	O	O
occurred	TECFIDERA.xml:S2:1085:8	occur	VBD	O	O
in	TECFIDERA.xml:S2:1094:2	in	IN	O	O
a	TECFIDERA.xml:S2:1097:1	a	DT	O	O
patient	TECFIDERA.xml:S2:1099:7	patient	NN	O	O
with	TECFIDERA.xml:S2:1107:4	with	IN	O	O
MS	TECFIDERA.xml:S2:1112:2	MS	NNP	O	O
who	TECFIDERA.xml:S2:1115:3	who	WP	O	O
received	TECFIDERA.xml:S2:1119:8	receiv	VBD	O	O
TECFIDERA	TECFIDERA.xml:S2:1128:9	tecfidera	NNP	O	O
for	TECFIDERA.xml:S2:1138:3	for	IN	O	O
4	TECFIDERA.xml:S2:1142:1	4	CD	O	O
years	TECFIDERA.xml:S2:1144:5	year	NNS	O	O
while	TECFIDERA.xml:S2:1150:5	while	IN	O	O
enrolled	TECFIDERA.xml:S2:1156:8	enrol	VBN	O	O
in	TECFIDERA.xml:S2:1165:2	in	IN	O	O
a	TECFIDERA.xml:S2:1168:1	a	DT	O	O
clinical	TECFIDERA.xml:S2:1170:8	clinic	JJ	O	O
trial	TECFIDERA.xml:S2:1179:5	trial	NN	O	O
.	TECFIDERA.xml:S2:1184:1	.	.	O	O

PML	TECFIDERA.xml:S2:1186:3	pml	NNP	O	B-AdverseReaction
is	TECFIDERA.xml:S2:1190:2	is	VBZ	O	O
an	TECFIDERA.xml:S2:1193:2	an	DT	O	O
opportunistic	TECFIDERA.xml:S2:1196:13	opportunist	JJ	O	O
viral	TECFIDERA.xml:S2:1210:5	viral	JJ	O	O
infection	TECFIDERA.xml:S2:1216:9	infect	NN	O	O
of	TECFIDERA.xml:S2:1226:2	of	IN	O	O
the	TECFIDERA.xml:S2:1229:3	the	DT	O	O
brain	TECFIDERA.xml:S2:1233:5	brain	NN	O	O
caused	TECFIDERA.xml:S2:1239:6	caus	VBN	O	O
by	TECFIDERA.xml:S2:1246:2	by	IN	O	O
the	TECFIDERA.xml:S2:1249:3	the	DT	O	O
JC	TECFIDERA.xml:S2:1253:2	JC	NNP	O	B-AdverseReaction
virus	TECFIDERA.xml:S2:1256:5	viru	NN	O	I-AdverseReaction
(	TECFIDERA.xml:S2:1262:1	(	(	O	O
JCV	TECFIDERA.xml:S2:1263:3	jcv	NNP	O	B-AdverseReaction
)	TECFIDERA.xml:S2:1266:1	)	)	O	O
that	TECFIDERA.xml:S2:1268:4	that	WDT	O	O
typically	TECFIDERA.xml:S2:1273:9	typic	RB	O	O
only	TECFIDERA.xml:S2:1283:4	onli	RB	O	O
occurs	TECFIDERA.xml:S2:1288:6	occur	VBZ	O	O
in	TECFIDERA.xml:S2:1295:2	in	IN	O	O
patients	TECFIDERA.xml:S2:1298:8	patient	NNS	O	O
who	TECFIDERA.xml:S2:1307:3	who	WP	O	O
are	TECFIDERA.xml:S2:1311:3	are	VBP	O	O
immunocompromised	TECFIDERA.xml:S2:1315:17	immunocompromis	VBN	O	O
,	TECFIDERA.xml:S2:1332:1	,	,	O	O
and	TECFIDERA.xml:S2:1334:3	and	CC	O	O
that	TECFIDERA.xml:S2:1338:4	that	IN	O	O
usually	TECFIDERA.xml:S2:1343:7	usual	RB	O	O
leads	TECFIDERA.xml:S2:1351:5	lead	VBZ	O	O
to	TECFIDERA.xml:S2:1357:2	to	TO	O	O
death	TECFIDERA.xml:S2:1360:5	death	NN	O	B-AdverseReaction
or	TECFIDERA.xml:S2:1366:2	or	CC	O	O
severe	TECFIDERA.xml:S2:1369:6	sever	JJ	O	O
disability	TECFIDERA.xml:S2:1376:10	disabl	NN	O	O
.	TECFIDERA.xml:S2:1386:1	.	.	O	O

During	TECFIDERA.xml:S2:1388:6	dure	IN	O	O
the	TECFIDERA.xml:S2:1395:3	the	DT	O	O
clinical	TECFIDERA.xml:S2:1399:8	clinic	JJ	O	O
trial	TECFIDERA.xml:S2:1408:5	trial	NN	O	O
,	TECFIDERA.xml:S2:1413:1	,	,	O	O
the	TECFIDERA.xml:S2:1415:3	the	DT	O	O
patient	TECFIDERA.xml:S2:1419:7	patient	NN	O	O
experienced	TECFIDERA.xml:S2:1427:11	experienc	VBD	O	O
prolonged	TECFIDERA.xml:S2:1439:9	prolong	JJ	O	B-AdverseReaction
lymphopenia	TECFIDERA.xml:S2:1449:11	lymphopenia	NN	B-AdverseReaction	I-AdverseReaction
(	TECFIDERA.xml:S2:1461:1	(	(	O	O
lymphocyte	TECFIDERA.xml:S2:1462:10	lymphocyt	JJ	O	B-AdverseReaction
counts	TECFIDERA.xml:S2:1473:6	count	VBZ	O	I-AdverseReaction
predominantly	TECFIDERA.xml:S2:1480:13	predominantli	RB	O	I-AdverseReaction
0.5	TECFIDERA.xml:S2:1495:3	0.5	CD	O	O
x10	TECFIDERA.xml:S2:1498:3	x10	JJ	O	O
9	TECFIDERA.xml:S2:1503:1	9	CD	O	O
L	TECFIDERA.xml:S2:1507:1	L	NNP	O	O
for	TECFIDERA.xml:S2:1509:3	for	IN	O	O
3.5	TECFIDERA.xml:S2:1513:3	3.5	CD	O	O
years	TECFIDERA.xml:S2:1517:5	year	NNS	O	O
)	TECFIDERA.xml:S2:1522:1	)	)	O	O
while	TECFIDERA.xml:S2:1524:5	while	IN	O	O
taking	TECFIDERA.xml:S2:1530:6	take	VBG	O	O
TECFIDERA	TECFIDERA.xml:S2:1537:9	tecfidera	NNP	O	O
[	TECFIDERA.xml:S2:1547:1	[	NNP	O	O
see	TECFIDERA.xml:S2:1548:3	see	VBP	O	O
Warnings	TECFIDERA.xml:S2:1552:8	warn	NNP	O	O
and	TECFIDERA.xml:S2:1561:3	and	CC	O	O
Precautions	TECFIDERA.xml:S2:1565:11	precaut	NNP	O	O
(	TECFIDERA.xml:S2:1577:1	(	(	O	O
5.3	TECFIDERA.xml:S2:1580:3	5.3	CD	O	O
)]	TECFIDERA.xml:S2:1585:2	)]	NN	O	O
.	TECFIDERA.xml:S2:1589:1	.	.	O	O

The	TECFIDERA.xml:S2:1591:3	the	DT	O	O
role	TECFIDERA.xml:S2:1595:4	role	NN	O	O
of	TECFIDERA.xml:S2:1600:2	of	IN	O	O
lymphopenia	TECFIDERA.xml:S2:1603:11	lymphopenia	NN	B-AdverseReaction	O
in	TECFIDERA.xml:S2:1615:2	in	IN	O	O
this	TECFIDERA.xml:S2:1618:4	thi	DT	O	O
case	TECFIDERA.xml:S2:1623:4	case	NN	O	O
is	TECFIDERA.xml:S2:1628:2	is	VBZ	O	O
unknown	TECFIDERA.xml:S2:1631:7	unknown	JJ	O	O
.	TECFIDERA.xml:S2:1638:1	.	.	O	O

The	TECFIDERA.xml:S2:1640:3	the	DT	O	O
patient	TECFIDERA.xml:S2:1644:7	patient	NN	O	O
had	TECFIDERA.xml:S2:1652:3	had	VBD	O	O
no	TECFIDERA.xml:S2:1656:2	no	DT	O	O
other	TECFIDERA.xml:S2:1659:5	other	JJ	O	O
identified	TECFIDERA.xml:S2:1665:10	identifi	VBN	O	O
systemic	TECFIDERA.xml:S2:1676:8	system	JJ	O	O
medical	TECFIDERA.xml:S2:1685:7	medic	JJ	O	O
conditions	TECFIDERA.xml:S2:1693:10	condit	NNS	O	O
resulting	TECFIDERA.xml:S2:1704:9	result	VBG	O	O
in	TECFIDERA.xml:S2:1714:2	in	IN	O	O
compromised	TECFIDERA.xml:S2:1717:11	compromis	VBN	O	B-AdverseReaction
immune	TECFIDERA.xml:S2:1729:6	immun	NN	O	I-AdverseReaction
system	TECFIDERA.xml:S2:1736:6	system	NN	O	I-AdverseReaction
function	TECFIDERA.xml:S2:1743:8	function	NN	O	O
and	TECFIDERA.xml:S2:1752:3	and	CC	O	O
had	TECFIDERA.xml:S2:1756:3	had	VBD	O	O
not	TECFIDERA.xml:S2:1760:3	not	RB	O	O
previously	TECFIDERA.xml:S2:1764:10	previous	RB	O	O
been	TECFIDERA.xml:S2:1775:4	been	VBN	O	O
treated	TECFIDERA.xml:S2:1780:7	treat	VBN	O	O
with	TECFIDERA.xml:S2:1788:4	with	IN	O	O
natalizumab	TECFIDERA.xml:S2:1793:11	natalizumab	NN	O	O
,	TECFIDERA.xml:S2:1804:1	,	,	O	O
which	TECFIDERA.xml:S2:1806:5	which	WDT	O	O
has	TECFIDERA.xml:S2:1812:3	ha	VBZ	O	O
a	TECFIDERA.xml:S2:1816:1	a	DT	O	O
known	TECFIDERA.xml:S2:1818:5	known	VBN	O	O
association	TECFIDERA.xml:S2:1824:11	associ	NN	O	O
with	TECFIDERA.xml:S2:1836:4	with	IN	O	O
PML	TECFIDERA.xml:S2:1841:3	pml	NNP	O	B-AdverseReaction
.	TECFIDERA.xml:S2:1844:1	.	.	O	O

The	TECFIDERA.xml:S2:1846:3	the	DT	O	O
patient	TECFIDERA.xml:S2:1850:7	patient	NN	O	O
was	TECFIDERA.xml:S2:1858:3	wa	VBD	O	O
also	TECFIDERA.xml:S2:1862:4	also	RB	O	O
not	TECFIDERA.xml:S2:1867:3	not	RB	O	O
taking	TECFIDERA.xml:S2:1871:6	take	VBG	O	O
any	TECFIDERA.xml:S2:1878:3	ani	DT	O	O
immunosuppressive	TECFIDERA.xml:S2:1882:17	immunosuppress	JJ	O	O
or	TECFIDERA.xml:S2:1900:2	or	CC	O	O
immunomodulatory	TECFIDERA.xml:S2:1903:16	immunomodulatori	JJ	O	O
medications	TECFIDERA.xml:S2:1920:11	medic	NNS	O	O
concomitantly	TECFIDERA.xml:S2:1932:13	concomitantli	RB	O	O
.	TECFIDERA.xml:S2:1945:1	.	.	O	O

At	TECFIDERA.xml:S2:1951:2	At	IN	O	O
the	TECFIDERA.xml:S2:1954:3	the	DT	O	O
first	TECFIDERA.xml:S2:1958:5	first	JJ	O	O
sign	TECFIDERA.xml:S2:1964:4	sign	NN	O	O
or	TECFIDERA.xml:S2:1969:2	or	CC	O	O
symptom	TECFIDERA.xml:S2:1972:7	symptom	JJ	O	O
suggestive	TECFIDERA.xml:S2:1980:10	suggest	NN	O	O
of	TECFIDERA.xml:S2:1991:2	of	IN	O	O
PML	TECFIDERA.xml:S2:1994:3	pml	NNP	O	O
,	TECFIDERA.xml:S2:1997:1	,	,	O	O
withhold	TECFIDERA.xml:S2:1999:8	withhold	VBD	O	O
TECFIDERA	TECFIDERA.xml:S2:2008:9	tecfidera	NNP	O	O
and	TECFIDERA.xml:S2:2018:3	and	CC	O	O
perform	TECFIDERA.xml:S2:2022:7	perform	VB	O	O
an	TECFIDERA.xml:S2:2030:2	an	DT	O	O
appropriate	TECFIDERA.xml:S2:2033:11	appropri	JJ	O	O
diagnostic	TECFIDERA.xml:S2:2045:10	diagnost	JJ	O	O
evaluation	TECFIDERA.xml:S2:2056:10	evalu	NN	O	O
.	TECFIDERA.xml:S2:2066:1	.	.	O	O

Typical	TECFIDERA.xml:S2:2068:7	typic	JJ	O	O
symptoms	TECFIDERA.xml:S2:2076:8	symptom	NNS	O	O
associated	TECFIDERA.xml:S2:2085:10	associ	VBN	O	O
with	TECFIDERA.xml:S2:2096:4	with	IN	O	O
PML	TECFIDERA.xml:S2:2101:3	pml	NNP	O	B-AdverseReaction
are	TECFIDERA.xml:S2:2105:3	are	VBP	O	O
diverse	TECFIDERA.xml:S2:2109:7	divers	JJ	O	O
,	TECFIDERA.xml:S2:2116:1	,	,	O	O
progress	TECFIDERA.xml:S2:2118:8	progress	NN	O	O
over	TECFIDERA.xml:S2:2127:4	over	IN	O	O
days	TECFIDERA.xml:S2:2132:4	day	NNS	O	O
to	TECFIDERA.xml:S2:2137:2	to	TO	O	O
weeks	TECFIDERA.xml:S2:2140:5	week	NNS	O	O
,	TECFIDERA.xml:S2:2145:1	,	,	O	O
and	TECFIDERA.xml:S2:2147:3	and	CC	O	O
include	TECFIDERA.xml:S2:2151:7	includ	VBP	O	O
progressive	TECFIDERA.xml:S2:2159:11	progress	JJ	O	B-AdverseReaction
weakness	TECFIDERA.xml:S2:2171:8	weak	NN	O	I-AdverseReaction
on	TECFIDERA.xml:S2:2180:2	on	IN	O	I-AdverseReaction
one	TECFIDERA.xml:S2:2183:3	one	CD	O	I-AdverseReaction
side	TECFIDERA.xml:S2:2187:4	side	NN	O	I-AdverseReaction
of	TECFIDERA.xml:S2:2192:2	of	IN	O	I-AdverseReaction
the	TECFIDERA.xml:S2:2195:3	the	DT	O	I-AdverseReaction
body	TECFIDERA.xml:S2:2199:4	bodi	NN	O	I-AdverseReaction
or	TECFIDERA.xml:S2:2204:2	or	CC	O	O
clumsiness	TECFIDERA.xml:S2:2207:10	clumsi	NN	O	B-AdverseReaction
of	TECFIDERA.xml:S2:2218:2	of	IN	O	I-AdverseReaction
limbs	TECFIDERA.xml:S2:2221:5	limb	NNS	O	I-AdverseReaction
,	TECFIDERA.xml:S2:2226:1	,	,	O	O
disturbance	TECFIDERA.xml:S2:2228:11	disturb	NN	O	B-AdverseReaction
of	TECFIDERA.xml:S2:2240:2	of	IN	O	I-AdverseReaction
vision	TECFIDERA.xml:S2:2243:6	vision	NN	O	I-AdverseReaction
,	TECFIDERA.xml:S2:2249:1	,	,	O	O
and	TECFIDERA.xml:S2:2251:3	and	CC	O	O
changes	TECFIDERA.xml:S2:2255:7	chang	NNS	O	B-AdverseReaction
in	TECFIDERA.xml:S2:2263:2	in	IN	O	I-AdverseReaction
thinking	TECFIDERA.xml:S2:2266:8	think	NN	O	I-AdverseReaction
,	TECFIDERA.xml:S2:2274:1	,	,	O	O
memory	TECFIDERA.xml:S2:2276:6	memori	NN	O	I-AdverseReaction
,	TECFIDERA.xml:S2:2282:1	,	,	O	O
and	TECFIDERA.xml:S2:2284:3	and	CC	O	O
orientation	TECFIDERA.xml:S2:2288:11	orient	NN	O	I-AdverseReaction
leading	TECFIDERA.xml:S2:2300:7	lead	VBG	O	O
to	TECFIDERA.xml:S2:2308:2	to	TO	O	O
confusion	TECFIDERA.xml:S2:2311:9	confus	NN	O	B-AdverseReaction
and	TECFIDERA.xml:S2:2321:3	and	CC	O	O
personality	TECFIDERA.xml:S2:2325:11	person	NN	O	B-AdverseReaction
changes	TECFIDERA.xml:S2:2337:7	chang	NNS	O	I-AdverseReaction
.	TECFIDERA.xml:S2:2344:1	.	.	O	O

5.3	TECFIDERA.xml:S2:2353:3	5.3	CD	O	O
Lymphopenia	TECFIDERA.xml:S2:2357:11	lymphopenia	NNP	O	O

TECFIDERA	TECFIDERA.xml:S2:2377:9	tecfidera	NNP	O	O
may	TECFIDERA.xml:S2:2387:3	may	MD	O	O
decrease	TECFIDERA.xml:S2:2391:8	decreas	VB	B-AdverseReaction	B-AdverseReaction
lymphocyte	TECFIDERA.xml:S2:2400:10	lymphocyt	NN	I-AdverseReaction	I-AdverseReaction
counts	TECFIDERA.xml:S2:2411:6	count	NNS	I-AdverseReaction	I-AdverseReaction
.	TECFIDERA.xml:S2:2417:1	.	.	O	O

In	TECFIDERA.xml:S2:2419:2	In	IN	O	O
the	TECFIDERA.xml:S2:2422:3	the	DT	O	O
MS	TECFIDERA.xml:S2:2426:2	MS	NNP	O	O
placebo	TECFIDERA.xml:S2:2429:7	placebo	NN	O	O
controlled	TECFIDERA.xml:S2:2437:10	control	VBD	O	O
trials	TECFIDERA.xml:S2:2448:6	trial	NNS	O	O
,	TECFIDERA.xml:S2:2454:1	,	,	O	O
mean	TECFIDERA.xml:S2:2456:4	mean	JJ	O	B-AdverseReaction
lymphocyte	TECFIDERA.xml:S2:2461:10	lymphocyt	NN	B-AdverseReaction	I-AdverseReaction
counts	TECFIDERA.xml:S2:2472:6	count	NNS	I-AdverseReaction	I-AdverseReaction
decreased	TECFIDERA.xml:S2:2479:9	decreas	VBN	I-AdverseReaction	I-AdverseReaction
by	TECFIDERA.xml:S2:2489:2	by	IN	O	O
approximately	TECFIDERA.xml:S2:2492:13	approxim	RB	O	O
30%	TECFIDERA.xml:S2:2506:3	30%	CD	O	O
during	TECFIDERA.xml:S2:2510:6	dure	IN	O	O
the	TECFIDERA.xml:S2:2517:3	the	DT	O	O
first	TECFIDERA.xml:S2:2521:5	first	JJ	O	O
year	TECFIDERA.xml:S2:2527:4	year	NN	O	O
of	TECFIDERA.xml:S2:2532:2	of	IN	O	O
treatment	TECFIDERA.xml:S2:2535:9	treatment	NN	O	O
with	TECFIDERA.xml:S2:2545:4	with	IN	O	O
TECFIDERA	TECFIDERA.xml:S2:2550:9	tecfidera	NNP	O	O
and	TECFIDERA.xml:S2:2560:3	and	CC	O	O
then	TECFIDERA.xml:S2:2564:4	then	RB	O	O
remained	TECFIDERA.xml:S2:2569:8	remain	VBD	O	O
stable	TECFIDERA.xml:S2:2578:6	stabl	JJ	O	O
.	TECFIDERA.xml:S2:2584:1	.	.	O	O

Four	TECFIDERA.xml:S2:2586:4	four	CD	O	O
weeks	TECFIDERA.xml:S2:2591:5	week	NNS	O	O
after	TECFIDERA.xml:S2:2597:5	after	IN	O	O
stopping	TECFIDERA.xml:S2:2603:8	stop	VBG	O	O
TECFIDERA	TECFIDERA.xml:S2:2612:9	tecfidera	NNP	O	O
,	TECFIDERA.xml:S2:2621:1	,	,	O	O
mean	TECFIDERA.xml:S2:2623:4	mean	JJ	O	O
lymphocyte	TECFIDERA.xml:S2:2628:10	lymphocyt	NN	O	B-AdverseReaction
counts	TECFIDERA.xml:S2:2639:6	count	NNS	O	I-AdverseReaction
increased	TECFIDERA.xml:S2:2646:9	increas	VBD	O	I-AdverseReaction
but	TECFIDERA.xml:S2:2656:3	but	CC	O	O
did	TECFIDERA.xml:S2:2660:3	did	VBD	O	O
not	TECFIDERA.xml:S2:2664:3	not	RB	O	O
return	TECFIDERA.xml:S2:2668:6	return	VB	O	O
to	TECFIDERA.xml:S2:2675:2	to	TO	O	O
baseline	TECFIDERA.xml:S2:2678:8	baselin	VB	O	O
.	TECFIDERA.xml:S2:2686:1	.	.	O	O

Six	TECFIDERA.xml:S2:2688:3	six	CD	O	O
percent	TECFIDERA.xml:S2:2692:7	percent	NN	O	O
(	TECFIDERA.xml:S2:2700:1	(	(	O	O
6%	TECFIDERA.xml:S2:2701:2	6%	CD	O	O
)	TECFIDERA.xml:S2:2703:1	)	)	O	O
of	TECFIDERA.xml:S2:2705:2	of	IN	O	O
TECFIDERA	TECFIDERA.xml:S2:2708:9	tecfidera	NNP	O	O
patients	TECFIDERA.xml:S2:2718:8	patient	NNS	O	O
and	TECFIDERA.xml:S2:2727:3	and	CC	O	O
1%	TECFIDERA.xml:S2:2732:2	1%	CD	O	O
of	TECFIDERA.xml:S2:2735:2	of	IN	O	O
placebo	TECFIDERA.xml:S2:2738:7	placebo	NN	O	O
patients	TECFIDERA.xml:S2:2746:8	patient	NNS	O	O
experienced	TECFIDERA.xml:S2:2755:11	experienc	VBD	O	O
lymphocyte	TECFIDERA.xml:S2:2767:10	lymphocyt	JJ	B-AdverseReaction	B-AdverseReaction
counts	TECFIDERA.xml:S2:2778:6	count	NNS	I-AdverseReaction	I-AdverseReaction
0.5	TECFIDERA.xml:S2:2786:3	0.5	CD	I-AdverseReaction	I-AdverseReaction
x10	TECFIDERA.xml:S2:2789:3	x10	$	I-AdverseReaction	I-AdverseReaction
9	TECFIDERA.xml:S2:2794:1	9	CD	I-AdverseReaction	O
L	TECFIDERA.xml:S2:2798:1	L	NNP	I-AdverseReaction	O
(	TECFIDERA.xml:S2:2800:1	(	(	O	O
lower	TECFIDERA.xml:S2:2801:5	lower	JJR	O	O
limit	TECFIDERA.xml:S2:2807:5	limit	NN	O	O
of	TECFIDERA.xml:S2:2813:2	of	IN	O	O
normal	TECFIDERA.xml:S2:2816:6	normal	JJ	O	O
0.91	TECFIDERA.xml:S2:2823:4	0.91	CD	O	O
x10	TECFIDERA.xml:S2:2827:3	x10	JJ	O	O
9	TECFIDERA.xml:S2:2832:1	9	CD	O	O
L	TECFIDERA.xml:S2:2836:1	L	NNP	O	O
)	TECFIDERA.xml:S2:2837:1	)	)	O	O
.	TECFIDERA.xml:S2:2838:1	.	.	O	O

The	TECFIDERA.xml:S2:2840:3	the	DT	O	O
incidence	TECFIDERA.xml:S2:2844:9	incid	NN	O	O
of	TECFIDERA.xml:S2:2854:2	of	IN	O	O
infections	TECFIDERA.xml:S2:2857:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
(	TECFIDERA.xml:S2:2868:1	(	(	O	O
60%	TECFIDERA.xml:S2:2869:3	60%	CD	O	O
vs	TECFIDERA.xml:S2:2873:2	vs	RB	O	O
58%	TECFIDERA.xml:S2:2876:3	58%	CD	O	O
)	TECFIDERA.xml:S2:2879:1	)	)	O	O
and	TECFIDERA.xml:S2:2881:3	and	CC	O	O
serious	TECFIDERA.xml:S2:2885:7	seriou	JJ	O	O
infections	TECFIDERA.xml:S2:2893:10	infect	NNS	B-AdverseReaction	B-AdverseReaction
(	TECFIDERA.xml:S2:2904:1	(	(	O	O
2%	TECFIDERA.xml:S2:2905:2	2%	CD	O	O
vs	TECFIDERA.xml:S2:2908:2	vs	RB	O	O
2%	TECFIDERA.xml:S2:2911:2	2%	CD	O	O
)	TECFIDERA.xml:S2:2913:1	)	)	O	O
was	TECFIDERA.xml:S2:2915:3	wa	VBD	O	O
similar	TECFIDERA.xml:S2:2919:7	similar	JJ	O	O
in	TECFIDERA.xml:S2:2927:2	in	IN	O	O
patients	TECFIDERA.xml:S2:2930:8	patient	NNS	O	O
treated	TECFIDERA.xml:S2:2939:7	treat	VBN	O	O
with	TECFIDERA.xml:S2:2947:4	with	IN	O	O
TECFIDERA	TECFIDERA.xml:S2:2952:9	tecfidera	NNP	O	O
or	TECFIDERA.xml:S2:2962:2	or	CC	O	O
placebo	TECFIDERA.xml:S2:2965:7	placebo	NN	O	O
,	TECFIDERA.xml:S2:2972:1	,	,	O	O
respectively	TECFIDERA.xml:S2:2974:12	respect	RB	O	O
.	TECFIDERA.xml:S2:2986:1	.	.	O	O

There	TECFIDERA.xml:S2:2988:5	there	EX	O	O
was	TECFIDERA.xml:S2:2994:3	wa	VBD	O	O
no	TECFIDERA.xml:S2:2998:2	no	DT	O	O
increased	TECFIDERA.xml:S2:3001:9	increas	JJ	B-AdverseReaction	O
incidence	TECFIDERA.xml:S2:3011:9	incid	NN	O	O
of	TECFIDERA.xml:S2:3021:2	of	IN	O	O
serious	TECFIDERA.xml:S2:3024:7	seriou	JJ	O	O
infections	TECFIDERA.xml:S2:3032:10	infect	NNS	I-AdverseReaction	B-AdverseReaction
observed	TECFIDERA.xml:S2:3043:8	observ	VBN	O	O
in	TECFIDERA.xml:S2:3052:2	in	IN	O	O
patients	TECFIDERA.xml:S2:3055:8	patient	NNS	O	O
with	TECFIDERA.xml:S2:3064:4	with	IN	O	O
lymphocyte	TECFIDERA.xml:S2:3069:10	lymphocyt	JJ	O	O
counts	TECFIDERA.xml:S2:3080:6	count	NNS	O	O
0.8	TECFIDERA.xml:S2:3088:3	0.8	CD	O	O
x10	TECFIDERA.xml:S2:3091:3	x10	$	O	O
9	TECFIDERA.xml:S2:3096:1	9	CD	O	O
L	TECFIDERA.xml:S2:3100:1	L	NNP	O	O
or	TECFIDERA.xml:S2:3102:2	or	CC	O	O
0.5	TECFIDERA.xml:S2:3105:3	0.5	CD	O	O
x10	TECFIDERA.xml:S2:3108:3	x10	JJ	O	O
9	TECFIDERA.xml:S2:3113:1	9	CD	O	O
L	TECFIDERA.xml:S2:3117:1	L	NNP	O	O
in	TECFIDERA.xml:S2:3119:2	in	IN	O	O
controlled	TECFIDERA.xml:S2:3122:10	control	JJ	O	O
trials	TECFIDERA.xml:S2:3133:6	trial	NNS	O	O
,	TECFIDERA.xml:S2:3139:1	,	,	O	O
although	TECFIDERA.xml:S2:3141:8	although	IN	O	O
one	TECFIDERA.xml:S2:3150:3	one	CD	O	O
patient	TECFIDERA.xml:S2:3154:7	patient	NN	O	O
in	TECFIDERA.xml:S2:3162:2	in	IN	O	O
an	TECFIDERA.xml:S2:3165:2	an	DT	O	O
extension	TECFIDERA.xml:S2:3168:9	extens	NN	O	O
study	TECFIDERA.xml:S2:3178:5	studi	NN	O	O
developed	TECFIDERA.xml:S2:3184:9	develop	VBD	O	O
PML	TECFIDERA.xml:S2:3194:3	pml	NNP	B-AdverseReaction	B-AdverseReaction
in	TECFIDERA.xml:S2:3198:2	in	IN	O	O
the	TECFIDERA.xml:S2:3201:3	the	DT	O	O
setting	TECFIDERA.xml:S2:3205:7	set	NN	O	O
of	TECFIDERA.xml:S2:3213:2	of	IN	O	O
prolonged	TECFIDERA.xml:S2:3216:9	prolong	JJ	B-AdverseReaction	O
lymphopenia	TECFIDERA.xml:S2:3226:11	lymphopenia	NN	I-AdverseReaction	O
(	TECFIDERA.xml:S2:3238:1	(	(	O	O
lymphocyte	TECFIDERA.xml:S2:3239:10	lymphocyt	JJ	O	B-AdverseReaction
counts	TECFIDERA.xml:S2:3250:6	count	VBZ	O	I-AdverseReaction
predominantly	TECFIDERA.xml:S2:3257:13	predominantli	RB	O	I-AdverseReaction
0.5	TECFIDERA.xml:S2:3272:3	0.5	CD	O	O
x10	TECFIDERA.xml:S2:3275:3	x10	JJ	O	O
9	TECFIDERA.xml:S2:3280:1	9	CD	O	O
L	TECFIDERA.xml:S2:3284:1	L	NNP	O	O
for	TECFIDERA.xml:S2:3286:3	for	IN	O	O
3.5	TECFIDERA.xml:S2:3290:3	3.5	CD	O	O
years	TECFIDERA.xml:S2:3294:5	year	NNS	O	O
)	TECFIDERA.xml:S2:3299:1	)	)	O	O
[	TECFIDERA.xml:S2:3301:1	[	VBP	O	O
see	TECFIDERA.xml:S2:3302:3	see	VBP	O	O
Warnings	TECFIDERA.xml:S2:3306:8	warn	NNS	O	O
and	TECFIDERA.xml:S2:3315:3	and	CC	O	O
Precautions	TECFIDERA.xml:S2:3319:11	precaut	NNP	O	O
(	TECFIDERA.xml:S2:3331:1	(	(	O	O
5.2	TECFIDERA.xml:S2:3334:3	5.2	CD	O	O
)]	TECFIDERA.xml:S2:3339:2	)]	NN	O	O
.	TECFIDERA.xml:S2:3343:1	.	.	O	O

In	TECFIDERA.xml:S2:3345:2	In	IN	O	O
controlled	TECFIDERA.xml:S2:3348:10	control	VBN	O	O
and	TECFIDERA.xml:S2:3359:3	and	CC	O	O
uncontrolled	TECFIDERA.xml:S2:3363:12	uncontrol	JJ	O	O
clinical	TECFIDERA.xml:S2:3376:8	clinic	JJ	O	O
trials	TECFIDERA.xml:S2:3385:6	trial	NNS	O	O
,	TECFIDERA.xml:S2:3391:1	,	,	O	O
2%	TECFIDERA.xml:S2:3393:2	2%	CD	O	O
of	TECFIDERA.xml:S2:3396:2	of	IN	O	O
patients	TECFIDERA.xml:S2:3399:8	patient	NNS	O	O
experienced	TECFIDERA.xml:S2:3408:11	experienc	JJ	O	O
lymphocyte	TECFIDERA.xml:S2:3420:10	lymphocyt	JJ	B-AdverseReaction	B-AdverseReaction
counts	TECFIDERA.xml:S2:3431:6	count	NNS	I-AdverseReaction	I-AdverseReaction
0.5	TECFIDERA.xml:S2:3439:3	0.5	CD	I-AdverseReaction	I-AdverseReaction
x	TECFIDERA.xml:S2:3443:1	x	VBD	I-AdverseReaction	I-AdverseReaction
10	TECFIDERA.xml:S2:3445:2	10	CD	I-AdverseReaction	O
9	TECFIDERA.xml:S2:3449:1	9	CD	I-AdverseReaction	O
L	TECFIDERA.xml:S2:3453:1	L	NN	I-AdverseReaction	O
for	TECFIDERA.xml:S2:3455:3	for	IN	O	O
at	TECFIDERA.xml:S2:3459:2	at	IN	O	O
least	TECFIDERA.xml:S2:3462:5	least	JJS	O	O
six	TECFIDERA.xml:S2:3468:3	six	CD	O	O
months	TECFIDERA.xml:S2:3472:6	month	NNS	O	O
.	TECFIDERA.xml:S2:3478:1	.	.	O	O

In	TECFIDERA.xml:S2:3480:2	In	IN	O	O
these	TECFIDERA.xml:S2:3483:5	these	DT	O	O
patients	TECFIDERA.xml:S2:3489:8	patient	NNS	O	O
,	TECFIDERA.xml:S2:3497:1	,	,	O	O
the	TECFIDERA.xml:S2:3499:3	the	DT	O	O
majority	TECFIDERA.xml:S2:3503:8	major	NN	O	O
of	TECFIDERA.xml:S2:3512:2	of	IN	O	O
lymphocyte	TECFIDERA.xml:S2:3515:10	lymphocyt	JJ	B-AdverseReaction	B-AdverseReaction
counts	TECFIDERA.xml:S2:3526:6	count	NNS	I-AdverseReaction	I-AdverseReaction
remained	TECFIDERA.xml:S2:3533:8	remain	VBD	O	I-AdverseReaction
0.5	TECFIDERA.xml:S2:3543:3	0.5	CD	I-AdverseReaction	O
x10	TECFIDERA.xml:S2:3546:3	x10	JJ	I-AdverseReaction	O
9	TECFIDERA.xml:S2:3551:1	9	CD	I-AdverseReaction	O
L	TECFIDERA.xml:S2:3555:1	L	NN	I-AdverseReaction	O
with	TECFIDERA.xml:S2:3557:4	with	IN	O	O
continued	TECFIDERA.xml:S2:3562:9	continu	JJ	O	O
therapy	TECFIDERA.xml:S2:3572:7	therapi	NN	O	O
.	TECFIDERA.xml:S2:3579:1	.	.	O	O

TECFIDERA	TECFIDERA.xml:S2:3581:9	tecfidera	NNP	O	O
has	TECFIDERA.xml:S2:3591:3	ha	VBZ	O	O
not	TECFIDERA.xml:S2:3595:3	not	RB	O	O
been	TECFIDERA.xml:S2:3599:4	been	VBN	O	O
studied	TECFIDERA.xml:S2:3604:7	studi	VBN	O	O
in	TECFIDERA.xml:S2:3612:2	in	IN	O	O
patients	TECFIDERA.xml:S2:3615:8	patient	NNS	O	O
with	TECFIDERA.xml:S2:3624:4	with	IN	O	O
pre	TECFIDERA.xml:S2:3629:3	pre	JJ	O	O
-	TECFIDERA.xml:S2:3632:1	-	:	O	O
existing	TECFIDERA.xml:S2:3633:8	exist	VBG	O	O
low	TECFIDERA.xml:S2:3642:3	low	JJ	O	O
lymphocyte	TECFIDERA.xml:S2:3646:10	lymphocyt	NN	O	O
counts	TECFIDERA.xml:S2:3657:6	count	NNS	O	O
.	TECFIDERA.xml:S2:3663:1	.	.	O	O

Before	TECFIDERA.xml:S2:3672:6	befor	IN	O	O
initiating	TECFIDERA.xml:S2:3679:10	initi	VBG	O	O
treatment	TECFIDERA.xml:S2:3690:9	treatment	NN	O	O
with	TECFIDERA.xml:S2:3700:4	with	IN	O	O
TECFIDERA	TECFIDERA.xml:S2:3705:9	tecfidera	NNP	O	O
,	TECFIDERA.xml:S2:3714:1	,	,	O	O
a	TECFIDERA.xml:S2:3716:1	a	DT	O	O
CBC	TECFIDERA.xml:S2:3718:3	cbc	NNP	O	O
including	TECFIDERA.xml:S2:3722:9	includ	VBG	O	O
lymphocyte	TECFIDERA.xml:S2:3732:10	lymphocyt	JJ	O	O
count	TECFIDERA.xml:S2:3743:5	count	NN	O	O
should	TECFIDERA.xml:S2:3749:6	should	MD	O	O
be	TECFIDERA.xml:S2:3756:2	be	VB	O	O
obtained	TECFIDERA.xml:S2:3759:8	obtain	VBN	O	O
.	TECFIDERA.xml:S2:3767:1	.	.	O	O

A	TECFIDERA.xml:S2:3769:1	A	DT	O	O
CBC	TECFIDERA.xml:S2:3771:3	cbc	NNP	O	O
including	TECFIDERA.xml:S2:3775:9	includ	VBG	O	O
lymphocyte	TECFIDERA.xml:S2:3785:10	lymphocyt	JJ	O	O
count	TECFIDERA.xml:S2:3796:5	count	NN	O	O
should	TECFIDERA.xml:S2:3802:6	should	MD	O	O
also	TECFIDERA.xml:S2:3809:4	also	RB	O	O
be	TECFIDERA.xml:S2:3814:2	be	VB	O	O
obtained	TECFIDERA.xml:S2:3817:8	obtain	VBN	O	O
after	TECFIDERA.xml:S2:3826:5	after	IN	O	O
6	TECFIDERA.xml:S2:3832:1	6	CD	O	O
months	TECFIDERA.xml:S2:3834:6	month	NNS	O	O
of	TECFIDERA.xml:S2:3841:2	of	IN	O	O
treatment	TECFIDERA.xml:S2:3844:9	treatment	NN	O	O
,	TECFIDERA.xml:S2:3853:1	,	,	O	O
every	TECFIDERA.xml:S2:3855:5	everi	DT	O	O
6	TECFIDERA.xml:S2:3861:1	6	CD	O	O
to	TECFIDERA.xml:S2:3863:2	to	TO	O	O
12	TECFIDERA.xml:S2:3866:2	12	CD	O	O
months	TECFIDERA.xml:S2:3869:6	month	NNS	O	O
thereafter	TECFIDERA.xml:S2:3876:10	thereaft	RB	O	O
,	TECFIDERA.xml:S2:3886:1	,	,	O	O
and	TECFIDERA.xml:S2:3888:3	and	CC	O	O
as	TECFIDERA.xml:S2:3892:2	as	IN	O	O
clinically	TECFIDERA.xml:S2:3895:10	clinic	RB	O	O
indicated	TECFIDERA.xml:S2:3906:9	indic	VBN	O	O
.	TECFIDERA.xml:S2:3915:1	.	.	O	O

Consider	TECFIDERA.xml:S2:3917:8	consid	VB	O	O
interruption	TECFIDERA.xml:S2:3926:12	interrupt	NN	O	O
of	TECFIDERA.xml:S2:3939:2	of	IN	O	O
TECFIDERA	TECFIDERA.xml:S2:3942:9	tecfidera	NNP	O	O
in	TECFIDERA.xml:S2:3952:2	in	IN	O	O
patients	TECFIDERA.xml:S2:3955:8	patient	NNS	O	O
with	TECFIDERA.xml:S2:3964:4	with	IN	O	O
lymphocyte	TECFIDERA.xml:S2:3969:10	lymphocyt	JJ	O	B-AdverseReaction
counts	TECFIDERA.xml:S2:3980:6	count	NNS	O	I-AdverseReaction
0.5	TECFIDERA.xml:S2:3988:3	0.5	CD	O	I-AdverseReaction
x	TECFIDERA.xml:S2:3992:1	x	VBD	O	I-AdverseReaction
10	TECFIDERA.xml:S2:3994:2	10	CD	O	O
9	TECFIDERA.xml:S2:3998:1	9	CD	O	O
L	TECFIDERA.xml:S2:4002:1	L	NNP	O	O
persisting	TECFIDERA.xml:S2:4004:10	persist	VBG	O	O
for	TECFIDERA.xml:S2:4015:3	for	IN	O	O
more	TECFIDERA.xml:S2:4019:4	more	JJR	O	O
than	TECFIDERA.xml:S2:4024:4	than	IN	O	O
six	TECFIDERA.xml:S2:4029:3	six	CD	O	O
months	TECFIDERA.xml:S2:4033:6	month	NNS	O	O
.	TECFIDERA.xml:S2:4039:1	.	.	O	O

Given	TECFIDERA.xml:S2:4041:5	given	VBN	O	O
the	TECFIDERA.xml:S2:4047:3	the	DT	O	O
potential	TECFIDERA.xml:S2:4051:9	potenti	NN	O	O
for	TECFIDERA.xml:S2:4061:3	for	IN	O	O
delay	TECFIDERA.xml:S2:4065:5	delay	NN	O	O
in	TECFIDERA.xml:S2:4071:2	in	IN	O	O
lymphocyte	TECFIDERA.xml:S2:4074:10	lymphocyt	JJ	O	O
recovery	TECFIDERA.xml:S2:4085:8	recoveri	NN	O	O
after	TECFIDERA.xml:S2:4094:5	after	IN	O	O
discontinuation	TECFIDERA.xml:S2:4100:15	discontinu	NN	O	O
of	TECFIDERA.xml:S2:4116:2	of	IN	O	O
TECFIDERA	TECFIDERA.xml:S2:4119:9	tecfidera	NNP	O	O
,	TECFIDERA.xml:S2:4128:1	,	,	O	O
consider	TECFIDERA.xml:S2:4130:8	consid	VB	O	O
following	TECFIDERA.xml:S2:4139:9	follow	VBG	O	O
lymphocyte	TECFIDERA.xml:S2:4149:10	lymphocyt	NN	O	O
counts	TECFIDERA.xml:S2:4160:6	count	NNS	O	O
until	TECFIDERA.xml:S2:4167:5	until	IN	O	O
lymphopenia	TECFIDERA.xml:S2:4173:11	lymphopenia	NN	O	O
is	TECFIDERA.xml:S2:4185:2	is	VBZ	O	O
resolved	TECFIDERA.xml:S2:4188:8	resolv	VBN	O	O
.	TECFIDERA.xml:S2:4196:1	.	.	O	O

Withholding	TECFIDERA.xml:S2:4198:11	withhold	VBG	O	O
treatment	TECFIDERA.xml:S2:4210:9	treatment	NN	O	O
should	TECFIDERA.xml:S2:4220:6	should	MD	O	O
be	TECFIDERA.xml:S2:4227:2	be	VB	O	O
considered	TECFIDERA.xml:S2:4230:10	consid	VBN	O	O
in	TECFIDERA.xml:S2:4241:2	in	IN	O	O
patients	TECFIDERA.xml:S2:4244:8	patient	NNS	O	O
with	TECFIDERA.xml:S2:4253:4	with	IN	O	O
serious	TECFIDERA.xml:S2:4258:7	seriou	JJ	O	O
infections	TECFIDERA.xml:S2:4266:10	infect	NNS	O	O
until	TECFIDERA.xml:S2:4277:5	until	IN	O	O
the	TECFIDERA.xml:S2:4283:3	the	DT	O	O
infection	TECFIDERA.xml:S2:4287:9	infect	NN	O	O
(	TECFIDERA.xml:S2:4296:1	(	(	O	O
s	TECFIDERA.xml:S2:4297:1	s	NN	O	O
)	TECFIDERA.xml:S2:4298:1	)	)	O	O
is	TECFIDERA.xml:S2:4300:2	is	VBZ	O	O
resolved	TECFIDERA.xml:S2:4303:8	resolv	VBN	O	O
.	TECFIDERA.xml:S2:4311:1	.	.	O	O

Decisions	TECFIDERA.xml:S2:4313:9	decis	NNS	O	O
about	TECFIDERA.xml:S2:4323:5	about	IN	O	O
whether	TECFIDERA.xml:S2:4329:7	whether	IN	O	O
or	TECFIDERA.xml:S2:4337:2	or	CC	O	O
not	TECFIDERA.xml:S2:4340:3	not	RB	O	O
to	TECFIDERA.xml:S2:4344:2	to	TO	O	O
restart	TECFIDERA.xml:S2:4347:7	restart	VB	O	O
TECFIDERA	TECFIDERA.xml:S2:4355:9	tecfidera	NNP	O	O
should	TECFIDERA.xml:S2:4365:6	should	MD	O	O
be	TECFIDERA.xml:S2:4372:2	be	VB	O	O
individualized	TECFIDERA.xml:S2:4375:14	individu	VBN	O	O
based	TECFIDERA.xml:S2:4390:5	base	VBN	O	O
on	TECFIDERA.xml:S2:4396:2	on	IN	O	O
clinical	TECFIDERA.xml:S2:4399:8	clinic	JJ	O	O
circumstances	TECFIDERA.xml:S2:4408:13	circumst	NNS	O	O
.	TECFIDERA.xml:S2:4421:1	.	.	O	O

5.4	TECFIDERA.xml:S2:4430:3	5.4	CD	O	O
Flushing	TECFIDERA.xml:S2:4434:8	flush	VBG	O	O

TECFIDERA	TECFIDERA.xml:S2:4451:9	tecfidera	NNP	O	O
may	TECFIDERA.xml:S2:4461:3	may	MD	O	O
cause	TECFIDERA.xml:S2:4465:5	caus	VB	O	O
flushing	TECFIDERA.xml:S2:4471:8	flush	NN	B-AdverseReaction	B-AdverseReaction
(	TECFIDERA.xml:S2:4480:1	(	(	O	O
e	TECFIDERA.xml:S2:4481:1	e	NN	O	O
.	TECFIDERA.xml:S2:4482:1	.	.	O	O
g	TECFIDERA.xml:S2:4483:1	g	NN	O	O
.	TECFIDERA.xml:S2:4484:1	.	.	O	O
,	TECFIDERA.xml:S2:4485:1	,	,	O	O
warmth	TECFIDERA.xml:S2:4487:6	warmth	NN	B-AdverseReaction	O
,	TECFIDERA.xml:S2:4493:1	,	,	O	O
redness	TECFIDERA.xml:S2:4495:7	red	NN	B-AdverseReaction	B-AdverseReaction
,	TECFIDERA.xml:S2:4502:1	,	,	O	O
itching	TECFIDERA.xml:S2:4504:7	itch	NN	B-AdverseReaction	O
,	TECFIDERA.xml:S2:4511:1	,	,	O	O
and	TECFIDERA.xml:S2:4513:3	and	CC	O	O
or	TECFIDERA.xml:S2:4517:2	or	CC	O	O
burning	TECFIDERA.xml:S2:4520:7	burn	VBG	B-AdverseReaction	O
sensation	TECFIDERA.xml:S2:4528:9	sensat	NN	I-AdverseReaction	O
)	TECFIDERA.xml:S2:4537:1	)	)	O	O
.	TECFIDERA.xml:S2:4538:1	.	.	O	O

In	TECFIDERA.xml:S2:4540:2	In	IN	O	O
clinical	TECFIDERA.xml:S2:4543:8	clinic	JJ	O	O
trials	TECFIDERA.xml:S2:4552:6	trial	NNS	O	O
,	TECFIDERA.xml:S2:4558:1	,	,	O	O
40%	TECFIDERA.xml:S2:4560:3	40%	CD	O	O
of	TECFIDERA.xml:S2:4564:2	of	IN	O	O
TECFIDERA	TECFIDERA.xml:S2:4567:9	tecfidera	NNP	O	O
treated	TECFIDERA.xml:S2:4577:7	treat	VBD	O	O
patients	TECFIDERA.xml:S2:4585:8	patient	NNS	O	O
experienced	TECFIDERA.xml:S2:4594:11	experienc	JJ	O	O
flushing	TECFIDERA.xml:S2:4606:8	flush	NN	B-AdverseReaction	O
.	TECFIDERA.xml:S2:4614:1	.	.	O	O

Flushing	TECFIDERA.xml:S2:4616:8	flush	VBG	B-AdverseReaction	O
symptoms	TECFIDERA.xml:S2:4625:8	symptom	NNS	O	O
generally	TECFIDERA.xml:S2:4634:9	gener	RB	O	O
began	TECFIDERA.xml:S2:4644:5	began	VBD	O	O
soon	TECFIDERA.xml:S2:4650:4	soon	RB	O	O
after	TECFIDERA.xml:S2:4655:5	after	IN	O	O
initiating	TECFIDERA.xml:S2:4661:10	initi	VBG	O	O
TECFIDERA	TECFIDERA.xml:S2:4672:9	tecfidera	NNP	O	O
and	TECFIDERA.xml:S2:4682:3	and	CC	O	O
usually	TECFIDERA.xml:S2:4686:7	usual	RB	O	O
improved	TECFIDERA.xml:S2:4694:8	improv	VBN	O	O
or	TECFIDERA.xml:S2:4703:2	or	CC	O	O
resolved	TECFIDERA.xml:S2:4706:8	resolv	VBN	O	O
over	TECFIDERA.xml:S2:4715:4	over	IN	O	O
time	TECFIDERA.xml:S2:4720:4	time	NN	O	O
.	TECFIDERA.xml:S2:4724:1	.	.	O	O

In	TECFIDERA.xml:S2:4726:2	In	IN	O	O
the	TECFIDERA.xml:S2:4729:3	the	DT	O	O
majority	TECFIDERA.xml:S2:4733:8	major	NN	O	O
of	TECFIDERA.xml:S2:4742:2	of	IN	O	O
patients	TECFIDERA.xml:S2:4745:8	patient	NNS	O	O
who	TECFIDERA.xml:S2:4754:3	who	WP	O	O
experienced	TECFIDERA.xml:S2:4758:11	experienc	VBD	O	O
flushing	TECFIDERA.xml:S2:4770:8	flush	NN	B-AdverseReaction	B-AdverseReaction
,	TECFIDERA.xml:S2:4778:1	,	,	O	O
it	TECFIDERA.xml:S2:4780:2	it	PRP	O	O
was	TECFIDERA.xml:S2:4783:3	wa	VBD	O	O
mild	TECFIDERA.xml:S2:4787:4	mild	JJ	O	O
or	TECFIDERA.xml:S2:4792:2	or	CC	O	O
moderate	TECFIDERA.xml:S2:4795:8	moder	JJ	O	O
in	TECFIDERA.xml:S2:4804:2	in	IN	O	O
severity	TECFIDERA.xml:S2:4807:8	sever	NN	O	O
.	TECFIDERA.xml:S2:4815:1	.	.	O	O

Three	TECFIDERA.xml:S2:4817:5	three	CD	O	O
percent	TECFIDERA.xml:S2:4823:7	percent	NN	O	O
(	TECFIDERA.xml:S2:4831:1	(	(	O	O
3%	TECFIDERA.xml:S2:4832:2	3%	CD	O	O
)	TECFIDERA.xml:S2:4834:1	)	)	O	O
of	TECFIDERA.xml:S2:4836:2	of	IN	O	O
patients	TECFIDERA.xml:S2:4839:8	patient	NNS	O	O
discontinued	TECFIDERA.xml:S2:4848:12	discontinu	VBN	O	O
TECFIDERA	TECFIDERA.xml:S2:4861:9	tecfidera	NNP	O	O
for	TECFIDERA.xml:S2:4871:3	for	IN	O	O
flushing	TECFIDERA.xml:S2:4875:8	flush	VBG	B-AdverseReaction	O
and	TECFIDERA.xml:S2:4884:3	and	CC	O	O
1%	TECFIDERA.xml:S2:4889:2	1%	CD	O	O
had	TECFIDERA.xml:S2:4892:3	had	VBD	O	O
serious	TECFIDERA.xml:S2:4896:7	seriou	JJ	O	O
flushing	TECFIDERA.xml:S2:4904:8	flush	NN	B-AdverseReaction	O
symptoms	TECFIDERA.xml:S2:4913:8	symptom	NNS	O	O
that	TECFIDERA.xml:S2:4922:4	that	WDT	O	O
were	TECFIDERA.xml:S2:4927:4	were	VBD	O	O
not	TECFIDERA.xml:S2:4932:3	not	RB	O	O
life	TECFIDERA.xml:S2:4936:4	life	NN	O	O
-	TECFIDERA.xml:S2:4940:1	-	:	O	O
threatening	TECFIDERA.xml:S2:4941:11	threaten	NN	O	O
but	TECFIDERA.xml:S2:4953:3	but	CC	O	O
led	TECFIDERA.xml:S2:4957:3	led	VBD	O	O
to	TECFIDERA.xml:S2:4961:2	to	TO	O	O
hospitalization	TECFIDERA.xml:S2:4964:15	hospit	NN	O	O
.	TECFIDERA.xml:S2:4979:1	.	.	O	O

Administration	TECFIDERA.xml:S2:4981:14	administr	NN	O	O
of	TECFIDERA.xml:S2:4996:2	of	IN	O	O
TECFIDERA	TECFIDERA.xml:S2:4999:9	tecfidera	NNP	O	O
with	TECFIDERA.xml:S2:5009:4	with	IN	O	O
food	TECFIDERA.xml:S2:5014:4	food	NN	O	O
may	TECFIDERA.xml:S2:5019:3	may	MD	O	O
reduce	TECFIDERA.xml:S2:5023:6	reduc	VB	O	O
the	TECFIDERA.xml:S2:5030:3	the	DT	O	O
incidence	TECFIDERA.xml:S2:5034:9	incid	NN	O	O
of	TECFIDERA.xml:S2:5044:2	of	IN	O	O
flushing	TECFIDERA.xml:S2:5047:8	flush	NN	B-AdverseReaction	B-AdverseReaction
.	TECFIDERA.xml:S2:5055:1	.	.	O	O

Alternatively	TECFIDERA.xml:S2:5057:13	altern	RB	O	O
,	TECFIDERA.xml:S2:5070:1	,	,	O	O
administration	TECFIDERA.xml:S2:5072:14	administr	NN	O	O
of	TECFIDERA.xml:S2:5087:2	of	IN	O	O
non	TECFIDERA.xml:S2:5090:3	non	JJ	O	O
-	TECFIDERA.xml:S2:5093:1	-	:	O	O
enteric	TECFIDERA.xml:S2:5094:7	enter	NN	O	O
coated	TECFIDERA.xml:S2:5102:6	coat	VBN	O	O
aspirin	TECFIDERA.xml:S2:5109:7	aspirin	NN	O	O
(	TECFIDERA.xml:S2:5117:1	(	(	O	O
up	TECFIDERA.xml:S2:5118:2	up	IN	O	O
to	TECFIDERA.xml:S2:5121:2	to	TO	O	O
a	TECFIDERA.xml:S2:5124:1	a	DT	O	O
dose	TECFIDERA.xml:S2:5126:4	dose	NN	O	O
of	TECFIDERA.xml:S2:5131:2	of	IN	O	O
325	TECFIDERA.xml:S2:5134:3	325	CD	O	O
mg	TECFIDERA.xml:S2:5138:2	mg	NN	O	O
)	TECFIDERA.xml:S2:5140:1	)	)	O	O
30	TECFIDERA.xml:S2:5142:2	30	CD	O	O
minutes	TECFIDERA.xml:S2:5145:7	minut	NNS	O	O
prior	TECFIDERA.xml:S2:5153:5	prior	RB	O	O
to	TECFIDERA.xml:S2:5159:2	to	TO	O	O
TECFIDERA	TECFIDERA.xml:S2:5162:9	tecfidera	NNP	O	O
dosing	TECFIDERA.xml:S2:5172:6	dose	NN	O	O
may	TECFIDERA.xml:S2:5179:3	may	MD	O	O
reduce	TECFIDERA.xml:S2:5183:6	reduc	VB	O	O
the	TECFIDERA.xml:S2:5190:3	the	DT	O	O
incidence	TECFIDERA.xml:S2:5194:9	incid	NN	O	O
or	TECFIDERA.xml:S2:5204:2	or	CC	O	O
severity	TECFIDERA.xml:S2:5207:8	sever	NN	O	O
of	TECFIDERA.xml:S2:5216:2	of	IN	O	O
flushing	TECFIDERA.xml:S2:5219:8	flush	VBG	B-AdverseReaction	O
[	TECFIDERA.xml:S2:5228:1	[	NNP	O	O
see	TECFIDERA.xml:S2:5229:3	see	NN	O	O
Dosing	TECFIDERA.xml:S2:5233:6	dose	NNP	O	O
and	TECFIDERA.xml:S2:5240:3	and	CC	O	O
Administration	TECFIDERA.xml:S2:5244:14	administr	NNP	O	O
(	TECFIDERA.xml:S2:5259:1	(	(	O	O
2.1	TECFIDERA.xml:S2:5262:3	2.1	CD	O	O
)	TECFIDERA.xml:S2:5267:1	)	)	O	O
and	TECFIDERA.xml:S2:5269:3	and	CC	O	O
Clinical	TECFIDERA.xml:S2:5273:8	clinic	JJ	O	O
Pharmacology	TECFIDERA.xml:S2:5282:12	pharmacolog	NNP	O	O
(	TECFIDERA.xml:S2:5295:1	(	(	O	O
12.3	TECFIDERA.xml:S2:5298:4	12.3	CD	O	O
)]	TECFIDERA.xml:S2:5304:2	)]	NN	O	O
.	TECFIDERA.xml:S2:5308:1	.	.	O	O

